FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU Zhang, WL
   Eitel, RE
AF Zhang, Wenli
   Eitel, Richard E.
TI An integrated multilayer ceramic piezoelectric micropump for
   microfluidic systems
SO JOURNAL OF INTELLIGENT MATERIAL SYSTEMS AND STRUCTURES
LA English
DT Article
DE Micropump; multilayer; piezoelectric bimorph; low-temperature cofired
   ceramics
ID LTCC; MICROSYSTEMS; FABRICATION; TECHNOLOGY
AB A package-level peristaltic piezoelectric micropump has been designed and fabricated in utilizing multilayer ceramic fabrication methods. The device was fabricated using commercially available low-temperature cofired ceramic materials and a custom-designed low-temperature cofired ceramic compatible piezoelectric ceramic composition. The assembled multilayer pump structure was sintered in single cofiring step. Performance testing resulted in observed unloaded bidirectional flow rates of 450 mu L/min and a blocking pressure of 1.4 kPa when the pump was operated at a voltage of 100 V-pp (with a phase difference of 120 degrees) with a frequency of 100 Hz. It was further shown that incorporation of diffuser elements into the microfluidic interconnects was used to increase the blocking pressure capabilities at the expense of flow rate and bidirectional flow characteristics. Alternatively, by maintaining a uniform channel width but varying channel cross section width over height ratio (W/H), an unloaded flow rate of 630 mu L/min with an enhancement of blocking pressure (1.55 kPa) was achieved for W/H = 3 (and the same drive conditions as above). The resulting multilayer ceramic-based piezoelectric micropump offers a compact planar pump design, with significant performance advantages, and design flexibility compared to competing micropump technologies.
C1 [Zhang, Wenli] Virginia Polytech Inst & State Univ, Ctr Power Elect Syst, Blacksburg, VA 24061 USA.
   [Eitel, Richard E.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40536 USA.
RP Eitel, RE (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40536 USA.
EM reitel@engr.uky.edu
RI Eitel, Richard/E-2889-2010
OI Eitel, Richard/0000-0002-5090-2075
FU DEPSCoR; Office of Naval Research [N0001 40911156 DEPSCoR]
FX Support for Wenli Zhang was provided in part by DEPSCoR and Office of
   Naval Research under grant number N0001 40911156 DEPSCoR.
CR Baker A, 2006, INT J APPL CERAM TEC, V3, P413, DOI 10.1111/j.1744-7402.2006.02104.x
   Chen CH, 2002, J MICROELECTROMECH S, V11, P672, DOI 10.1109/JMEMS.2002.805055
   Chia BT, 2011, SENSOR ACTUAT A-PHYS, V165, P86, DOI 10.1016/j.sna.2010.02.018
   Erickson D, 2004, ANAL CHIM ACTA, V507, P11, DOI 10.1016/j.aca.2003.09.019
   Golonka LJ, 2005, SENSOR ACTUAT B-CHEM, V111, P396, DOI 10.1016/j.snb.2005.03.065
   Gongora-Rubio MR, 2001, SENSOR ACTUAT A-PHYS, V89, P222, DOI 10.1016/S0924-4247(00)00554-9
   Hsu YC, 2009, MICROSYST TECHNOL, V15, P565, DOI 10.1007/s00542-008-0761-6
   Ibanez-Garcia N, 2008, TRAC-TREND ANAL CHEM, V27, P24, DOI 10.1016/j.trac.2007.11.002
   Kang HJ, 2011, SENSOR ACTUAT A-PHYS, V165, P439, DOI 10.1016/j.sna.2010.11.011
   Koch M, 1998, J MICROMECH MICROENG, V8, P119, DOI 10.1088/0960-1317/8/2/019
   Laser DJ, 2004, J MICROMECH MICROENG, V14, pR35, DOI 10.1088/0960-1317/14/6/R01
   Laser DL, 2003, 12 INT C SOL STAT SE
   Lim CW, 2001, INT J SOLIDS STRUCT, V38, P2833, DOI 10.1016/S0020-7683(00)00186-4
   Mamanee W, 2006, J PHYS CONF SER, V34, P564, DOI 10.1088/1742-6596/34/1/093
   MANZ A, 1992, J CHROMATOGR, V593, P253, DOI 10.1016/0021-9673(92)80293-4
   Olsson A, 2000, SENSOR ACTUAT A-PHYS, V84, P165, DOI 10.1016/S0924-4247(99)00320-9
   Olsson A, 1997, J MICROELECTROMECH S, V6, P161, DOI 10.1109/84.585794
   PAUL PH, 1998, MICRO TOTAL ANAL SYS, P49
   SMITS JG, 1990, SENSOR ACTUAT A-PHYS, V21, P203, DOI 10.1016/0924-4247(90)85039-7
   Sobocinski M, 2009, SENSOR ACTUAT A-PHYS, V149, P315, DOI 10.1016/j.sna.2008.11.025
   Thelemann T, 2002, MICROELECTRON INT, V19, P19, DOI 10.1108/1356536021044505
   Woias P, 2005, SENSOR ACTUAT B-CHEM, V105, P28, DOI 10.1016/j.snb.2004.02.033
   Yang W., 2002, MECHATRONIC RELIABIL
   Yoon JS, 2007, SENSOR ACTUAT A-PHYS, V135, P833, DOI 10.1016/j.sna.2006.08.017
   Zeng SL, 2001, SENSOR ACTUAT B-CHEM, V79, P107, DOI 10.1016/S0925-4005(01)00855-3
   Zhang W, 2012, INT J APPL CERAMIC T, V11, DOI 10.1111/j.1744-7402.2011.02747.x
   Zhang WL, 2011, J AM CERAM SOC, V94, P3386, DOI 10.1111/j.1551-2916.2011.04504.x
   Zhong JH, 2002, SENSOR ACTUAT A-PHYS, V96, P59, DOI 10.1016/S0924-4247(01)00764-6
NR 28
TC 1
Z9 1
U1 2
U2 58
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1045-389X
J9 J INTEL MAT SYST STR
JI J. Intell. Mater. Syst. Struct.
PD SEP
PY 2013
VL 24
IS 13
BP 1637
EP 1646
DI 10.1177/1045389X13483023
PG 10
WC Materials Science, Multidisciplinary
SC Materials Science
GA 206AE
UT WOS:000323486500009
DA 2018-03-19
ER

PT J
AU Orellana, BR
   Thomas, MV
   Dziubla, TD
   Shah, NM
   Hilt, JZ
   Puleo, DA
AF Orellana, Bryan R.
   Thomas, Mark V.
   Dziubla, Thomas D.
   Shah, Nihar M.
   Hilt, J. Zach
   Puleo, David A.
TI Bioerodible calcium sulfate/poly(beta-amino ester) hydrogel composites
SO JOURNAL OF THE MECHANICAL BEHAVIOR OF BIOMEDICAL MATERIALS
LA English
DT Article
DE Calcium sulfate; Composite; Bioerodible; Biodegradable; Bone
   regeneration; Controlled release
ID BONE-GRAFT SUBSTITUTES; PHOSPHATE-BASED BONE; RIDGE AUGMENTATION;
   CONTROLLED-RELEASE; ALVEOLAR RIDGE; DRUG-RELEASE; SULFATE; CURCUMIN;
   CEMENTS; RAT
AB The capacity to quickly regenerate or augment bone lost as a result of resorption is crucial to ensure suitable application of prosthetics for restoring masticatory function. Calcium sulfate hemihydrate (CS)-based bone graft substitute composites containing poly(p-amino ester) (PBAE) biodegradable hydrogel particles were developed to act as a 'tenting' barrier to soft tissue infiltration, potentially providing adequate space to enable vertical bone regeneration. CS has long been recognized as an osteoconductive biomaterial with an excellent reputation as a biocompatible substance. Composite samples were fabricated with varying amounts (1 or 10 wt%) and sizes (53-150 or 150-250 mu m) of gel particles embedded in CS. The swelling and degradation rates of PBAE gels alone were rapid, resulting in complete degradation in less than 24 h, an important characteristic to aid in controlled release of drug. MicroCT images revealed a homogeneous distribution of gel particles within the CS matrix. All CS samples degraded via surface erosion, with the amount of gel particles (i.e., 10 wt% gel particles) having only a small, but significant, effect on the dissolution rate (4% vs. 5% per day). Compression testing determined that the amount, but not the size, of gel particles had a significant effect on the overall strength of the composites. As much as a 75% drop in strength was seen with a 10 wt% loading of particles. A pilot study using PBAE particles loaded with the multipotential drug curcumin demonstrated sustained release of drug from CS composites. By adjusting the amount and/or size of the biodegradable gel particles embedded in CS, mechanical strength and degradation rates of the composites, as well as the drug release kinetics, can be tuned to fabricate, multi-functional 'space-making' bone grafting substitutes. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Orellana, Bryan R.; Puleo, David A.] Univ Kentucky, Ctr Biomed Engn, Wenner Gren Res Lab, Lexington, KY 40506 USA.
   [Thomas, Mark V.] Univ Kentucky, Coll Dent, Lexington, KY 40536 USA.
   [Dziubla, Thomas D.; Shah, Nihar M.; Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Puleo, DA (reprint author), Univ Kentucky, Ctr Biomed Engn, 209 Wenner Gren Lab, Lexington, KY 40506 USA.
EM puleo@uky.edu
FU National Institutes of Health [DE019645]; Kentucky NASA EPSCoR
   [NNX08BA13A]; National Science Foundation [EPS-0814194]
FX This research supported by the National Institutes of Health (DE019645),
   Kentucky NASA EPSCoR (NNX08BA13A), and the National Science Foundation
   (EPS-0814194).
CR Anderson DG, 2006, ADV MATER, V18, P2614, DOI 10.1002/adma.200600529
   Chiapasco M., 2009, BONE AUGMENTATION PR
   Chiapasco M, 2007, CLIN ORAL IMPLAN RES, V18, P432, DOI 10.1111/j.1600-0501.2007.01351.x
   Cho DC, 2012, ACTA NEUROCHIR, V154, P2215, DOI 10.1007/s00701-012-1516-9
   Choi BH, 2004, J CRANIO MAXILL SURG, V32, P51, DOI 10.1016/j.jcms.2003.08.006
   Clavero Jaime, 2003, Clin Implant Dent Relat Res, V5, P154, DOI 10.1111/j.1708-8208.2003.tb00197.x
   Donos N, 2002, CLIN ORAL IMPLAN RES, V13, P203, DOI 10.1034/j.1600-0501.2002.130211.x
   Gao CJ, 2007, J BIOMAT SCI-POLYM E, V18, P799, DOI 10.1163/156856207781367710
   Ginebra MP, 2006, J CONTROL RELEASE, V113, P102, DOI 10.1016/j.jconrel.2006.04.007
   Gu QL, 2012, PHARMACOGN MAG, V8, P202, DOI 10.4103/0973-1296.99285
   Guarnieri R, 2006, INT J PERIODONT REST, V26, P79
   Guarnieri R, 2004, J PERIODONTOL, V75, P902, DOI 10.1902/jop.2004.75.6.902
   Hak DJ, 2007, J AM ACAD ORTHOP SUR, V15, P525, DOI 10.5435/00124635-200709000-00003
   Handschel J, 2002, BIOMATERIALS, V23, P1689, DOI 10.1016/S0142-9612(01)00296-4
   Hawkins AM, 2011, J APPL POLYM SCI, V122, P1420, DOI 10.1002/app.34093
   Hawkins AM, 2009, PHARM RES-DORD, V26, P667, DOI 10.1007/s11095-008-9804-z
   Hesaraki S, 2009, J BIOMED MATER RES B, V91B, P651, DOI 10.1002/jbm.b.31441
   Hitti RA, 2011, OPEN PATHOL J, V5, P33
   Jamali A, 2002, CALCIFIED TISSUE INT, V71, P172, DOI 10.1007/s00223-001-1087-x
   Karadag E, 2002, POLYM BULL, V48, P299, DOI 10.1007/s00289-002-0029-8
   KENLEY RA, 1993, PHARMACEUT RES, V10, P1393, DOI 10.1023/A:1018902720816
   Kenny SM, 2003, J MATER SCI-MATER M, V14, P923, DOI 10.1023/A:1026394530192
   Kim SY, 2012, J IND ENG CHEM, V18, P128, DOI 10.1016/j.jiec.2011.11.001
   Lewis KN, 2006, J MATER SCI-MATER M, V17, P531, DOI 10.1007/s10856-006-8936-0
   Ozaki K, 2000, BIOCHEM PHARMACOL, V59, P1577, DOI 10.1016/S0006-2952(00)00277-X
   Pecora G, 1997, ORAL SURG ORAL MED O, V84, P424, DOI 10.1016/S1079-2104(97)90043-3
   Shimazu C, 2006, J ORAL REHABIL, V33, P609, DOI 10.1111/j.1365-2842.2005.01593.x
   Simion M, 2007, CLIN ORAL IMPLAN RES, V18, P620, DOI 10.1111/j.1600-0501.2007.01389.x
   Strietzel FP, 2007, CLIN ORAL IMPLAN RES, V18, P743, DOI 10.1111/j.1600-0501.2007.01416.x
   Tamimi F, 2009, BIOMATERIALS, V30, P6318, DOI 10.1016/j.biomaterials.2009.07.049
   Tay BKB, 1999, ORTHOP CLIN N AM, V30, P615, DOI 10.1016/S0030-5898(05)70114-0
   Thomas Mark V, 2005, J Long Term Eff Med Implants, V15, P599
   Thomas MV, 2009, J BIOMED MATER RES B, V88B, P597, DOI 10.1002/jbm.b.31269
   Triplett RG, 1996, J ORAL MAXIL SURG, V54, P486, DOI 10.1016/S0278-2391(96)90126-3
   Urban RM, 2007, CLIN ORTHOP RELAT R, P110, DOI 10.1097/BLO.0b013e318059b902
   Wattamwar PP, 2012, ACTA BIOMATER, V8, P2529, DOI 10.1016/j.actbio.2012.03.022
   Yamamoto M, 2003, BIOMATERIALS, V24, P4375, DOI 10.1016/S0142-9612(03)00337-5
   Zhang Y, 2002, J BIOMED MATER RES, V62, P378, DOI 10.1002/jbm.10312
   Zhou WJ, 1996, J APPL POLYM SCI, V62, P911, DOI 10.1002/(SICI)1097-4628(19961107)62:6<911::AID-APP7>3.3.CO;2-G
NR 39
TC 8
Z9 10
U1 0
U2 42
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1751-6161
J9 J MECH BEHAV BIOMED
JI J. Mech. Behav. Biomed. Mater.
PD OCT
PY 2013
VL 26
BP 43
EP 53
DI 10.1016/j.jmbbm.2013.05.021
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 198NP
UT WOS:000322929900005
PM 23811276
OA green_accepted
DA 2018-03-20
ER

PT J
AU Song, ES
   Jang, H
   Guo, HF
   Juliano, MA
   Juliano, L
   Morris, AJ
   Galperin, E
   Rodgers, DW
   Hersh, LB
AF Song, Eun Suk
   Jang, Hyein
   Guo, Hou-Fu
   Juliano, Maria A.
   Juliano, Luiz
   Morris, Andrew J.
   Galperin, Emilia
   Rodgers, David W.
   Hersh, Louis B.
TI Inositol phosphates and phosphoinositides activate insulin-degrading
   enzyme, while phosphoinositides also mediate binding to endosomes
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE insulin-degrading enzyme; inositols; phosphatidylinositols; activation;
   subcellular localization
ID GENOME-WIDE ASSOCIATION; AMYLOID-BETA PEPTIDE; IN-VIVO;
   ALZHEIMER-DISEASE; RISK LOCI; RAT-LIVER; PROTEIN; DEGRADATION; CELLS;
   INSULYSIN
AB Insulin-degrading enzyme (IDE) hydrolyzes bioactive peptides, including insulin, amylin, and the amyloid beta peptides. Polyanions activate IDE toward some substrates, yet an endogenous polyanion activator has not yet been identified. Here we report that inositol phosphates (InsPs) and phosphatdidylinositol phosphates (PtdInsPs) serve as activators of IDE. InsPs and PtdInsPs interact with the polyanion-binding site located on an inner chamber wall of the enzyme. InsPs activate IDE by up to similar to 95-fold, affecting primarily V-max. The extent of activation and binding affinity correlate with the number of phosphate groups on the inositol ring, with phosphate positional effects observed. IDE binds PtdInsPs from solution, immobilized on membranes, or presented in liposomes. Interaction with PtdInsPs, likely PtdIns(3)P, plays a role in localizing IDE to endosomes, where the enzyme reportedly encounters physiological substrates. Thus, InsPs and PtdInsPs can serve as endogenous modulators of IDE activity, as well as regulators of its intracellular spatial distribution.
C1 [Song, Eun Suk; Jang, Hyein; Guo, Hou-Fu; Galperin, Emilia; Rodgers, David W.; Hersh, Louis B.] Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA.
   [Juliano, Maria A.; Juliano, Luiz] Univ Fed Sao Paulo, Escola Paulista Med, Dept Biophys, BR-04044020 Sao Paulo, Brazil.
   [Morris, Andrew J.] Univ Kentucky, Coll Med, Div Cardiovasc Med, Lexington, KY 40536 USA.
   [Rodgers, David W.; Hersh, Louis B.] Univ Kentucky, Struct Biol Ctr, Lexington, KY 40536 USA.
RP Rodgers, DW; Hersh, LB (reprint author), Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA.; Rodgers, DW; Hersh, LB (reprint author), Univ Kentucky, Struct Biol Ctr, Lexington, KY 40536 USA.
EM david.rodgers@uky.edu; lhersh@uky.edu
OI Guo, Hou-Fu/0000-0002-3659-9399
FU National Institutes of Health [P20 GM103486, GM 11787, NS38041,
   GM113087]; American Cancer Society [RSG-14-172-01-CSM]; American Heart
   Association [15PRE25090207]; National Science Foundation [IIA-1355438];
   Fundacao de Amparo a Pesquisado Estado de Sao Paulo [12/50191-4R];
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   [443978-2014-0, 467478-2014-7]
FX We thank Dr. A. Saiardi for providing the isomer of InsP7 used in this
   study and acknowledge the use of facilities at the University of
   Kentucky Center for Structural Biology and the Center for Molecular
   Medicine Protein Core (supported by National Institutes of Health Grant
   P20 GM103486). This work was supported by National Institutes of Health
   grants GM 11787 (to L.B.H.), NS38041 (to D.W.R.), GM113087 (to E.G.);
   American Cancer Society Grant RSG-14-172-01-CSM (to E.G.); American
   Heart Association Grant 15PRE25090207 (to H.J.); and National Science
   Foundation Grant IIA-1355438 (to D.W.R.). Part of this work was
   supported by the Fundacao de Amparo a Pesquisado Estado de Sao Paulo
   (Project 12/50191-4R) and the Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (Projects 443978-2014-0 and 467478-2014-7).
CR Abdul-Hay SO, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020818
   Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925
   ANANTHAPADMANABHAN KP, 1985, LANGMUIR, V1, P352, DOI 10.1021/la00063a015
   AUTHIER F, 1995, P NATL ACAD SCI USA, V92, P3859, DOI 10.1073/pnas.92.9.3859
   Azevedo C, 2010, METHODS MOL BIOL, V645, P73, DOI 10.1007/978-1-60327-175-2_5
   Balla T, 2013, PHYSIOL REV, V93, P1019, DOI 10.1152/physrev.00028.2012
   Barenholz Y., 1993, LIPOSOME TECHNOLOGY, VI, P527
   Barker CJ, 2004, BIOCHEM J, V380, P465, DOI 10.1042/BJ20031872
   Behnia R, 2005, NATURE, V438, P597, DOI 10.1038/nature04397
   Bennett RG, 2003, J ENDOCRINOL, V177, P399, DOI 10.1677/joe.0.1770399
   BERGERON JJM, 1985, ANNU REV PHYSIOL, V47, P383
   Bissig C, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a016816
   Bulloj A, 2010, J ALZHEIMERS DIS, V19, P79, DOI 10.3233/JAD-2010-1206
   Burd C., 2014, COLD SPRING HARB PER, V6, DOI DOI 10.1101/CSHPERSPECT.A016774
   Buser CA, 1998, METH MOL B, V84, P267
   Chakraborty A, 2010, CELL, V143, P897, DOI 10.1016/j.cell.2010.11.032
   Costes SV, 2004, BIOPHYS J, V86, P3993, DOI [10.1529/biophysj.103.038422, 10.1529/biophysi.103.038422]
   Csuhai E, 1999, ANAL BIOCHEM, V269, P149, DOI 10.1006/abio.1999.4033
   Currinn H, 2016, BIOCHEM SOC T, V44, P185, DOI 10.1042/BST20150179
   de Araujo Mariana Eca Guimaraes, 2008, V424, P317, DOI 10.1007/978-1-60327-064-9_25
   Deprez-Poulain R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9250
   DUCKWORTH WC, 1994, J BIOL CHEM, V269, P24575
   Duckworth WC, 1998, ENDOCR REV, V19, P608, DOI 10.1210/er.19.5.608
   Durham TB, 2015, J BIOL CHEM, V290, P20044, DOI 10.1074/jbc.M115.638205
   Edbauer D, 2002, J BIOL CHEM, V277, P13389, DOI 10.1074/jbc.M111571200
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Falguieres T, 2009, EXP CELL RES, V315, P1567, DOI 10.1016/j.yexcr.2008.12.006
   Farris W, 2003, P NATL ACAD SCI USA, V100, P4162, DOI 10.1073/pnas.0230450100
   Fernandez-Gamba A, 2009, CURR PHARM DESIGN, V15, P3644, DOI 10.2174/138161209789271799
   Glebov K, 2011, J BIOL CHEM, V286, P22711, DOI 10.1074/jbc.C110.217893
   GOLDFINE ID, 1984, DIABETES, V33, P64, DOI 10.2337/diabetes.33.1.64
   Grasso G, 2015, BIOPHYS CHEM, V203, P33, DOI 10.1016/j.bpc.2015.05.010
   Guo Q, 2010, J MOL BIOL, V395, P430, DOI 10.1016/j.jmb.2009.10.072
   HAMEL FG, 1991, DIABETES, V40, P436, DOI 10.2337/diabetes.40.4.436
   HAMEL FG, 1988, J BIOL CHEM, V263, P6703
   Hersh LB, 2006, CELL MOL LIFE SCI, V63, P2432, DOI 10.1007/s00018-006-6238-9
   Hu YB, 2015, TRANSL NEURODEGENER, V4, DOI 10.1186/s40035-015-0041-1
   Illies C, 2007, SCIENCE, V318, P1299, DOI 10.1126/science.1146824
   Jang ER, 2015, J CELL SCI, V128, P4428, DOI 10.1242/jcs.177543
   Kim M, 2007, J BIOL CHEM, V282, P7825, DOI 10.1074/jbc.M609168200
   KIRSCHNER RJ, 1983, J BIOL CHEM, V258, P967
   Kowal J, 2014, CURR OPIN CELL BIOL, V29, P116, DOI 10.1016/j.ceb.2014.05.004
   Krieger E, 2002, BIOINFORMATICS, V18, P315, DOI 10.1093/bioinformatics/18.2.315
   KUO WL, 1994, J BIOL CHEM, V269, P22599
   Kutateladze TG, 2012, CURR TOP MICROBIOL, V362, P111, DOI 10.1007/978-94-007-5025-8_6
   Kutateladze TG, 2010, NAT CHEM BIOL, V6, P507, DOI [10.1038/NCHEMBIO.390, 10.1038/nchembio.390]
   Leissring MA, 2004, BIOCHEM J, V383, P439, DOI 10.1042/BJ20041081
   Leissring MA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010504
   Li QX, 2006, CELL, V127, P305, DOI 10.1016/j.cell.2006.08.046
   Liang WG, 2015, J MOL BIOL, V427, P1345, DOI 10.1016/j.jmb.2015.01.012
   Liu XM, 2015, MOL CELL, V59, P1035, DOI 10.1016/j.molcel.2015.07.034
   Maianti JP, 2014, NATURE, V511, P94, DOI 10.1038/nature13297
   Manning BD, 2010, CELL, V143, P861, DOI 10.1016/j.cell.2010.11.040
   Manolopoulou M, 2009, J BIOL CHEM, V284, P14177, DOI 10.1074/jbc.M900068200
   Miller BC, 2003, P NATL ACAD SCI USA, V100, P6221, DOI 10.1073/pnas.1031520100
   Moriarty NW, 2009, ACTA CRYSTALLOGR D, V65, P1074, DOI 10.1107/S0907444909029436
   Morita M, 2000, CELL STRUCT FUNCT, V25, P309, DOI 10.1247/csf.25.309
   Nixon RA, 2005, NEUROBIOL AGING, V26, P373, DOI 10.1016/j.neurobiolaging.2004.09.018
   Noinaj N, 2012, J BIOL CHEM, V287, P48, DOI 10.1074/jbc.M111.264614
   Noinaj N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020864
   Qiu WQ, 2006, NEUROBIOL AGING, V27, P190, DOI 10.1016/j.neurobiolaging.2005.01.004
   Radulescu RT, 2010, BIOCHEM BIOPH RES CO, V395, P196, DOI 10.1016/j.bbrc.2010.03.157
   Ralat LA, 2011, J MOL BIOL, V406, P454, DOI 10.1016/j.jmb.2010.12.026
   Ralat LA, 2011, J BIOL CHEM, V286, P4670, DOI 10.1074/jbc.M110.173252
   Sahu R, 2011, DEV CELL, V20, P131, DOI 10.1016/j.devcel.2010.12.003
   Saiardi A, 2004, SCIENCE, V306, P2101, DOI 10.1126/science.1103344
   SASAKAWA N, 1995, BIOCHEM PHARMACOL, V50, P137, DOI 10.1016/0006-2952(95)00059-9
   Sbardella D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132455
   Shen YQ, 2006, NATURE, V443, P870, DOI 10.1038/nature05143
   Shewan A, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004796
   Sladek R, 2007, NATURE, V445, P881, DOI 10.1038/nature05616
   Song ES, 2004, J BIOL CHEM, V279, P54216, DOI 10.1074/jbc.M411177200
   Song ES, 2003, J BIOL CHEM, V278, P49789, DOI 10.1074/jbc.M308983200
   Song ES, 2001, J BIOL CHEM, V276, P1152, DOI 10.1074/jbc.M008702200
   Song ES, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133114
   Steneberg P, 2013, DIABETES, V62, P2004, DOI 10.2337/db12-1045
   Tamboli IY, 2010, J BIOL CHEM, V285, P37405, DOI 10.1074/jbc.M110.149468
   Tarasoff-Conway JM, 2015, NAT REV NEUROL, V11, P457, DOI 10.1038/nrneurol.2015.119
   Trikha S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073080
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Tsui MM, 2010, ADV ENZYME REGUL, V50, P324, DOI 10.1016/j.advenzreg.2009.12.002
   Tundo GR, 2013, J BIOL CHEM, V288, P2281, DOI 10.1074/jbc.M112.393108
   Wang ST, 2015, J GERIATR PSYCH NEUR, V28, P94, DOI 10.1177/0891988714554707
   Wilson MSC, 2013, BIOCHEM J, V452, P369, DOI 10.1042/BJ20130118
   Yao HB, 2006, ARCH BIOCHEM BIOPHYS, V451, P175, DOI 10.1016/j.abb.2006.04.011
   YOKONO K, 1982, ENDOCRINOLOGY, V111, P1102, DOI 10.1210/endo-111-4-1102
   Zeggini E, 2007, SCIENCE, V316, P1336, DOI 10.1126/science.1142364
   Zhao J, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-4
   Zolov SN, 2012, P NATL ACAD SCI USA, V109, P17472, DOI 10.1073/pnas.1203106109
NR 89
TC 2
Z9 2
U1 3
U2 8
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 4
PY 2017
VL 114
IS 14
BP E2826
EP E2835
DI 10.1073/pnas.1613447114
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EQ5YM
UT WOS:000398159000006
PM 28325868
OA green_published
DA 2018-03-20
ER

PT J
AU Authimoolam, SP
   Puleo, DA
   Dziubla, TD
AF Authimoolam, Sundar P.
   Puleo, David A.
   Dziubla, Thomas D.
TI Affinity Based Multilayered Polymeric Self-Assemblies for Oral Wound
   Applications
SO ADVANCED HEALTHCARE MATERIALS
LA English
DT Article
DE anti-adhesion; barrier stability; biotin-streptavidin; layer-by-layer;
   oral mucositis
ID DRUG-DELIVERY; MUCOSITIS; PROTEINS; ADSORPTION; SURFACES; CARBODIIMIDE;
   ENHANCEMENT; PERFORMANCE; STRATEGIES; MANAGEMENT
AB Oral mucositis, a painful and debilitating ulcerative wound condition, is a frequently occurring complication following chemo- and/or radiotherapy. While the current standards of therapy (e.g., gels and mouth rinses) provide temporary relief, there is still an unmet need for a robust, long acting barrier that can provide lubricating protection in oral wounds, thereby enhancing the wound healing response. It is proposed that an affinity based layer-by-layer (LBL) self-assembly that can be administered as a series of mouth rinses could permit the formation of protective barriers, providing a modular approach to regenerative oral therapy. In this study, biotinylated poly(acrylic acid) was synthesized for developing LBL assemblies using biotin-streptavidin affinity linkages. To explore the ability of developed LBL assemblies to potentially resist the harsh intraoral environment, in vitro chemical and ex vivo mechanical tests were performed. The stability results demonstrated significant LBL barrier stability with wear resistance. From statistical analyses, it was deduced that polymer MW and the number of LBL layers contributed significantly to chemical barrier stability. Also, the extent of biotin conjugation played a key role for LBL development and in mechanical barrier stability. Thus, the proposed affinity based LBLs with their excellent barrier properties offer a modular treatment approach in oral mucosal injuries.
C1 [Authimoolam, Sundar P.; Dziubla, Thomas D.] Univ Kentucky, Coll Engn, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Puleo, David A.] Univ Kentucky, Coll Engn, Ctr Biomed Engn, Wenner Gren Lab, Lexington, KY 40506 USA.
RP Dziubla, TD (reprint author), Univ Kentucky, Coll Engn, Dept Chem & Mat Engn, 177 F Paul Anderson Tower, Lexington, KY 40506 USA.
EM dziubla@engr.uky.edu
FU National Institutes of Health [R03 DE019496]
FX The authors would like to thank Mr. Ravinder K. Garlapalli (Department
   of Chemical & Materials Engineering, University of Kentucky) for AFM
   imaging of LBL assemblies and Mr. Sandeep K. Ramineni (Center for
   Biomedical Engineering, University of Kentucky) for his assistance with
   Bose Electroforce equipment during adhesion tests. The authors would
   also like to thank Dr. Nihar Shah for his stimulating discussions and
   advice on analysis. The authors also give thanks to Cardiac Rhythm
   Laboratory (Center for Biomedical Engineering, University of Kentucky)
   for their generous donation of porcine skin samples. This work was
   funded by National Institutes of Health (Grant R03 DE019496).
CR ANDRADE JD, 1992, PURE APPL CHEM, V64, P1777, DOI 10.1351/pac199264111777
   BESSELINK GAJ, 1993, APPL BIOCHEM BIOTECH, V43, P227, DOI 10.1007/BF02916455
   Cernuda-Morollon E, 2001, J BIOL CHEM, V276, P35530, DOI 10.1074/jbc.M104518200
   Christiano SP, 2003, J IND MICROBIOL BIOT, V30, P13, DOI 10.1007/s10295-002-0003-3
   Duncan M, 2003, ALIMENT PHARM THER, V18, P853, DOI 10.1046/j.0269-2813.2003.01784x
   Epstein Joel B, 2004, Semin Oncol Nurs, V20, P30
   Farrington M., 2010, ONCOLOGY NURSE ADVIS, P24
   GRABAREK Z, 1990, ANAL BIOCHEM, V185, P131, DOI 10.1016/0003-2697(90)90267-D
   GREEN NM, 1965, BIOCHEM J, V94, pC23, DOI 10.1042/bj0940023C
   Haddleton D. M., 2011, J POLYM SCI POL CHEM, V49, P1163
   Izumi K, 2003, INT J ORAL MAX SURG, V32, P188, DOI 10.1054/ijom.2002.0365
   JENSEN EV, 1959, SCIENCE, V130, P1319, DOI 10.1126/science.130.3385.1319
   Jeyachandran YL, 2010, J COLLOID INTERF SCI, V341, P136, DOI 10.1016/j.jcis.2009.09.007
   Karmali PP, 2009, NANOMED-NANOTECHNOL, V5, P73, DOI 10.1016/j.nano.2008.07.007
   Karthaus M, 1999, BONE MARROW TRANSPL, V24, P1095, DOI 10.1038/sj.bmt.1702024
   KING CA, 1968, BIOCHIM BIOPHYS ACTA, V154, P269, DOI 10.1016/0005-2795(68)90040-8
   Lavalle P, 2005, J MEMBRANE SCI, V253, P49, DOI 10.1016/j.memsci.2004.12.033
   Lee JY, 2007, ORAL DIS, V13, P550, DOI 10.1111/j.1601-0825.2006.01332.x
   Liu YS, 1999, P NATL ACAD SCI USA, V96, P14694, DOI 10.1073/pnas.96.26.14694
   Medley JM, 2011, J BIOMAT SCI-POLYM E, V22, P1363, DOI 10.1163/092050610X508419
   Medly J, 2011, GASTROENTEROLOGY, V140, pS445
   MEYER W, 1982, J ANAT, V134, P139
   MUELLER BA, 1995, J PAIN SYMPTOM MANAG, V10, P510, DOI 10.1016/0885-3924(95)00064-6
   Needleman IG, 1997, J CLIN PERIODONTOL, V24, P394, DOI 10.1111/j.1600-051X.1997.tb00203.x
   NIMERI G, 1994, J BIOMAT SCI-POLYM E, V6, P573
   Nonzee NJ, 2009, CANCER, V115, P2805, DOI 10.1002/cncr.24097
   Oguchi M, 1998, INT J RADIAT ONCOL, V40, P1033, DOI 10.1016/S0360-3016(97)00903-6
   Peters D, 2009, P NATL ACAD SCI USA, V106, P9815, DOI 10.1073/pnas.0903369106
   Peterson DE, 2009, ANN ONCOL, V20, P174, DOI 10.1093/annonc/mdp165
   Picart C, 2001, LANGMUIR, V17, P7414, DOI 10.1021/la010848g
   Reimhult K, 2008, LANGMUIR, V24, P8695, DOI 10.1021/la800224s
   Saadeh CE, 2005, PHARMACOTHERAPY, V25, P540, DOI 10.1592/phco.25.4.540.61035
   Sankar V, 2011, ORAL DIS, V17, P73, DOI 10.1111/j.1601-0825.2011.01793.x
   Shuvaev Vladimir V., 2004, V283, P3
   Sonis ST, 2011, ANTI-CANCER DRUG, V22, P607, DOI 10.1097/CAD.0b013e3283462086
   Sonis ST, 2009, ORAL ONCOL, V45, P1015, DOI 10.1016/j.oraloncology.2009.08.006
   STAROS JV, 1986, ANAL BIOCHEM, V156, P220, DOI 10.1016/0003-2697(86)90176-4
   Svensson O, 2006, J COLLOID INTERF SCI, V299, P608, DOI 10.1016/j.jcis.2006.02.027
   TIMKOVICH R, 1977, ANAL BIOCHEM, V79, P135, DOI 10.1016/0003-2697(77)90387-6
   Xu YY, 2009, J WUHAN UNIV TECHNOL, V24, P619, DOI 10.1007/s11595-009-4619-2
   Yamamura K, 1998, J BIOMED MATER RES, V43, P313, DOI 10.1002/(SICI)1097-4636(199823)43:3<313::AID-JBM12>3.0.CO;2-G
NR 41
TC 4
Z9 4
U1 2
U2 22
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2192-2640
EI 2192-2659
J9 ADV HEALTHC MATER
JI Adv. Healthc. Mater.
PD JUL
PY 2013
VL 2
IS 7
BP 983
EP 992
DI 10.1002/adhm.201200375
PG 10
WC Engineering, Biomedical; Nanoscience & Nanotechnology; Materials
   Science, Biomaterials
SC Engineering; Science & Technology - Other Topics; Materials Science
GA 267VX
UT WOS:000328127500009
PM 23335358
OA green_accepted
DA 2018-03-20
ER

PT J
AU Rankin, SE
   Wu, QL
   Koganti, VR
AF Rankin, Stephen E.
   Wu, Qingliu
   Koganti, Venkat R.
TI PHYS 238-Tuning the properties of orthogonally oriented hexagonal
   mesoporous titania for photovoltaics
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
CT 235th American-Chemical-Society National Meeting
CY APR 06-10, 2008
CL New Orleans, LA
SP Amer Chem Soc
C1 [Rankin, Stephen E.; Wu, Qingliu] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Koganti, Venkat R.] Pfizer Global Res & Dev, Parenteral Ctr Emphasis, Groton, CT 06340 USA.
EM srankin@engr.uky.edu
RI wu, qingliu/C-7631-2012
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD APR 6
PY 2008
VL 235
MA 238-PHYS
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA 519OA
UT WOS:000271775109724
DA 2018-03-20
ER

PT J
AU Asato, CM
   Gonzalez-Estrella, J
   Jerke, AC
   Bang, SS
   Stone, JJ
   Gilcrease, PC
AF Asato, Caitlin M.
   Gonzalez-Estrella, Jorge
   Jerke, Amber C.
   Bang, Sookie S.
   Stone, James J.
   Gilcrease, Patrick C.
TI Batch anaerobic digestion of synthetic military base food waste and
   cardboard mixtures
SO BIORESOURCE TECHNOLOGY
LA English
DT Article
DE Solid waste; Specific methanogenic activity; Methane yield; Response
   surface methodology; Relative abundance
ID CO-DIGESTION; COMMUNITY; DATABASE; DEGRADATION; DIVERSITY; DYNAMICS;
   IMPACTS; IMPROVE; PROJECT
AB Austere US military bases typically dispose of solid wastes, including large fractions of food waste (FW) and corrugated cardboard (CCB), by open dumping, landfilling, or burning. Anaerobic digestion (AD) offers an opportunity to reduce pollution and recover useful energy. This study aimed to evaluate the rates and yields of AD for FW-CCB mixtures. Batch AD was analyzed at substrate concentrations of 1-50 g total chemical oxygen demand (COD) L-1 using response surface methodology. At low concentrations, higher proportions of FW were correlated with faster specific methanogenic activities and greater final methane yields; however, concentrations of FW >= 18.75 g COD L-1 caused inhibition. Digestion of mixtures with >= 75% CCB occurred slowly but achieved methane yields >70%. Greater shifts in microbial communities were observed at higher substrate concentrations. Statistical models of methane yield and specific methanogenic activity indicated that FW and CCB exhibited no considerable interactions as substrates for AD. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Asato, Caitlin M.; Gonzalez-Estrella, Jorge; Jerke, Amber C.; Bang, Sookie S.; Gilcrease, Patrick C.] South Dakota Sch Mines & Technol, Dept Chem & Biol Engn, Rapid City, SD 57701 USA.
   [Stone, James J.] South Dakota Sch Mines & Technol, Dept Civil & Environm Engn, Rapid City, SD 57701 USA.
RP Gilcrease, PC (reprint author), 501 East St Joseph St, Rapid City, SD 57701 USA.
EM patrick.gilcrease@sdsmt.edu
RI Gonzalez-Estrella, Jorge/B-1707-2013
OI Gonzalez-Estrella, Jorge/0000-0002-4873-0454
FU Air Force Civil Engineer Center (AFCEC) [FA4819-14-C-0004]
FX This material is based upon work supported by the Air Force Civil
   Engineer Center (AFCEC) under Contract No. FA4819-14-C-0004. The authors
   would like to thank Andrea Vargas Castano for her assistance in the
   laboratory and Dr. Glenn Johnson for his valuable comments.
CR Abbassi-Guendouz A, 2012, BIORESOURCE TECHNOL, V111, P55, DOI 10.1016/j.biortech.2012.01.174
   APHA, 2012, STANDARD METHODS EXA
   Astals S, 2014, BIORESOURCE TECHNOL, V169, P421, DOI 10.1016/j.biortech.2014.07.024
   BRAY RH, 1945, SOIL SCI, V59, P39, DOI 10.1097/00010694-194501000-00006
   Carucci G, 2005, J ENVIRON ENG-ASCE, V131, P1037, DOI 10.1061/(ASCE)0733-9372(2005)131:7(1037)
   De Vrieze J, 2012, BIORESOURCE TECHNOL, V112, P1, DOI 10.1016/j.biortech.2012.02.079
   DeSantis TZ, 2006, APPL ENVIRON MICROB, V72, P5069, DOI 10.1128/AEM.03006-05
   De Vos P, 2009, THE FIRMICUTES, V3
   Dowd SF, 2008, FOODBORNE PATHOG DIS, V5, P459, DOI 10.1089/fpd.2008.0107
   El-Mashad H. M., 2008, Biological Engineering, V1, P235
   ElFadel M, 1997, J ENVIRON MANAGE, V50, P1, DOI 10.1006/jema.1995.0131
   Garcia-Pena EI, 2011, BIORESOURCE TECHNOL, V102, P9447, DOI 10.1016/j.biortech.2011.07.068
   Garrity G, 2012, BERGEYS MANUAL SYSTE, V1
   Gerardi MH, 2003, MICROBIOLOGY ANAEROB
   Hess W. T., 1995, KIRK OTHMER ENCY CHE
   Ike M, 2010, BIORESOURCE TECHNOL, V101, P3952, DOI 10.1016/j.biortech.2010.01.028
   Jimenez J, 2014, BIOMASS BIOENERG, V71, P84, DOI 10.1016/j.biombioe.2014.10.023
   Krieg N.R., 2010, BACTEROIDETES SPIROC
   Maidak BL, 2001, NUCLEIC ACIDS RES, V29, P173, DOI 10.1093/nar/29.1.173
   MCGEEHAN SL, 1988, COMMUN SOIL SCI PLAN, V19, P493, DOI 10.1080/00103628809367953
   Medina V.F., 2011, WASTE HDB MANAGEMENT, P604
   Molinuevo-Salces B, 2010, BIORESOURCE TECHNOL, V101, P9479, DOI 10.1016/j.biortech.2010.07.093
   Mosier NS, 2002, BIOTECHNOL BIOENG, V79, P610, DOI 10.1002/bit.10316
   Noblis, 2013, SUST FORW OP BAS STR, P1
   NOIKE T, 1985, BIOTECHNOL BIOENG, V27, P1482, DOI 10.1002/bit.260271013
   O'Sullivan CA, 2005, BIOTECHNOL BIOENG, V92, P871, DOI 10.1002/bit.20669
   Sawatdeenarunat C, 2015, BIORESOURCE TECHNOL, V178, P178, DOI 10.1016/j.biortech.2014.09.103
   Sayers EW, 2009, NUCLEIC ACIDS RES, V37, pD5, DOI 10.1093/nar/gkn741
   Sluiter A, 2012, DETERMINATION STRUCT
   Stouter S.D., 2006, REDUCING SOLID WASTE, P42
   USALIA, 2013, USA CENTR AR RESP CO
   Zhang CS, 2014, RENEW SUST ENERG REV, V38, P383, DOI 10.1016/j.rser.2014.05.038
   Zhang Y, 2012, BIORESOURCE TECHNOL, V114, P168, DOI 10.1016/j.biortech.2012.03.040
   Zhou Q, 2014, BIORESOURCE TECHNOL, V166, P31, DOI 10.1016/j.biortech.2014.04.074
   Ziganshin AM, 2013, APPL MICROBIOL BIOT, V97, P5161, DOI 10.1007/s00253-013-4867-0
NR 35
TC 9
Z9 9
U1 0
U2 14
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0960-8524
EI 1873-2976
J9 BIORESOURCE TECHNOL
JI Bioresour. Technol.
PD SEP
PY 2016
VL 216
BP 894
EP 903
DI 10.1016/j.biortech.2016.06.033
PG 10
WC Agricultural Engineering; Biotechnology & Applied Microbiology; Energy &
   Fuels
SC Agriculture; Biotechnology & Applied Microbiology; Energy & Fuels
GA DQ9UX
UT WOS:000379555900112
PM 27323241
DA 2018-03-20
ER

PT J
AU Lynch, AL
   Bhattacharyya, D
AF Lynch, Andrew L.
   Bhattacharyya, Dibakar
TI PRES 1-Functionalized polystyrene resin for enhanced oxidation of
   trichloroethylene in near-neutral pH systems
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
CT 235th American-Chemical-Society National Meeting
CY APR 06-10, 2008
CL New Orleans, LA
C1 [Lynch, Andrew L.; Bhattacharyya, Dibakar] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM andrewleelynch@gmail.com; db@engr.uky.edu
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD APR 6
PY 2008
VL 235
MA 1-PRES
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA 519XJ
UT WOS:000271802801061
DA 2018-03-19
ER

PT J
AU Wydra, RJ
   Rychahou, PG
   Evers, BM
   Anderson, KW
   Dziubla, TD
   Hilt, JZ
AF Wydra, Robert J.
   Rychahou, Piotr G.
   Evers, B. Mark
   Anderson, Kimberly W.
   Dziubla, Thomas D.
   Hilt, J. Zach
TI The role of ROS generation from magnetic nanoparticles in an alternating
   magnetic field on cytotoxicity
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Iron oxide; Glyconanoparticles; Magnetically mediated energy delivery;
   Reactive oxygen species
ID IRON-OXIDE NANOPARTICLES; CANCER STEM-CELLS; OXIDATIVE STRESS;
   REMOTE-CONTROL; FREE-RADICALS; HYPERTHERMIA; GLYCONANOPARTICLES;
   BIOMEDICINE; METASTASES; APOPTOSIS
AB Monosaccharide coated iron oxide nanoparticles were developed to selectively target colon cancer cell lines for magnetically mediated energy delivery therapy. The nanoparticles were prepared using a coupling reaction to attach the glucose functional group to the iron oxide core, and functionality was confirmed with physicochemical characterization techniques. The targeted nanoparticles were internalized into CT26 cells at a greater extent than non-targeted nanoparticles, and the nanoparticles were shown to be localized within lysosomes. Cells with internalized nanoparticles were exposed to an AMF to determine the potential to delivery therapy. Cellular ROS generation and apoptotic cell death was enhanced with field exposure. The nanoparticle coatings inhibit the Fenton-like surface generation of ROS suggesting a thermal or mechanical effect is more likely the source of the intracellular effect, unless the nanoparticle coating is unstable in the cellular environment.
   Statement of Significance
   This is the first study to assess glucose coated MNPs for the delivery of MagMED therapy. With exposure of an AMF, the glucose-coated nanoparticles displayed a significant increase in cellular ROS and apoptotic cell death with no measurable increase in media temperature. To determine the mechanism of toxicity, we investigated the surface generation of ROS through Fenton-like chemistry. The coated systems displayed negligible ROS generation compared to uncoated nanoparticles. These observations suggest the cellular ROS measured is attributed to a thermal or mechanical effect of the internalized nanoparticles. In summary, this manuscript reports on some new insights as to the mechanism of MagMED therapies, which are of high interest to the biomaterials and cancer nanomedicine fields. (C) 2015 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Wydra, Robert J.; Anderson, Kimberly W.; Dziubla, Thomas D.; Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Rychahou, Piotr G.; Evers, B. Mark] Univ Kentucky, Dept Surg, Coll Med, Lexington, KY 40506 USA.
   [Evers, B. Mark] Univ Kentucky, Markey Canc Ctr, Lexington, KY 40506 USA.
RP Hilt, JZ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 F Paul Anderson Tower, Lexington, KY 40506 USA.
EM hilt@engr.uky.edu
FU NCI-CNTC; National Cancer Institute [R25CA153954]
FX RW acknowledges the financial support from a NCI-CNTC pre-doctoral
   traineeship and the project described was supported by Grant No.
   R25CA153954 from the National Cancer Institute. The content is solely
   the responsibility of the authors and does not necessarily represent the
   official views of the National Cancer Institute or the National
   Institutes of Health.
CR Amstad E, 2011, NANO LETT, V11, P1664, DOI 10.1021/nl2001499
   Berry C. C., 2009, J PHYS D, V42, P9
   Cochran DB, 2013, BIOMATERIALS, V34, P9615, DOI 10.1016/j.biomaterials.2013.08.025
   Creixell M, 2011, ACS NANO, V5, P7124, DOI 10.1021/nn201822b
   De la Fuente JM, 2006, BBA-GEN SUBJECTS, V1760, P636, DOI 10.1016/j.bbagen.2005.12.001
   Domenech M, 2013, ACS NANO, V7, P5091, DOI 10.1021/nn4007048
   El-Boubbou K, 2011, CURR MED CHEM, V18, P2060, DOI 10.2174/092986711795656144
   Frimpong RA, 2010, NANOMEDICINE-UK, V5, P1401, DOI 10.2217/NNM.10.114
   Frimpong RA, 2010, J MAGN MAGN MATER, V322, P326, DOI 10.1016/j.jmmm.2009.09.050
   Geng F., 2011, NANOTECHNOLOGY, V22
   Ghosh P, 2012, J CHEM TECHNOL BIOT, V87, P914, DOI 10.1002/jctb.3699
   Hilger I, 2006, J PHYS-CONDENS MAT, V18, pS2951, DOI 10.1088/0953-8984/18/38/S28
   Huang H, 2010, NAT NANOTECHNOL, V5, P602, DOI [10.1038/NNANO.2010.125, 10.1038/nnano.2010.125]
   Ito A, 2005, J BIOSCI BIOENG, V100, P1, DOI 10.1263/jbb.100.1
   Johansson AC, 2010, APOPTOSIS, V15, P527, DOI 10.1007/s10495-009-0452-5
   Joshi-Barr S, 2014, ANTIOXID REDOX SIGN, V21, P730, DOI 10.1089/ars.2013.5754
   Keblinski P., 2006, J APPL PHYS, P100
   Kievit FM, 2012, ACS NANO, V6, P2591, DOI 10.1021/nn205070h
   Klein S, 2012, BIOCHEM BIOPH RES CO, V425, P393, DOI 10.1016/j.bbrc.2012.07.108
   Kozissnik B, 2013, INT J HYPERTHER, V29, P706, DOI 10.3109/02656736.2013.837200
   Kruse AM, 2014, ACTA BIOMATER, V10, P2622, DOI 10.1016/j.actbio.2014.01.025
   Li X, 2011, BIOMATERIALS, V32, P2540, DOI 10.1016/j.biomaterials.2010.12.031
   Li X, 2014, J MATER CHEM B, V2, P5569, DOI 10.1039/c4tb00852a
   lyer A. K., 2006, DRUG DISCOV TODAY, V11, P812, DOI DOI 10.1016/J.DRUDIS.2006.07.005
   Malvindi M. A., 2014, PLOS ONE, V9
   Marradi M, 2013, CHEM SOC REV, V42, P4728, DOI 10.1039/c2cs35420a
   Moros M, 2012, ACS NANO, V6, P1565, DOI 10.1021/nn204543c
   Moros M, 2010, NANOSCALE, V2, P1746, DOI 10.1039/c0nr00104j
   Naqvi S, 2010, INT J NANOMED, V5, P983, DOI 10.2147/IJN.S13244
   Persson HL, 2006, IUBMB LIFE, V58, P395, DOI 10.1080/15216540600755998
   Persson HL, 2005, TOXICOL LETT, V159, P124, DOI 10.1016/j.toxlet.2005.05.002
   Polo-Corrales L., 2012, J APPL PHYS, V111, P3
   Rabin Y, 2002, INT J HYPERTHER, V18, P194, DOI 10.1080/02656730110116713
   Sadhukha T, 2013, MOL PHARMACEUT, V10, P1432, DOI 10.1021/mp400015b
   Schieber M, 2014, CURR BIOL, V24, pR453, DOI 10.1016/j.cub.2014.03.034
   Schmidtke C, 2013, LANGMUIR, V29, P12593, DOI 10.1021/la402826f
   Seton-Rogers S, 2009, NAT REV CANCER, V9, P147, DOI 10.1038/nrc2614
   Shan XH, 2012, EUR J RADIOL, V81, P95, DOI 10.1016/j.ejrad.2011.03.013
   Singh N, 2009, BIOMATERIALS, V30, P3891, DOI 10.1016/j.biomaterials.2009.04.009
   Sun C, 2008, ADV DRUG DELIVER REV, V60, P1252, DOI 10.1016/j.addr.2008.03.018
   Sunderland CJ, 2006, DRUG DEVELOP RES, V67, P70, DOI 10.1002/ddr.20069
   Valko M, 2006, CHEM-BIOL INTERACT, V160, P1, DOI 10.1016/j.cbi.2005.12.009
   Voinov MA, 2011, J AM CHEM SOC, V133, P35, DOI 10.1021/ja104683w
   Wang B, 2013, J PHYS CHEM C, V117, P383, DOI 10.1021/jp3101392
   Wu XY, 2010, INT J NANOMED, V5, P385
   Wydra RJ, 2015, RSC ADV, V5, P18888, DOI 10.1039/c4ra13564d
   Xiong F, 2012, PHARM RES-DORDR, V29, P1087, DOI 10.1007/s11095-011-0653-9
   Yu M, 2012, INT J MOL SCI, V13, P5554, DOI 10.3390/ijms13055554
   Zhang EM, 2014, ACS NANO, V8, P3192, DOI 10.1021/nn406302j
   Zhuang H, 2000, NUCL MED COMMUN, V21, P793, DOI 10.1097/00006231-200009000-00002
NR 50
TC 17
Z9 17
U1 9
U2 68
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742-7061
EI 1878-7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD OCT 1
PY 2015
VL 25
BP 284
EP 290
DI 10.1016/j.actbio.2015.06.037
PG 7
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA CS2WX
UT WOS:000361933800026
PM 26143604
OA green_accepted
DA 2018-03-19
ER

PT J
AU Jackson, KS
   Yeom, J
   Han, YM
   Bae, Y
   Ryou, C
AF Jackson, Karen S.
   Yeom, Jihyun
   Han, Youngmi
   Bae, Younsoo
   Ryou, Chongsuk
TI Preference toward a polylysine enantiomer in inhibiting prions
SO AMINO ACIDS
LA English
DT Article
DE Polylysine; Enantiomers; Prion; Inhibition; Plasminogen
ID POLY-D-LYSINE; BRANCHED POLYAMINES; CYCLIC AMPLIFICATION; RABBIT
   PLASMINOGEN; PROTEIN; CELLS; PROPAGATION; DELIVERY; CULTURE
AB Differential anti-prion activity of polylysine enantiomers was studied. Based on our recent discovery that poly-l-lysine (PLK) is a potent anti-prion agent, we investigated suppression of prions in cultured cells using poly-d-lysine (PDK). The results showed that PDK was more efficacious than PLK to inhibit prions. Protein misfolding cyclic amplification assay demonstrated improved efficacy of PDK in inhibiting plasminogen-mediated prion propagation, corresponding to the enantio-preference of PDK observed in cultured cells. Furthermore, our study demonstrated that polylysines formed a complex with plasminogen. These results propose to hypothesize a plausible mechanism that elicits prion inhibition by polylysine enantiomers.
C1 [Jackson, Karen S.] Univ Kentucky, Div Lab Anim Resources, Lexington, KY USA.
   [Yeom, Jihyun; Han, Youngmi; Ryou, Chongsuk] Univ Kentucky, Coll Med, Sanders Brown Ctr Aging, Lexington, KY 40536 USA.
   [Bae, Younsoo] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY USA.
   [Ryou, Chongsuk] Univ Kentucky, Coll Med, Dept Microbiol Immunol & Mol Genet, Lexington, KY USA.
   [Ryou, Chongsuk] Hanyang Univ, Coll Pharm, Dept Pharmacol, Ansan 426791, Gyeonggi Do, South Korea.
RP Ryou, C (reprint author), Hanyang Univ, Coll Pharm, Dept Pharmacol, 309 Pharm Bldg,55 Hanyangdaehak Ro, Ansan 426791, Gyeonggi Do, South Korea.
EM cryou2@hanyang.ac.kr
CR ARNOLD LJ, 1979, P NATL ACAD SCI USA, V76, P3246, DOI 10.1073/pnas.76.7.3246
   Bae Y, 2003, ANGEW CHEM INT EDIT, V42, P4640, DOI 10.1002/anie.200250653
   Banecerraf B, 1964, J EXP MED, V120, P955
   BUTLER DA, 1988, J VIROL, V62, P1558
   CLARKE MC, 1970, NATURE, V225, P100, DOI 10.1038/225100a0
   David JT, 1997, DRUG DISCOV TODAY, V2, P138
   GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031
   HATTON MWC, 1975, BIOCHIM BIOPHYS ACTA, V379, P504, DOI 10.1016/0005-2795(75)90157-9
   LANGELAND N, 1988, J GEN VIROL, V69, P1137, DOI 10.1099/0022-1317-69-6-1137
   Lim YB, 2010, BIOMATERIALS, V31, P2025, DOI 10.1016/j.biomaterials.2009.11.085
   Luo D, 2000, NAT BIOTECHNOL, V18, P33
   Mays CE, 2008, BRAIN RES, V1208, P170, DOI 10.1016/j.brainres.2008.02.103
   Mays CE, 2010, FASEB J, V24, P5102, DOI 10.1096/fj.10-163600
   Mays CE, 2009, BIOCHEM BIOPH RES CO, V388, P306, DOI 10.1016/j.bbrc.2009.07.163
   Park Sang-Hyun, 2004, Methods Mol Biol, V261, P155
   Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363
   Ryou C, 2003, LAB INVEST, V83, P837, DOI 10.1097/01.LAB.0000074919.08232.A2
   Ryou C, 2010, MOL ASPECTS INFECT D, P129
   Saleh M, 2010, MOL ASPECTS INFECT D, P151
   Ryou C, 2011, ENCY LIFE SCI, DOI [10.1002/9780470015902.a0000428.pub2, DOI 10.1002/9780470015902.A0000428.PUB2]
   Ryou C, 2007, J MICROBIOL BIOTECHN, V17, P1059
   Ryou C, 2011, BIOMATERIALS, V32, P3141, DOI 10.1016/j.biomaterials.2011.01.017
   Saborio GP, 2001, NATURE, V411, P810, DOI 10.1038/35081095
   SHIMA S, 1984, J ANTIBIOT, V37, P1449, DOI 10.7164/antibiotics.37.1449
   SODETZ JM, 1972, BIOCHEMISTRY-US, V11, P4451, DOI 10.1021/bi00774a005
   Supattapone S, 1999, P NATL ACAD SCI USA, V96, P14529, DOI 10.1073/pnas.96.25.14529
   Supattapone S, 2001, J VIROL, V75, P3453, DOI 10.1128/JVI.75.7.3453-3461.2001
   TSUYUKI E, 1956, J BIOL CHEM, V222, P479
   Xu Z, 2011, FASEB J, V25, P3426, DOI 10.1096/fj.11-187534
   YAVIN E, 1974, J CELL BIOL, V62, P540, DOI 10.1083/jcb.62.2.540
NR 30
TC 6
Z9 6
U1 0
U2 4
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
SN 0939-4451
J9 AMINO ACIDS
JI Amino Acids
PD MAR
PY 2013
VL 44
IS 3
BP 993
EP 1000
DI 10.1007/s00726-012-1430-8
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 087KR
UT WOS:000314760700018
PM 23179088
DA 2018-03-19
ER

PT J
AU Yu, CG
   Li, YZ
   Raza, K
   Yu, XX
   Ghoshal, S
   Geddes, JW
AF Yu, Chen-Guang
   Li, YongChao
   Raza, Kashif
   Yu, Xin Xin
   Ghoshal, Sarbani
   Geddes, James W.
TI Calpain 1 Knockdown Improves Tissue Sparing and Functional Outcomes
   after Spinal Cord Injury in Rats
SO JOURNAL OF NEUROTRAUMA
LA English
DT Article
DE behavior; gene therapy; lentiviral; locomotor; pathology; RNAi; tissue
   sparing
ID CONVECTION-ENHANCED DELIVERY; RNA INTERFERENCE; I ACTIVATION; BRAIN;
   CELLS; NEUROPROTECTION; PRETREATMENT; DEGRADATION; INHIBITION; PATHWAYS
AB To evaluate the hypothesis that calpain 1 knockdown would reduce pathological damage and functional deficits after spinal cord injury (SCI), we developed lentiviral vectors encoding calpain 1 shRNA and eGFP as a reporter (LV-CAPN1 shRNA). The ability of LV-CAPN1 shRNA to knockdown calpain 1 was confirmed in rat NRK cells using Northern and Western blot analysis. To investigate the effects on spinal cord injury, LV-CAPN1shRNA or LV-mismatch control shRNA (LV-control shRNA) were administered by convection enhanced diffusion at spinal cord level T10 in Long-Evans female rats (200-250 g) 1 week before contusion SCI, 180 kdyn force, or sham surgery at the same thoracic level. Intraspinal administration of the lentiviral particles resulted in transgene expression, visualized by eGFP, in spinal tissue at 2 weeks after infection. Calpain 1 protein levels were reduced by 54% at T10 2 weeks after shRNA-mediated knockdown (p < 0.05, compared with the LV-control group, n = 3 per group) while calpain 2 levels were unchanged. Intraspinal administration of LV-CAPN1shRNA 1 week before contusion SCI resulted in a significant improvement in locomotor function over 6 weeks postinjury, compared with LV-control administration (p < 0.05, n = 10 per group). Histological analysis of spinal cord sections indicated that pre- injury intraspinal administration of LV-CAPN1shRNA significantly reduced spinal lesion volume and improved total tissue sparing, white matter sparing, and gray matter sparing (p < 0.05, n = 10 per group). Together, results support the hypothesis that calpain 1 activation contributes to the tissue damage and impaired locomotor function after SCI, and that calpain1 represents a potential therapeutic target.
C1 Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, Lexington, KY USA.
   Univ Kentucky, Coll Med, Dept Anat & Neurobiol, Lexington, KY USA.
RP Yu, CG (reprint author), Spinal Cord & Brain Injury Res Ctr, BBSRB, B465,741 S Limestone St, Lexington, KY 40536 USA.
EM cyu4@uky.edu
FU Kentucky Spinal Cord; Head Injury Research Trust
FX This research was supported by the Kentucky Spinal Cord and Head Injury
   Research Trust.
CR Azam M, 2001, MOL CELL BIOL, V21, P2213, DOI 10.1128/MCB.21.6.2213-2220.2001
   Baekelandt V, 2002, HUM GENE THER, V13, P841, DOI 10.1089/10430340252899019
   Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098
   Bevers MB, 2010, EXP NEUROL, V224, P170, DOI 10.1016/j.expneurol.2010.03.007
   BOBO RH, 1994, P NATL ACAD SCI USA, V91, P2076, DOI 10.1073/pnas.91.6.2076
   Das A, 2008, CNS NEUROL DISORD-DR, V7, P313, DOI 10.2174/187152708784936699
   Doshi Shachee, 2009, Front Biosci (Schol Ed), V1, P466, DOI 10.2741/e38
   Dutt P, 2006, BMC DEV BIOL, V6, DOI 10.1186/1471-213X-6-3
   Friedrich P, 2005, BIOL CHEM, V386, P609, DOI 10.1515/BC.2005.071
   Geddes JW, 2010, EXP NEUROL, V226, P6, DOI 10.1016/j.expneurol.2010.07.025
   Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002
   Guyton MK, 2009, J NEUROCHEM, V110, P1895, DOI 10.1111/j.1471-4159.2009.06287.x
   Kuchay SM, 2007, CURR OPIN HEMATOL, V14, P249, DOI 10.1097/MOH.0b013e3280ef68f8
   Li YZ, 2009, EXP NEUROL, V220, P316, DOI 10.1016/j.expneurol.2009.09.004
   Liu J, 2008, SCI SIGNAL, V1, DOI [10.1126/stke.114re1, 10.1126/scisignal.123tr3]
   McTigue DM, 2007, EXP NEUROL, V205, P396, DOI 10.1016/j.expneurol.2007.02.009
   Park E, 2004, J NEUROTRAUM, V21, P754, DOI 10.1089/0897715041269641
   Rabchevsky AG, 2002, J NEUROSCI RES, V68, P7, DOI 10.1002/jnr.10187
   Ray SK, 2003, BRAIN RES REV, V42, P169, DOI 10.1016/S0165-0173(03)00152-8
   Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936
   Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117
   Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099
   Schumacher PA, 2000, J NEUROCHEM, V74, P1646, DOI 10.1046/j.1471-4159.2000.0741646.x
   Springer JE, 1997, J NEUROCHEM, V69, P1592, DOI 10.1046/j.1471-4159.1997.69041592.x
   Szerlip NJ, 2007, J NEUROSURG, V107, P560, DOI 10.3171/JNS-07/09/0560
   Sanchez-Gomez MV, 2011, J NEUROSCI, V31, P2996, DOI 10.1523/JNEUROSCI.5578-10.2011
   Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4
   Yu CG, 2005, MOL BRAIN RES, V138, P244, DOI 10.1016/j.molbrainres.2005.04.013
   Yu CG, 2008, J NEUROTRAUM, V25, P833, DOI 10.1089/neu.2007.0490
   Yu CG, 2007, NEUROCHEM RES, V32, P2046, DOI 10.1007/s11064-007-9347-4
   Yu CG, 2010, J NEUROCHEM, V113, P131, DOI 10.1111/j.1471-4159.2010.06579.x
   Zhang WL, 1996, J BIOL CHEM, V271, P18825, DOI 10.1074/jbc.271.31.18825
   Zhao X, 1999, NEUROCHEM RES, V24, P371, DOI 10.1023/A:1020933616351
NR 33
TC 5
Z9 7
U1 1
U2 3
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0897-7151
J9 J NEUROTRAUM
JI J. Neurotrauma
PD MAR
PY 2013
VL 30
IS 6
BP 427
EP 433
DI 10.1089/neu.2012.2561
PG 7
WC Critical Care Medicine; Clinical Neurology; Neurosciences
SC General & Internal Medicine; Neurosciences & Neurology
GA 127ZK
UT WOS:000317737400001
PM 23102374
OA green_published
DA 2018-03-20
ER

PT J
AU Blalock, EM
   Buechel, HM
   Popovic, J
   Geddes, JW
   Landfield, PW
AF Blalock, Eric M.
   Buechel, Heather M.
   Popovic, Jelena
   Geddes, James W.
   Landfield, Philip W.
TI Microarray analyses of laser-captured hippocampus reveal distinct gray
   and white matter signatures associated with incipient Alzheimer's
   disease
SO JOURNAL OF CHEMICAL NEUROANATOMY
LA English
DT Article
DE Cognitive impairment; Aging; Neurodegeneration; Neurofibrillary tangles;
   Myelin; Glia
ID MILD COGNITIVE IMPAIRMENT; GENE-EXPRESSION; SYNAPTIC PLASTICITY; MOUSE
   MODELS; ANIMAL-MODEL; CA1 NEURONS; CALCIUM; BRAIN; PATHOGENESIS;
   PROGRESSION
AB Alzheimer's disease (AD) is a devastating neurodegenerative disorder that threatens to reach epidemic proportions as our population ages. Although much research has examined molecular pathways associated with AD, relatively few such studies have focused on the disease's critical early stages. In a prior microarray study we correlated gene expression in hippocampus with degree of Alzheimer's disease and found close associations between upregulation of apparent glial transcription factor/epigenetic/tumor suppressor genes and incipient AD. The results suggested a new model in which AD pathology spreads along myelinated axons (Blalock et al., 2004). However, the microarray analyses were performed on RNA extracted from frozen hand-dissected hippocampal CA1 tissue blocks containing both gray and white matter, limiting the confidence with which transcriptional changes in gray matter could be distinguished from those in white matter. Here, we used laser capture microdissection (LCM) to exclude major white matter tracts while selectively collecting CM hippocampal gray matter from formalin-fixed, paraffin-embedded (FFPE) hippocampal sections of the same subjects assessed in our prior study. Microarray analyses of this gray matter-enriched tissue revealed many transcriptional changes similar to those seen in our past study and in studies by others, particularly for downregulated neuron-related genes. Additionally, the present analyses identified several previously undetected pathway alterations, including downregulation of molecules that stabilize ryanodine receptor Ca2+ release and upregulation of vasculature development. Conversely, we found a striking paucity of the upregulated changes in the putative glial and growth-related genes that had been strongly overrepresented in the prior mixed-tissue study. We conclude that FFPE tissue can be a reliable resource for microarray studies of brain tissue, that upregulation of growth-related epigenetic/transcription factors during incipient AD is predominantly localized in and around white matter (supporting our prior findings and model), and that novel alterations in vascular and ryanodine receptor-related pathways in gray matter are closely associated with incipient AD. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Blalock, Eric M.; Buechel, Heather M.; Popovic, Jelena; Landfield, Philip W.] Univ Kentucky, Dept Mol & Biomed Pharmacol, Coll Med, Lexington, KY 40536 USA.
   [Geddes, James W.] Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, Lexington, KY USA.
RP Blalock, EM (reprint author), Univ Kentucky, Dept Mol & Biomed Pharmacol, Coll Med, MS-309,800 Rose St, Lexington, KY 40536 USA.
EM emblal@uky.edu
FU University of Kentucky Alzheimer's Disease Center [AG028383]; NIH
   Research Resources Center [S10RR024704]; National Institute on Aging
   [AG034605, AG004542, P01AG010836]
FX We thank Sonya Anderson and Ela Patel from the Sanders-Brown Center on
   Aging for sectioning and mounting hippocampal specimens, Jeff Gilbert
   and Zeiss Microscopy, as well as Woods Hole Research Center for
   generously allowing US to use their Zeiss PALM Microbeam system, Anjali
   Chhabra for performing RNA isolation and amplification protocols, and
   Dr. Kuey Chu Chen and Donna Wall of the University of Kentucky
   Microarray Core Facility for microarray hybridization and scanning. This
   work was supported in part by Grants from the University of Kentucky
   Alzheimer's Disease Center (AG028383) and the NIH Research Resources
   Center (S10RR024704) (to E.M.B.), and by Grants AG034605, AG004542 and
   P01AG010836 from the National Institute on Aging (to P.W.L.).
CR Abdueva D, 2010, J MOL DIAGN, V12, P409, DOI 10.2353/jmoldx.2010.090155
   Ambati J, 2011, INVEST OPHTH VIS SCI, V52, P2165, DOI DOI 10.1167/IOVS.11-7328
   Arendt T, 2000, ANN NY ACAD SCI, V920, P249
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Barrett T, 2006, METHOD ENZYMOL, V411, P352, DOI 10.1016/S0076-6879(06)11019-8
   Bezprozvanny I, 2008, TRENDS NEUROSCI, V31, P454, DOI 10.1016/j.tins.2008.06.005
   Bickford PC, 2000, BRAIN RES, V866, P211, DOI 10.1016/S0006-8993(00)02280-0
   Bishop NA, 2010, NATURE, V464, P529, DOI 10.1038/nature08983
   Blalock EM, 2005, AGEING RES REV, V4, P481, DOI 10.1016/j.arr.2005.06.006
   Blalock EM, 2004, P NATL ACAD SCI USA, V101, P2173, DOI 10.1073/pnas.0308512100
   Blalock EM, 2010, J NEUROSCI, V30, P6058, DOI 10.1523/JNEUROSCI.3956-09.2010
   Bowser Robert, 2002, Journal of Alzheimer's Disease, V4, P249
   Brinton RD, 2008, ADV DRUG DELIVER REV, V60, P1504, DOI 10.1016/j.addr.2008.06.003
   BURGER C, 2010, AGING NEUROSCI, V2, P140
   Butterfield DA, 2007, J ALZHEIMERS DIS, V12, P61
   Colangelo V, 2002, J NEUROSCI RES, V70, P462, DOI 10.1002/jnr.10351
   Coudry RA, 2007, J MOL DIAGN, V9, P70, DOI 10.2353/jmoldx.2007.060004
   Craft S, 2007, CURR ALZHEIMER RES, V4, P147, DOI 10.2174/156720507780362137
   Davies Peter, 2009, Dialogues Clin Neurosci, V11, P159
   DISTERHOFT JF, 1994, ANN NY ACAD SCI, V747, P382
   Farragher SM, 2008, HISTOCHEM CELL BIOL, V130, P435, DOI 10.1007/s00418-008-0479-7
   FINCH CE, 2002, MICROGLIA DEGENERATI
   Forman MS, 2003, TRENDS NEUROSCI, V26, P407, DOI 10.1016/S0166-2236(03)00197-8
   Foster TC, 1997, HIPPOCAMPUS, V7, P602, DOI 10.1002/(SICI)1098-1063(1997)7:6<602::AID-HIPO3>3.0.CO;2-G
   Gant JC, 2011, J NEUROSCI, V31, P1693, DOI 10.1523/JNEUROSCI.4805-10.2011
   Gemma C, 2002, J NEUROSCI, V22, P6114
   GIBSON GE, 1987, NEUROBIOL AGING, V8, P329, DOI 10.1016/0197-4580(87)90072-8
   Ginsberg SD, 2000, ANN NEUROL, V48, P77, DOI 10.1002/1531-8249(200007)48:1<77::AID-ANA12>3.3.CO;2-1
   Ginsberg Stephen D, 2006, NeuroRx, V3, P302, DOI 10.1016/j.nurx.2006.05.007
   Ginsberg SD, 2010, BIOL PSYCHIAT, V68, P885, DOI 10.1016/j.biopsych.2010.05.030
   Gustafson D, 2006, LANCET NEUROL, V5, P713, DOI 10.1016/S1474-4422(06)70526-9
   HOCHBERG Y, 1990, STAT MED, V9, P811, DOI 10.1002/sim.4780090710
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Johnson Gail V. W., 2002, Journal of Alzheimer's Disease, V4, P375
   Khachaturian Z S, 1989, Aging (Milano), V1, P17
   Klein WL, 2001, TRENDS NEUROSCI, V24, P219, DOI 10.1016/S0166-2236(00)01749-5
   Landfield PW, 2007, CURR ALZHEIMER RES, V4, P205, DOI 10.2174/156720507780362083
   LANDFIELD PW, 1987, NEUROBIOL AGING, V8, P346, DOI 10.1016/0197-4580(87)90074-1
   Liang WS, 2008, PHYSIOL GENOMICS, V33, P240, DOI 10.1152/physiolgenomics.00242.2007
   Loring JF, 2001, DNA CELL BIOL, V20, P683, DOI 10.1089/10445490152717541
   MARINKOVIC S, 1992, SURG NEUROL, V37, P339, DOI 10.1016/0090-3019(92)90001-4
   MASLIAH E, 1994, NEUROSCI LETT, V174, P67, DOI 10.1016/0304-3940(94)90121-X
   Michaelis ML, 1996, LIFE SCI, V59, P405, DOI 10.1016/0024-3205(96)00319-0
   Morgan D, 2003, NEUROCHEM RES, V28, P1029, DOI 10.1023/A:1023255106106
   Morris M, 2011, NEURON, V70, P410, DOI 10.1016/j.neuron.2011.04.009
   Mrak RE, 2001, NEUROBIOL AGING, V22, P903, DOI 10.1016/S0197-4580(01)00287-1
   Mucke L, 2000, J NEUROSCI, V20, P4050
   Mufson EJ, 2007, CURR ALZHEIMER RES, V4, P340, DOI 10.2174/156720507781788855
   MULLAN M, 1994, MOL NEUROBIOL, V9, P15, DOI 10.1007/BF02816100
   NIXON BA, 1994, ANN NY ACAD SCI, V747, P77
   Nixon Ralph A., 2001, Journal of Alzheimer's Disease, V3, P97
   Noble W, 2003, NEURON, V38, P555, DOI 10.1016/S0896-6273(03)00259-9
   Norris CM, 1998, J NEUROSCI, V18, P3171
   Okello JBA, 2010, ANAL BIOCHEM, V400, P110, DOI 10.1016/j.ab.2010.01.014
   Pasinetti GM, 2001, J NEUROSCI RES, V65, P471, DOI 10.1002/jnr.1176
   Perry G, 2003, NEUROCHEM RES, V28, P1549, DOI 10.1023/A:1025678510480
   Petanceska SS, 2002, J MOL NEUROSCI, V19, P155, DOI 10.1007/s12031-002-0026-2
   Price DL, 1998, ANNU REV NEUROSCI, V21, P479, DOI 10.1146/annurev.neuro.21.1.479
   Puglielli L, 2001, NAT CELL BIOL, V3, P905, DOI 10.1038/ncb1001-905
   Rogers J, 1996, NEUROBIOL AGING, V17, P681, DOI 10.1016/0197-4580(96)00115-7
   Scheff Stephen W., 2001, Journal of Alzheimer's Disease, V3, P495
   Scicchitano MS, 2006, J HISTOCHEM CYTOCHEM, V54, P1229, DOI 10.1369/jhc.6A6999.2006
   Simpkins JW, 2005, ANN NY ACAD SCI, V1052, P233, DOI 10.1196/annals.1347.019
   Sohrabji F, 2006, FRONT NEUROENDOCRIN, V27, P404, DOI 10.1016/j.yfrne.2006.09.003
   Stefani M, 2003, J MOL MED-JMM, V81, P678, DOI 10.1007/s00109-003-0464-5
   Stutzmann GE, 2005, NEUROSCIENTIST, V11, P110, DOI 10.1177/1073858404270899
   Stutzmann GE, 2007, ANN NY ACAD SCI, V1097, P265, DOI 10.1196/annals.1379.025
   Sze CI, 1997, J NEUROPATH EXP NEUR, V56, P933, DOI 10.1097/00005072-199708000-00011
   Tanzi RE, 2001, NEURON, V32, P181, DOI 10.1016/S0896-6273(01)00476-7
   Thibault O, 2007, AGING CELL, V6, P307, DOI 10.1111/j.1474-9726.2007.00295.x
   Turner L, 2011, METHODS MOL BIOL, V724, P269, DOI 10.1007/978-1-61779-055-3_17
   TUSZYNSKI MH, 1990, ACTA NEUROBIOL EXP, V50, P311
   Vercellino M, 2009, J NEUROPATH EXP NEUR, V68, P489, DOI 10.1097/NEN.0b013e3181a19a5a
   WANG XK, 2010, CURR GENOMICS, V11, P618
   Whitmer RA, 2007, CURR ALZHEIMER RES, V4, P103, DOI 10.2174/156720507780362047
   Williams BJ, 2006, PROG NEUROBIOL, V80, P114, DOI 10.1016/j.pneurobio.2006.09.001
   Yaffe K, 2004, NEUROLOGY, V63, P658, DOI 10.1212/01.WNL.0000134666.64593.BA
   Yao PJ, 2003, NEUROBIOL DIS, V12, P97, DOI 10.1016/S0969-9961(02)0009-8
   Zahn JM, 2007, PLOS GENET, V3, P2326, DOI 10.1371/journal.pgen.0030201
   Zhao XY, 2001, J COMP NEUROL, V441, P187, DOI 10.1002/cne.1406
NR 80
TC 63
Z9 63
U1 0
U2 14
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0891-0618
J9 J CHEM NEUROANAT
JI J. Chem. Neuroanat.
PD OCT
PY 2011
VL 42
IS 2
SI SI
BP 118
EP 126
DI 10.1016/j.jchemneu.2011.06.007
PG 9
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 825CD
UT WOS:000295247600004
PM 21756998
OA green_accepted
DA 2018-03-20
ER

PT J
AU Smuleac, V
   Varma, R
   Baruwati, B
   Sikdar, S
   Bhattacharyya, D
AF Smuleac, Vasile
   Varma, Rajender
   Baruwati, Babita
   Sikdar, Subhas
   Bhattacharyya, Dibakar
TI Nanostructured Membranes for Enzyme Catalysis and Green Synthesis of
   Nanoparticles
SO CHEMSUSCHEM
LA English
DT Article
DE electrostatic interactions; enzymes; immobilization; membranes;
   nanoparticles
ID MICROFILTRATION MEMBRANES; NANOTUBE MEMBRANES; PD NANOPARTICLES;
   HYDRODECHLORINATION; SELECTIVITY; DECHLORINATION; NANOCOMPOSITE;
   CHANNEL; REACTOR; SIZE
AB Macroporous membranes functionalized with ionizable macromolecules provide promising applications in high capacity toxic metal capture, nanoparticle syntheses, and catalysis. Our low-pressure membrane approach has good reaction and separation selectivities, which are tunable by varying pH, ionic strength, or pressure. The sustainable green chemistry approach under ambient conditions and the evaluation of a reactive poly(acrylic acid) (PAA)-modified polyvinylidene fluoride (PVDF) membrane is described. Two distinct membrane types were obtained through different methods: 1) a stacked membrane through layer-by-layer assembly for the incorporation of enzymes (catalase and glucose oxidase), providing tunable product yields and 2) Fe/Pd nanoparticles for degradation of pollutants, obtained through an in situ green synthesis. Bioreactornanodomain interactions and mixed matrix nanocomposite membranes provide remarkable versatility compared to conventional membranes.
C1 [Smuleac, Vasile; Bhattacharyya, Dibakar] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Varma, Rajender; Baruwati, Babita; Sikdar, Subhas] US EPA, Sustainable Technol Div, Natl Risk Management Res Lab, Cincinnati, OH 45268 USA.
RP Bhattacharyya, D (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM db@engr.uky.edu
FU NIEHS; DOE-KRCEE
FX This study was supported by the NIEHS-SRP program and by DOE-KRCEE.
CR Baruwati B, 2009, CHEMSUSCHEM, V2, P1041, DOI 10.1002/cssc.200900220
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999
   Bruening ML, 2008, LANGMUIR, V24, P7663, DOI 10.1021/la800179z
   Butterfield DA, 2001, J MEMBRANE SCI, V181, P29, DOI 10.1016/S0376-7388(00)00342-2
   CHEN W, 2010, ANGEW CHEM, V122, P8115
   Chen W, 2010, ANGEW CHEM INT EDIT, V49, P7943, DOI 10.1002/anie.201002711
   CLAPP PA, 1989, ANAL CHIM ACTA, V218, P331, DOI 10.1016/S0003-2670(00)80309-8
   Datta S, 2008, IND ENG CHEM RES, V47, P4586, DOI 10.1021/ie800142d
   Decher G, 1997, SCIENCE, V277, P1232, DOI 10.1126/science.277.5330.1232
   Drioli E, 2010, COMPREHENSIVE MEMBRA
   Fu DX, 2000, SCIENCE, V290, P481, DOI 10.1126/science.290.5491.481
   He F, 2009, IND ENG CHEM RES, V48, P6550, DOI 10.1021/ie801962f
   He F, 2008, APPL CATAL B-ENVIRON, V84, P533, DOI 10.1016/j.apcatb.2008.05.008
   Hinds BJ, 2004, SCIENCE, V303, P62, DOI 10.1126/science.1092048
   Ikkala O, 2002, SCIENCE, V295, P2407, DOI 10.1126/science.1067794
   Kohli P, 2004, SCIENCE, V305, P984, DOI 10.1126/science.1100024
   Li NN, 2008, ADV MEMBRANE TECHNOL
   Li SJ, 2010, ACS NANO, V4, P6417, DOI 10.1021/nn101050r
   Li SJ, 2010, CHEM-EUR J, V16, P10186, DOI 10.1002/chem.201000318
   Liu JC, 2009, LANGMUIR, V25, P7116, DOI 10.1021/la900228d
   Lu A. H., 2007, ANGEW CHEM, V119, P1242
   Lu AH, 2007, ANGEW CHEM INT EDIT, V46, P1222, DOI 10.1002/anie.200602866
   Merkel TC, 2002, SCIENCE, V296, P519, DOI 10.1126/science.1069580
   Nadagouda MN, 2007, CRYST GROWTH DES, V7, P2582, DOI 10.1021/cg070554e
   Ritchie SMC, 1999, LANGMUIR, V15, P6346, DOI 10.1021/la9814438
   Rosi NL, 2006, SCIENCE, V312, P1027, DOI 10.1126/science.1125559
   Savariar EN, 2008, NAT NANOTECHNOL, V3, P112, DOI 10.1038/nnano.2008.6
   Schrick B, 2002, CHEM MATER, V14, P5140, DOI 10.1021/cm020737i
   Shannon MA, 2008, NATURE, V452, P301, DOI 10.1038/nature06599
   Smuleac V, 2006, LANGMUIR, V22, P10118, DOI 10.1021/la061124d
   Smuleac V, 2010, J MEMBRANE SCI, V346, P310, DOI 10.1016/j.memsci.2009.09.052
   Sun SH, 2000, SCIENCE, V287, P1989, DOI 10.1126/science.287.5460.1989
   Tajkhorshid E, 2002, SCIENCE, V296, P525, DOI 10.1126/science.1067778
   Tao F, 2008, SCIENCE, V322, P932, DOI 10.1126/science.1164170
   Ulbricht M, 2006, POLYMER, V47, P2217, DOI 10.1016/j.polymer.2006.01.084
   Virkutyte J, 2011, CHEM SCI, V2, P837, DOI 10.1039/c0sc00338g
   Wang YJ, 2004, ADV FUNCT MATER, V14, P1012, DOI 10.1002/adfm.200400144
   Xu J, 2008, J PHYS CHEM C, V112, P9133, DOI 10.1021/jp7097262
   Yave W, 2007, MACROMOLECULES, V40, P8991, DOI 10.1021/ma0714518
   Zhu NR, 2010, J HAZARD MATER, V176, P1101, DOI 10.1016/j.jhazmat.2009.11.092
NR 40
TC 7
Z9 7
U1 2
U2 26
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1864-5631
EI 1864-564X
J9 CHEMSUSCHEM
JI ChemSusChem
PY 2011
VL 4
IS 12
BP 1773
EP 1777
DI 10.1002/cssc.201100211
PG 5
WC Chemistry, Multidisciplinary; GREEN & SUSTAINABLE SCIENCE & TECHNOLOGY
SC Chemistry; Science & Technology - Other Topics
GA 860MW
UT WOS:000297953400011
PM 22086852
DA 2018-03-19
ER

PT J
AU Luo, J
   Eitel, R
AF Luo, Jin
   Eitel, Richard E.
TI An Integrated Low Temperature Co-Fired Ceramic-Based Clark-Type Oxygen
   Sensor
SO IEEE SENSORS JOURNAL
LA English
DT Article
DE Clark-type; oxygen sensor; LTCC; electrochemistry
ID ELECTRODE; SYSTEM; DIFFUSION; CHIP; RESPIRATION; CONSUMPTION;
   FABRICATION; CELLS; PO(2); TIME
AB Low temperature co-fired ceramic (LTCC) electronic packaging materials are applied for the advantages of their mechanical durability, low cost, flexibility of the layered manufacturing, and capability to integrate both electronic and microfluidic functions in a single LTCC module. Clark-type oxygen sensors are electrochemical devices that are widely used for sensing dissolved oxygen in biological applications. In this paper, a Clark-type oxygen sensor has been developed using the LTCC thick-film technique instead of the traditional silicone/ glass micromachining, and it consisted of an LTCC substrate with three electrodes (working electrode, counter electrode, and Ag/AgCl reference electrode), a polydimethylsiloxane (PDMS) oxygen permeable membrane and a PDMS reservoir. The fabricated Ag/AgCl reference electrode demonstrated high density with longtime stability. Cyclic voltammetry and chronoamperometry were measured to evaluate the electrochemical properties of the LTCC-based Clark-type oxygen sensor. The reduction current had a linear relationship with oxygen concentration. Meanwhile, the LTCC-based Clark-type oxygen sensor exhibited comparative performances, including low residual current, < 5%, and fast response time, 7.5 s, compared with the literatures.
C1 [Luo, Jin] Tsinghua Univ, Sch Mat Sci & Engn, State Key Lab New Ceram & Fine Proc, Beijing 100084, Peoples R China.
   [Luo, Jin] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Eitel, Richard] Stevens Inst Technol, Dept Chem Engn & Mat Sci, Hoboken, NJ 07030 USA.
RP Luo, J (reprint author), Tsinghua Univ, Sch Mat Sci & Engn, State Key Lab New Ceram & Fine Proc, Beijing 100084, Peoples R China.; Luo, J (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM jluuky2014@sina.com; reitel@stevens.edu
RI Eitel, Richard/E-2889-2010
OI Eitel, Richard/0000-0002-5090-2075
FU Office of Naval Research Department of Defense Experimental Program to
   Stimulate Competitive Research (ONR DEPSCoR); University of Kentucky
   Center for Clinical and Translational Science (CTSA)
FX This work was supported in part by the Office of Naval Research
   Department of Defense Experimental Program to Stimulate Competitive
   Research (ONR DEPSCoR) and the University of Kentucky Center for
   Clinical and Translational Science (CTSA).
CR Banerjee S, 2016, SENSOR ACTUAT B-CHEM, V230, P434, DOI 10.1016/j.snb.2016.02.062
   Bembnowicz P, 2011, OPT APPL, V41, P471
   Brandenburg A, 2016, SENSOR ACTUAT A-PHYS, V241, P145, DOI 10.1016/j.sna.2016.02.011
   CHA CS, 1990, SENSOR ACTUAT B-CHEM, V2, P239, DOI 10.1016/0925-4005(90)80148-S
   Chang-Yen DA, 2003, LAB CHIP, V3, P297, DOI 10.1039/b305358j
   COX ME, 1986, J POLYM SCI POL CHEM, V24, P621, DOI 10.1002/pola.1986.080240405
   Cui Y, 2007, SENSOR ACTUAT B-CHEM, V123, P696, DOI 10.1016/j.snb.2006.10.004
   Gerencser AA, 2009, ANAL CHEM, V81, P6868, DOI 10.1021/ac900881z
   Golonka LJ, 2006, INT J APPL CERAM TEC, V3, P150, DOI 10.1111/j.1744-7402.2006.02072.x
   Golonka L.J., 2006, B POL ACAD SCI-TECH, V54, P2
   Gongora-Rubio MR, 2001, SENSOR ACTUAT A-PHYS, V89, P222, DOI 10.1016/S0924-4247(00)00554-9
   Gongora-Rubio MR, 2004, SENSOR ACTUAT B-CHEM, V103, P468, DOI 10.1016/j.snb.2004.05.007
   Hartmann P, 1997, SENSOR ACTUAT B-CHEM, V38, P110, DOI 10.1016/S0925-4005(97)80179-7
   Ibanez-Garcia N, 2006, SENSOR ACTUAT B-CHEM, V118, P67, DOI 10.1016/j.snb.2006.04.063
   JU LK, 1985, BIOTECHNOL BIOENG, V27, P1495, DOI 10.1002/bit.260271015
   Jurkow D, 2015, SENSOR ACTUAT A-PHYS, V233, P125, DOI 10.1016/j.sna.2015.05.023
   Kim CS, 2004, IEEE SENS J, V4, P568, DOI 10.1109/JSEN.2004.832857
   Kondrashina AV, 2013, ANALYST, V138, P4915, DOI 10.1039/c3an00658a
   LIPPITSCH ME, 1988, ANAL CHIM ACTA, V205, P1, DOI 10.1016/S0003-2670(00)82310-7
   Lu GY, 2016, SENSOR ACTUAT B-CHEM, V233, P347, DOI 10.1016/j.snb.2016.04.078
   McLaughlin GW, 2002, SENSOR ACTUAT B-CHEM, V83, P138, DOI 10.1016/S0925-4005(02)00021-7
   McLaughlin G. W., 2001, THESIS
   Medina-Rodriguez S, 2016, ANALYST, V141, P3090, DOI 10.1039/c6an00497k
   Onal E, 2016, RSC ADV, V6, P9967, DOI 10.1039/c5ra24817e
   Park J, 2013, SENSOR ACTUAT B-CHEM, V176, P913, DOI 10.1016/j.snb.2012.09.037
   Park J, 2010, SENSOR ACTUAT B-CHEM, V147, P263, DOI 10.1016/j.snb.2010.03.069
   Peterson KA, 2005, INT J APPL CERAM TEC, V2, P345, DOI 10.1111/j.1744-7402.2005.02039.x
   Polk BJ, 2006, SENSOR ACTUAT B-CHEM, V114, P239, DOI 10.1016/j.snb.2005.03.121
   Sadler DJ, 2003, IEEE T COMPON PACK T, V26, P309, DOI 10.1109/TCAPT.2003.815093
   Shan G., 2015, SENSORS, V16, P91
   Suzuki H, 1999, ANAL CHEM, V71, P5069, DOI 10.1021/ac990437t
   Suzuki H, 2000, ANAL CHIM ACTA, V405, P57, DOI 10.1016/S0003-2670(99)00748-5
   Suzuki H, 2001, ANAL CHIM ACTA, V431, P249, DOI 10.1016/S0003-2670(00)01325-8
   Vollmer AP, 2005, LAB CHIP, V5, P1059, DOI 10.1039/b508097e
   von Heimburg D, 2005, RESP PHYSIOL NEUROBI, V146, P107, DOI 10.1016/j.resp.2004.12.013
   Wang P, 2011, SENSOR ACTUAT B-CHEM, V153, P145, DOI 10.1016/j.snb.2010.09.075
   WHALEN WJ, 1967, J APPL PHYSIOL, V23, P798
   Wu CC, 2005, SENSOR ACTUAT B-CHEM, V110, P342, DOI 10.1016/j.snb.2005.02.014
   Wu CC, 2010, TALANTA, V81, P228, DOI 10.1016/j.talanta.2009.11.062
   Yang Z, 1997, ANAL CHIM ACTA, V357, P41, DOI 10.1016/S0003-2670(97)00560-6
   Clark LC, 1959, Electrochemical device for chemical analysis, Patent No. [2913386, US 2913386 A]
NR 41
TC 0
Z9 0
U1 7
U2 26
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 1530-437X
EI 1558-1748
J9 IEEE SENS J
JI IEEE Sens. J.
PD MAR 15
PY 2017
VL 17
IS 6
BP 1590
EP 1595
DI 10.1109/JSEN.2016.2645792
PG 6
WC Engineering, Electrical & Electronic; Instruments & Instrumentation;
   Physics, Applied
SC Engineering; Instruments & Instrumentation; Physics
GA EN3FU
UT WOS:000395895200002
DA 2018-03-19
ER

PT J
AU Dan, M
   Scott, DF
   Hardy, PA
   Wydra, RJ
   Hilt, JZ
   Yokel, RA
   Bae, Y
AF Dan, Mo
   Scott, Daniel F.
   Hardy, Peter A.
   Wydra, Robert J.
   Hilt, J. Zach
   Yokel, Robert A.
   Bae, Younsoo
TI Block Copolymer Cross-Linked Nanoassemblies Improve Particle Stability
   and Biocompatibility of Superparamagnetic Iron Oxide Nanoparticles
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE cross-linked nanoassemblies; hyperthermia; magnetic resonance imaging;
   nanoparticles; superparamagnetic iron oxide
ID MAGNETIC-RESONANCE NANOPARTICLES; DRUG-DELIVERY; CONTRAST AGENTS;
   BIOMEDICAL APPLICATIONS; INTRACEREBRAL TUMOR; RAT-BRAIN; IN-VITRO;
   HYPERTHERMIA; THERAPY; FUNCTIONALIZATION
AB To develop cross-linked nanoassemblies (CNAs) as carriers for superparamagnetic iron oxide nanoparticles (IONPs).
   Ferric and ferrous ions were co-precipitated inside core-shell type nanoparticles prepared by cross-linking poly(ethylene glycol)-poly(aspartate) block copolymers to prepare CNAs entrapping Fe3O4 IONPs (CNA-IONPs). Particle stability and biocompatibility of CNA-IONPs were characterized in comparison to citrate-coated Fe3O4 IONPs (Citrate-IONPs).
   CNA-IONPs, approximately 30 nm in diameter, showed no precipitation in water, PBS, or a cell culture medium after 3 or 30 h, at 22, 37, and 43A degrees C, and 1, 2.5, and 5 mg/mL, whereas Citrate-IONPs agglomerated rapidly (> 400 nm) in all aqueous media tested. No cytotoxicity was observed in a mouse brain endothelial-derived cell line (bEnd.3) exposed to CNA-IONPs up to 10 mg/mL for 30 h. Citrate-IONPs (> 0.05 mg/mL) reduced cell viability after 3 h. CNA-IONPs retained the superparamagnetic properties of entrapped IONPs, enhancing T2-weighted magnetic resonance images (MRI) at 0.02 mg/mL, and generating heat at a mild hyperthermic level (40 similar to 42A degrees C) with an alternating magnetic field (AMF).
   Compared to citric acid coating, CNAs with a cross-linked anionic core improved particle stability and biocompatibility of IONPs, which would be beneficial for future MRI and AMF-induced remote hyperthermia applications.
C1 [Dan, Mo; Scott, Daniel F.; Yokel, Robert A.; Bae, Younsoo] Univ Kentucky, Dept Pharmaceut Sci, Coll Pharm, Lexington, KY 40536 USA.
   [Dan, Mo; Yokel, Robert A.] Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA.
   [Wydra, Robert J.; Hilt, J. Zach] Univ Kentucky, Lexington, KY 40506 USA.
RP Bae, Y (reprint author), Univ Kentucky, Dept Pharmaceut Sci, Coll Pharm, 789 S Limestone, Lexington, KY 40536 USA.
EM younsoo.bae@uky.edu
FU NCI-CNTC (National Cancer Institute Cancer Nanotechnology Training
   Center) [NCI 5R25CA153954]
FX MD and DS acknowledge the financial support from a NCI-CNTC (National
   Cancer Institute Cancer Nanotechnology Training Center) predoctoral and
   postdoctoral traineeship (NCI 5R25CA153954).
CR Allouni ZE, 2009, COLLOID SURFACE B, V68, P83, DOI 10.1016/j.colsurfb.2008.09.014
   Andreas K, 2012, BIOMATERIALS
   Beduneau A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004343
   Berret JF, 2006, J AM CHEM SOC, V128, P1755, DOI 10.1021/ja0562999
   Berry CC, 2003, BIOMATERIALS, V24, P4551, DOI 10.1016/S0142-9612(03)00237-0
   CAVALIER.R, 1967, CANCER, V20, P1351, DOI 10.1002/1097-0142(196709)20:9<1351::AID-CNCR2820200902>3.0.CO;2-#
   Chanteau B, 2009, LANGMUIR, V25, P9064, DOI 10.1021/la900833v
   Cole AJ, 2011, BIOMATERIALS, V32, P2183, DOI 10.1016/j.biomaterials.2010.11.040
   Deng Z. J., 2009, NANOTECHNOLOGY, V20
   Di Marco M, 2007, INT J NANOMED, V2, P609
   Euliss LE, 2003, NANO LETT, V3, P1489, DOI 10.1021/nl034472y
   Farrell D, 2003, J PHYS CHEM B, V107, P11022, DOI 10.1021/jp0351831
   Forrest ML, 2008, PHARM RES, V25, P194, DOI 10.1007/s11095-007-9451-9
   Foucaud L, 2007, TOXICOL LETT, V174, P1, DOI 10.1016/j.toxlet.2007.08.001
   Frimpong RA, 2010, NANOMEDICINE-UK, V5, P1401, DOI 10.2217/NNM.10.114
   Frimpong RA, 2010, J MAGN MAGN MATER, V322, P326, DOI 10.1016/j.jmmm.2009.09.050
   Goloverda G, 2009, J MAGN MAGN MATER, V321, P1372, DOI 10.1016/j.jmmm.2009.02.041
   Guo R, 2005, J AM CHEM SOC, V127, P2752, DOI 10.1021/ja044638c
   Gupta AK, 2005, BIOMATERIALS, V26, P3995, DOI 10.1016/j.biomaterials.2004.10.012
   Hadjipanayis CG, 2010, CANCER RES, V70, P6303, DOI 10.1158/0008-5472.CAN-10-1022
   Hatakeyama M, 2011, J MATER CHEM, V21, P5959, DOI 10.1039/c0jm04381h
   Hu JM, 2012, LANGMUIR, V28, P2073, DOI 10.1021/la203992q
   Huang HC, 2011, J CONTROL RELEASE, V155, P344, DOI 10.1016/j.jconrel.2011.06.004
   Khan MI, 2012, BIOMATERIALS, V33, P1477, DOI 10.1016/j.biomaterials.2011.10.080
   Kim BS, 2005, NANO LETT, V5, P1987, DOI 10.1021/nl0513939
   Kim DH, 2009, IEEE T MAGN, V45, P4821, DOI 10.1109/TMAG.2009.2024000
   Kim S, 2010, EXPERT OPIN DRUG DEL, V7, P49, DOI 10.1517/17425240903380446
   Kiyatkin EA, 2009, NEUROSCIENCE, V161, P926, DOI 10.1016/j.neuroscience.2009.04.004
   Kobayashi T, 2011, BIOTECHNOL J, V6, P1342, DOI 10.1002/biot.201100045
   Krishnan KM, 2010, IEEE T MAGN, V46, P2523, DOI 10.1109/TMAG.2010.2046907
   Kumagai M, 2007, COLLOID SURFACE B, V56, P174, DOI 10.1016/j.colsurfb.2006.12.019
   Lattuada M, 2007, LANGMUIR, V23, P2158, DOI 10.1021/la062092x
   Lee HJ, 2011, BIOMACROMOLECULES, V12, P2686, DOI 10.1021/bm200483t
   Li Mingguang, 2010, ACS Nano, V4, P6303, DOI 10.1021/nn1018818
   Lin MM, 2008, IEEE T NANOBIOSCI, V7, P298, DOI 10.1109/TNB.2008.2011864
   Lodhia J, 2010, Biomed Imaging Interv J, V6, pe12, DOI 10.2349/biij.6.2.e12
   Lu AH, 2007, ANGEW CHEM INT EDIT, V46, P1222, DOI 10.1002/anie.200602866
   Mahmoudi M, 2011, CHEM REV
   Mahmoudi M, 2011, ADV DRUG DELIVER REV, V63, P24, DOI 10.1016/j.addr.2010.05.006
   Maier-Hauff K, 2011, J NEURO-ONCOL, V103, P317, DOI 10.1007/s11060-010-0389-0
   Meenach SA, 2010, J POLYM SCI POL CHEM, V48, P3229, DOI 10.1002/pola.24087
   Meenach SA, 2010, ACTA BIOMATER, V6, P1039, DOI 10.1016/j.actbio.2009.10.017
   Muldoon LL, 2005, NEUROSURGERY, V57, P785, DOI 10.1227/01.NEU.0000175731.25414.4c
   Neuberger T, 2005, J MAGN MAGN MATER, V293, P483, DOI 10.1016/j.jmmm.2005.01.064
   Novotna B, 2012, TOXICOL LETT, V210, P53, DOI 10.1016/j.toxlet.2012.01.008
   O'Brien J, 2000, EUR J BIOCHEM, V267, P5421, DOI 10.1046/j.1432-1327.2000.01606.x
   Owens DE, 2006, INT J PHARM, V307, P93, DOI 10.1016/j.ijpharm.2005.10.010
   Park Y, 2012, LANGMUIR, V28, P6246, DOI 10.1021/la204628c
   Ponta Andrei, 2011, Pharmaceuticals (Basel), V4, P1281
   Qiao RR, 2009, J MATER CHEM, V19, P6274, DOI 10.1039/b902394a
   Rock JP, 2005, NEUROSURGERY, V57, P796
   Rumenapp C, 2012, PHARM RES-DORDR, V29, P1165, DOI 10.1007/s11095-012-0711-y
   Safi M, 2011, BIOMATERIALS, V32, P9353, DOI 10.1016/j.biomaterials.2011.08.048
   Satarkar NS, 2010, SOFT MATTER, V6, P2364, DOI 10.1039/b925218p
   Scott D, 2011, INT J NANOMED, V6, P2757, DOI 10.2147/IJN.S25427
   Silva AC, 2011, INT J NANOMED, V6, P591, DOI 10.2147/IJN.S14737
   Soenen SJH, 2010, NANOMEDICINE-UK, V5, P1261, DOI [10.2217/nnm.10.106, 10.2217/NNM.10.106]
   Stephen ZR, 2011, MATER TODAY, V14, P330, DOI 10.1016/S1369-7021(11)70163-8
   Tantra R, 2010, COLLOID SURFACE B, V75, P275, DOI 10.1016/j.colsurfb.2009.08.049
   Varanda LC, 2002, J APPL PHYS, V92, P2079, DOI 10.1063/1.1496124
   Wagner M, 2011, J MAGN RESON IMAGING, V34, P816, DOI 10.1002/jmri.22683
   Wankhede M, 2012, EXPERT REV CLIN PHAR, V5, P173, DOI [10.1586/ECP.12.1, 10.1586/ecp.12.1]
   Weinstein JS, 2010, J CEREBR BLOOD F MET, V30, P15, DOI 10.1038/jcbfm.2009.192
   Woehrle GH, 2005, J AM CHEM SOC, V127, P2172, DOI 10.1021/ja0457718
   Yanase M, 1997, JPN J CANCER RES, V88, P630, DOI 10.1111/j.1349-7006.1997.tb00429.x
NR 65
TC 21
Z9 21
U1 3
U2 63
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
J9 PHARM RES-DORDR
JI Pharm. Res.
PD FEB
PY 2013
VL 30
IS 2
BP 552
EP 561
DI 10.1007/s11095-012-0900-8
PG 10
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 077NO
UT WOS:000314034600020
PM 23080062
OA green_accepted
DA 2018-03-20
ER

PT J
AU Geddes, JW
   Sullivan, PG
AF Geddes, James W.
   Sullivan, Patrick G.
TI Special Issue: Mitochondria and neurodegeneration
SO EXPERIMENTAL NEUROLOGY
LA English
DT Editorial Material
ID CA-2&-INDUCED MEMBRANE TRANSITION; PHOSPHORYLATION; CA-2
C1 [Geddes, James W.; Sullivan, Patrick G.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Dept Anat & Neurobiol, Lexington, KY 40536 USA.
RP Geddes, JW (reprint author), Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Dept Anat & Neurobiol, Lexington, KY 40536 USA.
EM jgeddes@uky.edu; patsullivan@uky.edu
CR Budd SL, 1996, J NEUROCHEM, V66, P403
   CHANCE B, 1955, J BIOL CHEM, V217, P383
   Cheng WC, 2006, ONCOGENE, V25, P4697, DOI 10.1038/sj.onc.1209596
   Friel DD, 2000, CELL CALCIUM, V28, P307, DOI 10.1054/ceca.2000.0172
   GUNTER TE, 1994, AM J PHYSIOL, V267, pC313
   HAWORTH RA, 1979, ARCH BIOCHEM BIOPHYS, V195, P460, DOI 10.1016/0003-9861(79)90372-2
   HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P453, DOI 10.1016/0003-9861(79)90371-0
   HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P468, DOI 10.1016/0003-9861(79)90373-4
   Lehninger AL, 1965, MITOCHONDRION MOL BA
   Martin W, 2006, NATURE, V440, P41, DOI 10.1038/nature04531
   MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0
   Scheffler IE, 2008, MITOCHONDRIA, 2NDEDITION, P1
   Westermann B, 2007, TRENDS CELL BIOL, V17, P417, DOI 10.1016/j.tcb.2007.07.006
NR 13
TC 4
Z9 5
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4886
EI 1090-2430
J9 EXP NEUROL
JI Exp. Neurol.
PD AUG
PY 2009
VL 218
IS 2
SI SI
BP 169
EP 170
DI 10.1016/j.expneurol.2009.05.011
PG 2
WC Neurosciences
SC Neurosciences & Neurology
GA 472GE
UT WOS:000268117400001
PM 19446552
DA 2018-03-20
ER

PT J
AU Koganti, VR
   Das, S
   Rankin, SE
AF Koganti, Venkat R.
   Das, Saikat
   Rankin, Stephen E.
TI In Situ FTIR Investigation of the Kinetics of Silica Polycondensation in
   Surfactant Templated, Mesostructured Thin Films
SO JOURNAL OF PHYSICAL CHEMISTRY C
LA English
DT Article
ID RESOLVED INFRARED-SPECTROSCOPY; X-RAY-SCATTERING; MONTE CARLO/CONTINUUM
   MODEL; ORDERED MESOPOROUS SILICA; SOL-GEL POLYMERIZATION; HYDROLYSIS
   PSEUDOEQUILIBRIUM; MECHANICAL-PROPERTIES; NANOSTRUCTURED FILMS; ACIDIC
   CONDITIONS; TITANIA FILMS
AB A detailed Fourier transform infrared spectroscopy (FTIR) study of the kinetics of polycondensation of surfactant-templated mesostructured silica thin films was carried out with the goal of understanding how to manipulate the synthesis and processing of these films to achieve a desired architecture. The evolution of silica condensation was followed both during the sol preparation process and in situ for a time period on the order of minutes to hours after initial film deposition. The kinetics were measured in the presence of three commonly used classes of surfactant templates: P123 [poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) triblock copolymer), Brij-56 (poly(ethylene oxide] [n similar to 10] hexadecyl ether), and CTAB (cetyltrimethylammonium bromide). The induction period for polycondensation (an initial period during which the rate of change of silanol content is slow) was different in each case, with P123 giving the longest induction time followed by Brij-56 and finally CTAB. Humidity was found to increase the induction time for polycondensation in general, and the initial period of up to 30 min after film deposition was identified as a critical "tunable steady state" interval during which conditions can be adjusted to tune the film properties for different applications, for instance, to alter the nature of the mesophase or its orientation by imposing external forces by confining interfaces or by electrical, magnetic, or flow fields.
C1 [Koganti, Venkat R.; Das, Saikat; Rankin, Stephen E.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Rankin, SE (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 FP Anderson Tower, Lexington, KY 40506 USA.
EM srankin@engr.uky.edu
OI Rankin, Stephen/0000-0002-8615-7564
FU U.S. Department of Energy EPSCoR University-National Laboratory
   Partnership Award [DE-FG02-03ER46033]; U.S. Department of Energy EPSCoR
   Implementation Award [DE-FG02-07ER46375]
FX This material is based upon initial FTIR analysis which was conducted as
   part of a U.S. Department of Energy EPSCoR University-National
   Laboratory Partnership Award under Grant DE-FG02-03ER46033 and analysis
   and interpretation of the data performed as part of a U.S. Department of
   Energy EPSCoR Implementation Award under Grant DE-FG02-07ER46375.
CR ALLINGER NL, 1990, J AM CHEM SOC, V112, P8293, DOI 10.1021/ja00179a012
   Alonso B, 2002, NEW J CHEM, V26, P1270, DOI 10.1039/b205501p
   Alonso B, 2010, J PHYS CHEM C, V114, P11730, DOI 10.1021/jp101652a
   ASSINK RA, 1991, ANNU REV MATER SCI, V21, P491
   Assink R. A., 1984, MATER RES SOC S P, V32, P301
   ASSINK RA, 1988, MATER RES SOC S P, V121, P25
   Assink R. A., 1991, POLYM PREPR AM CHEM, V32, P506
   Besson S, 2003, J MATER CHEM, V13, P404, DOI 10.1039/b206698j
   Bonhomme C, 2007, ACCOUNTS CHEM RES, V40, P738, DOI 10.1021/ar600030j
   Boudot M, 2014, CHEM MATER, V26, P1822, DOI 10.1021/cm403787v
   Brinker CJ, 2006, CURR OPIN COLLOID IN, V11, P126, DOI 10.1016/j.cocis.2005.10.006
   Brinker CJ, 2004, MRS BULL, V29, P631, DOI 10.1557/mrs2004.183
   Brinker CJ, 1999, ADV MATER, V11, P579, DOI 10.1002/(SICI)1521-4095(199905)11:7<579::AID-ADMA579>3.0.CO;2-R
   Cagnol F, 2003, J MATER CHEM, V13, P61, DOI 10.1039/b209640b
   Calabro DC, 1996, MICROPOROUS MATER, V7, P243, DOI 10.1016/S0927-6513(96)00045-4
   Chen Z, 2010, NAT MATER, V9, P667, DOI [10.1038/NMAT2805, 10.1038/nmat2805]
   Coll C, 2013, ACCOUNTS CHEM RES, V46, P339, DOI 10.1021/ar3001469
   Collard X, 2013, J COLLOID INTERF SCI, V401, P23, DOI 10.1016/j.jcis.2013.02.051
   DEVREUX F, 1990, PHYS REV LETT, V65, P614, DOI 10.1103/PhysRevLett.65.614
   DEVREUX F, 1990, PHYS REV A, V41, P6901, DOI 10.1103/PhysRevA.41.6901
   Doshi DA, 2003, J AM CHEM SOC, V125, P11646, DOI 10.1021/ja0295523
   DOUGHTY DH, 1990, ADV CHEM SER, V224, P241
   Elbert J, 2014, ADV FUNCT MATER, V24, P1591, DOI 10.1002/adfm.201302304
   Faustini M, 2014, CHEM MATER, V26, P709, DOI 10.1021/cm402132y
   Fidalgo A, 2004, J NON-CRYST SOLIDS, V347, P128, DOI 10.1016/j.jnoncrysol.2004.07.059
   Flodstrom K, 2004, LANGMUIR, V20, P4885, DOI 10.1021/la049637c
   Fujita S, 2013, CHEM MATER, V25, P1584, DOI 10.1021/cm303950u
   Gage RA, 2001, MACROMOLECULES, V34, P5078, DOI 10.1021/ma0018695
   Gibaud A, 2003, J PHYS CHEM B, V107, P6114, DOI 10.1021/jp027612l
   Gibaud A., 2004, PHYS REV B, V70, P4
   Goncalves M. C., 2003, REV ADV MATER SCI, V4, P147
   Grosso D, 2004, ADV FUNCT MATER, V14, P309, DOI 10.1002/adfm.200305036
   Grosso D, 2002, CHEM MATER, V14, P931, DOI 10.1021/cm011255u
   Grosso D, 2003, J SOL-GEL SCI TECHN, V26, P561, DOI 10.1023/A:1020715803241
   Grosso D, 2001, CHEM MATER, V13, P1848, DOI 10.1021/cm001225b
   Grosso D, 2006, J SOL-GEL SCI TECHN, V40, P141, DOI 10.1007/s10971-006-8990-6
   Grosso D, 2011, CHEM SOC REV, V40, P829, DOI 10.1039/c0cs00039f
   Guliants VV, 2004, J MEMBRANE SCI, V235, P53, DOI 10.1016/j.memsci.2004.01.019
   Guo DJ, 2012, ELECTROANAL, V24, P2035, DOI 10.1002/elan.201200450
   Holmes JD, 2002, STUD SURF SCI CATAL, V141, P337
   Holmes SM, 1998, J CHEM SOC FARADAY T, V94, P2025, DOI 10.1039/a801898g
   Innocenzi P, 2006, J PHYS CHEM B, V110, P10837, DOI 10.1021/jp060097x
   Innocenzi P, 2005, J SYNCHROTRON RADIAT, V12, P734, DOI 10.1107/S0909049505014585
   Innocenzi P, 2005, CHEM COMMUN, P2384, DOI 10.1039/b418381a
   Innocenzi P, 2003, J PHYS CHEM B, V107, P4711, DOI 10.1021/jp026609z
   Innocenzi P, 2003, J NON-CRYST SOLIDS, V316, P309, DOI 10.1016/S0022-3093(02)01637-X
   Innocenzi P, 2008, J SOL-GEL SCI TECHN, V48, P253, DOI 10.1007/s10971-008-1716-1
   Innocenzi P, 2007, J PHYS CHEM C, V111, P5345, DOI 10.1021/jp066566c
   Innocenzi P, 2013, CHEM SOC REV, V42, P4198, DOI 10.1039/c3cs35377j
   Innocenzi P, 2011, J PHYS CHEM A, V115, P10438, DOI 10.1021/jp204314b
   Innocenzi P, 2010, J PHYS CHEM C, V114, P10806, DOI 10.1021/jp9099732
   Innocenzi P, 2010, J PHYS CHEM A, V114, P304, DOI 10.1021/jp908162z
   Innocenzi P, 2009, J PHYS CHEM A, V113, P2745, DOI 10.1021/jp806608d
   Kasehagen LJ, 1997, MACROMOLECULES, V30, P3921, DOI 10.1021/ma9619142
   Kay B. D., 1986, MATER RES SOC S P, V73, P157
   Keller A, 2013, PHYS CHEM CHEM PHYS, V15, P13637, DOI 10.1039/c3cp52033a
   Khodakov AY, 2005, J PHYS CHEM B, V109, P22780, DOI 10.1021/jp052786z
   Koganti VR, 2006, NANO LETT, V6, P2567, DOI 10.1021/nl061992v
   Koganti VR, 2005, J PHYS CHEM B, V109, P3279, DOI 10.1021/jp045037a
   Koltz M., 2000, CHEM MATER, V12, P1721
   Kumar P, 2010, MICROPOR MESOPOR MAT, V132, P1, DOI 10.1016/j.micromeso.2010.02.007
   Lee KR, 2010, NANO, V5, P75, DOI 10.1142/S1793292010001950
   Lee YF, 2011, RSC ADV, V1, P401, DOI 10.1039/c1ra00204j
   Lei JH, 2006, J SOL-GEL SCI TECHN, V39, P169, DOI 10.1007/s10971-006-7745-8
   Li DF, 2006, COLLOID SURFACE A, V272, P194, DOI 10.1016/j.colsurfa.2005.07.027
   Li X, 2013, AICHE J, V59, P707, DOI 10.1002/aic.13853
   Li X, 2011, CHEM ENG SCI, V66, P1015, DOI 10.1016/j.ces.2010.11.007
   Li X, 2010, AICHE J, V56, P2946, DOI 10.1002/aic.12202
   Li X, 2008, J PHYS CHEM C, V112, P53, DOI 10.1021/jp0762727
   Liu NG, 2004, NANO LETT, V4, P551, DOI 10.1021/nl0350783
   Lu YF, 1997, NATURE, V389, P364, DOI 10.1038/38699
   Malfatti L, 2011, J SOL-GEL SCI TECHN, V60, P226, DOI 10.1007/s10971-011-2475-y
   Marcelli A, 2012, J SYNCHROTRON RADIAT, V19, P892, DOI 10.1107/S0909049512041106
   MATOS MC, 1992, J NON-CRYST SOLIDS, V147, P232, DOI 10.1016/S0022-3093(05)80622-2
   Melde BJ, 2010, ANAL BIOANAL CHEM, V398, P1565, DOI 10.1007/s00216-010-3688-6
   MONDRAGON MA, 1995, VIB SPECTROSC, V9, P293, DOI 10.1016/0924-2031(95)00002-C
   MORITA M, 1990, J APPL PHYS, V68, P1272, DOI 10.1063/1.347181
   Muroya M, 1999, COLLOID SURFACE A, V157, P147, DOI 10.1016/S0927-7757(99)00054-0
   Ogawa M, 1996, CHEM COMMUN, P1149, DOI 10.1039/cc9960001149
   OGAWA M, 1994, J AM CHEM SOC, V116, P7941, DOI 10.1021/ja00096a079
   Ogawa M, 1998, SUPRAMOL SCI, V5, P247, DOI 10.1016/S0968-5677(98)00015-7
   PARRILL TM, 1992, J MATER RES, V7, P2230, DOI 10.1557/JMR.1992.2230
   Platschek B, 2011, ADV MATER, V23, P2395, DOI 10.1002/adma.201002828
   Plawsky JL, 2009, MATER TODAY, V12, P36, DOI 10.1016/S1369-7021(09)70179-8
   POUXVIEL JC, 1987, J NON-CRYST SOLIDS, V89, P345, DOI 10.1016/S0022-3093(87)80277-6
   POUXVIEL JC, 1988, MATER RES SOC S P, V121, P37
   Primeau N, 1997, THIN SOLID FILMS, V310, P47, DOI 10.1016/S0040-6090(97)00340-4
   Rankin SE, 1999, IND ENG CHEM RES, V38, P3191, DOI 10.1021/ie990027v
   Rankin SE, 1998, AICHE J, V44, P1141, DOI 10.1002/aic.690440512
   Rankin SE, 2000, CHEM ENG SCI, V55, P1955, DOI 10.1016/S0009-2509(99)00486-8
   Rankin SE, 1998, CHEM MATER, V10, P2037, DOI 10.1021/cm980256s
   Rankin SE, 2000, MACROMOLECULES, V33, P7639, DOI 10.1021/ma000132c
   Ruthstein S, 2006, J AM CHEM SOC, V128, P3366, DOI 10.1021/ja0559911
   Ryan KM, 2003, J AM CHEM SOC, V125, P6284, DOI 10.1021/ja0345064
   Ryoo R., 2000, J PHYS CHEM B, V104, P11464
   Sanchez J, 1996, IND ENG CHEM RES, V35, P117, DOI 10.1021/ie950246q
   Sefcik J, 2003, J PHYS CHEM B, V107, P52, DOI 10.1021/jp026361d
   Sellinger A, 1998, NATURE, V394, P256, DOI 10.1038/28354
   Soler-Illia GJAA, 2006, CHEM-EUR J, V12, P4478, DOI 10.1002/chem.200500801
   Stein A, 2014, CHEM MATER, V26, P259, DOI 10.1021/cm402184h
   Sundblom A, 2010, LANGMUIR, V26, P1983, DOI 10.1021/la902144h
   Tejedor-Tejedor MI, 1998, CHEM MATER, V10, P3410, DOI 10.1021/cm980146l
   Tellez L, 2004, SPECTROSC LETT, V37, P11, DOI 10.1081/SL-120028420
   Tian BZ, 2004, J AM CHEM SOC, V126, P865, DOI 10.1021/ja037877t
   Urade VN, 2007, LANGMUIR, V23, P4268, DOI 10.1021/la062641z
   Urbanova V, 2014, Z ANORG ALLG CHEM, V640, P537, DOI 10.1002/zaac.201300442
   Urek S. K., 2013, J NANOMATER, V2013, P1
   Van der Voort P, 2002, J PHYS CHEM B, V106, P9027, DOI 10.1021/jp0261152
   VANBEEK JJ, 1991, J NON-CRYST SOLIDS, V134, P14, DOI 10.1016/0022-3093(91)90006-R
   VANDERVIS MGM, 1992, J MOL STRUCT, V274, P47, DOI 10.1016/0022-2860(92)80145-8
   Volksen W, 2010, CHEM REV, V110, P56, DOI 10.1021/cr9002819
   Wagner T, 2013, CHEM SOC REV, V42, P4036, DOI 10.1039/c2cs35379b
   Walcarius A, 2013, CHEM SOC REV, V42, P4098, DOI 10.1039/c2cs35322a
   Wang DH, 2003, ADV MATER, V15, P130, DOI 10.1002/adma.200390025
   Wang JF, 2012, CHEM SOC REV, V41, P1111, DOI 10.1039/c1cs15106a
   Wood D. L., 1989, APPL SPECTROSC, V43
   Yamauchi Y, 2009, CHEM REC, V9, P321, DOI 10.1002/tcr.200900022
   Yang HF, 2005, J MATER CHEM, V15, P1217, DOI 10.1039/b414402c
   YOSHINO H, 1990, J NON-CRYST SOLIDS, V126, P68, DOI 10.1016/0022-3093(90)91024-L
   Zhao DY, 1998, J AM CHEM SOC, V120, P6024, DOI 10.1021/ja974025i
NR 120
TC 13
Z9 13
U1 2
U2 34
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1932-7447
J9 J PHYS CHEM C
JI J. Phys. Chem. C
PD AUG 21
PY 2014
VL 118
IS 33
BP 19450
EP 19461
DI 10.1021/jp505651j
PG 12
WC Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science,
   Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA AN7VR
UT WOS:000340809600072
DA 2018-03-20
ER

PT J
AU Akter, S
   Clem, BF
   Lee, HJ
   Chesney, J
   Bae, Y
AF Akter, Shanjida
   Clem, Brian F.
   Lee, Hyun Jin
   Chesney, Jason
   Bae, Younsoo
TI Block Copolymer Micelles for Controlled Delivery of Glycolytic Enzyme
   Inhibitors
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE drug delivery; polymer micelles; glycolysis; fructose-2,6-bisphosphate;
   cancer
ID DRUG-DELIVERY; BIOLOGICAL SIGNIFICANCE; POLYMERIC MICELLES; SYSTEMS;
   DESIGN; RAS; 6-PHOSPHOFRUCTO-2-KINASE; BIODISTRIBUTION; TRANSFORMATION;
   VEHICLES
AB To develop block copolymer micelles as an aqueous dosage form for a potent glycolytic enzyme inhibitor, 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO).
   The micelles were prepared from poly(ethylene glycol)-poly(aspartate hydrazide) [PEG-p(HYD)] block copolymers to which 3PO was conjugated through an acid-labile hydrazone bond. The optimal micelle formulation was determined following the screening of block copolymer library modified with various aromatic and aliphatic pendant groups. Both physical drug entrapment and chemical drug conjugation methods were tested to maximize 3PO loading in the micelles during the screening.
   Particulate characterization showed that the PEG-p(HYD) block copolymers conjugated with 3PO (2.08 similar to 2.21 wt.%) appeared the optimal polymer micelles. Block copolymer compositions greatly affected the micelle size, which was 38 nm and 259 nm when 5 kDa and 12 kDa PEG chains were used, respectively. 3PO release from the micelles was accelerated at pH 5.0, potentiating effective drug release in acidic tumor environments. The micelles retained biological activity of 3PO, inhibiting various cancer cells (Jurkat, He-La and LLC) in concentration ranges similar to free 3PO.
   A novel micelle formulation for controlled delivery of 3PO was successfully prepared.
C1 [Akter, Shanjida; Lee, Hyun Jin; Bae, Younsoo] Univ Kentucky, Dept Pharmaceut Sci, Coll Pharm, Lexington, KY 40536 USA.
   [Clem, Brian F.; Chesney, Jason] Univ Louisville, Dept Med, James Graham Brown Canc Ctr, Louisville, KY 40202 USA.
RP Bae, Y (reprint author), Univ Kentucky, Dept Pharmaceut Sci, Coll Pharm, 789 South Limestone, Lexington, KY 40536 USA.
EM younsoo.bae@uky.edu
FU Kentucky Lung Cancer Research Program
FX This research is supported by the Kentucky Lung Cancer Research Program.
CR Allen C, 1999, COLLOID SURFACE B, V16, P3, DOI 10.1016/S0927-7765(99)00058-2
   Bae Y, 2005, MOL BIOSYST, V1, P242, DOI 10.1039/b500266d
   Bae Y, 2005, BIOCONJUGATE CHEM, V16, P122, DOI 10.1021/bc0498166
   Bae Y, 2009, ADV DRUG DELIVER REV, V61, P768, DOI 10.1016/j.addr.2009.04.016
   Berdanier CD, 2005, OXID STRESS DIS, V16, P455
   CAMMAS S, 1995, MACROMOL CHEM PHYSIC, V196, P1899, DOI 10.1002/macp.1995.021960609
   Clem B, 2008, MOL CANCER THER, V7, P110, DOI 10.1158/1535-7163.MCT-07-0482
   Cukierman E, 2010, BIOCHEM PHARMACOL, V80, P762, DOI 10.1016/j.bcp.2010.04.020
   GAO ZS, 1993, MACROMOLECULES, V26, P7353, DOI 10.1021/ma00078a035
   Gillies RJ, 2008, J NUCL MED, V49, p24S, DOI 10.2967/jnumed.107.047258
   HUE L, 1993, ADV ENZYME REGUL, V33, P97
   Jain RK, 1997, ADV DRUG DELIVER REV, V26, P71, DOI 10.1016/S0169-409X(97)00027-6
   Jones AT, 2003, ADV DRUG DELIVER REV, V55, P1353, DOI 10.1016/j.addr.2003.07.002
   Kataoka K, 2000, J CONTROL RELEASE, V64, P143, DOI 10.1016/S0168-3659(99)00133-9
   KATAOKA K, 1993, J CONTROL RELEASE, V24, P119
   Kataoka K, 2001, ADV DRUG DELIVER REV, V47, P113, DOI 10.1016/S0169-409X(00)00124-1
   KWON GS, 1993, PHARMACEUT RES, V10, P970, DOI 10.1023/A:1018998203127
   KWON GS, 1994, COLLOID SURFACE B, V2, P429
   Lavasanifar A, 2002, ADV DRUG DELIVER REV, V54, P169, DOI 10.1016/S0169-409X(02)00015-7
   Lee HJ, 2010, THER DELIV, V1, P803, DOI 10.4155/TDE.10.70
   Matsumura Y, 2008, ADV DRUG DELIVER REV, V60, P899, DOI 10.1016/j.addr.2007.11.010
   Matsumura Y, 2009, CANCER SCI, V100, P572, DOI 10.1111/j.1349-7006.2009.01103.x
   Mazurek S, 2001, ONCOGENE, V20, P6891, DOI 10.1038/sj.onc.1204792
   Ponta A, 2010, PHARM RES-DORDR, V27, P2330, DOI 10.1007/s11095-010-0120-z
   Rarnanathan A, 2005, P NATL ACAD SCI USA, V102, P5992, DOI 10.1073/pnas.0502267102
   Suzuki H, 1996, ADV DRUG DELIVER REV, V19, P335, DOI 10.1016/0169-409X(96)00008-7
   Takakura Y, 1996, PHARMACEUT RES, V13, P820, DOI 10.1023/A:1016084508097
   Telang S, 2006, ONCOGENE, V25, P7225, DOI 10.1038/sj.onc.1209709
   Vander Heiden MG, 2009, SCIENCE, V324, P1029, DOI DOI 10.1126/SCIENCE.1160809
   Vizan P, 2005, CANCER RES, V65, P5512, DOI 10.1158/0008-5472.CAN-05-0074
   West Kevin R, 2005, Curr Drug Discov Technol, V2, P123, DOI 10.2174/1570163054866882
   Wexler EJ, 2000, CLIN CANCER RES, V6, P3361
   YOKOYAMA M, 1992, BIOCONJUGATE CHEM, V3, P295, DOI 10.1021/bc00016a007
   YOKOYAMA M, 1994, J CONTROL RELEASE, V28, P59
NR 34
TC 13
Z9 14
U1 1
U2 16
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
EI 1573-904X
J9 PHARM RES-DORDR
JI Pharm. Res.
PD MAR
PY 2012
VL 29
IS 3
BP 847
EP 855
DI 10.1007/s11095-011-0613-4
PG 9
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 894WF
UT WOS:000300457500019
PM 22033882
DA 2018-03-19
ER

PT J
AU Li, XS
   Turanek, J
   Knotigova, P
   Kudlackova, H
   Masek, J
   Pennington, DB
   Rankin, SE
   Knutson, BL
   Lehmler, HJ
AF Li, Xueshu
   Turanek, Jaroslav
   Knotigova, Pavlina
   Kudlackova, Hana
   Masek, Josef
   Pennington, D. Brant
   Rankin, Stephen E.
   Knutson, Barbara L.
   Lehmler, Hans-Joachim
TI Synthesis and biocompatibility evaluation of fluorinated, single-tailed
   glucopyranoside surfactants
SO NEW JOURNAL OF CHEMISTRY
LA English
DT Article
ID BETA-D-GLUCOPYRANOSIDES; AIR-WATER-INTERFACE; CHAIN ALKYL
   GLYCOPYRANOSIDES; IN-FLUOROCARBON EMULSIONS; KOENIGS-KNORR REACTION;
   BIOMEDICAL APPLICATIONS; CARBOXYLIC-ACIDS; PERFLUOROALKYLATED
   AMPHIPHILES; LYOTROPIC PROPERTIES; PHASE-BEHAVIOR
AB Partially fluorinated non-ionic surfactants are of interest for a range of biomedical applications, such as the pulmonary administration of drugs using reverse water-in-perfluorocarbon microemulsions. We herein report the synthesis and characterization of a series of partially fluorinated beta-D-glucopyranoside surfactants from the respective alcohols and peracetylated beta-D-glucopyranoside using BF(3)center dot Et(2)O as catalyst. The surfactant packing parameter of the fluorinated surfactants ranged from 0.472 to 0.534 (MOPAC calculations) or 0.562 to 0.585 (calculated from literature values), which is comparable to surfactants with a similar partially fluorinated tail. Based on an initial biocompatibility assessment, the b-D-glucopyranoside surfactants have low toxicities in the B16F10 mouse melanoma cell line and comparatively low haemolytic activities towards rabbit red blood cells. The fluorinated surfactants appear to be less toxic towards cells in culture and to have a lower haemolytic activity compared to their hydrocarbon analogs. Furthermore, an increasing degree of fluorination appears to reduce both the cytotoxicity and the haemolytic activity. Similar structure-activity relationships have been reported for other partially fluorinated surfactants. Overall, these findings suggest that the surfactants may be useful for biomedical applications, such as novel drug delivery systems.
C1 [Turanek, Jaroslav; Knotigova, Pavlina; Kudlackova, Hana; Masek, Josef] Vet Res Inst Vvi, Dept Vaccinol & Immunotherapy, Brno, Czech Republic.
   [Li, Xueshu; Lehmler, Hans-Joachim] Univ Iowa, Dept Environm & Occupat Hlth, Iowa City, IA 52242 USA.
   [Pennington, D. Brant; Rankin, Stephen E.; Knutson, Barbara L.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Turanek, J (reprint author), Vet Res Inst Vvi, Dept Vaccinol & Immunotherapy, Brno, Czech Republic.
EM turanek@vri.cz; hans-joachim-lehmler@uiowa.edu
RI Masek, Josef/B-3734-2015; Rankin, Stephen/A-3265-2013; Li,
   Xueshu/C-2262-2011
OI Masek, Josef/0000-0001-6788-8487; Rankin, Stephen/0000-0002-8615-7564;
   Lehmler, Hans-Joachim/0000-0001-9163-927X
FU National Institute of Environmental Health Sciences [ES12475]; National
   Science Foundation [NIRT 0210517]; US Department of Agriculture Biomass
   Research and Development Initiative [68-3A75-7-608]; Commonwealth of
   Kentucky; Ministry of Agriculture of the Czech Republic
   [MZE-0002716201];  [NAZV QF-3115]
FX The authors thank Dr Paul Bummer (University of Kentucky) for access to
   the DSC instrument. This work was supported by grants from the National
   Institute of Environmental Health Sciences (ES12475), the National
   Science Foundation (NIRT 0210517), the US Department of Agriculture
   Biomass Research and Development Initiative (Grant Agreement
   68-3A75-7-608) and the Department of Energy Development and
   Independence, Energy and Environment Cabinet of The Commonwealth of
   Kentucky. Additional support was provided by grants from the Ministry of
   Agriculture of the Czech Republic (grant No. MZE-0002716201) and NAZV
   QF-3115 to J.T. Its contents are solely the responsibility of the
   authors and do not necessarily represent the official views of the
   funding agencies.
CR ABOUHILALE S, 1992, J AM OIL CHEM SOC, V69, P1, DOI 10.1007/BF02635867
   Adasch V, 1998, CARBOHYD RES, V314, P177, DOI 10.1016/S0008-6215(98)00302-4
   Andreana PR, 2002, ORG LETT, V4, P1863, DOI 10.1021/ol0258379
   Arora M, 2003, LANGMUIR, V19, P8843, DOI 10.1021/la034734b
   BANK U, 1991, Allergie und Immunologie (Leipzig), V37, P119
   Boyd BJ, 2000, LANGMUIR, V16, P7359, DOI 10.1021/la991573w
   CESCHIN C, 1985, J CHEM TECH BIOT A, V35, P73
   Courrier HA, 2004, COLLOID SURFACE A, V244, P141, DOI 10.1016/j.colsurfa.2004.06.003
   Courrier HM, 2004, INT J PHARM, V282, P131, DOI 10.1016/j.ijpharm.2004.06.011
   Courrier HM, 2003, BIOMATERIALS, V24, P689, DOI 10.1016/S0142-9612(02)00407-6
   GIULIERI F, 1994, COLLOID SURFACE A, V84, P121, DOI 10.1016/0927-7757(93)02732-T
   Graupe M, 1999, J FLUORINE CHEM, V93, P107, DOI 10.1016/S0022-1139(98)00284-X
   GREINER J, 1988, TETRAHEDRON LETT, V29, P2193, DOI 10.1016/S0040-4039(00)86708-8
   Hein M, 2000, LIQ CRYST, V27, P163, DOI 10.1080/026782900202921
   Hein M, 1999, J FLUORINE CHEM, V98, P55, DOI 10.1016/S0022-1139(99)00076-7
   Hein M, 1998, TETRAHEDRON LETT, V39, P6679, DOI 10.1016/S0040-4039(98)01435-X
   IDZIOREK T, 1995, J IMMUNOL METHODS, V185, P249, DOI 10.1016/0022-1759(95)00172-7
   ISRAELACHVILI JN, 1976, J CHEM SOC FARAD T 2, V72, P1525, DOI 10.1039/f29767201525
   Kasuya MCZ, 2004, BIOCHEM BIOPH RES CO, V316, P599, DOI 10.1016/j.bbrc.2004.02.094
   Kasuya MCZ, 2005, J CARBOHYD CHEM, V24, P705, DOI 10.1080/07328300500208107
   Kasuya MCZ, 2005, CHEM LETT, V34, P856, DOI 10.1246/cl.2005.856
   KIWADA H, 1985, CHEM PHARM BULL, V33, P753
   Konstantinovic S, 2002, INDIAN J CHEM B, V41, P598
   KRAFFT MP, 1990, NEW J CHEM, V14, P869
   Ladmiral V, 2006, J AM CHEM SOC, V128, P4823, DOI 10.1021/ja058364k
   Lehmler HJ, 2007, EXPERT OPIN DRUG DEL, V4, P247, DOI 10.1517/17425247.4.3.247
   Lehmler HJ, 2005, J LIPID RES, V46, P2415, DOI 10.1194/jlr.M500231-JLR200
   Lehmler HJ, 2005, COLLOID SURFACE B, V44, P74, DOI 10.1016/j.colsurfb.2005.05.014
   Lehmler HJ, 2004, BBA-BIOMEMBRANES, V1664, P141, DOI 10.1016/j.bbamem.2004.05.002
   Lehmler HJ, 2002, J FLUORINE CHEM, V117, P17, DOI 10.1016/S0022-1139(02)00169-0
   Lehmler HJ, 2001, J FLUORINE CHEM, V107, P141, DOI 10.1016/S0022-1139(00)00384-5
   Lehmler HJ, 1999, CHEMTECH, V29, P7
   Lehmler HJ, 2000, LANGMUIR, V16, P10161, DOI 10.1021/la991598v
   LI ZJ, 1992, SYNTHETIC COMMUN, V22, P2121, DOI 10.1080/00397919208021347
   LoNostro P, 1999, J PHYS CHEM B, V103, P5347, DOI 10.1021/jp9827025
   MATHIS G, 1984, J AM CHEM SOC, V106, P6162, DOI 10.1021/ja00333a007
   Miethchen R, 2000, CARBOHYD RES, V327, P169, DOI 10.1016/S0008-6215(99)00317-1
   MILIUS A, 1991, NEW J CHEM, V15, P337
   Milkereit G, 2004, CHEM PHYS LIPIDS, V127, P47, DOI 10.1016/j.chemphyslip.2003.09.007
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Naud C, 2000, J FLUORINE CHEM, V104, P173, DOI 10.1016/S0022-1139(00)00215-3
   NIVET JB, 1991, EUR J MED CHEM, V26, P953, DOI 10.1016/0223-5234(91)90138-D
   PAULSEN H, 1985, CARBOHYD RES, V137, P39, DOI 10.1016/0008-6215(85)85148-X
   Petrovic Z, 2004, INDIAN J CHEM B, V43, P132
   Riess JG, 2002, J FLUORINE CHEM, V114, P119, DOI 10.1016/S0022-1139(02)00017-9
   Riess JG, 2000, CARBOHYD RES, V327, P147, DOI 10.1016/S0008-6215(00)00012-4
   Sadtler VM, 1996, ANGEW CHEM INT EDIT, V35, P1976, DOI 10.1002/anie.199619761
   Sadtler VM, 1998, NEW J CHEM, V22, P609, DOI 10.1039/a708757h
   SCHUBERT KV, 1994, COLLOID SURFACE A, V84, P97, DOI 10.1016/0927-7757(93)02704-I
   STEVENS CL, 1974, J ORG CHEM, V39, P298, DOI 10.1021/jo00917a004
   Tickle D, 1998, J CHEM SOC PERK T 2, P467, DOI 10.1039/a708418h
   TSUI DSK, 1985, CARBOHYD RES, V144, P137, DOI 10.1016/0008-6215(85)85014-X
   Turanek J, 2004, ANTI-CANCER DRUG, V15, P537, DOI 10.1097/01.cad.0000127147.57796.e5
   VILL V, 1989, LIQ CRYST, V6, P349, DOI 10.1080/02678298908029086
   Vill V, 2000, CHEM PHYS LIPIDS, V104, P75, DOI 10.1016/S0009-3084(99)00119-X
   Vyas SM, 2006, NEW J CHEM, V30, P944, DOI 10.1039/b516039a
   Yuasa Y, 2004, ORG PROCESS RES DEV, V8, P405, DOI 10.1021/op0300488
   ZARIF L, 1989, J FLUORINE CHEM, V44, P73, DOI 10.1016/S0022-1139(00)84372-9
   ZARIF L, 1990, J MED CHEM, V33, P1262, DOI 10.1021/jm00166a028
NR 59
TC 21
Z9 21
U1 0
U2 14
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1144-0546
J9 NEW J CHEM
JI New J. Chem.
PY 2008
VL 32
IS 12
BP 2169
EP 2179
DI 10.1039/b805015e
PG 11
WC Chemistry, Multidisciplinary
SC Chemistry
GA 384MA
UT WOS:000261747700015
DA 2018-03-20
ER

PT J
AU Garcia, M
   Badugu, R
   Bondada, V
   Geddes, J
AF Garcia, Matthew
   Badugu, RamaKrishna
   Bondada, Vimala
   Geddes, James W.
TI Mu-calpain is located in the mitochondrial intermembrane space
SO JOURNAL OF NEUROTRAUMA
LA English
DT Meeting Abstract
CT 25th Annual National-Neurotrauma-Society Symposium
CY JUL 29-AUG 01, 2007
CL Kansas City, MO
SP Natl Neurotrauma Soc
C1 Univ Kentucky, Lexington, KY USA.
RI Badugu, RamaKrishna/A-8572-2008
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0897-7151
J9 J NEUROTRAUM
JI J. Neurotrauma
PD JUL
PY 2007
VL 24
IS 7
MA P55
BP 1242
EP 1242
PG 1
WC Critical Care Medicine; Clinical Neurology; Neurosciences
SC General & Internal Medicine; Neurosciences & Neurology
GA 186DV
UT WOS:000247760200065
DA 2018-03-20
ER

PT J
AU Nagpure, S
   Browning, JF
   Rankin, SE
AF Nagpure, Suraj
   Browning, James F.
   Rankin, Stephen E.
TI Incorporating poly(3-hexyl thiophene) into orthogonally aligned
   cylindrical nanopores of titania for optoelectronics
SO MICROPOROUS AND MESOPOROUS MATERIALS
LA English
DT Article
DE Titania; Organic-inorganic; P3HT; Oriented; Nanopores
ID HETEROJUNCTION SOLAR-CELLS; TIO2 THIN-FILMS; MESOPOROUS TITANIA;
   CONJUGATED POLYMERS; PHOTOVOLTAIC APPLICATIONS; PHOTOCATALYTIC ACTIVITY;
   PORE ORIENTATION; CHARGE-TRANSFER; NANOTUBE ARRAY; QUANTUM DOTS
AB The incorporation of hole conducting polymer poly(3-hexyl thiophene) (P3HT) into the 8-9 nm cylindrical nanopores of titania is investigated using films with a unique orthogonally oriented hexagonal close packed mesostructure. The films are synthesized using evaporation induced self-assembly (EISA) with Pluronic triblock copolymer F127 as the structure directing agent. The orthogonally oriented cylindrical nanopore structure was chosen over a cubic structure because confinement in uniform cylindrical channels is hypothesized to enhance hole conductivity of P3HT by inducing local polymer chain ordering. Orthogonal orientation of the cylindrical nanopores is achieved by modifying the substrate (FTO-coated glass slides) with crosslinked F127. After thermal treatment to remove organic templates from the films, P3HT is infiltrated into the nanopores by spin coating a 1 wt% P3HT solution in chlorobenzene onto the titania films followed by thermal annealing under vacuum at 200 degrees C. The results show that infiltration is essentially complete after 30 min of annealing, with little or no further infiltration thereafter. A final infiltration depth of -14 nm is measured for P3HT into the nanopores of titania using neutron reflectometry measurements. Photoluminescence measurements demonstrate that charge transfer at the P3HT-TiO2 interface improves as the P3HT is infiltrated into the pores, suggesting that an active organic-inorganic heterojuction is formed in the materials. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Nagpure, Suraj; Rankin, Stephen E.] Univ Kentucky, Dept Chem & Mat Engn, 177 FP Anderson Tower, Lexington, KY 40506 USA.
   [Browning, James F.] Oak Ridge Natl Lab, Spallat Neutron Source, Oak Ridge, TN USA.
RP Rankin, SE (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 FP Anderson Tower, Lexington, KY 40506 USA.
EM srankin@engr.uky.edu
RI Browning, James/C-9841-2016
OI Browning, James/0000-0001-8379-259X
FU U.S. Department of Energy EPSCoR Implementation [DEFG02-07-ER46375];
   Scientific User Facilities Division; Office of Basic Energy Sciences,
   U.S. DOE; U. S. Department of Energy, Office of Science, Office of Basic
   Energy Sciences [DE-ACO2-06CH11357]; NSF EPSCoR research infrastructure
   award [IIA-1355438]
FX All experiments were performed as part of a U.S. Department of Energy
   EPSCoR Implementation award supported by grant no. DEFG02-07-ER46375.
   Neutron reflectometry measurements were carried out on the liquids
   reflectometer at the Spallation Neutron Source, which is sponsored by
   the Scientific User Facilities Division, Office of Basic Energy
   Sciences, U.S. DOE (J.F.B.J.K.K.). The use of the Advanced Photon Source
   at Argonne National Laboratory for GISAXS measurements was supported by
   the U. S. Department of Energy, Office of Science, Office of Basic
   Energy Sciences, under Contract No. DE-ACO2-06CH11357. SEM
   characterization was performed at the Electron Microscopy Center,
   University of Kentucky. PL spectroscopy experiments were performed at
   Advanced Materials Characterization Service Center, University of
   Louisville. Final data analysis and refinement were completed as part of
   a NSF EPSCoR research infrastructure award (grant no. IIA-1355438).
CR Bkakri R, 2015, J LUMIN, V161, P264, DOI 10.1016/j.jlumin.2015.01.014
   Boucle J, 2008, ADV FUNCT MATER, V18, P622, DOI 10.1002/adfm.200700280
   Brinker CJ, 2004, MRS BULL, V29, P631, DOI 10.1557/mrs2004.183
   Brown PJ, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.064203
   Campus F, 1999, SOL ENERG MAT SOL C, V56, P281, DOI 10.1016/S0927-0248(98)00138-X
   Chandrasekaran J, 2011, RENEW SUST ENERG REV, V15, P1228, DOI 10.1016/j.rser.2010.09.017
   Coakley KM, 2005, MRS BULL, V30, P37, DOI 10.1557/mrs2005.7
   Coakley KM, 2003, ADV FUNCT MATER, V13, P301, DOI 10.1002/adfm.200304361
   Coakley KM, 2003, APPL PHYS LETT, V83, P3380, DOI 10.1063/1.1616197
   Crepaldi EL, 2003, J AM CHEM SOC, V125, P9770, DOI 10.1021/ja030070g
   Das S, 2016, PHYS CHEM CHEM PHYS, V18, P2896, DOI 10.1039/c5cp05178a
   Das S, 2014, J PHYS CHEM C, V118, P968, DOI 10.1021/jp406165v
   Feng PY, 2000, LANGMUIR, V16, P5304, DOI 10.1021/la991444f
   FORRO L, 1994, J APPL PHYS, V75, P633, DOI 10.1063/1.355801
   Fujibayashi T, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2200741
   Guo W, 2012, CHEM COMMUN, V48, P6133, DOI 10.1039/c2cc31903a
   Hao YZ, 2012, SOL ENERG MAT SOL C, V101, P107, DOI 10.1016/j.solmat.2012.02.032
   Harrison MG, 1997, PHYS REV B, V55, P7831, DOI 10.1103/PhysRevB.55.7831
   Huang YC, 2011, J MATER CHEM, V21, P4450, DOI 10.1039/c0jm03615c
   Islam SZ, 2016, MATER CHEM PHYS, V182, P382, DOI 10.1016/j.matchemphys.2016.07.046
   Islam SZ, 2016, J PHYS CHEM C, V120, P14069, DOI 10.1021/acs.jpcc.6b02622
   Islam SZ, 2016, MICROPOR MESOPOR MAT, V220, P120, DOI 10.1016/j.micromeso.2015.08.030
   Ismail AA, 2010, J PHOTOCH PHOTOBIO A, V216, P183, DOI 10.1016/j.jphotochem.2010.05.016
   Ismail AA, 2010, CHEM MATER, V22, P108, DOI 10.1021/cm902500e
   Jarzab D, 2009, J PHYS CHEM B, V113, P16513, DOI 10.1021/jp907840z
   Jiang KJ, 2009, ADV FUNCT MATER, V19, P2481, DOI 10.1002/adfm.200900283
   Kandiel TA, 2011, PHYS CHEM CHEM PHYS, V13, P20155, DOI 10.1039/c1cp22612f
   Kim DJ, 2010, J NANOELECTRON OPTOE, V5, P277, DOI 10.1166/jno.2010.1109
   Kim MH, 2010, J NANOSCI NANOTECHNO, V10, P279, DOI 10.1166/jnn.2010.1489
   Kim S, 2010, IEEE J SEL TOP QUANT, V16, P1573, DOI 10.1109/JSTQE.2009.2035334
   Kim SS, 2007, J PHOTOCH PHOTOBIO A, V188, P364, DOI 10.1016/j.jphotochem.2006.12.037
   Kimura T, 2009, CHEM-ASIAN J, V4, P1486, DOI 10.1002/asia.200900154
   Koganti VR, 2006, NANO LETT, V6, P2567, DOI 10.1021/nl061992v
   Kroeze JE, 2003, J PHYS CHEM B, V107, P7696, DOI 10.1021/jp0217738
   Kwong CY, 2004, NANOTECHNOLOGY, V15, P1156, DOI 10.1088/0957-4484/15/9/008
   Lee J, 2011, SOL ENERG MAT SOL C, V95, P3152, DOI 10.1016/j.solmat.2011.06.046
   Li Y, 2012, J SOLID STATE CHEM, V196, P349, DOI 10.1016/j.jssc.2012.06.041
   Lim CS, 2012, NANOSCALE, V4, P429, DOI 10.1039/c1nr11476j
   Lin CC, 2012, J PHYS CHEM C, V116, P25081, DOI 10.1021/jp306921e
   Lin Y, 2012, MACROMOLECULES, V45, P8665, DOI 10.1021/ma3019393
   Lu N, 2008, J SOLID STATE CHEM, V181, P2852, DOI 10.1016/j.jssc.2008.07.004
   Mall M, 2010, CHEM PHYS LETT, V495, P236, DOI 10.1016/j.cplett.2010.06.067
   Manceau M, 2009, POLYM DEGRAD STABIL, V94, P898, DOI 10.1016/j.polymdegradstab.2009.03.005
   Martin J, 2012, POLYMER, V53, P1149, DOI 10.1016/j.polymer.2012.01.028
   Meng XJ, 2009, J MATER CHEM, V19, P1894, DOI 10.1039/b815165b
   Muktha B, 2007, J SOLID STATE CHEM, V180, P2986, DOI 10.1016/j.jssc.2007.07.017
   Nagpure S, 2015, J PHYS CHEM C, V119, P22970, DOI 10.1021/acs.jpcc.5b06945
   Nakayama K, 2008, JPN J APPL PHYS, V47, P6610, DOI 10.1143/JJAP.47.6610]
   Nelson A, 2006, J APPL CRYSTALLOGR, V39, P273, DOI 10.1107/S0021889806005073
   Neyshtadt S, 2008, ADV MATER, V20, P2541, DOI 10.1002/adma.200702485
   Nunzi JM, 2002, CR PHYS, V3, P523, DOI 10.1016/S1631-0705(02)01335-X
   OREGAN B, 1991, NATURE, V353, P737, DOI 10.1038/353737a0
   Pan JH, 2006, CHEM MATER, V18, P847, DOI 10.1021/cm0522782
   Pan JH, 2012, CATAL SCI TECHNOL, V2, P147, DOI 10.1039/c1cy00171j
   Park B, 2010, J MATER CHEM, V20, P10862, DOI 10.1039/c0jm02091e
   Po R, 2010, J PHYS CHEM C, V114, P695, DOI 10.1021/jp9061362
   Rawolle M, 2013, ACS APPL MATER INTER, V5, P719, DOI 10.1021/am302255c
   Steim R, 2010, J MATER CHEM, V20, P2499, DOI 10.1039/b921624c
   Stylianakis MM, 2012, ACS APPL MATER INTER, V4, P4864, DOI 10.1021/am301204g
   Tepavcevic S, 2009, SMALL, V5, P1776, DOI 10.1002/smll.200900093
   Tricoli A, 2012, J MATER CHEM, V22, P14254, DOI 10.1039/c2jm15953h
   Veith GM, 2014, CHEM COMMUN, V50, P3081, DOI 10.1039/c3cc49269a
   Wang JY, 2012, CHEM PHYS LETT, V541, P105, DOI 10.1016/j.cplett.2012.05.074
   Wu QL, 2011, J SOL-GEL SCI TECHN, V60, P81, DOI 10.1007/s10971-011-2553-1
   Xu J, 2007, J AM CHEM SOC, V129, P12828, DOI 10.1021/ja074133x
   Xu TT, 2012, RSC ADV, V2, P854, DOI 10.1039/c1ra00739d
   Yodyingyong S, 2010, J PHYS CHEM C, V114, P21851, DOI 10.1021/jp1077888
   Yuan Q, 2009, MICROPOR MESOPOR MAT, V124, P169, DOI 10.1016/j.micromeso.2009.05.006
   Zeng TW, 2011, LANGMUIR, V27, P15255, DOI 10.1021/la203533u
   Zhang TH, 2012, CHINESE PHYS B, V21, DOI 10.1088/1674-1056/21/11/118401
   Zhang XW, 2009, MATER RES BULL, V44, P1070, DOI 10.1016/j.materresbull.2008.10.017
NR 71
TC 0
Z9 0
U1 4
U2 13
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1387-1811
EI 1873-3093
J9 MICROPOR MESOPOR MAT
JI Microporous Mesoporous Mat.
PD MAR 1
PY 2017
VL 240
BP 65
EP 72
DI 10.1016/j.micromeso.2016.10.050
PG 8
WC Chemistry, Applied; Chemistry, Physical; Nanoscience & Nanotechnology;
   Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA EM9BA
UT WOS:000395604600008
DA 2018-03-20
ER

PT J
AU Bhattacharyya, D
   Xu, J
   Bachas, L
   Datta, S
   Tee, Y
AF Bhattacharyya, Dibakar
   Xu, Jian
   Bachas, Leonidas G.
   Datta, Saurav
   Tee, Yit-Hong
TI I&EC 20-Degradation of chlorinated organics from water by membrane-based
   nanosized metallic systems and by hydroxyl radical reaction
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
CT 235th American-Chemical-Society National Meeting
CY APR 06-10, 2008
CL New Orleans, LA
SP Amer Chem Soc
C1 [Bhattacharyya, Dibakar; Xu, Jian; Tee, Y.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Bachas, Leonidas] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
EM db@engr.uky.edu; jxu1@engr.uky.edu; bachas@uky.edu; sdatt0@engr.uky.edu
RI Bachas, Leonidas/G-2479-2015
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD APR 6
PY 2008
VL 235
MA 20-IEC
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA 519OA
UT WOS:000271775105316
DA 2018-03-19
ER

PT J
AU Wydra, RJ
   Kruse, AM
   Bae, Y
   Anderson, KW
   Hilt, JZ
AF Wydra, Robert J.
   Kruse, Anastasia M.
   Bae, Younsoo
   Anderson, Kimberly W.
   Hilt, J. Zach
TI Synthesis and characterization of PEG-iron oxide core-shell composite
   nanoparticles for thermal therapy
SO MATERIALS SCIENCE & ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS
LA English
DT Article
DE Magnetic nanoparticles; Atom transfer radical polymerization; Thermal
   therapy
ID TRANSFER RADICAL POLYMERIZATION; MAGNETIC NANOPARTICLES;
   SUPERPARAMAGNETIC NANOPARTICLES; BIOMEDICAL APPLICATIONS; HYPERTHERMIA;
   CANCER; FUNCTIONALIZATION; DESIGN; TUMORS; FLUID
AB In this study, core-shell nanoparticles were developed to achieve thermal therapy that can ablate cancer cells in a remotely controlled manner. The core-shell nanoparticles were prepared using atomic transfer radical polymerization (ATRP) to coat iron oxide (Fe3O4) nanoparticles with a poly( ethylene glycol) (PEG) based polymer shell. The iron oxide core allows for the remote heating of the particles in an alternating magnetic field (AMF). The coating of iron oxide with PEG was verified through Fourier transform infrared spectroscopy and thermal gravimetric analysis. A thermoablation (55 degrees C) study was performed on A549 lung carcinoma cells exposed to nanoparticles and over a 10 min AMF exposure. The successful thermoablation of A549 demonstrates the potential use of polymer coated particles for thermal therapy. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Wydra, Robert J.; Kruse, Anastasia M.; Anderson, Kimberly W.; Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Bae, Younsoo] Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40506 USA.
RP Hilt, JZ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 F Paul Anderson Tower, Lexington, KY 40506 USA.
EM hilt@engr.uky.edu
FU National Science Foundation grant: NSF IGERT Training Grant
   [DGE-0653710]; National Science Foundation grant: NSF REU Grant
   [EEC-1156667]
FX The authors acknowledge Dr. Li Chen of the University of Kentucky
   Biostatistics Shared Resource Facility for her assistance with the
   statistical analysis. This work was supported by the following National
   Science Foundation grants: NSF IGERT Training Grant (# DGE-0653710) and
   NSF REU Grant (# EEC-1156667).
CR Berry CC, 2009, J PHYS D APPL PHYS, V42, DOI 10.1088/0022-3727/42/22/224003
   Falk MH, 2001, INT J HYPERTHER, V17, P1, DOI 10.1080/02656730150201552
   Fan QL, 2007, BIOMATERIALS, V28, P5426, DOI 10.1016/j.biomaterials.2007.08.039
   Fortin JP, 2008, EUR BIOPHYS J BIOPHY, V37, P223, DOI 10.1007/s00249-007-0197-4
   Frimpong RA, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/17/175101
   Frimpong RA, 2010, NANOMEDICINE-UK, V5, P1401, DOI 10.2217/NNM.10.114
   Frimpong RA, 2010, J MAGN MAGN MATER, V322, P326, DOI 10.1016/j.jmmm.2009.09.050
   Gupta AK, 2005, BIOMATERIALS, V26, P3995, DOI 10.1016/j.biomaterials.2004.10.012
   Gupta AK, 2004, IEEE T NANOBIOSCI, V3, P66, DOI 10.1109/TNB.2003.820277
   Hao R, 2010, ADV MATER, V22, P2729, DOI 10.1002/adma.201000260
   Hergt R, 2006, J PHYS-CONDENS MAT, V18, pS2919, DOI 10.1088/0953-8984/18/38/S26
   Hildebrandt B, 2002, CRIT REV ONCOL HEMAT, V43, P33, DOI 10.1016/S1040-8428(01)00179-2
   Hilger I, 2001, RADIOLOGY, V218, P570, DOI 10.1148/radiology.218.2.r01fe19570
   Hilger I, 2006, J PHYS-CONDENS MAT, V18, pS2951, DOI 10.1088/0953-8984/18/38/S28
   Hu FX, 2006, BIOMACROMOLECULES, V7, P809, DOI 10.1021/bm050870e
   Issels RD, 2008, EUR J CANCER, V44, P2546, DOI 10.1016/j.ejca.2008.07.038
   Ito A, 2006, CANCER IMMUNOL IMMUN, V55, P320, DOI 10.1007/s00262-005-0049-y
   Jordan A, 1999, J MAGN MAGN MATER, V201, P413, DOI 10.1016/S0304-8853(99)00088-8
   Laurent S, 2008, CHEM REV, V108, P2064, DOI 10.1021/cr068445e
   Majewski P, 2007, CRIT REV SOLID STATE, V32, P203, DOI 10.1080/10408430701776680
   Meenach SA, 2010, ACTA BIOMATER, V6, P1039, DOI 10.1016/j.actbio.2009.10.017
   Miles WC, 2011, LANGMUIR, V27, P5456, DOI 10.1021/la105097d
   Miles WC, 2009, LANGMUIR, V25, P803, DOI 10.1021/la8030655
   Moroz P, 2002, INT J HYPERTHER, V18, P267, DOI 10.1080/02656730110108785
   Neoh KG, 2011, POLYM CHEM-UK, V2, P747, DOI 10.1039/c0py00266f
   Oh JK, 2011, PROG POLYM SCI, V36, P168, DOI 10.1016/j.progpolymsci.2010.08.005
   Pankhurst QA, 2009, J PHYS D APPL PHYS, V42, DOI 10.1088/0022-3727/42/22/224001
   Peppas NA, 2006, ADV MATER, V18, P1345, DOI 10.1002/adma.200501612
   Pyun J, 2001, CHEM MATER, V13, P3436, DOI 10.1021/cm011065j
   Rodriguez-Luccioni HL, 2011, INT J NANOMED, V6, P373, DOI 10.2147/IJN.S14613
   Rosensweig RE, 2002, J MAGN MAGN MATER, V252, P370, DOI 10.1016/S0304-8853(02)00706-0
   Wust P, 2002, LANCET ONCOL, V3, P487, DOI 10.1016/S1470-2045(02)00818-5
   Wust P, 2006, INT J HYPERTHER, V22, P673, DOI 10.1080/02656730601106037
   Xu FJ, 2009, PROG POLYM SCI, V34, P719, DOI 10.1016/j.progpolymsci.2009.04.005
   Yallapu MM, 2011, BIOMATERIALS, V32, P1890, DOI 10.1016/j.biomaterials.2010.11.028
   Zhou LL, 2011, J MATER CHEM, V21, P2823, DOI 10.1039/c0jm02172e
   Zhou Y, 2008, CHEM ENG J, V138, P578, DOI 10.1016/j.cej.2007.07.030
NR 37
TC 18
Z9 18
U1 5
U2 92
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0928-4931
EI 1873-0191
J9 MAT SCI ENG C-MATER
JI Mater. Sci. Eng. C-Mater. Biol. Appl.
PD DEC 1
PY 2013
VL 33
IS 8
BP 4660
EP 4666
DI 10.1016/j.msec.2013.07.019
PG 7
WC Materials Science, Biomaterials
SC Materials Science
GA 261TG
UT WOS:000327686900024
PM 24094173
DA 2018-03-19
ER

PT J
AU Reneer, DV
   Hisel, R
   Ghoshal, S
   Corkins, J
   Hoffman, J
   Kryscio, R
   Lusk, B
   Geddes, J
AF Reneer, Dexter V.
   Hisel, Richard D.
   Ghoshal, Sarbani
   Corkins, Julie
   Hoffman, Joshua M.
   Kryscio, Richard J.
   Lusk, Braden T.
   Geddes, James W.
TI BLAST-INDUCED BRAIN INJURY: INFLUENCE OF SHOCKWAVE COMPONENTS ON INJURY
   TO THE RAT BRAIN
SO JOURNAL OF NEUROTRAUMA
LA English
DT Meeting Abstract
CT 30th Annual National Neurotrauma Symposium
CY JUL 22-25, 2012
CL Phoenix, AZ
DE Blast-Injury; mTBI; Military; Model; Shockwave
C1 [Geddes, James] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr SCoBIRC, Dept Anat & Neurobiol, Lexington, KY USA.
   [Hisel, Richard] GLR Enterprises LLC, Lexington, KY USA.
NR 0
TC 0
Z9 0
U1 0
U2 6
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0897-7151
J9 J NEUROTRAUM
JI J. Neurotrauma
PD JUL
PY 2012
VL 29
IS 10
BP A163
EP A164
PG 2
WC Critical Care Medicine; Clinical Neurology; Neurosciences
SC General & Internal Medicine; Neurosciences & Neurology
GA 971YV
UT WOS:000306244400283
DA 2018-03-20
ER

PT J
AU Akbari, A
   Sheath, P
   Martin, ST
   Shinde, DB
   Shaibani, M
   Banerjee, PC
   Tkacz, R
   Bhattacharyya, D
   Majumder, M
AF Akbari, Abozar
   Sheath, Phillip
   Martin, Samuel T.
   Shinde, Dhanraj B.
   Shaibani, Mahdokht
   Banerjee, Parama Chakraborty
   Tkacz, Rachel
   Bhattacharyya, Dibakar
   Majumder, Mainak
TI Large-area graphene-based nanofiltration membranes by shear alignment of
   discotic nematic liquid crystals of graphene oxide
SO NATURE COMMUNICATIONS
LA English
DT Article
ID WATER DESALINATION; POROUS GRAPHENE; INTERFACIAL-TENSION; CARBON
   NANOTUBES; THIN-FILMS; DISPERSIONS; PERMEATION; FLOW; TRANSPARENT;
   FABRICATION
AB Graphene-based membranes demonstrating ultrafast water transport, precise molecular sieving of gas and solvated molecules shows great promise as novel separation platforms; however, scale-up of these membranes to large-areas remains an unresolved problem. Here we demonstrate that the discotic nematic phase of graphene oxide (GO) can be shear aligned to form highly ordered, continuous, thin films of multi-layered GO on a support membrane by an industrially adaptable method to produce large-area membranes (13 X 14 cm(2)) in <5 s. Pressure driven transport data demonstrate high retention (490%) for charged and uncharged organic probe molecules with a hydrated radius above 5 A as well as modest (30-40%) retention of monovalent and divalent salts. The highly ordered graphene sheets in the plane of the membrane make organized channels and enhance the permeability (71 +/- 5lm(-2) hr(-1) bar(-1) for 150 +/- 15 nm thick membranes).
C1 [Akbari, Abozar; Sheath, Phillip; Martin, Samuel T.; Shinde, Dhanraj B.; Shaibani, Mahdokht; Banerjee, Parama Chakraborty; Tkacz, Rachel; Majumder, Mainak] Monash Univ, Dept Mech & Aerosp Engn, Nanoscale Sci & Engn Lab, Clayton, Vic 3800, Australia.
   [Bhattacharyya, Dibakar] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Majumder, M (reprint author), Monash Univ, Dept Mech & Aerosp Engn, Nanoscale Sci & Engn Lab, Clayton, Vic 3800, Australia.
EM mainak.majumder@monash.edu
RI Majumder, Mainak/B-4667-2011; Akabri, Abozar/I-4960-2017
FU Australian Research Council through an ARC Discovery [DP 110100082]; ARC
   Linkage [LP 140100959]; University of Kentucky NSF EPSCoR grant
FX We acknowledge funding from the Australian Research Council through an
   ARC Discovery (DP 110100082), ARC Linkage (LP 140100959) grant and also
   partial support from University of Kentucky NSF EPSCoR grant. We thank
   Professor Tam Sridhar and Dr Duc Nguyen for the rheological
   measurements.
CR Asatekin A, 2006, J MEMBRANE SCI, V285, P81, DOI 10.1016/j.memsci.2006.07.042
   Barroso T, 2011, J SUPERCRIT FLUID, V56, P312, DOI 10.1016/j.supflu.2010.10.035
   Behabtu N, 2010, NAT NANOTECHNOL, V5, P406, DOI [10.1038/NNANO.2010.86, 10.1038/nnano.2010.86]
   Benedict JB, 2006, J AM CHEM SOC, V128, P5548, DOI 10.1021/ja0601181
   Berry JD, 2015, J COLLOID INTERF SCI, V454, P226, DOI 10.1016/j.jcis.2015.05.012
   Bieleman J., 2008, ADDITIVES COATINGS
   Bunch JS, 2008, NANO LETT, V8, P2458, DOI 10.1021/nl801457b
   CARLSSON T, 1983, J PHYS-PARIS, V44, P909, DOI 10.1051/jphys:01983004408090900
   CARLSSON T, 1982, MOL CRYST LIQ CRYST, V89, P57, DOI 10.1080/00268948208074469
   Celebi K, 2014, SCIENCE, V344, P289, DOI 10.1126/science.1249097
   Chmelik C, 2011, CHEM-ING-TECH, V83, P104, DOI 10.1002/cite.201000179
   Cohen-Tanugi D, 2012, NANO LETT, V12, P3602, DOI 10.1021/nl3012853
   Connolly ML., 1983, J APPL CRYSTALLOGR, V221, P709, DOI DOI 10.1126/SCIENCE.6879170
   Cote LJ, 2010, PURE APPL CHEM, V83, P95
   Dan B, 2011, SOFT MATTER, V7, P11154, DOI 10.1039/c1sm06418e
   Dan B, 2009, ACS NANO, V3, P835, DOI 10.1021/nn8008307
   De Visscher J., 2004, P 3 EUR EUR C VIENN
   Dikin DA, 2007, NATURE, V448, P457, DOI 10.1038/nature06016
   Eda G, 2008, NAT NANOTECHNOL, V3, P270, DOI 10.1038/nnano.2008.83
   Falk K., 2010, NANO LETT, V10, P7
   Fornasiero F, 2008, P NATL ACAD SCI USA, V105, P17250, DOI 10.1073/pnas.0710437105
   Gao W, 2011, ACS APPL MATER INTER, V3, P1821, DOI 10.1021/am200300u
   Guo F, 2011, ACS NANO, V5, P8019, DOI 10.1021/nn2025644
   Han Y, 2013, ADV FUNCT MATER, V23, P3693, DOI 10.1002/adfm.201202601
   Huang K, 2014, ANGEW CHEM INT EDIT, V53, P6929, DOI 10.1002/anie.201401061
   HUMMERS WS, 1958, J AM CHEM SOC, V80, P1339, DOI 10.1021/ja01539a017
   Jalili R, 2013, ADV FUNCT MATER, V23, P5345, DOI 10.1002/adfm.201300765
   Jiang DE, 2009, NANO LETT, V9, P4019, DOI 10.1021/nl9021946
   Joshi RK, 2014, SCIENCE, V343, P752, DOI 10.1126/science.1245711
   KHESHGI HS, 1991, CHEM ENG SCI, V46, P519, DOI 10.1016/0009-2509(91)80012-N
   Kim HW, 2013, SCIENCE, V342, P91, DOI 10.1126/science.1236098
   Kim JE, 2011, ANGEW CHEM INT EDIT, V50, P3043, DOI 10.1002/anie.201004692
   Koenig SP, 2012, NAT NANOTECHNOL, V7, P728, DOI [10.1038/nnano.2012.162, 10.1038/NNANO.2012.162]
   KORESH JE, 1986, J CHEM SOC FARAD T 1, V82, P2057, DOI 10.1039/f19868202057
   Kumar P, 2014, CARBON, V80, P453, DOI 10.1016/j.carbon.2014.08.085
   KURUCSEV T, 1957, J PHYS CHEM-US, V61, P1567, DOI 10.1021/j150557a026
   Lim HN, 2011, INT J NANOMED, V6, P1817, DOI 10.2147/IJN.S23392
   Majumder M, 2005, NATURE, V438, P44, DOI 10.1038/43844a
   Medhekar NV, 2010, ACS NANO, V4, P2300, DOI 10.1021/nn901934u
   Mezzenga R, 2005, LANGMUIR, V21, P3322, DOI 10.1021/la046964b
   NIGHTINGALE ER, 1959, J PHYS CHEM-US, V63, P1381, DOI 10.1021/j150579a011
   PROST J., 1995, PHYS LIQUID CRYSTALS
   REDON C, 1991, PHYS REV LETT, V66, P715, DOI 10.1103/PhysRevLett.66.715
   REITER G, 1994, MACROMOLECULES, V27, P3046, DOI 10.1021/ma00089a023
   Robinson JT, 2008, NANO LETT, V8, P3137, DOI 10.1021/nl8013007
   Rusanov A. I., 1996, INTERFACIAL TENSIOME
   Saliba S, 2013, NANOSCALE, V5, P6641, DOI 10.1039/c3nr01175e
   SATO H, 1975, J CELL BIOL, V67, P501, DOI 10.1083/jcb.67.3.501
   SCHULTZ SG, 1961, J GEN PHYSIOL, V44, P1189, DOI 10.1085/jgp.44.6.1189
   Schweizer S. F. K. a. P. M., 1997, LIQUID FILM COATING
   Senyuk B., 2015, NAT COMMUN, V6
   Sun PZ, 2015, NPG ASIA MATER, V7, DOI 10.1038/am.2015.7
   Surwade SP, 2015, NAT NANOTECHNOL, V10, P459, DOI [10.1038/nnano.2015.37, 10.1038/NNANO.2015.37]
   Tie W, 2013, OPT EXPRESS, V21, P19867, DOI 10.1364/OE.21.019867
   Tkacz R, 2014, CHEM COMMUN, V50, P6668, DOI 10.1039/c4cc00970c
   Tkacz R, 2014, J PHYS CHEM C, V118, P259, DOI 10.1021/jp4080114
   Van der Bruggen B, 1999, J MEMBRANE SCI, V156, P29, DOI 10.1016/S0376-7388(98)00326-3
   van der Marel P, 2010, J MEMBRANE SCI, V348, P66, DOI 10.1016/j.memsci.2009.10.054
   Vatanpour V, 2012, SEP PURIF TECHNOL, V90, P69, DOI 10.1016/j.seppur.2012.02.014
   Vatanpour V, 2011, J MEMBRANE SCI, V375, P284, DOI 10.1016/j.memsci.2011.03.055
   Xu Z, 2011, ACS NANO, V5, P2908, DOI 10.1021/nn200069w
   Xue LJ, 2012, PROG MATER SCI, V57, P947, DOI 10.1016/j.pmatsci.2012.01.003
   Yakhshi-Tafti E, 2011, INT J OPTOMECHATRONI, V5, P393, DOI 10.1080/15599612.2011.633206
   Yang XW, 2011, ANGEW CHEM INT EDIT, V50, P7325, DOI 10.1002/anie.201100723
   Yeh CN, 2015, NAT CHEM, V7, P166, DOI [10.1038/NCHEM.2145, 10.1038/nchem.2145]
   Yoon Y, 2006, J MEMBRANE SCI, V270, P88, DOI 10.1016/j.memsci.2005.06.045
   Zheng HQ, 2012, J MATER CHEM, V22, P14465, DOI 10.1039/c2jm30612c
   Zohuriaan-Mehr MJ, 2008, IRAN POLYM J, V17, P451
NR 68
TC 87
Z9 87
U1 43
U2 314
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD MAR
PY 2016
VL 7
AR 10891
DI 10.1038/ncomms10891
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DF9YX
UT WOS:000371719700001
PM 26947916
OA gold
DA 2018-03-19
ER

PT J
AU Reichert, WM
   Harris, TR
   Lemons, J
   Mikos, AG
   Puleo, DA
   Schoen, FJ
   Temenoff, JS
AF Reichert, William M.
   Harris, Thomas R.
   Lemons, Jack
   Mikos, Antonios G.
   Puleo, David A.
   Schoen, Frederick J.
   Temenoff, Johnna S.
TI 2011 panel on developing a biomaterials curriculum
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
LA English
DT Review
DE biomaterials; curriculum; education; undergraduate; graduate
ID EDUCATION; CHALLENGE; VIEWPOINT
AB This article provides the transcript for the Panel on Developing a Biomaterials Curriculum held at the 2011 annual meeting of the Society for Biomaterials in Orlando, FL. The panelists were Thomas R. Harris of Vanderbilt University, Jack Lemons of the University of Alabama, Birmingham, Antonios G. Mikos of Rice University, David A. Puleo on the University of Kentucky, Frederick J. Schoen of Harvard Medical School, and Johnna S. Temenoff of Georgia Tech/Emory. The panelists, each an expert in engineering education and textbook author, presented their perspectives on key issues of developing undergraduate and graduate curricula that contain a biomaterials focus. The presentations were followed by a lively and informative discussion with the audience. A redacted portion of this discussion is included. (C) 2011 Wiley Periodicals, Inc. J Biomed Mater Res Part A, 2012.
C1 [Reichert, William M.] Duke Univ, Dept Biomed Engn, Durham, NC 27708 USA.
   [Harris, Thomas R.] Vanderbilt Univ, Dept Biomed Engn, Nashville, TN 37235 USA.
   [Mikos, Antonios G.] Rice Univ, Dept Bioengn, Houston, TX 77251 USA.
   [Puleo, David A.] Univ Kentucky, Ctr Biomed Engn, Lexington, KY 40506 USA.
   [Schoen, Frederick J.] Harvard Univ, Sch Med, Dept Pathol, Brigham & Womens Hosp, Boston, MA 02115 USA.
   [Temenoff, Johnna S.] Georgia Tech & Emory Univ, Wallace H Coulter Dept Biomed Engn, Atlanta, GA 30332 USA.
   [Lemons, Jack] Univ Alabama, Sch Dent, Birmingham, AL 35294 USA.
RP Reichert, WM (reprint author), Duke Univ, Dept Biomed Engn, Durham, NC 27708 USA.
EM reichert@duke.edu
CR BLACK J, 1992, J APPL BIOMATER, V3, P231, DOI 10.1002/jab.770030311
   BURNY F, 1995, MAT SCI ENG A-STRUCT, V199, P53, DOI 10.1016/0921-5093(95)09907-7
   Cordray DS, 2009, J ENG EDUC, V98, P335, DOI 10.1002/j.2168-9830.2009.tb01031.x
   Dee K., 2002, INTRO TISSUE BIOMATE
   FELDMAN DS, 1991, J APPL BIOMATER, V2, P133, DOI 10.1002/jab.770020209
   Gatchell DW, 2007, P AM SOC ENG ED HON
   Johnson PC, 2007, TISSUE ENG, V13, P2827, DOI 10.1089/ten.2007.0335
   LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529
   Majno G, 1996, TISSUES DIS, P974
   Park J., 2007, BIOMATERIALS INTRO
   Ratner BD, 2004, BIOMATERIALS SCI INT
   Temenoff J. S., 2008, BIOMATERIALS INTERSE
   [Anonymous], 2007, ADV TISS SCI ENG MUL
   Voronov R, 2010, J BIOMECH, V43, P1279, DOI 10.1016/j.jbiomech.2010.01.007
   Yfantis CD, 2008, P 5 WSEAS IASME INT
NR 15
TC 0
Z9 0
U1 0
U2 13
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1549-3296
J9 J BIOMED MATER RES A
JI J. Biomed. Mater. Res. Part A
PD MAR
PY 2012
VL 100A
IS 3
BP 802
EP 816
DI 10.1002/jbm.a.33242
PG 15
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 880NP
UT WOS:000299414400029
PM 22238222
DA 2018-03-20
ER

PT J
AU Chirra, HD
   Hilt, JZ
AF Chirra, Hariharasudhan D.
   Hilt, J. Zach
TI Nanoscale Characterization of the Equilibrium and Kinetic Response of
   Hydrogel Structures
SO LANGMUIR
LA English
DT Article
ID QUARTZ-CRYSTAL MICROBALANCE; SURFACE-INITIATED POLYMERIZATION;
   POLY(N-ISOPROPYLACRYLAMIDE) BRUSHES; SOLID-SURFACE; QCM-D; AFM;
   NANOCOMPOSITES; NANOPATTERNS; LITHOGRAPHY; FABRICATION
AB The use of hydrogel nanostructured patterns and films in biomedical micro- and nanodevices requires the ability to analyze and understand their response properties at the nanoscale. Herein, the thermoresponse behavior of atom transfer radical polymerization (ATRP) grown poly(ethylene glycol) n dimethacrylate (PEGnDMA) cross-linked poly(N-isopropyl acrylamide) (PNIPAAm) hydrogel thin films over gold was studied. By controlling the mesh size of the hydrogel matrix through tuning the cross-linking density (i.e., using different molecular weight cross-linker and/or various amounts of cross-linker), the hydrogel volume swelling ratio was tailored for response applications. Thermoresponsive patterns exhibited a broad lower critical solution temperature (LCST) swelling transition, while rms roughness analysis of the hydrogel surface showed a sharp LCST transition. Mass and viscoelastic property changes were monitored using quartz crystal microbalance with dissipation (QCM-D), and the rapid response behavior of the thin hydrogel films was observed. The tunable response behavior along with the controlled growth of the hydrogel achieved via ATRP at the nanoscale make them applicable as functional components in diagnostic and therapeutic devices.
C1 [Chirra, Hariharasudhan D.; Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Hilt, JZ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM hilt@engr.uky.edu
CR Agarwal AK, 2007, LAB CHIP, V7, P310, DOI 10.1039/b617767k
   Ali M, 2007, J CONTROL RELEASE, V124, P154, DOI 10.1016/j.jconrel.2007.09.006
   Baldi A, 2006, SENSOR ACTUAT B-CHEM, V114, P9, DOI 10.1016/j.snb.2005.04.020
   Bunsow J, 2008, J COLLOID INTERF SCI, V326, P61, DOI 10.1016/j.jcis.2008.07.009
   CHIRRA HD, 2009, POLYM ADV TECHNOL
   Cushing MC, 2007, SCIENCE, V316, P1133, DOI 10.1126/science.1140171
   Frimpong RA, 2007, J BIOMED MATER RES A, V80A, P1, DOI 10.1002/jbm.a.30962
   He Q, 2007, LANGMUIR, V23, P3981, DOI 10.1021/la062793u
   Hilt JZ, 2003, BIOMED MICRODEVICES, V5, P177, DOI 10.1023/A:1025786023595
   Hook F, 2001, ANAL CHEM, V73, P5796, DOI 10.1021/ac0106501
   HUFFNER J, 1986, J PHYS C SOLID STATE, V4, P3
   Ishida N, 2007, MACROMOLECULES, V40, P9045, DOI 10.1021/ma071878e
   Ishida N, 2007, LANGMUIR, V23, P11083, DOI 10.1021/la701461b
   Kaholek M, 2004, CHEM MATER, V16, P3688, DOI 10.1021/cm049562y
   Kaholek M, 2004, NANO LETT, V4, P373, DOI 10.1021/nl035054w
   Liu GM, 2005, J PHYS CHEM B, V109, P743, DOI 10.1021/jp046903m
   Low LM, 2000, SENSOR ACTUAT B-CHEM, V67, P149, DOI 10.1016/S0925-4005(00)00396-8
   Lutz JF, 2006, MACROMOLECULES, V39, P893, DOI 10.1021/ma0517042
   Matyjaszewski K, 2007, LANGMUIR, V23, P4528, DOI 10.1021/la063402e
   OKANO T, 1990, J CONTROL RELEASE, V11, P255, DOI 10.1016/0168-3659(90)90138-J
   Peppas NA, 2006, ADV MATER, V18, P1345, DOI 10.1002/adma.200501612
   RITGER P L, 1987, Journal of Controlled Release, V5, P23, DOI 10.1016/0168-3659(87)90034-4
   RODAHL M, 1995, REV SCI INSTRUM, V66, P3924, DOI 10.1063/1.1145396
   Rodahl M, 1996, REV SCI INSTRUM, V67, P3238, DOI 10.1063/1.1147494
   Satarkar NS, 2008, ACTA BIOMATER, V4, P11, DOI 10.1016/j.actbio.2007.07.009
   SCHILD HG, 1992, PROG POLYM SCI, V17, P163, DOI 10.1016/0079-6700(92)90023-R
   Takada K, 1997, J AM CHEM SOC, V119, P10763, DOI 10.1021/ja9716315
   Tamirisa PA, 2006, MACROMOLECULES, V39, P7092, DOI 10.1021/ma060944u
   Tu H, 2004, LANGMUIR, V20, P8313, DOI 10.1021/la049663a
   Wang J, 2005, BIOMED MICRODEVICES, V7, P313, DOI 10.1007/s10544-005-6073-z
   ZENG X, 2008, APPL PHYS LETT, V93
   Zhang GZ, 2004, MACROMOLECULES, V37, P6553, DOI 10.1021/ma035937+
   Zhou F, 2006, J AM CHEM SOC, V128, P16253, DOI 10.1021/ja0654377
NR 33
TC 18
Z9 21
U1 7
U2 31
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0743-7463
J9 LANGMUIR
JI Langmuir
PD JUL 6
PY 2010
VL 26
IS 13
BP 11249
EP 11257
DI 10.1021/la1005677
PG 9
WC Chemistry, Multidisciplinary; Chemistry, Physical; Materials Science,
   Multidisciplinary
SC Chemistry; Materials Science
GA 616VX
UT WOS:000279239900114
PM 20486693
DA 2018-03-20
ER

PT J
AU Gui, M
   Ormsbee, LE
   Bhattacharyya, D
AF Gui, Minghui
   Ormsbee, Lindell R.
   Bhattacharyya, Dibakar
TI Reactive Functionalized Membranes for Polychlorinated Biphenyl
   Degradation
SO INDUSTRIAL & ENGINEERING CHEMISTRY RESEARCH
LA English
DT Article
ID ZERO-VALENT IRON; HYDROGEN-PEROXIDE; BIMETALLIC NANOPARTICLES;
   OXIDATIVE-DEGRADATION; PD/FE NANOPARTICLES; HYDROXYL RADICALS; FENTON
   REACTION; ACRYLIC-ACID; DECHLORINATION; PARTICLES
AB Membranes have been widely used in water remediation (e.g., desalination and heavy metal removal) because of the ability to control membrane pore size and surface charge. The incorporation of nanomaterials into the membranes provides added benefits through increased reactivity with different functionality. In this study, we report the dechlorination of 2-chlorobiphenyl in the aqueous phase by a reactive membrane system. Fe/Pd bimetallic nanoparticles (NPs) were synthesized (in situ) within poly(acrylic acid) (PAA) functionalized polyvinylidene fluoride (PVDF) membranes for degradation of polychlorinated biphenyls (PCBs). Biphenyl formed in the reduction was further oxidized into hydroxylated biphenyls and benzoic acid by an iron-catalyzed hydroxyl radical (OH center dot) reaction. The formation of magnetite on Fe surface was observed. This combined pathway (reductive/oxidative) could reduce the toxicity of PCBs effectively while eliminating the formation of chlorinated degradation byproducts. The successful manufacturing of full-scale functionalized membranes demonstrates the possibility of applying reactive membranes in practical water treatment.
C1 [Gui, Minghui; Bhattacharyya, Dibakar] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Ormsbee, Lindell E.] Univ Kentucky, Dept Civil Engn, Lexington, KY 40506 USA.
RP Bhattacharyya, D (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM db@engr.uky.edu
FU National Institute of Environmental Health Sciences Superfund Research
   (NIEHS-SRP) program [P42ES007380]; Department of Energy DOE-KRCEE
   program [DE-FG05-03OR23032]
FX This study was supported by the National Institute of Environmental
   Health Sciences Superfund Research (NIEHS-SRP) program (P42ES007380) and
   by the Department of Energy DOE-KRCEE program (DE-FG05-03OR23032). We
   thank Dr. Jia Ye from the Electron Microscopy Center (University of
   Kentucky) for STEM-EELS mapping analytical support and John May from
   Environmental Research and Training Laboratory (ERTL) at UK for GC-MS
   analytical assistance. The authors acknowledge the highly significant
   contributions of Sepro Membrane Co. of Oceanside, CA towards the joint
   development of full-scale PVDF functionalized membranes.
CR Ahmad M, 2011, CHEMOSPHERE, V84, P855, DOI 10.1016/j.chemosphere.2011.06.021
   Bergendahl JA, 2004, WATER RES, V38, P327, DOI 10.1016/j.watres.2003.10.003
   CHEN XF, 1993, J PHYS CHEM-US, V97, P421, DOI 10.1021/j100104a025
   CLAPP PA, 1989, ANAL CHIM ACTA, V218, P331, DOI 10.1016/S0003-2670(00)80309-8
   Costa RCC, 2008, APPL CATAL B-ENVIRON, V83, P131, DOI 10.1016/j.apcatb.2008.01.039
   Dai JH, 2002, NANO LETT, V2, P497, DOI 10.1021/nl0255471
   Datta S, 2008, IND ENG CHEM RES, V47, P4586, DOI 10.1021/ie800142d
   Fang Y, 2008, ENVIRON SCI TECHNOL, V42, P6942, DOI 10.1021/es800805y
   Fang YX, 2008, APPL CATAL B-ENVIRON, V78, P371, DOI 10.1016/j.apcatb.2007.09.009
   Gui MH, 2012, J NANOPART RES, V14, DOI 10.1007/s11051-012-0861-1
   HALPAAP K, 1978, J CHROMATOGR, V166, P479, DOI 10.1016/S0021-9673(00)95631-0
   He F, 2008, APPL CATAL B-ENVIRON, V84, P533, DOI 10.1016/j.apcatb.2008.05.008
   Hoag GE, 2009, J MATER CHEM, V19, P8671, DOI 10.1039/b909148c
   Hu K, 2007, J MEMBRANE SCI, V301, P19, DOI 10.1016/j.memsci.2007.05.031
   Johnson TL, 1996, ENVIRON SCI TECHNOL, V30, P2634, DOI 10.1021/es9600901
   Joo SH, 2004, ENVIRON SCI TECHNOL, V38, P2242, DOI 10.1021/es035157g
   Keenan CR, 2008, ENVIRON SCI TECHNOL, V42, P1262, DOI 10.1021/es7025664
   Kim J, 2010, ENVIRON POLLUT, V158, P2335, DOI 10.1016/j.envpol.2010.03.024
   Lewis S, 2009, SEPAR SCI TECHNOL, V44, P3289, DOI 10.1080/01496390903212805
   Lewis SR, 2011, P NATL ACAD SCI USA, V108, P8577, DOI 10.1073/pnas.1101144108
   Li Y. C., 2007, THESIS U KENTUCKY LE
   Li YC, 2007, IND ENG CHEM RES, V46, P7984, DOI 10.1021/ie070393b
   Lien HL, 2007, APPL CATAL B-ENVIRON, V77, P110, DOI 10.1016/j.apcatb.2007.07.014
   Lowry GV, 2004, ENVIRON SCI TECHNOL, V38, P5208, DOI 10.1021/es049835q
   Mohn WW, 1997, APPL ENVIRON MICROB, V63, P3378
   Nurmi JT, 2005, ENVIRON SCI TECHNOL, V39, P1221, DOI 10.1021/es049190u
   Okada S, 2011, CHEM-EUR J, V17, P9047, DOI 10.1002/chem.201101241
   Pham ALT, 2009, ENVIRON SCI TECHNOL, V43, P8930, DOI 10.1021/es902296k
   Pignatello JJ, 2006, CRIT REV ENV SCI TEC, V36, P1, DOI 10.1080/10643380500326564
   PIGNATELLO JJ, 1994, ENVIRON TOXICOL CHEM, V13, P423, DOI 10.1897/1552-8618(1994)13[423:DOPBFI]2.0.CO;2
   SCHWARTZ RD, 1980, APPL ENVIRON MICROB, V39, P702
   SEDLAK DL, 1991, ENVIRON SCI TECHNOL, V25, P1419, DOI 10.1021/es00020a009
   Smuleac V, 2011, J MEMBRANE SCI, V379, P131, DOI 10.1016/j.memsci.2011.05.054
   Smuleac V, 2010, J MEMBRANE SCI, V346, P310, DOI 10.1016/j.memsci.2009.09.052
   Stuart MAC, 2010, NAT MATER, V9, P101, DOI [10.1038/NMAT2614, 10.1038/nmat2614]
   Sun SP, 2011, J MOL CATAL A-CHEM, V349, P71, DOI 10.1016/j.molcata.2011.08.022
   Tee YH, 2009, J PHYS CHEM C, V113, P9454, DOI 10.1021/jp809098z
   TYRE BW, 1991, J ENVIRON QUAL, V20, P832, DOI 10.2134/jeq1991.00472425002000040021x
   Ulbricht M, 2006, POLYMER, V47, P2217, DOI 10.1016/j.polymer.2006.01.084
   Valentine RL, 1998, J ENVIRON ENG-ASCE, V124, P31, DOI 10.1061/(ASCE)0733-9372(1998)124:1(31)
   Voinov MA, 2011, J AM CHEM SOC, V133, P35, DOI 10.1021/ja104683w
   Wandera D, 2010, J MEMBRANE SCI, V357, P6, DOI 10.1016/j.memsci.2010.03.046
   Wang CB, 1997, ENVIRON SCI TECHNOL, V31, P2154, DOI 10.1021/es970039c
   WANG GJ, 1994, J ORG CHEM, V59, P4076, DOI 10.1021/jo00094a014
   Wang XY, 2008, WATER RES, V42, P4656, DOI 10.1016/j.watres.2008.08.005
   Watts RJ, 1999, ENVIRON ENG SCI, V16, P93, DOI 10.1089/ees.1999.16.93
   Wu LF, 2008, ENVIRON PROG, V27, P218, DOI 10.1002/ep.10277
   Xu J, 2005, J NANOPART RES, V7, P449, DOI 10.1007/s11051-005-4273-3
   Xu J, 2007, IND ENG CHEM RES, V46, P2348, DOI 10.1021/ie0611498
   Yang S, 2008, CHEMOSPHERE, V71, P328, DOI 10.1016/j.chemosphere.2007.09.002
   Zelmanov G, 2008, WATER RES, V42, P492, DOI 10.1016/j.watres.2007.07.045
   Zhang WX, 2003, J NANOPART RES, V5, P323, DOI 10.1023/A:1025520116015
   Zhu BW, 2007, ENVIRON SCI TECHNOL, V41, P7523, DOI 10.1021/es0712625
NR 53
TC 14
Z9 15
U1 1
U2 46
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0888-5885
J9 IND ENG CHEM RES
JI Ind. Eng. Chem. Res.
PD AUG 7
PY 2013
VL 52
IS 31
BP 10430
EP 10440
DI 10.1021/ie400507c
PG 11
WC Engineering, Chemical
SC Engineering
GA 199TQ
UT WOS:000323018800012
PM 24954974
OA green_accepted
DA 2018-03-19
ER

PT J
AU Satarkar, NS
   Zhang, WL
   Eitel, RE
   Hilt, JZ
AF Satarkar, Nitin S.
   Zhang, Wenli
   Eitel, Richard E.
   Hilt, J. Zach
TI Magnetic hydrogel nanocomposites as remote controlled microfluidic
   valves
SO LAB ON A CHIP
LA English
DT Article
ID TEMPERATURE COFIRED CERAMICS; FLOW-CONTROL; THERMORESPONSIVE HYDROGELS;
   DRUG-DELIVERY; POLYMER; SYSTEM; LTCC; COMPOSITES; MICROVALVE; CHIPS
AB In recent years, hydrogels have attracted attention as active components in microfluidic devices. Here, we present a demonstration of remote controlled flow regulation in a microfluidic device using a hydrogel nanocomposite valve. To create the nanocomposite hydrogel, magnetic nanoparticles were dispersed in temperature-responsive N-isopropylacrylamide (NIPAAm) hydrogels. The swelling and collapse of the resultant nanocomposite can be remotely controlled by application of an alternating magnetic field (AMF). A ceramic microfluidic device with Y-junction channels was fabricated using low temperature co-fired ceramic (LTCC) technology. The nanocomposite was incorporated as a valve in one of the channels of the device. An AMF of frequency 293 kHz was then applied to the device and ON-OFF control on flow was achieved. A pressure transducer was placed at the inlet of the channel and pressure measurements were done for multiple AMF ON-OFF cycles to evaluate the reproducibility of the valve. Furthermore, the effect of the hydrogel geometry on the response time was characterized by hydrogels with different dimensions. Magnetic hydrogel nanocomposite films of different thicknesses (0.5, 1, 1.5 mm) were subjected to AMF and the kinetics of collapse and recovery were studied.
C1 [Satarkar, Nitin S.; Zhang, Wenli; Eitel, Richard E.; Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Hilt, JZ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RI Eitel, Richard/E-2889-2010
OI Eitel, Richard/0000-0002-5090-2075
FU National Science Foundation [ECS-0508254, CTS-0609117]
FX This material is based in part on work supported by the National Science
   Foundation under grant numbers ECS-0508254 (NSF NER) and CTS-0609117
   (NSF NIRT). The authors thank Mr Michel Spencer for valuable assistance
   with infrared thermography. The authors also acknowledge the support of
   W. C. Heraeus Thick Film Materials Division for supplying LTCC materials
   used in this study.
CR Agarwal AK, 2007, LAB CHIP, V7, P310, DOI 10.1039/b617767k
   Baldi A, 2003, J MICROELECTROMECH S, V12, P613, DOI 10.1109/JMEMS.2003.818070
   Beebe DJ, 2000, NATURE, V404, P588, DOI 10.1038/35007047
   Chaterji S, 2007, PROG POLYM SCI, V32, P1083, DOI 10.1016/j.progpolymsci.2007.05.018
   Chen GF, 2008, LAB CHIP, V8, P1198, DOI 10.1039/b803293a
   Dong L, 2007, SOFT MATTER, V3, P1223, DOI 10.1039/b706563a
   Eddington DT, 2004, J MICROELECTROMECH S, V13, P586, DOI 10.1109/JMEMS.2004.832190
   Eddington DT, 2004, ADV DRUG DELIVER REV, V56, P199, DOI 10.1016/j.addr.2003.08.013
   Eddington DT, 2001, LAB CHIP, V1, P96, DOI 10.1039/b108078d
   Filipcsei G, 2007, ADV POLYM SCI, V206, P137, DOI 10.1007/12_2006_104
   Frimpong R. A., 2007, NANOTECHNOLOGY THERA, P241
   Gil ES, 2004, PROG POLYM SCI, V29, P1173, DOI 10.1016/j.progpolymsci.2004.08.003
   Golonka L. J., 2006, Bulletin of the Polish Academy of Sciences, Technical Sciences, V54, P221
   Gongora-Rubio MR, 2001, SENSOR ACTUAT A-PHYS, V89, P222, DOI 10.1016/S0924-4247(00)00554-9
   Gross GA, 2008, CHEM ENG SCI, V63, P2773, DOI 10.1016/j.ces.2008.02.030
   HAHN R, 2006, 56 EL COMP TECHN C 2, P6
   Harmon ME, 2003, POLYMER, V44, P4547, DOI 10.1016/S0032-3861(03)00463-4
   Hoare TR, 2008, POLYMER, V49, P1993, DOI 10.1016/j.polymer.2008.01.027
   Ibanez-Garcia N, 2006, SENSOR ACTUAT B-CHEM, V118, P67, DOI 10.1016/j.snb.2006.04.063
   Ibanez-Garcia N, 2008, ANAL CHEM, V80, P5320, DOI 10.1021/ac800012q
   KIM H, 2006, MAGN C 2006 INTERMAG, P353
   Liu CW, 2007, J MICROMECH MICROENG, V17, P1985, DOI 10.1088/0960-1317/17/10/009
   Liu Y. J., 2007, J APPL PHYS, V102
   Luo QZ, 2003, ELECTROPHORESIS, V24, P3694, DOI 10.1002/elps.200305577
   MOELLER K, 2006, THERMEC 2006 C MIN M
   Pamme N, 2006, LAB CHIP, V6, P24, DOI 10.1039/b513005k
   Peppas NA, 2006, ADV MATER, V18, P1345, DOI 10.1002/adma.200501612
   Richter A, 2003, J MICROELECTROMECH S, V12, P748, DOI 10.1109/JMEMS.2003.817898
   Satarkar NS, 2008, J CONTROL RELEASE, V130, P246, DOI 10.1016/j.jconrel.2008.06.008
   Satarkar NS, 2008, ACTA BIOMATER, V4, P11, DOI 10.1016/j.actbio.2007.07.009
   Sershen SR, 2000, J BIOMED MATER RES, V51, P293, DOI 10.1002/1097-4636(20000905)51:3<293::AID-JBM1>3.0.CO;2-T
   Sershen SR, 2005, ADV MATER, V17, P1366, DOI 10.1002/adma.200401239
   Siegel AC, 2006, ANGEW CHEM, V118, P7031
   Sugiura S, 2007, SENSOR ACTUAT A-PHYS, V140, P176, DOI 10.1016/j.sna.2007.06.024
   Thelemann T, 2002, MICROELECTRON INT, V19, P19, DOI 10.1108/1356536021044505
   Wang J, 2005, BIOMED MICRODEVICES, V7, P313, DOI 10.1007/s10544-005-6073-z
   Whitesides GM, 2006, NATURE, V442, P368, DOI 10.1038/nature05058
   Yu C, 2003, ANAL CHEM, V75, P1958, DOI 10.1021/ac026455j
   Yu Q, 2001, APPL PHYS LETT, V78, P2589, DOI 10.1063/1.1367010
NR 39
TC 83
Z9 83
U1 2
U2 76
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1473-0197
J9 LAB CHIP
JI Lab Chip
PY 2009
VL 9
IS 12
BP 1773
EP 1779
DI 10.1039/b822694f
PG 7
WC Biochemical Research Methods; Chemistry, Multidisciplinary; Chemistry,
   Analytical; Nanoscience & Nanotechnology
SC Biochemistry & Molecular Biology; Chemistry; Science & Technology -
   Other Topics
GA 453MZ
UT WOS:000266616000018
PM 19495462
DA 2018-03-19
ER

PT J
AU Ghosh, G
   Bachas, LG
   Anderson, KW
AF Ghosh, Gargi
   Bachas, Leonidas G.
   Anderson, Kimberly W.
TI Biosensor incorporating cell barrier architectures for detecting
   Staphylococcus aureus alpha toxin
SO ANALYTICAL AND BIOANALYTICAL CHEMISTRY
LA English
DT Article
DE potassium-selective electrodes; biosensor; alpha toxin; intercellular
   gaps; silver staining
ID LINKED-IMMUNOSORBENT-ASSAY; SELECTIVE ELECTRODES; ENDOTHELIAL-CELLS;
   TEICHOIC-ACID; RABBIT LUNGS; INVITRO; MODEL; PERMEABILITY; INFECTIONS;
   ADRENOMEDULLIN
AB Alpha toxin is a common virulent factor of Staphylococcus aureus and is believed to play crucial roles in pathogenicity induced by S. aureus. Alpha toxin is also known to induce permeability to endothelial cell monolayers in vitro due to the formation of interendothelial gaps. The present study is directed towards measuring alpha toxin using a whole-cell-based biosensor. The biosensor, consisting of a confluent monolayer of human umbilical vein endothelial cells (HUVECs) on a potassium ion-selective electrode, takes advantage of cell permeability dysfunction to detect the presence of small quantities of alpha toxin. When a confluent monolayer of cells was formed on the membrane surface, the response of the electrode toward the marker ion, potassium, was inhibited. Upon exposing this sensor to varying concentrations of alpha toxin for 20 min, an increase in sensor response to potassium was observed. The response thus obtained was indirectly related to the concentration of alpha toxin. The detection limit of this sensor for alpha toxin was found to be 0.1 ng/ml. Cell monolayers were stained with silver nitrate to quantify the formation of intercellular gaps as well as to study the effect of this toxin on HUVECs morphology. A strong positive correlation was observed between the response obtained from the biosensor and the area of the intercellular gaps. Silver staining also revealed the tendency of cells to round up upon being exposed to alpha toxin.
C1 Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
RP Anderson, KW (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM kanderson@engr.uky.edu
RI Bachas, Leonidas/G-2479-2015
OI Bachas, Leonidas/0000-0002-3308-6264
CR BALUK P, 1997, AM J PHYSIOL, V272, P155
   BHAKDI S, 1989, INFECT IMMUN, V57, P3214
   BHAKDI S, 1991, MICROBIOL REV, V55, P733
   BHAKDI S, 1988, J EXP MED, V168, P527, DOI 10.1084/jem.168.2.527
   Brell B, 2005, CRIT CARE MED, V33, P819, DOI 10.1097/01.CCM.0000159194.53695.7A
   Brooks K A, 1996, Anal Chem, V68, P1439, DOI 10.1021/ac950915+
   BUCK RP, 1994, PURE APPL CHEM, V66, P2527, DOI 10.1351/pac199466122527
   Burns AR, 1997, J IMMUNOL, V159, P2893
   Caiazza NC, 2003, J BACTERIOL, V185, P3214, DOI 10.1128/JB.185.10.3214-3217.2003
   CHA GS, 1989, TALANTA, V36, P271, DOI 10.1016/0039-9140(89)80106-7
   CHA MJ, 1995, ANAL CHIM ACTA, V315, P311, DOI 10.1016/0003-2670(95)00337-Y
   CHRISTENSSON B, 1983, ACTA PATH MICRO IM B, V91, P351
   CHRISTENSSON B, 1989, ARTHRITIS RHEUM, V32, P1268, DOI 10.1002/anr.1780321012
   Dorsch W, 1999, INT ARCH ALLERGY IMM, V118, P236, DOI 10.1159/000024084
   GEHRON MJ, 1984, J MICROBIOL METH, V2, P165, DOI 10.1016/0167-7012(84)90005-8
   GEMMELL CG, 1982, INFECT IMMUN, V38, P981
   GOUAUX JE, 1994, P NATL ACAD SCI USA, V91, P12828, DOI 10.1073/pnas.91.26.12828
   HIRATA A, 1995, AM J PHYSIOL-LUNG C, V269, pL403
   Hocke AC, 2006, HISTOCHEM CELL BIOL, V126, P305, DOI 10.1007/s00418-006-0174-5
   Hume EBH, 2000, INFECT IMMUN, V68, P6052, DOI 10.1128/IAI.68.10.6052-6055.2000
   JONSSON P, 1985, INFECT IMMUN, V49, P765
   JULANDER IG, 1983, INFECTION, V11, P77, DOI 10.1007/BF01641071
   Kielian T, 2001, INFECT IMMUN, V69, P6902, DOI 10.1128/IAI.69.11.6902-6911.2001
   KILLACKEY JJF, 1986, AM J PATHOL, V122, P50
   Koncki R, 1997, TRAC-TREND ANAL CHEM, V16, P528, DOI 10.1016/S0165-9936(97)00066-6
   LOEFFLER DA, 1988, J CLIN MICROBIOL, V26, P1331
   MARRIE TJ, 1982, CIRCULATION, V66, P1339, DOI 10.1161/01.CIR.66.6.1339
   MARRIE TJ, 1984, J CLIN MICROBIOL, V19, P687
   May KML, 2005, ANAL BIOANAL CHEM, V382, P1010, DOI 10.1007/s00216-005-3224-2
   May KML, 2004, ANAL CHEM, V76, P4156, DOI 10.1021/ac049810+
   MCDONALD DM, 1994, AM J PHYSIOL, V266, pL61
   Menzies BE, 2000, FEMS IMMUNOL MED MIC, V29, P39, DOI 10.1016/S0928-8244(00)00185-1
   MOELLBY R, 1994, ZBL BAKT, V26, P441
   MOLLBY R, 1983, ISOLATION PROPERTIES
   OCallaghan RJ, 1997, INFECT IMMUN, V65, P1571
   ROSTEN PM, 1987, J CLIN MICROBIOL, V25, P327
   Ryding U, 2002, DIAGN MICR INFEC DIS, V42, P9, DOI 10.1016/S0732-8893(01)00311-X
   Sakong DS, 1996, SENSOR ACTUAT B-CHEM, V32, P161, DOI 10.1016/0925-4005(96)80126-2
   SARUJBALLI OP, 1984, J CLIN MICROBIOL, V19, P394
   SEEGER W, 1984, J CLIN INVEST, V74, P849, DOI 10.1172/JCI111502
   SEEGER W, 1990, LAB INVEST, V63, P341
   Sista Ramachandra R, 2004, Anesthesiol Clin North America, V22, P405, DOI 10.1016/j.atc.2004.04.006
   Soderquist BC-N P, 1993, SERODIAGN IMMUNOTHER, V1, P23
   SUTTORP N, 1985, AM J PHYSIOL, V248, pC127
   SUTTORP N, 1988, AM J PHYSIOL, V255, pC368
   SUTTORP N, 1987, INFECT IMMUN, V55, P104
   THELESTAM M, 1988, TOXICON, V26, P51, DOI 10.1016/0041-0101(88)90137-7
   Wu PZJ, 2005, CURR EYE RES, V30, P63, DOI 10.1080/02713680490894630
NR 48
TC 6
Z9 7
U1 0
U2 5
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1618-2642
J9 ANAL BIOANAL CHEM
JI Anal. Bioanal. Chem.
PD JAN
PY 2007
VL 387
IS 2
BP 567
EP 574
DI 10.1007/s00216-006-0949-5
PG 8
WC Biochemical Research Methods; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA 124FX
UT WOS:000243354400024
PM 17119934
DA 2018-03-19
ER

PT J
AU Fugit, KD
   Anderson, BD
AF Fugit, Kyle D.
   Anderson, Bradley D.
TI Dynamic, Nonsink Method for the Simultaneous Determination of Drug
   Permeability and Binding Coefficients in Liposomes
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE liposomes; nanoparticles; lipid bilayers; membrane partitioning;
   ultrafiltration; dynamic dialysis; drug release
ID HYDROPHOBIC CAMPTOTHECIN; PHYSICAL STABILITY; INTRALIPOSOMAL PH;
   RIGOROUS THEORY; LIPID-BILAYERS; IN-VITRO; TOPOTECAN; GRADIENT;
   DELIVERY; RELEASE
AB Drug release from liposomal formulations is governed by a complex interplay of kinetic (i.e., drug permeability) and thermodynamic factors (i.e., drug partitioning to the bilayer surface). Release studies under sink conditions that attempt to mimic physiological conditions are insufficient to decipher these separate contributions. The present study explores release studies performed under nonsink conditions coupled with appropriate mathematical models to describe both the release kinetics and the conditions in which equilibrium is established. Liposomal release profiles for a model anticancer agent, topotecan, under nonsink conditions provided values for both the first-order rate constant for drug release and the bilayer/water partition coefficient. These findings were validated by conducting release studies under sink conditions via dynamic dialysis at the same temperature and buffer pH. A nearly identical rate constant for drug release could be obtained from dynamic dialysis data when appropriate volume corrections were applied and a mechanism-based mathematical model was employed to account for lipid bilayer binding and dialysis membrane transport. The usefulness of the nonsink method combined with mathematical modeling was further explored by demonstrating the effects of topotecan dimerization and bilayer surface charge potential on the bilayer/water partition coefficient at varying suspension concentrations of lipid and drug.
C1 [Fugit, Kyle D.; Anderson, Bradley D.] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40506 USA.
RP Anderson, BD (reprint author), Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, A323A ASTeCC Bldg, Lexington, KY 40506 USA.
EM bande2@email.uky.edu
FU National Cancer Institute [R25CA153954]
FX This project was supported by Grant Number R25CA153954 from the National
   Cancer Institute.
CR Abraham SA, 2004, J CONTROL RELEASE, V96, P449, DOI 10.1016/j.jconrel.2004.02.017
   Atyabi F, 2009, ACTA PHARMACEUT, V59, P133, DOI 10.2478/v10007-009-0020-0
   Austin RP, 1998, J PHARM SCI, V87, P599, DOI 10.1021/js9703481
   Bocian W, 2004, CHEM-EUR J, V10, P5776, DOI 10.1002/chem.200305624
   CEH B, 1995, LANGMUIR, V11, P3356, DOI 10.1021/la00009a016
   Ceh B, 1997, J COLLOID INTERF SCI, V185, P9, DOI 10.1006/jcis.1996.4555
   Cho EJ, 2013, MOL PHARMACEUT, V10, P2093, DOI 10.1021/mp300697h
   Clerc S, 1998, ANAL BIOCHEM, V259, P104, DOI 10.1006/abio.1998.2639
   Domingo C, 2012, ANAL CHIM ACTA, V744, P8, DOI 10.1016/j.aca.2012.07.010
   Ferraretto A, 1996, CHEM PHYS LIPIDS, V82, P133, DOI 10.1016/0009-3084(96)02569-8
   Franzen U, 2012, J CHROMATOGR A, V1267, P32, DOI 10.1016/j.chroma.2012.07.018
   Fugit KD, 2014, J CONTROL RELEASE, V174, P88, DOI 10.1016/j.jconrel.2013.11.003
   Gajbhiye V, 2013, EUR J PHARM SCI, V48, P668, DOI 10.1016/j.ejps.2012.12.027
   GRIT M, 1992, CHEM PHYS LIPIDS, V62, P113, DOI 10.1016/0009-3084(92)90089-8
   GRIT M, 1993, CHEM PHYS LIPIDS, V64, P3, DOI 10.1016/0009-3084(93)90053-6
   GRIT M, 1989, INT J PHARM, V50, P1, DOI 10.1016/0378-5173(89)90173-7
   Huang C. H. A, 1993, BIOCHEMISTRY-MOSCOW, V32, P11
   Joguparthi V, 2008, INT J PHARM, V352, P17, DOI 10.1016/j.ijpharm.2007.10.003
   Joguparthi V, 2008, J PHARM SCI-US, V97, P433, DOI 10.1002/jps.21135
   Joguparthi V, 2008, J PHARM SCI-US, V97, P400, DOI 10.1002/jps.21125
   Liko F, 2013, J LIPOSOME RES, V23, P61, DOI 10.3109/08982104.2012.742538
   Liu JJ, 2002, ANTI-CANCER DRUG, V13, P709, DOI 10.1097/00001813-200208000-00005
   Lu DX, 2008, CHINESE J POLYM SCI, V26, P369, DOI 10.1142/S0256767908003023
   Maurer-Spurej E, 1999, BBA-BIOMEMBRANES, V1416, P1, DOI 10.1016/S0005-2736(98)00204-1
   Modi S, 2013, MOL PHARMACEUT, V10, P3076, DOI 10.1021/mp400154a
   Modi S, 2012, J CONTROL RELEASE, V162, P330, DOI 10.1016/j.jconrel.2012.07.001
   Moth S., 2013, PHARM RES, P1
   Park JH, 2006, COLLOID POLYM SCI, V284, P763, DOI 10.1007/s00396-005-1438-7
   SEELIG A, 1974, BIOCHEMISTRY-US, V13, P4839, DOI 10.1021/bi00720a024
   Strel'tsov SA, 2001, MOL BIOL+, V35, P365, DOI 10.1023/A:1010422711817
   Streltsov S, 2003, BIOPOLYMERS, V72, P442, DOI 10.1002/bip.10479
   Tejwani RW, 2008, J PHARM SCI-US, V97, P381, DOI 10.1002/jps.21108
   Tejwani RW, 2009, J PHARM SCI-US, V98, P4534, DOI 10.1002/jps.21775
   Xiang TX, 2006, ADV DRUG DELIVER REV, V58, P1357, DOI 10.1016/j.addr.2006.09.002
   Xiang TX, 1998, BIOPHYS J, V75, P2658, DOI 10.1016/S0006-3495(98)77711-2
   Xiang TX, 1997, BIOPHYS J, V72, P223, DOI 10.1016/S0006-3495(97)78661-2
   Zhang W, 2011, BIOMATERIALS, V32, P2894, DOI 10.1016/j.biomaterials.2010.12.039
   Zucker D, 2009, J CONTROL RELEASE, V139, P73, DOI 10.1016/j.jconrel.2009.05.036
NR 38
TC 9
Z9 11
U1 1
U2 26
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD APR
PY 2014
VL 11
IS 4
BP 1314
EP 1325
DI 10.1021/mp400765n
PG 12
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA AE6IB
UT WOS:000334092700023
PM 24628304
OA gold
DA 2018-03-20
ER

PT J
AU Lai, TC
   Bae, Y
   Yoshida, T
   Kataoka, K
   Kwon, GS
AF Lai, T. S. Z. Chung
   Bae, Younsoo
   Yoshida, Takayuki
   Kataoka, Kazunori
   Kwon, Glen S.
TI pH-Sensitive Multi-PEGylated Block Copolymer as a Bioresponsive pDNA
   Delivery Vector
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE non-viral gene delivery; PEG; pH-sensitive; polyplex
ID GENE DELIVERY; IN-VIVO; MEDIATED ENDOCYTOSIS; POLYPLEX MICELLES;
   NANOPARTICLES; PEG; DNA; TRANSFECTION; POLYMERS; THERAPY
AB A reversibly-PEGylated diblock copolymer, poly(aspartate-hydrazide-poly(ethylene glycol))-block-poly(aspartate-diaminoethane) (p[Asp(Hyd-PEG)]-b-p[Asp(DET)]) was reported here for enhanced gene transfection and colloidal stability. The diblock copolymer possessed a unique architecture based on a poly(aspartamide) backbone. The first block, p[Asp(Hyd)], was used for multi-PEG conjugations, and the second block, p[Asp(DET)], was used for DNA condensation and endosomal escape.
   p[Asp(Hyd-PEG)]-b-p[Asp(DET)] was synthesized and characterized by (1)H-NMR. Polyplexes were formed by mixing the synthesized polymers and pDNA. The polyplex size, zeta-potential, and in vitro transfection efficiency were determined by dynamic light scattering, zeta-potential measurements, and luciferase assays, respectively. pH-dependent release of PEG from the polymer was monitored by cationic-exchange chromatography.
   The polyplexes were 70-90 nm in size, and the surface charge was effectively shielded by a PEG layer. The transfection efficiency of the reversibly PEGylated polyplexes was confirmed to be comparable to that of the non-PEGylated counterparts and 1,000 times higher than that of the irreversibly PEGylated polyplexes. PEG release was demonstrated to be pH-sensitive. Fifty percent of the PEG was released within 30 min at pH 5, while the polymer incubated at pH 7.4 could still maintain 50% of PEG after 8 h.
   The reversibly PEGylated polyplexes were shown to maintain polyplex stability without compromising transfection efficiency.
C1 [Lai, Tsz Chung; Kwon, Glen S.] Univ Wisconsin, Div Pharmaceut Sci, Sch Pharm, Madison, WI 53705 USA.
   [Bae, Younsoo] Univ Kentucky, Div Pharmaceut Sci, Coll Pharm, Lexington, KY 40536 USA.
   [Yoshida, Takayuki] Astellas Pharma Inc, Yaizu, Shizuoka 4250072, Japan.
   [Kataoka, Kazunori] Univ Tokyo, Grad Sch Engn, Dept Mat Engn, Bunkyo Ku, Tokyo 1138656, Japan.
RP Kwon, GS (reprint author), Univ Wisconsin, Div Pharmaceut Sci, Sch Pharm, 777 Highland Ave, Madison, WI 53705 USA.
EM gskwon@pharmacy.wisc.edu
RI Kwon, Glen/A-1919-2014; Kataoka, Kazunori/K-7108-2012
OI Kataoka, Kazunori/0000-0002-8591-413X
FU NIAID NIH HHS [R01 AI043346]
CR Bareford LA, 2007, ADV DRUG DELIVER REV, V59, P748, DOI 10.1016/j.addr.2007.06.008
   Cavazzana-Calvo Marina, 2005, Annu Rev Med, V56, P585, DOI 10.1146/annurev.med.56.090203.104142
   Choi JS, 2003, BIOCONJUGATE CHEM, V14, P420, DOI 10.1021/bc025625w
   CHONN A, 1992, J BIOL CHEM, V267, P18759
   DARLY WH, 1988, TETRAHEDRON LETT, V29, P5859
   Gref R, 2000, COLLOID SURFACE B, V18, P301, DOI 10.1016/S0927-7765(99)00156-3
   Han M, 2007, J CONTROL RELEASE, V121, P38, DOI 10.1016/j.jconrel.2007.05.012
   Harada A, 1996, MACROMOLECULES, V29, P6183, DOI 10.1021/ma960487p
   Harada-Shiba M, 2009, MOL THER, V17, P1180, DOI 10.1038/mt.2009.63
   Hatakeyama H, 2009, J CONTROL RELEASE, V139, P127, DOI 10.1016/j.jconrel.2009.06.008
   Huang M, 2002, PHARMACEUT RES, V19, P1488, DOI 10.1023/A:1020404615898
   Kim HR, 2007, CELL MOL LIFE SCI, V64, P356, DOI 10.1007/s00018-007-6390-x
   Lehrman S, 1999, NATURE, V401, P517, DOI 10.1038/43977
   Mastrobattista E, 2006, NAT REV DRUG DISCOV, V5, P115, DOI 10.1038/nrd1960
   Merdan T, 2002, ADV DRUG DELIVER REV, V54, P715, DOI 10.1016/S0169-409X(02)00046-7
   Meyer M, 2008, J AM CHEM SOC, V130, P3272, DOI 10.1021/ja710344v
   Meyer M, 2006, HUM GENE THER, V17, P1062, DOI 10.1089/hum.2006.17.1062
   Mishra S, 2004, EUR J CELL BIOL, V83, P97, DOI 10.1078/0171-9335-00363
   Miyata K, 2007, J CONTROL RELEASE, V122, P252, DOI 10.1016/j.jconrel.2007.06.020
   Miyata K, 2008, J AM CHEM SOC, V130, P16287, DOI 10.1021/ja804561g
   Mukherjee S, 1997, PHYSIOL REV, V77, P759
   O'Riordan CR, 1999, HUM GENE THER, V10, P1349, DOI 10.1089/10430349950018021
   Ogris M, 1999, GENE THER, V6, P595, DOI 10.1038/sj.gt.3300900
   Pack DW, 2005, NAT REV DRUG DISCOV, V4, P581, DOI 10.1038/nrd1775
   Park TG, 2006, ADV DRUG DELIVER REV, V58, P467, DOI 10.1016/j.addr.2006.03.007
   Pathak Atul, 2009, Biotechnology Journal, V4, P1559, DOI 10.1002/biot.200900161
   Petersen H, 2002, BIOCONJUGATE CHEM, V13, P845, DOI 10.1021/bc025529v
   Pun SH, 2002, BIOCONJUGATE CHEM, V13, P630, DOI 10.1021/bc0155768
   Rejman J, 2004, BIOCHEM J, V377, P159, DOI 10.1042/BJ20031253
   Remaut K, 2007, J CONTROL RELEASE, V117, P256, DOI 10.1016/j.jconrel.2006.10.029
   SKOOG B, 1979, VOX SANG, V37, P345, DOI 10.1111/j.1423-0410.1979.tb02314.x
   Takae S, 2008, J AM CHEM SOC, V130, P6001, DOI 10.1021/ja800336v
   Walker GF, 2005, MOL THER, V11, P418, DOI 10.1016/j.ymthe.2004.11.006
   West Kevin R, 2005, Curr Drug Discov Technol, V2, P123, DOI 10.2174/1570163054866882
   *WIL, 2009, J GENE MED
   Wolfert MA, 1996, HUM GENE THER, V7, P2123, DOI 10.1089/hum.1996.7.17-2123
   Woodle MC, 1998, ADV DRUG DELIVER REV, V32, P139, DOI 10.1016/S0169-409X(97)00136-1
   Xiong MP, 2007, CHEMMEDCHEM, V2, P1321, DOI 10.1002/cmdc.200700093
   [Anonymous], 2002, HUM GENE THER, V13, P3, DOI DOI 10.1089/10430340152712629
NR 39
TC 26
Z9 28
U1 0
U2 17
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
J9 PHARM RES-DORDR
JI Pharm. Res.
PD NOV
PY 2010
VL 27
IS 11
BP 2260
EP 2273
DI 10.1007/s11095-010-0092-z
PG 14
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 669RN
UT WOS:000283368000002
PM 20300803
OA green_accepted
DA 2018-03-19
ER

PT J
AU Safazadeh, L
   Berron, BJ
AF Safazadeh, Leila
   Berron, Brad J.
TI Photopatterning of Stable, Low-Density, Self-Assembled Mono layers on
   Gold
SO LANGMUIR
LA English
DT Article
ID FREE-RADICAL POLYMERIZATION; ELECTROCHEMICAL DESORPTION; ALKANETHIOL
   MONOLAYERS; REDUCTIVE DESORPTION; ETHANOL SOLUTION; AU(111) SURFACE;
   SINGLE-CRYSTAL; CONTACT ANGLES; ELECTRODES; STABILITY
AB Photoinitiated thiol-yne chemistry is utilized as a click reaction for grafting of acid-terminated alkynes to thiol-terminated monolayers on a gold substrate to create stable, low-density monolayers. The resulting monolayers are compared with a well-packed 11-mercaptoundecanoic acid monolayer and the analogous low-density monolayers prepared through a solution phase synthetic approach. The overall structuring of the monolayer prepared by solid-phase grafting is characterized by contact angle goniometry and Fourier transform infrared spectroscopy. The results show that the product monolayer has an intermediate surface energy and a more disordered chemical structuring compared to a traditional well-packed self-assembled monolayer, showing a low-packing density of the chains at the monolayer surface. The monolayers structure and electrochemical stability were studied by reductive desorption of the thiolates. The prepared low-density monolayers have a higher electrochemical stability than traditional well-packed monolayers, which results from the crystalline structure at the gold interface. This technique allows for simple, fast preparation of low-density monolayers of higher stability than well-packed monolayers. The use of a photomask to restrict light access to the substrate yielded these low-density monolayers in patterned regions defined by light exposure. This general thiol-yne approach is adaptable to a variety of analogous low-density monolayers with diverse chemical functionalities.
C1 [Safazadeh, Leila; Berron, Brad J.] Univ Kentucky, Chem & Mat Engn, Lexington, KY 40506 USA.
RP Berron, BJ (reprint author), Univ Kentucky, Chem & Mat Engn, Lexington, KY 40506 USA.
EM brad.berron@uky.edu
FU American Chemical Society Petroleum Research Fund [52743-DNI5]
FX Acknowledgment is made to the Donors of the American Chemical Society
   Petroleum Research Fund (52743-DNI5) for partial support of this
   research. The authors also acknowledge UK Center for Nanoscale Science
   and Engineering for use of a sputtering machine and a spectroscopic
   ellipsometer.
CR Alexander MR, 1996, SURF INTERFACE ANAL, V24, P217
   BAIN CD, 1989, J AM CHEM SOC, V111, P7164, DOI 10.1021/ja00200a040
   Berron B, 2006, LANGMUIR, V22, P7235, DOI 10.1021/la0531650
   Choi EJ, 2002, LANGMUIR, V18, P557, DOI 10.1021/la010964j
   Cokbaglan L, 2003, MACROMOLECULES, V36, P2649, DOI 10.1021/ma0214613
   Cooper S. L., 1996, J BIOMED MATER RES, V30, P171
   Drelich J, 1996, LANGMUIR, V12, P1913, DOI 10.1021/la9509763
   Drelich J, 1996, J COLLOID INTERF SCI, V179, P37, DOI 10.1006/jcis.1996.0186
   EVERETT WR, 1995, ANAL CHIM ACTA, V307, P253, DOI 10.1016/0003-2670(95)00004-J
   FINKLEA HO, 1987, LANGMUIR, V3, P409, DOI 10.1021/la00075a024
   FOLKERS JP, 1992, LANGMUIR, V8, P1330, DOI 10.1021/la00041a015
   Garg N, 1998, LANGMUIR, V14, P3815, DOI 10.1021/la980238p
   Hoogenboom R, 2010, ANGEW CHEM INT EDIT, V49, P3415, DOI 10.1002/anie.201000401
   Karasu F, 2009, MACROMOLECULES, V42, P7318, DOI 10.1021/ma9008669
   Lahann J, 2003, SCIENCE, V299, P371, DOI 10.1126/science.1078933
   LAIBINIS PE, 1991, J AM CHEM SOC, V113, P7152, DOI 10.1021/ja00019a011
   LAIBINIS PE, 1992, J AM CHEM SOC, V114, P1990, DOI 10.1021/ja00032a009
   Laibinis P. E., 1998, THIN FILMS, V24, P2
   Love C. J., 2005, CHEM REV, V105, P1103
   Lowe AB, 2014, POLYMER, V55, P5517, DOI 10.1016/j.polymer.2014.08.015
   Lowe AB, 2010, J MATER CHEM, V20, P4745, DOI 10.1039/b917102a
   Luo MX, 2012, J PHYS CHEM C, V116, P13964, DOI 10.1021/jp3020996
   Luo MX, 2010, J PHYS CHEM C, V114, P20167, DOI 10.1021/jp108018f
   MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025
   Olivier GK, 2009, LANGMUIR, V25, P2159, DOI 10.1021/la803057x
   Park JS, 2005, LANGMUIR, V21, P2902, DOI 10.1021/la0475573
   Park JS, 2004, LANGMUIR, V20, P5829, DOI 10.1021/la036424z
   Peng DK, 2007, LANGMUIR, V23, P10184, DOI 10.1021/la701607e
   Pesika NS, 2006, LANGMUIR, V22, P3474, DOI 10.1021/la052286x
   PORTER MD, 1987, J AM CHEM SOC, V109, P3559, DOI 10.1021/ja00246a011
   Prashar D, 2012, INT J CHEMTECH RES, V4, P258
   Schlenoff JB, 1995, J AM CHEM SOC, V117, P12528, DOI 10.1021/ja00155a016
   Shon YS, 2000, J PHYS CHEM B, V104, P8192, DOI 10.1021/jp000651h
   Smith RK, 2004, PROG SURF SCI, V75, P1, DOI 10.1016/j.progsurf.2003.12.001
   Stevens CA, 2014, LANGMUIR, V30, P1949, DOI 10.1021/la404940q
   Sullivan TP, 2003, EUR J ORG CHEM, P17
   Sumi T, 2004, J PHYS CHEM B, V108, P6422, DOI 10.1021/jp049558+
   Sumi T, 2003, J ELECTROANAL CHEM, V550, P321, DOI 10.1016/S0022-0728(03)00141-4
   Temel G, 2010, J POLYM SCI POL CHEM, V48, P5306, DOI 10.1002/pola.24330
   TUDOS AJ, 1995, ANAL CHEM, V67, P557, DOI 10.1021/ac00099a012
   WIDRIG CA, 1991, J ELECTROANAL CHEM, V310, P335, DOI 10.1016/0022-0728(91)85271-P
   Xiaoying L., 2004, MACROMOL RAPID COMM, V25, P1606
   Yang DF, 1997, LANGMUIR, V13, P243, DOI 10.1021/la960430w
   Yang DF, 1996, LANGMUIR, V12, P6570, DOI 10.1021/la960365q
   Yang WR, 2001, J ELECTROANAL CHEM, V516, P10, DOI 10.1016/S0022-0728(01)00649-0
NR 45
TC 5
Z9 6
U1 0
U2 49
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0743-7463
J9 LANGMUIR
JI Langmuir
PD MAR 10
PY 2015
VL 31
IS 9
BP 2689
EP 2696
DI 10.1021/acs.langmuir.5b00001
PG 8
WC Chemistry, Multidisciplinary; Chemistry, Physical; Materials Science,
   Multidisciplinary
SC Chemistry; Materials Science
GA CD2OI
UT WOS:000350918500010
PM 25689672
DA 2018-03-19
ER

PT J
AU McPherson, T
   Manek, RV
   Kolling, W
   Long, SH
   Li, TL
AF McPherson, Timothy
   Manek, Rahul V.
   Kolling, William
   Long, Sihui
   Li, Tonglei
TI Physical Characterization of 1,3-dipropyl-8-cyclopentylxanthine (CPX)
SO AAPS PHARMSCITECH
LA English
DT Article
DE CPX; pH solubility profile; physico-chemical characterization; thermal
   analysis; X-ray crystal structure
ID A(1) ADENOSINE RECEPTORS; CYSTIC-FIBROSIS; DRUG ABSORPTION; CHLORIDE
   EFFLUX; ANTAGONISTS; A1-ADENOSINE; XANTHINES; POTENT; CELLS; CFTR
AB 1,3-dipropyl-8-cyclopentylxanthine (CPX) has been shown to stimulate in vitro CFTR activity in a dagger F508 cells. Data from a phase I study demonstrated erratic bioavailability and no measurable clinical response to oral CPX. One cause for its poor bioavailability may have been dissolution rate limited absorption, but there is little published physicochemical data on which to base an analysis. The objective of this study was to determine the solubility and solid-state characteristics of CPX. CPX is a weak acid with pKa of 9.83 and water solubility at pH 7.0 of 15.6 mu M. Both laureth-23 and poloxamer 407 increased the apparent water solubility linearly with increasing concentrations. CPX exists in two crystal forms, one of which (form II) has been solved. Form II is a triclinic crystal with space group P1 and calculated density of 1.278 g/cm(3). X-ray powder diffraction and differential scanning calorimetry studies (DSC) indicated that CPX crystals prepared at room temperature were mixtures of forms I and II. DSC results indicated a melting point of approximately 195A degrees C for form I and 198A degrees C for form II. Thermogravimetric analysis indicated no solvent loss upon heating. Dynamic water vapor sorption data indicated no significant water uptake by CPX up to 90% RH. Analysis of the data indicates that CPX may not be amenable to traditional formulation approaches for oral delivery.
C1 [McPherson, Timothy; Kolling, William] So Illinois Univ, Dept Pharmaceut Sci, Edwardsville Sch Pharm, Edwardsville, IL 62026 USA.
   [Manek, Rahul V.] Exelixis Inc, San Francisco, CA USA.
   [Long, Sihui; Li, Tonglei] Univ Kentucky, Coll Pharm, Lexington, KY USA.
RP McPherson, T (reprint author), So Illinois Univ, Dept Pharmaceut Sci, Edwardsville Sch Pharm, Edwardsville, IL 62026 USA.
EM tmcpher@siue.edu
FU National Science Foundation [DMR-0449633, DUE-0410642]
FX The authors acknowledge SciClone Pharmaceuticals, Inc. for providing CPX
   for solubility experiments and Dr. A. Michael Crider for assistance with
   CPX synthesis. We acknowledge support via National Science Foundation
   grants DMR-0449633 (TL) and DUE-0410642 (SIUE).
CR Andersson C, 2000, EUR RESPIR J, V15, P937, DOI 10.1034/j.1399-3003.2000.15e21.x
   *BASF CORP, TECHN DAT PLUR R POL
   Benet LZ, 2008, PHARM RES, V25, P483, DOI 10.1007/s11095-007-9523-x
   CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8
   Cohen BE, 1997, BIOCHEMISTRY-US, V36, P6455, DOI 10.1021/bi970150v
   Cohen JL., 1975, ANAL PROFILES DRUG S, V4, P466
   *CYST FIBR FDN, 2005, ANN REP CYST FIBR FD
   *CYST FIBR FDN, 2006, ANN REP CYST FIBR FD
   DALY JW, 1985, J MED CHEM, V28, P487, DOI 10.1021/jm00382a018
   EIDELMAN O, 1992, P NATL ACAD SCI USA, V89, P5562, DOI 10.1073/pnas.89.12.5562
   Eidelman O, 2002, BIOCHEMISTRY-US, V41, P11161, DOI 10.1021/bi020289s
   ERICKSON RH, 1991, J MED CHEM, V34, P1431, DOI 10.1021/jm00108a029
   GADSBY DC, 2006, NATURE, V477, P83
   Gu CH, 2007, PHARM RES, V24, P1118, DOI 10.1007/s11095-007-9236-1
   JACOBSON KA, 1995, BIOCHEMISTRY-US, V34, P9088, DOI 10.1021/bi00028a018
   Martin A., 1993, PHYS PHARM
   Martinez MN, 2002, J CLIN PHARMACOL, V42, P620, DOI 10.1177/00970002042006005
   McCarty NA, 2002, PEDIATR PULM, V33, P90, DOI 10.1002/ppul.10041
   MCPHERSON TB, 2006, AAPS J, V8, pT2278
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   SCAMMELLS PJ, 1994, J MED CHEM, V37, P2704, DOI 10.1021/jm00043a010
   *SCIFINDER SCHOL, 102146076 SCIFINDER
   SHAMIM MT, 1988, J MED CHEM, V31, P613, DOI 10.1021/jm00398a020
   SHELDRICK G, 1995, SHELXTL PC COMPUTER
   SHELDRICK G, 1997, SHELXL97 SHELXS97 CO
   Stephenson GA, 2006, J PHARM SCI-US, V95, P821, DOI 10.1002/jps.20442
   Strausbaugh SD, 2007, CLIN CHEST MED, V28, P279, DOI 10.1016/j.ccm.2007.02.011
   *US FDA, GUID IND WAIV IN VIV
   *US FDA, CUM LIST ALL ORPH DE
   Wu CY, 2005, PHARM RES, V22, P11, DOI 10.1007/s11095-004-9004-4
   Yu LX, 1999, PHARMACEUT RES, V16, P1883, DOI 10.1023/A:1018911728161
   RUDOLPH A, 2006, Patent No. 20060052404
   POLLARD HB, 1994, Patent No. 5366977
NR 33
TC 1
Z9 1
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1530-9932
J9 AAPS PHARMSCITECH
JI AAPS PharmSciTech
PD JUN
PY 2010
VL 11
IS 2
BP 720
EP 728
DI 10.1208/s12249-010-9436-6
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 612RY
UT WOS:000278921400028
PM 20440586
OA green_published
DA 2018-03-20
ER

PT J
AU Li, TL
   Feng, SX
AF Li, Tonglei
   Feng, Shaoxin
TI Empirically augmented density functional theory for predicting lattice
   energies of aspirin, acetaminophen polymorphs, and ibuprofen homochiral
   and racemic crystals
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE acetaminophen; aspirin; density function theory; dispersion energy;
   ibuprofen; lattice energy; organic crystal; polymorphism; van der Waals
   interaction
ID SMALL ORGANIC-MOLECULES; HARTMAN-PERDOK THEORY; DISPERSION COEFFICIENTS;
   NEUTRON-DIFFRACTION; AB-INITIO; INTERMOLECULAR POTENTIALS;
   VARIABLE-TEMPERATURE; DIPOLE PROPERTIES; BASIS SET; MORPHOLOGY
AB Purpose. Lattice energies of drug crystals are closely associated with many important physicochemical properties including polymorphism of the crystals. Current quantum mechanical methods that can be applied to calculate the lattice energy of most drug crystals are not capable of fully considering the van der Waals interaction energy, a dominant component in the lattice energy. Herein, we report the results of using empirically augmented quantum mechanical methods for predicting the lattice energies of selected drug crystals.
   Methods. Long-range van der Waals energies were evaluated by atom-atom pairwise C-6 R-6 functions that were damped at short interatomic distance where interatomic interactions could be better evaluated by density functional theory (DFT). The atomic C-6 coefficients were taken from literature, and three damping functions were tested. For the quantum mechanical calculations, different basis sets were tested with aspirin as the model system. Basis set superposition error (BSSE) was considered. In addition to aspirin, acetaminophen Form I and Form II, and s(+)- and (+/-)-ibuprofen were calculated and the results were compared to experimental values. Experimentally determined single crystal structures were optimized prior to both empirical and DFT energy calculations.
   Results. Lattice energies calculated by the empirically augmented quantum mechanical methods are in very good agreement with experimental values, suggesting the approach is acceptable. The results also indicate that the long-range van der Waals or dispersion energy is a significant part of the lattice energy, which cannot be accurately estimated by the DFT methods alone.
   Conclusions. Due to the empirical nature for estimating the dispersion energy, choosing the right empirical parameters is crucial. The methods and parameters tested seem to be able to produce reliable values of lattice energies of the drug crystals.
C1 Univ Kentucky, Lexington, KY 40536 USA.
RP Li, TL (reprint author), Univ Kentucky, Lexington, KY 40536 USA.
EM tonglei@uky.edu
CR AHLRICHS R, 1977, CHEM PHYS, V19, P119, DOI 10.1016/0301-0104(77)85124-0
   Allen FH, 2002, ACTA CRYSTALLOGR B, V58, P380, DOI 10.1107/S0108768102003890
   AZIZ RA, 1977, J CHEM PHYS, V67, P5719, DOI 10.1063/1.434827
   BECKE AD, 1993, J CHEM PHYS, V98, P5648, DOI 10.1063/1.464913
   BECKE AD, 1988, PHYS REV A, V38, P3098, DOI 10.1103/PhysRevA.38.3098
   Bennema P, 1996, J CRYST GROWTH, V166, P17, DOI 10.1016/0022-0248(96)00043-7
   BERKOVITCHYELLIN Z, 1985, J AM CHEM SOC, V107, P8239, DOI 10.1021/ja00312a070
   BEYER T, 2001, CRYSTENGCOMM, V3, P213
   Boldyreva EV, 2002, J THERM ANAL CALORIM, V68, P437
   BONDI A, 1964, J PHYS CHEM-US, V68, P441, DOI 10.1021/j100785a001
   BOYS SF, 1970, MOL PHYS, V19, P553, DOI 10.1080/00268977000101561
   BUCKINGHAM AD, 1988, CHEM REV, V88, P963, DOI 10.1021/cr00088a008
   Chickos JS, 2002, J PHYS CHEM REF DATA, V31, P537, DOI 10.1063/1.1475333
   DAVIDSON ER, 1986, CHEM REV, V86, P681, DOI 10.1021/cr00074a002
   Dion M, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.246401
   Dobson JF, 2005, INT J QUANTUM CHEM, V101, P579, DOI 10.1002/qua.20314
   Dobson JF, 2001, AUST J CHEM, V54, P513, DOI 10.1071/CH01052
   DOCHERTY R, 1991, J PHYS D APPL PHYS, V24, P89, DOI 10.1088/0022-3727/24/2/001
   Donnay JDH, 1937, AM MINERAL, V22, P446
   Dovesi R, 2005, Z KRISTALLOGR, V220, P571, DOI 10.1524/zkri.220.5.571.65065
   Elstner M, 2001, J CHEM PHYS, V114, P5149, DOI 10.1063/1.1329889
   Espeau P, 2005, J PHARM SCI-US, V94, P524, DOI 10.1002/jps.20261
   French RH, 2000, J AM CERAM SOC, V83, P2117, DOI 10.1111/j.1151-2916.2000.tb01527.x
   Friedel G., 1907, B SOC FR MINERAL CR, V30, P326
   GAVEZZOTTI A, 1994, STRUCTURE CORRELATIO, V2, P509, DOI DOI 10.1002/9783527616091.CH12
   GAVEZZOTTI A, 1997, MOL SOLID STATE THEO, P61
   GIBBS JW, 2006, EQUILIBRIUM HETEROGE, V1, P315
   Grimbergen RFP, 1998, ACTA CRYSTALLOGR A, V54, P491, DOI 10.1107/S0108767397019806
   HALGREN TA, 1992, J AM CHEM SOC, V114, P7827, DOI 10.1021/ja00046a032
   Hansen LK, 2003, ACTA CRYSTALLOGR E, V59, pO1357, DOI 10.1107/S160053680301451X
   HARTMAN P, 1955, ACTA CRYSTALLOGR, V8, P49, DOI 10.1107/S0365110X55000121
   HEPBURN J, 1975, CHEM PHYS LETT, V36, P451, DOI 10.1016/0009-2614(75)80278-8
   Becke AD, 2005, J CHEM PHYS, V123, DOI 10.1063/1.2065267
   KOHN W, 1965, PHYS REV, V140, P1133, DOI 10.1103/PhysRev.140.A1133
   Kohn W, 1998, PHYS REV LETT, V80, P4153, DOI 10.1103/PhysRevLett.80.4153
   Kumar A, 1997, MOL PHYS, V90, P389, DOI 10.1080/002689797172507
   KUMAR A, 1994, CHEM PHYS, V189, P467, DOI 10.1016/0301-0104(94)00309-2
   LEE CT, 1988, PHYS REV B, V37, P785, DOI 10.1103/PhysRevB.37.785
   Lommerse JPM, 2000, ACTA CRYSTALLOGR B, V56, P697, DOI 10.1107/S0108768100004584
   Moller C, 1934, PHYS REV, V46, P0618, DOI 10.1103/PhysRev.46.618
   Mooij WTM, 1999, J PHYS CHEM A, V103, P9872
   Motherwell WDS, 2002, ACTA CRYSTALLOGR B, V58, P647, DOI 10.1107/S0108768102005669
   Pellenq RJM, 1998, MOL PHYS, V95, P549, DOI 10.1080/00268979809483189
   Perdew JP, 1996, PHYS REV B, V54, P16533, DOI 10.1103/PhysRevB.54.16533
   Perlovich GL, 2004, J PHARM SCI-US, V93, P654, DOI 10.1002/jps.10586
   Perlovich G. L., 2004, AAPS PHARMSCI, V6, P1
   PERLOVICH GL, 2005, COMMUNICATION
   Shankland N, 1997, ACTA CRYSTALLOGR C, V53, P951, DOI 10.1107/S0108270197003193
   SPACKMAN MA, 1991, J CHEM PHYS, V94, P1295, DOI 10.1063/1.460039
   STANTON JF, 1994, PHYS REV A, V49, P1698, DOI 10.1103/PhysRevA.49.1698
   TANG KT, 1984, J CHEM PHYS, V80, P3726, DOI 10.1063/1.447150
   Wilson CC, 2000, Z KRISTALLOGR, V215, P693, DOI 10.1524/zkri.2000.215.11.693
   Wilson CC, 2002, NEW J CHEM, V26, P1733, DOI 10.1039/b203775k
   Wu Q, 2002, J CHEM PHYS, V116, P515, DOI 10.1063/1.1424928
   Wulff G, 1901, Z KRYSTALLOGR MINERA, V34, P449
   YU L, 1995, J PHARM SCI, V84, P966, DOI 10.1002/jps.2600840812
NR 56
TC 32
Z9 33
U1 3
U2 22
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
EI 1573-904X
J9 PHARM RES-DORDR
JI Pharm. Res.
PD OCT
PY 2006
VL 23
IS 10
BP 2326
EP 2332
DI 10.1007/s11095-006-9006-5
PG 7
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 092QI
UT WOS:000241112000010
PM 16927187
DA 2018-03-20
ER

PT J
AU Majumder, M
   Hinds, BJ
AF Majumder, Mainak
   Hinds, Bruce J.
TI PMSE 491-Self-assembly and (de)aggregation of conjugated materials in
   solid polymer hosts: A general approach for new mechanochromic and
   thermochromic materials
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
C1 [Majumder, Mainak; Hinds, Bruce J.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
NR 0
TC 0
Z9 0
U1 0
U2 4
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD SEP 10
PY 2006
VL 232
MA 497-PMSE
BP 272
EP 272
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA V15DC
UT WOS:000207781700265
DA 2018-03-20
ER

PT J
AU Yu, CG
   Geddes, JW
AF Yu, Chen-Guang
   Geddes, James W.
TI Sustained calpain inhibition improves locomotor function and tissue
   sparing following contusive spinal cord injury
SO NEUROCHEMICAL RESEARCH
LA English
DT Article
DE neurodegeneration; neuroprotection; necrosis; cytoskeleton
ID NEURONAL CELL-DEATH; NEUROLOGICAL FUNCTION; I ACTIVATION; MOUSE MODEL;
   CYTOSKELETAL; DEGRADATION; RAT; APOPTOSIS; EXPRESSION; PROTEIN
AB Following contusive spinal cord injury (SCI), calpain activity is dramatically increased and remains elevated for days to weeks. Although calpain inhibition has previously been demonstrated to be neuroprotective following spinal cord injury, most studies administered the calpain inhibitor at a single time point. We hypothesized that sustained calpain inhibition would improve functional and pathological outcomes, as compared to the results obtained with a single postinjury administration of the calpain inhibitor. Contusion SCI was produced in female Long-Evans rats using the Infinite Horizon spinal cord injury impactor at the 200 kdyn force setting. Open-field locomotor function was evaluated until 6 weeks postinjury. Histological assessment of lesion volume and tissue sparing was performed at 6 weeks after SCI. Calpain inhibitor MDL28170 administered as a single postinjury i.v. bolus (20 mg/kg) or as a daily i.p. dose (1 mg/kg) improved locomotor function, but did not increase tissue sparing. Combined i.v. and daily i.p. MDL28170 administration resulted in significant improvement in both functional and pathological outcome measures, supporting the calpain theory of SCI proposed by Dr. Banik and colleagues.
C1 Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA.
   Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA.
RP Geddes, JW (reprint author), Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, B379,Biomed & Biol Sci Res Bldg,741 S Limestone S, Lexington, KY 40536 USA.
EM jgeddes@uky.edu
RI Yu, Chen Guang/C-6176-2011
FU NINDS NIH HHS [R01 NS 045726]
CR Arataki S, 2005, J NEUROTRAUM, V22, P398, DOI 10.1089/neu.2005.22.398
   Banik N L, 1984, Prog Clin Biol Res, V146, P145
   Banik NL, 1998, ANN NY ACAD SCI, V844, P131, DOI 10.1111/j.1749-6632.1998.tb08228.x
   Banik NL, 1997, BRAIN RES, V752, P301, DOI 10.1016/S0006-8993(96)01488-6
   BANIK NL, 1982, NEUROCHEM RES, V7, P1465, DOI 10.1007/BF00965089
   BANIK NL, 1980, J NEUROPATH EXP NEUR, V39, P232, DOI 10.1097/00005072-198005000-00002
   BANIK NL, 1986, J NEUROL SCI, V73, P245, DOI 10.1016/0022-510X(86)90149-8
   Bano D, 2005, CELL, V120, P275, DOI 10.1016/j.cell.2004.11.049
   Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098
   BLIGHT AR, 1983, NEUROSCIENCE, V10, P521, DOI 10.1016/0306-4522(83)90150-1
   BRORSON JR, 1995, STROKE, V26, P1259, DOI 10.1161/01.STR.26.7.1259
   BRORSON JR, 1995, STROKE, V26, P1267
   Crocker SJ, 2003, J NEUROSCI, V23, P4081
   Cuzzocrea S, 2000, AM J PATHOL, V157, P2065, DOI 10.1016/S0002-9440(10)64845-6
   Das BP, 2005, J THEOR COMPUT CHEM, V4, P1, DOI 10.1142/S0219633605001441
   HAPPEL RD, 1981, BRAIN RES, V2, P476
   Hung KS, 2005, J NEUROPATH EXP NEUR, V64, P15, DOI 10.1093/jnen/64.1.15
   James T, 1998, J NEUROSCI RES, V51, P218, DOI 10.1002/(SICI)1097-4547(19980115)51:2<218::AID-JNR10>3.3.CO;2-#
   Kieran D, 2004, NEUROSCIENCE, V125, P427, DOI 10.1016/j.neuroscience.2004.01.046
   Kupina NC, 2001, J NEUROTRAUM, V18, P1229, DOI 10.1089/089771501317095269
   Liu XL, 2004, ANNU REV PHARMACOL, V44, P349, DOI 10.1146/annurev.pharmtox.44.101802.121804
   Magnuson DSK, 1999, EXP NEUROL, V156, P191, DOI 10.1006/exnr.1999.7016
   Markgraf CG, 1998, STROKE, V29, P152, DOI 10.1161/01.STR.29.1.152
   MEHDI S, 1991, TRENDS BIOCHEM SCI, V16, P150, DOI 10.1016/0968-0004(91)90058-4
   Momeni HR, 2005, NEUROREPORT, V16, P1065, DOI 10.1097/00001756-200507130-00007
   Moore JD, 2002, BRIT J PHARMACOL, V135, P1069, DOI 10.1038/sj.bjp.0704538
   O'Hanlon GM, 2003, BRAIN, V126, P2497, DOI 10.1093/brain/awg254
   Pianetti S, 2001, ONCOGENE, V20, P1287, DOI 10.1038/sj.onc.1204257
   Rabchevsky AG, 2001, J NEUROTRAUM, V18, P513, DOI 10.1089/089771501300227314
   Ray SK, 2003, J CHEM NEUROANAT, V26, P119, DOI 10.1016/S0891-0618(03)00044-9
   Ray SK, 1999, BRAIN RES, V816, P375, DOI 10.1016/S0006-8993(98)01128-7
   Ray SK, 2003, BRAIN RES REV, V42, P169, DOI 10.1016/S0165-0173(03)00152-8
   Ray SK, 2002, J NEUROSCI RES, V70, P561, DOI 10.1002/jnr.10414
   Ray SK, 1999, ANN NY ACAD SCI, V890, P261, DOI 10.1111/j.1749-6632.1999.tb08001.x
   Ray SK, 2000, BRAIN RES, V867, P80, DOI 10.1016/S0006-8993(00)02260-5
   Rock MT, 2000, EXP CELL RES, V261, P260, DOI 10.1006/excr.2000.5048
   Saatman KE, 2000, J CEREBR BLOOD F MET, V20, P66, DOI 10.1097/00004647-200001000-00010
   Schaecher KE, 2001, NEUROCHEM RES, V26, P731, DOI 10.1023/A:1010903823668
   Schaub FJ, 2003, CIRC RES, V93, P515, DOI 10.1161/01.RES.0000093205.42313.7C
   Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099
   Schumacher PA, 2000, J NEUROCHEM, V74, P1646, DOI 10.1046/j.1471-4159.2000.0741646.x
   Schumacher PA, 1999, NEUROSCIENCE, V91, P733, DOI 10.1016/S0306-4522(98)00552-1
   Shields DC, 2000, J NEUROSCI RES, V61, P146
   Springer JE, 1997, J NEUROCHEM, V69, P1592, DOI 10.1046/j.1471-4159.1997.69041592.x
   Stewart MP, 1998, J CELL BIOL, V140, P699, DOI 10.1083/jcb.140.3.699
   Teng YD, 1997, J NEUROSCI, V17, P4359
   Volbracht C, 2005, J NEUROCHEM, V93, P1280, DOI 10.1111/j.1471-4159.2005.03122.x
   Wang K K, 1997, Adv Pharmacol, V37, P117
   WANG KKW, 1990, TRENDS PHARMACOL SCI, V11, P139, DOI 10.1016/0165-6147(90)90060-L
   WATANABE N, 1994, CYTOKINE, V6, P597, DOI 10.1016/1043-4666(94)90046-9
   Yu CG, 2000, NEUROREPORT, V11, P3203, DOI 10.1097/00001756-200009280-00031
   Zhang SX, 2000, J NEUROPATH EXP NEUR, V59, P287, DOI 10.1093/jnen/59.4.287
   Zhang SX, 2003, J NEUROTRAUM, V20, P59, DOI 10.1089/08977150360517182
NR 53
TC 27
Z9 30
U1 0
U2 0
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0364-3190
J9 NEUROCHEM RES
JI Neurochem. Res.
PD DEC
PY 2007
VL 32
IS 12
BP 2046
EP 2053
DI 10.1007/s11064-007-9347-4
PG 8
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 226ZK
UT WOS:000250626800006
PM 17476592
DA 2018-03-20
ER

PT J
AU Long, SH
   Li, TL
AF Long, Sihui
   Li, Tonglei
TI Enforcing Molecule's pi-Conjugation and Consequent Formation of the
   Acid-Acid Homosynthon over the Acid-Pyridine Heterosynthon in
   2-Anilinonicotinic Acids
SO CRYSTAL GROWTH & DESIGN
LA English
DT Article
ID HYDROGEN-BOND PATTERNS; GRAPH-SET ANALYSIS; CRYSTAL-STRUCTURES;
   CONFORMATIONAL POLYMORPHISM; ORGANIC-CRYSTALS; X-RAY; SYNTHONS; DONOR
AB Two different synthons, acid-acid and acid-pyridine, are present in the crystal structures of 2-(phenylamino)nicotinic acid. The intermolecular hydrogen-bonding motifs are determined by molecular conformation and conformational energy. By covalently linking electron-withdrawing groups to the phenyl ring, it is possible to strengthen the molecule's global pi-conjugation and thereby lead to only the acid-acid homosynthon in crystal packing and prohibit the competing acid-pyridine heterosynthon.
C1 [Li, Tonglei] Univ Kentucky, Coll Pharm 514, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
RP Li, TL (reprint author), Univ Kentucky, Coll Pharm 514, Dept Pharmaceut Sci, 725 Rose St, Lexington, KY 40536 USA.
EM tonglei@uky.edu
FU NSF [DMR-0449633]
FX The authors are grateful to the NSF for financial support of this study
   (DMR-0449633). The authors also thank Drs. Sean Parkin and Arthur
   Cammers for helpful discussions.
CR Aakeroy CB, 2001, ANGEW CHEM INT EDIT, V40, P3240, DOI 10.1002/1521-3773(20010903)40:17<3240::AID-ANIE3240>3.0.CO;2-X
   BERNSTEIN J, 1995, ANGEW CHEM INT EDIT, V34, P1555, DOI 10.1002/anie.199515551
   Bernstein J., 1987, ORGANIC SOLID STATE, V32, P471
   Bernstein J., 2002, POLYMORPHISM MOL CRY
   CORRADINI P, 1973, CHIM IND-MILAN, V55, P122
   Desiraju GR, 2002, NAT MATER, V1, P77, DOI 10.1038/nmat726
   Dunitz JD, 2004, P NATL ACAD SCI USA, V101, P14309, DOI 10.1073/pnas.0405744101
   Dunitz JD, 2003, CHEM COMMUN, P545, DOI 10.1039/b211531j
   ETTER MC, 1990, ACCOUNTS CHEM RES, V23, P120, DOI 10.1021/ar00172a005
   ETTER MC, 1990, ACTA CRYSTALLOGR B, V46, P256, DOI 10.1107/S0108768189012929
   GAVEZZOTTI A, 1994, ACCOUNTS CHEM RES, V27, P309, DOI 10.1021/ar00046a004
   HAGLER AT, 1978, J AM CHEM SOC, V100, P6349, DOI 10.1021/ja00488a012
   Long SH, 2008, CRYST GROWTH DES, V8, P4006, DOI 10.1021/cg800123z
   Nangia A, 2008, ACCOUNTS CHEM RES, V41, P595, DOI 10.1021/ar700203k
   PANAGIOTOPOULOS NC, 1974, ACTA CRYSTALLOGR B, V30, P1421, DOI 10.1107/S0567740874005012
   REED AE, 1988, CHEM REV, V88, P899, DOI 10.1021/cr00088a005
   Shattock TR, 2008, CRYST GROWTH DES, V8, P4533, DOI 10.1021/cg800565a
   Steiner T, 2001, ACTA CRYSTALLOGR B, V57, P103, DOI 10.1107/S0108768100014348
   Vishweshwar P, 2003, CRYST GROWTH DES, V3, P783, DOI 10.1021/cg034037h
NR 19
TC 14
Z9 14
U1 0
U2 9
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1528-7483
J9 CRYST GROWTH DES
JI Cryst. Growth Des.
PD JUN
PY 2010
VL 10
IS 6
BP 2465
EP 2469
DI 10.1021/cg100227s
PG 5
WC Chemistry, Multidisciplinary; Crystallography; Materials Science,
   Multidisciplinary
SC Chemistry; Crystallography; Materials Science
GA 602OE
UT WOS:000278147900007
DA 2018-03-20
ER

PT J
AU Hayes, D
   Mansour, H
AF Hayes, Don, Jr.
   Mansour, Heidi M.
TI Improved Outcomes of Patients with End-stage Cystic Fibrosis Requiring
   Invasive Mechanical Ventilation for Acute Respiratory Failure
SO LUNG
LA English
DT Article
DE Cystic fibrosis; Invasive mechanical ventilation; Continuous infusion;
   beta-Lactam antibiotic; Respiratory failure; Tobramycin; Pseudomonas
   aeruginos
ID BETA-LACTAM ANTIBIOTICS; ONCE-DAILY TOBRAMYCIN; CONTINUOUS-INFUSION;
   ASSISTED VENTILATION; CEFTAZIDIME; CHILDREN; EFFICACY; PHARMACOKINETICS;
   INFECTIONS; THERAPY
AB Study Objectives The aim of this study was to determine the effects of an antibiotic strategy with intravenous (IV) continuous infusion of a beta-lactam (CIBL) antibiotic and high-dose extended-interval (HDEI) tobramycin upon outcomes in patients with cystic fibrosis (CF) requiring invasive mechanical ventilation (IMV) for acute respiratory failure.
   Design The study was a retrospective review from June 1, 2006, to December 1, 2010, of patients at a university hospital with an adult CF center.
   Results The study population included adult CF patients requiring IMV. A total of 15 hospitalizations with IMV episodes were reviewed, involving 10 adult (31.4 +/- A 11.1 years) CF patients with end-stage lung disease (FEV(1) = 23.6 +/- A 7.8% predicted) and malnutrition (body mass index = 20.5 +/- A 3.1). Each patient survived to discharge and to follow-up 6 months later without the need for lung transplantation during the study period.
   Conclusions A novel antibiotic strategy with a CIBL antibiotic and HDEI tobramycin improved survival in a small cohort of critically ill CF patients with end-stage lung disease and malnutrition requiring IMV.
C1 [Hayes, Don, Jr.] C424 Univ Kentucky, Med Ctr, Adv Lung Dis Program, Lexington, KY 40536 USA.
   [Hayes, Don, Jr.] C424 Univ Kentucky, Med Ctr, Lung Transplant Program, Lexington, KY 40536 USA.
   [Mansour, Heidi M.] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Drug Dev Div, Lexington, KY 40536 USA.
RP Hayes, D (reprint author), C424 Univ Kentucky, Med Ctr, Adv Lung Dis Program, 800 Rose St, Lexington, KY 40536 USA.
EM don.hayes@uky.edu; heidi.mansour@uky.edu
CR Aminimanizani A, 2002, J ANTIMICROB CHEMOTH, V50, P553, DOI 10.1093/jac/dkf168
   Bates RD, 1997, CHEST, V112, P1208, DOI 10.1378/chest.112.5.1208
   Berlinski A, 2002, PEDIATR PULM, V34, P297, DOI 10.1002/ppul.10159
   Boat T F, 1989, Acta Paediatr Scand Suppl, V363, P25
   Boat TF, 1989, ACTA PAEDIATR SC   S, V363, P29
   Bragonier R, 1998, J ANTIMICROB CHEMOTH, V42, P103, DOI 10.1093/jac/42.1.103
   Burkhardt O, 2006, J ANTIMICROB CHEMOTH, V58, P822, DOI 10.1093/jac/dkl328
   Contopoulos-Ioannidis DG, 2004, PEDIATRICS, V114, pE111, DOI 10.1542/peds.114.1.e111
   CRAIG WA, 1992, ANTIMICROB AGENTS CH, V36, P2577, DOI 10.1128/AAC.36.12.2577
   DAENEN S, 1995, EUR J CLIN MICROBIOL, V14, P188, DOI 10.1007/BF02310354
   DAVIS PB, 1978, JAMA-J AM MED ASSOC, V239, P1851, DOI 10.1001/jama.239.18.1851
   Davis PB, 1999, CYSTIC FIBROSIS IN ADULTS, P45
   Flume PA, 2009, AM J RESP CRIT CARE, V180, P802, DOI 10.1164/rccm.200812-1845PP
   GARLAND JS, 1989, CHEST, V96, P136, DOI 10.1378/chest.96.1.136
   Hubert D, 2009, ANTIMICROB AGENTS CH, V53, P3650, DOI 10.1128/AAC.00174-09
   Lau WK, 2006, ANTIMICROB AGENTS CH, V50, P3556, DOI 10.1128/AAC.00329-06
   LEEDER JS, 1984, CLIN PHARMACOL THER, V36, P355, DOI 10.1038/clpt.1984.187
   LLOYDSTI.JD, 1974, PEDIATRICS, V53, P678
   Matsui H, 1998, J CLIN INVEST, V102, P1125, DOI 10.1172/JCI2687
   Nicolau DP, 1996, ANTIMICROB AGENTS CH, V40, P61
   PADOAN R, 1987, PEDIATR INFECT DIS J, V6, P648, DOI 10.1097/00006454-198707000-00006
   PARADISI F, 1995, J CHEMOTHERAPY, V7, P338, DOI 10.1179/joc.1995.7.4.338
   POWELL SH, 1983, J INFECT DIS, V147, P918, DOI 10.1093/infdis/147.5.918
   Prescott WA, 2010, PHARMACOTHERAPY, V30, P95, DOI 10.1592/phco.30.1.95
   Puchelle Edith, 2002, Paediatr Respir Rev, V3, P115, DOI 10.1016/S1526-0550(02)00005-7
   Rafati MR, 2006, INT J ANTIMICROB AG, V28, P122, DOI 10.1016/j.ijantimicag.2006.02.020
   Rappaz I, 2000, EUR J PEDIATR, V159, P919, DOI 10.1007/PL00008370
   Riethmueller J, 2009, INFECTION, V37, P418, DOI 10.1007/s15010-009-8116-5
   Riethmueller J, 2009, INFECTION, V37, P424, DOI 10.1007/s15010-009-8117-4
   Roberts JA, 2007, INT J ANTIMICROB AG, V30, P11, DOI 10.1016/j.ijantimicag.2007.02.002
   Roberts JA, 2009, CRIT CARE MED, V37, P2071, DOI 10.1097/CCM.0b013e3181a0054d
   ROOSENDAAL R, 1989, EUR J CLIN MICROBIOL, V8, P878, DOI 10.1007/BF01963774
   Rosenstein BJ, 1998, J PEDIATR-US, V132, P589, DOI 10.1016/S0022-3476(98)70344-0
   Slieker MG, 2006, INTENS CARE MED, V32, P754, DOI 10.1007/s00134-006-0085-x
   Smyth A, 2005, LANCET, V365, P573, DOI 10.1016/S0140-6736(05)17906-9
   Smyth AR, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002009.pub3
   Sood N, 2001, AM J RESP CRIT CARE, V163, P335, DOI 10.1164/ajrccm.163.2.2003076
   Soulsby N, 2009, INTERN MED J, V39, P527, DOI 10.1111/j.1445-5994.2008.01787.x
   Ulrich M, 2010, J CYST FIBROS, V9, P217, DOI 10.1016/j.jcf.2010.03.001
   Vedam Hima, 2004, J Cyst Fibros, V3, P8, DOI 10.1016/j.jcf.2003.12.003
   Vic P, 1998, ARCH DIS CHILD, V78, P536, DOI 10.1136/adc.78.6.536
   VOGELMAN B, 1986, J PEDIATR-US, V108, P835, DOI 10.1016/S0022-3476(86)80754-5
   VONDRACEK TG, 1995, ANN PHARMACOTHER, V29, P415, DOI 10.1177/106002809502900413
NR 43
TC 4
Z9 4
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0341-2040
J9 LUNG
JI Lung
PD OCT
PY 2011
VL 189
IS 5
BP 409
EP 415
DI 10.1007/s00408-011-9311-6
PG 7
WC Respiratory System
SC Respiratory System
GA 814SX
UT WOS:000294478600007
PM 21805164
DA 2018-03-20
ER

PT J
AU Underwood, RM
   Shin, H
AF Underwood, Ryan Matthew
   Shin, Hainsworth Y.
TI Effects of Hydrostatic Pressure on Endothelial Tubulogenic Processes
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 [Underwood, Ryan Matthew; Shin, Hainsworth] Univ Kentucky, Ctr Biomed Engn, Lexington, KY 40506 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2010
VL 24
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA V28IW
UT WOS:000208675504793
DA 2018-03-20
ER

PT J
AU Naga, KK
   Sullivan, PG
   Geddes, JW
AF Naga, Kranthi Kumari
   Sullivan, Patrick G.
   Geddes, James W.
TI High cyclophilin D content in neuronal mitochondria results in greater
   vulnerability to Ca2+ overload
SO JOURNAL OF NEUROTRAUMA
LA English
DT Meeting Abstract
CT 25th Annual National-Neurotrauma-Society Symposium
CY JUL 29-AUG 01, 2007
CL Kansas City, MO
SP Natl Neurotrauma Soc
C1 Univ Kentucky, Lexington, KY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0897-7151
J9 J NEUROTRAUM
JI J. Neurotrauma
PD JUL
PY 2007
VL 24
IS 7
MA P205
BP 1280
EP 1280
PG 1
WC Critical Care Medicine; Clinical Neurology; Neurosciences
SC General & Internal Medicine; Neurosciences & Neurology
GA 186DV
UT WOS:000247760200214
DA 2018-03-20
ER

PT J
AU Venkatachalam, K
   Chopra, N
   Gavalas, VG
   Bhattacharyya, D
   Bachas, LG
AF Venkatachalam, Karthik
   Chopra, Nitin
   Gavalas, Vasilis G.
   Bhattacharyya, Dibakar
   Bachas, Leonidas G.
TI I&EC 90-Hydration of industrially obtained magnesium oxide
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
C1 [Venkatachalam, Karthik; Chopra, Nitin; Gavalas, Vasilis G.; Bachas, Leonidas G.] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
   [Bhattacharyya, Dibakar] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM kvenk2@uky.edu; nchop2@gmail.com; db@engr.uky.edu; bachas@uky.edu
RI VENKATACHALAM, KARTHIK/D-1013-2011; Bachas, Leonidas/G-2479-2015; Nitin,
   Chopra/F-8236-2011
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD MAR 25
PY 2007
VL 233
MA 165-IEC
BP 835
EP 835
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA V14GL
UT WOS:000207722802737
DA 2018-03-19
ER

PT J
AU Jyoti, A
   Fugit, KD
   Sethi, P
   McGarry, RC
   Anderson, BD
   Upreti, M
AF Jyoti, Amar
   Fugit, Kyle D.
   Sethi, Pallavi
   McGarry, Ronald C.
   Anderson, Bradley D.
   Upreti, Meenakshi
TI An in vitro assessment of liposomal topotecan simulating metronomic
   chemotherapy in combination with radiation in tumor-endothelial
   spheroids
SO SCIENTIFIC REPORTS
LA English
DT Article
ID PROSTATE-CANCER; ORAL TOPOTECAN; INDUCED APOPTOSIS; OVARIAN-CANCER;
   DRUG-DELIVERY; BREAST-CANCER; CELL-CULTURE; SOLID TUMORS; THERAPY;
   MURINE
AB Low dose metronomic chemotherapy (LDMC) refers to prolonged administration of low dose chemotherapy designed to minimize toxicity and target the tumor endothelium, causing tumor growth inhibition. Topotecan (TPT) when administered at its maximum tolerated dose (MTD) is often associated with systemic hematological toxicities. Liposomal encapsulation of TPT enhances efficacy by shielding it from systemic clearance, allowing greater uptake and extended tissue exposure in tumors. Extended release of TPT from liposomal formulations also has the potential to mimic metronomic therapies with fewer treatments. Here we investigate potential toxicities of equivalent doses of free and actively loaded liposomal TPT (LTPT) and compare them to a fractionated low dose regimen of free TPT in tumor-endothelial spheroids (TES) with/without radiation exposure for a prolonged period of 10 days. Using confocal microscopy, TPT fluorescence was monitored to determine the accumulation of drug within TES. These studies showed TES, being more reflective of the in vivo tumor microenvironment, were more sensitive to LTPT in comparison to free TPT with radiation. More importantly, the response of TES to low-dose metronomic TPT with radiation was comparable to similar treatment with LTPT. This TES study suggests nanoparticle formulations designed for extended release of drug can simulate LDMC in vivo.
C1 [Jyoti, Amar; Fugit, Kyle D.; Sethi, Pallavi; Anderson, Bradley D.; Upreti, Meenakshi] Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40506 USA.
   [McGarry, Ronald C.] Univ Kentucky, Dept Radiat Med, Chandler Hosp, Lexington, KY USA.
RP Upreti, M (reprint author), Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40506 USA.
EM m.upreti@uky.edu
FU National Cancer Institute [R25CA153954, R21CA173609]
FX This project was supported by R25CA153954 and R21CA173609 (MU) from the
   National Cancer Institute. The content is solely the responsibility of
   the authors and does not necessarily represent the official views of the
   National Cancer Institute or the National Institute of Health.
CR Aljuffali IA, 2011, CANCER BIOL THER, V12, P407, DOI 10.4161/cbt.12.5.15950
   Amoozgar Z, 2014, BIOMACROMOLECULES, V15, P4187, DOI 10.1021/bm5011933
   Andre N., 2013, ESAIM Proceedings, V41, P77, DOI 10.1051/proc/201341004
   Bausero MA, 2006, TUMOR BIOL, V27, P17, DOI 10.1159/000090152
   Becker EBE, 2004, J NEUROSCI, V24, P8762, DOI 10.1523/JNEUROSCI.2953-04.2004
   Breslin S, 2013, DRUG DISCOV TODAY, V18, P240, DOI 10.1016/j.drudis.2012.10.003
   Browder T, 2000, CANCER RES, V60, P1878
   Cai BB, 2006, J BIOL CHEM, V281, P25215, DOI 10.1074/jbc.M512627200
   Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220
   Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929
   Costa-Pereira AP, 2000, BRIT J CANCER, V82, P1827, DOI 10.1054/bjoc.2000.1149
   Drummond DC, 2008, J PHARM SCI-US, V97, P4696, DOI 10.1002/jps.21358
   Emmenegger U, 2010, RECENT RESULTS CANC, V180, P165, DOI 10.1007/978-3-540-78281-0_10
   Eriksson D., 2007, CLIN CANCER RES, V13, P5501
   Faivre C, 2013, CANCER CHEMOTH PHARM, V71, P1013, DOI 10.1007/s00280-013-2095-z
   Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339
   Fugit KD, 2015, J CONTROL RELEASE, V197, P10, DOI 10.1016/j.jconrel.2014.10.011
   Fugit KD, 2014, MOL PHARMACEUT, V11, P1314, DOI 10.1021/mp400765n
   Fugit KD, 2014, J CONTROL RELEASE, V174, P88, DOI 10.1016/j.jconrel.2013.11.003
   Gasparini G, 2001, LANCET ONCOL, V2, P733, DOI 10.1016/S1470-2045(01)00587-3
   Hackl C, 2013, GUT, V62, P259, DOI 10.1136/gutjnl-2011-301585
   Hanahan D, 2000, J CLIN INVEST, V105, P1045, DOI 10.1172/JCI9872
   Jain RK, 2001, P NATL ACAD SCI USA, V98, P14748, DOI 10.1073/pnas.261606598
   Jedeszko C, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010722
   Joguparthi V, 2008, J PHARM SCI-US, V97, P433, DOI 10.1002/jps.21135
   Junttila MR, 2013, NATURE, V501, P346, DOI 10.1038/nature12626
   Kaur Punit, 2012, BMC Cancer, V12, P120, DOI 10.1186/1471-2407-12-120
   Khodarev NN, 2004, INT J CANCER, V109, P214, DOI 10.1002/ijc.11728
   Kim B, 2010, NAT NANOTECHNOL, V5, P465, DOI [10.1038/NNANO.2010.58, 10.1038/nnano.2010.58]
   Kirstein MN, 2008, CANCER CHEMOTH PHARM, V61, P291, DOI 10.1007/s00280-007-0474-z
   Klement GL, 2011, J PEDIAT HEMATOL ONC, V33, P1, DOI 10.1097/MPH.0b013e3182024918
   Kumar P, 2004, J BIOL CHEM, V279, P43352, DOI 10.1074/jbc.M405777200
   Kumar S, 2013, TRANSL ONCOL, V6, P493, DOI 10.1593/tlo.13286
   Kummar S, 2011, CLIN CANCER RES, V17, P5123, DOI 10.1158/1078-0432.CCR-11-0682
   Lam T, 2006, ANTI-CANCER DRUG, V17, P113, DOI 10.1097/00001813-200602000-00001
   Langley RR, 2011, INT J CANCER, V128, P2527, DOI 10.1002/ijc.26031
   Li DD, 2009, ONCOGENE, V28, P886, DOI 10.1038/onc.2008.441
   Liu JJ, 2002, ANTI-CANCER DRUG, V13, P709, DOI 10.1097/00001813-200208000-00005
   Luo Y, 2012, ANAL CHEM, V84, P6731, DOI 10.1021/ac301191j
   Maeda H, 2001, J CONTROL RELEASE, V74, P47, DOI 10.1016/S0168-3659(01)00309-1
   Mainardes RM, 2004, CURR DRUG TARGETS, V5, P449, DOI 10.2174/1389450043345407
   Marshall JL, 2012, J CLIN ONCOL, V30, P2815, DOI 10.1200/JCO.2012.43.4233
   Merritt WM, 2010, MOL CANCER THER, V9, P985, DOI 10.1158/1535-7163.MCT-09-0967
   Merritt WM, 2009, CANCER BIOL THER, V8, P1596, DOI 10.4161/cbt.8.16.9004
   Minturn JE, 2011, PEDIATR BLOOD CANCER, V56, P39, DOI 10.1002/pbc.22690
   Moore A, 1998, METHOD CELL BIOL, V57, P265
   Netti PA, 2000, CANCER RES, V60, P2497
   Norrby K, 2014, APMIS, V122, P565, DOI 10.1111/apm.12201
   O'Brien MER, 2004, ANN ONCOL, V15, P440, DOI 10.1093/annone/mdh097
   O'Leary JJ, 1999, CLIN CANCER RES, V5, P181
   OCONNELL K, 1991, AM J PATHOL, V139, P743
   OCONNELL KA, 1990, J IMMUNOL, V144, P521
   Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8
   ODWYER PJ, 1994, CANCER CHEMOTH PHARM, V34, pS46, DOI 10.1007/BF00684863
   Pasquier E, 2010, NAT REV CLIN ONCOL, V7, P455, DOI 10.1038/nrclinonc.2010.82
   Pietras K, 2005, J CLIN ONCOL, V23, P939, DOI 10.1200/JCO.2005.07.093
   Podo F, 2010, MOL ONCOL, V4, P209, DOI 10.1016/j.molonc.2010.04.006
   Ran XZ, 2010, J RADIAT RES, V51, P527, DOI 10.1269/jrr.09119
   Rejniak KA, 2011, WIRES SYST BIOL MED, V3, P115, DOI 10.1002/wsbm.102
   Rodriguez-Berriguete G., 2012, J SIGNAL TRANSDUCT, V2012, DOI DOI 10.1155/2012/169170
   Sang HX, 2005, CANCER GENE THER, V12, P427, DOI 10.1038/sj.cgt.7700809
   Scharovsky O G, 2009, Curr Oncol, V16, P7
   Sorensen P, 1999, ACTA ONCOL, V38, P1043
   Swartz MA, 2012, CANCER RES, V72, P2473, DOI 10.1158/0008-5472.CAN-12-0122
   Tang L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083962
   Tardi P, 2000, CANCER RES, V60, P3389
   Taylor CA, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-35
   Thompson RF, 2014, ADV EXP MED BIOL, V772, P147, DOI 10.1007/978-1-4614-5915-6_7
   Upreti M, 2013, TRANSL CANCER RES, V2, P309, DOI 10.3978/j.issn.2218-676X.2013.08.11
   Upreti M, 2011, TRANSL ONCOL, V4, P365, DOI 10.1593/tlo.11187
   Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556
   Wallace DI, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00051
   Walter-Yohrling J, 2004, CLIN CANCER RES, V10, P2179, DOI 10.1158/1078-0432.CCR-03-1013
   Wang X, 2013, BIOMATERIALS, V34, P4667, DOI 10.1016/j.biomaterials.2013.03.008
   Yagata H, 2011, BREAST CANCER-TOKYO, V18, P165, DOI 10.1007/s12282-011-0254-9
   Zamboni WC, 2004, CANCER CHEMOTH PHARM, V53, P329, DOI 10.1007/s00280-003-0719-4
NR 76
TC 4
Z9 4
U1 1
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 15
PY 2015
VL 5
AR 15236
DI 10.1038/srep15236
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CT4UV
UT WOS:000362803700002
PM 26468877
OA gold
DA 2018-03-20
ER

PT J
AU Hersh, LB
   Rodgers, DW
AF Hersh, Louis B.
   Rodgers, David W.
TI Neprilysin and amyloid beta peptide degradation
SO CURRENT ALZHEIMER RESEARCH
LA English
DT Article
ID DEGRADING ENZYME NEPRILYSIN; DEPENDENT TRANSCRIPTIONAL CONTROL; PROTEIN
   INTRACELLULAR DOMAIN; AMINO-ACID-SEQUENCE; ANGIOTENSIN-CONVERTING
   ENZYME; SPORADIC ALZHEIMERS-DISEASE; KIDNEY BRUSH-BORDER; PIQUARD
   ET-AL.; NEUTRAL ENDOPEPTIDASE; IN-VIVO
AB Neprilysin is a zinc metalloendopeptidase with relatively broad substrate specificity. The enzyme is localized to the plasma membrane of cells where it can function to degrade extracellular peptides. Structural studies show that neprilysin preferentially cleaves peptides on the amino side of hydrophobic amino acids. Neprilysin has been implicated in the catabolism of amyloid beta peptides in the brain and as such has received considerable attention, particularly as a therapeutic target for Alzheimer's disease. An inverse relationship between neprilysin levels and amyloid beta peptide levels and between neprilysin levels and amyloid plaque formation has been observed in human brain. Neprilysin levels decline with aging in the temporal and frontal cortex possibly contributing to higher amyloid beta peptide levels. A number of studies have shown that increasing neprilysin levels in the brain leads to a decrease in brain amyloid peptide levels. Most recently a potential relationship between amyloid beta peptide synthesis from the amyloid precursor protein and neprilysin activity has been proposed.
C1 [Hersh, Louis B.] Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA.
   Univ Kentucky, Struct Biol Ctr, Lexington, KY 40536 USA.
RP Hersh, LB (reprint author), Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, B283 Biomed Biol Res Bldg,741 S Limestone St, Lexington, KY 40536 USA.
EM lhersh@uky.edu
CR Akiyama H, 2001, BRAIN RES, V902, P277, DOI 10.1016/S0006-8993(01)02390-3
   Barrett A.J., 2003, HDB PROTEOLYTIC ENZY
   Barros NMT, 2007, BIOL CHEM, V388, P447, DOI 10.1515/BC.2007.048
   BORSON DB, 1991, AM J PHYSIOL, V260, pL83
   Caccamo A, 2005, NEUROBIOL AGING, V26, P645, DOI 10.1016/j.neurobiolaging.2004.06.013
   CASEY ML, 1991, J BIOL CHEM, V266, P23041
   CHEN AC, 2007, NEURON, V46, P541
   Chen AC, 2007, NEURON, V53, P479, DOI 10.1016/j.neuron.2007.01.023
   Chen HX, 2000, J MED CHEM, V43, P1398, DOI 10.1021/jm990483l
   Daily A, 2006, J NEUROVIROL, V12, P153, DOI 10.1080/13550280600760677
   DEVAULT A, 1987, EMBO J, V6, P2506
   DEVAULT A, 1987, EMBO J, V6, P1317
   Eckman EA, 2006, J BIOL CHEM, V281, P30471, DOI 10.1074/jbc.M605827200
   Edbauer D, 2002, J BIOL CHEM, V277, P13389, DOI 10.1074/jbc.M111571200
   Eisele YS, 2007, MOL BIOL CELL, V18, P3591, DOI 10.1091/mbc.E07-01-0035
   Esiri MM, 1998, J NEUROL NEUROSUR PS, V65, P29, DOI 10.1136/jnnp.65.1.29
   Farris W, 2003, P NATL ACAD SCI USA, V100, P4162, DOI 10.1073/pnas.0230450100
   FARRIS W, AM J PATHOL, V71, P241
   Green DA, 2005, AIDS, V19, P407, DOI 10.1097/01.aids.0000161770.06158.5c
   Helisalmi S, 2004, J NEUROL NEUROSUR PS, V75, P1746, DOI 10.1136/jnnp.2004.036574
   HELLSTROMLINDAH.E, 2006, NEUROBIOL AGING
   HERSH LB, 1986, J BIOL CHEM, V261, P6433
   Hong CS, 2006, GENE THER, V13, P1068, DOI 10.1038/sj.gt.3302719
   HOOPER NM, 1994, FEBS LETT, V354, P1, DOI 10.1016/0014-5793(94)01079-X
   HOWELL S, 1995, PEPTIDES, V16, P647, DOI 10.1016/0196-9781(95)00021-B
   Huang SM, 2006, J BIOL CHEM, V281, P17941, DOI 10.1074/jbc.M601372200
   Iwata N, 2000, NAT MED, V6, P143
   Izycka-Swieszewska E, 2000, FOLIA NEUROPATHOL, V38, P175
   JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001
   Johnson GD, 1999, J BIOL CHEM, V274, P4053, DOI 10.1074/jbc.274.7.4053
   Kanemitsu H, 2003, NEUROSCI LETT, V350, P113, DOI 10.1016/S0304-3940(03)00898-X
   KENNY AJ, 1986, BIOMED BIOCHIM ACTA, V45, P1503
   KERR MA, 1974, BIOCHEM J, V137, P477, DOI 10.1042/bj1370477
   KERR MA, 1974, BIOCHEM J, V137, P489, DOI 10.1042/bj1370489
   KIM YA, 1992, J BIOL CHEM, V267, P12330
   Lazarov O, 2005, CELL, V120, P701, DOI 10.1016/j.cell.2005.01.015
   Leissring MA, 2003, NEURON, V40, P1087, DOI 10.1016/S0896-6273(03)00787-6
   Leissring MA, 2003, J BIOL CHEM, V278, P37314, DOI 10.1074/jbc.M305627200
   LETARTE M, 1988, J EXP MED, V168, P1247, DOI 10.1084/jem.168.4.1247
   LI CW, 1995, J BIOL CHEM, V270, P5723, DOI 10.1074/jbc.270.11.5723
   Li CW, 1998, ARCH BIOCHEM BIOPHYS, V358, P189, DOI 10.1006/abbi.1998.0855
   Liao MQ, 2007, FEBS LETT, V581, P1161, DOI 10.1016/j.febslet.2007.02.026
   Lilius L, 2003, NEUROSCI LETT, V337, P111, DOI 10.1016/S0304-3940(02)01300-9
   Liu RT, 2004, J NEUROSCI RES, V75, P162, DOI 10.1002/jnr.10859
   Madani R, 2006, J NEUROSCI RES, V84, P1871, DOI 10.1002/jnr.21074
   MALFROY B, 1982, BIOCHEM BIOPH RES CO, V106, P276, DOI 10.1016/0006-291X(82)91106-8
   MALFROY B, 1988, FEBS LETT, V229, P206, DOI 10.1016/0014-5793(88)80828-7
   MALFROY B, 1987, BIOCHEM BIOPH RES CO, V144, P59, DOI 10.1016/S0006-291X(87)80475-8
   MALFROY B, 1978, NATURE, V276, P523, DOI 10.1038/276523a0
   MALFROY B, 1985, BIOCHEM BIOPH RES CO, V130, P372, DOI 10.1016/0006-291X(85)90427-9
   Marr RA, 2003, J NEUROSCI, V23, P1992
   Marr RA, 2004, J MOL NEUROSCI, V22, P5, DOI 10.1385/JMN:22:1-2:5
   MATSAS R, 1984, BIOCHEM J, V223, P433, DOI 10.1042/bj2230433
   MATSAS R, 1986, NEUROSCIENCE, V18, P991, DOI 10.1016/0306-4522(86)90113-2
   MATTHEWS BW, 1974, J BIOL CHEM, V249, P8030
   Miller BC, 2003, P NATL ACAD SCI USA, V100, P6221, DOI 10.1073/pnas.1031520100
   Misiti F, 2005, NEUROCHEM INT, V46, P575, DOI 10.1016/j.neuint.2005.01.001
   Mohajeri MH, 2002, J BIOL CHEM, V277, P35460, DOI 10.1074/jbc.M202899200
   Mukherjee A, 2000, J NEUROSCI, V20, P8745
   Oda M, 2002, NEUROSCI LETT, V320, P105, DOI 10.1016/S0304-3940(02)00057-5
   Oefner C, 2000, J MOL BIOL, V296, P341, DOI 10.1006/jmbi.1999.3492
   Oefner C, 2004, ACTA CRYSTALLOGR D, V60, P392, DOI 10.1107/S0907444903027410
   Pardossi-Piquard R, 2006, J NEUROCHEM, V97, P1052, DOI 10.1111/j.1471-4159.2006.03822.x
   Pardossi-Piquard R, 2005, NEURON, V46, P541, DOI 10.1016/j.neuron.2005.04.008
   Pardossi-Piquard R, 2007, NEURON, V53, P483, DOI 10.1016/j.neuron.2007.01.024
   Poirier R, 2006, NEUROBIOL DIS, V24, P475, DOI 10.1016/j.nbd.2006.08.003
   POZSGAY M, 1986, BIOCHEMISTRY-US, V25, P1292, DOI 10.1021/bi00354a015
   QUAY T, 1994, ARCH BIOCHEM BIOPHYS, V308, P133, DOI 10.1006/abbi.1994.1019
   Rempel HC, 2005, AIDS, V19, P127, DOI 10.1097/00002030-200501280-00004
   Sakai A, 2004, DEMENT GERIATR COGN, V17, P164, DOI 10.1159/000076351
   Shen RQ, 2002, ANTICANCER RES, V22, P2533
   Shen RQ, 2000, MOL CELL ENDOCRINOL, V170, P131, DOI 10.1016/S0303-7207(00)00326-9
   Shi JJ, 2005, J GERONTOL A-BIOL, V60, P301, DOI 10.1093/gerona/60.3.301
   SHIPP MA, 1988, P NATL ACAD SCI USA, V85, P4819, DOI 10.1073/pnas.85.13.4819
   Sumitomo M, 2000, J CLIN INVEST, V106, P1399, DOI 10.1172/JCI10536
   Takaki Y, 2000, J BIOCHEM-TOKYO, V128, P897, DOI 10.1093/oxfordjournals.jbchem.a022839
   Turner AJ, 2001, BIOESSAYS, V23, P261, DOI 10.1002/1521-1878(200103)23:3<261::AID-BIES1036>3.0.CO;2-K
   VANNESTE Y, 1988, BIOCHEM J, V254, P531, DOI 10.1042/bj2540531
   VOGTSCHADEN M, 1989, BIOCHEM BIOPH RES CO, V161, P1177, DOI 10.1016/0006-291X(89)91366-1
   Wang DS, 2005, J NEUROPATH EXP NEUR, V64, P378, DOI 10.1093/jnen/64.5.378
   Yasojima K, 2001, NEUROSCI LETT, V297, P97, DOI 10.1016/S0304-3940(00)01675-X
   Yasojima K, 2001, BRAIN RES, V919, P115, DOI 10.1016/S0006-8993(01)03008-6
   Zheng R, 2006, MOL CELL ENDOCRINOL, V259, P10, DOI 10.1016/j.mce.2006.07.004
NR 83
TC 55
Z9 56
U1 0
U2 12
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1567-2050
J9 CURR ALZHEIMER RES
JI Curr. Alzheimer Res.
PD APR
PY 2008
VL 5
IS 2
BP 225
EP 231
DI 10.2174/156720508783954703
PG 7
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 283RG
UT WOS:000254653600014
PM 18393807
DA 2018-03-20
ER

PT J
AU Bhandari, R
   Gupta, P
   Dziubla, T
   Hilt, JZ
AF Bhandari, Rohit
   Gupta, Prachi
   Dziubla, Thomas D.
   Hilt, J. Zach
TI Single step synthesis, characterization and applications of curcumin
   functionalized iron oxide magnetic nanoparticles
SO MATERIALS SCIENCE & ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS
LA English
DT Article
DE Curcumin; Iron oxide; Functionalization; Cell viability;
   Anti-inflammatory
ID FE3O4 NANOPARTICLES; HYPERTHERMIA; FERROFLUIDS; CARCINOMA; CELLS; ACID
AB Magnetic iron oxide nanoparticles have been well known for their applications in magnetic resonance imaging (MRI), hyperthermia, targeted drug delivery, etc. The surface modification of these magnetic nanoparticles has been explored extensively to achieve functionalized materials with potential application in biomedical, environmental and catalysis field. Herein, we report a novel and versatile single step methodology for developing curcumin functionalized magnetic Fe3O4 nanoparticles without any additional linkers, using a simple coprecipitation technique. The magnetic nanoparticles (MNPs) were characterized using transmission electron microscopy, X-ray diffraction, fourier transform infrared spectroscopy and thermogravimetric analysis. The developed MNPs were employed in a cellular application for protection against an inflammatory agent, a polychlorinated biphenyl (PCB) molecule. (C) 2016 Published by Elsevier B.V.
C1 [Bhandari, Rohit; Gupta, Prachi; Dziubla, Thomas; Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Hilt, JZ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM zach.hilt@uky.edu
FU National Institute of Environmental Health Sciences (NIEHS)
   [P42ES007380]
FX The project described was supported by Grant Number P42ES007380 from the
   National Institute of Environmental Health Sciences (NIEHS). The content
   is solely the responsibility of the authors and does not necessarily
   represent the official views of the National Institute of Environmental
   Health Sciences or the National Institutes of Health.
CR Borsari M, 2002, INORG CHIM ACTA, V328, P61, DOI 10.1016/S0020-1693(01)00687-9
   Brullot W, 2012, J MAGN MAGN MATER, V324, P1919, DOI 10.1016/j.jmmm.2012.01.032
   Chen ZP, 2014, FOOD CHEM, V155, P81, DOI 10.1016/j.foodchem.2014.01.034
   Cochran DB, 2013, BIOMATERIALS, V34, P9615, DOI 10.1016/j.biomaterials.2013.08.025
   Correa-Duarte MA, 1998, LANGMUIR, V14, P6430, DOI 10.1021/la9805342
   Daou TJ, 2006, CHEM MATER, V18, P4399, DOI 10.1021/cm060805r
   Frimpong RA, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/17/175101
   Frimpong RA, 2010, J MAGN MAGN MATER, V322, P326, DOI 10.1016/j.jmmm.2009.09.050
   Hatamie S, 2015, MAT SCI ENG C-MATER, V55, P482, DOI 10.1016/j.msec.2015.05.077
   Hong RY, 2008, BIOCHEM ENG J, V42, P290, DOI 10.1016/j.bej.2008.07.009
   Kitture R, 2012, J APPL PHYS, V111, DOI 10.1063/1.3696001
   Kruse AM, 2014, ACTA BIOMATER, V10, P2622, DOI 10.1016/j.actbio.2014.01.025
   Kundu S, 2013, RSC ADV, V3, P25278, DOI 10.1039/c3ra44471f
   Li GY, 2008, J ALLOY COMPD, V466, P451, DOI 10.1016/j.jallcom.2007.11.100
   Lubbe AS, 2001, J SURG RES, V95, P200, DOI 10.1006/jsre.2000.6030
   Mandavi M., 2013, MOLECULES, V18, P7533, DOI DOI 10.3390/M0LECULES18077533
   Mandel K, 2015, CHEM COMMUN, V51, P2863, DOI 10.1039/c4cc09277e
   Mascolo MC, 2013, MATERIALS, V6, P5549, DOI 10.3390/ma6125549
   Mathew A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032616
   Mohammadi-Samani S, 2013, RES PHARM SCI, V8, P25
   Mohan PRK, 2012, VIB SPECTROSC, V62, P77, DOI 10.1016/j.vibspec.2012.05.002
   Moradi S, 2015, RSC ADV, V5, P47529, DOI 10.1039/c5ra03331d
   Moroz P, 2002, INT J HYPERTHER, V18, P267, DOI 10.1080/02656730110108785
   Mulik R, 2009, EUR J PHARM SCI, V37, P395, DOI 10.1016/j.ejps.2009.03.009
   Nagpal Monika, 2013, J Nat Sci Biol Med, V4, P3, DOI 10.4103/0976-9668.107253
   Park J, 2004, NAT MATER, V3, P891, DOI 10.1038/nmat1251
   Racuciu M, 2006, EUR PHYS J E, V21, P117, DOI 10.1140/epje/i2006-10051-y
   Reiss G, 2005, NAT MATER, V4, P725, DOI 10.1038/nmat1494
   Rignall B, 2013, TOXICOL SCI, V133, P29, DOI 10.1093/toxsci/kft034
   Si SF, 2005, CRYST GROWTH DES, V5, P391, DOI 10.1021/cg0497905
   Sindhu K, 2014, RSC ADV, V4, P1808, DOI 10.1039/c3ra45345f
   Singh DK, 2013, NANOSCALE, V5, P1882, DOI 10.1039/c2nr33776b
   Sun C, 2008, ADV DRUG DELIVER REV, V60, P1252, DOI 10.1016/j.addr.2008.03.018
   Sun SH, 2002, J AM CHEM SOC, V124, P8204, DOI 10.1021/ja026501x
   Tang NJ, 2004, J MAGN MAGN MATER, V282, P92, DOI 10.1016/j.jmmm.2004.04.022
   Unal B, 2010, MATER CHEM PHYS, V123, P184, DOI 10.1016/j.matchemphys.2010.03.080
   van den Dungen MW, 2015, TOXICOL IN VITRO, V29, P769, DOI 10.1016/j.tiv.2015.03.002
   Wang SG, 2013, CATAL SCI TECHNOL, V3, P2104, DOI 10.1039/c3cy00223c
   Wani K. D., 2011, Journal of Bionanoscience, V5, P59, DOI 10.1166/jbns.2011.1041
   Wilken R, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-12
   Wydra RJ, 2015, RSC ADV, V5, P18888, DOI 10.1039/c4ra13564d
   Yen SK, 2015, CHEM-EUR J, V21, P3914, DOI 10.1002/chem.201406388
NR 42
TC 5
Z9 5
U1 5
U2 66
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0928-4931
EI 1873-0191
J9 MAT SCI ENG C-MATER
JI Mater. Sci. Eng. C-Mater. Biol. Appl.
PD OCT 1
PY 2016
VL 67
BP 59
EP 64
DI 10.1016/j.msec.2016.04.093
PG 6
WC Materials Science, Biomaterials
SC Materials Science
GA DQ1HT
UT WOS:000378952800008
PM 27287099
OA green_accepted
DA 2018-03-20
ER

PT J
AU Lewis, S
   Smuleac, V
   Montague, A
   Bachas, L
   Bhattacharyya, D
AF Lewis, Scott R.
   Smuleac, Vasile
   Montague, Alex
   Bachas, Leonidas G.
   Bhattacharyya, Dibakar
TI Iron-Functionalized Membranes for Nanoparticle Synthesis and Reactions
SO SEPARATION SCIENCE AND TECHNOLOGY
LA English
DT Article; Proceedings Paper
CT Engineering with Membrances Conference 2008
CY 2008
CL Algarve, PORTUGAL
DE Dechlorination; Fe; Pd nanoparticles; free radical; PCB; TCE
ID MULTILAYERED POLYELECTROLYTE FILMS; HYDROGEN-PEROXIDE; FENTON REACTION;
   MICROFILTRATION MEMBRANES; CATALYTIC DECOMPOSITION; ENZYMATIC CATALYSIS;
   SELECTIVE OXIDATION; METAL SORPTION; ACRYLIC-ACID; DESTRUCTION
AB Membrane-based separation processes have been used extensively for drinking water purification, wastewater treatment, and numerous other applications. More recent developments in membrane functionalization have made the use of membrane science important in diverse fields, from tunable separations to catalysis. The focus of this work is to create a common membrane platform for the incorporation of technologies capable of degrading target pollutants. Functionalized membranes capable of metal capture were created using water-based and solvent-based acrylic acid polymerization to synthesize poly(acrylic acid) (PAA) within poly(vinylidene fluoride) (PVDF) membrane pores. The COO- groups of PAA were used to capture Fe(II), which was then either reduced and doped with Pd to form Fe/Pd nanoparticles or used as-is for free radical generation with hydrogen peroxide. Fe/Pd nanoparticles were synthesized within the pores of a PAA/PVDF membrane functionalized via aqueous (green) chemistry and used to dechlorinate trichloroethylene (TCE) and 2,2'-dichlorobiphenyl (DiCB). A PAA/PVDF membrane containing immobilized Fe(III) was used to obtain controlled free radical generation and target organic (pentachlorophenol) degradation within the membrane pore under convective flow conditions.
C1 [Lewis, Scott; Smuleac, Vasile; Montague, Alex; Bhattacharyya, Dibakar] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Bachas, Leonidas] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
RP Bhattacharyya, D (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM db@engr.uky.edu
RI Bachas, Leonidas/G-2479-2015
OI Bachas, Leonidas/0000-0002-3308-6264
FU NIEHS NIH HHS [P42 ES007380, P42 ES007380-130010]
CR Ahuja DK, 2007, CHEMOSPHERE, V66, P2193, DOI 10.1016/j.chemosphere.2006.08.035
   Bhattacharyya D., 2003, NEW INSIGHTS MEMBRAN
   Charcosset C, 2006, BIOTECHNOL ADV, V24, P482, DOI 10.1016/j.biotechadv.2006.03.002
   Dai JH, 2002, NANO LETT, V2, P497, DOI 10.1021/nl0255471
   Datta S, 2008, IND ENG CHEM RES, V47, P4586, DOI 10.1021/ie800142d
   DAYAL U, 1999, POLYM REV, V39, P507, DOI DOI 10.1081/MC-100101426
   De Laat J, 1999, ENVIRON SCI TECHNOL, V33, P2726, DOI 10.1021/es981171v
   Dotzauer DM, 2006, NANO LETT, V6, P2268, DOI 10.1021/nl061700q
   Engwall MA, 1999, WATER RES, V33, P1151, DOI 10.1016/S0043-1354(98)00323-6
   Espro C, 2000, J MOL CATAL A-CHEM, V159, P359, DOI 10.1016/S1381-1169(00)00157-6
   Espro C, 2001, CATAL TODAY, V67, P247, DOI 10.1016/S0920-5861(01)00312-1
   Fernandez J, 2003, INT J PHOTOENERGY, V5, P107, DOI 10.1155/S1110662X03000217
   Fernandez J, 1998, CHEM COMMUN, P1493, DOI 10.1039/a802539h
   Fritzmann C, 2007, DESALINATION, V216, P1, DOI 10.1016/j.desal.2006.12.009
   Fukushima M, 2001, ENVIRON SCI TECHNOL, V35, P1771, DOI 10.1021/es001088j
   Haber F, 1934, P ROY SOC LOND A MAT, V134, P332, DOI [10.1098/rspa.1934.0221, DOI 10.1098/rspa.1934.0221]
   Hestekin JA, 2001, IND ENG CHEM RES, V40, P2668, DOI 10.1021/ie000572s
   HO WSW, 1992, MEMBRANE HDB
   Holland AM, 2004, DIABETES-METAB RES, V20, P13, DOI 10.1002/dmrr.430
   Hu K, 2007, J MEMBRANE SCI, V301, P19, DOI 10.1016/j.memsci.2007.05.031
   Kidambi S, 2005, CHEM MATER, V17, P301, DOI 10.1021/cm048421t
   Klein E, 2000, J MEMBRANE SCI, V179, P1, DOI 10.1016/S0376-7388(00)00514-7
   Ladhe AR, 2009, J MEMBRANE SCI, V326, P460, DOI 10.1016/j.memsci.2008.10.025
   Laine DF, 2007, MICROCHEM J, V85, P183, DOI 10.1016/j.microc.2006.07.002
   Li YC, 2005, ENVIRON ENG SCI, V22, P756, DOI 10.1089/ees.2005.22.756
   Lin SS, 1998, ENVIRON SCI TECHNOL, V32, P1417, DOI 10.1021/es970648k
   Liou RM, 2004, CHEMOSPHERE, V55, P1271, DOI 10.1016/j.chemosphere.2003.12.015
   Jiang LZ, 2007, SMART MATER STRUCT, V16, P2169, DOI 10.1088/0964-1726/16/6/019
   Ng ANL, 2007, DESALINATION, V212, P261, DOI 10.1016/j.desal.2006.10.013
   Noble R. D, 1995, MEMBRANE SEPARATIONS
   Nutt MO, 2005, ENVIRON SCI TECHNOL, V39, P1346, DOI 10.1021/es048560b
   Parra S, 2004, LANGMUIR, V20, P5621, DOI 10.1021/la049768d
   Pignatello JJ, 2006, CRIT REV ENV SCI TEC, V36, P1, DOI 10.1080/10643380500326564
   Ritchie SMC, 1999, LANGMUIR, V15, P6346, DOI 10.1021/la9814438
   Seol Y, 2008, CHEMOSPHERE, V72, P537, DOI 10.1016/j.chemosphere.2008.03.052
   Sgarlata C, 2008, J MEMBRANE SCI, V323, P444, DOI 10.1016/j.memsci.2008.07.004
   Shah TN, 2005, J MEMBRANE SCI, V251, P81, DOI 10.1016/j.memsci.2004.10.037
   Shi W, 2008, J MEMBRANE SCI, V325, P801, DOI 10.1016/j.memsci.2008.09.003
   Singh N, 2008, J MEMBRANE SCI, V309, P64, DOI 10.1016/j.memsci.2007.10.007
   Smith BA, 2006, J CONTAM HYDROL, V85, P229, DOI 10.1016/j.jconhyd.2006.02.002
   Smuleac V, 2006, LANGMUIR, V22, P10118, DOI 10.1021/la061124d
   Stamatialis DF, 2008, J MEMBRANE SCI, V308, P1, DOI 10.1016/j.memsci.2007.09.059
   STOOKEY LL, 1970, ANAL CHEM, V42, P779, DOI 10.1021/ac60289a016
   Vasudevan T, 2009, TALANTA, V78, P171, DOI 10.1016/j.talanta.2008.10.053
   Voelker BM, 1996, ENVIRON SCI TECHNOL, V30, P1106, DOI 10.1021/es9502132
   Watts R. J., 2006, Practice Periodical of Hazardous, Toxic and Radioactive Waste Management, V10, P2, DOI 10.1061/(ASCE)1090-025X(2006)10:1(2)
   Xu J, 2005, J NANOPART RES, V7, P449, DOI 10.1007/s11051-005-4273-3
   Xu J, 2008, J PHYS CHEM C, V112, P9133, DOI 10.1021/jp7097262
   Xu J, 2007, IND ENG CHEM RES, V46, P2348, DOI 10.1021/ie0611498
NR 49
TC 9
Z9 9
U1 0
U2 21
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 0149-6395
J9 SEPAR SCI TECHNOL
JI Sep. Sci. Technol.
PY 2009
VL 44
IS 14
BP 3289
EP 3311
AR PII 915735572
DI 10.1080/01496390903212805
PG 23
WC Chemistry, Multidisciplinary; Engineering, Chemical
SC Chemistry; Engineering
GA 553EA
UT WOS:000274347600002
PM 20556223
OA green_accepted
DA 2018-03-19
ER

PT J
AU Khan, MA
   Wallace, WT
   Islam, SZ
   Nagpure, S
   Strzalka, J
   Littleton, JM
   Rankin, SE
   Knutson, BL
AF Khan, M. Arif
   Wallace, William T.
   Islam, Syed Z.
   Nagpure, Suraj
   Strzalka, Joseph
   Littleton, John M.
   Rankin, Stephen E.
   Knutson, Barbara L.
TI Adsorption and Recovery of Polyphenolic Flavonoids Using
   TiO2-Functionalized Mesoporous Silica Nanoparticles
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE silica nanoparticles; functionalization; flavonoid; adsorption;
   stability
ID TIO2 NANOPARTICLES; SURFACE FUNCTIONALIZATION; SELECTIVE ENRICHMENT;
   ANTIOXIDANT ACTIVITY; AQUEOUS-SOLUTIONS; FACILE SYNTHESIS; OXIDE
   SURFACES; QUERCETIN; TITANIA; METAL
AB Exploiting specific interactions with titania (TiO2) has been proposed for the separation and recovery of a broad range of biomolecules and natural products, including therapeutic polyphenolic flavonoids which are susceptible to degradation, such as quercetin. Functionalizing mesoporous silica with TiO2 has many potential advantages over bulk and mesoporous TiO2 as an adsorbent for natural products, including robust synthetic approaches leading to high surface area, and stable separation platforms. Here, TiO2-surface-functionalized mesoporous silica nanoparticles (MSNPs) are synthesized and characterized as a function of TiO2 content (up to 636 mg TiO2/g). The adsorption isotherms of two polyphenolic flavonoids, quercetin and rutin, were determined (0.05-10 mg/mL in ethanol), and a 100-fold increase in the adsorption capacity was observed relative to functionalized nonporous particles with similar TiO2 surface coverage. An optimum extent of functionalization (approximately 440 mg TiO2/g particles) is interpreted from characterization techniques including grazing incidence X-ray scattering (GM), high-resolution transmission electron microscopy (HRTEM), and nitrogen adsorption, which examined the interplay between the extent of TiO2 functionalization and the accessibility of the porous structures. The recovery of flavonoids is demonstrated using ligand displacement in ethanolic citric acid solution (20% w/v), in which greater than 90% recovery can be achieved in a multistep extraction process. The radical scavenging activity (RSA) of the recovered and particle bound quercetin as measured by a 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging assay demonstrates greater than 80% retention of antioxidant activity by both particle-bound and recovered quercetin. These mesoporous titanosilicate materials can serve as a synthetic platform to isolate, recover, and potentially deliver degradation-sensitive natural products to biological systems.
C1 [Khan, M. Arif; Wallace, William T.; Islam, Syed Z.; Nagpure, Suraj; Rankin, Stephen E.; Knutson, Barbara L.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Strzalka, Joseph] Argonne Natl Lab, Xray Sci Div, Argonne, IL 60439 USA.
   [Littleton, John M.] Naprogenix Inc, Lexington, KY 40506 USA.
RP Rankin, SE; Knutson, BL (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM stephen.rankin@uky.edu; bknutson@engr.uky.edu
OI Khan, M. Arif/0000-0001-8471-4200
FU United States National Institute of Health (NIH Grant) [R41AT008312];
   Kentucky Science and Engineering Foundation [KSEF-2929-RDE-016]; DOE
   Office of Science [DE-AC02-06CH11357]
FX The authors wish to acknowledge financial support for this work from the
   United States National Institute of Health (NIH Grant R41AT008312) and
   Kentucky Science and Engineering Foundation (KSEF-2929-RDE-016). We
   thank Dr. Daniel M. Schlipf for his help during the initiation of this
   project. This research used resources of the Advanced Photon Source, a
   U.S. Department of Energy (DOE) Office of Science User Facility operated
   for the DOE Office of Science by Argonne National Laboratory under
   Contract DE-AC02-06CH11357.
CR Acosta-Silva YJ, 2013, MICROPOR MESOPOR MAT, V170, P181, DOI 10.1016/j.micromeso.2012.11.027
   Arriagada F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164507
   Belessi V, 2009, J HAZARD MATER, V170, P836, DOI 10.1016/j.jhazmat.2009.05.045
   Berlier G, 2013, J COLLOID INTERF SCI, V393, P109, DOI 10.1016/j.jcis.2012.10.073
   Beyers E, 2009, APPL CATAL B-ENVIRON, V88, P515, DOI 10.1016/j.apcatb.2008.10.009
   Bian J, 2014, TALANTA, V123, P233, DOI 10.1016/j.talanta.2014.02.001
   Bishop LM, 2012, LANGMUIR, V28, P1322, DOI 10.1021/la204145t
   BOGUSH GH, 1988, J NON-CRYST SOLIDS, V104, P95, DOI 10.1016/0022-3093(88)90187-1
   Busuioc AM, 2006, APPL CATAL A-GEN, V312, P153, DOI 10.1016/j.apcata.2006.06.043
   Cendrowski K., 2013, J NANOMED NANOTECHNO, V04
   Costa D, 2016, J PHYS CHEM B, V120, P7039, DOI 10.1021/acs.jpcb.6b05954
   Dahl M, 2014, CHEM REV, V114, P9853, DOI 10.1021/cr400634p
   Dai J, 2010, MOLECULES, V15, P7313, DOI 10.3390/molecules15107313
   Do QD, 2014, J FOOD DRUG ANAL, V22, P296, DOI 10.1016/j.jfda.2013.11.001
   Gupta P, 2015, ACTA BIOMATER, V27, P194, DOI 10.1016/j.actbio.2015.08.039
   Hanprasopwattana A, 1996, LANGMUIR, V12, P3173, DOI 10.1021/la950808a
   Hirpara KV, 2009, ANTI-CANCER AGENT ME, V9, P138, DOI 10.2174/187152009787313855
   Isono R, 2005, J COLLOID INTERF SCI, V288, P177, DOI 10.1016/j.jcis.2005.02.078
   Jaroniec M, 1999, LANGMUIR, V15, P5410, DOI 10.1021/la990136e
   Jiang Z, 2015, J APPL CRYSTALLOGR, V48, P917, DOI 10.1107/S1600576715004434
   Jiang Z, 2012, J SYNCHROTRON RADIAT, V19, P627, DOI 10.1107/S0909049512022017
   Jurasekova Z, 2012, J RAMAN SPECTROSC, V43, P1913, DOI 10.1002/jrs.4114
   Khoddami A, 2013, MOLECULES, V18, P2328, DOI 10.3390/molecules18022328
   Kim MH, 2011, ACS NANO, V5, P3568, DOI 10.1021/nn103130q
   Kim TW, 2010, CHEM MATER, V22, P5093, DOI 10.1021/cm1017344
   Kumar VD, 2015, LWT-FOOD SCI TECHNOL, V61, P330, DOI 10.1016/j.lwt.2014.12.020
   Kurepa J, 2014, PLANT J, V77, P443, DOI 10.1111/tpj.12361
   Lemanska K, 2001, FREE RADICAL BIO MED, V31, P869, DOI 10.1016/S0891-5849(01)00638-4
   Li ZX, 2012, CHEM SOC REV, V41, P2590, DOI 10.1039/c1cs15246g
   Liberman A, 2014, SURF SCI REP, V69, P132, DOI 10.1016/j.surfrep.2014.07.001
   Liu C, 2016, MATER RES BULL, V75, P25, DOI 10.1016/j.materresbull.2015.10.052
   Liu HL, 2015, TALANTA, V143, P431, DOI 10.1016/j.talanta.2015.05.019
   Lu ZD, 2010, ANGEW CHEM INT EDIT, V49, P1862, DOI 10.1002/anie.200906648
   Masolo E, 2014, NANOMATERIALS-BASEL, V4, P583, DOI 10.3390/nano4030583
   Morsella M, 2016, ACS OMEGA, V1, P464, DOI 10.1021/acsomega.6b00177
   Mudunkotuwa IA, 2014, LANGMUIR, V30, P8751, DOI 10.1021/la500722n
   Mudunkotuwa IA, 2010, J AM CHEM SOC, V132, P14986, DOI 10.1021/ja106091q
   Mukhopadhyay P, 2015, RSC ADV, V5, P97547, DOI 10.1039/c5ra18896b
   Murakami A, 2008, CANCER LETT, V269, P315, DOI 10.1016/j.canlet.2008.03.046
   Nayab S, 2014, ACS APPL MATER INTER, V6, P4408, DOI 10.1021/am500123k
   Nijveldt RJ, 2001, AM J CLIN NUTR, V74, P418
   Perez-Vizcaino F, 2010, MOL ASPECTS MED, V31, P478, DOI 10.1016/j.mam.2010.09.002
   Sakurai K, 2010, ANAL CHEM, V82, P3519, DOI 10.1021/ac9024126
   Sayari A, 1997, CHEM MATER, V9, P2499, DOI 10.1021/cm970128o
   Schlipf DM, 2017, ADV MATER INTERFACES, V4, DOI 10.1002/admi.201601103
   Schlipf DM, 2015, COLLOID SURFACE A, V478, P15, DOI 10.1016/j.colsurfa.2015.03.039
   Schlipf DM, 2013, ACS APPL MATER INTER, V5, P10111, DOI 10.1021/am402754h
   Signoretto M, 2010, APPL CATAL B-ENVIRON, V95, P130, DOI 10.1016/j.apcatb.2009.12.019
   Singh R, 2016, ACS CATAL, V6, P2770, DOI 10.1021/acscatal.6b00418
   Smilgies DM, 2009, J APPL CRYSTALLOGR, V42, P1030, DOI [10.1107/S0021889809040126, 10.1107/S00218898090401]
   Song XL, 2009, TALANTA, V80, P694, DOI 10.1016/j.talanta.2009.07.051
   Sriprang P, 2014, J SOL-GEL SCI TECHN, V71, P86, DOI 10.1007/s10971-014-3327-3
   Suligoj A, 2016, APPL CATAL B-ENVIRON, V184, P119, DOI 10.1016/j.apcatb.2015.11.007
   Tel H, 2004, J HAZARD MATER, V112, P225, DOI 10.1016/j.jhazmat.2004.05.025
   Thomas AG, 2012, CHEM SOC REV, V41, P4207, DOI 10.1039/c2cs35057b
   Tseng PJ, 2014, ANAL METHODS-UK, V6, P1759, DOI 10.1039/c3ay42209g
   van Acker SABE, 1998, BIOCHEM PHARMACOL, V56, P935, DOI 10.1016/S0006-2952(98)00102-6
   Vivero-Escoto JL, 2012, SCI TECHNOL ADV MAT, V13, DOI 10.1088/1468-6996/13/1/013003
   Vradman L, 2005, MICROPOR MESOPOR MAT, V79, P307, DOI 10.1016/j.micromeso.2004.11.023
   Wang HJ, 2008, MATER LETT, V62, P422, DOI 10.1016/j.matlet.2007.05.039
   Wang XS, 2008, J HAZARD MATER, V157, P374, DOI 10.1016/j.jhazmat.2008.01.004
   Wang ZG, 2015, ACS APPL MATER INTER, V7, P8377, DOI 10.1021/acsami.5b01254
   Wijeratne AB, 2015, ACS APPL MATER INTER, V7, P11155, DOI 10.1021/acsami.5b00799
   Wu HP, 2007, LANGMUIR, V23, P7880, DOI 10.1021/la700555y
   Xu LY, 2011, J SEP SCI, V34, P1347, DOI 10.1002/jssc.201100024
   Zaccariello G, 2014, RSC ADV, V4, P37826, DOI 10.1039/c4ra06767c
   Zdyb A, 2014, CHEM PHYS, V443, P61, DOI 10.1016/j.chemphys.2014.08.009
   Zhang JM, 2005, J AM SOC MASS SPECTR, V16, P139, DOI 10.1016/j.jasms.2004.10.005
   Zhang L, 2011, HYDROMETALLURGY, V107, P40, DOI 10.1016/j.hydromet.2011.01.006
   Zhao BY, 2015, ACS SUSTAIN CHEM ENG, V3, P2746, DOI 10.1021/acssuschemeng.5b00619
NR 70
TC 1
Z9 1
U1 22
U2 22
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944-8244
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD SEP 20
PY 2017
VL 9
IS 37
BP 32114
EP 32125
DI 10.1021/acsami.7b09510
PG 12
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA FI2LW
UT WOS:000411771400096
PM 28825464
DA 2018-03-20
ER

PT J
AU Chirra, HD
   Sexton, T
   Biswal, D
   Hersh, LB
   Hilt, JZ
AF Chirra, Hariharasudhan D.
   Sexton, Travis
   Biswal, Dipti
   Hersh, Louis B.
   Hilt, J. Zach
TI Catalase-coupled gold nanoparticles: Comparison between the carbodiimide
   and biotin-streptavidin methods
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Gold nanoparticles; Carbodiimide chemistry; Biotin-streptavidin binding;
   Catalase; Bionanotechnology
ID COLLOIDAL GOLD; PULMONARY ENDOTHELIUM; ENZYME ELECTRODE;
   MAMMALIAN-CELLS; DRUG-DELIVERY; DNA; IMMOBILIZATION; CONJUGATION;
   PLATFORM; CARRIERS
AB The use of proteins for therapeutic applications requires the protein to maintain sufficient activity for the period of in vivo treatment. Many proteins exhibit a short half-life in vivo and, thus, require delivery systems for them to be applied as therapeutics. The relative biocompatibility and the ability to form functionalized bioconjugates via simple chemistry make gold nanoparticles excellent candidates as protein delivery systems. Herein, two protocols for coupling proteins to gold nanoparticles have been compared. In the first, strong biomolecular binding between biotin and streptavidin was used to couple catalase to the surface of gold nanoparticles. In the second protocol the formation of an amide bond between carboxylic acid-coated gold nanoparticles and free surface amines of catalase using carbodiimide chemistry was performed. The stability and kinetics of the different steps involved in these protocols were studied using UV-visible spectroscopy, dynamic light scattering, and transmission electron microscopy. The addition of mercapto-undecanoic acid in conjugation with (N-(6-(biotinamido)hexyl)-3'-(2'-pyridyldithio)-propionamide increased the stability of biotinylated gold nanoparticles. Although the carbodiimide chemistry-based bioconjugation approach exhibited a decrease in catalase activity, the carbodiimide chemistry-based bioconjugation approach resulted in more active catalase per gold nanoparticle compared with that of mercapto-undecanoic acid-stabilized biotinylated gold nanoparticles. Both coupling protocols resulted in gold nanoparticles loaded with active catalase. Thus, these gold nanoparticle systems and coupling protocols represent promising methods for the application of gold nanoparticles for protein delivery. (C) 2011 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Chirra, Hariharasudhan D.; Biswal, Dipti; Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Sexton, Travis; Hersh, Louis B.] Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40506 USA.
RP Hilt, JZ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM hilt@engr.uky.edu
FU National Institute of Health NIDA [5 R01 DA002243, 5 T32DA016176]
FX This project was funded by the National Institute of Health NIDA grants
   5 R01 DA002243 and 5 T32DA016176.
CR Angelatos AS, 2005, J PHYS CHEM B, V109, P3071, DOI 10.1021/jp045070x
   Aslan K, 2002, LANGMUIR, V18, P6059, DOI 10.1021/la025795x
   Bergen JM, 2006, MACROMOL BIOSCI, V6, P506, DOI 10.1002/mabi.200600075
   Bhumkar DR, 2007, PHARM RES, V24, P1415, DOI 10.1007/s11095-007-9257-9
   Chen XH, 2001, BIOSENS BIOELECTRON, V16, P115, DOI 10.1016/S0956-5663(00)00138-X
   Chen YH, 2007, MOL PHARM, V4, P713, DOI 10.1021/mp060132k
   CHIRRA HD, 2009, NANOPARTICULATE DRUG, V2, P90
   Dixit V, 2006, BIOCONJUGATE CHEM, V17, P603, DOI 10.1021/bc050335b
   Duncan B, 2010, J CONTROL RELEASE, V148, P122, DOI 10.1016/j.jconrel.2010.06.004
   Dziubla Thomas D, 2006, Biotechnol Genet Eng Rev, V22, P267
   Dzuibla TD, 2008, BIOMATERIALS, V29, P215
   Eghtedari M, 2009, NANO LETT, V9, P287, DOI 10.1021/nl802915q
   Gibson JD, 2007, J AM CHEM SOC, V129, P11653, DOI 10.1021/ja075181k
   Haiss W, 2007, ANAL CHEM, V79, P4215, DOI 10.1021/ac0702084
   Han G, 2006, CHEM BIOL DRUG DES, V67, P78, DOI 10.1111/j.1747-0285.2005.00324.x
   Hirsch LR, 2003, ANAL CHEM, V75, P2377, DOI 10.1021/ac0262210
   Hirsch LR, 2003, P NATL ACAD SCI USA, V100, P13549, DOI 10.1073/pnas.2232479100
   Hone DC, 2002, LANGMUIR, V18, P2985, DOI 10.1021/la0256230
   Kozower BD, 2003, NAT BIOTECHNOL, V21, P392, DOI 10.1038/nbt806
   McIntosh CM, 2001, J AM CHEM SOC, V123, P7626, DOI 10.1021/ja015556g
   Moghimi SM, 2005, FASEB J, V19, P311, DOI 10.1096/fj.04-2747rev
   Muzykantov VR, 1996, P NATL ACAD SCI USA, V93, P5213, DOI 10.1073/pnas.93.11.5213
   Patel N, 1997, LANGMUIR, V13, P6485, DOI 10.1021/la970933h
   Phadtare S, 2003, CHEM MATER, V15, P1944, DOI 10.1021/cm020784a
   Radt B, 2004, ADV MATER, V16, P2184, DOI 10.1002/adma.200400920
   RICHES AC, 1973, J PHYSIOL-LONDON, V228, P279, DOI 10.1113/jphysiol.1973.sp010086
   Rosi NL, 2006, SCIENCE, V312, P1027, DOI 10.1126/science.1125559
   Saito G, 2003, ADV DRUG DELIVER REV, V55, P199, DOI 10.1016/S0169-409X(02)00179-5
   Sandhu KK, 2002, BIOCONJUGATE CHEM, V13, P3, DOI 10.1021/bc015545c
   Sapsford KE, 2006, ANGEW CHEM INT EDIT, V45, P4562, DOI 10.1002/anie.200503873
   Simone EA, 2009, PHARM RES-DORD, V26, P250, DOI 10.1007/s11095-008-9744-7
   Sonavane G, 2008, COLLOID SURFACE B, V66, P274, DOI 10.1016/j.colsurfb.2008.07.004
   STONEHUERNER JG, 1992, BIOSENS BIOELECTRON, V7, P421, DOI 10.1016/0956-5663(92)85041-8
   Strzelczyk AA, 2001, J MOL STRUC-THEOCHEM, V541, P283, DOI 10.1016/S0166-1280(00)00804-6
   Thomas M, 2003, P NATL ACAD SCI USA, V100, P9138, DOI 10.1073/pnas.1233634100
   Tong J, 2010, MOL PHARMACEUT, V7, P984, DOI 10.1021/mp100102p
   TURKEVICH J, 1951, DISCUSS FARADAY SOC, P55, DOI 10.1039/df9511100055
   West JL, 2000, CURR OPIN BIOTECH, V11, P215, DOI 10.1016/S0958-1669(00)00082-3
   Xiao Y, 2003, SCIENCE, V299, P1877, DOI 10.1126/science.1080664
   Yokoyama M, 1996, ADV DRUG DELIVER REV, V21, P77, DOI 10.1016/S0169-409X(96)00439-5
   Zhang JD, 1998, ELECTROANAL, V10, P738, DOI 10.1002/(SICI)1521-4109(199809)10:11<738::AID-ELAN738>3.0.CO;2-D
   Zhao JG, 1996, BIOSENS BIOELECTRON, V11, P493, DOI 10.1016/0956-5663(96)86786-8
NR 42
TC 16
Z9 17
U1 0
U2 43
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742-7061
EI 1878-7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD JUL
PY 2011
VL 7
IS 7
BP 2865
EP 2872
DI 10.1016/j.actbio.2011.01.003
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 785JT
UT WOS:000292226000011
PM 21232642
OA green_accepted
DA 2018-03-20
ER

PT J
AU Vyas, SM
   Turanek, J
   Knotigova, P
   Kasna, A
   Kvardova, V
   Koganti, V
   Rankin, SE
   Knutson, BL
   Lehmler, HJ
AF Vyas, Sandhya M.
   Turanek, Jaroslav
   Knoetigova, Pavlina
   Kasna, Andrea
   Kvardova, Veronika
   Koganti, Venkat R.
   Rankin, Stephen E.
   Knutson, Barbara L.
   Lehmler, Hans-Joachim
TI Synthesis and biocompatibility evaluation of partially fluorinated
   pyridinium bromides
SO NEW JOURNAL OF CHEMISTRY
LA English
DT Article
ID LONG-CHAIN ALKANETHIOLS; KOENIGS-KNORR REACTION; AIR-WATER-INTERFACE;
   BIOMEDICAL APPLICATIONS; SURFACTANTS; SILICA; BEHAVIOR; ESTERS;
   HYDROCARBON; TOXICITY
AB Although cationic surfactants are of general interest for a variety of consumer and biomedical applications, only a limited number of partially fluorinated, single-tailed, cationic surfactants have been synthesized. To study the potential usefulness of fluorinated cationic surfactants for these applications we synthesized a series of partially fluorinated pyridinium bromide surfactants. Three 10-perfluoroalkyldecyl pyridinium surfactants were synthesized by coupling a perfluoroalkyl iodide with 9-decene-1-yl acetate using an AIBN mediated radical reaction. The resulting 9-iodo-10-perfluoroalkyldec-1-yl acetates were deiodinated using HI-Zn-EtOH and hydrolyzed using KOH-EtOH to yield the corresponding 10-perfluoroalkyldecanol. The partially fluorinated alcohol was converted into the bromide using Br-2-PPh3. Alkylation of excess pyridine with the bromides gave the desired 10-perfluoroalkyldecyl pyridinium bromides in good yields. Three 10-perfluoroalkylundecyl surfactants were synthesized using a similar approach with 10-undecenoic acid methyl ester as starting material. Based on an initial in vitro toxicity assessment, the toxicity of the partially fluorinated pyridinium surfactants was slightly lower or comparable to benzalkonium chloride, a typically cationic surfactant (with IC(50)s of tested compounds ranging from 5 to 15 mu M). An increase in the length and/or the degree of fluorination of the hydrophobic tail correlated with a mild decrease of cytotoxicity and haemolytic activity. Partially fluorinated pyridinium surfactants may, therefore, be useful for biomedical applications such as components for novel gene and drug delivery systems.
C1 Univ Iowa, Dept Environm & Occupat Hlth, Iowa City, IA 52242 USA.
   Vet Res Inst, Dept Immunol, Brno 62133, Czech Republic.
   Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40536 USA.
RP Lehmler, HJ (reprint author), Univ Iowa, Dept Environm & Occupat Hlth, Iowa City, IA 52242 USA.
EM hans-joachim-lehmler@uiowa.edu
RI Rankin, Stephen/A-3265-2013
OI Rankin, Stephen/0000-0002-8615-7564; Lehmler,
   Hans-Joachim/0000-0001-9163-927X
CR ASAKAWA T, 1995, LANGMUIR, V11, P478, DOI 10.1021/la00002a019
   BANK U, 1991, Allergie und Immunologie (Leipzig), V37, P119
   BRACE NO, 1982, J FLUORINE CHEM, V20, P313, DOI 10.1016/S0022-1139(00)82223-X
   BRACE NO, 1962, J CHEM SOC, P4491
   Bramer T, 2003, PHARMACEUT RES, V20, P1661, DOI 10.1023/A:1026103805283
   DROBECK HP, 1994, SURF SCI SER, V53, P61
   Ghosh K, 2005, LANGMUIR, V21, P6145, DOI 10.1021/la050311t
   Graupe M, 1999, J FLUORINE CHEM, V93, P107, DOI 10.1016/S0022-1139(98)00284-X
   GREINER J, 1988, TETRAHEDRON LETT, V29, P2193, DOI 10.1016/S0040-4039(00)86708-8
   Guillod F, 1995, CHEM PHYS LIPIDS, V78, P149, DOI 10.1016/0009-3084(95)02492-2
   IDZIOREK T, 1995, J IMMUNOL METHODS, V185, P249, DOI 10.1016/0022-1759(95)00172-7
   Kissa E., 2001, FLUORINATED SURFACTA, V97
   KRAFFT MP, 1990, NEW J CHEM, V14, P869
   KRAFFT MP, 1991, EUR J MED CHEM, V26, P545, DOI 10.1016/0223-5234(91)90151-C
   Kuo JHS, 2005, COLLOID SURFACE B, V41, P189, DOI 10.1016/j.colsurfb.2004.12.008
   Lasic D. D., 1997, LIPOSOMES GENE DELIV
   Lehmler HJ, 2002, J FLUORINE CHEM, V117, P17, DOI 10.1016/S0022-1139(02)00169-0
   Lehmler HJ, 2001, J FLUORINE CHEM, V107, P141, DOI 10.1016/S0022-1139(00)00384-5
   Lehmler HJ, 1999, CHEMTECH, V29, P7
   MILIUS A, 1991, NEW J CHEM, V15, P337
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Murphy KE, 2003, J AM CHEM SOC, V125, P4690, DOI 10.1021/ja0300618
   Naud C, 2000, J FLUORINE CHEM, V104, P173, DOI 10.1016/S0022-1139(00)00215-3
   NIVET JB, 1991, EUR J MED CHEM, V26, P953, DOI 10.1016/0223-5234(91)90138-D
   NIVET JB, 1992, EUR J MED CHEM, V27, P891, DOI 10.1016/0223-5234(92)90020-2
   Osei-Prempeh G, 2005, MICROPOR MESOPOR MAT, V85, P16, DOI 10.1016/j.micromeso.2005.06.014
   Pitten FA, 2001, ARZNEIMITTEL-FORSCH, V51, P588
   Rankin SE, 2004, MICROPOR MESOPOR MAT, V73, P197, DOI 10.1016/j.micromeso.2004.05.013
   Ravi S, 2001, J INDIAN I SCI, V81, P299
   Riess JG, 2002, J FLUORINE CHEM, V114, P119, DOI 10.1016/S0022-1139(02)00017-9
   RIESS JG, 1991, ADV MATER, V3, P249, DOI 10.1002/adma.19910030507
   Sadtler VM, 1998, NEW J CHEM, V22, P609, DOI 10.1039/a708757h
   Tan B, 2005, NANOTECHNOLOGY, V16, pS502, DOI 10.1088/0957-4484/16/7/026
   Tan B, 2005, CHEM MATER, V17, P916, DOI 10.1021/cm048991t
   Tan B, 2004, LANGMUIR, V20, P6981, DOI 10.1021/la049474s
   Tondre C, 2001, ADV COLLOID INTERFAC, V93, P115, DOI 10.1016/S0001-8686(00)00081-6
   Turanek J, 2004, ANTI-CANCER DRUG, V15, P537, DOI 10.1097/01.cad.0000127147.57796.e5
   ZARIF L, 1989, J FLUORINE CHEM, V44, P73, DOI 10.1016/S0022-1139(00)84372-9
   ZARIF L, 1990, J MED CHEM, V33, P1262, DOI 10.1021/jm00166a028
NR 39
TC 30
Z9 30
U1 1
U2 9
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1144-0546
J9 NEW J CHEM
JI New J. Chem.
PD JUN
PY 2006
VL 30
IS 6
BP 944
EP 951
DI 10.1039/b516039a
PG 8
WC Chemistry, Multidisciplinary
SC Chemistry
GA 056RS
UT WOS:000238543400027
DA 2018-03-20
ER

PT J
AU Hauser, MR
   Zhakarov, L
   Doxsee, KM
   Li, TL
AF Hauser, Melanie R.
   Zhakarov, Lev
   Doxsee, Kenneth M.
   Li, Tonglei
TI Polymorphism of a Simple Organic Amide
SO CRYSTAL GROWTH & DESIGN
LA English
DT Article; Proceedings Paper
CT 12th International Conference on Crystalization of Biological
   Macromolecules
CY MAY 06-08, 2008
CL Cancun, MEXICO
ID DENSITY-FUNCTIONAL THEORY; HYDROGEN-BOND PATTERNS; CRYSTALS; ENERGIES
AB Glycolanilide (2-hydroxy-N-phenylacetamide), a simple amide, may be reproducibly crystallized in either of two polymorphic forms. The crystal and molecular structures of each polymorph have been determined, revealing that the two polymorphs differ in the extent and arrangement of intermolecular hydrogen bonding. The more stable polymorph displays one-dimensional chains linked through hydrogen bonds between the amide carbonyl and the alpha-hydroxyl group. In the metastable polymorph, analogous chain structures are overlain with cyclic hydrogen-bonded amide dimers, with an additional set of hydrogen bonding contacts joining the chain and cyclic motifs.
C1 [Hauser, Melanie R.; Zhakarov, Lev; Doxsee, Kenneth M.] Univ Oregon, Dept Chem, Eugene, OR 97403 USA.
   [Li, Tonglei] Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
RP Doxsee, KM (reprint author), Univ Oregon, Dept Chem, Eugene, OR 97403 USA.
EM doxsee@uoregon.edu
CR AHLRICHS R, 1977, CHEM PHYS, V19, P119, DOI 10.1016/0301-0104(77)85124-0
   *AM CRYST ASS, 2007 ANN M AM CRYST
   AZIZ RA, 1977, J CHEM PHYS, V67, P5719, DOI 10.1063/1.434827
   BOYS SF, 1970, MOL PHYS, V19, P553, DOI 10.1080/00268977000101561
   Dovesi R, 2005, Z KRISTALLOGR, V220, P571, DOI 10.1524/zkri.220.5.571.65065
   DOXSEE KM, 1993, J ORG CHEM, V58, P7557, DOI 10.1021/jo00078a040
   ETTER MC, 1990, ACCOUNTS CHEM RES, V23, P120, DOI 10.1021/ar00172a005
   ETTER MC, 1990, ACTA CRYSTALLOGR B, V46, P256, DOI 10.1107/S0108768189012929
   Feng SX, 2006, J CHEM THEORY COMPUT, V2, P149, DOI 10.1021/ct050189a
   HEPBURN J, 1975, CHEM PHYS LETT, V36, P451, DOI 10.1016/0009-2614(75)80278-8
   Hilfiker R, 2006, POLYMORPHISM PHARM I
   IWAMOTO HK, 1946, J AM PHARM ASSOC SCI, V35, P50, DOI 10.1002/jps.3030350206
   Kissinger HE, 1957, ANAL CHEM, V24, P1702, DOI DOI 10.1021/AC60131A045
   KNAPMAN K, 2000, MODERN DRUG DISCOVER, V3, P5354
   LEHMANN O, 1891, KRYSTALLANALYSE
   Li TL, 2006, PHARM RES-DORDR, V23, P2326, DOI 10.1007/s11095-006-9006-5
   McCrone W. C., 1965, PHYSICS CHEMISTRY OR, VII, P725
   MITSCHERLICH E, 1822, ABH KONIGL AKAD WISS, P43
   PALMORE GTR, 2003, AMIDE LINKAGE STRUCT
   SARMA B, 2006, CHEM COMMUN, V491, P8
   Sheldrick G. M, 1998, SADABS 2 01 BRUKER S
   SHELDRICK GM, BRUKER XRD
   SHIN JM, 1986, TETRAHEDRON LETT, V27, P1921, DOI 10.1016/S0040-4039(00)84412-3
   Snider DA, 2004, ADV DRUG DELIVER REV, V56, P391, DOI 10.1016/j.addr.2003.10.010
   Wu Q, 2002, J CHEM PHYS, V116, P515, DOI 10.1063/1.1424928
NR 25
TC 6
Z9 6
U1 0
U2 10
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1528-7483
J9 CRYST GROWTH DES
JI Cryst. Growth Des.
PD DEC
PY 2008
VL 8
IS 12
BP 4428
EP 4431
DI 10.1021/cg800171h
PG 4
WC Chemistry, Multidisciplinary; Crystallography; Materials Science,
   Multidisciplinary
SC Chemistry; Crystallography; Materials Science
GA 379EL
UT WOS:000261379400037
DA 2018-03-20
ER

PT J
AU Ladipo, FT
   Gupta, N
   Saangonyo, D
   Knutson, B
   Rankin, S
   Smith, B
AF Ladipo, Folami T.
   Gupta, Neeraj
   Saangonyo, Daudi
   Knutson, Barbara L.
   Rankin, Stephen E.
   Smith, Brianna
TI Catalytic conversion of saccharides into 5-hydroxymethylfurfural using
   aluminum Lewis acid catalysts
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
CT 246th National Meeting of the American-Chemical-Society (ACS)
CY SEP 08-12, 2013
CL Indianapolis, IN
SP Amer Chem Soc
C1 [Ladipo, Folami T.; Gupta, Neeraj; Saangonyo, Daudi] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
   [Knutson, Barbara; Rankin, Stephen; Smith, Brianna] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM fladip0@uky.edu
NR 0
TC 0
Z9 0
U1 0
U2 3
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD SEP 8
PY 2013
VL 246
MA 186-INOR
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA 288NJ
UT WOS:000329618404222
DA 2018-03-20
ER

PT J
AU Wu, J
   Gerstandt, K
   Majumder, M
   Zhan, X
   Hinds, BJ
AF Wu, Ji
   Gerstandt, Karen
   Majumder, Mainak
   Zhan, Xin
   Hinds, Bruce J.
TI Highly efficient electroosmotic flow through functionalized carbon
   nanotube membranes
SO NANOSCALE
LA English
DT Article
ID MOLECULAR-INTERACTIONS; MASS-TRANSPORT; DEVICES; MICROFLUIDICS;
   ELECTRODE; CHANNEL; SURFACE; WATER
AB Carbon nanotube membranes with inner diameter ranging from 1.5-7 nm were examined for enhanced electroosmotic flow. After functionalization via electrochemical diazonium grafting and carbodiimide coupling reaction, it was found that neutral caffeine molecules can be efficiently pumped via electroosmosis. An electroosmotic velocity as high as 0.16 cm s(-1) V(-1) has been observed. Power efficiencies were 25-110 fold improved compared to related nanoporous materials, which has important applications in chemical separations and compact medical devices. Nearly ideal electroosmotic flow was seen in the case where the mobile cation diameter nearly matched the inner diameter of the single-walled carbon nanotube resulting in a condition of using one ion is to pump one neutral molecule at equivalent concentrations.
C1 [Wu, Ji; Gerstandt, Karen; Majumder, Mainak; Zhan, Xin; Hinds, Bruce J.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Hinds, BJ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM bjhinds@engr.uky.edu
RI WU, JI/F-6371-2013; WU, JI/F-6379-2013; Majumder, Mainak/B-4667-2011;
   WU, JI/J-4580-2016
FU NIH NIDA [R01DA018822]; NSF [0348544]; DARPA [W911NF-09-1-0267]
FX We would like to thank Dali Qian and Rodney Andrews from the Center for
   Applied Energy, University of Kentucky, for supplying MWCNTs. Facility
   support was provided by the Center for Nanoscale Science and Engineering
   and Electron Microscopy Center at the University of Kentucky. Financial
   support from NIH NIDA (R01DA018822), NSF CAREER (0348544), and DARPA
   (W911NF-09-1-0267).
CR Andrews R, 1999, CHEM PHYS LETT, V303, P467, DOI 10.1016/S0009-2614(99)00282-1
   Bahr JL, 2001, J AM CHEM SOC, V123, P6536, DOI 10.1021/ja010462s
   Bard A. J., 1980, ELECTROCHEMICAL METH
   Beckers JL, 1997, J CHROMATOGR A, V764, P111, DOI 10.1016/S0021-9673(96)00882-5
   Chen W, 2005, ANAL CHEM, V77, P8102, DOI 10.1021/ac0513055
   Chen Y., 2007, NANO LETT, V8, P42
   Crow D.R., 1994, PRINCIPLES APPL ELEC
   D'Amours M, 2003, J PHYS CHEM B, V107, P4811, DOI 10.1021/jp027223r
   Daiguji H, 2004, NANO LETT, V4, P137, DOI 10.1021/nl0348185
   Fornasiero F, 2008, P NATL ACAD SCI USA, V105, P17250, DOI 10.1073/pnas.0710437105
   Guo ZL, 2005, J CHEM PHYS, V122, DOI 10.1063/1.1874813
   Hinds BJ, 2004, SCIENCE, V303, P62, DOI 10.1126/science.1092048
   Hodgman C.D., 1951, HDB CHEM PHYS
   Holt JK, 2006, SCIENCE, V312, P1034, DOI 10.1126/science.1126298
   Hummer G, 2001, NATURE, V414, P188, DOI 10.1038/35102535
   Joseph S, 2003, NANO LETT, V3, P1399, DOI 10.1021/nl0346326
   Joseph S, 2008, NANO LETT, V8, P452, DOI 10.1021/nl072385q
   Katz E, 2003, ELECTROANAL, V15, P913, DOI 10.1002/elan.200390114
   Kim S, 2007, NANO LETT, V7, P2806, DOI 10.1021/nl071414u
   Lee CY, 2010, SCIENCE, V329, P1320, DOI 10.1126/science.1193383
   Liang ZY, 2004, MAT SCI ENG A-STRUCT, V365, P228, DOI 10.1016/j.msea.2003.09.032
   Majumder M, 2005, NATURE, V438, P44, DOI 10.1038/43844a
   Majumder M, 2005, J AM CHEM SOC, V127, P9062, DOI 10.1021/ja043013b
   Majumder M, 2008, J MEMBRANE SCI, V316, P89, DOI 10.1016/j.memsci.2007.09.068
   Majumder M, 2007, LANGMUIR, V23, P8624, DOI 10.1021/la700686k
   Miao JY, 2007, ADV MATER, V19, P4234, DOI 10.1002/adma.200700767
   Miller SA, 2001, J AM CHEM SOC, V123, P12335, DOI 10.1021/ja011926p
   Nachod F. C., 1971, DETERMINATION ORGANI
   Nednoor P, 2005, CHEM MATER, V17, P3595, DOI 10.1021/cm047844s
   PINSON J, 2005, CHEMINFORM, V36, P429
   Qiao R, 2003, NANO LETT, V3, P1013, DOI 10.1021/nl034236n
   Reyes DR, 2002, ANAL CHEM, V74, P2623, DOI 10.1021/ac0202435
   Stone HA, 2004, ANNU REV FLUID MECH, V36, P381, DOI 10.1146/annurev.fluid.36.050802.122124
   Strasinger Caroline L, 2009, Subst Abuse, V3, P31
   Sun L, 2000, J AM CHEM SOC, V122, P12340, DOI 10.1021/ja002429w
   Takamura Y, 2003, ELECTROPHORESIS, V24, P185, DOI 10.1002/elps.200390012
   van den Berg A, 2010, CHEM SOC REV, V39, P899, DOI 10.1039/c001349h
   Vlassiouk I, 2008, NANO LETT, V8, P1978, DOI 10.1021/nl800949k
   Wu J, 2010, P NATL ACAD SCI USA, V107, P11698, DOI 10.1073/pnas.1004714107
   Yu M., 2008, NANO LETT, V9, P225
   Zheng QB, 2007, J PHYS CHEM C, V111, P4628, DOI 10.1021/jp066077c
NR 41
TC 31
Z9 31
U1 6
U2 52
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2040-3364
J9 NANOSCALE
JI Nanoscale
PY 2011
VL 3
IS 8
BP 3321
EP 3328
DI 10.1039/c1nr10303b
PG 8
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 802OU
UT WOS:000293521700049
PM 21727982
DA 2018-03-20
ER

PT J
AU Chotibut, T
   Davis, R
   Arnold, JC
   Frenchek, Z
   Gurwara, S
   Bondada, V
   Geddes, JW
   Salvatore, MF
AF Chotibut, Tanya
   Davis, RichardW.
   Arnold, Jennifer C.
   Frenchek, Zachary
   Gurwara, Shawn
   Bondada, Vimala
   Geddes, James W.
   Salvatore, Michael F.
TI Ceftriaxone increases glutamate uptake and reduces striatal tyrosine
   hydroxylase loss in 6-OHDA Parkinson's model
SO MOLECULAR NEUROBIOLOGY
LA English
DT Article
DE Parkinson's disease; Ceftriaxone; GLT-1; Tyrosine hydroxylase; 6-OHDA;
   Neuroprotection
ID AMYOTROPHIC-LATERAL-SCLEROSIS; DOPA-INDUCED DYSKINESIA;
   HUNTINGTONS-DISEASE; BASAL GANGLIA; TRANSPORTER GLT-1; UP-REGULATION;
   RECEPTOR ANTAGONISTS; NIGROSTRIATAL SYSTEM; FUNCTIONAL-ANATOMY;
   CAUDATE-PUTAMEN
AB Excess glutamatergic neurotransmission may contribute to excitotoxic loss of nigrostriatal neurons in Parkinson's disease (PD). Here, we determined if increasing glutamate uptake could reduce the extent of tyrosine hydroxylase (TH) loss in PD progression. The beta-lactam antibiotic, ceftriaxone, increases the expression of glutamate transporter 1 (GLT-1), a glutamate transporter that plays a major role in glutamate clearance in central nervous system and may attenuate adverse behavioral or neurobiological function in other neurodegenerative disease models. In association with >80 % TH loss, we observed a significant decrease in glutamate uptake in the established 6-hydroxydopamine (6-OHDA) PD model. Ceftriaxone (200 mg/kg, i.p.) increased striatal glutamate uptake with >= 5 consecutive days of injection in nonlesioned rats and lasted out to 14 days postinjection, a time beyond that required for 6-OHDA to produce >70 % TH loss (similar to 9 days). When ceftriaxone was given at the time of 6-OHDA, TH loss was similar to 57% compared to similar to 85% in temporally matched vehicle-injected controls and amphetamine-induced rotation was reduced about 2-fold. This attenuation of TH loss was associated with increased glutamate uptake, increased GLT-1 expression, and reduced Serine 19 TH phosphorylation, a calcium-dependent target specific for nigrostriatal neurons. These results reveal that glutamate uptake can be targeted in a PD model, decrease the rate of TH loss in a calcium-dependent manner, and attenuate locomotor behavior associated with 6-OHDA lesion. Given that detection of reliable PD markers will eventually be employed in susceptible populations, our results give credence to the possibility that increasing glutamate uptake may prolong the time period before locomotor impairment occurs.
C1 [Chotibut, Tanya; Davis, RichardW.; Arnold, Jennifer C.; Frenchek, Zachary; Gurwara, Shawn] Louisiana State Univ, Hlth Sci Ctr Shreveport, Dept Pharmacol Toxicol & Neurosci, Shreveport, LA 71106 USA.
   [Bondada, Vimala; Geddes, James W.] Univ Kentucky, Med Ctr, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA.
   [Salvatore, Michael F.] Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol Toxicol & Neurosci, Shreveport, LA 71106 USA.
RP Salvatore, MF (reprint author), Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol Toxicol & Neurosci, 1501 Kings Highway, Shreveport, LA 71106 USA.
EM msalva@lsuhsc.edu
FU Edward P. Stiles Trust Fund-LSUHSC-Shreveport; Biomedical Research
   Foundation of NW Louisiana; Ike Muslow Predoctoral Fellowship
FX The authors wish to thank Victoria Fields for her outstanding technical
   assistance at various points throughout the study. This study was funded
   by the Edward P. Stiles Trust Fund-LSUHSC-Shreveport and Biomedical
   Research Foundation of NW Louisiana awards to MFS and the Ike Muslow
   Predoctoral Fellowship to TC.
CR ALBIN RL, 1989, TRENDS NEUROSCI, V12, P366, DOI 10.1016/0166-2236(89)90074-X
   Albin Roger L., 1995, Trends in Neurosciences, V18, P63, DOI 10.1016/0166-2236(95)93872-U
   Ambrosi G, 2010, BRAIN RES BULL, V82, P29, DOI 10.1016/j.brainresbull.2010.01.011
   Anderson CM, 2000, GLIA, V32, P1
   Andre VM, 2010, CNS NEUROSCI THER, V16, P163, DOI 10.1111/j.1755-5949.2010.00134.x
   Armentero MT, 2006, NEUROBIOL DIS, V22, P1, DOI 10.1016/j.nbd.2005.09.010
   Bamford NS, 2004, J NEUROSCI, V24, P9541, DOI 10.1523/JNEUROSCI.2891-04.2004
   Behrens PF, 2002, BRAIN, V125, P1908, DOI 10.1093/brain/awf180
   BERNHEIMER H, 1973, J NEUROL SCI, V20, P415, DOI 10.1016/0022-510X(73)90175-5
   Bevers MB, 2008, J CEREBR BLOOD F MET, V28, P655, DOI 10.1038/sj.jcbfm.9600595
   Black YD, 2010, NEUROSCI LETT, V486, P161, DOI 10.1016/j.neulet.2010.09.043
   Blandini F, 1996, FUNCT NEUROL, V11, P3
   Brown RH, 2005, NEW ENGL J MED, V352, P1376, DOI 10.1056/NEJMcibr050274
   Cenci MA, 2007, CURR OPIN NEUROBIOL, V17, P665, DOI 10.1016/j.conb.2008.01.004
   Cenci MA, 2006, J NEUROCHEM, V99, P381, DOI 10.1111/j.1471-4159.2006.04124.x
   Chase TN, 2000, TRENDS NEUROSCI, V23, pS86, DOI 10.1016/S1471-1931(00)00018-5
   CHOI DW, 1985, NEUROSCI LETT, V58, P293, DOI 10.1016/0304-3940(85)90069-2
   Chotibut T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052322
   Chung EKY, 2008, J COMP NEUROL, V511, P421, DOI 10.1002/cne.21852
   Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8
   David HN, 2005, BRAIN RES REV, V50, P336, DOI 10.1016/j.brainreserv.2005.09.002
   Dervan AG, 2004, EXP NEUROL, V190, P145, DOI 10.1016/j.expneurol.2004.07.004
   DIFIGLIA M, 1990, TRENDS NEUROSCI, V13, P286, DOI 10.1016/0166-2236(90)90111-M
   Duan SM, 1999, J NEUROSCI, V19, P10193
   FADEN AI, 1989, SCIENCE, V244, P789
   FONNUM F, 1984, J NEUROCHEM, V42, P1, DOI 10.1111/j.1471-4159.1984.tb09689.x
   Geddes JW, 2010, EXP NEUROL, V226, P6, DOI 10.1016/j.expneurol.2010.07.025
   Grant RJ, 2009, NEUROSCIENCE, V158, P558, DOI 10.1016/j.neuroscience.2008.10.023
   Greenamyre JT, 2004, SCIENCE, V304, P1120, DOI 10.1126/science.1098966
   GREENAMYRE JT, 1993, J NEURAL TRANSM-GEN, V91, P255, DOI 10.1007/BF01245235
   Hallett PJ, 2004, PHARMACOL THERAPEUT, V102, P155, DOI 10.1016/j.pharmthera.2004.04.001
   Hazell AS, 1997, J NEUROCHEM, V68, P2216
   HENN FA, 1976, BRAIN RES, V101, P341, DOI 10.1016/0006-8993(76)90274-2
   Hirsch EC, 2000, ANN NEUROL, V47, pS115
   Hubsher G, 2012, NEUROLOGY, V78, P1096, DOI 10.1212/WNL.0b013e31824e8f0d
   HUDSON JL, 1993, BRAIN RES, V626, P167, DOI 10.1016/0006-8993(93)90576-9
   Izumi Y, 2009, J NEUROCHEM, V110, P745, DOI 10.1111/j.1471-4159.2009.06178.x
   Kim K, 2011, J CELL PHYSIOL, V226, P2484, DOI 10.1002/jcp.22609
   Koller M, 2006, EXPERT OPIN THER PAT, V20, P1683
   Lau A, 2010, PFLUG ARCH EUR J PHY, V460, P525, DOI 10.1007/s00424-010-0809-1
   Leung TCH, 2012, ACS CHEM NEUROSCI, V3, P22, DOI 10.1021/cn200072h
   Levesque S, 2010, BRAIN, V133, P808, DOI 10.1093/brain/awp333
   Lievens JC, 2001, J NEUROCHEM, V79, P893, DOI 10.1046/j.1471-4159.2001.00644.x
   LINDEFORS N, 1990, NEUROSCI LETT, V115, P248, DOI 10.1016/0304-3940(90)90463-J
   Lindgren N, 2000, J NEUROCHEM, V74, P2470, DOI 10.1046/j.1471-4159.2000.0742470.x
   LIPTON SA, 1994, NEW ENGL J MED, V330, P613
   Lipton SA, 2006, NAT REV DRUG DISCOV, V5, P160, DOI 10.1038/nrd1958
   Maetzler W, 2009, LANCET NEUROL, V8, P1158, DOI 10.1016/S1474-4422(09)70291-1
   MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A
   Meredith GE, 2009, EXP NEUROL, V219, P334, DOI 10.1016/j.expneurol.2009.06.005
   Meshul CK, 1999, NEUROSCIENCE, V88, P1, DOI 10.1016/S0306-4522(98)00189-4
   Miller BR, 2008, NEUROSCIENCE, V153, P329, DOI 10.1016/j.neuroscience.2008.02.004
   Minger SL, 1998, BRAIN RES, V810, P181, DOI 10.1016/S0006-8993(98)00921-4
   Nafia I, 2008, J NEUROCHEM, V105, P484, DOI 10.1111/j.1471-4159.2007.05146.x
   Nakashima A, 2011, BIOCHEM BIOPH RES CO, V407, P343, DOI 10.1016/j.bbrc.2011.03.020
   Nickell J, 2005, J NEURAL TRANSM, V112, P87, DOI 10.1007/s00702-004-0151-x
   Nutt JG, 2008, MOVEMENT DISORD, V23, P1860, DOI 10.1002/mds.22169
   Watson C., 1986, RAT BRAIN STEREOTAXI
   Plaitakis A, 2000, J NEUROL S2, V247, pS1125
   Rao VLR, 2001, EUR J NEUROSCI, V13, P119, DOI 10.1046/j.1460-9568.2001.01367.x
   Robinson Siobhan, 2003, Exp Neurol, V180, P74, DOI 10.1016/S0014-4886(02)00050-X
   Ross CA, 2002, NEURON, V35, P819, DOI 10.1016/S0896-6273(02)00872-3
   Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0
   ROTHSTEIN JD, 1995, ANN NEUROL, V38, P73, DOI 10.1002/ana.410380114
   Rothstein JD, 2005, NATURE, V433, P73, DOI 10.1038/nature03180
   Salvatore MF, 2003, NEUROBIOL AGING, V24, P1147, DOI 10.1016/S0197-4580(03)00129-5
   Salvatore MF, 2001, J NEUROCHEM, V79, P349, DOI 10.1046/j.1471-4159.2001.00593.x
   Salvatore MF, 2012, JOVE-J VIS EXP, DOI 10.3791/4171
   Salvatore MF, 2012, EXP NEUROL, V234, P428, DOI 10.1016/j.expneurol.2012.01.012
   Sanchez-Pernaute R, 2008, NEUROIMAGE, V42, P248, DOI 10.1016/j.neuroimage.2008.04.170
   Sari Y, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-62
   Schlag BD, 1998, MOL PHARMACOL, V53, P355
   Selkirk JV, 2005, EUR J NEUROSCI, V21, P3217, DOI 10.1111/j.1460-9568.2005.04162.x
   Smeyne RJ, 2005, MOL BRAIN RES, V134, P57, DOI 10.1016/j.molbrainres.2004.09.017
   STARR MS, 1995, SYNAPSE, V19, P264, DOI 10.1002/syn.890190405
   Suchak SK, 2003, J NEUROCHEM, V84, P522, DOI 10.1046/j.1471-4159.2003.01553.x
   Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699
   Tian GL, 2007, J BIOL CHEM, V282, P1727, DOI 10.1074/jbc.M609822200
   Touchon JC, 2005, EXP NEUROL, V193, P131, DOI 10.1016/j.expneurol.2004.11.023
   ULAS J, 1994, J NEUROSCI, V14, P6317
   Van Landeghem FKH, 2006, J NEUROTRAUM, V23, P1518
   Vernon AC, 2007, J NEUROCHEM, V103, P1075, DOI 10.1111/j.1471-4159.2007.04860.x
   Wang J, 2013, DRUG DISCOV TODAY, V18, P155, DOI 10.1016/j.drudis.2012.09.001
   Wassum KM, 2008, SENSORS-BASEL, V8, P5023, DOI 10.3390/s8085023
   WEIHMULLER FB, 1992, NEUROREPORT, V3, P977, DOI 10.1097/00001756-199211000-00007
   Wu YC, 2011, ARCH NEUROL-CHICAGO, V68, P22, DOI 10.1001/archneurol.2010.321
   YAMAMOTO BK, 1992, J NEUROCHEM, V58, P1736, DOI 10.1111/j.1471-4159.1992.tb10048.x
NR 87
TC 20
Z9 20
U1 0
U2 5
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0893-7648
EI 1559-1182
J9 MOL NEUROBIOL
JI Mol. Neurobiol.
PD JUN
PY 2014
VL 49
IS 3
BP 1282
EP 1292
DI 10.1007/s12035-013-8598-0
PG 11
WC Neurosciences
SC Neurosciences & Neurology
GA AG8KE
UT WOS:000335666500012
PM 24297323
OA green_accepted
DA 2018-03-20
ER

PT J
AU Li, XJ
   Vogt, FG
   Hayes, D
   Mansour, HM
AF Li, Xiaojian
   Vogt, Frederick G.
   Hayes, Don, Jr.
   Mansour, Heidi M.
TI Design, Characterization, and Aerosol Dispersion Performance Modeling of
   Advanced Spray-Dried Microparticulate/Nanoparticulate Mannitol Powders
   for Targeted Pulmonary Delivery as Dry Powder Inhalers
SO JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY
LA English
DT Article
DE particle engineering design; osmotic agent; respiratory; cystic
   fibrosis; aerosol performance modeling; lung; solid-state; confocal
   Raman chemical imaging; DPI
ID WATER-VAPOR ABSORPTION; CYSTIC-FIBROSIS; PHYSICOCHEMICAL
   CHARACTERIZATION; PHYSICAL-CHARACTERIZATION; INHALATION; PARTICLES;
   MICROPARTICLES; MUCUS; NANOPARTICLES; NANOMEDICINE
AB Background: The purpose was to design and characterize inhalable microparticulate/nanoparticulate dry powders of mannitol with essential particle properties for targeted dry powder delivery for cystic fibrosis mucolytic treatment by dilute organic solution spray drying, and, in addition, to tailor and correlate aerosol dispersion performance delivered as dry powder inhalers based on spray-drying conditions and solid-state physicochemical properties.
   Methods: Organic solution advanced spray drying from dilute solution followed by comprehensive solid-state physicochemical characterization and in vitro dry powder aerosolization were used.
   Results: The particle size distribution of the spray-dried (SD) powders was narrow, unimodal, and in the range of similar to 500 nm to 2.0 mu m. The particles possessed spherical particle morphology, relatively smooth surface morphology, low water content and vapor sorption (crystallization occurred at exposure above 65% relative humidity), and retention of crystallinity by polymorphic interconversion. The emitted dose, fine particle fraction (FPF), and respirable fraction (RF) were all relatively high. The mass median aerodynamic diameters were below 4 mu m for all SD mannitol aerosols.
   Conclusion: The in vitro aerosol deposition stage patterns could be tailored based on spray-drying pump rate. Positive linear correlation was observed between both FPF and RF values with spray-drying pump rates. The interplay between various spray-drying conditions, particle physicochemical properties, and aerosol dispersion performance was observed and examined, which enabled tailoring and modeling of high aerosol deposition patterns.
C1 [Li, Xiaojian] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Drug Dev Div, Lexington, KY 40536 USA.
   [Vogt, Frederick G.] GlaxoSmithKline, Analyt Sci, Prod Dev, King Of Prussia, PA 19406 USA.
   [Hayes, Don, Jr.] Ohio State Univ, Coll Med, Dept Pediat, Lung Transplant Program, Columbus, OH 43205 USA.
   [Hayes, Don, Jr.] Ohio State Univ, Coll Med, Dept Internal Med, Lung Transplant Program, Columbus, OH 43205 USA.
   [Hayes, Don, Jr.] Ohio State Univ, Coll Med, Dept Pediat, Heart Lung Transplant Program, Columbus, OH 43205 USA.
   [Hayes, Don, Jr.] Ohio State Univ, Coll Med, Dept Internal Med, Heart Lung Transplant Program, Columbus, OH 43205 USA.
   [Hayes, Don, Jr.] Ohio State Univ, Coll Med, Davis Heart & Lung Res Inst, Columbus, OH 43205 USA.
   [Mansour, Heidi M.] Univ Arizona Tucson, Coll Pharm, Skaggs Pharmaceut Sci Ctr, Tucson, AZ 85721 USA.
RP Mansour, HM (reprint author), Univ Arizona Tucson, Coll Pharm, Skaggs Pharmaceut Sci Ctr, 1703 E Mabel St, Tucson, AZ 85721 USA.
EM mansour@pharmacy.arizona.edu
FU UK Center of Membrane Sciences; Graduate School Academic Year
   Fellowship; Daniel R. Reedy Quality Achievement Fellowship
FX The authors gratefully acknowledge fellowship support from the UK Center
   of Membrane Sciences, the Graduate School Academic Year Fellowship, and
   the Daniel R. Reedy Quality Achievement Fellowship awarded to Xiaojian
   Li. The authors thank Dr. Dicky Sick Ki Yu for SEM access, Dr. Tonglei
   Li for XRPD and HSM access, and Dr. Hilt for ATR-FTIR access at the
   University of Kentucky.
CR Adi H, 2008, J PHARM SCI-US, V97, P2780, DOI 10.1002/jps.21195
   Brannan JD, 2003, EUR RESPIR J, V22, P491, DOI 10.1183/09031936.03.00113403
   Burger A, 2000, J PHARM SCI-US, V89, P457, DOI 10.1002/(SICI)1520-6017(200004)89:4<457::AID-JPS3>3.0.CO;2-G
   Chan HK, 2004, J PHARM SCI-US, V93, P792, DOI 10.1002/jps.10594
   Daviskas E, 2006, J AEROSOL MED, V19, P100, DOI 10.1089/jam.2006.19.100
   Daviskas E, 2001, CHEST, V119, P414, DOI 10.1378/chest.119.2.414
   Donovan MJ, 2011, J PHARM SCI, V101, P1097
   Dunbar CA, 1998, KONA, V16, P7
   Elphick H, 2000, COCHRANE DATABASE SY
   Finlay Warren, 2008, ARLA RESP DEPOSITION
   Gibson RL, 2003, AM J RESP CRIT CARE, V168, P918, DOI 10.1164/rccm.200304-505SO
   Hickey A.J., 2007, INHALATION AEROSOLS
   Hickey A.J., 2008, MODIFIED RELEASE DRU, V2, P573
   Hickey AJ, 2009, MODERN PHARM, P191
   Hickey AJ, 2007, J PHARM SCI-US, V96, P1302, DOI 10.1002/jps.20943
   Hickey AJ, 2007, J PHARM SCI-US, V96, P1282, DOI 10.1002/jps.20916
   Jaques A, 2008, CHEST, V133, P1388, DOI 10.1378/chest.07-2294
   King M, 2002, ADV DRUG DELIVER REV, V54, P1475, DOI 10.1016/S0169-409X(02)00156-4
   Kumon M, 2010, EUR J PHARM SCI, V40, P16, DOI 10.1016/j.ejps.2010.02.004
   Li XJ, 2011, AAPS PHARMSCITECH, V12, P1420, DOI 10.1208/s12249-011-9704-0
   Mansour HM, 2007, J PHARM SCI-US, V96, P377, DOI 10.1002/jps.20810
   Mansour HM, 2010, J PHARM SCI-US, V99, P3430, DOI 10.1002/jps.22101
   Mansour HM, 2009, INT J NANOMED, V4, P299
   Mansour HM, 2007, AAPS PHARMSCITECH, V8, pE01
   Meenach SA, 2013, INT J NANOMED, V8, P275, DOI 10.2147/IJN.S30724
   Mitchell H., 2006, SWEETENERS SUGAR ALT
   Mizoe T, 2007, J CONTROL RELEASE, V122, P10, DOI 10.1016/j.jconrel.2007.06.001
   Murray J. F., 1988, TXB RESP MED
   Nunes C, 2004, J PHARM SCI-US, V93, P2800, DOI 10.1002/jps.20185
   Park CW, 2012, ADV DRUG DELIVER REV, V64, P344, DOI 10.1016/j.addr.2011.08.004
   RAABE OG, 1982, ANN OCCUP HYG, V26, P33, DOI 10.1093/annhyg/26.1.33
   STAHLHOFEN W, 1980, AM IND HYG ASSOC J, V41, P385, DOI 10.1080/15298668091424933
   Suarez S, 2000, Respir Care, V45, P652
   Takada A, 2009, PHARM RES-DORD, V26, P1112, DOI 10.1007/s11095-009-9829-y
   Tang P, 2009, INT J PHARM, V367, P51, DOI 10.1016/j.ijpharm.2008.09.024
   TAYLOR RFH, 1992, THORAX, V47, P426, DOI 10.1136/thx.47.6.426
   Teper A, 2011, J CYST FIBROS, V10, P1, DOI 10.1016/j.jcf.2010.08.020
   Tiddens HAWM, 2002, PEDIATR PULM, V34, P228, DOI 10.1002/ppul.10134
   Tong P, 2004, AAPS PHARMSCITECH, V5
   [Anonymous], 2006, 601 AER NAS SPRAYS M, V29, P2617
   Usmani OS, 2005, AM J RESP CRIT CARE, V172, P1497, DOI 10.1164/rccm.200410-1414OC
   Wills PJ, 1996, PULM PHARMACOL THER, V9, P197, DOI 10.1006/pulp.1996.0024
   Worlitzsch D, 2002, J CLIN INVEST, V109, P317, DOI 10.1172/JCI200213870
   Wu X., 2013, INT J NANOMED, V8, P1
   Wu X, 2013, DRUG DES DEV THER, V7, P59, DOI [10.2147/DDDT.540166, 10.2147/DDDT.S40166]
   Wu XA, 2010, KONA POWDER PART J, P3
   Xu Z, 2011, J ADHES SCI TECHNOL, V25, P451, DOI 10.1163/016942410X525669
   Xu Z, 2010, J PHARM SCI-US, V99, P3442, DOI 10.1002/jps.22057
   Ye P, 2008, AM LAB, V40, P24
   Yoshinari T, 2002, INT J PHARM, V247, P69, DOI 10.1016/S0378-5173(02)00380-0
NR 50
TC 9
Z9 9
U1 1
U2 23
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1941-2711
EI 1941-2703
J9 J AEROSOL MED PULM D
JI J. Aerosol Med. Pulm. Drug Deliv.
PD APR 1
PY 2014
VL 27
IS 2
BP 81
EP 93
DI 10.1089/jamp.2013.1078
PG 13
WC Respiratory System
SC Respiratory System
GA AD6XV
UT WOS:000333405700002
PM 24502451
OA green_published
DA 2018-03-20
ER

PT J
AU Brown, ME
   Zou, Y
   Peyyala, R
   Dziubla, TD
   Puleo, DA
AF Brown, Matthew E.
   Zou, Yuan
   Peyyala, Rebecca
   Dziubla, Thomas D.
   Puleo, David A.
TI Temporal Separation in the Release of Bioactive Molecules from a
   Moldable Calcium Sulfate Bone Graft Substitute
SO CURRENT DRUG DELIVERY
LA English
DT Article
DE Bone filler; bone graft substitute; calcium sulfate; composite;
   moldable; sequential release; simvastatin; vancomycin
ID INFECTED NONUNION; OSTEOMYELITIS; MANAGEMENT; DELIVERY; DEFECT;
   MICROSPHERES; SIMVASTATIN; GENTAMICIN; COMPOSITE; IMPLANTS
AB Treatment of infected bone defects presents a considerable challenge due to the complications that occur from significant bone damage concomitant with contaminated tissue. These wounds are most often treated in a two-step sequence, where the infection is first eliminated before any attempt to repair the bone is undertaken. In order to combine these two treatment steps into one procedure, a moldable bone grafting material was developed to deliver drugs in a temporally separated manner. This was accomplished by a two-layered calcium sulfate composite consisting of a moldable outer shell containing antibiotic-loaded poly (lactic-co-glycolic acid) microspheres wrapped around a preformed core containing an osteogenic drug. The release of vancomycin from the shell portion began immediately and continued over the course of 6 weeks, while the release of simvastatin from the core was delayed for 12 days before being released over the next 4 weeks. Bioactivity of vancomycin was shown in modified Kirby-Bauer experiments in which whole samples inhibited Staphylococcus aureus (S. aureus) growth for 2 weeks. This two-layered system is capable of delivering antibiotics locally for clinically relevant periods of time and delaying the release of osteogenic drugs to mimic a two-step procedure that has potential for treating infected bone defects.
C1 [Brown, Matt E.; Zou, Yuan; Puleo, David A.] Univ Kentucky, Dept Biomed Engn, Lexington, KY 40506 USA.
   [Peyyala, R.] Univ Kentucky, Coll Dent, Ctr Oral Hlth Res, Lexington, KY 40506 USA.
   [Dziubla, Thomas D.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Puleo, DA (reprint author), Univ Kentucky, Dept Biomed Engn, 522A Robot & Mfg Bldg, Lexington, KY 40506 USA.
EM puleo@uky.edu
FU US Army Medical Research Acquisition Activity [W81XWH-09-1-0461]; NSF
   IGERT [DGE-0653710]
FX This work was supported by a grant from the US Army Medical Research
   Acquisition Activity (W81XWH-09-1-0461). The contents herein do not
   necessarily represent the position or policy of the Government, and no
   official endorsement should be inferred. MEB was supported by NSF IGERT
   (DGE-0653710).
CR Athanasiou VT, 2010, MED SCI MONITOR, V16, pBR24
   Aviv M, 2007, J BIOMED MATER RES A, V83A, P10, DOI 10.1002/jbm.a.31184
   Azi ML, 2010, ACTA ORTOP BRAS, V18, P31, DOI 10.1590/S1413-78522010000100006
   Brady RA, 2008, FEMS IMMUNOL MED MIC, V52, P13, DOI 10.1111/j.1574-695X.2007.00357.x
   Brown ME, 2013, J BIOMED MATER RES A, V101, P973, DOI 10.1002/jbm.a.34399
   Brydone AS, 2010, P I MECH ENG H, V224, P1329, DOI 10.1243/09544119JEIM770
   Carek PJ, 2001, AM FAM PHYSICIAN, V63, P2413
   Chen CE, 2005, ARCH ORTHOP TRAUM SU, V125, P369, DOI 10.1007/s00402-005-0794-6
   Chen PY, 2010, NUTR RES, V30, P191, DOI 10.1016/j.nutres.2010.03.004
   Chen XQ, 2006, J BONE JOINT SURG AM, V88A, P1510, DOI 10.2106/JBJS.E.01136
   Geiger S, 2008, PLAST RECONSTR SURG, V122, P146, DOI 10.1097/PRS.0b013e3181773d19
   Gentry LO, 1997, INT J ANTIMICROB AG, V9, P37, DOI 10.1016/S0924-8579(97)00375-0
   Guelcher SA, 2011, J ORTHOP TRAUMA, V25, P477, DOI 10.1097/BOT.0b013e31821f624c
   Hak DJ, 2007, J AM ACAD ORTHOP SUR, V15, P525, DOI 10.5435/00124635-200709000-00003
   Hasegawa S, 2007, J BIOMED MATER RES A, V81A, P930, DOI 10.1002/jbm.a.31109
   Henderson B, 2003, TRENDS MICROBIOL, V11, P570, DOI 10.1016/j.tim.2003.10.005
   Jamal T, 2012, CURR DRUG DELIV, V9, P515, DOI 10.2174/156720112802650644
   Kanakaris NK, 2009, INJURY, V40, P54
   Kelly CM, 2001, CLIN ORTHOP RELAT R, P42
   MAKINEN PL, 1995, INFECT IMMUN, V63, P3567
   Martinez M, 2010, J VET PHARMACOL THER, V33, P213, DOI 10.1111/j.1365-2885.2009.01139.x
   Mckee MD, 2010, J ORTHOP TRAUMA, V24, P483, DOI 10.1097/BOT.0b013e3181df91d9
   Moghaddam A, 2010, ARCH ORTHOP TRAUM SU, V130, P71, DOI 10.1007/s00402-009-0982-x
   Motsitsi NS, 2008, INJURY, V39, P155, DOI 10.1016/j.injury.2007.08.032
   Mourino V, 2010, J R SOC INTERFACE, V7, P209, DOI 10.1098/rsif.2009.0379
   Nandi SK, 2009, MAT SCI ENG C-MATER, V29, P2478, DOI 10.1016/j.msec.2009.07.014
   Nayak AK, 2013, CURR DRUG DELIV, V10, P241
   Nyan M, 2007, J PHARMACOL SCI, V104, P384, DOI 10.1254/jphs.SC0070184
   Sayin B, 2006, J MICROENCAPSUL, V23, P553, DOI 10.1080/02652040600775632
   Sener M, 2010, INT ORTHOP, V34, P419, DOI 10.1007/s00264-009-0750-0
   Varani J., 1994, NEUROSIGNALS, V3, P1
   WEI GX, 1991, J BONE JOINT SURG BR, V73, P246
   WEISS SJ, 1981, J CLIN INVEST, V68, P714, DOI 10.1172/JCI110307
   Wright JA, 2010, INT J MED MICROBIOL, V300, P193, DOI 10.1016/j.ijmm.2009.10.003
   Yang L, 2012, FEMS IMMUNOL MED MIC, V65, P146, DOI 10.1111/j.1574-695X.2011.00858.x
   Yuan HP, 2010, P NATL ACAD SCI USA, V107, P13614, DOI 10.1073/pnas.1003600107
NR 36
TC 1
Z9 1
U1 1
U2 3
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1567-2018
EI 1875-5704
J9 CURR DRUG DELIV
JI Curr. Drug Deliv.
PY 2014
VL 11
IS 5
BP 605
EP 612
DI 10.2174/1567201811666140616160948
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA AQ9HD
UT WOS:000343159400007
PM 24934226
DA 2018-03-19
ER

PT J
AU Medley, JM
   Kaplan, E
   Oz, HS
   Sundararaj, SC
   Puleo, DA
   Dziubla, TD
AF Medley, John M.
   Kaplan, Eugene
   Oz, Helieh S.
   Sundararaj, Sharath Kumar C.
   Puleo, David A.
   Dziubla, Thomas D.
TI Fibrin-targeted block copolymers for the prevention of postsurgical
   adhesions
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B-APPLIED BIOMATERIALS
LA English
DT Article
DE postsurgical adhesion; fibrin; in vivo; block copolymer; CREKA
ID UTERINE HORN MODEL; POLYTETRAFLUOROETHYLENE MESH; POSTOPERATIVE
   ADHESION; TUMORS; RABBIT; AGENTS; RAT; GEL; NANOPARTICLES; REDUCTION
AB Despite advances in surgical methods, postsurgical adhesions (PSA) remain a significant clinical challenge affecting millions of patients each year. These permanent fibrous connections between tissues result from the bridging of wounded internal surfaces by an extended fibrin gel matrix (FGM). Adhesion formation is a result of a systems level convergence of wound healing pathways, complicating the design of materials that could inhibit their occurrence. In this study, a systematic approach that identifies key material properties required for functional performance optimization was used to design a new fibrin-targeted PSA prevention material. A series of multifunctional polymers with varied molecular architectures was synthesized to investigate the effect of changing polymer structural parameters on the ability to disrupt the formation of an extended FGM. Initial studies in a murine adhesion model demonstrated a statistically significant reduction in the degree of PSA formation, demonstrating the potential value of this systematic approach. (C) 2011 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater 99B: 102-110, 2011.
C1 [Dziubla, Thomas D.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Medley, John M.] Ctr Coll Danville, Danville, KY 40422 USA.
   [Kaplan, Eugene] Ctr Adv Gynecol Surg, Walnut Creek, CA 94598 USA.
   [Oz, Helieh S.] Univ Kentucky, Med Ctr, Ctr Oral Hlth Res, Lexington, KY 40536 USA.
   [Sundararaj, Sharath C.; Puleo, David A.] Univ Kentucky, Ctr Biomed Engn, Lexington, KY 40506 USA.
RP Dziubla, TD (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM Dziubla@engr.uky.edu
FU National Institute of Dental and Craniofacial Research; National
   Institutes of Health [R03 DE019496]; University of Kentucky Research
   Foundation
FX Contract grant sponsor: National Institute of Dental and Craniofacial
   Research; Contract grant sponsor: National Institutes of Health;
   contract grant number: R03 DE019496; Contract grant sponsor: University
   of Kentucky Research Foundation
CR Ahmed TAE, 2008, TISSUE ENG PT B-REV, V14, P199, DOI 10.1089/ten.teb.2007.0435
   Anderson Joshua C., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000768
   Armstrong PW, 1995, EUR HEART J, V16, P75, DOI 10.1093/eurheartj/16.suppl_L.75
   ARRAJAB A, 1991, J SURG RES, V50, P212, DOI 10.1016/0022-4804(91)90180-T
   Boland GM, 2006, J SURG RES, V132, P3, DOI 10.1016/j.jss.2005.12.002
   Brown JM, 1998, CANCER RES, V58, P1408
   Burns JM, 1995, J SURG RES, V59, P644, DOI 10.1006/jsre.1995.1218
   Burns JW, 1996, FERTIL STERIL, V66, P814, DOI 10.1016/S0015-0282(16)58642-7
   Cooper K, 2007, J SURG RES, V141, P153, DOI 10.1016/j.jss.2006.05.044
   Derex L, 2008, J NEUROL NEUROSUR PS, V79, P1093, DOI 10.1136/jnnp.2007.133371
   DIAMOND MP, 1994, FERTIL STERIL, V62, P984
   Diamond MP, 2001, HUM REPROD UPDATE, V7, P567, DOI 10.1093/humupd/7.6.567
   DVORAK HF, 1990, PROG CLIN BIOL RES, V354, P317
   ELKINS TE, 1987, OBSTET GYNECOL, V70, P225
   ELLIS H, 1971, SURG GYNECOL OBSTETR, V133, P497
   ELLIS H, 2000, PERITONEAL SURG, P297
   Gref R, 2000, COLLOID SURFACE B, V18, P301, DOI 10.1016/S0927-7765(99)00156-3
   Hanson AD, 2007, J BIOMAT SCI-POLYM E, V18, P1387, DOI 10.1163/156856207782246812
   Hellebrekers BWJ, 2000, FERTIL STERIL, V74, P203, DOI 10.1016/S0015-0282(00)00656-7
   Hildebrand HF, 2006, SURF COAT TECH, V200, P6318, DOI 10.1016/j.surfcoat.2005.11.086
   HillWest JL, 1995, J SURG RES, V59, P759, DOI 10.1006/jsre.1995.1236
   Jeon JH, 2007, INT J PHARM, V340, P6, DOI 10.1016/j.ijpharm.2007.03.007
   Karmali PP, 2009, NANOMED-NANOTECHNOL, V5, P73, DOI 10.1016/j.nano.2008.07.007
   Kelekci S, 2004, TOHOKU J EXP MED, V204, P189, DOI 10.1620/tjem.204.189
   Krsko P, 2005, MATER TODAY, V8, P36, DOI 10.1016/S1369-7021(05)71223-2
   LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7
   Leach RE, 1998, FERTIL STERIL, V69, P415, DOI 10.1016/S0015-0282(97)00573-6
   LEGRAND EK, 1994, J SURG RES, V56, P67, DOI 10.1006/jsre.1994.1011
   Matthews BD, 2005, J SURG RES, V123, P227, DOI 10.1016/j.jss.2004.08.012
   Matthews BD, 2003, J SURG RES, V114, P126, DOI 10.1016/S0022-4804(03)00158-6
   Medley JM, 2011, J BIOMAT SCI-POLYM E, V22, P1363, DOI 10.1163/092050610X508419
   Medley JM, 2010, ACTA BIOMATER, V6, P72, DOI 10.1016/j.actbio.2009.07.014
   MONTZ FJ, 1994, FERTIL STERIL, V61, P1136
   Morra M, 2006, J BIOMED MATER RES A, V78A, P449, DOI 10.1002/jbm.a.30783
   Muller SA, 2005, EUR J OBSTET GYN R B, V120, P222, DOI 10.1016/j.ejorgb.2004.09.011
   Park JH, 2009, SMALL, V5, P694, DOI 10.1002/smll.200801789
   Rathore AS, 2009, TRENDS BIOTECHNOL, V27, P546, DOI 10.1016/j.tibtech.2009.06.006
   Riedel T, 2009, J BIOMED MATER RES A, V88A, P437, DOI 10.1002/jbm.a.31755
   RISBERG B, 1997, EUR J SURG S, V577, P32
   Simberg D, 2007, P NATL ACAD SCI USA, V104, P932, DOI 10.1073/pnas.0610298104
   Topal E, 2010, ACTA CHIR BELG, V110, P71
   WISEMAN DM, 1993, FERTIL STERIL S, pS25
   Zanuy D, 2009, J PHYS CHEM B, V113, P7879, DOI 10.1021/jp9006119
NR 43
TC 1
Z9 1
U1 1
U2 9
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1552-4973
J9 J BIOMED MATER RES B
JI J. Biomed. Mater. Res. Part B
PD OCT
PY 2011
VL 99B
IS 1
BP 102
EP 110
DI 10.1002/jbm.b.31876
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 820NJ
UT WOS:000294912400012
PM 21695779
OA green_accepted
DA 2018-03-20
ER

PT J
AU Meeks, ND
   Rankin, S
   Bhattacharyya, D
AF Meeks, Noah D.
   Rankin, Stephen E.
   Bhattacharyya, Dibakar
TI Sulfur-Functionalization of Porous Silica Particles and Application to
   Mercury Vapor Sorption
SO INDUSTRIAL & ENGINEERING CHEMISTRY RESEARCH
LA English
DT Article
ID MESOPOROUS SILICA; SURFACE MODIFICATION; SILYLATION; STABILITY; REMOVAL;
   THIOL; CHROMATOGRAPHY; ENHANCEMENT; SELECTIVITY; SORBENT
AB Silanol (SiOH) groups on silica particle surfaces undergo silylation reactions with organosilane molecules to give functionalized particles, which are used in many applications. The determination of the extent of this reaction is important for proper design of functionalized materials, depending upon the application. Two types of porous silica particles (206 and 484 m(2) g(-1); 9.6 and 2.9 nm average pore diameter, respectively), and colloidal silica (Ludox) with a nonporous base particle of 22 nm diameter, were functionalized with sulfur-containing silanes, 3-mercaptopropyl trimethoxy silane (MPTMS), and bis[3-(triethoxysilyl) propyl]-tetrasulfide (S4). Maximum extent of functionalization was determined with S4 using Fourier transform infrared spectrometry (FTIR), thermogravimetric analysis (TGA), and total S analysis. For the two types of porous silica particles, FTIR indicated that 54 and 17% of the silanol groups were functionalized with S4, and TGA indicated that the functionalized particles were 12 and 11 mass % MPTMS, respectively. These results were independently confirmed with total sulfur analysis. Extents of functionalization were determined for varying the silane structure on the same silica particle. MPTMS reacted with 38% of functional groups, while S4 reacted with 17%; the mass % of si lane is the same regardless of silane structure on the same silica particle. Characterization by DSC indicated a glass transition occurs in the silane layer of the S4-functionalized silica at about 85 degrees C, but not in the MPTMS functionalized particles. Finally, mercury sorption breakthrough curves indicate the pore characteristics of the S4 functionalized samples.
C1 [Meeks, Noah D.; Rankin, Stephen; Bhattacharyya, Dibakar] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Bhattacharyya, D (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 Anderson Hall, Lexington, KY 40506 USA.
EM db@engr.uky.edu
OI Rankin, Stephen/0000-0002-8615-7564
FU J. M. Huber Corporation; NIEHS-SRP [P42ES007380]
FX This work was funded by J. M. Huber Corporation (Havre de Grace, MD).
   Part of the silica functionalization work was also supported by the
   NIEHS-SRP (P42ES007380) program. The authors acknowledge the analytical
   assistance of Tricia Coakley at UK Environmental Research and Training
   Laboratories (ERTL), and Prof. John Selegue at UK Department of
   Chemistry. The mercury detector was provided by the U.S. Environmental
   Protection Agency.
CR Abu-Daabes MA, 2005, CHEM ENG SCI, V60, P1901, DOI 10.1016/j.ces.2004.11.028
   BOCCUZZI F, 1978, J PHYS CHEM-US, V82, P1298, DOI 10.1021/j100500a020
   BOGART GR, 1994, J COLLOID INTERF SCI, V167, P27, DOI 10.1006/jcis.1994.1330
   CESTARI AR, 1995, J THERM ANAL, V44, P79, DOI 10.1007/BF02547136
   Deng G, 2000, MAT SCI ENG C-BIO S, V11, P165, DOI 10.1016/S0928-4931(00)00203-4
   Etienne M, 2003, TALANTA, V59, P1173, DOI 10.1016/S0039-9140(03)00024-9
   Feng X, 1997, SCIENCE, V276, P923, DOI 10.1126/science.276.5314.923
   GALLI B, 1987, J CHROMATOGR, V409, P377, DOI 10.1016/S0021-9673(01)86816-3
   Han DM, 2005, J CHROMATOGR A, V1100, P131, DOI 10.1016/j.chroma.2005.09.035
   HOHNE GWH, 2003, DIFFERENTIAL SCANNIN, V1, P298
   Hutson ND, 2007, ENVIRON SCI TECHNOL, V41, P1747, DOI 10.1021/es062121q
   Iiskola EI, 1997, APPL SURF SCI, V121, P372, DOI 10.1016/S0169-4332(97)00335-8
   Iler R.K, 1979, CHEM SILICA
   Impens NREN, 1999, MICROPOR MESOPOR MAT, V28, P217, DOI 10.1016/S1387-1811(98)00239-X
   KIM S, 1993, J COLLOID INTERF SCI, V161, P6, DOI 10.1006/jcis.1993.1433
   Lazghab M, 2008, AICHE J, V54, P897, DOI 10.1002/aic.11436
   Lee JY, 2006, ENVIRON SCI TECHNOL, V40, P2714, DOI 10.1021/es051951l
   Liu YH, 2004, LANGMUIR, V20, P3231, DOI 10.1021/la0358421
   Ma YR, 2003, COLLOID SURFACE A, V229, P1, DOI 10.1016/j.colsurfa.2003.08.010
   Mahmoud ME, 2004, ANAL CHIM ACTA, V525, P123, DOI 10.1016/j.aca.2004.06.032
   Makkuni A., 2005, Clean Technologies and Environmental Policy, V7, P87, DOI 10.1007/s10098-004-0260-0
   Makkuni A, 2007, IND ENG CHEM RES, V46, P1305, DOI 10.1021/ie060713b
   Mercier L, 1998, ENVIRON SCI TECHNOL, V32, P2749, DOI 10.1021/es970622t
   Meyer DE, 2008, ENERG FUEL, V22, P2290, DOI 10.1021/ef8001873
   Meyer DE, 2007, ENERG FUEL, V21, P2688, DOI 10.1021/ef070120t
   Nooney RI, 2001, LANGMUIR, V17, P528, DOI 10.1021/la000720j
   Park DH, 2001, IND ENG CHEM RES, V40, P6105, DOI 10.1021/ie0103761
   Pitoniak E, 2005, ENVIRON SCI TECHNOL, V39, P1269, DOI 10.1021/es049202b
   Revillon A, 1995, REACT FUNCT POLYM, V26, P105, DOI 10.1016/1381-5148(95)00009-5
   RUBINSZTAJN S, 1989, J ORGANOMET CHEM, V367, P27, DOI 10.1016/0022-328X(89)87202-X
   SING KSW, 1985, PURE APPL CHEM, V57, P603, DOI 10.1351/pac198557040603
   SRIVASTAVA RK, 2006, ENV SCI TECHNOL
   Sutra P, 1999, COLLOID SURFACE A, V158, P21, DOI 10.1016/S0927-7757(99)00126-0
   Switaj-Zawadka A, 2004, J CHROMATOGR A, V1033, P145, DOI 10.1016/j.chroma.2004.01.025
   Walcarius A, 2005, ANAL CHIM ACTA, V547, P3, DOI 10.1016/j.aca.2004.11.047
   Yang LM, 2005, MICROPOR MESOPOR MAT, V84, P275, DOI 10.1016/j.micromeso.2005.05.037
NR 36
TC 14
Z9 15
U1 3
U2 20
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0888-5885
J9 IND ENG CHEM RES
JI Ind. Eng. Chem. Res.
PD MAY 19
PY 2010
VL 49
IS 10
BP 4687
EP 4693
DI 10.1021/ie901580k
PG 7
WC Engineering, Chemical
SC Engineering
GA 593HH
UT WOS:000277443100025
DA 2018-03-19
ER

PT J
AU Ren, WJ
   Bradley, KD
   Lumpp, JK
AF Ren, Weijia
   Bradley, Kelly D.
   Lumpp, Janet K.
TI Applying the Rasch Model to Evaluate an Implementation of the Kentucky
   Electronics Education Project
SO JOURNAL OF SCIENCE EDUCATION AND TECHNOLOGY
LA English
DT Article
DE Rasch model; Science education; Engineering; Circuit building; Program
   evaluation
AB Kentucky Electronics Education Project (KEEP) uses microelectronics to connect real world content to K-12 science education. KEEP trains teachers in a series of circuit building activities through summer workshops and in-service professional development. Teachers are expected to implement components of their training into their curriculum, and then participating students are asked to evaluate their experience. Here, survey responses of 61 Midwest high school students, who completed a circuit building activity in the classroom setting, are analyzed using a Rasch rating scale model. Insights are provided regarding the inquiry based, hands-on engineering activity, while introducing a tool for program evaluation. Results characterize students' perceptions regarding difficulty of the project and potential misunderstandings. Suggestions for project enhancement, based on empirical evidence and practical experience, are described.
C1 [Ren, Weijia; Bradley, Kelly D.; Lumpp, Janet K.] Univ Kentucky, Lexington, KY 40506 USA.
RP Bradley, KD (reprint author), Univ Kentucky, Lexington, KY 40506 USA.
EM kdbrad2@uky.edu
CR Cantrell P., 2002, B SCI TECHNOL SOC, V22, P31
   Fleischman H., 1996, INTRO PROGRAM EVALUA
   JASCHIK S, 2005, LOST DOMINANCE PHD P
   LUMPP JK, 2003, P EL COMP TECH C NEW
   LUMPP JK, 2006, AM SOC ENG ED ANN C
   RUDNER LM, 2001, ITEM RESPONSE THEORY
   Rutherford F., 1990, SCI ALL AM
   SHAW F, 2006, FITS ABOUT MISFIT
   *USDOE, 2000, ITS TOO LAT REP NAT
   Waxman H. C., 2002, QUANTITATIVE SYNTHES
   *WINST HELP, 2007, LOG PROB WHAT AR THE
   Wright BD, 1982, RATING SCALE ANAL RA
NR 12
TC 4
Z9 4
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1059-0145
J9 J SCI EDUC TECHNOL
JI J. Sci. Educ. Technol.
PD DEC
PY 2008
VL 17
IS 6
BP 618
EP 625
DI 10.1007/s10956-008-9132-4
PG 8
WC Education & Educational Research; Education, Scientific Disciplines
SC Education & Educational Research
GA 498KT
UT WOS:000270139600010
DA 2018-03-20
ER

PT J
AU Slusarewicz, P
   Pagano, S
   Mills, C
   Popa, G
   Chow, KM
   Mendenhall, M
   Rodgers, DW
   Nielsen, MK
AF Slusarewicz, Paul
   Pagano, Stefanie
   Mills, Christopher
   Popa, Gabriel
   Chow, K. Martin
   Mendenhall, Michael
   Rodgers, David W.
   Nielsen, Martin K.
TI Automated parasite faecal egg counting using fluorescence labelling,
   smartphone image capture and computational image analysis
SO INTERNATIONAL JOURNAL FOR PARASITOLOGY
LA English
DT Article
DE Egg count; Chitin; Fluorescence; Smartphone; Image analysis; Strongyle;
   Ascarid; Equine
ID SOIL-TRANSMITTED HELMINTHS; FIELD-OF-VIEW; ANTHELMINTIC RESISTANCE;
   MINI-FLOTAC; DIAGNOSIS; MICROSCOPY; MCMASTER; RUMINANTS; EGGSHELL; SHEEP
AB Intestinal parasites are a concern in veterinary medicine worldwide and for human health in the developing world. Infections are identified by microscopic visualisation of parasite eggs in faeces, which is time-consuming, requires technical expertise and is impractical for use on-site. For these reasons, recommendations for parasite surveillance are not widely adopted and parasite control is based on administration of rote prophylactic treatments with anthelmintic drugs. This approach is known to promote anthelmintic resistance, so there is a pronounced need for a convenient egg counting assay to promote good clinical practice. Using a fluorescent chitin-binding protein, we show that this structural carbohydrate is present and accessible in shells of ova of strongyle, ascarid, trichurid and coccidian parasites. Furthermore, we show that a cellular smartphone can be used as an inexpensive device to image fluorescent eggs and, by harnessing the computational power of the phone, to perform image analysis to count the eggs. Strongyle egg counts generated by the smartphone system had a significant linear correlation with manual McMaster counts (R-2 = 0.98), but with a significantly lower coefficient of variation (P = 0.0177). Furthermore, the system was capable of differentiating equine strongyle and ascarid eggs similar to the McMaster method, but with significantly lower coefficients of variation (P < 0.0001). This demonstrates the feasibility of a simple, automated on-site test to detect and/or enumerate parasite eggs in mammalian faeces without the need for a laboratory microscope, and highlights the potential of smart phones as relatively sophisticated, inexpensive and portable medical diagnostic devices. (C) 2016 Australian Society for Parasitology. Published by Elsevier Ltd. All rights reserved.
C1 [Slusarewicz, Paul; Pagano, Stefanie; Mills, Christopher] MEP Equine Solut, 3905 English Oak Circle, Lexington, KY 40514 USA.
   [Slusarewicz, Paul; Pagano, Stefanie; Mills, Christopher; Nielsen, Martin K.] Univ Kentucky, Dept Vet Sci, MH Gluck Equine Res Ctr, Lexington, KY USA.
   [Popa, Gabriel; Chow, K. Martin; Mendenhall, Michael; Rodgers, David W.] Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY USA.
RP Slusarewicz, P (reprint author), MEP Equine Solut, 3905 English Oak Circle, Lexington, KY 40514 USA.
EM pslusarewicz@mepequinesolutions.com
RI Emchi, Karma/Q-1952-2016
FU Small Business Innovation Research grant from the United States
   Department of Agriculture, USA [2015-33610-23497]; MEP Equine Solutions,
   LLC, USA; UK COBRE Center for Molecular Medicine Protein and Molecular
   Technologies cores; National Institutes of Health, USA [P20GM110787];
   National Science Foundation, USA [IIA-1355438]
FX This work was partially funded by an Small Business Innovation Research
   grant from the United States Department of Agriculture, USA
   (#2015-33610-23497; P.S.) and by grants from MEP Equine Solutions, LLC,
   USA, (M.K.N.). CBD protein production was supported in part by the UK
   COBRE Center for Molecular Medicine Protein and Molecular Technologies
   cores (which are supported in part by National Institutes of Health,
   USA, Grant Number P20GM110787; G.P., K.M.C., M.M., and D.W.R. and
   National Science Foundation, USA, Grant IIA-1355438; D.W.R). We thank
   Eric Hauck, David Ward, Ellie Hawes and Winston Walker for their
   assistance in designing and building the imaging units, and Richard Chan
   for his suggestion of using a cell phone and the Sapphire PrepOne for
   imaging eggs in McMaster chambers.
CR Alum A, 2010, INT J INFECT DIS, V14, pE732, DOI 10.1016/j.ijid.2009.11.036
   Barda B, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-271
   Barda BD, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002344
   BIRD AF, 1976, PARASITOLOGY, V72, P19, DOI 10.1017/S0031182000043158
   Bogoch II, 2016, AM J TROP MED HYG, V94, P158, DOI 10.4269/ajtmh.15-0525
   Bogoch II, 2013, AM J TROP MED HYG, V88, P626, DOI 10.4269/ajtmh.12-0742
   Burgwyn B, 2003, EXP PARASITOL, V104, P47, DOI 10.1016/S0014-4894(03)00118-8
   Castanon CAB, 2007, PATTERN RECOGN, V40, P1899, DOI 10.1016/j.patcog.2006.12.006
   Cezar AS, 2010, VET PARASITOL, V173, P157, DOI 10.1016/j.vetpar.2010.06.013
   Cooke IR, 2015, J MICROSC-OXFORD, V257, P133, DOI 10.1111/jmi.12192
   Cringoli G, 2004, VET PARASITOL, V123, P121, DOI 10.1016/j.vetpar.2004.05.021
   Cringoli G, 2010, NAT PROTOC, V5, P503, DOI 10.1038/nprot.2009.235
   da Cruz DG, 2010, VET PARASITOL, V170, P340, DOI 10.1016/j.vetpar.2010.02.030
   Dogantekin E, 2008, EXPERT SYST APPL, V35, P728, DOI 10.1016/j.eswa.2007.07.020
   Ephraim RKD, 2015, AM J TROP MED HYG, V92, P1253, DOI 10.4269/ajtmh.14-0741
   Ghazali K. H., 2013, Modern Applied Science, V7, P98
   Gordon H. M., 1939, J COUNC SCI IND RES, V12, P52
   Howell SB, 2008, JAVMA-J AM VET MED A, V233, P1913, DOI 10.2460/javma.233.12.1913
   Kaplan RM, 2004, TRENDS PARASITOL, V20, P477, DOI 10.1016/j.pt.2004.08.001
   Kenyon F, 2009, VET PARASITOL, V164, P3, DOI 10.1016/j.vetpar.2009.04.015
   Leathwick DM, 2014, VET PARASITOL, V204, P44, DOI 10.1016/j.vetpar.2013.12.022
   Levecke B, 2012, VET PARASITOL, V188, P194, DOI 10.1016/j.vetpar.2012.03.017
   Linder E, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002547
   Mes THM, 2007, NAT PROTOC, V2, P486, DOI 10.1038/nprot.2007.56
   Nielsen MK, 2014, VET PARASITOL, V202, P95, DOI 10.1016/j.vetpar.2014.03.020
   Olson SK, 2012, J CELL BIOL, V198, P731, DOI 10.1083/jcb.201206008
   Peregrine AS, 2014, VET PARASITOL, V201, P1, DOI 10.1016/j.vetpar.2014.01.004
   PERRY R N, 1986, Revue de Nematologie, V9, P399
   Quiles F, 2006, ANAL BIOANAL CHEM, V386, P249, DOI 10.1007/s00216-006-0638-4
   Robert M, 2015, EQUINE VET J, V47, P694, DOI 10.1111/evj.12344
   Roepstorff A., 1998, FAO ANIMAL HLTH MANU
   Sowerby SJ, 2016, AM J TROP MED HYG, V94, P227, DOI 10.4269/ajtmh.15-0427
   STOLL NORMAN R., 1930, PARASITOLOGY, V22, P116
   Suzuki CTN, 2013, IEEE T BIO-MED ENG, V60, P803, DOI 10.1109/TBME.2012.2187204
   Vadlejch J, 2011, PARASITOL RES, V109, P1387, DOI 10.1007/s00436-011-2385-5
   Vercruysse J, 2012, CURR OPIN INFECT DIS, V25, P703, DOI 10.1097/QCO.0b013e328358993a
   Vercruysse J, 2011, INT J PARASITOL-DRUG, V1, P14, DOI 10.1016/j.ijpddr.2011.09.002
   WHARTON DA, 1983, PARASITOLOGY, V86, P85, DOI 10.1017/S003118200005085X
   World Health Organization, 2006, PREV CHEM HUM HELM C
   WOOD IB, 1995, VET PARASITOL, V58, P181, DOI 10.1016/0304-4017(95)00806-2
   Yang YS, 2001, IEEE T BIO-MED ENG, V48, P718, DOI 10.1109/10.923789
   Zhang YH, 2005, DEV BIOL, V285, P330, DOI 10.1016/j.ydbio.2005.06.037
   Zhu HY, 2013, LAB CHIP, V13, P51, DOI [10.1039/c2lc40864c, 10.1039/c21c40864c]
NR 43
TC 3
Z9 3
U1 2
U2 23
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0020-7519
EI 1879-0135
J9 INT J PARASITOL
JI Int. J. Parasit.
PD JUL
PY 2016
VL 46
IS 8
BP 485
EP 493
DI 10.1016/j.ijpara.2016.02.004
PG 9
WC Parasitology
SC Parasitology
GA DR7HB
UT WOS:000380069500004
PM 27025771
DA 2018-03-20
ER

PT J
AU Ambati, J
   Song, Y
   Rankin, SE
   Lehmler, HJ
AF Ambati, Jyothirmai
   Song, Yang
   Rankin, Stephen E.
   Lehmler, Hans-Joachim
TI Density Functional Theory Study of Semiquinone Radical Anions of
   Polychlorinated Biphenyls in the Syn- and Anti-like Conformation
SO JOURNAL OF PHYSICAL CHEMISTRY A
LA English
DT Article
ID TOPOISOMERASE-II-ALPHA; P-BENZOQUINONE; ELECTRONIC-STRUCTURE;
   VIBRATIONAL-SPECTRA; QUINONE METABOLITES; PCB METABOLITES; BINDING;
   REDOX; HYDROQUINONE; PARAMETERS
AB Polychlorinated biphenyls (PCBs) can be metabolized to reactive metabolites, such as PCB semiquinone radical anions (SQ(center dot-)), whose structure and role in PCB-induced toxicity are difficult to investigate due to their relative instability. The unrestricted LTB3LYP/6-311G** method was used to investigate several molecular descriptors of the syn- and anti-like conformation of SQs(center dot-). The bond lengths and angles of the quinone moiety of the SQs(center dot-) were in between the values reported for PCB quinones and hydroquinones, which is consistent with the distribution of the a highest occupied molecular orbital (alpha-HOMO). The dihedral angles between the two ring systems increased in the presence of ortho chlorine substituents and were smaller compared to the corresponding PCB quinones. The ground-state energies indicate that the anti-like conformation of the SQs(center dot-) is more favorable than the syn-like conformation. Molecular descriptor used for modeling of quantitative structure-activity relationships displayed some dependence on the conformation. These findings suggest that SOs center dot- in both the syn- and antilike conformation may interact differently writh target molecules, which may have implications for the toxicity of PCBs.
C1 [Ambati, Jyothirmai; Rankin, Stephen E.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Song, Yang] Southwest Univ, Coll Pharmaceut Sci, Chongqing 400716, Peoples R China.
   [Song, Yang; Lehmler, Hans-Joachim] Univ Iowa, Dept Occupat & Environm Hlth, Iowa City, IA 52242 USA.
   [Lehmler, Hans-Joachim] Univ Iowa, Interdisciplinary Grad Program Human Toxicol, Iowa City, IA 52242 USA.
RP Rankin, SE (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 FP Anderson Tower, Lexington, KY 40506 USA.
EM srankin@engr.uky.edu; hans-joachim-lehmler@uiowa.edu
RI Rankin, Stephen/A-3265-2013
OI Rankin, Stephen/0000-0002-8615-7564; Ambati,
   Jyothirmai/0000-0003-2420-3665; Lehmler,
   Hans-Joachim/0000-0001-9163-927X
FU National Institute of Environmental Health Sciences [ES0560S, ES013661,
   ES017425]
FX We acknowledge the High Performance Computing Center at University of
   Kentucky for using the facility for the Gaussian calculations. This
   research was supported by grants ES0560S, ES013661, and ES017425 from
   the National Institute of Environmental Health Sciences (H.J.L.).
CR Allouche AR, 2011, J COMPUT CHEM, V32, P174, DOI 10.1002/jcc.21600
   Amaro AR, 1996, CHEM RES TOXICOL, V9, P623, DOI 10.1021/tx950117e
   Arbuznikov AV, 2011, INT J QUANTUM CHEM, V111, P2625, DOI 10.1002/qua.22721
   Arif JM, 2003, CHEM-BIOL INTERACT, V142, P307, DOI 10.1016/S0009-2797(02)00141-2
   Arulmozhiraja S, 2002, J PHYS CHEM A, V106, P10590, DOI [10.1021/jp021014p, 10.1021/ip021014p]
   Arulmozhiraja S, 2002, J PHYS CHEM A, V106, P1765, DOI 10.1021/jp013558h
   Bender RP, 2007, BIOCHEMISTRY-US, V46, P2856, DOI 10.1021/bi062017l
   Bender RP, 2006, BIOCHEMISTRY-US, V45, P10140, DOI 10.1021/bi0524666
   Boesch SE, 1997, J PHYS CHEM A, V101, P5799, DOI 10.1021/jp9705840
   Boesch SE, 1997, J PHYS CHEM A, V101, P8351, DOI 10.1021/jp9719974
   Cao H, 2003, BIOORG MED CHEM LETT, V13, P1869, DOI 10.1016/S0960-894X(03)00283-X
   Cape JL, 2006, PHYTOCHEMISTRY, V67, P1781, DOI 10.1016/j.phytochem.2006.06.015
   CHIPMAN DM, 1986, J PHYS CHEM-US, V90, P5557, DOI 10.1021/j100280a015
   Espandiari P, 2004, TOXICOL SCI, V79, P41, DOI 10.1093/toxsci/kfh097
   Fehir RJ, 2009, J PHYS CHEM A, V113, P9249, DOI 10.1021/jp905314h
   Frisch M. J., 2009, GAUSSIAN 09 REVISION
   Frontana C, 2006, J PHYS CHEM A, V110, P9411, DOI 10.1021/jp060836+
   Gu CG, 2007, CHEMOSPHERE, V67, P1325, DOI 10.1016/j.chemosphere.2006.10.057
   Hansen L. G., 1999, ORTHO SIDE PCBS OCCU
   Hornbuckle KC, 2006, HANDB ENVIRON CHEM, V5, P13, DOI 10.1007/698_5_039
   Hu DF, 2010, ENVIRON SCI TECHNOL, V44, P2822, DOI 10.1021/es902413k
   James Margaret O., 2001, P35
   Karelson M, 1996, CHEM REV, V96, P1027, DOI 10.1021/cr950202r
   Kaupp M, 2011, PHYS CHEM CHEM PHYS, V13, P16973, DOI 10.1039/c1cp21772k
   Kundu T, 2011, INORG CHEM, V50, P4753, DOI 10.1021/ic102280q
   Lehmer HJ, 2002, CHEMOSPHERE, V46, P485, DOI 10.1016/S0045-6535(01)00177-1
   Letcher RJ, 2000, HANDB ENVIRON CHEM, V3, P315
   Liu Y, 2006, CHEM RES TOXICOL, V19, P1420, DOI 10.1021/tx060160+
   Machala M, 2004, CHEM RES TOXICOL, V17, P340, DOI 10.1021/tx030034v
   MacMillan F, 1995, MAGN RESON CHEM, V33, pS81, DOI 10.1002/mrc.1260331314
   Mariam YH, 1998, J MOL STRUC-THEOCHEM, V454, P237, DOI 10.1016/S0166-1280(98)00294-2
   MCKINNEY JD, 1985, QUANT STRUCT-ACT REL, V4, P166, DOI 10.1002/qsar.19850040405
   McLean MR, 1996, CHEM RES TOXICOL, V9, P158, DOI 10.1021/tx950083a
   McLean MR, 2000, ARCH BIOCHEM BIOPHYS, V376, P449, DOI 10.1006/abbi.2000.1754
   Mekenyan OG, 1996, ENVIRON HEALTH PERSP, V104, P1302, DOI 10.2307/3432966
   Michaelis L, 1935, CHEM REV, V16, P243, DOI 10.1021/cr60054a004
   Mohandas P, 1997, J PHYS CHEM A, V101, P4449, DOI 10.1021/jp9701597
   Nonella M, 1997, J PHYS CHEM B, V101, P1235, DOI 10.1021/jp9626071
   Novak I, 2008, J PHYS CHEM A, V112, P3061, DOI 10.1021/jp711661t
   OMalley PJ, 1996, CHEM PHYS LETT, V259, P296, DOI 10.1016/0009-2614(96)00744-0
   Oostenbrink C, 2004, PROTEINS, V54, P237, DOI 10.1002/prot.10558
   Pan DH, 2000, CHEM PHYS LETT, V316, P395, DOI 10.1016/S0009-2614(99)01359-7
   Pan DH, 2000, CHEM PHYS LETT, V318, P214, DOI 10.1016/S0009-2614(00)00025-7
   Renz M, 2009, J AM CHEM SOC, V131, P16292, DOI 10.1021/ja9070859
   Robertson LW, 2001, RECENT ADV ENV TOXIC
   Song Y, 2008, CHEM RES TOXICOL, V21, P1359, DOI 10.1021/tx8000175
   Song Y, 2011, CHEMOSPHERE, V85, P386, DOI 10.1016/j.chemosphere.2011.07.004
   Song Y, 2009, P NATL ACAD SCI USA, V106, P9725, DOI 10.1073/pnas.0810352106
   Song Y, 2008, J ORG CHEM, V73, P8296, DOI 10.1021/jo801397g
   Song YZ, 2005, BIOORGAN MED CHEM, V13, P5658, DOI 10.1016/j.bmc.2005.05.029
   Srinivasan A, 2002, CHEM RES TOXICOL, V15, P497, DOI 10.1021/tx010128+
   Srinivasan P, 2008, SPECTROCHIM ACTA A, V71, P592, DOI 10.1016/j.saa.2007.12.044
   Tampal N, 2002, CHEM RES TOXICOL, V15, P1259, DOI 10.1021/tx0200212
   Thanthiriwatte KS, 2002, J MOL STRUC-THEOCHEM, V617, P169, DOI 10.1016/S0166-1280(02)00419-0
   Thompson M., ARGUSLAB 4 0 1
   Venkatesha VA, 2008, FREE RADICAL BIO MED, V45, P1094, DOI 10.1016/j.freeradbiomed.2008.07.007
   Verma P, 2011, INORG CHEM, V50, P9816, DOI 10.1021/ic200958g
   Wang YN, 2001, THEOR CHEM ACC, V106, P158, DOI 10.1007/s002140000208
   Wheeler DE, 1999, J PHYS CHEM A, V103, P4101, DOI 10.1021/jp990166q
   Witwicki M, 2008, CHEM PHYS LETT, V462, P300, DOI 10.1016/j.cplett.2008.07.086
   Witwicki M, 2011, J PHYS CHEM B, V115, P3172, DOI 10.1021/jp110515j
   Witwicki M, 2010, CHEM PHYS LETT, V493, P364, DOI 10.1016/j.cplett.2010.05.063
   Witwicki M, 2009, CHEM PHYS LETT, V473, P160, DOI 10.1016/j.cplett.2009.03.035
NR 63
TC 0
Z9 0
U1 0
U2 11
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1089-5639
J9 J PHYS CHEM A
JI J. Phys. Chem. A
PD FEB 16
PY 2012
VL 116
IS 6
BP 1586
EP 1595
DI 10.1021/jp2077193
PG 10
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA 892HQ
UT WOS:000300277700012
PM 22257259
OA green_accepted
DA 2018-03-20
ER

PT J
AU Avery, MA
   Rooney, TM
   Pandya, JD
   Wishart, TM
   Gillingwater, TH
   Geddes, JW
   Sullivan, PG
   Freeman, MR
AF Avery, Michelle A.
   Rooney, Timothy M.
   Pandya, Jignesh D.
   Wishart, Thomas M.
   Gillingwater, Thomas H.
   Geddes, James W.
   Sullivan, Patrick G.
   Freeman, Marc R.
TI Wld(S) Prevents Axon Degeneration through Increased Mitochondrial Flux
   and Enhanced Mitochondrial Ca2+ Buffering
SO CURRENT BIOLOGY
LA English
DT Article
ID SLOW WALLERIAN DEGENERATION; TRAUMATIC BRAIN-INJURY; PERMEABILITY
   TRANSITION; PERIPHERAL-NERVE; C57BL/OLA MICE; MECHANISMS; TRANSPORT;
   NEURITES; MOTILITY
AB Wld(S) (slow Wallerian degeneration) is a remarkable protein that can suppress Wallerian degeneration of axons and synapses [1], but how it exerts this effect remains unclear [2]. Here, using Drosophila and mouse models, we identify mitochondria as a key site of action for Wd(S) neuroprotective function. Targeting the NAD(+) biosynthetic enzyme Nmnat to mitochondria was sufficient to fully phenocopy Wld(S), and Wld(S) was specifically localized to mitochondria in synaptic preparations from mouse brain. Axotomy of live wild-type axons induced a dramatic spike in axoplasmic Ca2+ and termination of mitochondrial movement-Wld(S) potently suppressed both of these events. Surprisingly, Wld(S) also promoted increased basal mitochondrial motility in axons before injury, and genetically suppressing mitochondrial motility in vivo dramatically reduced the protective effect of Wld(S). Intriguingly, purified mitochondria from Wld(S) mice exhibited enhanced Ca2+ buffering capacity. We propose that the enhanced Ca2+ buffering capacity of Wld(S+) mitochondria leads to increased mitochondrial motility, suppression of axotomy-induced Ca2+ elevation in axons, and thereby suppression of Wallerian degeneration.
C1 [Avery, Michelle A.; Rooney, Timothy M.; Freeman, Marc R.] Univ Massachusetts, Sch Med, Dept Neurobiol, Worcester, MA 01605 USA.
   [Avery, Michelle A.; Rooney, Timothy M.; Freeman, Marc R.] Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Worcester, MA 01605 USA.
   [Wishart, Thomas M.; Gillingwater, Thomas H.] Univ Edinburgh, Euan MacDonald Ctr Motor Neurone Dis Res, Edinburgh EH8 9XD, Midlothian, Scotland.
   [Wishart, Thomas M.; Gillingwater, Thomas H.] Univ Edinburgh, Ctr Integrat Physiol, Edinburgh EH8 9XD, Midlothian, Scotland.
   [Pandya, Jignesh D.; Geddes, James W.; Sullivan, Patrick G.] Univ Kentucky, Dept Anat & Neurobiol, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA.
RP Freeman, MR (reprint author), Univ Massachusetts, Sch Med, Dept Neurobiol, Worcester, MA 01605 USA.
EM marc.freeman@umassmed.edu
OI Gillingwater, Thomas/0000-0002-0306-5577
FU NIH [NS062993, NS059991]; Wellcome Trust; Department of Defense
   [BC093796]
FX All animal procedures were carried out in accordance with National
   Institutes of Health (NIH) guidelines and the Institutional Animal Care
   and Use Committee regulations of the University of Kentucky and the
   University of Edinburgh. This work was supported by NIH grant NS062993
   (J.W.G. and P.G.S.), the Wellcome Trust (T.H.G. and M.R.F.), and NIH
   grant NS059991 (to M.R.F.). M.R.F. is an Early Career Scientist with the
   Howard Hughes Medical Institute. T.M.R. was supported by a grant from
   the Department of Defense (BC093796). We thank Vimala Bondada and
   Dingyuan Lou for preliminary work on the mitochondrial Ca<SUP>2+</SUP>
   dynamics and all members of the laboratories for helpful discussions.
CR Avery MA, 2009, J CELL BIOL, V184, P501, DOI 10.1083/jcb.200808042
   Barrientos SA, 2011, J NEUROSCI, V31, P966, DOI 10.1523/JNEUROSCI.4065-10.2011
   Brown MR, 2004, J NEUROSCI METH, V137, P299, DOI 10.1016/j.jneumeth.2004.02.028
   Chang DTW, 2006, NEUROBIOL DIS, V22, P388, DOI 10.1016/j.nbd.2005.12.007
   Coleman MP, 2010, ANNU REV NEUROSCI, V33, P245, DOI 10.1146/annurev-neuro-060909-153248
   Conforti L, 2000, P NATL ACAD SCI USA, V97, P11377, DOI 10.1073/pnas.97.21.11377
   De Vos KJ, 2007, HUM MOL GENET, V16, P2720, DOI 10.1093/hmg/ddm226
   Ganitkevich VY, 2003, EXP PHYSIOL, V88, P91, DOI 10.1113/eph8802504
   GEORGE EB, 1995, J NEUROSCI, V15, P6445
   Gillingwater TH, 2006, BRAIN, V129, P1546, DOI 10.1093/brain/awl101
   GLASS JD, 1993, J NEUROCYTOL, V22, P311, DOI 10.1007/BF01195555
   Ikegami K, 2003, NEUROSCIENCE, V122, P617, DOI 10.1016/j.neuroscience.2003.08.057
   Knoferle J, 2010, P NATL ACAD SCI USA, V107, P6064, DOI 10.1073/pnas.0909794107
   LUNN ER, 1989, EUR J NEUROSCI, V1, P27, DOI 10.1111/j.1460-9568.1989.tb00771.x
   Mack TGA, 2001, NAT NEUROSCI, V4, P1199, DOI 10.1038/nn770
   Naga KK, 2007, J NEUROSCI, V27, P7469, DOI 10.1523/JNEUROSCI.0646-07.2007
   Pandya JD, 2007, J NEUROTRAUM, V24, P798, DOI 10.1089/neu.2006.3673
   Pandya JD, 2009, EXP NEUROL, V218, P381, DOI 10.1016/j.expneurol.2009.05.023
   PERRY VH, 1990, EUR J NEUROSCI, V2, P802, DOI 10.1111/j.1460-9568.1990.tb00472.x
   Russo GJ, 2009, J NEUROSCI, V29, P5443, DOI 10.1523/JNEUROSCI.5417-08.2009
   Santo-Domingo J, 2010, BBA-BIOENERGETICS, V1797, P907, DOI 10.1016/j.bbabio.2010.01.005
   Sasaki Y, 2010, J BIOL CHEM, V285, P41211, DOI 10.1074/jbc.C110.193904
   Schon EA, 2011, NEURON, V70, P1033, DOI 10.1016/j.neuron.2011.06.003
   Shi P, 2010, BBA-MOL BASIS DIS, V1802, P707, DOI 10.1016/j.bbadis.2010.05.008
   Sievers C, 2003, NEUROSCI RES, V46, P161, DOI 10.1016/S0168-0102(03)00039-7
   Sunio A, 1997, EXP NEUROL, V146, P46, DOI 10.1006/exnr.1997.6484
   Wang XL, 2009, J NEUROCHEM, V109, P153, DOI 10.1111/j.1471-4159.2009.05867.x
   Wang XN, 2009, CELL, V136, P163, DOI 10.1016/j.cell.2008.11.046
   Yahata N, 2009, J NEUROSCI, V29, P6276, DOI 10.1523/JNEUROSCI.4304-08.2009
   Yi MQ, 2004, J CELL BIOL, V167, P661, DOI 10.1083/jcb.200406038
NR 30
TC 71
Z9 71
U1 0
U2 2
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0960-9822
J9 CURR BIOL
JI Curr. Biol.
PD APR 10
PY 2012
VL 22
IS 7
BP 596
EP 600
DI 10.1016/j.cub.2012.02.043
PG 5
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 926QC
UT WOS:000302844900021
PM 22425157
OA gold
DA 2018-03-20
ER

PT J
AU Majumder, M
   Keis, K
   Zhan, X
   Meadows, C
   Cole, J
   Hinds, BJ
AF Majumder, Mainak
   Keis, Karin
   Zhan, Xin
   Meadows, Corey
   Cole, Jeggan
   Hinds, Bruce J.
TI Enhanced electrostatic modulation of ionic diffusion through carbon
   nanotube membranes by diazonium grafting chemistry
SO JOURNAL OF MEMBRANE SCIENCE
LA English
DT Article
DE carbon nanotube; surface functionalization; ionic diffusion;
   ultrafiltration
ID ELECTROCHEMICAL REDUCTION; SURFACE-CHEMISTRY; FUNCTIONALIZATION;
   ELECTRODES; GRAPHITE; SALTS; CAPACITANCE; TRANSPORT; FLOW
AB A membrane structure consisting of an aligned array of open ended carbon nanotubes (similar to 7 nm i.d.) spanning across an inert polymer matrix allows the diffusive transport of aqueous ionic species through CNT cores. The plasma oxidation process that opens CNTs tips inherently introduces carboxylic acid groups at the CNT tips, which allows for a limited amount of chemical functional at the CNT pore entrance. However for numerous applications, it is important to increase the density of carboxylic acid groups at the pore entrance for effective separation processes. Aqueous diazonium-based electrochemistry significantly increases the functional density of carboxylic acid groups. pH dependent dye adsorption-desorption and interfacial capacitance measurements indicate similar to 5-6 times increase in functional density. To further control the spatial location of the functional chemistry, a fast flowing inert liquid column inside the CNT core is found to restrict the diazonium grafting to the CNT tips only. This is confirmed by the increased flux of positively charged Ru(bipy)(3)(+2) with anionic functionality. The electrostatic enhancement of ion diffusion is readily screened in 0.1 M electrolyte solution consistent with the membrane pore geometry and increased functional density. (C) 2007 Elsevier B.V. All rights reserved.
C1 [Majumder, Mainak; Keis, Karin; Meadows, Corey; Cole, Jeggan; Hinds, Bruce J.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Zhan, Xin; Hinds, Bruce J.] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
RP Hinds, BJ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM bjhinds@engr.uky.edu
RI Majumder, Mainak/B-4667-2011
FU NIDA NIH HHS [R01 DA018822]
CR ABIMAN P, 2007, LANGMUIR
   Ago H, 1999, J PHYS CHEM B, V103, P8116, DOI 10.1021/jp991659y
   Allongue P, 1997, J AM CHEM SOC, V119, P201, DOI 10.1021/ja963354s
   Bahr JL, 2001, J AM CHEM SOC, V123, P6536, DOI 10.1021/ja010462s
   Banerjee S, 2005, ADV MATER, V17, P17, DOI 10.1002/adma.200401340
   Barisci JN, 2000, J ELECTROANAL CHEM, V488, P92, DOI 10.1016/S0022-0728(00)00179-0
   Barsoukov E, 2005, IMPEDANCE SPECTROSCOPY: THEORY, EXPERIMENT, AND APPLICATIONS, 2ND EDITION, pXII
   BRYANT MA, 1993, LANGMUIR, V9, P385, DOI 10.1021/la00026a005
   Chopra N, 2005, ADV FUNCT MATER, V15, P858, DOI 10.1002/adfm.200400399
   Combellas C, 2005, LANGMUIR, V21, P280, DOI 10.1021/la048106l
   Corgier BP, 2005, J AM CHEM SOC, V127, P18328, DOI 10.1021/ja056946w
   D'Amours M, 2003, J PHYS CHEM B, V107, P4811, DOI 10.1021/jp027223r
   Daiguji H, 2004, NANO LETT, V4, P2315, DOI 10.1021/nl0489945
   Domingo-Garcia M, 2000, J COLLOID INTERF SCI, V222, P233, DOI 10.1006/jcis.1999.6619
   *EG G PRINC APPL R, 1985, AC1 EG G PRINC APPL
   GERISCHER H, 1987, J PHYS CHEM-US, V91, P1930, DOI 10.1021/j100291a049
   Hinds BJ, 2004, SCIENCE, V303, P62, DOI 10.1126/science.1092048
   Hollman AM, 2004, LANGMUIR, V20, P5418, DOI 10.1021/la049688+
   Hou CH, 2006, J COLLOID INTERF SCI, V302, P54, DOI 10.1016/j.jcis.2006.06.009
   Huang SM, 2002, J PHYS CHEM B, V106, P3543, DOI 10.1021/jp014047y
   KIM YT, 2005, APPL PHYS LETT, V87
   Lee CS, 2004, NANO LETT, V4, P1713, DOI 10.1021/nl048995x
   Lefebvre X, 2004, J PHYS CHEM B, V108, P16811, DOI 10.1021/jp048631t
   Majumder M, 2005, NATURE, V438, P44, DOI 10.1038/43844a
   Majumder M, 2005, J AM CHEM SOC, V127, P9062, DOI 10.1021/ja043013b
   MAJUMDER M, LANGMUIR IN PRESS
   Marwan J, 2005, CHEM MATER, V17, P2395, DOI 10.1021/cm047871i
   Miller SA, 2001, J AM CHEM SOC, V123, P12335, DOI 10.1021/ja011926p
   Monk P. M. S, 2001, FUNDAMENTALS ELECTRO
   NISHIZAWA M, 1995, SCIENCE, V268, P700, DOI 10.1126/science.268.5211.700
   OREN Y, 1984, J ELECTROANAL CHEM, V162, P87, DOI 10.1016/S0022-0728(84)80157-6
   Tesema Y, 2004, J APPL POLYM SCI, V93, P2445, DOI 10.1002/app.20787
   Wong SS, 1998, NATURE, V394, P52
   Xu TW, 2005, J MEMBRANE SCI, V263, P1, DOI 10.1016/j.memsci.2005.05.002
   Zhang H, 2007, NANOTECHNOLOGY, V18, DOI 10.1088/0957-4484/18/19/195607
NR 35
TC 36
Z9 36
U1 0
U2 26
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0376-7388
EI 1873-3123
J9 J MEMBRANE SCI
JI J. Membr. Sci.
PD MAY 15
PY 2008
VL 316
IS 1-2
BP 89
EP 96
DI 10.1016/j.memsci.2007.09.068
PG 8
WC Engineering, Chemical; Polymer Science
SC Engineering; Polymer Science
GA 315DR
UT WOS:000256858600011
PM 25132719
OA green_accepted
DA 2018-03-20
ER

PT J
AU Yewle, JN
   Puleo, DA
   Bachas, LG
AF Yewle, Jivan N.
   Puleo, David A.
   Bachas, Leonidas G.
TI Enhanced Affinity Bifunctional Bisphosphonates for Targeted Delivery of
   Therapeutic Agents to Bone
SO BIOCONJUGATE CHEMISTRY
LA English
DT Article
ID DRUG-DELIVERY; PHARMACEUTICAL NANOCARRIERS; BIOMEDICAL APPLICATIONS;
   OSTEOPOROSIS; MECHANISMS; PH; SYSTEMS; HYDROXYAPATITE; INTELLIGENT;
   DERIVATIVES
AB Skeletal diseases have a major impact on the worldwide population and economy. Although several therapeutic agents and treatments are available for addressing bone diseases, they are not being fully utilized because of their uptake in nontargeted sites and related side effects. Active targeting with controlled delivery is an ideal approach for treatment of such diseases. Because bisphosphonates are known to have high affinity to bone and are being widely used in treatment of osteoporosis, they are well-suited for drug targeting to bone. In this study, a targeted delivery of therapeutic agent to resorption sites and wound healing sites of bone was explored. Toward this goal, bifunctional hydrazine-bisphosphonates (HBPs), with spacers of various lengths, were synthesized and studied for their enhanced affinity to bone. Crystal growth inhibition studies showed that these HBPs have high affinity to hydroxyapatite, and HBPs with shorter spacers bind more strongly than alendronate to hydroxyapatite. The HBPs did not affect proliferation of MC3T3-E1 preosteoblasts, did not induce apoptosis, and were not cytotoxic at the concentration range tested (10(-6)-10(-4) M). Furthermore, drugs can be linked to the HBPs through a hydrazone linkage that is cleavable at the low pH of bone resorption and wound healing sites, leading to release of the drug. This was demonstrated using hydroxyapatite as a model material of bone and 4-nitrobenzaldehyde as a model drug. This study suggests that these HBPs could be used for targeted delivery of therapeutic agents to bone.
C1 [Bachas, Leonidas G.] Univ Miami, Dept Chem, Coral Gables, FL 33146 USA.
   [Yewle, Jivan N.] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
   [Puleo, David A.] Univ Kentucky, Ctr Biomed Engn, Lexington, KY 40506 USA.
RP Bachas, LG (reprint author), Univ Miami, Dept Chem, 1301 Mem Dr, Coral Gables, FL 33146 USA.
EM bachas@miami.edu
RI Bachas, Leonidas/G-2479-2015
OI Bachas, Leonidas/0000-0002-3308-6264
FU US Army Medical Research and Materiel Command [W81XWH-09-1-0461];
   National Institutes of Health [AR048700]; University of Kentucky for a
   Research Challenge Trust
FX This research was supported by the US Army Medical Research and Materiel
   Command (W81XWH-09-1-0461) and the National Institutes of Health
   (AR048700). J.Y. thanks the University of Kentucky for a Research
   Challenge Trust Fund fellowship supporting this research. We thank Drs.
   M. Watson, A. Cammers, Y. Wei, E. Dikici, and E. Zahran for useful
   discussions.
CR Arstad E, 2003, J MED CHEM, V46, P3021, DOI 10.1021/jm021107v
   Betre H, 2006, J CONTROL RELEASE, V115, P175, DOI 10.1016/j.jconrel.2006.07.022
   Blower P, 2006, DALTON T, P1705, DOI 10.1039/b516860k
   Chapurlat RD, 2006, NAT CLIN PRACT ENDOC, V2, P211, DOI 10.1038/ncpendmet0121
   Chebbi I, 2010, INT J PHARMACEUT, V383, P116, DOI 10.1016/j.ijpharm.2009.09.011
   de Rosales RTM, 2010, BIOCONJUGATE CHEM, V21, P811, DOI 10.1021/bc100071k
   Deal C, 2009, CURR OPIN RHEUMATOL, V21, P380, DOI 10.1097/BOR.0b013e32832cbc2a
   Doschak MR, 2009, MOL PHARMACEUT, V6, P634, DOI 10.1021/mp8002368
   Ehrick RS, 2008, BIOCONJUGATE CHEM, V19, P315, DOI 10.1021/bc700196q
   El-Mabhouh A, 2004, CANCER BIOTHER RADIO, V19, P627, DOI 10.1089/1084978042484830
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Gil L, 1999, BIOORGAN MED CHEM, V7, P901, DOI 10.1016/S0968-0896(99)00045-0
   Goltzman D, 2002, NAT REV DRUG DISCOV, V1, P784, DOI 10.1038/nrd916
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Herczegh P, 2002, J MED CHEM, V45, P2338, DOI 10.1021/jm0105326
   Hirabayashi H, 2001, J CONTROL RELEASE, V70, P183, DOI 10.1016/S0168-3659(00)00355-2
   Kale AA, 2007, BIOCONJUGATE CHEM, V18, P363, DOI 10.1021/bc060228x
   Kieczykowski GR, 1995, J ORG CHEM, V60, P8310, DOI 10.1021/jo00130a036
   KOUTSOUKOS P, 1980, J AM CHEM SOC, V102, P1553, DOI 10.1021/ja00525a015
   Langer R, 2003, AICHE J, V49, P2990, DOI 10.1002/aic.690491202
   Langer R, 2001, SCIENCE, V293, P58, DOI 10.1126/science.1063273
   LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0
   Lumachi F, 2008, CURR MED CHEM, V15, P415, DOI 10.2174/092986708783497346
   MacEwan SR, 2010, BIOPOLYMERS, V94, P60, DOI 10.1002/bip.21327
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Ogawa K, 2006, J NUCL MED, V47, P2042
   Oh YK, 2009, BIOCONJUGATE CHEM, V20, P1813, DOI 10.1021/bc900260x
   Ora M, 2008, J ORG CHEM, V73, P4123, DOI 10.1021/jo800317e
   ORME MW, 1994, BIOORG MED CHEM LETT, V4, P1375, DOI 10.1016/S0960-894X(01)80365-6
   Pan HZ, 2006, J DRUG TARGET, V14, P425, DOI 10.1080/10611860600834219
   Peppas N. -A., 2006, Annales Pharmaceutiques Francaises, V64, P260
   Peppas NA, 2004, ADV DRUG DELIVER REV, V56, P1529, DOI 10.1016/j.addr.2004.07.001
   Polascik TJ, 2008, DRUG DES DEV THER, V3, P27
   Prommer EE, 2009, J PALLIAT MED, V12, P1061, DOI 10.1089/jpm.2009.9936
   Rodan GA, 1996, J CLIN INVEST, V97, P2692, DOI 10.1172/JCI118722
   Rodan GA, 1998, ANNU REV PHARMACOL, V38, P375, DOI 10.1146/annurev.pharmtox.38.1.375
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078-0432.CCR-06-0843
   Salo J, 1997, SCIENCE, V276, P270, DOI 10.1126/science.276.5310.270
   Sawant RM, 2006, BIOCONJUGATE CHEM, V17, P943, DOI 10.1021/bc060080h
   Schneider LA, 2007, ARCH DERMATOL RES, V298, P413, DOI 10.1007/s00403-006-0713-x
   Segal E, 2011, BIOMATERIALS, V32, P4450, DOI 10.1016/j.biomaterials.2011.02.059
   Segal E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005233
   SUNBERG RJ, 1991, CHEMTECH, V21, P304
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Uludag H, 2002, CURR PHARM DESIGN, V8, P1929, DOI 10.2174/1381612023393585
   vanBeek E, 1996, J BONE MINER RES, V11, P1492
   Vondracek SF, 2009, CLIN INTERV AGING, V4, P121
   Wang D, 2007, BIOCONJUGATE CHEM, V18, P1375, DOI 10.1021/bc7002132
   Wang D, 2006, MOL PHARMACEUT, V3, P717, DOI 10.1021/mp0600539
   Wang JB, 2005, CHINESE CHEM LETT, V16, P859
   Xu SJ, 2006, J DRUG TARGET, V14, P367, DOI 10.1080/10611860600834011
   Zaheer A, 2001, NAT BIOTECHNOL, V19, P1148, DOI 10.1038/nbt1201-1148
   Zhang SF, 2007, CHEM SOC REV, V36, P507, DOI 10.1039/b512310k
   Zheng H, 1997, Patent No. [5698542, US 5,698,542]
   Thompson WJ, 1989, Polymalonic acids as boneaffinity agents, Patent No. [EP 0341961, 0341961]
NR 56
TC 20
Z9 23
U1 2
U2 27
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1043-1802
J9 BIOCONJUGATE CHEM
JI Bioconjugate Chem.
PD DEC
PY 2011
VL 22
IS 12
BP 2496
EP 2506
DI 10.1021/bc2003132
PG 11
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Multidisciplinary; Chemistry, Organic
SC Biochemistry & Molecular Biology; Chemistry
GA 864FL
UT WOS:000298222300016
PM 22073906
OA green_accepted
DA 2018-03-20
ER

PT J
AU Hayes, D
   Kirkby, S
   Mccoy, KS
   Mansour, HM
   Khosravi, M
   Strawbridge, H
   Tobias, JD
AF Hayes, Don, Jr.
   Kirkby, Stephen
   McCoy, Karen S.
   Mansour, Heidi M.
   Khosravi, Medhi
   Strawbridge, Heather
   Tobias, Joseph D.
TI Reduction of lipid-laden macrophage index after laparoscopic Nissen
   fundoplication in cystic fibrosis patients after lung transplantation
SO CLINICAL TRANSPLANTATION
LA English
DT Article
DE aspiration; cystic fibrosis; gastroesophageal reflux; laparoscopic
   Nissen fundoplication; lipid-laden macrophage index; lung
   transplantation; Oil Red O stain
ID GASTROESOPHAGEAL-REFLUX DISEASE; BRONCHOALVEOLAR LAVAGE FLUID; ALVEOLAR
   MACROPHAGES; PULMONARY ASPIRATION; CHRONIC REJECTION; FAT-EMBOLISM;
   CHILDREN; MARKER; PEPSIN; ASSOCIATION
AB Background Lipid-laden macrophage (LLM) index could be potentially useful in assessing gastroesophageal (GE) reflux and aspiration after lung transplantation (LT) in patients with cystic fibrosis (CF). Methods A retrospective review of CF patients undergoing LT and/or laparoscopic Nissen fundoplication (LNF) from January 1, 2009, to December 31, 2011, was performed. Results Seventeen CF patients (nine women), mean (+/- SD) age 27.9 +/- 7.5 yr, underwent LT with mean (+/- SD) pre-transplant FEV1 of 20.9 +/- 5.0% predicted. Seventy percentage (12/17) of patients underwent LNF without complications within 12 wk of LT. After LT, but prior to antireflux surgery, there was no significant difference in the mean (+/- SD) baseline LLM index (154 +/- 41 vs. 146 +/- 51, p = NS) between patients who were to undergo LNF and patients who did not. After LNF, a significant reduction in the mean (+/- SD) LLM index occurred following the procedure (154 +/- 4174 +/- 54, p < 0.0001) while each patient reported resolution of symptoms of GE reflux, whereas 40% (2/5) undergoing only medical treatment reported resolution of symptoms. Conclusions Significant reduction in the LLM index occurred after LNF in CF patients after LT that correlated with resolution of clinical symptoms of GE reflux.
C1 [Hayes, Don, Jr.; Kirkby, Stephen; McCoy, Karen S.; Tobias, Joseph D.] Ohio State Univ, Coll Med, Columbus, OH 43205 USA.
   [Mansour, Heidi M.] Univ Kentucky, Coll Pharm, Lexington, KY USA.
   [Khosravi, Medhi] Univ Kentucky, Coll Med, Lexington, KY USA.
   [Strawbridge, Heather] NE Ohio Med Univ, Rootstown, OH USA.
RP Hayes, D (reprint author), Ohio State Univ, Nationwide Childrens Hosp, 700 Childrens Dr, Columbus, OH 43205 USA.
EM hayes.705@osu.edu
CR Ahrens P, 1999, PEDIATR PULM, V28, P83, DOI 10.1002/(SICI)1099-0496(199908)28:2<83::AID-PPUL2>3.3.CO;2-1
   Bandla HPR, 1999, PEDIATRICS, V103, part. no., DOI 10.1542/peds.103.2.e19
   Bauer ML, 1999, PEDIATR PULM, V28, P94, DOI 10.1002/(SICI)1099-0496(199908)28:2<94::AID-PPUL4>3.0.CO;2-0
   Blondeau K, 2008, EUR RESPIR J, V31, P707, DOI 10.1183/09031936.00064807
   Cantu E, 2004, ANN THORAC SURG, V78, P1142, DOI 10.1016/j.athoracsur.2004.04.044
   Chang AB, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-72
   COLOMBO JL, 1987, PEDIATR PULM, V3, P86, DOI 10.1002/ppul.1950030209
   CORWIN RW, 1985, AM REV RESPIR DIS, V132, P576
   D'Ovidio F, 2005, J THORAC CARDIOV SUR, V129, P1144, DOI 10.1016/j.jtcvs.2004.10.035
   Davis RD, 2003, J THORAC CARDIOV SUR, V125, P533, DOI 10.1067/mtc.2003.166
   Farrell S, 2006, J PEDIATR SURG, V41, P289, DOI 10.1016/j.jpedsurg.2005.11.002
   Fisichella PM, 2011, SURGERY, V150, P598, DOI 10.1016/j.surg.2011.07.053
   Hopkins PM, 2010, J HEART LUNG TRANSPL, V29, P859, DOI 10.1016/j.healun.2010.03.015
   Jacobson W, 1997, ARCH PATHOL LAB MED, V121, P1269
   Kazachkov MY, 2001, EUR RESPIR J, V18, P790, DOI 10.1183/09031936.01.00047301
   Knauer-Fischer S, 1999, PEDIATR PULM, V27, P419, DOI 10.1002/(SICI)1099-0496(199906)27:6<419::AID-PPUL9>3.0.CO;2-U
   Knoop C, 2006, SEMIN RESP CRIT CARE, V27, P521, DOI 10.1055/s-2006-954609
   NUSSBAUM E, 1987, J PEDIATR-US, V110, P190, DOI 10.1016/S0022-3476(87)80152-X
   Reider E, 1997, ISRAEL J MED SCI, V33, P654
   STAUGAS R, 1985, AUST PAEDIATR J, V21, P275
   Stovold R, 2007, AM J RESP CRIT CARE, V175, P1298, DOI 10.1164/rccm.200610-1485OC
   VICHINSKY E, 1994, BLOOD, V83, P3107
NR 22
TC 4
Z9 4
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0902-0063
EI 1399-0012
J9 CLIN TRANSPLANT
JI Clin. Transplant.
PD JAN-FEB
PY 2013
VL 27
IS 1
BP 121
EP 125
DI 10.1111/ctr.12020
PG 5
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 079YL
UT WOS:000314208000026
PM 23004684
DA 2018-03-20
ER

PT J
AU Hamza, A
   Wagner, JM
   Wei, NN
   Kwiatkowski, S
   Zhan, CG
   Watt, DS
   Korotkov, KV
AF Hamza, Adel
   Wagner, Jonathan M.
   Wei, Ning-Ning
   Kwiatkowski, Stefan
   Zhan, Chang-Guo
   Watt, David S.
   Korotkov, Konstantin V.
TI Application of the 4D Fingerprint Method with a Robust Scoring Function
   for Scaffold-Hopping and Drug Repurposing Strategies
SO JOURNAL OF CHEMICAL INFORMATION AND MODELING
LA English
DT Article
ID VII SECRETION SYSTEM; MOLECULAR-SHAPE; CONFORMER GENERATION; GAUSSIAN
   DESCRIPTION; DISCOVERY; INHIBITORS; PROTEASE; DOCKING; DESIGN; MODELS
AB Two factors contribute to the inefficiency associated with screening pharmaceutical library collections as a means of identifying new drugs: [1] the limited success of virtual screening (VS) methods in identifying new scaffolds; [2] the limited accuracy of computational methods in predicting off-target effects. We recently introduced a 3D shape-based similarity algorithm of the SABRE program, which encodes a consensus molecular shape pattern of a set of active ligands into a 4D fingerprint descriptor. Here, we report a mathematical model for shape similarity comparisons and ligand database filtering using this 4D fingerprint method and benchmarked the scoring function HWK (Hamza-Wei-Korotkov), using the 81 targets of the DEKOIS database. Subsequently, we applied our combined 4D fingerprint and HWK scoring function VS approach in scaffold-hopping and drug repurposing using the National Cancer Institute (NCI) and Food and Drug Administration (FDA) databases, and we identified new inhibitors with different scaffolds of MycP1 protease from the mycobacterial ESX-1 secretion system. Experimental evaluation of nine compounds from the NCI database and three from the FDA database displayed IC50 values ranging from 70 to 100 mu M against MycP1 and possessed high structural diversity, which provides departure points for further structure-activity relationship (SAR) optimization. In addition, this study demonstrates that the combination of our 4D fingerprint algorithm and the HWK scoring function may provide a means for identifying repurposed drugs for the treatment of infectious diseases and may be used in the drug-target profile strategy.
C1 [Hamza, Adel; Wagner, Jonathan M.; Kwiatkowski, Stefan; Watt, David S.; Korotkov, Konstantin V.] Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA.
   [Hamza, Adel; Wagner, Jonathan M.; Korotkov, Konstantin V.] Univ Kentucky, Ctr Struct Biol, Lexington, KY 40536 USA.
   [Kwiatkowski, Stefan; Zhan, Chang-Guo; Watt, David S.] Univ Kentucky, Ctr Pharmaceut Res & Innovat, Coll Pharm, Lexington, KY 40536 USA.
   [Zhan, Chang-Guo] Univ Kentucky, Mol Modeling & Biopharmaceut Ctr, Lexington, KY 40536 USA.
   [Zhan, Chang-Guo] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
   [Wei, Ning-Ning] Dalian Univ Technol, Sch Life Sci & Med, Panjin 124221, LN, Peoples R China.
RP Korotkov, KV (reprint author), Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA.
EM kkorotkov@uky.edu
OI Korotkov, Konstantin/0000-0002-2182-6843
FU National Institute of General Medical Sciences [1P30GM110787]; NIH/NIGMS
   [P20GM103486]
FX We thank Timothy J. Evans for assistance with protein purification. We
   acknowledge the Drug Synthesis and Chemistry Branch of National Cancer
   Institute for supplying the compounds used in the virtual screening and
   in vitro testing. We thank the University of Kentucky Information
   Technology department and Center for Computational Sciences for
   computing time on the Lipscomb High Performance Computing Cluster. We
   acknowledge the use of OpenEye Scientific Software via free academic
   licensing program. We acknowledge the University of Kentucky Organic
   Synthesis Core that is partially supported by grant 1P30GM110787 from
   the National Institute of General Medical Sciences (to Louis B. Hersh).
   This study was supported by NIH/NIGMS grant P20GM103486 (to K.V.K.), and
   its contents are solely the responsibility of the authors and do not
   necessarily represent the official views of the NIH or the NIGMS.
CR Akula N, 2011, BIOORG MED CHEM LETT, V21, P4183, DOI 10.1016/j.bmcl.2011.05.086
   Andrade CH, 2010, MOLECULES, V15, P3281, DOI 10.3390/molecules15053281
   Baell JB, 2010, J MED CHEM, V53, P2719, DOI 10.1021/jm901137j
   Bauer MR, 2013, J CHEM INF MODEL, V53, P1447, DOI [10.1021/ci400115b, 10.1021/ci400115bl]
   Bender A, 2007, CHEMMEDCHEM, V2, P861, DOI 10.1002/cmdc.200700026
   Bi JJ, 2011, J THEOR BIOL, V281, P133, DOI 10.1016/j.jtbi.2011.04.018
   Bleicher KH, 2004, CURR OPIN CHEM BIOL, V8, P287, DOI 10.1016/j.cbpa.2004.04.008
   Boguski MS, 2009, SCIENCE, V324, P1394, DOI 10.1126/science.1169920
   Bottai D, 2014, CURR PHARM DESIGN, V20, P4346
   Charifson PS, 1999, J MED CHEM, V42, P5100, DOI 10.1021/jm990352k
   Chen JM, 2013, MOL MICROBIOL, V89, P1154, DOI 10.1111/mmi.12336
   Chen JM, 2010, DRUG DISCOV TODAY DI, V7, pe25
   Conticello C, 2012, INT J CANCER, V131, P2197, DOI 10.1002/ijc.27482
   Diller DJ, 2003, J MED CHEM, V46, P4638, DOI 10.1021/jm020503a
   DOCA G, 2013, FUTURE MED CHEM, V5, P1372
   Dror O, 2009, J CHEM INF MODEL, V49, P2333, DOI 10.1021/ci900263d
   Englebienne P, 2009, J CHEM INF MODEL, V49, P1568, DOI 10.1021/ci8004308
   Fischbach MA, 2009, SCIENCE, V325, P1089, DOI 10.1126/science.1176667
   Giganti D, 2010, J CHEM INF MODEL, V50, P992, DOI 10.1021/ci900507g
   Gleeson MP, 2011, NAT REV DRUG DISCOV, V10, P197, DOI 10.1038/nrd3367
   Gohlke H, 2002, ANGEW CHEM INT EDIT, V41, P2645
   Good AC, 2004, J COMPUT AID MOL DES, V18, P529, DOI 10.1007/s10822-004-4067-1
   Grant JA, 1996, J COMPUT CHEM, V17, P1653, DOI 10.1002/(SICI)1096-987X(19961115)17:14<1653::AID-JCC7>3.0.CO;2-K
   Grant JA, 1996, J PHYS CHEM-US, V100, P2456, DOI 10.1021/jp953707u
   GRANT JA, 1995, J PHYS CHEM-US, V99, P3503, DOI 10.1021/j100011a016
   Hamza A., 2012, J BIOMOL STRUCT DYN, V31, P1236
   Hamza A, 2014, J CHEM INF MODEL, V54, P1166, DOI 10.1021/ci500025r
   Hamza A, 2012, J CHEM INF MODEL, V52, P963, DOI 10.1021/ci200617d
   Hawkins PCD, 2012, J CHEM INF MODEL, V52, P2919, DOI 10.1021/ci300314k
   Hawkins PCD, 2010, J CHEM INF MODEL, V50, P572, DOI 10.1021/ci100031x
   Hecker EA, 2002, J CHEM INF COMP SCI, V42, P1204, DOI 10.1021/ci020368a
   Hert J, 2006, J CHEM INF MODEL, V46, P462, DOI 10.1021/ci050348j
   Hert J, 2004, J CHEM INF COMP SCI, V44, P1177, DOI 10.1021/ci034231b
   Hopfinger AJ, 1997, J AM CHEM SOC, V119, P10509, DOI 10.1021/ja9718937
   Houben E. N., 2014, BIOCHIM BIOPHYS ACTA, V1844, P1707
   Irwin JJ, 2005, J CHEM INF MODEL, V45, P177, DOI 10.1021/ci049714+
   Iyer M, 2007, J CHEM INF MODEL, V47, P1945, DOI 10.1021/ci700153g
   Jacobsson M, 2003, J MED CHEM, V46, P5781, DOI 10.1021/jm030896t
   Jain AN, 2008, J COMPUT AID MOL DES, V22, P133, DOI 10.1007/s10822-008-9196-5
   John S, 2011, J ENZYM INHIB MED CH, V26, P535, DOI 10.3109/14756366.2010.535795
   Kirchmair J, 2009, J CHEM INF MODEL, V49, P678, DOI 10.1021/ci8004226
   Langer T, 2001, CURR PHARM DESIGN, V7, P509, DOI 10.2174/1381612013397861
   MacDonald ML, 2006, NAT CHEM BIOL, V2, P329, DOI 10.1038/nchembio790
   Mavridis L, 2007, J CHEM INF MODEL, V47, P1787, DOI 10.1021/ci7001507
   McLaughlin B, 2007, PLOS PATHOG, V3, P1051, DOI 10.1371/journal.ppat.0030105
   MEZEY PG, 1993, J MATH CHEM, V12, P365, DOI 10.1007/BF01164644
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33
   Ohol YM, 2010, CELL HOST MICROBE, V7, P210, DOI 10.1016/j.chom.2010.02.006
   Pan DH, 2004, J CHEM INF COMP SCI, V44, P2083, DOI 10.1021/ci0498057
   Pasqualoto KFM, 2004, J MED CHEM, V47, P3755, DOI 10.1021/jm049913k
   Payne DJ, 2007, NAT REV DRUG DISCOV, V6, P29, DOI 10.1038/nrd2201
   Polgar T, 2011, COMB CHEM HIGH T SCR, V14, P889, DOI 10.2174/138620711797537148
   ROGERS DJ, 1960, SCIENCE, V132, P1115, DOI 10.1126/science.132.3434.1115
   SCHMUED LC, 1986, BRAIN RES, V377, P147, DOI 10.1016/0006-8993(86)91199-6
   Senese CL, 2004, J CHEM INF COMP SCI, V44, P1526, DOI 10.1021/ci049898s
   Solomonson M, 2013, J BIOL CHEM, V288, P17782, DOI 10.1074/jbc.M113.462036
   Stanley SA, 2003, P NATL ACAD SCI USA, V100, P13001, DOI 10.1073/pnas.2235593100
   Stoop EJM, 2012, TRENDS MICROBIOL, V20, P477, DOI 10.1016/j.tim.2012.07.001
   Sun DM, 2013, PROTEIN CELL, V4, P921, DOI 10.1007/s13238-013-3089-7
   Venkatraman V, 2010, J CHEM INF MODEL, V50, P2079, DOI 10.1021/ci100263p
   Wagner JM, 2013, J STRUCT BIOL, V184, P115, DOI 10.1016/j.jsb.2013.09.022
   WALKER PD, 1991, J COMPUT CHEM, V12, P220, DOI 10.1002/jcc.540120212
   Wang RX, 2001, J CHEM INF COMP SCI, V41, P1422, DOI 10.1021/ci010025x
   Wei NN, 2014, J CHEM INF MODEL, V54, P338, DOI 10.1021/ci4005496
   [Anonymous], 2013, WHO GLOB TUB REP
   Xu J, 2007, MOL MICROBIOL, V66, P787, DOI 10.1111/j.1365-2958.2007.05959.x
   Yan X, 2013, J CHEM INF MODEL, V53, P1967, DOI 10.1021/ci300601q
NR 67
TC 5
Z9 5
U1 4
U2 27
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1549-9596
EI 1549-960X
J9 J CHEM INF MODEL
JI J. Chem Inf. Model.
PD OCT
PY 2014
VL 54
IS 10
BP 2834
EP 2845
DI 10.1021/ci5003872
PG 12
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Computer Science,
   Information Systems; Computer Science, Interdisciplinary Applications
SC Pharmacology & Pharmacy; Chemistry; Computer Science
GA AR8UL
UT WOS:000343849600020
PM 25229183
OA gold
DA 2018-03-20
ER

PT J
AU Kim, JK
   Howard, MD
   Dziubla, TD
   Rinehart, JJ
   Jay, M
   Lu, XL
AF Kim, Jin-Ki
   Howard, Melissa D.
   Dziubla, Thomas D.
   Rinehart, John J.
   Jay, Michael
   Lu, Xiuling
TI Uniformity of Drug Payload and Its Effect on Stability of Solid Lipid
   Nanoparticles Containing an Ester Prodrug
SO ACS NANO
LA English
DT Article
DE nanoparticle; dexamethasone; encapsulation; stability; gel; filtration
   chromatography
ID SIZE-EXCLUSION CHROMATOGRAPHY; ANTIINFLAMMATORY AGENTS; CHEMOTHERAPY
   ADJUVANTS; CANCER-CHEMOTHERAPY; PHARMACOKINETICS; BIODISTRIBUTION;
   DEXAMETHASONE; GEMCITABINE; CARBOPLATIN; EFFICACY
AB Nanocarrier systems re frequently characterized by their size distribution, while drug encapsulation in nanocarriers is generally characterized in terms of an entire population assuming drug distribution is uniform. Careful characterization of nanocarriers and assessment of their behavior in biological environments are essential for adequate prediction of the fate of the nanoparticles in vivo. Solid lipid nanoparticles containing [H-3]-dexamethasone palmitate (an ester, prodrug) and [C-14]-stearyl alcohol (a component of the nanoparticle matrix) were prepared using the nanotemplate engineering method for bioresponsive tumor delivery to overcome interstitial fluid pressure gradients, a physiological barrier to tumor uptake of chemotherapeutic agents. While particle size analysis indicated a uniform size distribution of 93.2 +/- 0.5 nm, gel filtration chromatography (GFC) revealed two nanoparticle populations. Drug encapsulation efficiency was 97%, but it distributed differently in the two populations, with average drug/lipid ratios of 0.04 and 0.25, respectively. The difference in surface properties resulted in distinguishing protein adsorption features of the two populations,:GFC and HPLC profiles of the mixture of nanoparticles and human serum albumin (HSA) showed that no HSA was; adsorbed to the first population of nanoparticles, but minor amounts were adsorbed to the second population:After, 24 h incubation in 50% human plasma, >= 80% of the [H-3]-dexamethasone palmitate was associated with nanoparticles. Thus, characterization of solid lipid nanoparticles produced by this method may be challenging from a regulatory perspective, but the strong association of the drug with the nanoparticles in plasma indicates that this nanocarrier system has the potential for in vivo application.
C1 [Kim, Jin-Ki; Jay, Michael; Lu, Xiuling] Univ N Carolina, Div Mol Pharmaceut, Ctr Nanotechnol Drug Delivery, Eshelman Sch Pharm, Chapel Hill, NC 27515 USA.
   [Kim, Jin-Ki; Jay, Michael; Lu, Xiuling] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
   [Howard, Melissa D.] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY USA.
   [Dziubla, Thomas D.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY USA.
   [Rinehart, John J.] Univ Kentucky, Dept Med, Lexington, KY 40506 USA.
   [Jay, Michael] N Carolina State Univ, Univ N Carolina Chapel Hill, Joint Dept Biomed Engn, Chapel Hill, NC USA.
RP Lu, XL (reprint author), Univ N Carolina, Div Mol Pharmaceut, Ctr Nanotechnol Drug Delivery, Eshelman Sch Pharm, Chapel Hill, NC 27515 USA.
EM xiuling.lu@unc.edu
FU Education and Research Foundation for the Society of Nuclear Medicine;
   NSF IGERT Program [DGE-0653710]; Carolina Partnership
FX The authors are grateful for financial support from the Benedict Cassen
   Postdoctoral Fellowship from the Education and Research Foundation for
   the Society of Nuclear Medicine (X.L.), the Carolina Partnership, and
   grant DGE-0653710 from the NSF IGERT Program (M.D.H.).
CR Aggarwal P, 2009, ADV DRUG DELIVER REV, V61, P428, DOI 10.1016/j.addr.2009.03.009
   Brissova M, 1996, ANAL BIOCHEM, V242, P104, DOI 10.1006/abio.1996.0435
   Brown SC, 2010, METHODS MOL BIOL, V624, P39, DOI 10.1007/978-1-60761-609-2_4
   Farrell D, 2011, PHARM RES-DORDR, V28, P273, DOI 10.1007/s11095-010-0214-7
   Gil Pilar Rivera, 2008, ACS Nano, V2, P2200, DOI 10.1021/nn800716j
   Hall JB, 2007, NANOMEDICINE-UK, V2, P789, DOI 10.2217/17435889.2.6.789
   HAUMAIER L, 1990, ORG GEOCHEM, V15, P413, DOI 10.1016/0146-6380(90)90168-Y
   Heidel JD, 2011, PHARM RES-DORDR, V28, P187, DOI 10.1007/s11095-010-0178-7
   Leggas M, 2009, CANCER CHEMOTH PHARM, V63, P731, DOI 10.1007/s00280-008-0767-x
   Li SD, 2008, MOL PHARMACEUT, V5, P496, DOI 10.1021/mp800049w
   Liederer BM, 2006, J PHARM SCI-US, V95, P1177, DOI 10.1002/jps.20542
   Lu XL, 2008, AAPS J, V10, P133, DOI 10.1208/s12248-008-9013-z
   Lu XL, 2009, AAPS J, V11, P120, DOI 10.1208/s12248-009-9086-3
   Maeda H, 2010, BIOCONJUGATE CHEM, V21, P797, DOI 10.1021/bc100070g
   Meng HA, 2010, ACS NANO, V4, P4539, DOI 10.1021/nn100690m
   MORI S, 1989, ANAL CHEM, V61, P530, DOI 10.1021/ac00181a006
   Owens DE, 2006, INT J PHARM, V307, P93, DOI 10.1016/j.ijpharm.2005.10.010
   Oyewumi MO, 2004, J CONTROL RELEASE, V95, P613, DOI 10.1016/j.jconrel.2004.01.002
   SUSAN L P, 1976, Urology, V7, P598, DOI 10.1016/0090-4295(76)90084-4
   Tang Y, 2010, PHARM RES-DORDR, V27, P2242, DOI 10.1007/s11095-010-0231-6
   Torchilin VP, 2010, HDB EXP PHARM, V197, P3, DOI DOI 10.1007/978-3-642-00477-3_
   Wang H, 2004, CANCER CHEMOTH PHARM, V53, P459, DOI 10.1007/s00280-003-0759-9
   Wang H, 2004, CLIN CANCER RES, V10, P1633, DOI 10.1158/1078-0432.CCR-0829-3
NR 23
TC 7
Z9 8
U1 4
U2 35
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936-0851
J9 ACS NANO
JI ACS Nano
PD JAN
PY 2011
VL 5
IS 1
BP 209
EP 216
DI 10.1021/nn102357y
PG 8
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA 710CA
UT WOS:000286487300027
PM 21158414
DA 2018-03-20
ER

PT J
AU Hernandez, S
   Porter, C
   Zhang, XY
   Wei, YN
   Bhattacharyya, D
AF Hernandez, Sebastian
   Porter, Cassandra
   Zhang, Xinyi
   Wei, Yinan
   Bhattacharyya, Dibakar
TI Layer-by-layer assembled membranes with immobilized porins
SO RSC ADVANCES
LA English
DT Article
ID ARTIFICIAL WATER CHANNELS; ESCHERICHIA-COLI; OUTER-MEMBRANE; OMPF PORIN;
   BIOMIMETIC MEMBRANES; AQUAPORIN-Z; MICROFILTRATION MEMBRANES; BACTERIAL
   PORIN; MATRIX PROTEIN; SINGLE-CHANNEL
AB New and advanced opportunities are arising for the synthesis and functionalization of membranes with selective separation, reactivity, and stimuli-responsive behavior. One such advancement is the integration of bio-based channels in membrane technologies. By a layer-by-layer (LbL) assembly of polyelectrolytes, outer membrane protein F trimers (OmpF) or "porins" from Escherichia coli with central pores similar to 2 nm in diameter at their opening and similar to 0.7 x 1.1 nm at their constricted region are immobilized within the pores of poly(vinylidene fluoride) microfiltration membranes, in contrast to traditional ruptured lipid bilayer or vesicle processes. These OmpF-membranes demonstrate selective rejection of non-charged organics over ionic solutes, allowing the passage of up to 2 times more salts than traditional nanofiltration membranes starting with rejections of 84% for 0.4 to 1.0 kDa organics. The presence of charged groups in OmpF-membranes also leads to pH-dependent salt rejection through Donnan exclusion. These OmpF-membranes also show exceptional durability and stability, delivering consistent and constant permeability and recovery for over 160 h of operation. Characterization of the solutions containing OmpF and the membranes was conducted during each stage of the process, including detection by fluorescence labelling (FITC), zeta potential, pH responsiveness, flux changes, and rejection of organic-inorganic solutions.
C1 [Hernandez, Sebastian; Porter, Cassandra; Bhattacharyya, Dibakar] Univ Kentucky, Dept Chem & Mat Engn, 177 F Paul Anderson Tower, Lexington, KY 40506 USA.
   [Zhang, Xinyi; Wei, Yinan] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
RP Bhattacharyya, D (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 F Paul Anderson Tower, Lexington, KY 40506 USA.
EM db@uky.edu
OI Hernandez, Sebastian/0000-0002-7513-5511
FU National Science Foundation NSF KY EPSCoR program [1355438]; National
   Institutes of Environmental Health Sciences NIEHS-SRC [P42ES007380]
FX Funding: This work was supported by the National Science Foundation NSF
   KY EPSCoR program (Grant no: 1355438) and the National Institutes of
   Environmental Health Sciences NIEHS-SRC (grant number P42ES007380). The
   authors want to thank Nanostone Water Inc. for collaboration related to
   PVDF membrane scale-up, and the Environmental Research Training
   Laboratories at the University of Kentucky.
CR Aguilella VM, 2011, INTEGR BIOL-UK, V3, P159, DOI 10.1039/c0ib00048e
   Arcidiacono S, 2002, PROTEIN EXPRES PURIF, V25, P134, DOI 10.1006/prep.2002.1619
   BARONEPEL O, 1988, PLANTA, V175, P389, DOI 10.1007/BF00396345
   BENZ R, 1979, BIOCHIM BIOPHYS ACTA, V551, P238, DOI 10.1016/0005-2736(89)90002-3
   BUEHLER LK, 1993, BIOCHEM BIOPH RES CO, V190, P624, DOI 10.1006/bbrc.1993.1094
   Butterfield DA, 2001, J MEMBRANE SCI, V181, P29, DOI 10.1016/S0376-7388(00)00342-2
   Cama J, 2015, J AM CHEM SOC, V137, P13836, DOI 10.1021/jacs.5b08960
   Choi JJ, 2010, ULTRASOUND MED BIOL, V36, P58, DOI 10.1016/j.ultrasmedbio.2009.08.006
   Colburn AS, 2016, IND ENG CHEM RES, V55, P4089, DOI 10.1021/acs.iecr.6b00098
   DECHER G, 1992, THIN SOLID FILMS, V210, P831, DOI 10.1016/0040-6090(92)90417-A
   Dove PM, 1997, GEOCHIM COSMOCHIM AC, V61, P3329, DOI 10.1016/S0016-7037(97)00217-2
   GARAVITO RM, 1986, METHOD ENZYMOL, V125, P309
   Ghandehari H, 1997, J PHARMACOL EXP THER, V280, P747
   Hernandez S, 2016, ACS SUSTAIN CHEM ENG, V4, P907, DOI 10.1021/acssuschemeng.5b01005
   Hernandez S, 2014, IND ENG CHEM RES, V53, P1130, DOI 10.1021/ie403353g
   Hijkoop V. J. v., 2007, J CHEM PHYS, V127
   Hinds B., 2012, RESPONSIVE MEMBRANES, P51, DOI [10.1002/9781118389553.ch3., DOI 10.1002/9781118389553.CH3]
   HOLZENBURG A, 1989, BIOCHEMISTRY-US, V28, P4187, DOI 10.1021/bi00436a010
   Husson S. M., 2012, RESPONSIVE MEMBRANES, P73, DOI [10.1002/9781118389553.ch4., DOI 10.1002/9781118389553.CH4]
   Jap BK, 1996, PHYSIOL REV, V76, P1073
   Jarzab A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070539
   Kang GD, 2014, J MEMBRANE SCI, V463, P145, DOI 10.1016/j.memsci.2014.03.055
   Kasianowicz J. J., 2012, P NATO ADV RES WORKS
   Kim YR, 2012, SENSORS-BASEL, V12, P9530, DOI 10.3390/s120709530
   Klara SS, 2016, J AM CHEM SOC, V138, P28, DOI 10.1021/jacs.5b03320
   Kojima S, 2013, P NATL ACAD SCI USA, V110, pE2629, DOI 10.1073/pnas.1310333110
   Kumar M, 2007, P NATL ACAD SCI USA, V104, P20719, DOI 10.1073/pnas.0708762104
   LEBRUN L, 1993, ENZYME MICROB TECH, V15, P1057, DOI 10.1016/0141-0229(93)90054-6
   Leitao TJ, 2012, BRAZ ORAL RES, V26, P100, DOI 10.1590/S1806-83242012000200003
   Lewis S. R., 2012, RESPONSIVE MEMBRANES, P97, DOI 10.1002/9781118389553.ch5.
   Li XS, 2015, J MEMBRANE SCI, V494, P68, DOI 10.1016/j.memsci.2015.07.040
   Licsandru E, 2016, J AM CHEM SOC, V138, P5403, DOI 10.1021/jacs.6b01811
   Ling K, 2013, NANOSCALE RES LETT, V8, DOI 10.1186/1556-276X-8-538
   Liu YQ, 2015, ACS APPL MATER INTER, V7, P20930, DOI 10.1021/acsami.5b06326
   Masuelli MA, 2013, J POLYM BIOPOLYM PHY, V1, P13
   Mehta A, 2005, J MEMBRANE SCI, V249, P245, DOI 10.1016/j.memsci.2004.09.040
   NIGHTINGALE ER, 1959, J PHYS CHEM-US, V63, P1381, DOI 10.1021/j150579a011
   NIKAIDO H, 1983, J BACTERIOL, V153, P232
   NIKAIDO H, 1985, MICROBIOL REV, V49, P1
   NIKAIDO H, 1981, J GEN PHYSIOL, V77, P121, DOI 10.1085/jgp.77.2.121
   NIKAIDO H, 1983, J BACTERIOL, V153, P241
   PAPPENHEIMER JR, 1953, PHYSIOL REV, V33, P387
   Pluen A, 1999, BIOPHYS J, V77, P542, DOI 10.1016/S0006-3495(99)76911-0
   Qi SR, 2016, J MEMBRANE SCI, V508, P94, DOI 10.1016/j.memsci.2016.02.013
   RAMM LE, 1982, P NATL ACAD SCI-BIOL, V79, P4751, DOI 10.1073/pnas.79.15.4751
   Ribeiro ACF, 2006, J CHEM ENG DATA, V51, P1836, DOI 10.1021/je0602061
   Robertson KM, 2002, FEBS LETT, V528, P53, DOI 10.1016/S0014-5793(02)03173-3
   Sabek OM, 2013, LAB CHIP, V13, P3675, DOI 10.1039/c3lc50601k
   Saint N, 1996, J BIOL CHEM, V271, P20676, DOI 10.1074/jbc.271.34.20676
   SCHINDLER H, 1978, P NATL ACAD SCI USA, V75, P3751, DOI 10.1073/pnas.75.8.3751
   Schirmer T, 1999, J MOL BIOL, V294, P1159, DOI 10.1006/jmbi.1999.3326
   Schneider S, 2017, J AM CHEM SOC, V139, P3721, DOI 10.1021/jacs.6b12094
   SCHULTZ SG, 1961, J GEN PHYSIOL, V44, P1189, DOI 10.1085/jgp.44.6.1189
   Shen YX, 2015, P NATL ACAD SCI USA, V112, P9810, DOI 10.1073/pnas.1508575112
   Shen YX, 2014, J MEMBRANE SCI, V454, P359, DOI 10.1016/j.memsci.2013.12.019
   Sholl DS, 2016, NATURE, V532, P435, DOI 10.1038/532435a
   Smuleac V, 2006, LANGMUIR, V22, P10118, DOI 10.1021/la061124d
   Smuleac V, 2011, J MEMBRANE SCI, V379, P131, DOI 10.1016/j.memsci.2011.05.054
   Smuleac V, 2010, J MEMBRANE SCI, V346, P310, DOI 10.1016/j.memsci.2009.09.052
   Tansel B, 2006, SEP PURIF TECHNOL, V51, P40, DOI 10.1016/j.seppur.2005.12.020
   Taylor R, 1998, J BIOL CHEM, V273, P31113, DOI 10.1074/jbc.273.47.31113
   TODT JC, 1992, BIOCHEMISTRY-US, V31, P10471, DOI 10.1021/bi00158a009
   TODT JC, 1992, BIOCHEM BIOPH RES CO, V189, P1498, DOI 10.1016/0006-291X(92)90244-F
   Turner K., 2012, RESPONSIVE MEMBRANES, P243, DOI 10.1002/9781118389553.ch11.
   Umpuch C, 2010, PROCESS BIOCHEM, V45, P1763, DOI 10.1016/j.procbio.2010.01.015
   Wandera D, 2010, J MEMBRANE SCI, V357, P6, DOI 10.1016/j.memsci.2010.03.046
   Wang HL, 2012, SMALL, V8, P1185, DOI 10.1002/smll.201102120
   Wang MQ, 2015, ENVIRON SCI TECHNOL, V49, P3761, DOI 10.1021/es5056337
   Werber JR, 2016, NAT REV MATER, V1, DOI 10.1038/natrevmats.2016.18
   Wisniewska M, 2014, COLLOID POLYM SCI, V292, P699, DOI 10.1007/s00396-013-3103-x
   Xiao H, 2009, J APPL ELECTROCHEM, V39, P1163, DOI 10.1007/s10800-009-9778-5
   Xiao L, 2015, IND ENG CHEM RES, V54, P4174, DOI 10.1021/ie504149t
   YOSHIMURA F, 1983, J BIOL CHEM, V258, P2308
   Yuk H, 2016, NAT MATER, V15, P190, DOI [10.1038/nmat4463, 10.1038/NMAT4463]
   Zhang XY, 2012, J POLYM SCI POL CHEM, V50, P2293, DOI 10.1002/pola.26000
   Ziervogel BK, 2013, STRUCTURE, V21, P76, DOI 10.1016/j.str.2012.10.014
   Zydney A., 2015, ENCY MEMBRANES, P1, DOI [10.1007/978-3-642-40872-4_129-4., DOI 10.1007/978-3-642-40872-4_129-4.]
NR 77
TC 0
Z9 0
U1 1
U2 1
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2046-2069
J9 RSC ADV
JI RSC Adv.
PY 2017
VL 7
IS 88
BP 56123
EP 56136
DI 10.1039/c7ra08737c
PG 14
WC Chemistry, Multidisciplinary
SC Chemistry
GA FQ5BA
UT WOS:000418372100073
PM 29391943
OA gold
DA 2018-03-19
ER

PT J
AU Biswal, D
   Chirra, HD
   Hilt, JZ
AF Biswal, Dipti
   Chirra, Hariharasudhan D.
   Hilt, J. Zach
TI Fabrication of hydrogel microstructures using polymerization controlled
   by microcontact printing (PC mu CP)
SO BIOMEDICAL MICRODEVICES
LA English
DT Article
DE hydrogel; microcontact printing; FTIR imaging; intelligent materials;
   microdevices
ID SOFT LITHOGRAPHY; MICROFABRICATION; MICROPARTICLES
AB Hydrogels are widely applied as functional biomaterials in the diagnostic and therapeutic fields. For example, intelligent hydrogels containing ionic groups (pH responsive) and poly(ethylene glycol) have promising applications as pH responsive materials in the biomedical and pharmaceutical fields. For potential use of hydrogels in micro- and nano devices, methods are needed to fabricate structures of various geometries at the micro- and nano scale. In this work, polymerization controlled by microcontact printing (PC mu CP) is utilized, which is a method that uses microcontact printing to spatially define polymerization zones. Specifically, gold surfaces were modified by a hydrophobic thiol self assembled monolayer via microcontact printing and then a hydrophilic prepolymer solution was applied and only spatially occupied the regions confined by the hydrophobic thiol. Subsequently, polymerization reactions were carried out to create hydrogel microstructures. The patterned hydrogel produced using these methods are highly uniform in size and shape, having potential application in the field of biomedical microdevices.
C1 [Biswal, Dipti; Chirra, Hariharasudhan D.; Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Hilt, JZ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 F Paul Anderson Tower, Lexington, KY 40506 USA.
EM hilt@engr.uky.edu
CR Baldi A, 2006, SENSOR ACTUAT B-CHEM, V114, P9, DOI 10.1016/j.snb.2005.04.020
   BASIR R, 2002, APPL PHYS LETT, V81, P3091
   Beebe DJ, 2000, NATURE, V404, P588, DOI 10.1038/35007047
   Bernard A, 1998, LANGMUIR, V14, P2225, DOI 10.1021/la980037l
   Biswal D, 2006, POLYMER, V47, P7355, DOI 10.1016/j.polymer.2006.08.028
   Guan JJ, 2006, BIOMATERIALS, V27, P4034, DOI 10.1016/j.biomaterials.2006.03.011
   Guan JJ, 2005, CHEM MATER, V17, P6227, DOI 10.1021/cm049392p
   Hilt JZ, 2003, BIOMED MICRODEVICES, V5, P177, DOI 10.1023/A:1025786023595
   KUMAR A, 1993, APPL PHYS LETT, V63, P2002, DOI 10.1063/1.110628
   PEPPAS NA, 1993, ADV DRUG DELIVER REV, V11, P1, DOI 10.1016/0169-409X(93)90025-Y
   Peppas NA, 2006, ADV MATER, V18, P1345, DOI 10.1002/adma.200501612
   Sershen SR, 2005, ADV MATER, V17, P1366, DOI 10.1002/adma.200401239
   Xia YN, 1997, LANGMUIR, V13, P2059, DOI 10.1021/la960936e
   XIA YN, 1995, J AM CHEM SOC, V117, P9576, DOI 10.1021/ja00142a031
   Xia YN, 1996, CHEM MATER, V8, P601, DOI 10.1021/cm950464+
   Yan L, 1998, J AM CHEM SOC, V120, P6179, DOI 10.1021/ja980770z
NR 16
TC 8
Z9 8
U1 0
U2 15
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1387-2176
J9 BIOMED MICRODEVICES
JI Biomed. Microdevices
PD APR
PY 2008
VL 10
IS 2
BP 213
EP 219
DI 10.1007/s10544-007-9127-6
PG 7
WC Engineering, Biomedical; Nanoscience & Nanotechnology
SC Engineering; Science & Technology - Other Topics
GA 267QY
UT WOS:000253525500009
PM 17876708
DA 2018-03-20
ER

PT J
AU Authimoolam, SP
   Vasilakes, AL
   Shah, NM
   Puleo, DA
   Dziubla, TD
AF Authimoolam, Sundar P.
   Vasilakes, Andrew L.
   Shah, Nihar M.
   Puleo, David A.
   Dziubla, Thomas D.
TI Synthetic Oral Mucin Mimic from Polymer Micelle Networks
SO BIOMACROMOLECULES
LA English
DT Article
ID BLOCK-COPOLYMER MICELLES; INTERFACIAL INSTABILITIES; BIOMEDICAL
   APPLICATIONS; GASTROINTESTINAL MUCUS; THERAPEUTIC ENZYME; SALIVARY
   MUCINS; DRUG-DELIVERY; LAYER; FILMS; MORPHOLOGIES
AB Mucin networks are formed in the oral cavity by complexation of glycoproteins with other salivary proteins, yielding a hydrated lubricating barrier. The function of these networks is linked to their structural, chemical, and mechanical properties. Yet, as these properties are interdependent, it is difficult to tease out their relative importance. Here, we demonstrate the ability to recreate the fibrous like network through a series of complementary rinses of polymeric wormlike micelles, resulting in a 3-dimensional (3D) porous network that can be deposited layer-by-layer onto any surface. In this work, stability, structure, and microbial capture capabilities were evaluated as a function of network properties. It was found that network structure alone was sufficient for bacterial capture, even with networks composed of the adhesion-resistant polymer, poly(ethylene glycol). The synthetic networks provide an excellent, yet simple, means of independently characterizing mucin network properties (e.g., surface chemistry, stiffness, and pore size).
C1 [Authimoolam, Sundar P.; Vasilakes, Andrew L.; Shah, Nihar M.; Dziubla, Thomas D.] Univ Kentucky, Coll Engn, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Puleo, David A.] Univ Kentucky, Coll Engn, Dept Biomed Engn, Wenner Gren Lab, Lexington, KY 40506 USA.
RP Dziubla, TD (reprint author), Univ Kentucky, Coll Engn, Dept Chem & Mat Engn, 177 F Paul Anderson Tower, Lexington, KY 40506 USA.
EM dziubla@engr.uky.edu
FU National Institutes of Health [R03 DE019496]
FX This work was funded by National Institutes of Health (Grant R03
   DE019496). Authors would like to acknowledge James G. Begley and Cindy
   Meier for performing confocal laser scanning measurements, and Dr.
   Bradley Berron and Leila Safazadeh for their help with the
   goniometer-contact angle measurements. Authors also thank Dr. Paritosh
   Wattamwar for insightful discussions.
CR Ahmed F, 2004, J CONTROL RELEASE, V96, P37, DOI 10.1016/j.jconrel.2003.12.021
   AMERONGEN AVN, 1987, CARIES RES, V21, P297
   Atuma C, 2001, AM J PHYSIOL-GASTR L, V280, pG922
   Authimoolam SP, 2013, ADV HEALTHC MATER, V2, P983, DOI 10.1002/adhm.201200375
   Baek JH, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3158994
   Bansil R, 2006, CURR OPIN COLLOID IN, V11, P164, DOI 10.1016/j.cocis.2005.11.001
   Cai SS, 2007, PHARM RES, V24, P2099, DOI 10.1007/s11095-007-9335-z
   Chen SF, 2010, POLYMER, V51, P5283, DOI 10.1016/j.polymer.2010.08.022
   Chung WJ, 2011, NATURE, V478, P364, DOI 10.1038/nature10513
   COLLINS LMC, 1987, J DENT RES, V66, P1300, DOI 10.1177/00220345870660080201
   Cone RA, 2009, ADV DRUG DELIVER REV, V61, P75, DOI 10.1016/j.addr.2008.09.008
   Crater JS, 2010, MACROMOL BIOSCI, V10, P1473, DOI 10.1002/mabi.201000137
   Critchfield A. S., 2013, PLOS ONE, V8
   Derrien M., 2010, GUT MICROBES, V1, P254, DOI DOI 10.4161/GMIC.1.4.12778
   Groschel A. H., 2012, NAT COMMUN, V3
   Gunes H., 2013, TOXICOL IND HEALTH, DOI [10.1186/1472-6882-13-269, DOI 10.1186/1472-6882-13-269]
   Hong ZN, 2005, BIOMACROMOLECULES, V6, P3458, DOI 10.1021/bm0505843
   Hoperaft M.S., 2010, AUST DENT J, V55, P353
   Hoperaft M.S., 2010, AUST DENT J, V55, P238
   Jeon J, 2006, LANGMUIR, V22, P4629, DOI 10.1021/la053444n
   Johansson MEV, 2008, P NATL ACAD SCI USA, V105, P15064, DOI 10.1073/pnas.0803124105
   Kaditi E, 2012, CURR MED CHEM, V19, P5088
   Karabulut E, 2012, ACS NANO, V6, P4731, DOI 10.1021/nn204620j
   Kim Y, 2005, NANOTECHNOLOGY, V16, pS484, DOI 10.1088/0957-4484/16/7/024
   Kingshott P, 2003, LANGMUIR, V19, P6912, DOI 10.1021/la034032m
   Kirch J, 2012, P NATL ACAD SCI USA, V109, P18355, DOI 10.1073/pnas.1214066109
   KLEINFELD ER, 1994, SCIENCE, V265, P370, DOI 10.1126/science.265.5170.370
   Lai SK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004294
   Lieleg O, 2010, BIOPHYS J, V98, P1782, DOI 10.1016/j.bpj.2010.01.012
   Matsuzawa A, 2013, LANGMUIR, V29, P7362, DOI 10.1021/la303459v
   Melvin J E, 1991, Curr Opin Dent, V1, P795
   Merritt JH, 2005, CURR PROTOC MICROBIO, DOI DOI 10.1002/9780471729259.MC01B01S00
   Mese H, 2007, J ORAL REHABIL, V34, P711, DOI 10.1111/j.1365-2842.2007.01794.x
   Mohanta V, 2013, LANGMUIR, V29, P13123, DOI 10.1021/la401731a
   Nordgard CT, 2014, BIOMACROMOLECULES, V15, P2294, DOI 10.1021/bm500464b
   O'Leary LER, 2011, NAT CHEM, V3, P821, DOI [10.1038/NCHEM.1123, 10.1038/nchem.1123]
   Olmsted SS, 2001, BIOPHYS J, V81, P1930, DOI 10.1016/S0006-3495(01)75844-4
   Ostrander JW, 2001, J AM CHEM SOC, V123, P1101, DOI 10.1021/ja0029578
   Ott C, 2009, SOFT MATTER, V5, P84, DOI 10.1039/b813161a
   Qiu HB, 2012, ANGEW CHEM INT EDIT, V51, P11882, DOI 10.1002/anie.201205764
   Ranc H, 2006, COLLOID SURFACE A, V276, P155, DOI 10.1016/j.colsurfa.2005.10.033
   ROUSSEL P, 1988, BIOCHIMIE, V70, P1471, DOI 10.1016/0300-9084(88)90284-2
   SHEEHAN JK, 1991, AM REV RESPIR DIS, V144, pS4, DOI 10.1164/ajrccm/144.3_pt_2.S4
   Shi L, 2000, J COLLOID INTERF SCI, V224, P372, DOI 10.1006/jcis.2000.6724
   Simone EA, 2007, BIOMACROMOLECULES, V8, P3914, DOI 10.1021/bm700888h
   Simone EA, 2009, BIOMACROMOLECULES, V10, P1324, DOI 10.1021/bm900189x
   Simone EA, 2009, PHARM RES-DORD, V26, P250, DOI 10.1007/s11095-008-9744-7
   TABAK LA, 1982, J ORAL PATHOL MED, V11, P1, DOI 10.1111/j.1600-0714.1982.tb00138.x
   TABAK LA, 1995, ANNU REV PHYSIOL, V57, P547, DOI 10.1146/annurev.ph.57.030195.002555
   Tang ZY, 2006, ADV MATER, V18, P3203, DOI 10.1002/adma.200600113
   Thornton DJ, 1999, GLYCOBIOLOGY, V9, P293, DOI 10.1093/glycob/9.3.293
   Turner MD, 2007, J AM DENT ASSOC, V138, p15S, DOI 10.14219/jada.archive.2007.0358
   Visvanathan V, 2010, INT J CLIN PRACT, V64, P404, DOI 10.1111/j.1742-1241.2009.02132.x
   Wang MJ, 2004, ELECTROANAL, V16, P757, DOI 10.1002/elan.200302884
   Wong CF, 1999, INT J PHARM, V180, P47, DOI 10.1016/S0378-5173(98)00402-5
   Wu JJ, 2011, LANGMUIR, V27, P13684, DOI 10.1021/la2027237
   Zhao Y, 2009, LANGMUIR, V25, P13151, DOI 10.1021/la901835z
   Zhu JT, 2008, J AM CHEM SOC, V130, P7496, DOI 10.1021/ja801268e
   Zhu J, 2008, ANGEW CHEM INT EDIT, V47, P2113, DOI 10.1002/anie.200704863
   Zhu JT, 2009, SOFT MATTER, V5, P2471, DOI 10.1039/b818065b
   Zhu ZC, 2013, J CONTROL RELEASE, V171, P73, DOI 10.1016/j.jconrel.2013.06.031
NR 61
TC 6
Z9 6
U1 3
U2 44
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1525-7797
EI 1526-4602
J9 BIOMACROMOLECULES
JI Biomacromolecules
PD AUG
PY 2014
VL 15
IS 8
BP 3099
EP 3111
DI 10.1021/bm5006917
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Organic; Polymer Science
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA AN1MS
UT WOS:000340348600030
PM 24992241
OA gold
DA 2018-03-20
ER

PT J
AU Xiao, L
   Isner, A
   Waldrop, K
   Saad, A
   Takigawa, D
   Bhattacharyya, D
AF Xiao, Li
   Isner, Austin B.
   Waldrop, Krysta
   Saad, Anthony
   Takigawa, Doreen
   Bhattacharyya, Dibakar
TI Development of bench and full-scale temperature and pH responsive
   functionalized PVDF membranes with tunable properties
SO JOURNAL OF MEMBRANE SCIENCE
LA English
DT Article
DE Polymerization; Poly(N-isopropylacrylamide); Polyacrylic acid; Tunable
   separation; Nanoparticle synthesis
ID POLY(ACRYLIC ACID)-GRAFT-POLY(VINYLIDENE FLUORIDE); MICROPOROUS
   POLYETHYLENE MEMBRANE; N-ISOPROPYLACRYLAMIDE; SENSITIVE MEMBRANES;
   ULTRAFILTRATION MEMBRANES; POLYCARBONATE FILMS;
   POLY(N-ISOPROPYLACRYLAMIDE); POLYMERIZATION; COPOLYMERS; MICROFILTRATION
AB Temperature and pH responsive polymers (poly(N-isopropylacrylamide) (PNIPAAm), and polyacrylic acid, PAA) were synthesized in one common macrofiltration PVDF membrane platform by pore-filling method. The microstructure and morphology of the PNIPAAm-PVDF, and PNIPAAm-FPAA-PVDF membranes were studied by attenuated total reflectance Fourier transform infrared (ATR-FTIR), thermogravimetric analysis (TGA), scanning electron microscopy (SEM) and atomic force microscopy (AFM). The membrane pore size was controlled by the swelling and shrinking of the PNIPAAm at the temperature around lower critical solution temperature (LCST). The composite membrane demonstrated a rapid and reversible swelling and deswelling change within a small temperature range. The controllable flux makes it possible to utilize this temperature responsive membrane as a valve to regulate filtration properties by temperature change. Dextran solution (M-w=2,000,000 g/mol, 26 nm diameter) was used to evaluate the separation performance of the temperature responsive membranes. The ranges of dextran rejection are from 4% to 95% depending on the temperature, monomer amount and pressure. The full-scale membrane was also developed to confirm the feasibility of our bench-scale experimental results. The full-scale membrane also exhibited both temperature and pH responsivity. This system was also used for controlled nanoparticles synthesis and for dechlorination reaction. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Xiao, Li; Isner, Austin; Waldrop, Krysta; Saad, Anthony; Bhattacharyya, Dibakar] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Takigawa, Doreen] Sepro Membranes Inc, Oceanside, CA 92056 USA.
RP Bhattacharyya, D (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM db@engr.uky.edu
FU National Institute of Environmental Health Sciences Superfund Research
   Program (NIEHS-SRP); US Department of Energy (DOE) KRCEE programs
FX This research was supported by National Institute of Environmental
   Health Sciences Superfund Research Program (NIEHS-SRP) and by the US
   Department of Energy (DOE) KRCEE programs. Austin Isner was in our
   NSF/REU program, Krysta Waldrop, and Anthony Saad (MIT, Chemical
   Engineering Student) were undergraduate researchers. The authors
   acknowledge Sepro Membrane, Inc., Oceanside, CA for the joint
   development work on the PVDF functionalized membranes.
CR Adem E, 2009, RADIAT PHYS CHEM, V78, P549, DOI 10.1016/j.radphyschem.2009.03.040
   Alexander C, 2008, NAT MATER, V7, P767, DOI 10.1038/nmat2281
   Cakmak S, 2013, MAT SCI ENG C-MATER, V33, P3033, DOI 10.1016/j.msec.2013.03.039
   Chan A, 2013, ADV DRUG DELIVER REV, V65, P497, DOI 10.1016/j.addr.2012.07.007
   Chen YC, 2013, J MEMBRANE SCI, V442, P206, DOI 10.1016/j.memsci.2013.04.041
   Chen Z, 2012, LANGMUIR, V28, P13452, DOI 10.1021/la3022535
   Cheng ZP, 2006, MACROMOLECULES, V39, P1660, DOI 10.1021/ma0520601
   Choi YJ, 2000, IND ENG CHEM RES, V39, P2491, DOI 10.1021/ie9907627
   Costa E, 2012, LANGMUIR, V28, P10082, DOI 10.1021/la301586t
   Curti PS, 2002, J MATER SCI-MATER M, V13, P1175, DOI 10.1023/A:1021154424189
   Debord JD, 2003, LANGMUIR, V19, P7662, DOI 10.1021/la0342924
   Du HB, 2010, J PHYS CHEM B, V114, P16594, DOI 10.1021/jp105652c
   Fan QX, 2009, J MEMBRANE SCI, V337, P175, DOI 10.1016/j.memsci.2009.03.032
   Fleige E, 2012, ADV DRUG DELIVER REV, V64, P866, DOI 10.1016/j.addr.2012.01.020
   Gui M, 2013, IND ENG CHEM RES, V52, P10430, DOI 10.1021/ie400507c
   He F, 2007, IND ENG CHEM RES, V46, P29, DOI 10.1021/ie0610896
   Hu JM, 2010, MACROMOLECULES, V43, P8315, DOI 10.1021/ma1005815
   Huang J, 2002, DESALINATION, V146, P345, DOI 10.1016/S0011-9164(02)00511-8
   Jones CD, 2003, LANGMUIR, V19, P4544, DOI 10.1021/la034392+
   Kobayashi J, 2011, COMPREHENSIVE BIOTECHNOLOGY, VOL 5: MEDICAL BIOTECHNOLOGY AND HEALTHCARE, 2ND EDITION, P51
   Lewis SR, 2011, P NATL ACAD SCI USA, V108, P8577, DOI 10.1073/pnas.1101144108
   Li Y, 2004, IND ENG CHEM RES, V43, P2643, DOI 10.1021/ie03433j
   Liang L, 2000, J MEMBRANE SCI, V177, P97, DOI 10.1016/S0376-7388(00)00453-1
   Lien HL, 2001, COLLOID SURFACE A, V191, P97, DOI 10.1016/S0927-7757(01)00767-1
   Lue SJ, 2007, J MEMBRANE SCI, V301, P142, DOI 10.1016/j.memsci.2007.06.020
   Lue SJ, 2011, J MEMBRANE SCI, V379, P330, DOI 10.1016/j.memsci.2011.06.002
   MATHESON LJ, 1994, ENVIRON SCI TECHNOL, V28, P2045, DOI 10.1021/es00061a012
   Perez RA, 2013, ADV DRUG DELIVER REV, V65, P471, DOI 10.1016/j.addr.2012.03.009
   Reijenga JC, 2007, J CHROMATOGR A, V1155, P142, DOI 10.1016/j.chroma.2006.09.084
   Roy D, 2010, PROG POLYM SCI, V35, P278, DOI 10.1016/j.progpolymsci.2009.10.008
   Russell TP, 2002, SCIENCE, V297, P964, DOI 10.1126/science.1075997
   Rzaev ZMO, 2007, PROG POLYM SCI, V32, P534, DOI 10.1016/j.progpolymsci.2007.01.006
   Shim JK, 1999, J APPL POLYM SCI, V74, P75, DOI 10.1002/(SICI)1097-4628(19991003)74:1<75::AID-APP8>3.0.CO;2-4
   Shtanko NI, 2000, J MEMBRANE SCI, V179, P155, DOI 10.1016/S0376-7388(00)00494-4
   Sieradzki K, 2011, SCIENCE, V332, P1158, DOI 10.1126/science.1206856
   Smuleac V, 2010, J MEMBRANE SCI, V346, P310, DOI 10.1016/j.memsci.2009.09.052
   Stuart MAC, 2010, NAT MATER, V9, P101, DOI [10.1038/NMAT2614, 10.1038/nmat2614]
   Susanto H, 2007, LANGMUIR, V23, P7818, DOI 10.1021/la700579x
   Tan XY, 2006, J MEMBRANE SCI, V271, P59, DOI 10.1016/j.memsci.2005.06.057
   Wandera D, 2010, J MEMBRANE SCI, V357, P6, DOI 10.1016/j.memsci.2010.03.046
   Wang XL, 2002, DESALINATION, V146, P337, DOI 10.1016/S0011-9164(02)00509-X
   Wong MCY, 2012, DESALINATION, V287, P340, DOI 10.1016/j.desal.2011.10.013
   Xiao L, 2013, J APPL POLYM SCI, V128, P1804, DOI 10.1002/app.38335
   Xiaoling W., 2007, J APPL POLYM SCI, V104, P3614
   Xing ZM, 2010, COLLOID POLYM SCI, V288, P1723, DOI 10.1007/s00396-010-2316-5
   Xu J, 2007, IND ENG CHEM RES, V46, P2348, DOI 10.1021/ie0611498
   Ying L, 2004, LANGMUIR, V20, P6032, DOI 10.1021/la049383v
   Ying L, 2003, J MEMBRANE SCI, V224, P93, DOI 10.1016/j.memsci.2003.07.002
   Ying L, 2002, LANGMUIR, V18, P6416, DOI 10.1021/la020241f
   Ying L, 2002, MACROMOLECULES, V35, P673, DOI 10.1021/ma0112568
   Yu JZ, 2011, J MEMBRANE SCI, V366, P176, DOI 10.1016/j.memsci.2010.09.055
   Zhang Y, 2013, ADV DRUG DELIVER REV, V65, P104, DOI 10.1016/j.addr.2012.10.003
NR 52
TC 15
Z9 15
U1 8
U2 86
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0376-7388
EI 1873-3123
J9 J MEMBRANE SCI
JI J. Membr. Sci.
PD MAY 1
PY 2014
VL 457
BP 39
EP 49
DI 10.1016/j.memsci.2014.01.033
PG 11
WC Engineering, Chemical; Polymer Science
SC Engineering; Polymer Science
GA AD8AB
UT WOS:000333487800005
PM 24944434
OA green_accepted
DA 2018-03-19
ER

PT J
AU Rabek, CL
   Van Stelle, R
   Dziubla, TD
   Puleo, DA
AF Rabek, Cheryl L.
   Van Stelle, Rachel
   Dziubla, Thomas D.
   Puleo, David A.
TI The effect of plasticizers on the erosion and mechanical properties of
   polymeric films
SO JOURNAL OF BIOMATERIALS APPLICATIONS
LA English
DT Article
DE Drug delivery film; plasticizer; cellulose acetate phthalate; erosion;
   tensile testing
ID CONTROLLED-RELEASE; DRUG-DELIVERY; COMPOSITE; SYSTEM; ACID; DRY
AB Cellulose acetate phthalate and Pluronic F-127 combined together (70:30 wt:wt) create a rigid, surface-eroding association polymer. To impart flexibility into the polymer system and allow for a drug delivery film that can contour to varying wound shapes, plasticizers were added. Triethyl citrate or tributyl citrate was combined with cellulose acetate phthalate and Pluronic F-127 at 0, 10, or 20wt%. Mechanical analysis was performed on the films as they were prepared and following a 2-h incubation in phosphate-buffered saline. Tensile tests showed that higher plasticizer content increased the % elongation but decreased the elastic modulus and ultimate tensile strength. The effect triethyl citrate had on the % elongation was twice as much than that of tributyl citrate. After incubation, % elongation, elastic modulus, and ultimate tensile strength all increased because plasticizer leached out of the films. Microcomputed tomography and scanning electron microscopy were performed on the samples both before and after incubation to determine how erosion and leaching of plasticizer affected the interior and exterior structure of the films. Porosity increased as plasticizer content increased; however, plasticizer content did not have a significant effect on the rate of erosion. The mechanical properties of cellulose acetate phthalate-Pluronic films can be adjusted by the type and amount of plasticizer added to the system and therefore can be tailored for different drug delivery applications.
C1 [Rabek, Cheryl L.; Puleo, David A.] Univ Kentucky, Ctr Biomed Engn, Lexington, KY 40506 USA.
   [Van Stelle, Rachel] Lockheed Martin Corp, Denver, CO USA.
   [Dziubla, Thomas D.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY USA.
RP Puleo, DA (reprint author), Univ Kentucky, Ctr Biomed Engn, Wenner Gren Res Lab 209, Lexington, KY 40506 USA.
EM puleo@uky.edu
FU NIH [DE019645, AR060964]; NSF [EPS-0814194, EEC-0851716]; NSF IGERT
   [DGE-0653710]
FX This research was supported in part by the NIH (DE019645 and AR060964)
   and NSF (EPS-0814194 and EEC-0851716). CR was supported by NSF IGERT
   (DGE-0653710).
CR Anderson JM, 2001, ANNU REV MATER RES, V31, P81, DOI 10.1146/annurev.matsci.31.1.81
   Azeredo HMC, 2010, J FOOD SCI, V75, pN1, DOI 10.1111/j.1750-3841.2009.01386.x
   Baumgart F, 2000, INJURY, V31, P14
   BECHARD SR, 1995, INT J PHARM, V114, P205, DOI 10.1016/0378-5173(94)00239-2
   BODMEIER R, 1993, INT J PHARM, V96, P129, DOI 10.1016/0378-5173(93)90220-A
   Bruggeman JP, 2008, BIOMATERIALS, V29, P4726, DOI 10.1016/j.biomaterials.2008.08.037
   Chaibundit C, 2010, J COLLOID INTERF SCI, V351, P190, DOI 10.1016/j.jcis.2010.07.023
   Chan LMS, 2004, EUR J PHARM SCI, V21, P25, DOI 10.1016/j.ejps.2003.07.003
   El-Gendy NA, 2012, CURR DRUG DELIV, V9, P148
   Elgindy N, 2009, INT J PHARMACEUT, V376, P1, DOI 10.1016/j.ijpharm.2009.03.026
   FINKELSTEIN M, 1959, TOXICOL APPL PHARM, V1, P283, DOI 10.1016/0041-008X(59)90113-9
   GLARE PA, 1991, THER DRUG MONIT, V13, P1, DOI 10.1097/00007691-199101000-00001
   Gungor S, 2012, RECENT ADVANCES IN PLASTICIZERS, P91
   Huang SJ, 2009, EUR J PHARM SCI, V38, P64, DOI 10.1016/j.ejps.2009.06.002
   Jeon JH, 2008, BIOMATERIALS, V29, P3591, DOI 10.1016/j.biomaterials.2008.05.011
   Jeon JH, 2007, INT J PHARM, V340, P6, DOI 10.1016/j.ijpharm.2007.03.007
   Jeu L, 2003, CLIN THER, V25, P1321, DOI 10.1016/S0149-2918(03)80126-1
   Kranz H, 2000, J PHARM SCI, V89, P1558
   Kumar AR, 2009, J TRAUMA, V67, P752, DOI 10.1097/TA.0b013e3181808115
   Lemperle G, 2003, AESTHET PLAST SURG, V27, P354, DOI 10.1007/s00266-003-3022-1
   Liu JP, 2002, EUR J PHARM SCI, V17, P31, DOI 10.1016/S0928-0987(02)00131-8
   Palmieri GF, 2000, DRUG DEV IND PHARM, V26, P837, DOI 10.1081/DDC-100101307
   Platzer N., 1982, J POLYM SCI POL LETT
   Polisson R, 1996, AM J MED, V100, pS31, DOI 10.1016/S0002-9343(97)89544-7
   Rahman M, 2004, PROG POLYM SCI, V29, P1223, DOI 10.1016/j.progpolymsci.2004.10.001
   Sastri VR, 2010, PDL HANDB SER, P1
   Shelke NB, 2007, INT J PHARM, V345, P51, DOI 10.1016/j.ijpharm.2007.05.036
   Snejdrova E, 2012, RECENT ADVANCES IN PLASTICIZERS, P45
   Tan Q, 2011, INT J NANOMED, V6, P1621, DOI 10.2147/IJN.S22411
   Thummel KE, 1996, CLIN PHARMACOL THER, V59, P491, DOI 10.1016/S0009-9236(96)90177-0
   Thummel KE, 1997, ADV DRUG DELIVER REV, V27, P99, DOI 10.1016/S0169-409X(97)00039-2
   Triethyl Citrate, 2012, TRIETHYL CITRATE
   Wu LB, 2006, J BIOMED MATER RES A, V76A, P264, DOI 10.1002/jbm.a.30544
   Wypach G, 2004, HDB PLASTICIZERS
   XU X, 1993, PHARMACEUT RES, V10, P1144, DOI 10.1023/A:1018960016756
   Yano H, 2002, J CONTROL RELEASE, V79, P103, DOI 10.1016/S0168-3659(01)00532-6
   Zheng XT, 2008, J BIOMED MATER RES B, V86B, P170, DOI 10.1002/jbm.b.31003
   Zhu YC, 2006, PHARM DEV TECHNOL, V11, P285, DOI 10.1080/10409230600767551
NR 38
TC 5
Z9 5
U1 0
U2 6
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0885-3282
EI 1530-8022
J9 J BIOMATER APPL
JI J. Biomater. Appl.
PD JAN
PY 2014
VL 28
IS 5
BP 779
EP 789
DI 10.1177/0885328213480979
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 278HT
UT WOS:000328880600013
PM 23520360
OA green_accepted
DA 2018-03-20
ER

PT J
AU Singh, R
   Benson, A
   Saatman, K
   Geddes, J
AF Singh, Ranjana
   Benson, Adam
   Saatman, Kathryn E.
   Geddes, James W.
TI CALPAIN 5 IS EXPRESSED IN NEURONS AND MAY CONTRIBUTE TO
   NEURODEGENERATION FOLLOWING TRAUMATIC BRAIN INJURY
SO JOURNAL OF NEUROTRAUMA
LA English
DT Meeting Abstract
CT 29th Annual National Neurotrauma Symposium
CY JUL 10-13, 2011
CL Hollywood Beach, FL
C1 [Singh, Ranjana; Geddes, James] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA.
   [Singh, Ranjana; Benson, Adam; Saatman, Kathryn; Geddes, James] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr SCoBIRC, Lexington, KY 40536 USA.
   [Saatman, Kathryn] Univ Kentucky, Dept Physiol, Lexington, KY 40536 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0897-7151
J9 J NEUROTRAUM
JI J. Neurotrauma
PD JUN
PY 2011
VL 28
IS 6
BP A86
EP A86
PG 1
WC Critical Care Medicine; Clinical Neurology; Neurosciences
SC General & Internal Medicine; Neurosciences & Neurology
GA 788PT
UT WOS:000292457600271
DA 2018-03-20
ER

PT J
AU Sewell, MK
   Fugit, KD
   Ankareddi, I
   Zhang, CQ
   Hampel, ML
   Kim, DH
   Brazel, CS
AF Sewell, Mary Kathryn
   Fugit, Kyle D.
   Ankareddi, Induvadana
   Zhang, Chuanqian
   Hampel, Mary L.
   Kim, Dong-Hyun
   Brazel, Christopher S.
TI PMSE 391-Magnetothermally-triggered drug delivery using hydrogels with
   imbedded cobalt ferrite, iron platinum or manganese ferrite
   nanoparticles
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
CT 235th American-Chemical-Society National Meeting
CY APR 06-10, 2008
CL New Orleans, LA
C1 [Sewell, Mary Kathryn; Fugit, Kyle D.; Ankareddi, Induvadana; Zhang, Chuanqian; Hampel, Mary L.; Kim, Dong-Hyun; Brazel, Christopher S.] Univ Alabama, Dept Chem & Biol Engn, Tuscaloosa, AL 35487 USA.
EM dhkim0405@gmail.com; cbrazel@eng.ua.edu
RI Brazel, Christopher/E-9085-2012
NR 0
TC 0
Z9 0
U1 0
U2 5
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD APR 6
PY 2008
VL 235
MA 391-PMSE
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA 519XJ
UT WOS:000271802800032
DA 2018-03-20
ER

PT J
AU Hauser, AK
   Wydra, RJ
   Stocke, NA
   Anderson, KW
   Hilt, JZ
AF Hauser, Anastasia K.
   Wydra, Robert J.
   Stocke, Nathanael A.
   Anderson, Kimberly W.
   Hilt, J. Zach
TI Magnetic nanoparticles and nanocomposites for remote controlled
   therapies
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Magnetic nanoparticles; Remote controlled drug delivery; Nanocomposites
ID IRON-OXIDE NANOPARTICLES; CONTROLLED DRUG-RELEASE; ON-DEMAND RELEASE;
   LYSOSOMAL MEMBRANE PERMEABILIZATION; BILAYER-DECORATED MAGNETOLIPOSOMES;
   MESOPOROUS SILICA NANOPARTICLES; CHAIN-LIKE NANOPARTICLE; CELLS
   IN-VITRO; FLUID HYPERTHERMIA; PROSTATE-CANCER
AB This review highlights the state-of-the-art in the application of magnetic nanoparticles (MNPs) and their composites for remote controlled therapies. Novel macro-to nano-scale systems that utilize remote controlled drug release due to actuation of MNPs by static or alternating magnetic fields and magnetic field guidance of MNPs for drug delivery applications are summarized. Recent advances in controlled energy release for thermal therapy and nanoscale energy therapy are addressed as well. Additionally, studies that utilize MNP-based thermal therapy in combination with other treatments such as chemotherapy or radiation to enhance the efficacy of the conventional treatment are discussed. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Hauser, Anastasia K.; Wydra, Robert J.; Stocke, Nathanael A.; Anderson, Kimberly W.; Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Hilt, JZ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 F Paul Anderson Tower, Lexington, KY 40506 USA.
EM hilt@engr.uky.edu
FU National Cancer Institute [R25CA153954]; National Science Foundation
   [DGE-1247392]
FX AKH, RJW, and NAS were partially supported by Grant Number R25CA153954
   from the National Cancer Institute. The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the National Cancer Institute or the National
   Institutes of Health. Additionally, AKH was partially supported by the
   National Science Foundation Graduate Research Fellowship Program Grant
   No. DGE-1247392. Any opinions, findings, and conclusions or
   recommendations expressed in this material are those of the author(s)
   and do not necessarily reflect the views of the National Science
   Foundation.
CR Ally J, 2005, J MAGN MAGN MATER, V293, P442, DOI 10.1016/j.jmmm.2005.02.038
   Alvarez-Berrios MP, 2015, BIOMATER SCI-UK, V3, P391, DOI 10.1039/c4bm00223g
   Alvarez-Berrios MP, 2014, INT J NANOMED, V9, P145, DOI 10.2147/IJN.S51435
   Alvarez-Berrios MP, 2013, INT J NANOMED, V8, P1003, DOI 10.2147/IJN.S38842
   Amorino GP, 1996, J MEMBRANE BIOL, V152, P217, DOI 10.1007/s002329900099
   Amstad E, 2011, NANOSCALE, V3, P2819, DOI 10.1039/c1nr10173k
   Amstad E, 2011, NANO LETT, V11, P1664, DOI 10.1021/nl2001499
   Auerbach M, 2008, AM J KIDNEY DIS, V52, P826, DOI 10.1053/j.ajkd.2008.09.006
   Babincova M, 2007, OPTOELECTRON ADV MAT, V1, P644
   Babincova M, 2002, BIOELECTROCHEMISTRY, V55, P17, DOI 10.1016/S1567-5394(01)00171-2
   Babincova M, 2008, IEEE T NANOBIOSCI, V7, P15, DOI 10.1109/TNB.2008.2000145
   Babincova M, 2009, DIG J NANOMATER BIOS, V4, P395
   Bae KH, 2012, ACS NANO, V6, P5266, DOI 10.1021/nn301046w
   Baeza A, 2012, CHEM MATER, V24, P517, DOI 10.1021/cm203000u
   Balasubramanian S., 2014, INT J NANOMEDICINE, V9
   Bannwarth MB, 2014, MACROMOL BIOSCI, V14, P1205, DOI 10.1002/mabi.201400122
   Berry CC, 2009, J PHYS D APPL PHYS, V42, DOI 10.1088/0022-3727/42/22/224003
   Berry CC, 2003, J PHYS D APPL PHYS, V36, pR198, DOI 10.1088/0022-3727/36/13/203
   Bertoglio P, 2010, J APPL POLYM SCI, V115, P1859, DOI 10.1002/app.31315
   Bonini M, 2013, CURR OPIN COLLOID IN, V18, P459, DOI 10.1016/j.cocis.2013.07.007
   Bothun GD, 2011, NANOMED-NANOTECHNOL, V7, P797, DOI 10.1016/j.nano.2011.02.007
   Brazel CS, 2009, PHARM RES-DORD, V26, P644, DOI 10.1007/s11095-008-9773-2
   Bringas E, 2012, CHEM COMMUN, V48, P5647, DOI 10.1039/c2cc31563g
   Brule S, 2011, ADV MATER, V23, P787, DOI 10.1002/adma.201003763
   Brusentsov NA, 2007, J MAGN MAGN MATER, V311, P176, DOI 10.1016/j.jmmm.2006.11.159
   Bruvera IJ, 2015, J MAGN MAGN MATER, V377, P446, DOI 10.1016/j.jmmm.2014.10.149
   Byrne JD, 2008, ADV DRUG DELIVER REV, V60, P1615, DOI 10.1016/j.addr.2008.08.005
   Cai KY, 2009, ADV MATER, V21, P4045, DOI 10.1002/adma.200900593
   Campbell S, 2015, ACS MACRO LETT, V4, P312, DOI 10.1021/acsmacrolett.5b00057
   Campbell SB, 2013, BIOMACROMOLECULES, V14, P644, DOI 10.1021/bm301703x
   Cezar CA, 2014, ADV HEALTHC MATER, V3, P1869, DOI 10.1002/adhm.201400095
   Chen YJ, 2014, COLLOID SURFACE B, V116, P452, DOI 10.1016/j.colsurfb.2014.01.022
   Chen YJ, 2010, ACS NANO, V4, P3215, DOI 10.1021/nn100274v
   Chertok B, 2008, BIOMATERIALS, V29, P487, DOI 10.1016/j.biomaterials.2007.08.050
   Chiang WL, 2012, SMALL, V8, P3584, DOI 10.1002/smll.201201743
   Cho MH, 2012, NAT MATER, V11, P1038, DOI [10.1038/NMAT3430, 10.1038/nmat3430]
   Chorny M, 2013, FASEB J, V27, P2198, DOI 10.1096/fj.12-224659
   Chorny M, 2011, IUBMB LIFE, V63, P613, DOI [10.1002/iub.479, 10.1002/iub.00479]
   Chorny M, 2010, P NATL ACAD SCI USA, V107, P8346, DOI 10.1073/pnas.0909506107
   Chu X., 2015, CHINESE PHYS B, V24, P8
   Cochran DB, 2013, BIOMATERIALS, V34, P9615, DOI 10.1016/j.biomaterials.2013.08.025
   Connord V., 2015, SMALL
   Creixell M, 2011, ACS NANO, V5, P7124, DOI 10.1021/nn201822b
   Creixell M, 2010, J MAGN MAGN MATER, V322, P2244, DOI 10.1016/j.jmmm.2010.02.019
   Dames P, 2007, NAT NANOTECHNOL, V2, P495, DOI 10.1038/nnano.2007.217
   Danhier F, 2010, J CONTROL RELEASE, V148, P135, DOI 10.1016/j.jconrel.2010.08.027
   De la Fuente JM, 2006, BBA-GEN SUBJECTS, V1760, P636, DOI 10.1016/j.bbagen.2005.12.001
   Demarchi CA, 2014, SOFT MATTER, V10, P3441, DOI 10.1039/c3sm53157k
   Derfus AM, 2007, ADV MATER, V19, P3932, DOI 10.1002/adma.200700091
   Di Corato R, 2014, BIOMATERIALS, V35, P6400, DOI 10.1016/j.biomaterials.2014.04.036
   Dobson J, 2006, DRUG DEVELOP RES, V67, P55, DOI 10.1002/ddr.20067
   Domenech M, 2013, ACS NANO, V7, P5091, DOI 10.1021/nn4007048
   DRISCOLL CF, 1984, MICROVASC RES, V27, P353, DOI 10.1016/0026-2862(84)90065-7
   Duguet E, 2006, NANOMEDICINE-UK, V1, P157, DOI 10.2217/17435889.1.2.157
   EDELMAN ER, 1993, BIOMATERIALS, V14, P621, DOI 10.1016/0142-9612(93)90182-2
   EDELMAN ER, 1984, T AM SOC ART INT ORG, V30, P445
   EDELMAN ER, 1985, J BIOMED MATER RES, V19, P67, DOI 10.1002/jbm.820190107
   EDELMAN ER, 1987, J BIOMED MATER RES, V21, P339, DOI 10.1002/jbm.820210307
   Erdal H, 2005, P NATL ACAD SCI USA, V102, P192, DOI 10.1073/pnas.0408592102
   Fattahi H, 2011, NANOMEDICINE-UK, V6, P529, DOI [10.2217/nnm.11.14, 10.2217/NNM.11.14]
   Fortin JP, 2008, EUR BIOPHYS J BIOPHY, V37, P223, DOI 10.1007/s00249-007-0197-4
   Francois NJ, 2007, J APPL POLYM SCI, V105, P647, DOI 10.1002/app.26321
   Frimpong RA, 2010, NANOMEDICINE-UK, V5, P1401, DOI 10.2217/NNM.10.114
   Gajda AM, 2014, J MATER CHEM B, V2, P1317, DOI 10.1039/c3tb21400a
   Gao F.P., 2012, J NANOPARTICLE RES, V14
   Gautier J, 2013, J CONTROL RELEASE, V169, P48, DOI 10.1016/j.jconrel.2013.03.018
   GORDON RT, 1979, MED HYPOTHESES, V5, P83, DOI 10.1016/0306-9877(79)90063-X
   Goya GF, 2008, CURR NANOSCI, V4, P1, DOI 10.2174/157341308783591861
   Guilherme MR, 2012, SOFT MATTER, V8, P6629, DOI 10.1039/c2sm25638j
   Guo HY, 2015, CARBOHYD POLYM, V118, P209, DOI 10.1016/j.carbpol.2014.10.076
   Gupta AK, 2005, BIOMATERIALS, V26, P3995, DOI 10.1016/j.biomaterials.2004.10.012
   Halamikova A, 2007, CHEMBIOCHEM, V8, P2008, DOI 10.1002/cbic.200700288
   Hasenpusch G, 2012, PHARM RES-DORDR, V29, P1308, DOI 10.1007/s11095-012-0682-z
   Hawkins AM, 2012, ADV HEALTHC MATER, V1, P96, DOI 10.1002/adhm.201100013
   Hawkins AM, 2009, PHARM RES-DORD, V26, P667, DOI 10.1007/s11095-008-9804-z
   Hayashi K, 2014, THERANOSTICS, V4, P834, DOI 10.7150/thno.9199
   Hayashi K, 2010, ACS APPL MATER INTER, V2, P1903, DOI 10.1021/am100237p
   He ZW, 2011, ADV MATER, V23, P3192, DOI 10.1002/adma.201100646
   Hervault A, 2014, NANOSCALE, V6, P11553, DOI 10.1039/c4nr03482a
   Hildebrandt B, 2002, CRIT REV ONCOL HEMAT, V43, P33, DOI 10.1016/S1040-8428(01)00179-2
   Ho D, 2011, ACCOUNTS CHEM RES, V44, P875, DOI 10.1021/ar200090c
   Hoare T, 2011, NANO LETT, V11, P1395, DOI 10.1021/nl200494t
   Hoare T, 2009, NANO LETT, V9, P3651, DOI 10.1021/nl9018935
   Horsman MR, 2007, CLIN ONCOL-UK, V19, P418, DOI 10.1016/j.clon.2007.03.015
   HSIEH DST, 1981, P NATL ACAD SCI-BIOL, V78, P1863, DOI 10.1073/pnas.78.3.1863
   Hu RL, 2011, ONCOL LETT, V2, P1161, DOI 10.3892/ol.2011.379
   Hu SH, 2008, ADV FUNCT MATER, V18, P2946, DOI 10.1002/adfm.200800428
   Hu SH, 2008, LANGMUIR, V24, P11811, DOI 10.1021/la801138e
   Hu SH, 2008, ADV MATER, V20, P2690, DOI 10.1002/adma.200800193
   Hu SH, 2008, LANGMUIR, V24, P239, DOI 10.1021/la701570z
   Hu SH, 2007, J CONTROL RELEASE, V121, P181, DOI 10.1016/j.jconrel.2007.06.002
   Hu SH, 2007, MACROMOLECULES, V40, P6786, DOI 10.1021/ma0707584
   Hu SH, 2012, ADV MATER, V24, P3627, DOI 10.1002/adma.201201251
   Hu SH, 2012, ACS NANO, V6, P2558, DOI 10.1021/nn205023w
   Huang H, 2010, NAT NANOTECHNOL, V5, P602, DOI [10.1038/NNANO.2010.125, 10.1038/nnano.2010.125]
   Huang JY, 2015, CERAM INT, V41, P2399, DOI 10.1016/j.ceramint.2014.10.054
   Huang WC, 2009, J CONTROL RELEASE, V139, P221, DOI 10.1016/j.jconrel.2009.07.002
   Hughes S, 2005, MED ENG PHYS, V27, P754, DOI 10.1016/j.medengphy.2005.04.006
   Hurwitz MD, 2011, CANCER-AM CANCER SOC, V117, P510, DOI 10.1002/cncr.25619
   Islam T, 2009, CANCER BIOMARK, V5, P99, DOI 10.3233/CBM-2009-0615
   Issels RD, 2008, EUR J CANCER, V44, P2546, DOI 10.1016/j.ejca.2008.07.038
   Itoh Y, 2010, EXP THER MED, V1, P319, DOI 10.3892/etm_00000049
   Ivkov R, 2005, CLIN CANCER RES, V11, p7093S, DOI 10.1158/1078-0432.CCR-1004-0016
   Iyer AK, 2006, DRUG DISCOV TODAY, V11, P812, DOI 10.1016/j.drudis.2006.07.005
   Jaattela M, 2004, ONCOGENE, V23, P2746, DOI 10.1038/sj.onc.1207513
   Jaiswal MK, 2014, ACS APPL MATER INTER, V6, P6237, DOI 10.1021/am501067j
   Jhaveri A, 2014, J CONTROL RELEASE, V190, P352, DOI 10.1016/j.jconrel.2014.05.002
   Johannsen M, 2004, J ENDOUROL, V18, P495, DOI 10.1089/0892779041271715
   Johannsen M, 2006, PROSTATE, V66, P97, DOI 10.1002/pros.20324
   Johannsen M, 2005, PROSTATE, V64, P283, DOI 10.1002/pros.20213
   Johannsen M, 2007, INT J HYPERTHER, V23, P315, DOI 10.1080/02656730601175479
   Johannsen M, 2007, EUR UROL, V52, P1653, DOI 10.1016/j.eururo.2006.11.023
   Johansson AC, 2010, APOPTOSIS, V15, P527, DOI 10.1007/s10495-009-0452-5
   Jordan A, 1999, J MAGN MAGN MATER, V194, P185, DOI 10.1016/S0304-8853(98)00558-7
   Jordan A, 2006, J NEURO-ONCOL, V78, P7, DOI 10.1007/s11060-005-9059-z
   Jordan A, 1996, INT J HYPERTHER, V12, P705, DOI 10.3109/02656739609027678
   Joshi-Barr S, 2014, ANTIOXID REDOX SIGN, V21, P730, DOI 10.1089/ars.2013.5754
   Kalambur VS, 2007, LANGMUIR, V23, P12329, DOI 10.1021/la701100r
   Kallumadil M, 2009, J MAGN MAGN MATER, V321, P1509, DOI 10.1016/j.jmmm.2009.02.075
   Katagiri K, 2011, J COLLOID INTERF SCI, V361, P109, DOI 10.1016/j.jcis.2011.05.035
   Katagiri K, 2011, SMALL, V7, P1683, DOI 10.1002/smll.201002180
   Katagiri K, 2010, ACS APPL MATER INTER, V2, P768, DOI 10.1021/am900784a
   Kettering M, 2007, NANOTECHNOLOGY, V18, DOI 10.1088/0957-4484/18/17/175101
   Kievit FM, 2012, ACS NANO, V6, P2591, DOI 10.1021/nn205070h
   Kievit FM, 2011, ACCOUNTS CHEM RES, V44, P853, DOI 10.1021/ar2000277
   Kim DH, 2013, LANGMUIR, V29, P7425, DOI 10.1021/la3044158
   Kirkegaard T, 2009, BBA-MOL CELL RES, V1793, P746, DOI 10.1016/j.bbamcr.2008.09.008
   Klein S, 2012, BIOCHEM BIOPH RES CO, V425, P393, DOI 10.1016/j.bbrc.2012.07.108
   Kolosnjaj-Tabi J, 2014, ACS NANO, V8, P4268, DOI 10.1021/nn405356r
   Kong SD, 2012, J VAC SCI TECHNOL B, V30, DOI 10.1116/1.3694833
   KOST J, 1986, PHARM INT, V7, P60
   KOST J, 1985, J BIOMED MATER RES, V19, P935, DOI 10.1002/jbm.820190805
   KOST J, 1987, J BIOMED MATER RES, V21, P1367, DOI 10.1002/jbm.820211202
   Kozissnik B, 2013, INT J HYPERTHER, V29, P706, DOI 10.3109/02656736.2013.837200
   Kruse AM, 2014, ACTA BIOMATER, V10, P2622, DOI 10.1016/j.actbio.2014.01.025
   Kulshrestha P, 2012, COLLOID SURFACE B, V96, P1, DOI 10.1016/j.colsurfb.2012.02.029
   Kumar CSSR, 2011, ADV DRUG DELIVER REV, V63, P789, DOI 10.1016/j.addr.2011.03.008
   Kut C, 2012, NANOMEDICINE-UK, V7, P1697, DOI [10.2217/NNM.12.65, 10.2217/nnm.12.65]
   LANGER R, 1985, ANN NY ACAD SCI, V446, P1, DOI 10.1111/j.1749-6632.1985.tb18386.x
   LANGER R, 1985, METHOD ENZYMOL, V112, P399
   Lartigue L, 2012, ACS NANO, V6, P10935, DOI 10.1021/nn304477s
   Laurent S, 2011, ADV COLLOID INTERFAC, V166, P8, DOI 10.1016/j.cis.2011.04.003
   Le B, 2001, J CHEM ENG JPN, V34, P66, DOI 10.1252/jcej.34.66
   Lee JH, 2011, NAT NANOTECHNOL, V6, P418, DOI [10.1038/nnano.2011.95, 10.1038/NNANO.2011.95]
   Lee JS, 2011, J NANOSCI NANOTECHNO, V11, P4153, DOI 10.1166/jnn.2011.3821
   Li J.B., 2012, NANOTECHNOLOGY, V23, P10
   Li TJ, 2013, BIOMATERIALS, V34, P7873, DOI 10.1016/j.biomaterials.2013.07.012
   Li YH, 2013, ADV FUNCT MATER, V23, P660, DOI 10.1002/adfm.201201708
   Liu JW, 2010, J PHYS CHEM C, V114, P7673, DOI 10.1021/jp911933b
   Liu J, 2015, SCI ADV MATER, V7, P672, DOI 10.1166/sam.2015.1887
   Liu M, 2015, J BIOMED NANOTECHNOL, V11, P979, DOI 10.1166/jbn.2015.2013
   Liu TY, 2008, J CONTROL RELEASE, V126, P228, DOI 10.1016/j.jconrel.2007.12.006
   Liu TY, 2006, LANGMUIR, V22, P5974, DOI 10.1021/la060371e
   Liu TY, 2006, J MAGN MAGN MATER, V304, pE397, DOI 10.1016/j.jmmm.2006.01.203
   Liu TY, 2009, NANO TODAY, V4, P52, DOI 10.1016/j.nantod.2008.10.011
   Liu TY, 2009, ADV FUNCT MATER, V19, P616, DOI 10.1002/adfm.200801304
   Liu TY, 2008, LANGMUIR, V24, P13306, DOI 10.1021/la801451v
   Louguet S, 2012, POLYM CHEM-UK, V3, P1408, DOI 10.1039/c2py20089a
   Lu ZH, 2005, LANGMUIR, V21, P2042, DOI 10.1021/la047629q
   Lubbe AS, 1996, CANCER RES, V56, P4686
   Corchero J, 2009, TRENDS BIOTECHNOL, V27, P468, DOI 10.1016/j.tibtech.2009.04.003
   Mahmoudi M, 2012, CHEM REV, V112, P2323, DOI 10.1021/cr2002596
   Mahon E, 2012, J CONTROL RELEASE, V161, P164, DOI 10.1016/j.jconrel.2012.04.009
   Maier-Hauff K, 2011, J NEURO-ONCOL, V103, P317, DOI 10.1007/s11060-010-0389-0
   Malvindi MA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085835
   Mannix RJ, 2008, NAT NANOTECHNOL, V3, P36, DOI 10.1038/nnano.2007.418
   McGill SL, 2009, IEEE T NANOBIOSCI, V8, P33, DOI 10.1109/TNB.2009.2017292
   Mengesha AE, 2013, PHARM RES-DORDR, V30, P3214, DOI 10.1007/s11095-013-1230-1
   Mornet S, 2004, J MATER CHEM, V14, P2161, DOI 10.1039/b402025a
   Moroz P, 2002, INT J HYPERTHER, V18, P267, DOI 10.1080/02656730110108785
   MOSBACH K, 1979, FEBS LETT, V102, P112, DOI 10.1016/0014-5793(79)80940-0
   Muller-Schulte D, 2006, J MAGN MAGN MATER, V302, P267, DOI 10.1016/j.jmmm.2005.05.043
   Muro S, 2012, J CONTROL RELEASE, V164, P125, DOI 10.1016/j.jconrel.2012.05.052
   Mustafa T, 2013, BIOMATER SCI-UK, V1, P870, DOI 10.1039/c3bm60015g
   Muthiah M, 2013, BIOTECHNOL ADV, V31, P1224, DOI 10.1016/j.biotechadv.2013.03.005
   N'Guyen TTT, 2013, ANGEW CHEM INT EDIT, V52, P14152, DOI 10.1002/anie.201306724
   Nair M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3729
   Nappini S, 2010, SOFT MATTER, V6, P154, DOI 10.1039/b915651h
   Nappini S, 2011, SOFT MATTER, V7, P4801, DOI 10.1039/c0sm01264e
   Nappini S, 2011, J PHYS CHEM LETT, V2, P713, DOI 10.1021/jz2000936
   Nappini S, 2011, SOFT MATTER, V7, P1025, DOI 10.1039/c0sm00789g
   Naqvi S, 2010, INT J NANOMED, V5, P983, DOI 10.2147/IJN.S13244
   Neshasteh-Riz A, 2014, CELL J, V16, P335
   Oliveira H, 2013, J CONTROL RELEASE, V169, P165, DOI 10.1016/j.jconrel.2013.01.013
   Pankhurst QA, 2009, J PHYS D APPL PHYS, V42, DOI 10.1088/0022-3727/42/22/224001
   Pankhurst QA, 2003, J PHYS D APPL PHYS, V36, pR167, DOI 10.1088/0022-3727/36/13/201
   Peiris PM, 2015, CANCER RES, V75, P1356, DOI 10.1158/0008-5472.CAN-14-1540
   Peiris PM, 2014, PHARM RES-DORDR, V31, P1460, DOI 10.1007/s11095-013-1102-8
   Peiris PM, 2014, J CONTROL RELEASE, V173, P51, DOI 10.1016/j.jconrel.2013.10.031
   Peiris PM, 2012, ACS NANO, V6, P4157, DOI 10.1021/nn300652p
   Petryk AA, 2013, INT J HYPERTHER, V29, P845, DOI 10.3109/02656736.2013.825014
   Plank C, 2003, EXPERT OPIN BIOL TH, V3, P745, DOI 10.1517/14712598.3.5.745
   Polo-Corrales L, 2012, J APPL PHYS, V111, DOI 10.1063/1.3680532
   Polyak B, 2009, EXPERT OPIN DRUG DEL, V6, P53, DOI [10.1517/17425240802662795, 10.1517/17425240802662795 ]
   Purushotham S, 2010, ACTA BIOMATER, V6, P502, DOI 10.1016/j.actbio.2009.07.004
   Purushotham S, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/30/305101
   Qin J, 2009, ADV MATER, V21, P1354, DOI 10.1002/adma.200800764
   Qiu D, 2013, COLLOID SURFACE B, V104, P326, DOI 10.1016/j.colsurfb.2012.11.033
   Qu Y, 2014, NANOSCALE, V6, P12408, DOI 10.1039/c4nr03384a
   Qu Y, 2014, ACS APPL MATER INTER, V6, P16867, DOI 10.1021/am5042934
   Rabin Y, 2002, INT J HYPERTHER, V18, P194, DOI 10.1080/02656730110116713
   Reddy NN, 2011, J APPL POLYM SCI, V122, P1364, DOI 10.1002/app.34016
   Regmi R, 2010, J MATER CHEM, V20, P6158, DOI 10.1039/c0jm00844c
   Reimer P, 2003, EUR RADIOL, V13, P1266, DOI 10.1007/s00330-002-1721-7
   Rejinold NS, 2015, J CONTROL RELEASE, V204, P85, DOI 10.1016/j.jconrel.2015.02.036
   Ridi F, 2014, ADV COLLOID INTERFAC, V207, P3, DOI 10.1016/j.cis.2013.09.006
   Rivet CJ, 2014, INT J HYPERTHER, V30, P79, DOI 10.3109/02656736.2013.873825
   Rodriguez-Luccioni HL, 2011, INT J NANOMED, V6, P373, DOI 10.2147/IJN.S14613
   Rovers SA, 2012, SOFT MATTER, V8, P1623, DOI 10.1039/c2sm06557f
   Ruiz-Hernandez E, 2011, ACS NANO, V5, P1259, DOI 10.1021/nn1029229
   Sanchez C, 2014, ACS NANO, V8, P1350, DOI 10.1021/nn404954s
   Sanson C, 2011, ACS NANO, V5, P1122, DOI 10.1021/nn102762f
   SASLAWSKI O, 1988, LIFE SCI, V42, P1521, DOI 10.1016/0024-3205(88)90009-4
   Satarkar NS, 2008, J CONTROL RELEASE, V130, P246, DOI 10.1016/j.jconrel.2008.06.008
   Satarkar NS, 2008, ACTA BIOMATER, V4, P11, DOI 10.1016/j.actbio.2007.07.009
   Satarkar NS, 2011, AICHE J, V57, P852, DOI 10.1002/aic.12309
   Satarkar NS, 2010, SOFT MATTER, V6, P2364, DOI 10.1039/b925218p
   Satarkar NS, 2009, LAB CHIP, V9, P1773, DOI 10.1039/b822694f
   Sawdon A, 2014, J BIOMED NANOTECHNOL, V10, P1894, DOI 10.1166/jbn.2014.1917
   Schieber M, 2014, CURR BIOL, V24, pR453, DOI 10.1016/j.cub.2014.03.034
   Schleich N, 2015, J CONTROL RELEASE, V198, P35, DOI 10.1016/j.jconrel.2014.11.024
   Schleich N, 2014, J CONTROL RELEASE, V194, P82, DOI 10.1016/j.jconrel.2014.07.059
   Sensenig R, 2012, NANOMEDICINE-UK, V7, P1425, DOI 10.2217/NNM.12.109
   Shah SA, 2012, MATER CHEM PHYS, V137, P365, DOI 10.1016/j.matchemphys.2012.09.035
   Shapiro B, 2015, WIRES NANOMED NANOBI, V7, P446, DOI 10.1002/wnan.1311
   Sharifi I, 2012, J MAGN MAGN MATER, V324, P903, DOI 10.1016/j.jmmm.2011.10.017
   Shinkai M, 1999, J MAGN MAGN MATER, V194, P176, DOI 10.1016/S0304-8853(98)00586-1
   Shubayev VI, 2009, ADV DRUG DELIVER REV, V61, P467, DOI 10.1016/j.addr.2009.03.007
   Singh D, 2014, NANOMEDICINE-UK, V9, P501, DOI 10.2217/NMM.14.5
   Singh N, 2009, BIOMATERIALS, V30, P3891, DOI 10.1016/j.biomaterials.2009.04.009
   Soenen SJ, 2011, WIRES NANOMED NANOBI, V3, P197, DOI 10.1002/wnan.122
   Soenen SJH, 2009, NANOMEDICINE-UK, V4, P177, DOI 10.2217/17435889.4.2.177
   Soni S, 2014, J THERM BIOL, V43, P70, DOI 10.1016/j.jtherbio.2014.05.003
   Spera R, 2014, BIOELECTROMAGNETICS, V35, P309, DOI 10.1002/bem.21841
   Sperling RA, 2010, PHILOS T R SOC A, V368, P1333, DOI 10.1098/rsta.2009.0273
   Sunderland CJ, 2006, DRUG DEVELOP RES, V67, P70, DOI 10.1002/ddr.20069
   Suto M, 2009, J MAGN MAGN MATER, V321, P1493, DOI 10.1016/j.jmmm.2009.02.070
   Suzuki M, 2003, MELANOMA RES, V13, P129, DOI 10.1097/01.cmr.0000056212.78713.62
   Tai LA, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/13/135101
   Tartaj P, 2003, J PHYS D APPL PHYS, V36, pR182, DOI 10.1088/0022-3727/36/13/202
   Thevenot J, 2013, CHEM SOC REV, V42, P7099, DOI 10.1039/c3cs60058k
   Thomas CR, 2010, J AM CHEM SOC, V132, P10623, DOI 10.1021/ja1022267
   Toraya-Brown S, 2014, NANOMED-NANOTECHNOL, V10, P1273, DOI 10.1016/j.nano.2014.01.011
   Valko M, 2006, CHEM-BIOL INTERACT, V160, P1, DOI 10.1016/j.cbi.2005.12.009
   Voinov MA, 2011, J AM CHEM SOC, V133, P35, DOI 10.1021/ja104683w
   Walther W, 2009, ADV DRUG DELIVER REV, V61, P641, DOI 10.1016/j.addr.2009.02.009
   Wang B, 2013, J PHYS CHEM C, V117, P383, DOI 10.1021/jp3101392
   Wang GH, 2014, ONCOL LETT, V7, P1370, DOI 10.3892/ol.2014.1893
   Wang LF, 2012, ONCOL REP, V27, P719, DOI 10.3892/or.2011.1567
   Wang M, 2010, PHARMACOL RES, V62, P90, DOI 10.1016/j.phrs.2010.03.005
   WIDDER KJ, 1983, PHARMACOL THERAPEUT, V20, P377, DOI 10.1016/0163-7258(83)90033-5
   Wong C, 2011, P NATL ACAD SCI USA, V108, P2426, DOI 10.1073/pnas.1018382108
   Wong JE, 2007, J MAGN MAGN MATER, V311, P219, DOI 10.1016/j.jmmm.2006.10.1201
   Wydra RJ, 2015, ACTA BIOMATER, V25, P284, DOI 10.1016/j.actbio.2015.06.037
   Wydra RJ, 2015, RSC ADV, V5, P18888, DOI 10.1039/c4ra13564d
   Wydra RJ, 2013, MAT SCI ENG C-MATER, V33, P4660, DOI 10.1016/j.msec.2013.07.019
   Xu Y, 2012, ADV HEALTHC MATER, V1, P493, DOI 10.1002/adhm.201200079
   Xu Y, 2010, J PHYS CHEM C, V114, P5020, DOI 10.1021/jp9103036
   Yanase M, 1998, JPN J CANCER RES, V89, P775, DOI 10.1111/j.1349-7006.1998.tb03283.x
   Yang LL, 2009, SMALL, V5, P235, DOI 10.1002/smll.200800714
   Yao AH, 2011, J MATER SCI-MATER M, V22, P2239, DOI 10.1007/s10856-011-4413-5
   Yin PT, 2014, SMALL, V10, P4106, DOI 10.1002/smll.201400963
   Yoo D, 2013, ANGEW CHEM INT EDIT, V52, P13047, DOI 10.1002/anie.201306557
   Zhang EM, 2014, ACS NANO, V8, P3192, DOI 10.1021/nn406302j
   Zheng CL, 2014, INT J PHARMACEUT, V475, P17, DOI 10.1016/j.ijpharm.2014.08.042
NR 265
TC 22
Z9 22
U1 10
U2 104
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD DEC 10
PY 2015
VL 219
BP 76
EP 94
DI 10.1016/j.jconrel.2015.09.039
PG 19
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA CX3HK
UT WOS:000365587800008
PM 26407670
OA green_accepted
DA 2018-03-19
ER

PT J
AU Brousseau, S
   Wang, ZM
   Gupta, SK
   Meenach, SA
AF Brousseau, Sarah
   Wang, Zimeng
   Gupta, Sweta K.
   Meenach, Samantha A.
TI Development of Aerosol Phospholipid Microparticles for the Treatment of
   Pulmonary Hypertension
SO AAPS PHARMSCITECH
LA English
DT Article
DE pulmonary arterial hypertension; microparticles; aerosol delivery; spray
   drying; phospholipid
ID ARTERIAL-HYPERTENSION; DRUG-DELIVERY; PHYSICOCHEMICAL CHARACTERIZATION;
   MULTIFUNCTIONAL PARTICLES; LUNG-CANCER; DRY POWDERS; TACROLIMUS;
   INHALATION; NANOPARTICLES; DISPERSION
AB Pulmonary arterial hypertension (PAH) is an incurable cardiovascular disease characterized by high blood pressure in the arteries leading from the heart to the lungs. Over two million people in the USA are diagnosed with PAH annually and the typical survival rate is only 3 years after diagnosis. Current treatments are insufficient because of limited bioavailability, toxicity, and costs associated with approved therapeutics. Aerosol delivery of drugs is an attractive approach to treat respiratory diseases because it increases localized drug concentration while reducing systemic side effects. In this study, we developed phospholipid-based aerosol microparticles via spray drying consisting of the drug tacrolimus and the excipients dipalmitoylphosphatidylcholine and dipalmitoylphosphatidylglycerol. The phospholipid-based spray-dried aerosol microparticles were shown to be smooth and spherical in size, ranging from 1 to 3 mu m in diameter. The microparticles exhibited thermal stability and were amorphous after spray drying. Water content in the microparticles was under 10%, which will allow successful aerosol dispersion and long-term storage stability. In vitro aerosol dispersion showed that the microparticles could successfully deposit in the deep lung, as they exhibited favorable aerodynamic diameters and high fine particle fractions. In vitro dose-response analysis showed that TAC is nontoxic in the low concentrations that would be delivered to the lungs. Overall, this work shows that tacrolimus-loaded phospholipid-based microparticles can be successfully created with optimal physicochemical and toxicological characteristics.
C1 [Brousseau, Sarah; Wang, Zimeng; Gupta, Sweta K.; Meenach, Samantha A.] Univ Rhode Isl, Dept Chem Engn, 51 Lower Coll Rd,215A Pastore Hall, Kingston, RI 02881 USA.
   [Meenach, Samantha A.] Univ Rhode Isl, Dept Biomed & Pharmaceut Sci, Kingston, RI 02881 USA.
RP Meenach, SA (reprint author), Univ Rhode Isl, Dept Chem Engn, 51 Lower Coll Rd,215A Pastore Hall, Kingston, RI 02881 USA.; Meenach, SA (reprint author), Univ Rhode Isl, Dept Biomed & Pharmaceut Sci, Kingston, RI 02881 USA.
EM smeenach@uri.edu
FU Institutional Development Award (IDeA) from the National Institute of
   General Medical Sciences of the National Institutes of Health
   [P20GM103430]
FX The authors gratefully acknowledge financial support from an
   Institutional Development Award (IDeA) from the National Institute of
   General Medical Sciences of the National Institutes of Health under
   grant number P20GM103430. The content is solely the responsibility of
   the authors and does not necessarily represent the official views of the
   National Institutes of Health. Finally, the authors thank RI-INBRE for
   UPLC access and RIN2 for SEM, PXRD, and DSC access.
CR Abramoff MD, 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100
   Alves GP, 2004, POWDER TECHNOL, V145, P139, DOI 10.1016/j.powtec.2004.06.008
   Archer SL, 2010, CIRCULATION, V121, P2045, DOI 10.1161/CIRCULATIONAHA.108.847707
   Bosquillon C, 2001, J CONTROL RELEASE, V70, P329, DOI 10.1016/S0168-3659(00)00362-X
   Chen L, 2011, HYPERTENSION, V57, P343, DOI 10.1161/HYPERTENSIONAHA.110.157032
   Cho JH, 2014, EUR J PHARM SCI, V54, P1, DOI 10.1016/j.ejps.2013.12.016
   Chow AHL, 2007, PHARM RES, V24
   Evora C, 1998, J CONTROL RELEASE, V51, P143, DOI 10.1016/S0168-3659(97)00149-1
   Gao SS, 2012, INT J PHARMACEUT, V427, P410, DOI 10.1016/j.ijpharm.2012.01.054
   Gupta V, 2013, J CONTROL RELEASE, V167, P189, DOI 10.1016/j.jconrel.2013.01.011
   Hayes D, 2010, TRANSPL P, V42, P3876, DOI 10.1016/j.transproceed.2010.08.029
   Hickey A.J., 2009, MODERN PHARM, V2, P191
   Hoe S, 2014, PHARM RES-DORDR, V31, P449, DOI 10.1007/s11095-013-1174-5
   Hong KH, 2008, CIRCULATION, V118, P722, DOI 10.1161/CIRCULATIONAHA.107.736801
   Humbert M, 2004, J AM COLL CARDIOL, V43, p13S, DOI 10.1016/j.jaac.2004.02.029
   Humbert M, 2010, CIRCULATION, V122, P156, DOI 10.1161/CIRCULATIONAHA.109.911818
   Iskandar F, 2003, J COLLOID INTERF SCI, V265, P296, DOI 10.1016/S0021-9797(03)00519-8
   Kimura S, 2009, HYPERTENSION, V53, P877, DOI 10.1161/HYPERTENSIONAHA.108.121418
   Mansour H, 2001, LANGMUIR, V17, P6622, DOI 10.1021/la0108454
   Mansour HM, 2007, LANGMUIR, V23, P3809, DOI 10.1021/la063053o
   Mansour HM, 2007, J PHARM SCI-US, V96, P377, DOI 10.1002/jps.20810
   Mansour HM, 2010, INT J MOL SCI, V11, P3298, DOI 10.3390/ijms11093298
   Mansour HM, 2013, DRUG DELIVERY
   Meenach SA, 2014, AAPS PHARMSCITECH, V15, P1574, DOI 10.1208/s12249-014-0182-z
   Meenach SA, 2013, EUR J PHARM SCI, V49, P699, DOI 10.1016/j.ejps.2013.05.012
   Meenach SA, 2013, INT J NANOMED, V8, P275, DOI 10.2147/IJN.S30724
   Re MI, 2006, DRY TECHNOL, V24, P433, DOI 10.1080/07373930600611877
   Saigal A, 2013, INT J PHARMACEUT, V450, P114, DOI 10.1016/j.ijpharm.2013.04.011
   Schrepfer S, 2007, AM J TRANSPLANT, V7, P1733, DOI 10.1111/j.1600-6143.2007.01858.x
   Shen Q, 2011, AAPS PHARMSCITECH, V12, P1044, DOI 10.1208/s12249-011-9672-4
   Shoyele SA, 2006, ADV DRUG DELIVER REV, V58, P1009, DOI 10.1016/j.addr.2006.07.010
   Spiekerkoetter E, 2013, J CLIN INVEST, V123, P3600, DOI 10.1172/JCI65592
   Sung JC, 2007, TRENDS BIOTECHNOL, V25, P563, DOI 10.1016/j.tibtech.2007.09.005
   Wang ZM, 2016, INT J PHARMACEUT, V512, P305, DOI 10.1016/j.ijpharm.2016.08.047
   Watts AB, 2011, EUR J PHARM BIOPHARM, V77, P207, DOI 10.1016/j.ejpb.2010.11.013
   Wu X, 2013, DRUG DES DEV THER, V7, P59, DOI [10.2147/DDDT.540166, 10.2147/DDDT.S40166]
NR 36
TC 0
Z9 0
U1 6
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1530-9932
J9 AAPS PHARMSCITECH
JI AAPS PharmSciTech
PD NOV
PY 2017
VL 18
IS 8
BP 3247
EP 3257
DI 10.1208/s12249-017-0821-2
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA FK7BP
UT WOS:000413659200040
PM 28584899
DA 2018-03-20
ER

PT J
AU Tang, S
   Bhandari, R
   Delaney, SP
   Munson, EJ
   Dziubla, TD
   Hilt, JZ
AF Tang, Shuo
   Bhandari, Rohit
   Delaney, Sean P.
   Munson, Eric J.
   Dziubla, Thomas D.
   Hilt, J. Zach
TI Synthesis and characterization of thermally responsive
   N-isopropylacrylamide hydrogels copolymerized with novel hydrophobic
   polyphenolic crosslinkers
SO MATERIALS TODAY COMMUNICATIONS
LA English
DT Article
ID POLY(N-ISOPROPYLACRYLAMIDE-CO-ACRYLIC ACID) HYDROGELS; CRITICAL SOLUTION
   TEMPERATURE; DRUG-DELIVERY; THERMOSENSITIVE HYDROGELS; SENSITIVE
   HYDROGELS; SOLUTE TRANSPORT; RELEASE; WATER; CURCUMIN; BEHAVIOR
AB Two series of thermosensitive hydrogels were synthesized by copolymerizing N-isopropylacrylamide (NIPAAm) with various contents of novel hydrophobic crosslinkers, curcumin multiacrylate (CMA) and quercetin multiacrylate (QMA). The compositions of the resulting hydrogels were characterized using solid state-NMR (ss-NMR), and the temperature dependent swelling behavior and lower critical solution temperature (LCST) were characterized using swelling studies and differential scanning calorimetry (DSC). Increasing the crosslinker content resulted in a significant decrease in the LCST and swelling ratio of hydrogels, which could be attributed to the increased hydrophobicity introduced by CMA or QMA. All of the hydrogels demonstrated temperature responsive swelling with the extent of swelling decreasing with increasing crosslinker content. The lower crosslinker content gels displayed sharper phase transitions, while the high crosslinker content gels had broader phase transitions. (C) 2017 Elsevier Ltd. All rights reserved.
C1 [Tang, Shuo; Bhandari, Rohit; Dziubla, Thomas D.; Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Delaney, Sean P.; Munson, Eric J.] Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40506 USA.
RP Hilt, JZ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM hilt@uky.edu
FU National Institute of Environmental Health Sciences (NIEHS)
   [P42ES007380]
FX The project described was supported by research grant from National
   Institute of Environmental Health Sciences (NIEHS) (Project No:
   P42ES007380). The authors declare the following competing financial
   interest(s): EJM is a partial owner of Kansas Analytical Services, a
   company that provides solid-state NMR services to the pharmaceutical
   industry. The results presented here are from academic work at
   University of Kentucky, and no data from Kansas Analytical Services are
   presented.
CR Anand P, 2007, MOL PHARM, V4, P807, DOI 10.1021/mp700113r
   Andrew E., 1959, REMOVAL DIPOLAR BROA
   Atta AM, 2008, J APPL POLYM SCI, V108, P1706, DOI 10.1002/app.27291
   BAE YH, 1991, PHARMACEUT RES, V8, P624, DOI 10.1023/A:1015860824953
   BAE YH, 1991, PHARMACEUT RES, V8, P531, DOI 10.1023/A:1015871732706
   Barich DH, 2006, SOLID STATE NUCL MAG, V30, P125, DOI 10.1016/j.ssnmr.2006.06.001
   Cheng AL, 2001, ANTICANCER RES, V21, P2895
   Choi C, 2006, POLYMER, V47, P4571, DOI 10.1016/j.polymer.2006.05.011
   Dai HJ, 2006, MACROMOLECULES, V39, P6584, DOI 10.1021/ma060486p
   Dimitrov I, 2007, PROG POLYM SCI, V32, P1275, DOI 10.1016/j.progpolymsci.2007.07.001
   Dixon W., 1969, J MAGN RESON, V49, P341
   Fung BM, 2000, J MAGN RESON, V142, P97, DOI 10.1006/jmre.1999.1896
   Galaev IY, 1999, TRENDS BIOTECHNOL, V17, P335, DOI 10.1016/S0167-7799(99)01345-1
   Glauert HP, 2008, ENVIRON TOXICOL PHAR, V25, P247, DOI 10.1016/j.etap.2007.10.025
   GUTOWSKA A, 1992, J CONTROL RELEASE, V22, P95, DOI 10.1016/0168-3659(92)90194-V
   HIROKAWA Y, 1984, J CHEM PHYS, V81, P6379, DOI 10.1063/1.447548
   Hou Y, 2008, BIOMATERIALS, V29, P3175, DOI 10.1016/j.biomaterials.2008.04.024
   Huang S., 2015, J APPL POLYM SCI, V132
   Jing GH, 2013, COLLOID SURFACE A, V416, P86, DOI 10.1016/j.colsurfa.2012.09.043
   Ju HK, 2001, POLYMER, V42, P6851, DOI 10.1016/S0032-3861(01)00143-4
   Kim S, 2003, BIOMACROMOLECULES, V4, P1214, DOI 10.1021/bm0340467
   Kim SY, 2000, J APPL POLYM SCI, V78, P1381, DOI 10.1002/1097-4628(20001114)78:7<1381::AID-APP90>3.0.CO;2-M
   Klouda L, 2008, EUR J PHARM BIOPHARM, V68, P34, DOI 10.1016/j.ejpb.2007.02.025
   Kureha T, 2014, LANGMUIR, V30, P8717, DOI 10.1021/la501838c
   Lao Christopher D, 2006, BMC Complement Altern Med, V6, P10, DOI 10.1186/1472-6882-6-10
   Lue SJ, 2007, J MEMBRANE SCI, V301, P142, DOI 10.1016/j.memsci.2007.06.020
   Lue SJ, 2011, J MACROMOL SCI B, V50, P563, DOI 10.1080/00222341003784550
   Nguyen HTP, 2015, NANOTECHNOLOGY, V26, DOI 10.1088/0957-4484/26/25/255101
   OGATA T, 1995, J MEMBRANE SCI, V103, P159, DOI 10.1016/0376-7388(94)00316-Q
   Parasuraman D, 2013, COLLOID POLYM SCI, V291, P1795, DOI 10.1007/s00396-013-2915-z
   Patil VS, 2015, POLYMER, V75, P88, DOI 10.1016/j.polymer.2015.08.034
   PINES A, 1973, J CHEM PHYS, V59, P569, DOI 10.1063/1.1680061
   Prior-Cabanillas A, 2005, POLYMER, V46, P685, DOI 10.1016/j.polymer.2004.11.088
   Qiu Y, 2001, ADV DRUG DELIVER REV, V53, P321, DOI 10.1016/S0169-409X(01)00203-4
   Rzaev ZMO, 2007, PROG POLYM SCI, V32, P534, DOI 10.1016/j.progpolymsci.2007.01.006
   SCHILD HG, 1992, PROG POLYM SCI, V17, P163, DOI 10.1016/0079-6700(92)90023-R
   Shoba G, 1998, PLANTA MED, V64, P353, DOI 10.1055/s-2006-957450
   Spizzirri UG, 2011, J APPL POLYM SCI, V121, P342, DOI 10.1002/app.33543
   Stile RA, 2001, BIOMACROMOLECULES, V2, P185, DOI 10.1021/bm0000945
   Teong B., 2015, J MAT SCI MAT MED, V26
   Tharappel JC, 2008, FOOD CHEM TOXICOL, V46, P3467, DOI 10.1016/j.fct.2008.08.023
   Vihola H, 2008, J PHARM SCI-US, V97, P4783, DOI 10.1002/jps.21348
   Wattamwar PP, 2012, ACTA BIOMATER, V8, P2529, DOI 10.1016/j.actbio.2012.03.022
   Xue W, 2002, POLYMER, V43, P3069, DOI 10.1016/S0032-3861(02)00133-7
   Yoo MK, 2000, POLYMER, V41, P5713, DOI 10.1016/S0032-3861(99)00779-X
   YOSHIDA R, 1994, J BIOMAT SCI-POLYM E, V6, P585
   Zhang XZ, 2004, J MATER SCI-MATER M, V15, P865, DOI 10.1023/B:JMSM.0000036274.83104.fe
   Zhao CW, 2009, POLYMER, V50, P4308, DOI 10.1016/j.polymer.2009.07.010
NR 48
TC 2
Z9 2
U1 22
U2 26
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2352-4928
J9 MATER TODAY COMMUN
JI Mater. Today Commun.
PD MAR
PY 2017
VL 10
BP 46
EP 53
DI 10.1016/j.mtcomm.2016.12.003
PG 8
WC Materials Science, Multidisciplinary
SC Materials Science
GA ER6QK
UT WOS:000398931200006
PM 28989952
DA 2018-03-20
ER

PT J
AU Zhou, QF
   Fursule, I
   Berron, BJ
   Beck, MJ
AF Zhou, Qunfei
   Fursule, Ishan A.
   Berron, Brad J.
   Beck, Matthew J.
TI Toward Spatiotemporally Controlled Synthesis of Photoresponsive
   Polymers: Computational Design of Azobenzene-Containing Monomers for
   Light-Mediated ROMP
SO JOURNAL OF PHYSICAL CHEMISTRY A
LA English
DT Article
ID OPENING METATHESIS POLYMERIZATION; CIS-TRANS PHOTOISOMERIZATION; LOWEST
   ELECTRONIC STATES; AB-INITIO CALCULATION; RING STRAIN ENERGIES;
   CRYSTAL-STRUCTURE; CLICK CHEMISTRY; ISOMERIZATION; WETTABILITY;
   DERIVATIVES
AB Density functional theory calculations have been used to identify the optimum design for a novel, light-responsive ring monomer expected to allow spatial and temporal control of ring-opening metathesis polymerization (ROMP) via light mediated changes in ring strain energy. The monomer design leverages ring-shaped molecules composed of 4,4'-diaminoazobenzene (ABn) closed by alkene-alpha,omega-dioic acid linkers. The atomic geometries, formation enthalpies and ring strain energies of azobenzene (AB)-containing rings with various length linkers have been calculated. The AB(2,2) monomer is identified as having optimal properties for light-mediated ROMP, including high thermodynamic stability, low ring strain energy (RSE) with cis-AB, and high RSE with trans-AB. Time-dependent DFT calculations have been used to explore the photoisomerization mechanism of isolated AB and AB-containing rings, and calculations show that trans-to-cis and cis-to-trans photoisomerization of the optimal AB(2,2) ring molecule can be achieved with monochromatic green and blue light, respectively. The AB(2,2) monomer identified here is expected to allow precise, reversible, spatial and temporal light-mediated control of ROMP through AB photoisomerization, and to have promising potential applications in the fabrication of patterned and/or responsive AB-containing polymer materials.
C1 [Zhou, Qunfei; Fursule, Ishan; Berron, Brad J.; Beck, Matthew J.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Zhou, Qunfei; Beck, Matthew J.] Univ Kentucky, Ctr Computat Sci, Lexington, KY 40506 USA.
RP Berron, BJ; Beck, MJ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.; Beck, MJ (reprint author), Univ Kentucky, Ctr Computat Sci, Lexington, KY 40506 USA.
EM brad.berron@uky.edu; beck@engr.uky.edu
FU National Science Fundation [CMMI 1334403]
FX This work and all the authors were supported by National Science
   Fundation (Grant No. CMMI 1334403). We also thank the Center for
   Computational Sciences at the University of Kentucky for the computation
   resources.
CR Astrand PO, 2000, J AM CHEM SOC, V122, P3482, DOI 10.1021/ja993154r
   Barrett CJ, 2007, SOFT MATTER, V3, P1249, DOI 10.1039/b705619b
   BECKE AD, 1993, J CHEM PHYS, V98, P5648, DOI 10.1063/1.464913
   Bhattacharya A, 2012, AICHE J, V58, P600, DOI 10.1002/aic.12596
   Bielawski CW, 2007, PROG POLYM SCI, V32, P1, DOI 10.1016/j.progpolymsci.2006.08.006
   Binder WH, 2008, MACROMOL RAPID COMM, V29, P952, DOI 10.1002/marc.200800089
   Biswas N, 1997, J PHYS CHEM A, V101, P5555, DOI 10.1021/jp970312x
   BOUWSTRA JA, 1983, ACTA CRYSTALLOGR C, V39, P1121, DOI 10.1107/S0108270183007611
   Browne WR, 2006, NAT NANOTECHNOL, V1, P25, DOI 10.1038/nnano.2006.45
   Cattaneo P, 1999, PHYS CHEM CHEM PHYS, V1, P4739, DOI 10.1039/a905055h
   Cembran A, 2004, J AM CHEM SOC, V126, P3234, DOI 10.1021/ja038327y
   Choi T. L., 2003, ANGEW CHEM, V115, P1785
   Comstock MJ, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.038301
   Coti KK, 2009, NANOSCALE, V1, P16, DOI 10.1039/b9nr00162j
   Crecca CR, 2006, J PHYS CHEM A, V110, P8188, DOI 10.1021/jp057413c
   Davis DA, 2009, NATURE, V459, P68, DOI 10.1038/nature07970
   Dokic J, 2009, J PHYS CHEM A, V113, P6763, DOI 10.1021/jp9021344
   Dudev T, 1998, J AM CHEM SOC, V120, P4450, DOI 10.1021/ja973895x
   Durr H., 2003, PHOTOCHROMISM MOL SY, P165
   Feng JX, 2007, LANGMUIR, V23, P1004, DOI 10.1021/la0630110
   Fliegl H, 2003, J AM CHEM SOC, V125, P9821, DOI 10.1021/ja034433o
   Frisch M. J., 2009, GAUSSIAN 09 REVISION
   Fujino T, 2001, J PHYS CHEM A, V105, P8123, DOI 10.1021/jp0110713
   Gagliardi L, 2004, THEOR CHEM ACC, V111, P363, DOI 10.1007/s00214-003-0528-1
   Guerrero L, 2005, J AM CHEM SOC, V127, P15624, DOI 10.1021/ja0550428
   Hansell C, 2015, NAT CHEM, V7, P88, DOI 10.1038/nchem.2134
   HARIHARAN PC, 1974, MOL PHYS, V27, P209, DOI 10.1080/00268977400100171
   Henzl J, 2012, PHYS REV B, V85, DOI 10.1103/PhysRevB.85.035410
   Hoersch D, 2013, NAT NANOTECHNOL, V8, P928, DOI [10.1038/nnano.2013.242, 10.1038/NNANO.2013.242]
   Howell J, 2009, TETRAHEDRON, V65, P4562, DOI 10.1016/j.tet.2009.03.090
   Iamsaard S, 2014, NAT CHEM, V6, P229, DOI [10.1038/nchem.1859, 10.1038/NCHEM.1859]
   IKEDA T, 1995, SCIENCE, V268, P1873, DOI 10.1126/science.268.5219.1873
   Iqbal D, 2013, MATERIALS, V6, P116, DOI 10.3390/ma6010116
   Ishikawa T, 2001, J CHEM PHYS, V115, P7503, DOI 10.1063/1.1406975
   Jewett JC, 2010, CHEM SOC REV, V39, P1272, DOI 10.1039/b901970g
   Kamber NE, 2007, CHEM REV, V107, P5813, DOI 10.1021/cr068415b
   Koskela JE, 2014, J AM CHEM SOC, V136, P6850, DOI 10.1021/ja502623m
   KUMAR GS, 1989, CHEM REV, V89, P1915, DOI 10.1021/cr00098a012
   Kurita N, 2000, J PHYS CHEM A, V104, P8114, DOI 10.1021/jp001307n
   Lerum MFZ, 2011, LANGMUIR, V27, P5403, DOI 10.1021/la2002892
   Lu YC, 2005, J PHYS CHEM A, V109, P2090, DOI 10.1021/jp044934b
   Lynn DM, 1996, J AM CHEM SOC, V118, P784, DOI 10.1021/ja950327d
   Maurer RJ, 2011, J CHEM PHYS, V135, DOI 10.1063/1.3664305
   MIERTUS S, 1981, CHEM PHYS, V55, P117, DOI 10.1016/0301-0104(81)85090-2
   MOSTAD A, 1971, ACTA CHEM SCAND, V25, P3561, DOI 10.3891/acta.chem.scand.25-3561
   Natansohn A, 2002, CHEM REV, V102, P4139, DOI 10.1021/cr970155y
   Nuyken O, 2013, POLYMERS-BASEL, V5, P361, DOI 10.3390/polym5020361
   Oliveira ON, 2005, ADV COLLOID INTERFAC, V116, P179, DOI 10.1016/j.cis.2005.05.008
   Osella S, 2014, J PHYS CHEM C, V118, P18721, DOI 10.1021/jp504582a
   Pang J, 2014, CHEM PHYS LETT, V613, P110, DOI [10.1016/j.cplett.2014.08.048, 10.1016/j.cplett.2014.07.048]
   Pathem BK, 2012, J PHYS CHEM LETT, V3, P2388, DOI 10.1021/jz300968m
   Pederzoli M, 2011, J PHYS CHEM A, V115, P11136, DOI 10.1021/jp2013094
   Pei XW, 2011, LANGMUIR, V27, P9403, DOI 10.1021/la201526u
   Petroffe G, 2015, J MATER CHEM A, V3, P11533, DOI 10.1039/c5ta01710f
   Piotti ME, 1999, CURR OPIN SOLID ST M, V4, P539, DOI 10.1016/S1359-0286(00)00010-3
   Rodriquez CF, 1997, J CHEM SOC PERK T 2, P953, DOI 10.1039/a606820k
   Satzger H, 2004, J PHYS CHEM A, V108, P6265, DOI 10.1021/jp049509x
   SCHULZE FW, 1977, Z PHYS CHEM NEUE FOL, V107, P1, DOI 10.1524/zpch.1977.107.1.001
   Seki T, 2014, MACROMOL RAPID COMM, V35, P271, DOI 10.1002/marc.201300763
   Spitale RC, 2015, NATURE, V519, P486, DOI 10.1038/nature14263
   Sutthasupa S, 2010, POLYM J, V42, P905, DOI 10.1038/pj.2010.94
   Talbot A, 2015, J ORG CHEM, V80, P548, DOI 10.1021/jo5025514
   Tanchak OM, 2005, MACROMOLECULES, V38, P10566, DOI 10.1021/ma051564w
   Thirumurugan P, 2013, CHEM REV, V113, P4905, DOI 10.1021/cr200409f
   Tiago ML, 2005, J CHEM PHYS, V122, DOI 10.1063/1.1861873
   Tomasi J, 2005, CHEM REV, V105, P2999, DOI 10.1021/cr9904009
   Ullrich CA, 2014, BRAZ J PHYS, V44, P154, DOI 10.1007/s13538-013-0141-2
   Uttamapinant C, 2015, J AM CHEM SOC, V137, P4602, DOI 10.1021/ja512838z
   Velema WA, 2014, J AM CHEM SOC, V136, P2178, DOI 10.1021/ja413063e
   Wagner N, 2014, POLYMER, V55, P3436, DOI 10.1016/j.polymer.2014.05.033
   Wheeler SE, 2009, J AM CHEM SOC, V131, P2547, DOI 10.1021/ja805843n
   Xi WX, 2014, ADV FUNCT MATER, V24, P2572, DOI 10.1002/adfm.201302847
   Yang LM, 2012, RSC ADV, V2, P1618, DOI 10.1039/c1ra00187f
   Yang Y, 2014, J AM CHEM SOC, V136, P13190, DOI 10.1021/ja508125n
   Yeung HHM, 2011, CRYST GROWTH DES, V11, P221, DOI 10.1021/cg101170k
NR 75
TC 2
Z9 2
U1 7
U2 31
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1089-5639
J9 J PHYS CHEM A
JI J. Phys. Chem. A
PD SEP 15
PY 2016
VL 120
IS 36
BP 7101
EP 7111
DI 10.1021/acs.jpca.6b05807
PG 11
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA DW4VR
UT WOS:000383641600008
PM 27552379
DA 2018-03-19
ER

PT J
AU Badugu, R
   Garcia, M
   Bondada, V
   Joshi, A
   Geddes, JW
AF Badugu, RamaKrishna
   Garcia, Matthew
   Bondada, Vimala
   Joshi, Aashish
   Geddes, James W.
TI N terminus of calpain 1 is a mitochondrial targeting sequence
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID APOPTOSIS-INDUCING FACTOR; RAT-LIVER MITOCHONDRIA; SMALL-SUBUNIT GENE;
   MU-CALPAIN; INTERMEMBRANE SPACE; PROTEIN IMPORT; CALPAIN/CALPASTATIN
   NETWORK; PERMEABILITY TRANSITION; SUBCELLULAR ORGANELLES;
   EMBRYONIC-DEVELOPMENT
AB The ubiquitous m- and mu-calpains are thought to be localized in the cytosolic compartment, as is their endogenous inhibitor calpastatin. Previously, mu-calpain was found to be enriched in mitochondrial fractions isolated from rat cerebral cortex and SH-SY5Y neuroblastoma cells, but the submitochondrial localization of mu-calpain was not determined. In the present study, submitochondrial fractionation and digitonin permeabilization studies indicated that both calpain 1 and calpain small subunit 1, which together form mu-calpain, are present in the mitochondrial intermembrane space. The N terminus of calpain 1 contains an amphipathic alpha-helical domain, and is distinct from the N terminus of calpain 2. Calpain 1, but not calpain 2, was imported into mitochondria. Removal of the N-terminal 22 amino acids of calpain 1 blocked the mitochondrial calpain import, while addition of this N-terminal region to calpain 2 or green fluorescent protein enabled mitochondrial import. The N terminus of calpain 1 was not processed following mitochondrial import, but was removed by autolysis following calpain activation. Calpain small subunit 1 was not directly imported into mitochondria, but was imported in the presence of calpain 1. The presence of a mitochondrial targeting sequence in the N-terminal region of calpain 1 is consistent with the localization of mu-calpain to the mitochondrial intermembrane space and provides new insight into the possible functions of this cysteine protease.
C1 [Badugu, RamaKrishna; Bondada, Vimala] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA.
   [Garcia, Matthew; Joshi, Aashish; Geddes, James W.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA.
RP Geddes, JW (reprint author), Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, B477 BBSRB, Lexington, KY 40536 USA.
EM jgeddes@uky.edu
RI Badugu, RamaKrishna/A-8572-2008
FU NINDS NIH HHS [P01NS058484, R01NS045726]; NIA NIH HHS [P01AG010836]
CR ADACHI Y, 1991, J BIOL CHEM, V266, P3968
   Arrington DD, 2006, AM J PHYSIOL-CELL PH, V291, pC1159, DOI 10.1152/ajpcell.00207.2006
   Arthur JSC, 2000, MOL CELL BIOL, V20, P4474, DOI 10.1128/MCB.20.12.4474-4481.2000
   Azam M, 2001, MOL CELL BIOL, V21, P2213, DOI 10.1128/MCB.21.6.2213-2220.2001
   BAUDRY M, 1987, SYNAPSE, V1, P506, DOI 10.1002/syn.890010603
   BEER DG, 1982, BIOCHEM BIOPH RES CO, V109, P1276, DOI 10.1016/0006-291X(82)91915-5
   Bernardi P, 1998, BIOFACTORS, V8, P273, DOI 10.1002/biof.5520080315
   BOLLIGER L, 1994, EMBO J, V13, P1998
   Cao GD, 2007, J NEUROSCI, V27, P9278, DOI 10.1523/JNEUROSCI.2826-07.2007
   Carragher NO, 2006, CURR PHARM DESIGN, V12, P615, DOI 10.2174/138161206775474314
   CHAKRABARTI AK, 1988, J NEUROSCI RES, V20, P351, DOI 10.1002/jnr.490200309
   Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x
   CONG JY, 1989, J BIOL CHEM, V264, P10096
   CROALL DE, 1991, PHYSIOL REV, V71, P813
   Diekert K, 1999, P NATL ACAD SCI USA, V96, P11752, DOI 10.1073/pnas.96.21.11752
   Duret L, 1996, COMPUT APPL BIOSCI, V12, P507
   Dutt P, 2006, BMC DEV BIOL, V6, DOI 10.1186/1471-213X-6-3
   Elce JS, 1997, BIOCHEM J, V326, P31, DOI 10.1042/bj3260031
   Emanuelsson O, 2007, NAT PROTOC, V2, P953, DOI 10.1038/nprot.2007.131
   Endo T, 2002, BBA-MOL CELL RES, V1592, P3, DOI 10.1016/S0167-4889(02)00259-8
   Fan ACY, 2006, J BIOL CHEM, V281, P33313, DOI 10.1074/jbc.M605250200
   Friedrich P, 2005, BIOL CHEM, V386, P609, DOI 10.1515/BC.2005.071
   Friedrich P, 2004, EUR J NEUROSCI, V19, P1819, DOI 10.1111/j.1460.9568.2004.03313.x
   Garcia M, 2005, BIOCHEM BIOPH RES CO, V338, P1241, DOI 10.1016/j.bbrc.2005.10.081
   Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002
   GOPALAKRISHNA R, 1986, J BIOL CHEM, V261, P13936
   GRAHAMSIEGENTHALER K, 1994, J BIOL CHEM, V269, P30457
   Griparic L, 2005, METHOD ENZYMOL, V404, P620, DOI 10.1016/S0076-6879(05)04054-1
   Herrmann JM, 2005, TRENDS BIOCHEM SCI, V30, P205, DOI 10.1016/j.tibs.2005.02.005
   Herrmann JM, 2007, J CELL BIOL, V176, P559, DOI 10.1083/jcb.200611060
   Hood JL, 2004, J BIOL CHEM, V279, P43126, DOI 10.1074/jbc.M408100200
   Hood JL, 2003, BIOCHEM BIOPH RES CO, V310, P1200, DOI 10.1016/j.bbrc.2003.09.142
   Horton P, 2007, NUCLEIC ACIDS RES, V35, pW585, DOI 10.1093/nar/gkm259
   HUANG XQ, 1991, ADV APPL MATH, V12, P337, DOI 10.1016/0196-8858(91)90017-D
   Huang YH, 2001, TRENDS MOL MED, V7, P355, DOI 10.1016/S1471-4914(01)02049-4
   Kar P, 2007, ARCH BIOCHEM BIOPHYS, V466, P290, DOI 10.1016/j.abb.2007.07.022
   Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006
   Kumar M, 2006, J BIOL CHEM, V281, P5357, DOI 10.1074/jbc.M511061200
   Leslie DM, 2004, MOL CELL BIOL, V24, P8487, DOI 10.1128/MCB.24.19.8487-8503.2004
   Melloni E, 2000, J BIOL CHEM, V275, P82, DOI 10.1074/jbc.275.1.82
   Mesecke N, 2005, CELL, V121, P1059, DOI 10.1016/j.cell.2005.04.011
   Molinari M, 1997, J MEMBRANE BIOL, V156, P1, DOI 10.1007/s002329900181
   Moubarak RS, 2007, MOL CELL BIOL, V27, P4844, DOI 10.1128/MCB.02141-06
   MURAKAMI T, 1981, J BIOCHEM-TOKYO, V90, P1809, DOI 10.1093/oxfordjournals.jbchem.a133659
   Naga KK, 2007, J NEUROSCI, V27, P7469, DOI 10.1523/JNEUROSCI.0646-07.2007
   Neupert W, 2002, NAT REV MOL CELL BIO, V3, P555, DOI 10.1038/nrm878
   Ohsato T, 2002, EUR J BIOCHEM, V269, P5765, DOI 10.1046/j.1432-1033.2002.03238.x
   Otera H, 2005, EMBO J, V24, P1375, DOI 10.1038/sj.emboj.7600614
   Ozaki T, 2007, J BIOCHEM, V142, P365, DOI 10.1093/jb/mvm143
   Pang Z, 2003, J NEUROPATH EXP NEUR, V62, P633, DOI 10.1093/jnen/62.6.633
   Polster BM, 2005, J BIOL CHEM, V280, P6447, DOI 10.1074/jbc.M413269200
   Raynaud F, 2006, FEBS J, V273, P3437, DOI 10.1111/j.1742-4658.2006.05352.x
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   ROISE D, 1986, EMBO J, V5, P1327
   Saga Kenji, 2005, Medical Molecular Morphology, V38, P155, DOI 10.1007/s00795-005-0287-2
   Shulga N, 2006, J BIOL CHEM, V281, P30824, DOI 10.1074/jbc.M602503200
   Silvestri L, 2005, HUM MOL GENET, V14, P3477, DOI 10.1093/hmg/ddi377
   Small I, 2004, PROTEOMICS, V4, P1581, DOI 10.1002/pmic.200300776
   Suzuki K., 2004, DIABETES, V53, P12
   Syntichaki P, 2002, NATURE, V419, P939, DOI 10.1038/nature01108
   Szabadkai G, 2006, BBA-MOL CELL RES, V1763, P442, DOI 10.1016/j.bbamer.2006.04.002
   TAKANO E, 1982, J BIOCHEM-TOKYO, V92, P2021, DOI 10.1093/oxfordjournals.jbchem.a134134
   TAVARES A, 1991, BIOMED BIOCHIM ACTA, V50, P523
   TAYLOR RG, 1991, BIOMED BIOCHIM ACTA, V50, P491
   Thompson VF, 2000, METH MOL B, V144, P3
   TULLIO RD, 1999, BIOCHEM J, V343, P467
   VONHEIJNE G, 1986, EMBO J, V5, P1335
   Weil R, 1999, MOL CELL BIOL, V19, P6345
   Yermovsky-Kammerer AE, 1999, MOL CELL BIOL, V19, P6253
   Yuste VJ, 2005, CELL DEATH DIFFER, V12, P1445, DOI 10.1038/sj.cdd.4401687
   Zimmerman UJP, 2000, IUBMB LIFE, V50, P63
   ZIMMERMAN UJP, 1991, BIOCHIM BIOPHYS ACTA, V1078, P192, DOI 10.1016/0167-4838(91)99009-H
NR 72
TC 38
Z9 38
U1 0
U2 17
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD FEB 8
PY 2008
VL 283
IS 6
BP 3409
EP 3417
DI 10.1074/jbc.M706851200
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 261MJ
UT WOS:000253083000046
PM 18070881
OA gold
DA 2018-03-20
ER

PT J
AU Gonzalez-Estrella, J
   Asato, CM
   Jerke, AC
   Stone, JJ
   Gilcrease, PC
AF Gonzalez-Estrella, Jorge
   Asato, Caitlin M.
   Jerke, Amber C.
   Stone, James J.
   Gilcrease, Patrick C.
TI Effect of structural carbohydrates and lignin content on the anaerobic
   digestion of paper and paper board materials by anaerobic granular
   sludge
SO BIOTECHNOLOGY AND BIOENGINEERING
LA English
DT Article
DE methanogenesis; solid waste; biomethane potential; lignocellulose;
   predicting parameters; linear regression
ID BREWERY WASTE-WATER; METHANE PRODUCTION; MICROBIAL COMMUNITY; BIOGAS
   PRODUCTION; ENZYMATIC-HYDROLYSIS; BIODEGRADABILITY; PRETREATMENT;
   SOLUBILIZATION; COMPONENTS; CARDBOARD
AB Anaerobic digestion (AD) of lignocellulosic materials is commonly limited by the hydrolysis step. Unlike unprocessed lignocellulosic materials, paper and paper board (PPB) are processed for their fabrication. Such modifications may affect their methane yields and methane production rates. Previous studies have investigated the correlation between lignin and biomethane yields of unprocessed lignocellulosic materials; nevertheless, there is limited knowledge regarding the relationship between the AD kinetic parameters and composition of PPB. This study evaluated correlations of methane yields and Monod and Gompertz kinetic parameters with structural carbohydrates, lignin, and ash concentration of five types of PPBs. All components were used as single and combined independent variables in linear regressions to predict methane yield, maximum specific methanogenic activity (SMA(max)), saturation constant (K-s), and lag phase (). Additionally, microbial community profiles were obtained for each PPB assay. Results showed methane yields ranging from 69.2 +/- 8.61 to 97.2 +/- 2.29% of PPB substrates provided. The highest correlation coefficients were obtained for SMA(max) as function of hemicellulose/(lignin+ash) (R-2=0.86) and for as a function of lignin+cellulose (R-2=0.85). All other parameters exhibited weaker correlations (R(2)0.77). Relative abundance analyses revealed no major changes in the community profile for each of the substrates evaluated. The overall findings of this study are: (i) combinations of structural carbohydrates, lignin, and ash used as ratios of degradable to either non-degradable or slowly degradable fractions predict AD kinetic parameters of PPB materials better than single independent variables; and (ii) other components added during their fabrication may also influence both methane yield and kinetic parameters. Biotechnol. Bioeng. 2017;114: 951-960. (C) 2016 Wiley Periodicals, Inc.
C1 [Gonzalez-Estrella, Jorge; Asato, Caitlin M.; Jerke, Amber C.; Gilcrease, Patrick C.] South Dakota Sch Mines & Technol, Dept Chem & Biol Engn, 501 East St Joseph St, Rapid City, SD 57701 USA.
   [Stone, James J.] South Dakota Sch Mines & Technol, Dept Civil & Environm Engn, Rapid City, SD USA.
RP Gilcrease, PC (reprint author), South Dakota Sch Mines & Technol, Dept Chem & Biol Engn, 501 East St Joseph St, Rapid City, SD 57701 USA.
EM patrick.gilcrease@sdsmt.edu
RI Gonzalez-Estrella, Jorge/B-1707-2013
OI Gonzalez-Estrella, Jorge/0000-0002-4873-0454
FU Air Force Civil Engineer Center (AFCEC) [FA4819-14-C-0004]
FX Contract grant sponsor: Air Force Civil Engineer Center (AFCEC);
   Contract grant number: FA4819-14-C-0004
CR Abbassi-Guendouz A, 2013, BIORESOURCE TECHNOL, V133, P256, DOI 10.1016/j.biortech.2013.01.121
   Abbassi-Guendouz A, 2012, BIORESOURCE TECHNOL, V111, P55, DOI 10.1016/j.biortech.2012.01.174
   Anwar Z, 2014, J RADIAT RES APPL SI, V7, P163, DOI 10.1016/j.jrras.2014.02.003
   APHA-AWWA-WEF, 2012, STANDARD METHODS EXA
   Asato CM, 2016, BIORESOURCE TECHNOL, V216, P894, DOI 10.1016/j.biortech.2016.06.033
   Baba Y, 2013, BIORESOURCE TECHNOL, V128, P94, DOI 10.1016/j.biortech.2012.09.077
   Blechschmidt J, 2013, FIBROUS MAT PAPER BO, P33
   BRAY RH, 1945, SOIL SCI, V59, P39, DOI 10.1097/00010694-194501000-00006
   Brown D, 2012, BIORESOURCE TECHNOL, V124, P379, DOI 10.1016/j.biortech.2012.08.051
   Casey J. P, 1980, PULP PAPER CHEM CHEM
   Chen H, 2012, APPL BIOCHEM BIOTECH, V166, P1121, DOI 10.1007/s12010-011-9498-2
   Diaz EE, 2006, APPL ENVIRON MICROB, V72, P4942, DOI 10.1128/AEM.02985-05
   ElFadel M, 1997, J ENVIRON MANAGE, V50, P1, DOI 10.1006/jema.1995.0131
   Fox M, 2004, BIORESOURCE TECHNOL, V91, P273, DOI 10.1016/j.biortech.2003.06.001
   Grady CL, 2011, BIOL WASTEWATER TREA, p91 
   Gunaseelan VN, 2007, BIORESOURCE TECHNOL, V98, P1270, DOI 10.1016/j.biortech.2006.05.014
   Hoornweg D., 2012, URBAN DEV SERIES KNO, V15, P1
   Jokela JPY, 2005, BIORESOURCE TECHNOL, V96, P501, DOI 10.1016/j.biortech.2004.03.009
   Labatut RA, 2011, BIORESOURCE TECHNOL, V102, P2255, DOI 10.1016/j.biortech.2010.10.035
   Lay J-J, 1996, J ENV SYSTEMS ENG, V1, P101
   Lesteur M, 2010, PROCESS BIOCHEM, V45, P431, DOI 10.1016/j.procbio.2009.11.018
   Leven L, 2007, FEMS MICROBIOL ECOL, V59, P683, DOI 10.1111/j.1574-6941.2006.00263.x
   Liu WT, 2002, WATER RES, V36, P1767, DOI 10.1016/S0043-1354(01)00377-3
   Madigan MT, 2012, BROCK BIOL MICROORGA, p125 
   MCGEEHAN SL, 1988, COMMUN SOIL SCI PLAN, V19, P493, DOI 10.1080/00103628809367953
   O'Sullivan C, 2007, J APPL MICROBIOL, V103, P1332, DOI 10.1111/j.1365-2672.2007.03362.x
   OWENS JM, 1993, WATER SCI TECHNOL, V27, P1
   Pommier S, 2010, BIORESOURCE TECHNOL, V101, P463, DOI 10.1016/j.biortech.2009.07.034
   Reith J, 2003, BIOMETHANE BIOHYDROG, p111 
   Rolfe MD, 2012, J BACTERIOL, V194, P686, DOI 10.1128/JB.06112-11
   Sambusiti C, 2014, BIORESOURCE TECHNOL, V155, P122, DOI 10.1016/j.biortech.2013.12.055
   Sawatdeenarunat C, 2015, BIORESOURCE TECHNOL, V178, P178, DOI 10.1016/j.biortech.2014.09.103
   Schluter A, 2008, J BIOTECHNOL, V136, P77, DOI 10.1016/j.jbiotec.2008.05.008
   Shin CS, 2000, APPL BIOCHEM BIOTECH, V84-6, P237, DOI 10.1385/ABAB:84-86:1-9:237
   Sluiter A, 2012, DETERMINATION STRUCT
   Taherzadeh MJ, 2008, INT J MOL SCI, V9, P1621, DOI 10.3390/ijms9091621
   TONG XG, 1990, BIOMASS, V21, P239, DOI 10.1016/0144-4565(90)90075-U
   Triolo JM, 2012, BIORESOURCE TECHNOL, V125, P226, DOI 10.1016/j.biortech.2012.08.079
   Triolo JM, 2011, BIORESOURCE TECHNOL, V102, P9395, DOI 10.1016/j.biortech.2011.07.026
   USEPA, 2015, ADV SUST MAT MAN FAC
   Vavilin VA, 2004, BIORESOURCE TECHNOL, V94, P69, DOI 10.1016/j.biortech.2003.10.034
   Wang L, 2012, APPL ENERG, V99, P23, DOI 10.1016/j.apenergy.2012.03.045
   Xiao WP, 1997, BIODEGRADATION, V8, P61, DOI 10.1023/A:1008297211954
   Yuan XF, 2012, BIORESOURCE TECHNOL, V118, P281, DOI 10.1016/j.biortech.2012.05.058
   Ziganshin AM, 2013, APPL MICROBIOL BIOT, V97, P5161, DOI 10.1007/s00253-013-4867-0
NR 45
TC 2
Z9 2
U1 9
U2 31
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0006-3592
EI 1097-0290
J9 BIOTECHNOL BIOENG
JI Biotechnol. Bioeng.
PD MAY
PY 2017
VL 114
IS 5
BP 951
EP 960
DI 10.1002/bit.26228
PG 10
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA EQ1AR
UT WOS:000397802200002
PM 27888663
DA 2018-03-20
ER

PT J
AU Jyoti, A
   Sethi, P
   Fugit, K
   Langner, U
   St Clair, W
   McGarry, RC
   Anderson, BD
   Upreti, M
AF Jyoti, Amar
   Sethi, Pallavi
   Fugit, Kyle D.
   Langner, Ulrich
   St Clair, William
   McGarry, Ronald C.
   Anderson, Bradley D.
   Upreti, Meenakshi
TI Assessing the chemotherapeutic response of nanoliposomal topotecan in
   conjunction with radiotherapy on tumor and its microenvironment
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 105th Annual Meeting of the American-Association-for-Cancer-Research
   (AACR)
CY APR 05-09, 2014
CL San Diego, CA
SP Amer Assoc Canc Res
C1 [Jyoti, Amar; Sethi, Pallavi; Fugit, Kyle; Anderson, Bradley D.; Upreti, Meenakshi] Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY USA.
   [Langner, Ulrich; St Clair, William; McGarry, Ronald C.] Univ Kentucky, Dept Radiat Med, Lexington, KY USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD OCT 1
PY 2014
VL 74
IS 19
SU S
MA 5377
DI 10.1158/1538-7445.AM2014-5377
PG 1
WC Oncology
SC Oncology
GA CB8VR
UT WOS:000349910204296
DA 2018-03-20
ER

PT J
AU Roth, JS
   Tharappel, J
   Whittington, J
   Puleo, D
   Zwischenberger, B
AF Roth, John S.
   Tharappel, Job C.
   Whittington, Jennifer
   Puleo, David A.
   Zwischenberger, Brittany A.
TI Doxycyline improves strength of mesh hernia repairs but not sutured
   repairs
SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
LA English
DT Meeting Abstract
CT 100th Annual Clinical Congress of the American-College-of-Surgeons
CY OCT 26-30, 2014
CL San Francisco, CA
SP Amer Coll Surg
C1 [Roth, John S.; Tharappel, Job; Whittington, Jennifer; Puleo, David; Zwischenberger, Brittany] Univ Kentucky, Lexington, KY USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1072-7515
EI 1879-1190
J9 J AM COLL SURGEONS
JI J. Am. Coll. Surg.
PD OCT
PY 2014
VL 219
IS 4
SU S
BP E14
EP E14
DI 10.1016/j.jamcollsurg.2014.07.423
PG 1
WC Surgery
SC Surgery
GA CR1UU
UT WOS:000361111400031
DA 2018-03-20
ER

PT J
AU Venkatachalam, K
   Gavalas, VG
   Xu, SF
   de Leon, AC
   Bhattacharyya, D
   Bachas, LG
AF Venkatachalam, Karthik
   Gavalas, Vasilis G.
   Xul, Shifen
   de Leon, Ame C.
   Bhattacharyya, Dibakar
   Bachas, Leonidas G.
TI Poly(amino acid)-facilitated electrochemical growth of metal
   nanoparticles
SO JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY
LA English
DT Article
DE poly(amino acid); zinc nanoparticles; electrochemical growth; doped
   polypyrrole films; dechlorination; halogenated organics
ID PD NANOPARTICLES; POLYELECTROLYTE MULTILAYERS; ELECTROCATALYTIC
   PROPERTIES; SUZUKI REACTIONS; PARTICLES; FILMS; ZINC; HYDROGENATION;
   SIZE; DECHLORINATION
AB Poly(amino acids) are natural chelating agents for various metal ions. Zinc ions were encapsulated in situ in a conductive polypyrrole film using polyglutamic acid as a localized complexing agent within the film. The subsequent electrochemical reduction of the metal ions to zero-valent metal leads to the formation of the nanoparticles. The electrochemical approach demonstrated in this report provides facile regeneration of the particles and also prevents aggregation of nanoparticles in the conductive polymeric film. The correlation of the amount of zinc with the thickness of the film indicates that the zinc resides largely in the outer layer of the film. TEM and EDS data show that the nanoparticles formed are composed of zinc and are 18 +/- 7 nm in diameter. The nanoparticle/polymer composite was used to reduce halogenated organics, indicating its potential usefulness in remediation applications.
C1 Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
   Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Bachas, LG (reprint author), Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
RI Bachas, Leonidas/G-2479-2015; VENKATACHALAM, KARTHIK/D-1013-2011
OI Bachas, Leonidas/0000-0002-3308-6264
FU NIEHS NIH HHS [P42 ES 07380]
CR ANGELOPOULOS M, 1993, J VAC SCI TECHNOL B, V11, P2794, DOI 10.1116/1.586604
   Bard A. J., 2001, ELECTROCHEMICAL METH, P590
   Bonnemann H, 2001, EUR J INORG CHEM, P2455
   BORONINA T, 1995, ENVIRON SCI TECHNOL, V29, P1511, DOI 10.1021/es00006a012
   BREIMER MA, 2001, NANO LETT, V6, P305
   Bryndzia LT, 1996, ENVIRON SCI TECHNOL, V30, P3642, DOI 10.1021/es960585q
   COCHE L, 1987, J AM CHEM SOC, V109, P6887, DOI 10.1021/ja00256a072
   Crooks RM, 2001, ACCOUNTS CHEM RES, V34, P181, DOI 10.1021/ar000110a
   Dante S, 1999, LANGMUIR, V15, P193, DOI 10.1021/la980497e
   Decher G, 1997, SCIENCE, V277, P1232, DOI 10.1126/science.277.5330.1232
   Ding JH, 2000, CHEM MATER, V12, P22, DOI 10.1021/cm990603d
   Feldheim DL, 1996, J AM CHEM SOC, V118, P7640, DOI 10.1021/ja9612007
   Fendler J.H., 1998, NANOPARTICLES NANOST, P429
   Fojas AM, 2002, IND ENG CHEM RES, V41, P2662, DOI 10.1021/ie010689w
   HOLDCROFT S, 1988, J ELECTROANAL CHEM, V240, P89, DOI 10.1016/0022-0728(88)80315-2
   Joly S, 2000, LANGMUIR, V16, P1354, DOI 10.1021/la991089t
   Kidambi S, 2004, J AM CHEM SOC, V126, P2658, DOI 10.1021/ja038804c
   Kim YH, 2003, ENVIRON TECHNOL, V24, P1455, DOI 10.1080/09593330309385690
   Li Y, 2001, J PHYS CHEM B, V105, P8938, DOI 10.1021/jp010904m
   Li Y, 2002, LANGMUIR, V18, P4921, DOI 10.1021/la011469q
   Lin CH, 1999, CHEMOSPHERE, V39, P2375, DOI 10.1016/S0045-6535(99)00153-8
   Lvov Y, 2000, LANGMUIR, V16, P8850, DOI 10.1021/la000110j
   Mamedov AA, 2001, J AM CHEM SOC, V123, P7738, DOI 10.1021/ja015857q
   O'Mullane AP, 2004, CHEM COMMUN, P1606, DOI 10.1039/b404636f
   Price WE, 1999, SYNTHETIC MET, V102, P1338, DOI 10.1016/S0379-6779(98)90212-0
   Rao CNR, 2002, CHEM-EUR J, V8, P28
   Ritchie SMC, 2001, ENVIRON SCI TECHNOL, V35, P3252, DOI 10.1021/es010617w
   Samuelson LA, 1998, MACROMOLECULES, V31, P4376, DOI 10.1021/ma980258y
   Sarrazin J, 2002, MACROMOL SYMP, V188, P1, DOI 10.1002/1521-3900(200211)188:1<1::AID-MASY1>3.0.CO;2-O
   Schmid G, 2001, NANOSCALE MATERIALS IN CHEMISTRY, P15, DOI 10.1002/0471220620.ch2
   Sigaud M, 2004, J MATER CHEM, V14, P2606, DOI 10.1039/b410534f
   Underhill RS, 2000, CHEM MATER, V12, P3633, DOI 10.1021/cm0005743
   Wallace GG, 2002, J NANOSCI NANOTECHNO, V2, P441, DOI 10.1166/jnn.2002.142
   WANG Q, 2003, ENCY NANOSCIENCE NAN, V5, P475
   Wang TC, 2003, CHEM MATER, V15, P299, DOI 10.1021/cm020934h
   Wang TC, 2002, LANGMUIR, V18, P3370, DOI 10.1021/la015725a
   Zhao MQ, 1998, J AM CHEM SOC, V120, P4877, DOI 10.1021/ja980438n
NR 37
TC 6
Z9 6
U1 1
U2 5
PU AMER SCIENTIFIC PUBLISHERS
PI STEVENSON RANCH
PA 25650 NORTH LEWIS WAY, STEVENSON RANCH, CA 91381-1439 USA
SN 1533-4880
J9 J NANOSCI NANOTECHNO
JI J. Nanosci. Nanotechnol.
PD AUG
PY 2006
VL 6
IS 8
BP 2408
EP 2412
DI 10.1166/jnn.2006.520
PG 5
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 073ZD
UT WOS:000239780500019
PM 17037848
DA 2018-03-19
ER

PT J
AU Brown, ME
   Zou, Y
   Dziubla, TD
   Puleo, DA
AF Brown, Matthew E.
   Zou, Yuan
   Dziubla, Thomas D.
   Puleo, David A.
TI Effects of composition and setting environment on mechanical properties
   of a composite bone filler
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
LA English
DT Article
DE bone filler; bone graft substitute; calcium sulfate; composite; moldable
ID CALCIUM-PHOSPHATE CEMENT; INFECTED NONUNION; GRAFT SUBSTITUTES;
   DRUG-DELIVERY; GROWTH-FACTOR; SULFATE; RELEASE; DEFECT; OSTEOMYELITIS;
   SIMVASTATIN
AB Large bone defects can be difficult to treat, even with autografts. Bone graft substitutes, such as calcium sulfate (CS), calcium phosphate cements, and hydroxyapatite, are receiving significant attention because of their biocompatibility and potential for incorporation of therapeutic agents. To create a bone filler capable of treating irregularly shaped, often infected, bony defects, microspheres and a plasticizer were added to CS, resulting in a moldable composite capable of being loaded with biomolecules. Different compositions and setting environments, such as immersion in saline, a humidified incubator, or room temperature air, were investigated to determine their effects on mechanical strength and degradation rate of the composites. Addition of any other components to the CS, such as plasticizers or microspheres composed of biopolymers (gelatin, hyaluronan [HY], cellulose acetate phthalate, and carboxymethylcellulose), increased its functionality but reduced mechanical strength. The compressive modulus and strength of the composite fillers ranged from 10 to 350 MPa and 5 to 20 MPa, respectively, depending on the composition. This moldable bone filler degraded in 1820 days when placed in solution and was able to set in harsh environments given a composition that did not retain too much water. By combining a plasticizing agent, such as HY with CS, a composite material has been developed that is moldable, sets in situ, and maintains its mechanical stability. With these desirable properties for a bone graft substitute and the potential to be loaded with bioactive drugs, this composite material merits further investigation for the future treatment of bony defects. (c) 2012 Wiley Periodicals, Inc. J Biomed Mater Res Part A, 2013.
C1 [Brown, Matthew E.; Zou, Yuan; Puleo, David A.] Univ Kentucky, Ctr Biomed Engn, Lexington, KY 40506 USA.
   [Dziubla, Thomas D.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Puleo, DA (reprint author), Univ Kentucky, Ctr Biomed Engn, Lexington, KY 40506 USA.
EM puleo@uky.edu
FU U.S. Army Medical Research Acquisition Activity [W81XWH-09-1-0461];
   Kentucky NASA EPSCoR [NNX08BA13A]; IGERT from the National Science
   Foundation [DGE-0653710]
FX Contract grant sponsor: U.S. Army Medical Research Acquisition Activity;
   contract grant number: W81XWH-09-1-0461; Contract grant sponsor:
   Kentucky NASA EPSCoR; contract grant number: NNX08BA13A; Contract grant
   sponsor: IGERT support from the National Science Foundation; contract
   grant number: DGE-0653710 (to M.E.B.)
CR Aberg J, 2012, J BIOMATER APPL, V26, P667, DOI 10.1177/0885328210373670
   ANUSAVICE KJ, 2003, PHILLIPS SCI DENT MA, P255
   Athanasiou VT, 2010, MED SCI MONITOR, V16, pBR24
   Badens E, 1999, COLLOID SURFACE A, V156, P373, DOI 10.1016/S0927-7757(99)00097-7
   Brydone AS, 2010, P I MECH ENG H, V224, P1329, DOI 10.1243/09544119JEIM770
   Guo H, 2006, BIOMED MATER, V1, P193, DOI 10.1088/1748-6041/1/4/003
   Habraken WJEM, 2009, J BIOMED MATER RES A, V91A, P614, DOI 10.1002/jbm.a.32263
   Hak DJ, 2007, J AM ACAD ORTHOP SUR, V15, P525, DOI 10.5435/00124635-200709000-00003
   HARDINGHAM TE, 1992, FASEB J, V6, P861
   Hasegawa M, 2004, J BIOMED MATER RES B, V70B, P332, DOI 10.1002/jbm.b.30047
   He YQ, 2010, J BIOMAT SCI-POLYM E, V21, P1313, DOI 10.1163/092050609X12517190417678
   Hing KA, 2005, INT J APPL CERAM TEC, V2, P184, DOI 10.1111/j.1744-7402.2005.02020.x
   Ishikawa K, 1997, J BIOMED MATER RES, V36, P393, DOI 10.1002/(SICI)1097-4636(19970905)36:3<393::AID-JBM14>3.0.CO;2-F
   Jeon JH, 2008, J PERIODONTOL, V79, P1457, DOI [10.1902/jop.2008.080004, 10.1902/jop.2008.080004 ]
   Jeon JH, 2007, INT J PHARM, V340, P6, DOI 10.1016/j.ijpharm.2007.03.007
   Kanakaris NK, 2009, INJURY, V40, P54
   Kelly CM, 2001, CLIN ORTHOP RELAT R, P42
   Lewis G, 2010, CLIN ORTHOP RELAT R, V468, P2092, DOI 10.1007/s11999-010-1281-0
   Lewis KN, 2006, J MATER SCI-MATER M, V17, P531, DOI 10.1007/s10856-006-8936-0
   Li B, 2010, J CONTROL RELEASE, V145, P221, DOI 10.1016/j.jconrel.2010.04.002
   Mamidwar SS, 2007, J BIOMED MATER RES B, V81B, P57, DOI 10.1002/jbm.30636
   Mckee MD, 2010, J ORTHOP TRAUMA, V24, P483, DOI 10.1097/BOT.0b013e3181df91d9
   Moghaddam A, 2010, ARCH ORTHOP TRAUM SU, V130, P71, DOI 10.1007/s00402-009-0982-x
   Motsitsi NS, 2008, INJURY, V39, P155, DOI 10.1016/j.injury.2007.08.032
   Mourino V, 2010, J R SOC INTERFACE, V7, P209, DOI 10.1098/rsif.2009.0379
   Nyan M, 2007, J PHARMACOL SCI, V104, P384, DOI 10.1254/jphs.SC0070184
   Park YB, 2011, BIOMED MATER, V6, P11
   Parker AC, 2011, CLIN ORTHOP RELAT R, V469, P3008, DOI 10.1007/s11999-011-1911-1
   Petersen K, 2007, ANN SURG, V245, P803, DOI 10.1097/01.sla.0000251707.32332.c1
   Rajzer I, 2010, J MATER SCI-MATER M, V21, P2049, DOI 10.1007/s10856-010-4078-5
   Reynolds MA, 2007, J BIOMED MATER RES B, V83B, P451, DOI 10.1002/jbm.b.30815
   Ricci J, 2000, BONE ENG, P332
   Simon CG, 2002, J ORTHOPAED RES, V20, P473, DOI 10.1016/S0736-0266(01)00140-1
   Tang H, 2009, ARCH ORTHOP TRAUM SU, V129, P1301, DOI 10.1007/s00402-008-0782-8
   Thomas MV, 2009, J BIOMED MATER RES B, V88B, P597, DOI 10.1002/jbm.b.31269
   Thomas R, 2009, J TRAUMA, V66, pS99, DOI 10.1097/TA.0b013e31819d8695
   Tuzuner T, 2007, J ORTHOP SCI, V12, P170, DOI 10.1007/s00776-006-1107-9
   Woo KM, 2009, J BIOMED MATER RES B, V91B, P545, DOI 10.1002/jbm.b.31428
   Yun HC, 2008, J TRAUMA, V64, pS163, DOI 10.1097/TA.0b013e318160868c
   Zhu XH, 2008, TISSUE ENG PT A, V14, P1939, DOI 10.1089/ten.tea.2007.0346
   Zou Y, J BIOMED B IN PRESS
NR 41
TC 2
Z9 3
U1 0
U2 45
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1549-3296
EI 1552-4965
J9 J BIOMED MATER RES A
JI J. Biomed. Mater. Res. Part A
PD APR
PY 2013
VL 101
IS 4
BP 973
EP 980
DI 10.1002/jbm.a.34399
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 096LT
UT WOS:000315406300007
PM 22965932
DA 2018-03-20
ER

PT J
AU Novak, KF
   Diamond, WJ
   Kirakodu, S
   Peyyala, R
   Anderson, KW
   Montelaro, RC
   Mietzner, TA
AF Novak, Karen F.
   Diamond, William J.
   Kirakodu, Sreenatha
   Peyyala, Rebecca
   Anderson, Kimberly W.
   Montelaro, Ronald C.
   Mietzner, Timothy A.
TI Efficacy of the de novo-derived antimicrobial peptide WLBU2 against oral
   bacteria
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID CORONARY-ARTERY-DISEASE; LONG-TERM PROGNOSIS; PERIODONTAL-DISEASE;
   INFECTIOUS BURDEN; PROTEIN; IMPACT; PLAQUE; RISK
AB The efficacy of a novel synthetic antimicrobial peptide (WLBU2) was evaluated against three oral microorganisms (grown planktonically): Streptococcus gordonii, Fusobacterium nucleatum, and Porphyromonas gingivalis. WLBU2 killed all three species, with F. nucleatum being the most susceptible. WLBU2 also reduced the bacterial burden of S. gordonii and F. nucleatum biofilms.
C1 Univ Kentucky, Ctr Oral Hlth Res, Coll Dent, Lexington, KY 40536 USA.
   Univ Kentucky, Coll Engn, Dept Chem & Mat Engn, Lexington, KY 40536 USA.
   Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15260 USA.
RP Novak, KF (reprint author), Univ Kentucky, Ctr Oral Hlth Res, Coll Dent, 414 Hlth Sci Res Bldg,1095 VA Dr, Lexington, KY 40536 USA.
EM knova2@uky.edu
CR Aas JA, 2005, J CLIN MICROBIOL, V43, P5721, DOI 10.1128/JCM.43.11.5721-5732.2005
   Deslouches B, 2005, ANTIMICROB AGENTS CH, V49, P3208, DOI 10.1128/AAC.49.8.3208-3216.2005
   Deslouches B, 2005, ANTIMICROB AGENTS CH, V49, P316, DOI 10.1128/AAC.49.1.316-322.2005
   Desvarieux M, 2005, CIRCULATION, V111, P576, DOI 10.1161/01.CIR.0000154582.37101.15
   Engebretson SP, 2005, STROKE, V36, P561, DOI 10.1161/01.STR.0000155734.34652.6c
   Espinola-Klein C, 2002, CIRCULATION, V105, P15, DOI 10.1161/hc0102.101362
   Gatz Margaret, 2006, Alzheimers Dement, V2, P110, DOI 10.1016/j.jalz.2006.01.002
   Goepfert AR, 2004, OBSTET GYNECOL, V104, P777, DOI 10.1097/01.AOG.0000139836.47777.6d
   Kolenbrander PE, 2002, MICROBIOL MOL BIOL R, V66, P486, DOI 10.1128/MMBR.66.3.486-505.2002
   Leung KP, 2005, J DENT RES, V84, P1172, DOI 10.1177/154405910508401215
   MILLER MA, 1993, VIROLOGY, V196, P89, DOI 10.1006/viro.1993.1457
   Offenbacher S, 2006, OBSTET GYNECOL, V107, P29, DOI 10.1097/01.AOG.0000190212.87012.96
   Phadke SM, 2002, ANTIMICROB AGENTS CH, V46, P2041, DOI 10.1128/AAC.46.6.2041-2045.2002
   Rosan B, 2000, MICROBES INFECT, V2, P1599, DOI 10.1016/S1286-4579(00)01316-2
   Rupprecht HJ, 2001, CIRCULATION, V104, P25, DOI 10.1161/hc2601.091703
   Ryan Maria Emanuel, 2005, Dent Clin North Am, V49, P611, DOI 10.1016/j.cden.2005.03.010
   Tencza SB, 1997, ANTIMICROB AGENTS CH, V41, P2394
   Zhu JH, 2000, AM J CARDIOL, V85, P140, DOI 10.1016/S0002-9149(99)00653-0
NR 18
TC 8
Z9 8
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD MAY
PY 2007
VL 51
IS 5
BP 1837
EP 1839
DI 10.1128/AAC.00924-06
PG 3
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 168RK
UT WOS:000246541500037
PM 17325219
OA gold
DA 2018-03-19
ER

PT J
AU Modekrutti, S
   Cammers, A
AF Modekrutti, Subrahmanyam
   Cammers, Arthur
TI Synergy between p-interactions and electrostatics in triangulene ion
   pairs
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
CT 244th National Fall Meeting of the American-Chemical-Society (ACS)
CY AUG 19-23, 2012
CL Philadelphia, PA
SP Amer Chem Soc, Div Hist Chem, Amer Chem Soc
C1 [Modekrutti, Subrahmanyam; Cammers, Arthur] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
EM snmo222@g.uky.edu
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD AUG 19
PY 2012
VL 244
MA 438-ORGN
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA 220XX
UT WOS:000324621806643
DA 2018-03-19
ER

PT J
AU Li, XJ
   Vogt, FG
   Hayes, D
   Mansour, HM
AF Li, Xiaojian
   Vogt, Frederick G.
   Hayes, Don, Jr.
   Mansour, Heidi M.
TI Physicochemical characterization and aerosol dispersion performance of
   organic solution advanced spray-dried microparticulate/nanoparticulate
   antibiotic dry powders of tobramycin and azithromycin for pulmonary
   inhalation aerosol delivery
SO EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE Pulmonary infections; Cystic fibrosis; Glass transition; Dry powder
   inhalers (DPIs); Aerosol dispersion performance modeling; Respiratory
   delivery
ID CYSTIC-FIBROSIS; PHYSICAL-CHARACTERIZATION; DRUG-DELIVERY; PARTICLES;
   MICROPARTICLES; INHALERS; NANOPARTICLES; NANOMEDICINE; DEPOSITION;
   EFFICIENCY
AB The purpose of this study was to systematically design pure antibiotic drug dry powder inhalers (DPIs) for targeted antibiotic pulmonary delivery in the treatment of pulmonary infections and comprehensively correlate the physicochemical properties in the solid-state and spray-drying conditions effects on aerosol dispersion performance as dry powder inhalers (DPIs). The two rationally chosen model antibiotic drugs, tobramycin (TOB) and azithromycin (AZI), represent two different antibiotic drug classes of aminoglycosides and macrolides. respectively. The particle size distributions were narrow, unimodal, and in the microparticulate/nanoparticulate size range. The SD particles possessed relatively spherical particle morOhology, smooth surface morphology, low residual water content, and the absence of long-range molecular order. The emitted dose (ED%), fine particle fraction (FPF%) and respirable fraction (RF%) were all excellent. The MMAD values were in the inhalable range (<10 mu m) with smaller MMAD values for SD AZI powders in contrast to SD TOB powders. Positive linear correlations were observed between the aerosol dispersion performance parameter of FPF with increasing spray-drying pump rates and also with the difference between thermal parameters expressed as T-g - T-o (i.e. the difference between the glass transition temperature and outlet temperature) for SD AZI powders. The aerosol dispersion performance for SD TOB appeared to be influenced by its high water vapor sorption behavior (hygroscopicity) and pump rates or T-o. Aerosol dispersion performance of SD powders were distinct for both antibiotic drug aerosol systems and also between different pump rates for each system. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Li, Xiaojian] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Drug Dev Div, Lexington, KY 40536 USA.
   [Vogt, Frederick G.] GlaxoSmithKline, Analyt Sci, Prod Dev, King Of Prussia, PA 19406 USA.
   [Hayes, Don, Jr.] Ohio State Univ, Coll Med, Dept Pediat, Lung & Heart Lung Transplant Programs, Columbus, OH 43205 USA.
   [Hayes, Don, Jr.] Ohio State Univ, Coll Med, Dept Internal Med, Lung & Heart Lung Transplant Programs, Columbus, OH 43205 USA.
   [Hayes, Don, Jr.] Ohio State Univ, Coll Med, Davis Heart & Lung Res Inst, Columbus, OH 43205 USA.
   [Mansour, Heidi M.] Univ Arizona, Coll Pharm, Skaggs Pharmaceut Sci Ctr, Tucson, AZ 85721 USA.
RP Mansour, HM (reprint author), Univ Arizona, Coll Pharm, Skaggs Pharmaceut Sci Ctr, 1703 E Mabel St, Tucson, AZ 85721 USA.
EM mansour@pharmacy.arizona.edu
RI Li, Xiaojian/N-3421-2015
FU UK Center of Membrane Sciences; Graduate School Academic Year
   Fellowship; Daniel R. Reedy Quality Achievement Fellowship
FX The authors gratefully acknowledge fellowship support from the UK Center
   of Membrane Sciences, the Graduate School Academic Year Fellowship and
   the Daniel R. Reedy Quality Achievement Fellowship awarded to Xiaojian
   Li. The authors thank Dr. Dicky Sick Ki Yu for SEM access, Dr. Tonglei
   Li for XRPD and HSM access, and Dr. Hilt for ATR-FTIR access at the
   University of Kentucky.
CR Adi H, 2008, J PHARM SCI-US, V97, P2780, DOI 10.1002/jps.21195
   Adi S, 2008, EUR J PHARM SCI, V35, P12, DOI 10.1016/j.ejps.2008.05.009
   Burnett D., 2009, CHARACTERIZING AMORP
   DASH AK, 1991, PHARMACEUT RES, V8, P1159, DOI 10.1023/A:1015858503031
   Finlay Warren, 2008, ARLA RESP DEPOSITION
   Gandhi R, 2002, EUR J PHARM SCI, V16, P175, DOI 10.1016/S0928-0987(02)00087-8
   Garcia-Contreras L, 2002, ADV DRUG DELIVER REV, V54, P1491, DOI 10.1016/S0169-409X(02)00159-X
   HANCOCK BC, 1994, PHARMACEUT RES, V11, P471, DOI 10.1023/A:1018941810744
   Hayes D.J., 2009, RESPIROLOGY, V15, P182
   Hickey A.J., 2008, MODIFIED RELEASE DRU, V2, P573
   Hickey AJ, 2009, MODERN PHARM, P191
   Hickey AJ, 2007, J PHARM SCI-US, V96, P1302, DOI 10.1002/jps.20943
   Hickey AJ, 2007, J PHARM SCI-US, V96, P1282, DOI 10.1002/jps.20916
   Li XJ, 2011, AAPS PHARMSCITECH, V12, P1420, DOI 10.1208/s12249-011-9704-0
   LIGHTBOWN JW, 1982, J BIOL STAND, V10, P157, DOI 10.1016/S0092-1157(82)80038-3
   Louey MD, 2004, PHARM RES, V21, P1200, DOI 10.1023/B:PHAM.0000033007.27278.60
   Mansour HM, 2007, AAPS PHARMSCITECH, V8, DOI 10.1208/pt0804099
   Mansour HM, 2007, J PHARM SCI-US, V96, P377, DOI 10.1002/jps.20810
   Mansour HM, 2009, INT J NANOMED, V4, P299
   Meenach SA, 2013, INT J NANOMED, V8, P275, DOI 10.2147/IJN.S30724
   Mizoe T, 2007, J CONTROL RELEASE, V122, P10, DOI 10.1016/j.jconrel.2007.06.001
   Murray J. F., 1988, TXB RESP MED
   Park CW, 2012, ADV DRUG DELIVER REV, V64, P344, DOI 10.1016/j.addr.2011.08.004
   Park CW, 2011, EUROPEAN PHARM REV, V16, P32
   Paterson DL, 2006, CURR OPIN PHARMACOL, V6, P486, DOI 10.1016/j.coph.2006.07.001
   Prescott WA, 2005, PHARMACOTHERAPY, V25, P555, DOI 10.1592/phco.25.4.555.61025
   RAABE OG, 1982, ANN OCCUP HYG, V26, P33, DOI 10.1093/annhyg/26.1.33
   Shitrit D, 2005, J HEART LUNG TRANSPL, V24, P1440, DOI 10.1016/j.healun.2004.08.006
   Song JH, 2008, INT J ANTIMICROB AG, V32, pS207, DOI 10.1016/S0924-8579(09)70004-4
   STAHLHOFEN W, 1980, AM IND HYG ASSOC J, V41, P385, DOI 10.1080/15298668091424933
   Suarez S, 2000, Respir Care, V45, P652
   TAYLOR RFH, 1992, THORAX, V47, P426, DOI 10.1136/thx.47.6.426
   Tiddens HAWM, 2002, PEDIATR PULM, V34, P228, DOI 10.1002/ppul.10134
   The United States Pharmacopeial Convention Inc, 2006, 601 AER NAS SPRAYS M, P2617
   Usmani OS, 2005, AM J RESP CRIT CARE, V172, P1497, DOI 10.1164/rccm.200410-1414OC
   Worlitzsch D, 2002, J CLIN INVEST, V109, P317, DOI 10.1172/JCI200213870
   Wu X., 2013, INT J NANOMED, V8, P1
   Wu X, 2013, DRUG DES DEV THER, V7, P59, DOI [10.2147/DDDT.540166, 10.2147/DDDT.S40166]
   Wu XA, 2010, KONA POWDER PART J, P3
   Xu Z, 2011, J ADHES SCI TECHNOL, V25, P451, DOI 10.1163/016942410X525669
   Xu Z, 2010, J PHARM SCI-US, V99, P3442, DOI 10.1002/jps.22057
NR 41
TC 12
Z9 12
U1 1
U2 27
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0928-0987
EI 1879-0720
J9 EUR J PHARM SCI
JI Eur. J. Pharm. Sci.
PD FEB 14
PY 2014
VL 52
BP 191
EP 205
DI 10.1016/j.ejps.2013.10.016
PG 15
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA AA3VF
UT WOS:000331022100021
PM 24215736
DA 2018-03-20
ER

PT J
AU Madathil, SK
   Tuttle, B
   Yu, CG
   Geddes, J
   Saatman, K
AF Madathil, Sindhu Kizhakke
   Tuttle, Benjamin
   Yu, Chen-Guang
   Geddes, James W.
   Saatman, Kathryn E.
TI CONDITIONAL OVEREXPRESSION OF INSULIN-LIKE GROWTH FACTOR-1 IMPROVES
   WHITE MATTER SPARING AND FUNCTIONAL OUTCOME FOLLOWING SPINAL CORD INJURY
SO JOURNAL OF NEUROTRAUMA
LA English
DT Meeting Abstract
CT 30th Annual National Neurotrauma Symposium
CY JUL 22-25, 2012
CL Phoenix, AZ
DE IGF-1; astrocytosis; behaviour; locomotor function
C1 [Geddes, James] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr SCoBIRC, Dept Anat & Neurobiol, Lexington, KY 40506 USA.
   [Saatman, Kathryn] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr SCoBIRC, Dept Physiol, Lexington, KY 40506 USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0897-7151
J9 J NEUROTRAUM
JI J. Neurotrauma
PD JUL
PY 2012
VL 29
IS 10
BP A181
EP A181
PG 1
WC Critical Care Medicine; Clinical Neurology; Neurosciences
SC General & Internal Medicine; Neurosciences & Neurology
GA 971YV
UT WOS:000306244400314
DA 2018-03-20
ER

PT J
AU Oldham, ED
   Seelam, S
   Lema, C
   Aguilera, RJ
   Fiegel, J
   Rankin, SE
   Knutson, BL
   Lehmler, HJ
AF Oldham, Edward Davis
   Seelam, Srivenu
   Lema, Carolina F.
   Aguilera, Renato J.
   Fiegel, Jennifer
   Rankin, Stephen E.
   Knutson, Barbara L.
   Lehmler, Hans-Joachim
TI Synthesis, surface properties, and biocompatibility of
   1,2,3-triazole-containing alkyl beta-D-xylopyranoside surfactants
SO CARBOHYDRATE RESEARCH
LA English
DT Article
DE Click chemistry; Huisgen cycloaddition; Carbohydrate surfactants;
   Langmuir monolayers; Cytotoxicity
ID LIQUID-CRYSTALLINE PROPERTIES; AIR-WATER-INTERFACE; CLICK CHEMISTRY;
   COPPER(I)-CATALYZED CYCLOADDITION; TEMPERATURE-DEPENDENCE;
   PHASE-BEHAVIOR; CHAIN-LENGTH; CELL LINES; D-XYLITOLS; D-XYLOSE
AB We are interested in the development of surfactants derived from hemicellulosic biomass, as they are potential components in pharmaceuticals, personal care products, and other detergents. Such surfactants should exhibit low toxicity in mammalian cells. In this study we synthesized a series of alkyl or fluoro-alkyl beta-xylopyranosides from azides and an alkyne using the copper-catalyzed azide-alkyne (CuAAC) 'click' reaction in 4 steps from xylose. The purified products were evaluated for both their surfactant properties, and for their biocompatibility. Unlike other carbohydrate-based surfactants, liquid-crystalline behavior was not observed by differential scanning calorimetry. The triazole-containing beta-xylopyranosides with short (6 carbons) and long (>12 carbons) chains exhibited no toxicity at concentrations ranging from 1 to 1000 mu M. Triazole-containing beta-xylopyranosides with 8, 10, or 12 carbons caused toxicity via apoptosis, with CC50 values ranging from 26-890 mu M. The two longest chain compounds did form stable monolayers at the air-water interface over a range of temperatures, although a brief transition to an the unstable monolayer was observed. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Oldham, E. Davis; Lehmler, Hans-Joachim] Univ Iowa, Dept Occupat & Environm Hlth, IREH, Iowa City, IA 52242 USA.
   [Seelam, Srivenu; Rankin, Stephen E.; Knutson, Barbara L.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Lema, Carolina; Aguilera, Renato J.] Univ Texas El Paso, Dept Biol Sci, El Paso, TX 79968 USA.
   [Fiegel, Jennifer] Univ Iowa, Dept Pharmaceut Sci & Expt Therapeut, Coll Pharm, Iowa City, IA 52242 USA.
   [Fiegel, Jennifer] Univ Iowa, Dept Chem & Biochem Engn, Coll Engn, Iowa City, IA 52242 USA.
   [Lehmler, Hans-Joachim] Univ Iowa, Interdisciplinary Grad Program Human Toxicol, Iowa City, IA 52242 USA.
RP Lehmler, HJ (reprint author), Univ Iowa, Dept Occupat & Environm Hlth, IREH, UI Res Pk, Iowa City, IA 52242 USA.
EM hans-joachim-lehmler@uiowa.edu
RI Henderson, Luke/C-9764-2009
FU National Science Foundation [CBET-0967381/0967390]; U.S. Department of
   Agriculture Biomass Research and Development Initiative [68-3A75-7-608];
   Department of Energy Development and Independence, Energy and
   Environment Cabinet of The Common-wealth of Kentucky; National Center
   for Research Resources (NCRR) of the NIH [8G12MD007592]
FX This work was supported by the National Science Foundation
   (CBET-0967381/0967390), the U.S. Department of Agriculture Biomass
   Research and Development Initiative (Grant Agreement 68-3A75-7-608) and
   the Department of Energy Development and Independence, Energy and
   Environment Cabinet of The Common-wealth of Kentucky. The cell culture
   work was performed at the Cell Culture Core of the Border Biomedical
   Research Center (BBRC) supported by grant 8G12MD007592 from the National
   Center for Research Resources (NCRR) of the NIH, granted to the
   University of Texas at El Paso.
CR Alvarez S. G., 1997, SYNTHESIS-STUTTGART, V1997, P414
   Balgavy P, 1996, ADV COLLOID INTERFAC, V66, P23, DOI 10.1016/0001-8686(96)00295-3
   BERG JM, 1994, LANGMUIR, V10, P1213, DOI 10.1021/la00016a040
   Boullanger P, 1996, LANGMUIR, V12, P1771, DOI 10.1021/la950485i
   Bouxin F, 2010, CARBOHYD RES, V345, P2469, DOI 10.1016/j.carres.2010.09.003
   Boyd BJ, 2000, LANGMUIR, V16, P7359, DOI 10.1021/la991573w
   Boyum A, 1968, Scand J Clin Lab Invest Suppl, V97, P77
   Cea P, 2006, J PHYS CHEM B, V110, P963, DOI 10.1021/jp055673o
   Chambert S, 2007, J CARBOHYD CHEM, V26, P27, DOI 10.1080/07328300701252565
   Clemente MJ, 2011, LANGMUIR, V27, P15236, DOI 10.1021/la203447e
   Damez C, 2007, CARBOHYD RES, V342, P154, DOI 10.1016/j.carres.2006.11.013
   DEVINSKY F, 1990, J PHARM PHARMACOL, V42, P790, DOI 10.1111/j.2042-7158.1990.tb07022.x
   Deyrieux AF, 2007, CYTOTECHNOLOGY, V54, P77, DOI 10.1007/s10616-007-9076-1
   Donnio B, 2000, ORGANOMETALLICS, V19, P3077, DOI 10.1021/om0001568
   Frey SL, 2007, LANGMUIR, V23, P2631, DOI 10.1021/la0626398
   Gaines G., 1966, INSOLUBLE MONOLAYERS
   Galema SA, 1997, CARBOHYD RES, V303, P423, DOI 10.1016/S0008-6215(97)00185-7
   Garofalakis G, 2002, LANGMUIR, V18, P4765, DOI 10.1021/la011784c
   Goodby JW, 2007, CHEM SOC REV, V36, P1971, DOI 10.1039/b708458g
   Goodby JW, 1998, LIQ CRYST, V24, P25, DOI 10.1080/026782998207550
   GOODBY JW, 1988, LIQ CRYST, V3, P1569, DOI 10.1080/02678298808086696
   Goodby JW, 1997, LIQ CRYST, V22, P497, DOI 10.1080/026782997209225
   Gruzman A, 2008, J MED CHEM, V51, P8096, DOI 10.1021/jm8008713
   Harmouch B, 1997, J CARBOHYD CHEM, V16, P479, DOI 10.1080/07328309708007329
   Hill K., 2009, SUGAR BASED SURFACTA
   Kaganer VM, 1999, PHYS REV E, V59, P2141, DOI 10.1103/PhysRevE.59.2141
   Kamp F, 2006, PROSTAG LEUKOTR ESS, V75, P149, DOI 10.1016/j.plefa.2006.05.003
   KELLNER BMJ, 1978, J COLLOID INTERF SCI, V66, P597, DOI 10.1016/0021-9797(78)90086-3
   Kim JH, 2010, APPL MICROBIOL BIOT, V88, P1077, DOI 10.1007/s00253-010-2839-1
   Kolb HC, 2003, DRUG DISCOV TODAY, V8, P1128, DOI 10.1016/S1359-6446(03)02933-7
   Lehmler HJ, 2005, J LIPID RES, V46, P535, DOI 10.1194/jlr.M400406-JLR200
   Lehmler HJ, 2002, J COLLOID INTERF SCI, V249, P381, DOI 10.1006/jcis.2002.8282
   Li XY, 2012, ECOTOX ENVIRON SAFE, V83, P102, DOI 10.1016/j.ecoenv.2012.06.013
   Li XS, 2009, COLLOID SURFACE B, V73, P65, DOI 10.1016/j.colsurfb.2009.04.023
   Li XS, 2008, NEW J CHEM, V32, P2169, DOI 10.1039/b805015e
   Lu WY, 2010, TETRAHEDRON, V66, P750, DOI 10.1016/j.tet.2009.11.044
   Martinez A, 2010, J INORG BIOCHEM, V104, P967, DOI 10.1016/j.jinorgbio.2010.05.002
   Matsumura S, 1999, BIOTECHNOL LETT, V21, P17, DOI 10.1023/A:1005464025881
   MILIUS A, 1992, NEW J CHEM, V16, P771
   Miyoshi N, 2006, P NATL ACAD SCI USA, V103, P1727, DOI 10.1073/pnas.0510346103
   MLYNARCIK D, 1981, MICROBIOS, V30, P27
   Moses JE, 2007, CHEM SOC REV, V36, P1249, DOI 10.1039/b613014n
   MUKERJEE P, 1982, J AM OIL CHEM SOC, V59, P573, DOI 10.1007/BF02636327
   Neto V, 2008, J CARBOHYD CHEM, V27, P231, DOI 10.1080/07328300802105365
   Nguyen DM, 2011, SYNTHETIC COMMUN, V41, P1759, DOI 10.1080/00397911.2010.492081
   NIELSON DW, 1986, J APPL PHYSIOL, V60, P972
   Noller CR, 1938, J AM CHEM SOC, V60, P1938, DOI 10.1021/ja01275a061
   O'Neil EJ, 2007, ORG LETT, V9, P199, DOI 10.1021/ol062557a
   Oldham ED, 2012, J PHYS CHEM B, V116, P9999, DOI 10.1021/jp304412p
   Paul KJV, 2008, TETRAHEDRON LETT, V49, P6356, DOI 10.1016/j.tetlet.2008.08.073
   Pavillard V, 2004, BIOCHEM PHARMACOL, V67, P1587, DOI 10.1016/j.bcp.2004.01.006
   PRADE H, 1995, J PRAK CHEM-CHEM ZTG, V337, P427, DOI 10.1002/prac.19953370195
   Prakash G, 2011, BIORESOURCE TECHNOL, V102, P3304, DOI 10.1016/j.biortech.2010.10.074
   Read RW, 2012, J FLUORINE CHEM, V135, P25, DOI 10.1016/j.jfluchem.2011.07.030
   Read RW, 2009, CHIANG MAI J SCI, V36, P247
   Rostovtsev V. V., 2002, ANGEW CHEM, V114, P2708, DOI DOI 10.1002/1521-3757(20020715)114:14<2708::AID-ANGE2708>3.0.CO;2-0
   Rowan AS, 2009, ORG BIOMOL CHEM, V7, P4029, DOI 10.1039/b909729e
   Sani FA, 2012, COLLOID SURFACE B, V97, P196, DOI 10.1016/j.colsurfb.2012.03.030
   Shaik N, 2009, INORG CHEM, V48, P1577, DOI 10.1021/ic801925k
   Soderlind E, 2003, INT J PHARM, V252, P61, DOI 10.1016/S0378-5173(02)00599-9
   SUN RC, 1995, IND CROP PROD, V4, P127, DOI 10.1016/0926-6690(95)00025-8
   Tamada K, 1996, LANGMUIR, V12, P1666, DOI 10.1021/la9503257
   Varela-Ramirez A, 2011, CELL BIOL TOXICOL, V27, P159, DOI 10.1007/s10565-010-9178-y
   Vollhardt D, 2004, LANGMUIR, V20, P7670, DOI 10.1021/la049345b
   Wang Y, 2012, TOXICOL RES-UK, V1, P103, DOI 10.1039/c2tx20017a
   Xu WJ, 2012, CARBOHYD RES, V349, P12, DOI 10.1016/j.carres.2011.11.020
   ZARIF L, 1989, J FLUORINE CHEM, V44, P73, DOI 10.1016/S0022-1139(00)84372-9
   ZARIF L, 1990, J MED CHEM, V33, P1262, DOI 10.1021/jm00166a028
   ZINNER H, 1959, NATURWISSENSCHAFTEN, V46, P531, DOI 10.1007/BF00627610
NR 69
TC 18
Z9 19
U1 5
U2 31
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0008-6215
EI 1873-426X
J9 CARBOHYD RES
JI Carbohydr. Res.
PD SEP 20
PY 2013
VL 379
BP 68
EP 77
DI 10.1016/j.carres.2013.06.020
PG 10
WC Biochemistry & Molecular Biology; Chemistry, Applied; Chemistry, Organic
SC Biochemistry & Molecular Biology; Chemistry
GA 216RI
UT WOS:000324301300013
PM 23872788
OA green_accepted
DA 2018-03-20
ER

PT J
AU Nednoor, P
   Gavalas, VG
   Chopra, N
   Hinds, BJ
   Bachas, LG
AF Nednoor, Pramod
   Gavalas, Vasilis G.
   Chopra, Nitin
   Hinds, Bruce J.
   Bachas, Leonidas G.
TI Carbon nanotube based biomimetic membranes: Mimicking protein channels
   regulated by phosphorylation
SO JOURNAL OF MATERIALS CHEMISTRY
LA English
DT Article
ID ION CHANNELS; TRANSPORT; SEPARATIONS; ELECTRODES
AB Membranes based on an array of aligned carbon nanotubes were used to mimic biological protein channels by functionalizing the open tips of the nanotubes with a synthetic peptide to obtain a biomimetic system where phosphorylation regulates the flow.
C1 Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
RP Hinds, BJ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM bjhinds@engr.uky.edu; bachas@uky.edu
RI Nitin, Chopra/F-8236-2011; Bachas, Leonidas/G-2479-2015
OI Bachas, Leonidas/0000-0002-3308-6264
CR Chopra N, 2005, ADV FUNCT MATER, V15, P858, DOI 10.1002/adfm.200400399
   COHEN P, 2002, NAT CELL BIOL, V4, P127
   DAVIS MJ, 2001, AM J PHYSIOL, V281, P1835
   Feng X, 1997, SCIENCE, V276, P923, DOI 10.1126/science.276.5314.923
   Harrell CC, 2004, J AM CHEM SOC, V126, P15646, DOI 10.1021/ja044948v
   Hinds BJ, 2004, SCIENCE, V303, P62, DOI 10.1126/science.1092048
   Lee SB, 2002, SCIENCE, V296, P2198, DOI 10.1126/science.1071396
   LEVITAN IB, 1994, ANNU REV PHYSIOL, V56, P193, DOI 10.1146/annurev.ph.56.030194.001205
   Maisterrena B, 2001, J PHYS CHEM B, V105, P9623, DOI 10.1021/jp010625z
   Majumder M, 2005, J AM CHEM SOC, V127, P9062, DOI 10.1021/ja043013b
   Mammen A L, 1999, Methods Enzymol, V294, P353
   Martin CR, 2003, NAT REV DRUG DISCOV, V2, P29, DOI 10.1038/nrd988
   Nednoor P, 2005, CHEM MATER, V17, P3595, DOI 10.1021/cm047844s
   Nigon C, 1998, J MEMBRANE SCI, V144, P223, DOI 10.1016/S0376-7388(98)00060-X
   Ramirez P, 2003, J PHYS CHEM B, V107, P13178, DOI 10.1021/jp035778w
   Randon J, 1997, J MEMBRANE SCI, V134, P219, DOI 10.1016/S0376-7388(97)00110-5
   Schon P, 2005, J AM CHEM SOC, V127, P11486, DOI 10.1021/ja051574c
   Siwy Z, 2005, J AM CHEM SOC, V127, P5000, DOI 10.1021/ja043910f
   Umezawa Y, 2004, ANAL CHEM, V76, p320A, DOI 10.1021/ac0416259
   Wang GL, 2006, J AM CHEM SOC, V128, P7679, DOI 10.1021/ja061357r
   Webster SM, 2004, NATURE, V428, P864, DOI 10.1038/nature02468
   Yu SF, 2001, NANO LETT, V1, P495, DOI 10.1021/nl010044l
NR 22
TC 34
Z9 34
U1 0
U2 13
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 0959-9428
J9 J MATER CHEM
JI J. Mater. Chem.
PD MAY 14
PY 2007
VL 17
IS 18
BP 1755
EP 1757
DI 10.1039/b703365f
PG 3
WC Chemistry, Physical; Materials Science, Multidisciplinary
SC Chemistry; Materials Science
GA 170VL
UT WOS:000246694200010
DA 2018-03-20
ER

PT J
AU Li, XJ
   Mansour, HM
AF Li, Xiaojian
   Mansour, Heidi M.
TI Physicochemical Characterization and Water Vapor Sorption of Organic
   Solution Advanced Spray-Dried Inhalable Trehalose Microparticles and
   Nanoparticles for Targeted Dry Powder Pulmonary Inhalation Delivery
SO AAPS PHARMSCITECH
LA English
DT Article
DE microparticulate/nanoparticulate inhalable powders; non-reducing sugar
   excipient; organic solution advanced spray drying; respiratory delivery;
   trehalose
ID AMORPHOUS TREHALOSE; FORMULATION EXCIPIENTS; NANOCARRIER SYSTEMS;
   AEROSOL PERFORMANCE; PHYSICAL-PROPERTIES; PHASE-TRANSITIONS; CARRIERS;
   CRYSTALLIZATION; DIHYDRATE; BEHAVIOR
AB Novel advanced spray-dried inhalable trehalose microparticulate/nanoparticulate powders with low water content were successfully produced by organic solution advanced spray drying from dilute solution under various spray-drying conditions. Laser diffraction was used to determine the volumetric particle size and size distribution. Particle morphology and surface morphology was imaged and examined by scanning electron microscopy. Hot-stage microscopy was used to visualize the presence/absence of birefringency before and following particle engineering design pharmaceutical processing, as well as phase transition behavior upon heating. Water content in the solid state was quantified by Karl Fisher (KF) coulometric titration. Solid-state phase transitions and degree of molecular order were examined by differential scanning calorimetry (DSC) and powder X-ray diffraction, respectively. Scanning electron microscopy showed a correlation between particle morphology, surface morphology, and spray drying pump rate. All advanced spray-dried microparticulate/nanoparticulate trehalose powders were in the respirable size range and exhibited a unimodal distribution. All spray-dried powders had very low water content, as quantified by KF. The absence of crystallinity in spray-dried particles was reflected in the powder X-ray diffractograms and confirmed by thermal analysis. DSC thermal analysis indicated that the novel advanced spray-dried inhalable trehalose microparticles and nanoparticles exhibited a clear glass transition (T (g)). This is consistent with the formation of the amorphous glassy state. Spray-dried amorphous glassy trehalose inhalable microparticles and nanoparticles exhibited vapor-induced (lyotropic) phase transitions with varying levels of relative humidity as measured by gravimetric vapor sorption at 25A degrees C and 37A degrees C.
C1 [Li, Xiaojian; Mansour, Heidi M.] Univ Kentucky, Dept Pharmaceut Sci, Drug Dev Div, Coll Pharm, Lexington, KY 40536 USA.
RP Mansour, HM (reprint author), Univ Kentucky, Dept Pharmaceut Sci, Drug Dev Div, Coll Pharm, 789 S Limestone St, Lexington, KY 40536 USA.
EM heidi.mansour@uky.edu
FU UK Daniel P. Reedy Fellowship; UK Center of Membrane Sciences
FX The authors gratefully acknowledge financial support from the UK Daniel
   P. Reedy Fellowship and Fellowship support from the UK Center of
   Membrane Sciences awarded to Xiaojian Li. The authors thank Dr. Dicky
   Sick Ki Yu for SEM access and Dr. Tonglei Li for XRPD and HSM access.
CR Abdelwahed W, 2006, ADV DRUG DELIVER REV, V58, P1688, DOI 10.1016/j.addr.2006.09.017
   Adi H, 2008, J PHARM SCI-US, V97, P2780, DOI 10.1002/jps.21195
   Adi S, 2008, EUR J PHARM SCI, V35, P12, DOI 10.1016/j.ejps.2008.05.009
   Andya JD, 1999, PHARMACEUT RES, V16, P350, DOI 10.1023/A:1018805232453
   Bosquillon C, 2004, J CONTROL RELEASE, V99, P357, DOI 10.1016/j.jconrel.2004.07.022
   Bosquillon C, 2001, J CONTROL RELEASE, V70, P329, DOI 10.1016/S0168-3659(00)00362-X
   Chacon M, 1999, EUR J PHARM SCI, V8, P99, DOI 10.1016/S0928-0987(98)00066-9
   Crowe LM, 1996, BIOPHYS J, V71, P2087, DOI 10.1016/S0006-3495(96)79407-9
   Fakes MG, 2000, PDA J PHARM SCI TECH, V54, P144
   Garmise RJ, 2007, AAPS PHARMSCITECH, V8, DOI 10.1208/pt0804081
   Hickey A. J., 2008, MODIFIED RELEASE DRU, P573
   Hickey AJ, 2009, MODERN PHARM, P191
   Hickey AJ, 2007, J PHARM SCI-US, V96, P1282, DOI 10.1002/jps.20916
   Horvat M, 2005, INT J PHARM, V294, P1, DOI 10.1016/j.ijpharm.2004.08.025
   Jones MD, 2006, INT J PHARM, V313, P87, DOI 10.1016/j.ijpharm.2006.01.026
   Katzenstein ALA, 1998, AM J RESP CRIT CARE, V157, P1301, DOI 10.1164/ajrccm.157.4.9707039
   Lo YL, 2004, J CONTROL RELEASE, V94, P259, DOI 10.1016/j.jconrel.2003.09.019
   Mansour HM, 2007, J PHARM SCI-US, V96, P377, DOI 10.1002/jps.20810
   Mansour HM, 2010, J PHARM SCI-US, V99, P3430, DOI 10.1002/jps.22101
   Mansour HM, 2009, INT J NANOMED, V4, P299
   Mansour HM, 2007, AAPS PHARMSCITECH, V8, pE01
   Marsac PJ, 2010, J PHARM SCI-US, V99, P169, DOI 10.1002/jps.21809
   Masters K, 1991, SPRAY DRYING HDB, P725
   Moran A, 2007, INT J PHARM, V343, P12, DOI 10.1016/j.ijpharm.2007.04.018
   Moran A, 2009, AAPS PHARMSCITECH, V10, P297, DOI 10.1208/s12249-009-9195-4
   Park CW, 2011, EUROPEAN PHARM REV, V16, P32
   Patton JS, 2007, NAT REV DRUG DISCOV, V6, P67, DOI 10.1038/nrd2153
   Rhee YS, 2011, INT J NANOTECHNOL, V8, P84, DOI 10.1504/IJNT.2011.037172
   Sethi S, 2007, AM J RESP CRIT CARE, V176, P356, DOI 10.1164/rccm.200703-417OC
   Sexauer WP, 2003, SEM RESP CRIT CARE M, V24, P717
   Steckel H, 2004, INT J PHARM, V270, P297, DOI 10.1016/j.ijpharm.2003.10.039
   Surana R, 2004, PHARM RES, V21, P1167, DOI 10.1023/B:PHAM.0000033003.17251.c3
   Surana R, 2004, PHARM RES, V21, P867, DOI 10.1023/B:PHAM.0000026441.77567.75
   Takeuchi H, 2000, PHARM DEV TECHNOL, V5, P355, DOI 10.1081/PDT-100100551
   Taylor LS, 1998, J PHARM SCI, V87, P347, DOI 10.1021/js970239m
   Vehring R, 2008, PHARM RES, V25, P999, DOI 10.1007/s11095-007-9475-1
   Wu XA, 2011, INT J NANOTECHNOL, V8, P115, DOI 10.1504/IJNT.2011.037173
   Xu Z, 2011, J ADHES SCI TECHNOL, V25, P451, DOI 10.1163/016942410X525669
   Xu Z, 2010, J PHARM SCI-US, V99, P3442, DOI 10.1002/jps.22057
   Zeng XM, 2001, PARTICULATE INTERACT, P225
NR 40
TC 21
Z9 21
U1 0
U2 19
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1530-9932
J9 AAPS PHARMSCITECH
JI AAPS PharmSciTech
PD DEC
PY 2011
VL 12
IS 4
BP 1420
EP 1430
DI 10.1208/s12249-011-9704-0
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 855TC
UT WOS:000297586500044
PM 22038473
OA green_published
DA 2018-03-20
ER

PT J
AU Tharappel, JC
   Harris, JW
   Zwischenberger, BA
   Levy, SM
   Puleo, DA
   Roth, JS
AF Tharappel, Job C.
   Harris, Jennifer Whittington
   Zwischenberger, Brittany A.
   Levy, Salomon M.
   Puleo, David A.
   Roth, John S.
TI Doxycycline shows dose-dependent changes in hernia repair strength after
   mesh repair
SO SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES
LA English
DT Article
DE Extracellular matrix; Doxycycline; Matrix metalloproteinase; Hernia
   repair
ID MATRIX METALLOPROTEINASES; INCISIONAL HERNIA; HYPERTENSION; INHIBITOR;
   TISSUE; MMP-9
AB Ventral hernia is a commonly occurring surgical problem. Our earlier studies have shown that a 30 mg/kg dose of doxycycline can significantly impact the strength of polypropylene (PP) mesh in a rat hernia repair model at 6 and 12 weeks. The objective of the present study was to investigate the dose dependence of doxycycline treatment on hernia repair strengths in rats.
   Fifty-six Sprague-Dawley rats underwent hernia repair with either PP mesh (n = 28) or sutures only (primary; n = 28); both groups were further divided into four doxycycline groups of seven animals each: control (0 mg/kg), low (3 mg/kg), medium (10 mg/kg), and high (30 mg/kg). One day before hernia repair surgery, animals received doxycycline doses by gavage and continued receiving daily until euthanasia. After 8 weeks, rats were euthanized and tissue samples from hernia repaired area were collected and analyzed for tensile strength using a tensiometer (Instron, Canton, MA, USA), while MMPs 2, 3, and 9, and collagen type 1 and 3 were analyzed by western blotting.
   In mesh-repaired animals, medium and high doxycycline dose repaired mesh fascia interface (MFI) showed significant increase in tensile strength when compared to control. In the primary repaired animals, there was no significant difference in MFI tensile strength in any dose group. In medium-dose MFI, there was a significant reduction in MMPs 2, 3, and 9. In this animal group, MFI showed significant increase in collagen 1 and significant reduction in collagen type 3 when compared to control.
   It is possible to improve the strength of mesh-repaired tissue by administering a significantly lower dose of the drug, which has implications for translation of the findings.
C1 [Tharappel, Job C.; Harris, Jennifer W.; Zwischenberger, Brittany A.; Levy, Salomon M.; Roth, J. Scott] Univ Kentucky, Coll Med, Dept Surg, Div Gen Surg, 800 Rose St,UKMC C-222, Lexington, KY 40536 USA.
   [Puleo, David A.] Univ Kentucky, Coll Med, Dept Biomed Engn, Lexington, KY USA.
RP Roth, JS (reprint author), Univ Kentucky, Coll Med, Dept Surg, Div Gen Surg, 800 Rose St,UKMC C-222, Lexington, KY 40536 USA.
EM jsroth2@uky.edu
FU Davol, Inc., Warwick, Rhode Island
FX This research was supported by a grant from Davol, Inc., Warwick, Rhode
   Island. Timely help in the preparation and submission of the manuscript
   by Ms. Linda Combs is greatly appreciated.
CR Anthony T, 2000, WORLD J SURG, V24, P95, DOI 10.1007/s002689910018
   Antonio RC, 2014, MOL CELL BIOCHEM, V386, P99, DOI 10.1007/s11010-013-1848-7
   Antoniou SA, 2009, EUR J CLIN INVEST, V39, P953, DOI 10.1111/j.1365-2362.2009.02199.x
   Castro MM, 2013, CURR DRUG TARGETS, V14, P335
   Flanigan TP, 1991, CLIN INFECT DIS, V63, P388
   Franz MG, 2008, SURG CLIN N AM, V88, P1, DOI 10.1016/j.suc.2007.10.007
   GEORGE CD, 1986, ANN ROY COLL SURG, V68, P185
   Guedez L, 1998, BLOOD, V92, P1342
   Guimaraes DA, 2011, BASIC CLIN PHARMACOL, V108, P318, DOI 10.1111/j.1742-7843.2010.00656.x
   HATSU M, 1992, J ANTIBIOT, V45, P320, DOI 10.7164/antibiotics.45.320
   Kingsnorth A, 2006, ANN ROY COLL SURG, V88, P252, DOI 10.1308/003588406X106324
   LANGER S, 1985, ACTA CHIR SCAND, V151, P217
   Leber GE, 1998, ARCH SURG-CHICAGO, V133, P378, DOI 10.1001/archsurg.133.4.378
   Lee HM, 2004, J PERIODONTOL, V75, P453, DOI 10.1902/jop.2004.75.3.453
   Lorenzl S, 2002, EXP NEUROL, V178, P13, DOI 10.1006/exnr.2002.8019
   Mignatti P, 1996, MOL CELLULAR BIOL WO, P427
   MUDGE M, 1985, BRIT J SURG, V72, P70, DOI 10.1002/bjs.1800720127
   MURPHY G, 1994, ANN NY ACAD SCI, V732, P31, DOI 10.1111/j.1749-6632.1994.tb24722.x
   Nagase N, 2001, CANC DRUG DISCOVERY
   Rice RD, 2010, AESTHET PLAST SURG, V34, P290, DOI 10.1007/s00266-009-9449-2
   RUTKOW IM, 1993, SURG CLIN N AM, V73, P413
   Ryan M E, 1998, Adv Dent Res, V12, P149
   Salameh JR, 2007, AM SURGEON, V73, P561
   Tharappel JC, 2014, J SURG RES, V190, P692, DOI 10.1016/j.jss.2014.05.013
   Tharappel JC, 2013, J SURG RES, V184, P699, DOI 10.1016/j.jss.2013.05.101
   White AC, 1987, J INFECT DIS, V28, P781
   Wilcox JR, 2012, WOUNDS, V24, P339
   WOESSNER JF, 1994, ANN NY ACAD SCI, V732, P11
   WYSOCKI AB, 1993, J INVEST DERMATOL, V101, P64, DOI 10.1111/1523-1747.ep12359590
NR 29
TC 2
Z9 2
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0930-2794
EI 1432-2218
J9 SURG ENDOSC
JI Surg. Endosc.
PD MAY
PY 2016
VL 30
IS 5
BP 2016
EP 2021
DI 10.1007/s00464-015-4434-0
PG 6
WC Surgery
SC Surgery
GA DK7EG
UT WOS:000375087100041
PM 26264696
DA 2018-03-20
ER

PT J
AU Kruse, AM
   Meenach, SA
   Anderson, KW
   Hilt, JZ
AF Kruse, Anastasia M.
   Meenach, Samantha A.
   Anderson, Kimberly W.
   Hilt, J. Zach
TI Synthesis and characterization of CREKA-conjugated iron oxide
   nanoparticles for hyperthermia applications
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Iron oxide nanoparticles; CREKA; Fibrinogen; Magnetically mediated
   hyperthermia
ID MAGNETIC NANOPARTICLES; THERMAL ENHANCEMENT; CISPLATIN ACTION;
   LUNG-CANCER; IN-VITRO; CELLS; CHEMOTHERAPY; TUMORS; POTENTIATION;
   MECHANISM
AB One of the current challenges in the systemic delivery of nanoparticles in cancer therapy applications is the lack of effective tumor localization. Iron oxide nanoparticles (IONPs) coated with crosslinked dextran were functionalized with the tumor-homing peptide CREKA, which binds to fibrinogen complexes in the extracellular matrix of tumors. This allows for the homing of these nanoparticles to tumor tissue. The IONP core allows for particle heating upon exposure to an alternating magnetic field (AMF), while the dextran coating stabilizes the particles in suspension and decreases the cytotoxicity of the system. Magnetically mediated hyperthermia (MMH) allows for the heating of tumor tissue to increase the efficacy of traditional cancer treatments using IONPs. While MMH provides the opportunity for localized heating, this method is currently limited by the lack of particle penetration into tumor tissue, even after effective targeted delivery to the tumor site. The CREKA-conjugated nanoparticles presented were characterized for their size, stability, heating capabilities and biocompatibility. The particles had a hydrated diameter of 52 nm, were stable in phosphate buffered saline solution and media with 10% v/v fetal bovine serum over at least 12 h, and generated enough heat to raise solution temperatures well into the hyperthermia range (41-45 degrees C) when exposed to an AMF, owing to an average specific absorption rate of 83.5 W g(-1). Cytotoxicity studies demonstrated that the particles have low cytotoxicity over long exposure times at low concentrations. A fibrinogen clotting assay was used to determine the binding affinity of CREKA-conjugated particles, which was significantly greater than the binding affinity of dextran, only coated IONPs demonstrating the potential for this particle system to effectively home to a variety of tumor locations. Finally, it was shown that in vitro MMH increased the effects of cisplatin compared with cisplatin or MMH treatments alone. (C) 2014 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Kruse, Anastasia M.; Anderson, Kimberly W.; Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Meenach, Samantha A.] Univ Rhode Isl, Dept Chem Engn, Kingston, RI 02881 USA.
RP Anderson, KW (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 F Paul Anderson Tower, Lexington, KY 40506 USA.
EM hilt@engr.uky.edu
FU National Cancer Institute [R25CA153954]; National Science Foundation
   IGERT Training [DGE-0653710]; Graduate Research Fellowship Program
   [DGE-1247392]
FX The project described was partially supported by Grant Number
   R25CA153954 from the National Cancer Institute. The content is solely
   the responsibility of the authors and does not necessarily represent the
   official views of the National Cancer Institute or the National
   Institutes of Health. Additionally, this material is based upon work
   supported by the National Science Foundation IGERT Training under Grant
   No. DGE-0653710 and the Graduate Research Fellowship Program Grant No.
   DGE-1247392. Any opinions, findings, and conclusions or recommendations
   expressed in this material are those of the author(s) and do not
   necessarily reflect the views of the National Science Foundation.
CR American Cancer Society, 2013, CANC FACTS FIG
   Alvarez-Berrios MP, 2013, INT J NANOMED, V8, P1003, DOI 10.2147/IJN.S38842
   ATKINSON WJ, 1984, IEEE T BIO-MED ENG, V31, P70, DOI 10.1109/TBME.1984.325372
   Babincova M, 2008, IEEE T NANOBIOSCI, V7, P15, DOI 10.1109/TNB.2008.2000145
   Bautista MC, 2005, J MAGN MAGN MATER, V293, P20, DOI 10.1016/j.jmmm.2005.01.038
   BUTOUR JL, 1991, EUR J BIOCHEM, V202, P975, DOI 10.1111/j.1432-1033.1991.tb16458.x
   Charras GT, 2008, BIOPHYS J, V94, P1836, DOI 10.1529/biophysj.107.113605
   Creixell M, 2011, ACS NANO, V5, P7124, DOI 10.1021/nn201822b
   Dennis CL, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/39/395103
   Fox ME, 2009, ACCOUNTS CHEM RES, V42, P1141, DOI 10.1021/ar900035f
   Frimpong RA, 2010, J MAGN MAGN MATER, V322, P326, DOI 10.1016/j.jmmm.2009.09.050
   Hettinga JVE, 1997, BRIT J CANCER, V75, P1735, DOI 10.1038/bjc.1997.297
   HETTINGA JVE, 1995, INT J CANCER, V61, P722, DOI 10.1002/ijc.2910610521
   HETZEL FW, 1984, RADIAT PHYS CHEM, V24, P337, DOI 10.1016/0146-5724(84)90070-0
   Imren D, 2006, J APPL POLYM SCI, V102, P4213, DOI 10.1002/app.24670
   Issels RD, 2008, EUR J CANCER, V44, P2546, DOI 10.1016/j.ejca.2008.07.038
   Itoh Y, 2010, EXP THER MED, V1, P319, DOI 10.3892/etm_00000049
   Kozissnik B, 2013, INT J HYPERTHER, V29, P706, DOI 10.3109/02656736.2013.837200
   Krpetic Z, 2010, NANO LETT, V10, P4549, DOI 10.1021/nl103142t
   Kumar CSSR, 2011, ADV DRUG DELIVER REV, V63, P789, DOI 10.1016/j.addr.2011.03.008
   Laurent S, 2011, ADV COLLOID INTERFAC, V166, P8, DOI 10.1016/j.cis.2011.04.003
   Lee JS, 2011, J NANOSCI NANOTECHNO, V11, P4153, DOI 10.1166/jnn.2011.3821
   MEYN RE, 1980, CANCER RES, V40, P1136
   OHNO S, 1994, CANCER CHEMOTH PHARM, V34, P302, DOI 10.1007/s002800050146
   Stephen Palmacci L.J, 1993, SYNTHESIS POLYSACCHA
   Phillips MA, 2010, NANO TODAY, V5, P143, DOI 10.1016/j.nantod.2010.03.003
   Ruoslahti E, 2010, J CELL BIOL, V188, P759, DOI 10.1083/jcb.200910104
   Simberg D, 2007, P NATL ACAD SCI USA, V104, P932, DOI 10.1073/pnas.0610298104
   Takahashi I, 2002, SURGERY, V131, pS78, DOI 10.1067/msy.2002.119308
   Vertrees RA, 2005, CANCER BIOL THER, V4, P1144, DOI 10.4161/cbt.4.10.2074
   Zwischenberger JB, 2004, ANN THORAC SURG, V77, P1916, DOI 10.1016/j.athoracsur.2003.10.111
NR 31
TC 28
Z9 28
U1 1
U2 55
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742-7061
EI 1878-7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD JUN
PY 2014
VL 10
IS 6
BP 2622
EP 2629
DI 10.1016/j.actbio.2014.01.025
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA AH7WK
UT WOS:000336345900026
PM 24486913
OA green_accepted
DA 2018-03-19
ER

PT J
AU Clark, A
   Milbrandt, TA
   Hilt, JZ
   Puleo, DA
AF Clark, Amanda
   Milbrandt, Todd A.
   Hilt, J. Zach
   Puleo, David A.
TI Mechanical properties and dual drug delivery application of
   poly(lactic-co-glycolic acid) scaffolds fabricated with a
   poly(beta-amino ester) porogen
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Scaffolds; Poly(lactic-co-glycolic acid); Poly(beta-amino ester); Drug
   delivery; Porogen
ID SOLVENT EXTRACTION/EVAPORATION METHOD; IN-VITRO; REGENERATIVE MEDICINE;
   TISSUE REGENERATION; DEGRADABLE HYDROGEL; ARTICULAR-CARTILAGE;
   CONTROLLED-RELEASE; PLGA MICROSPHERES; POROUS SCAFFOLDS; BONE DEFECTS
AB Polymeric scaffolds that are biocompatible and biodegradable are widely used for tissue engineering applications. Scaffolds can be further enhanced by enabling the release of one or more drugs to stimulate regeneration or for the treatment of a specific disease or condition. In this study, poly(lactic-co-glycolic acid) (PLGA) microspheres were mixed with poly( beta-amino ester) (PBAE) particles to create novel hybrid scaffolds capable of dual release of drug and growth factor. Fast-degrading PBAE particles loaded with the drug ketoprofen acted as porogens that provided a rapid 12 h release. The PLGA microspheres were loaded with a growth factor, bone morphogenetic protein 2, and fused together around the porogens to create a slow-degrading matrix that provided sustained release lasting 70 days. Drug release was further tailored by varying the amount of porogen added to the scaffold. Bioactivity measurements demonstrated that the scaffold fabrication technique did not damage the drug or protein. The compressive modulus was affected by the amount of porogen added, extending from 50 to 111 MPa for loadings from 60 to 40% PBAE, and after 5 days of degradation, it decreased to 0.6 to 1.1 kPa when the porogen was gone. PLGA containing a quick-degrading porogen can be used to release two drugs while developing a porous microarchitecture for cell ingrowth within a matrix capable of maintaining a compressive modulus applicable for soft tissue implants. (C) 2014 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Clark, Amanda; Puleo, David A.] Univ Kentucky, Dept Biomed Engn, Lexington, KY 40506 USA.
   [Hilt, J. Zach] Univ Kentucky, Lexington, KY USA.
   [Milbrandt, Todd A.] Univ Kentucky, Dept Orthopaed Surg, Lexington, KY USA.
   [Milbrandt, Todd A.] Shriners Hosp Children, Lexington, KY USA.
RP Puleo, DA (reprint author), Univ Kentucky, Dept Biomed Engn, Lexington, KY 40506 USA.
EM puleo@uky.edu
FU Kosair Charities, Inc.; Pediatric Orthopaedic Society of North America;
   NSF [EPS-0814194]; NSF IGERT [DGE-0653710]
FX This research was supported in part by Kosair Charities, Inc., the
   Pediatric Orthopaedic Society of North America, the NSF (EPS-0814194)
   and an NSF IGERT traineeship to AC (DGE-0653710).
CR Anderson DG, 2006, ADV MATER, V18, P2614, DOI 10.1002/adma.200600529
   Barichello JM, 1999, DRUG DEV IND PHARM, V25, P471, DOI 10.1081/DDC-100102197
   Baserga R, 1998, HEART FAIL REV, V3, P5
   Batycky RP, 1997, J PHARM SCI, V86, P1464, DOI 10.1021/js9604117
   Brey DM, 2008, ACTA BIOMATER, V4, P207, DOI 10.1016/j.actbio.2007.10.002
   Cabre F, 1998, J CLIN PHARMACOL, V38, P3
   CHI SC, 1991, J PHARM SCI, V80, P280, DOI 10.1002/jps.2600800318
   Clark A, 2014, J BIOMED MATER RES A, V102, P348, DOI 10.1002/jbm.a.34706
   Cleland JL, 1997, PHARMACEUT RES, V14, P420, DOI 10.1023/A:1012031012367
   Coleman J, 2012, J BIOMAT SCI-POLYM E, V23, P1129, DOI [10.1163/092050611X576648, 10.1163/092050611x576648]
   DAHLIN C, 1988, PLAST RECONSTR SURG, V81, P672, DOI 10.1097/00006534-198805000-00004
   Ebara S, 2002, SPINE, V27, pS10, DOI 10.1097/01.BRS.0000020727.98493.20
   England JL, 2011, ANNU REV PHYS CHEM, V62, P257, DOI 10.1146/annurev-physchem-032210-103531
   Fredenberg S, 2011, INT J PHARMACEUT, V415, P34, DOI 10.1016/j.ijpharm.2011.05.049
   Garcia JT, 1999, J MICROENCAPSUL, V16, P83, DOI 10.1080/026520499289338
   Griffon DJ, 2006, ACTA BIOMATER, V2, P313, DOI 10.1016/j.actbio.2005.12.007
   Hawkins AM, 2013, J BIOMED MAT RES A
   Hawkins AM, 2014, J BIOMED MATER RES A, V102, P400, DOI 10.1002/jbm.a.34697
   Hawkins AM, 2011, J APPL POLYM SCI, V122, P1420, DOI 10.1002/app.34093
   Hawkins AM, 2011, ACTA BIOMATER, V7, P1956, DOI 10.1016/j.actbio.2011.01.024
   Hoare TR, 2008, POLYMER, V49, P1993, DOI 10.1016/j.polymer.2008.01.027
   Holland TA, 2007, OSTEOARTHR CARTILAGE, V15, P187, DOI 10.1016/j.joca.2006.07.006
   Inai K, 2008, DEV BIOL, V315, P383, DOI 10.1016/j.ydbio.2007.12.028
   Jaklenec A, 2008, BIOMATERIALS, V29, P1518, DOI 10.1016/j.biomaterials.2007.12.004
   Kempen DHR, 2008, BIOMATERIALS, V29, P3245, DOI 10.1016/j.biomaterials.2008.04.031
   Kempen DHR, 2009, BIOMATERIALS, V30, P2816, DOI 10.1016/j.biomaterials.2009.01.031
   Kim BH, 2008, BACTERIAL PHYSIOLOGY AND METABOLISM, P386, DOI 10.1017/CBO9780511790461.012
   KLAWITTER JJ, 1976, J BIOMED MATER RES, V10, P311, DOI 10.1002/jbm.820100212
   Kuhn LT, 2013, J GERONTOL A
   Li J, 2004, J SPINAL DISORD TECH, V17, P423, DOI 10.1097/01.bsd.0000112084.85112.5d
   Lin CC, 2006, ADV DRUG DELIVER REV, V58, P1379, DOI 10.1016/j.addr.2006.09.004
   LOTZ JC, 1990, J COMPUT ASSIST TOMO, V14, P107, DOI 10.1097/00004728-199001000-00020
   Makadia HK, 2011, POLYMERS-BASEL, V3, P1377, DOI 10.3390/polym3031377
   Martinez MN, 2002, J CLIN PHARMACOL, V42, P620, DOI 10.1177/00970002042006005
   MASON JM, 2000, CLIN ORTHOP S, V379, pS171
   Meenach SA, 2012, INT J PHARMACEUT, V427, P177, DOI 10.1016/j.ijpharm.2012.01.052
   Nishiyama N, 2006, PHARMACOL THERAPEUT, V112, P630, DOI 10.1016/j.pharmthera.2006.05.006
   Pan QH, 2008, J CELL PHYSIOL, V217, P228, DOI 10.1002/jcp.21496
   Pan Z, 2012, INTERFACE FOCUS, V2, P366, DOI 10.1098/rsfs.2011.0123
   Pattison MA, 2005, BIOMATERIALS, V26, P2491, DOI 10.1016/j.biomaterials.2004.07.011
   Pfeifer BA, 2005, INT J PHARM, V304, P210, DOI 10.1016/j.ijpharm.2005.08.001
   RAGHUVANSHI RS, 1993, INT J PHARM, V93, pR1, DOI 10.1016/0378-5173(93)90188-L
   Ricci M, 2005, J CONTROL RELEASE, V107, P395, DOI 10.1016/j.jconrel.2005.06.023
   Richardson TP, 2001, NAT BIOTECHNOL, V19, P1029, DOI 10.1038/nbt1101-1029
   Schinagl RM, 1997, J ORTHOPAED RES, V15, P499, DOI 10.1002/jor.1100150404
   Schwarz C, 2013, TISSUE ENG PT A, V19, P247, DOI [10.1089/ten.tea.2012.0265, 10.1089/ten.TEA.2012.0265]
   Sekiya I, 2005, CELL TISSUE RES, V320, P269, DOI 10.1007/s00441-004-1075-3
   Shenoy D, 2005, PHARM RES, V22, P2107, DOI 10.1007/s11095-005-8343-0
   Shin HJ, 2006, J BIOMAT SCI-POLYM E, V17, P103, DOI 10.1163/156856206774879126
   Slaughter BV, 2009, ADV MATER, V21, P3307, DOI 10.1002/adma.200802106
   Sundararaj SC, 2013, BIOMATERIALS, V34, P8835, DOI 10.1016/j.biomaterials.2013.07.093
   Sundararaj SK, 2012, J TISSUE ENG REGEN M
   Tabata Yasuhiko, 2000, Pharmaceutical Science and Technology Today, V3, P80, DOI 10.1016/S1461-5347(00)00242-X
   Tita D, 2011, J THERM ANAL CALORIM, V105, P501, DOI 10.1007/s10973-010-1187-9
   Tracy MA, 1999, BIOMATERIALS, V20, P1057, DOI 10.1016/S0142-9612(99)00002-2
   Uematsu K, 2005, BIOMATERIALS, V26, P4273, DOI 10.1016/j.biomaterials.2004.10.037
   van Tienen TG, 2002, BIOMATERIALS, V23, P1731, DOI 10.1016/S0142-9612(01)00280-0
   Winkler L, 2006, MATERIALWISS WERKST, V37, P436, DOI 10.1002/mawe.200600016
   Wu LB, 2006, J BIOMED MATER RES A, V76A, P264, DOI 10.1002/jbm.a.30544
   Yang YF, 2011, J BIOMED MATER RES B, V96B, P139, DOI 10.1002/jbm.b.31752
   Yang YY, 2000, J CONTROL RELEASE, V69, P81, DOI 10.1016/S0168-3659(00)00291-1
   Yang YY, 2001, BIOMATERIALS, V22, P231, DOI 10.1016/S0142-9612(00)00178-2
   YANNAS I V, 1992, Clinical Materials, V9, P179, DOI 10.1016/0267-6605(92)90098-E
   Yoon SJ, 2007, TISSUE ENG, V13, P1125, DOI 10.1089/ten.2006.0287
   Zhang Y, 2013, ADV DRUG DELIVER REV, V65, P104, DOI 10.1016/j.addr.2012.10.003
NR 65
TC 10
Z9 10
U1 0
U2 65
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742-7061
EI 1878-7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD MAY
PY 2014
VL 10
IS 5
BP 2125
EP 2132
DI 10.1016/j.actbio.2013.12.061
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA AG0HA
UT WOS:000335095300034
PM 24424269
DA 2018-03-19
ER

PT J
AU Cheng, R
   Zhang, XY
   Shin, H
   Yu, GQ
AF Cheng, Ran
   Zhang, Xiaoyan
   Shin, Hainsworth Y.
   Yu, Guoqiang
TI Noninvasive Quantification Of Skeletal Muscle Microvasculature Blood
   Flow In Mouse Thigh By Diffuse Correlation Spectroscopy
SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE
LA English
DT Meeting Abstract
CT 60th Annual Meeting of the American-College-of-Sports-Medicine
CY MAY 28-JUN 01, 2013
CL Indianapolis, IN
SP Amer Coll Sports Med
C1 [Cheng, Ran; Zhang, Xiaoyan; Shin, Hainsworth; Yu, Guoqiang] Univ Kentucky, Lexington, KY USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0195-9131
EI 1530-0315
J9 MED SCI SPORT EXER
JI Med. Sci. Sports Exerc.
PD MAY
PY 2013
VL 45
IS 5
SU 1
MA 2725
BP 638
EP 638
PG 1
WC Sport Sciences
SC Sport Sciences
GA 300ND
UT WOS:000330469705087
DA 2018-03-20
ER

PT J
AU Chen, AY
   DeLano, FA
   Valdez, SR
   Ha, JN
   Shin, HY
   Schmid-Schonbein, GW
AF Chen, Angela Y.
   DeLano, Frank A.
   Valdez, Shakti R.
   Ha, Jung-Myung
   Shin, Hainsworth Y.
   Schmid-Schoenbein, Geert W.
TI Attenuation of Fluid Shear Response by Proteolytic Cleavage of the
   Formyl Peptide Receptor on Neutrophils of the Spontaneously Hypertensive
   Rat
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Experimental Biology Meeting 2011
CY APR 09-13, 2011
CL Washington, DC
SP Amer Assoc Anatomists (AAA), Amer Physiolog Soc (APS), Amer Soc Biochem & Mol Biol (ASBMB), Amer Soc Investigat Pathol (ASIP), Amer Soc Nutrit (ASN), Amer Soc Pharmacol & Expt Therapeut (ASPET)
C1 [Chen, Angela Y.; DeLano, Frank A.; Valdez, Shakti R.; Ha, Jessica N.; Schmid-Schoenbein, Geert W.] Univ Calif San Diego, La Jolla, CA 92093 USA.
   [Shin, Hainsworth Y.] Univ Kentucky, Ctr Biomed Engn, Lexington, KY 40506 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2011
VL 25
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 032IE
UT WOS:000310708403683
DA 2018-03-20
ER

PT J
AU Dan, M
   Cochran, DB
   Yokel, RA
   Dziubla, TD
AF Dan, Mo
   Cochran, David B.
   Yokel, Robert A.
   Dziubla, Thomas D.
TI Binding, Transcytosis and Biodistribution of Anti-PECAM-1 Iron Oxide
   Nanoparticles for Brain-Targeted Delivery
SO PLOS ONE
LA English
DT Article
ID CELL-ADHESION MOLECULE-1; DRUG-DELIVERY; MAGNETIC NANOPARTICLES; POLYMER
   NANOCARRIERS; BARRIER TRANSPORT; LUNG-CANCER; TRANSFERRIN; PECAM-1;
   ENDOCYTOSIS; PROTEINS
AB Objective: Characterize the flux of platelet-endothelial cell adhesion molecule (PECAM-1) antibody-coated superparamagnetic iron oxide nanoparticles (IONPs) across the blood-brain barrier (BBB) and its biodistribution in vitro and in vivo.
   Methods: Anti-PECAM-1 IONPs and IgG IONPs were prepared and characterized in house. The binding affinity of these nanoparticles was investigated using human cortical microvascular endothelial cells (hCMEC/D3). Flux assays were performed using a hCMEC/D3 BBB model. To test their immunospecificity index and biodistribution, nanoparticles were given to Sprague Dawley rats by intra-carotid infusion. The capillary depletion method was used to elucidate their distribution between the BBB and brain parenchyma.
   Results: Anti-PECAM-1 IONPs were similar to 130 nm. The extent of nanoparticle antibody surface coverage was 63.6+/-8.4%. Only 6.39+/-1.22% of labeled antibody dissociated from IONPs in heparin-treated whole blood over 4 h. The binding affinity of PECAM-1 antibody (K-D) was 32 nM with a maximal binding (B-max) of 17610 5 antibody molecules/cell. Anti-PECAM-1 IONP flux across a hCMEC/D3 monolayer was significantly higher than IgG IONP's with 31% of anti-PECAM-1 IONPs in the receiving chamber after 6 h. Anti-PECAM-1 IONPs showed higher concentrations in lung and brain, but not liver or spleen, than IgG IONPs after infusion. The capillary depletion method showed that 17+/-12% of the anti-PECAM-1 IONPs crossed the BBB into the brain ten minutes after infusion.
   Conclusions: PECAM-1 antibody coating significantly increased IONP flux across the hCMEC/D3 monolayer. In vivo results showed that the PECAM-1 antibody enhanced BBB association and brain parenchymal accumulation of IONPs compared to IgG. This research demonstrates the benefit of anti-PECAM-1 IONPs for association and flux across the BBB into the brain in relation to its biodistribution in peripheral organs. The results provide insight into potential application and toxicity concerns of anti-PECAM-1 IONPs in the central nervous system.
C1 [Dan, Mo; Yokel, Robert A.] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY USA.
   [Dan, Mo; Yokel, Robert A.] Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA.
   [Cochran, David B.; Dziubla, Thomas D.] Univ Kentucky, Lexington, KY USA.
RP Yokel, RA (reprint author), Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY USA.
EM ryokel@email.uky.edu
FU NCI-CNTC (National Cancer Institute Cancer Nanotechnology Training
   Center) [NCI 5R25CA153954]
FX Financial support from a NCI-CNTC (National Cancer Institute Cancer
   Nanotechnology Training Center) predoctoral traineeship (NCI
   5R25CA153954)(http://www.cancer.gov/). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Bernacki J, 2008, PHARMACOL REP, V60, P600
   Bhaskar S, 2010, PART FIBRE TOXICOL, V7, DOI 10.1186/1743-8977-7-3
   Carl SM, 2010, MOL PHARMACEUT, V7, P1057, DOI 10.1021/mp900178j
   Chacko AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034958
   Chang J, 2009, INT J PHARMACEUT, V379, P285, DOI 10.1016/j.ijpharm.2009.04.035
   Cole AJ, 2011, BIOMATERIALS, V32, P6291, DOI 10.1016/j.biomaterials.2011.05.024
   Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451
   Corot C, 2006, ADV DRUG DELIVER REV, V58, P1471, DOI 10.1016/j.addr.2006.09.013
   Crossgrove JS, 2003, NEUROTOXICOLOGY, V24, P3, DOI 10.1016/S0161-813X(02)00089-X
   CROWE A, 1992, BRAIN RES, V592, P8, DOI 10.1016/0006-8993(92)91652-U
   Dan M, 2013, PHARM RES-DORDR, V30, P552, DOI 10.1007/s11095-012-0900-8
   Danilov SM, 2001, AM J PHYSIOL-LUNG C, V280, pL1335
   Dilnawaz F, 2012, BIOMATERIALS, V33, P2936, DOI 10.1016/j.biomaterials.2011.12.046
   Ding BS, 2006, MOL INTERV, V6, P98, DOI 10.1124/mi.6.2.7
   Doherty GJ, 2009, ANNU REV BIOCHEM, V78, P857, DOI 10.1146/annurev.biochem.78.081307.110540
   Dziubla TD, 2008, BIOMATERIALS, V29, P215, DOI 10.1016/j.biomaterials.2007.09.023
   Frimpong RA, 2010, NANOMEDICINE-UK, V5, P1401, DOI 10.2217/NNM.10.114
   Frimpong RA, 2010, J MAGN MAGN MATER, V322, P326, DOI 10.1016/j.jmmm.2009.09.050
   Garnacho C, 2008, BLOOD, V111, P3024, DOI 10.1182/blood-2007-06-098657
   HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61
   Hillaireau H, 2009, CELL MOL LIFE SCI, V66, P2873, DOI 10.1007/s00018-009-0053-z
   Hu JM, 2012, LANGMUIR, V28, P2073, DOI 10.1021/la203992q
   Jiang WL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037376
   Jones AR, 2007, PHARM RES, V24, P1759, DOI 10.1007/s11095-007-9379-0
   Kalinowska A, 2006, EUR J NEUROL, V13, P1284, DOI 10.1111/j.1468-1331.2006.01640.x
   Kawabe T, 2012, PROG NEUROL SURG, V25, P148, DOI 10.1159/000331188
   Kuang BH, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0536-5
   Meenach SA, 2010, ACTA BIOMATER, V6, P1039, DOI 10.1016/j.actbio.2009.10.017
   Minshall RD, 2000, J CELL BIOL, V150, P1057, DOI 10.1083/jcb.150.5.1057
   Morgan EH, 2002, DEV NEUROSCI-BASEL, V24, P106, DOI 10.1159/000065699
   Muro S, 2006, J PHARMACOL EXP THER, V317, P1161, DOI 10.1124/jpet.105.098970
   Muro S, 2003, J CELL SCI, V116, P1599, DOI 10.1242/jcs.00367
   Nozinic D, 2010, CROAT CHEM ACTA, V83, P323
   Papademetriou J, 2013, J INHERIT METAB DIS, V36, P467, DOI 10.1007/s10545-012-9534-6
   Peng XH, 2008, INT J NANOMED, V3, P311
   Poller B, 2008, J NEUROCHEM, V107, P1358, DOI 10.1111/j.1471-4159.2008.05730.x
   SALACINSKI PRP, 1981, ANAL BIOCHEM, V117, P136, DOI 10.1016/0003-2697(81)90703-X
   Scherpereel A, 2002, J PHARMACOL EXP THER, V300, P777, DOI 10.1124/jpet.300.3.777
   SHIN SU, 1995, P NATL ACAD SCI USA, V92, P2820, DOI 10.1073/pnas.92.7.2820
   Shuvaev VV, 2007, J PHARMACOL EXP THER, V323, P450, DOI 10.1124/jpet.107.127126
   Silva AC, 2011, INT J NANOMED, V6, P591, DOI 10.2147/IJN.S14737
   Smith Q R, 1996, Pharm Biotechnol, V8, P285
   TRIGUERO D, 1990, J NEUROCHEM, V54, P1882, DOI 10.1111/j.1471-4159.1990.tb04886.x
   Veiseh O, 2009, CANCER RES, V69, P6200, DOI 10.1158/0008-5472.CAN-09-1157
   Wankhede M, 2012, EXPERT REV CLIN PHAR, V5, P173, DOI [10.1586/ECP.12.1, 10.1586/ecp.12.1]
   Weinstein JS, 2010, J CEREBR BLOOD F MET, V30, P15, DOI 10.1038/jcbfm.2009.192
   Weksler BB, 2005, FASEB J, V19, P1872
   Wong D, 1996, BRAIN RES, V731, P217, DOI 10.1016/0006-8993(96)00673-7
   Wu DF, 1997, DRUG METAB DISPOS, V25, P768
   Yu YJ, 2011, SCI TRANSL MED, V3
   Zhang PC, 2012, J CONTROL RELEASE, V159, P429, DOI 10.1016/j.jconrel.2012.01.031
NR 51
TC 12
Z9 12
U1 1
U2 33
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 20
PY 2013
VL 8
IS 11
AR e81051
DI 10.1371/journal.pone.0081051
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 256LY
UT WOS:000327313100138
PM 24278373
OA gold
DA 2018-03-19
ER

PT J
AU Zhang, WL
   Eitel, RE
AF Zhang, Wenli
   Eitel, Richard E.
TI Biostability of Low-Temperature Co-Fired Ceramic Materials for
   Microfluidic and Biomedical Devices
SO INTERNATIONAL JOURNAL OF APPLIED CERAMIC TECHNOLOGY
LA English
DT Article
ID SYSTEM; LTCC
AB Integrated low-temperature co-fired ceramic (LTCC) modules are widely used in commercial wireless data and cellular communication devices. Recently, a number of researchers have demonstrated the use of LTCC materials and assembly processes to build integrated microelectromechanical and microfluidic devices, incorporating a variety of electrical, optical, electromechanical, and fluidic functions. However, the long-term stability and biocompatibility of the LTCC materials for microfluidic and specifically biomedical devices have yet to be addressed. The biostability of LTCC materials has been examined in three different commercial LTCC materials using a bioleaching approach. The leaching rate has been obtained in several common biological fluids using weight loss and elemental analysis to quantify the leaching rate. Our results indicate significant dissolution of LTCC materials in simulated gastric fluid and highly basic solutions. However, only minimal leaching was demonstrated in both phosphate buffer saline and simulated body fluid solutions.
C1 [Zhang, Wenli; Eitel, Richard E.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Zhang, WL (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM reitel@engr.uky.edu
RI Eitel, Richard/E-2889-2010
OI Eitel, Richard/0000-0002-5090-2075
CR Andersson H, 2003, SENSOR ACTUAT B-CHEM, V92, P315, DOI 10.1016/S0925-4005(03)00266-1
   Agency for Toxic Substances and Disease Registry (ATSDR), 1990, TOX PROF SILV, P11
   Carlo D. D., 2006, LAB CHIP, V6, P1445, DOI DOI 10.1039/B605937F
   CARRE A, 1992, J COLLOID INTERF SCI, V154, P174, DOI 10.1016/0021-9797(92)90090-9
   Erickson D, 2004, ANAL CHIM ACTA, V507, P11, DOI 10.1016/j.aca.2003.09.019
   The Expert Group on Vitamins and Minerals, 2003, SAF UPP LEV VIT MIN
   Golonka L. J., 2006, Bulletin of the Polish Academy of Sciences, Technical Sciences, V54, P221
   Golonka LJ, 2006, INT J APPL CERAM TEC, V3, P150, DOI 10.1111/j.1744-7402.2006.02072.x
   Golonka LJ, 2005, SENSOR ACTUAT B-CHEM, V111, P396, DOI 10.1016/j.snb.2005.03.065
   Gongora-Rubio MR, 2001, SENSOR ACTUAT A-PHYS, V89, P222, DOI 10.1016/S0924-4247(00)00554-9
   Gongora-Rubio MR, 2004, SENSOR ACTUAT B-CHEM, V103, P468, DOI 10.1016/j.snb.2004.05.007
   Ibanez-Garcia N, 2006, SENSOR ACTUAT B-CHEM, V118, P67, DOI 10.1016/j.snb.2006.04.063
   Integrated Risk Information System (IRIS) Database, 1994, 7440224 CASRN IRIS
   McCauley R. A., 2004, CORROSION CERAMIC CO, P67
   U.S. Pharmacopoeia, 1995, US PHARMACOPEIA 23 N
   Scientific Opinion of the Panel on Food Additives, 2008, EFSA J, V754, P1
   Srook A. D., 2006, MRS BULL, V31, P114
   Thelemann T, 2002, MICROELECTRON INT, V19, P19, DOI 10.1108/1356536021044505
   Zhang XL, 2006, MRS BULL, V31, P95, DOI 10.1557/mrs2006.22
NR 19
TC 10
Z9 10
U1 0
U2 6
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1546-542X
J9 INT J APPL CERAM TEC
JI Int. J. Appl. Ceram. Technol.
PD JAN-FEB
PY 2012
VL 9
IS 1
BP 60
EP 66
DI 10.1111/j.1744-7402.2010.02581.x
PG 7
WC Materials Science, Ceramics
SC Materials Science
GA 875YM
UT WOS:000299072100008
DA 2018-03-19
ER

PT J
AU Satarkar, NS
   Hilt, JZ
AF Satarkar, Nitin S.
   Hilt, J. Zach
TI Magnetic hydrogel nanocomposites for remote controlled pulsatile drug
   release
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Hydrogel; Magnetic; Composite; Remote control; Drug delivery
ID N-ISOPROPYLACRYLAMIDE; DELIVERY; NANOPARTICLES; SYSTEMS; DEVICES; FIELD;
   GELS
AB Hydrogel nanocomposites are novel macromolecular biomaterials that promise to impact various applications in medical and pharmaceutical fields. In this paper, magnetic nanocomposites of temperature responsive hydrogels were used to illustrate remote controlled (RC) drug delivery. A high frequency alternating magnetic field (AMF) was used to trigger the on-demand pulsatile drug release from the nanocomposites. Nanocomposites were synthesized by incorporation of superparamagnetic Fe3O4 particles in negative temperature sensitive poly (N-isopropylacrylamide) hydrogels. Pulses of AMF were applied to the nanocomposites and the kinetics of collapse and recovery were characterized. Application of AMF resulted in uniform heating within the nanocomposites leading to accelerated collapse and squeezing out large amounts of imbibed drug (release at a faster rate). Remote controlled pulsatile drug release was characterized for different drugs as well as for different ON-OFF durations of the AMF. (C) 2008 Elsevier B.V. All rights reserved
C1 [Satarkar, Nitin S.; Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Hilt, JZ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM hilt@engr.uky.edu
FU National Science Foundation [ECS-0508254, CTS-0609117]
FX This material is based in part on work supported by the National Science
   Foundation under grant numbers ECS-0508254 (NSF NER) and CTS-0609117
   (NSF NIRT). The authors thank Dr. Dipti Biswal for assistance with
   acquisition of SEM images.
CR Andra W, 1998, MAGNETISM MED, P455
   Bussemer T, 2001, CRIT REV THER DRUG, V18, P433
   Chaterji S, 2007, PROG POLYM SCI, V32, P1083, DOI 10.1016/j.progpolymsci.2007.05.018
   Derfus AM, 2007, ADV MATER, V19, P3932, DOI 10.1002/adma.200700091
   Filipcsei G, 2007, ADV POLYM SCI, V206, P137, DOI 10.1007/12_2006_104
   Frimpong R. A., 2007, NANOTECHNOLOGY THERA, P241
   Frimpong RA, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/17/175101
   Frimpong RA, 2007, J BIOMED MATER RES A, V80A, P1, DOI 10.1002/jbm.a.30962
   Gil ES, 2004, PROG POLYM SCI, V29, P1173, DOI 10.1016/j.progpolymsci.2004.08.003
   Grayson ACR, 2003, NAT MATER, V2, P767, DOI 10.1038/nmat998
   He CL, 2008, J CONTROL RELEASE, V127, P189, DOI 10.1016/j.jconrel.2008.01.005
   HOFFMAN A S, 1987, Journal of Controlled Release, V6, P297, DOI 10.1016/0168-3659(87)90083-6
   Hu SH, 2007, MACROMOLECULES, V40, P6786, DOI 10.1021/ma0707584
   KANEKO Y, 1995, J MEMBRANE SCI, V101, P13, DOI 10.1016/0376-7388(94)00268-4
   Kikuchi A, 2002, ADV DRUG DELIVER REV, V54, P53, DOI 10.1016/S0169-409X(01)00243-5
   Kost J, 2001, ADV DRUG DELIVER REV, V46, P125, DOI 10.1016/S0169-409X(00)00136-8
   KOST J, 1987, J BIOMED MATER RES, V21, P1367, DOI 10.1002/jbm.820211202
   Liu TY, 2008, J CONTROL RELEASE, V126, P228, DOI 10.1016/j.jconrel.2007.12.006
   Lowman A.M., 1999, ENCY CONTROLLED DRUG, P397
   Lu ZH, 2005, LANGMUIR, V21, P2042, DOI 10.1021/la047629q
   Nayak S, 2005, ANGEW CHEM INT EDIT, V44, P7686, DOI 10.1002/anie.200501321
   Pankhurst QA, 2003, J PHYS D APPL PHYS, V36, pR167, DOI 10.1088/0022-3727/36/13/201
   Paoli V.M., 2006, LANGMUIR, V22, P5894
   PARK TG, 1994, J APPL POLYM SCI, V52, P85, DOI 10.1002/app.1994.070520110
   Peppas NA, 2006, ADV MATER, V18, P1345, DOI 10.1002/adma.200501612
   Rzaev ZMO, 2007, PROG POLYM SCI, V32, P534, DOI 10.1016/j.progpolymsci.2007.01.006
   Satarkar NS, 2008, ACTA BIOMATER, V4, P11, DOI 10.1016/j.actbio.2007.07.009
   SCHILD HG, 1992, PROG POLYM SCI, V17, P163, DOI 10.1016/0079-6700(92)90023-R
   Sershen S, 2002, ADV DRUG DELIVER REV, V54, P1225, DOI 10.1016/S0169-409X(02)00090-X
   Sershen SR, 2005, ADV MATER, V17, P1366, DOI 10.1002/adma.200401239
   Stubbe BG, 2004, PHARM RES, V21, P1732, DOI 10.1023/B:PHAM.0000045223.45400.01
   Vaishnava PP, 2007, J APPL PHYS, V102, DOI 10.1063/1.2784080
   YOSHIDA R, 1995, J BIOMAT SCI-POLYM E, P585
   Youan BBC, 2004, J CONTROL RELEASE, V98, P337, DOI 10.1016/j.jconrel.2004.05.015
NR 34
TC 248
Z9 255
U1 23
U2 180
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
J9 J CONTROL RELEASE
JI J. Control. Release
PD SEP 24
PY 2008
VL 130
IS 3
BP 246
EP 251
DI 10.1016/j.jconrel.2008.06.008
PG 6
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 363LU
UT WOS:000260269600008
PM 18606201
DA 2018-03-20
ER

PT J
AU Biswal, D
   Wattamwar, PR
   Dziubla, TD
   Hilt, JZ
AF Biswal, Dipti
   Wattamwar, Paritosh P.
   Dziubla, Thomas D.
   Hilt, J. Zach
TI A single-step polymerization method for poly(beta-amino ester)
   biodegradable hydrogels
SO POLYMER
LA English
DT Article
DE Hydrogel; Poly(beta-amino ester); Swelling
ID TUMOR-TARGETED DELIVERY; PH-SENSITIVE SYSTEM; GENE DELIVERY; NETWORK
   PROPERTIES; PARALLEL SYNTHESIS; HYDROPHOBIC DRUGS; LIBRARY;
   NANOPARTICLES; TRANSFECTION; DEGRADATION
AB A novel one-step method for the preparation of poly(beta-amino ester) hydrogels has been developed. The one-step method utilizes a Michael type addition reaction between a difunctional diacrylate and a tetrafunctional primary diamine to create a crosslinked biodegradable hydrogel. It was shown that the molar ratio of the reactive acrylate to amine controlled the extent of polymerization and crosslinking density of the hydrogel system, which enabled for the end properties of the network (e.g., swelling, degradation, and mechanical) to be tuned. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Biswal, Dipti; Wattamwar, Paritosh R.; Dziubla, Thomas D.; Hilt, J. Zach] Univ Kentucky, Lexington, KY 40506 USA.
RP Hilt, JZ (reprint author), Univ Kentucky, Lexington, KY 40506 USA.
EM hilt@engr.uky.edu
CR Akinc A, 2003, J AM CHEM SOC, V125, P5316, DOI 10.1021/ja034429c
   Anderson DG, 2006, ADV MATER, V18, P2614, DOI 10.1002/adma.200600529
   Anderson DG, 2005, MOL THER, V11, P426, DOI 10.1016/j.ymthe.2004.11.015
   Berry D, 2004, CHEM BIOL, V11, P487, DOI 10.1016/j.chembiol.2004.03.023
   Biswal D, 2006, POLYMER, V47, P7355, DOI 10.1016/j.polymer.2006.08.028
   Brandrup J., 1999, POLYM HDB
   Brey DM, 2008, J BIOMED MATER RES A, V85A, P731, DOI 10.1002/jbm.a.31494
   Brey DM, 2008, ACTA BIOMATER, V4, P207, DOI 10.1016/j.actbio.2007.10.002
   Brito L, 2008, BIOMACROMOLECULES, V9, P1179, DOI 10.1021/bm7011373
   Burkoth AK, 2000, BIOMATERIALS, V21, P2395, DOI 10.1016/S0142-9612(00)00107-1
   Chen J, 2007, POLYMER, V48, P675, DOI 10.1016/j.polymer.2006.12.008
   Devalapally H, 2007, CANCER CHEMOTH PHARM, V59, P477, DOI 10.1007/s00280-006-0287-5
   Dinc CO, 2010, J APPL POLYM SCI, V117, P1100, DOI 10.1002/app.31829
   Frimpong RA, 2007, J BIOMED MATER RES A, V80A, P1, DOI 10.1002/jbm.a.30962
   Green JJ, 2008, ACCOUNTS CHEM RES, V41, P749, DOI 10.1021/ar7002336
   Hawkins AM, 2011, ACTA BIOMATER, V7, P1956, DOI 10.1016/j.actbio.2011.01.024
   Hoffman AS, 2002, ADV DRUG DELIVER REV, V54, P3, DOI 10.1016/S0169-409X(01)00239-3
   Ifkovits JL, 2007, TISSUE ENG, V13, P2369, DOI 10.1089/ten.2007.0093
   Jere D, 2008, BIOMATERIALS, V29, P2535, DOI 10.1016/j.biomaterials.2008.02.018
   Kim TI, 2005, BIOCONJUGATE CHEM, V16, P1140, DOI 10.1021/bc0497012
   Krevelen D.W.V., 1990, PROPERTIES POLYM THE, Vxxii
   Lee JS, 2009, NANO LETT, V9, P2402, DOI 10.1021/nl9009793
   Lim YB, 2000, J AM CHEM SOC, V122, P6524, DOI 10.1021/ja001033h
   Lynn DM, 2001, J AM CHEM SOC, V123, P8155, DOI 10.1021/ja016288p
   Lynn DM, 2000, J AM CHEM SOC, V122, P10761, DOI 10.1021/ja0015388
   Mann BK, 2001, BIOMATERIALS, V22, P3045, DOI 10.1016/S0142-9612(01)00051-5
   Scott RA, 1999, BIOMATERIALS, V20, P1371, DOI 10.1016/S0142-9612(99)00040-X
   Shen YQ, 2009, NANOMED-NANOTECHNOL, V5, P192, DOI 10.1016/j.nano.2008.09.003
   Shenoy D, 2005, PHARM RES, V22, P2107, DOI 10.1007/s11095-005-8343-0
   Tan HP, 2010, MATERIALS, V3, P1746, DOI 10.3390/ma3031746
   Ward JH, 2001, J CONTROL RELEASE, V71, P183, DOI 10.1016/S0168-3659(01)00213-9
NR 31
TC 8
Z9 8
U1 1
U2 38
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0032-3861
J9 POLYMER
JI Polymer
PD DEC 13
PY 2011
VL 52
IS 26
BP 5985
EP 5992
DI 10.1016/j.polymer.2011.10.058
PG 8
WC Polymer Science
SC Polymer Science
GA 861NY
UT WOS:000298027600006
DA 2018-03-20
ER

PT J
AU Fisher, PD
   Clemens, J
   Hilt, JZ
   Puleo, DA
AF Fisher, Paul D.
   Clemens, Justin
   Hilt, J. Zach
   Puleo, David A.
TI Multifunctional poly(beta-amino ester) hydrogel microparticles in
   periodontal in situ forming drug delivery systems
SO BIOMEDICAL MATERIALS
LA English
DT Article
DE in situ forming; hydrogel; PLGA; doxycycline; simvastatin
ID MECHANICAL-PROPERTIES; SCAFFOLDS; IMPLANT; DOXYCYCLINE; MORPHOLOGY;
   POROSITY; LIGAMENT; RELEASE; POROGEN; TISSUE
AB In situ forming implants (ISIs) formed from poly(lactic-co-glycolic acid) (PLGA) have been commercialized for local drug delivery to treat periodontitis, but drug release from these bulk materials is typically subject to an initial burst. In addition, PLGA has inferior material properties for the dynamic mechanical environment of gingival tissue. In this work, poly(beta-amino ester) (PBAE) hydrogel microparticles were incorporated into a PLGA matrix to provide several new functions: mechanical support, porosity, space-filling, and controlled co-delivery of antimicrobial and osteogenic drugs. First, the effects of PBAE microparticles on ISI architecture and material properties throughout degradation were investigated. Second, the influence of PBAE microparticles on drug release kinetics was quantified. Over a 15 d period, ISIs containing PBAE microparticles possessed greater porosity, ranging from 42-80%, compared to controls, which ranged from 24-54% (p < 0.001), and these ISIs also developed significantly greater accessible volume to simulated cell-sized spheres after 5 d or more of degradation (p < 0.001). PBAE-containing ISIs possessed a more uniform microarchitecture, which preserved mechanical resilience after cyclical loading (p < 0.001), and the materials swelled to fill the injected space, which significantly increased interfacial strength in an artificial periodontal pocket (p < 0.0001). PBAE microparticles eliminated the burst of freely-mixed simvastatin compared to 36% burst from controls (p < 0.0001), and high-dose doxycycline release was prolonged from 2 d to 7 d by pre-loading drug into the microparticles. PBAE-containing PLGA ISIs are more effective space-filling scaffolds and offer improved release kinetics compared to existing ISIs used to treat periodontitis.
C1 [Fisher, Paul D.; Puleo, David A.] Univ Kentucky, Dept Biomed Engn, Lexington, KY 40506 USA.
   [Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Puleo, DA (reprint author), Univ Kentucky, Dept Biomed Engn, Lexington, KY 40506 USA.
EM puleo@uky.edu
CR Amini AR, 2012, TISSUE ENG PT A, V18, P1376, DOI [10.1089/ten.tea.2011.0076, 10.1089/ten.TEA.2011.0076]
   ANDERSEN KL, 1991, AM J ORTHOD DENTOFAC, V99, P427, DOI 10.1016/S0889-5406(05)81576-8
   Anderson DG, 2006, ADV MATER, V18, P2614, DOI 10.1002/adma.200600529
   Anderson H H, 1996, Pract Periodontics Aesthet Dent, V8, P565
   Astaneh R, 2009, J PHARM SCI-US, V98, P135, DOI 10.1002/jps.21415
   Beertsen W, 1997, PERIODONTOL 2000, V13, P20, DOI 10.1111/j.1600-0757.1997.tb00094.x
   Chang SJ, 2012, CARBOHYD POLYM, V88, P684, DOI 10.1016/j.carbpol.2012.01.017
   Clark A, 2014, ACTA BIOMATER, V10, P2125, DOI 10.1016/j.actbio.2013.12.061
   Cobb CM, 2002, J CLIN PERIODONTOL, V29, P22
   Do MP, 2014, EUR J PHARM BIOPHARM, V88, P342, DOI 10.1016/j.ejpb.2014.05.006
   Drisko CH, 1998, J CLIN PERIODONTOL, V25, P947, DOI 10.1111/j.1600-051X.1998.tb02396.x
   Fisher PD, 2014, J BIOMAT SCI-POLYM E, V25, P1174, DOI 10.1080/09205063.2014.923368
   Goktas S, 2011, J PERIODONTOL, V82, P1178, DOI 10.1902/jop.2011.100573
   Goodson JM, 2003, PERIODONTOL 2000, V31, P43, DOI 10.1034/j.1600-0757.2003.03104.x
   Hawkins AM, 2014, J BIOMED MATER RES A, V102, P400, DOI 10.1002/jbm.a.34697
   Hawkins AM, 2013, POLYMER, V54, P4422, DOI 10.1016/j.polymer.2013.06.010
   Hawkins AM, 2011, ACTA BIOMATER, V7, P1956, DOI 10.1016/j.actbio.2011.01.024
   Inoue K, 1985, Dent Mater J, V4, P47
   Izumi K, 2007, J DENT RES, V86, P341, DOI 10.1177/154405910708600408
   Izumi Y, 2011, PERIODONTOL 2000, V56, P166, DOI 10.1111/j.1600-0757.2010.00366.x
   Jorgensen M G, 2000, Compend Contin Educ Dent, V21, P111
   Joshi D, 2014, DRUG DELIV, V23, P363
   Karageorgiou V, 2005, BIOMATERIALS, V26, P5474, DOI 10.1016/j.biomaterials.2005.02.002
   Karimbux N, 2012, CLIN CASES PERIODONT
   Krebs MD, 2009, ACTA BIOMATER, V5, P2847, DOI 10.1016/j.actbio.2009.04.035
   Lavenus S, 2011, ACTA BIOMATER, V7, P1525, DOI 10.1016/j.actbio.2010.12.033
   Li HL, 2004, MATER TRANS, V45, P1124, DOI 10.2320/matertrans.45.1124
   Mundargi RC, 2007, J CONTROL RELEASE, V119, P59, DOI 10.1016/j.jconrel.2007.01.008
   Pihlstrom BL, 2005, LANCET, V366, P1809, DOI 10.1016/S0140-6736(05)67728-8
   Qin YY, 2012, J BIOMED MATER RES B, V100B, P2197, DOI 10.1002/jbm.b.32788
   Sawada A, 2011, J DENT RES, V90, P590, DOI 10.1177/0022034510396881
   Scannapieco Frank A, 2003, Ann Periodontol, V8, P38, DOI 10.1902/annals.2003.8.1.38
   Spencer D, 2014, KALEIDOSCOPE, V11, P20
   Sundararaj SC, 2013, BIOMATERIALS, V34, P8835, DOI 10.1016/j.biomaterials.2013.07.093
   Tanaka E, 2006, J DENT RES, V85, P571, DOI 10.1177/154405910608500618
   Taylor G W, 2001, Ann Periodontol, V6, P99, DOI 10.1902/annals.2001.6.1.99
   Yu HY, 2008, J BIOMED MATER RES B, V86B, P541, DOI 10.1002/jbm.b.31054
NR 37
TC 2
Z9 2
U1 1
U2 30
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 1748-6041
EI 1748-605X
J9 BIOMED MATER
JI Biomed. Mater.
PD APR
PY 2016
VL 11
IS 2
AR 025002
DI 10.1088/1748-6041/11/2/025002
PG 12
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA DL3GY
UT WOS:000375523400007
PM 26947556
DA 2018-03-20
ER

PT J
AU Wu, QL
   Rankin, SE
AF Wu, Qingliu
   Rankin, Stephen E.
TI Tuning the wall thickness and pore orientation in mesoporous titania
   films prepared with low-temperature aging
SO JOURNAL OF SOL-GEL SCIENCE AND TECHNOLOGY
LA English
DT Article
DE Mesoporous; Titania; Thin film; Wall thickness; P123
ID HYBRID SOLAR-CELLS; SILICA THIN-FILMS; X-RAY-DIFFRACTION; TRIBLOCK
   COPOLYMERS; HIGHLY CRYSTALLINE; THERMAL-STABILITY; MOLECULAR-SIEVES;
   FACILE SYNTHESIS; TIO2; PHOTOCATALYSIS
AB Porous titania thin films with well-ordered mesostructures are prepared by using Pluronic surfactant P123 as the pore template and aging the films in a high-humidity environment at -6 degrees C. These structures are stable enough to undergo calcination at 400 degrees C to generate nanocrystalline TiO(2) walls with retention of mesoporosity. Under the aging conditions used, the films have well-ordered mesostructures even with a molar ratio of P123 to titanium (R) as small as 0.006. Because the P123 micelle diameter remains constant across a range of compositions, the pore diameter also remains fixed but the wall thickness of the titania thin films increases as the P123 concentration decreases without decreasing the long-range order of the products. Furthermore, mesoporous titania thin films with hexagonal close-packed channels oriented perpendicular to the substrate can be obtained R values of 0.008-0.012 by sandwiching the as-prepared films between glass slides modified with crosslinked P123. Analysis of the meso-phases obtained here indicates that a transition from films containing significant 2D hexagonal channels to 3D hexagonal structure occurs below P123/Ti = 0.008. This does not match the expected volume fraction for this transition based on the mesophases behavior of aqueous P123 at room temperature, suggesting that a more detailed model would be needed to predict mesostructure in titania films aged below the freezing point of water.
C1 [Wu, Qing Liu; Rankin, Stephen E.] Univ Kentucky, Chem & Mat Engn Dept, Lexington, KY 40506 USA.
RP Rankin, SE (reprint author), Univ Kentucky, Chem & Mat Engn Dept, 177 FP Anderson Tower, Lexington, KY 40506 USA.
EM srankin@engr.uky.edu
RI Rankin, Stephen/A-3265-2013; wu, qingliu/C-7631-2012
OI Rankin, Stephen/0000-0002-8615-7564; 
FU US Department of Energy [DE-FG02-07ER46375]
FX This work was supported by the US Department of Energy under grant
   number DE-FG02-07ER46375.
CR Alberius PCA, 2002, CHEM MATER, V14, P3284, DOI 10.1021/cm011209u
   Baglio V, 2005, J ELECTROCHEM SOC, V152, pA1373, DOI 10.1149/1.1931427
   Bannat I, 2009, CHEM MATER, V21, P1645, DOI 10.1021/cm803455k
   Beck J.S., 1992, AM CHEM SOC, V114, P10834, DOI DOI 10.1021/JA00053A020
   Chen W, 2007, ELECTROCHEM COMMUN, V9, P382, DOI 10.1016/j.elecom.2006.10.002
   Choi M, 2003, CHEM COMMUN, P1340, DOI 10.1039/b303696k
   Choi SG, 2007, THIN SOLID FILMS, V516, P212, DOI 10.1016/j.tsf.2007.07.001
   Choi SY, 2006, ADV FUNCT MATER, V16, P1731, DOI 10.1002/adfm.200500507
   Choi SY, 2004, ADV FUNCT MATER, V14, P335, DOI 10.1002/adfm.200305039
   Coakley KM, 2005, MRS BULL, V30, P37, DOI 10.1557/mrs2005.7
   Coakley KM, 2003, ADV FUNCT MATER, V13, P301, DOI 10.1002/adfm.200304361
   Coquil T, 2010, J PHYS CHEM C, V114, P12451, DOI 10.1021/jp103251t
   Crepaldi EL, 2003, J AM CHEM SOC, V125, P9770, DOI 10.1021/ja030070g
   Crepaldi EL, 2003, ANGEW CHEM INT EDIT, V42, P347, DOI 10.1002/anie.200390113
   Crepaldi EL, 2003, NEW J CHEM, V27, P9, DOI 10.1039/b205497n
   Eggiman BW, 2006, CHEM MATER, V18, P723, DOI 10.1021/cm0520766
   Firouzi A, 1997, J AM CHEM SOC, V119, P3596, DOI 10.1021/ja963007i
   Grosso D, 2003, CHEM MATER, V15, P4562, DOI 10.1021/cm031060h
   Grosso D, 2004, ADV FUNCT MATER, V14, P309, DOI 10.1002/adfm.200305036
   Grosso D, 2006, J SOL-GEL SCI TECHN, V40, P141, DOI 10.1007/s10971-006-8990-6
   HAGFELDT A, 1995, CHEM REV, V95, P49, DOI 10.1021/cr00033a003
   He Xun, 2002, Angew Chem Int Ed Engl, V41, P215
   Hillhouse HW, 2001, MICROPOR MESOPOR MAT, V44, P639, DOI 10.1016/S1387-1811(01)00244-X
   Holmqvist P, 1998, J PHYS CHEM B, V102, P1149, DOI 10.1021/jp9730297
   Imperor-Clerc M, 2000, J AM CHEM SOC, V122, P11925, DOI 10.1021/ja002245h
   Ismail AA, 2010, CHEMSUSCHEM, V3, P1057, DOI 10.1002/cssc.201000158
   Jang KS, 2004, CHEM COMMUN, P1514, DOI 10.1039/b404409f
   Jiang X, 2007, ENVIRON SCI TECHNOL, V41, P4441, DOI 10.1021/es070106v
   Jiu JT, 2007, J MATER SCI-MATER EL, V18, P593, DOI 10.1007/s10854-006-9100-9
   Kambe S, 2002, J MATER CHEM, V12, P723, DOI 10.1039/b105142n
   Kirsch BL, 2004, J PHYS CHEM B, V108, P12698, DOI 10.1021/jp036442p
   Koganti VR, 2006, NANO LETT, V6, P2567, DOI 10.1021/nl061992v
   Koh CW, 2008, CHEM-ASIAN J, V3, P862, DOI 10.1002/asia.200700331
   KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0
   Kruk M, 1997, LANGMUIR, V13, P6267, DOI 10.1021/la970776m
   Kruk M, 2001, CHEM MATER, V13, P3169, DOI 10.1021/cm0101069
   Lancelle-Beltran E, 2006, CHEM MATER, V18, P6152, DOI 10.1021/cm060925z
   Lee UH, 2006, MICROPOR MESOPOR MAT, V88, P48, DOI 10.1016/j.micromeso.2005.08.017
   Lettow JS, 2000, LANGMUIR, V16, P8291, DOI 10.1021/la000660h
   LIU KJ, 1969, MACROMOLECULES, V2, P529, DOI 10.1021/ma60011a015
   Liu YC, 1998, MACROMOLECULES, V31, P2236, DOI 10.1021/ma971253o
   Lu YF, 1997, NATURE, V389, P364, DOI 10.1038/38699
   Oey CC, 2006, NANOTECHNOLOGY, V17, P706, DOI 10.1088/0957-4484/17/3/015
   Oveisi H, 2010, THIN SOLID FILMS, V518, P6714, DOI [10.1016/jtsf2010.05.112, 10.1016/j.tsf.2010.05.112]
   Pan JH, 2005, NEW J CHEM, V29, P841, DOI 10.1039/b417310d
   Prene P, 2006, ADV MATER, V18, P2579, DOI 10.1002/adma.200502023
   Sanchez C, 2008, CHEM MATER, V20, P682, DOI 10.1021/cm702100t
   Smarsly B, 2004, CHEM MATER, V16, P2948, DOI 10.1021/cm0495966
   Soler-Illia GJAA, 2006, CHEM-EUR J, V12, P4478, DOI 10.1002/chem.200500801
   Soler-illia GJD, 2002, CHEM REV, V102, P4093, DOI 10.1021/cr0200062
   Soler-Illia GJDA, 2000, NEW J CHEM, V24, P493, DOI 10.1039/b002518f
   Soni SS, 2006, J PHYS CHEM B, V110, P15157, DOI 10.1021/jp062159p
   SREETHAWONG T, 2006, P EL SOC 2004 2022 E, P177
   Stengl V, 2010, NEW J CHEM, V34, P1999, DOI 10.1039/c0nj00167h
   STUCKY GD, 1994, MOL CRYST LIQ CRYS A, V240, P187, DOI 10.1080/10587259408029730
   Tang J, 2004, CHEM COMMUN, P1670, DOI 10.1039/b403690e
   Uchida H, 2010, THIN SOLID FILMS, V518, P3169, DOI 10.1016/j.tsf.2009.08.050
   Urade VN, 2007, LANGMUIR, V23, P4268, DOI 10.1021/la062641z
   Vichi FM, 2000, CHEM MATER, V12, P1762, DOI 10.1021/cm9907460
   Wan Y, 2007, CHEM REV, V107, P2821, DOI 10.1021/cr068020s
   Wang XC, 2005, CHEM-EUR J, V11, P2997, DOI 10.1002/chem.200401248
   Wang XC, 2006, ENVIRON SCI TECHNOL, V40, P2369, DOI 10.1021/es052000a
   WANKA G, 1994, MACROMOLECULES, V27, P4145, DOI 10.1021/ma00093a016
   Wijnhoven JEGJ, 1998, SCIENCE, V281, P802, DOI 10.1126/science.281.5378.802
   Wu CW, 2006, J AM CHEM SOC, V128, P4544, DOI 10.1021/ja060453p
   Yang PD, 1999, CHEM MATER, V11, P2813, DOI 10.1021/cm990185c
   Zhang Y, 2009, ACS APPL MATER INTER, V1, P2789, DOI 10.1021/am900529e
   Zhao DY, 1998, J AM CHEM SOC, V120, P6024, DOI 10.1021/ja974025i
   Zhao L, 2005, APPL SURF SCI, V239, P285, DOI 10.1016/j.apsusc.2004.05.277
NR 69
TC 9
Z9 9
U1 0
U2 16
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0928-0707
J9 J SOL-GEL SCI TECHN
JI J. Sol-Gel Sci. Technol.
PD OCT
PY 2011
VL 60
IS 1
BP 81
EP 90
DI 10.1007/s10971-011-2553-1
PG 10
WC Materials Science, Ceramics
SC Materials Science
GA 861QD
UT WOS:000298033400012
DA 2018-03-20
ER

PT J
AU Hayes, D
   Mansour, HM
AF Hayes, Don, Jr.
   Mansour, Heidi M.
TI Vanishing bronchus intermedius syndrome in a pediatric patient with
   cystic fibrosis after lung transplantation
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE vanishing bronchus intermedius syndrome; cystic fibrosis; lung
   transplantation; Aspergillus fumigatus
ID AIRWAY COMPLICATIONS; ANASTOMOSES; MANAGEMENT; STENOSIS
AB Airway complications occur frequently after lung transplantation. Bronchial stenosis is the most frequently encountered complication with the most severe form of that being the vanishing bronchus intermedius syndrome (VBIS). This rare disorder has never been reported in the pediatric population. This is the first report of VBIS in a pediatric patient, specifically a 16-yr-old male patient with cystic fibrosis whose course was complicated by a lower airway infection with Aspergillus fumigatus. The VBIS responded to bronchoscopic balloon dilation and placement of an airway stent.
C1 [Hayes, Don, Jr.] Ohio State Univ, Coll Med, Columbus, OH 43205 USA.
   [Mansour, Heidi M.] Univ Kentucky, Coll Pharm, Lexington, KY USA.
RP Hayes, D (reprint author), Ohio State Univ, Nationwide Childrens Hosp, 700 Childrens Dr, Columbus, OH 43205 USA.
EM hayes.705@osu.edu
CR Aigner C, 2003, EUR J CARDIO-THORAC, V23, P488, DOI 10.1016/S1010-7940(03)000018-6
   Alvarez A, 2001, EUR J CARDIO-THORAC, V19, P381, DOI 10.1016/S1010-7940(01)00619-4
   Choong CK, 2006, J THORAC CARDIOV SUR, V131, P198, DOI 10.1016/j.jtcvs.2005.06.053
   DATE H, 1995, J THORAC CARDIOV SUR, V110, P1424, DOI 10.1016/S0022-5223(95)70065-X
   Date H, 1995, J THORAC CARDIOVASC, V110, P1432
   De Gracia J, 2007, RESP MED, V101, P27, DOI 10.1016/j.rmed.2006.04.019
   Fernandez-Bussy S, 2011, ARCH BRONCONEUMOL, V47, P128, DOI 10.1016/j.arbres.2010.10.011
   Hasegawa T, 2000, ANN THORAC SURG, V69, P1020, DOI 10.1016/S0003-4975(99)01556-8
   Herrera JM, 2001, ANN THORAC SURG, V71, P989, DOI 10.1016/S0003-4975(00)02127-5
   Herrera JM, 2001, ANN THORAC SURG, V71, P993
   Kesavan RB, 2007, CHEST, V132, p595S
   Kshettry VR, 1997, ANN THORAC SURG, V63, P1576, DOI 10.1016/S0003-4975(97)83852-0
   LIMA O, 1981, J THORAC CARDIOV SUR, V82, P211
   Marulli G, 2007, TRANSPL P, V39, P1973, DOI 10.1016/j.transproceed.2007.05.021
   Murthy SC, 2007, ANN THORAC SURG, V84, P401, DOI 10.1016/j.athoracsur.2007.05.018
   Ruttmann E, 2005, J HEART LUNG TRANSPL, V24, P275, DOI 10.1016/j.healun.2004.01.008
   Samano MN, 2009, TRANSPL P, V41, P921, DOI 10.1016/j.transproceed.2009.01.047
   Schroder C, 2003, ANN THORAC SURG, V75, P1697, DOI 10.1016/S0003-4975(03)00011-0
   Shah SS, 2006, CHEST, V130, p236S, DOI 10.1378/chest.130.4_MeetingAbstracts.236S-a
   SHENNIB H, 1994, ANN THORAC SURG, V57, P506, DOI 10.1016/0003-4975(94)91038-3
   TAKAO M, 1991, J HEART LUNG TRANSPL, V10, P956
   Van de Wauwer C, 2007, EUR J CARDIO-THORAC, V31, P703
   VEITH FJ, 1983, TRANSPLANTATION, V35, P271, DOI 10.1097/00007890-198304000-00001
   Weder W, 2009, EUR J CARDIO-THORAC, V35, P293, DOI 10.1016/j.ejcts.2008.09.035
NR 24
TC 7
Z9 7
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD DEC
PY 2012
VL 16
IS 8
BP E333
EP E337
DI 10.1111/j.1399-3046.2012.01682.x
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 033NM
UT WOS:000310804300001
PM 22489792
DA 2018-03-20
ER

PT J
AU Hellman, LM
   Rodgers, DW
   Fried, MG
AF Hellman, Lance M.
   Rodgers, David W.
   Fried, Michael Gregory
TI Phenomenological partial-specific volumes for G-quadruplex DNAs
SO EUROPEAN BIOPHYSICS JOURNAL WITH BIOPHYSICS LETTERS
LA English
DT Article; Proceedings Paper
CT 17th International Symposium on Analytical Ultracentrifugation and
   Hydrodynamics
CY SEP 11-12, 2008
CL Univ Newcastle, Inst Cell & Mol Biosci, Newcastle upon Tyne, ENGLAND
HO Univ Newcastle, Inst Cell & Mol Biosci
DE Partial-specific volume; Analytical ultracentrifugation; G-quadruplex
   DNA; Single-stranded DNA
ID TELOMERIC DNA; CRYSTAL-STRUCTURE; SEDIMENTATION; PROTEINS;
   OLIGONUCLEOTIDES; STABILITY; SEQUENCE; MODEL; ACID
AB Accurate partial-specific volume (v) values are required for sedimentation velocity and sedimentation equilibrium analyses. For nucleic acids, the estimation of these values is complicated by the fact that v depends on base composition, secondary structure, solvation and the concentrations and identities of ions in the surrounding buffer. Here we describe sedimentation equilibrium measurements of the apparent isopotential partial-specific volume phi' for two G-quadruplex DNAs and a single-stranded DNA of similar molecular weight and base composition. The G-quadruplex DNAs are a 22 nucleotide fragment of the human telomere consensus sequence and a 27 nucleotide fragment from the human c-myc promoter. The single-stranded DNA is 26 nucleotides long and is designed to have low propensity to form secondary structures. Parallel measurements were made in buffers containing NaCl and in buffers containing KCl, spanning the range 0.09 M <= [salt] <= 2.3 M. Limiting values of phi', extrapolated to [salt] = 0 M, were: 22-mer (NaCl-form), 0.525 +/- 0.004 mL/g; 22-mer (KCl-form), 0.531 +/- 0.006 mL/g; 27-mer (NaCl-form), 0.548 +/- 0.005 mL/g; 27-mer (KCl-form), 0.557 +/- 0.006 mL/g; 26-mer (NaCl-form), 0.555 +/- 0.004 mL/g; 26-mer (KCl-form), 0.564 +/- 0.006 mL/g. Small changes in phi' with [salt] suggest that large changes in counterion association or hydration are unlikely to take place over these concentration ranges.
C1 [Hellman, Lance M.; Rodgers, David W.; Fried, Michael Gregory] Univ Kentucky, Dept Mol & Cellular Biochem, Struct Biol Ctr, Lexington, KY 40536 USA.
RP Fried, MG (reprint author), Univ Kentucky, Dept Mol & Cellular Biochem, Struct Biol Ctr, 741 S Limestone, Lexington, KY 40536 USA.
EM michael.fried@uky.edu
FU NIGMS NIH HHS [R01 GM070662-04, R01 GM070662-02, R01 GM070662-05, R01
   GM070662, R01 GM070662-03, R01 GM070662-06, R01 GM070662-01]
CR Ambrus A, 2006, NUCLEIC ACIDS RES, V34, P2723, DOI 10.1093/nar/gkl348
   Ambrus A, 2005, BIOCHEMISTRY-US, V44, P2048, DOI 10.1021/bi048242p
   Bonifacio GF, 1997, BIOPHYS J, V73, P1532, DOI 10.1016/S0006-3495(97)78185-2
   Burge S, 2006, NUCLEIC ACIDS RES, V34, P5402, DOI 10.1093/nar/gkl655
   CHAPMAN RE, 1969, BIOPOLYMERS, V7, P527, DOI 10.1002/bip.1969.360070410
   COHEN G, 1968, BIOPOLYMERS, V6, P1077, DOI 10.1002/bip.1968.360060805
   CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170
   DURCHSCHLAG H, 1989, COLLOID POLYM SCI, V267, P1139, DOI 10.1007/BF01496937
   Durchschlag H., 1986, THERMODYNAMIC DATA B, P45
   Ebel C, 2000, BIOPHYS J, V78, P385, DOI 10.1016/S0006-3495(00)76601-X
   Edelstein S J, 1973, Methods Enzymol, V27, P82
   EDELSTEIN SJ, 1967, J BIOL CHEM, V242, P306
   GELLERT M, 1962, P NATL ACAD SCI USA, V48, P2013, DOI 10.1073/pnas.48.12.2013
   GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9
   Hatters DM, 2001, BIOPHYS J, V81, P371, DOI 10.1016/S0006-3495(01)75706-2
   HENDERSON E, 1987, CELL, V51, P899, DOI 10.1016/0092-8674(87)90577-0
   KANG C, 1992, NATURE, V356, P126, DOI 10.1038/356126a0
   Lane AN, 2008, NUCLEIC ACIDS RES, V36, P5482, DOI 10.1093/nar/gkn517
   Laue TM, 1995, METHOD ENZYMOL, V259, P427
   Laue T., 1992, ANAL ULTRACENTRIFUGA, P90
   Lee J C, 1979, Methods Enzymol, V61, P26
   Li J, 2005, NUCLEIC ACIDS RES, V33, P4649, DOI 10.1093/nar/gki782
   MANNING GS, 1978, Q REV BIOPHYS, V11, P179, DOI 10.1017/S0033583500002031
   Mekmaysy CS, 2008, J AM CHEM SOC, V130, P6710, DOI 10.1021/ja801976h
   NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407
   Parkinson GN, 2002, NATURE, V417, P876, DOI 10.1038/nature755
   Phan AT, 2007, NUCLEIC ACIDS RES, V35, P6517, DOI 10.1093/nar/gkm706
   Schuck P, 2002, BIOPHYS J, V82, P1096, DOI 10.1016/S0006-3495(02)75469-6
   WANG Y, 1993, STRUCTURE, V1, P263, DOI 10.1016/0969-2126(93)90015-9
   WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7
NR 30
TC 11
Z9 11
U1 0
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0175-7571
J9 EUR BIOPHYS J BIOPHY
JI Eur. Biophys. J. Biophys. Lett.
PD FEB
PY 2010
VL 39
IS 3
SI SI
BP 389
EP 396
DI 10.1007/s00249-009-0411-7
PG 8
WC Biophysics
SC Biophysics
GA 556IM
UT WOS:000274584300006
PM 19238377
OA green_accepted
DA 2018-03-20
ER

PT J
AU Chopra, N
   Hu, B
   Hinds, BJ
AF Chopra, Nitin
   Hu, Bing
   Hinds, Bruce J.
TI Selective growth and kinetic study of copper oxide nanowires from
   patterned thin-film multilayer structures
SO JOURNAL OF MATERIALS RESEARCH
LA English
DT Article
ID DIAMETER-CONTROLLED SYNTHESIS; CARBON NANOTUBE DIAMETER; THERMAL
   EVAPORATION; SILICON NANOWIRES; SELF-DIFFUSION; SINGLE-CRYSTAL; WHISKER
   GROWTH; OXIDATION; CUO; MECHANISM
AB Selective growth of CuO nanowires on the etched face of Al2O3/Cu/Al2O3 thin-film multilayer patterns was achieved by ambient oxidation at 400 C. The nanowires were observed to selectively grow only from the pattern edge with diameter limited by the thickness of Cu thin film. Transmission-electron-microscopy (TEM) characterization confirmed CuO nanowires of a monoclinic CuO growing in the [010] crystallographic direction. Nanowire growth kinetics was studied at 400 C for different cumulative growth durations with initial growth rates of similar to 1 nin/min. A base growth mechanism with kinetics limited by oxygen diffusion through defects of a scaling oxide film is consistent with observed kinetics. The oxygen diffusivity is found to be similar to 10(-11) cm(2)/s, consistent with the grain-boundary diffusion of oxygen through polycrystalline copper oxide.
C1 Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Hinds, BJ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM bjhinds@engr.uky.edu
RI Nitin, Chopra/F-8236-2011
CR ALI SI, 1968, CORROS SCI, V8, P413, DOI 10.1016/S0010-938X(68)90072-3
   Ancona MG, 2003, NANO LETT, V3, P135, DOI 10.1021/nl0258224
   Bogart TE, 2005, ADV MATER, V17, P114, DOI 10.1002/adma.200400373
   BRENNER SS, 1956, ACTA METALL MATER, V4, P268, DOI 10.1016/0001-6160(56)90064-5
   BUSCH H, 1992, SUPERCOND SCI TECH, V5, P624, DOI 10.1088/0953-2048/5/11/004
   Cheung CL, 2002, J PHYS CHEM B, V106, P2429, DOI 10.1021/jp0142278
   Chopra N, 2005, NANOTECHNOLOGY, V16, P133, DOI 10.1088/0957-4484/16/1/027
   Chopra N, 2004, INORG CHIM ACTA, V357, P3920, DOI 10.1016/j.ica.2004.08.022
   Chopra N, 2002, NANO LETT, V2, P1177, DOI 10.1021/nl0257061
   CHOPRA N, 2003, NONTRADITIONAL APPRO
   Cui Y, 2001, APPL PHYS LETT, V78, P2214, DOI 10.1063/1.1363692
   Dai ZR, 2003, ADV FUNCT MATER, V13, P9, DOI 10.1002/adfm.200390013
   Develos-Bagarinao K, 2004, SUPERCOND SCI TECH, V17, P1253, DOI 10.1088/0953-2048/17/11/005
   Echigoya J, 2004, J MATER SCI, V39, P6215, DOI 10.1023/B:JMSC.0000043589.23138.b6
   Fan SS, 1999, SCIENCE, V283, P512, DOI 10.1126/science.283.5401.512
   Franklin NR, 2000, ADV MATER, V12, P890, DOI 10.1002/1521-4095(200006)12:12<890::AID-ADMA890>3.0.CO;2-K
   Gu G, 2002, NANO LETT, V2, P849, DOI 10.1021/nl025618g
   GULBRANSEN EA, 1960, J ELECTROCHEM SOC, V108, P119
   Haraguchi K, 1996, APPL PHYS LETT, V69, P386, DOI 10.1063/1.118069
   HAUFFE K, 1965, OXID MET, P159
   HOMMA T, 1964, ACTA METALL MATER, V12, P1092, DOI 10.1016/0001-6160(64)90082-3
   Hsieh CT, 2003, APPL PHYS LETT, V82, P3316, DOI 10.1063/1.1569043
   Hsu YJ, 2005, J PHYS CHEM B, V109, P4398, DOI 10.1021/jp046354k
   Huang LS, 2004, J CRYST GROWTH, V260, P130, DOI 10.1016/j.jcrysgro.2003.08.012
   Islam MS, 2004, NANOTECHNOLOGY, V15, pL5, DOI 10.1088/0957-4484/15/5/L01
   JIANG K, 2002, NANO LETT, V2, P1333
   JO SH, 2004, APPL PHYS LETT, V85, P1405
   KAITO C, 1986, J CRYST GROWTH, V74, P469, DOI 10.1016/0022-0248(86)90192-2
   Kaur I., 1989, HDB GRAIN INTERPHASE
   Kumar A, 2004, J PHYS-CONDENS MAT, V16, P8531, DOI 10.1088/0953-8984/16/47/007
   LASKO WR, 1962, ANAL CHEM, V34, P1795, DOI 10.1021/ac60193a039
   Lefebvre J, 2000, APPL PHYS LETT, V76, P3828, DOI 10.1063/1.126795
   LUMPP JK, 1990, HIGH TEMP MAT PROCES, V9, P1
   Miyayama M., 1995, SENSOR ACTUAT B-CHEM, V24-25, P383
   Musa AO, 1998, SOL ENERG MAT SOL C, V51, P305, DOI 10.1016/S0927-0248(97)00233-X
   OISHI Y, 1960, J CHEM PHYS, V33, P480, DOI 10.1063/1.1731170
   OREILLY M, 1995, APPL SURF SCI, V91, P152, DOI 10.1016/0169-4332(95)00111-5
   PERINET F, 1982, MAT SCI MONOGR, V10, P234
   Rebane JA, 1997, J MATER CHEM, V7, P2085, DOI 10.1039/a702798b
   Reitz JB, 1998, J AM CHEM SOC, V120, P11467, DOI 10.1021/ja981579s
   Suh YS, 2004, THIN SOLID FILMS, V450, P341, DOI 10.1016/j.tsf.2003.11.165
   Vaddiraju S, 2003, J AM CHEM SOC, V125, P10792, DOI 10.1021/ja035868e
   WALLWORK GR, 1969, CORROS SCI, V9, P561, DOI 10.1016/0010-938X(69)90025-0
   Wang SH, 2002, PHYS CHEM CHEM PHYS, V4, P3425, DOI 10.1039/b201561g
   Wang WZ, 2002, ADV MATER, V14, P67, DOI 10.1002/1521-4095(20020104)14:1<67::AID-ADMA67>3.0.CO;2-Z
   Williford RE, 2005, J NON-CRYST SOLIDS, V351, P2217, DOI 10.1016/j.jnoncrysol.2005.06.001
   Xu CH, 2004, CHEM PHYS LETT, V399, P62, DOI 10.1016/j.cplett.2004.10.005
   Zhang DH, 2004, NANO LETT, V4, P1919, DOI 10.1021/nl0489283
   Zhong ZH, 2003, SCIENCE, V302, P1377, DOI 10.1126/science.1090899
   ZHU Y, 2005, CORROS SCI, V47, P534
NR 50
TC 20
Z9 20
U1 3
U2 16
PU MATERIALS RESEARCH SOC
PI WARRENDALE
PA 506 KEYSTONE DR, WARRENDALE, PA 15086 USA
SN 0884-2914
J9 J MATER RES
JI J. Mater. Res.
PD OCT
PY 2007
VL 22
IS 10
BP 2691
EP 2699
DI 10.1557/JMR.2007.0377
PG 9
WC Materials Science, Multidisciplinary
SC Materials Science
GA 218RY
UT WOS:000250033800009
DA 2018-03-20
ER

PT J
AU Huang, HQ
   Cammers, A
   Penn, LS
AF Huang, Heqing
   Cammers, Arthur
   Penn, Lynn S.
TI Grafting of free chains in the presence of preexisting polymer brushes
SO MACROMOLECULES
LA English
DT Article
ID GAS-LIQUID-CHROMATOGRAPHY; SELF-CONSISTENT-FIELD; TETHERED CHAINS;
   MOLECULAR-WEIGHT; GOOD SOLVENT; MATRICES; SYSTEMS; LAYER; PENETRATION;
   ADSORPTION
AB Experiments were conducted on the grafting of end-functionalized free chains from dilute solution to a solid bearing a preexisting polymer brush. The hypothesis was that grafting behavior would parallel the theoretical predictions made for penetration of a preexisting brush by free chains. Paralleling penetration theory, the grafting of free chains increased with concentration of the bulk solution and decreased with molecular weight of the free chains, although the decrease was less pronounced than predicted by theory. Free chains chemically identical to, but longer than, the chains in the brush did not become grafted. However, free chains longer but more flexible than the chains in the preexisting brush did become grafted. Contrary to penetration theory, which predicts an exponential decrease in penetration with grafting density of the preexisting brush, grafting of free chains (of three different molecular weights and two different chemical structures) appeared to have little to no sensitivity to density of the preexisting brush. This insensitivity, unexplained at present, suggests that there are aspects of penetration that have not been identified by theory and also suggests a direction for future experiments. One of the most surprising findings was the rapidity with which free chains penetrated the preexisting brush. They became grafted almost as rapidly as free chains diffuse to a bare surface to form a mushroom layer. This indicates that the preexisting brush does not constitute a strong barrier to diffusion of free chains but, instead, facilitates their diffusion to the surface.
C1 Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
RP Penn, LS (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM penn@engr.uky.edu
RI Cammers, Arthur/B-8681-2013
OI Cammers, Arthur/0000-0002-1682-3488
CR ALEXANDER S, 1977, J PHYS-PARIS, V38, P983, DOI 10.1051/jphys:01977003808098300
   AUBOUY M, 1994, MACROMOLECULES, V27, P5182, DOI 10.1021/ma00096a048
   AUBOUY M, 1995, MACROMOLECULES, V28, P2979, DOI 10.1021/ma00112a051
   CHANDA M, 2000, ADV POLYM CHEM PROBL, P174
   DEGENNES PG, 1980, MACROMOLECULES, V13, P1069, DOI 10.1021/ma60077a009
   DUDA JL, 1982, AICHE J, V28, P279, DOI 10.1002/aic.690280217
   FETTERS LJ, 1994, MACROMOLECULES, V27, P4639, DOI 10.1021/ma00095a001
   GAST AP, 1985, J PHYS CHEM-US, V89, P3947, DOI 10.1021/j100265a001
   GAST AP, 1986, MACROMOLECULES, V19, P686, DOI 10.1021/ma00157a035
   Grest GS, 1996, J CHEM PHYS, V105, P5532, DOI 10.1063/1.472395
   HIEMENZ PC, 2007, POLYM CHEM, pCH6
   Huang H, 2004, MACROMOLECULES, V37, P5807, DOI 10.1021/ma030591o
   Huang H, 2004, MACROMOLECULES, V37, P516, DOI 10.1021/ma030333r
   HUANG H, 2004, LANGMUIR, V27, P5770
   HUANG H, 2004, THESIS U KENTUCKY LE
   Huang HQ, 2005, MACROMOLECULES, V38, P4837, DOI 10.1021/ma0501444
   KENT MS, 1995, J CHEM PHYS, V103, P2320, DOI 10.1063/1.469707
   LECOURTIER J, 1979, MACROMOLECULES, V12, P141, DOI 10.1021/ma60067a029
   Lee LT, 1997, PHYS REV LETT, V79, P2899, DOI 10.1103/PhysRevLett.79.2899
   Lin R, 1996, J ADHES SCI TECHNOL, V10, P327, DOI 10.1163/156856196X00733
   MARTIN JI, 1995, J PHYS CHEM-US, V99, P2833, DOI 10.1021/j100009a045
   Penn LS, 2002, MACROMOLECULES, V35, P7054, DOI 10.1021/ma020618o
   Penn LS, 2000, MACROMOLECULES, V33, P1105, DOI 10.1021/ma990987t
   Pepin MP, 2001, J CHEM PHYS, V114, P8181, DOI 10.1063/1.1362296
   ROMDHANE IH, 1991, J CHEM ENG DATA, V36, P15, DOI 10.1021/je00001a005
   SHULL KR, 1991, J CHEM PHYS, V94, P5723, DOI 10.1063/1.460456
   Shull KR, 1996, MACROMOLECULES, V29, P2659, DOI 10.1021/ma951290k
   TEWARI YB, 1972, MACROMOLECULES, V5, P329, DOI 10.1021/ma60027a021
   TSENG HS, 1991, J POLYM SCI POL PHYS, V29, P161, DOI 10.1002/polb.1991.090290203
   WIJMANS CM, 1994, MACROMOLECULES, V27, P3238, DOI 10.1021/ma00090a017
   Wijmans CM, 1996, MACROMOLECULES, V29, P4406, DOI 10.1021/ma9514028
   ZHULINA EB, 1991, MACROMOLECULES, V24, P4679, DOI 10.1021/ma00016a031
   ZHULINA EB, 1989, VYSOKOMOL SOEDIN A, V31, P196
NR 33
TC 15
Z9 15
U1 0
U2 9
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0024-9297
J9 MACROMOLECULES
JI Macromolecules
PD OCT 3
PY 2006
VL 39
IS 20
BP 7064
EP 7070
AR 060623I
DI 10.1021/ma060623i
PG 7
WC Polymer Science
SC Polymer Science
GA 087OY
UT WOS:000240752900038
DA 2018-03-19
ER

PT J
AU Shin, HY
   Frechette, DM
   Rohner, N
   Zhang, XY
   Puleo, DA
   Bjursten, LM
AF Shin, Hainsworth Y.
   Frechette, Danielle M.
   Rohner, Nathan
   Zhang, Xiaoyan
   Puleo, David A.
   Bjursten, Lars M.
TI Dependence of macrophage superoxide release on the pulse amplitude of an
   applied pressure regime: a potential factor at the soft tissue-implant
   interface
SO JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE
LA English
DT Article
DE mechanotransduction; macrophage; pressure; cell adhesion; superoxide;
   tissue-implant interface
ID PROMYELOCYTIC LEUKEMIA-CELLS; IN-VITRO; HUMAN MONOCYTE/MACROPHAGES;
   EXTRACELLULAR PRESSURE; HYDROSTATIC-PRESSURE; CYTOKINE PRODUCTION;
   CYCLIC PRESSURE; NADPH OXIDASE; PROPOSED ROLE; PHAGOCYTOSIS
AB Failure of soft tissue implants has been largely attributed to the influence of biomaterial surface properties on the foreign body response, but some implant complications, e.g. macrophage accumulation and necrosis, are still not effectively addressed with surface treatments to minimize deleterious biomaterial effects. We explored an alternative explanation for implant failure, linking biocompatibility with implant micromotion-induced pressure fluctuations at the tissue-biomaterial interface. For this purpose, we used a custom in vitro system to characterize the effects of pressure fluctuations on the activity of macrophages, the predominant cells at a healing implant site. Initially, we quantified superoxide production by HL60-derived macrophage-like cells under several different pressure regimes with means of 5-40mmHg, amplitudes of 0-15mmHg and frequencies of 0-1.5 Hz. All pressure regimes tested elicited significantly (p < 0.05) reduced superoxide production by macrophage-like cells relative to parallel controls. Notably, pressure-sensitive reductions in superoxide release correlated (r(2) = 0.74; p < 0.01) only with pulse pressures. Based on the connection between superoxide production and cell viability, we also explored the influence of cyclic pressure on macrophage numbers and death. Compared to controls, adherent macrophage-like cells exposed to 7.5/2.5 mmHg cyclic pressures for 6 h exhibited significantly (p < 0.01) reduced cell numbers, independent of cell death. A similar effect was observed for cells treated with 10 U/ml superoxide dismutase. Collectively, our results suggest that pressure pulses are a putative regulator of macrophage adhesion via a superoxide-related effect. Pressure fluctuations, e.g. due to implant micromotion, may, therefore, potentially modulate macrophage-dependent wound healing. Copyright (C) 2013 John Wiley & Sons, Ltd.
C1 [Shin, Hainsworth Y.; Frechette, Danielle M.; Rohner, Nathan; Zhang, Xiaoyan; Puleo, David A.] Univ Kentucky, Ctr Biomed Engn, Lexington, KY USA.
   [Bjursten, Lars M.] Lund Univ, Clin Sci, Malmo, Sweden.
RP Shin, HY (reprint author), Univ Kentucky, Ctr Biomed Engn, Wenner Gren Res Lab, Lexington, KY 40506 USA.
EM hy.shin@uky.edu
FU University of Kentucky Research Support Fund; National Science
   Foundation Research Experiences for Undergraduates; American Heart
   Association Beginning-Grant-Aid; NSF-Kentucky EPSCoR Bioengineering
   Initiative grant
FX This study was supported by the University of Kentucky Research Support
   Fund (to H.Y.S.), an American Heart Association Beginning-Grant-Aid (to
   H.Y.S.), a National Science Foundation Research Experiences for
   Undergraduates (to D.M.F. and N.R.; PI, K. W. Anderson) and an
   NSF-Kentucky EPSCoR Bioengineering Initiative grant (to X.Z.; PIs, J.
   Connelly and R. Andrews). We thank Dr S. Lai-Fook and Dr E. Bruce of the
   Center for Biomedical Engineering, University of Kentucky, for their
   technical and material assistance with setting up the pressure system.
CR ALBREKTSSON T, 1981, ACTA ORTHOP SCAND, V52, P155, DOI 10.3109/17453678108991776
   Anderson JM, 2008, SEMIN IMMUNOL, V20, P86, DOI 10.1016/j.smim.2007.11.004
   Anderson JM, 1999, J MATER SCI-MATER M, V10, P579, DOI 10.1023/A:1008976531592
   Andrade J D, 1973, Med Instrum, V7, P110
   AUKLAND K, 1993, PHYSIOL REV, V73, P1
   Baskin DS, 2003, TOXICOL SCI, V74, P361, DOI 10.1093/toxsci/kfg126
   Bauer G, 2002, PROSTAG LEUKOTR ESS, V66, P41, DOI 10.1054/plef.2001.0332
   Beriault DR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031320
   Bertram P, 1997, LANGENBECK ARCH CHIR, V382, P291, DOI 10.1007/s004230050069
   Bhalla S, 2009, AM J SURG, V198, P611, DOI 10.1016/j.amjsurg.2009.07.006
   Boutonnat J, 1999, CELL PROLIFERAT, V32, P203, DOI 10.1046/j.1365-2184.1999.3240203.x
   BRAUKER JH, 1995, J BIOMED MATER RES, V29, P1517, DOI 10.1002/jbm.820291208
   Brown BN, 2012, BIOMATERIALS, V33, P3792, DOI 10.1016/j.biomaterials.2012.02.034
   Bryers JD, 2012, BIOTECHNOL BIOENG, V109, P1898, DOI 10.1002/bit.24559
   Cathcart MK, 2004, ARTERIOSCL THROM VAS, V24, P23, DOI 10.1161/01.ATV.0000097769.47306.12
   COLLINS SJ, 1987, BLOOD, V70, P1233
   Crowther JE, 2004, J IMMUNOL, V172, P6866, DOI 10.4049/jimmunol.172.11.6866
   Evans CE, 2008, ATHEROSCLEROSIS, V197, P596, DOI 10.1016/j.atherosclerosis.2007.08.027
   Ferrier GM, 2000, J BONE JOINT SURG BR, V82B, P755, DOI 10.1302/0301-620X.82B5.9561
   Fleming AJ, 2003, TISSUE ENG, V9, P1023, DOI 10.1089/107632703322495664
   Forman Henry Jay, 2001, Molecular Aspects of Medicine, V22, P189
   Fujishiro T, 2004, J BIOMED MATER RES A, V68A, P531, DOI 10.1002/jbm.a..20098
   GOLDRING SR, 1983, J BONE JOINT SURG AM, V65, P575, DOI 10.2106/00004623-198365050-00001
   Guyton A., 1996, TXB MED PHYSL
   HARRIS P, 1985, J LEUKOCYTE BIOL, V37, P407
   Helton Kristen L, 2011, J Diabetes Sci Technol, V5, P632
   HICKSTEIN DD, 1987, J IMMUNOL, V138, P513
   Hilborn J, 2007, J TISSUE ENG REGEN M, V1, P110, DOI 10.1002/term.4
   Hunt JA, 1997, J BIOMED MATER RES, V36, P542
   Ko JK, 2011, J BIOL CHEM, V286, P9038, DOI 10.1074/jbc.M110.198457
   Kurbel S, 2007, ADV PHYSIOL EDUC, V31, P116
   Laurila JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005786
   Matheson LA, 2006, J BIOMED MATER RES A, V76A, P52, DOI 10.1002/jbm.a.30448
   MATLAGA BF, 1976, J BIOMED MATER RES, V10, P391, DOI 10.1002/jbm.820100308
   MCCARTHY KF, 1988, TOXICOL LETT, V43, P219, DOI 10.1016/0378-4274(88)90030-6
   McEvoy A, 2002, BONE, V30, P171
   Miguel L, 2011, J IMMUNOL, V186, P3505, DOI 10.4049/jimmunol.1002980
   MOREHEAD JM, 1994, OTOLARYNG CLIN N AM, V27, P195
   Paquay YCGJ, 1996, BIOMATERIALS, V17, P1251, DOI 10.1016/0142-9612(96)84946-5
   Park JB, 2003, EXP MOL MED, V35, P325, DOI 10.1038/emm.2003.44
   Patel RP, 2000, FREE RADICAL BIO MED, V28, P1780, DOI 10.1016/S0891-5849(00)00235-5
   Pugin J, 1998, AM J PHYSIOL-LUNG C, V275, pL1040
   Ratner BD, 2002, J CONTROL RELEASE, V78, P211, DOI 10.1016/S0168-3659(01)00502-8
   Ratner BD, 2011, J CARDIOVASC TRANSL, V4, P523, DOI 10.1007/s12265-011-9287-x
   RATNR BD, 1987, J BIOMED MATER RES-A, V21, P59
   Rhodes NP, 1997, J BIOMED MATER RES, V37, P481, DOI 10.1002/(SICI)1097-4636(19971215)37:4<481::AID-JBM6>3.0.CO;2-H
   Rosengren A, 1999, J BIOMED MATER RES, V46, P458, DOI 10.1002/(SICI)1097-4636(19990915)46:4<458::AID-JBM3>3.0.CO;2-I
   Rosengren A, 2002, IEEE T BIO-MED ENG, V49, P392, DOI 10.1109/10.991167
   ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779
   Sakamoto H, 2001, CIRCULATION, V104, P109, DOI 10.1161/hc2701.091070
   Sampathkumar K, 2003, J BONE JOINT SURG BR, V85B, P288, DOI 10.1302/0301-620X.85B2.13211
   Schaser KD, 2003, LANGENBECK ARCH SURG, V388, P323, DOI 10.1007/s00423-003-0411-5
   Shin HY, 2012, TISSUE ENG PT A, V18, P2590, DOI [10.1089/ten.tea.2011.0588, 10.1089/ten.TEA.2011.0588]
   Shiratsuch H, 2005, AM J SURG, V190, P757, DOI 10.1016/j.amjsurg.2005.07.016
   Shiratsuchi H, 2005, AM J PHYSIOL-CELL PH, V288, pC1083, DOI 10.1152/ajpcell.00543.2004
   Shiratsuchi H, 2004, AM J PHYSIOL-CELL PH, V286, pC1358, DOI 10.1152/ajpcell.00553.2003
   Shiratsuchi H, 2007, J CELL BIOCHEM, V102, P353, DOI 10.1002/jcb.21295
   SKARLATOS S, 1994, J PHYSIOL-LONDON, V481, P743, DOI 10.1113/jphysiol.1994.sp020478
   Stromberg DD, 1977, MICROCIRCULATION
   Takahashi H, 2010, J CONTROL RELEASE, V147, P400, DOI 10.1016/j.jconrel.2010.08.019
   Vendrov AE, 2007, ARTERIOSCL THROM VAS, V27, P2714, DOI 10.1161/ATVBAHA.107.152629
   Victor VM, 1998, MOL CELL BIOCHEM, V189, P25, DOI 10.1023/A:1006891926301
   Yang PY, 2009, MOL CANCER THER, V8, P2319, DOI 10.1158/1535-7163.MCT-08-1085
   Yasui K, 2006, INFLAMM RES, V55, P359, DOI 10.1007/s00011-006-5195-y
   Yokoyama Y, 2009, BLOOD, V113, P6584, DOI 10.1182/blood-2008-06-160838
NR 65
TC 1
Z9 1
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1932-6254
EI 1932-7005
J9 J TISSUE ENG REGEN M
JI J. Tissue Eng. Regen. Med.
PD MAR
PY 2016
VL 10
IS 3
BP E227
EP E238
DI 10.1002/term.1789
PG 12
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology; Engineering, Biomedical
SC Cell Biology; Biotechnology & Applied Microbiology; Engineering
GA DH6RV
UT WOS:000372920000008
PM 23881832
DA 2018-03-20
ER

PT J
AU Joshi, S
   Lehmler, HJ
   Knutson, BL
   Rankin, SE
AF Joshi, Suvid
   Lehmler, Hans-Joachim
   Knutson, Barbara L.
   Rankin, Stephen E.
TI Imprinting of Stober particles for chirally-resolved adsorption of
   target monosaccharides and disaccharides
SO NEW JOURNAL OF CHEMISTRY
LA English
DT Article
ID HYDROPHILIC-INTERACTION CHROMATOGRAPHY; SOL-GEL MATERIALS;
   LIQUID-CHROMATOGRAPHY; MESOPOROUS SILICA; POLYMER HYDROGELS;
   ION-EXCHANGE; RECOGNITION; SEPARATION; GLUCOSE; SUGARS
AB A simple, inexpensive, and tunable imprinting technique to produce nonporous particles for selective chirally-resolved adsorption of saccharides has been developed. A sugar-based surfactant is added early in the Stober particle synthesis process (60 seconds after the silica precursor addition) to create molecularly imprinted sites on the surface of the silica particles which are sensitive to the chirality of carbohydrate adsorbates. Mixtures of hexadecyltrimethylammonium bromide (CTAB), and n-octyl-beta-D-glucopyranoside (C8G1) or n-dodecyl-beta-D-maltopyranoside (C12G2) are employed to target adsorption of D-glucose or D-maltose, respectively. The adsorption of D-glucose on these imprinted materials is enhanced by almost 1.5 times over adsorption of other hexoses like D-mannose and D-galactose which differ by a change at only one chiral center. D-Glucose showed a difference in adsorption of greater than 3 times over the enantiomer L-glucose. Materials imprinted to target D-maltose showed nearly 5 times enhancement in adsorption of D-maltose over cellobiose at the lowest tested concentration. This study shows that a direct molecular imprinting approach of the surface of freshly prepared, soft silica particles can yield particles that exhibit preferential adsorption for a chiral target over similar molecules differing by one or more chiral centers, or by the anomeric attachment within polysaccharides.
C1 [Joshi, Suvid] Ingevity Corp, 5255 Virginia Ave, N Charleston, SC 29406 USA.
   [Lehmler, Hans-Joachim] Univ Iowa, Dept Occupat & Environm Hlth, UI Res Pk,164 MTF, Iowa City, IA 52242 USA.
   [Knutson, Barbara L.; Rankin, Stephen E.] Univ Kentucky, Dept Chem & Mat Engn, 177 FP Anderson Tower, Lexington, KY 40506 USA.
RP Rankin, SE (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 FP Anderson Tower, Lexington, KY 40506 USA.
EM stephen.rankin@uky.edu
OI Lehmler, Hans-Joachim/0000-0001-9163-927X
FU National Science Foundation [CBET-0967381/0967390]; U.S. Department of
   Agriculture Biomass Research and Development Initiative [68-3A75-7-608,
   2011-10006-30363]
FX We thank Jia Ye for help in training and obtaining images with SEM.
   Development of the surfactant-based imprinting strategy and particle
   synthesis procedure was carried out as part of a project supported by
   the National Science Foundation (CBET-0967381/0967390). Characterization
   of saccharide adsorption and selectivity was carried out as part of a
   project supported by the U.S. Department of Agriculture Biomass Research
   and Development Initiative (award numbers 68-3A75-7-608 and
   2011-10006-30363).
CR Abel S, 2011, J PHYS CHEM B, V115, P487, DOI 10.1021/jp109545v
   ALPERT AJ, 1994, J CHROMATOGR A, V676, P191, DOI 10.1016/0021-9673(94)00467-6
   Bass JD, 2006, CHEM MATER, V18, P1611, DOI 10.1021/cm052382j
   Brunauer S, 1938, J AM CHEM SOC, V60, P309, DOI 10.1021/ja01269a023
   Che S, 2004, NATURE, V429, P281, DOI 10.1038/nature02529
   Chen GH, 1997, NAT BIOTECHNOL, V15, P354, DOI 10.1038/nbt0497-354
   Collinson M. M., 2010, SUPRAMOL CHEM, P581, DOI [10.1002/9780470552704.ch20, DOI 10.1002/9780470552704.CH20]
   Curcio P, 2009, MACROMOL BIOSCI, V9, P596, DOI 10.1002/mabi.200900056
   Di B, 2013, NEW J CHEM, V37, P1603, DOI 10.1039/c3nj00219e
   Diaz-Garcia ME, 2005, MICROCHIM ACTA, V149, P19, DOI 10.1007/s00604-004-0274-7
   Do C., 2002, J AM CHEM SOC, V124, P14838
   Fireman-Shoresh S, 2003, CHEM MATER, V15, P3607, DOI 10.1021/cm0340734
   GOULDING RW, 1975, J CHROMATOGR, V103, P229, DOI 10.1016/S0021-9673(00)87215-5
   Hilt JZ, 2006, CHEM MATER, V18, P5869, DOI 10.1021/cm061343k
   Holthoff EL, 2007, ACCOUNTS CHEM RES, V40, P756, DOI 10.1021/ar700087t
   JANDERA P, 1974, J CHROMATOGR, V91, P207, DOI 10.1016/S0021-9673(01)97901-4
   Jayasundera S, 2006, J PHYS CHEM B, V110, P18121, DOI 10.1021/jp063880y
   JONES JKN, 1960, CAN J CHEM, V38, P2290, DOI 10.1139/v60-310
   Joshi S, 2014, J COLLOID INTERF SCI, V428, P101, DOI 10.1016/j.jcis.2014.04.041
   Kakita H, 2002, J CHROMATOGR A, V961, P77, DOI 10.1016/S0021-9673(02)00655-6
   Karlsson G, 2005, J CHROMATOGR A, V1092, P246, DOI 10.1016/j.chroma.2005.08.025
   Katz A, 2000, NATURE, V403, P286, DOI 10.1038/35002032
   KEMPE M, 1995, J CHROMATOGR A, V694, P3, DOI 10.1016/0021-9673(94)01070-U
   KHYM JX, 1951, J AM CHEM SOC, V73, P2399, DOI 10.1021/ja01149a555
   Kirk C, 2009, BIOSENS BIOELECTRON, V25, P623, DOI 10.1016/j.bios.2009.01.021
   Kriz D, 1997, ANAL CHEM, V69, pA345, DOI 10.1021/ac971657e
   Lerbret A, 2011, J PHYS CHEM B, V115, P910, DOI 10.1021/jp1097519
   Maier NM, 2007, ANAL BIOANAL CHEM, V389, P377, DOI 10.1007/s00216-007-1427-4
   Markowitz MA, 2001, ANAL CHIM ACTA, V435, P177, DOI 10.1016/S0003-2670(00)01246-0
   Markowitz MA, 2000, LANGMUIR, V16, P1759, DOI 10.1021/la990809t
   Markowitz MA, 2000, LANGMUIR, V16, P6148, DOI 10.1021/la000477o
   MAYES AG, 1994, ANAL BIOCHEM, V222, P483, DOI 10.1006/abio.1994.1521
   Mujahid A, 2010, MATERIALS, V3, P2196, DOI 10.3390/ma3042196
   Okutucu B, 2009, TALANTA, V78, P1190, DOI 10.1016/j.talanta.2009.01.047
   Pagliaro M, 2010, CHEM REC, V10, P17, DOI 10.1002/tcr.200900023
   Paik P, 2012, J SOLID STATE CHEM, V192, P127, DOI 10.1016/j.jssc.2012.03.058
   Paik P, 2010, MICROPOR MESOPOR MAT, V129, P82, DOI 10.1016/j.micromeso.2009.09.001
   Parmpi P, 2004, BIOMATERIALS, V25, P1969, DOI 10.1016/j.biomaterials.2003.08.025
   Peric-Hassler L, 2010, CARBOHYD RES, V345, P1781, DOI 10.1016/j.carres.2010.05.026
   Rajkumar R, 2008, TALANTA, V76, P1119, DOI 10.1016/j.talanta.2008.05.022
   Ramstrom O, 1998, CHIRALITY, V10, P195, DOI 10.1002/(SICI)1520-636X(1998)10:3<195::AID-CHIR1>3.0.CO;2-9
   Schumacher S, 2011, POLYMER, V52, P2485, DOI 10.1016/j.polymer.2011.04.002
   Seeberger PH, 2009, NAT CHEM BIOL, V5, P368, DOI 10.1038/nchembio0609-368
   Sineriz F, 2007, TETRAHEDRON, V63, P1857, DOI 10.1016/j.tet.2006.12.026
   STOBER W, 1968, J COLLOID INTERF SCI, V26, P62, DOI 10.1016/0021-9797(68)90272-5
   Striegler S, 2003, MACROMOLECULES, V36, P1310, DOI 10.1021/ma0258071
   Striegler S, 2001, BIOSEPARATION, V10, P307, DOI 10.1023/A:1021589619501
   TAYLOR JB, 1957, T FARADAY SOC, V53, P1198, DOI 10.1039/tf9575301198
   Vega E, 2011, J COLLOID INTERF SCI, V359, P542, DOI 10.1016/j.jcis.2011.03.017
   Wizeman WJ, 2001, BIOMATERIALS, V22, P1485
   Wu JW, 2013, J COLLOID INTERF SCI, V399, P107, DOI 10.1016/j.jcis.2013.02.045
   Wulff G, 2002, CHEM REV, V102, P1, DOI 10.1021/cr980039a
   Yang DH, 2008, SENSOR ACTUAT B-CHEM, V130, P379, DOI 10.1016/j.snb.2007.09.035
   Yokoi T, 2010, ADSORPTION, V16, P577, DOI 10.1007/s10450-010-9252-z
   Zhang HQ, 2006, J MOL RECOGNIT, V19, P248, DOI 10.1002/jmr.793
NR 55
TC 0
Z9 0
U1 4
U2 4
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1144-0546
EI 1369-9261
J9 NEW J CHEM
JI New J. Chem.
PD OCT 21
PY 2017
VL 41
IS 20
BP 11525
EP 11532
DI 10.1039/c7nj01938f
PG 8
WC Chemistry, Multidisciplinary
SC Chemistry
GA FJ3NV
UT WOS:000412639800009
DA 2018-03-20
ER

PT J
AU Osei-Prempeh, G
   Lehmier, HJ
   Miller, AF
   Knutson, BL
   Rankin, SE
AF Osei-Prempeh, Gifty
   Lehmier, Hans-Joachim
   Miller, Anne-Frances
   Knutson, Barbara L.
   Rankin, Stephen E.
TI Fluorocarbon and hydrocarbon functional group incorporation into
   nanoporous silica employing fluorinated and hydrocarbon surfactants as
   templates
SO MICROPOROUS AND MESOPOROUS MATERIALS
LA English
DT Article
DE Functionalized nanoporous silica; Fluorocarbon surfactants;
   Decyltriethoxysilane;
   Heptadecafluoro-1,1,2,2-tetrahydro-decyltriethoxysilane; n-Decyl;
   Perfluoro-decyl
ID INORGANIC NANOCOMPOSITE MATERIALS; ORGANICALLY MODIFIED SILICATES;
   MESOPOROUS SILICA; CO-CONDENSATION; PORE-SIZE; ORGANOSILICATE FILMS;
   CATIONIC SURFACTANT; MOLECULAR-SIEVES; BINDING-SITES; CHAIN-LENGTH
AB Ordered mesoporous hydrocarbon functionalized (n-decyl) silica samples are synthesized by the 'one-pot' (direct) synthesis method using two cationic fluorinated surfactants, C(6)F(13)C(2)H(2)NC(5)H(5)Cl (HFOPC) and C(8)F(17)C(2)H(2)NC(5)H(5)Cl (HFDePC), and a typical hydrocarbon surfactant, C(16)H(33)N(CH(3))(3)Br (CrAB), as templates. The properties of the materials are compared to those of silica samples functionalized with a fluorocarbon functional group, heptadecafluoro-1,1,2,2-tetrahydro-decyl, whose fluorocarbon separating ability was reported earlier [33]. The pore characteristics, organic loading, and wetting properties of the resulting materials are determined for the following combinations of surfactant/functional groups: hydrocarbon/hydrocarbon, hydrocarbon/fluorocarbon, fluorocarbon/hydrocarbon and fluorocarbon/fluorocarbon. Synthesis using the longer chain fluoro-surfactant (HFDePC) template results in the highest incorporation of both n-decyl and fluorocarbon functional groups, with a corresponding loss of long-range pore order in the fluorinated material. Materials synthesized using the HFOPC template have very low levels of functional group incorporation compared to the HFDePC-templated materials. CTAB-templated materials display greater long-range pore order than the fluorocarbon templated materials. The incorporation of the fluorocarbon functional precursor is more effective (on a % yield basis) than the hydrocarbon functional precursor for silica materials synthesized using CTAB. Similarly, the use of fluorinated surfactant templates enhances fluorocarbon incorporation relative to hydrocarbon incorporation in the mesoporous material. Solubility of the precursors (n-decyltriethoxysilane and heptadecafluoro-1,1,2,2-tetrahydro-decyltriethoxysilane) in the synthesis medium and favorable aggregation behavior of the alkane/fluoroalkane functional groups with the surfactant micelles improves the incorporation of the functional group. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Osei-Prempeh, Gifty; Knutson, Barbara L.; Rankin, Stephen E.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Lehmier, Hans-Joachim] Univ Iowa, Coll Publ Hlth, Dept Environm & Occupat Hlth, Iowa City, IA 52242 USA.
   [Miller, Anne-Frances] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
RP Rankin, SE (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM srankin@engr.uky.edu
RI Rankin, Stephen/A-3265-2013; Miller, Anne-Frances/M-7703-2017
OI Rankin, Stephen/0000-0002-8615-7564; Lehmler,
   Hans-Joachim/0000-0001-9163-927X
FU National Science Foundation [DMR-0210517, CBET-0348234]; US Department
   of Agriculture [683-A75-7-608]
FX This material is based on work sponsored by the National Science
   Foundation under Grant Nos. DMR-0210517 and CBET-0348234 and the US
   Department of Agriculture, Grant No. 683-A75-7-608. We thank
CR Almgren M, 2005, J PHYS CHEM B, V109, P11348, DOI 10.1021/jp0502510
   Asakawa T, 1996, LANGMUIR, V12, P1204, DOI 10.1021/la950758+
   ASAKAWA T, 1995, LANGMUIR, V11, P478, DOI 10.1021/la00002a019
   Bae JY, 2004, J MATER RES, V19, P2503, DOI 10.1557/JMR.2004.0315
   BECK JS, 1992, J AM CHEM SOC, V114, P10834, DOI 10.1021/ja00053a020
   Berggren A, 2005, SOFT MATTER, V1, P219, DOI 10.1039/b507551n
   Blin JL, 2005, MICROPOR MESOPOR MAT, V87, P67, DOI 10.1016/j.micromeso.2005.06.041
   Brittain SM, 2005, NAT BIOTECHNOL, V23, P463, DOI 10.1038/nbt1076
   Curran D, 2001, GREEN CHEM, V3, pG3, DOI 10.1039/b100266j
   Flodstrom K, 2003, J AM CHEM SOC, V125, P4402, DOI 10.1021/ja029353j
   Fowler CE, 1997, CHEM COMMUN, P1769, DOI 10.1039/a704644h
   Ganesan V, 2004, LANGMUIR, V20, P3632, DOI 10.1021/la0364082
   Gladysz J. A., 2004, HDB FLUOROUS CHEM
   Gregg S. J., 1967, ADSORPTION SURFACE A
   Gu ZZ, 2003, ANGEW CHEM INT EDIT, V42, P894, DOI 10.1002/anie.200390235
   Guari Y, 2003, CHEM MATER, V15, P2017, DOI 10.1021/cm0213218
   Han L, 2007, CHEM MATER, V19, P2860, DOI 10.1021/cm0705845
   Hatakeyama T., 1999, THERMAL ANAL FUNDAME
   Holmes SM, 1998, J CHEM SOC FARADAY T, V94, P2025, DOI 10.1039/a801898g
   Huh S, 2003, CHEM MATER, V15, P4247, DOI 10.1021/cm0210041
   Huh S, 2005, ANGEW CHEM INT EDIT, V44, P1826, DOI 10.1002/anie.200462424
   Jaroniec CP, 1997, J PHYS CHEM B, V101, P6861, DOI 10.1021/jp964002a
   Jaroniec M, 1999, LANGMUIR, V15, P5410, DOI 10.1021/la990136e
   Jung JI, 2004, J MATER CHEM, V14, P1988, DOI 10.1039/b401774a
   Kadi M, 2002, LANGMUIR, V18, P9243, DOI 10.1021/la020579+
   Kamiusuki T, 1999, CHROMATOGRAPHIA, V49, P649, DOI 10.1007/BF02466907
   Kamiusuki T, 1999, J COLLOID INTERF SCI, V220, P123, DOI 10.1006/jcis.1999.6518
   Kapoor MP, 2002, J AM CHEM SOC, V124, P15176, DOI 10.1021/ja0290678
   Karukstis KK, 1997, J PHYS CHEM B, V101, P1968, DOI 10.1021/jp962537y
   Kim MJ, 1999, CHEM MATER, V11, P487, DOI 10.1021/cm980691m
   Kosuge K, 2003, CHEM MATER, V15, P3184, DOI 10.1021/cm030225j
   Kruk M, 1997, LANGMUIR, V13, P6267, DOI 10.1021/la970776m
   Kruk M, 2002, J AM CHEM SOC, V124, P6383, DOI 10.1021/ja025573I
   Kruk M, 2001, CHEM MATER, V13, P3169, DOI 10.1021/cm0101069
   Kumar D, 2001, COLLOID SURFACE A, V187, P109, DOI 10.1016/S0927-7757(01)00638-0
   Lebeau B, 2003, NEW J CHEM, V27, P166, DOI 10.1039/b206924p
   Lei CH, 2002, J AM CHEM SOC, V124, P11242, DOI 10.1021/ja026855o
   Lim MH, 1999, CHEM MATER, V11, P3285, DOI 10.1021/cm990369r
   Lin-Vien D, 1991, HDB INFRARED RAMAN C
   Liu SQ, 2003, J PHYS CHEM B, V107, P10405, DOI 10.1021/jp034410w
   Lo Nostro P, 2005, J CHEM ENG DATA, V50, P1148, DOI 10.1021/je049620w
   Markowitz MA, 2000, J PHYS CHEM B, V104, P10820, DOI 10.1021/jp0008389
   Meng XJ, 2004, CHEM MATER, V16, P5518, DOI 10.1021/cm0497475
   Mercier L, 2000, CHEM MATER, V12, P188, DOI 10.1021/cm990532i
   Osei-Prempeh G, 2005, MICROPOR MESOPOR MAT, V85, P16, DOI 10.1016/j.micromeso.2005.06.014
   Osei-Prempeh G, 2008, IND ENG CHEM RES, V47, P530, DOI 10.1021/ie070538e
   Pagliaro M, 2005, J MATER CHEM, V15, P4981, DOI 10.1039/b507583c
   Patist A, 1997, LANGMUIR, V13, P432, DOI 10.1021/la960838t
   Porcherie O, 2005, NEW J CHEM, V29, P538, DOI 10.1039/b417756h
   Ravindra R, 2004, J AM CHEM SOC, V126, P12224, DOI 10.1021/ja046900n
   Rodriguez-Abreu C, 2007, COLLOID SURFACE A, V298, P284, DOI 10.1016/j.colsurfa.2006.11.019
   Sayari A, 2001, CHEM MATER, V13, P3151, DOI 10.1021/cm0110391
   Shea KJ, 2001, CHEM MATER, V13, P3306, DOI 10.1021/cm011074s
   Tan B, 2004, J PHYS CHEM B, V108, P20122, DOI 10.1021/jp046425f
   Tan B, 2005, CHEM MATER, V17, P916, DOI 10.1021/cm048991t
   Tan B, 2004, LANGMUIR, V20, P6981, DOI 10.1021/la049474s
   Tan B, 2007, ADV FUNCT MATER, V17, P2500, DOI 10.1002/adfm.200600635
   TUNG CH, 1995, J PHYS CHEM-US, V99, P8311, DOI 10.1021/j100020a065
   Walcarius A, 2003, CHEM MATER, V15, P4181, DOI 10.1021/cm031089l
   Walcarius A, 2003, CHEM MATER, V15, P2161, DOI 10.1021/cm021310e
   Wang YJ, 2005, CHEM MATER, V17, P953, DOI 10.1021/cm0483137
   Wight AP, 2002, CHEM REV, V102, P3589, DOI 10.1021/cr010334m
   Yokoi T, 2004, J MATER CHEM, V14, P951, DOI 10.1039/b310576h
   Yokoi T, 2003, CHEM MATER, V15, P4536, DOI 10.1021/cm034499i
   Zeidan RK, 2006, ANGEW CHEM INT EDIT, V45, P6332, DOI 10.1002/anie.200602243
NR 65
TC 4
Z9 4
U1 2
U2 26
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1387-1811
J9 MICROPOR MESOPOR MAT
JI Microporous Mesoporous Mat.
PD APR 1
PY 2010
VL 129
IS 1-2
BP 189
EP 199
DI 10.1016/j.micromeso.2009.09.015
PG 11
WC Chemistry, Applied; Chemistry, Physical; Nanoscience & Nanotechnology;
   Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA 547CK
UT WOS:000273862900025
DA 2018-03-20
ER

PT J
AU Wagner, JM
   Evans, TJ
   Korotkov, KV
AF Wagner, Jonathan M.
   Evans, Timothy J.
   Korotkov, Konstantin V.
TI Crystal structure of the N-terminal domain of EccA(1) ATPase from the
   ESX-1 secretion system of Mycobacterium tuberculosis
SO PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS
LA English
DT Article
DE Rv3868; tetratricopeptide repeat; TPR domain; AAA plus ATPase; type VII
   secretion system
ID PSEUDOMONAS-AERUGINOSA; PROTEIN; PILF
AB EccA(1) is an important component of the type VII secretion system (T7SS) that is responsible for transport of virulence factors in pathogenic mycobacteria. EccA(1) has an N-terminal domain of unknown function and a C-terminal AAA+ (ATPases associated with various cellular activities) domain. Here we report the crystal structure of the N-terminal domain of EccA(1) from Mycobacterium tuberculosis, which shows an arrangement of six tetratricopeptide repeats that may mediate interactions of EccA(1) with secreted substrates. Furthermore, the size and shape of the N-terminal domain suggest its orientation in the context of a hexamer model of full-length EccA(1). Proteins 2014; 82:159-163. (c) 2013 Wiley Periodicals, Inc.
C1 [Korotkov, Konstantin V.] Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA.
   Univ Kentucky, Struct Biol Ctr, Lexington, KY 40536 USA.
RP Korotkov, KV (reprint author), Univ Kentucky, Dept Mol & Cellular Biochem, 741 South Limestone, Lexington, KY 40536 USA.
EM kkorotkov@uky.edu
OI Wagner, Jonathan M./0000-0001-9161-7222; Korotkov,
   Konstantin/0000-0002-2182-6843
FU National Center for Research Resources [P20RR020171]; National Institute
   of General Medical Sciences [P20GM103486]; US Department of Energy,
   Office of Science, Office of Basic Energy Sciences [W-31-109-Eng-38];
   National Institute of General Medical Sciences (COBRE) [P20GM103486];
   National Institutes of Health
FX Grant sponsor: National Center for Research Resources; Grant number:
   P20RR020171; Grant sponsor: National Institute of General Medical
   Sciences; Grant number: P20GM103486; Grant sponsor: US Department of
   Energy, Office of Science, Office of Basic Energy Sciences; Grant
   number: W-31-109-Eng-38; Grant sponsor: National Institute of General
   Medical Sciences (COBRE); Grant number: P20GM103486; Grant sponsor:
   National Institutes of Health.
CR Champion PAD, 2009, MOL MICROBIOL, V73, P950, DOI 10.1111/j.1365-2958.2009.06821.x
   Cowtan K, 2012, ACTA CRYSTALLOGR D, V68, P328, DOI 10.1107/S0907444911039655
   Cowtan K, 2010, ACTA CRYSTALLOGR D, V66, P470, DOI 10.1107/S090744490903947X
   D'Andrea LD, 2003, TRENDS BIOCHEM SCI, V28, P655, DOI 10.1016/j.tibs.2003.10.007
   Das AK, 1998, EMBO J, V17, P1192, DOI DOI 10.1093/EMB0J/17.5.1192
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Jinek M, 2004, NAT STRUCT MOL BIOL, V11, P1001, DOI 10.1038/nsmb833
   Joshi SA, 2012, CHEM BIOL, V19, P372, DOI 10.1016/j.chembiol.2012.01.008
   Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337
   Kim K, 2006, BIOCHEM BIOPH RES CO, V340, P1028, DOI 10.1016/j.bbrc.2005.12.108
   Koo J, 2008, J BACTERIOL, V190, P6961, DOI 10.1128/JB.00996-08
   Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022
   Lapouge K, 2000, MOL CELL, V6, P899, DOI 10.1016/S1097-2765(05)00091-2
   Luthra A, 2008, J BIOL CHEM, V283, P36532, DOI 10.1074/jbc.M807144200
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206
   Mueller-Cajar O, 2011, NATURE, V479, P194, DOI 10.1038/nature10568
   Murshudov GN, 2011, ACTA CRYSTALLOGR D, V67, P355, DOI 10.1107/S0907444911001314
   Painter J, 2006, ACTA CRYSTALLOGR D, V62, P439, DOI 10.1107/S0907444906005270
   Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930
   Stoop EJM, 2012, TRENDS MICROBIOL, V20, P477, DOI 10.1016/j.tim.2012.07.001
   Sun PD, 2002, ACTA CRYSTALLOGR D, V58, P1092, DOI 10.1107/S0907444902006510
NR 21
TC 6
Z9 9
U1 1
U2 12
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0887-3585
EI 1097-0134
J9 PROTEINS
JI Proteins
PD JAN
PY 2014
VL 82
IS 1
BP 159
EP 163
DI 10.1002/prot.24351
PG 5
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 267IO
UT WOS:000328090900014
PM 23818233
OA green_accepted
DA 2018-03-20
ER

PT J
AU Asafo-Adjei, TA
   Dziubla, TD
   Puleo, DA
AF Asafo-Adjei, Theodora A.
   Dziubla, Thomas D.
   Puleo, David A.
TI Synthesis and characterization of a poly(ethylene
   glycol)-poly(simvastatin) diblock copolymer
SO RSC ADVANCES
LA English
DT Article
ID RING-OPENING POLYMERIZATION; CONTROLLED DRUG-DELIVERY; HMG-COA
   REDUCTASE; L-LACTIDE; IN-VITRO; SIMVASTATIN; KINETICS; POLYESTERS;
   RELEASE; ACID
AB Biodegradable polyesters are commonly used as drug delivery vehicles, but their role is typically passive, and encapsulation approaches have limited drug payload. An alternative drug delivery method is to polymerize the active agent or its precursor into a degradable polymer. The prodrug simvastatin contains a lactone ring that lends itself to ring-opening polymerization (ROP). Consequently, simvastatin polymerization was initiated with 5 kDa monomethyl ether poly(ethylene glycol) (mPEG) and catalyzed via stannous octoate. Melt condensation reactions produced a 9.5 kDa copolymer with a polydispersity index of 1.1 at 150 degrees C up to a 75 kDa copolymer with an index of 6.9 at 250 degrees C. Kinetic analysis revealed first-order propagation rates. Infrared spectroscopy of the copolymer showed carboxylic and methyl ether stretches unique to simvastatin and mPEG, respectively. Slow degradation was demonstrated in neutral and alkaline conditions. Lastly, simvastatin, simvastatin-incorporated molecules, and mPEG were identified as the degradation products released. The present results show the potential of using ROP to polymerize lactone-containing drugs such as simvastatin.
C1 [Asafo-Adjei, Theodora A.; Puleo, David A.] Univ Kentucky, Dept Biomed Engn, Lexington, KY 40506 USA.
   [Dziubla, Thomas D.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Puleo, DA (reprint author), Univ Kentucky, Dept Biomed Engn, 522A Robot & Mfg Bldg, Lexington, KY 40506 USA.
EM puleo@uky.edu
FU NIH [AR060964-02S1, EB017902]; NSF IGERT fellowship [DGE-0653710]
FX This research was funded in part by the NIH (AR060964-02S1, EB017902),
   and TAA was supported by an NSF IGERT fellowship (DGE-0653710). NMR data
   were obtained at the Nuclear Magnetic Resonance Facility at the
   University of Kentucky. Mass spectral data and help with analysis were
   obtained from the Mass Spectrometry Facility at the University of
   Kentucky.
CR Ahuja R, 2008, CHEM COMMUN, P253, DOI 10.1039/b712197k
   Aleman C, 2009, J ORG CHEM, V74, P6237, DOI 10.1021/jo9010969
   Alexis F, 2004, J CONTROL RELEASE, V98, P67, DOI 10.1016/j.jconrel.2004.04.011
   Ambike AA, 2005, DRUG DEV IND PHARM, V31, P895, DOI 10.1080/03639040500272025
   Armitage J, 2009, BMC CLIN PHARM, V9, P6
   Banerjee SS, 2012, J DRUG DELIV, DOI 10.1155/2012/103973
   Carbone AL, 2009, MACROMOL RAPID COMM, V30, P1021, DOI 10.1002/marc.200900029
   Chen PY, 2010, NUTR RES, V30, P191, DOI 10.1016/j.nutres.2010.03.004
   Cleek RL, 1997, J CONTROL RELEASE, V48, P259, DOI 10.1016/S0168-3659(97)00052-7
   Dhandayuthapani B, 2011, INT J POLYM SCI, DOI 10.1155/2011/290602
   Disjkstra P. J., 2011, POLYM CHEM, V2, P520
   Duda A., 2009, HDB RING OPENING POL
   Duncan R, 2006, NAT REV CANCER, V6, P688, DOI 10.1038/nrc1958
   Dziubla TD, 2005, J CONTROL RELEASE, V102, P427, DOI 10.1016/j.jconrel.2004.10.017
   Gorniak A, 2013, J THERM ANAL CALORIM, V111, P2125, DOI 10.1007/s10973-012-2641-7
   Gunatillake Pathiraja A., 2003, European Cells & Materials, V5, P1
   Hakkarainen M, 2008, ADV POLYM SCI, V211, P85, DOI 10.1007/12_2007_128
   Huang X, 2001, J CONTROL RELEASE, V73, P121, DOI 10.1016/S0168-3659(01)00248-6
   In't Veld PJA, 1997, J POLYM SCI POL CHEM, V35, P219, DOI 10.1002/(SICI)1099-0518(19970130)35:2<219::AID-POLA3>3.0.CO;2-N
   Istvan ES, 2001, SCIENCE, V292, P1160, DOI 10.1126/science.1059344
   Jeon JH, 2007, INT J PHARM, V340, P6, DOI 10.1016/j.ijpharm.2007.03.007
   Joshi H. N., 1988, PHARM TECHNOL, V12, P120
   Kaesemeyer WH, 1999, J AM COLL CARDIOL, V33, P234, DOI 10.1016/S0735-1097(98)00514-2
   Kaihara S, 2007, NAT PROTOC, V2, P2767, DOI 10.1038/nprot.2007.391
   Katiyar V, 2010, POLYM CHEM-UK, V1, P1491, DOI 10.1039/c0py00125b
   Keller BO, 2000, J AM SOC MASS SPECTR, V11, P88, DOI 10.1016/S1044-0305(99)00126-9
   Knop K, 2010, ANGEW CHEM INT EDIT, V49, P6288, DOI 10.1002/anie.200902672
   KRICHELDORF HR, 1995, POLYMER, V36, P1253, DOI 10.1016/0032-3861(95)93928-F
   Kureishi Y, 2000, NAT MED, V6, P1004
   Labet M, 2009, CHEM SOC REV, V38, P3484, DOI 10.1039/b820162p
   LANGER R, 1990, SCIENCE, V249, P1527, DOI 10.1126/science.2218494
   Lewis KJ, 2000, ENCY ANAL CHEM, P5880
   McKee MG, 2005, PROG POLYM SCI, V30, P507, DOI 10.1016/j.progpolymsci.2005.01.009
   Middleton JC, 2000, BIOMATERIALS, V21, P2335, DOI 10.1016/S0142-9612(00)00101-0
   Nuyken O, 2013, POLYMERS-BASEL, V5, P361, DOI 10.3390/polym5020361
   Odian G., 2004, PRINCIPLES POLYM
   OTERA J, 1993, CHEM REV, V93, P1449, DOI 10.1021/cr00020a004
   Porter JR, 2009, BIOTECHNOL PROGR, V25, P1539, DOI 10.1002/btpr.246
   Prueksaritanont T, 1997, DRUG METAB DISPOS, V25, P1191
   Puaux JP, 2007, MACROMOL SYMP, V259, P318, DOI 10.1002/masy.200751336
   Rohini N. A., 2013, J ANTIVIRALS ANTIR S, VS15, P7
   Saltzman WM, 1997, ADV DRUG DELIV REV, V26, P209
   Save M, 2002, MACROMOL CHEM PHYSIC, V203, P889, DOI 10.1002/1521-3935(20020401)203:5/6<889::AID-MACP889>3.0.CO;2-O
   Slivniak R, 2005, BIOMACROMOLECULES, V6, P1679, DOI 10.1021/bm049194r
   Sparrow CP, 2001, ARTERIOSCL THROM VAS, V21, P115, DOI 10.1161/01.ATV.21.1.115
   Storey RF, 2002, MACROMOLECULES, V35, P1504, DOI 10.1021/ma010986c
   Sunder A, 1999, MACROMOLECULES, V32, P4240, DOI 10.1021/ma990090w
   Tasaka F, 2001, MACROMOL RAPID COMM, V22, P820, DOI 10.1002/1521-3927(20010701)22:11<820::AID-MARC820>3.0.CO;2-7
   Tessmar JK, 2007, MACROMOL BIOSCI, V7, P23, DOI 10.1002/mabi.200600096
   Wang H, 2001, J MASS SPECTROM, V36, P58, DOI 10.1002/jms.104
   Wattamwar PP, 2010, ADV FUNCT MATER, V20, P147, DOI 10.1002/adfm.200900839
   Wong Ricky W K, 2006, World J Orthod, V7, P35
   Xie WH, 2007, POLYMER, V48, P6791, DOI 10.1016/j.polymer.2007.09.021
   Yeo Y, 2004, ARCH PHARM RES, V27, P1, DOI 10.1007/BF02980037
   YOSHITO I, 2000, MACROMOL RAPID COMM, V21, P117
   Zhang J., 2007, J APPL POLYM SCI, V105, P3780
NR 56
TC 3
Z9 3
U1 1
U2 4
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2046-2069
J9 RSC ADV
JI RSC Adv.
PY 2014
VL 4
IS 102
BP 58287
EP 58298
DI 10.1039/c4ra10310f
PG 12
WC Chemistry, Multidisciplinary
SC Chemistry
GA AU2PQ
UT WOS:000345460800025
PM 25431653
OA green_accepted
DA 2018-03-19
ER

PT J
AU Schlipf, DM
   Rankin, SE
   Knutson, BL
AF Schlipf, Daniel M.
   Rankin, Stephen E.
   Knutson, Barbara L.
TI Selective external surface functionalization of large-pore silica
   materials capable of protein loading
SO MICROPOROUS AND MESOPOROUS MATERIALS
LA English
DT Article
DE Protein capture; Selective functionalization; Amine functionalization;
   Mesoporous silica; Interfacial engineering
ID MESOPOROUS SILICA; ENZYME IMMOBILIZATION; ADSORPTION; NANOPARTICLES;
   PARTICLES; MCM-41; BIOSENSOR; COPOLYMER; TRIBLOCK; SYSTEMS
AB Differentiating the chemical properties of the external and pore surfaces of sol-gel derived mesoporous materials by selective functionalization is important to advancing their application as platforms for biological catalysis, sensing and drug delivery. Prior selective functionalization approaches to concentrating functional groups at the external surface of particles have been limited to small pores (<= 5.5 nm diameter) incapable of loading large biological molecules. This work investigates the selective exterior surface functionalization by amines of larger-pored (>7 nm diameter) mesoporous silica particles, which are synthesized by dual surfactant templating and hydrothermal aging. Previously developed selective functionalization techniques rely on choice of functionalization precursor, functionalization reaction time. or pore blocking (by leaving pore templates in as-synthesized materials). The effectiveness of these strategies are compared for larger-pored materials using the precursors (3-aminopropyl)tris(methoxyethoxyethoxy)silane (APTMEES) and (3-aminopropyl)triethoxysilane (APTES). The extent of amine functionalization is determined as a function of precursor reaction time (10 or 20 min) in both as synthesized and template-extracted materials by confocal laser scanning microscopy of the similar to 10 mu m diameter particles tagged with fluorescein isothiocyanate. Reaction time, regardless of pore template presence, is demonstrated to be the controlling variable for achieving selective exterior functionalization in these larger pored mesoporous materials. Under the conditions used, 10 min of functionalization with APTMEES localizes amine groups at the exterior of the particles, while 20 min functionalizes both the exterior and the interior pore surfaces. Protein accessibility within pores, before and after selective and full functionalization, is visually confirmed by confocal fluorescence imaging of Rhodamine B tagged lysozyme loaded particles. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Schlipf, Daniel M.; Rankin, Stephen E.; Knutson, Barbara L.] Univ Kentucky, Dept Chem & Mat Engn, 177E Paul Anderson Tower, Lexington, KY 40506 USA.
RP Knutson, BL (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177E Paul Anderson Tower, Lexington, KY 40506 USA.
EM bknut2@uky.edu
FU National Science Foundation Integrated Graduate Education and Research
   Training program on Bioactive Interfaces and Devices [DGE-0653710];
   Kentucky Science and Engineering Foundation [KSEF-2929-RDE-016]
FX This work was supported by the National Science Foundation Integrated
   Graduate Education and Research Training program on Bioactive Interfaces
   and Devices (grant # DGE-0653710) and the Kentucky Science and
   Engineering Foundation (grant # KSEF-2929-RDE-016).
CR Alberius PCA, 2002, CHEM MATER, V14, P3284, DOI 10.1021/cm011209u
   Antochshuk V, 2000, CHEM MATER, V12, P2496, DOI 10.1021/cm000268p
   ARKLES B, 1992, J ADHES SCI TECHNOL, V6, P193, DOI 10.1163/156856192X00133
   BARRETT EP, 1951, J AM CHEM SOC, V73, P373, DOI 10.1021/ja01145a126
   Benson K, 2012, SOFT MATTER, V8, P10845, DOI 10.1039/c2sm26563j
   BHAMBHANI MR, 1972, J COLLOID INTERF SCI, V38, P109, DOI 10.1016/0021-9797(72)90226-3
   Bouchoucha M, 2014, ADV FUNCT MATER, V24, P5911, DOI 10.1002/adfm.201400524
   Bruhwiler D, 2010, NANOSCALE, V2, P887, DOI 10.1039/c0nr00039f
   Brunauer S, 1938, J AM CHEM SOC, V60, P309, DOI 10.1021/ja01269a023
   Cauda V, 2009, J AM CHEM SOC, V131, P11361, DOI 10.1021/ja809346n
   Chen BW, 2013, SMALL, V9, P2228, DOI 10.1002/smll.201202409
   Cheng K, 2007, J AM CHEM SOC, V129, P9674, DOI 10.1021/ja070598b
   Dai ZH, 2005, ELECTROANAL, V17, P1571, DOI 10.1002/elan.200403256
   de Juan F, 2000, ADV MATER, V12, P430, DOI 10.1002/(SICI)1521-4095(200003)12:6<430::AID-ADMA430>3.0.CO;2-3
   Di Pasqua AJ, 2008, J INORG BIOCHEM, V102, P1416, DOI 10.1016/j.jinorgbio.2007.12.028
   Diaz JF, 1996, J MOL CATAL B-ENZYM, V2, P115, DOI 10.1016/S1381-1177(96)00017-3
   Dordick JS, 2006, CURR OPIN BIOTECH, V17, P559, DOI 10.1016/j.copbio.2006.10.012
   Etienne M, 2003, TALANTA, V59, P1173, DOI 10.1016/S0039-9140(03)00024-9
   Fried DI, 2013, CHEMCATCHEM, V5, P862, DOI 10.1002/cctc.201200640
   Gartmann N, 2011, MATERIALS, V4, P1096, DOI 10.3390/ma4061096
   Gartmann N, 2009, ANGEW CHEM INT EDIT, V48, P6354, DOI 10.1002/anie.200902436
   Hara K, 2012, J PHYS CHEM C, V116, P7083, DOI 10.1021/jp300580f
   Hartmann M, 2013, CHEM SOC REV, V42, P6277, DOI 10.1039/c3cs60021a
   Hartmann M, 2010, J MATER CHEM, V20, P844, DOI 10.1039/b907869j
   He J, 2008, AICHE J, V54, P2495, DOI 10.1002/aic.11561
   Jaladi H, 2009, CHEM ENG SCI, V64, P1474, DOI 10.1016/j.ces.2008.10.042
   Jaroniec M, 1999, LANGMUIR, V15, P5410, DOI 10.1021/la990136e
   Jia F, 2014, BIOTECHNOL BIOENG, V111, P209, DOI 10.1002/bit.25136
   Katiyar A, 2006, SMALL, V2, P644, DOI 10.1002/smll.200500473
   Kecht J, 2008, CHEM MATER, V20, P7207, DOI 10.1021/cm801484r
   Kim J, 2013, MICROPOR MESOPOR MAT, V170, P95, DOI 10.1016/j.micromeso.2012.11.033
   Kim MS, 2013, MICROPOR MESOPOR MAT, V172, P118, DOI 10.1016/j.micromeso.2013.01.028
   Kuthati Y, 2013, J NANOSCI NANOTECHNO, V13, P2399, DOI 10.1166/jnn.2013.7363
   Lankoff A, 2013, NANOTOXICOLOGY, V7, P235, DOI 10.3109/17435390.2011.649796
   Lei CH, 2007, J ENVIRON QUAL, V36, P233, DOI 10.2134/jeq2006.0216
   Lu AH, 2004, J AM CHEM SOC, V126, P8616, DOI 10.1021/ja0486521
   Lunn JD, 2010, CHEM COMMUN, V46, P2926, DOI 10.1039/b927487a
   Ma YR, 2003, COLLOID SURFACE A, V229, P1, DOI 10.1016/j.colsurfa.2003.08.010
   Ma YJ, 2011, J COLLOID INTERF SCI, V356, P123, DOI 10.1016/j.jcis.2010.12.082
   Magner E, 2013, CHEM SOC REV, V42, P6213, DOI 10.1039/c2cs35450k
   Malmsten M, 2013, CURR OPIN COLLOID IN, V18, P468, DOI 10.1016/j.cocis.2013.06.002
   Mesa M, 2003, SOLID STATE SCI, V5, P1303, DOI 10.1016/S1293-2558(03)00185-7
   Nieto A, 2010, LANGMUIR, V26, P5038, DOI 10.1021/la904820k
   Puddu V, 2014, LANGMUIR, V30, P227, DOI 10.1021/la403242f
   Ritter H, 2009, J PHYS CHEM C, V113, P10667, DOI 10.1021/jp901983j
   Ritter H, 2009, MICROPOR MESOPOR MAT, V121, P79, DOI 10.1016/j.micromeso.2009.01.006
   Rosenholm JM, 2011, CURR DRUG TARGETS, V12, P1166
   Russo PA, 2011, COLLOID SURFACE A, V386, P25, DOI 10.1016/j.colsurfa.2011.06.022
   Salmio H, 2007, J PHYS CHEM C, V111, P923, DOI 10.1021/jp0651440
   Sarah P. Hudson, 2008, BIOMOLECULAR CATALYS, P49
   Sayari A, 1997, CHEM MATER, V9, P2499, DOI 10.1021/cm970128o
   Schlipf DM, 2013, ACS APPL MATER INTER, V5, P10111, DOI 10.1021/am402754h
   Shen SC, 2011, MATER RES BULL, V46, P1665, DOI 10.1016/j.materresbull.2011.06.004
   Shimomura T, 2008, SENSOR ACTUAT B-CHEM, V135, P268, DOI 10.1016/j.snb.2008.08.025
   SHIRAHAMA H, 1990, J COLLOID INTERF SCI, V139, P177, DOI 10.1016/0021-9797(90)90455-W
   Sotiropoulou S, 2005, BIOSENS BIOELECTRON, V20, P1674, DOI 10.1016/j.bios.2004.07.019
   Tang FQ, 2012, ADV MATER, V24, P1504, DOI 10.1002/adma.201104763
   Thermo Fischer Scientific, 2010, INSTR PROT DES SPIN
   VRANCKEN KC, 1995, COLLOID SURFACE A, V98, P235, DOI 10.1016/0927-7757(95)03119-X
   VRANCKEN KC, 1992, J CHEM SOC FARADAY T, V88, P3197, DOI 10.1039/ft9928803197
   Wei Q, 2009, MICROPOR MESOPOR MAT, V117, P98, DOI 10.1016/j.micromeso.2008.06.033
   Yokoi T, 2004, J MATER CHEM, V14, P951, DOI 10.1039/b310576h
   Zhai Z, 2008, J SEP SCI, V31, P3527, DOI 10.1002/jssc.200800323
   Zhao DY, 1998, SCIENCE, V279, P548, DOI 10.1126/science.279.5350.548
   Zhao DY, 1998, J AM CHEM SOC, V120, P6024, DOI 10.1021/ja974025i
   Zhao DY, 2000, CHEM MATER, V12, P275, DOI 10.1021/cm9911363
   Zhou Z, 2013, CHEM SOC REV, V42, P3894, DOI 10.1039/c3cs60059a
NR 67
TC 1
Z9 1
U1 16
U2 38
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1387-1811
EI 1873-3093
J9 MICROPOR MESOPOR MAT
JI Microporous Mesoporous Mat.
PD MAY 15
PY 2017
VL 244
BP 199
EP 207
DI 10.1016/j.micromeso.2016.10.023
PG 9
WC Chemistry, Applied; Chemistry, Physical; Nanoscience & Nanotechnology;
   Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA ES4OV
UT WOS:000399515500025
DA 2018-03-20
ER

PT J
AU Long, SH
   Zhou, PP
   Parkin, S
   Li, TL
AF Long, Sihui
   Zhou, Panpan
   Parkin, Sean
   Li, Tonglei
TI From Competition to Commensuration by Two Major Hydrogen-Bonding Motifs
SO CRYSTAL GROWTH & DESIGN
LA English
DT Article
ID DENSITY-FUNCTIONAL THEORY; SOLID-STATE; CRYSTAL; POLYMORPHISM; ACID;
   REACTIVITY; RECOGNITION; ASSEMBLIES; CHEMISTRY; ACCEPTOR
AB Carboxylic acid acid hydrogen-bonding dimer and acid pyridine hydrogen-bonding motif are two competing supramolecular synthons that a molecule possessing both carboxylic acid and pyridine functional groups could form in the solid state. Their coexistence has been observed but for the molecules with the molar ratio of carboxylic acid and pyridine groups being greater than 1:1. In this crystal engineering study, 2-[phenyl(propyl)amino]nicotinic acid with a 1:1 molar ratio of these two functional groups was discovered to have two polymorphs, in which one consists of unique hydrogen-bonded tetramer units bearing both acid acid and acid pyridine hydrogen-bonding motifs, while the other is composed of acid pyridine hydrogen-bonded chains. Quantum mechanical calculations were employed to unravel the essence of the coexistence of the two vying counterparts as well as the origins of the tetramer and chain structures.
C1 [Long, Sihui] Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
   [Zhou, Panpan] Lanzhou Univ, Dept Chem, Lanzhou 730000, Peoples R China.
   [Parkin, Sean] Univ Kentucky, Dept Chem, Lexington, KY 40536 USA.
   [Li, Tonglei] Purdue Univ, Dept Ind & Phys Pharm, W Lafayette, IN 47907 USA.
RP Li, TL (reprint author), Purdue Univ, Dept Ind & Phys Pharm, W Lafayette, IN 47907 USA.
EM tonglei@purdue.edu
FU NSF [DMR-1006364]
FX The research was supported by NSF (DMR-1006364).
CR AAKEROY CB, 1993, CHEM SOC REV, V22, P397, DOI 10.1039/cs9932200397
   Atwood JL, 2002, SCIENCE, V298, P1000, DOI 10.1126/science.1077591
   BERNSTEIN J, 1995, ANGEW CHEM INT EDIT, V34, P1555, DOI 10.1002/anie.199515551
   Bernstein, 2011, J CRYST GROWTH, V11, P632, DOI DOI 10.1021/CG1013335
   Boiadjiev SE, 2000, J AM CHEM SOC, V122, P11328, DOI 10.1021/ja002069c
   Dalgarno SJ, 2007, CHEM SOC REV, V36, P236, DOI 10.1039/b606047c
   Dannenberg J.J., 2010, J AM CHEM SOC, V132, P3229
   Desiraju GR, 2002, ACCOUNTS CHEM RES, V35, P565, DOI 10.1021/ar010054t
   ETTER MC, 1991, J PHYS CHEM-US, V95, P4601, DOI 10.1021/j100165a007
   Feldman KS, 1997, J ORG CHEM, V62, P8814, DOI 10.1021/jo9714167
   FOSTER JP, 1980, J AM CHEM SOC, V102, P7211, DOI 10.1021/ja00544a007
   Fourmigue M, 2009, CURR OPIN SOLID ST M, V13, P36, DOI 10.1016/j.cossms.2009.05.001
   Geerlings P, 2003, CHEM REV, V103, P1793, DOI 10.1021/cr990029p
   Gilli G, 2000, J MOL STRUCT, V552, P1, DOI 10.1016/S0022-2860(00)00454-3
   GILLI G, 1989, J AM CHEM SOC, V111, P1023, DOI 10.1021/ja00185a035
   Grabowski SJ, 2009, CROAT CHEM ACTA, V82, P185
   Hoeben FJM, 2005, CHEM REV, V105, P1491, DOI 10.1021/cr030070z
   HUNTER CA, 1994, CHEM SOC REV, V23, P101, DOI 10.1039/cs9942300101
   Li TL, 2011, CRYSTENGCOMM, V13, P6356, DOI 10.1039/c1ce05967j
   Liu SB, 2009, ACTA PHYS-CHIM SIN, V25, P590, DOI 10.3866/PKU.WHXB20090332
   Long SH, 2008, CRYST GROWTH DES, V8, P4006, DOI 10.1021/cg800123z
   Long SH, 2008, CRYST GROWTH DES, V8, P3137, DOI 10.1021/cg800339h
   Long SH, 2010, CRYST GROWTH DES, V10, P2465, DOI 10.1021/cg100227s
   Long SH, 2009, CRYST GROWTH DES, V9, P4993, DOI 10.1021/cg900786b
   Macgillivray LR, 2008, ACCOUNTS CHEM RES, V41, P280, DOI 10.1021/ar700145r
   Metrangolo P, 2008, ANGEW CHEM INT EDIT, V47, P6114, DOI 10.1002/anie.200800128
   Meyer EA, 2003, ANGEW CHEM INT EDIT, V42, P1210, DOI 10.1002/anie.200390319
   Morell C, 2005, J PHYS CHEM A, V109, P205, DOI 10.1021/jp046577a
   Mukherjee A, 2011, CHEM COMMUN, V47, P4090, DOI 10.1039/c0cc05857b
   Nangia A, 2008, ACCOUNTS CHEM RES, V41, P595, DOI 10.1021/ar700203k
   Papaefstathiou GS, 2001, CHEM COMMUN, P2462, DOI 10.1039/b106584j
   REED AE, 1988, CHEM REV, V88, P899, DOI 10.1021/cr00088a005
   Sreekanth BR, 2007, CHEM COMMUN, P2375, DOI 10.1039/b700082k
   Steiner T, 2002, ANGEW CHEM INT EDIT, V41, P48, DOI 10.1002/1521-3773(20020104)41:1<48::AID-ANIE48>3.0.CO;2-U
   Wheeler KA, 2012, CHEM COMMUN, V48, P519, DOI 10.1039/c1cc15068e
   White DP, 1999, J ORG CHEM, V64, P7707, DOI 10.1021/jo982405w
NR 36
TC 8
Z9 8
U1 2
U2 20
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1528-7483
EI 1528-7505
J9 CRYST GROWTH DES
JI Cryst. Growth Des.
PD JAN
PY 2014
VL 14
IS 1
BP 27
EP 31
DI 10.1021/cg401532j
PG 5
WC Chemistry, Multidisciplinary; Crystallography; Materials Science,
   Multidisciplinary
SC Chemistry; Crystallography; Materials Science
GA 284RC
UT WOS:000329337000006
DA 2018-03-20
ER

PT J
AU Zheng, ZJ
   Zhang, WF
   Sun, WQ
   Li, XJ
   Duan, JH
   Cui, JJ
   Feng, ZQ
   Mansour, HM
AF Zheng, Zengjuan
   Zhang, Weifen
   Sun, Weiqing
   Li, Xiaojian
   Duan, Jinghua
   Cui, Juanjuan
   Feng, Zhanqin
   Mansour, Heidi M.
TI Influence of the carboxymethyl chitosan anti-adhesion solution on the
   TGF-beta 1 in a postoperative peritoneal adhesion rat
SO JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE
LA English
DT Article
ID KERATINOCYTE GROWTH-FACTOR; N,O-CARBOXYMETHYL CHITOSAN; PERICARDIAL
   ADHESIONS; IN-VIVO; PREVENTION; MODEL; REDUCTION; HYDROGEL; AGENTS
AB The aim of this paper was to investigate the effect of carboxymethyl chitosan anti-adhesion solution on prevention of postsurgical adhesion. Forty adult male Wistar rats were randomly divided into three groups: 0.9 % normal saline solution (group A), hyaluronic acid gels (group B) and carboxymethyl chitosan anti-adhesion solution (group C). The animals were treated with normal saline, hyaluronic acid gels or carboxymethyl chitosan anti-adhesion solution at the time of surgery. After 2 or 3 weeks, the degree of adhesions and histological effects were determined. The adhesions in groups B and C were significantly decreased, and the levels of TGF-beta(1) and hydroxyproline in group C were significantly lower than that in group A (P < 0.05). The histopathology in group C showed fewer inflammatory cells and fibroblasts. Carboxymethyl chitosan anti-adhesion solution can effectively prevent postoperative adhesion which is a promising drug delivery system in the context of postsurgical anti-adhesion.
C1 [Zheng, Zengjuan; Zhang, Weifen; Cui, Juanjuan; Feng, Zhanqin] Weifang Med Univ, Coll Pharm & Biol Sci, Weifang 261053, Peoples R China.
   [Sun, Weiqing] Hangzhou Singclean Med Prod Co Ltd, Hang Zhou Western Lake, Hangzhou 311402, Zhejiang, Peoples R China.
   [Li, Xiaojian; Duan, Jinghua; Mansour, Heidi M.] Univ Kentucky, Drug Dev Div, Dept Pharmaceut Sci, Coll Pharm, Lexington, KY 40536 USA.
RP Mansour, HM (reprint author), Univ Kentucky, Drug Dev Div, Dept Pharmaceut Sci, Coll Pharm, 789 S Limestone St, Lexington, KY 40536 USA.
EM zwf2024@126.com; heidi.mansour@uky.edu
RI duan, jinghua/H-2738-2014
FU Shandong Provincial Natural Science Foundation, China [Y2008F15,
   ZR2012CM025]; Scientific and Technological Development Project of
   Shandong Province [2012YD18063]; Shandong Province Higher Educational
   Science, Technology Program [J11LF67]; Health Department of Shandong
   Province [2011HZ115]; Weifang Science and Technology Bureau Project
   [201232112]
FX The authors are grateful for the generous financial support from
   Shandong Provincial Natural Science Foundation, China (Y2008F15;
   ZR2012CM025) for grant support; The Scientific and Technological
   Development Project of Shandong Province (2012YD18063); Shandong
   Province Higher Educational Science, Technology Program (J11LF67) and
   the Health Department of Shandong Province (2011HZ115) and Weifang
   Science and Technology Bureau Project (201232112).
CR Attard JAP, 2007, CAN J SURG, V50, P291
   Axel S, 2006, DIGEST DIS SCI, V51, P566
   Chang J, 2000, PLAST RECONSTR SURG, V105, P148, DOI 10.1097/00006534-200001000-00025
   Daroz LRD, 2008, REV BRAS CIR CARDIOV, V23, P480, DOI 10.1590/S0102-76382008000400005
   Dong W, 2010, BIOMACROMOLECULES, V11, P1527, DOI 10.1021/bm100158p
   Filippo CD, 2012, MEDIAT INFLAMM, V2012, P1
   Francesko A, 2011, ADV BIOCHEM ENG BIOT, V125, P1, DOI [10.1007/10_2010_93, 10.10007/10_2010_93]
   HARRIS ES, 1995, SURGERY, V117, P663, DOI 10.1016/S0039-6060(95)80010-7
   Hong X, 2009, J SURG CONCEPTS PRAC, V14, P426
   Jiang DP, 2010, MED SCI MONITOR, V16, pBR250
   Jiang LY, 2009, J MATER SCI-MATER M, V20, P1645, DOI 10.1007/s10856-009-3720-6
   Kennedy R, 1996, SURGERY, V120, P866, DOI 10.1016/S0039-6060(96)80096-1
   Kutlay J, 2004, WORLD J SURG, V28, P662, DOI 10.1007/s00268-004-6825-6
   Lauder CIW, 2011, J SURG RES, V171, P877, DOI 10.1016/j.jss.2010.06.028
   Liakakos T, 2001, DIGEST SURG, V18, P260, DOI 10.1159/000050149
   Lopes JB, 2010, ANN THORAC SURG, V90, P566, DOI 10.1016/j.athoracsur.2010.03.086
   Lou WW, 2012, CARBOHYD POLYM, V90, P1024, DOI 10.1016/j.carbpol.2012.06.037
   Mulier KE, 2011, HERNIA, V15, P315, DOI 10.1007/s10029-010-0777-6
   Muzzarelli RAA, 2005, ADV POLYM SCI, V186, P151, DOI 10.1007/b136820
   Na NH, 2010, MACROMOL RES, V10, P1001
   NAIR SK, 1974, ARCH SURG-CHICAGO, V108, P849
   [潘仕荣 PAN ShiRong], 2006, [中国生物医学工程学报, Chinese Journal of Biomedical Engineering], V25, P277
   Park SH, 2011, MACROMOL RES, V19, P921, DOI 10.1007/s13233-011-0914-9
   RYAN CK, 1995, AM J SURG, V169, P154, DOI 10.1016/S0002-9610(99)80125-1
   Sahin M, 2007, INFLAMMATION, V30, P244, DOI 10.1007/s10753-007-9043-1
   Trowbridge JM, 2002, J BIOL CHEM, V277, P42815, DOI 10.1074/jbc.M204959200
   Wang DJ, 2010, CLIN INVEST MED, V33, pE254
   Wei CZ, 2009, BIOMATERIALS, V30, P5534, DOI 10.1016/j.biomaterials.2009.05.084
   Yang B, 2012, INT J NANOMED, V7, P547, DOI 10.2147/IJN.S26141
   Yang Z, 2012, J MATER SCI-MATER M, V23, P457, DOI 10.1007/s10856-011-4467-4
   Zhang ZP, 2010, J CLIN RES, V27, P101
   Zhou J, 2004, SURGERY, V135, P307, DOI 10.1016/j.surg.2003.07.005
   Zhou J, 2008, J THORAC CARDIOV SUR, V135, P777, DOI 10.1016/j.jtcvs.2007.09.033
NR 33
TC 9
Z9 11
U1 2
U2 18
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0957-4530
EI 1573-4838
J9 J MATER SCI-MATER M
JI J. Mater. Sci.-Mater. Med.
PD NOV
PY 2013
VL 24
IS 11
BP 2549
EP 2559
DI 10.1007/s10856-013-4981-7
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 239TZ
UT WOS:000326049900007
PM 23820936
DA 2018-03-20
ER

PT J
AU Yu, CG
   Oistilli, CK
   Dayaram, K
   Iqbal, H
   Sands, M
   Geddes, JW
AF Yu, Chen-Guang
   Oistilli, Christina K.
   Dayaram, Kavi
   Iqbal, Hina
   Sands, Madison
   Geddes, James W.
TI FLUBENDAZOLE ANTIMITOTIC THERAPY TARGETING PROLIFERATION OF B CELLS AND
   ASTROCYTES FOR SPINAL CORD INJURY
SO JOURNAL OF NEUROTRAUMA
LA English
DT Meeting Abstract
CT 35th Annual National Neurotrauma Symposium
CY JUL 07-12, 2017
CL Snowbird, UT
DE flubendazole; B cells; astrocytes; spinal cord injury; neuropathic pain;
   paralysis
C1 [Yu, Chen-Guang; Oistilli, Christina K.; Dayaram, Kavi; Iqbal, Hina; Sands, Madison; Geddes, James W.] Univ Kentucky, Neurosci Spinal Cord & Brain Injury Res Ctr SCBIR, Lexington, KY 40506 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0897-7151
EI 1557-9042
J9 J NEUROTRAUM
JI J. Neurotrauma
PD JUL 1
PY 2017
VL 34
IS 13
MA A22-12
BP A79
EP A79
PG 1
WC Critical Care Medicine; Clinical Neurology; Neurosciences
SC General & Internal Medicine; Neurosciences & Neurology
GA EZ2HM
UT WOS:000404530400213
DA 2018-03-20
ER

PT J
AU Howard, MD
   Jay, M
   Dziublal, TD
   Lu, XL
AF Howard, Melissa D.
   Jay, Michael
   Dziublal, Thomas D.
   Lu, Xiuling
TI PEGylation of nanocarrier drug delivery systems: State of the art
SO JOURNAL OF BIOMEDICAL NANOTECHNOLOGY
LA English
DT Review
DE poly(ethylene glycol); stealth; nanoparticles; liposomes; micelles; drug
   delivery
ID SOLID LIPID NANOPARTICLES; LONG-CIRCULATING NANOPARTICLES; MONONUCLEAR
   PHAGOCYTE SYSTEM; PROTEIN SURFACE INTERACTIONS; GRAFTED POLYETHYLENE
   OXIDE; IN-VITRO CHARACTERIZATION; TUMOR-TARGETED DELIVERY; WATER-SOLUBLE
   DRUGS; POLY(ETHYLENE GLYCOL); POLYCYANOACRYLATE NANOPARTICLES
AB "PEGylation" has become the most widely used method for imparting stealth properties to drug nanocarriers. PEGylation of nanoparticles provides a steric barrier to the adsorption of opsonin proteins due to the neutrality, hydrophilicity, flexibility, and capacity for hydration of the PEG moiety. PEGylation of particle surfaces can be achieved by simple adsorption or through the covalent attachment of PEG to activated functional groups on the surface of the particles. PEG molecules have also been modified to enhance their uptake by specific targets (e.g., tumors) and to achieve the controlled release of entrapped therapeutic agents. Accompanying the prevalence of PEGylation has been the development of a wide variety of characterization techniques and the increasing use of mathematical modeling to guide formulation development. This review summarizes the theories behind PEGylation, PEGylation methodology, the characterization of PEGylated particles, and related mathematical modeling as well as how it can be utilized in the optimization of nanocarrier drug delivery systems. The current successes and failures of PEGylation are evaluated in order to provide a vision for the future of nanocarrier PEGylation and nanomedicine in general.
C1 [Howard, Melissa D.; Jay, Michael; Lu, Xiuling] Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
   [Dziublal, Thomas D.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40536 USA.
RP Lu, XL (reprint author), Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
RI Xu, Qingguo/C-1962-2014
OI Xu, Qingguo/0000-0003-3191-0771
CR ALLEN TM, 1994, ADV DRUG DELIVER REV, V13, P285, DOI 10.1016/0169-409X(94)90016-7
   Arima Y, 2008, BIOMATERIALS, V29, P551, DOI 10.1016/j.biomaterials.2007.10.015
   AURIOLA SOK, 1993, J PHARMACEUT BIOMED, V11, P1027, DOI 10.1016/0731-7085(93)80065-9
   BAZILE D, 1995, J PHARM SCI, V84, P493, DOI 10.1002/jps.2600840420
   BERGSTROM K, 1994, J BIOMAT SCI-POLYM E, V6, P123
   Bocca C, 1998, INT J PHARM, V175, P185, DOI 10.1016/S0378-5173(98)00282-8
   Bondi ML, 2007, DRUG DELIV, V14, P61, DOI 10.1080/10717540600739914
   Brigger I, 2000, PHARMACEUT RES, V17, P1124, DOI 10.1023/A:1026465931525
   BRINDLEY A, 1995, J COLLOID INTERF SCI, V171, P150, DOI 10.1006/jcis.1995.1161
   Bummer PM, 2004, CRIT REV THER DRUG, V21, P1
   Calvo P, 2001, PHARMACEUT RES, V18, P1157, DOI 10.1023/A:1010931127745
   Champion JA, 2007, J CONTROL RELEASE, V121, P3, DOI 10.1016/j.jconrel.2007.03.022
   Chavanpatil MD, 2007, J PHARM SCI-US, V96, P3379, DOI 10.1002/jps.20961
   CHONN A, 1991, J IMMUNOL, V146, P4234
   CHONN A, 1992, J BIOL CHEM, V267, P18759
   CHURAEV NV, 1991, COLLOID SURFACE, V59, P71, DOI 10.1016/0166-6622(91)80238-J
   COLEMAN DL, 1982, J BIOMED MATER RES, V16, P381, DOI 10.1002/jbm.820160407
   Craparo EF, 2006, BIOMACROMOLECULES, V7, P3083, DOI 10.1021/bm060570c
   DADASHZADEH S, 2007, INT J PHARMACEUT, V23, P23
   Devalapally H, 2007, CANCER CHEMOTH PHARM, V59, P477, DOI 10.1007/s00280-006-0287-5
   DEVINE DV, 1994, BBA-BIOMEMBRANES, V1191, P43, DOI 10.1016/0005-2736(94)90231-3
   DUNN SE, 1994, PHARMACEUT RES, V11, P1016, DOI 10.1023/A:1018939521589
   DZIUBLA T, 2006, NANOPARTICULATES DRU
   Dziubla TD, 2005, J CONTROL RELEASE, V102, P427, DOI 10.1016/j.jconrel.2004.10.017
   Dziubla TD, 2008, BIOMATERIALS, V29, P215, DOI 10.1016/j.biomaterials.2007.09.023
   Fernandez-Carballido A, 2008, INT J PHARM, V352, P50, DOI 10.1016/j.ijpharm.2007.10.007
   Francis GE, 1996, J DRUG TARGET, V3, P321, DOI 10.3109/10611869608996824
   Fundaro A, 2000, PHARMACOL RES, V42, P337, DOI 10.1006/phrs.2000.0695
   GABIZON A, 1988, P NATL ACAD SCI USA, V85, P6949, DOI 10.1073/pnas.85.18.6949
   Gabizon A, 1996, J DRUG TARGET, V3, P391, DOI 10.3109/10611869608996830
   Garcia-Fuentes M, 2004, LANGMUIR, V20, P8839, DOI 10.1021/la049505j
   Gauchel G, 2003, J CHROMATOGR B, V787, P271, DOI 10.1016/S1570-0232(02)00925-X
   Gbadamosi JK, 2002, FEBS LETT, V532, P338, DOI 10.1016/S0014-5793(02)03710-9
   Gennes PA, 1987, ADV COLLOID INTERFAC, V27, P189
   GOMBOTZ WR, 1991, J BIOMED MATER RES, V25, P1547, DOI 10.1002/jbm.820251211
   Gref R, 2000, COLLOID SURFACE B, V18, P301, DOI 10.1016/S0927-7765(99)00156-3
   GREF R, 1994, SCIENCE, V263, P1600, DOI 10.1126/science.8128245
   Harashima H, 1996, PHARMACEUT RES, V13, P1049, DOI 10.1023/A:1016058724452
   Harashima H, 1998, ADV DRUG DELIVER REV, V32, P61, DOI 10.1016/S0169-409X(97)00132-4
   HARPER GR, 1991, BIOMATERIALS, V12, P695, DOI 10.1016/0142-9612(91)90119-U
   Harris TJ, 2006, ANGEW CHEM INT EDIT, V45, P3161, DOI 10.1002/anie.200600259
   Hobbs SK, 1998, P NATL ACAD SCI USA, V95, P4607, DOI 10.1073/pnas.95.8.4607
   HRISTOVA K, 1994, J COLLOID INTERF SCI, V168, P302, DOI 10.1006/jcis.1994.1424
   Hu FX, 2006, BIOMACROMOLECULES, V7, P809, DOI 10.1021/bm050870e
   HUANG G, 2007, INT J PHARMACEUT, V23, P23
   ILLUM L, 1986, INT J PHARM, V29, P53
   ISHIDA T, 2007, INT J PHARMACEUT, V9, P9
   Ishida T, 2008, J CONTROL RELEASE, V126, P162, DOI 10.1016/j.jconrel.2007.11.009
   Jain TK, 2005, MOL PHARMACEUT, V2, P194, DOI 10.1021/mp0500014
   JANSEN B, 1984, J BIOMED MATER RES, V18, P655, DOI 10.1002/jbm.820180607
   JEON SI, 1991, J COLLOID INTERF SCI, V142, P159, DOI 10.1016/0021-9797(91)90044-9
   JEON SI, 1991, J COLLOID INTERF SCI, V142, P149, DOI 10.1016/0021-9797(91)90043-8
   Jie P, 2005, J CONTROL RELEASE, V110, P20, DOI 10.1016/j.jconrel.2005.09.011
   Kataoka K, 2000, J CONTROL RELEASE, V64, P143, DOI 10.1016/S0168-3659(99)00133-9
   KENWORTHY AK, 1995, BIOPHYS J, V68, P1921, DOI 10.1016/S0006-3495(95)80369-3
   Khalil IA, 2007, GENE THER, V14, P682, DOI 10.1038/sj.gt.3302910
   Khosravi-Darani K, 2007, MICRON, V38, P804, DOI 10.1016/j.micron.2007.06.009
   Kiss E, 1987, PROG COLLOID POLYM S, V73, P113
   Lasic DD, 1997, ACS SYM SER, V680, P31
   Li LH, 2008, BIOMATERIALS, V29, P1509, DOI 10.1016/j.biomaterials.2007.11.014
   Li SD, 2008, MOL THER, V16, P163, DOI 10.1038/sj.mt.6300323
   Li YP, 2001, ACTA PHARMACOL SIN, V22, P645
   Liu D, 1995, BBA-BIOMEMBRANES, V1240, P277, DOI 10.1016/0005-2736(95)00184-0
   LIU DX, 1995, BBA-BIOMEMBRANES, V1235, P140, DOI 10.1016/0005-2736(95)00005-N
   Liu F, 1996, BBA-BIOMEMBRANES, V1278, P5, DOI 10.1016/0005-2736(95)00196-4
   Liu M, 2004, J CHROMATOGR A, V1046, P121, DOI 10.1016/j.chroma.2004.06.005
   Liu YY, 2007, INT J CANCER, V120, P2527, DOI 10.1002/ijc.22709
   LLANOS GR, 1993, J BIOMAT SCI-POLYM E, V4, P381
   Loch-Neckel G, 2007, J PHARM PHARMACOL, V59, P1359, DOI 10.1211/jpp.59.10.0005
   Lu XL, 2008, AAPS J, V10, P133, DOI 10.1208/s12248-008-9013-z
   Manjunath K, 2005, J CONTROL RELEASE, V107, P215, DOI 10.1016/j.jconrel.2005.06.006
   MILNER ST, 1991, SCIENCE, V251, P905, DOI 10.1126/science.251.4996.905
   MILNER ST, 1988, EUROPHYS LETT, V5, P413, DOI 10.1209/0295-5075/5/5/006
   MILNER ST, 1988, EUROPHYS LETT, V7, P695, DOI 10.1209/0295-5075/7/8/005
   MILNER ST, 1988, MACROMOLECULES, V21, P2610, DOI 10.1021/ma00186a051
   Moghimi S. Moein, 1993, Biochemical Society Transactions, V21, p128S
   MOGHIMI SM, 1988, FEBS LETT, V233, P143, DOI 10.1016/0014-5793(88)81372-3
   MOGHIMI SM, 1989, BIOCHIM BIOPHYS ACTA, V984, P379
   Moghimi SM, 1998, ADV DRUG DELIVER REV, V32, P45, DOI 10.1016/S0169-409X(97)00131-2
   MOGHIMI SM, 1989, BIOCHIM BIOPHYS ACTA, V984, P384
   MOGHIMI SM, 1993, BIOCHIM BIOPHYS ACTA, V1179, P157, DOI 10.1016/0167-4889(93)90137-E
   Moghimi SM, 2003, PROG LIPID RES, V42, P463, DOI 10.1016/S0163-7827(03)00033-X
   Moore NW, 2006, LANGMUIR, V22, P8485, DOI 10.1021/la0608462
   Mosqueira VCF, 1999, J DRUG TARGET, V7, P65, DOI 10.3109/10611869909085493
   MUIR IS, 1991, BIOCHEM SOC T, V19, pS329, DOI 10.1042/bst019329s
   Muller RH, 1997, PHARMACEUT RES, V14, P458, DOI 10.1023/A:1012043315093
   Muller RH, 2000, EUR J PHARM BIOPHARM, V50, P161, DOI 10.1016/S0939-6411(00)00087-4
   Mumper RJ, 2003, J DISPER SCI TECHNOL, V24, P569, DOI 10.1081/DIS-120021814
   NAGAOKA S, 1984, POLYM BIOMATERIALS, P361
   Neal JC, 1998, J PHARM SCI, V87, P1242, DOI 10.1021/js970462j
   Neu M, 2007, J CONTROL RELEASE, V124, P69, DOI 10.1016/j.jconrel.2007.08.009
   Northfelt DW, 1998, J CLIN ONCOL, V16, P2445, DOI 10.1200/JCO.1998.16.7.2445
   Otsuka H, 2003, ADV DRUG DELIVER REV, V55, P403, DOI 10.1016/S0169-409X(02)00226-0
   Owens DE, 2006, INT J PHARM, V307, P93, DOI 10.1016/j.ijpharm.2005.10.010
   Owens DE, 2007, J BIOMED MATER RES A, V83A, P692, DOI 10.1002/jbm.a.31284
   Oyewumi MO, 2004, J CONTROL RELEASE, V95, P613, DOI 10.1016/j.jconrel.2004.01.002
   PASQUALI I, 2008, INT J PHARMACEUT, V17, P17
   Peracchia MT, 1998, PHARMACEUT RES, V15, P550, DOI 10.1023/A:1011973625803
   Peracchia MT, 1999, J CONTROL RELEASE, V60, P121, DOI 10.1016/S0168-3659(99)00063-2
   Peracchia MT, 1999, BIOMATERIALS, V20, P1269, DOI 10.1016/S0142-9612(99)00021-6
   Photos PJ, 2003, J CONTROL RELEASE, V90, P323, DOI 10.1016/S0168-3659(03)00201-3
   Pirollo KF, 2007, CANCER RES, V67, P2938, DOI 10.1158/0008-5472.CAN-06-4535
   Puri S, 2008, J CONTROL RELEASE, V125, P59, DOI 10.1016/j.jconrel.2007.09.009
   Ricci M, 2004, INT J PHARM, V275, P61, DOI 10.1016/j.ijpharm.2004.01.030
   Romberg B, 2008, PHARM RES, V25, P55, DOI 10.1007/s11095-007-9348-7
   Sahoo SK, 2003, DRUG DISCOV TODAY, V8, P1112, DOI 10.1016/S1359-6446(03)02903-9
   Sawant RM, 2006, BIOCONJUGATE CHEM, V17, P943, DOI 10.1021/bc060080h
   Semple SC, 1998, ADV DRUG DELIVER REV, V32, P3, DOI 10.1016/S0169-409X(97)00128-2
   Sengupta S, 2005, NATURE, V436, P568, DOI 10.1038/nature03794
   Sheth SR, 1997, P NATL ACAD SCI USA, V94, P8399, DOI 10.1073/pnas.94.16.8399
   Shi B, 2006, J PHARM SCI-US, V95, P1873, DOI 10.1002/jps.20491
   Silva GA, 2007, SURG NEUROL, V67, P113, DOI 10.1016/j.surneu.2006.08.033
   Simone EA, 2007, BIOMACROMOLECULES, V8, P3914, DOI 10.1021/bm700888h
   Sinha R, 2006, MOL CANCER THER, V5, P1909, DOI 10.1158/1535-7163.MCT-06-0141
   Sofia SJ, 1998, MACROMOLECULES, V31, P5059, DOI 10.1021/ma971016l
   Steenpass T, 2006, BBA-BIOMEMBRANES, V1758, P20, DOI 10.1016/j.bbamen.2005.12.010
   STOLNIK S, 1995, ADV DRUG DELIVER REV, V16, P195, DOI 10.1016/0169-409X(95)00025-3
   STORM G, 1995, ADV DRUG DELIVER REV, V17, P31, DOI 10.1016/0169-409X(95)00039-A
   Studart AR, 2007, LANGMUIR, V23, P1081, DOI 10.1021/la062042s
   SUZAWA T, 1991, ADV COLLOID INTERFAC, V35, P139, DOI 10.1016/0001-8686(91)80021-B
   Tiwari Sandip B., 2006, Current Drug Delivery, V3, P219, DOI 10.2174/156720106776359230
   Torchilin VP, 2007, BIOCHEM SOC T, V35, P816, DOI 10.1042/BST0350816
   Torchilin VP, 2007, PHARM RES-DORDR, V24, P1, DOI 10.1007/s11095-006-9132-0
   Torchilin VP, 2007, AAPS J, V9, pE128, DOI 10.1208/aapsj0902015
   Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P6039, DOI 10.1073/pnas.0931428100
   TORCHILIN VP, 1994, BBA-BIOMEMBRANES, V1195, P11, DOI 10.1016/0005-2736(94)90003-5
   Torchilin VP, 2001, J CONTROL RELEASE, V73, P137, DOI 10.1016/S0168-3659(01)00299-1
   Torchilin VP, 1998, J MICROENCAPSUL, V15, P1, DOI 10.3109/02652049809006831
   Ugazio E, 2002, INT J PHARM, V241, P341, DOI 10.1016/S0378-5173(02)00268-5
   Uner M, 2007, INT J NANOMED, V2, P289
   Vittaz M, 1996, BIOMATERIALS, V17, P1575, DOI 10.1016/0142-9612(95)00322-3
   Vonarbourg A, 2006, BIOMATERIALS, V27, P4356, DOI 10.1016/j.biomaterials.2006.03.039
   Wagner E, 2007, EXPERT OPIN BIOL TH, V7, P587, DOI 10.1517/14712598.7.5.587
   Walsh M, 2006, MOL PHARMACEUT, V3, P644, DOI 10.1021/mp0600034
   Webb MS, 1998, BBA-BIOMEMBRANES, V1372, P272, DOI 10.1016/S0005-2736(98)00077-7
   Zabaleta V, 2007, J PHARMACEUT BIOMED, V44, P1072, DOI 10.1016/j.jpba.2007.05.006
   Zahr AS, 2006, LANGMUIR, V22, P8178, DOI 10.1021/la060951b
   Zhang L, 2008, CLIN PHARMACOL THER, V83, P761, DOI 10.1038/sj.clpt.6100400
NR 138
TC 86
Z9 90
U1 6
U2 104
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381-0751 USA
SN 1550-7033
EI 1550-7041
J9 J BIOMED NANOTECHNOL
JI J. Biomed. Nanotechnol.
PD JUN
PY 2008
VL 4
IS 2
BP 133
EP 148
DI 10.1166/jbn.2008.021
PG 16
WC Nanoscience & Nanotechnology; Materials Science, Biomaterials
SC Science & Technology - Other Topics; Materials Science
GA 328JH
UT WOS:000257794200002
DA 2018-03-20
ER

PT J
AU Knecht, LD
   Ali, N
   Wei, YN
   Hilt, JZ
   Daunert, S
AF Knecht, Leslie D.
   Ali, Nur
   Wei, Yinan
   Hilt, J. Zach
   Daunert, Sylvia
TI Nanoparticle-Mediated Remote Control of Enzymatic Activity
SO ACS NANO
LA English
DT Article
DE dehalogenase; hydrogel nanocomposites; remote actuation; alternating
   magnetic field
ID IRON-OXIDE NANOPARTICLES; MAGNETIC-HYDROGEL NANOCOMPOSITES; BIOMEDICAL
   APPLICATIONS; GOLD NANOPARTICLES; CANCER-THERAPY; RELEASE; DNA;
   NANORODS; NANOSHELLS; DELIVERY
AB Nanomaterials have found numerous applications as tunable, remotely controlled platforms for drug delivery, hyperthermia cancer treatment, and various other biomedical applications. The basis for the interest lies in their unique properties achieved at the nanoscale that can be accessed via remote stimuli. These properties could then be exploited to simultaneously activate secondary systems that are not remotely actuatable. In this work, iron oxide nanoparticles are encapsulated in a bisacrylamide cross-linked polyacrylamide hydrogel network along with a model dehalogenase enzyme, L-2-HAD(ST). This thermophilic enzyme is activated at elevated temperatures and his been shown to have optimal activity at 70 degrees C. By exposing the Fe3O4 nanoparticles to a remote stimulus, an alternating magnetic field (AMF), enhanced system heating can be achieved, thus remotely activating the enzyme. The internal heating of the nanocomposite hydrogel network in the AMF results in a 2-fold increase in enzymatic activity as compared to the same hydrogel heated externally In a water bath, suggesting that the internal heating of the nanoparticles is more efficient than the diffusion-limited heating of the water bath. This system may prove useful for remote actuation of biomedical and environmentally relevant enzymes and find applications in a variety of fields.
C1 [Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Ali, Nur] Paul Laurence Dunbar High Sch, Lexington, KY 40502 USA.
   [Knecht, Leslie D.] Univ Miami, Dept Chem, Miami, FL 33136 USA.
   [Wei, Yinan] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
   [Daunert, Sylvia] Univ Miami, Miller Sch Med, Dept Biochem & Mol Biol, Miami, FL 33136 USA.
RP Hilt, JZ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM hilt@uky.edu; sdaunert@med.miami.edu
FU National Science Foundation [ECC-08017788, DGE-0653710]; National
   Institute of Environmental Health Sciences [P42ES07380]
FX The authors would like to thank the National Science Foundation Grant
   ECC-08017788 and the National Institute of Environmental Health Sciences
   Grant P42ES07380 for funding this work. S.D. thanks the University of
   Kentucky for a Gill Eminent Professorship and the Miller School of
   Medicine of the University of Miami for the Lucille P. Markey Chair in
   Biochemistry and Molecular Biology. L.D.K. would like to thank the
   National Science Foundation Integrative Graduate Education Research
   Traineeship (Grant DGE-0653710).
CR Al Faraj A, 2012, RADIOLOGY, V263, P169, DOI 10.1148/radiol.11111329
   Alkilany AM, 2012, ADV DRUG DELIVER REV, V64, P190, DOI 10.1016/j.addr.2011.03.005
   Bachas-Daunert PG, 2009, APPL BIOCHEM BIOTECH, V159, P382, DOI 10.1007/s12010-009-8589-9
   Bachas-Daunert PG, 2009, ANAL BIOANAL CHEM, V395, P1173, DOI 10.1007/s00216-009-3057-5
   Burtea C, 2011, CONTRAST MEDIA MOL I, V6, P236, DOI 10.1002/cmmi.423
   Cardenas-Fernandez M, 2012, BIOCHEM ENG J, V63, P15, DOI 10.1016/j.bej.2012.01.009
   Cude MP, 2011, ECS TRANSACTIONS, V33, P79, DOI 10.1149/1.3583517
   Dreaden EC, 2012, CHEM SOC REV, V41, P2740, DOI 10.1039/c1cs15237h
   Fabbro A, 2012, ACS NANO, V6, P2041, DOI 10.1021/nn203519r
   Frimpong RA, 2007, J BIOMED MATER RES A, V80A, P1, DOI 10.1002/jbm.a.30962
   Grosova Z, 2008, BIOTECHNOL LETT, V30, P763, DOI 10.1007/s10529-007-9606-0
   Hamad-Schifferli K, 2002, NATURE, V415, P152, DOI 10.1038/415152a
   Hao R, 2010, ADV MATER, V22, P2729, DOI 10.1002/adma.201000260
   Haraguchi K, 2002, ADV MATER, V14, P1120, DOI 10.1002/1521-4095(20020816)14:16<1120::AID-ADMA1120>3.0.CO;2-9
   Hilt JZ, 2006, CHEM MATER, V18, P5869, DOI 10.1021/cm061343k
   Huschka R, 2011, J AM CHEM SOC, V133, P12247, DOI 10.1021/ja204578e
   Liedl T, 2007, SMALL, V3, P1688, DOI 10.1002/smll.200700366
   Miyako E, 2009, LAB CHIP, V9, P788, DOI 10.1039/b816201h
   Morton JG, 2010, METHODS MOL BIOL, V624, P101, DOI 10.1007/978-1-60761-609-2_7
   Ntziachristos V, 2002, OPT LETT, V27, P1652, DOI 10.1364/OL.27.001652
   Pan Y, 2012, CHEM SOC REV, V41, P2912, DOI 10.1039/c2cs15315g
   Pardo-Yissar V, 2001, ADV MATER, V13, P1320, DOI 10.1002/1521-4095(200109)13:17<1320::AID-ADMA1320>3.0.CO;2-8
   Park JH, 2010, P NATL ACAD SCI USA, V107, P981, DOI 10.1073/pnas.0909565107
   Ren YH, 2011, BMC BIOTECHNOL, V11, DOI 10.1186/1472-6750-11-63
   Satarkar NS, 2008, J CONTROL RELEASE, V130, P246, DOI 10.1016/j.jconrel.2008.06.008
   Satarkar NS, 2011, AICHE J, V57, P852, DOI 10.1002/aic.12309
   Satarkar NS, 2010, J APPL POLYM SCI, V117, P1813, DOI 10.1002/app.32138
   Satarkar NS, 2010, SOFT MATTER, V6, P2364, DOI 10.1039/b925218p
   Satarkar NS, 2009, LAB CHIP, V9, P1773, DOI 10.1039/b822694f
   Schroeder A, 2012, NANO LETT, V12, P2685, DOI 10.1021/nl2036047
   Stanley SA, 2012, SCIENCE, V336, P604, DOI 10.1126/science.1216753
   Tartaj P, 2003, J PHYS D APPL PHYS, V36, pR182, DOI 10.1088/0022-3727/36/13/202
   Thomas CR, 2010, J AM CHEM SOC, V132, P10623, DOI 10.1021/ja1022267
   Tietze R, 2012, NANOMEDICINE-UK, V7, P447, DOI [10.2217/NNM.12.10, 10.2217/nnm.12.10]
   Wei B, 2008, ANGEW CHEM INT EDIT, V47, P331, DOI 10.1002/anie.200704143
   Wijaya A, 2009, ACS NANO, V3, P80, DOI 10.1021/nn800702n
   Zadrazil A, 2012, SOFT MATTER, V8, P1811, DOI 10.1039/c1sm06707a
   Zhao XL, 2006, NEW J CHEM, V30, P915, DOI 10.1039/b601069e
NR 38
TC 16
Z9 16
U1 7
U2 121
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936-0851
J9 ACS NANO
JI ACS Nano
PD OCT
PY 2012
VL 6
IS 10
BP 9079
EP 9086
DI 10.1021/nn303308v
PG 8
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA 024FW
UT WOS:000310096100068
PM 22989219
OA green_accepted
DA 2018-03-20
ER

PT J
AU Meenach, SA
   Anderson, KW
   Hilt, JZ
   McGarry, RC
   Mansour, HM
AF Meenach, Samantha A.
   Anderson, Kimberly W.
   Hilt, J. Zach
   McGarry, Ronald C.
   Mansour, Heidi M.
TI Characterization and aerosol dispersion performance of advanced
   spray-dried chemotherapeutic PEGylated phospholipid particles for dry
   powder inhalation delivery in lung cancer
SO EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE Dry powder inhaler (DPI); Respiratory drug delivery; Biocompatible
   biodegradable lipopolymers; Nanotechnology; Nanomedicine; Lung
   surfactant
ID PULMONARY DRUG-DELIVERY; PHYSICOCHEMICAL CHARACTERIZATION;
   MULTIFUNCTIONAL PARTICLES; THERAPEUTIC EFFECTIVENESS; POLY(ETHYLENE
   GLYCOL); NANOCARRIER SYSTEMS; PLGA MICROPARTICLES; NANOPARTICLES;
   PACLITAXEL; NANOMEDICINE
AB Pulmonary inhalation chemotherapeutic drug delivery offers many advantages for lung cancer patients in comparison to conventional systemic chemotherapy. Inhalable particles are advantageous in their ability to deliver drug deep in the lung by utilizing optimally sized particles and higher local drug dose delivery. In this work, spray-dried and co-spray dried inhalable lung surfactant-mimic PEGylated lipopolymers as microparticulate/nanoparticulate dry powders containing paclitaxel were rationally designed via organic solution advanced spray drying (no water) in closed-mode from dilute concentration feed solution. Dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylethanolamine poly(ethylene glycol) (DPPE-PEG) with varying PEG chain length were mixed with varying amounts of paclitaxel in methanol to produce co-spray dried microparticles and nanoparticles. Scanning electron microscopy showed the spherical particle morphology of the inhalable particles. Thermal analysis and X-ray powder diffraction confirmed the retention of the phospholipid bilayer structure in the solid-state following spray drying, the degree of solid-state molecular order, and solid-state phase transition behavior. The residual water content of the particles was very low as quantified analytically Karl Fisher titration. The amount of paclitaxel loaded into the particles was quantified which indicated high encapsulation efficiencies (43-99%). Dry powder aerosol dispersion performance was measured in vitro using the Next Generation Impactor (TM) (NGI (TM)) coupled with the Handihaler (R) dry powder inhaler device and showed mass median aerodynamic diameters in the range of 3.4-7 mu m. These results demonstrate that this novel microparticulate/nanoparticulate chemotherapeutic PEGylated phospholipid dry powder inhalation aerosol platform has great potential in lung cancer drug delivery. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Meenach, Samantha A.; Mansour, Heidi M.] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Drug Dev Div, Lexington, KY 40536 USA.
   [Meenach, Samantha A.; Anderson, Kimberly W.; Hilt, J. Zach] Univ Kentucky, Coll Engn, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Anderson, Kimberly W.; Hilt, J. Zach; Mansour, Heidi M.] Univ Kentucky, Ctr Membrane Sci, Lexington, KY 40506 USA.
   [McGarry, Ronald C.] Univ Kentucky, Coll Med, Dept Radiat Med, Lexington, KY 40506 USA.
RP Mansour, HM (reprint author), Univ Arizona, Coll Pharm, Skaggs Ctr Pharmaceut Sci, 1703 E Mabel St, Tucson, AZ 85712 USA.
EM mansour@pharmacy.arizona.edu
RI Meenach, Samantha/F-7542-2014
FU National Cancer Institute (NCI) [R25CA153954]; National Cancer Institute
   Cancer Nanotechnology Training Center (NCI-CNTC)
FX The authors gratefully acknowledge financial support from the National
   Cancer Institute (NCI) Grant Number R25CA153954 and a National Cancer
   Institute Cancer Nanotechnology Training Center (NCI-CNTC) Postdoctoral
   Traineeship awarded to SAM. The content is solely the responsibility of
   the authors and does not necessarily represent the official views of the
   National Cancer Institute or the National Institutes of Health. The
   authors thank Dr. Tonglei Li for XRPD and HSM access and Dr. J. Zach
   Hilt for ATR-FTIR access.
CR Alves GP, 2004, POWDER TECHNOL, V145, P139, DOI 10.1016/j.powtec.2004.06.008
   Arnold MM, 2007, J CONTROL RELEASE, V121, P100, DOI 10.1016/j.jconrel.2007.05.039
   Bosquillon C, 2001, J CONTROL RELEASE, V70, P329, DOI 10.1016/S0168-3659(00)00362-X
   Cartiera MS, 2010, MOL PHARMACEUT, V7, P86, DOI 10.1021/mp900138a
   Carvalho TC, 2011, J AEROSOL MED PULM D, V24, P61, DOI 10.1089/jamp.2009.0794
   Chow AHL, 2007, PHARM RES, V24, P411, DOI 10.1007/s11095-006-9174-3
   Coates A.L., 2006, DRUG ADM AEROSOL CHI
   Dunbar CA, 1998, KONA, V16, P7
   Edwards DA, 1998, J APPL PHYSIOL, V85, P379
   EDWARDS DA, 1995, J AEROSOL SCI, V26, P293, DOI 10.1016/0021-8502(94)00101-4
   Eldar-Boock A, 2011, BIOMATERIALS, V32, P3862, DOI 10.1016/j.biomaterials.2011.01.073
   Finlay Warren, 2008, ARLA RESP DEPOSITION
   Gagnadoux F, 2008, J AEROSOL MED PULM D, V21, P61, DOI 10.1089/jamp.2007.0656
   Ganguly S., 2008, J AEROSOL MED PULM D, V23, P181
   Gill KK, 2011, EUR J PHARM BIOPHARM, V79, P276, DOI 10.1016/j.ejpb.2011.04.017
   Gill S, 2007, J BIOMED NANOTECHNOL, V3, P107, DOI 10.1166/jbn.2007.015
   Hickey A. J., 2008, MODIFIED RELEASE DRU, P573
   Hickey AJ, 2009, MODERN PHARM, P191
   Hickey AJ, 2007, J PHARM SCI-US, V96, P1282, DOI 10.1002/jps.20916
   Ishihara K, 1998, J BIOMED MATER RES, V39, P323, DOI 10.1002/(SICI)1097-4636(199802)39:2<323::AID-JBM21>3.3.CO;2-0
   Kang E, 2007, J CONTROL RELEASE, V122, P261, DOI 10.1016/j.jconrel.2007.05.007
   KIKUCHI H, 1991, CHEM PHARM BULL, V39, P1522
   Labiris NR, 2003, BRIT J CLIN PHARMACO, V56, P600, DOI 10.1046/j.1365-2125.2003.01893.x
   Labiris NR, 2003, BRIT J CLIN PHARMACO, V56, P588, DOI 10.1046/j.1365-2125.2003.01892.x
   Lai SK, 2009, ADV DRUG DELIVER REV, V61, P158, DOI 10.1016/j.addr.2008.11.002
   Lai SK, 2009, ADV DRUG DELIVER REV, V61, P86, DOI 10.1016/j.addr.2008.09.012
   Lee JH, 2001, B KOR CHEM SOC, V22, P925
   Li X, 2011, PEDIATR PULM, P346
   Li XJ, 2011, AAPS PHARMSCITECH, V12, P1420, DOI 10.1208/s12249-011-9704-0
   Liggins RT, 1997, J PHARM SCI, V86, P1458, DOI 10.1021/js9605226
   Mansour H, 2001, LANGMUIR, V17, P6622, DOI 10.1021/la0108454
   Mansour HM, 2007, LANGMUIR, V23, P3809, DOI 10.1021/la063053o
   Mansour HM, 2007, J PHARM SCI-US, V96, P377, DOI 10.1002/jps.20810
   Mansour HM, 2010, INT J MOL SCI, V11, P3298, DOI 10.3390/ijms11093298
   Mansour HM, 2009, INT J NANOMED, V4, P299
   Mansour HM, 2011, LIPIDS NANOTECHNOLOG, P221
   Marupudi NI, 2007, EXPERT OPIN DRUG SAF, V6, P609, DOI 10.1517/14740338.6.5.609
   Meenach SA, 2013, INT J NANOMED, V8, P275, DOI 10.2147/IJN.S30724
   Zhang J, 2012, ACTA PHYS-CHIM SIN, V28, P290, DOI [10.1021/mp2003785, 10.3866/PKU.WHXB201112121]
   Pappalardo M, 2005, J THERM ANAL CALORIM, V80, P413, DOI 10.1007/s10973-005-0669-7
   Patton JS, 2007, NAT REV DRUG DISCOV, V6, P67, DOI 10.1038/nrd2153
   Rhee YS, 2011, INT J NANOTECHNOL, V8, P84, DOI 10.1504/IJNT.2011.037172
   Sharma S, 2001, J CLIN ONCOL, V19, P1839, DOI 10.1200/JCO.2001.19.6.1839
   Suarez S, 2000, Respir Care, V45, P652
   Sung JC, 2007, TRENDS BIOTECHNOL, V25, P563, DOI 10.1016/j.tibtech.2007.09.005
   Tang BC, 2010, BIOMATERIALS, V31, P339, DOI 10.1016/j.biomaterials.2009.09.033
   Tomoda K, 2009, COLLOID SURFACE B, V71, P177, DOI 10.1016/j.colsurfb.2009.02.001
   Tong HH, 2006, KONA, V24, P27
   TORMALA P, 1974, EUR POLYM J, V10, P519, DOI 10.1016/0014-3057(74)90201-8
   Aerosols, 2006, NAS SPRAYS MET DOS I, P2617
   Vaughn JM, 2006, EUR J PHARM BIOPHARM, V63, P95, DOI 10.1016/j.ejpb.2006.01.006
   Vehring R, 2007, J AEROSOL SCI, V38, P728, DOI 10.1016/j.jaerosci.2007.04.005
   Watts AB, 2008, DRUG DEV IND PHARM, V34, P913, DOI [10.1080/03639040802144211, 10.1080/03639040802144211 ]
   Wu X, 2013, INT J NANOMED, V8, P1269, DOI 10.2147/IJN.S40904
   Wu X, 2013, DRUG DES DEV THER, V7, P59, DOI [10.2147/DDDT.540166, 10.2147/DDDT.S40166]
   Wu XA, 2011, INT J NANOTECHNOL, V8, P115, DOI 10.1504/IJNT.2011.037173
   Yang T, 2007, J CONTROL RELEASE, V120, P169, DOI 10.1016/j.jconrel.2007.05.011
   Yang Y, 2009, BIOMATERIALS, V30, P1947, DOI 10.1016/j.biomaterials.2008.12.044
NR 58
TC 42
Z9 42
U1 6
U2 85
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0928-0987
EI 1879-0720
J9 EUR J PHARM SCI
JI Eur. J. Pharm. Sci.
PD JUL 16
PY 2013
VL 49
IS 4
BP 699
EP 711
DI 10.1016/j.ejps.2013.05.012
PG 13
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 196CV
UT WOS:000322751900030
PM 23707466
OA green_accepted
DA 2018-03-19
ER

PT J
AU Howard, MD
   Greineder, CF
   Hood, ED
   Muzykantov, VR
AF Howard, Melissa D.
   Greineder, Colin F.
   Hood, Elizabeth D.
   Muzykantov, Vladimir R.
TI Endothelial targeting of liposomes encapsulating SOD/catalase mimetic
   EUK-134 alleviates acute pulmonary inflammation
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Targeted drug delivery; Endothelial targeting; Liposomes; Inflammation;
   Antioxidant therapy; Antioxidant enzyme mimetic
ID ANGIOTENSIN-CONVERTING ENZYME; CELL-ADHESION MOLECULE-1; ISCHEMIC
   BRAIN-INJURY; SUPEROXIDE-DISMUTASE; OXIDATIVE STRESS; VASCULAR
   ENDOTHELIUM; N-ACETYLCYSTEINE; NADPH OXIDASES; IN-VIVO; CATALASE
AB Production of excessive levels of reactive oxygen species (ROS) in the vascular endothelium is a common pathogenic pathway in many dangerous conditions, including acute lung injury, ischemia-reperfusion, and inflammation. Ineffective delivery of antioxidants to the endothelium limits their utility for management of these conditions. In this study, we devised a novel translational antioxidant intervention targeted to the vascular endothelium using PEG-liposomes loaded with EUK-134 (EUK), a potent superoxide dismutase/catalasemimetic. EUK loaded into antibody-coated liposomes (size 197.8 +/- 4.5 nm diameter, PDI 0.179 +/- 0.066) exerted partial activity in the intact carrier, while full activity was recovered upon liposome disruption. For targeting we used antibodies (Abs) to platelet-endothelial cell adhesion molecule (PECAM-1). Both streptavidin-biotin and SATA/SMCC conjugation chemistries provided binding of 125-150 Ab molecules per liposome. Ab/EUK/liposomes, but not IgG/EUK/liposomes: i) bound to endothelial cells and inhibited cytokine-induced inflammatory activation in vitro; and, ii) accumulated in lungs after intravascular injection, providing >60% protection against pulmonary edema in endotoxin-challenged mice (vs <6% protection afforded by IgG/liposome/EUK counterpart). Since the design elements of this drug delivery system are already in clinical use (PEG-liposomes, antibodies, SATA/SMCC conjugation), it is an attractive candidate for translational interventions using antioxidant molecules such as EUK and other clinically acceptable drugs. (C) 2014 Elsevier B. V. All rights reserved.
C1 [Howard, Melissa D.; Greineder, Colin F.; Hood, Elizabeth D.; Muzykantov, Vladimir R.] Univ Penn, Perelman Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA.
   [Howard, Melissa D.; Greineder, Colin F.; Hood, Elizabeth D.; Muzykantov, Vladimir R.] Univ Penn, Ctr Targeted Therapeut & Translat Nanomed, Philadelphia, PA 19104 USA.
   [Greineder, Colin F.] Univ Penn, Perelman Sch Med, Dept Emergency Med, Philadelphia, PA 19104 USA.
RP Muzykantov, VR (reprint author), Univ Penn, Perelman Sch Med, Dept Pharmacol, TRC10-125,3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA.
EM muzykant@mail.med.upenn.edu
OI Greineder, Colin/0000-0001-9740-7672
FU NIH NHLBI [HL087036, HL073940]; University of Pennsylvania Hematology
   T32 Training Grant [T32 HL07439]
FX This work was supported by NIH NHLBI grants HL087036 and HL073940. MH
   acknowledges financial support from the University of Pennsylvania
   Hematology T32 Training Grant (Grant number T32 HL07439).
CR Adrian JE, 2010, J CONTROL RELEASE, V144, P341, DOI 10.1016/j.jconrel.2010.03.003
   Baker K, 1998, J PHARMACOL EXP THER, V284, P215
   Batinic-Haberle I, 2010, ANTIOXID REDOX SIGN, V13, P877, DOI 10.1089/ars.2009.2876
   Bernard GR, 1997, CHEST, V112, P164, DOI 10.1378/chest.112.1.164
   Christofidou-Solomidou M, 2003, AM J PHYSIOL-LUNG C, V285, pL283, DOI 10.1152/ajplung.00021.2003
   Christofidou-Solomidou Melpo, 2006, Treat Respir Med, V5, P47, DOI 10.2165/00151829-200605010-00004
   Conner EM, 1996, NUTRITION, V12, P274, DOI 10.1016/S0899-9007(96)00000-8
   Ding BS, 2009, AM J RESP CRIT CARE, V180, P247, DOI 10.1164/rccm.200809-1433OC
   Ding BS, 2006, MOL INTERV, V6, P98, DOI 10.1124/mi.6.2.7
   Fisher AB, 2009, ANTIOXID REDOX SIGN, V11, P1349, DOI [10.1089/ars.2008.2378, 10.1089/ARS.2008.2378]
   FLAHERTY JT, 1994, CIRCULATION, V89, P1982
   Guzik TJ, 2006, DRUG DISCOV TODAY, V11, P524, DOI 10.1016/j.drudis.2006.04.003
   Han JY, 2012, ACS NANO, V6, P8824, DOI 10.1021/nn302687n
   Han JY, 2011, J PHARMACOL EXP THER, V338, P82, DOI 10.1124/jpet.111.180620
   Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801
   Hood ED, 2012, J CONTROL RELEASE, V163, P161, DOI 10.1016/j.jconrel.2012.08.031
   Janssen-Heininger YMW, 2008, FREE RADICAL BIO MED, V45, P1, DOI 10.1016/j.freeradbiomed.2008.03.011
   Kozower BD, 2003, NAT BIOTECHNOL, V21, P392, DOI 10.1038/nbt806
   Manickam DS, 2012, J CONTROL RELEASE, V162, P636, DOI 10.1016/j.jconrel.2012.07.044
   MARUYAMA K, 1990, J PHARM SCI, V79, P978, DOI 10.1002/jps.2600791107
   Mitsopoulos P, 2008, INT J PHARMACEUT, V363, P106, DOI 10.1016/j.ijpharm.2008.07.015
   Muro S, 2005, CURR PHARM DESIGN, V11, P2383, DOI 10.2174/1381612054367274
   Muro S, 2003, J CELL SCI, V116, P1599, DOI 10.1242/jcs.00367
   Muzykantov VR, 1999, P NATL ACAD SCI USA, V96, P2379, DOI 10.1073/pnas.96.5.2379
   Muzykantov VR, 1996, P NATL ACAD SCI USA, V93, P5213, DOI 10.1073/pnas.93.11.5213
   Muzykantov VR, 2001, J CONTROL RELEASE, V71, P1, DOI 10.1016/S0168-3659(01)00215-2
   Muzykantov VR, 1996, AM J PHYSIOL-LUNG C, V270, pL704
   Nowak K, 2007, AM J PHYSIOL-LUNG C, V293, pL162, DOI 10.1152/ajplung.00001.2007
   Park W, 2009, BIOORG MED CHEM LETT, V19, P614, DOI 10.1016/j.bmcl.2008.12.063
   Riley DP, 1999, CHEM REV, V99, P2573, DOI 10.1021/cr980432g
   Rong YQ, 1999, P NATL ACAD SCI USA, V96, P9897, DOI 10.1073/pnas.96.17.9897
   Shuvaev VV, 2007, J PHARMACOL EXP THER, V323, P450, DOI 10.1124/jpet.107.127126
   Shuvaev VV, 2011, J CONTROL RELEASE, V153, P56, DOI 10.1016/j.jconrel.2011.03.022
   Shuvaev VV, 2011, FASEB J, V25, P348, DOI 10.1096/fj.10-169789
   Shuvaev VV, 2009, J PHARMACOL EXP THER, V331, P404, DOI 10.1124/jpet.109.156877
   Supinski GS, 2006, AM J RESP CRIT CARE, V173, P1240, DOI 10.1164/rccm.200410-1346OC
   Thomas SR, 2008, ANTIOXID REDOX SIGN, V10, P1713, DOI 10.1089/ars.2008.2027
   van der Vliet A, 2008, FREE RADICAL BIO MED, V44, P938, DOI 10.1016/j.freeradbiomed.2007.11.016
   Yusuf S, 2000, NEW ENGL J MED, V342, P154, DOI 10.1056/NEJM200001203420302
NR 39
TC 26
Z9 28
U1 3
U2 32
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD MAR 10
PY 2014
VL 177
BP 34
EP 41
DI 10.1016/j.jconrel.2013.12.035
PG 8
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA AC3CQ
UT WOS:000332393000005
PM 24412573
OA green_accepted
DA 2018-03-20
ER

PT J
AU Ojogun, V
   Vyas, SM
   Lehmler, HJ
   Knutson, BL
AF Ojogun, Vivian A.
   Vyas, Sandhya M.
   Lehmler, Hans-Joachim
   Knutson, Barbara L.
TI Partitioning of homologous nicotinic acid ester prodrugs (nicotinates)
   into dipalmitoylphosphatidylcholine (DPPC) membrane bilayers
SO COLLOIDS AND SURFACES B-BIOINTERFACES
LA English
DT Article
DE Perhydrocarbon nicotinate; DPPC bilayers; Prod rug; Membrane partition
   coefficient
ID PHASE-TRANSITION; DRUG-DELIVERY; LIPID-BILAYER; PHYSICOCHEMICAL
   PROPERTIES; LIQUID VENTILATION; NAD METABOLISM; NIACIN; COEFFICIENTS;
   CHOLESTEROL; TRANSPORT
AB The partitioning behavior of a series of perhydrocarbon nicotinic acid esters (nicotinates) between aqueous solution and dipalmitoylphosphatidylcholine (DPPC) membrane bilayers is investigated as a function of increasing alkyl chain length. The hydrocarbon nicotinates represent putative prodrugs. derivatives of the polar drug nicotinic acid, whose functionalization provides the hydrophobic character necessary for pulmonary delivery in a hydrophobic, fluorocarbon solvent, such as perfluorooctyl bromide. Independent techniques of differential scanning calorimetry and 1,6-dipheny1-1,3,5-hexatriene (DPH) fluorescence anisotropy measurements are used to analyze the thermotropic phase behavior and lipid bilayer fluidity as a function of nicotinate concentration. At increasing concentrations of nicotinates over the DPPC mole fraction range examined (X(DPPC) = 0.6-1.0), all the nicotinates (ethyl (C2H5); butyl (C4H9); hexyl (C6H13); and octyl (C8H17)) partition into the lipid bilayer at sufficient levels to eliminate the pre-transition, and decrease and broaden the gel to fluid phase transition temperature. The concentration at which these effects occur is chain length-dependent; the shortest chain nicotinate, C2H5, elicits the least dramatic response. Similarly, the DPH anisotropy results demonstrate an alteration of the bilayer organization in the liposomes as a consequence of the chain length-dependent partitioning of the nicotinates into DPPC bilayers. The membrane partition coefficients (logarithm values), determined from the depressed bilayer phase transition temperatures, increase from 2.18 for C2H5 to 5.25 for C8H17. The DPPC membrane/water partitioning of the perhydrocarbon nicotinate series correlates with trends in the octanol/water partitioning of these solutes, suggesting that their incorporation into the bilayer is driven by increasing hydrophobicity. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Ojogun, Vivian; Knutson, Barbara L.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Vyas, Sandhya M.; Lehmler, Hans-Joachim] Univ Iowa, Dept Occupat & Environm Hlth, Iowa City, IA 52242 USA.
RP Knutson, BL (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 Anderson Hall, Lexington, KY 40506 USA.
EM bknutson@engr.uky.edu
OI Lehmler, Hans-Joachim/0000-0001-9163-927X
FU National Institute of Environmental Health Sciences; NIH [ES07380,
   ES012475]
FX This work was funded by National Institute of Environmental Health
   Sciences, NIH, grants ES07380 and ES012475.
CR AGUILAR LF, 1996, COLLOID SURF A, V103, P287
   ALTSCHUL R, 1955, ARCH BIOCHEM BIOPHYS, V54, P558, DOI 10.1016/0003-9861(55)90070-9
   Austin RP, 2005, PHARM RES, V22, P1649, DOI 10.1007/s11095-005-6336-7
   BANGHAM AD, 1965, J MOL BIOL, V13, P238, DOI 10.1016/S0022-2836(65)80093-6
   Bothun GD, 2005, LANGMUIR, V21, P530, DOI 10.1021/la0496542
   DEYOUNG LR, 1988, BIOCHEMISTRY-US, V27, P5281, DOI 10.1021/bi00414a050
   GOBAS FAPC, 1988, J PHARM SCI, V77, P265, DOI 10.1002/jps.2600770317
   Hsu CH, 2003, PHARMACEUT RES, V20, P918, DOI 10.1023/A:1023899505837
   INOUE T, 1986, CHEM PHYS LIPIDS, V42, P261, DOI 10.1016/0009-3084(86)90085-X
   Jacobson EL, 1999, MOL CELL BIOCHEM, V193, P69, DOI 10.1023/A:1006960126369
   Kamanna V S, 2000, Curr Atheroscler Rep, V2, P36, DOI 10.1007/s11883-000-0093-1
   Koynova R, 1998, BBA-REV BIOMEMBRANES, V1376, P91, DOI 10.1016/S0304-4157(98)00006-9
   Krafft MP, 1998, BIOCHIMIE, V80, P489, DOI 10.1016/S0300-9084(00)80016-4
   Kwon JH, 2006, ENVIRON TOXICOL CHEM, V25, P1984, DOI 10.1897/05-550R.1
   LADBROOKE BD, 1969, CHEM PHYS LIPIDS, V3, P304, DOI 10.1016/0009-3084(69)90040-1
   LAKOWICZ JR, 1999, PRINCIPLES FLUORESCE
   Le VH, 1998, INT J PHARM, V163, P11, DOI 10.1016/S0378-5173(97)00286-X
   LEE AG, 1976, BIOCHEMISTRY-US, V15, P2448, DOI 10.1021/bi00656a031
   Lehmler HJ, 2006, COLLOID SURFACE B, V51, P25, DOI 10.1016/j.colsurfb.2006.05.013
   Lehmler HJ, 2008, INT J PHARM, V353, P35, DOI 10.1016/j.ijpharm.2007.1
   Lehmler HJ, 2007, EXPERT OPIN DRUG DEL, V4, P247, DOI 10.1517/17425247.4.3.247
   Lehmler HJ, 2005, J LIPID RES, V46, P535, DOI 10.1194/jlr.M400406-JLR200
   Lehmler HJ, 1999, CHEMTECH, V29, P7
   Linderoth L, 2009, ANGEW CHEM INT EDIT, V48, P1823, DOI 10.1002/anie.200805241
   MCINTOSH TJ, 1980, BIOPHYS J, V29, P237, DOI 10.1016/S0006-3495(80)85128-9
   MORISHITA S, 1988, J MED CHEM, V31, P1205, DOI 10.1021/jm00401a022
   Murray MF, 1999, MED HYPOTHESES, V53, P375, DOI 10.1054/mehy.1999.0908
   NAGAI A, 1994, EUR RESPIR J, V7, P1125
   NAGLE JF, 1980, ANNU REV PHYS CHEM, V31, P157, DOI 10.1146/annurev.pc.31.100180.001105
   Neunert G, 2010, BIOPHYS CHEM, V146, P92, DOI 10.1016/j.bpc.2009.10.009
   OLSON F, 1979, BIOCHIM BIOPHYS ACTA, V557, P9, DOI 10.1016/0005-2736(79)90085-3
   Riess JG, 1998, BIOMATERIALS, V19, P1529, DOI 10.1016/S0142-9612(98)00071-4
   Rocaboy C, 2000, J PHYS ORG CHEM, V13, P596, DOI 10.1002/1099-1395(200010)13:10<596::AID-POC284>3.0.CO;2-M
   Rongvaux A, 2003, BIOESSAYS, V25, P683, DOI 10.1002/bies.10297
   Schachter M, 2005, CARDIOVASC DRUG THER, V19, P415, DOI 10.1007/s10557-005-5685-0
   SKLAR LA, 1977, BIOCHEMISTRY-US, V16, P813, DOI 10.1021/bi00624a001
   van der Heijden SA, 2009, ENVIRON SCI TECHNOL, V43, P8854, DOI 10.1021/es902278x
   Vogt A, 2007, VASC HEALTH RISK MAN, V3, P467, DOI 10.2147/VHRM.S1023
   WANG QJ, 1990, J BIOCHEM TOXICOL, V5, P13, DOI 10.1002/jbt.2570050104
   Xiang TX, 2006, ADV DRUG DELIVER REV, V58, P1357, DOI 10.1016/j.addr.2006.09.002
   Xie W, 2007, BBA-BIOMEMBRANES, V1768, P1299, DOI 10.1016/j.bbamem.2007.02.003
NR 41
TC 0
Z9 0
U1 1
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0927-7765
J9 COLLOID SURFACE B
JI Colloid Surf. B-Biointerfaces
PD JUN 15
PY 2010
VL 78
IS 1
BP 75
EP 84
DI 10.1016/j.colsurfb.2010.02.015
PG 10
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
SC Biophysics; Chemistry; Materials Science
GA 586CN
UT WOS:000276879100011
PM 20227859
OA green_accepted
DA 2018-03-20
ER

PT J
AU Kauffman, KJ
   Kanthamneni, N
   Meenach, SA
   Pierson, BC
   Bachelder, EM
   Ainslie, KM
AF Kauffman, Kevin J.
   Kanthamneni, Naveen
   Meenach, Samantha A.
   Pierson, Benjamin C.
   Bachelder, Eric M.
   Ainslie, Kristy M.
TI Optimization of rapamycin-loaded acetalated dextran microparticles for
   immunosuppression
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE sensitive polymer; Rapamycin; Microparticle optimization; Macrophages;
   Immunosuppression
ID DENDRITIC CELL-DIFFERENTIATION; CD4(+) T-CELLS; IN-VITRO; PLGA
   MICROSPHERES; BIODEGRADABLE NANOPARTICLES; DRUG-DELIVERY; INITIAL BURST;
   RELEASE; MONOMETHYLFUMARATE; TRANSPLANTATION
AB Immunosuppressive drugs can treat autoimmune disorders and limit rejection with organ transplants. However, delivering immunosuppressants like rapamycin systemically can have harmful side-effects. We aim to potentially reduce these toxic side-effects by encapsulating rapamycin in a polymeric microparticle to passively target phagocytes, the cells integral in immunosuppression. Acetalated dextran (Ac-DEX) is a recently described, biocompatible polymer which undergoes tunable burst degradation at the acidic conditions present in the phagosome (pH 5) but slower degradation at extracellular conditions (pH 7.4), thereby making it an ideal candidate for immune applications. Rapamycin-loaded microparticles were fabricated from Ac-DEX through a single emulsion (water/oil) technique. Optimized microparticles were determined by varying the chemical and physical parameters during particle synthesis. Microparticles synthesized from Ac-DEX with a molecular weight of 71k had higher encapsulation efficiency of rapamycin and slower overall degradation than microparticles synthesized from 10k Ac-DEX. To evaluate the ability of rapamycin-loaded Ac-DEX microparticles to reduce a pro-inflammatory response, they were incubated with lipopolysaccharide-stimulated RAW macrophages. RAW macrophages treated with rapamycin-loaded microparticles exhibited reduced nitric oxide production and favorable cell viability. Overall, we have shown optimization of immunosuppressive rapamycin-loaded microparticles using the novel polymer Ac-DEX. These particles will be advantageous for future applications in immune suppression therapies. (c) 2011 Elsevier B.V. All rights reserved.
C1 [Kauffman, Kevin J.; Pierson, Benjamin C.; Ainslie, Kristy M.] Ohio State Univ, William G Lowrie Dept Chem & Biomol Engn, Coll Engn, Columbus, OH 43210 USA.
   [Kanthamneni, Naveen; Meenach, Samantha A.; Bachelder, Eric M.; Ainslie, Kristy M.] Ohio State Univ, Div Pharmaceut, Coll Pharm, Columbus, OH 43210 USA.
RP Ainslie, KM (reprint author), 242 Parks Hall,500W 12th Ave, Columbus, OH 43210 USA.
EM ainslie@pharmacy.ohio-state.edu
RI Kanthamneni, Naveen/N-7082-2016; Meenach, Samantha/F-7542-2014
OI Kanthamneni, Naveen/0000-0002-5794-9642; Ainslie,
   Kristy/0000-0002-1820-8382; /0000-0002-9436-2453
FU Ohio State University College of Pharmacy
FX This work was supported in part by The Ohio State University College of
   Pharmacy Summer Undergraduate Research Fellowship Program. The authors
   also thank Yu Jeong Kim, Claire Parker, and Dr. Sadhana Sharma for their
   collaboration.
CR Alexis F, 2005, POLYM INT, V54, P36, DOI 10.1002/pi.1697
   Allison SD, 2008, EXPERT OPIN DRUG DEL, V5, P615, DOI [10.1517/17425240802157184, 10.1517/17425247.5.6.615 ]
   Bachelder EM, 2008, J AM CHEM SOC, V130, P10494, DOI 10.1021/ja803947s
   Bachelder EM, 2010, MOL PHARMACEUT, V7, P826, DOI 10.1021/mp900311x
   Barrat FJ, 2002, J EXP MED, V195, P603, DOI 10.1084/jem.20011629
   Beaudette TT, 2009, J AM CHEM SOC, V131, P10360, DOI 10.1021/ja903984s
   Bosma BM, 2008, IMMUNOLOGY, V125, P91, DOI 10.1111/j.1365-2567.2008.02824.x
   Broaders KE, 2009, P NATL ACAD SCI USA, V106, P5497, DOI 10.1073/pnas.0901592106
   Cong YZ, 2009, EUR J IMMUNOL, V39, P3134, DOI 10.1002/eji.200939052
   Droge W, 2002, PHYSIOL REV, V82, P47
   Drosos AA, 2002, DRUGS, V62, P891, DOI 10.2165/00003495-200262060-00003
   Fernandez-Carballido A, 2004, INT J PHARM, V279, P33, DOI 10.1016/j.ijpharm.2004.04.003
   FISCHER R, 2009, HEMATOL-AM SOC HEMAT, P215, DOI [10.1007/978-3-540-71029-5_10, 10.1182/asheducation-2009.1.215]
   Foged C, 2005, INT J PHARM, V298, P315, DOI 10.1016/j.ijpharm.2005.03.035
   Foged C, 2002, PHARMACEUT RES, V19, P229, DOI 10.1023/A:1014474414097
   Griffin MD, 2000, BIOCHEM BIOPH RES CO, V270, P701, DOI 10.1006/bbrc.2000.2490
   Haddadi A, 2008, J BIOMED MATER RES A, V84A, P885, DOI 10.1002/jbm.a.31373
   Hamdy S, 2011, PHARM RES-DORDR, V28, P2288, DOI 10.1007/s11095-011-0459-9
   Hans ML, 2002, CURR OPIN SOLID ST M, V6, P319, DOI 10.1016/S1359-0286(02)00117-1
   Hartung HP, 2002, LANCET, V360, P2018, DOI 10.1016/S0140-6736(02)12023-X
   Hirota K, 2007, J CONTROL RELEASE, V119, P69, DOI 10.1016/j.jconrel.2007.01.013
   Jhunjhunwala S, 2009, J CONTROL RELEASE, V133, P191, DOI 10.1016/j.jconrel.2008.10.011
   Johansen P, 2000, EUR J PHARM BIOPHARM, V50, P129, DOI 10.1016/S0939-6411(00)00079-5
   Kahan BD, 2003, TRANSPLANT P, V35, p37S, DOI 10.1016/S0041-1345(03)00353-1
   Khanafer M., 2009, INT C IM SIGN PROC, P1
   Kou PM, 2011, J BIOMED MATER RES A, V96A, P239, DOI 10.1002/jbm.a.32971
   Litjens NHR, 2006, BRIT J DERMATOL, V154, P211, DOI 10.1111/j.1365-2133.2005.07002.x
   Litjens NHR, 2004, EUR J IMMUNOL, V34, P565, DOI 10.1002/eji.200324174
   Lu L, 2000, BIOMATERIALS, V21, P1837, DOI 10.1016/S0142-9612(00)00047-8
   Manicassamya S, 2009, SEMIN IMMUNOL, V21, P22, DOI 10.1016/j.smim.2008.07.007
   Manolova V, 2008, EUR J IMMUNOL, V38, P1404, DOI 10.1002/eji.200737984
   Mao SR, 2007, INT J PHARM, V334, P137, DOI 10.1016/j.ijpharm.2006.10.036
   Norton LW, 2010, J CONTROL RELEASE, V146, P341, DOI 10.1016/j.jconrel.2010.05.032
   Paul W. E., 1994, FUNDAMENTAL IMMUNOLO
   Saunders RN, 2001, KIDNEY INT, V59, P3, DOI 10.1046/j.1523-1755.2001.00460.x
   Simamora P, 2001, INT J PHARM, V213, P25, DOI 10.1016/S0378-5173(00)00617-7
   Song CX, 1997, J CONTROL RELEASE, V43, P197, DOI 10.1016/S0168-3659(96)01484-8
   Turnquist HR, 2007, J IMMUNOL, V178, P7018, DOI 10.4049/jimmunol.178.11.7018
   Venkatraman S, 2007, J CONTROL RELEASE, V120, P149, DOI 10.1016/j.jconrel.2007.04.022
   Wada Y, 2009, INFLAMM BOWEL DIS, V15, P1548, DOI 10.1002/ibd.20934
   Xu YM, 2003, INT J PHARM, V250, P215, DOI 10.1016/S0378-5173(02)00548-3
   Yeo Y, 2004, ARCH PHARM RES, V27, P1, DOI 10.1007/BF02980037
   Zhu KJ, 2001, J INVEST DERMATOL, V116, P203, DOI 10.1046/j.1523-1747.2001.01159.x
NR 43
TC 35
Z9 36
U1 1
U2 27
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD JAN 17
PY 2012
VL 422
IS 1-2
BP 356
EP 363
DI 10.1016/j.ijpharm.2011.10.034
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 920IV
UT WOS:000302398700045
PM 22037446
DA 2018-03-20
ER

PT J
AU Doleman, LA
   Morris, JD
   Davies, LL
   Rowe, L
   Moschou, EA
   Deo, SK
   Daunert, S
AF Doleman, Leslie Ann
   Morris, Jonathan David
   Davies, Logan L.
   Rowe, Laura
   Moschou, Elizabeth A.
   Deo, Sapna K.
   Daunert, Sylvia
TI Development of DNA hybridization assay for Plasmodium falciparum
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
CT 231st National Meeting of the American-Chemical-Society
CY MAR 26-30, 2006
CL Atlanta, GA
SP Amer Chem Soc
C1 Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD MAR 26
PY 2006
VL 231
MA 159-ANYL
PG 2
WC Chemistry, Multidisciplinary
SC Chemistry
GA 050YE
UT WOS:000238125900266
DA 2018-03-19
ER

PT J
AU Ayers, PW
   Liu, SB
   Li, TL
AF Ayers, Paul W.
   Liu, Shubin
   Li, Tonglei
TI Chargephilicity and chargephobicity: Two new reactivity indicators for
   external potential changes from density functional reactivity theory
SO CHEMICAL PHYSICS LETTERS
LA English
DT Article
ID DESCRIBING CHEMICAL-REACTIONS; CHARGE SENSITIVITY-ANALYSIS;
   FRONTIER-ELECTRON THEORY; ELECTROPHILICITY INDEX;
   VARIATIONAL-PRINCIPLES; DESIGNING MOLECULES; FUKUI FUNCTION; HARDNESS;
   EXCHANGE; SOFTNESS
AB In analogy to the electrophilicity and the potentialphilicity, we de. ne the chargephilicity and chargephobicity to describe the energetic response of a molecule to a change in its charge distribution. The chargephilicity captures the 'best' way to change the underlying charge distribution; the chargephobicity captures the 'worst' way to change the underlying charge distribution. The Coulomb potential induced by the linear-response function plays a very important role in this approach, analogous to the role of the hardness for the electrophilicity, the hardness kernel for the Fukui function, and the linear-response function for the potentialphilicity and potentialphobicity. (c) 2009 Elsevier B.V. All rights reserved.
C1 [Ayers, Paul W.] McMaster Univ, Dept Chem, Hamilton, ON L8S 4M1, Canada.
   [Liu, Shubin] Univ N Carolina, Ctr Res Comp, Chapel Hill, NC 27599 USA.
   [Li, Tonglei] Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
RP Ayers, PW (reprint author), McMaster Univ, Dept Chem, 1280 Main St W, Hamilton, ON L8S 4M1, Canada.
EM ayers@mcmaster.ca
RI Liu, Shubin/B-1502-2009; Ayers, Paul/A-1154-2008
OI Liu, Shubin/0000-0001-9331-0427; Ayers, Paul/0000-0003-2605-3883
FU NSF [DMR-0449633]; Canada Research Chairs; NSERC; Sharcnet
FX This study was partially supported by the NSF (DMR-0449633). P. W. A.
   thanks the Canada Research Chairs, NSERC, and Sharcnet for financial
   support.
CR Anderson JSM, 2007, J CHEM THEORY COMPUT, V3, P358, DOI 10.1021/ct600164j
   Ayers PW, 2007, FARADAY DISCUSS, V135, P161, DOI 10.1039/b606877d
   Ayers PW, 2005, INT J QUANTUM CHEM, V101, P520, DOI 10.1002/qua.20307
   Ayers PW, 2000, THEOR CHEM ACC, V103, P353, DOI 10.1007/s002149900093
   Ayers PW, 2001, J CHEM PHYS, V115, P4438, DOI 10.1063/1.1379333
   Ayers PW, 2001, J AM CHEM SOC, V123, P2007, DOI 10.1021/ja002966g
   Ayers PW, 2000, J AM CHEM SOC, V122, P2010, DOI 10.1021/ja9924039
   BERKOWITZ M, 1988, J CHEM PHYS, V88, P2554, DOI 10.1063/1.454034
   Cedillo A, 2007, J PHYS CHEM A, V111, P2442, DOI 10.1021/jp068459o
   Chattaraj PK, 2003, J PHYS CHEM A, V107, P4973, DOI 10.1021/jp034707u
   Chattaraj PK, 2006, CHEM REV, V106, P2065, DOI 10.1021/cr040109f
   Chermette H, 1999, J COMPUT CHEM, V20, P129, DOI 10.1002/(SICI)1096-987X(19990115)20:1<129::AID-JCC13>3.3.CO;2-1
   COHEN MH, 1995, J CHEM PHYS, V103, P3543, DOI 10.1063/1.470238
   GADRE SR, 1992, J CHEM PHYS, V96, P5253, DOI 10.1063/1.462710
   Gazquez JL, 2008, J MEX CHEM SOC, V52, P3
   Geerlings P, 2003, CHEM REV, V103, P1793, DOI 10.1021/cr990029p
   Gorling A, 1999, PHYS REV LETT, V83, P5459, DOI 10.1103/PhysRevLett.83.5459
   Keinan S, 2007, J PHYS CHEM A, V111, P176, DOI 10.1021/jp0646168
   Langenaeker W, 2001, J MOL STRUC-THEOCHEM, V535, P279, DOI 10.1016/S0166-1280(00)00579-0
   Liu SB, 1999, J CHEM PHYS, V111, P6197, DOI 10.1063/1.479924
   LIU SB, J CHEM PHYS IN PRESS
   Liu SB, 2009, ACTA PHYS-CHIM SIN, V25, P590, DOI 10.3866/PKU.WHXB20090332
   Menconi G, 2000, PHYS CHEM CHEM PHYS, V2, P3739, DOI 10.1039/b003049j
   NAKATSUJ.H, 1974, J AM CHEM SOC, V96, P30, DOI 10.1021/ja00808a005
   NAKATSUJ.H, 1974, J AM CHEM SOC, V96, P24, DOI 10.1021/ja00808a004
   NALEWAJSKI RF, 1989, ACTA PHYS POL A, V76, P747
   Nalewajski RF, 2000, COMPUT CHEM, V24, P243, DOI 10.1016/S0097-8485(99)00070-4
   NALEWAJSKI RF, 1995, INT J QUANTUM CHEM, V56, P453, DOI 10.1002/qua.560560505
   NALEWAJSKI RF, 1997, CHARGE SENSITIVITY A
   Nalewajski RF, 2006, ADV QUANTUM CHEM, V51, P235, DOI 10.1016/S0065-3276(06)51006-8
   Parr RG, 1999, J AM CHEM SOC, V121, P1922, DOI 10.1021/ja983494x
   PARR RG, 1983, J AM CHEM SOC, V105, P7512, DOI 10.1021/ja00364a005
   PARR RG, 1978, J CHEM PHYS, V68, P3801, DOI 10.1063/1.436185
   PARR RG, 1984, J AM CHEM SOC, V106, P4049, DOI 10.1021/ja00326a036
   Parr RG, 1989, DENSITY FUNCTIONAL T
   Perez P, 2008, J CHEM PHYS, V128, DOI 10.1063/1.2916714
   Politzer P, 2002, THEOR CHEM ACC, V108, P134, DOI 10.1007/s00214-002-0363-9
   Senet P, 1996, J CHEM PHYS, V105, P6471, DOI 10.1063/1.472498
   von Lilienfeld OA, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.153002
   VONLILIENFELD OA, 2005, J CHEM PHYS, V122
   Wang ML, 2006, J AM CHEM SOC, V128, P3228, DOI 10.1021/ja0572046
   YANG WT, 1985, P NATL ACAD SCI USA, V82, P6723, DOI 10.1073/pnas.82.20.6723
NR 42
TC 8
Z9 8
U1 0
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0009-2614
J9 CHEM PHYS LETT
JI Chem. Phys. Lett.
PD OCT 8
PY 2009
VL 480
IS 4-6
BP 318
EP 321
DI 10.1016/j.cplett.2009.08.067
PG 4
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA 501ZI
UT WOS:000270423000033
DA 2018-03-20
ER

PT J
AU Long, SH
   Siegler, M
   Li, TL
AF Long, Sihui
   Siegler, Maxime A.
   Li, Tonglei
TI 2-(2-isopropylanilino)pyridine-3-carboxylic acid
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article
ID X-RAY
AB b The asymmetric unit of the title compound, C15H16N2O2, contains two molecules and in each of the molecules, the two aromatic rings, lying in two different planes, are bridged by a secondary amino group. This might be due to steric hindrance caused by the isopropyl group. Intra- and intermolecular N - H center dot center dot center dot O hydrogen bonds link the molecules, forming an infinite one-dimensional tape structure; they may be effective in the stabilization of the crystal structure.
C1 Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40506 USA.
   Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
RP Li, TL (reprint author), Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40506 USA.
EM tonglei@uky.edu
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   NONIUS BV, 1999, COLLECT
   OTWINOWSKI Z, METHODS ENZYMOLOGY, V276
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   SHELDRICK GM, 1995, XP SHELXTLPC
   TAKASUKA M, 1982, J CHEM SOC PERK T 2, P1061, DOI 10.1039/p29820001061
   TING PC, 1990, J MED CHEM, V33, P2697, DOI 10.1021/jm00172a004
NR 7
TC 2
Z9 2
U1 0
U2 5
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD SEP
PY 2006
VL 62
BP O4211
EP O4213
DI 10.1107/S1600536806034131
PN 9
PG 3
WC Crystallography
SC Crystallography
GA 080DO
UT WOS:000240227400417
DA 2018-03-20
ER

PT J
AU Lakes, AL
   Peyyala, R
   Ebersole, JL
   Puleo, DA
   Hilt, JZ
   Dziubla, TD
AF Lakes, Andrew L.
   Peyyala, Rebecca
   Ebersole, Jeffrey L.
   Puleo, David A.
   Hilt, J. Zach
   Dziubla, Thomas D.
TI Synthesis and Characterization of an Antibacterial Hydrogel Containing
   Covalently Bound Vancomycin
SO BIOMACROMOLECULES
LA English
DT Article
ID CONTROLLED-RELEASE; SUSTAINED-RELEASE; LOCAL-DELIVERY; DRUG-RELEASE;
   BONE-CEMENT; PMMA BEADS; ANTIBIOTICS; OSTEOMYELITIS; INFECTION; KINETICS
AB The release of freely loaded small molecules from biomaterials often exhibits an initial burst, inhibiting the ability of these materials to match drug release with the biomaterial's degradation period. In terms of antibiotic release systems, the remaining vehicle may become a substrate for colonization by bacterial biofilms once the payload is depleted, which can become life threatening. Secondary surgeries are typically performed to remove these empty depots as a means of preventing this type of infection. To maintain the effectiveness of a locally delivered antibiotic without the drawback of a second surgery, we propose a hydrogel drug delivery system in which the drug release rate of vancomycin and degradation rate of the hydrogel are linked via covalent incorporation of vancomycin in the hydrogel backbone. This was achieved through coupling PEG based monomer with vancomycin to create poly(beta-amino ester) chemistry and verified through drug release and matrix degradation studies. Antibiotic release and material degradation were tunable via hydrophobic/hydrophilic content of the hydrogel matrix and extended up to 3 weeks in PBS sink conditions. Covalent addition of vancomycin to the hydrogel polymer backbone was verified through mass spectroscopy and HPLC peak addition, as well as radiotracing of collected HPLC fractions. Bioactivity of released vancomycin was also confirmed alongside the resulting antimicrobial activity of the reacted vancomycin releasate.
C1 [Lakes, Andrew L.; Hilt, J. Zach; Dziubla, Thomas D.] Univ Kentucky, Coll Engn, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Puleo, David. A.] Univ Kentucky, Coll Engn, Dept Biomed Engn, Lexington, KY 40506 USA.
   [Peyyala, Rebecca; Ebersole, Jeffrey L.] Univ Kentucky, Coll Dent, Ctr Oral Hlth Res, Lexington, KY 40506 USA.
RP Dziubla, TD (reprint author), Univ Kentucky, Coll Engn, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM dziubla@engr.uky.edu
FU U.S. Army Medical Research Acquisition Activity [W81XWH-09-1-0461];
   IGERT/NSF [DGE-0653710]
FX This work was supported by a grant from the U.S. Army Medical Research
   Acquisition Activity (W81XWH-09-1-0461), as well as through IGERT/NSF
   (DGE-0653710). The contents herein do not necessarily represent the
   position or policy of the Government, and no official endorsement should
   be inferred. Special thanks to Mark C. Bailey and Haoyang Zhou for their
   aid and expertise in cell culture from the University of Kentucky.
CR Baral A, 2014, LANGMUIR, V30, P929, DOI 10.1021/la4043638
   Bastari K, 2014, J MATER SCI-MATER M, V25, P747, DOI 10.1007/s10856-013-5125-9
   Bhattarai N, 2010, ADV DRUG DELIVER REV, V62, P83, DOI 10.1016/j.addr.2009.07.019
   BISNO AL, 1995, INFECT CONT HOSP EP, V16, P648
   Brandl F, 2010, J CONTROL RELEASE, V142, P221, DOI 10.1016/j.jconrel.2009.10.030
   Brooks BD, 2014, J BIOMED MATER RES B, V102, P1074, DOI 10.1002/jbm.b.33089
   Campoccia D, 2010, BIOMATERIALS, V31, P6363, DOI 10.1016/j.biomaterials.2010.05.005
   Chilukuri DM, 2005, PHARM RES, V22, P563, DOI 10.1007/s11095-005-2492-z
   Cui X, 2014, J MATER SCI-MATER M, V25, P733, DOI 10.1007/s10856-013-5122-z
   El-Husseiny M, 2011, J BONE JOINT SURG BR, V93B, P151, DOI 10.1302/0301-620X.93B2.24933
   Gao P, 2011, J ANTIBIOT, V64, P625, DOI 10.1038/ja.2011.58
   Gitelis Steven, 2002, J Orthop Surg (Hong Kong), V10, P53
   Gogia J. S., 2009, SEMIN PLAST SURG, V23
   Harth KC, 2010, J SURG RES, V163, P337, DOI 10.1016/j.jss.2010.03.065
   Hawkins AM, 2013, POLYMER, V54, P4422, DOI 10.1016/j.polymer.2013.06.010
   Hawkins AM, 2011, J APPL POLYM SCI, V122, P1420, DOI 10.1002/app.34093
   Hawkins AM, 2011, ACTA BIOMATER, V7, P1956, DOI 10.1016/j.actbio.2011.01.024
   Huang JG, 2013, MOL MED REP, V8, P1221, DOI 10.3892/mmr.2013.1624
   Justinger C, 2009, SURGERY, V146, P468
   Khodaverdi Elham, 2013, PDA J Pharm Sci Technol, V67, P135, DOI 10.5731/pdajpst.2013.00908
   Kluin OS, 2013, EXPERT OPIN DRUG DEL, V10, P341, DOI 10.1517/17425247.2013.751371
   Kuechle DK, 1991, CLIN ORTHOP RELAT R, V264, P302
   Lalidou Fani, 2014, Surg Technol Int, V24, P353
   Lawson MC, 2007, CLIN ORTHOP RELAT R, P96, DOI 10.1097/BLO.0b013e3180986706
   Lawson MC, 2009, BIOMACROMOLECULES, V10, P2221, DOI 10.1021/bm900410a
   Li B, 2010, J CONTROL RELEASE, V145, P221, DOI 10.1016/j.jconrel.2010.04.002
   Mohan YM, 2006, J APPL POLYM SCI, V101, P3202, DOI 10.1002/app.23277
   Mohanty S P, 2003, J Orthop Surg (Hong Kong), V11, P73
   Moojen DJF, 2008, J ARTHROPLASTY, V23, P1152, DOI 10.1016/j.arth.2007.08.020
   Nandi SK, 2009, MAT SCI ENG C-MATER, V29, P2478, DOI 10.1016/j.msec.2009.07.014
   NELSON CL, 1992, CLIN ORTHOP RELAT R, P303
   Overstreet DJ, 2013, J BIOMED MATER RES A, V101, P1437, DOI 10.1002/jbm.a.34443
   Robibaro B, 1998, J ANTIMICROB CHEMOTH, V41, P297, DOI 10.1093/jac/41.2.297
   Schnieders J, 2011, J BIOMED MATER RES B, V99B, P391, DOI 10.1002/jbm.b.31910
   Shinsako K, 2008, BIO-MED MATER ENG, V18, P377, DOI 10.3233/BME-2008-0554
   Shukla A, 2012, J CONTROL RELEASE, V157, P64, DOI 10.1016/j.jconrel.2011.09.062
   Thatiparti TR, 2010, BIOMATERIALS, V31, P2335, DOI 10.1016/j.biomaterials.2009.11.087
   Wattamwar PP, 2012, ACTA BIOMATER, V8, P2529, DOI 10.1016/j.actbio.2012.03.022
NR 38
TC 14
Z9 14
U1 6
U2 87
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1525-7797
EI 1526-4602
J9 BIOMACROMOLECULES
JI Biomacromolecules
PD AUG
PY 2014
VL 15
IS 8
BP 3009
EP 3018
DI 10.1021/bm5006323
PG 10
WC Biochemistry & Molecular Biology; Chemistry, Organic; Polymer Science
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA AN1MS
UT WOS:000340348600021
PM 25000243
DA 2018-03-20
ER

PT J
AU Islam, SZ
   Reed, A
   Wanninayake, N
   Kim, DY
   Rankin, SE
AF Islam, Syed Z.
   Reed, Allen
   Wanninayake, Namal
   Kim, Doo Young
   Rankin, Stephen E.
TI Remarkable Enhancement of Photocatalytic Water Oxidation in N-2/Ar
   Plasma Treated, Mesoporous TiO2 Films
SO JOURNAL OF PHYSICAL CHEMISTRY C
LA English
DT Article
ID NITROGEN-DOPED TIO2; VISIBLE-LIGHT PHOTOCATALYSIS; TITANIA THIN-FILMS;
   HYDROGEN-PRODUCTION; NANOWIRE ARRAYS; ELECTRONIC-STRUCTURE;
   ION-IMPLANTATION; NANOTUBE ARRAYS; NANOPARTICLES; NANOSTRUCTURES
AB Mesoporous TiO2 films treated with N-2/argon plasma were studied for ultraviolet and visible-light-induced photocatalytic water oxidation activity. Compared to pristine TiO2 films, plasma-treated TiO2 films showed remarkable enhancement of photocurrents (up to 80-240 times) in both ultraviolet light and visible light, greatly surpassing enhancements previously reported in the literature. The cubic-ordered mesoporous TiO2 thin films were prepared by a surfactant-templated sol gel method and were treated with N-2/argon plasma, an approach hypothesized to capitalize on the high degree of disorder in the material and the high energy of the plasma species to achieve efficient nitrogen doping. The effects of reaction gas pressure and N-2 gas flow rate on photoelectrochemical (PEC) response were investigated. UV-vis absorbance spectra indicated that the incorporated N atoms significantly reduced the band gap of TiO2 with the enhancement of visible-light absorption, and XPS analysis showed primarily substitutional N atom incorporation rather than interstitial. The photocatalytic activity of nitrogen-doped TiO2 (N-TiO2) films was evaluated by chronoamperometry and linear sweep voltammetry. The effect of light sources on PEC performance was explored using UV (365 nm), blue (455 nm), and green (530 nm) LEDs. N-TiO, films showed 242X and 240X enhancement of photocurrent, compared to undoped TiO2 films under UV and blue LED irradiation, respectively. The N-doped films also showed overall enhancement of up to 70x and 92x with a broad spectrum Xe arc lamp and halogen bulb, respectively, and photocatalytic activity even with green LED illumination, compared to no measurable activity without doping. The present study shows that plasma-induced doping of sol gel materials enables the efficient incorporation of heteroatoms into disordered metal oxide nanostructures, thereby leading to remarkable enhancement in visible-light-driven photoelectrochemical water oxidation.
C1 [Islam, Syed Z.; Rankin, Stephen E.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Reed, Allen; Wanninayake, Namal; Kim, Doo Young] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
RP Rankin, SE (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.; Kim, DY (reprint author), Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
EM dooyoung.kim@uky.edu; srankin@engr.uky.edu
FU University of Kentucky; National Science Foundation EPSCoR Researc
   Infrastructure Initiative award [IIA-1355438];  [DE-FG02-07-ER46375]
FX The authors acknowledge financial support from University of Kentucky
   faculty start-up funds (DYK). Experiments to develop the mesoporous
   titania film synthesis approach were performed as part of a U.S.
   Department of Energy EPSCoR Implementation award supported by grant no.
   DE-FG02-07-ER46375. The detailed study as a function of plasma
   parameters, further analysis of the spectroscopic and structural
   characteristics of the doped films, and water oxidation experiments were
   performed as part of a National Science Foundation EPSCoR Researc
   Infrastructure Initiative award supported by grant no. IIA-1355438.
   Finally, the authors thank Prof. Y.T. Cheng, Prof. Dibakar Bhattacharyya
   and Andrew Colburn, and Prof. Brad Berron and Ishan Fursule, Prof.
   Anne-Frances Miller and Dr. Rupam Sarma, and Prof. Vijay Singh and Sai
   Guduru for access and assistance with the XPS, zeta potential, contact
   angle measurements, oxygen measurement, and water oxidation using the Xe
   arc lamp, respectively.
CR Aman N, 2010, J MATER CHEM, V20, P10876, DOI 10.1039/c0jm01342k
   Ananpattarachai J, 2009, J HAZARD MATER, V168, P253, DOI 10.1016/j.jhazmat.2009.02.036
   Asahi R, 2001, SCIENCE, V293, P269, DOI 10.1126/science.1061051
   Babu VJ, 2012, INT J HYDROGEN ENERG, V37, P8897, DOI 10.1016/j.ijhydene.2011.12.015
   Bingham S, 2011, J MATER CHEM, V21, P2041, DOI 10.1039/c0jm02271c
   Bloh JZ, 2014, J PHYS CHEM C, V118, P21281, DOI 10.1021/jp507264g
   BOEHM HP, 1971, DISCUSS FARADAY SOC, P264
   Burda C, 2003, NANO LETT, V3, P1049, DOI 10.1021/nl034332o
   Cao JY, 2012, CHEM COMMUN, V48, P8649, DOI 10.1039/c2cc33662f
   Chen C, 2007, J PHYS CHEM C, V111, P15228, DOI 10.1021/jp0716233
   Crepaldi EL, 2003, J AM CHEM SOC, V125, P9770, DOI 10.1021/ja030070g
   Das S, 2014, J PHYS CHEM C, V118, P968, DOI 10.1021/jp406165v
   Deka RC, 1998, INDIAN J CHEM TECHN, V5, P109
   Dholam R, 2009, INT J HYDROGEN ENERG, V34, P5337, DOI 10.1016/j.ijhydene.2009.05.011
   Fakhouri H, 2014, APPL CATAL B-ENVIRON, V144, P12, DOI 10.1016/j.apcatb.2013.06.028
   Feng D, 2013, J MATER CHEM A, V1, P1591, DOI 10.1039/c2ta00588c
   FUJISHIMA A, 1972, NATURE, V238, P37, DOI 10.1038/238037a0
   Ghicov A, 2006, NANO LETT, V6, P1080, DOI 10.1021/nl0600979
   Ghicov A, 2006, CHEM PHYS LETT, V419, P426, DOI 10.1016/j.cplett.2005.11.102
   Gohin M, 2010, J MATER CHEM, V20, P8070, DOI 10.1039/c0jm01499k
   Gratzel M, 2001, NATURE, V414, P338, DOI 10.1038/35104607
   Hanzu I, 2011, J PHYS CHEM C, V115, P5989, DOI 10.1021/jp1111982
   Hoang S, 2012, J AM CHEM SOC, V134, P3659, DOI 10.1021/ja211369s
   Hu SZ, 2014, J POWER SOURCES, V250, P30, DOI 10.1016/j.jpowsour.2013.10.132
   Huang CM, 2007, J MOL CATAL A-CHEM, V261, P218, DOI 10.1016/j.molcata.2006.08.020
   Ishihara H, 2010, CHEM PHYS LETT, V489, P81, DOI 10.1016/j.cplett.2010.02.038
   Islam SZ, 2016, MICROPOR MESOPOR MAT, V220, P120, DOI 10.1016/j.micromeso.2015.08.030
   Ismail AA, 2011, J MATER CHEM, V21, P11686, DOI 10.1039/c1jm10407a
   Jinlong L., 2010, THIN SOLID FILMS, V519, P101, DOI DOI 10.1016/J.TSF.2010.07.070
   Kafizas A, 2010, J MATER CHEM, V20, P2157, DOI 10.1039/b914117k
   Kisch H, 2007, J PHYS CHEM C, V111, P11445, DOI 10.1021/jp066457y
   Lee HU, 2014, CHEM ENG J, V254, P268, DOI 10.1016/j.cej.2014.06.011
   Leung DYC, 2010, CHEMSUSCHEM, V3, P681, DOI 10.1002/cssc.201000014
   Li LD, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6881
   Li X, 2015, APPL CATAL B-ENVIRON, V164, P352, DOI 10.1016/j.apcatb.2014.09.053
   Liao YT, 2012, APPL ENERG, V100, P75, DOI 10.1016/j.apenergy.2012.02.053
   Lin H., 2010, J APPL PHYS, V107
   Liu HJ, 2010, COLLOID SURFACE A, V363, P35, DOI 10.1016/j.colsurfa.2010.04.010
   Liu X, 2011, J ALLOY COMPD, V509, P9970, DOI 10.1016/j.jallcom.2011.08.003
   Lynch J, 2015, J PHYS CHEM C, V119, P7443, DOI 10.1021/jp512775s
   Mao CY, 2014, ANGEW CHEM INT EDIT, V53, P10485, DOI 10.1002/anie.201406017
   McDonnell KA, 2012, PHYS REV B, V86, DOI 10.1103/PhysRevB.86.115306
   Mi L, 2008, APPL SURF SCI, V255, P2574, DOI 10.1016/j.apsusc.2008.07.150
   Miao L, 2005, APPL SURF SCI, V244, P412, DOI 10.1016/j.apsusc.2004.10.098
   Miyauchi M, 2004, PHYS CHEM CHEM PHYS, V6, P865, DOI 10.1039/b314692h
   Napoli F, 2009, CHEM PHYS LETT, V477, P135, DOI 10.1016/j.cplett.2009.06.050
   Pan H, 2011, J PHYS CHEM C, V115, P12224, DOI 10.1021/jp202385q
   Pulsipher DJV, 2010, ACS APPL MATER INTER, V2, P1743, DOI 10.1021/am100233j
   Qiu XF, 2007, CHEM PHYS, V339, P1, DOI 10.1016/j.chemphys.2007.06.039
   Rane KS, 2006, J SOLID STATE CHEM, V179, P3033, DOI 10.1016/j.jssc.2006.05.033
   Sakai N, 2004, J AM CHEM SOC, V126, P5851, DOI 10.1021/ja0394582
   Salari M, 2015, PHYS CHEM CHEM PHYS, V17, P5642, DOI 10.1039/c4cp03177f
   Sathish M, 2005, CHEM MATER, V17, P6349, DOI 10.1021/cm052047v
   Selvam K, 2012, RSC ADV, V2, P2848, DOI 10.1039/c2ra01178f
   Sharma R, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/7/075704
   Siuzdak K, 2015, NEW J CHEM, V39, P2741, DOI 10.1039/c5nj00127g
   Sivaranjani K, 2011, J MATER CHEM, V21, P2639, DOI 10.1039/c0jm03825c
   Soni SS, 2008, ADV MATER, V20, P1493, DOI 10.1002/adma.200701066
   Spadavecchia F, 2011, J PHYS CHEM C, V115, P6381, DOI 10.1021/jp2003968
   Sun HQ, 2008, SOL ENERG MAT SOL C, V92, P76, DOI 10.1016/j.solmat.2007.09.003
   Suttiponpamit K., 2011, NANOSCALE RES LETT, V6, P1
   Tong H, 2012, ADV MATER, V24, P229, DOI 10.1002/adma.201102752
   Varghese OK, 2009, NANO LETT, V9, P731, DOI 10.1021/nl803258p
   Varley JB, 2011, ADV MATER, V23, P2343, DOI 10.1002/adma.201003603
   Wang GM, 2015, NANO LETT, V15, P4692, DOI 10.1021/acs.nanolett.5b01547
   Wang GM, 2011, NANO LETT, V11, P3026, DOI 10.1021/nl201766h
   Wang J, 2009, J AM CHEM SOC, V131, P12290, DOI 10.1021/ja903781h
   Wu QL, 2011, LANGMUIR, V27, P9557, DOI 10.1021/la201388n
   Xu JJ, 2010, APPL SURF SCI, V256, P4397, DOI 10.1016/j.apsusc.2010.02.037
   Yang CY, 2013, J AM CHEM SOC, V135, P17831, DOI 10.1021/ja4076748
   Zakrzewska K, 2015, INT J HYDROGEN ENERG, V40, P815, DOI 10.1016/j.ijhydene.2014.09.097
   Zhang P, 2014, ACS APPL MATER INTER, V6, P4622, DOI 10.1021/am405510a
NR 72
TC 10
Z9 10
U1 3
U2 37
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1932-7447
J9 J PHYS CHEM C
JI J. Phys. Chem. C
PD JUL 7
PY 2016
VL 120
IS 26
BP 14069
EP 14081
DI 10.1021/acs.jpcc.6b02622
PG 13
WC Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science,
   Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA DQ8JL
UT WOS:000379457000024
OA gold
DA 2018-03-20
ER

PT J
AU Cochran, DB
   Wattamwar, PP
   Wydra, R
   Hilt, JZ
   Anderson, KW
   Eitel, RE
   Dziubla, TD
AF Cochran, David B.
   Wattamwar, Paritosh P.
   Wydra, Robert J.
   Hilt, J. Zach
   Anderson, Kimberly W.
   Eitel, Richard E.
   Dziubla, Thomas D.
TI Suppressing iron oxide nanoparticle toxicity by vascular targeted
   antioxidant polymer nanoparticles
SO BIOMATERIALS
LA English
DT Article
DE Nanoparticle; Antioxidant; Oxidation; Endothelial cell; Adhesion
   molecule
ID SMALL-MOLECULE ANTIOXIDANTS; OXIDATIVE STRESS; DRUG-DELIVERY; MAGNETIC
   NANOPARTICLES; GASTROINTESTINAL-TRACT; ENDOTHELIAL-CELLS; FREE-RADICALS;
   IN-VIVO; PECAM-1; NANOCARRIERS
AB The biomedical use of superparamagnetic iron oxide nanoparticles has been of continued interest in the literature and clinic. Their ability to be used as contrast agents for imaging and/or responsive agents for remote actuation makes them exciting materials for a wide range of clinical applications. Recently, however, concern has arisen regarding the potential health effects of these particles. Iron oxide toxicity has been demonstrated in in vivo and in vitro models, with oxidative stress being implicated as playing a key role in this pathology. One of the key cell types implicated in this injury is the vascular endothelial cells. Here, we report on the development of a targeted polymeric antioxidant, poly(trolox ester), nanoparticle that can suppress oxidative damage. As the polymer undergoes enzymatic hydrolysis, active trolox is locally released, providing a long term protection against pro-oxidant agents. In this work, poly(trolox) nanoparticles are targeted to platelet endothelial cell adhesion molecules (PECAM-1), which are able to bind to and internalize in endothelial cells and provide localized protection against the cytotoxicity caused by iron oxide nanoparticles. These results indicate the potential of using poly(trolox ester) as a means of mitigating iron oxide toxicity, potentially expanding the clinical use and relevance of these exciting systems. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Cochran, David B.; Wattamwar, Paritosh P.; Wydra, Robert; Hilt, J. Zach; Anderson, Kimberly W.; Eitel, Richard E.; Dziubla, Thomas D.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40508 USA.
RP Dziubla, TD (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40508 USA.
EM thomas.dziubla@uky.edu
RI Eitel, Richard/E-2889-2010
OI Eitel, Richard/0000-0002-5090-2075
FU Office of Naval Research Department of Defense Experimental Program to
   Stimulate Competitive Research (ONR DEPSCoR); NSF [IGERT 0653710]
FX Funding for this study was provided by the Office of Naval Research
   Department of Defense Experimental Program to Stimulate Competitive
   Research (ONR DEPSCoR) and the NSF Integrative Graduate Education and
   Research Traineeship (IGERT 0653710) Bioactive interfaces and Devices
   program.
CR ALBELDA SM, 1991, J CELL BIOL, V114, P1059, DOI 10.1083/jcb.114.5.1059
   Anderson ME, 2003, PHARMACEUT RES, V20, P1523, DOI 10.1023/A:1026188212126
   Bannerman DD, 2003, AM J PHYSIOL-LUNG C, V284, pL899, DOI 10.1152/ajplung.00338.2002
   BOGEN S, 1994, J EXP MED, V179, P1059, DOI 10.1084/jem.179.3.1059
   Buyukhatipoglu K, 2011, J BIOMED MATER RES A, V96A, P186, DOI 10.1002/jbm.a.32972
   Chertok B, 2008, BIOMATERIALS, V29, P487, DOI 10.1016/j.biomaterials.2007.08.050
   Christofidou-Solomidou M, 2003, AM J PHYSIOL-LUNG C, V285, pL283, DOI 10.1152/ajplung.00021.2003
   COMPORTI M, 1985, LAB INVEST, V53, P599
   Ding BS, 2006, MOL INTERV, V6, P98, DOI 10.1124/mi.6.2.7
   DUNLAP WC, 1995, COMP BIOCHEM PHYS B, V112, P105, DOI 10.1016/0305-0491(95)00086-N
   Dziubla TD, 2005, J CONTROL RELEASE, V102, P427, DOI 10.1016/j.jconrel.2004.10.017
   Dziubla TD, 2008, BIOMATERIALS, V29, P215, DOI 10.1016/j.biomaterials.2007.09.023
   Frei B, 1999, FASEB J, V13, P963
   Frimpong RA, 2010, NANOMEDICINE-UK, V5, P1401, DOI 10.2217/NNM.10.114
   Frimpong RA, 2010, J MAGN MAGN MATER, V322, P326, DOI 10.1016/j.jmmm.2009.09.050
   Garnacho C, 2008, J CONTROL RELEASE, V130, P226, DOI 10.1016/j.jconrel.2008.06.007
   Griffiths SM, 2011, ANAL CHEM, V83, P3778, DOI 10.1021/ac200103x
   Gupta AK, 2005, BIOMATERIALS, V26, P3995, DOI 10.1016/j.biomaterials.2004.10.012
   HALLIWELL B, 1992, J LAB CLIN MED, V119, P598
   Hanini A, 2011, INT J NANOMED, V6, P787, DOI 10.2147/IJN.S17574
   Hilger I, 2002, INVEST RADIOL, V37, P580, DOI 10.1097/00004424-200210000-00008
   Jansen T, 2010, J MOL CELL CARDIOL, V49, P186, DOI 10.1016/j.yjmcc.2010.04.011
   KALRA J, 1991, INT J EXP PATHOL, V72, P1
   Kosaraju SL, 2006, CARBOHYD POLYM, V64, P163, DOI 10.1016/j.carbpol.2005.11.027
   Lu M, 2010, AM J HEMATOL, V85, P315, DOI 10.1002/ajh.21656
   Macdonald J, 2003, BRIT J ANAESTH, V90, P221, DOI 10.1093/bja/aeg034
   Madamanchi NR, 2005, ARTERIOSCL THROM VAS, V25, P29, DOI 10.1161/01.ATV.0000150649.39934.13
   Muro S, 2006, J PHARMACOL EXP THER, V317, P1161, DOI 10.1124/jpet.105.098970
   Muro S, 2003, J CELL SCI, V116, P1599, DOI 10.1242/jcs.00367
   Muro S, 2008, MOL THER, V16, P1450, DOI 10.1038/mt.2008.127
   Newman PJ, 1997, J CLIN INVEST, V99, P3, DOI 10.1172/JCI119129
   POULIQUEN D, 1992, MAGNET RESON MED, V24, P75, DOI 10.1002/mrm.1910240108
   Qiao RR, 2009, J MATER CHEM, V19, P6274, DOI 10.1039/b902394a
   Rinaldi S, 2009, CURR DRUG TARGETS, V10, P872, DOI 10.2174/138945009789108774
   Sasaki M, 2007, J CLIN BIOCHEM NUTR, V40, P1, DOI 10.3164/jcbn.40.1
   Seo JY, 2002, PHARMACOLOGY, V64, P63, DOI 10.1159/000056152
   SHEK PN, 1994, J DRUG TARGET, V2, P431, DOI 10.3109/10611869408996819
   Spencer JPE, 2003, J NUTR, V133, p3255S
   Stroh A, 2004, FREE RADICAL BIO MED, V36, P976, DOI 10.1016/j.freeradbiomed.2004.01.016
   Sun BW, 2008, INT J BIOL SCI, V4, P270
   Taupitz M, 2004, INVEST RADIOL, V39, P394, DOI 10.1097/01.rli.0000129472.45832.b0
   Thorek DLJ, 2006, ANN BIOMED ENG, V34, P23, DOI 10.1007/s10439-005-9002-7
   Wattamwar PP, 2011, J BIOMED MATER RES A, V99A, P184, DOI 10.1002/jbm.a.33174
   Wattamwar PP, 2010, ADV FUNCT MATER, V20, P147, DOI 10.1002/adfm.200900839
   Wu XY, 2010, INT J NANOMED, V5, P385
   Xia T, 2008, ACS NANO, V2, P2121, DOI 10.1021/nn800511k
   Zhang CF, 2007, CANCER RES, V67, P1555, DOI 10.1158/0008-5475.CAN-06-1668
   Zhu MT, 2010, J NANOSCI NANOTECHNO, V10, P8584, DOI 10.1166/jnn.2010.2488
NR 48
TC 32
Z9 34
U1 5
U2 72
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
EI 1878-5905
J9 BIOMATERIALS
JI Biomaterials
PD DEC
PY 2013
VL 34
IS 37
BP 9615
EP 9622
DI 10.1016/j.biomaterials.2013.08.025
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 251AW
UT WOS:000326901200037
PM 24016851
DA 2018-03-19
ER

PT J
AU Rodgers, DW
AF Rodgers, David W.
TI LOW TEMPERATURE TECHNIQUES IN MACROMOLECULAR CRYSTALLOGRAPHY
SO ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES
LA English
DT Meeting Abstract
C1 [Rodgers, David W.] Univ Kentucky, Coll Med, Dept Biochem, Lexington, KY 40536 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU INT UNION CRYSTALLOGRAPHY
PI CHESTER
PA 2 ABBEY SQ, CHESTER, CH1 2HU, ENGLAND
SN 2053-2733
J9 ACTA CRYSTALLOGR A
JI Acta Crystallogr. Sect. A
PY 1996
VL 52
SU S
MA MS01.0103
BP C8
EP C8
DI 10.1107/S0108767396098674
PG 1
WC Chemistry, Multidisciplinary; Crystallography
SC Chemistry; Crystallography
GA VA8NO
UT WOS:000410481900033
OA gold
DA 2018-03-20
ER

PT J
AU Xu, J
   Bhattacharyya, D
AF Xu, Jian
   Bhattacharyya, Dibakar
TI Modeling of Fe/Pd nanoparticle-based functionalized membrane reactor for
   PCB dechlorination at room temperature
SO JOURNAL OF PHYSICAL CHEMISTRY C
LA English
DT Article
ID POLYELECTROLYTE NANOFILTRATION MEMBRANES; POLYCHLORINATED-BIPHENYLS;
   MICROFILTRATION MEMBRANES; BIMETALLIC NANOPARTICLES; TRANSPORT MODEL;
   ULTRAFILTRATION; FILMS; WATER; IMMOBILIZATION; COEFFICIENTS
AB This research deals with the modeling and experimental verification of polychlorinated biphenyl (PCB) dechlorination using a porous membrane reactor embedded with Fe/Pd nanoparticles. We synthesized core/shell Fe/Pd nanoparticles in polyvinylidene fluoride (PVDF) microfiltration membranes functionalized with poly(acrylic acid) (PAA). PAA functionalization was achieved by in situ free radical polymerization of acrylic acid in microfiltration membrane pores. Target ferrous ions were then introduced into the membranes by the ion exchange process. Subsequent reduction resulted in the in situ formation of 20-40 nm Fe nanoparticles. Bimetallic nanoparticles can be formed by post-deposition of Pd. The membranes and Fe/Pd nanoparticles were characterized by thermogravimetric analyzer (TGA), FTIR, scanning electron microscopy (SEM), and transmission electron microscopy (TEM). 2,2'-Dichlorobiphenyl (PCB4) and 3,3',4,4'-tertrachlorobiphenyl (PCB77) were chosen as the model compounds to investigate the catalytic properties of bimetallic nanoparticles, the reaction mechanism, and the intrinsic kinetics. A two-dimensional steady-state model was developed to correlate and simulate mass transfer and reaction in the membrane pores under pressure-driven convective flow conditions. The 2D model equations were solved by a finite element technique. The influence of changing parameters such as reactor geometry (i.e., membrane pore size) and Pd coating composition were evaluated by the model and compared well with the experimental data.
C1 [Xu, Jian; Bhattacharyya, Dibakar] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Bhattacharyya, D (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM db@engr.uky.edu
CR Avramescu ME, 2003, J MEMBRANE SCI, V216, P177, DOI 10.1016/S0376-7388(03)00070-X
   Bhattacharyya D, 1998, J MEMBRANE SCI, V141, P121, DOI 10.1016/S0376-7388(97)00301-3
   CHUANG FW, 1995, ENVIRON SCI TECHNOL, V29, P2460, DOI 10.1021/es00009a044
   Dotzauer DM, 2006, NANO LETT, V6, P2268, DOI 10.1021/nl061700q
   Ferry JD, 1936, J GEN PHYSIOL, V20, P95, DOI 10.1085/jgp.20.1.95
   Geismann C, 2005, MACROMOL CHEM PHYSIC, V206, P268, DOI 10.1002/macp.200400374
   Hagel L., 1988, J CHROMATOGRAPHY LIB, V40, P119
   He F, 2005, ENVIRON SCI TECHNOL, V39, P3314, DOI 10.1021/es048743y
   Hestekin JA, 2001, IND ENG CHEM RES, V40, P2668, DOI 10.1021/ie000572s
   Hong SU, 2006, IND ENG CHEM RES, V45, P6284, DOI 10.1021/ie060239+
   Hong SU, 2006, J MEMBRANE SCI, V280, P1, DOI 10.1016/j.memsci.2006.04.028
   Hussain I, 2003, LANGMUIR, V19, P4831, DOI 10.1021/la020710d
   Kiadambi S., 2005, CHEM MATER, V17, P301
   Legrand JC, 2004, CATAL TODAY, V89, P177, DOI 10.1016/j.cattod.2003.11.024
   Lindau J, 1998, J MEMBRANE SCI, V149, P11, DOI 10.1016/S0376-7388(98)00161-6
   Lowry GV, 2004, ENVIRON SCI TECHNOL, V38, P5208, DOI 10.1021/es049835q
   MEYER DE, 2007, PHYS CHEM B, V111, P7142
   Moharram MA, 2006, J APPL POLYM SCI, V102, P4049, DOI 10.1002/app.24367
   Nakano Y, 2003, WATER RES, V37, P2595, DOI 10.1016/S0043-1354(03)00077-0
   Noma Y, 2003, FRESEN ENVIRON BULL, V12, P302
   Rhim JW, 2004, J MEMBRANE SCI, V238, P143, DOI 10.1016/j.memsci.2004.03.030
   Ritchie SMC, 2001, ENVIRON SCI TECHNOL, V35, P3252, DOI 10.1021/es010617w
   Shah TN, 2005, APPL CATAL A-GEN, V296, P12, DOI 10.1016/j/apcata.2005.06.034
   SHAUB WM, 1983, ENVIRON SCI TECHNOL, V17, P721, DOI 10.1021/es00118a007
   Smuleac V, 2006, LANGMUIR, V22, P10118, DOI 10.1021/la061124d
   Tu SC, 2005, J MEMBRANE SCI, V265, P29, DOI 10.1016/j.memsci.2005.04.051
   Tu SC, 2001, AICHE J, V47, P1346, DOI 10.1002/aic.690470612
   ULBFICHT M, 2005, CHEM MATER, V17, P2622
   VANDENBERG GB, 1989, J MEMBRANE SCI, V47, P25, DOI 10.1016/S0376-7388(00)80858-3
   WILEY DE, 1985, DESALINATION, V52, P249, DOI 10.1016/0011-9164(85)80036-9
   WILKE CR, 1955, AICHE J, V1, P264, DOI 10.1002/aic.690010222
   Xu J, 2005, ENVIRON PROG, V24, P358, DOI 10.1002/ep.10106
   Xu J, 2005, J NANOPART RES, V7, P449, DOI 10.1007/s11051-005-4273-3
   Xu J, 2007, IND ENG CHEM RES, V46, P2348, DOI 10.1021/ie0611498
   Yang CF, 2001, AICHE J, V47, P295, DOI 10.1002/aic.690470208
   Ying L, 2004, LANGMUIR, V20, P6032, DOI 10.1021/la049383v
   Zanaroli G, 2006, BIODEGRADATION, V17, P19, DOI 10.1007/s10532-005-3752-7
   Zheng NF, 2006, J AM CHEM SOC, V128, P14278, DOI 10.1021/ja0659929
NR 38
TC 44
Z9 45
U1 1
U2 38
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1932-7447
J9 J PHYS CHEM C
JI J. Phys. Chem. C
PD JUN 26
PY 2008
VL 112
IS 25
BP 9133
EP 9144
DI 10.1021/jp7097262
PG 12
WC Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science,
   Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA 315ZZ
UT WOS:000256920000005
DA 2018-03-19
ER

PT J
AU Ghosh, K
   Lehmler, HJ
   Rankin, SE
   Knutson, BL
AF Ghosh, Kaustav
   Lehmler, Hans-Joachim
   Rankin, Stephen E.
   Knutson, Barbara L.
TI Supercritical carbon dioxide swelling of fluorinated and hydrocarbon
   surfactant templates in mesoporous silica thin films
SO JOURNAL OF COLLOID AND INTERFACE SCIENCE
LA English
DT Article
DE Carbon-dioxide penetration; 'CO2-philic' surfactants; Surfactant
   templated silica; Dip-coated films; Surfactant solution spreading
ID SOL-GEL METHOD; STUBBY SURFACTANTS; WATER; CO2; MICROEMULSIONS;
   STABILIZATION; SUBSTRATE; ENERGY; LIQUID; NANOPARTICLES
AB The penetration of compressed CO2 in hydrocarbon and fluorocarbon regions of concentrated surfactant mesophases are interpreted from differences in the CO2-processed pore expansion of mesoporous silica thin films templated by three surfactants containing varying degrees of hydrocarbon and fluorocarbon functionality. Ordered silica thin films are synthesized for the first time using the 16-carbon (C-16) Partly fluorinated surfactant, 11,11,12,12,13,13,14,14,15,15,16,16,16-tridecafluorocetyl pyridinium bromide (HFCPB), as a templating agent. Silica films templated with surfactants containing a 8-carbon (C-8) fluorocarbon tail (3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl pyridinium chloride (HFOPC)) and a 16-carbon (C-16) hydrocarbon tail (cetyl pyridinium bromide (CPB)) and HFCPB (C-16) are processed in compressed CO2 (69172 bar, 25 degrees C and 45 degrees C) during synthesis. CO2 processing results in significant pore expansion for films templated with both fluorinated surfactants, while pore expansion is negligible for the hydrocarbon templated material suggesting that preferential CO2 penetration occurs in the 'CO2-philic' fluorocarbon segments of the surfactant template. The effect of substrate surface energy on the final uniformity of the dip-coated films is studied by varying the substrate from unmodified glass to a fluorocarbon-capped substrate. The ability to create dip-coated thin films on low surface energy substrates through favorable interaction of surfactant template tail with the substrate surface functional groups is demonstrated. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Ghosh, Kaustav; Rankin, Stephen E.; Knutson, Barbara L.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Lehmler, Hans-Joachim] Univ Iowa, Dept Occupat & Environm Hlth, Iowa City, IA 52242 USA.
RP Knutson, BL (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM bknutson@engr.uky.edu
RI Rankin, Stephen/A-3265-2013
OI Rankin, Stephen/0000-0002-8615-7564; Lehmler,
   Hans-Joachim/0000-0001-9163-927X
FU National Science Foundation NIRT [DMR-0210517]; Kentucky Science and
   Engineering Foundation [KSEF-159-RDE-001]
FX The authors would like to acknowledge National Science Foundation NIRT
   Grant # DMR-0210517 and Kentucky Science and Engineering Foundation
   Grant KSEF-159-RDE-001 for funding this research project. We would also
   like to thank Dr. Sandhya Vyas for the synthesis of the fluorinated
   surfactants, Dr. Tonglei Li and Clare Aubrey Medendrop for assistance
   with the contact angle measurements and Dr. Todd Hastings for help with
   the profilometer.
CR Anand M, 2006, J PHYS CHEM B, V110, P14693, DOI 10.1021/jp0614401
   Baumer S, 2005, HANDBOOK OF PLASTIC OPTICS, P1
   Bearzotti A, 2004, J EUR CERAM SOC, V24, P1969, DOI 10.1016/S0955-2219(03)00521-1
   Beckman EJ, 2004, CHEM COMMUN, P1885, DOI 10.1039/b404406c
   Beckman EJ, 2004, J SUPERCRIT FLUID, V28, P121, DOI 10.1016/S0896-8446(03)00029-9
   BERNETT MK, 1959, J PHYS CHEM-US, V63, P1911, DOI 10.1021/j150581a028
   Blin JL, 2000, LANGMUIR, V16, P4229, DOI 10.1021/la9914615
   Boyle TJ, 1999, COMMENT INORG CHEM, V20, P209, DOI 10.1080/02603599908021444
   Callaghan J. M., 2008, LANGMUIR, V24, P6959
   Cece A, 1996, J PHYS CHEM-US, V100, P7435, DOI 10.1021/jp953627q
   Choi SY, 2004, ADV FUNCT MATER, V14, P335, DOI 10.1002/adfm.200305039
   Consan K. A., 1990, J SUPERCRIT FLUID, V3, P51, DOI DOI 10.1016/0896-8446(90)90008-A
   Crepaldi EL, 2003, J AM CHEM SOC, V125, P9770, DOI 10.1021/ja030070g
   da Rocha SRP, 2003, LANGMUIR, V19, P3114, DOI 10.1021/la026608y
   da Rocha SRP, 2002, J PHYS CHEM B, V106, P13250, DOI 10.1021/jp021485b
   Dardin A, 1998, J PHYS CHEM B, V102, P1775, DOI 10.1021/jp972127p
   DeSimone JM, 2002, SCIENCE, V297, P799, DOI 10.1126/science.1069622
   Devaprakasam D, 2004, LANGMUIR, V20, P1329, DOI 10.1021/la0359676
   Diaz ME, 2004, THIN SOLID FILMS, V460, P274, DOI 10.1016/j.tsf.2004.02.002
   Diep P, 1998, J PHYS CHEM A, V102, P2231, DOI 10.1021/jp9730306
   Fan FQ, 2004, LANGMUIR, V20, P3062, DOI 10.1021/la030380c
   FRANK B, 1995, LANGMUIR, V11, P87, DOI 10.1021/la00001a018
   Fustin CA, 2004, LANGMUIR, V20, P9114, DOI 10.1021/la0489413
   Ghosh K, 2005, LANGMUIR, V21, P6145, DOI 10.1021/la050311t
   Ghosh K, 2008, MICROPOR MESOPOR MAT, V113, P106, DOI 10.1016/j.micromeso.2007.11.017
   Ghosh K, 2007, J PHYS CHEM B, V111, P363, DOI 10.1021/jp0656680
   Hamadi F, 2009, MAT SCI ENG C-BIO S, V29, P1302, DOI 10.1016/j.msec.2008.10.023
   Hanrahan JP, 2005, LANGMUIR, V21, P4163, DOI 10.1021/la0470636
   HARRISON K, 1994, LANGMUIR, V10, P3536, DOI 10.1021/la00022a028
   Hillhouse HW, 2001, MICROPOR MESOPOR MAT, V44, P639, DOI 10.1016/S1387-1811(01)00244-X
   Holmes JD, 1998, LANGMUIR, V14, P6371, DOI 10.1021/la9806956
   Jacobson GB, 1999, J ORG CHEM, V64, P1201, DOI 10.1021/jo981825i
   Jannsen D., 2006, THIN SOLID FILMS, V515, P1433
   Kang S, 2006, J ELECTROCHEM SOC, V153, pA554, DOI 10.1149/1.2164769
   Kho YW, 2003, FLUID PHASE EQUILIBR, V206, P179, DOI 10.1016/S0378-3812(02)00316-3
   Klauk H., 2006, ORGANIC ELECT
   Koganti VR, 2005, J PHYS CHEM B, V109, P3279, DOI 10.1021/jp045037a
   Krechetnikov R, 2005, PHYS FLUIDS, V17, DOI 10.1063/1.2112647
   Krechetnikov R, 2006, J FLUID MECH, V559, P429, DOI 10.1017/S0022112006000425
   Kruk M, 2001, CHEM MATER, V13, P3169, DOI 10.1021/cm0101069
   Landau L, 1942, ACTA PHYSICOCHIM URS, V17, P42
   Lee CH, 2006, PHYS FLUIDS, V18, DOI 10.1063/1.2199874
   LEE JW, 1993, J MATER RES, V8, P3151, DOI 10.1557/JMR.1993.3151
   Li XX, 2008, CHEM MATER, V20, P3229, DOI 10.1021/cm8003479
   Lu YF, 1997, NATURE, V389, P364, DOI 10.1038/38699
   McLeod MC, 2003, J PHYS CHEM B, V107, P2693, DOI 10.1021/jp0218645
   Mourougou-Candoni N, 1999, LANGMUIR, V15, P6563, DOI 10.1021/la9901074
   *NIST CHEM WEBB, 2003, NIST STAND REF DAT N
   Novick BJ, 2004, IND ENG CHEM RES, V43, P515, DOI 10.1021/ie030688z
   O'Neill ML, 1998, IND ENG CHEM RES, V37, P3067, DOI 10.1021/ie980010x
   Pakizeh M, 2007, INT J HYDROGEN ENERG, V32, P2032, DOI 10.1016/j.ijhydene.2006.10.004
   Petit R.B., 1988, SOL GEL TECHNOLOGY T
   Rankin SE, 2004, MICROPOR MESOPOR MAT, V73, P197, DOI 10.1016/j.micromeso.2004.05.013
   Rankin S.E., 2001, MAT RES SOC S P, V636, pD12/1
   ROUFFIGNAC PD, 2004, ELECTROCHEM SOLID ST, V7, pG306
   Rubingh D. N., 1991, SURFACTANT SCI SERIE, V37
   Ryoo W, 2003, IND ENG CHEM RES, V42, P6348, DOI 10.1021/ie0300427
   Sagisaka M, 2004, LANGMUIR, V20, P2560, DOI 10.1021/la036074g
   Sagisaka M, 2003, LANGMUIR, V19, P8161, DOI 10.1021/la027040w
   Schlehter M., 1994, PLASTICS AUTOMOBILES
   Scriven L.E., 1988, MATER RES SOC S P, V121, P717, DOI DOI 10.1557/PR0C-121-717
   Senapati S, 2003, J PHYS CHEM B, V107, P12906, DOI 10.1021/jp035128s
   Shukla N., 2004, J MAGN MAGN MATER, P272
   Stone MT, 2004, J PHYS CHEM B, V108, P1962, DOI 10.1021/jp036224w
   Stone MT, 2003, J PHYS CHEM B, V107, P10185, DOI 10.1021/jp035422k
   Vazquez Z., 1995, J CHEM ENG DATA SER, V40, P611
   Vyas SM, 2006, NEW J CHEM, V30, P944, DOI 10.1039/b516039a
   SPARTAN, 1998, SPARTAN STUD VERS
   Wongcharee K, 2004, J SOL-GEL SCI TECHN, V29, P115, DOI 10.1023/B:JSST.0000023012.39842.c0
   Yang H, 1998, J MATER CHEM, V8, P1205, DOI 10.1039/a800004b
   YAZDI AV, 1995, J MATER RES, V10, P530, DOI 10.1557/JMR.1995.0530
   YERUSHALMIROZEN R, 1995, LANGMUIR, V11, P2806, DOI 10.1021/la00007a074
   Yonker CR, 2001, J PHYS CHEM A, V105, P308, DOI 10.1021/jp0031202
   Zisman W. A., 1964, ADV CHEM SER, P1
   [Anonymous], OPTICAL COATING APPL
   [Anonymous], HIGH PERFORMANCE EC
   [Anonymous], IMAGEJ IMAGE PROCESS
NR 77
TC 6
Z9 6
U1 0
U2 36
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0021-9797
J9 J COLLOID INTERF SCI
JI J. Colloid Interface Sci.
PD FEB 1
PY 2012
VL 367
BP 183
EP 192
DI 10.1016/j.jcis.2011.10.051
PG 10
WC Chemistry, Physical
SC Chemistry
GA 880LB
UT WOS:000299407500023
PM 22137851
DA 2018-03-20
ER

PT J
AU Tharappel, JC
   Ramineni, SK
   Reynolds, D
   Puleo, DA
   Roth, JS
AF Tharappel, Job C.
   Ramineni, Sandeep K.
   Reynolds, Drew
   Puleo, David A.
   Roth, John S.
TI Doxycycline impacts hernia repair outcomes
SO JOURNAL OF SURGICAL RESEARCH
LA English
DT Article
DE Doxycycline; Hernia; Collagen; Matrix metalloproteinase; MMP
ID INCISIONAL HERNIA; METALLOPROTEINASE INHIBITOR; MATRIX
   METALLOPROTEINASES; REPERFUSION INJURY; COLLAGEN; EXPRESSION; SKIN;
   DEGRADATION; DISEASE; MODEL
AB Background: Incisional hernias occur commonly in up to 20% of all abdominal operations. Incisional hernia formation has been associated with increased levels of matrix metalloproteinases (MMPs), reduced collagen 1, and increased collagen 3 expression. Doxycycline, a nonspecific inhibitor of MMPs, has been shown to beneficially reduce MMP levels in both cancer and aneurysm models. This study evaluates the impact of doxycycline upon MMP expression, collagen subtypes, and hernia repair distraction forces in an animal model of incisional hernia repair.
   Materials and methods: Twenty-four Sprague Dawley rats underwent incisional hernia creation and subsequent repair with polypropylene mesh. Animals were administered doxycycline or saline daily beginning 1 d prior to hernia repair and survived for 1, 2, or 4 wk. Serum and tissue were evaluated for MMP content and collagen subtyping utilizing enzyme-linked immunosorbent assay and Western blot. Tensiometric properties of the native abdominal wall after hernia repair were measured with an Instron Corp. (Canton, MA) mechanical testing system.
   Results: There were no differences in control and experimental groups 1 and 2 wk following hernia repair; 4 wk following hernia repair, doxycycline treated animals demonstrated reduced serum MMP-2 and MMP-9 levels, reduced tissue levels of MMP-2, MMP-3, and MMP-9, and increased collagen 1 to 3 ratios. Distraction forces required to disrupt the hernia repair were increased in the doxycycline treated group compared with controls.
   Conclusions: Doxycycline administration is associated with improved hernia repair strength with concomitant reduction of MMP levels with increased collagen 1 deposition. Longer term studies are required to better understand the impact of this treatment. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Tharappel, Job C.; Reynolds, Drew; Roth, J. Scott] Univ Kentucky, Coll Med, Dept Surg, Div Gen Surg, Lexington, KY 40536 USA.
   [Ramineni, Sandeep K.; Puleo, David A.] Univ Kentucky, Coll Engn, Ctr Biomed Engn, Lexington, KY 40536 USA.
RP Roth, JS (reprint author), Univ Kentucky, Med Ctr, Dept Surg, Div Gen Surg, 800 Rose St,C-226 UKMC, Lexington, KY 40536 USA.
EM tc.job@uky.edu
CR Antoniou SA, 2009, EUR J CLIN INVEST, V39, P953, DOI 10.1111/j.1365-2362.2009.02199.x
   Boyle JR, 1998, J VASC SURG, V27, P354, DOI 10.1016/S0741-5214(98)70367-2
   Casanova AB, 2009, AM J SURG, V198, P1, DOI 10.1016/j.amjsurg.2008.07.021
   Chow AK, 2007, BRIT J PHARMACOL, V152, P189, DOI 10.1038/sj.bjp.0707344
   Flum DR, 2003, ANN SURG, V237, P129, DOI 10.1097/00000658-200301000-00018
   Golub L M, 1998, Adv Dent Res, V12, P12
   GOLUB LM, 1991, CRIT REV ORAL BIOL M, V2, P297, DOI 10.1177/10454411910020030201
   Guimaraes DA, 2011, BASIC CLIN PHARMACOL, V108, P318, DOI 10.1111/j.1742-7843.2010.00656.x
   Harth KC, 2011, SURG ENDOSC, V25, P2224, DOI 10.1007/s00464-010-1534-8
   Kingsnorth A, 2006, ANN ROY COLL SURG, V88, P252, DOI 10.1308/003588406X106324
   Klinge U, 1999, EUR SURG RES, V31, P480, DOI 10.1159/000008728
   Lee HM, 2004, J PERIODONTOL, V75, P453, DOI 10.1902/jop.2004.75.3.453
   Liu J, 2003, J VASC SURG, V38, P1376, DOI 10.1016/S0741-5214(03)01022-X
   Luijendijk RW, 2000, NEW ENGL J MED, V343, P392, DOI 10.1056/NEJM200008103430603
   Rice RD, 2010, AESTHET PLAST SURG, V34, P290, DOI 10.1007/s00266-009-9449-2
   Roach DM, 2002, EUR J VASC ENDOVASC, V23, P260, DOI 10.1053/ejvs.2002.1598
   RUTKOW IM, 1993, SURG CLIN N AM, V73, P413
   Si ZY, 2002, SURGERY, V131, P324, DOI 10.1067/msy.2002.121376
   Stadelmann WK, 1998, AM J SURG, V176, p26S, DOI 10.1016/S0002-9610(98)00183-4
   Tae HJ, 2012, J PHARMACOL EXP THER, V343, P246, DOI 10.1124/jpet.112.197020
   Tessone A, 2005, CARDIOVASC DRUG THER, V19, P383, DOI 10.1007/s10557-005-5201-6
   Tharappel JC, 2003, TOXICOL SCI, V75, P300, DOI 10.1093/toxsci/kfg201
   UITTO VJ, 1994, ANN NY ACAD SCI, V732, P140, DOI 10.1111/j.1749-6632.1994.tb24731.x
   Villarreal FJ, 2003, CIRCULATION, V108, P1487, DOI 10.1161/01.CIR.0000089090.05757.34
   WAGH PV, 1974, J SURG RES, V17, P425, DOI 10.1016/0022-4804(74)90155-3
   Wang WJ, 2002, CIRCULATION, V106, P1543, DOI 10.1161/01.CIR.0000028818.33488.7B
   White B, 2007, AM SURGEON, V73, P1254
   Yaras N, 2008, BRIT J PHARMACOL, V155, P1174, DOI 10.1038/bjp.2008.373
NR 28
TC 5
Z9 5
U1 0
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0022-4804
J9 J SURG RES
JI J. Surg. Res.
PD SEP
PY 2013
VL 184
IS 1
BP 699
EP 704
DI 10.1016/j.jss.2013.05.101
PG 6
WC Surgery
SC Surgery
GA 207NX
UT WOS:000323609400111
PM 23830364
DA 2018-03-20
ER

PT J
AU Zhang, L
   Zhan, XW
   Cheng, YT
   Shirpour, M
AF Zhang, Long
   Zhan, Xiaowen
   Cheng, Y-T.
   Shirpour, Mona
TI Charge Transport in Electronic-Ionic Composites
SO JOURNAL OF PHYSICAL CHEMISTRY LETTERS
LA English
DT Article
ID LIFEPO4 SINGLE-CRYSTALS; AL-DOPED LI7LA3ZR2O12; SOLID-STATE BATTERIES;
   LITHIUM; CONDUCTIVITIES; CONDUCTOR; GARNETS
AB Composite electrodes consisting of cathode particles and an ion-conducting phase can address the limited ion accessibility of the cathode in high-energy all-solid-state lithium batteries. In this Letter, we discuss the microstructure-conductivity relationship in an electronic-ionic composite with a focus on lithium ion conductivity. This study is the first step toward further understanding of electrochemical reactions in all solid multiphase systems.
C1 [Zhang, Long; Zhan, Xiaowen; Cheng, Y. T.; Shirpour, Mona] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Shirpour, M (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM mona.shirpour@uky.edu
RI Cheng, Yang-Tse/B-5424-2012
OI Cheng, Yang-Tse/0000-0003-0737-9212; Zhan, Xiaowen/0000-0002-1422-6233
FU National Science Foundation [1355438]
FX The authors acknowledge financial support from the National Science
   Foundation (Award Number 1355438, Powering the Kentucky Bioeconomy for a
   Sustainable Future). The authors would also like to thank Dr. Nicolas
   Briot from the University of Kentucky EMC center for assisting with 3D
   reconstructed FIB-SEM measurements and Shuang Gao for helpful
   discussions.
CR Amin R, 2008, SOLID STATE IONICS, V179, P1683, DOI 10.1016/j.ssi.2008.01.079
   Amin R, 2008, PHYS CHEM CHEM PHYS, V10, P3524, DOI 10.1039/b801795f
   Amin R, 2007, ELECTROCHEM SOLID ST, V10, pA13, DOI 10.1149/1.2388240
   Amin R, 2016, J ELECTROCHEM SOC, V163, pA1512, DOI 10.1149/2.0131608jes
   Amin R, 2009, ADV FUNCT MATER, V19, P1697, DOI 10.1002/adfm.200801604
   Buannic L, 2017, CHEM MATER, V29, P1769, DOI 10.1021/acs.chemmater.6b05369
   Chen DF, 2013, ENERGIES, V6, P1632, DOI 10.3390/en6031632
   Chen DF, 2009, J POWER SOURCES, V191, P240, DOI 10.1016/j.jpowsour.2009.02.051
   Chen RJ, 2016, MATER HORIZ, V3, P487, DOI 10.1039/c6mh00218h
   El-Shinawi H, 2017, J MATER CHEM A, V5, P319, DOI 10.1039/c6ta06961d
   Gellert M, 2012, J PHYS CHEM C, V116, P22675, DOI 10.1021/jp305309r
   Han FD, 2016, ADV ENERGY MATER, V6, DOI 10.1002/aenm.201501590
   Hansel C, 2016, NANOSCALE, V8, P18412, DOI 10.1039/c6nr06955j
   Jian ZL, 2017, ADV MATER, V29, DOI 10.1002/adma.201601925
   Kamaya N, 2011, NAT MATER, V10, P682, DOI [10.1038/nmat3066, 10.1038/NMAT3066]
   Kotobuki M, 2010, J ELECTROCHEM SOC, V157, pA1076, DOI 10.1149/1.3474232
   Maier J., 2004, PHYS CHEM IONIC MAT
   MANTHIRAM A, 2017, NATURE REV MAT, V2
   Maram PS, 2013, ANGEW CHEM INT EDIT, V52, P12139, DOI 10.1002/anie.201305375
   Orikasa Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep26382
   Shin DO, 2015, SCI REP-UK, V5, DOI 10.1038/srep18053
   Siroma Z, 2016, J POWER SOURCES, V316, P215, DOI 10.1016/j.jpowsour.2016.03.059
   Tao XY, 2017, NANO LETT, V17, P2967, DOI 10.1021/acs.nanolett.7b00221
   Wu JF, 2017, ACS APPL MATER INTER, V9, P12461, DOI 10.1021/acsami.7b00614
   Xia WH, 2016, ACS APPL MATER INTER, V8, P5335, DOI 10.1021/acsami.5b12186
   Yan XF, 2017, J PHYS CHEM C, V121, P1431, DOI 10.1021/acs.jpcc.6b10268
   Yan YG, 2017, ADV ENERGY MATER, V7, DOI 10.1002/aenm.201700294
   YOKOTA I, 1961, J PHYS SOC JPN, V16, P2213, DOI 10.1143/JPSJ.16.2213
   Zhan X., 2017, DEFECT CHEM ELECT PR, P247
   Zhang JJ, 2017, J MATER CHEM A, V5, P4940, DOI 10.1039/c6ta10066j
NR 30
TC 0
Z9 0
U1 24
U2 24
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1948-7185
J9 J PHYS CHEM LETT
JI J. Phys. Chem. Lett.
PD NOV 2
PY 2017
VL 8
IS 21
BP 5385
EP 5389
DI 10.1021/acs.jpclett.7b02267
PG 5
WC Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science,
   Multidisciplinary; Physics, Atomic, Molecular & Chemical
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA FM0BE
UT WOS:000414623000025
PM 29016135
DA 2018-03-19
ER

PT J
AU Li, TL
AF Li, Tonglei
TI Materials engineering of solid-state dosage forms
SO PHARMACEUTICAL RESEARCH
LA English
DT Editorial Material
ID NUCLEATION; POLYMORPH; CRYSTALLIZATION; CRYSTALS
C1 Univ Kentucky, Lexington, KY 40536 USA.
EM tonglei@uky.edu
CR Day GM, 2005, ACTA CRYSTALLOGR B, V61, P511, DOI 10.1107/S0108768105016563
   GARETZ BA, 2002, PHYS REV LETT, V61
   Gu CH, 2002, J CRYST GROWTH, V235, P471, DOI 10.1016/S0022-0248(01)01784-5
   Hancock BC, 1997, J PHARM SCI, V86, P1, DOI 10.1021/js9601896
   Hilden JL, 2003, CRYST GROWTH DES, V3, P921, DOI 10.1021/cg034061v
   KAWASHIMA Y, 1982, SCIENCE, V216, P1127, DOI 10.1126/science.216.4550.1127
   Lang MD, 2002, J AM CHEM SOC, V124, P14834, DOI 10.1021/ja0286526
   Lee AY, 2002, LANGMUIR, V18, P5886, DOI 10.1021/la025704w
   Li TL, 2002, CRYST GROWTH DES, V2, P177, DOI 10.1021/cg020002q
   McCrone W. C., 1965, PHYSICS CHEMISTRY OR, VII, P725
   Mitchell CA, 2001, J AM CHEM SOC, V123, P10830, DOI 10.1021/ja004085f
   Peterson ML, 2002, J AM CHEM SOC, V124, P10958, DOI 10.1021/ja020751w
   Thayer AM, 2007, CHEM ENG NEWS, V85, P17, DOI 10.1021/cen-v085n025.p017
   van Veenendaal E, 1998, SURF SCI, V417, P121, DOI 10.1016/S0039-6028(98)00676-1
   WEISSBUCH I, 1991, SCIENCE, V253, P637, DOI 10.1126/science.253.5020.637
   WEISSBUCH I, 1995, ACTA CRYSTALLOGR B, V51, P115, DOI 10.1107/S0108768194012061
   Yu L, 2003, J AM CHEM SOC, V125, P6380, DOI 10.1021/ja0351544
NR 17
TC 2
Z9 2
U1 0
U2 1
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
J9 PHARM RES
JI Pharm. Res.
PD APR
PY 2008
VL 25
IS 4
BP 949
EP 952
DI 10.1007/s11095-007-9474-2
PG 4
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 285AE
UT WOS:000254748900023
PM 17985215
DA 2018-03-20
ER

PT J
AU Duan, JH
   Vogt, FG
   Li, XJ
   Hayes, D
   Mansour, HM
AF Duan, Jinghua
   Vogt, Frederick G.
   Li, Xiaojian
   Hayes, Don, Jr.
   Mansour, Heidi M.
TI Design, characterization, and aerosolization of organic solution
   advanced spray-dried moxifloxacin and ofloxacin
   dipalmitoylphosphatidylcholine (DPPC) microparticulate/nanoparticulate
   powders for pulmonary inhalation aerosol delivery
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE lung infection; respiratory; lung surfactant; solid-state particle
   engineering design; aerosol; fluoroquinolone antibiotic drug delivery
ID PHYSICOCHEMICAL CHARACTERIZATION; DRUG-DELIVERY; MULTIFUNCTIONAL
   PARTICLES; PHYSICAL-CHARACTERIZATION; CHITOSAN MICROSPHERES; LUNG;
   TUBERCULOSIS; MICROPARTICLES; NANOMEDICINE; PERFORMANCE
AB The aim of this study was to design and develop respirable antibiotics moxifloxacin (MOXI) hydrochloride and ofloxacin (OFLX) microparticles and nanoparticles, and multifunctional antibiotics particles with or without lung surfactant 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) for targeted dry powder inhalation delivery as a pulmonary nanomedicine. Particles were rationally designed and produced by advanced spray-drying particle engineering from an organic solution in closed mode (no water) from dilute solution. Scanning electron microscopy indicated that these particles had both optimal particle morphology and surface morphology, and the particle size distributions were suitable for pulmonary delivery. Comprehensive and systematic physicochemical characterization and in vitro aerosol dispersion performance revealed significant differences between these two fluoroquinolone antibiotics following spray drying as drug aerosols and as cospray-dried antibiotic drug: DPPC aerosols. Fourier transform infrared spectroscopy and confocal Raman microspectroscopy were employed to probe composition and interactions in the solid state. Spray-dried MOXI was rendered noncrystalline (amorphous) following organic solution advanced spray drying. This was in contrast to spray-dried OFLX, which retained partial crystallinity, as did OFLX: DPPC powders at certain compositions. Aerosol dispersion performance was conducted using inertial impaction with a dry powder inhaler device approved for human use. The present study demonstrates that the use of DPPC offers improved aerosol delivery of MOXI as cospray-dried microparticulate/nanoparticulate powders, whereas residual partial crystallinity influenced aerosol dispersion of OFLX and most of the compositions of OFLX: DPPC inhalation powders.
C1 [Duan, Jinghua; Li, Xiaojian] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Drug Dev Div, Lexington, KY USA.
   [Duan, Jinghua] Univ Washington, Dept Pharmaceut, Coll Pharm, Seattle, WA 98195 USA.
   [Vogt, Frederick G.] GlaxoSmithKline, Analyt Sci, Prod Dev, King Of Prussia, PA USA.
   [Hayes, Don, Jr.] Ohio State Univ, Coll Med, Dept Pediat, Columbus, OH 43210 USA.
   [Hayes, Don, Jr.] Ohio State Univ, Coll Med, Dept Internal Med, Nationwide Childrens Hosp Lung & Heart Lung Trans, Columbus, OH 43210 USA.
   [Hayes, Don, Jr.] Ohio State Univ, Davis Heart & Lung Res Inst, Columbus, OH 43210 USA.
   [Mansour, Heidi M.] Univ Arizona, Coll Pharm, Skaggs Ctr Pharmaceut Sci, Tucson, AZ 85721 USA.
RP Mansour, HM (reprint author), Univ Arizona, Coll Pharm, Skaggs Ctr Pharmaceut Sci, 1703 E Mabel St, Tucson, AZ 85721 USA.
EM mansour@pharmacy.arizona.edu
RI duan, jinghua/H-2738-2014; Li, Xiaojian/N-3421-2015
FU UK Center of Membrane Sciences; Graduate School Academic Year
   Fellowship; Daniel R Reedy Quality Achievement Fellowship
FX The authors thank Dr Dicky Sick Ki Yu for SEM access, Dr Tonglei Li for
   XRPD and HSM access, and Dr Hilt for ATR-FTIR access at the University
   of Kentucky. The authors gratefully acknowledge Visiting Scholarship
   support to Dr Jinghua Duan. The authors gratefully acknowledge
   fellowship support from the UK Center of Membrane Sciences, the Graduate
   School Academic Year Fellowship, and the Daniel R Reedy Quality
   Achievement Fellowship awarded to Xiaojian Li.
CR Adi H, 2008, J PHARM SCI-US, V97, P2780, DOI 10.1002/jps.21195
   Alangaden GJ, 1997, CLIN INFECT DIS, V25, P1213, DOI 10.1086/516116
   Alves GP, 2004, POWDER TECHNOL, V145, P139, DOI 10.1016/j.powtec.2004.06.008
   Brittain HG, 2001, SPECTROSCOPY, V16, P7
   Chimote G, 2009, J BIOMED MATER RES A, V89A, P281, DOI 10.1002/jbm.a.31959
   Dunbar CA, 1998, KONA, V16, P7
   Finlay Warren, 2008, ARLA RESP DEPOSITION
   Finlay W. H., 2001, MECH INHALED PHARM A
   Ganguly S, 2008, J AEROSOL MED PULM D, V21, P343, DOI 10.1089/jamp.2007.0675
   Garcia-Contreras L, 2002, ADV DRUG DELIVER REV, V54, P1491, DOI 10.1016/S0169-409X(02)00159-X
   Gilbert BE, 1996, J AEROSOL MED, V9, P111, DOI 10.1089/jam.1996.9.111
   Gosling RD, 2003, AM J RESP CRIT CARE, V168, P1342, DOI 10.1164/rccm.200305-682OC
   Hayes D, 2010, RESPIROLOGY, V15, P184, DOI 10.1111/j.1440-1843.2009.01647.x
   Hickey A. J., 2008, MODIFIED RELEASE DRU, P573
   Hickey AJ, 2009, MODERN PHARM, P191
   Hickey AJ, 2007, J PHARM SCI-US, V96, P1302, DOI 10.1002/jps.20943
   Hickey AJ, 2007, J PHARM SCI-US, V96, P1282, DOI 10.1002/jps.20916
   Humma LM, 1996, AM J HEALTH-SYST PH, V53, P2291
   Hwang SM, 2008, J CONTROL RELEASE, V129, P100, DOI 10.1016/j.jconrel.2008.04.009
   Kawahara S, 1999, Kekkaku, V74, P71
   Kurmi BD, 2010, EXPERT OPIN DRUG DEL, V7, P781, DOI 10.1517/17425247.2010.492212
   Li X, 2011, PEDIATR PULM, P346
   Li XJ, 2011, AAPS PHARMSCITECH, V12, P1420, DOI 10.1208/s12249-011-9704-0
   Ludwig E, 1993, Int J Antimicrob Agents, V3, P49, DOI 10.1016/0924-8579(93)90005-P
   Mansour H, 2001, LANGMUIR, V17, P6622, DOI 10.1021/la0108454
   Mansour HM, 2007, AAPS PHARMSCITECH, V8, DOI 10.1208/pt0804099
   Mansour HM, 2007, LANGMUIR, V23, P3809, DOI 10.1021/la063053o
   Mansour HM, 2007, J PHARM SCI-US, V96, P377, DOI 10.1002/jps.20810
   Mansour HM, 2009, INT J NANOMED, V4, P299
   Mansour HM, 2011, LIPIDS NANOTECHNOLOG, P221
   Meenach SA, 2013, INT J NANOMED, V8, P275, DOI 10.2147/IJN.S30724
   Okusanya OO, 2009, ANTIMICROB AGENTS CH, V53, P3847, DOI 10.1128/AAC.00872-08
   Palazzo F, 2013, INT J PHARMACEUT, V440, P273, DOI 10.1016/j.ijpharm.2012.05.045
   Park CW, 2012, ADV DRUG DELIVER REV, V64, P344, DOI 10.1016/j.addr.2011.08.004
   Park CW, 2011, EUROPEAN PHARM REV, V16, P32
   Park JH, 2013, INT J PHARMACEUT, V441, P562, DOI 10.1016/j.ijpharm.2012.10.044
   Pison U, 2006, EUR J PHARMACOL, V533, P341, DOI 10.1016/j.ejphar.2005.12.068
   Song JH, 2008, INT J ANTIMICROB AG, V32, pS207, DOI 10.1016/S0924-8579(09)70004-4
   Suarez S, 2000, Respir Care, V45, P652
   TODD PA, 1991, DRUGS, V42, P825, DOI 10.2165/00003495-199142050-00008
   Ventura CA, 2008, EUR J PHARM BIOPHARM, V68, P235, DOI 10.1016/j.ejpb.2007.05.011
   Weers J, 2009, J AEROSOL MED PULM D, V22, P131, DOI 10.1089/jamp.2008.0693
   Willis L, 2012, LUNG, V190, P251, DOI 10.1007/s00408-011-9360-x
   Wu X, 2013, INT J NANOMED, V8, P1269, DOI 10.2147/IJN.S40904
   Wu X, 2013, DRUG DES DEV THER, V7, P59, DOI [10.2147/DDDT.540166, 10.2147/DDDT.S40166]
   Wu XA, 2010, KONA POWDER PART J, P3
   Xu Z, 2011, J ADHES SCI TECHNOL, V25, P451, DOI 10.1163/016942410X525669
   Xu Z, 2010, J PHARM SCI-US, V99, P3442, DOI 10.1002/jps.22057
   Zeng XM, 2001, PHARM SCI SERIES
   [Anonymous], 2006, USP 29 NF 24 US PHAR, V29/24, P2617
NR 50
TC 17
Z9 18
U1 0
U2 19
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2013
VL 8
BP 3489
EP 3505
DI 10.2147/IJN.S48631
PG 17
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA 217NO
UT WOS:000324366400001
PM 24092972
OA gold
DA 2018-03-20
ER

PT J
AU Davenport, DM
   Gui, MH
   Ormsbee, LR
   Bhattacharyya, D
AF Davenport, Douglas M.
   Gui, Minghui
   Ormsbee, Lindell R.
   Bhattacharyya, Dibakar
TI Development of PVDF Membrane Nanocomposites via Various
   Functionalization Approaches for Environmental Applications
SO POLYMERS
LA English
DT Article
DE phase inversion; free radical polymerization; polyelectrolyte; water
   remediation
ID SPONGE-LIKE; POLY(VINYLIDENE FLUORIDE); COUNTERION CONDENSATION;
   PHASE-SEPARATION; DISTILLATION; TEMPERATURE; WATER; ULTRAFILTRATION;
   BEHAVIOR; SYSTEMS
AB Membranes are finding wide applications in various fields spanning biological, water, and energy areas. Synthesis of membranes to provide tunable flux, metal sorption, and catalysis has been done through pore functionalization of microfiltration (MF) type membranes with responsive behavior. This methodology provides an opportunity to improve synthetic membrane performance via polymer fabrication and surface modification. By optimizing the polymer coagulation conditions in phase inversion fabrication, spongy polyvinylidene fluoride (PVDF) membranes with high porosity and large internal pore volume were created in lab and full scale. This robust membrane shows a promising mechanical strength as well as high capacity for loading of adsorptive and catalytic materials. By applying surface modification techniques, synthetic membranes with different functionality (carboxyl, amine, and nanoparticle-based) were obtained. These functionalities provide an opportunity to fine-tune the membrane surface properties such as charge and reactivity. The incorporation of stimuli-responsive acrylic polymers (polyacrylic acid or sodium polyacrylate) in membrane pores also results in tunable pore size and ion-exchange capacity. This provides the added benefits of adjustable membrane permeability and metal capture efficiency. The equilibrium and dynamic binding capacity of these functionalized spongy membranes were studied via calcium ion-exchange. Iron/palladium catalytic nanoparticles were immobilized in the polymer matrix in order to perform the challenging degradation of the environmental pollutant trichloroethylene (TCE).
C1 [Davenport, Douglas M.; Gui, Minghui; Bhattacharyya, Dibakar] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Davenport, Douglas M.; Gui, Minghui; Bhattacharyya, Dibakar] Univ Kentucky, Ctr Membrane Sci, Lexington, KY 40506 USA.
   [Ormsbee, Lindell R.] Univ Kentucky, Dept Civil Engn, Lexington, KY 40506 USA.
RP Bhattacharyya, D (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.; Bhattacharyya, D (reprint author), Univ Kentucky, Ctr Membrane Sci, Lexington, KY 40506 USA.
EM dougdvnprt@gmail.com; guiminghui@gmail.com; lindell.ormsbee@uky.edu;
   db@uky.edu
FU National Institute of Environmental Health Sciences Superfund Research
   Program of the National Institutes of Health (NIH-NIEHS-SRP)
   [P42ES007380]; NSF KY EPSCoR program
FX This project has been supported by the National Institute of
   Environmental Health Sciences Superfund Research Program of the National
   Institutes of Health (NIH-NIEHS-SRP) under Award Number P42ES007380, and
   by NSF KY EPSCoR program. The content is solely the responsibility of
   the authors and does not necessarily represent the official views of
   NIH. We thank the significant contributions of Nanostone Water Co.
   (Oceanside, CA, USA) for joint development of larger-scale
   functionalized and spongy membranes.
CR BOTTINO A, 1988, DESALINATION, V68, P167, DOI 10.1016/0011-9164(88)80052-3
   BOTTINO A, 1991, J MEMBRANE SCI, V57, P1, DOI 10.1016/S0376-7388(00)81159-X
   Calo VM, 2015, INT J ADV ENG SCI AP, V7, P2, DOI 10.1007/s12572-015-0132-3
   Chen Q, 2014, J BIOMECH, V47, P1332, DOI 10.1016/j.jbiomech.2014.02.010
   Chen Q, 2013, J MECH BEHAV BIOMED, V19, P3, DOI 10.1016/j.jmbbm.2012.10.012
   Cheng LP, 1999, MACROMOLECULES, V32, P6668, DOI 10.1021/ma990418l
   Darvishmanesh S, 2015, CURR OPIN CHEM ENG, V8, P98, DOI 10.1016/j.coche.2015.04.002
   Dukhin SS, 2007, J PHYS CHEM B, V111, P979, DOI 10.1021/jp065585j
   Elimelech M, 2011, SCIENCE, V333, P712, DOI 10.1126/science.1200488
   Greenlee LF, 2009, WATER RES, V43, P2317, DOI 10.1016/j.watres.2009.03.010
   Gui MH, 2015, J MEMBRANE SCI, V488, P79, DOI 10.1016/j.memsci.2015.03.089
   Gui M, 2013, IND ENG CHEM RES, V52, P10430, DOI 10.1021/ie400507c
   Guo YF, 2010, J APPL POLYM SCI, V116, P1005, DOI 10.1002/app.31457
   Ji GL, 2007, POLYMER, V48, P6415, DOI 10.1016/j.polymer.2007.08.049
   Kinasiewicz A, 2007, TRANSPL P, V39, P2914, DOI 10.1016/j.transproceed.2007.08.061
   Kotte MR, 2015, ENVIRON SCI TECHNOL, V49, P9431, DOI 10.1021/acs.est.5b01594
   LAKES R, 1993, NATURE, V361, P511, DOI 10.1038/361511a0
   Li L, 2014, RSC ADV, V4, P3938, DOI 10.1039/c3ra45134h
   Li Q, 2010, J APPL POLYM SCI, V115, P2277, DOI 10.1002/app.31324
   Liu F, 2011, J MEMBRANE SCI, V375, P1, DOI 10.1016/j.memsci.2011.03.014
   Loo SL, 2015, DESALIN WATER TREAT, V53, P1506, DOI 10.1080/19443994.2014.943064
   MANNING GS, 1969, J CHEM PHYS, V51, P924, DOI 10.1063/1.1672157
   Mao YC, 2014, ADV ENERGY MATER, V4, DOI 10.1002/aenm.201301624
   Mi FL, 2001, BIOMATERIALS, V22, P165, DOI 10.1016/S0142-9612(00)00167-8
   Miserez A, 2008, ADV FUNCT MATER, V18, P1241, DOI 10.1002/adfm.200701135
   Nejati S, 2015, J MEMBRANE SCI, V492, P355, DOI 10.1016/j.memsci.2015.05.033
   Nurmi JT, 2005, ENVIRON SCI TECHNOL, V39, P1221, DOI 10.1021/es049190u
   Shao X, 2014, J MATER CHEM A, V2, P410, DOI 10.1039/c3ta13744a
   Silva TLS, 2015, DESALINATION, V357, P233, DOI 10.1016/j.desal.2014.11.025
   Smuleac V, 2010, J MEMBRANE SCI, V346, P310, DOI 10.1016/j.memsci.2009.09.052
   Sun ST, 2013, SOFT MATTER, V9, P2878, DOI 10.1039/c2sm27544a
   Tomaszewska M, 1996, DESALINATION, V104, P1, DOI 10.1016/0011-9164(96)00020-3
   Wandera D, 2010, J MEMBRANE SCI, V357, P6, DOI 10.1016/j.memsci.2010.03.046
   Wang ZY, 2014, EUR POLYM J, V60, P262, DOI 10.1016/j.eurpolymj.2014.09.015
   Wei J, 2011, J MEMBRANE SCI, V372, P292, DOI 10.1016/j.memsci.2011.02.013
   Xiao L, 2015, IND ENG CHEM RES, V54, P4174, DOI 10.1021/ie504149t
   Yeow ML, 2004, J APPL POLYM SCI, V92, P1782, DOI 10.1002/app.20141
   Yeow ML, 2003, J APPL POLYM SCI, V90, P2150, DOI 10.1002/app.12846
   Zhu YZ, 2015, J MEMBRANE SCI, V477, P131, DOI 10.1016/j.memsci.2014.12.026
NR 39
TC 4
Z9 4
U1 3
U2 43
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 2073-4360
J9 POLYMERS-BASEL
JI Polymers
PD FEB
PY 2016
VL 8
IS 2
AR 32
DI 10.3390/polym8020032
PG 17
WC Polymer Science
SC Polymer Science
GA DG2KJ
UT WOS:000371895500015
OA gold
DA 2018-03-19
ER

PT J
AU Hollis, CP
   Weiss, HL
   Evers, BM
   Gemeinhart, RA
   Li, TL
AF Hollis, Christin P.
   Weiss, Heidi L.
   Evers, B. Mark
   Gemeinhart, Richard A.
   Li, Tonglei
TI In Vivo Investigation of Hybrid Paclitaxel Nanocrystals with Dual
   Fluorescent Probes for Cancer Theranostics
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE breast cancer; MMPSense; nanocrystals; paclitaxel; theranostics
ID NEAR-INFRARED FLUORESCENT; DRUG-DELIVERY SYSTEM; MICELLAR NANOMEDICINE;
   CARCINOMA-CELLS; NUDE-MICE; TUMORS; NANOPARTICLES; FIBROBLASTS;
   METASTASIS; EXPRESSION
AB To develop novel hybrid paclitaxel (PTX) nanocrystals, in which bioactivatable (MMPSenseA (R) 750 FAST) and near infrared (Flamma FluorA (R) FPR-648) fluorophores are physically incorporated, and to evaluate their anticancer efficacy and diagnostic properties in breast cancer xenograft murine model.
   The pure and hybrid paclitaxel nanocrystals were prepared by an anti-solvent method, and their physical properties were characterized. The tumor volume change and body weight change were evaluated to assess the treatment efficacy and toxicity. Bioimaging of treated mice was obtained non-invasively in vivo.
   The released MMPSense molecules from the hybrid nanocrystals were activated by matrix metalloproteinases (MMPs) in vivo, similarly to the free MMPSense, demonstrating its ability to monitor cancer progression. Concurrently, the entrapped FPR-648 was imaged at a different wavelength. Furthermore, when administered at 20 mg/kg, the nanocrystal formulations exerted comparable efficacy as TaxolA (R), but with decreased toxicity.
   Hybrid nanocrystals that physically integrated two fluorophores were successfully prepared from solution. Hybrid nanocrystals were shown not only exerting antitumor activity, but also demonstrating the potential of multi-modular bioimaging for diagnostics.
C1 [Hollis, Christin P.] Univ Kentucky, Dept Pharmaceut Sci, Coll Pharm, Lexington, KY 40536 USA.
   [Weiss, Heidi L.] Univ Kentucky, Div Canc Biostat, Markey Canc Ctr, Lexington, KY 40506 USA.
   [Evers, B. Mark] Univ Kentucky, Dept Surg, Lexington, KY 40506 USA.
   [Evers, B. Mark] Univ Kentucky, Markey Canc Ctr, Lexington, KY 40506 USA.
   [Gemeinhart, Richard A.] Univ Illinois, Dept Biopharmaceut Sci, Chicago, IL 60612 USA.
   [Gemeinhart, Richard A.] Univ Illinois, Dept Bioengn, Chicago, IL 60612 USA.
   [Gemeinhart, Richard A.] Univ Illinois, Dept Ophthalmol & Visual Sci, Chicago, IL 60612 USA.
   [Li, Tonglei] Purdue Univ, Dept Ind & Phys Pharm, Coll Pharm, W Lafayette, IN 47907 USA.
RP Li, TL (reprint author), Purdue Univ, Dept Ind & Phys Pharm, Coll Pharm, Heine Pharm Bldg,575 Stadium Mall Dr, W Lafayette, IN 47907 USA.
EM tonglei@purdue.edu
RI Gemeinhart, Richard/B-8017-2008
OI Gemeinhart, Richard/0000-0002-1580-7304
FU National Cancer Institute [R25CA153954]
FX The project described was supported by Grant Number R25CA153954 from the
   National Cancer Institute. The content is solely the responsibility of
   the authors and does not necessarily represent the official views of the
   National Cancer Institute or the National Institutes of Health.
CR Al-Jamal WT, 2011, ACCOUNTS CHEM RES, V44, P1094, DOI 10.1021/ar200105p
   Blanco E, 2009, EXP BIOL MED, V234, P123, DOI 10.3181/0808-MR-250
   Caldorera-Moore ME, 2011, ACCOUNTS CHEM RES, V44, P1061, DOI 10.1021/ar2001777
   Clapper ML, 2011, NEOPLASIA, V13, P685, DOI 10.1593/neo.11400
   Groves K, 2009, MMPSENSE 750 FAST AA
   Guthi JS, 2010, MOL PHARMACEUT, V7, P32, DOI 10.1021/mp9001393
   Iwata H, 1996, JPN J CANCER RES, V87, P602, DOI 10.1111/j.1349-7006.1996.tb00266.x
   Janib SM, 2010, ADV DRUG DELIVER REV, V62, P1052, DOI 10.1016/j.addr.2010.08.004
   KOZLOWSKI JM, 1984, CANCER RES, V44, P3522
   Levine DH, 2008, METHODS, V46, P25, DOI 10.1016/j.ymeth.2008.05.006
   Li SH, 2012, BIOCONJUGATE CHEM, V23, P1322, DOI 10.1021/bc300175d
   Maeng JH, 2010, BIOMATERIALS, V31, P4995, DOI 10.1016/j.biomaterials.2010.02.068
   MEYVISCH C, 1983, CANCER METAST REV, V2, P295, DOI 10.1007/BF00048482
   MORIKAWA K, 1988, CANCER RES, V48, P6863
   POULSOM R, 1993, J CLIN PATHOL, V46, P429, DOI 10.1136/jcp.46.5.429
   Sanson C, 2011, ACS NANO, V5, P1122, DOI 10.1021/nn102762f
   SHAFIE SM, 1980, CANCER LETT, V11, P81, DOI 10.1016/0304-3835(80)90097-X
   Singer CF, 2002, BREAST CANCER RES TR, V72, P69, DOI 10.1023/A:1014918512569
   Sparreboom A, 1996, CANCER RES, V56, P2112
   Vartak DG, 2007, J DRUG TARGET, V15, P1, DOI 10.1080/10611860600968967
   VOLPE JPG, 1990, CLIN EXP METASTAS, V8, P381, DOI 10.1007/BF01810682
   Weissleder R, 1999, NAT BIOTECHNOL, V17, P375, DOI 10.1038/7933
   Weng KC, 2008, NANO LETT, V8, P2851, DOI 10.1021/nl801488u
   Zhao RS, 2011, MOL PHARMACEUT, V8, P1985, DOI 10.1021/mp200154k
NR 24
TC 20
Z9 20
U1 3
U2 38
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
EI 1573-904X
J9 PHARM RES-DORDR
JI Pharm. Res.
PD JUN
PY 2014
VL 31
IS 6
BP 1450
EP 1459
DI 10.1007/s11095-013-1048-x
PG 10
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA AI3FK
UT WOS:000336745800009
PM 23619595
DA 2018-03-20
ER

PT J
AU Wagner, J
   Yao, JY
   Rodgers, D
   Hinds, B
AF Wagner, Jonathan M.
   Yao, Jingyuan
   Rodgers, David W.
   Hinds, Bruce J.
TI Template synthesis of test tube nanoparticles using non-destructive
   replication
SO NANOTECHNOLOGY
LA English
DT Article
ID NANO TEST TUBES; DRUG-DELIVERY; NANOTUBES; ARRAYS; TOXICITY; SURFACES;
   ENZYMES; ALUMINA; DESIGN
AB Nano test tubes are a promising delivery vehicle for a range of therapeutics, including small molecule drugs and biologics. However, current template synthesis methods of producing nano test tubes are prohibitively expensive and time consuming. Here, non-destructive template replication was used to increase nano test tube yield from porous alumina by more than a hundredfold. We demonstrate how to produce nano test tubes of several sizes and compositions, including hybrid tubes with different inner and outer surfaces for targeted surface chemistry. Nano test tubes were readily suspended and stored in aqueous solutions without the need for chemical treatment. These nano test tubes should find application as delivery vehicles for therapeutics, particularly for processive 'bionanoreactors' loaded with enzymes.
C1 [Wagner, Jonathan; Rodgers, David] Univ Kentucky, Dept Biochem, Lexington, KY 40536 USA.
   [Wagner, Jonathan; Rodgers, David] Univ Kentucky, Struct Biol Ctr, Lexington, KY 40536 USA.
   [Wagner, Jonathan; Yao, Jingyuan; Hinds, Bruce] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Wagner, J (reprint author), Univ Kentucky, Dept Biochem, Lexington, KY 40536 USA.
EM bjhinds@engr.uky.edu
FU DOE EPSCoR [DE-FG02-07ER46375]; National Science Foundation Integrative
   Graduate Education and Research Traineeship grant [DGE0653710]; NIH
   [NS38041, P20RR20171]
FX The authors would like to thank the staff of the University of Kentucky
   Center for Nanoscale Science and Engineering and the University of
   Kentucky College of Engineering Electron Microscopy Center for their
   dedicated support. JY was funded by DOE EPSCoR grant No
   DE-FG02-07ER46375 (to BJH). JW was funded by a National Science
   Foundation Integrative Graduate Education and Research Traineeship grant
   No DGE0653710 and also by NIH grants NS38041 and P20RR20171 (to DWR).
CR Buyukserin F, 2008, NANOMEDICINE-UK, V3, P283, DOI 10.2217/17435889.3.3.283
   Choi MK, 2011, LANGMUIR, V27, P2132, DOI 10.1021/la104839a
   Couvreur P, 2006, PHARM RES, V23, P1417, DOI 10.1007/s11095-006-0284-8
   De Vocht C, 2009, J CONTROL RELEASE, V137, P246, DOI 10.1016/j.jconrel.2009.03.020
   Gasparac R, 2004, NANO LETT, V4, P513, DOI 10.1021/nl0352494
   Gratton SEA, 2008, P NATL ACAD SCI USA, V105, P11613, DOI 10.1073/pnas.0801763105
   Grimm S, 2008, NANO LETT, V8, P1954, DOI 10.1021/nl080842c
   Han LL, 2009, CHINESE SCI BULL, V54, P2193, DOI [10.1007/S11434-009-0212-5, 10.1007/s11434-009-0212-5]
   Sree Harsha KS, 2006, PRINCIPLES PHYS VAPO
   Hermanson G. T., 1996, BIOCONJUGATE TECHNIQ
   Hillebrenner H, 2006, NANOMEDICINE-UK, V1, P39, DOI 10.2217/17435889.1.1.39
   Kim E, 1997, ADV MATER, V9, P651
   Kim J, 2006, CHEM ENG SCI, V61, P1017, DOI 10.1016/j.ces.2005.05.067
   Kim JB, 2008, TRENDS BIOTECHNOL, V26, P639, DOI 10.1016/j.tibtech.2008.07.009
   Marder A.R., 1989, ASM HDB, V17
   MASUDA H, 1995, SCIENCE, V268, P1466, DOI 10.1126/science.268.5216.1466
   Moghimi SM, 2001, PHARMACOL REV, V53, P283
   Moghimi SM, 2005, FASEB J, V19, P311, DOI 10.1096/fj.04-2747rev
   Murphy CJ, 2008, ACCOUNTS CHEM RES, V41, P1721, DOI 10.1021/ar800035u
   Nanci A, 1998, J BIOMED MATER RES, V40, P324
   Nasseau M, 2001, BIOTECHNOL BIOENG, V75, P615, DOI 10.1002/bit.10074
   Nel AE, 2009, NAT MATER, V8, P543, DOI [10.1038/nmat2442, 10.1038/NMAT2442]
   Okuyama T, 2010, MOL GENET METAB, V99, P18, DOI 10.1016/j.ymgme.2009.08.006
   PARTHASARATHY RV, 1994, NATURE, V369, P298, DOI 10.1038/369298a0
   Perry JL, 2011, CHEM-EUR J, V17, P6296, DOI 10.1002/chem.201002835
   Perry JL, 2010, NANOMEDICINE-UK, V5, P1151, DOI [10.2217/nnm.10.110, 10.2217/NNM.10.110]
   Son SJ, 2005, J AM CHEM SOC, V127, P7316, DOI 10.1021/ja0517365
   Walde P, 2001, BIOMOL ENG, V18, P143, DOI 10.1016/S1389-0344(01)00088-0
   Xia YN, 1998, ANNU REV MATER SCI, V28, P153, DOI 10.1146/annurev.matsci.28.1.153
NR 29
TC 0
Z9 0
U1 0
U2 23
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0957-4484
J9 NANOTECHNOLOGY
JI Nanotechnology
PD MAR 1
PY 2013
VL 24
IS 8
AR 085601
DI 10.1088/0957-4484/24/8/085601
PG 7
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary;
   Physics, Applied
SC Science & Technology - Other Topics; Materials Science; Physics
GA 088FD
UT WOS:000314818300007
PM 23376956
OA green_accepted
DA 2018-03-20
ER

PT J
AU Zhao, RS
   Hollis, CP
   Zhang, H
   Sun, LL
   Gemeinhart, RA
   Li, TL
AF Zhao, Rongsheng
   Hollis, Christin P.
   Zhang, Hua
   Sun, Lili
   Gemeinhart, Richard A.
   Li, Tonglei
TI Hybrid Nanocrystals: Achieving Concurrent Therapeutic and Bioimaging
   Functionalities toward Solid Tumors
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE nanocrystals; anticancer; bioimaging; theranostics; paclitaxel
ID DRUG-DELIVERY; NANOPARTICLES; TECHNOLOGY; ANTITUMOR
AB Bioimaging and therapeutic agents accumulated in ectopic tumors following intravenous administration of hybrid nanocrystals to tumor-bearing mice. Solid, nanosized paclitaxel crystals physically incorporated fluorescent molecules throughout the crystal lattice and retained fluorescent properties in the solid state. Hybrid nanocrystals were significantly localized in solid tumors and remained in the tumor for several days. An anticancer effect is expected of these hybrid nanocrystals.
C1 [Zhao, Rongsheng; Hollis, Christin P.; Zhang, Hua; Sun, Lili; Li, Tonglei] Univ Kentucky, Lexington, KY 40536 USA.
   [Gemeinhart, Richard A.] Univ Illinois, Chicago, IL 60612 USA.
RP Li, TL (reprint author), 375 Biopharm Complex,789 S Limestone St, Lexington, KY 40536 USA.
EM tonglei@uky.edu
RI Gemeinhart, Richard/B-8017-2008
OI Gemeinhart, Richard/0000-0002-1580-7304
FU DOD [BC050287]
FX This work was supported by DOD Breast Cancer Research Program
   (BC050287). The authors would like to thank University of Kentucky
   Department of Toxicology for allowing us to use the IVIS system.
CR Allen TM, 2004, SCIENCE, V303, P1818, DOI 10.1126/science.1095833
   Baba K, 2007, MOL PHARM, V4, P289, DOI 10.1021/mp060117f
   Hermus L, 2010, EUR J VASC ENDOVASC, V39, P125, DOI 10.1016/j.ejvs.2009.11.020
   Hobbs SK, 1998, P NATL ACAD SCI USA, V95, P4607, DOI 10.1073/pnas.95.8.4607
   Horn D, 2001, ANGEW CHEM INT EDIT, V40, P4331
   Junghanns JUAH, 2008, INT J NANOMED, V3, P295
   Kahr B, 2001, CHEM REV, V101, P893, DOI 10.1021/cr980088n
   Kim DE, 2010, ARTERIOSCL THROM VAS, V30, P449, DOI 10.1161/ATVBAHA.109.194613
   Liggins RT, 1997, J PHARM SCI, V86, P1458, DOI 10.1021/js9605226
   Maeda H, 2000, J CONTROL RELEASE, V65, P271, DOI 10.1016/S0168-3659(99)00248-5
   MeriskoLiversidge E, 1996, PHARMACEUT RES, V13, P272, DOI 10.1023/A:1016051316815
   Muller RH, 2004, J BIOTECHNOL, V113, P151, DOI 10.1016/j.jbiotec.2004.06.007
   Peer D, 2007, NAT NANOTECHNOL, V2, P751, DOI 10.1038/nnano.2007.387
   Rabinow B, 2007, INT J PHARM, V339, P251, DOI 10.1016/j.ijpharm.2007.02.030
   Rabinow BE, 2004, NAT REV DRUG DISCOV, V3, P785, DOI 10.1038/nrd1494
   Zhang H, 2011, INT J PHARMACEUT, V415, P293, DOI 10.1016/j.ijpharm.2011.05.075
NR 16
TC 30
Z9 30
U1 1
U2 20
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD SEP-OCT
PY 2011
VL 8
IS 5
BP 1985
EP 1991
DI 10.1021/mp200154k
PG 7
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 826IJ
UT WOS:000295347500057
PM 21812439
DA 2018-03-20
ER

PT J
AU Borgohain, R
   Li, JC
   Selegue, JP
   Cheng, YT
AF Borgohain, Rituraj
   Li, Juchuan
   Selegue, John P.
   Cheng, Y-T.
TI Electrochemical Study of Functionalized Carbon Nano-Onions for
   High-Performance Supercapacitor Electrodes
SO JOURNAL OF PHYSICAL CHEMISTRY C
LA English
DT Article
ID HYDROUS RUTHENIUM OXIDE; HIGH-POWER; ANNEALING NANODIAMOND; COMPOSITE
   ELECTRODES; LOWER TEMPERATURE; HIGH-ENERGY; CAPACITORS; RUO2; NANOTUBES;
   NANOPARTICLES
AB Carbon nano-onions (NCNOs), concentrically multilayered fullerenes, are among the least studied carbon allotropes. NCNOs have high surface area, high mesoporosity, facile electrical conductivity, and electrochemical stability. NCNOs are chemically oxidized (ONCNOs) to introduce hydrophilic functional groups, improving their wettability for use in supercapacitor electrodes. RuO2 center dot xH(2)O/ONCNOs composites are prepared by chemical precipitation of RuO2 on ONCNOs, optimized for homogeneous distribution and maximum utilization of the metal oxide nanoparticles. The materials are characterized by high-resolution transmission electron microscopy, N-2 absorption-desorption isotherm, and thermogravimetric analysis. Electrochemical performance of the electrodes is studied by cyclic voltammetry, galvanostatic charge-discharge, and electrochemical impedance measurements in 1.0 M H2SO4. While ONCNOs have specific capacitance of 45 F.g(-1), a composite with 67.5 wt.% RuO2 has specific capacitance of 334 F.g(-1) at a potential sweep rate of 20 mV.s(-1) with high power (242.8 kW.kg(-1)) and high energy density (11.6 Wh.kg(-1)). Both the ONCNO and the composites show excellent capacitance behaviors even at very high potential scan rates (>8 V.s(-1)). Simple preparation of high-purity NCNOs and excellent electrochemical behavior of functionalized NCNOs make them a promising electrode material in supercapacitor applications.
C1 [Borgohain, Rituraj; Selegue, John P.] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
   [Li, Juchuan; Cheng, Y-T] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Selegue, JP (reprint author), Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
EM selegue@uky.edu
RI Cheng, Yang-Tse/B-5424-2012; Li, Juchuan/A-2992-2009
OI Cheng, Yang-Tse/0000-0003-0737-9212; Li, Juchuan/0000-0002-6587-5591
FU National Science Foundation (Center for Advanced Materials)
   [EPS-0814194]
FX We thank the National Science Foundation (Center for Advanced Materials,
   Grant EPS-0814194) for partial support of this research, and Stephen M.
   Lipka and Doo Young Kim for helpful discussions.
CR An KH, 2001, ADV FUNCT MATER, V11, P387, DOI 10.1002/1616-3028(200110)11:5<387::AID-ADFM387>3.0.CO;2-G
   Bi RR, 2010, J PHYS CHEM C, V114, P2448, DOI 10.1021/jp9116563
   Bock C, 2004, J AM CHEM SOC, V126, P8028, DOI 10.1021/ja0495819
   Borgohain R, 2012, 243 ACS NAT M SAN DI
   Burke A, 2007, ELECTROCHIM ACTA, V53, P1083, DOI 10.1016/j.electacta.2007.01.011
   Bushueva EG, 2008, PHYS STATUS SOLIDI B, V245, P2296, DOI 10.1002/pssb.200879608
   Chen YL, 2011, J PHYS CHEM C, V115, P2563, DOI 10.1021/jp109597n
   Chen ZY, 2006, J AM CHEM SOC, V128, P10568, DOI 10.1021/ja063283p
   Du CS, 2006, NANOTECHNOLOGY, V17, P5314, DOI 10.1088/0957-4484/17/21/005
   Emmenegger C, 2003, J POWER SOURCES, V124, P321, DOI 10.1016/S0378-7753(03)00590-1
   Frackowiak E, 2001, CARBON, V39, P937, DOI 10.1016/S0008-6223(00)00183-4
   Gujar TP, 2007, INT J ELECTROCHEM SC, V2, P666
   Gujar TP, 2007, ELECTROCHEM COMMUN, V9, P504, DOI 10.1016/j.elecom.2006.10.017
   Hu CC, 2004, J ELECTROCHEM SOC, V151, pA281, DOI 10.1149/1.1639020
   Huang WJ, 2003, NANO LETT, V3, P565, DOI 10.1021/nl0340834
   Jang JH, 2003, J POWER SOURCES, V123, P79, DOI 10.1016/S0378-7753(03)00459-2
   Khomenko V, 2005, ELECTROCHIM ACTA, V50, P2499, DOI 10.1016/j.electacta.2004.10.078
   Kim H, 2002, J POWER SOURCES, V104, P52, DOI 10.1016/S0378-7753(01)00903-X
   Kim Y., 2005, APPL PHYS LETT, V87
   Kotz R, 2000, ELECTROCHIM ACTA, V45, P2483, DOI 10.1016/S0013-4686(00)00354-6
   Lee S. W., 2008, J AM CHEM SOC, V131, P671, DOI DOI 10.1021/JA807059K
   Li J, 2007, J APPL ELECTROCHEM, V37, P1129, DOI 10.1007/s10800-007-9372-7
   Lin YS, 2009, APPL SURF SCI, V256, P1042, DOI 10.1016/j.apsusc.2009.08.026
   Liu HY, 2005, CARBON, V43, P559, DOI 10.1016/j.carbon.2004.10.020
   Liu XR, 2008, J POWER SOURCES, V176, P410, DOI 10.1016/j.jpowsour.2007.10.076
   Miller JM, 1999, LANGMUIR, V15, P799, DOI 10.1021/la980799g
   Miller JM, 1997, J ELECTROCHEM SOC, V144, pL309, DOI 10.1149/1.1838142
   Oren Y, 2003, J PHYS CHEM SOLIDS, V64, P1395, DOI 10.1016/S0022-3697(03)00165-3
   Pan H, 2010, NANOSCALE RES LETT, V5, P654, DOI 10.1007/s11671-009-9508-2
   Pandolfo AG, 2006, J POWER SOURCES, V157, P11, DOI 10.1016/j.jpowsour.2006.02.065
   Park JH, 2003, J ELECTROCHEM SOC, V150, pA864, DOI 10.1149/1.1576222
   Park S, 2009, J ELECTROCHEM SOC, V156, pA921, DOI 10.1149/1.3223964
   Patake VD, 2008, APPL SURF SCI, V254, P2820, DOI 10.1016/j.apsusc.2007.10.044
   Pech D, 2010, NAT NANOTECHNOL, V5, P651, DOI [10.1038/nnano.2010.162, 10.1038/NNANO.2010.162]
   Plonska-Brzezinska ME, 2011, CHEMPHYSCHEM, V12, P2659, DOI 10.1002/cphc.201100198
   Plonska-Brzezinska ME, 2010, ELECTROCHEM SOLID ST, V13, pK35, DOI 10.1149/1.3299252
   Qian J, 2004, CARBON, V42, P2691, DOI 10.1016/j.carbon.2004.06.017
   Qao Z., 2005, SCRIPTA MATER, V54, P225
   Raymundo-Pinero E, 2005, J ELECTROCHEM SOC, V152, pA229, DOI 10.1149/1.1834913
   Reddy ALM, 2007, J PHYS CHEM C, V111, P7727, DOI 10.1021/jp069006m
   Reddy ALM, 2010, J PHYS CHEM C, V114, P658, DOI 10.1021/jp908739q
   Ruiz V, 2008, ELECTROCHIM ACTA, V54, P305, DOI 10.1016/j.electacta.2008.07.079
   Stoller MD, 2010, ENERG ENVIRON SCI, V3, P1294, DOI 10.1039/c0ee00074d
   Su DS, 2010, CHEMSUSCHEM, V3, P136, DOI 10.1002/cssc.200900182
   Tomita S, 2002, CARBON, V40, P1469, DOI 10.1016/S0008-6223(01)00311-6
   Tomita S, 2001, J CHEM PHYS, V114, P7477, DOI 10.1063/1.1360197
   Tomita S, 2000, DIAM RELAT MATER, V9, P856, DOI 10.1016/S0925-9635(99)00217-4
   Wang Y, 2009, J PHYS CHEM C, V113, P13103, DOI 10.1021/jp902214f
   Wen JG, 2009, J PHYS CHEM SOLIDS, V70, P816, DOI 10.1016/j.jpcs.2009.03.015
   Wu ZS, 2010, ADV FUNCT MATER, V20, P3595, DOI 10.1002/adfm.201001054
   Xing W, 2006, CARBON, V44, P216, DOI 10.1016/j.carbon.2005.07.029
   ZHENG JP, 1995, J ELECTROCHEM SOC, V142, P2699, DOI 10.1149/1.2050077
   Zheng JP, 1996, J POWER SOURCES, V62, P155, DOI 10.1016/S0378-7753(96)02424-X
   Zou Q, 2010, J EXP NANOSCI, V5, P473, DOI 10.1080/17458081003646982
   Zou Q, 2010, J EXP NANOSCI, V5, P375, DOI 10.1080/17458080903583899
   Zou Q, 2010, J VAC SCI TECHNOL B, V28, P935, DOI 10.1116/1.3475530
   Zou Q, 2010, MATER RES INNOV, V14, P285, DOI 10.1179/143307510X12777574294902
   Zou Q, 2010, INORG MATER+, V46, P127, DOI 10.1134/S002016851002007X
   Zou Q, 2010, ADV MATER RES-SWITZ, V123-125, P747, DOI 10.4028/www.scientific.net/AMR.123-125.747
NR 59
TC 39
Z9 42
U1 3
U2 96
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1932-7447
J9 J PHYS CHEM C
JI J. Phys. Chem. C
PD JUL 19
PY 2012
VL 116
IS 28
BP 15068
EP 15075
DI 10.1021/jp301642s
PG 8
WC Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science,
   Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA 975IF
UT WOS:000306503200040
DA 2018-03-19
ER

PT J
AU Tee, YH
   Bachas, L
   Bhattacharyya, D
AF Tee, Yit-Hong
   Bachas, Leonidas G.
   Bhattacharyya, Dibakar
TI Degradation of Trichloroethylene and Dichlorobiphenyls by Iron-Based
   Bimetallic Nanoparticles
SO JOURNAL OF PHYSICAL CHEMISTRY C
LA English
DT Article
ID ZERO-VALENT IRON; GROUNDWATER TREATMENT PROCESSES; CHLORINATED ACETYLENE
   REACTION; GRANULAR IRON; REDUCTIVE DEHALOGENATION; NITROAROMATIC
   COMPOUNDS; DECHLORINATION; SURFACE; NICKEL; ADSORPTION
AB Bimetallic nanoparticles of Ni/Fe and Pd/Fe were used to study the degradation of trichloroethylene (TCE) at room temperature. The activity for different iron-based nanoparticles with nickel as the catalytic dopant was analyzed using the iron mass-normalized hydrogen generation rate. Degradation kinetics in terms of surface area-normalized rate constant were observed to have a strong correlation with the hydrogen generated by iron oxidation. A sorption study was conducted, and a mathematical model was derived that incorporates the reaction and Langmuirian-type sorption terms to estimate the intrinsic rate constant and rate-limiting step in the degradation process, assuming negligible mass transfer resistance of TCE to the solid particles phase. A longevity study through repeated cycle experiments was conducted to analyze the effect of activity loss on the reaction mechanistic pathway, and the results showed that the attenuation in the nanoparticles activity did not adversely affect the reaction mechanisms in generating gaseous products, such as ethylene and ethane.
C1 [Tee, Yit-Hong; Bhattacharyya, Dibakar] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Bachas, Leonidas] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
RP Bhattacharyya, D (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM db@engr.uky.edu
RI Bachas, Leonidas/G-2479-2015
OI Bachas, Leonidas/0000-0002-3308-6264
FU NIEHS-SBRP [P42ES007380]
FX Financial support from the NIEHS-SBRP program (P42ES007380) is
   gratefully acknowledged. Instrumentation assistance from the University
   of. Kentucky Electron Microscopy Facility (UK-EMS) and Environmental
   Research and Training Laboratory (UK-ERTL) are also greatly appreciated.
CR Arnold WA, 2000, ENVIRON SCI TECHNOL, V34, P1794, DOI 10.1021/es990884q
   Arnold WA, 1998, ENVIRON SCI TECHNOL, V32, P3017, DOI 10.1021/es980252o
   Barbosa MR, 1998, ELECTROCHIM ACTA, V44, P957, DOI 10.1016/S0013-4686(98)00199-6
   Burris DR, 1998, J ENVIRON ENG-ASCE, V124, P1012, DOI 10.1061/(ASCE)0733-9372(1998)124:10(1012)
   BURRIS DR, 1995, ENVIRON SCI TECHNOL, V29, P2850, DOI 10.1021/es00011a022
   Campbell I.M., 1988, CATALYSIS SURFACES
   Diez-Perez I, 2006, ELECTROCHEM COMMUN, V8, P627, DOI 10.1016/j.elecom.2006.02.003
   Farrell J, 2000, ENVIRON SCI TECHNOL, V34, P514, DOI 10.1021/es990716y
   FURUKAWA Y, 2002, ENVIRON SCI TECHNOL, V36, P2867
   Gotpagar J, 1999, LANGMUIR, V15, P8412, DOI 10.1021/la990325x
   Gotpagar JK, 1998, J HAZARD MATER, V62, P243, DOI 10.1016/S0304-3894(98)00184-8
   He F, 2008, APPL CATAL B-ENVIRON, V84, P533, DOI 10.1016/j.apcatb.2008.05.008
   HSU YS, 1987, J MATER SCI LETT, V6, P1246, DOI 10.1007/BF01794577
   Huang WX, 2002, J PHYS CHEM B, V106, P5645, DOI 10.1021/jp025717i
   Kamolpornwijit W, 2003, J CONTAM HYDROL, V66, P161, DOI 10.1016/S0169-7722(03)00031-7
   Kanel SR, 2006, ENVIRON SCI TECHNOL, V40, P2045, DOI 10.1021/es0520924
   Karanfil T, 2004, ENVIRON SCI TECHNOL, V38, P5834, DOI 10.1021/es0497936
   Klausen J, 2003, ENVIRON SCI TECHNOL, V37, P1208, DOI 10.1021/es025965s
   Klausen J, 2001, CHEMOSPHERE, V44, P511, DOI 10.1016/S0045-6535(00)00385-4
   Kohn T, 2005, ENVIRON SCI TECHNOL, V39, P2867, DOI 10.1021/es048851k
   Liu YQ, 2005, ENVIRON SCI TECHNOL, V39, P1338, DOI 10.1021/es049195r
   Meyer DE, 2007, J PHYS CHEM B, V111, P7142, DOI 10.1021/jp070972u
   Murzin DY, 2004, REACT KINET CATAL L, V83, P205, DOI 10.1023/B:REAC.0000046078.18808.f6
   Odziemkowski MS, 2000, ENVIRON SCI TECHNOL, V34, P3495, DOI 10.1021/es9909780
   Panczyk T, 2005, J PHYS CHEM B, V109, P10986, DOI 10.1021/jp047230a
   REARDON EJ, 1995, ENVIRON SCI TECHNOL, V29, P2936, DOI 10.1021/es00012a008
   Satapanajaru T, 2003, ENVIRON SCI TECHNOL, V37, P5219, DOI 10.1021/es0303485
   Scherer MM, 2000, CRIT REV ENV SCI TEC, V30, P363, DOI 10.1080/10643380091184219
   Schrick B, 2002, CHEM MATER, V14, P5140, DOI 10.1021/cm020737i
   TAMAN K, 2005, ENVIRON SCI TECHNOL, V39, P2867
   Tee YH, 2005, IND ENG CHEM RES, V44, P7062, DOI 10.1021/ie050086a
   Uhlig H. H., 1971, CORROSION CORROSION
   Vikesland PJ, 2003, J CONTAM HYDROL, V64, P3, DOI 10.1016/S0169-7722(02)00150-X
   Wang CB, 1997, ENVIRON SCI TECHNOL, V31, P2154, DOI 10.1021/es970039c
   Wang J, 2003, ENVIRON SCI TECHNOL, V37, P3891, DOI 10.1021/es0254605
   Wu YX, 2005, ENVIRON SCI TECHNOL, V39, P9197, DOI 10.1021/es051052x
   Xu J, 2008, J PHYS CHEM C, V112, P9133, DOI 10.1021/jp7097262
   Zhang NL, 2008, ENVIRON SCI TECHNOL, V42, P2015, DOI 10.1021/es0717663
NR 38
TC 40
Z9 42
U1 4
U2 33
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1932-7447
J9 J PHYS CHEM C
JI J. Phys. Chem. C
PD JUN 4
PY 2009
VL 113
IS 22
BP 9454
EP 9464
DI 10.1021/jp809098z
PG 11
WC Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science,
   Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA 451CF
UT WOS:000266447600006
PM 20161161
OA green_accepted
DA 2018-03-19
ER

PT J
AU Park, CW
   Li, XJ
   Vogt, FG
   Hayes, D
   Zwischenberger, JB
   Park, ES
   Mansour, HM
AF Park, Chun-Woong
   Li, Xiaojian
   Vogt, Frederick G.
   Hayes, Don, Jr.
   Zwischenberger, Joseph B.
   Park, Eun-Seok
   Mansour, Heidi M.
TI Advanced spray-dried design, physicochemical characterization, and
   aerosol dispersion performance of vancomycin and clarithromycin
   multifunctional controlled release particles for targeted respiratory
   delivery as dry powder inhalation aerosols
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Antibiotic; Solid-state; Particle engineering design; Controlled release
   lung delivery; Aerosol performance enhancer;
   Dipalmitoylphosphatidylcholine (DPPC)
ID CYSTIC-FIBROSIS THERAPY; AIR-WATER-INTERFACE; DRUG-DELIVERY;
   PHYSICAL-CHARACTERIZATION; NANOCARRIER SYSTEMS; PULMONARY DELIVERY;
   PHASE-TRANSITIONS; DOSAGE FORMS; MICROSPHERES; LUNG
AB Respirable microparticles/nanoparticles of the antibiotics vancomycin (VCM) and clarithromycin (CLM) were successfully designed and developed by novel organic solution advanced spray drying from methanol solution. Formulation optimization was achieved through statistical experimental design of pump feeding rates of 25% (Low P), 50% (Medium P) and 75% (High P). Systematic and comprehensive physicochemical characterization and imaging were carried out using scanning electron microscopy (SEM), hot-stage microscopy (HSM), differential scanning calorimetry (DSC), X-ray powder diffraction (XRPD), Karl Fischer titration (KFT), laser size diffraction (LSD), gravimetric vapor sorption (GVS), confocal Raman microscopy (CRM) and spectroscopy for chemical imaging mapping. These novel spray-dried (SD) microparticulate/nanoparticulate dry powders displayed excellent aerosol dispersion performance as dry powder inhalers (DPIs) with high values in emitted dose (ED), respirable fraction (RF), and fine particle fraction (FPF). VCM DPIs displayed better aerosol dispersion performance compared to CLM DPIs which was related to differences in the physicochemical and particle properties of VCM and CLM.
   In addition, organic solution advanced co-spray drying particle engineering design was employed to successfully produce co-spray-dried (co-SD) multifunctional microparticulate/nanoparticulate aerosol powder formulations of VCM and CLM with the essential lung surfactant phospholipid, dipalmitoylphosphatidylcholine (DPPC), for controlled release pulmonary nanomedicine delivery as inhalable dry powder aerosols. Formulation optimization was achieved through statistical experimental design of molar ratios of co-SD VCM:DPPC and co-SD CLM:DPPC. XRPD and DSC confirmed that the phospholipid bilayer structure in the solid-state was preserved following spray drying. Co-SD VCM:DPPC and co-SD CLM:DPPC dry powder aerosols demonstrated controlled release of antibiotic drug that was fitted to various controlled release mathematical fitting models. The Korsmeyer-Peppas model described the best data fit for all powders suggesting super case-II transport mechanism of controlled release. Excellent aerosol dispersion performance for all co-SD microparticulate/nanoparticulate DPIs was higher than the SD antibiotic drugs suggesting that DPPC acts as an aerosol performance enhancer for these antibiotic aerosol dry powders. Co-SD VCM:DPPC DPIs had higher aerosol dispersion parameters compared to co-SD CLM:DPPC which was related to differences in the physicochemical properties of VCM and CLM. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Park, Chun-Woong; Li, Xiaojian; Mansour, Heidi M.] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Drug Dev Div, Lexington, KY 40536 USA.
   [Park, Chun-Woong] Chungbuk Natl Univ, Coll Pharm, Cheongju 361763, South Korea.
   [Vogt, Frederick G.] GlaxoSmithKline, Analyt Sci, Product Dev, King Of Prussia, PA 19406 USA.
   [Hayes, Don, Jr.] Ohio State Univ, Coll Med, Dept Pediat, Lung Transplant Program, Columbus, OH 43205 USA.
   [Hayes, Don, Jr.] Ohio State Univ, Coll Med, Dept Pediat, Heart Lung Transplant Program, Columbus, OH 43205 USA.
   [Hayes, Don, Jr.] Ohio State Univ, Coll Med, Dept Internal Med, Lung Transplant Program, Columbus, OH 43205 USA.
   [Hayes, Don, Jr.] Ohio State Univ, Coll Med, Dept Internal Med, Heart Lung Transplant Program, Columbus, OH 43205 USA.
   [Hayes, Don, Jr.] Ohio State Univ, Coll Med, Davis Heart & Lung Res Inst, Columbus, OH 43205 USA.
   [Zwischenberger, Joseph B.] Univ Kentucky, Coll Med, Dept Pediat, Lexington, KY 40536 USA.
   [Zwischenberger, Joseph B.] Univ Kentucky, Coll Med, Dept Biomed Engn, Lexington, KY 40536 USA.
   [Zwischenberger, Joseph B.] Univ Kentucky, Coll Med, Dept Diagnost Radiol, Lexington, KY 40536 USA.
   [Zwischenberger, Joseph B.] Univ Kentucky, Coll Med, Dept Surg, Lexington, KY 40536 USA.
   [Park, Eun-Seok] Sungkyunkwan Univ, Sch Pharm, Suwon 440746, South Korea.
   [Mansour, Heidi M.] Univ Kentucky, Ctr Membrane Sci, Lexington, KY 40536 USA.
   [Mansour, Heidi M.] Univ Arizona, Coll Pharm, Skaggs Ctr Pharmaceut Sci, Tucson, AZ 85721 USA.
RP Mansour, HM (reprint author), Univ Arizona, Coll Pharm, Skaggs Ctr Pharmaceut Sci, 1703 E Mabel St, Tucson, AZ 85721 USA.
EM mansour@pharmacy.arizona.edu
RI Li, Xiaojian/N-3421-2015
FU Sungkyunkwan University; Daniel P. Reedy Quality Achievement Fellowship;
   Graduate School Academic Year Fellowship; UK Center of Membrane Sciences
   Fellowship
FX The authors gratefully acknowledge financial support from the
   Sungkyunkwan University for an International Postdoctoral Visiting
   Scholar Fellowship awarded to Dr. Chun-Woong Park. The authors
   gratefully acknowledge financial support from the Daniel P. Reedy
   Quality Achievement Fellowship, the Graduate School Academic Year
   Fellowship, and the UK Center of Membrane Sciences Fellowship awarded to
   Xiaojian Li. The authors thank Dr. Dicky Sick Ki Yu for SEM access and
   Dr. Tonglei Li for XRPD and HSM access.
CR Acerbi D, 2007, PULM PHARMACOL THER, V20, P290, DOI 10.1016/j.pupt.2006.05.005
   Adi H, 2010, EUR J PHARM SCI, V40, P239, DOI 10.1016/j.ejps.2010.03.020
   Adi H, 2010, DRUG DEV IND PHARM, V36, P119, DOI 10.3109/03639040903099769
   Alves GP, 2004, POWDER TECHNOL, V145, P139, DOI 10.1016/j.powtec.2004.06.008
   Ameri M, 2006, DRY TECHNOL, V24, P763, DOI 10.1080/03602550600685275
   Arifin DY, 2006, ADV DRUG DELIVER REV, V58, P1274, DOI 10.1016/j.addr.2006.09.007
   BATTS DH, 1980, J PEDIATR-US, V97, P151, DOI 10.1016/S0022-3476(80)80158-2
   Carvalho TC, 2011, J AEROSOL MED PULM D, V24, P61, DOI 10.1089/jamp.2009.0794
   Clark AR, 2006, ANNU REP MED CHEM, V41, P383, DOI 10.1016/S0065-7743(06)41026-5
   Costa P, 2001, EUR J PHARM SCI, V13, P123, DOI 10.1016/S0928-0987(01)00095-1
   Cruz L, 2006, INT J PHARM, V313, P198, DOI 10.1016/j.ijpharm.2006.01.035
   EI-Arini SK, 1995, INT J PHARMACEUT, V121, P141
   Finlay Warren, 2008, ARLA RESP DEPOSITION
   Forbes B, 2011, ADV DRUG DELIVER REV, V63, P69, DOI 10.1016/j.addr.2010.11.004
   Furuta I, 2000, CLIN CHIM ACTA, V301, P31, DOI 10.1016/S0009-8981(00)00307-7
   Ganguly S., 2008, J AEROSOL MED PULM D, V23, P181
   Garcia-Contreras L, 2002, ADV DRUG DELIVER REV, V54, P1491, DOI 10.1016/S0169-409X(02)00159-X
   Gasparini G, 2008, COLLOID SURFACE B, V61, P199, DOI 10.1016/j.colsurfb.2007.08.011
   Groneberg DA, 2006, EXP TOXICOL PATHOL, V57, P49, DOI 10.1016/j.etp.2006.02.007
   Hadinoto K, 2007, INT J PHARM, V333, P187, DOI 10.1016/j.ijpharm.2006.10.009
   HARDY DJ, 1992, DIAGN MICR INFEC DIS, V15, P39, DOI 10.1016/0732-8893(92)90055-X
   Hayes D.J., 2009, RESPIROLOGY, V15, P182
   Hickey A.J., 2008, MODIFIED RELEASE DRU, V2, P573
   Hickey AJ, 2009, MODERN PHARM, P191
   Hickey AJ, 2007, J PHARM SCI-US, V96, P1302, DOI 10.1002/jps.20943
   Hickey AJ, 2007, J PHARM SCI-US, V96, P1282, DOI 10.1002/jps.20916
   Hrvacic B, 2009, EUR J PHARMACOL, V616, P236, DOI 10.1016/j.ejphar.2009.06.032
   Hwang SM, 2008, J CONTROL RELEASE, V129, P100, DOI 10.1016/j.jconrel.2008.04.009
   Johnson KA, 1997, ADV DRUG DELIVER REV, V26, P3, DOI 10.1016/S0169-409X(97)00506-1
   KIKUCHI H, 1991, CHEM PHARM BULL, V39, P1522
   Le Brun PPH, 2002, EUR J PHARM BIOPHARM, V54, P25, DOI 10.1016/S0939-6411(02)00044-9
   Li XJ, 2011, AAPS PHARMSCITECH, V12, P1420, DOI 10.1208/s12249-011-9704-0
   MABREY S, 1976, P NATL ACAD SCI USA, V73, P3862, DOI 10.1073/pnas.73.11.3862
   Mansour H, 2001, LANGMUIR, V17, P6622, DOI 10.1021/la0108454
   Mansour HM, 2008, MOL PHARMACEUT, V5, P681, DOI 10.1021/mp700123p
   Mansour HM, 2007, LANGMUIR, V23, P3809, DOI 10.1021/la063053o
   Mansour HM, 2007, J PHARM SCI-US, V96, P377, DOI 10.1002/jps.20810
   Mansour HM, 2010, INT J MOL SCI, V11, P3298, DOI 10.3390/ijms11093298
   Mansour HM, 2009, INT J NANOMED, V4, P299
   Mansour H.M., 2007, AAPS PHARMSCITECH, V8
   Mansour HM, 2011, LIPIDS NANOTECHNOLOG, P221
   Masters K., 1991, SPRAY DRYING HDB
   Maury M, 2005, EUR J PHARM BIOPHARM, V59, P251, DOI 10.1016/j.ejpb.2004.07.010
   MCCALDEN T A, 1990, Advanced Drug Delivery Reviews, V5, P253, DOI 10.1016/0169-409X(90)90019-O
   Meenach SA, 2013, INT J NANOMED, V8, P275, DOI 10.2147/IJN.S30724
   Mizoe T, 2007, J CONTROL RELEASE, V122, P10, DOI 10.1016/j.jconrel.2007.06.001
   Morinaga Y, 2009, PULM PHARMACOL THER, V22, P580, DOI 10.1016/j.pupt.2009.08.004
   O'Hara P, 2000, PHARMACEUT RES, V17, P955, DOI 10.1023/A:1007527204887
   Park CW, 2012, ADV DRUG DELIVER REV, V64, P344, DOI 10.1016/j.addr.2011.08.004
   Park CW, 2011, EUROPEAN PHARM REV, V16, P32
   Paterson DL, 2006, CURR OPIN PHARMACOL, V6, P486, DOI 10.1016/j.coph.2006.07.001
   Rhee YS, 2011, INT J NANOTECHNOL, V8, P84, DOI 10.1504/IJNT.2011.037172
   Richter K, 2004, RESP MED, V98, pS22, DOI 10.1016/j.rmed.2004.07.013
   Salama Rania, 2009, Current Drug Delivery, V6, P404
   Sethuraman V. V., 2002, AAPS PHARMSCITECH, V3, P1
   Siepmann J, 2001, ADV DRUG DELIVER REV, V48, P139, DOI 10.1016/S0169-409X(01)00112-0
   Siepmann J, 2008, INT J PHARMACEUT, V364, P328, DOI 10.1016/j.ijpharm.2008.09.004
   Song JH, 2008, INT J ANTIMICROB AG, V32, pS207, DOI 10.1016/S0924-8579(09)70004-4
   Suarez S, 2000, Respir Care, V45, P652
   Sung JC, 2009, PHARM RES-DORD, V26, P1847, DOI 10.1007/s11095-009-9894-2
   USP, 1995, US PHARM 1995 OFF MO, P383
   Aerosols, 2006, AER NAS SPRAYS MET D, P2617
   Ventura CA, 2008, EUR J PHARM BIOPHARM, V68, P235, DOI 10.1016/j.ejpb.2007.05.011
   Willis L, 2012, LUNG, V190, P251, DOI 10.1007/s00408-011-9360-x
   Wu X., 2013, INT J NANOMED, V8, P1
   Wu X, 2013, DRUG DES DEV THER, V7, P59, DOI [10.2147/DDDT.540166, 10.2147/DDDT.S40166]
   Wu XA, 2010, KONA POWDER PART J, P3
   Wu XA, 2011, INT J NANOTECHNOL, V8, P115, DOI 10.1504/IJNT.2011.037173
   Xu Z, 2011, J ADHES SCI TECHNOL, V25, P451, DOI 10.1163/016942410X525669
   Xu Z, 2010, J PHARM SCI-US, V99, P3442, DOI 10.1002/jps.22057
   Zijlstra GS, 2004, EUR J PHARM SCI, V23, P139, DOI 10.1016/j.ejps.2004.06.005
NR 71
TC 30
Z9 30
U1 5
U2 63
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
EI 1873-3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD OCT 15
PY 2013
VL 455
IS 1-2
BP 374
EP 392
DI 10.1016/j.ijpharm.2013.06.047
PG 19
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 219QC
UT WOS:000324522100043
PM 23820131
DA 2018-03-20
ER

PT J
AU Ryou, C
   Titlow, WB
   Mays, CE
   Bae, Y
   Kim, S
AF Ryou, Chongsuk
   Titlow, William B.
   Mays, Charles E.
   Bae, Younsoo
   Kim, Sehun
TI The suppression of prion propagation using poly-L-lysine by targeting
   plasminogen that stimulates prion protein conversion
SO BIOMATERIALS
LA English
DT Article
DE Poly-L-lysine; Prion conversion; Cofactor; Plasminogen; Therapeutic
   target; Translational research
ID BRANCHED POLYAMINES; CYCLIC AMPLIFICATION; MOLECULAR-WEIGHT;
   CULTURED-CELLS; DRUG-DELIVERY; GENE-THERAPY; IN-VITRO; INHIBITION;
   PEPTIDES; BINDING
AB Poly-L-lysine (PLL), a homopolymer of amino acid L-lysine (LL), has been frequently used for drug delivery. Here, we report that PLL is an effective agent to inhibit propagation of prions that cause fatal and incurable neurologic disorders in humans and animals, termed prion diseases. In our recent investigation on prion propagation facilitated by conversion of the cellular prion protein (PrP) to the misfolded, disease-associated PrP (PrP(Sc)), we demonstrated that plasminogen stimulates PrP conversion as a cellular cofactor. In the current study, we targeted plasminogen using PLL and assessed its anti-prion efficacy. The results showed that PLL strongly inhibited PrP(Sc) propagation in the cell-free, cell culture, and mouse models of prion disease. These results confirm the role of plasminogen in PrPs(Sc) propagation, validates plasminogen as a therapeutic target to combat prion disease, and suggests PLL as a potential anti-prion agent. Therefore, our study represents a proof-of-concept that targeting plasminogen, a cofactor for PrP conversion, using PLL results in suppression of prion propagation, which represents a successful translation of our understanding on details of prion propagation into a potential therapeutic strategy for prion diseases. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Ryou, Chongsuk; Titlow, William B.; Kim, Sehun] Univ Kentucky, Coll Med, Sanders Brown Ctr Aging, Lexington, KY 40536 USA.
   [Mays, Charles E.] Univ Kentucky, Coll Med, Dept Microbiol Immunol & Mol Genet, Lexington, KY 40536 USA.
   [Bae, Younsoo] Univ Kentucky, Coll Med, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
RP Ryou, C (reprint author), Univ Kentucky, Coll Med, Sanders Brown Ctr Aging, 800 Rose St,HSRB 326, Lexington, KY 40536 USA.
EM cryou2@email.uky.edu
FU NIH [P20 RR 020171]; College of Medicine, University of Kentucky
FX The authors thank Glenn Telling for providing Tg4112 mice, Linda Van
   Eldik for constructive suggestions, and Paula Thomason for editing this
   manuscript. This work was supported in part by NIH grant (P20 RR 020171)
   and funds from the College of Medicine, University of Kentucky.
CR ARNOLD LJ, 1979, P NATL ACAD SCI USA, V76, P3246, DOI 10.1073/pnas.76.7.3246
   Bareford LA, 2007, ADV DRUG DELIVER REV, V59, P748, DOI 10.1016/j.addr.2007.06.008
   Nicholas Delihas LWR, 1995, FEMS MICROBIOL LETT, V132, P233
   De Vries A, 1953, P SOC EXP BIOL MED, V76, P237
   Fischer MB, 2000, NATURE, V408, P479, DOI 10.1038/35044100
   Harada-Shiba M, 2002, GENE THER, V9, P407, DOI 10.1038/sj.gt/3301665
   Kim Y, 2009, MOL CELL BIOCHEM, V328, P177, DOI 10.1007/s11010-009-0087-4
   Klink D, 2003, MOL THER, V7, P73, DOI 10.1016/S1525-0016(02)00016-3
   LANGELAND N, 1988, J GEN VIROL, V69, P1137, DOI 10.1099/0022-1317-69-6-1137
   Lim YB, 2010, BIOMATERIALS, V31, P2025, DOI 10.1016/j.biomaterials.2009.11.085
   May BCH, 2003, P NATL ACAD SCI USA, V100, P3416, DOI 10.1073/pnas.2627988100
   Mays CE, 2008, BRAIN RES, V1208, P170, DOI 10.1016/j.brainres.2008.02.103
   Mays CE, 2011, PRION, V5, P22, DOI 10.4161/pri.5.1.14460
   Mays CE, 2010, FASEB J, V24, P5102, DOI 10.1096/fj.10-163600
   Mays CE, 2009, BIOCHEM BIOPH RES CO, V388, P306, DOI 10.1016/j.bbrc.2009.07.163
   Meister A., 1965, BIOCH AMINO ACIDS
   Plank C, 1999, HUM GENE THER, V10, P319, DOI 10.1089/10430349950019101
   PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487
   PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762
   Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363
   Ryou C, 2003, LAB INVEST, V83, P837, DOI 10.1097/01.LAB.0000074919.08232.A2
   Ryou C, 2003, J MOL BIOL, V329, P323, DOI 10.1016/S0022-2836(03)00342-5
   Saborio GP, 2001, NATURE, V411, P810, DOI 10.1038/35081095
   Sakharov DV, 2001, ARTERIOSCL THROM VAS, V21, P943, DOI 10.1161/01.ATV.21.6.943
   Schick BP, 2004, BLOOD, V103, P1356, DOI 10.1182/blood-2003-07-2334
   SCOTT MRD, 1988, PROTEIN ENG, V2, P69, DOI 10.1093/protein/2.1.69
   SHIMA S, 1984, J ANTIBIOT, V37, P1449, DOI 10.7164/antibiotics.37.1449
   Soto C, 2000, LANCET, V355, P192, DOI 10.1016/S0140-6736(99)11419-3
   Supattapone S, 1999, P NATL ACAD SCI USA, V96, P14529, DOI 10.1073/pnas.96.25.14529
   Supattapone S, 2001, J VIROL, V75, P3453, DOI 10.1128/JVI.75.7.3453-3461.2001
   Trevitt CR, 2006, BRAIN, V129, P2241, DOI 10.1093/brain/aw1150
   WAGNER E, 1991, P NATL ACAD SCI USA, V88, P4255, DOI 10.1073/pnas.88.10.4255
   Ward CM, 2001, BLOOD, V97, P2221, DOI 10.1182/blood.V97.8.2221
   White MD, 2008, P NATL ACAD SCI USA, V105, P10238, DOI 10.1073/pnas.0802759105
   Xu B, 1998, GENE THER, V5, P1235, DOI 10.1038/sj.gt.3300719
NR 35
TC 13
Z9 15
U1 0
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD APR
PY 2011
VL 32
IS 11
BP 3141
EP 3149
DI 10.1016/j.biomaterials.2011.01.017
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 736BY
UT WOS:000288465800044
PM 21288569
OA green_accepted
DA 2018-03-19
ER

PT J
AU Islam, SZ
   Reed, A
   Kim, DY
   Rankin, SE
AF Islam, Syed Z.
   Reed, Allen
   Kim, Doo Young
   Rankin, Stephen E.
TI N-2/Ar plasma induced doping of ordered mesoporous TiO2 thin films for
   visible light active photocatalysis
SO MICROPOROUS AND MESOPOROUS MATERIALS
LA English
DT Article
DE Mesoporous; Thin films; Surfactant templating; Photochemistry; Sol-gel
ID ION-IMPLANTATION; NITROGEN; TITANIA; WATER; NANOPARTICLES; HYDROGEN;
   SPHERES
AB This study reports the rapid and effective nitrogen doping of ordered, mesoporous TiO2 thin films using nitrogen/argon (N-2/Ar) plasma. The resulting nitrogen-doped TiO2 (N-TiO2) films show significant enhancement in both visible light absorption and photocatalytic activity. The cubic ordered mesoporous TiO2 thin films are prepared via a sol-gel method using titanium tetrachloride (TiCl4) as precursor and triblock copolymer Pluronic F127 as the template. Following brief calcination, the TiO2 films are treated with N-2/Ar plasma under controlled conditions of reactive gas pressure, microwave power, and plasma exposure duration. To vary the degree of nitrogen doping, the plasma exposure time was varied from zero up to 210 min. The nitrogen content of the films increases with plasma exposure duration, up to over 3 at% N. X-ray photoelectron spectroscopic (XPS) analyses and UV-vis absorbance spectra of N-TiO2 films indicate that the incorporated N atoms reduce the band gap of TiO2 and thus enhance the absorption of visible light. Finally, the visible-light photocatalytic activity of N-TiO2 films is determined from the photocatalytic degradation of methylene blue under visible-light illumination (with a 455 nm LED). The N-TiO2 films prepared by 150 min treatment show the optimum photocatalytic activity with a pseudo-first order rate coefficient of 0.24 h(-1), which is six times greater than that of undoped TiO2 films. Treatment for excessive time (e.g. 210 min) leads to a decline in photocatalytic activity due to coarsening of the porous structure. The present study suggests that plasma-induced doping is a promising approach to enable the efficient incorporation of heteroatoms into surfactant-templated TiO2 thin films while maintaining their nanostructures, thereby leading to the significant enhancement of visible-light photoactivity. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Islam, Syed Z.; Rankin, Stephen E.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Reed, Allen; Kim, Doo Young] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
RP Rankin, SE (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM dooyoung.kim@uky.edu; srankin@engr.uky.edu
OI Islam, Syed/0000-0002-5149-8094; Rankin, Stephen/0000-0002-8615-7564
FU University of Kentucky; U.S. Department of Energy EPSCoR Implementation
   award [DE-FG02-07-ER46375]; National Science Foundation EPSCoR Research
   Infrastructure Initiative award [IIA-1355438]
FX DYK appreciates the support from the University of Kentucky faculty
   start-up grant. Preliminary experiments to develop nitrogen doping and
   photocatalytic testing methods were performed as part of a U.S.
   Department of Energy EPSCoR Implementation award supported by grant no.
   DE-FG02-07-ER46375. The detailed study as a function of plasma exposure
   time and further analysis of the spectroscopic and structural
   characteristics of the doped films was performed as part of an National
   Science Foundation EPSCoR Research Infrastructure Initiative award
   supported by grant no. IIA-1355438. The authors appreciate Dr. Xudong
   Fan at Michigan State University for the TEM analysis of TiO<INF>2</INF>
   thin films. The authors would like to acknowledge Richard Passey's help
   in the STEM measurement at FBI Company. Finally, the authors thank Prof.
   Y.T. Cheng for access to the XPS instrument.
CR Aman N, 2010, J MATER CHEM, V20, P10876, DOI 10.1039/c0jm01342k
   Ananpattarachai J, 2009, J HAZARD MATER, V168, P253, DOI 10.1016/j.jhazmat.2009.02.036
   Ao YH, 2009, MICROPOR MESOPOR MAT, V118, P382, DOI 10.1016/j.micromeso.2008.09.010
   Asahi R, 2001, SCIENCE, V293, P269, DOI 10.1126/science.1061051
   Bingham S, 2011, J MATER CHEM, V21, P2041, DOI 10.1039/c0jm02271c
   Burda C, 2003, NANO LETT, V3, P1049, DOI 10.1021/nl034332o
   Cao XP, 2012, J MATER CHEM, V22, P15309, DOI 10.1039/c2jm31576a
   Chen C, 2007, J PHYS CHEM C, V111, P15228, DOI 10.1021/jp0716233
   Chen DM, 2008, APPL SURF SCI, V255, P2879, DOI 10.1016/j.apsusc.2008.08.032
   Crepaldi EL, 2003, J AM CHEM SOC, V125, P9770, DOI 10.1021/ja030070g
   Das S, 2014, J PHYS CHEM C, V118, P968, DOI 10.1021/jp406165v
   Fakhouri H, 2014, APPL CATAL B-ENVIRON, V144, P12, DOI 10.1016/j.apcatb.2013.06.028
   FUJISHIMA A, 1972, NATURE, V238, P37, DOI 10.1038/238037a0
   Ghicov A, 2006, NANO LETT, V6, P1080, DOI 10.1021/nl0600979
   Ghicov A, 2006, CHEM PHYS LETT, V419, P426, DOI 10.1016/j.cplett.2005.11.102
   Gohin M, 2010, J MATER CHEM, V20, P8070, DOI 10.1039/c0jm01499k
   Hidetaka I., 2010, CHEM PHYS LETT, V489, P81
   Hu SZ, 2014, J POWER SOURCES, V250, P30, DOI 10.1016/j.jpowsour.2013.10.132
   Huang CM, 2007, J MOL CATAL A-CHEM, V261, P218, DOI 10.1016/j.molcata.2006.08.020
   Ismail AA, 2011, J MATER CHEM, V21, P11686, DOI 10.1039/c1jm10407a
   Jinlong L., 2010, THIN SOLID FILMS, V519, P101, DOI DOI 10.1016/J.TSF.2010.07.070
   Kafizas A, 2010, J MATER CHEM, V20, P2157, DOI 10.1039/b914117k
   Lan M., 2008, APPL SURF SCI, V255, P2574
   Lee HU, 2014, CHEM ENG J, V254, P268, DOI 10.1016/j.cej.2014.06.011
   Lewis NS, 2007, SCIENCE, V315, P798, DOI 10.1126/science.1137014
   Li L., 2015, NAT COMMUN, V6
   Li W, 2014, CHEM MATER, V26, P287, DOI 10.1021/cm4014859
   Li X, 2015, APPL CATAL B-ENVIRON, V164, P352, DOI 10.1016/j.apcatb.2014.09.053
   Liao YT, 2012, APPL ENERG, V100, P75, DOI 10.1016/j.apenergy.2012.02.053
   Liu G, 2010, J MATER CHEM, V20, P831, DOI [10.1039/b909930a, 10.1039/B909930A]
   Liu HJ, 2010, COLLOID SURFACE A, V363, P35, DOI 10.1016/j.colsurfa.2010.04.010
   Liu X, 2011, J ALLOY COMPD, V509, P9970, DOI 10.1016/j.jallcom.2011.08.003
   Liu ZQ, 2010, J ALLOY COMPD, V501, P54, DOI 10.1016/j.jallcom.2010.04.027
   Mao CY, 2014, ANGEW CHEM INT EDIT, V53, P10485, DOI 10.1002/anie.201406017
   McDonnell KA, 2012, PHYS REV B, V86, DOI 10.1103/PhysRevB.86.115306
   Miao L, 2005, APPL SURF SCI, V244, P412, DOI 10.1016/j.apsusc.2004.10.098
   Napoli F, 2009, CHEM PHYS LETT, V477, P135, DOI 10.1016/j.cplett.2009.06.050
   Pulsipher DJV, 2010, ACS APPL MATER INTER, V2, P1743, DOI 10.1021/am100233j
   Qiu XF, 2007, CHEM PHYS, V339, P1, DOI 10.1016/j.chemphys.2007.06.039
   Rane KS, 2006, J SOLID STATE CHEM, V179, P3033, DOI 10.1016/j.jssc.2006.05.033
   Salari M, 2015, PHYS CHEM CHEM PHYS, V17, P5642, DOI 10.1039/c4cp03177f
   Sathish M, 2005, CHEM MATER, V17, P6349, DOI 10.1021/cm052047v
   Selvam K, 2012, RSC ADV, V2, P2848, DOI 10.1039/c2ra01178f
   Shankar K, 2006, J PHYS D APPL PHYS, V39, P2361, DOI 10.1088/0022-3727/39/11/008
   Sharma R, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/7/075704
   Siuzdak K, 2015, NEW J CHEM, V39, P2741, DOI 10.1039/c5nj00127g
   Sivaranjani K, 2011, J MATER CHEM, V21, P2639, DOI 10.1039/c0jm03825c
   Soler-Illia GJAA, 2012, NANOSCALE, V4, P2549, DOI 10.1039/c2nr11817c
   Soni SS, 2008, ADV MATER, V20, P1493, DOI 10.1002/adma.200701066
   Sun HQ, 2008, SOL ENERG MAT SOL C, V92, P76, DOI 10.1016/j.solmat.2007.09.003
   Varghese OK, 2009, NANO LETT, V9, P731, DOI 10.1021/nl803258p
   Wang J, 2009, J AM CHEM SOC, V131, P12290, DOI 10.1021/ja903781h
   Wu QL, 2011, LANGMUIR, V27, P9557, DOI 10.1021/la201388n
   Yang CY, 2013, J AM CHEM SOC, V135, P17831, DOI 10.1021/ja4076748
   Zhang HJ, 2009, J MATER CHEM, V19, P5089, DOI 10.1039/b821991e
NR 55
TC 19
Z9 19
U1 4
U2 47
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1387-1811
EI 1873-3093
J9 MICROPOR MESOPOR MAT
JI Microporous Mesoporous Mat.
PD JAN 15
PY 2016
VL 220
BP 120
EP 128
DI 10.1016/j.micromeso.2015.08.030
PG 9
WC Chemistry, Applied; Chemistry, Physical; Nanoscience & Nanotechnology;
   Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA CZ2UX
UT WOS:000366961200014
DA 2018-03-20
ER

PT J
AU Hernandez, S
   Lei, S
   Rong, W
   Ormsbee, L
   Bhattacharyya, D
AF Hernandez, Sebastian
   Lei, Shi
   Rong, Wang
   Ormsbee, Lindell R.
   Bhattacharyya, Dibakar
TI Functionalization of Flat Sheet and Hollow Fiber Microfiltration
   Membranes for Water Applications
SO ACS SUSTAINABLE CHEMISTRY & ENGINEERING
LA English
DT Article
DE Sponge-like membranes; Surface modification; Nanoparticles; TCE
   dechlorination
ID POLYVINYLIDENE FLUORIDE PVDF; CONTACT-ANGLE HYSTERESIS; NANOSCALE IRON
   PARTICLES; FE-PD NANOPARTICLES; ZERO-VALENT IRON; POLY(VINYLIDENE
   FLUORIDE); CROSS-LINKING; NANOSTRUCTURED MEMBRANES; SURFACE
   MODIFICATION; SIZE DISTRIBUTION
AB Functionalized membranes containing nano particles provide a novel platform for organic pollutant degradation reactions and for selective removal of contaminants without the drawback of potential nanoparticle loss to the environment. These eco-friendly and sustainable technology approaches allow various water treatment applications by enhanced water transport through the membrane pores. This paper presents "green" techniques to create nanocomposite materials based on sponge-like membranes for water remediation applications involving chlorinated organic compounds. First, hydrophobic hollow fiber microfiltration membranes (HF) of polyvinylidene fluoride were hydrophilized using a water-based green chemistry process with polyvinylpyrrolidone and persulfate. HF and flat sheet membrane pores were then functionalized with poly(acrylic acid) and synthesized Fe/Pd nanoparticles. Surface modifications were determined by contact angle, surface free energy and infrared spectroscopy. The synthesized nanoparticles were characterized by electronic microscopy, X-ray spectrometry and image analysis. Nanoparticle mean sizes obtained were 203 +/- 10 and 300 +/- 11 nm for each of the membranes. Depending on the concentration of the dopant (Pd) in the membrane, catalytic activity (established by trichloroethylene (TCE) reduction), was enhanced up to 10-fold compared to other reported results. Chloride produced in reduction was close to the stoichiometric 3/1 (Cl-/TCE), indicating complete absence of reaction intermediates.
C1 [Hernandez, Sebastian; Bhattacharyya, Dibakar] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Ormsbee, Lindell] Univ Kentucky, Dept Civil Engn, Lexington, KY 40506 USA.
   [Lei, Shi; Rong, Wang] Nanyang Technol Univ, Singapore Membrane Technol Ctr, Singapore 639798, Singapore.
RP Bhattacharyya, D (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM db@uky.edu
RI Hernandez, Sebastian/I-7374-2017; Wang, Rong/A-3800-2011
OI Hernandez, Sebastian/0000-0002-7513-5511; 
FU National Institute of Environmental Health Sciences [P42ES007380]; NSF
   KY EPSCoR [1355438]
FX Grant Number P42ES007380 from the National Institute of Environmental
   Health Sciences supported this project. NSF KY EPSCoR (1355438) program
   also provided partial support.
CR ANDERSON CC, 1979, J APPL POLYM SCI, V23, P2453, DOI 10.1002/app.1979.070230823
   Basha MAF, 2010, POLYM J, V42, P728, DOI 10.1038/pj.2010.60
   Bell NC, 2012, LANGMUIR, V28, P10860, DOI 10.1021/la301351k
   Bhattacharya A, 2004, PROG POLYM SCI, V29, P767, DOI 10.1016/j.progpolymsci.2004.05.002
   Bi QY, 2013, J APPL POLYM SCI, V127, P394, DOI 10.1002/app.37629
   Bueno VB, 2010, QUIM NOVA, V33, P2083, DOI 10.1590/S0100-40422010001000015
   Cavarretta I, 2009, AIP CONF PROC, V1145, P833, DOI 10.1063/1.3180057
   Chibowski E, 2003, ADV COLLOID INTERFAC, V103, P149, DOI 10.1016/S0001-8686(02)00093-3
   DEMEJO LP, 1999, FUNDAMENTALS ADHESIO
   Dickson JM, 1998, J MEMBRANE SCI, V148, P25, DOI 10.1016/S0376-7388(98)00142-2
   Du JR, 2009, WATER RES, V43, P4559, DOI 10.1016/j.watres.2009.08.008
   Duca MD, 1998, POLYM DEGRAD STABIL, V61, P65, DOI 10.1016/S0141-3910(97)00130-4
   Ebert M, 2006, ENVIRON SCI TECHNOL, V40, P2004, DOI 10.1021/es051720e
   Fechine GJM, 2004, POLYMER, V45, P4705, DOI 10.1016/j.polymer.2004.05.006
   Fisker R, 2000, J NANOPART RES, V2, P267, DOI 10.1023/A:1010023316775
   FRANKEN ACM, 1987, J MEMBRANE SCI, V33, P315, DOI 10.1016/S0376-7388(00)80288-4
   Gabelman A, 1999, J MEMBRANE SCI, V159, P61, DOI 10.1016/S0376-7388(99)00040-X
   Gotpagar J, 1997, ENVIRON PROG, V16, P137, DOI 10.1002/ep.3300160221
   Gui M., 2012, J NANOPART RES, V14, P1
   Gui M, 2013, IND ENG CHEM RES, V52, P10430, DOI 10.1021/ie400507c
   Hayakawa Y, 2005, COMPUT GEOSCI-UK, V31, P735, DOI 10.1016/j.cageo.2005.01.004
   Hayama M, 2004, BIOMATERIALS, V25, P1019, DOI 10.1016/S0142-9612(03)00629-X
   He F, 2007, IND ENG CHEM RES, V46, P29, DOI 10.1021/ie0610896
   He F, 2008, APPL CATAL B-ENVIRON, V84, P533, DOI 10.1016/j.apcatb.2008.05.008
   Hernandez S, 2014, IND ENG CHEM RES, V53, P1130, DOI 10.1021/ie403353g
   Holdich R. G., 2002, FUNDAMENTALS PARTICL
   Huang FL, 2010, EXPRESS POLYM LETT, V4, P551, DOI 10.3144/expresspolymlett.2010.69
   Jurak M, 2010, COLLOID SURFACE B, V75, P165, DOI 10.1016/j.colsurfb.2009.08.034
   Kadlubowski S, 2007, POLYMER, V48, P4974, DOI 10.1016/j.polymer.2007.06.033
   Kang JS, 2003, J MEMBRANE SCI, V214, P311, DOI 10.1016/S0376-7388(02)00597-5
   Kim EJ, 2013, IND ENG CHEM RES, V52, P9343, DOI 10.1021/ie400165a
   Kuo CY, 2008, DESALINATION, V233, P40, DOI 10.1016/j.desal.2007.09.025
   Le Roux JP, 2004, J SEDIMENT RES, V74, P135, DOI 10.1306/060603740135
   Lewis SR, 2011, P NATL ACAD SCI USA, V108, P8577, DOI 10.1073/pnas.1101144108
   Lewis S. R., 2012, RESPONSIVE MEMBRANES, P97, DOI 10.1002/9781118389553.ch5.
   Liang S, 2013, ACS APPL MATER INTER, V5, P6694, DOI 10.1021/am401462e
   Liu F, 2011, J MEMBRANE SCI, V375, P1, DOI 10.1016/j.memsci.2011.03.014
   Lopergolo LC, 2003, POLYMER, V44, P6217, DOI 10.1016/S0032-3861(03)00686-4
   Ma WZ, 2008, APPL SURF SCI, V254, P5635, DOI 10.1016/j.apsusc.2008.03.012
   Markova Z, 2014, ACS SUSTAIN CHEM ENG, V2, P1674, DOI 10.1021/sc5001435
   Nunes S. P., 2006, SONS MEMBRANE TECHNO
   Olson E, 2011, J GXP COMPLIANCE, V15, P85
   Parshetti GK, 2009, WATER RES, V43, P3086, DOI 10.1016/j.watres.2009.04.037
   Pathak TS, 2006, J IND ENG CHEM, V12, P539
   Petty GW, 2011, J ATMOS SCI, V68, P1460, DOI 10.1175/2011JAS3645.1
   Pogorzelski SJ, 2012, APPL SURF SCI, V258, P3652, DOI 10.1016/j.apsusc.2011.11.132
   Rodriguez J. M., 2013, ELECT J GEOTECHNICAL, V18, P169
   Ross GJ, 2000, POLYMER, V41, P1685, DOI 10.1016/S0032-3861(99)00343-2
   Schrick B, 2002, CHEM MATER, V14, P5140, DOI 10.1021/cm020737i
   Sharma VK, 2015, ACCOUNTS CHEM RES, V48, P182, DOI 10.1021/ar5004219
   Smuleac V, 2011, J MEMBRANE SCI, V379, P131, DOI 10.1016/j.memsci.2011.05.054
   Smuleac V, 2010, J MEMBRANE SCI, V346, P310, DOI 10.1016/j.memsci.2009.09.052
   Smuleac V, 2011, CHEMSUSCHEM, V4, P1773, DOI 10.1002/cssc.201100211
   Song LZ, 2007, J MATER SCI TECHNOL, V23, P55
   Sun MM, 2014, MACROMOL CHEM PHYS, V215, P493, DOI 10.1002/macp.201300688
   Sun YP, 2006, ADV COLLOID INTERFAC, V120, P47, DOI 10.1016/j.cis.2006.03.001
   Taylor LS, 2001, J PHARM SCI-US, V90, P888, DOI 10.1002/jps.1041
   Thomas V, 2008, J MACROMOL SCI A, V45, P107, DOI 10.1080/10601320701683470
   Ulbricht M, 2006, POLYMER, V47, P2217, DOI 10.1016/j.polymer.2006.01.084
   VARGAFTIK NB, 1983, J PHYS CHEM REF DATA, V12, P817, DOI 10.1063/1.555688
   VAZ MF, 1988, SCRIPTA METALL MATER, V22, P35, DOI 10.1016/S0036-9748(88)80302-8
   Wang CB, 1997, ENVIRON SCI TECHNOL, V31, P2154, DOI 10.1021/es970039c
   Wang KY, 2008, CHEM ENG SCI, V63, P2587, DOI 10.1016/j.ces.2008.02.020
   Wang XY, 2008, WATER RES, V42, P4656, DOI 10.1016/j.watres.2008.08.005
   Weibel A, 2005, CHEM MATER, V17, P2378, DOI 10.1021/cm0403762
   WIENK IM, 1995, J POLYM SCI POL CHEM, V33, P49, DOI 10.1002/pola.1995.080330105
   Wienk I. M., 1993, THESIS U TWENTE ENSC
   Woehrle GH, 2006, TURK J CHEM, V30, P1
   Wu S., 2007, J POLYM SCI C, V34, P19, DOI DOI 10.1002/POLC.5070340105
   Wu TF, 2015, RSC ADV, V5, P7880, DOI 10.1039/c4ra13476a
   Xiao L, 2014, J MEMBRANE SCI, V457, P39, DOI 10.1016/j.memsci.2014.01.033
   Xu J, 2007, IND ENG CHEM RES, V46, P2348, DOI 10.1021/ie0611498
   Xu WJ, 2005, COLLOID SURFACE A, V266, P68, DOI 10.1016/j.colsurfa.2005.05.072
   Xu Z, 2009, ADV TOP SCI TECH CHI, P1, DOI 10.1007/978-3-540-88413-2
   Yin MZ, 2013, MACROMOL RAPID COMM, V34, P616, DOI 10.1002/marc.201200750
   Zhang Qinglei, 2014, Membranes (Basel), V4, P81, DOI 10.3390/membranes4010081
   Zhang QG, 2013, RSC ADV, V3, P1855, DOI 10.1039/c2ra21827e
   Zhang WX, 2003, J NANOPART RES, V5, P323, DOI 10.1023/A:1025520116015
   Zhao CS, 2011, PROG POLYM SCI, V36, P1499, DOI 10.1016/j.progpolymsci.2011.05.004
   O'neill L., 2006, U.S. Patent, Patent No. [8178168 B2, 8178168]
NR 80
TC 7
Z9 7
U1 2
U2 61
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2168-0485
J9 ACS SUSTAIN CHEM ENG
JI ACS Sustain. Chem. Eng.
PD MAR
PY 2016
VL 4
IS 3
BP 907
EP 918
DI 10.1021/acssuschemeng.5b01005
PG 12
WC Chemistry, Multidisciplinary; GREEN & SUSTAINABLE SCIENCE & TECHNOLOGY;
   Engineering, Chemical
SC Chemistry; Science & Technology - Other Topics; Engineering
GA DG0LD
UT WOS:000371755400035
PM 29392097
OA green_published
DA 2018-03-19
ER

PT J
AU Nasr, P
   Carbery, T
   Geddes, JW
AF Nasr, Payman
   Carbery, Timothy
   Geddes, James W.
TI N-Methyl-d-aspartate Receptor Antagonists Have Variable Affect in
   3-Nitropropionic Acid Toxicity
SO NEUROCHEMICAL RESEARCH
LA English
DT Article
DE N-Methyl-D-aspartate; 3-Nitropropionic acid; Memantine; Ifenprodil;
   MK-801; Metabolic impairment; Excitotoxicity
ID HUNTINGTONS-DISEASE; MITOCHONDRIAL TOXIN; NITRIC-OXIDE; OXIDATIVE
   STRESS; NEURONAL DEATH; IN-VITRO; POLY(ADP-RIBOSE) POLYMERASE-1;
   NEURODEGENERATIVE DISEASES; ACTIVATED CHANNELS; INHIBITOR MALONATE
AB There is accumulating evidence that excitotoxicity and oxidative stress resulting from excessive activation of glutamate (N-methyl-d-aspartate) NMDA receptors are major participants in striatal degeneration associated with 3-nitropropionic acid (3NP) administration. Although excitotoxic and oxidative mechanisms are implicated in 3NP toxicity, there are conflicting reports as to whether NMDA receptor antagonists attenuate or exacerbate the 3NP-induced neurodegeneration. In the present study, we investigated the involvement of NMDA receptors in striatal degeneration, protein oxidation and motor impairment following systemic 3NP administration. We examined whether NMDA receptor antagonists, memantine and ifenprodil, influence the neurotoxicity of 3NP. The development of striatal lesion and protein oxidation following 3NP administration is delayed by memantine but not affected by ifenprodil. However, in behavioral experiments, memantine failed to improve and ifenprodil exacerbated the motor deficits associated with 3NP toxicity. Together, these findings suggest caution in the application of NMDA receptor antagonists as a neuroprotective agent in neurodegenerative disorders associated with metabolic impairment.
C1 [Nasr, Payman] Kent State Univ, Dept Biol Sci, Ashtabula, OH 44004 USA.
   [Carbery, Timothy] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA.
   [Geddes, James W.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA.
RP Nasr, P (reprint author), Kent State Univ, Dept Biol Sci, Ashtabula, OH 44004 USA.
EM pnasr@kent.edu
FU NINDS NIH HHS [P01 NS058484]
CR ALBIN RL, 1992, NEUROLOGY, V42, P733, DOI 10.1212/WNL.42.4.733
   AMBROZI L, 1988, PHARMACOPSYCHIATRY, V21, P144, DOI 10.1055/s-2007-1014666
   Andreassen OA, 2000, J NEUROCHEM, V75, P847, DOI 10.1046/j.1471-4159.2000.0750847.x
   ARAI Y, 1991, NEUROPHARMACOLOGY, V30, P809, DOI 10.1016/0028-3908(91)90190-M
   BEAL MF, 1993, J NEUROCHEM, V61, P1147, DOI 10.1111/j.1471-4159.1993.tb03633.x
   BEAL MF, 1993, TRENDS NEUROSCI, V16, P125, DOI 10.1016/0166-2236(93)90117-5
   Beal MF, 1997, ANN NEUROL, V42, P644, DOI 10.1002/ana.410420416
   BEAL MF, 1993, J NEUROSCI, V13, P4181
   BEAL MF, 1994, CURR OPIN NEUROL, V7, P542, DOI 10.1097/00019052-199412000-00012
   Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445
   Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424
   BEHRENS MI, 1995, NEUROREPORT, V6, P545, DOI 10.1097/00001756-199502000-00034
   BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0
   Berlett BS, 1996, P NATL ACAD SCI USA, V93, P1776, DOI 10.1073/pnas.93.5.1776
   Blanpied TA, 1997, J NEUROPHYSIOL, V77, P309
   BLOOM FE, 1990, PHARMACOL BASIS THER, P244
   Borlongan CV, 1997, NEUROSCI BIOBEHAV R, V21, P289, DOI 10.1016/S0149-7634(96)00027-9
   Borlongan CV, 1997, BRAIN RES PROTOC, V1, P253, DOI 10.1016/S1385-299X(96)00037-2
   BOSSI SR, 1993, NEUROREPORT, V4, P73, DOI 10.1097/00001756-199301000-00019
   Brouillet E, 1998, J NEUROCHEM, V70, P794
   BROUILLET E, 1993, J NEUROCHEM, V60, P356, DOI 10.1111/j.1471-4159.1993.tb05859.x
   Butler TW, 1998, J MED CHEM, V41, P1172, DOI 10.1021/jm9707986
   Calabresi P, 2001, J NEUROSCI, V21, P5110
   Chen HSV, 1997, J PHYSIOL-LONDON, V499, P27, DOI 10.1113/jphysiol.1997.sp021909
   Chenard BL, 1999, CURR PHARM DESIGN, V5, P381
   CHOI DW, 1985, NEUROSCI LETT, V58, P293, DOI 10.1016/0304-3940(85)90069-2
   Christopherson KS, 1999, J BIOL CHEM, V274, P27467, DOI 10.1074/jbc.274.39.27467
   COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908
   Danysz W, 1997, NEUROSCI BIOBEHAV R, V21, P455, DOI 10.1016/S0149-7634(96)00037-1
   Davis SM, 1997, LANCET, V349, P32, DOI 10.1016/S0140-6736(05)62166-6
   Ferger B, 1999, J NEUROCHEM, V73, P1329, DOI 10.1046/j.1471-4159.1999.0731329.x
   Finucane TE, 2004, JAMA-J AM MED ASSOC, V291, P1695, DOI 10.1001/jama.291.14.1695-a
   Frankiewicz T, 2004, NEUROTOX RES, V5, P617
   Gallagher MJ, 1997, J BIOL CHEM, V272, P24971, DOI 10.1074/jbc.272.40.24971
   Gobeil S, 2001, CELL DEATH DIFFER, V8, P588, DOI 10.1038/sj.cdd.4400851
   Goebel DJ, 1999, MOL BRAIN RES, V69, P164
   GOULD DH, 1985, TOXICOL LETT, V27, P83, DOI 10.1016/0378-4274(85)90123-7
   Guyot MC, 1997, NEUROSCIENCE, V79, P45, DOI 10.1016/S0306-4522(96)00602-1
   Ha HC, 2000, NEUROBIOL DIS, V7, P225, DOI 10.1006/nbdi.2000.0324
   Halliwell B, 1997, FEBS LETT, V411, P157, DOI 10.1016/S0014-5793(97)00469-9
   Hirsch Calvin H, 2004, ACP J Club, V141, P38
   Ikonomidou C, 2000, P NATL ACAD SCI USA, V97, P12885, DOI 10.1073/pnas.220412197
   ISCHIROPOULOS H, 1995, FEBS LETT, V364, P279, DOI 10.1016/0014-5793(95)00307-U
   JACQUARD C, 2006, FASEB J, V20, P245, DOI DOI 10.1096/FJ.05-5085FJE
   Karanian DA, 2006, HIPPOCAMPUS, V16, P834, DOI 10.1002/hipo.20214
   KAUFMANN SH, 1989, CANCER RES, V49, P5870
   Kim GW, 2000, J CEREBR BLOOD F MET, V20, P119, DOI 10.1097/00004647-200001000-00016
   Kong SK, 1996, P NATL ACAD SCI USA, V93, P3377, DOI 10.1073/pnas.93.8.3377
   KURIHARA J, 1993, EUR J PHARMACOL, V240, P73, DOI 10.1016/0014-2999(93)90547-U
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Laurie D J, 1997, Brain Res Mol Brain Res, V51, P23
   LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0
   Le Page F, 2003, J BIOL CHEM, V278, P18471, DOI 10.1074/jbc.M212905200
   Lee ST, 2006, BRAIN RES, V1118, P199, DOI 10.1016/j.brainres.2006.08.035
   LIPTON SA, 1993, TRENDS NEUROSCI, V16, P527, DOI 10.1016/0166-2236(93)90198-U
   MCCOOL BA, 1995, NEUROPHARMACOLOGY, V34, P621, DOI 10.1016/0028-3908(95)00030-A
   McCracken E, 2001, BRAIN RES, V892, P329, DOI 10.1016/S0006-8993(00)03266-2
   MUIR KW, 1995, STROKE, V26, P503, DOI 10.1161/01.STR.26.3.503
   Nasr P, 2003, NEUROCHEM INT, V43, P89, DOI 10.1016/S0197-0186(02)00229-2
   NOVELLI A, 1988, BRAIN RES, V451, P205, DOI 10.1016/0006-8993(88)90765-2
   NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0
   Olney J W, 1990, Can Dis Wkly Rep, V16 Suppl 1E, P47
   Ouary S, 2000, NEUROSCIENCE, V97, P521, DOI 10.1016/S0306-4522(00)00020-8
   Palfi SP, 1996, J NEUROSCI, V16, P3019
   Palmer GC, 2001, CURR DRUG TARGETS, V2, P241, DOI 10.2174/1389450013348335
   Pang Z, 1997, J NEUROSCI, V17, P3064
   Pang Z, 1996, J NEUROCHEM, V66, P474
   Parsons CG, 1999, NEUROPHARMACOLOGY, V38, P735, DOI 10.1016/S0028-3908(99)00019-2
   Parsons CG, 2000, AMINO ACIDS, V19, P157, DOI 10.1007/s007260070044
   ROTHMAN SM, 1987, NEUROSCIENCE, V22, P471, DOI 10.1016/0306-4522(87)90347-2
   Sattler R, 1999, SCIENCE, V284, P1845, DOI 10.1126/science.284.5421.1845
   Schulz JB, 1995, CURR OPIN NEUROL, V8, P480, DOI 10.1097/00019052-199512000-00016
   Schulz JB, 1995, J NEUROSCI, V15, P8419
   Shah GM, 1996, BIOCHEM BIOPH RES CO, V229, P838, DOI 10.1006/bbrc.1996.1889
   SIMPSON JR, 1993, EXP NEUROL, V121, P57, DOI 10.1006/exnr.1993.1071
   Stefani A, 1998, DEV NEUROSCI-BASEL, V20, P242, DOI 10.1159/000017318
   Tariot PN, 2004, JAMA-J AM MED ASSOC, V291, P317, DOI 10.1001/jama.291.3.317
   Teunissen CE, 2002, BRAIN RES, V931, P5, DOI 10.1016/S0006-8993(01)03331-5
   Tozzi A, 2007, EXP NEUROL, V207, P218, DOI 10.1016/j.expneurol.2007.06.008
   VEZZANI A, 1989, J PHARMACOL EXP THER, V249, P278
   Volbracht C, 2006, EUR J NEUROSCI, V23, P2611, DOI 10.1111/j.1460-9568.2006.04787.x
NR 81
TC 10
Z9 10
U1 0
U2 2
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0364-3190
EI 1573-6903
J9 NEUROCHEM RES
JI Neurochem. Res.
PD MAR
PY 2009
VL 34
IS 3
BP 490
EP 498
DI 10.1007/s11064-008-9809-3
PG 9
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 404JQ
UT WOS:000263148200013
PM 18688711
OA green_accepted
DA 2018-03-20
ER

PT J
AU Lu, XL
   Howard, MD
   Talbert, DR
   Rinehart, JJ
   Potter, PM
   Jay, M
   Leggas, M
AF Lu, Xiuling
   Howard, Melissa D.
   Talbert, Dominique R.
   Rinehart, John J.
   Potter, Philip M.
   Jay, Michael
   Leggas, Markos
TI Nanoparticles Containing Anti-inflammatory Agents as Chemotherapy
   Adjuvants II: Role of Plasma Esterases in Drug Release
SO AAPS JOURNAL
LA English
DT Article
DE carboxylesterase; dexamethasone palmitate; esterolysis; release; solid
   lipid nanoparticle
ID CANCER-CHEMOTHERAPY; DEXAMETHASONE; CARBOPLATIN; PHARMACOKINETICS;
   GEMCITABINE; STABILITY; PRODRUGS
C1 [Howard, Melissa D.; Talbert, Dominique R.; Leggas, Markos] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
   [Lu, Xiuling; Jay, Michael] Univ N Carolina, Div Mol Pharmaceut, Chapel Hill, NC 27599 USA.
   [Rinehart, John J.] Univ Kentucky, Dept Med, Lexington, KY 40536 USA.
   [Potter, Philip M.] St Jude Childrens Hosp, Dept Mol Pharmacol, Memphis, TN 38105 USA.
RP Leggas, M (reprint author), Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
EM mark.leggas@uky.edu
RI Leggas, Markos/E-6618-2011; Potter, Philip/J-4515-2013
OI Potter, Philip/0000-0001-8922-8535
FU Markey Cancer Center Experimental Therapeutics Program; Buck-Kentucky
   Lung Cancer Research Chair; Education and Research Foundation for the
   Society of Nuclear Medicine; Lyman T. Johnson Postdoctoral Fellowship;
   NSF IGERT Program [DGE-0653710]
FX The authors are grateful for financial support from the Markey Cancer
   Center Experimental Therapeutics Program (ML), the Buck-Kentucky Lung
   Cancer Research Chair (JJR), the Benedict Cassen Postdoctoral Fellowship
   from the Education and Research Foundation for the Society of Nuclear
   Medicine (XL), the Lyman T. Johnson Postdoctoral Fellowship (DT), and
   grant DGE-0653710 from the NSF IGERT Program (MDH).
CR BENAMEUR H, 1993, INT J PHARM, V89, P157, DOI 10.1016/0378-5173(93)90239-C
   Leggas M, 2009, CANCER CHEMOTH PHARM, V63, P731, DOI 10.1007/s00280-008-0767-x
   Liederer BM, 2006, J PHARM SCI-US, V95, P1177, DOI 10.1002/jps.20542
   Liederer BM, 2005, J PHARM SCI-US, V94, P2198, DOI 10.1002/jps.20452
   Lu XL, 2008, AAPS J, V10, P133, DOI 10.1208/s12248-008-9013-z
   Moghimi SM, 2003, PROG LIPID RES, V42, P463, DOI 10.1016/S0163-7827(03)00033-X
   Morton CL, 1999, CANCER RES, V59, P1458
   Pan H, 2007, PHARM RES, V24, P2270, DOI 10.1007/s11095-007-9449-3
   Rinehart J, 2003, AM J CLIN ONCOL-CANC, V26, P448, DOI 10.1097/01.coc.0000027268.23258.7D
   Rinehart JJ, 1997, CANCER BIOTHER RADIO, V12, P101, DOI 10.1089/cbr.1997.12.101
   Wang H, 2004, CANCER CHEMOTH PHARM, V53, P459, DOI 10.1007/s00280-003-0759-9
   Wang H, 2004, CLIN CANCER RES, V10, P1633, DOI 10.1158/1078-0432.CCR-0829-3
NR 12
TC 20
Z9 20
U1 1
U2 16
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1550-7416
J9 AAPS J
JI AAPS J.
PD MAR
PY 2009
VL 11
IS 1
BP 120
EP 122
DI 10.1208/s12248-009-9086-3
PG 3
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 428VY
UT WOS:000264880800015
PM 19225893
OA green_published
DA 2018-03-20
ER

PT J
AU Liu, SB
   Li, TL
   Ayers, PW
AF Liu, Shubin
   Li, Tonglei
   Ayers, Paul W.
TI Potentialphilicity and potentialphobicity: Reactivity indicators for
   external potential changes from density functional reactivity theory
SO JOURNAL OF CHEMICAL PHYSICS
LA English
DT Article
ID CHARGE SENSITIVITY-ANALYSIS; FRACTIONAL PARTICLE NUMBER;
   FRONTIER-ELECTRON THEORY; CHEMICAL-REACTIVITY; DERIVATIVE
   DISCONTINUITIES; ELECTROPHILICITY INDEX; DUAL DESCRIPTOR; FUKUI
   FUNCTIONS; NORMAL-MODES; HARDNESS
AB In analogy to the electrophilicity, we define potentialphilicity indicators that represent energetically favorable ways to change the external potential of a molecule at fixed electron number. Similarly, we define a potentialphobicity to represent the least favorable way to change the external potential of a molecule. The resulting indicators should be useful for describing how molecular geometries change and predicting favorable and unfavorable ways for a reagent to approach a molecule. The linear response function enters plays a very important role in this approach, analogous to the role of the hardness for the electrophilicity or the hardness kernel for the Fukui function. The mathematical properties of the response function and its implications for these reactivity indicators are discussed in depth. (C) 2009 American Institute of Physics. [doi: 10.1063/1.3231687]
C1 [Liu, Shubin] Univ N Carolina, Ctr Res Comp, Chapel Hill, NC 27599 USA.
   [Li, Tonglei] Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
   [Ayers, Paul W.] McMaster Univ, Dept Chem, Hamilton, ON L8S 4M1, Canada.
RP Liu, SB (reprint author), Univ N Carolina, Ctr Res Comp, Chapel Hill, NC 27599 USA.
EM shubin@email.unc.edu; ayers@mcmaster.ca
RI Ayers, Paul/A-1154-2008; Liu, Shubin/B-1502-2009
OI Ayers, Paul/0000-0003-2605-3883; Liu, Shubin/0000-0001-9331-0427
CR Ayers PW, 2008, J MATH CHEM, V43, P285, DOI 10.1007/s10910-006-9195-5
   Ayers PW, 2007, FARADAY DISCUSS, V135, P161, DOI 10.1039/b606877d
   Ayers PW, 2000, J CHEM PHYS, V113, P10886, DOI 10.1063/1.1327268
   Ayers PW, 2005, INT J QUANTUM CHEM, V101, P520, DOI 10.1002/qua.20307
   Ayers PW, 2000, THEOR CHEM ACC, V103, P353, DOI 10.1007/s002149900093
   Ayers PW, 2001, J AM CHEM SOC, V123, P2007, DOI 10.1021/ja002966g
   Ayers PW, 2001, THEOR CHEM ACC, V106, P271, DOI 10.1007/PL00012385
   Ayers P. W., 2009, CHEM REACTIVITY THEO, P255
   BAEKELANDT BG, 1995, J PHYS CHEM-US, V99, P9784, DOI 10.1021/j100024a020
   BERKOWITZ M, 1988, J CHEM PHYS, V88, P2554, DOI 10.1063/1.454034
   Cardenas C, 2009, J PHYS CHEM A, V113, P8660, DOI 10.1021/jp902792n
   Casida M. E., 1995, RECENT ADV DENSITY F, P155
   Cedillo A, 2007, J PHYS CHEM A, V111, P2442, DOI 10.1021/jp068459o
   Chattaraj PK, 2006, CHEM REV, V106, P2065, DOI 10.1021/cr040109f
   Chermette H, 1999, J COMPUT CHEM, V20, P129, DOI 10.1002/(SICI)1096-987X(19990115)20:1<129::AID-JCC13>3.3.CO;2-1
   COHEN MH, 1995, J CHEM PHYS, V103, P3543, DOI 10.1063/1.470238
   COHEN MH, 1994, J CHEM PHYS, V101, P8988, DOI 10.1063/1.468026
   Cohen MH, 2007, J PHYS CHEM A, V111, P2229, DOI 10.1021/jp066449h
   FUENTEALBA P, 1991, J CHEM PHYS, V94, P5559, DOI 10.1063/1.460491
   Gazquez JL, 2008, J MEX CHEM SOC, V52, P3
   Geerlings P, 2008, PHYS CHEM CHEM PHYS, V10, P3028, DOI 10.1039/b717671f
   Geerlings P, 2003, CHEM REV, V103, P1793, DOI 10.1021/cr990029p
   HOHENBERG P, 1964, PHYS REV B, V136, pB864, DOI 10.1103/PhysRev.136.B864
   Langenaeker W, 2001, J MOL STRUC-THEOCHEM, V535, P279, DOI 10.1016/S0166-1280(00)00579-0
   LIEB EH, 1983, INT J QUANTUM CHEM, V24, P243, DOI 10.1002/qua.560240302
   Liu SB, 1999, J CHEM PHYS, V111, P6197, DOI 10.1063/1.479924
   Liu S., 2009, CHEM REACTIVITY THEO, P179
   Liu SB, 2009, ACTA PHYS-CHIM SIN, V25, P590, DOI 10.3866/PKU.WHXB20090332
   MERMIN ND, 1965, PHYS REV, V137, P1441
   Morell C, 2005, J PHYS CHEM A, V109, P205, DOI 10.1021/jp046577a
   Morell C, 2008, PHYS CHEM CHEM PHYS, V10, P7239, DOI 10.1039/b810343g
   NALEWAJSKI RF, 1985, J PHYS CHEM-US, V89, P2831, DOI 10.1021/j100259a025
   NALEWAJSKI RF, 1992, INT J QUANTUM CHEM, V42, P243, DOI 10.1002/qua.560420202
   NALEWAJSKI RF, 1989, J MOL CATAL, V54, P324, DOI 10.1016/0304-5102(89)80150-6
   NALEWAJSKI RF, 1984, J CHEM PHYS, V81, P2088, DOI 10.1063/1.447833
   Nalewajski RF, 2000, COMPUT CHEM, V24, P243, DOI 10.1016/S0097-8485(99)00070-4
   NALEWAJSKI RF, 1995, INT J QUANTUM CHEM, V56, P453, DOI 10.1002/qua.560560505
   NALEWAJSKI RF, 1982, J CHEM PHYS, V77, P399, DOI 10.1063/1.443620
   NALEWAJSKI RF, 1996, TOPICS CURRENT CHEM
   Nocedal J., 1999, NUMERICAL OPTIMIZATI
   Padmanabhan J, 2007, J PHYS CHEM A, V111, P9130, DOI 10.1021/jp0718909
   Parr RG, 1999, J AM CHEM SOC, V121, P1922, DOI 10.1021/ja983494x
   PARR RG, 1983, J AM CHEM SOC, V105, P7512, DOI 10.1021/ja00364a005
   PARR RG, 1978, J CHEM PHYS, V68, P3801, DOI 10.1063/1.436185
   PARR RG, 1984, J AM CHEM SOC, V106, P4049, DOI 10.1021/ja00326a036
   Parr RG, 1989, DENSITY FUNCTIONAL T
   PEARSON RG, 1987, J CHEM EDUC, V64, P561, DOI 10.1021/ed064p561
   Pearson RG, 1999, J CHEM EDUC, V76, P267, DOI 10.1021/ed076p267
   Pearson R. G., 1997, CHEM HARDNESS
   PERDEW JP, 1982, PHYS REV LETT, V49, P1691, DOI 10.1103/PhysRevLett.49.1691
   Roncero O, 2008, J CHEM PHYS, V129, DOI 10.1063/1.3007987
   RYCHLEWSKI J, 1986, J CHEM PHYS, V84, P1696, DOI 10.1063/1.450467
   Senet P, 1996, J CHEM PHYS, V105, P6471, DOI 10.1063/1.472498
   Senet P, 1997, J CHEM PHYS, V107, P2516, DOI 10.1063/1.474591
   WESOLOWSKI TA, 1993, J PHYS CHEM-US, V97, P8050, DOI 10.1021/j100132a040
   Wesolowski TA, 2004, CHIMIA, V58, P311, DOI 10.2533/000942904777677885
   YANG W, 1984, J CHEM PHYS, V81, P2862, DOI 10.1063/1.447964
   Yang WT, 2000, PHYS REV LETT, V84, P5172, DOI 10.1103/PhysRevLett.84.5172
   YANG WT, 1991, PHYS REV LETT, V66, P1438, DOI 10.1103/PhysRevLett.66.1438
   Zhang YK, 2000, THEOR CHEM ACC, V103, P346, DOI 10.1007/s002149900021
NR 60
TC 26
Z9 26
U1 0
U2 15
PU AMER INST PHYSICS
PI MELVILLE
PA CIRCULATION & FULFILLMENT DIV, 2 HUNTINGTON QUADRANGLE, STE 1 N O 1,
   MELVILLE, NY 11747-4501 USA
SN 0021-9606
EI 1089-7690
J9 J CHEM PHYS
JI J. Chem. Phys.
PD SEP 21
PY 2009
VL 131
IS 11
AR 114106
DI 10.1063/1.3231687
PG 7
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA 497XG
UT WOS:000270097400008
PM 19778099
DA 2018-03-20
ER

PT J
AU Bains, M
   Cebak, JE
   Gilmer, LK
   Barnes, CC
   Thompson, SN
   Geddes, JW
   Hall, ED
AF Bains, Mona
   Cebak, John E.
   Gilmer, Lesley K.
   Barnes, Colleen C.
   Thompson, Stephanie N.
   Geddes, James W.
   Hall, Edward D.
TI Pharmacological analysis of the cortical neuronal cytoskeletal
   protective efficacy of the calpain inhibitor SNJ-1945 in a mouse
   traumatic brain injury model
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Article
DE alpha-spectrin; calpain; neuroprotection; SNJ-1945; traumatic brain
   injury
ID ACID 5-METHOXY-3-OXAPENTYL ESTER; CEREBROSPINAL-FLUID; CORPUS-CALLOSUM;
   HEAD-INJURY; PROTEOLYSIS; NEURODEGENERATION; BREAKDOWN; DEGRADATION;
   MECHANISMS; RATS
AB The efficacy of the amphipathic ketoamide calpain inhibitor SNJ-1945 in attenuating calpain-mediated degradation of the neuronal cytoskeletal protein -spectrin was examined in the controlled cortical impact (CCI) traumatic brain injury (TBI) model in male CF-1 mice. Using a single early (15min after CCI-TBI) i.p. bolus administration of SNJ-1945 (6.25, 12.5, 25, or 50-mg/kg), we identified the most effective dose on -spectrin degradation in the cortical tissue of mice at its 24h peak after severe CCI-TBI. We then investigated the effects of a pharmacokinetically optimized regimen by examining multiple treatment paradigms that varied in dose and duration of treatment. Finally, using the most effective treatment regimen, the therapeutic window of -spectrin degradation attenuation was assessed by delaying treatment from 15min to 1 or 3h post-injury. The effect of SNJ-1945 on -spectrin degradation exhibited a U-shaped doseresponse curve when treatment was initiated 15min post-TBI. The most effective 12.5mg/kg dose of SNJ-1945 significantly reduced -spectrin degradation by similar to 60% in cortical tissue. Repeated dosing of SNJ-1945 beginning with a 12.5mg/kg dose did not achieve a more robust effect compared with a single bolus treatment, and the required treatment initiation was less than 1h. Although calpain has been firmly established to play a major role in post-traumatic secondary neurodegeneration, these data suggest that even brain and cell-permeable calpain inhibitors, when administered alone, do not show sufficient cytoskeletal protective efficacy or a practical therapeutic window in a mouse model of severe TBI. Such conclusions need to be verified in the human clinical situation.
C1 [Bains, Mona; Cebak, John E.; Gilmer, Lesley K.; Barnes, Colleen C.; Thompson, Stephanie N.; Geddes, James W.; Hall, Edward D.] Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA.
RP Hall, ED (reprint author), Univ Kentucky, Med Ctr, SCoBIRC, Room B477,Biomed & Biol Sci Res Bldg,741 S Limest, Lexington, KY 40536 USA.
EM edhall@uky.edu
FU National Institute of Neurological Disorders and Stroke [2P01 NS058484,
   2P30 NS051220]; Kentucky Spinal Cord & Head Injury Research Trust
FX This study was supported by funding from the National Institute of
   Neurological Disorders and Stroke (2P01 NS058484, 2P30 NS051220) and the
   Kentucky Spinal Cord & Head Injury Research Trust. The authors have no
   conflicts of interest to declare in relation to the contents of this
   manuscript.
CR Ai JL, 2007, J NEUROTRAUM, V24, P960, DOI 10.1089/neu.2006.0224
   Bartus RT, 1997, NEUROSCIENTIST, V3, P314, DOI 10.1177/107385849700300513
   Brophy GM, 2009, J NEUROTRAUM, V26, P471, DOI 10.1089/neu.2008.0657
   Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365
   Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023
   Farkas O, 2005, ACTA NEUROCHIR, V147, P855, DOI 10.1007/s00701-005-0559-6
   Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383
   Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121
   Kampfl A, 1996, J NEUROCHEM, V67, P1575
   Koumura A, 2008, NEUROSCIENCE, V157, P309, DOI 10.1016/j.neuroscience.2008.09.007
   Kupina NC, 2001, J NEUROTRAUM, V18, P1229, DOI 10.1089/089771501317095269
   Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1
   Mbye LH, 2009, J CEREBR BLOOD F MET, V29, P87, DOI 10.1038/jcbfm.2008.93
   McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749
   McIntosh TK, 1997, NEUROSCIENTIST, V3, P169, DOI 10.1177/107385849700300310
   Mellgren RL, 2007, J BIOL CHEM, V282, P2567, DOI 10.1074/jbc.M604560200
   Mellgren RL, 2009, BBA-MOL CELL RES, V1793, P1886, DOI 10.1016/j.bbamcr.2009.09.013
   Mustafa AG, 2011, J NEUROCHEM, V117, P579, DOI 10.1111/j.1471-4159.2011.07228.x
   Oka T, 2006, NEUROSCIENCE, V141, P2139, DOI 10.1016/j.neuroscience.2006.05.060
   Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6
   Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002
   Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010
   Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428
   Shirasaki Y, 2008, BIOORG MED CHEM LETT, V18, P5174, DOI 10.1016/j.bmcl.2008.08.089
   Shirasaki Y, 2006, J OCUL PHARMACOL TH, V22, P417, DOI 10.1089/jop.2006.22.417
   Thompson SN, 2006, EXP NEUROL, V201, P253, DOI 10.1016/j.expneurol.2006.04.013
   Thompson SN, 2010, J NEUROTRAUM, V27, P2233, DOI 10.1089/neu.2010.1474
   Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4
   Yoshikawa Y, 2010, AM J PHYSIOL-HEART C, V298, pH643, DOI 10.1152/ajpheart.00849.2009
NR 29
TC 13
Z9 13
U1 2
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3042
J9 J NEUROCHEM
JI J. Neurochem.
PD APR
PY 2013
VL 125
IS 1
BP 125
EP 132
DI 10.1111/jnc.12118
PG 8
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 112YR
UT WOS:000316631900013
PM 23216523
OA gold
DA 2018-03-20
ER

PT J
AU Diezi, TA
   Bae, Y
   Kwon, GS
AF Diezi, Thomas A.
   Bae, Younsoo
   Kwon, Glen S.
TI Enhanced Stability of PEG-block-poly(N-hexyl stearate L-aspartamide)
   Micelles in the Presence of Serum Proteins
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE Amphotericin B; drug solubilization; FRET; micelle stability; PEG-DSPE;
   polymeric micelle
ID AMPHOTERICIN-B; RELEASE; DERIVATIVES; CHOLESTEROL; COPOLYMER; DELIVERY;
   MEDIA
AB Polyethylene glycol-phospholipid micelles form a major class of nanocarriers in pharmacy and medicine due to proven capability in drug solubilization, sustained drug release, and evidence for targeted drug delivery in vivo. In this report, we have prepared micelles composed of PEG-block-poly(N-hexyl stearate L-aspartamide) (PEG-b-PHSA), having nine stearic acid side chains, and have studied their stability in the presence of serum proteins by Forster resonance energy transfer (FRET) experiments. In the presence of serum albumin, alpha and beta globulins, or gamma globulins, there are minimal changes in FRET over two hours in vitro, indicating integrity of PEG-b-PHSA micelles. In contrast, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-5000] (PEG-DSPE) micelles lose FRET over two hours in vitro, especially in the presence of alpha and beta globulins, indicating the disruption of PEG-DSPE micelles and leakage of fluorescent probes. Owing to the aliphatic nature of DSPE and PHSA, both PEG-b-PHSA and PEG-DSPE micelles efficiently solubilize amphotericin B (AmB), a poorly water-soluble antifungal agent used to combat systemic mycoses. However, only PEG-b-PHSA micelles gradually liberate AmB in the presence of alpha and beta globulins, based on time-dependent changes in the self-aggregation state of AmB, monitored by UV/vis spectroscopy. PEG-b-PHSA micelles are remarkably stable in the presence of serum proteins and a more stable alternative for poorly water-soluble drugs, which have been solubilized by PEG-DSPE micelles.
C1 [Diezi, Thomas A.; Kwon, Glen S.] Univ Wisconsin, Sch Pharm, Div Pharmaceut Sci, Madison, WI 53705 USA.
   [Bae, Younsoo] Univ Kentucky, Coll Pharm, Lexington, KY 40536 USA.
RP Kwon, GS (reprint author), Univ Wisconsin, Sch Pharm, Div Pharmaceut Sci, 777 Highland Ave, Madison, WI 53705 USA.
EM gskwon@pharmacy.wisc.edu
RI Kwon, Glen/A-1919-2014
FU NIH [R01 AI-43346]
FX We thank Gary Girdaukas for his help with the fluorescence experiments.
   We thank Dr. Masayuki Yokoyama at Jikei University School of Medicine,
   Tokyo, Japan, for the gift of P3P. We thank Dr. Melgardt De Villiers and
   Dr. Adam Alani at the School of Pharmacy, University of Wisconsin, for
   thoughtful suggestions on this manuscript. Fluorescence and nuclear
   magnetic resonance spectra were obtained in the Analytical
   Instrumentation Center of the School of Pharmacy, University of
   Wisconsin-Madison. We acknowledge financial support from the NIH (R01
   AI-43346).
CR Adams ML, 2002, J BIOMAT SCI-POLYM E, V13, P991, DOI 10.1163/156856202760319144
   Aramwit P, 2000, J PHARM SCI, V89, P1589, DOI 10.1002/1520-6017(200012)89:12<1589::AID-JPS10>3.3.CO;2-Y
   BOLARD J, 1991, BIOCHEMISTRY-US, V30, P5707, DOI 10.1021/bi00237a011
   Chen H, 2008, LANGMUIR, V24, P5213, DOI 10.1021/la703570m
   DALY WH, 1988, TETRAHEDRON LETT, V29, P5859, DOI 10.1016/S0040-4039(00)82209-1
   Lavasanifar A, 2001, COLLOID SURFACE B, V22, P115, DOI 10.1016/S0927-7765(01)00147-3
   Lavasanifar A, 2002, PHARMACEUT RES, V19, P418, DOI 10.1023/A:1015127225021
   Lavasanifar A, 2002, J CONTROL RELEASE, V79, P165, DOI 10.1016/S0168-3659(01)00537-5
   Liu JB, 2007, EUR J PHARM BIOPHARM, V65, P309, DOI 10.1016/j.ejpb.2006.11.010
   Lukyanov AN, 2004, ADV DRUG DELIVER REV, V56, P1273, DOI 10.1016/j.addr.2003.12.004
   Matsumura Y, 2009, CANCER SCI, V100, P572, DOI 10.1111/j.1349-7006.2009.01103.x
   Savic R, 2006, LANGMUIR, V22, P3570, DOI 10.1021/la0531998
   Vakil R, 2008, MOL PHARM, V5, P98, DOI 10.1021/mp700081v
   Vakil R, 2006, LANGMUIR, V22, P9723, DOI 10.1021/la061408y
   WINNIK FM, 1993, CHEM REV, V93, P587, DOI 10.1021/cr00018a001
   Wolszczak M, 2002, J PHOTOCH PHOTOBIO A, V147, P45, DOI 10.1016/S1010-6030(01)00611-6
   YOKOYAMA M, 1992, BIOCONJUGATE CHEM, V3, P295, DOI 10.1021/bc00016a007
NR 17
TC 40
Z9 41
U1 1
U2 23
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD JUL-AUG
PY 2010
VL 7
IS 4
BP 1355
EP 1360
DI 10.1021/mp100069p
PG 6
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 632SM
UT WOS:000280448100046
PM 20575526
OA green_accepted
DA 2018-03-19
ER

PT J
AU Noinaj, N
   Song, ES
   Bhasin, S
   Alper, BJ
   Schmidt, WK
   Hersh, LB
   Rodgers, DW
AF Noinaj, Nicholas
   Song, Eun Suk
   Bhasin, Sonia K.
   Alper, Benjamin J.
   Schmidt, Walter K.
   Hersh, Louis B.
   Rodgers, David W.
TI Anion Activation Site of Insulin-degrading Enzyme
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID SACCHAROMYCES-CEREVISIAE; A-FACTOR; IN-VIVO; INTRACELLULAR DOMAIN;
   GENETIC SYSTEM; RAT-BRAIN; G1 ARREST; DEGRADATION; PROTEIN; YEAST
AB Insulin-degrading enzyme (IDE) (insulysin) is a zinc metallopeptidase that metabolizes several bioactive peptides, including insulin and the amyloid beta peptide. IDE is an unusual metallopeptidase in that it is allosterically activated by both small peptides and anions, such as ATP. Here, we report that the ATP-binding site is located on a portion of the substrate binding chamber wall arising largely from domain 4 of the four-domain IDE. Two variants having residues in this site mutated, IDEK898A,K899A,S901A and IDER429S, both show greatly decreased activation by the polyphosphate anions ATP and PPPi. IDEK898A,K899A,S901A is also deficient in activation by small peptides, suggesting a possible mechanistic link between the two types of allosteric activation. Sodium chloride at high concentrations can also activate IDE. There are no observable differences in average conformation between the IDE-ATP complex and unliganded IDE, but regions of the active site and C-terminal domain do show increased crystallographic thermal factors in the complex, suggesting an effect on dynamics. Activation by ATP is shown to be independent of the ATP hydrolysis activity reported for the enzyme. We also report that IDEK898A,K899A,S901A has reduced intracellular function relative to unmodified IDE, consistent with a possible role for anion activation of IDE activity in vivo. Together, the data suggest a model in which the binding of anions activates by reducing the electrostatic attraction between the two halves of the enzyme, shifting the partitioning between open and closed conformations of IDE toward the open form.
C1 [Hersh, Louis B.] Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA.
   [Noinaj, Nicholas; Song, Eun Suk; Bhasin, Sonia; Hersh, Louis B.; Rodgers, David W.] Univ Kentucky, Struct Biol Ctr, Lexington, KY 40536 USA.
   [Alper, Benjamin J.; Schmidt, Walter K.] Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA.
RP Hersh, LB (reprint author), Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, 741 S Limestone, Lexington, KY 40536 USA.
EM lhersh@uky.edu; david.rodgers@uky.edu
FU National Institutes of Health [DA02243, NS38041, DA016176, T32 DA016176,
   GM067092, P20 RR20171]
FX This work was supported, in whole or in part, by National Institutes of
   Health Grants DA02243, NS38041, DA016176, T32 DA016176, GM067092, and
   P20 RR20171.
CR Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657
   Ahmadian MR, 1997, NAT STRUCT BIOL, V4, P686, DOI 10.1038/nsb0997-686
   Alper BJ, 2006, BIOCHEM J, V398, P145, DOI 10.1042/BJ20060311
   BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987
   BEIS I, 1975, BIOCHEM J, V152, P23, DOI 10.1042/bj1520023
   Bennett RG, 2003, J ENDOCRINOL, V177, P399, DOI 10.1677/joe.0.1770399
   Cabrol C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005274
   Camberos MD, 2007, EXP BIOL MED, V232, P281
   Camberos MC, 2001, EXP BIOL MED, V226, P334
   CHAN RK, 1982, MOL CELL BIOL, V2, P11, DOI 10.1128/MCB.2.1.11
   Dixon M., 1979, ENZYMES, P381
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Farris W, 2003, P NATL ACAD SCI USA, V100, P4162, DOI 10.1073/pnas.0230450100
   FujimuraKamada K, 1997, J CELL BIOL, V136, P271, DOI 10.1083/jcb.136.2.271
   GOLDSTEIN BJ, 1981, METABOLISM, V30, P825, DOI 10.1016/0026-0495(81)90030-5
   HARDER KW, 1994, BIOCHEM J, V298, P395, DOI 10.1042/bj2980395
   HARI J, 1987, ENDOCRINOLOGY, V120, P829, DOI 10.1210/endo-120-2-829
   Heras B, 2005, ACTA CRYSTALLOGR D, V61, P1173, DOI 10.1107/S0907444905019451
   Im H, 2007, J BIOL CHEM, V282, P25453, DOI 10.1074/jbc.M701590200
   Jones LS, 2004, MOL CELL PROTEOMICS, V3, P746, DOI 10.1074/mcp.R400008-MCP200
   Kim S, 2005, J BIOL CHEM, V280, P27481, DOI 10.1074/jbc.M414192200
   KUPFER SR, 1994, J BIOL CHEM, V269, P20622
   KUROCHKIN IV, 1994, FEBS LETT, V345, P33, DOI 10.1016/0014-5793(94)00387-4
   Li QX, 2007, J VIROL, V81, P8525, DOI 10.1128/JVI.00286-07
   Li QX, 2006, CELL, V127, P305, DOI 10.1016/j.cell.2006.08.046
   Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286
   MARCUS S, 1991, MOL CELL BIOL, V11, P1030, DOI 10.1128/MCB.11.2.1030
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206
   McDermott JR, 1997, NEUROCHEM RES, V22, P49, DOI 10.1023/A:1027325304203
   MICHAELIS S, 1988, MOL CELL BIOL, V8, P1309, DOI 10.1128/MCB.8.3.1309
   Miller BC, 2003, P NATL ACAD SCI USA, V100, P6221, DOI 10.1073/pnas.1031520100
   MISBIN RI, 1983, ENDOCRINOLOGY, V113, P1525, DOI 10.1210/endo-113-4-1525
   Morita M, 2000, CELL STRUCT FUNCT, V25, P309, DOI 10.1247/csf.25.309
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Nadanaciva S, 1999, BIOCHEMISTRY-US, V38, P15493, DOI 10.1021/bi9917683
   Noinaj N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020864
   Oldenburg KR, 1997, NUCLEIC ACIDS RES, V25, P451, DOI 10.1093/nar/25.2.451
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   REISER M, 1987, ACTA HISTOCHEM, V82, P35, DOI 10.1016/S0065-1281(87)80047-8
   Rodgers DW, 1997, METHOD ENZYMOL, V276, P183, DOI 10.1016/S0076-6879(97)76059-2
   Safavi A, 1996, BIOCHEMISTRY-US, V35, P14318, DOI 10.1021/bi960582q
   Shen YQ, 2006, NATURE, V443, P870, DOI 10.1038/nature05143
   SIKORSKI RS, 1989, GENETICS, V122, P19
   Song ES, 2004, J BIOL CHEM, V279, P54216, DOI 10.1074/jbc.M411177200
   Song ES, 2003, J BIOL CHEM, V278, P49789, DOI 10.1074/jbc.M308983200
   Song ES, 2001, J BIOL CHEM, V276, P1152, DOI 10.1074/jbc.M008702200
   Song ES, 2005, J BIOL CHEM, V280, P17701, DOI 10.1074/jbc.M501896200
   Song ES, 2011, J BIOL CHEM, V286, P13852, DOI 10.1074/jbc.M110.191668
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Unni S, 2011, J COMPUT CHEM, V32, P1488, DOI 10.1002/jcc.21720
   Vepsalainen S, 2007, J MED GENET, V44, DOI 10.1136/jmg.2006.048470
   Yao HB, 2006, ARCH BIOCHEM BIOPHYS, V451, P175, DOI 10.1016/j.abb.2006.04.011
   YONEZAWA K, 1986, ENDOCRINOLOGY, V118, P1989, DOI 10.1210/endo-118-5-1989
   Zhang YM, 2001, MOL BIOL CELL, V12, P1303, DOI 10.1091/mbc.12.5.1303
NR 55
TC 14
Z9 15
U1 1
U2 9
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JAN 2
PY 2012
VL 287
IS 1
BP 48
EP 57
DI 10.1074/jbc.M111.264614
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 870PW
UT WOS:000298682400008
PM 22049080
OA gold
DA 2018-03-20
ER

PT J
AU Ao, L
   Reichel, D
   Hu, D
   Jeong, H
   Kim, KB
   Bae, Y
   Lee, W
AF Ao, Lin
   Reichel, Derek A.
   Hu, Di
   Jeong, Hyunyoung
   Kim, Kyung Bo
   Bae, Younsoo
   Lee, Wooin
TI Polymer Micelle Formulations of Proteasome Inhibitor Carfilzomib for
   Improved Metabolic Stability and Anticancer Efficacy in Human Multiple
   Myeloma and Lung Cancer Cell Lines
SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
LA English
DT Article
ID SINGLE-AGENT CARFILZOMIB; DRUG-DELIVERY; SOLID TUMORS; OPEN-LABEL;
   IN-VIVO; NANOPARTICLES; PHARMACOKINETICS; DEXAMETHASONE; LENALIDOMIDE;
   CHOLESTEROL
AB Carfilzomib (CFZ) is a second-generation proteasome inhibitor drug approved for the treatment of multiple myeloma. Contrary to its excellent antimyeloma activity, CFZ has shown only limited efficacy in patients with solid malignancies. This lack of efficacy has been attributed in part to rapid degradation of CFZ in the body, possibly hindering the ability of CFZ to access the proteasome target in solid tumors. We hypothesized that polymer micelles, a currently Food and Drug Administration-approved nanoparticle drug delivery formulation, may protect CFZ from metabolic degradation and thus expand the clinical utility of the drug as an anticancer agent. To test our hypothesis, we prepared CFZ-entrapped polymer micelle particles with various compositions and drug release profiles and examined the extent of the CFZ metabolism in vitro using mouse liver homogenates. We also assessed the cytotoxic activities of the CFZ-entrapped micelle formulations in human cancer cell lines derived from B lymphocytes (RPMI-8226) and the lung (H460). Our data indicated that polymer micelle-based formulations can improve metabolic stability and cytotoxic effects of CFZ compared with free CFZ in human cancer cell lines tested. Taken together, these results suggest that polymer micelles may have potential as a delivery system for CFZ with an extended therapeutic utility for nonhematologic malignancies in the future.
C1 [Ao, Lin; Reichel, Derek; Kim, Kyung Bo; Bae, Younsoo] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY USA.
   [Hu, Di; Jeong, Hyunyoung] Univ Illinois, Coll Pharm, Dept Pharm Practice, Chicago, IL USA.
   [Lee, Wooin] Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea.
   [Lee, Wooin] Seoul Natl Univ, Pharmaceut Sci Res Inst, Seoul 151742, South Korea.
RP Lee, W (reprint author), Seoul Natl Univ, Coll Pharm, 1 Gwanak Ro, Seoul 151742, South Korea.
EM wooin.lee@snu.ac.kr
FU National Institutes of Health [R01-CA128903, R15-CA156601]; American
   Foundation for Pharmaceutical Education Pre-Doctoral Fellowship; Basic
   Science Research Program, National Research Foundation of Korea,
   Ministry of Science, ICT and Future Planning [NRF-2014R1A1A3050645]
FX This work was supported by the National Institutes of Health [Grants
   R01-CA128903 and R15-CA156601]; American Foundation for Pharmaceutical
   Education Pre-Doctoral Fellowship; and Basic Science Research Program,
   National Research Foundation of Korea, Ministry of Science, ICT and
   Future Planning [NRF-2014R1A1A3050645].
CR Adams J, 2004, CANCER CELL, V5, P417, DOI 10.1016/S1535-6108(04)00120-5
   Adams ML, 2003, J PHARM SCI, V92, P1343, DOI 10.1002/jps.10397
   Ahmad Z, 2014, RSC ADV, V4, P17028, DOI 10.1039/c3ra47370h
   Ao L, 2012, MOL PHARMACEUT, V9, P2197, DOI 10.1021/mp300044b
   Arastu-Kapur S, 2011, CLIN CANCER RES, V17, P2734, DOI 10.1158/1078-0432.CCR-10-1950
   Ashley JD, 2014, J CONTROL RELEASE, V196, P113, DOI 10.1016/j.jconrel.2014.10.005
   Bae Y, 2005, BIOCONJUGATE CHEM, V16, P122, DOI 10.1021/bc0498166
   Chen D, 2011, CURR CANCER DRUG TAR, V11, P239, DOI 10.2174/156800911794519752
   Demo SD, 2007, CANCER RES, V67, P6383, DOI 10.1158/0008-5472.CAN-06-4086
   Jagannath S, 2012, CL LYMPH MYELOM LEUK, V12, P310, DOI 10.1016/j.clml.2012.08.003
   Jakubowiak AJ, 2012, BLOOD, V120, P1801, DOI 10.1182/blood-2012-04-422683
   Kim KB, 2013, NAT PROD REP, V30, P600, DOI 10.1039/c3np20126k
   Knop K, 2010, ANGEW CHEM INT EDIT, V49, P6288, DOI 10.1002/anie.200902672
   Kumar SK, 2008, BLOOD, V111, P2516, DOI 10.1182/blood-2007-10-116129
   Li L, 2015, SMALL, V11, P3082
   Mani A, 2005, J CLIN ONCOL, V23, P4776, DOI 10.1200/JCO.2005.05.081
   Nishiyama N, 2006, PHARMACOL THERAPEUT, V112, P630, DOI 10.1016/j.pharmthera.2006.05.006
   Oe Y, 2014, BIOMATERIALS, V35, P7887, DOI 10.1016/j.biomaterials.2014.05.041
   Papadopoulos KP, 2013, CANCER CHEMOTH PHARM, V72, P861, DOI 10.1007/s00280-013-2267-x
   Perkin KK, 2005, NANO LETT, V5, P1457, DOI 10.1021/nl050817w
   Sanvicens N, 2008, TRENDS BIOTECHNOL, V26, P425, DOI 10.1016/j.tibtech.2008.04.005
   Shen M, 2013, EXPERT OPIN THER TAR, V17, P1091, DOI 10.1517/14728222.2013.815728
   Stewart AK, 2015, NEW ENGL J MED, V372, P142, DOI 10.1056/NEJMoa1411321
   Swami A, 2014, P NATL ACAD SCI USA, V111, P10287, DOI 10.1073/pnas.1401337111
   Tan Chalet, 2013, Pharmaceutics, V5, P201, DOI 10.3390/pharmaceutics5010201
   Tsukioka Y, 2002, JPN J CANCER RES, V93, P1145, DOI 10.1111/j.1349-7006.2002.tb01217.x
   Vakil R, 2008, MOL PHARM, V5, P98, DOI 10.1021/mp700081v
   Vij R, 2012, BLOOD, V119, P5661, DOI 10.1182/blood-2012-03-414359
   Wang ZP, 2013, DRUG METAB DISPOS, V41, P230, DOI 10.1124/dmd.112.047662
   Werner ME, 2013, INT J RADIAT ONCOL, V86, P463, DOI 10.1016/j.ijrobp.2013.02.009
   Yang JF, 2011, DRUG METAB DISPOS, V39, P1873, DOI 10.1124/dmd.111.039164
   Yang WD, 2006, CANCER LETT, V243, P217, DOI 10.1016/j.canlet.2005.11.033
   Zhang L, 2008, CLIN PHARMACOL THER, V83, P761, DOI 10.1038/sj.clpt.6100400
NR 33
TC 8
Z9 8
U1 1
U2 22
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0022-3565
EI 1521-0103
J9 J PHARMACOL EXP THER
JI J. Pharmacol. Exp. Ther.
PD NOV
PY 2015
VL 355
IS 2
BP 168
EP 173
DI 10.1124/jpet.115.226993
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CV3MT
UT WOS:000364164000005
PM 26311812
OA gold
DA 2018-03-19
ER

PT J
AU Timmons, MD
   Knutson, BL
   Nokes, SE
   Strobel, HJ
   Lynn, BC
AF Timmons, Michael D.
   Knutson, Barbara L.
   Nokes, Sue E.
   Strobel, Herbert J.
   Lynn, Bert C.
TI Analysis of composition and structure of Clostridium thermocellum
   membranes from wild-type and ethanol-adapted strains
SO APPLIED MICROBIOLOGY AND BIOTECHNOLOGY
LA English
DT Article
DE Clostridium thermocellum; Biofuels; Ethanol; Anisotropy; Fatty acid
   methyl esters (FAMEs); Picolinyl esters; Consolidated bioprocessing
ID LIPID-COMPOSITION; GROWTH TEMPERATURE; MASS-SPECTROMETRY; PICOLINYL
   ESTERS; FATTY-ACIDS; SACCHAROMYCES-CEREVISIAE; FLUORESCENCE ANISOTROPY;
   CELLULOSE FERMENTATION; KLOECKERA-APICULATA; ESCHERICHIA-COLI
AB Clostridium thermocellum is a candidate organism for consolidated bioprocessing of lignocellulosic biomass into ethanol. However, commercial use is limited due to growth inhibition at modest ethanol concentrations. Recently, an ethanol-adapted strain of C. thermocellum was produced. Since ethanol adaptation in microorganisms has been linked to modification of membrane lipids, we tested the hypothesis that ethanol adaptation in C. thermocellum involves lipid modification by comparing the fatty acid composition and membrane anisotropy of wild-type and ethanol-adapted strains. Derivatization to fatty acid methyl esters provided quantitative lipid analysis. Compared to wild-type, the ethanol-adapted strain had a larger percentage of fatty acids with chain lengths > 16:0 and showed a significant increase in the percentage of 16:0 plasmalogens. Structural identification of fatty acids was confirmed through mass spectral fragmentation patterns of picolinyl esters. Ethanol adaptation did not involve modification at sites of methyl branching or the unsaturation index. Comparison of steady-state fluorescence anisotropy experiments, in the absence and presence of ethanol, provided evidence for the effects of ethanol on membrane fluidity. In the presence of ethanol, both strains displayed increased fluidity by approximately 12%. These data support the model that ethanol adaptation was the result of fatty acid changes that increased membrane rigidity that counter-acted the fluidizing effect of ethanol.
C1 [Timmons, Michael D.; Lynn, Bert C.] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
   [Knutson, Barbara L.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Nokes, Sue E.] Univ Kentucky, Dept Biosyst & Agr Engn, Lexington, KY 40506 USA.
   [Strobel, Herbert J.] Univ Kentucky, Dept Anim & Food Sci, Lexington, KY 40506 USA.
RP Lynn, BC (reprint author), Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
EM bclynn2@uky.edu
CR ALEXANDRE H, 1994, FEMS MICROBIOL LETT, V124, P17, DOI 10.1016/0378-1097(94)90326-3
   ALEXANDRE H, 1994, BIOTECHNOL TECH, V8, P295, DOI 10.1007/BF02428970
   Aricha B, 2004, J BACTERIOL, V186, P4638, DOI 10.1128/JB.186.14.4638-4644.2004
   Berberich JA, 2000, IND ENG CHEM RES, V39, P4500, DOI 10.1021/ie0001265
   Bothun GD, 2005, LANGMUIR, V21, P530, DOI 10.1021/la0496542
   BOTHUN GD, 2001, THESIS U KENTUCKY
   BRENNA JT, 2006, STRUCTURAL ANAL UNSA, P157
   CHRISTIE WW, 2007, LIPID LIB
   Destaillats F, 2002, J AM OIL CHEM SOC, V79, P253, DOI 10.1007/s11746-002-0469-7
   Evans RI, 1998, INT J FOOD MICROBIOL, V40, P159, DOI 10.1016/S0168-1605(98)00029-4
   Hamilton JTG, 2000, CHEM PHYS LIPIDS, V105, P93, DOI 10.1016/S0009-3084(99)00133-4
   HARVEY DJ, 1982, BIOMED MASS SPECTROM, V9, P33, DOI 10.1002/bms.1200090107
   Harvey D. J., 1992, ADV LIPID METHODOLOG, V1, P19
   HERRERO AA, 1982, BIOCHIM BIOPHYS ACTA, V693, P195, DOI 10.1016/0005-2736(82)90487-4
   HERRERO AA, 1980, APPL ENVIRON MICROB, V40, P571
   INGRAM LO, 1976, J BACTERIOL, V125, P670
   INGRAM LO, 1990, CRIT REV BIOTECHNOL, V9, P305
   JOHNSTON NC, 1994, EUR J BIOCHEM, V223, P957, DOI 10.1111/j.1432-1033.1994.tb19073.x
   JOHNSTON NC, 1994, MICROBIOL-UK, V140, P105, DOI 10.1099/13500872-140-1-105
   JONES RP, 1989, ENZYME MICROB TECH, V11, P130, DOI 10.1016/0141-0229(89)90073-2
   Kikukawa T, 1997, BIOPHYS J, V73, P357, DOI 10.1016/S0006-3495(97)78076-7
   Konings WN, 2002, ANTON LEEUW INT J G, V81, P61, DOI 10.1023/A:1020573408652
   KROPINSKI AMB, 1987, J BACTERIOL, V169, P1960, DOI 10.1128/jb.169.5.1960-1966.1987
   Kurkiewicz S, 2003, J AM SOC MASS SPECTR, V14, P58, DOI 10.1016/S1044-0305(02)00817-6
   Lawrence P, 2006, ANAL CHEM, V78, P1312, DOI 10.1021/ac0516584
   LEPAGE G, 1988, J LIPID RES, V29, P227
   Lynd LR, 2002, MICROBIOL MOL BIOL R, V66, P506, DOI 10.1128/MMBR.66.3.506-577.2002
   Michaud AL, 2005, RAPID COMMUN MASS SP, V19, P363, DOI 10.1002/rcm.1797
   MICHAUD AL, 2006, ADV CONJUGATED LINOL, V3, P119
   Morein S, 1996, J BIOL CHEM, V271, P6801, DOI 10.1074/jbc.271.12.6801
   Nagan N, 2001, PROG LIPID RES, V40, P199, DOI 10.1016/S0163-7827(01)00003-0
   Rani KS, 1996, WORLD J MICROB BIOT, V12, P57, DOI 10.1007/BF00327802
   SHINITZKY M, 1978, BIOCHIM BIOPHYS ACTA, V515, P367, DOI 10.1016/0304-4157(78)90010-2
   SINENSKY M, 1974, P NATL ACAD SCI USA, V71, P522, DOI 10.1073/pnas.71.2.522
   Son CK, 2005, BBA-BIOMEMBRANES, V1717, P118, DOI 10.1016/j.bbamem.2005.09.015
   TAILLIEZ P, 1989, APPL ENVIRON MICROB, V55, P207
   TAILLIEZ P, 1989, APPL ENVIRON MICROB, V55, P203
   Tymczyszyn EE, 2005, ARCH BIOCHEM BIOPHYS, V443, P66, DOI 10.1016/j.abb.2005.09.004
   Weber FJ, 1996, BBA-REV BIOMEMBRANES, V1286, P225, DOI 10.1016/S0304-4157(96)00010-X
   Williams TI, 2007, APPL MICROBIOL BIOT, V74, P422, DOI 10.1007/s00253-006-0689-7
   YUN I, 1993, ASIA PAC J PHARMACOL, V8, P9
NR 41
TC 26
Z9 27
U1 2
U2 16
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0175-7598
EI 1432-0614
J9 APPL MICROBIOL BIOT
JI Appl. Microbiol. Biotechnol.
PD APR
PY 2009
VL 82
IS 5
BP 929
EP 939
DI 10.1007/s00253-009-1891-1
PG 11
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA 422XH
UT WOS:000264460500015
PM 19221734
DA 2018-03-20
ER

PT J
AU Howard, MD
   Lu, XL
   Rinehart, JJ
   Jay, M
   Dziubla, TD
AF Howard, Melissa D.
   Lu, Xiuling
   Rinehart, John J.
   Jay, Michael
   Dziubla, Thomas D.
TI Physicochemical Characterization of Nanotemplate Engineered Solid Lipid
   Nanoparticles
SO LANGMUIR
LA English
DT Article
ID DIFFERENTIAL SCANNING CALORIMETRY; CONTROLLED DRUG-DELIVERY; OF-THE-ART;
   IN-VITRO; TRIGLYCERIDE NANOPARTICLES; ANTIINFLAMMATORY AGENTS;
   CHEMOTHERAPY ADJUVANTS; STEARIC-ACID; SLN; RELEASE
AB As the physicochemical characteristics of solid lipid nanoparticles (SLNs) play a critical role in their success, it is important to understand how the materials and process used in their preparation affect these properties. In this study, two stearyl alcohol-based formulations were prepared using nanotemplate engineering technology and characterized. Both formulations were of a small particle size (< 100 nm), ellipsoidal shape, and low polydispersity. (1)H NMR spectroscopy confirmed that the SLNs have the expected solid core structure and PEGylated surface. Analysis of the bulk materials indicated that a number of complex interactions are present among the SLN components, including a eutectic between stearyl alcohol and Brij 78. The decreased crystallinity resulting from these interactions may allow for enhanced drug loading. Physiological stability was identified and confirmed as a potential problem due to the low melting point of the eutectic. However, it is expected that with appropriate formulation modifications nanotemplate engineered SLNs will possess the properties necessary for a successful drug delivery system.
C1 [Dziubla, Thomas D.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Howard, Melissa D.] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
   [Lu, Xiuling; Jay, Michael] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
   [Lu, Xiuling; Jay, Michael] Univ N Carolina, Eshelman Sch Pharm, Div Mol Pharmaceut, Chapel Hill, NC 27599 USA.
   [Rinehart, John J.] Univ Kentucky, Markey Canc Ctr, Div Hematol Oncol Blood & Marrow Transplantat, Lexington, KY 40536 USA.
   [Rinehart, John J.] Univ Kentucky, Expt Therapeut Program, Lexington, KY 40536 USA.
RP Dziubla, TD (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 F Paul Anderson Tower, Lexington, KY 40506 USA.
EM Dziubla@engr.uky.edu
FU NSF [DGE-0653710]
FX We thank Dr. Paul Bummer for use of the differential scanning
   calorimeter as well as helpful discussions. This work was supported by
   grant DGE-0653710 from the NSF IGERT program (M.D.H.).
CR Attama AA, 2007, EUR J PHARM BIOPHARM, V67, P48, DOI 10.1016/j.ejpb.2006.12.004
   Awad TS, 2009, CRYST GROWTH DES, V9, P3405, DOI 10.1021/cg8011684
   Blasi P, 2007, ADV DRUG DELIVER REV, V59, P454, DOI 10.1016/j.addr.2007.04.011
   Bunjes H, 1996, INT J PHARM, V129, P159, DOI 10.1016/0378-5173(95)04286-5
   Bunjes H, 2003, J PHARM SCI, V92, P1509, DOI 10.1002/jps.10413
   Bunjes H, 2007, ADV DRUG DELIVER REV, V59, P379, DOI 10.1016/j.addr.2007.04.013
   Bunjes H, 2007, LANGMUIR, V23, P4005, DOI 10.1021/la062904p
   Carlotti ME, 2009, J DISPER SCI TECHNOL, V30, P1517, DOI 10.1080/01932690903123726
   Castelli F, 2005, INT J PHARM, V304, P231, DOI 10.1016/j.ijpharm.2005.08.011
   Cavalli R, 2003, J PHARM SCI, V92, P1085, DOI 10.1002/jps.10368
   Champion JA, 2007, J CONTROL RELEASE, V121, P3, DOI 10.1016/j.jconrel.2007.03.022
   Chen HB, 2006, J CONTROL RELEASE, V110, P296, DOI 10.1016/jjconrel.2005.09.052
   Coldren B, 2003, LANGMUIR, V19, P5632, DOI 10.1021/la034311+
   Cui ZR, 2002, BIOCONJUGATE CHEM, V13, P1319, DOI 10.1021/bc0255586
   Dong X., 2009, CANCER RES, V21, P21
   Dong XW, 2009, EUR J PHARM BIOPHARM, V72, P9, DOI 10.1016/j.ejpb.2008.11.012
   Freitas C, 1999, EUR J PHARM BIOPHARM, V47, P125, DOI 10.1016/S0939-6411(98)00074-5
   FRIEDRICH, 2005, INT J PHARMACEUT, V305, P167
   Gandolfo FG, 2003, THERMOCHIM ACTA, V404, P9, DOI 10.1016/S0040-6031(03)00086-8
   Garcia-Fuentes M, 2005, J COLLOID INTERF SCI, V285, P590, DOI 10.1016/j.jcis.2004.10.012
   Garcia-Fuentes M, 2004, LANGMUIR, V20, P8839, DOI 10.1021/la049505j
   Helgason T, 2008, J AM OIL CHEM SOC, V85, P501, DOI 10.1007/s11746-008-1219-9
   Helgason T, 2009, J COLLOID INTERF SCI, V334, P75, DOI 10.1016/j.jcis.2009.03.012
   Hobbs SK, 1998, P NATL ACAD SCI USA, V95, P4607, DOI 10.1073/pnas.95.8.4607
   Howard MD, 2008, J BIOMED NANOTECHNOL, V4, P133, DOI 10.1166/jbn.2008.021
   Hsu Cheng-Hsuan, 2003, AAPS PharmSciTech, V4, pE32
   Hu FQ, 2005, COLLOID SURFACE B, V45, P167, DOI 10.1016/j.colsurfb.2005.08.005
   Jenning V, 2000, INT J PHARM, V196, P219, DOI 10.1016/S0378-5173(99)00426-3
   Jenning V, 2000, INT J PHARM, V199, P167, DOI 10.1016/S0378-5173(00)00378-1
   Jensen LB, 2010, INT J PHARMACEUT, V390, P53, DOI 10.1016/j.ijpharm.2009.10.022
   Koziara JM, 2006, J CONTROL RELEASE, V112, P312, DOI 10.1016/j.jconrel.2006.03.001
   Lu XL, 2008, AAPS J, V10, P133, DOI 10.1208/s12248-008-9013-z
   Lu XL, 2009, AAPS J, V11, P120, DOI 10.1208/s12248-009-9086-3
   Ma P, 2009, J BIOMED NANOTECHNOL, V5, P151, DOI 10.1166/jbn.2009.1021
   Mehnert W, 2001, ADV DRUG DELIVER REV, V47, P165, DOI 10.1016/S0169-409X(01)00105-3
   Muller RH, 2002, INT J PHARM, V242, P121, DOI 10.1016/S0378-5173(02)00180-1
   Muller RH, 2000, EUR J PHARM BIOPHARM, V50, P161, DOI 10.1016/S0939-6411(00)00087-4
   Mumper RJ, 2003, J DISPER SCI TECHNOL, V24, P569, DOI 10.1081/DIS-120021814
   Olbrich C, 1999, INT J PHARM, V180, P31, DOI 10.1016/S0378-5173(98)00404-9
   Oyewumi MO, 2002, DRUG DEV IND PHARM, V28, P317, DOI 10.1081/DDC-120002847
   Rasband W, 1997, IMAGEJ
   Rawat M. K., 2010, Current Drug Delivery, V7, P44
   Schubert MA, 2006, EUR J PHARM SCI, V27, P226, DOI 10.1016/j.ejps.2005.10.004
   SIEKMANN B, 1994, COLLOID SURFACE B, V3, P159
   Uner M, 2006, PHARMAZIE, V61, P375
   Uner M, 2004, PHARMAZIE, V59, P331
   Unruh T, 1999, J PHYS CHEM B, V103, P10373, DOI 10.1021/jp9912612
   Venkateswarlu V, 2004, J CONTROL RELEASE, V95, P627, DOI 10.1016/j.jconrel.2004.01.005
   Ventola L, 2002, CHEM MATER, V14, P508, DOI 10.1021/cm011010h
   Wang Dongkai, 2007, PDA J Pharm Sci Technol, V61, P110
   Westesen K, 1997, J CONTROL RELEASE, V48, P223, DOI 10.1016/S0168-3659(97)00046-1
   Westesen K, 1997, INT J PHARM, V151, P35, DOI 10.1016/S0378-5173(97)04890-4
   Williams J, 2003, J CONTROL RELEASE, V91, P167, DOI 10.1016/S0168-3659(03)00241-4
   Wong HL, 2007, ADV DRUG DELIVER REV, V59, P491, DOI 10.1016/j.addr.2007.04.008
   Zhu D, 2008, INVEST RADIOL, V43, P129, DOI 10.1097/RLI.0b013e31815878dd
   Zhu RR, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/5/055702
   zur Muhlen A, 1998, EUR J PHARM BIOPHARM, V45, P149, DOI 10.1016/S0939-6411(97)00150-1
NR 57
TC 7
Z9 7
U1 0
U2 18
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0743-7463
J9 LANGMUIR
JI Langmuir
PD MAR 1
PY 2011
VL 27
IS 5
BP 1964
EP 1971
DI 10.1021/la104262k
PG 8
WC Chemistry, Multidisciplinary; Chemistry, Physical; Materials Science,
   Multidisciplinary
SC Chemistry; Materials Science
GA 725DF
UT WOS:000287624700056
PM 21190351
DA 2018-03-20
ER

PT J
AU Leifer, J
   Black, JT
   Smith, SW
   Ma, N
   Lumpp, JK
AF Leifer, Jack
   Black, Jonathan T.
   Smith, Suzanne Weaver
   Ma, Ning
   Lumpp, Janet K.
TI Measurement of in-plane motion of thin-film structures using
   videogrammetry
SO JOURNAL OF SPACECRAFT AND ROCKETS
LA English
DT Article; Proceedings Paper
CT AIAA/AAS Astrodynamics Specialist Conference
CY AUG 21-24, 2006
CL Keystone, CO
SP AIAA, AAS
ID SPECKLE PATTERN INTERFEROMETRY; DISPLACEMENT MEASUREMENT; LASER SPECKLE;
   RECONSTRUCTION
AB An electrodynamic shaker was used to apply a 1-Hz, 1.5-mm-amplitude, in-plane harmonic excitation to a thin-film gossamer material mounted in an aluminum fixture. Using a two-camera videogrammetric setup that simultaneously imaged the test article at 75 frames per second (per camera), the x,y, and z motion components of two points on the thin film (F1 and F2) as well as of two points on the aluminum holder (R] and 112) were tracked for a total of 4 s. The in-plane motion components of each tracked point closely corresponded to the excitation provided by the shaker. The presence of modally induced in-plane film deformation was confirmed by tracking the change in distance between points F1 and F2. The standard deviation of the value of the measured distance between these two points was found to be about 57 Am. This value was well above the noise floor for this measurement, 11 Am, experimentally determined by calculating the standard deviation of the measured distance between points R1 and R2 on the aluminum film holder, which was considered to be rigid and hence was not expected to undergo in-plane deformation.
C1 [Leifer, Jack] Trinity Univ, Dept Engn Sci, San Antonio, TX 78212 USA.
   [Black, Jonathan T.; Smith, Suzanne Weaver] Univ Kentucky, Air Force Inst Technol, Lexington, KY 40506 USA.
   [Ma, Ning; Lumpp, Janet K.] Univ Kentucky, Dept Elect & Comp Engn, Lexington, KY 40506 USA.
RP Leifer, J (reprint author), Trinity Univ, Dept Engn Sci, San Antonio, TX 78212 USA.
RI Black, Jonathan/R-4875-2016
OI Black, Jonathan/0000-0001-9315-3994
CR Aebischer HA, 1999, OPT COMMUN, V162, P205, DOI 10.1016/S0030-4018(99)00116-9
   BLACK JT, 2003, TM2003212148 NASA
   Cloud G. L., 1998, OPTICAL METHODS ENG
   KAY IW, 1973, 730278 AUT ENG C SOC
   MA N, 2004, THESIS U KENTUCKY LE
   MESQUI F, 1984, J BIOMECH ENG-T ASME, V106, P357, DOI 10.1115/1.3138505
   Mikhail E. M., 2001, INTRO MODERN PHOTOGR
   MILLER NR, 1980, J BIOMECH, V13, P535, DOI 10.1016/0021-9290(80)90054-8
   PAPPA RS, 2000, TM2000210627 NASA
   POST D, 1991, EXP MECH, V31, P276, DOI 10.1007/BF02326072
   SARRAFZADEHKHOE.A, 1986, EXPT TECHNIQUES, P18
   SINGH M, 1991, IEEE T BIO-MED ENG, V38, P483, DOI 10.1109/10.81568
   Sirohi RS, 1997, APPL OPTICS, V36, P5787, DOI 10.1364/AO.36.005787
   SJODAHL M, 1995, APPL OPTICS, V34, P5799, DOI 10.1364/AO.34.005799
   Thota P, 2005, EXP MECH, V45, P18, DOI 10.1177/0014485105050006
   THOTA P, 2003, THESIS U KENTUCKY
   Tong JW, 1996, OPT ENG, V35, P1080, DOI 10.1117/1.600787
   Waldner S., 2000, TRENDS OPTICAL NONDE, P257
NR 18
TC 5
Z9 5
U1 0
U2 3
PU AMER INST AERONAUT ASTRONAUT
PI RESTON
PA 1801 ALEXANDER BELL DRIVE, STE 500, RESTON, VA 22091-4344 USA
SN 0022-4650
J9 J SPACECRAFT ROCKETS
JI J. Spacecr. Rockets
PD NOV-DEC
PY 2007
VL 44
IS 6
BP 1317
EP 1325
DI 10.2514/1.25566
PG 9
WC Engineering, Aerospace
SC Engineering
GA 241JN
UT WOS:000251652800021
DA 2018-03-20
ER

PT J
AU Wang, ZM
   Cuddigan, JL
   Gupta, SK
   Meenach, SA
AF Wang, Zimeng
   Cuddigan, Julie L.
   Gupta, Sweta K.
   Meenach, Samantha A.
TI Nanocomposite microparticles (nCmP) for the delivery of tacrolimus in
   the treatment of pulmonary arterial hypertension
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Nanocomposite microparticles; Pulmonary delivery; Pulmonary arterial
   hypertension; Spray drying; Tacrolimus
ID DRY POWDER INHALATION; AEROSOL DISPERSION PERFORMANCE; PHYSICOCHEMICAL
   CHARACTERIZATION; ACETALATED DEXTRAN; DRIED MANNITOL; MULTIFUNCTIONAL
   PARTICLES; LUNG-TRANSPLANTATION; INHALED TACROLIMUS; PLGA NANOPARTICLES;
   OPTIMIZATION
AB Tacrolimus (TAC) has exhibited promising therapeutic potential in the treatment of pulmonary arterial hypertension (PAH); however, its application is prevented by its poor solubility, instability, poor bioavailability, and negative systemic side effects. To overcome the obstacles of using TAC for the treatment of PAH, we developed nanocomposite microparticles (nCmP) for the pulmonary delivery of tacrolimus in the form of dry powder aerosols. These particles can provide targeted pulmonary delivery, improved solubility of tacrolimus, the potential of penetration through mucus barrier, and controlled drug release. In this system, tacrolimus-loaded polymeric nanoparticles (NP) were prepared via emulsion solvent evaporation and nCmP were prepared by spray drying these NP with mannitol.
   The NP were approximately 200 nm in diameter with narrow size distribution both before loading into and after redispersion from nCmP. The NP exhibited smooth, spherical morphology and the nCmP were raisin-like spheres. High encapsulation efficacy was achieved both in the encapsulation of tacrolimus in NP and that of NP in nCmP. nCmP exhibited desirable aerosol dispersion properties, allowing them to deposit into the deep lung regions for effective drug delivery. A549 cells were used as in vitro models to demonstrate the non-cytotoxicity of TAC nCmP. Overall, the designed nCmP have the potential to aid in the delivery of tacrolimus for the treatment of PAH. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Wang, Zimeng; Cuddigan, Julie L.; Gupta, Sweta K.; Meenach, Samantha A.] Univ Rhode Isl, Coll Engn, Dept Chem Engn, Kingston, RI 02881 USA.
   [Meenach, Samantha A.] Univ Rhode Isl, Coll Pharm, Dept Biomed & Pharmaceut Sci, Kingston, RI 02881 USA.
RP Meenach, SA (reprint author), Univ Rhode Isl, 205 Crawford Hall,16 Greenhouse Rd, Kingston, RI 02881 USA.
EM smeenach@uri.edu
OI Meenach, Samantha/0000-0002-3833-2110
FU Institutional Development Award (IDeA) from the National Institute of
   General Medical Sciences of the National Institutes of Health
   [P20GM103430]; National Science Foundation EPSCoR [EPS-1004057];
   National Science Foundation [1508868]
FX The authors gratefully acknowledge financial support from an
   Institutional Development Award (IDeA) from the National Institute of
   General Medical Sciences of the National Institutes of Health under
   grant number P20GM103430. The content is solely the responsibility of
   the authors and does not necessarily represent the official views of the
   National Institutes of Health. This material is based upon work
   conducted at a Rhode Island NSF EPSCoR research facility, supported in
   part by the National Science Foundation EPSCoR Cooperative Agreement
   #EPS-1004057. In addition, this material is based in part upon work
   supported by the National Science Foundation under grant number
   #1508868. Any opinions, findings, and conclusions or recommendations
   expressed in this material are those of the authors and do not
   necessarily reflect the view of the National Science Foundation.
   Finally, the authors thank RI-INBRE for UPLC access and RIN2 for SEM,
   DLS, PXRD, and DSC access.
CR Arima H, 2001, J PHARM SCI, V90, P690, DOI 10.1002/jps.1025
   Bachelder EM, 2008, J AM CHEM SOC, V130, P10494, DOI 10.1021/ja803947s
   Badiani B, 2016, HEART LUNG CIRC, V25, P46, DOI 10.1016/j.hlc.2015.05.020
   Bootz A, 2004, EUR J PHARM BIOPHARM, V57, P369, DOI 10.1016/S0939-6411(03)00193-0
   Broaders KE, 2009, P NATL ACAD SCI USA, V106, P5497, DOI 10.1073/pnas.0901592106
   Chew NYK, 2002, J AEROSOL MED, V15, P325, DOI 10.1089/089426802760292672
   Chin KM, 2008, J AM COLL CARDIOL, V51, P1527, DOI 10.1016/j.jacc.2008.01.024
   Coelho JF, 2010, EPMA J, V1, P164, DOI 10.1007/s13167-010-0001-x
   Edda S., 2012, FK506 TACROLIMUS PUL
   EDWARDS DA, 1995, J AEROSOL SCI, V26, P293, DOI 10.1016/0021-8502(94)00101-4
   Evans J. D. W., LANCET RESP MED
   Guimaraes TF, 2015, ADV POWDER TECHNOL, V26, P1094, DOI 10.1016/j.apt.2015.05.004
   Hayes D, 2010, TRANSPL P, V42, P3876, DOI 10.1016/j.transproceed.2010.08.029
   Hickey A.J., 2008, MODIFIED RELEASE DRU
   Hickey AJ, 2009, MODERN PHARM, P191
   Hickey AJ, 2007, J PHARM SCI-US, V96, P1282, DOI 10.1002/jps.20916
   Householder KT, 2015, INT J PHARMACEUT, V479, P374, DOI 10.1016/j.ijpharm.2015.01.002
   Jensen DMK, 2010, J CONTROL RELEASE, V142, P138, DOI 10.1016/j.jconrel.2009.10.010
   Kaialy W, 2015, EUR J PHARM SCI, V68, P56, DOI 10.1016/j.ejps.2014.12.005
   Kaialy W, 2012, PHARM RES-DORDR, V29, P2139, DOI 10.1007/s11095-012-0743-3
   Kauffman KJ, 2012, INT J PHARMACEUT, V422, P356, DOI 10.1016/j.ijpharm.2011.10.034
   Kramek-Romanowska K, 2011, IND ENG CHEM RES, V50, P13922, DOI 10.1021/ie2006998
   Kur F, 1999, THORAC CARDIOV SURG, V47, P174, DOI 10.1055/s-2007-1013136
   Li XJ, 2012, INT J PHARMACEUT, V433, P79, DOI 10.1016/j.ijpharm.2012.04.081
   Littringer EM, 2013, POWDER TECHNOL, V239, P162, DOI 10.1016/j.powtec.2013.01.065
   Littringer EM, 2012, EUR J PHARM BIOPHARM, V82, P194, DOI 10.1016/j.ejpb.2012.05.001
   Meenach SA, 2013, EUR J PHARM SCI, V49, P699, DOI 10.1016/j.ejps.2013.05.012
   Meenach SA, 2013, INT J NANOMED, V8, P275, DOI 10.2147/IJN.S30724
   Zhang J, 2012, ACTA PHYS-CHIM SIN, V28, P290, DOI [10.1021/mp2003785, 10.3866/PKU.WHXB201112121]
   Mohammadi G, 2010, COLLOID SURFACE B, V80, P34, DOI 10.1016/j.colsurfb.2010.05.027
   Montani D, 2014, PHARMACOL THERAPEUT, V141, P172, DOI 10.1016/j.pharmthera.2013.10.002
   Ong HX, 2014, AAPS J, V16, P269, DOI 10.1208/s12248-014-9560-4
   Park C.W., 2011, EUR PHARM REV
   Patton JS, 2007, NAT REV DRUG DISCOV, V6, P67, DOI 10.1038/nrd2153
   Roham T. Z., 2013, B64 MANAGEMENT PULMO, pA3275
   Rubin LJ, 2004, J AM COLL CARDIOL, V43, p89S, DOI 10.1016/j.jacc.2004.02.030
   Schrepfer S, 2007, AM J TRANSPLANT, V7, P1733, DOI 10.1111/j.1600-6143.2007.01858.x
   Shivshankar P, 2014, J DRUG DELIV SCI TEC, V24, P469, DOI 10.1016/S1773-2247(14)50090-1
   Soubrier F, 2013, J AM COLL CARDIOL, V62, pD13, DOI 10.1016/j.jacc.2013.10.035
   Spiekerkoetter E, 2015, AM J RESP CRIT CARE, V192, P254, DOI 10.1164/rccm.201411-2061LE
   Spiekerkoetter E, 2013, J CLIN INVEST, V123, P3600, DOI 10.1172/JCI65592
   Stegemann S, 2013, EUR J PHARM SCI, V48, P181, DOI 10.1016/j.ejps.2012.10.021
   Suarez S., 2016, RESP CARE, P652
   Trulock EP, 2006, J HEART LUNG TRANSPL, V25, P880, DOI 10.1016/j.healun.2006.06.001
   Ungaro F, 2006, EUR J PHARM SCI, V28, P423, DOI 10.1016/j.ejps.2006.05.005
   Vehring R, 2008, PHARM RES, V25, P999, DOI 10.1007/s11095-007-9475-1
   Vicari-Christensen M, 2009, PROG TRANSPLANT, V19, P277, DOI 10.7182/prtr.19.3.22u4114wn0l01140
   West J, 2014, DRUG DISCOV TODAY, V19, P1241, DOI 10.1016/j.drudis.2014.04.015
   [Anonymous], 2008, RESP DEP CALC
   Wu LN, 2014, ASIAN J PHARM SCI, V9, P336, DOI 10.1016/j.ajps.2014.07.006
   Wu X, 2013, INT J NANOMED, V8, P1269, DOI 10.2147/IJN.S40904
   Wu X, 2013, DRUG DES DEV THER, V7, P59, DOI [10.2147/DDDT.540166, 10.2147/DDDT.S40166]
   Xu W, 2014, INT J PHARMACEUT, V460, P173, DOI 10.1016/j.ijpharm.2013.10.035
   Yang XF, 2015, ASIAN J PHARM SCI, V10, P541, DOI 10.1016/j.ajps.2015.08.002
   You Y, 2007, J PHARM PHARMACOL, V59, P927, DOI 10.1211/jpp.59.7.0003
   Zhang ZL, 2014, J PHARM PHARMACOL, V66, P557, DOI 10.1111/jphp.12089
NR 56
TC 7
Z9 7
U1 1
U2 10
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
EI 1873-3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD OCT 15
PY 2016
VL 512
IS 1
BP 305
EP 313
DI 10.1016/j.ijpharm.2016.08.047
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA DY1OG
UT WOS:000384863700033
PM 27568494
OA green_accepted
DA 2018-03-20
ER

PT J
AU Orellana, BR
   Puleo, DA
AF Orellana, Bryan R.
   Puleo, David A.
TI Tailored sequential drug release from bilayered calcium sulfate
   composites
SO MATERIALS SCIENCE & ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS
LA English
DT Article
DE Calcium sulfate; Sequential drug release; Bioceramic; Simvastatin;
   Metronidazole
ID BONE-GRAFT SUBSTITUTES; IN-VITRO; PERIODONTAL-DISEASE; SIMVASTATIN;
   METRONIDAZOLE; REGENERATION; STATINS; DEFECT; CELLS; PERFORMANCE
AB The current standard for treating infected bony defects, such as those caused by periodontal disease, requires multiple time-consuming steps and often multiple procedures to fight the infection and recover lost tissue. Releasing an antibiotic followed by an osteogenic agent from a synthetic bone graft substitute could allow for a streamlined treatment, reducing the need for multiple surgeries and thereby shortening recovery time. Tailorable bilayered calcium sulfate (CS) bone graft substitutes were developed with the ability to sequentially release multiple therapeutic agents. Bilayered composite samples having a shell and core geometry were fabricated with varying amounts (1 or 10 wt.%) of metronidazole-loaded poly(lactic-co-glycolic acid) (PLGA) particles embedded in the shell and simvastatin directly loaded into either the shell, core, or both. Microcomputed tomography showed the overall layered geometry as well as the uniform distribution of PLGA within the shells. Dissolution studies demonstrated that the amount of PLGA particles (i.e., 1 vs. 10 wt.%) had a small but significant effect on the erosion rate (3% vs. 3.4%/d). Mechanical testing determined that introducing a layered geometry had a significant effect on the compressive strength, with an average reduction of 35%, but properties were comparable to those of mandibular trabecular bone. Sustained release of simvastatin directly loaded into CS demonstrated that changing the shell to core volume ratio dictates the duration of drug release from each layer. When loaded together in the shell or in separate layers, sequential release of metronidazole and simvastatin was achieved. By introducing a tunable, layered geometry capable of releasing multiple drugs, CS-based bone graft substitutes could be tailored in order to help streamline the multiple steps needed to regenerate tissue in infected defects. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Orellana, Bryan R.; Puleo, David A.] Univ Kentucky, Dept Biomed Engn, Lexington, KY 40506 USA.
RP Puleo, DA (reprint author), Univ Kentucky, Dept Biomed Engn, 522A Robot & Mfg Bldg, Lexington, KY 40506 USA.
EM puleo@uky.edu
FU National Institutes of Health [DE019645]; National Science Foundation
   [EPS-0814194]
FX This research was supported in part by the National Institutes of Health
   (DE019645) and the National Science Foundation (EPS-0814194).
CR Berglundh T, 1998, J CLIN PERIODONTOL, V25, P354, DOI 10.1111/j.1600-051X.1998.tb02455.x
   Bernimoulin J.P., 1999, J MED MICROBIOL, V26, P710
   Boyce T, 1999, ORTHOP CLIN N AM, V30, P571, DOI 10.1016/S0030-5898(05)70110-3
   Chen FM, 2010, TISSUE ENG PART B-RE, V16, P219, DOI [10.1089/ten.teb.2009.0562, 10.1089/ten.TEB.2009.0562]
   Chen XQ, 2006, J BONE JOINT SURG AM, V88A, P1510, DOI 10.2106/JBJS.E.01136
   Chiapasco M., 2009, BONE AUGMENTATION PR
   Chiapasco M, 2007, CLIN ORAL IMPLAN RES, V18, P432, DOI 10.1111/j.1600-0501.2007.01351.x
   Clavero Jaime, 2003, Clin Implant Dent Relat Res, V5, P154, DOI 10.1111/j.1708-8208.2003.tb00197.x
   Cochran DL, 2008, J PERIODONTOL, V79, P1569, DOI 10.1902/jop.2008.080233
   Dowling N. E., 1999, MECH BEHAV MAT ENG M
   Eick S, 2004, J PERIODONTOL, V75, P1327, DOI 10.1902/jop.2004.75.10.1327
   Gao CJ, 2007, J BIOMAT SCI-POLYM E, V18, P799, DOI 10.1163/156856207781367710
   Garrett IR, 2002, ARTHRITIS RES, V4, P237, DOI 10.1186/ar413
   Garrett IR, 2001, CURR PHARM DESIGN, V7, P715, DOI 10.2174/1381612013397762
   Guarnieri R, 2006, INT J PERIODONT REST, V26, P79
   Guarnieri R, 2004, J PERIODONTOL, V75, P902, DOI 10.1902/jop.2004.75.6.902
   Guelcher SA, 2011, J ORTHOP TRAUMA, V25, P477, DOI 10.1097/BOT.0b013e31821f624c
   Hak DJ, 2007, J AM ACAD ORTHOP SUR, V15, P525, DOI 10.5435/00124635-200709000-00003
   Han GH, 2010, AM J ORTHOD DENTOFAC, V138, P550, DOI 10.1016/j.ajodo.2010.07.006
   Henderson B, 2002, J MED MICROBIOL, V51, P1013, DOI 10.1099/0022-1317-51-12-1013
   Hitti RA, 2011, OPEN PATHOL J, V5, P33
   Houshmand B, 2011, J PERIODONTOL IMPLAN, V2, P12
   Jain N, 2008, DRUG DISCOV TODAY, V13, P932, DOI 10.1016/j.drudis.2008.07.010
   Jamali A, 2002, CALCIFIED TISSUE INT, V71, P172, DOI 10.1007/s00223-001-1087-x
   Jeon JH, 2007, INT J PHARM, V340, P6, DOI 10.1016/j.ijpharm.2007.03.007
   Kempen DHR, 2009, BIOMATERIALS, V30, P2816, DOI 10.1016/j.biomaterials.2009.01.031
   KENLEY RA, 1993, PHARMACEUT RES, V10, P1393, DOI 10.1023/A:1018902720816
   Kenny SM, 2003, J MATER SCI-MATER M, V14, P923, DOI 10.1023/A:1026394530192
   Lee FY, 2011, AAPS PHARMSCITECH, V12, P1110, DOI 10.1208/s12249-011-9681-3
   Lewis KN, 2006, J MATER SCI-MATER M, V17, P531, DOI 10.1007/s10856-006-8936-0
   LOESCHE WJ, 1984, J PERIODONTOL, V55, P325, DOI 10.1902/jop.1984.55.6.325
   Maeda T, 2001, BIOCHEM BIOPH RES CO, V280, P874, DOI 10.1006/bbrc.2000.4232
   McLaren AC, 2002, CLIN ORTHOP RELAT R, P54, DOI 10.1097/01.blo.0000030069.92399.9b
   Misch CE, 1999, J ORAL MAXIL SURG, V57, P700, DOI 10.1016/S0278-2391(99)90437-8
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Nguyen AH, 2012, ANTIMICROB AGENTS CH, V56, P3776, DOI 10.1128/AAC.00114-12
   Nyan M, 2007, J PHARMACOL SCI, V104, P384, DOI 10.1254/jphs.SC0070184
   Orellana B. R., 2014, J BIOMED MAT RES B
   Orellana BR, 2013, J MECH BEHAV BIOMED, V26, P43, DOI 10.1016/j.jmbbm.2013.05.021
   Park J.B., 2009, MED ORAL PATOL ORAL, V14, P485
   Reis ECC, 2011, BIOMATERIALS, V32, P9244, DOI 10.1016/j.biomaterials.2011.08.040
   ROSENBLUM SF, 1993, J APPL BIOMATER, V4, P67, DOI 10.1002/jab.770040109
   Sundararaj SC, 2013, BIOMATERIALS, V34, P8835, DOI 10.1016/j.biomaterials.2013.07.093
   Tay BKB, 1999, ORTHOP CLIN N AM, V30, P615, DOI 10.1016/S0030-5898(05)70114-0
   Thomas MV, 2011, J DENT RES, V90, P1052, DOI 10.1177/0022034510393967
   Thomas Mark V, 2005, J Long Term Eff Med Implants, V15, P599
   Thomas MV, 2009, J BIOMED MATER RES B, V88B, P597, DOI 10.1002/jbm.b.31269
   Tiwari G., 2010, INT J PHARM BIO SCI, P1
   Triplett RG, 1996, J ORAL MAXIL SURG, V54, P486, DOI 10.1016/S0278-2391(96)90126-3
   Walker CB, 1996, PERIODONTOL 2000, V10, P12, DOI 10.1111/j.1600-0757.1996.tb00066.x
   Wright TL, 1997, J PERIODONTAL RES, V32, P473, DOI 10.1111/j.1600-0765.1997.tb00560.x
   Wu Z, 2008, INT J ORAL MAX SURG, V37, P170, DOI 10.1016/j.ijom.2007.06.018
   Yin H, 2012, J BIOMED MATER RES A, V100A, P2991, DOI 10.1002/jbm.a.34228
NR 53
TC 2
Z9 2
U1 1
U2 16
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0928-4931
EI 1873-0191
J9 MAT SCI ENG C-MATER
JI Mater. Sci. Eng. C-Mater. Biol. Appl.
PD OCT 1
PY 2014
VL 43
BP 243
EP 252
DI 10.1016/j.msec.2014.06.044
PG 10
WC Materials Science, Biomaterials
SC Materials Science
GA AQ1GD
UT WOS:000342529000031
PM 25175211
OA green_accepted
DA 2018-03-20
ER

PT J
AU Zhang, XL
   Stocke, NA
   Hilt, JZ
   DeRouchey, J
AF Zhang, Xiaolu
   Stocke, Nathanael A.
   Hilt, J. Zach
   DeRouchey, Jason E.
TI Probe and nanoparticles diffusion in polymer gels
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
CT 245th National Spring Meeting of the American-Chemical-Society (ACS)
CY APR 07-11, 2013
CL New Orleans, LA
SP Amer Chem Soc
C1 [Zhang, Xiaolu; DeRouchey, Jason] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
   [Stocke, Nathanael A.; Hilt, James Z.] Univ Kentucky, Dept Chem Engn, Lexington, KY 40506 USA.
EM xiaolu.zhang@uky.edu
NR 0
TC 0
Z9 0
U1 1
U2 3
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD APR 7
PY 2013
VL 245
MA 281-POLY
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA 216SF
UT WOS:000324303604775
DA 2018-03-20
ER

PT J
AU Petriello, MC
   Newsome, BJ
   Dziubla, TD
   Hilt, JZ
   Bhattacharyya, D
   Hennig, BH
AF Petriello, Michael C.
   Newsome, Bradley J.
   Dziubla, Thomas D.
   Hilt, J. Zach
   Bhattacharyya, Dibakar
   Hennig, Bernhard
TI Modulation of persistent organic pollutant toxicity through nutritional
   intervention: Emerging opportunities in biomedicine and environmental
   remediation
SO SCIENCE OF THE TOTAL ENVIRONMENT
LA English
DT Article
DE POP toxicity; Oxidative stress; Polyphenol; Antioxidant response;
   Nutrition; Sustainable remediation
ID ENDOTHELIAL-CELL ACTIVATION; INDUCED OXIDATIVE STRESS; IN-VIVO EVIDENCE;
   POLYCHLORINATED-BIPHENYLS; CARDIOVASCULAR-DISEASE; MAGNETIC
   NANOPARTICLES; FECAL EXCRETION; GREEN TEA; FATTY-ACIDS; PCBS
AB Environmental pollution is increasing worldwide, and there is evidence that exposure to halogenated persistent organic pollutants (POPs) such as polychlorinated biphenyls can contribute to the pathology of inflammatory diseases such as atherosclerosis, diabetes, and cancer. Pollutant removal from contaminated sites and subsequent pollutant degradation are critical for reducing the long-term health risks associated with exposure. However, complete remediation of a toxicant from the environment is very difficult and cost-prohibitive. Furthermore, remediation technologies often result in the generation of secondary toxicants. Considering these circumstances, environmentally-friendly and sustainable remediation technologies and biomedical solutions to reduce vulnerability to environmental chemical insults need to be explored to reduce the overall health risks associated with exposure to environmental pollutants. We propose that positive lifestyle changes such as healthful nutrition and consumption of diets rich in fruits and vegetables or bioactive nutrients with antioxidant and/or anti-inflammatory properties will reduce the body's vulnerability to environmental stressors and thus reduce toxicant-mediated disease pathologies. Interestingly, emerging evidence now implicates the incorporation of bioactive nutrients, such as plant-derived polyphenols, in technologies focused on the capture, sensing and remediation of halogenated POPs. We propose that human nutritional intervention in concert with the use of natural polyphenol sensing and remediation platforms may provide a sensible means to develop primary and long-term prevention strategies of diseases associated with many environmental toxic insults including halogenated POPs. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Petriello, Michael C.; Newsome, Bradley J.; Dziubla, Thomas D.; Hilt, J. Zach; Bhattacharyya, Dibakar; Hennig, Bernhard] Univ Kentucky, Superfund Res Ctr, Lexington, KY 40536 USA.
   [Petriello, Michael C.; Hennig, Bernhard] Univ Kentucky, Coll Med, Grad Ctr Toxicol, Lexington, KY 40536 USA.
   [Newsome, Bradley J.] Univ Kentucky, Coll Arts & Sci, Dept Chem, Lexington, KY 40506 USA.
   [Dziubla, Thomas D.; Hilt, J. Zach; Bhattacharyya, Dibakar] Univ Kentucky, Coll Engn, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Hennig, Bernhard] Univ Kentucky, Coll Agr Food & Environm, Dept Anim & Food Sci, Lexington, KY 40546 USA.
RP Hennig, BH (reprint author), Univ Kentucky, Superfund Res Ctr, 900 S Limestone St, Lexington, KY 40536 USA.
OI Petriello, Michael/0000-0002-5583-8092
FU National Institute of Environmental Health Sciences at the National
   Institutes of Health [P42E5007380]; University of Kentucky Agricultural
   Experiment Station
FX This work was supported by the National Institute of Environmental
   Health Sciences at the National Institutes of Health [P42E5007380] and
   the University of Kentucky Agricultural Experiment Station.
CR Aozasa O, 2001, CHEMOSPHERE, V45, P195, DOI 10.1016/S0045-6535(00)00557-9
   Arguin H, 2010, BRIT J NUTR, V103, P1433, DOI 10.1017/S000711450999331X
   Avino P, 2011, ANAL BIOANAL CHEM, V400, P3561, DOI 10.1007/s00216-011-5039-7
   Awawdeh AM, 2005, BIOSENS BIOELECTRON, V20, P1595, DOI 10.1016/j.bios.2004.07.028
   Baur JA, 2006, NAT REV DRUG DISCOV, V5, P493, DOI 10.1038/nrd2060
   Biswal D, 2011, POLYMER, V52, P5985, DOI 10.1016/j.polymer.2011.10.058
   Carpenter D, 2011, EPIDEMIOLOGY, V22, pS147, DOI 10.1097/01.ede.0000392123.34740.fc
   Castro-Jimenez J, 2011, J ENVIRON MONITOR, V13, P894, DOI 10.1039/c0em00569j
   Choi YJ, 2010, ENVIRON INT, V36, P931, DOI 10.1016/j.envint.2009.06.009
   Ciftci O, 2012, ANDROLOGIA, V44, P164, DOI 10.1111/j.1439-0272.2010.01126.x
   Cochran DB, 2013, BIOMATERIALS, V34, P9615, DOI 10.1016/j.biomaterials.2013.08.025
   Crinnion WJ, 2011, ALTERN MED REV, V16, P5
   De Vos S, 2005, CHEMOSPHERE, V61, P374, DOI 10.1016/j.chemosphere.2005.02.086
   ESKE K, 2013, ENV SCI POLLUT RES I
   Frimpong RA, 2010, NANOMEDICINE-UK, V5, P1401, DOI 10.2217/NNM.10.114
   Frimpong RA, 2010, J MAGN MAGN MATER, V322, P326, DOI 10.1016/j.jmmm.2009.09.050
   Gao JH, 2009, ACCOUNTS CHEM RES, V42, P1097, DOI 10.1021/ar9000026
   Geusau A, 1999, LANCET, V354, P1266, DOI 10.1016/S0140-6736(99)04271-3
   Geusau A, 2002, ARCH TOXICOL, V76, P316, DOI 10.1007/s00204-002-0345-7
   Gomes HI, 2013, SCI TOTAL ENVIRON, V445, P237, DOI 10.1016/j.scitotenv.2012.11.098
   Goncharov A, 2008, ENVIRON RES, V106, P226, DOI 10.1016/j.envres.2007.10.006
   Ham SY, 2008, CHEMOSPHERE, V70, P1685, DOI 10.1016/j.cheniosphere.2007.07.050
   Harris DL, 2009, INTERDISC STUD ENV C, V2, P227
   Haupt K, 2000, CHEM REV, V100, P2495, DOI 10.1021/cr990099w
   Hennig B, 2002, TOXICOL APPL PHARM, V181, P174, DOI 10.1006/taap.2002.9408
   Hennig B, 2012, ENVIRON HEALTH PERSP, V120, P771, DOI 10.1289/ehp.1104712
   Higgins LG, 2011, DRUG METAB REV, V43, P92, DOI 10.3109/03602532.2011.567391
   Hilt JZ, 2006, CHEM MATER, V18, P5869, DOI 10.1021/cm061343k
   Hilt JZ, 2004, ADV DRUG DELIVER REV, V56, P1599, DOI 10.1016/j.addr.2004.04.002
   Hilt JZ, 2004, ADV DRUG DELIVER REV, V56, P1533, DOI 10.1016/j.addr.2004.07.002
   Houston MC, 2011, J CLIN HYPERTENS, V13, P621, DOI 10.1111/j.1751-7176.2011.00489.x
   HUTZINGER O, 1985, ENVIRON HEALTH PERSP, V60, P3, DOI 10.2307/3429939
   Jandacek RJ, 2010, ENVIRON INT, V36, P880, DOI 10.1016/j.envint.2009.06.010
   Johnson BJ, 2010, SENSORS-BASEL, V10, P2315, DOI 10.3390/s100302315
   Jomova K, 2011, TOXICOLOGY, V283, P65, DOI 10.1016/j.tox.2011.03.001
   Kang HJ, 2012, TOXICOL LETT, V209, P154, DOI 10.1016/j.toxlet.2011.12.002
   Kim J, 2012, J NUTR BIOCHEM, V23, P1007, DOI 10.1016/j.jnutbio.2011.05.007
   Kim MJ, 2011, ENVIRON HEALTH PERSP, V119, P377, DOI 10.1289/ehp.1002848
   Koo SI, 2007, J NUTR BIOCHEM, V18, P179, DOI 10.1016/j.jnutbio.2006.12.005
   Libby P, 2012, ARTERIOSCL THROM VAS, V32, P2045, DOI 10.1161/ATVBAHA.108.179705
   Lim EJ, 2007, AM J PHYSIOL-HEART C, V293, pH3340, DOI 10.1152/ajpheart.00921.2007
   Mahmoudi M, 2012, CHEM REV, V112, P2323, DOI 10.1021/cr2002596
   Majkova Z, 2011, TOXICOL APPL PHARM, V251, P41, DOI 10.1016/j.taap.2010.11.013
   Majkova Z, 2009, TOXICOL APPL PHARM, V237, P1, DOI 10.1016/j.taap.2009.02.016
   Meenach SA, 2010, J POLYM SCI POL CHEM, V48, P3229, DOI 10.1002/pola.24087
   Morita Kunimasa, 1997, Fukuoka Acta Medica, V88, P162
   Mornet S, 2004, J MATER CHEM, V14, P2161, DOI 10.1039/b402025a
   Moser GA, 1999, CHEMOSPHERE, V39, P1513, DOI 10.1016/S0045-6535(99)00219-2
   Nadtochiy SM, 2011, NUTRITION, V27, P733, DOI 10.1016/j.nut.2010.12.006
   *NCI, 2013, TABL 2 FOOD SOURC TO
   NEWSOME B, 2013, 2013 M PAC BAS CONS
   NEWSOME B, 2014, BIOMIMETIC NANOCOMPO
   Newsome BJ, 2014, J NUTR BIOCHEM, V25, P126, DOI 10.1016/j.jnutbio.2013.10.003
   [NRC] National Research Council, 2001, RISK MAN STRAT PCB C
   Oshita K, 2010, CHEMOSPHERE, V78, P1148, DOI 10.1016/j.chemosphere.2009.12.017
   Pellequer JL, 2005, J MOL RECOGNIT, V18, P282, DOI 10.1002/jmr.740
   PETRIELLO MC, 2013, ENVIRON SCI POLLUT R
   Qu XL, 2013, WATER RES, V47, P3931, DOI 10.1016/j.watres.2012.09.058
   Ramadass P, 2003, TOXICOL SCI, V76, P212, DOI 10.1093/toxsci/kfg227
   Redgrave TG, 2005, J NUTR BIOCHEM, V16, P383, DOI 10.1016/j.jnutbio.2004.12.014
   Schlezinger JJ, 2006, AQUAT TOXICOL, V77, P422, DOI 10.1016/j.aquatox.2006.01.012
   Schulze P Christian, 2005, Curr Atheroscler Rep, V7, P242, DOI 10.1007/s11883-005-0013-5
   Sciullo EM, 2010, ARCH TOXICOL, V84, P957, DOI 10.1007/s00204-010-0592-y
   Sera N, 2005, J NUTR BIOCHEM, V16, P50, DOI 10.1016/j.jnutbio.2004.09.005
   Silverstone AE, 2012, ENVIRON HEALTH PERSP, V120, P727, DOI 10.1289/ehp.1104247
   Slim R, 1999, TOXICOL SCI, V52, P232, DOI 10.1093/toxsci/52.2.232
   Tang SCN, 2013, WATER RES, V47, P2613, DOI 10.1016/j.watres.2013.02.039
   Uemura Hirokazu, 2012, Nihon Eiseigaku Zasshi, V67, P363
   Wang L, 2008, METABOLISM, V57, P1328, DOI 10.1016/j.metabol.2008.01.036
   Watkins BA, 2007, J NUTR BIOCHEM, V18, P196, DOI 10.1016/j.jnutbio.2006.12.002
   WATTAMWAR P, 2010, FREE RADIC BIOL MED, V49, P5184
   Wattamwar PP, 2012, ACTA BIOMATER, V8, P2529, DOI 10.1016/j.actbio.2012.03.022
   Wattamwar PP, 2010, ADV FUNCT MATER, V20, P147, DOI 10.1002/adfm.200900839
   Wu JM, 2001, INT J MOL MED, V8, P3
   Yaktine AL, 2006, NUTR REV, V64, P403, DOI 10.1301/nr.2006.sept.403-409
   Zakkar M, 2009, ARTERIOSCL THROM VAS, V29, P1851, DOI 10.1161/ATVBAHA.109.193375
   Zhao X, 2011, CHEM ENG J, V170, P381, DOI 10.1016/j.cej.2011.02.071
   Zheng YY, 2012, J NUTR BIOCHEM, V23, P163, DOI 10.1016/j.jnutbio.2010.12.002
   Zhu JH, 2013, ADV POWDER TECHNOL, V24, P459, DOI 10.1016/j.apt.2012.10.012
NR 79
TC 11
Z9 11
U1 1
U2 48
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0048-9697
EI 1879-1026
J9 SCI TOTAL ENVIRON
JI Sci. Total Environ.
PD SEP 1
PY 2014
VL 491
SI SI
BP 11
EP 16
DI 10.1016/j.scitotenv.2014.01.109
PG 6
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA AM0KO
UT WOS:000339534700003
PM 24530186
OA green_accepted
DA 2018-03-19
ER

PT J
AU Satarkar, NS
   Biswal, D
   Hilt, JZ
AF Satarkar, Nitin S.
   Biswal, Dipti
   Hilt, J. Zach
TI Hydrogel nanocomposites: a review of applications as remote controlled
   biomaterials
SO SOFT MATTER
LA English
DT Review
ID PULSATILE DRUG-RELEASE; MAGNETIC-FIELD; N-ISOPROPYLACRYLAMIDE; METAL
   NANOPARTICLES; GOLD NANOPARTICLES; IRON-OXIDE; POLYMER;
   POLY(N-ISOPROPYLACRYLAMIDE); DESTRUCTION; IRRADIATION
AB In the past few years, there has been increased interest in the development and applications of hydrogel nanocomposites, specifically as a new class of biomaterials. In some cases, the nanoparticles (e.g., gold, magnetic, carbon nanotubes) can absorb specific stimuli (e. g., alternating magnetic fields, near-IR light) and generate heat. This unique ability to remotely heat the nanocomposites allows for their remote controlled (RC) applications, including the ability to remotely drive the polymer through a transition event (e. g., swelling transition, glass transition). This review highlights some of the recent studies in the development of the RC hydrogel nanocomposites. In particular, some of the important applications of RC nanocomposites as RC drug delivery devices, as RC actuators, and in cancer treatment are discussed.
C1 [Satarkar, Nitin S.; Biswal, Dipti; Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Satarkar, NS (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
CR Babincova M, 2007, OPTOELECTRON ADV MAT, V1, P644
   Bikram M, 2007, J CONTROL RELEASE, V123, P219, DOI 10.1016/j.jconrel.2007.08.013
   Biswal D, 2008, BIOMED MICRODEVICES, V10, P213, DOI 10.1007/s10544-007-9127-6
   Brazel CS, 2009, PHARM RES-DORD, V26, P644, DOI 10.1007/s11095-008-9773-2
   Budhlall BM, 2008, LANGMUIR, V24, P11959, DOI 10.1021/la8019556
   Chen GF, 2008, LAB CHIP, V8, P1198, DOI 10.1039/b803293a
   Chen J, 2005, MACROMOL SYMP, V225, P71, DOI 10.1002/masy.200550706
   CHIRRA HD, 2009, NANOPARTICULATE DRUG, V2, P90
   Das M, 2007, LANGMUIR, V23, P196, DOI 10.1021/la061596s
   Dong L, 2007, SOFT MATTER, V3, P1223, DOI 10.1039/b706563a
   Dresco PA, 1999, LANGMUIR, V15, P1945, DOI 10.1021/la980971g
   Frimpong RA, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/17/175101
   Frimpong RA, 2007, J BIOMED MATER RES A, V80A, P1, DOI 10.1002/jbm.a.30962
   Fuhrer R, 2009, SMALL, V5, P383, DOI 10.1002/smll.200801091
   Gannon CJ, 2007, CANCER-AM CANCER SOC, V110, P2654, DOI 10.1002/cncr.23155
   Ghosh S, 2009, J PHYS D APPL PHYS, V42, DOI 10.1088/0022-3727/42/13/135501
   Gong PJ, 2006, J APPL POLYM SCI, V101, P1283, DOI 10.1002/app.23250
   Govorov AO, 2007, NANO TODAY, V2, P30, DOI 10.1016/S1748-0132(07)70017-8
   Hawkins AM, 2009, PHARM RES-DORD, V26, P667, DOI 10.1007/s11095-008-9804-z
   Hoare T, 2009, NANO LETT, V9, P3651, DOI 10.1021/nl9018935
   HSIEH DST, 1981, P NATL ACAD SCI-BIOL, V78, P1863, DOI 10.1073/pnas.78.3.1863
   Hu SH, 2007, MACROMOLECULES, V40, P6786, DOI 10.1021/ma0707584
   Jiang XW, 2007, J POLYM SCI POL CHEM, V45, P2812, DOI 10.1002/pola.22037
   Kam NWS, 2005, P NATL ACAD SCI USA, V102, P11600, DOI 10.1073/pnas.0502680102
   KAMULEGEYA A, 2006, J DRUG TARGET, V14, P243
   Kato N, 1997, J INTEL MAT SYST STR, V8, P588, DOI 10.1177/1045389X9700800703
   Kawano T, 2009, BIOCONJUGATE CHEM, V20, P209, DOI 10.1021/bc800480k
   Kim JH, 2004, CHEM MATER, V16, P3647, DOI 10.1021/cm049764u
   Liu TY, 2008, J CONTROL RELEASE, V126, P228, DOI 10.1016/j.jconrel.2007.12.006
   Liu TY, 2006, LANGMUIR, V22, P5974, DOI 10.1021/la060371e
   Mart RJ, 2009, CHEM COMMUN, P2287, DOI 10.1039/b901472a
   Meenach SA, 2010, ACTA BIOMATER, V6, P1039, DOI 10.1016/j.actbio.2009.10.017
   Meenach SA, 2009, J BIOMED MATER RES A, V91A, P903, DOI 10.1002/jbm.a.32322
   Miyako E, 2008, SMALL, V4, P1711, DOI 10.1002/smll.200800601
   Muller-Schulte D, 2006, J MAGN MAGN MATER, V302, P267, DOI 10.1016/j.jmmm.2005.05.043
   Paoli V.M., 2006, LANGMUIR, V22, P5894
   Park S, 2009, REACT FUNCT POLYM, V69, P293, DOI 10.1016/j.reactfunctpolym.2009.02.001
   Pyun J, 2007, POLYM REV, V47, P231, DOI 10.1080/15583720701271294
   Satarkar NS, 2008, J CONTROL RELEASE, V130, P246, DOI 10.1016/j.jconrel.2008.06.008
   Satarkar NS, 2008, ACTA BIOMATER, V4, P11, DOI 10.1016/j.actbio.2007.07.009
   Satarkar NS, 2009, LAB CHIP, V9, P1773, DOI 10.1039/b822694f
   SCHILD HG, 1992, PROG POLYM SCI, V17, P163, DOI 10.1016/0079-6700(92)90023-R
   Schmidt AM, 2007, COLLOID POLYM SCI, V285, P953, DOI [10.1007/s00396-007-1667-z, 10.1007/S00396-007-1667-z]
   Sershen SR, 2000, J BIOMED MATER RES, V51, P293, DOI 10.1002/1097-4636(20000905)51:3<293::AID-JBM1>3.0.CO;2-T
   Sershen SR, 2005, ADV MATER, V17, P1366, DOI 10.1002/adma.200401239
   Shiotani A, 2007, LANGMUIR, V23, P4012, DOI 10.1021/la0627967
   Sun HW, 2008, BIOMED MICRODEVICES, V10, P281, DOI 10.1007/s10544-007-9134-7
   Wang XM, 2005, J MAGN MAGN MATER, V293, P334, DOI 10.1016/j.jmmm.2005.02.028
   Xu ZZ, 2004, J MAGN MAGN MATER, V277, P136, DOI 10.1016/j.jmmm.2003.10.018
   Yakacki CM, 2009, J APPL POLYM SCI, V112, P3166, DOI 10.1002/app.29845
   Yang LQ, 2008, ADV MATER, V20, P2271, DOI 10.1002/adma.200702953
   Zeng XF, 2008, APPL PHYS LETT, V93, DOI 10.1063/1.2996271
   Zrinyi M, 2000, COLLOID POLYM SCI, V278, P98, DOI 10.1007/s003960050017
NR 53
TC 152
Z9 159
U1 16
U2 218
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1744-683X
EI 1744-6848
J9 SOFT MATTER
JI Soft Matter
PY 2010
VL 6
IS 11
BP 2364
EP 2371
DI 10.1039/b925218p
PG 8
WC Chemistry, Physical; Materials Science, Multidisciplinary; Physics,
   Multidisciplinary; Polymer Science
SC Chemistry; Materials Science; Physics; Polymer Science
GA 601GM
UT WOS:000278046300003
DA 2018-03-20
ER

PT J
AU Colburn, AS
   Meeks, N
   Weinman, ST
   Bhattacharyya, D
AF Colburn, Andrew S.
   Meeks, Noah D.
   Weinman, Steven T.
   Bhattacharyya, Dibakar
TI High Total Dissolved Solids Water Treatment by Charged Nanofiltration
   Membranes Relating to Power Plant Applications
SO INDUSTRIAL & ENGINEERING CHEMISTRY RESEARCH
LA English
DT Article
ID HOLLOW-FIBER MEMBRANES; DIELECTRIC EXCLUSION; OPERATING-CONDITIONS;
   SALT-SOLUTIONS; NF MEMBRANES; REJECTION; SEPARATION; IONS; DESALINATION;
   MECHANISMS
AB Selective desalination through nanofiltration (NF) is of great interest for many industrial applications including reuse of power plant scrubber wastewater and treatment of water containing high concentrations of TDS (total dissolved solids). This work seeks to understand the effect ion interactions at the membrane interface have on rejection and flux performance of charged NF membranes. NF membranes were also effective for low energy desalination of scrubber wastewater from Georgia Power Plant Bowen, composed primarily of Ca2+, Mg-2, Cl-, and SO42-. As NF membranes have the capability for selective separations, 80% water recovery was achieved experimentally while maintaining an overall rejection of over 60% for Ca2+ and Cl-. The occurrence of CaSO4 precipitation at high water recovery was observed. The effect of precipitation on osmotic pressure and the effect of Cl- counterions on increasing gypsum solubility were explored for water recovery operation. This work expands on a previous work on the topics of desalination of multi-ionic solutions by incorporating the use of large scale membrane modules (0.59 m(2)) with several synthetic solutions as well as actual scrubber water containing precipitating elements, Ca2+ and SO42-. It was observed that the spiral wound membrane modules maintained a stable water permeability over the 144 day course of tests.
C1 [Colburn, Andrew S.; Weinman, Steven T.; Bhattacharyya, Dibakar] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Meeks, Noah] Southern Co Serv Inc, Birmingham, AL 35203 USA.
RP Bhattacharyya, D (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM db@uky.edu
OI Weinman, Steven/0000-0001-9911-0119
FU Southern Company; National Science Foundation EPSCoR; National Institute
   of Environmental Health Sciences [P42ES007380]
FX The author acknowledges the support of the Southern Company in funding
   and collaboration, and additional funding from the National Science
   Foundation EPSCoR for funding, and from the National Institute of
   Environmental Health Sciences (P42ES007380). Nanostone Membrane of
   Oceanside, CA, provided support and collaboration in the development of
   membranes and spiral wound membrane modules.
CR Alzahrani S., 2014, J WATER PROCESS ENG, V4, P107, DOI DOI 10.1016/J.JWPE.2014.09.007
   Aydiner C, 2014, J MEMBRANE SCI, V458, P66, DOI 10.1016/j.memsci.2014.01.058
   Azimi G, 2007, FLUID PHASE EQUILIBR, V260, P300, DOI 10.1016/j.fluid.2007.07.069
   Boussu K, 2006, J MEMBRANE SCI, V278, P418, DOI 10.1016/j.memsci.2005.11.027
   Cakmakci M, 2008, DESALINATION, V222, P176, DOI 10.1016/j.desal.2007.01.147
   Cheng SY, 2012, WATER RES, V46, P33, DOI 10.1016/j.watres.2011.10.011
   Coday BD, 2015, J MEMBRANE SCI, V478, P58, DOI 10.1016/j.memsci.2014.12.047
   Deon S, 2013, WATER RES, V47, P2260, DOI 10.1016/j.watres.2013.01.044
   Ernst M, 2000, J MEMBRANE SCI, V165, P251, DOI 10.1016/S0376-7388(99)00238-0
   Fang WX, 2014, J MEMBRANE SCI, V468, P52, DOI 10.1016/j.memsci.2014.05.047
   Fang WX, 2013, J MEMBRANE SCI, V430, P129, DOI 10.1016/j.memsci.2012.12.011
   Freger V, 2004, ENVIRON SCI TECHNOL, V38, P3168, DOI 10.1021/es034815u
   Garcia-Aleman J, 2004, J MEMBRANE SCI, V239, P163, DOI 10.1016/j.memsci.2004.02.036
   Gur-Reznik S, 2011, DESALINATION, V277, P250, DOI 10.1016/j.desal.2011.04.029
   Hagmeyer G, 1999, SEP PURIF TECHNOL, V15, P19, DOI 10.1016/S1383-5866(98)00050-1
   Hagmeyer G, 1998, DESALINATION, V117, P247, DOI 10.1016/S0011-9164(98)00109-X
   Haynes WM., 2014, CRC HDB CHEM PHYS
   KESTIN J, 1978, J PHYS CHEM REF DATA, V7, P941, DOI 10.1063/1.555581
   Le Gouellec YA, 2002, J MEMBRANE SCI, V205, P279, DOI 10.1016/S0376-7388(02)00128-X
   McCool BC, 2013, DESALINATION, V317, P116, DOI 10.1016/j.desal.2013.01.010
   Mi BX, 2010, ENVIRON SCI TECHNOL, V44, P2022, DOI 10.1021/es903623r
   Mondal S, 2008, J MEMBRANE SCI, V322, P162, DOI 10.1016/j.memsci.2008.05.039
   Morao AIC, 2008, J MEMBRANE SCI, V322, P320, DOI 10.1016/j.memsci.2008.06.003
   NIGHTINGALE ER, 1959, J PHYS CHEM-US, V63, P1381, DOI 10.1021/j150579a011
   Perez-Gonzalez A, 2015, J MEMBRANE SCI, V473, P16, DOI 10.1016/j.memsci.2014.08.045
   Salgin S., 2013, INT J ELECTROCHEM SC, V2013, P4073
   Setiawan L, 2014, POLYMER, V55, P1367, DOI 10.1016/j.polymer.2013.12.032
   Sharma RR, 2008, J COLLOID INTERF SCI, V328, P353, DOI 10.1016/j.jcis.2008.09.036
   SIMONS R, 1993, DESALINATION, V89, P325, DOI 10.1016/0011-9164(93)80145-D
   Tanninen J, 2004, J MEMBRANE SCI, V240, P11, DOI 10.1016/j.memsci.2004.04.006
   Van der Bruggen B, 2004, WATER RES, V38, P1347, DOI 10.1016/j.watres.2003.11.008
   Yaroshchuk AE, 2000, ADV COLLOID INTERFAC, V85, P193, DOI 10.1016/S0001-8686(99)00021-4
   Yaroshchuk AE, 2001, SEP PURIF TECHNOL, V22-3, P143, DOI 10.1016/S1383-5866(00)00159-3
NR 33
TC 3
Z9 3
U1 3
U2 30
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0888-5885
J9 IND ENG CHEM RES
JI Ind. Eng. Chem. Res.
PD APR 13
PY 2016
VL 55
IS 14
BP 4089
EP 4097
DI 10.1021/acs.iecr.6b00098
PG 9
WC Engineering, Chemical
SC Engineering
GA DJ5TY
UT WOS:000374274200022
DA 2018-03-19
ER

PT J
AU Tang, WW
   Mo, HP
   Zhang, MT
   Parkin, S
   Gong, JB
   Wang, JK
   Li, TL
AF Tang, Weiwei
   Mo, Huaping
   Zhang, Mingtao
   Parkin, Sean
   Gong, Junbo
   Wang, Jingkang
   Li, Tonglei
TI Persistent Self-Association of Solute Molecules in Solution
SO JOURNAL OF PHYSICAL CHEMISTRY B
LA English
DT Article
ID TOLFENAMIC ACID; CRYSTAL NUCLEATION; CARBOXYLIC-ACIDS; PERSPECTIVE;
   CRYSTALLIZATION; SPECTROSCOPY; POLYMORPHISM; GROWTH
AB The structural evolvement of a solute determines the crystallization outcome. The self-association mechanism leading to nucleation, however, remains poorly understood. Our current study explored the solution chemistry of a model compound, tolfenamic acid (TFA), in three different solvents mainly by solution NMR It was found that hydrogen-bonded pairs of solute-solute or solute-solvent stack with each through forming a much weaker pi-pi interaction as the concentration increases. Depending on the solvent, configurations of the solution species may be retained in the resultant crystal structure or undergo rearrangement. Yet, the pi-pi stacking is always retained in the crystal regardless of the solvent used for the crystallization. The finding suggests that nucleation not only involves the primary intermolecular interaction (hydrogen bonding) but also engages the secondary forces in the self-assembly process.
C1 [Tang, Weiwei; Gong, Junbo; Wang, Jingkang] Tianjin Univ, Sch Chem Engn & Technol, State Key Lab Chem Engn, Coinnovat Ctr Chem & Chem Engn Tianjin, Tianjin 300072, Peoples R China.
   [Zhang, Mingtao; Li, Tonglei] Purdue Univ, Coll Pharm, Dept Ind & Phys Pharm, W Lafayette, IN 47907 USA.
   [Mo, Huaping] Purdue Univ, Coll Pharm, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA.
   [Parkin, Sean] Univ Kentucky, Dept Chem, Xray Facil, Lexington, KY 40506 USA.
RP Gong, JB (reprint author), Tianjin Univ, Sch Chem Engn & Technol, State Key Lab Chem Engn, Coinnovat Ctr Chem & Chem Engn Tianjin, Tianjin 300072, Peoples R China.; Li, TL (reprint author), Purdue Univ, Coll Pharm, Dept Ind & Phys Pharm, W Lafayette, IN 47907 USA.
EM junbo_gong@tju.edu.cn; tonglei@purdue.edu
RI Tang, Weiwei/U-4080-2017
OI Tang, Weiwei/0000-0002-7998-4350
FU China Scholarship Council (CSC); National Natural Science Foundation of
   China (NSFC) [21676179, 91634117]; Chao Endowment at Purdue University
FX W.T. acknowledges funding support from the China Scholarship Council
   (CSC) and the National Natural Science Foundation of China (NSFC; Nos.
   21676179 and 91634117). The work was also supported by Chao Endowment at
   Purdue University.
CR ANDERSEN KV, 1989, J CHEM SOC PERK T 2, P1443, DOI 10.1039/p29890001443
   Chattopadhyay S, 2005, CRYST GROWTH DES, V5, P523, DOI 10.1021/cg0497344
   Davey RJ, 2006, CRYST GROWTH DES, V6, P1788, DOI 10.1021/cg060058a
   Davey RJ, 2013, ANGEW CHEM INT EDIT, V52, P2166, DOI 10.1002/anie.201204824
   Dovesi R., 2014, CRYSTAL14 USERS MANU
   Dovesi R, 2014, INT J QUANTUM CHEM, V114, P1287, DOI 10.1002/qua.24658
   Du W, 2015, CHEM SCI, V6, P3515, DOI 10.1039/c5sc00522a
   Frisch M. J., 2009, GAUSSIAN 09
   Gibson JM, 2006, J AM CHEM SOC, V128, P5364, DOI 10.1021/ja056731m
   Gidalevitz D, 1997, ANGEW CHEM INT EDIT, V36, P955, DOI 10.1002/anie.199709551
   HAGEN R, 1969, J AM CHEM SOC, V91, P4504, DOI 10.1021/ja01044a032
   Holmes DL, 1996, TETRAHEDRON, V52, P5319, DOI 10.1016/0040-4020(96)00153-6
   Huang J, 2008, J AM CHEM SOC, V130, P13973, DOI 10.1021/ja804836d
   Kellermeier M, 2012, FARADAY DISCUSS, V159, P23, DOI 10.1039/c2fd20060k
   Khamar D, 2014, J AM CHEM SOC, V136, P11664, DOI 10.1021/ja503131w
   Lohani S, 2011, CRYST GROWTH DES, V11, P2368, DOI 10.1021/cg200138b
   Lopez-Mejias V, 2009, J AM CHEM SOC, V131, P4554, DOI 10.1021/ja806289a
   Mattei A, 2013, CRYST GROWTH DES, V13, P3303, DOI 10.1021/cg401026j
   Mattei A, 2012, PHARM RES-DORDR, V29, P460, DOI 10.1007/s11095-011-0574-7
   Mattei A, 2011, INT J PHARMACEUT, V418, P179, DOI 10.1016/j.ijpharm.2011.04.062
   PERDEW JP, 1992, PHYS REV B, V46, P6671, DOI 10.1103/PhysRevB.46.6671
   Pratt LM, 2007, J ORG CHEM, V72, P2962, DOI 10.1021/jo062557
   Sharma A, 2007, MOL PHYS, V105, P117, DOI 10.1080/00268970601146856
   Vogeli B, 2014, PROG NUCL MAG RES SP, V78, P1, DOI 10.1016/j.pnmrs.2013.11.001
NR 24
TC 1
Z9 1
U1 26
U2 26
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1520-6106
J9 J PHYS CHEM B
JI J. Phys. Chem. B
PD NOV 2
PY 2017
VL 121
IS 43
BP 10118
EP 10124
DI 10.1021/acs.jpcb.7b07763
PG 7
WC Chemistry, Physical
SC Chemistry
GA FM0BA
UT WOS:000414622600015
PM 29017013
DA 2018-03-20
ER

PT J
AU Yewle, JN
   Puleo, DA
   Bachas, LG
AF Yewle, Jivan N.
   Puleo, David A.
   Bachas, Leonidas G.
TI Bifunctional bisphosphonates for delivering PTH (1-34) to bone mineral
   with enhanced bioactivity
SO BIOMATERIALS
LA English
DT Article
DE Bone regeneration; Bisphosphonate; Bioactivity; Parathyroid hormone;
   Protein delivery
ID DRUG-DELIVERY; THERAPEUTIC NANOPARTICLES; PARATHYROID-HORMONE; PROTEINS;
   AFFINITY; CONJUGATION; OSTEOPOROSIS; AGENTS; PHARMACOKINETICS;
   DERIVATIVES
AB The objective of this work was to demonstrate the bioactivity of parathyroid hormone (1-34) (PTH) delivered through a single molecule of bisphosphonate to improve tissue/cell interactions. Bifunctional hydrazine-bisphosphonates (HBPs) with varying length and lipophilicity were used as a drug delivery vehicle. PTH was oxidized with periodate treatment to obtain an N-terminal aldehyde that was then conjugated to HBPs. The toxicity and apoptotic properties of HBPs and HBP-PTH conjugates were studied with macrophages (RAW 264.7). It was found that one of the HBPs had significant apoptotic characteristics similar to alendronate, which is a widely prescribed drug in the treatment of osteoporosis. The improved binding affinity of PTH following conjugation to HBP was determined using a hydroxyapatite binding assay. The amount of PTH delivered to bone through HBPs was not affected by the length or lipophilicity of the HBPs. Furthermore, the improved bioactivity of PTH delivered to bone through HBPs, in comparison to adsorbed PTH, was demonstrated by quantifying the CAMP produced by pre-osteoblastic (MOT3-E1) cells in response to PTH. The delivery of bioactive PTH to bone tissue by HBP conjugation demonstrates the potential use of HBPs in delivering therapeutic macromolecules to bone for the treatment of several skeletal diseases. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Yewle, Jivan N.] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
   [Puleo, David A.] Univ Kentucky, Ctr Biomed Engn, Lexington, KY 40506 USA.
   [Bachas, Leonidas G.] Univ Miami, Dept Chem, Coral Gables, FL 33146 USA.
RP Bachas, LG (reprint author), Univ Miami, Dept Chem, 1301 Mem Dr, Coral Gables, FL 33146 USA.
EM Bachas@miami.edu
RI Bachas, Leonidas/G-2479-2015
OI Bachas, Leonidas/0000-0002-3308-6264
FU US Army Medical Research and Materiel Command [W81XWH-09-1-0461];
   Kentucky NASA EPSCoR [NNX08BA13A]; University of Kentucky for a Research
   Challenge Trust Fund
FX This research was supported in part by the US Army Medical Research and
   Materiel Command (W81XWH-09-1-0461) and Kentucky NASA EPSCoR
   (NNX08BA13A). J.Y. thanks the University of Kentucky for a Research
   Challenge Trust Fund for fellowship support.
CR Bansal G, 2005, J BIOMED MATER RES A, V74A, P618, DOI 10.1002/jbm.a.30334
   Blower P, 2006, DALTON T, P1705, DOI 10.1039/b516860k
   Chebbi I, 2010, INT J PHARMACEUT, V383, P116, DOI 10.1016/j.ijpharm.2009.09.011
   Cho KJ, 2008, CLIN CANCER RES, V14, P1310, DOI 10.1158/1078-0432.CCR-07-1441
   Coleman RE, 2011, BONE, V49, P71, DOI 10.1016/j.bone.2011.02.003
   de Rosales RTM, 2010, BIOCONJUGATE CHEM, V21, P811, DOI 10.1021/bc100071k
   Doschak MR, 2009, MOL PHARMACEUT, V6, P634, DOI 10.1021/mp8002368
   Fischer J, 2011, J CRANIO MAXILL SURG, V39, P54, DOI 10.1016/j.jcms.2010.03.016
   Gaertner HF, 1996, BIOCONJUGATE CHEM, V7, P38, DOI 10.1021/bc950074d
   GEOGHEGAN KF, 1992, BIOCONJUGATE CHEM, V3, P138, DOI 10.1021/bc00014a008
   Gil L, 1999, BIOORGAN MED CHEM, V7, P901, DOI 10.1016/S0968-0896(99)00045-0
   Gittens SA, 2004, J CONTROL RELEASE, V98, P255, DOI 10.1016/j.jconrel.2004.05.001
   Gittens SA, 2003, PHARMACEUT RES, V20, P978, DOI 10.1023/A:1024445903306
   Green J, 2010, SEMIN ONCOL, V37, pS3, DOI 10.1053/j.seminoncol.2010.06.003
   Henriksen K, 2013, BONE, V53, P160, DOI 10.1016/j.bone.2012.11.045
   Herczegh P, 2002, J MED CHEM, V45, P2338, DOI 10.1021/jm0105326
   Hirabayashi H, 2001, J CONTROL RELEASE, V70, P183, DOI 10.1016/S0168-3659(00)00355-2
   Hoare TR, 2008, POLYMER, V49, P1993, DOI 10.1016/j.polymer.2008.01.027
   Kamaly N, 2012, CHEM SOC REV, V41, P2971, DOI 10.1039/c2cs15344k
   Kieczykowski GR, 1995, J ORG CHEM, V60, P8310, DOI 10.1021/jo00130a036
   Langer R, 2003, AICHE J, V49, P2990, DOI 10.1002/aic.690491202
   Langer R, 2001, SCIENCE, V293, P58, DOI 10.1126/science.1063273
   Lin JG, 2012, APPL RADIAT ISOTOPES, V70, P848, DOI 10.1016/j.apradiso.2011.12.019
   Liu H, 2010, BONE, V46, P1328, DOI 10.1016/j.bone.2009.11.017
   Malam Y, 2009, TRENDS PHARMACOL SCI, V30, P592, DOI 10.1016/j.tips.2009.08.004
   MIKOLAJCZYK SD, 1994, BIOCONJUGATE CHEM, V5, P636, DOI 10.1021/bc00030a020
   Monkkonen H, 2001, PHARMACEUT RES, V18, P1550, DOI 10.1023/A:1013026313647
   Nishiyama N, 2006, PHARMACOL THERAPEUT, V112, P630, DOI 10.1016/j.pharmthera.2006.05.006
   ORME MW, 1994, BIOORG MED CHEM LETT, V4, P1375, DOI 10.1016/S0960-894X(01)80365-6
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078-0432.CCR-06-0843
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   SCHETZ JA, 1995, J PHARMACOL EXP THER, V274, P1456
   Serada M, 2012, XENOBIOTICA, V42, P398, DOI 10.3109/00498254.2011.622811
   Serda RE, 2011, BBA-GEN SUBJECTS, V1810, P317, DOI 10.1016/j.bbagen.2010.05.004
   Sibai T, 2011, CLIN ORTHOP RELAT R, V469, P2215, DOI 10.1007/s11999-010-1722-9
   Suzuki K, 2011, NUCL MED BIOL, V38, P1011, DOI 10.1016/j.nucmedbio.2011.02.015
   Trivedi R, 2010, EXPERT OPIN INV DRUG, V19, P995, DOI 10.1517/13543784.2010.501077
   Uludag H, 2000, BIOTECHNOL PROGR, V16, P258, DOI 10.1021/bp990154m
   Uludag H, 2002, CURR PHARM DESIGN, V8, P1929, DOI 10.2174/1381612023393585
   Vermonden T, 2012, CHEM REV, V112, P2853, DOI 10.1021/cr200157d
   Wang D, 2007, BIOCONJUGATE CHEM, V18, P1375, DOI 10.1021/bc7002132
   Wang D, 2006, MOL PHARMACEUT, V3, P717, DOI 10.1021/mp0600539
   Wang GL, 2012, J BIOMED MATER RES A, V100A, P684, DOI 10.1002/jbm.a.34002
   Wang G, 2011, MOL PHARMACEUT, V8, P1025, DOI 10.1021/mp200028w
   WOLFE CAC, 1995, ANAL BIOCHEM, V231, P123, DOI 10.1006/abio.1995.1511
   Wright JEI, 2006, BIOMATERIALS, V27, P769, DOI 10.1016/j.biomaterials.2005.06.012
   Yewle JN, 2012, BIOMACROMOLECULES, V13, P1742, DOI 10.1021/bm201865r
   Yewle JN, 2011, BIOCONJUGATE CHEM, V22, P2496, DOI 10.1021/bc2003132
   Zaheer A, 2001, NAT BIOTECHNOL, V19, P1148, DOI 10.1038/nbt1201-1148
   Zhang SF, 2007, CHEM SOC REV, V36, P507, DOI 10.1039/b512310k
   Zhou H, 2012, J MATER SCI-MATER M, V23, P365, DOI 10.1007/s10856-011-4524-z
   Zheng H, 1997, Patent No. [5698542, US 5,698,542]
   Thompson WJ, 1989, Polymalonic acids as boneaffinity agents, Patent No. [EP 0341961, 0341961]
NR 53
TC 9
Z9 9
U1 0
U2 34
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
EI 1878-5905
J9 BIOMATERIALS
JI Biomaterials
PD APR
PY 2013
VL 34
IS 12
BP 3141
EP 3149
DI 10.1016/j.biomaterials.2013.01.059
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 105AV
UT WOS:000316038900028
PM 23369219
DA 2018-03-20
ER

PT J
AU Xiao, L
   Davenport, DM
   Ormsbee, L
   Bhattacharyya, D
AF Xiao, Li
   Davenport, Douglas M.
   Ormsbee, Lindell R.
   Bhattacharyya, Dibakar
TI Polymerization and Functionalization of Membrane Pores for Water Related
   Applications
SO INDUSTRIAL & ENGINEERING CHEMISTRY RESEARCH
LA English
DT Article
ID NANOSCALE IRON PARTICLES; FLUORIDE) PVDF MEMBRANES; POLY(VINYLIDENE
   FLUORIDE); MICROFILTRATION MEMBRANES; MICROPOROUS MEMBRANES; PHASE
   INVERSION; BIMETALLIC NANOPARTICLES; DECHLORINATION; DEGRADATION;
   PERFORMANCE
AB Poly(vinylidene fluoride) (PVDF) was modified by chemical treatments in order to create active double bonds to obtain covalent grafting of poly(acrylic acid) (PAA) on membrane. The attenuated total reflectance Fourier transform infrared (ATR-ETIlt) 'spectrum confirms the formation of conjugated' C=C double bonds with surface dehydrofluorination. The membrane' morphology was studied by scanning electron microscopy (SEM). The surface composition was characterized by X-ray photoelectron spectroscopy (XPS). The thermal stability of the dehydrofluorinated membrane (Def-PVDF) and functidnalized membranes were investigated by differential scanning,calorimetry (DSC) analysis. The influence of covalemly attached PAA on Def PVDF membrane has been investigated to determine its effect on the transport of water and charged solute. VariationS in the solution pH show an effect on both permeability and,Solute retention in a reversible fashion. Metal nanopafficles were also immobilized in the membrane for the degradation Of toxic chlorinated organics from water. In addition, PVDF Membranes with ariasymmetric and sponge-like Morphology were developed by immersion-precipitation phase-inversion ihethodsin both lab-scale and large-scale. The new type of spongy PVDF-rnembrane shows high surface area with higher yield of PAA functionalization. The ion-capacity with Ca2+ ions was also investigated.
C1 [Xiao, Li; Davenport, Douglas M.; Bhattacharyya, Dibakar] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Ormsbee, Lindell] Univ Kentucky, Dept Civil Engn, Lexington, KY 40506 USA.
RP Bhattacharyya, D (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM db@engr.uky.edu
FU National Institute of Environmental Health Sciences Superfund Research
   Program (NIEHS-SRP) [P42ES007380]; NSF KY EPSCoR (NSF) [1355438]
FX This research was supported by National Institute of Environmental
   Health Sciences Superfund Research Program (NIEHS-SRP, Award Number
   P42ES007380) and by the NSF KY EPSCoR (NSF Award no. 1355438) program.
   The authors acknowledge Ultura Inc., Oceanside, CA, for the joint
   development of full-scale PVDF membranes.
CR Abitoye JO, 2005, ENVIRON SCI TECHNOL, V39, P6487, DOI 10.1021/es050102v
   AKHTAR S, 1995, J MEMBRANE SCI, V107, P209, DOI 10.1016/0376-7388(95)00118-9
   Bhattacharyya D, 2007, CLEAN TECHNOL ENVIR, V9, P81, DOI 10.1007/s10098-007-0096-5
   BOTTINO A, 1991, J MEMBRANE SCI, V57, P1, DOI 10.1016/S0376-7388(00)81159-X
   BRINK LES, 1993, J MEMBRANE SCI, V76, P281, DOI 10.1016/0376-7388(93)85225-L
   Crowe R., 1991, J CHEM SOC CHEM COMM, P958
   Cui Z, 2014, PROG POLYM SCI, V39, P164, DOI 10.1016/j.progpolymsci.2013.07.008
   Fontananova E, 2006, DESALINATION, V192, P190, DOI 10.1016/j.desal.2005.09.021
   Gu MH, 2006, DESALINATION, V192, P160, DOI 10.1016/j.desal.2005.10.015
   He F, 2007, IND ENG CHEM RES, V46, P29, DOI 10.1021/ie0610896
   Hester JF, 2002, J MEMBRANE SCI, V202, P119, DOI 10.1016/S0376-7388(01)00735-9
   Himstedt HH, 2013, IND ENG CHEM RES, V52, P9259, DOI 10.1021/ie400982p
   Hollman AM, 2004, J MEMBRANE SCI, V239, P65, DOI 10.1016/j.memsci.2003.07.026
   Hollman AM, 2002, LANGMUIR, V18, P5946, DOI 10.1021/la025662b
   ISHIHARA K, 1984, POLYM J, V16, P625, DOI 10.1295/polymj.16.625
   ISHIHARA K, 1984, J APPL POLYM SCI, V29, P211, DOI 10.1002/app.1984.070290119
   IWATA H, 1988, J MEMBRANE SCI, V38, P185, DOI 10.1016/S0376-7388(00)80879-0
   Kang GD, 2014, J MEMBRANE SCI, V463, P145, DOI 10.1016/j.memsci.2014.03.055
   KISE H, 1983, J POLYM SCI POL CHEM, V21, P3443, DOI 10.1002/pol.1983.170211208
   Lewis S., 2011, THESIS U KENTUCKY
   Lewis SR, 2011, P NATL ACAD SCI USA, V108, P8577, DOI 10.1073/pnas.1101144108
   Lien HL, 2001, COLLOID SURFACE A, V191, P97, DOI 10.1016/S0927-7757(01)00767-1
   Liu F, 2011, J MEMBRANE SCI, V375, P1, DOI 10.1016/j.memsci.2011.03.014
   Lu J, 2008, ADV FUNCT MATER, V18, P1290, DOI 10.1002/adfm.200701133
   MATHESON LJ, 1994, ENVIRON SCI TECHNOL, V28, P2045, DOI 10.1021/es00061a012
   Mi FL, 2001, BIOMATERIALS, V22, P165, DOI 10.1016/S0142-9612(00)00167-8
   Mika AM, 1999, J MEMBRANE SCI, V153, P45, DOI 10.1016/S0376-7388(98)00246-4
   MIKA AM, 1995, J MEMBRANE SCI, V108, P37, DOI 10.1016/0376-7388(95)00140-2
   MUNARI S, 1983, J MEMBRANE SCI, V16, P181, DOI 10.1016/S0376-7388(00)81309-5
   NUNES SP, 1995, J MEMBRANE SCI, V106, P49, DOI 10.1016/0376-7388(95)00076-O
   Owen ED, 1996, POLYM DEGRAD STABIL, V51, P151, DOI 10.1016/0141-3910(95)00154-9
   Qu T, 2014, IND ENG CHEM RES, V53, P8228, DOI 10.1021/ie5012905
   Rahbari-Sisakht M, 2014, CHEM ENG J, V246, P306, DOI 10.1016/j.cej.2014.02.082
   Ross GJ, 2000, POLYMER, V41, P1685, DOI 10.1016/S0032-3861(99)00343-2
   Smuleac V, 2011, J MEMBRANE SCI, V379, P131, DOI 10.1016/j.memsci.2011.05.054
   Smuleac V, 2010, J MEMBRANE SCI, V346, P310, DOI 10.1016/j.memsci.2009.09.052
   Song JF, 2013, WATER RES, V47, P2065, DOI 10.1016/j.watres.2013.01.032
   Song LZ, 2007, J MATER SCI TECHNOL, V23, P55
   Sun AC, 2013, DESALINATION, V309, P156, DOI 10.1016/j.desal.2012.10.005
   Thomas R, 2014, J MEMBRANE SCI, V452, P470, DOI 10.1016/j.memsci.2013.11.036
   Wang CB, 1997, ENVIRON SCI TECHNOL, V31, P2154, DOI 10.1021/es970039c
   Wootthikanokkhan J., 2008, J MET MAT MINER, V18, P57
   Xiao L, 2014, J MEMBRANE SCI, V457, P39, DOI 10.1016/j.memsci.2014.01.033
   Xiao L, 2013, J APPL POLYM SCI, V128, P1804, DOI 10.1002/app.38335
   Xu J, 2005, ENVIRON PROG, V24, P358, DOI 10.1002/ep.10106
   Xu J., 2007, THESIS U KENTUCKY
   Xu J, 2007, IND ENG CHEM RES, V46, P2348, DOI 10.1021/ie0611498
   Ying L, 2003, J MEMBRANE SCI, V224, P93, DOI 10.1016/j.memsci.2003.07.002
   Zhang WX, 1998, CATAL TODAY, V40, P387, DOI 10.1016/S0920-5861(98)00067-4
   Zhao CS, 2011, PROG POLYM SCI, V36, P1499, DOI 10.1016/j.progpolymsci.2011.05.004
NR 50
TC 6
Z9 6
U1 0
U2 30
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0888-5885
J9 IND ENG CHEM RES
JI Ind. Eng. Chem. Res.
PD APR 29
PY 2015
VL 54
IS 16
BP 4174
EP 4182
DI 10.1021/ie504149t
PG 9
WC Engineering, Chemical
SC Engineering
GA CH3LC
UT WOS:000353931200019
PM 26074669
OA gold
DA 2018-03-19
ER

PT J
AU Stocke, NA
   Meenach, SA
   Arnold, SM
   Mansour, HM
   Hilt, JZ
AF Stocke, Nathanael A.
   Meenach, Samantha A.
   Arnold, Susanne M.
   Mansour, Heidi M.
   Hilt, J. Zach
TI Formulation and characterization of inhalable magnetic nanocomposite
   microparticles (MnMs) for targeted pulmonary delivery via spray drying
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Magnetic nanoparticles; Iron oxide; Remote heating; Dry powder
   inhalation aerosols; Nanocomposites; Spray drying
ID IRON-OXIDE NANOPARTICLES; DRUG-DELIVERY; PHYSICOCHEMICAL
   CHARACTERIZATION; SUPERPARAMAGNETIC NANOPARTICLES; HYDROGEL
   NANOCOMPOSITES; FLUID HYPERTHERMIA; CANCER-THERAPY; LUNG-CANCER;
   D-MANNITOL; AEROSOLS
AB Targeted pulmonary delivery facilitates the direct application of bioactive materials to the lungs in a controlled manner and provides an exciting platform for targeting magnetic nanoparticles (MNPs) to the lungs. Iron oxide MNPs remotely heat in the presence of an alternating magnetic field (AMF) providing unique opportunities for therapeutic applications such as hyperthermia. In this study, spray drying was used to formulate magnetic nanocomposite microparticles (MnMs) consisting of iron oxide MNPs and D-mannitol. The physicochemical properties of these MnMs were evaluated and the in vitro aerosol dispersion performance of the dry powders was measured by the Next Generation Impactor (R). For all powders, the mass median aerosol diameter (MMAD) was < 5 mu m and deposition patterns revealed that MnMs could deposit throughout the lungs. Heating studies with a custom AMF showed that MNPs retain excellent thermal properties after spray drying into composite dry powders, with specific absorption ratios (SAR) > 200 W/g, and in vitro studies on a human lung cell line indicated moderate cytotoxicity of these materials. These inhalable composites present a class of materials with many potential applications and pose a promising approach for thermal treatment of the lungs through targeted pulmonary administration of MNPs. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Stocke, Nathanael A.; Meenach, Samantha A.; Hilt, J. Zach] Univ Kentucky, Coll Engn, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Meenach, Samantha A.; Mansour, Heidi M] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40506 USA.
   [Arnold, Susanne M.] Univ Kentucky, Coll Med, Dept Internal Med, Lexington, KY 40506 USA.
RP Hilt, JZ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 F Paul Anderson Tower, Lexington, KY 40506 USA.
EM mansour@pharmacy.arizona.edu; zach.hilt@uky.edu
FU National Cancer Institute [R25CA153954]
FX The project described was partially supported by grant number
   R25CA153954 from the National Cancer Institute. The content is solely
   the responsibility of the authors and does not necessarily represent the
   official views of the National Cancer Institute or the National
   Institutes of Health.
CR Azarmi S, 2008, ADV DRUG DELIVER REV, V60, P863, DOI 10.1016/j.addr.2007.11.006
   Burger A, 2000, J PHARM SCI-US, V89, P457, DOI 10.1002/(SICI)1520-6017(200004)89:4<457::AID-JPS3>3.0.CO;2-G
   Carpenter JF, 1997, PHARMACEUT RES, V14, P969, DOI 10.1023/A:1012180707283
   Chow AHL, 2007, PHARM RES, V24, P411, DOI 10.1007/s11095-006-9174-3
   Dames P, 2007, NAT NANOTECHNOL, V2, P495, DOI 10.1038/nnano.2007.217
   Dolovich MB, 2005, CHEST, V127, P335, DOI 10.1378/chest.127.1.335
   Finlay Warren, 2008, ARLA RESP DEPOSITION
   Frimpong RA, 2010, NANOMEDICINE-UK, V5, P1401, DOI 10.2217/NNM.10.114
   Fronczek FR, 2003, ACTA CRYSTALLOGR C, V59, pO567, DOI 10.1107/S0108270103018961
   Gjoerup J, 2012, RESPIROLOGY, V17, P927, DOI 10.1111/j.1440-1843.2012.02189.x
   Hasenpusch G, 2012, PHARM RES-DORDR, V29, P1308, DOI 10.1007/s11095-012-0682-z
   Hawkins AM, 2009, PHARM RES-DORD, V26, P667, DOI 10.1007/s11095-008-9804-z
   Horsman MR, 2007, CLIN ONCOL-UK, V19, P418, DOI 10.1016/j.clon.2007.03.015
   Issels RD, 2008, EUR J CANCER, V44, P2546, DOI 10.1016/j.ejca.2008.07.038
   Johannsen M, 2010, INT J HYPERTHER, V26, P790, DOI 10.3109/02656731003745740
   Jordan A, 1999, J MAGN MAGN MATER, V201, P413, DOI 10.1016/S0304-8853(99)00088-8
   Jordan A, 2006, J NEURO-ONCOL, V78, P7, DOI 10.1007/s11060-005-9059-z
   Jordan A, 2001, J MAGN MAGN MATER, V225, P118, DOI 10.1016/S0304-8853(00)01239-7
   Knecht LD, 2012, ACS NANO, V6, P9079, DOI 10.1021/nn303308v
   Kwon JT, 2009, J OCCUP HEALTH, V51, P423, DOI 10.1539/joh.L8159
   Li L, 2013, J CONTROL RELEASE, V168, P142, DOI 10.1016/j.jconrel.2013.03.011
   Li XJ, 2011, AAPS PHARMSCITECH, V12, P1420, DOI 10.1208/s12249-011-9704-0
   Mansour HM, 2009, INT J NANOMED, V4, P299
   McBride AA, 2013, MOL PHARMACEUT, V10, P3574, DOI 10.1021/mp3007264
   McGill SL, 2009, IEEE T NANOBIOSCI, V8, P33, DOI 10.1109/TNB.2009.2017292
   Meenach SA, 2013, INT J NANOMED, V8, P275, DOI 10.2147/IJN.S30724
   Meenach SA, 2010, ACTA BIOMATER, V6, P1039, DOI 10.1016/j.actbio.2009.10.017
   Nahar K, 2014, INT J PHARMACEUT, V464, P185, DOI 10.1016/j.ijpharm.2014.01.007
   Nolan LM, 2009, EUR J PHARM SCI, V37, P593, DOI 10.1016/j.ejps.2009.05.007
   Otterson GA, 2010, CLIN CANCER RES, V16, P2466, DOI 10.1158/1078-0432.CCR-09-3015
   Pankhurst QA, 2003, J PHYS D APPL PHYS, V36, pR167, DOI 10.1088/0022-3727/36/13/201
   Patton JS, 2007, NAT REV DRUG DISCOV, V6, P67, DOI 10.1038/nrd2153
   Pena MA, 2000, CHEM PHARM BULL, V48, P179
   Ragab DM, 2013, AAPS PHARMSCITECH, V14, P977, DOI 10.1208/s12249-013-9980-y
   Redman G. E. S., 2011, J NANOMATER, V7
   Sadhukha T, 2013, BIOMATERIALS, V34, P5163, DOI 10.1016/j.biomaterials.2013.03.061
   Satarkar NS, 2008, ACTA BIOMATER, V4, P11, DOI 10.1016/j.actbio.2007.07.009
   Satarkar NS, 2011, AICHE J, V57, P852, DOI 10.1002/aic.12309
   Satarkar NS, 2010, SOFT MATTER, V6, P2364, DOI 10.1039/b925218p
   Suarez S, 2000, Respir Care, V45, P652
   Szalay B, 2012, J APPL TOXICOL, V32, P446, DOI 10.1002/jat.1779
   Tewes F, 2014, EUR J PHARM BIOPHARM, V86, P98, DOI 10.1016/j.ejpb.2013.09.004
   [Anonymous], 2006, USP 29 NF 24 US PHAR, P2617
   Vehring R, 2008, PHARM RES, V25, P999, DOI 10.1007/s11095-007-9475-1
   Verma N. K., 2013, J NANOBIOTECHNOL, V11, P12
   Vernon CC, 1996, INT J RADIAT ONCOL, V35, P731
   Wittgen BPH, 2007, CLIN CANCER RES, V13, P2414, DOI 10.1158/1078-0432.CCR-06-1480
   Wu X., 2013, INT J NANOMED, V8, P1
   Wydra RJ, 2013, MAT SCI ENG C-MATER, V33, P4660, DOI 10.1016/j.msec.2013.07.019
   Xie YY, 2010, PHARM RES-DORDR, V27, P855, DOI 10.1007/s11095-010-0078-x
NR 50
TC 14
Z9 14
U1 2
U2 33
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
EI 1873-3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD FEB 20
PY 2015
VL 479
IS 2
BP 320
EP 328
DI 10.1016/j.ijpharm.2014.12.050
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CC6CP
UT WOS:000350452600008
PM 25542988
OA green_accepted
DA 2018-03-20
ER

PT J
AU Geddes, JW
   Saatman, KE
AF Geddes, James W.
   Saatman, Kathryn E.
TI Targeting individual calpain isoforms for neuroprotection
SO EXPERIMENTAL NEUROLOGY
LA English
DT Editorial Material
ID RAT-BRAIN; NEURONAL INJURY; NEURODEGENERATION; EXPRESSION; PROTEINS;
   DELIVERY; DISEASE; SIRNA; MICE
C1 [Geddes, James W.; Saatman, Kathryn E.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA.
RP Geddes, JW (reprint author), Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, B477 Biomed & Biol Sci Res Bldg BBSRB,741 S Limes, Lexington, KY 40536 USA.
EM jgeddes@uky.edu; k.saatman@uky.edu
FU NINDS NIH HHS [R13 NS071693-01, P01 NS058484-03S1, P01 NS058484-030003,
   P01 NS058484-040003, P01 NS058484-04, P01 NS058484-010003, P01
   NS058484-03, P01 NS058484-020003, P01 NS058484-020001, P01 NS058484-01,
   P01 NS058484-03S2, P01 NS058484-03S10003, P01 NS058484-03S10001, P01
   NS058484-040001, R13 NS071693, P01 NS058484-05, P01 NS058484-030001, P01
   NS058484-010001, P01 NS058484, P01 NS058484-02]
CR Azam M, 2001, MOL CELL BIOL, V21, P2213, DOI 10.1128/MCB.21.6.2213-2220.2001
   Bevers MB, 2008, J CEREBR BLOOD F MET, V28, P655, DOI 10.1038/sj.jcbfm.9600595
   Bevers MB, 2010, EXP NEUROL, V224, P170, DOI 10.1016/j.expneurol.2010.03.007
   Bevers MB, 2009, J NEUROCHEM, V108, P1237, DOI 10.1111/j.1471-4159.2008.05860.x
   Cao GD, 2007, J NEUROSCI, V27, P9278, DOI 10.1523/JNEUROSCI.2826-07.2007
   Croall DE, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-6-218
   DAYTON WR, 1982, BIOCHIM BIOPHYS ACTA, V709, P166, DOI 10.1016/0167-4838(82)90457-5
   Dutt P, 2006, BMC DEV BIOL, V6, DOI 10.1186/1471-213X-6-3
   Franco S, 2004, EXP CELL RES, V299, P179, DOI 10.1016/j.yexcr.2004.05.021
   Franco SJ, 2005, J CELL SCI, V118, P3829, DOI 10.1242/jcs.02562
   Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002
   Grynspan F, 1997, BRAIN RES, V763, P145, DOI 10.1016/S0006-8993(97)00384-3
   HAMAKUBO T, 1986, J NEUROSCI, V6, P3103
   Konig N, 2003, J CHEM NEUROANAT, V25, P129, DOI 10.1016/S0891-0618(02)00102-3
   Li YZ, 2009, EXP NEUROL, V220, P316, DOI 10.1016/j.expneurol.2009.09.004
   Ma H, 2001, J BIOL CHEM, V276, P28525, DOI 10.1074/jbc.M100603200
   Mathupala SP, 2009, EXPERT OPIN THER PAT, V19, P137, DOI 10.1517/13543770802680195
   Pardridge WM, 2007, ADV DRUG DELIVER REV, V59, P141, DOI 10.1016/j.addr.2007.03.008
   Pfister EL, 2009, EXP NEUROL, V220, P226, DOI 10.1016/j.expneurol.2009.09.017
   ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934
   Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002
   Shin SJ, 2004, PROTEOMICS, V4, P3359, DOI 10.1002/pmic.200400961
   SIMAN R, 1985, BRAIN RES, V347, P399, DOI 10.1016/0006-8993(85)90208-2
   Vosler PS, 2008, MOL NEUROBIOL, V38, P78, DOI 10.1007/s12035-008-8036-x
   Waghray A, 2004, BIOCHEM BIOPH RES CO, V324, P46, DOI 10.1016/j.bbrc.2004.09.012
   WANG KKW, 1999, PHARM TOXICOLOGY CAL, P77
   Zadran S, 2010, J NEUROSCI, V30, P1086, DOI 10.1523/JNEUROSCI.5120-09.2010
   Zhang WL, 1996, J BIOL CHEM, V271, P18825, DOI 10.1074/jbc.271.31.18825
NR 28
TC 11
Z9 12
U1 0
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4886
J9 EXP NEUROL
JI Exp. Neurol.
PD NOV
PY 2010
VL 226
IS 1
BP 6
EP 7
DI 10.1016/j.expneurol.2010.07.025
PG 2
WC Neurosciences
SC Neurosciences & Neurology
GA 672XH
UT WOS:000283619800002
PM 20682310
OA green_accepted
DA 2018-03-20
ER

PT J
AU Li, TL
AF Li, Tonglei
TI Understanding the large librational motion of the methyl group in
   aspirin and acetaminophen crystals: Insights from density functional
   theory
SO CRYSTAL GROWTH & DESIGN
LA English
DT Article
ID ELECTROSTATIC FORCE THEORY; NUCLEAR FUKUI FUNCTION; INTERACTING
   MOLECULES; ACETYLSALICYLIC-ACID; VARIABLE-TEMPERATURE;
   ELECTRONIC-STRUCTURE; NEUTRON-DIFFRACTION; CHEMICAL REACTIVITY;
   AB-INITIO; HARDNESS
AB Single-crystal neutron diffraction studies indicated that the terminal methyl groups of aspirin and acetaminophen crystals demonstrated large librational or torsional motions as compared to other atoms. Herein, we report a study using density functional theory for understanding the Hellmann-Feynman forces and how the nuclear Fukui function may provide the underlying cause for the large disorders of the methyl group.
C1 Univ Kentucky, Coll Pharm 514, Lexington, KY 40536 USA.
RP Li, TL (reprint author), Univ Kentucky, Coll Pharm 514, 725 Rose St, Lexington, KY 40536 USA.
EM tonglei@uky.edu
CR Baekelandt BG, 1996, J CHEM PHYS, V105, P4664, DOI 10.1063/1.472329
   BECKE AD, 1988, PHYS REV A, V38, P3098, DOI 10.1103/PhysRevA.38.3098
   COHEN MH, 1994, J CHEM PHYS, V101, P8988, DOI 10.1063/1.468026
   De Proft F, 1998, J CHEM PHYS, V108, P7549, DOI 10.1063/1.476188
   Dovesi R, 2005, Z KRISTALLOGR, V220, P571, DOI 10.1524/zkri.220.5.571.65065
   Feynman RP, 1939, PHYS REV, V56, P340, DOI 10.1103/PhysRev.56.340
   Geerlings P, 2003, CHEM REV, V103, P1793, DOI 10.1021/cr990029p
   Hellmann H., 1937, EINFUHRUNG QUANTENCH
   HOHENBERG P, 1964, PHYS REV B, V136, pB864, DOI 10.1103/PhysRev.136.B864
   KLOPMAN G, 1968, J AM CHEM SOC, V90, P223, DOI 10.1021/ja01004a002
   Kohn W, 1996, J PHYS CHEM-US, V100, P12974, DOI 10.1021/jp960669l
   LEE CT, 1988, PHYS REV B, V37, P785, DOI 10.1103/PhysRevB.37.785
   NAKATSUJ.H, 1974, J AM CHEM SOC, V96, P30, DOI 10.1021/ja00808a005
   NAKATSUJ.H, 1974, J AM CHEM SOC, V96, P24, DOI 10.1021/ja00808a004
   NAKATSUJI H, 1973, J AM CHEM SOC, V95, P345, DOI 10.1021/ja00783a008
   NAKATSUJI H, 1973, J AM CHEM SOC, V95, P354, DOI 10.1021/ja00783a009
   PARR RG, 1983, J AM CHEM SOC, V105, P7512, DOI 10.1021/ja00364a005
   PARR RG, 1978, J CHEM PHYS, V68, P3801, DOI 10.1063/1.436185
   PARR RG, 1995, ANNU REV PHYS CHEM, V46, P701, DOI 10.1146/annurev.pc.46.100195.003413
   Trueblood KN, 1996, ACTA CRYSTALLOGR A, V52, P770, DOI 10.1107/S0108767396005697
   Wilson CC, 2000, Z KRISTALLOGR, V215, P693, DOI 10.1524/zkri.2000.215.11.693
   Wilson CC, 2002, NEW J CHEM, V26, P1733, DOI 10.1039/b203775k
   Wilson CC, 2001, CHEM PHYS LETT, V335, P57, DOI 10.1016/S0009-2614(01)00019-7
   YANG WT, 1985, P NATL ACAD SCI USA, V82, P6723, DOI 10.1073/pnas.82.20.6723
NR 24
TC 4
Z9 4
U1 0
U2 8
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1528-7483
EI 1528-7505
J9 CRYST GROWTH DES
JI Cryst. Growth Des.
PD SEP 6
PY 2006
VL 6
IS 9
BP 2000
EP 2003
DI 10.1021/cg060238k
PG 4
WC Chemistry, Multidisciplinary; Crystallography; Materials Science,
   Multidisciplinary
SC Chemistry; Crystallography; Materials Science
GA 081DD
UT WOS:000240296500004
DA 2018-03-20
ER

PT J
AU Yang, S
   Dillon, OW
   Puleo, DA
   Jawahir, IS
AF Yang, Shu
   Dillon, Oscar W., Jr.
   Puleo, David A.
   Jawahir, Ibrahim S.
TI Effect of cryogenic burnishing on surface integrity modifications of
   Co-Cr-Mo biomedical alloy
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B-APPLIED BIOMATERIALS
LA English
DT Article
DE cobalt-chromium (alloys); surface modification; surface
   characterization; cryogenic burnishing
ID MECHANICAL ATTRITION TREATMENT; HALL-PETCH RELATION; MAGNESIUM ALLOY;
   TOTAL HIP; DYNAMIC RECRYSTALLIZATION; TEMPERATURE-MEASUREMENT;
   PLASTIC-DEFORMATION; FATIGUE PERFORMANCE; RESIDUAL-STRESSES;
   GRAIN-REFINEMENT
AB Severe plastic deformation (SPD) processes have been used to modify the surface integrity properties of many materials by generating ultrafine or even nanometer-sized grains in the surface and subsurface region. These fine grained materials created by SPD and dynamic recrystallization in a thin layer near the surface usually have higher hardness and frequently exhibit enhanced mechanical properties (wear resistance, corrosion resistance, fatigue life, etc.). Cryogenic burnishing, a SPD process, was used to improve several surface integrity parameters of a Co-Cr-Mo biomedical alloy. Application of liquid nitrogen during the burnishing process significantly suppressed the temperature rise within and outside the nitrogen application zone. Better surface finish, high hardness value, thick burnishing-influenced surface layer, and significant grain refinement were simultaneously achieved with the application of cryogenic cooling. Current results show that cryogenic burnishing can be an effective processing method for modifying the studied surface integrity properties of Co-Cr-Mo biomedical alloy. (c) 2012 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater 101B: 139152, 2013.
C1 [Yang, Shu; Dillon, Oscar W., Jr.; Jawahir, Ibrahim S.] Univ Kentucky, Dept Mech Engn, Lexington, KY 40506 USA.
   [Yang, Shu; Dillon, Oscar W., Jr.; Jawahir, Ibrahim S.] Univ Kentucky, Inst Sustainable Mfg, Lexington, KY 40506 USA.
   [Puleo, David A.] Univ Kentucky, Ctr Biomed Engn, Wenner Gren Lab, Lexington, KY 40506 USA.
RP Yang, S (reprint author), Univ Kentucky, Dept Mech Engn, Lexington, KY 40506 USA.
EM shu.yang@uky.edu
RI Jawahir, I.S./E-8447-2014
CR Alghamdi A, 2012, MINERVA ORTOP TRAUMA, V63, P85
   Arzt E, 1998, ACTA MATER, V46, P5611, DOI 10.1016/S1359-6454(98)00231-6
   ASTM International, 2005, F203305 ASTM INT, P1071
   Brown R, 2001, COBALT NEWS, V1/4, P9
   Buscher R, 2005, WEAR, V259, P887, DOI 10.1016/j.wear.2005.02.036
   Caicedo MS, 2009, J ORTHOP RES, V27, P847, DOI 10.1002/jor.20826
   Chiba A, 2007, ACTA MATER, V55, P1309, DOI 10.1016/j.actamat.2006.10.005
   Chiba A, 2009, MAT SCI ENG A-STRUCT, V513-14, P286, DOI 10.1016/j.msea.2009.02.044
   Dhar NR, 2007, INT J MACH TOOL MANU, V47, P754, DOI 10.1016/j.ijmachtools.2006.09.018
   El-Tayeb NSM, 1993, P 4 INT C PROD ENG D, P198
   El-Tayeb NSM, 1994, ENG RES B, P171
   Fatemi-Varzaneh SM, 2007, MAT SCI ENG A-STRUCT, V456, P52, DOI 10.1016/j.msea.2006.11.095
   FATTOUH M, 1989, INT J MACH TOOL MANU, V29, P153, DOI 10.1016/0890-6955(89)90062-X
   Fischer A, 2006, MATERIALWISS WERKST, V37, P747, DOI 10.1002/mawe.200600059
   Fischer A, 2009, COMP MATER SCI, V46, P586, DOI 10.1016/j.commatsci.2009.01.016
   Gardin C, 2007, FATIGUE FRACT ENG M, V30, P342, DOI 10.1111/j.1460-2695.2007.01111.x
   Germain MA, 2003, BIOMATERIALS, V24, P469, DOI 10.1016/S0142-9612(02)00360-5
   Greenwald AS, 2001, J BONE JOINT SURG AM, V83A, P68, DOI 10.2106/00004623-200100022-00002
   HALL EO, 1951, P PHYS SOC LOND B, V64, P747, DOI 10.1088/0370-1301/64/9/303
   Hamadache H, 2006, J MATER PROCESS TECH, V180, P130, DOI 10.1016/j.jmatprotec.2006.05.013
   Hassan AM, 1996, WEAR, V199, P1, DOI 10.1016/0043-1648(95)06847-3
   Heisel C, 2003, J BONE JOINT SURG AM, V85A, P1366, DOI 10.2106/00004623-200307000-00026
   Huang P, 1999, MATER SCI TECH-LOND, V15, P157, DOI 10.1179/026708399101505699
   IMMARIGEON JP, 1984, METALL TRANS A, V15, P339, DOI 10.1007/BF02645120
   Ingham E, 2000, P I MECH ENG H, V214, P21, DOI 10.1243/0954411001535219
   Jawahir IS, 2011, CIRP ANN-MANUF TECHN, V60, P603, DOI 10.1016/j.cirp.2011.05.002
   Jayal AD, 2010, T NAMRI SME, V38, P57
   Jiang XP, 2006, MAT SCI ENG A-STRUCT, V429, P30, DOI 10.1016/j.msea.2006.04.024
   Kamikawa N, 2007, ACTA MATER, V55, P5873, DOI 10.1016/j.actamat.2007.07.002
   Shingo Kurosu YL, 2010, MATER SCI FORUM, V654-656, P2184
   Kurtz S, 2005, J BONE JOINT SURG AM, V87A, P1487, DOI 10.2106/JBJS.D.02441
   Lee SH, 2002, SCRIPTA MATER, V46, P281, DOI 10.1016/S1359-6462(01)01239-8
   Bingyun Li AM, 2003, MATER RES INNOV, V7, P245
   Li WL, 2008, SCRIPTA MATER, V59, P546, DOI 10.1016/j.scriptamat.2008.05.003
   Liang GL, 2008, MATER LETT, V62, P2282, DOI 10.1016/j.matlet.2007.11.096
   Lopez HF, 2008, METALL MATER TRANS A, V39A, P8, DOI 10.1007/s11661-007-9370-8
   M'Saoubi R, 2008, International Journal of Sustainable Manufacturing, V1, P203
   Nalla RK, 2003, MAT SCI ENG A-STRUCT, V355, P216, DOI 10.1016/S0921-5093(03)00069-8
   Nasab M.B., 2010, TRENDS BIOMATER ARTI, V24, P69
   Natu S, 2012, J CLIN PATHOL, V65, P409, DOI 10.1136/jclinpath-2011-200398
   Ni H, 2004, MAT SCI ENG A-STRUCT, V385, P267, DOI 10.1016/j.msea.2004.06.048
   NIEH TG, 1991, SCRIPTA METALL MATER, V25, P955, DOI 10.1016/0956-716X(91)90256-Z
   Nikitin I, 2005, MAT SCI ENG A-STRUCT, V403, P318, DOI 10.1016/j.msea.2005.05.030
   O'Sullivan D, 2002, P I MECH ENG B-J ENG, V216, P135, DOI 10.1243/0954405021519645
   Outeiro JC, 2008, CIRP ANN-MANUF TECHN, V57, P77, DOI 10.1016/j.cirp.2008.03.076
   Park J. P., 2003, METALLIC BIOMATERIAL, P1
   PETCH NJ, 1953, J IRON STEEL I, V174, P25
   Pourzal R, 2011, WEAR, V271, P1658, DOI 10.1016/j.wear.2010.12.045
   Prevey P, 2001, NAS399116 SBIR NASA
   Prevey P, 2000, 5 NAT TURB ENG HIGH
   Prevey PS, 2001, J MATER ENG PERFORM, V10, P548, DOI 10.1361/105994901770344692
   Pu Z, 2012, INT J MACH TOOL MANU, V56, P17, DOI 10.1016/j.ijmachtools.2011.12.006
   Pu Z, 2011, SCRIPTA MATER, V65, P520, DOI 10.1016/j.scriptamat.2011.06.013
   Pu Z, 2011, P MAGN TECHN, P635
   Qi ZQ, 2009, J NANOSCI NANOTECHNO, V9, P4227, DOI 10.1166/jnn.2009.M37
   Radziejewska J, 2009, J MATER PROCESS TECH, V209, P2047, DOI 10.1016/j.jmatprotec.2008.04.067
   Radziejewska J, 2005, P 13 INT SCI C CO MA
   RIGNEY DA, 1978, WEAR, V46, P241, DOI 10.1016/0043-1648(78)90125-4
   Rigney DA, 2000, WEAR, V245, P1, DOI 10.1016/S0043-1648(00)00460-9
   Sato M, 2004, SCI TECHNOL ADV MAT, V5, P145, DOI 10.1016/j.stam.2003.10.015
   Sato Y, 2008, J JPN I MET, V72, P875, DOI 10.2320/jinstmet.72.875
   Shi YN, 2008, KEY ENG MATER, V384, P321, DOI 10.4028/www.scientific.net/KEM.384.321
   Smith AJ, 2012, LANCET, V379, P1199, DOI 10.1016/S0140-6736(12)60353-5
   SURY P, 1978, J BIOMED MATER RES, V12, P723, DOI 10.1002/jbm.820120512
   Takeuchi S, 2001, SCRIPTA MATER, V44, P1483, DOI 10.1016/S1359-6462(01)00713-8
   Tao NR, 2002, ACTA MATER, V50, P4603, DOI 10.1016/S1359-6454(02)00310-5
   Tsuji N, 2009, SCRIPTA MATER, V60, P1044, DOI 10.1016/j.scriptamat.2009.02.028
   Umbrello D, 2011, 2011 ASME INT MECH E
   Valiev RZ, 2010, REV ADV MATER SCI, V25, P1
   Vandamme NS, 2005, J MATER SCI-MATER M, V16, P647, DOI 10.1007/s10856-005-2536-2
   Varano R, 2006, J BIOMED MATER RES B, V76B, P281, DOI 10.1002/jbm.b.30370
   Villegas JC, 2005, PHIL MAG LETT, V85, P427, DOI 10.1080/09500830500311705
   Wang ZB, 2003, MAT SCI ENG A-STRUCT, V352, P144, DOI 10.1016/S0921-5093(02)00870-5
   Williams SR, 2009, P I MECH ENG H, V223, P941, DOI 10.1243/09544119JEIM590
   Wimmer MA, 2001, WEAR, V250, P129, DOI 10.1016/S0043-1648(01)00654-8
   Wu X, 2005, ACTA MATER, V53, P681, DOI 10.1016/j.actamat.2004.10.021
   Xiao GH, 2008, SCRIPTA MATER, V59, P975, DOI 10.1016/j.scriptamat.2008.06.060
   Yamanaka K, 2009, METALL MATER TRANS A, V40A, P1980, DOI 10.1007/s11661-009-9879-0
   Yanagimoto J, 1998, J MANUF SCI E-T ASME, V120, P316, DOI 10.1115/1.2830129
   Yang S, 2011, PROCEDIA ENGINEER, V19, DOI 10.1016/j.proeng.2011.11.129
   Zhang P, 2005, SCRIPTA MATER, V52, P1011, DOI 10.1016/j.scriptamat.2005.01.026
   ZHAO Z, 1992, J MATER ENG PERFORM, V1, P669, DOI 10.1007/BF02649248
   Zhu KY, 2004, ACTA MATER, V52, P4101, DOI 10.1016/j.actamat.2004.05.023
   Zhuang WZ, 2001, INT J FATIGUE, V23, pS31
NR 84
TC 8
Z9 9
U1 0
U2 21
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1552-4973
EI 1552-4981
J9 J BIOMED MATER RES B
JI J. Biomed. Mater. Res. Part B
PD JAN
PY 2013
VL 101B
IS 1
BP 139
EP 152
DI 10.1002/jbm.b.32827
PG 14
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 057CS
UT WOS:000312540100017
PM 23090709
DA 2018-03-20
ER

PT J
AU Guerrieri, P
   Rumondor, ACF
   Li, TL
   Taylor, LS
AF Guerrieri, Peter
   Rumondor, Alfred C. F.
   Li, Tonglei
   Taylor, Lynne S.
TI Analysis of Relationships Between Solid-State Properties, Counterion,
   and Developability of Pharmaceutical Salts
SO AAPS PHARMSCITECH
LA English
DT Article
DE counterion; hygroscopicity; salts; solid-state; solubility
ID WATER-VAPOR SORPTION; AQUEOUS SOLUBILITY; ORGANIC-COMPOUNDS;
   MOLECULAR-STRUCTURE; CRYSTALLINE SOLIDS; DISSOLUTION RATES; DIVERSE SET;
   PREDICTION; DRUG; SELECTION
AB The solid-state properties of pharmaceutical salts, which are dependent on the counterion used to form the salt, are critical for successful development of a stable dosage form. In order to better understand the relationship between counterion and salt properties, 11 salts of procaine, which is a base, were synthesized and characterized using a variety of experimental and computational methods. Correlations between the various experimental and calculated physicochemical properties of the salts and counterions were probed. In addition to investigating the key factors affecting solubility, the hygroscopicity of the crystalline salts was studied to determine which solid-state and counterion properties might be responsible for enhancements in moisture uptake, thus providing the potential for adverse chemical stability. Multivariate principal components and partial least squares projection to latent structures analyses were performed in an attempt to establish predictive models capable of describing the relationships between these characteristics and both measured and calculated properties of the counterion and salt. Some success was achieved with respect to modeling crystalline salt solubility and the glass transition temperature of the amorphous salts. Through the modeling, insight into the relative importance of various descriptors on salt properties was achieved. The solid-state properties of crystalline and amorphous salts of procaine are highly dependent on the nature of the counterion. Important properties including aqueous solubility, melting point, hygroscopicity, and glass transition temperature were found to vary considerably between the different salts.
C1 [Guerrieri, Peter; Rumondor, Alfred C. F.; Taylor, Lynne S.] Purdue Univ, Dept Ind & Phys Pharm, Coll Pharm, W Lafayette, IN 47907 USA.
   [Li, Tonglei] Univ Kentucky, Coll Pharm, Lexington, KY 40536 USA.
RP Taylor, LS (reprint author), Purdue Univ, Dept Ind & Phys Pharm, Coll Pharm, W Lafayette, IN 47907 USA.
EM lstaylor@purdue.edu
OI Taylor, Lynne/0000-0002-4568-6021
FU AstraZeneca RD Lund, Sweden
FX The authors acknowledge AstraZeneca R&D Lund, Sweden for funding this
   research. Dr. Kjell Jarring is sincerely thanked for helpful
   discussions. Nathan Hesse is gratefully acknowledged for performing the
   solution calorimetry experiments.
CR AGHARKAR S, 1976, J PHARM SCI, V65, P747, DOI 10.1002/jps.2600650533
   ANDERSON BD, 1985, J PHARM SCI, V74, P815, DOI 10.1002/jps.2600740803
   Ayers PW, 2006, J CHEM PHYS, V124, DOI 10.1063/1.2196882
   Bastin RJ, 2000, ORG PROCESS RES DEV, V4, P427, DOI 10.1021/op000018u
   BERGE SM, 1977, J PHARM SCI, V66, P1, DOI 10.1002/jps.2600660104
   Black SN, 2007, J PHARM SCI-US, V96, P1053, DOI 10.1002/jps.20927
   Blagden N, 2007, ADV DRUG DELIVER REV, V59, P617, DOI 10.1016/j.addr.2007.05.011
   BODOR N, 1992, J PHARM SCI, V81, P954, DOI 10.1002/jps.2600810924
   Brunauer S, 1938, J AM CHEM SOC, V60, P309, DOI 10.1021/ja01269a023
   Chen XQ, 2002, J PHARM SCI, V91, P1838, DOI 10.1002/jps.10178
   Chow K, 2008, J PHARM SCI-US, V97, P2855, DOI 10.1002/jps.21212
   CHOWHAN ZT, 1978, J PHARM SCI, V67, P1257, DOI 10.1002/jps.2600670918
   Datta S, 2004, NAT REV DRUG DISCOV, V3, P42, DOI 10.1038/nrd1280
   Dittgen M, 1997, STP PHARMA SCI, V7, P403
   FINI A, 1996, INT J PHARM ADV, V1, P269
   Gao H, 2002, PHARMACEUT RES, V19, P497, DOI 10.1023/A:1015103914543
   Ghasemi J, 2007, CHEM PHARM BULL, V55, P669, DOI 10.1248/cpb.55.669
   Giron D, 2003, J THERM ANAL CALORIM, V73, P441, DOI 10.1023/A:1025461625782
   GOULD PL, 1986, INT J PHARM, V33, P201, DOI 10.1016/0378-5173(86)90055-4
   Graziano G, 2006, CHEM PHYS LETT, V429, P114, DOI 10.1016/j.cplett.2006.08.006
   GU L, 1987, PHARMACEUT RES, V4, P255, DOI 10.1023/A:1016420514689
   GUERRIERI P, 2010, J PHARM SCI
   Guerrieri P, 2007, PHARM RES, V24, P147, DOI 10.1007/s11095-006-9134-y
   Hancock BC, 1996, J PHARM SCI, V85, P246, DOI 10.1021/js9501091
   Hildebrand JH, 1970, REGULAR RELATED SOLU
   Huang LF, 2004, ADV DRUG DELIVER REV, V56, P321, DOI 10.1016/j.addr.2003.10.007
   Huibers PDT, 1998, J CHEM INF COMP SCI, V38, P283, DOI 10.1021/ci9700438
   Huuskonen J, 1997, J PHARM SCI, V86, P450, DOI 10.1021/js960358m
   Huuskonen J, 1998, J CHEM INF COMP SCI, V38, P450, DOI 10.1021/ci970100x
   Huuskonen J, 2000, J CHEM INF COMP SCI, V40, P773, DOI 10.1021/ci9901338
   Jain N, 2001, J PHARM SCI, V90, P234, DOI 10.1002/1520-6017(200102)90:2<234::AID-JPS14>3.0.CO;2-V
   Jones HP, 2005, J PHYS CHEM B, V109, P5273, DOI 10.1021/jp045000q
   Jorgensen WL, 2002, ADV DRUG DELIVER REV, V54, P355, DOI 10.1016/S0169-409X(02)00008-X
   KLOPMAN G, 1992, J CHEM INF COMP SCI, V32, P474, DOI 10.1021/ci00009a013
   Martinez F, 2001, J SOLUTION CHEM, V30, P909, DOI 10.1023/A:1012723731104
   Mitchell BE, 1998, J CHEM INF COMP SCI, V38, P489, DOI 10.1021/ci970117f
   MORRIS KR, 1994, INT J PHARM, V105, P209, DOI 10.1016/0378-5173(94)90104-X
   NELSON TM, 1994, J CHEM INF COMP SCI, V34, P601, DOI 10.1021/ci00019a019
   NICKLASSON M, 1983, ACTA PHARM SUEC, V20, P321
   O'Connor KM, 2001, INT J PHARM, V222, P281, DOI 10.1016/S0378-5173(01)00717-7
   O'Connor KM, 2001, INT J PHARM, V226, P163, DOI 10.1016/S0378-5173(01)00800-6
   Parr RG, 1999, J AM CHEM SOC, V121, P1922, DOI 10.1021/ja983494x
   PARR RG, 1995, ANNU REV PHYS CHEM, V46, P701, DOI 10.1146/annurev.pc.46.100195.003413
   Parshad H, 2004, INT J PHARM, V269, P157, DOI 10.1016/j.ijpharm.2003.09.009
   Parshad H, 2002, INT J PHARM, V237, P193, DOI 10.1016/S0378-5173(02)00042-X
   PATIL GS, 1991, CHEMOSPHERE, V22, P723, DOI 10.1016/0045-6535(91)90049-J
   Pinho SP, 1996, FLUID PHASE EQUILIBR, V116, P209, DOI 10.1016/0378-3812(95)02889-7
   ROSS KD, 1975, FOOD TECHNOL-CHICAGO, V29, P26
   Salameh AK, 2005, PHARM RES-DORDR, V22, P318, DOI 10.1007/s11095-005-1563-5
   SALEKIGERHARDT A, 1994, INT J PHARM, V101, P237, DOI 10.1016/0378-5173(94)90219-4
   Schravendijk P, 2005, J CHEM THEORY COMPUT, V1, P643, DOI 10.1021/ct049841c
   Sutter JM, 1996, J CHEM INF COMP SCI, V36, P100, DOI 10.1021/ci9501507
   Tantishaiyakul V, 2004, INT J PHARM, V275, P133, DOI 10.1016/j.ijpharm.2004.01.028
   Tantishaiyakul V, 2005, J PHARMACEUT BIOMED, V37, P411, DOI 10.1016/j.jpba.2004.11.005
   Tong P, 2002, PHARMACEUT RES, V19, P649, DOI 10.1023/A:1015310213887
   Tong P, 1999, PHARM RES-DORDR, V16, P1186, DOI 10.1023/A:1018985110956
   Tong W Q, 1998, Pharm Dev Technol, V3, P215, DOI 10.3109/10837459809028498
   Towler CS, 2008, MOL PHARMACEUT, V5, P946, DOI 10.1021/mp8000342
   VANCAMPEN L, 1983, J PHARM SCI, V72, P1381, DOI 10.1002/jps.2600721204
   Vippagunta SR, 2001, ADV DRUG DELIVER REV, V48, P3, DOI 10.1016/S0169-409X(01)00097-7
   Ware EC, 2004, PHARM RES, V21, P177, DOI 10.1023/B:PHAM.0000012167.60180.c3
   Yu L, 2001, ADV DRUG DELIVER REV, V48, P27, DOI 10.1016/S0169-409X(01)00098-9
   ZOGRAFI G, 1988, DRUG DEV IND PHARM, V14, P1905, DOI 10.3109/03639048809151997
NR 63
TC 28
Z9 30
U1 1
U2 19
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1530-9932
J9 AAPS PHARMSCITECH
JI AAPS PharmSciTech
PD SEP
PY 2010
VL 11
IS 3
BP 1212
EP 1222
DI 10.1208/s12249-010-9499-4
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 735OS
UT WOS:000288427400026
PM 20680707
OA green_published
DA 2018-03-20
ER

PT J
AU Yang, S
   Umbrello, D
   Dillon, OW
   Puleo, DA
   Jawahir, IS
AF Yang, Shu
   Umbrello, Domenico
   Dillon, Oscar W., Jr.
   Puleo, David A.
   Jawahir, Ibrahim S.
TI Cryogenic cooling effect on surface and subsurface microstructural
   modifications in burnishing of Co-Cr-Mo biornaterial
SO JOURNAL OF MATERIALS PROCESSING TECHNOLOGY
LA English
DT Article
DE Cryogenic burnishing; Co-Cr-Mo biomaterial; Surface and subsurface
   microstructural modifications; Severe plastic deformation (SPD)
ID WEAR-RESISTANCE; MECHANICAL-PROPERTIES; PHASE-TRANSFORMATION; ALLOY;
   PARAMETERS; TOOL; DEFORMATION; COMPONENTS; INTEGRITY; STRENGTH
AB The aim of the present work is to investigate the effect of a severe plastic deformation (SPD) process, cryogenic burnishing, on the surface integrity modifications of a Co-Cr-Mo alloy due to the burnishing-induced surface integrity properties. A set of experiments was conducted to investigate the influence of different burnishing parameters on distribution of grain size, phase structure and hardness of the processed material. The results from this work show that the proper selection of burnishing conditions can significant improve the surface integrity of the Co-Cr-Mo alloy due to refined microstructure, high hardness, and favorable phase structure on the surface layer, which could potentially lead to advanced wear performance of such material. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Yang, Shu; Dillon, Oscar W., Jr.; Jawahir, I. S.] Univ Kentucky, Inst Sustainable Mfg, Lexington, KY 40506 USA.
   [Umbrello, Domenico] Univ Calabria, Dept Mech Energy & Management Engn, I-87036 Arcavacata Di Rende, CS, Italy.
   [Puleo, David A.] Univ Kentucky, Dept Biomed Engn, Lexington, KY 40506 USA.
RP Yang, S (reprint author), Univ Kentucky, Inst Sustainable Mfg, Lexington, KY 40506 USA.
EM shuyang1031@gmail.com
RI Umbrello, Domenico/C-5519-2012
OI Umbrello, Domenico/0000-0002-4211-6322
CR Ben Fredj N, 2006, CRYOGENICS, V46, P439, DOI 10.1016/j.cryogenics.2006.01.015
   Buckley H, 1968, COBALT, P20
   Buscher R, 2005, WEAR, V259, P887, DOI 10.1016/j.wear.2005.02.036
   Buscher R, 2003, MATERIALWISS WERKST, V34, P966, DOI 10.1002/mawe.200300680
   Chan CLH, 1996, J BONE JOINT SURG BR, V78B, P78
   CHAPELLIER P, 1990, ACTA METALL MATER, V38, P1475, DOI 10.1016/0956-7151(90)90116-X
   CROOK P, 1983, WEAR MAT, P272
   El-Axir MH, 2003, J MATER PROCESS TECH, V132, P82, DOI 10.1016/S0924-0136(02)00269-8
   GRAHAM AH, 1970, METALL TRANS, V1, P423, DOI 10.1007/BF02811551
   HALL EO, 1951, P PHYS SOC LOND B, V64, P747, DOI 10.1088/0370-1301/64/9/303
   Hassan AM, 1999, J MATER PROCESS TECH, V96, P73
   Hassan AM, 1996, J MATER PROCESS TECH, V59, P250, DOI 10.1016/0924-0136(95)02149-3
   HUANG JY, 1995, APPL PHYS LETT, V66, P308, DOI 10.1063/1.113527
   Khan AA, 2008, J MATER PROCESS TECH, V196, P149, DOI 10.1016/j.jmatprotec.2007.05.030
   Kohzu M, 2007, MATER TRANS, V48, P764, DOI 10.2320/matertrans.48.764
   Kumar KVBSK, 2008, J MATER PROCESS TECH, V203, P95, DOI 10.1016/j.jmatprotec.2007.10.036
   Kuroda M, 2005, AIP CONF PROC, V778, P445
   LOH NH, 1989, J MECH WORK TECHNOL, V18, P53, DOI 10.1016/0378-3804(89)90109-5
   Maximov JT, 2009, INT J MACH TOOL MANU, V49, P824, DOI 10.1016/j.ijmachtools.2009.05.011
   O'Sullivan D, 2002, P I MECH ENG B-J ENG, V216, P135, DOI 10.1243/0954405021519645
   OLSON GB, 1975, METALL TRANS, VA  6, P791, DOI 10.1007/BF02672301
   Park J. B., 2003, BIOMATERIALS PRINCIP, P1
   PETCH NJ, 1953, J IRON STEEL I, V174, P25
   Prevey P. S., 2000, EFFECT COLD WORK THE
   RAJAN K, 1982, J MATER SCI, V17, P769, DOI 10.1007/BF00540374
   Rao DS, 2008, MATER MANUF PROCESS, V23, P295, DOI 10.1080/10426910801937306
   Saldivar-Garcia AJ, 2005, J BIOMED MATER RES A, V74A, P269, DOI 10.1002/jbm.a.30392
   Salinas-Rodrfguez A., 1999, ASTM STP, V1365
   Seemikeri CY, 2008, TRIBOL INT, V41, P724, DOI 10.1016/j.triboint.2008.01.003
   Stoot F.H., 1977, MET TECHNOL, V4, P66
   Vandamme NS, 2005, J MATER SCI-MATER M, V16, P647, DOI 10.1007/s10856-005-2536-2
   Yamanaka K, 2009, METALL MATER TRANS A, V40A, P1980, DOI 10.1007/s11661-009-9879-0
   Yang S, 2013, J BIOMED MATER RES B, V101B, P139, DOI 10.1002/jbm.b.32827
   Zhang P, 2005, SCRIPTA MATER, V52, P1011, DOI 10.1016/j.scriptamat.2005.01.026
   Zurecki Z., 2003, P IMECE 03 WASH DC
NR 35
TC 4
Z9 4
U1 0
U2 10
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0924-0136
J9 J MATER PROCESS TECH
JI J. Mater. Process. Technol.
PD MAR
PY 2015
VL 217
BP 211
EP 221
DI 10.1016/j.jmatprotec.2014.11.004
PG 11
WC Engineering, Industrial; Engineering, Manufacturing; Materials Science,
   Multidisciplinary
SC Engineering; Materials Science
GA AY5AM
UT WOS:000347585900021
DA 2018-03-20
ER

PT J
AU Lewis, S
   Lynch, A
   Bachas, L
   Hampson, S
   Ormsbee, L
   Bhattacharyya, D
AF Lewis, Scott R.
   Lynch, Andrew L.
   Bachas, Leonidas G.
   Hampson, Steve
   Ormsbee, Lindell R.
   Bhattacharyya, Dibakar
TI Chelate-Modified Fenton Reaction for the Degradation of
   Trichloroethylene in Aqueous and Two-Phase Systems
SO ENVIRONMENTAL ENGINEERING SCIENCE
LA English
DT Article
DE iron; citrate; TCE droplet; DNAPL; groundwater; hydroxyl radical
ID ADVANCED OXIDATION PROCESSES; OZONE-HYDROGEN PEROXIDE; CATALYTIC
   DECOMPOSITION; CARBON-TETRACHLORIDE; MASS-TRANSFER; DESTRUCTION;
   GROUNDWATER; MECHANISM; REAGENT; PARTICLES
AB The primary objective of this research was to model and understand the chelate-modified Fenton reaction for the destruction of trichloroethylene (TCE) present in both the aqueous and organic (in the form of droplets) phases. The addition of a nontoxic chelate (L), such as citrate or gluconic acid, allows for operation at near-neutral pH and controlled release of Fe(II)/Fe(III). For the standard Fenton reaction at low pH in two-phase systems, an optimum H(2)O(2):Fe(II) molar ratio was found to be between 1:1 and 2:1. Experimentation proved the chelate-modified Fenton reaction effectively dechlorinated TCE in both the aqueous and organic phases at pH 6-7 using low H(2)O(2): Fe(II) molar ratios (4:1 to 8:1). Increasing the L: Fe ratio was found to decrease the rate of H2O2 degradation in both Fe(II) and Fe(III) systems at near-neutral pH. Generalized models were developed to predict the concentration of TCE in the aqueous phase and TCE droplet radius as a function of time using literature-reported hydroxyl radical reaction kinetics and mass transfer relationships. Additional aspects of this work include the reusability of the Fe-citrate complex under repeated H(2)O(2) injections in real water systems as well as packed column studies for simulated groundwater injection.
C1 [Bhattacharyya, Dibakar] Univ Kentucky, Dept Chem & Mat Engn, Kentucky Res Consortium Energy & Environm, Lexington, KY 40506 USA.
   [Bachas, Leonidas] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
RP Bhattacharyya, D (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Kentucky Res Consortium Energy & Environm, 177 F Paul Anderson Tower, Lexington, KY 40506 USA.
EM db@engr.uky.edu
RI Bachas, Leonidas/G-2479-2015; Ormsbee, Lindell/C-4814-2009
OI Bachas, Leonidas/0000-0002-3308-6264
FU NIEHS/SBRP [P42ES007380]; NSF-IGERT,; DOE-KRCEE [DE-FG05-03OR2302]
FX This research was supported by the NIEHS/SBRP (Grant number:
   P42ES007380), NSF-IGERT, and by the DOE-KRCEE (DOE Grant Number
   DE-FG05-03OR2302) programs.
CR Ahuja DK, 2007, CHEMOSPHERE, V66, P2193, DOI 10.1016/j.chemosphere.2006.08.035
   AMARANTE D, 2000, POLLUT ENG
   Baes C. F., 1976, HYDROLYSIS CATIONS
   Brady J. E., 1982, GEN CHEM PRINCIPLES
   Brown PP, 2003, J ENVIRON ENG-ASCE, V129, P222, DOI 10.1061/(ASCE)0733-9372(2003)129:3(222)
   BRUNET R, 1984, OZONE-SCI ENG, V6, P163, DOI 10.1080/01919518408551019
   De Laat J, 1999, ENVIRON SCI TECHNOL, V33, P2726, DOI 10.1021/es981171v
   Fogler HS, 2006, ELEMENTS CHEM REACTI
   HAAG WR, 1992, ENVIRON SCI TECHNOL, V26, P1005, DOI 10.1021/es00029a021
   Haber F, 1934, P ROY SOC LOND A MAT, V134, P332, DOI [10.1098/rspa.1934.0221, DOI 10.1098/rspa.1934.0221]
   HARRIOTT P, 1962, AICHE J, V8, P93, DOI 10.1002/aic.690080122
   Inczedy J., 1976, ANAL APPL COMPLEX EQ
   Kennedy CA, 1997, J CONTAM HYDROL, V24, P221, DOI 10.1016/S0169-7722(96)00011-3
   Kosaka K, 1998, ENVIRON SCI TECHNOL, V32, P3821, DOI 10.1021/es9800784
   Kwan WP, 2003, ENVIRON SCI TECHNOL, V37, P1150, DOI 10.1021/es020874g
   Laine DF, 2007, MICROCHEM J, V85, P183, DOI 10.1016/j.microc.2006.07.002
   Li K, 2007, ENVIRON SCI TECHNOL, V41, P1696, DOI 10.1021/es0607638
   Li YC, 2005, ENVIRON ENG SCI, V22, P756, DOI 10.1089/ees.2005.22.756
   Li YC, 2007, IND ENG CHEM RES, V46, P7984, DOI 10.1021/ie070393b
   Lin SS, 1998, ENVIRON SCI TECHNOL, V32, P1417, DOI 10.1021/es970648k
   MASTEN SJ, 1992, OZONE-SCI ENG, V14, P197, DOI 10.1080/01919519208552475
   Montgomery J. H., 2000, GROUNDWATER CHEM
   MORGAN P, 1992, WATER RES, V26, P73, DOI 10.1016/0043-1354(92)90113-I
   Munson B.R., 2002, FUNDAMENTALS FLUID M
   Pignatello JJ, 1999, ENVIRON SCI TECHNOL, V33, P1832, DOI 10.1021/es980969b
   Pignatello JJ, 2006, CRIT REV ENV SCI TEC, V36, P1, DOI 10.1080/10643380500326564
   RAVIKUMAR JX, 1994, ENVIRON SCI TECHNOL, V28, P394, DOI 10.1021/es00052a009
   Reichert C, 2004, POWDER TECHNOL, V145, P131, DOI 10.1016/j.powtec.2004.06.010
   Rivett MO, 2001, J CONTAM HYDROL, V49, P111, DOI 10.1016/S0169-7722(00)00191-1
   Roy-Perreault A, 2005, J CONTAM HYDROL, V77, P17, DOI 10.1016/j.conhyd.2004.11.001
   Russell H.H., 1992, TCE REMOVAL CONTAMIN
   Seol Y, 2008, CHEMOSPHERE, V72, P537, DOI 10.1016/j.chemosphere.2008.03.052
   SEXTON J, 2005, THESIS
   SIEGRIST RL, 2000, SITU CHEM OXIDATION
   Smith BA, 2006, J CONTAM HYDROL, V85, P229, DOI 10.1016/j.jconhyd.2006.02.002
   SUN YF, 1992, J AGR FOOD CHEM, V40, P322, DOI 10.1021/jf00014a031
   Teel AL, 2001, WATER RES, V35, P977, DOI 10.1016/S0043-1354(00)00332-8
   VOGEL TM, 1987, ENVIRON SCI TECHNOL, V21, P722, DOI 10.1021/es00162a001
   WALLING C, 1975, ACCOUNTS CHEM RES, V8, P125, DOI 10.1021/ar50088a003
   Wang QQ, 2001, ENVIRON SCI TECHNOL, V35, P4509, DOI 10.1021/es0109693
   Watts RJ, 2005, J ENVIRON ENG-ASCE, V131, P1114, DOI 10.1061/(ASCE)0733-9372(2005)131:7(1114)
   WATTS RJ, 1994, J HAZARD MATER, V39, P33, DOI 10.1016/0304-3894(94)00055-7
   WATTS RJ, 2005, J ENV ENG, P131
   Yaron-Marcovich D, 2007, CHEMOSPHERE, V69, P1593, DOI 10.1016/j.chemosphere.2007.05.056
   Yasunaga N, 2008, OZONE-SCI ENG, V30, P127, DOI 10.1080/01919510701861284
NR 45
TC 44
Z9 46
U1 1
U2 26
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1092-8758
J9 ENVIRON ENG SCI
JI Environ. Eng. Sci.
PD APR
PY 2009
VL 26
IS 4
BP 849
EP 859
DI 10.1089/ees.2008.0277
PG 11
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA 424KF
UT WOS:000264564900019
PM 20418966
OA green_published
DA 2018-03-19
ER

PT J
AU Lu, XL
   Howard, MD
   Mazik, M
   Eldridge, J
   Rinehart, JJ
   Jay, M
   Leggas, M
AF Lu, Xiuling
   Howard, Melissa D.
   Mazik, Marta
   Eldridge, Joshua
   Rinehart, John J.
   Jay, Michael
   Leggas, Markos
TI Nanoparticles containing anti-inflammatory agents as chemotherapy
   adjuvants: Optimization and in vitro characterization
SO AAPS JOURNAL
LA English
DT Article
DE adsorption; biodegradable; dexamethasone; macrophage; microemulsion;
   nanoparticle; tumor
ID NF-KAPPA-B; TUMOR-BEARING MICE; CANCER-CHEMOTHERAPY; TISSUE
   DISTRIBUTION; PLGA NANOPARTICLES; IMMUNE-RESPONSE; LIPID EMULSION;
   DRUG-DELIVERY; DEXAMETHASONE; GLUCOCORTICOIDS
AB The pre-administration of dexamethasone (DEX) has previously been shown to enhance the anti-tumor efficacy of chemotherapeutic agents. The delivery of anti-inflammatory agents specifically to tumors via nanoparticle carriers is expected to promote the effectiveness of chemotherapeutic agents while avoiding systemic toxicities. The process for preparing solid lipid nanoparticles containing anti-inflammatory agents using the nanotemplate engineering method was optimized. Due to the solubilization of DEX in the bulk aqueous phase, its more lipophilic palmitate ester was synthesized and incorporated in nanoparticles that included a pegylating agent, PEG6000 mono-stearate, as part of the formulation. The stealth properties of these nanoparticles were demonstrated to be enhanced compared to latex particles by measuring the adsorption of radioiodinated IgG (185 mu g vs. 6.7 mu g IgG/mg NP). In addition, the uptake of C-14-labeled nanoparticles by murine macrophages was shown to decrease from 36.6% to 14.7% of the nanoparticles/mg cell protein as the amount of pegylating agent in the formulation increased from 0 to 4 mg/mL. The high loading values and low burst effect observed for these DEX palmitate-containing nanoparticles in addition to their stealth properties are expected to allow for the delivery of sufficient amounts of DEX to tumors to enhance the uptake of chemotherapeutic agents.
C1 [Lu, Xiuling; Howard, Melissa D.; Mazik, Marta; Eldridge, Joshua; Jay, Michael; Leggas, Markos] Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
   [Rinehart, John J.] Univ Kentucky, Dept Med, Lexington, KY 40536 USA.
RP Lu, XL (reprint author), Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
EM xiuling.lu@uky.edu
RI Leggas, Markos/E-6618-2011
CR AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286
   Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0
   BENAMEUR H, 1993, INT J PHARM, V89, P157, DOI 10.1016/0378-5173(93)90239-C
   Cascone MG, 2002, J MATER SCI-MATER M, V13, P265, DOI 10.1023/A:1014006800514
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   De Bosscher K, 2000, P NATL ACAD SCI USA, V97, P3919, DOI 10.1073/pnas.97.8.3919
   Dranoff G, 2004, NAT REV CANCER, V4, P11, DOI 10.1038/nrc1252
   Franchimont D, 2004, ANN NY ACAD SCI, V1024, P124, DOI 10.1196/annals.1321.009
   Franchimont D, 2000, J IMMUNOL, V164, P1768, DOI 10.4049/jimmunol.164.4.1768
   Gomez-Graete C, 2007, INT J PHARM, V331, P153, DOI 10.1016/j.ijpharm.2006.11.028
   GRILLI M, 1993, INT REV CYTOL, V143, P1
   Harris TJ, 2006, ANGEW CHEM INT EDIT, V45, P3161, DOI 10.1002/anie.200600259
   Heldin CH, 2004, NAT REV CANCER, V4, P806, DOI 10.1038/nrc1456
   Hickey T, 2002, BIOMATERIALS, V23, P1649, DOI 10.1016/S0142-9612(01)00291-5
   Hobbs SK, 1998, P NATL ACAD SCI USA, V95, P4607, DOI 10.1073/pnas.95.8.4607
   Jain RK, 1996, SCIENCE, V271, P1079, DOI 10.1126/science.271.5252.1079
   JAIN RK, 1987, CANCER RES, V47, P3039
   Kim DH, 2006, BIOMATERIALS, V27, P3031, DOI 10.1016/j.biomaterials.2005.12.021
   MIZUSHIMA Y, 1982, ANN RHEUM DIS, V41, P263, DOI 10.1136/ard.41.3.263
   MIZUSHIMA Y, 1982, J PHARM PHARMACOL, V34, P49, DOI 10.1111/j.2042-7158.1982.tb04678.x
   Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477
   Mumper RJ, 2003, J DISPER SCI TECHNOL, V24, P569, DOI 10.1081/DIS-120021814
   Oyewumi MO, 2004, J CONTROL RELEASE, V95, P613, DOI 10.1016/j.jconrel.2004.01.002
   Panyam J, 2004, J PHARM SCI-US, V93, P1804, DOI 10.1002/jps.20094
   Rinehart J, 2003, AM J CLIN ONCOL-CANC, V26, P448, DOI 10.1097/01.coc.0000027268.23258.7D
   Rinehart JJ, 1997, CANCER BIOTHER RADIO, V12, P101, DOI 10.1089/cbr.1997.12.101
   SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283
   Simonsen L, 2004, DRUG DEV IND PHARM, V30, P1095, DOI 10.1081/DDC-200040297
   Sinha R, 2006, MOL CANCER THER, V5, P1909, DOI 10.1158/1535-7163.MCT-06-0141
   Teshima M, 2004, J CONTROL RELEASE, V97, P211, DOI 10.1016/j.jconrel.2004.03.011
   Wang H, 2004, CANCER CHEMOTH PHARM, V53, P459, DOI 10.1007/s00280-003-0759-9
   Wang H, 2004, CLIN CANCER RES, V10, P1633, DOI 10.1158/1078-0432.CCR-0829-3
   Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914
   Yokoyama K, 1996, ADV DRUG DELIVER REV, V20, P195, DOI 10.1016/0169-409X(95)00122-N
   [张海艳 Zhang Haiyan], 2004, [波谱学杂志, Chinese Journal of Magnetic Resonance], V21, P405
   Zhang Z, 2006, J CONTROL RELEASE, V111, P263, DOI 10.1016/j.jconrel.2005.12.001
NR 36
TC 22
Z9 23
U1 1
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 1550-7416
J9 AAPS J
PD MAR
PY 2008
VL 10
IS 1
BP 133
EP 140
DI 10.1208/s12248-008-9013-z
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 291LG
UT WOS:000255198200014
PM 18446513
OA green_published
DA 2018-03-20
ER

PT J
AU Chen, ZQ
   Chen, T
   Sun, XH
   Hinds, BJ
AF Chen, Zhiqiang
   Chen, Tao
   Sun, Xinghua
   Hinds, Bruce J.
TI Dynamic Electrochemical Membranes for Continuous Affinity Protein
   Separation
SO ADVANCED FUNCTIONAL MATERIALS
LA English
DT Article
ID SELF-ASSEMBLED MONOLAYERS; NANOPOROUS MEMBRANES; NANOTUBE MEMBRANES;
   ULTRAFILTRATION; PURIFICATION; FRACTIONATION; OPPORTUNITIES;
   THERAPEUTICS; FILTRATION; TRANSPORT
AB A membrane system with nanometer-scale thick electrodes is able to selectively bind genetically modified proteins and pump them across the membrane with sequential voltage pulses. The electrodes are located at the first 20 nm of pore entrances to specifically capture targeted proteins and block non-specific protein transport through the pores during the binding cycle. During the release cycle, concentration of imidazole is controlled to keep the pore blocked while releasing proteins at the bottom edge of the electrode. A separation factor for GFP:BSA of 16 was achieved with observed GFP electrophoretic mobility of 2.54 x 10(-6) cm(2) V-1 s(-1). This non-optimized system with a membrane area of 0.75 cm(2) has the same throughput as 1 mL of commercially available chromatography columns showing viability as a continuous process. This system will enable continuous separation of expressed proteins directly from fermentation broths dramatically simplifying the separation process as well as reducing bio-pharmaceutical production costs.
C1 [Chen, Zhiqiang; Chen, Tao; Sun, Xinghua; Hinds, Bruce. J.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Chen, ZQ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM bjhinds@engr.uky.edu
RI chen, zhiqiang/O-5564-2016
FU NIH NIDA [5R01DA018822-05]; DARPA [W911NF-09-1-0267]
FX The authors thank the Center for Nanoscale Science and Engineering for
   critical infrastructure. This work was supported by NIH NIDA,
   #5R01DA018822-05 and DARPA, W911NF-09-1-0267.
CR Adebuer A., 2004, LANGMUIR, V20, P8243
   Cheang BL, 2004, J MEMBRANE SCI, V231, P159, DOI 10.1016/j.memsci.2003.11.014
   Chun KY, 2002, LANGMUIR, V18, P4653, DOI 10.1021/la011250b
   Ghosh R, 2000, J MEMBRANE SCI, V167, P47, DOI 10.1016/S0376-7388(99)00275-6
   Ghosh R, 2002, J CHROMATOGR A, V952, P13, DOI 10.1016/S0021-9673(02)00057-2
   Hinds B, 2012, CURR OPIN SOLID ST M, V16, P1, DOI 10.1016/j.cossms.2011.05.003
   Huisman IH, 2000, J MEMBRANE SCI, V179, P79, DOI 10.1016/S0376-7388(00)00501-9
   Jain P, 2010, BIOMACROMOLECULES, V11, P1019, DOI 10.1021/bm9014792
   Jirage KB, 1997, SCIENCE, V278, P655, DOI 10.1126/science.278.5338.655
   Kowalczyk S. W., 2011, TRENDS BIOTECHNOL, V29, P608
   Lam P, 1999, J ELECTROCHEM SOC, V146, P2517, DOI 10.1149/1.1391964
   Leader B, 2008, NAT REV DRUG DISCOV, V7, P21, DOI 10.1038/nrd2399
   Losic D, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/24/245704
   Love JC, 2005, CHEM REV, V105, P1103, DOI 10.1021/cr0300789
   Luo QZ, 2001, J CHROMATOGR A, V926, P255, DOI 10.1016/S0021-9673(01)01055-X
   Osmanbeyoglu HU, 2009, J MEMBRANE SCI, V343, P1, DOI 10.1016/j.memsci.2009.07.027
   Pavlou AK, 2004, NAT BIOTECHNOL, V22, P1513, DOI 10.1038/nbt1204-1513
   Savariar EN, 2008, NAT NANOTECHNOL, V3, P112, DOI 10.1038/nnano.2008.6
   SCHMITT J, 1993, MOL BIOL REP, V18, P223, DOI 10.1007/BF01674434
   Steinbrecht RA, 1997, INT J INSECT MORPHOL, V26, P229, DOI 10.1016/S0020-7322(97)00024-X
   Striemer CC, 2007, NATURE, V445, P749, DOI 10.1038/nature05532
   Sun XH, 2011, LANGMUIR, V27, P3150, DOI 10.1021/la104242p
   Ueda EKM, 2003, J CHROMATOGR A, V988, P1, DOI 10.1016/S0021-9673(02)02057-5
   Walsh G, 2010, NAT BIOTECHNOL, V28, P917, DOI 10.1038/nbt0910-917
   Wu J, 2012, NAT NANOTECHNOL, V7, P133, DOI [10.1038/nnano.2011.240, 10.1038/NNANO.2011.240]
   Yu SF, 2003, ANAL CHEM, V75, P1239, DOI 10.1021/ac020711a
   Yu SF, 2001, NANO LETT, V1, P495, DOI 10.1021/nl010044l
   Yusko EC, 2011, NAT NANOTECHNOL, V6, P253, DOI 10.1038/nnano.2011.12
   Zydney AL, 1998, INT DAIRY J, V8, P243, DOI 10.1016/S0958-6946(98)00045-4
NR 29
TC 8
Z9 8
U1 1
U2 47
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY
SN 1616-301X
EI 1616-3028
J9 ADV FUNCT MATER
JI Adv. Funct. Mater.
PD JUL 16
PY 2014
VL 24
IS 27
BP 4317
EP 4323
DI 10.1002/adfm.201303707
PG 7
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA AM2XC
UT WOS:000339713500013
PM 25383076
OA green_accepted
DA 2018-03-20
ER

PT J
AU Chin-Chan, M
   Segovia, J
   Quintanar, L
   Arcos-Lopez, T
   Hersh, LB
   Chow, KM
   Rodgers, DW
   Quintanilla-Vega, B
AF Chin-Chan, Miguel
   Segovia, Jose
   Quintanar, Liliana
   Arcos-Lopez, Trinidad
   Hersh, Louis B.
   Chow, K. Martin
   Rodgers, David W.
   Quintanilla-Vega, Betzabet
TI Mercury Reduces the Enzymatic Activity of Neprilysin in Differentiated
   SH-SY5Y Cells
SO TOXICOLOGICAL SCIENCES
LA English
DT Article
DE neprilysin; mercury; lead; beta-amyloid peptide; Alzheimer's disease;
   amyloid precursor protein; retinoic acid
ID AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; A-BETA;
   NEUROBLASTOMA-CELLS; INORGANIC MERCURY; GENE-EXPRESSION; RETINOIC ACID;
   BRAIN; EXPOSURE; ACCUMULATION
AB Levels of amyloid beta (A beta) in the central nervous system are regulated by the balance between its synthesis and degradation. Neprilysin (NEP) is associated with Alzheimer's disease (AD) by its ability to degrade A beta. Some studies have involved the exposure to mercury (Hg) in AD pathogenesis; therefore, our aim was to investigate the effects on the anabolism and catabolism of A beta in differentiated SH-SY5Y cells incubated with 1-20 mu M of Hg. Exposure to 20 A mu M of Hg induced an increase in A beta-42 secretion, but did not increase the expression of the amyloid precursor protein (APP). Hg incubation (10 and 20 A mu M) increased NEP protein levels; however, it did not change NEP mRNA levels nor the levels of the amyloid intracellular domain peptide, a protein fragment with transcriptional activity. Interestingly, Hg reduced NEP activity at 10 and 20 A mu M, and circular dichroism analysis using human recombinant NEP showed conformational changes after incubation with molar equivalents of Hg. This suggests that the Hg-induced inhibition of NEP activity may be mediated by a conformational change resulting in reduced A beta-42 degradation. Finally, the comparative effects of lead (Pb, 50 mu M) were evaluated. We found a significant increase in A beta-42 levels and a dramatic increase in APP protein levels; however, no alteration in NEP levels was observed nor in the enzymatic activity of this metalloprotease, despite the fact that Pb slightly modified the rhNEP conformation. Overall, our data suggest that Hg and Pb increase A beta levels by different mechanisms.
C1 [Chin-Chan, Miguel; Quintanilla-Vega, Betzabet] Dept Toxicol, Mexico City 07360, DF, Mexico.
   [Segovia, Jose] CINVESTAV, Dept Physiol Biophys & Neurosc, Mexico City 07360, DF, Mexico.
   [Quintanar, Liliana; Arcos-Lopez, Trinidad] CINVESTAV, Dept Chem, Mexico City 07360, DF, Mexico.
   [Hersh, Louis B.; Chow, K. Martin; Rodgers, David W.] Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA.
   [Hersh, Louis B.; Chow, K. Martin; Rodgers, David W.] Univ Kentucky, Struct Biol Ctr, Lexington, KY 40536 USA.
RP Quintanilla-Vega, B (reprint author), Dept Toxicol, Ave IPN 2508, Mexico City 07360, DF, Mexico.
EM mquintan@cinvestav.mx
RI Segovia, Jose/C-9277-2011
OI Segovia, Jose/0000-0001-8215-4772; Chin-Chan, Miguel/0000-0001-8549-5134
FU CONACYT-Mexico [127357]
FX This study was partially supported by CONACYT-Mexico grant # 127357
   given to J.S.
CR Alattia JR, 2011, FASEB J, V25, P2287, DOI 10.1096/fj.10-174078
   Arima J, 2009, BIOCHIMIE, V91, P568, DOI 10.1016/j.biochi.2009.01.015
   ARMSTRONG RA, 1994, NEUROSCI LETT, V169, P133, DOI 10.1016/0304-3940(94)90374-3
   Atwood CS, 1998, J BIOL CHEM, V273, P12817, DOI 10.1074/jbc.273.21.12817
   Beckman M, 1997, NEUROSCI LETT, V221, P73, DOI 10.1016/S0304-3940(96)13292-4
   Belyaev ND, 2009, EMBO REP, V10, P94, DOI 10.1038/embor.2008.222
   Cheung YT, 2009, NEUROTOXICOLOGY, V30, P127, DOI 10.1016/j.neuro.2008.11.001
   Clarkson TW, 2006, CRIT REV TOXICOL, V36, P609, DOI 10.1080/10408440600845619
   Culpan D, 2011, INT J MOL EPIDEMIOL, V2, P409
   Dale GE, 2000, ACTA CRYSTALLOGR D, V56, P894, DOI 10.1107/S0907444900004947
   Duce JA, 2010, PROG NEUROBIOL, V92, P1, DOI 10.1016/j.pneurobio.2010.04.003
   El-Amouri SS, 2008, AM J PATHOL, V172, P1342, DOI 10.2353/ajpath.2008.070620
   FRIBERG L, 1989, BIOL TRACE ELEM RES, V21, P201, DOI 10.1007/BF02917253
   Fujimura M, 2009, NEUROTOXICOLOGY, V30, P1000, DOI 10.1016/j.neuro.2009.08.001
   Godfrey Michael E, 2003, J Alzheimers Dis, V5, P189
   Grasso G, 2011, CHEM-EUR J, V17, P2752, DOI 10.1002/chem.201002809
   HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067
   Hock C, 1998, J NEURAL TRANSM, V105, P59, DOI 10.1007/s007020050038
   Holback S, 2008, BIOCHEM BIOPH RES CO, V365, P298, DOI 10.1016/j.bbrc.2007.10.167
   Huang H, 2011, NEUROTOXICOLOGY, V32, P300, DOI 10.1016/j.neuro.2011.02.001
   Hussain S, 1999, J ENVIRON SCI HEAL B, V34, P645, DOI 10.1080/03601239909373219
   Iwata N, 2005, PHARMACOL THERAPEUT, V108, P129, DOI 10.1016/j.pharmthera.2005.03.010
   Kim DK, 2014, J TOXICOL SCI, V39, P625, DOI 10.2131/jts.39.625
   Leong CCW, 2001, NEUROREPORT, V12, P733, DOI 10.1097/00001756-200103260-00024
   LI CW, 1995, METHOD ENZYMOL, V248, P253
   Li XL, 2012, EXP THER MED, V4, P125, DOI 10.3892/etm.2012.562
   Liu FL, 2014, J TRACE ELEM MED BIO, V28, P227, DOI 10.1016/j.jtemb.2014.01.002
   Miners JS, 2009, J NEUROPATH EXP NEUR, V68, P902, DOI 10.1097/NEN.0b013e3181afe475
   Mohajeri MH, 2002, J BIOL CHEM, V277, P35460, DOI 10.1074/jbc.M202899200
   Monnet-Tschudi Florianne, 2006, Reviews on Environmental Health, V21, P105
   Mutter J, 2010, J ALZHEIMERS DIS, V22, P357, DOI 10.3233/JAD-2010-100705
   Olivieri G, 2000, J NEUROCHEM, V74, P231, DOI 10.1046/j.1471-4159.2000.0740231.x
   Petroni D, 2012, ENVIRON TOXICOL, V27, P549, DOI 10.1002/tox.20672
   Rajanna B, 1995, TOXICOL LETT, V81, P197, DOI 10.1016/0378-4274(95)03433-1
   Santos AN, 2002, BIOCHEM BIOPH RES CO, V295, P423
   Shapiro AM, 2008, CHEMOSPHERE, V74, P112, DOI 10.1016/j.chemosphere.2008.09.019
   Shinall H, 2005, BIOCHEMISTRY-US, V44, P15345, DOI 10.1021/bi050650l
   Song Ji-Won, 2013, Toxicol Res, V29, P235, DOI 10.5487/TR.2013.29.4.235
   Tai HC, 2006, J PHYS CHEM A, V110, P452, DOI 10.1021/jp0529826
   Thinakaran G, 2008, J BIOL CHEM, V283, P29615, DOI 10.1074/jbc.R800019200
   Turner AJ, 2001, BIOESSAYS, V23, P261, DOI 10.1002/1521-1878(200103)23:3<261::AID-BIES1036>3.0.CO;2-K
   VAHTER ME, 1995, TOXICOL APPL PHARM, V134, P273, DOI 10.1006/taap.1995.1193
   Wang DS, 2005, J NEUROPATH EXP NEUR, V64, P378, DOI 10.1093/jnen/64.5.378
   WENSTRUP D, 1990, BRAIN RES, V533, P125, DOI 10.1016/0006-8993(90)91804-P
   Wojcik DP, 2006, NEUROENDOCRINOL LETT, V27, P415
   Wu J, 2008, J NEUROSCI, V28, P3, DOI 10.1523/JNEUROSCI.4405-07.2008
   Yasojima K, 2001, NEUROSCI LETT, V297, P97, DOI 10.1016/S0304-3940(00)01675-X
NR 47
TC 4
Z9 4
U1 0
U2 10
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1096-6080
EI 1096-0929
J9 TOXICOL SCI
JI Toxicol. Sci.
PD MAY
PY 2015
VL 145
IS 1
BP 128
EP 137
DI 10.1093/toxsci/kfv037
PG 10
WC Toxicology
SC Toxicology
GA CJ1YL
UT WOS:000355280900014
PM 25673500
OA gold
DA 2018-03-20
ER

PT J
AU Frimpong, RA
   Dou, J
   Pechan, M
   Hilt, JZ
AF Frimpong, Reynolds A.
   Dou, Jian
   Pechan, Michael
   Hilt, J. Zach
TI Enhancing remote controlled heating characteristics in hydrophilic
   magnetite nanoparticles via facile co-precipitation
SO JOURNAL OF MAGNETISM AND MAGNETIC MATERIALS
LA English
DT Article
DE Magnetic nanoparticle; Iron oxide; Specific absorption rate;
   Functionalization
ID IRON-OXIDE NANOPARTICLES; PARTICLES; HYPERTHERMIA; NANOCRYSTALS;
   DELIVERY; AGENTS
AB Citric acid coated magnetite nanoparticles were synthesized using a one-step and two-step coprecipitation method at different temperatures. The stability of the nanoparticles in aqueous media was compared. The magnetic heating characteristics in an alternating magnetic field we reexamined and specific absorption rates were determined. The nanoparticles were characterized by various techniques (Fourier transform infrared, UV spectrophotometry, thermogravimetric analysis, dynamic light scattering, transmission electron microscopy, X-ray diffraction and vibrating sample magnetometry). The temperature of synthesis and mode of functionalizing the particles affected their physical and magnetic properties. Higher temperatures led to increased specific absorption rates for both methods but more stable hydrophilic superparamagnetic nanoparticles were obtained in the one-step method. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Frimpong, Reynolds A.; Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Dou, Jian; Pechan, Michael] Miami Univ, Dept Phys, Oxford, OH 45056 USA.
RP Hilt, JZ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM hilt@engr.uky.edu
FU National Science Foundation [ECS-0508254, CTS-0609117]; US Department of
   Energy [FG02-86ER45281]
FX This work was supported in part by the National Science Foundation under
   Grant numbers ECS-0508254 (NSF NER), CTS-0609117 (NSF NIRT), and at
   Miami University by US Department of Energy Grant FG02-86ER45281
CR Baker I, 2006, J APPL PHYS, V99
   BEE A, 1995, J MAGN MAGN MATER, V149, P6, DOI 10.1016/0304-8853(95)00317-7
   Daou TJ, 2008, CHEM MATER, V20, P5869, DOI 10.1021/cm801405n
   Dennis CL, 2008, J APPL PHYS, V103, DOI 10.1063/1.2837647
   FONER S, 1959, REV SCI INSTRUM, V30, P548, DOI 10.1063/1.1716679
   Fried T, 2001, ADV MATER, V13, P1158, DOI 10.1002/1521-4095(200108)13:15<1158::AID-ADMA1158>3.0.CO;2-6
   Gupta AK, 2005, BIOMATERIALS, V26, P3995, DOI 10.1016/j.biomaterials.2004.10.012
   Hilger I, 2002, ACAD RADIOL, V9, P198, DOI 10.1016/S1076-6332(03)80171-X
   Hu FQ, 2007, J COLLOID INTERF SCI, V311, P469, DOI 10.1016/j.jcis.2007.03.023
   Hui C, 2008, J PHYS CHEM C, V112, P11336, DOI 10.1021/jp801632p
   Jain TK, 2005, MOL PHARMACEUT, V2, P194, DOI 10.1021/mp0500014
   Kim DK, 2001, J MAGN MAGN MATER, V225, P30, DOI 10.1016/S0304-8853(00)01224-5
   Kodama RH, 1999, J MAGN MAGN MATER, V200, P359, DOI 10.1016/S0304-8853(99)00347-9
   Liu XQ, 2006, J MAGN MAGN MATER, V306, P248, DOI 10.1016/j.jmmm.2006.03.049
   MASSART R, 1981, IEEE T MAGN, V17, P1247, DOI 10.1109/TMAG.1981.1061188
   Moroz P, 2002, INT J HYPERTHER, V18, P267, DOI 10.1080/02656730110108785
   Pardoe H, 2001, J MAGN MAGN MATER, V225, P41, DOI 10.1016/S0304-8853(00)01226-9
   Pradhan N, 2007, J AM CHEM SOC, V129, P9500, DOI 10.1021/ja0725089
   Racuciu M, 2006, EUR PHYS J E, V21, P117, DOI 10.1140/epje/i2006-10051-y
   Sun C, 2008, ADV DRUG DELIVER REV, V60, P1252, DOI 10.1016/j.addr.2008.03.018
   Tartaj P, 2003, J PHYS D APPL PHYS, V36, pR182, DOI 10.1088/0022-3727/36/13/202
   Taupitz M, 2004, INVEST RADIOL, V39, P394, DOI 10.1097/01.rli.0000129472.45832.b0
   WEISSLEDER R, 1990, RADIOLOGY, V175, P489, DOI 10.1148/radiology.175.2.2326474
   Zhang J, 2007, ACTA BIOMATER, V3, P838, DOI 10.1016/j.actbio.2007.05.011
   Zhang LY, 2007, J MAGN MAGN MATER, V311, P228, DOI 10.1016/j.jmmm.2006.11.179
NR 25
TC 42
Z9 42
U1 7
U2 36
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-8853
EI 1873-4766
J9 J MAGN MAGN MATER
JI J. Magn. Magn. Mater.
PD FEB
PY 2010
VL 322
IS 3
BP 326
EP 331
DI 10.1016/j.jmmm.2009.09.050
PG 6
WC Materials Science, Multidisciplinary; Physics, Condensed Matter
SC Materials Science; Physics
GA 516JC
UT WOS:000271537200009
DA 2018-03-20
ER

PT J
AU Eckman, AM
   Tsakalozou, E
   Kang, NY
   Ponta, A
   Bae, Y
AF Eckman, Allison M.
   Tsakalozou, Eleftheria
   Kang, Nayon Y.
   Ponta, Andrei
   Bae, Younsoo
TI Drug Release Patterns and Cytotoxicity of PEG-poly(aspartate) Block
   Copolymer Micelles in Cancer Cells
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE cytotoxicity; doxorubicin; drug delivery; intracellular drug uptake;
   polymer micelles
ID POLYMERIC MICELLES; ANTICANCER AGENT; DELIVERY-SYSTEMS; SOLID TUMORS;
   IONIC CORES; ADRIAMYCIN; NANOCARRIERS; DOXORUBICIN; EFFICACY; CARRIERS
AB To test physicochemical and biological properties of PEG-poly(aspartate) [PEG-p(Asp)] block copolymer micelles entrapping doxorubicin hydrochloride (DOX) through ionic interaction.
   PEG-p(Asp) was synthesized from 5 kDa PEG and 20 Asp units. Carboxyl groups of p(Asp) were present as benzyl ester [PEG-p(Asp/Bz)], sodium salt [PEG-p(Asp/Na)] or free acid [PEG-p(Asp/H)]. Block copolymers and DOX were mixed at various ratios to prepare polymer micelles, which were subsequently characterized to determine particle size, drug loading and release patterns, and cytotoxicity against prostate (PC3 and DU145) and lung (A549) cancer cell lines.
   PEG-p(Asp/Bz), Na- and H-micelles entrapped 1.1, 56.8 and 40.6 wt.% of DOX, respectively. Na- and H-micelles (< 100 nm) showed time-dependent DOX release at pH 7.4, which was accelerated at pH 5.0. Na-micelles were most stable at pH 7.4, retaining 31.8% of initial DOX for 48 h. Cytotoxicity of Na-micelles was 23.2% (A549), 28.5% (PC3) and 45.9% (DU145) more effective than free DOX.
   Ionic interaction appeared to entrap DOX efficiently in polymer micelles from PEG-p(Asp) block copolymers. Polymer micelles possessing counter ions (Na) of DOX in the core were the most stable, releasing drugs for prolonged time in a pH-dependent manner, and suppressing cancer cells effectively.
C1 [Eckman, Allison M.; Tsakalozou, Eleftheria; Kang, Nayon Y.; Ponta, Andrei; Bae, Younsoo] Univ Kentucky, Dept Pharmaceut Sci, Coll Pharm, Lexington, KY 40536 USA.
RP Bae, Y (reprint author), Univ Kentucky, Dept Pharmaceut Sci, Coll Pharm, 789 S Limestone, Lexington, KY 40536 USA.
EM younsoo.bae@uky.edu
FU Kentucky Lung Cancer Research Program
FX Authors acknowledge financial support provided by the Kentucky Lung
   Cancer Research Program.
CR Alani AWG, 2010, BIOMATERIALS, V31, P1765, DOI 10.1016/j.biomaterials.2009.11.038
   Alexis Frank, 2010, Handb Exp Pharmacol, P55, DOI 10.1007/978-3-642-00477-3_2
   Allen C, 1999, COLLOID SURFACE B, V16, P3, DOI 10.1016/S0927-7765(99)00058-2
   Bae Y, 2003, ANGEW CHEM INT EDIT, V42, P4640, DOI 10.1002/anie.200250653
   Bae Y, 2005, BIOCONJUGATE CHEM, V16, P122, DOI 10.1021/bc0498166
   Bae Y, 2007, BIOCONJUGATE CHEM, V18, P1131, DOI 10.1021/bc060401p
   Bae Y, 2010, PHARM RES-DORDR, V27, P2421, DOI 10.1007/s11095-010-0234-3
   Bae Y, 2009, ADV DRUG DELIVER REV, V61, P768, DOI 10.1016/j.addr.2009.04.016
   Blanco E, 2011, CANCER SCI, V102, P1247, DOI 10.1111/j.1349-7006.2011.01941.x
   Bontha S, 2006, J CONTROL RELEASE, V114, P163, DOI 10.1016/j.jconrel.2006.06.015
   Bures P, 2007, NANOTECHNOL THER, P349
   Chan JM, 2010, METHODS MOL BIOL, V624, P163, DOI 10.1007/978-1-60761-609-2_11
   Cukierman E, 2010, BIOCHEM PHARMACOL, V80, P762, DOI 10.1016/j.bcp.2010.04.020
   Dang TT, 2011, BIOMATERIALS, V32, P4464, DOI 10.1016/j.biomaterials.2011.02.048
   Devlin HL, 2008, MOL CANCER RES, V6, P808, DOI 10.1158/1541-7786.MCR-07-2027
   Grattoni A, 2011, PHARM RES-DORDR, V28, P292, DOI 10.1007/s11095-010-0195-6
   Greco F, 2007, J CONTROL RELEASE, V117, P28, DOI 10.1016/j.jconrel.2006.10.012
   Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020
   Howard MD, 2011, PHARM RES-DORDR, V28, P2435, DOI 10.1007/s11095-011-0470-1
   Jain RK, 1997, ADV DRUG DELIVER REV, V26, P71, DOI 10.1016/S0169-409X(97)00027-6
   Kataoka K, 2000, J CONTROL RELEASE, V64, P143, DOI 10.1016/S0168-3659(99)00133-9
   KATAOKA K, 1993, J CONTROL RELEASE, V24, P119
   Kim JO, 2010, BIOMACROMOLECULES, V11, P919, DOI 10.1021/bm9013364
   Kwon G, 1997, J CONTROL RELEASE, V48, P195, DOI 10.1016/S0168-3659(97)00039-4
   KWON GS, 1995, PHARMACEUT RES, V12, P192, DOI 10.1023/A:1016266523505
   KWON GS, 1994, J CONTROL RELEASE, V28, P334, DOI 10.1016/0168-3659(94)90203-8
   Lee HJ, 2010, THER DELIV, V1, P803, DOI 10.4155/TDE.10.70
   Levy-Nissenbaum E, 2008, TRENDS BIOTECHNOL, V26, P442, DOI 10.1016/j.tibtech.2008.04.006
   Liu JB, 2004, J PHARM SCI-US, V93, P132, DOI 10.1002/jps.10533
   Lvov YM, 2011, LANGMUIR, V27, P1212, DOI 10.1021/la1041635
   Maeda H, 2010, BIOCONJUGATE CHEM, V21, P797, DOI 10.1021/bc100070g
   Maruyama K, 2011, ADV DRUG DELIVER REV, V63, P161, DOI 10.1016/j.addr.2010.09.003
   Matsumura Y, 2009, CANCER SCI, V100, P572, DOI 10.1111/j.1349-7006.2009.01103.x
   Murakami M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001385
   Musacchio T, 2011, FRONT BIOSCI-LANDMRK, V16, P1388, DOI 10.2741/3795
   Nishiyama N, 2003, ADV EXP MED BIOL, V519, P155
   Oberoi HS, 2011, J CONTROL RELEASE, V153, P64, DOI 10.1016/j.jconrel.2011.03.028
   Park K, 2008, J CONTROL RELEASE, V130, P139, DOI 10.1016/j.jconrel.2008.07.028
   Pirollo KF, 2008, TRENDS BIOTECHNOL, V26, P552, DOI 10.1016/j.tibtech.2008.06.007
   Pommier Y, 2010, CHEM BIOL, V17, P421, DOI 10.1016/j.chembiol.2010.04.012
   Ponta A, 2010, PHARM RES-DORDR, V27, P2330, DOI 10.1007/s11095-010-0120-z
   Redon CE, 2010, CLIN CANCER RES, V16, P4532, DOI 10.1158/1078-0432.CCR-10-0523
   Robinson BW, 2008, BRIT J HAEMATOL, V141, P827, DOI 10.1111/j.1365-2141.2008.07100.x
   Ruenraroengsak P, 2010, J CONTROL RELEASE, V141, P265, DOI 10.1016/j.jconrel.2009.10.032
   SEIDLITS S, 2007, NANOTECHNOLOGY THERA, P317
   Shaheen FS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020311
   Torchilin V, 2011, ADV DRUG DELIVER REV, V63, P131, DOI 10.1016/j.addr.2010.03.011
   Urasaki Y, 2001, CANCER RES, V61, P1964
   van Vlerken LE, 2010, AAPS J, V12, P171, DOI 10.1208/s12248-010-9174-4
   Wong H., 2007, NANOTECHNOLOGY CANC, P741
   YOKOYAMA M, 1987, MAKROMOL CHEM-RAPID, V8, P431
   YOKOYAMA M, 1994, J CONTROL RELEASE, V32, P269, DOI 10.1016/0168-3659(94)90237-2
   Yokoyama M, 2010, EXPERT OPIN DRUG DEL, V7, P145, DOI 10.1517/17425240903436479
NR 53
TC 20
Z9 20
U1 2
U2 43
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
EI 1573-904X
J9 PHARM RES-DORDR
JI Pharm. Res.
PD JUL
PY 2012
VL 29
IS 7
BP 1755
EP 1767
DI 10.1007/s11095-012-0697-5
PG 13
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 958FN
UT WOS:000305222000005
PM 22322898
DA 2018-03-19
ER

PT J
AU Gutierrez, AM
   Dziubla, TD
   Hilt, JZ
AF Gutierrez, Angela M.
   Dziubla, Thomas D.
   Hilt, J. Zach
TI Recent advances on iron oxide magnetic nanoparticles as sorbents of
   organic pollutants in water and wastewater treatment
SO REVIEWS ON ENVIRONMENTAL HEALTH
LA English
DT Review
AB The constant growth in population worldwide over the past decades continues to put forward the need to provide access to safe, clean water to meet human needs. There is a need for cost-effective technologies for water and wastewater treatment that can meet the global demands and the rigorous water quality standards and at the same maximizing pollutant efficiency removal. Current remediation technologies have failed in keeping up with these factors without becoming cost-prohibitive. Most recently, nanotechnology has been sought as the best alternative to increase access to water supplies by remediating those already contaminated and offering ways to access unconventional sources. The use of iron oxide magnetic nanoparticles as nanoadsorbents has led way to a new class of magnetic separation strategies for water treatment. This review focuses on highlighting some of the most recent advances in core-shell iron oxide magnetic nanoparticles and nanocomposites containing iron oxide nanoparticles currently being developed for water and wastewater treatment of organic pollutants. We discuss the novelty of these novel materials and the insight gained from their advances that can help develop cost-effective reusable technologies for scale-up and commercial use.
C1 [Gutierrez, Angela M.; Dziubla, Thomas D.; Hilt, J. Zach] Univ Kentucky, Superfund Res Ctr, Lexington, KY 40536 USA.
   [Gutierrez, Angela M.; Dziubla, Thomas D.; Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Hilt, JZ (reprint author), Univ Kentucky, Superfund Res Ctr, Lexington, KY 40536 USA.; Hilt, JZ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM zach.hilt@uky.edu
FU National Institute of Environmental Health Sciences (NIEHS)
   [P42ES007380]
FX The project was supported by grant number P42ES007380 from the National
   Institute of Environmental Health Sciences (NIEHS).
CR Aggarwal BB, 2006, BIOCHEM PHARMACOL, V71, P1397, DOI 10.1016/j.bcp.2006.02.009
   Ahmaruzzaman M, 2008, ADV COLLOID INTERFAC, V143, P48, DOI 10.1016/j.cis.2008.07.002
   Ajayan PS, 2003, NANOCOMPOSITE SCI TE, P239
   Alsbaiee A, 2016, NATURE, V529, P190, DOI 10.1038/nature16185
   Arya V, 2016, MICROPOR MESOPOR MAT, V232, P273, DOI 10.1016/j.micromeso.2016.06.033
   Basnet M, 2013, ENVIRON SCI TECHNOL, V47, P13355, DOI 10.1021/es402619v
   Beless B, 2014, ENVIRON SCI TECHNOL, V48, P10372, DOI 10.1021/es502647n
   Bhandari R, 2016, MAT SCI ENG C-MATER, V67, P59, DOI 10.1016/j.msec.2016.04.093
   Bystrzejewski M, 2009, CARBON, V47, P1201, DOI 10.1016/j.carbon.2009.01.007
   Clark KK, 2012, WATER RES, V46, P635, DOI 10.1016/j.watres.2011.11.025
   Dang Viet D., 2012, American Journal of Environmental Sciences, V8, P11, DOI 10.3844/ajessp.2012.11.15
   Del Valle EMM, 2004, PROCESS BIOCHEM, V39, P1033, DOI 10.1016/S0032-9592(03)00258-9
   Fava F, 2003, BIOTECHNOL BIOENG, V81, P381, DOI 10.1002/bit.10579
   Geng ZG, 2012, J MATER CHEM, V22, P3527, DOI 10.1039/c2jm15544c
   Gomes HI, 2013, SCI TOTAL ENVIRON, V445, P237, DOI 10.1016/j.scitotenv.2012.11.098
   Hopf NB, 2009, SCI TOTAL ENVIRON, V407, P6109, DOI 10.1016/j.scitotenv.2009.08.035
   Huang YX, 2015, WATER RES, V80, P159, DOI 10.1016/j.watres.2015.05.011
   Huang YX, 2013, ACS SUSTAIN CHEM ENG, V1, P731, DOI 10.1021/sc400047q
   Jones KC, 1999, ENVIRON POLLUT, V100, P209, DOI 10.1016/S0269-7491(99)00098-6
   Landy D, 2012, ENVIRON CHEM LETT, V10, P225, DOI 10.1007/s10311-011-0351-1
   Li J, 2013, CHEM ENG J, V229, P296, DOI 10.1016/j.cej.2013.06.016
   Liu JF, 2008, ENVIRON SCI TECHNOL, V42, P6949, DOI 10.1021/es800924c
   Liu YQ, 2005, CHEM MATER, V17, P5315, DOI 10.1021/cm0511217
   Lowry GV., 2007, ENV NANOTECHNOLOGY, P297
   Masciangioli T, 2003, ENVIRON SCI TECHNOL, V37, p102A, DOI 10.1021/es0323998
   Ormad MP, 2008, CHEMOSPHERE, V71, P97, DOI 10.1016/j.chemosphere.2007.10.006
   Qu XL, 2013, ACCOUNTS CHEM RES, V46, P834, DOI 10.1021/ar300029v
   Redding AM, 2009, WATER RES, V43, P3849, DOI 10.1016/j.watres.2009.05.026
   Richardson SD, 2014, ANAL CHEM, V86, P2813, DOI 10.1021/ac500508t
   Saleh N, 2007, ENVIRON ENG SCI, V24, P45, DOI 10.1089/ees.2007.24.45
   Schwartz E, 2001, BIODEGRADATION, V12, P201, DOI 10.1023/A:1013136524377
   Tang SCN, 2013, WATER RES, V47, P2613, DOI 10.1016/j.watres.2013.02.039
   Vince F, 2008, DESALINATION, V220, P37, DOI 10.1016/j.desal.2007.01.021
   Wang ML, 2015, J COLLOID INTERF SCI, V447, P1, DOI 10.1016/j.jcis.2015.01.061
   Wang P, 2009, J AM CHEM SOC, V131, P182, DOI 10.1021/ja806556a
   WanNgah W. S., 2011, CARBOHYD POLYM, V83, P1446, DOI DOI 10.1016/J.CARBPOL.2010.11.004
   Wilken R, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-12
   Xu JS, 2012, J COLLOID INTERF SCI, V385, P58, DOI 10.1016/j.jcis.2012.06.082
   Zhao ZS, 2015, AQUANANOTECHNOLOGY: GLOBAL PROSPECTS, P265
   Zhou CG, 2016, REACT FUNCT POLYM, V100, P97, DOI 10.1016/j.reactfunctpolym.2015.11.010
NR 40
TC 2
Z9 2
U1 5
U2 9
PU WALTER DE GRUYTER GMBH
PI BERLIN
PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY
SN 0048-7554
EI 2191-0308
J9 REV ENVIRON HEALTH
JI Rev. Environ. Health
PD MAR
PY 2017
VL 32
IS 1-2
SI SI
BP 111
EP 117
DI 10.1515/reveh-2016-0063
PG 7
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA EN5GJ
UT WOS:000396033300015
PM 28231068
DA 2018-03-20
ER

PT J
AU Meenach, SA
   Vogt, FG
   Anderson, KW
   Hilt, JZ
   McGarry, RC
   Mansour, HM
AF Meenach, Samantha A.
   Vogt, Frederick G.
   Anderson, Kimberly W.
   Hilt, J. Zach
   McGarry, Ronald C.
   Mansour, Heidi M.
TI Design, physicochemical characterization, and optimization of organic
   solution advanced spray-dried inhalable dipalmitoylphosphatidylcholine
   (DPPC) and dipalmitoylphosphatidylethanolamine poly(ethylene glycol)
   (DPPE-PEG) microparticles and nanoparticles for targeted respiratory
   nanomedicine delivery as dry powder inhalation aerosols
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE biocompatible biodegradable lipopolymers; lung surfactant; pulmonary
   delivery; self-assemblies; solid-state; lipospheres
ID PULMONARY DRUG-DELIVERY; AIR-WATER-INTERFACE; ACUTE LUNG INJURY;
   THERAPEUTIC EFFECTIVENESS; NANOCARRIER SYSTEMS; PLGA MICROPARTICLES;
   INHALED PARTICLES; PHASE-TRANSITIONS; SUSTAINED-RELEASE; BILAYER
AB Novel advanced spray-dried and co-spray-dried inhalable lung surfactant-mimic phospholipid and poly(ethylene glycol) (PEG)ylated lipopolymers as microparticulate/nanoparticulate dry powders of biodegradable biocompatible lipopolymers were rationally formulated via an organic solution advanced spray-drying process in closed mode using various phospholipid formulations and rationally chosen spray-drying pump rates. Ratios of dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylethanolamine PEG (DPPE-PEG) with varying PEG lengths were mixed in a dilute methanol solution. Scanning electron microscopy images showed the smooth, spherical particle morphology of the inhalable particles. The size of the particles was statistically analyzed using the scanning electron micrographs and SigmaScan (R) software and were determined to be 600 nm to 1.2 mu m in diameter, which is optimal for deep-lung alveolar penetration. Differential scanning calorimetry (DSC) and powder X-ray diffraction (PXRD) were performed to analyze solid-state transitions and long-range molecular order, respectively, and allowed for the confirmation of the presence of phospholipid bilayers in the solid state of the particles. The residual water content of the particles was very low, as quantified analytically via Karl Fischer titration. The composition of the particles was confirmed using attenuated total-reflectance Fourier-transform infrared (ATR-FTIR) spectroscopy and confocal Raman microscopy (CRM), and chemical imaging confirmed the chemical homogeneity of the particles. The dry powder aerosol dispersion properties were evaluated using the Next Generation Impactor (TM) (NGI (TM)) coupled with the HandiHaler (R) dry powder inhaler device, where the mass median aerodynamic diameter from 2.6 to 4.3 mu m with excellent aerosol dispersion performance, as exemplified by high values of emitted dose, fine particle fraction, and respirable fraction. Overall, it was determined that the pump rates defined in the spray-drying process had a significant effect on the solid-state particle properties and that a higher pump rate produced the most optimal system. Advanced dry powder inhalers of inhalable lipopolymers for targeted dry powder inhalation delivery were successfully achieved.
C1 [Meenach, Samantha A.; Mansour, Heidi M.] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Drug Dev Div, Lexington, KY 40506 USA.
   [Meenach, Samantha A.; Anderson, Kimberly W.; Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY USA.
   [Vogt, Frederick G.] GlaxoSmithKline, Analyt Sci, Prod Dev, King Of Prussia, PA USA.
   [Anderson, Kimberly W.; Hilt, J. Zach; Mansour, Heidi M.] Univ Kentucky, Ctr Membrane Sci, Lexington, KY 40506 USA.
   [McGarry, Ronald C.] Univ Kentucky, Coll Med, Dept Radiat Med, Lexington, KY USA.
RP Mansour, HM (reprint author), Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Drug Dev Div, Lexington, KY 40506 USA.
EM heidi.mansour@uky.edu
RI Meenach, Samantha/F-7542-2014
FU National Cancer Institute (NCI) [R25CA153954]; National Cancer Institute
   Cancer Nanotechnology Training Center (NCI-CNTC) Postdoctoral
   Traineeship
FX The authors gratefully acknowledge financial support from the National
   Cancer Institute (NCI) grant number R25CA153954 and a National Cancer
   Institute Cancer Nanotechnology Training Center (NCI-CNTC) Postdoctoral
   Traineeship awarded to SAM. The content is solely the responsibility of
   the authors and does not necessarily represent the official views of the
   National Cancer Institute or the National Institutes of Health. The
   authors thank Dr Tonglei Li for PXRD and HSM access, and Dr J Zach Hilt
   for ATR-FTIR access.
CR Alves GP, 2004, POWDER TECHNOL, V145, P139, DOI 10.1016/j.powtec.2004.06.008
   Arnold MM, 2007, J CONTROL RELEASE, V121, P100, DOI 10.1016/j.jconrel.2007.05.039
   Azarmi S, 2008, ADV DRUG DELIVER REV, V60, P863, DOI 10.1016/j.addr.2007.11.006
   Bi R, 2008, J DRUG TARGET, V16, P639, DOI [10.1080/10611860802201134, 10.1080/10611860802201134 ]
   Bosquillon C, 2001, J CONTROL RELEASE, V70, P329, DOI 10.1016/S0168-3659(00)00362-X
   Cartiera MS, 2010, MOL PHARMACEUT, V7, P86, DOI 10.1021/mp900138a
   Carvalho TC, 2011, J AEROSOL MED PULM D, V24, P61, DOI 10.1089/jamp.2009.0794
   Cruz L, 2011, J CONTROL RELEASE, V152, P370, DOI 10.1016/j.jconrel.2011.02.030
   Edwards DA, 1998, J APPL PHYSIOL, V85, P379
   EDWARDS DA, 1995, J AEROSOL SCI, V26, P293, DOI 10.1016/0021-8502(94)00101-4
   Ganguly S., 2008, J AEROSOL MED PULM D, V23, P181
   Gautam A, 2003, CURR CANCER DRUG TAR, V3, P57
   Gill S, 2007, J BIOMED NANOTECHNOL, V3, P107, DOI 10.1166/jbn.2007.015
   Hickey A.J., 2009, MODERN PHARM, V2, P191
   Hickey A.J., 2008, MODIFIED RELEASE DRU, V2, P573
   Hickey AJ, 2007, J PHARM SCI-US, V96, P1282, DOI 10.1002/jps.20916
   Ishihara K, 1998, J BIOMED MATER RES, V39, P323, DOI 10.1002/(SICI)1097-4636(199802)39:2<323::AID-JBM21>3.3.CO;2-0
   Jones BG, 2002, INT J PHARM, V236, P65, DOI 10.1016/S0378-5173(02)00016-9
   Kang E, 2007, J CONTROL RELEASE, V122, P261, DOI 10.1016/j.jconrel.2007.05.007
   KIKUCHI H, 1991, CHEM PHARM BULL, V39, P1522
   Labiris NR, 2003, BRIT J CLIN PHARMACO, V56, P600, DOI 10.1046/j.1365-2125.2003.01893.x
   Labiris NR, 2003, BRIT J CLIN PHARMACO, V56, P588, DOI 10.1046/j.1365-2125.2003.01892.x
   Lai SK, 2007, P NATL ACAD SCI USA, V104, P1482, DOI 10.1073/pnas.0608611104
   Laube BL, 2011, EUR RESPIR J, V37, P1308, DOI 10.1183/09031936.00166410
   Li X, 2011, PEDIATR PULM, P346
   Li XJ, 2011, AAPS PHARMSCITECH, V12, P1420, DOI 10.1208/s12249-011-9704-0
   Lim SB, 2011, PHARM RES-DORDR, V28, P662, DOI 10.1007/s11095-010-0322-4
   MABREY S, 1976, P NATL ACAD SCI USA, V73, P3862, DOI 10.1073/pnas.73.11.3862
   Mansour H, 2001, LANGMUIR, V17, P6622, DOI 10.1021/la0108454
   Mansour HM, 2008, MOL PHARMACEUT, V5, P681, DOI 10.1021/mp700123p
   Mansour HM, 2007, LANGMUIR, V23, P3809, DOI 10.1021/la063053o
   Mansour HM, 2007, J PHARM SCI-US, V96, P377, DOI 10.1002/jps.20810
   Mansour HM, 2010, INT J MOL SCI, V11, P3298, DOI 10.3390/ijms11093298
   Mansour HM, 2009, INT J NANOMED, V4, P299
   Mansour HM, 2011, LIPIDS NANOTECHNOLOG, P221
   Masters K., 1991, SPRAY DRYING HDB
   Zhang J, 2012, ACTA PHYS-CHIM SIN, V28, P290, DOI [10.1021/mp2003785, 10.3866/PKU.WHXB201112121]
   Oh YJ, 2011, J CONTROL RELEASE, V150, P56, DOI 10.1016/j.jconrel.2010.11.001
   Park CW, 2012, ADV DRUG DELIVER REV, V64, P344, DOI 10.1016/j.addr.2011.08.004
   Patton JS, 2007, NAT REV DRUG DISCOV, V6, P67, DOI 10.1038/nrd2153
   Rhee YS, 2011, INT J NANOTECHNOL, V8, P84, DOI 10.1504/IJNT.2011.037172
   Sadikot RT, 2009, J BIOMED NANOTECHNOL, V5, P614, DOI 10.1166/jbn.2009.1078
   Sharma S, 2001, J CLIN ONCOL, V19, P1839, DOI 10.1200/JCO.2001.19.6.1839
   Sung JC, 2007, TRENDS BIOTECHNOL, V25, P563, DOI 10.1016/j.tibtech.2007.09.005
   Ungaro F, 2006, EUR J PHARM SCI, V28, P423, DOI 10.1016/j.ejps.2006.05.005
   [Anonymous], 2006, USP 29 NF 24 US PHAR, V29/24, P2617
   Vanbever R, 1999, DRUG DEVELOP RES, V48, P178, DOI 10.1002/(SICI)1098-2299(199912)48:4<178::AID-DDR5>3.3.CO;2-9
   Vaughn JM, 2006, EUR J PHARM BIOPHARM, V63, P95, DOI 10.1016/j.ejpb.2006.01.006
   Watts AB, 2008, DRUG DEV IND PHARM, V34, P913, DOI [10.1080/03639040802144211, 10.1080/03639040802144211 ]
   Willis L, 2012, LUNG, V190, P251, DOI 10.1007/s00408-011-9360-x
   Wu XA, 2010, KONA POWDER PART J, P3
   Wu XA, 2011, INT J NANOTECHNOL, V8, P115, DOI 10.1504/IJNT.2011.037173
   Wu YP, 2009, NANOSCALE RES LETT, V4, P738, DOI 10.1007/s11671-009-9314-x
   Xu Z, 2011, J ADHES SCI TECHNOL, V25, P451, DOI 10.1163/016942410X525669
   Yang Y, 2009, BIOMATERIALS, V30, P1947, DOI 10.1016/j.biomaterials.2008.12.044
NR 55
TC 33
Z9 33
U1 1
U2 41
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2013
VL 8
BP 275
EP 293
DI 10.2147/IJN.S30724
PG 19
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA 130MU
UT WOS:000317922700027
PM 23355776
OA gold
DA 2018-03-19
ER

PT J
AU Doleman, L
   Davies, L
   Rowe, L
   Moschou, EA
   Deo, S
   Daunert, S
AF Doleman, Leslie Ann
   Davies, Logan L.
   Rowe, Laura
   Moschou, Elizabeth A.
   Deo, Sapna K.
   Daunert, Sylvia
TI Bioluminescence DNA hybridization assay for Plasmodium falciparum based
   on the photoprotein aequorin
SO ANALYTICAL CHEMISTRY
LA English
DT Article
ID POLYMERASE-CHAIN-REACTION; TOTAL ANALYSIS SYSTEMS; CD COMPACT DISC;
   DIAGNOSTIC DEVICES; MALARIA; MICROFLUIDICS; INFECTION; STANDARD; PCR
AB A bioluminescence DNA hybridization assay for the detection of Plasmodium falciparum, the most deadly species of malaria, using the photoprotein aequorin as a bioluminescent label has been developed. The current gold standard for the detection of malaria is light microscopy, which can detect down to similar to 50 parasites/mu L of blood, but has low-throughput, high costs, and requires high skill, which limit the applicability of the method, especially in the developing regions where malaria detection is mostly needed. The utilization of aequorin as a bioluminescence label offers the advantages of high signal-to-noise ratio and reliable detection down to attomole levels, allowing for the development of highly sensitive and miniaturized high-throughput bioluminescence assays. Herein, we developed a DNA hybridization assay for the detection of P. falciparum based on the competition between the target DNA and the signal generating DNA streptavidin-aequorin for hybridization with the probe DNA. This bioluminescence hybridization assay demonstrated a detection limit of 3 pg/mu L and was employed for the detection of target DNA in standard and spiked human serum samples. The DNA hybridization assay was developed in a microplate format without the need for sample PCR amplification, showing the potential suitability of this method in the parallel analysis of samples by low-trained personnel, such as that typically encountered in developing regions.
C1 Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
RP Daunert, S (reprint author), Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
EM daunert@uky.edu
FU NIGMS NIH HHS [GM 5R01GM047915-12, R01 GM047915, R29 GM047915]
CR Aguilar ZP, 2006, ANAL CHEM, V78, P1122, DOI 10.1021/ac051450i
   Auroux PA, 2002, ANAL CHEM, V74, P2637, DOI 10.1021/ac020239t
   BARKER RH, 1992, AM J TROP MED HYG, V46, P416, DOI 10.4269/ajtmh.1992.46.416
   Bell D, 2006, NAT REV MICROBIOL, V4, P682, DOI 10.1038/nrmicro1474
   Dikici E, 2006, PHOTOPROTEINS BIOANA, P179, DOI 10.1002/3527609148.ch10
   Felton MJ, 2003, ANAL CHEM, V75, p505A, DOI 10.1021/ac031418t
   Galvan B, 1996, ANAL CHEM, V68, P3545, DOI 10.1021/ac960413b
   Glynou K, 2003, BIOCONJUGATE CHEM, V14, P1024, DOI 10.1021/bc0341021
   Hansen C, 2003, CURR OPIN STRUC BIOL, V13, P538, DOI 10.1016/j.sbi.2003.09.010
   HAYDEN T, 2006, ANAL CHEM, V15, P5252
   Head JF, 2000, NATURE, V405, P372, DOI 10.1038/35012659
   HERMANSON GT, 1996, BIOCONJUGATE TECHNIQ, P575
   Jia GY, 2004, PROC SPIE, V5455, P341, DOI 10.1117/12.548754
   Kim J, 2004, LAB CHIP, V4, P516, DOI 10.1039/b401106f
   Lewis JC, 1998, ANAL CHEM, V70, p579A, DOI 10.1021/ac9819638
   Lewis JC, 2000, BIOCONJUGATE CHEM, V11, P65, DOI 10.1021/bc9900800
   Lewis JC, 2000, FRESEN J ANAL CHEM, V366, P760, DOI 10.1007/s002160051570
   Madou MJ, 2001, BIOMED MICRODEVICES, V3, P245, DOI 10.1023/A:1011419515576
   Mangold KA, 2005, J CLIN MICROBIOL, V43, P2435, DOI 10.1128/JCM.43.5.2435-2440.2005
   McNamara DT, 2004, J CLIN MICROBIOL, V42, P2403, DOI 10.1128/JCM.42.6.2403-2410.2004
   Murray CK, 2003, TROP MED INT HEALTH, V8, P876, DOI 10.1046/j.1365-3156.2003.01115.x
   Reyes DR, 2002, ANAL CHEM, V74, P2623, DOI 10.1021/ac0202435
   Scholl PF, 2004, AM J TROP MED HYG, V71, P546
   SHIMOMURA O, 1988, BIOCHEM J, V251, P405, DOI 10.1042/bj2510405
   Thayer AM, 2005, CHEM ENG NEWS, V83, P69, DOI 10.1021/cen-v083n043.p069
   Verhaegen M, 1998, ANAL CHEM, V70, P4120, DOI 10.1021/ac980512k
   Whitesides GM, 2006, NATURE, V442, P368, DOI 10.1038/nature05058
   Willis RC, 2006, ANAL CHEM, V78, P5261, DOI 10.1021/ac069435g
   Wongsrichanalai C, 2003, AM J TROP MED HYG, V69, P26
   Yager P, 2006, NATURE, V442, P412, DOI 10.1038/nature05064
NR 30
TC 26
Z9 27
U1 0
U2 7
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0003-2700
J9 ANAL CHEM
JI Anal. Chem.
PD JUN 1
PY 2007
VL 79
IS 11
BP 4149
EP 4153
DI 10.1021/ac0702847
PG 5
WC Chemistry, Analytical
SC Chemistry
GA 172ZA
UT WOS:000246842100021
PM 17477506
DA 2018-03-19
ER

PT J
AU Meenach, SA
   Tsoras, AN
   McGarry, RC
   Mansour, HM
   Hilt, JZ
   Anderson, KW
AF Meenach, Samantha A.
   Tsoras, Alexandra N.
   McGarry, Ronald C.
   Mansour, Heidi M.
   Hilt, J. Zach
   Anderson, Kimberly W.
TI Development of three-dimensional lung multicellular spheroids in air-
   and liquid-interface culture for the evaluation of anticancer
   therapeutics
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE multicellular spheroids; air interface culture; paclitaxel;
   three-dimensional cell culture; lung cancer
ID TUMOR SPHEROIDS; CANCER BIOLOGY; DRUG-DELIVERY; CELL-CULTURE; MODEL;
   AEROSOL; THERAPY
AB Three-dimensional (3D) lung multicellular spheroids (MCS) in liquid-covered culture (LCC) and air-interface culture (AIC) conditions have both been developed for the evaluation of aerosol anticancer therapeutics in solution and aerosols, respectively. The MCS were formed by seeding lung cancer cells on top of collagen where they formed spheroids due to the prevalence of cell-to-cell interactions. LCC MCS were exposed to paclitaxel (PTX) in media whereas AIC MCS were exposed to dry powder PEGylated phospholipid aerosol microparticles containing paclitaxel. The difference in viability for 2D versus 3D culture for both LCC and AIC was evaluated along with the effects of the particles on lung epithelium via transepithelial electrical resistance (TEER) measurements. For LCC and AIC conditions, the 3D spheroids were more resistant to treatment with higher IC50 values for A549 and H358 cell lines. TEER results initially indicated a decrease in resistance upon drug or particle exposure, however, these values increased over the course of several days indicating the ability of the cells to recover. Overall, these studies offer a comprehensive in vitro evaluation of aerosol particles used in the treatment of lung cancer while introducing a new method for culturing lung cancer MCS in both LCC and AIC conditions.
C1 [Meenach, Samantha A.; Mansour, Heidi M.] Univ Kentucky, Dept Pharmaceut Sci, Drug Dev Div, Lexington, KY 40536 USA.
   [Meenach, Samantha A.; Tsoras, Alexandra N.; Hilt, J. Zach; Anderson, Kimberly W.] Univ Kentucky, Dept Chem & Mat Engn, Coll Engn, Lexington, KY 40506 USA.
   [McGarry, Ronald C.] Univ Kentucky, Dept Radiat Med, Lexington, KY 40536 USA.
   [Meenach, Samantha A.] Univ Rhode Isl, Dept Chem Engn, 205 Crawford Hall,16 Greenhouse Rd, Kingston, RI 02881 USA.
   [Mansour, Heidi M.] Univ Arizona, Dept Pharm Practice & Sci, Tucson, AZ 85721 USA.
RP Meenach, SA (reprint author), Univ Kentucky, Dept Pharmaceut Sci, Drug Dev Div, Lexington, KY 40536 USA.; Meenach, SA (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Coll Engn, Lexington, KY 40506 USA.; Meenach, SA (reprint author), Univ Rhode Isl, Dept Chem Engn, 205 Crawford Hall,16 Greenhouse Rd, Kingston, RI 02881 USA.
EM smeenach@uri.edu
OI Meenach, Samantha/0000-0002-3833-2110
FU National Cancer Institute (NCI) [R25CA153954]; National Cancer Institute
   Cancer Nanotechnology Training Center (NCI-CNTC) Postdoctoral
   Traineeship
FX The authors gratefully acknowledge financial support from the National
   Cancer Institute (NCI) grant no. R25CA153954 and a National Cancer
   Institute Cancer Nanotechnology Training Center (NCI-CNTC) Postdoctoral
   Traineeship awarded to S. A. M. The content is solely the responsibility
   of the authors and does not necessarily represent the official views of
   the National Cancer Institute or the National Institutes of Health.
CR Alipour S, 2010, COLLOID SURFACE B, V81, P521, DOI 10.1016/j.colsurfb.2010.07.050
   Burdett E, 2010, TISSUE ENG PART B-RE, V16, P351, DOI [10.1089/ten.teb.2009.0676, 10.1089/ten.TEB.2009.0676]
   FJELLBIRKELAND L, 1995, VIRCHOWS ARCH, V426, P169
   Forbes B, 2005, EUR J PHARM BIOPHARM, V60, P193, DOI 10.1016/j.ejpb.2005.02.010
   Forbes B, 2000, J AEROSOL MED, V13, P281, DOI 10.1089/jam.2000.13.281
   Foster KA, 2000, INT J PHARM, V208, P1, DOI 10.1016/S0378-5173(00)00452-X
   Friedrich J, 2007, INT J RADIAT BIOL, V83, P849, DOI 10.1080/09553000701727531
   Goodman TT, 2008, BIOTECHNOL BIOENG, V101, P388, DOI 10.1002/bit.21910
   Goodman TT, 2007, INT J NANOMED, V2, P265
   Grainger CI, 2009, EUR J PHARM BIOPHARM, V71, P318, DOI 10.1016/j.ejpb.2008.09.006
   Grainger CI, 2006, PHARM RES, V23, P1482, DOI 10.1007/s11095-006-0255-0
   Haghi M, 2010, DRUG DEV IND PHARM, V36, P1207, DOI 10.3109/03639041003695113
   Hehlgans S, 2009, RADIOTHER ONCOL, V92, P371, DOI 10.1016/j.radonc.2009.08.001
   Hendricks P, 2012, FUND CLIN PHARMACOL, V26, P632, DOI 10.1111/j.1472-8206.2011.00964.x
   Ingram M, 2010, BIOTECH HISTOCHEM, V85, P213, DOI 10.3109/10520295.2010.483655
   Ivascu A, 2006, J BIOMOL SCREEN, V11, P922, DOI 10.1177/1087057106292763
   Jin HJ, 2011, LAB CHIP, V11, P115, DOI [10.1039/c0lc00134a, 10.1039/c01c00134a]
   Kelly K, 2001, J CLIN ONCOL, V19, P3210, DOI 10.1200/JCO.2001.19.13.3210
   Koshkina NV, 2004, J AEROSOL MED, V17, P7, DOI 10.1089/089426804322994415
   Koshkina NV, 2001, CLIN CANCER RES, V7, P3258
   Lin Ruei-Zhen, 2008, Biotechnology Journal, V3, P1172, DOI 10.1002/biot.200700228
   Meenach SA, 2013, EUR J PHARM SCI, V49, P699, DOI 10.1016/j.ejps.2013.05.012
   Meenach SA, 2013, INT J NANOMED, V8, P275, DOI 10.2147/IJN.S30724
   Nirmalanandhan VS, 2010, ASSAY DRUG DEV TECHN, V8, P581, DOI 10.1089/adt.2010.0276
   Pfister DG, 2004, J CLIN ONCOL, V22, P330, DOI 10.1200/JCO.2004.09.053
   Schiller JH, 2002, NEW ENGL J MED, V346, P92, DOI 10.1056/NEJMoa011954
   Smalley KSM, 2006, IN VITRO CELL DEV-AN, V42, P242
   Society AC, 2013, CANC FACTS FIG 2013, P4
   Tazzyman S, 2011, INT J CANCER, V129, P847, DOI 10.1002/ijc.25987
   Vertrees RA, 2009, CANCER BIOL THER, V8, P356, DOI 10.4161/cbt.8.4.7432
   Wisnivesky JP, 2005, CHEST, V128, P1461, DOI 10.1378/chest.128.3.1461
NR 31
TC 5
Z9 5
U1 0
U2 13
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD APR
PY 2016
VL 48
IS 4
BP 1701
EP 1709
DI 10.3892/ijo.2016.3376
PG 9
WC Oncology
SC Oncology
GA DH1TF
UT WOS:000372567100041
PM 26846376
OA green_published
DA 2018-03-19
ER

PT J
AU Fugit, KD
   Jyoti, A
   Upreti, M
   Anderson, BD
AF Fugit, Kyle D.
   Jyoti, Amar
   Upreti, Meenakshi
   Anderson, Bradley D.
TI Insights into accelerated liposomal release of topotecan in plasma
   monitored by a non-invasive fluorescence spectroscopic method
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Release kinetics; Topotecan; Liposomes; Fluorescence spectroscopy;
   Nanotechnology
ID IN-VIVO; HYDROPHOBIC CAMPTOTHECIN; CIRCULATION LIFETIMES; UNILAMELLAR
   LIPOSOMES; INTRALIPOSOMAL PH; BLOOD; DRUG; ENCAPSULATION; PERMEABILITY;
   DEGRADATION
AB Anon-invasive fluorescence method was developed to monitor liposomal release kinetics of the anticancer agent topotecan (TPT) in physiological fluids and subsequently used to explore the cause of accelerated release in plasma. Analyses of fluorescence excitation spectra confirmed that unencapsulated TPT exhibits a red shift in its spectrum as pH is increased. This property was used to monitor TPT release from actively loaded liposomal formulations having a low intravesicular pH. Mathematical release models were developed to extract reliable rate constants for TPT release in aqueous solutions monitored by fluorescence and release kinetics obtained by HPLC. Using the fluorescence method, accelerated TPT release was observed in plasma as previously reported in the literature. Simulations to estimate the intravesicular pH were conducted to demonstrate that accelerated release correlated with alterations in the low intravesicular pH. This was attributed to the presence of ammonia in plasma samples rather than proteins and other plasma components generally believed to alter release kinetics in physiological samples. These findings shed light on the critical role that ammonia may play in contributing to the preclinical/clinical variability and performance seen with actively-loaded liposomal formulations of TPT and other weakly-basic anticancer agents. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Fugit, Kyle D.; Jyoti, Amar; Upreti, Meenakshi; Anderson, Bradley D.] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
RP Anderson, BD (reprint author), Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, A323A ASTeCC Bldg, Lexington, KY 40506 USA.
EM bande2@email.uky.edu
FU National Cancer Institute [R25CA153954]
FX This project was supported by Grant Number R25CA153954 from the National
   Cancer Institute. The content is solely the responsibility of the
   authors and does not necessarily represent the official views of the
   National Cancer Institute or the National Institutes of Health.
CR Abraham SA, 2004, J CONTROL RELEASE, V96, P449, DOI 10.1016/j.jconrel.2004.02.017
   Ahl PL, 1997, BBA-BIOMEMBRANES, V1329, P370, DOI 10.1016/S0005-2736(97)00129-6
   Aihara Arihiro, 2012, Gan To Kagaku Ryoho, V39, P839
   Antonenko YN, 1997, BIOPHYS J, V72, P2187, DOI 10.1016/S0006-3495(97)78862-3
   Barsotti RJ, 2001, J PEDIATR-US, V138, pS11, DOI 10.1067/mpd.2001.111832
   Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442
   Brusilow S., 1991, DETERMINATION URINE
   Brusilow S W, 1996, Adv Pediatr, V43, P127
   BURKE TG, 1994, J PHARM SCI, V83, P967, DOI 10.1002/jps.2600830710
   Caron WP, 2012, CLIN PHARMACOL THER, V91, P802, DOI 10.1038/clpt.2012.12
   Chobanyan K, 2007, J CHROMATOGR B, V851, P240, DOI 10.1016/j.jchromb.2007.03.006
   CHONN A, 1992, J BIOL CHEM, V267, P18759
   DACOSTA KA, 1990, ANAL BIOCHEM, V187, P234, DOI 10.1016/0003-2697(90)90449-J
   DIAZ J, 1995, CLIN CHEM, V41, P1048
   Dos Santos N, 2007, BBA-BIOMEMBRANES, V1768, P1367, DOI 10.1016/j.bbamen.2006.12.013
   Drummond DC, 2010, J CONTROL RELEASE, V141, P13, DOI 10.1016/j.jconrel.2009.08.006
   Efremova NV, 2000, BIOCHEMISTRY-US, V39, P3441, DOI 10.1021/bi992095r
   Errington RJ, 2005, ADV DRUG DELIVER REV, V57, P153, DOI 10.1016/j.addr.2004.05.005
   FASSBERG J, 1992, J PHARM SCI, V81, P676, DOI 10.1002/jps.2600810718
   Fugit KD, 2014, MOL PHARMACEUT, V11, P1314, DOI 10.1021/mp400765n
   Fugit KD, 2014, J CONTROL RELEASE, V174, P88, DOI 10.1016/j.jconrel.2013.11.003
   Hao YL, 2005, J PHARM PHARMACOL, V57, P1279, DOI 10.1211/jpp.57.10.0006
   Hao YL, 2005, ARCH PHARM RES, V28, P626, DOI 10.1007/BF02977769
   HARAN G, 1993, BIOCHIM BIOPHYS ACTA, V1151, P201, DOI 10.1016/0005-2736(93)90105-9
   HARASHIMA H, 1994, BIOPHARM DRUG DISPOS, V15, P217, DOI 10.1002/bdd.2510150304
   Harashima H, 1995, J DRUG TARGET, V3, P253, DOI 10.3109/10611869509015954
   HARASHIMA H, 1993, BIOPHARM DRUG DISPOS, V14, P265, DOI 10.1002/bdd.2510140309
   Huang C. H. A, 1993, BIOCHEMISTRY-MOSCOW, V32, P11
   HUIZENGA JR, 1994, ANN CLIN BIOCHEM, V31, P529, DOI 10.1177/000456329403100602
   Joguparthi V, 2008, INT J PHARM, V352, P17, DOI 10.1016/j.ijpharm.2007.10.003
   Joguparthi V, 2008, J PHARM SCI-US, V97, P433, DOI 10.1002/jps.21135
   Joguparthi V, 2008, J PHARM SCI-US, V97, P400, DOI 10.1002/jps.21125
   KIRBY C, 1981, BIOCHEM J, V199, P251, DOI 10.1042/bj1990251
   Kirpotin DB, 2006, CANCER RES, V66, P6732, DOI 10.1158/0008-5472.CAN-05-4199
   Laverman P, 2001, J PHARMACOL EXP THER, V298, P607
   Liu JJ, 2002, ANTI-CANCER DRUG, V13, P709, DOI 10.1097/00001813-200208000-00005
   Mayer Lawrence D., 1994, Journal of Liposome Research, V4, P529, DOI 10.3109/08982109409037060
   MAYER LD, 1990, BIOCHIM BIOPHYS ACTA, V1025, P143, DOI 10.1016/0005-2736(90)90091-2
   MI ZH, 1995, BIOCHEMISTRY-US, V34, P13722, DOI 10.1021/bi00042a002
   Modi S, 2013, MOL PHARMACEUT, V10, P3076, DOI 10.1021/mp400154a
   Modi S, 2012, J CONTROL RELEASE, V162, P330, DOI 10.1016/j.jconrel.2012.07.001
   Nakamura Masamoto, 2009, Nihon Shokakibyo Gakkai Zasshi, V106, P1744
   Nott L, 2008, INTERN MED J, V38, P800, DOI 10.1111/j.1445-5994.2008.01772.x
   Patankar NA, 2013, INVEST NEW DRUG, V31, P46, DOI 10.1007/s10637-012-9832-8
   Patel K, 1997, INT J PHARM, V151, P7, DOI 10.1016/S0378-5173(97)04892-8
   Ramsay E, 2006, PHARM RES, V23, P2799, DOI 10.1007/s11095-006-9111-5
   Strel'tsov SA, 2001, MOL BIOL+, V35, P365, DOI 10.1023/A:1010422711817
   Streltsov S, 2003, BIOPOLYMERS, V72, P442, DOI 10.1002/bip.10479
   SUBRAMANIAN D, 1995, ONCOL RES, V7, P461
   Taggar AS, 2006, J CONTROL RELEASE, V114, P78, DOI 10.1016/j.jconrel.2006.05.019
   Tardi P, 2000, CANCER RES, V60, P3389
   Teerlink T, 1997, J CHROMATOGR B, V691, P269, DOI 10.1016/S0378-4347(96)00476-8
   WALTER A, 1986, J MEMBRANE BIOL, V90, P207, DOI 10.1007/BF01870127
   WEBB MS, 1995, BRIT J CANCER, V72, P896, DOI 10.1038/bjc.1995.430
   White G, 1996, BIOPHYS J, V71, P2701, DOI 10.1016/S0006-3495(96)79461-4
   Willson Kaspar J, 2013, Gastrointest Cancer Res, V6, P11
   Xiang TX, 1997, BIOPHYS J, V72, P223, DOI 10.1016/S0006-3495(97)78661-2
   YOSHIKAWA W, 1983, BIOCHIM BIOPHYS ACTA, V735, P397, DOI 10.1016/0005-2736(83)90154-2
   YOSHIMURA T, 1994, J BIOCHEM-TOKYO, V115, P715, DOI 10.1093/oxfordjournals.jbchem.a124401
   Zamboni WC, 2012, CLIN CANCER RES, V18, P3229, DOI 10.1158/1078-0432.CCR-11-2938
NR 60
TC 5
Z9 5
U1 0
U2 22
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD JAN 10
PY 2015
VL 197
BP 10
EP 19
DI 10.1016/j.jconrel.2014.10.011
PG 10
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA AW9HT
UT WOS:000346568700002
PM 25456833
OA green_accepted
DA 2018-03-20
ER

PT J
AU Wattamwar, PP
   Hardas, SS
   Butterfield, DA
   Anderson, KW
   Dziubla, TD
AF Wattamwar, Paritosh P.
   Hardas, Sarita S.
   Butterfield, D. Allan
   Anderson, Kimberly W.
   Dziubla, Thomas D.
TI Tuning of the pro-oxidant and antioxidant activity of trolox through the
   controlled release from biodegradable poly(trolox ester) polymers
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
LA English
DT Article
DE oxidative stress; antioxidant polymers; trolox; nanoparticles;
   biocompatibility
ID OXIDATIVE STRESS; IN-VITRO; SUPEROXIDE-DISMUTASE; PROTEIN OXIDATION;
   REDOX STATE; VITAMIN-C; CELLS; NEUROTOXICITY; CULTURES; DAMAGE
AB In a variety of biomedical applications (e.g., tissue engineering, drug delivery, etc.), the role of a bioactive material is to serve as a platform by which one can modulate the cellular response into a desired role. Of the methods by which one may achieve this control (e.g., shape, structure, binding, growth factor release), the control of the cellular redox state has been under evaluated. Ideally, the ability to tune the redox state of a cell provides an additional level of control over a variety of cellular responses including, cell differentiation, proliferation, and apoptosis. Yet, in order to achieve such control, it is important to know both the overall oxidative status of the cell and what molecular targets are being oxidized. In this work, poly (trolox ester) nanoparticles were evaluated for their ability to either inhibit or induce cellular oxidative stress in a dose-dependent fashion. This polymer delivery form possessed a unique ability to suppress protein oxidation, a feature not seen in the free drug form, emphasizing the advantage of the delivery/dosage formulation has upon regulating cellular response. (C) 2011 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 99A: 184-191, 2011.
C1 [Wattamwar, Paritosh P.; Anderson, Kimberly W.; Dziubla, Thomas D.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Hardas, Sarita S.; Butterfield, D. Allan] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
   [Butterfield, D. Allan] Univ Kentucky, Ctr Membrane Sci, Lexington, KY 40506 USA.
RP Dziubla, TD (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM dziubla@engr.uky.edu
FU University of Kentucky Research Foundation; Office of Naval Research
   (ONR DEPSCoR)
FX Contract grant sponsors: University of Kentucky Research Foundation;
   Office of Naval Research (ONR DEPSCoR)
CR de la Lastral CA, 2007, BIOCHEM SOC T, V35, P1156, DOI 10.1042/BST0351156
   Azmi AS, 2005, FEBS LETT, V579, P3131, DOI 10.1016/j.febslet.2005.04.077
   Banerjee A, 2008, CHEM-BIOL INTERACT, V174, P134, DOI 10.1016/j.cbi.2008.05.009
   Betters JL, 2004, AM J RESP CRIT CARE, V170, P1179, DOI 10.1164/rccm.200407-939OC
   Brown GC, 2008, BBA-BIOENERGETICS, V1777, P877, DOI 10.1016/j.bbabio.2008.03.024
   Butterfield DA, 2010, BBA-MOL CELL BIOL L, V1801, P924, DOI 10.1016/j.bbalip.2010.02.005
   BUTTERFIELD DA, 1997, ADV CELL AGING GERON, V2, P161
   CADENAS E, 1989, FEBS LETT, V253, P235, DOI 10.1016/0014-5793(89)80966-4
   Dziubla T, 2006, OXIDATIVE STRESS, DISEASE AND CANCER, P1023, DOI 10.1142/9781860948046_0037
   Esterbauer H, 1996, REV PHYSIOL BIOCH P, V127, P31, DOI 10.1007/BFb0048264
   Fleming C, 2005, NAT CHEM BIOL, V1, P270, DOI 10.1038/nchembio730
   Friaa O, 2006, ORG BIOMOL CHEM, V4, P2417, DOI 10.1039/b602147f
   Geurtsen W, 1998, J BIOMED MATER RES, V41, P474, DOI 10.1002/(SICI)1097-4636(19980905)41:3<474::AID-JBM18>3.0.CO;2-I
   Hadi SM, 2010, PHARM RES-DORDR, V27, P979, DOI 10.1007/s11095-010-0055-4
   Jiang WW, 2007, J BIOMED MATER RES A, V82A, P492, DOI 10.1002/jbm.a.31175
   Kaur P, 2010, TOXICOLOGY, V276, P73, DOI 10.1016/j.tox.2010.07.006
   KO KM, 1994, MOL CELL BIOCHEM, V141, P65, DOI 10.1007/BF00935592
   Lampe KJ, 2009, BIOTECHNOL BIOENG, V103, P1214, DOI 10.1002/bit.22352
   Lankin V Z, 1999, Biull Eksp Biol Med, V128, P314
   LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012
   Lefeuvre M, 2005, BIOMATERIALS, V26, P5130, DOI 10.1016/j.biomaterials.2005.01.014
   Majd ES, 2003, BIOMATERIALS, V24, P3
   Malcolm CS, 2000, FREE RADICAL BIO MED, V28, P102, DOI 10.1016/S0891-5849(99)00215-4
   Mayo JC, 2003, BBA-GEN SUBJECTS, V1620, P139, DOI 10.1016/S0304-4165(02)00527-5
   Muzykantov VR, 2001, J CONTROL RELEASE, V71, P1, DOI 10.1016/S0168-3659(01)00215-2
   Ogasawara MA, 2009, ANTIOXID REDOX SIGN, V11, P1107, DOI [10.1089/ars.2008.2308, 10.1089/ARS.2008.2308]
   Poljsak B, 2008, J APPL TOXICOL, V28, P183, DOI 10.1002/jat.1264
   Priyadarsini KI, 2001, CHEM RES TOXICOL, V14, P567, DOI 10.1021/tx000239t
   Rota C, 1999, J BIOL CHEM, V274, P28161, DOI 10.1074/jbc.274.40.28161
   ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222
   Sandur SK, 2007, FREE RADICAL BIO MED, V43, P568, DOI 10.1016/j.freeradbiomed.2007.05.009
   Serrano MC, 2005, BIOMATERIALS, V26, P5827, DOI 10.1016/j.biomaterials.2005.02.039
   Sharm RK, 2008, BRAIN RES, V1243, P19, DOI 10.1016/j.brainres.2008.08.025
   Smith J, 2000, P NATL ACAD SCI USA, V97, P10032, DOI 10.1073/pnas.170209797
   Spizzirri UG, 2009, BIOMACROMOLECULES, V10, P1923, DOI 10.1021/bm900325t
   Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142
   Stanic B, 2010, ARTERIOSCL THROM VAS, V30, P2234, DOI 10.1161/ATVBAHA.110.207639
   Sultana R, 2005, J NEUROCHEM, V92, P749, DOI 10.1111/j.1471-4159.2004.02899.x
   Tafazoli S, 2005, CHEM RES TOXICOL, V18, P1567, DOI 10.1021/tx0500575
   Udipi K, 2000, J BIOMED MATER RES, V51, P549, DOI 10.1002/1097-4636(20000915)51:4<549::AID-JBM2>3.0.CO;2-Z
   Wang YZ, 2006, BIOMATERIALS, V27, P3265, DOI 10.1016/j.biomaterials.2006.01.036
   Wattamwar PP, 2010, ADV FUNCT MATER, V20, P147, DOI 10.1002/adfm.200900839
   Williams SR, 2009, BIOMACROMOLECULES, V10, P155, DOI 10.1021/bm801058j
   Wongmekiat O, 2007, CLIN EXP PHARMACOL P, V34, P753, DOI 10.1111/j.1440-1681.2007.04651.x
   Wrona M, 2008, FREE RADICAL BIO MED, V44, P56, DOI 10.1016/j.freeradbiomed.2007.09.005
NR 45
TC 15
Z9 15
U1 0
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1549-3296
J9 J BIOMED MATER RES A
JI J. Biomed. Mater. Res. Part A
PD NOV
PY 2011
VL 99A
IS 2
BP 184
EP 191
DI 10.1002/jbm.a.33174
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 823RQ
UT WOS:000295142400005
PM 21976443
DA 2018-03-19
ER

PT J
AU Curtis, LT
   Rychahou, P
   Bae, Y
   Frieboes, HB
AF Curtis, Louis T.
   Rychahou, Piotr G.
   Bae, Younsoo
   Frieboes, Hermann B.
TI A Computational/Experimental Assessment of Antitumor Activity of Polymer
   Nanoassemblies for pH-Controlled Drug Delivery to Primary and Metastatic
   Tumors
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE cancer nanotherapy; computational simulation; mathematical modeling;
   nanoparticles; pH-controlled release; polymer micelles
ID LYMPHATIC VASCULAR SYSTEMS; BLOCK-COPOLYMER MICELLES; INTERSTITIAL
   PRESSURE; NONLINEAR SIMULATION; SOLID TUMORS; GROWTH; RELEASE;
   CYTOTOXICITY; BLOOD; NANOCARRIERS
AB Polymer nanoassemblies (PNAs) with drug release fine-tuned to occur in acidic tumor regions (pH < 7) while sparing normal tissues (pH = 7.4) were previously shown to hold promise as nanoparticle drug carriers to effectively suppress tumor growth with reduced systemic toxicity. However, therapeutic benefits of pH-controlled drug delivery remain elusive due to complex interactions between the drug carriers, tumor cells with varying drug sensitivity, and the tumor microenvironment.
   We implement a combined computational and experimental approach to evaluate the in vivo antitumor activity of acid-sensitive PNAs controlling drug release in pH 5 similar to 7.4 at different rates [PNA1 (fastest) > PNA2 > PNA3 (slowest)].
   Computational simulations projecting the transport, drug release, and antitumor activity of PNAs in primary and metastatic tumor models of colorectal cancer correspond well with experimental observations in vivo. The simulations also reveal that all PNAs could reach peak drug concentrations in tumors at 11 h post injection, while PNAs with slower drug release (PNA2 and PNA3) reduced tumor size more effectively than fast drug releasing PNA1 (24.5 and 20.3 vs 7.5%, respectively, as fraction of untreated control).
   A combined computational/experimental approach may help to evaluate pH-controlled drug delivery targeting aggressive tumors that have substantial acidity.
C1 [Curtis, Louis T.; Frieboes, Hermann B.] Univ Louisville, Dept Bioengn, Lutz Hall 419, Louisville, KY 40208 USA.
   [Rychahou, Piotr] Univ Kentucky, Markey Canc Ctr, 741 South Limestone, Lexington, KY 40506 USA.
   [Rychahou, Piotr] Univ Kentucky, Dept Surg, 741 South Limestone, Lexington, KY 40506 USA.
   [Bae, Younsoo] Univ Kentucky, Dept Pharmaceut Sci, Coll Pharm, 789 South Limestone, Lexington, KY 40506 USA.
   [Frieboes, Hermann B.] Univ Louisville, Dept Pharmacol & Toxicol, Louisville, KY 40208 USA.
   [Frieboes, Hermann B.] Univ Louisville, James Graham Brown Canc Ctr, Louisville, KY 40208 USA.
RP Frieboes, HB (reprint author), Univ Louisville, Dept Bioengn, Lutz Hall 419, Louisville, KY 40208 USA.; Bae, Y (reprint author), Univ Kentucky, Dept Pharmaceut Sci, Coll Pharm, 789 South Limestone, Lexington, KY 40506 USA.; Frieboes, HB (reprint author), Univ Louisville, Dept Pharmacol & Toxicol, Louisville, KY 40208 USA.; Frieboes, HB (reprint author), Univ Louisville, James Graham Brown Canc Ctr, Louisville, KY 40208 USA.
EM younsoo.bae@uky.edu; hbfrie01@louisville.edu
FU University of Kentucky, College of Pharmacy; NIH/NCI [U54CA143907]
FX YB acknowledges the University of Kentucky, College of Pharmacy, for its
   financial and institutional support of this collaborative study. HBF
   acknowledges partial support from NIH/NCI U54CA143907.
CR Bae Y, 2005, MOL BIOSYST, V1, P242, DOI 10.1039/b500266d
   Bae Y, 2003, ANGEW CHEM INT EDIT, V42, P4640, DOI 10.1002/anie.200250653
   Bae Y, 2009, ADV DRUG DELIVER REV, V61, P768, DOI 10.1016/j.addr.2009.04.016
   Bennewith KL, 2004, CANCER RES, V64, P6183, DOI 10.1158/0008-5472.CAN-04-0289
   Binauld S, 2013, CHEM COMMUN, V49, P2082, DOI 10.1039/c2cc36589h
   Cao P, 2012, J APPL PHARM SCI, V2, P1, DOI DOI 10.7324/JAPS.2012.2901
   Curtis LT, 2016, NANOMEDICINE-UK, V11, P197, DOI 10.2217/nnm.15.195
   Curtis LT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144888
   Eckman AM, 2012, PHARM RES-DORDR, V29, P1755, DOI 10.1007/s11095-012-0697-5
   Farokhzad OC, 2009, ACS NANO, V3, P16, DOI 10.1021/nn900002m
   Frieboes HB, 2006, BIOMEMS BIOMEDICAL N, P435
   Gillies ER, 2003, CHEM COMMUN, P1640, DOI 10.1039/b304251k
   Jain RK, 2010, NAT REV CLIN ONCOL, V7, P653, DOI 10.1038/nrclinonc.2010.139
   Jin ZH, 2014, ACTA PHARMACOL SIN, V35, P839, DOI 10.1038/aps.2014.12
   KANEKO T, 1991, BIOCONJUGATE CHEM, V2, P133, DOI 10.1021/bc00009a001
   Kawabata-Shoda E, 2012, J CLIN PHARM THER, V37, P547, DOI 10.1111/j.1365-2710.2012.01332.x
   Leonard F, 2016, NANOSCALE, V8, P12544, DOI 10.1039/c5nr07796f
   Macklin P, 2008, J SCI COMPUT, V35, P266, DOI 10.1007/s10915-008-9190-z
   Macklin P, 2007, J THEOR BIOL, V245, P677, DOI 10.1016/j.jtbi.2006.12.004
   Macklin P, 2009, J MATH BIOL, V58, P765, DOI 10.1007/s00285-008-0216-9
   Matsumura Y, 2009, CANCER SCI, V100, P572, DOI 10.1111/j.1349-7006.2009.01103.x
   McDougall SR, 2006, J THEOR BIOL, V241, P564, DOI 10.1016/j.jtbi.2005.12.022
   Murakami M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001385
   NUGENT LJ, 1984, CANCER RES, V44, P238
   Phadke AP, 2011, DNA CELL BIOL, V30, P715, DOI 10.1089/dna.2011.1240
   Ponta A., 2013, THESIS
   Ponta A, 2015, PHARM RES-DORDR, V32, P1752, DOI 10.1007/s11095-014-1573-2
   Ponta A, 2014, J DRUG TARGET, V22, P619, DOI 10.3109/1061186X.2014.910793
   Ponta A, 2010, PHARM RES-DORDR, V27, P2330, DOI 10.1007/s11095-010-0120-z
   Shi JJ, 2014, ACTA BIOMATER, V10, P1280, DOI 10.1016/j.actbio.2013.10.037
   Siegel R, 2012, CA-CANCER J CLIN, V62, DOI [10.3322/caac.21153, 10.3322/caac.21149, 10.3322/caac.20138]
   Song CW, 2006, CANC DRUG DISC DEV, P21, DOI 10.1007/978-1-59745-035-5_2
   Stessels F, 2004, BRIT J CANCER, V90, P1429, DOI 10.1038/sj.bjc.6601727
   TANNOCK IF, 1989, CANCER RES, V49, P4373
   Torchilin VP, 2007, PHARM RES-DORDR, V24, P1, DOI 10.1007/s11095-006-9132-0
   van de Ven AL, 2012, AIP ADV, V2, DOI 10.1063/1.3699060
   Van den Eynden GG, 2012, CLIN EXP METASTAS, V29, P541, DOI 10.1007/s10585-012-9469-1
   Vazquez A, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-58
   Waite Carolyn L., 2012, Critical Reviews in Biomedical Engineering, V40, P21, DOI 10.1615/CritRevBiomedEng.v40.i1.20
   Wu M, 2014, J THEOR BIOL, V355, P194, DOI 10.1016/j.jtbi.2014.04.012
   Wu M, 2013, J THEOR BIOL, V320, P131, DOI 10.1016/j.jtbi.2012.11.031
   Yang XQ, 2010, BIOCONJUGATE CHEM, V21, P496, DOI 10.1021/bc900422j
NR 42
TC 2
Z9 2
U1 0
U2 13
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
EI 1573-904X
J9 PHARM RES-DORDR
JI Pharm. Res.
PD OCT
PY 2016
VL 33
IS 10
BP 2552
EP 2564
DI 10.1007/s11095-016-1981-6
PG 13
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA DV2NP
UT WOS:000382757600020
PM 27356524
DA 2018-03-19
ER

PT J
AU Liu, SQ
   Bae, Y
   Leggas, M
   Daily, A
   Bhatnagar, S
   Miriyala, S
   St Clair, DK
   Moscow, JA
AF Liu, Shuqian
   Bae, Younsoo
   Leggas, Markos
   Daily, Abigail
   Bhatnagar, Saloni
   Miriyala, Sumitra
   St Clair, Daret K.
   Moscow, Jeffrey A.
TI Pharmacologic Properties of Polyethylene Glycol-Modified Bacillus
   thiaminolyticus Thiaminase I Enzyme
SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
LA English
DT Article
ID GENE-EXPRESSION; BREAST-CANCER
AB We have previously shown that the bacterial enzyme thiaminase 1 has antitumor activity. In an attempt to make thiaminase I a more effective pharmaceutical agent, we have modified it by adding polyethylene glycol (PEG) chains of various lengths. We were surprised to find that 5k-PEGylation eliminated thiaminase cytotoxic activity in all cell lines tested. Both native thiaminase and 5k- PEGylated thiaminase efficiently depleted thiamine from cell culture medium, and both could use intracellular phosphorylated thiamine as substrates. However, native enzyme more effectively depleted thiamine and thiamine diphosphate in RS4 leukemia cell cytosol, and native thiaminase depressed cellular respiration, whereas PEGylated thiaminase did not. Despite the lack of in vitro cytotoxicity, PEGylation markedly increased the in vivo toxicity of the enzyme. Pharmacokinetic studies revealed that the half-life of native thiaminase was 1.5 h compared with 34.4 h for the 5k- PEGylated enzyme. Serum thiamine levels were depleted by both native and 5k-PEGylated enzyme. Despite superior pharmacokinetics, 5k-PEGylated thiaminase showed no antitumor effect against an RS4 leukemia xenograft, in contrast to native thiaminase, which showed antitumor activity. PEGylation of thiaminase I has demonstrated that depression of mitochondrial function contributes, at least in part, to its anticancer activity. PEGylation also enhances plasma retention time, which increased its vivo toxicity and decreased its activity against a leukemia xenograft, the opposite of the desired effects. These studies suggest that the mechanism of anticancer cytotoxicity of thiaminase requires acute depression of cellular respiration, whereas systemic toxicity is related to the duration of extracellular thiamine depletion.
C1 [Liu, Shuqian; Daily, Abigail; Bhatnagar, Saloni; Moscow, Jeffrey A.] Univ Kentucky, Dept Pediat, Coll Med, Lexington, KY 40536 USA.
   [Miriyala, Sumitra; St Clair, Daret K.] Univ Kentucky, Grad Ctr Toxicol, Coll Med, Lexington, KY 40536 USA.
   [Bae, Younsoo; Leggas, Markos] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
RP Moscow, JA (reprint author), Univ Kentucky, Dept Pediat, Coll Med, 740 S Limestone St,Room J457 Lexington, Lexington, KY 40536 USA.
EM jmoscow@uky.edu
FU William Lawrence and Blanche Hughes Foundation; University of Kentucky
   student community
FX This work was supported by the William Lawrence and Blanche Hughes
   Foundation and DanceBlue, an effort of the University of Kentucky
   student community to support pediatric oncology care and research.
CR Costello CA, 1996, J BIOL CHEM, V271, P3445, DOI 10.1074/jbc.271.7.3445
   COX TM, 2010, J BIOL, V4, P299
   Daily A, 2011, MOL CANCER THER, V10, P1563, DOI 10.1158/1535-7163.MCT-11-0003
   Gangolf M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013616
   Hanes JW, 2007, ANAL BIOCHEM, V368, P33, DOI 10.1016/j.ab.2007.06.001
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Liu SQ, 2010, CANCER CHEMOTH PHARM, V66, P171, DOI 10.1007/s00280-009-1148-9
   Liu SQ, 2004, MOL CANCER RES, V2, P477
   Liu SQ, 2003, MOL CANCER RES, V1, P665
   Lu J, 2008, CLIN CHEM, V54, P901, DOI 10.1373/clinchem.2007.099077
   Richardson AD, 2010, CANCER BIOL THER, V10, P1112, DOI 10.4161/cbt.10.11.14061
NR 11
TC 4
Z9 4
U1 0
U2 5
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0022-3565
EI 1521-0103
J9 J PHARMACOL EXP THER
JI J. Pharmacol. Exp. Ther.
PD JUN
PY 2012
VL 341
IS 3
BP 775
EP 783
DI 10.1124/jpet.112.191817
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 947QQ
UT WOS:000304445000023
PM 22431205
OA gold
DA 2018-03-19
ER

PT J
AU Miller, AF
   Rodgers, DW
   Yikilmaz, E
AF Miller, Anne-Frances
   Rodgers, David W.
   Yikilmaz, Emine
TI The crucial importance of chemistry in the structure-function equation:
   Manipulating H-bonding in Fe-superoxide dismutase
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
CT 231st National Meeting of the American-Chemical-Society
CY MAR 26-30, 2006
CL Atlanta, GA
SP Amer Chem Soc
C1 Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
EM afm@uky.edu
RI Miller, Anne-Frances/M-7703-2017
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD MAR 26
PY 2006
VL 231
MA 697-INOR
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA 050YE
UT WOS:000238125906088
DA 2018-03-20
ER

PT J
AU Singh, R
   Lou, DY
   Bondada, V
   Ghoshal, S
   Benson, A
   Saatman, K
   Geddes, J
AF Singh, Ranjana
   Lou, Dingyuan
   Bondada, Vimala
   Ghoshal, Sarbani
   Benson, Adam
   Saatman, Kathryn E.
   Geddes, James W.
TI ATYPICAL CALPAIN, CALPAIN 5 IS PREDOMINANTLY PRESENT IN NEURONAL
   MITOCHONDRIA; AND CONTRIBUTES TO NEURODEGENERATION FOLLOWING TRAUMATIC
   BRAIN INJURY VIA CASPASE DEPENDENT PATHWAY
SO JOURNAL OF NEUROTRAUMA
LA English
DT Meeting Abstract
CT 30th Annual National Neurotrauma Symposium
CY JUL 22-25, 2012
CL Phoenix, AZ
DE Calpain 5; Capn5; TBI; neurodegeneration
C1 [Singh, Ranjana; Geddes, James] Univ Kentucky, Dept Anat & Neurobiol, Spinal Cord & Brain Injury Res Ctr SCoBIRC, Lexington, KY 40536 USA.
   [Saatman, Kathryn] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr SCoBIRC, Dept Physiol, Lexington, KY USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0897-7151
J9 J NEUROTRAUM
JI J. Neurotrauma
PD JUL
PY 2012
VL 29
IS 10
BP A65
EP A66
PG 2
WC Critical Care Medicine; Clinical Neurology; Neurosciences
SC General & Internal Medicine; Neurosciences & Neurology
GA 971YV
UT WOS:000306244400108
DA 2018-03-20
ER

PT J
AU Zahran, EM
   Bhattacharyya, D
   Bachas, LG
AF Zahran, Elsayed M.
   Bhattacharyya, Dibakar
   Bachas, Leonidas G.
TI Development of reactive Pd/Fe bimetallic nanotubes for dechlorination
   reactions
SO JOURNAL OF MATERIALS CHEMISTRY
LA English
DT Article
ID STABILIZED PALLADIUM NANOPARTICLES; VASCULAR ENDOTHELIAL-CELLS;
   NANOSCALE IRON PARTICLES; CROSS-COUPLING REACTIONS;
   POLYCHLORINATED-BIPHENYLS; REDUCTIVE DECHLORINATION; INORGANIC
   NANOTUBES; TEMPLATE SYNTHESIS; ZEROVALENT IRON; ENVIRONMENTAL
   REMEDIATION
AB We described the synthesis and characterization of a new class of bimetallic nanotubes based on Pd/Fe and demonstrated their efficacy in the dechlorination of PCB 77, a polychlorinated biphenyl. One-dimensional iron metal nanotubes of different diameters were prepared by electroless deposition within the pores of PVP-coated polycarbonate membranes using a simple technique under ambient conditions. The longitudinal nucleation of the nanotubes along the pore walls was achieved by mounting the PC membrane between two halves of a U-shape reaction tube. The composition, morphology, and structure of the Pd/Fe nanotubes were characterized by transmission electron microscopy, scanning electron microscopy, inductively coupled plasma-atomic emission spectroscopy, and X-ray powder diffraction spectroscopy. The as-prepared Pd/Fe bimetallic nanotubes were used in dechlorination of 3,3',4,4'-tetrachlorobiphenyl (PCB 77). In comparison with Pd/Fe nanoparticles, the Pd/Fe nanotubes demonstrated higher efficiency and faster dechlorination of the PCB.
C1 [Bachas, Leonidas G.] Univ Miami, Dept Chem, Coral Gables, FL 33146 USA.
   [Zahran, Elsayed M.] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
   [Bhattacharyya, Dibakar] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Bachas, LG (reprint author), Univ Miami, Dept Chem, Coral Gables, FL 33146 USA.
EM bachas@miami.edu
RI Bachas, Leonidas/G-2479-2015
OI Bachas, Leonidas/0000-0002-3308-6264; Zahran,
   Elsayed/0000-0003-3456-515X
FU NIEHS [P42ES007380]
FX The authors acknowledge support from the NIEHS-SRP program
   (P42ES007380).
CR ARBON RE, 1994, ENVIRON SCI TECHNOL, V28, P2191, DOI 10.1021/es00061a030
   Barbara PF, 1999, ACCOUNTS CHEM RES, V32, P387
   Bell AT, 2003, SCIENCE, V299, P1688, DOI 10.1126/science.1083671
   Boldt R, 2010, NANO LETT, V10, P208, DOI [10.1021/nl903291j, 10.1021/nl903291J]
   Bracey CL, 2009, CHEM SOC REV, V38, P2231, DOI 10.1039/b817729p
   BRUMLIK CJ, 1991, J AM CHEM SOC, V113, P3174, DOI 10.1021/ja00008a057
   Calo V, 2009, ANGEW CHEM INT EDIT, V48, P6101, DOI 10.1002/anie.200902337
   Campbell CT, 2004, SCIENCE, V306, P234, DOI 10.1126/science.1104246
   Cao HQ, 2006, CHEMPHYSCHEM, V7, P1500, DOI 10.1002/cphc.200500690
   Cao XL, 2009, MATER LETT, V63, P2215, DOI 10.1016/j.matlet.2009.07.047
   Cassol CC, 2005, J AM CHEM SOC, V127, P3298, DOI 10.1021/ja0430043
   Chen C, 2009, J PHYS CHEM C, V113, P5472, DOI 10.1021/jp9001065
   Chen H, 2007, J MATER CHEM, V17, P1593, DOI 10.1039/b611039h
   Cochran RE, 2007, ACTA MATER, V55, P3007, DOI 10.1016/j.actamat.2007.01.005
   Collins PG, 1997, SCIENCE, V278, P100, DOI 10.1126/science.278.5335.100
   Cui CH, 2010, CHEM COMMUN, V46, P940, DOI 10.1039/b920705h
   Dash P, 2008, J MOL CATAL A-CHEM, V286, P114, DOI 10.1016/j.molcata.2008.02.003
   El-Sayed MA, 2004, ACCOUNTS CHEM RES, V37, P326, DOI 10.1021/ar020204f
   Eustis S, 2006, CHEM SOC REV, V35, P209, DOI 10.1039/b514191e
   Gauthard F, 2003, J CATAL, V220, P182, DOI 10.1016/S0021-9517(03)00252-5
   Goodman DW, 2008, NATURE, V454, P948, DOI 10.1038/454948a
   GRITTINI C, 1995, ENVIRON SCI TECHNOL, V29, P2898, DOI 10.1021/es00011a029
   He F, 2005, ENVIRON SCI TECHNOL, V39, P3314, DOI 10.1021/es048743y
   HEATH JR, 1995, SCIENCE, V270, P1315, DOI 10.1126/science.270.5240.1315
   Hennig B, 2002, TOXICOL APPL PHARM, V181, P174, DOI 10.1006/taap.2002.9408
   Hu JT, 1999, ACCOUNTS CHEM RES, V32, P435, DOI 10.1021/ar9700365
   HUANG CW, 2009, NANOTECHNOLOGY, V20
   Hulteen JC, 1997, J MATER CHEM, V7, P1075, DOI 10.1039/a700027h
   IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0
   Johnson TL, 1996, ENVIRON SCI TECHNOL, V30, P2634, DOI 10.1021/es9600901
   Joo SH, 2008, CHEMOSPHERE, V70, P418, DOI 10.1016/j.chemosphere.2007.06.070
   Katz E, 2004, ANGEW CHEM INT EDIT, V43, P6042, DOI 10.1002/anie.200400651
   Kaur A, 2009, J MATER CHEM, V19, P8279, DOI 10.1039/b901933b
   Kijima T, 2004, ANGEW CHEM INT EDIT, V43, P228, DOI 10.1002/anie.200352630
   Kim JH, 2008, ENVIRON SCI TECHNOL, V42, P4106, DOI 10.1021/es702560k
   Kim SW, 2002, J AM CHEM SOC, V124, P7642, DOI 10.1021/ja026032z
   Kinkead B, 2010, J MATER CHEM, V20, P448, DOI 10.1039/b911641a
   Lee CL, 2009, ELECTROCHIM ACTA, V54, P5544, DOI 10.1016/j.electacta.2009.04.056
   Lee W, 2005, ANGEW CHEM INT EDIT, V44, P6050, DOI 10.1002/anie.200501341
   Lewis S, 2009, SEPAR SCI TECHNOL, V44, P3289, DOI 10.1080/01496390903212805
   Li F, 2003, COLLOID SURFACE A, V223, P103, DOI 10.1016/S0927-7757(03)00187-0
   Li Y, 2000, ORG LETT, V2, P2385, DOI 10.1021/ol0061687
   Li ZP, 2010, J PHYS CHEM C, V114, P723, DOI 10.1021/jp907745v
   Liu XY, 2003, CHEM PHYS LETT, V374, P348, DOI 10.1016/S0009-2614(03)00730-9
   Luo CC, 2005, J MOL CATAL A-CHEM, V229, P7, DOI 10.1016/j.molcata.2004.10.039
   Ma DK, 2007, J CRYST GROWTH, V304, P163, DOI 10.1016/j.jcrysgro.2007.02.008
   Mao YB, 2004, J AM CHEM SOC, V126, P15245, DOI 10.1021/ja046331j
   MARTIN CR, 1990, J AM CHEM SOC, V112, P8976, DOI 10.1021/ja00180a050
   MARTIN CR, 1994, SCIENCE, V266, P1961, DOI 10.1126/science.266.5193.1961
   Martin CR, 1996, CHEM MATER, V8, P1739, DOI 10.1021/cm960166s
   Marx S, 2009, J PHYS CHEM C, V113, P6191, DOI 10.1021/jp808362m
   Meier MAR, 2006, J MATER CHEM, V16, P3001, DOI 10.1039/b602548j
   Mitchell DRG, 2008, ULTRAMICROSCOPY, V108, P367, DOI 10.1016/j.ultramic.2007.06.003
   Narayanan R, 2008, TOP CATAL, V48, P60, DOI 10.1007/s11244-008-9057-4
   NISHIZAWA M, 1995, SCIENCE, V268, P700, DOI 10.1126/science.268.5211.700
   Nurmi JT, 2005, ENVIRON SCI TECHNOL, V39, P1221, DOI 10.1021/es049190u
   O'Dwyer C, 2006, CHEM MATER, V18, P3016, DOI 10.1021/cm0603809
   OGAWAWARA S, 2010, J AM CHEM SOC, V132, P4609
   Peng ZM, 2009, J AM CHEM SOC, V131, P7542, DOI 10.1021/ja902256a
   Ponder SM, 2000, ENVIRON SCI TECHNOL, V34, P2564, DOI 10.1021/es9911420
   Ponder SM, 2001, CHEM MATER, V13, P479, DOI 10.1021/cm000288r
   Rahim EH, 2001, NANO LETT, V1, P499, DOI 10.1021/nl015574w
   Ramadass P, 2003, TOXICOL SCI, V76, P212, DOI 10.1093/toxsci/kfg227
   Rao CNR, 2003, DALTON T, P1, DOI 10.1039/b208990b
   Remskar M, 2004, ADV MATER, V16, P1497, DOI 10.1002/adma.200306428
   Roduner E, 2006, CHEM SOC REV, V35, P583, DOI 10.1039/b502142c
   Sander MS, 2003, ADV FUNCT MATER, V13, P393, DOI 10.1002/adfm.200304290
   Schlogl R, 2004, ANGEW CHEM INT EDIT, V43, P1628, DOI 10.1002/anie.200301684
   Serov A, 2009, APPL CATAL B-ENVIRON, V90, P313, DOI 10.1016/j.apcatb.2009.03.030
   She GW, 2009, CRYST GROWTH DES, V9, P663, DOI 10.1021/cg800948w
   Smuleac V, 2010, J MEMBRANE SCI, V346, P310, DOI 10.1016/j.memsci.2009.09.052
   Steinhart M, 2004, ANGEW CHEM INT EDIT, V43, P1334, DOI 10.1002/anie.200300614
   Steinhart M, 2003, ADV MATER, V15, P706, DOI 10.1002/adma.200304502
   Sun YG, 2004, J AM CHEM SOC, V126, P9399, DOI 10.1021/ja048789r
   Sun YG, 2004, ADV MATER, V16, P264, DOI 10.1002/adma.200305780
   Sun YG, 2003, ADV MATER, V15, P641, DOI 10.1002/adma.200301639
   Talapin DV, 2010, CHEM REV, V110, P389, DOI 10.1021/cr900137k
   Tao FF, 2006, ADV MATER, V18, P2161, DOI 10.1002/adma.200600275
   Tee YH, 2009, J PHYS CHEM C, V113, P12616, DOI 10.1021/jp905273a
   Tsuji J, 2004, PALLADIUM REAGENTS C
   Venkatachalam K, 2008, J HAZARD MATER, V159, P483, DOI 10.1016/j.jhazmat.2008.02.109
   Verbeeck J, 2003, J ELECTROCHEM SOC, V150, pE468, DOI 10.1149/1.1601230
   Wang CB, 1997, ENVIRON SCI TECHNOL, V31, P2154, DOI 10.1021/es970039c
   Xia YN, 2003, ADV MATER, V15, P353, DOI 10.1002/adma.200390087
   Xu J, 2005, ENVIRON PROG, V24, P358, DOI 10.1002/ep.10106
   Xu J, 2005, J NANOPART RES, V7, P449, DOI 10.1007/s11051-005-4273-3
   Xu J, 2007, IND ENG CHEM RES, V46, P2348, DOI 10.1021/ie0611498
   Xu XJ, 2008, J PHYS CHEM C, V112, P4168, DOI 10.1021/jp711597r
   XY Y, 2008, J PHYS D, V41
   Yak HK, 2000, ENVIRON SCI TECHNOL, V34, P2792, DOI 10.1021/es990689b
   Zhang F, 2008, CHEM MATER, V20, P5500, DOI 10.1021/cm800011j
   Zhang WX, 2003, J NANOPART RES, V5, P323, DOI 10.1023/A:1025520116015
   Zhang X, 2008, J MATER CHEM, V18, P463, DOI 10.1039/b714959j
   Zheng ZH, 2009, J HAZARD MATER, V170, P895, DOI 10.1016/j.jhazmat.2009.05.052
   Zhou HJ, 2008, ACS NANO, V2, P944, DOI 10.1021/nn700428x
   Zhu Y, 2006, ANGEW CHEM INT EDIT, V45, P7211, DOI 10.1002/anie.200602610
NR 96
TC 15
Z9 16
U1 4
U2 26
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 0959-9428
J9 J MATER CHEM
JI J. Mater. Chem.
PY 2011
VL 21
IS 28
BP 10454
EP 10462
DI 10.1039/c1jm11435b
PG 9
WC Chemistry, Physical; Materials Science, Multidisciplinary
SC Chemistry; Materials Science
GA 795OF
UT WOS:000292982800036
DA 2018-03-19
ER

PT J
AU Chopra, N
   Gavalas, VG
   Hinds, BJ
   Bachas, LG
AF Chopra, Nitin
   Gavalas, Vasilis G.
   Hinds, Bruce J.
   Bachas, Leonidas G.
TI Functional one-dimensional nanomaterials: Applications in nanoscale
   biosensors
SO ANALYTICAL LETTERS
LA English
DT Review
DE nanotube; nanowire; chemical functionalization; biomolecules; sensors;
   membranes
ID WALLED CARBON NANOTUBES; CONDUCTING POLYMER NANOWIRES; DIIMIDE-ACTIVATED
   AMIDATION; SILICON NANOWIRES; ELECTROCHEMICAL BIOSENSORS;
   GLUCOSE-OXIDASE; PROTEIN IMMOBILIZATION; NANOELECTRODE ARRAYS; GOLD
   NANORODS; RESPIRATORY TOXICITY
AB Nanostructures such as nanotubes (NTs), nanowires (NWs), and nanoparticles present new opportunities as sensing platforms for biological and environmental applications. Having micrometer-scale lengths and nanometer-scale diameters, NTs and NWs can be manipulated with current microfabrication, as well as self-assembly techniques to fabricate nanoscale devices and sensors. Alignment, uniform dispersion, selective growth, and diameter control are parameters that are critical to the successful integration of nanostructures into sensors and devices. Overcoming these challenges should lead to sensors with better selectivity, sensitivity, and longer operational lifetime. This review discusses biosensors based on nanostructured material.
C1 Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
   Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY USA.
RP Bachas, LG (reprint author), Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
EM bachas@uky.edu
RI Nitin, Chopra/F-8236-2011; Bachas, Leonidas/G-2479-2015
OI Bachas, Leonidas/0000-0002-3308-6264
CR ALMAWLAWI D, 1994, J MATER RES, V9, P1014, DOI 10.1557/JMR.1994.1014
   Andrews R, 1999, CHEM PHYS LETT, V303, P467, DOI 10.1016/S0009-2614(99)00282-1
   Arnold MS, 2003, J PHYS CHEM B, V107, P659, DOI 10.1021/jp0271054
   Arrigan DWM, 2004, ANALYST, V129, P1157, DOI 10.1039/b415395m
   Awang AA, 2006, NANOTECHNOLOGY, V17, P3375, DOI 10.1088/0957-4484/17/14/006
   Azamian BR, 2002, J AM CHEM SOC, V124, P12664, DOI 10.1021/ja0272989
   Baer DR, 2007, SURF INTERFACE ANAL, V39, P283, DOI 10.1002/sia.2508
   Baeumner A, 2004, FOOD TECHNOL-CHICAGO, V58, P51
   Baker LA, 2005, CRIT REV SOLID STATE, V30, P183, DOI 10.1080/10408430500198169
   BAKER RTK, 1972, J CATAL, V26, P51, DOI 10.1016/0021-9517(72)90032-2
   Baker SE, 2002, NANO LETT, V2, P1413, DOI 10.1021/nl025729f
   Balavoine F, 1999, ANGEW CHEM INT EDIT, V38, P1912, DOI 10.1002/(SICI)1521-3773(19990712)38:13/14<1912::AID-ANIE1912>3.0.CO;2-2
   Bauer LA, 2004, J MATER CHEM, V14, P517, DOI 10.1039/b312655b
   Baughman RH, 2002, SCIENCE, V297, P787, DOI 10.1126/science.1060928
   Bayley H, 2000, CHEM REV, V100, P2575, DOI 10.1021/cr980099g
   Besteman K, 2003, NANO LETT, V3, P727, DOI 10.1021/nl034139u
   Bhattacharjee Y, 2005, SCIENCE, V309, P1810
   Birenbaum NS, 2003, LANGMUIR, V19, P9580, DOI 10.1021/la035657n
   Boussaad S, 2003, CHEM COMMUN, P1502, DOI 10.1039/b302681g
   Bradley K, 2004, NANO LETT, V4, P253, DOI 10.1021/nl0349855
   BRENNER SS, 1956, ACTA METALL MATER, V4, P268, DOI 10.1016/0001-6160(56)90064-5
   BRIGHT FV, 1990, ANAL CHEM, V62, P1065, DOI 10.1021/ac00209a019
   Britto PJ, 1996, BIOELECTROCH BIOENER, V41, P121, DOI 10.1016/0302-4598(96)05078-7
   Bustero I, 2006, MICROCHIM ACTA, V152, P239, DOI 10.1007/s00604-005-0442-4
   Campbell JK, 1999, J AM CHEM SOC, V121, P3779, DOI 10.1021/ja990001v
   Carrero-Sanchez JC, 2006, NANO LETT, V6, P1609, DOI 10.1021/nl060548p
   Cattanach K, 2006, NANOTECHNOLOGY, V17, P4123, DOI 10.1088/0957-4484/17/16/022
   Che JW, 2000, NANOTECHNOLOGY, V11, P65, DOI 10.1088/0957-4484/11/2/305
   Chen HJ, 2007, BIOSENS BIOELECTRON, V22, P1811, DOI 10.1016/j.bios.2006.08.013
   Chen M, 2007, DIAM RELAT MATER, V16, P1110, DOI 10.1016/j.diamond.2006.12.061
   Chen RJ, 2003, P NATL ACAD SCI USA, V100, P4984, DOI 10.1073/pnas.0837064100
   Chen RJ, 2001, J AM CHEM SOC, V123, P3838, DOI 10.1021/ja010172b
   CHEN Y, 2006, APPL PHYS LETT, V89
   Chopra N, 2004, INORG CHIM ACTA, V357, P3920, DOI 10.1016/j.ica.2004.08.022
   Chopra N, 2002, NANO LETT, V2, P1177, DOI 10.1021/nl0257061
   Chung SW, 2005, SMALL, V1, P64, DOI 10.1002/smll.200400005
   Correa-Duarte MA, 2004, NANO LETT, V4, P2233, DOI 10.1021/nl048574f
   Cui DX, 2007, J NANOSCI NANOTECHNO, V7, P1298, DOI 10.1166/jnn.2007.654
   Cui DX, 2003, BIOTECHNOL PROGR, V19, P683, DOI 10.1021/bp025791i
   Cui Y, 2001, SCIENCE, V293, P1289, DOI 10.1126/science.1062711
   Cui Y, 2001, APPL PHYS LETT, V78, P2214, DOI 10.1063/1.1363692
   Curtis John, 2006, Toxicol Rev, V25, P245, DOI 10.2165/00139709-200625040-00005
   Curulli A, 2006, MICROCHIM ACTA, V152, P225, DOI 10.1007/s00604-005-0440-6
   da Silva LB, 2004, NANO LETT, V4, P65, DOI 10.1021/nl034873d
   Dai ZR, 2003, ADV FUNCT MATER, V13, P9, DOI 10.1002/adfm.200390013
   Dayen JF, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2731681
   Deo RP, 2005, ANAL CHIM ACTA, V530, P185, DOI 10.1016/j.aca.2004.09.072
   Ding Y, 2004, J AM CHEM SOC, V126, P2066, DOI 10.1021/ja039354r
   Donaldson K, 2006, TOXICOL SCI, V92, P5, DOI 10.1093/toxsci/kfj130
   DRESSALHAUS M, 2001, CARBON NANOTUBES SYN, V80
   DRESSALHAUS MS, 1996, SCI FULLERENES CARBO
   Dwyer C, 2002, NANOTECHNOLOGY, V13, P601, DOI 10.1088/0957-4484/13/5/311
   ENDO M, 1988, CHEMTECH, V18, P568
   Fan Y, 2007, J AM CHEM SOC, V129, P5437, DOI 10.1021/ja067477g
   Fond AM, 2007, J PHOTOCH PHOTOBIO A, V186, P57, DOI 10.1016/j.jphotochem.2006.07.011
   Fritzsche W, 2003, NANOTECHNOLOGY, V14, pR63, DOI 10.1088/0957-4484/14/12/R01
   Fuhrer MS, 2002, NANO LETT, V2, P755, DOI 10.1021/nl025577o
   Gao M, 2003, SYNTHETIC MET, V137, P1393, DOI 10.1016/S0379-6779(02)01156-6
   Garibaldi S, 2006, NANOTECHNOLOGY, V17, P391, DOI 10.1088/0957-4484/17/2/008
   Gavalas VG, 2004, ANAL BIOCHEM, V329, P247, DOI 10.1016/j.ab.2004.02.025
   Gavalas VG, 2001, NANO LETT, V1, P719, DOI 10.1021/nl015614w
   Ghosh S, 2002, PURE APPL CHEM, V74, P1719, DOI 10.1351/pac200274091719
   Gindulyte A, 1998, INORG CHEM, V37, P6544, DOI 10.1021/ic980559o
   Gooding JJ, 2003, J AM CHEM SOC, V125, P9006, DOI 10.1021/ja035722f
   Gorbitz CH, 2003, NEW J CHEM, V27, P1789, DOI 10.1039/b305984g
   Grobert N, 2007, MATER TODAY, V10, P28, DOI 10.1016/S1369-7021(06)71789-8
   Gruner G, 2006, ANAL BIOANAL CHEM, V384, P322, DOI 10.1007/s00216-005-3400-4
   Guiseppi-Elie A, 2002, NANOTECHNOLOGY, V13, P559, DOI 10.1088/0957-4484/13/5/303
   Guo ZJ, 1998, ADV MATER, V10, P701, DOI 10.1002/(SICI)1521-4095(199806)10:9<701::AID-ADMA701>3.0.CO;2-4
   HAES AJ, 2007, NANOTECHNOL BIOL MED
   Hahm J, 2004, NANO LETT, V4, P51, DOI 10.1021/nl034853b
   HAUFFE K, 1965, OXIDATION METALS
   He PA, 2006, MICROCHIM ACTA, V152, P175, DOI 10.1007/s00604-005-0445-1
   He PG, 2005, SYNTHETIC MET, V154, P17, DOI 10.1016/j.synthmet.2005.07.007
   He PG, 2004, CHEM COMMUN, P348, DOI 10.1039/b313030b
   Hinds BJ, 2004, SCIENCE, V303, P62, DOI 10.1126/science.1092048
   Hirsch A, 2002, ANGEW CHEM INT EDIT, V41, P1853, DOI 10.1002/1521-3773(20020603)41:11<1853::AID-ANIE1853>3.0.CO;2-N
   Holmes JD, 2000, SCIENCE, V287, P1471, DOI 10.1126/science.287.5457.1471
   Holt JK, 2006, SCIENCE, V312, P1034, DOI 10.1126/science.1126298
   Holt JK, 2004, NANO LETT, V4, P2245, DOI 10.1021/nl048876h
   Hone J, 1999, PHYS REV B, V59, pR2514, DOI 10.1103/PhysRevB.59.R2514
   Huang SM, 2002, J PHYS CHEM B, V106, P3543, DOI 10.1021/jp014047y
   Huang WJ, 2002, NANO LETT, V2, P311, DOI 10.1021/n1010095i
   Hurst SJ, 2006, ANGEW CHEM INT EDIT, V45, P2672, DOI 10.1002/anie.200504025
   Huynh WU, 2002, SCIENCE, V295, P2425, DOI 10.1126/science.1069156
   IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0
   Ito T, 2003, ELECTROCHEM SOLID ST, V6, pC4, DOI 10.1149/1.1526779
   Ji QM, 2004, CHEM LETT, V33, P504, DOI 10.1246/cl.2004.504
   Jiang KY, 2004, J MATER CHEM, V14, P37, DOI 10.1039/b310359e
   Kagan VE, 2005, NANOMED-NANOTECHNOL, V1, P313, DOI 10.1016/j.nano.2005.10.003
   Kam NWS, 2004, J AM CHEM SOC, V126, P6850, DOI 10.1021/ja0486059
   Kane RS, 2007, BIOTECHNOL PROGR, V23, P316, DOI 10.1021/bp060388n
   Kasili PM, 2005, J NANOSCI NANOTECHNO, V5, P2057, DOI 10.1166/jnn.2005.426
   Kasili RM, 2002, J NANOSCI NANOTECHNO, V2, P653, DOI 10.1166/jnn.2002.155
   KELLEY SO, 2007, NANOWIRES BIOMOLECUL
   Kodambaka S, 2007, SCIENCE, V316, P729, DOI 10.1126/science.1139105
   Koehne J, 2004, J MATER CHEM, V14, P676, DOI 10.1039/b311728f
   Kong J, 2000, SCIENCE, V287, P622, DOI 10.1126/science.287.5453.622
   Krishnan A, 1998, PHYS REV B, V58, P14013, DOI 10.1103/PhysRevB.58.14013
   Lam CW, 2006, CRIT REV TOXICOL, V36, P189, DOI 10.1080/10408440600570233
   Lao CS, 2007, NANO LETT, V7, P1323, DOI 10.1021/nl070359m
   Lee K, 2002, SYNTHETIC MET, V128, P279, DOI 10.1016/S0379-6779(02)00006-1
   Lenihan JS, 2004, J NANOSCI NANOTECHNO, V4, P600, DOI 10.1166/jnn.2004.150
   Lew KK, 2003, J CRYST GROWTH, V254, P14, DOI 10.1016/S0022-0248(03)01146-1
   Li C, 2003, APPL PHYS LETT, V83, P4014, DOI 10.1063/1.1625421
   Li D, 2003, NANO LETT, V3, P1167, DOI 10.1021/nl0344256
   Li JX, 2007, J NANOSCI NANOTECHNO, V7, P1525, DOI 10.1166/jnn.2007.336
   Li JY, 2004, SOLID STATE COMMUN, V131, P769, DOI 10.1016/j.ssc.2004.07.001
   Li Z, 2004, NANO LETT, V4, P245, DOI 10.1021/nl034958e
   Li Z, 2005, APPL PHYS A-MATER, V80, P1257, DOI 10.1007/s00339-004-3157-1
   Lim SH, 2005, BIOSENS BIOELECTRON, V20, P2341, DOI 10.1016/j.bios.2004.08.005
   Lin Y, 2006, MICROCHIM ACTA, V152, P249, DOI 10.1007/s00604-005-0443-3
   Lin YH, 2004, NANO LETT, V4, P191, DOI 10.1021/nl0347233
   LINSKY JP, 1971, J POLYM SCI A2, V9, P143, DOI 10.1002/pol.1971.160090110
   Liopo AV, 2006, J NANOSCI NANOTECHNO, V6, P1365, DOI 10.1166/jnn.2006.155
   Liu HQ, 2004, NANO LETT, V4, P671, DOI 10.1021/nl049826f
   Liu J, 2003, CHEM-EUR J, V9, P604, DOI 10.1002/chem.200390064
   Luong JHT, 2005, ELECTROANAL, V17, P47, DOI 10.1002/elan.200403117
   Luong JHT, 2004, ELECTROANAL, V16, P132, DOI 10.1002/elan.200302931
   Luque GL, 2006, MICROCHIM ACTA, V152, P277, DOI 10.1007/s00604-005-0447-z
   Ma YF, 2004, J AM CHEM SOC, V126, P7097, DOI 10.1021/ja039621t
   Martin BR, 1999, ADV MATER, V11, P1021, DOI 10.1002/(SICI)1521-4095(199908)11:12<1021::AID-ADMA1021>3.0.CO;2-S
   Martin CR, 1996, CHEM MATER, V8, P1739, DOI 10.1021/cm960166s
   Masciangioli T, 2003, ENVIRON SCI TECHNOL, V37, p102A, DOI 10.1021/es0323998
   Mbindyo JKN, 2001, ADV MATER, V13, P249, DOI 10.1002/1521-4095(200102)13:4<249::AID-ADMA249>3.0.CO;2-9
   McAlpine MC, 2007, NAT MATER, V6, P379, DOI 10.1038/nmat1891
   Merkoci A, 2006, MICROCHIM ACTA, V152, P157, DOI 10.1007/s00604-005-0439-z
   Meyyappan M, 2004, CARBON NANOTUBES SCI
   Modi A, 2003, NATURE, V424, P171, DOI 10.1038/nature01777
   Motesharei K, 1997, J AM CHEM SOC, V119, P11306, DOI 10.1021/ja9727171
   Muller J, 2006, CARBON, V44, P1048, DOI 10.1016/j.carbon.2005.10.019
   Muller J, 2005, TOXICOL APPL PHARM, V207, P221, DOI 10.1016/j.taap.2005.01.008
   Nednoor P, 2007, J MATER CHEM, V17, P1755, DOI 10.1039/b703365f
   Nguyen CV, 2002, NANO LETT, V2, P1079, DOI 10.1021/nl025689f
   Niemeyer CM, 2003, ANGEW CHEM INT EDIT, V42, P5796, DOI 10.1002/anie.200301703
   Niidome Y, 2004, CHEM LETT, V33, P454, DOI 10.1246/cl.2004.454
   Niidome Y, 2003, CHEM COMMUN, P2376, DOI 10.1039/b307836a
   Novak JP, 2003, APPL PHYS LETT, V83, P4026, DOI 10.1063/1.1626265
   OConnell M. J., 2006, CARBON NANOTUBES PRO
   Parikh K, 2006, SENSOR ACTUAT B-CHEM, V113, P55, DOI 10.1016/j.snb.2005.02.021
   PATOLSKY F, 2005, MATER TODAY, V8, P1
   Peng S, 2003, NANO LETT, V3, P513, DOI 10.1021/nl034064u
   Ramanathan K, 2005, J AM CHEM SOC, V127, P496, DOI 10.1021/ja044486l
   Ramanathan K, 2004, NANO LETT, V4, P1237, DOI 10.1021/nl049477p
   Reiss BD, 2002, J ELECTROANAL CHEM, V522, P95, DOI 10.1016/S0022-0728(01)00716-1
   Robertson J, 2006, MATER TODAY, V10, P36, DOI 10.1016/S1369-7021(06)71790-4
   RODRIGUEZ NM, 1993, J MATER RES, V8, P3233, DOI 10.1557/JMR.1993.3233
   Salaita K, 2006, ANGEW CHEM INT EDIT, V45, P7220, DOI 10.1002/anie.200603142
   Saleh OA, 2003, NANO LETT, V3, P37, DOI 10.1021/nl0255202
   Sanchez-Quesada J, 2000, J AM CHEM SOC, V122, P11757, DOI 10.1021/ja002436k
   Santos D.H., 2002, ELECTROANAL, V14, P1225
   Sau TK, 2004, LANGMUIR, V20, P6414, DOI 10.1021/la049463z
   Serp P, 2003, APPL CATAL A-GEN, V253, P337, DOI 10.1016/S0926-860X(03)00549-0
   Shim M, 2002, NANO LETT, V2, P285, DOI 10.1021/nl015692j
   Snow ES, 2005, NANO LETT, V5, P2414, DOI 10.1021/nl051669c
   Sotiropoulou S, 2003, ANAL BIOANAL CHEM, V375, P103, DOI 10.1007/s00216-002-1617-z
   Soundarrajan P, 2003, J VAC SCI TECHNOL A, V21, P1198, DOI 10.1116/1.1569926
   Stone V, 2006, NAT NANOTECHNOL, V1, P23, DOI 10.1038/nnano.2006.69
   Su M, 2003, J AM CHEM SOC, V125, P9930, DOI 10.1021/ja035727c
   Sun SH, 2003, J PHYS CHEM B, V107, P13029, DOI 10.1021/jp035763y
   Tans SJ, 1997, NATURE, V386, P474, DOI 10.1038/386474a0
   Terrones M, 2004, MATER TODAY, V7, P30, DOI 10.1016/S1369-7021(04)00447-X
   Thess A, 1996, SCIENCE, V273, P483, DOI 10.1126/science.273.5274.483
   Tsai YC, 2005, LANGMUIR, V21, P3653, DOI 10.1021/la0470535
   Tu Y, 2003, NANO LETT, V3, P107, DOI 10.1021/nl025879q
   Ung D, 2007, CHEM MATER, V19, P2084, DOI 10.1021/cm0627387
   VISHWANATH S, 1995, J MEMBRANE SCI, V108, P1, DOI 10.1016/0376-7388(95)00135-9
   Vo-Dinh T, 2000, NAT BIOTECHNOL, V18, P764, DOI 10.1038/77337
   Vo-Dinh T, 2005, ANAL BIOANAL CHEM, V382, P918, DOI 10.1007/s00216-005-3256-7
   Vo-Dinh T, 2002, J CELL BIOCHEM, P154, DOI 10.1002/jcb.10427
   Vo-Dinh T, 2006, NANOMED-NANOTECHNOL, V2, P22, DOI 10.1016/j.nano.2005.10.012
   WAGNER RS, 1965, T METALL SOC AIME, V233, P1053
   Wanekaya AK, 2006, ELECTROANAL, V18, P533, DOI 10.1002/elan.200503449
   Wang J, 2003, ANAL CHEM, V75, P2075, DOI 10.1021/ac030007+
   Wang J, 2005, ANALYST, V130, P421, DOI 10.1039/b414248a
   WANG J, 1993, ANAL CHIM ACTA, V283, P683, DOI 10.1016/0003-2670(93)85282-O
   Wang J, 2003, J AM CHEM SOC, V125, P2408, DOI 10.1021/ja028951v
   Wang SQ, 2003, NAT MATER, V2, P196, DOI 10.1038/nmat833
   Wang XD, 2004, NANO LETT, V4, P423, DOI 10.1021/nl035102c
   Wang ZL, 2003, ADV MATER, V15, P432, DOI 10.1002/adma.200390100
   WANGSA J, 1988, ANAL CHEM, V60, P1080, DOI 10.1021/ac00161a027
   Wei SH, 2006, MICROCHIM ACTA, V152, P285, DOI 10.1007/s00604-005-0437-1
   Wirtz M, 2002, ANALYST, V127, P871, DOI 10.1039/b201939f
   Wu YY, 2002, CHEM-EUR J, V8, P1261
   Yamamoto K, 2003, ANALYST, V128, P249, DOI 10.1039/b209698f
   Yang YH, 2004, J PHYS CHEM B, V108, P846, DOI 10.1021/jp030663d
   Yin AJ, 2001, APPL PHYS LETT, V79, P1039, DOI 10.1063/1.1389765
   Yu CX, 2007, ANAL CHEM, V79, P572, DOI 10.1021/ac061730d
   Yu MF, 2000, PHYS REV LETT, V84, P5552, DOI 10.1103/PhysRevLett.84.5552
   Yun MH, 2004, NANO LETT, V4, P419, DOI 10.1021/nl035069u
   Zhao Q, 2005, ELECTROANAL, V17, P85, DOI 10.1002/elan.200403123
   Zhong ZH, 2003, SCIENCE, V302, P1377, DOI 10.1126/science.1090899
   Zhu Y, 2006, J NANOSCI NANOTECHNO, V6, P1357, DOI 10.1166/jnn.2006.194
NR 193
TC 54
Z9 54
U1 3
U2 76
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0003-2719
EI 1532-236X
J9 ANAL LETT
JI Anal. Lett.
PY 2007
VL 40
IS 11
BP 2067
EP 2096
DI 10.1080/00032710701567170
PG 30
WC Chemistry, Analytical
SC Chemistry
GA 229VT
UT WOS:000250834700001
DA 2018-03-20
ER

PT J
AU Chen, AY
   DeLano, FA
   Valdez, SR
   Ha, JN
   Shin, HY
   Schmid-Schonbein, GW
AF Chen, Angela Y.
   DeLano, Frank A.
   Valdez, Shakti R.
   Ha, Jung-Myung
   Shin, Hainsworth Y.
   Schmid-Schoenbein, Geert W.
TI Receptor cleavage reduces the fluid shear response in neutrophils of the
   spontaneously hypertensive rat
SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
LA English
DT Article
DE formyl peptide receptor; pseudopod projection; cone-and-plate device;
   N-formyl-methionine-leucine-phenylalanine; immunohistochemistry
ID FORMYL-PEPTIDE RECEPTORS; CIRCULATING LEUKOCYTES; MICROVESSEL
   PERMEABILITY; STRESS; ENDOTHELIUM; ACTIVATION; EXPRESSION; RESISTANCE;
   MEMBRANE; ADHESION
AB Chen AY, DeLano FA, Valdez SR, Ha JN, Shin HY, Schmid-Schonbein GW. Receptor cleavage reduces the fluid shear response in neutrophils of the spontaneously hypertensive rat. Am J Physiol Cell Physiol 299: C1441-C1449, 2010. First published September 22, 2010; doi:10.1152/ajpcell.00157.2010.-Physiological fluid shear stress evokes pseudopod retraction in normal leukocytes by a mechanism that involves the formyl peptide receptor (FPR) as mechanosensor. In hypertensives, such as the spontaneously hypertensive rat (SHR), leukocytes lack the normal fluid shear response. The increased activity of matrix metalloproteinases (MMPs, including MMP-9) in SHR plasma is associated with cleavage of several cell membrane receptors. We hypothesize that the attenuated fluid shear response in leukocytes (neutrophils) of the SHR is due to extracellular proteolytic cleavage of the FPR. We show that suspended SHR neutrophils in whole blood sheared in a cone-and-plate device or individual neutrophils adherent to a glass surface and subject to fluid shear exhibited reduced pseudopod retractions compared with neutrophils of control Wistar-Kyoto (WKY) rats. SHR neutrophils and naive Wistar rat neutrophils exposed to SHR plasma also exhibited impaired fluid shear responses as shown by their inability to project pseudopods with fluid shear. Labeling of extracellular FPR revealed that the FPR density in SHR neutrophils is on average 27% reduced compared with those of the WKY rats. Exposure of Wistar rat neutrophils to the gelatinase MMP-9 (final concentration 5 nM) led to attenuation of fluid shear response and decrease in extracellular FPR density. Chronic treatment of the SHR with a broad-acting MMP inhibitor, doxycycline, significantly improved the fluid shear response and increased the FPR extracellular density of SHR neutrophils. These results suggest that proteolytic cleavage of the FPR may interfere with normal fluid shear-induced pseudopod retractions in SHR neutrophils.
C1 [Chen, Angela Y.; DeLano, Frank A.; Valdez, Shakti R.; Ha, Jessica N.; Schmid-Schoenbein, Geert W.] Univ Calif San Diego, Inst Engn Med, Dept Bioengn, La Jolla, CA 92093 USA.
   [Shin, Hainsworth Y.] Univ Kentucky, Ctr Biomed Engn, Lexington, KY 40506 USA.
RP Chen, AY (reprint author), Univ Calif San Diego, Inst Engn Med, Dept Bioengn, 9500 Gilman Dr, La Jolla, CA 92093 USA.
FU National Heart Lung and Blood Institute [HL-10881]
FX This research was supported by National Heart Lung and Blood Institute
   Grant HL-10881.
CR Abdulla MH, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000298
   BARR TL, 2009, STROKE, V41, pE123
   Boz C, 2006, CLIN NEUROL NEUROSUR, V108, P124, DOI 10.1016/j.clineuro.2005.01.005
   DeLano FA, 2008, HYPERTENSION, V52, P415, DOI 10.1161/HYPERTENSIONAHA.107.104356
   Delano Frank A, 2010, Expert Rev Endocrinol Metab, V5, P149
   Friese RS, 2009, CLIN EXP HYPERTENS, V31, P521, DOI 10.3109/10641960802668730
   Fukuda S, 2004, CIRC RES, V95, P100, DOI 10.1161/01.RES.0000133677.77465.38
   Fukuda S, 2003, P NATL ACAD SCI USA, V100, P13152, DOI 10.1073/pnas.2336130100
   Fukuda S, 2000, CIRC RES, V86, pE13
   Fukuda S, 2002, J LEUKOCYTE BIOL, V72, P133
   Hamilton CA, 2001, HYPERTENSION, V37, P529, DOI 10.1161/01.HYP.37.2.529
   Kerr S, 1999, HYPERTENSION, V33, P1353, DOI 10.1161/01.HYP.33.6.1353
   Kimoto S., 1995, Clinical and Experimental Pharmacology and Physiology, V22, pS160, DOI 10.1111/j.1440-1681.1995.tb02863.x
   Komai Y, 2005, ANN BIOMED ENG, V33, P1375, DOI 10.1007/s10439-005-6768-6
   Le YY, 2002, TRENDS IMMUNOL, V23, P541, DOI 10.1016/S1471-4906(02)02316-5
   Lee S, 2005, J CELL BIOL, V169, P681, DOI 10.1083/jcb.200409115
   Levy AS, 2009, VASC HEALTH RISK MAN, V5, P1075
   Loitto VM, 2001, J LEUKOCYTE BIOL, V69, P762
   Lominadze D, 1998, AM J HYPERTENS, V11, P784, DOI 10.1016/S0895-7061(98)00056-9
   Makino A, 2006, AM J PHYSIOL-CELL PH, V290, pC1633, DOI 10.1152/ajpcell.00576.2005
   Makino A, 2005, AM J PHYSIOL-CELL PH, V288, pC863, DOI 10.1152/ajpcell.00358.2004
   Makino A, 2007, BIORHEOLOGY, V44, P221
   MARASCO WA, 1983, AM J PATHOL, V111, P273
   Marschel P, 2002, ANN BIOMED ENG, V30, P333, DOI 10.1114/1.1475342
   Mendoza V, 2009, BIOCHEMISTRY-US, V48, P11755, DOI 10.1021/bi901528w
   Moazzam F, 1997, P NATL ACAD SCI USA, V94, P5338, DOI 10.1073/pnas.94.10.5338
   Obata T, 2007, DIABETES, V56, P2028, DOI 10.2337/db07-0394
   Panaro MA, 2007, IMMUNOPHARM IMMUNOT, V29, P1, DOI 10.1080/08923970701277569
   Pliyev BK, 2010, INFLAMMATION, V33, P1, DOI 10.1007/s10753-009-9152-0
   Plotnikov MB, 1998, B EXP BIOL MED+, V126, P775, DOI 10.1007/BF02446906
   Rodrigues SF, 2010, AM J PHYSIOL-HEART C, V299, pH25, DOI 10.1152/ajpheart.00620.2009
   SchmidSchonbein G, 1997, ATHEROSCLEROSIS, V131, pS1
   Shin HY, 2008, J CELL PHYSIOL, V214, P528, DOI 10.1002/jcp.21235
   Su SS, 2008, ANN BIOMED ENG, V36, P298, DOI 10.1007/s10439-007-9406-7
   SUEMATSU M, 1995, J CLIN INVEST, V96, P2009, DOI 10.1172/JCI118248
   Sugihara-Seki M, 2003, J BIOMECH ENG-T ASME, V125, P628, DOI 10.1115/1.1611515
   Thrailkill K, 2006, CLIN CHEM LAB MED, V44, P503, DOI 10.1515/CCLM.2006.090
   Tran ED, 2010, J VASC RES, V47, P423, DOI 10.1159/000281582
   Turk BE, 2001, NAT BIOTECHNOL, V19, P661, DOI 10.1038/90273
   *UNIPROT CONS, 2010, NUCL ACIDS RES, V0038
   WATTS RG, 1991, CELL MOTIL CYTOSKEL, V19, P159, DOI 10.1002/cm.970190304
   Yang AL, 2010, EXP PHYSIOL, V95, P622, DOI 10.1113/expphysiol.2009.050146
   Zhan CD, 2004, J HYPERTENS, V22, P2025, DOI 10.1097/00004872-200410000-00027
   Zhu LK, 2006, AM J PHYSIOL-HEART C, V290, pH365, DOI 10.1152/ajpheart.00812.2005
   Zhu LK, 2005, AM J PHYSIOL-HEART C, V288, pH1331, DOI 10.1152/ajpheart.00802.2004
NR 45
TC 21
Z9 21
U1 1
U2 5
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6143
J9 AM J PHYSIOL-CELL PH
JI Am. J. Physiol.-Cell Physiol.
PD DEC
PY 2010
VL 299
IS 6
BP C1441
EP C1449
DI 10.1152/ajpcell.00157.2010
PG 9
WC Cell Biology; Physiology
SC Cell Biology; Physiology
GA 688BC
UT WOS:000284822100026
PM 20861466
OA gold
DA 2018-03-20
ER

PT J
AU Mattei, A
   Mei, XN
   Miller, AF
   Li, TL
AF Mattei, Alessandra
   Mei, Xiaonan
   Miller, Anne-Frances
   Li, Tonglei
TI Two Major Pre-Nucleation Species that are Conformationally Distinct and
   in Equilibrium of Self-Association
SO CRYSTAL GROWTH & DESIGN
LA English
DT Article
ID AQUEOUS-SOLUTION; MOLECULAR-CONFORMATION; TOLFENAMIC ACID; POLYMORPHISM;
   CRYSTALLIZATION; CRYSTAL; SOLVENT; DIFFUSION; MANNITOL; SORBITOL
AB To understand how solution chemistry governs polymorphic formation of organic crystals, solution NMR measurements of tolfenamic acid were conducted in ethanol. It was unveiled by chemical shift and diffusivity results that the solute molecules self-associated as dimers in solution. Further nOe (nuclear Overhauser effect) analyses indicate that a more twisted conformation became dominant over a planar conformation under the solution conditions that favored the dimer formation. This discovery is rationalized in terms of the energy balance between the conformation and intermolecular hydrogen bonding of the solute molecule, suggesting a significant role of the cooperability between a molecule's conformation and its intermolecular interaction in determining the nucleation outcome of distinct crystal structures.
C1 [Mattei, Alessandra] Univ Kentucky, Dept Pharmaceut Chem, Lexington, KY 40506 USA.
   [Mei, Xiaonan; Miller, Anne-Frances] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
   [Li, Tonglei] Purdue Univ, Dept Ind & Phys Pharm, W Lafayette, IN 47907 USA.
RP Li, TL (reprint author), Purdue Univ, Dept Ind & Phys Pharm, 575 Stadium Mall Dr, W Lafayette, IN 47907 USA.
EM tonglei@purdue.edu
RI Miller, Anne-Frances/M-7703-2017
FU NSF [DMR-1006364]
FX The authors thank W. J. Layton for assistance with the NMR spectrometer.
   The research was supported by NSF (DMR-1006364).
CR ATTWOOD D, 1994, MAGN RESON CHEM, V32, P468, DOI 10.1002/mrc.1260320807
   Bensouissi A, 2010, FOOD CHEM, V122, P443, DOI 10.1016/j.foodchem.2009.03.075
   BERNSTEIN J, 1978, J AM CHEM SOC, V100, P673, DOI 10.1021/ja00471a001
   Bernstein J., 1999, ANGEW CHEM INT EDIT, V38, P3441
   Bernstein J, 2011, CRYST GROWTH DES, V11, P632, DOI 10.1021/cg1013335
   Chen J, 2008, J PHYS CHEM B, V112, P7794, DOI 10.1021/jp7106582
   Davey RJ, 1997, J AM CHEM SOC, V119, P1767, DOI 10.1021/ja9626345
   Davey RJ, 2001, CRYST GROWTH DES, V1, P59, DOI 10.1021/cg000009c
   Davies DB, 1996, J CHEM SOC FARADAY T, V92, P383, DOI 10.1039/ft9969200383
   Desiraju GR, 2007, CRYSTENGCOMM, V9, P91, DOI 10.1039/b614933b
   DUNITZ JD, 1995, ACCOUNTS CHEM RES, V28, P193, DOI 10.1021/ar00052a005
   Erdemir D, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.115702
   ETTER MC, 1991, J PHYS CHEM-US, V95, P4601, DOI 10.1021/j100165a007
   Gidalevitz D, 1997, ANGEW CHEM INT EDIT, V36, P955, DOI 10.1002/anie.199709551
   Hamad S, 2006, J PHYS CHEM B, V110, P3323, DOI 10.1021/jp055982e
   Hamad S, 2008, J PHYS CHEM B, V112, P7280, DOI 10.1021/jp711271z
   Huang J, 2008, J AM CHEM SOC, V130, P13973, DOI 10.1021/ja804836d
   Hunter CA, 2012, CRYSTENGCOMM, V14, P7115, DOI 10.1039/c2ce25941a
   JABRANE S, 1995, THERMOCHIM ACTA, V258, P33, DOI 10.1016/0040-6031(94)02235-G
   JEFFREY GA, 1990, ACTA CRYSTALLOGR B, V46, P89, DOI 10.1107/S0108768189012449
   JEFFREY GA, 1970, CARBOHYD RES, V14, P207, DOI 10.1016/S0008-6215(00)80488-7
   Mattei A, 2012, PHARM RES-DORDR, V29, P460, DOI 10.1007/s11095-011-0574-7
   Mattei A, 2011, INT J PHARMACEUT, V418, P179, DOI 10.1016/j.ijpharm.2011.04.062
   MYERSON AS, 1991, J CRYST GROWTH, V110, P26, DOI 10.1016/0022-0248(91)90862-Y
   Nangia A, 2008, ACCOUNTS CHEM RES, V41, P595, DOI 10.1021/ar700203k
   Panreen S., 2005, CHEM COMMUN, P1531
   Schouten A, 1998, CARBOHYD RES, V312, P131, DOI 10.1016/S0008-6215(98)00243-2
   Siniti M, 1999, THERMOCHIM ACTA, V325, P171, DOI 10.1016/S0040-6031(98)00576-0
   Steed JW, 2003, CRYSTENGCOMM, P169, DOI 10.1039/b304631a
   STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690
   Weissbuch L, 2003, CRYST GROWTH DES, V3, P125
   Yu L, 2000, ORG PROCESS RES DEV, V4, P396, DOI 10.1021/op000028v
   Yu Lian, 2002, Journal of Pharmaceutical Sciences, V91, P2367, DOI 10.1002/jps.10225
NR 33
TC 10
Z9 10
U1 4
U2 34
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1528-7483
J9 CRYST GROWTH DES
JI Cryst. Growth Des.
PD AUG
PY 2013
VL 13
IS 8
BP 3303
EP 3307
DI 10.1021/cg401026j
PG 5
WC Chemistry, Multidisciplinary; Crystallography; Materials Science,
   Multidisciplinary
SC Chemistry; Crystallography; Materials Science
GA 199UC
UT WOS:000323020000007
DA 2018-03-20
ER

PT J
AU Howard, MD
   Ponta, A
   Eckman, A
   Jay, M
   Bae, Y
AF Howard, Melissa D.
   Ponta, Andrei
   Eckman, Allison M.
   Jay, Michael
   Bae, Younsoo
TI Polymer Micelles with Hydrazone-Ester Dual Linkers for Tunable Release
   of Dexamethasone
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE dexamethasone; drug delivery; ester; hydrazone; polymer micelles
ID DRUG-DELIVERY SYSTEMS; INTERSTITIAL FLUID PRESSURE; CANCER-CHEMOTHERAPY;
   ANTITUMOR-ACTIVITY; SOLID TUMORS; DESIGN; INHIBITION; THERAPY;
   PHARMACOKINETICS; CARBOXYLESTERASE
AB To develop polymer micelles for the tunable release of Dexamethasone (DEX) in tumors.
   DEX was conjugated to poly(ethylene glycol)-poly(aspartate) block copolymers using hydrazone, ester, or hydrazone-ester dual linkers. Ketonic acids containing 3, 4, and 5 methylene groups were used as spacers to separate the dual linkers. Polymer micelles from the DEX-conjugated polymers were tested for drug release at different pH values and carboxylesterase activity levels.
   DLS measurements and H-1-NMR analysis confirmed all DEX-loaded micelles were < 100 nm with core-shell structure. Single linker micelles appeared unsuitable to release DEX preferentially in acidic tumor tissues. Hydrazone linkages between DEX and polymers were non-degradable at both pH 7.4 and 5.0. Ester linkages stable at pH 5.0 were unstable at pH 7.4. Hydrazone-ester dual linkers suppressed DEX release at pH 7.4 while accelerating drug release at pH 5.0. DEX release decreased at pH 5.0 as the length of ketonic acid increased but was independent of spacer length at pH 7.4. Dual linker micelles were stable in the presence of carboxylesterases, suggesting DEX release was primarily due to pH-dependent hydrolysis.
   Tunable release of DEX was achieved using pH-sensitive polymer micelles with hydrazone-ester dual linkers.
C1 [Howard, Melissa D.; Ponta, Andrei; Eckman, Allison; Jay, Michael; Bae, Younsoo] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
   [Jay, Michael] Univ N Carolina, Lineberger Comprehens Canc Ctr, Div Mol Pharmaceut, Eshelman Sch Pharm, Chapel Hill, NC 27599 USA.
RP Bae, Y (reprint author), Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, 789 South Limestone, Lexington, KY 40536 USA.
EM younsoo.bae@uky.edu
FU Kentucky Lung Cancer Research Program
FX Authors acknowledge financial support provided by the Kentucky Lung
   Cancer Research Program.
CR Alani AWG, 2010, BIOMATERIALS, V31, P1765, DOI 10.1016/j.biomaterials.2009.11.038
   Andresen TL, 2010, MOL MEMBR BIOL, V27, P353, DOI 10.3109/09687688.2010.515950
   Atkins JH, 2002, NAT REV CANCER, V2, P645, DOI 10.1038/nrc900
   AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286
   Bae Y, 2003, ANGEW CHEM INT EDIT, V42, P4640, DOI 10.1002/anie.200250653
   Bae Y, 2005, BIOCONJUGATE CHEM, V16, P122, DOI 10.1021/bc0498166
   Bae Y, 2007, J CONTROL RELEASE, V122, P324, DOI 10.1016/j.jconrel.2007.05.038
   Bae Y, 2007, BIOCONJUGATE CHEM, V18, P1131, DOI 10.1021/bc060401p
   Bae Y, 2010, PHARM RES-DORDR, V27, P2421, DOI 10.1007/s11095-010-0234-3
   Bae Y, 2009, ADV DRUG DELIVER REV, V61, P768, DOI 10.1016/j.addr.2009.04.016
   Baker MA, 1996, J CONTROL RELEASE, V40, P89, DOI 10.1016/0168-3659(95)00177-8
   Croy SR, 2006, CURR PHARM DESIGN, V12, P4669, DOI 10.2174/138161206779026245
   Dreher MR, 2006, J NATL CANCER I, V98, P335, DOI 10.1093/jnci/djj070
   Duncan R, 2003, NAT REV DRUG DISCOV, V2, P347, DOI 10.1038/nrd1088
   Duncan R, 2006, NAT REV CANCER, V6, P688, DOI 10.1038/nrc1958
   Franchimont D, 2000, J IMMUNOL, V164, P1768, DOI 10.4049/jimmunol.164.4.1768
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Hobbs SK, 1998, P NATL ACAD SCI USA, V95, P4607, DOI 10.1073/pnas.95.8.4607
   Howard MD, 2008, J BIOMED NANOTECHNOL, V4, P133, DOI 10.1166/jbn.2008.021
   Jain RK, 1997, ADV DRUG DELIVER REV, V26, P71, DOI 10.1016/S0169-409X(97)00027-6
   Jordan CGM, 1998, J PHARM SCI, V87, P880, DOI 10.1021/js970280p
   Kale AA, 2007, BIOCONJUGATE CHEM, V18, P363, DOI 10.1021/bc060228x
   Kano MR, 2007, P NATL ACAD SCI USA, V104, P3460, DOI 10.1073/pnas.0611660104
   Kataoka K, 2001, ADV DRUG DELIVER REV, V47, P113, DOI 10.1016/S0169-409X(00)00124-1
   Kim MS, 2007, ANESTH ANALG, V104, P1052, DOI 10.1213/01.ane.0000263276.52287.3b
   Krakovicova H, 2009, EUR J PHARM SCI, V37, P405, DOI 10.1016/j.ejps.2009.03.011
   Kratz F, 1999, CRIT REV THER DRUG, V16, P245, DOI 10.1615/CritRevTherDrugCarrierSyst.v16.i3.10
   KRISTJANSEN PEG, 1993, CANCER RES, V53, P4764
   Lee ES, 2008, J CONTROL RELEASE, V132, P164, DOI 10.1016/j.jconrel.2008.05.003
   Leopold CS, 1995, INT J PHARM, V126, P139, DOI 10.1016/0378-5173(95)04107-9
   Li B, 2005, BIOCHEM PHARMACOL, V70, P1673, DOI 10.1016/j.bcp.2005.09.002
   Lian T, 2001, J PHARM SCI, V90, P667, DOI 10.1002/jps.1023
   Liu XM, 2008, PHARM RES-DORD, V25, P2910, DOI 10.1007/s11095-008-9683-3
   MATSUMURA Y, 1986, CANCER RES, V46, P6387
   Matsumura Y, 2009, CANCER SCI, V100, P572, DOI 10.1111/j.1349-7006.2009.01103.x
   Navalitloha Y, 2006, NEURO-ONCOLOGY, V8, P227, DOI 10.1215/15228517-2006-007
   Oosterhoff D, 2002, BRIT J CANCER, V87, P659, DOI 10.1038/sj.bjc.6600519
   Oyewumi MO, 2004, J CONTROL RELEASE, V95, P613, DOI 10.1016/j.jconrel.2004.01.002
   Ponta A, 2010, PHARM RES-DORDR, V27, P2330, DOI 10.1007/s11095-010-0120-z
   Putnam D, 1995, ADV POLYM SCI, V122, P55
   Scripture CD, 2006, NAT REV CANCER, V6, P546, DOI 10.1038/nrc.1887
   SEYMOUR LW, 1987, J BIOMED MATER RES, V21, P1341, DOI 10.1002/jbm.820211106
   Smalley KSM, 2006, MOL CANCER THER, V5, P1136, DOI 10.1158/1535-7163.MCT-06-0084
   Takakura Y, 1996, PHARMACEUT RES, V13, P820, DOI 10.1023/A:1016084508097
   Torchilin VP, 2001, J CONTROL RELEASE, V73, P137, DOI 10.1016/S0168-3659(01)00299-1
   Wang D, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2106
   Wang H, 2004, CLIN CANCER RES, V10, P1633, DOI 10.1158/1078-0432.CCR-0829-3
   Wang H, 2007, INT J ONCOL, V30, P947
   West Kevin R, 2005, Curr Drug Discov Technol, V2, P123, DOI 10.2174/1570163054866882
   YAMAOKA T, 1994, J PHARM SCI, V83, P601, DOI 10.1002/jps.2600830432
   Yoshioka S, 2000, STABILITY DRUGS DOSA
NR 52
TC 28
Z9 28
U1 4
U2 42
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
EI 1573-904X
J9 PHARM RES-DORDR
JI Pharm. Res.
PD OCT
PY 2011
VL 28
IS 10
BP 2435
EP 2446
DI 10.1007/s11095-011-0470-1
PG 12
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 819FV
UT WOS:000294811700008
PM 21614636
DA 2018-03-19
ER

PT J
AU Biswal, D
   Hilt, JZ
AF Biswal, Dipti
   Hilt, J. Zach
TI Microscale analysis of patterning reactions via FTIR imaging:
   Application to intelligent hydrogel systems
SO POLYMER
LA English
DT Article
DE FTIR imaging; hydrogel; microcontact printing
ID DRUG-DELIVERY; MEDICINE; RELEASE; GLYCOL); BIOLOGY
AB A novel application of FTIR imaging for real-time characterization of patterning polymerization processes with microscale spatial resolution is presented. These methods will enable the microscale analysis of the reactions of polymeric systems with various substrates and devices. Specifically, intelligent hydrogels containing ionic groups (pH responsive) and poly(ethylene glycol) have been micropatterned onto gold surfaces, and the free-radical polymerization reaction, has been characterized. It was demonstrated that differences in the reaction rates across a patterned region could be successfully resolved and characterized. This novel characterization method based on FTIR imaging will facilitate the optimization of integration processes of patterned polymeric films leading to enhanced (and reproducible) application of these materials as functional components in a variety of microdevices. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Hilt, JZ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 F Paul Anderson Tower, Lexington, KY 40506 USA.
EM hilt@engr.uky.edu
CR Bashir R, 2002, APPL PHYS LETT, V81, P3091, DOI 10.1063/1.1514825
   Beebe DJ, 2000, NATURE, V404, P588, DOI 10.1038/35007047
   Bhargava R, 2003, ADV POLYM SCI, V163, P137, DOI 10.1007/b11052
   Chan KLA, 2005, J COMB CHEM, V7, P185, DOI 10.1021/cc049840q
   Coutts-Lendon CA, 2003, J CONTROL RELEASE, V93, P223, DOI 10.1016/j.jconrel.2003.06.003
   Ehrick JD, 2005, NAT MATER, V4, P298, DOI 10.1038/nmat1352
   Fernandez DC, 2005, NAT BIOTECHNOL, V23, P469, DOI 10.1038/nbt1080
   Fleming OS, 2006, POLYMER, V47, P4649, DOI 10.1016/j.polymer.2006.04.059
   Gonzalez-Benito J, 2006, POLYMER, V47, P3065, DOI 10.1016/j.polymer.2006.02.086
   Hilt JZ, 2004, ADV DRUG DELIVER REV, V56, P1599, DOI 10.1016/j.addr.2004.04.002
   Hilt JZ, 2003, BIOMED MICRODEVICES, V5, P177, DOI 10.1023/A:1025786023595
   Hoffman AS, 2002, ADV DRUG DELIVER REV, V54, P3, DOI 10.1016/S0169-409X(01)00239-3
   Kazarian SG, 2003, MACROMOLECULES, V36, P9866, DOI 10.1021/ma035210l
   Kim B, 2003, POLYMER, V44, P3701, DOI 10.1016/S0032-3861(03)00307-0
   LEWIS EN, 1995, ANAL CHEM, V67, P3377, DOI 10.1021/ac00115a003
   Odian G., 2004, PRINCIPLES POLYM
   Peppas NA, 2006, ADV MATER, V18, P1345, DOI 10.1002/adma.200501612
   Peppas NA, 2000, ANNU REV BIOMED ENG, V2, P9, DOI 10.1146/annurev.bioeng.2.1.9
   Peppas N. A., 1986, HYDROGELS MED PHARM
   PHILIPPOVA OE, 1994, MACROMOLECULES, V27, P2398, DOI 10.1021/ma00087a006
   Rafferty DW, 2002, APPL SPECTROSC, V56, P1549, DOI 10.1366/000370202321116002
   Sershen SR, 2005, ADV MATER, V17, P1366, DOI 10.1002/adma.200401239
   van der Weerd J, 2004, J CONTROL RELEASE, V98, P295, DOI 10.1016/j.jconrel.2004.05.007
NR 23
TC 20
Z9 22
U1 0
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0032-3861
J9 POLYMER
JI Polymer
PD OCT 4
PY 2006
VL 47
IS 21
BP 7355
EP 7360
DI 10.1016/j.polymer.2006.08.028
PG 6
WC Polymer Science
SC Polymer Science
GA 097CU
UT WOS:000241424800005
DA 2018-03-20
ER

PT J
AU Hayes, D
   Winkler, MA
   Kirkby, S
   Capasso, P
   Mansour, HM
   Attili, AK
AF Hayes, Don, Jr.
   Winkler, Michael A.
   Kirkby, Stephen
   Capasso, Patrizio
   Mansour, Heidi M.
   Attili, Anil K.
TI Preprocedural Planning with Prospectively Triggered Multidetector Row CT
   Angiography Prior to Bronchial Artery Embolization in Cystic Fibrosis
   Patients with Massive Hemoptysis
SO LUNG
LA English
DT Article
DE Angiography; Prospectively triggered; Multidetector row; Computed
   tomography; Cystic fibrosis Hemoptysis
ID NONBRONCHIAL SYSTEMIC ARTERIES; FIBEROPTIC BRONCHOSCOPY; PULMONARY
   COMPLICATIONS; BLEEDING SITE
AB The aim of this study was to determine if electrocardiographically synchronized, prospectively triggered multidetector row computed tomography (ECG-MDR-CT) angiography of the aorta can accurately predict the location of ectopic bronchial arteries in patients with cystic fibrosis (CF) with massive hemoptysis prior to bronchial artery embolization (BAE).
   The study was a prospective, observational study from September 1, 2009 to June 30, 2011, conducted at a university hospital with an adult CF center.
   The study included adult CF patients with massive hemoptysis.
   A total of four adult patients (mean [+/- SD] age = 31.5 +/- A 7.9 years) with CF and massive hemoptysis underwent ECG-MDR-CT angiography. The location of the bleeding source was predicted in each case based on lung pathology observed on ECG-MDR-CT angiography. All four patients eventually required BAE without the need for conventional aortograms since the locations of the bronchial arteries were determined prior to the procedure. Review of lung pathology and arterial networks from the ECG-MDR-CT angiography data limited the number of selective catheterizations necessary to complete the procedures. BAE resulted in complete resolution of hemoptysis in three patients and successful mitigation of the bleeding in the fourth patient until lung transplantation was performed 1 week later.
   ECG-MDR-CT angiography accurately depicted bronchial artery anatomy in CF patients with massive hemoptysis and provided excellent preprocedural planning for BAE. The information provided by ECG-MDR-CT angiography of the aorta prior to conventional angiography decreased the BAE radiation dose and contrast volume and likely reduced table time.
C1 [Hayes, Don, Jr.; Kirkby, Stephen] Ohio State Univ, Coll Med, Dept Pediat, Columbus, OH 43210 USA.
   [Winkler, Michael A.; Capasso, Patrizio; Attili, Anil K.] Univ Kentucky, Coll Med, Dept Radiol, Lexington, KY USA.
   [Mansour, Heidi M.] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY USA.
   [Hayes, Don, Jr.; Kirkby, Stephen] Ohio State Univ, Coll Med, Dept Internal Med, Columbus, OH 43210 USA.
RP Hayes, D (reprint author), Ohio State Univ, Coll Med, Dept Pediat, Columbus, OH 43210 USA.
EM Don.Hayes@nationwidechildrens.org
OI Winkler, Michael/0000-0001-5858-3841
CR Barben Juerg U, 2003, J Cyst Fibros, V2, P105, DOI 10.1016/S1569-1993(03)00066-3
   Brinson GM, 1998, AM J RESP CRIT CARE, V157, P1951, DOI 10.1164/ajrccm.157.6.9708067
   Chun JY, 2010, EUR RADIOL, V20, P558, DOI 10.1007/s00330-009-1591-3
   de Gracia J, 2003, RESP MED, V97, P790, DOI 10.1016/S0954-1114(03)00032-5
   Dweik RA, 1999, CLIN CHEST MED, V20, P89, DOI 10.1016/S0272-5231(05)70129-5
   Flume PA, 2005, CHEST, V128, P729, DOI 10.1378/chest.128.2.729
   Flume PA, 2010, AM J RESP CRIT CARE, V182, P298, DOI 10.1164/rccm.201002-0157CI
   GONG H, 1981, AM REV RESPIR DIS, V124, P221
   Hartmann IJC, 2007, EUR RADIOL, V17, P1943, DOI 10.1007/s00330-006-0576-8
   Khalil A, 2007, AM J ROENTGENOL, V188, pW117, DOI 10.2214/AJR.05.1578
   Lordan JL, 2003, THORAX, V58, P814, DOI 10.1136/thorax.58.9.814
   Mundo-Sagardia Jorge A, 2007, J Cardiovasc Comput Tomogr, V1, P110, DOI 10.1016/j.jcct.2007.06.002
   REMY J, 1977, RADIOLOGY, V122, P33, DOI 10.1148/122.1.33
   Remy-Jardin M, 2004, RADIOLOGY, V233, P741, DOI 10.1148/radiol.2333040031
   SAUMENCH J, 1989, ANN THORAC SURG, V48, P272, DOI 10.1016/0003-4975(89)90087-8
   SCHIDLOW DV, 1993, PEDIATR PULM, V15, P187, DOI 10.1002/ppul.1950150311
   Sidhu Manrita, 2008, Semin Intervent Radiol, V25, P310, DOI 10.1055/s-0028-1085931
   Swanson KL, 2002, CHEST, V121, P789, DOI 10.1378/chest.121.3.789
   Yoon YC, 2005, RADIOLOGY, V234, P292, DOI 10.1148/radiol.2341032079
   Yu H, 2010, EUR J RADIOL, V75, P147, DOI 10.1016/j.ejrad.2009.04.055
NR 20
TC 8
Z9 8
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0341-2040
J9 LUNG
JI Lung
PD APR
PY 2012
VL 190
IS 2
BP 221
EP 225
DI 10.1007/s00408-011-9343-y
PG 5
WC Respiratory System
SC Respiratory System
GA 917BL
UT WOS:000302146900012
PM 22037830
DA 2018-03-20
ER

PT J
AU Swadley, MJ
   Zhou, PP
   Li, TL
AF Swadley, Matthew J.
   Zhou, Panpan
   Li, Tonglei
TI Reactivity of triacetone triperoxide and diacetone diperoxide: Insights
   from nuclear Fukui function
SO FRONTIERS OF CHEMICAL SCIENCE AND ENGINEERING
LA English
DT Article
DE nuclear Fukui function; electronic perturbation; Hellmann-Feynman force;
   organic crystals; unimolecular decomposition
ID NEGATIVE ELECTRON-AFFINITIES; MOLECULES; HARDNESS; DECOMPOSITION; TATP;
   TRIACETONETRIPEROXIDE; INITIATION; ENERGIES; ATOMS; MODEL
AB Triacetone triperoxide (TATP) is more sensitive than diacetone diperoxide (DADP) in the solid-state explosion. To explain this reactivity difference, we analyzed the electronic structures and properties of the crystals of both compounds by using Ab initio method to calculate the structures of their individual molecules as well as their lattice structures and particularly calculating Nuclear Fukui function to gain insight into the sensitivity of the initial, rate-determining step of their decomposition. Our results indicate that TATP and DADP crystal structures exhibit significantly different electronic properties. Most notably, the electronic structure of the TATP crystal shows asymmetry among its reactive oxygen atoms as supported by magnitudes of their nuclear Fukui functions. The greater explosion sensitivity of crystalline TATP may be attributed to the properties of its electronic structure. The electronic calculations provided valuable insight into the decomposition sensitivity difference between TATP and DADP crystals.
C1 [Swadley, Matthew J.] Univ Kentucky, Pharmaceut Sci, Lexington, KY 40536 USA.
   [Zhou, Panpan] Lanzhou Univ, Dept Chem, Lanzhou 730000, Gansu, Peoples R China.
   [Li, Tonglei] Purdue Univ, Ind & Phys Pharm, W Lafayette, IN 47907 USA.
RP Li, TL (reprint author), Purdue Univ, Ind & Phys Pharm, W Lafayette, IN 47907 USA.
EM tonglei@purdue.edu
FU NSF [DMR-0449633]; National Natural Science Foundation of China
   [21403097]; Fundamental Research Funds for the Central Universities
   [lzujbky-2014-182]
FX This research was supported by NSF (DMR-0449633). PPZ thanks the
   financial support by the National Natural Science Foundation of China
   (Grant No. 21403097) and the Fundamental Research Funds for the Central
   Universities (lzujbky-2014-182). The authors would like to thank Dr.
   Shaoxin Feng for his technical supports on this project. TL also thanks
   Dr. Shubin Liu (UNC) for sharing his insights on DFT.
CR Ayers PW, 2007, FARADAY DISCUSS, V135, P161, DOI 10.1039/b606877d
   COHEN MH, 1994, J CHEM PHYS, V101, P8988, DOI 10.1063/1.468026
   De Proft F, 1998, J CHEM PHYS, V108, P7549, DOI 10.1063/1.476188
   De Proft F, 2007, FARADAY DISCUSS, V135, P151, DOI 10.1039/b605302p
   Doll K, 2001, INT J QUANTUM CHEM, V82, P1, DOI 10.1002/1097-461X(2001)82:1<1::AID-QUA1017>3.0.CO;2-W
   Dubnikova F, 2005, J AM CHEM SOC, V127, P1146, DOI 10.1021/ja0464903
   EVANS HK, 1986, J FORENSIC SCI, V31, P1119
   Feng SX, 2005, J PHYS CHEM A, V109, P7258, DOI 10.1021/jp0519666
   Feynman RP, 1939, PHYS REV, V56, P340, DOI 10.1103/PhysRev.56.340
   Galbraith JM, 1996, J CHEM PHYS, V105, P862, DOI 10.1063/1.471933
   Geerlings P, 2003, CHEM REV, V103, P1793, DOI 10.1021/cr990029p
   Gelalcha F G, 2004, ACTA CRYSTALLOGR C, V60, P180
   GHANTY TK, 1993, J PHYS CHEM-US, V97, P4951, DOI 10.1021/j100121a015
   GROTH P, 1969, ACTA CHEM SCAND, V23, P1311, DOI 10.3891/acta.chem.scand.23-1311
   GUERRA M, 1990, CHEM PHYS LETT, V167, P315, DOI 10.1016/0009-2614(90)87174-P
   Hellmann H., 1937, EINFUHRUNG QUANTENCH
   HOHENBERG P, 1964, PHYS REV B, V136, pB864, DOI 10.1103/PhysRev.136.B864
   Kohn W, 1996, J PHYS CHEM-US, V100, P12974, DOI 10.1021/jp960669l
   Li TL, 2005, PHARM RES-DORDR, V22, P1964, DOI 10.1007/s11095-005-7392-8
   Luty T, 2002, J CHEM PHYS, V117, P1775, DOI 10.1063/1.1485968
   Murray JS, 2009, MOL PHYS, V107, P89, DOI 10.1080/00268970902744375
   Oxley JC, 2002, PROPELL EXPLOS PYROT, V27, P209, DOI 10.1002/1521-4087(200209)27:4<209::AID-PREP209>3.0.CO;2-J
   Pacheco-Londono L, 2004, PROC SPIE, V5617, P190, DOI 10.1117/12.578803
   PARR RG, 1995, ANNU REV PHYS CHEM, V46, P701, DOI 10.1146/annurev.pc.46.100195.003413
   Parr RG, 1989, DENSITY FUNCTIONAL T
   Politzer P, 2002, THEOR CHEM ACC, V108, P134, DOI 10.1007/s00214-002-0363-9
   Rice BM, 1999, COMBUST FLAME, V118, P445, DOI 10.1016/S0010-2180(99)00008-5
   SANDERSON JR, 1974, J ORG CHEM, V39, P3463, DOI 10.1021/jo00938a001
   Tozer DJ, 2005, J PHYS CHEM A, V109, P8923, DOI 10.1021/jp053504y
   van Duin ACT, 2005, J AM CHEM SOC, V127, P11053, DOI 10.1021/ja052067y
   WHITE GM, 1992, J FORENSIC SCI, V37, P652
NR 31
TC 0
Z9 0
U1 0
U2 12
PU HIGHER EDUCATION PRESS
PI BEIJING
PA SHATANHOU ST 55, BEIJING 100009, PEOPLES R CHINA
SN 2095-0179
EI 2095-0187
J9 FRONT CHEM SCI ENG
JI Front. Chem. Sci. Eng.
PD MAR
PY 2015
VL 9
IS 1
BP 114
EP 123
DI 10.1007/s11705-015-1507-5
PG 10
WC Engineering, Chemical
SC Engineering
GA CI6WK
UT WOS:000354904300012
DA 2018-03-20
ER

PT J
AU Xu, Z
   Mansour, HM
   Hickey, AJ
AF Xu, Zhen
   Mansour, Heidi M.
   Hickey, Anthony J.
TI Particle Interactions in Dry Powder Inhaler Unit Processes: A Review
SO JOURNAL OF ADHESION SCIENCE AND TECHNOLOGY
LA English
DT Article
DE Dry powder inhaler; dry powder aerosol formulation; interparticulate
   interaction; resuspension; pharmaceutical processing; formulation
   optimization; performance prediction
ID LACTOSE CARRIER PARTICLES; STANDARDIZED ENTRAINMENT TUBES; CLASSIFIER
   TECHNOLOGY ACT; ATOMIC-FORCE MICROSCOPY; PULMONARY DRUG-DELIVERY;
   IN-VITRO DEPOSITION; AEROSOLIZED SALBUTAMOL SULFATE;
   DISODIUM-CROMOGLYCATE POWDERS; COHESIVE-ADHESIVE BALANCES; BLEND
   UNIFORMITY ANALYSIS
AB Recent development and methods of designing and optimizing dry powder formulations have extended the therapeutic potential of inhaled dosage forms. Successful drug delivery as indicated by a high and reproducible fine particle fraction, required to achieve the desired therapeutic effect while minimizing potential toxicity, depends on an understanding of the physico-chemical properties of powder blends, their performance and availability of adequate tools to screen and predict their behavior. The scope of this review includes three important perspectives for inhaled drug delivery: (1) Fundamental aspects of interparticulate interactions of pharmaceutical dry powder aerosols at rest and in resuspension; (2) The influences of pharmaceutical processing including milling, mixing, filling and storage, and their influence on powder dispersion; (3) Current strategies for formulation optimization and methods for in vitro aerosolization performance prediction. (C) Koninklijke Brill NV, Leiden, 2011
C1 [Xu, Zhen; Hickey, Anthony J.] Univ N Carolina, Sch Pharm, Div Mol Pharmaceut, Chapel Hill, NC 27599 USA.
   [Mansour, Heidi M.] Univ Kentucky, Coll Pharm, Drug Dev Div, Lexington, KY 40536 USA.
RP Hickey, AJ (reprint author), Univ N Carolina, Sch Pharm, Div Mol Pharmaceut, Chapel Hill, NC 27599 USA.
EM ahickey@unc.edu
RI Mansour, Heidi/D-1074-2011
FU DMV-Fonterra Excipients; Pfizer, Inc.
FX This work was supported by DMV-Fonterra Excipients and Pfizer, Inc.
CR Adi H, 2008, J PHARM SCI-US, V97, P3356, DOI 10.1002/jps.21239
   Adi H, 2008, J PHARM SCI-US, V97, P3140, DOI 10.1002/jps.21228
   Adi H, 2008, J PHARM SCI-US, V97, P2780, DOI 10.1002/jps.21195
   Adi H, 2007, INT J PHARM, V337, P229, DOI 10.1016/j.ijpharm.2007.01.007
   Adi S, 2008, EUR J PHARM SCI, V35, P12, DOI 10.1016/j.ejps.2008.05.009
   AHLNECK C, 1990, INT J PHARM, V62, P87, DOI 10.1016/0378-5173(90)90221-O
   Antal Istvan, 2006, Acta Pharm Hung, V76, P149
   Atkins Paul J, 2005, Respir Care, V50, P1304
   Barry PW, 2003, ADV DRUG DELIVER REV, V55, P879, DOI 10.1016/S0169-409X(03)00083-8
   Begat P, 2004, PHARM RES, V21, P1591, DOI 10.1023/B:PHAM.0000041453.24419.8a
   Begat P, 2004, PHARM RES, V21, P1826, DOI 10.1023/B:PHAM.0000045236.60029.cb
   Begat P, 2005, KONA, V23, P109
   Berard V, 2002, INT J PHARM, V232, P213, DOI 10.1016/S0378-5173(01)00913-9
   Berman J, 2001, PDA J PHARM SCI TECH, V55, P209
   Berman J., 1997, PDA, V51, pS1
   Bhavna, 2009, EUR J PHARM BIOPHARM, V71, P282, DOI 10.1016/j.ejpb.2008.09.018
   Boehm G, 2003, PDA J PHARM SCI TECH, V57, P64
   Bouchard A, 2008, EUR J PHARM BIOPHARM, V68, P781, DOI 10.1016/j.ejpb.2007.06.019
   BRAATEN DA, 1990, J AEROSOL SCI, V21, P613, DOI 10.1016/0021-8502(90)90117-G
   Bridson RH, 2007, INT J PHARM, V339, P84, DOI 10.1016/j.ijpharm.2007.02.022
   Brodka-Pfeiffer K, 2003, EUR J PHARM BIOPHARM, V56, P393, DOI 10.1016/S0939-6411(03)00134-6
   Burnett DJ, 2006, INT J PHARM, V313, P23, DOI 10.1016/j.ijpharm.2006.01.012
   Buttini F, 2008, J PHARM SCI-US, V97, P1257, DOI 10.1002/jps.21126
   Cantor A. S., 2008, RESP DRUG DELIVERY, V1, P309
   CARSTENSEN JT, 1984, DRUG DEV IND PHARM, V10, P1017, DOI 10.3109/03639048409038302
   Carstensen J.T., 1993, PHARM PRINCIPLES SOL
   CARTILIER LH, 1989, DRUG DEV IND PHARM, V15, P1911, DOI 10.3109/03639048909052510
   Castellanos A, 2005, ADV PHYS, V54, P263, DOI 10.1080/17461390500402657
   Chan HK, 2006, J AEROSOL MED, V19, P21, DOI 10.1089/jam.2006.19.21
   Chan HK, 2003, ADV DRUG DELIVER REV, V55, P793, DOI 10.1016/S0169-409X(03)00078-4
   Chan LW, 2003, J PHARM SCI, V92, P975, DOI 10.1002/jps.10372
   Chen Y, 2004, J PHARM SCI-US, V93, P886, DOI 10.1002/jps.10568
   Chew NYK, 2000, INT J PHARM, V206, P75, DOI 10.1016/S0378-5173(00)00516-0
   Chew NYK, 2005, J PHARM SCI-US, V94, P2289, DOI 10.1002/jps.20426
   Chew NYK, 2005, PHARM RES, V22, P148, DOI 10.1007/s11095-004-9020-4
   Chew NYK, 2002, J AEROSOL MED, V15, P325, DOI 10.1089/089426802760292672
   Chew NYK, 2002, J PHARM PHARM SCI, V5, P162
   Chew NYK, 2001, PHARMACEUT RES, V18, P1570, DOI 10.1023/A:1013082531394
   Chougule Mahavir B, 2007, Recent Pat Drug Deliv Formul, V1, P11, DOI 10.2174/187221107779814159
   Chow AHL, 2007, PHARM RES, V24, P411, DOI 10.1007/s11095-006-9174-3
   CHOWHAN ZT, 1981, POWDER TECHNOL, V29, P251, DOI 10.1016/0032-5910(81)87027-1
   CLARK AR, 1993, J AEROSOL MED, V6, P99, DOI 10.1089/jam.1993.6.99
   CLEAVER JW, 1973, J COLLOID INTERF SCI, V44, P464, DOI 10.1016/0021-9797(73)90323-8
   Cline D, 2002, PHARMACEUT RES, V19, P1274, DOI 10.1023/A:1020338405947
   Colombo I, 2009, J PHARM SCI-US, V98, P3961, DOI 10.1002/jps.21733
   Concessio N. M., 1997, THESIS U N CAROLINA
   Corrigan DO, 2006, INT J PHARM, V322, P22, DOI 10.1016/j.ijpharm.2006.05.022
   Crowder T. M., 2003, GUIDE PHARM PARTICUL
   Dalby R, 2003, ADV DRUG DELIVER REV, V55, P779, DOI 10.1016/S0169-409X(03)00077-2
   Das S, 2009, J PHARM SCI-US, V98, P1015, DOI 10.1002/jps.21500
   de Boer AH, 2006, INT J PHARM, V310, P72, DOI 10.1016/j.ijpharm.2005.11.030
   de Boer AH, 2006, INT J PHARM, V310, P81, DOI 10.1016/j.ijpharm.2005.11.029
   de Boer AH, 2003, INT J PHARM, V260, P187, DOI 10.1016/S0378-5173(03)00250-3
   de Boer AH, 2003, INT J PHARM, V260, P201, DOI 10.1016/S0378-5173(03)00264-3
   de Boer AH, 2005, INT J PHARM, V294, P173, DOI 10.1016/j.ijpharm.2005.01.035
   DELEUIL M, 1994, HANDB POWD TECHNOL, V9, P115
   Derjaguin B, 1934, KOLLOID Z, V69, P155, DOI 10.1007/BF01433225
   DERJAGUIN BV, 1975, J COLLOID INTERF SCI, V53, P314, DOI 10.1016/0021-9797(75)90018-1
   deVilliers MM, 1997, INT J PHARM, V151, P1, DOI 10.1016/S0378-5173(97)04893-X
   Dhumal RS, 2008, PHARM RES-DORD, V25, P2835, DOI 10.1007/s11095-008-9653-9
   Do D. D., 1998, ADSORPTION ANAL EQUI
   Duddu SP, 2002, PHARMACEUT RES, V19, P689, DOI 10.1023/A:1015322616613
   Dunbar CA, 1998, KONA, V16, P7
   Edwards DA, 1997, SCIENCE, V276, P1868, DOI 10.1126/science.276.5320.1868
   El-Gendy N, 2009, J PHARM SCI-US, V98, P2731, DOI 10.1002/jps.21630
   El-Sabawi D, 2006, DRUG DEV IND PHARM, V32, P243, DOI 10.1080/03639040500466395
   Elajnaf A, 2006, EUR J PHARM SCI, V29, P375, DOI 10.1016/j.ejps.2006.07.006
   Elajnaf A, 2007, DRUG DEV IND PHARM, V33, P967, DOI 10.1080/03639040601134207
   Ferrari F, 2004, AAPS PHARMSCITECH, V5
   Finlay W. H., 2001, MECH INHALED PHARM A
   Flament MP, 2004, INT J PHARM, V275, P201, DOI 10.1016/j.ipharm.2004.02.002
   French DL, 1996, J AEROSOL SCI, V27, P769, DOI 10.1016/0021-8502(96)00021-3
   Frijlink H W, 2004, Expert Opin Drug Deliv, V1, P67, DOI 10.1517/17425247.1.1.67
   Fults K A, 1997, Pharm Dev Technol, V2, P67, DOI 10.3109/10837459709022610
   Gilani K, 2005, J PHARM SCI-US, V94, P1048, DOI 10.1002/jps.20315
   Giry K, 2006, INT J PHARM, V321, P162, DOI 10.1016/j.ijpharm.2006.05.009
   Guchardi R, 2008, INT J PHARM, V348, P10, DOI 10.1016/j.ijpharm.2007.06.041
   HALL D, 1989, J AEROSOL SCI, V20, P907, DOI 10.1016/0021-8502(89)90723-4
   Hancock BC, 1998, PHARM SCI TECHNOL TO, V1, P345, DOI 10.1016/S1461-5347(98)00088-1
   Hardy IJ, 2003, J PHARM PHARMACOL, V55, P1593, DOI 10.1211/0022357022610
   Harjunen P, 2002, EUR J PHARM SCI, V16, P313, DOI 10.1016/S0928-0987(02)00126-4
   Heng PWS, 2000, CHEM PHARM BULL, V48, P393
   HERSEY JA, 1975, POWDER TECHNOL, V11, P41, DOI 10.1016/0032-5910(75)80021-0
   HICKEY AJ, 1993, AEROSOL SCI TECH, V18, P290, DOI 10.1080/02786829308959606
   Hickey A. J., 1996, INHALATION AEROSOLS
   Hickey A.J., 2009, MODERN PHARM, V2, P191
   Hickey A. J., 2001, PHARM PROCESS ENG
   Hickey A. J., 2004, PHARM INHALATION AER
   Hickey A.J., 2008, MODIFIED RELEASE DRU, V2, P573
   Hickey AJ, 2007, J PHARM SCI-US, V96, P1302, DOI 10.1002/jps.20943
   Hickey AJ, 2007, J PHARM SCI-US, V96, P1282, DOI 10.1002/jps.20916
   Hiemenz P. C., 1977, PRINCIPLES COLLOID S
   Hiestand E. N., 2002, MECH PHYS PRINCIPLES
   Hinds W. C, 1999, AEROSOL TECHNOLOGY P
   Hooton JC, 2006, J PHARM SCI-US, V95, P1288, DOI 10.1002/jps.20618
   Hooton JC, 2004, PHARM RES, V21, P953, DOI 10.1023/B:PHAM.0000029283.47643.9c
   Hooton JC, 2008, DRUG DEV IND PHARM, V34, P974, DOI [10.1080/03639040802149087, 10.1080/03639040802149087 ]
   Howard-Sparks M, 2004, PDA J PHARM SCI TECH, V58, P222
   Iida K, 2005, CHEM PHARM BULL, V53, P431, DOI 10.1248/cpb.53.431
   Iida K, 2004, CHEM PHARM BULL, V52, P938, DOI 10.1248/cpb.52.938
   Iida K, 2004, CHEM PHARM BULL, V52, P444, DOI 10.1248/cpb.52.444
   Iida K, 2004, CHEM PHARM BULL, V52, P350, DOI 10.1248/cpb.52.350
   Iida K, 2003, CHEM PHARM BULL, V51, P1455, DOI 10.1248/cpb.51.1455
   Iida K, 2003, CHEM PHARM BULL, V51, P1, DOI 10.1248/cpb.51.1
   Iida K, 2000, YAKUGAKU ZASSHI, V120, P113, DOI 10.1248/yakushi1947.120.1_113
   Ikegami K, 2002, PHARMACEUT RES, V19, P1439, DOI 10.1023/A:1020492213172
   Irngartinger M, 2004, EUR J PHARM BIOPHARM, V58, P7, DOI 10.1016/j.ejpb.2004.03.016
   Islam N, 2004, PHARM RES, V21, P492, DOI 10.1023/B:PHAM.0000019304.91412.18
   Islam N, 2008, INT J PHARM, V360, P1, DOI 10.1016/j.ijpharm.2008.04.044
   Israelachvili J. N., 1992, INTERMOLECULAR SURFA
   Jaroniec M., 1988, PHYS ADSORPTION HETE
   Jashnani RN, 1996, INT J PHARMACEUT, V130, P13, DOI 10.1016/0378-5173(95)04211-3
   JOHNSON KL, 1971, PROC R SOC LON SER-A, V324, P301, DOI 10.1098/rspa.1971.0141
   Jones BE, 2001, INT J PHARM, V227, P5, DOI 10.1016/S0378-5173(01)00781-5
   Jones MD, 2008, PHARM RES-DORD, V25, P337, DOI 10.1007/s11095-007-9467-1
   Jones MD, 2008, EUR J PHARM BIOPHARM, V69, P496, DOI 10.1016/j.ejpb.2007.11.019
   Jones MD, 2006, PHARM RES, V23, P1665, DOI 10.1007/s11095-006-9012-7
   KASSEM N M, 1989, Journal of Pharmacy and Pharmacology, V41, p14P
   Kawashima Y, 1998, INT J PHARM, V172, P179, DOI 10.1016/S0378-5173(98)00202-6
   Kawashima Y, 1998, PHARMACEUT RES, V15, P1748, DOI 10.1023/A:1011916930655
   KONTNY MJ, 1987, PHARMACEUT RES, V4, P104, DOI 10.1023/A:1016458701059
   Kumon M, 2008, CHEM PHARM BULL, V56, P617, DOI 10.1248/cpb.56.617
   Kumon M, 2006, CHEM PHARM BULL, V54, P1508, DOI 10.1248/cpb.54.1508
   Larhrib H, 2003, INT J PHARM, V257, P283, DOI 10.1016/S0378-5173(03)00156-X
   Lechuga-Ballesteros D, 2008, J PHARM SCI-US, V97, P287, DOI 10.1002/jps.21078
   Linsenbuhler M, 2005, POWDER TECHNOL, V158, P3, DOI 10.1016/j.powtec.2005.04.035
   LOTH H, 1986, INT J PHARM, V32, P265, DOI 10.1016/0378-5173(86)90188-2
   Louey MD, 2006, J AEROSOL SCI, V37, P1520, DOI 10.1016/j.jaerosci.2006.04.002
   Louey MD, 2004, PHARM RES, V21, P1207, DOI 10.1023/B:PHAM.0000032991.74736.3e
   Louey MD, 2004, PHARM RES, V21, P1200, DOI 10.1023/B:PHAM.0000033007.27278.60
   Louey MD, 2003, INT J PHARM, V252, P87, DOI 10.1016/S0378-5173(02)00621-X
   Louey MD, 2002, PHARMACEUT RES, V19, P1524, DOI 10.1023/A:1020464801786
   Lucas P, 1999, PHARMACEUT RES, V16, P1643, DOI 10.1023/A:1011981326827
   Lucas P, 1998, PHARMACEUT RES, V15, P562, DOI 10.1023/A:1011977826711
   Lucas P., 1998, P RESP DRUG DELIVERY, V6, P243
   Mansour HM, 2010, J PHARM SCI-US, V99, P3430, DOI 10.1002/jps.22101
   Miyanami K., 2006, POWDER TECHNOLOGY HD, V1, P577
   Mohammed A., 2008, CURR RESP MED REV, V4, P2
   Mosharraf M, 1999, INT J PHARM, V177, P29, DOI 10.1016/S0378-5173(98)00317-2
   Murnane D, 2009, J PHARM SCI-US, V98, P503, DOI 10.1002/jps.21450
   Muzzio FJ, 2003, INT J PHARM, V250, P51, DOI 10.1016/S0378-5173(02)00481-7
   Muzzio FJ, 1997, INT J PHARM, V155, P153, DOI 10.1016/S0378-5173(97)04865-5
   Newman SP, 2004, EXPERT OPIN BIOL TH, V4, P23
   Newman SP, 2003, CURR OPIN PULM MED, V9, pS17, DOI 10.1097/00063198-200304001-00005
   Ng WK, 2008, PHARM RES, V25, P1175, DOI 10.1007/s11095-007-9497-8
   Nichols SC, 2008, RESP DRUG DELIVERY, V1, P175
   O'Callaghan C., 2001, DRUG DELIVERY LUNG, V162, P1
   Ohta M, 2004, INT J PHARM, V269, P81, DOI 10.1016/j.ijpharm.2003.08.015
   Perkins M, 2007, INT J PHARM, V332, P168, DOI 10.1016/j.ijpharm.2006.09.032
   Pfeffer R, 2001, POWDER TECHNOL, V117, P40, DOI 10.1016/S0032-5910(01)00314-X
   Podczeck F, 1998, INT J PHARM, V160, P119, DOI 10.1016/S0378-5173(97)00313-X
   Podczeck F, 1999, AEROSOL SCI TECH, V31, P301, DOI 10.1080/027868299304174
   Podczeck F, 1999, INT J PHARM, V178, P93, DOI 10.1016/S0378-5173(98)00363-9
   PODCZECK F, 1995, J PHARM SCI, V84, P1067, DOI 10.1002/jps.2600840907
   Podczeck F., 1998, PARTICLE PARTICLE AD
   Price R, 2002, INT J PHARM, V246, P47, DOI 10.1016/S0378-5173(02)00359-9
   Prime D, 1997, ADV DRUG DELIVER REV, V26, P51, DOI 10.1016/S0169-409X(97)00510-3
   Pu Y, 2009, J PHARM SCI-US, V98, P2412, DOI 10.1002/jps.21595
   Rasenack N, 2004, PHARM DEV TECHNOL, V9, P1, DOI 10.1081/PDT-120027417
   Rasenack N, 2003, J PHARM SCI, V92, P35, DOI 10.1002/jps.10274
   Raula J, 2008, PHARM RES-DORDR, V25, P2250, DOI 10.1007/s11095-008-9613-4
   REEKS MW, 1988, J PHYS D APPL PHYS, V21, P574, DOI 10.1088/0022-3727/21/4/006
   REIER G, 1968, J PHARM SCI-US, V57, P660, DOI 10.1002/jps.2600570428
   Reverchon E, 2003, INT J PHARM, V258, P1, DOI 10.1016/S0378-5173(03)00024-3
   Rowe R. C., 2006, HDB PHARM EXCIPIENTS, V1, P385
   Sacchetti M, 2006, PHARM DEV TECHNOL, V11, P351, DOI 10.1080/10837450600769793
   Saleem I, 2008, DRUG DEV IND PHARM, V34, P1002, DOI 10.1080/03639040802154905 
   Schiavone H, 2004, INT J PHARMACEUT, V281, P55, DOI 10.1016/j.ijpharm.2004.05.029
   Seville PC, 2007, CRIT REV THER DRUG, V24, P307, DOI 10.1615/CritRevTherDrugCarrierSyst.v24.i4.10
   SHAH KB, 1986, J PHARM SCI, V75, P291, DOI 10.1002/jps.2600750318
   Shekunov BY, 2003, J AEROSOL SCI, V34, P553, DOI 10.1016/S0021-8502(03)00022-3
   Shinohara K., 2006, POWDER TECHNOLOGY HD, V1, P371
   Smith IJ, 2003, PULM PHARMACOL THER, V16, P79, DOI 10.1016/S1094-5539(02)00147-5
   Smyth H. D. C., 2005, AM J DRUG DELIV, V3, P117
   Son YJ, 2008, DRUG DEV IND PHARM, V34, P948, DOI 10.1080/03639040802235902 
   Srichana T, 1998, EUR J PHARM SCI, V7, P73, DOI 10.1016/S0928-0987(98)00008-6
   Srichana T, 1998, INT J PHARM, V167, P13, DOI 10.1016/S0378-5173(98)00037-4
   STANIFORTH JN, 1981, J PHARM PHARMACOL, V33, P175, DOI 10.1111/j.2042-7158.1981.tb13745.x
   STANIFORTH JN, 1981, POWDER TECHNOL, V30, P255, DOI 10.1016/0032-5910(81)80019-8
   Steckel H, 2006, INT J PHARM, V309, P51, DOI 10.1016/j.ijpharm.2005.10.043
   Steckel H, 2004, INT J PHARM, V278, P187, DOI 10.1016/j.ijpharm.2004.03.010
   Steckel H, 2004, INT J PHARM, V270, P297, DOI 10.1016/j.ijpharm.2003.10.039
   Steckel H, 2003, EUR J PHARM BIOPHARM, V55, P173, DOI 10.1016/S0939-6411(02)00168-6
   Steckel H, 2003, INT J PHARM, V258, P65, DOI 10.1016/S0378-5173(03)00153-4
   Steckel H, 1997, INT J PHARM, V154, P31, DOI 10.1016/S0378-5173(97)00115-4
   Sudah OS, 2002, INT J PHARM, V247, P57, DOI 10.1016/S0378-5173(02)00377-0
   Sudah OS, 2002, DRUG DEV IND PHARM, V28, P905, DOI 10.1081/DDC-120006423
   TABOR D, 1977, J COLLOID INTERF SCI, V58, P2, DOI 10.1016/0021-9797(77)90366-6
   TAN SB, 1990, INT J PHARM, V66, P207, DOI 10.1016/0378-5173(90)90401-O
   Tanaka T., 2006, POWDER TECHNOLOGY HD, V1, P503
   Tay T, 2010, INT J PHARMACEUT, V383, P62, DOI 10.1016/j.ijpharm.2009.09.006
   Tee SK, 2000, INT J PHARM, V208, P111, DOI 10.1016/S0378-5173(00)00553-6
   Thielmann F, 2007, DRUG DEV IND PHARM, V33, P1240, DOI 10.1080/03639040701378035
   Ticehurst MD, 2000, INT J PHARM, V193, P247
   Traini D, 2006, EUR J PHARM SCI, V27, P243, DOI 10.1016/j.ejps.2005.10.005
   Traini D, 2008, DRUG DEV IND PHARM, V34, P992, DOI 10.1080/03639040802154889 
   Tuley R, 2008, INT J PHARM, V358, P238, DOI 10.1016/j.ijpharm.2008.03.038
   U. S. Food and Drug Administration, 2005, US OZ DEPL SUBST REM
   [Anonymous], 2004, US PHARM
   van der Kolk H, 1991, Eur J Drug Metab Pharmacokinet, VSpec No 3, P415
   Vehring R, 2008, PHARM RES, V25, P999, DOI 10.1007/s11095-007-9475-1
   Venables HJ, 2001, DRUG DEV IND PHARM, V27, P599, DOI 10.1081/DDC-100107316
   Verheezen JJAM, 2004, INT J PHARM, V278, P165, DOI 10.1016/j.ijpharm.2004.03.006
   VERRAES J, 1979, J PHARM BELG, V34, P297
   Visser J, 1995, PARTICUL SCI TECHNOL, V13, P169, DOI 10.1080/02726359508906677
   Voss A, 2002, INT J PHARM, V248, P39, DOI 10.1016/S0378-5173(02)00319-8
   Ward G., 2001, Stabilized Dry Powder Formulations, Patent No. 0170198
   WARD GH, 1995, PHARMACEUT RES, V12, P773, DOI 10.1023/A:1016232230638
   Ward S, 2005, PHARM RES, V22, P1195, DOI 10.1007/s11095-005-6027-4
   Weers JG, 2007, EXPERT OPIN DRUG DEL, V4, P297, DOI 10.1517/17425247.4.3.297
   Weiler C, 2010, J PHARM SCI-US, V99, P303, DOI 10.1002/jps.21849
   Westmeier R, 2008, J PHARM SCI-US, V97, P2299, DOI 10.1002/jps.21154
   White Steven, 2005, Diabetes Technol Ther, V7, P896, DOI 10.1089/dia.2005.7.896
   Wright P., 2004, PHARM PREFORMULATION, V1, P355
   Xu Z., 2008, RESP DRUG DELIVERY, V3, P897
   Xu Z, 2010, J PHARM SCI-US, V99, P3442, DOI 10.1002/jps.22057
   Xu Z, 2010, J PHARM SCI-US, V99, P3415, DOI 10.1002/jps.22100
   Xu Z, 2010, J PHARM SCI-US, V99, P3398, DOI 10.1002/jps.22107
   York P, 1999, PHARM SCI TECHNOL TO, V2, P430
   Young PA, 2005, INT J PHARM, V296, P26, DOI 10.1016/j.ijpharm.2005.02.004
   Young PM, 2008, J AEROSOL SCI, V39, P82, DOI 10.1016/j.jaerosci.2007.10.003
   Young PM, 2007, J PHARM SCI-US, V96, P1331, DOI 10.1002/jps.20933
   Young PM, 2006, J PHARM SCI-US, V95, P1800, DOI 10.1002/jps.20660
   Young PM, 2009, PHARM RES-DORD, V26, P802, DOI 10.1007/s11095-008-9779-9
   Young PM, 2004, EUR J PHARM SCI, V22, P235, DOI 10.1016/j.ejps.2004.03.006
   Young PM, 2004, J PHARM SCI-US, V93, P753, DOI 10.1002/jps.10549
   Young PM, 2003, DRUG DEV IND PHARM, V29, P959, DOI 10.1081/DDC-120025453
   Young PM, 2003, J PHARM SCI, V92, P815, DOI 10.1002/jps.10250
   Young PM, 2002, J PHARM PHARMACOL, V54, P1339, DOI 10.1211/002235702760345400
   Zeng XM, 2007, INT J PHARM, V333, P45, DOI 10.1016/j.ijpharm.2006.09.048
   Zeng XM, 1998, INT J PHARM, V176, P99, DOI 10.1016/S0378-5173(98)00300-7
   Zeng XM, 2001, EUR J PHARM BIOPHARM, V51, P55
   Zeng XM, 2000, INT J PHARM, V200, P93, DOI 10.1016/S0378-5173(00)00347-1
   Zeng XM, 2001, J PHARM SCI, V90, P1424, DOI 10.1002/jps.1094
   Zeng XM, 2000, INT J PHARM, V197, P41, DOI 10.1016/S0378-5173(99)00400-7
   Zeng XM, 2000, J PHARM PHARMACOL, V52, P1211, DOI 10.1211/0022357001777342
   Zeng XM, 1999, INT J PHARM, V182, P133, DOI 10.1016/S0378-5173(99)00021-6
   Zeng XM, 2001, PARTICULATE INTERACT
   Zijlstra GS, 2004, EUR J PHARM SCI, V23, P139, DOI 10.1016/j.ejps.2004.06.005
   ZISKIND G, 1995, J AEROSOL SCI, V26, P613, DOI 10.1016/0021-8502(94)00139-P
   [Anonymous], 1987, MONTREAL PROTOCOL SU
NR 241
TC 35
Z9 35
U1 3
U2 41
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0169-4243
EI 1568-5616
J9 J ADHES SCI TECHNOL
JI J. Adhes. Sci. Technol.
PY 2011
VL 25
IS 4-5
SI SI
BP 451
EP 482
DI 10.1163/016942410X525669
PG 32
WC Engineering, Chemical; Materials Science, Multidisciplinary; Mechanics
SC Engineering; Materials Science; Mechanics
GA 721TG
UT WOS:000287377500009
DA 2018-03-20
ER

PT J
AU Sun, XH
   Wu, J
   Chen, ZQ
   Su, X
   Hinds, BJ
AF Sun, Xinghua
   Wu, Ji
   Chen, Zhiqiang
   Su, Xin
   Hinds, Bruce J.
TI Fouling Characteristics and Electrochemical Recovery of Carbon Nanotube
   Membranes
SO ADVANCED FUNCTIONAL MATERIALS
LA English
DT Article
DE carbon nanotubes; membranes; fouling; electrochemical defouling; ionic
   pumping
ID DIAMOND ELECTRODES; MASS-TRANSPORT; MICROFILTRATION; FLOW; MODEL;
   PROTEINS; WATER; OPPORTUNITIES; TECHNOLOGY; CHALLENGES
AB The fouling behavior of carbon nanotube (CNT) membranes is investigated for large protein biomolecules and a wide variety of small molecules. The CNT membranes are largely fouling resistant, even to untreated river water, due to size exclusion and an inert graphitic core that supports fast fluid flow. However, it is found that bovine serum albumin (BSA) and naphthalene significantly foul membranes due to solution coagulation and stacking, respectively. Small single-walled (SW) CNTs (<1.5 nm i.d.) are difficult to foul with BSA when precipitation is prevented, showing that size exclusion at SWCNT tips can prevent fouling. Electrochemical oxidation, bubble generation and ionic pumping are shown to recover membrane performance. Electrochemical oxidation at greater than +1.4 V is seen to oxidize CNTs as well as biofoulants, but H2 bubble generation at 2 V lifts foulants without damage to the membrane allowing for repeated cycles. Ionic pumping using large cations is seen to remove small molecule foulants adsorbed to the CNT core. The relatively narrow class of foulants and three complementary methods of membrane defouling make the CNT membrane platform a potentially robust system for a wide variety of chemical separations and environmental water treatments.
C1 [Sun, Xinghua; Wu, Ji; Chen, Zhiqiang; Su, Xin; Hinds, Bruce J.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Sun, XH (reprint author), Univ Louisville, Dept Bioengn, Louisville, KY 40292 USA.
EM bjhinds@engr.uky.edu
RI WU, JI/F-6379-2013; WU, JI/J-4580-2016; Su, Xin/M-1162-2013; WU,
   JI/F-6371-2013
OI Su, Xin/0000-0002-1615-2856; 
FU NIDA [5R01DA018822-05]; DOE EPSCoR [DE-FG02-07ER46375]; DARPA
   [W911NF-09-1-0267]
FX This work was supported by NIDA, #5R01DA018822-05, DOE EPSCoR,
   DE-FG02-07ER46375 and DARPA, W911NF-09-1-0267. Critical infrastructure
   provided by the University of Kentucky, Center for Nanoscale Science and
   Engineering.
CR Agarwal A, 2011, CHEMOSPHERE, V84, P1175, DOI 10.1016/j.chemosphere.2011.05.054
   Andrews R, 1999, CHEM PHYS LETT, V303, P467, DOI 10.1016/S0009-2614(99)00282-1
   BELFORT G, 1994, J MEMBRANE SCI, V96, P1, DOI 10.1016/0376-7388(94)00119-7
   Chan R, 2004, J MEMBRANE SCI, V242, P169, DOI 10.1016/j.memsci.2004.01.029
   Chiku M, 2008, ANAL CHEM, V80, P5783, DOI 10.1021/ac800394n
   Chiku M, 2008, J ELECTROANAL CHEM, V612, P201, DOI 10.1016/j.jelechem.2007.09.027
   Duclos-Orsello C, 2006, J MEMBRANE SCI, V280, P856, DOI 10.1016/j.memsci.2006.03.005
   FIELD RW, 1995, J MEMBRANE SCI, V100, P259, DOI 10.1016/0376-7388(94)00265-Z
   Fornasiero F, 2008, P NATL ACAD SCI USA, V105, P17250, DOI 10.1073/pnas.0710437105
   Ghosh R, 2002, J CHROMATOGR A, V952, P13, DOI 10.1016/S0021-9673(02)00057-2
   Gong XJ, 2010, J AM CHEM SOC, V132, P1873, DOI 10.1021/ja905753p
   Hinds BJ, 2004, SCIENCE, V303, P62, DOI 10.1126/science.1092048
   Hinds B, 2012, CURR OPIN SOLID ST M, V16, P1, DOI 10.1016/j.cossms.2011.05.003
   Ho CC, 2000, J COLLOID INTERF SCI, V232, P389, DOI 10.1006/jcis.2000.7231
   Holt JK, 2006, SCIENCE, V312, P1034, DOI 10.1126/science.1126298
   Hong SK, 1997, J MEMBRANE SCI, V132, P159, DOI 10.1016/S0376-7388(97)00060-4
   Ito T, 2003, ELECTROCHEM SOLID ST, V6, pC4, DOI 10.1149/1.1526779
   Kanani DA, 2008, J MEMBRANE SCI, V315, P1, DOI 10.1016/j.memsci.2008.01.053
   Majumder M, 2005, NATURE, V438, P44, DOI 10.1038/43844a
   Majumder M, 2005, J AM CHEM SOC, V127, P9062, DOI 10.1021/ja043013b
   Majumder M, 2007, LANGMUIR, V23, P8624, DOI 10.1021/la700686k
   Mansouri J, 2010, J MATER CHEM, V20, P4567, DOI 10.1039/b926440j
   Mao ZG, 2000, J PHYS CHEM B, V104, P4618, DOI 10.1021/jp9944280
   Pang P, 2011, ACS NANO, V5, P7277, DOI 10.1021/nn202115s
   Peng WH, 2004, J MEMBRANE SCI, V238, P33, DOI 10.1016/j.memsci.2004.02.035
   Striemer CC, 2007, NATURE, V445, P749, DOI 10.1038/nature05532
   Su X, 2011, CARBON, V49, P1145, DOI 10.1016/j.carbon.2010.11.029
   Sun L, 2000, J AM CHEM SOC, V122, P12340, DOI 10.1021/ja002429w
   Sun XH, 2008, J MEMBRANE SCI, V320, P372, DOI 10.1016/j.memsci.2008.04.017
   Sun XH, 2006, COLLOID SURFACE A, V286, P8, DOI 10.1016/j.colsurfa.2006.02.034
   Sun XH, 2011, LANGMUIR, V27, P3150, DOI 10.1021/la104242p
   Wei DC, 2009, ADV FUNCT MATER, V19, P3618, DOI 10.1002/adfm.200900924
   Wu J, 2012, CHEM COMMUN, V48, P7979, DOI 10.1039/c2cc33355d
   Wu J, 2012, NAT NANOTECHNOL, V7, P133, DOI [10.1038/nnano.2011.240, 10.1038/NNANO.2011.240]
   Wu J, 2011, NANOSCALE, V3, P3321, DOI 10.1039/c1nr10303b
   Wu J, 2010, P NATL ACAD SCI USA, V107, P11698, DOI 10.1073/pnas.1004714107
   Yuan JK, 2008, NAT NANOTECHNOL, V3, P332, DOI 10.1038/nnano.2008.136
   Zhu YC, 2001, BIOPHYS CHEM, V90, P1, DOI 10.1016/S0301-4622(00)00238-6
   Zydney AL, 2009, BIOTECHNOL BIOENG, V103, P227, DOI 10.1002/bit.22308
NR 39
TC 30
Z9 30
U1 3
U2 106
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY
SN 1616-301X
J9 ADV FUNCT MATER
JI Adv. Funct. Mater.
PD MAR 25
PY 2013
VL 23
IS 12
BP 1500
EP 1506
DI 10.1002/adfm.201201265
PG 7
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 108UN
UT WOS:000316321800004
DA 2018-03-20
ER

PT J
AU Ambati, J
   Rankin, SE
AF Ambati, Jyothirmai
   Rankin, Stephen E.
TI Si-29 NMR investigation of the polymerization kinetics of
   bis(triethoxysilyl) ethane in acidic alcohol/water solution
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
CT 231st National Meeting of the American-Chemical-Society
CY MAR 26-30, 2006
CL Atlanta, GA
SP Amer Chem Soc
C1 Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM Jyothirmai.Ambati@uky.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD MAR 26
PY 2006
VL 231
MA 361-PMSE
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA 050YE
UT WOS:000238125909357
DA 2018-03-20
ER

PT J
AU Rockcliffe, DA
   Cammers, A
   Murali, A
   Russell, WK
   DeRose, VJ
AF Rockcliffe, David A.
   Cammers, Arthur
   Murali, Ayaluru
   Russell, William K.
   DeRose, Victoria J.
TI Copper binding characteristics of a designed dinucleating peptide
   developed to be an oxyhemocyanin active site model
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
CT 231st National Meeting of the American-Chemical-Society
CY MAR 26-30, 2006
CL Atlanta, GA
SP Amer Chem Soc
C1 Kentucky State Univ, Div Math & Sci, Frankfort, KY 40601 USA.
   Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
   Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA.
EM david.rockcliffe@kysu.edu
RI Cammers, Arthur/B-8681-2013
OI Cammers, Arthur/0000-0002-1682-3488
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD MAR 26
PY 2006
VL 231
MA 53-INOR
PG 2
WC Chemistry, Multidisciplinary
SC Chemistry
GA 050YE
UT WOS:000238125905053
DA 2018-03-19
ER

PT J
AU Dickerson, MT
   Abney, MB
   Cameron, CE
   Knecht, M
   Bachas, LG
   Anderson, KW
AF Dickerson, Matthew T.
   Abney, Morgan B.
   Cameron, Caroline E.
   Knecht, Marc
   Bachas, Leonidas G.
   Anderson, Kimberly W.
TI Fibronectin Binding to the Treponema pallidum Adhesin Protein Fragment
   rTp0483 on Functionalized Self-Assembled Monolayers
SO BIOCONJUGATE CHEMISTRY
LA English
DT Article
ID OUTER-MEMBRANE PROTEINS; IMMUNE-RESPONSE; SURFACE; ADSORPTION;
   CYTADHERENCE; CONFORMATION; ACTIVATION; CONSISTENT; FIBRINOGEN; SEQUENCE
AB Past work has shown that Treponema pallidum, the causative agent of syphilis, binds host fibronectin (FN). FN and other host proteins are believed to bind to rare outer membrane proteins (OMPs) of T. pallidum, and it is postulated that this interaction may facilitate cell attachment and mask antigenic targets on the surface. This research seeks to prepare a surface capable of mimicking the FN binding ability of T. pallidum in order to investigate the impact of FN binding with adsorbed Tp0483 on the host response to the surface. By understanding this interaction, it may be possible to develop more effective treatments for infection and possibly mimic the stealth properties of the bacteria. Functionalized self-assembled monolayers (SAMs) on gold were used to investigate rTp0483 and FN adsorption. Using a quartz crystal microbalance (QCM), rTp0483 adsorption and subsequent FN adsorption onto rTp0483 were determined to be higher on negatively charged carboxylate-terminated self-assembled monolayers (-COO- SAMs) compared to the other surfaces analyzed. Kinetic analysis of rTp0483 adsorption using surface plasmon resonance (SPR) supported this finding. Kinetic analysis of FN adsorption using SPR revealed a multistep event, where the concentration of immobilized rTp0483 plays a role in FN binding. An examination of relative QCM dissipation energy compared to the shift in frequency showed a correlation between the physical properties of adsorbed rTp0483 and SAM surface chemistry. In addition, AFM images of rTp0483 on selected SAMs illustrated a preference of rTp0483 to bind as aggregates. Adsorption on -COO- SAMs was more uniform across the surface, which may help further explain why FN bound more strongly. rTp0483 antibody studies suggested the involvement of amino acids 274-289 and 316-333 in binding between rTp0483 to FN, while a peptide blocking study only showed inhibition of binding with amino acids 316-333. Finally, surface adsorbed rTp0483 with FN bound significantly less anti-RGD and gelatin compared to FN adsorbed directly to -COO- SAMs, indicating that one or both binding regions may play a role in binding between rTp0483 and FN.
C1 [Dickerson, Matthew T.; Abney, Morgan B.; Anderson, Kimberly W.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Cameron, Caroline E.] Univ Victoria, Dept Biochem & Microbiol, Victoria, BC V8P 5C2, Canada.
   [Knecht, Marc; Bachas, Leonidas G.] Univ Miami, Dept Chem, Miami, FL 33124 USA.
RP Anderson, KW (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM kanderson@engr.uky.edu
RI Bachas, Leonidas/G-2479-2015
OI Bachas, Leonidas/0000-0002-3308-6264
FU NSF [DGE-0653710]; NASA; National Institutes of Health [AI-51334]
FX We would like to thank Dr. Tonglei Li for the use of his contact angle
   goniometer, Jeffrey Lenihan for his protein purification contributions,
   and the Institute of Advanced Materials and Renewable Energy at the
   University of Louisville for the use of its XPS facility. This work was
   supported by an NSF Integrative Graduate Education and Research
   Traineeship (IGERT) program on Engineered Bioactive Interfaces and
   Devices at the University of Kentucky (DGE-0653710), by NASA (KWA and
   MBA), and by the Public Health Service grant AI-51334 (CEC) from the
   National Institutes of Health.
CR Anderson KV, 2000, CURR OPIN IMMUNOL, V12, P13, DOI 10.1016/S0952-7915(99)00045-X
   Atkin KE, 2010, J BIOL CHEM, V285, P36977, DOI 10.1074/jbc.M110.156935
   Benesch J, 2001, J BIOMAT SCI-POLYM E, V12, P581, DOI 10.1163/156856201316883421
   Biacore AB., 1997, BIAEVALUATION 3 0 SO
   Brinkman MB, 2008, INFECT IMMUN, V76, P1848, DOI 10.1128/IAI.01424-07
   Cameron CE, 2000, J INFECT DIS, V181, P1401, DOI 10.1086/315399
   Cameron CE, 2004, J BACTERIOL, V186, P7019, DOI 10.1128/JB.186.20.7019-7022.2004
   Cameron CE, 2003, INFECT IMMUN, V71, P2525, DOI 10.1128/IAI.71.5.2525-2533.2003
   Chung YC, 2005, BIOMATERIALS, V26, P2313, DOI 10.1016/j.biomaterials.2004.06.043
   Cox DL, 2010, INFECT IMMUN, V78, P5178, DOI 10.1128/IAI.00834-10
   Desrosiers DC, 2011, MOL MICROBIOL, V80, P1496, DOI 10.1111/j.1365-2958.2011.07662.x
   Dixon Matthew C, 2008, J Biomol Tech, V19, P151
   Fischer M, 2010, J MATER SCI-MATER M, V21, P931, DOI 10.1007/s10856-009-3912-0
   FITZGERALD TJ, 1985, GENITOURIN MED, V61, P147
   HARPAZ Y, 1994, STRUCTURE, V2, P641, DOI 10.1016/S0969-2126(00)00065-4
   Hemmersam AG, 2008, J COLLOID INTERF SCI, V320, P110, DOI 10.1016/j.jcis.2007.11.047
   Keselowsky BG, 2003, J BIOMED MATER RES A, V66A, P247, DOI 10.1002/jbm.a.10537
   Lee JH, 2003, YONSEI MED J, V44, P371, DOI 10.3349/ymj.2003.44.3.371
   Lestelius M, 1997, LANGMUIR, V13, P5900, DOI 10.1021/la970187g
   Ling J. C., 2000, J BIOMED MATER RES, V51, P413
   Liu SQ, 2010, SCI CHINA LIFE SCI, V53, P229, DOI 10.1007/s11427-010-0038-z
   Michael KE, 2003, LANGMUIR, V19, P8033, DOI 10.1021/la034810a
   NUZZO RG, 1990, J AM CHEM SOC, V112, P558, DOI 10.1021/ja00158a012
   OUAISSI MA, 1988, PARASITOL TODAY, V4, P169, DOI 10.1016/0169-4758(88)90153-6
   Pankov R, 2002, J CELL SCI, V115, P3861, DOI 10.1242/jcs.00059
   PETERSON KM, 1983, J EXP MED, V157, P1958, DOI 10.1084/jem.157.6.1958
   Radolf Justin D., 1994, Trends in Microbiology, V2, P307, DOI 10.1016/0966-842X(94)90446-4
   Rodrigues SN, 2006, BIOMATERIALS, V27, P5357, DOI 10.1016/j.biomaterials.2006.06.010
   Salazar JC, 2002, MICROBES INFECT, V4, P1133, DOI 10.1016/S1286-4579(02)01638-6
   Sperling C, 2005, BIOMATERIALS, V26, P6547, DOI 10.1016/j.biomaterials.2005.04.042
   Sperling C, 2009, BIOMATERIALS, V30, P4447, DOI 10.1016/j.biomaterials.2009.05.044
   STENBERG E, 1991, J COLLOID INTERF SCI, V143, P513, DOI 10.1016/0021-9797(91)90284-F
   Tanahashi M, 1997, J BIOMED MATER RES, V34, P305
   THOMAS DD, 1985, J EXP MED, V162, P1715, DOI 10.1084/jem.162.5.1715
   THOMAS DD, 1985, J EXP MED, V161, P514, DOI 10.1084/jem.161.3.514
   Tomson FL, 2007, MICROBES INFECT, V9, P1267, DOI 10.1016/j.micinf.2007.05.018
   VANDERFLIER M, 1995, INFECT IMMUN, V63, P4317
   Zhang HWH, 1999, J BACTERIOL, V181, P7168
NR 38
TC 7
Z9 7
U1 1
U2 24
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1043-1802
J9 BIOCONJUGATE CHEM
JI Bioconjugate Chem.
PD FEB
PY 2012
VL 23
IS 2
BP 184
EP 195
DI 10.1021/bc200436x
PG 12
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Multidisciplinary; Chemistry, Organic
SC Biochemistry & Molecular Biology; Chemistry
GA 891JQ
UT WOS:000300213400005
PM 22175441
OA green_accepted
DA 2018-03-19
ER

PT J
AU Hawkins, AM
   Milbrandt, TA
   Puleo, DA
   Hilt, JZ
AF Hawkins, Ashley M.
   Milbrandt, Todd A.
   Puleo, David A.
   Hilt, J. Zach
TI Composite hydrogel scaffolds with controlled pore opening via
   biodegradable hydrogel porogen degradation
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
LA English
DT Article
DE biodegradation; hydrogel; porosity; controlled drug release; cell
   viability; scaffold
ID ESTER) NETWORK PROPERTIES; CARTILAGE; POROSITY; DESIGN
AB Poly(-amino ester) (PBAE) biodegradable hydrogel systems have garnered much attention in recent years due to their appealing properties for biomedical applications. These hydrogel systems exhibit properties similar to natural soft tissue, degrade in aqueous environments, and have easily tunable properties that have been well studied and understood. In most cases, tissue engineering scaffolds must possess a three-dimensional interconnected porous network for tissue ingrowth and construct vascularization. Here, PBAE properties were explored and systems were selected to serve as both the pore-forming agent and the outer matrix of a scaffold that exhibits controlled pore opening upon degradation. To our knowledge, this is the first demonstration of a biodegradable hydrogel porogen system entrapped in a degradable hydrogel outer matrix. Scaffolds were prepared, and the degradation, compressive moduli, and porosity were analyzed. An added advantage of a degradable porogen is the potential for controlled drug release, and a model protein was released from the porogen particles to demonstrate this application. Finally, pluripotent cells seeded onto predegraded scaffolds were viable during the first 24 h of exposure, and furthermore, cell tracking confirmed the presence of cells within the pores of the scaffold. Overall, these present studies demonstrate the possibility of using these biodegradable hydrogel porogen-matrix systems as tissue engineering scaffolding materials. (c) 2013 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 102A: 400-412, 2014.
C1 [Hawkins, Ashley M.; Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Milbrandt, Todd A.] Univ Kentucky, Dept Orthopaed Surg, Lexington, KY 40506 USA.
   [Puleo, David A.] Univ Kentucky, Ctr Biomed Engn, Lexington, KY 40506 USA.
RP Hilt, JZ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM hilt@engr.uky.edu
FU National Science Foundation [0814194]; Pediatric Orthopaedic Society of
   North America
FX Contract grant sponsor: National Science Foundation; contract grant
   numbers: 0814194; Pediatric Orthopaedic Society of North America
CR Anderson DG, 2006, ADV MATER, V18, P2614, DOI 10.1002/adma.200600529
   Annabi N, 2010, TISSUE ENG PART B-RE, V16, P371, DOI [10.1089/ten.teb.2009.0639, 10.1089/ten.TEB.2009.0639]
   Brey DM, 2008, J BIOMED MATER RES A, V85A, P731, DOI 10.1002/jbm.a.31494
   Brey DM, 2008, ACTA BIOMATER, V4, P207, DOI 10.1016/j.actbio.2007.10.002
   Chung C, 2009, BIOMATERIALS, V30, P4287, DOI 10.1016/j.biomaterials.2009.04.040
   Freed LE, 1998, ADV DRUG DELIVER REV, V33, P15, DOI 10.1016/S0169-409X(98)00017-9
   Hawkins AM, 2011, J APPL POLYM SCI, V122, P1420, DOI 10.1002/app.34093
   Hawkins AM, 2011, ACTA BIOMATER, V7, P1956, DOI 10.1016/j.actbio.2011.01.024
   Holland TA, 2004, J CONTROL RELEASE, V94, P101, DOI 10.1016/j.jconrel.2003.09.007
   Holland TA, 2005, J CONTROL RELEASE, V101, P111, DOI 10.1016/j.jconrel.2004.07.004
   Hudalla GA, 2008, BIOMACROMOLECULES, V9, P842, DOI 10.1021/bm701179s
   Hutmacher DW, 2000, BIOMATERIALS, V21, P2529, DOI 10.1016/S0142-9612(00)00121-6
   Joshi A, 2006, BIOMATERIALS, V27, P176, DOI 10.1016/j.biomaterials.2005.06.003
   Karande TS, 2004, ANN BIOMED ENG, V32, P1728, DOI 10.1007/s10439-004-7825-2
   Kim J, 2009, TISSUE ENG PART C-ME, V15, P583, DOI 10.1089/ten.TEC.2008.0642
   Mansour J M, 2003, BIOMECHANICS CARTILA, P66
   Peyton SR, 2011, BIOTECHNOL BIOENG, V108, P1181, DOI 10.1002/bit.23027
   Sachlos E., 2003, European Cells & Materials, V5, P29
   Sachlos E, 2003, EUR CELLS MATER, V5, P39
   Shastri VP, 2003, BIOMATERIALS, V24, P3133, DOI 10.1016/S0142-9612(03)00144-3
   Slaughter BV, 2009, ADV MATER, V21, P3307, DOI 10.1002/adma.200802106
   Treppo S, 2000, J ORTHOPAED RES, V18, P739, DOI 10.1002/jor.1100180510
   Woodfield TBF, 2004, BIOMATERIALS, V25, P4149, DOI 10.1016/j.biomaterials.2003.10.056
   Yuksel E, 2005, SEMIN PLAST SURG, V19, P261
NR 24
TC 9
Z9 9
U1 1
U2 30
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1549-3296
EI 1552-4965
J9 J BIOMED MATER RES A
JI J. Biomed. Mater. Res. Part A
PD FEB
PY 2014
VL 102
IS 2
BP 400
EP 412
DI 10.1002/jbm.a.34697
PG 13
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 269MT
UT WOS:000328246100012
PM 23686850
DA 2018-03-20
ER

PT J
AU Park, CW
   Rhee, YS
   Vogt, FG
   Hayes, D
   Zwischenberger, JB
   DeLuca, PP
   Mansour, HM
AF Park, Chun-Woong
   Rhee, Yun-Seok
   Vogt, Frederick G.
   Hayes, Don, Jr.
   Zwischenberger, Joseph B.
   DeLuca, Patrick P.
   Mansour, Heidi M.
TI Advances in microscopy and complementary imaging techniques to assess
   the fate of drugs ex vivo in respiratory drug delivery An invited paper
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE Multimodal/multifunctional imaging; Targeted pulmonary delivery; Ex
   vivo; In vivo; Optical imaging; Non-optical imaging; Confocal Raman
   microspectroscopy; Chemical imaging
ID POSITRON-EMISSION-TOMOGRAPHY; LUNG-CANCER CELLS; EFFICIENT TELOMERASE
   INHIBITION; RAMAN-SCATTERING MICROSCOPY; IN-VIVO; PULMONARY DELIVERY;
   F-18 FLUOROMISONIDAZOLE; FLUORESCENCE MICROSCOPY; 3RD-HARMONIC
   GENERATION; MULTIPHOTON MICROSCOPY
AB The technical advances in microscopy imaging techniques have been applied to assess the fate of drugs for researching respiratory drug delivery in ex vivo and in vivo experiments. Recent developments in optical imaging (confocal microscopy, multi-photon microscopy, fluorescence imaging (FLI) and bioluminescence imaging (BLI)), and in non-optical imaging (magnetic resonance imaging (MRI), computing tomography (CT), positron-emission tomography (PET) and single-photon-emission computed tomography (SPECT)) are presented with their derivative medical devices. Novel microscopy have been utilized to address many biological questions in basic research and are becoming powerful clinical tools for non-invasive objective diagnosis, guided treatment, and monitoring therapies. The goal of this paper is to present recent advances in microscopy imaging techniques and to discuss their novel applications in respiratory drug delivery imaging. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Park, Chun-Woong; DeLuca, Patrick P.; Mansour, Heidi M.] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Drug Dev Div, Lexington, KY 40536 USA.
   [Rhee, Yun-Seok] Gyeongsang Natl Univ, Coll Pharm, Jinju 660751, Gyeongnam, South Korea.
   [Vogt, Frederick G.] GlaxoSmithKline, Prod Dev, Analyt Sci, King Of Prussia, PA 19406 USA.
   [Zwischenberger, Joseph B.] Univ Kentucky, Coll Med, Dept Pulmonol, Lexington, KY 40536 USA.
   [Zwischenberger, Joseph B.] Univ Kentucky, Coll Med, Dept Internal Med, Lexington, KY 40536 USA.
   [Zwischenberger, Joseph B.] Univ Kentucky, Coll Med, Dept Surg, Lexington, KY 40536 USA.
   [Hayes, Don, Jr.] Ohio State Univ, Nationwide Childrens Hosp, Coll Med, Dept Pediat,Lung Transplant Program, Columbus, OH 43205 USA.
   [Hayes, Don, Jr.] Ohio State Univ, Nationwide Childrens Hosp, Coll Med, Dept Pediat,Heart Lung Transplant Program, Columbus, OH 43205 USA.
   [Hayes, Don, Jr.] Ohio State Univ, Nationwide Childrens Hosp, Coll Med, Dept Internal Med,Lung Transplant Program, Columbus, OH 43205 USA.
   [Hayes, Don, Jr.] Ohio State Univ, Nationwide Childrens Hosp, Coll Med, Dept Internal Med,Heart Lung Transplant Program, Columbus, OH 43205 USA.
   [Hayes, Don, Jr.] Ohio State Univ, Nationwide Childrens Hosp, Coll Med, Dept Surg,Lung Transplant Program, Columbus, OH 43205 USA.
   [Hayes, Don, Jr.] Ohio State Univ, Nationwide Childrens Hosp, Coll Med, Dept Surg,Heart Lung Transplant Program, Columbus, OH 43205 USA.
RP Mansour, HM (reprint author), Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Drug Dev Div, 789 S Limestone St, Lexington, KY 40536 USA.
EM heidi.mansour@uky.edu
CR AMBROSE J, 1973, BRIT J RADIOL, V46, P148
   Amidi M, 2008, EUR J PHARM BIOPHARM, V68, P191, DOI 10.1016/j.ejpb.2007.05.007
   Amornphimoltham P., 2010, ADV DRUG DELIV REV
   Antoch G, 2003, RADIOLOGY, V229, P526, DOI 10.1148/radiol.2292021598
   Badea C, 2004, MED PHYS, V31, P3324, DOI 10.1118/1.1812604
   Badea Cristian T, 2005, Mol Imaging, V4, P110
   Balas C, 2009, MEAS SCI TECHNOL, V20, DOI 10.1088/0957-0233/20/10/104020
   Bao HC, 2010, OPT EXPRESS, V18, P1255, DOI 10.1364/OE.18.001255
   Beisner J, 2010, LUNG CANCER, V68, P346, DOI 10.1016/j.lungcan.2009.07.010
   Beisner J, 2009, J PHARM SCI-US, V98, P1765, DOI 10.1002/jps.21553
   Bellani G, 2009, CRIT CARE MED, V37, P2216, DOI 10.1097/CCM.0b013e3181aab31f
   Bergstrom M, 1999, CLIN PHARMACOKINET, V36, P33, DOI 10.2165/00003088-199936001-00004
   Bestvater F, 2002, J MICROSC-OXFORD, V208, P108, DOI 10.1046/j.1365-2818.2002.01074.x
   Beyer T, 2000, J NUCL MED, V41, P1369
   Bhirde AA, 2009, ACS NANO, V3, P307, DOI 10.1021/nn800551s
   Blasberg RG, 2002, J CELL BIOCHEM, P172, DOI 10.1002/jcb.10433
   Buck AK, 2008, J NUCL MED, V49, P1305, DOI 10.2967/jnumed.107.050195
   Bugaj JE, 2001, J BIOMED OPT, V6, P122, DOI 10.1117/1.1352748
   Bullen A, 2008, NAT REV DRUG DISCOV, V7, P54, DOI 10.1038/nrd2446
   Buranachai C, 2008, J FLUORESC, V18, P929, DOI 10.1007/s10895-008-0332-3
   Cabeza R, 1997, J COGNITIVE NEUROSCI, V9, P1, DOI 10.1162/jocn.1997.9.1.1
   Campagnola PJ, 2003, NAT BIOTECHNOL, V21, P1356, DOI 10.1038/nbt894
   Chan J, 2008, LASER PHOTONICS REV, V2, P325, DOI 10.1002/lpor.200810012
   Chan R, 2001, ARCH PATHOL LAB MED, V125, P1469
   Chen DL, 2010, J MAGN RESON IMAGING, V32, P1409, DOI 10.1002/jmri.22385
   Chen D.L., 2006, AM J RESP CRIT CARE
   CHERRY SR, 2003, PHYS NUCL MED
   Cluff GM, 2009, J RAMAN SPECTROSC, V40, P1087, DOI 10.1002/jrs.2257
   Cohade C, 2003, EUR J NUCL MED MOL I, V30, P721, DOI 10.1007/s00259-002-1055-3
   Croix CMS, 2006, ADV DRUG DELIVER REV, V58, P834, DOI 10.1016/j.addr.2006.07.007
   De Koker S, 2010, J IMMUNOL, V184, P203, DOI 10.4049/jimmunol.0803591
   Debarre D, 2006, NAT METHODS, V3, P47, DOI 10.1038/NMETH813
   DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027
   DEWET JR, 1985, P NATL ACAD SCI USA, V82, P7870
   Diaspro A., 2002, CONFOCAL 2 PHOTON MI
   Dolovich MB, 2001, J AEROSOL MED, V14, pS35
   Dolovich Myrna, 2004, Proc Am Thorac Soc, V1, P329, DOI 10.1513/pats.200404-030MS
   Dothager Robin S, 2009, Proc Am Thorac Soc, V6, P403, DOI 10.1513/pats.200901-004AW
   Dothager RS, 2009, CURR OPIN BIOTECH, V20, P45, DOI 10.1016/j.copbio.2009.01.007
   Dougall NJ, 2004, AM J GERIAT PSYCHIAT, V12, P554, DOI 10.1176/appi.ajgp.12.6.554
   Duan XY, 2008, ANN NUCL MED, V22, P49, DOI 10.1007/s12149-007-0080-5
   Dziubla TD, 2008, BIOMATERIALS, V29, P215, DOI 10.1016/j.biomaterials.2007.09.023
   Edinger M, 2003, BLOOD, V101, P640, DOI 10.1182/blood-2002-06-1751
   Elfinger M, 2009, J CONTROL RELEASE, V135, P234, DOI 10.1016/j.jconrel.2009.01.012
   Erasmus JJ, 1999, CLIN CHEST MED, V20, P715, DOI 10.1016/S0272-5231(05)70250-1
   Evans CL, 2008, ANNU REV ANAL CHEM, V1, P883, DOI 10.1146/annurev.anchem.1.031207.112754
   Frank JA, 2002, ACAD RADIOL, V9, pS484, DOI 10.1016/S1076-6332(03)80271-4
   Fu Y, 2007, J NEUROSCI RES, V85, P2870, DOI 10.1002/jnr.21403
   Fuchs F.S., 2010, RESPIRATION
   Garbuzenko OB, 2010, P NATL ACAD SCI USA, V107, P10737, DOI 10.1073/pnas.1004604107
   Garbuzenko OB, 2009, PHARM RES-DORD, V26, P382, DOI 10.1007/s11095-008-9755-4
   Gelman AE, 2009, J IMMUNOL, V182, P3969, DOI 10.4049/jimmunol.0803514
   Gibson EA, 2011, J OPHTHALMOL, DOI 10.1155/2011/870879
   Glenny RW, 2009, INTENS CARE MED, V35, P1833, DOI 10.1007/s00134-009-1649-3
   Goerres GW, 2004, J NUCL MED, V45, p66S
   Gonda I, 1996, J AEROSOL MED, V9, pS59
   Griesenbach U, 2008, BIOMATERIALS, V29, P1533, DOI 10.1016/j.biomaterials.2007.11.017
   Grosse S, 2008, J CONTROL RELEASE, V132, P105, DOI 10.1016/j.jconrel.2008.08.018
   Guthi JS, 2010, MOL PHARMACEUT, V7, P32, DOI 10.1021/mp9001393
   Hickey A.J., 2008, FORMULATION CHALLENG, P573
   Hickey A.J, 2009, DELIVERY DRUGS PULMO, P191
   Hoffman A, 2006, ENDOSCOPY, V38, P1275, DOI 10.1055/s-2006-944813
   Hofmann M, 2009, EUR J NUCL MED MOL I, V36, P93, DOI 10.1007/s00259-008-1007-7
   Jere D, 2009, INT J PHARMACEUT, V378, P194, DOI 10.1016/j.ijpharm.2009.05.046
   Jones HA, 1997, EUR RESPIR J, V10, P795
   Jones HA, 2003, EUR RESPIR J, V21, P567, DOI 10.1183/09030936.03.00048502
   Judenhofer MS, 2008, NAT MED, V14, P459, DOI 10.1038/nm1700
   Kim H., 2010, BIOMATERIALS
   Kinahan PE, 1998, MED PHYS, V25, P2046, DOI 10.1118/1.598392
   Kinahan P.E., 2003, XRAY BASED ATTENUATI, P166
   Klein M, 2009, CHEST, V136, P1220, DOI 10.1378/chest.09-0610
   KOH WJ, 1995, INT J RADIAT ONCOL, V33, P391, DOI 10.1016/0360-3016(95)00170-4
   KOH WJ, 1992, INT J RADIAT ONCOL, V22, P199, DOI 10.1016/0360-3016(92)91001-4
   Konig K, 2000, J MICROSC-OXFORD, V200, P83, DOI 10.1046/j.1365-2818.2000.00738.x
   Kortylewski M, 2009, NAT BIOTECHNOL, V27, P925, DOI 10.1038/nbt.1564
   Krafft C, 2006, ANAL CHEM, V78, P4424, DOI 10.1021/ac060205b
   Krafft C, 2008, ANALYST, V133, P361, DOI 10.1039/b712958k
   Kraitchman DL, 2003, CIRCULATION, V107, P2290, DOI 10.1161/01.CIR.0000070931.62772.4E
   Leach MO, 2006, PHYS MED BIOL, V51, pR61, DOI 10.1088/0031-9155/51/13/R05
   Lee ZG, 2000, INT J PHARM, V199, P7, DOI 10.1016/S0378-5173(00)00342-2
   Li Y, 2010, PROCEEDINGS OF 2009 INTERNATIONAL TEXTILE SCIENCE AND TECHNOLOGY FORUM, P1
   Lim RS, 2010, J LIPID RES, V51, P1729, DOI 10.1194/jlr.M003616
   Lipshutz GS, 2001, MOL THER, V3, P284, DOI 10.1006/mthe.2001.0267
   Lipson DA, 2002, MAGNET RESON MED, V47, P1073, DOI 10.1002/mrm.10172
   Liu Z, 2010, J NANOMATER, DOI 10.1155/2010/894303
   Luker KE, 2008, ANTIVIR RES, V78, P179, DOI 10.1016/j.antiviral.2008.01.158
   Mah K, 2002, INT J RADIAT ONCOL, V52, P339, DOI 10.1016/S0360-3016(01)01824-7
   Mansour HM, 2007, AAPS PHARMSCITECH, V8, DOI 10.1208/pt0804099
   Mansour HM, 2009, INT J NANOMED, V4, P299
   Masters B. R., 2008, HDB BIOMEDICAL NONLI
   Mertz J, 2004, CURR OPIN NEUROBIOL, V14, P610, DOI 10.1016/j.conb.2004.08.013
   Milman N, 2003, RESPIRATION, V70, P408, DOI 10.1159/000072906
   MINSKY M, 1988, SCANNING, V10, P128, DOI 10.1002/sca.4950100403
   Mizuno T, 2009, J CONTROL RELEASE, V134, P149, DOI 10.1016/j.jconrel.2008.11.018
   Mohri K, 2010, J CONTROL RELEASE, V144, P221, DOI 10.1016/j.jconrel.2010.02.018
   Morris C.J., 2010, J CONTROL RELEASE
   Moss BL, 2008, J BIOL CHEM, V283, P8687, DOI 10.1074/jbc.M706831200
   Muller M, 1998, J MICROSC-OXFORD, V191, P266
   Murugkar S, 2009, J MICROSC-OXFORD, V233, P244, DOI 10.1111/j.1365-2818.2009.03114.x
   Nasongkla N, 2006, NANO LETT, V6, P2427, DOI 10.1021/nl061412u
   Nassimi M, 2010, EUR J PHARM BIOPHARM, V75, P107, DOI 10.1016/j.ejpb.2010.02.014
   Nassimi Matthias, 2009, Inhal Toxicol, V21 Suppl 1, P104, DOI 10.1080/08958370903005769
   Nava R.G., 2010, 2 PHOTON MICROSCOPY, P1
   NGUYEN VT, 1988, ANAL BIOCHEM, V171, P404, DOI 10.1016/0003-2697(88)90505-2
   Noh MS, 2009, BIOMATERIALS, V30, P3915, DOI 10.1016/j.biomaterials.2009.03.059
   NOLOP KB, 1987, CANCER, V60, P2682, DOI 10.1002/1097-0142(19871201)60:11<2682::AID-CNCR2820601118>3.0.CO;2-H
   Nuiachristos V, 2006, ANNU REV BIOMED ENG, V8, P1, DOI 10.1146/annurev.bioeng.8.061505.095831
   Oheim M, 2006, ADV DRUG DELIVER REV, V58, P788, DOI 10.1016/j.addr.2006.07.005
   Oros AM, 2004, PHYS MED BIOL, V49, pR105, DOI 10.1088/0031-9155/49/20/R01
   Ortner A., 2010, J DRUG TARGET, P1
   Patlolla RR, 2010, J CONTROL RELEASE, V144, P233, DOI 10.1016/j.jconrel.2010.02.006
   Paulus MJ, 2000, NEOPLASIA, V2, P62, DOI 10.1038/sj.neo.7900069
   Pauwels EKJ, 1998, EUR J NUCL MED, V25, P277, DOI 10.1007/s002590050229
   Pena AM, 2007, MICROSC RES TECHNIQ, V70, P162, DOI 10.1002/jemt.20400
   PHIPPS PR, 1989, AM REV RESPIR DIS, V139, P1516, DOI 10.1164/ajrccm/139.6.1516
   Piwnica-Worms D, 2004, CELL MICROBIOL, V6, P319, DOI 10.1111/j.1462-5822.2004.00379.x
   Plathow C, 2004, RADIOTHER ONCOL, V73, P349, DOI 10.1016/j.radonc.2004.07.017
   Rasey JS, 1996, INT J RADIAT ONCOL, V36, P417, DOI 10.1016/S0360-3016(96)00325-2
   RHODES CG, 1995, EUR RESPIR J, V8, P1001
   Richard J.C., 2002, AM J RESP CRIT CARE
   Ritman EL, 2004, ANNU REV BIOMED ENG, V6, P185, DOI 10.1146/annurev.bioeng.6.040803.140130
   Rolle A, 2002, ANN THORAC SURG, V74, P865, DOI 10.1016/S0003-4975(02)03805-5
   Rubart M, 2004, CIRC RES, V95, P1154, DOI 10.1161/01.RES.0000150593.30324.42
   Rudin M, 2003, NAT REV DRUG DISCOV, V2, P123, DOI 10.1038/nrd1007
   Sadikot Ruxana T, 2005, Proc Am Thorac Soc, V2, P537, DOI 10.1513/pats.200507-067DS
   Salaun M, 2010, EUR RESPIR J, V36, P451, DOI 10.1183/09031936.00194509
   Savage C, 2000, Clin Lung Cancer, V2, P101, DOI 10.3816/CLC.2000.n.022
   Schlemmer HPW, 2008, RADIOLOGY, V248, P1028, DOI 10.1148/radiol.2483071927
   Schmolze DB, 2011, ARCH PATHOL LAB MED, V135, P255, DOI 10.1043/1543-2165-135.2.255
   Singh M, 2000, ADV DRUG DELIVER REV, V41, P7, DOI 10.1016/S0169-409X(99)00053-8
   Sosnovik D, 2005, PROG DRUG RES, V62, P83
   Spiess E, 2005, J MICROSC-OXFORD, V217, P200, DOI 10.1111/j.1365-2818.2005.01437.x
   Squier JA, 1998, OPT EXPRESS, V3, P315, DOI 10.1364/OE.3.000315
   Suga K, 2003, AM J RESP CRIT CARE, V167, P1704, DOI 10.1164/rccm.200207-665OC
   Suga K, 2002, ACTA RADIOL, V43, P282, DOI 10.1034/j.1600-0455.2002.430309.x
   Surti N, 2008, DRUG DELIV, V15, P81, DOI [10.1080/10717540801904846, 10.1080/10717540801904846 ]
   Sutton EJ, 2008, EUR RADIOL, V18, P2021, DOI 10.1007/s00330-008-0984-z
   Taetz S, 2009, EUR J PHARM BIOPHARM, V72, P358, DOI 10.1016/j.ejpb.2008.07.011
   Tahara K, 2009, INT J PHARMACEUT, V382, P198, DOI 10.1016/j.ijpharm.2009.07.023
   Takemoto H., 2010, BIOMATERIALS
   Taylor IK, 1996, LANCET, V347, P937, DOI 10.1016/S0140-6736(96)91416-6
   Thiberville L., 2009, CONFOCAL FLUORESCENC, P444
   Tseng CL, 2007, BIOMATERIALS, V28, P3996, DOI 10.1016/j.biomaterials.2007.05.006
   Ungaro F, 2009, J CONTROL RELEASE, V135, P25, DOI 10.1016/j.jconrel.2008.12.011
   van Beek EJR, 2004, J MAGN RESON IMAGING, V20, P540, DOI 10.1002/jmri.20154
   Videbech P, 2000, ACTA PSYCHIAT SCAND, V101, P11, DOI 10.1034/j.1600-0447.2000.101001011.x
   Volkmer A, 2010, BIOL MED PHYS BIOMED, P111, DOI 10.1007/978-3-642-02649-2_6
   Wachsmann-Hogiu S, 2009, CURR OPIN BIOTECH, V20, P63, DOI 10.1016/j.copbio.2009.02.006
   Wang C.C., 2010, APPL PHYS LETT, V97
   Wang HF, 2005, BIOPHYS J, V89, P581, DOI 10.1529/biophysj.105.061911
   Weber WA, 2008, NAT CLIN PRACT ONCOL, V5, P160, DOI 10.1038/ncponc1041
   Weissleder Ralph, 2000, Nature Medicine, V6, P351, DOI 10.1038/73219
   Wijagkanalan W, 2008, J CONTROL RELEASE, V125, P121, DOI 10.1016/j.jconrel.2007.10.011
   Willmann JK, 2008, NAT REV DRUG DISCOV, V7, P591, DOI 10.1038/nrd2290
   Yang Y, 2009, BIOMATERIALS, V30, P1947, DOI 10.1016/j.biomaterials.2008.12.044
   Yang YT, 2010, AAPS J, V12, P138, DOI 10.1208/s12248-009-9172-6
   Yelin D, 1999, OPT EXPRESS, V5, P169, DOI 10.1364/OE.5.000169
   Zipfel WR, 2003, NAT BIOTECHNOL, V21, P1368, DOI 10.1038/nbt899
NR 158
TC 22
Z9 22
U1 2
U2 31
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-409X
EI 1872-8294
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD MAR 30
PY 2012
VL 64
IS 4
BP 344
EP 356
DI 10.1016/j.addr.2011.08.004
PG 13
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 928MD
UT WOS:000302986000005
PM 21920394
DA 2018-03-20
ER

PT J
AU Hayes, D
   Ball, AM
   Mansour, HM
   Martin, CA
   Flynn, JD
AF Hayes, Don, Jr.
   Ball, Amanda M.
   Mansour, Heidi M.
   Martin, Craig A.
   Flynn, Jeremy D.
TI Fungal Infection in Heart-Lung Transplant Recipients Receiving
   Single-agent Prophylaxis with Itraconazole
SO EXPERIMENTAL AND CLINICAL TRANSPLANTATION
LA English
DT Article
DE Itraconazole; Antifungal prophylaxis; Heart transplant; Lung transplant
ID INVASIVE ASPERGILLOSIS; RISK-FACTORS; ANTIFUNGAL PROPHYLAXIS;
   COMPLICATIONS; MANAGEMENT
AB Objectives: Heart and lung transplant recipients are at risk for invasive fungal infections. This study evaluated the affect of single-agent antifungal prophylaxis with itraconazole on the rate of fungal infections after heart or lung transplant.
   Materials and Methods: An observational, retrospective study was performed to evaluate the rate of fungal infections in heart and lung transplant recipients at the University of Kentucky Medical Center over 4.5 years who received itraconazole as a single therapy prophylaxis.
   Results: Eighty-three recipients (42 heart, 41 lung) had an overall fungal infection incidence of 16.9% (14/83), while the incidence was 11.9% for heart recipients (5/42), and 22.0% for lung recipients (9/41).
   Conclusions: Single-agent use with itraconazole in heart or lung transplant recipients did not affect the rate of fungal infection as compared with previous reports. The incidence of fungal infection increased significantly within 3 months after escalation of immunosuppressant for treatment of acute rejection.
C1 [Hayes, Don, Jr.] Univ Kentucky, Med Ctr, Adv Lung Dis & Lung Transplant Programs, Lexington, KY 40536 USA.
   [Ball, Amanda M.] Hosp Univ Penn, Philadelphia, PA 19104 USA.
RP Hayes, D (reprint author), Univ Kentucky, Med Ctr, Adv Lung Dis & Lung Transplant Programs, C424,800 Rose St, Lexington, KY 40536 USA.
EM don.hayes@uky.edu
CR Alexander B D, 2001, Transpl Infect Dis, V3, P128, DOI 10.1034/j.1399-3062.2001.003003128.x
   Ascioglu S, 2002, CLIN INFECT DIS, V34, P7, DOI 10.1086/323335
   Cadena J, 2009, AM J TRANSPLANT, V9, P2085, DOI 10.1111/j.1600-6143.2009.02734.x
   DAUBER JH, 1990, CLIN CHEST MED, V11, P291
   DUMMER JS, 1986, TRANSPLANTATION, V41, P725, DOI 10.1097/00007890-198606000-00012
   Dummer JS, 2004, J HEART LUNG TRANSPL, V23, P1376, DOI 10.1016/j.healun.2003.09.028
   Gavalda J, 2005, CLIN INFECT DIS, V41, P52, DOI 10.1086/430602
   Gordon S M, 2001, Transpl Infect Dis, V3, P161, DOI 10.1034/j.1399-3062.2001.003003161.x
   Groetzner J, 2008, J HEART LUNG TRANSPL, V27, P1, DOI 10.1016/j.healun.2007.10.002
   HORVATH J, 1993, CHEST, V104, P681, DOI 10.1378/chest.104.3.681
   Iversen M, 2007, EUR J CLIN MICROBIOL, V26, P879, DOI 10.1007/s10096-007-0376-3
   Kanj SS, 1996, MEDICINE, V75, P142, DOI 10.1097/00005792-199605000-00004
   Kubak B M, 2002, Transpl Infect Dis, V4 Suppl 3, P24, DOI 10.1034/j.1399-3062.4.s3.4.x
   MAURER JR, 1992, CHEST, V101, P1056, DOI 10.1378/chest.101.4.1056
   Mehrad B, 2001, CHEST, V119, P169, DOI 10.1378/chest.119.1.169
   Minari A, 2002, Transpl Infect Dis, V4, P195, DOI 10.1034/j.1399-3062.2002.t01-2-02002.x
   Montoya JG, 2003, CLIN INFECT DIS, V37, pS281, DOI 10.1086/376527
   Munoz P, 2004, AM J TRANSPLANT, V4, P636, DOI 10.1111/j.1600-6143.2004.00390.x
   Neoh CF, 2011, AM J TRANSPLANT, V11, P361, DOI 10.1111/j.1600-6143.2010.03375.x
   Palmer SM, 2001, TRANSPLANTATION, V72, P545, DOI 10.1097/00007890-200108150-00036
   Martin MJP, 2010, TRANSPL P, V42, P3014, DOI 10.1016/j.transproceed.2010.08.013
   Paterson DL, 1999, MEDICINE, V78, P123, DOI 10.1097/00005792-199903000-00003
   Rubin R H, 2002, Transpl Infect Dis, V4 Suppl 3, P12, DOI 10.1034/j.1399-3062.4.s3.2.x
   Salavert M., 2008, INT J ANTIMICROB S2, pS149
   Singh N, 2005, CLIN MICROBIOL REV, V18, P44, DOI 10.1128/CMR.18.1.44-69.2005
   Singh N, 2003, J HEART LUNG TRANSPL, V22, P258, DOI 10.1016/S1053-2498(02)00477-1
   Sole A, 2005, CLIN MICROBIOL INFEC, V11, P359, DOI 10.1111/j.1469-0691.2005.01128.x
   Sole Amparo, 2008, Transplant Rev (Orlando), V22, P89, DOI 10.1016/j.trre.2007.12.007
   Thompson GR, 2009, CLIN CHEST MED, V30, P203, DOI 10.1016/j.ccm.2009.02.001
   Villacian J S, 1999, Transpl Infect Dis, V1, P50, DOI 10.1034/j.1399-3062.1999.10106.x
   YELDANDI V, 1995, J HEART LUNG TRANSPL, V14, P883
NR 31
TC 10
Z9 11
U1 0
U2 0
PU BASKENT UNIV
PI ANKARA
PA TASKENT CADDESI NO 77, KAT 4, BAHCELIEVLER, ANKARA, 06490, TURKEY
SN 1304-0855
J9 EXP CLIN TRANSPLANT
JI Exp. Clin. Transplant.
PD DEC
PY 2011
VL 9
IS 6
BP 399
EP 404
PG 6
WC Transplantation
SC Transplantation
GA 886MM
UT WOS:000299858500008
PM 22142048
DA 2018-03-20
ER

PT J
AU Lenihan, JS
   Ball, JC
   Gayalas, VG
   Lumpp, JK
   Hines, J
   Daunert, S
   Bachas, LG
AF Lenihan, Jeffrey S.
   Ball, J. Christopher
   Gavalas, Vasilis G.
   Lumpp, Janet K.
   Hines, John
   Daunert, Sylvia
   Bachas, Leonidas G.
TI ANYL 118-Ion-selective sensing in micromachined electrochemical cells
   with nanoliter-range volume
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
C1 [Lenihan, Jeffrey S.; Gayalas, Vasilis G.; Daunert, Sylvia; Bachas, Leonidas G.] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
   [Ball, J. Christopher] American Univ, Washington, DC 20016 USA.
   [Lumpp, Janet K.] Univ Kentucky, Dept Elect Engn, Lexington, KY 40506 USA.
   [Hines, John] NASA, Ames Res Ctr, Washington, DC USA.
RI Bachas, Leonidas/G-2479-2015
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD SEP 10
PY 2006
VL 232
MA 118-ANYL
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA V15DB
UT WOS:000207781601003
DA 2018-03-20
ER

PT J
AU Zeng, ZP
   Yu, DS
   He, ZM
   Liu, J
   Xiao, FX
   Zhang, Y
   Wang, R
   Bhattacharyya, D
   Tan, TTY
AF Zeng, Zhiping
   Yu, Dingshan
   He, Ziming
   Liu, Jing
   Xiao, Fang-Xing
   Zhang, Yan
   Wang, Rong
   Bhattacharyya, Dibakar
   Tan, Timothy Thatt Yang
TI Graphene Oxide Quantum Dots Covalently Functionalized PVDF Membrane with
   Significantly-Enhanced Bactericidal and Antibiofouling Performances
SO SCIENTIFIC REPORTS
LA English
DT Article
ID WALLED CARBON NANOTUBES; ANTIBACTERIAL PROPERTIES; SURFACE MODIFICATION;
   POLYAMIDE MEMBRANES; FABRICATION; NANOSHEETS; COMPOSITE
AB Covalent bonding of graphene oxide quantum dots (GOQDs) onto amino modified polyvinylidene fluoride (PVDF) membrane has generated a new type of nano-carbon functionalized membrane with significantly enhanced antibacterial and antibiofouling properties. A continuous filtration test using E. coli containing feedwater shows that the relative flux drop over GOQDs modified PVDF is 23%, which is significantly lower than those over pristine PVDF (86%) and GO-sheet modified PVDF (62%) after 10 h of filtration. The presence of GOQD coating layer effectively inactivates E. coli and S. aureus cells, and prevents the biofilm formation on the membrane surface, producing excellent antimicrobial activity and potentially antibiofouling capability, more superior than those of previously reported two-dimensional GO sheets and one-dimensional CNTs modified membranes. The distinctive antimicrobial and antibiofouling performances could be attributed to the unique structure and uniform dispersion of GOQDs, enabling the exposure of a larger fraction of active edges and facilitating the formation of oxidation stress. Furthermore, GOQDs modified membrane possesses satisfying long-term stability and durability due to the strong covalent interaction between PVDF and GOQDs. This study opens up a new synthetic avenue in the fabrication of efficient surface-functionalized polymer membranes for potential waste water treatment and biomolecules separation.
C1 [Zeng, Zhiping; Wang, Rong] Nanyang Technol Univ, Interdisciplinary Grad Sch, Nanyang Environm & Water Res Inst, Singapore Membrane Technol Ctr, Singapore 639798, Singapore.
   [Zeng, Zhiping; He, Ziming; Liu, Jing; Xiao, Fang-Xing; Zhang, Yan; Tan, Timothy Thatt Yang] Nanyang Technol Univ, Sch Chem & Biomed Engn, Singapore 639798, Singapore.
   [Yu, Dingshan] Sun Yat Sen Univ, Sch Chem & Chem Engn, Guangzhou 510275, Guangdong, Peoples R China.
   [Bhattacharyya, Dibakar] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY USA.
RP Wang, R (reprint author), Nanyang Technol Univ, Interdisciplinary Grad Sch, Nanyang Environm & Water Res Inst, Singapore Membrane Technol Ctr, Singapore 639798, Singapore.; Tan, TTY (reprint author), Nanyang Technol Univ, Sch Chem & Biomed Engn, Singapore 639798, Singapore.
EM rwang@ntu.edu.sg; tytan@ntu.edu.sg
RI Xiao, Fang-Xing/B-7299-2016; Wang, Rong/A-3800-2011; He,
   Ziming/C-5083-2013
OI He, Ziming/0000-0001-8569-6008; Yu, Dingshan/0000-0002-2913-2432
FU Nanyang Technological University [M4081326]; Youth 1000 Talent Program
   of China
FX The authors gratefully acknowledge the financial supported by Nanyang
   Technological University Start-up Grant (M4081326). We would like to
   thank Dr Loh Chun Heng of NEWRI NTU for assisting in the permeation
   studies. This work is also supported by the Youth 1000 Talent Program of
   China.
CR Akhavan O, 2010, ACS NANO, V4, P5731, DOI 10.1021/nn101390x
   Angert ER, 2005, NAT REV MICROBIOL, V3, P214, DOI 10.1038/nrmicro1096
   Castrillon SRV, 2015, ENVIRON SCI TECH LET, V2, P112, DOI 10.1021/acs.estlett.5b00066
   Cong HP, 2014, CHEM SOC REV, V43, P7295, DOI 10.1039/c4cs00181h
   Fang WX, 2012, J MEMBRANE SCI, V394, P140, DOI 10.1016/j.memsci.2011.12.034
   Fu FY, 2015, ACS APPL MATER INTER, V7, P2597, DOI 10.1021/am507639b
   Garcia-Garcia G, 2015, NAT REV NEPHROL, V11, P127, DOI 10.1038/nrneph.2015.4
   Gunawan P., 2011, ACS NANO, V5, P7
   Guo CX, 2013, ADV ENERGY MATER, V3, P997, DOI 10.1002/aenm.201300171
   He ZM, 2013, ADV MATER, V25, P6900, DOI 10.1002/adma.201303327
   Hummers W. S., 1998, J AM CHEM SOC, V120, P3464
   Kang GD, 2014, J MEMBRANE SCI, V463, P145, DOI 10.1016/j.memsci.2014.03.055
   Kang S, 2007, LANGMUIR, V23, P8670, DOI 10.1021/la701067r
   Li D, 2008, NAT NANOTECHNOL, V3, P101, DOI 10.1038/nnano.2007.451
   Li Y, 2008, MACROMOLECULES, V41, P5339, DOI 10.1021/ma8006834
   Liu SB, 2011, ACS NANO, V5, P6971, DOI 10.1021/nn202451x
   Luna SM, 2011, J BIOMATER APPL, V26, P101, DOI 10.1177/0885328210362924
   Mauter MS, 2011, ACS APPL MATER INTER, V3, P2861, DOI 10.1021/am200522v
   Moshe B., 2014, ENVIRON SCI TECHNOL, V48, P384
   Nurunnabi M, 2013, ACS NANO, V7, P6858, DOI 10.1021/nn402043c
   Pendergast MM, 2011, ENERG ENVIRON SCI, V4, P1946, DOI 10.1039/c0ee00541j
   Perreault F, 2014, ENVIRON SCI TECH LET, V1, P71, DOI 10.1021/ez4001356
   Ruiz ON, 2011, ACS NANO, V5, P8100, DOI 10.1021/nn202699t
   Setiawan L, 2011, J MEMBRANE SCI, V369, P196, DOI 10.1016/j.memsci.2010.11.067
   Shannon MA, 2008, NATURE, V452, P301, DOI 10.1038/nature06599
   Shen JH, 2012, CHEM COMMUN, V48, P3686, DOI 10.1039/c2cc00110a
   Shi HY, 2013, J MEMBRANE SCI, V437, P205, DOI 10.1016/j.memsci.2013.03.009
   Sima LC, 2013, ENVIRON SCI TECHNOL, V47, P7580, DOI 10.1021/es304384n
   Sun HJ, 2014, ACS NANO, V8, P6202, DOI 10.1021/nn501640q
   Tiraferri A, 2011, ACS APPL MATER INTER, V3, P2869, DOI 10.1021/am200536p
   Tu T. S., 2013, NAT NANOTECHNOL, V8, P594
   Wang P, 2002, J MEMBRANE SCI, V195, P103, DOI 10.1016/S0376-7388(01)00548-8
   Wick P, 2014, ANGEW CHEM INT EDIT, V53, P7714, DOI 10.1002/anie.201403335
   Wu CY, 2013, ADV HEALTHC MATER, V2, P1613, DOI 10.1002/adhm.201300066
   Wu X, 2013, J MATER CHEM C, V1, P4676, DOI 10.1039/c3tc30820k
   Yu L, 2013, J MEMBRANE SCI, V447, P452, DOI 10.1016/j.memsci.2013.07.042
   Zhang Y, 2013, NANOSCALE, V5, P1816, DOI 10.1039/c3nr33954h
   Zheng AX, 2013, BIOSENS BIOELECTRON, V49, P519, DOI 10.1016/j.bios.2013.05.038
   Zuo GZ, 2013, J MEMBRANE SCI, V447, P26, DOI 10.1016/j.memsci.2013.06.053
NR 39
TC 28
Z9 28
U1 17
U2 187
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD FEB 2
PY 2016
VL 6
AR 20142
DI 10.1038/srep20142
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DC3SL
UT WOS:000369139000001
PM 26832603
OA gold
DA 2018-03-19
ER

PT J
AU Mengesha, AE
   Wydra, RJ
   Hilt, JZ
   Bummer, PM
AF Mengesha, Abebe E.
   Wydra, Robert J.
   Hilt, J. Zach
   Bummer, Paul M.
TI Binary Blend of Glyceryl Monooleate and Glyceryl Monostearate for
   Magnetically Induced Thermo-Responsive Local Drug Delivery System
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE local drug delivery; monoolein; monostearin; oleic acid-modified iron
   oxide nanoparticles; thermo-responsive monoglycerides
ID HYDROGEL NANOCOMPOSITES; TRIGGERED RELEASE; PHASE-BEHAVIOR; IN-VITRO;
   NANOPARTICLES; HYPERTHERMIA; STABILITY; STIMULI; MAGNETOLIPOSOMES;
   CRYSTALLIZATION
AB To develop a novel monoglycerides-based thermal-sensitive drug delivery system, specifically for local intracavitary chemotherapy.
   Lipid matrices containing mixtures of glyceryl monooleate (GMO) and glyceryl monostearate (GMS) were evaluated for their potential application as magnetically induced thermo-responsive local drug delivery systems using a poorly water-soluble model drug, nifedipine (NF). Oleic acid-modified iron oxide (OA-Fe3O4) nanoparticles were embedded into the GMO-GMS matrix for remote activation of the drug release using an alternating magnetic field (AMF).
   The crystallization behavior of binary blends of GMO and GMS as characterized by DSC did show temperature dependent phase transition. GMO-GMS (75:25 wt%) blend showed a melting (T (m) ) and crystallization (T (c) ) points at 42A degrees C and 37A degrees C, respectively indicating the potential of the matrix to act as an 'on-demand' drug release. The matrix released only 35% of the loaded drug slowly in 10 days at 37A degrees C whereas 96% release was obtained at 42A degrees C. A concentration of 0.5% OA-Fe3O4 heated the matrix to 42.3 and 45.5A degrees C within 5 min and 10 min of AMF exposure, respectively.
   The in vitro NF release profiles form the monoglycerides matrix containing 0.5% OA-Fe3O4 nanoparticles after AMF activation confirmed the thermo-responsive nature of the matrix that could provide pulsatile drug release 'on-demand'.
C1 [Mengesha, Abebe E.] Drake Univ, Coll Pharm & Hlth Sci, Des Moines, IA 50311 USA.
   [Wydra, Robert J.; Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Bummer, Paul M.] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
RP Bummer, PM (reprint author), Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
EM pbumm01@email.uky.edu
CR Abraham G, 2011, J BIOMAT SCI-POLYM E, V22, P1001, DOI 10.1163/092050610X497872
   Abutaltelleh SR, 2011, MACROMOL BIOSCI, V11, P1722
   Batte HD, 2007, FOOD BIOPHYS, V2, P29, DOI 10.1007/s11483-007-9026-7
   Biltonen RL, 1993, CHEM PHYS LIPIDS, V64, P128
   Bolfarini GC, 2012, J PHOTOCH PHOTOBIO B, V115, P1, DOI 10.1016/j.jphotobiol.2012.05.009
   Chan AS, 2010, J NANOSCI NANOTECHNO, V10, P6283, DOI 10.1166/jnn.2010.2536
   Chen PY, 2010, NEURO-ONCOLOGY, V12, P1050, DOI 10.1093/neuonc/noq054
   Cheng R, 2013, BIOMATERIALS, V34, P3647, DOI 10.1016/j.biomaterials.2013.01.084
   Chong JYT, 2012, LANGMUIR, V28, P9223, DOI 10.1021/la301874v
   Clogston J, 2000, CHEM PHYS LIPIDS, V107, P191, DOI 10.1016/S0009-3084(00)00182-1
   Date AA, 2008, INT J PHARMACEUT, V355, P19, DOI 10.1016/j.ijpharm.2008.01.004
   De Geest BG, 2007, SMALL, V3, P804, DOI 10.1002/smll.200600441
   Dilnawaz F, 2010, BIOMATERIALS, V31, P3694, DOI 10.1016/j.biomaterials.2010.01.057
   Fong WK, 2009, J CONTROL RELEASE, V135, P218, DOI 10.1016/j.jconrel.2009.01.009
   Frimpong RA, 2008, NANOTECHNOLOGY, V19, P0957
   Gan L, 2010, INT J PHARMACEUT, V396, P179, DOI 10.1016/j.ijpharm.2010.06.015
   Ganem-Quintanar A, 2000, DRUG DEV IND PHARM, V26, P809, DOI 10.1081/DDC-100101304
   Grayson SM, 2008, J DRUG TARGET, V16, P329, DOI [10.1080/10611860801969616, 10.1080/10611860801969616 ]
   Hawkins AM, 2009, PHARM RES-DORD, V26, P667, DOI 10.1007/s11095-008-9804-z
   Heertje I, 1998, FOOD SCI TECHNOL-LEB, V31, P387
   Heurtault B, 2003, BIOMATERIALS, V24, P4283, DOI 10.1016/S0142-9612(03)00331-4
   Hua MY, 2011, BIOMATERIALS, V32, P516, DOI 10.1016/j.biomaterials.2010.09.065
   Kono K, 2011, BIOMATERIALS, V32, P1387, DOI 10.1016/j.biomaterials.2010.10.050
   Kulkarni CV, 2011, PHYS CHEM CHEM PHYS, V13, P3004, DOI 10.1039/c0cp01539c
   Kumar CSSR, 2011, ADV DRUG DELIVER REV, V63, P789, DOI 10.1016/j.addr.2011.03.008
   Lai J, 2009, AAPS PHARMSCITECH, V10, P960, DOI 10.1208/s12249-009-9292-4
   Laquintana V, 2009, EXPERT OPIN DRUG DEL, V6, P1017, DOI 10.1517/17425240903167942
   Lee ES, 2007, J CONTROL RELEASE, V123, P19, DOI 10.1016/j.jconrel.2007.08.006
   Liu Y, 2010, AAPS PHARMSCITECH, V11, P1005, DOI 10.1208/s12249-010-9458-0
   Meenach SA, 2012, INT J PHARMACEUT, V427, P177, DOI 10.1016/j.ijpharm.2012.01.052
   Meng H, 2010, J INTEL MAT SYST STR, V21, P859, DOI 10.1177/1045389X10369718
   Misra RDK, 2010, MATER TECHNOL, V25, P118, DOI 10.1179/175355510X12723642365241
   Mulet X, 2013, J COLLOID INTERF SCI, V393, P1, DOI 10.1016/j.jcis.2012.10.014
   Nappini S, 2011, J PHYS CHEM LETT, V2, P713, DOI 10.1021/jz2000936
   Petri-Fink A, 2008, EUR J PHARM BIOPHARM, V68, P129, DOI 10.1016/j.ejpb.2007.02.024
   QUI H, 2000, BIOMATERIALS, V21, P223
   Robinson I, 2009, J MAGN MAGN MATER, V321, P1421, DOI 10.1016/j.jmmm.2009.02.055
   Rodriguez-Nino MR, 1996, IND ENG CHEM RES, V35, P4449
   Satarkar NS, 2008, J CONTROL RELEASE, V130, P246, DOI 10.1016/j.jconrel.2008.06.008
   Satarkar NS, 2011, AICHE J, V57, P852, DOI 10.1002/aic.12309
   Sato K, 2001, CHEM ENG SCI, V56, P2255, DOI 10.1016/S0009-2509(00)00458-9
   Sein A, 2002, J COLLOID INTERF SCI, V249, P412, DOI 10.1006/jcis.2002.8287
   Talelli M, 2009, LANGMUIR, V25, P2060, DOI 10.1021/la8036499
   Nguyen TH, 2011, J CONTROL RELEASE, V153, P180, DOI 10.1016/j.jconrel.2011.03.033
   Vereecken J, 2009, FOOD RES INT, V42, P1415, DOI 10.1016/j.foodres.2009.07.006
   Yarmolenko PS, 2010, INT J HYPERTHER, V26, P485, DOI 10.3109/02656731003789284
   Zhu L, 2009, INT J PHARMACEUT, V370, P136, DOI 10.1016/j.ijpharm.2008.12.003
NR 47
TC 11
Z9 11
U1 0
U2 35
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
EI 1573-904X
J9 PHARM RES-DORDR
JI Pharm. Res.
PD DEC
PY 2013
VL 30
IS 12
BP 3214
EP 3224
DI 10.1007/s11095-013-1230-1
PG 11
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 264LI
UT WOS:000327878300018
PM 24158728
DA 2018-03-20
ER

PT J
AU Scott, DF
   Ensor, CM
   Anderson, KW
   Daunert, S
AF Scott, Daniel F.
   Ensor, C. Mark
   Anderson, Kimberly W.
   Daunert, Sylvia
TI Simultaneous, multiplexed cytokine analysis via semi-synthetic aequorin
   fusion proteins
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
C1 Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
   Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD MAR 21
PY 2010
VL 239
MA 85-ANYL
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA V21DW
UT WOS:000208189300342
DA 2018-03-19
ER

PT J
AU Gupta, P
   Lacerda, C
   Patil, VS
   Biswal, D
   Wattamwar, P
   Hilt, JZ
   Dziubla, TD
AF Gupta, Prachi
   Lacerda, Caroline
   Patil, Vinod S.
   Biswal, Dipti
   Wattamwar, Paritosh P.
   Hilt, J. Zach
   Dziubla, Thomas D.
TI Degradation of poly(-amino ester) gels in alcohols through
   transesterification: Method to conjugate drugs to polymer matrices
SO JOURNAL OF POLYMER SCIENCE PART A-POLYMER CHEMISTRY
LA English
DT Article
DE biomaterials; drug delivery; gels; polymer drug conjugate
ID POLY(BETA-AMINO ESTER); DELIVERY; HYDROGEL; RELEASE; NANOPARTICLES;
   SCAFFOLDS; PRODRUGS; LIBRARY; PH
AB Poly( amino ester) (PAE) polymers have received growing attention in the literature, owing to their ease of synthesis, versatile co-monomer selection, and highly tunable degradation kinetics. As such, they have shown extensive potential in many biomedical applications as well. In this work, it is demonstrated for the first time that PAE polymers containing primary and secondary amine groups can undergo degradation by primary alcohols via transesterification mechanism. While this work emphasizes an important aspect of solvent compatibility of these networks, it also represents an interesting, simple mechanism for post synthesis drug incorporation, with riboflavin conjugation being demonstrated as a model compound. (c) 2017 Wiley Periodicals, Inc. J. Polym. Sci., Part A: Polym. Chem. 2017, 55, 2019-2026
C1 [Gupta, Prachi; Lacerda, Caroline; Patil, Vinod S.; Wattamwar, Paritosh; Hilt, J. Zach; Dziubla, Thomas D.] Univ Kentucky, Chem & Mat Engn, Lexington, KY 40506 USA.
   [Biswal, Dipti] Virginia State Univ, Petersburg, VA 23806 USA.
RP Dziubla, TD (reprint author), Univ Kentucky, Chem & Mat Engn, Lexington, KY 40506 USA.
EM dziubla@engr.uky.edu
FU NIEHS NIH HHS [P42 ES007380]
CR Anderson DG, 2006, ADV MATER, V18, P2614, DOI 10.1002/adma.200600529
   Anderson DG, 2003, ANGEW CHEM INT EDIT, V42, P3153, DOI 10.1002/anie.200351244
   Aratani Y, 2002, MED MYCOL, V40, P557, DOI 10.1080/714031156
   Biswal D, 2011, POLYMER, V52, P5985, DOI 10.1016/j.polymer.2011.10.058
   Brey D.M., 2008, ABSTRACTS OF PAPERS, P236
   Chen J, 2007, POLYMER, V48, P675, DOI 10.1016/j.polymer.2006.12.008
   Ettmayer P, 2004, J MED CHEM, V47, P2393, DOI 10.1021/jm0303812
   Fisher PD, 2014, J BIOMAT SCI-POLYM E, V25, P1174, DOI 10.1080/09205063.2014.923368
   Hawkins AM, 2014, J BIOMED MATER RES A, V102, P400, DOI 10.1002/jbm.a.34697
   Hawkins AM, 2011, ACTA BIOMATER, V7, P1956, DOI 10.1016/j.actbio.2011.01.024
   Jain S, 2010, BIORESOURCE TECHNOL, V101, P7701, DOI 10.1016/j.biortech.2010.05.034
   Keeney M, 2013, ACS NANO, V7, P7241, DOI 10.1021/nn402657d
   Kim M, 2010, BIORESOURCE TECHNOL, V101, P4409, DOI 10.1016/j.biortech.2010.01.099
   Lakes AL, 2014, BIOMACROMOLECULES, V15, P3009, DOI 10.1021/bm5006323
   Lynn DM, 2001, ANGEW CHEM INT EDIT, V40, P1707, DOI 10.1002/1521-3773(20010504)40:9<1707::AID-ANIE17070>3.0.CO;2-F
   Meenach SA, 2012, INT J PHARMACEUT, V427, P177, DOI 10.1016/j.ijpharm.2012.01.052
   OTERA J, 1993, CHEM REV, V93, P1449, DOI 10.1021/cr00020a004
   Patil VS, 2015, POLYMER, V75, P88, DOI 10.1016/j.polymer.2015.08.034
   Powers HJ, 2003, AM J CLIN NUTR, V77, P1352
   Rautio J, 2008, NAT REV DRUG DISCOV, V7, P255, DOI 10.1038/nrd2468
   Shenoy D, 2005, PHARM RES, V22, P2107, DOI 10.1007/s11095-005-8343-0
   Singh AK, 2007, ENERG FUEL, V21, P1161, DOI 10.1021/ef060507g
   Song LY, 2014, J BIOMED MATER RES B, V102, P1473, DOI 10.1002/jbm.b.33126
   Sunshine JC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037543
   Wattamwar PP, 2012, ACTA BIOMATER, V8, P2529, DOI 10.1016/j.actbio.2012.03.022
NR 25
TC 0
Z9 0
U1 8
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0887-624X
EI 1099-0518
J9 J POLYM SCI POL CHEM
JI J. Polym. Sci. Pol. Chem.
PD JUN 15
PY 2017
VL 55
IS 12
BP 2019
EP 2026
DI 10.1002/pola.28579
PG 8
WC Polymer Science
SC Polymer Science
GA ET9PN
UT WOS:000400639600007
PM 29398778
DA 2018-03-20
ER

PT J
AU Long, SH
   Siegler, M
   Li, TL
AF Long, Sihui
   Siegler, Maxime A.
   Li, Tonglei
TI 2-oxo-1,2-dihydropyridine-3-carboxylic acid
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article
AB The title compound, C6H5NO2, a tautomer of 2-hydroxynicotinic acid, adopts a planar conformation. An intramolecular O-H center dot center dot center dot O hydrogen bond of 2.504 (2) angstrom is found. The compound forms one-dimensional hydrogen-bonded chains along the [<(1over bar > 01] direction via an intermolecular N-H center dot center dot center dot O hydrogen bond of 2.810 (2) angstrom.
C1 Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40506 USA.
   Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
RP Li, TL (reprint author), Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40506 USA.
EM tonglei@uky.edu
CR *BRUK AXS INC, 1997, SHELXTL VERS 5 10
   Dogra SK, 2005, J MOL STRUCT, V737, P189, DOI 10.1016/j.molstruc.2004.10.060
   ETTER MC, 1990, ACCOUNTS CHEM RES, V23, P120, DOI 10.1021/ar00172a005
   Nonius, 2002, COLLECT
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Sheldrick G. M., 1997, SHELXL97 SHELXS97
   SHELDRICK GM, 1995, XP SHELXTL PC
   TING PC, 1990, J MED CHEM, V33, P2697, DOI 10.1021/jm00172a004
   Tinschert A, 1997, ARCH MICROBIOL, V168, P355, DOI 10.1007/s002030050509
NR 9
TC 7
Z9 7
U1 0
U2 4
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD DEC
PY 2006
VL 62
BP O5664
EP O5665
DI 10.1107/S1600536806048768
PN 12
PG 2
WC Crystallography
SC Crystallography
GA 111EQ
UT WOS:000242434600325
DA 2018-03-20
ER

PT J
AU Ponta, A
   Fugit, K
   Anderson, BD
   Bae, Y
AF Ponta, Andrei
   Fugit, Kyle D.
   Anderson, Bradley D.
   Bae, Younsoo
TI Release, Partitioning, and Conjugation Stability of Doxorubicin in
   Polymer Micelles Determined by Mechanistic Modeling
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE controlled drug release; doxorubicin; hydrazone; mechanistic modeling;
   nanoparticles
ID BLOCK-COPOLYMER MICELLES; VIVO ANTITUMOR EFFICACY; DRUG-DELIVERY
   SYSTEMS; HYDROPHOBIC CAMPTOTHECIN; DYNAMIC DIALYSIS; PH; LIPOSOMES;
   NANOPARTICLES; PERMEABILITY; COEFFICIENTS
AB To better understand the mechanistic parameters that govern drug release from polymer micelles with acid-labile linkers.
   A mathematical model was developed to describe drug release from block copolymer micelles composed of a poly(ethylene glycol) shell and a poly(aspartate) core, modified with drug binding linkers for pH-controlled release [hydrazide (HYD), aminobenzoate-hydrazide (ABZ), or glycine-hydrazide (GLY)]. Doxorubicin (Dox) was conjugated to the block copolymers through acid-labile hydrazone bonds. The polymer drug conjugates were used to prepare three polymer micelles (HYD-M, ABZ-M, and GLY-M). Drug release studies were performed to identify the factors governing pH-sensitive release of Dox. The effect of prolonged storage of copolymer material on release kinetics was also observed.
   Biphasic drug release kinetics were observed for all three micelle formulations. The developed model was able to quantify observed release kinetics upon the inclusion of terms for unconjugated Dox and two populations of conjugated Dox. Micelle/water partitioning of Dox was also incorporated into the model and found significant in all micelles under neutral conditions but reduced under acidic conditions. The drug binding linker played a major role in drug release as the extent of Dox release at specific time intervals was greater at pH 5.0 than at pH 7.4 (HYD-M > ABZ-M > GLY-M). Mathematical modeling was also able to correlate changes in release kinetics with the instability of the hydrazone conjugation of Dox during prolonged storage.
   These results illustrate the potential utility of mechanistic modeling to better assess release characteristics intrinsic to a particular drug/nanoparticle system.
C1 [Ponta, Andrei; Fugit, Kyle D.; Anderson, Bradley D.; Bae, Younsoo] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
RP Bae, Y (reprint author), Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, 789 South Limestone, Lexington, KY 40536 USA.
EM younsoo.bae@uky.edu
FU Kentucky Lung Cancer Research Program; University of Kentucky Cancer
   Nanotechnology Training Center (UK-CNTC) from the National Cancer
   Institute [R25CA153954]
FX This work is partially supported by the Kentucky Lung Cancer Research
   Program and the University of Kentucky Cancer Nanotechnology Training
   Center (UK-CNTC), grant R25CA153954 from the National Cancer Institute.
   The content herein is solely the responsibility of the authors and does
   not necessarily represent the official views of the National Cancer
   Institute or the National Institutes of Health.
CR Amstad E, 2011, NANO LETT, V11, P1664, DOI 10.1021/nl2001499
   Bae Y, 2003, ANGEW CHEM INT EDIT, V42, P4640, DOI 10.1002/anie.200250653
   Bae Y, 2005, BIOCONJUGATE CHEM, V16, P122, DOI 10.1021/bc0498166
   Bae Y, 2009, ADV DRUG DELIVER REV, V61, P768, DOI 10.1016/j.addr.2009.04.016
   Baker MA, 1996, J CONTROL RELEASE, V40, P89, DOI 10.1016/0168-3659(95)00177-8
   BARBOUR NP, 1995, PHARMACEUT RES, V12, P215, DOI 10.1023/A:1016274825322
   Barenholz Y, 2012, J CONTROL RELEASE, V160, P117, DOI 10.1016/j.jconrel.2012.03.020
   Batrakova EV, 2008, J CONTROL RELEASE, V130, P98, DOI 10.1016/j.jconrel.2008.04.013
   Cho EJ, 2013, MOL PHARMACEUT, V10, P2093, DOI 10.1021/mp300697h
   Domingo C, 2012, ANAL CHIM ACTA, V744, P8, DOI 10.1016/j.aca.2012.07.010
   Drummond DC, 2008, J PHARM SCI-US, V97, P4696, DOI 10.1002/jps.21358
   Etrych T, 2002, MACROMOL BIOSCI, V2, P43, DOI 10.1002/1616-5195(20020101)2:1<43::AID-MABI43>3.3.CO;2-#
   Ferrari M, 2005, NAT REV CANCER, V5, P161, DOI 10.1038/nrc1566
   Frimpong RA, 2007, J BIOMED MATER RES A, V80A, P1, DOI 10.1002/jbm.a.30962
   Fugit KD, 2014, MOL PHARMACEUT, V11, P1314, DOI 10.1021/mp400765n
   Fugit KD, 2014, J CONTROL RELEASE, V174, P88, DOI 10.1016/j.jconrel.2013.11.003
   Gaber MH, 1996, INT J RADIAT ONCOL, V36, P1177, DOI 10.1016/S0360-3016(96)00389-6
   Guo X, 2013, BIOMATERIALS, V34, P4544, DOI 10.1016/j.biomaterials.2013.02.071
   GUPTA PK, 1987, J PHARM SCI, V76, P141, DOI 10.1002/jps.2600760211
   HARAN G, 1993, BIOCHIM BIOPHYS ACTA, V1151, P201, DOI 10.1016/0005-2736(93)90105-9
   Joguparthi V, 2008, INT J PHARM, V352, P17, DOI 10.1016/j.ijpharm.2007.10.003
   Joguparthi V, 2008, J PHARM SCI-US, V97, P400, DOI 10.1002/jps.21125
   Kong G, 1999, INT J HYPERTHER, V15, P345
   Kozlov MY, 2000, MACROMOLECULES, V33, P3305, DOI 10.1021/ma991634x
   Kwon G, 1997, J CONTROL RELEASE, V48, P195, DOI 10.1016/S0168-3659(97)00039-4
   La SB, 1996, J PHARM SCI, V85, P85, DOI 10.1021/js950204r
   Lee HJ, 2013, PHARM RES-DORDR, V30, P478, DOI 10.1007/s11095-012-0893-3
   Lee SJ, 2008, POLYM J, V40, P171, DOI 10.1295/polymj.PJ2007179
   Li F, 2010, BIOMACROMOLECULES, V11, P2610, DOI 10.1021/bm100561v
   Lu DX, 2008, CHINESE J POLYM SCI, V26, P369, DOI 10.1142/S0256767908003023
   Mehnert W, 2012, ADV DRUG DELIVER REV, V64, P83, DOI 10.1016/j.addr.2012.09.021
   Modi S, 2013, MOL PHARMACEUT, V10, P3076, DOI 10.1021/mp400154a
   Moreno-Bautista G, 2011, COLLOID SURFACE A, V389, P299, DOI 10.1016/j.colsurfa.2011.07.032
   Ono A, 2002, BIOL PHARM BULL, V25, P97, DOI 10.1248/bpb.25.97
   Ponta A, 2014, J DRUG TARGET, V22, P619, DOI 10.3109/1061186X.2014.910793
   Ponta A, 2010, PHARM RES-DORDR, V27, P2330, DOI 10.1007/s11095-010-0120-z
   STURGEON RJ, 1977, J PHARM SCI, V66, P958, DOI 10.1002/jps.2600660714
   Sutton D, 2007, EXP BIOL MED, V232, P1090, DOI 10.3181/0702-RM-31
   Tai L.A., 2009, NANOTECHNOLOGY, V20, P1
   Thomas CR, 2010, J AM CHEM SOC, V132, P10623, DOI 10.1021/ja1022267
   Torchilin VP, 2001, J CONTROL RELEASE, V73, P137, DOI 10.1016/S0168-3659(01)00299-1
   WASHINGTON C, 1989, INT J PHARM, V56, P71, DOI 10.1016/0378-5173(89)90062-8
   WASHINGTON C, 1990, INT J PHARM, V58, P1, DOI 10.1016/0378-5173(90)90280-H
   West Kevin R, 2005, Curr Drug Discov Technol, V2, P123, DOI 10.2174/1570163054866882
NR 44
TC 5
Z9 5
U1 3
U2 54
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
EI 1573-904X
J9 PHARM RES-DORDR
JI Pharm. Res.
PD MAY
PY 2015
VL 32
IS 5
BP 1752
EP 1763
DI 10.1007/s11095-014-1573-2
PG 12
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA CF0HZ
UT WOS:000352225300018
PM 25407546
OA green_accepted
DA 2018-03-19
ER

PT J
AU Mansour, HM
AF Mansour, Heidi M.
TI AEROSOL FORMULATION ISSUES
SO PEDIATRIC PULMONOLOGY
LA English
DT Meeting Abstract
ID STANDARDIZED ENTRAINMENT TUBES; DRY POWDER INHALERS;
   PHYSICAL-CHARACTERIZATION; DRUG BLENDS; DELIVERY; MONOHYDRATE
C1 Univ Kentucky, Coll Pharm, Lexington, KY USA.
   Univ Kentucky, Ctr Membrane Sci, Lexington, KY 40506 USA.
CR [Anonymous], 2006, METERED DOSE INHALER, P2617
   Hayes D, 2012, TRANSPL INFECT DIS, V14, P548, DOI 10.1111/j.1399-3062.2012.00748.x
   Hayes DJ, 2012, TRANSPL P, V42, P3876
   Hayes D, 2012, PEDIATR TRANSPLANT, V16, pE333, DOI 10.1111/j.1399-3046.2012.01682.x
   Hayes D, 2012, LUNG, V190, P221, DOI 10.1007/s00408-011-9343-y
   Hickey A. J., 2008, MODIFIED RELEASE DRU, P573
   Hickey AJ, 2009, MODERN PHARM, P191
   Hickey AJ, 2007, J PHARM SCI-US, V96, P1302, DOI 10.1002/jps.20943
   Hickey AJ, 2007, J PHARM SCI-US, V96, P1282, DOI 10.1002/jps.20916
   Li XJ, 2011, AAPS PHARMSCITECH, V12, P1420, DOI 10.1208/s12249-011-9704-0
   Mansour HM, 2012, J PHARM SCI, V99, P3430
   Mansour HM, 2007, AAPS PHARMSCITECH, V8, DOI 10.1208/pt0804099
   Mansour HM, 2009, INT J NANOMED, V4, P299
   Mansour HM, 2011, LIPIDS NANOTECHNOLOG, P221
   Mansour HM, 2011, SERIES NANOMEDICINE, P1
   Mansour HM, 2012, NANOMEDICIN IN PRESS
   Park CW, 2012, ADV DRUG DELIVER REV, V64, P344, DOI 10.1016/j.addr.2011.08.004
   Park CW, 2011, EUROPEAN PHARM REV, V16, P32
   Willis L, 2012, LUNG, V190, P251, DOI 10.1007/s00408-011-9360-x
   Wu X, 2010, KONA POWDER PARTICLE, V28, P3
   Xu Z, 2008, RESP DRUG DELIVERY, P897
   Xu Z, 2011, J ADHES SCI TECHNOL, V25, P451, DOI 10.1163/016942410X525669
   Xu Z, 2010, J PHARM SCI-US, V99, P3442, DOI 10.1002/jps.22057
   Xu Z, 2010, J PHARM SCI-US, V99, P3415, DOI 10.1002/jps.22100
   Xu Z, 2010, J PHARM SCI-US, V99, P3398, DOI 10.1002/jps.22107
NR 25
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 8755-6863
EI 1099-0496
J9 PEDIATR PULM
JI Pediatr. Pulmonol.
PD SEP
PY 2012
VL 47
SU 35
SI SI
BP 149
EP 151
PG 3
WC Pediatrics; Respiratory System
SC Pediatrics; Respiratory System
GA 007IM
UT WOS:000308882000034
DA 2018-03-20
ER

PT J
AU Zhang, XY
   Zhan, DY
   Shin, HY
AF Zhang, Xiaoyan
   Zhan, Dongying
   Shin, Hainsworth Y.
TI Integrin subtype-dependent CD18 cleavage under shear and its influence
   on leukocyte-platelet binding
SO JOURNAL OF LEUKOCYTE BIOLOGY
LA English
DT Article
DE mechanotransduction; anti-inflammatory; neutrophil; protease; Mac-1
ID SURFACE-ADHERENT PLATELETS; P-SELECTIN; NEUTROPHIL INTERACTIONS;
   EXTRACELLULAR DOMAIN; CELL FILTRATION; STRESS RESPONSE; WHOLE-BLOOD;
   CROSS-TALK; ADHESION; MAC-1
AB Previous studies showed that exposure of neutrophils to shear stress induces cysteine protease-mediated shedding of surface CD18 integrins involved in leukocyte-platelet interactions. Based on this, we hypothesized that, under noninflamed conditions, shear-induced CD18 cleavage is a control mechanism to minimize spontaneous leukocyte-platelet binding. For this purpose, we characterized the influence of shear on CD18 surface expression and platelet binding by the different leukocyte subsets. Shear stress elicited magnitude( between 0 and 5 dyn/cm(2)) and time-dependent reductions in CD18 surface expression. This response was integrin-and cell type-specific, with neutrophils and monocytes exhibiting Mac-1 proteolysis but lymphocytes displaying LFA-1 shedding. Correspondingly, platelet binding, through CD18-fibrinogen interactions, was also influenced by shear exposure in a leukocyte-dependent manner. After treatment with cysteine protease inhibitor E64, neutrophils, but neither monocytes nor lymphocytes, exhibited significantly (P<0.05) enhanced platelet binding and CD18 surface expression under shear. Furthermore, shear exposure significantly (P<0.05) inhibited binding of naive but not E64-treated neutrophils to fibrinogen. Combined, we provide first evidence that the CD18-cleavage responses of neutrophils to shear interfere with fibrinogen binding and platelet adhesion. These findings have implications as it relates to the efficiency of leukocyte passage through the microcirculation. J. Leukoc. Biol. 93: 251-258; 2013.
C1 [Zhang, Xiaoyan; Zhan, Dongying; Shin, Hainsworth Y.] Univ Kentucky, Ctr Biomed Engn, Lexington, KY 40506 USA.
RP Shin, HY (reprint author), Univ Kentucky, Ctr Biomed Engn, Wenner Gren Res Lab 213, Lexington, KY 40506 USA.
EM hy.shin@uky.edu
FU University of Kentucky; American Heart Association; National Science
   Foundation-Kentucky EPSCoR Bioengineering Initiative
FX This work was supported by the University of Kentucky Research Support
   Fund, an American Heart Association Beginning Grant-in-Aid, and a
   National Science Foundation-Kentucky EPSCoR Bioengineering Initiative
   grant. We thank Dr. Alan Daugherty for his assistance in data analyses
   and Dr. Charles Knapp for his material contributions to our custom
   cone-plate viscometer.
CR Abitorabi MA, 1997, J CELL BIOL, V139, P563, DOI 10.1083/jcb.139.2.563
   ARNAOUT MA, 1990, BLOOD, V75, P1037
   BENNETT JS, 1983, P NATL ACAD SCI-BIOL, V80, P2417, DOI 10.1073/pnas.80.9.2417
   Chen AY, 2010, AM J PHYSIOL-CELL PH, V299, pC1441, DOI 10.1152/ajpcell.00157.2010
   Diacovo TG, 1996, BLOOD, V88, P146
   DIACOVO TG, 1994, J CLIN INVEST, V94, P1243, DOI 10.1172/JCI117442
   Ding ZM, 1999, J IMMUNOL, V163, P5029
   Drbal K, 2001, BLOOD, V98, P1561, DOI 10.1182/blood.V98.5.1561
   Eppihimer MJ, 1996, MICROVASC RES, V51, P187, DOI 10.1006/mvre.1996.0020
   ERLANDSEN SL, 1993, J HISTOCHEM CYTOCHEM, V41, P327, DOI 10.1177/41.3.7679125
   Evangelista V, 1996, BLOOD, V88, P4183
   Evans BJ, 2006, BLOOD, V107, P3593, DOI 10.1182/blood-2005-09-3695
   Fukuda S, 2003, P NATL ACAD SCI USA, V100, P13152, DOI 10.1073/pnas.2336130100
   Fukuda S, 2000, CIRC RES, V86, pE13
   Hafezi-Moghadam A, 2001, J EXP MED, V193, P863, DOI 10.1084/jem.193.7.863
   Helmke BP, 1998, BIORHEOLOGY, V35, P437, DOI 10.1016/S0006-355X(99)80021-3
   Hinshaw LB, 1996, CRIT CARE MED, V24, P1072, DOI 10.1097/00003246-199606000-00031
   Kirschenbaum LA, 2002, SHOCK, V17, P508, DOI 10.1097/00024382-200206000-00012
   Kirschenbaum LA, 2000, AM J RESP CRIT CARE, V161, P1602, DOI 10.1164/ajrccm.161.5.9902105
   Konstantopoulos K, 1998, CIRCULATION, V98, P873
   KONSTANTOPOULOS K, 1995, BIORHEOLOGY, V32, P73
   Kuijper PHM, 1998, J LEUKOCYTE BIOL, V64, P467
   Li N, 2008, J LEUKOCYTE BIOL, V83, P1069, DOI 10.1189/jlb.0907615
   Lopez S, 1998, CELL ADHES COMMUN, V5, P151, DOI 10.3109/15419069809040288
   Makino A, 2007, BIORHEOLOGY, V44, P221
   MILLER LJ, 1986, J IMMUNOL, V137, P2891
   Moazzam F, 1997, P NATL ACAD SCI USA, V94, P5338, DOI 10.1073/pnas.94.10.5338
   Pfaff M, 1999, FEBS LETT, V460, P17, DOI 10.1016/S0014-5793(99)01250-8
   Popel AS, 2005, ANNU REV FLUID MECH, V37, P43, DOI 10.1146/annurev.fluid.37.042604.133933
   REDDY VY, 1995, P NATL ACAD SCI USA, V92, P3849, DOI 10.1073/pnas.92.9.3849
   RINDER HM, 1991, BLOOD, V78, P1730
   Sarantos MR, 2005, J BIOL CHEM, V280, P28290, DOI 10.1074/jbc.M501662200
   Shin HY, 2008, J CELL PHYSIOL, V214, P528, DOI 10.1002/jcp.21235
   Simon SI, 2005, ANNU REV BIOMED ENG, V7, P151, DOI 10.1146/annurev.biomed.7.060804.100423
   Vaisar T, 2009, MOL CELL PROTEOMICS, V8, P1044, DOI 10.1074/mcp.M800449-MCP200
   Weber C, 1997, J CLIN INVEST, V100, P2085, DOI 10.1172/JCI119742
   WORTHEN GS, 1989, SCIENCE, V245, P183, DOI 10.1126/science.2749255
   Youker KA, 2000, J IMMUNOL, V164, P2752, DOI 10.4049/jimmunol.164.5.2752
   Zen K, 2011, BLOOD, V117, P4885, DOI 10.1182/blood-2010-05-287722
   Zhang XY, 2011, AM J PHYSIOL-CELL PH, V301, pC451, DOI 10.1152/ajpcell.00458.2010
NR 40
TC 8
Z9 9
U1 0
U2 2
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0741-5400
J9 J LEUKOCYTE BIOL
JI J. Leukoc. Biol.
PD FEB
PY 2013
VL 93
IS 2
BP 251
EP 258
DI 10.1189/jlb.0612302
PG 8
WC Cell Biology; Hematology; Immunology
SC Cell Biology; Hematology; Immunology
GA 081YH
UT WOS:000314358100010
PM 23125457
DA 2018-03-20
ER

PT J
AU Aher, A
   Cai, YG
   Majumder, M
   Bhattacharyya, D
AF Aher, Ashish
   Cai, Yuguang
   Majumder, Mainak
   Bhattacharyya, Dibakar
TI Synthesis of graphene oxide membranes and their behavior in water and
   isopropanol
SO CARBON
LA English
DT Article
ID GRAPHITE OXIDE; SEPARATION MEMBRANES; ATOMIC-STRUCTURE; NANOFILTRATION;
   STABILITY; TRANSPORT; SPECTROSCOPY; ULTRATHIN; PORES
AB Graphene oxide (GO) membrane has been synthesized on commercial polysulfone ultrafiltration membranes (Pore size: 17 nm) using the drop casting method followed by baking at 90 degrees C for 24 h. Baking resulted in the reduction of GO and removal of bulk water intercalated in the GO sheets. Deposited GO film showed high stability under shear stress variation. This work shows that water adsorption on the GO membrane determines its permeation performance. Despite the higher viscosity of isopropyl alcohol (IPA), its permeability was 7 times higher than water through the baked ("dry") GO membranes, which were never contacted with water. However, IPA permeability of GO membranes dropped to 44% (of deionized water) when contacted with water ("hydrated" or "wet" GO membranes). Extensive size exclusion (rejection) studies with various dye and dendrimer molecules showed pore size reduced from 3.3 nm in the "dry" state to 1.3 nm in the "wet" state of GO membranes. FT-IR characterization of GO membrane suggested adsorption of water on the nanochannels of the active layer. Also, significant decay in flux was observed for water (82% of its initial flux) as compared to IPA (38% of its initial flux) for initially dry GO membranes. (C) 2017 Published by Elsevier Ltd.
C1 [Aher, Ashish; Cai, Yuguang; Bhattacharyya, Dibakar] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Majumder, Mainak] Monash Univ, Dept Mech Engn & Aerosp Engn, Nanoscale Sci & Engn Lab, Clayton, Vic 3800, Australia.
RP Bhattacharyya, D (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM db@uky.edu
FU NSF KY EPSCoR grant [1355438]; NIH-NIEHS-SRC [P42ES007380]; Australian
   Research Council (through an A ARC Linkage grant) [LP140100959]
FX This research was supported by NSF KY EPSCoR grant (Grant no: 1355438),
   NIH-NIEHS-SRC (Award number: P42ES007380), and by Australian Research
   Council (through an A ARC Linkage LP140100959 grant). The authors thank
   Nicolas J. Briot, Dr. Rupam Sharma, Syed Islam, Michael Detisch for
   their contributions.Authors also thank the Nanostone Water Co.,
   Oceanside, CA for providing the full-scale size PS35 membrane.
CR Aba NFD, 2015, J MEMBRANE SCI, V484, P87, DOI 10.1016/j.memsci.2015.03.001
   Akbari A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10891
   Bao CL, 2011, J MATER CHEM, V21, P13942, DOI 10.1039/c1jm11662b
   BENJAMIN I, 1994, PHYS REV LETT, V73, P2083, DOI 10.1103/PhysRevLett.73.2083
   Cohen-Tanugi D, 2012, NANO LETT, V12, P3602, DOI 10.1021/nl3012853
   Compton OC, 2010, SMALL, V6, P711, DOI 10.1002/smll.200901934
   Deegan RD, 2000, PHYS REV E, V61, P475, DOI 10.1103/PhysRevE.61.475
   Dreyer DR, 2010, CHEM SOC REV, V39, P228, DOI 10.1039/b917103g
   Fornasiero F, 2008, P NATL ACAD SCI USA, V105, P17250, DOI 10.1073/pnas.0710437105
   Gao W., 2015, GRAPHENE OXIDE REDUC
   Gao XF, 2010, J PHYS CHEM C, V114, P832, DOI 10.1021/jp909284g
   Goh K, 2016, CARBON, V109, P694, DOI 10.1016/j.carbon.2016.08.077
   Goh KL, 2015, J MEMBRANE SCI, V474, P244, DOI 10.1016/j.memsci.2014.09.057
   Gomez-Navarro C, 2010, NANO LETT, V10, P1144, DOI 10.1021/nl9031617
   Guo F, 2011, ACS NANO, V5, P8019, DOI 10.1021/nn2025644
   Han Y, 2013, ADV FUNCT MATER, V23, P3693, DOI 10.1002/adfm.201202601
   Hu M, 2013, ENVIRON SCI TECHNOL, V47, P3715, DOI 10.1021/es400571g
   Huang HB, 2013, CHEM COMMUN, V49, P5963, DOI 10.1039/c3cc41953c
   Huisken F, 1996, J CHEM PHYS, V104, P17, DOI 10.1063/1.470871
   Hung WS, 2014, CARBON, V68, P670, DOI 10.1016/j.carbon.2013.11.048
   Jeong HK, 2009, CHEM PHYS LETT, V470, P255, DOI 10.1016/j.cplett.2009.01.050
   Jia XT, 2011, NANOSCALE, V3, P86, DOI 10.1039/c0nr00600a
   Joshi RK, 2015, APPL MATER TODAY, V1, P1, DOI 10.1016/j.apmt.2015.06.002
   Joshi RK, 2014, SCIENCE, V343, P752, DOI 10.1126/science.1245711
   Kielland J, 1937, J AM CHEM SOC, V59, P1675, DOI 10.1021/ja01288a032
   Kim HW, 2013, SCIENCE, V342, P91, DOI 10.1126/science.1236098
   Korobov MV, 2016, CARBON, V102, P297, DOI 10.1016/j.carbon.2016.02.070
   Li GF, 2015, J MEMBRANE SCI, V495, P439, DOI 10.1016/j.memsci.2015.08.042
   Li H, 2013, SCIENCE, V342, P95, DOI 10.1126/science.1236686
   Lu R, 2005, J PHYS CHEM B, V109, P14118, DOI 10.1021/jp051565q
   Luo YZ, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3894
   Mi BX, 2014, SCIENCE, V343, P740, DOI 10.1126/science.1250247
   O'Hern SC, 2014, NANO LETT, V14, P1234, DOI 10.1021/nl404118f
   Pacile D, 2011, CARBON, V49, P966, DOI 10.1016/j.carbon.2010.09.063
   Rafiee J, 2012, NAT MATER, V11, P217, DOI [10.1038/NMAT3228, 10.1038/nmat3228]
   Shakaib M, 2009, J MEMBRANE SCI, V326, P270, DOI 10.1016/j.memsci.2008.09.052
   Shi G, 2015, ACS APPL MATER INTER, V7, P13745, DOI 10.1021/am5091287
   Suk ME, 2010, J PHYS CHEM LETT, V1, P1590, DOI 10.1021/jz100240r
   Sun PZ, 2013, ACS NANO, V7, P428, DOI 10.1021/nn304471w
   Talyzin AV, 2014, NANOSCALE, V6, P272, DOI 10.1039/c3nr04631a
   Tsunomori F, 1999, PHYS LETT A, V258, P171, DOI 10.1016/S0375-9601(99)00346-1
   Wang X, 2012, J MATER CHEM, V22, P22037, DOI 10.1039/c2jm35479a
   Wei N, 2014, ACS APPL MATER INTER, V6, P5877, DOI 10.1021/am500777b
   Wei Y, 2016, CARBON, V108, P568, DOI 10.1016/j.carbon.2016.07.056
   Xu C, 2013, CARBON, V62, P465, DOI 10.1016/j.carbon.2013.06.035
   Yang D, 2009, CARBON, V47, P145, DOI 10.1016/j.carbon.2008.09.045
   Yeh CN, 2015, NAT CHEM, V7, P166, DOI [10.1038/NCHEM.2145, 10.1038/nchem.2145]
   Yuan X, 2007, J COLLOID INTERF SCI, V310, P83, DOI 10.1016/j.jcis.2007.01.069
   Yunker PJ, 2011, NATURE, V476, P308, DOI 10.1038/nature10344
   Zhang JL, 2010, CHEM COMMUN, V46, P1112, DOI 10.1039/b917705a
   Zhang Y, 2015, ENVIRON SCI TECHNOL, V49, P10235, DOI 10.1021/acs.est.5b02086
   Zhao CQ, 2013, J ENVIRON CHEM ENG, V1, P349, DOI 10.1016/j.jece.2013.05.014
   Zhou S., 2013, SCI REP, V3
   Zhu YW, 2010, ADV MATER, V22, P3906, DOI 10.1002/adma.201001068
   [Anonymous], 1990, WATER ENCY
   [Anonymous], 2010, CRC HDB CHEM PHYS
NR 56
TC 5
Z9 5
U1 23
U2 65
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0008-6223
EI 1873-3891
J9 CARBON
JI Carbon
PD MAY
PY 2017
VL 116
BP 145
EP 153
DI 10.1016/j.carbon.2017.01.086
PG 9
WC Chemistry, Physical; Materials Science, Multidisciplinary
SC Chemistry; Materials Science
GA EP7HQ
UT WOS:000397549300019
DA 2018-03-19
ER

PT J
AU Song, Y
   Ambati, J
   Parkin, S
   Rankin, SE
   Robertson, LW
   Lehmler, HJ
AF Song, Yang
   Ambati, Jyothirmai
   Parkin, Sean
   Rankin, Stephen E.
   Robertson, Larry W.
   Lehmler, Hans-Joachim
TI Crystal structure and density functional theory studies of toxic quinone
   metabolites of polychlorinated biphenyls
SO CHEMOSPHERE
LA English
DT Article
DE Quinone; Metabolite; Solid state structure; Dihedral angle; Ground state
   energies
ID TOPOISOMERASE-II-ALPHA; PCB METABOLITES; 3-DIMENSIONAL STRUCTURE;
   INTERNAL-ROTATION; DIPHENYL ETHERS; GASEOUS STATE; FREE-RADICALS;
   DERIVATIVES; 4-CHLOROBIPHENYL; CHLOROBIPHENYLS
AB Lower chlorinated polychlorinated biphenyls (PCBs) are readily metabolized via hydroxylated metabolites to reactive PCB quinones. Although these PCB metabolites elicit biochemical changes by mechanisms involving cellular target molecules, such as the aryl hydrocarbon receptor, and toxicity by interacting with enzymes like topoisomerases, only few PCB quinones have been synthesized and their conformational properties investigated. Similar to the parent compounds, knowledge of the three-dimensional structure of PCB quinones may therefore be important to assess their fate and risk. To address this gap in our knowledge, the gas phase molecular structure of a series of PCB quinones was predicted using HF/3-21G, B3LYP/6-31G** and UB3LYP/6-311G** calculations and compared to the respective solid state structure. All three methods overestimated the Cl-C bond length, but otherwise provided a reasonable approximation of the solid state bond angles and bond lengths. Overall, the UB3LYP/6-311G** level of theory yielded the best approximation of the molecular structure of PCB quinones in the solid state. Chlorine addition at the ortho position of both rings was found to increase the dihedral angle of the resulting quinone compound, which may have important implications for their interaction with cellular targets and, thus, their toxicity. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Song, Yang; Robertson, Larry W.; Lehmler, Hans-Joachim] Univ Iowa, Dept Occupat & Environm Hlth, Iowa City, IA 52242 USA.
   [Song, Yang] Southwest Univ, Coll Pharmaceut Sci, Minist Educ, Key Lab Luminescence & Real Time Anal, Chongqing 400716, Peoples R China.
   [Ambati, Jyothirmai; Rankin, Stephen E.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Parkin, Sean] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
   [Robertson, Larry W.; Lehmler, Hans-Joachim] Univ Iowa, Interdisciplinary Grad Program Human Toxicol, Iowa City, IA 52242 USA.
RP Lehmler, HJ (reprint author), Univ Iowa, Dept Occupat & Environm Hlth, Univ Iowa Res Campus,221 IREH, Iowa City, IA 52242 USA.
EM hans-joachim-lehmler@uiowa.edu
RI Rankin, Stephen/A-3265-2013
OI Rankin, Stephen/0000-0002-8615-7564; Lehmler,
   Hans-Joachim/0000-0001-9163-927X; Ambati, Jyothirmai/0000-0003-2420-3665
FU National Institute of Environmental Health Sciences [ES05605, ES013661,
   ES017425]; MRI from National Science Foundation [0319176]
FX We acknowledge the High Performance Computing Center at University of
   Kentucky for use of their facility for the Gaussian calculations. This
   research was supported by grants ES05605, ES013661 and ES017425 from the
   National Institute of Environmental Health Sciences (HJL and LWR) and
   MRI grant #0319176 (SP) from the National Science Foundation. The
   content is solely the responsibility of the authors and does not
   necessarily represent the official views of the National Institute of
   Environmental Health Sciences, National Institutes of Health, or the
   National Science Foundation.
CR Allen F. H., 1992, INT TABLES CRYSTALLO, VC, P685
   ALMENNINGEN A, 1985, J MOL STRUCT, V128, P95, DOI 10.1016/0022-2860(85)85043-2
   ALMENNINGEN A, 1985, J MOL STRUCT, V128, P59, DOI 10.1016/0022-2860(85)85041-9
   Amaro AR, 1996, CHEM RES TOXICOL, V9, P623, DOI 10.1021/tx950117e
   Arif JM, 2003, CHEM-BIOL INTERACT, V142, P307, DOI 10.1016/S0009-2797(02)00141-2
   Arulmozhiraja S, 2002, J PHYS CHEM A, V106, P10590, DOI [10.1021/jp021014p, 10.1021/ip021014p]
   Bender RP, 2007, BIOCHEMISTRY-US, V46, P2856, DOI 10.1021/bi062017l
   Bender RP, 2006, BIOCHEMISTRY-US, V45, P10140, DOI 10.1021/bi0524666
   *BRUK NON AXS, 2004, APEX2 PROGR DAT COLL
   Espandiari P, 2004, TOXICOL SCI, V79, P41, DOI 10.1093/toxsci/kfh097
   Frisch M.J., 2004, GAUSSIAN 03
   Hansen L. G., 1999, ORTHO SIDE PCBS OCCU
   Hornbuckle KC, 2006, HANDB ENVIRON CHEM, V5, P13, DOI 10.1007/698_5_039
   Hu DF, 2010, ENVIRON SCI TECHNOL, V44, P2822, DOI 10.1021/es902413k
   Hu JW, 2005, CHEMOSPHERE, V59, P1033, DOI 10.1016/j.chemosphere.2004.11.028
   James Margaret O., 2001, P35
   Kostyniak PJ, 2005, TOXICOL SCI, V88, P400, DOI 10.1093/toxsci/kfi338
   Lehmer HJ, 2002, CHEMOSPHERE, V46, P485, DOI 10.1016/S0045-6535(01)00177-1
   Lehmler HJ, 2002, ACTA CRYSTALLOGR E, V58, pO366, DOI 10.1107/S160053680200291X
   Letcher RJ, 2000, HANDB ENVIRON CHEM, V3, P315
   Machala M, 2004, CHEM RES TOXICOL, V17, P340, DOI 10.1021/tx030034v
   McLean MR, 1996, CHEM RES TOXICOL, V9, P158, DOI 10.1021/tx950083a
   McLean MR, 2000, ARCH BIOCHEM BIOPHYS, V376, P449, DOI 10.1006/abbi.2000.1754
   Pan DH, 2000, CHEM PHYS LETT, V316, P395, DOI 10.1016/S0009-2614(99)01359-7
   Pan DH, 2000, CHEM PHYS LETT, V318, P214, DOI 10.1016/S0009-2614(00)00025-7
   Robertson LW, 2001, RECENT ADV ENV TOXIC
   SCHOMAKER V, 1968, ACTA CRYSTALL B-STRU, VB 24, P63, DOI 10.1107/S0567740868001718
   Shaikh NS, 2008, CHEMOSPHERE, V70, P1694, DOI 10.1016/j.chemosphere.2007.07.017
   Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930
   Song Y, 2008, CHEM RES TOXICOL, V21, P1359, DOI 10.1021/tx8000175
   Song Y, 2009, P NATL ACAD SCI USA, V106, P9725, DOI 10.1073/pnas.0810352106
   Song Y, 2008, J ORG CHEM, V73, P8296, DOI 10.1021/jo801397g
   Srinivasan A, 2002, CHEM RES TOXICOL, V15, P497, DOI 10.1021/tx010128+
   Thompson M., ARGUSLAB 4 0 1
   Tuppurainen K, 2003, CHEMOSPHERE, V50, P603, DOI 10.1016/S0045-6535(02)00618-5
   Venkatesha VA, 2008, FREE RADICAL BIO MED, V45, P1094, DOI 10.1016/j.freeradbiomed.2008.07.007
   Vyas SM, 2006, ACTA CRYSTALLOGR E, V62, pO2905, DOI 10.1107/S1600536806022240
   Wangpradit O, 2010, CHEMOSPHERE, V81, P1501, DOI 10.1016/j.chemosphere.2010.08.041
   Zhao YY, 2008, CHEMOSPHERE, V70, P901, DOI 10.1016/j.chemosphere.2007.06.080
NR 39
TC 2
Z9 2
U1 0
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0045-6535
J9 CHEMOSPHERE
JI Chemosphere
PD OCT
PY 2011
VL 85
IS 3
BP 386
EP 392
DI 10.1016/j.chemosphere.2011.07.004
PG 7
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA 856RU
UT WOS:000297661900014
PM 21824639
OA green_accepted
DA 2018-03-20
ER

PT J
AU Scott, D
   Chen, JM
   Bae, Y
   Rohr, J
AF Scott, Daniel F.
   Chen, Jhong-Min
   Bae, Younsoo
   Rohr, Juergen
TI Semi-Synthetic Mithramycin SA Derivatives with Improved AntiCancer
   Activity
SO CHEMICAL BIOLOGY & DRUG DESIGN
LA English
DT Article
DE anticancer; aureolic acid; mithramycin; mithramycin SA; semi-synthesis
ID PRODUCER STREPTOMYCES-ARGILLACEUS; TRANSCRIPTION FACTOR;
   PANCREATIC-CANCER; NATURAL-PRODUCTS; PAGETS DISEASE; FACTOR FAMILY; MDR1
   GENE; DRUG; DNA; THERAPY
AB Mithramycin (MTM) is a potent anti-cancer agent that has recently garnered renewed attention. This manuscript describes the design and development of mithramycin derivatives through a combinational approach of biosynthetic analogue generation followed by synthetic manipulation for further derivatization. Mithramycin SA is a previously discovered analogue produced by the M7W1 mutant strain alongside the improved mithramycin analogues mithramycin SK and mithramycin SDK. Mithramycin SA shows decreased anti-cancer activity compared to mithramycin and has a shorter, two carbon aglycon side chain that is terminated in a carboxylic acid. The aglycon side chain is responsible for an interaction with the DNA-phosphate backbone as mithramycin interacts with its target DNA. It was therefore decided to further functionalize this side chain through reactions with the terminal carboxylic acid in an effort to enhance the interaction with the DNA phosphate backbone and improve the anti-cancer activity. This side chain was modified with a variety of molecules increasing the anti-cancer activity to a comparable level to mithramycin SK. This work shows the ability to transform the previously useless mithramycin SA into a valuable molecule and opens the door to further functionalization and semi-synthetic modification for the development of molecules with increased specificity and/or drug formulation.
C1 [Scott, Daniel; Chen, Jhong-Min; Bae, Younsoo; Rohr, Juergen] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
RP Rohr, J (reprint author), Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, 789 South Limestone St, Lexington, KY 40536 USA.
EM jrohr2@email.uky.edu
RI Rohr, Jurgen/G-5375-2014
OI Rohr, Jurgen/0000-0001-6447-5951; Chen, Jhong-Min/0000-0002-3900-168X
FU National Institutes of Health [CA 091901]; Kentucky Lung Cancer Research
   Program; NCI-CNTC postdoctoral traineeship; National Cancer Institute
   [5R25CA153954]
FX This research was supported in part by the National Institutes of Health
   (grant CA 091901 to JR) and the Kentucky Lung Cancer Research Program
   (to YB). DS acknowledges the financial support from a NCI-CNTC
   postdoctoral traineeship and the project described was supported by
   Grant Number 5R25CA153954 from the National Cancer Institute. The
   content is solely the responsibility of the authors and does not
   necessarily represent the official views of the National Cancer
   Institute or the National Institutes of Health.
CR Abdelrahim M, 2004, CANCER RES, V64, P6740, DOI 10.1158/0008-5472.CAN-04-0713
   Albertini V, 2006, NUCLEIC ACIDS RES, V34, P1721, DOI 10.1093/nar/gkl063
   Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111
   BLUME SW, 1991, J CLIN INVEST, V88, P1613, DOI 10.1172/JCI115474
   BROWN JH, 1965, NEW ENGL J MED, V272, P111, DOI 10.1056/NEJM196501212720301
   Cragg GM, 1997, J NAT PROD, V60, P52, DOI 10.1021/np9604893
   Gao Y, 2011, CANCER RES, V71, P5182, DOI 10.1158/0008-5472.CAN-10-2016
   Gibson M, 2005, J AM CHEM SOC, V127, P17594, DOI 10.1021/ja055750t
   Grohar PJ, 2011, JNCI-J NATL CANCER I, V103, P962, DOI 10.1093/jnci/djr156
   Jin HJ, 2011, J BIOL CHEM, V286, P19840, DOI 10.1074/jbc.M110.203687
   KENNEDY BJ, 1970, AM J MED, V49, P494, DOI 10.1016/S0002-9343(70)80044-4
   KOLLER CA, 1986, NEW ENGL J MED, V315, P1433, DOI 10.1056/NEJM198612043152301
   Koo AN, 2008, CHEM COMMUN, P6570, DOI 10.1039/b815918a
   Li YT, 2006, MACROMOLECULES, V39, P2726, DOI 10.1021/ma0604035
   Mann CM, 1998, J APPL MICROBIOL, V84, P538, DOI 10.1046/j.1365-2672.1998.00379.x
   MILLER DM, 1987, AM J MED SCI, V294, P388, DOI 10.1097/00000441-198711000-00015
   Newman DJ, 2012, J NAT PROD, V75, P311, DOI 10.1021/np200906s
   Newman DJ, 2003, J NAT PROD, V66, P1022, DOI 10.1021/np030096l
   Remsing LL, 2003, BIOCHEMISTRY-US, V42, P8313, DOI 10.1021/bi034091z
   Remsing LL, 2003, J AM CHEM SOC, V125, P5745, DOI 10.1021/ja034162j
   RYAN WG, 1970, NEW ENGL J MED, V283, P1171
   RYAN WG, 1970, J AMER MED ASSOC, V213, P1153, DOI 10.1001/jama.213.7.1153
   Safe S, 2005, EUR J CANCER, V41, P2438, DOI 10.1016/j.ejca.2005.08.006
   SASTRY M, 1995, J MOL BIOL, V251, P674, DOI 10.1006/jmbi.1995.0464
   SASTRY M, 1993, BIOCHEMISTRY-US, V32, P6588, DOI 10.1021/bi00077a012
   Scott D, 2011, INT J NANOMED, V6, P2757, DOI 10.2147/IJN.S25427
   Seznec J, 2011, J NEURO-ONCOL, V101, P365, DOI 10.1007/s11060-010-0266-x
   Sleiman SF, 2011, J NEUROSCI, V31, P6858, DOI 10.1523/JNEUROSCI.0710-11.2011
   Tagashira M, 2000, CHEM PHARM BULL, V48, P575
   Tagashira M, 2000, BIOL PHARM BULL, V23, P926
   Tevyashova AN, 2011, BIOORGAN MED CHEM, V19, P7387, DOI 10.1016/j.bmc.2011.10.055
   Tevyashova AN, 2009, BIOORGAN MED CHEM, V17, P4961, DOI 10.1016/j.bmc.2009.05.076
   Tevyashova AN, 2009, J ANTIBIOT, V62, P117, DOI 10.1038/ja.2009.3
NR 33
TC 7
Z9 7
U1 0
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1747-0277
J9 CHEM BIOL DRUG DES
JI Chem. Biol. Drug Des.
PD MAY
PY 2013
VL 81
IS 5
BP 615
EP 624
DI 10.1111/cbdd.12107
PG 10
WC Biochemistry & Molecular Biology; Chemistry, Medicinal
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 133WW
UT WOS:000318172600008
PM 23331575
OA green_accepted
DA 2018-03-19
ER

PT J
AU Linck, N
   Peek, A
   Hinds, BJ
AF Linck, Nicholas
   Peek, Alex
   Hinds, Bruce J.
TI Monolayer Growth Front of Precious Metals through Insulating Mesoporous
   Membranes
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE energy; monolayer; mesoporous; electrocatalysis; membrane
ID PEM WATER ELECTROLYSIS; UNDERPOTENTIAL DEPOSITION; ELECTROCHEMICAL
   DEPOSITION; EVOLUTION REACTION; OXYGEN REDUCTION; SULFURIC-ACID;
   PLATINUM; PERFORMANCE; AU(111); CARBON
AB Monolayers of precious metals are deposited within the pores of insulating. mesoporous anodized aluminum oxide (AAO) membranes via a new electrochemical underpotential Cu deposition growth front mechanism, followed by spontaneous galvanic replacement of copper by platinum or iridium as demonstrated by XPS, ICP-OES, conductivity, and current analysis. Applications include fuel cells, hydrogen storage, flow batteries, and electrocatalytic conversions.
C1 [Linck, Nicholas] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Peek, Alex; Hinds, Bruce J.] Univ Washington, Dept Mat Sci & Engn, Seattle, WA 98105 USA.
RP Hinds, BJ (reprint author), Univ Washington, Dept Mat Sci & Engn, Seattle, WA 98105 USA.
EM bjhinds@uw.edu
FU DOE EPSCoR [DE-FG02-07ER46375]; NSF CBET [1460922]
FX Funding support by DOE EPSCoR (DE-FG02-07ER46375) and NSF CBET (1460922)
CR Arico AS, 2001, FUEL CELLS, V1, P133
   BORGES GL, 1994, J ELECTROANAL CHEM, V364, P281, DOI 10.1016/0022-0728(93)03169-P
   Brankovic SR, 2001, SURF SCI, V474, pL173, DOI 10.1016/S0039-6028(00)01103-1
   BRUMLIK CJ, 1994, J MATER RES, V9, P1174, DOI 10.1557/JMR.1994.1174
   Carmo M, 2013, INT J HYDROGEN ENERG, V38, P4901, DOI 10.1016/j.ijhydene.2013.01.151
   FAGERSON IS, 1969, J AGR FOOD CHEM, V17, P747, DOI 10.1021/jf60164a019
   GASTEIGER HA, 1995, J PHYS CHEM-US, V99, P8290, DOI 10.1021/j100020a063
   Gollas B, 2000, ELECTROCHIM ACTA, V45, P3711, DOI 10.1016/S0013-4686(00)00464-3
   GREEN MP, 1992, J VAC SCI TECHNOL A, V10, P3012, DOI 10.1116/1.577858
   Grigoriev SA, 2008, J POWER SOURCES, V177, P281, DOI 10.1016/j.jpowsour.2007.11.072
   Grigoriev SA, 2006, INT J HYDROGEN ENERG, V31, P171, DOI 10.1016/j.ijhydene.2005.04.038
   Herrero E, 1997, LANGMUIR, V13, P4446, DOI 10.1021/la970109t
   Hou LX, 2012, J POWER SOURCES, V216, P28, DOI 10.1016/j.jpowsour.2012.05.064
   Joo SH, 2009, ELECTROCHIM ACTA, V54, P5746, DOI 10.1016/j.electacta.2009.05.022
   Liu HS, 2006, J POWER SOURCES, V155, P95, DOI 10.1016/j.jpowsour.2006.01.030
   Maity P, 2007, ADV SYNTH CATAL, V349, P1955, DOI 10.1002/adsc.200700034
   Mededovic S, 2006, APPL CATAL B-ENVIRON, V67, P149, DOI 10.1016/j.apcatb.2006.05.001
   Mentus S, 2004, J NEW MAT ELECTR SYS, V7, P213
   Millet P, 2011, INT J HYDROGEN ENERG, V36, P4134, DOI 10.1016/j.ijhydene.2010.06.105
   Podlovchenko BI, 2011, J ELECTROANAL CHEM, V651, P30, DOI 10.1016/j.jelechem.2010.11.007
   Qu DY, 2011, J ELECTROANAL CHEM, V662, P80, DOI 10.1016/j.jelechem.2011.03.020
   Schlapbach L, 2001, NATURE, V414, P353, DOI 10.1038/35104634
   SOMORJAI GA, 1975, NATURE, V258, P580, DOI 10.1038/258580a0
   Song SD, 2008, INT J HYDROGEN ENERG, V33, P4955, DOI 10.1016/j.ijhydene.2008.06.039
   Su X, 2012, J MATER CHEM, V22, P7979, DOI 10.1039/c2jm15395e
   TONEY MF, 1995, PHYS REV LETT, V75, P4472, DOI 10.1103/PhysRevLett.75.4472
   Wang RY, 2010, ADV MATER, V22, P1845, DOI 10.1002/adma.200903548
   Yagi M, 2005, J ELECTROANAL CHEM, V579, P83, DOI 10.1016/j.jelechem.2005.01.030
   Yu YL, 2009, ELECTROCHIM ACTA, V54, P3092, DOI 10.1016/j.electacta.2008.12.004
   Zuttel A, 2004, NATURWISSENSCHAFTEN, V91, P157, DOI 10.1007/s00114-004-0516-x
NR 30
TC 0
Z9 0
U1 11
U2 11
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944-8244
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD SEP 13
PY 2017
VL 9
IS 36
BP 30964
EP 30968
DI 10.1021/acsami.7b03135
PG 5
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA FH3JR
UT WOS:000411043600081
PM 28783302
DA 2018-03-20
ER

PT J
AU Li, J
   Lumpp, JK
   Andrews, R
   Jacques, D
AF Li, Juchuan
   Lumpp, Janet K.
   Andrews, Rodney
   Jacques, David
TI Aspect Ratio and Loading Effects of Multiwall Carbon Nanotubes in Epoxy
   for Electrically Conductive Adhesives
SO JOURNAL OF ADHESION SCIENCE AND TECHNOLOGY
LA English
DT Article
DE Isotropic conductive adhesive; multiwall carbon nanotubes; MWCNTs;
   percolation threshold; epoxy
ID PERCOLATION; COMPOSITES; VOLUME
AB Isotropic conductive adhesives (ICAs) filled with metal particles are commercially available as alternatives to solder joining in electronic packaging. Replacing metal fillers with multiwall carbon nanotubes (MWCNTs) offers the potential benefits of being corrosion resistant, high strength and lightweight. Traditional metal filled ICAs require high metal loading to ensure electrical conductivity, which may cause problems with respect to reliability and strength to weight ratio. The ultra-high aspect ratio and surface area of multiwall carbon nanotubes induce a low percolation threshold of less than 0.25 wt% in epoxy. MWCNTs dispersed in epoxy increase the thermal diffusivity of the polymer by a factor of 2 to 3 and decrease the volume resitivity to less than 10 Omega cm for loadings up to 12 wt%. Lap shear strength decreases with increased MWCNT loading. The dependences of electrical, thermal and mechanical properties on loading and aspect ratio of MWCNTs are reported, and the electrical conduction mechanism is discussed. (c) Koninklijke Brill NV, Leiden, 2008
C1 [Li, Jing; Lumpp, Janet K.] Dept Elect & Comp Engn, Lexington, KY 40506 USA.
   [Andrews, Rodney; Jacques, David] Univ Kentucky, Ctr Appl Energy Res, Lexington, KY 40506 USA.
RP Lumpp, JK (reprint author), Dept Elect & Comp Engn, 453 F Paul Anderson Tower, Lexington, KY 40506 USA.
EM jklumpp@uky.edu
FU Kentucky NASA EPSCoR; Army Research Laboratory [W911NF-04-2-0023]
FX This research was sponsored by Kentucky NASA EPSCoR and the Army
   Research Laboratory under Cooperative Agreement Number W911NF-04-2-0023.
   The views and conclusions contained in this document are those of the
   authors and should not be interpreted as representing the official
   policies, either expressed or implied, of the Army Research Laboratory
   or the US Government. The US Government is authorized to reproduce and
   distribute reprints for Government purposes notwithstanding any
   copyright notation hereon.
CR Andrews R, 1999, CHEM PHYS LETT, V303, P467, DOI 10.1016/S0009-2614(99)00282-1
   BALBERG I, 1984, PHYS REV B, V30, P3933, DOI 10.1103/PhysRevB.30.3933
   Kaneto K, 1999, SYNTHETIC MET, V103, P2543, DOI 10.1016/S0379-6779(98)00221-5
   Lau J.H., 2003, ELECT MANUFACTURING
   Li J., 2006, P 2006 IEEE AER C BI
   Li J., 2006, P INT MICR PACK S, P100
   LI J, 2007, P 2007 IEEE AER C BI
   Li J., 2003, P 2003 IMAPS INT MIC, P35
   Meincke O, 2004, POLYMER, V45, P739, DOI 10.1016/j.polymer.2003.12.013
   RUSCHAU GR, 1992, J COMPOS MATER, V26, P2727, DOI 10.1177/002199839202601805
   Sandler JKW, 2003, POLYMER, V44, P5893, DOI 10.1016/S0032-3861(03)00539-1
   Shiraishi M, 2001, CARBON, V39, P1913, DOI 10.1016/S0008-6223(00)00322-5
   Weast R. C., 1984, HDB CHEM PHYS
NR 13
TC 6
Z9 7
U1 0
U2 14
PU BRILL ACADEMIC PUBLISHERS
PI LEIDEN
PA PLANTIJNSTRAAT 2, P O BOX 9000, 2300 PA LEIDEN, NETHERLANDS
SN 0169-4243
J9 J ADHES SCI TECHNOL
JI J. Adhes. Sci. Technol.
PY 2008
VL 22
IS 14
BP 1659
EP 1671
DI 10.1163/156856108X320528
PG 13
WC Engineering, Chemical; Materials Science, Multidisciplinary; Mechanics
SC Engineering; Materials Science; Mechanics
GA 360ZZ
UT WOS:000260098600003
DA 2018-03-20
ER

PT J
AU Hernandez, S
   Papp, JK
   Bhattacharyya, D
AF Hernandez, Sebastian
   Papp, Joseph K.
   Bhattacharyya, Dibakar
TI Iron-Based Redox Polymerization of Acrylic Acid for Direct Synthesis of
   Hydrogel/Membranes and Metal Nanoparticles for Water Treatment
SO INDUSTRIAL & ENGINEERING CHEMISTRY RESEARCH
LA English
DT Article
ID FE-PD NANOPARTICLES; ASCORBIC-ACID; SWELLING KINETICS; MEMBRANES;
   HYDROGELS; DEGRADATION; MECHANISM; PH; DECHLORINATION; CATALYSIS
AB Functionalized polymer materials with ion-exchange groups and the integration of nanostructured materials is an emerging area for catalytic and water pollution control applications. The polymerization of materials such as acrylic acid often requires persulfate initiator and a high-temperature start. However, is generally known that metal ions accelerate such polymerizations starting from room temperature. If the metal is properly selected, then it can be used in environmental applications, adding two advantages simultaneously. This article deals with this by polymerizing acrylic acid using iron as an accelerant and subsequently using it for nanoparticle synthesis in hydrogels and PVDF membranes. Characterizations of hydrogels, membranes, and nanoparticles were carried out with different techniques. Nanoparticles sizes of 30-60 nm were synthesized. Permeability and swelling measurements demonstrate an inverse relationship between the hydrogel mesh size (6.30 to 8.34 nm) and the membrane pore size (222 to 110 nm). The quantitative reduction of trichloroethylene/chloride generation by Fe/Pd nanoparticles in hydrogel/membrane platforms was also performed.
C1 [Hernandez, Sebastian; Papp, Joseph K.; Bhattacharyya, Dibakar] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Bhattacharyya, D (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM db@engr.uky.edu
RI Hernandez, Sebastian/I-7374-2017
OI Hernandez, Sebastian/0000-0002-7513-5511
FU National Institute of Environmental Health Sciences/National Institutes
   of Health Superfund (NIEHS-SRP) program; NSF-REU program
FX This study was supported by the National Institute of Environmental
   Health Sciences/National Institutes of Health Superfund (NIEHS-SRP)
   program. J.K.P. was also supported by the NSF-REU program. This group
   thanks the Electron Microscopy Center (University of Kentucky) and the
   Environmental Research and Training Laboratory (University of Kentucky).
CR Andrij Z. P., 2007, POLYM INT, V56, P291
   Braun D., 2005, POLYM SYNTHESIS THEO
   Bruening ML, 2008, LANGMUIR, V24, P7663, DOI 10.1021/la800179z
   Carotenuto G, 2003, J MATER CHEM, V13, P2927, DOI 10.1039/b310898h
   Carotenuto G, 2001, EUR PHYS J B, V24, P437, DOI 10.1007/s10051-001-8696-z
   Chen J, 1998, SCIENCE, V282, P95, DOI 10.1126/science.282.5386.95
   Cohen-Ofri I, 2006, J ARCHAEOL SCI, V33, P428, DOI 10.1016/j.jas.2005.08.008
   Cutie SS, 1997, J POLYM SCI POL PHYS, V35, P2029, DOI 10.1002/(SICI)1099-0488(19970930)35:13<2029::AID-POLB4>3.3.CO;2-K
   Ebert M, 2006, ENVIRON SCI TECHNOL, V40, P2004, DOI 10.1021/es051720e
   FORDHAM JWL, 1951, J AM CHEM SOC, V73, P4855, DOI 10.1021/ja01154a114
   Fumio U., 1990, INT J PHARMACEUT, V58, P135
   GIBBS MM, 1979, WATER RES, V13, P295, DOI 10.1016/0043-1354(79)90209-4
   GLAVEE GN, 1995, INORG CHEM, V34, P28, DOI 10.1021/ic00105a009
   Gui M, 2013, IND ENG CHEM RES, V52, P10430, DOI 10.1021/ie400507c
   He F, 2007, IND ENG CHEM RES, V46, P29, DOI 10.1021/ie0610896
   He F, 2008, APPL CATAL B-ENVIRON, V84, P533, DOI 10.1016/j.apcatb.2008.05.008
   Hsieh YHP, 1997, J AGR FOOD CHEM, V45, P1126, DOI 10.1021/jf960684n
   Hu K, 2007, J MEMBRANE SCI, V301, P19, DOI 10.1016/j.memsci.2007.05.031
   KABANOV VA, 1975, EUR POLYM J, V11, P153, DOI 10.1016/0014-3057(75)90140-8
   Katime I, 1996, POLYM INT, V40, P281
   KHAN MMT, 1967, J AM CHEM SOC, V89, P4176, DOI 10.1021/ja00992a036
   Kricheldorf H., 2004, HDB POLYM SYNTHESIS
   Lewis S. R., 2012, RESPONSIVE MEMBRANES, P97, DOI 10.1002/9781118389553.ch5.
   Li W, 2002, REACT FUNCT POLYM, V52, P31, DOI 10.1016/S1381-5148(02)00055-X
   Liang CJ, 2004, CHEMOSPHERE, V55, P1225, DOI 10.1016/j.chemosphere.2004.01.030
   MANICKAM SP, 1979, EUR POLYM J, V15, P483, DOI 10.1016/0014-3057(79)90063-6
   Meng ZH, 2011, J MEMBRANE SCI, V372, P165, DOI 10.1016/j.memsci.2011.01.064
   Misra G. S, 1982, PROG POLYM SCI, V8, P61
   Nagaraja GK, 2011, J APPL POLYM SCI, V121, P1299, DOI 10.1002/app.33365
   Odian G., 2004, PRINCIPLES POLYM
   Pa Achia S., 2007, REV ROUM CHIM, V52, P1145
   Peak CW, 2013, COLLOID POLYM SCI, V291, P2031, DOI 10.1007/s00396-013-3021-y
   Peppas NA, 1996, MACROMOLECULES, V29, P8798, DOI 10.1021/ma9613392
   Quintana JR, 1999, LANGMUIR, V15, P4728, DOI 10.1021/la980982+
   Sahiner N, 2012, J COLLOID INTERF SCI, V373, P122, DOI 10.1016/j.jcis.2011.08.080
   Sarac AS, 1999, PROG POLYM SCI, V24, P1149, DOI 10.1016/S0079-6700(99)00026-X
   Schexnailder P, 2009, COLLOID POLYM SCI, V287, P1, DOI 10.1007/s00396-008-1949-0
   Smuleac V, 2011, J MEMBRANE SCI, V379, P131, DOI 10.1016/j.memsci.2011.05.054
   Smuleac V, 2010, J MEMBRANE SCI, V346, P310, DOI 10.1016/j.memsci.2009.09.052
   STOOKEY LL, 1970, ANAL CHEM, V42, P779, DOI 10.1021/ac60289a016
   Sudipta S E, 2012, J NANOPART RES, V14, P715
   Sun XL, 1998, ACTA BIOCH BIOPH SIN, V30, P407
   Sun YP, 2006, ADV COLLOID INTERFAC, V120, P47, DOI 10.1016/j.cis.2006.03.001
   Thakur A, 2011, CHEM BIOCHEM ENG Q, V25, P181
   Thomas V, 2008, J MACROMOL SCI A, V45, P107, DOI 10.1080/10601320701683470
   Ulbricht M, 2006, POLYMER, V47, P2217, DOI 10.1016/j.polymer.2006.01.084
   Wu W, 2008, NANOSCALE RES LETT, V3, P397, DOI 10.1007/s11671-008-9174-9
   Xu J, 2005, J NANOPART RES, V7, P449, DOI 10.1007/s11051-005-4273-3
   Xu J, 2007, IND ENG CHEM RES, V46, P2348, DOI 10.1021/ie0611498
   Yan L., 2007, MACROMOLECULAR CHEM, V208, P254
   Yuvakkumar R, 2011, DIG J NANOMATER BIOS, V6, P1771
   Zhang JG, 2004, J AM CHEM SOC, V126, P7908, DOI 10.1021/ja031523k
   Zheng YA, 2013, IND ENG CHEM RES, V52, P4957, DOI 10.1021/ie302562f
NR 53
TC 11
Z9 12
U1 5
U2 71
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0888-5885
J9 IND ENG CHEM RES
JI Ind. Eng. Chem. Res.
PD JAN 22
PY 2014
VL 53
IS 3
BP 1130
EP 1142
DI 10.1021/ie403353g
PG 13
WC Engineering, Chemical
SC Engineering
GA 296RN
UT WOS:000330203200012
PM 24954975
OA green_accepted
DA 2018-03-19
ER

PT J
AU Wu, J
   Paudel, KS
   Strasinger, C
   Hammell, D
   Stinchcomb, AL
   Hinds, BJ
AF Wu, Ji
   Paudel, Kalpana S.
   Strasinger, Caroline
   Hammell, Dana
   Stinchcomb, Audra L.
   Hinds, Bruce J.
TI Programmable transdermal drug delivery of nicotine using carbon nanotube
   membranes
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE electroosmosis; electrophoresis; smoking cessation; medical device
ID HAIRLESS GUINEA-PIGS; ELECTROOSMOTIC FLOW; MASS-TRANSPORT; SKIN; MODEL;
   PHARMACOKINETICS; IONTOPHORESIS; NALTREXONE; ELECTRODE; PRODRUGS
AB Carbon nanotube (CNT) membranes were employed as the active element of a switchable transdermal drug delivery device that can facilitate more effective treatments of drug abuse and addiction. Due to the dramatically fast flow through CNT cores, high charge density, and small pore dimensions, highly efficient electrophoretic pumping through functionalized CNT membrane was achieved. These membranes were integrated with a nicotine formulation to obtain switchable transdermal nicotine delivery rates on human skin (in vitro) and are consistent with a Fickian diffusion in series model. The transdermal nicotine delivery device was able to successfully switch between high (1.3 +/- 0.65 mu mol/hr-cm(2)) and low (0.33 +/- 0.22 mu mol/hr-cm(2)) fluxes that coincide with therapeutic demand levels for nicotine cessation treatment. These highly energy efficient programmable devices with minimal skin irritation and no skin barrier disruption would open an avenue for single application long-wear patches for therapies that require variable or programmable delivery rates.
C1 [Paudel, Kalpana S.; Strasinger, Caroline; Hammell, Dana; Stinchcomb, Audra L.] Univ Kentucky, Coll Pharm, Lexington, KY 40536 USA.
   [Wu, Ji; Hinds, Bruce J.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Stinchcomb, AL (reprint author), Univ Kentucky, Coll Pharm, Lexington, KY 40536 USA.
EM audra.stinchcomb@uky.edu; bjhinds@engr.uky.edu
RI WU, JI/F-6379-2013; WU, JI/J-4580-2016; WU, JI/F-6371-2013
FU Center for Nanoscale Science and Engineering and Electron Microscopy
   Center at the University of Kentucky; National Institutes of Health
   (NIH) NIDA [R01DA018822]; National Science Foundation [0348544]
FX We thank Karen Gerstandt and Xin Su for helpful discussions. Rodney
   Andrews and Dalli Qian from the Center for Applied Energy, University of
   Kentucky supplied MWCNTs. Facility support was provided by the Center
   for Nanoscale Science and Engineering and Electron Microscopy Center at
   the University of Kentucky. Financial support from the National
   Institutes of Health (NIH) NIDA (R01DA018822) and National Science
   Foundation (0348544) is greatly appreciated by the authors. Human skin
   was obtained through the NIH-sponsored Cooperative Human Tissue Network.
CR Abrams LS, 2002, BRIT J CLIN PHARMACO, V53, P141, DOI 10.1046/j.0306-5251.2001.01532.x
   Bahr JL, 2001, J AM CHEM SOC, V123, P6536, DOI 10.1021/ja010462s
   Baumgartner S, 2002, AAPS PHARMSCITECH, V3, P86, DOI DOI 10.1208/PT030436
   BRAND RM, 1995, J CONTROL RELEASE, V33, P285, DOI 10.1016/0168-3659(94)00093-A
   Chen YF, 2008, NANO LETT, V8, P42, DOI 10.1021/nl0718566
   D'Amours M, 2003, J PHYS CHEM B, V107, P4811, DOI 10.1021/jp027223r
   FEYERABEND C, 1985, BRIT J CLIN PHARMACO, V19, P239, DOI 10.1111/j.1365-2125.1985.tb02637.x
   *FOOD DRUG ADM, 2007, APPR DRUG PROD THER
   Hinds BJ, 2004, SCIENCE, V303, P62, DOI 10.1126/science.1092048
   HO H, 1993, DRUG DEV IND PHARM, V19, P295, DOI 10.3109/03639049309038769
   Holt JK, 2006, SCIENCE, V312, P1034, DOI 10.1126/science.1126298
   Katz E, 2003, ELECTROANAL, V15, P913, DOI 10.1002/elan.200390114
   Kim S, 2007, NANO LETT, V7, P2806, DOI 10.1021/nl071414u
   Majumder M, 2005, NATURE, V438, P44, DOI 10.1038/43844a
   Majumder M, 2008, J MEMBRANE SCI, V316, P89, DOI 10.1016/j.memsci.2007.09.068
   Majumder M, 2007, LANGMUIR, V23, P8624, DOI 10.1021/la700686k
   Malin DH, 2001, PHARMACOL BIOCHEM BE, V70, P551, DOI 10.1016/S0091-3057(01)00699-2
   Manchikanti Laxmaiah, 2007, Pain Physician, V10, P399
   Miller SA, 2001, J AM CHEM SOC, V123, P12335, DOI 10.1021/ja011926p
   Prausnitz MR, 2008, NAT BIOTECHNOL, V26, P1261, DOI 10.1038/nbt.1504
   Prausnitz MR, 1996, ADV DRUG DELIVER REV, V18, P395, DOI 10.1016/0169-409X(95)00081-H
   Prausnitz MR, 2004, NAT REV DRUG DISCOV, V3, P115, DOI 10.1038/nrd1304
   SRINIVASAN V, 1990, INT J PHARM, V60, P133, DOI 10.1016/0378-5173(90)90298-I
   Stone HA, 2004, ANNU REV FLUID MECH, V36, P381, DOI 10.1146/annurev.fluid.36.050802.122124
   Sun L, 2000, J AM CHEM SOC, V122, P12340, DOI 10.1021/ja002429w
   TENJARLA SN, 1994, DRUG DEV IND PHARM, V20, P49, DOI 10.3109/03639049409047213
   Valiveti S, 2005, PHARM RES, V22, P981, DOI 10.1007/s11095-005-4593-0
   Valiveti S, 2005, J CONTROL RELEASE, V102, P509, DOI 10.1016/j.jconrel.2004.10.005
   Wermeling DP, 2008, P NATL ACAD SCI USA, V105, P2058, DOI 10.1073/pnas.0710355105
   Wills S., 2005, DRUGS ABUSE
NR 30
TC 72
Z9 72
U1 2
U2 45
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUN 29
PY 2010
VL 107
IS 26
BP 11698
EP 11702
DI 10.1073/pnas.1004714107
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 618DT
UT WOS:000279332300011
PM 20547880
OA gold
DA 2018-03-20
ER

PT J
AU Meenach, SA
   Shapiro, JM
   Hilt, JZ
   Anderson, KW
AF Meenach, Samantha A.
   Shapiro, Jenna M.
   Hilt, J. Zach
   Anderson, Kimberly W.
TI Characterization of PEG-iron oxide hydrogel nanocomposites for dual
   hyperthermia and paclitaxel delivery
SO JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION
LA English
DT Article
DE poly(ethylene glycol) (PEG); hydrogel nanocomposites; hyperthermia;
   paclitaxel; iron oxide nanoparticles
ID ELECTROMAGNETIC HYPERTHERMIA; POLY(ETHYLENE GLYCOL); CONTROLLED-RELEASE;
   DRUG-RELEASE; TUMOR-GROWTH; IN-VITRO; CANCER; CHEMOTHERAPY;
   POLY(N-ISOPROPYLACRYLAMIDE); INHIBITION
AB Hyperthermia, the heating of tissue from 41 to 45 degrees C, has been shown to improve the efficacy of cancer therapy when used in conjunction with irradiation and/or chemotherapy. In this work, hydrogel nanocomposites have been developed that can control the delivery of both heat and a chemotherapeutic agent (e.g. paclitaxel). The nanocomposites studied involve a stealth, poly(ethylene glycol) (PEG)-based system comprised of PEG (n=1000) methyl ether methacrylate and PEG (n=400) dimethacrylate with iron oxide nanoparticles physically entrapped within the hydrogel matrices. The capability of the hydrogel nanocomposites to be heated in an alternating magnetic field was demonstrated. The heating of the hydrogel systems was dependent on the crosslinking of the hydrogel network where hydrogels with lower swelling ratios were found to heat to a greater extent than those with higher ratios. In addition, paclitaxel was shown to exhibit non-Fickian release from the hydrogel systems, with the amount of drug released dependent on the hydrogel network structure. Three cell lines: M059K (glioblastoma), MDA MB 231 (breast carcinoma), and A549 (lung adenocarcinoma) were exposed to paclitaxel only, hyperthermia only, and both paclitaxel and hyperthermia to determine if a synergistic cytotoxic effect was possible for these cell lines. The efficacy of paclitaxel was greater with hyperthermia for the A549 cells; however, the M059K and MDA MB 231 did not show the same response.
C1 [Meenach, Samantha A.; Shapiro, Jenna M.; Hilt, J. Zach; Anderson, Kimberly W.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Meenach, Samantha A.] Univ Kentucky, Dept Pharmaceut, Coll Pharm, Drug Dev Div, Lexington, KY 40536 USA.
RP Anderson, KW (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 F Paul Anderson Tower, Lexington, KY 40506 USA.
EM kanderson@engr.uky.edu
RI Meenach, Samantha/F-7542-2014
FU Kentucky Science and Engineering Foundation [KSEF0148-502-06-188];
   Engineered Bioactive Interfaces & Devices NSF IGERT [DGE-0653710]; NSF
   IGERT REU [EEC-0851716]
FX Partial funding for this research was provided by the Kentucky Science
   and Engineering Foundation (Award Number KSEF0148-502-06-188). S.
   Meenach and J. Shapiro acknowledge the Engineered Bioactive Interfaces &
   Devices NSF IGERT (Award Number DGE-0653710) and NSF IGERT REU (Award
   Number EEC-0851716) for providing partial funding for this research,
   respectively.
CR *ACS, 2009, CANC FACTS FIG
   Babincova M, 2000, MED HYPOTHESES, V55, P459, DOI 10.1054/mehy.2000.1089
   Babincova M, 2001, J MAGN MAGN MATER, V225, P109, DOI 10.1016/S0304-8853(00)01237-3
   Babincova M, 2008, IEEE T NANOBIOSCI, V7, P15, DOI 10.1109/TNB.2008.2000145
   Bahadur D, 2003, SADHANA-ACAD P ENG S, V28, P639, DOI 10.1007/BF02706451
   DiRamio JA, 2005, BIOTECHNOL PROGR, V21, P1281, DOI 10.1021/bp0495670
   Falk MH, 2001, INT J HYPERTHER, V17, P1, DOI 10.1080/02656730150201552
   Frimpong R.A., 2006, J BIOMED MATER RES A, V80, P1
   Hawkins AM, 2009, PHARM RES-DORD, V26, P667, DOI 10.1007/s11095-008-9804-z
   Hergt R, 2006, J PHYS-CONDENS MAT, V18, pS2919, DOI 10.1088/0953-8984/18/38/S26
   HIGUCHI T, 1961, J PHARM SCI, V50, P874, DOI 10.1002/jps.2600501018
   Hildebrandt B, 2002, CRIT REV ONCOL HEMAT, V43, P33, DOI 10.1016/S1040-8428(01)00179-2
   Hilt JZ, 2004, BIOMEDICAL APPL TISS, P247
   Issels RD, 2008, EUR J CANCER, V44, P2546, DOI 10.1016/j.ejca.2008.07.038
   Ito A, 2007, CANCER SCI, V98, P424, DOI 10.1111/j.1349-7006.2006.00382.x
   Lin HH, 2001, MACROMOLECULES, V34, P3710, DOI 10.1021/ma001852m
   Meenach SA, 2009, ACTA BIOMATER, V6, P1039
   Meenach SA, 2010, J POLYM SCI POL CHEM, V48, P3229, DOI 10.1002/pola.24087
   Meenach SA, 2009, J BIOMED MATER RES A, V91A, P903, DOI 10.1002/jbm.a.32322
   Meenach Samantha A., 2009, P131, DOI 10.1007/978-0-387-78608-7_7
   Michalakis J, 2007, ANN SURG ONCOL, V14, P1220, DOI 10.1245/s10434-006-9305-4
   Nakao Keiichi, 2000, Medical Electron Microscopy, V33, P44, DOI 10.1007/s007950000007
   Obara K, 2005, J CONTROL RELEASE, V110, P79, DOI 10.1016/j.jconrel.2005.09.026
   Peppas NA, 2000, EUR J PHARM BIOPHARM, V50, P27, DOI 10.1016/S0939-6411(00)00090-4
   Peppas NA, 2006, ADV MATER, V18, P1345, DOI 10.1002/adma.200501612
   Satarkar NS, 2008, J CONTROL RELEASE, V130, P246, DOI 10.1016/j.jconrel.2008.06.008
   Satarkar NS, 2009, LAB CHIP, V9, P1773, DOI 10.1039/b822694f
   Shen HC, 2008, EUR J PHARMACOL, V601, P23, DOI 10.1016/j.ejphar.2008.10.035
   Wust P, 2002, LANCET ONCOL, V3, P487, DOI 10.1016/S1470-2045(02)00818-5
NR 29
TC 13
Z9 13
U1 3
U2 51
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0920-5063
EI 1568-5624
J9 J BIOMAT SCI-POLYM E
JI J. Biomater. Sci.-Polym. Ed.
PD JUN 1
PY 2013
VL 24
IS 9
BP 1112
EP 1126
DI 10.1080/09205063.2012.741321
PG 15
WC Engineering, Biomedical; Materials Science, Biomaterials; Polymer
   Science
SC Engineering; Materials Science; Polymer Science
GA 159YU
UT WOS:000320084000007
PM 23683041
DA 2018-03-19
ER

PT J
AU Wu, QL
   Rankin, SE
AF Wu, Qingliu
   Rankin, Stephen E.
TI Tuning the Mesopore Size of Titania Thin Films Using a Polymeric
   Swelling Agent
SO JOURNAL OF PHYSICAL CHEMISTRY C
LA English
DT Article
ID RESOLVED INFRARED-SPECTROSCOPY; PHASE-BEHAVIOR; MESOSTRUCTURED FILMS;
   POLYPROPYLENE GLYCOL; PHOTOVOLTAIC CELLS; AQUEOUS-SOLUTION; SILICA;
   SYSTEMS; WATER; TIO2
AB A method is reported to generate mesoporous titania thin films with large pores and large surface areas by adding poly(propylene glycol), PPG, to the coating sol of films prepared by templating with Pluronic surfactant P123. Because P123 has an average structure (PEO)(20)(PPO)(70)(PEO)(20) where PEO is a poly(ethylene oxide) unit and PPO is a poly(propylene oxide) unit, the hypothesis underlying this work is that PPG segregates to the PPO domains to induce swelling of the template micelles. With the introduction of PPG, the final calcined films are observed to have well-defined mesoporous structures, although the degree of long-range order diminishes with added PPG. The mesopore size of the films increases with increasing amounts of PPG, but PPG also introduces smaller mesopores into the films under our synthesis conditions to generate a bimodal pore size distribution. The size of these smaller pores remains nearly constant at similar to 2.4 nm over a large range of PPG:P123 mass ratios, even as the larger mesopore size continues to increase. To understand the effect of PPG on mesostructured titania, the behavior in aqueous solution of the PPG polymer used for swelling is investigated and modeled with Flory-Huggins theory to estimate the full two-phase envelope. The phase diagram reveals that PPG (M(n) approximate to 3500) and water have a lower consolute temperature of about -9 degrees C, so at the temperature used for aging of the films immediately after coating (4 degrees C), the composition is well within the two-phase region. Therefore, repulsion between PPG molecules and polar species is expected to drive PPG into the hydrophobic cores of P123 micelles, thus leading to final products with large pore size. However, because of partitioning of some PPG into the polar phase, a bimodal pore size distribution and decreasing long-range pore order are observed as the amount of PPG increases.
C1 [Wu, Qing Liu; Rankin, Stephen E.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Rankin, SE (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 FP Anderson Tower, Lexington, KY 40506 USA.
EM srankin@engr.uky.edu
RI wu, qingliu/C-7631-2012; Rankin, Stephen/A-3265-2013
OI Rankin, Stephen/0000-0002-8615-7564
FU U.S. Department of Energy [DE-FG02-07ER46375]
FX This work was supported by the U.S. Department of Energy under grant
   number DE-FG02-07ER46375.
CR Bannat I, 2009, CHEM MATER, V21, P1645, DOI 10.1021/cm803455k
   BAWENDI MG, 1987, J CHEM PHYS, V87, P5534, DOI 10.1063/1.453638
   BELFIORE LA, 1988, IND ENG CHEM RES, V27, P284, DOI 10.1021/ie00074a014
   Brinker CJ, 1999, ADV MATER, V11, P579, DOI 10.1002/(SICI)1521-4095(199905)11:7<579::AID-ADMA579>3.0.CO;2-R
   Choi SG, 2007, THIN SOLID FILMS, V516, P212, DOI 10.1016/j.tsf.2007.07.001
   Choi SY, 2004, ADV FUNCT MATER, V14, P335, DOI 10.1002/adfm.200305039
   Coakley KM, 2004, CHEM MATER, V16, P4533, DOI 10.1021/cm049654n
   Coakley KM, 2003, ADV FUNCT MATER, V13, P301, DOI 10.1002/adfm.200304361
   Coakley KM, 2003, APPL PHYS LETT, V83, P3380, DOI 10.1063/1.1616197
   Colin AC, 1999, PHYS CHEM CHEM PHYS, V1, P319
   Crepaldi EL, 2003, J AM CHEM SOC, V125, P9770, DOI 10.1021/ja030070g
   Cui XG, 2003, STUD SURF SCI CATAL, V146, P117
   Czuryszkiewicz T, 2003, CHEM MATER, V15, P3704, DOI 10.1021/cm021293t
   De Witte K, 2008, APPL CATAL B-ENVIRON, V84, P125, DOI 10.1016/j.apcatb.2008.03.015
   Dormidontova EE, 2002, MACROMOLECULES, V35, P987, DOI 10.1021/ma010804e
   Eckert S, 2002, PHYS CHEM CHEM PHYS, V4, P3743, DOI 10.1039/b203060h
   Fang H, 2006, J NON-CRYST SOLIDS, V352, P2279, DOI 10.1016/j.jnoncrysol.2006.02.057
   Feng PY, 2000, LANGMUIR, V16, P5304, DOI 10.1021/la991444f
   FIRMAN P, 1986, COLLOID POLYM SCI, V264, P936, DOI 10.1007/BF01410858
   Flory PJ, 1941, J CHEM PHYS, V9, P660, DOI 10.1063/1.1750971
   Guo W, 2005, COLLOID SURFACE A, V252, P71, DOI 10.1016/j.colsurfa.2004.10.013
   HAGFELDT A, 1995, CHEM REV, V95, P49, DOI 10.1021/cr00033a003
   Holmqvist P, 1998, J PHYS CHEM B, V102, P1149, DOI 10.1021/jp9730297
   HU Y, 1991, MACROMOLECULES, V24, P4356, DOI 10.1021/ma00015a017
   Huggins ML, 1942, ANN NY ACAD SCI, V43, P1, DOI DOI 10.1111/J.1749-6632.1942.TB47940.X
   Huo QS, 1996, CHEM MATER, V8, P1147, DOI 10.1021/cm960137h
   Imperor-Clerc M, 2000, J AM CHEM SOC, V122, P11925, DOI 10.1021/ja002245h
   Innocenzi P, 2006, J PHYS CHEM B, V110, P10837, DOI 10.1021/jp060097x
   Innocenzi P, 2008, J PHYS CHEM A, V112, P6512, DOI 10.1021/jp7111395
   Innocenzi P, 2007, J PHYS CHEM C, V111, P5345, DOI 10.1021/jp066566c
   Ismail AA, 2010, CHEMSUSCHEM, V3, P1057, DOI 10.1002/cssc.201000158
   Kim BS, 2000, BIOMATERIALS, V21, P259, DOI 10.1016/S0142-9612(99)00174-X
   Kirsch BL, 2004, J PHYS CHEM B, V108, P12698, DOI 10.1021/jp036442p
   Koganti VR, 2006, NANO LETT, V6, P2567, DOI 10.1021/nl061992v
   KONTOGEORGIS GM, 1995, IND ENG CHEM RES, V34, P1823, DOI 10.1021/ie00044a033
   Kruk M, 1997, LANGMUIR, V13, P6267, DOI 10.1021/la970776m
   Kruk M, 2001, CHEM MATER, V13, P3169, DOI 10.1021/cm0101069
   Lancelle-Beltran E, 2006, CHEM MATER, V18, P6152, DOI 10.1021/cm060925z
   LANCELLEBELTRAN E, 2006, ADV MAT WEINHEIM, V18, P2579
   Liu KS, 2005, J PHYS CHEM B, V109, P18719, DOI 10.1021/jp054546p
   Liu YC, 1998, MACROMOLECULES, V31, P2236, DOI 10.1021/ma971253o
   Lu YF, 1997, NATURE, V389, P364, DOI 10.1038/38699
   Malfatti L, 2009, CHEM MATER, V21, P2763, DOI 10.1021/cm900289c
   Mohite LV, 2009, FLUID PHASE EQUILIBR, V278, P41, DOI 10.1016/j.fluid.2009.01.003
   Mosquera MJ, 2003, LANGMUIR, V19, P951, DOI 10.1021/la0265981
   Oveisi H, 2010, THIN SOLID FILMS, V518, P6714, DOI [10.1016/jtsf2010.05.112, 10.1016/j.tsf.2010.05.112]
   QIAN CB, 1991, MACROMOLECULES, V24, P1655, DOI 10.1021/ma00007a031
   Saadoun L, 2000, MATER RES BULL, V35, P193, DOI 10.1016/S0025-5408(00)00204-X
   Sanchez C, 2008, CHEM MATER, V20, P682, DOI 10.1021/cm702100t
   Smarsly B, 2004, CHEM MATER, V16, P2948, DOI 10.1021/cm0495966
   Stengl V, 2010, NEW J CHEM, V34, P1999, DOI 10.1039/c0nj00167h
   Sujka M, 2010, STARCH-STARKE, V62, P229, DOI 10.1002/star.200900226
   THOMAS ER, 1984, IND ENG CHEM PROC DD, V23, P194, DOI 10.1021/i200025a002
   Uchida H, 2010, THIN SOLID FILMS, V518, P3169, DOI 10.1016/j.tsf.2009.08.050
   Wijnhoven JEGJ, 1998, SCIENCE, V281, P802, DOI 10.1126/science.281.5378.802
   Wu CW, 2006, J AM CHEM SOC, V128, P4544, DOI 10.1021/ja060453p
   Yang PD, 1999, CHEM MATER, V11, P2813, DOI 10.1021/cm990185c
   YU M, 1993, FLUID PHASE EQUILIBR, V83, P357, DOI 10.1016/0378-3812(93)87039-4
   Zafarani-Moattar MT, 2005, J CHEM ENG DATA, V50, P947, DOI 10.1021/je049570v
   Zhang Y, 2009, ACS APPL MATER INTER, V1, P2789, DOI 10.1021/am900529e
   Zhao TB, 2010, CATAL LETT, V136, P266, DOI 10.1007/s10562-009-0131-8
NR 61
TC 17
Z9 17
U1 0
U2 31
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1932-7447
J9 J PHYS CHEM C
JI J. Phys. Chem. C
PD JUN 23
PY 2011
VL 115
IS 24
BP 11925
EP 11933
DI 10.1021/jp2021193
PG 9
WC Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science,
   Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA 778MW
UT WOS:000291709600006
DA 2018-03-20
ER

PT J
AU Majumder, M
   Chopra, N
   Hinds, BJ
AF Majumder, Mainak
   Chopra, Nitin
   Hinds, Bruce J.
TI Mass Transport through Carbon Nanotube Membranes in Three Different
   Regimes: Ionic Diffusion and Gas and Liquid Flow
SO ACS NANO
LA English
DT Article
DE membrane; separations; biomimetic; nanofluidics
ID MOLECULAR-DYNAMICS SIMULATIONS; WATER; SEPARATION; NANOPORES; MIXTURES;
   SURFACES; CHANNEL; PORES; FILMS; SLIP
AB Transport phenomena through the hollow conduits of carbon nanotubes (CNTs) are subjects of intense theoretical and experimental research. We have studied molecular transport over the large spectrum of ionic diffusion to pressure-driven gaseous and liquid flow. Plasma oxidation during the fabrication of the membrane introduces carboxylic acid groups at the CNT entrance, which provides electrostatic "gatekeeper" effects on ionic transport. Diffusive transport of ions of different charge and size through the core of the CNT is close to bulk diffusion expectations and allows estimation of the number of open pores or porosity of the membrane. Flux of gases such as N(2), CO(2), Ar, H(2), and CH(4) scaled Inversely with their molecular weight by an exponent of 0.4, close to expected kinetic theory velocity expectations. However, the magnitude of the fluxes was similar to 15- to 30-fold higher than predicted from Knudsen diffusion kinetics and consistent with specular momentum reflection inside smooth pores. Polar liquids such as water, ethanol, and isopropyl alcohol and nonpolar liquids such as hexane and decane were dramatically enhanced, with water flow over 4 orders of magnitude larger than "no-slip" hydrodynamic flow predictions. As direct experimental proof for the mechanism of near perfect slip conditions within CNT cores, a stepwise hydrophilic functionalization of CNT membranes from as-produced, tip-functionalized, and core-functionalized was performed. Pressure-driven water flow through the membrane was reduced from 5 x 10(4) to 2 x 10(2) to less than a factor of 5 enhancement over conventional Newtonian flow, while retaining nearly the same pore area.
C1 [Majumder, Mainak; Hinds, Bruce J.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Chopra, Nitin; Hinds, Bruce J.] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
RP Hinds, BJ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM bjhinds@engr.uky.edu
RI Nitin, Chopra/F-8236-2011; Majumder, Mainak/B-4667-2011
FU NSF [0348544]
FX We would like to thank Dali Qian and Rodney Andrews from the Center for
   Applied Energy, University of Kentucky, for supplying MWCNTs. We also
   thank Xin Su for the H-TEM image of the MWCNT. Facility support was
   provided by the Center for Nanoscale Science and Engineering and
   Electron Microscopy Center at the University of Kentucky. Financial
   support was from NSF CAREER (0348544)
CR Ackerman DM, 2003, MOL SIMULAT, V29, P677, DOI 10.1080/0892702031000103239
   Ago H, 1999, J PHYS CHEM B, V103, P8116, DOI 10.1021/jp991659y
   ARMSTRONG DW, 1986, ANAL CHEM, V58, P579, DOI 10.1021/ac00294a019
   Arya G, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.026102
   Arya G, 2003, MOL SIMULAT, V29, P697, DOI 10.1080/0892702031000103257
   Bhatia SK, 2005, MOL SIMULAT, V31, P643, DOI 10.1080/00268970500108403
   Bittner EW, 2003, CARBON, V41, P1231, DOI 10.1016/S0008-6223(03)00055-1
   Chiang IW, 2001, J PHYS CHEM B, V105, P1157, DOI 10.1021/jp003453z
   Chopra N, 2005, ADV FUNCT MATER, V15, P858, DOI 10.1002/adfm.200400399
   Cooper SM, 2004, NANO LETT, V4, P377, DOI 10.1021/nl0350682
   CUSSLER EL, 2003, DIFFUSION MASS TRANS, P176
   de Gennes PG, 2002, LANGMUIR, V18, P3413, DOI 10.1021/la0116342
   DELANGE RSA, 1995, J MEMBRANE SCI, V104, P81, DOI 10.1016/0376-7388(95)00014-4
   Domingo-Garcia M, 2000, J COLLOID INTERF SCI, V222, P233, DOI 10.1006/jcis.1999.6619
   Fornasiero F, 2008, P NATL ACAD SCI USA, V105, P17250, DOI 10.1073/pnas.0710437105
   Fu Y, 2006, J PHYS CHEM B, V110, P9164, DOI 10.1021/jp054178p
   Fuertes AB, 2000, J MEMBRANE SCI, V177, P9, DOI 10.1016/S0376-7388(00)00458-0
   GRULKE JBE, 1999, POLYM HDB, P675
   Hinds BJ, 2004, SCIENCE, V303, P62, DOI 10.1126/science.1092048
   Holt JK, 2006, SCIENCE, V312, P1034, DOI 10.1126/science.1126298
   Hummer G, 2001, NATURE, V414, P188, DOI 10.1038/35102535
   Jirage KB, 1997, SCIENCE, V278, P655, DOI 10.1126/science.278.5338.655
   Joseph S, 2008, NANO LETT, V8, P452, DOI 10.1021/nl072385q
   Kim S, 2007, NANO LETT, V7, P2806, DOI 10.1021/nl071414u
   Lauga E, 2004, PHYS REV E, V70, DOI 10.1103/PhysRevE.70.026311
   Lee SB, 2002, SCIENCE, V296, P2198, DOI 10.1126/science.1071396
   Majumder M, 2005, NATURE, V438, P44, DOI 10.1038/43844a
   Majumder M, 2005, J AM CHEM SOC, V127, P9062, DOI 10.1021/ja043013b
   Majumder M, 2008, J MEMBRANE SCI, V316, P89, DOI 10.1016/j.memsci.2007.09.068
   Majumder M, 2007, LANGMUIR, V23, P8624, DOI 10.1021/la700686k
   Mao ZG, 2001, J PHYS CHEM B, V105, P6916, DOI 10.1021/jp0103272
   Martin CR, 2001, ADV MATER, V13, P1351, DOI 10.1002/1521-4095(200109)13:18<1351::AID-ADMA1351>3.0.CO;2-W
   MARTIN CR, 1983, J ELECTROANAL CHEM, P151
   Matranga C, 2006, LANGMUIR, V22, P1235, DOI 10.1021/la0516577
   Mattia D, 2006, LANGMUIR, V22, P1789, DOI 10.1021/la0518288
   Mi WL, 2007, J MEMBRANE SCI, V304, P1, DOI 10.1016/j.memsci.2007.07.021
   Miller SA, 2001, J AM CHEM SOC, V123, P12335, DOI 10.1021/ja011926p
   Mulder M., 1997, BASIC PRINCIPLES MEM
   Murata K, 2000, NATURE, V407, P599
   Naguib N, 2004, NANO LETT, V4, P2237, DOI 10.1021/nl0484907
   Ohba T, 2005, NANO LETT, V5, P227, DOI 10.1021/nl048327b
   Peter C, 2005, BIOPHYS J, V89, P2222, DOI 10.1529/biophysj.105.065946
   Rani SA, 2005, ANTIMICROB AGENTS CH, V49, P728, DOI 10.1128/AAC.49.2.728-732.2005
   RAO MB, 1993, J MEMBRANE SCI, V85, P253, DOI 10.1016/0376-7388(93)85279-6
   Roy S, 2005, J MEMBRANE SCI, V253, P209, DOI 10.1016/j.memsci.2004.11.033
   Roy S, 2003, J APPL PHYS, V93, P4870, DOI 10.1063/1.1559936
   Sinnott SB, 2002, CMES-COMP MODEL ENG, V3, P575
   Skoulidas AI, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.185901
   SMITH I, 1983, J COLLOID INTERF SCI, V91, P571
   Sokhan VP, 2002, J CHEM PHYS, V117, P8531, DOI 10.1063/1.1512643
   Srivastava A, 2004, NAT MATER, V3, P610, DOI 10.1038/nmat1192
   Steinle ED, 2002, ANAL CHEM, V74, P2416, DOI 10.1021/ac020024j
   THORTON A, 2011, NANO LETT UNPUB
   Wu J, 2010, P NATL ACAD SCI USA, V107, P11698, DOI 10.1073/pnas.1004714107
   YAWS CL, 2001, MATHESON GAS HDB
   Yu M, 2009, NANO LETT, V9, P225, DOI 10.1021/nl802816h
   Zhu YX, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.096105
NR 57
TC 151
Z9 154
U1 11
U2 154
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936-0851
J9 ACS NANO
JI ACS Nano
PD MAY
PY 2011
VL 5
IS 5
BP 3867
EP 3877
DI 10.1021/nn200222g
PG 11
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA 767AD
UT WOS:000290826800054
PM 21500837
DA 2018-03-20
ER

PT J
AU Zahran, EM
   Bhattacharyya, D
   Bachas, LG
AF Zahran, Elsayed M.
   Bhattacharyya, Dibakar
   Bachas, Leonidas G.
TI Reactivity of Pd/Fe bimetallic nanotubes in dechlorination of coplanar
   polychlorinated biphenyls
SO CHEMOSPHERE
LA English
DT Article
DE Polychlorinated biphenyls; Bimetallic nanotubes; Dechlorination;
   Palladium/iron
ID ZERO-VALENT IRON; REDUCTIVE DECHLORINATION; CONTAMINATED WATER;
   ACTIVATED CARBON; ZEROVALENT IRON; NANOPARTICLES; KINETICS; FE/PD; PCBS;
   TEMPERATURE
AB A new class of bimetallic materials based on palladium-decorated iron nanotubes is described that demonstrates high reactivity in dechlorination reactions. This high dechlorination efficiency was attributed to the high surface area to volume ratio of the hollow nanotubes structure. Herein, we evaluated the effect of different conditions, such as the nanotube size, and the palladium loading on the efficiency of the dechlorination of PCB 77, a model coplanar polychlorinated biphenyl (PCB), by the Pd/Fe bimetallic nanotubes system. The efficiency of the dechlorination was lowered by decreasing the tube diameter from 200 to 100 nm. In addition, the interior surface as well as the exterior surface of the as-synthesized Pd/Fe bimetallic nanotubes was found to contribute to the high efficiency of the dechlorination of PCB 77. The dechlorination of PCB 77 by Pd/Fe bimetallic nanotubes demonstrated small activation energy indicating diffusion controlled reaction. The as-prepared Pd/Fe bimetallic nanotubes showed extended lifetime activity when used in multiple dechlorination cycles. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Zahran, Elsayed M.; Bachas, Leonidas G.] Univ Miami, Dept Chem, Coral Gables, FL 33146 USA.
   [Bhattacharyya, Dibakar] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Bachas, LG (reprint author), Univ Miami, Dept Chem, Coral Gables, FL 33146 USA.
EM bachas@miami.edu
RI Bachas, Leonidas/G-2479-2015
OI Bachas, Leonidas/0000-0002-3308-6264; Zahran,
   Elsayed/0000-0003-3456-515X
FU NIEHS-SRP program [P42ES007380]; University of Miami; National Research
   Center, Egypt
FX The authors acknowledge support from the NIEHS-SRP program
   (P42ES007380). Partial funding from the University of Miami is also
   acknowledged. E.M.Z acknowledges the National Research Center, Egypt for
   granting an academic leave.
CR Agarwal S, 2009, ENVIRON SCI TECHNOL, V43, P915, DOI 10.1021/es802538d
   Aliyu MH, 2010, J ENVIRON HEALTH, V73, P8
   Beyer A, 2009, REV ENVIRON CONTAM T, V201, P137, DOI 10.1007/978-1-4419-0032-6_5
   Bhattacharyya D, 2007, CLEAN TECHNOL ENVIR, V9, P81, DOI 10.1007/s10098-007-0096-5
   Chang BV, 2006, WATER ENVIRON RES, V78, P764, DOI 10.2175/106143006X107380
   Choi H, 2008, CHEM MATER, V20, P3649, DOI 10.1021/cm8003613
   Choi H, 2009, ENVIRON SCI TECHNOL, V43, P4137, DOI 10.1021/es803535b
   CHUANG FW, 1995, ENVIRON SCI TECHNOL, V29, P2460, DOI 10.1021/es00009a044
   Chun CL, 2010, ENVIRON SCI TECHNOL, V44, P5079, DOI 10.1021/es903278e
   Fang YX, 2008, APPL CATAL B-ENVIRON, V78, P371, DOI 10.1016/j.apcatb.2007.09.009
   Gorbunova TI, 2010, RUSS CHEM REV+, V79, P511, DOI 10.1070/RC2010v079n06ABEH004047
   GREAVES J, 1994, J AM SOC MASS SPECTR, V5, P44, DOI 10.1016/1044-0305(94)85083-6
   Joo SH, 2008, CHEMOSPHERE, V70, P418, DOI 10.1016/j.chemosphere.2007.06.070
   Laidler KJ, 1987, CHEM KINETICS
   Liu YQ, 2006, ENVIRON SCI TECHNOL, V40, P6085, DOI 10.1021/es060685o
   Miyoshi K, 2000, CHEMOSPHERE, V41, P819, DOI 10.1016/S0045-6535(99)00557-3
   Nurmi JT, 2005, ENVIRON SCI TECHNOL, V39, P1221, DOI 10.1021/es049190u
   Ross PS, 2000, SCIENCE, V289, P1878
   Sarathy V, 2008, J PHYS CHEM C, V112, P2286, DOI 10.1021/jp0777418
   Scherer MM, 1997, ENVIRON SCI TECHNOL, V31, P2385, DOI 10.1021/es960999j
   SCHREIER CG, 1995, CHEMOSPHERE, V31, P3475, DOI 10.1016/0045-6535(95)00200-R
   Siantar DP, 1996, WATER RES, V30, P2315, DOI 10.1016/0043-1354(96)00120-0
   Su CM, 1999, ENVIRON SCI TECHNOL, V33, P163, DOI 10.1021/es980481a
   Van Aken B, 2010, ENVIRON SCI TECHNOL, V44, P2767, DOI 10.1021/es902514d
   Venkatachalam K, 2008, J HAZARD MATER, V159, P483, DOI 10.1016/j.jhazmat.2008.02.109
   Wang CB, 1997, ENVIRON SCI TECHNOL, V31, P2154, DOI 10.1021/es970039c
   Wu L, 2005, J NANOPART RES, V7, P469, DOI 10.1007/s11051-005-4271-5
   Xu J, 2008, J PHYS CHEM C, V112, P9133, DOI 10.1021/jp7097262
   Xu J, 2007, IND ENG CHEM RES, V46, P2348, DOI 10.1021/ie0611498
   Yak HK, 2000, ENVIRON SCI TECHNOL, V34, P2792, DOI 10.1021/es990689b
   Yan WL, 2010, ENVIRON SCI TECHNOL, V44, P4288, DOI 10.1021/es100051q
   Zahran EM, 2011, J MATER CHEM, V21, P10454, DOI 10.1039/c1jm11435b
   Zhang WX, 2003, J NANOPART RES, V5, P323, DOI 10.1023/A:1025520116015
NR 33
TC 14
Z9 15
U1 5
U2 85
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0045-6535
J9 CHEMOSPHERE
JI Chemosphere
PD APR
PY 2013
VL 91
IS 2
BP 165
EP 171
DI 10.1016/j.chemosphere.2012.12.037
PG 7
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA 105SA
UT WOS:000316091600009
PM 23332879
OA green_accepted
DA 2018-03-19
ER

PT J
AU Bhattacharyya, D
   Datta, S
   Bachas, LG
   Meyer, D
   Xu, J
   Smuleac, V
AF Bhattacharyya, Dibakar
   Datta, Saurav
   Bachas, Leonidas G.
   Meyer, David
   Xu, Jian
   Smuleac, Vasile
TI Nanostructured materials/membranes for toxic metal separations and
   enzyme catalysis: An overview
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
C1 [Bhattacharyya, Dibakar; Xu, Jian; Smuleac, Vasile] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Bachas, Leonidas G.] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
EM db@engr.uky.edu; sdatt0@engr.uky.edu; bachas@uky.edu; demeye1@uky.edu;
   jxu1@engr.uky.edu
RI Bachas, Leonidas/G-2479-2015
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD MAR 22
PY 2009
VL 237
MA 111-IEC
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA V16GJ
UT WOS:000207857802760
DA 2018-03-19
ER

PT J
AU Jiang, YH
   Arounleut, P
   Rheiner, S
   Bae, Y
   Kabanov, AV
   Milligan, C
   Manickama, DS
AF Jiang, Yuhang
   Arounleut, Phonepasong
   Rheiner, Steven
   Bae, Younsoo
   Kabanov, Alexander V.
   Milligan, Carol
   Manickama, Devika S.
TI SOD1 nanozyme with reduced toxicity and MPS accumulation
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article; Proceedings Paper
CT 13th Nanomedicine and Drug Delivery Symposium (NanoDDS)
CY SEP 16-18, 2015
CL Univ Washington, Seattle, WA
SP Precision NanoSystems, Inc, Sigma Aldrich, Izon Sci, Perkin Elmer, Univ Washington, Coll Engn, UW Bioengineering, UW Mol Engn & Sci Inst, Bio Pact, iThera Med, Quidel, Wyatt Technol, Miltenyi Biotec
HO Univ Washington
DE Antioxidant; Superoxide dismutase; Protein delivery; Stroke; ALS; MPS;
   PEG-PLL; PEG-PAsp(DET); Toxicity; Mouse
ID AMYOTROPHIC-LATERAL-SCLEROSIS; ENTRAPPED SUPEROXIDE-DISMUTASE; LINKED
   ANTIOXIDANT NANOZYMES; BRAIN TRANSFER CONSTANTS; SOD1(G93A) MOUSE MODEL;
   TIME UPTAKE DATA; GENE-TRANSFER; IN-VIVO; POLYPLEX NANOMICELLES;
   OXIDATIVE STRESS
AB We previously developed a "cage"-like nano-formulation (nanozyme) for copper/Zinc superoxide dismutase (SOD1) by polyion condensation with a conventional block copolymer poly(ethylene glycol)-b-poly(L-lysine) (PEG-PLL) followed by chemical cross-linking. Herein we report a new SOD1 nanozyme based on PEG-b-poly(aspartate diethyltriamine) (PEG-PAsp(DET), or PEG-DET for short) engineered for chronic dosing. This new nanozyme was spherical (R-g/R-h = 0.785), and hollow(60% water composition) nanoparticles with colloidal properties similar to PLL-based nanozyme. It was better tolerated by brain microvessel endothelial/neuronal cells, and accumulated less in the liver and spleen. This formulation reduced the infarct volumes by more than 50% in a mouse model of ischemic stroke. However, it was not effective at preventing neuromuscular junction denervation in a mutant SOD1(G93A) mouse model of amyotrophic lateral sclerosis (ALS). To our knowledge, this work is the first report of using PEG-DET for protein delivery and a direct comparison between two cationic block copolymers demonstrating the effect of polymer structure in modulating the mononuclear phagocyte system (MPS) accumulation of polyion complexes. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Jiang, Yuhang; Kabanov, Alexander V.; Manickama, Devika S.] Univ N Carolina, Eshelman Sch Pharm, Div Mol Pharmaceut, Ctr Nanotechnol Drug Delivery, Chapel Hill, NC 27599 USA.
   [Arounleut, Phonepasong; Milligan, Carol] Wake Forest Univ, Bowman Gray Sch Med, Dept Neurobiol & Anat, ALS Ctr Translat Sci Unit, Winston Salem, NC 27106 USA.
   [Rheiner, Steven; Bae, Younsoo] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
   [Kabanov, Alexander V.] Moscow MV Lomonosov State Univ, Fac Chem, Lab Chem Design Bionanomat, Moscow 117234, Russia.
   [Manickama, Devika S.] Duquesne Univ, Mylan Sch Pharm, Div Pharmaceut Sci, Pittsburgh, PA 15282 USA.
RP Manickama, DS (reprint author), Univ N Carolina, Eshelman Sch Pharm, Div Mol Pharmaceut, Ctr Nanotechnol Drug Delivery, Chapel Hill, NC 27599 USA.; Manickama, DS (reprint author), Duquesne Univ, Mylan Sch Pharm, Div Pharmaceut Sci, Pittsburgh, PA 15282 USA.
EM dsmanickam@gmail.com
OI Jiang, Yuhang/0000-0003-1982-3237
CR ABERNETHY JL, 1974, J BIOL CHEM, V249, P7339
   Akagi D, 2007, GENE THER, V14, P1029, DOI 10.1038/dj.gt.3302945
   Auclair J.R., 2013, BIOCHEMISTRY, V52
   Axthelm F, 2008, J PHYS CHEM B, V112, P8211, DOI 10.1021/jp803032w
   Baba M, 2015, J CONTROL RELEASE, V201, P41, DOI 10.1016/j.jconrel.2015.01.017
   Banks WA, 2008, BIOPOLYMERS, V90, P589, DOI 10.1002/bip.20980
   Barber SC, 2006, BBA-MOL BASIS DIS, V1762, P1051, DOI 10.1016/j.bbadis.2006.03.008
   CHAN PH, 1987, ANN NEUROL, V21, P540, DOI 10.1002/ana.410210604
   Dautzenberg H, 2000, LANGMUIR, V16, P9070, DOI 10.1021/la000368+
   De Jong WH, 2008, INT J NANOMED, V3, P133
   Dziubla TD, 2008, BIOMATERIALS, V29, P215, DOI 10.1016/j.biomaterials.2007.09.023
   Ernsting MJ, 2013, J CONTROL RELEASE, V172, P782, DOI 10.1016/j.jconrel.2013.09.013
   Eum WS, 2004, FREE RADICAL BIO MED, V37, P1656, DOI 10.1016/j.freeradbiomed.2004.07.028
   Francis JW, 1997, EXP NEUROL, V146, P435, DOI 10.1006/exnr.1997.6547
   Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515
   Furukawa Y, 2006, P NATL ACAD SCI USA, V103, P7148, DOI 10.1073/pnas.0602048103
   Gifondorwa DJ, 2007, J NEUROSCI, V27, P13173, DOI 10.1523/JNEUROSCI.4057-07.2007
   Gifondorwa D.J., 2012, NEUROL RES INT, V2012, DOI DOI 10.1155/2012/170426
   Grotta J.C., 2015, STROKE PATHOPHYSIOLO
   GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258
   Han M, 2007, J CONTROL RELEASE, V121, P38, DOI 10.1016/j.jconrel.2007.05.012
   Harada-Shiba M, 2009, MOL THER, V17, P1180, DOI 10.1038/mt.2009.63
   Hayakawa K, 2015, J CONTROL RELEASE, V197, P1, DOI 10.1016/j.jconrel.2014.10.027
   Hough MA, 2004, P NATL ACAD SCI USA, V101, P5976, DOI 10.1073/pnas.0305143101
   IMAIZUMI S, 1990, STROKE, V21, P1312, DOI 10.1161/01.STR.21.9.1312
   Iriyama A, 2011, CORNEA, V30, P1423, DOI 10.1097/ICO.0b013e318206c893
   Itaka K, 2007, MOL THER, V15, P1655, DOI 10.1038/sj.mt.6300218
   JADOT G, 1995, CLIN PHARMACOKINET, V28, P17, DOI 10.2165/00003088-199528010-00003
   Jiang YH, 2015, J CONTROL RELEASE, V213, P36, DOI 10.1016/j.jconrel.2015.06.021
   Klyachko NL, 2012, NANOMED-NANOTECHNOL, V8, P119, DOI 10.1016/j.nano.2011.05.010
   Lai TC, 2010, PHARM RES-DORDR, V27, P2260, DOI 10.1007/s11095-010-0092-z
   LIN CT, 1995, PLANT MOL BIOL, V28, P303, DOI 10.1007/BF00020249
   Maeda M, 2004, NEUROSCI RES, V48, P305, DOI 10.1016/j.neures.2003.11.008
   Manickam DS, 2012, J CONTROL RELEASE, V162, P636, DOI 10.1016/j.jconrel.2012.07.044
   Miyata K, 2008, J AM CHEM SOC, V130, P16287, DOI 10.1021/ja804561g
   Moghimi SM, 2001, CRIT REV THER DRUG, V18, P527
   Muller FL, 2007, AM J PHYSIOL-REG I, V293, pR1159, DOI 10.1152/ajpregu.00767.2006
   NELSON SK, 1994, FREE RADICAL BIO MED, V16, P195, DOI 10.1016/0891-5849(94)90143-0
   Ogihara NL, 1996, BIOCHEMISTRY-US, V35, P2316, DOI 10.1021/bi951930b
   Onaca O, 2010, MACROMOL BIOSCI, V10, P531, DOI 10.1002/mabi.200900379
   Pan WH, 1998, NEUROPHARMACOLOGY, V37, P1553, DOI 10.1016/S0028-3908(98)00141-5
   PATLAK CS, 1985, J CEREBR BLOOD F MET, V5, P584, DOI 10.1038/jcbfm.1985.87
   PATLAK CS, 1983, J CEREBR BLOOD F MET, V3, P1, DOI 10.1038/jcbfm.1983.1
   Quillin ML, 2000, ACTA CRYSTALLOGR D, V56, P791, DOI 10.1107/S090744490000679X
   Robinson MB, 2005, J NEUROSCI, V25, P9735, DOI 10.1523/JNEUROSCI.1912-05.2005
   Rocha MC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073846
   ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0
   Schieber M, 2014, CURR BIOL, V24, pR453, DOI 10.1016/j.cub.2014.03.034
   Shah NB, 2012, MOL PHARMACEUT, V9, P2146, DOI 10.1021/mp200626j
   SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47
   TAKEDA Y, 1993, AM J PHYSIOL, V264, pH1708
   Toichi K, 2013, J BIOL CHEM, V288, P4970, DOI 10.1074/jbc.M112.414235
   Truett GE, 2000, BIOTECHNIQUES, V29, P52
   Uttara B, 2009, CURR NEUROPHARMACOL, V7, P65, DOI 10.2174/157015909787602823
   Veronese FM, 2002, ADV DRUG DELIVER REV, V54, P587, DOI 10.1016/S0169-409X(02)00029-7
   Vinsant S, 2013, BRAIN BEHAV, V3, P335, DOI 10.1002/brb3.143
   Vinsant S, 2013, BRAIN BEHAV, V3, P431, DOI 10.1002/brb3.142
   Xiao K, 2011, BIOMATERIALS, V32, P3435, DOI 10.1016/j.biomaterials.2011.01.021
   Xiong MP, 2007, CHEMMEDCHEM, V2, P1321, DOI 10.1002/cmdc.200700093
   Yun X, 2013, J CEREBR BLOOD F MET, V33, P583, DOI 10.1038/jcbfm.2012.209
   Zheng CY, 2007, ELECTROPHORESIS, V28, P2801, DOI 10.1002/elps.200600807
NR 61
TC 5
Z9 5
U1 2
U2 28
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD JUN 10
PY 2016
VL 231
BP 38
EP 49
DI 10.1016/j.jconrel.2016.02.038
PG 12
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA DM6EY
UT WOS:000376444600005
PM 26928528
DA 2018-03-19
ER

PT J
AU Park, JE
   Chun, SE
   Reichel, D
   Park, J
   Min, JS
   Ryoo, G
   Oh, Y
   Bae, SK
   Yeo, Y
   Bae, Y
   Lee, W
AF Park, Ji Eun
   Chun, Se-Eun
   Reichel, Derek A.
   Park, Joonyoung
   Min, Jee Sun
   Ryoo, Gongmi
   Oh, Yunseok
   Bae, Soo Kyung
   Yeo, Yoon
   Bae, Younsoo
   Lee, Wooin
TI Novel Polymer Micelle and Nanocrystal Formulations for the Proteasome
   Inhibitor Drug Carfilzomib: Pharmacokinetic and Pharmacodynamic Studies
   in Human Lung and Breast Cancer Models
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Annual Meeting of the
   American-Society-for-Pharmacology-and-Experimental-Therapeutics (ASPET)
   at Experimental Biology Meeting
CY APR 22-26, 2017
CL Chicago, IL
SP Amer Soc Pharmacol & Expt Therapeut, Amer Assoc Anatomists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, Amer Soc Investigat Pathol, Amer Soc Nutr
C1 [Park, Ji Eun; Chun, Se-Eun; Ryoo, Gongmi; Oh, Yunseok; Lee, Wooin] Seoul Natl Univ, Coll Pharm, Seoul, South Korea.
   [Reichel, Derek; Bae, Younsoo] Univ Kentucky, Pharmaceut Sci, Lexington, KY USA.
   [Park, Joonyoung; Yeo, Yoon] Purdue Univ, Ind & Phys Pharm, Lafayette, IN USA.
   [Min, Jee Sun; Bae, Soo Kyung] Catholic Univ Korea, Coll Pharm, Bucheon, South Korea.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD APR
PY 2017
VL 31
SU 1
MA 822.6
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA FB2PU
UT WOS:000405986502155
DA 2018-03-19
ER

PT J
AU Rhee, YS
   Sohn, M
   Woo, BH
   Thanoo, BC
   DeLuca, PP
   Mansour, HM
AF Rhee, Yun-Seok
   Sohn, MinJi
   Woo, Byung H.
   Thanoo, B. C.
   DeLuca, Patrick P.
   Mansour, Heidi M.
TI Sustained-Release Delivery of Octreotide from Biodegradable Polymeric
   Microspheres
SO AAPS PHARMSCITECH
LA English
DT Article
DE in vivo drug release; pharmacokinetic simulation; PLGA microspheres;
   polypeptide/protein drug delivery; single depot injection
ID PREPARATION NUTROPIN DEPOT; PLGA MICROSPHERES;
   POLY(D,L-LACTIDE-CO-GLYCOLIDE) MICROSPHERES; PHARMACODYNAMIC
   CHARACTERISTICS; INJECTED PHARMACEUTICALS; PROSTATE-CANCER; IN-VITRO;
   GROWTH; PROTEINS; RATS
AB The study reports on the drug release behavior of a potent synthetic somatostatin analogue, octreotide acetate, from biocompatible and biodegradable microspheres composed of poly-lactic-co-glycolic acid (PLGA) following a single intramuscular depot injection. The serum octreotide levels of three Oakwood Laboratories formulations and one Sandostatin LAR(A (R)) formulation were compared. Three formulations of octreotide acetate-loaded PLGA microspheres were prepared by a solvent extraction and evaporation procedure using PLGA polymers with different molecular weights. The in vivo drug release study was conducted in male Sprague-Dawley rats. Blood samples were taken at predetermined time points for up to 70 days. Drug serum concentrations were quantified using a radioimmunoassay procedure consisting of radiolabeled octreotide. The three octreotide PLGA microsphere formulations and Sandostatin LAR(A (R)) all showed a two-phase drug release profile (i.e., bimodal). The peak serum drug concentration of octreotide was reached in 30 min for all formulations followed by a decline after 6 h. Following this initial burst and decline, a second-release phase occurred after 3 days. This second-release phase exhibited sustained-release behavior, as the drug serum levels were discernible between days 7 and 42. Using pharmacokinetic computer simulations, it was estimated that the steady-state octreotide serum drug levels would be predicted to fall in the range of 40-130 pg/10 mu L and 20-100 pg/10 mu L following repeat dosing of the Oakwood formulations and Sandostatin LAR(A (R)) every 28 days and every 42 days at a dose of 3 mg/rat, respectively.
C1 [Rhee, Yun-Seok; Sohn, MinJi; DeLuca, Patrick P.; Mansour, Heidi M.] Univ Kentucky, Dept Pharmaceut Sci, Drug Dev Div, Coll Pharm, Lexington, KY 40536 USA.
   [Woo, Byung H.; Thanoo, B. C.] Oakwood Labs, Oakwood Village, OH USA.
RP Mansour, HM (reprint author), Univ Kentucky, Dept Pharmaceut Sci, Drug Dev Div, Coll Pharm, 789 S Limestone St, Lexington, KY 40536 USA.
EM heidi.mansour@uky.edu
FU Oakwood Laboratories
FX This research was supported by Oakwood Laboratories. Senior laboratory
   technicians, Ms. Wei Qiu and Mr. Charles Ritchie, are gratefully
   acknowledged for their technical assistance.
CR Abouelfadel Zinelabidine, 2008, Ther Clin Risk Manag, V4, P513
   Anthony L, 2009, CURR MED RES OPIN, V25, P2989, DOI 10.1185/03007990903328959
   BergeS R, 2006, CURR MED RES OPIN, V22, P649, DOI 10.1185/030079906X96425
   BODMER D, 1992, J CONTROL RELEASE, V21, P129, DOI 10.1016/0168-3659(92)90014-I
   Brandhonneur N, 2009, INT J PHARMACEUT, V373, P16, DOI 10.1016/j.ijpharm.2009.01.020
   Chen X, 2005, J MICROENCAPSUL, V22, P621, DOI 10.1080/02652040500162782
   Chung HJ, 2006, PHARM RES, V23, P1835, DOI 10.1007/s11095-006-9039-9
   Cleland JL, 1998, BIOTECHNOL PROGR, V14, P102, DOI 10.1021/bp970128t
   Comets E, 1999, J CONTROL RELEASE, V59, P197, DOI 10.1016/S0168-3659(98)00194-1
   Cook DM, 2002, J CLIN ENDOCR METAB, V87, P4508, DOI 10.1210/jc.2002-020480
   Eratalay A, 2009, J MICROENCAPSUL
   Faisant N, 2002, EUR J PHARM SCI, V15, P355, DOI 10.1016/S0928-0987(02)00023-4
   FLYVBJERG A, 1991, AM J PHYSIOL, V260, pE568
   Gebrekidan S, 2000, AAPS PHARMSCITECH, V1
   Gefvert O, 2005, INT J NEUROPSYCHOPH, V8, P27, DOI 10.1017/S1461145704004924
   Geng Y, 2008, J CONTROL RELEASE, V130, P259, DOI 10.1016/j.jconrel.2008.06.011
   Grischke EM, 2008, GEBURTSH FRAUENHEILK, V68, P1008, DOI 10.1055/s-2008-1038944
   Hamishehkar H, 2009, COLLOID SURFACE B, V74, P340, DOI 10.1016/j.colsurfb.2009.08.003
   Horvath JE, 2002, P NATL ACAD SCI USA, V99, P15048, DOI 10.1073/pnas.232579499
   Ignatius AA, 1996, BIOMATERIALS, V17, P831, DOI 10.1016/0142-9612(96)81421-9
   Irani J, 2009, J UROLOGY, V181, P231, DOI 10.1016/S0022-5347(09)60657-1
   Jiang WL, 2008, MOL PHARMACEUT, V5, P808, DOI 10.1021/mp800027f
   Jiang WL, 2005, ADV DRUG DELIVER REV, V57, P391, DOI 10.1016/j.addr.2004.09.003
   Kang J, 2008, INT J PHARMACEUT, V357, P235, DOI 10.1016/j.ijpharm.2008.02.004
   Kemp SF, 2004, J CLIN ENDOCR METAB, V89, P3234, DOI 10.1210/jc.2003-030825
   Kendall-Taylor P, 2000, Pituitary, V3, P61, DOI 10.1023/A:1009997506216
   Kundi Salma Aslam, 2005, J Ayub Med Coll Abbottabad, V17, P63
   LANCRANJAN I, 1995, METABOLISM, V44, P18, DOI 10.1016/0026-0495(95)90306-2
   LEMAIRE M, 1989, DRUG METAB DISPOS, V17, P699
   Lewis KJ, 1998, J DRUG TARGET, V5, P291, DOI 10.3109/10611869808995882
   Lieb JG, 2009, J PANCREAS, V10, P518
   Logue S, 2001, AAPS PHARMSCI S1, V3, P549
   Mansour HM, 2010, INT J MOL SCI, V11, P3298, DOI 10.3390/ijms11093298
   Murty Santos B, 2004, AAPS PharmSciTech, V5, pe49
   Parames Filipa, 2009, Rev Port Cardiol, V28, P799
   PERUGINI P, 2001, AAPS PHARMSCITECH, V2
   Ren XH, 2009, ANIM BIOTECHNOL, V20, P124, DOI 10.1080/10495390902945787
   Rhee Y-S, 2010, PHARM TECH, V11, P16
   SANDERS LM, 1984, J PHARM SCI, V73, P1294, DOI 10.1002/jps.2600730927
   Shive MS, 1997, ADV DRUG DELIV REV, V28, P5
   Sophocleous AM, 2009, J CONTROL RELEASE, V137, P179, DOI 10.1016/j.jconrel.2009.03.006
   Susini C, 2006, ANN ONCOL, V17, P1733, DOI 10.1093/annonc/mdl105
   van der Walle CF, 2009, EXPERT OPIN DRUG DEL, V6, P177, DOI [10.1517/17425240802680169 , 10.1517/17425240802680169]
   WANG HT, 1990, BIOMATERIALS, V11, P679, DOI 10.1016/0142-9612(90)90026-M
   Wang J, 2002, J CONTROL RELEASE, V82, P289, DOI 10.1016/S0168-3659(02)00137-2
   ZUIDEMA J, 1988, INT J PHARM, V47, P1, DOI 10.1016/0378-5173(88)90209-8
   ZUIDEMA J, 1994, INT J PHARM, V105, P189, DOI 10.1016/0378-5173(94)90103-1
NR 47
TC 10
Z9 10
U1 0
U2 14
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1530-9932
J9 AAPS PHARMSCITECH
JI AAPS PharmSciTech
PD DEC
PY 2011
VL 12
IS 4
BP 1293
EP 1301
DI 10.1208/s12249-011-9693-z
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 855TC
UT WOS:000297586500031
PM 21948321
OA green_published
DA 2018-03-20
ER

PT J
AU Ojogun, V
   Knutson, BL
   Vyas, S
   Lehmler, HJ
AF Ojogun, Vivian A.
   Knutson, Barbara L.
   Vyas, Sandhya M.
   Lehmler, Hans-Joachim
TI Fluorophilicity of alkyl and polyfluoroalkyl nicotinic acid ester
   prodrugs
SO JOURNAL OF FLUORINE CHEMISTRY
LA English
DT Article
DE Fluorophilicity; Fluorinated solutes; Nicotinates; Phase behavior;
   Prodrug
ID PARTITION-COEFFICIENTS; LIQUID VENTILATION; DISORDER THEORY;
   DRUG-DELIVERY; MOBILE ORDER; FORCE-FIELD; PREDICTION; BEHAVIOR; SOLUTES;
   SYSTEMS
AB The fluorophilicity of a series of hydrocarbon and fluorocarbon-functionalized nicotinic acid esters (nicotinates) is measured from their partitioning behavior (log K(p)) in the biphasic solvent system of perfluoro(methylcyclohexane) (PFMC) and toluene. The chain length of the hydrocarbon or fluorocarbon alkyl group of the ester ranges from one to twelve carbon atoms. Knowledge of the fluorophilicity of these solutes is relevant to the design of these prodrugs for fluorocarbon-based drug delivery. The experimental log K(p) values range from -1.72 to -3.40 for the hydrocarbon nicotinates and -1.64 to 0.13 for the fluorinated nicotinates, where only the prodrug with the longest fluorinated chain (2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctyl nicotinic acid ester) partitions preferentially into the fluorinated phase (log K(p) = 0.13). Predictions of the partition coefficients using solubility parameters calculated from group contribution techniques or molecular dynamics simulation are in reasonable agreement for the perhydrocarbon nicotinates and short chained perfluorinated nicotinates (approximate to 0.3-39% deviation). Significant deviations from experimental partition coefficients (greater than 100%) are observed for the longest chain perfluoroalkyl nicotinates. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Ojogun, Vivian; Knutson, Barbara L.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Vyas, Sandhya; Lehmler, Hans-Joachim] Univ Iowa, Dept Occupat & Environm Hlth, Iowa City, IA 52242 USA.
RP Knutson, BL (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 Anderson Hall, Lexington, KY 40506 USA.
EM bknutson@engr.uky.edu
OI Lehmler, Hans-Joachim/0000-0001-9163-927X
FU National Institute of Environmental Health Sciences, NIH [ES07380,
   ES012475]
FX Special thanks to John May of the Environmental Research Training
   Laboratory (ERTL, University of Kentucky) for assistance with the GC
   analysis of the nicotinate partitioning. This work is funded by National
   Institute of Environmental Health Sciences, NIH, grants ES07380 and
   ES012475.
CR Allen M. P., 1987, COMPUTER SIMULATION
   Bodor N, 1997, J PHYS CHEM B, V101, P3404, DOI 10.1021/jp9638503
   Daniels SM, 2004, J FLUORINE CHEM, V125, P1291, DOI 10.1016/j.jfluchem.2004.03.014
   Danielsson LG, 1996, TRAC-TREND ANAL CHEM, V15, P188, DOI 10.1016/0165-9936(96)00003-9
   de Wolf E, 2004, J PHYS CHEM B, V108, P1458, DOI 10.1021/jp036751f
   Downer A, 1999, LANGMUIR, V15, P7591, DOI 10.1021/la990549f
   Duchowicz PR, 2004, J FLUORINE CHEM, V125, P43, DOI 10.1016/j.jfluchem.2003.09.003
   Eastoe J, 2001, LANGMUIR, V17, P7873, DOI 10.1021/la010958n
   Eichinger BE, 1995, COMPUT POLYMER SCI, V5, P147
   FEDORS RF, 1974, POLYM ENG SCI, V14, P147, DOI 10.1002/pen.760140211
   FEDORS RF, 1983, CRC HDB SOLUBILITY P, P64
   Hsu CH, 2003, PHARMACEUT RES, V20, P918, DOI 10.1023/A:1023899505837
   Huque FTT, 2002, J FLUORINE CHEM, V115, P119, DOI 10.1016/S0022-1139(02)00034-9
   Jacobson EL, 1999, MOL CELL BIOCHEM, V193, P69, DOI 10.1023/A:1006960126369
   Kani I, 2006, J MOL CATAL A-CHEM, V259, P142, DOI 10.1016/j.molcata.2006.06.028
   Kiss LE, 2001, J FLUORINE CHEM, V108, P95, DOI 10.1016/S0022-1139(01)00342-6
   Krafft MP, 1998, BIOCHIMIE, V80, P489, DOI 10.1016/S0300-9084(00)80016-4
   Lehmler HJ, 2008, INT J PHARM, V353, P35, DOI 10.1016/j.ijpharm.2007.1
   Lehmler HJ, 2007, EXPERT OPIN DRUG DEL, V4, P247, DOI 10.1517/17425247.4.3.247
   Lehmler HJ, 1999, CHEMTECH, V29, P7
   LoNostro P, 1999, J PHYS CHEM B, V103, P5347, DOI 10.1021/jp9827025
   MORISHITA S, 1988, J MED CHEM, V31, P1205, DOI 10.1021/jm00401a022
   Prausnitz J., 1986, MOL THERMODYNAMICS F
   Riess JG, 1998, BIOMATERIALS, V19, P1529, DOI 10.1016/S0142-9612(98)00071-4
   Rigby D, 1997, POLYM INT, V44, P311, DOI 10.1002/(SICI)1097-0126(199711)44:3<311::AID-PI880>3.3.CO;2-8
   Rocaboy C, 2000, J PHYS ORG CHEM, V13, P596, DOI 10.1002/1099-1395(200010)13:10<596::AID-POC284>3.0.CO;2-M
   Ruelle P, 2000, J CHEM INF COMP SCI, V40, P681, DOI 10.1021/ci9902752
   Sarraf EG, 1997, J CHEM SOC FARADAY T, V93, P2519, DOI 10.1039/a702009k
   Spyriouni T, 2001, MACROMOLECULES, V34, P5306, DOI 10.1021/ma001669t
   Sun H, 1998, J PHYS CHEM B, V102, P7338, DOI 10.1021/jp980939v
   Weers JG, 2004, LANGMUIR, V20, P7430, DOI 10.1021/la049375e
   YI WB, 2006, CATAL COMMUN, V9, P1291
   Zhang MZ, 2003, POLYMER, V44, P1979, DOI 10.1016/S0032-3861(03)00054-5
NR 33
TC 5
Z9 5
U1 0
U2 3
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0022-1139
J9 J FLUORINE CHEM
JI J. Fluor. Chem.
PD JUL
PY 2010
VL 131
IS 7
BP 784
EP 790
DI 10.1016/j.jfluchem.2010.04.001
PG 7
WC Chemistry, Inorganic & Nuclear; Chemistry, Organic
SC Chemistry
GA 616DZ
UT WOS:000279190300007
PM 20567608
OA green_accepted
DA 2018-03-20
ER

PT J
AU Long, SH
   Siegler, M
   Li, TL
AF Long, Sihui
   Siegler, Maxime A.
   Li, Tonglei
TI N-(3-chloro-2-methylphenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article
AB The title compound, C13H11ClN2O2, contains two aromatic rings linked by an amide group, and adopts a near-planar conformation. There are intra- and intermolecular N-H center dot center dot center dot O hydrogen bonds, forming centrosymmetric dimers.
C1 Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40506 USA.
   Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
RP Li, TL (reprint author), Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40506 USA.
EM tonglei@uky.edu
CR Nonius, 2002, COLLECT
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Sheldrick G. M., 1997, SHELXL97 SHELXS97
   SHELDRICK GM, 1995, XP SHELXTL PC
   TING PC, 1990, J MED CHEM, V33, P2697, DOI 10.1021/jm00172a004
   ALVAREZ M, 1979, Patent No. ES478821
NR 6
TC 2
Z9 2
U1 0
U2 3
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD OCT
PY 2006
VL 62
BP O4278
EP O4279
DI 10.1107/S160053680603488X
PN 10
PG 2
WC Crystallography
SC Crystallography
GA 089XE
UT WOS:000240914400180
DA 2018-03-20
ER

PT J
AU Zhang, WL
   Eitel, RE
AF Zhang, Wenli
   Eitel, Richard E.
TI Low-Temperature Sintering and Properties of 0.98PZT-0.02SKN Ceramics
   with LiBiO2 and CuO Addition
SO JOURNAL OF THE AMERICAN CERAMIC SOCIETY
LA English
DT Article
ID PZT THICK-FILMS; PIEZOELECTRIC PROPERTIES; ELECTRICAL-PROPERTIES; LTCC;
   MICROSYSTEMS; ACTUATORS; BOUNDARY; BIFEO3; AIDS
AB The low-temperature sintering behavior of Pb(Zr-0.53, Ti-0.47) O-3-Sr(K-0.25, Nb-0.75)O-3 (PZT-SKN) piezoelectric ceramics with LiBiO2 and CuO addition has been investigated. The addition of 6 wt% LiBiO2 or 1 wt% LiBiO2+1 wt% CuO promotes the sinterability of 0.98PZT-0.02SKN ceramics owing to the generation of a liquid phase, resulting in a reduction of sintering temperature by about 300 degrees-350 degrees C. The microstructure, dielectric, and piezoelectric properties of flux-sintered ceramics were examined and compared with materials conventionally sintered at 1250 degrees C. PZT-SKN ceramics with 1 wt% LiBiO2+1 wt% CuO addition were sintered to high density at 900 degrees C for 1 h. The resulting samples exhibited a high-field d(33) piezoelectric coefficient of 415 pm/V with a Curie temperature T-c of around 351 degrees C, dielectric constant epsilon(r) of 1235, and planar coupling factor k(p) of 0.54. The reduced sintering temperature and short soaking time, together with the favorable dielectric and piezoelectric properties of the fluxed PZT-SKN ceramics, demonstrate the potential opportunity of integration with low-temperature cofired ceramic materials and low-fire electrode materials for the multilayer piezoelectric transducer application.
C1 [Zhang, Wenli; Eitel, Richard E.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Eitel, RE (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM reitel@engr.uky.edu
RI Eitel, Richard/E-2889-2010
OI Eitel, Richard/0000-0002-5090-2075
CR Ahn CW, 2006, J AM CERAM SOC, V89, P921, DOI 10.1111/j.1551-2916.2005.00823.x
   [Anonymous], 1976, IEEE STAND PIEZ
   Belavic D, 2006, INT J APPL CERAM TEC, V3, P448, DOI 10.1111/j.1744-7402.2006.02105.x
   Chao XL, 2008, SENSOR ACTUAT A-PHYS, V141, P482, DOI 10.1016/j.sna.2007.10.035
   Chung K, 2006, SENSOR ACTUAT A-PHYS, V125, P340, DOI 10.1016/j.sna.2005.06.018
   Chung K, 2005, SENSOR ACTUAT A-PHYS, V121, P142, DOI 10.1016/j.sna.2005.01.022
   Donnelly NJ, 2008, J AM CERAM SOC, V91, P2182, DOI 10.1111/j.1551-2916.2008.02403.x
   Donnelly NJ, 2007, J AM CERAM SOC, V90, P490, DOI 10.1111/j.1551-2916.2006.01450.x
   Hayashi T, 2004, JPN J APPL PHYS 1, V43, P6683, DOI 10.1143/JJAP.43.6683
   Hayashi T, 2003, JPN J APPL PHYS 1, V42, P6074, DOI 10.1143/JJAP.42.6074
   Hayashi T, 1999, JPN J APPL PHYS 1, V38, P5549, DOI 10.1143/JJAP.38.5549
   Helke G, 1999, J EUR CERAM SOC, V19, P1265, DOI 10.1016/S0955-2219(98)00417-8
   Hrovat M, 2003, J MATER SCI LETT, V22, P1193, DOI 10.1023/A:1025388214955
   Imanaka Y., 2005, MULTILAYERED LOW TEM, P24
   Jiang XP, 2001, J MATER SCI TECHNOL, V17, P287
   Kaneko S, 1998, J AM CERAM SOC, V81, P1013
   Lee HG, 2006, J ELECTROCERAM, V17, P1035, DOI 10.1007/s10832-006-0384-1
   Levin E. M., 1975, PHASE DIAGRAMS CERAM, VIII, P20
   Mao YC, 2000, J SOLID STATE CHEM, V149, P314, DOI 10.1006/jssc.1999.8532
   MURAKAMI K, 1995, JPN J APPL PHYS 1, V34, P5457, DOI 10.1143/JJAP.34.5457
   Randall CA, 2005, J ELECTROCERAM, V14, P177, DOI 10.1007/s10832-005-0956-5
   Randall CA, 1998, J AM CERAM SOC, V81, P677
   Rusu C, 2006, J MICROMECH MICROENG, V16, pS13, DOI 10.1088/0960-1317/16/6/S03
   Thelemann T, 2002, MICROELECTRON INT, V19, P19, DOI 10.1108/1356536021044505
   Torah RN, 2007, J ELECTROCERAM, V19, P97, DOI 10.1007/s10832-007-9040-7
   Tsai CC, 2009, J ALLOY COMPD, V478, P516, DOI 10.1016/j.jallcom.2008.11.084
   Uchino K., 1998, ACTA MAT, V46, P3475
   Ursic H, 2008, J ELECTROCERAM, V20, P11, DOI 10.1007/s10832-007-9327-8
   Wan DD, 2010, JPN J APPL PHYS, V49, DOI 10.1143/JJAP.49.071503
   Wang XX, 2001, J EUR CERAM SOC, V21, P1367, DOI 10.1016/S0955-2219(01)00020-6
   Wang ZH, 2010, J ELECTROCERAM, V24, P25, DOI 10.1007/s10832-008-9454-x
   Yoo J, 2006, J ELECTROCERAM, V17, P525, DOI 10.1007/s10832-006-8567-3
   Zhang SJ, 2006, MAT SCI ENG B-SOLID, V129, P131, DOI 10.1016/j.mseb.2006.01.001
NR 33
TC 13
Z9 15
U1 1
U2 25
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-7820
EI 1551-2916
J9 J AM CERAM SOC
JI J. Am. Ceram. Soc.
PD OCT
PY 2011
VL 94
IS 10
BP 3386
EP 3390
DI 10.1111/j.1551-2916.2011.04504.x
PG 5
WC Materials Science, Ceramics
SC Materials Science
GA 828SY
UT WOS:000295524300044
DA 2018-03-19
ER

PT J
AU Hines, CS
   Ray, K
   Schmidt, JJ
   Xiong, F
   Feenstra, RW
   Pras-Raves, M
   de Moes, JP
   Lange, JHM
   Melikishvili, M
   Fried, MG
   Mortenson, P
   Charlton, M
   Patel, Y
   Courtney, SM
   Kruse, CG
   Rodgers, DW
AF Hines, Christina S.
   Ray, Kallol
   Schmidt, Jack J.
   Xiong, Fei
   Feenstra, Rolf W.
   Pras-Raves, Mia
   de Moes, Jan Peter
   Lange, Jos H. M.
   Melikishvili, Manana
   Fried, Michael Gregory
   Mortenson, Paul
   Charlton, Michael
   Patel, Yogendra
   Courtney, Stephen M.
   Kruse, Chris G.
   Rodgers, David W.
TI Allosteric Inhibition of the Neuropeptidase Neurolysin
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE Allosteric Regulation; Hydrolase; Metalloprotease; Neurochemistry;
   Neuropeptide; Peptidase; X-ray Crystallography
ID MAST-CELL DEGRANULATION; HINGE-BENDING MOTION; CRYSTAL-STRUCTURE; THIMET
   OLIGOPEPTIDASE; MATRIX METALLOPROTEINASES; COMBINATORIAL CHEMISTRY;
   ENDOPEPTIDASE 3.4.24.16; SELECTIVE INHIBITOR; GLOBULAR-PROTEINS;
   CONVERTING-ENZYME
AB Neuropeptidases specialize in the hydrolysis of the small bioactive peptides that play a variety of signaling roles in the nervous and endocrine systems. One neuropeptidase, neurolysin, helps control the levels of the dopaminergic circuit modulator neurotensin and is a member of a fold group that includes the antihypertensive target angiotensin converting enzyme. We report the discovery of a potent inhibitor that, unexpectedly, binds away from the enzyme catalytic site. The location of the bound inhibitor suggests it disrupts activity by preventing a hinge-like motion associated with substrate binding and catalysis. In support of this model, the inhibition kinetics are mixed, with both noncompetitive and competitive components, and fluorescence polarization shows directly that the inhibitor reverses a substrate-associated conformational change. This new type of inhibition may have widespread utility in targeting neuropeptidases.
C1 [Melikishvili, Manana; Fried, Michael G.] Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA.
   [Melikishvili, Manana; Fried, Michael G.] Univ Kentucky, Struct Biol Ctr, Lexington, KY 40536 USA.
   [Feenstra, Rolf W.; Pras-Raves, Mia; de Moes, Jan Peter; Lange, Jos H. M.; Kruse, Chris G.] Abbott Healthcare Prod BV, NL-1381 CP Weesp, Netherlands.
   [Mortenson, Paul; Charlton, Michael; Patel, Yogendra; Courtney, Stephen M.] Evotec UK Ltd, Abingdon OX14 4SA, Oxon, England.
RP Rodgers, DW (reprint author), 741 South Limestone, Lexington, KY 40536 USA.
EM david.rodgers@uky.edu
OI Mortenson, Paul/0000-0002-3583-3163
FU National Institute of General Medical Sciences [P20 GM103486]
FX We thank the staffs of Advanced Photon Source beamline 19-ID (SBC) and
   beamline 22-ID (SER-CAT) for their help with data collection. Use of the
   Advanced Photon Source is supported by the United States Department of
   Energy. We thank Dr. Louis B. Hersh for comments on the manuscript. Use
   of the Protein Core of the Center for Molecular Medicine was supported
   by Grant P20 GM103486 from the National Institute of General Medical
   Sciences.
CR Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925
   Alexacos N, 1999, UROLOGY, V53, P1035, DOI 10.1016/S0090-4295(98)00627-X
   Arndt JW, 2002, STRUCTURE, V10, P215, DOI 10.1016/S0969-2126(02)00698-6
   BARRETT AJ, 1995, METHOD ENZYMOL, V248, P529
   Bates D.M., 1988, NONLINEAR REGRESSION
   BROOKS I, 1994, METHOD ENZYMOL, V240, P459
   Brown CK, 2001, P NATL ACAD SCI USA, V98, P3127, DOI 10.1073/pnas.051633198
   Brown S, 2004, CURR TOP MED CHEM, V4, P1227, DOI 10.2174/1568026043387854
   Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254
   Burnham KP, 2002, MODEL SELECTION MULT
   CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3
   Chen JM, 2000, J AM CHEM SOC, V122, P9648, DOI 10.1021/ja0001547g
   Cohn EJ, 1943, PROTEINS AMINO ACIDS
   Comellas-Bigier M, 2005, J MOL BIOL, V349, P99, DOI 10.1016/j.jmb.2005.03.016
   Croy CH, 2004, BIOCHEMISTRY-US, V43, P5246, DOI 10.1021/bi0499718
   Cuniasse P, 2005, BIOCHIMIE, V87, P393, DOI 10.1016/j.biochi.2004.09.025
   de la Torre JG, 2000, BIOPHYS J, V78, P719, DOI 10.1016/S0006-3495(00)76630-6
   Dennis MS, 2000, NATURE, V404, P465, DOI 10.1038/35006574
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   ERTL G, 1993, AM J PHYSIOL, V264, pH1062
   Fredrickson P, 2005, PSYCHIAT CLIN N AM, V28, P737, DOI 10.1016/j.psc.2005.05.001
   Fuentes-Prior P, 2000, NATURE, V404, P518, DOI 10.1038/35006683
   Grams F, 1996, NAT STRUCT BIOL, V3, P671, DOI 10.1038/nsb0896-671
   Hardy JA, 2004, P NATL ACAD SCI USA, V101, P12461, DOI 10.1073/pnas.0404781101
   HOLLAND DR, 1992, BIOCHEMISTRY-US, V31, P11310, DOI 10.1021/bi00161a008
   JIRACEK J, 1995, J BIOL CHEM, V270, P21701, DOI 10.1074/jbc.270.37.21701
   Jiracek J, 1996, J BIOL CHEM, V271, P19606, DOI 10.1074/jbc.271.32.19606
   JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224
   Kelder J, 1999, PHARMACEUT RES, V16, P1514, DOI 10.1023/A:1015040217741
   Ketelhuth DFJ, 2011, CURR ATHEROSCLER REP, V13, P162, DOI 10.1007/s11883-010-0159-7
   Kinkead B, 2004, INT REV NEUROBIOL, V59, P327
   Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100
   Konkoy CS, 1996, TRENDS PHARMACOL SCI, V17, P288, DOI 10.1016/0165-6147(96)10036-5
   Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238
   Kuzmic P, 2009, METHOD ENZYMOL, V467, P247, DOI 10.1016/S0076-6879(09)67010-5
   Lamm T., 1929, ARK MAT ASTR FYS B, V21B, P1
   Laue T., 1992, ANAL ULTRACENTRIFUGA, P90
   Lian W, 2000, ACTA CRYSTALLOGR D, V56, P1644, DOI 10.1107/S0907444900012683
   London N, 2011, NUCLEIC ACIDS RES, V39, pW249, DOI 10.1093/nar/gkr431
   LUTTINGER D, 1982, BRAIN RES, V237, P183, DOI 10.1016/0006-8993(82)90566-2
   Malone JF, 1997, J CHEM SOC FARADAY T, V93, P3429, DOI 10.1039/a700669a
   MargetaMitrovic M, 1997, J NEUROPHYSIOL, V78, P1341
   MATTHEWS BW, 1974, J BIOL CHEM, V249, P8030
   Meier Pascal, 2005, Current Drug Targets - Cardiovascular & Haematological Disorders, V5, P15, DOI 10.2174/1568006053004994
   Morales R, 2004, J MOL BIOL, V341, P1063, DOI 10.1016/j.jmb.2004.06.039
   Natesh R, 2004, BIOCHEMISTRY-US, V43, P8718, DOI 10.1021/bi049480n
   Natesh R, 2003, NATURE, V421, P551, DOI 10.1038/nature01370
   NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407
   Oliveira V, 2001, ANAL BIOCHEM, V292, P257, DOI 10.1006/abio.2001.5083
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Pang XZ, 1998, J PHARMACOL EXP THER, V287, P307
   Pytliak M, 2012, ONKOLOGIE, V35, P49, DOI 10.1159/000336304
   Raveh B, 2010, PROTEINS, V78, P2029, DOI 10.1002/prot.22716
   Rawlings ND, 2004, NUCLEIC ACIDS RES, V32, pD160, DOI 10.1093/nar/gkh071
   Ray K, 2004, J BIOL CHEM, V279, P20480, DOI 10.1074/jbc.M400795200
   REICH JG, 1992, CURVE FITTING MODELL
   Rioli V, 1998, BIOCHEM BIOPH RES CO, V250, P5, DOI 10.1006/bbrc.1998.8941
   ROSTENE W, 1992, ANN NY ACAD SCI, V668, P217, DOI 10.1111/j.1749-6632.1992.tb27352.x
   Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0
   Segel I. H., 1993, ENZYME KINETICS BEHA
   Sharma RP, 1997, AM J PSYCHIAT, V154, P1019
   Skiles JW, 2004, CURR MED CHEM, V11, P2911, DOI 10.2174/0929867043364018
   Steiner T, 2001, J MOL BIOL, V305, P535, DOI 10.1006/jmbi.2000.4301
   Towler P, 2004, J BIOL CHEM, V279, P17996, DOI 10.1074/jbc.M311191200
   Tyndall JDA, 2005, CHEM REV, V105, P973, DOI 10.1021/cr040669e
   Verhamme IM, 2002, J BIOL CHEM, V277, P6788, DOI 10.1074/jbc.M110257200
   VINCENT B, 1995, BRIT J PHARMACOL, V115, P1053, DOI 10.1111/j.1476-5381.1995.tb15918.x
   Vincent B, 1997, BRIT J PHARMACOL, V121, P705, DOI 10.1038/sj.bjp.0701182
   WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127
   Wasserman ZR, 2005, CHEM BIOL, V12, P143, DOI 10.1016/j.chembiol.2005.01.008
   Feenstra R. W., 2004, U. S. Patent, Patent No. [2004/0242493, 20040242493]
NR 71
TC 5
Z9 5
U1 0
U2 25
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD DEC 19
PY 2014
VL 289
IS 51
BP 35605
EP 35619
DI 10.1074/jbc.M114.620930
PG 15
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AX0RT
UT WOS:000346660200047
PM 25378390
OA gold
DA 2018-03-20
ER

PT J
AU Wang, ZM
   Meenach, SA
AF Wang, Zimeng
   Meenach, Samantha A.
TI Optimization of Acetalated Dextran-Based Nanocomposite Microparticles
   for Deep Lung Delivery of Therapeutics via Spray-Drying
SO JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE nanocomposite microparticles; pulmonary delivery; design of experiment;
   spray-drying; particle engineering
ID PULMONARY DRUG-DELIVERY; AEROSOL DISPERSION PERFORMANCE;
   RESPONSE-SURFACE METHODOLOGY; CHITOSAN NANOPARTICLES; POWDER INHALATION;
   DRIED MICROPARTICLES; DRYER INLET; PARTICLES; FORMULATION; MICROSPHERES
AB Nanocomposite microparticle (nCmP) systems exhibit promising potential in the application of therapeutics for pulmonary drug delivery. This work aimed at identifying the optimal spray-drying condition(s) to prepare nCmP with specific drug delivery properties including small aerodynamic diameter, effective nanoparticle (NP) redispersion upon nCmP exposure to an aqueous solution, high drug loading, and low water content. Acetalated dextran (Ac-Dex) was used to form NPs, curcumin was used as a model drug, and mannitol was the excipient in the nCmP formulation. Box-Behnken design was applied using Design Expert software for nCmP parameter optimization. NP ratio (NP%) and feed concentration (Fc) are significant parameters that affect the aerodynamic diameters of nCmP systems. NP% is also a significant parameter that affects the drug loading. Fc is the only parameter that influenced the water content of the particles significantly. All nCmP systems could be completely redispersed into the parent NPs, indicating that none of the factors have an influence on this property within the design range. The optimal spray-drying condition to prepare nCmP with a small aerodynamic diameter, redispersion of the NPs, low water content, and high drug loading is 80% NP%, 0.5% Fc, and an inlet temperature lower than 130 degrees C. (C) 2017 American Pharmacists Association (R). Published by Elsevier Inc. All rights reserved.
C1 [Wang, Zimeng; Meenach, Samantha A.] Univ Rhode Isl, Coll Engn, Dept Chem Engn, Kingston, RI 02881 USA.
   [Meenach, Samantha A.] Univ Rhode Isl, Coll Pharm, Dept Biomed & Pharmaceut Sci, Kingston, RI 02881 USA.
RP Meenach, SA (reprint author), Univ Rhode Isl, Coll Engn, Dept Chem Engn, Kingston, RI 02881 USA.; Meenach, SA (reprint author), Univ Rhode Isl, Coll Pharm, Dept Biomed & Pharmaceut Sci, Kingston, RI 02881 USA.
EM smeenach@uri.edu
FU Institutional Development Award (IDeA) from the National Institute of
   General Medical Sciences of the National Institutes of Health
   [P20GM103430]; National Science Foundation EPSCoR [EPS-1004057];
   National Science Foundation [1508868]
FX The authors gratefully acknowledge financial support from an
   Institutional Development Award (IDeA) from the National Institute of
   General Medical Sciences of the National Institutes of Health under
   grant number P20GM103430. The content is solely the responsibility of
   the authors and does not necessarily represent the official views of the
   National Institutes of Health. This material is based upon work
   conducted at a Rhode Island NSF EPSCoR research facility, supported in
   part by the National Science Foundation EPSCoR Cooperative Agreement
   #EPS-1004057. In addition, this material is based in part upon work
   supported by the National Science Foundation under grant number
   #1508868. Any opinions, findings, and conclusions or recommendations
   expressed in this material are those of the authors and do not
   necessarily reflect the view of the National Science Foundation.
   Finally, the authors thank RI-INBRE for UPLC access and RIN2 for SEM,
   DLS, PXRD, and DSC access.
CR Agu RU, 2001, RESPIR RES, V2, P198
   Atalar I, 2015, LWT-FOOD SCI TECHNOL, V60, P751, DOI 10.1016/j.lwt.2014.10.023
   Azarmi S, 2006, INT J PHARM, V319, P155, DOI 10.1016/j.ijpharm.2006.03.052
   Bachelder EM, 2008, J AM CHEM SOC, V130, P10494, DOI 10.1021/ja803947s
   Bailey MM, 2009, MED RES REV, V29, P196, DOI 10.1002/med.20140
   Beck-Broichsitter M, 2012, J CONTROL RELEASE, V158, P329, DOI 10.1016/j.jconrel.2011.10.030
   Broaders KE, 2009, P NATL ACAD SCI USA, V106, P5497, DOI 10.1073/pnas.0901592106
   BUCHI, MIN SPRAY DRYER B 29
   Capan Y, 1999, J CONTROL RELEASE, V60, P279, DOI 10.1016/S0168-3659(99)00076-0
   Cheow WS, 2011, COLLOID SURFACE A, V389, P158, DOI 10.1016/j.colsurfa.2011.08.035
   Cook RO, 2005, J CONTROL RELEASE, V104, P79, DOI 10.1016/j.jconrel.2005.01.003
   Dolovich MB, 2005, CHEST, V127, P335, DOI 10.1378/chest.127.1.335
   Durrigl M, 2011, J MICROENCAPSUL, V28, P108, DOI 10.3109/02652048.2010.535620
   Duret C, 2012, INT J NANOMED, V7, P5475, DOI 10.2147/IJN.S34091
   Ely L, 2007, EUR J PHARM BIOPHARM, V65, P346, DOI 10.1016/j.ejpb.2006.10.021
   Finlay W., ARLA RESP DEPOSITION
   Grenha A, 2005, EUR J PHARM SCI, V25, P427, DOI 10.1016/j.ejps.2005.04.009
   Grenha A, 2007, EUR J PHARM SCI, V31, P73, DOI 10.1016/j.ejps.2007.02.008
   Gu B, 2015, INT J PHARMACEUT, V491, P208, DOI 10.1016/j.ijpharm.2015.06.006
   Hickey AJ, 2009, DELIVERY DRUGS PULMO
   Hickey AJ, 2007, J PHARM SCI-US, V96, P1282, DOI 10.1002/jps.20916
   Jafarinejad S, 2012, POWDER TECHNOL, V222, P65, DOI 10.1016/j.powtec.2012.01.045
   Jensen DMK, 2010, J CONTROL RELEASE, V142, P138, DOI 10.1016/j.jconrel.2009.10.010
   Kauffman KJ, 2012, INT J PHARMACEUT, V422, P356, DOI 10.1016/j.ijpharm.2011.10.034
   Kho K, 2010, POWDER TECHNOL, V203, P432, DOI 10.1016/j.powtec.2010.06.003
   Kilicarslan M, 2014, CURR DRUG DELIV, V11, P98, DOI 10.2174/15672018113109990055
   Kunda NK, 2015, INT J PHARMACEUT, V495, P903, DOI 10.1016/j.ijpharm.2015.09.034
   Kunda NK, 2015, INT J PHARMACEUT, V492, P213, DOI 10.1016/j.ijpharm.2015.07.015
   Labiris NR, 2003, BRIT J CLIN PHARMACO, V56, P588, DOI 10.1046/j.1365-2125.2003.01892.x
   Lai SK, 2009, ADV DRUG DELIVER REV, V61, P158, DOI 10.1016/j.addr.2008.11.002
   Lee WH, 2015, ASIAN J PHARM SCI, V10, P481, DOI 10.1016/j.ajps.2015.08.009
   Li YZ, 2010, PHARM RES-DORDR, V27, P1977, DOI 10.1007/s11095-010-0201-z
   Mansour HM, 2009, INT J NANOMED, V4, P299
   Meenach SA, 2013, EUR J PHARM SCI, V49, P699, DOI 10.1016/j.ejps.2013.05.012
   Mizoe T, 2007, J CONTROL RELEASE, V122, P10, DOI 10.1016/j.jconrel.2007.06.001
   Muralidharan P, 2015, NANOMED-NANOTECHNOL, V11, P1189, DOI 10.1016/j.nano.2015.01.007
   Muzaffar K, 2015, POWDER TECHNOL, V279, P179, DOI 10.1016/j.powtec.2015.04.010
   Ochs M, 2009, GEN THORACIC SURG, P47
   Ohashi K, 2009, J CONTROL RELEASE, V135, P19, DOI 10.1016/j.jconrel.2008.11.027
   Ong HX, 2014, AAPS J, V16, P269, DOI 10.1208/s12248-014-9560-4
   Park CW, 2011, EUR PHARM REV, V1
   Patton JS, 2007, NAT REV DRUG DISCOV, V6, P67, DOI 10.1038/nrd2153
   Pilcer G, 2009, INT J PHARM, V365, P162, DOI 10.1016/j.ijpharm.2008.08.014
   Pourshahab PS, 2011, J MICROENCAPSUL, V28, P605, DOI 10.3109/02652048.2011.599437
   Sham JOH, 2004, INT J PHARM, V269, P457, DOI 10.1016/j.ijpharm.2003.09.041
   Stegemann S, 2013, EUR J PHARM SCI, V48, P181, DOI 10.1016/j.ejps.2012.10.021
   Stocke NA, 2015, INT J PHARMACEUT, V479, P320, DOI 10.1016/j.ijpharm.2014.12.050
   Sung JC, 2007, TRENDS BIOTECHNOL, V25, P563, DOI 10.1016/j.tibtech.2007.09.005
   Sung JC, 2009, PHARM RES-DORD, V26, P1847, DOI 10.1007/s11095-009-9894-2
   Takashima Y, 2007, INT J PHARM, V343, P262, DOI 10.1016/j.ijpharm.2007.05.042
   Tomoda K, 2008, COLLOID SURFACE B, V64, P70, DOI 10.1016/j.colsurfb.2008.01.016
   Tomoda K, 2008, COLLOID SURFACE B, V61, P138, DOI 10.1016/j.colsurfb.2007.07.016
   Ungaro F, 2012, J CONTROL RELEASE, V157, P149, DOI 10.1016/j.jconrel.2011.08.010
   Varshosaz J, 2015, PHARM DEV TECHNOL, V20, P183, DOI 10.3109/10837450.2013.852576
   Vehring R, 2008, PHARM RES, V25, P999, DOI 10.1007/s11095-007-9475-1
   Wang ZM, 2016, INT J PHARMACEUT, V512, P305, DOI 10.1016/j.ijpharm.2016.08.047
   Wang ZM, 2016, PHARM RES-DORDR, V33, P1862, DOI 10.1007/s11095-016-1921-5
   Wu X, 2013, INT J NANOMED, V8, P1269, DOI 10.2147/IJN.S40904
   You Y, 2007, J PHARM PHARMACOL, V59, P927, DOI 10.1211/jpp.59.7.0003
NR 59
TC 0
Z9 0
U1 5
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3549
EI 1520-6017
J9 J PHARM SCI-US
JI J. Pharm. Sci.
PD DEC
PY 2017
VL 106
IS 12
BP 3539
EP 3547
DI 10.1016/j.xphs.2017.07.022
PG 9
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology &
   Pharmacy
SC Pharmacology & Pharmacy; Chemistry
GA FP1AB
UT WOS:000417340700016
PM 28827039
DA 2018-03-20
ER

PT J
AU Xing, R
   Lehmler, HJ
   Knutson, BL
   Rankin, SE
AF Xing, Rong
   Lehmler, Hans-Joachim
   Knutson, Barbara L.
   Rankin, Stephen E.
TI Demixed Micelle Morphology Control in Hydrocarbon/Huorocarbon Cationic
   Surfactant Templating of Mesoporous Silica
SO JOURNAL OF PHYSICAL CHEMISTRY C
LA English
DT Article
ID NONIONIC FLUORINATED SURFACTANT; MCM-41 MOLECULAR-SIEVES; HYDROCARBON
   SURFACTANTS; PHASE-BEHAVIOR; PORE-SIZE; HYDROTHERMAL STABILITY;
   FLUOROCARBON; ADSORPTION; SYSTEM; FLUOROSURFACTANT
AB We report a study of the coassembly behavior of mixed hydrocarbon surfactant cetyltrimethylammoniurn chloride (CTAC) and the fluorocarbon surfactant 1H,1H,2H,1H-perfluorodecylpyridinium chloride (HFDePC) with precipitated silica at room temperature. This pair of surfactants is known to segregate into demixed fluorocarbon-rich and hydrocarbon-rich micelles in dilute solution for a range of compositions. Synthesis parameters (including the molar composition of the surfactant mixture, the ammonia concentration, and the addition of NaCl or ethanol to the initial sols) are varied to show how the mixed or demixed micelles found in dilute aqueous solutions act as templates to form mesoporous silica. Four distinct types of pore structures are found. The first are particles with a single mesopore size and structure whose morphology is influenced by the addition of a second surfactant. Adding HFDePC:PC to CTAC for this series of samples induces a transition from 2D hexagonal mesopores to disordered mesopores to mesh phase pores. At intermediate 1 HFDePC: compositions, large voids (templated by HFDePC vesicles) are introduced. A second class of particles, with a biphasic 2D hexagonal/mesh phase structure, is formed when the amount of ammonia increases. The third class of particles, with separate fluorocarbon and hydrocarbon micelles combined in a single disordered phase. forms when a moderate amount of salt is added, most likely due to a reduction in the rates of coassembly and precipitation. Finally, a sample consisting of two types or particles with differing shape and more structure is prepared by adding ethanol to enhance the rate of precipitation. The conditions explored here Can he used for the design and synthesis of mesoporous silica with controlled pore structures and morphologies.
C1 [Xing, Rong; Knutson, Barbara L.; Rankin, Stephen E.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Lehmler, Hans-Joachim] Univ Iowa, Dept Occupat & Environm Hlth, Iowa City, IA 52242 USA.
RP Rankin, SE (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 FP Anderson Tower, Lexington, KY 40506 USA.
EM srankin@engr.uky.edu
RI Rankin, Stephen/A-3265-2013
OI Rankin, Stephen/0000-0002-8615-7564; Lehmler,
   Hans-Joachim/0000-0001-9163-927X
FU National Science Foundation (NSF) [DMR-0210517, CTS-0348234,
   EAR-0521405]
FX This work is partially supported by the National Science Foundation
   (NSF) under Grant Nos. DMR-0210517, CTS-0348234, and EAR-0521405. We
   thank Dr. Sandhya Vyas for the synthesis of the fluorinated surfactant
   and Dr. Alan Dozier for the assistance with TEM imaging.
CR ALMGREN M, 2005, J PHYS CHEM B, V109, P11345
   Anderson MT, 1998, CHEM MATER, V10, P311, DOI 10.1021/cm9704600
   Areva S, 2004, CHEM COMMUN, P1630, DOI 10.1039/b405690f
   ASAKAWA T, 1991, LANGMUIR, V7, P2112, DOI 10.1021/la00058a025
   Asakawa T, 1996, LANGMUIR, V12, P1204, DOI 10.1021/la950758+
   ASAKAWA T, 1995, LANGMUIR, V11, P478, DOI 10.1021/la00002a019
   Blin JL, 2006, J COLLOID INTERF SCI, V302, P643, DOI 10.1016/j.jcis.2006.07.002
   Blin JL, 2006, MICROPOR MESOPOR MAT, V94, P74, DOI 10.1016/j.micromeso.2006.03.023
   Blin JL, 2005, STUD SURF SCI CATAL, V156, P97
   Blin JL, 2005, MICROPOR MESOPOR MAT, V87, P67, DOI 10.1016/j.micromeso.2005.06.041
   Blin JL, 2004, J PHYS CHEM B, V108, P11399, DOI 10.1021/jp049379s
   Blin JL, 2004, LANGMUIR, V20, P491, DOI 10.1021/la035834k
   Brunauer S, 1938, J AM CHEM SOC, V60, P309, DOI 10.1021/ja01269a023
   Calabro DC, 1996, MICROPOROUS MATER, V7, P243, DOI 10.1016/S0927-6513(96)00045-4
   Chen FX, 1997, CHEM MATER, V9, P2685, DOI 10.1021/cm9703942
   Djojoputro H, 2006, J AM CHEM SOC, V128, P6320, DOI 10.1021/ja0607537
   Ghosh K, 2005, LANGMUIR, V21, P6145, DOI 10.1021/la050311t
   Groenewolt M, 2004, LANGMUIR, V20, P7811, DOI 10.1021/la049147k
   Han Y, 2005, ANGEW CHEM INT EDIT, V44, P288, DOI 10.1002/anie.200460892
   Hillmyer MA, 2002, J POLYM SCI POL CHEM, V40, P1, DOI 10.1002/pola.10074
   Hind AR, 1997, LANGMUIR, V13, P6255, DOI 10.1021/la970559l
   Hoffmann H, 1997, J MOL LIQ, V72, P191, DOI 10.1016/S0167-7322(97)00039-1
   IKARI K, 2004, LANGMUIR, V20, P7811
   IMAE T, 1987, COLLOID POLYM SCI, V265, P1090, DOI 10.1007/BF01417467
   Innocenzi P, 2003, J NON-CRYST SOLIDS, V316, P309, DOI 10.1016/S0022-3093(02)01637-X
   Jaroniec M, 1999, LANGMUIR, V15, P5410, DOI 10.1021/la990136e
   Kadi M, 2002, LANGMUIR, V18, P9243, DOI 10.1021/la020579+
   Kissa E., 2001, FLUORINATED SURFACTA
   Kruk M, 1997, LANGMUIR, V13, P6267, DOI 10.1021/la970776m
   Li DF, 2004, CHEM-EUR J, V10, P5911, DOI 10.1002/chem.200400188
   Liu S, 2005, STUD SURF SCI CATAL, V156, P379
   Liu SQ, 2003, J PHYS CHEM B, V107, P10405, DOI 10.1021/jp034410w
   Magid LJ, 1997, J PHYS CHEM B, V101, P7919, DOI 10.1021/jp970864f
   MATHIS G, 1984, J AM CHEM SOC, V106, P6162, DOI 10.1021/ja00333a007
   MATSUMOTO M, 2000, COLLOIS POLYM SCI, V273, P619
   Pang JB, 2004, CHEM COMMUN, P682, DOI 10.1039/b316501a
   Pena ML, 2001, MICROPOR MESOPOR MAT, V44, P9, DOI 10.1016/S1387-1811(01)00163-9
   Rankin SE, 2004, MICROPOR MESOPOR MAT, V73, P197, DOI 10.1016/j.micromeso.2004.05.013
   RAVEY JC, 1989, PROG COLL POL SCI S, V79, P272
   RAVEY JC, 1987, PROGR COLLOID POLYM, V73, P127
   Romsted LS, 2007, LANGMUIR, V23, P414, DOI 10.1021/la062411k
   Rothlisberger U, 1996, J CHEM PHYS, V104, P3692
   Ryoo R, 1996, J PHYS CHEM-US, V100, P17718, DOI 10.1021/jp9620835
   Sayari A, 1997, CHEM MATER, V9, P2499, DOI 10.1021/cm970128o
   SCHERER BL, 1991, OPERA NEWS, V55, P11
   Sen T, 2004, CHEM MATER, V16, P2044, DOI 10.1021/cm034946u
   SING KSW, 1985, PURE APPL CHEM, V57, P607
   Song MG, 2002, LANGMUIR, V18, P6110, DOI 10.1021/la011691v
   Sprik M, 1999, MOL PHYS, V97, P355, DOI 10.1080/00268979909482837
   TAMORI K, 1991, J COLLOID INTERF SCI, V142, P236, DOI 10.1016/0021-9797(91)90051-9
   Tan B, 2005, ADV MATER, V17, P2368, DOI 10.1002/adma.200500344
   Tan B, 2005, J PHYS CHEM B, V109, P23225, DOI 10.1021/jp054219h
   Tan B, 2005, CHEM MATER, V17, P916, DOI 10.1021/cm048991t
   Tan B, 2004, LANGMUIR, V20, P6981, DOI 10.1021/la049474s
   TAN B, 2005, NANOTECHNOLOGY, V16, P502
   Tsao MW, 1997, LANGMUIR, V13, P4317, DOI 10.1021/la970293i
   Valle K, 2006, NAT MATER, V5, P107, DOI 10.1038/nmat1570
   VARTULI JC, 1994, CHEM MATER, V6, P2317, DOI 10.1021/cm00048a018
   Wang K, 2000, LANGMUIR, V16, P1042, DOI 10.1021/la9909603
   XING R, 2009, LANGMUIR, V23, P6486
   Yu J, 2001, MICROPOR MESOPOR MAT, V46, P153, DOI 10.1016/S1387-1811(01)00269-4
   Zhang Q, 2003, STUD SURF SCI CATAL, V146, P465
NR 62
TC 2
Z9 2
U1 1
U2 28
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1932-7447
J9 J PHYS CHEM C
JI J. Phys. Chem. C
PD OCT 21
PY 2010
VL 114
IS 41
BP 17390
EP 17400
DI 10.1021/jp1051563
PG 11
WC Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science,
   Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA 663AM
UT WOS:000282855400020
DA 2018-03-20
ER

PT J
AU Ponta, A
   Bae, Y
AF Ponta, Andrei
   Bae, Younsoo
TI Tumor-preferential sustained drug release enhances antitumor activity of
   block copolymer micelles
SO JOURNAL OF DRUG TARGETING
LA English
DT Article
DE Acid-labile linkers; doxorubicin; drug delivery; hydrazone;
   nanoparticles; pH-controlled drug release
ID IN-VIVO; POLYMERIC MICELLES; CANCER-CELLS; DELIVERY; PH; CYTOTOXICITY;
   MICROENVIRONMENT; BIODISTRIBUTION; NANOASSEMBLIES; NANOTECHNOLOGY
AB Nanoparticles are widely used as drug carriers for controlled, tumor-targeted delivery of various anticancer agents that have biopharmaceutical limitations such as water solubility and tissue permeability. Growing evidence suggests that nanoparticles not only reduce toxic side effects of anticancer drugs but also improve the therapeutic efficacy as a function of their drug-release profile. The purpose of this study is to confirm such hypothetical effects of tunable drug release on improving antitumor activity of nanoparticles in vitro and in vivo, using block copolymer micelles as drug carriers. Micelles were prepared from poly(ethylene glycol)-poly(aspartate) block copolymers modified with hydrazide (HYD), aminobenzoate hydrazide (ABZ) and glycine hydrazide (GLY) linkers to achieve a pH-dependent, tunable release of doxorubicin (DOX), a model anticancer drug. Regardless of the drug-release profile, all three micelles showed similar properties in vitro, such as pH-dependent drug release, intracellular drug delivery and cancer cell growth inhibition. However, micelles releasing DOX slowly in vitro showed that the most effective antitumor activity in vivo, compared to the micelles releasing drugs faster. These results demonstrate that tumor-preferential sustained drug release can enhance the antitumor activity of the micelles.
C1 [Ponta, Andrei; Bae, Younsoo] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
RP Bae, Y (reprint author), Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, 789 South Limestone, Lexington, KY 40536 USA.
EM younsoo.bae@uky.edu
FU Kentucky Lung Cancer Research Program
FX The authors report no declarations of interest. This study was supported
   by the Kentucky Lung Cancer Research Program. The authors acknowledge Dr
   Pengxiao Cao for his technical support in performing the in vivo study.
CR Akter S, 2012, PHARM RES-DORDR, V29, P847, DOI 10.1007/s11095-011-0613-4
   Bae Y, 2005, MOL BIOSYST, V1, P242, DOI 10.1039/b500266d
   Bae Y, 2003, ANGEW CHEM INT EDIT, V42, P4640, DOI 10.1002/anie.200250653
   Bae Y, 2005, BIOCONJUGATE CHEM, V16, P122, DOI 10.1021/bc0498166
   Bae Y, 2007, BIOCONJUGATE CHEM, V18, P1131, DOI 10.1021/bc060401p
   Bae Y, 2009, ADV DRUG DELIVER REV, V61, P768, DOI 10.1016/j.addr.2009.04.016
   Bareford LA, 2007, ADV DRUG DELIVER REV, V59, P748, DOI 10.1016/j.addr.2007.06.008
   Becelli R, 2007, J CRANIOFAC SURG, V18, P1051, DOI 10.1097/scs.0b013e3180de63eb
   Binauld S, 2013, CHEM COMMUN, V49, P2082, DOI 10.1039/c2cc36589h
   Cao P, 2012, J APPL PHARM SCI, V2, P1, DOI DOI 10.7324/JAPS.2012.2901
   Caron J, 2013, ADV HEALTHC MATER, V2, P172, DOI 10.1002/adhm.201200099
   Crommelin DJA, 2010, J CONTROL RELEASE, V141, P263, DOI 10.1016/j.jconrel.2009.11.019
   Cukierman E, 2010, BIOCHEM PHARMACOL, V80, P762, DOI 10.1016/j.bcp.2010.04.020
   Decuzzi P, 2010, J CONTROL RELEASE, V141, P320, DOI 10.1016/j.jconrel.2009.10.014
   Duncan R, 2003, NAT REV DRUG DISCOV, V2, P347, DOI 10.1038/nrd1088
   Duncan R, 2012, MOL PHARMACEUT, V9, P2380, DOI 10.1021/mp300293n
   Eckman AM, 2012, PHARM RES-DORDR, V29, P1755, DOI 10.1007/s11095-012-0697-5
   Forrest ML, 2002, MOL THER, V6, P57, DOI 10.1006/mthe.2002.0631
   Fukumura D, 2010, MICROCIRCULATION, V17, P206, DOI 10.1111/j.1549-8719.2010.00029.x
   Hillaireau H, 2009, CELL MOL LIFE SCI, V66, P2873, DOI 10.1007/s00018-009-0053-z
   Jain R, 2011, AM J NEURORADIOL, V32, P388, DOI 10.3174/ajnr.A2280
   Jain RK, 2002, NAT REV CANCER, V2, P266, DOI 10.1038/nrc778
   KANEKO T, 1991, BIOCONJUGATE CHEM, V2, P133, DOI 10.1021/bc00009a001
   Lee ES, 2008, J CONTROL RELEASE, V132, P164, DOI 10.1016/j.jconrel.2008.05.003
   Lee HJ, 2013, PHARM RES-DORDR, V30, P478, DOI 10.1007/s11095-012-0893-3
   MAEDA H, 1989, CRIT REV THER DRUG, V6, P193
   Mahon E, 2012, J CONTROL RELEASE, V161, P164, DOI 10.1016/j.jconrel.2012.04.009
   Min KH, 2012, BIOMATERIALS, V33, P5788, DOI 10.1016/j.biomaterials.2012.04.057
   Musacchio T, 2011, FRONT BIOSCI-LANDMRK, V16, P1388, DOI 10.2741/3795
   Ostman A, 2012, NAT MED, V18, P1332, DOI 10.1038/nm.2938
   Ponta A, 2010, PHARM RES-DORDR, V27, P2330, DOI 10.1007/s11095-010-0120-z
   Rubin EH, 2012, NAT REV CLIN ONCOL, V9, P215, DOI 10.1038/nrclinonc.2012.22
   Ruenraroengsak P, 2010, J CONTROL RELEASE, V141, P265, DOI 10.1016/j.jconrel.2009.10.032
   Sauvant C, 2008, INT J CANCER, V123, P2532, DOI 10.1002/ijc.23818
   Scott D, 2011, INT J NANOMED, V6, P2757, DOI 10.2147/IJN.S25427
   Siegel R, 2012, CA-CANCER J CLIN, V62, DOI [10.3322/caac.21153, 10.3322/caac.21149, 10.3322/caac.20138]
   Veronese FM, 2005, BIOCONJUGATE CHEM, V16, P775, DOI 10.1021/bc040241m
   West Kevin R, 2005, Curr Drug Discov Technol, V2, P123, DOI 10.2174/1570163054866882
   Wojtkowiak JW, 2011, MOL PHARMACEUT, V8, P2032, DOI 10.1021/mp200292c
   Zhang XM, 2010, J NUCL MED, V51, P1167, DOI 10.2967/jnumed.109.068981
NR 40
TC 8
Z9 8
U1 2
U2 12
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1061-186X
EI 1029-2330
J9 J DRUG TARGET
JI J. Drug Target.
PD AUG
PY 2014
VL 22
IS 7
BP 619
EP 628
DI 10.3109/1061186X.2014.910793
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA AM4DW
UT WOS:000339804000008
PM 24766185
DA 2018-03-19
ER

PT J
AU Long, SH
   Siegler, M
   Li, T
AF Long, Sihui
   Siegler, Maxime A.
   Li, Tonglei
TI 2,4,6-Trimethylanilinium chloride
SO ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS
LA English
DT Article
AB The title compound, C9H14N+center dot Cl-, is a hydrochloric acid salt of 2,4,6-trimethylaniline. In the crystal structure, all the hydrogen-bond donors and acceptors are involved in hydrogen bonds. The packing can be described as columns, two ion-pairs wide, propagating along the a axis. The columns are formed through N-H center dot center dot center dot Cl hydrogen bonds linking pairs of cations and anions around centers of symmetry and further connecting these pairs in the [ 100] direction. In addition, the aromatic rings on each side of the columns are stacked above each other, indicating pi-pi stacking ( the distance between aromatic rings is 4.811 angstrom).
C1 Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40506 USA.
   Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
RP Li, TL (reprint author), Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40506 USA.
EM tonglei@uky.edu
CR *NON, 2002, COLLECT
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Sheldrick G. M., 1997, SHELXL97 SHELXS97
   SHELDRICK GM, 1995, XP SHELXTL PC
   TING PC, 1990, J MED CHEM, V33, P2697, DOI 10.1021/jm00172a004
NR 5
TC 2
Z9 2
U1 0
U2 7
PU INT UNION CRYSTALLOGRAPHY
PI CHESTER
PA 2 ABBEY SQ, CHESTER, CH1 2HU, ENGLAND
SN 2056-9890
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Crystallogr. Commun.
PD JUL
PY 2007
VL 63
BP O3080
EP U2373
DI 10.1107/S1600536807025718
PN 7
PG 9
WC Crystallography
SC Crystallography
GA 191RP
UT WOS:000248149900224
DA 2018-03-20
ER

PT J
AU Howard, MD
   Lu, XL
   Jay, M
   Dziubla, TD
AF Howard, Melissa D.
   Lu, Xiuling
   Jay, Michael
   Dziubla, Thomas D.
TI Optimization of the lyophilization process for long-term stability of
   solid-lipid nanoparticles
SO DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY
LA English
DT Article
DE Lyoprotectant; sucrose; storage; particle size; drug loading
ID ANTIINFLAMMATORY AGENTS; CHEMOTHERAPY ADJUVANTS; AQUEOUS-SOLUTIONS;
   FREEZING RATE; DRUG; SLN; SUSPENSIONS; FORMULATION; PALMITATE; DELIVERY
AB Objectives: To optimize a lyophilization protocol for solid-lipid nanoparticles (SLNs) loaded with dexamethasone palmitate (Dex-P) and to compare the long-term stability of lyophilized SLNs and aqueous SLN suspensions at two storage conditions.
   Materials and Methods: The effect of various parameters of the lyophilization process on SLN redispersibility was evaluated. A three month stability study was conducted to compare changes in the particle size and drug loading of lyophilized SLNs with SLNs stored as aqueous suspensions at either 4 degrees C or 25 degrees C/60% relative humidity (RH).
   Results and Discussion: Of nine possible lyoprotectants tested, sucrose was shown to be the most efficient at achieving SLN redispersibility. Higher freezing temperatures, slower freezing rates, and longer secondary drying times were also shown to be beneficial. Loading of the SLNs with Dex-P led to slightly larger particle size and polydispersity index increases, but both parameters remained within an acceptable range. Drug loading and particle shape were maintained following lyophilization, and no large aggregates were detected. During the stability study, significant growth and drug loss were observed for aqueous SLN suspensions stored at 25 degrees C/60% RH. In comparison, lyophilized SLNs stored at 4 degrees C exhibited a consistent particle size and showed <20% drug loss. Other storage conditions led to intermediate results.
   Conclusions: A lyophilization protocol was developed that allowed SLNs to be reconstituted with minimal changes in their physicochemical properties. During a three month period, lyophilized SLNs stored at 4 degrees C exhibited the greatest stability, showing no change in the particle size and a minimal reduction in drug retention.
C1 [Dziubla, Thomas D.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Howard, Melissa D.] Univ Kentucky, Dept Pharmaceut Sci, Coll Pharm, Lexington, KY 40506 USA.
   [Lu, Xiuling] Univ Connecticut, Dept Pharmaceut Sci, Sch Pharm, Storrs, CT USA.
   [Jay, Michael] Univ N Carolina, Div Mol Pharmaceut, Eshelman Sch Pharm, Chapel Hill, NC USA.
   [Jay, Michael] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
RP Dziubla, TD (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 F Paul Anderson Tower, Lexington, KY 40506 USA.
EM Dziubla@engr.uky.edu
FU NSF IGERT program [DGE-06537]; Philanthropic Educational Organization
   Scholar Award; University of Kentucky Dissertation Year Fellowship
FX The authors are grateful for financial support from the NSF IGERT
   program through grant DGE-06537 as well as from a Philanthropic
   Educational Organization Scholar Award and a University of Kentucky
   Dissertation Year Fellowship (MDH).
CR Abdelwahed W, 2006, ADV DRUG DELIVER REV, V58, P1688, DOI 10.1016/j.addr.2006.09.017
   Awad TS, 2009, CRYST GROWTH DES, V9, P3405, DOI 10.1021/cg8011684
   Bochkova O D, 2011, Journal of Physics: Conference Series, V291, DOI 10.1088/1742-6596/291/1/012038
   Bunjes H, 1996, INT J PHARM, V129, P159, DOI 10.1016/0378-5173(95)04286-5
   Carlotti ME, 2009, J DISPER SCI TECHNOL, V30, P1517, DOI 10.1080/01932690903123726
   Choi KY, 2011, BIOMATERIALS, V32, P1880, DOI 10.1016/j.biomaterials.2010.11.010
   Cui ZR, 2003, DRUG DEV IND PHARM, V29, P689, DOI 10.1081/DDC-120021318
   De Jaeghere F, 2000, PHARM DEV TECHNOL, V5, P473, DOI 10.1081/PDT-100102031
   deChasteigner S, 1996, DRUG DEVELOP RES, V38, P116, DOI 10.1002/(SICI)1098-2299(199606)38:2<116::AID-DDR6>3.0.CO;2-M
   GREENSPAN L, 1977, J RES NBS A PHYS CH, V81, P89, DOI 10.6028/jres.081A.011
   Gura KM, 2009, NUTR CLIN PRACT, V24, P709, DOI 10.1177/0884533609351318
   Heiati H, 1998, J MICROENCAPSUL, V15, P173, DOI 10.3109/02652049809006847
   Hobbs SK, 1998, P NATL ACAD SCI USA, V95, P4607, DOI 10.1073/pnas.95.8.4607
   Jenning V, 2000, INT J PHARM, V196, P219, DOI 10.1016/S0378-5173(99)00426-3
   Kamiya S, 2006, CHEM PHARM BULL, V54, P181, DOI 10.1248/cpb.54.181
   Kristl J, 2003, EUR J PHARM SCI, V19, P181, DOI 10.1016/S0928-0987(03)00104-0
   Lee J, 2006, J CONTROL RELEASE, V111, P185, DOI 10.1016/j.jconrel.2005.12.003
   Lee MK, 2009, J PHARM SCI-US, V98, P4808, DOI 10.1002/jps.21786
   Lim SJ, 2002, INT J PHARM, V243, P135, DOI 10.1016/S0378-5173(02)00269-7
   Lu XL, 2008, AAPS J, V10, P133, DOI 10.1208/s12248-008-9013-z
   Lu XL, 2009, AAPS J, V11, P120, DOI 10.1208/s12248-009-9086-3
   Muller RH, 2000, EUR J PHARM BIOPHARM, V50, P161, DOI 10.1016/S0939-6411(00)00087-4
   Mumper RJ, 2003, J DISPER SCI TECHNOL, V24, P569, DOI 10.1081/DIS-120021814
   NANGO M, 1980, J CHEM SOC CHEM COMM, P104, DOI 10.1039/c39800000104
   Ohshima H, 2009, INT J PHARMACEUT, V377, P180, DOI 10.1016/j.ijpharm.2009.05.004
   Sameti M, 2003, INT J PHARM, V266, P51, DOI 10.1016/S0378-5173(03)00380-6
   Schwarz C, 1997, INT J PHARM, V157, P171, DOI 10.1016/S0378-5173(97)00222-6
   Subramanian S, 2010, CANCER BIOTHER RADIO, V25, P637, DOI 10.1089/cbr.2010.0817
   Varshosaz J, 2011, PHARM DEV TECHNOL, V16, P529, DOI 10.3109/10837450.2010.502175
   Westesen K, 1997, J CONTROL RELEASE, V48, P223, DOI 10.1016/S0168-3659(97)00046-1
   Westesen K, 1997, INT J PHARM, V151, P35, DOI 10.1016/S0378-5173(97)04890-4
   WILLIAMS N A, 1984, Journal of Parenteral Science and Technology, V38, P48
   Yen FL, 2010, J AGR FOOD CHEM, V58, P7376, DOI 10.1021/jf100135h
NR 33
TC 11
Z9 11
U1 1
U2 23
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0363-9045
J9 DRUG DEV IND PHARM
JI Drug Dev. Ind. Pharm.
PD OCT
PY 2012
VL 38
IS 10
BP 1270
EP 1279
DI 10.3109/03639045.2011.645835
PG 10
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 004BI
UT WOS:000308654700013
PM 22235767
DA 2018-03-20
ER

PT J
AU Mattei, A
   Li, TL
AF Mattei, Alessandra
   Li, Tonglei
TI Nucleation of Conformational Polymorphs: A Computational Study of
   Tolfenamic Acid by Explicit Solvation
SO CRYSTAL GROWTH & DESIGN
LA English
DT Article
ID MOLECULAR-CONFORMATION; CRYSTAL NUCLEATION; ORGANIC-CHEMISTRY; TETROLIC
   ACID; SOLID-STATE; ASSOCIATION
AB The nucleation mechanism of polymorph formation remains poorly understood. For conformational polymorphism, the nature and strength of molecular interactions influence the conformation of a molecule, and such interplay between conformation and intermolecular interaction likely plays out through the self-assembling process of nucleation governing the outcome of resultant crystal structures. This study investigates molecular interactions and structural properties of a conformationally flexible molecule, tolfenamic acid, in explicit solvent by means of molecular dynamics and combined quantum mechanics and molecular mechanics methods. The results point out that tolfenamic acid prefers to take a relatively flat conformation, stabilized by intermolecular interactions between the solute and solvent molecules. Tolfenamic acid molecules can also adopt a more twisted conformation in a homodimeric state which exhibits lower solvation energy but greater stability. The computational work unravels the important influence by intermolecular interactions-between the solute and solvent or between the solute and solute- on stabilizing the conformation of solute molecules and, thus, highlights the underlying cooperation between a molecule's conformation and its intermolecular interaction leading to the nucleation of distinct polymorphic structures.
C1 [Mattei, Alessandra] Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
   [Li, Tonglei] Purdue Univ, Dept Ind & Phys Pharm, W Lafayette, IN 47907 USA.
RP Li, TL (reprint author), Purdue Univ, Dept Ind & Phys Pharm, W Lafayette, IN 47907 USA.
EM tonglei@purdue.edu
FU NSF [DMR-1006364]
FX The authors thank Allen Chao Endowment Fund. The research was supported
   by NSF (DMR-1006364).
CR BERNSTEIN J, 1978, J AM CHEM SOC, V100, P673, DOI 10.1021/ja00471a001
   BROCK CP, 1989, J AM CHEM SOC, V111, P4586, DOI 10.1021/ja00195a010
   BYRN SR, 1986, J PHARM SCI, V75, P596, DOI 10.1002/jps.2600750615
   BYRN SR, 1976, J ORG CHEM, V41, P2283, DOI 10.1021/jo00875a015
   Cruz-Cabeza AJ, 2014, CHEM REV, V114, P2170, DOI 10.1021/cr400249d
   Erdemir D, 2009, ACCOUNTS CHEM RES, V42, P621, DOI 10.1021/ar800217x
   ETTER MC, 1991, J PHYS CHEM-US, V95, P4601, DOI 10.1021/j100165a007
   Gao JL, 1996, ACCOUNTS CHEM RES, V29, P298, DOI 10.1021/ar950140r
   Gavezzotti A, 1997, CHEM-EUR J, V3, P893, DOI 10.1002/chem.19970030610
   HAGLER AT, 1978, J AM CHEM SOC, V100, P6349, DOI 10.1021/ja00488a012
   Mattei A, 2013, CRYST GROWTH DES, V13, P3303, DOI 10.1021/cg401026j
   Mattei A, 2012, PHARM RES-DORDR, V29, P460, DOI 10.1007/s11095-011-0574-7
   Mattei A, 2011, INT J PHARMACEUT, V418, P179, DOI 10.1016/j.ijpharm.2011.04.062
   MIGLIACCIO GP, 1981, J PHARM SCI, V70, P284, DOI 10.1002/jps.2600700315
   Parveen S, 2005, CHEM COMMUN, P1531, DOI 10.1039/b418603f
   Uzoh OG, 2012, CRYST GROWTH DES, V12, P4230, DOI 10.1021/cg3007348
   Vekilov PG, 2010, CRYST GROWTH DES, V10, P5007, DOI 10.1021/cg1011633
   Vekilov PG, 2004, CRYST GROWTH DES, V4, P671, DOI 10.1021/cg049977w
   Weissbuch I, 2003, CRYST GROWTH DES, V3, P125, DOI 10.1021/cg0200560
   Yu L, 2000, ORG PROCESS RES DEV, V4, P396, DOI 10.1021/op000028v
NR 20
TC 4
Z9 4
U1 3
U2 39
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1528-7483
EI 1528-7505
J9 CRYST GROWTH DES
JI Cryst. Growth Des.
PD JUN
PY 2014
VL 14
IS 6
BP 2709
EP 2713
DI 10.1021/cg5000815
PG 5
WC Chemistry, Multidisciplinary; Crystallography; Materials Science,
   Multidisciplinary
SC Chemistry; Crystallography; Materials Science
GA AI6WY
UT WOS:000337018900003
DA 2018-03-20
ER

PT J
AU Tyagi, P
   Li, DF
   Holmes, SM
   Hinds, BJ
AF Tyagi, Pawan
   Li, Dongfeng
   Holmes, Stephen M.
   Hinds, Bruce J.
TI Molecular electrodes at the exposed edge of metal/insulator/metal
   trilayer structures
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article
ID SELF-ASSEMBLED MONOLAYERS; JUNCTIONS; ALKANETHIOLS; LITHOGRAPHY;
   CONDUCTANCE; TRANSISTORS; CIRCUITS; QUANTUM
AB Producing reliable electrical contacts of molecular dimensions has been a critical challenge in the field of molecule-based electronics. Conventional thin film deposition and photolithography techniques have been utilized to construct novel nanometer-sized electrodes on the exposed vertical plane on the edge of a thin film multilayer structure (metal/insulator/metal). Via thiol surface attachment to metal leads, an array of paramagnetic, cyanide-bridged octametal complexes, [(pzTp)Fe-III(CN)(3)](4)[Ni-II(L)](4)[O3SCF3](4) (1) [(pzTp) = tetra(pyrazol-1-yl)borate; L = 1-S(acetyl)tris(pyrazolyl)decane], were covalently linked onto the electrodes forming a dominant conduction pathway. A series of molecule-based devices were fabricated using Ni, NiFe, Ta, and Au as metal electrodes separated by insulating Al2O3 spacers, followed by treatment with 1. A series of control experiments were also performed to demonstrate that the conduction path was through tethered metal clusters. The molecular current was analyzed via the Simmons tunnel model, and calculations are consistent with electron tunneling through the alkane ethers to the central metal core. With a Ni/Al2O3/Au molecular electrode, the tether binding was found to be reversible to the top Au layer, allowing for a new class of chemical detection based on the steric bulk of coordinating analytes to disconnect the molecular current path. Simple and economical photolithography/liftoff/self-assembly fabrication techniques afford robust molecular junctions with high reproducibility (> 90%) and long operational lifetimes (> 1 year).
C1 Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   Univ Kentucky, Ctr Nanoscale Sci & Engn, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
RP Hinds, BJ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM bjhinds@engr.uky.edu
RI LI, Dongfeng/F-9558-2015
OI Tyagi, Pawan/0000-0002-7541-1344
CR Akkerman HB, 2006, NATURE, V441, P69, DOI 10.1038/nature04699
   Anariba F, 2002, J PHYS CHEM B, V106, P10355, DOI 10.1021/jp026285e
   AVERIN DV, 1990, PHYS REV LETT, V65, P2446, DOI 10.1103/PhysRevLett.65.2446
   AVIRAM A, 1974, CHEM PHYS LETT, V29, P277, DOI 10.1016/0009-2614(74)85031-1
   Beckman R, 2005, SCIENCE, V310, P465, DOI 10.1126/science.1114757
   BERG J, 2005, APPL PHYS LETT, V87, P22
   Chen J, 1999, SCIENCE, V286, P1550, DOI 10.1126/science.286.5444.1550
   Collier CP, 1999, SCIENCE, V285, P391, DOI 10.1126/science.285.5426.391
   Cui XD, 2002, NANOTECHNOLOGY, V13, P5, DOI 10.1088/0957-4484/13/1/302
   Di Ventra M, 2000, APPL PHYS LETT, V76, P3448, DOI 10.1063/1.126673
   Dirk SM, 2005, NANOTECHNOLOGY, V16, P1983, DOI 10.1088/0957-4484/16/10/001
   Dorneles LS, 2002, J APPL PHYS, V91, P7971, DOI 10.1063/1.1452234
   Gittins DI, 2000, NATURE, V408, P67
   GOSSNER H, 1995, ELECTRON LETT, V31, P1394, DOI 10.1049/el:19950890
   Inman CE, 2004, LANGMUIR, V20, P9144, DOI 10.1021/la049627b
   Jeon DM, 2004, J MAGN MAGN MATER, V272, P1956, DOI 10.1016/j.jmmm.2003.12.1196
   Li DF, 2006, J AM CHEM SOC, V128, P4214, DOI 10.1021/ja058626i
   Li DF, 2006, INORG CHEM, V45, P7569, DOI 10.1021/ic060695q
   Liang WJ, 2002, NATURE, V417, P725, DOI 10.1038/nature00790
   Lide D. R., CRC HDB CHEM PHYS
   Maya F, 2004, CHEM MATER, V16, P2987, DOI 10.1021/cm049504c
   Mbindyo JKN, 2002, J AM CHEM SOC, V124, P4020, DOI 10.1021/ja016696t
   Mekhalif Z, 2003, LANGMUIR, V19, P637, DOI 10.1021/la020332c
   Melosh NA, 2003, SCIENCE, V300, P112, DOI 10.1126/science.1081940
   MOODERA JS, 1988, PHYS REV LETT, V61, P637, DOI 10.1103/PhysRevLett.61.637
   Park CS, 2003, J MAGN MAGN MATER, V267, P281, DOI 10.1016/S0304-8853(03)00382-2
   Park J, 2002, NATURE, V417, P722, DOI 10.1038/nature00791
   Piccinin S, 2003, J CHEM PHYS, V119, P6729, DOI 10.1063/1.1602057
   Qin LD, 2005, SCIENCE, V309, P113, DOI 10.1126/science.1112666
   Reed MA, 1997, SCIENCE, V278, P252, DOI 10.1126/science.278.5336.252
   RICCO B, 1984, PHYS REV B, V29, P1970, DOI 10.1103/PhysRevB.29.1970
   Ruan CM, 2002, THIN SOLID FILMS, V419, P95, DOI 10.1016/S0040-6090(02)00730-7
   SIMMONS JG, 1963, J APPL PHYS, V34, P1793, DOI 10.1063/1.1702682
   Song YS, 2004, ELECTROCHEM SOLID ST, V7, pC64, DOI 10.1149/1.1652423
   WANG WY, 2003, PHYS REV B, V68, P3
   Yu LH, 2004, NANO LETT, V4, P79, DOI 10.1021/nl034893f
NR 36
TC 25
Z9 25
U1 1
U2 15
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD APR 25
PY 2007
VL 129
IS 16
BP 4929
EP 4938
DI 10.1021/ja065789d
PG 10
WC Chemistry, Multidisciplinary
SC Chemistry
GA 158HQ
UT WOS:000245782800030
PM 17391029
DA 2018-03-20
ER

PT J
AU Hayes, D
   Younger, BR
   Mansour, HM
   Strawbridge, H
AF Hayes, Don, Jr.
   Younger, Bradley R.
   Mansour, Heidi M.
   Strawbridge, Heather
TI Precordial Catch Syndrome in Elite Swimmers With Asthma
SO PEDIATRIC EMERGENCY CARE
LA English
DT Article
DE asthma; elite; precordial catch syndrome; swimmer
ID CHEST-PAIN; CHILDREN
AB Precordial catch syndrome is a benign cause of chest pain in children and adolescents that remains underrecognized. Because of distinctive symptoms, precordial catch syndrome is not necessarily a diagnosis of exclusion. However, a detailed history eliciting diagnostic features is important, along with a physical examination excluding other pathologic disorders. We present the cases of 2 elite swimmers with asthma who had acute episodes of precordial catch syndrome, one associated with an acute asthma exacerbation and one not, while swimming during competitive swim meets that required rescue efforts for both and eventual evaluation in the emergency department.
C1 [Hayes, Don, Jr.] Ohio State Univ, Coll Med, Nationwide Childrens Hosp, Dept Pediat, Columbus, OH 43210 USA.
   [Younger, Bradley R.] Univ Kentucky, Univ Studies Program, Lexington, KY USA.
   [Mansour, Heidi M.] Univ Arizona, Tucson Coll Pharm, Skaggs Ctr Pharmaceut Sci, Tucson, AZ 85721 USA.
   [Strawbridge, Heather] Northeast Ohio Med Univ, Coll Med, Dept Pediat, Rootstown, OH USA.
   [Strawbridge, Heather] Akron Childrens Hosp, Akron, OH USA.
RP Hayes, D (reprint author), Ohio State Univ, Nationwide Childrens Hosp, 700 Childrens Dr, Columbus, OH 43205 USA.
EM hayes.705@osu.edu
CR MILLER AJ, 1955, JAMA-J AM MED ASSOC, V159, P1364, DOI 10.1001/jama.1955.02960310028012a
   MILLER AJ, 1959, ANN INTERN MED, V51, P461, DOI 10.7326/0003-4819-51-3-461
   PICKERING D, 1981, ARCH DIS CHILD, V56, P401, DOI 10.1136/adc.56.5.401
   REYNOLDS JL, 1989, SOUTHERN MED J, V82, P1228, DOI 10.1097/00007611-198910000-00007
   Sert A, 2013, CARDIOL YOUNG, V23, P361, DOI 10.1017/S1047951112000881
   SPARROW MJ, 1978, NEW ZEAL MED J, V88, P325
NR 6
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0749-5161
EI 1535-1815
J9 PEDIATR EMERG CARE
JI Pediatr. Emerg. Care
PD FEB
PY 2016
VL 32
IS 2
BP 104
EP 106
DI 10.1097/PEC.0000000000000715
PG 3
WC Emergency Medicine; Pediatrics
SC Emergency Medicine; Pediatrics
GA DI3OJ
UT WOS:000373407700011
PM 26835568
DA 2018-03-20
ER

PT J
AU Uribe, GR
   Lilly, J
   Berron, BJ
AF Uribe, Gabriela Romero
   Lilly, Jacob L.
   Berron, Brad J.
TI Antigen specific lysis for large-volume, high-purity cell isolation
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
CT 246th National Meeting of the American-Chemical-Society (ACS)
CY SEP 08-12, 2013
CL Indianapolis, IN
SP Amer Chem Soc
C1 [Uribe, Gabriela Romero; Lilly, Jacob; Berron, Brad J.] Univ Kentucky, Chem & Mat Engn Deparment, Lexington, KY 40506 USA.
EM gabyromerouribe@gmail.com
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD SEP 8
PY 2013
VL 246
MA 245-COLL
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA 288NJ
UT WOS:000329618402271
DA 2018-03-19
ER

PT J
AU Howard, MD
   Hood, ED
   Greineder, CF
   Alferiev, IS
   Chorny, M
   Muzykantov, V
AF Howard, Melissa D.
   Hood, Elizabeth D.
   Greineder, Colin F.
   Alferiev, Ivan S.
   Chorny, Michael
   Muzykantov, Vladimir R.
TI Targeting to Endothelial Cells Augments the Protective Effect of Novel
   Dual Bioactive Antioxidant/Anti-Inflammatory Nanoparticles
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE inflammation; oxidative stress; SOD mimetic; nanocarrier; ROS;
   tocopherol; cytokines; targeted drug delivery; nanoparticles;
   antioxidants/anti-inflammatory; tocopherol/vitamin E; endothelial cells
ID TOCOPHERYL PHOSPHATE; GENE-EXPRESSION; MODULATION; PECAM-1;
   ATHEROSCLEROSIS; VASCULATURE; DELIVERY; STRESS; INJURY; DRUGS
AB Oxidative stress and inflammation are intertwined contributors to numerous acute vascular pathologies. A novel dual bioactive nanopartide with antioxidant/anti-inflammatory properties was developed based on the interactions of tocopherol phosphate and the manganese porphyrin SOD mimetic, MnTMPyP. The size and drug incorporation efficiency were shown to be dependent on the amount of MnTMPyP added as well as the choice of surfactant. MnTMPyP was shown to retain its SOD-like activity while in intact particles and to release in a slow and controlled manner. Conjugation of anti-PECAN' antibody to the nanopartides provided endothelial targeting and potentiated nanopartide-mediated suppression of inflammatory activation of these cells manifested by expression of VCAM, E-selectin, and IL-8. This nanopartide technology may find applicability with drug combinations relevant for other pathologies.
C1 [Howard, Melissa D.; Hood, Elizabeth D.; Greineder, Colin F.; Muzykantov, Vladimir] Univ Penn, Dept Pharmacol, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Howard, Melissa D.; Hood, Elizabeth D.; Greineder, Colin F.; Muzykantov, Vladimir] Univ Penn, Ctr Targeted Therapeut & Translat Nanomed, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Greineder, Colin F.] Univ Penn, Dept Emergency Med, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Alferiev, Ivan S.; Chorny, Michael] Childrens Hosp Philadelphia, Abramson Res Ctr, Div Cardiol, Philadelphia, PA 19104 USA.
   [Alferiev, Ivan S.; Chorny, Michael] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA.
RP Muzykantov, V (reprint author), Univ Penn, Dept Pharmacol, Perelman Sch Med, TRC10-125,3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA.
EM muzykant@mail.med.upenn.edu
RI Chorny, Michael/O-1313-2017
OI Greineder, Colin/0000-0001-9740-7672
FU University of Pennsylvania Hematology T32 Training Grant [T32 HL07439];
   NIH [HL087036]
FX M.D.H. acknowledges financial support from the University of
   Pennsylvania Hematology T32 Training Grant (Grant No. T32 HL07439). This
   study was in part supported by the NIH Grant HL087036 (V.M.).
CR Bae Y, 2010, PHARM RES-DORDR, V27, P2421, DOI 10.1007/s11095-010-0234-3
   Batinic-Haberle I, 2010, ANTIOXID REDOX SIGN, V13, P877, DOI 10.1089/ars.2009.2876
   Chorny M., 2013, FASEB J, V27, P2198
   Chorny M, 2010, J CONTROL RELEASE, V146, P144, DOI 10.1016/j.jconrel.2010.05.003
   Christofidou-Solomidou Melpo, 2006, Treat Respir Med, V5, P47, DOI 10.2165/00151829-200605010-00004
   Ding BS, 2009, AM J RESP CRIT CARE, V180, P247, DOI 10.1164/rccm.200809-1433OC
   Ding BS, 2005, BLOOD, V106, P4191, DOI 10.1182/blood-2005-05-2002
   Dwyer BE, 1998, J NEUROCHEM, V71, P2497
   Dziubla TD, 2008, BIOMATERIALS, V29, P215, DOI 10.1016/j.biomaterials.2007.09.023
   Guzik TJ, 2006, DRUG DISCOV TODAY, V11, P524, DOI 10.1016/j.drudis.2006.04.003
   Han JY, 2012, THER DELIV, V3, P263, DOI 10.4155/TDE.11.151
   Han JY, 2011, J PHARMACOL EXP THER, V338, P82, DOI 10.1124/jpet.111.180620
   Liang HL, 2009, AM J PHYSIOL-RENAL, V296, pF266, DOI 10.1152/ajprenal.90533.2008
   Libinaki R, 2010, CLIN EXP PHARMACOL P, V37, P587, DOI 10.1111/j.1440-1681.2010.05356.x
   Muro S, 2005, CURR PHARM DESIGN, V11, P2383, DOI 10.2174/1381612054367274
   Muro S, 2003, J CELL SCI, V116, P1599, DOI 10.1242/jcs.00367
   Muzykantov Vladimir R, 2005, Expert Opin Drug Deliv, V2, P909, DOI 10.1517/17425247.2.5.909
   Muzykantov VR, 1999, P NATL ACAD SCI USA, V96, P2379, DOI 10.1073/pnas.96.5.2379
   Muzykantov VR, 2001, ANTIOXID REDOX SIGN, V3, P39, DOI 10.1089/152308601750100489
   Newman PJ, 1997, J CLIN INVEST, V99, P3, DOI 10.1172/JCI119129
   Ogru E, 2004, ANN NY ACAD SCI, V1031, P405, DOI 10.1196/annals.1331.058
   Partridge J, 2007, FASEB J, V21, P3553, DOI 10.1096/fj.06-8059com
   Scherpereel A, 2002, J PHARMACOL EXP THER, V300, P777, DOI 10.1124/jpet.300.3.777
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Seija M., 2012, SHOCK, P38
   Shuvaev VV, 2011, J CONTROL RELEASE, V153, P56, DOI 10.1016/j.jconrel.2011.03.022
   Shuvaev VV, 2011, FASEB J, V25, P348, DOI 10.1096/fj.10-169789
   Shuvaev VV, 2011, J CONTROL RELEASE, V149, P236, DOI 10.1016/j.jconrel.2010.10.026
   Simone E, 2009, CELL TISSUE RES, V335, P283, DOI 10.1007/s00441-008-0676-7
   Thomas SR, 2008, ANTIOXID REDOX SIGN, V10, P1713, DOI 10.1089/ars.2008.2027
   Wei W, 2013, BIOMATERIALS, V34, P3912, DOI 10.1016/j.biomaterials.2013.02.030
   Zhang Y., 2013, MOL THER
   Zingg JM, 2010, FREE RADICAL BIO MED, V49, P1989, DOI 10.1016/j.freeradbiomed.2010.09.034
NR 33
TC 7
Z9 8
U1 0
U2 16
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD JUL
PY 2014
VL 11
IS 7
BP 2262
EP 2270
DI 10.1021/mp400677y
PG 9
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA AK9LI
UT WOS:000338748200034
PM 24877560
OA gold
DA 2018-03-20
ER

PT J
AU Lee, HJ
   Bae, Y
AF Lee, Hyun Jin
   Bae, Younsoo
TI Brushed Block Copolymer Micelles with pH-Sensitive Pendant Groups for
   Controlled Drug Delivery
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE block copolymers; drug delivery; nanoparticles; pH-controlled release;
   polymer micelles
ID POLYMERIC MICELLES; CANCER-CHEMOTHERAPY; THERAPEUTICS; NANOCARRIERS;
   RELEASE; SYSTEMS; 17-AAG; GLUTATHIONE; DOXORUBICIN; CARRIERS
AB To investigate the effects of small aliphatic pendent groups conjugated through an acid-sensitive linker to the core of brushed block copolymer micelles on particle properties.
   The brushed block copolymers were synthesized by conjugating five types of 2-alkanone (2-butanone, 2-hexanone, 2-octanone, 2-decanone, and 2-dodecanone) through an acid-labile hydrazone linker to poly(ethylene glycol)-poly(aspartate hydrazide) block copolymers.
   Only block copolymers with 2-hexanone and 2-octanone (PEG-HEX and PEG-OCT) formed micelles with a clinically relevant size (< 50 nm in diameter), low critical micelle concentration (CMC, < 20 mu M), and drug entrapment yields (approximately 5 wt.%). Both micelles degraded in aqueous solutions in a pH-dependent manner, while the degradation was accelerated in an acidic condition (pH 5.0) in comparison to pH 7.4. Despite these similar properties, PEG-OCT micelles controlled the entrapment and pH-dependent release of a hydrophobic drug most efficiently, without altering particle size, shape, and stability. The molecular weight of PEG (12 kDa vs 5 kDa) induced no change in pH-controlled drug release rates of PEG-OCT micelles.
   Acid-labile small aliphatic pendant groups are useful to control the entrapment and release of a hydrophobic drug physically entrapped in the core of brushed block copolymer micelles.
C1 [Lee, Hyun Jin; Bae, Younsoo] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
RP Bae, Y (reprint author), Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, 789 South Limestone, Lexington, KY 40536 USA.
EM younsoo.bae@uky.edu
FU Kentucky Lung Cancer Research Program
FX This research is supported by the Kentucky Lung Cancer Research Program.
CR Alani AWG, 2010, BIOMATERIALS, V31, P1765, DOI 10.1016/j.biomaterials.2009.11.038
   Bae Y, 2005, MOL BIOSYST, V1, P242, DOI 10.1039/b500266d
   Bae Y, 2003, ANGEW CHEM INT EDIT, V42, P4640, DOI 10.1002/anie.200250653
   Bae Y, 2005, BIOCONJUGATE CHEM, V16, P122, DOI 10.1021/bc0498166
   Bae Y, 2007, J CONTROL RELEASE, V122, P324, DOI 10.1016/j.jconrel.2007.05.038
   Bae Y, 2007, BIOCONJUGATE CHEM, V18, P1131, DOI 10.1021/bc060401p
   Bae Y, 2009, ADV DRUG DELIVER REV, V61, P768, DOI 10.1016/j.addr.2009.04.016
   Chandran T, 2010, INT J PHARMACEUT, V392, P170, DOI 10.1016/j.ijpharm.2010.03.056
   Davis ME, 2008, NAT REV DRUG DISCOV, V7, P771, DOI 10.1038/nrd2614
   Duncan R, 2003, NAT REV DRUG DISCOV, V2, P347, DOI 10.1038/nrd1088
   Gillies RJ, 2008, J NUCL MED, V49, p24S, DOI 10.2967/jnumed.107.047258
   Haag R, 2004, ANGEW CHEM INT EDIT, V43, P278, DOI 10.1002/anie.200301694
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   KATAOKA K, 1993, J CONTROL RELEASE, V24, P119
   Kim D, 2009, MOL PHARMACEUT, V6, P1353, DOI 10.1021/mp900021q
   Klose D, 2011, INT J PHARMACEUT, V404, P75, DOI 10.1016/j.ijpharm.2010.10.054
   Koo AN, 2008, CHEM COMMUN, P6570, DOI 10.1039/b815918a
   Kratz F, 1999, CRIT REV THER DRUG, V16, P245, DOI 10.1615/CritRevTherDrugCarrierSyst.v16.i3.10
   Kwon GS, 1996, ADV DRUG DELIVER REV, V21, P107, DOI 10.1016/S0169-409X(96)00401-2
   Lee ES, 2005, NANO LETT, V5, P325, DOI 10.1021/nl0479987
   Lee ES, 2008, J CONTROL RELEASE, V132, P164, DOI 10.1016/j.jconrel.2008.05.003
   Lee HJ, 2010, CHEM COMMUN, V46, P3559, DOI 10.1039/b925106e
   Lee SC, 2007, BIOMACROMOLECULES, V8, P202, DOI 10.1021/bm060307b
   Liu HB, 2000, J CONTROL RELEASE, V68, P167, DOI 10.1016/S0168-3659(00)00247-9
   Lomaestro BM, 1995, ANN PHARMACOTHER, V29, P1263, DOI 10.1177/106002809502901213
   MAEDA H, 1989, CRIT REV THER DRUG, V6, P193
   Matsumoto S, 2009, BIOMACROMOLECULES, V10, P119, DOI 10.1021/bm800985e
   MATSUMURA Y, 1986, CANCER RES, V46, P6387
   Matsumura Y, 2008, ADV DRUG DELIVER REV, V60, P899, DOI 10.1016/j.addr.2007.11.010
   Mikhail AS, 2009, J CONTROL RELEASE, V138, P214, DOI 10.1016/j.jconrel.2009.04.010
   Nasongkla N, 2004, ANGEW CHEM INT EDIT, V43, P6323, DOI 10.1002/anie.200460800
   Onyuksel H, 2009, INT J PHARM, V365, P157, DOI 10.1016/j.ijpharm.2008.08.024
   Peer D, 2007, NAT NANOTECHNOL, V2, P751, DOI 10.1038/nnano.2007.387
   Ponta A, 2010, PHARM RES-DORDR, V27, P2330, DOI 10.1007/s11095-010-0120-z
   Saravanakumar G, 2009, J CONTROL RELEASE, V140, P210, DOI 10.1016/j.jconrel.2009.06.015
   Shin HC, 2009, J CONTROL RELEASE, V140, P294, DOI 10.1016/j.jconrel.2009.04.024
   Siepmann J, 2001, ADV DRUG DELIVER REV, V48, P139, DOI 10.1016/S0169-409X(01)00112-0
   Stravopodis DJ, 2007, CURR MED CHEM, V14, P3122, DOI 10.2174/092986707782793925
   Takakura Y, 1996, PHARMACEUT RES, V13, P820, DOI 10.1023/A:1016084508097
   Torchilin V, 2011, ADV DRUG DELIVER REV, V63, P131, DOI 10.1016/j.addr.2010.03.011
   West Kevin R, 2005, Curr Drug Discov Technol, V2, P123, DOI 10.2174/1570163054866882
   Won YW, 2011, ACS NANO, V5, P3839, DOI 10.1021/nn200173u
   Xiong MP, 2009, J PHARM SCI-US, V98, P1577, DOI 10.1002/jps.21509
   Yang SR, 2006, J CONTROL RELEASE, V114, P60, DOI 10.1016/j.jconrel.2006.05.016
NR 44
TC 14
Z9 16
U1 1
U2 60
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
EI 1573-904X
J9 PHARM RES-DORDR
JI Pharm. Res.
PD AUG
PY 2013
VL 30
IS 8
BP 2077
EP 2086
DI 10.1007/s11095-013-1060-1
PG 10
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 174DH
UT WOS:000321133100013
PM 23636840
DA 2018-03-19
ER

PT J
AU Hollis, CP
   Weiss, HL
   Leggas, M
   Evers, BM
   Gemeinhart, RA
   Li, TL
AF Hollis, Christin P.
   Weiss, Heidi L.
   Leggas, Markos
   Evers, B. Mark
   Gemeinhart, Richard A.
   Li, Tonglei
TI Biodistribution and bioimaging studies of hybrid paclitaxel
   nanocrystals: Lessons learned of the EPR effect and image-guided drug
   delivery
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Paclitaxel; Nanocrystals; Theranostics; Chemotherapy; EPR;
   Biodistribution
ID PHARMACOKINETIC EVALUATION; TISSUE DISTRIBUTION; POLYMERIC
   NANOPARTICLES; VASCULAR-PERMEABILITY; INTRAVENOUS DELIVERY; TUMOR
   ACCUMULATION; ANTITUMOR EFFICACY; IN-VIVO; FORMULATION; THERAPY
AB Paclitaxel (PTX) nanocrystals (200 nm) were produced by crystallization from a solution. Antitumor efficacy and toxicity were examined through a survival study in a human HT-29 colon cancer xenograft murine model. The antitumor activity of the nanocrystal treatments was comparable with that by the conventional solubilization formulation (Taxol (R)), but yielded less toxicity as indicated by the result of a survival study. Tritium-labeled PTX nanocrystals were further produced with a near infrared (NIR) fluorescent dye physically integrated in the crystal lattice. Biodistribution and tumor accumulation of the tritium-labeled PTX nanocrystals were determined immediately after intravenous administration and up to 48 h by scintillation counting. Whole-body optical imaging of animals was concurrently carried out; fluorescent intensities were also measured from excised tumors and major organs of euthanized animals. It was found that drug accumulation in the tumor was less than 1% of 20 mg/kg intravenous dose. Qualitatively correlation was identified between the biodistribution determined by using tritium-labeled particles and that using optical imaging, but quantitative divergence existed. The divergent results suggest possible ways to improve the design of hybrid nanocrystals for cancer therapy and diagnosis. The study also raises questions of the general role of the enhanced permeability and retention (EPR) effect in tumor targeting and the effectiveness of bioimaging, specifically for theranostics, in tracking drug distribution and pharmacokinetics. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Hollis, Christin P.; Leggas, Markos] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
   [Weiss, Heidi L.] Univ Kentucky, Markey Canc Ctr, Div Canc Biostat, Lexington, KY 40506 USA.
   [Evers, B. Mark] Univ Kentucky, Markey Canc Ctr, Dept Surg, Lexington, KY 40506 USA.
   [Gemeinhart, Richard A.] Univ Illinois, Dept Biopharmaceut Sci, Chicago, IL 60612 USA.
   [Gemeinhart, Richard A.] Univ Illinois, Dept Bioengn, Chicago, IL 60612 USA.
   [Gemeinhart, Richard A.] Univ Illinois, Dept Ophthalmol & Visual Sci, Chicago, IL 60612 USA.
   [Li, Tonglei] Purdue Univ, Dept Ind & Phys Pharm, Coll Pharm, W Lafayette, IN 47907 USA.
RP Li, TL (reprint author), Purdue Univ, Dept Ind & Phys Pharm, Coll Pharm, Heine Pharm Bldg,575 Stadium Mall Dr, W Lafayette, IN 47907 USA.
EM tonglei@purdue.edu
RI Gemeinhart, Richard/B-8017-2008
OI Gemeinhart, Richard/0000-0002-1580-7304
FU National Cancer Institute [R25 CA153954]
FX The project described was supported by Grant Number R25 CA153954 from
   the National Cancer Institute. The content is solely the responsibility
   of the authors and does not necessarily represent the official views of
   the National Cancer Institute or the National Institutes of Health.
CR Ait-Oudhia S, 2012, PHARM RES-DORDR, V29, P2833, DOI 10.1007/s11095-012-0775-8
   Al-Jamal WT, 2011, ACCOUNTS CHEM RES, V44, P1094, DOI 10.1021/ar200105p
   Arbuck SG, 1993, J NATL CANC I MONO, V15, P117
   Bae YH, 2011, J CONTROL RELEASE, V153, P198, DOI 10.1016/j.jconrel.2011.06.001
   Barbe C, 2004, ADV MATER, V16, P1959, DOI 10.1002/adma.200400771
   Blanco E, 2009, EXP BIOL MED, V234, P123, DOI 10.3181/0808-MR-250
   Caldorera-Moore ME, 2011, ACCOUNTS CHEM RES, V44, P1061, DOI 10.1021/ar2001777
   Chan HK, 2011, ADV DRUG DELIVER REV, V63, P406, DOI 10.1016/j.addr.2011.03.011
   Daldrup H, 1998, AM J ROENTGENOL, V171, P941, DOI 10.2214/ajr.171.4.9762973
   Du SZ, 2012, DRUG DEV IND PHARM, V38, P431, DOI 10.3109/03639045.2011.609560
   EISEMAN JL, 1994, CANCER CHEMOTH PHARM, V34, P465, DOI 10.1007/s002800050174
   Fang J, 2011, ADV DRUG DELIVER REV, V63, P136, DOI 10.1016/j.addr.2010.04.009
   FRANK MM, 1991, IMMUNOL TODAY, V12, P322, DOI 10.1016/0167-5699(91)90009-I
   Fujii T, 2003, ANTICANCER RES, V23, P2405
   Ganta S, 2009, INT J PHARM, V367, P179, DOI 10.1016/j.ijpharm.2008.09.022
   Gao L, 2008, INT J PHARM, V355, P321, DOI 10.1016/j.ijpharm.2007.12.016
   Gulati M, 1998, INT J PHARMACEUT, V165, P129, DOI 10.1016/S0378-5173(98)00006-4
   Hao LL, 2012, INT J PHARMACEUT, V433, P157, DOI 10.1016/j.ijpharm.2012.05.002
   Hashizume H, 2000, AM J PATHOL, V156, P1363, DOI 10.1016/S0002-9440(10)65006-7
   Hennenfent KL, 2006, ANN ONCOL, V17, P735, DOI 10.1093/annonc/mdj100
   Hilderbrand SA, 2010, CURR OPIN CHEM BIOL, V14, P71, DOI 10.1016/j.cbpa.2009.09.029
   Hobbs SK, 1998, P NATL ACAD SCI USA, V95, P4607, DOI 10.1073/pnas.95.8.4607
   Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685
   Kherlopian A.R., 2008, BMC SYST BIOL, V2
   Kim JH, 2008, J CONTROL RELEASE, V127, P41, DOI 10.1016/j.jconrel.2007.12.014
   Koo AN, 2012, BIOMATERIALS, V33, P1489, DOI 10.1016/j.biomaterials.2011.11.013
   Lee BS, 2010, J CONTROL RELEASE, V147, P253, DOI 10.1016/j.jconrel.2010.07.096
   LESS JR, 1991, CANCER RES, V51, P265
   Levine DH, 2008, METHODS, V46, P25, DOI 10.1016/j.ymeth.2008.05.006
   Li C, 2010, ADV FUNCT MATER, V20, P2222, DOI 10.1002/adfm.201000038
   Liu F, 2010, J PHARM SCI-US, V99, P3542, DOI 10.1002/jps.22112
   Liu Y, 2012, PHARM RES-DORDR, V29, P3273, DOI 10.1007/s11095-012-0818-1
   Lyons SK, 2005, J PATHOL, V205, P194, DOI 10.1002/path.1697
   Maeda H, 2001, ADV ENZYME REGUL, V41, P189, DOI 10.1016/S0065-2571(00)00013-3
   Maeda H, 2000, J CONTROL RELEASE, V65, P271, DOI 10.1016/S0168-3659(99)00248-5
   Maeda H, 2010, J CONTROL RELEASE, V142, P296, DOI 10.1016/j.jconrel.2010.01.002
   Mayer LD, 2000, J LIPOSOME RES, V10, P99, DOI 10.3109/08982100009029381
   Merisko-Liversidge E, 2003, EUR J PHARM SCI, V18, P113, DOI 10.1016/S0928-0987(02)00251-8
   Min KH, 2012, BIOMATERIALS, V33, P5788, DOI 10.1016/j.biomaterials.2012.04.057
   Moghimi SM, 2001, PHARMACOL REV, V53, P283
   Montet X, 2005, CANCER RES, V65, P6330, DOI 10.1158/0008-5472.CAN-05-0382
   Muller RH, 2001, ADV DRUG DELIVER REV, V47, P3, DOI 10.1016/S0169-409X(00)00118-6
   Ntziachristos V, 2003, EUR RADIOL, V13, P195, DOI 10.1007/s00330-002-1524-x
   Owens DE, 2006, INT J PHARM, V307, P93, DOI 10.1016/j.ijpharm.2005.10.010
   Park K, 2007, J CONTROL RELEASE, V120, P1, DOI 10.1016/j.jconrel.2007.05.003
   Pham W, 2005, BIOCONJUGATE CHEM, V16, P735, DOI 10.1021/bc049700+
   Rabinow B, 2007, INT J PHARM, V339, P251, DOI 10.1016/j.ijpharm.2007.02.030
   Shegokar R, 2010, INT J PHARMACEUT, V399, P129, DOI 10.1016/j.ijpharm.2010.07.044
   Sparreboom A, 1996, ANTI-CANCER DRUG, V7, P78, DOI 10.1097/00001813-199601000-00009
   Wang YL, 2011, INT J NANOMED, V6, P1497, DOI 10.2147/IJN.S21097
   Yang Z., 2009, NANOTECHNOLOGY, V20
   YUAN F, 1995, CANCER RES, V55, P3752
   Zhao RS, 2011, MOL PHARMACEUT, V8, P1985, DOI 10.1021/mp200154k
NR 53
TC 66
Z9 67
U1 1
U2 64
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD NOV 28
PY 2013
VL 172
IS 1
BP 12
EP 21
DI 10.1016/j.jconrel.2013.06.039
PG 10
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 260NI
UT WOS:000327601200003
PM 23920039
OA green_accepted
DA 2018-03-20
ER

PT J
AU Lilly, JL
   Romero, G
   Xu, WJ
   Shin, HY
   Berron, BJ
AF Lilly, Jacob L.
   Romero, Gabriela
   Xu, Weijie
   Shin, Hainsworth Y.
   Berron, Brad J.
TI Characterization of Molecular Transport in Ultrathin Hydrogel Coatings
   for Cellular Immunoprotection
SO BIOMACROMOLECULES
LA English
DT Article
ID POLY(ETHYLENE GLYCOL) DIACRYLATE; TISSUE ENGINEERING APPLICATIONS;
   NUCLEAR-PORE COMPLEXES; PEGDA HYDROGELS; PORCINE ISLETS; DRUG-DELIVERY;
   IN-VITRO; POLYMERIZATION; ENCAPSULATION; PHOTOPOLYMERIZATION
AB PEG hydrogels are routinely used in immunoprotection applications to hide foreign cells from a host immune system. Size-dependent transport is typically exploited in these systems to prevent access by macromolecular elements of the immune system while allowing the transport of low molecular weight nutrients. This work studies a nanoscale hydrogel coating for improved transport of beneficial low molecular weight materials across thicker hydrogel coatings while completely blocking transport of undesired larger molecular weight materials. Coatings composed of PEG diacrylate of molecular weight 575 and 3500 Da were studied by tracking the transport of fluorescently labeled dextrans across the coatings. The molecular weight of dextran at which the transport is blocked by these coatings are consistent with cutoff values in analogous bulk PEG materials. Additionally, the diffusion constants of 4 kDa dextrans across PEG 575 coatings (9.5 x 10(-10)-2.0 x 10(-9) cm(2)/s) was lower than across PEG 3500 coatings (5.9-9.8 x 10(-9) cm(2)/s), and these trends and magnitudes agree with bulk scale models. Overall, these nanoscale thin PEG diacrylate films offer the same size selective transport behavior of bulk PEG diacrylate materials, while the lower thickness translates directly to increased flux of beneficial low molecular weight materials.
C1 [Lilly, Jacob L.; Romero, Gabriela; Xu, Weijie; Berron, Brad J.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Shin, Hainsworth Y.] Univ Kentucky, Dept Biomed Engn, Lexington, KY 40506 USA.
RP Berron, BJ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM berron@engr.uky.edu
FU NIH [R21 EB012188]; National Science Foundation [CBET-1351531]; National
   Cancer Institute (NCI) [R25CA153954]; National Cancer Institute Cancer
   Nanotechnology Training Center (NCI-CNTC) Postdoctoral Traineeship
FX The authors acknowledge financial support by NIH Grant R21 EB012188 and
   by the National Science Foundation Grant CBET-1351531. Further, the
   authors acknowledge financial support from the National Cancer Institute
   (NCI) Grant Number R25CA153954 and a National Cancer Institute Cancer
   Nanotechnology Training Center (NCI-CNTC) Postdoctoral Traineeship
   awarded to J.L.L. The views expressed in this manuscript do not
   represent the views of the NCI, NIBIB, NIH, DHHS, NSF, or any other
   government agency or official. They also thank the U.K. Electron
   Microscopy Center for their support on SEM images and Jim Begley and
   Cindy Meier with the U.K. Imaging Core Facility for their guidance in
   CSLM experiments.
CR ADAM SA, 1992, METHOD ENZYMOL, V219, P97
   Armstrong JK, 2004, BIOPHYS J, V87, P4259, DOI 10.1529/biophysj.104.047746
   Avens HJ, 2008, POLYMER, V49, P4762, DOI 10.1016/j.polymer.2008.08.054
   Avens HJ, 2011, J HISTOCHEM CYTOCHEM, V59, P76, DOI 10.1369/jhc.2010.955948
   Avens HJ, 2011, J NANOPART RES, V13, P331, DOI 10.1007/s11051-010-0034-z
   Avens HJ, 2010, ACTA BIOMATER, V6, P83, DOI 10.1016/j.actbio.2009.06.008
   Baroli B, 2006, J CHEM TECHNOL BIOT, V81, P491, DOI 10.1002/jctb.1468
   Browning MB, 2014, J BIOMED MATER RES A, V102, P4244, DOI 10.1002/jbm.a.35096
   Bryant SJ, 2000, J BIOMAT SCI-POLYM E, V11, P439, DOI 10.1163/156856200743805
   CANAL T, 1989, J BIOMED MATER RES, V23, P1183, DOI 10.1002/jbm.820231007
   Cruise GM, 1998, BIOTECHNOL BIOENG, V57, P655, DOI 10.1002/(SICI)1097-0290(19980320)57:6<655::AID-BIT3>3.0.CO;2-K
   Cruise GM, 1999, CELL TRANSPLANT, V8, P293, DOI 10.1177/096368979900800310
   Cruise GM, 1998, BIOMATERIALS, V19, P1287, DOI 10.1016/S0142-9612(98)00025-8
   Cuchiara MP, 2010, BIOMATERIALS, V31, P5491, DOI 10.1016/j.biomaterials.2010.03.031
   Drury JL, 2003, BIOMATERIALS, V24, P4337, DOI 10.1016/S0142-9612(03)00340-5
   Fedorovich NE, 2007, TISSUE ENG, V13, P1905, DOI 10.1089/ten.2006.0175
   Hamidi M, 2008, ADV DRUG DELIVER REV, V60, P1638, DOI 10.1016/j.addr.2008.08.002
   Hansen RR, 2008, ANAL BIOANAL CHEM, V392, P167, DOI 10.1007/s00216-008-2259-6
   Kizilel S, 2004, LANGMUIR, V20, P8652, DOI 10.1021/la0496744
   Kizilel S, 2009, MACROMOL REACT ENG, V3, P271, DOI 10.1002/mren.200900005
   Lee JK, 2012, BIOMACROMOLECULES, V13, P1136, DOI 10.1021/bm300037t
   Lin CC, 2011, BIOMATERIALS, V32, P9685, DOI 10.1016/j.biomaterials.2011.08.083
   Lin CC, 2009, PHARM RES-DORD, V26, P631, DOI 10.1007/s11095-008-9801-2
   Mohr D, 2009, EMBO J, V28, P2541, DOI 10.1038/emboj.2009.200
   Mumaw J, 2012, INT J BIOMATER, DOI 10.1155/2012/861794
   Naim B, 2007, J BIOL CHEM, V282, P3881, DOI 10.1074/jbc.M608329200
   Nguyen KT, 2002, BIOMATERIALS, V23, P4307, DOI 10.1016/S0142-9612(02)00175-8
   Nicodemus GD, 2008, TISSUE ENG PT B-REV, V14, P149, DOI 10.1089/ten.teb.2007.0332
   Romero G, 2010, BIOMACROMOLECULES, V11, P2993, DOI 10.1021/bm1007822
   Santos E, 2013, J CONTROL RELEASE, V170, P1, DOI 10.1016/j.jconrel.2013.04.015
   SCHMIDSCHONBEIN GW, 1980, BLOOD, V56, P866
   Shenoy R, 2013, MACROMOL THEOR SIMUL, V22, P115, DOI 10.1002/mats.201200062
   Shih H, 2013, MACROMOL RAPID COMM, V34, P269, DOI 10.1002/marc.201200605
   Uludag H, 2000, ADV DRUG DELIVER REV, V42, P29, DOI 10.1016/S0169-409X(00)00053-3
NR 34
TC 7
Z9 7
U1 0
U2 24
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1525-7797
EI 1526-4602
J9 BIOMACROMOLECULES
JI Biomacromolecules
PD FEB
PY 2015
VL 16
IS 2
BP 541
EP 549
DI 10.1021/bm501594x
PG 9
WC Biochemistry & Molecular Biology; Chemistry, Organic; Polymer Science
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA CA9VN
UT WOS:000349273000013
PM 25592156
OA green_accepted
DA 2018-03-19
ER

PT J
AU Li, YC
   Bachas, LG
   Bhattacharyya, D
AF Li, YongChao
   Bachas, Leonidas G.
   Bhattacharyya, Dibakar
TI Selected chloro-organic detoxifications by polychelate (Poly(acrylic
   acid)) and citrate-based Fenton reaction at neutral pH environment
SO INDUSTRIAL & ENGINEERING CHEMISTRY RESEARCH
LA English
DT Article
ID POLYCHLORINATED-BIPHENYLS PCBS; ADVANCED OXIDATION PROCESSES;
   HYDROGEN-PEROXIDE; CARBON-TETRACHLORIDE; CATALYTIC DECOMPOSITION;
   HYDROXYL RADICALS; AQUEOUS-PHASE; REAGENT; IRON; DEGRADATION
AB The use of chelating agents to modify the Fenton reaction is well-documented in the literature. Polymeric chelates (such as poly(acrylic acid), PAA) provide multiple binding sites and can complex iron ion (ferrous/ ferric ion) and prevent ferric hydroxideprecipitation even at neutral pH environment. In this study, it was proven that poly(acrylic acid) could act as a polychelate in the modified Fenton reaction for the oxidation of chlorinated organic compounds (such as 2,2'-dichlorobiphenyl and biphenyl) at neutral pH environment. Numerical simulation based on the kinetic model developed from the well-known Fenton reaction and iron-chelate chemistry fits the experimental data well for both standard and chelate-based modified Fenton reactions without pollutant. This is the first reported confirmation of the dechlorination of carbon tetrachloride from the aqueous phase by superoxide radical anion using both monomeric (citrate) and polymeric (PAA) chelate-based modified Fenton reactions. The main purpose of this research is to understand and model a chelate-based modified Fenton reaction in a homogeneous phase. The oxidation reactions involving immobilized iron on PAA-functionalized solid support (silica particles and PVDF membrane) were also explored.
C1 Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
RP Bhattacharyya, D (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM db@ener.ukv.edu
RI Bachas, Leonidas/G-2479-2015
OI Bachas, Leonidas/0000-0002-3308-6264
CR ARONSTEIN BN, 1995, J IND MICROBIOL, V15, P55, DOI 10.1007/BF01570014
   Augusti R, 1998, J PHYS CHEM A, V102, P10723, DOI 10.1021/jp983256o
   Baes C. F., 1976, HYDROLYSIS CATIONS
   Basu S, 1998, CHEM ENG COMMUN, V164, P111, DOI 10.1080/00986449808912361
   Benitez FJ, 2001, J CHEM TECHNOL BIOT, V76, P312, DOI 10.1002/jctb.384
   Benitez FJ, 1999, IND ENG CHEM RES, V38, P1341, DOI 10.1021/ie980441f
   Cassidy D, 2002, J CHEM TECHNOL BIOT, V77, P663, DOI 10.1002/jctb.628
   CHADEREK S, 1959, ORGANIC SEQUESTERING
   Chen H, 2005, J DISPER SCI TECHNOL, V26, P27, DOI 10.1081/DIS-200040232
   CHEN XF, 1993, J PHYS CHEM-US, V97, P421, DOI 10.1021/j100104a025
   De Laat J, 1999, ENVIRON SCI TECHNOL, V33, P2726, DOI 10.1021/es981171v
   Dwyer F. P., 1964, CHELATING AGENTS MET
   EIMORSI TM, 2002, CHEMOSPHERE, V47, P343
   Inczedy J., 1976, ANAL APPL COMPLEX EQ
   Kiwi J, 2000, ENVIRON SCI TECHNOL, V34, P2162, DOI 10.1021/es991406i
   Konigsberger LC, 2000, J INORG BIOCHEM, V78, P175, DOI 10.1016/S0162-0134(99)00222-6
   Kosaka K, 1998, ENVIRON SCI TECHNOL, V32, P3821, DOI 10.1021/es9800784
   Kwan WP, 2003, ENVIRON SCI TECHNOL, V37, P1150, DOI 10.1021/es020874g
   Kwan WP, 2002, ENVIRON SCI TECHNOL, V36, P1467, DOI 10.1021/es011109p
   Li YC, 2005, ENVIRON ENG SCI, V22, P756, DOI 10.1089/ees.2005.22.756
   Lin SS, 1998, ENVIRON SCI TECHNOL, V32, P1417, DOI 10.1021/es970648k
   Lowry GV, 2004, ENVIRON SCI TECHNOL, V38, P5208, DOI 10.1021/es049835q
   Luo N, 1997, J PHYS CHEM A, V101, P926, DOI 10.1021/jp962021e
   McKinzi AM, 1999, ENVIRON SCI TECHNOL, V33, P1886, DOI 10.1021/es980810z
   Neyens E, 2003, J HAZARD MATER, V98, P33, DOI 10.1016/S0304-3894(02)00282-0
   Perez M, 2002, WATER RES, V36, P2703, DOI 10.1016/S0043-1354(01)00506-1
   Pignatello JJ, 2006, CRIT REV ENV SCI TEC, V36, P1, DOI 10.1080/10643380500326564
   SEDLAK DL, 1991, ENVIRON SCI TECHNOL, V25, P1419, DOI 10.1021/es00020a009
   SEDLAK DL, 1994, WATER RES, V28, P1207, DOI 10.1016/0043-1354(94)90209-7
   Smith BA, 2004, ENVIRON SCI TECHNOL, V38, P5465, DOI 10.1021/es0352754
   Smith BA, 2006, J CONTAM HYDROL, V85, P229, DOI 10.1016/j.jconhyd.2006.02.002
   STOOKEY LL, 1970, ANAL CHEM, V42, P779, DOI 10.1021/ac60289a016
   SUN YF, 1992, J AGR FOOD CHEM, V40, P322, DOI 10.1021/jf00014a031
   SUN YF, 1993, J AGR FOOD CHEM, V41, P308, DOI 10.1021/jf00026a034
   Tang WZ, 1996, ENVIRON TECHNOL, V17, P1371, DOI 10.1080/09593331708616506
   Teel AL, 2002, J HAZARD MATER, V94, P179, DOI 10.1016/S0304-3894(02)00068-7
   Teel AL, 2001, WATER RES, V35, P977, DOI 10.1016/S0043-1354(00)00332-8
   *US EPA, 1984, HLTH ENV EFF PROF 1
   U. S. Environmental Protection Agency. National Center for Environmental Assessment. Office of Research and Development, 1999, INT RISK INF SYST IR
   Voelker BM, 1996, ENVIRON SCI TECHNOL, V30, P1106, DOI 10.1021/es9502132
   WALLING C, 1975, ACCOUNTS CHEM RES, V8, P125, DOI 10.1021/ar50088a003
   Willey JD, 2005, ENVIRON SCI TECHNOL, V39, P2579, DOI 10.1021/es0404522
   Xu J, 2005, ENVIRON PROG, V24, P358, DOI 10.1002/ep.10106
   ZEPP RG, 1992, ENVIRON SCI TECHNOL, V26, P313, DOI 10.1021/es00026a011
NR 44
TC 23
Z9 23
U1 1
U2 24
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0888-5885
J9 IND ENG CHEM RES
JI Ind. Eng. Chem. Res.
PD NOV 21
PY 2007
VL 46
IS 24
BP 7984
EP 7992
DI 10.1021/ie070393b
PG 9
WC Engineering, Chemical
SC Engineering
GA 231FH
UT WOS:000250931400019
DA 2018-03-19
ER

PT J
AU Zhang, WL
   Eitel, RE
AF Zhang, Wenli
   Eitel, Richard E.
TI Sintering Behavior, Properties, and Applications of Co-Fired
   Piezoelectric/Low Temperature Co-Fired Ceramic (PZT-SKN/LTCC) Multilayer
   Ceramics
SO INTERNATIONAL JOURNAL OF APPLIED CERAMIC TECHNOLOGY
LA English
DT Article
ID THICK-FILMS; LTCC; MEMS; FABRICATION; TECHNOLOGY; VISCOSITY; SHRINKAGE;
   CURVE
AB Materials and processing conditions have been developed allowing co-firing of fluxed PZT-SKN materials with commercial low temperature co-fired ceramic (LTCC) tapes. Previously, Pb(Zr0.53, Ti0.47)O3Sr(K0.25, Nb0.75)O3 (PZT-SKN) ceramics fluxed with 1wt% LiBiO2 and 1wt% CuO addition were shown to sinter to high density at 900 degrees C for 1h, with a large d33 piezoelectric coefficient of similar to 415pm/V. Currently, the master sintering curve (MSC) approach has been used to study the densification behaviors of fluxed PZT-SKN and LTCC tapes. Different sintering mechanisms for fluxed PZT-SKN ceramics and LTCC materials are confirmed by analyzing the apparent activation energy (Qa). Using knowledge gained from MSC results, an optimized sintering profile was developed. Multilayer PZT-SKN/HL2000 (HeraLock Tape, Heraeus) stacks co-fired at 900 degrees C for 0.5h maintain large piezoelectric coefficient (high field d33>340pm/V). EDS analysis reveal limited interdiffusion of Pb from PZT-SKN layers in LTCC and the appearance of Al, Ca, and Si in the PZT-SKN near the PZT-SKN/LTCC interface. Further, elemental interdiffusion was not detected at the center of piezoelectric layer in PZT-SKN/LTCC multilayer ceramics and no subsequent reduction in piezoelectric coefficient d33 was observed. Finally, a piezoelectric microbalance with mass sensitivity of 150kHz/mg was fabricated using the materials and methods developed.
C1 [Zhang, Wenli; Eitel, Richard E.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Zhang, WL (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM reitel@engr.uky.edu
RI Eitel, Richard/E-2889-2010
OI Eitel, Richard/0000-0002-5090-2075
FU DEPSCOR; Office of Naval Research [N000140911156 DEPSCoR]
FX Wenli Zhang was supported in part by DEPSCOR and the Office of Naval
   Research under Grant No. (N000140911156 DEPSCoR). The authors also thank
   Heraeus, Thick Film Division for providing the LTCC materials used in
   the current work.
CR Belavi D, 2009, J ELECTROCERAM, V23, P1, DOI 10.1007/s10832-008-9495-1
   Belavic D, 2007, J ELECTROCERAM, V19, P363, DOI 10.1007/s10832-007-9064-z
   Belavic D, 2006, INT J APPL CERAM TEC, V3, P448, DOI 10.1111/j.1744-7402.2006.02105.x
   Birol H, 2007, SENSOR ACTUAT A-PHYS, V134, P334, DOI 10.1016/j.sna.2006.05.025
   Bochenek A., 2001, Microelectronics International, V18, P11, DOI 10.1108/13565360110391556
   CHENG TN, 1989, J AM CERAM SOC, V72, P1649, DOI 10.1111/j.1151-2916.1989.tb06297.x
   Dorey RA, 2004, J ELECTROCERAM, V12, P19, DOI 10.1023/B:JECR.0000033999.74149.a3
   Ekinci KL, 2004, J APPL PHYS, V95, P2682, DOI 10.1063/1.1642738
   Gardner J. W., 2001, MICROSENSORS MEMS SM, P117
   Harrington BP, 2010, P IEEE INT FREQ CONT, P238, DOI 10.1109/FREQ.2010.5556336
   Harris NR, 2006, SENSOR ACTUAT A-PHYS, V132, P311, DOI 10.1016/j.sna.2006.06.006
   Hrovat M, 2003, J MATER SCI LETT, V22, P1193, DOI 10.1023/A:1025388214955
   Jean JH, 1997, J MATER RES, V12, P2743, DOI 10.1557/JMR.1997.0365
   Jeong Y, 2009, J ELECTROCERAM, V23, P387, DOI 10.1007/s10832-008-9473-7
   Kiani S, 2006, J AM CERAM SOC, V89, P3393, DOI 10.1111/j.1551-2916.2006.01252.x
   Lee JY, 2009, J ELECTROCERAM, V23, P572, DOI 10.1007/s10832-008-9552-9
   Lim WB, 2009, J EUR CERAM SOC, V29, P711, DOI 10.1016/j.jeurceramsoc.2008.07.058
   Lou-Moeller R, 2007, J ELECTROCERAM, V19, P333, DOI 10.1007/s10832-007-9055-0
   Mohanram A, 2005, J AM CERAM SOC, V88, P2681, DOI 10.1111/j.1551-2916.2005.00497.x
   MORTEN B, 1992, SENSOR ACTUAT A-PHYS, V31, P153, DOI 10.1016/0924-4247(92)80096-L
   Nam C. H., 2009, J ALLOY COMPD, V509, P3686
   Rabe T, 2005, INT J APPL CERAM TEC, V2, P374, DOI 10.1111/j.1744-7402.2005.02038.x
   Su HH, 1996, J AM CERAM SOC, V79, P3211, DOI 10.1111/j.1151-2916.1996.tb08097.x
   TENG MAO-HUA, 2002, W PACIFIC EARTH SCI, V2, P171
   Torah RN, 2007, J ELECTROCERAM, V19, P97, DOI 10.1007/s10832-007-9040-7
   Tzeng SY, 2002, J AM CERAM SOC, V85, P335
   Ursic H, 2008, J ELECTROCERAM, V20, P11, DOI 10.1007/s10832-007-9327-8
   Wang X., 2002, SHIZUOKA U GRADUATE, V23, P105
   Wang ZH, 2010, J ELECTROCERAM, V24, P25, DOI 10.1007/s10832-008-9454-x
   White NM, 2001, SMART MATER STRUCT, V10, P850, DOI 10.1088/0964-1726/10/4/403
   Xie RJ, 2005, J EUR CERAM SOC, V25, P417, DOI 10.1016/j.jeurceramsoc.2004.01.022
   ZARNIK M, 2005, P 6 INT C THERM MECH, P338
   Zhang WL, 2011, J AM CERAM SOC, V94, P3386, DOI 10.1111/j.1551-2916.2011.04504.x
NR 33
TC 11
Z9 11
U1 2
U2 33
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1546-542X
EI 1744-7402
J9 INT J APPL CERAM TEC
JI Int. J. Appl. Ceram. Technol.
PD MAR-APR
PY 2013
VL 10
IS 2
BP 354
EP 364
DI 10.1111/j.1744-7402.2011.02747.x
PG 11
WC Materials Science, Ceramics
SC Materials Science
GA 102PZ
UT WOS:000315857800019
DA 2018-03-19
ER

PT J
AU Kulbe, JR
   Geddes, JW
AF Kulbe, Jacqueline R.
   Geddes, James W.
TI Current status of fluid biomarkers in mild traumatic brain injury
SO EXPERIMENTAL NEUROLOGY
LA English
DT Article
DE Mild traumatic brain injury; Biomarkers; Serum; Cerebral spinal fluid;
   Biofluid; Novel; Discovery; Unbiased
ID NEURON-SPECIFIC-ENOLASE; MINOR HEAD-INJURY; FIBRILLARY ACIDIC PROTEIN;
   MYELIN BASIC-PROTEIN; ALPHA-II-SPECTRIN; POSTTRAUMATIC-STRESS-DISORDER;
   CONTROLLED CORTICAL IMPACT; POST-CONCUSSION SYMPTOMS; C-TERMINAL
   HYDROLASE-L1; PHAGE DISPLAY TECHNIQUE
AB Mild traumatic brain injury (mTBI) affects millions of people annually and is difficult to diagnose. Mild injury is insensitive to conventional imaging techniques and diagnoses are often made using subjective criteria such as self-reported symptoms. Many people who sustain a mTBI develop persistent post-concussive symptoms. Athletes and military personnel are at great risk for repeat injury which can result in second impact syndrome or chronic traumatic encephalopathy. An objective and quantifiable measure, such as a serum biomarker, is needed to aid in mTBI diagnosis, prognosis, return to play/duty assessments, and would further elucidate mTBI pathophysiology. The majority of TBI biomarker research focuses on severe TBI with few studies specific to mild injury. Most studies use a hypothesis-driven approach, screening biofluids for markers known to be associated with TBI pathophysiology. This approach has yielded limited success in identifying markers that can be used clinically, additional candidate biomarkers are needed. Innovative and unbiased methods such as proteomics, microRNA arrays, urinary screens, autoantibody identification and phage display would complement more traditional approaches to aid in the discovery of novel mTBI biomarkers. (C) 2015 Elsevier Inc. All rights reserved.
C1 Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Coll Med, Lexington, KY 40536 USA.
   Univ Kentucky, Dept Anat & Neurobiol, Coll Med, Lexington, KY 40536 USA.
RP Geddes, JW (reprint author), Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, B483 BBSRB,741 S Limestone St, Lexington, KY 40536 USA.
EM jgeddes@uky.edu
FU NIH [R21 NS084088, RO1 NS062993]
FX The author's research was supported by NIH grants R21 NS084088 and RO1
   NS062993.
CR Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029
   Agoston DV, 2009, J NEUROTRAUM, V26, P901, DOI 10.1089/neu.2008.0724
   Ahmed FA, 2013, ELECTROPHORESIS, V34, P2229, DOI 10.1002/elps.201300077
   Alsaif M, 2012, PROTEOM CLIN APPL, V6, P297, DOI 10.1002/prca.201100061
   Ambros V, 2001, CELL, V107, P823, DOI 10.1016/S0092-8674(01)00616-X
   Anderson KJ, 2008, J NEUROTRAUM, V25, P1079, DOI 10.1089/neu.2007.0488
   Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012
   Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311
   Astrand R, 2011, CLIN CHIM ACTA, V412, P2190, DOI 10.1016/j.cca.2011.08.009
   Babak T, 2004, RNA, V10, P1813, DOI 10.1261/rna.7119904
   BAKAY RAE, 1983, J NEUROSURG, V58, P27, DOI 10.3171/jns.1983.58.1.0027
   Baker JG, 2014, INT J CLIN PRACT, V68, P1286, DOI 10.1111/ijcp.12517
   Balakathiresan N, 2012, J NEUROTRAUM, V29, P1379, DOI 10.1089/neu.2011.2146
   BARBARESE E, 1988, J NEUROCHEM, V51, P1737, DOI 10.1111/j.1471-4159.1988.tb01153.x
   Bay Esther, 2005, J Neurosci Nurs, V37, P4
   Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005
   Bazarian JJ, 2006, BRAIN INJURY, V20, P759, DOI 10.1080/02699050500488207
   Begaz T, 2006, J NEUROTRAUM, V23, P1201, DOI 10.1089/neu.2006.23.1201
   Berger RP, 2012, J NEUROTRAUM, V29, P162, DOI 10.1089/neu.2011.1989
   Berger RP, 2009, PEDIATR RES, V65, P97, DOI 10.1203/PDR.0b013e31818c7e27
   Berger RP, 2006, J HEAD TRAUMA REHAB, V21, P315, DOI 10.1097/00001199-200607000-00004
   Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711
   Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061
   Bigler ED, 2013, NEUROPSYCHOL REV, V23, P169, DOI 10.1007/s11065-013-9237-2
   Biomarkers Definitions Working Group, 2001, CLIN PHARMACOL THER, V69, P89, DOI DOI 10.1067/MCP.2001.113989
   Boggs JM, 2006, CELL MOL LIFE SCI, V63, P1945, DOI 10.1007/s00018-006-6094-7
   BOHNEN N, 1992, INT J NEUROSCI, V64, P97, DOI 10.3109/00207459209000536
   Bolton AN, 2014, J NEUROPATH EXP NEUR, V73, P933, DOI 10.1097/NEN.0000000000000115
   Bradbury A.R., 2010, CURR PROTOC NEUROSCI
   Brain Trauma Foundation; American Association of Neurological Surgeons; Congress of Neurological Surgeons, 2007, J NEUROTRAUMA S, V24, pS1
   Bruns JJ, 2009, MT SINAI J MED, V76, P129, DOI 10.1002/msj.20101
   Cadosch D, 2010, ANZ J SURG, V80, P542, DOI 10.1111/j.1445-2197.2010.05268.x
   Cai XY, 2011, ATHEROSCLEROSIS, V217, P536, DOI 10.1016/j.atherosclerosis.2011.05.023
   Campbell LK, 2003, MODERN PATHOL, V16, P963, DOI 10.1097/01.MP.0000087088.88280.B0
   Cancelliere Carol, 2014, Arch Phys Med Rehabil, V95, pS201, DOI 10.1016/j.apmr.2013.10.010
   Caner H, 2004, ACTA NEUROCHIR, V146, P611, DOI 10.1007/s00701-003-0209-9
   Canu N, 1998, J NEUROSCI, V18, P7061
   Carroll Linda J, 2014, Arch Phys Med Rehabil, V95, pS152, DOI 10.1016/j.apmr.2013.08.300
   Carroll Linda J, 2004, J Rehabil Med, P84
   Chen FJ, 2010, P NATL ACAD SCI USA, V107, P1636, DOI 10.1073/pnas.0911516107
   Chen JX, 2014, OTOLARYNG HEAD NECK, V151, P554, DOI 10.1177/0194599814542588
   Conti A, 2004, J NEUROTRAUM, V21, P854, DOI 10.1089/0897715041526212
   Corcoran TB, 2011, ANTIOXID REDOX SIGN, V15, P2663, DOI 10.1089/ars.2011.4125
   Cortes DF, 2012, ELECTROPHORESIS, V33, P3712, DOI 10.1002/elps.201200341
   Crawford F, 2012, J NEUROTRAUM, V29, P246, DOI 10.1089/neu.2011.1789
   Dash PK, 2010, NEUROTHERAPEUTICS, V7, P100, DOI 10.1016/j.nurt.2009.10.019
   de Boussard CN, 2005, J REHABIL MED, V37, P53, DOI 10.1080/16501970410015587
   De Guire V, 2013, CLIN BIOCHEM, V46, P846, DOI 10.1016/j.clinbiochem.2013.03.015
   de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727
   de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x
   Denslow N, 2003, J NEUROTRAUM, V20, P401, DOI 10.1089/089771503765355487
   Diamandis EP, 2004, J NATL CANCER I, V96, P353, DOI 10.1093/jnci/djh056
   Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040
   Doolan AW, 2012, ANN BIOMED ENG, V40, P106, DOI 10.1007/s10439-011-0413-3
   DORAN JF, 1983, J NEUROCHEM, V40, P1542, DOI 10.1111/j.1471-4159.1983.tb08124.x
   ENG LF, 1971, BRAIN RES, V28, P351, DOI 10.1016/0006-8993(71)90668-8
   Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006
   Farkas O, 2005, ACTA NEUROCHIR, V147, P855, DOI 10.1007/s00701-005-0559-6
   Floyd CL, 2007, PROG BRAIN RES, V161, P61, DOI 10.1016/S0079-6123(06)61005-4
   Gao WM, 2014, PEDIATR RES, V76, P280, DOI 10.1038/pr.2014.86
   Gatson JW, 2014, J NEUROSURG, V121, P1232, DOI 10.3171/2014.7.JNS132474
   Giacoppo S, 2012, NEUROCRIT CARE, V16, P470, DOI 10.1007/s12028-012-9707-z
   Gogas H, 2009, ANN ONCOL, V20, pvi8, DOI DOI 10.1093/ANN0NC/MDP251
   Good DM, 2007, J PROTEOME RES, V6, P4549, DOI 10.1021/pr070529w
   Greer JE, 2013, ACTA NEUROPATHOL, V126, P59, DOI 10.1007/s00401-013-1119-4
   Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324
   Guingab-Cagmat JD, 2012, ELECTROPHORESIS, V33, P3786, DOI 10.1002/elps.201200326
   Guzel A, 2010, AM J EMERG MED, V28, P399, DOI 10.1016/j.ajem.2008.12.025
   Gyorgy A, 2011, J NEUROTRAUM, V28, P1121, DOI 10.1089/neu.2010.1561
   Gyorgy AB, 2010, J NEUROSCI METH, V192, P96, DOI 10.1016/j.jneumeth.2010.07.029
   HAIMOTO H, 1987, LAB INVEST, V57, P489
   HALL ED, 1993, RES P ARNMD, V71, P81
   Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021
   Hallen M, 2010, J TRAUMA, V69, P284, DOI 10.1097/TA.0b013e3181ca060b
   Hanrieder J, 2009, J NEUROSCI METH, V177, P469, DOI 10.1016/j.jneumeth.2008.10.038
   Haqqani AS, 2007, J NEUROTRAUM, V24, P54, DOI 10.1089/neu.2006.0079
   Haskins WE, 2005, J NEUROTRAUM, V22, P629, DOI 10.1089/neu.2005.22.629
   Hergenroeder G, 2008, J NEUROTRAUM, V25, P79, DOI 10.1089/neu.2007.0386
   Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972
   Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606
   Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321
   Hylin MJ, 2013, J NEUROTRAUM, V30, P702, DOI 10.1089/neu.2012.2630
   Inci S, 1998, NEUROSURGERY, V43, P330, DOI 10.1097/00006123-199808000-00095
   INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a
   Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171
   Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047
   JACKSON P, 1981, J NEUROL SCI, V49, P429, DOI 10.1016/0022-510X(81)90032-0
   Jagoda Andy S, 2009, J Emerg Nurs, V35, pe5, DOI 10.1016/j.jen.2008.12.010
   Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101
   Jeter CB, 2013, J NEUROTRAUM, V30, P671, DOI 10.1089/neu.2012.2491
   Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439
   Jeter CB, 2012, J NEUROTRAUM, V29, P119, DOI 10.1089/neu.2011.2029
   Johnsson P, 2000, ANN THORAC SURG, V69, P750, DOI 10.1016/S0003-4975(99)01393-4
   Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33
   Kamnaksh A, 2012, ELECTROPHORESIS, V33, P3680, DOI 10.1002/elps.201200319
   Kavalci C, 2007, AM J EMERG MED, V25, P391, DOI 10.1016/j.ajem.2006.10.008
   Kleindienst A, 2006, J NEUROTRAUM, V23, P1185, DOI 10.1089/neu.2006.23.1185
   Kobeissy FH, 2008, PROTEOM CLIN APPL, V2, P1467, DOI 10.1002/prca.200800011
   Kobeissy FH, 2006, MOL CELL PROTEOMICS, V5, P1887, DOI 10.1074/mcp.M600157-MCP200
   Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564
   Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, P1
   Koh SXT, 2014, SPORTS MED, V44, P369, DOI 10.1007/s40279-013-0119-9
   Kontogeorgis D, 2013, EMERG MED J, V30, P597, DOI 10.1136/emermed-2013-202853.3
   Kou ZF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080296
   Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7
   Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6
   Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921
   Lakshmanan R, 2010, NEUROCRIT CARE, V12, P324, DOI 10.1007/s12028-010-9342-5
   Lamers KJB, 2003, BRAIN RES BULL, V61, P261, DOI 10.1016/S0361-9230(03)00089-3
   Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001
   Lash GE, 2006, J IMMUNOL METHODS, V309, P205, DOI 10.1016/j.jim.2005.12.007
   Laterza OF, 2009, CLIN CHEM, V55, P1977, DOI [10.1373/clinchem.2009.131737, 10.1373/clinchem.2009.131797]
   Liu MC, 2006, BIOCHEM J, V394, P715, DOI 10.1042/BJ20050905
   Lundblad R., 2003, INTERNET J GENOMICS, V1
   Ma M, 2008, AM J EMERG MED, V26, P763, DOI 10.1016/j.ajem.2007.10.029
   Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9
   MAIR J, 1992, CRIT REV CL LAB SCI, V29, P31, DOI 10.3109/10408369209105245
   Manley GT, 2010, ARCH PHYS MED REHAB, V91, P1667, DOI 10.1016/j.apmr.2010.05.018
   Marion DW, 2011, J NEUROTRAUM, V28, P517, DOI 10.1089/neu.2010.1638
   Martins TB, 2002, AM J CLIN PATHOL, V118, P346
   Mazzini GS, 2005, LIFE SCI, V77, P882, DOI 10.1016/j.lfs.2004.12.035
   McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05
   Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503
   Meric E, 2010, J EMERG MED, V38, P297, DOI 10.1016/j.jemermed.2007.11.032
   Michetti F, 2012, J NEUROCHEM, V120, P644, DOI 10.1111/j.1471-4159.2011.07612.x
   Miller EC, 1996, ANN EMERG MED, V27, P290, DOI 10.1016/S0196-0644(96)70261-5
   Missler U, 1999, CLIN CHEM, V45, P138
   Mondello S, 2014, MED RES REV, V34, P503, DOI 10.1002/med.21295
   Mondello S, 2011, EXPERT REV MOL DIAGN, V11, P65, DOI [10.1586/erm.10.104, 10.1586/ERM.10.104]
   Morris M, 2011, NEURON, V70, P410, DOI 10.1016/j.neuron.2011.04.009
   Mussack T, 2002, SHOCK, V18, P395, DOI 10.1097/00024382-200211000-00002
   O'Neal WK, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-9
   Ojo JO, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00213
   Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883
   Ottens AK, 2006, MASS SPECTROM REV, V25, P380, DOI 10.1002/mas.20073
   Ottens AK, 2007, PROG BRAIN RES, V161, P401, DOI 10.1016/S0079-6123(06)61029-7
   Ottens AK, 2014, J NEUROTRAUM, V31, P782, DOI 10.1089/neu.2013.3116
   Ottens AK, 2010, J NEUROTRAUM, V27, P1837, DOI 10.1089/neu.2010.1374
   Papa L, 2014, J NEUROTRAUM, V31, P1815, DOI 10.1089/neu.2013.3245
   Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021
   Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d
   Berger RP, 2006, PEDIATR CRIT CARE ME, V7, P557, DOI 10.1097/01.PCC.0000244426.37793.23
   Pasinetti Giulio M, 2012, Am J Neurodegener Dis, V1, P88
   Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0
   Pelinka LE, 2005, SHOCK, V24, P119, DOI 10.1097/01.shk.0000168876.68154.43
   Pelinka LE, 2004, SHOCK, V22, P88, DOI 10.1097/01.shk.0000130157.34382.3f
   Pelinka LE, 2004, SHOCK, V21, P72, DOI 10.1097/01.shk.0000101672.49265.14
   Pelsers MMAL, 2004, CLIN CHEM, V50, P1568, DOI 10.1373/clinchem.2003.030361
   Petzold A, 2005, J NEUROL SCI, V233, P183, DOI 10.1016/j.jns.2005.03.015
   Pickering A, 2008, EMERG MED J, V25, P88, DOI 10.1136/emj.2007.046631
   Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x
   Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002
   Pineda JA, 2004, BRAIN PATHOL, V14, P202, DOI 10.1111/j.1750-3639.2004.tb00054.x
   Pogoda TK, 2014, J REHABIL RES DEV, V51, P363, DOI 10.1682/JRRD.2013.05.0115
   Puvenna V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096296
   Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012
   Ramont L, 2005, CLIN CHEM LAB MED, V43, P1215, DOI 10.1515/CCLM.2005.210
   RAND Corporation, 2008, INV WOUNDS MENT HLTH
   Redell JB, 2010, J NEUROTRAUM, V27, P2147, DOI 10.1089/neu.2010.1481
   Ringger NC, 2004, J NEUROTRAUM, V21, P1443, DOI 10.1089/neu.2004.21.1443
   ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934
   Rodriguez-Rodriguez A, 2012, CLIN CHIM ACTA, V414, P228, DOI 10.1016/j.cca.2012.09.025
   Romeo MJ, 2005, EXPERT REV PROTEOMIC, V2, P57, DOI 10.1586/14789450.2.1.57
   Rosenbaum SB, 2012, BRAIN IMAGING BEHAV, V6, P255, DOI 10.1007/s11682-012-9162-7
   Rostami Elham, 2012, Front Neurol, V3, P115, DOI 10.3389/fneur.2012.00115
   Rubenstein R, 2015, J NEUROTRAUM, V32, P342, DOI 10.1089/neu.2014.3548
   Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692
   Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586
   Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010
   Sakai K, 2003, J CLIN NEUROSCI, V10, P677, DOI 10.1016/S0967-5868(03)00073-0
   Sandler SJI, 2010, CHILD NERV SYST, V26, P205, DOI 10.1007/s00381-009-1009-1
   Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x
   SCHMECHEL D, 1978, NATURE, V276, P834, DOI 10.1038/276834a0
   Schroeter ML, 2013, CURR DRUG TARGETS, V14, P1237
   SCHWAB C, 1994, HIPPOCAMPUS, V4, P210, DOI 10.1002/hipo.450040212
   Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476
   Seifman MA, 2008, J CEREBR BLOOD F MET, V28, P684, DOI 10.1038/sj.jcbfm.9600603
   Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367
   Sharp DJ, 2011, CURR OPIN NEUROL, V24, P558, DOI 10.1097/WCO.0b013e32834cd523
   Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5
   Shultz SR, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-26
   SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1
   Siman R, 2004, NEUROBIOL DIS, V16, P311, DOI 10.1016/j.nbd.2004.03.016
   SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572
   Siman R., 2014, J NEUROTRAU IN PRESS
   Siman R, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00190
   SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367
   Sojka P, 2006, BRAIN INJURY, V20, P613, DOI 10.1080/02699050600676982
   Somers V, 2008, J IMMUNOL, V180, P3957, DOI 10.4049/jimmunol.180.6.3957
   Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910
   Stalnacke BM, 2007, J REHABIL MED, V39, P405, DOI 10.2340/16501977-0057
   Stapert S, 2005, EUR NEUROL, V53, P22, DOI 10.1159/000083678
   Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604
   Stein SC, 2001, J TRAUMA, V50, P759, DOI 10.1097/00005373-200104000-00032
   Stranjalis G, 2004, J NEUROTRAUM, V21, P1070, DOI 10.1089/0897715041651088
   Svetlov SI, 2009, J NEUROTRAUM, V26, P913, DOI 10.1089/neu.2008.0609
   Takami Y, 2007, ARTERIOSCL THROM VAS, V27, P2184, DOI 10.1161/ATVBAHA.107.142505
   Tandler N, 2012, AMINO ACIDS, V43, P2203, DOI 10.1007/s00726-012-1409-5
   THOMPSON RJ, 1983, BRAIN RES, V278, P224, DOI 10.1016/0006-8993(83)90241-X
   Tolan NV, 2013, CLIN CHIM ACTA, V424, P216, DOI 10.1016/j.cca.2013.06.009
   Topolovec-Vranic J, 2011, J TRAUMA, V71, pS478, DOI 10.1097/TA.0b013e318232fa70
   Townend WJ, 2002, J NEUROL NEUROSUR PS, V73, P542, DOI 10.1136/jnnp.73.5.542
   Tsai YD, 2013, BRAIN INJURY, V27, P361, DOI 10.3109/02699052.2012.750738
   Unden J, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-50
   Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200
   Varma S, 2003, J NEUROTRAUM, V20, P781, DOI 10.1089/089771503767870005
   VINORES SA, 1984, J HISTOCHEM CYTOCHEM, V32, P1295, DOI 10.1177/32.12.6389693
   Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490
   Wang KKW, 2004, INT REV NEUROBIOL, V61, P215
   Wang KKW, 2005, EXPERT REV PROTEOMIC, V2, P603, DOI 10.1586/14789450.2.4.603
   Wang KKW, 1996, ARCH BIOCHEM BIOPHYS, V331, P208, DOI 10.1006/abbi.1996.0300
   Wang M, 2011, RHEUMATOL INT, V31, P1009, DOI 10.1007/s00296-010-1403-8
   Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864
   Weiss ES, 2009, ANN THORAC SURG, V88, P543, DOI 10.1016/j.athoracsur.2009.04.016
   Weng XJ, 2012, CLIN BIOCHEM, V45, P303, DOI 10.1016/j.clinbiochem.2011.12.018
   WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014
   Woertgen C, 2001, J NEUROTRAUM, V18, P569, DOI 10.1089/089771501300227378
   Wolf H, 2013, J NEUROSURG, V118, P1298, DOI 10.3171/2013.1.JNS121181
   Yang SH, 2013, SHOCK, V40, P471, DOI 10.1097/SHK.0000000000000037
   Yang SH, 2013, J SURG RES, V184, P981, DOI 10.1016/j.jss.2013.03.075
   Yokobori S, 2013, CNS NEUROSCI THER, V19, P556, DOI 10.1111/cns.12127
   Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9
   Zhang Z, 2014, EURASIP J AUDIO SPEE, V2014, P1, DOI DOI 10.1038/0NC.2014.208
   Zhang ZJ, 2011, J CLIN LAB ANAL, V25, P402, DOI 10.1002/jcla.20491
   Zurbig P, 2012, ELECTROPHORESIS, V33, P3617, DOI 10.1002/elps.201200360
NR 225
TC 23
Z9 23
U1 7
U2 39
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4886
EI 1090-2430
J9 EXP NEUROL
JI Exp. Neurol.
PD JAN
PY 2016
VL 275
SI SI
BP 334
EP 352
DI 10.1016/j.expneurol.2015.05.004
PN 3
PG 19
WC Neurosciences
SC Neurosciences & Neurology
GA DB2ED
UT WOS:000368320200005
PM 25981889
OA green_accepted
DA 2018-03-20
ER

PT J
AU Meenach, SA
   Anderson, KW
   Hilt, JZ
AF Meenach, Samantha A.
   Anderson, Kimberly W.
   Hilt, J. Zach
TI Synthesis and Characterization of Thermoresponsive Poly(ethylene
   glycol)-Based Hydrogels and Their Magnetic Nanocomposites
SO JOURNAL OF POLYMER SCIENCE PART A-POLYMER CHEMISTRY
LA English
DT Article
DE hydrogels; magnetic; nanocomposites; PEG; stimulisensitive polymers;
   temperature-responsive
ID DRUG-DELIVERY; RELEASE; POLYMERIZATION; NETWORKS; POLYMERS; PROTEIN
AB Temperature-responsive hydrogels are one of the most widely studied types of stimuli-responsive hydrogel systems. Their ability to transition between their swollen and collapsed states makes them attractive for controlled drug delivery, microfluidic devices, and biosensor applications. Recent work has shown that poly(ethylene glycol) (PEG) methacrylate polymers are temperature-responsive and exhibit a wide range of lower critical solution temperatures based on the length of ethylene glycol units in the macromer chain. The addition of iron oxide nanoparticles into the hydrogel matrix can provide the ability to remotely heat the gels upon exposure to an alternating magnetic field (AMF). In this work, diethylene glycol (n = 2) methyl ether methacrylate and PEG (n = 4.5) methyl ether methacrylate copolymers were polymerized into hydrogels with 5 mol PEG 600 (n = 13.6) dimethacrylate as the crosslinker along with 5 wt % iron oxide nanoparticles. Volumetric swelling studies were completed from 22 to 80 degrees C and confirmed the temperature-responsive nature of the hydrogel systems. The ability of the gels to collapse in response to rapid temperature changes when exposed to an AMF was demonstrated showing their potential use in biomedical applications such as controlled drug delivery and hyperthermia therapy. (C) 2010 Wiley Periodicals, Inc. J Polym Sci Part A: Polym Chem 48: 3229-3235, 2010
C1 [Meenach, Samantha A.; Anderson, Kimberly W.; Hilt, J. Zach] Univ Kentucky, Lexington, KY 40506 USA.
RP Hilt, JZ (reprint author), Univ Kentucky, 177 F Paul Anderson Tower, Lexington, KY 40506 USA.
EM hilt@engr.uky.edu
RI Meenach, Samantha/F-7542-2014
FU KSEF [1169-RDE-009]; NSF IGERT
FX The authors acknowledge the funding from KSEF 1169-RDE-009 and NSF IGERT
   for their funding support.
CR Babincova M, 2001, J MAGN MAGN MATER, V225, P109, DOI 10.1016/S0304-8853(00)01237-3
   Brazel CS, 2009, PHARM RES-DORD, V26, P644, DOI 10.1007/s11095-008-9773-2
   BRAZEL CS, 1995, MACROMOLECULES, V28, P8016, DOI 10.1021/ma00128a007
   DiRamio JA, 2005, BIOTECHNOL PROGR, V21, P1281, DOI 10.1021/bp0495670
   Elbert DL, 2001, J CONTROL RELEASE, V76, P11, DOI 10.1016/S0168-3659(01)00398-4
   Flory P. J., 1953, PRINCIPLES POLYM CHE
   Fournier D, 2007, MACROMOLECULES, V40, P915, DOI 10.1021/ma062199r
   Frimpong R.A., 2006, J BIOMED MATER RES A, V80, P1
   Lutz JF, 2008, J POLYM SCI POL CHEM, V46, P3459, DOI 10.1002/pola.22706
   Lutz JF, 2006, J AM CHEM SOC, V128, P13046, DOI 10.1021/ja065324n
   Lutz JF, 2006, MACROMOLECULES, V39, P893, DOI 10.1021/ma0517042
   Meenach SA, 2009, ACTA BIOMATER, V6, P1039
   Meenach SA, 2009, J BIOMED MATER RES A, V91A, P903, DOI 10.1002/jbm.a.32322
   Meenach Samantha A., 2009, P131, DOI 10.1007/978-0-387-78608-7_7
   Mellott MB, 2001, BIOMATERIALS, V22, P929, DOI 10.1016/S0142-9612(00)00258-1
   MERRILL EW, 1993, BIOMATERIALS, V14, P1117, DOI 10.1016/0142-9612(93)90154-T
   Peppas NA, 2000, EUR J PHARM BIOPHARM, V50, P27, DOI 10.1016/S0939-6411(00)00090-4
   Peppas NA, 2006, ADV MATER, V18, P1345, DOI 10.1002/adma.200501612
   PEPPAS NA, 1976, J POLYM SCI POL CHEM, V14, P441, DOI 10.1002/pol.1976.170140215
   Peppas NA, 1999, J CONTROL RELEASE, V62, P81, DOI 10.1016/S0168-3659(99)00027-9
   Qiu Y, 2001, ADV DRUG DELIVER REV, V53, P321, DOI 10.1016/S0169-409X(01)00203-4
   Satarkar NS, 2008, J CONTROL RELEASE, V130, P246, DOI 10.1016/j.jconrel.2008.06.008
   Satarkar NS, 2009, LAB CHIP, V9, P1773, DOI 10.1039/b822694f
   Thomas JB, 2007, POLYMER, V48, P5042, DOI 10.1016/j.polymer.2007.06.035
NR 24
TC 25
Z9 25
U1 1
U2 33
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0887-624X
J9 J POLYM SCI POL CHEM
JI J. Polym. Sci. Pol. Chem.
PD AUG 1
PY 2010
VL 48
IS 15
BP 3229
EP 3235
DI 10.1002/pola.24087
PG 7
WC Polymer Science
SC Polymer Science
GA 633EN
UT WOS:000280482400002
DA 2018-03-19
ER

PT J
AU Wooten, MKC
   Koganti, VR
   Zhou, SS
   Rankin, SE
   Knutson, BL
AF Wooten, M. Kaitlyn Clark
   Koganti, Venkat R.
   Zhou, Shanshan
   Rankin, Stephen E.
   Knutson, Barbara L.
TI Synthesis and Nanofiltration Membrane Performance of Oriented Mesoporous
   Silica Thin Films on Macroporous Supports
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE mesoporous silica; self-assembly; oriented pores; ceramic membranes;
   size selective
ID POROUS ALUMINA MEMBRANE; PORE-SIZE; ULTRAFILTRATION MEMBRANE; MCM-48
   MEMBRANE; ORIENTATION; ENHANCEMENT; SEPARATION; MECHANISM; SUBSTRATE;
   TRANSPORT
AB Silica thin films with accessible hexagonal close-packed (HCP) pores have been deposited on macroporous supports to achieve composite nanofiltration membranes. The properties of these pore channels have been characterized through solvent flux and solute diffusion experiments. A chemically neutral surface (provided by a cross-linked layer of P123 copolymer) for silica thin film synthesis on the alumina macroporous support promotes the alignment of HCP channels vertical to the substrate, where the mesopore templating agent is block copolymer P123 (poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol)). Vertical pore alignment is achieved for thin films (less than similar to 100 nm) on a neutral surface and by sandwiching thicker films (similar to 240 nm) between two chemically neutral surfaces. Solvent flux through the composite membranes is consistent with accessible 10 nm diameter pores. Size selectivity of the membranes is characterized from the permeability of fluorescently tagged solutes (ranging from 4000 to 70 000 Da), where a size cut off occurs at 69 000 Da for the model protein bovine serum albumin. These permeability studies of the nanofiltration membranes serve to demonstrate solute transport in oriented silica thin film membranes and also highlight their versatility for membrane-based separations.
C1 [Wooten, M. Kaitlyn Clark; Koganti, Venkat R.; Zhou, Shanshan; Rankin, Stephen E.; Knutson, Barbara L.] Univ Kentucky, Dept Chem & Mat Engn, 177 F Paul Anderson Tower, Lexington, KY 40506 USA.
RP Rankin, SE; Knutson, BL (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 F Paul Anderson Tower, Lexington, KY 40506 USA.
EM serank2@uky.edu; bknut2@uky.edu
FU National Science Foundation Integrated Graduate Education and Research
   Training (IGERT) program on Bioactive Interfaces and Devices
   [DGE-0653710]; University of Kentucky Research Experience for
   Undergraduates (REU) program [EEC 0851716]; United States Department of
   Agriculture Biomass Research and Development Initiative (BRDI) grant
   [2011-10006-30363]; Kentucky Science and Engineering Foundation
   [KSEF-2929-RDE-016]; Kentucky NSF Experimental Program to Stimulate
   Competitive Research EPSCoR grant [1355438]
FX This work was supported by the National Science Foundation Integrated
   Graduate Education and Research Training (IGERT) program on Bioactive
   Interfaces and Devices (grant no. DGE-0653710), the University of
   Kentucky Research Experience for Undergraduates (REU) program no. EEC
   0851716, the United States Department of Agriculture Biomass Research
   and Development Initiative (BRDI) grant (award no. 2011-10006-30363),
   Kentucky Science and Engineering Foundation (KSEF-2929-RDE-016), and
   Kentucky NSF Experimental Program to Stimulate Competitive Research
   EPSCoR grant (grant no. 1355438).
CR Ariga K, 2012, B CHEM SOC JPN, V85, P1, DOI 10.1246/bcsj.20110162
   Boissiere C, 2005, J MEMBRANE SCI, V251, P17, DOI 10.1016/j.memsci.2004.09.037
   Boissiere C, 2003, CHEM MATER, V15, P460, DOI 10.1021/cm021319g
   Brinker CJ, 1999, ADV MATER, V11, P579, DOI 10.1002/(SICI)1521-4095(199905)11:7<579::AID-ADMA579>3.0.CO;2-R
   Chowdhury SR, 2003, J MEMBRANE SCI, V225, P177, DOI 10.1016/j.memsci.2003.07.018
   Das S, 2014, J PHYS CHEM C, V118, P968, DOI 10.1021/jp406165v
   Davis ME, 2002, NATURE, V417, P813, DOI 10.1038/nature00785
   Edler KJ, 2001, MICROPOR MESOPOR MAT, V44, P661, DOI 10.1016/S1387-1811(01)00247-5
   Edler KJ, 2001, INT REV PHYS CHEM, V20, P387
   Fan HY, 2007, NAT MATER, V6, P418, DOI 10.1038/nmat1913
   Fujita S, 2013, CHEM MATER, V25, P1584, DOI 10.1021/cm303950u
   Guliants VV, 2004, J MEMBRANE SCI, V235, P53, DOI 10.1016/j.memsci.2004.01.019
   Jiang FJ, 2013, J MEMBRANE SCI, V441, P25, DOI 10.1016/j.memsci.2013.04.008
   Kanno Y, 2012, J PHYS CHEM C, V116, P24672, DOI 10.1021/jp308772b
   Koganti VR, 2006, NANO LETT, V6, P2567, DOI 10.1021/nl061992v
   Koganti V. R., 2006, THESIS
   Ku AY, 2005, J AM CHEM SOC, V127, P6934, DOI 10.1021/ja042202r
   Lu QY, 2004, J AM CHEM SOC, V126, P8650, DOI 10.1021/ja0488378
   Lu YF, 1997, NATURE, V389, P364, DOI 10.1038/38699
   Maeda K, 2008, MICROPOR MESOPOR MAT, V112, P603, DOI 10.1016/j.micromeso.2007.10.043
   McCool BA, 2003, J MEMBRANE SCI, V218, P55, DOI 10.1016/S0376-7388(03)00136-4
   Miller CC, 1924, P R SOC LOND A-CONTA, V106, P724, DOI 10.1098/rspa.1924.0100
   Miyata H, 1999, CHEM MATER, V11, P1609, DOI 10.1021/cm9900507
   Nagpure S, 2015, J PHYS CHEM C, V119, P22970, DOI 10.1021/acs.jpcc.5b06945
   Nazeeruddin MK, 2006, ADV FUNCT MATER, V16, P189, DOI 10.1002/adfm.200500309
   Nishiyama N, 2001, J MEMBRANE SCI, V182, P235, DOI 10.1016/S0376-7388(00)00570-6
   Palaniappan A, 2006, SENSOR ACTUAT B-CHEM, V119, P220, DOI 10.1016/j.snb.2005.12.015
   Park DH, 2003, MICROPOR MESOPOR MAT, V66, P69, DOI 10.1016/j.micromeso.2003.08.025
   Park DH, 2001, IND ENG CHEM RES, V40, P6105, DOI 10.1021/ie0103761
   PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4
   Platschek B, 2006, ANGEW CHEM INT EDIT, V45, P1134, DOI 10.1002/anie.200503301
   Platschek B, 2011, ADV MATER, V23, P2395, DOI 10.1002/adma.201002828
   Ruiz-Hitzky E, 2010, ADV MATER, V22, P323, DOI 10.1002/adma.200901134
   Stein A, 2001, CURR OPIN SOLID ST M, V5, P553, DOI 10.1016/S1359-0286(01)00022-5
   Stein A, 2014, CHEM MATER, V26, P259, DOI 10.1021/cm402184h
   Urbanova V, 2014, Z ANORG ALLG CHEM, V640, P537, DOI 10.1002/zaac.201300442
   Velleman L, 2009, MICROPOR MESOPOR MAT, V126, P87, DOI 10.1016/j.micromeso.2009.05.024
   Walcarius A, 2007, NAT MATER, V6, P602, DOI 10.1038/nmat1951
   Wu YY, 2004, NAT MATER, V3, P816, DOI 10.1038/nmat1230
   Yamaguchi A, 2004, NAT MATER, V3, P337, DOI 10.1038/nmat1107
   Yamauchi Y, 2005, J MATER CHEM, V15, P1137, DOI 10.1039/b418478e
   Zhang JL, 2003, J MEMBRANE SCI, V222, P219, DOI 10.1016/S0376-7388(03)00292-8
   Zhao DY, 1998, SCIENCE, V279, P548, DOI 10.1126/science.279.5350.548
NR 43
TC 2
Z9 2
U1 3
U2 34
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944-8244
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD AUG 24
PY 2016
VL 8
IS 33
BP 21806
EP 21815
DI 10.1021/acsami.6b06765
PG 10
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA DU4JR
UT WOS:000382179400079
PM 27479791
OA gold
DA 2018-03-20
ER

PT J
AU Naga, KK
   Sullivan, PG
   Geddes, JW
AF Naga, Kranthi Kumari
   Sullivan, Patrick G.
   Geddes, James W.
TI High cyclophilin D content of synaptic mitochondria results in increased
   vulnerability to permeability transition
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
DE calcium; necrosis; cyclosporine A; Ppif; caspase-independent; astrocytes
ID ADENINE-NUCLEOTIDE TRANSLOCASE; CYCLOSPORINE-A; BRAIN MITOCHONDRIA;
   CELL-DEATH; HIPPOCAMPAL-NEURONS; CYTOCHROME-OXIDASE; LIVER-MITOCHONDRIA;
   CORTICAL-NEURONS; RAT; INHIBITION
AB Mitochondria isolated from synaptosomes are more sensitive to Ca(2+) overload and the resultant opening of the mitochondrial permeability transition pore (mPTP) than nonsynaptic mitochondria. To identify the mechanisms underlying these differences in Ca(2+) dynamics, we examined relative levels of mPTP components in synaptic versus nonsynaptic mitochondria. Synaptic mitochondria had higher levels of cyclophilinDwhencompared with nonsynaptic mitochondria, whereas levels of the voltage-dependent anion channel and the adenine nucleotide translocase were similar in the two mitochondrial fractions. These differences in Ca(2+) handling between synaptic and nonsynaptic mitochondria were greatly reduced in cyclophilin D null [Ppif(-/-) ( peptidylprolyl isomerase F)] mice. Higher concentrations of cyclosporine A, which interacts with cyclophilin Dto delay m PTP opening, were necessary to increase the Ca(2+) uptake capacity of synaptic versus nonsynaptic mitochondria. To determine whether the differences in Ca(2+) handling might reflect the relative abundance of neuronal and glial mitochondria in the two mitochondrial fractions, we compared cyclophilin D levels in primary cortical neurons and astrocytes. Primary rat cortical neurons possess higher cyclophilin D levels than do primary astrocytes. In the adult rat brain, cyclophilin D immunoreactivity was abundant in neurons but sparse in astrocytes. Together, these results demonstrate that the Ca(2+) handling differences observed in synaptic versus nonsynaptic mitochondria are primarily the result of the high levels of cyclophilin D in synaptic mitochondria, reflecting the greater proportion of neuronal mitochondria in this fraction. The high levels of cyclophilin D in neuronal mitochondria result in their greater vulnerability to mPT and in higher levels of cyclosporine A being required to inhibit mPTP opening.
C1 Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA.
RP Geddes, JW (reprint author), Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, B379 Biomed & Biol Sci Res Bldg741 S Limestone St, Lexington, KY 40536 USA.
EM jgeddes@uky.edu
FU NINDS NIH HHS [NS058484, NS045726]; NIA NIH HHS [AG10836]
CR Baines CP, 2007, NAT CELL BIOL, V9, P550, DOI 10.1038/ncb1575
   Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434
   Bambrick LL, 2006, J BIOENERG BIOMEMBR, V38, P43, DOI 10.1007/s10863-006-9004-7
   Basso E, 2005, J BIOL CHEM, V280, P18558, DOI 10.1074/jbc.C500089200
   Bernardi P, 2006, FEBS J, V273, P2077, DOI 10.1111/j.1742-4658.2006.05213.x
   Bernardi P, 1998, BIOFACTORS, V8, P273, DOI 10.1002/biof.5520080315
   BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513
   BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826
   Brown MR, 2004, J NEUROSCI METH, V137, P299, DOI 10.1016/j.jneumeth.2004.02.028
   Brown MR, 2006, J BIOL CHEM, V281, P11658, DOI 10.1074/jbc.M510303200
   Brustovetsky N, 2000, J NEUROSCI, V20, P8229
   Chalmers S, 2003, J BIOL CHEM, V278, P19062, DOI 10.1074/jbc.M212661200
   Chinopoulos C, 2003, J BIOL CHEM, V278, P27382, DOI 10.1074/jbc.M303808200
   Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x
   Fox DA, 2003, EUR J OPHTHALMOL, V13, pS44
   Friberg H, 1998, J NEUROSCI, V18, P5151
   Gijtenbeek JMM, 1999, J NEUROL, V246, P339, DOI 10.1007/s004150050360
   Gulyas AI, 2006, EUR J NEUROSCI, V23, P2581, DOI 10.1111/j.1460-9568.2006.04814.x
   HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153
   Hansson MJ, 2004, J BIOENERG BIOMEMBR, V36, P407, DOI 10.1023/B:JOBB.0000041776.31885.45
   Hansson MJ, 2004, J NEUROCHEM, V89, P715, DOI 10.1111/j.1471-4159.2004.02400.x
   Hansson MJ, 2003, BRAIN RES, V960, P99, DOI 10.1016/S0006-8993(02)03798-8
   HAWORTH RA, 1979, ARCH BIOCHEM BIOPHYS, V195, P460, DOI 10.1016/0003-9861(79)90372-2
   Hertz L, 2007, J CEREBR BLOOD F MET, V27, P219, DOI 10.1038/sj.jcbfm.9600343
   HEVNER RF, 1989, J NEUROSCI, V9, P3884
   KAGEYAMA GH, 1982, NEUROSCIENCE, V7, P2337, DOI 10.1016/0306-4522(82)90199-3
   Kahlert S, 2001, J NEUROSCI RES, V66, P1019, DOI 10.1002/jnr.10052
   Khaspekov L, 1999, EUR J NEUROSCI, V11, P3194, DOI 10.1046/j.1460-9568.1999.00743.x
   Kim JS, 2003, BIOCHEM BIOPH RES CO, V304, P463, DOI 10.1016/S0006-291X(03)00618-1
   Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229
   Kristal BS, 1997, J NEUROCHEM, V69, P524
   Kristian T, 2000, J NEUROCHEM, V74, P1999, DOI 10.1046/j.1471-4159.2000.0741999.x
   Matsumoto S, 2002, LIFE SCI, V72, P591, DOI 10.1016/S0024-3205(02)02267-1
   McDonald JW, 1996, ANN NEUROL, V40, P750, DOI 10.1002/ana.410400511
   MULLEN RJ, 1992, DEVELOPMENT, V116, P201
   Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317
   Nieminen AL, 1996, NEUROSCIENCE, V75, P993
   Okonkwo DO, 2003, NEUROREPORT, V14, P463, DOI 10.1097/01.wnr.0000058958.85541.d3
   Pang Z, 2003, J NEUROPATH EXP NEUR, V62, P633, DOI 10.1093/jnen/62.6.633
   Schinder AF, 1996, J NEUROSCI, V16, P6125
   SCORRANO L, 2002, J NEUROSCI, V2, P55
   Sengoku T, 2004, EXP NEUROL, V188, P161, DOI 10.1016/j.expneurol.2004.03.018
   SIMS NR, 1990, J NEUROCHEM, V55, P698, DOI 10.1111/j.1471-4159.1990.tb04189.x
   Sinigaglia-Coimbra R, 2002, J NEUROL SCI, V203, P273, DOI 10.1016/S0022-510X(02)00304-0
   Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292
   SZABO I, 1992, J BIOENERG BIOMEMBR, V24, P111, DOI 10.1007/BF00769537
   Vachon P, 2002, BRAIN RES, V943, P1, DOI 10.1016/S0006-8993(02)02413-7
   White RJ, 1996, J NEUROSCI, V16, P5688
   Woodfield K, 1998, BIOCHEM J, V336, P287, DOI 10.1042/bj3360287
   ZOCCARATO F, 1982, EUR J BIOCHEM, V127, P333, DOI 10.1111/j.1432-1033.1982.tb06875.x
NR 50
TC 93
Z9 93
U1 1
U2 2
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD JUL 11
PY 2007
VL 27
IS 28
BP 7469
EP 7475
DI 10.1523/JNEUROSCI.0646-07.2007
PG 7
WC Neurosciences
SC Neurosciences & Neurology
GA 191RD
UT WOS:000248147900011
PM 17626207
OA gold
DA 2018-03-20
ER

PT J
AU Miller, AF
   Yikilmaz, E
   Porta, J
   Grove, LE
   Bronshteyn, Y
   Xie, J
   Vahedi-Faridi, A
   Rodgers, DW
   Brunold, TC
   Borgstahl, GE
AF Miller, Anne-Frances
   Yikilmaz, Emine
   Porta, J.
   Grove, L. E.
   Bronshteyn, Y.
   Xie, J.
   Vahedi-Faridi, A.
   Rodgers, David W.
   Brunold, T. C.
   Borgstahl, G. E.
TI CATL 40-Redox tuning over 100s of mV via H-bonding and control of
   redox-coupled protons, in superoxide dismutase
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
C1 [Miller, A-F] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
   [Grove, L. E.; Xie, J.; Brunold, T. C.] Univ Wisconsin, Madison, WI USA.
   [Rodgers, David W.] Univ Kentucky, Med Ctr, Lexington, KY 40536 USA.
EM afm@uky.edu; david.rodgers@uky.edu
RI Miller, Anne-Frances/M-7703-2017
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD AUG 19
PY 2007
VL 234
MA 40-CATL
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA V12IW
UT WOS:000207593900822
DA 2018-03-20
ER

PT J
AU Mansour, HM
   Rhee, YS
   Wu, XA
AF Mansour, Heidi M.
   Rhee, Yun-Seok
   Wu, Xiao
TI Nanomedicine in pulmonary delivery
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Review
DE pulmonary delivery; colloidal carriers; nanocarrier systems; liposome;
   polymeric nanoparticle; solid lipid nanoparticle; submicron emulsion;
   dendrimer
ID SOLID LIPID NANOPARTICLES; DRY POWDER INHALER; SUPERCRITICAL-FLUID
   EXTRACTION; VASOACTIVE-INTESTINAL-PEPTIDE; MEDIATED GENE DELIVERY;
   CELL-CULTURE MODELS; ENGINEERED DRUG THERAPIES; AIRWAY EPITHELIAL-CELLS;
   IN-VIVO; ALVEOLAR MACROPHAGES
AB The lung is an attractive target for drug delivery due to noninvasive administration via inhalation aerosols, avoidance of first-pass metabolism, direct delivery to the site of action for the treatment of respiratory diseases, and the availability of a huge surface area for local drug action and systemic absorption of drug. Colloidal carriers (ie, nanocarrier systems) in pulmonary drug delivery offer many advantages such as the potential to achieve relatively uniform distribution of drug dose among the alveoli, achievement of improved solubility of the drug from its own aqueous solubility, a sustained drug release which consequently reduces dosing frequency, improves patient compliance, decreases incidence of side effects, and the potential of drug internalization by cells. This review focuses on the current status and explores the potential of colloidal carriers (ie, nanocarrier systems) in pulmonary drug delivery with special attention to their pharmaceutical aspects. Manufacturing processes, in vitro/in vivo evaluation methods, and regulatory/toxicity issues of nanomedicines in pulmonary delivery are also discussed.
C1 [Mansour, Heidi M.; Rhee, Yun-Seok; Wu, Xiao] Univ Kentucky, Coll Pharm, Div Pharmaceut Sci, Drug Dev Div, Lexington, KY 40536 USA.
RP Mansour, HM (reprint author), Univ Kentucky, Coll Pharm, Div Pharmaceut Sci, Drug Dev Div, 725 Rose St, Lexington, KY 40536 USA.
EM heidi.mansour@uky.edu
RI Wu, Xiao/A-4265-2011; Mansour, Heidi/D-1074-2011
CR Agu RU, 2001, RESPIR RES, V2, P198
   Almeida AJ, 2007, ADV DRUG DELIVER REV, V59, P478, DOI 10.1016/j.addr.2007.04.007
   ALTON EWFW, 1993, NAT GENET, V5, P135, DOI 10.1038/ng1093-135
   Avram MJ, 2007, DRUG METAB DISPOS, V35, P262, DOI 10.1124/dmd.106.010652
   Azarmi S, 2008, ADV DRUG DELIVER REV, V60, P863, DOI 10.1016/j.addr.2007.11.006
   Azarmi S, 2006, INT J PHARM, V319, P155, DOI 10.1016/j.ijpharm.2006.03.052
   Bai SH, 2007, J PHARM SCI-US, V96, P2090, DOI 10.1002/jps.20849
   Bai SH, 2009, PHARM RES-DORD, V26, P539, DOI 10.1007/s11095-008-9769-y
   Bailey MM, 2009, MED RES REV, V29, P196, DOI 10.1002/med.20140
   Ballou B, 2004, BIOCONJUGATE CHEM, V15, P79, DOI 10.1021/bc034153y
   Barry PW, 1999, J ALLERGY CLIN IMMUN, V104, P1168, DOI 10.1016/S0091-6749(99)70009-6
   Bates S, 2006, PHARM RES, V23, P2333, DOI 10.1007/s11095-006-9086-2
   Beaulac C, 1999, J DRUG TARGET, V7, P33, DOI 10.3109/10611869909085490
   Beck-Broichsitter M, 2009, INT J PHARM, V367, P169, DOI 10.1016/j.ijpharm.2008.09.017
   Bi R, 2008, J DRUG TARGET, V16, P639, DOI [10.1080/10611860802201134, 10.1080/10611860802201134 ]
   Bivas-Benita M, 2004, J CONTROL RELEASE, V100, P145, DOI 10.1016/j.jconrel.2004.08.008
   Bivas-Benita M, 2004, VACCINE, V22, P1609, DOI 10.1016/j.vaccine.2003.09.044
   Boas U, 2004, CHEM SOC REV, V33, P43, DOI 10.1039/b309043b
   Borchard G, 2002, J PHARM SCI, V91, P1561, DOI 10.1002/jps.10151
   Brigger I, 2002, ADV DRUG DELIVER REV, V54, P631, DOI 10.1016/S0169-409X(02)00044-3
   Brzoska M, 2004, BIOCHEM BIOPH RES CO, V318, P562, DOI 10.1016/j.bbrc/2004.04.067
   Bunker Matthew, 2005, Expert Opin Drug Deliv, V2, P613, DOI 10.1517/17425247.2.4.613
   Carpenter M, 2005, GENE THER, V12, P685, DOI 10.1038/sj.gt.3302468
   Chadwick SL, 1997, GENE THER, V4, P937, DOI 10.1038/sj.gt.3300481
   Changsan N, 2009, J PHARM SCI-US, V98, P628, DOI 10.1002/jps.21441
   Chattopadhyay P, 2007, ADV DRUG DELIVER REV, V59, P444, DOI 10.1016/j.addr.2007.04.010
   Chattopadhyay P, 2006, J PHARM SCI-US, V95, P667, DOI 10.1002/jps.20555
   Chen J, 2008, BIOCHEM BIOPH RES CO, V375, P378, DOI 10.1016/j.bbrc.2008.08.006
   Chollet P, 2002, J GENE MED, V4, P84, DOI 10.1002/jgm.237
   Chono S, 2008, J CONTROL RELEASE, V131, P64, DOI 10.1016/j.jconrel.2008.07.006
   Chono S, 2006, J DRUG TARGET, V14, P557, DOI 10.1080/10611860600834375
   Chougule M, 2007, INT J NANOMED, V2, P675
   Chougule MB, 2006, J NANOSCI NANOTECHNO, V6, P3001, DOI 10.1166/jnn.2006.405
   Chow AHL, 2007, PHARM RES, V24, P411, DOI 10.1007/s11095-006-9174-3
   Cryan SA, 2005, AAPS J, V7, pE20, DOI 10.1208/aapsj070104
   Cryan SA, 2006, MOL PHARMACEUT, V3, P104, DOI 10.1021/mp050070i
   De Fougerolles AR, 2008, HUM GENE THER, V19, P125, DOI 10.1089/hum.2008.928
   de Semir D, 2002, J GENE MED, V4, P308, DOI 10.1002/jgm.264
   De Smedt SC, 2000, PHARMACEUT RES, V17, P113, DOI 10.1023/A:1007548826495
   Densmore Charles L., 2006, Current Drug Delivery, V3, P55, DOI 10.2174/156720106775197547
   Densmore CL, 1999, J GENE MED, V1, P251
   Densmore CL, 2001, CANCER GENE THER, V8, P619, DOI 10.1038/sj.cgt.7700343
   Deshpande DS, 2005, J AEROSOL MED, V18, P34, DOI 10.1089/jam.2005.18.34
   DRISCOLL DF, 1995, AM J HEALTH-SYST PH, V52, P623
   Duddu SP, 2002, PHARMACEUT RES, V19, P689, DOI 10.1023/A:1015322616613
   Ehrhardt C, 2002, J AEROSOL MED, V15, P131, DOI 10.1089/089426802320282257
   ElBaseir MM, 1997, INT J PHARM, V151, P145, DOI 10.1016/S0378-5173(96)04873-9
   Eliyahu H, 2007, BIOMATERIALS, V28, P2339, DOI 10.1016/j.biomaterials.2006.09.001
   Ely L, 2007, EUR J PHARM BIOPHARM, V65, P346, DOI 10.1016/j.ejpb.2006.10.021
   Epperly MW, 2003, GENE THER, V10, P163, DOI 10.1038/sj.gt.3301852
   Esmaeili F, 2007, NANOMED-NANOTECHNOL, V3, P161, DOI 10.1016/j.nano.2007.03.003
   FERIN J, 1991, J AEROSOL MED, V4, P57, DOI 10.1089/jam.1991.4.57
   Forbes B, 2005, EUR J PHARM BIOPHARM, V60, P193, DOI 10.1016/j.ejpb.2005.02.010
   Foster KA, 2000, INT J PHARM, V208, P1, DOI 10.1016/S0378-5173(00)00452-X
   Foster KA, 1998, EXP CELL RES, V243, P359, DOI 10.1006/excr.1998.4172
   Freitas S, 2004, J CONTROL RELEASE, V95, P185, DOI 10.1016/j.jconrel.2003.11.005
   Fujitani Y, 2006, ATMOS ENVIRON, V40, P3221, DOI 10.1016/j.atmosenv.2006.02.001
   Gautam A, 2000, MOL THER, V2, P318, DOI 10.1006/mthe.2000.0138
   Gautam A, 2002, CANCER GENE THER, V9, P28, DOI 10.1038/sj.cgt.7700405
   Gautam A, 2001, GENE THER, V8, P254, DOI 10.1038/sj.gt.3301369
   Geller MD, 2002, AEROSOL SCI TECH, V36, P748, DOI 10.1080/02786820290038447
   GIBBONS AM, 2008, J MICROENCAPSUL, P1
   Gilani K, 2005, J PHARM SCI-US, V94, P1048, DOI 10.1002/jps.20315
   Gilbert BE, 1997, AM J RESP CRIT CARE, V156, P1789, DOI 10.1164/ajrccm.156.6.9702101
   Gong FQ, 2005, PEDIATR INT, V47, P242, DOI 10.1111/j.1442-200x.2005.02060.x
   Gratton SEA, 2008, P NATL ACAD SCI USA, V105, P11613, DOI 10.1073/pnas.0801763105
   Gratton SEA, 2007, J CONTROL RELEASE, V121, P10, DOI 10.1016/j.jconrel.2007.05.027
   Gratton SEA, 2008, PHARM RES-DORD, V25, P2845, DOI 10.1007/s11095-008-9654-8
   Grenha A, 2005, EUR J PHARM SCI, V25, P427, DOI 10.1016/j.ejps.2005.04.009
   Groneberg DA, 2003, RESP MED, V97, P382, DOI 10.1053/rmed.2002.1457
   Gupta R, 2003, AEROSOL SCI TECH, V37, P672, DOI 10.1080/02786820390204900
   Hajos F, 2008, INT J PHARMACEUT, V357, P286, DOI 10.1016/j.ijpharm.2008.01.046
   Harjunen P, 2003, INT J PHARM, V263, P151, DOI 10.1016/S0378-5173(03)00357-0
   Heckel K, 2004, AM J PHYSIOL-LUNG C, V287, pL867, DOI 10.1152/ajplung.00078.2004
   Heydenreich AV, 2003, INT J PHARM, V254, P83, DOI 10.1016/S0378-5173(02)00688-9
   HICKEY AJ, 1993, AEROSOL SCI TECH, V18, P290, DOI 10.1080/02786829308959606
   Hickey A. J., 2008, MODIFIED RELEASE DRU, P573
   HICKEY AJ, 2008, MODERN PHARM, P191
   Hickey AJ, 2007, J PHARM SCI-US, V96, P1282, DOI 10.1002/jps.20916
   Hong JN, 2002, J AEROSOL MED, V15, P359, DOI 10.1089/08942680260473434
   Howard KA, 2006, MOL THER, V14, P476, DOI 10.1016/j.ymthe.2006.04.010
   Huang YY, 2006, J CONTROL RELEASE, V113, P9, DOI 10.1016/j.jconrel.2006.03.014
   Hwang SK, 2007, GENE THER, V14, P1353, DOI 10.1038/sj.gt.3302983
   Issa MM, 2006, J CONTROL RELEASE, V115, P103, DOI 10.1016/j.jconrel.2006.06.029
   Jere D, 2008, BIOMATERIALS, V29, P2535, DOI 10.1016/j.biomaterials.2008.02.018
   Jin H, 2006, MOL CANCER THER, V5, P1041, DOI 10.1158/1535-7163.MCT-05-0433
   Joshi M, 2003, CLIN EXP PHARMACOL P, V30, P153, DOI 10.1046/j.1440-1681.2003.03813.x
   Joshi M, 2001, METHOD FIND EXP CLIN, V23, P531, DOI 10.1358/mf.2001.23.10.677118
   Joshi M R, 2001, AAPS PharmSciTech, V2, P25
   Justo OR, 2003, DRUG DELIV, V10, P201, DOI 10.1080/10717540390215627
   Kaipel M, 2008, J AEROSOL MED PULM D, V21, P281, DOI 10.1089/jamp.2007.0667
   Kato T, 2003, CELL TISSUE RES, V311, P47, DOI 10.1007/s00441-002-0647-3
   Kaul G, 2005, PHARM RES, V22, P951, DOI 10.1007/s11095-005-4590-3
   Kaur IP, 2008, J CONTROL RELEASE, V127, P97, DOI 10.1016/j.jconrel.2007.12.018
   Kawashima Y, 1998, INT J PHARM, V172, P179, DOI 10.1016/S0378-5173(98)00202-6
   Khanna C, 1997, CANCER, V79, P1409, DOI 10.1002/(SICI)1097-0142(19970401)79:7<1409::AID-CNCR19>3.0.CO;2-3
   Kichler A, 2001, J GENE MED, V3, P135, DOI 10.1002/jgm.173
   Kim TW, 2000, MOL CELLS, V10, P142, DOI 10.1007/s10059-000-0142-1
   KIMURA S, 2009, HYPERTENSION
   Ko YT, 2009, J CONTROL RELEASE, V133, P132, DOI 10.1016/j.jconrel.2008.09.079
   Konduri KS, 2003, J ALLERGY CLIN IMMUN, V111, P321, DOI 10.1067/mai.2003.104
   Koping-Hoggard M, 2004, GENE THER, V11, P1441, DOI 10.1038/sj.gt.3302312
   Koshkina NV, 2003, MOL THER, V8, P249, DOI 10.1016/S1525-0016(03)00177-1
   Koster VS, 1996, INT J PHARM, V134, P235, DOI 10.1016/0378-5173(95)04409-4
   KREUTER J, 1991, J CONTROL RELEASE, V16, P169, DOI 10.1016/0168-3659(91)90040-K
   Kreyling WG, 2002, J TOXICOL ENV HEAL A, V65, P1513, DOI 10.1080/00984100290071649
   Kukowska-Latallo JF, 2000, HUM GENE THER, V11, P1385, DOI 10.1089/10430340050057468
   Kuo JHS, 2004, J PHARM PHARMACOL, V56, P27, DOI 10.1211/0022357022494
   Labana S, 2002, INT J ANTIMICROB AG, V20, P301, DOI 10.1016/S0924-8579(02)00175-9
   Larhrib H, 1999, INT J PHARM, V191, P1, DOI 10.1016/S0378-5173(99)00164-7
   Li SD, 2006, ANN NY ACAD SCI, V1082, P1, DOI 10.1196/annals.1348.001
   Li XH, 2005, INT J PHARM, V303, P113, DOI 10.1016/j.ijpharm.2005.07.010
   Lin CC, 2005, ENVIRON SCI TECHNOL, V39, P8113, DOI 10.1021/es048182a
   Lin HX, 2007, J PHARM SCI-US, V96, P341, DOI 10.1002/jps.20803
   Liu F, 1996, PHARMACEUT RES, V13, P1642, DOI 10.1023/A:1016480421204
   Liu H, 2008, INT J PHARM, V356, P333, DOI 10.1016/j.ijpharm.2008.01.008
   Lynch J, 2007, J AEROSOL MED, V20, P257, DOI 10.1089/jam.2007.0605
   Maa YF, 1999, PHARMACEUT RES, V16, P249, DOI 10.1023/A:1018828425184
   Maa YF, 1998, BIOTECHNOL BIOENG, V60, P301, DOI 10.1002/(SICI)1097-0290(19981105)60:3<301::AID-BIT5>3.3.CO;2-V
   Maa Yuh-Fun, 2000, Current Pharmaceutical Biotechnology, V1, P283, DOI 10.2174/1389201003378898
   Manford F, 2005, EUR J PHARM SCI, V26, P414, DOI 10.1016/j.ejps.2005.07.010
   Mansour HM, 2007, J PHARM SCI-US, V96, P377, DOI 10.1002/jps.20810
   Marier JF, 2003, J ANTIMICROB CHEMOTH, V52, P247, DOI 10.1093/jac/dkg317
   Mathias NR, 1996, ADV DRUG DELIVER REV, V22, P215, DOI 10.1016/S0169-409X(96)00420-6
   McConville JT, 2006, PHARM RES, V23, P901, DOI 10.1007/s11095-006-9904-6
   Mehnert W, 2001, ADV DRUG DELIVER REV, V47, P165, DOI 10.1016/S0169-409X(01)00105-3
   Merisko-Liversidge E, 2004, PHARM RES, V21, P1545, DOI 10.1023/B:PHAM.0000041446.14569.e2
   Miguel AH, 2005, AEROSOL SCI TECH, V39, P415, DOI 10.1080/027868290950338
   Mizuno T, 2009, J CONTROL RELEASE, V134, P149, DOI 10.1016/j.jconrel.2008.11.018
   Mobley C, 2001, DRUG DISCOV TODAY, V6, P367, DOI 10.1016/S1359-6446(01)01691-9
   Morille M, 2008, BIOMATERIALS, V29, P3477, DOI 10.1016/j.biomaterials.2008.04.036
   Mosen K, 2004, PHARM DEV TECHNOL, V9, P409, DOI 10.1081/PDT-200035795
   Muller RH, 1997, PHARMACEUT RES, V14, P458, DOI 10.1023/A:1012043315093
   Muller RH, 2000, EUR J PHARM BIOPHARM, V50, P161, DOI 10.1016/S0939-6411(00)00087-4
   Myers DJ, 2007, PHARM RES, V24, P336, DOI 10.1007/s11095-006-9153-8
   Newman AW, 2003, DRUG DISCOV TODAY, V8, P898, DOI 10.1016/S1359-6446(03)02832-0
   Nguyen J, 2008, J GENE MED, V10, P1236, DOI 10.1002/jgm.1255
   OBERDORSTER G, 1992, EXP LUNG RES, V18, P87, DOI 10.3109/01902149209020653
   Oberdorster G, 2002, J TOXICOL ENV HEAL A, V65, P1531, DOI 10.1080/00984100290071658
   Oberdorster G, 2005, ENVIRON HEALTH PERSP, V113, P823, DOI 10.1289/ehp.7339
   Oberdorster G, 2000, PHILOS T ROY SOC A, V358, P2719, DOI 10.1098/rsta.2000.0680
   Oberdorster G, 2004, INHAL TOXICOL, V16, P437, DOI 10.1080/08958370490439597
   Oberdorster G., 2000, RES REP HLTH EFF I, V5-74, P75
   Ogris Manfred, 2002, Somatic Cell and Molecular Genetics, V27, P85, DOI 10.1023/A:1022988008131
   Ohashi K, 2009, J CONTROL RELEASE, V135, P19, DOI 10.1016/j.jconrel.2008.11.027
   Oudrhiri N, 1997, P NATL ACAD SCI USA, V94, P1651, DOI 10.1073/pnas.94.5.1651
   Pandey R, 2005, TUBERCULOSIS, V85, P227, DOI 10.1016/j.tube.2004.11.003
   Pandey R, 2003, J ANTIMICROB CHEMOTH, V52, P981, DOI 10.1093/jac/dkg477
   Park JH, 2008, PROG POLYM SCI, V33, P113, DOI 10.1016/j.progpolymsci.2007.09.003
   Park K, 2003, ENVIRON SCI TECHNOL, V37, P577, DOI 10.1021/es025960v
   Park MR, 2008, J GENE MED, V10, P198, DOI 10.1002/jgm.1139
   Patton JS, 2007, NAT REV DRUG DISCOV, V6, P67, DOI 10.1038/nrd2153
   Pillai R, 1998, PHARMACEUT RES, V15, P1743, DOI 10.1023/A:1011964813817
   Piras AM, 2008, INT J PHARMACEUT, V357, P260, DOI 10.1016/j.ijpharm.2008.01.035
   Pitard B, 2001, J GENE MED, V3, P478, DOI 10.1002/jgm.211
   Plumley C, 2009, INT J PHARMACEUT, V369, P136, DOI 10.1016/j.ijpharm.2008.10.016
   Rabinow BE, 2004, NAT REV DRUG DISCOV, V3, P785, DOI 10.1038/nrd1494
   Rabinowitz JD, 2004, J PHARMACOL EXP THER, V309, P769, DOI 10.1124/jpet.103.062893
   Rabinowitz JD, 2006, J PHARM SCI-US, V95, P2438, DOI 10.1002/jps.20694
   Rasenack N, 2003, J PHARM SCI, V92, P35, DOI 10.1002/jps.10274
   Rehman M, 2004, EUR J PHARM SCI, V22, P1, DOI 10.1016/j.ejps.2004.02.001
   Resnik DB, 2007, CONTEMP CLIN TRIALS, V28, P433, DOI 10.1016/j.cct.2006.11.001
   Rogers TL, 2001, DRUG DEV IND PHARM, V27, P1003, DOI 10.1081/DDC-100108363
   Rudolph C, 2000, J GENE MED, V2, P269, DOI 10.1002/1521-2254(200007/08)2:4<269::AID-JGM112>3.0.CO;2-F
   Rudolph C, 2004, PHARM RES, V21, P1662, DOI 10.1023/B:PHAM.0000041463.56768.ec
   Rudolph C, 2002, BBA-GEN SUBJECTS, V1573, P75, DOI 10.1016/S0304-4165(02)00334-3
   Sakagami M, 2006, ADV DRUG DELIVER REV, V58, P1030, DOI 10.1016/j.addr.2006.07.012
   SALEKIGERHARDT A, 1994, INT J PHARM, V101, P237, DOI 10.1016/0378-5173(94)90219-4
   Sardar SB, 2005, ENVIRON SCI TECHNOL, V39, P932, DOI 10.1021/es049478j
   Schauer JJ, 2008, AEROSOL SCI TECH, V42, P210, DOI 10.1080/02786820801958742
   SCHREIER H, 1993, J CONTROL RELEASE, V24, P209, DOI 10.1016/0168-3659(93)90180-D
   SCHWARZ C, 1994, J CONTROL RELEASE, V30, P83, DOI 10.1016/0168-3659(94)90047-7
   Seong JH, 2006, J GENE MED, V8, P314, DOI 10.1002/jgm.848
   Sethuraman Vasu V, 2002, AAPS PharmSciTech, V3, pE28
   Shah SP, 2004, PHARMAZIE, V59, P812
   Shah SP, 2004, DRUG DELIV, V11, P247, DOI 10.1080/10717540490467375
   Shahiwala A, 2005, AAPS PHARMSCITECH, V6
   Sham JOH, 2004, INT J PHARM, V269, P457, DOI 10.1016/j.ijpharm.2003.09.041
   Shekunov B, 2005, IDRUGS, V8, P399
   Shekunov BY, 2006, PHARM RES, V23, P196, DOI 10.1007/s11095-005-8635-4
   Stahl K, 2002, INT J PHARM, V233, P227, DOI 10.1016/S0378-5173(01)00945-0
   Stark B, 2007, BBA-BIOMEMBRANES, V1768, P705, DOI 10.1016/j.bbamem.2006.11.017
   Steckel H, 2004, INT J PHARM, V270, P297, DOI 10.1016/j.ijpharm.2003.10.039
   Steckel H, 1997, INT J PHARM, V152, P99, DOI 10.1016/S0378-5173(97)00071-9
   Steckel H, 1998, INT J PHARM, V173, P25, DOI 10.1016/S0378-5173(98)00237-3
   Steimer A, 2005, J AEROSOL MED, V18, P137, DOI 10.1089/jam.2005.18.137
   Stenton GR, 2002, J IMMUNOL, V169, P1028, DOI 10.4049/jimmunol.169.2.1028
   STRIBLING R, 1992, P NATL ACAD SCI USA, V89, P11277, DOI 10.1073/pnas.89.23.11277
   Sung JC, 2007, TRENDS BIOTECHNOL, V25, P563, DOI 10.1016/j.tibtech.2007.09.005
   Sweeney LG, 2005, INT J PHARM, V305, P180, DOI 10.1016/j.ijpharm.2005.09.010
   Taetz S, 2009, EUR J PHARM BIOPHARM, V72, P358, DOI 10.1016/j.ejpb.2008.07.011
   Tang MX, 1997, GENE THER, V4, P823, DOI 10.1038/sj.gt.3300454
   TAYLOR KMG, 1990, INT J PHARM, V58, P57, DOI 10.1016/0378-5173(90)90287-E
   Templeton N, 2009, WORLD J SURG, V33, P685, DOI 10.1007/s00268-008-9825-0
   Tiwari Sandip B., 2006, Current Drug Delivery, V3, P219, DOI 10.2174/156720106776359230
   TOM JW, 1991, J AEROSOL SCI, V22, P555, DOI 10.1016/0021-8502(91)90013-8
   Tomoda K, 2009, COLLOID SURFACE B, V71, P177, DOI 10.1016/j.colsurfb.2009.02.001
   Traini D, 2008, DRUG DEV IND PHARM, V34, P992, DOI 10.1080/03639040802154889 
   US Food and Drug Administration, 1998, GUID IND MET DOS INH
   Vanderbist F, 1999, J PHARM PHARMACOL, V51, P1229, DOI 10.1211/0022357991776958
   Vaughn JM, 2006, EUR J PHARM BIOPHARM, V63, P95, DOI 10.1016/j.ejpb.2006.01.006
   Venkatachari P, 2007, AEROSOL SCI TECH, V41, P97, DOI 10.1080/02786820601116004
   Verschraegen CF, 2004, CLIN CANCER RES, V10, P2319, DOI 10.1158/1078-0432.CCR-0929-3
   Videira MA, 2006, J MICROENCAPSUL, V23, P855, DOI 10.1080/02652040600788221
   Videira MA, 2002, J DRUG TARGET, V10, P607, DOI 10.1080/1061186021000054933
   VIDGREN MT, 1987, INT J PHARM, V35, P139, DOI 10.1016/0378-5173(87)90082-2
   Vyas SP, 2005, INT J PHARM, V296, P12, DOI 10.1016/j.ijpharm.2005.02.003
   Vyas SP, 2004, INT J PHARM, V269, P37, DOI 10.1016/j.ijpharm.2003.08.017
   Wernig K, 2008, J CONTROL RELEASE, V130, P192, DOI 10.1016/j.jconrel.2008.06.005
   Westesen K, 2000, COLLOID POLYM SCI, V278, P608, DOI 10.1007/s003969900257
   White Steven, 2005, Diabetes Technol Ther, V7, P896, DOI 10.1089/dia.2005.7.896
   Wightman L, 2001, J GENE MED, V3, P362, DOI 10.1002/jgm.187
   Wijagkanalan W, 2008, J CONTROL RELEASE, V125, P121, DOI 10.1016/j.jconrel.2007.10.011
   Williams RO, 1999, PHARM DEV TECHNOL, V4, P167, DOI 10.1081/PDT-100101351
   Wong JP, 2003, J CONTROL RELEASE, V92, P265, DOI 10.1016/S0168-3659(03)00358-4
   Xu CX, 2008, AM J RESP CRIT CARE, V178, P60, DOI 10.1164/rccm.200707-1022OC
   Yamamoto H, 2005, J CONTROL RELEASE, V102, P373, DOI 10.1016/j.jconrel.2004.10.010
   Yang W, 2008, INT J PHARM, V361, P177, DOI 10.1016/j.ijpharm.2008.05.003
   Yang W, 2008, INT J PHARMACEUT, V356, P239, DOI 10.1016/j.ijpharm.2008.02.011
   Yi SW, 2000, PHARMACEUT RES, V17, P314, DOI 10.1023/A:1007553106681
   Yu ZS, 2004, EUR J PHARM BIOPHARM, V58, P529, DOI 10.1016/j.ejpb.2004.04.018
   Zahoor A, 2005, INT J ANTIMICROB AG, V26, P298, DOI 10.1016/j.ijantimicag.2005.07.012
   ZENG XM, 1995, INT J PHARM, V124, P149, DOI 10.1016/0378-5173(95)00104-Q
   Zhang Q, 2001, INT J PHARM, V218, P75, DOI 10.1016/S0378-5173(01)00614-7
   Ziady AG, 2003, MOL THER, V8, P936, DOI 10.1016/j.ymthe.2003.07.007
   Ziady AG, 2003, MOL THER, V8, P948, DOI 10.1016/j.ymthe.2003.09.002
   ZIMMER A, 1995, ADV DRUG DELIVER REV, V16, P61, DOI 10.1016/0169-409X(95)00017-2
NR 227
TC 185
Z9 193
U1 6
U2 75
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2009
VL 4
BP 299
EP 319
PG 21
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA 662GX
UT WOS:000282796600002
PM 20054434
DA 2018-03-20
ER

PT J
AU Zhang, XY
   Cheng, R
   Rowe, D
   Sethu, P
   Daugherty, A
   Yu, GQ
   Shin, HY
AF Zhang, Xiaoyan
   Cheng, Ran
   Rowe, Dylan
   Sethu, Palaniappan
   Daugherty, Alan
   Yu, Guoqiang
   Shin, Hainsworth Y.
TI Shear-Sensitive Regulation of Neutrophil Flow Behavior and Its Potential
   Impact on Microvascular Blood Flow Dysregulation in Hypercholesterolemia
SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
LA English
DT Article
DE inflammation; mechanotransduction; cellular; microcirculation; optical
   devices; regional blood flow
ID DIFFUSE CORRELATION SPECTROSCOPY; REDUCE CARDIOVASCULAR RISK; MEMBRANE
   CHOLESTEROL; CIRCULATING LEUKOCYTES; REACTIVE HYPEREMIA; LIPID
   MANAGEMENT; STRESS RESPONSE; NITRIC-OXIDE; IN-VIVO; INFLAMMATION
AB Objective Shear stress-induced pseudopod retraction is an anti-inflammatory measure that minimizes neutrophil activity and is regulated by membrane cholesterol. We tested the hypothesis that a hypercholesterolemic impairment of shear mechanotransduction alters the neutrophil flow behavior leading to microvascular dysfunction.
   Approach and Results We examined the shear effects on the flow behavior of human leukocytes. When subjected to shearing during cone-plate viscometry, leukocyte suspensions exhibited parallel time-dependent reductions in viscosity and pseudopod activity. Shear-induced reductions in suspension viscosity were attenuated by membrane cholesterol enrichment. We also showed that enhanced pseudopod activity of leukocyte suspensions in 10% hematocrit significantly (P<0.05) raised the flow resistance of microvascular mimics. These results implicate an impaired neutrophil pseudopod retraction response to shear in hypercholesterolemic microvascular dysfunction. We confirmed this using near-infrared diffuse correlation spectroscopy to assess skeletal muscle blood flow regulation in the hindlimbs of mice subjected to reactive hyperemia. Using a custom protocol for the mouse, we extrapolated an adjusted peak flow and time to adjusted peak flow to quantify the early phase of the blood flow recovery response during reactive hyperemia when shear mechanobiology likely has a maximal impact. Compared with mice on normal diet, hypercholesterolemic mice exhibited significantly (P<0.05) reduced adjusted peak flow and prolonged time to adjusted peak flow which correlated (r=0.4 and r=-0.3, respectively) with neutrophil shear responsiveness and were abrogated by neutropenia.
   Conclusions These results provide the first evidence that the neutrophils contribute to tissue blood flow autoregulation. Moreover, a deficit in the neutrophil responsiveness to shear may be a feature of hypercholesterolemia-related microvascular dysfunction.
C1 [Zhang, Xiaoyan; Cheng, Ran; Rowe, Dylan; Yu, Guoqiang; Shin, Hainsworth Y.] Univ Kentucky, Dept Biomed Engn, Lexington, KY 40506 USA.
   [Rowe, Dylan] Paul L Dunbar High Sch, Math Sci & Technol Ctr, Lexington, KY USA.
   [Sethu, Palaniappan] Univ Alabama Birmingham, Div Cardiovasc Dis, Birmingham, AL USA.
   [Daugherty, Alan] Univ Kentucky, Saha Cardiovasc Res Ctr, Lexington, KY 40506 USA.
RP Shin, HY (reprint author), Univ Kentucky, Dept Biomed Engn, Wenner Gren Res Lab, Lexington, KY 40506 USA.
EM hy.shin@uky.edu
RI Cheng, Ran/E-5609-2014
OI Cheng, Ran/0000-0002-0031-6983
FU American Heart Association; National Science Foundation
FX This work was supported by an American Heart Association
   Beginning-Grant-in-Aid and a National Science Foundation-Kentucky
   Experimental Program to Stimulate Competitive Research, Bioengineering
   Initiative Grant.
CR Bertoldi D, 2008, MAGN RESON IMAGING, V26, P1259, DOI 10.1016/j.mri.2008.02.012
   Buckley EM, 2009, OPT EXPRESS, V17, P12571, DOI 10.1364/OE.17.012571
   Cheng R, 2013, APPL OPTICS, V52, P7324, DOI 10.1364/AO.52.007324
   Durduran T, 2004, OPT LETT, V29, P1766, DOI 10.1364/OL.29.001766
   FLEMING TJ, 1993, J IMMUNOL, V151, P2399
   Fukuda S, 2004, J LEUKOCYTE BIOL, V75, P664, DOI 10.1189/jlb.1003464
   Fukuda S, 2004, CIRC RES, V95, P100, DOI 10.1161/01.RES.0000133677.77465.38
   Fukuda S, 2000, CIRC RES, V86, pE13
   Furlow M, 2011, BIORHEOLOGY, V48, P49, DOI 10.3233/BIR-2011-0583
   HAYOZ D, 1995, HYPERTENSION, V26, P497, DOI 10.1161/01.HYP.26.3.497
   Helmke BP, 1997, AM J PHYSIOL-HEART C, V273, pH2884
   Helmke BP, 1998, BIORHEOLOGY, V35, P437, DOI 10.1016/S0006-355X(99)80021-3
   KANNEL WB, 1971, ANN INTERN MED, V74, P1, DOI 10.7326/0003-4819-74-1-1
   Kim MN, 2010, NEUROCRIT CARE, V12, P173, DOI 10.1007/s12028-009-9305-x
   Kirschenbaum LA, 2000, AM J RESP CRIT CARE, V161, P1602, DOI 10.1164/ajrccm.161.5.9902105
   LICHTENSTEIN IH, 1987, J LEUKOCYTE BIOL, V42, P156
   Lipowsky HH, 2005, MICROCIRCULATION, V12, P5, DOI 10.1080/10739680590894966
   Mesquita RC, 2010, BIOMED OPT EXPRESS, V1, P1173, DOI 10.1364/BOE.1.001173
   Murphy AJ, 2011, ARTERIOSCL THROM VAS, V31, P1333, DOI 10.1161/ATVBAHA.111.226258
   Oh H, 2009, ARTERIOSCL THROM VAS, V29, P1290, DOI 10.1161/ATVBAHA.109.189571
   Rim SJ, 2001, CIRCULATION, V104, P2704, DOI 10.1161/hc4701.099580
   Roche-Labarbe N, 2010, HUM BRAIN MAPP, V31, P341, DOI 10.1002/hbm.20868
   Schmid-Schonbein GW, 2006, ANNU REV BIOMED ENG, V8, P93, DOI 10.1146/annurev.bioeng.8.061505.095708
   SCHMIDSCHONBEIN GW, 1991, HYPERTENSION, V17, P323, DOI 10.1161/01.HYP.17.3.323
   Schuck RN, 2013, PHARMACOTHERAPY, V33, P754, DOI 10.1002/phar.1268
   Shang Y, 2011, OPT EXPRESS, V19, P20301, DOI 10.1364/OE.19.020301
   Shen K, 1995, BIOCHEM CELL BIOL, V73, P491, DOI 10.1139/o95-054
   Stokes KY, 2006, MICROCIRCULATION, V13, P377, DOI 10.1080/10739680600745877
   Stokes KY, 2005, J PHYSIOL-LONDON, V562, P647, DOI 10.1113/jphysiol.2004.079640
   Stokes KY, 2002, FREE RADICAL BIO MED, V33, P1026, DOI 10.1016/S0891-5849(02)01015-8
   Superko HR, 2008, CIRCULATION, V117, P560, DOI 10.1161/CIRCULATIONAHA.106.667428
   SUTTON DW, 1992, AM J PHYSIOL, V262, pH1646
   Swirski FK, 2007, J CLIN INVEST, V117, P195, DOI 10.1172/JCI29950
   TAGAWA T, 1994, CIRCULATION, V90, P2285
   VanTeeffelen JWGE, 2005, AM J PHYSIOL-HEART C, V289, pH447, DOI 10.1152/ajpheart.01298.2004
   Yu G, 2005, J BIOMED OPT, V10
   Yu GQ, 2005, CLIN CANCER RES, V11, P3543, DOI 10.1158/1078-0432.CCR-04-2582
   Zhang XY, 2012, LIPOPROTEINS - ROLE IN HEALTH AND DISEASES, P223, DOI 10.5772/47867
   Zhang XY, 2013, J LEUKOCYTE BIOL, V93, P251, DOI 10.1189/jlb.0612302
   Zhang XY, 2011, AM J PHYSIOL-CELL PH, V301, pC451, DOI 10.1152/ajpcell.00458.2010
   Zhelev DV, 2004, BIOPHYS J, V87, P688, DOI 10.1529/biophysj.103.036699
   Zhou C, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3146814
   Zidovetzki R, 2007, BBA-BIOMEMBRANES, V1768, P1311, DOI 10.1016/j.bbamen.2007.03.026
NR 43
TC 5
Z9 6
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1079-5642
EI 1524-4636
J9 ARTERIOSCL THROM VAS
JI Arterioscler. Thromb. Vasc. Biol.
PD MAR
PY 2014
VL 34
IS 3
BP 587
EP 593
DI 10.1161/ATVBAHA.113.302868
PG 7
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA AD1LX
UT WOS:000332996600016
PM 24458712
OA gold
DA 2018-03-20
ER

PT J
AU Ambati, J
   Rankin, SE
AF Ambati, Jyothirmai
   Rankin, Stephen E.
TI Determination of Si-29-H-1 Spin-Spin Coupling Constants in
   Organoalkoxysilanes with Nontrivial Scalar Coupling Patterns
SO JOURNAL OF PHYSICAL CHEMISTRY A
LA English
DT Article
ID ORGANIC-INORGANIC MATERIALS; SOL-GEL POLYCONDENSATION; COSY 2D
   EXPERIMENTS; POLARIZATION TRANSFER; BRIDGED POLYSILSESQUIOXANES;
   NMR-SPECTROSCOPY; POLYMERIZATION REACTIONS; MODIFIED ALKOXYSILANES;
   HYDROLYSIS; METHYLTRIMETHOXYSILANE
AB Application of polarization transfer techniques such as DEPT and INEPT in Si-29 NMR investigation of bridged silane polymerization requires knowledge of indirect Si-29-H-1 scalar coupling constants in the silane system. However, the fully coupled Si-29 NMR spectra of these molecules, specifically those containing ethylene bridging groups, are too complicated to measure the coupling constants directly by visual inspection. This is because unlike hydrocarbon systems where one-bond proton carbon coupling constants exceed other coupling constants by an order of magnitude, in silanes the closest proton silicon pairs are separated by two bonds and all coupling coefficients (both homonuclear and heteronuclear) are of similar magnitude. In these systems, theoretical tools are required to interpret the spectra of even simple molecules. Here, we determine density functional theory estimates of Si-29-H-1 scalar coupling constants and use these along with homonuclear coupling constant estimates to resolve the nontrivial nature of these spectra. We also report a Karplus equation consistent with the dihedral angle dependence of the three-bond homo- and heteronuclear coupling in the ethylene bridge. By thermal averaging of DFT coupling constants, a good initial guess of the coupled Si-29 spectral pattern is made, which is easily refined by curve fitting to determine estimates of all coupling constants in the system.
C1 [Ambati, Jyothirmai; Rankin, Stephen E.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Rankin, SE (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM srankin@engr.uky.edu
RI Rankin, Stephen/A-3265-2013
OI Rankin, Stephen/0000-0002-8615-7564; Ambati,
   Jyothirmai/0000-0003-2420-3665
FU NSF [CTS-0348234]; U.S. DOE [DE-FG02-07ER46375]
FX This report is partially based on work supported by the NSF through
   grant no. CTS-0348234 and by the U.S. DOE through grant no.
   DE-FG02-07ER46375. We acknowledge the Department of Chemistry NMR Center
   and the Center for Computational Sciences at the University of Kentucky
   for providing the facilities for this study. We are thankful to John
   Layton, NMR Spectroscopist in the Department of Chemistry, for his
   well-directed support in performing NMR experiments.
CR Alam TM, 1996, CHEM MATER, V8, P2366, DOI 10.1021/cm960183h
   Alam TM, 1996, MAGN RESON CHEM, V34, P603, DOI 10.1002/(SICI)1097-458X(199608)34:8<603::AID-OMR917>3.0.CO;2-L
   Alam TM, 1997, SPECTROCHIM ACTA A, V53, P545, DOI 10.1016/S1386-1425(96)01806-9
   Alkorta I, 2004, THEOR CHEM ACC, V111, P31, DOI 10.1007/s00214-003-0486-7
   AMBATI J, 2006, PMSE PREPR, V94, P610
   Ambati J, 2010, J PHYS CHEM A, V114, P5279, DOI 10.1021/jp911327a
   BECKE AD, 1993, J CHEM PHYS, V98, P5648, DOI 10.1063/1.464913
   BERGER S, 2004, 200 MORE NMR EXP A P
   Brinker C.J., 1990, SOL GEL SCI PHYS CHE
   BRUNET F, 1994, NEW J CHEM, V18, P1059
   Brunet F, 1998, J NON-CRYST SOLIDS, V231, P58, DOI 10.1016/S0022-3093(98)00403-7
   Brus J, 1996, CHEM LISTY, V90, P316
   Claridge T. D. W., 1999, HIGH RESOLUTION NMR
   Dabrowski A, 2007, CROAT CHEM ACTA, V80, P367
   Delak KM, 2005, J NON-CRYST SOLIDS, V351, P2244, DOI 10.1016/j.jnoncrysol.2005.05.013
   DEWAR MJS, 1985, J AM CHEM SOC, V107, P3902, DOI 10.1021/ja00299a024
   DODDRELL DM, 1982, J MAGN RESON, V48, P323, DOI 10.1016/0022-2364(82)90286-4
   Dong HJ, 2007, J SOL-GEL SCI TECHN, V41, P11, DOI 10.1007/s10971-006-0115-8
   Dong HJ, 2003, J SOL-GEL SCI TECHN, V28, P5, DOI 10.1023/A:1025690300105
   FRANCL MM, 1982, J CHEM PHYS, V77, P3654, DOI 10.1063/1.444267
   Frisch M. J., 2004, GAUSSIAN03
   GIBSON SE, 1991, ORGANIC SYNTHESIS RO
   Harris R. K., 1983, NUCL MAGNETIC RESONA
   Hunks WJ, 2005, J MATER CHEM, V15, P3716, DOI 10.1039/b504511h
   KRISHNAN PSG, 2007, POLYM NANOSTRUCTURES, P153
   Lebeau B, 2009, ORDERED POROUS SOLIDS: RECENT ADVANCES AND PROSPECTS, P283, DOI 10.1016/B978-0-444-53189-6.00011-1
   LEE C, 1988, PHYS REV B, V785, P37
   Loy DA, 1999, J AM CHEM SOC, V121, P5413, DOI 10.1021/ja982751v
   LOY DA, 1995, CHEM REV, V95, P1431, DOI 10.1021/cr00037a013
   Lux P, 1996, MAGN RESON CHEM, V34, P173
   Lux P, 1996, MAGN RESON CHEM, V34, P100, DOI 10.1002/(SICI)1097-458X(199602)34:2<100::AID-OMR844>3.0.CO;2-4
   MIYAZIMA G, 1969, J PHYS CHEM-US, V73, P1370, DOI 10.1021/j100725a033
   Moreau JJE, 2004, J SOL-GEL SCI TECHN, V31, P151, DOI 10.1023/B:JSST.0000047977.44966.53
   MORRIS GA, 1979, J AM CHEM SOC, V101, P760, DOI 10.1021/ja00497a058
   NEESE F, 2008, ORCA REVISION 2 6 35
   Palermo G, 2010, J ORG CHEM, V75, P1982, DOI 10.1021/jo902704u
   Pu ZC, 1997, J ADHES SCI TECHNOL, V11, P29
   Rakow JR, 2009, J PHYS CHEM A, V113, P12035, DOI 10.1021/jp906502y
   Rankin SE, 2000, MACROMOLECULES, V33, P7743, DOI 10.1021/ma0004920
   Rankin SE, 1997, J POLYM SCI POL CHEM, V35, P1293
   Rankin SE, 1998, AICHE J, V44, P1141, DOI 10.1002/aic.690440512
   Sakka S., 2005, HDB SOL GEL SCI TECH
   Sanchez J, 1996, IND ENG CHEM RES, V35, P117, DOI 10.1021/ie950246q
   SANFABIAN J, 1994, MOL PHYS, V82, P913, DOI 10.1080/00268979400100664
   SCHAEFER T, 1959, CAN J CHEM, V37, P882, DOI 10.1139/v59-120
   Shea KJ, 2001, MRS BULL, V26, P368, DOI 10.1557/mrs2001.90
   Shea KJ, 2001, CHEM MATER, V13, P3306, DOI 10.1021/cm011074s
   Stewart JJP, 2004, J MOL MODEL, V10, P6, DOI 10.1007/s00894-003-0157-6
   STEWART JJP, 1989, J COMPUT CHEM, V10, P209, DOI 10.1002/jcc.540100208
   Stewart J. J. P., 2002, MOPAC
   Tan B, 2006, J PHYS CHEM B, V110, P22353, DOI 10.1021/jp060376k
   Thompson M. A., 2004, ARGUSLAB 4 0 1
   Wada K, 2005, CATAL SURV ASIA, V9, P229, DOI 10.1007/s10563-005-9158-z
   Williams E. A., 1983, Annual reports on NMR spectroscopy. Vol.15, P235
   Zhang ZP, 2003, J SOL-GEL SCI TECHN, V28, P159, DOI 10.1023/A:1026098729993
   ZHAO XS, 2004, NANOPOROUS MAT SCI E, P393
NR 56
TC 6
Z9 6
U1 0
U2 10
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1089-5639
J9 J PHYS CHEM A
JI J. Phys. Chem. A
PD DEC 9
PY 2010
VL 114
IS 48
BP 12613
EP 12621
DI 10.1021/jp105644p
PG 9
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA 686YP
UT WOS:000284738500008
PM 21077652
DA 2018-03-20
ER

PT J
AU Reichel, D
   Curtis, LT
   Ehlman, E
   Evers, BM
   Rychahou, P
   Frieboes, HB
   Bae, Y
AF Reichel, Derek A.
   Curtis, Louis T.
   Ehlman, Elizabeth
   Evers, B. Mark
   Rychahou, Piotr G.
   Frieboes, Hermann B.
   Bae, Younsoo
TI Development of Halofluorochromic Polymer Nanoassemblies for the
   Potential Detection of Liver Metastatic Colorectal Cancer Tumors Using
   Experimental and Computational Approaches
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE computational tumor simulation; nanoparticle distribution simulation;
   theranostics; tissue acidity; tumor microenvironment
ID CROSS-LINKED NANOASSEMBLIES; LYMPHATIC VASCULAR SYSTEMS; DRUG-DELIVERY;
   INTERSTITIAL PRESSURE; SILICA NANOPARTICLES; INDOCYANINE GREEN; IN-VIVO;
   RELEASE; NANOMEDICINE; BIODISTRIBUTION
AB To develop polymer nanoassemblies (PNAs) modified with halofluorochromic dyes to allow for the detection of liver metastatic colorectal cancer (CRC) to improve therapeutic outcomes.
   We combine experimental and computational approaches to evaluate macroscopic and microscopic PNA distributions in patient-derived xenograft primary and orthotropic liver metastatic CRC tumors. Halofluorochromic and non-halofluorochromic PNAs (hfPNAs and n-hfPNAs) were prepared from poly(ethylene glycol), fluorescent dyes (Nile blue, Alexa546, and IR820), and hydrophobic groups (palmitate), all of which were covalently tethered to a cationic polymer scaffold [poly(ethylene imine) or poly(lysine)] forming particles with an average diameter < 30 nm.
   Dye-conjugated PNAs showed no aggregation under opsonizing conditions for 24 h and displayed low tissue diffusion and cellular uptake. Both hfPNAs and n-hfPNAs accumulated in primary and liver metastatic CRC tumors within 12 h post intravenous injection. In comparison to n-hfPNAs, hfPNAs fluoresced strongly only in the acidic tumor microenvironment (pH < 7.0) and distinguished small metastatic CRC tumors from healthy liver stroma. Computational simulations revealed that PNAs would steadily accumulate mainly in acidic (hypoxic) interstitium of metastatic tumors, independently of the vascularization degree of the tissue surrounding the lesions.
   The combined experimental and computational data confirms that hfPNAs detecting acidic tumor tissue can be used to identify small liver metastatic CRC tumors with improved accuracy.
C1 [Reichel, Derek; Bae, Younsoo] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, 789 South Limestone, Lexington, KY 40536 USA.
   [Curtis, Louis T.; Ehlman, Elizabeth; Frieboes, Hermann B.] Univ Louisville, Sch Engn, Dept Bioengn, 2301 South Third, Louisville, KY 40292 USA.
   [Evers, B. Mark; Rychahou, Piotr] Univ Kentucky, Markey Canc Ctr, 800 Rose, Lexington, KY 40536 USA.
   [Evers, B. Mark; Rychahou, Piotr] Univ Kentucky, Coll Med, Dept Surg, 741 South Limestone, Lexington, KY 40536 USA.
   [Frieboes, Hermann B.] Univ Louisville, Sch Med, Dept Pharmacol & Toxicol, 505 South Hancock, Louisville, KY 40292 USA.
   [Frieboes, Hermann B.] Univ Louisville, James Graham Brown Canc Ctr, 529 South Jackson, Louisville, KY 40292 USA.
RP Bae, Y (reprint author), Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, 789 South Limestone, Lexington, KY 40536 USA.
EM younsoo.bae@uky.edu
OI Bae, Younsoo/0000-0003-1360-3524
FU University of Kentucky Graduate School Allocated Year (GSAY) Fellowship;
   National Institutes of Health [R01CA195573]; National Institutes of
   Health / National Cancer Institute [R15CA203605]
FX This work was supported by the University of Kentucky Graduate School
   Allocated Year (GSAY) Fellowship (DR) and the National Institutes of
   Health grant R01CA195573 (BME and PR). HBF acknowledges partial support
   by the National Institutes of Health / National Cancer Institute
   (R15CA203605).
CR Ao L, 2015, J PHARMACOL EXP THER, V355, P168, DOI 10.1124/jpet.115.226993
   Bae Y, 2010, THER DELIV, V1, P361, DOI 10.4155/TDE.10.28
   Barnes KD, 2013, INT J HYPERTHER, V29, P474, DOI 10.3109/02656736.2013.817615
   Beck-Broichsitter M, 2015, EUR J PHARM BIOPHARM, V97, P304, DOI 10.1016/j.ejpb.2015.03.033
   Blanco E, 2011, CANCER SCI, V102, P1247, DOI 10.1111/j.1349-7006.2011.01941.x
   Cabral H, 2011, NAT NANOTECHNOL, V6, P815, DOI [10.1038/nnano.2011.166, 10.1038/NNANO.2011.166]
   Cao PX, 2013, BRIT J PHARM RES, V3, P523, DOI 10.9734/BJPR/2013/4574
   Chaudhari KR, 2012, PHARM RES-DORDR, V29, P53, DOI 10.1007/s11095-011-0510-x
   Crist RM, 2013, INTEGR BIOL-UK, V5, P66, DOI 10.1039/c2ib20117h
   Curtis LT, 2016, PHARM RES-DORDR, V33, P2552, DOI 10.1007/s11095-016-1981-6
   Dan M, 2013, PHARM RES-DORDR, V30, P552, DOI 10.1007/s11095-012-0900-8
   Dickerson M, 2016, J MATER CHEM B, V4, P394, DOI 10.1039/c5tb01613d
   Dickerson M, 2014, PHARM RES-DORDR, V31, P1254, DOI 10.1007/s11095-013-1246-6
   Dickerson M, 2013, THER DELIV, V4, P1431, DOI [10.4155/tde.13.105, 10.4155/TDE.13.105]
   Durymanov MO, 2015, THERANOSTICS, V5, P1007, DOI 10.7150/thno.11742
   Elliott VA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097432
   Ernsting MJ, 2013, J CONTROL RELEASE, V172, P782, DOI 10.1016/j.jconrel.2013.09.013
   Etrych T, 2016, J CONTROL RELEASE, V226, P168, DOI 10.1016/j.jconrel.2016.02.022
   Fang J, 2011, ADV DRUG DELIVER REV, V63, P136, DOI 10.1016/j.addr.2010.04.009
   Gao HL, 2014, EXPERT OPIN DRUG DEL, V11, P409, DOI 10.1517/17425247.2014.877442
   Gulhati P, 2011, CANCER RES, V71, P3246, DOI 10.1158/0008-5472.CAN-10-4058
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Hugen N, 2014, ANN ONCOL, V25, P651, DOI 10.1093/annonc/mdt591
   Kamiya M, 2016, CURR OPIN CHEM BIOL, V33, P9, DOI 10.1016/j.cbpa.2016.04.004
   Kekelidze M, 2013, WORLD J GASTROENTERO, V19, P8502, DOI 10.3748/wjg.v19.i46.8502
   Kim BYS, 2010, NEW ENGL J MED, V363, P2434, DOI 10.1056/NEJMra0912273
   Kumar R, 2010, ACS NANO, V4, P699, DOI 10.1021/nn901146y
   Lee HJ, 2013, PHARM RES-DORDR, V30, P478, DOI 10.1007/s11095-012-0893-3
   Lee HJ, 2011, BIOMACROMOLECULES, V12, P2686, DOI 10.1021/bm200483t
   Lee HJ, 2010, THER DELIV, V1, P803, DOI 10.4155/TDE.10.70
   Maffione AM, 2015, EUR J NUCL MED MOL I, V42, P152, DOI 10.1007/s00259-014-2930-4
   Mittapalli RK, 2017, CANCER RES, V77, P238, DOI 10.1158/0008-5472.CAN-16-1711
   Moghimi SM, 2014, NANOMED-NANOTECHNOL, V10, P1661, DOI 10.1016/j.nano.2014.04.011
   Opitz AW, 2013, BBA-BIOMEMBRANES, V1828, P294, DOI 10.1016/j.bbamem.2012.09.016
   Rannard S, 2009, NANO TODAY, V4, P382, DOI 10.1016/j.nantod.2009.07.002
   Rausch K, 2010, BIOMACROMOLECULES, V11, P2836, DOI 10.1021/bm100971q
   Reichel D, 2017, PHARM RES-DORDR, V34, P394, DOI 10.1007/s11095-016-2070-6
   Reichel D, 2016, THER DELIV, V7, P665, DOI 10.4155/tde-2016-0041
   Reichel D, 2015, THER DELIV, V6, P1221, DOI 10.4155/tde.15.59
   Rheiner S, 2015, AIMS BIOPHYS, V2, P284, DOI 10.3934/biophy.2015.3.284
   Rheiner S, 2016, AIMS BIOENG, V3, P454, DOI 10.3934/bioeng.2016.4.454
   Robinson P.J., 2002, CANC IMAGING, V2, P1
   Rychahou PG, 2008, P NATL ACAD SCI USA, V105, P20315, DOI 10.1073/pnas.0810715105
   Shao D, 2017, ACTA BIOMATER, V49, P531, DOI 10.1016/j.actbio.2016.11.007
   Shrinivas P, 2009, LANGMUIR, V25, P8763, DOI 10.1021/la9002127
   Sindhwani S, 2016, ACS NANO, V10, P5468, DOI 10.1021/acsnano.6b01879
   Spano D, 2012, SEMIN CANCER BIOL, V22, P234, DOI 10.1016/j.semcancer.2012.03.006
   Svenson S, 2014, WIRES NANOMED NANOBI, V6, P125, DOI 10.1002/wnan.1257
   Terranova N, 2015, CPT-PHARMACOMET SYST, V4, P320, DOI 10.1002/psp4.45
   Torchilin V, 2011, ADV DRUG DELIVER REV, V63, P131, DOI 10.1016/j.addr.2010.03.011
   Tufto I, 1996, BRIT J CANCER, V74, pS252
   Van Cutsem E, 2016, CANCERS, V8, DOI 10.3390/cancers8090081
   van de Ven AL, 2013, NEW J PHYS, V15, DOI 10.1088/1367-2630/15/5/055004
   van de Ven AL, 2012, AIP ADV, V2, DOI 10.1063/1.3699060
   Vazquez A, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-58
   Venditto VJ, 2013, ADV DRUG DELIVER REV, V65, P80, DOI 10.1016/j.addr.2012.09.038
   Verkman AS, 2013, PHYS BIOL, V10, DOI 10.1088/1478-3975/10/4/045003
   Watson KD, 2012, CANCER RES, V72, P1485, DOI 10.1158/0008-5472.CAN-11-3232
   Wu L, 2013, BIOMACROMOLECULES, V14, P3027, DOI 10.1021/bm400839b
   Wu M, 2014, J THEOR BIOL, V355, P194, DOI 10.1016/j.jtbi.2014.04.012
   Wu M, 2013, J THEOR BIOL, V320, P131, DOI 10.1016/j.jtbi.2012.11.031
   Zamboni WC, 2012, CLIN CANCER RES, V18, P3229, DOI 10.1158/1078-0432.CCR-11-2938
   Zaytseva YY, 2014, CARCINOGENESIS, V35, P1341, DOI 10.1093/carcin/bgu042
   Zaytseva YY, 2012, CANCER RES, V72, P1504, DOI 10.1158/0008-5472.CAN-11-4057
   Zhang M, 2011, ANALYST, V136, P4558, DOI 10.1039/c1an15632b
NR 65
TC 0
Z9 0
U1 5
U2 5
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
EI 1573-904X
J9 PHARM RES-DORDR
JI Pharm. Res.
PD NOV
PY 2017
VL 34
IS 11
BP 2385
EP 2402
DI 10.1007/s11095-017-2245-9
PG 18
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA FJ9SI
UT WOS:000413120800014
PM 28840432
DA 2018-03-19
ER

PT J
AU Su, X
   Zhan, X
   Hinds, BJ
AF Su, Xin
   Zhan, Xin
   Hinds, Bruce J.
TI Pt monolayer deposition onto carbon nanotube mattes with high
   electrochemical activity
SO JOURNAL OF MATERIALS CHEMISTRY
LA English
DT Article
ID PEM FUEL-CELLS; CATALYST SUPPORT; SURFACE; METHANOL; ELECTROCATALYSTS;
   OXIDATION; ELECTROOXIDATION; NANOPARTICLES; PERFORMANCE; FABRICATION
AB Pt monolayers with high catalytic activity were deposited onto carbon nanotube mattes by the chemical displacement of Cu monolayers on CNTs produced using an underpotential electro-deposition method. The electrochemical surface modification of graphitic CNT surface by fluorinated benzoic acid was critical to coordinate Cu ions resulting in uniform Cu monolayer formation. For MeOH fuel cell applications, the mass activity of Pt monolayer reached 2711 A g(-1) at a scan rate of 20 mV s(-1) and in a solution of 1 M CH3OH/0.5 M H2SO4. This is a 13 fold improvement than that of the similar to 10 nm thick Pt film coated on MWCNTs. Besides the high mass activity that is needed for the widespread used of rare catalytic metals in fuel cell applications, the Pt monolayer coated on buckypaper has several other advantages such as low cost, high surface area, flexibility, mechanical robust and enhanced mass transport.
C1 [Su, Xin; Hinds, Bruce J.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Zhan, Xin] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
RP Hinds, BJ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM bjhinds@engr.uky.edu
RI Su, Xin/M-1162-2013
OI Su, Xin/0000-0002-1615-2856
FU DOE EPSCoR [DE-FG02-07ER46375]; NSF [0348544]; NIH NIDA [R01DA018822]
FX The authors would like to thank Rodney Andrews and Dali Qian from the
   Center for Applied Energy, University of Kentucky, for supplying MWCNTs.
   Facility support was provided by the Center for Nanoscale Science and
   Engineering and Electron Microscopy Center at the University of
   Kentucky. Financial support from DOE EPSCoR (DE-FG02-07ER46375), NSF
   CAREER (0348544), and NIH NIDA (R01DA018822) is greatly appreciated by
   the authors.
CR Andrews R, 2002, ACCOUNTS CHEM RES, V35, P1008, DOI 10.1021/ar010151m
   Damian A, 2010, ELECTROCHIM ACTA, V55, P8087, DOI 10.1016/j.electacta.2010.03.067
   de Oca MGM, 2010, ELECTROCHIM ACTA, V55, P8986, DOI 10.1016/j.electacta.2010.08.031
   DEINHAMMER RS, 1994, LANGMUIR, V10, P1306, DOI 10.1021/la00016a054
   Fu Q, 2010, SCIENCE, V328, P1141, DOI 10.1126/science.1188267
   Guha A, 2007, CARBON, V45, P1506, DOI 10.1016/j.carbon.2007.03.023
   Herrero E, 2001, CHEM REV, V101, P1897, DOI 10.1021/cr9600363
   Holt JK, 2006, SCIENCE, V312, P1034, DOI 10.1126/science.1126298
   Hull RV, 2006, CHEM MATER, V18, P1780, DOI 10.1021/cm0518978
   Iwasita T, 2002, ELECTROCHIM ACTA, V48, P289, DOI 10.1016/S0013-4686(02)00692-8
   Kim YA, 2006, CHEM VAPOR DEPOS, V12, P327, DOI 10.1002/cvde.200504217
   Lee JRI, 2010, ELECTROCHIM ACTA, V55, P8532, DOI 10.1016/j.electacta.2010.07.046
   Liu JY, 2000, LANGMUIR, V16, P7471, DOI 10.1021/la9913506
   Liu P., 2008, LANGMUIR, V25, P561
   Liu Y, 2008, CHEM MATER, V20, P2603, DOI 10.1021/cm703471x
   LU JP, 1991, SURF SCI, V258, P269, DOI 10.1016/0039-6028(91)90921-E
   Majumder M, 2005, NATURE, V438, P44, DOI 10.1038/43844a
   Mu YY, 2005, J PHYS CHEM B, V109, P22212, DOI 10.1021/jp0555448
   Murray EP, 1999, NATURE, V400, P649
   Shulga OV, 2007, CHEM MATER, V19, P3902, DOI 10.1021/cm070238n
   Silien C, 2011, LANGMUIR, V27, P2567, DOI 10.1021/la104561j
   Su X, 2011, CARBON, V49, P1145, DOI 10.1016/j.carbon.2010.11.029
   Sun SH, 2008, ADV MATER, V20, P3900, DOI 10.1002/adma.200800491
   Tadanaga K, 2010, ADV MATER, V22, P4401, DOI 10.1002/adma.201001766
   Tang H, 2004, J COLLOID INTERF SCI, V269, P26, DOI 10.1016/S0021-9797(03)00608-8
   Tian N, 2007, SCIENCE, V316, P732, DOI 10.1126/science.1140484
   Wang RY, 2010, ADV MATER, V22, P1845, DOI 10.1002/adma.200903548
   Wu J, 2010, P NATL ACAD SCI USA, V107, P11698, DOI 10.1073/pnas.1004714107
   Xu GH, 2008, APPL PHYS A-MATER, V92, P531, DOI 10.1007/s00339-008-4606-z
   Yang H, 2007, J PHYS CHEM C, V111, P19058, DOI 10.1021/jp075929l
   Yang L, 2007, ELECTROCHIM ACTA, V53, P777, DOI 10.1016/j.electacta.2007.07.052
   Yang W, 2008, ADV MATER, V20, P2579, DOI 10.1002/adma.200702949
   Yu M., 2008, NANO LETT, V9, P225
NR 33
TC 10
Z9 10
U1 1
U2 52
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 0959-9428
J9 J MATER CHEM
JI J. Mater. Chem.
PY 2012
VL 22
IS 16
BP 7979
EP 7984
DI 10.1039/c2jm15395e
PG 6
WC Chemistry, Physical; Materials Science, Multidisciplinary
SC Chemistry; Materials Science
GA 915LC
UT WOS:000302026100048
DA 2018-03-20
ER

PT J
AU Lehmler, HJ
   Xu, L
   Vyas, SM
   Qjogun, VA
   Knutson, BL
   Ludewig, G
AF Lehmler, Hans-Joachim
   Xu, Ling
   Vyas, Sandhya M.
   Qjogun, Vivian A.
   Knutson, Barbara L.
   Ludewig, Gabriele
TI Synthesis, physicochemical properties and in vitro cytotoxicity of
   nicotinic acid ester prodrugs intended for pulmonary delivery using
   perfluorooctyl bromide as vehicle
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE drug delivery; lung; fluorocarbon; cell culture
ID TRANSPORT BLOOD SUBSTITUTES; METERED-DOSE INHALERS; LIQUID VENTILATION;
   DRUG-DELIVERY; FLUOROCARBON EMULSIONS; LUNG INJURY; NIACIN; GENTAMICIN;
   OXYGEN; FLUOROPHILICITY
AB This study explores perfluorooctyl bromide (P17013) as a potential vehicle for the pulmonary delivery of a series of prodrugs of nicotinic acid using cell culture studies. The prodrugs investigated have PF013-water (log K-p = 0.78 to > 2.2), perfluoromethylcyclohexane-toluene (log K-p = -2-62 to 0.13) and octanol-water (log K-p = 0.90-10.2) partition coefficients spanning several orders of magnitude. In confluent NCI-H358 human lung cancer cells, the toxicity of prodrugs administered in culture medium or PFOB depends on the medium of administration, with EC20's above 8 mM and 2.5 mM for culture medium and PFOB, respectively. Short-chain nicotinates administered both in P17013 and medium increase cellular NAD/NADP levels at I mM nicotinate concentrations. Long-chain nicotinates, which could not be administered in medium due to their poor aqueous solubility, increased NAD/NADP levels if administered in PFOB at concentrations >= 10 mM. These findings suggest that even highly lipophilic prodrugs can partition out of the PFOB phase into cells, where nicotinic acid is released and converted to NAD. Thus, P17013 may be a novel and biocompatible vehicle for the delivery of lipophilic prodrugs of nicotinic acid and other drugs directly to the lung of laboratory animals and humans. (c) 2007 Elsevier B.V. All rights reserved.
C1 [Lehmler, Hans-Joachim; Xu, Ling; Vyas, Sandhya M.; Ludewig, Gabriele] Univ Iowa, Coll Publ Hlth, Dept Environm & Occupat Hlth, Iowa City, IA 52242 USA.
   [Qjogun, Vivian A.; Knutson, Barbara L.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Lehmler, HJ (reprint author), Univ Iowa, Coll Publ Hlth, Dept Environm & Occupat Hlth, Iowa City, IA 52242 USA.
EM hans-joachim-lehmler@uiowa.edu
RI Ludewig, Gabriele/A-2745-2008
OI Lehmler, Hans-Joachim/0000-0001-9163-927X; Ludewig,
   Gabriele/0000-0003-2385-7720
FU NIEHS NIH HHS [K25 ES012475-03, K25 ES012475, ES 12475]; NIBIB NIH HHS
   [EB 02748, R21 EB002748-02, R21 EB002748]
CR Babu Polani B Ramesh, 2005, Pediatr Crit Care Med, V6, P188
   Butz N, 2002, INT J PHARM, V238, P257, DOI 10.1016/S0378-5173(02)00086-8
   Courrier HA, 2004, COLLOID SURFACE A, V244, P141, DOI 10.1016/j.colsurfa.2004.06.003
   Courrier HM, 2004, INT J PHARM, V282, P131, DOI 10.1016/j.ijpharm.2004.06.011
   Courrier HM, 2003, BIOMATERIALS, V24, P689, DOI 10.1016/S0142-9612(02)00407-6
   Cullen AB, 1999, RESP MED, V93, P770, DOI 10.1016/S0954-6111(99)90261-5
   Daniels SM, 2004, J FLUORINE CHEM, V125, P1291, DOI 10.1016/j.jfluchem.2004.03.014
   Danielsson LG, 1996, TRAC-TREND ANAL CHEM, V15, P188, DOI 10.1016/0165-9936(96)00003-9
   Duchowicz PR, 2004, J FLUORINE CHEM, V125, P43, DOI 10.1016/j.jfluchem.2003.09.003
   Fox WW, 1997, PEDIATRICS, V100, part. no., DOI 10.1542/peds.100.5.e5
   Franz AR, 2001, AM J RESP CRIT CARE, V164, P1595, DOI 10.1164/ajrccm.164.9.2104088
   Gensler HL, 1999, NUTR CANCER, V34, P36, DOI 10.1207/S15327914NC340105
   Gurujeyalakshmi G, 2000, J PHARMACOL EXP THER, V293, P82
   Gurujeyalakshmi G, 2000, NITRIC OXIDE-BIOL CH, V4, P399, DOI 10.1006/niox.2000.0297
   HIRSCHL RB, 1994, SURGERY, V116, P159
   Hsu CH, 2003, PHARMACEUT RES, V20, P918, DOI 10.1023/A:1023899505837
   Jacobson EL, 1997, METHOD ENZYMOL, V280, P221
   Jacobson EL, 1999, MOL CELL BIOCHEM, V193, P69, DOI 10.1023/A:1006960126369
   JACOBSON EL, 1995, BIOCHIMIE, V77, P394, DOI 10.1016/0300-9084(96)88152-1
   Keller M, 1999, INT J PHARM, V186, P81, DOI 10.1016/S0378-5173(99)00132-5
   KimlessGarber DB, 1997, RESP MED, V91, P255, DOI 10.1016/S0954-6111(97)90028-7
   Kiss LE, 2001, J FLUORINE CHEM, V108, P95, DOI 10.1016/S0022-1139(01)00342-6
   Lehmler HJ, 2007, EXPERT OPIN DRUG DEL, V4, P247, DOI 10.1517/17425247.4.3.247
   Lehmler HJ, 2005, J LIPID RES, V46, P2415, DOI 10.1194/jlr.M500231-JLR200
   Lehmler HJ, 2005, J LIPID RES, V46, P535, DOI 10.1194/jlr.M400406-JLR200
   Lehmler HJ, 2005, CHEMOSPHERE, V58, P1471, DOI 10.1016/j.chemosphere.2004.11.078
   Lehmler HJ, 1999, CHEMTECH, V29, P7
   Lowe KC, 1998, TRENDS BIOTECHNOL, V16, P272, DOI 10.1016/S0167-7799(98)01205-0
   PATRICK CR, 1971, CHEM BRIT, V7, P154
   Riess JG, 1999, MRS BULL, V24, P42
   Riess JG, 2005, ARTIF CELL BLOOD SUB, V33, P47, DOI 10.1081/BIO-200046659
   Riess JG, 1997, ARTIF CELL BLOOD SUB, V25, P43, DOI 10.3109/10731199709118896
   Riess JG, 1998, BIOMATERIALS, V19, P1529, DOI 10.1016/S0142-9612(98)00071-4
   Rocaboy C, 2000, J PHYS ORG CHEM, V13, P596, DOI 10.1002/1099-1395(200010)13:10<596::AID-POC284>3.0.CO;2-M
   Rotta Alexandre T, 2003, Pediatr Crit Care Med, V4, P233, DOI 10.1097/01.PCC.0000059729.21375.D0
   Sadtler VM, 1996, ANGEW CHEM INT EDIT, V35, P1976, DOI 10.1002/anie.199619761
   VENKATESAN N, 1994, EUR J PHARM-ENVIRON, V292, P75, DOI 10.1016/0926-6917(94)90028-0
   Vyas SM, 2007, J ENVIRON SCI HEAL A, V42, P249, DOI 10.1080/10934520601134031
   Waldrep JC, 1997, CHEST, V111, P316, DOI 10.1378/chest.111.2.316
   WERNLYCHUNG GN, 1990, INT J PHARM, V63, P129
   Williams JD, 1998, J PHARM SCI, V87, P1585
   Wolfson Marla R, 2005, Paediatr Respir Rev, V6, P117, DOI 10.1016/j.prrv.2005.03.010
   Zelinka MA, 1997, EUR J PEDIATR, V156, P401, DOI 10.1007/s004310050625
NR 43
TC 10
Z9 10
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
J9 INT J PHARM
JI Int. J. Pharm.
PD APR 2
PY 2008
VL 353
IS 1-2
BP 35
EP 44
DI 10.1016/j.ijpharm.2007.1
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 293FF
UT WOS:000255320000006
PM 18164563
DA 2018-03-20
ER

PT J
AU Das, S
   Xu, WJ
   Lehmler, HJ
   Miller, AF
   Knutson, BL
   Rankin, SE
AF Das, Saikat
   Xu, Wenjin
   Lehmler, Hans-Joachim
   Miller, Anne-Frances
   Knutson, Barbara L.
   Rankin, Stephen E.
TI Inverted Micelle-in-Micelle Configuration in Cationic/Carbohydrate
   Surfactant Mixtures
SO CHEMPHYSCHEM
LA English
DT Article
DE asymmetric vesicles; micelle structure; mixed surfactants; nuclear
   magnetic resonance spectroscopy; selfassembly
ID D-XYLOPYRANOSIDE SURFACTANTS; X-RAY-SCATTERING; BETA-D-MALTOSIDE;
   AQUEOUS-SOLUTIONS; MIXED MICELLES; SUGAR SURFACTANTS; LYOTROPIC PHASES;
   OCTYL GLUCOSIDE; BEHAVIOR; NMR
AB Nuclear magnetic resonance is applied to investigate the relative positions and interactions between cationic and non-ionic carbohydrate-based surfactants in mixed micelles with D2O as the solvent. This is accomplished by using relaxation measurements [spin-lattice (T-1) and spin-spin (T-2) analysis] and nuclear Overhauser effect spectroscopy (NOESY). This study focuses on the interactions of n-octyl beta-D-glucopyranoside (C8G1) and beta-D-xylopyranoside (C8X1) with the cationic surfactant hexadecyltrimethylammonium bromide (C(16)TAB). Whereas the interactions between carbohydrate and cationic surfactants are thermodynamically favorable, the NOESY results suggest that both of the sugar head groups are located preferentially at the interior core of the mixed micelles, so that they are not directly exposed to the bulk solution. The more hydrophilic sugar headgroups of C8G1 have more mobility than sugar heads of C8X1 owing to increased hydration. Herein, an inverted carbohydrate configuration in mixed micelles is proposed for the first time and supported by fluorescence spectroscopy experiments. This inverted carbohydrate headgroup configuration would limit the use of these mixed surfactants when access to the carbohydrate headgroup is important, but may present new opportunities where the carbohydrate-rich core of the micelles can be exploited.
C1 [Das, Saikat; Knutson, Barbara L.; Rankin, Stephen E.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Xu, Wenjin; Lehmler, Hans-Joachim] Univ Iowa, Dept Environm & Occupat Hlth, Iowa City, IA 52242 USA.
   [Miller, Anne-Frances] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
RP Rankin, SE (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM srankin@engr.uky.edu
RI Miller, Anne-Frances/M-7703-2017
OI Lehmler, Hans-Joachim/0000-0001-9163-927X
FU United States Department of Agriculture [68-3A75-7-608,
   2011-10006-30363]; U.S. National Science Foundation
   [CBET-0967381/0967390]
FX This work was funded by the United States Department of Agriculture
   (grant numbers 68-3A75-7-608 and 2011-10006-30363) and the U.S. National
   Science Foundation (grant no. CBET-0967381/0967390). All of the NMR
   experiments were performed in the NMR facility of the Department of
   Chemistry at the University of Kentucky and we thank John Layton from
   that facility for helpful discussions of the NMR experiments.
CR Angelov B, 1999, LANGMUIR, V15, P8225, DOI 10.1021/la9902338
   Bakshi MS, 2005, J COLLOID INTERF SCI, V289, P551, DOI 10.1016/j.jcis.2005.03.078
   BLOEMBERGEN N, 1948, PHYS REV, V73, P679, DOI 10.1103/PhysRev.73.679
   Bogusz S, 2000, J PHYS CHEM B, V104, P5462, DOI 10.1021/jp000159y
   Bonicelli MG, 1998, COLLOID POLYM SCI, V276, P109, DOI 10.1007/s003960050217
   Cui J, 2014, LANGMUIR, V30, P9219, DOI 10.1021/la501674a
   Gaida L. B., 2006, Food Chemistry, V96, P387, DOI 10.1016/j.foodchem.2005.02.053
   Gao HC, 2002, J COLLOID INTERF SCI, V249, P200, DOI 10.1006/jcis.2002.8258
   Hato M, 2004, LANGMUIR, V20, P11366, DOI 10.1021/la030410b
   Hato M, 2004, PROG COLL POL SCI S, V123, P56, DOI 10.1007/b11629
   HOLLAND PM, 1983, J PHYS CHEM-US, V87, P1984, DOI 10.1021/j100234a030
   Israelachvili JN, 2011, INTERMOLECULAR AND SURFACE FORCES, 3RD EDITION, P1
   Joshi S., 2014, THESIS
   KAMEYAMA K, 1990, J COLLOID INTERF SCI, V137, P1, DOI 10.1016/0021-9797(90)90037-O
   Liew CY, 2015, RSC ADV, V5, P99125, DOI 10.1039/c5ra17828b
   Martel F., 2010, DEV AGR LEFT OVERS F, P79
   Misran O, 2013, J PHYS CHEM B, V117, P7335, DOI 10.1021/jp401787b
   Modaressi A, 2007, COLLOID SURFACE A, V296, P104, DOI 10.1016/j.colsurfa.2006.09.031
   Molina-Bolivar J. A., 2009, SELF ASSEMBLY MICELL, V143, P61
   Movchan TG, 2012, COLLOID J+, V74, P239, DOI 10.1134/S1061933X1202007X
   Oldham ED, 2013, CARBOHYD RES, V379, P68, DOI 10.1016/j.carres.2013.06.020
   Ruiz CC, 2008, SURFACTANT SCI SER, V143, P1
   Ruiz C. C., 2009, MICELLAR PROPERTIES, V143, P413
   Shah SS, 1997, J CHEM SOC PAKISTAN, V19, P186
   Sheng YP, 2013, SOFT MATTER, V9, P6254, DOI 10.1039/c3sm00029j
   Stangar U. L., 2003, SILICON CHEM, V2, P157
   Stubenrauch C, 2001, CURR OPIN COLLOID IN, V6, P160, DOI 10.1016/S1359-0294(01)00080-2
   SUENAGA H, 1995, TETRAHEDRON LETT, V36, P4825
   SUGGETT A, 1976, J SOLUTION CHEM, V5, P17, DOI 10.1007/BF00647178
   Sutherland E, 2009, J CHEM ENG DATA, V54, P272, DOI 10.1021/je800284g
   Talagala S. L., 1982, THESIS
   ULMIUS J, 1978, J COLLOID INTERF SCI, V65, P88, DOI 10.1016/0021-9797(78)90261-8
   Warner KS, 2003, J PHARM SCI, V92, P1305, DOI 10.1002/jps.10367
   Wenk MR, 1997, BIOPHYS J, V72, P1719, DOI 10.1016/S0006-3495(97)78818-0
   Xing R, 2007, J COLLOID INTERF SCI, V316, P930, DOI 10.1016/j.jcis.2007.08.019
   Xu WJ, 2012, CARBOHYD RES, V349, P12, DOI 10.1016/j.carres.2011.11.020
   Yang QQ, 2008, COLLOID SURFACE A, V322, P40, DOI 10.1016/j.colsurfa.2008.02.026
   Yang QQ, 2007, COLLOID SURFACE A, V305, P22, DOI 10.1016/j.colsurfa.2007.04.050
   Yang XY, 2004, COLLOID POLYM SCI, V282, P280, DOI 10.1007/s00396-003-0940-z
   Zahid NI, 2013, LANGMUIR, V29, P15794, DOI 10.1021/la4040134
NR 40
TC 1
Z9 1
U1 2
U2 8
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1439-4235
EI 1439-7641
J9 CHEMPHYSCHEM
JI ChemPhysChem
PD JAN
PY 2017
VL 18
IS 1
BP 79
EP 86
DI 10.1002/cphc.201600908
PG 8
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA EJ4MA
UT WOS:000393190100014
PM 27788284
OA gold
DA 2018-03-20
ER

PT J
AU Doleman, LA
   Bachas-Daunert, P
   Wei, YA
   Hilt, JZ
   Daunert, S
AF Doleman, Leslie Ann
   Bachas-Daunert, Philip
   Wei, Yinan
   Hilt, J. Zach
   Daunert, Sylvia
TI ANYL 142-Haloacid bioremediation using a hydrogel encapsulated
   thermophilic enzyme
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
C1 [Doleman, Leslie Ann; Wei, Yinan; Daunert, Sylvia] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
   [Bachas-Daunert, Philip] Paul Laurence Dunbar High Sch, Lexington, KY USA.
   [Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM daunert@uky.edu
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD AUG 16
PY 2009
VL 238
MA 142-ANYL
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA V16HY
UT WOS:000207861901235
DA 2018-03-19
ER

PT J
AU Koganti, VR
   Dunphy, D
   Gowrishankar, V
   McGehee, MD
   Li, XF
   Wang, J
   Rankin, SE
AF Koganti, Venkat R.
   Dunphy, Darren
   Gowrishankar, Vignesh
   McGehee, Michael D.
   Li, Xuefa
   Wang, Jin
   Rankin, Stephen E.
TI Generalized coating route to silica and titania films with orthogonally
   tilted cylindrical nanopore arrays
SO NANO LETTERS
LA English
DT Article
ID COPOLYMER THIN-FILMS; X-RAY-DIFFRACTION; ALUMINA MEMBRANE;
   BLOCK-COPOLYMERS; MESOPOROUS FILMS; NANOSTRUCTURES; MESOSTRUCTURES;
   ORIENTATION; SURFACTANTS; DEPOSITION
AB We describe a simple, inexpensive coating method to produce thin silica and titania films with surfactant templated, orthogonally tilted cylindrical nanopore arrays. These films can be deposited onto any substrate because orientation of the 2D hexagonally close packed (HCP) mesophases out of the plane of the film is directed by a chemically neutral sacrificial copolymer layer. Orientation of the HCP mesophases through the entire thickness of films cured in open air is achieved by limiting the coating thickness. This generalizes the coating method by making it possible to deposit oriented films on substrates of any curvature and size. We find a critical thickness between 70 and 100 nm, below which the triblock copolymer surfactant-templated HCP phase aligns completely out of the plane of glass and silicon wafer substrates. Above this thickness, the effect of the chemically neutral bottom layer does not propagate across the entire film, and alignment of the HCP mesophases parallel to the (nonpolar) air interface produces a mixed orientation.
C1 Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   Sandia Natl Labs, Albuquerque, NM 87106 USA.
   Stanford Univ, Dept Mat Sci & Engn, Stanford, CA 94305 USA.
   Argonne Natl Lab, Adv Photon Source, Argonne, IL 60439 USA.
RP Rankin, SE (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM srankin@engr.uky.edu
RI Rankin, Stephen/A-3265-2013
OI Rankin, Stephen/0000-0002-8615-7564
CR Bearzotti A, 2004, J EUR CERAM SOC, V24, P1969, DOI 10.1016/S0955-2219(03)00521-1
   Bearzotti A, 2003, SENSOR ACTUAT B-CHEM, V95, P107, DOI 10.1016/S0925-4005(03)00416-7
   Besson S, 2003, J MATER CHEM, V13, P404, DOI 10.1039/b206698j
   Brinker CJ, 1999, ADV MATER, V11, P579, DOI 10.1002/(SICI)1521-4095(199905)11:7<579::AID-ADMA579>3.0.CO;2-R
   Chik H, 2004, MAT SCI ENG R, V43, P103, DOI 10.1016/j.mser.2003.12.001
   Choi SY, 2004, ADV FUNCT MATER, V14, P335, DOI 10.1002/adfm.200305039
   Freer EM, 2005, NANO LETT, V5, P2014, DOI 10.1021/nl051517h
   Guliants VV, 2004, J MEMBRANE SCI, V235, P53, DOI 10.1016/j.memsci.2004.01.019
   Hillhouse HW, 2001, MICROPOR MESOPOR MAT, V44, P639, DOI 10.1016/S1387-1811(01)00244-X
   Jeong HK, 2005, IND ENG CHEM RES, V44, P8933, DOI 10.1021/ie050809q
   Kirsch BL, 2004, J PHYS CHEM B, V108, P12698, DOI 10.1021/jp036442p
   Koganti VR, 2005, J PHYS CHEM B, V109, P3279, DOI 10.1021/jp045037a
   Ku AY, 2005, J AM CHEM SOC, V127, P6934, DOI 10.1021/ja042202r
   Lu YF, 1997, NATURE, V389, P364, DOI 10.1038/38699
   McCool BA, 2003, J MEMBRANE SCI, V218, P55, DOI 10.1016/S0376-7388(03)00136-4
   Melde BJ, 2005, CHEM MATER, V17, P4743, DOI 10.1021/cm051407b
   Nishiyama N, 2001, J MEMBRANE SCI, V182, P235, DOI 10.1016/S0376-7388(00)00570-6
   Ogawa M, 1998, SUPRAMOL SCI, V5, P247, DOI 10.1016/S0968-5677(98)00015-7
   Platschek B, 2006, ANGEW CHEM INT EDIT, V45, P1134, DOI 10.1002/anie.200503301
   Segalman RA, 2005, MAT SCI ENG R, V48, P191, DOI 10.1016/j.mser.2004.12.003
   Shioya Y, 2003, APPL CATAL A-GEN, V254, P251, DOI 10.1016/S0926-860X(03)00487-3
   Smarsly B, 2005, LANGMUIR, V21, P3858, DOI 10.1021/la046916r
   Wu YY, 2004, NAT MATER, V3, P816, DOI 10.1038/nmat1230
   Xomeritakis G, 2003, MICROPOR MESOPOR MAT, V66, P91, DOI 10.1016/j.micromeso.2003.08.024
   Yamaguchi A, 2004, NAT MATER, V3, P337, DOI 10.1038/nmat1107
   Yoo SJ, 2006, LANGMUIR, V22, P1839, DOI 10.1021/la0525291
   Zhang JL, 2003, J MEMBRANE SCI, V222, P219, DOI 10.1016/S0376-7388(03)00292-8
NR 27
TC 77
Z9 77
U1 6
U2 34
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1530-6984
J9 NANO LETT
JI Nano Lett.
PD NOV 8
PY 2006
VL 6
IS 11
BP 2567
EP 2570
DI 10.1021/nl061992v
PG 4
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 103AT
UT WOS:000241856700031
PM 17090092
DA 2018-03-20
ER

PT J
AU Jennings, CL
   Dziubla, TD
   Puleo, DA
AF Jennings, Cheryl L.
   Dziubla, Thomas D.
   Puleo, David A.
TI Combined effects of drugs and plasticizers on the properties of drug
   delivery films
SO JOURNAL OF BIOACTIVE AND COMPATIBLE POLYMERS
LA English
DT Article
DE Drug release; plasticizer; drug delivery film; erosion; cellulose
   acetate phthalate
ID MECHANICAL-PROPERTIES; POLYMERIC SYSTEMS; HAMSTER MODEL; RELEASE;
   PIRFENIDONE; QUERCETIN; FIBROSIS; NANOPARTICLES; ASSOCIATION; RESPONSES
AB Formation of scar tissue may be reduced or prevented if wounds are locally treated with a combination of molecules tuned to the different healing phases, guiding tissue regeneration along a scar free path. To this end, drug delivery devices made of cellulose acetate phthalate and Pluronic F-127 were loaded with either quercetin or pirfenidone and plasticized with either triethyl citrate or tributyl citrate. Quercetin inhibits oxidative stress, and pirfenidone has been shown to reduce production of pro-inflammatory and fibrogenic molecules. The combined effects of drug and plasticizer on erosion, release, and mechanical properties of the drug delivery films were investigated. Triethyl citrate-plasticized films containing quercetin released drug at a slower rate than did tributyl citrate films. Pirfenidone-loaded films released drug at a faster rate than erosion occurred for both types of plasticizers. Higher plasticizer contents of both triethyl citrate and tributyl citrate increased the elongation and decreased the elastic modulus. In contrast, increased pirfenidone loading in both triethyl citrate and tributyl citrate films resulted in a significantly higher modulus, an antiplasticizer effect. Adding pirfenidone significantly decreased elongation for all film types, but quercetin-loaded samples had significantly greater elongation with increasing drug content. Films containing quercetin elongated more than did pirfenidone-loaded films. Quercetin is over 1.5 times larger than pirfenidone, has water solubility over 12 times lower, and has 6 times more bonding sites than pirfenidone. These differences affected how the two drugs interacted with cellulose acetate phthalate and Pluronic F-127 and thereby determined polymer properties. Drug release, erosion, and mechanical properties of association polymer films can be tailored by the characteristics of the drugs and plasticizers included in the system.
C1 [Jennings, Cheryl L.; Puleo, David A.] Univ Kentucky, Dept Biomed Engn, 522 Robot & Mfg Bldg, Lexington, KY 40506 USA.
   [Dziubla, Thomas D.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY USA.
RP Puleo, DA (reprint author), Univ Kentucky, Dept Biomed Engn, 522 Robot & Mfg Bldg, Lexington, KY 40506 USA.
EM puleo@uky.edu
FU NIH [DE019645, AR060964]; NSF IGERT [DGE-0653710]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This
   research was funded by the NIH (DE019645 and AR060964). C.L.J. was
   supported by NSF IGERT (DGE-0653710).
CR ABERCROMBIE M, 1954, J EMBRYOL EXP MORPH, V2, P264
   Anderson JM, 2001, ANNU REV MATER RES, V31, P81, DOI 10.1146/annurev.matsci.31.1.81
   Braiman-Wiksman L, 2007, TOXICOL PATHOL, V35, P767, DOI 10.1080/01926230701584189
   Card JW, 2003, TOXICOL SCI, V75, P169, DOI 10.1093/toxsci/kfg167
   Chamarthy SP, 2008, COLLOID SURFACE A, V331, P25, DOI 10.1016/j.colsurfa.2008.05.047
   CIERNY G, 1983, CLIN ORTHOP RELAT R, P54
   COTRAN R. S., 1994, ROBBINS PATHOLOGIC B
   Dittrich ESAM, 2012, RECENT ADV PLASTICIZ, P45
   Gomathi K, 2003, BIOMATERIALS, V24, P2767, DOI 10.1016/S0142-9612(03)00059-0
   Govender T, 1999, J CONTROL RELEASE, V57, P171, DOI 10.1016/S0168-3659(98)00116-3
   Grassi M, 2006, UNDERSTANDING DRUG R
   Guo S, 2010, J DENT RES, V89, P219, DOI 10.1177/0022034509359125
   Gute DC, 1998, MOL CELL BIOCHEM, V179, P169, DOI 10.1023/A:1006832207864
   GUTIERREZROCCA JC, 1994, INT J PHARM, V103, P293, DOI 10.1016/0378-5173(94)90180-5
   Harte I, 2013, J APPL POLYM SCI, V127, P1997, DOI 10.1002/app.37600
   HELLER J, 1985, Journal of Controlled Release, V2, P167, DOI 10.1016/0168-3659(85)90042-2
   HELLER J, 1990, BIOMATERIALS, V11, P659, DOI 10.1016/0142-9612(90)90024-K
   Hewitson TD, 2001, J NEPHROL, V14, P453
   Huang CL, 2013, NPG ASIA MATER, V5, DOI 10.1038/am.2013.26
   Iyer SN, 1999, J PHARMACOL EXP THER, V289, P211
   JACKSON WJ, 1967, J APPL POLYM SCI, V11, P211, DOI 10.1002/app.1967.070110205
   Jeon JH, 2008, BIOMATERIALS, V29, P3591, DOI 10.1016/j.biomaterials.2008.05.011
   Jeon JH, 2007, INT J PHARM, V340, P6, DOI 10.1016/j.ijpharm.2007.03.007
   Kaneko M, 1998, CLIN EXP IMMUNOL, V113, P72, DOI 10.1046/j.1365-2249.1998.00618.x
   Kibria G, 2008, AAPS PHARMSCITECH, V9, P1240, DOI 10.1208/s12249-008-9163-4
   Kim J, 2004, INT J PHARM, V273, P23, DOI 10.1016/j.ijpharm.2003.12.004
   Kim YS, 2010, J KOREAN MED SCI, V25, P589, DOI 10.3346/jkms.2010.25.4.589
   Kunze C, 2002, J MATER SCI-MATER M, V13, P1051, DOI 10.1023/A:1020392606225
   Kwan P, 2009, HAND CLIN, V25, P511, DOI 10.1016/j.hcl.2009.06.007
   Lee SB, 2010, KIDNEY INT, V78, pS22, DOI 10.1038/ki.2010.418
   Lei L, 2010, J CONTROL RELEASE, V146, P45, DOI 10.1016/j.jconrel.2010.05.017
   Li YC, 2014, J PHARM PHARMACOL, V66, P148, DOI 10.1111/jphp.12183
   Margolis DJ, 2002, DIABETES CARE, V25, P1835, DOI 10.2337/diacare.25.10.1835
   Medlicott NJ, 1996, INT J PHARM, V143, P25, DOI 10.1016/S0378-5173(96)04675-3
   Vicentini FTMD, 2009, BRAZ J PHARM SCI, V45, P357, DOI 10.1590/S1984-82502009000200022
   Okarter TU, 2000, DRUG DEV IND PHARM, V26, P323, DOI 10.1081/DDC-100100360
   Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875
   Pongjanyakul T, 2007, INT J PHARM, V333, P34, DOI 10.1016/j.ijpharm.2006.09.046
   Rabek CL, 2014, J BIOMATER APPL, V28, P779, DOI 10.1177/0885328213480979
   RiceEvans CA, 1996, FREE RADICAL BIO MED, V20, P933, DOI 10.1016/0891-5849(95)02227-9
   Richeldi L, 2011, NAT REV DRUG DISCOV, V10, P489, DOI 10.1038/nrd3495
   Schreml S, 2010, J AM ACAD DERMATOL, V63, P866, DOI 10.1016/j.jaad.2009.10.048
   Sears J. K., 1982, SPE MONOGRAPH SERIES
   Siepmann F, 2006, J CONTROL RELEASE, V115, P298, DOI 10.1016/j.jconrel.2006.08.016
   Sundararaj SC, 2016, J BIOMED MATER RES B, V104, P1302, DOI 10.1002/jbm.b.33472
   Sundararaj SC, 2014, ACTA BIOMATER, V10, P115, DOI 10.1016/j.actbio.2013.09.031
   Sundararaj SC, 2013, BIOMATERIALS, V34, P8835, DOI 10.1016/j.biomaterials.2013.07.093
   Tan Q, 2011, INT J NANOMED, V6, P1621, DOI 10.2147/IJN.S22411
   Uhrich KE, 1999, CHEM REV, V99, P3181, DOI 10.1021/cr940351u
   Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(00)00088-5
   XU X, 1993, PHARMACEUT RES, V10, P1144, DOI 10.1023/A:1018960016756
   [Anonymous], 2002, WORLD REPORT ROAD TR
NR 52
TC 1
Z9 1
U1 1
U2 7
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0883-9115
EI 1530-8030
J9 J BIOACT COMPAT POL
JI J. Bioact. Compat. Polym.
PD JUL
PY 2016
VL 31
IS 4
BP 323
EP 333
DI 10.1177/0883911515627178
PG 11
WC Biotechnology & Applied Microbiology; Materials Science, Biomaterials;
   Polymer Science
SC Biotechnology & Applied Microbiology; Materials Science; Polymer Science
GA DQ9EM
UT WOS:000379513200001
PM 27821905
OA green_accepted
DA 2018-03-20
ER

PT J
AU Islam, SZ
   Nagpure, S
   Kim, DY
   Rankin, SE
AF Islam, Syed Z.
   Nagpure, Suraj
   Kim, Doo Young
   Rankin, Stephen E.
TI Synthesis and Catalytic Applications of Non-Metal Doped Mesoporous
   Titania
SO INORGANICS
LA English
DT Review
DE mesoporous; titania; non-metal doping; catalysis; photocatalysis;
   self-assembly
ID LIGHT PHOTOCATALYTIC ACTIVITY; TIO2 THIN-FILMS; VISIBLE-LIGHT; SOL-GEL;
   IN-SITU; HYDROGEN-PRODUCTION; H-2 PRODUCTION; PHOTOELECTROCHEMICAL
   CELLS; NANOCRYSTALLINE TIO2; THERMAL-STABILITY
AB Mesoporous titania (mp-TiO2) has drawn tremendous attention for a diverse set of applications due to its high surface area, interfacial structure, and tunable combination of pore size, pore orientation, wall thickness, and pore connectivity. Its pore structure facilitates rapid diffusion of reactants and charge carriers to the photocatalytically active interface of TiO2. However, because the large band gap of TiO2 limits its ability to utilize visible light, non-metal doping has been extensively studied to tune the energy levels of TiO2. While first-principles calculations support the efficacy of this approach, it is challenging to efficiently introduce active non-metal dopants into the lattice of TiO2. This review surveys recent advances in the preparation of mp-TiO2 and their doping with non-metal atoms. Different doping strategies and dopant sources are discussed. Further, co-doping with combinations of non-metal dopants are discussed as strategies to reduce the band gap, improve photogenerated charge separation, and enhance visible light absorption. The improvements resulting from each doping strategy are discussed in light of potential changes in mesoporous architecture, dopant composition and chemical state, extent of band gap reduction, and improvement in photocatalytic activities. Finally, potential applications of non-metal-doped mp-TiO2 are explored in water splitting, CO2 reduction, and environmental remediation with visible light.
C1 [Islam, Syed Z.; Nagpure, Suraj; Rankin, Stephen E.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Kim, Doo Young] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
RP Rankin, SE (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM syedislam@uky.edu; suraj.nagpure@uky.edu; dooyoung.kim@uky.edu;
   srankin@engr.uky.edu
OI Islam, Syed/0000-0002-5149-8094
FU National Science Foundation EPSCoR Research Infrastructure Initiative
   award [IIA-1355438]
FX The authors acknowledge financial support from National Science
   Foundation EPSCoR Research Infrastructure Initiative award supported by
   grant No. IIA-1355438.
CR Alberius PCA, 2002, CHEM MATER, V14, P3284, DOI 10.1021/cm011209u
   Aman N, 2010, J MATER CHEM, V20, P10876, DOI 10.1039/c0jm01342k
   Ananpattarachai J, 2009, J HAZARD MATER, V168, P253, DOI 10.1016/j.jhazmat.2009.02.036
   ANTONELLI DM, 1995, ANGEW CHEM INT EDIT, V34, P2014, DOI 10.1002/anie.199520141
   Antonelli DM, 1999, MICROPOR MESOPOR MAT, V30, P315, DOI 10.1016/S1387-1811(99)00042-6
   Ao YH, 2009, MICROPOR MESOPOR MAT, V122, P1, DOI 10.1016/j.micromeso.2008.11.010
   Ao YH, 2009, MICROPOR MESOPOR MAT, V118, P382, DOI 10.1016/j.micromeso.2008.09.010
   Asahi R, 2001, SCIENCE, V293, P269, DOI 10.1126/science.1061051
   Asahi R, 2014, CHEM REV, V114, P9824, DOI 10.1021/cr5000738
   Atabaev TS, 2016, RESULTS PHYS, V6, P373, DOI 10.1016/j.rinp.2016.07.002
   Aurora P, 2010, J ELECTROCHEM SOC, V157, pK152, DOI 10.1149/1.3417096
   Bagheri S, 2015, MICROPOR MESOPOR MAT, V218, P206, DOI 10.1016/j.micromeso.2015.05.028
   Banerjee S, 2014, J PHYS CHEM LETT, V5, P2543, DOI 10.1021/jz501030x
   Bingham S, 2011, J MATER CHEM, V21, P2041, DOI 10.1039/c0jm02271c
   Bleta R, 2010, J PHYS CHEM C, V114, P2039, DOI 10.1021/jp909646h
   Bosc F, 2004, CHEM MATER, V16, P2208, DOI 10.1021/cm049893a
   Brinker CJ, 1999, ADV MATER, V11, P579, DOI 10.1002/(SICI)1521-4095(199905)11:7<579::AID-ADMA579>3.0.CO;2-R
   Burda C, 2003, NANO LETT, V3, P1049, DOI 10.1021/nl034332o
   Cao XP, 2012, J MATER CHEM, V22, P15309, DOI 10.1039/c2jm31576a
   Cavalcante RP, 2015, CATAL TODAY, V252, P27, DOI 10.1016/j.cattod.2014.09.030
   Chang PY, 2012, CARBON, V50, P4259, DOI 10.1016/j.carbon.2012.05.009
   Chen C, 2007, J PHYS CHEM C, V111, P15228, DOI 10.1021/jp0716233
   Chen XB, 2005, ADV FUNCT MATER, V15, P41, DOI 10.1002/adfm.200400184
   Chen XB, 2011, SCIENCE, V331, P746, DOI 10.1126/science.1200448
   Cheng YH, 2012, J SOLID STATE CHEM, V196, P518, DOI 10.1016/j.jssc.2012.07.011
   Chi B, 2007, J PHYS CHEM C, V111, P6189, DOI 10.1021/jp067490n
   Choi J, 2010, J PHYS CHEM C, V114, P783, DOI 10.1021/jp908088x
   Choi SY, 2004, ADV FUNCT MATER, V14, P335, DOI 10.1002/adfm.200305039
   CHOI WY, 1994, J PHYS CHEM-US, V98, P13669, DOI 10.1021/j100102a038
   Cong Y, 2007, J PHYS CHEM C, V111, P6976, DOI 10.1021/jp0685030
   Crepaldi EL, 2003, J AM CHEM SOC, V125, P9770, DOI 10.1021/ja030070g
   Da Silva RO, 2011, NANOSCALE, V3, P1910, DOI 10.1039/c0nr01016b
   Das S, 2016, PHYS CHEM CHEM PHYS, V18, P2896, DOI 10.1039/c5cp05178a
   Das S, 2014, J PHYS CHEM C, V118, P968, DOI 10.1021/jp406165v
   Devi LG, 2013, APPL CATAL B-ENVIRON, V140, P559, DOI 10.1016/j.apcatb.2013.04.035
   Dhakshinamoorthy A, 2012, ENERG ENVIRON SCI, V5, P9217, DOI 10.1039/c2ee21948d
   Dholam R, 2009, INT J HYDROGEN ENERG, V34, P5337, DOI 10.1016/j.ijhydene.2009.05.011
   Di Valentin C, 2013, CATAL TODAY, V206, P12, DOI 10.1016/j.cattod.2011.11.030
   El-Sheikh SM, 2014, J HAZARD MATER, V280, P723, DOI 10.1016/j.jhazmat.2014.08.038
   Elghniji K, 2012, J IND ENG CHEM, V18, P178, DOI 10.1016/j.jiec.2011.11.011
   Fan XX, 2008, APPL SURF SCI, V254, P5191, DOI 10.1016/j.apsusc.2008.02.038
   Fang J, 2010, J PHYS CHEM C, V114, P7940, DOI 10.1021/jp100519q
   Faustini M, 2014, CHEM MATER, V26, P709, DOI 10.1021/cm402132y
   Feng D, 2013, J MATER CHEM A, V1, P1591, DOI 10.1039/c2ta00588c
   Feng HJ, 2013, J NANOSCI NANOTECHNO, V13, P4981, DOI 10.1166/jnn.2013.7606
   Fu J, 2013, CHEM ENG J, V219, P155, DOI 10.1016/j.cej.2013.01.032
   FUJISHIMA A, 1972, NATURE, V238, P37, DOI 10.1038/238037a0
   Gandhe AR, 2005, MICROPOR MESOPOR MAT, V87, P103, DOI 10.1016/j.micromeso.2005.07.017
   Gao MY, 2014, ACTA CHIM SINICA, V72, P1092, DOI 10.6023/A14070535
   Ghicov A, 2006, NANO LETT, V6, P1080, DOI 10.1021/nl0600979
   Ghicov A, 2006, CHEM PHYS LETT, V419, P426, DOI 10.1016/j.cplett.2005.11.102
   Gohin M, 2010, J MATER CHEM, V20, P8070, DOI 10.1039/c0jm01499k
   Gratzel M, 2001, NATURE, V414, P338, DOI 10.1038/35104607
   Grosso D, 2003, CHEM MATER, V15, P4562, DOI 10.1021/cm031060h
   Grosso D, 2004, ADV FUNCT MATER, V14, P309, DOI 10.1002/adfm.200305036
   Grosso D, 2002, CHEM MATER, V14, P931, DOI 10.1021/cm011255u
   Grosso D, 2003, J SOL-GEL SCI TECHN, V26, P561, DOI 10.1023/A:1020715803241
   Grosso D, 2002, CHEM COMMUN, P748, DOI 10.1039/b111499a
   Grosso D, 2001, CHEM MATER, V13, P1848, DOI 10.1021/cm001225b
   Guo CS, 2012, RSC ADV, V2, P4720, DOI 10.1039/c2ra01164f
   Guo SY, 2013, MATER RES BULL, V48, P3032, DOI 10.1016/j.materresbull.2013.04.056
   Han OH, 2007, CHEM MATER, V19, P3615, DOI 10.1021/cm062916w
   Hartmann P, 2010, ACS NANO, V4, P3147, DOI 10.1021/nn1004765
   Haseloh S, 2004, CHEM COMMUN, P1460, DOI 10.1039/b403607g
   He TN, 2014, RSC ADV, V4, P5880, DOI 10.1039/c3ra44046j
   Hidetaka I., 2010, CHEM PHYS LETT, V489, P81
   Horikawa T, 2008, MICROPOR MESOPOR MAT, V110, P397, DOI 10.1016/j.micromeso.2007.06.048
   Hou YD, 2008, CHEMOSPHERE, V72, P414, DOI 10.1016/j.chemosphere.2008.02.035
   Hu SZ, 2014, J POWER SOURCES, V250, P30, DOI 10.1016/j.jpowsour.2013.10.132
   Hu YH, 2012, ANGEW CHEM INT EDIT, V51, P12410, DOI 10.1002/anie.201206375
   Hu ZY, 2013, MATER LETT, V106, P421, DOI 10.1016/j.matlet.2013.05.076
   Huang CM, 2007, J MOL CATAL A-CHEM, V261, P218, DOI 10.1016/j.molcata.2006.08.020
   Huang E, 1998, MACROMOLECULES, V31, P7641, DOI 10.1021/ma980705+
   Huang E, 1999, MACROMOLECULES, V32, P5299, DOI 10.1021/ma990483v
   Huang Y, 2008, LANGMUIR, V24, P3510, DOI 10.1021/la703333z
   Huinink HP, 2000, J CHEM PHYS, V112, P2452, DOI 10.1063/1.480811
   Huo QS, 1996, CHEM MATER, V8, P1147, DOI 10.1021/cm960137h
   INOUE T, 1979, NATURE, V277, P637, DOI 10.1038/277637a0
   Islam SZ, 2016, MATER CHEM PHYS, V182, P382, DOI 10.1016/j.matchemphys.2016.07.046
   Islam SZ, 2016, J PHYS CHEM C, V120, P14069, DOI 10.1021/acs.jpcc.6b02622
   Islam SZ, 2016, SEP SCI TECHNOL, V51, P1176, DOI 10.1080/01496395.2015.1109661
   Islam SZ, 2016, MICROPOR MESOPOR MAT, V220, P120, DOI 10.1016/j.micromeso.2015.08.030
   Ismail AA, 2011, J MATER CHEM, V21, P11686, DOI 10.1039/c1jm10407a
   ISRAELACHVILI J, 1992, INTERMOLECULAR SURFA, P366
   Jang KS, 2004, CHEM COMMUN, P1514, DOI 10.1039/b404409f
   Jia TK, 2014, INT J PHOTOENERGY, DOI 10.1155/2014/516806
   Jinlong L., 2010, THIN SOLID FILMS, V519, P101, DOI DOI 10.1016/J.TSF.2010.07.070
   Joo JB, 2012, ADV FUNCT MATER, V22, P166, DOI 10.1002/adfm.201101927
   Joshi MM, 2009, APPL CATAL A-GEN, V357, P26, DOI 10.1016/j.apcata.2008.12.030
   Kafizas A, 2010, J MATER CHEM, V20, P2157, DOI 10.1039/b914117k
   Kakrondi MA, 2014, J MOL CATAL A-CHEM, V392, P112, DOI 10.1016/j.molcata.2014.04.036
   KALLALA M, 1993, PHYS REV E, V48, P3692, DOI 10.1103/PhysRevE.48.3692
   Katsanaki AV, 2013, APPL CATAL B-ENVIRON, V140, P619, DOI 10.1016/j.apcatb.2013.04.070
   Kellogg GJ, 1996, PHYS REV LETT, V76, P2503, DOI 10.1103/PhysRevLett.76.2503
   Kim S, 2005, J PHYS CHEM B, V109, P24260, DOI 10.1021/jp055278y
   Kirsch BL, 2004, J PHYS CHEM B, V108, P12698, DOI 10.1021/jp036442p
   Ko YS, 2011, MICROPOR MESOPOR MAT, V145, P141, DOI 10.1016/j.micromeso.2011.05.008
   Koganti VR, 2006, NANO LETT, V6, P2567, DOI 10.1021/nl061992v
   Koganti VR, 2014, J PHYS CHEM C, V118, P19450, DOI 10.1021/jp505651j
   Koh CW, 2008, CHEM-ASIAN J, V3, P862, DOI 10.1002/asia.200700331
   Kondratenko EV, 2013, ENERG ENVIRON SCI, V6, P3112, DOI 10.1039/c3ee41272e
   Kontos AG, 2011, PHOTOCH PHOTOBIO SCI, V10, P350, DOI 10.1039/c0pp00159g
   Lan M., 2008, APPL SURF SCI, V255, P2574
   Landmann M, 2012, PHYS REV B, V86, DOI 10.1103/PhysRevB.86.064201
   Lee DW, 2007, CHEM MATER, V19, P937, DOI 10.1021/cm062465f
   Lee HU, 2014, CHEM ENG J, V254, P268, DOI 10.1016/j.cej.2014.06.011
   Lee JH, 2015, CERAM INT, V41, P11899, DOI 10.1016/j.ceramint.2015.05.157
   Lee UH, 2006, MICROPOR MESOPOR MAT, V88, P48, DOI 10.1016/j.micromeso.2005.08.017
   Leung DYC, 2010, CHEMSUSCHEM, V3, P681, DOI 10.1002/cssc.201000014
   Lewis NS, 2007, SCIENCE, V315, P798, DOI 10.1126/science.1137014
   Li GS, 2009, SEP PURIF TECHNOL, V67, P152, DOI 10.1016/j.seppur.2009.03.022
   Li H, 2010, RES CHEM INTERMEDIAT, V36, P27, DOI 10.1007/s11164-010-0111-z
   Li JT, 2015, CATAL SCI TECHNOL, V5, P1360, DOI 10.1039/c4cy00974f
   Li LD, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6881
   Li W, 2014, CHEM MATER, V26, P287, DOI 10.1021/cm4014859
   Li X, 2015, APPL CATAL B-ENVIRON, V164, P352, DOI 10.1016/j.apcatb.2014.09.053
   Li XS, 2004, LANGMUIR, V20, P9095, DOI 10.1021/la0486279
   Li YY, 2012, J ALLOY COMPD, V512, P23, DOI 10.1016/j.jallcom.2011.08.072
   Liao YT, 2012, APPL ENERG, V100, P75, DOI 10.1016/j.apenergy.2012.02.053
   Lin XX, 2012, ADV MATER RES-SWITZ, V374-377, P895, DOI 10.4028/www.scientific.net/AMR.374-377.895
   Lin XX, 2011, MICROPOR MESOPOR MAT, V142, P276, DOI 10.1016/j.micromeso.2010.12.010
   Liu EQ, 2012, CHINESE J CATAL, V33, P1665, DOI 10.1016/S1872-2067(11)60437-3
   Liu G, 2008, ANGEW CHEM INT EDIT, V47, P4516, DOI 10.1002/anie.200705633
   Liu G, 2006, J PHYS CHEM B, V110, P20823, DOI 10.1021/jp062946m
   Liu G, 2010, J MATER CHEM, V20, P831, DOI [10.1039/b909930a, 10.1039/B909930A]
   Liu G, 2009, J COLLOID INTERF SCI, V334, P171, DOI 10.1016/j.jcis.2009.02.047
   Liu GL, 2013, J MOL CATAL A-CHEM, V372, P58, DOI 10.1016/j.molcata.2013.02.006
   Liu HJ, 2010, COLLOID SURFACE A, V363, P35, DOI 10.1016/j.colsurfa.2010.04.010
   Liu KS, 2005, J PHYS CHEM B, V109, P18719, DOI 10.1021/jp054546p
   Liu SH, 2013, INT J HYDROGEN ENERG, V38, P13856, DOI 10.1016/j.ijhydene.2013.08.094
   Liu SH, 2012, APPL ENERG, V100, P148, DOI 10.1016/j.apenergy.2012.03.063
   Liu XL, 2010, LANGMUIR, V26, P7671, DOI 10.1021/la1009384
   Liu X, 2011, J ALLOY COMPD, V509, P9970, DOI 10.1016/j.jallcom.2011.08.003
   Liu ZQ, 2010, J ALLOY COMPD, V501, P54, DOI 10.1016/j.jallcom.2010.04.027
   LIVAGE J, 1988, PROG SOLID STATE CH, V18, P259, DOI 10.1016/0079-6786(88)90005-2
   Lu XH, 2012, NANO LETT, V12, P1690, DOI 10.1021/nl300173j
   Lynch J, 2015, J PHYS CHEM C, V119, P7443, DOI 10.1021/jp512775s
   Mahoney L, 2014, MATERIALS, V7, P2697, DOI 10.3390/ma7042697
   Mao CY, 2014, ANGEW CHEM INT EDIT, V53, P10485, DOI 10.1002/anie.201406017
   Martinez-Ferrero E, 2007, ADV FUNCT MATER, V17, P3348, DOI 10.1002/adfm.200700396
   McDonnell KA, 2012, PHYS REV B, V86, DOI 10.1103/PhysRevB.86.115306
   Mei P, 2010, J PHYS CHEM SOLIDS, V71, P1, DOI 10.1016/j.jpcs.2009.08.002
   Miao L, 2005, APPL SURF SCI, V244, P412, DOI 10.1016/j.apsusc.2004.10.098
   Moonoosawmy KR, 2012, LANGMUIR, V28, P6706, DOI 10.1021/la3006458
   Nagaveni K, 2004, J PHYS CHEM B, V108, P20204, DOI 10.1021/jp047917v
   Nagpure S, 2015, J PHYS CHEM C, V119, P22970, DOI 10.1021/acs.jpcc.5b06945
   Naldoni A, 2012, J AM CHEM SOC, V134, P7600, DOI 10.1021/ja3012676
   Napoli F, 2009, CHEM PHYS LETT, V477, P135, DOI 10.1016/j.cplett.2009.06.050
   Nassoko D, 2012, J ALLOY COMPD, V540, P228, DOI 10.1016/j.jallcom.2012.06.085
   Nolan NT, 2012, J HAZARD MATER, V211, P88, DOI 10.1016/j.jhazmat.2011.08.074
   Pan H, 2011, J PHYS CHEM C, V115, P12224, DOI 10.1021/jp202385q
   Pan JH, 2008, J AM CHEM SOC, V130, P11256, DOI 10.1021/ja803582m
   Pan L, 2013, APPL SURF SCI, V268, P252, DOI 10.1016/j.apsusc.2012.12.074
   Parida KM, 2009, J COLLOID INTERF SCI, V333, P269, DOI 10.1016/j.jcis.2009.02.017
   Park H, 2004, J PHYS CHEM B, V108, P4086, DOI 10.1021/jp036735i
   Park JK, 2003, B KOR CHEM SOC, V24, P671
   Pelaez M, 2012, APPL CATAL B-ENVIRON, V125, P331, DOI 10.1016/j.apcatb.2012.05.036
   Pelaez M, 2012, APPL CATAL B-ENVIRON, V121, P30, DOI 10.1016/j.apcatb.2012.03.010
   Pelaez M, 2009, CATAL TODAY, V144, P19, DOI 10.1016/j.cattod.2008.12.022
   Periyat P, 2009, J PHYS CHEM C, V113, P3246, DOI 10.1021/jp808444y
   Pickett GT, 1997, MACROMOLECULES, V30, P3097, DOI 10.1021/ma9617173
   Pulsipher DJV, 2010, ACS APPL MATER INTER, V2, P1743, DOI 10.1021/am100233j
   Qiao M, 2010, J SOL-GEL SCI TECHN, V55, P377, DOI 10.1007/s10971-010-2253-2
   Rankin S. E., 2001, P NONL LITH METH NAN, pD121
   Ren WJ, 2007, APPL CATAL B-ENVIRON, V69, P138, DOI 10.1016/j.apcatb.2006.06.015
   Richman EK, 2008, NAT MATER, V7, P712, DOI 10.1038/nmat2257
   Salari M, 2015, PHYS CHEM CHEM PHYS, V17, P5642, DOI 10.1039/c4cp03177f
   Sanchez C, 2008, CHEM MATER, V20, P682, DOI 10.1021/cm702100t
   Schubert U, 2005, J MATER CHEM, V15, P3701, DOI [10.1039/b504269k, 10.1039/B504269K]
   Selvam K, 2012, APPL CATAL A-GEN, V413, P213, DOI 10.1016/j.apcata.2011.11.011
   Serpone N, 2006, J PHYS CHEM B, V110, P24287, DOI 10.1021/jp065659r
   Shahid M, 2013, B KOREAN CHEM SOC, V34, P2271, DOI 10.5012/bkcs.2013.34.8.2271
   Shao GS, 2008, APPL CATAL B-ENVIRON, V82, P208, DOI 10.1016/j.ctpcatb.2008.01.026
   Shao GS, 2009, APPL CATAL B-ENVIRON, V92, P61, DOI 10.1016/j.apcatb.2009.07.024
   Sharma R, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/7/075704
   Shi JW, 2012, APPL CATAL A-GEN, V435, P86, DOI 10.1016/j.apcata.2012.05.044
   Shi Q, 2013, APPL SURF SCI, V273, P769, DOI 10.1016/j.apsusc.2013.02.132
   Sivaranjani K, 2011, J MATER CHEM, V21, P2639, DOI 10.1039/c0jm03825c
   Soler-Illia GJDA, 2000, NEW J CHEM, V24, P493, DOI 10.1039/b002518f
   Soni SS, 2013, THIN SOLID FILMS, V531, P559, DOI 10.1016/j.tsf.2012.12.056
   Soni SS, 2008, ADV MATER, V20, P1493, DOI 10.1002/adma.200701066
   Sreethawong T, 2008, INT J HYDROGEN ENERG, V33, P5947, DOI 10.1016/j.ijhydene.2008.08.007
   Sreethawong T, 2009, CATAL COMMUN, V10, P538, DOI 10.1016/j.catcom.2008.10.029
   Su J, 2014, RSC ADV, V4, P13979, DOI 10.1039/c3ra47757f
   Sun HQ, 2008, SOL ENERG MAT SOL C, V92, P76, DOI 10.1016/j.solmat.2007.09.003
   Tasinkevych M, 2001, J CHEM PHYS, V115, P8705, DOI 10.1063/1.1412606
   Thurn-Albrecht T, 2000, ADV MATER, V12, P787, DOI 10.1002/(SICI)1521-4095(200006)12:11<787::AID-ADMA787>3.0.CO;2-1
   Tian BZ, 2008, APPL CATAL B-ENVIRON, V79, P394, DOI 10.1016/j.apcatb.2007.11.001
   Tong H, 2012, ADV MATER, V24, P229, DOI 10.1002/adma.201102752
   Varghese OK, 2009, NANO LETT, V9, P731, DOI 10.1021/nl803258p
   Varley JB, 2011, ADV MATER, V23, P2343, DOI 10.1002/adma.201003603
   Wang GM, 2015, NANO LETT, V15, P4692, DOI 10.1021/acs.nanolett.5b01547
   Wang GM, 2011, NANO LETT, V11, P3026, DOI 10.1021/nl201766h
   Wang H, 2004, LANGMUIR, V20, P11738, DOI 10.1021/la0477892
   Wang JG, 2013, APPL CATAL B-ENVIRON, V134, P198, DOI 10.1016/j.apcatb.2013.01.006
   Wang JS, 2012, J PHYS CHEM C, V116, P9517, DOI 10.1021/jp211995t
   Wang JS, 2010, SOLID STATE SCI, V12, P490, DOI 10.1016/j.solidstatesciences.2009.12.013
   Wang JW, 2010, NANOSCALE, V2, P2257, DOI 10.1039/c0nr00313a
   Wang T, 2010, J SOLID STATE CHEM, V183, P2797, DOI 10.1016/j.jssc.2010.09.028
   Wang Z, 2013, ADV FUNCT MATER, V23, P5444, DOI 10.1002/adfm.201300486
   WANKA G, 1994, MACROMOLECULES, V27, P4145, DOI 10.1021/ma00093a016
   Weymann-Schildknetch S, 2001, J CHEM SOC DALTON, P2425, DOI 10.1039/b103398k
   Wu QL, 2011, J SOL-GEL SCI TECHN, V60, P81, DOI 10.1007/s10971-011-2553-1
   Wu YM, 2010, CHEM ENG J, V162, P710, DOI 10.1016/j.cej.2010.06.030
   Xiang QJ, 2012, J AM CHEM SOC, V134, P6575, DOI 10.1021/ja302846n
   Xiao Q, 2011, APPL SURF SCI, V257, P3652, DOI 10.1016/j.apsusc.2010.11.098
   Xu JH, 2008, APPL CATAL B-ENVIRON, V79, P72, DOI 10.1016/j.apcatb.2007.10.008
   Xu JA, 2010, J PHYS CHEM C, V114, P15251, DOI 10.1021/jp101168y
   Xu JJ, 2010, APPL SURF SCI, V256, P4397, DOI 10.1016/j.apsusc.2010.02.037
   Yang CY, 2013, J AM CHEM SOC, V135, P17831, DOI 10.1021/ja4076748
   Yang GD, 2010, J MATER CHEM, V20, P5301, DOI 10.1039/c0jm00376j
   Yao NA, 2012, CERAM INT, V38, P1671, DOI 10.1016/j.ceramint.2011.09.059
   Yin JB, 2006, J PHYS CHEM B, V110, P12916, DOI 10.1021/jp0554588
   You XF, 2005, CATAL LETT, V102, P247, DOI 10.1007/s10562-005-5863-5
   Yu CL, 2010, CATAL LETT, V140, P172, DOI 10.1007/s10562-010-0434-9
   Yu CL, 2010, J PHYS CHEM SOLIDS, V71, P1337, DOI 10.1016/j.jpcs.2010.06.001
   Yu CL, 2009, J SOLID STATE CHEM, V182, P1061, DOI 10.1016/j.jssc.2009.01.033
   Yu JC, 2002, CHEM MATER, V14, P3808, DOI 10.1021/cm020027c
   Yu JC, 2003, CHEM MATER, V15, P2280, DOI 10.1021/cm0340781
   Yu JC, 2003, LANGMUIR, V19, P3889, DOI 10.1021/la025775v
   Yu JG, 2007, J PHYS CHEM C, V111, P10582, DOI 10.1021/jp0707889
   Yu JG, 2009, J PHYS CHEM C, V113, P6743, DOI 10.1021/jp900136q
   Yue WB, 2009, CHEM MATER, V21, P2540, DOI 10.1021/cm900197p
   Zalas M, 2014, CATAL TODAY, V230, P91, DOI 10.1016/j.cattod.2013.12.032
   Zhang HJ, 2009, J MATER CHEM, V19, P5089, DOI 10.1039/b821991e
   Zhang K, 2014, POWDER TECHNOL, V253, P608, DOI 10.1016/j.powtec.2013.12.024
   Zhang L, 2014, ACS APPL MATER INTER, V6, P3623, DOI 10.1021/am405872r
   Zhang L, 2013, PHYSICA E, V47, P279, DOI 10.1016/j.physe.2012.10.008
   Zhang RY, 2012, NANO TODAY, V7, P344, DOI 10.1016/j.nantod.2012.06.012
   Zhang Y, 2012, APPL CATAL B-ENVIRON, V115, P236, DOI 10.1016/j.apcatb.2011.12.031
   Zhang ZY, 2010, J MATER CHEM, V20, P2206, DOI 10.1039/b921157h
   Zhao C, 2014, CATAL TODAY, V224, P70, DOI 10.1063/j.cattod.2013.09.042
   Zhou H, 2014, J ALLOY COMPD, V597, P1, DOI 10.1016/j.jallcom.2014.01.213
   Zhou Wq, 2013, CHINESE J CATAL, V34, P1250, DOI 10.1016/S1872-2067(12)60578-6
   Zhou W, 2013, CHEMCATCHEM, V5, P885, DOI 10.1002/cctc.201200519
   Zhou XS, 2011, J SOLID STATE CHEM, V184, P134, DOI 10.1016/j.jssc.2010.10.039
   Zuo F, 2012, ANGEW CHEM INT EDIT, V51, P6223, DOI 10.1002/anie.201202191
   Zuo F, 2010, J AM CHEM SOC, V132, P11856, DOI 10.1021/ja103843d
NR 238
TC 2
Z9 2
U1 6
U2 22
PU MDPI AG
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2304-6740
J9 INORGANICS
JI Inorganics
PD MAR
PY 2017
VL 5
IS 1
AR 15
DI 10.3390/inorganics5010015
PG 43
WC Chemistry, Inorganic & Nuclear
SC Chemistry
GA ER3HE
UT WOS:000398686600014
OA gold
DA 2018-03-20
ER

PT J
AU Alani, AWG
   Bae, Y
   Rao, DA
   Kwon, GS
AF Alani, Adam W. G.
   Bae, Younsoo
   Rao, Deepa A.
   Kwon, Glen S.
TI Polymeric micelles for the pH-dependent controlled, continuous low dose
   release of paclitaxel
SO BIOMATERIALS
LA English
DT Article
DE Controlled drug release; Hydrazone; Mixed micelle; Paclitaxel; Prodrug
ID ACID) BLOCK-COPOLYMER; INTRACELLULAR DRUG-DELIVERY; CREMOPHOR-EL;
   IN-VITRO; CANCER-CHEMOTHERAPY; ANTITUMOR-ACTIVITY; ADRIAMYCIN; TAXOL;
   DERIVATIVES; EXTRACTION
AB Poly(ethylene glycol)-block-poly(aspartate-hydrazide) (PEG-p(Asp-Hyd)) was modified using either levulinic acid (LEV) or 4-acetyl benzoic acid (4AB) attached via hydrazone bonds. Paclitaxel (PT-X) conjugated to the linkers formed PEG-p(Asp-Hyd-LEV-PTX) and PEG-p(Asp-Hyd-4AB-PTX). PEG-p(Asp-Hyd-LEV-PTX) and PEG-p(Asp-Hyd-4AB-PTX) assemble into unimodal polymeric micelles with diameters of 42 nm and 137 nm, respectively. PEG-p(Asp-Hyd-LEV-PTX) and PEG-p(Asp-Hyd-4AB-PTX) at a 1:1 and 1:5 molar ratio assemble into unimodal mixed polymeric micelles with diameters of 85 and 113 nm, respectively. PEG-p(Asp-Hyd-LEV-PTX) micelles release LEV-PTX faster at pH 5.0 than at pH 7.4 over 24 h. At pH 7.4 mixed polymeric micelles at 1:5 ratio show no difference in LEV-PTX release from PEG-p(Asp-Hyd-LEV-PTX) micelles. Mixed polymeric micelles at 1:5 molar ratio gradually release LEV-PTX at pH 5.0, with no release of 4AB-PTX. PEG-p(Asp-Hyd-LEV-PTX) micelles and mixed polymeric micelles exert comparable cytotoxicity against SK-OV-3 and MCF-7 cancer cell lines. In summary, mixed polymeric micelles based on PEG-p(Asp-Hyd-LEV-PTX) and PEG-p(Asp-Hyd-4AB-PTX) offer prospects for pH-dependent release of M, offering a novel prodrug strategy for adjusting its pharmacokinetic and pharmacodynamic properties for cancer therapy. If successful this delivery system offers an alternative new mode of delivery for paclitaxel with a new scope for its efficacy along with a minimal synthetic framework needed to accomplish this. Published by Elsevier Ltd.
C1 [Alani, Adam W. G.; Kwon, Glen S.] Univ Wisconsin, Sch Pharm, Div Pharmaceut Sci, Madison, WI 53705 USA.
   [Bae, Younsoo] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
   [Rao, Deepa A.] Drake Univ, Coll Pharm & Hlth Sci, Dept Pharmaceut Biomed & Adm Sci, Des Moines, IA 50311 USA.
RP Kwon, GS (reprint author), Univ Wisconsin, Sch Pharm, Div Pharmaceut Sci, 777 Highland Ave, Madison, WI 53705 USA.
EM gskwon@pharmacy.wisc.edu
RI Alani, Adam/E-2327-2013; Kwon, Glen/A-1919-2014
FU NIAID NIH HHS [R01 AI043346]
CR Allwood MC, 1996, INT J PHARM, V127, P65, DOI 10.1016/0378-5173(95)04128-1
   Bae Y, 2005, MOL BIOSYST, V1, P242, DOI 10.1039/b500266d
   Bae Y, 2003, ANGEW CHEM INT EDIT, V42, P4640, DOI 10.1002/anie.200250653
   Bae Y, 2007, J CONTROL RELEASE, V122, P324, DOI 10.1016/j.jconrel.2007.05.038
   Bae Y, 2007, BIOCONJUGATE CHEM, V18, P1131, DOI 10.1021/bc060401p
   Belotti D, 1996, CLIN CANCER RES, V2, P1725
   DYE D, 1980, BRIT MED J, V280, P1353, DOI 10.1136/bmj.280.6228.1353
   Hawkins MJ, 2008, ADV DRUG DELIVER REV, V60, P876, DOI 10.1016/j.addr.2007.08.044
   Kerbel RS, 2004, NAT REV CANCER, V4, P423, DOI 10.1038/nrc1369
   Lee SC, 2007, BIOMACROMOLECULES, V8, P202, DOI 10.1021/bm060307b
   LORENZ W, 1977, AGENTS ACTIONS, V7, P63, DOI 10.1007/BF01964882
   MATHEW AE, 1992, J MED CHEM, V35, P145, DOI 10.1021/jm00079a019
   MATSUMURA Y, 1986, CANCER RES, V46, P6387
   Matsumura Y, 2008, ADV DRUG DELIVER REV, V60, P899, DOI 10.1016/j.addr.2007.11.010
   McGuire W. P., 1995, PACLITAXEL CANC TREA
   MELLADO W, 1984, BIOCHEM BIOPH RES CO, V124, P329, DOI 10.1016/0006-291X(84)91557-2
   Ng SSW, 2004, CANCER RES, V64, P821, DOI 10.1158/0008-5472.CAN-03-3391
   Ng SSW, 2006, CLIN CANCER RES, V12, P4331, DOI 10.1158/1078-0432.CCR-05-2762
   Rodrigues PCA, 2003, BIOORG MED CHEM LETT, V13, P355, DOI 10.1016/S0960-894X(02)01002-8
   *US PHARM CONV INC, 2000, 24NF19 USP, P2231
   WAUGH WN, 1991, AM J HOSP PHARM, V48, P1520
   WEISS RB, 1990, J CLIN ONCOL, V8, P1263, DOI 10.1200/JCO.1990.8.7.1263
   YOKOYAMA M, 1990, J CONTROL RELEASE, V11, P269
   YOKOYAMA M, 1994, J CONTROL RELEASE, V32, P269, DOI 10.1016/0168-3659(94)90237-2
   YOKOYAMA M, 1992, BIOCONJUGATE CHEM, V3, P295, DOI 10.1021/bc00016a007
   YOKOYAMA M, 1990, CANCER RES, V50, P1693
NR 26
TC 94
Z9 97
U1 3
U2 74
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD MAR
PY 2010
VL 31
IS 7
BP 1765
EP 1772
DI 10.1016/j.biomaterials.2009.11.038
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 553GM
UT WOS:000274354400033
PM 19959225
OA green_accepted
DA 2018-03-19
ER

PT J
AU Puleo, DA
AF Puleo, David A.
TI Using controlled release strategies to modulate tissue regeneration
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
CT 242nd National Meeting of the American-Chemical-Society (ACS)
CY AUG 28-SEP 01, 2011
CL Denver, CO
SP Amer Chem Soc (ACS)
C1 [Puleo, David A.] Univ Kentucky, Ctr Biomed Engn, Lexington, KY 40506 USA.
EM puleo@uky.edu
NR 0
TC 0
Z9 0
U1 0
U2 3
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD AUG 28
PY 2011
VL 242
MA 492-POLY
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA 880BE
UT WOS:000299378307195
DA 2018-03-20
ER

PT J
AU Melikishvili, M
   Rodgers, DW
   Fried, MG
AF Melikishvili, Manana
   Rodgers, David W.
   Fried, Michael Gregory
TI 6-Carboxyfluorescein and structurally similar molecules inhibit DNA
   binding and repair by O-6-alkylguanine DNA alkyltransferase
SO DNA REPAIR
LA English
DT Article
DE DNA repair; DNA alkyltransferase; Substrate analogue; Fluorescein; EMSA;
   Analytical ultracentrifugation; Fluorescence assay
ID POLYACRYLAMIDE-GEL ELECTROPHORESIS; RESTRICTION ENZYMES; NUCLEIC-ACIDS;
   HILL EQUATION; STRANDED DNAS; PROTEIN; FLUORESCENCE; METHYLTRANSFERASE;
   AGT; SEDIMENTATION
AB Human O-6-alkylguanine-DNA alkyltransferase (AGT) repairs mutagenic O-6-alkylguanine and O-4-alkylthymine adducts in single-stranded and duplex DNAs. These activities protect normal cells and tumor cells against drugs that alkylate DNA; drugs that inactivate ACT are under test as chemotherapeutic enhancers. In studies using 6-carboxyfluorescein (FAM)-labeled DNAs, ACT reduced the fluorescence intensity by similar to 40% at binding saturation, whether the FAM was located at the 5' or the 3' end of the DNA. ACT protected residual fluorescence from quenching, indicating a solute-inaccessible binding site for FAM. Sedimentation equilibrium analyses showed that saturating AGT-stoichiometries were higher with FAM-labeled DNAs than with unlabeled DNAs, suggesting that the FAM provides a protein binding site that is not present in unlabeled DNAs. Additional fluorescence and sedimentation measurements showed that ACT forms a 1:1 complex with free FAM. Active site benzylation experiments and docking calculations support models in which the primary binding site is located in or near the active site of the enzyme. Electrophoretic analyses show that FAM inhibits DNA binding (IC50 similar to 76 mu M) and repair of DNA containing an O-6-methylguanine residue (IC50 similar to 63 mu M). Similar results were obtained with other polycyclic aromatic compounds. These observations demonstrate the existence of a new class of non-covalent ACT-inhibitors. After optimization for binding-affinity, members of this class might be useful in cancer chemotherapy. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Melikishvili, Manana; Rodgers, David W.; Fried, Michael G.] Univ Kentucky, Dept Mol & Cellular Biochem, Struct Biol Ctr, Lexington, KY 40536 USA.
RP Fried, MG (reprint author), Univ Kentucky, Dept Mol & Cellular Biochem, Struct Biol Ctr, 741 S Limestone, Lexington, KY 40536 USA.
EM michael.fried@uky.edu
FU NIH [NS-38041, P20 RR-20171, GM-070662]
FX We thank the reviewers for their thoughtful suggestions. This work was
   supported by NIH grants NS-38041 and P20 RR-20171 to D.W.R. and
   GM-070662 to M.G.F.
CR Adams CA, 2009, J MOL BIOL, V389, P248, DOI 10.1016/j.jmb.2009.03.067
   Chen BE, 2010, MOL BIOSYST, V6, P2143, DOI 10.1039/c005148a
   COHEN G, 1968, BIOPOLYMERS, V6, P1077, DOI 10.1002/bip.1968.360060805
   COHN EJ, 1943, PROTEINS AMINO ACIDS, P370
   Dam J, 2004, METHOD ENZYMOL, V384, P185
   Daniels DS, 2000, MUTAT RES-DNA REPAIR, V460, P151, DOI 10.1016/S0921-8777(00)00024-0
   Daniels DS, 2004, NAT STRUCT MOL BIOL, V11, P714, DOI 10.1038/nsmb791
   Duguid EM, 2005, J MOL BIOL, V350, P657, DOI 10.1016/j.jmb.2005.05.028
   EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035
   EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7
   Fang QM, 2010, J BIOL CHEM, V285, P8185, DOI 10.1074/jbc.M109.045518
   FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505
   Gautier A, 2008, CHEM BIOL, V15, P128, DOI 10.1016/j.chembiol.2008.01.007
   Goutelle S, 2008, FUND CLIN PHARMACOL, V22, P633, DOI 10.1111/j.1472-8206.2008.00633.x
   Hellman LM, 2007, NAT PROTOC, V2, P1849, DOI 10.1038/nprot.2007.249
   Heyduk T, 1996, METHOD ENZYMOL, V274, P492
   Hinner MJ, 2010, CURR OPIN BIOTECH, V21, P766, DOI 10.1016/j.copbio.2010.09.011
   Hopkins BB, 2004, J BIOL CHEM, V279, P37049, DOI 10.1074/jbc.M404573200
   Jeltsch A, 2006, CURR TOP MICROBIOL, V301, P203
   Kaina B, 2010, CELL MOL LIFE SCI, V67, P3663, DOI 10.1007/s00018-010-0491-7
   Kanugula S, 1998, BIOCHEM J, V329, P545, DOI 10.1042/bj3290545
   Kefford RF, 2009, BRIT J CANCER, V100, P1245, DOI 10.1038/sj.bjc.6605016
   Klonis N, 1998, PHOTOCHEM PHOTOBIOL, V67, P500, DOI 10.1111/j.1751-1097.1998.tb09446.x
   Kreft S, 2007, NATURWISSENSCHAFTEN, V94, P935, DOI 10.1007/s00114-007-0272-9
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lakowicz J. R., 1983, PRINCIPLES FLUORESCE
   Laue T., 1992, ANAL ULTRACENTRIFUGA, P90
   Liu LP, 2002, CANCER RES, V62, P3037
   Luu KX, 2002, BIOCHEMISTRY-US, V41, P8689, DOI 10.1021/bi025857i
   MAHER VM, 1990, MUTAT RES, V233, P235, DOI 10.1016/0027-5107(90)90166-2
   Maniatis T, 1980, Methods Enzymol, V65, P299
   Margison GP, 2002, BIOESSAYS, V24, P255, DOI 10.1002/bies.10063
   MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560
   Melikishvili M., 2009, METHOD ENZYMOL, V466, P66
   Melikishvili M, 2008, BIOCHEMISTRY-US, V47, P13754, DOI 10.1021/bi801666c
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Neely RK, 2009, NUCLEIC ACIDS RES, V37, P6859, DOI 10.1093/nar/gkp688
   NG M, 1992, ANAL CHEM, V64, P1682, DOI 10.1021/ac00039a010
   Pegg AE, 2000, MUTAT RES-REV MUTAT, V462, P83, DOI 10.1016/S1383-5742(00)00017-X
   PEGG AE, 1990, MUTAT RES, V233, P165, DOI 10.1016/0027-5107(90)90160-6
   PEGG AE, 1981, CANCER RES, V41, P3128
   PEGG AE, 1993, BIOCHEMISTRY-US, V32, P11998, DOI 10.1021/bi00096a009
   Pegg Anthony E., 2000, P471
   Quinn JA, 2009, CLIN CANCER RES, V15, P1064, DOI 10.1158/1078-0432.CCR-08-2130
   Rasimas JJ, 2003, BIOCHEMISTRY-US, V42, P980, DOI 10.1021/bi026970b
   Rasimas JJ, 2003, J BIOL CHEM, V278, P7973, DOI 10.1074/jbc.M211854200
   Rasimas JJ, 2007, J BIOL CHEM, V282, P3357, DOI 10.1074/jbc.M608876200
   Roberts RJ, 1998, ANNU REV BIOCHEM, V67, P181, DOI 10.1146/annurev.biochem.67.1.181
   Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0
   SJOBACK R, 1995, SPECTROCHIM ACTA A, V51, pL7, DOI 10.1016/0584-8539(95)01421-P
   TAKASHI R, 1977, P NATL ACAD SCI USA, V74, P2334, DOI 10.1073/pnas.74.6.2334
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Tubbs JL, 2007, DNA REPAIR, V6, P1100, DOI 10.1016/j.dnarep.2007.03.011
   Verbeek B, 2008, BRIT MED BULL, V85, P17, DOI 10.1093/bmb/ldm036
   VOIGT JM, 1990, BIOCHEMISTRY-US, V29, P1632, DOI 10.1021/bi00458a039
   WARING MJ, 1965, J MOL BIOL, V13, P269, DOI 10.1016/S0022-2836(65)80096-1
   Watson AJ, 2009, BRIT J CANCER, V100, P1250, DOI 10.1038/sj.bjc.6605015
   WEBER K, 1969, J BIOL CHEM, V244, P4406
   Weiss JN, 1997, FASEB J, V11, P835
   Wu LX, 2008, ORG LETT, V10, P1779, DOI 10.1021/ol800526s
   Xu-Welliver M, 2002, CARCINOGENESIS, V23, P823, DOI 10.1093/carcin/23.5.823
NR 61
TC 8
Z9 8
U1 1
U2 13
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1568-7864
J9 DNA REPAIR
JI DNA Repair
PD DEC 10
PY 2011
VL 10
IS 12
BP 1193
EP 1202
DI 10.1016/j.dnarep.2011.09.007
PG 10
WC Genetics & Heredity; Toxicology
SC Genetics & Heredity; Toxicology
GA 864EU
UT WOS:000298220600002
PM 21982443
OA green_accepted
DA 2018-03-20
ER

PT J
AU Zhou, SS
   Li, HF
   Garlapalli, R
   Nokes, SE
   Flythe, M
   Rankin, SE
   Knutson, BL
AF Zhou, Shanshan
   Li, Hsin-Fen
   Garlapalli, Ravinder K.
   Nokes, Sue E.
   Flythe, Michael D.
   Rankin, Stephen E.
   Knutson, Barbara L.
TI Hydrolysis of model cellulose films by cellulosomes: Extension of quartz
   crystal microbalance technique to multienzymatic complexes
SO JOURNAL OF BIOTECHNOLOGY
LA English
DT Article
DE Cellulosomes; QCM-D; Solid substrate; Cellobiose inhibition
ID CLOSTRIDIUM-THERMOCELLUM; ENZYMATIC-HYDROLYSIS; QCM-D; LIGNOCELLULOSIC
   NANOFIBRILS; THIN-FILMS; CELLULASES; KINETICS; ADSORPTION; LIGNIN;
   MICROGRAVIMETRY
AB Bacterial cellulosomes contain highly efficient complexed cellulases and have been studied extensively for the production of lignocellulosic biofuels and bioproducts. A surface measurement technique, quartz crystal microbalance with dissipation (QCM-D), was extended for the investigation of real-time binding and hydrolysis of model cellulose surfaces from free fungal cellulases to the cellulosomes of Clostridium thermocellum (Ruminiclostridium thermocellum). In differentiating the activities of cell-free and cell-bound cellulosomes, greater than 68% of the cellulosomes in the crude cell broth were found to exist unattached to the cell across multiple growth stages. The initial hydrolysis rate of crude cell broth measured by QCM was greater than that of cell-free cellulosomes, but the corresponding frequency drop (a direct measure of the mass of enzyme adsorbed to the film) of crude cell broth was less than that of the cell free cellulosomes, consistent with the underestimation of the cell mass adsorbed using QCM. Inhibition of hydrolysis by cellobiose (0-10 g/L), which is similar for crude cell broth and cell-free cellulosomes, demonstrates the sensitivity of the QCM to environmental perturbations of multienzymatic complexes. QCM measurements using multienzymatic complexes may be used to screen and optimize hydrolysis conditions and to develop mechanistic, surface-based models of enzymatic cellulose deconstruction. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Zhou, Shanshan; Li, Hsin-Fen; Garlapalli, Ravinder; Rankin, Stephen E.; Knutson, Barbara L.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Nokes, Sue E.] Univ Kentucky, Dept Biosyst & Agr Engn, Lexington, KY 40506 USA.
   [Flythe, Michael] Univ Kentucky, Dept Anim & Food Sci, Lexington, KY 40506 USA.
   [Flythe, Michael] USDA ARS, Forage Anim Prod Res Unit, Lexington, KY 40546 USA.
EM bknutson@engr.uky.edu
OI Flythe, Michael/0000-0002-8868-9169
FU United States Department of Agriculture Biomass Research and Development
   Initiative (BRDI) grant [68-3A75-7-6082011-10006-30363]; Kentucky
   Science and Engineering Foundation [KSEF-2187-RDE-013]; Kentucky NSF
   Experimental Program to Stimulate Competitive Research EPSCoR grant
   [1355438]
FX This work was financially supported by the United States Department of
   Agriculture Biomass Research and Development Initiative (BRDI) grant
   (Award # 68-3A75-7-6082011-10006-30363), the Kentucky Science and
   Engineering Foundation (KSEF-2187-RDE-013), and the Kentucky NSF
   Experimental Program to Stimulate Competitive Research EPSCoR grant
   (grant # 1355438).
CR Ahola S, 2008, LANGMUIR, V24, P11592, DOI 10.1021/la801550j
   Aulin C, 2009, LANGMUIR, V25, P7675, DOI 10.1021/la900323n
   BAYER EA, 1985, J BACTERIOL, V163, P552
   BAYER EA, 1983, J BACTERIOL, V156, P818
   Bouchet-Spinelli A, 2013, SENSOR ACTUAT B-CHEM, V176, P1038, DOI 10.1016/j.snb.2012.10.013
   Cerclier CV, 2013, BIOMACROMOLECULES, V14, P3599, DOI 10.1021/bm400967e
   Cheng G., 2011, NEUTRON REFLECTOMETR
   Cheng G, 2012, LANGMUIR, V28, P8348, DOI 10.1021/la300955q
   Demain AL, 2005, MICROBIOL MOL BIOL R, V69, P124, DOI 10.1128/MMBR.69.1.124-154.2005
   Erbeznik M, 1997, APPL ENVIRON MICROB, V63, P2949
   Eriksson J, 2005, J COLLOID INTERF SCI, V284, P99, DOI 10.1016/j.jcis.2004.10.041
   Ferreira GNM, 2009, TRENDS BIOTECHNOL, V27, P689, DOI 10.1016/j.tibtech.2009.09.003
   Fritz C, 2015, BIOMACROMOLECULES, V16, P3878, DOI 10.1021/acs.biomac.5b01203
   Gold ND, 2007, J BACTERIOL, V189, P6787, DOI 10.1128/JB.00882-07
   Gruno M, 2004, BIOTECHNOL BIOENG, V86, P503, DOI 10.1002/bit.10838
   GUSAKOV AV, 1985, J BIOTECHNOL, V3, P167, DOI 10.1016/0168-1656(85)90017-3
   Holmberg M, 1997, J COLLOID INTERF SCI, V186, P369, DOI 10.1006/jcis.1996.4657
   Jiang F, 2013, LANGMUIR, V29, P3280, DOI 10.1021/la3040193
   Johnson E., 1982, J APPL BIOCHEM, V4, P64
   Josefsson P, 2008, BIOMACROMOLECULES, V9, P249, DOI 10.1021/bm700980b
   KUDO H, 1987, CAN J MICROBIOL, V33, P267, DOI 10.1139/m87-045
   Kumagai A, 2014, CELLULOSE, V21, P2433, DOI 10.1007/s10570-014-0312-5
   Kumagai A, 2013, BIOMACROMOLECULES, V14, P2420, DOI 10.1021/bm400553s
   Li H.-F., 2012, APPL THIN FILM ANAL
   Lin XL, 2015, BIORESOURCE TECHNOL, V193, P266, DOI 10.1016/j.biortech.2015.06.089
   Lou HM, 2013, BIORESOURCE TECHNOL, V146, P478, DOI 10.1016/j.biortech.2013.07.115
   Lu YP, 2006, P NATL ACAD SCI USA, V103, P16165, DOI 10.1073/pnas.0605381103
   Lynd LR, 2002, MICROBIOL MOL BIOL R, V66, P506, DOI 10.1128/MMBR.66.3.506-577.2002
   Martin-Sampedro R, 2013, BIOMACROMOLECULES, V14, P1231, DOI 10.1021/bm400230s
   Maurer SA, 2013, J COLLOID INTERF SCI, V394, P498, DOI 10.1016/j.jcis.2012.12.022
   Maurer SA, 2012, LANGMUIR, V28, P14598, DOI 10.1021/la3024524
   MAYER F, 1987, APPL ENVIRON MICROB, V53, P2785
   MCCLEARY BV, 1987, J I BREWING, V93, P87, DOI 10.1002/j.2050-0416.1987.tb04481.x
   Mohan T, 2013, CARBOHYD POLYM, V93, P191, DOI 10.1016/j.carbpol.2012.02.033
   Morgenstern B, 1996, TRENDS POLYM SCI, V4, P87
   Notley SM, 2006, LANGMUIR, V22, P3154, DOI 10.1021/la052886w
   Olsson ALJ, 2009, LANGMUIR, V25, P1627, DOI 10.1021/la803301q
   Pfeiffer KA, 2015, BIOTECHNOL BIOENG, V112, P2256, DOI 10.1002/bit.25657
   Rahikainen JL, 2013, BIORESOURCE TECHNOL, V133, P270, DOI 10.1016/j.biortech.2013.01.075
   Reviakine I, 2011, ANAL CHEM, V83, P8838, DOI 10.1021/ac201778h
   Rojas OJ, 2007, ACS SYM SER, V954, P478
   SAUERBREY G, 1959, Z PHYS, V155, P206, DOI 10.1007/BF01337937
   Schofield AL, 2007, BIOSENS BIOELECTRON, V23, P407, DOI 10.1016/j.bios.2007.05.001
   Turon X, 2008, LANGMUIR, V24, P3880, DOI 10.1021/la7032753
   Voinova MV, 2002, BIOSENS BIOELECTRON, V17, P835, DOI 10.1016/S0956-5663(02)00050-7
   Zhang YH, 2003, ANAL CHEM, V75, P219, DOI 10.1021/ac020271n
NR 46
TC 0
Z9 0
U1 8
U2 24
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-1656
EI 1873-4863
J9 J BIOTECHNOL
JI J. Biotechnol.
PD JAN 10
PY 2017
VL 241
BP 42
EP 49
DI 10.1016/j.jbiotec.2016.11.008
PG 8
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA EI7KY
UT WOS:000392677900006
PM 27838255
DA 2018-03-20
ER

PT J
AU Eske, K
   Newsome, B
   Han, SG
   Murphy, M
   Bhattacharyya, D
   Hennig, B
AF Eske, Katryn
   Newsome, Bradley J.
   Han, Sung Gu
   Murphy, Margaret
   Bhattacharyya, Dibakar
   Hennig, Bernhard
TI PCB 77 dechlorination products modulate pro-inflammatory events in
   vascular endothelial cells
SO ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH
LA English
DT Article; Proceedings Paper
CT 7th International PCB Workshop - Chemical mixtures in a complex world
CY MAY 27-31, 2012
CL Arcachon, FRANCE
DE Dechlorination; Endothelial cell dysfunction; Oxidative stress; PCBs;
   Pollutant remediation
ID POLYCHLORINATED-BIPHENYLS; ENVIRONMENTAL SOURCES; ATHEROSCLEROSIS;
   DEFICIENT; GENE; MICE
AB Persistent organic pollutants such as polychlorinated biphenyls (PCBs) are associated with detrimental health outcomes including cardiovascular diseases. Remediation of these compounds is a critical component of environmental policy. Although remediation efforts aim to completely remove toxicants, little is known about the effects of potential remediation byproducts. We previously published that Fe/Pd nanoparticles effectively dechlorinate PCB 77 to biphenyl, thus eliminating PCB-induced endothelial dysfunction using primary vascular endothelial cells. Herein, we analyzed the toxic effects of PCB congener mixtures (representative mixtures of commercial PCBs based on previous dechlorination data) produced at multiple time points during the dechlorination of PCB 77 to biphenyl. Compared with pure PCB 77, exposing endothelial cells to lower chlorinated PCB byproducts led to improved cellular viability, decreased superoxide production, and decreased nuclear factor kappa B activation based on duration of remediation. Presence of the parent compound, PCB 77, led to significant increases in mRNA and protein inflammatory marker expression. These data implicate that PCB dechlorination reduces biological toxicity to vascular endothelial cells.
C1 [Eske, Katryn; Newsome, Bradley; Han, Sung Gu; Murphy, Margaret; Bhattacharyya, Dibakar; Hennig, Bernhard] Univ Kentucky, SRP Ctr, Lexington, KY 40536 USA.
   [Eske, Katryn; Murphy, Margaret] Univ Kentucky, Grad Ctr Nutr Sci, Kentucky SRP Ctr, Lexington, KY 40536 USA.
   [Newsome, Bradley] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
   [Han, Sung Gu] Konkuk Univ, Dept Food Sci Anim Resources, Coll Anim Biosci & Technol, Seoul 143701, South Korea.
   [Bhattacharyya, Dibakar] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Hennig, BH (reprint author), Univ Kentucky, SRP Ctr, Lexington, KY 40536 USA.
EM bhennig@uky.edu
OI Han, Sung Gu/0000-0002-1485-861X
FU National Institutes of Health/National Institute of Environmental Health
   Sciences [P42ES007380]; American Recovery and Reinvestment Act (ARRA)
   funds [3P42ES007380-13S1]; University of Kentucky Agricultural
   Experiment Station
FX This work was supported by National Institutes of Health/National
   Institute of Environmental Health Sciences grant P42ES007380, American
   Recovery and Reinvestment Act (ARRA) funds (3P42ES007380-13S1), and with
   funds from the University of Kentucky Agricultural Experiment Station.
   We would like to thank Christopher R. Barton<SUP>1</SUP> and Alex N.
   Palumbo<SUP>1</SUP> for their contributions to the preliminary work on
   this project. Thanks also to Dr. Seong-Su Han for his work with the NF
   kappa B binding assay. A special thanks to Michael Petriello for his
   editorial assistance.
CR Arsenescu V, 2011, TOXICOL APPL PHARM, V257, P148, DOI 10.1016/j.taap.2011.08.028
   Beyer A, 2009, REV ENVIRON CONTAM T, V201, P137, DOI 10.1007/978-1-4419-0032-6_5
   BROWN JF, 1987, ENVIRON TOXICOL CHEM, V6, P579, DOI 10.1897/1552-8618(1987)6[579:EDOP]2.0.CO;2
   de Winther MPJ, 2005, ARTERIOSCL THROM VAS, V25, P904, DOI 10.1161/01.ATV.0000160340.72641.87
   Doskey PV, 1981, J GREAT LAKES RES, V7, P15, DOI 10.1016/S0380-1330(81)72018-5
   Environmental Protection Agency, 2011, CLEAN DISP POL BIPH
   Environmental Protection Agency, 2012, HAZ WAST REG
   Espandiari P, 2003, TOXICOL APPL PHARM, V186, P55, DOI 10.1016/S0041-008X(02)00018-2
   Ganey PE, 2005, ENVIRON HEALTH PERSP, V113, P180, DOI 10.1289/ehp.6935
   Han SS, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-97
   Han SG, 2012, TOXICOL APPL PHARM, V261, P181, DOI 10.1016/j.taap.2012.03.024
   Han SG, 2010, TOXICOL APPL PHARM, V246, P74, DOI 10.1016/j.taap.2010.04.009
   HAWARI J, 1992, ENVIRON SCI TECHNOL, V26, P2022, DOI 10.1021/es00034a022
   Hennig B, 2005, ENVIRON HEALTH PERSP, V113, P83
   Hennig B, 2002, TOXICOL APPL PHARM, V181, P174, DOI 10.1006/taap.2002.9408
   HENNIG B, 1984, ARTERIOSCLEROSIS, V4, P489, DOI 10.1161/01.ATV.4.5.489
   Hennig B, 2007, NUTR METAB CARDIOVAS, V17, P162, DOI 10.1016/j.numecd.2006.01.003
   Hu DF, 2010, ENVIRON SCI TECHNOL, V44, P2822, DOI 10.1021/es902413k
   Kopf PG, 2010, TOXICOL APPL PHARM, V245, P91, DOI 10.1016/j.taap.2010.02.007
   Kopf PG, 2010, TOXICOL SCI, V117, P537, DOI 10.1093/toxsci/kfq218
   Lim EJ, 2007, GENE, V386, P183, DOI 10.1016/j.gene.2006.09.007
   Lim EJ, 2008, CHEM-BIOL INTERACT, V176, P71, DOI 10.1016/j.cbi.2008.08.007
   Majkova Z, 2011, TOXICOL APPL PHARM, V251, P41, DOI 10.1016/j.taap.2010.11.013
   Majkova Z, 2009, TOXICOL APPL PHARM, V237, P1, DOI 10.1016/j.taap.2009.02.016
   Oakley GG, 1996, CARCINOGENESIS, V17, P109, DOI 10.1093/carcin/17.1.109
   Puga Alvaro, 2004, Cardiovasc Toxicol, V4, P385, DOI 10.1385/CT:4:4:385
   Rodenburg LA, 2012, ENVIRON SCI TECHNOL, V46, P6612, DOI 10.1021/es300560q
   Rodenburg LA, 2010, ENVIRON SCI TECHNOL, V44, P2816, DOI 10.1021/es901155h
   RUZO LO, 1974, J AGR FOOD CHEM, V22, P199, DOI 10.1021/jf60192a045
   Schlezinger JJ, 2006, AQUAT TOXICOL, V77, P422, DOI 10.1016/j.aquatox.2006.01.012
   Sergeev Alexander V, 2010, Prim Prev Insights, V2, P1
   Sergeev AV, 2010, INT J OCCUP MED ENV, V23, P5, DOI 10.2478/v10001-010-0010-y
   Venkatachalam K, 2008, J HAZARD MATER, V159, P483, DOI 10.1016/j.jhazmat.2008.02.109
   Zahran EM, 2011, J MATER CHEM, V21, P10454, DOI 10.1039/c1jm11435b
NR 34
TC 9
Z9 9
U1 0
U2 10
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0944-1344
EI 1614-7499
J9 ENVIRON SCI POLLUT R
JI Environ. Sci. Pollut. Res.
PD MAY
PY 2014
VL 21
IS 10
BP 6354
EP 6364
DI 10.1007/s11356-013-1591-3
PG 11
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA AH7LO
UT WOS:000336314900010
PM 23504249
OA green_accepted
DA 2018-03-19
ER

PT J
AU Chirra, HD
   Biswal, D
   Hilt, JZ
AF Chirra, Hariharasudhan D.
   Biswal, Dipti
   Hilt, J. Zach
TI Controlled synthesis of responsive hydrogel nanostructures via
   microcontact printing and ATRP
SO POLYMERS FOR ADVANCED TECHNOLOGIES
LA English
DT Article
DE ATRP; microcontact printing; NIPAAm; hydrogels; surface initiated
   polymerization
ID TRANSFER RADICAL POLYMERIZATION; SURFACE-INITIATED POLYMERIZATIONS; POLY
   N-ISOPROPYLACRYLAMIDE; POLY(N-ISOPROPYLACRYLAMIDE) BRUSHES;
   POLY(ETHYLENE GLYCOL); AQUEOUS-MEDIA; ACID) BRUSHES; LITHOGRAPHY;
   TEMPERATURE; FABRICATION
AB Surfaces that are spatially functionalized with intelligent hydrogels, especially at the micro-and nanoscale, are of high interest in the diagnostic and therapeutic fields. Conventional methods of the semiconductor industry have been successfully employed for the patterning of hydrogels for various applications, but methods for fabricating precise 3 D patterns of hydrogels at the micro-and nanoscale over material surfaces remain limited. Herein, microcontact printing (mu CP) followed by atom transfer radical polymerization (ATRP) was applied as a platform to synthesize temperature responsive poly(N-isopropylacrylamide) hydrogels with varied network structures (e. g. different molecular weight crosslinkers) over gold surfaces. The XY control of the hydrogels was achieved using mu CP, and the Z (thickness) control was achieved using ATRP. The controlled growth and the responsive behavior of hydrogels to temperature stimuli were characterized using Fourier transform infrared (FTIR) spectroscopy and atomic force microscopy (AFM). The results demonstrate that this platform allows for the controlled growth of hydrogel nanostructures using the controlled ATRP mechanism. It is also shown that the molecular weight of the crosslinker affects the rate of hydrogel growth. These PNIPAAm-based crosslinked hydrogel patterns were also demonstrated to have a temperature-dependent swelling response. Using this technique, it is possible to synthesize responsive hydrogel patterns over various surfaces for potential applications in the biomedical field. Copyright (C) 2009 John Wiley & Sons, Ltd.
C1 [Chirra, Hariharasudhan D.; Biswal, Dipti; Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Hilt, JZ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 F Paul Anderson Tower, Lexington, KY 40506 USA.
EM hilt@engr.uky.edu
CR Advincula RC, 2003, J DISPER SCI TECHNOL, V24, P343, DOI 10.1081/DIS-120021794
   Ali M, 2007, J CONTROL RELEASE, V124, P154, DOI 10.1016/j.jconrel.2007.09.006
   Andruzzi L, 2004, LANGMUIR, V20, P10498, DOI 10.1021/la049264f
   Ashford EJ, 1999, CHEM COMMUN, P1285, DOI 10.1039/a903773j
   Baldi A, 2006, SENSOR ACTUAT B-CHEM, V114, P9, DOI 10.1016/j.snb.2005.04.020
   Beebe DJ, 2000, NATURE, V404, P588, DOI 10.1038/35007047
   BIEBUYCK HA, 1994, LANGMUIR, V10, P4581, DOI 10.1021/la00024a032
   Biswal D, 2008, BIOMED MICRODEVICES, V10, P213, DOI 10.1007/s10544-007-9127-6
   Biswal D, 2006, POLYMER, V47, P7355, DOI 10.1016/j.polymer.2006.08.028
   BOWMAN CN, 1988, POLYM BULL, V20, P329
   BRAUN M, 2002, MACROMOLECULES, V35, P610
   Chiellini F, 2001, MACROMOL RAPID COMM, V22, P1284, DOI 10.1002/1521-3927(20011001)22:15<1284::AID-MARC1284>3.0.CO;2-M
   Cushing MC, 2007, SCIENCE, V316, P1133, DOI 10.1126/science.1140171
   Dingenouts N, 1998, MACROMOLECULES, V31, P8912, DOI 10.1021/ma980985t
   Dong L, 2007, SOFT MATTER, V3, P1223, DOI 10.1039/b706563a
   Edmondson S, 2004, CHEM SOC REV, V33, P14, DOI 10.1039/b210143m
   He Q, 2007, LANGMUIR, V23, P3981, DOI 10.1021/la062793u
   Hilt JZ, 2003, BIOMED MICRODEVICES, V5, P177, DOI 10.1023/A:1025786023595
   HILT JZ, 2004, DEKKER ENCY NANOSCIE, P247
   Huang WX, 2001, ANGEW CHEM INT EDIT, V40, P1510, DOI 10.1002/1521-3773(20010417)40:8<1510::AID-ANIE1510>3.0.CO;2-U
   Husseman M, 1999, MACROMOLECULES, V32, P1424, DOI 10.1021/ma981290v
   Huther A, 2004, FLUID PHASE EQUILIBR, V226, P321, DOI 10.1016/j.fluid.2004.10.012
   Jones DM, 2001, ADV MATER, V13, P1256, DOI 10.1002/1521-4095(200108)13:16<1256::AID-ADMA1256>3.0.CO;2-B
   Jones DM, 2002, ADV MATER, V14, P1130, DOI 10.1002/1521-4095(20020816)14:16<1130::AID-ADMA1130>3.0.CO;2-7
   Kaholek M, 2004, CHEM MATER, V16, P3688, DOI 10.1021/cm049562y
   Kaholek M, 2004, NANO LETT, V4, P373, DOI 10.1021/nl035054w
   Kim JB, 2000, J AM CHEM SOC, V122, P7616, DOI 10.1021/ja001652q
   Low LM, 2000, SENSOR ACTUAT B-CHEM, V67, P149, DOI 10.1016/S0925-4005(00)00396-8
   Matyjaszewski K, 1999, MACROMOLECULES, V32, P8716, DOI 10.1021/ma991146p
   Matyjaszewski K, 2001, J CHEM EDUC, V78, P547, DOI 10.1021/ed078p547
   Matyjaszewski K, 2007, LANGMUIR, V23, P4528, DOI 10.1021/la063402e
   Nath N, 2002, ADV MATER, V14, P1243, DOI 10.1002/1521-4095(20020903)14:17<1243::AID-ADMA1243>3.0.CO;2-M
   Papavasiliou G, 2008, TISSUE ENG PT C-METH, V14, P129, DOI 10.1089/ten.tec.2007.0355
   PEPPAS NA, 1993, ADV DRUG DELIVER REV, V11, P1, DOI 10.1016/0169-409X(93)90025-Y
   Peppas NA, 2000, EUR J PHARM BIOPHARM, V50, P27, DOI 10.1016/S0939-6411(00)00090-4
   Peppas NA, 2006, ADV MATER, V18, P1345, DOI 10.1002/adma.200501612
   Peppas NA, 2000, ANNU REV BIOMED ENG, V2, P9, DOI 10.1146/annurev.bioeng.2.1.9
   Prucker O, 1998, MACROMOLECULES, V31, P592, DOI 10.1021/ma970660x
   RITGER P L, 1987, Journal of Controlled Release, V5, P23, DOI 10.1016/0168-3659(87)90034-4
   Satarkar NS, 2008, ACTA BIOMATER, V4, P11, DOI 10.1016/j.actbio.2007.07.009
   SCHILD HG, 1992, PROG POLYM SCI, V17, P163, DOI 10.1016/0079-6700(92)90023-R
   Schmaljohann D, 2003, BIOMACROMOLECULES, V4, P1733, DOI 10.1021/bm034160p
   Schneider GB, 2004, BIOMATERIALS, V25, P3023, DOI 10.1016/j.biomaterials.2003.09.084
   Shibayama M., 1993, RESPONSIVE GELS VOLU, VI, P1, DOI DOI 10.1007/3-540-56791-7_
   TAKEI YG, 1994, MACROMOLECULES, V27, P6163, DOI 10.1021/ma00099a035
   Treat ND, 2006, MACROMOLECULES, V39, P26, DOI 10.1021/ma052001n
   Tu H, 2004, LANGMUIR, V20, P8313, DOI 10.1021/la049663a
   Tugulu S, 2007, MACROMOLECULES, V40, P168, DOI 10.1021/ma060739e
   Wang W, 2007, MACROMOLECULES, V40, P9564, DOI 10.1021/ma0710535
   Xia YN, 1998, ANNU REV MATER SCI, V28, P153, DOI 10.1146/annurev.matsci.28.1.153
   Xia YN, 1998, ANGEW CHEM INT EDIT, V37, P550, DOI 10.1002/(SICI)1521-3773(19980316)37:5<550::AID-ANIE550>3.3.CO;2-7
   Xu FJ, 2004, BIOMACROMOLECULES, V5, P2392, DOI 10.1021/bm049675a
   Yildiz Y, 2006, J MACROMOL SCI A, V43, P1091, DOI 10.1080/10601320600740322
   YOSHIDA R, 1994, J BIOMAT SCI-POLYM E, V6, P585
   Zeng XF, 2008, APPL PHYS LETT, V93, DOI 10.1063/1.2996271
   Zhou F, 2006, J AM CHEM SOC, V128, P16253, DOI 10.1021/ja0654377
   Zourob M, 2006, ADV MATER, V18, P655, DOI 10.1002/adma.200501840
NR 57
TC 5
Z9 5
U1 3
U2 41
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1042-7147
J9 POLYM ADVAN TECHNOL
JI Polym. Adv. Technol.
PD JUN
PY 2011
VL 22
IS 6
BP 773
EP 780
DI 10.1002/pat.1576
PG 8
WC Polymer Science
SC Polymer Science
GA 764LQ
UT WOS:000290631400001
DA 2018-03-20
ER

PT J
AU Lim, EJ
   Sampath, S
   Coll-Rodriguez, J
   Schmidt, J
   Ray, K
   Rodgers, DW
AF Lim, Eun Jeong
   Sampath, Sowmya
   Coll-Rodriguez, Jerry
   Schmidt, Jack J.
   Ray, Kallol
   Rodgers, David W.
TI Swapping the substrate specificities of the neuropeptidases neurolysin
   and thimet oligopeptidase
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID METALLOENDOPEPTIDASE EC 3.4.24.15; SENSITIVE NEUTRAL ENDOPEPTIDASE;
   ENKEPHALIN-CONTAINING PEPTIDES; ANGIOTENSIN-CONVERTING ENZYME; I ANTIGEN
   PRESENTATION; RAT-BRAIN; CRYSTAL-STRUCTURE; SOLUBLE
   METALLOENDOPEPTIDASE; MOLECULAR-CLONING; NATURAL PEPTIDES
AB Thimet oligopeptidase (EC 3.4.24.15) and neurolysin (EC 3.4.24.16) are closely related zinc-dependent metallopeptidases that metabolize small bioactive peptides. They cleave many substrates at the same sites, but they recognize different positions on others, including neurotensin, a 13-residue peptide involved in modulation of dopaminergic circuits, pain perception, and thermoregulation. On the basis of crystal structures and previous mapping studies, four sites (Glu-469/Arg-470, Met-490/Arg-491, His-495/Asn-496, and Arg-498/Thr-499; thimet oligopeptidase residues listed first) in their substrate-binding channels appear positioned to account for differences in specificity. Thimet oligopeptidase mutated so that neurolysin residues are at all four positions cleaves neurotensin at the neurolysin site, and the reverse mutations in neurolysin switch hydrolysis to the thimet oligopeptidase site. Using a series of constructs mutated at just three of the sites, it was determined that mutations at only two (Glu-469/Arg-470 and Arg-498/Thr-499) are required to swap specificity, a result that was confirmed by testing the two-mutant constructs. If only either one of the two sites is mutated in thimet oligopeptidase, then the enzyme cleaves almost equally at the two hydrolysis positions. Crystal structures of both two-mutant constructs show that the mutations do not perturb local structure, but side chain conformations at the Arg-498/Thr-499 position differ from those of the mimicked enzyme. A model for differential recognition of neurotensin based on differences in surface charge distribution in the substrate binding sites is proposed. The model is supported by the finding that reducing the positive charge on the peptide results in cleavage at both hydrolysis sites.
C1 Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA.
   Univ Kentucky, Ctr Struct Biol, Lexington, KY 40536 USA.
RP Rodgers, DW (reprint author), Univ Kentucky, Dept Mol & Cellular Biochem, 741 S Limestone, Lexington, KY 40536 USA.
EM david.rodgers@uky.edu
FU NINDS NIH HHS [NS38041]; NCRR NIH HHS [P20 RR20171]
CR ACKER GR, 1987, J NEUROCHEM, V48, P284, DOI 10.1111/j.1471-4159.1987.tb13160.x
   Arndt JW, 2002, STRUCTURE, V10, P215, DOI 10.1016/S0969-2126(02)00698-6
   BARELLI H, 1988, EUR J BIOCHEM, V175, P481, DOI 10.1111/j.1432-1033.1988.tb14220.x
   BARELLI H, 1994, BRIT J PHARMACOL, V112, P127, DOI 10.1111/j.1476-5381.1994.tb13041.x
   BARRETT AJ, 1995, METHOD ENZYMOL, V248, P529
   Bevington P., 2002, DATA REDUCTION ERROR
   Brown CK, 2001, P NATL ACAD SCI USA, V98, P3127, DOI 10.1073/pnas.051633198
   Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254
   CARRAWAY R, 1973, J BIOL CHEM, V248, P6854
   CHABRY J, 1990, J NEUROSCI, V10, P3916
   CHECLER F, 1986, J BIOL CHEM, V261, P1274
   CHECLER F, 1995, METHOD ENZYMOL, V248, P593
   CHU TG, 1985, ENDOCRINOLOGY, V116, P1418, DOI 10.1210/endo-116-4-1418
   Comellas-Bigier M, 2005, J MOL BIOL, V349, P99, DOI 10.1016/j.jmb.2005.03.016
   Crack PJ, 1999, BRAIN RES, V835, P113, DOI 10.1016/S0006-8993(99)01494-8
   CSUHAI E, 1998, PROTEOLYTIC CELLULAR, P173
   DAHMS P, 1992, EUR J BIOCHEM, V208, P145, DOI 10.1111/j.1432-1033.1992.tb17168.x
   DANDO PM, 1993, BIOCHEM J, V294, P451, DOI 10.1042/bj2940451
   DAUCH P, 1995, J BIOL CHEM, V270, P27266, DOI 10.1074/jbc.270.45.27266
   DeSantis G, 1999, BIOCHEMISTRY-US, V38, P13391, DOI 10.1021/bi990861o
   EIPPER BA, 1986, TRENDS NEUROSCI, V9, P463, DOI 10.1016/0166-2236(86)90149-9
   Ferro ES, 2004, PROTEIN PEPTIDE LETT, V11, P415, DOI 10.2174/0929866043406706
   Ferro ES, 1999, DNA CELL BIOL, V18, P781, DOI 10.1089/104454999314926
   GOEDERT M, 1984, TRENDS NEUROSCI, V7, P3, DOI 10.1016/S0166-2236(84)80176-9
   GRAF L, 1988, P NATL ACAD SCI USA, V85, P4961, DOI 10.1073/pnas.85.14.4961
   Grams F, 1996, NAT STRUCT BIOL, V3, P671, DOI 10.1038/nsb0896-671
   Gutfreund H., 1995, KINETICS LIFE SCI RE
   HEALY DP, 1992, BRAIN RES, V571, P121, DOI 10.1016/0006-8993(92)90517-D
   HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324
   HOLDEN HM, 1987, BIOCHEMISTRY-US, V26, P8542, DOI 10.1021/bi00400a008
   Jeske NA, 2004, J NEUROCHEM, V90, P819, DOI 10.1111/j.1471-4159.2004.02557.x
   Jeske NA, 2003, J NEUROSCI RES, V74, P468, DOI 10.1002/jnr.10778
   JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224
   Judice WAS, 2005, MOL BIOCHEM PARASIT, V144, P36, DOI 10.1016/j.molbiopara.2005.07.004
   KASCKOW J, 1991, REGUL PEPTIDES, V36, P153, DOI 10.1016/0167-0115(91)90053-J
   Kato A, 1997, J BIOL CHEM, V272, P15313, DOI 10.1074/jbc.272.24.15313
   Kim SI, 2003, BIOCHEM J, V375, P111, DOI 10.1042/BJ20030490
   Kinkead B, 2004, INT REV NEUROBIOL, V59, P327
   KNIGHT CG, 1995, BIOCHEM J, V308, P145, DOI 10.1042/bj3080145
   Konkoy CS, 1996, TRENDS PHARMACOL SCI, V17, P288, DOI 10.1016/0165-6147(96)10036-5
   Lian W, 2000, ACTA CRYSTALLOGR D, V56, P1644, DOI 10.1107/S0907444900012683
   LITTLEWOOD GM, 1988, NEUROCHEM INT, V12, P383, DOI 10.1016/0197-0186(88)90178-7
   MCKELVY JF, 1986, ANNU REV NEUROSCI, V9, P415
   MENTLEIN R, 1994, J NEUROCHEM, V62, P27
   Moodie SL, 1996, J MOL BIOL, V263, P486, DOI 10.1006/jmbi.1996.0591
   Motulsky H, 2004, FITTING MODELS BIOL
   Natesh R, 2003, NATURE, V421, P551, DOI 10.1038/nature01370
   Oefner C, 2000, J MOL BIOL, V296, P341, DOI 10.1006/jmbi.1999.3492
   Oefner C, 2004, ACTA CRYSTALLOGR D, V60, P392, DOI 10.1107/S0907444903027410
   Oliveira V, 2001, BIOCHEMISTRY-US, V40, P4417, DOI 10.1021/bi002715k
   Oliveira V, 2001, ANAL BIOCHEM, V292, P257, DOI 10.1006/abio.2001.5083
   ORLOWSKI M, 1983, EUR J BIOCHEM, V135, P81, DOI 10.1111/j.1432-1033.1983.tb07620.x
   ORLOWSKI M, 1989, BIOCHEM J, V261, P951, DOI 10.1042/bj2610951
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   PERONA JJ, 1995, BIOCHEMISTRY-US, V34, P1489, DOI 10.1021/bi00005a004
   PERONA JJ, 1995, PROTEIN SCI, V4, P337
   PIEROTTI A, 1990, BIOCHEMISTRY-US, V29, P10323, DOI 10.1021/bi00497a006
   Portaro FCV, 1999, BIOCHEM BIOPH RES CO, V255, P596, DOI 10.1006/bbrc.1999.0251
   RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183
   Ray K, 2004, J BIOL CHEM, V279, P20480, DOI 10.1074/jbc.M400795200
   Ray K, 2002, PROTEIN SCI, V11, P2237, DOI 10.1110/ps.0216302
   Rodgers DW, 1997, METHOD ENZYMOL, V276, P183, DOI 10.1016/S0076-6879(97)76059-2
   Saric T, 2004, J BIOL CHEM, V279, P46723, DOI 10.1074/jbc.M406537200
   Saric T, 2001, J BIOL CHEM, V276, P36474, DOI 10.1074/jbc.M105517200
   Schultheis MT, 2001, PRESENCE-TELEOP VIRT, V10, P431, DOI 10.1162/1054746011470271
   Silva CL, 1999, BIOCHEM BIOPH RES CO, V255, P591, DOI 10.1006/bbrc.1999.0250
   Szeltner Z, 2003, J BIOL CHEM, V278, P48786, DOI 10.1074/jbc.M309555200
   Tzakos AG, 2003, PROTEIN ENG, V16, P993, DOI 10.1093/protein/gzg122
   Varadarajan N, 2005, P NATL ACAD SCI USA, V102, P6855, DOI 10.1073/pnas.0500063102
   Villa JP, 2003, J BIOL CHEM, V278, P42545, DOI 10.1074/jbc.M303718200
   Vincent B, 1996, J NEUROSCI, V16, P5049
   VINCENT B, 1995, BRIT J PHARMACOL, V115, P1053, DOI 10.1111/j.1476-5381.1995.tb15918.x
   WILK S, 1980, J NEUROCHEM, V35, P1172, DOI 10.1111/j.1471-4159.1980.tb07873.x
   WILK S, 1982, J CHROMATOGR, V249, P121, DOI 10.1016/S0021-9673(00)80238-1
   WILK S, 1979, LIFE SCI, V24, P457, DOI 10.1016/0024-3205(79)90218-2
   Yamin R, 1999, J BIOL CHEM, V274, P18777, DOI 10.1074/jbc.274.26.18777
   York IA, 2003, IMMUNITY, V18, P429, DOI 10.1016/S1074-7613(03)00058-X
NR 77
TC 16
Z9 17
U1 0
U2 6
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAR 30
PY 2007
VL 282
IS 13
BP 9722
EP 9732
DI 10.1074/jbc.M609897200
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 153HA
UT WOS:000245421700046
PM 17251185
OA gold
DA 2018-03-20
ER

PT J
AU Meenach, SA
   Anderson, KW
   Hilt, JZ
   McGarry, RC
   Mansour, HM
AF Meenach, Samantha A.
   Anderson, Kimberly W.
   Hilt, J. Zach
   McGarry, Ronald C.
   Mansour, Heidi M.
TI High-Performing Dry Powder Inhalers of Paclitaxel DPPC/DPPG Lung
   Surfactant-Mimic Multifunctional Particles in Lung Cancer:
   Physicochemical Characterization, In Vitro Aerosol Dispersion, and
   Cellular Studies
SO AAPS PHARMSCITECH
LA English
DT Article
DE lung surfactant; NBD-PC fluorescent microscopy imaging; Next Generation
   Impactor (NGI); particle engineering design; pulmonary cell lines
ID PULMONARY DRUG-DELIVERY; THERAPEUTIC EFFECTIVENESS;
   PHYSICAL-CHARACTERIZATION; INHALATION THERAPIES; MICROPARTICLES;
   NANOPARTICLES; RIFAMPICIN; DESIGN; PHARMACOKINETICS; NANOMEDICINE
AB Inhalable lung surfactant-based carriers composed of synthetic phospholipids, dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylglycerol (DPPG), along with paclitaxel (PTX), were designed and optimized as respirable dry powders using organic solution co-spray-drying particle engineering design. These materials can be used to deliver and treat a wide variety of pulmonary diseases with this current work focusing on lung cancer. In particular, this is the first time dry powder lung surfactant-based particles have been developed and characterized for this purpose. Comprehensive physicochemical characterization was carried out to analyze the particle morphology, surface structure, solid-state transitions, amorphous character, residual water content, and phospholipid bilayer structure. The particle chemical composition was confirmed using attenuated total reflectance-Fourier-transform infrared (ATR-FTIR) spectroscopy. PTX loading was high, as quantified using UV-VIS spectroscopy, and sustained PTX release was measured over weeks. In vitro cellular characterization on lung cancer cells demonstrated the enhanced chemotherapeutic cytotoxic activity of paclitaxel from co-spray-dried DPPC/DPPG (co-SD DPPC/DPPG) lung surfactant-based carrier particles and the cytotoxicity of the particles via pulmonary cell viability analysis, fluorescent microscopy imaging, and transepithelial electrical resistance (TEER) testing at air-interface conditions. In vitro aerosol performance using a Next Generation Impactor (TM) (NGI (TM)) showed measurable powder deposition on all stages of the NGI and was relatively high on the lower stages (nanometer aerodynamic size). Aerosol dispersion analysis of these high-performing DPIs showed mass median diameters (MMADs) that ranged from 1.9 to 2.3 mu m with excellent aerosol dispersion performance as exemplified by high values of emitted dose, fine particle fractions, and respirable fractions.
C1 [Meenach, Samantha A.] Univ Kentucky, Coll Pharm, Drug Dev Div, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
   [Meenach, Samantha A.; Anderson, Kimberly W.; Hilt, J. Zach] Univ Kentucky, Coll Engn, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Anderson, Kimberly W.; Hilt, J. Zach] Univ Kentucky, Ctr Membrane Sci, Lexington, KY 40506 USA.
   [McGarry, Ronald C.] Univ Kentucky, Dept Radiat Med, Coll Med, Lexington, KY 40536 USA.
   [Mansour, Heidi M.] Univ Arizona, Coll Pharm, Skaggs Pharmaceut Sci Ctr, Tucson, AZ 85721 USA.
RP Mansour, HM (reprint author), Univ Arizona, Coll Pharm, Skaggs Pharmaceut Sci Ctr, 1703 E Mabel St, Tucson, AZ 85721 USA.
EM mansour@pharmacy.arizona.edu
FU National Institutes of Health (NIH)-National Cancer Institute (NCI)
   [R25CA153954]; NIH-NCI Cancer Nanotechnology Training Center (CNTC)
   Post-doctoral Traineeship
FX The authors gratefully acknowledge financial support from the National
   Institutes of Health (NIH)-National Cancer Institute (NCI) Grant Number
   R25CA153954 and an NIH-NCI Cancer Nanotechnology Training Center (CNTC)
   Post-doctoral Traineeship awarded to SAM. The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the NCI or the NIH. The authors thank Dr. Tonglei Li
   for XRPD and HSM access and Dr. J. Zach Hilt for ATR-FTIR access.
CR Alipour S, 2010, COLLOID SURFACE B, V81, P521, DOI 10.1016/j.colsurfb.2010.07.050
   Alves GP, 2004, POWDER TECHNOL, V145, P139, DOI 10.1016/j.powtec.2004.06.008
   American Cancer Society, 2013, CANC FACTS FIG 2013, P4
   Azarmi S, 2008, ADV DRUG DELIVER REV, V60, P863, DOI 10.1016/j.addr.2007.11.006
   Carvalho TC, 2011, J AEROSOL MED PULM D, V24, P61, DOI 10.1089/jamp.2009.0794
   Chow AHL, 2007, PHARM RES, V24, P411, DOI 10.1007/s11095-006-9174-3
   E-Sherbiny IM, 2012, MOL PHARMACEUT, V9, P269, DOI 10.1021/mp200351y
   Edwards DA, 1998, J APPL PHYSIOL, V85, P379
   EDWARDS DA, 1995, J AEROSOL SCI, V26, P293, DOI 10.1016/0021-8502(94)00101-4
   El-Sherbiny Ibrahim M, 2010, Int J Pharm, V395, P132, DOI 10.1016/j.ijpharm.2010.05.032
   El-Sherbiny IM, 2010, J PHARM SCI-US, V99, P2343, DOI 10.1002/jps.22003
   Eldar-Boock A, 2011, BIOMATERIALS, V32, P3862, DOI 10.1016/j.biomaterials.2011.01.073
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Finlay W., 2010, ARLA RESP DEPOSITION
   Forbes B, 2005, EUR J PHARM BIOPHARM, V60, P193, DOI 10.1016/j.ejpb.2005.02.010
   Gagnadoux F, 2008, J AEROSOL MED PULM D, V21, P61, DOI 10.1089/jamp.2007.0656
   Gautam A, 2003, CURR CANCER DRUG TAR, V3, P57
   Gill KK, 2011, EUR J PHARM BIOPHARM, V79, P276, DOI 10.1016/j.ejpb.2011.04.017
   Grainger CI, 2006, PHARM RES, V23, P1482, DOI 10.1007/s11095-006-0255-0
   Haigentz Missak Jr, 2003, Methods Mol Med, V75, P771
   Hickey AJ, 2009, MODERN PHARM, P191
   Hickey AJ, 2007, J PHARM SCI-US, V96, P1302, DOI 10.1002/jps.20943
   Hickey AJ, 2007, J PHARM SCI-US, V96, P1282, DOI 10.1002/jps.20916
   Hitzman CJ, 2006, J PHARM SCI-US, V95, P1114, DOI 10.1002/jps.20591
   Hureaux J, 2009, EUR J PHARM BIOPHARM, V73, P239, DOI 10.1016/j.ejpb.2009.06.013
   JOBE AH, 1993, NEW ENGL J MED, V328, P861
   Labiris NR, 2003, BRIT J CLIN PHARMACO, V56, P600, DOI 10.1046/j.1365-2125.2003.01893.x
   Labiris NR, 2003, BRIT J CLIN PHARMACO, V56, P588, DOI 10.1046/j.1365-2125.2003.01892.x
   Laube BL, 2011, EUR RESPIR J, V37, P1308, DOI 10.1183/09031936.00166410
   Mansour H, 2001, LANGMUIR, V17, P6622, DOI 10.1021/la0108454
   Mansour HM, 2007, LANGMUIR, V23, P3809, DOI 10.1021/la063053o
   Mansour HM, 2009, INT J NANOMED, V4, P299
   Mansour HM, 2011, LIPIDS NANOTECHNOLOG, P221
   Meenach SA, 2013, EUR J PHARM SCI, V49, P699, DOI 10.1016/j.ejps.2013.05.012
   Meenach SA, 2013, INT J NANOMED, V8, P275, DOI 10.2147/IJN.S30724
   O'Hara P, 2000, PHARMACEUT RES, V17, P955, DOI 10.1023/A:1007527204887
   Park CW, 2013, INT J PHARMACEUT, V455, P374, DOI 10.1016/j.ijpharm.2013.06.047
   Rubin BK, 2010, OTOLARYNG CLIN N AM, V43, P27, DOI 10.1016/j.otc.2009.11.002
   Salama RO, 2008, EUR J PHARM BIOPHARM, V70, P145, DOI 10.1016/j.ejpb.2008.04.009
   Sharma S, 2001, J CLIN ONCOL, V19, P1839, DOI 10.1200/JCO.2001.19.6.1839
   Son YJ, 2012, J PHARM PHARMACOL, V64, P1291, DOI 10.1111/j.2042-7158.2012.01531.x
   Son YJ, 2009, INT J PHARMACEUT, V382, P15, DOI 10.1016/j.ijpharm.2009.07.034
   Suarez S, 2000, Respir Care, V45, P652
   Sung JC, 2007, TRENDS BIOTECHNOL, V25, P563, DOI 10.1016/j.tibtech.2007.09.005
   Sung JC, 2009, PHARM RES-DORD, V26, P1847, DOI 10.1007/s11095-009-9894-2
   Vehring R, 2007, J AEROSOL SCI, V38, P728, DOI 10.1016/j.jaerosci.2007.04.005
   Weers JG, 2010, J AEROSOL MED PULM D, V23, pS5, DOI 10.1089/jamp.2010.0838
   Willis L, 2012, LUNG, V190, P251, DOI 10.1007/s00408-011-9360-x
   Wu X, 2013, INT J NANOMED, V8, P1269, DOI 10.2147/IJN.S40904
   Wu X, 2013, DRUG DES DEV THER, V7, P59, DOI [10.2147/DDDT.540166, 10.2147/DDDT.S40166]
   [Anonymous], 2006, USP 29 NF 24 US PHAR, P2617
NR 51
TC 10
Z9 10
U1 0
U2 26
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1530-9932
J9 AAPS PHARMSCITECH
JI AAPS PharmSciTech
PD DEC
PY 2014
VL 15
IS 6
BP 1574
EP 1587
DI 10.1208/s12249-014-0182-z
PG 14
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA AX2PZ
UT WOS:000346787700023
PM 25139763
OA green_published
DA 2018-03-19
ER

PT J
AU Hawkins, AM
   Tolbert, ME
   Newton, B
   Milbrandt, TA
   Puleo, DA
   Hilt, JZ
AF Hawkins, Ashley M.
   Tolbert, Melanie E.
   Newton, Brittany
   Milbrandt, Todd A.
   Puleo, David A.
   Hilt, J. Zach
TI Tuning biodegradable hydrogel properties via synthesis procedure
SO POLYMER
LA English
DT Article
DE Biodegradable hydrogel; Poly(beta-amino ester); Hydrophilic/hydrophobic
ID ESTER) NETWORK PROPERTIES; DEGRADATION
AB Biodegradable hydrogels have become a rapidly expanding area of research for biomedical applications. Poly(beta-amino ester) (PBAE) biodegradable hydrogels, in particular, have been studied extensively because of the ease of synthesis and range of properties exhibited. In this work, PBAE macromers were created with poly(ethylene glycol) diacrylate (PEGDA), diethylene glycol diacrylate (DEGDA), and isobutylamine. Many methods have been presented that allow control over the resulting hydrogel behavior. Here, properties were varied by combining multiple diacrylate components in the macromer synthesis step (single macromer (SM)) or through the combination of multiple macromers prior to polymerization (double macromer (DM)). The exhibited properties are a result of the hydrophilic/hydrophobic contributions of the different diacrylate molecules to the macromer. The SM systems exhibited linear degradation profiles, the rate of degradation increased as the PEGDA concentration increased. DM systems exhibited a multiphase degradation profile as a result of the combination of macromers with different hydrophilic properties. (c) 2013 Elsevier Ltd. All rights reserved.
C1 [Hawkins, Ashley M.; Newton, Brittany; Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Tolbert, Melanie E.] Tuskegee Univ, Dept Chem Engn, Tuskegee, AL 36088 USA.
   [Milbrandt, Todd A.] Univ Kentucky, Dept Orthopaed Surg, Lexington, KY 40506 USA.
   [Puleo, David A.] Univ Kentucky, Ctr Biomed Engn, Lexington, KY 40506 USA.
RP Hilt, JZ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 F Paul Anderson Tower, Lexington, KY 40506 USA.
EM hilt@engr.uky.edu
FU National Science Foundation's Integrative Graduate Education Research
   and Traineeship (IGERT); NSF research experience for undergraduates
   (REU) program; Orthopaedic Research & Education Foundation-Pediatric
   Orthopaedic Society of North America (OREF-POSNA)
FX The authors would like to acknowledge the National Science Foundation's
   Integrative Graduate Education Research and Traineeship (IGERT), the NSF
   research experience for undergraduates (REU) program, and the
   Orthopaedic Research & Education Foundation-Pediatric Orthopaedic
   Society of North America (OREF-POSNA) for funding this research. We
   would also like to thank Prachi Gupta for her assistance on the gel
   permeation chromatography.
CR Anderson DG, 2006, ADV MATER, V18, P2614, DOI 10.1002/adma.200600529
   Anseth KS, 2002, J CONTROL RELEASE, V78, P199, DOI 10.1016/S0168-3659(01)00500-4
   Brey DM, 2008, J BIOMED MATER RES A, V85A, P731, DOI 10.1002/jbm.a.31494
   Brey DM, 2008, ACTA BIOMATER, V4, P207, DOI 10.1016/j.actbio.2007.10.002
   Bryant SJ, 2003, J BIOMED MATER RES A, V64A, P70, DOI 10.1002/jbm.a.10319
   Hawkins AM, 2011, J APPL POLYM SCI, V122, P1420, DOI 10.1002/app.34093
   Hawkins AM, 2011, ACTA BIOMATER, V7, P1956, DOI 10.1016/j.actbio.2011.01.024
   Hawkins AM, 2009, PHARM RES-DORD, V26, P667, DOI 10.1007/s11095-008-9804-z
   Kopecek J, 2007, POLYM INT, V56, P1078, DOI 10.1002/pi.2253
   Rice MA, 2004, J BIOMED MATER RES A, V70A, P560, DOI 10.1002/jbm.a.30106
   Slaughter BV, 2009, ADV MATER, V21, P3307, DOI 10.1002/adma.200802106
   Tan HP, 2010, MATERIALS, V3, P1746, DOI 10.3390/ma3031746
NR 12
TC 7
Z9 8
U1 0
U2 29
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0032-3861
J9 POLYMER
JI Polymer
PD AUG 2
PY 2013
VL 54
IS 17
BP 4422
EP 4426
DI 10.1016/j.polymer.2013.06.010
PG 5
WC Polymer Science
SC Polymer Science
GA 195FJ
UT WOS:000322687400005
DA 2018-03-20
ER

PT J
AU Sexton, T
   Hitchcook, LJ
   Rodgers, DW
   Bradley, LH
   Hersh, LB
AF Sexton, Travis
   Hitchcook, Lisa J.
   Rodgers, David W.
   Bradley, Luke H.
   Hersh, Louis B.
TI Active Site Mutations Change the Cleavage Specificity of Neprilysin
SO PLOS ONE
LA English
DT Article
ID ENDOPEPTIDASE 24.11 ENKEPHALINASE; NEUTRAL ENDOPEPTIDASE;
   ALZHEIMERS-DISEASE; TRANSGENIC MICE; AMYLOID BURDEN; PURIFICATION;
   DEGRADATION; EXPRESSION; INHIBITORS; PATHOLOGY
AB Neprilysin (NEP), a member of the M13 subgroup of the zinc-dependent endopeptidase family is a membrane bound peptidase capable of cleaving a variety of physiological peptides. We have generated a series of neprilysin variants containing mutations at either one of two active site residues, Phe(563) and Ser(546). Among the mutants studied in detail we observed changes in their activity towards leucine(5)-enkephalin, insulin B chain, and amyloid beta(1-40). For example, NEPF563I displayed an increase in preference towards cleaving leucine(5)-enkephalin relative to insulin B chain, while mutant NEPS546E was less discriminating than neprilysin. Mutants NEPF563L and NEPS546E exhibit different cleavage site preferences than neprilysin with insulin B chain and amyloid beta(1-40) as substrates. These data indicate that it is possible to alter the cleavage site specificity of neprilysin opening the way for the development of substrate specific or substrate exclusive forms of the enzyme with enhanced therapeutic potential.
C1 [Sexton, Travis; Hitchcook, Lisa J.; Rodgers, David W.; Hersh, Louis B.] Univ Kentucky, Struct Biol Ctr, Dept Mol & Cellular Biochem, Lexington, KY 40506 USA.
   [Bradley, Luke H.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA.
RP Sexton, T (reprint author), Univ Kentucky, Struct Biol Ctr, Dept Mol & Cellular Biochem, Lexington, KY 40506 USA.
EM lhersh@uky.edu
FU Alzheimer's Association; National Institutes of Health [RO1DA02243,
   T32DA016176, P2ORR020171]
FX This work was supported in part by grants from the Alzheimer's
   Association (DR. Rodgers, Dr. Bradley, Dr. Hersh), and the National
   Institutes of Health RO1DA02243 (Dr. Hersh), T32DA016176 (Dr. Sexton),
   and P2ORR020171 (DR. Rodgers, Dr. Bradley, Dr. Hersh). The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Becker MH, 2010, PLOS ONE, V5
   Bradley LH, 2005, PROTEIN ENG DES SEL, V18, P201, DOI 10.1093/protein/gzi020
   Bradley LH, 2011, PROTEIN EXPRES PURIF, V75, P186, DOI 10.1016/j.pep.2010.08.007
   CAMERON CE, 1994, J BIOL CHEM, V269, P11170
   CRAIK CS, 1985, SCIENCE, V228, P291, DOI 10.1126/science.3838593
   ERDOS EG, 1989, FASEB J, V3, P145
   GEE NS, 1985, BIOCHEM J, V228, P119, DOI 10.1042/bj2280119
   Guan H, 2009, J NEUROSCI RES, V87, P1462, DOI 10.1002/jnr.21944
   HERSH LB, 1986, J BIOL CHEM, V261, P6433
   HOWELL S, 1995, PEPTIDES, V16, P647, DOI 10.1016/0196-9781(95)00021-B
   Jeffrey JL, 2003, J BIOL CHEM, V278, P18971, DOI 10.1074/jbc.M210113200
   KERR MA, 1974, BIOCHEM J, V137, P477, DOI 10.1042/bj1370477
   Lee CC, 2005, PLASMID, V54, P80, DOI 10.1016/j.plasmid.2004.12.001
   Leissring MA, 2003, NEURON, V40, P1087, DOI 10.1016/S0896-6273(03)00787-6
   Leissring MA, 2003, J BIOL CHEM, V278, P37314, DOI 10.1074/jbc.M305627200
   LI CW, 1995, METHOD ENZYMOL, V248, P253
   Liu YX, 2009, MOL THER, V17, P1381, DOI 10.1038/mt.2009.115
   MALFROY B, 1978, NATURE, V276, P523, DOI 10.1038/276523a0
   Marr RA, 2003, J NEUROSCI, V23, P1992
   MATSAS R, 1983, P NATL ACAD SCI-BIOL, V80, P3111, DOI 10.1073/pnas.80.10.3111
   Oefner C, 2000, J MOL BIOL, V296, P341, DOI 10.1006/jmbi.1999.3492
   PAINTER RG, 1988, J BIOL CHEM, V263, P9456
   Poirier R, 2006, NEUROBIOL DIS, V24, P475, DOI 10.1016/j.nbd.2006.08.003
   ROQUES BP, 1993, PHARMACOL REV, V45, P87
   Spengler J, 1998, J CHEM SOC PERK T 1, P2091, DOI 10.1039/a801052h
   Thanawala V, 2008, CURR DRUG TARGETS, V9, P887, DOI 10.2174/138945008785909356
   Thompson MW, 2003, PEPTIDES, V24, P1359, DOI 10.1016/j.peptides.2003.07.012
   Turner AJ, 1997, FASEB J, V11, P355
   Turner AJ, 2001, BIOESSAYS, V23, P261, DOI 10.1002/1521-1878(200103)23:3<261::AID-BIES1036>3.0.CO;2-K
   VIJAYARAGHAVAN J, 1990, BIOCHEMISTRY-US, V29, P8052, DOI 10.1021/bi00487a009
   Wang DS, 2006, J BIOMED BIOTECHNOL, DOI 10.1155/JBB/2006/58406
   Wayman CP, 2010, BRIT J PHARMACOL, V160, P51, DOI 10.1111/j.1476-5381.2010.00691.x
   WOLZ RL, 1991, BIOCHEMISTRY-US, V30, P8488, DOI 10.1021/bi00098a029
NR 33
TC 4
Z9 4
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 23
PY 2012
VL 7
IS 2
AR e32343
DI 10.1371/journal.pone.0032343
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 927NZ
UT WOS:000302916100072
PM 22384224
OA gold
DA 2018-03-20
ER

PT J
AU Noinaj, N
   Bhasin, SK
   Song, ES
   Scoggin, KE
   Juliano, MA
   Juliano, L
   Hersh, LB
   Rodgers, DW
AF Noinaj, Nicholas
   Bhasin, Sonia K.
   Song, Eun Suk
   Scoggin, Kirsten E.
   Juliano, Maria A.
   Juliano, Luiz
   Hersh, Louis B.
   Rodgers, David W.
TI Identification of the Allosteric Regulatory Site of Insulysin
SO PLOS ONE
LA English
DT Article
ID INSULIN-DEGRADING ENZYME; AMYLOID-BETA-PEPTIDE; CRYSTALLOGRAPHIC
   STRUCTURE DETERMINATION; ALZHEIMERS-DISEASE; IN-VIVO; PROTEIN; SOFTWARE;
   IDE; ATP; BINDING
AB Background: Insulin degrading enzyme (IDE) is responsible for the metabolism of insulin and plays a role in clearance of the Ab peptide associated with Alzheimer's disease. Unlike most proteolytic enzymes, IDE, which consists of four structurally related domains and exists primarily as a dimer, exhibits allosteric kinetics, being activated by both small substrate peptides and polyphosphates such as ATP.
   Principal Findings: The crystal structure of a catalytically compromised mutant of IDE has electron density for peptide ligands bound at the active site in domain 1 and a distal site in domain 2. Mutating residues in the distal site eliminates allosteric kinetics and activation by a small peptide, as well as greatly reducing activation by ATP, demonstrating that this site plays a key role in allostery. Comparison of the peptide bound IDE structure (using a low activity E111F IDE mutant) with unliganded wild type IDE shows a change in the interface between two halves of the clamshell-like molecule, which may enhance enzyme activity by altering the equilibrium between closed and open conformations. In addition, changes in the dimer interface suggest a basis for communication between subunits.
   Conclusions/Significance: Our findings indicate that a region remote from the active site mediates allosteric activation of insulysin by peptides. Activation may involve a small conformational change that weakens the interface between two halves of the enzyme.
C1 [Noinaj, Nicholas; Bhasin, Sonia K.; Song, Eun Suk; Scoggin, Kirsten E.; Hersh, Louis B.; Rodgers, David W.] Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA.
   [Noinaj, Nicholas; Bhasin, Sonia K.; Song, Eun Suk; Scoggin, Kirsten E.; Hersh, Louis B.; Rodgers, David W.] Univ Kentucky, Struct Biol Ctr, Lexington, KY USA.
   [Juliano, Maria A.; Juliano, Luiz] Univ Fed Sao Paulo, Dept Biophys, Escola Paulista Med, Sao Paulo, Brazil.
RP Noinaj, N (reprint author), Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA.
EM david.rodgers@uky.edu
RI Fluidos Complexos, INCT/H-9172-2013; Juliano, Luiz/D-7204-2012
OI Juliano, Luiz/0000-0002-5589-2822
FU United States Public Health Services [NS38041, DA02243, DA016176, P20
   RR20171, T32 DA016176]
FX This work was supported by United States Public Health Services grants
   NS38041, DA02243, DA016176, and P20 RR20171. N.N. was supported by a
   United States Public Health Services training grant (T32 DA016176). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925
   Adams PD, 2004, J SYNCHROTRON RADIAT, V11, P53, DOI 10.1107/S0909049503024130
   Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657
   Authier F, 1996, CLIN INVEST MED, V19, P149
   Barrett A.J., 2003, HDB PROTEOLYTIC ENZY
   BAUMEISTER H, 1993, FEBS LETT, V317, P250, DOI 10.1016/0014-5793(93)81286-9
   Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254
   Camberos MC, 2001, EXP BIOL MED, V226, P334
   CCP4, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112
   Chalkley RJ, 2005, MOL CELL PROTEOMICS, V4, P1194, DOI 10.1074/mcp.D500002-MCP200
   Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0
   Duckworth WC, 1998, ENDOCR REV, V19, P608, DOI 10.1210/er.19.5.608
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Fakhrai-Rad H, 2000, HUM MOL GENET, V9, P2149, DOI 10.1093/hmg/9.14.2149
   Farris W, 2003, P NATL ACAD SCI USA, V100, P4162, DOI 10.1073/pnas.0230450100
   GOMISRUTH FX, 1994, J BIOL CHEM, V269, P17111
   Guo Q, 2010, J MOL BIOL, V395, P430, DOI 10.1016/j.jmb.2009.10.072
   Gutfreund H., 1995, KINETICS LIFE SCI RE
   Heras B, 2005, ACTA CRYSTALLOGR D, V61, P1173, DOI 10.1107/S0907444905019451
   Hersh LB, 2003, CURR PHARM DESIGN, V9, P449, DOI 10.2174/1381612033391676
   Im H, 2007, J BIOL CHEM, V282, P25453, DOI 10.1074/jbc.M701590200
   Karamohamed S, 2003, DIABETES, V52, P1562, DOI 10.2337/diabetes.52.6.1562
   Kim M, 2007, J BIOL CHEM, V282, P7825, DOI 10.1074/jbc.M609168200
   Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Malito E, 2008, BIOCHEMISTRY-US, V47, P12822, DOI 10.1021/bi801192h
   Manolopoulou M, 2009, J BIOL CHEM, V284, P14177, DOI 10.1074/jbc.M900068200
   MATTHEWS BW, 1988, ACCOUNTS CHEM RES, V21, P333, DOI 10.1021/ar00153a003
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206
   Miller BC, 2003, P NATL ACAD SCI USA, V100, P6221, DOI 10.1073/pnas.1031520100
   Motulsky H, 2004, FITTING MODELS BIOL
   Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255
   Ogino T, 2004, J VIROL, V78, P11766, DOI 10.1128/JVI.78.21.11766-11777.2004
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Painter J, 2006, ACTA CRYSTALLOGR D, V62, P439, DOI 10.1107/S0907444906005270
   Qiu WQ, 2006, NEUROBIOL AGING, V27, P190, DOI 10.1016/j.neurobiolaging.2005.01.004
   Qiu WQ, 1998, J BIOL CHEM, V273, P32730, DOI 10.1074/jbc.273.49.32730
   Safavi A, 1996, BIOCHEMISTRY-US, V35, P14318, DOI 10.1021/bi960582q
   Shen YQ, 2006, NATURE, V443, P870, DOI 10.1038/nature05143
   Song ES, 2005, J MOL NEUROSCI, V25, P201, DOI 10.1385/JMN:25:3:201
   Song ES, 2004, J BIOL CHEM, V279, P54216, DOI 10.1074/jbc.M411177200
   Song ES, 2003, J BIOL CHEM, V278, P49789, DOI 10.1074/jbc.M308983200
   Song ES, 2001, J BIOL CHEM, V276, P1152, DOI 10.1074/jbc.M008702200
   Song ES, 2005, J BIOL CHEM, V280, P17701, DOI 10.1074/jbc.M501896200
   Song ES, 2006, BIOCHEMISTRY-US, V45, P15085, DOI 10.1021/bi061298u
   Song ES, 2011, J BIOL CHEM, V286, P13852, DOI 10.1074/jbc.M110.191668
   Song ES, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009719
   Vepsalainen S, 2009, J NEUROL NEUROSUR PS, V80, P1268, DOI 10.1136/jnnp.2008.160002
   Vepsalainen S, 2007, J MED GENET, V44, DOI 10.1136/jmg.2006.048470
   Yao HB, 2006, ARCH BIOCHEM BIOPHYS, V451, P175, DOI 10.1016/j.abb.2006.04.011
   Zuo XM, 2009, BRAIN RES, V1249, P1, DOI 10.1016/j.brainres.2008.10.034
NR 51
TC 21
Z9 21
U1 1
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 24
PY 2011
VL 6
IS 6
AR e20864
DI 10.1371/journal.pone.0020864
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 782UF
UT WOS:000292036900008
PM 21731629
OA gold
DA 2018-03-20
ER

PT J
AU Li, X
   Rankin, SE
AF Li, Xin
   Rankin, Stephen E.
TI Multiscale Dynamic Monte Carlo/Continuum Model of Drying and Nonideal
   Polycondensation in Sol-Gel Silica Films
SO AICHE JOURNAL
LA English
DT Article
DE multiscale modeling; sol-gel silica films; dynamic Monte Carlo;
   polycondensation; first shell substitution effect
ID GAS-SENSING APPLICATIONS; MOLECULAR-SIZE DISTRIBUTION; FUNCTIONAL-GROUP
   KINETICS; COATED POLYMER-FILMS; OPTICAL APPLICATIONS; MESOPOROUS SILICA;
   THIN-FILMS; HYDROLYSIS PSEUDOEQUILIBRIUM; CARLO SIMULATIONS; CYCLIZATION
AB The process of forming sol-gel silica thin films involves multiple length and time scales ranging from molecular to macroscopic, and it is challenging to fully model because the polymerization is non ideal. A multiscale model is described to link macroscopic flow and drying (controlled by process parameters) to film microstructure (which dictates the properties of the films). In this modeling strategy, dynamic Monte Carlo (DMC) polymerization simulations are coupled to a continuum model of drying. The entire DMC simulation is treated as a particle of sol whose position and composition are tracked using a diffusion/evaporation finite difference method. By simulating swarms of particles starting from different positions in the film, the multiscale model predicts different drying/gelation phenomena, and predicts the occurrence of gradients of concentration and gelation in the films which can lead to the formation of a gel skin near the top surface of the film. (C) 2010 American Institute of Chemical Engineers AIChE J, 56: 2946-2956, 2010
C1 [Li, Xin; Rankin, Stephen E.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Rankin, SE (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM srankin@engr.uky.edu
RI Rankin, Stephen/A-3265-2013
OI Rankin, Stephen/0000-0002-8615-7564
FU U.S. Department of Energy [DE-FG02-03ER46033, DE-FG02-07ER46375]
FX This work is supported by the U.S. Department of Energy under grant
   numbers DE-FG02-03ER46033 and DE-FG02-07ER46375.
CR Alsoy S, 1998, DRY TECHNOL, V16, P15, DOI 10.1080/07373939808917390
   Anitha K, 2004, BIOSENS BIOELECTRON, V20, P848, DOI 10.1016/j.bios.2004.03.024
   ASSINK RA, 1993, COLLOID SURFACE A, V74, P1, DOI 10.1016/0927-7757(93)80392-R
   ASSINK RA, 1988, J NON-CRYST SOLIDS, V99, P359, DOI 10.1016/0022-3093(88)90441-3
   BAILEY JK, 1990, J NON-CRYST SOLIDS, V125, P208, DOI 10.1016/0022-3093(90)90851-C
   Blanc D, 2006, OPT MATER, V28, P331, DOI 10.1016/j.optmat.2005.01.020
   BLANDIN HP, 1987, PROG ORG COAT, V15, P163, DOI 10.1016/0033-0655(87)80005-5
   Brinker CJ, 2006, CURR OPIN COLLOID IN, V11, P126, DOI 10.1016/j.cocis.2005.10.006
   Brinker CJ, 1999, ADV MATER, V11, P579, DOI 10.1002/(SICI)1521-4095(199905)11:7<579::AID-ADMA579>3.0.CO;2-R
   Brinker C.J., 1990, SOL GEL SCI PHYS CHE
   Buso D, 2006, J SOL-GEL SCI TECHN, V40, P299, DOI 10.1007/s10971-006-8958-6
   Cairncross RA, 1996, AICHE J, V42, P55, DOI 10.1002/aic.690420107
   CAIRNCROSS RA, 1997, IS TS ANN C, V50, P554
   CERRO RL, 1980, IND ENG CHEM FUND, V19, P40, DOI 10.1021/i160073a008
   Crank J., 1988, FREE MOVING BOUNDARY
   Di JW, 2007, BIOSENS BIOELECTRON, V23, P682, DOI 10.1016/j.bios.2007.08.002
   Dollet A, 2004, SURF COAT TECH, V177, P245, DOI 10.1016/j.surfcoat.2003.09.040
   Drews TO, 2004, AICHE J, V50, P226, DOI 10.1002/aic.10021
   FICHTHORN KA, 1991, J CHEM PHYS, V95, P1090, DOI 10.1063/1.461138
   Flory PJ, 1941, J AM CHEM SOC, V63, P3083, DOI 10.1021/ja01856a061
   GILLESPIE DT, 1976, J COMPUT PHYS, V22, P403, DOI 10.1016/0021-9991(76)90041-3
   Guerrier B, 1998, AICHE J, V44, P791, DOI 10.1002/aic.690440404
   HENDRICKSON RC, 1994, COMPUT POLYMER SCI, V4, P53
   Jensen KF, 1998, CURR OPIN SOLID ST M, V3, P562, DOI 10.1016/S1359-0286(98)80026-0
   Kambhampati DK, 2001, LANGMUIR, V17, P1169, DOI 10.1021/la001250w
   Karakasidis TE, 2007, MAT SCI ENG C-BIO S, V27, P1082, DOI 10.1016/j.msec.2006.06.029
   Kasehagen LJ, 1997, MACROMOLECULES, V30, P3921, DOI 10.1021/ma9619142
   KAY BD, 1988, J NON-CRYST SOLIDS, V104, P112, DOI 10.1016/0022-3093(88)90189-5
   Konjhodzic D, 2006, THIN SOLID FILMS, V495, P333, DOI 10.1016/j.tsf.2005.08.223
   Li XH, 2007, J ELECTROCHEM SOC, V154, pD230, DOI 10.1149/1.2434686
   Lou HH, 2000, IND ENG CHEM RES, V39, P500, DOI 10.1021/ie990171g
   Lou YM, 2003, AICHE J, V49, P2099, DOI 10.1002/aic.690490818
   Martucci A, 2004, J MATER CHEM, V14, P2889, DOI 10.1039/b405301j
   Molenkamp WC, 2004, J AM CHEM SOC, V126, P4476, DOI 10.1021/ja039296
   Musat V, 2008, THIN SOLID FILMS, V516, P1499, DOI 10.1016/j.tsf.2007.07.197
   NG LV, 1995, MACROMOLECULES, V28, P6471, DOI 10.1021/ma00123a012
   Nostell P, 1999, THIN SOLID FILMS, V351, P170, DOI 10.1016/S0040-6090(99)00257-6
   Olding T, 2001, THIN SOLID FILMS, V398, P581, DOI 10.1016/S0040-6090(01)01322-0
   Palaniappan A, 2006, J ELECTROCERAM, V16, P503, DOI 10.1007/s10832-006-9906-0
   POUXVIEL JC, 1987, J NON-CRYST SOLIDS, V94, P374, DOI 10.1016/S0022-3093(87)80072-8
   Praprotnik M, 2008, ANNU REV PHYS CHEM, V59, P545, DOI 10.1146/annurev.physchem.59.032607.093707
   Raimondeau S, 2002, CHEM ENG J, V90, P3, DOI 10.1016/S1385-8947(02)00065-7
   Rankin SE, 1999, IND ENG CHEM RES, V38, P3191, DOI 10.1021/ie990027v
   Rankin SE, 1998, AICHE J, V44, P1141, DOI 10.1002/aic.690440512
   Rankin SE, 2000, CHEM ENG SCI, V55, P1955, DOI 10.1016/S0009-2509(99)00486-8
   Rankin SE, 1998, CHEM MATER, V10, P2037, DOI 10.1021/cm980256s
   Rankin SE, 2000, MACROMOLECULES, V33, P7639, DOI 10.1021/ma000132c
   REGLAT O, 1993, J COMPUT PHYS, V109, P238, DOI 10.1006/jcph.1993.1215
   Sanchez C, 2008, CHEM MATER, V20, P715
   Sanchez J, 1996, IND ENG CHEM RES, V35, P117, DOI 10.1021/ie950246q
   Sefcik J, 2003, J PHYS CHEM B, V107, P52, DOI 10.1021/jp026361d
   STEIN A, 2000, ADV MATER, V12, P1412
   Stockmayer WH, 1944, J CHEM PHYS, V12, P125, DOI 10.1063/1.1723922
   Stockmayer WH, 1943, J CHEM PHYS, V11, P45, DOI 10.1063/1.1723803
   Teyssier J, 2004, J NON-CRYST SOLIDS, V341, P152, DOI 10.1016/j.jnoncrysol.2004.05.002
   Verros GD, 2001, COMPUT MECH, V27, P332, DOI 10.1007/s004660000229
   VRENTAS JS, 1994, J POLYM SCI POL PHYS, V32, P187, DOI 10.1002/polb.1994.090320122
NR 57
TC 9
Z9 9
U1 1
U2 12
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0001-1541
J9 AICHE J
JI AICHE J.
PD NOV
PY 2010
VL 56
IS 11
BP 2946
EP 2956
DI 10.1002/aic.12202
PG 11
WC Engineering, Chemical
SC Engineering
GA 666HF
UT WOS:000283104700017
DA 2018-03-20
ER

PT J
AU Long, SH
   Mao, TF
   Chen, P
   Liu, M
   Parkin, S
   Zhang, MT
   Li, TL
   Zhou, PP
   Yu, FQ
AF Long, Sihui
   Mao, Tengfei
   Chen, Peng
   Liu, Meng
   Parkin, Sean
   Zhang, Mingtao
   Li, Tonglei
   Zhou, Panpan
   Yu, Faquan
TI Strong Hydrogen Bond Leads to a Fifth Crystalline Form and Polymorphism
   of Clonixin
SO CHEMISTRYSELECT
LA English
DT Article
DE Clonixin; conformation; hydrogen bond; polymorphs; solvate; theoretical
   studies
ID 2-(2-METHYL-3-CHLOROANILINO) NICOTINIC-ACID; 2-ANILINONICOTINIC ACIDS;
   ZWITTERIONIC POLYMORPHS; PYRIDINE HETEROSYNTHON; IMPROVED MEDICINES;
   PLATELET-FUNCTION; SOLUBILITY; COCRYSTALS; PATTERNS; PHASE
AB Over 30 years since the discovery of four crystal forms (I, II, III and IV) of Clonixin [2-(3-chloro-2-methyl-phenylamino)-nicotinic acid], a fifth form, a dimethylformamide (DMF) solvate, has been obtained by crystal growth in DMF. The new form was characterized by single-crystal X-ray diffraction, FT-IR, and Raman spectroscopy. The crystal structure is stabilized by the strong hydrogen bond between the carboxylic acid OH and the DMF carbonyl whose strength is on par with those of the four solvent-free forms, which are based on either the acid-acid homosynthon or the acid-pyridine heterosynthon, depending on the dihedral angle between the two aromatic rings. This solvate loses DMF to convert into form I, as confirmed by differential scanning calorimetry (DSC) and powder X-ray diffraction (PXRD). Other aspects of this polymorphic/solvatomorphic system were investigated both experimentally and theoretically. Theoretical studies such as lattice energy calculation, hydrogen-bond strength estimation and Hirshfeld analysis were performed, providing further insight into the polymorphism/solvatomorphism of this system. Based on the analysis of the new form and the whole system, more solvates/cocrystals could be designed and unveiled in due time.
C1 [Long, Sihui; Mao, Tengfei; Chen, Peng; Liu, Meng; Yu, Faquan] Wuhan Inst Technol, Key Lab Green Chem Proc, Minist Educ, Sch Chem Engn & Pharm, 693 Xiongchu Rd, Wuhan 430073, Hubei, Peoples R China.
   [Parkin, Sean] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
   [Zhang, Mingtao; Li, Tonglei] Purdue Univ, Dept Ind & Phys Pharm, W Lafayette, IN 47907 USA.
   [Zhou, Panpan] Lanzhou Univ, Dept Chem, Lanzhou, Gansu, Peoples R China.
RP Long, SH; Yu, FQ (reprint author), Wuhan Inst Technol, Key Lab Green Chem Proc, Minist Educ, Sch Chem Engn & Pharm, 693 Xiongchu Rd, Wuhan 430073, Hubei, Peoples R China.
EM Sihuilong@wit.edu.cn; fyuwucn@gmail.com
FU Natural Science Foundation of Hubei Province [2014CFB787]; National
   Natural Science Foundation of China [21403097]; Fundamental Research
   Funds for the Central Universities [lzujbky-2014-182]; NSF [DMR1006364]
FX SL thanks Natural Science Foundation of Hubei Province for financial
   support (2014CFB787). PPZ acknowledges the financial support by the
   National Natural Science Foundation of China (Grant No. 21403097) and
   the Fundamental Research Funds for the Central Universities
   (lzujbky-2014-182). TL is grateful to NSF for supporting the work
   (DMR1006364).
CR Almarsson O, 2004, CHEM COMMUN, P1889, DOI 10.1039/b402150a
   ARKEL YS, 1976, J CLIN PHARMACOL, V16, P30, DOI 10.1002/j.1552-4604.1976.tb01488.x
   BERNSTEIN J, 1995, ANGEW CHEM INT EDIT, V34, P1555, DOI 10.1002/anie.199515551
   Bernstein J., 2002, POLYMORPHISM MOL CRY
   Brittain H. G., 1999, POLYMORPHISM PHARM S
   Chen P, 2016, RSC ADV, V6, P81101, DOI 10.1039/c6ra20019b
   Duggirala NK, 2016, CHEM COMMUN, V52, P640, DOI 10.1039/c5cc08216a
   ETTER MC, 1990, ACCOUNTS CHEM RES, V23, P120, DOI 10.1021/ar00172a005
   FINCH JS, 1971, J CLIN PHARMACOL N D, V11, P371
   Franckaerts K, 1997, ELECTRON J THEOR CH, V2, P168, DOI 10.1002/ejtc.50
   Golob S, 2016, J PHARM SCI-US, V105, P3626, DOI 10.1016/j.xphs.2016.09.017
   Hilfiker R, 2006, POLYMORPHISM PHARM I
   Juby P. F., 1972, ANNU REP MED CHEM, V7, P208
   Krymchantowski AV, 2008, ARQ NEURO-PSIQUIAT, V66, P216, DOI 10.1590/S0004-282X2008000200015
   Kumar SS, 2014, CRYST GROWTH DES, V14, P1865, DOI 10.1021/cg5000205
   Lee JM, 2002, J PHARM PHARMACOL, V54, P43, DOI 10.1211/0022357021771904
   Long SH, 2008, CRYST GROWTH DES, V8, P4006, DOI 10.1021/cg800123z
   Long SH, 2008, CRYST GROWTH DES, V8, P3137, DOI 10.1021/cg800339h
   Long SH, 2014, CRYST GROWTH DES, V14, P27, DOI 10.1021/cg401532j
   Long SH, 2011, CRYST GROWTH DES, V11, P414, DOI 10.1021/cg101009g
   Long SH, 2010, CRYST GROWTH DES, V10, P2465, DOI 10.1021/cg100227s
   Long SH, 2009, CRYST GROWTH DES, V9, P4993, DOI 10.1021/cg900786b
   Lopez-Majias V, 2015, CRYST GROWTH DES, V15, P3955, DOI 10.1021/acs.cgd.5b00570
   MORSE EE, 1977, ANN CLIN LAB SCI, V7, P68
   Nath NK, 2011, CRYST GROWTH DES, V11, P4594, DOI 10.1021/cg200853u
   Shan N, 2008, DRUG DISCOV TODAY, V13, P440, DOI 10.1016/j.drudis.2008.03.004
   Starbuck J., 1999, J CHEM SOC P1, V4, P677
   Swerts B, 2002, J PHYS CHEM A, V106, P4245, DOI 10.1021/jp014513j
   TAKASUKA M, 1982, J CHEM SOC PERK T 2, P1061, DOI 10.1039/p29820001061
   Tian F, 2010, J PHARM PHARMACOL, V62, P1534, DOI 10.1111/j.2042-7158.2010.01186.x
   Trask AV, 2005, CHEM COMMUN, P880, DOI 10.1039/b416980h
   Uzoh OG, 2012, CRYST GROWTH DES, V12, P4230, DOI 10.1021/cg3007348
   Weyna DR, 2012, MOL PHARMACEUT, V9, P2094, DOI 10.1021/mp300169c
   WIDMER K, 1975, THROMB RES, V6, P9, DOI 10.1016/0049-3848(75)90146-2
   Sherlock M. H., 1969, Brit. Pat., GB, Patent No. 1147701
   Hwang Y. I., 2003, KR, Patent No. 2003042935
   Sherlock M. H., 1972, U.S., Patent No. [3689653 A, 3689653]
   Sherlock M. H., 1969, Brit. Pat., GB, Patent No. 1147703
   Sherlock M. H., 1969, Brit. Pat., GB, Patent No. 1147702
NR 39
TC 0
Z9 0
U1 7
U2 12
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 2365-6549
J9 CHEMISTRYSELECT
JI ChemistrySelect
PD JUN 12
PY 2017
VL 2
IS 17
BP 4942
EP 4950
DI 10.1002/slct.201700947
PG 9
WC Chemistry, Multidisciplinary
SC Chemistry
GA EY3PX
UT WOS:000403886100053
DA 2018-03-20
ER

PT J
AU Strasinger, C
   Paudel, KS
   Wu, J
   Hammell, D
   Pinninti, RR
   Hinds, BJ
   Stinchcomb, A
AF Strasinger, Caroline
   Paudel, Kalpana S.
   Wu, Ji
   Hammell, Dana
   Pinninti, Raghotham R.
   Hinds, Bruce J.
   Stinchcomb, Audra L.
TI Programmable Transdermal Clonidine Delivery Through Voltage-Gated Carbon
   Nanotube Membranes
SO JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE transdermal delivery; carbon nanotube membrane; programmable drug
   delivery; drug addiction; clonidine; diffusion; skin permeation; active
   transport; membrane transport; nanotechnology
ID OPIOID DETOXIFICATION; BUPRENORPHINE; HEROIN; WITHDRAWAL; FLOW
AB Oral dosage forms and traditional transdermal patches are inadequate for complex clonidine therapy dosing schemes, because of the variable dose/flux requirement for the treatment of opioid withdrawal symptoms. The purpose of this study was to evaluate the in vitro transdermal flux changes of clonidine in response to alterations in carbon nanotube (CNT) delivery rates by applying various electrical bias. Additional skin diffusion studies were carried out to demonstrate the therapeutic feasibility of the system. This study demonstrated that application of a small electrical bias (-600 mV) to the CNT membrane on the skin resulted in a 4.7-fold increase in clonidine flux as compared with no bias (0 mV) application. The high and low clonidine flux values were very close to the desired variable flux of clonidine for the treatment of opioid withdrawal symptoms. Therapeutic feasibility studies demonstrated that CNT membrane served as the rate-limiting step to clonidine diffusion and lag and transition times were suitable for the clonidine therapy. Skin elimination studies revealed that clonidine depletion from the skin would not negatively affect clonidine therapy. Overall, this study showed that clonidine administration difficulties associated with the treatment of opiate withdrawal symptoms can be reduced with the programmable CNT membrane transdermal system. (c) 2014 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci
C1 [Strasinger, Caroline; Paudel, Kalpana S.; Hammell, Dana; Pinninti, Raghotham R.; Stinchcomb, Audra] Univ Kentucky, Coll Pharm, Lexington, KY 40506 USA.
   [Paudel, Kalpana S.] South Coll, Sch Pharm, Knoxville, TN USA.
   [Wu, Ji; Hinds, Bruce J.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY USA.
   [Hammell, Dana; Stinchcomb, Audra] AllTranz Inc, Lexington, KY USA.
   [Stinchcomb, Audra] Univ Maryland, Sch Pharm, Baltimore, MD 21201 USA.
   [Wu, Ji] Georgia So Univ, Dept Chem, Statesboro, GA 30460 USA.
RP Stinchcomb, A (reprint author), Univ Kentucky, Coll Pharm, Lexington, KY 40506 USA.
EM bjhinds@engr.uky.edu; astinchc@rx.umaryland.edu
RI WU, JI/J-4580-2016
FU NIH [R01DA18822]
FX The authors thank Rodney Andrews and Dalli Qian from the Center for
   Applied Energy, University of Kentucky, who supplied MWCNTs. Facility
   support was provided by the Center for Nanoscale Science and Engineering
   and Electron Microscopy Center at the University of Kentucky. Human skin
   was obtained through the NIH-sponsored Cooperative Human Tissue Network.
   This work was supported by NIH grant number R01DA18822.
CR ASHBURN MA, 1995, ANESTHESIOLOGY, V82, P1146, DOI 10.1097/00000542-199505000-00009
   BERNER B, 1994, CLIN PHARMACOKINET, V26, P121, DOI 10.2165/00003088-199426020-00005
   Chen SQ, 2007, ACTA PHARMACOL SIN, V28, P473, DOI 10.1111/j.1745-7254.2007.00526.x
   Claxton AJ, 2001, CLIN THER, V23, P1296, DOI 10.1016/S0149-2918(01)80109-0
   D'Amours M, 2003, J PHYS CHEM B, V107, P4811, DOI 10.1021/jp027223r
   Gowing L, 2009, COCHRANE DB SYST REV, V15
   Hinds BJ, 2004, SCIENCE, V303, P62, DOI 10.1126/science.1092048
   Lanier RK, 2008, PSYCHOPHARMACOLOGY, V198, P149, DOI 10.1007/s00213-008-1105-z
   Lochner S, 2010, INTERNIST, V51, P667, DOI 10.1007/s00108-009-2545-1
   Majumder M, 2005, NATURE, V438, P44, DOI 10.1038/43844a
   Majumder M, 2008, J MEMBRANE SCI, V316, P89, DOI 10.1016/j.memsci.2007.09.068
   Majumder M, 2007, LANGMUIR, V23, P8624, DOI 10.1021/la700686k
   Majumder M, 2010, LIFE SCI, V86, P563, DOI 10.1016/j.lfs.2009.04.006
   National Institute on Drug Addiction, 2006, RES REP SER HER AB A
   Oreskovich MR, 2005, DRUG ALCOHOL DEPEN, V77, P71, DOI 10.1016/j.drugalcdep.2004.07.008
   Paudel KS, 2010, THER DELIV, V1, P109, DOI 10.4155/TDE.10.16
   Raith K, 2004, INT J CLIN PHARM TH, V42, P191
   SEGAL IS, 1991, ANESTHESIOLOGY, V74, P220, DOI 10.1097/00000542-199102000-00005
   Sica Domenic A, 2005, J Clin Hypertens (Greenwich), V7, P558, DOI 10.1111/j.1524-6175.2005.04133.x
   Sobey PW, 2003, J ADDICT DIS, V22, P13, DOI 10.1300/J069v22n04_03
   Strobbe S, 2003, AM J ADDICTION, V12, P260, DOI 10.1080/10550490390203243
   DRUGDEX, 2008, DRUGDEX SYST
   Umbricht A, 2003, DRUG ALCOHOL DEPEN, V69, P263, DOI 10.1016/S0376-8716(02)00325-3
   Wills S., 2005, DRUGS ABUSE
   Wu J, 2011, NANOSCALE, V3, P3321, DOI 10.1039/c1nr10303b
   Wu J, 2010, P NATL ACAD SCI USA, V107, P11698, DOI 10.1073/pnas.1004714107
NR 26
TC 5
Z9 5
U1 2
U2 21
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3549
EI 1520-6017
J9 J PHARM SCI-US
JI J. Pharm. Sci.
PD JUN
PY 2014
VL 103
IS 6
BP 1829
EP 1838
DI 10.1002/jps.23940
PG 10
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology &
   Pharmacy
SC Pharmacology & Pharmacy; Chemistry
GA AI1OA
UT WOS:000336619300026
PM 24788096
OA green_accepted
DA 2018-03-20
ER

PT J
AU Venkatachalam, K
   Arzuaga, X
   Chopra, N
   Gavalas, VG
   Xu, J
   Bhattacharyya, D
   Hennig, B
   Bachas, LG
AF Venkatachalam, Karthik
   Arzuaga, Xabier
   Chopra, Nitin
   Gavalas, Vasilis G.
   Xu, Jian
   Bhattacharyya, Dibakar
   Hennig, Bernhard
   Bachas, Leonidas G.
TI Reductive dechlorination of 3,3 ',4,4 '-tetrachlorobiphenyl (PCB77)
   using palladium or palladium/iron nanoparticles and assessment of the
   reduction in toxic potency in vascular endothelial cells
SO JOURNAL OF HAZARDOUS MATERIALS
LA English
DT Article
DE Palladium nanoparticles; Palladium/iron nanoparticles; Polychlorinated
   biphenyls; Remediation; Cytotoxicity
ID NF-KAPPA-B; POLYCHLORINATED-BIPHENYLS; SELECTIVE HYDROGENATION;
   IN-VITRO; CYCLOOXYGENASE-2; EXPRESSION; COPLANAR; CONTAMINANTS;
   ENHANCEMENT; COMPOSITES
AB Palladium-based nanoparticles immobilized in polymeric matrices were applied to the reductive dechlorination of 3,3',4,4'-tetrachlorobiphenyl (PCB77) at room temperature. Two different dechlorination platforms were evaluated using (1) Pd nanoparticles within conductive polypyrrole films; or (2) immobilized Fe/Pd nanoparticles within polyvinylidene fluoride microfiltration membranes. For the first approach, the polypyrrole film was electrochemically formed in the presence of perchlorate ions that were incorporated into the film to counter-balance the positive charges of the polypyrrole chain. The film was then incubated in a solution containing tetrachloropalladate ions, which were exchanged with the perchlorate ions within the film. During this exchange, reduction of tetrachloropalladate by polypyrrole occurred, which led to the formation of palladium nanoparticles within the film. For the second approach, the membrane-supported Fe/Pd nanoparticles were prepared in three steps: polymerization of acrylic acid in polyvinylidene fluoride microfiltration membrane pores was followed by ion exchange of Fe2+, and then chemical reduction of the ferrous ions bound to the carboxylate groups. The membrane-supported iron nanoparticles were then soaked in a solution of tetrachloropalladate resulting in the deposition of Pd on the Fe surface. The nanoparticles prepared by both approaches were employed in the dechlorination of PCB77. The presence of hydrogen was required when the monometallic Pd nanoparticles were employed. The results indicate the removal of chlorine atoms from PCB77, which led to the formation of lower chlorinated intermediates and ultimately biphenyl. Toxicity associated with vascular dysfunction by PCB77 and biphenyl was compared using cultured endothelial cells. The data strongly suggest that the dechlorination system used in this study markedly reduced the proinflammatory activity of PCB77, a persistent organic pollutant. (C) 2008 Elsevier B.V. All rights reserved.
C1 [Venkatachalam, Karthik; Chopra, Nitin; Gavalas, Vasilis G.; Bachas, Leonidas G.] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
   [Arzuaga, Xabier; Hennig, Bernhard] Univ Kentucky, Coll Agr, Mol & Cell Nutr Lab, Lexington, KY 40506 USA.
   [Xu, Jian; Bhattacharyya, Dibakar] Univ Kentucky, Dept Chem Engn, Lexington, KY 40506 USA.
RP Bachas, LG (reprint author), Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
EM bachas@uky.edu
RI VENKATACHALAM, KARTHIK/D-1013-2011; Nitin, Chopra/F-8236-2011; Bachas,
   Leonidas/G-2479-2015
OI Bachas, Leonidas/0000-0002-3308-6264
FU National Institute of Environmental Health Sciences (NIEHS), NIH [P42 ES
   07380]
FX This publication was made possible by grant number P42 ES 07380 from the
   National Institute of Environmental Health Sciences (NIEHS), NIH. Its
   contents are solely the responsibility of the authors and do not
   necessarily represent the official views of the NIEHS, NIH. The authors
   thank Toray Composites America, Tacoma, WA for providing Toray carbon
   composite paper, and Larry W. Robertson for providing PCB77 for the cell
   culture experiments.
CR Alvarez MM, 1997, J PHYS CHEM B, V101, P3706, DOI 10.1021/jp962922n
   Astruc D, 2005, ANGEW CHEM INT EDIT, V44, P7852, DOI 10.1002/anie.200500766
   Birke V, 2004, J MATER SCI, V39, P5111, DOI 10.1023/B:JMSC.0000039192.61817.dd
   Burleigh ME, 2002, CIRCULATION, V105, P1816, DOI 10.1161/01.CIR.0000014927.74465.7F
   Cioffi N, 2000, J ELECTROANAL CHEM, V488, P42, DOI 10.1016/S0022-0728(00)00180-7
   Coq B, 1998, COORDIN CHEM REV, V178, P1753, DOI 10.1016/S0010-8545(98)00058-7
   EPA, 2003, EPA PUBL, VEPA 454/R-03-005
   Fendler J.H., 1998, NANOPARTICLES NANOST, P429
   Giesy JP, 1998, CRIT REV TOXICOL, V28, P511, DOI 10.1080/10408449891344263
   GRITTINI C, 1995, ENVIRON SCI TECHNOL, V29, P2898, DOI 10.1021/es00011a029
   Hasik M, 2003, EUR POLYM J, V39, P1669, DOI 10.1016/S0014-3057(03)00053-3
   He F, 2007, IND ENG CHEM RES, V46, P29, DOI 10.1021/ie0610896
   Hennig B, 2002, TOXICOL APPL PHARM, V181, P174, DOI 10.1006/taap.2002.9408
   Hennig B, 2007, NUTR METAB CARDIOVAS, V17, P162, DOI 10.1016/j.numecd.2006.01.003
   Huang SW, 1998, J MATER CHEM, V8, P1743, DOI 10.1039/a802245c
   Huang SW, 1998, SYNTHETIC MET, V96, P117, DOI 10.1016/S0379-6779(98)00072-1
   *INT CTR DIFFR DAT, 461043 INT CTR DIFFR
   KAFAFI SA, 1993, CARCINOGENESIS, V14, P2063, DOI 10.1093/carcin/14.10.2063
   Kamat PV, 2007, J PHYS CHEM C, V111, P2834, DOI 10.1021/jp066952u
   KANNAN N, 1987, J ASSOC OFF ANA CHEM, V70, P451
   Kidambi S, 2005, CHEM MATER, V17, P301, DOI 10.1021/cm048421t
   Korte NE, 2002, WASTE MANAGE, V22, P343, DOI 10.1016/S0956-053X(01)00050-2
   Lee SK, 2004, J IND ENG CHEM, V10, P173
   Leopold JA, 2005, ARTERIOSCL THROM VAS, V25, P1332, DOI 10.1161/01.ATV.0000163846.51473.09
   Li L, 2006, J NANOSCI NANOTECHNO, V6, P2571, DOI 10.1166/jnn.2006.542
   Lowry GV, 2004, ENVIRON SCI TECHNOL, V38, P5208, DOI 10.1021/es049835q
   Mangold KM, 2004, SYNTHETIC MET, V144, P221, DOI 10.1016/j.synthmet.2004.03.003
   Niu YH, 2001, J AM CHEM SOC, V123, P6840, DOI 10.1021/ja0105257
   Noma Y, 2003, FRESEN ENVIRON BULL, V12, P302
   Nutt MO, 2006, APPL CATAL B-ENVIRON, V69, P115, DOI 10.1016/j.apcatb.2006.06.005
   Park JH, 2004, CHEM MATER, V16, P688, DOI 10.1021/cm0304142
   PATTERSON DG, 1994, ENVIRON HEALTH PERSP, V102, P195, DOI 10.1289/ehp.94102s1195
   Pocar P, 2006, REPROD TOXICOL, V22, P242, DOI 10.1016/j.reprotox.2006.04.023
   Puga A, 1997, BIOCHEM PHARMACOL, V54, P1287, DOI 10.1016/S0006-2952(97)00417-6
   Quinn BM, 2003, J AM CHEM SOC, V125, P6644, DOI 10.1021/ja0349305
   Ramadass P, 2003, TOXICOL SCI, V76, P212, DOI 10.1093/toxsci/kfg227
   Schmid G, 2001, NANOSCALE MATERIALS IN CHEMISTRY, P15, DOI 10.1002/0471220620.ch2
   Sergeev AV, 2005, ENVIRON HEALTH PERSP, V113, P756, DOI 10.1289/ehp.7595
   Sigaud M, 2004, J MATER CHEM, V14, P2606, DOI 10.1039/b410534f
   Slim R, 1999, TOXICOL SCI, V52, P232, DOI 10.1093/toxsci/52.2.232
   Tiedje JM, 2006, BIOREMEDIATION OF RELCALCITRANT COMPOUNDS, P147
   Toborek M, 2002, METHOD ENZYMOL, V352, P198
   Venkatachalam K, 2006, J NANOSCI NANOTECHNO, V6, P2408, DOI 10.1166/jnn.2006.520
   Wallace GG, 2002, J NANOSCI NANOTECHNO, V2, P441, DOI 10.1166/jnn.2002.142
   Weng MW, 2004, TOXICOL LETT, V151, P345, DOI 10.1016/j.toxlet.2004.03.007
   Wolfle D, 2000, CARCINOGENESIS, V21, P15, DOI 10.1093/carcin/21.1.15
   Xu J, 2007, IND ENG CHEM RES, V46, P2348, DOI 10.1021/ie0611498
   Yakushiji K, 2005, NAT MATER, V4, P57, DOI 10.1038/nmat1278
   Yan ZP, 2000, J BIOL CHEM, V275, P4949, DOI 10.1074/jbc.275.7.4949
   Ye JS, 2003, BIOELECTROCHEMISTRY, V59, P65, DOI 10.1016/S1567-5394(03)00003-3
   Zhang WX, 1998, CATAL TODAY, V40, P387, DOI 10.1016/S0920-5861(98)00067-4
NR 51
TC 32
Z9 34
U1 0
U2 22
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-3894
J9 J HAZARD MATER
JI J. Hazard. Mater.
PD NOV 30
PY 2008
VL 159
IS 2-3
BP 483
EP 491
DI 10.1016/j.jhazmat.2008.02.109
PG 9
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA 373AC
UT WOS:000260942400043
PM 18423858
OA green_accepted
DA 2018-03-19
ER

PT J
AU Pandya, J
   Yonutas, HM
   Sebastian, A
   Freeman, MR
   Geddes, JW
   Sullivan, PG
AF Pandya, Jignesh D.
   Yonutas, Heather M.
   Sebastian, Andrea
   Freeman, Marc R.
   Geddes, James W.
   Sullivan, Patrick G.
TI INVESTIGATING MITOCHONDRIAL MECHANISMS OF NEUROPROTECTION USING WLDS AND
   SARM-/- MICE FOLLOWING TRAUMATIC BRAIN INJURY
SO JOURNAL OF NEUROTRAUMA
LA English
DT Meeting Abstract
CT 31st Annual National Neurotrauma Symposium
CY AUG 04-07, 2013
CL Nashville, TN
DE mitochondria; neuroprotection; therapeutic target; traumatic brain
   injury; wallerian degeneration
C1 [Pandya, Jignesh] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY USA.
   [Pandya, Jignesh; Geddes, James W.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA.
   [Yonutas, Heather M.; Sebastian, Andrea] Univ Kentucky, Lexington, KY USA.
   [Freeman, Marc R.] Univ Massachusetts, Sch Med, Amherst, MA 01003 USA.
   [Geddes, James W.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr SCoBIRC, Lexington, KY USA.
   [Sullivan, Patrick G.] Univ Kentucky, Chandler Coll Med, Lexington, KY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0897-7151
J9 J NEUROTRAUM
JI J. Neurotrauma
PD AUG
PY 2013
VL 30
IS 15
BP A169
EP A169
PG 1
WC Critical Care Medicine; Clinical Neurology; Neurosciences
SC General & Internal Medicine; Neurosciences & Neurology
GA 191WY
UT WOS:000322446800319
DA 2018-03-20
ER

PT J
AU Zhou, PP
   Ayers, PW
   Liu, SB
   Li, TL
AF Zhou, Panpan
   Ayers, Paul W.
   Liu, Shubin
   Li, Tonglei
TI Natural orbital Fukui function and application in understanding
   cycloaddition reaction mechanisms
SO PHYSICAL CHEMISTRY CHEMICAL PHYSICS
LA English
DT Article
ID CHARGE SENSITIVITY-ANALYSIS; GENERAL CHEMICAL-REACTIONS;
   FRONTIER-ELECTRON THEORY; FUNCTION INDEXES; 1,3-DIPOLAR CYCLOADDITIONS;
   HETEROSUBSTITUTED ANALOGS; LOCAL SOFTNESS; NUMERICAL EVALUATION;
   POPULATION ANALYSIS; HARDNESS TENSOR
AB A new condensed form of the Fukui function, the natural orbital Fukui function (NOFF), is proposed and derived from natural bond orbital occupancy. It is defined as the change in natural bond orbital occupancy upon electronic perturbation (electron addition to, or depletion from, a molecular system). Applying NOFF to a series of cycloaddition reactions (e.g., [4 + 2] and [2 + 1] cycloadditions) illustrates the effectiveness of the concept in interpreting bond breakage and formation mechanisms.
C1 [Zhou, Panpan; Li, Tonglei] Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
   [Ayers, Paul W.] McMaster Univ, Dept Chem, Hamilton, ON L8S 4M1, Canada.
   [Liu, Shubin] Univ N Carolina, Ctr Res Comp, Chapel Hill, NC 27599 USA.
RP Li, TL (reprint author), Univ Kentucky, Dept Pharmaceut Sci, 375 Biopharm Complex,789 S Limestone St, Lexington, KY 40536 USA.
EM tonglei@uky.edu
RI Liu, Shubin/B-1502-2009; Ayers, Paul/A-1154-2008
OI Liu, Shubin/0000-0001-9331-0427; Ayers, Paul/0000-0003-2605-3883
FU NSF [DMR-1006364]; UNC EFRC: Solar Fuels, Energy Frontier Research
   Center; U.S. Department of Energy, Office of Science, Office of Basic
   Energy Sciences [DE-SC0001011]; NSERC; Canada Research Chairs; Sharcnet
FX PZ and TL thank NSF for supporting the study (DMR-1006364). S. B. L. was
   supported as part of the UNC EFRC: Solar Fuels, an Energy Frontier
   Research Center funded by the U.S. Department of Energy, Office of
   Science, Office of Basic Energy Sciences under Award No. DE-SC0001011.
   The work of PWA is supported by NSERC, the Canada Research Chairs, and
   Sharcnet.
CR Anderson JSM, 2007, J CHEM THEORY COMPUT, V3, P358, DOI 10.1021/ct600164j
   Anderson JSM, 2007, J CHEM THEORY COMPUT, V3, P375, DOI 10.1021/ct6001658
   Aurell MJ, 2004, TETRAHEDRON, V60, P11503, DOI 10.1016/j.tet.2004.09.057
   Ayers PW, 2008, J MATH CHEM, V43, P285, DOI 10.1007/s10910-006-9195-5
   Ayers PW, 2007, CHEM-EUR J, V13, P8240, DOI 10.1002/chem.200700365
   Ayers PW, 2006, PHYS CHEM CHEM PHYS, V8, P3387, DOI 10.1039/b606167b
   Ayers PW, 2000, THEOR CHEM ACC, V103, P353, DOI 10.1007/s002149900093
   Ayers PW, 2002, J CHEM PHYS, V116, P8731, DOI 10.1063/1.1467338
   Ayers P. W., 2009, CHEM REACTIVITY THEO, P255
   Baekelandt BG, 1996, J CHEM PHYS, V105, P4664, DOI 10.1063/1.472329
   Balawender R, 1998, J CHEM PHYS, V109, P5203, DOI 10.1063/1.477137
   BECKE AD, 1993, J CHEM PHYS, V98, P5648, DOI 10.1063/1.464913
   Bultinck P, 2003, J MATH CHEM, V34, P67, DOI 10.1023/A:1025136721324
   Bultinck P, 2003, J CHEM PHYS, V118, P4349, DOI 10.1063/1.1542875
   Bultinck P, 2007, J CHEM PHYS, V127, DOI 10.1063/1.2749518
   Bultinck P, 2011, PHYS CHEM CHEM PHYS, V13, P6110, DOI 10.1039/c0cp02268c
   Cabaleiro-Lago EM, 2005, J PHYS CHEM A, V109, P5636, DOI 10.1021/jp050624x
   Chamorro E, 2007, CHEM PHYS LETT, V443, P136, DOI 10.1016/j.cplett.2007.06.025
   Chamorro E, 2005, J CHEM PHYS, V123, DOI 10.1063/1.2033689
   Chamorro E, 2005, J CHEM PHYS, V123, DOI 10.1063/1.1996576
   Chandra AK, 1998, J COMPUT CHEM, V19, P195, DOI 10.1002/(SICI)1096-987X(19980130)19:2<195::AID-JCC12>3.0.CO;2-H
   Chandra AK, 1999, J CHEM SOC PERK T 2, P2117, DOI 10.1039/a904151f
   Chandra AK, 1997, J ORG CHEM, V62, P6417, DOI 10.1021/jo9703055
   Chattaraj PK, 2003, J PHYS CHEM A, V107, P4973, DOI 10.1021/jp034707u
   Chattaraj P. K., 2009, CHEM REACTIVITY THEO
   Chattaraj PK, 2006, CHEM REV, V106, P2065, DOI 10.1021/cr040109f
   Chermette H, 1999, J COMPUT CHEM, V20, P129, DOI 10.1002/(SICI)1096-987X(19990115)20:1<129::AID-JCC13>3.3.CO;2-1
   De Proft F, 2006, J CHEM PHYS, V125, DOI 10.1063/1.2387953
   Domingo LR, 2005, LETT ORG CHEM, V2, P68, DOI 10.2174/1570178053399958
   Domingo LR, 2002, J ORG CHEM, V67, P959, DOI 10.1021/jo011003c
   DUNNING TH, 1989, J CHEM PHYS, V90, P1007, DOI 10.1063/1.456153
   Ess DH, 2006, ADV SYNTH CATAL, V348, P2337, DOI 10.1002/adsc.200600431
   Flores-Moreno R, 2008, J CHEM PHYS, V129, DOI 10.1063/1.3036926
   FOSTER JP, 1980, J AM CHEM SOC, V102, P7211, DOI 10.1021/ja00544a007
   FRISCH MJ, 2004, GAUSSIAN 03 REVISION
   Fuentealba P, 2010, J CHEM THEORY COMPUT, V6, P1470, DOI 10.1021/ct100022w
   FUKUI K, 1952, J CHEM PHYS, V20, P722, DOI 10.1063/1.1700523
   GALVAN M, 1992, J PHYS CHEM-US, V96, P1625, DOI 10.1021/j100183a026
   GALVAN M, 1988, J PHYS CHEM-US, V92, P6470, DOI 10.1021/j100333a056
   Garcia VM, 1996, MOL PHYS, V87, P1395
   Gayatri G, 2005, J CHEM SCI, V117, P573, DOI 10.1007/BF02708364
   Gayatri G, 2009, J PHYS CHEM A, V113, P12013, DOI 10.1021/jp9038072
   Geerlings P, 2003, CHEM REV, V103, P1793, DOI 10.1021/cr990029p
   Gilardoni F, 1998, J PHYS CHEM A, V102, P3607, DOI 10.1021/jp980521x
   Gonzalez-Rivas N, 2005, J CHEM SCI, V117, P555, DOI 10.1007/BF02708362
   Gonzalez-Suarez M, 2012, J ORG CHEM, V77, P90, DOI 10.1021/jo201465g
   Gonzalez-Suarez M, 2010, THEOR CHEM ACC, V126, P45, DOI 10.1007/s00214-009-0674-1
   Goodman L, 2007, J COMPUT CHEM, V28, P269, DOI 10.1002/jcc.20519
   Grigorov M, 1997, INT J QUANTUM CHEM, V61, P551, DOI 10.1002/(SICI)1097-461X(1997)61:3<551::AID-QUA24>3.0.CO;2-A
   Grigorov MG, 1998, J CHEM PHYS, V108, P8790, DOI 10.1063/1.476325
   HOFFMANN R, 1968, ACCOUNTS CHEM RES, V1, P17, DOI 10.1021/ar50001a003
   Huckel E, 1931, Z PHYS, V70, P204, DOI 10.1007/BF01339530
   Jones M., 2000, ORGANIC CHEM
   Komorowski L, 2009, J CHEM PHYS, V131, DOI 10.1063/1.3239503
   KORCHOWIEC J, 1994, CHEM PHYS LETT, V222, P58, DOI 10.1016/0009-2614(94)00319-X
   LEE CT, 1988, PHYS REV B, V37, P785, DOI 10.1103/PhysRevB.37.785
   Li TL, 2005, J AM CHEM SOC, V127, P1364, DOI 10.1021/ja0476009
   Liu SB, 2009, ACTA PHYS-CHIM SIN, V25, P590, DOI 10.3866/PKU.WHXB20090332
   Liu SB, 2011, J PHYS CHEM A, V115, P4738, DOI 10.1021/jp112319d
   Melin J, 2007, J PHYS CHEM A, V111, P10017, DOI 10.1021/jp075573d
   Mendez F, 1998, J PHYS CHEM A, V102, P6292, DOI 10.1021/jp973016t
   Morell C, 2008, PHYS CHEM CHEM PHYS, V10, P7239, DOI 10.1039/b810343g
   NALEWAJSKI RF, 1992, INT J QUANTUM CHEM, V44, P67, DOI 10.1002/qua.560440106
   NALEWAJSKI RF, 1992, INT J QUANTUM CHEM, V43, P353, DOI 10.1002/qua.560430306
   Nalewajski RF, 1996, TOP CURR CHEM, V183, P25
   Nalewajski R.F., 1997, CHARGE SENSITIVITY A
   Nguyen LT, 2001, J ORG CHEM, V66, P4316, DOI 10.1021/jo015584h
   PARR RG, 1983, J AM CHEM SOC, V105, P7512, DOI 10.1021/ja00364a005
   PARR RG, 1995, ANNU REV PHYS CHEM, V46, P701, DOI 10.1146/annurev.pc.46.100195.003413
   PARR RG, 1984, J AM CHEM SOC, V106, P4049, DOI 10.1021/ja00326a036
   Parr RG, 1989, DENSITY FUNCTIONAL T
   PERDEW JP, 1982, PHYS REV LETT, V49, P1691, DOI 10.1103/PhysRevLett.49.1691
   Pinter B, 2005, J CHEM SCI, V117, P561, DOI 10.1007/BF02708363
   REED AE, 1985, J CHEM PHYS, V83, P735, DOI 10.1063/1.449486
   REED AE, 1988, CHEM REV, V88, P899, DOI 10.1021/cr00088a005
   ROBLES J, 1984, J AM CHEM SOC, V106, P3723, DOI 10.1021/ja00325a003
   Rodriguez-Otero J, 2003, CHEM-EUR J, V9, P1837, DOI 10.1002/chem.200390211
   Rodriguez-Otero J, 2002, ANGEW CHEM INT EDIT, V41, P1147
   Rodriguez-Otero J, 1999, J ORG CHEM, V64, P6842, DOI 10.1021/jo990881w
   Rodriguez-Otero J., 2002, ANGEW CHEM, V114, P1195
   Roy RK, 1999, J CHEM PHYS, V110, P8236, DOI 10.1063/1.478792
   Roy RK, 2000, J CHEM PHYS, V113, P1372, DOI 10.1063/1.481927
   Roy RK, 2001, J CHEM PHYS, V115, P2901, DOI 10.1063/1.1386699
   Saha S, 2010, PHYS CHEM CHEM PHYS, V12, P9328, DOI 10.1039/b925441b
   Shaik S, 2008, CHEMIST'S GUIDE TO VALENCE BOND THEORY, P1
   Torrent-Sucarrat M, 2008, J COMPUT CHEM, V29, P1064, DOI 10.1002/jcc.20866
   Vanfleteren D, 2010, J CHEM PHYS, V133, DOI 10.1063/1.3521493
   Xia Y, 2008, J PHYS CHEM A, V112, P9970, DOI 10.1021/jp805410c
   YANG W, 1986, J AM CHEM SOC, V108, P5708, DOI 10.1021/ja00279a008
   Yang WT, 2000, PHYS REV LETT, V84, P5172, DOI 10.1103/PhysRevLett.84.5172
   YANG WT, 1985, P NATL ACAD SCI USA, V82, P6723, DOI 10.1073/pnas.82.20.6723
NR 91
TC 12
Z9 12
U1 0
U2 35
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1463-9076
EI 1463-9084
J9 PHYS CHEM CHEM PHYS
JI Phys. Chem. Chem. Phys.
PY 2012
VL 14
IS 28
BP 9890
EP 9896
DI 10.1039/c2cp40488e
PG 7
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA 967EX
UT WOS:000305890300008
PM 22711288
DA 2018-03-20
ER

PT J
AU Rankin, SE
   Xing, R
   Knutson, BL
   Lehmler, HJ
AF Rankin, Stephen E.
   Xing, Rong
   Knutson, Barbara L.
   Lehmler, Hans-Joachim
TI COLL 238-Synthesis and tuning of bimodal mesoporous silica by combined
   hydrocarbon/fluorocarbon surfactant templating
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
CT 235th American-Chemical-Society National Meeting
CY APR 06-10, 2008
CL New Orleans, LA
SP Amer Chem Soc
C1 [Rankin, Stephen E.; Knutson, Barbara L.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Xing, Rong] Ohio State Univ, Dept Chem & Biol Engn, Columbus, OH 43210 USA.
   [Lehmler, Hans-Joachim] Univ Iowa, Dept Occupat & Environm Hlth, Iowa City, IA 52242 USA.
EM srankin@engr.uky.edu; xing@chbmeng.ohio-state.edu;
   bknutson@engr.uky.edu; hans-joachim-lehmler@uiowa.edu
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD APR 6
PY 2008
VL 235
MA 238-COLL
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA 519OA
UT WOS:000271775103737
DA 2018-03-20
ER

PT J
AU Wu, X
   Zhang, WF
   Hayes, D
   Mansour, HM
AF Wu, Xiao
   Zhang, Weifen
   Hayes, Don, Jr.
   Mansour, Heidi M.
TI Physicochemical characterization and aerosol dispersion performance of
   organic solution advanced spray-dried cyclosporine A multifunctional
   particles for dry powder inhalation aerosol delivery
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE dry powder inhaler (DPI); polypeptide drug; lung surfactant; calcineurin
   inhibitor; lung immunosuppression; dipalmitoylphosphatidylcholine
   (DPPC); dipalmitoylphosphatidylglycerol (DPPG); targeted lung
   immunosuppression
ID STANDARDIZED ENTRAINMENT TUBES; AIR-WATER-INTERFACE; PULMONARY
   SURFACTANT; LUNG-TRANSPLANT; PHYSICAL-CHARACTERIZATION; INHALED
   CYCLOSPORINE; NANOCARRIER SYSTEMS; SOLID DISPERSION; DRUG BLENDS;
   DEPOSITION
AB In this systematic and comprehensive study, inhalation powders of the polypeptide immunosuppressant drug - cyclosporine A - for lung delivery as dry powder inhalers (DPIs) were successfully designed, developed, and optimized. Several spray drying pump rates were rationally chosen. Comprehensive physicochemical characterization and imaging was carried out using scanning electron microscopy, hot-stage microscopy, differential scanning calorimetry, powder X-ray diffraction, Karl Fischer titration, laser size diffraction, and gravimetric vapor sorption. Aerosol dispersion performance was conducted using a next generation impactor with a Food and Drug Administration-approved DPI device. These DPIs displayed excellent aerosol dispersion performance with high values in emitted dose, respirable fraction, and fine particle fraction. In addition, novel multifunctional inhalation aerosol powder formulations of cyclosporine A with lung surfactant-mimic phospholipids were also successfully designed and developed by advanced organic solution cospray drying in closed mode. The lung surfactant-mimic phospholipids were 1,2-dipalmitoyl-sn-glycero-3-phosphocholine and 1,2-dipalmitoyl-sn-glycero-3-(phosphor-rac-1-glycerol). These cyclosporine A lung surfactant-mimic aerosol powder formulations were comprehensively characterized. Powder X-ray diffraction and differential scanning calorimetry confirmed that the phospholipid bilayer structure in the solid state was preserved following advanced organic solution spray drying in closed mode. These novel multifunctional inhalation powders were optimized for DPI delivery with excellent aerosol dispersion performance and high aerosol performance parameters.
C1 [Wu, Xiao; Zhang, Weifen; Mansour, Heidi M.] Univ Kentucky, Drug Dev Div, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
   [Zhang, Weifen] Weifang Med Univ, Coll Pharm & Biol Sci, Weifang, Peoples R China.
   [Hayes, Don, Jr.] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA.
   [Hayes, Don, Jr.] Ohio State Univ, Coll Med, Dept Internal Med, Nationwide Childrens Hosp,Lung & Heart Lung Trans, Columbus, OH 43210 USA.
   [Hayes, Don, Jr.] Ohio State Univ, Davis Heart & Lung Res Inst, Columbus, OH 43210 USA.
   [Mansour, Heidi M.] Univ Kentucky, Ctr Membrane Sci, Lexington, KY 40536 USA.
RP Mansour, HM (reprint author), Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Drug Dev Div, 789 S Limestone St, Lexington, KY 40536 USA.
EM heidi.mansour@uky.edu
CR Alves GP, 2004, POWDER TECHNOL, V145, P139, DOI 10.1016/j.powtec.2004.06.008
   Andya JD, 1999, PHARMACEUT RES, V16, P350, DOI 10.1023/A:1018805232453
   Behr J, 2009, J AEROSOL MED PULM D, V22, P121, DOI 10.1089/jamp.2008.0714
   Burkart G.J., 2003, PHARM RES, V20, P252
   Chen XX, 2002, INT J PHARM, V242, P3, DOI 10.1016/S0378-5173(02)00147-3
   Corcoran TE, 2004, EUR RESPIR J, V23, P378, DOI 10.1183/09031936.04.00059204
   DOLOVICH M, 1993, AEROSOL SCI TECH, V18, P230, DOI 10.1080/02786829308959600
   Ganguly S, 2008, J AEROSOL MED PULM D, V21, P343, DOI 10.1089/jamp.2007.0675
   Goerke J, 1998, BBA-MOL BASIS DIS, V1408, P79, DOI 10.1016/S0925-4439(98)00060-X
   Hayes D, 2012, TRANSPL INFECT DIS, V14, P548, DOI 10.1111/j.1399-3062.2012.00748.x
   Hayes D, 2010, TRANSPL P, V42, P3876, DOI 10.1016/j.transproceed.2010.08.029
   Hickey A.J., 2009, MODERN PHARM, V2, P191
   Hickey A.J., 2008, MODIFIED RELEASE DRU, V2, P573
   Hickey AJ, 2007, J PHARM SCI-US, V96, P1302, DOI 10.1002/jps.20943
   Hickey AJ, 2007, J PHARM SCI-US, V96, P1282, DOI 10.1002/jps.20916
   Holt J., 2009, MMAD CALC
   Iacono AT, 2004, EUR RESPIR J, V23, P384, DOI 10.1183/09031936.04.00058504
   KAHAN BD, 1989, NEW ENGL J MED, V321, P1725
   KATAKAI R, 1984, BIOPOLYMERS, V23, P1411, DOI 10.1002/bip.360230722
   Li XJ, 2011, AAPS PHARMSCITECH, V12, P1420, DOI 10.1208/s12249-011-9704-0
   Mansour H, 2001, LANGMUIR, V17, P6622, DOI 10.1021/la0108454
   Mansour HM, 2008, MOL PHARMACEUT, V5, P681, DOI 10.1021/mp700123p
   Mansour HM, 2007, LANGMUIR, V23, P3809, DOI 10.1021/la063053o
   Mansour HM, 2007, J PHARM SCI-US, V96, P377, DOI 10.1002/jps.20810
   Mansour HM, 2010, J PHARM SCI-US, V99, P3430, DOI 10.1002/jps.22101
   Mansour HM, 2009, INT J NANOMED, V4, P299
   Mansour HM, 2011, LIPIDS NANOTECHNOLOG, P221
   Mansour HM, 2013, NANOMEDICIN IN PRESS
   Masters K., 1991, SPRAY DRYING HDB
   Matsuda S, 2000, IMMUNOPHARMACOLOGY, V47, P119, DOI 10.1016/S0162-3109(00)00192-2
   Meenach SA, 2013, INT J NANOMED, V8, P275, DOI 10.2147/IJN.S30724
   Mitruka SN, 2000, J HEART LUNG TRANSPL, V19, P969, DOI 10.1016/S1053-2498(00)00176-5
   Morrow MR, 2007, BIOPHYS J, V93, P164, DOI 10.1529/biophysj.106.102681
   Niven RW, 2011, ADV DRUG DELIVER REV, V63, P88, DOI 10.1016/j.addr.2010.10.004
   Onoue S, 2009, J CONTROL RELEASE, V138, P16, DOI 10.1016/j.jconrel.2009.04.014
   Park CW, 2011, EUROPEAN PHARM REV, V16, P32
   Patton JS, 2007, NAT REV DRUG DISCOV, V6, P67, DOI 10.1038/nrd2153
   Postle AD, 2001, COMP BIOCHEM PHYS A, V129, P65, DOI 10.1016/S1095-6433(01)00306-3
   Rhee YS, 2011, INT J NANOTECHNOL, V8, P84, DOI 10.1504/IJNT.2011.037172
   Rohatagi S, 2000, J CLIN PHARMACOL, V40, P1211
   Shirbacheh MV, 1998, TRANSPLANT P, V30, P2739, DOI 10.1016/S0041-1345(98)00800-8
   Sollohub K, 2010, J PHARM SCI-US, V99, P587, DOI 10.1002/jps.21963
   Suarez S, 2000, Respir Care, V45, P652
   Tam JM, 2008, J PHARM SCI-US, V97, P4915, DOI 10.1002/jps.21367
   Tandya A, 2006, J SUPERCRIT FLUID, V37, P272, DOI 10.1016/j.supflu.2005.10.004
   Underwood SL, 2001, EUR J PHARMACOL, V420, P165, DOI 10.1016/S0014-2999(01)00975-X
   [Anonymous], 2006, USP 29 NF 24 US PHAR, V29/24, P2617
   Veldhuizen R, 1998, BBA-MOL BASIS DIS, V1408, P90, DOI 10.1016/S0925-4439(98)00061-1
   WALDREP JC, 1993, INT J PHARM, V97, P205, DOI 10.1016/0378-5173(93)90140-B
   Willis L, 2012, LUNG, V190, P251, DOI 10.1007/s00408-011-9360-x
   Wu X, 2013, DRUG DES DEV THER, V7, P59, DOI [10.2147/DDDT.540166, 10.2147/DDDT.S40166]
   Wu XA, 2010, KONA POWDER PART J, P3
   Wu XA, 2011, INT J NANOTECHNOL, V8, P115, DOI 10.1504/IJNT.2011.037173
   Xu Z, 2010, J PHARM SCI-US, V99, P3415, DOI 10.1002/jps.22100
   Xu Z, 2010, J PHARM SCI-US, V99, P3398, DOI 10.1002/jps.22107
   Yamasaki K, 2011, INT J PHARMACEUT, V420, P34, DOI 10.1016/j.ijpharm.2011.08.010
   Zijlstra GS, 2007, AAPS J, V9, pE190, DOI 10.1208/aapsj0902021
NR 57
TC 23
Z9 23
U1 1
U2 13
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2013
VL 8
BP 1269
EP 1283
DI 10.2147/IJN.S40904
PG 15
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA 130MU
UT WOS:000317922700113
PM 23569375
OA gold
DA 2018-03-20
ER

PT J
AU Zhang, SX
   Holmberg, EG
   Geddes, JW
AF Zhang, Shu-Xin
   Holmberg, Eric G.
   Geddes, James W.
TI Artifactual dendritic beading in rat spinal cord induced by perfusion
   with cold saline and paraformaldehyde
SO JOURNAL OF NEUROSCIENCE METHODS
LA English
DT Article
DE perfusion; fixative; paraformaldehyde; spinal cord injury; rat
ID MICROTUBULE-ASSOCIATED PROTEIN-2; GLUTAMATE-RECEPTOR ACTIVATION;
   CALPAIN; INJURY; DEGRADATION; HIPPOCAMPUS; SPECTRIN; NEURONS; SITES;
   CELLS
AB Extensive dendritic beading of MAP2 (microtubule-associated protein 2) immunoreactivity has previously been observed in the contused rat spinal cord. However, we have also observed dendritic beading in occasional uninjured animals. The purpose of this study was to examine the possibility that perfusion conditions contributed to the dendritic beading. Under deep anesthesia, uninjured rats (adult female Long-Evans, 200-225 g) were transcardially perfused with 0.9%,saline solution followed by 4% paraformaldehyde at cold (4 degrees C) or warm (20 degrees C) temperature, and at a low (20 ml/min) or high (50 ml/min) flow rate. Dendrites were visualized by MAP2 immunoreactivity. The results demonstrate that perfusion with cold solutions at a high flow rate induces pronounced dendritic beading, and when perfused at a low flow rate, results in moderate dendritic beading. Warm perfusates did not induce dendrific beading when administered at a low flow rate, but occasional beading was observed with a high flow rate. Western blots revealed spectrin breakdown, but not MAP2 loss, in rats perfused with cold saline solution at a high flow rate, conditions that also resulted in dendritic beading. These findings demonstrate that dendritic morphology is sensitive to both temperature and flow rate of the perfusate. Warm fixative and a low perfusion flow rate minimized the perfusion-induced dendritic beading. (c) 2007 Published by Elsevier B.V.
C1 Spinal Cord Soc Res Ctr, Ft Collins, CO 80526 USA.
   Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA.
   Univ Alaska, Anchorage, AK 99508 USA.
RP Zhang, SX (reprint author), Spinal Cord Soc Res Ctr, 2401 Res Blvd,Suite 104, Ft Collins, CO 80526 USA.
EM szhang@scs.cbeyond.com
FU NINDS NIH HHS [R01 NS045726]
CR Al-Noori S, 2000, NEUROSCIENCE, V101, P337, DOI 10.1016/S0306-4522(00)00384-5
   Banik NL, 1997, BRAIN RES, V752, P301, DOI 10.1016/S0006-8993(96)01488-6
   BINDOKAS VP, 1995, J NEUROSCI, V15, P6999
   CAJAL SRY, 1928, HIST NEUROSCIENCE, P769
   EMERY DG, 1995, BRAIN RES, V692, P161, DOI 10.1016/0006-8993(95)00726-7
   Faddis BT, 1997, J NEUROSCI, V17, P951
   Hasbani MJ, 2001, J NEUROSCI, V21, P2393
   Hermanns S, 2001, BRAIN RES PROTOC, V7, P162, DOI 10.1016/S1385-299X(01)00059-9
   HORI N, 1994, NEUROSCI LETT, V173, P75, DOI 10.1016/0304-3940(94)90153-8
   HOSKISON MM, 2007, CALCIUM DEPENDENT NM
   JOHNSON GVW, 1991, J NEUROCHEM, V56, P1630, DOI 10.1111/j.1471-4159.1991.tb02061.x
   Kirov SA, 2004, NEUROSCIENCE, V127, P69, DOI 10.1016/j.neuroscience.2004.04.052
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   MATESIC DF, 1994, J NEUROCHEM, V63, P1012
   Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683
   Ochs S, 1997, PROG NEUROBIOL, V52, P391, DOI 10.1016/S0301-0082(97)00022-1
   Pang JH, 1996, EXP GERONTOL, V31, P97, DOI 10.1016/0531-5565(95)02019-5
   Park JS, 1996, NEUROBIOL DIS, V3, P215, DOI 10.1006/nbdi.1996.0022
   Ray SK, 1999, BRAIN RES, V816, P375, DOI 10.1016/S0006-8993(98)01128-7
   Roelandse M, 2004, J NEUROSCI, V24, P7843, DOI 10.1523/JNEUROSCI.2872-04.2004
   Schumacher PA, 1999, NEUROSCIENCE, V91, P733, DOI 10.1016/S0306-4522(98)00552-1
   Swann JW, 2000, HIPPOCAMPUS, V10, P617, DOI 10.1002/1098-1063(2000)10:5<617::AID-HIPO13>3.0.CO;2-R
   Yang XF, 2006, NEUROBIOL DIS, V23, P637, DOI 10.1016/j.nbd.2006.05.006
   Yu WR, 2000, ACTA NEUROPATHOL, V100, P546, DOI 10.1007/s004010000206
   Zhang SX, 2000, J NEUROPATH EXP NEUR, V59, P287, DOI 10.1093/jnen/59.4.287
NR 25
TC 4
Z9 4
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-0270
J9 J NEUROSCI METH
JI J. Neurosci. Methods
PD JUN 15
PY 2007
VL 163
IS 1
BP 38
EP 43
DI 10.1016/j.jneumeth.2007.02.013
PG 6
WC Biochemical Research Methods; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 174HX
UT WOS:000246934100006
PM 17397933
DA 2018-03-20
ER

PT J
AU Zhan, X
   Wu, J
   Chen, ZQ
   Hinds, BJ
AF Zhan, Xin
   Wu, Ji
   Chen, Zhiqiang
   Hinds, Bruce J.
TI Single-step electrochemical functionalization of double-walled carbon
   nanotube (DWCNT) membranes and the demonstration of ionic rectification
SO NANOSCALE RESEARCH LETTERS
LA English
DT Article
DE Carbon nanotube membranes; Rectification; Voltage gatekeeper; Amine
   electrooxidation
ID GLASSY-CARBON; COVALENT MODIFICATION; SURFACE MODIFICATION;
   METAL-SURFACES; ELECTRODE MATERIALS; DIAZONIUM SALTS; GOLD ELECTRODES;
   REDOX PROBES; OXIDATION; ATTACHMENT
AB Carbon nanotube (CNT) membranes allow the mimicking of natural ion channels for applications in drug delivery and chemical separation. Double-walled carbon nanotube membranes were simply functionalized with dye in a single step instead of the previous two-step functionalization. Non-faradic electrochemical impedance spectra indicated that the functionalized gatekeeper by single-step modification can be actuated to mimic the protein channel under bias. This functional chemistry was proven by a highly efficient ion rectification, wherein the highest experimental rectification factor of ferricyanide was up to 14.4. One-step functionalization by electrooxidation of amine provides a simple and promising functionalization chemistry for the application of CNT membranes.
C1 [Zhan, Xin; Hinds, Bruce J.] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
   [Wu, Ji; Chen, Zhiqiang; Hinds, Bruce J.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Hinds, BJ (reprint author), Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
EM bjhinds@engr.uky.edu
RI WU, JI/J-4580-2016
FU NIDA [5R01DA018822-05]; DOE EPSCoR [DE-FG02-07ER46375]; DARPA
   [W911NF-09-1-0267]
FX This work was supported by NIDA, #5R01DA018822-05, DOE EPSCoR,
   DE-FG02-07ER46375, and DARPA, W911NF-09-1-0267. Critical infrastructure
   provided by the University of KY Center for Nanoscale Science and
   Engineering.
CR Adenier A, 2004, LANGMUIR, V20, P8243, DOI 10.1021/la049194c
   Aramata A, 2003, THIN SOLID FILMS, V424, P239, DOI 10.1016/S0040-6090(02)01102-1
   Bahr JL, 2001, J AM CHEM SOC, V123, P6536, DOI 10.1021/ja010462s
   Bahr JL, 2002, J MATER CHEM, V12, P1952, DOI 10.1039/b201013p
   BARBIER B, 1990, J ELECTROCHEM SOC, V137, P1757, DOI 10.1149/1.2086794
   Belanger D, 2011, CHEM SOC REV, V40, P3995, DOI 10.1039/c0cs00149j
   Bruce H., 2012, CURRENT OPINION SOLI, V16, P1
   Buriez O, 2008, J ELECTROANAL CHEM, V619, P169, DOI 10.1016/j.jelechem.2008.04.012
   Chehimi MM, 2008, J PHYS CHEM C, V112, P18559, DOI 10.1021/jp807044j
   Cheng WWL, 2011, P NATL ACAD SCI USA, V108, P5272, DOI 10.1073/pnas.1014186108
   Cruickshank AC, 2007, ELECTROCHEM COMMUN, V9, P1456, DOI 10.1016/j.elecom.2007.02.004
   DEINHAMMER RS, 1994, LANGMUIR, V10, P1306, DOI 10.1021/la00016a054
   Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69
   Gallardo I, 2006, J PHYS CHEM B, V110, P19521, DOI 10.1021/jp063368c
   Gao GY, 2007, ELECTROCHEM COMMUN, V9, P1582, DOI 10.1016/j.elecom.2007.02.026
   Ghanem MA, 2008, J MATER CHEM, V18, P4917, DOI 10.1039/b809040h
   Herlem G, 1997, J ELECTROANAL CHEM, V435, P259, DOI 10.1016/S0022-0728(97)00271-4
   Herlem G, 2000, J ELECTROCHEM SOC, V147, P597, DOI 10.1149/1.1393239
   Herlem M, 2002, ELECTROCHIM ACTA, V47, P2597, DOI 10.1016/S0013-4686(02)00120-2
   Hinds BJ, 2004, SCIENCE, V303, P62, DOI 10.1126/science.1092048
   Hou X, 2011, CHEM SOC REV, V40, P2385, DOI 10.1039/c0cs00053a
   Jensen MO, 2010, P NATL ACAD SCI USA, V107, P5833, DOI 10.1073/pnas.0911691107
   Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580
   Kim TH, 2010, ELECTROCHEM COMMUN, V12, P788, DOI 10.1016/j.elecom.2010.03.034
   Li XF, 2004, J ELECTROANAL CHEM, V569, P79, DOI 10.1016/j.jelechem.2004.01.036
   Liu GZ, 2005, CHEM PHYS, V319, P136, DOI 10.1016/j.chemphys.2005.03.033
   Liu JY, 2000, LANGMUIR, V16, P7471, DOI 10.1021/la9913506
   Lopez-Lorente AI, 2010, ANAL CHEM, V82, P5399, DOI 10.1021/ac902629n
   Majumder M, 2005, NATURE, V438, P44, DOI 10.1038/43844a
   Majumder M, 2005, J AM CHEM SOC, V127, P9062, DOI 10.1021/ja043013b
   Majumder M, 2008, J MEMBRANE SCI, V316, P89, DOI 10.1016/j.memsci.2007.09.068
   Majumder M, 2007, LANGMUIR, V23, P8624, DOI 10.1021/la700686k
   Majumder M, 2011, ACS NANO, V5, P3867, DOI 10.1021/nn200222g
   McCreery RL, 2008, CHEM REV, V108, P2646, DOI 10.1021/cr068076m
   Nednoor P, 2007, J MATER CHEM, V17, P1755, DOI 10.1039/b703365f
   Pinson J, 2005, CHEM SOC REV, V34, P429, DOI 10.1039/b406228k
   Sandroni M, 2010, CATAL TODAY, V158, P22, DOI 10.1016/j.cattod.2010.06.025
   SANO S, 1993, BIOMATERIALS, V14, P817, DOI 10.1016/0142-9612(93)90003-K
   Scruggs NR, 2009, NANO LETT, V9, P3853, DOI 10.1021/nl9020683
   Siwy Z, 2004, J AM CHEM SOC, V126, P10850, DOI 10.1021/ja047675c
   Siwy ZS, 2010, CHEM SOC REV, V39, P1115, DOI 10.1039/b909105j
   Su X, 2012, J MATER CHEM, V22, P7979, DOI 10.1039/c2jm15395e
   Tanaka M, 2010, LANGMUIR, V27, P170
   Vlassiouk I, 2007, NANO LETT, V7, P552, DOI 10.1021/nl062924b
   Wu J, 2012, CHEM COMMUN, V48, P7979, DOI 10.1039/c2cc33355d
   Wu J, 2011, NANOSCALE, V3, P3321, DOI 10.1039/c1nr10303b
   Wu J, 2010, P NATL ACAD SCI USA, V107, P11698, DOI 10.1073/pnas.1004714107
   Yan RX, 2009, NANO LETT, V9, P3820, DOI 10.1021/nl9020123
   Yang L, 2007, ELECTROCHIM ACTA, V53, P777, DOI 10.1016/j.electacta.2007.07.052
   Yin C, 2003, J BIOMED MATER RES A, V67A, P1093, DOI 10.1002/jbm.a.10033
NR 50
TC 9
Z9 9
U1 2
U2 39
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1931-7573
J9 NANOSCALE RES LETT
JI Nanoscale Res. Lett.
PD JUN 10
PY 2013
VL 8
AR 279
DI 10.1186/1556-276X-8-279
PG 11
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary;
   Physics, Applied
SC Science & Technology - Other Topics; Materials Science; Physics
GA 185GH
UT WOS:000321954400001
PM 23758999
OA gold
DA 2018-03-20
ER

PT J
AU Chen, ZQ
   Akenhead, MA
   Sun, XH
   Sapper, H
   Shin, HY
   Hinds, BJ
AF Chen, Zhiqiang
   Akenhead, Michael L.
   Sun, Xinghua
   Sapper, Harrison
   Shin, Hainsworth Y.
   Hinds, Bruce J.
TI Flow-Through Electroporation of HL-60 White Blood Cell Suspensions using
   Nanoporous Membrane Electrodes
SO ADVANCED HEALTHCARE MATERIALS
LA English
DT Article
DE cell electroporation; electrophoresis pumping; nanoporous membrane
   electrodes; white blood cells
ID MAMMALIAN-CELLS; MICROFLUIDIC ELECTROPORATION; CONSTANT VOLTAGE; GENE
   DELIVERY; TRANSFECTION; CAPILLARY; VECTORS
AB A flow-through electroporation system, based on a novel nanoporous membrane/electrode design, for the delivery of cell wall-impermeant molecules into model leukocytes, HL-60 promyelocytes, was demonstrated. The ability to apply low voltages to cell populations, with nm-scale concentrated electric field in a periodic array, contributes to high cell viability. With applied biases of 1-4V, delivery of target molecules was achieved with 90% viability and up to 65% transfection efficiency. More importantly, the system allowed electrophoretic pumping of molecules from a microscale reservoir across the membrane/electrode system into a microfluidic flow channel for transfection of cells, a design that can reduce reagent amount by eightfold compared to current strategies. The flow-through system, which forces intimate membrane/electrode contact by using a 10m channel height, can be easily scaled-up by adjusting the microfluidic channel geometry and/or the applied voltage pulse frequency to control cell residence times at the cell membrane/electrode interface. The demonstrated system shows promise in clinical applications where low-cost, high cell viability and high volume transfection methods are needed without the risk of viral vectors. In particular genetic modification of freely mobile white blood cells to either target disease cells or to express desired protein/enzyme biomolecules is an important target platform enabled by this device system.
C1 [Chen, Zhiqiang; Sun, Xinghua; Sapper, Harrison] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Akenhead, Michael A.; Shin, Hainsworth Y.] Univ Kentucky, Ctr Biomed Engn, Lexington, KY 40506 USA.
   [Hinds, Bruce J.] Univ Washington, Dept Mat Engn, Seattle, WA 98195 USA.
   [Chen, Zhiqiang] Bristol Myers Squibb, Biol Proc Dev, Devens, MA 01434 USA.
RP Shin, HY (reprint author), Univ Kentucky, Ctr Biomed Engn, Lexington, KY 40506 USA.; Hinds, BJ (reprint author), Univ Washington, Dept Mat Engn, Seattle, WA 98195 USA.
EM hy.shin@uky.edu; bjhinds@uw.edu
FU NIH NIDA [5R01DA018822-05]; DARPA [W911NF-09-1-0267]
FX The authors thank the Center for Nanoscale Science and Engineering for
   critical infrastructure. This work was supported by NIH NIDA,
   #5R01DA018822-05, and DARPA, W911NF-09-1-0267.
CR Chen ZQ, 2014, ADV FUNCT MATER, V24, P4317, DOI 10.1002/adfm.201303707
   Condreay JP, 1999, P NATL ACAD SCI USA, V96, P127, DOI 10.1073/pnas.96.1.127
   CONE RD, 1984, P NATL ACAD SCI-BIOL, V81, P6349, DOI 10.1073/pnas.81.20.6349
   Corovic S, 2008, IEEE T PLASMA SCI, V36, P1665, DOI 10.1109/TPS.2008.2000996
   DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127
   FELGNER PL, 1989, NATURE, V337, P387, DOI 10.1038/337387a0
   Fox MB, 2006, ANAL BIOANAL CHEM, V385, P474, DOI 10.1007/s00216-006-0327-3
   Ganatella P. J., 2001, BIOPHYS J, V80, P755
   Geng T, 2011, NAT PROTOC, V6, P1192, DOI 10.1038/nprot.2011.360
   Geng T, 2010, J CONTROL RELEASE, V144, P91, DOI 10.1016/j.jconrel.2010.01.030
   Guignet EG, 2008, NAT METHODS, V5, P393, DOI [10.1038/nmeth.1201, 10.1038/NMETH.1201]
   Haney MJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061852
   Ishibashi T, 2007, SENSOR ACTUAT B-CHEM, V128, P5, DOI 10.1016/j.snb.2007.05.027
   Kim JA, 2008, BIOSENS BIOELECTRON, V23, P1353, DOI 10.1016/j.bios.2007.12.009
   Lam P, 1999, J ELECTROCHEM SOC, V146, P2517, DOI 10.1149/1.1391964
   De Laporte L., 2006, BIOMATERIALS, V27, P947
   Li WJ, 2004, ADV DRUG DELIVER REV, V56, P967, DOI 10.1016/j.addr.2003.10.041
   Lin YC, 2004, LAB CHIP, V4, P104, DOI 10.1039/b312804k
   Liu GJ, 2010, BIOMATERIALS, V31, P7575, DOI 10.1016/j.biomaterials.2010.06.021
   Liu Q, 2003, GENE THER, V10, P935, DOI 10.1038/sj.gt.3302036
   Liu Z, 2007, ANGEW CHEM INT EDIT, V46, P2023, DOI 10.1002/anie.200604295
   Lu H, 2005, LAB CHIP, V5, P23, DOI 10.1039/b406205a
   Movahed S, 2011, MICROFLUID NANOFLUID, V10, P703, DOI 10.1007/s10404-010-0716-y
   Pedraza CE, 2008, BIOMATERIALS, V29, P3384, DOI 10.1016/j.biomaterials.2008.04.043
   Polson NA, 2000, ANAL CHEM, V72, P1088, DOI 10.1021/ac9912698
   Porter DL, 2011, NEW ENGL J MED, V365, P725, DOI 10.1056/NEJMoa1103849
   Sunkara V, 2012, RSC ADV, V2, P9066, DOI 10.1039/c2ra20880f
   Tomanin R, 2004, CURR GENE THER, V4, P357
   Wang HY, 2008, BIOTECHNOL BIOENG, V100, P579, DOI 10.1002/bit.21784
   Wang HY, 2006, ANAL CHEM, V78, P5158, DOI 10.1021/ac060733n
   Yin L. H., 1998, STEM CELLS, V16S1, P247
   Zhan YH, 2012, J CONTROL RELEASE, V160, P570, DOI 10.1016/j.jconrel.2012.04.006
   Zhan YH, 2009, ANAL CHEM, V81, P2027, DOI 10.1021/ac9001172
NR 33
TC 0
Z9 0
U1 3
U2 12
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2192-2640
EI 2192-2659
J9 ADV HEALTHC MATER
JI Adv. Healthc. Mater.
PD AUG 24
PY 2016
VL 5
IS 16
BP 2105
EP 2112
DI 10.1002/adhm.201600204
PG 8
WC Engineering, Biomedical; Nanoscience & Nanotechnology; Materials
   Science, Biomaterials
SC Engineering; Science & Technology - Other Topics; Materials Science
GA DV9RM
UT WOS:000383278800012
PM 27377174
DA 2018-03-19
ER

PT J
AU Ramineni, SK
   Fowler, CB
   Fisher, PD
   Cunningham, LL
   Puleo, DA
AF Ramineni, Sandeep K.
   Fowler, Craig B.
   Fisher, Paul D.
   Cunningham, Larry L., Jr.
   Puleo, David A.
TI Effects of epidermal growth factor-loaded mucoadhesive films on wounded
   oral tissue rafts
SO BIOMEDICAL MATERIALS
LA English
DT Article
DE mucoadhesive films; epidermal growth factor (EGF); epithelial rafts;
   controlled release; hyperparakeratosis
ID EPITHELIAL-CELL LINE; FACTOR RECEPTOR; PHYSIOLOGICAL LEVELS; MUCOSA
   REGENERATION; DRUG-DELIVERY; DIFFERENTIATION; EXPRESSION; LEUKOPLAKIA;
   MIGRATION; IMIQUIMOD
AB Current treatments for traumatic oral mucosal wounds include the gold standard of autologous tissue and alternative tissue-engineered grafts. While use of autografts has disadvantages of minimal availability of oral keratinized tissue, second surgery, and donor site discomfort, tissue-engineered grafts are limited by their unavailability as off-the-shelf products owing to their fabrication time of 4-8 weeks. Hence, the current work aimed to develop a potentially cost-effective, readily available device capable of enhancing native mucosal regeneration. Considering the key role of epidermal growth factor (EGF) in promoting mucosal wound regeneration and the advantages of mucoadhesive delivery systems, mucoadhesive films composed of polyvinylpyrrolidone and carboxymethylcellulose were developed to provide sustained release of EGF for a minimum of 6 h. Bioactivity of released EGF supernatants was then confirmed by its ability to promote proliferation of BALB/3T3 fibroblasts. Efficacy of the developed system was then investigated in vitro using buccal tissues (ORL 300-FT) as a potential replacement for small animal studies. Although the mucoadhesive films achieved their desired role of delivering bioactive EGF in a sustained manner, treatment with EGF, irrespective of its release from the films or solubilized in medium, caused a hyperparakeratotic response from in vitro tissues with distinguishable histological features including thickening of the spinous layer, intra-and intercellular edema, and pyknotic nuclei. These significant morphological changes were associated with no improvements in wound closure. These observations raise questions about the potential of using in vitro tissues as a wound healing model and substitute for small animal studies. The mucoadhesive delivery system developed, however, with its potential for sustained release of bioactive growth factors and small molecules, may be loaded with other desired compounds, with or without EGF, to accelerate the process of wound healing.
C1 [Ramineni, Sandeep K.; Fisher, Paul D.; Puleo, David A.] Univ Kentucky, Dept Biomed Engn, Lexington, KY 40506 USA.
   [Fowler, Craig B.; Cunningham, Larry L.] Univ Kentucky, Coll Dent, Lexington, KY 40536 USA.
RP Ramineni, SK (reprint author), Univ Kentucky, Dept Biomed Engn, 522 Robot & Mfg Bldg, Lexington, KY 40506 USA.
EM puleo@uky.edu
FU National Institutes of Health [DE019645]
FX This work was supported in part by the National Institutes of Health
   (DE019645).
CR Ahuja A, 1997, DRUG DEV IND PHARM, V23, P489, DOI 10.3109/03639049709148498
   Barbagli G, 2010, EUR UROL, V58, P33, DOI 10.1016/j.eururo.2010.01.012
   BROWN GL, 1989, NEW ENGL J MED, V321, P76, DOI 10.1056/NEJM198907133210203
   Choi HJ, 2012, INFECT IMMUN, V80, P1079, DOI 10.1128/IAI.05820-11
   Danisovic L, 2012, TISSUE CELL, V44, P69, DOI 10.1016/j.tice.2011.11.005
   Desai KGH, 2011, PHARM RES-DORDR, V28, P2599, DOI 10.1007/s11095-011-0489-3
   Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000
   Feinberg SE, 2005, J ORAL MAXIL SURG, V63, P1418, DOI 10.1016/j.joms.2005.07.004
   FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X
   Gassner R, 2003, J CRANIO MAXILL SURG, V31, P51, DOI 10.1016/S1010-5182(02)00168-3
   Gonul B, 2003, GAZI MED J, V14, P97
   Hardwicke J, 2008, SURG-J R COLL SURG E, V6, P172, DOI 10.1016/S1479-666X(08)80114-X
   Izumi K, 2003, INT J ORAL MAX SURG, V32, P188, DOI 10.1054/ijom.2002.0365
   Janmaat ML, 2003, DRUGS TODAY, V39, P61
   Keswani SG, 2013, WOUND REPAIR REGEN, V21, P554, DOI 10.1111/wrr.12065
   Khutoryanskiy VV, 2011, MACROMOL BIOSCI, V11, P748, DOI 10.1002/mabi.201000388
   Kobayashi H, 2013, INT J ORAL SCI, V5, P14, DOI 10.1038/ijos.2013.10
   KONDO S, 1990, J INVEST DERMATOL, V95, P397, DOI 10.1111/1523-1747.ep12555492
   Lew TA, 2010, J ORAL MAXIL SURG, V68, P3, DOI 10.1016/j.joms.2009.06.006
   Liu JR, 2011, TISSUE ENG PART B-RE, V17, P25, DOI 10.1089/ten.TEB.2010.0489
   Makarova G, 2013, CELL TISSUE RES, V351, P59, DOI 10.1007/s00441-012-1500-y
   MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7
   Nagy A, 2001, DIABETES, V50, P2100, DOI 10.2337/diabetes.50.9.2100
   NOGUCHI S, 1991, AM J PHYSIOL, V260, pE620
   NordiQC, 2008, CYT HIGH MOL WEIGHT
   NordiQC, 2011, CYT HIGH MOL WEIGHT
   NordiQC, CYT
   NordiQC, 2013, CYT HIGH MOL WEIGHT
   Oda Y, 2004, J ORAL MAXIL SURG, V62, P73, DOI 10.1016/j.joms.2003.05.007
   Ohshima M, 2002, EUR J ORAL SCI, V110, P130, DOI 10.1034/j.1600-0722.2002.11179.x
   Oxford GE, 1999, J ORAL MAXIL SURG, V57, P154, DOI 10.1016/S0278-2391(99)90230-6
   Ramineni SK, 2014, OR SURG OR MED OR PA, V118, P667, DOI 10.1016/j.oooo.2014.08.015
   Ramineni SK, 2013, BIOMATER SCI-UK, V1, P753, DOI 10.1039/c3bm60064e
   Rouabhia M, 2010, BIOMATERIALS, V31, P5798, DOI 10.1016/j.biomaterials.2010.04.004
   ROYCE LS, 1991, BIOCHIM BIOPHYS ACTA, V1092, P401, DOI 10.1016/S0167-4889(97)90019-7
   Salamat-Miller N, 2005, ADV DRUG DELIVER REV, V57, P1666, DOI 10.1016/j.addr.2005.07.003
   Schneider A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001410
   Shklar G, 1987, DIS ORAL MUCOSA
   Toro M J, 2002, EPITHELIALIZATION OR
   WALDRON CA, 1975, CANCER, V36, P1386, DOI 10.1002/1097-0142(197510)36:4<1386::AID-CNCR2820360430>3.0.CO;2-7
   Wong CF, 1999, INT J PHARM, V180, P47, DOI 10.1016/S0378-5173(98)00402-5
   WOODCOCKMITCHELL J, 1982, J CELL BIOL, V95, P580, DOI 10.1083/jcb.95.2.580
NR 42
TC 0
Z9 1
U1 0
U2 8
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 1748-6041
EI 1748-605X
J9 BIOMED MATER
JI Biomed. Mater.
PD FEB
PY 2015
VL 10
IS 1
AR 015026
DI 10.1088/1748-6041/10/1/015026
PG 13
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA CD3JU
UT WOS:000350975400027
PM 25729882
OA green_accepted
DA 2018-03-20
ER

PT J
AU Cao, PX
   Bae, Y
AF Cao, Pengxiao
   Bae, Younsoo
TI Polymer nanoparticulate drug delivery and combination cancer therapy
SO FUTURE ONCOLOGY
LA English
DT Review
DE biomaterials; cancer; chemotherapy; combination therapy; drug delivery;
   drug formulation; gene therapy; nanotechnology; pharmaceutical science;
   polymer nanoparticles
ID CELL LUNG-CANCER; SYNERGISTIC ANTITUMOR-ACTIVITY; PHASE-II TRIAL;
   BREAST-CANCER; CO-DELIVERY; CHEMOTHERAPEUTIC-AGENTS; TUMOR
   NEOVASCULATURE; MICELLE FORMULATION; TARGETED DELIVERY; OVARIAN-CANCER
AB This review describes the scientific background, current achievement and future perspective of combination therapy using polymer nanoparticle drug carriers in cancer treatment. Nanotechnology-based drug delivery is expected to dramatically change combination cancer therapy by controlling accumulation and distribution patterns of multiple drugs selectively in disease sites. Rationally designed polymer materials can produce functional nanoparticulate drug carriers that can be used in various biomedical applications. In comparison with conventional drug combination approaches, using polymer nanoparticle drug carriers appears to suppress tumor growth more efficiently, potentially overcoming multidrug resistance in many cancers. It also provides versatile combination options for a variety of therapeutic agents, molecular targeting agents and nucleotide drugs.
C1 [Cao, Pengxiao; Bae, Younsoo] Univ Kentucky, Coll Pharm, Lexington, KY 40536 USA.
RP Bae, Y (reprint author), Univ Kentucky, Coll Pharm, Lexington, KY 40536 USA.
EM younsoo.bae@uky.edu
FU Kentucky Lung Cancer Research Program
FX The authors acknowledge financial support provided by the Kentucky Lung
   Cancer Research Program. The authors have no relevant affiliations or
   financial involvement with any organization or entity with a financial
   interest in or financial conflict with the subject matter or materials
   discussed in the manuscript. This includes employment, consultancies,
   honoraria, stock ownership or options, expert testimony, grants or
   patents received or pending, or royalties.
CR Afonin KA, 2010, NAT NANOTECHNOL, V5, P676, DOI [10.1038/NNANO.2010.160, 10.1038/nnano.2010.160]
   Aryal S, 2011, MOL PHARMACEUT, V8, P1401, DOI 10.1021/mp200243k
   Bae Y, 2005, MOL BIOSYST, V1, P242, DOI 10.1039/b500266d
   Bae Y, 2007, J CONTROL RELEASE, V122, P324, DOI 10.1016/j.jconrel.2007.05.038
   Bae Y, 2010, PHARM RES-DORDR, V27, P2421, DOI 10.1007/s11095-010-0234-3
   Bae Y, 2009, ADV DRUG DELIVER REV, V61, P768, DOI 10.1016/j.addr.2009.04.016
   Baselga J, 2012, LANCET, V379, P633, DOI 10.1016/S0140-6736(11)61847-3
   Benoit DSW, 2010, MOL PHARMACEUT, V7, P442, DOI 10.1021/mp9002255
   Bliesath J, 2012, CANCER LETT, V322, P113, DOI 10.1016/j.canlet.2012.02.032
   Brewer E, 2011, J NANOMATER, DOI 10.1155/2011/408675
   Cervello M, 2012, ONCOTARGET, V3, P236
   Cho EC, 2010, SMALL, V6, P517, DOI 10.1002/smll.200901622
   Cho H, 2011, ACS NANO, V5, P8721, DOI 10.1021/nn202676u
   Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947
   Chute JP, 1999, J CLIN ONCOL, V17, P1794, DOI 10.1200/JCO.1999.17.6.1794
   Dicko A, 2010, EXPERT OPIN DRUG DEL, V7, P1329, DOI 10.1517/17425247.2010.538678
   Duncan R, 2006, J DRUG TARGET, V14, P333, DOI 10.1080/10611860600833880
   Fleige E, 2012, ADV DRUG DELIVER REV, V64, P866, DOI 10.1016/j.addr.2012.01.020
   Ganta S, 2008, J CONTROL RELEASE, V126, P187, DOI 10.1016/j.jconrel.2007.12.017
   Gardner GJ, 2011, CANCER CONTROL, V18, P44, DOI 10.1177/107327481101800106
   Gaspar R, 2009, ADV DRUG DELIVER REV, V61, P1220, DOI 10.1016/j.addr.2009.06.003
   Graham JS, 2012, EXPERT REV ANTICANC, V12, P99, DOI [10.1586/era.11.189, 10.1586/ERA.11.189]
   Guo PX, 2010, NAT NANOTECHNOL, V5, P833, DOI 10.1038/NNANO.2010.231
   Haley B, 2008, UROL ONCOL-SEMIN ORI, V26, P57, DOI 10.1016/j.urolonc.2007.03.015
   He CB, 2010, BIOMATERIALS, V31, P3657, DOI 10.1016/j.biomaterials.2010.01.065
   Holt SV, 2012, BRIT J CANCER, V106, P858, DOI 10.1038/bjc.2012.8
   Hu CMJ, 2012, BIOCHEM PHARMACOL, V83, P1104, DOI 10.1016/j.bcp.2012.01.008
   Hu CMJ, 2010, THER DELIV, V1, P323, DOI 10.4155/TDE.10.13
   Huang HY, 2011, J BIOMED MATER RES A, V97A, P330, DOI 10.1002/jbm.a.33055
   Jaglowski S, 2011, EXPERT REV ANTICANC, V11, P1379, DOI [10.1586/ERA.11.132, 10.1586/era.11.132]
   Jin H, 2009, ACS NANO, V3, P149, DOI 10.1021/nn800532m
   Kenmotsu H, 2010, CANCER-AM CANCER SOC, V116, P4597, DOI 10.1002/cncr.25233
   Kim DW, 2007, ANN ONCOL, V18, P2009, DOI 10.1093/annonc/mdm374
   Kim S, 2009, EUR J PHARM BIOPHARM, V71, P420, DOI 10.1016/j.ejpb.2008.09.021
   Kinsella P, 2011, J NEURO-ONCOL, V101, P189, DOI 10.1007/s11060-010-0246-1
   Lammers T, 2012, J CONTROL RELEASE, V161, P175, DOI 10.1016/j.jconrel.2011.09.063
   Larbouret C, 2012, NEOPLASIA, V14, P121, DOI 10.1593/neo.111602
   Lee HJ, 2010, THER DELIV, V1, P803, DOI 10.4155/TDE.10.70
   Lee JH, 2012, J DRUG DELIV, DOI 10.1155/2012/915375
   Lee KS, 2008, BREAST CANCER RES TR, V108, P241, DOI 10.1007/s10549-007-9591-y
   Lee SW, 2007, BIOTECHNOL BIOPROC E, V12, P185, DOI 10.1007/BF02931092
   Malam Y, 2011, CURR MED CHEM, V18, P1067, DOI 10.2174/092986711794940860
   McNeil SE, 2011, METHODS MOL BIOL, V697, P3, DOI 10.1007/978-1-60327-198-1_1
   Na HS, 2010, INT J PHARMACEUT, V383, P192, DOI 10.1016/j.ijpharm.2009.08.041
   Nagano T, 2010, INT J CANCER, V127, P2699, DOI 10.1002/ijc.25282
   Nagano T, 2009, CLIN CANCER RES, V15, P4348, DOI 10.1158/1078-0432.CCR-08-3334
   Nakajima TE, 2008, INT J CANCER, V122, P2148, DOI 10.1002/ijc.23381
   Patil Y, 2009, J CONTROL RELEASE, V136, P21, DOI 10.1016/j.jconrel.2009.01.021
   Patil YB, 2010, BIOMATERIALS, V31, P358, DOI 10.1016/j.biomaterials.2009.09.048
   Pattekari P, 2011, PHYS CHEM CHEM PHYS, V13, P9014, DOI 10.1039/c0cp02549f
   Pichot CS, 2009, BRIT J CANCER, V101, P38, DOI 10.1038/sj.bjc.6605101
   Radjenovic B, 2011, CENT EUR J PHYS, V9, P265, DOI 10.2478/s11534-010-0096-7
   Shimomura M, 2001, CURR OPIN COLLOID IN, V6, P11, DOI 10.1016/S1359-0294(00)00081-9
   Shin HC, 2011, MOL PHARMACEUT, V8, P1257, DOI 10.1021/mp2000549
   Shu D, 2011, NAT NANOTECHNOL, V6, P658, DOI [10.1038/nnano.2011.105, 10.1038/NNANO.2011.105]
   Siegel R, 2012, CA-CANCER J CLIN, V62, DOI [10.3322/caac.21153, 10.3322/caac.21149, 10.3322/caac.20138]
   Sun TM, 2008, BIOMATERIALS, V29, P4348, DOI 10.1016/j.biomaterials.2008.07.036
   Sun TM, 2011, ACS NANO, V5, P1483, DOI 10.1021/nn103349h
   Torchilin V, 2011, ADV DRUG DELIVER REV, V63, P131, DOI 10.1016/j.addr.2010.03.011
   Torchilin VP, 2010, HDB EXP PHARM, V197, P3, DOI DOI 10.1007/978-3-642-00477-3_
   Tu RS, 2004, ADV DRUG DELIVER REV, V56, P1537, DOI 10.1016/j.addr.2003.10.047
   van Meerbeeck JP, 2011, LANCET, V378, P1741, DOI 10.1016/S0140-6736(11)60165-7
   van Vlerken LE, 2007, CANCER RES, V67, P4843, DOI 10.1158/0008-5472.CAN-06-1648
   van Vlerken LE, 2010, AAPS J, V12, P171, DOI 10.1208/s12248-010-9174-4
   von Minckwitz G, 2012, ONCOLOGY-NY, V26, P20
   Wang AZ, 2012, ANNU REV MED, V63, P185, DOI 10.1146/annurev-med-040210-162544
   Wang H, 2011, BIOMATERIALS, V32, P8281, DOI 10.1016/j.biomaterials.2011.07.032
   Wang Z, 2011, PHARM RES-DORDR, V28, P585, DOI 10.1007/s11095-010-0308-2
   Wang Z, 2010, BIOMATERIALS, V31, P7115, DOI 10.1016/j.biomaterials.2010.05.075
   West Kevin R, 2005, Curr Drug Discov Technol, V2, P123, DOI 10.2174/1570163054866882
   Wu CL, 2012, KAOHSIUNG J MED SCI, V28, P194, DOI 10.1016/j.kjms.2011.06.020
   Xiong XB, 2011, ACS NANO, V5, P5202, DOI 10.1021/nn2013707
   Yang H, 2009, J APPL TOXICOL, V29, P69, DOI 10.1002/jat.1385
   Yang TY, 2012, NANOMED-NANOTECHNOL, V8, P81, DOI 10.1016/j.nano.2011.05.003
   Zhang L, 2008, CLIN PHARMACOL THER, V83, P761, DOI 10.1038/sj.clpt.6100400
   Zhu CH, 2010, BIOMATERIALS, V31, P2408, DOI 10.1016/j.biomaterials.2009.11.077
NR 76
TC 12
Z9 12
U1 1
U2 108
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1479-6694
EI 1744-8301
J9 FUTURE ONCOL
JI Future Oncol.
PD NOV
PY 2012
VL 8
IS 11
BP 1471
EP 1480
DI 10.2217/FON.12.139
PG 10
WC Oncology
SC Oncology
GA 036GT
UT WOS:000311015100015
PM 23148619
DA 2018-03-19
ER

PT J
AU Ramineni, SK
   Cunningham, LL
   Dziubla, TD
   Puleo, DA
AF Ramineni, Sandeep K.
   Cunningham, Larry L., Jr.
   Dziubla, Thomas D.
   Puleo, David A.
TI Competing properties of mucoadhesive films designed for localized
   delivery of imiquimod
SO BIOMATERIALS SCIENCE
LA English
DT Article
ID PORCINE BUCCAL MUCOSA; IN-VIVO EVALUATION; DRUG-DELIVERY; POLYMERIC
   FILMS; PATCHES; SYSTEMS; VITRO; PERMEABILITY; EPITHELIUM; CHITOSAN
AB Oral mucosal delivery has gained prominence in the last two decades because the rich vasculature of the tissue enables rapid delivery and avoidance of first pass metabolism. Although commercial mucoadhesives are used for systemic delivery, systems are not currently available for treatment of local conditions. In the present work, mucoadhesive films are being developed for locally controlled release of an immune response modifier for preventing precancerous lesions from progressing to oral squamous cell carcinoma. Previous research showed that films composed of polyvinylpyrrolidone (PVP) and carboxymethylcellulose (CMC) released imiquimod in a sustained manner for 3 h. In continuing development of the system, additional key properties were investigated with changes in composition. While adhesive properties in pull-off (0.42 +/- 0.03 to 1.1 +/- 0.1 N cm(-2)) and shear adhesion (1.7 +/- 0.25 to 5.6 +/- 1.4 N cm(-2)) increased with increasing PVP content of films, tensile properties, such as modulus (6.9 +/- 1.5 to 1.8 +/- 0.2 MPa) and ultimate strength (4.2 +/- 0.7 to 2.1 +/- 0.02 MPa), decreased as PVP content increased. Release profiles of the films showed that an increased PVP content resulted in burst release and faster erosion compared to sustained release and slower erosion with more CMC. Studies of transport kinetics showed that the films doubled the amount of imiquimod localized within epithelium compared to drug in solution, increasing their potential for local treatment of oral dysplasia. The mucoadhesive drug delivery system based on CMC and PVP offers a wide range of these properties without addition of new constituents.
C1 [Ramineni, Sandeep K.; Puleo, David A.] Univ Kentucky, Ctr Biomed Engn, Lexington, KY 40506 USA.
   [Cunningham, Larry L., Jr.] Univ Kentucky, Coll Dent, Lexington, KY 40506 USA.
   [Dziubla, Thomas D.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Ramineni, SK (reprint author), Univ Kentucky, Ctr Biomed Engn, Lexington, KY 40506 USA.
EM puleo@uky.edu
FU National Institutes of Health [DE019645]; Kentucky NASA EPSCoR
   [NNX08BA13A]
FX This work was supported in part by the National Institutes of Health
   (DE019645) and Kentucky NASA EPSCoR (NNX08BA13A).
CR Abu-Huwaij R, 2007, DRUG DEV IND PHARM, V33, P437, DOI 10.1080/03639040601150211
   Ahuja A, 1997, DRUG DEV IND PHARM, V23, P489, DOI 10.3109/03639049709148498
   Alam Mohd Aftab, 2007, AAPS PharmSciTech, V8, pE109, DOI 10.1208/pt0804109
   Averineni RK, 2009, PHARM DEV TECHNOL, V14, P199, DOI 10.1080/10837450802498928
   Boateng JS, 2009, DRUG DEV IND PHARM, V35, P986, DOI 10.1080/03639040902744704
   Cui FY, 2009, J BIOMED MATER RES A, V89A, P1063, DOI 10.1002/jbm.a.32071
   del Consuelo ID, 2007, J CONTROL RELEASE, V122, P135, DOI 10.1016/j.jconrel.2007.05.017
   Desai KGH, 2011, PHARM RES-DORDR, V28, P2599, DOI 10.1007/s11095-011-0489-3
   Donnelly RF, 2006, INT J PHARM, V307, P318, DOI 10.1016/j.ijpharm.2005.10.023
   Glaholm J., 2003, ORAL ONCOL, P339
   Jones DS, 2009, INT J PHARMACEUT, V372, P49, DOI 10.1016/j.ijpharm.2009.01.006
   Khutoryanskiy VV, 2011, MACROMOL BIOSCI, V11, P748, DOI 10.1002/mabi.201000388
   Kulkarni U, 2009, J PHARM SCI-US, V98, P471, DOI 10.1002/jps.21436
   Lee J, 2002, ARCH PHARM RES, V25, P546, DOI 10.1007/BF02976616
   Luo K, 2008, MACROMOL BIOSCI, V8, P184, DOI 10.1002/mabi.200700185
   Madhav NVS, 2009, J CONTROL RELEASE, V140, P2, DOI 10.1016/j.jconrel.2009.07.016
   Mishra RK, 2008, AAPS PHARMSCITECH, V9, P395, DOI 10.1208/s12249-008-9048-6
   Mohamed Magdy I., 2011, J CHEM PHARM RES, V3, P665
   Mura P, 2010, J PHARM SCI-US, V99, P3019, DOI 10.1002/jps.22068
   Nafee Noha Adel, 2003, Acta Pharmaceutica (Zagreb), V53, P199
   National Cancer Institute (U.S.), 2007, NIH PUBLICATION, V11-7156
   Peh KK, 1999, J PHARM PHARM SCI, V2, P53
   Perioli L, 2004, J CONTROL RELEASE, V99, P73, DOI 10.1016/j.jconrel.2004.06.005
   Ramineni SK, 2013, J PHARM SCI-US, V102, P593, DOI 10.1002/jps.23386
   Salamat-Miller N, 2005, ADV DRUG DELIVER REV, V57, P1666, DOI 10.1016/j.addr.2005.07.003
   Serra L, 2009, EUR J PHARM BIOPHARM, V71, P519, DOI 10.1016/j.ejpb.2008.09.022
   Shidhaye SS, 2008, AAPS PHARMSCITECH, V9, P909, DOI 10.1208/s12249-008-9125-x
   Shojaei AH, 2000, J CONTROL RELEASE, V67, P223, DOI 10.1016/S0168-3659(00)00216-9
   SMART JD, 1984, J PHARM PHARMACOL, V36, P295, DOI 10.1111/j.2042-7158.1984.tb04377.x
   Sonis Stephen T, 2007, J Support Oncol, V5, P3
   Vishnu Y. Vamshi, 2007, Current Drug Delivery, V4, P27
   WERTZ PW, 1991, CRIT REV THER DRUG, V8, P237
   Wong CF, 1999, INT J PHARM, V180, P47, DOI 10.1016/S0378-5173(98)00402-5
   Wu P, 2005, SOC BIOM 30 ANN M T
NR 34
TC 12
Z9 12
U1 0
U2 7
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2047-4830
EI 2047-4849
J9 BIOMATER SCI-UK
JI Biomater. Sci.
PY 2013
VL 1
IS 7
BP 753
EP 762
DI 10.1039/c3bm60064e
PG 10
WC Materials Science, Biomaterials
SC Materials Science
GA 295SP
UT WOS:000330136100008
PM 23750320
OA green_accepted
DA 2018-03-20
ER

PT J
AU Stocke, NA
   Arnold, SM
   Hilt, JZ
AF Stocke, Nathanael A.
   Arnold, Susanne M.
   Hilt, J. Zach
TI Responsive hydrogel nanoparticles for pulmonary delivery
SO JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
LA English
DT Article
DE Responsive hydrogels; Nanoparticles; Drug delivery; Pulmonary delivery;
   Inhalation; Aerosol performance
ID DRY POWDER INHALATION; DRUG-DELIVERY; PHYSICOCHEMICAL CHARACTERIZATION;
   CONTROLLED-RELEASE; CANCER-THERAPY; MICROPARTICLES; SYSTEMS; PH;
   PERFORMANCE; PARTICLES
AB Nanoparticles represent one of the most widely studied classes of advanced drug delivery platforms in recent years due to a wide range of unique properties and capabilities that can be utilized to improve upon traditional drug administration. Conversely, hydrogel nanoparticles (HNPs) also called nanogels represent a unique class of materials that combine the intrinsic advantages of nanotechnology with the inherent capabilities of hydrogels. Responsive hydrogels pose a particularly interesting class of materials that can sense and respond to external stimuli and previous reports of inhalable hydrogel particles have highlighted their potential in pulmonary delivery. Here, we synthesized two different pH-responsive HNPs, designated HNP120 and HNP270, by incorporating functional monomers with a common crosslinker and characterized their physicochemical properties. One of the HNP systems was selected for incorporation into a composite dry powder by spray drying, and the aerodynamic performance of the resulting powder was evaluated. The HNP120s displayed a hydrodynamic diameter of approximately 120 nm in their fully swollen state and a minimal diameter of around 80 nm while the HNP270s were approximately 270 nm and 115 nm, respectively. Electron microscopy confirmed particle size- and morphological uniformity of the HNPs. The HNP120s were spray dried into composite dry powders for inhalation and cascade impaction studies showed good aerosol performance with a mass median aerodynamic diameter (MMAD) of 4.82 +/- 037 and a fine particle fraction >30%. The HNPs released from the spray dried composites retained their responsive behavior thereby illustrating the potential for these materials as intelligent drug delivery systems that combine the advantages of nanotechnology, lung targeting through pulmonary delivery, and stimuli-responsive hydrogels. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Stocke, Nathanael A.; Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Arnold, Susanne M.] Univ Kentucky, Dept Internal Med, Coll Med, Lexington, KY 40506 USA.
RP Hilt, JZ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 F Paul Anderson Tower, Lexington, KY 40506 USA.
EM zach.hilt@uky.edu
FU National Cancer Institute [R25CA153954]
FX This work would not have been possible without the efforts of Marjorie
   L. Guy. The project described was supported by Grant Number R25CA153954
   from the National Cancer Institute. The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the National Cancer Institute or the National
   Institutes of Health.
CR Anselmo AC, 2014, J CONTROL RELEASE, V190, P15, DOI 10.1016/j.jconrel.2014.03.053
   Anthony J.H., 2009, MODERN PHARM APPL AD, V2, P191
   Baeza A, 2015, EXPERT OPIN DRUG DEL, V12, P319, DOI 10.1517/17425247.2014.953051
   Brannon-Peppas L, 2004, ADV DRUG DELIVER REV, V56, P1649, DOI 10.1016/j.addr.2004.02.014
   Courrier HM, 2002, CRIT REV THER DRUG, V19, P425, DOI 10.1615/CritRevTherDrugCarrierSyst.v19.i45.40
   de Boer AH, 2003, INT J PHARM, V260, P201, DOI 10.1016/S0378-5173(03)00264-3
   De SK, 2002, J MICROELECTROMECH S, V11, P544, DOI 10.1109/JMEMS.2002.803281
   Du J, 2014, AAPS PHARMSCITECH, V15, P1535, DOI 10.1208/s12249-014-0176-x
   El-Sherbiny IM, 2010, J MICROENCAPSUL, V27, P657, DOI 10.3109/02652041003739840
   Estrella V, 2013, CANCER RES, V73, P1524, DOI 10.1158/0008-5472.CAN-12-2796
   Farhat A, 2009, J PHARM PHARMACOL, V61, pA43
   Finlay Warren, 2008, ARLA RESP DEPOSITION
   Foley K., 1984, J AM CHEM SOC, V106, P1173
   Ghandehari H, 1997, BIOMATERIALS, V18, P861, DOI 10.1016/S0142-9612(97)00007-0
   Gupta P, 2002, DRUG DISCOV TODAY, V7, P569, DOI 10.1016/S1359-6446(02)02255-9
   Hamidi M, 2008, ADV DRUG DELIVER REV, V60, P1638, DOI 10.1016/j.addr.2008.08.002
   Harjunen P, 2002, EUR J PHARM SCI, V16, P313, DOI 10.1016/S0928-0987(02)00126-4
   Lee J, 2012, J CONTROL RELEASE, V161, P728, DOI 10.1016/j.jconrel.2012.05.029
   Li XJ, 2011, AAPS PHARMSCITECH, V12, P1420, DOI 10.1208/s12249-011-9704-0
   Liu SQ, 2010, J MATER CHEM, V20, P24, DOI 10.1039/b911328m
   Coto-Garcia AM, 2011, ANAL BIOANAL CHEM, V399, P29, DOI 10.1007/s00216-010-4330-3
   Martinelli F, 2015, INT J PHARMACEUT, V487, P197, DOI 10.1016/j.ijpharm.2015.04.003
   Meenach SA, 2013, INT J NANOMED, V8, P275, DOI 10.2147/IJN.S30724
   Oh JK, 2008, PROG POLYM SCI, V33, P448, DOI 10.1016/j.progpolymsci.2008.01.002
   Peer D, 2007, NAT NANOTECHNOL, V2, P751, DOI 10.1038/nnano.2007.387
   Peppas NA, 2000, EUR J PHARM BIOPHARM, V50, P27, DOI 10.1016/S0939-6411(00)00090-4
   Peppas NA, 2006, ADV MATER, V18, P1345, DOI 10.1002/adma.200501612
   Rosiak JM, 1999, NUCL INSTRUM METH B, V151, P56, DOI 10.1016/S0168-583X(99)00118-4
   Secret E, 2014, ACS APPL MATER INTER, V6, P10313, DOI 10.1021/am501754s
   Selvam P, 2011, J AEROSOL MED PULM D, V24, P25, DOI 10.1089/jamp.2010.0830
   Soppimath KS, 2002, DRUG DEV IND PHARM, V28, P957, DOI 10.1081/DDC-120006428
   STEIN A, 1979, P NATL ACAD SCI USA, V76, P5000, DOI 10.1073/pnas.76.10.5000
   Stocke NA, 2015, INT J PHARMACEUT, V479, P320, DOI 10.1016/j.ijpharm.2014.12.050
   TANNOCK IF, 1989, CANCER RES, V49, P4373
   [Anonymous], 2006, USP 29 NF 24 US PHAR, P2617
   Wu X., 2013, INT J NANOMED, V8, P1
   Yang W, 2008, INT J PHARMACEUT, V356, P239, DOI 10.1016/j.ijpharm.2008.02.011
NR 37
TC 1
Z9 1
U1 1
U2 35
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1773-2247
J9 J DRUG DELIV SCI TEC
JI J. Drug Deliv. Sci. Technol.
PD OCT
PY 2015
VL 29
BP 143
EP 151
DI 10.1016/j.jddst.2015.06.013
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CT2CF
UT WOS:000362608900017
PM 26339298
OA green_accepted
DA 2018-03-20
ER

PT J
AU Bae, Y
   Kataoka, K
AF Bae, Younsoo
   Kataoka, Kazunori
TI Intelligent polymeric micelles from functional poly(ethylene
   glycol)-poly(amino acid) block copolymers
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE Intelligent polymeric micelles; PEG-poly(ammo acid) block copolymers;
   Controlled drug delivery
ID INTRACELLULAR DRUG-DELIVERY; POLYION COMPLEX MICELLES; VIVO
   ANTITUMOR-ACTIVITY; IN-VIVO; ANTICANCER DRUG; SOLID TUMORS; CARRIER
   SYSTEM; POLY(BETA-BENZYL L-ASPARTATE); BIOLOGICAL SIGNIFICANCE;
   CANCER-CHEMOTHERAPY
AB This review describes our recent efforts on the design and preparation of intelligent polymeric micelles from functional poly(ethylene glycol)-poly(amino acid) (PEG-PAA) block copolymers. The polymeric micelles feature a spherical sub-100 nm core-shell structure in which anticancer drugs are loaded avoiding undesirable interactions in vivo. Chemical modification of the core-forming block of PEG-PAA with a hydrazone linkage allows the polymeric micelles to release drugs selectively at acidic pH (4-6). Installation of folic acids on the micelle surface improves cancer cell-specific drug delivery efficiency along with pH-controlled drug release. These intelligent micelles appear to be superior over classical micelles that physically incorporate drugs. Studies showed both controlled drug release and targeted delivery features of the micelles reduced toxicity and improved efficacy significantly. Further developments potentiate combination delivery of multiple drugs using mixed micelles. Therefore clinically relevant performance of the polymeric micelles provides a promising approach for more efficient and patient-friendly cancer therapy. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Kataoka, Kazunori] Univ Tokyo, Dept Mat Engn, Grad Sch Engn, Bunkyo Ku, Tokyo 1138656, Japan.
   [Bae, Younsoo] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
   [Kataoka, Kazunori] Univ Tokyo, Ctr Dis Biol & Integrat Med, Grad Sch Med, Bunkyo Ku, Tokyo 1130033, Japan.
   [Kataoka, Kazunori] Univ Tokyo, Ctr NanoBio Integrat, Tokyo 1138656, Japan.
RP Kataoka, K (reprint author), Univ Tokyo, Dept Mat Engn, Grad Sch Engn, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138656, Japan.
EM kataoka@bmw.t.u-tokyo.ac.jp
RI Kataoka, Kazunori/K-7108-2012
OI Kataoka, Kazunori/0000-0002-8591-413X
CR Adams ML, 2003, J PHARM SCI, V92, P1343, DOI 10.1002/jps.10397
   Allen C, 1999, COLLOID SURFACE B, V16, P3, DOI 10.1016/S0927-7765(99)00058-2
   Allen TM, 2002, NAT REV CANCER, V2, P750, DOI 10.1038/nrc903
   ATKINS JH, 2002, NATURE REV CANC, V1, P645
   Bae Y, 2005, MOL BIOSYST, V1, P242, DOI 10.1039/b500266d
   Bae Y, 2003, ANGEW CHEM INT EDIT, V42, P4640, DOI 10.1002/anie.200250653
   Bae Y, 2005, BIOCONJUGATE CHEM, V16, P122, DOI 10.1021/bc0498166
   BAE Y, 2005, POLYM DRUG DELIVERY, V148, P491
   Bae Y, 2007, J CONTROL RELEASE, V122, P324, DOI 10.1016/j.jconrel.2007.05.038
   Bae Y, 2007, BIOCONJUGATE CHEM, V18, P1131, DOI 10.1021/bc060401p
   Cabral H, 2007, J CONTROL RELEASE, V121, P146, DOI 10.1016/j.jconrel.2007.05.024
   Cammas S, 1996, MACROMOLECULES, V29, P3227, DOI 10.1021/ma951025z
   CAMMAS S, 1995, MACROMOL CHEM PHYSIC, V196, P1899, DOI 10.1002/macp.1995.021960609
   Chen HT, 2008, P NATL ACAD SCI USA, V105, P6596, DOI 10.1073/pnas.0707046105
   Duncan R, 2003, NAT REV DRUG DISCOV, V2, P347, DOI 10.1038/nrd1088
   Fukushima S, 1999, COLLOID SURFACE B, V16, P227, DOI 10.1016/S0927-7765(99)00073-9
   GAO ZS, 1993, MACROMOLECULES, V26, P7353, DOI 10.1021/ma00078a035
   GARINCHESA P, 1993, AM J PATHOL, V142, P557
   Hamilton G, 1998, CANCER LETT, V131, P29, DOI 10.1016/S0304-3835(98)00198-0
   Harada A, 1996, MACROMOLECULES, V29, P6183, DOI 10.1021/ma960487p
   Harada A, 2001, EUR J PHARM SCI, V13, P35, DOI 10.1016/S0928-0987(00)00205-0
   HARADA A, 1995, MACROMOLECULES, V28, P5294, DOI 10.1021/ma00119a019
   Jain RK, 1997, ADV DRUG DELIVER REV, V26, P71, DOI 10.1016/S0169-409X(97)00027-6
   Jain RK, 2002, NAT REV CANCER, V2, P266, DOI 10.1038/nrc778
   Jones AT, 2003, ADV DRUG DELIVER REV, V55, P1353, DOI 10.1016/j.addr.2003.07.002
   Jule E, 2004, J CONTROL RELEASE, V97, P407, DOI 10.1016/j.jconrel.2004.02.012
   KABANOV AV, 1992, J CONTROL RELEASE, V22, P141, DOI 10.1016/0168-3659(92)90199-2
   KANAYAMA N, 2006, MED CHEM, V1, P439
   KANEKO T, 1991, BIOCONJUGATE CHEM, V2, P133, DOI 10.1021/bc00009a001
   Kano MR, 2007, P NATL ACAD SCI USA, V104, P3460, DOI 10.1073/pnas.0611660104
   Kataoka K, 2000, J CONTROL RELEASE, V64, P143, DOI 10.1016/S0168-3659(99)00133-9
   KATAOKA K, 1993, J CONTROL RELEASE, V24, P119
   Kataoka K, 2001, ADV DRUG DELIVER REV, V47, P113, DOI 10.1016/S0169-409X(00)00124-1
   Kratz F, 1999, CRIT REV THER DRUG, V16, P245, DOI 10.1615/CritRevTherDrugCarrierSyst.v16.i3.10
   Kwon G, 1997, J CONTROL RELEASE, V48, P195, DOI 10.1016/S0168-3659(97)00039-4
   KWON G, 1994, J CONTROL RELEASE, V29, P17, DOI 10.1016/0168-3659(94)90118-X
   KWON G, 1993, LANGMUIR, V9, P945, DOI 10.1021/la00028a012
   KWON GS, 1995, ADV DRUG DELIVER REV, V16, P295, DOI 10.1016/0169-409X(95)00031-2
   KWON GS, 1993, PHARMACEUT RES, V10, P970, DOI 10.1023/A:1018998203127
   KWON GS, 1994, COLLOID SURFACE B, V2, P429
   Lavasanifar A, 2002, ADV DRUG DELIVER REV, V54, P169, DOI 10.1016/S0169-409X(02)00015-7
   Leamon CP, 2003, BIOCONJUGATE CHEM, V14, P738, DOI 10.1021/bc020089t
   Lian T, 2001, J PHARM SCI, V90, P667, DOI 10.1002/jps.1023
   MAEDA H, 1989, CRIT REV THER DRUG, V6, P193
   MATSUMURA Y, 1986, CANCER RES, V46, P6387
   Matsumura Y, 1999, JPN J CANCER RES, V90, P122, DOI 10.1111/j.1349-7006.1999.tb00675.x
   Nagasaki Y, 2001, BIOMACROMOLECULES, V2, P1067, DOI 10.1021/bm015574q
   Nakanishi T, 2001, J CONTROL RELEASE, V74, P295, DOI 10.1016/S0168-3659(01)00341-8
   Nishiyama N, 2003, CANCER RES, V63, P8977
   Nishiyama N, 1999, LANGMUIR, V15, P377, DOI 10.1021/la980572l
   Nishiyama N, 2006, PHARMACOL THERAPEUT, V112, P630, DOI 10.1016/j.pharmthera.2006.05.006
   Nishiyama Nobuhiro, 2005, Drug Discov Today Technol, V2, P21, DOI 10.1016/j.ddtec.2005.05.007
   Otsuka H, 2003, ADV DRUG DELIVER REV, V55, P403, DOI 10.1016/S0169-409X(02)00226-0
   Putnam D, 1995, ADV POLYM SCI, V122, P55
   Ringsdorf H., 1975, J POLYM SCI POLYM S, V51, P135
   Scripture CD, 2006, NAT REV CANCER, V6, P546, DOI 10.1038/nrc.1887
   SEYMOUR LW, 1987, J BIOMED MATER RES, V21, P1341, DOI 10.1002/jbm.820211106
   Smalley KSM, 2006, MOL CANCER THER, V5, P1136, DOI 10.1158/1535-7163.MCT-06-0084
   Stella B, 2000, J PHARM SCI, V89, P1452, DOI 10.1002/1520-6017(200011)89:11<1452::AID-JPS8>3.0.CO;2-P
   SUTHERLAND RM, 1988, SCIENCE, V240, P177, DOI 10.1126/science.2451290
   Suzuki H, 1996, ADV DRUG DELIVER REV, V19, P335, DOI 10.1016/0169-409X(96)00008-7
   TAKAKURA Y, 1990, PHARMACEUT RES, V7, P339, DOI 10.1023/A:1015807119753
   Takakura Y, 1996, PHARMACEUT RES, V13, P820, DOI 10.1023/A:1016084508097
   Tsukioka Y, 2002, JPN J CANCER RES, V93, P1145, DOI 10.1111/j.1349-7006.2002.tb01217.x
   Webber SE, 1996, SOLVENTS SELF ORG PO, V327, P383
   WEITMAN SD, 1992, CANCER RES, V52, P3396
   West Kevin R, 2005, Curr Drug Discov Technol, V2, P123, DOI 10.2174/1570163054866882
   Yamamoto Y, 2002, J CONTROL RELEASE, V82, P359, DOI 10.1016/S0168-3659(02)00147-5
   Yamamoto Y, 2001, J CONTROL RELEASE, V77, P27, DOI 10.1016/S0168-3659(01)00451-5
   YAMAOKA T, 1994, J PHARM SCI, V83, P601, DOI 10.1002/jps.2600830432
   Yasugi K, 1999, MACROMOLECULES, V32, P8024, DOI 10.1021/ma991066l
   Yokoyama M, 1998, J CONTROL RELEASE, V55, P219, DOI 10.1016/S0168-3659(98)00054-6
   Yokoyama M, 1998, J CONTROL RELEASE, V50, P79, DOI 10.1016/S0168-3659(97)00115-6
   YOKOYAMA M, 1993, PHARMACEUT RES, V10, P895, DOI 10.1023/A:1018921513605
   YOKOYAMA M, 1991, CANCER RES, V51, P3229
   YOKOYAMA M, 1990, J CONTROL RELEASE, V11, P269
   YOKOYAMA M, 1994, J CONTROL RELEASE, V32, P269, DOI 10.1016/0168-3659(94)90237-2
   YOKOYAMA M, 1994, J CONTROL RELEASE, V28, P336, DOI 10.1016/0168-3659(94)90204-6
   YOKOYAMA M, 1990, CANCER RES, V50, P1693
   YOKOYAMA M, 1994, J CONTROL RELEASE, V28, P59
   Yokoyama M, 1999, J DRUG TARGET, V7, P171, DOI 10.3109/10611869909085500
   Yokoyama M, 1993, DRUG DELIV, V1, P11
NR 82
TC 402
Z9 410
U1 20
U2 294
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-409X
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD AUG 10
PY 2009
VL 61
IS 10
BP 768
EP 784
DI 10.1016/j.addr.2009.04.016
PG 17
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 474ND
UT WOS:000268289900002
PM 19422866
DA 2018-03-19
ER

PT J
AU Yakacki, CM
   Satarkar, NS
   Gall, K
   Likos, R
   Hilt, JZ
AF Yakacki, Christopher M.
   Satarkar, Nitin S.
   Gall, Ken
   Likos, Roxanne
   Hilt, J. Zach
TI Shape-Memory Polymer Networks with Fe3O4 Nanoparticles for Remote
   Activation
SO JOURNAL OF APPLIED POLYMER SCIENCE
LA English
DT Article
DE shape memory polymer; magnetite; remote heating; inductive
ID HYDROGEL NANOCOMPOSITES; BIOMEDICAL APPLICATIONS; MAGNETIC
   NANOPARTICLES; MEDICAL APPLICATIONS; IN-VITRO; POLYURETHANE; COMPOSITES;
   SYSTEMS
AB Shape-memory polymers (SMPs) have recently shown the capacity to actuate by remote heating via the incorporation of magnetic nanoparticles into the polymer matrix and exposure to an alternating magnetic field. In this study, methacrylate-based thermoset SMP networks were synthesized through free-radical polymerization with varying amounts of Fe3O4 magnetite (0, 1, and 2.5 wt %). Furthermore, the chemistry of the networks was controlled to maintain a constant glass transition temperature (T-g) while varying the degree of chemical crosslinking. Remote heating of the networks was shown to be a direct function of the nanoparticle concentration and independent of the chemistry. Magnetite reinforcement was shown to influence the thermomechanical properties of the networks; increasing Fe3O4 concentrations led to decreases in T-g and rubbery modulus. However, networks with a higher degree of crosslinking were more resistant to thermomechanical changes with respect to magnetite concentration. Strain to failure was shown to decrease with the addition of nanoparticles and the free-strain shape-memory cycle was investigated for all of the networks. Networks with lower degrees of crosslinking and high magnetite concentrations showed a significant amount of irrecoverable strain. Last, the use of remotely heated shape-memory materials is discussed in light of potential biomedical applications. (c) 2009 Wiley Periodicals, Inc. J Appl Polym Sci 112: 3166-3176, 2009
C1 [Yakacki, Christopher M.; Gall, Ken; Likos, Roxanne] MedShape Solut, Res & Dev, Atlanta, GA 30318 USA.
   [Yakacki, Christopher M.; Gall, Ken] Georgia Inst Technol, Sch Mat Sci & Engn, Atlanta, GA 30332 USA.
   [Satarkar, Nitin S.; Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Gall, Ken] Georgia Inst Technol, George W Woodruff Sch Mech Engn, Atlanta, GA 30318 USA.
   [Likos, Roxanne] Georgia Inst Technol, Dept Biomed Engn, Atlanta, GA 30318 USA.
RP Yakacki, CM (reprint author), MedShape Solut, Res & Dev, Atlanta, GA 30318 USA.
EM chris@medshapesolutions.com
CR Baer G, 2007, J APPL POLYM SCI, V103, P3882, DOI 10.1002/app.25567
   BAER GM, 2007, BIOMED ENG ONLINE, P6
   Behl M, 2007, SOFT MATTER, V3, P58, DOI 10.1039/b610611k
   Behl M, 2007, MATER TODAY, V10, P20, DOI 10.1016/S1369-7021(07)70047-0
   Buckley PR, 2006, IEEE T BIO-MED ENG, V53, P2075, DOI 10.1109/TBME.2006.877113
   Cabanlit M, 2007, MACROMOL BIOSCI, V7, P48, DOI 10.1002/mabi.200600177
   El Feninat F, 2002, ADV ENG MATER, V4, P91, DOI 10.1002/1527-2648(200203)4:3<91::AID-ADEM91>3.0.CO;2-B
   Frimpong RA, 2007, J BIOMED MATER RES A, V80A, P1, DOI 10.1002/jbm.a.30962
   Gall K, 2005, J BIOMED MATER RES A, V73A, P339, DOI 10.1002/jbm.a.30296
   Gall K, 2004, J MICROELECTROMECH S, V13, P472, DOI 10.1109/JMEMS.2004.828727
   Kunzelman J, 2008, J MATER CHEM, V18, P1082, DOI 10.1039/b718445j
   Lendlein A, 2005, CLIN HEMORHEOL MICRO, V32, P105
   Lendlein A, 2005, NATURE, V434, P879, DOI 10.1038/nature03496
   Liu C, 2007, J MATER CHEM, V17, P1543, DOI 10.1039/b615954k
   Mather P T, 2002, J APPL MED POLYM, V6, P47
   Maitland DJ, 2002, LASER SURG MED, V30, P1
   Mohr R, 2006, P NATL ACAD SCI USA, V103, P3540, DOI 10.1073/pnas.0600079103
   Muller-Schulte D, 2006, J MAGN MAGN MATER, V302, P267, DOI 10.1016/j.jmmm.2005.05.043
   Ratna D, 2008, J MATER SCI, V43, P254, DOI 10.1007/s10853-007-2176-7
   Razzaq MY, 2007, MAT SCI ENG A-STRUCT, V444, P227, DOI 10.1016/j.msea.2006.08.083
   Rickert D, 2003, J BIOMED MATER RES B, V67B, P722, DOI 10.1002/jbm.b.10069
   Satarkar NS, 2008, ACTA BIOMATER, V4, P11, DOI 10.1016/j.actbio.2007.07.009
   Schmidt AM, 2006, MACROMOL RAPID COMM, V27, P1168, DOI 10.1002/marc.200600225
   Small W, 2005, OPT EXPRESS, V13, P8204, DOI 10.1364/OPEX.13.008204
   Sokolowski W, 2007, BIOMED MATER, V2, pS23, DOI 10.1088/1748-6041/2/1/S04
   Wache HM, 2003, J MATER SCI-MATER M, V14, P109, DOI 10.1023/A:1022007510352
   Wei ZG, 1998, J MATER SCI, V33, P3743, DOI 10.1023/A:1004692329247
   Yakacki CM, 2008, BIOMED MATER, V3, DOI 10.1088/1748-6041/3/1/015010
   Yakacki CM, 2008, ADV FUNCT MATER, V18, P2428, DOI 10.1002/adfm.200701049
   Yakacki CM, 2008, ADV ENG MATER, V10, P112, DOI 10.1002/adem.200700184
   Yakacki CM, 2007, BIOMATERIALS, V28, P2255, DOI 10.1016/j.biomaterials.2007.01.030
NR 31
TC 74
Z9 83
U1 6
U2 69
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0021-8995
J9 J APPL POLYM SCI
JI J. Appl. Polym. Sci.
PD JUN 5
PY 2009
VL 112
IS 5
BP 3166
EP 3176
DI 10.1002/app.29845
PG 11
WC Polymer Science
SC Polymer Science
GA 431PV
UT WOS:000265076100070
DA 2018-03-20
ER

PT J
AU Stocke, NA
   Sethi, P
   Jyoti, A
   Chan, R
   Arnold, SM
   Hilt, JZ
   Upreti, M
AF Stocke, Nathanael A.
   Sethi, Pallavi
   Jyoti, Amar
   Chan, Ryan
   Arnold, Susanne M.
   Hilt, J. Zach
   Upreti, Meenakshi
TI Toxicity evaluation of magnetic hyperthermia induced by remote actuation
   of magnetic nanoparticles in 3D micrometastasic tumor tissue analogs for
   triple negative breast cancer
SO BIOMATERIALS
LA English
DT Article
DE Magnetic nanoparticles (MNP); Tumor tissue analogs (TTA); Alternating
   magnetic field (AMF); Triple negative breast cancer (TNBC); Metastasis
   and Transmission electron microscopy (TEM)
ID IRON-OXIDE NANOPARTICLES; CELL LUNG-CANCER; HYDROGEL NANOCOMPOSITES;
   INHALED DOXORUBICIN; CHEMOTHERAPY; METASTASIS; DELIVERY; THERAPY; DRUG;
   FUNCTIONALIZATION
AB Magnetic hyperthermia as a treatment modality is acquiring increased recognition for loco-regional therapy of primary and metastatic lung malignancies by pulmonary delivery of magnetic nano particles (MNP). The unique characteristic of magnetic nanoparticles to induce localized hyperthermia in the presence of an alternating magnetic field (AMF) allows for preferential killing of cells at the tumor site. In this study we demonstrate the effect of hyperthermia induced by low and high dose of MNP under the influence of an AMF using 3D tumor tissue analogs (TTA) representing the micrometastatic, perfusion independent stage of triple negative breast cancer (TNBC) that infiltrates the lungs. While application of inhalable magnetic nanocomposite microparticles or magnetic nanocomposites (MnMs) to the micrometastatic TNBC model comprised of TTA generated from cancer and stromal cells, showed no measureable adverse effects in the absence of AMF-exposure, magnetic hyperthermia generated under the influence of an AMF in TTA incubated in a high concentration of MNP (1 mg/mL) caused significant increase in cellular death/damage with mechanical disintegration and release of cell debris indicating the potential of these inhalable composites as a promising approach for thermal treatment of diseased lungs. The novelty and significance of this study lies in the development of methods to evaluate in vitro the application of inhalable composites containing MNPs in thermal therapy using a physiologically relevant metastatic TNBC model representative of the microenvironmental characteristics in secondary lung malignancies. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Stocke, Nathanael A.; Hilt, J. Zach.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Sethi, Pallavi; Jyoti, Amar; Chan, Ryan; Upreti, Meenakshi] Univ Kentucky, Dept Pharmaceut Sci, 789 S Limestone St, Lexington, KY 40506 USA.
   [Arnold, Susanne M.] Univ Kentucky, Coll Med, Dept Internal Med, Lexington, KY 40506 USA.
RP Upreti, M (reprint author), Univ Kentucky, Dept Pharmaceut Sci, 789 S Limestone St, Lexington, KY 40506 USA.
EM m.upreti@uky.edu
FU NCI [R25CA153954, R21CA173609]
FX NAS and AJ were supported by the R25CA153954 from the NCI. Additional
   support for the study was provided by the R21CA173609 (MU) also from the
   NCI. The content is solely the responsibility of the authors and does
   not necessarily represent the official views of the National Cancer
   Institute or the National Institutes of Health.
CR Andre F, 2012, ANN ONCOL, V23, P46, DOI 10.1093/annonc/mds195
   Babincova M, 2008, IEEE T NANOBIOSCI, V7, P15, DOI 10.1109/TNB.2008.2000145
   Blanco-Andujar C, 2016, NANOMEDICINE-UK, V11, P121, DOI 10.2217/nnm.15.185
   Calatayud MP, 2016, CURR NANOSCI, V12, P372, DOI 10.2174/1573413712666151124195846
   Carrey J, 2013, APPL PHYS LETT, V102, DOI 10.1063/1.4810972
   Cheng DF, 2014, NANOSCALE RES LETT, V9, DOI 10.1186/1556-276X-9-195
   Dames P, 2007, NAT NANOTECHNOL, V2, P495, DOI 10.1038/nnano.2007.217
   DeSantis C, 2014, CA-CANCER J CLIN, V64, P52, DOI 10.3322/caac.21203
   Frimpong RA, 2010, NANOMEDICINE-UK, V5, P1401, DOI 10.2217/NNM.10.114
   Frimpong RA, 2010, J MAGN MAGN MATER, V322, P326, DOI 10.1016/j.jmmm.2009.09.050
   Galluzzi L, 2007, CELL DEATH DIFFER, V14, P1237, DOI 10.1038/sj.cdd.4402148
   Gerratana L, 2015, CLIN EXP METASTAS, V32, P125, DOI 10.1007/s10585-015-9697-2
   Hao R, 2010, ADV MATER, V22, P2729, DOI 10.1002/adma.201000260
   Hasenpusch G, 2012, PHARM RES-DORDR, V29, P1308, DOI 10.1007/s11095-012-0682-z
   Hauser AK, 2015, J CONTROL RELEASE, V219, P76, DOI 10.1016/j.jconrel.2015.09.039
   Hudis CA, 2011, ONCOLOGIST, V16, P1, DOI 10.1634/theoncologist.2011-S1-01
   Jordan A, 1999, J MAGN MAGN MATER, V201, P413, DOI 10.1016/S0304-8853(99)00088-8
   Kassam F, 2009, CLIN BREAST CANCER, V9, P29, DOI 10.3816/CBC.2009.n.005
   Kau P, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-120
   Kirstein MN, 2008, CANCER CHEMOTH PHARM, V61, P291, DOI 10.1007/s00280-007-0474-z
   Kobayashi T, 2014, NANOMEDICINE-UK, V9, P1715, DOI [10.2217/NNM.14.106, 10.2217/nnm.14.106]
   Kolosnjaj-Tabi J, 2014, ACS NANO, V8, P4268, DOI 10.1021/nn405356r
   Kruse AM, 2014, ACTA BIOMATER, V10, P2622, DOI 10.1016/j.actbio.2014.01.025
   Kuzmov A, 2015, J CONTROL RELEASE, V219, P500, DOI 10.1016/j.jconrel.2015.07.024
   Lubner MG, 2010, J VASC INTERV RADIOL, V21, pS192, DOI 10.1016/j.jvir.2010.04.007
   Mahmoudi M, 2011, ADV DRUG DELIVER REV, V63, P24, DOI 10.1016/j.addr.2010.05.006
   Mitra SK, 2006, ONCOGENE, V25, P4429, DOI 10.1038/sj.onc.1209482
   Oh Y, 2016, NANOTECHNOLOGY, V27, DOI 10.1088/0957-4484/27/11/115101
   Otterson GA, 2007, CLIN CANCER RES, V13, P1246, DOI 10.1158/1078-0432.CCR-06-1096
   Otterson GA, 2010, CLIN CANCER RES, V16, P2466, DOI 10.1158/1078-0432.CCR-09-3015
   Sadhukha T, 2014, BIOMATERIALS, V35, P7860, DOI 10.1016/j.biomaterials.2014.05.085
   Sadhukha T, 2013, BIOMATERIALS, V34, P5163, DOI 10.1016/j.biomaterials.2013.03.061
   Satarkar NS, 2008, J CONTROL RELEASE, V130, P246, DOI 10.1016/j.jconrel.2008.06.008
   Satarkar NS, 2008, ACTA BIOMATER, V4, P11, DOI 10.1016/j.actbio.2007.07.009
   Satarkar NS, 2011, AICHE J, V57, P852, DOI 10.1002/aic.12309
   Sethi P, 2015, NANOMED-NANOTECHNOL, V11, P2013, DOI 10.1016/j.nano.2015.07.013
   Shenoi MM, 2011, NANOMEDICINE-UK, V6, P545, DOI [10.2217/NNM.10.153, 10.2217/nnm.10.153]
   Shetake NG, 2015, INT J HYPERTHER, V31, P909, DOI 10.3109/02656736.2015.1075072
   Stocke NA, 2015, INT J PHARMACEUT, V479, P320, DOI 10.1016/j.ijpharm.2014.12.050
   Thiesen B, 2008, INT J HYPERTHER, V24, P467, DOI 10.1080/02656730802104757
   Torres-Lugo M, 2013, NANOMEDICINE-UK, V8, P1689, DOI [10.2217/nnm.13.146, 10.2217/NNM.13.146]
   Tseng LM, 2013, NEOPLASMA, V60, P290, DOI 10.4149/neo_2013_038
   Upreti M, 2011, TRANSL ONCOL, V4, P365, DOI 10.1593/tlo.11187
   Vertrees RA, 2002, PERFUSION-UK, V17, P279, DOI 10.1191/0267659102pf588oa
   Walter-Yohrling J, 2004, CLIN CANCER RES, V10, P2179, DOI 10.1158/1078-0432.CCR-03-1013
   Wydra RJ, 2013, MAT SCI ENG C-MATER, V33, P4660, DOI 10.1016/j.msec.2013.07.019
   Zarogoulidis K, 2013, J THORAC DIS, V5, pS389, DOI 10.3978/j.issn.2072-1439.2013.07.10
   Zarogoulidis P, 2012, INVEST NEW DRUG, V30, P1628, DOI 10.1007/s10637-011-9714-5
NR 48
TC 6
Z9 6
U1 13
U2 46
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
EI 1878-5905
J9 BIOMATERIALS
JI Biomaterials
PD MAR
PY 2017
VL 120
BP 115
EP 125
DI 10.1016/j.biomaterials.2016.12.019
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA EL1RO
UT WOS:000394398900011
PM 28056401
DA 2018-03-20
ER

PT J
AU Hawkins, AM
   Puleo, DA
   Hilt, JZ
AF Hawkins, Ashley M.
   Puleo, David A.
   Hilt, J. Zach
TI Effect of Macromer Synthesis Time on the Properties of the Resulting
   Poly(beta-amino ester) Degradable Hydrogel
SO JOURNAL OF APPLIED POLYMER SCIENCE
LA English
DT Article
DE biodegradable; hydrogels; poly(beta-amino esters); biological
   applications of polymers; kinetics (of polymerization)
ID POLYMER LIBRARY APPROACH; NETWORK PROPERTIES; FIBROUS SCAFFOLDS; GENE
   DELIVERY
AB Poly(beta-amino ester) biodegradable hydrogels are common in biomedical applications because of their tunable properties and similarities to natural soft tissue. Previous work has shown property adjustments through the choice of monomers, the ratio between monomers and the addition of a crosslinking component. Here, we show that the reaction time for the creation of the macromer can affect the resulting hydrogel properties, and thus provides another method of tuning properties. Macromer was created through the reaction of isobutylamine with poly(ethylene glycol) diacrylate (n = 400). The reaction progress was analyzed using IR and GPC analysis. Hydrogels were created through UV photopolymerization from macromers synthesized for 24, 36, and 48 h. The degradation, compressive moduli, and swelling were measured in an aqueous solution. All showed significant differences between hydrogels of different macromer synthesis times. These differences likely stem from the incomplete macromer synthesis reaction and resulting PEG-rich regions in hydrogels from shorter synthesis times. These regions will not readily degrade, but do increase the mechanical properties and extent of swelling. (C) 2011 Wiley Periodicals, Inc. J Appl Polym Sci 122: 1420-1426, 2011
C1 [Hawkins, Ashley M.; Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Puleo, David A.] Univ Kentucky, Ctr Biomed Engn, Lexington, KY 40506 USA.
RP Hilt, JZ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM hilt@engr.uky.edu
FU NSF-IGERT
FX The authors would like to acknowledge NSF-IGERT for their funding
   support and thank Paritosh Wattamwar for his assistance in the GPC
   analysis.
CR Anderson DG, 2006, ADV MATER, V18, P2614, DOI 10.1002/adma.200600529
   Anderson DG, 2004, P NATL ACAD SCI USA, V101, P16028, DOI 10.1073/pnas.0407218101
   Atzet S, 2008, BIOMACROMOLECULES, V9, P3370, DOI 10.1021/bm800686h
   Brey DM, 2008, J BIOMED MATER RES A, V85A, P731, DOI 10.1002/jbm.a.31494
   Brey DM, 2008, ACTA BIOMATER, V4, P207, DOI 10.1016/j.actbio.2007.10.002
   Green JJ, 2008, ACCOUNTS CHEM RES, V41, P749, DOI 10.1021/ar7002336
   Green JJ, 2006, BIOCONJUGATE CHEM, V17, P1162, DOI 10.1021/bc0600968
   Hawkins AM, 2009, PHARM RES-DORD, V26, P667, DOI 10.1007/s11095-008-9804-z
   Jia XQ, 2009, MACROMOL BIOSCI, V9, P140, DOI 10.1002/mabi.200800284
   Lynn DM, 2000, J AM CHEM SOC, V122, P10761, DOI 10.1021/ja0015388
   Metter RB, 2010, ACTA BIOMATER, V6, P1219, DOI 10.1016/j.actbio.2009.10.027
   Padmavathi NC, 1996, MACROMOLECULES, V29, P1976, DOI 10.1021/ma950827r
   Qiu Y, 2001, ADV DRUG DELIVER REV, V53, P321, DOI 10.1016/S0169-409X(01)00203-4
   Rakovsky A, 2009, J APPL POLYM SCI, V112, P390, DOI 10.1002/app.29420
   Slaughter BV, 2009, ADV MATER, V21, P3307, DOI 10.1002/adma.200802106
   STILLE JK, 1981, J CHEM EDUC, V58, P862, DOI 10.1021/ed058p862
   Tan AR, 2008, J BIOMED MATER RES A, V87A, P1034, DOI 10.1002/jbm.a.31853
   Zhu JM, 2010, BIOMATERIALS, V31, P4639, DOI 10.1016/j.biomaterials.2010.02.044
NR 18
TC 10
Z9 10
U1 0
U2 23
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0021-8995
J9 J APPL POLYM SCI
JI J. Appl. Polym. Sci.
PD OCT 15
PY 2011
VL 122
IS 2
BP 1420
EP 1426
DI 10.1002/app.34093
PG 7
WC Polymer Science
SC Polymer Science
GA 805PQ
UT WOS:000293741800082
DA 2018-03-20
ER

PT J
AU Park, CW
   Mansour, HM
   Oh, TO
   Kim, JY
   Ha, JM
   Lee, BJ
   Chi, SC
   Rhee, YS
   Park, ES
AF Park, Chun-Woong
   Mansour, Heidi M.
   Oh, Tack-Oon
   Kim, Ju-Young
   Ha, Jung-Myung
   Lee, Beom-Jin
   Chi, Sang-Cheol
   Rhee, Yun-Seok
   Park, Eun-Seok
TI Phase behavior of itraconazole-phenol mixtures and its pharmaceutical
   applications
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Itraconazole; Phenol; Eutectic mixture; Topical; Skin permeation
ID SOLID DISPERSION; BETA-CYCLODEXTRIN; DOSE PHARMACOKINETICS;
   POLYETHYLENE-GLYCOL; MOLECULAR MOBILITY; T-G; FORMULATION; RATS;
   BIOAVAILABILITY; ASPERGILLOSIS
AB The aims of this study were to examine the phase behavior of itraconazole-phenol mixtures and assess the feasibility of topical formulations of itraconazole using eutectic mixture systems. Itraconazole-phenol eutectic mixtures were characterized using differential scanning calorimetry, Fourier transform infrared spectroscopy, H-1-nuclear magnetic resonance, and powder X-ray diffractometry. The skin permeation rates of itraconazole-phenol eutectic formulations were determined using Franz diffusion cells fitted with excised hairless mouse skins. Itraconazole can form eutectic compounds with phenol, and the hydrogen-bonding interactions between the carbonyl group in the itraconazole and hydroxyl group in phenol play a major role in itraconazole-phenol eutectic formation. Despite its high molecular weight and hydrophobicity, the drug (i.e., itraconazole) can be permeated through excised hairless mouse skins from itraconazole-phenol eutectic formulations. The findings of this study emphasize the capabilities of the topical application of itraconazole via external preparations. (c) 2012 Elsevier B.V. All rights reserved.
C1 [Park, Chun-Woong; Oh, Tack-Oon; Kim, Ju-Young; Ha, Jung-Myung; Chi, Sang-Cheol; Park, Eun-Seok] Sungkyunkwan Univ, Sch Pharm, Suwon 440746, Gyeonggi Do, South Korea.
   [Park, Chun-Woong] Chungbuk Natl Univ, Coll Pharm, Cheongju 361763, Chungbuk, South Korea.
   [Mansour, Heidi M.] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Drug Dev Div, Lexington, KY 40536 USA.
   [Lee, Beom-Jin] Ajou Univ, Coll Pharm, Suwon 443749, Gyeonggi Do, South Korea.
   [Rhee, Yun-Seok] Gyeongsang Natl Univ, Coll Pharm, Jinju 660751, Gyeongnam, South Korea.
   [Rhee, Yun-Seok] Gyeongsang Natl Univ, Res Inst Pharmaceut Sci, Jinju 660751, Gyeongnam, South Korea.
RP Park, ES (reprint author), Sungkyunkwan Univ, Sch Pharm, 300 Cheoncheon Dong, Suwon 440746, Gyeonggi Do, South Korea.
EM ysrhee@gnu.ac.kr; espark@skku.edu
FU Korean Health Technology R&D Project, Ministry for Health, Welfare &
   Family Affairs, Republic of Korea [A092018]
FX This study was supported by a grant of the Korean Health Technology R&D
   Project, Ministry for Health, Welfare & Family Affairs, Republic of
   Korea (A092018).
CR Abdel-Rahman SM, 2007, ANTIMICROB AGENTS CH, V51, P2668, DOI 10.1128/AAC.00297-07
   Al-Marzouqi AH, 2006, J PHARM SCI-US, V95, P292, DOI 10.1002/jps.20535
   Anaissie E., 1992, CLIN INFECT DIS   S1, V14, pS43L
   Barry BW, 1983, DERMATOLOGICAL FORMU
   BRADFORD CR, 1991, J ANTIMICROB CHEMOTH, V28, P555, DOI 10.1093/jac/28.4.555
   Brewster ME, 2008, EUR J PHARM SCI, V34, P94, DOI 10.1016/j.ejps.2008.02.007
   Buchanan CM, 2007, J PHARM SCI-US, V96, P3100, DOI 10.1002/jps.20878
   Cho H.J., 2005, J KOREAN PHARM SCI, V35, P165
   Chowdary KPR, 2000, DRUG DEV IND PHARM, V26, P1207, DOI 10.1081/DDC-100100993
   COMO JA, 1994, NEW ENGL J MED, V330, P263
   Damian F, 2000, EUR J PHARM SCI, V10, P311, DOI 10.1016/S0928-0987(00)00084-1
   DeBeule K, 1996, INT J ANTIMICROB AG, V6, P175, DOI 10.1016/0924-8579(95)00043-7
   DEBEULE K, 1988, MYCOSES, V31, P476
   deChasteigner S, 1996, DRUG DEVELOP RES, V38, P125, DOI 10.1002/(SICI)1098-2299(199606)38:2<125::AID-DDR7>3.3.CO;2-Q
   DUPONT B, 1990, J AM ACAD DERMATOL, V23, P607, DOI 10.1016/0190-9622(90)70263-H
   Francois M, 2003, AAPS PHARMSCI, V5
   ISAMA K, 1993, J BIOMED MATER RES, V27, P539, DOI 10.1002/jbm.820270415
   Jung JY, 1999, INT J PHARM, V187, P209, DOI 10.1016/S0378-5173(99)00191-X
   KAUR R, 1980, J PHARM SCI, V69, P1317, DOI 10.1002/jps.2600691121
   Kipp JE, 2004, INT J PHARM, V284, P109, DOI 10.1016/j.ijpharm.2004.07.019
   Lee E. A., 2007, J KOREAN PHARM SCI, V37, P167
   Martinez-Ramos M, 2008, CLIN EXP OPHTHALMOL, V36, P335, DOI 10.1111/j.1442-9071.2008.01767.x
   Nesseem DI, 2001, J PHARMACEUT BIOMED, V26, P387, DOI 10.1016/S0731-7085(01)00414-9
   Rabinow B, 2007, INT J PHARM, V339, P251, DOI 10.1016/j.ijpharm.2007.02.030
   Rhee YS, 2007, ARCH PHARM RES, V30, P114, DOI 10.1007/BF02977787
   Silverstein R. M., 1991, SPECTROMETRIC IDENTI
   Six K, 2001, INT J PHARM, V213, P163, DOI 10.1016/S0378-5173(00)00662-1
   Stott PW, 1998, J CONTROL RELEASE, V50, P297, DOI 10.1016/S0168-3659(97)00153-3
   Tang JL, 2010, DRUG DELIV, V17, P223, DOI 10.3109/10717541003667822
   TRICOT G, 1987, REV INFECT DIS, V9, pS94
   VANCUTSEM J, 1984, ANTIMICROB AGENTS CH, V26, P527, DOI 10.1128/AAC.26.4.527
   Weuts I, 2003, INT J PHARM, V259, P17, DOI 10.1016/S0378-5173(03)00233-3
   Yang W, 2008, INT J PHARM, V361, P177, DOI 10.1016/j.ijpharm.2008.05.003
   Yang W, 2010, EUR J PHARM BIOPHARM, V75, P33, DOI 10.1016/j.ejpb.2010.01.011
   Yao WW, 2005, THERMOCHIM ACTA, V437, P17, DOI 10.1016/j.tca.2005.06.012
   Ye GH, 2007, INT J PHARM, V337, P80, DOI 10.1016/j.ijpharm.2006.12.028
   Yi Y, 2007, J CONTROL RELEASE, V117, P59, DOI 10.1016/j.jconret.2006.10.001
   Yoo SD, 2000, DRUG DEV IND PHARM, V26, P27, DOI 10.1081/DDC-100100324
   Yoo SD, 2000, CHEM PHARM BULL, V48, P798
NR 39
TC 5
Z9 5
U1 1
U2 17
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD OCT 15
PY 2012
VL 436
IS 1-2
BP 652
EP 658
DI 10.1016/j.ijpharm.2012.07.054
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 003GS
UT WOS:000308597600073
PM 22871560
DA 2018-03-20
ER

PT J
AU Korotkova, N
   Piton, J
   Wagner, JM
   Boy-Rottger, S
   Japaridze, A
   Evans, TJ
   Cole, ST
   Pojer, F
   Korotkov, KV
AF Korotkova, Natalia
   Piton, Jeremie
   Wagner, Jonathan M.
   Boy-Roettger, Stefanie
   Japaridze, Aleksandre
   Evans, Timothy J.
   Cole, Stewart T.
   Pojer, Florence
   Korotkov, Konstantin V.
TI Structure of EspB, a secreted substrate of the ESX-1 secretion system of
   Mycobacterium tuberculosis
SO JOURNAL OF STRUCTURAL BIOLOGY
LA English
DT Article
DE PE domain; PPE domain; Type VII secretion system; ESX
ID VII SECRETION; PROTEIN SECRETION; PATHOGENIC MYCOBACTERIA; VIRULENCE
   FACTORS; DATA QUALITY; COMPLEX; PATHWAY; MODEL; PE; CRYSTALLOGRAPHY
AB Mycobacterium tuberculosis secretes multiple virulence factors during infection via the general Sec and Tat pathways, and via specialized ESX secretion systems, also referred to as type VII secretion systems. The ESX-1 secretion system is an important virulence determinant because deletion of ESX-1 leads to attenuation of M. tuberculosis. ESX-1 secreted protein B (EspB) contains putative PE (Pro-Glu) and PPE (Pro-Pro-Glu) domains, and a C-terminal domain, which is processed by MycP(1) protease during secretion. We determined the crystal structure of PE-PPE domains of EspB, which represents an all-helical, elongated molecule closely resembling the structure of the PE25-PPE41 heterodimer despite limited sequence similarity. Also, we determined the structure of full-length EspB, which does not have interpretable electron density for the C-terminal domain confirming that it is largely disordered. Comparative analysis of EspB in cell lysate and culture filtrates of M. tuberculosis revealed that mature secreted EspB forms oligomers. Electron microscopy analysis showed that the N-terminal fragment of EspB forms donut-shaped particles. These data provide a rationale for the future investigation of EspB's role in M. tuberculosis pathogenesis. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Korotkova, Natalia; Wagner, Jonathan M.; Evans, Timothy J.; Korotkov, Konstantin V.] Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA.
   [Korotkova, Natalia; Wagner, Jonathan M.; Evans, Timothy J.; Korotkov, Konstantin V.] Univ Kentucky, Struct Biol Ctr, Lexington, KY 40536 USA.
   [Piton, Jeremie; Boy-Roettger, Stefanie; Cole, Stewart T.; Pojer, Florence] Ecole Polytech Fed Lausanne, Global Hlth Inst, CH-1015 Lausanne, Switzerland.
   [Japaridze, Aleksandre] Ecole Polytech Fed Lausanne, Lab Phys Living Matter, CH-1015 Lausanne, Switzerland.
RP Pojer, F (reprint author), Ecole Polytech Fed Lausanne, Global Hlth Inst, CH-1015 Lausanne, Switzerland.
EM florence.pojer@epfl.ch; kkorotkov@uky.edu
RI EPFL, Physics/O-6514-2016
OI Korotkova, Natalia/0000-0002-8696-4892; Japaridze,
   Aleksandre/0000-0002-9581-9128; Korotkov, Konstantin/0000-0002-2182-6843
FU U.S. Department of Energy, Office of Science, Office of Basic Energy
   Sciences [W-31-109-Eng-38]; NIH/NIGMS [P30GM110787, P20GM103486]; Swiss
   National Science Foundation [31003A-140778]
FX Authors thank staff members of Southeast Regional Collaborative Access
   Team (SER-CAT) at the Advanced Photon Source, Argonne National
   Laboratory, for assistance during data collection. Use of the Advanced
   Photon Source was supported by the U.S. Department of Energy, Office of
   Science, Office of Basic Energy Sciences, under Contract No.
   W-31-109-Eng-38. We thank the EPFL Bioelectron Microscopy and Protein
   Crystallography Core Facilities, and the Swiss Light Source for beam
   time and excellent support. We acknowledge the University of Kentucky
   Protein Analytical Core that is supported by NIH/NIGMS grant
   P30GM110787. This study was supported in part by NIH/NIGMS grant
   P20GM103486 to K.V.K. This study received funding from the Swiss
   National Science Foundation to S.T.C. (31003A-140778).
CR Abdallah AM, 2011, J IMMUNOL, V187, P4744, DOI 10.4049/jimmunol.1101457
   Afonine PV, 2012, ACTA CRYSTALLOGR D, V68, P352, DOI 10.1107/S0907444912001308
   Arbing MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081753
   Bottai D, 2012, MOL MICROBIOL, V83, P1195, DOI 10.1111/j.1365-2958.2012.08001.x
   Carlsson F, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000285
   Champion PAD, 2009, MOL MICROBIOL, V73, P950, DOI 10.1111/j.1365-2958.2009.06821.x
   Chen JM, 2013, MOL MICROBIOL, V89, P1154, DOI 10.1111/mmi.12336
   Chen JM, 2012, J BACTERIOL, V194, P884, DOI 10.1128/JB.06417-11
   Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073
   Chovancova E, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002708
   Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159
   Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112
   Cowtan K, 2006, ACTA CRYSTALLOGR D, V62, P1002, DOI 10.1107/S0907444906022116
   Daleke MH, 2012, J BIOL CHEM, V287, P31939, DOI 10.1074/jbc.M112.397596
   Daleke MH, 2012, P NATL ACAD SCI USA, V109, P11342, DOI 10.1073/pnas.1119453109
   Daleke MH, 2011, J BIOL CHEM, V286, P19024, DOI 10.1074/jbc.M110.204966
   Ekiert DC, 2014, P NATL ACAD SCI USA, V111, P14758, DOI 10.1073/pnas.1409345111
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Evans P, 2006, ACTA CRYSTALLOGR D, V62, P72, DOI 10.1107/S0907444905036693
   Guinn KM, 2004, MOL MICROBIOL, V51, P359, DOI 10.1046/j.1365-2958.2003.03844.x
   Houben D, 2012, CELL MICROBIOL, V14, P1287, DOI 10.1111/j.1462-5822.2012.01799.x
   Houben ENG, 2014, BBA-MOL CELL RES, V1843, P1707, DOI 10.1016/j.bbamcr.2013.11.003
   Ilghari D, 2011, J BIOL CHEM, V286, P29993, DOI 10.1074/jbc.M111.248732
   Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337
   Karplus PA, 2012, SCIENCE, V336, P1030, DOI [10.1126/science.121823, 10.1126/science.1218231]
   Korotkova N, 2014, MOL MICROBIOL, V94, P367, DOI 10.1111/mmi.12770
   Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460
   Langer G, 2008, NAT PROTOC, V3, P1171, DOI 10.1038/nprot.2008.91
   Majlessi L, 2005, J IMMUNOL, V174, P3570, DOI 10.4049/jimmunol.174.6.3570
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206
   McLaughlin B, 2007, PLOS PATHOG, V3, P1051, DOI 10.1371/journal.ppat.0030105
   Mishra KC, 2008, INFECT IMMUN, V76, P127, DOI 10.1128/IAI.00410-07
   Murshudov GN, 2011, ACTA CRYSTALLOGR D, V67, P355, DOI 10.1107/S0907444911001314
   O'Maille PE, 2004, METHOD ENZYMOL, V388, P75
   Ohol YM, 2010, CELL HOST MICROBE, V7, P210, DOI 10.1016/j.chom.2010.02.006
   Painter J, 2006, ACTA CRYSTALLOGR D, V62, P439, DOI 10.1107/S0907444906005270
   Pallen MJ, 2002, TRENDS MICROBIOL, V10, P209, DOI 10.1016/S0966-842X(02)02345-4
   Poulsen C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089313
   Renshaw PS, 2005, EMBO J, V24, P2491, DOI 10.1038/sj.emboj.7600732
   Robert X, 2014, NUCLEIC ACIDS RES, V42, pW320, DOI 10.1093/nar/gku316
   Serafini A, 2009, J BACTERIOL, V191, P6340, DOI 10.1128/JB.00756-09
   Siegrist MS, 2009, P NATL ACAD SCI USA, V106, P18792, DOI 10.1073/pnas.0900589106
   Siegrist M.S., 2014, MBIO, V5
   Simeone R, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002507
   Solomonson M, 2015, STRUCTURE, V23, P571, DOI 10.1016/j.str.2015.01.002
   Solomonson M, 2013, J BIOL CHEM, V288, P17782, DOI 10.1074/jbc.M113.462036
   Stanley SA, 2003, P NATL ACAD SCI USA, V100, P13001, DOI 10.1073/pnas.2235593100
   Strong M, 2006, P NATL ACAD SCI USA, V103, P8060, DOI 10.1073/pnas.0602606103
   Sultana R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055320
   Sultana R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016745
   Ummels R., 2014, MBIO, V5
   van der Wel N, 2007, CELL, V129, P1287, DOI 10.1016/j.cell.2007.05.059
   Gey van Pittius N. C., 2006, BMC EVOL BIOL, V6, P95, DOI DOI 10.1186/1471-2148-6-95
   Wagner JM, 2013, J STRUCT BIOL, V184, P115, DOI 10.1016/j.jsb.2013.09.022
   Xu J, 2007, MOL MICROBIOL, V66, P787, DOI 10.1111/j.1365-2958.2007.05959.x
   Zhang KYJ, 1997, METHOD ENZYMOL, V277, P53, DOI 10.1016/S0076-6879(97)77006-X
NR 56
TC 6
Z9 7
U1 7
U2 27
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1047-8477
EI 1095-8657
J9 J STRUCT BIOL
JI J. Struct. Biol.
PD AUG
PY 2015
VL 191
IS 2
BP 236
EP 244
DI 10.1016/j.jsb.2015.06.003
PG 9
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA CO3YH
UT WOS:000359096700017
PM 26051906
OA green_accepted
DA 2018-03-20
ER

PT J
AU Yu, SA
   Luo, AQ
   Biswal, D
   Hilt, JZ
   Puleo, DA
AF Yu, Shuang
   Luo, Ai-qin
   Biswal, Dipti
   Hilt, J. Zach
   Puleo, David A.
TI Lysozyme-imprinted polymer synthesized using UV free-radical
   polymerization
SO TALANTA
LA English
DT Article
DE Lysozyme; Molecular imprinting; Molecularly imprinted polymer; Molecular
   recognition
ID PROTEIN RECOGNITION; HYDROGELS; ULTRAFILTRATION; PURIFICATION;
   SEPARATION; NETWORKS; FILMS
AB Molecular imprinting is a method to fabricate a polymeric material (molecularly imprinted polymer or MIP) capable of selectively recognizing template molecules Molecular imprinting of small molecules has been studied widely Less common however is the imprinting of biological macromolecules including proteins among which lysozyme is an important molecule in the food pharmaceutical and diagnostic sciences In this study lysozyme MIP was fabricated in two steps First lysozyme PEG600DMA and methacrylic acid were used as the template molecule cross-linking monomer and the functional monomer respectively in a UV free-radical polymerization process to synthesize a polymeric gel Second lysozyme was removed by enzymatic digestion Non-imprinted polymer (NIP) was synthesized without lysozyme addition To evaluate the preferential binding capability of MIP lysozyme RNase A or a 50 50 mixture of lysozyme and RNase A was added to MIP and NIP and then released by digestion It was found that when more lysozyme was added to the reaction mixture the quantity of protein released from the polymer increased reflecting more potential binding sites Tests of MIP with a competitive binding mixture of lysozyme and RNase A showed the MIP preferentially bound a greater amount of lysozyme up to 20 times more than RNase A NIP bound only small amounts of both proteins and did not show a preference for binding either lysozyme or RNase A These results demonstrate that lysozyme was successfully imprinted into the MIP by UV free-radical polymerization and the fabricated MIP was able to preferentially bind its template protein (C) 2010 Elsevier B V All rights reserved
C1 [Puleo, David A.] Univ Kentucky, Ctr Biomed Engn, Wenner Gren Lab, Lexington, KY 40506 USA.
   [Yu, Shuang; Luo, Ai-qin] Beijing Inst Technol, Sch Life Sci, Beijing 100081, Peoples R China.
   [Biswal, Dipti; Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Puleo, DA (reprint author), Univ Kentucky, Ctr Biomed Engn, Wenner Gren Lab, Lexington, KY 40506 USA.
FU China Scholarship Council (CSC)
FX This work was financially supported by a national scholarship from the
   China Scholarship Council (CSC) Ms Yu was a visiting student under the
   supervision of Dr Puleo in the Center for Biomedical Engineering
   University of Kentucky USA
CR Alexander C, 2006, J MOL RECOGNIT, V19, P106, DOI 10.1002/jmr.760
   Bereli N, 2008, J CHROMATOGR A, V1190, P18, DOI 10.1016/j.chroma.2008.02.110
   Byrne ME, 2002, POLYM ADVAN TECHNOL, V13, P798, DOI 10.1002/pat.272
   Dai S, 1997, CHEM MATER, V9, P2521, DOI 10.1021/cm970209k
   DAS S, 1992, CHEMOTHERAPY, V38, P350, DOI 10.1159/000239025
   Ghosh R, 2000, BIOCHEM ENG J, V6, P19, DOI 10.1016/S1369-703X(00)00069-3
   Ghosh R, 2000, J MEMBRANE SCI, V167, P47, DOI 10.1016/S0376-7388(99)00275-6
   Gupta R, 2008, BIOTECHNOL ADV, V26, P533, DOI 10.1016/j.biotechadv.2008.07.002
   He HY, 2010, BIOSENS BIOELECTRON, V26, P760, DOI 10.1016/j.bios.2010.06.043
   Hilt JZ, 2006, CHEM MATER, V18, P5869, DOI 10.1021/cm061343k
   Hilt JZ, 2003, BIOMED MICRODEVICES, V5, P177, DOI 10.1023/A:1025786023595
   Kimhi O, 2007, LANGMUIR, V23, P6329, DOI 10.1021/la700248s
   Kindschy LM, 2004, T ASAE, V47, P1375
   Knubovets T, 1999, P NATL ACAD SCI USA, V96, P1262, DOI 10.1073/pnas.96.4.1262
   Lee K, 2007, ACTA BIOMATER, V3, P515, DOI 10.1016/j.actbio.2007.01.003
   Liu Q, 2000, BIOMATERIALS, V21, P2163, DOI 10.1016/S0142-9612(00)00137-X
   Matsui J, 1996, ANAL CHIM ACTA, V335, P71, DOI 10.1016/S0003-2670(96)00356-X
   MOSBACH K, 1994, TRENDS BIOCHEM SCI, V19, P9, DOI 10.1016/0968-0004(94)90166-X
   NEAR KA, 1992, J CLIN MICROBIOL, V30, P1105
   Odabasi M, 2007, MAT SCI ENG C-BIO S, V27, P90, DOI 10.1016/j.msec.2006.03.002
   Ou SH, 2004, ANAL CHIM ACTA, V504, P163, DOI 10.1016/S0003-2670(03)00531-2
   PORSTMANN B, 1989, CLIN BIOCHEM, V22, P349, DOI 10.1016/S0009-9120(89)80031-1
   Purice A, 2007, APPL SURF SCI, V253, P6451, DOI 10.1016/j.apsusc.2007.01.066
   Takeuchi T, 2008, ORG BIOMOL CHEM, V6, P2459, DOI 10.1039/b715737c
   Tov OY, 2010, J SEP SCI, V33, P1673, DOI 10.1002/jssc.200900874
   Ward JH, 2001, J BIOMED MATER RES, V56, P351, DOI 10.1002/1097-4636(20010905)56:3<351::AID-JBM1103>3.0.CO;2-A
NR 26
TC 13
Z9 15
U1 2
U2 43
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0039-9140
J9 TALANTA
JI Talanta
PD NOV 15
PY 2010
VL 83
IS 1
BP 156
EP 161
DI 10.1016/j.talanta.2010.08.055
PG 6
WC Chemistry, Analytical
SC Chemistry
GA 690AQ
UT WOS:000284972800023
PM 21035657
DA 2018-03-20
ER

PT J
AU Leontsev, SO
   Eitel, RE
AF Leontsev, Serhiy O.
   Eitel, Richard E.
TI Progress in engineering high strain lead-free piezoelectric ceramics
SO SCIENCE AND TECHNOLOGY OF ADVANCED MATERIALS
LA English
DT Review
DE lead-free; ferroelectric ceramics; piezoelectricity; morphotropic phase
   boundary; polymorphic phase transformation; domain engineering;
   templated grain growth; grain size effect
ID MORPHOTROPIC-PHASE-BOUNDARY; POTASSIUM-SODIUM NIOBATE; BARIUM-TITANATE
   CERAMICS; HIGH CURIE-TEMPERATURE; ELECTRICAL-PROPERTIES;
   SOLID-SOLUTIONS; (BI1/2K1/2)TIO3 CERAMICS; SINGLE-CRYSTALS;
   DEPOLARIZATION TEMPERATURE; FERROELECTRIC PROPERTIES
AB Environmental concerns are strongly driving the need to replace the lead-based piezoelectric materials currently employed as multilayer actuators. The current review describes both compositional and structural engineering approaches to achieve enhanced piezoelectric properties in lead-free materials. The review of the compositional engineering approach focuses on compositional tuning of the properties and phase behavior in three promising families of lead-free perovskite ferroelectrics: the titanate, alkaline niobate and bismuth perovskites and their solid solutions. The 'structural engineering' approaches focus instead on optimization of microstructural features including grain size, grain orientation or texture, ferroelectric domain size and electrical bias field as potential paths to induce large piezoelectric properties in lead-free piezoceramics. It is suggested that a combination of both compositional and novel structural engineering approaches will be required in order to realize viable lead-free alternatives to current lead-based materials for piezoelectric actuator applications.
C1 [Leontsev, Serhiy O.; Eitel, Richard E.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Leontsev, SO (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM reitel@engr.uky.edu
RI Eitel, Richard/E-2889-2010
OI Eitel, Richard/0000-0002-5090-2075
CR AHTEE M, 1976, ACTA CRYSTALLOGR A, V32, P434, DOI 10.1107/S0567739476000983
   AHTEE M, 1978, ACTA CRYSTALLOGR A, V34, P309, DOI 10.1107/S056773947800056X
   Akdogan EK, 2008, APPL PHYS LETT, V92, DOI 10.1063/1.2897033
   BECHMANN R, 1956, J ACOUST SOC AM, V28, P347, DOI 10.1121/1.1908324
   Birol H, 2006, J EUR CERAM SOC, V26, P861, DOI 10.1016/j.jeurceramsoc.2004.11.022
   BUHRER CF, 1962, J CHEM PHYS, V36, P798, DOI 10.1063/1.1732613
   CHANG YF, 2007, APPL PHYS LETT, V90
   Chang YF, 2009, APPL PHYS LETT, V95, DOI 10.1063/1.3271682
   Chen M, 2008, J EUR CERAM SOC, V28, P843, DOI 10.1016/j.jeurceramsoc.2007.08.007
   Chu BJ, 2002, J EUR CERAM SOC, V22, P2115, DOI 10.1016/S0955-2219(02)00027-4
   Cross E, 2004, NATURE, V432, P24, DOI 10.1038/nature03142
   Davis M, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2472524
   Donnelly NJ, 2007, J AM CERAM SOC, V90, P490, DOI 10.1111/j.1551-2916.2006.01450.x
   Du HL, 2006, MAT SCI ENG B-SOLID, V131, P83, DOI 10.1016/j.mseb.2006.03.039
   Du HL, 2008, J APPL PHYS, V104, DOI 10.1063/1.2969773
   EGERTON L, 1968, AM CERAM SOC BULL, V47, P1151
   EGERTON L, 1959, J AM CERAM SOC, V42, P438, DOI 10.1111/j.1151-2916.1959.tb12971.x
   Eitel RE, 2002, JPN J APPL PHYS 1, V41, P2099, DOI 10.1143/JJAP.41.2099
   Eitel RE, 2001, JPN J APPL PHYS 1, V40, P5999, DOI 10.1143/JJAP.40.5999
   Elkechai O, 1996, PHYS STATUS SOLIDI A, V157, P499, DOI 10.1002/pssa.2211570234
   Fu J, 2010, J MATER SCI-MATER EL, V21, P241, DOI 10.1007/s10854-009-9899-y
   GRAY RB, 1949, TRANSDUCER METHOD MA
   Guo YP, 2005, MATER LETT, V59, P241, DOI 10.1016/j.matlet.2004.07.057
   Guo YP, 2004, APPL PHYS LETT, V85, P4121, DOI 10.1063/1.1813636
   HAERTLING GH, 1967, J AM CERAM SOC, V50, P329, DOI 10.1111/j.1151-2916.1967.tb15121.x
   Hao JG, 2009, J ALLOY COMPD, V479, P376, DOI 10.1016/j.jallcom.2008.12.069
   Hikita K, 2009, JPN J APPL PHYS, V48, DOI 10.1143/JJAP.48.07GA05
   Hiruma Y, 2005, JPN J APPL PHYS 1, V44, P5040, DOI 10.1143/JJAP.44.5040
   HIRUMA Y, 2006, ELECTROCERAMIES JAPA, V9, P23
   Hiruma Y, 2008, J APPL PHYS, V103, DOI 10.1063/1.2903498
   Hiruma Y, 2007, JPN J APPL PHYS 1, V46, P1081, DOI 10.1143/JJAP.46.1081
   Hiruma Y, 2008, J ELECTROCERAM, V21, P296, DOI 10.1007/s10832-007-9146-y
   Hollenstein E, 2005, APPL PHYS LETT, V87, DOI 10.1063/1.2123387
   Itoh N., 2007, FERROELECTRICS, V356, P19
   JAEGER RE, 1962, J AM CERAM SOC, V45, P209, DOI 10.1111/j.1151-2916.1962.tb11127.x
   Jaffe B., 1971, PIEZOELECTRIC CERAMI
   Jones GO, 2002, ACTA CRYSTALLOGR B, V58, P168, DOI 10.1107/S0108768101020845
   Karaki T, 2007, JPN J APPL PHYS 1, V46, P7035, DOI 10.1143/JJAP.46.7035
   Karaki T, 2007, JPN J APPL PHYS 2, V46, pL97, DOI 10.1143/JJAP.46.L97
   Kim MS, 2007, J AM CERAM SOC, V90, P3338, DOI 10.1111/j.1551-2916.2007.01893.x
   Kumar MM, 2000, J APPL PHYS, V87, P855, DOI 10.1063/1.371953
   Lebeugle D, 2007, APPL PHYS LETT, V91, DOI 10.1063/1.2753390
   Lei C, 2008, APPL PHYS LETT, V93, DOI 10.1063/1.2956410
   Leontsev SO, 2009, J AM CERAM SOC, V92, P2957, DOI 10.1111/j.1551-2916.2009.03313.x
   LEONTSEV SO, UNPUB
   Li EZ, 2008, JPN J APPL PHYS, V47, P7702, DOI 10.1143/JJAP.47.7702
   Li EZ, 2009, APPL PHYS LETT, V94, DOI 10.1063/1.3112564
   Li HD, 2004, MATER LETT, V58, P1194, DOI 10.1016/j.matlet.2003.08.034
   Li JF, 2006, J AM CERAM SOC, V89, P706, DOI 10.1111/j.1551-2916.2005.00743.x
   Lin DM, 2005, PHYS STATUS SOLIDI A, V202, pR89, DOI 10.1002/pssa.200510034
   Lin D, 2008, SOLID STATE IONICS, V178, P1930, DOI 10.1016/j.ssi.2007.12.096
   Lin DM, 2006, J EUR CERAM SOC, V26, P3247, DOI 10.1016/j.jeurceramsoc.2005.09.038
   Makiuchi Y, 2005, JPN J APPL PHYS 1, V44, P4350, DOI 10.1143/JJAP.44.4350
   Matsubara M, 2005, JPN J APPL PHYS 1, V44, P6618, DOI 10.1143/JJAP.44.6618
   Matsubara M, 2005, J AM CERAM SOC, V88, P1190, DOI 10.1111/j.1551-2916.2005.00229.x
   Matsubara M, 2004, JPN J APPL PHYS 1, V43, P7159, DOI 10.1143/JJAP.43.7159
   MATTHIAS BT, 1951, PHYS REV, V82, P727, DOI 10.1103/PhysRev.82.727
   Messing GL, 2004, CRIT REV SOLID STATE, V29, P45, DOI 10.1080/10408430490490905
   MICHEL C, 1969, SOLID STATE COMMUN, V7, P701, DOI 10.1016/0038-1098(69)90597-3
   Nagata H, 2003, JPN J APPL PHYS 1, V42, P7401, DOI 10.1143/JJAP.42.7401
   NAGATA H, 2004, CERAM T, V167, P8
   Nagata H, 2007, JPN J APPL PHYS 1, V46, P7084, DOI 10.1143/JJAP.46.7084
   Nakamura K, 1997, APPL PHYS LETT, V71, P3203, DOI 10.1063/1.120290
   Nakamura K, 2000, IEEE T ULTRASON FERR, V47, P750, DOI 10.1109/58.842064
   Nemoto M, 2008, JPN J APPL PHYS, V47, P3829, DOI 10.1143/JJAP.47.3829
   Nemoto M, 2009, JPN J APPL PHYS, V48, DOI 10.1143/JJAP.48.07GA04
   Oh T, 2006, MAT SCI ENG B-SOLID, V132, P239, DOI 10.1016/j.mseb.2006.02.070
   Oh T, 2006, JPN J APPL PHYS 1, V45, P5138, DOI 10.1143/JJAP.45.5138
   Park SE, 1999, J APPL PHYS, V86, P2746, DOI 10.1063/1.371120
   Park SE, 1997, J APPL PHYS, V82, P1804, DOI 10.1063/1.365983
   Popper P., 1957, BRIT CERAM T, V56
   Randall CA, 2005, J ELECTROCERAM, V14, P177, DOI 10.1007/s10832-005-0956-5
   ROBERTS S, 1947, PHYS REV, V71, P890, DOI 10.1103/PhysRev.71.890
   ROLEDER K, 1989, FERROELECTRICS, V89, P1, DOI 10.1080/00150198908017878
   Rubio-Marcos F, 2007, J EUR CERAM SOC, V27, P4125, DOI 10.1016/j.jeurceramsoc.2007.02.110
   Safari A, 2009, IEEE T ULTRASON FERR, V56, P1586, DOI 10.1109/TUFFC.2009.1223
   Saito Y, 2004, NATURE, V432, P84, DOI 10.1038/nature03028
   Saito Y, 2006, FERROELECTRICS, V338, P1433, DOI 10.1080/00150190600732512
   SAKATA K, 1974, FERROELECTRICS, V7, P347, DOI 10.1080/00150197408238042
   Sasaki A, 1999, JPN J APPL PHYS 1, V38, P5564, DOI 10.1143/JJAP.38.5564
   SAWAGUCHI E, 1953, J PHYS SOC JPN, V8, P615, DOI 10.1143/JPSJ.8.615
   SETTER N, 2005, CERAMICS LAB
   SHIRANE G, 1954, PHYS REV, V93, P672, DOI 10.1103/PhysRev.93.672
   SHIRANE G, 1954, PHYS REV, V96, P581, DOI 10.1103/PhysRev.96.581
   Shrout TR, 2007, J ELECTROCERAM, V19, P113, DOI 10.1007/s10832-007-9047-0
   Shrout T.R., 2002, PIEZOELECTRIC MAT DE
   Shvartsman VV, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2731312
   SMOLENSKII GA, 1960, SOV PHYS-SOLID STATE, V2, P2651
   SUCHANICZ J, 1988, FERROELECTRICS, V77, P107, DOI 10.1080/00150198808223232
   Takahashi H, 2006, JPN J APPL PHYS 2, V45, pL30, DOI 10.1143/JJAP.45.L30
   Takahashi H, 2006, JPN J APPL PHYS 1, V45, P7405, DOI 10.1143/JJAP.45.7405
   Takahashi H, 2008, JPN J APPL PHYS, V47, P8468, DOI 10.1143/JJAP.47.8468
   TAKENAKA T, 1991, JPN J APPL PHYS 1, V30, P2236, DOI 10.1143/JJAP.30.2236
   TAKENAKA T, 1990, FERROELECTRICS, V106, P375, DOI 10.1080/00150199008214612
   TAKENAKA T, 1999, ELECTROCERAMICS JAPA, V1, P57
   Takenaka T, 2008, JPN J APPL PHYS, V47, P3787, DOI 10.1143/JJAP.47.3787
   Tani T, 1998, J KOREAN PHYS SOC, V32, pS1217
   Tressler JF, 1999, COMPOS PART A-APPL S, V30, P477, DOI 10.1016/S1359-835X(98)00137-7
   UCHINOIN K, 1997, PIEZOELECTRIC ACTUAT
   Wada S, 2005, J APPL PHYS, V98, DOI 10.1063/1.1957130
   Wada S, 2008, FERROELECTRICS, V373, P11, DOI 10.1080/00150190802408531
   Wada T, 2001, JPN J APPL PHYS 1, V40, P5703, DOI 10.1143/JJAP.40.5703
   Wang J, 2003, SCIENCE, V299, P1719, DOI 10.1126/science.1080615
   Wang R, 2008, J ELECTROCERAM, V21, P263, DOI 10.1007/s10832-007-9136-0
   Wang RP, 2004, MATER RES BULL, V39, P1709, DOI [10.1016/j.materresbull.2004.05.007, 10.1016/j.matterresbull.2004.05.007]
   Wang YY, 2008, J ALLOY COMPD, V459, P414, DOI 10.1016/j.jallcom.2007.04.287
   Wang YY, 2009, J AM CERAM SOC, V92, P755, DOI 10.1111/j.1551-2916.2009.02935.x
   WOOD EA, 1951, ACTA CRYSTALLOGR, V4, P353, DOI 10.1107/S0365110X51001112
   Wu JG, 2008, J AM CERAM SOC, V91, P319, DOI 10.1111/j.1551-2916.2007.02102.x
   Xu CG, 2008, SOLID STATE SCI, V10, P934, DOI 10.1016/j.solidstatesciences.2007.11.003
   Yamamoto T, 1996, JPN J APPL PHYS 1, V35, P5104, DOI 10.1143/JJAP.35.5104
   Yang ZP, 2008, MATER RES BULL, V43, P81, DOI 10.1016/j.materresbull.2007.02.016
   Yang Z, 2006, MAT SCI ENG A-STRUCT, V432, P292, DOI 10.1016/j.msea.2006.06.034
   Yoshii K, 2006, JPN J APPL PHYS 1, V45, P4493, DOI 10.1143/JJAP.45.4493
   ZGONIK M, 1993, J APPL PHYS, V74, P1287, DOI 10.1063/1.354934
   Zhang BP, 2006, J AM CERAM SOC, V89, P1605, DOI 10.1111/j.1551-2916.2006.00960.x
   Zhang JL, 2009, APPL PHYS LETT, V95, DOI 10.1063/1.3182725
   Zhang SJ, 2008, APPL PHYS LETT, V92, DOI 10.1063/1.2908960
   Zhang SJ, 2007, APPL PHYS LETT, V91, DOI 10.1063/1.2794400
   Zhang SJ, 2007, J ELECTROCERAM, V19, P251, DOI 10.1007/s10832-007-9056-z
   Zhang SJ, 2007, IEEE T ULTRASON FERR, V54, P910, DOI 10.1109/TUFFC.2007.336
   Zhang SJ, 2006, J APPL PHYS, V100, DOI 10.1063/1.2382348
   Zhang YR, 2008, J AM CERAM SOC, V91, P2716, DOI 10.1111/j.1551-2916.2008.02469.x
   Zhao SC, 2006, J PHYS D APPL PHYS, V39, P2277, DOI 10.1088/0022-3727/39/10/042
   Zuo RZ, 2009, J AM CERAM SOC, V92, P283, DOI 10.1111/j.1551-2916.2008.02871.x
   2003, OFF J EUR UNION, V46, P4
   2003, OFF J EUR UNION, V46, P14
   2000, OFF J EUR UNION L, V269, P34
NR 128
TC 104
Z9 106
U1 7
U2 250
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 1468-6996
EI 1878-5514
J9 SCI TECHNOL ADV MAT
JI Sci. Technol. Adv. Mater.
PD AUG
PY 2010
VL 11
IS 4
AR 044302
DI 10.1088/1468-6996/11/4/044302
PG 13
WC Materials Science, Multidisciplinary
SC Materials Science
GA 668IE
UT WOS:000283261000004
PM 27877343
OA gold
DA 2018-03-19
ER

PT J
AU Hauser, AK
   Anderson, KW
   Hilt, JZ
AF Hauser, Anastasia K.
   Anderson, Kimberly W.
   Hilt, J. Zach
TI Peptide conjugated magnetic nanoparticles for magnetically mediated
   energy delivery to lung cancer cells
SO NANOMEDICINE
LA English
DT Article
DE cell penetrating peptide; iron oxide nanoparticles; magnetically
   medicated energy delivery; reactive oxygen species; TAT
ID IRON-OXIDE NANOPARTICLES; TARGETED DRUG-DELIVERY; TAT PEPTIDE; FLUID
   HYPERTHERMIA; INTRACELLULAR HYPERTHERMIA; GOLD NANOPARTICLES;
   SURFACE-CHARGE; REMOTE-CONTROL; APOPTOSIS; FIELD
AB Aim: In the present study, we examine the effects of internalized peptide-conjugated iron oxide nanoparticles and their ability to locally convert alternating magnetic field (AMF) energy into other forms of energy (e.g., heat and rotational work). Materials & methods: Dextran-coated iron oxide nanoparticles were functionalized with a cell penetrating peptide and after internalization by A549 and H358 cells were activated by an AMF. Results: TAT-functionalized nanoparticles and AMF exposure increased reactive oxygen species generation compared with the nanoparticle system alone. The TAT-functionalized nanoparticles induced lysosomal membrane permeability and mitochondrial membrane depolarization, but these effects were not further enhanced by AMF treatment. Although not statistically significant, there are trends suggesting an increase in apoptosis via the Caspase 3/7 pathways when cells are exposed to TAT-functionalized nanoparticles combined with AMF. Conclusion: Our results indicate that internalized TAT-functionalized iron oxide nanoparticles activated by an AMF elicit cellular responses without a measurable temperature rise.
   [GRAPHICS]
   .
C1 [Hauser, Anastasia K.; Anderson, Kimberly W.; Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Hilt, JZ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM hilt@engr.uky.edu
FU National Cancer Institute [R25CA153954]; National Science Foundation
   [DGE-1247392]
FX The project described was partially supported by grant number
   R25CA153954 from the National Cancer Institute. Additionally, this work
   was supported by the National Science Foundation Graduate Research
   Fellowship Program grant no. DGE-1247392. The authors have no other
   relevant affiliations or financial involvement with any organization or
   entity with a financial interest in or financial conflict with the
   subject matter or materials discussed in the manuscript apart from those
   disclosed.
CR Austin LA, 2011, BIOCONJUGATE CHEM, V22, P2324, DOI 10.1021/bc200386m
   Ayala V, 2013, J NANOPART RES, V15, DOI 10.1007/s11051-013-1874-0
   Brunk UT, 2001, REDOX REP, V6, P91, DOI 10.1179/135100001101536094
   Connord V, 2015, SMALL, V11, P2437, DOI 10.1002/smll.201402669
   Creixell M, 2011, ACS NANO, V5, P7124, DOI 10.1021/nn201822b
   de la Fuente JM, 2005, BIOCONJUGATE CHEM, V16, P1176, DOI 10.1021/bc050033+
   Dennis CL, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/39/395103
   Domenech M, 2013, ACS NANO, V7, P5091, DOI 10.1021/nn4007048
   GORDON RT, 1979, MED HYPOTHESES, V5, P83, DOI 10.1016/0306-9877(79)90063-X
   Grazu V, 2012, INT J NANOMED, V7, P5351, DOI 10.2147/IJN.S35510
   Hauser AK, 2015, ACTA BIOMATER, V25, P284, DOI DOI 10.1016/J.ACTBIO.2015.06.037
   Hauser AK, 2015, MATER CHEM PHYS, V160, P177, DOI 10.1016/j.matchemphys.2015.04.022
   Hu RL, 2011, ONCOL LETT, V2, P1161, DOI 10.3892/ol.2011.379
   Huang G, 2013, THERANOSTICS, V3, P116, DOI 10.7150/thno.5411
   Huang H, 2010, NAT NANOTECHNOL, V5, P602, DOI [10.1038/NNANO.2010.125, 10.1038/nnano.2010.125]
   Jaattela M, 2004, ONCOGENE, V23, P2746, DOI 10.1038/sj.onc.1207513
   Johansson AC, 2010, APOPTOSIS, V15, P527, DOI 10.1007/s10495-009-0452-5
   Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h
   Kehrer JP, 2000, TOXICOLOGY, V149, P43, DOI 10.1016/S0300-483X(00)00231-6
   Kirkegaard T, 2009, BBA-MOL CELL RES, V1793, P746, DOI 10.1016/j.bbamcr.2008.09.008
   Klein S, 2012, BIOCHEM BIOPH RES CO, V425, P393, DOI 10.1016/j.bbrc.2012.07.108
   Kozissnik B, 2013, INT J HYPERTHER, V29, P706, DOI 10.3109/02656736.2013.837200
   Kruse AM, 2014, ACTA BIOMATER, V10, P2622, DOI 10.1016/j.actbio.2014.01.025
   Laurent S, 2011, ADV COLLOID INTERFAC, V166, P8, DOI 10.1016/j.cis.2011.04.003
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Li ZH, 2014, ADV FUNCT MATER, V24, P3612, DOI 10.1002/adfm.201303662
   Linder ST, 2005, P NATL ACAD SCI USA, V102, P192
   Ly JD, 2003, APOPTOSIS, V8, P115, DOI 10.1023/A:1022945107762
   McCormack PL, 2012, DRUGS, V72, P2013, DOI 10.2165/11209880-000000000-00000
   Min KA, 2013, ACS NANO, V7, P2161, DOI 10.1021/nn3057565
   Ogawara K, 1999, J CONTROL RELEASE, V59, P15, DOI 10.1016/S0168-3659(99)00015-2
   Oliveira TR, 2013, INT J HYPERTHER, V29, P835, DOI 10.3109/02656736.2013.834384
   Osaka T, 2009, COLLOID SURFACE B, V71, P325, DOI 10.1016/j.colsurfb.2009.03.004
   Oyelere AK, 2007, BIOCONJUGATE CHEM, V18, P1490, DOI 10.1021/bc070132i
   Pan LM, 2012, J AM CHEM SOC, V134, P5722, DOI 10.1021/ja211035w
   Petters C, 2014, NEUROCHEM RES, V39, P372, DOI 10.1007/s11064-013-1234-6
   Plouffe BD, 2015, REP PROG PHYS, V78, DOI 10.1088/0034-4885/78/1/016601
   Rabin Y, 2002, INT J HYPERTHER, V18, P194, DOI 10.1080/02656730110116713
   Rao KS, 2008, BIOMATERIALS, V29, P4429, DOI 10.1016/j.biomaterials.2008.08.004
   Rodriguez-Luccioni HL, 2011, INT J NANOMED, V6, P373, DOI 10.2147/IJN.S14613
   Sanchez C, 2014, ACS NANO, V8, P1350, DOI 10.1021/nn404954s
   Shintani Y, 2008, AM J RESP CELL MOL, V38, P95, DOI 10.1165/rcmb.2007-0071OC
   Singh A, 2009, CANCER CELL, V15, P489, DOI 10.1016/j.ccr.2009.03.022
   Sinthupibulyakit C, 2010, INT J ONCOL, V37, P1575, DOI 10.3892/ijo_00000811
   Song LX, 2006, CANCER RES, V66, P5542, DOI 10.1158/0008-5472.CAN-05-4620
   Terman A, 2006, IUBMB LIFE, V58, P531, DOI 10.1080/15216540600904885
   Thorek DLJ, 2008, BIOMATERIALS, V29, P3583, DOI 10.1016/j.biomaterials.2008.05.015
   Torchilin VP, 2008, ADV DRUG DELIVER REV, V60, P548, DOI 10.1016/j.addr.2007.10.008
   Trachootham D, 2006, CANCER CELL, V10, P241, DOI 10.1016/j.ccr.2006.08.009
   Villanueva A, 2010, J PHYS CHEM C, V114, P1976, DOI 10.1021/jp907046f
   Villanueva A, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/11/115103
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010
   Wang CH, 2012, INT J PHARMACEUT, V430, P372, DOI 10.1016/j.ijpharm.2012.04.035
   Wang J, 2008, CANCER BIOL THER, V7, P1875, DOI 10.4161/cbt.7.12.7067
   Wang LF, 2012, ONCOL REP, V27, P719, DOI 10.3892/or.2011.1567
   Wydra RJ, 2015, ACTA BIOMATER, V25, P284, DOI 10.1016/j.actbio.2015.06.037
   Wydra RJ, 2015, RSC ADV, V5, P18888, DOI 10.1039/c4ra13564d
   Wydra RJ, 2013, MAT SCI ENG C-MATER, V33, P4660, DOI 10.1016/j.msec.2013.07.019
   Xu CJ, 2008, CHEM-ASIAN J, V3, P548, DOI 10.1002/asia.200700301
   Yang C, 2014, J NANOSCI NANOTECHNO, V14, P4813, DOI 10.1166/jnn.2014.9280
   Zhang EM, 2014, ACS NANO, V8, P3192, DOI 10.1021/nn406302j
   Zhao M, 2003, EUR J BIOCHEM, V270, P3778, DOI 10.1046/j.1432-1033.2003.03765.x
   PALMACCI S, 1993, Patent No. 5262176
NR 63
TC 5
Z9 5
U1 3
U2 32
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1743-5889
EI 1748-6963
J9 NANOMEDICINE-UK
JI Nanomedicine
PD JUL
PY 2016
VL 11
IS 14
BP 1769
EP 1785
DI 10.2217/nnm-2016-0050
PG 17
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA DR2UJ
UT WOS:000379759100002
PM 27388639
DA 2018-03-19
ER

PT J
AU Wu, PJ
   Lilly, JL
   Arreaza, R
   Berron, BJ
AF Wu, Pei-Jung
   Lilly, Jacob L.
   Arreaza, Roberto
   Berron, Brad J.
TI Hydrogel Patches on Live Cells through Surface-Mediated Polymerization
SO LANGMUIR
LA English
DT Article
ID POLY(ETHYLENE GLYCOL) DIACRYLATE; TARGETED DRUG-DELIVERY; COATINGS;
   PHOTOPOLYMERIZATION; NANOPARTICLES
AB Many naturally occurring cells possess an intrinsic ability to cross biological barriers that block conventional drug delivery, and these cells offer a possible mode of active transport across the bloodbrain barrier or into the core of tumor masses. While many technologies for the formation of complete, nanoparticle-loaded coatings on cells exist, a complete coating on the cell surface would disrupt the interaction of cells with their environments. To address this issue, cell surface patches that partially cover cell surfaces might provide a superior approach for cell-mediated therapeutic delivery. The goal of this study is to establish a simplified approach to producing polymeric patches of arbitrary shapes on a live cell via surface-mediated photopolymerization. Cell surfaces were nonspecifically labeled with eosin, and polyethylene (glycol) diacrylate (PEGDA) coatings were directed to specific sites using 530 nm irradiation through a chrome-coated photomask. These coatings may entrap drug-loaded or imaging particles. The extent of nonspecific formation of PEGDA hydrogel coatings increased with irradiation time, light intensity, and initiating species; 40 mW/cm(2) irradiation for 5 min delivered high-resolution patterns on the surface of A549 cells, and these cells remained viable for 48 h postpatterning with fluorescent nanoparticle-loaded coatings. This work first demonstrated the feasibility of photopatterning polymer patches directly on the surface of cells.
C1 [Wu, Pei-Jung; Lilly, Jacob L.; Arreaza, Roberto; Berron, Brad J.] Univ Kentucky, Chem & Mat Engn, 153 FPAT, Lexington, KY 40506 USA.
RP Berron, BJ (reprint author), Univ Kentucky, Chem & Mat Engn, 153 FPAT, Lexington, KY 40506 USA.
EM brad.berron@uky.edu
FU National Science Foundation [ROl HL127682-01, CBET-1351531]
FX We thank Dr. Robert R. McLeod's group (University of Colorado Boulder,
   Boulder, CO) for guidance with respect to the irradiation system for
   PEGDA photopolymerization. This work was partially supported by Grant
   ROl HL127682-01 and by the National Science Foundation under Award
   CBET-1351531.
CR Anselmo AC, 2015, J CONTROL RELEASE, V199, P29, DOI 10.1016/j.jconrel.2014.11.027
   Avens HJ, 2008, POLYMER, V49, P4762, DOI 10.1016/j.polymer.2008.08.054
   Avens HJ, 2011, J NANOPART RES, V13, P331, DOI 10.1007/s11051-010-0034-z
   Avens HJ, 2010, ACTA BIOMATER, V6, P83, DOI 10.1016/j.actbio.2009.06.008
   Bae YH, 2011, J CONTROL RELEASE, V153, P198, DOI 10.1016/j.jconrel.2011.06.001
   Cheng H, 2010, ACS NANO, V4, P625, DOI 10.1021/nn901319y
   Comen E, 2011, NAT REV CLIN ONCOL, V8, P369, DOI 10.1038/nrclinonc.2011.64
   Cruise GM, 1998, BIOTECHNOL BIOENG, V57, P655, DOI 10.1002/(SICI)1097-0290(19980320)57:6<655::AID-BIT3>3.0.CO;2-K
   Doshi N, 2011, ADV MATER, V23, pH105, DOI 10.1002/adma.201004074
   Goel A, 2013, INT J PHARM INVESTIG, V3, P8, DOI 10.4103/2230-973X.108959
   Harris J. M, 2013, POLYETHYLENE GLYCOL
   Kizilel S, 2004, LANGMUIR, V20, P8652, DOI 10.1021/la0496744
   Leung CT, 2009, CELL, V139, P1226, DOI 10.1016/j.cell.2009.12.013
   Li LL, 2011, ACS NANO, V5, P7462, DOI 10.1021/nn202399w
   Lilly JL, 2015, BIOMACROMOLECULES, V16, P541, DOI 10.1021/bm501594x
   Lin S, 2011, PHARM RES-DORDR, V28, P1422, DOI 10.1007/s11095-011-0378-9
   Lin WS, 2006, TOXICOL APPL PHARM, V217, P252, DOI 10.1016/j.taap.2006.10.004
   Manish G, 2011, RES J CHEM SCI, V1, P135
   Romero G, 2015, ACS APPL MATER INTER, V7, P17598, DOI 10.1021/acsami.5b06298
   Ruoslahti E, 2012, ADV MATER, V24, P3747, DOI 10.1002/adma.201200454
   Singh R, 2009, EXP MOL PATHOL, V86, P215, DOI 10.1016/j.yexmp.2008.12.004
   Swiston AJ, 2010, BIOMACROMOLECULES, V11, P1826, DOI 10.1021/bm100305h
   Swiston AJ, 2008, NANO LETT, V8, P4446, DOI 10.1021/nl802404h
   Zhang Y, 2016, CELL MOL BIOENG, V9, P382, DOI 10.1007/s12195-016-0445-8
NR 24
TC 0
Z9 0
U1 12
U2 16
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0743-7463
J9 LANGMUIR
JI Langmuir
PD JUL 11
PY 2017
VL 33
IS 27
BP 6778
EP 6784
DI 10.1021/acs.langmuir.7601139
PG 7
WC Chemistry, Multidisciplinary; Chemistry, Physical; Materials Science,
   Multidisciplinary
SC Chemistry; Materials Science
GA FA6EM
UT WOS:000405536100016
PM 28605895
DA 2018-03-19
ER

PT J
AU Song, ES
   Rodgers, DW
   Hersh, LB
AF Song, Eun Suk
   Rodgers, David W.
   Hersh, Louis B.
TI A Monomeric Variant of Insulin Degrading Enzyme (IDE) Loses Its
   Regulatory Properties
SO PLOS ONE
LA English
DT Article
ID IN-VIVO; INSULYSIN; GENE; ATP; RECOGNITION; DEGRADATION; DISEASE; TARGET
AB Background: Insulin degrading enzyme (IDE) is a key enzyme in the metabolism of both insulin and amyloid beta peptides. IDE is unique in that it is subject to allosteric activation which is hypothesized to occur through an oligomeric structuture.
   Methodology/Principal Findings: IDE is known to exist as an equilibrium mixture of monomers, dimers, and higher oligomers, with the dimer being the predominant form. Based on the crystal structure of IDE we deleted the putative dimer interface in the C-terminal region, which resulted in a monomeric variant. Monomeric IDE retained enzymatic activity, however instead of the allosteric behavior seen with wild type enzyme it displayed Michaelis-Menten kinetic behavior. With the substrate Abz-GGFLRKHGQ-EDDnp, monomeric IDE retained similar to 25% of the wild type activity. In contrast with the larger peptide substrates beta-endorphin and amyloid beta peptide 1-40, monomeric IDE retained only 1 to 0.25% of wild type activity. Unlike wild type IDE neither bradykinin nor dynorphin B-9 activated the monomeric variant of the enzyme. Similarly, monomeric IDE was not activated by polyphosphates under conditions in which the activity of wild type enzyme was increased more than 50 fold.
   Conclusions/Significance: These findings serve to establish the dimer interface in IDE and demonstrate the requirement for an oligomeric form of the enzyme for its regulatory properties. The data support a mechanism where the binding of activators to oligomeric IDE induces a conformational change that cannot occur in the monomeric variant. Since a conformational change from a closed to a more open structure is likely the rate-determining step in the IDE reaction, the subunit induced conformational change likely shifts the structure of the oligomeric enzyme to a more open conformation.
C1 [Song, Eun Suk] Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40506 USA.
   Univ Kentucky, Struct Biol Ctr, Lexington, KY USA.
RP Song, ES (reprint author), Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40506 USA.
EM lhersh@uky.edu
FU NIH [DA02243, NS046517, DA016176, P20RR20171]
FX This work was supported by NIH grants DA02243, NS046517, DA016176, and
   P20RR20171. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Fakhrai-Rad H, 2000, HUM MOL GENET, V9, P2149, DOI 10.1093/hmg/9.14.2149
   Farris W, 2003, P NATL ACAD SCI USA, V100, P4162, DOI 10.1073/pnas.0230450100
   GOLDSTEIN BJ, 1981, METABOLISM, V30, P825, DOI 10.1016/0026-0495(81)90030-5
   Gu HF, 2004, DIABETES, V53, P2137, DOI 10.2337/diabetes.53.8.2137
   HARI J, 1987, ENDOCRINOLOGY, V120, P829, DOI 10.1210/endo-120-2-829
   Im H, 2007, J BIOL CHEM, V282, P25453, DOI 10.1074/jbc.M701590200
   Karamohamed S, 2003, DIABETES, V52, P1562, DOI 10.2337/diabetes.52.6.1562
   Kim M, 2007, J BIOL CHEM, V282, P7825, DOI 10.1074/jbc.M609168200
   Malito E, 2008, BIOCHEMISTRY-US, V47, P12822, DOI 10.1021/bi801192h
   Miller BC, 2003, P NATL ACAD SCI USA, V100, P6221, DOI 10.1073/pnas.1031520100
   Shen YQ, 2006, NATURE, V443, P870, DOI 10.1038/nature05143
   Song ES, 2004, J BIOL CHEM, V279, P54216, DOI 10.1074/jbc.M411177200
   Song ES, 2003, J BIOL CHEM, V278, P49789, DOI 10.1074/jbc.M308983200
   Song ES, 2001, J BIOL CHEM, V276, P1152, DOI 10.1074/jbc.M008702200
   Song ES, 2005, J BIOL CHEM, V280, P17701, DOI 10.1074/jbc.M501896200
   Vepsalainen S, 2007, J MED GENET, V44, DOI 10.1136/jmg.2006.048470
   Yao HB, 2006, ARCH BIOCHEM BIOPHYS, V451, P175, DOI 10.1016/j.abb.2006.04.011
   YONEZAWA K, 1986, ENDOCRINOLOGY, V118, P1989, DOI 10.1210/endo-118-5-1989
NR 18
TC 14
Z9 14
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 16
PY 2010
VL 5
IS 3
AR e9719
DI 10.1371/journal.pone.0009719
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 570ZC
UT WOS:000275716400017
PM 20300529
OA gold
DA 2018-03-20
ER

PT J
AU Scott, DF
   Hamorsky, KT
   Ensor, CM
   Anderson, KW
   Daunert, S
AF Scott, Daniel F.
   Hamorsky, Krystal Teasley
   Ensor, C. Mark
   Anderson, Kimberly W.
   Daunert, Sylvia
TI ANYL 180-Bioluminescent cAMP molecular switch for in vivo detection and
   imaging
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
CT 236th National Meeting of the American-Chemical-Society
CY AUG 17-21, 2008
CL Philadelphia, PA
SP Amer Chem Soc
C1 [Scott, Daniel F.; Hamorsky, Krystal Teasley; Ensor, C. Mark; Daunert, Sylvia] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
   [Anderson, Kimberly W.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM daniel.scott@uky.edu; kanderson@engr.uky.edu; daunert@uky.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD AUG 17
PY 2008
VL 236
MA 180-ANYL
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA 499WD
UT WOS:000270256301099
DA 2018-03-19
ER

PT J
AU Ghosh, K
   Rankin, SE
   Lehmler, HJ
   Knutson, BL
AF Ghosh, Kaustav
   Rankin, Stephen E.
   Lehmler, Hans-Joachim
   Knutson, Barbara L.
TI Processing of Surfactant Templated Nano-Structured Silica Films Using
   Compressed Carbon Dioxide as Interpreted from In Situ Fluorescence
   Spectroscopy
SO JOURNAL OF PHYSICAL CHEMISTRY B
LA English
DT Article
ID NONRADIATIVE ENERGY-TRANSFER; GEL THIN-FILMS; POLYCYCLIC
   AROMATIC-HYDROCARBONS; MESOPOROUS SILICA; SUPERCRITICAL CO2; LUMINESCENT
   MOLECULES; CONTROLLED-RELEASE; REVERSE MICELLES; STEADY-STATE; WATER
AB The local environment and dynamics of compressed carbon dioxide (CO2) penetration in surfactant templated silica film synthesis is interpreted from the in situ fluorescence emission spectra of pyrene (Py) and a modified pyrene probe. Pyrene emission in cetyltrimethylammonium bromide (CTAB) and cetylpyridinium bromide (CPB) templated silica films is monitored immediately after casting and during processing with gaseous and supercritical (sc) CO2 (17-172 bar, 45 degrees C). The solvatochromic emission spectra of pyrene in CTAB templated films suggest CO2 penetration in both the micelle interface and its interior. An anchored derivative of pyrene, 1-pyrenehexadecanoic acid (C-16-pyr), is established for probing CPB films, where the pyrene moiety is preferentially oriented toward the micelle interior, thus limiting quenching by the pyridinium headgroup of CPB. CO2 processing of CPB templated silica films results in an increase in the time scale for probe mobility, suggesting an increased time scale of silica condensation through CO, processing. The mobility of C-16-pyr increases with pressure from gaseous to sc CO2 processing and persists for over 5 h for sc CO2 processing at 172 bar and 45 degrees C compared to about 25 min for the unprocessed film. The delivery of CO2 soluble solutes to specific regions of surfactant templated mesoporous materials is examined via the nonradiative energy transfer (NRET) between pyrene and CO2-solubilized naphthalene.
C1 [Ghosh, Kaustav; Rankin, Stephen E.; Knutson, Barbara L.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Lehmler, Hans-Joachim] Univ Iowa, Dept Occupat & Environm Hlth, Iowa City, IA 52242 USA.
RP Knutson, BL (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM bknutson@engr.uky.edu
RI Rankin, Stephen/A-3265-2013
OI Rankin, Stephen/0000-0002-8615-7564; Lehmler,
   Hans-Joachim/0000-0001-9163-927X
FU National Science Foundation NIRT [DMR-0210517]; Kentucky Science and
   Engineering Foundation [KSEF-159-RDE-001]
FX The authors would like to acknowledge National Science Foundation NIRT
   Grant # DMR-0210517 and Kentucky Science and Engineering Foundation
   grant KSEF-159-RDE-001 for funding of this research project.
CR Albo S, 2003, J PHYS CHEM B, V107, P1672, DOI 10.1021/jp026894m
   Alonso B, 2002, NEW J CHEM, V26, P1270, DOI 10.1039/b205501p
   Anandan C, 2004, EUR POLYM J, V40, P335, DOI 10.1016/j.eurpolymj.2003.10.002
   ARTAKI I, 1986, J NON-CRYST SOLIDS, V81, P381, DOI 10.1016/0022-3093(86)90504-1
   Ayala JH, 1997, APPL SPECTROSC, V51, P380, DOI 10.1366/0003702971940242
   Bartl MH, 2003, CHEMPHYSCHEM, V4, P392, DOI 10.1002/cphc.200390069
   BECK JS, 1992, J AM CHEM SOC, V114, P10834, DOI 10.1021/ja00053a020
   Blin JL, 2000, LANGMUIR, V16, P4229, DOI 10.1021/la9914615
   BRANTON PJ, 1997, CHARACTERIZATION POR, V4, P668
   BRENNECKE JF, 1990, IND ENG CHEM RES, V29, P1682, DOI 10.1021/ie00104a017
   Brennecke J. F., 1989, ACS SYM SER, V14, P406
   Brinker CJ, 1989, SOL GEL SCI PHYS CHE
   Buboltz JT, 2007, PHYS REV E, V76, DOI 10.1103/PhysRevE.76.021903
   Cagnol F, 2003, J MATER CHEM, V13, P61, DOI 10.1039/b209640b
   Callaghan J. M., 2008, LANGMUIR, V24, P6959
   Cao T, 2004, MACROMOLECULES, V37, P1897, DOI 10.1021/ma035606x
   Caragheorgheopol A, 2004, J PHYS CHEM B, V108, P7735, DOI 10.1021/jp049482h
   CHEN SH, 1991, LANGMUIR, V7, P1719, DOI 10.1021/la00056a025
   Clarke MJ, 1997, J AM CHEM SOC, V119, P6399, DOI 10.1021/ja9639527
   DAVIS GA, 1973, J CHEM SOC CHEM COMM, P728, DOI 10.1039/c39730000728
   Dominska M, 2008, LANGMUIR, V24, P8785, DOI 10.1021/la801687w
   Eastoe J, 2003, CURR OPIN COLLOID IN, V8, P267, DOI 10.1016/S1359-0294(03)00053-0
   Fuertes AB, 2005, ELECTROCHIM ACTA, V50, P2799, DOI 10.1016/j.electacta.2004.11.027
   Ghenciu EG, 1998, BIOTECHNOL BIOENG, V58, P572, DOI 10.1002/(SICI)1097-0290(19980620)58:6<572::AID-BIT2>3.0.CO;2-F
   Ghosh K, 2005, LANGMUIR, V21, P6145, DOI 10.1021/la050311t
   Ghosh K, 2007, J PHYS CHEM B, V111, P363, DOI 10.1021/jp0656680
   Ghosh K, 2012, J COLLOID INTERF SCI, V367, P183, DOI 10.1016/j.jcis.2011.10.051
   Gibaud A, 2003, J PHYS CHEM B, V107, P6114, DOI 10.1021/jp027612l
   Gilliland JW, 2005, CHEM MATER, V17, P6702, DOI 10.1021/cm050658h
   Gonzalez-Garcia J., 2001, J CHEM ENG DATE, V46, P918
   Guney O, 2002, AICHE J, V48, P856, DOI 10.1002/aic.690480419
   Gupta RR, 2003, MACROMOLECULES, V36, P1295, DOI 10.1021/ma021557x
   Hanrahan JP, 2005, LANGMUIR, V21, P4163, DOI 10.1021/la0470636
   Hasegawa M, 1996, J PHYS CHEM-US, V100, P15575, DOI 10.1021/jp961528m
   Hernandez R, 2001, J AM CHEM SOC, V123, P1248, DOI 10.1021/ja003634e
   Holmes JD, 1998, LANGMUIR, V14, P6371, DOI 10.1021/la9806956
   Huang MH, 2000, J AM CHEM SOC, V122, P3739, DOI 10.1021/ja993882e
   Jacobson GB, 1999, J ORG CHEM, V64, P1201, DOI 10.1021/jo981825i
   Ji M, 1999, J AM CHEM SOC, V121, P2631, DOI 10.1021/ja9840403
   Johnston KP, 1996, SCIENCE, V271, P624, DOI 10.1126/science.271.5249.624
   KALYANASUNDARAM K, 1977, J AM CHEM SOC, V99, P2039, DOI 10.1021/ja00449a004
   Kimura T, 1998, CHEM COMMUN, P559, DOI 10.1039/a708463c
   Klaas Z. A., 1984, SURFACTANTS SOLUTION, V1, P565
   Koganti VR, 2005, J PHYS CHEM B, V109, P3279, DOI 10.1021/jp045037a
   Koganti V. R., 2006, THESIS U KENTUCKY
   Kramer MC, 1996, MACROMOLECULES, V29, P1992, DOI 10.1021/ma951087p
   Kujawa P, 2002, J PHYS CHEM B, V106, P5578, DOI 10.1021/jp0145053
   Kukulka-Walkiewicz J., 2001, SOLID STATE IONICS, V157, P263
   Kunieda H, 1998, J PHYS CHEM B, V102, P831, DOI 10.1021/jp9726908
   Lee CT, 2003, J AM CHEM SOC, V125, P3181, DOI 10.1021/ja025735d
   LHEUREUX GP, 1987, J COLLOID INTERF SCI, V117, P513, DOI 10.1016/0021-9797(87)90412-7
   Li XX, 2008, CHEM MATER, V20, P3229, DOI 10.1021/cm8003479
   LISSI EA, 1992, J COLLOID INTERF SCI, V152, P104, DOI 10.1016/0021-9797(92)90011-A
   Liu DX, 2004, J PHYS CHEM B, V108, P2851, DOI 10.1021/jp036681c
   Liu H, 2005, LANGMUIR, V21, P379, DOI 10.1021/la047934b
   Lu YF, 1997, NATURE, V389, P364, DOI 10.1038/38699
   Ma YR, 2003, COLLOID SURFACE A, V229, P1, DOI 10.1016/j.colsurfa.2003.08.010
   McCool B, 2005, J PHYS CHEM B, V109, P8914, DOI 10.1021/jp050192q
   MCFANN GJ, 1993, THESIS U TEXAS AUSTI
   McLeod MC, 2003, J PHYS CHEM B, V107, P2693, DOI 10.1021/jp0218645
   Meng QG, 2003, J PHYS CHEM SOLIDS, V64, P63, DOI 10.1016/S0022-3697(02)00212-3
   Minoofar PN, 2002, J AM CHEM SOC, V124, P14388, DOI 10.1021/ja020817n
   MIOLA L, 1983, J PHYS CHEM-US, V87, P4417, DOI 10.1021/j100245a020
   NAKAJIMA A, 1971, B CHEM SOC JPN, V44, P3272, DOI 10.1246/bcsj.44.3272
   NAKAJIMA A, 1974, SPECTROCHIM ACTA A, VA 30, P860, DOI 10.1016/0584-8539(74)80203-5
   Niemeyer ED, 1998, J PHYS CHEM B, V102, P1474, DOI 10.1021/jp973157v
   Ogawa M, 1998, CHEM MATER, V10, P1382, DOI 10.1021/cm970770i
   Osei-Prempeh G., 2007, THESIS U KENTUCKY
   Pathak P, 2004, J AM CHEM SOC, V126, P10842, DOI 10.1021/ja046914t
   Qu FY, 2006, J SOLID STATE CHEM, V179, P2027, DOI 10.1016/j.jssc.2006.04.002
   Raveendran P, 2005, ACCOUNTS CHEM RES, V38, P478, DOI 10.1021/ar040082m
   Sabirzyanov A.N., 2002, HIGH TEMP-USSR, V40, P231
   Salazar-Hernandez C, 2009, J SOL-GEL SCI TECHN, V49, P301, DOI 10.1007/s10971-008-1879-9
   Suwa M, 2000, MACROMOLECULES, V33, P7884, DOI 10.1021/ma0008342
   Tripp CP, 1998, LANGMUIR, V4, P7348, DOI DOI 10.1021/LA9805701
   Tsekhanskaya Y. V., 1964, RUSS J PHYS CHEM, V38, P1173
   Ulagappan N, 1996, CHEM COMMUN, P2759, DOI 10.1039/cc9960002759
   Wade DA, 2000, TALANTA, V53, P571, DOI 10.1016/S0039-9140(00)00527-0
   WINNIK FM, 1990, POLYMER, V31, P2125, DOI 10.1016/0032-3861(90)90085-D
   Yamauchi Y, 2005, J MATER CHEM, V15, P1137, DOI 10.1039/b418478e
   Yao YF, 2001, MATER LETT, V48, P44, DOI 10.1016/S0167-577X(00)00278-0
   Yates MZ, 2001, CHEM COMMUN, P25, DOI 10.1039/b007331h
   Yusa S, 2002, MACROMOLECULES, V35, P10182, DOI 10.1021/ma0212947
   Zuniga-Moreno A, 2005, FLUID PHASE EQUILIBR, V234, P151, DOI 10.1016/j.fluid.2005.06.010
NR 84
TC 2
Z9 2
U1 0
U2 21
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1520-6106
J9 J PHYS CHEM B
JI J. Phys. Chem. B
PD SEP 27
PY 2012
VL 116
IS 38
BP 11646
EP 11655
DI 10.1021/jp305113b
PG 10
WC Chemistry, Physical
SC Chemistry
GA 011FI
UT WOS:000309150000010
PM 22946494
DA 2018-03-20
ER

PT J
AU Zhang, XY
   Zhan, DY
   Shin, HY
AF Zhang, Xiaoyan
   Zhan, Dongying
   Shin, Hainsworth Y.
TI Leukocyte Mechanosensitivity to Fluid Shear Stress Depends on the
   Subtypes of CD18 Integrins
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Experimental Biology Meeting
CY APR 21-25, 2012
CL San Diego, CA
C1 [Zhang, Xiaoyan; Zhan, Dongying; Shin, Hainsworth Y.] Univ Kentucky, Ctr Biomed Engn, Lexington, KY 40506 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2012
VL 26
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 032IZ
UT WOS:000310711305237
DA 2018-03-20
ER

PT J
AU Sundararaj, SC
   Thomas, MV
   Peyyala, R
   Dziubla, TD
   Puleo, DA
AF Sundararaj, Sharath Kumar C.
   Thomas, Mark V.
   Peyyala, Rebecca
   Dziubla, Thomas D.
   Puleo, David A.
TI Design of a multiple drug delivery system directed at periodontitis
SO BIOMATERIALS
LA English
DT Article
DE Controlled drug release; Drug delivery; Drug release; Periodontium;
   Sequential drug release
ID BONE MORPHOGENETIC PROTEIN-2; GROWTH-FACTOR; IN-VITRO;
   PORPHYROMONAS-GINGIVALIS; CONTROLLED-RELEASE; ADULT PERIODONTITIS;
   CREVICULAR FLUID; POLYMER SYSTEM; LOCAL-DELIVERY; CLINICAL-TRIAL
AB Periodontal disease is highly prevalent, with 90% of the world population affected by either periodontitis or its preceding condition, gingivitis. These conditions are caused by bacterial biofilms on teeth, which stimulate a chronic inflammatory response that leads to loss of alveolar bone and, ultimately, the tooth. Current treatment methods for periodontitis address specific parts of the disease, with no individual treatment serving as a complete therapy. The present research sought to demonstrate development of a multiple drug delivery system for stepwise treatment of different stages of periodontal disease. More specifically, multilayered films were fabricated from an association polymer comprising cellulose acetate phthalate and Pluronic F-127 to achieve sequential release of drugs. The four types of drugs used were metronidazole, ketoprofen, doxycycline, and simvastatin to eliminate infection, inhibit inflammation, prevent tissue destruction, and aid bone regeneration, respectively. Different erosion times and adjustable sequential release profiles were achieved by modifying the number of layers or by inclusion of a slower-eroding polymer layer. Analysis of antibiotic and anti-inflammatory bioactivity showed that drugs released from the devices retained 100% bioactivity. The multilayered CAPP delivery system offers a versatile approach for releasing different drugs based on the pathogenesis of periodontitis and other conditions. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Sundararaj, Sharath C.; Puleo, David A.] Univ Kentucky, Dept Biomed Engn, Lexington, KY 40506 USA.
   [Thomas, Mark V.; Peyyala, Rebecca] Univ Kentucky, Coll Dent, Lexington, KY 40536 USA.
   [Dziubla, Thomas D.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Puleo, DA (reprint author), Univ Kentucky, Dept Biomed Engn, Wenner Gren Lab 209, Lexington, KY 40506 USA.
EM puleo@uky.edu
FU NIH [DE019645, AR060964]; Kentucky NASA EPSCoR [NNX08BA13A]
FX This research was supported by NIH (DE019645 and AR060964) and Kentucky
   NASA EPSCoR (NNX08BA13A).
CR Albandar JM, 1999, J PERIODONTOL, V70, P30, DOI 10.1902/jop.1999.70.1.30
   Basmanav FB, 2008, BIOMATERIALS, V29, P4195, DOI 10.1016/j.biomaterials.2008.07.017
   Binderman I, 2000, J PERIODONTOL, V71, P1236, DOI 10.1902/jop.2000.71.8.1236
   Borselli C, 2010, P NATL ACAD SCI USA, V107, P3287, DOI 10.1073/pnas.0903875106
   BROWN LJ, 1989, J PERIODONTOL, V60, P363, DOI 10.1902/jop.1989.60.7.363
   Chen FM, 2010, TISSUE ENG PART B-RE, V16, P219, DOI [10.1089/ten.teb.2009.0562, 10.1089/ten.TEB.2009.0562]
   Chen FM, 2010, BIOMATERIALS, V31, P6279, DOI 10.1016/j.biomaterials.2010.04.053
   Chen FM, 2009, BIOMATERIALS, V30, P5215, DOI 10.1016/j.biomaterials.2009.06.009
   Chen PY, 2010, NUTR RES, V30, P191, DOI 10.1016/j.nutres.2010.03.004
   Chen RR, 2007, PHARM RES, V24, P258, DOI 10.1007/s11095-006-9173-4
   Cochran DL, 2003, BIOMIMETICS PERIODON
   Dogan AK, 2005, J BIOMED MATER RES B, V74B, P504
   Edwards CJ, 2002, ARTHRITIS RES, V4, P151, DOI 10.1186/ar399
   Eick S, 2004, J PERIODONTOL, V75, P1327, DOI 10.1902/jop.2004.75.10.1327
   Etienne D, 2003, ORAL DIS, V9, P45, DOI 10.1034/j.1601-0825.9.s1.8.x
   GATES KA, 1994, PHARMACEUT RES, V11, P1605, DOI 10.1023/A:1018913921956
   Griffiths GS, 2011, J CLIN PERIODONTOL, V38, P43, DOI 10.1111/j.1600-051X.2010.01632.x
   Hopfenberg H. B., 1976, CONTROLLED RELEASE P, P26
   Jaklenec A, 2008, BIOMATERIALS, V29, P1518, DOI 10.1016/j.biomaterials.2007.12.004
   Japoni A, 2011, MED ORAL PATOL ORAL, V16, pC1031, DOI 10.4317/medoral.17174
   Jeon JH, 2008, BIOMATERIALS, V29, P3591, DOI 10.1016/j.biomaterials.2008.05.011
   Jeon JH, 2008, J PERIODONTOL, V79, P1457, DOI [10.1902/jop.2008.080004, 10.1902/jop.2008.080004 ]
   Karring T, 2000, PERIODONTOL, V1993, P26
   Kempen DHR, 2009, BIOMATERIALS, V30, P2816, DOI 10.1016/j.biomaterials.2009.01.031
   King GN, 1998, J PERIODONTAL RES, V33, P226, DOI 10.1111/j.1600-0765.1998.tb02194.x
   Larsen T, 2002, ORAL MICROBIOL IMMUN, V17, P267, DOI 10.1034/j.1399-302X.2002.170501.x
   Lawrence HP, 1998, J DENT RES, V77, P1904, DOI 10.1177/00220345980770110701
   LINDHE J, 1979, J CLIN PERIODONTOL, V6, P141
   LYNCH SE, 1991, J PERIODONTOL, V62, P458, DOI 10.1902/jop.1991.62.7.458
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Paquette DW, 1997, J CLIN PERIODONTOL, V24, P521, DOI 10.1111/j.1600-051X.1997.tb00223.x
   Paquette DW, 2000, J CLIN PERIODONTOL, V27, P558, DOI 10.1034/j.1600-051x.2000.027008558.x
   Patel ZS, 2008, BONE, V43, P931, DOI 10.1016/j.bone.2008.06.019
   Peattie RA, 2006, BIOMATERIALS, V27, P1868, DOI 10.1016/j.biomaterials.2005.09.035
   Polimeni G, 2006, PERIODONTOL 2000, V41, P30, DOI 10.1111/j.1600-0757.2006.00157.x
   Pradeep AR, 2010, J PERIODONTOL, V81, P214, DOI 10.1902/jop.2009.090429
   Queiroz CM, 2009, J PERIODONTAL RES, V44, P153, DOI 10.1111/j.1600-0765.2007.01069.x
   Raiche AT, 2003, IEEE ENG MED BIOL, V22, P35, DOI 10.1109/MEMB.2003.1256270
   Rosen PS, 2001, J PERIODONTOL, V72, P250, DOI 10.1902/jop.2001.72.2.250
   Salvi GE, 2005, CURR PHARM DESIGN, V11, P1757, DOI 10.2174/1381612053764878
   Santo VE, 2013, TISSUE ENG PART B-RE, V19, P327, DOI [10.1089/ten.teb.2012.0727, 10.1089/ten.TEB.2012.0727]
   Sato Sandra, 2008, Braz. oral res., V22, P145, DOI 10.1590/S1806-83242008000200009
   Schwach-Abdellaoui K, 2000, EUR J PHARM BIOPHARM, V50, P83, DOI 10.1016/S0939-6411(00)00086-2
   Selvig KA, 2002, J PERIODONTOL, V73, P1020, DOI 10.1902/jop.2002.73.9.1020
   Seto H, 2008, J PERIODONTAL RES, V43, P261, DOI 10.1111/j.1600-0765.2007.01024.x
   Simmons CA, 2004, BONE, V35, P562, DOI 10.1016/j.bone.2004.02.027
   Soskolne W A, 2001, Ann Periodontol, V6, P91, DOI 10.1902/annals.2001.6.1.91
   Srinivas M, 2011, J Indian Soc Periodontol, V15, P255, DOI 10.4103/0972-124X.85670
   Sundararaj SC, 2013, BIOERODIBLE IN PRESS
   TENENBAUM H, 1993, J CLIN PERIODONTOL, V20, P505, DOI 10.1111/j.1600-051X.1993.tb00398.x
   Tengood JE, 2010, BIOMATERIALS, V31, P7805, DOI 10.1016/j.biomaterials.2010.07.010
   Thomas MV, 2011, J DENT RES, V90, P1052, DOI 10.1177/0022034510393967
   TODD PA, 1990, DRUGS, V40, P583, DOI 10.2165/00003495-199040040-00007
   Tribble GD, 2007, J BACTERIOL, V189, P6382, DOI 10.1128/JB.00460-07
   VANOOSTEN MAC, 1986, J DENT RES, V65, P1420, DOI 10.1177/00220345860650120801
   Vernillo A T, 1998, Adv Dent Res, V12, P56
   Vyas SP, 2000, J CLIN PHARM THER, V25, P21, DOI 10.1046/j.1365-2710.2000.00261.x
   WILLIAMS RC, 1990, NEW ENGL J MED, V322, P373, DOI 10.1056/NEJM199002083220606
   Wright TL, 1997, J PERIODONTAL RES, V32, P473, DOI 10.1111/j.1600-0765.1997.tb00560.x
   XU X, 1993, PHARMACEUT RES, V10, P1144, DOI 10.1023/A:1018960016756
   Yazawa H, 2005, J PERIODONTOL, V76, P295, DOI 10.1902/jop.2005.76.2.295
NR 61
TC 33
Z9 35
U1 2
U2 87
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
EI 1878-5905
J9 BIOMATERIALS
JI Biomaterials
PD NOV
PY 2013
VL 34
IS 34
BP 8835
EP 8842
DI 10.1016/j.biomaterials.2013.07.093
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 218RR
UT WOS:000324450600027
PM 23948165
OA green_accepted
DA 2018-03-20
ER

PT J
AU Song, ES
   Rodgers, DW
   Hersh, LB
AF Song, Eun Suk
   Rodgers, David W.
   Hersh, Louis B.
TI Mixed Dimers of Insulin-degrading Enzyme Reveal a Cis Activation
   Mechanism
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID INSULYSIN; RECOGNITION; ATP
AB Insulin-degrading enzyme (IDE) exists primarily as a dimer being unique among the zinc metalloproteases in that it exhibits allosteric kinetics with small synthetic peptide substrates. In addition the IDE reaction rate is increased by small peptides that bind to a distal site within the substrate binding site. We have generated mixed dimers of IDE in which one or both subunits contain mutations that affect activity. The mutation Y609F in the distal part of the substrate binding site of the active subunit blocks allosteric activation regardless of the activity of the other subunit. This effect shows that substrate or small peptide activation occurs through a cis effect. A mixed dimer composed of one wild-type subunit and the other subunit containing a mutation that neither permits substrate binding nor catalysis (H112Q) exhibits the same turnover number per active subunit as wild-type IDE. In contrast, a mixed dimer in which one subunit contains the wild-type sequence and the other contains a mutation that permits substrate binding, but not catalysis (E111F), exhibits a decrease in turnover number. This indicates a negative trans effect of substrate binding at the active site. On the other hand, activation in trans is observed with extended substrates that occupy both the active and distal sites. Comparison of the binding of an amyloid beta peptide analog to wild-type IDE and to the Y609F mutant showed no difference in affinity, indicating that Y609 does not play a significant role in substrate binding at the distal site.
C1 [Hersh, Louis B.] Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA.
   [Hersh, Louis B.] Univ Kentucky, Struct Biol Ctr, Lexington, KY 40536 USA.
RP Hersh, LB (reprint author), Univ Kentucky, Dept Mol & Cellular Biochem, B283 BBSRB,741 S Limestone St, Lexington, KY 40536 USA.
EM lhersh@uky.edu
FU National Institutes of Health [DA02243, NS38041, P20 RR020171]
FX This work was supported, in whole or in part, by National Institutes of
   Health Grants DA02243, NS38041, and P20 RR020171.
CR Fakhrai-Rad H, 2000, HUM MOL GENET, V9, P2149, DOI 10.1093/hmg/9.14.2149
   HARI J, 1987, ENDOCRINOLOGY, V120, P829, DOI 10.1210/endo-120-2-829
   Leissring MA, 2003, NEURON, V40, P1087, DOI 10.1016/S0896-6273(03)00787-6
   Leissring MA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010504
   Malito E, 2008, BIOCHEMISTRY-US, V47, P12822, DOI 10.1021/bi801192h
   Miller BC, 2003, P NATL ACAD SCI USA, V100, P6221, DOI 10.1073/pnas.1031520100
   Parker MW, 2010, BIOCHEMISTRY-US, V49, P4068, DOI 10.1021/bi100327r
   Safavi A, 1996, BIOCHEMISTRY-US, V35, P14318, DOI 10.1021/bi960582q
   Shen YQ, 2006, NATURE, V443, P870, DOI 10.1038/nature05143
   SHII K, 1986, P NATL ACAD SCI USA, V83, P4147, DOI 10.1073/pnas.83.12.4147
   Song ES, 2004, J BIOL CHEM, V279, P54216, DOI 10.1074/jbc.M411177200
   Song ES, 2003, J BIOL CHEM, V278, P49789, DOI 10.1074/jbc.M308983200
   Song ES, 2001, J BIOL CHEM, V276, P1152, DOI 10.1074/jbc.M008702200
   Song ES, 2005, J BIOL CHEM, V280, P17701, DOI 10.1074/jbc.M501896200
   Song ES, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009719
   Yao HB, 2006, ARCH BIOCHEM BIOPHYS, V451, P175, DOI 10.1016/j.abb.2006.04.011
NR 16
TC 11
Z9 11
U1 0
U2 1
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD APR 22
PY 2011
VL 286
IS 16
BP 13852
EP 13858
DI 10.1074/jbc.M110.191668
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 750NW
UT WOS:000289556200008
PM 21343292
OA gold
DA 2018-03-20
ER

PT J
AU Moore, IM
   Merkle, CJ
   Byrne, H
   Ross, A
   Hawkins, AM
   Ameli, SS
   Montgomery, DW
AF Moore, Ida M. (Ki)
   Merkle, Carrie J.
   Byrne, Howard
   Ross, Adam
   Hawkins, Ashley M.
   Ameli, Sara S.
   Montgomery, David W.
TI Effects of Intraventricular Methotrexate on Neuronal Injury and Gene
   Expression in a Rat Model: Findings From an Exploratory Study
SO BIOLOGICAL RESEARCH FOR NURSING
LA English
DT Article
DE methotrexate; brain injury; rat model; neuronal degeneration; gene
   expression; laser capture microdissection
ID ACUTE LYMPHOBLASTIC-LEUKEMIA; HIPPOCAMPAL CELL-PROLIFERATION;
   MESSENGER-RNA EXPRESSION; TRAUMATIC BRAIN-INJURY;
   CENTRAL-NERVOUS-SYSTEM; NECROSIS-FACTOR-ALPHA; MEDIAL TEMPORAL-LOBE;
   LONG-TERM SURVIVORS; OXIDATIVE STRESS; NEUROCOGNITIVE FUNCTION
AB Central nervous system (CNS)-directed treatment for acute lymphoblastic leukemia, used to prevent disease recurrence in the brain, is essential for survival. Systemic and intrathecal methotrexate, commonly used for CNS-directed treatment, have been associated with cognitive problems during and after treatment. The cortex, hippocampus, and caudate putamen, important brain regions for learning and memory, may be involved in methotrexate-induced brain injury. Objectives of this study were to (1) quantify neuronal degeneration in selected regions of the cortex, hippocampus, and caudate putamen and (2) measure changes in the expression of genes with known roles in oxidant defense, apoptosis/inflammation, and protection from injury. Male Sprague Dawley rats were administered 2 or 4 mg/kg of methotrexate diluted in artificial cerebrospinal fluid (aCSF) or aCSF only into the left cerebral lateral ventricle. Gene expression changes were measured using customized reverse transcription (RT)(2) polymerase chain reaction arrays. The greatest percentage of degenerating neurons in methotrexate-treated animals was in the medial region of the cortex; percentage of degenerating neurons in the dentate gyrus and cornu ammonis 3 regions of the hippocampus was also greater in rats treated with methotrexate compared to perfusion and vehicle controls. There was a greater percentage of degenerating neurons in the inferior cortex of control versus methotrexate-treated animals. Eight genes involved in protection from injury, oxidant defense, and apoptosis/inflammation were significantly downregulated in different brain regions of methotrexate-treated rats. To our knowledge, this is the first study to investigate methotrexate-induced injury in selected brain regions and gene expression changes using a rat model of intraventricular drug administration.
C1 [Moore, Ida M. (Ki); Merkle, Carrie J.; Ross, Adam; Ameli, Sara S.; Montgomery, David W.] Univ Arizona, Coll Nursing, 1305N Martin Ave,POB 210203, Tucson, AZ 85721 USA.
   [Hawkins, Ashley M.; Montgomery, David W.] Southern Arizona VA Healthcare Syst, Tucson, AZ USA.
RP Moore, IM (reprint author), Univ Arizona, Coll Nursing, 1305N Martin Ave,POB 210203, Tucson, AZ 85721 USA.
EM imoore@email.arizona.edu
FU Alex's Lemonade Stand Foundation
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This work
   was supported by a Discovery Grant from Alex's Lemonade Stand
   Foundation.
CR Ahles TA, 2007, NAT REV CANCER, V7, P192, DOI 10.1038/nrc2073
   Ashford J, 2010, CANCER-AM CANCER SOC, V116, P4638, DOI 10.1002/cncr.25343
   Bernardino L, 2005, J NEUROSCI, V25, P6734, DOI 10.1523/JNEUROSCI.1510-05.2005
   Bisen-Hersh EB, 2011, J CANCER, V2, P292, DOI 10.7150/jca.2.292
   Bonefeld BE, 2008, SYNAPSE, V62, P302, DOI 10.1002/syn.20496
   Brunet N, 2007, J COMP NEUROL, V501, P669, DOI 10.1002/cne.21157
   Buizer AI, 2005, PEDIATR BLOOD CANCER, V45, P281, DOI 10.1002/pbc.20397
   Buizer AI, 2005, J INT NEUROPSYCH SOC, V11, P554, DOI 10.1017/S135561770505666
   Buizer AI, 2009, PEDIATR BLOOD CANCER, V52, P447, DOI 10.1002/pbc.21869
   Carey ME, 2007, J PEDIATR PSYCHOL, V32, P189, DOI 10.1093/jpepsy/jsj114
   Caron JE, 2009, PEDIATR BLOOD CANCER, V53, P551, DOI 10.1002/pbc.22128
   Cheng Y, 2011, CELL PHYSIOL BIOCHEM, V27, P191, DOI 10.1159/000327944
   Christopherson KS, 2005, CELL, V120, P421, DOI 10.1016/j.cell.2004.12.020
   Cook NL, 2009, J NEUROSCI RES, V87, P34, DOI 10.1002/jnr.21846
   Dave KR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022057
   DeCoteau WE, 2000, BEHAV NEUROSCI, V114, P1096, DOI 10.1037//0735-7044.114.6.1096
   Deng X., 2013, SCI WORLD J, V2013, P8, DOI DOI 10.1371/J0URNAL.P0NE.0069881
   Eichenbaum H, 2004, NEURON, V44, P109, DOI 10.1016/j.neuron.2004.08.028
   Eichenbaum H, 2001, BEHAV BRAIN RES, V127, P199, DOI 10.1016/S0166-4328(01)00365-5
   Engel T, 2011, J CEREBR BLOOD F MET, V31, P1196, DOI 10.1038/jcbfm.2011.26
   Fardell JE, 2010, PHARMACOL BIOCHEM BE, V97, P333, DOI 10.1016/j.pbb.2010.08.019
   Fortin NJ, 2002, NAT NEUROSCI, V5, P458, DOI 10.1038/nn834
   Franco R., 2007, Archives of Physiology and Biochemistry, V113, P234, DOI 10.1080/13813450701661198
   FURUTA A, 1995, AM J PATHOL, V146, P357
   Giovannoni G, 2006, DIS MARKERS, V22, P187, DOI 10.1155/2006/509476
   Goldminz AM, 2015, JAMA DERMATOL, V151, P837, DOI 10.1001/jamadermatol.2015.0452
   Grahn JA, 2008, PROG NEUROBIOL, V86, P141, DOI 10.1016/j.pneurobio.2008.09.004
   Graybiel AM, 2005, CURR OPIN NEUROBIOL, V15, P638, DOI 10.1016/j.conb.2005.10.006
   Guerra R, 2013, TOXICOL LETT, V222, P146, DOI 10.1016/j.toxlet.2013.07.012
   Harris JL, 2009, J NEUROTRAUM, V26, P1669, DOI 10.1089/neu.2009-0875
   Hockenberry M, 2007, J PEDIAT HEMATOL ONC, V29, P535, DOI 10.1097/MPH.0b013e3180f61b92
   Hockenberry MJ, 2015, ONCOL NURS FORUM, V42, P542, DOI 10.1188/15.ONF.542-549
   Hockenberry MJ, 2014, BIOL RES NURS, V16, P303, DOI 10.1177/1099800413498507
   Huang B, 2012, NEUROBIOL DIS, V46, P204, DOI 10.1016/j.nbd.2012.01.008
   Huang HF, 2012, CNS NEUROSCI THER, V18, P811, DOI 10.1111/j.1755-5949.2012.00380.x
   Hunger SP, 2012, J CLIN ONCOL, V30, P1663, DOI 10.1200/JCO.2011.37.8018
   IGARASHI H, 1989, NEUROPEDIATRICS, V20, P196, DOI 10.1055/s-2008-1071291
   Jahovic N, 2003, J PINEAL RES, V34, P282, DOI 10.1034/j.1600-079X.2003.00043.x
   Janelsins MC, 2010, CANCER INVEST, V28, P544, DOI 10.3109/07357900903405942
   Kaemingk KL, 2004, CHILD NEUROPSYCHOL, V10, P14
   Kesner RP, 2006, EUR J NEUROSCI, V23, P1888, DOI 10.1111/j.1460-9568.2006.04709.x
   Krull KR, 2008, J CLIN ONCOL, V26, P4138, DOI 10.1200/JCO.2008.16.8864
   Krull KR, 2013, LEUKEMIA LYMPHOMA, V54, P535, DOI 10.3109/10428194.2012.717080
   Langnaese K, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-53
   Torres LHL, 2012, J TOXICOL ENV HEAL A, V75, P971, DOI 10.1080/15287394.2012.695985
   Marini F, 2006, BRAIN RES, V1067, P25, DOI 10.1016/j.brainres.2005.10.002
   Merkle C J, 2000, Biol Res Nurs, V2, P5, DOI 10.1177/109980040000200102
   Miketova Petra, 2005, Biol Res Nurs, V6, P187, DOI 10.1177/1099800404271916
   MIYASHITA Y, 1993, ANNU REV NEUROSCI, V16, P245, DOI 10.1146/annurev.ne.16.030193.001333
   Moleski M, 2000, ARCH CLIN NEUROPSYCH, V15, P603, DOI 10.1016/S0887-6177(99)00050-5
   Montour-Proulx I, 2005, J CHILD NEUROL, V20, P129, DOI 10.1177/08830738050200020901
   Moore I., 2014, STAT SCI C NURS RES
   Moore IM, 2015, J PEDIAT HEMATOL ONC, V37, pE86, DOI 10.1097/MPH.0000000000000258
   Moore IM, 2006, BIOL RES NURS, V7, P289, DOI 10.1177/1099800405286138
   Ki Moore IM, 2013, SEMIN ONCOL NURS, V29, P248, DOI DOI 10.1016/j.soncn.2013.08.005
   Nagel BJ, 2004, AM J NEURORADIOL, V25, P1575
   Pernot F, 2010, J NEUROSCI RES, V88, P1000, DOI 10.1002/jnr.22282
   Pertusa A, 2008, NEUROBIOL AGING, V29, P1366, DOI 10.1016/j.neurobiolaging.2007.02.026
   Pui CH, 2003, J CLIN ONCOL, V21, P179, DOI 10.1200/JCO.2003.10.032
   Pui CH, 2006, NEW ENGL J MED, V354, P166, DOI 10.1056/NEJMra052603
   Pui CH, 2006, HEMATOL-AM SOC HEMAT, V2006, P142, DOI DOI 10.1182/ASHEDUCATI0N-2006.1.142
   Raju R., 2014, J SIGNAL TRANSDUCT, V2014, DOI [10.1155/2014/962962, DOI 10.1155/2014/962962]
   Reddick WE, 2006, CANCER, V106, P941, DOI 10.1002/cncr.21679
   Reddick WE, 2005, AM J NEURORADIOL, V26, P2371
   Reddick WE, 2005, AM J NEURORADIOL, V26, P1263
   Rieckmann A, 2010, NEUROIMAGE, V50, P1303, DOI 10.1016/j.neuroimage.2010.01.015
   Rodriguez-Martinez E, 2013, NEUROSCIENCE, V252, P384, DOI 10.1016/j.neuroscience.2013.08.018
   Santos ARA, 2008, J NEUROSCI RES, V86, P3684, DOI 10.1002/jnr.21796
   Schendan HE, 2003, NEURON, V37, P1013, DOI 10.1016/S0896-6273(03)00123-5
   SCHUNIOR A, 1994, PEDIATR RES, V35, P416, DOI 10.1203/00006450-199404000-00007
   Seigers R, 2008, BEHAV BRAIN RES, V186, P168, DOI 10.1016/j.bbr.2007.08.004
   Seigers R, 2011, NEUROSCI BIOBEHAV R, V35, P729, DOI 10.1016/j.neubiorev.2010.09.006
   Seigers R, 2009, BEHAV BRAIN RES, V201, P279, DOI 10.1016/j.bbr.2009.02.025
   Siemionow K, 2009, SPINE, V34, P1631, DOI 10.1097/BRS.0b013e3181ab1f68
   Tan XF, 2014, NEUROSCI LETT, V571, P23, DOI 10.1016/j.neulet.2014.04.019
   Tsai MC, 2008, MOL CELL PROTEOMICS, V7, P1668, DOI 10.1074/mcp.M800076-MCP200
   VANDERKOGEL AJ, 1985, RADIOTHER ONCOL, V4, P239, DOI 10.1016/S0167-8140(85)80089-X
   Viviani B, 1998, TOXICOL APPL PHARM, V150, P271, DOI 10.1006/taap.1998.8406
   Waber Deborah P, 1997, Oncology (Williston Park), V11, P259
   WABER DP, 1995, J CLIN ONCOL, V13, P2490, DOI 10.1200/JCO.1995.13.10.2490
   Ward E, 2014, CA-CANCER J CLIN, V64, P83, DOI 10.3322/caac.21219
   Winick NJ, 2004, NEW ENGL J MED, V351, P601, DOI 10.1056/NEJMe048154
   Wood TK, 2005, J NEUROSCI RES, V80, P759, DOI 10.1002/jnr.20507
   Xu JY, 2010, NAT NEUROSCI, V13, P22, DOI 10.1038/nn.2459
   Yang LB, 2002, J NEUROSCI, V22, P3025
   YANOVSKI JA, 1989, MED PEDIATR ONCOL, V17, P216, DOI 10.1002/mpo.2950170309
   Zhao ZQ, 2004, EXP NEUROL, V190, P356, DOI 10.1016/j.expneurol.2004.06.015
NR 87
TC 0
Z9 0
U1 1
U2 4
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1099-8004
EI 1552-4175
J9 BIOL RES NURS
JI Biol. Res. Nurs.
PD OCT
PY 2016
VL 18
IS 5
BP 505
EP 514
DI 10.1177/1099800416644780
PG 10
WC Nursing
SC Nursing
GA DV9MC
UT WOS:000383263600004
PM 27142250
DA 2018-03-20
ER

PT J
AU Chirra, HD
   Spencer, D
   Hilt, JZ
AF Chirra, Hariharasudhan D.
   Spencer, David
   Hilt, J. Zach
TI Isolate, functionalize, and release: the ISOFURE platform for the
   functionalization of nanoparticles
SO JOURNAL OF NANOPARTICLE RESEARCH
LA English
DT Article
DE ISOFURE; Degradable polymers; Gold nanoparticles; Poly(beta amino
   ester); ATRP; PNIPAAm
ID COATED GOLD NANOPARTICLES; RADICAL POLYMERIZATION; NANOSTRUCTURES;
   HYDROGELS; PROSPECTS; MEDICINE
AB Polymer-coated inorganic nanoparticles are widely studied as carrier systems for various biomedical applications. For their translation into clinical applications, it is critical that they remain in a stable, non-agglomerated state and are also produced at a high yield with ease. Herein, we introduce a novel methodology called the isolate-functionalize-release (ISOFURE) strategy to synthesize stable hydrogel-coated nanoparticles in the absence of a stabilizing reagent. As a model platform, we isolated and functionalized gold nanoparticles (GNPs) in a degradable poly(beta amino ester) (PBAE) hydrogel composite. Isolation was done either by adding GNPs to the PBAE hydrogel precursor solution or via in situ precipitation of GNPs inside the pre-synthesized PBAE hydrogel. Atom transfer radical polymerization (ATRP) was used as the model reaction to grow a temperature responsive poly(ethylene glycol) 600 dimethacrylate crosslinked poly(N-isopropyl acrylamide) hydrogel shell over the GNP core. Release of the temperature responsive hydrogel-coated GNPs was done by degrading the PBAE ISOFURE matrix in water. Characterization of the various nanoparticles using UV-Vis spectroscopy confirmed in situ precipitation of GNPs as well as ATRP over the GNPs. Light scattering confirmed the presence of temperature sensitive hydrogel shell over the GNP surface. Aging studies showed that the ISOFURE method based crosslinked hydrogel-coated GNPs showed higher stability and yield than that of the solution-based functionalized GNPs. The use of ISOFURE strategy shows promise as a simple tool for enhanced functionalization and stabilization over various nanocarriers under flexible experimental conditions.
C1 [Chirra, Hariharasudhan D.; Spencer, David; Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Hilt, JZ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM hilt@engr.uky.edu
CR Anderson DG, 2006, ADV MATER, V18, P2614, DOI 10.1002/adma.200600529
   Boisselier E, 2010, J AM CHEM SOC, V132, P2729, DOI 10.1021/ja909133f
   Chakraborty S, 2010, J PHYS CHEM C, V114, P5947, DOI 10.1021/jp910417g
   Chirra HD, 2011, POLYM ADVAN TECHNOL, V22, P773, DOI 10.1002/pat.1576
   Chirra HD, 2010, LANGMUIR, V26, P11249, DOI 10.1021/la1005677
   CHIRRA HD, 2009, NANOPARTICULATE DRUG, V2, P90
   De M, 2008, ADV MATER, V20, P4225, DOI 10.1002/adma.200703183
   Dong HC, 2008, J AM CHEM SOC, V130, P12852, DOI 10.1021/ja8038097
   DZIDIC I, 1972, J AM CHEM SOC, V94, P8333, DOI 10.1021/ja00779a009
   El-Sayed IH, 2006, CANCER LETT, V239, P129, DOI 10.1016/j.canlet.2005.07.035
   Hawkins AM, 2009, PHARM RES-DORD, V26, P667, DOI 10.1007/s11095-008-9804-z
   Houbenov N, 2003, MACROMOLECULES, V36, P5897, DOI 10.1021/ma0341869
   Jordan R, 2001, MACROMOLECULES, V34, P1606, DOI 10.1021/ma001615j
   Ke YC, 2005, CHARACTERIZATION TEC, P275
   Kim JH, 2004, CHEM MATER, V16, P3647, DOI 10.1021/cm049764u
   Kim JH, 2006, DRUG DEVELOP RES, V67, P61, DOI 10.1002/ddr.20068
   Krsko P, 2005, MATER TODAY, V8, P36, DOI 10.1016/S1369-7021(05)71223-2
   Li DX, 2007, CHEM-EUR J, V13, P2224, DOI 10.1002/chem.200600839
   Moghimi SM, 2005, FASEB J, V19, P311, DOI 10.1096/fj.04-2747rev
   Ohno K, 2002, MACROMOLECULES, V35, P8989, DOI 10.1021/ma0209491
   Sanvicens N, 2008, TRENDS BIOTECHNOL, V26, P425, DOI 10.1016/j.tibtech.2008.04.005
   Satarkar NS, 2008, J CONTROL RELEASE, V130, P246, DOI 10.1016/j.jconrel.2008.06.008
   Sidorenko A, 2007, SCIENCE, V315, P487, DOI 10.1126/science.1135516
   Slaughter BV, 2009, ADV MATER, V21, P3307, DOI 10.1002/adma.200802106
   Zhao MQ, 1998, J AM CHEM SOC, V120, P4877, DOI 10.1021/ja980438n
NR 25
TC 1
Z9 1
U1 0
U2 20
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1388-0764
J9 J NANOPART RES
JI J. Nanopart. Res.
PD NOV
PY 2012
VL 14
IS 11
AR 1230
DI 10.1007/s11051-012-1230-9
PG 8
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA 030ZG
UT WOS:000310608100020
DA 2018-03-20
ER

PT J
AU Mansour, HM
AF Mansour, Heidi M.
TI Rational design, development, and optimization of nanopharmaceuticals
   for targeted drug delivery in nanomedicine: An interfacial and colloidal
   science approach
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
CT 242nd National Meeting of the American-Chemical-Society (ACS)
CY AUG 28-SEP 01, 2011
CL Denver, CO
SP Amer Chem Soc (ACS)
C1 [Mansour, Heidi M.] Univ Kentucky, Dept Pharmaceut Sci, Coll Pharm, Lexington, KY 40536 USA.
EM heidi.mansour@uky.edu
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD AUG 28
PY 2011
VL 242
MA 281-COLL
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA 880BE
UT WOS:000299378301697
DA 2018-03-20
ER

PT J
AU Dan, M
   Bae, Y
   Pittman, TA
   Yokel, RA
AF Dan, Mo
   Bae, Younsoo
   Pittman, Thomas A.
   Yokel, Robert A.
TI Alternating Magnetic Field-Induced Hyperthermia Increases Iron Oxide
   Nanoparticle Cell Association/Uptake and Flux in Blood-Brain Barrier
   Models
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE alternating magnetic field; blood-brain barrier permeability;
   cross-linked nanoassemblies; flux; superparamagnetic iron oxide
   nanoparticles
ID CROSS-LINKED NANOASSEMBLIES; JUNCTION PROTEIN EXPRESSION;
   CENTRAL-NERVOUS-SYSTEM; ENDOTHELIAL-CELLS; DRUG-DELIVERY; MOUSE-BRAIN;
   GASTROINTESTINAL ABSORPTION; TEMPERATURE; TRANSPORT; GLIOMA
AB Superparamagnetic iron oxide nanoparticles (IONPs) are being investigated for brain cancer therapy because alternating magnetic field (AMF) activates them to produce hyperthermia. For central nervous system applications, brain entry of diagnostic and therapeutic agents is usually essential. We hypothesized that AMF-induced hyperthermia significantly increases IONP blood-brain barrier (BBB) association/uptake and flux.
   Cross-linked nanoassemblies loaded with IONPs (CNA-IONPs) and conventional citrate-coated IONPs (citrate-IONPs) were synthesized and characterized in house. CNA-IONP and citrate-IONP BBB cell association/uptake and flux were studied using two BBB Transwell(A (R)) models (bEnd.3 and MDCKII cells) after conventional and AMF-induced hyperthermia exposure.
   AMF-induced hyperthermia for 0.5 h did not alter CNA-IONP size but accelerated citrate-IONP agglomeration. AMF-induced hyperthermia for 0.5 h enhanced CNA-IONP and citrate-IONP BBB cell association/uptake. It also enhanced the flux of CNA-IONPs across the two in vitro BBB models compared to conventional hyperthermia and normothermia, in the absence of cell death. Citrate-IONP flux was not observed under these conditions. AMF-induced hyperthermia also significantly enhanced paracellular pathway flux. The mechanism appears to involve more than the increased temperature surrounding the CNA-IONPs.
   Hyperthermia induced by AMF activation of CNA-IONPs has potential to increase the BBB permeability of therapeutics for the diagnosis and therapy of various brain diseases.
C1 [Dan, Mo; Yokel, Robert A.] Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA.
   [Pittman, Thomas A.] Univ Kentucky, Dept Neurosurg, Lexington, KY 40536 USA.
   [Dan, Mo] Natl Inst Food & Drug Control, Natl Ctr Safety Evaluat Drugs, Beijing 100176, Peoples R China.
   [Dan, Mo; Bae, Younsoo; Yokel, Robert A.] Univ Kentucky, Coll Pharm, Acad Med Ctr, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
RP Yokel, RA (reprint author), Univ Kentucky, Coll Pharm, Acad Med Ctr, Dept Pharmaceut Sci, 335 Biopharmaceut Complex Coll Pharm Bldg, Lexington, KY 40536 USA.
EM ryokel@uky.edu
FU National Cancer Institute [R25CA153954]
FX The authors gratefully acknowledge J. Zack Hilt for sharing his AMF
   equipment and the citrate-IONP synthesis method, Daniel F. Scott for
   assisting in CNA synthesis, and Markos Leggas and Kuei-Ling Kuo for
   providing the MDCKII cell line and assisting in the Transwell (R) model
   establishment. Mo Dan and the project described were supported by Grant
   Number R25CA153954 from the National Cancer Institute. The content is
   solely the responsibility of the authors and does not necessarily
   represent the official views of the National Cancer Institute or the
   National Institutes of Health.
CR Abbott NJ, 2012, METHODS MOL BIOL, V814, P415, DOI 10.1007/978-1-61779-452-0_28
   Agarwal A, 2009, CURR PHARM DESIGN, V15, P917, DOI 10.2174/138161209787582057
   Ambruosi A, 2006, J MICROENCAPSUL, V23, P582, DOI 10.1080/02652040600788080
   Basel MT, 2012, INT J NANOMED, V7, P297, DOI 10.2147/IJN.S28344
   Bernacki J, 2008, PHARMACOL REP, V60, P600
   Bhaskar S., 2010, PART FIBRE TOXICOL, V7
   Bostrom M, 2014, INT J RADIAT BIOL, V90, P778, DOI 10.3109/09553002.2014.931612
   Brown RC, 2007, BRAIN RES, V1130, P17, DOI 10.1016/j.brainres.2006.10.083
   Dan M, 2013, PHARM RES-DORDR, V30, P552, DOI 10.1007/s11095-012-0900-8
   Dhanikula RS, 2009, J PHARM SCI-US, V98, P3748, DOI 10.1002/jps.21669
   Fazlollahi F, 2011, NANOMED-NANOTECHNOL, V7, P588, DOI 10.1016/j.nano.2011.01.008
   Gong W, 2011, BIOL PHARM BULL, V34, P1058, DOI 10.1248/bpb.34.1058
   Hellinger E, 2012, EUR J PHARM BIOPHARM, V82, P340, DOI 10.1016/j.ejpb.2012.07.020
   Hoff D, 2012, INT J NANOMED, V8, P703
   Huang H, 2010, NAT NANOTECHNOL, V5, P602, DOI [10.1038/NNANO.2010.125, 10.1038/nnano.2010.125]
   Kadam RS, 2012, MOL PHARMACEUT, V9, P3228, DOI 10.1021/mp300305f
   Kenzaoui BH, 2012, NANOMEDICINE-UK, V7, P39, DOI [10.2217/NNM.11.85, 10.2217/nnm.11.85]
   Kiyatkin EA, 2009, NEUROSCIENCE, V161, P926, DOI 10.1016/j.neuroscience.2009.04.004
   Lee HJ, 2011, BIOMACROMOLECULES, V12, P2686, DOI 10.1021/bm200483t
   Mannix RJ, 2008, NAT NANOTECHNOL, V3, P36, DOI 10.1038/nnano.2007.418
   Meenach SA, 2010, J POLYM SCI POL CHEM, V48, P3229, DOI 10.1002/pola.24087
   MORIYAMA E, 1991, SURG NEUROL, V35, P177, DOI 10.1016/0090-3019(91)90068-K
   Nakagawa Minoru, 1994, Neurologia Medico-Chirurgica, V34, P668, DOI 10.2176/nmc.34.668
   Neuberger T, 2005, J MAGN MAGN MATER, V293, P483, DOI 10.1016/j.jmmm.2005.01.064
   Nozinic D, 2010, CROAT CHEM ACTA, V83, P323
   Peetla C, 2008, MOL PHARM, V5, P418, DOI 10.1021/mp700140a
   Riemer J, 2004, ANAL BIOCHEM, V331, P370, DOI 10.1016/j.ab.2004.03.049
   Scott D, 2011, INT J NANOMED, V6, P2757, DOI 10.2147/IJN.S25427
   Sharma HS, 2012, INT REV NEUROBIOL, V102, P249, DOI 10.1016/B978-0-12-386986-9.00010-7
   Sharma HS, 2012, WIRES NANOMED NANOBI, V4, P184, DOI 10.1002/wnan.172
   Sharma HS, 2003, INT J HYPERTHER, V19, P325, DOI 10.1080/0265673021000054621
   Silva AC, 2011, INT J NANOMED, V6, P591, DOI 10.2147/IJN.S14737
   Strober W, 2001, CURR PROTOC IMMUNOL
   Sun ZZ, 2014, INT J NANOMED, V9, P3013, DOI 10.2147/IJN.S62260
   Tabatabaei SN, 2012, IEEE INT C ROB AUT, V14, P727
   TRIGUERO D, 1990, J NEUROCHEM, V54, P1882, DOI 10.1111/j.1471-4159.1990.tb04886.x
   Uzuka T, 2006, NEUROL MED-CHIR, V46, P19, DOI 10.2176/nmc.46.19
   van der Zee J, 2002, ANN ONCOL, V13, P1173, DOI 10.1093/annonc/mdf280
   Wang JX, 2008, TOXICOL LETT, V183, P72, DOI 10.1016/j.toxlet.2008.10.001
   Wang Q, 2005, INT J PHARMACEUT, V288, P349, DOI 10.1016/j.ijpharm.2004.10.007
   Watanabe T, 2013, BIOL PHARM BULL, V36, P492, DOI 10.1248/bpb.b12-00915
   Wilhelm I, 2011, ACTA NEUROBIOL EXP, V71, P113
   Zhang LL, 2011, TOXICOL LETT, V207, P73, DOI 10.1016/j.toxlet.2011.08.001
   Zhou YH, 2008, J INORG BIOCHEM, V102, P798, DOI 10.1016/j.jinorgbio.2007.11.019
   Zhou YZ, 2005, TOXICOL SCI, V87, P15, DOI 10.1093/toxsci/kfi216
NR 45
TC 10
Z9 10
U1 2
U2 40
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
EI 1573-904X
J9 PHARM RES-DORDR
JI Pharm. Res.
PD MAY
PY 2015
VL 32
IS 5
BP 1615
EP 1625
DI 10.1007/s11095-014-1561-6
PG 11
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA CF0HZ
UT WOS:000352225300007
PM 25377069
OA green_accepted
DA 2018-03-19
ER

PT J
AU Zhang, XY
   Hurng, J
   Rateri, DL
   Daugherty, A
   Schmid-Schonbein, GW
   Shin, HY
AF Zhang, Xiaoyan
   Hurng, Jonathan
   Rateri, Debra L.
   Daugherty, Alan
   Schmid-Schoenbein, Geert W.
   Shin, Hainsworth Y.
TI Membrane Cholesterol Enrichment Alters Leukocyte Shear Responses via an
   Effect on Membrane Fluidity
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Experimental Biology Meeting 2011
CY APR 09-13, 2011
CL Washington, DC
SP Amer Assoc Anatomists (AAA), Amer Physiolog Soc (APS), Amer Soc Biochem & Mol Biol (ASBMB), Amer Soc Investigat Pathol (ASIP), Amer Soc Nutrit (ASN), Amer Soc Pharmacol & Expt Therapeut (ASPET)
C1 [Zhang, Xiaoyan; Shin, Hainsworth Y.] Univ Kentucky, Ctr Biomed Engn, Lexington, KY 40506 USA.
   [Rateri, Debra L.; Daugherty, Alan; Shin, Hainsworth Y.] Univ Kentucky, Saha Cardiovasc Res Ctr, Lexington, KY 40506 USA.
   [Hurng, Jonathan; Schmid-Schoenbein, Geert W.] Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2011
VL 25
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 032IE
UT WOS:000310708403692
DA 2018-03-20
ER

PT J
AU Hauser, AK
   Mathias, R
   Anderson, KW
   Hilt, JZ
AF Hauser, Anastasia K.
   Mathias, Ronita
   Anderson, Kimberly W.
   Hilt, J. Zach
TI The effects of synthesis method on the physical and chemical properties
   of dextran coated iron oxide nanoparticles
SO MATERIALS CHEMISTRY AND PHYSICS
LA English
DT Article
DE Nanomaterials; Magnetic materials; Co-precipitation; Characterization
ID MAGNETITE NANOPARTICLES; BIOMEDICAL APPLICATIONS; LIVER FIBROSIS;
   HYPERTHERMIA; PARTICLES; PRECIPITATION; AGENT; FE3O4; MRI
AB Iron oxide nanoparticles coated with dextran were synthesized via four variations on the co-precipitation method. The methods ranged from in situ formation of the nanoparticles within the dextran solution to the adsorption of dextran to the nanoparticle surface following nucleation and extensive washing. The timing of the addition of dextran into the reaction mixture was found to greatly influence the physical and chemical properties of the magnetic nanoparticles. Batches of dextran coated iron oxide nanoparticles were synthesized by each method in triplicate, and the nanoparticles were further crosslinked with epichlorohydrin. The properties of the nanoparticles such as size, percentage of dextran coating, stability in solution, crystallinity, and magnetic properties were evaluated. The simultaneous semi-two-step method injected the reducing agent and the dextran solution into the reaction vessel at the same time. This method resulted in the greatest batch-to-batch reproducibility of nanoparticle properties and the least variation in nanoparticles synthesized in the same batch. The two-step method resulted in the greatest variation of the characteristics examined between batches. The one-step method was synthesized with both five grams and one gram of dextran to investigate the effects of solution viscosity on the resulting nanoparticle characteristics. The one-step method with five grams of dextran resulted in nanoparticles with significantly smaller crystal sizes (5.4 +/- 1.9 nm) and lower specific adsorption rate (SAR) values (138.4 +/- 13.6 W/g) in an alternating magnetic field (58 kA/m, 292 kHz). However, this method resulted in nanoparticles that were very stable in PBS over 12 h, which is most likely due to the greater dextran coating (60.0 +/- 2.7 weight percent). For comparison, the simultaneous semi-two-step method generated nanoparticles 179.2 +/- 18.3 nm in diameter (crystal size 12.1 +/- 0.2 nm) containing 183 +/- 1.2 weight percent dextran with a SAR value of 321.1 +/- 137.3 W/g. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Hauser, Anastasia K.; Mathias, Ronita; Anderson, Kimberly W.; Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Hilt, JZ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM hilt@engr.uky.edu
FU National Cancer Institute [R25CA153954]; National Science Foundation
   Graduate Research Fellowship Program [DGE-1247392]
FX The project described was partially supported by Grant Number
   R25CA153954 from the National Cancer Institute. The content is solely
   the responsibility of the authors and does not necessarily represent the
   official views of the National Cancer Institute or the National
   Institutes of Health. Additionally, this material is based upon work
   supported by the National Science Foundation Graduate Research
   Fellowship Program Grant No. DGE-1247392. Any opinions, findings, and
   conclusions or recommendations expressed in this material are those of
   the author(s) and do not necessarily reflect the views of the National
   Science Foundation.
CR Andrade AL, 2010, QUIM NOVA, V33, P524, DOI 10.1590/S0100-40422010000300006
   Arbain R, 2011, MINER ENG, V24, P1, DOI 10.1016/j.mineng.2010.08.025
   Ayala V., 2013, J NANOPART RES, P15
   BEE A, 1995, J MAGN MAGN MATER, V149, P6, DOI 10.1016/0304-8853(95)00317-7
   Buyukhatipoglu K, 2010, J NANOPART RES, V12, P1495, DOI 10.1007/s11051-009-9724-9
   Daou TJ, 2008, CHEM MATER, V20, P5869, DOI 10.1021/cm801405n
   Dennis CL, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/39/395103
   Easo SL, 2013, CARBOHYD POLYM, V92, P726, DOI 10.1016/j.carbpol.2012.09.098
   FEEST TG, 1976, BRIT MED J, V2, P1300, DOI 10.1136/bmj.2.6047.1300
   Fortin JP, 2007, J AM CHEM SOC, V129, P2628, DOI 10.1021/ja067457e
   Frimpong RA, 2010, NANOMEDICINE-UK, V5, P1401, DOI 10.2217/NNM.10.114
   Frimpong RA, 2010, J MAGN MAGN MATER, V322, P326, DOI 10.1016/j.jmmm.2009.09.050
   Gupta AK, 2005, BIOMATERIALS, V26, P3995, DOI 10.1016/j.biomaterials.2004.10.012
   Hergt R, 2004, J MAGN MAGN MATER, V270, P345, DOI 10.1016/j.jmmm.2003.09.001
   Janot R, 2002, J ALLOY COMPD, V333, P302, DOI 10.1016/S0925-8388(01)01737-6
   Kallumadil M, 2009, J MAGN MAGN MATER, V321, P3650, DOI 10.1016/j.jmmm.2009.06.069
   Kang YS, 1996, CHEM MATER, V8, P2209, DOI 10.1021/cm960157j
   Kodama RH, 1999, J MAGN MAGN MATER, V200, P359, DOI 10.1016/S0304-8853(99)00347-9
   Kruse AM, 2014, ACTA BIOMATER, V10, P2622, DOI 10.1016/j.actbio.2014.01.025
   Laurent S, 2011, ADV COLLOID INTERFAC, V166, P8, DOI 10.1016/j.cis.2011.04.003
   Lee Y, 2005, ADV FUNCT MATER, V15, P503, DOI 10.1002/adfm.200400187
   Lee YT, 2008, IEEE T NANOTECHNOL, V7, P111, DOI 10.1109/TNANO.2007.909949
   Mahmoudi M, 2009, J COLLOID INTERF SCI, V336, P510, DOI 10.1016/j.jcis.2009.04.046
   MASSART R, 1981, IEEE T MAGN, V17, P1247, DOI 10.1109/TMAG.1981.1061188
   Murbe J, 2008, MATER CHEM PHYS, V110, P426, DOI 10.1016/j.matchemphys.2008.02.037
   Palmacci S, 1993, SYNTHESIS POLYSACCHA
   Pardoe H, 2001, J MAGN MAGN MATER, V225, P41, DOI 10.1016/S0304-8853(00)01226-9
   Park J, 2004, NAT MATER, V3, P891, DOI 10.1038/nmat1251
   Park JH, 2008, ADV MATER, V20, P1630, DOI 10.1002/adma.200800004
   Qiao RR, 2009, J MATER CHEM, V19, P6274, DOI 10.1039/b902394a
   Saraswathy A, 2014, COLLOID SURFACE B, V117, P216, DOI 10.1016/j.colsurfb.2014.02.034
   Saraswathy A, 2014, CARBOHYD POLYM, V101, P760, DOI 10.1016/j.carbpol.2013.10.015
   Sharapova VA, 2010, PHYS MET METALLOGR+, V110, P5, DOI 10.1134/S0031918X10070021
   Simberg D, 2007, P NATL ACAD SCI USA, V104, P932, DOI 10.1073/pnas.0610298104
   Sreeja V, 2011, INT J NANOTECHNOL, V8, P907, DOI 10.1504/IJNT.2011.044435
   Sun SH, 2004, J AM CHEM SOC, V126, P273, DOI 10.1021/ja0380852
   Tassa C, 2011, ACCOUNTS CHEM RES, V44, P842, DOI 10.1021/ar200084x
   Vayssieres L, 1998, J COLLOID INTERF SCI, V205, P205, DOI 10.1006/jcis.1998.5614
   Xu XQ, 2005, APPL SURF SCI, V252, P494, DOI 10.1016/j.apsusc.2005.01.027
   Yoffe S, 2013, CURR PHARM DESIGN, V19, P493, DOI 10.2174/138161213804143707
NR 40
TC 11
Z9 11
U1 3
U2 59
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0254-0584
EI 1879-3312
J9 MATER CHEM PHYS
JI Mater. Chem. Phys.
PD JUN 15
PY 2015
VL 160
BP 177
EP 186
DI 10.1016/j.matchemphys.2015.04.022
PG 10
WC Materials Science, Multidisciplinary
SC Materials Science
GA CK4RF
UT WOS:000356210200023
PM 26097275
OA green_accepted
DA 2018-03-19
ER

PT J
AU Cochran, DB
   Gray, LN
   Anderson, KW
   Dziubla, TD
AF Cochran, David B.
   Gray, Lindsay N.
   Anderson, Kimberly W.
   Dziubla, Thomas D.
TI Degradable poly(apigenin) polymer inhibits tumor cell adhesion to
   vascular endothelial cells
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B-APPLIED BIOMATERIALS
LA English
DT Article
DE nanoparticles; antioxidant polymers; cancer inhibition; cellular
   adhesion molecules; apigenin
ID BREAST-CANCER; CONTROLLED-RELEASE; NANOPARTICLES; MODULATION; MOLECULES;
   FLAVONES; WOMEN; MICE
AB Cancer and the inflammatory system share a complex intertwined relationship. For instance, in response to an injury or stress, vascular endothelial cells will express cell adhesion molecules as a means of recruiting leukocytes. However, circulating tumor cells (CTCs) have been shown to highjack this expression for the adhesion and invasion during the metastatic cascade. As such, the initiation of endothelial cell inflammation, either by surgical procedures (cancer resection) or chemotherapy can inadvertently increase the metastatic potential of CTCs. Yet, systemic delivery of anti-inflammatories, which weaken the entire immune system, may not be preferred in some treatment settings. In this work, we demonstrate that a long-term releasing flavone-based polymer and subsequent nanoparticle delivery system can inhibit tumor cell adhesion, through the suppression of endothelial cell adhesion molecule expression. The degradation of a this anti-inflammatory polymer provides longer term, localized release profile of active therapeutic drug in nanoparticle form as compared with that of the free drug, permitting more targeted anti-metastatic therapies. (c) 2015 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 104B: 1438-1447, 2016.
C1 [Cochran, David B.; Gray, Lindsay N.; Anderson, Kimberly W.; Dziubla, Thomas D.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Dziubla, TD (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM dziubla@engr.uky.edu
FU NSF Integrative Graduate Education and Research Traineeship (IGERT)
   [653710]; Bioactive Interfaces and Devices Program
FX Contract grant sponsor: NSF Integrative Graduate Education and Research
   Traineeship (IGERT); contract grant number: 653710; Contract grant
   sponsors: Bioactive Interfaces and Devices Program
CR Ahlemeyer B, 2003, PHARMACOPSYCHIATRY, V36, pS8
   ALBELDA SM, 1990, FASEB J, V4, P2868
   Aoudjit F, 1998, J IMMUNOL, V161, P2333
   Biswal D, 2011, POLYMER, V52, P5985, DOI 10.1016/j.polymer.2011.10.058
   Calixto JB, 2004, PLANTA MED, V70, P93, DOI 10.1055/s-2004-815483
   Choi JS, 2004, J NUTR, V134, P1013
   Cochran DB, 2013, BIOMATERIALS, V34, P9615, DOI 10.1016/j.biomaterials.2013.08.025
   Cotelle N, 1996, FREE RADICAL BIO MED, V20, P35, DOI 10.1016/0891-5849(95)02014-4
   Damas P, 1997, CRIT CARE MED, V25, P405, DOI 10.1097/00003246-199703000-00006
   Dan M, 2013, PLOS ONE, V11
   Di Carlo G, 1999, LIFE SCI, V65, P337, DOI 10.1016/S0024-3205(99)00120-4
   Disibio G, 2008, ARCH PATHOL LAB MED, V132, P931, DOI 10.1043/1543-2165(2008)132[931:MPOCRF]2.0.CO;2
   Dziubla TD, 2008, BIOMATERIALS, V29, P215, DOI 10.1016/j.biomaterials.2007.09.023
   Hans ML, 2002, CURR OPIN SOLID ST M, V6, P319, DOI 10.1016/S1359-0286(02)00117-1
   Herr I, 2006, LANCET ONCOL, V7, P425, DOI 10.1016/S1470-2045(06)70694-5
   Hillner BE, 2003, J CLIN ONCOL, V21, P4042, DOI 10.1200/JCO.2003.08.017
   Jang SI, 2003, IMMUNOPHARM IMMUNOT, V25, P585, DOI 10.1081/IPH-120026443
   Kim JD, 2006, J NUTR BIOCHEM, V17, P165, DOI 10.1016/j.jnutbio.2005.06.006
   Kumari A, 2010, COLLOID SURFACE B, V75, P1, DOI 10.1016/j.colsurfb.2009.09.001
   Lee Song Jin, 1993, Archives of Pharmacal Research (Seoul), V16, P25, DOI 10.1007/BF02974123
   Lotito SB, 2006, FREE RADICAL BIO MED, V41, P1727, DOI 10.1016/j.freeradbiomed.2006.04.033
   Moiniche S, 2003, ANESTH ANALG, V96, P68, DOI 10.1213/01.ANE.0000040583.65135.57
   Moss MA, 2000, ANTICANCER RES, V20, P1425
   Ross JA, 2002, ANNU REV NUTR, V22, P19, DOI 10.1146/annurev.nutr.22.111401.144957
   Shen KH, 2010, MOL CELL BIOCHEM, V333, P279, DOI 10.1007/s11010-009-0229-8
   Song XR, 2008, EUR J PHARM BIOPHARM, V69, P445, DOI 10.1016/j.ejpb.2008.01.013
   Vera-Llonch M, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-250
   Wattamwar PP, 2012, ACTA BIOMATER, V8, P2529, DOI 10.1016/j.actbio.2012.03.022
   Wattamwar PP, 2011, J BIOMED MATER RES A, V99A, P184, DOI 10.1002/jbm.a.33174
   Whinney Christopher, 2009, Cleve Clin J Med, V76 Suppl 4, pS126, DOI 10.3949/ccjm.76.s4.20
NR 30
TC 4
Z9 4
U1 0
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1552-4973
EI 1552-4981
J9 J BIOMED MATER RES B
JI J. Biomed. Mater. Res. Part B
PD OCT
PY 2016
VL 104
IS 7
BP 1438
EP 1447
DI 10.1002/jbm.b.33486
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA DW6PM
UT WOS:000383773400018
PM 26251070
DA 2018-03-19
ER

PT J
AU Zahran, EM
   Bhattacharyya, D
   Bachas, LG
AF Zahran, Elsayed M.
   Bhattacharyya, Dibakar
   Bachas, Leonidas G.
TI Ambient synthesis of Pd/Fe bimetallic nanotubes and their application in
   dechlorination reactions
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
C1 Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
   Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY USA.
RI Bachas, Leonidas/G-2479-2015
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD MAR 21
PY 2010
VL 239
MA 331-ENVR
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA V21DW
UT WOS:000208189302328
DA 2018-03-19
ER

PT J
AU Lewis, SR
   Datta, S
   Gui, MH
   Coker, EL
   Huggins, FE
   Daunert, S
   Bachas, L
   Bhattacharyya, D
AF Lewis, Scott R.
   Datta, Saurav
   Gui, Minghui
   Coker, Eric L.
   Huggins, Frank E.
   Daunert, Sylvia
   Bachas, Leonidas G.
   Bhattacharyya, Dibakar
TI Reactive nanostructured membranes for water purification
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE enzyme catalysis; functionalized membranes; pollutant; microfiltration;
   responsive materials
ID POLYELECTROLYTE MULTILAYERS; FUNCTIONALIZED MEMBRANES; MICROPOROUS
   MEMBRANES; HYDROGEN-PEROXIDE; DECOMPOSITION; NANOPARTICLE; TECHNOLOGY;
   PARTICLES; NETWORKS; POLYMERS
AB Many current treatments for the reclamation of contaminated water sources are chemical-intensive, energy-intensive, and/or require posttreatment due to unwanted by-product formation. We demonstrate that through the integration of nanostructured materials, enzymatic catalysis, and iron-catalyzed free radical reactions within pore-functionalized synthetic membrane platforms, we are able to conduct environmentally important oxidative reactions for toxic organic degradation and detoxification from water without the addition of expensive or harmful chemicals. In contrast to conventional, passive membrane technologies, our approach utilizes two independently controlled, nanostructured membranes in a stacked configuration for the generation of the necessary oxidants. These include biocatalytic and organic/inorganic (polymer/iron) nanocomposite membranes. The bioactive (top) membrane contains an electrostatically immobilized enzyme for the catalytic production of one of the main reactants, hydrogen peroxide (H(2)O(2)), from glucose. The bottom membrane contains either immobilized iron ions or ferrihydrite/iron oxide nanoparticles for the decomposition of hydrogen peroxide to form powerful free radical oxidants. By permeating (at low pressure) a solution containing a model organic contaminant, such as trichlorophenol, with glucose in oxygen-saturated water through the membrane stack, significant contaminant degradation was realized. To illustrate the effectiveness of this membrane platform in real-world applications, membrane-immobilized ferrihydrite/iron oxide nanoparticles were reacted with hydrogen peroxide to form free radicals for the degradation of a chlorinated organic contaminant in actual groundwater. Although we establish the development of these nanostructured materials for environmental applications, the practical and methodological advances demonstrated here permit the extension of their use to applications including disinfection and/or virus inactivation.
C1 [Lewis, Scott R.; Datta, Saurav; Gui, Minghui; Coker, Eric L.; Huggins, Frank E.; Bhattacharyya, Dibakar] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Huggins, Frank E.] Univ Kentucky, Consortium Fossil Fuel Sci, Lexington, KY 40506 USA.
   [Daunert, Sylvia] Univ Miami, Dept Biochem & Mol Biol, Miami, FL 33136 USA.
   [Bachas, Leonidas] Univ Miami, Dept Chem, Miami, FL 33136 USA.
RP Bhattacharyya, D (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM db@engr.uky.edu
RI Bachas, Leonidas/G-2479-2015
OI Bachas, Leonidas/0000-0002-3308-6264
FU National Institute of Environmental Health Sciences [P42ES007380];
   Department of Energy-Kentucky Research Consortium for Energy and
   Environment; National Science Foundation; NSF/REU
FX The authors thank Joseph Amundson for experimental contributions and Mr.
   John May for analytical assistance. This work was funded by National
   Institute of Environmental Health Sciences-Superfund Research Program
   (Grant P42ES007380), Department of Energy-Kentucky Research Consortium
   for Energy and Environment, and National Science Foundation-Integrative
   Graduate Education and Research Traineeship programs. E. C. was funded
   by the NSF/REU program.
CR BARB WG, 1949, NATURE, V163, P692, DOI 10.1038/163692a0
   BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620
   Benitez FJ, 1999, IND ENG CHEM RES, V38, P1341, DOI 10.1021/ie980441f
   Bruening ML, 2008, LANGMUIR, V24, P7663, DOI 10.1021/la800179z
   Caruso F, 1998, J AM CHEM SOC, V120, P8523, DOI 10.1021/ja9815024
   Datta S, 2008, IND ENG CHEM RES, V47, P4586, DOI 10.1021/ie800142d
   Decher G, 1997, SCIENCE, V277, P1232, DOI 10.1126/science.277.5330.1232
   DUKE FR, 1969, J AM CHEM SOC, V91, P3904, DOI 10.1021/ja01042a038
   GABRIEL EM, 1993, J APPL POLYM SCI, V48, P2081, DOI 10.1002/app.1993.070481202
   Hermanek M, 2007, J AM CHEM SOC, V129, P10929, DOI 10.1021/ja072918x
   Hu K, 2009, J MEMBRANE SCI, V337, P9, DOI 10.1016/j.memsci.2009.03.021
   Huang HH, 2001, WATER RES, V35, P2291, DOI 10.1016/S0043-1354(00)00496-6
   Jirage KB, 1997, SCIENCE, V278, P655, DOI 10.1126/science.278.5338.655
   Karppi J, 2010, J POLYM RES, V17, P71, DOI 10.1007/s10965-009-9291-x
   Kohanski MA, 2010, NAT REV MICROBIOL, V8, P423, DOI 10.1038/nrmicro2333
   Kumar A, 2007, PROG POLYM SCI, V32, P1205, DOI 10.1016/j.progpolymsci.2007.05.003
   Lee SB, 2002, SCIENCE, V296, P2198, DOI 10.1126/science.1071396
   Letant SE, 2003, NAT MATER, V2, P391, DOI 10.1038/nmat888
   Lewis S, 2009, SEPAR SCI TECHNOL, V44, P3289, DOI 10.1080/01496390903212805
   Lu Y, 2006, ANGEW CHEM INT EDIT, V45, P813, DOI 10.1002/anie.200502731
   MATSON SL, 1986, ANN NY ACAD SCI, V469, P152, DOI 10.1111/j.1749-6632.1986.tb26494.x
   Merkel TC, 2002, SCIENCE, V296, P519, DOI 10.1126/science.1069580
   Omenn GS, 2006, SCIENCE, V314, P1696, DOI 10.1126/science.1135003
   Park HB, 2007, SCIENCE, V318, P254, DOI 10.1126/science.1146744
   Pignatello JJ, 2006, CRIT REV ENV SCI TEC, V36, P1, DOI 10.1080/10643380500326564
   Shannon MA, 2008, NATURE, V452, P301, DOI 10.1038/nature06599
   Stuart MAC, 2010, NAT MATER, V9, P101, DOI [10.1038/NMAT2614, 10.1038/nmat2614]
   Tang ZY, 2006, ADV MATER, V18, P3203, DOI 10.1002/adma.200600113
   Wandera D, 2010, J MEMBRANE SCI, V357, P6, DOI 10.1016/j.memsci.2010.03.046
   Winnik FM, 1998, CAN J CHEM, V76, P10, DOI 10.1139/cjc-76-1-10
   Xu J, 2007, IND ENG CHEM RES, V46, P2348, DOI 10.1021/ie0611498
NR 31
TC 60
Z9 61
U1 4
U2 101
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 24
PY 2011
VL 108
IS 21
BP 8577
EP 8582
DI 10.1073/pnas.1101144108
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 768CB
UT WOS:000290908000018
PM 21606340
OA gold
DA 2018-03-19
ER

PT J
AU Cai, YY
   Chin, HF
   Lazarova, D
   Menon, S
   Fu, CM
   Cai, HQ
   Sclafani, A
   Rodgers, DW
   De La Cruz, EM
   Ferro-Novick, S
   Reinisch, KM
AF Cai, Yiying
   Chin, Harvey F.
   Lazarova, Darina
   Menon, Shekar
   Fu, Chunmei
   Cai, Huaqing
   Sclafani, Anthony
   Rodgers, David W.
   De La Cruz, Enrique M.
   Ferro-Novick, Susan
   Reinisch, Karin M.
TI The structural basis for activation of the Rab Ypt1p by the TRAPP
   membrane-tethering complexes
SO CELL
LA English
DT Article
ID GUANINE-NUCLEOTIDE EXCHANGE; CRYSTAL-STRUCTURE; CIS-GOLGI; VESICLE;
   TRANSPORT; PROTEINS; GTPASE; BET3; SPECIFICITY; MECHANISM
AB The multimeric membrane-tethering complexes TRAPPI and TRAPPII share seven subunits, of which four (Bet3p, Bet5p, Trs23p, and Trs31p) are minimally needed to activate the Rab GTPase Ypt1p in an event preceding membrane fusion. Here, we present the structure of a heteropentameric TRAPPI assembly complexed with Ypt1p. We propose that TRAPPI facilitates nucleotide exchange primarily by stabilizing the nucleotide-binding pocket of Ypt1p in an open, solvent-accessible form. Bet3p, Bet5p, and Trs23p interact directly with Ypt1p to stabilize this form, while the C terminus of Bet3p invades the pocket to participate in its remodeling. The Trs31p subunit does not interact directly with the GTPase but allosterically regulates the TRAPPI interface with Ypt1p. Our findings imply that TRAPPII activates Ypt1p by an identical mechanism. This view of a multimeric membrane-tethering assembly complexed with a Rab provides a framework for understanding events preceding membrane fusion at the molecular level.
C1 [Cai, Yiying; Lazarova, Darina; Menon, Shekar; Fu, Chunmei; Cai, Huaqing; Sclafani, Anthony; Ferro-Novick, Susan; Reinisch, Karin M.] Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA.
   [Chin, Harvey F.; De La Cruz, Enrique M.] Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA.
   [Rodgers, David W.] Univ Kentucky, Dept Mol & Cellular Biochem, Coll Med, Lexington, KY 40536 USA.
   [Cai, Yiying; Lazarova, Darina; Menon, Shekar; Cai, Huaqing; Sclafani, Anthony; Ferro-Novick, Susan] Yale Univ, Howard Hughes Med Inst, Dept Cell Biol, Sch Med, New Haven, CT 06519 USA.
RP Reinisch, KM (reprint author), Yale Univ, Sch Med, Dept Cell Biol, 333 Cedar St, New Haven, CT 06520 USA.
EM susan.ferronovick@yale.edu; karin.reinisch@yale.edu
FU Howard Hughes Medical Institute; NCRR NIH HHS [RR020171, P20 RR020171];
   NIDA NIH HHS [R01 DA002243, DA02243]; NIDCD NIH HHS [F31 DC009143,
   1F31DC009143-01, F31 DC009143-01]; NIGMS NIH HHS [R01 GM071688-02,
   GM080616, GM071688, T32-GM07223, R01 GM080616, R01 GM071688, R01
   GM080616-01]; NINDS NIH HHS [R56 NS038041, NS38041, R01 NS038041-04, R01
   NS038041]
CR Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548
   Bos JL, 2007, CELL, V129, P865, DOI 10.1016/j.cell.2007.05.018
   Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254
   Cai HQ, 2005, J CELL BIOL, V171, P823, DOI 10.1083/jcb.200505145
   Cai HQ, 2007, DEV CELL, V12, P671, DOI 10.1016/j.devcel.2007.04.005
   Cai HQ, 2007, NATURE, V445, P941, DOI 10.1038/nature05527
   Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7
   delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7
   Delprato A, 2004, CELL, V118, P607, DOI 10.1016/j.cell.2004.08.009
   Delprato A, 2007, NAT STRUCT MOL BIOL, V14, P406, DOI 10.1038/nsmb1232
   Dong G, 2007, MOL CELL, V25, P455, DOI 10.1016/j.molcel.2007.01.013
   Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0
   Eathiraj S, 2005, NATURE, V436, P415, DOI 10.1038/nature03798
   Esters H, 2001, J MOL BIOL, V310, P141, DOI 10.1006/jmbi.2001.4735
   Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7
   Hannemann DE, 2005, BIOCHEMISTRY-US, V44, P8826, DOI 10.1021/bi0473509
   Heras B, 2005, ACTA CRYSTALLOGR D, V61, P1173, DOI 10.1107/S0907444905019451
   Itzen A, 2007, J MOL BIOL, V365, P1359, DOI 10.1016/j.jmb.2006.10.096
   Jahn R, 2006, NAT REV MOL CELL BIO, V7, P631, DOI 10.1038/nrm2002
   Jones S, 2000, MOL BIOL CELL, V11, P4403, DOI 10.1091/mbc.11.12.4403
   Kim MS, 2005, TRAFFIC, V6, P1183, DOI 10.1111/j.1600-0854.2005.00352.x
   Kim YG, 2006, CELL, V127, P817, DOI 10.1016/j.cell.2006.09.029
   Kim YG, 2005, NAT STRUCT MOL BIOL, V12, P38, DOI 10.1038/nsmb871
   KLEBE C, 1995, BIOCHEMISTRY-US, V34, P12543, DOI 10.1021/bi00039a008
   Kleywegt G. J., 2001, INT TABLES CRYSTALLO, P353, DOI DOI 10.1107/97809553602060000111
   Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P208, DOI 10.1016/S0076-6879(97)77013-7
   Koumandou VL, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-29
   Kuehn MJ, 1998, NATURE, V391, P187
   Kummel D, 2006, P NATL ACAD SCI USA, V103, P12701, DOI 10.1073/pnas.0603513103
   Kummel D, 2006, J MOL BIOL, V361, P22, DOI 10.1016/j.jmb.2006.06.012
   Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.0.CO;2-U
   Morozova N, 2006, NAT CELL BIOL, V8, P1263, DOI 10.1038/ncb1489
   Moyer BD, 2001, TRAFFIC, V2, P268, DOI 10.1034/j.1600-0854.2001.1o007.x
   Nicholls A., 1993, GRASP GRAPHICAL REPR
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Renault L, 2001, CELL, V105, P245, DOI 10.1016/S0092-8674(01)00315-4
   Rodgers DW, 2001, INT TABLES CRYSTAL F, P202
   Sacher M, 2000, EUR J CELL BIOL, V79, P71, DOI 10.1078/S0171-9335(04)70009-6
   Sacher M, 1998, EMBO J, V17, P2494, DOI 10.1093/emboj/17.9.2494
   Sacher M, 2001, MOL CELL, V7, P433, DOI 10.1016/S1097-2765(01)00190-3
   Sato Y, 2007, P NATL ACAD SCI USA, V104, P8305, DOI 10.1073/pnas.0701550104
   Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678
   Turnbull AP, 2005, EMBO J, V24, P875, DOI 10.1038/sj.emboj.7600565
   Wang W, 2000, J CELL BIOL, V151, P289, DOI 10.1083/jcb.151.2.289
   Wang W, 2002, MOL BIOL CELL, V13, P3336, DOI 10.1091/mbc.01-12-0577
   Yu S, 2006, J CELL BIOL, V174, P359, DOI 10.1083/jcb.200603044
   [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760
NR 47
TC 98
Z9 100
U1 1
U2 12
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
J9 CELL
JI Cell
PD JUN 27
PY 2008
VL 133
IS 7
BP 1202
EP 1213
DI 10.1016/j.cell.2008.04.049
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 319DP
UT WOS:000257144600017
PM 18585354
OA gold
DA 2018-03-20
ER

PT J
AU Romero, G
   Lilly, JJ
   Abraham, NS
   Shin, HY
   Balasubramaniam, V
   Izumi, T
   Berron, BJ
AF Romero, Gabriela
   Lilly, Jacob L.
   Abraham, Nathan S.
   Shin, Hainsworth Y.
   Balasubramaniam, Vivek
   Izumi, Tadahide
   Berron, Brad J.
TI Protective Polymer Coatings for High-Throughput, High-Purity Cellular
   Isolation
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE cell isolation; photopolymerization; polymer; coatings; protein
   expression; sorting
ID HISTONE H2AX; DNA-DAMAGE; STEM-CELLS; HYDROGELS; MEDICINE; FILMS
AB Cell-based therapies are emerging as the next frontier of medicine, offering a plausible path forward in the treatment of many devastating diseases. Critically, current methods for antigen positive cell sorting lack a high throughput method for delivering ultrahigh purity populations, prohibiting the application of some cell-based therapies to widespread diseases. Here we show the first use of targeted, protective polymer coatings on cells for the high speed enrichment of cells. Individual, antigen-positive cells are coated with a bio compatible hydrogel which protects the cells from a surfactant solution, while uncoated cells are immediately lysed. After lysis, the polymer coating is removed through orthogonal photochemistry, and the isolate has >50% yield of viable cells and these cells proliferate at rates comparable to control cells. Minority cell populations are enriched from erythrocyte-depleted blood to >99% purity, whereas the entire batch process requires 1 h and <$2000 in equipment. Batch scale-up is only contingent on irradiation area for the coating photopolymerization, as surfactant-based lysis can be easily achieved on any scale.
C1 [Romero, Gabriela; Lilly, Jacob J.; Berron, Brad J.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Shin, Hainsworth Y.] Univ Kentucky, Dept Biomed Engn, Lexington, KY 40506 USA.
   [Abraham, Nathan S.] Univ Massachusetts, Dept Chem Engn, Amherst, MA 01003 USA.
   [Balasubramaniam, Vivek] Univ Wisconsin, Dept Pediat, Madison, WI 53792 USA.
   [Izumi, Tadahide] Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA.
RP Berron, BJ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM brad.berron@uky.edu
FU NIH [R21 EB012188, R01 HL127682-01]; National Science Foundation
   [CBET-1351531, EEC-0851716]; National Cancer Institute (NCI)
   [R25CA153954]; National Cancer Institute Cancer Nanotechnology Training
   Center (NCI-CNTC) Traineeship
FX This work was supported partially by NIH R21 EB012188 and R01
   HL127682-01. This work was supported partially by the National Science
   Foundation under Awards CBET-1351531 and EEC-0851716. The authors
   acknowledge the financial support from the National Cancer Institute
   (NCI) Grant R25CA153954 and a National Cancer Institute Cancer
   Nanotechnology Training Center (NCI-CNTC) Traineeship awarded to J.L.L.
   The views expressed in this manuscript do not represent the views of the
   NCI, NIH, NSF, or any other government agency or official.
CR Amabile G, 2009, TRENDS MOL MED, V15, P59, DOI 10.1016/j.molmed.2008.12.003
   Arnold L. W., 2010, CURRENT PROTOCOLS CY
   Asahara T, 2011, STEM CELLS, V29, P1650, DOI 10.1002/stem.745
   Avens HJ, 2011, J HISTOCHEM CYTOCHEM, V59, P76, DOI 10.1369/jhc.2010.955948
   Avens HJ, 2011, J NANOPART RES, V13, P331, DOI 10.1007/s11051-010-0034-z
   Barzilai A, 2004, DNA REPAIR, V3, P1109, DOI 10.1016/j.dnarep.2004.03.002
   Berron BJ, 2012, LAB CHIP, V12, P708, DOI 10.1039/c2lc21101g
   BRITTBERG M, 1994, NEW ENGL J MED, V331, P889, DOI 10.1056/NEJM199410063311401
   Brown RB, 2008, J R SOC INTERFACE, V5, pS131, DOI 10.1098/rsif.2008.0009.focus
   Chalmers JJ, 2010, BIOTECHNOL BIOENG, V105, P1078, DOI 10.1002/bit.22635
   Chatterjee A, 2001, J PHYS CHEM B, V105, P12823, DOI 10.1021/jp0123029
   Fong CY, 2010, J CELL BIOCHEM, V111, P769, DOI 10.1002/jcb.22775
   Geens M, 2007, HUM REPROD, V22, P733, DOI 10.1093/humrep/del418
   Hansen RR, 2008, ANAL BIOANAL CHEM, V392, P167, DOI 10.1007/s00216-008-2259-6
   Harrison RG, 2003, BIOSEPARATIONS SCI E
   Kloxin AM, 2009, SCIENCE, V324, P59, DOI 10.1126/science.1169494
   Lee JK, 2012, BIOMACROMOLECULES, V13, P1136, DOI 10.1021/bm300037t
   Lilly JL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115630
   Lilly JL, 2015, BIOMACROMOLECULES, V16, P541, DOI 10.1021/bm501594x
   Lin CC, 2011, P NATL ACAD SCI USA, V108, P6380, DOI 10.1073/pnas.1014026108
   Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858
   Sedelnikova OA, 2003, CANCER BIOL THER, V2, P233
   Shah AM, 2012, ANAL CHEM, V84, P3682, DOI 10.1021/ac300190j
   Stott SL, 2010, P NATL ACAD SCI USA, V107, P18392, DOI 10.1073/pnas.1012539107
   Uygun BE, 2010, NAT MED, V16, P814, DOI 10.1038/nm.2170
   Wu SM, 2011, NAT CELL BIOL, V13, P497, DOI 10.1038/ncb0511-497
   Yu M, 2011, J CELL BIOL, V192, P373, DOI 10.1083/jcb.201010021
NR 27
TC 5
Z9 5
U1 1
U2 11
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944-8244
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD AUG 19
PY 2015
VL 7
IS 32
BP 17598
EP 17602
DI 10.1021/acsami.5b06298
PG 5
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA CP6VU
UT WOS:000360027100010
PM 26244409
OA gold
DA 2018-03-19
ER

PT J
AU Bothun, GD
   Knutson, BL
   Strobel, HJ
   Nokes, SE
AF Bothun, Geoffrey D.
   Knutson, Barbara L.
   Strobel, Herbert J.
   Nokes, Sue E.
TI Liposome fluidization and melting point depression by compressed and
   liquid n-alkanes
SO COLLOIDS AND SURFACES A-PHYSICOCHEMICAL AND ENGINEERING ASPECTS
LA English
DT Article
DE liposome; lipid bilayer; DPPC; compressed solvent; supercritical fluid;
   cell membrane
ID LIPID-BILAYER; SUPERCRITICAL ETHANE; HIGH-PRESSURE; MEMBRANES; SOLVENTS;
   WATER; EQUILIBRIUM; SOLUTES; MICROORGANISMS; PHOSPHOLIPIDS
AB Fluidization and melting point depression of aqueous dipalmitoylphosphatidylcholine (DPPC, T-m approximate to 315 K) liposomes by compressed/supercritical n-alkanes (C-2 and C-3; 0.8-20.7 MPa) was quantified and compared to fluidization by liquid n-alkanes (C-5-C-10) using fluorescence anisotropy. The adsorption of ethane and propane into DPPC bilayers resulted in significant depression of the melting temperature (up to Delta T-m = - 16.2 K at 7.0 MPa ethane and propane). Pressure-dependent fluidization by gaseous n-atkanes (1.8-20.7 MPa) and pressure-induced reversal of this fluidization was observed at temperatures corresponding to gel (295 K) and fluid (333 K) phases at atmospheric pressure. The ability to manipulate the degree of bilayer ordering, melting temperature, and width of the phase transition region is discussed in terms of the n-alkane concentration in the bilayer, effect of n-alkane molecular size, and van't Hoff enthalpy of the gel-fluid phase transition. The permeability, phase, and solvent properties of the bilayer can be altered with pressurized ethane or propane, which may provide enhanced control for liposome formation and processing. (c) 2006 Elsevier B.V. All rights reserved.
C1 Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   Univ Kentucky, Dept Anim Sci, Lexington, KY 40506 USA.
   Univ Kentucky, Dept Agr & Biosyst Engn, Lexington, KY 40506 USA.
RP Knutson, BL (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM bknutson@engr.uky.edu
CR BANGHAM AD, 1965, J MOL BIOL, V13, P238, DOI 10.1016/S0022-2836(65)80093-6
   Beney L, 2001, APPL MICROBIOL BIOT, V57, P34
   Berberich JA, 2000, BIOTECHNOL BIOENG, V70, P491, DOI 10.1002/1097-0290(20001205)70:5<491::AID-BIT3>3.0.CO;2-U
   Bothun GD, 2005, LANGMUIR, V21, P530, DOI 10.1021/la0496542
   Cason JP, 2000, J PHYS CHEM B, V104, P1217, DOI 10.1021/jp9931051
   Collier JH, 2001, ANNU REV MATER RES, V31, P237, DOI 10.1146/annurev.matsci.31.1.237
   CULBERSON OL, 1950, PETRO T AIME, V189, P319
   DEYOUNG LR, 1990, J PHYS CHEM-US, V94, P801, DOI 10.1021/j100365a054
   Dhima A, 1999, IND ENG CHEM RES, V38, P3144, DOI 10.1021/ie980768g
   Eckert CA, 1998, J SUPERCRIT FLUID, V13, P187, DOI 10.1016/S0896-8446(98)00051-5
   Gawrisch K, 1996, CHEM PHYS LIPIDS, V81, P105, DOI 10.1016/0009-3084(96)02576-5
   GRUEN DWR, 1980, PURE APPL CHEM, V52, P1229, DOI 10.1351/pac198052051229
   Harvey AH, 1996, AICHE J, V42, P1491, DOI 10.1002/aic.690420531
   HAYDON DA, 1977, BIOCHIM BIOPHYS ACTA, V470, P17, DOI 10.1016/0005-2736(77)90058-X
   IIYAMA S, 1992, BIOPHYS CHEM, V45, P91, DOI 10.1016/0301-4622(92)87001-Y
   KAMAYA H, 1981, BIOCHIM BIOPHYS ACTA, V646, P135, DOI 10.1016/0005-2736(81)90280-7
   KANESHINA S, 1995, PROG ANESTH MECH, V3, P471
   Knez Z, 2002, J SUPERCRIT FLUID, V23, P29
   Knutson BL, 1999, J SUPERCRIT FLUID, V16, P149, DOI 10.1016/S0896-8446(99)00026-1
   KOBAYASHI R, 1953, IND ENG CHEM, V45, P440, DOI 10.1021/ie50518a051
   Koynova R, 1998, BBA-REV BIOMEMBRANES, V1376, P91, DOI 10.1016/S0304-4157(98)00006-9
   Krichevsky IR, 1935, J AM CHEM SOC, V57, P2168, DOI 10.1021/ja01314a036
   LAKOWICZ JR, 1999, PRINCIPLES FLUORESCE
   Lemmich J, 1996, EUR BIOPHYS J BIOPHY, V25, P61, DOI 10.1007/s002490050018
   LYCKMAN EW, 1965, CHEM ENG SCI, V20, P685, DOI 10.1016/0009-2509(65)80005-7
   Marche C, 2003, J CHEM ENG DATA, V48, P967, DOI 10.1021/je025659u
   MARKY LA, 1987, BIOPOLYMERS, V26, P1601, DOI 10.1002/bip.360260911
   Marrink SJ, 1996, J PHYS CHEM-US, V100, P16729, DOI 10.1021/jp952956f
   MAXWELL IA, 1995, LANGMUIR, V11, P1987, DOI 10.1021/la00006a027
   MCINTOSH TJ, 1980, BIOCHIM BIOPHYS ACTA, V597, P445, DOI 10.1016/0005-2736(80)90219-9
   MESIANO AJ, 1999, J CHEM REV, V99, P623
   Metselaar JM, 2002, MINI-REV MED CHEM, V2, P319, DOI 10.2174/1389557023405873
   Oberholzer T, 1999, BBA-BIOMEMBRANES, V1416, P57, DOI 10.1016/S0005-2736(98)00210-7
   Pautot S, 2003, LANGMUIR, V19, P2870, DOI 10.1021/la026100v
   POPE JM, 1984, CHEM PHYS LIPIDS, V35, P259, DOI 10.1016/0009-3084(84)90051-3
   POPE JM, 1989, BIOCHIM BIOPHYS ACTA, V980, P69, DOI 10.1016/0005-2736(89)90201-0
   RANDOLPH TW, 1990, TRENDS BIOTECHNOL, V8, P78, DOI 10.1016/0167-7799(90)90140-S
   Reverchon E, 1997, J SUPERCRIT FLUID, V10, P1, DOI 10.1016/S0896-8446(97)00014-4
   Sangster J., 1997, OCANOL WATER PARTITI
   Shah PS, 2002, J PHYS CHEM B, V106, P2545, DOI [10.1021/jjp0139311, 10.1021/jp0139311]
   SIKKEMA J, 1994, J BIOL CHEM, V269, P8022
   Tien HT, 2001, J MEMBRANE SCI, V189, P83, DOI 10.1016/S0376-7388(01)00394-5
   Vemuri S, 1995, Pharm Acta Helv, V70, P95, DOI 10.1016/0031-6865(95)00010-7
   WANN KT, 1988, PROG NEUROBIOL, V30, P271, DOI 10.1016/0301-0082(88)90025-1
   Weber FJ, 1996, BBA-REV BIOMEMBRANES, V1286, P225, DOI 10.1016/S0304-4157(96)00010-X
   WHITE SH, 1976, NATURE, V262, P421, DOI 10.1038/262421a0
   Xiang TX, 1999, J CHEM PHYS, V110, P1807, DOI 10.1063/1.477878
   Xiang TX, 1998, BIOPHYS J, V75, P2658, DOI 10.1016/S0006-3495(98)77711-2
   Ye XG, 2003, J CHEM EDUC, V80, P198, DOI 10.1021/ed080p198
NR 49
TC 3
Z9 3
U1 0
U2 11
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0927-7757
EI 1873-4359
J9 COLLOID SURFACE A
JI Colloid Surf. A-Physicochem. Eng. Asp.
PD MAY 15
PY 2006
VL 279
IS 1-3
BP 50
EP 57
DI 10.1016/j.colsurfa.2005.12.034
PG 8
WC Chemistry, Physical
SC Chemistry
GA 047VW
UT WOS:000237907800007
DA 2018-03-20
ER

PT J
AU Reneer, DV
   Hisel, RD
   Hoffman, JM
   Kryscio, RJ
   Lusk, BT
   Geddes, JW
AF Reneer, Dexter V.
   Hisel, Richard D.
   Hoffman, Joshua M.
   Kryscio, Richard J.
   Lusk, Braden T.
   Geddes, James W.
TI A Multi-Mode Shock Tube for Investigation of Blast-Induced Traumatic
   Brain Injury
SO JOURNAL OF NEUROTRAUMA
LA English
DT Article
DE helium; overpressure; oxyhydrogen; pressure-time signature; RDX
ID EXPLOSIVE BLAST; RAT-BRAIN; PRESSURE; OVERPRESSURE; EXPOSURE; MODEL;
   WAVE; NEUROTRAUMA; CARE
AB Blast-induced mild traumatic brain injury (bTBI) has become increasingly common in recent military conflicts. The mechanisms by which non-impact blast exposure results in bTBI are incompletely understood. Current small animal bTBI models predominantly utilize compressed air-driven membrane rupture as their blast wave source, while large animal models use chemical explosives. The pressure-time signature of each blast mode is unique, making it difficult to evaluate the contributions of the different components of the blast wave to bTBI when using a single blast source. We utilized a multi-mode shock tube, the McMillan blast device, capable of utilizing compressed air- and compressed helium-driven membrane rupture, and the explosives oxyhydrogen and cyclotrimethylenetrinitramine (RDX, the primary component of C-4 plastic explosives) as the driving source. At similar maximal blast overpressures, the positive pressure phase of compressed air-driven blasts was longer, and the positive impulse was greater, than those observed for shockwaves produced by other driving sources. Helium-driven shockwaves more closely resembled RDX blasts, but by displacing air created a hypoxic environment within the shock tube. Pressure-time traces from oxyhydrogen-driven shockwaves were very similar those produced by RDX, although they resulted in elevated carbon monoxide levels due to combustion of the polyethylene bag used to contain the gases within the shock tube prior to detonation. Rats exposed to compressed air-driven blasts had more pronounced vascular damage than those exposed to oxyhydrogen-driven blasts of the same peak overpressure, indicating that differences in blast wave characteristics other than peak overpressure may influence the extent of bTBI. Use of this multi-mode shock tube in small animal models will enable comparison of the extent of brain injury with the pressure-time signature produced using each blast mode, facilitating evaluation of the blast wave components contributing to bTBI.
C1 [Reneer, Dexter V.; Geddes, James W.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA.
   [Reneer, Dexter V.; Geddes, James W.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA.
   [Hoffman, Joshua M.; Lusk, Braden T.] Univ Kentucky, Dept Min Engn, Lexington, KY 40536 USA.
   [Kryscio, Richard J.] Univ Kentucky, Dept Biostat, Lexington, KY 40536 USA.
   [Kryscio, Richard J.] Univ Kentucky, Dept Stat, Lexington, KY 40536 USA.
   [Hisel, Richard D.] GLR Enterprises LLC, Nicholasville, KY USA.
RP Geddes, JW (reprint author), Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, B477 Biomed & Biol Sci Res Bldg BBSRB,741 S Limes, Lexington, KY 40536 USA.
EM jgeddes@uky.edu
FU National Institutes of Health (NIH) [T32DA022738, P30NS051220]
FX D.V.R. was supported by National Institutes of Health (NIH) grant
   T32DA022738. We would also like to thank GLR Enterprises, L.L.C., for
   their generous donation of time and materials, without which this work
   would not have been possible. Additional support was provided by NIH
   grant P30NS051220.
CR Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94
   Baker W. E., 1973, EXPLOSIONS AIR
   Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898
   Benzinger TLS, 2009, J NEUROTRAUM, V26, P2127, DOI [10.1089/neu.2009.0885, 10.1089/neu.2009-0885]
   CASSEN BK, 1950, J AVIAT MED, V23
   CELANDER H, 1955, ACTA PHYSIOL SCAND, V33, P6, DOI 10.1111/j.1748-1716.1955.tb01188.x
   Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017
   Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203
   Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018
   Chavko M, 2006, J TRAUMA, V61, P933, DOI 10.1097/01.ta.0000233742.75450.47
   Cheng JM, 2010, J NEUROL SCI, V294, P23, DOI 10.1016/j.jns.2010.04.010
   CLEMEDSON CJ, 1956, PHYSIOL REV, V36, P336
   Clemedson C.J., 1949, ACTA PHYSL SCAND S61, V18
   Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098
   Elsayed NM, 1997, TOXICOLOGY, V121, P1, DOI 10.1016/S0300-483X(97)03651-2
   Garner JP, 2009, WORLD J SURG, V33, P2194, DOI 10.1007/s00268-009-0105-4
   Gruss E, 2006, J TRAUMA, V60, P1284, DOI 10.1097/01.ta.0000220015.21948.ec
   Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972
   Kato K, 2007, J NEUROSURG, V106, P667, DOI 10.3171/jns.2007.106.4.667
   Kopp C., 2008, DEFENCE TODAY, P46
   LEVI L, 1990, ISRAEL J MED SCI, V26, P555
   Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484
   Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748
   Lu FK, 2003, SHOCK WAVES, V12, P457, DOI 10.1007/s00193-003-0186-1
   MARKS ME, 2002, EMERGENCY RESPONDERS, P30
   Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4
   MICHAL J, 1983, FIRE MATER, V7, P163, DOI 10.1002/fam.810070402
   Moochhala SM, 2004, J TRAUMA, V56, P393, DOI 10.1097/01.TA.0000066181.50879.7A
   MURTHY JMK, 1979, J NEUROSURG, V50, P260, DOI 10.3171/jns.1979.50.2.0260
   RICHMOND DR, 1968, ANN NY ACAD SCI, V152, P103, DOI 10.1111/j.1749-6632.1968.tb11970.x
   Richmond DR, 1967, 1854 DASA FISS PROD, P1
   Saljo A, 2009, J NEUROTRAUM, V26, P1345, DOI [10.1089/neu.2008.0856, 10.1089/neu.2008-0856]
   Saljo A, 2008, J NEUROTRAUM, V25, P1397, DOI 10.1089/neu.2008.0602
   SCOTT BA, 1986, NEUROSURGERY, V18, P107, DOI 10.1227/00006123-198601000-00020
   Suneson A, 2000, MIL MED, V165, P119
   Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885
   *US DEP HHS, 1995, TOX PROF RDX
   *USA, 1984, 91300214 TM US ARM
   WARREN WR, 1970, P 7 INT SHOCK TUB S, P143
   Zhang JK, 1996, J TRAUMA, V40, pS77
NR 40
TC 52
Z9 53
U1 4
U2 20
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0897-7151
J9 J NEUROTRAUM
JI J. Neurotrauma
PD JAN
PY 2011
VL 28
IS 1
BP 95
EP 104
DI 10.1089/neu.2010.1513
PG 10
WC Critical Care Medicine; Clinical Neurology; Neurosciences
SC General & Internal Medicine; Neurosciences & Neurology
GA 710DT
UT WOS:000286491800009
PM 21083431
OA green_published
DA 2018-03-20
ER

PT J
AU Cheng, R
   Zhang, XY
   Daugherty, A
   Shin, H
   Yu, GQ
AF Cheng, Ran
   Zhang, Xiaoyan
   Daugherty, Alan
   Shin, Hainsworth Y.
   Yu, Guoqiang
TI Noninvasive quantification of postocclusive reactive hyperemia in mouse
   thigh muscle by near-infrared diffuse correlation spectroscopy
SO APPLIED OPTICS
LA English
DT Article
ID PERIPHERAL ARTERIAL-DISEASE; BLOOD-FLOW MEASUREMENTS; CEREBRAL
   HEMODYNAMICS; WAVE SPECTROSCOPY; HINDLIMB ISCHEMIA; SKELETAL-MUSCLE;
   PERFUSION; SCATTERING; OXYGENATION; MEDIA
AB Many vasculature-related diseases affecting skeletal muscle function have been studied in mouse models. Noninvasive quantification of muscle blood flow responses during postocclusive reactive hyperemia (PORH) is often used to evaluate vascular function in human skeletal muscles. However, blood flow measurements during PORH in small skeletal muscles of mice are rare due to the lack of appropriate technologies coupled with the challenge of measurement setup resulting from the lack of large enough test sites. In this study, we explored adapting diffuse correlation spectroscopy (DCS) for noninvasive measurement of the relative changes of blood flow (rBF) in mouse thigh muscles during PORH. A small fiber-optic probe was designed and glued on the mouse thigh to reduce the motion artifact induced by the occlusion procedure. Arterial occlusion was created by tying a polyvinyl chloride (PVC) tube around the mouse thigh while the muscle rBF was continuously monitored by DCS to ensure the success of the occlusion. After 5 min, the occlusion was rapidly released by severing the PVC tube using a cautery pen. Typical rBF responses during PORH were observed in all mice (n = 7), which are consistent with those observed by arterial-spin-labeled magnetic resonance imaging (ASL-MRI) as reported in the literature. On average, rBF values from DCS during occlusion were lower than 10% (3.1 +/- 2.2%) of the baseline values (assigning 100%), indicating the success of arterial occlusion in all mice. Peak values of rBF during PORH measured by the DCS (357.6 +/- 36.3%) and ASL-MRI (387.5 +/- 150.0%) were also similar whereas the values of time-to-peak (the time duration from the end of occlusion to the peak rBF) were quite different (112.6 +/- 35.0 s versus 48.0 +/- 27.0 s). Simultaneous measurements by these two techniques are needed to identify the factors that may cause such discrepancy. This study highlights the utility of DCS technology to quantitatively evaluate tissue blood flow responses during PORH in mouse skeletal muscles. DCS holds promise as valuable tool to assess blood flow regulation in mouse models with a variety of vascular diseases (e.g., hypercholesterolemia, diabetes, peripheral artery disease). (C) 2013 Optical Society of America
C1 [Cheng, Ran; Zhang, Xiaoyan; Shin, Hainsworth; Yu, Guoqiang] Univ Kentucky, Dept Biomed Engn, Lexington, KY 40506 USA.
   [Daugherty, Alan] Univ Kentucky, Saha Cardiovasc Res Ctr, Lexington, KY 40506 USA.
RP Yu, GQ (reprint author), Univ Kentucky, Dept Biomed Engn, 600 Rose St, Lexington, KY 40506 USA.
EM guoqiang.yu@uky.edu
RI Cheng, Ran/E-5609-2014; Daugherty, Alan/C-8282-2009
OI Cheng, Ran/0000-0002-0031-6983; 
FU American Heart Association [9BGIA2250309, 09BGIA2350015]; National
   Science Foundation Kentucky EPSCoR-Bioengineering Initiative [0814194]
FX This work was supported by an American Heart Association (Nos.
   09BGIA2250309 and 09BGIA2350015) and a National Science Foundation
   Kentucky EPSCoR-Bioengineering Initiative grant (No. 0814194). We thank
   the Saha Cardiovascular Research Center at the University of Kentucky
   for the use of their animal research facility.
CR Baligand C, 2011, NMR BIOMED, V24, P281, DOI 10.1002/nbm.1587
   Bertoldi D, 2008, MAGN RESON IMAGING, V26, P1259, DOI 10.1016/j.mri.2008.02.012
   BOAS DA, 1995, PHYS REV LETT, V75, P1855, DOI 10.1103/PhysRevLett.75.1855
   Boas DA, 1997, J OPT SOC AM A, V14, P192, DOI 10.1364/JOSAA.14.000192
   Buckley EM, 2009, OPT EXPRESS, V17, P12571, DOI 10.1364/OE.17.012571
   Caballero AE, 1999, DIABETES, V48, P1856, DOI 10.2337/diabetes.48.9.1856
   Carlier PG, 2006, NMR BIOMED, V19, P954, DOI 10.1002/nbm.1081
   Cheng R, 2012, NEUROIMAGE, V62, P1445, DOI 10.1016/j.neuroimage.2012.05.069
   Cheung C, 2001, PHYS MED BIOL, V46, P2053, DOI 10.1088/0031-9155/46/8/302
   CRIQUI MH, 1985, CIRCULATION, V71, P510, DOI 10.1161/01.CIR.71.3.510
   Durduran T., 2004, NONINVASIVE MEASUREM
   Emanueli C, 2001, CIRCULATION, V103, P125
   FANTINI S, 1994, J OPT SOC AM B, V11, P2128, DOI 10.1364/JOSAB.11.002128
   FRONEK A, 1973, CIRCULATION, V48, P149
   Guo Z., 2004, DIABETES, V54, P190
   Gurley K, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.7.075010
   Helisch A, 2006, ARTERIOSCL THROM VAS, V26, P520, DOI 10.1161/01.ATV.0000202677.55012.a0
   Huang AL, 2007, ARTERIOSCL THROM VAS, V27, P2113, DOI 10.1161/ATVBAHA.107.147322
   Irwin D, 2011, BIOMED OPT EXPRESS, V2, P1969, DOI 10.1364/BOE.2.001969
   Kim MN, 2010, NEUROCRIT CARE, V12, P173, DOI 10.1007/s12028-009-9305-x
   KREGE JH, 1995, HYPERTENSION, V25, P1111, DOI 10.1161/01.HYP.25.5.1111
   Li J, 2008, OPT LETT, V33, P2233, DOI 10.1364/OL.33.002233
   LOMBARD JH, 1981, AM J PHYSIOL, V241, pH748
   MARET G, 1987, Z PHYS B CON MAT, V65, P409, DOI 10.1007/BF01303762
   Mesquita RC, 2010, BIOMED OPT EXPRESS, V1, P1173, DOI 10.1364/BOE.1.001173
   Munk N, 2012, J BODYW MOV THER, V16, P22, DOI 10.1016/j.jbmt.2011.01.018
   Petersen ET, 2006, BRIT J RADIOL, V79, P688, DOI 10.1259/bjr/67705974
   PINE DJ, 1988, PHYS REV LETT, V60, P1134, DOI 10.1103/PhysRevLett.60.1134
   Prinzen FW, 2000, CARDIOVASC RES, V45, P13, DOI 10.1016/S0008-6363(99)00252-7
   Roche-Labarbe N, 2010, HUM BRAIN MAPP, V31, P341, DOI 10.1002/hbm.20868
   Roustit M, 2012, MICROCIRCULATION, V19, P47, DOI 10.1111/j.1549-8719.2011.00129.x
   Rufaihah AJ, 2011, ARTERIOSCL THROM VAS, V31, pE72, DOI 10.1161/ATVBAHA.111.230938
   Shang Y, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4079
   Shang Y, 2011, OPT EXPRESS, V19, P20301, DOI 10.1364/OE.19.020301
   Shang Y, 2010, BIOMED OPT EXPRESS, V1, P500, DOI 10.1364/BOE.1.000500
   Shang Y, 2009, OPT LETT, V34, P3556, DOI 10.1364/OL.34.003556
   Yu GQ, 2005, J BIOMED OPT, V10, DOI 10.1117/1.18846031
   Yu GQ, 2005, CLIN CANCER RES, V11, P3543, DOI 10.1158/1078-0432.CCR-04-2582
   Yu GQ, 2007, OPT EXPRESS, V15, P1064, DOI 10.1364/OE.15.001064
   Yu GQ, 2011, J BIOMED OPT, V16, DOI 10.1117/1.3533320
   Zhou C, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3146814
NR 41
TC 6
Z9 6
U1 0
U2 8
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 1559-128X
EI 2155-3165
J9 APPL OPTICS
JI Appl. Optics
PD OCT 20
PY 2013
VL 52
IS 30
BP 7324
EP 7330
DI 10.1364/AO.52.007324
PG 7
WC Optics
SC Optics
GA 238EY
UT WOS:000325926600013
PM 24216586
DA 2018-03-20
ER

PT J
AU Xing, R
   Lehmler, HJ
   Knutson, BL
   Rankin, SE
AF Xing, Rong
   Lehmler, Hans-Joachim
   Knutson, Barbara L.
   Rankin, Stephen E.
TI Synthesis and Tuning of Bimodal Mesoporous Silica by Combined
   Hydrocarbon/Fluorocarbon Surfactant Templating
SO LANGMUIR
LA English
DT Article
ID HYDROCARBON SURFACTANTS; FLUOROCARBON; NANOPARTICLES; MICELLES;
   FLUOROSURFACTANT; ADSORPTION; MIXTURES; REGIONS
AB Hydrocarbon and fluorocarbon surfactants show highly nonideal mixing that under some conditions results in demixing of the two types of surfactants into distinct populations of fluorocarbon-rich and hydrocarbon-rich aggregates. This also occurs in materials prepared by cooperative assembly of hydrolyzed tetraethoxysilane with mixtures of cetyltrimethylammonium chloride (CTAC) and 1,1,2,2-tetrahydro-perfluorodecylpyridinium chloride (HFDePC). Here, we report conditions under which demixed micelles lead to bimodal mesoporous materials (including specific concentrations of ammonia and salt in the synthesis solution) and show that the sizes of the hydrocarbon-templated and fluorocarbon-templated pores can be finely and independently controlled by adding lipophilic or fluorophilic oils, respectively. Nitrogen sorption isotherms and transmission electron microscopy provide clear evidence for a single phase of demixed but disordered wormhole-like pores.
C1 [Xing, Rong; Knutson, Barbara L.; Rankin, Stephen E.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Lehmler, Hans-Joachim] Univ Iowa, Dept Occupat & Environm Hlth, Iowa City, IA 52242 USA.
RP Rankin, SE (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 FP Anderson Tower, Lexington, KY 40506 USA.
EM srankin@engr.uky.edu
RI Rankin, Stephen/A-3265-2013
OI Rankin, Stephen/0000-0002-8615-7564; Lehmler,
   Hans-Joachim/0000-0001-9163-927X
FU National Science Foundation (NSF) [DMR-0210517, CBET-0348234]
FX This report is based on work partially funded by the National Science
   Foundation (NSF) under Grant No. DMR-0210517 and Grant No. CBET-0348234.
   We thank Prof. W. S. Winston Ho at The Ohio State University for
   providing access to the TGA instrument.
CR Almgren M, 2005, J PHYS CHEM B, V109, P11348, DOI 10.1021/jp0502510
   Areva S, 2004, CHEM COMMUN, P1630, DOI 10.1039/b405690f
   ASAKAWA T, 1995, LANGMUIR, V11, P478, DOI 10.1021/la00002a019
   ASAKAWA T, 1985, LANGMUIR, V1, P347, DOI 10.1021/la00063a014
   BARRETT EP, 1951, J AM CHEM SOC, V73, P373, DOI 10.1021/ja01145a126
   Brunauer S, 1938, J AM CHEM SOC, V60, P309, DOI 10.1021/ja01269a023
   Djojoputro H, 2006, J AM CHEM SOC, V128, P6320, DOI 10.1021/ja0607537
   Groenewolt M, 2004, LANGMUIR, V20, P7811, DOI 10.1021/la049147k
   Han Y, 2005, ANGEW CHEM INT EDIT, V44, P288, DOI 10.1002/anie.200460892
   Jaroniec M, 1999, LANGMUIR, V15, P5410, DOI 10.1021/la990136e
   Kadi M, 2002, LANGMUIR, V18, P9243, DOI 10.1021/la020579+
   Kotzev A, 2002, MACROMOLECULES, V35, P1091, DOI 10.1021/ma011047n
   Li DF, 2004, CHEM-EUR J, V10, P5911, DOI 10.1002/chem.200400188
   Lodge TP, 2005, J AM CHEM SOC, V127, P17608, DOI 10.1021/ja056841t
   MUKERJEE P, 1976, J PHYS CHEM-US, V80, P1388, DOI 10.1021/j100553a028
   Ottaviani MF, 2004, J PHYS CHEM B, V108, P12123, DOI 10.1021/jp049032p
   Sayari A, 1997, CHEM MATER, V9, P2499, DOI 10.1021/cm970128o
   SING KSW, 1985, PURE APPL CHEM, V57, P603, DOI 10.1351/pac198557040603
   Tan B, 2005, ADV MATER, V17, P2368, DOI 10.1002/adma.200500344
   Tan B, 2004, LANGMUIR, V20, P6981, DOI 10.1021/la049474s
   Wang K, 2000, LANGMUIR, V16, P1042, DOI 10.1021/la9909603
   Xing R, 2008, MICROPOR MESOPOR MAT, V108, P65, DOI 10.1016/j.micromeso.2007.03.028
   Yu J, 2001, MICROPOR MESOPOR MAT, V46, P153, DOI 10.1016/S1387-1811(01)00269-4
   Zhao DY, 1998, SCIENCE, V279, P548, DOI 10.1126/science.279.5350.548
NR 24
TC 22
Z9 22
U1 0
U2 18
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0743-7463
J9 LANGMUIR
JI Langmuir
PD JUN 2
PY 2009
VL 25
IS 11
BP 6486
EP 6492
DI 10.1021/la9000939
PG 7
WC Chemistry, Multidisciplinary; Chemistry, Physical; Materials Science,
   Multidisciplinary
SC Chemistry; Materials Science
GA 453IL
UT WOS:000266604000067
PM 19323503
DA 2018-03-20
ER

PT J
AU Miller, AF
   Pitsawong, W
   Haynes, C
   Koder, R
   Rodgers, D
AF Miller, Anne-Frances
   Pitsawong, Warintra
   Haynes, Chad A.
   Koder, Ronald, Jr.
   Rodgers, David W.
TI Rate-Contributing Proton Transfers And Crystal Structures Of The
   Flavoenzyme Nitroreductase
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Experimental Biology Meeting
CY APR 02-06, 2016
CL San Diego, CA
SP Amer Assoc Anatomists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, Amer Soc Investigat Pathol, Amer Soc Nutr, Amer Soc Pharmacol & Expt Therapeut
C1 [Miller, Anne-Frances; Rodgers, David] Univ Kentucky, Lexington, KY USA.
   [Pitsawong, Warintra] Brandeis Univ, Waltham, MA USA.
   [Haynes, Chad] Booz Allen Hamilton, Washington, DC USA.
   [Koder, Ronald, Jr.] CUNY City Coll, New York, NY 10031 USA.
FU University of Kentuckty College of Arts and Sciences; Center for
   Pharmaceutical Development, NSF IUCRC
FX With support from the University of Kentuckty College of Arts and
   Sciences and the Center for Pharmaceutical Development, NSF IUCRC.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD APR
PY 2016
VL 30
SU 1
MA 636.1
PG 2
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA FB9FC
UT WOS:000406444002118
DA 2018-03-20
ER

PT J
AU Wu, XA
   Li, XJ
   Mansour, HM
AF Wu, Xiao
   Li, Xiaojian
   Mansour, Heidi M.
TI Surface Analytical Techniques in Solid-State Particle Characterization
   for Predicting Performance in Dry Powder Inhalers
SO KONA POWDER AND PARTICLE JOURNAL
LA English
DT Review
DE pulmonary drug delivery; inhalation aerosols; surface chemistry;
   interparticulate forces; particle engineering; pharmaceutical powders
ID INVERSE GAS-CHROMATOGRAPHY; ATOMIC-FORCE MICROSCOPY; PULMONARY
   DRUG-DELIVERY; SUPERCRITICAL-FLUID EXTRACTION; STANDARDIZED ENTRAINMENT
   TUBES; IGE MONOCLONAL-ANTIBODY; LARGE POROUS PARTICLES; METERED-DOSE
   INHALERS; SPRAY-DRIED POWDERS; AEROSOL PERFORMANCE
AB The pulmonary route is of interest for both effective local therapy for respiratory and lung diseases, such as asthma, chronic obstructive pulmonary disease and cystic fibrosis, and systemic administration of drugs, such as proteins and peptides. Dry powder inhalers (DPIs) are devices through which a dry powder formulation of drug is delivered via the pulmonary route. The DPIs are highly efficient but complicated systems, the performance of which relies on many aspects, including aerodynamic diameter of the powder formulation, particle density, bulk density, surface morphology and composition, particle shape, interparticulate cohesive forces between drug particles and interparticulate adhesive forces between drug and carrier particles. Among them, surface morphology of both drug particles and carrier particles within the formulation is a very important factor in determining the interparticulate contact area and forces, aerosolization efficiency and subsequent lung deposition. Techniques that have been applied to study surface properties of solid-state particles in DPIs include atomic force microscopy, micro- and nanothermal analysis, inverse gas chromatography and X-ray photoelectron spectroscopy. This paper reviews different aspects of DPIs, with emphasis on their surface properties and influence on aerosol performance, and the techniques that are utilized to examine their surface properties.
C1 [Wu, Xiao; Li, Xiaojian; Mansour, Heidi M.] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Drug Dev Div, Lexington, KY 40536 USA.
RP Mansour, HM (reprint author), Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Drug Dev Div, 789 S Limestone St, Lexington, KY 40536 USA.
EM heidi.mansour@uky.edu
RI Wu, Xiao/A-4265-2011; Mansour, Heidi/D-1074-2011
CR Adi S, 2008, EUR J PHARM SCI, V35, P12, DOI 10.1016/j.ejps.2008.05.009
   Ambarkhane AV, 2005, INT J PHARM, V294, P129, DOI 10.1016/j.ijpharm.2005.01.034
   Andya JD, 1999, PHARMACEUT RES, V16, P350, DOI 10.1023/A:1018805232453
   Ashurst I., 2000, PHARM SCI TECHNOL TO, V3, P246
   Atkins Paul J, 2005, Respir Care, V50, P1304
   Bandyopadhyay R, 2000, PHARM DEV TECHNOL, V5, P27, DOI 10.1081/PDT-100100516
   BARNES PJ, 1983, AM REV RESPIR DIS, V127, P758
   BARNES PJ, 1982, NATURE, V299, P444, DOI 10.1038/299444a0
   Begat P, 2004, PHARM RES, V21, P1591, DOI 10.1023/B:PHAM.0000041453.24419.8a
   BELL JH, 1971, J PHARM SCI, V60, P1559, DOI 10.1002/jps.2600601028
   Berard V, 2002, INT J PHARM, V247, P127, DOI 10.1016/S0378-5173(02)00400-3
   Bhattacharya S, 2009, J PHARM SCI-US, V98, P2935, DOI 10.1002/jps.21728
   BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930
   Bonacucina G, 2005, J PHARM SCI-US, V94, P2452, DOI 10.1002/jps.20446
   Borgstrom L, 1996, AM J RESP CRIT CARE, V153, P1636, DOI 10.1164/ajrccm.153.5.8630614
   Bosquillon C, 2004, J CONTROL RELEASE, V99, P357, DOI 10.1016/j.jconrel.2004.07.022
   Bouche R, 1977, J Pharm Belg, V32, P23
   Brown E, 2008, J PHYS CONF SER, V100, DOI 10.1088/1742-6596/100/5/052012
   Buckton G, 2004, PHARM RES, V21, P1554, DOI 10.1023/B:PHAM.0000041447.15874.f7
   Buckton G, 2007, ADV DRUG DELIVER REV, V59, P1474, DOI 10.1016/j.addr.2007.06.017
   Builders PF, 2009, EUR J PHARM BIOPHARM, V72, P34, DOI 10.1016/j.ejpb.2008.12.011
   Bunker MJ, 2006, EUR J PHARM SCI, V29, P405, DOI 10.1016/j.ejps.2006.08.001
   BYRN SR, 1982, SOLID STATE CHEM DRU
   CARSTAIRS JR, 1985, AM REV RESPIR DIS, V132, P541
   Chan HK, 2006, J AEROSOL MED, V19, P21, DOI 10.1089/jam.2006.19.21
   Charmas B, 2000, J CHROMATOGR A, V886, P133, DOI 10.1016/S0021-9673(00)00432-5
   Chattopadhyay P, 2007, ADV DRUG DELIVER REV, V59, P444, DOI 10.1016/j.addr.2007.04.010
   Chattopadhyay P, 2006, J PHARM SCI-US, V95, P667, DOI 10.1002/jps.20555
   Chew NYK, 2005, PHARM RES, V22, P148, DOI 10.1007/s11095-004-9020-4
   Chew NYK, 2001, PHARMACEUT RES, V18, P1570, DOI 10.1023/A:1013082531394
   Chow AHL, 2007, PHARM RES, V24, P411, DOI 10.1007/s11095-006-9174-3
   Clarke MJ, 2000, J PHARM SCI, V89, P1160, DOI 10.1002/1520-6017(200009)89:9<1160::AID-JPS8>3.3.CO;2-4
   Clas SD, 2003, CURR OPIN DRUG DI DE, V6, P550
   Coates MS, 2005, PHARM RES, V22, P1445, DOI 10.1007/s11095-005-6155-x
   Columbano A, 2003, INT J PHARM, V253, P61, DOI 10.1016/S0378-5173(02)00634-8
   Concessio N, 1994, PHARM TECH, V18, P88
   Costantino HR, 1998, J PHARM SCI, V87, P1406, DOI 10.1021/js9800679
   Craig DQM, 1999, INT J PHARM, V179, P179, DOI 10.1016/S0378-5173(98)00338-X
   Cui Y, 2007, INT J PHARMACEUT, V339, P3, DOI 10.1016/j.ijpharm.2007.04.021
   Dai X, 2009, J PHARM SCI-US, V98, P1499, DOI 10.1002/jps.21538
   Danesh A, 2000, LANGMUIR, V16, P866, DOI 10.1021/la990470a
   Dannenfelser RM, 2004, J PHARM SCI-US, V93, P1165, DOI 10.1002/jps.20044
   Datta S, 2004, NAT REV DRUG DISCOV, V3, P42, DOI 10.1038/nrd1280
   Davies MJ, 2009, COLLOID SURFACE B, V73, P97, DOI 10.1016/j.colsurfb.2009.05.003
   Dellamary LA, 2000, PHARMACEUT RES, V17, P168, DOI 10.1023/A:1007513213292
   Descamps M, 2005, J PHYS CHEM B, V109, P16092, DOI 10.1021/jp040494c
   Dolovich MB, 2005, CHEST, V127, P335, DOI 10.1378/chest.127.1.335
   Duddu SP, 2002, PHARMACEUT RES, V19, P689, DOI 10.1023/A:1015322616613
   Dunbar CA, 1998, KONA, V16, P7
   Eaton P, 2002, LANGMUIR, V18, P10011, DOI 10.1021/la0110747
   Edwards DA, 2002, ANNU REV BIOMED ENG, V4, P93, DOI 10.1146/annurev.bioeng.4.100101.132311
   Edwards DA, 1997, SCIENCE, V276, P1868, DOI 10.1126/science.276.5320.1868
   Efrat R, 2008, LANGMUIR, V24, P7590, DOI 10.1021/la800603f
   El-Sabawi D, 2006, DRUG DEV IND PHARM, V32, P243, DOI 10.1080/03639040500466395
   Elversson J, 2005, J PHARM SCI-US, V94, P2049, DOI 10.1002/jps.20418
   Eve JK, 2002, INT J PHARM, V238, P17, DOI 10.1016/S0378-5173(02)00055-8
   Feeley JC, 1998, INT J PHARM, V172, P89, DOI 10.1016/S0378-5173(98)00179-3
   Fults K A, 1997, Pharm Dev Technol, V2, P67, DOI 10.3109/10837459709022610
   Ganderton D, 1997, RESP MED, V91, P13, DOI 10.1016/S0954-6111(97)90099-8
   Geller David E, 2005, Respir Care, V50, P1313
   Geller D. E., 2005, RESP CARE, V50, P1313
   Genina N, 2010, INT J PHARMACEUT, V387, P65, DOI 10.1016/j.ijpharm.2009.12.005
   Ghebremeskel AN, 2007, INT J PHARM, V328, P119, DOI 10.1016/j.ijpharm.2006.08.010
   Gilani K, 2005, J PHARM SCI-US, V94, P1048, DOI 10.1002/jps.20315
   Giron D, 2002, J THERM ANAL CALORIM, V68, P453, DOI 10.1023/A:1016031517430
   GREBOWICZ J, 1986, J POLYM SCI POL PHYS, V24, P675, DOI 10.1002/polb.1986.090240313
   Grimsey IM, 2002, J PHARM SCI-US, V91, P571, DOI 10.1002/jps.10060
   Gupta MK, 2003, J PHARM SCI, V92, P536, DOI 10.1002/jps.10308
   Gupta P, 2005, PHARM DEV TECHNOL, V10, P273, DOI 10.1081/PDT-200054460
   HALEBLIA.J, 1969, J PHARM SCI, V58, P911, DOI 10.1002/jps.2600580802
   Hancock BC, 2000, PHARMACEUT RES, V17, P397, DOI 10.1023/A:1007516718048
   Hancock BC, 1997, J PHARM SCI, V86, P1, DOI 10.1021/js9601896
   Harding L, 2007, PHARM RES, V24, P2048, DOI 10.1007/s11095-007-9339-8
   Harjunen P, 2003, INT J PHARM, V263, P151, DOI 10.1016/S0378-5173(03)00357-0
   Parojcic J, 2008, EUR J PHARM BIOPHARM, V69, P640, DOI 10.1016/j.ejpb.2008.04.020
   Heinz A, 2009, J PHARM PHARMACOL, V61, P971, DOI 10.1211/jpp/61.08.0001
   Heinz WF, 1999, TRENDS BIOTECHNOL, V17, P143, DOI 10.1016/S0167-7799(99)01304-9
   Heng JYY, 2006, LANGMUIR, V22, P2760, DOI 10.1021/la0532407
   HENG PWS, 1988, J PHARM PHARMACOL, V40, P360, DOI 10.1111/j.2042-7158.1988.tb05267.x
   HICKEY AJ, 1988, J PHARM SCI, V77, P804, DOI 10.1002/jps.2600770919
   Hickey A. J., 2008, MODIFIED RELEASE DRU, P573
   Hickey AJ, 2009, MODERN PHARM, P191
   Hickey AJ, 2007, J PHARM SCI-US, V96, P1302, DOI 10.1002/jps.20943
   Hickey AJ, 2007, J PHARM SCI-US, V96, P1282, DOI 10.1002/jps.20916
   Hilden LR, 2004, J PHARM SCI-US, V93, P3, DOI 10.1002/jps.10489
   Hilfiker R, 2006, POLYMORPHISM PHARM I
   Hooton JC, 2006, J PHARM SCI-US, V95, P1288, DOI 10.1002/jps.20618
   Hooton JC, 2003, PHARMACEUT RES, V20, P508, DOI 10.1023/A:1022684911383
   Hooton JC, 2008, DRUG DEV IND PHARM, V34, P974, DOI [10.1080/03639040802149087, 10.1080/03639040802149087 ]
   Horvat M, 2005, INT J PHARM, V294, P1, DOI 10.1016/j.ijpharm.2004.08.025
   Howarth PH, 1997, RESP MED, V91, P2, DOI 10.1016/S0954-6111(97)90096-2
   Irngartinger M, 2004, EUR J PHARM BIOPHARM, V58, P7, DOI 10.1016/j.ejpb.2004.03.016
   Junghanns JUAH, 2008, INT J NANOMED, V3, P295
   Kaushal Aditya Mohan, 2004, Crit Rev Ther Drug Carrier Syst, V21, P133, DOI 10.1615/CritRevTherDrugCarrierSyst.v21.i3.10
   Kim JS, 2008, INT J PHARM, V359, P211, DOI 10.1016/j.ijpharm.2008.04.006
   Kleinstreuer C, 2008, ANNU REV BIOMED ENG, V10, P195, DOI 10.1146/annurev.bioeng.10.061807.160544
   Labiris NR, 2003, BRIT J CLIN PHARMACO, V56, P588, DOI 10.1046/j.1365-2125.2003.01892.x
   Leach CL, 1998, EUR RESPIR J, V12, P1346, DOI 10.1183/09031936.98.12061346
   Learoyd TP, 2008, EUR J PHARM BIOPHARM, V68, P224, DOI 10.1016/j.ejpb.2007.04.017
   Lee Y. S., 2000, AAPS PHARMSCITECH, V1, P21
   Li HT, 2009, EUR J PHARM SCI, V38, P426, DOI 10.1016/j.ejps.2009.09.003
   Liu JS, 2006, PHARM DEV TECHNOL, V11, P3, DOI 10.1080/10837450500463729
   Louey MD, 2002, PHARMACEUT RES, V19, P1524, DOI 10.1023/A:1020464801786
   Louey MD, 2001, J PHARMACEUT BIOMED, V25, P559, DOI 10.1016/S0731-7085(00)00523-9
   Maa Y F, 1997, Pharm Dev Technol, V2, P213, DOI 10.3109/10837459709031441
   Mansour HM, 2010, J PHARM SCI-US, V99, P3430, DOI 10.1002/jps.22101
   Mansour HM, 2009, INT J NANOMED, V4, P299
   Merisko-Liversidge E, 2003, EUR J PHARM SCI, V18, P113, DOI 10.1016/S0928-0987(02)00251-8
   MeriskoLiversidge E, 1996, PHARMACEUT RES, V13, P272, DOI 10.1023/A:1016051316815
   Mosen K, 2004, PHARM DEV TECHNOL, V9, P409, DOI 10.1081/PDT-200035795
   Murphy JR, 2003, PHARMACEUT RES, V20, P500, DOI 10.1023/A:1022632927312
   Muster TH, 2002, J PHARM SCI, V91, P1432, DOI 10.1002/jps.10125
   Nelson BA, 2007, REV SCI INSTRUM, V78, DOI 10.1063/1.2435589
   Newell HE, 2001, INT J PHARM, V217, P45, DOI 10.1016/S0378-5173(01)00589-0
   Newell HE, 2004, PHARM RES, V21, P1440, DOI 10.1023/B:PHAM.0000036918.79205.4b
   Newman AW, 2003, DRUG DISCOV TODAY, V8, P898, DOI 10.1016/S1359-6446(03)02832-0
   Newman SP, 1996, J AEROSOL MED, V9, P55, DOI 10.1089/jam.1996.9.55
   NEWMAN SP, 1993, CHEST, V103, P1442, DOI 10.1378/chest.103.5.1442
   Newman SP, 2002, RESP MED, V96, P293, DOI 10.1053/rmed.2001.1276
   NORWOOD DL, 1995, J PHARMACEUT BIOMED, V13, P293, DOI 10.1016/0731-7085(95)01273-N
   Ohta M, 2004, INT J PHARM, V272, P121, DOI 10.1016/j.ijpharm.2003.12.007
   Ohta M, 2004, INT J PHARM, V269, P81, DOI 10.1016/j.ijpharm.2003.08.015
   Ozeki T, 2006, PHARM RES, V23, P177, DOI 10.1007/s11095-005-8718-2
   Patterson JE, 2005, J PHARM SCI-US, V94, P1998, DOI 10.1002/jps.20424
   Pedersen S, 1997, ALLERGY, V52, P1, DOI 10.1111/j.1398-9995.1997.tb05047.x
   Pollock HM, 2001, J PHYS D APPL PHYS, V34, pR23, DOI 10.1088/0022-3727/34/9/201
   Rasenack N, 2004, PHARM DEV TECHNOL, V9, P1, DOI 10.1081/PDT-120027417
   Reading M, 2001, MACROMOL SYMP, V167, P45, DOI 10.1002/1521-3900(200103)167:1<45::AID-MASY45>3.0.CO;2-N
   Rehman M, 2004, EUR J PHARM SCI, V22, P1, DOI 10.1016/j.ejps.2004.02.001
   Rey R, 2008, J PHYS CHEM B, V112, P344, DOI 10.1021/jp0754177
   Rodriguez-Spong B, 2004, ADV DRUG DELIVER REV, V56, P241, DOI 10.1016/j.addr.2003.10.005
   Sedman VL, 2009, LANGMUIR, V25, P7256, DOI 10.1021/la9016273
   Seville PC, 2007, CRIT REV THER DRUG, V24, P307, DOI 10.1615/CritRevTherDrugCarrierSyst.v24.i4.10
   Sharma P, 2009, INT J PHARMACEUT, V380, P40, DOI 10.1016/j.ijpharm.2009.06.029
   Shekunov BY, 2006, PHARM RES, V23, P196, DOI 10.1007/s11095-005-8635-4
   Singh LP, 2009, PHYS CHEM CHEM PHYS, V11, P5110, DOI 10.1039/b817964f
   Singhal D, 2004, ADV DRUG DELIVER REV, V56, P335, DOI 10.1016/j.addr.2003.10.008
   Steckel H, 2006, INT J PHARM, V309, P51, DOI 10.1016/j.ijpharm.2005.10.043
   Steckel H, 2004, INT J PHARM, V278, P187, DOI 10.1016/j.ijpharm.2004.03.010
   Steckel H, 2004, INT J PHARM, V270, P297, DOI 10.1016/j.ijpharm.2003.10.039
   Steckel H, 1997, INT J PHARM, V152, P99, DOI 10.1016/S0378-5173(97)00071-9
   Steckel H, 1998, INT J PHARM, V173, P25, DOI 10.1016/S0378-5173(98)00237-3
   Stevenson CL, 2005, J PHARM SCI-US, V94, P1861, DOI 10.1002/jps.20435
   STROM CS, 1975, ACTA CRYSTALLOGR A, V31, pS216
   Sunkersett MR, 2001, EUR J PHARM SCI, V13, P219, DOI 10.1016/S0928-0987(01)00105-1
   Takeuchi H, 2005, INT J PHARM, V293, P155, DOI 10.1016/j.ijpharm.2004.12.019
   Taylor LS, 1998, PHARMACEUT RES, V15, P755, DOI 10.1023/A:1011979221685
   TAYLOR M. K., 2000, AAPS PHARMSCITECH, V1
   Telko Martin J, 2005, Respir Care, V50, P1209
   Thielmann F, 2004, J CHROMATOGR A, V1037, P115, DOI 10.1016/j.chroma.2004.03.060
   TICEHURST MD, 1994, INT J PHARM, V111, P241, DOI 10.1016/0378-5173(94)90347-6
   TOM JW, 1991, J AEROSOL SCI, V22, P555, DOI 10.1016/0021-8502(91)90013-8
   Tong HHY, 2006, J PHARM SCI-US, V95, P228, DOI 10.1002/jps.20519
   Tong HHY, 2002, PHARMACEUT RES, V19, P640, DOI 10.1023/A:1015358129817
   Tong HHY, 2001, PHARMACEUT RES, V18, P852, DOI 10.1023/A:1011000915769
   Traini D, 2006, INT J PHARM, V320, P58, DOI 10.1016/j.ijpharm.2006.04.016
   Traini D, 2006, EUR J PHARM SCI, V27, P243, DOI 10.1016/j.ejps.2005.10.005
   Trojak A, 2001, INT J PHARM, V218, P145, DOI 10.1016/S0378-5173(01)00625-1
   Tsukruk VV, 2003, THERMOCHIM ACTA, V395, P151
   Vanbever R, 1999, PHARMACEUT RES, V16, P1735, DOI 10.1023/A:1018910200420
   VIDGREN MT, 1987, INT J PHARM, V35, P139, DOI 10.1016/0378-5173(87)90082-2
   Vippagunta SR, 2001, ADV DRUG DELIVER REV, V48, P3, DOI 10.1016/S0169-409X(01)00097-7
   Voelkel A, 2009, J CHROMATOGR A, V1216, P1551, DOI 10.1016/j.chroma.2008.10.096
   Weers JG, 2007, EXPERT OPIN DRUG DEL, V4, P297, DOI 10.1517/17425247.4.3.297
   White Steven, 2005, Diabetes Technol Ther, V7, P896, DOI 10.1089/dia.2005.7.896
   Willart JF, 2008, MOL PHARMACEUT, V5, P905, DOI 10.1021/mp800092t
   Wu JJ, 2008, PHARM RES, V25, P1396, DOI 10.1007/s11095-007-9530-y
   Xiang TX, 2004, J PHARM SCI-US, V93, P855, DOI 10.1002/jps.20004
   Xu Z., 2008, RESP DRUG DELIVERY, P897
   Xu Z, 2010, J PHARM SCI-US, V99, P3442, DOI 10.1002/jps.22057
   Xu Z, 2010, J PHARM SCI-US, V99, P3415, DOI 10.1002/jps.22100
   Xu Z, 2010, J PHARM SCI-US, V99, P3398, DOI 10.1002/jps.22107
   Ye J., 2007, MICROSC ANAL, V21, pS5
   York P, 1998, INT J PHARMACEUT, V174, P179, DOI 10.1016/S0378-5173(98)00247-6
   YORK P, 1983, INT J PHARMACEUT, V14, P1, DOI 10.1016/0378-5173(83)90111-4
   Young PM, 2009, PHARM RES-DORD, V26, P802, DOI 10.1007/s11095-008-9779-9
   Young PM, 2003, J PHARM SCI, V92, P815, DOI 10.1002/jps.10250
   Young PM, 2002, J PHARM PHARMACOL, V54, P1339, DOI 10.1211/002235702760345400
   Yu L, 2001, ADV DRUG DELIVER REV, V48, P27, DOI 10.1016/S0169-409X(01)00098-9
   Zeng XM, 2000, INT J PHARM, V200, P93, DOI 10.1016/S0378-5173(00)00347-1
   Zhang JX, 2009, INT J PHARMACEUT, V380, P170, DOI 10.1016/j.ijpharm.2009.07.003
   [Anonymous], 1987, MONTREAL PROTOCOL 19
NR 182
TC 14
Z9 14
U1 1
U2 13
PU HOSOKAWA POWDER TECHNOL FOUNDATION
PI HIRAKATA-SHI
PA NO 9, 1-CHOME, SHOUDAI TAJIKA, HIRAKATA-SHI, OSAKA 573-1132, JAPAN
SN 0288-4534
J9 KONA POWDER PART J
JI KONA Powder Part. J.
PY 2010
IS 28
BP 3
EP 19
PG 17
WC Engineering, Chemical; Materials Science, Multidisciplinary
SC Engineering; Materials Science
GA 698YS
UT WOS:000285631700003
DA 2018-03-20
ER

PT J
AU Yarana, C
   Carroll, D
   Chen, J
   Chaiswing, L
   Zhao, YM
   Noel, T
   Alstott, M
   Bae, Y
   Dressler, EV
   Moscow, JA
   Zhu, HN
   Butterfield, DA
   St Clair, DK
AF Yarana, Chontida
   Carroll, Dustin
   Chen, Jing
   Chaiswing, Luksana
   Zhao, Yanming
   Noel, Teresa
   Alstott, Michael
   Bae, Younsoo
   Dressler, Emily V.
   Moscow, Jeffrey A.
   Zhu, Haining
   Butterfield, D. Allan
   St Clair, Daret K.
TI Extracellular Vesicles Released by Cardiomyocytes in a
   Doxorubicin-induced Cardiac Injury Mouse Model Contain Protein
   Biomarkers of Early Cardiac Injury
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Meeting Abstract
CT 24th Annual Meeting of the Society-for-Redox-Biology-and-Medicine
   (SfRBM)
CY NOV 29-DEC 02, 2017
CL Baltimore, MD
SP Soc Redox Biol & Med
C1 [Yarana, Chontida; Carroll, Dustin; Chen, Jing; Chaiswing, Luksana; Zhao, Yanming; Noel, Teresa; Alstott, Michael; Bae, Younsoo; Zhu, Haining; Butterfield, D. Allan; St Clair, Daret K.] Univ Kentucky, Lexington, KY 40506 USA.
   [Yarana, Chontida] Mahidol Univ, Salaya, Nakhon Pathom, Thailand.
   [Dressler, Emily V.] Wake Forest Sch Med, Winston Salem, NC USA.
   [Moscow, Jeffrey A.] NCI, Invest Drug Branch, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0891-5849
EI 1873-4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD NOV
PY 2017
VL 112
SU 1
MA 177
BP 125
EP 126
DI 10.1016/j.freeradbiomed.2017.10.190
PG 2
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA FN2FB
UT WOS:000415805100202
DA 2018-03-19
ER

PT J
AU Meeks, ND
   Smuleac, V
   Stevens, C
   Bhattacharyya, D
AF Meeks, Noah D.
   Smuleac, Vasile
   Stevens, Christopher A.
   Bhattacharyya, Dibakar
TI Iron-Based Nanoparticles for Toxic Organic Degradation: Silica Platform
   and Green Synthesis
SO INDUSTRIAL & ENGINEERING CHEMISTRY RESEARCH
LA English
DT Article
ID FE-PD NANOPARTICLES; IN-SITU REMEDIATION; HYDROGEN-PEROXIDE; BIMETALLIC
   NANOPARTICLES; CATALYTIC DECOMPOSITION; MESOPOROUS SILICA; ACTIVATED
   CARBON; SUPPORTED IRON; TRICHLOROETHYLENE; DECHLORINATION
AB Iron and iron oxide nanoparticles (NPs) are finding wide applications for the remediation of various toxic chloro-organic compounds (such as trichloroethylene, TCE) via reductive and oxidative processes. In this study, Fe NPs (30-50 nm) were synthesized by reduction from ferric ions immobilized (by ion exchange) on a platform (two types of sulfonated silica particles) in order to prevent NP agglomeration. The Fe NPs were then oxidized and their effectiveness for the oxidative dechlorination of TCE via the heterogeneous decomposition of hydrogen peroxide to OH center dot on the surface of the iron oxide NPs was demonstrated. For the reductive approach, the use of ascorbic acid as a "green" reducing agent in conjunction with a secondary metal (Pd) inhibits NP oxidation and agglomeration through surface adsorbed species. The Fe/Pd NPs have been successfully applied For the dechlorination of TCE (k(SA), surface-area normalized reaction rate, = 8.1 x 10(-4) L/m(2) h).
C1 [Meeks, Noah D.; Smuleac, Vasile; Stevens, Christopher; Bhattacharyya, Dibakar] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Bhattacharyya, D (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 F Paul Anderson Tower, Lexington, KY 40506 USA.
EM db@engr.uky.edu
FU NIEHS-SRP; NSF/REU
FX We acknowledge the NIEHS-SRP program for support of this study. Also, we
   appreciate the contributions of Electron Microscopy Center and
   Environmental Research Training Laboratory, both at the University of
   Kentucky. C.S. was also supported by the NSF/REU program.
CR Benoit R, 2009, MICROPOR MESOPOR MAT, V120, P2, DOI 10.1016/j.micromeso.2008.12.017
   BUKUR DB, 1990, IND ENG CHEM RES, V29, P1588, DOI 10.1021/ie00104a003
   Bukur DB, 1999, IND ENG CHEM RES, V38, P3270, DOI 10.1021/ie990028n
   Choi H, 2008, CHEM MATER, V20, P3649, DOI 10.1021/cm8003613
   Christy AA, 2005, ANALYST, V130, P738, DOI 10.1039/b501895c
   De Laat J, 1999, ENVIRON SCI TECHNOL, V33, P2726, DOI 10.1021/es981171v
   De Corte S., 2011, ENV SCI TECHNOL
   He F, 2007, IND ENG CHEM RES, V46, P29, DOI 10.1021/ie0610896
   He F, 2008, APPL CATAL B-ENVIRON, V84, P533, DOI 10.1016/j.apcatb.2008.05.008
   Huber DL, 2005, SMALL, V1, P482, DOI 10.1002/smll.200500006
   Iler R.K, 1979, CHEM SILICA
   Impens NREN, 1999, MICROPOR MESOPOR MAT, V28, P217, DOI 10.1016/S1387-1811(98)00239-X
   Jin S, 2008, CHEM ENG J, V140, P642, DOI 10.1016/j.cej.2008.01.035
   Jin YM, 2000, J CATAL, V196, P8, DOI 10.1006/jcat.2000.3024
   Kim HJ, 2009, ENVIRON SCI TECHNOL, V43, P3824, DOI 10.1021/es802978s
   KITAJIMA N, 1978, J PHYS CHEM-US, V82, P1505, DOI 10.1021/j100502a009
   Laurent S, 2008, CHEM REV, V108, P2064, DOI 10.1021/cr068445e
   Lewis S, 2009, ENVIRON ENG SCI, V26, P849, DOI 10.1089/ees.2008.0277
   Li D, 2006, J AM CHEM SOC, V128, P968, DOI 10.1021/ja056609n
   Lim WTL, 2009, CHEM PHYS LETT, V471, P122, DOI 10.1016/j.cplett.2009.02.041
   Lin SS, 1998, ENVIRON SCI TECHNOL, V32, P1417, DOI 10.1021/es970648k
   Liu JC, 2008, LANGMUIR, V24, P328, DOI 10.1021/la702731h
   Liu JC, 2009, LANGMUIR, V25, P7116, DOI 10.1021/la900228d
   Lowry G.V., 2008, J NANOPART RES, V10, P795
   Lu AH, 2007, ANGEW CHEM INT EDIT, V46, P1222, DOI 10.1002/anie.200602866
   Meeks ND, 2010, IND ENG CHEM RES, V49, P4687, DOI 10.1021/ie901580k
   Meyer DE, 2008, ENERG FUEL, V22, P2290, DOI 10.1021/ef8001873
   MILLER CM, 1995, WATER RES, V29, P2353, DOI 10.1016/0043-1354(95)00059-T
   Mirkhalaf F, 2006, J AM CHEM SOC, V128, P7400, DOI 10.1021/ja058687g
   Miyake Y, 2003, WATER RES, V37, P1852, DOI 10.1016/S0043-1354(02)00564-X
   Nadagouda MN, 2007, CRYST GROWTH DES, V7, P2582, DOI 10.1021/cg070554e
   Nadagouda MN, 2009, J MATER CHEM, V19, P2026, DOI 10.1039/b817112b
   Nadagouda MN, 2008, J NANOMATER, DOI 10.1155/2008/782358
   Nath M, 2000, CHEM PHYS LETT, V322, P333, DOI 10.1016/S0009-2614(00)00437-1
   Nurmi JT, 2005, ENVIRON SCI TECHNOL, V39, P1221, DOI 10.1021/es049190u
   Pham ALT, 2009, ENVIRON SCI TECHNOL, V43, P8930, DOI 10.1021/es902296k
   Seger B, 2008, J ELECTROANAL CHEM, V621, P198, DOI 10.1016/j.jelechem.2007.09.037
   Serrano DP, 2007, J MATER CHEM, V17, P1178, DOI 10.1039/b614052a
   Smuleac V, 2011, J MEMBRANE SCI, V379, P131, DOI 10.1016/j.memsci.2011.05.054
   Sunkara B, 2010, ACS APPL MATER INTER, V2, P2854, DOI 10.1021/am1005282
   Tee YH, 2005, IND ENG CHEM RES, V44, P7062, DOI 10.1021/ie050086a
   Varma R.S., 2009, J MATER CHEM, V19, P8671
   Vinu A, 2005, J NANOSCI NANOTECHNO, V5, P347, DOI 10.1166/jnn.2005.089
   Virkutyte J, 2011, CHEM SCI, V2, P837, DOI 10.1039/c0sc00338g
   Wallace JM, 2004, J NON-CRYST SOLIDS, V350, P31, DOI 10.1016/j.jnoncrysol.2004.07.087
   Wang CB, 1997, ENVIRON SCI TECHNOL, V31, P2154, DOI 10.1021/es970039c
   Wang XY, 2008, IND ENG CHEM RES, V47, P8645, DOI 10.1021/ie701762d
   Watts RJ, 1997, WATER ENVIRON RES, V69, P269, DOI 10.2175/106143097X125443
   WIELERS AFH, 1989, J CATAL, V117, P1, DOI 10.1016/0021-9517(89)90216-9
   Xu J, 2005, ENVIRON PROG, V24, P358, DOI 10.1002/ep.10106
   Xu J, 2008, J PHYS CHEM C, V112, P9133, DOI 10.1021/jp7097262
   Yeh C.K.-J., 2004, PRACT PEDIOD HAZARD, V8
   Zahran EM, 2011, J MATER CHEM, V21, P10454, DOI 10.1039/c1jm11435b
   Zhan JJ, 2008, ENVIRON SCI TECHNOL, V42, P8871, DOI 10.1021/es800387p
   Zhang SB, 2008, CATAL COMMUN, V9, P995, DOI 10.1016/j.catcom.2007.09.033
   Zheng TH, 2008, ENVIRON SCI TECHNOL, V42, P4494, DOI 10.1021/es702214x
NR 56
TC 11
Z9 12
U1 0
U2 42
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0888-5885
J9 IND ENG CHEM RES
JI Ind. Eng. Chem. Res.
PD JUL 18
PY 2012
VL 51
IS 28
BP 9581
EP 9590
DI 10.1021/ie301031u
PG 10
WC Engineering, Chemical
SC Engineering
GA 974QY
UT WOS:000306452600016
PM 22899876
OA green_accepted
DA 2018-03-19
ER

PT J
AU Wang, ZM
   Gupta, SK
   Meenach, SA
AF Wang, Zimeng
   Gupta, Sweta K.
   Meenach, Samantha A.
TI Development and physicochemical characterization of acetalated dextran
   aerosol particle systems for deep lung delivery
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Acetalated dextran; Nanocomposite microparticles; Microparticles;
   Pulmonary delivery; Spray drying; Controlled release
ID NANOCOMPOSITE MICROPARTICLES NCMP; PULMONARY DELIVERY; DISPERSION
   PERFORMANCE; POWDER; OPTIMIZATION; INHALATION; NANOPARTICLES; RELEASE;
   NANOMEDICINE; POLYMERS
AB Biocompatible, biodegradable polymers are commonly used as excipients to improve the drug delivery properties of aerosol formulations, in which acetalated dextran (Ac-Dex) exhibits promising potential as a polymer in various therapeutic applications. Despite this promise, there is no comprehensive study on the use of Ac-Dex as an excipient for dry powder aerosol formulations. In this study, we developed and characterized pulmonary drug delivery aerosol microparticle systems based on spray-dried Ac-Dex with capabilities of (1) delivering therapeutics to the deep lung, (2) targeting the particles to a desired location within the lungs, and (3) releasing the therapeutics in a controlled fashion. Two types of Ac-Dex, with either rapid or slow degradation rates, were synthesized. Nanocomposite microparticle (nCmP) and microparticle (MP) systems were successfully formulated using both kinds of Ac-Dex as excipients and curcumin as a model drug. The resulting MP were collapsed spheres approximately 1 mm in diameter, while the nCmP were similar in size with wrinkled surfaces, and these systems dissociated into 200 nm nanoparticles upon reconstitution in water. The drug release rates of the Ac-Dex particles were tuned by modifying the particle size and ratio of fast to slow degrading Ac-Dex. The pH of the environment was also a significant factor that influenced the drug release rate. All nCmP and MP systems exhibited desirable aerodynamic diameters that are suitable for deep lung delivery (e.g. below 5 mu m). Overall, the engineered Ac-Dex aerosol particle systems have the potential to provide targeted and effective delivery of therapeutics into the deep lung. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Wang, Zimeng; Gupta, Sweta K.; Meenach, Samantha A.] Univ Rhode Isl, Coll Engn, Dept Chem Engn, Kingston, RI 02881 USA.
   [Meenach, Samantha A.] Univ Rhode Isl, Coll Pharm, Dept Biomed & Pharmaceut Sci, Kingston, RI 02881 USA.
RP Meenach, SA (reprint author), Univ Rhode Isl, 205 Crawford Hall,16 Greenhouse Rd, Kingston, RI 02881 USA.
EM smeenach@uri.edu
FU Institutional Development Award (IDeA) from National Institute of
   General Medical Sciences of the National Institutes of Health
   [P20GM103430]; National Science Foundation EPSCoR [EPS-1004057];
   National Science Foundation [1508868]
FX The authors gratefully acknowledge financial support from an
   Institutional Development Award (IDeA) from the National Institute of
   General Medical Sciences of the National Institutes of Health under
   grant number P20GM103430. The content is solely the responsibility of
   the authors and does not necessarily represent the official views of the
   National Institutes of Health. This material is based upon work
   conducted at a Rhode Island NSF EPSCoR research facility, supported in
   part by the National Science Foundation EPSCoR Cooperative Agreement #
   EPS-1004057. In addition, this material is based in part upon work
   supported by the National Science Foundation under grant number #
   1508868. Any opinions, findings, and conclusions or recommendations
   expressed in this material are those of the authors and do not
   necessarily reflect the view of the National Science Foundation.
   Finally, the authors thank RI-INBRE for UPLC access and RIN2 for SEM,
   DLS, PXRD, and DSC access.
CR Atalar I, 2015, LWT-FOOD SCI TECHNOL, V60, P751, DOI 10.1016/j.lwt.2014.10.023
   Bachelder EM, 2008, J AM CHEM SOC, V130, P10494, DOI 10.1021/ja803947s
   Belotti S, 2015, EUR J PHARM BIOPHARM, V93, P165, DOI 10.1016/j.ejpb.2015.03.023
   Bohrey S., 2016, NANOCONVERGENCE, V3, P1, DOI DOI 10.1186/S40580-016-0061-2
   Broaders KE, 2009, P NATL ACAD SCI USA, V106, P5497, DOI 10.1073/pnas.0901592106
   Cohen JA, 2010, ADV MATER, V22, P3593, DOI 10.1002/adma.201000307
   Collier MA, 2016, INT J PHARMACEUT, V499, P186, DOI 10.1016/j.ijpharm.2016.01.004
   Costa P, 2001, EUR J PHARM SCI, V13, P123, DOI 10.1016/S0928-0987(01)00095-1
   Cui LN, 2011, BIOCONJUGATE CHEM, V22, P949, DOI 10.1021/bc100596w
   Finlay Warren, 2008, ARLA RESP DEPOSITION
   Gu B, 2015, INT J PHARMACEUT, V491, P208, DOI 10.1016/j.ijpharm.2015.06.006
   He CB, 2010, BIOMATERIALS, V31, P3657, DOI 10.1016/j.biomaterials.2010.01.065
   Heyder Joachim, 2004, Proc Am Thorac Soc, V1, P315, DOI 10.1513/pats.200409-046TA
   Hickey AJ, 2007, J PHARM SCI-US, V96, P1282, DOI 10.1002/jps.20916
   Hoang KV, 2014, INT J PHARMACEUT, V477, P334, DOI 10.1016/j.ijpharm.2014.10.022
   Jensen DMK, 2010, J CONTROL RELEASE, V142, P138, DOI 10.1016/j.jconrel.2009.10.010
   Kamaly N, 2016, CHEM REV, V116, P2602, DOI 10.1021/acs.chemrev.5b00346
   Kanthamneni N, 2012, INT J PHARMACEUT, V431, P101, DOI 10.1016/j.ijpharm.2012.04.043
   Kauffman KJ, 2012, INT J PHARMACEUT, V422, P356, DOI 10.1016/j.ijpharm.2011.10.034
   Kho K, 2010, POWDER TECHNOL, V203, P432, DOI 10.1016/j.powtec.2010.06.003
   Lai SK, 2009, ADV DRUG DELIVER REV, V61, P158, DOI 10.1016/j.addr.2008.11.002
   Mansour HM, 2009, INT J NANOMED, V4, P299
   Meenach SA, 2013, EUR J PHARM SCI, V49, P699, DOI 10.1016/j.ejps.2013.05.012
   Meenach SA, 2013, INT J NANOMED, V8, P275, DOI 10.2147/IJN.S30724
   Zhang J, 2012, ACTA PHYS-CHIM SIN, V28, P290, DOI [10.1021/mp2003785, 10.3866/PKU.WHXB201112121]
   Mohammadi G, 2010, COLLOID SURFACE B, V80, P34, DOI 10.1016/j.colsurfb.2010.05.027
   Rasband W, 1997, IMAGEJ
   Seidlitz A, 2012, J PHARM PHARMACOL, V64, P969, DOI 10.1111/j.2042-7158.2011.01439.x
   Sung JC, 2009, PHARM RES-DORD, V26, P1847, DOI 10.1007/s11095-009-9894-2
   Takashima Y, 2007, INT J PHARM, V343, P262, DOI 10.1016/j.ijpharm.2007.05.042
   Tomoda K, 2008, COLLOID SURFACE B, V61, P138, DOI 10.1016/j.colsurfb.2007.07.016
   Ulery BD, 2011, J POLYM SCI POL PHYS, V49, P832, DOI 10.1002/polb.22259
   Ungaro F, 2006, EUR J PHARM SCI, V28, P423, DOI 10.1016/j.ejps.2006.05.005
   Vehring R, 2008, PHARM RES, V25, P999, DOI 10.1007/s11095-007-9475-1
   Wang ZM, 2016, INT J PHARMACEUT, V512, P305, DOI 10.1016/j.ijpharm.2016.08.047
   Wang ZM, 2016, PHARM RES-DORDR, V33, P1862, DOI 10.1007/s11095-016-1921-5
   Wu LN, 2014, ASIAN J PHARM SCI, V9, P336, DOI 10.1016/j.ajps.2014.07.006
   Wu X, 2013, INT J NANOMED, V8, P1269, DOI 10.2147/IJN.S40904
NR 38
TC 0
Z9 0
U1 6
U2 14
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
EI 1873-3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD JUN 15
PY 2017
VL 525
IS 1
BP 264
EP 274
DI 10.1016/j.ijpharm.2017.04.052
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA EU5ZD
UT WOS:000401112300027
PM 28450166
DA 2018-03-20
ER

PT J
AU Kim, DY
   Simeone, KA
   Simeone, TA
   Pandya, JD
   Wilke, JC
   Ahn, Y
   Geddes, JW
   Sullivan, PG
   Rho, JM
AF Kim, Doo Young
   Simeone, Kristina A.
   Simeone, Timothy A.
   Pandya, Jignesh D.
   Wilke, Julianne C.
   Ahn, Younghee
   Geddes, James W.
   Sullivan, Patrick G.
   Rho, Jong M.
TI Ketone bodies mediate antiseizure effects through mitochondrial
   permeability transition
SO ANNALS OF NEUROLOGY
LA English
DT Article
ID TRAUMATIC BRAIN-INJURY; K-ATP CHANNELS; KETOGENIC DIET;
   BETA-HYDROXYBUTYRATE; CALORIE RESTRICTION; ALZHEIMERS-DISEASE; BODY
   METABOLISM; NEURONAL DEATH; CYCLOSPORINE-A; CYCLOPHILIN D
AB ObjectiveKetone bodies (KB) are products of fatty acid oxidation and serve as essential fuels during fasting or treatment with the high-fat antiseizure ketogenic diet (KD). Despite growing evidence that KB exert broad neuroprotective effects, their role in seizure control has not been firmly demonstrated. The major goal of this study was to demonstrate the direct antiseizure effects of KB and to identify an underlying target mechanism.
   MethodsWe studied the effects of both the KD and KB in spontaneously epileptic Kcna1-null mice using a combination of behavioral, planar multielectrode, and standard cellular electrophysiological techniques. Thresholds for mitochondrial permeability transition (mPT) were determined in acutely isolated brain mitochondria.
   ResultsKB alone were sufficient to: (1) exert antiseizure effects in Kcna1-null mice, (2) restore intrinsic impairment of hippocampal long-term potentiation and spatial learning-memory defects in Kcna1-null mutants, and (3) raise the threshold for calcium-induced mPT in acutely prepared mitochondria from hippocampi of Kcna1-null animals. Targeted deletion of the cyclophilin D subunit of the mPT complex abrogated the effects of KB on mPT, and in vivo pharmacological inhibition and activation of mPT were found to mirror and reverse, respectively, the antiseizure effects of the KD in Kcna1-null mice.
   InterpretationThe present data reveal the first direct link between mPT and seizure control, and provide a potential mechanistic explanation for the KD. Given that mPT is increasingly being implicated in diverse neurological disorders, our results suggest that metabolism-based treatments and/or metabolic substrates might represent a worthy paradigm for therapeutic development. Ann Neurol 2015;78:77-87
C1 [Kim, Do Young; Wilke, Julianne C.] St Josephs Hosp, Barrow Neurol Inst, Phoenix, AZ USA.
   [Simeone, Kristina A.; Simeone, Timothy A.] Creighton Univ, Sch Med, Dept Pharmacol, Omaha, NE 68178 USA.
   [Pandya, Jignesh D.; Geddes, James W.; Sullivan, Patrick G.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY USA.
   [Ahn, Younghee; Rho, Jong M.] Univ Calgary, Fac Med, Alberta Childrens Hosp, Res Inst Child & Maternal Hlth,Dept Pediat, Calgary, AB T3B 6A8, Canada.
   [Ahn, Younghee; Rho, Jong M.] Univ Calgary, Fac Med, Alberta Childrens Hosp, Res Inst Child & Maternal Hlth,Dept Clin Neurosci, Calgary, AB T3B 6A8, Canada.
RP Rho, JM (reprint author), Univ Calgary, Cumming Sch Med, Alberta Childrens Hosp, Dept Paediat, 2888 Shaganappi Trail NW, Calgary, AB T3B 6A8, Canada.
EM jong.rho@albertahealthservices.ca
OI Simeone, Timothy/0000-0002-8716-7211
FU NIH National Institute of Neurological Disorders and Stroke [RO1
   NS070261, RO1 NS048191, RO1 NS062993, P30 NS051220, RO1 NS072179];
   Kentucky Spinal Cord and Head Injury Research Trust; Nebraska LB 692
   Grant; Health Future Foundation Award; Barrow Neurological Foundation,
   Phoenix, Arizona; Canadian Institutes of Health Research; Alberta
   Children's Hospital Research Institute for Child and Maternal Health
FX This work was supported by the NIH National Institute of Neurological
   Disorders and Stroke (RO1 NS070261, J.M.R., D.Y.K.; RO1 NS048191,
   P.G.S.; RO1 NS062993, P30 NS051220, J.W.G., P.G.S.; RO1 NS072179,
   K.A.S.); Kentucky Spinal Cord and Head Injury Research Trust (J.W.G.,
   P.G.S.); Nebraska LB 692 Grant (K.A.S.); Health Future Foundation Award
   (T.A.S.); Barrow Neurological Foundation, Phoenix, Arizona (J.M.R.,
   D.Y.K.); Canadian Institutes of Health Research (J.M.R.); and Alberta
   Children's Hospital Research Institute for Child and Maternal Health
   (J.M.R.).
CR Bannai H, 2009, NEURON, V62, P670, DOI 10.1016/j.neuron.2009.04.023
   BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579
   Barrientos SA, 2011, J NEUROSCI, V31, P966, DOI 10.1523/JNEUROSCI.4065-10.2011
   Bowser DN, 2002, FASEB J, V16, P1105, DOI 10.1096/fj.01-0828fje
   Brenner C, 2012, CIRC RES, V111, P1237, DOI 10.1161/CIRCRESAHA.112.265942
   Brown MR, 2004, J BIOENERG BIOMEMBR, V36, P401, DOI 10.1023/B:JOBB.0000041775.10388.23
   Chen D, 2005, SCIENCE, V310, P1641, DOI 10.1126/science.1118357
   Cock HR, 2002, EPILEPSY RES, V48, P157, DOI 10.1016/S0920-1211(01)00334-5
   Davis LM, 2008, J NEUROSCI RES, V86, P1812, DOI 10.1002/jnr.21628
   Kim do Y., 2007, J NEUROCHEM, V101, P1316
   Kim do Y., 2008, CURR OPIN CLIN NUTR, V11, P113
   Kim do Y., 2010, J NEUROCHEM, V114, P130
   Du H, 2008, NAT MED, V14, P1097, DOI 10.1038/nm.1868
   Du H, 2010, BBA-MOL BASIS DIS, V1802, P198, DOI 10.1016/j.bbadis.2009.07.005
   Duchen MR, 2012, PFLUG ARCH EUR J PHY, V464, P111, DOI 10.1007/s00424-012-1112-0
   EDMOND J, 1985, FED PROC, V44, P2359
   Elrod JW, 2013, CIRC J, V77, P1111, DOI 10.1253/circj.CJ-13-0321
   Fenoglio-Simeone KA, 2009, EPILEPSIA, V50, P2027, DOI 10.1111/j.1528-1167.2009.02163.x
   Garriga-Canut M, 2006, NAT NEUROSCI, V9, P1382, DOI 10.1038/nn1791
   Giorgio V, 2013, P NATL ACAD SCI USA, V110, P5887, DOI 10.1073/pnas.1217823110
   Halagappa VKM, 2007, NEUROBIOL DIS, V26, P212, DOI 10.1016/j.nbd.2006.12.019
   HASSELBALCH SG, 1995, AM J PHYSIOL-ENDOC M, V268, pE1161
   Jiang DM, 2001, J BIOL CHEM, V276, P47524, DOI 10.1074/jbc.M108834200
   Juge N, 2010, NEURON, V68, P99, DOI 10.1016/j.neuron.2010.09.002
   Jung S, 2012, NEUROSCI LETT, V529, P133, DOI 10.1016/j.neulet.2012.08.087
   Kashiwaya Y, 2000, P NATL ACAD SCI USA, V97, P5440, DOI 10.1073/pnas.97.10.5440
   Kawamura M, 2010, J NEUROSCI, V30, P3886, DOI 10.1523/JNEUROSCI.0055-10.2010
   Korde AS, 2007, J NEUROTRAUM, V24, P895, DOI 10.1089/neu.2006.0122
   Kossoff EH, 2009, NEUROTHERAPEUTICS, V6, P406, DOI 10.1016/j.nurt.2009.01.005
   Kovac S, 2012, J CELL SCI, V125, P1796, DOI 10.1242/jcs.099176
   Liu ZG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077131
   Lutas A, 2013, TRENDS NEUROSCI, V36, P32, DOI 10.1016/j.tins.2012.11.005
   Ma WY, 2007, J NEUROSCI, V27, P3618, DOI 10.1523/JNEUROSCI.0132-07.2007
   Maalouf M, 2007, NEUROSCIENCE, V145, P256, DOI 10.1016/j.neuroscience.2006.11.065
   Maalouf M, 2009, BRAIN RES REV, V59, P293, DOI 10.1016/j.brainresrev.2008.09.002
   MALAISSE WJ, 1990, AM J PHYSIOL, V259, pE123
   Masino S. A., 2012, JASPERS BASIC MECH E, P1001
   Morris AAM, 2005, J INHERIT METAB DIS, V28, P109, DOI 10.1007/s10545-005-5518-0
   Neal EG, 2008, LANCET NEUROL, V7, P500, DOI 10.1016/S1474-4422(08)70092-9
   Readnower RD, 2011, J NEUROTRAUM, V28, P1845, DOI 10.1089/neu.2011.1755
   Shimazu T, 2013, SCIENCE, V339, P211, DOI 10.1126/science.1227166
   Simeone TA, 2013, NEUROBIOL DIS, V54, P68, DOI 10.1016/j.nbd.2013.02.009
   Srivastava S, 2012, FASEB J, V26, P2351, DOI 10.1096/fj.11-200410
   Stafstrom CE, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00059
   Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292
   Swope SL, 1999, ADV SEC MESS PHOSPH, V33, P49
   SZABO I, 1991, J BIOL CHEM, V266, P3376
   Uchino Hiroyuki, 2013, Acta Neurochir Suppl, V118, P311, DOI 10.1007/978-3-7091-1434-6_61
   Waldbaum S, 2010, J NEUROCHEM, V115, P1172, DOI 10.1111/j.1471-4159.2010.07013.x
   Waldmeier PC, 2002, MOL PHARMACOL, V62, P22, DOI 10.1124/mol.62.1.22
   Wenzel HJ, 2007, EPILEPSIA, V48, P2023, DOI 10.1111/j.1528-1167.2007.01189.x
   Youm YH, 2015, NAT MED, V21, P263, DOI 10.1038/nm.3804
NR 52
TC 29
Z9 30
U1 3
U2 16
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0364-5134
EI 1531-8249
J9 ANN NEUROL
JI Ann. Neurol.
PD JUL
PY 2015
VL 78
IS 1
BP 77
EP 87
DI 10.1002/ana.24424
PG 11
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA CL3AQ
UT WOS:000356821200008
PM 25899847
OA green_accepted
DA 2018-03-20
ER

PT J
AU Scott, DF
   Hamorsky, KT
   Ensor, CM
   Anderson, KW
   Daunert, S
AF Scott, Daniel F.
   Hamorsky, Krystal Teasley
   Ensor, C. Mark
   Anderson, Kimberly W.
   Daunert, Sylvia
TI ANYL 124-Reagentless, intracellular cAMP monitoring of intact cells via
   a bioluminescent molecular switch
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
C1 [Scott, Daniel F.; Hamorsky, Krystal Teasley; Ensor, C. Mark; Daunert, Sylvia] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
   [Anderson, Kimberly W.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM daniel.scott@uky.edu; krystal.teasley@uky.edu; kanderson@engr.uky.edu;
   daunert@uky.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD AUG 16
PY 2009
VL 238
MA 124-ANYL
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA V16HY
UT WOS:000207861901264
DA 2018-03-19
ER

PT J
AU Hinds, BJ
AF Hinds, Bruce J.
TI POLY 311-Aligned carbon nanotube membranes as biomimetic platforms
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
C1 [Hinds, Bruce J.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM bjhinds@engr.uky.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD AUG 19
PY 2007
VL 234
MA 311-POLY
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA V12IW
UT WOS:000207593908518
DA 2018-03-20
ER

PT J
AU Reichel, D
   Rychahou, P
   Bae, Y
AF Reichel, Derek A.
   Rychahou, Piotr G.
   Bae, Younsoo
TI Polymer nanoassemblies with solvato-and halo-fluorochromism for drug
   release monitoring and metastasis imaging
SO THERAPEUTIC DELIVERY
LA English
DT Article
AB Background: Theranostics, an emerging technique that combines therapeutic and diagnostic modalities for various diseases, holds promise to detect cancer in early stages, eradicate metastatic tumors and ultimately reduce cancer mortality. Methods & results: This study reports unique polymer nanoassemblies that increase fluorescence intensity upon addition of hydrophobic drugs and either increase or decrease fluorescence intensity in acidic environments, depending on nanoparticle core environment properties. Extensive spectroscopic analyses were performed to determine optimal excitation and emission wavelengths, which enabled real time measurement of drugs releasing from the nanoassemblies and ex vivo imaging of acidic liver metastatic tumors from mice. Conclusion: Polymer nanoassemblies with solvato-and halo-fluorochromic properties are promising platforms to develop novel theranostic tools for the detection and treatment of metastatic tumors.
C1 [Reichel, Derek; Bae, Younsoo] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, 789 South Limestone, Lexington, KY 40536 USA.
   [Rychahou, Piotr] Univ Kentucky, Markey Canc Ctr, Lexington, KY 40536 USA.
   [Rychahou, Piotr] Univ Kentucky, Coll Med, Dept Surg, Lexington, KY 40536 USA.
RP Bae, Y (reprint author), Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, 789 South Limestone, Lexington, KY 40536 USA.
EM younsoo.bae@uky.edu
CR Alsina M, 2012, CLIN CANCER RES, V18, P4830, DOI 10.1158/1078-0432.CCR-11-3007
   Baker AF, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0111-8
   Barar J, 2013, BIOIMPACTS, V3, P149, DOI 10.5681/bi.2013.036
   Boens N, 2012, CHEM SOC REV, V41, P1130, DOI 10.1039/c1cs15132k
   Bravo-Cordero JJ, 2012, CURR OPIN CELL BIOL, V24, P277, DOI 10.1016/j.ceb.2011.12.004
   Carloni V, 2013, ONCOGENE, V32, P2649, DOI 10.1038/onc.2012.268
   Chen F, 2014, MOL PHARMACEUT, V11, P4007, DOI 10.1021/mp500306k
   Cheng L, 2012, ACS NANO, V6, P5605, DOI 10.1021/nn301539m
   Estrella V, 2013, CANCER RES, V73, P1524, DOI 10.1158/0008-5472.CAN-12-2796
   Ferber S, 2014, CANCER LETT, V352, P81, DOI 10.1016/j.canlet.2014.02.022
   Goetz M, 2013, ENDOSCOPY, V45, P469, DOI 10.1055/s-0032-1326361
   Gotta V, 2014, CANCER CHEMOTH PHARM, V74, P1307, DOI 10.1007/s00280-014-2599-1
   Haeno H, 2012, CELL, V148, P362, DOI 10.1016/j.cell.2011.11.060
   Hill TK, 2015, BIOCONJUGATE CHEM, V26, P294, DOI 10.1021/bc5005679
   Hu H, 2014, BIOMATERIALS, V35, P9868, DOI 10.1016/j.biomaterials.2014.08.038
   Jose J, 2006, TETRAHEDRON, V62, P11021, DOI 10.1016/j.tet.2006.08.056
   Jose J, 2009, CHEM-EUR J, V15, P418, DOI 10.1002/chem.200801104
   Junttila MR, 2013, NATURE, V501, P346, DOI 10.1038/nature12626
   Justus CR, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00354
   Kato Y, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-89
   Key J, 2014, INT J NANOMED, V9, P711, DOI 10.2147/IJN.S53717
   Lai JP, 2013, ACS NANO, V7, P2741, DOI 10.1021/nn400199t
   Lee HJ, 2013, PHARM RES-DORDR, V30, P2077, DOI 10.1007/s11095-013-1060-1
   Li D, 2014, CANCER BIOL MED, V11, P217, DOI 10.7497/j.issn.2095-3941.2014.04.001
   Liu JS, 2014, J LUMIN, V147, P155, DOI 10.1016/j.jlumin.2013.11.015
   Liu YJ, 2014, NANOSCALE, V6, P3231, DOI 10.1039/c3nr05647c
   Maawy AA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097965
   Maeda H, ADV DRUG DEL REV, V65, P71
   Maeda H, 2012, P JPN ACAD B-PHYS, V88, P53, DOI 10.2183/pjab.88.53
   Marini A, 2010, J PHYS CHEM B, V114, P17128, DOI 10.1021/jp1097487
   Mehta A, 2015, ENDOCR-RELAT CANCER, V22, P319, DOI 10.1530/ERC-14-0510
   Modi S, MOL PHARM, V10, P3076
   Moore T, 2014, MOL PHARMACEUT, V11, P24, DOI 10.1021/mp400419k
   Pivot X, 2011, EUR J CANCER, V47, P2387, DOI 10.1016/j.ejca.2011.06.018
   Ponta A, 2014, PHARM RES
   Ponta A, 2010, PHARM RES-DORDR, V27, P2330, DOI 10.1007/s11095-010-0120-z
   Reiner CS, 2014, EUR J NUCL MED MOL I, V41, P649, DOI 10.1007/s00259-013-2654-x
   Sanli S, 2014, J CHEM ENG DATA, V59, P4015, DOI 10.1021/je500595w
   Sarnat HB, 2015, CELL TISSUE RES, V359, P279, DOI 10.1007/s00441-014-1988-4
   Schroeder A, 2012, NAT REV CANCER, V12, P39, DOI 10.1038/nrc3180
   Shelley MD, 2011, BJU INT, V108, P168, DOI 10.1111/j.1464-410X.2011.10341.x
   Steichen SD, 2013, EUR J PHARM SCI, V48, P416, DOI 10.1016/j.ejps.2012.12.006
   Svenson S, 2013, MOL PHARMACEUT, V10, P848, DOI 10.1021/mp300644n
   Thapa U, 2013, J COLLOID INTERF SCI, V406, P172, DOI 10.1016/j.jcis.2013.06.009
   Uchida Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050678
   Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024
   Wang J, 2014, J MATER CHEM B, V2, P4379, DOI 10.1039/c4tb00221k
   Wang ZP, 2013, DRUG METAB DISPOS, V41, P230, DOI 10.1124/dmd.112.047662
   Xing MZ, 2014, J SURG ONCOL, V110, P182, DOI 10.1002/jso.23619
   Yao ZY, 2013, ACS APPL MATER INTER, V5, P5783, DOI 10.1021/am401761n
   Zhou J, 2013, J MATER CHEM B, V1, P661, DOI 10.1039/c2tb00179a
   Zou P, 2013, MOL PHARMACEUT, V10, P4185, DOI 10.1021/mp4002393
NR 52
TC 3
Z9 3
U1 0
U2 0
PU FUTURE SCI LTD
PI LONDON
PA UNITED HOUSE, 2 ALBERT PL, LONDON, N3 1QB, ENGLAND
SN 2041-5990
EI 2041-6008
J9 THER DELIV
JI Ther. Deliv.
PD OCT
PY 2015
VL 6
IS 10
BP 1221
EP 1237
DI 10.4155/tde.15.59
PG 17
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA V3G1V
UT WOS:000218226200010
PM 26446432
OA green_published
DA 2018-03-19
ER

PT J
AU Sun, XH
   Su, X
   Wu, J
   Hinds, BJ
AF Sun, Xinghua
   Su, Xin
   Wu, Ji
   Hinds, Bruce J.
TI Electrophoretic Transport of Biomolecules through Carbon Nanotube
   Membranes
SO LANGMUIR
LA English
DT Article
ID NANOPOROUS MEMBRANES; PROTEIN-TRANSPORT; MASS-TRANSPORT; NET CHARGE;
   SEPARATION; LYSOZYME; MOLECULES; FLOW; DIFFUSION; MOBILITY
AB Electrophoretic transport of proteins cross electrochemically oxidized multi-walled carbon nanotube (MWCNT) membranes has been investigated. A small charged protein, lysozyme, was successfully pumped MWCNT membranes by an electric field while rejecting larger of lysozome was reduced by a factor of about 30 in comparison to bulk mobility and consistent with the production for hindered transport. Mobilities between 0.33 and 1.4 x 10(-9) m(2) V(-1) s(-1) were observed and are approximately 10-fold faster than comparable ordered nanoporous membranes and consistent with continuum models. For mixtures of BSA and lysozyme, complete rejection of BSA is seen with electrophoretic separations.
C1 [Sun, Xinghua; Su, Xin; Wu, Ji; Hinds, Bruce J.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Hinds, BJ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM bjhinds@engr.uky.edu
RI WU, JI/F-6379-2013; Su, Xin/M-1162-2013; WU, JI/F-6371-2013; WU,
   JI/J-4580-2016
OI Su, Xin/0000-0002-1615-2856; 
FU National Science Foundation (NSF) [0348544]; Department of Energy (DOE)
   [DE-FG02-07ER46375]; National Institute on Drug Abuse (NIDA), National
   Institutes of Health (NIH) [R01DA018822]
FX We thank Dali Qian and Rodney Andrews from the Center for Applied
   Energy, University of Kentucky, for supplying MWCNTs and Xin Zhan for
   the synthesis of 4-sulfobenzene diazonium tetrafloroborate. Facility
   support was provided by the Center for Nanoscale Science and Engineering
   and Electron Microscopy Center at the University of Kentucky. Financial
   support was provided from the National Science Foundation (NSF) Faculty
   Early Career Development (CAREER) (0348544), Department of Energy (DOE)
   Experimental Program to Stimulate Competitive Research (EPSCoR)
   (DE-FG02-07ER46375), and National Institute on Drug Abuse (NIDA),
   National Institutes of Health (NIH) (R01DA018822).
CR Andrews R, 1999, CHEM PHYS LETT, V303, P467, DOI 10.1016/S0009-2614(99)00282-1
   Baker LA, 2005, CRIT REV SOLID STATE, V30, P183, DOI 10.1080/10408430500198169
   Bonincontro A, 1998, COLLOID SURFACE B, V12, P1, DOI 10.1016/S0927-7765(98)00048-4
   Bostrom M, 2003, BIOPHYS J, V85, P686, DOI 10.1016/S0006-3495(03)74512-3
   Chun KY, 2002, LANGMUIR, V18, P4653, DOI 10.1021/la011250b
   DEEN WM, 1987, AICHE J, V33, P1409, DOI 10.1002/aic.690330902
   Firnkes M, 2010, NANO LETT, V10, P2162, DOI 10.1021/nl100861c
   Fissell WH, 2009, J MEMBRANE SCI, V326, P58, DOI 10.1016/j.memsci.2008.09.039
   Fu JP, 2008, TRENDS BIOTECHNOL, V26, P311, DOI 10.1016/j.tibtech.2008.02.009
   Ghosh R, 2002, J CHROMATOGR A, V952, P13, DOI 10.1016/S0021-9673(02)00057-2
   Hinds BJ, 2004, SCIENCE, V303, P62, DOI 10.1126/science.1092048
   Ho AK, 1999, AICHE J, V45, P1434, DOI 10.1002/aic.690450708
   Holt JK, 2006, SCIENCE, V312, P1034, DOI 10.1126/science.1126298
   Howorka S, 2009, CHEM SOC REV, V38, P2360, DOI 10.1039/b813796j
   Ismail AF, 2001, J MEMBRANE SCI, V193, P1, DOI 10.1016/S0376-7388(01)00510-5
   Ito T, 2003, ELECTROCHEM SOLID ST, V6, pC4, DOI 10.1149/1.1526779
   Kang Y, 2009, BIOMATERIALS, V30, P2807, DOI 10.1016/j.biomaterials.2009.01.024
   Keh HJ, 1996, AICHE J, V42, P1397, DOI 10.1002/aic.690420520
   KEH HJ, 1985, J FLUID MECH, V153, P417, DOI 10.1017/S002211208500132X
   Kim S, 2007, NANO LETT, V7, P2806, DOI 10.1021/nl071414u
   Ku JR, 2004, LANGMUIR, V20, P2030, DOI 10.1021/la0357662
   Kuehner DE, 1999, J PHYS CHEM B, V103, P1368, DOI 10.1021/jp983852i
   Liu B, 2009, NANO LETT, V9, P1386, DOI 10.1021/nl8030339
   Liu HT, 2010, SCIENCE, V327, P64, DOI 10.1126/science.1181799
   Ma CB, 2010, ANAL CHEM, V82, P478, DOI 10.1021/ac902487c
   Majumder M, 2005, NATURE, V438, P44, DOI 10.1038/43844a
   Majumder M, 2005, J AM CHEM SOC, V127, P9062, DOI 10.1021/ja043013b
   Majumder M, 2007, LANGMUIR, V23, P8624, DOI 10.1021/la700686k
   Martin CR, 2003, NAT REV DRUG DISCOV, V2, P29, DOI 10.1038/nrd988
   Mi WL, 2007, J MEMBRANE SCI, V304, P1, DOI 10.1016/j.memsci.2007.07.021
   Miller SA, 2001, J AM CHEM SOC, V123, P12335, DOI 10.1021/ja011926p
   Nednoor P, 2007, J MATER CHEM, V17, P1755, DOI 10.1039/b703365f
   Nepal D, 2007, SMALL, V3, P1259, DOI 10.1002/smll.200600511
   Osmanbeyoglu HU, 2009, J MEMBRANE SCI, V343, P1, DOI 10.1016/j.memsci.2009.07.027
   Shah TN, 2007, J MEMBRANE SCI, V295, P40, DOI 10.1016/j.memsci.2007.02.030
   Shugai AA, 1999, J COLLOID INTERF SCI, V213, P298, DOI 10.1006/jcis.1999.6143
   SRINIVASAN V, 1990, INT J PHARM, V60, P133, DOI 10.1016/0378-5173(90)90298-I
   Stewart MP, 2004, J AM CHEM SOC, V126, P370, DOI 10.1021/ja0383120
   Striemer CC, 2007, NATURE, V445, P749, DOI 10.1038/nature05532
   Sun L, 2000, J AM CHEM SOC, V122, P12340, DOI 10.1021/ja002429w
   Sun XH, 2009, J MEMBRANE SCI, V344, P165, DOI 10.1016/j.memsci.2009.07.049
   Szymanski J, 2007, J PHYS CHEM B, V111, P5503, DOI 10.1021/jp067511d
   Wang L, 2010, ANAL CHEM, V82, P452, DOI 10.1021/ac902117f
   Williams S, 2004, J CHROMATOGR A, V1052, P1, DOI 10.1016/j.chroma.2004.07.110
   Wu J, 2010, P NATL ACAD SCI USA, V107, P11698, DOI 10.1073/pnas.1004714107
   Xie YH, 2007, J CHEM PHYS, V127, DOI 10.1063/1.2799989
   Yang WR, 2007, NANOTECHNOLOGY, V18, DOI 10.1088/0957-4484/18/41/412001
   Yu M, 2009, NANO LETT, V9, P225, DOI 10.1021/nl802816h
   Yu SF, 2003, ANAL CHEM, V75, P1239, DOI 10.1021/ac020711a
   Zhang SL, 2009, BIOTECHNOL PROGR, V25, P1379, DOI 10.1002/btpr.243
   Zydney AL, 2009, BIOTECHNOL BIOENG, V103, P227, DOI 10.1002/bit.22308
NR 51
TC 23
Z9 23
U1 0
U2 36
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0743-7463
J9 LANGMUIR
JI Langmuir
PD MAR 15
PY 2011
VL 27
IS 6
BP 3150
EP 3156
DI 10.1021/la104242p
PG 7
WC Chemistry, Multidisciplinary; Chemistry, Physical; Materials Science,
   Multidisciplinary
SC Chemistry; Materials Science
GA 730NE
UT WOS:000288039500142
PM 21338104
OA green_accepted
DA 2018-03-20
ER

PT J
AU Majumder, M
   Stinchcomb, A
   Hinds, BJ
AF Majumder, Mainak
   Stinchcomb, Audra L.
   Hinds, Bruce J.
TI Towards mimicking natural protein channels with aligned carbon nanotube
   membranes for active drug delivery
SO LIFE SCIENCES
LA English
DT Review
DE Drug delivery; Biomimetic; Nanostructure; Gatekeeper; Membrane;
   Transdermal; Nanoporous
ID WATER; TRANSPORT; POLYSTYRENE; GROWTH; FLOW
AB Aims: Carbon nanotube (CNT) membranes offer an exciting opportunity to mimic natural protein channels due to 1) a mechanism of dramatically enhanced fluid flow 2) ability to place 'gatekeeper' chemistry at the entrance to pores 3) the ability for biochemical reactions to occur on gatekeeper molecules and 4) an ability to chemically functionalize each side of the membrane independently.
   Main methods: Aligned CNT membranes were fabricated and CNT pore entrances modified with gatekeeper chemistry. Pressure driven fluid flow and diffusion experiments were performed to study the mechanisms of transport through CNTs.
   Key findings: The transport mechanism through CNT membranes is primarily 1) ionic diffusion near bulk expectation 2) gas flow enhanced 1-2 orders of magnitude primarily due to specular reflection 3) fluid flow 4-5 orders of magnitude faster than conventional materials due to a nearly ideal slip-boundary interface. The transport can be modulated by 'gatekeeper' chemistry at the pore entrance using steric hindrance, electrostatic attraction/repulsion, or biochemical state. The conformation of charged tethered molecules can be modulated by applied bias setting the stage for programmable drug release devices.
   Significance: The membrane structure is mechanically far more robust than lipid bilayer films, allowing for large-scale chemical separations, delivery or sensing based on the principles of protein channels. The performance of protein channels is several orders of magnitude faster than conventional membrane materials. The fundamental requirements of mimicking protein channels are present in the CNT membrane system. Crown Copyright (C) 2009 Published by Elsevier Inc. All rights reserved.
C1 [Majumder, Mainak; Hinds, Bruce J.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40502 USA.
   [Stinchcomb, Audra] Univ Kentucky, Coll Pharm, Lexington, KY 40502 USA.
RP Hinds, BJ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40502 USA.
EM bjhinds@engr.uky.edu
RI Majumder, Mainak/B-4667-2011
FU NSF CAREER [0348544]; NIH NIDA [R01DA018822]
FX The authors are grateful to Rodney Andrews and Dali Qian of the Center
   for Applied Energy Research (UKy) for providing aligned CNT mattes.
   Critical infrastructure was provided by the UKy Center for Nanoscale
   Science and Engineering. Gracious financial support was provided by NSF
   CAREER (0348544) and NIH NIDA (R01DA018822).
CR Andrews R, 1999, CHEM PHYS LETT, V303, P467, DOI 10.1016/S0009-2614(99)00282-1
   Bahr JL, 2001, CHEM MATER, V13, P3823, DOI 10.1021/cm0109903
   Chopra N, 2005, ADV FUNCT MATER, V15, P858, DOI 10.1002/adfm.200400399
   Hille B., 1984, IONIC CHANNELS EXCIT
   Hinds BJ, 2004, SCIENCE, V303, P62, DOI 10.1126/science.1092048
   Holt JK, 2006, SCIENCE, V312, P1034, DOI 10.1126/science.1126298
   Huang SM, 2002, J PHYS CHEM B, V106, P3543, DOI 10.1021/jp014047y
   Hummer G, 2001, NATURE, V414, P188, DOI 10.1038/35102535
   Jirage KB, 1997, SCIENCE, V278, P655, DOI 10.1126/science.278.5338.655
   Joseph S, 2008, NANO LETT, V8, P452, DOI 10.1021/nl072385q
   Lauga Eric, 2005, HDB EXPT FLUID DYNAM
   Lee SB, 2002, SCIENCE, V296, P2198, DOI 10.1126/science.1071396
   Majumder M, 2005, NATURE, V438, P44, DOI 10.1038/43844a
   Majumder M, 2005, J AM CHEM SOC, V127, P9062, DOI 10.1021/ja043013b
   Majumder M, 2008, J MEMBRANE SCI, V316, P89, DOI 10.1016/j.memsci.2007.09.068
   Majumder M, 2007, LANGMUIR, V23, P8624, DOI 10.1021/la700686k
   Mao ZG, 2001, J PHYS CHEM B, V105, P6916, DOI 10.1021/jp0103272
   Merkulov VI, 2002, APPL PHYS LETT, V80, P4816, DOI 10.1063/1.1487920
   Mitchell CA, 2002, MACROMOLECULES, V35, P8825, DOI 10.1021/ma020890y
   Mulder M, 1994, BASIC PRINCIPLES MEM
   Murata K, 2000, NATURE, V407, P599
   Nednoor P, 2005, CHEM MATER, V17, P3595, DOI 10.1021/cm047844s
   Nednoor P, 2007, J MATER CHEM, V17, P1755, DOI 10.1039/b703365f
   Ohba T, 2005, NANO LETT, V5, P227, DOI 10.1021/nl048327b
   Qian D, 2000, APPL PHYS LETT, V76, P2868, DOI 10.1063/1.126500
   Ren ZF, 1998, SCIENCE, V282, P1105, DOI 10.1126/science.282.5391.1105
   Sinnott SB, 1999, CHEM PHYS LETT, V315, P25, DOI 10.1016/S0009-2614(99)01216-6
   SKOULIDAS AI, 2002, PHYS REV LETT, V89
   Sokhan VP, 2002, J CHEM PHYS, V117, P8531, DOI 10.1063/1.1512643
   Steinle ED, 2002, ANAL CHEM, V74, P2416, DOI 10.1021/ac020024j
   Wong SS, 1998, J AM CHEM SOC, V120, P8557, DOI 10.1021/ja9817803
   Zhang ZJ, 2000, APPL PHYS LETT, V77, P3764, DOI 10.1063/1.1330751
NR 32
TC 20
Z9 21
U1 3
U2 37
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
J9 LIFE SCI
JI Life Sci.
PD APR 10
PY 2010
VL 86
IS 15-16
BP 563
EP 568
DI 10.1016/j.lfs.2009.04.006
PG 6
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 581UY
UT WOS:000276551500002
PM 19383500
OA green_accepted
DA 2018-03-20
ER

PT J
AU Acosta, MF
   Muralidharan, P
   Meenach, SA
   Hayes, D
   Black, SM
   Mansour, HM
AF Acosta, Maria F.
   Muralidharan, Priya
   Meenach, Samantha A.
   Hayes, Don, Jr.
   Black, Stephen M.
   Mansour, Heidi M.
TI In Vitro Pulmonary Cell Culture in Pharmaceutical Inhalation Aerosol
   Delivery: 2-D, 3-D, and In Situ Bioimpactor Models
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Article
DE Pulmonary delivery; aerosol deposition; lung cell culture; air-liquid
   interface (ALI) culture; liquid covered culture (LCC); multistage
   cascade impactors; two-dimensional culture; three-dimensional culture
ID BRONCHIAL EPITHELIAL-CELLS; AIR-LIQUID INTERFACE; DRUG-DELIVERY;
   RESPIRATORY-TRACT; PHYSICOCHEMICAL CHARACTERIZATION; LUNG; DEPOSITION;
   TRANSPORT; PARTICLES; BARRIER
AB Background: The use of non-invasive inhaled aerosols for pulmonary drug delivery continues to grow. This is due to the many unique advantages this delivery route offers for the treatment of both local and systemic diseases. The physicochemical properties of the formulated drugs as well as the physiology of the lungs play a key role in both the deposition and absorption of the particles. The airway and the alveolar epithelium are targets for the treatment of respiratory diseases. However, particles have to overcome biological barriers before they reach their target and produce an effect. Methods: In vitro aerosol dispersion performance (i.e. aerodynamic size and aerodynamic size distribution) of inhalable particles is quantified by inertial impaction, as required by regulatory agencies for an investigational pharmaceutical inhalation aerosol formulation to be approved for use in patients as a marketed pharmaceutical product. Using inertial impaction in conjunction with cell cultures of various pulmonary cells in situ as bioimpactors has unique aspects in correlating aerodynamic properties with pulmonary cellular behavior including viability and uptake. These can be as co-culture or in single culture, as 3-D multicellular spheroids or 2-D cellular monolayer using different conditions to grow them, such as air-liquid interface culture (ALI) or in liquid covered culture (LCC). Results: evaluation of the currently available in vitro models and the challenges in developing reliable cellular tools to predict the deposition of inhalable particles in the lungs as a function of aerodynamic particle properties is presented in the manuscript. Conclusion: The mechanistic aerodynamic and biophysical properties of inhaled aerosol particles on the entire respiratory tract at the cellular level based on aerodynamic size and aerodynamic size distribution will be better understood with the development of in vitro methods which are described in this work.
C1 [Acosta, Maria F.; Muralidharan, Priya; Mansour, Heidi M.] Univ Arizona, Coll Pharm, Skaggs Pharmaceut Sci Ctr, 1703 USA E Mabel St, Tucson, AZ 85721 USA.
   [Meenach, Samantha A.] Univ Rhode Isl, Dept Chem Engn, Kingston, RI 02881 USA.
   [Meenach, Samantha A.] Univ Rhode Isl, Dept Biomed & Pharmaceut Sci, Kingston, RI 02881 USA.
   [Hayes, Don, Jr.] Ohio State Univ, Coll Med, Dept Pediat, Lung Transplant Program, Columbus, OH 43205 USA.
   [Hayes, Don, Jr.] Ohio State Univ, Coll Med, Dept Pediat, Heart Lung Transplant Program, Columbus, OH 43205 USA.
   [Hayes, Don, Jr.] Ohio State Univ, Coll Med, Dept Internal Med, Lung Transplant Program, Columbus, OH 43205 USA.
   [Hayes, Don, Jr.] Ohio State Univ, Coll Med, Dept Internal Med, Heart Lung Transplant Program, Columbus, OH 43205 USA.
   [Hayes, Don, Jr.] Ohio State Univ, Coll Med, Davis Heart & Lung Res Inst, Columbus, OH 43205 USA.
   [Black, Stephen M.; Mansour, Heidi M.] Univ Arizona, Div Translat & Regenerat Med, Dept Med, Tucson, AZ 85724 USA.
   [Mansour, Heidi M.] Univ Arizona, Inst Environm, Tucson, AZ 85721 USA.
   [Mansour, Heidi M.] Univ Arizona, Ctr Comprehens Canc, Natl Canc Inst, Tucson, AZ 85721 USA.
   [Mansour, Heidi M.] Univ Arizona, Res Inst BIO5, Tucson, AZ 85721 USA.
RP Mansour, HM (reprint author), Univ Arizona, Coll Pharm, Skaggs Pharmaceut Sci Ctr, 1703 USA E Mabel St, Tucson, AZ 85721 USA.
EM mansour@pharmacy.arizona.edu
FU CONACyT (National Council of Science and Technology of Mexico); NIH
   NIAID; Cureveda grant
FX The authors gratefully acknowledge the CONACyT (National Council of
   Science and Technology of Mexico) Fellowship awarded to Maria F. Acosta.
   Partial support from NIH NIAID & Cureveda grants awarded to HMM are
   gratefully acknowledged. The authors thank Dr. Aikseng Ooi, Dr. Todd
   Camenisch, and Dr. Donna Zhang for access to inverted microscopes with
   digital camera acquisition.
CR Alfaro-Moreno E, 2008, EUR RESPIR J, V32, P1184, DOI 10.1183/09031936.00044008
   Bandara HMHN, 2015, BIOFOULING, V31, P443, DOI 10.1080/08927014.2015.1055326
   Bur M, 2010, J AEROSOL MED PULM D, V23, P119, DOI 10.1089/jamp.2009.0757
   Bur M, 2009, EUR J PHARM BIOPHARM, V72, P350, DOI 10.1016/j.ejpb.2008.07.019
   Cheng YS, 2014, AAPS PHARMSCITECH, V15, P630, DOI 10.1208/s12249-014-0092-0
   Cooney D, 2004, ATLA-ALTERN LAB ANIM, V32, P581
   Cooney DJ, 2011, TOXICOL IN VITRO, V25, P1953, DOI 10.1016/j.tiv.2011.06.019
   COZENS AL, 1994, AM J RESP CELL MOL, V10, P38, DOI 10.1165/ajrcmb.10.1.7507342
   de Souza Carvalho Cristiane, 2014, Adv Drug Deliv Rev, V75, P129, DOI 10.1016/j.addr.2014.05.014
   Elbert KJ, 1999, PHARMACEUT RES, V16, P601, DOI 10.1023/A:1018887501927
   FALZON M, 1986, CANCER RES, V46, P3484
   Fehrenbach H, 2001, RESP RES, V2, P33, DOI 10.1186/rr36
   Fernandes CA, 2009, EXPERT OPIN DRUG DEL, V6, P1231, DOI 10.1517/17425240903241788
   Fiegel J, 2003, PHARMACEUT RES, V20, P788, DOI 10.1023/A:1023441804464
   Forbes B, 1999, INT J PHARM, V180, P225, DOI 10.1016/S0378-5173(99)00009-5
   Forbes B, 2002, STP PHARMA SCI, V12, P75
   Forbes B, 2005, EUR J PHARM BIOPHARM, V60, P193, DOI 10.1016/j.ejpb.2005.02.010
   Forbes I., 2000, PHARM SCI TECHNOL TO, V3, P18, DOI DOI 10.1016/S1461-5347(99)00231
   Foster KA, 1998, EXP CELL RES, V243, P359, DOI 10.1006/excr.1998.4172
   Friedrich J, 2007, INT J RADIAT BIOL, V83, P849, DOI 10.1080/09553000701727531
   Fukuda J, 2006, BIOMATERIALS, V27, P5259, DOI 10.1016/j.biomaterials.2006.05.044
   Grainger CI, 2012, MOL PHARMACEUT, V9, P563, DOI 10.1021/mp200415g
   Grainger CI, 2009, EUR J PHARM BIOPHARM, V71, P318, DOI 10.1016/j.ejpb.2008.09.006
   Grainger CI, 2006, PHARM RES, V23, P1482, DOI 10.1007/s11095-006-0255-0
   Haghi M, 2014, PHARMACOL THERAPEUT, V144, P235, DOI 10.1016/j.pharmthera.2014.05.003
   Haghi M, 2014, PHARM RES-DORDR, V31, P1779, DOI 10.1007/s11095-013-1282-2
   Haghi M, 2012, MOL PHARMACEUT, V9, P1717, DOI 10.1021/mp200620m
   Haghi M, 2012, AAPS J, V14, P79, DOI 10.1208/s12248-011-9317-2
   Hermanns MI, 2004, LAB INVEST, V84, P736, DOI 10.1038/labinvest.3700081
   Labiris NR, 2003, BRIT J CLIN PHARMACO, V56, P588, DOI 10.1046/j.1365-2125.2003.01892.x
   Lehmann AD, 2011, EUR J PHARM BIOPHARM, V77, P398, DOI 10.1016/j.ejpb.2010.10.014
   Lenz AG, 2014, AM J RESP CELL MOL, V51, P526, DOI 10.1165/rcmb.2013-0479OC
   LIEBER M, 1976, INT J CANCER, V17, P62, DOI 10.1002/ijc.2910170110
   Lin Ruei-Zhen, 2008, Biotechnology Journal, V3, P1172, DOI 10.1002/biot.200700228
   Madlova M, 2009, J PHARM PHARMACOL, V61, P293, DOI 10.1211/jpp/61.03.0003
   Mathias NR, 1996, ADV DRUG DELIVER REV, V22, P215, DOI 10.1016/S0169-409X(96)00420-6
   Meenach SA, 2016, INT J ONCOL, V48, P1701, DOI 10.3892/ijo.2016.3376
   Meenach SA, 2014, AAPS PHARMSCITECH, V15, P1574, DOI 10.1208/s12249-014-0182-z
   Morello M, 2009, TUBERCULOSIS, V89, P371, DOI 10.1016/j.tube.2009.07.001
   Ong HX, 2015, EUR J PHARM BIOPHARM, V93, P320, DOI 10.1016/j.ejpb.2015.04.012
   Ong HX, 2014, EUR J PHARM BIOPHARM, V86, P83, DOI 10.1016/j.ejpb.2013.06.024
   Ong HX, 2013, MOL PHARMACEUT, V10, P2915, DOI 10.1021/mp400030n
   Ong HX, 2011, PHARM RES-DORDR, V28, P2327, DOI 10.1007/s11095-011-0462-1
   Park CW, 2013, INT J PHARMACEUT, V455, P374, DOI 10.1016/j.ijpharm.2013.06.047
   Qi YW, 2004, P NATL ACAD SCI USA, V101, P9867, DOI 10.1073/pnas.0402891101
   Rawlins EL, 2006, DEVELOPMENT, V133, P2455, DOI 10.1242/dev.02407
   REDDEL RR, 1995, INT J CANCER, V61, P199
   Reynolds SD, 2010, INT J BIOCHEM CELL B, V42, P1, DOI 10.1016/j.biocel.2009.09.002
   Rock JR, 2011, ANNU REV CELL DEV BI, V27, P493, DOI 10.1146/annurev-cellbio-100109-104040
   Rothen-Rutishauser B, 2008, ALTEX-ALTERN TIEREXP, V25, P191
   Rothen-Rutishauser BM, 2005, AM J RESP CELL MOL, V32, P281, DOI 10.1165/rcmb.2004-0187OC
   Rytting E, 2010, J CONTROL RELEASE, V141, P101, DOI 10.1016/j.jconrel.2009.08.021
   Scalia S, 2013, EUR J PHARM SCI, V49, P278, DOI 10.1016/j.ejps.2013.03.009
   Simon DB, 1999, SCIENCE, V285, P103, DOI 10.1126/science.285.5424.103
   Sporty JL, 2008, EXPERT OPIN DRUG MET, V4, P333, DOI [10.1517/17425255.4.4.333, 10.1517/17425255.4.4.333 ]
   Stearns RC, 2001, AM J RESP CELL MOL, V24, P108, DOI 10.1165/ajrcmb.24.2.4081
   Steimer A, 2005, J AEROSOL MED, V18, P137, DOI 10.1089/jam.2005.18.137
   Stocke NA, 2015, INT J PHARMACEUT, V479, P320, DOI 10.1016/j.ijpharm.2014.12.050
   Tsoras A, 2013, KALEIDOSCOPE, V11
   Widdicombe JG, EUR J RESP DISL, V63, P202
   Zabner J, 2003, AM J PHYSIOL-LUNG C, V284, pL844, DOI 10.1152/ajplung.00355.2002
   Zheng DH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071028
NR 62
TC 1
Z9 1
U1 1
U2 9
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PY 2016
VL 22
IS 17
BP 2522
EP 2531
DI 10.2174/1381612822666160202142104
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA DK8AM
UT WOS:000375148900008
PM 26831643
DA 2018-03-20
ER

PT J
AU Cullen, DK
   Xu, YA
   Reneer, DV
   Browne, KD
   Geddes, JW
   Yang, S
   Smith, DH
AF Cullen, D. Kacy
   Xu, Yongan
   Reneer, Dexter V.
   Browne, Kevin D.
   Geddes, James W.
   Yang, Shu
   Smith, Douglas H.
TI Color changing photonic crystals detect blast exposure
SO NEUROIMAGE
LA English
DT Article
ID TRAUMATIC BRAIN-INJURY; MULTIBEAM INTERFERENCE LITHOGRAPHY; HEAD-INJURY;
   ALZHEIMERS-DISEASE; RECURRENT CONCUSSION; FOOTBALL PLAYERS; FABRICATION;
   IRAQ; AFGHANISTAN; NEUROTRAUMA
AB Blast-induced traumatic brain injury (bTBI) is the "signaturewound" of the current wars in Iraq and Afghanistan. However, with no objective information of relative blast exposure, warfighters with bTBI may not receive appropriate medical care and are at risk of being returned to the battlefield. Accordingly, we have created a colorimetric blast injury dosimeter (BID) that exploits material failure of photonic crystals to detect blast exposure. Appearing like a colored sticker, the BID is fabricated in photosensitive polymers via multi-beam interference lithography. Although very stable in the presence of heat, cold or physical impact, sculpted micro -and nano-structures of the BID are physically altered in a precise manner by blast exposure, resulting in color changes that correspond with blast intensity. This approach offers a lightweight, power-free sensor that can be readily interpreted by the naked eye. Importantly, with future refinement this technology may be deployed to identify soldiers exposed to blast at levels suggested to be supra-threshold for non-impact blast-induced mild TBI. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Cullen, D. Kacy; Browne, Kevin D.; Smith, Douglas H.] Univ Penn, Dept Neurosurg, Sch Med, Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA.
   [Xu, Yongan; Yang, Shu] Univ Penn, Dept Mat Sci & Engn, Sch Engn & Appl Sci, Philadelphia, PA 19104 USA.
   [Reneer, Dexter V.; Geddes, James W.] Univ Kentucky, Coll Med,Dept Anat & Neurobiol, Albert B Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA.
RP Smith, DH (reprint author), Univ Penn, Dept Neurosurg, Sch Med, Ctr Brain Injury & Repair, 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.
EM shuyang@seas.upenn.edu; smithdou@mail.med.upenn.edu
RI Xu, Yongan/A-7078-2011; Yang, Shu/D-9758-2011
FU Nanotechnology Institute Proof-of-Concept (PoC) Fund; Office of Naval
   Research (ONR) [N00014-05-0303]; Air Force Office of Scientific Research
   (AFOSR) [FA9550-06-1-0228]; National Institutes of Health (NIH)
   [NS038104, NS048949, NS043126]
FX This work was supported in part by the Nanotechnology Institute
   Proof-of-Concept (PoC) Fund, the Office of Naval Research (ONR) (grant
   #N00014-05-0303), the Air Force Office of Scientific Research (AFOSR)
   (grant # FA9550-06-1-0228), and the National Institutes of Health (NIH)
   (grant #NS038104, #NS048949, and #NS043126). The funding sources had no
   involvement in any aspects of this work or the decision to publish.
CR Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898
   Campbell M, 2000, NATURE, V404, P53
   Cantu RC, 2003, CLIN SPORT MED, V22, P593, DOI 10.1016/S0278-5919(02)00095-9
   Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017
   Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963
   Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316
   Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD
   Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549
   Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972
   Jellinger KA, 2001, EUR J NEUROL, V8, P707, DOI 10.1046/j.1468-1331.2001.00322.x
   Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826
   Kato K, 2007, J NEUROSURG, V106, P667, DOI 10.3171/jns.2007.106.4.667
   LEE KY, 1994, J VAC SCI TECHNOL B, V12, P3425, DOI 10.1116/1.587525
   LING G, 2008, 26 ANN NAT NEUR S OR
   Lorenz H, 1997, J MICROMECH MICROENG, V7, P121, DOI 10.1088/0960-1317/7/3/010
   Loubeau A, 2006, J ACOUST SOC AM, V120, pEL29, DOI 10.1121/1.2234518
   Martin Elisabeth Moy, 2008, J Trauma Nurs, V15, P94, DOI 10.1097/01.JTN.0000337149.29549.28
   Martin EM, 2008, J TRAUMA NURS, V15, P100
   McMurtray A, 2006, DEMENT GERIATR COGN, V21, P59, DOI 10.1159/000089546
   Miklyaev YV, 2003, APPL PHYS LETT, V82, P1284, DOI 10.1063/1.1557328
   Moochhala SM, 2004, J TRAUMA, V56, P393, DOI 10.1097/01.TA.0000066181.50879.7A
   Moon JH, 2006, POLYM ADVAN TECHNOL, V17, P83, DOI 10.1002/pat.663
   Moon JH, 2005, J MACROMOL SCI-POL R, VC45, P351, DOI 10.1080/15321790500304163
   Mori T, 2006, ACTA NEUROCHIR SUPPL, V96, P40
   Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32
   Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102
   Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158
   Ribeiro JC, 2005, SENSOR ACTUAT A-PHYS, V123-24, P77, DOI 10.1016/j.sna.2005.03.032
   Saljo A., 2009, J NEUROTRAUM, V25, P1397
   Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068
   Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072
   Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141
   TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813
   Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004
   Warden DL, 2005, J NEUROTRAUM, V22, P1178
   Xu Y, 2008, CHEM MATER, V20, P1816, DOI 10.1021/cm702511k
   Yang S, 2002, CHEM MATER, V14, P2831, DOI 10.1021/cm0256007
NR 37
TC 14
Z9 14
U1 0
U2 19
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
J9 NEUROIMAGE
JI Neuroimage
PD JAN
PY 2011
VL 54
SU 1
BP S37
EP S44
DI 10.1016/j.neuroimage.2010.10.076
PG 8
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
   Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 813ZF
UT WOS:000294408600006
PM 21040795
OA green_accepted
DA 2018-03-20
ER

PT J
AU Long, SH
   Zhou, PP
   Parkin, S
   Li, TL
AF Long, Sihui
   Zhou, Panpan
   Parkin, Sean
   Li, Tonglei
TI Polymorphism and solid-to-solid phase transitions of a simple organic
   molecule, 3-chloroisonicotinic acid
SO CRYSTENGCOMM
LA English
DT Article
ID CRYSTAL-STRUCTURE PREDICTION; DENSITY-FUNCTIONAL THEORY; CONFORMATIONAL
   POLYMORPHISM; MECHANISM; TRANSFORMATION; ENERGIES
AB Three polymorphs (I, II, and III) have been discovered for 3-chloroisonicotinic acid. The torsion angle between the aromatic ring and the carboxylic acid in form I differs from that of forms II and III, which are similar. All three polymorphs form hydrogen-bonded chains based on the acid-pyridine heterosynthon. Despite the conformational similarity between forms II and III, the hydrogen-bonded chains in form II alternate in direction while those in form III all point in the same direction. Study of the phase behaviors of the three forms by differential scanning calorimetry, hot-stage microscopy, and thermogravimetric analysis revealed two solid-to-solid phase transitions from the metastable forms II and III to the most stable form I. Sublimation of 3-chloroisonicotinic acid also led to form I. A higher-temperature polymorph seemed to be possible but remained elusive. Lattice energy and hydrogen bonding strength calculations provided further insight into the stability of the polymorphs. A search of conformational space for the molecule suggested possibly additional polymorphs of this simple compound. The system may be valuable for further solidstate structure-property relationship studies.
C1 [Long, Sihui] Wuhan Inst Technol, Sch Chem Engn & Pharm, Wuhan, Hubei, Peoples R China.
   [Zhou, Panpan] Lanzhou Univ, Dept Chem, Lanzhou 730000, Gansu, Peoples R China.
   [Parkin, Sean] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
   [Li, Tonglei] Purdue Univ, Dept Ind & Phys Pharm, W Lafayette, IN 47907 USA.
RP Long, SH (reprint author), Wuhan Inst Technol, Sch Chem Engn & Pharm, Wuhan, Hubei, Peoples R China.
EM tonglei@purdue.edu
FU Natural Science Foundation of Hubei Province [2014CFB787]; National
   Natural Science Foundation of China [21403097]; Fundamental Research
   Funds for the Central Universities [lzujbky-2014-182]; NSF [DMR1006364]
FX SL thanks the Natural Science Foundation of Hubei Province for financial
   support (2014CFB787). PPZ thanks the financial support by the National
   Natural Science Foundation of China (grant no. 21403097) and the
   Fundamental Research Funds for the Central Universities
   (lzujbky-2014-182). TL is grateful to NSF for supporting the work
   (DMR1006364).
CR Beckham GT, 2008, J PHYS CHEM B, V112, P7460, DOI 10.1021/jp710192u
   BERKOVITCHYELLIN Z, 1982, J AM CHEM SOC, V104, P4052, DOI 10.1021/ja00379a003
   BERNSTEIN J, 1995, ANGEW CHEM INT EDIT, V34, P1555, DOI 10.1002/anie.199515551
   Bernstein J., 1987, ORGANIC SOLID STATE, V32, P471
   Bernstein J., 2002, POLYMORPHISM MOL CRY
   BOYS SF, 1970, MOL PHYS, V19, P553, DOI 10.1080/00268977000101561
   Brittain HG, 2007, J PHARM SCI-US, V96, P705, DOI 10.1002/jps.20772
   Brittain H. G., 1999, POLYMORPHISM PHARM S
   Byrn S. R., 1999, SOLID STATE CHEM DRU
   Cruz-Cabeza AJ, 2014, CHEM REV, V114, P2170, DOI 10.1021/cr400249d
   Della Valle RG, 2008, J PHYS CHEM A, V112, P1085, DOI 10.1021/jp710273r
   Dovesi R, 2005, Z KRISTALLOGR, V220, P571, DOI 10.1524/zkri.220.5.571.65065
   Ectors P, 2014, CRYST GROWTH DES, V14, P2972, DOI 10.1021/cg500247c
   Feng SX, 2006, J CHEM THEORY COMPUT, V2, P149, DOI 10.1021/ct050189a
   Frisch M. J., 2009, GAUSSIAN 09 REVISION
   FUJINAGA M, 1980, ACTA CRYSTALLOGR B, V36, P3196, DOI 10.1107/S0567740880011296
   Hilfiker R, 2006, POLYMORPHISM PHARM I
   Hiremath R, 2005, J AM CHEM SOC, V127, P18321, DOI 10.1021/ja0565119
   Hoarau C, 2001, J ORG CHEM, V66, P8064, DOI 10.1021/jo0105944
   Li TL, 2006, PHARM RES-DORDR, V23, P2326, DOI 10.1007/s11095-006-9006-5
   Llinas A, 2008, DRUG DISCOV TODAY, V13, P198, DOI 10.1016/j.drudis.2007.11.006
   Long SH, 2008, CRYST GROWTH DES, V8, P4006, DOI 10.1021/cg800123z
   Long SH, 2008, CRYST GROWTH DES, V8, P3137, DOI 10.1021/cg800339h
   Long SH, 2007, ACTA CRYSTALLOGR E, V63, pO279, DOI 10.1107/S1600536806053177
   Long SH, 2006, ACTA CRYSTALLOGR E, V62, pO5664, DOI 10.1107/S1600536806048768
   Long SH, 2014, CRYST GROWTH DES, V14, P27, DOI 10.1021/cg401532j
   Long SH, 2010, CRYST GROWTH DES, V10, P2465, DOI 10.1021/cg100227s
   Long SH, 2009, CRYST GROWTH DES, V9, P4993, DOI 10.1021/cg900786b
   Lopez-Mejias V, 2012, J AM CHEM SOC, V134, P9872, DOI 10.1021/ja302601f
   McCrone W. C., 1965, PHYSICS CHEMISTRY OR, VII, P725
   Misquitta AJ, 2008, CHEM PHYS LETT, V456, P105, DOI 10.1016/j.cplett.2008.02.113
   Mo YX, 2011, IND ENG CHEM RES, V50, P10385, DOI 10.1021/ie102152d
   Nangia A, 2008, ACCOUNTS CHEM RES, V41, P595, DOI 10.1021/ar700203k
   Neumann MA, 2008, J PHYS CHEM B, V112, P9810, DOI 10.1021/jp710575h
   Neumann MA, 2008, ANGEW CHEM INT EDIT, V47, P2427, DOI 10.1002/anie.200704247
   Nonius, 2002, COLLECT AND EVAL
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Price SL, 2008, PHYS CHEM CHEM PHYS, V10, P1996, DOI 10.1039/b719351c
   Price SL, 2014, CHEM SOC REV, V43, P2098, DOI 10.1039/c3cs60279f
   Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930
   Sun XY, 2006, CRYST GROWTH DES, V6, P684, DOI 10.1021/cg050460+
   TAKUSAGAWA F, 1976, ACTA CRYSTALLOGR B, V32, P1925, DOI 10.1107/S0567740876006754
   Tamboli MI, 2014, CRYST GROWTH DES, V14, P4985, DOI 10.1021/cg5005227
   Vasileiadis M, 2015, CHEM ENG SCI, V121, P60, DOI 10.1016/j.ces.2014.08.058
   Wishkerman S, 2008, CHEM-EUR J, V14, P197, DOI 10.1002/chem.200700463
   Yang XC, 2012, CRYST GROWTH DES, V12, P5521, DOI 10.1021/cg301092b
   Zhang JL, 2014, RSC ADV, V4, P21599, DOI 10.1039/c4ra01705f
   Zhao Y, 2008, THEOR CHEM ACC, V120, P215, DOI 10.1007/s00214-007-0310-x
   Zhao Y, 2008, ACCOUNTS CHEM RES, V41, P157, DOI 10.1021/ar700111a
   Zhao Y, 2006, J CHEM PHYS, V125, DOI 10.1063/1.2370993
NR 50
TC 3
Z9 3
U1 4
U2 20
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1466-8033
J9 CRYSTENGCOMM
JI Crystengcomm
PY 2015
VL 17
IS 11
BP 2389
EP 2397
DI 10.1039/c4ce02563f
PG 9
WC Chemistry, Multidisciplinary; Crystallography
SC Chemistry; Crystallography
GA CC6PH
UT WOS:000350487400020
DA 2018-03-20
ER

PT S
AU Howard, MD
   Hood, ED
   Zern, B
   Shuvaev, VV
   Grosser, T
   Muzykantov, VR
AF Howard, Melissa D.
   Hood, Elizabeth D.
   Zern, Blaine
   Shuvaev, Vladimir V.
   Grosser, Tilo
   Muzykantov, Vladimir R.
BE Insel, PA
TI Nanocarriers for Vascular Delivery of Anti-Inflammatory Agents
SO ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 54
SE Annual Review of Pharmacology and Toxicology
LA English
DT Review; Book Chapter
DE vascular immunotargeting; intracellular delivery; liposomes; polymeric
   nanocarriers; endothelium; cell adhesion molecules
ID LIVED CIRCULATING NANOPARTICLES; ANGIOGENIC ENDOTHELIAL-CELLS; SOLID
   LIPID NANOPARTICLES; INDUCED LUNG INJURIES; RELEASE NITRIC-OXIDE;
   IN-VIVO; TARGETED DELIVERY; DRUG-DELIVERY; SUPEROXIDE-DISMUTASE; POLYMER
   NANOCARRIERS
AB There is a need for improved treatment of acute vascular inflammation in conditions such as ischemia-reperfusion injury, acute lung injury, sepsis, and stroke. The vascular endothelium represents an important therapeutic target in these conditions. Furthermore, some anti-inflammatory agents (AIAs) (e.g., biotherapeutics) require precise delivery into subcellular compartments. In theory, optimized delivery to the desired site of action may improve the effects and enable new mechanisms of action of these AIAs. Diverse nanocarriers (NCs) and strategies for targeting them to endothelial cells have been designed and explored for this purpose. Studies in animal models suggest that delivery of AIAs using NCs may provide potent and specific molecular interventions in inflammatory pathways. However, the industrial development and clinical translation of complex NC-AIA formulations are challenging. Rigorous analysis of therapeutic/side effect and benefit/cost ratios is necessary to identify and optimize the approaches that may find clinical utility in the management of acute inflammation.
C1 [Howard, Melissa D.] Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA.
   Univ Penn, Ctr Targeted Therapeut & Translat Nanomed, Perelman Sch Med, Philadelphia, PA 19104 USA.
RP Howard, MD (reprint author), Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA.
EM muzykant@mail.med.upenn.edu
RI Shuvaev, Vladimir/O-1719-2014; Grosser, Tilo/A-1057-2007
OI Grosser, Tilo/0000-0001-8569-8396
FU NHLBI NIH HHS [R01 HL087036, T32 HL007439, R01 HL073940]
CR Asgeirsdottir SA, 2010, J CONTROL RELEASE, V141, P241
   Asgeirdottir SA, 2007, MOL PHARMACOL, V72, P121, DOI 10.1124/mol.107.034140
   Astete CE, 2011, ACS NANO, V5, P9313, DOI 10.1021/nn102845t
   Barenholz Y, 2012, J CONTROL RELEASE, V160, P117, DOI 10.1016/j.jconrel.2012.03.020
   Bernardi A, 2009, BRIT J PHARMACOL, V158, P1104, DOI 10.1111/j.1476-5381.2009.00244.x
   Bernardi A, 2012, INT J NANOMED, V7, P4927, DOI 10.2147/IJN.S35333
   Bhowmick T, 2012, J CONTROL RELEASE, V157, P485, DOI 10.1016/j.jconrel.2011.09.067
   BONANOMI MH, 1987, RHEUMATOL INT, V7, P203, DOI 10.1007/BF00541378
   Brynskikh AM, 2010, NANOMEDICINE-UK, V5, P379, DOI [10.2217/nnm.10.7, 10.2217/NNM.10.7]
   Cabrales P, 2010, FREE RADICAL BIO MED, V49, P530, DOI 10.1016/j.freeradbiomed.2010.04.034
   Calderon AJ, 2011, J CONTROL RELEASE, V150, P37, DOI 10.1016/j.jconrel.2010.10.025
   Calderon AJ, 2009, BIORHEOLOGY, V46, P323, DOI 10.3233/BIR-2009-0544
   Casi G, 2012, J CONTROL RELEASE, V161, P422, DOI 10.1016/j.jconrel.2012.01.026
   Champion JA, 2006, P NATL ACAD SCI USA, V103, P4930, DOI 10.1073/pnas.0600997103
   Chandrasekar D, 2007, BIOMATERIALS, V28, P504, DOI 10.1016/j.biomaterials.2006.07.046
   Cheng ZL, 2012, SCIENCE, V338, P903, DOI 10.1126/science.1226338
   Chorny M, 2010, P NATL ACAD SCI USA, V107, P8346, DOI 10.1073/pnas.0909506107
   Chorny M, 2009, MOL PHARMACEUT, V6, P1380, DOI 10.1021/mp900017m
   Christofidou-Solomidou Melpo, 2006, Treat Respir Med, V5, P47, DOI 10.2165/00151829-200605010-00004
   Corvo L. M., 2002, BIOCHIM BIOPHYS ACTA, V1564, P227
   Danielyan K, 2007, J PHARMACOL EXP THER, V321, P947, DOI 10.1124/jpet.107.120535
   Davis ME, 2009, MOL PHARMACEUT, V6, P659, DOI 10.1021/mp900015y
   Dziubla TD, 2005, J CONTROL RELEASE, V102, P427, DOI 10.1016/j.jconrel.2004.10.017
   Dziubla TD, 2008, BIOMATERIALS, V29, P215, DOI 10.1016/j.biomaterials.2007.09.023
   Everts M, 2003, PHARMACEUT RES, V20, P64, DOI 10.1023/A:1022298725165
   Fakhari A, 2011, J PHARM SCI-US, V100, P1045, DOI 10.1002/jps.22342
   Fan J, 2000, SURGERY, V128, P332, DOI 10.1067/msy.2000.108060
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Fleming C, 2005, NAT CHEM BIOL, V1, P270, DOI 10.1038/nchembio730
   Garnacho C, 2008, J CONTROL RELEASE, V130, P226, DOI 10.1016/j.jconrel.2008.06.007
   Gaspar MM, 2007, J CONTROL RELEASE, V117, P186, DOI 10.1016/j.jconrel.2006.10.018
   Geng Y, 2007, NAT NANOTECHNOL, V2, P249, DOI 10.1038/nnano.2007.70
   Giovagnoli S, 2005, J CONTROL RELEASE, V107, P65, DOI 10.1016/j.jconrel.2005.05.021
   Guillaudeu SJ, 2008, BIOCONJUGATE CHEM, V19, P461, DOI 10.1021/bc700264g
   Hak S, 2012, ACS NANO, V6, P5648, DOI 10.1021/nn301630n
   Han JY, 2012, ACS NANO, V6, P8824, DOI 10.1021/nn302687n
   Hegeman MA, 2011, BRIT J PHARMACOL, V163, P1048, DOI 10.1111/j.1476-5381.2011.01314.x
   Henne WA, 2012, MOL PHARMACEUT, V9, P1435, DOI 10.1021/mp3000138
   Hood E, 2011, NANOMEDICINE-UK, V6, P1257, DOI [10.2217/NNM.11.92, 10.2217/nnm.11.92]
   Howard MD, 2008, J BIOMED NANOTECHNOL, V4, P133, DOI 10.1166/jbn.2008.021
   Howard MD, 2011, PHARM RES-DORDR, V28, P2435, DOI 10.1007/s11095-011-0470-1
   HRISTOVA K, 1995, MACROMOLECULES, V28, P7693, DOI 10.1021/ma00127a015
   Hung CF, 2006, J NANOSCI NANOTECHNO, V6, P2950, DOI 10.1166/jnn.2006.420
   Ianiski FR, 2012, BEHAV BRAIN RES, V230, P100, DOI 10.1016/j.bbr.2012.01.055
   Ishihara T, 2009, INT J PHARMACEUT, V375, P148, DOI 10.1016/j.ijpharm.2009.04.001
   Ishihara T, 2009, J PHARMACOL EXP THER, V329, P412, DOI 10.1124/jpet.108.150276
   Johnson TA, 2010, NITRIC OXIDE-BIOL CH, V22, P30, DOI 10.1016/j.niox.2009.11.002
   Kataoka K, 2001, ADV DRUG DELIVER REV, V47, P113, DOI 10.1016/S0169-409X(00)00124-1
   Kheradmandnia S, 2010, NANOMED-NANOTECHNOL, V6, P753, DOI 10.1016/j.nano.2010.06.003
   Kim JY, 2012, J DRUG TARGET, V20, P667, DOI 10.3109/1061186X.2012.712127
   KIRBY C, 1984, BIO-TECHNOL, V2, P979, DOI 10.1038/nbt1184-979
   KLIBANOV AL, 1990, FEBS LETT, V268, P235, DOI 10.1016/0014-5793(90)81016-H
   Kohler D, 2012, ADV MATER, V24, P1095, DOI 10.1002/adma.201103958
   Koning GA, 2006, ARTHRITIS RHEUM, V54, P1198, DOI 10.1002/art.21719
   Krakovicova H, 2009, EUR J PHARM SCI, V37, P405, DOI 10.1016/j.ejps.2009.03.011
   Kuldo JM, 2013, J CONTROL RELEASE, V166, P57, DOI 10.1016/j.jconrel.2012.12.016
   Kuldo Joanna M., 2005, Current Vascular Pharmacology, V3, P11, DOI 10.2174/1570161052773898
   Kumar V, 2009, MOL PHARM, V7, P291
   Labouta HI, 2010, INT J PHARMACEUT, V395, P236, DOI 10.1016/j.ijpharm.2010.05.019
   Laursen JB, 1997, CIRCULATION, V95, P588
   Lee JB, 2012, INT J CANCER, V131, pE781, DOI 10.1002/ijc.27361
   Leuschner F, 2011, NAT BIOTECHNOL, V29, P1005, DOI 10.1038/nbt.1989
   Liu XP, 1998, J BIOL CHEM, V273, P18709, DOI 10.1074/jbc.273.30.18709
   Lu XL, 2009, AAPS J, V11, P120, DOI 10.1208/s12248-009-9086-3
   Merkel TJ, 2011, P NATL ACAD SCI USA, V108, P586, DOI 10.1073/pnas.1010013108
   Misra AC, 2012, ADV MATER, V24, P3850, DOI 10.1002/adma.201200372
   Mitsopoulos P, 2008, INT J PHARMACEUT, V363, P106, DOI 10.1016/j.ijpharm.2008.07.015
   Muro S, 2006, AM J PHYSIOL-LUNG C, V290, pL809, DOI 10.1152/ajplung.00311.2005
   Muro S, 2003, AM J PHYSIOL-CELL PH, V285, pC1339, DOI 10.1152/ajpcell.00099.2003
   Muro S, 2003, J CELL SCI, V116, P1599, DOI 10.1242/jcs.00367
   Muro S, 2008, MOL THER, V16, P1450, DOI 10.1038/mt.2008.127
   Muzykantov Vladimir R, 2005, Expert Opin Drug Deliv, V2, P909, DOI 10.1517/17425247.2.5.909
   Muzykantov VR, 2010, FREE RADICAL BIO MED, V49, P528, DOI 10.1016/j.freeradbiomed.2010.05.022
   Muzykantov VR, 2001, ANTIOXID REDOX SIGN, V3, P39, DOI 10.1089/152308601750100489
   Nacharaju P, 2012, NITRIC OXIDE-BIOL CH, V27, P150, DOI 10.1016/j.niox.2012.06.003
   Nicolai T, 2010, SOFT MATTER, V6, P3111, DOI 10.1039/b925666k
   Nishiwaki Y, 2003, BIOCHEM BIOPH RES CO, V310, P1062, DOI 10.1016/j.bbrc.2003.09.125
   Oh P, 2007, NAT BIOTECHNOL, V25, P327, DOI 10.1038/nbt1292
   Pober JS, 2007, NAT REV IMMUNOL, V7, P803, DOI 10.1038/nri2171
   Pochan DJ, 2011, SOFT MATTER, V7, P2500, DOI 10.1039/c0sm00960a
   Prajapati RN, 2009, MOL PHARMACEUT, V6, P940, DOI 10.1021/mp8002489
   Puri S, 2008, J CONTROL RELEASE, V125, P59, DOI 10.1016/j.jconrel.2007.09.009
   Quan LD, 2008, EXPERT OPIN THER PAT, V18, P723, DOI 10.1517/13543770802211686
   Rauchhaus U, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2889
   Rosenbaugh EG, 2010, BIOMATERIALS, V31, P5218, DOI 10.1016/j.biomaterials.2010.03.026
   Scherpereel A, 2002, J PHARMACOL EXP THER, V300, P777, DOI 10.1124/jpet.300.3.777
   Shuvaev VV, 2011, ACS NANO, V5, P6991, DOI 10.1021/nn2015453
   Shuvaev VV, 2011, J CONTROL RELEASE, V153, P56, DOI 10.1016/j.jconrel.2011.03.022
   Shuvaev VV, 2011, FASEB J, V25, P348, DOI 10.1096/fj.10-169789
   Shuvaev VV, 2011, J CONTROL RELEASE, V149, P236, DOI 10.1016/j.jconrel.2010.10.026
   Shuvaev VV, 2009, J PHARMACOL EXP THER, V331, P404, DOI 10.1124/jpet.109.156877
   Simone E, 2009, CELL TISSUE RES, V335, P283, DOI 10.1007/s00441-008-0676-7
   Simone EA, 2007, BIOMACROMOLECULES, V8, P3914, DOI 10.1021/bm700888h
   Spragg DD, 1997, P NATL ACAD SCI USA, V94, P8795, DOI 10.1073/pnas.94.16.8795
   Stasko NA, 2006, J AM CHEM SOC, V128, P8265, DOI 10.1021/ja060875z
   Stone WL, 2004, MOL BIOTECHNOL, V27, P217, DOI 10.1385/MB:27:3:217
   Suntres ZE, 2000, BIOCHEM PHARMACOL, V59, P1155, DOI 10.1016/S0006-2952(99)00411-6
   TANSWELL AK, 1987, J APPL PHYSIOL, V63, P347
   Ulmansky R, 2012, J CONTROL RELEASE, V160, P299, DOI 10.1016/j.jconrel.2011.12.024
   Vader P, 2012, J CONTROL RELEASE, V160, P211, DOI 10.1016/j.jconrel.2011.09.080
   Wang D, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2106
   WHITE CW, 1989, J APPL PHYSIOL, V66, P584
   Whitehead KA, 2009, NAT REV DRUG DISCOV, V8, P129, DOI 10.1038/nrd2742
   Williams SR, 2009, BIOMACROMOLECULES, V10, P155, DOI 10.1021/bm801058j
   Wissing SA, 2004, ADV DRUG DELIVER REV, V56, P1257, DOI 10.1016/j.addr.2003.12.002
   Wolfrum C, 2007, NAT BIOTECHNOL, V25, P1149, DOI 10.1038/nbt1339
   Xiang QY, 2007, ARCH PHARM RES, V30, P519, DOI 10.1007/BF02980228
   Xu XM, 2012, PHARM RES-DORDR, V29, P1919, DOI 10.1007/s11095-012-0720-x
   Yan M, 2010, NAT NANOTECHNOL, V5, P48, DOI [10.1038/NNANO.2009.341, 10.1038/nnano.2009.341]
   Yi XA, 2010, FREE RADICAL BIO MED, V49, P548, DOI 10.1016/j.freeradbiomed.2010.04.039
   Yuan XD, 2011, EXPERT OPIN DRUG DEL, V8, P521, DOI 10.1517/17425247.2011.559223
   Zern BJ, 2013, ACS NANO, V7, P2461, DOI 10.1021/nn305773f
   Zhang Z, 2006, J CONTROL RELEASE, V111, P263, DOI 10.1016/j.jconrel.2005.12.001
   Zheng XF, 2010, METHODS MOL BIOL, V623, P173, DOI 10.1007/978-1-60761-588-0_11
   Zhou HF, 2010, NANOMEDICINE-UK, V5, P1065, DOI 10.2217/NNM.10.78
   Zuckerman JE, 2012, P NATL ACAD SCI USA, V109, P3137, DOI 10.1073/pnas.1200718109
NR 116
TC 27
Z9 27
U1 1
U2 31
PU ANNUAL REVIEWS
PI PALO ALTO
PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA
SN 0362-1642
BN 978-0-8243-0454-6
J9 ANNU REV PHARMACOL
JI Annu. Rev. Pharmacol. Toxicol.
PY 2014
VL 54
BP 205
EP 226
DI 10.1146/annurev-pharmtox-011613-140002
PG 22
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA BJR57
UT WOS:000329822200011
PM 24392694
OA green_accepted
DA 2018-03-20
ER

PT J
AU Wan, HY
   Briot, NJ
   Saad, A
   Ormsbee, L
   Bhattacharyya, D
AF Wan, Hongyi
   Briot, Nicolas J.
   Saad, Anthony
   Ormsbee, Lindell R.
   Bhattacharyya, Dibakar
TI Pore functionalized PVDF membranes with in-situ synthesized metal
   nanoparticles: Material characterization, and toxic organic degradation
SO JOURNAL OF MEMBRANE SCIENCE
LA English
DT Article
DE Catalysis; PCB dechlorination; Water remediation; Fe and Pd; FIB
ID ZERO-VALENT IRON; ULTRAFILTRATION MEMBRANE; WATER-PURIFICATION;
   POLYCHLORINATED BIPHENYL; BIMETALLIC PARTICLES; ACTIVATED CARBON;
   CAPTIVE BUBBLE; CONTACT ANGLES; SESSILE DROP; DECHLORINATION
AB Functionalized PVDF membrane platforms were developed for environmentally benign in-situ nanostructured Fe/Pd synthesis and remediation of chlorinated organic compounds. To prevent leaching and aggregation, nanoparticle catalysts were integrated into membrane domains functionalized with poly (acrylic acid). Nanoparticles of 16-19 nm were observed inside the membrane pores by using focused ion beam (FIB). This technique prevents mechanical deformation of the membrane, compared to the normal SEM preparation methods, thus providing a clean, smooth surface for nanoparticles characterization. This allowed quantification of nanoparticle properties (size and distribution) versus depth underneath the membrane surface (0-20 mu m). The results showed that nanoparticles were uniformly sized and evenly distributed inside the membrane pores. However, the size of nanoparticles inside the membrane pores was 13.9% smaller than those nanoparticles located on the membrane surface. Investigating nanoparticles inside membrane pores increases the accuracy of kinetic analysis and modeling aspects. Furthermore, the Fe/Pd immobilized membranes showed excellent performance in the degradation of chlorinated organics: Over 96% degradation of 3,3',4,4',5-pentachlorobiphenyl (PCB 126) was achieved in less than 15 s residence time in convective flow mode. The regeneration and reuse of this catalytic membrane system were also studied. Particles were examined in XRD upon formation, after deliberate oxidation, and after regeneration. The regenerated sample showed the same crystalline pattern as the original sample. Repeated degradation experiments demonstrated successful PCB 126 dechlorination with nanoparticles regenerated for four cycles with only a small loss in reactivity. It demonstrated that Fe/Pd immobilized membranes have the potential for large-scale remediation applications.
C1 [Wan, Hongyi; Briot, Nicolas J.; Saad, Anthony; Bhattacharyya, Dibakar] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Ormsbee, Lindell] Univ Kentucky, Dept Civil Engn, Lexington, KY 40506 USA.
RP Bhattacharyya, D (reprint author), Univ Kentucky, Univ Alumni Chair, Chem & Mat Engn, 177 FPAT Bldg, Lexington, KY 40506 USA.
EM db@uky.edu
FU NIH-NIEHS-SRC [P42ES007380]; NSF KY EPSCoR [1355438]
FX This research is supported by the NIH-NIEHS-SRC (Award number:
   P42ES007380). Partial support is also provided by NSF KY EPSCoR grant
   (Grant no: 1355438). We thank John May and Tricia Coakley from
   Environmental Research and Training Laboratory (ERTL) at UK for GC-MS
   and ICP-OES analytical assistance. We also thank Dr. Sony Soman for the
   assistance with GC-MS analysis for PCB intermediates.
CR Agarwal S, 2009, ENVIRON SCI TECHNOL, V43, P915, DOI 10.1021/es802538d
   Agarwal S, 2007, ENVIRON SCI TECHNOL, V41, P3722, DOI 10.1021/es062886y
   Agarwal S, 2009, J HAZARD MATER, V172, P1156, DOI 10.1016/j.jhazmat.2009.07.117
   Association A.P.H., 1994, AM J PUBLIC HEALTH, V84, P514
   Baek Y, 2012, DESALINATION, V303, P23, DOI 10.1016/j.desal.2012.07.006
   Bai HW, 2015, J MEMBRANE SCI, V475, P245, DOI 10.1016/j.memsci.2014.10.036
   Chen N.H., 1983, PROCESS REACTOR DESI, P297
   Choi H, 2008, CHEM MATER, V20, P3649, DOI 10.1021/cm8003613
   Choi H, 2010, J HAZARD MATER, V179, P869, DOI 10.1016/j.jhazmat.2010.03.085
   Crane RA, 2012, J HAZARD MATER, V211, P112, DOI 10.1016/j.jhazmat.2011.11.073
   Davis M.E., 2003, FUNDAMENTALS CHEM RE, P260
   Doyle JG, 1998, MICROCHEM J, V60, P290, DOI 10.1006/mchj.1998.1668
   Elliott DW, 2001, ENVIRON SCI TECHNOL, V35, P4922, DOI 10.1021/es0108584
   Fang GD, 2013, APPL CATAL B-ENVIRON, V129, P325, DOI 10.1016/j.apcatb.2012.09.042
   Fu FL, 2014, J HAZARD MATER, V267, P194, DOI 10.1016/j.jhazmat.2013.12.062
   Greenlee LF, 2014, J NANOPART RES, V16, DOI 10.1007/s11051-014-2712-8
   Greenlee L.F., 2016, POLYMER
   Groll J, 2005, BIOMACROMOLECULES, V6, P956, DOI 10.1021/bm049350u
   Gu YY, 2015, J MEMBRANE SCI, V492, P331, DOI 10.1016/j.memsci.2015.05.051
   Gui MH, 2015, J MEMBRANE SCI, V488, P79, DOI 10.1016/j.memsci.2015.03.089
   Gui M, 2013, IND ENG CHEM RES, V52, P10430, DOI 10.1021/ie400507c
   Hacliipanayis CG, 2008, SMALL, V4, P1925, DOI 10.1002/smll.200800261
   Han YL, 2014, WATER RES, V66, P149, DOI 10.1016/j.watres.2014.08.001
   He F, 2007, ENVIRON SCI TECHNOL, V41, P6216, DOI 10.1021/es0705543
   He F, 2010, WATER RES, V44, P2360, DOI 10.1016/j.watres.2009.12.041
   He F, 2008, APPL CATAL B-ENVIRON, V84, P533, DOI 10.1016/j.apcatb.2008.05.008
   Hoag GE, 2009, J MATER CHEM, V19, P8671, DOI 10.1039/b909148c
   Hu K, 2008, J MEMBRANE SCI, V321, P162, DOI 10.1016/j.memsci.2008.04.046
   Hu K, 2007, J MEMBRANE SCI, V301, P19, DOI 10.1016/j.memsci.2007.05.031
   Huang LC, 2016, J MEMBRANE SCI, V499, P269, DOI 10.1016/j.memsci.2015.10.055
   Hudson R, 2013, GREEN CHEM, V15, P2141, DOI 10.1039/c3gc40789f
   Jiang JH, 2015, J MATER CHEM B, V3, P7698, DOI 10.1039/c5tb01336d
   Jiang JH, 2011, LANGMUIR, V27, P14180, DOI 10.1021/la202877k
   Kanel SR, 2005, ENVIRON SCI TECHNOL, V39, P1291, DOI 10.1021/es048991u
   Kim CS, 2012, VACUUM, V86, P1014, DOI 10.1016/j.vacuum.2011.11.004
   Kim J, 2016, J MEMBRANE SCI, V515, P54, DOI 10.1016/j.memsci.2016.05.029
   Lewis SR, 2011, P NATL ACAD SCI USA, V108, P8577, DOI 10.1073/pnas.1101144108
   Li X., 2016, J MEMBR SCI
   Li X, 2013, DESALINATION, V324, P48, DOI 10.1016/j.desal.2013.05.021
   Lin YH, 2009, COLLOID SURFACE A, V349, P137, DOI 10.1016/j.colsurfa.2009.08.007
   Luo N, 2004, J APPL POLYM SCI, V92, P1688, DOI 10.1002/app.20120
   Nollet H, 2003, CHEMOSPHERE, V53, P655, DOI 10.1016/S0045-6535(03)00517-4
   Nurmi JT, 2005, ENVIRON SCI TECHNOL, V39, P1221, DOI 10.1021/es049190u
   Pang RZ, 2011, J COLLOID INTERF SCI, V364, P373, DOI 10.1016/j.jcis.2011.09.001
   Petla R.K., 2012, J BIOMATER NANOBIOTE
   Rastogi A, 2009, APPL CATAL B-ENVIRON, V85, P171, DOI 10.1016/j.apcatb.2008.07.010
   Reyntjens S, 2001, J MICROMECH MICROENG, V11, P287, DOI 10.1088/0960-1317/11/4/301
   Saratchandran D., 2011, J CANC THER, V2011
   Schrick B, 2002, CHEM MATER, V14, P5140, DOI 10.1021/cm020737i
   Setiawan L, 2011, J MEMBRANE SCI, V369, P196, DOI 10.1016/j.memsci.2010.11.067
   Shannon MA, 2008, NATURE, V452, P301, DOI 10.1038/nature06599
   Shu HY, 2016, DESALIN WATER TREAT, V57, P7963, DOI 10.1080/19443994.2015.1061955
   Sun YP, 2007, COLLOID SURFACE A, V308, P60, DOI 10.1016/j.colsurfa.2007.05.029
   Tu C, 2011, J HAZARD MATER, V186, P1438, DOI 10.1016/j.jhazmat.2010.12.008
   Wang CB, 1997, ENVIRON SCI TECHNOL, V31, P2154, DOI 10.1021/es970039c
   Wang YB, 2015, APPL CATAL B-ENVIRON, V164, P396, DOI 10.1016/j.apcatb.2014.09.047
   Xu J, 2008, J PHYS CHEM C, V112, P9133, DOI 10.1021/jp7097262
   Yang CF, 2001, AICHE J, V47, P295, DOI 10.1002/aic.690470208
   Yang Y.N., 2008, J MEMBRANE SCI, V311, P200, DOI DOI 10.1016/J.MEMSCI.2007.12.014
   Yin J, 2015, J MEMBRANE SCI, V479, P256, DOI 10.1016/j.memsci.2014.11.019
   ZHANG W, 1989, DESALINATION, V72, P263, DOI 10.1016/0011-9164(89)80011-6
   Zhu NR, 2010, J HAZARD MATER, V176, P1101, DOI 10.1016/j.jhazmat.2009.11.092
NR 62
TC 0
Z9 0
U1 22
U2 57
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0376-7388
EI 1873-3123
J9 J MEMBRANE SCI
JI J. Membr. Sci.
PD MAY 15
PY 2017
VL 530
BP 147
EP 157
DI 10.1016/j.memsci.2017.02.021
PG 11
WC Engineering, Chemical; Polymer Science
SC Engineering; Polymer Science
GA EP9NA
UT WOS:000397699100016
PM 29398774
DA 2018-03-19
ER

PT J
AU Rockcliffe, DA
   Cammers, A
   Murali, A
   Russell, WK
   DeRose, VJ
AF Rockcliffe, David A.
   Cammers, Arthur
   Murali, Ayaluru
   Russell, William K.
   DeRose, Victoria J.
TI Comparison of copper binding characteristics of a His-Gly repeat
   dinucleating pentadecapeptide and a mononucleating tridecapeptide
   designed as copper binding mimics for the active sites of oxyhemocyanin
   and oxytyrosinase
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
C1 [Rockcliffe, David A.] Kentucky State Univ, Div Math & Sci, Frankfort, KY 40601 USA.
   [Cammers, Arthur] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
   [Murali, Ayaluru; Russell, William K.] Texas A&M Univ, Dept Chem, College Stn, TX 77842 USA.
   [DeRose, Victoria J.] Univ Oregon, Dept Chem, Eugene, OR 97403 USA.
EM david.rockcliffe@kysu.edu; a.cammers@uky.edu;
   wrussell@mail.chem.tamu.edu; derose@uoregon.edu
RI Cammers, Arthur/B-8681-2013
OI Cammers, Arthur/0000-0002-1682-3488
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD MAR 25
PY 2007
VL 233
MA 138-INOR
BP 375
EP 375
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA V14GL
UT WOS:000207722805364
DA 2018-03-19
ER

PT J
AU Ghoshal, S
   Bondada, V
   Saatman, KE
   Guttmann, RP
   Geddes, JW
AF Ghoshal, Sarbani
   Bondada, Vimala
   Saatman, Kathryn E.
   Guttmann, Rodney P.
   Geddes, James W.
TI Phage display for identification of serum biomarkers of traumatic brain
   injury
SO JOURNAL OF NEUROSCIENCE METHODS
LA English
DT Article
DE Traumatic brain injury; Biomarkers; Rodents; Animal models; Concussion;
   Blood
ID FIBRILLARY ACIDIC PROTEIN; CLINICAL-APPLICATIONS; BREAKDOWN PRODUCTS;
   EARLY INTERVENTION; FILAMENTOUS PHAGE; CORTICAL IMPACT; HEAD-INJURY;
   MILD; DIAGNOSIS; DAMAGE
AB Background: The extent and severity of traumatic brain injuries (TBIs) can be difficult to determine with current diagnostic methods. To address this, there has been increased interest in developing biomarkers to assist in the diagnosis, determination of injury severity, evaluation of recovery and therapeutic efficacy, and prediction of outcomes. Several promising serum TBI biomarkers have been identified using hypothesis-driven approaches, largely examining proteins that are abundant in neurons and non-neural cells in the CNS.
   New method: An unbiased approach, phage display, was used to identify serum TBI biomarkers. In this proof-of-concept study, mice received a TBI using the controlled cortical impact model of TBI (1 mm injury depth, 3.5 m/s velocity) and phage display was utilized to identify putative serum biomarkers at 6 h postinjury.
   Results: An engineered phage which preferentially bound to injured serum was sequenced to identify the 12-mer 'recognizer' peptide expressed on the coat protein. Following synthesis of the recognizer peptide, pull down, and mass spectrometry analysis, the target protein was identified as glial fibrillary acidic protein (GFAP).
   Comparison with existing methods and conclusions: GFAP has previously been identified as a promising TBI biomarker. The results provide proof of concept regarding the ability of phage display to identify TBI serum biomarkers. This methodology is currently being applied to serum biomarkers of mild TBI. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Ghoshal, Sarbani; Bondada, Vimala; Saatman, Kathryn E.; Geddes, James W.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, B483 Biomed & Biol Sci Res Bldg BBSRB, Lexington, KY 40536 USA.
   [Guttmann, Rodney P.] Univ Kentucky, Dept Gerontol, Lexington, KY USA.
   [Ghoshal, Sarbani] Scripps Res Inst, Dept Metab & Aging, Jupiter, FL USA.
   [Guttmann, Rodney P.] Univ West Florida, Ctr Aging, Pensacola, FL USA.
RP Geddes, JW (reprint author), Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, B483 Biomed & Biol Sci Res Bldg BBSRB, Lexington, KY 40536 USA.
EM jgeddes@uky.edu
OI Geddes, James/0000-0003-0369-3642
FU NIH [R21 NS084088, P30 NS051220]; Kentucky Spinal Cord and Head Injury
   Research Trust
FX This research was supported by NIH grants R21 NS084088 and P30 NS051220
   and by the Kentucky Spinal Cord and Head Injury Research Trust. We thank
   Kathleen Schoch, Ph.D. for the TBI surgeries.
CR Agoston Denes V, 2012, Front Neurol, V3, P107, DOI 10.3389/fneur.2012.00107
   Araujo GR, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0685-3
   Azzazy HME, 2002, CLIN BIOCHEM, V35, P425, DOI 10.1016/S0009-9120(02)00343-0
   Benhar I., 2002, CURRENT PROTOCOLS IM
   Bonnycastle LLC, 1996, J MOL BIOL, V258, P747, DOI 10.1006/jmbi.1996.0284
   Bradbury A.R., 2010, CURR PROTOC NEUROSCI
   Bratkovic T, 2010, CELL MOL LIFE SCI, V67, P749, DOI 10.1007/s00018-009-0192-2
   Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564
   Butler I.J., 2013, JAMA NEUROL, P1
   Cao T, 2012, NEUROSCIENCE, V225, P65, DOI 10.1016/j.neuroscience.2012.08.058
   Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859
   Czeiter E, 2012, J NEUROTRAUM, V29, P1770, DOI 10.1089/neu.2011.2127
   Dash PK, 2010, NEUROTHERAPEUTICS, V7, P100, DOI 10.1016/j.nurt.2009.10.019
   Diamandis EP, 2004, J NATL CANCER I, V96, P353, DOI 10.1093/jnci/djh056
   Ding J, 2015, ARQ NEURO-PSIQUIAT, V73, P342, DOI 10.1590/0004-282X20150006
   Eakin K, 2012, J NEUROTRAUM, V29, P1180, DOI 10.1089/neu.2011.2192
   Coelho EAF, 2015, REV SOC BRAS MED TRO, V48, P370, DOI 10.1590/0037-8682-0096-2015
   Giacoppo S, 2012, NEUROCRIT CARE, V16, P470, DOI 10.1007/s12028-012-9707-z
   Guingab-Cagmat JD, 2012, ELECTROPHORESIS, V33, P3786, DOI 10.1002/elps.201200326
   Guttmann RP, 2005, BIOCHEM BIOPH RES CO, V333, P1087, DOI 10.1016/j.bbrc.2005.06.036
   Hof D, 2006, MOL CELL PROTEOMICS, V5, P245, DOI 10.1074/mcp.M500239-MC200
   Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485
   Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439
   Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33
   Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564
   Kulbe JR, 2016, EXP NEUROL, V275, P334, DOI 10.1016/j.expneurol.2015.05.004
   Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001
   Loov C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055983
   Mackness B, 1998, GEN PHARMACOL-VASC S, V31, P329, DOI 10.1016/S0306-3623(98)00028-7
   Madathil SK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067204
   Manley GT, 2010, ARCH PHYS MED REHAB, V91, P1667, DOI 10.1016/j.apmr.2010.05.018
   Maroon JC, 2012, PHYSICIAN SPORTSMED, V40, P73, DOI 10.3810/psm.2012.11.1990
   MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0
   McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119
   Mondello S, 2012, NEUROSURGERY, V70, P666, DOI 10.1227/NEU.0b013e318236a809
   Mondello S, 2010, J NEUROTRAUM, V27, P1203, DOI 10.1089/neu.2010.1278
   Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021
   Park JP, 2010, BIOTECHNOL BIOENG, V105, P678, DOI 10.1002/bit.22597
   Pineda JA, 2004, BRAIN PATHOL, V14, P202, DOI 10.1111/j.1750-3639.2004.tb00054.x
   Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330
   Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297
   Ropper AH, 2007, NEW ENGL J MED, V356, P166, DOI 10.1056/NEJMcp064645
   Rosenbaum SB, 2012, BRAIN IMAGING BEHAV, V6, P255, DOI 10.1007/s11682-012-9162-7
   Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586
   Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241
   Sandler SJI, 2010, CHILD NERV SYST, V26, P205, DOI 10.1007/s00381-009-1009-1
   Schirrmann T, 2011, MOLECULES, V16, P412, DOI 10.3390/molecules16010412
   Shultz SR, 2011, BEHAV BRAIN RES, V224, P326, DOI 10.1016/j.bbr.2011.06.012
   Sidhu SS, 2000, METHOD ENZYMOL, V328, P333, DOI 10.1016/S0076-6879(00)28406-1
   Siman R, 2004, NEUROBIOL DIS, V16, P311, DOI 10.1016/j.nbd.2004.03.016
   Siman R, 2009, J NEUROTRAUM, V26, P1867, DOI 10.1089/neu.2009.0882
   SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169
   TAKAHASHI K, 1987, ARCH BIOCHEM BIOPHYS, V256, P677, DOI 10.1016/0003-9861(87)90624-2
   Topolovec-Vranic J, 2011, J TRAUMA, V71, pS478, DOI 10.1097/TA.0b013e318232fa70
   Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177
   Wang K.K., 2015, J NEUROTRAU IN PRESS
   Wang KKW, 2005, EXPERT REV PROTEOMIC, V2, P603, DOI 10.1586/14789450.2.4.603
   Wang M, 2011, RHEUMATOL INT, V31, P1009, DOI 10.1007/s00296-010-1403-8
   Weng XJ, 2012, CLIN BIOCHEM, V45, P303, DOI 10.1016/j.clinbiochem.2011.12.018
   Yang ZH, 2015, TRENDS NEUROSCI, V38, P364, DOI 10.1016/j.tins.2015.04.003
   Yokobori S, 2013, CNS NEUROSCI THER, V19, P556, DOI 10.1111/cns.12127
   Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9
   Zhang ZJ, 2011, J CLIN LAB ANAL, V25, P402, DOI 10.1002/jcla.20491
   Zurbig P, 2012, ELECTROPHORESIS, V33, P3617, DOI 10.1002/elps.201200360
NR 64
TC 1
Z9 1
U1 1
U2 10
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-0270
EI 1872-678X
J9 J NEUROSCI METH
JI J. Neurosci. Methods
PD OCT 15
PY 2016
VL 272
SI SI
BP 33
EP 37
DI 10.1016/j.jneumeth.2016.04.026
PG 5
WC Biochemical Research Methods; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA EA6LF
UT WOS:000386740000004
PM 27168498
OA green_accepted
DA 2018-03-20
ER

PT J
AU Hu, B
   Hinds, BJ
AF Hu, Bing
   Hinds, Bruce J.
TI Photocurrent Enhancement of Copper (II) Phthalocyanine on Nanogap Thin
   Film Electrodes
SO IEEE TRANSACTIONS ON NANOTECHNOLOGY
LA English
DT Article
DE Nanocontacts; nanofabrication; organic semiconductors; photodetectors;
   tunneling
ID SOLAR-CELLS; PHOTOVOLTAIC CELLS; HETEROJUNCTIONS; TRANSISTORS
AB Photovoltaic efficiency of organic semiconductors can be improved when the electrode separation distance is below the carrier recombination length. Nanogap electrodes formed by Au/Al2O3/Au tunnel junctions were used to study photovoltaic characteristics of Copper (II) phthalocyanine (CuPc) for electrode spacing distance within a 10nm scale. A large photocurrent enhancement over 50 times that of bulk CuPc film was observed when the electrode gap distance approached 10 nm. CuPc carrier recombination length is seen to be 10 nm, in our evaporation deposited materials, close to its exciton diffusion length in the literature reports. All devices show diode I-V properties due to a large Schotteky barrier contact resistance between the small top Au electrode and CuPc film.
C1 [Hu, Bing] MicroChip Technol, Chandler, AZ 85224 USA.
   [Hinds, Bruce J.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Hu, B (reprint author), MicroChip Technol, Chandler, AZ 85224 USA.
EM binghu.hu@gmail.com; bjhinds@engr.uky.edu
FU Department of Energy [EPSCoR DE-FG02-07ER46375]; National Science
   Foundation [CAREER 0348544, NIRT 0609064]
FX This work was supported in part by the Department of Energy under Grant
   EPSCoR DE-FG02-07ER46375 and by the National Science Foundation under
   Grant CAREER 0348544 and Grant NIRT 0609064. The review of this paper
   was arranged by Associate Editor M. M. De Souza.
CR Banerjee S, 2009, APPL PHYS LETT, V94, DOI 10.1063/1.3142869
   GOULD RD, 1985, THIN SOLID FILMS, V125, P63, DOI 10.1016/0040-6090(85)90396-7
   GUTMAN F, 1967, ORGANIC SEMICONDUCTO
   HALLS JJM, 1995, NATURE, V376, P498, DOI 10.1038/376498a0
   Hansel H, 2003, ADV MATER, V15, P2056, DOI 10.1002/adma.200305274
   Hoppe H, 2004, J MATER RES, V19, P1924, DOI 10.1557/JMR.2004.0252
   Hu B, 2010, APPL PHYS LETT, V97, DOI 10.1063/1.3514253
   Karan S, 2008, PHYS CHEM CHEM PHYS, V10, P6751, DOI 10.1039/b809648a
   Kasap S. O., 2006, PRINCIPLES ELECT MAT
   KREJA L, 1992, J MATER SCI LETT, V11, P538, DOI 10.1007/BF00728601
   Liang YY, 2010, ADV MATER, V22, pE135, DOI 10.1002/adma.200903528
   Murphy AR, 2007, CHEM REV, V107, P1066, DOI 10.1021/cr0501386
   Peumans P, 2003, J APPL PHYS, V93, P3693, DOI 10.1063/1.1534621
   Shaw PE, 2008, ADV MATER, V20, P3516, DOI 10.1002/adma.200800982
   Simon J., 1985, MOL SEMICONDUCTORS
   TANG CW, 1986, APPL PHYS LETT, V48, P183, DOI 10.1063/1.96937
   Tyagi P., 2007, P 2 IEEE INT C NANOM, P191
   Tyagi P, 2007, J AM CHEM SOC, V129, P4929, DOI 10.1021/ja065789d
   Tyagi P, 2010, J VAC SCI TECHNOL B, V28, P517, DOI 10.1116/1.3406143
   Xue JG, 2004, APPL PHYS LETT, V85, P5757, DOI 10.1063/1.1829776
   Yang F, 2005, NAT MATER, V4, P37, DOI 10.1038/nmat1285
   Yang LG, 2008, THIN SOLID FILMS, V516, P7701, DOI 10.1016/j.tsf.2008.03.027
   YU G, 1995, SCIENCE, V270, P1789, DOI 10.1126/science.270.5243.1789
   Zaumseil J, 2007, CHEM REV, V107, P1296, DOI 10.1021/cr0501543
NR 24
TC 0
Z9 0
U1 0
U2 32
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 1536-125X
J9 IEEE T NANOTECHNOL
JI IEEE Trans. Nanotechnol.
PD NOV
PY 2012
VL 11
IS 6
BP 1073
EP 1079
DI 10.1109/TNANO.2012.2193595
PG 7
WC Engineering, Electrical & Electronic; Nanoscience & Nanotechnology;
   Materials Science, Multidisciplinary; Physics, Applied
SC Engineering; Science & Technology - Other Topics; Materials Science;
   Physics
GA 045MT
UT WOS:000311701300004
DA 2018-03-20
ER

PT J
AU Stocke, NA
   Zhang, X
   Hilt, JZ
   DeRouchey, JE
AF Stocke, Nathanael A.
   Zhang, Xiaolu
   Hilt, J. Zach
   DeRouchey, Jason E.
TI Transport in PEG-Based Hydrogels: Role of Water Content at Synthesis and
   Crosslinker Molecular Weight
SO MACROMOLECULAR CHEMISTRY AND PHYSICS
LA English
DT Article
DE fluorescence correlation spectroscopy (FCS); mechanical properties;
   particle diffusion; polymeric hydrogels; swelling
ID FLUORESCENCE CORRELATION SPECTROSCOPY; DRUG-DELIVERY; DIFFUSION;
   POLY(N-ISOPROPYLACRYLAMIDE); NANOPARTICLES; DYNAMICS
AB Poly(ethylene glycol) (PEG) hydrogels are hydrophilic, high water content, polymeric networks that represent excellent candidates as engineering biomaterials for a broad range of applications. A key challenge for many biomedical applications is the control of transport properties within the resulting 3D crosslinked gels. The effects of the water content at synthesis and crosslinker molecular weights on gel chemical structure and equilibrium volumetric swelling ratio, Q, are studied for a series of PEG hydrogels. In addition, the translational diffusion coefficients of a model probe molecule, Rhodamine 110, are determined directly within the hydrogels by fluorescence correlation spectroscopy measurements. Increasing the water content at synthesis results in larger observed swelling behavior and faster particle transport within the formed PEG hydrogels for two different crosslinker molecular weights due to fewer physical crosslinks in the gels. Comparison of the particle translational diffusion coefficient to the swelling ratio shows a linear relationship for all crosslink densities examined.
C1 [Stocke, Nathanael A.; Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Zhang, Xiaolu; DeRouchey, Jason E.] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
RP Hilt, JZ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.; DeRouchey, JE (reprint author), Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
EM hilt@engr.uky.edu; derouchey@uky.edu
RI DeRouchey, Jason/C-5907-2011
OI DeRouchey, Jason/0000-0002-3624-4432
FU National Cancer Institute [5R25CA153954]; University of Kentucky;
   NCI-CNTC pre-doctoral traineeship; University of Kentucky Research
   Challenge Trust Fund (RCTF) Fellowship for Biochemistry
FX This work was supported by Grant Number 5R25CA153954 from the National
   Cancer Institute and start-up funds from the University of Kentucky.
   N.A.S. acknowledges financial support from an NCI-CNTC pre-doctoral
   traineeship and X.Z. acknowledges financial support from the University
   of Kentucky Research Challenge Trust Fund (RCTF) Fellowship for
   Biochemistry.
CR Amsden B, 1998, MACROMOLECULES, V31, P8382, DOI 10.1021/ma980765f
   Cherdhirankorn T, 2009, J PHYS CHEM B, V113, P3355, DOI 10.1021/jp809707y
   DELGADO C, 1992, CRIT REV THER DRUG, V9, P249
   DeRouchey J, 2008, BIOMACROMOLECULES, V9, P724, DOI 10.1021/bm7011482
   ELSON EL, 1974, BIOPOLYMERS, V13, P1, DOI 10.1002/bip.1974.360130102
   Gabizon A, 2004, ADV DRUG DELIVER REV, V56, P1177, DOI 10.1016/j.addr.2004.01.011
   Gendron PO, 2008, J FLUORESC, V18, P1093, DOI 10.1007/s10895-008-0357-7
   GREF R, 1995, ADV DRUG DELIVER REV, V16, P215, DOI 10.1016/0169-409X(95)00026-4
   Hawkins AM, 2014, J BIOMED MATER RES A, V102, P400, DOI 10.1002/jbm.a.34697
   Hawkins AM, 2013, POLYMER, V54, P4422, DOI 10.1016/j.polymer.2013.06.010
   Hawkins AM, 2011, J APPL POLYM SCI, V122, P1420, DOI 10.1002/app.34093
   Hess ST, 2002, BIOCHEMISTRY-US, V41, P697, DOI 10.1021/bi0118512
   Hinds KD, 2002, ADV DRUG DELIVER REV, V54, P505, DOI 10.1016/S0169-409X(02)00025-X
   Ishida T, 2007, J CONTROL RELEASE, V122, P349, DOI 10.1016/j.jconrel.2007.05.015
   Knop K, 2010, ANGEW CHEM INT EDIT, V49, P6288, DOI 10.1002/anie.200902672
   Kopecek J, 2009, J POLYM SCI POL CHEM, V47, P5929, DOI 10.1002/pola.23607
   Lin CC, 2009, PHARM RES-DORD, V26, P631, DOI 10.1007/s11095-008-9801-2
   Meenach SA, 2009, J BIOMED MATER RES A, V91A, P903, DOI 10.1002/jbm.a.32322
   Michelman-Ribeiro A, 2004, MACROMOLECULES, V37, P10212, DOI 10.1021/ma048043d
   Michelman-Ribeiro A, 2007, BIOMACROMOLECULES, V8, P1595, DOI 10.1021/bm061195r
   Miyata T, 1996, MACROMOL CHEM PHYSIC, V197, P1135, DOI 10.1002/macp.1996.021970330
   Otsuka H, 2003, ADV DRUG DELIVER REV, V55, P403, DOI 10.1016/S0169-409X(02)00226-0
   PEPPAS NA, 1993, ADV DRUG DELIVER REV, V11, P1, DOI 10.1016/0169-409X(93)90025-Y
   Peppas NA, 2000, EUR J PHARM BIOPHARM, V50, P27, DOI 10.1016/S0939-6411(00)00090-4
   Peppas NA, 2006, ADV MATER, V18, P1345, DOI 10.1002/adma.200501612
   Peppas NA, 1999, J CONTROL RELEASE, V62, P81, DOI 10.1016/S0168-3659(99)00027-9
   Raccis R, 2011, SOFT MATTER, V7, P7042, DOI 10.1039/c0sm01438a
   Schmidt JJ, 2013, BIOMACROMOLECULES, V14, P1361, DOI 10.1021/bm302004v
   Shapiro YE, 2011, PROG POLYM SCI, V36, P1184, DOI 10.1016/j.progpolymsci.2011.04.002
   Stocke NA, 2017, MACROMOL CHEM PHYS, V218, DOI 10.1002/macp.201600340
   Torchilin VP, 2002, ADV DRUG DELIVER REV, V54, P235, DOI 10.1016/S0169-409X(02)00019-4
   Vagias A, 2014, MACROMOLECULES, V47, P5303, DOI 10.1021/ma500928p
   Woll D, 2014, RSC ADV, V4, P2447, DOI 10.1039/c3ra44909b
   Wu YB, 2009, J PHYS CHEM B, V113, P3512, DOI 10.1021/jp808145x
   Yakacki CM, 2009, J APPL POLYM SCI, V112, P3166, DOI 10.1002/app.29845
   Yu SA, 2010, TALANTA, V83, P156, DOI 10.1016/j.talanta.2010.08.055
   Zustiak SP, 2011, BIOPHYS J, V101, P255, DOI 10.1016/j.bpj.2011.05.035
   Zustiak SP, 2010, SOFT MATTER, V6, P3609, DOI 10.1039/c0sm00111b
   Zustiak SP, 2010, BIOMACROMOLECULES, V11, P1348, DOI 10.1021/bm100137q
NR 39
TC 1
Z9 1
U1 4
U2 8
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1022-1352
EI 1521-3935
J9 MACROMOL CHEM PHYS
JI Macromol. Chem. Phys.
PD FEB
PY 2017
VL 218
IS 3
AR 1600340
DI 10.1002/macp.201600340
PG 9
WC Polymer Science
SC Polymer Science
GA EL6AY
UT WOS:000394704000002
DA 2018-03-20
ER

PT J
AU Majumder, M
   Zhan, X
   Andrews, R
   Hinds, BJ
AF Majumder, Mainak
   Zhan, Xin
   Andrews, Rodney
   Hinds, Bruce J.
TI Voltage gated carbon nanotube membranes
SO LANGMUIR
LA English
DT Article
ID ARYL DIAZONIUM SALTS; ELECTROCHEMICAL REDUCTION; ION CHANNELS;
   K+-CHANNEL; TRANSPORT; SURFACE; ELECTRODE; FUNCTIONALIZATION; DNA
AB Membranes composed of an array of aligned carbon nanotubes, functionalized with charged molecular tethers, show voltage gated control of ionic transport through the cores of carbon nanotubes. The functional density of tethered charge molecules is substantially increased by the use of electrochemical grafting of diazonium salts. Functionality can be forced to occur at the CNT tip entrances by fast fluid flow of an inert solvent through the core during electrochemical functionalization. The selectivity between Ru(bi-pyridine)(3)(2+) and methyl viologen(2+) flux is found to be as high as 23 with -130 mV bias applied to the membrane as the working electrode. Changes in the flux and selectivity support a model where charged tethered molecules at the tips are drawn into the CNT core at positive bias. For molecules grafted along the CNT core, negative bias extends the tethered molecules into the core. Electrostatically actuated tethers induce steric hindrance in the CNT core to mimic voltage gated ion channels in a robust large area platform.
C1 Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
   Univ Kentucky, Ctr Appl Energy Res, Lexington, KY 40511 USA.
RP Hinds, BJ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM bjhinds@engr.uky.edu
RI Majumder, Mainak/B-4667-2011
CR Allongue P, 1997, J AM CHEM SOC, V119, P201, DOI 10.1021/ja963354s
   Bahr JL, 2001, J AM CHEM SOC, V123, P6536, DOI 10.1021/ja010462s
   Combellas C, 2005, LANGMUIR, V21, P280, DOI 10.1021/la048106l
   Corgier BP, 2005, J AM CHEM SOC, V127, P18328, DOI 10.1021/ja056946w
   D'Amours M, 2003, J PHYS CHEM B, V107, P4811, DOI 10.1021/jp027223r
   DEEN WM, 1987, AICHE J, V33, P1409, DOI 10.1002/aic.690330902
   Harrell CC, 2004, J AM CHEM SOC, V126, P15646, DOI 10.1021/ja044948v
   Hector RS, 2005, SUPRAMOL CHEM, V17, P129, DOI 10.1080/10610270412331328871
   Hinds BJ, 2004, SCIENCE, V303, P62, DOI 10.1126/science.1092048
   Holt JK, 2006, SCIENCE, V312, P1034, DOI 10.1126/science.1126298
   Huang SM, 2002, J PHYS CHEM B, V106, P3543, DOI 10.1021/jp014047y
   Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580
   Jirage KB, 1997, SCIENCE, V278, P655, DOI 10.1126/science.278.5338.655
   Joseph S, 2003, NANO LETT, V3, P1399, DOI 10.1021/nl0346326
   Kang MS, 2001, LANGMUIR, V17, P2753, DOI 10.1021/la001186i
   Kariuki JK, 2001, LANGMUIR, V17, P5947, DOI 10.1021/la010415d
   Kontturi K, 1996, MACROMOLECULES, V29, P5740, DOI 10.1021/ma960501y
   Lahann J, 2003, SCIENCE, V299, P371, DOI 10.1126/science.1078933
   Majumder M, 2005, NATURE, V438, P44, DOI 10.1038/43844a
   Majumder M, 2005, J AM CHEM SOC, V127, P9062, DOI 10.1021/ja043013b
   Matrab T, 2006, COLLOID SURFACE A, V287, P217, DOI 10.1016/j.colsurfa.2006.05.028
   Nednoor P, 2005, CHEM MATER, V17, P3595, DOI 10.1021/cm047844s
   Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73
   Rant U, 2004, NANO LETT, V4, P2441, DOI 10.1021/nl0484494
   Siwy Z, 2002, EUROPHYS LETT, V60, P349, DOI 10.1209/epl/i2002-00271-3
   Wang GL, 2006, J AM CHEM SOC, V128, P7679, DOI 10.1021/ja061357r
   Yellen G, 1998, Q REV BIOPHYS, V31, P239, DOI 10.1017/S0033583598003448
NR 27
TC 92
Z9 92
U1 1
U2 38
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0743-7463
J9 LANGMUIR
JI Langmuir
PD JUL 31
PY 2007
VL 23
IS 16
BP 8624
EP 8631
DI 10.1021/la700686k
PG 8
WC Chemistry, Multidisciplinary; Chemistry, Physical; Materials Science,
   Multidisciplinary
SC Chemistry; Materials Science
GA 192UW
UT WOS:000248229900052
PM 17616216
DA 2018-03-20
ER

PT J
AU Mansour, HM
   Sohn, M
   Al-Ghananeem, A
   DeLuca, PP
AF Mansour, Heidi M.
   Sohn, MinJi
   Al-Ghananeem, Abeer
   DeLuca, Patrick P.
TI Materials for Pharmaceutical Dosage Forms: Molecular Pharmaceutics and
   Controlled Release Drug Delivery Aspects
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE polymers; copolymers; biomaterials; biodegradable; microparticle;
   nanoparticle; pharmaceutical dosage forms; particle engineering design;
   manufacture
ID IN-VIVO EVALUATION; TISSUE ENGINEERING APPLICATIONS; BLOCK-COPOLYMER
   MICELLES; LACTIDE-CO-GLYCOLIDE; OSMOTIC PUMP TABLETS; VITRO RELEASE;
   PLGA MICROSPHERES; PARTICLE-SIZE; GENE DELIVERY; DICLOFENAC SODIUM
AB Controlled release delivery is available for many routes of administration and offers many advantages (as microparticles and nanoparticles) over immediate release delivery. These advantages include reduced dosing frequency, better therapeutic control, fewer side effects, and, consequently, these dosage forms are well accepted by patients. Advances in polymer material science, particle engineering design, manufacture, and nanotechnology have led the way to the introduction of several marketed controlled release products and several more are in pre-clinical and clinical development.
C1 [Mansour, Heidi M.; Sohn, MinJi; Al-Ghananeem, Abeer; DeLuca, Patrick P.] Univ Kentucky, Coll Pharm, Div Pharmaceut Sci, Lexington, KY 40536 USA.
RP Mansour, HM (reprint author), Univ Kentucky, Coll Pharm, Div Pharmaceut Sci, Lexington, KY 40536 USA.
EM heidi.mansour@uky.edu; minjisohn@uky.edu; amalg0@email.uky.edu;
   ppdelu1@email.uky.edu
RI Mansour, Heidi/D-1074-2011
CR ABUCHOWSKI A, 1977, J BIOL CHEM, V252, P3582
   Adams ML, 2003, J PHARM SCI, V92, P1343, DOI 10.1002/jps.10397
   Agnihotri SA, 2004, J CONTROL RELEASE, V96, P245, DOI 10.1016/j.jconrel.2004.01.025
   Bae Y, 2007, BIOCONJUGATE CHEM, V18, P1131, DOI 10.1021/bc060401p
   Barichello JM, 1999, DRUG DEV IND PHARM, V25, P471, DOI 10.1081/DDC-100102197
   Batrakova EV, 2008, J CONTROL RELEASE, V130, P98, DOI 10.1016/j.jconrel.2008.04.013
   Berkland C, 2002, J CONTROL RELEASE, V82, P137, DOI 10.1016/S0168-3659(02)00136-0
   Bigucci F, 2008, DRUG DELIV, V15, P289, DOI 10.1080/10717540802006468 
   Blanco D, 1998, EUR J PHARM BIOPHARM, V45, P285, DOI 10.1016/S0939-6411(98)00011-3
   Bleich J, 1996, J MICROENCAPSUL, V13, P131, DOI 10.3109/02652049609052902
   Bonacucina G, 2006, INT J PHARM, V313, P72, DOI 10.1016/j.ijpharm.2006.01.046
   Brache V, 2006, CONTRACEPTION, V73, P364, DOI 10.1016/j.contraception.2005.10.015
   BUHLER V, 1999, KOLLIDON POLYVINYLPY
   CAPAN Y, 2003, AAPS PHARMSCITECH, V4
   Chen J, 2005, J CONTROL RELEASE, V101, P359
   Chen S, 2008, INT J PHARM, V352, P58, DOI 10.1016/j.ijpharm.2007.10.016
   Cheng JJ, 2006, PHARM RES, V23, P557, DOI 10.1007/s11095-005-9444-5
   Cheng YH, 2000, J DRUG TARGET, V8, P107, DOI 10.3109/10611860008996856
   Cheon LS, 2003, J CONTROL RELEASE, V89, P437, DOI DOI 10.1016/S0168-3659(03)00162-7
   Choi S, 2004, PHARM RES, V21, P827, DOI 10.1023/B:PHAM.0000026435.27086.94
   Chow AHL, 2007, PHARM RES, V24, P411, DOI 10.1007/s11095-006-9174-3
   Costantino HR, 2000, PHARMACEUT RES, V17, P1374, DOI 10.1023/A:1007570030368
   Coucke D, 2009, VACCINE, V27, P1279, DOI 10.1016/j.vaccine.2008.12.013
   d'Ayala GG, 2008, MOLECULES, V13, P2069, DOI 10.3390/molecules13092069
   D'Souza R, 2006, DRUG DEV IND PHARM, V32, P175, DOI 10.1080/03639040500466064
   D'Souza SS, 2006, PHARM RES-DORDR, V23, P460, DOI 10.1007/s11095-005-9397-8
   D'Souza SS, 2004, AAPS PHARMSCI, V6, DOI 10.1208/ps060110
   D'Souza Susan S, 2005, AAPS PharmSciTech, V6, pE553, DOI 10.1208/pt060470
   Dailey LA, 2005, J CONTROL RELEASE, V101, P137, DOI 10.1016/j.jconrel.2004.09.03
   Dani Bhas A, 2002, AAPS PharmSciTech, V3, pE21, DOI 10.1208/pt030321
   DASARATHA DM, 2003, INT J PHARMACEUT, V268, P23
   Dhanaraju MD, 2006, CONTRACEPTION, V74, P148, DOI 10.1016/j.contraception.2006.01.015
   Dhanikula AB, 1999, INT J PHARM, V183, P85, DOI 10.1016/S0378-5173(99)00087-3
   Dinarvand R, 2005, J BIOMED MATER RES A, V75A, P185, DOI 10.1002/jbm.a.30398
   Dunbar C A, 1998, Pharm Dev Technol, V3, P433, DOI 10.3109/10837459809028624
   Ebube N K, 1997, Pharm Dev Technol, V2, P161, DOI 10.3109/10837459709022621
   Elversson J, 2005, J PHARM SCI-US, V94, P2049, DOI 10.1002/jps.20418
   Elversson J, 2003, J PHARM SCI, V92, P900, DOI 10.1002/jps.10352
   Esposito P, 2003, ADV DRUG DELIVER REV, V55, P1279, DOI 10.1016/S0169-409X(03)00109-1
   Fernandes PAL, 2008, LANGMUIR, V24, P13677, DOI 10.1021/la801898t
   Fernandez-Carballido A, 2004, J MICROENCAPSUL, V21, P653, DOI 10.1080/09687860400008437
   FLORENCE AT, 2009, MODERN PHARM, V2, P453
   Francis L, 2010, ACTA BIOMATER, V6, P2773, DOI 10.1016/j.actbio.2009.12.054
   FRAUKE PK, 2001, J CONTROL RELEASE, V73, P7
   Friess W, 1998, EUR J PHARM BIOPHARM, V45, P113, DOI 10.1016/S0939-6411(98)00017-4
   Fundueanu G, 2004, BIOMATERIALS, V25, P159, DOI 10.1016/S0142-9612(03)00477-0
   Gilani K, 2005, J PHARM SCI-US, V94, P1048, DOI 10.1002/jps.20315
   Gillissen M, 2006, J CONTROL RELEASE, V116, pE90, DOI 10.1016/j.jconrel.2006.09.066
   Giovagnoli S, 2010, AAPS PHARMSCITECH, V11, P212, DOI 10.1208/s12249-009-9361-8
   Gupte A, 2004, INT J PHARM, V276, P93, DOI 10.1016/j.ijpharm.2004.02.023
   Guthmann C, 2008, EUR J PHARM BIOPHARM, V69, P667, DOI 10.1016/j.ejpb.2007.12.017
   Hafeli UO, 2004, INT J PHARM, V277, P19, DOI 10.1016/j.ijpharm.2003.03.002
   Hans ML, 2007, J BIOMED MATER RES B, V83B, P422, DOI 10.1002/jbm.b.30812
   Hayama M, 2004, BIOMATERIALS, V25, P1019, DOI 10.1016/S0142-9612(03)00629-X
   He LL, 2006, PHARMAZIE, V61, P1022
   Hickey A. J., 2008, MODIFIED RELEASE DRU, P573
   Hu JH, 2004, DRUG DEV IND PHARM, V30, P695, DOI 10.1081/DDC-120039212
   Huh KM, 2005, J CONTROL RELEASE, V101, P59, DOI 10.1016/j.jconrel.2004.07.003
   Jantzen Gwen M., 2002, VVolume 121, P501
   Jaraswekin S, 2007, J MICROENCAPSUL, V24, P117, DOI 10.1007/02652040701233655
   Jeon JH, 2008, BIOMATERIALS, V29, P3591, DOI 10.1016/j.biomaterials.2008.05.011
   Jeon JH, 2008, J PERIODONTOL, V79, P1457, DOI [10.1902/jop.2008.080004, 10.1902/jop.2008.080004 ]
   Jeon JH, 2007, INT J PHARM, V340, P6, DOI 10.1016/j.ijpharm.2007.03.007
   Jia YM, 2008, INT J PHARM, V359, P254, DOI 10.1016/j.ijpharm.2008.03.035
   Jung T, 2000, J CONTROL RELEASE, V67, P157, DOI 10.1016/S0168-3659(00)00201-7
   Jung T, 2002, PHARMACEUT RES, V19, P1105, DOI 10.1023/A:1019833822997
   Jung T, 2001, PHARMACEUT RES, V18, P352, DOI 10.1023/A:1011063232257
   Kabanov AV, 2002, ADV DRUG DELIVER REV, V54, P759, DOI 10.1016/S0169-409X(02)00047-9
   Kabanov AV, 2002, J CONTROL RELEASE, V82, P189, DOI 10.1016/S0168-3659(02)00009-3
   Kanagale Pritam, 2008, Current Drug Delivery, V5, P306, DOI 10.2174/156720108785914998
   Kane JM, 2003, AM J PSYCHIAT, V160, P1125, DOI 10.1176/appi.ajp.160.6.1125
   Kang F, 2001, AAPS PharmSciTech, V2, P30
   Kang JY, 2009, INT J PHARM, V369, P114, DOI 10.1016/j.ijpharm.2008.11.008
   Kataoka K, 2001, ADV DRUG DELIVER REV, V47, P113, DOI 10.1016/S0169-409X(00)00124-1
   Kiremitci AS, 2007, J BIOMED MATER RES B, V83B, P609, DOI 10.1002/jbm.b.30834
   Kleppner SR, 2006, J PHARM PHARMACOL, V58, P295, DOI 10.1211/jpp.58.3.0002
   Kostanski JW, 2000, PHARM DEV TECHNOL, V5, P585, DOI 10.1081/PDT-100102043
   Kumar N, 2001, ADV DRUG DELIVER REV, V53, P23, DOI 10.1016/S0169-409X(01)00219-8
   Kumar PS, 2006, PHARMAZIE, V61, P613
   La SB, 1996, J PHARM SCI, V85, P85, DOI 10.1021/js950204r
   Lecaroz C, 2006, J MICROENCAPSUL, V23, P782, DOI 10.1080/02652040600946886
   Lee LY, 2008, J CONTROL RELEASE, V125, P96, DOI 10.1016/j.jconrel.2007.10.002
   Lee PY, 2003, PHARM RES, V20, P1995, DOI 10.1023/B:PHAM.0000008048.58777.da
   LEGARRE, 2004, J CONTROL RELEASE, V99, P83
   Li W, 2007, COLLOID SURFACE B, V59, P11, DOI 10.1016/j.colsurfb.2007.04.011
   Liao YH, 2005, DRUG DELIV, V12, P327, DOI 10.1080/10717540590952555
   Lin W, 1993, J DRUG TARGET, V1, P237, DOI 10.3109/10611869308996081
   Liu FI, 2003, INT J PHARM, V257, P23, DOI 10.1016/S0378-5173(03)00110-8
   Longer M. A., 1990, REMINGTONS PHARM SCI, P1676
   Loughlin RG, 2008, EUR J PHARM BIOPHARM, V69, P1135, DOI 10.1016/j.ejpb.2008.01.033
   Lu YX, 2008, EUR J PHARM BIOPHARM, V68, P422, DOI 10.1016/j.ejpb.2007.05.016
   Lu YX, 2007, J PHARM SCI-US, V96, P3252, DOI 10.1002/jps.21091
   Lu Y, 2007, J MICROENCAPSUL, V24, P515, DOI 10.1080/02652040701433479
   Ma XF, 2008, BIOMACROMOLECULES, V9, P3314, DOI 10.1021/bm800987c
   Maa Y F, 1997, Pharm Dev Technol, V2, P213, DOI 10.3109/10837459709031441
   Maa Yuh-Fun, 2000, Current Pharmaceutical Biotechnology, V1, P283, DOI 10.2174/1389201003378898
   Maeda M, 2002, J CONTROL RELEASE, V84, P15, DOI 10.1016/S0168-3659(02)00236-5
   Makhija SN, 2003, J CONTROL RELEASE, V89, P5, DOI 10.1016/S0168-3659(02)00482-0
   Malafaya PB, 2007, ADV DRUG DELIVER REV, V59, P207, DOI 10.1016/j.addr.2007.03.012
   Mansour HM, 2009, INT J NANOMED, V4, P299
   Matsumura Y, 2008, ADV DRUG DELIVER REV, V60, P899, DOI 10.1016/j.addr.2007.11.010
   Mawad D, 2008, BIOMACROMOLECULES, V9, P263, DOI 10.1021/bm700754m
   MCCLELLAND GA, 1991, PHARMACEUT RES, V8, P88, DOI 10.1023/A:1015890525495
   MINKO T, 2006, MARTINS PHYS PHARM P, P667
   Mishima K, 2008, ADV DRUG DELIVER REV, V60, P411, DOI 10.1016/j.addr.2007.02.003
   Misra SK, 2010, BIOMATERIALS, V31, P2806, DOI 10.1016/j.biomaterials.2009.12.045
   Miyazaki Y, 2004, INT J PHARM, V287, P39, DOI 10.1016/j.ijpharm.2004.08.023
   Mohammadi-Samani S, 2000, DRUG DEV IND PHARM, V26, P91, DOI 10.1081/DDC-100100332
   Morales ME, 2004, J CONTROL RELEASE, V95, P75, DOI 10.1016/j.jconrel.2003.11.002
   Moss GP, 2006, DRUG DEV IND PHARM, V32, P163, DOI 10.1080/03639040500466049
   Mourino V, 2010, J R SOC INTERFACE, V7, P209, DOI 10.1098/rsif.2009.0379
   Mumper RJ, 1996, PHARMACEUT RES, V13, P701, DOI 10.1023/A:1016039330870
   Mundargi RC, 2008, J CONTROL RELEASE, V125, P193, DOI 10.1016/j.jconrel.2007.09.013
   Mundargi RC, 2007, J CONTROL RELEASE, V119, P59, DOI 10.1016/j.jconrel.2007.01.008
   Muschert S, 2009, EUR J PHARM BIOPHARM, V72, P130, DOI 10.1016/j.ejpb.2008.12.007
   Na DH, 2005, PHARM RES, V22, P743, DOI 10.1007/s11095-005-2590-y
   Na DH, 2005, PHARM RES, V22, P736, DOI 10.1007/s11095-005-2589-4
   Na DH, 2007, AAPS PHARMSCITECH, V8
   Nahar M, 2008, NANOMED-NANOTECHNOL, V4, P252, DOI 10.1016/j.nano.2008.03.007
   Nahata T, 2008, J MICROENCAPSUL, V25, P426, DOI 10.1080/02652040802033913 
   Nie SF, 2007, DRUG DEV IND PHARM, V33, P1024, DOI 10.1080/03639040601179897
   Nokhodchi A, 2008, DRUG DELIV, V15, P43, DOI 10.1080/10717540701829028 
   OKADA H, 1994, PHARMACEUT RES, V11, P1143, DOI 10.1023/A:1018936815654
   Otsuka H, 2003, ADV DRUG DELIVER REV, V55, P403, DOI 10.1016/S0169-409X(02)00226-0
   Ozbas-Turan S, 2002, J PHARM SCI, V91, P1245, DOI 10.1002/jps.10122
   Pai SS, 2009, AAPS J, V11, P88, DOI 10.1208/s12248-009-9081-8
   Pajic-Lijakovic I, 2007, J MICROENCAPSUL, V24, P420, DOI 10.1080/02652040701362843
   Palakodaty S, 1998, PHARMACEUT RES, V15, P1835, DOI 10.1023/A:1011949805156
   Panyam J, 2003, J CONTROL RELEASE, V92, P173, DOI 10.1016/S0168-3659(03)00328-6
   Park EJ, 2007, INT J PHARM, V343, P281, DOI 10.1016/j.ijpharm.2007.06.005
   Park K, 2005, J CONTROL RELEASE, V104, P167, DOI 10.1016/j.jconrel.2005.01.013
   Peng H, 2009, BIOMACROMOLECULES, V10, P95, DOI 10.1021/bm800937g
   Quaglia F, 2005, MACROMOL BIOSCI, V5, P945, DOI 10.1002/mabi.200500108
   Raiche AT, 2003, IEEE ENG MED BIOL, V22, P35, DOI 10.1109/MEMB.2003.1256270
   Rani M, 2004, AAPS PHARMSCITECH, V5
   Ratajczak-Enselme M, 2009, EUR J PHARM BIOPHARM, V72, P54, DOI 10.1016/j.ejpb.2008.11.003
   Reis RL, 2008, WOODHEAD PUBL MATER, P1
   Rogers TL, 2001, DRUG DEV IND PHARM, V27, P1003, DOI 10.1081/DDC-100108363
   Roullin VG, 2004, PHARM RES, V21, P1558, DOI 10.1023/B:PHAM.0000041448.22771.48
   Sahoo J, 2009, AAPS PHARMSCITECH, V10, P27, DOI 10.1208/s12249-008-9175-0
   Sandor M, 2001, J CONTROL RELEASE, V76, P297, DOI 10.1016/S0168-3659(01)00446-1
   Schoof H, 2001, J BIOMED MATER RES, V58, P352, DOI 10.1002/jbm.1028
   Sehra S, 2005, J MICROENCAPSUL, V22, P521, DOI 10.1080/02652040500162170
   Sendil D, 2003, BIOMATERIALS, V24, P1969, DOI 10.1016/S0142-9612(02)00567-7
   Sendil-Keskin D, 2003, J BIOMAT SCI-POLYM E, V14, P497, DOI 10.1163/15685620360674218
   Seo SA, 2003, J MICROENCAPSUL, V20, P569, DOI 10.1080/0265204031000148013
   Seo SA, 2002, INT J PHARM, V239, P93, DOI 10.1016/S0378-5173(02)00074-1
   Shenoy DB, 2002, J MICROENCAPSUL, V19, P523, DOI 10.1080/02652040210141084
   Shin ILG, 1998, J CONTROL RELEASE, V51, P1
   Shuai XT, 2004, J CONTROL RELEASE, V98, P415, DOI 10.1016/j.jconrel.2004.06.003
   Sinha VR, 2006, DRUG DELIV, V13, P221, DOI 10.1080/10717540500309180
   Sinha VR, 2004, INT J PHARM, V278, P1, DOI 10.1016/j.ijpharm.2004.01.044
   Steckel H, 2004, EUR J PHARM BIOPHARM, V57, P507, DOI 10.1016/j.ejph.2004.01.002
   Sun TM, 2008, BIOMATERIALS, V29, P4348, DOI 10.1016/j.biomaterials.2008.07.036
   Sun XD, 2009, BIOMATERIALS, V30, P1222, DOI 10.1016/j.biomaterials.2008.10.020
   Thakkar H, 2004, J DRUG TARGET, V12, P549, DOI 10.1080/10611860400010630
   Thakkar H, 2004, J PHARM PHARMACOL, V56, P1091, DOI 10.1211/0022357044166
   Tiwari Sandip B, 2003, AAPS PharmSciTech, V4, pE31
   Tracy MA, 1999, BIOMATERIALS, V20, P1057, DOI 10.1016/S0142-9612(99)00002-2
   Tsukada Y, 2009, INT J PHARMACEUT, V370, P196, DOI 10.1016/j.ijpharm.2008.11.019
   Tuncay M, 2000, INT J PHARM, V195, P179, DOI 10.1016/S0378-5173(99)00394-4
   Tuncay M, 2000, J MICROENCAPSUL, V17, P145
   Wang GL, 2008, PHARM RES-DORD, V25, P2896, DOI 10.1007/s11095-008-9692-2
   Wang SH, 2005, INT J PHARM, V301, P217, DOI 10.1016/j.ijpharm.2005.05.038
   Wang YZ, 2007, INT J PHARM, V337, P63, DOI 10.1016/j.ijpharm.2006.12.033
   Weber C, 2000, INT J PHARM, V194, P91, DOI 10.1016/S0378-5173(99)00370-1
   Wei GB, 2004, BIOMATERIALS, V25, P345, DOI 10.1016/S0142-9612(03)00528-3
   Wei H, 2006, BIOMATERIALS, V27, P2028, DOI 10.1016/j.biomaterials.2005.09.028
   Wei L, 2009, BIOMATERIALS, V30, P2606, DOI 10.1016/j.biomaterials.2009.01.006
   Williams JR, 2002, MOL BIOTECHNOL, V22, P263, DOI 10.1385/MB:22:3:263
   Wischke C, 2008, INT J PHARMACEUT, V364, P298, DOI 10.1016/j.ijpharm.2008.04.042
   Woo BH, 2002, PHARMACEUT RES, V19, P546, DOI 10.1023/A:1015168301339
   Wu ZQ, 2009, LANGMUIR, V25, P2900, DOI 10.1021/la8037523
   Xiong XB, 2009, BIOMATERIALS, V30, P242, DOI 10.1016/j.biomaterials.2008.09.025
   Yadav AK, 2007, NANOMED-NANOTECHNOL, V3, P246, DOI 10.1016/j.nano.2007.09.004
   York P., 2004, SUPERCRITICAL FLUID
   Young S, 2005, J CONTROL RELEASE, V109, P256, DOI 10.1016/j.jconrel.2005.09.023
   Yu ZS, 2002, EUR J PHARM BIOPHARM, V54, P221, DOI 10.1016/S0939-6411(02)00050-4
NR 178
TC 74
Z9 78
U1 4
U2 45
PU MDPI AG
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD SEP
PY 2010
VL 11
IS 9
BP 3298
EP 3322
DI 10.3390/ijms11093298
PG 25
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA 655DK
UT WOS:000282223500018
PM 20957095
OA gold
DA 2018-03-20
ER

PT J
AU Zou, Y
   Fisher, PD
   Horstmann, JK
   Talwalkar, V
   Milbrandt, TA
   Puleo, DA
AF Zou, Yuan
   Fisher, Paul D.
   Horstmann, Joanna K.
   Talwalkar, Vishwas
   Milbrandt, Todd A.
   Puleo, David A.
TI Synergistic local drug delivery in a piglet model of ischemic
   osteonecrosis: a preliminary study
SO JOURNAL OF PEDIATRIC ORTHOPAEDICS-PART B
LA English
DT Article
DE drug delivery; injectable; Legg-Calve-Perthes disease; osteonecrosis
ID CAPITAL FEMORAL EPIPHYSIS; STIMULATES BONE-FORMATION;
   CALVE-PERTHES-DISEASE; ADMINISTERED IBANDRONATE; AVASCULAR NECROSIS;
   HEAD DEFORMITY; RAT MODEL; RESORPTION; RELEASE
AB A locally injectable system sequentially delivering an antiresorptive drug (clodronate) followed by an osteogenic agent (simvastatin) was hypothesized to improve femoral head microarchitecture, size, and shape compared with untreated or partial treatment groups in an established piglet osteonecrosis model. After 6 weeks, the clodronate+simvastatin treatment resulted in no collapse, microCT measurements and epiphyseal quotients within 10% of control, normal microstructure, and healthy histology. All other groups exhibited collapse, lower epiphyseal quotients and total femoral head volumes (P<0.05), and abnormal histology. This pilot study provides evidence of synergistic antiresorptive and osteogenic activities, which may prevent femoral head collapse in Perthes disease.
C1 [Zou, Yuan; Fisher, Paul D.; Puleo, David A.] Univ Kentucky, Dept Biomed Engn, Lexington, KY 40506 USA.
   [Horstmann, Joanna K.; Talwalkar, Vishwas; Puleo, David A.] Univ Kentucky, Dept Orthopaed Surg, Lexington, KY 40506 USA.
   [Talwalkar, Vishwas] Shriners Hosp Children, Lexington, KY USA.
   [Milbrandt, Todd A.] Mayo Clin, Dept Orthoped Surg, Rochester, MN USA.
RP Puleo, DA (reprint author), Univ Kentucky, Dept Biomed Engn, 522 Robot & Mfg Bldg, Lexington, KY 40506 USA.
EM puleo@uky.edu
FU Department of Orthopaedic Surgery, University of Kentucky; Shriners
   Hospital for Children (Lexington, Kentucky, USA)
FX V.T., T.A.M., and D.A.P received funding from the Department of
   Orthopaedic Surgery, University of Kentucky, and the Shriners Hospital
   for Children (Lexington, Kentucky, USA). For the remaining authors there
   are no conflicts of interest.
CR Astrand J, 2002, BMC MUSCULOSKELET DI, V3, DOI 10.1186/1471-2474-3-19
   Aya-Ay J, 2007, J BONE MINER RES, V22, P93, DOI 10.1359/JBMR.060817
   Chen PY, 2010, NUTR RES, V30, P191, DOI 10.1016/j.nutres.2010.03.004
   Cheng Jack Chun-yiu, 2011, J Pediatr Orthop, V31, pS147, DOI 10.1097/BPO.0b013e318223b470
   HERRING JA, 1994, J BONE JOINT SURG AM, V76A, P448, DOI 10.2106/00004623-199403000-00017
   Herring JA, 2004, J BONE JOINT SURG AM, V86A, P2121, DOI 10.2106/00004623-200410000-00002
   HEYMAN CH, 1950, J BONE JOINT SURG AM, V32-A, P767, DOI 10.2106/00004623-195032040-00004
   Jeon JH, 2008, PHARM DEV TECHNOL, V13, P505, DOI [10.1080/10837450802282488, 10.1080/10837450802282488 ]
   Jeon JH, 2008, J PERIODONTOL, V79, P1457, DOI [10.1902/jop.2008.080004, 10.1902/jop.2008.080004 ]
   Joseph B, 2003, J PEDIATR ORTHOPED, V23, P590, DOI 10.1097/01241398-200309000-00005
   Kang JH, 2010, AM HEART J, V159, P803, DOI 10.1016/j.ahj.2010.02.020
   Kim HK, 2005, J BONE JOINT SURG AM, V87A, P550, DOI 10.2106/JBJS.D.02192
   Kim HKW, 2006, BONE, V39, P205, DOI 10.1016/j.bone.2005.12.019
   Kim HKW, 2002, J BONE JOINT SURG AM, V84A, P1329, DOI 10.2106/00004623-200208000-00006
   Lafforgue P, 2006, JOINT BONE SPINE, V73, P500, DOI 10.1016/j.jbspin.2006.01.025
   Little DG, 2005, J ORTHOP RES, V23, P862, DOI 10.1016/j.orthres.2004.11.015
   Loder RT, 2011, ISRN ORTHOP, V2011
   MUHLBAUER RC, 1991, J BONE MINER RES, V6, P1003
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Novais EN, 2011, ORTHOP CLIN N AM, V42, P401, DOI 10.1016/j.ocl.2011.05.003
   Peled E, 2009, INDIAN J ORTHOP, V43, P22, DOI 10.4103/0019-5413.44630
   Sugiyama T, 2007, ORAL DIS, V13, P228, DOI 10.1111/j.1601-0825.2006.01271.x
   Vandermeer JS, 2011, J BONE JOINT SURG AM, V93A, P905, DOI 10.2106/JBJS.J.00716
   Zou Y, 2012, J BIOMED MATER RES B, V100B, P155, DOI 10.1002/jbm.b.31933
NR 24
TC 1
Z9 1
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1060-152X
EI 1473-5865
J9 J PEDIATR ORTHOP B
JI J. Pediatr. Orthop.-Part B
PD NOV
PY 2015
VL 24
IS 6
BP 483
EP 492
DI 10.1097/BPB.0000000000000213
PG 10
WC Orthopedics; Pediatrics
SC Orthopedics; Pediatrics
GA CS5IR
UT WOS:000362112100001
PM 26196370
DA 2018-03-20
ER

PT J
AU Reichel, D
   Lee, MJ
   Lee, W
   Kim, KB
   Bae, Y
AF Reichel, Derek A.
   Lee, Min Jae
   Lee, Wooin
   Kim, Kyung Bo
   Bae, Younsoo
TI Tethered polymer nanoassemblies for sustained carfilzomib release and
   prolonged suppression of proteasome activity
SO THERAPEUTIC DELIVERY
LA English
DT Article
DE cancer chemotherapy; controlled release; nanoparticles; proteasome
   inhibitors; solid cancers
ID CROSS-LINKED NANOASSEMBLIES; IN-VIVO PHARMACOKINETICS; PACLITAXEL
   GENEXOL-PM; MULTIPLE-MYELOMA; CANCER-THERAPY; DRUG-DELIVERY; INHIBITOR
   CARFILZOMIB; KINETIC STABILITY; BLOCK-COPOLYMERS; LUNG-CANCER
AB Aim: Proteasome inhibitors, such as carfilzomib (CFZ), have shown potential to treat various types of cancers in preclinical models, but clinical applications are limited likely due to formulation and delivery issues. Results & methodology: Tethered polymer nanoassemblies (TNAs) were synthesized by tethering hydrophilic polymers and hydrophobic groups to charged polymer scaffolds, and then end-capping remaining amines on scaffold. Drug entrapment and drug release half-lives increased as charge was removed from scaffold. TNAs with sustained CFZ release maintained drug efficacy after preincubation and increased duration of proteasome inhibition in cancer cells compared with free CFZ. Conclusion: TNAs fine-tuned CFZ release as charge was removed from polymer scaffold, which allowed for sustained proteasome inhibition in cancer cells and potentially enhanced anticancer efficacy.
C1 [Reichel, Derek; Lee, Min Jae; Kim, Kyung Bo; Bae, Younsoo] Univ Kentucky, Dept Pharmaceut Sci, Coll Pharm, 789 South Limestone, Lexington, KY 40536 USA.
   [Lee, Wooin] Seoul Natl Univ, Coll Pharm, 1 Gwanak Ro, Seoul 151742, South Korea.
RP Bae, Y (reprint author), Univ Kentucky, Dept Pharmaceut Sci, Coll Pharm, 789 South Limestone, Lexington, KY 40536 USA.
EM younsoo.bae@uky.edu
FU National Research Foundation of Korea, Ministry of Science, ICT and
   Future Planning [NRF-2014R1A1A3050645]
FX Wooin Lee acknowledges financial support from Basic Science Research
   Program, National Research Foundation of Korea, Ministry of Science, ICT
   and Future Planning (NRF-2014R1A1A3050645). The authors have no other
   relevant affiliations or financial involvement with any organization or
   entity with a financial interest in or financial conflict with the
   subject matter or materials discussed in the manuscript apart from those
   disclosed.
CR Ahn HK, 2014, CANCER CHEMOTH PHARM, V74, P277, DOI 10.1007/s00280-014-2498-5
   Ao L, 2015, J PHARMACOL EXP THER, V355, P168, DOI 10.1124/jpet.115.226993
   Ashley JD, 2014, J CONTROL RELEASE, V196, P113, DOI 10.1016/j.jconrel.2014.10.005
   Attia ABE, 2013, BIOMATERIALS, V34, P3132, DOI 10.1016/j.biomaterials.2013.01.042
   Bae Y, 2010, THER DELIV, V1, P361, DOI 10.4155/TDE.10.28
   Baker AF, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0111-8
   Bobo D, 2016, PHARM RES-DORDR, V33, P2373, DOI 10.1007/s11095-016-1958-5
   Buac D, 2013, CURR PHARM DESIGN, V19, P4025, DOI 10.2174/1381612811319220012
   Chu KS, 2013, BIOMATERIALS, V34, P8424, DOI 10.1016/j.biomaterials.2013.07.038
   Ciechanover A, 2013, BIOORGAN MED CHEM, V21, P3400, DOI 10.1016/j.bmc.2013.01.056
   Crawford LJ, 2011, J CELL COMMUN SIGNAL, V5, P101, DOI 10.1007/s12079-011-0121-7
   Dan M, 2013, PHARM RES-DORDR, V30, P552, DOI 10.1007/s11095-012-0900-8
   Deshaies RJ, 2014, BMC BIOL, V12, DOI 10.1186/s12915-014-0094-0
   Dickerson M, 2016, J MATER CHEM B, V4, P394, DOI 10.1039/c5tb01613d
   Dickerson M, 2014, PHARM RES-DORDR, V31, P1254, DOI 10.1007/s11095-013-1246-6
   Dickerson M, 2013, THER DELIV, V4, P1431, DOI [10.4155/tde.13.105, 10.4155/TDE.13.105]
   Duan XP, 2016, WIRES NANOMED NANOBI, V8, P776, DOI 10.1002/wnan.1390
   Gu JJ, 2013, BRIT J HAEMATOL, V162, P657, DOI 10.1111/bjh.12452
   Hoshyar N, 2016, NANOMEDICINE-UK, V11, P673, DOI 10.2217/nnm.16.5
   Jager M, 2012, CHEM SOC REV, V41, P4755, DOI 10.1039/c2cs35146c
   Kim HS, 2015, J THORAC ONCOL, V10, P1800, DOI 10.1097/JTO.0000000000000692
   Kouroukis TC, 2014, CURR ONCOL, V21, pE573, DOI 10.3747/co.21.1798
   Lee HJ, 2013, PHARM RES-DORDR, V30, P478, DOI 10.1007/s11095-012-0893-3
   Lee HJ, 2011, BIOMACROMOLECULES, V12, P2686, DOI 10.1021/bm200483t
   Lee HJ, 2010, THER DELIV, V1, P803, DOI 10.4155/TDE.10.70
   Li Y, 2015, ACS APPL MATER INTER, V7, P25553, DOI 10.1021/acsami.5b07348
   Li ZB, 2014, MAT SCI ENG C-MATER, V45, P620, DOI 10.1016/j.msec.2014.06.003
   Liu H, 2015, INT J NANOMED, V10, P6395, DOI 10.2147/IJN.S91961
   Luke DR, 2012, NEPHROL DIAL TRANSPL, V27, P1207, DOI 10.1093/ndt/gfr472
   Mukherjee B, 2014, CURR DRUG METAB, V15, P565, DOI 10.2174/1389200215666140605150703
   Nauka PC, 2016, POLYM CHEM-UK, V7, P2352, DOI 10.1039/c6py00080k
   Nooka AK, 2015, BLOOD, V125, P3085, DOI 10.1182/blood-2014-11-568923
   Orlowski RZ, 2008, CLIN CANCER RES, V14, P1649, DOI 10.1158/1078-0432.CCR-07-2218
   Owen SC, 2012, NANO TODAY, V7, P53, DOI 10.1016/j.nantod.2012.01.002
   Papadopoulos KP, 2013, CANCER CHEMOTH PHARM, V72, P861, DOI 10.1007/s00280-013-2267-x
   Pinter B, 2012, PHYS CHEM CHEM PHYS, V14, P9846, DOI 10.1039/c2cp41090g
   Pitto-Barry A, 2014, POLYM CHEM-UK, V5, P3291, DOI 10.1039/c4py00039k
   Ponta A, 2015, PHARM RES-DORDR, V32, P1752, DOI 10.1007/s11095-014-1573-2
   Prabhu RH, 2015, INT J NANOMED, V10, P1001, DOI 10.2147/IJN.S56932
   Rabanel JM, 2014, J CONTROL RELEASE, V185, P71, DOI 10.1016/j.jconrel.2014.04.017
   Redic K, 2013, J PHARM PHARMACOL, V65, P1095, DOI 10.1111/jphp.12072
   Reichel D, 2015, THER DELIV, V6, P1221, DOI 10.4155/tde.15.59
   Richard I, 2013, BIOMACROMOLECULES, V14, P1732, DOI 10.1021/bm4000713
   Sebestyen Zita, 2013, Acta Pharm Hung, V83, P57
   Sestak V, 2016, J PHARMACEUT BIOMED, V124, P365, DOI 10.1016/j.jpba.2016.03.015
   Shirley M, 2016, DRUGS, V76, P405, DOI 10.1007/s40265-016-0548-5
   Sun C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108839
   Wang YC, 2013, AAPS PHARMSCITECH, V14, P585, DOI 10.1208/s12249-013-9943-3
   Wang ZP, 2013, DRUG METAB DISPOS, V41, P230, DOI 10.1124/dmd.112.047662
   Woodman JL, 2015, INT J CELL BIOL, V2015
   Yang C, 2012, BIOMATERIALS, V33, P2971, DOI 10.1016/j.biomaterials.2011.11.035
   Yoon HY, 2013, BIOMATERIALS, V34, P5273, DOI 10.1016/j.biomaterials.2013.03.050
NR 52
TC 3
Z9 3
U1 1
U2 1
PU FUTURE SCI LTD
PI LONDON
PA UNITED HOUSE, 2 ALBERT PL, LONDON, N3 1QB, ENGLAND
SN 2041-5990
EI 2041-6008
J9 THER DELIV
JI Ther. Deliv.
PD OCT
PY 2016
VL 7
IS 10
BP 665
EP 681
DI 10.4155/tde-2016-0041
PG 17
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA FC2JV
UT WOS:000406664600002
PM 27790952
DA 2018-03-19
ER

PT J
AU Joshi, A
   Bondada, V
   Geddes, JW
AF Joshi, Aashish
   Bondada, Vimala
   Geddes, James W.
TI Mitochondrial mu-calpain is not involved in the processing of
   apoptosis-inducing factor
SO EXPERIMENTAL NEUROLOGY
LA English
DT Article
DE Cell death; Apoptosis; Necrosis; Caspase; Cysteine; Protease
ID MEDIATED PROGRAMMED NECROSIS; NEURONAL CELL-DEATH; CATHEPSIN-B; RELEASE;
   AIF; MEMBRANE; CALCIUM; BRAIN; RAT; INHIBITION
AB Caspase-independent cell death, in important death pathway in many cells including neurons, is executed via apoptosis-inducing factor (AIF), an oxidoreductase, localized to the mitochondrial intermembrane space. AIF is processed and released from mitochondria following mitochondrial permeability transition pore (mPTP) formation, and translocates to the nucleus to induce DNA fragmentation and cell death. The release of AIF requires cleavage of its N-terminus anchored in the inner mitochondrial membrane. The protease responsible for this AIF truncation has not been established, although there is considerable evidence Suggesting a role for mu-calpain. We previously found that a pool of mu-calpain is localized to the mitochondrial intermembrane space, the submitochondrial compartment in which AIF truncation occurs. The close submitochondrial proximity of mitochondrial mu-calpain and AIF gives support to the hypothesis that mitochondrial mu-calpain may be the protease responsible for processing AIF prior to its release. In tire present Study, AIF was released from rat liver mitochondria following mPTP induction by atractyloside. This release was inhibited by the cysteine protease inhibitor MDL28170, but not by more specific calpain inhibitors PD150606 and calpastatin. Atractyloside caused swelling in rat brain mitochondria, but did not induce AIF release. In a mitochondrial fraction from SH-SY5Y neuroblastoma cells, incubation with 5 mM Ca(2+) resulted in the activation of mu-calpain but not in AIF truncation. In Summary, the localization of mu-calpain to the mitochondrial intermembrane space is Suggestive of its possible involvement in AIF processing, but direct experimental evidence supporting such a role has been elusive. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Geddes, James W.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA.
   Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA.
RP Geddes, JW (reprint author), Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, B477 BBSRB,741 S Limestone St, Lexington, KY 40536 USA.
EM jgeddes@uky.edu
FU NIH [PO1NS058484, PO1AG010836, P30NS051220]; Kentucky Spinal Cord and
   Head Injury Research Trust
FX This research was supported by NIH grants PO1NS058484, PO1AG010836, and
   P30NS051220, as well as funding from the Kentucky Spinal Cord and Head
   Injury Research Trust.
CR Badugu R, 2008, J BIOL CHEM, V283, P3409, DOI 10.1074/jbc.M706851200
   Baici A, 2006, BIOL CHEM, V387, P1017, DOI 10.1515/BC.2006.125
   Bernardi P., 2007, V45, P481
   Boujrad H, 2007, CELL CYCLE, V6, P2612, DOI 10.4161/cc.6.21.4842
   Brown MR, 2006, J BIOL CHEM, V281, P11658, DOI 10.1074/jbc.M510303200
   Brustovetsky N, 2002, J NEUROCHEM, V80, P207, DOI 10.1046/j.0022-3042.2001.00671.x
   Cao GD, 2007, J NEUROSCI, V27, P9278, DOI 10.1523/JNEUROSCI.2826-07.2007
   Chaitanya GV, 2008, BRAIN RES, V1246, P178, DOI 10.1016/j.brainres.2008.09.075
   CONG JY, 1989, J BIOL CHEM, V264, P10096
   Cregan SP, 2002, J CELL BIOL, V158, P507, DOI 10.1083/jcb.200202130
   Garcia M, 2005, BIOCHEM BIOPH RES CO, V338, P1241, DOI 10.1016/j.bbrc.2005.10.081
   Kroemer G, 2005, NAT MED, V11, P725, DOI 10.1038/nm1263
   Landshamer S, 2008, CELL DEATH DIFFER, V15, P1553, DOI 10.1038/cdd.2008.78
   Li HQ, 2004, BBA-MOL CELL RES, V1691, P91, DOI 10.1016/j.bbamer.2003.12.006
   Liou AKF, 2005, FASEB J, V19, P1350, DOI 10.1096/fj.04-3258fje
   MEHDI S, 1988, BIOCHEM BIOPH RES CO, V157, P1117, DOI 10.1016/S0006-291X(88)80989-6
   Moubarak RS, 2007, MOL CELL BIOL, V27, P4844, DOI 10.1128/MCB.02141-06
   Muntener K, 2004, J BIOL CHEM, V279, P41012, DOI 10.1074/jbc.M405333200
   Norberg E, 2008, CELL DEATH DIFFER, V15, P1857, DOI 10.1038/cdd.2008.123
   Otera H, 2005, EMBO J, V24, P1375, DOI 10.1038/sj.emboj.7600614
   Ozaki T, 2007, J BIOCHEM, V142, P365, DOI 10.1093/jb/mvm143
   Polster BM, 2005, J BIOL CHEM, V280, P6447, DOI 10.1074/jbc.M413269200
   RITOV VB, 1992, GEN PHYSIOL BIOPHYS, V11, P49
   Sasaki T, 1990, J Enzyme Inhib, V3, P195, DOI 10.3109/14756369009035837
   Shalbuyeva N, 2006, J BIOL CHEM, V281, P37547, DOI 10.1074/jbc.M607263200
   Shulga N, 2006, J BIOL CHEM, V281, P30824, DOI 10.1074/jbc.M602503200
   SIMS NR, 1990, J NEUROCHEM, V55, P698, DOI 10.1111/j.1471-4159.1990.tb04189.x
   Stoka V, 2006, FEBS LETT, V580, P3739, DOI 10.1016/j.febslet.2006.05.066
   Vieira HLA, 2000, CELL DEATH DIFFER, V7, P1146, DOI 10.1038/sj.cdd.4400778
   WANG JJ, 1999, CALPAIN PHARM TOXICO, P77
   Wang KKW, 1996, P NATL ACAD SCI USA, V93, P6687, DOI 10.1073/pnas.93.13.6687
   Wendt A, 2004, BIOL CHEM, V385, P465, DOI 10.1515/BC.2004.054
   Yuste VJ, 2005, CELL DEATH DIFFER, V12, P1445, DOI 10.1038/sj.cdd.4401687
NR 33
TC 24
Z9 27
U1 0
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4886
J9 EXP NEUROL
JI Exp. Neurol.
PD AUG
PY 2009
VL 218
IS 2
BP 221
EP 227
DI 10.1016/j.expneurol.2009.04.013
PG 7
WC Neurosciences
SC Neurosciences & Neurology
GA 472GE
UT WOS:000268117400007
PM 19393648
OA green_accepted
DA 2018-03-20
ER

PT J
AU Meenach, SA
   Kim, YJ
   Kauffman, KJ
   Kanthamneni, N
   Bachelder, EM
   Ainslie, KM
AF Meenach, Samantha A.
   Kim, Yu Jeong
   Kauffman, Kevin J.
   Kanthamneni, Naveen
   Bachelder, Eric M.
   Ainslie, Kristy M.
TI Synthesis, Optimization, and Characterization of Camptothecin-Loaded
   Acetalated Dextran Porous Microparticles for Pulmonary Delivery
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE local drug delivery; inhalable dry particles; pulmonary microparticles;
   camptothecin; optimization of emulsion chemistry
ID DRUG-DELIVERY; INHALED DOXORUBICIN; PLGA MICROSPHERES; IN-VITRO;
   PARTICLES; PROTEIN; LUNG
AB We propose the use of a new biopolymer, acetalated dextran (Ac-DEX), to synthesize porous microparticles for pulmonary drug delivery. Ac-DEX is derived from the polysaccharide dextran and, unlike polyesters, has tunable degradation from days to months and pH neutral degradation products. Ac-DEX microparticles fabricated through emulsion techniques were optimized using a variety of postprocessing techniques to enhance the respirable fraction for pulmonary delivery. Tangential flow filtration resulted in a maximum 37% respirable fraction for Ac-DEX porous microparticles, compared to a 10% respirable fraction for poly(lactic-co-glycolic acid) (PLGA) porous micropartides. Ac-DEX microparticles were of an optimum diameter to minimize macrophage clearance but had a low enough theoretical density for deep lung penetration. Transepithelial electrical resistance (TEER) measurements showed that the particles did not impinge on a monolayer of lung epithelial cells in either air or liquid conditions. Also, the release of the chemotherapeutic camptothecin was shown to be tunable depending on Ac-DEX degradation time and molecular weight, and drug release was shown to be bioactive over a range of concentrations. Our results indicate that both release kinetics and fraction of burst release of drug from Ac-DEX porous microparticles can be tuned by simply changing the Ac-DEX polymer properties, affording a large range of formulation options for drug delivery to the pulmonary cavity. Overall, Ac-DEX porous microparticles show promise as an emerging carrier for pulmonary delivery of drugs to the alveolar region of the lung, particularly for the treatment of lung diseases.
C1 [Meenach, Samantha A.; Kim, Yu Jeong; Kanthamneni, Naveen; Bachelder, Eric M.; Ainslie, Kristy M.] Ohio State Univ, Div Pharmaceut, Coll Pharm, Columbus, OH 43210 USA.
   [Kauffman, Kevin J.; Ainslie, Kristy M.] Ohio State Univ, Dept Chem & Biomol Engn, Columbus, OH 43210 USA.
RP Ainslie, KM (reprint author), Ohio State Univ, Div Pharmaceut, Coll Pharm, 500 W 12th Ave,242 LM Pk Hall, Columbus, OH 43210 USA.
EM ainslie@pharmacy.ohio-state.edu
RI Meenach, Samantha/F-7542-2014; Kanthamneni, Naveen/N-7082-2016
OI Kanthamneni, Naveen/0000-0002-5794-9642; Ainslie,
   Kristy/0000-0002-1820-8382; /0000-0002-9436-2453
FU Pelotonia Fellowship Program
FX We thank Dr. Ron Moutvic from the Battelle Memorial Institute, Columbus,
   Ohio, for his generosity in loaning the Andersen Cascade Impactor for
   the duration of the study and insight on experimental procedures. We
   also thank the support in part by the Pelotonia Fellowship Program. Any
   opinions, findings, and conclusions expressed in this material are those
   of the authors and do not necessarily reflect those of the Pelotonia
   Fellowship Program.
CR Bachelder EM, 2008, J AM CHEM SOC, V130, P10494, DOI 10.1021/ja803947s
   Bachelder EM, 2010, MOL PHARMACEUT, V7, P826, DOI 10.1021/mp900311x
   Broaders KE, 2009, P NATL ACAD SCI USA, V106, P5497, DOI 10.1073/pnas.0901592106
   Champion JA, 2006, P NATL ACAD SCI USA, V103, P4930, DOI 10.1073/pnas.0600997103
   Edwards DA, 1998, J APPL PHYSIOL, V85, P379
   Edwards DA, 1997, SCIENCE, V276, P1868, DOI 10.1126/science.276.5320.1868
   Fiegel J, 2003, PHARMACEUT RES, V20, P788, DOI 10.1023/A:1023441804464
   Fu K, 2003, J PHARM SCI, V92, P1582, DOI 10.1002/jps.10414
   Gagnadoux F, 2008, J AEROSOL MED PULM D, V21, P61, DOI 10.1089/jamp.2007.0656
   Kauffman K., INT J PHARM IN PRESS
   Koushik K, 2004, PHARM RES, V21, P1119, DOI 10.1023/B:PHAM.0000032997.96823.88
   Kwona MJ, 2007, INT J PHARM, V333, P5, DOI 10.1016/j.ijpharm.2007.01.016
   Lu L, 2000, BIOMATERIALS, V21, P1837, DOI 10.1016/S0142-9612(00)00047-8
   Mao SR, 2007, INT J PHARM, V334, P137, DOI 10.1016/j.ijpharm.2006.10.036
   Oh YJ, 2011, J CONTROL RELEASE, V150, P56, DOI 10.1016/j.jconrel.2010.11.001
   Otterson GA, 2007, CLIN CANCER RES, V13, P1246, DOI 10.1158/1078-0432.CCR-06-1096
   Otterson GA, 2010, CLIN CANCER RES, V16, P2466, DOI 10.1158/1078-0432.CCR-09-3015
   Thimma J., 2008, 13 INT C INF DIS KUA, pe227
   Vanbever R, 1999, PHARMACEUT RES, V16, P1735, DOI 10.1023/A:1018910200420
   Washington N, 2001, PHYSL PHARM BARRIERS, P5
   Yang Y, 2009, BIOMATERIALS, V30, P1947, DOI 10.1016/j.biomaterials.2008.12.044
NR 21
TC 34
Z9 39
U1 3
U2 14
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD FEB
PY 2012
VL 9
IS 2
BP 290
EP 298
DI 10.1021/mp2003785
PG 9
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 895CX
UT WOS:000300474900010
PM 22149217
DA 2018-03-20
ER

PT J
AU Xiao, L
   Isner, AB
   Hilt, JZ
   Bhattacharyya, D
AF Xiao, Li
   Isner, Austin B.
   Hilt, J. Zach
   Bhattacharyya, Dibakar
TI Temperature responsive hydrogel with reactive nanoparticles
SO JOURNAL OF APPLIED POLYMER SCIENCE
LA English
DT Article
DE catalysts; copolymers; gels; nanoparticles; stimuli-sensitive polymers
ID POLY N-ISOPROPYLACRYLAMIDE; NANOSCALE IRON PARTICLES; NANOSTRUCTURED
   MEMBRANES; WATER-PURIFICATION; CATALYTIC-ACTIVITY; SWELLING BEHAVIOR;
   PHASE-TRANSITION; POLY(N-ISOPROPYLACRYLAMIDE); DECHLORINATION; REDUCTION
AB The application of temperature responsive hydrogels with ion-exchange domain for nanoscale catalytic reactions is an emerging and attractive area because of the combination of individual unique features: temperature responsive tunability by the polymer domain and the high catalytic reactivity of the nanomaterial. Here, we report the entrapment and/or direct synthesis of reactive Fe and Fe/Pd nanoparticles (about 4070 nm) in a temperature responsive hydrogel network (N-isopropylacrylamide (NIPAAm), and NIPAAmPAA). These nanoparticles are stabilized in the hydrogel network and the dechlorination (using trichloroethylene, TCE, as a model compound) reactivity in water is enhanced and controllable in the temperature range of 3034 degrees C involving polymer domain transitions at lower critical solution temperature (LCST) from hydrophilic to collapsed hydrophobic state. Water fraction modulation of the network and the enhancement of pollutant partitioning by the thermally responsive polymers play an important role in the catalytic activity. (c) 2012 Wiley Periodicals, Inc. J. Appl. Polym. Sci., 2013
C1 [Xiao, Li; Isner, Austin B.; Hilt, J. Zach; Bhattacharyya, Dibakar] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Bhattacharyya, D (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM db@engr.uky.edu
FU National Institute of Environmental Health Sciences Superfund Research
   Program (NIEHS-SRP); US Department of Energy (DOE) KRCEE programs
FX This research was supported by National Institute of Environmental
   Health Sciences Superfund Research Program (NIEHS-SRP) and by the US
   Department of Energy (DOE) KRCEE programs.
CR Adem E, 2009, RADIAT PHYS CHEM, V78, P549, DOI 10.1016/j.radphyschem.2009.03.040
   Bergbreiter DE, 1998, MACROMOLECULES, V31, P6053, DOI 10.1021/ma980836a
   Borgschulte A, 2006, J CATAL, V239, P263, DOI 10.1016/j.jcat.2006.01.031
   Bransfield SJ, 2007, APPL CATAL B-ENVIRON, V76, P348, DOI 10.1016/j.apcatb.2007.06.003
   BROWN JF, 1987, SCIENCE, V236, P709, DOI 10.1126/science.236.4802.709
   Chen SF, 2011, J APPL POLYM SCI, V121, P3322, DOI 10.1002/app.33938
   Clancy P, 2011, NAT NANOTECHNOL, V6, P540, DOI 10.1038/nnano.2011.152
   Debord JD, 2003, LANGMUIR, V19, P7662, DOI 10.1021/la0342924
   Diez-Pascual AM, 2010, J COLLOID INTERF SCI, V347, P79, DOI 10.1016/j.jcis.2010.03.042
   Doty SL, 2000, P NATL ACAD SCI USA, V97, P6287, DOI 10.1073/pnas.97.12.6287
   Du HB, 2010, J PHYS CHEM B, V114, P16594, DOI 10.1021/jp105652c
   Estillore NC, 2011, LANGMUIR, V27, P5997, DOI 10.1021/la200089x
   FEIL H, 1993, MACROMOLECULES, V26, P2496, DOI 10.1021/ma00062a016
   Gan DJ, 2002, MACROMOLECULES, V35, P9634, DOI 10.1021/ma021186k
   Ghosh R, 2001, J MEMBRANE SCI, V192, P145, DOI 10.1016/S0376-7388(01)00477-X
   Gorey C, 2011, J MEMBRANE SCI, V383, P272, DOI 10.1016/j.memsci.2011.08.066
   Guilherme MR, 2003, POLYMER, V44, P4213, DOI 10.1016/S0032-3861(03)00370-7
   He F, 2007, ENVIRON SCI TECHNOL, V41, P6216, DOI 10.1021/es0705543
   He F, 2008, APPL CATAL B-ENVIRON, V84, P533, DOI 10.1016/j.apcatb.2008.05.008
   Kiso Y, 2001, J MEMBRANE SCI, V192, P1, DOI 10.1016/S0376-7388(01)00411-2
   Kuckling D, 2002, MACROMOLECULES, V35, P6377, DOI 10.1021/ma0203041
   La YH, 2011, J MEMBRANE SCI, V372, P285, DOI 10.1016/j.memsci.2011.02.005
   Lai JY, 2009, J APPL POLYM SCI, V113, P3944, DOI 10.1002/app.30436
   Lewis SR, 2011, P NATL ACAD SCI USA, V108, P8577, DOI 10.1073/pnas.1101144108
   Li W, 2002, REACT FUNCT POLYM, V52, P31, DOI 10.1016/S1381-5148(02)00055-X
   Lien HL, 2001, COLLOID SURFACE A, V191, P97, DOI 10.1016/S0927-7757(01)00767-1
   Liu SX, 2008, J APPL POLYM SCI, V109, P4036, DOI 10.1002/app.28602
   Lu Y, 2006, ANGEW CHEM INT EDIT, V45, P813, DOI 10.1002/anie.200502731
   MATHESON LJ, 1994, ENVIRON SCI TECHNOL, V28, P2045, DOI 10.1021/es00061a012
   Meyer DE, 2009, ENVIRON PROG SUSTAIN, V28, P507, DOI 10.1002/ep.10334
   Mohan YM, 2005, J APPL POLYM SCI, V98, P302, DOI 10.1002/app.21849
   Mulvaney P, 2002, NANOSCALE MAT CHEM, P121
   Muniz EC, 2000, J MEMBRANE SCI, V172, P287, DOI 10.1016/S0376-7388(00)00346-X
   Neoh KG, 2010, MRS BULL, V35, P673, DOI 10.1557/mrs2010.679
   Nurmi JT, 2005, ENVIRON SCI TECHNOL, V39, P1221, DOI 10.1021/es049190u
   Parshetti GK, 2012, CHEMOSPHERE, V86, P392, DOI 10.1016/j.chemosphere.2011.10.028
   Peppas NA, 2006, ADV MATER, V18, P1345, DOI 10.1002/adma.200501612
   Phenrat T, 2008, J NANOPART RES, V10, P795, DOI 10.1007/s11051-007-9315-6
   Postel SL, 2006, SCIENCE, V313, P1046, DOI 10.1126/science.1132334
   Pradeep T, 2009, THIN SOLID FILMS, V517, P6441, DOI 10.1016/j.tsf.2009.03.195
   Ritchie SMC, 2001, ENVIRON SCI TECHNOL, V35, P3252, DOI 10.1021/es010617w
   Sahiner N, 2010, APPL CATAL A-GEN, V385, P201, DOI 10.1016/j.apcata.2010.07.004
   Satarkar NS, 2008, J CONTROL RELEASE, V130, P246, DOI 10.1016/j.jconrel.2008.06.008
   Satarkar NS, 2010, SOFT MATTER, V6, P2364, DOI 10.1039/b925218p
   SCHILD HG, 1992, PROG POLYM SCI, V17, P163, DOI 10.1016/0079-6700(92)90023-R
   Shannon MA, 2008, NATURE, V452, P301, DOI 10.1038/nature06599
   Smuleac V, 2010, J MEMBRANE SCI, V346, P310, DOI 10.1016/j.memsci.2009.09.052
   Smuleac V, 2011, CHEMSUSCHEM, V4, P1773, DOI 10.1002/cssc.201100211
   Stuart MAC, 2010, NAT MATER, V9, P101, DOI [10.1038/NMAT2614, 10.1038/nmat2614]
   Tee YH, 2009, J PHYS CHEM C, V113, P9454, DOI 10.1021/jp809098z
   Tokarev I, 2009, SOFT MATTER, V5, P511, DOI 10.1039/b813827c
   Tratnyek PG, 2006, NANO TODAY, V1, P44, DOI 10.1016/S1748-0132(06)70048-2
   Wandera D, 2010, J MEMBRANE SCI, V357, P6, DOI 10.1016/j.memsci.2010.03.046
   Wang CB, 1997, ENVIRON SCI TECHNOL, V31, P2154, DOI 10.1021/es970039c
   Wang JJ, 2012, J APPL POLYM SCI, V125, P548, DOI 10.1002/app.35687
   Wang QF, 2009, J APPL POLYM SCI, V111, P1417, DOI 10.1002/app.29026
   Wang R, 1997, NATURE, V388, P431, DOI 10.1038/41233
   Whittell GR, 2011, NAT MATER, V10, P176, DOI 10.1038/nmat2966
   Xu J, 2005, J NANOPART RES, V7, P449, DOI 10.1007/s11051-005-4273-3
   Xu J., 2007, THESIS U KENTUCKY LE
   Yoshida M, 2008, ACS NANO, V2, P1101, DOI 10.1021/nn800332g
   YU H, 1993, J APPL POLYM SCI, V49, P1553, DOI 10.1002/app.1993.070490906
NR 62
TC 14
Z9 14
U1 2
U2 139
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-8995
J9 J APPL POLYM SCI
JI J. Appl. Polym. Sci.
PD MAY 5
PY 2013
VL 128
IS 3
BP 1804
EP 1814
DI 10.1002/app.38335
PG 11
WC Polymer Science
SC Polymer Science
GA 089RH
UT WOS:000314927200057
DA 2018-03-19
ER

PT J
AU Joshi, S
   Rao, A
   Lehmler, HJ
   Knutson, BL
   Rankin, SE
AF Joshi, Suvid
   Rao, Alexander
   Lehmler, Hans-Joachim
   Knutson, Barbara L.
   Rankin, Stephen E.
TI Interfacial molecular imprinting of Stober particle surfaces: A simple
   approach to targeted saccharide adsorption
SO JOURNAL OF COLLOID AND INTERFACE SCIENCE
LA English
DT Article
DE Nanoparticles; Separations; Glycobiology; Molecular imprinting;
   Adsorption
ID ALKYL ORANGE DYES; SILICA PARTICLES; SOL-GEL; CATIONIC SURFACTANT;
   MONOVALENT CATIONS; CONTROLLED GROWTH; BASIC SOLUTIONS; NANOPARTICLES;
   POLYMERS; SIZE
AB The use of surfactant headgroups for interfacial imprinting is established as a simple and tunable approach to create molecularly imprinted silica nanoparticles based on a modification of the Stober method. Adsorption of D-glucose and D-xylose (initial concentrations ranging from 0.139 to 1.67 mol/l) is measured on silica nanoparticles created by the addition of a glucose-based surfactant (n-octyl-beta-D-glucopyranoside (C8G1)) or surfactant mixtures (C8G1 and cetyltrimethylammonium bromide (CTAB)) to Stober particles shortly after their precipitation. Silica particles synthesized in the presence of C8G1 as an imprinting surfactant have a significantly higher affinity for glucose over xylose (as much as 3.25 times greater at 0.25 M saccharide), and an enhanced affinity for glucose relative to non-imprinted silica particles (as much as 4 times greater at 0.25 M), which adsorb glucose and xylose similarly. Glucose imprinting is significantly enhanced using a surfactant mixture of 1:1 C8G1/CTAB. The interfacial activity of the nonionic imprinting surfactant at the silica surface is suggested to be improved by the presence of interfacial cationic CTAB, which is driven to the silica surface through electrostatic interactions. The concept of imprinting through the interaction of surfactant headgroups with the soft surface of silica particles is supported by the importance of the time of addition of the surfactants. The greatest enhancement in glucose adsorption is observed when the surfactants are added 1 min after precursor addition (at the onset of aggregated particle formation, as indicated by solution turbidity) and the silica affinity for glucose decreases with the time of surfactant addition. The versatility of the surfactant imprinting of Stober particles is demonstrated by the enhanced adsorption of xylose relative to glucose on particles imprinted using a 1:1 mixture of n-octyl-beta-D-xylopyranoside and CTAB, suggesting that the process can be customized to selectively adsorb target molecules of interest. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Joshi, Suvid; Knutson, Barbara L.; Rankin, Stephen E.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Rao, Alexander] Univ Massachusetts, Dept Chem Engn, Amherst, MA 01003 USA.
   [Lehmler, Hans-Joachim] Univ Iowa, Dept Occupat & Environm Hlth, Iowa City, IA 52242 USA.
RP Rankin, SE (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 FP Anderson Hall, Lexington, KY 40506 USA.
EM stephen.rankin@uky.edu
OI Rankin, Stephen/0000-0002-8615-7564; Lehmler,
   Hans-Joachim/0000-0001-9163-927X
FU National Science Foundation [CBET-0967381/0967390]; U.S. Department of
   Agriculture Biomass Research and Development Initiative [68-3A75-7-608]
FX We thank Jia Ye for help in training and obtaining images with SEM. We
   would also like to thank Dr. Paritosh Wattamwar for help in obtaining
   zeta potential data. Development of the surfactant-based imprinting
   strategy and particle synthesis procedure was carried out as part of a
   project supported by the National Science Foundation
   (CBET-0967381/0967390). Characterization of saccharide adsorption and
   selectivity was carried out as part of a project supported by the U.S.
   Department of Agriculture Biomass Research and Development Initiative
   (Grant Agreement 68-3A75-7-608).
CR BAILEY JK, 1992, COLLOID SURFACE, V63, P151, DOI 10.1016/0166-6622(92)80081-C
   Bartl F, 1996, FRESEN J ANAL CHEM, V354, P1
   BLANDAMER MJ, 1995, J THERM ANAL, V45, P599, DOI 10.1007/BF02548875
   BOGUSH GH, 1988, J NON-CRYST SOLIDS, V104, P95, DOI 10.1016/0022-3093(88)90187-1
   Brunauer S, 1938, J AM CHEM SOC, V60, P309, DOI 10.1021/ja01269a023
   BURNEAU A, 1993, COLLOID SURFACE A, V75, P111, DOI 10.1016/0927-7757(93)80422-B
   Chen L., 2011, CHEM SOC REV, V40
   Collinson M. M., 2010, SUPRAMOL CHEM, P581, DOI [10.1002/9780470552704.ch20, DOI 10.1002/9780470552704.CH20]
   Cummins W, 2005, ANAL CHIM ACTA, V542, P52, DOI 10.1016/j.aca.2005.01.042
   Diaz-Garcia ME, 2005, MICROCHIM ACTA, V149, P19, DOI 10.1007/s00604-004-0274-7
   DICKEY FH, 1955, J PHYS CHEM-US, V59, P695, DOI 10.1021/j150530a006
   DICKEY FH, 1949, P NATL ACAD SCI USA, V35, P227, DOI 10.1073/pnas.35.5.227
   Gauczinski J., 2012, LANGMUIR
   GIESCHE H, 1994, J EUR CERAM SOC, V14, P205, DOI 10.1016/0955-2219(94)90088-4
   Green DL, 2003, J COLLOID INTERF SCI, V266, P346, DOI 10.1016/S0021-9797(03)00610-6
   Griffin W. C, 1949, J SOC COSMET CHEM, V1, P311, DOI DOI 10.1007/BFB0117162
   Gutig C, 2008, LANGMUIR, V24, P4806, DOI 10.1021/la800035w
   HALDEMAN RG, 1955, J PHYS CHEM-US, V59, P1039, DOI 10.1021/j150532a012
   HARRIS MT, 1990, J NON-CRYST SOLIDS, V121, P397, DOI 10.1016/0022-3093(90)90165-I
   He HY, 2010, BIOSENS BIOELECTRON, V26, P760, DOI 10.1016/j.bios.2010.06.043
   Hunnius M, 1999, MICROPOR MESOPOR MAT, V29, P389, DOI 10.1016/S1387-1811(99)00008-6
   Hwang CC, 2002, J CHROMATOGR A, V962, P69, DOI 10.1016/S0021-9673(02)00559-9
   Katz A, 2000, NATURE, V403, P286, DOI 10.1038/35002032
   Kemmer G, 2010, NAT PROTOC, V5, P267, DOI 10.1038/nprot.2009.182
   Kobayashi Y., 2006, CHARACTERIZATION CON, P135
   Kuhn R.C., 2010, INT J FOOD ENG, V6
   Lainez A, 2004, LANGMUIR, V20, P5745, DOI 10.1021/la049929d
   Lee K, 1997, J COLLOID INTERF SCI, V194, P78, DOI 10.1006/jcis.1997.5089
   Lerbret A, 2011, J PHYS CHEM B, V115, P910, DOI 10.1021/jp1097519
   Levenberg K., 1944, Quarterly of Applied Mathematics, V2, P164
   Luckarift HR, 2006, SMALL, V2, P640, DOI 10.1002/smll.200500376
   Luderitz LAC, 2013, J COLLOID INTERF SCI, V402, P19, DOI 10.1016/j.jcis.2012.11.007
   Macakova L, 2007, LANGMUIR, V23, P12436, DOI 10.1021/la7014308
   Markowitz MA, 2001, ANAL CHIM ACTA, V435, P177, DOI 10.1016/S0003-2670(00)01246-0
   Markowitz MA, 2000, LANGMUIR, V16, P1759, DOI 10.1021/la990809t
   Markowitz MA, 2000, LANGMUIR, V16, P6148, DOI 10.1021/la000477o
   Marx S, 2001, CHEM MATER, V13, P3624, DOI 10.1021/cm000983z
   Mer VKL, 1952, IND ENG CHEM, V44, P1270
   MORRISON JL, 1959, CAN J CHEM, V37, P1986, DOI 10.1139/v59-291
   Netrabukkana R, 1996, IND ENG CHEM RES, V35, P458, DOI 10.1021/ie950200x
   Ow H, 2005, NANO LETT, V5, P113, DOI [10.1021/nl0482478, 10.1012/nl0482478]
   Peng Y, 2010, ANAL CHIM ACTA, V674, P190, DOI 10.1016/j.aca.2010.06.022
   Ragauskas AJ, 2006, SCIENCE, V311, P484, DOI 10.1126/science.1114736
   Rimer JD, 2005, LANGMUIR, V21, P8960, DOI 10.1021/la0511384
   Rimer JD, 2006, CHEM-EUR J, V12, P2926, DOI 10.1002/chem.200500684
   Rimer JD, 2008, J PHYS CHEM C, V112, P14754, DOI 10.1021/jp802902x
   Rimer JD, 2007, CHEM MATER, V19, P4189, DOI 10.1021/cm070708d
   Schoeman BJ, 1996, ZEOLITES, V17, P447, DOI 10.1016/S0144-2449(96)00038-3
   STOBER W, 1968, J COLLOID INTERF SCI, V26, P62, DOI 10.1016/0021-9797(68)90272-5
   Tan B, 2004, J PHYS CHEM B, V108, P20122, DOI 10.1021/jp046425f
   Tleugabulova D, 2004, LANGMUIR, V20, P5924, DOI 10.1021/la0495478
   Turner NW, 2006, BIOTECHNOL PROGR, V22, P1474, DOI 10.1021/bp060122g
   VANBLAADEREN A, 1993, J COLLOID INTERF SCI, V156, P1, DOI 10.1006/jcis.1993.1073
   Wang Y, 2008, APPL SURF SCI, V254, P6560, DOI 10.1016/j.apsusc.2008.04.022
   WULFF G, 1995, ANGEW CHEM INT EDIT, V34, P1812, DOI 10.1002/anie.199518121
   Wulff G., 2001, CHEM REV, V102, P1, DOI DOI 10.1021/CR980039A
   Xie CG, 2011, MICROCHIM ACTA, V174, P311, DOI 10.1007/s00604-011-0626-z
   Xing R, 2007, J COLLOID INTERF SCI, V316, P930, DOI 10.1016/j.jcis.2007.08.019
   Xu WJ, 2012, CARBOHYD RES, V349, P12, DOI 10.1016/j.carres.2011.11.020
   Ye L, 2008, CHEM MATER, V20, P859, DOI 10.1021/cm703190w
   Zhang L, 2006, J COLLOID INTERF SCI, V302, P25, DOI 10.1016/j.jcis.2006.06.068
   Zhao WH, 2010, J HAZARD MATER, V179, P223, DOI 10.1016/j.jhazmat.2010.02.083
   Zhou Q, 2009, J COLLOID INTERF SCI, V331, P288, DOI 10.1016/j.jcis.2008.11.062
   Ziemys A, 2010, J PHYS CHEM B, V114, P11117, DOI 10.1021/jp103519d
NR 64
TC 4
Z9 4
U1 3
U2 79
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0021-9797
EI 1095-7103
J9 J COLLOID INTERF SCI
JI J. Colloid Interface Sci.
PD AUG 15
PY 2014
VL 428
BP 101
EP 110
DI 10.1016/j.jcis.2014.04.041
PG 10
WC Chemistry, Physical
SC Chemistry
GA AJ7EU
UT WOS:000337860800015
PM 24910041
DA 2018-03-20
ER

PT J
AU Wattamwar, P
   Hardas, SS
   Butterfield, DA
   Anderson, KW
   Dziubla, T
AF Wattamwar, Paritosh P.
   Hardas, Sarita S.
   Butterfield, D. Allan
   Anderson, Kimberly W.
   Dziubla, Thomas D.
TI Tuning of the Pro-oxidant and Antioxidant Activity of Trolox Through the
   Controlled Release from Biodegradable Poly(trolox ester) Polymers
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Meeting Abstract
CT 17th Annual Meeting of the Society-for-Free-Radical-Biology-Medicine
   /15th Biennial Meeting of the
   Society-for-Free-Radical-Research-International
CY NOV 17-21, 2010
CL Orlando, FL
SP Soc Free Radi Biol Med, Soc Free Radi Res Int
C1 [Wattamwar, Paritosh; Hardas, Sarita S.; Butterfield, D. Allan; Anderson, Kimberly W.; Dziubla, Thomas] Univ Kentucky, Lexington, KY 40506 USA.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0891-5849
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PY 2010
VL 49
SU 1
BP S184
EP S184
DI 10.1016/j.freeradbiomed.2010.10.525
PG 1
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 681VD
UT WOS:000284348000534
DA 2018-03-19
ER

PT J
AU Long, SH
   Parkin, S
   Li, TL
AF Long, Sihui
   Parkin, Sean
   Li, Tonglei
TI 3-Carboxy-2-(2,6-dimethylphenylamino)pyridinium trifluoroacetate
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article
AB In the title compound, C14H15N2O2+ center dot C2F3O2-, the two aromatic rings of the cation are almost perpendicular to each other. The cations and anions are connected through hydrogen bonds into a one-dimensional network. There is an intramolecular N-H center dot center dot center dot O hydrogen bond between the secondary amine group and the carboxylic acid group.
C1 Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40506 USA.
   Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
RP Li, TL (reprint author), Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40506 USA.
EM tonglei@uky.edu
RI Parkin, Sean/E-7044-2011
CR ETTER MC, 1990, ACCOUNTS CHEM RES, V23, P120, DOI 10.1021/ar00172a005
   Long SH, 2006, ACTA CRYSTALLOGR E, V62, pO4211, DOI 10.1107/S1600536806034131
   [Anonymous], 1998, COLLECT
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Sheldrick G. M., 1997, SHELXL97 SHELXS97
   SHELDRICK GM, 1995, XP SHELXTL PC
   TING PC, 1990, J MED CHEM, V33, P2697, DOI 10.1021/jm00172a004
NR 7
TC 0
Z9 0
U1 0
U2 3
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD FEB
PY 2007
VL 63
BP O906
EP O907
DI 10.1107/S1600536807002747
PN 2
PG 2
WC Crystallography
SC Crystallography
GA 150AF
UT WOS:000245187300368
DA 2018-03-20
ER

PT J
AU Shen, XM
   Crawford, TO
   Brengman, J
   Acsadi, G
   Iannaconne, S
   Karaca, E
   Khoury, C
   Mah, JK
   Edvardson, S
   Bajzer, Z
   Rodgers, D
   Engel, AG
AF Shen, Xin-Ming
   Crawford, Thomas O.
   Brengman, Joan
   Acsadi, Gyula
   Iannaconne, Susan
   Karaca, Emin
   Khoury, Chaouky
   Mah, Jean K.
   Edvardson, Shimon
   Bajzer, Zeljko
   Rodgers, David W.
   Engel, Andrew G.
TI Functional Consequences and Structural Interpretation of Mutations of
   Human Choline Acetyltransferase
SO HUMAN MUTATION
LA English
DT Article
DE choline acetyltransferase; CHAT; congenital myasthenic syndrome;
   kinetics; thermal stability
ID CONGENITAL MYASTHENIC SYNDROME; PLATE ACETYLCHOLINESTERASE DEFICIENCY;
   EPISODIC APNEA; RAPSYN MUTATIONS; RECEPTOR; UNDERLIE; CHANNEL; BINDING;
   ENZYME; GENE
AB Choline acetyltransferase (ChAT; EC 2.3.1.6) catalyzes synthesis of acetylcholine from acetylCoA (AcCoA) and choline in cholinergic neurons. Mutations in CHAT cause potentially lethal congenital myasthenic syndromes associated with episodic apnea (ChAT-CMS). Here, we analyze the functional consequences of 12 missense and one nonsense mutations of CHAT in 11 patients. Nine of the mutations are novel. We examine expression of the recombinant missense mutants in Bosc 23 cells, determine their kinetic properties and thermal stability, and interpret the functional effects of 11 mutations in the context of the atomic structural model of human ChAT. Five mutations (p.Trp421Ser, p.Ser498Pro, p.Thr553Asn, p.Ala557Thr, and p.Ser572Trp) reduce enzyme expression to less than 50% of wild-type. Mutations with severe kinetic effects are located in the active-site tunnel (p.Met202Arg, p.Thr553Asn, and p.Ala557Thr) or adjacent to the substrate binding site (p.Ser572Trp), or exert their effect allosterically (p.Trp421Ser and p.Ile689Ser). Two mutations with milder kinetic effects (p.Val136Met and p.Ala235Thr) are also predicted to act allosterically. One mutation (p.Thr608Asn) below the nucleotide binding site of CoA enhances dissociation of AcCoA from the enzyme-substrate complex. Two mutations introducing a proline residue into an a-helix (p.Ser498Pro and p.Ser704Pro) impair the thermal stability of ChAT. Hum Mutat 32: 1259-1267, 2011. (C) 2011 Wiley Periodicals, Inc.
C1 [Shen, Xin-Ming; Brengman, Joan; Engel, Andrew G.] Mayo Clin, Dept Neurol, Rochester, MN 55905 USA.
   [Shen, Xin-Ming; Brengman, Joan; Engel, Andrew G.] Mayo Clin, Muscle Res Lab, Rochester, MN 55905 USA.
   [Crawford, Thomas O.] Johns Hopkins Univ Hosp, Dept Neurol & Pediat, Baltimore, MD 21287 USA.
   [Acsadi, Gyula] Childrens Hosp Michigan, Detroit, MI 48201 USA.
   [Iannaconne, Susan] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA.
   [Khoury, Chaouky] Univ Oklahoma, Hlth Sci Ctr, Dept Neurol, Oklahoma City, OK USA.
   [Karaca, Emin] Ege Univ, Dept Med Genet, Izmir, Turkey.
   [Mah, Jean K.] Univ Calgary, Dept Pediat, Calgary, AB T2N 1N4, Canada.
   [Edvardson, Shimon] Hadassah Univ Hosp, Dept Pediat Neurol, IL-91120 Jerusalem, Israel.
   [Bajzer, Zeljko] Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN USA.
   [Rodgers, David] Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY USA.
   [Rodgers, David] Univ Kentucky, Struct Biol Ctr, Lexington, KY USA.
RP Engel, AG (reprint author), Mayo Clin, Dept Neurol, Rochester, MN 55905 USA.
EM age@mayo.edu
RI Crawford, Thomas/E-6307-2012
OI Edvardson, Simon/0000-0003-2878-1278
FU NIH [NS6277, NS38041, DA02243, P20 RR20171]; Muscular Dystrophy
   Association
FX Contract grant sponsors: This work was supported by NIH Grants NS6277
   and by a Research Grant by the Muscular Dystrophy Association (to A. G.
   Engel) and by NIH grants NS38041, DA02243, P20 RR20171 (to D. Rodgers).
CR Barisic N, 2005, EUR J PAEDIATR NEURO, V9, P7, DOI 10.1016/j.ejpn.2004.10.008
   Beeson D, 2006, SCIENCE, V313, P1975, DOI 10.1126/science.1130837
   Brownlow S, 2001, J CLIN INVEST, V108, P125, DOI 10.1172/JCI12935
   BUCKWITZ D, 1990, COMPUT MATH APPL, V20, P117, DOI 10.1016/0898-1221(90)90321-A
   Burke G, 2003, NEUROLOGY, V61, P826, DOI 10.1212/01.WNL.0000085865.55513.AE
   Cai YY, 2004, EMBO J, V23, P2047, DOI 10.1038/sj.emboj.7600221
   CARBINI LA, 1993, J NEUROCHEM, V61, P247, DOI 10.1111/j.1471-4159.1993.tb03561.x
   Chevessier F, 2004, HUM MOL GENET, V13, P3229, DOI 10.1093/hmg/ddh333
   COOK RD, 1990, STAT METHODOLOGY PHA, P163
   Dobransky T, 2001, J BIOL CHEM, V276, P22244, DOI 10.1074/jbc.M011702200
   Dunne V, 2003, J HUM GENET, V48, P204, DOI 10.1007/s10038-003-0005-7
   Engel A G, 1987, Electroencephalogr Clin Neurophysiol Suppl, V39, P91
   Engel AG, 2005, CURR OPIN PHARMACOL, V5, P308, DOI 10.1016/j.coph.2004.12.007
   Engel A.G., 2009, J MOL NEUROSCI, V40, P143
   Engel AG, 2007, NEUROTHERAPEUTICS, V4, P252, DOI 10.1016/j.nurt.2007.01.001
   FONNUM F, 1975, J NEUROCHEM, V24, P407, DOI 10.1111/j.1471-4159.1975.tb11895.x
   Huze C, 2009, AM J HUM GENET, V85, P155, DOI 10.1016/j.ajhg.2009.06.015
   Kim AR, 2006, BIOCHEMISTRY-US, V45, P14621, DOI 10.1021/bi061536l
   Kim AR, 2005, ACTA CRYSTALLOGR D, V61, P1306, DOI 10.1107/S0907444905018822
   Mallory LA, 2009, PEDIATR NEUROL, V41, P42, DOI 10.1016/j.pediatrneurol.2009.02.017
   Maselli RA, 2009, J MED GENET, V46, P203, DOI 10.1136/jmg.2008.063693
   Maselli RA, 2003, MUSCLE NERVE, V27, P180, DOI 10.1002/mus.10300
   MORA M, 1987, NEUROLOGY, V37, P206, DOI 10.1212/WNL.37.2.206
   Muller JS, 2006, BRAIN, V129, P2784, DOI 10.1093/brain/awl188
   Ohno K, 2002, AM J HUM GENET, V70, P875, DOI 10.1086/339465
   Ohno K, 2000, ANN NEUROL, V47, P162, DOI 10.1002/1531-8249(200002)47:2<162::AID-ANA5>3.0.CO;2-Q
   Ohno K, 1998, P NATL ACAD SCI USA, V95, P9654, DOI 10.1073/pnas.95.16.9654
   Ohno K, 2001, P NATL ACAD SCI USA, V98, P2017, DOI 10.1073/pnas.98.4.2017
   Schara U, 2010, EUR J PAEDIATR NEURO, V14, P326, DOI 10.1016/j.ejpn.2009.09.009
   Schmidt C, 2003, NEUROMUSCULAR DISORD, V13, P245, DOI 10.1016/S0960-8966(02)00273-0
   Segel I.H., 1975, ENZYME KINETICS BEHA, P505
   Selcen D, 2011, NEUROLOGY, V76, P327, DOI 10.1212/WNL.0b013e31820882bd
   Senderek J, 2011, AM J HUM GENET, V88, P162, DOI 10.1016/j.ajhg.2011.01.008
   Shapira YA, 2002, NEUROLOGY, V58, P603, DOI 10.1212/WNL.58.4.603
   Shen XM, 2003, J CLIN INVEST, V111, P497, DOI 10.1172/JC1200316997
   Tsujino A, 2003, P NATL ACAD SCI USA, V100, P7377, DOI 10.1073/pnas.1230273100
   Yeung WL, 2009, NEONATOLOGY, V95, P183, DOI 10.1159/000155612
NR 37
TC 13
Z9 13
U1 1
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1059-7794
J9 HUM MUTAT
JI Hum. Mutat.
PD NOV
PY 2011
VL 32
IS 11
BP 1259
EP 1267
DI 10.1002/humu.21560
PG 9
WC Genetics & Heredity
SC Genetics & Heredity
GA 840HJ
UT WOS:000296429800010
PM 21786365
OA green_accepted
DA 2018-03-20
ER

PT J
AU Long, SH
   Siegler, M
   Li, TL
AF Long, Sihui
   Siegler, Maxime A.
   Li, Tonglei
TI 6-chloronicotinic acid
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article
ID HYDROGEN-BOND
AB The title compound, C6H4ClNO2, forms centrosymmetric dimers via intermolecular hydrogen bonds between carboxylic groups. Weak (ClCl)-Cl-... interactions further bridge these dimers, leading to infinite chains. In contrast, acid-to-pyridine hydrogen-bonded catemer motifs are observed in both nicotinic acid and 2-chloronicotinic acid. Only intramolecular halogen-bonded S( 5) loops exist in 2-chloronicotinic acid.
C1 Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40506 USA.
   Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
RP Li, TL (reprint author), Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40506 USA.
EM tonglei@uky.edu
CR Almarsson O, 2004, CHEM COMMUN, P1889, DOI 10.1039/b402150a
   de Souza MVN, 2005, ACTA CRYSTALLOGR E, V61, pO1347, DOI 10.1107/S160053680501024X
   ETTER MC, 1990, ACCOUNTS CHEM RES, V23, P120, DOI 10.1021/ar00172a005
   Kuduva SS, 1999, J AM CHEM SOC, V121, P1936, DOI 10.1021/ja981967u
   KUTOGLU A, 1983, ACTA CRYSTALLOGR C, V39, P232, DOI 10.1107/S0108270183004230
   Malak MH, 2006, ACTA CRYSTALLOGR C, V62, pO669, DOI 10.1107/S0108270106041369
   Metrangolo P, 2005, ACCOUNTS CHEM RES, V38, P386, DOI 10.1021/ar0400995
   Nonius, 2002, COLLECT
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Pauling L., 1948, NATURE CHEM BOND
   ROSS WCJ, 1967, BIOCHEM PHARMACOL, V16, P675, DOI 10.1016/0006-2952(67)90080-9
   Sheldrick G. M., 1997, SHELXL97 SHELXS97
   SHELDRICK GM, 1995, SHELXTL PC
   Steiner T, 2002, ANGEW CHEM INT EDIT, V41, P48, DOI 10.1002/1521-3773(20020104)41:1<48::AID-ANIE48>3.0.CO;2-U
   WRIGHT WB, 1953, ACTA CRYSTALLOGR, V6, P305, DOI 10.1107/S0365110X53000867
NR 15
TC 6
Z9 6
U1 0
U2 3
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD JAN
PY 2007
VL 63
BP O279
EP O281
DI 10.1107/S1600536806053177
PN 1
PG 3
WC Crystallography
SC Crystallography
GA 121XT
UT WOS:000243191000235
DA 2018-03-20
ER

PT J
AU Xing, R
   Rankin, SE
AF Xing, Rong
   Rankin, Stephen E.
TI Use of the ternary phase diagram of a mixed cationic/glucopyranoside
   surfactant system to predict mesostructured silica synthesis
SO JOURNAL OF COLLOID AND INTERFACE SCIENCE
LA English
DT Article
DE lyotropic; liquid crystal; templating; mixed surfactants; nanocasting;
   polycondensation
ID LIQUID-CRYSTALLINE PHASES; ORDERED MESOPOROUS SILICA; MCM-41
   MOLECULAR-SIEVES; PORE-SIZE DISTRIBUTION; NONIONIC SURFACTANT; LAMELLAR
   SILICAS; BLOCK-COPOLYMER; CUBIC STRUCTURE; ADSORPTION; TEMPLATES
AB Mixed surfactant systems have the potential to impart controlled combinations of functionality and pore structure to mesoporous metal oxides. Here, we combine a functional glucopyranoside surfactant with a cationic surfactant that readily forms liquid crystalline mesophases. The phase diagram for the ternary system CTAB/H2O/n-octyl-beta-D-glucopyranoside (C(8)G(1)) at 50 degrees C is measured using polarized optical microscopy. At this temperature, the binary C(8)G(1)/H2O system forms disordered micellar solutions up to 72 wt% C(8)G(1), and there is no hexagonal phase. With the addition of CTAB, we identify a large area of hexagonal phase, as well as cubic, lamellar and solid surfactant phases. The ternary phase diagram is used to predict the synthesis of thick mesoporous silica films via a direct liquid crystal templating technique. By changing the relative concentration of mixed surfactants as well as inorganic precursor species, surfactant/silica mesostructured thick films can be synthesized with variable glucopyranoside content, and with 2D hexagonal, cubic and lamellar structures. The domains over which different mesophases are prepared correspond well with those of the ternary phase diagram if the hydrophilic inorganic species is assumed to act as an equivalent volume of water. (C) 2007 Elsevier Inc. All rights reserved.
C1 Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40546 USA.
RP Rankin, SE (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 Anderson Hall, Lexington, KY 40546 USA.
EM srankin@engr.uky.edu
RI Rankin, Stephen/A-3265-2013
OI Rankin, Stephen/0000-0002-8615-7564
CR Alberius PCA, 2002, CHEM MATER, V14, P3284, DOI 10.1021/cm011209u
   Antonietti M, 1998, ADV MATER, V10, P154, DOI 10.1002/(SICI)1521-4095(199801)10:2<154::AID-ADMA154>3.0.CO;2-I
   ATTARD GS, 1995, NATURE, V378, P366, DOI 10.1038/378366a0
   BARRETT EP, 1951, J AM CHEM SOC, V73, P373, DOI 10.1021/ja01145a126
   BECK JS, 1992, J AM CHEM SOC, V114, P10834, DOI 10.1021/ja00053a020
   BELLARE JR, 1990, J COLLOID INTERF SCI, V136, P305, DOI 10.1016/0021-9797(90)90379-3
   Brinker CJ, 1999, ADV MATER, V11, P579, DOI 10.1002/(SICI)1521-4095(199905)11:7<579::AID-ADMA579>3.0.CO;2-R
   Brunauer S, 1938, J AM CHEM SOC, V60, P309, DOI 10.1021/ja01269a023
   Calabro DC, 1996, MICROPOROUS MATER, V7, P243, DOI 10.1016/S0927-6513(96)00045-4
   Chen DH, 2005, CHEM MATER, V17, P3228, DOI 10.1021/cm050209h
   Chen FX, 1997, CHEM MATER, V9, P2685, DOI 10.1021/cm9703942
   Ciesla U, 1999, MICROPOR MESOPOR MAT, V27, P131, DOI 10.1016/S1387-1811(98)00249-2
   Corma A, 1998, STUD SURF SCI CATAL, V117, P201
   Cortes AB, 2003, COLLOID POLYM SCI, V281, P319, DOI 10.1007/s00396-002-0779-8
   Dai LR, 2001, COLLOID SURFACE A, V181, P151, DOI 10.1016/S0927-7757(00)00791-3
   Fan J, 2001, J AM CHEM SOC, V123, P12113, DOI 10.1021/ja011564l
   Feng PY, 2000, LANGMUIR, V16, P5304, DOI 10.1021/la991444f
   Firouzi A, 1997, J AM CHEM SOC, V119, P3596, DOI 10.1021/ja963007i
   FIROUZI A, 1995, SCIENCE, V267, P1138, DOI 10.1126/science.7855591
   Goltner CG, 1997, ADV MATER, V9, P431, DOI 10.1002/adma.19970090516
   Groenewolt M, 2004, LANGMUIR, V20, P7811, DOI 10.1021/la049147k
   Guizard CG, 1999, J MATER CHEM, V9, P55, DOI 10.1039/a805867i
   Hind AR, 1997, LANGMUIR, V13, P6255, DOI 10.1021/la970559l
   Hoffmann B, 2001, CURR OPIN COLLOID IN, V6, P171, DOI 10.1016/S1359-0294(01)00075-9
   Huo K., 2006, J PHYS CHEM B, V110, P9452
   HUO QS, 1994, CHEM MATER, V6, P1176, DOI 10.1021/cm00044a016
   Inagaki S, 2002, NATURE, V416, P304, DOI 10.1038/416304a
   Jaroniec M, 1999, LANGMUIR, V15, P5410, DOI 10.1021/la990136e
   JUNG JH, 2000, CHEM COMMUN, V2343
   Klotz M, 2000, J MATER CHEM, V10, P663, DOI 10.1039/a906181i
   Kong LD, 2005, MICROPOR MESOPOR MAT, V81, P251, DOI 10.1016/j.micromeso.2005.02.011
   KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0
   Kruk M, 1997, LANGMUIR, V13, P6267, DOI 10.1021/la970776m
   KUSHALANI D, 1996, ADV MATER, V7, P842
   Lavrencic-Stangar U., 2003, SILICON CHEM, V2, P157
   Lin HP, 2001, MICROPOR MESOPOR MAT, V44, P129, DOI 10.1016/S1387-1811(01)00176-7
   Lind A, 2003, CHEM MATER, V15, P813, DOI 10.1021/cm021243o
   Markowitz MA, 2000, LANGMUIR, V16, P1759, DOI 10.1021/la990809t
   MONNIER A, 1993, SCIENCE, V261, P1299, DOI 10.1126/science.261.5126.1299
   Nilsson F, 1996, LANGMUIR, V12, P902, DOI 10.1021/la950602+
   Pang JB, 2004, CHEM COMMUN, P682, DOI 10.1039/b316501a
   Persson G, 2003, LANGMUIR, V19, P5813, DOI 10.1021/la034492f
   Pinel C, 1997, ADV MATER, V9, P582, DOI 10.1002/adma.19970090715
   Rankin SE, 2004, MICROPOR MESOPOR MAT, V73, P197, DOI 10.1016/j.micromeso.2004.05.013
   Ryoo R, 1999, CHEM COMMUN, P1413, DOI 10.1039/a904355a
   SAKYA P, 1994, J PHYS II, V4, P1311, DOI 10.1051/jp2:1994202
   Sayari A, 1997, CHEM MATER, V9, P2499, DOI 10.1021/cm970128o
   SING KSW, 1985, PURE APPL CHEM, V57, P603, DOI 10.1351/pac198557040603
   Song MG, 2002, LANGMUIR, V18, P6110, DOI 10.1021/la011691v
   Spickermann C.G., 2003, TOP CURR CHEM, V226, P29
   Stubenrauch C, 2001, CURR OPIN COLLOID IN, V6, P160, DOI 10.1016/S1359-0294(01)00080-2
   Tan B, 2005, CHEM MATER, V17, P916, DOI 10.1021/cm048991t
   Tan B, 2004, LANGMUIR, V20, P6981, DOI 10.1021/la049474s
   Tanev PT, 1996, SCIENCE, V271, P1267, DOI 10.1126/science.271.5253.1267
   Wei Y, 1999, CHEM MATER, V11, P2023, DOI 10.1021/cm981004u
   XING R, 2007, MICROPOROUS MESOPORO
   Xu J, 1998, CHEM MATER, V10, P3690, DOI 10.1021/cm980440d
   Zhai SR, 2004, J SOL-GEL SCI TECHN, V30, P149, DOI 10.1023/B:JSST.0000039499.77472.4b
   Zhao DY, 1998, SCIENCE, V279, P548, DOI 10.1126/science.279.5350.548
   Zhao XS, 1996, IND ENG CHEM RES, V35, P2075, DOI 10.1021/ie950702a
   Zhou Y, 2004, CHEM MATER, V16, P544, DOI 10.1021/cm034442w
   Zhou Y, 2003, ADV MATER, V15, P1452, DOI 10.1002/adma.200305265
NR 62
TC 8
Z9 8
U1 0
U2 14
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0021-9797
J9 J COLLOID INTERF SCI
JI J. Colloid Interface Sci.
PD DEC 15
PY 2007
VL 316
IS 2
BP 930
EP 938
DI 10.1016/j.jcis.2007.08.019
PG 9
WC Chemistry, Physical
SC Chemistry
GA 231ZK
UT WOS:000250987500084
PM 17764683
DA 2018-03-20
ER

PT J
AU Greineder, CF
   Howard, MD
   Carnemolla, R
   Cines, DB
   Muzykantov, VR
AF Greineder, Colin F.
   Howard, Melissa D.
   Carnemolla, Ronald
   Cines, Douglas B.
   Muzykantov, Vladimir R.
TI Advanced drug delivery systems for antithrombotic agents
SO BLOOD
LA English
DT Review
ID RED-BLOOD-CELLS; TISSUE-PLASMINOGEN-ACTIVATOR; SINGLE-CHAIN UROKINASE;
   ACUTE MYOCARDIAL-INFARCTION; VASCULAR ENDOTHELIAL-CELLS; IN-VIVO;
   PROPHYLACTIC FIBRINOLYSIS; PULMONARY VASCULATURE; THROMBOLYTIC AGENTS;
   FUSION PROTEIN
AB Despite continued achievements in antithrombotic pharmacotherapy, difficulties remain in managing patients at high risk for both thrombosis and hemorrhage. Utility of antithrombotic agents (ATAs) in these settings is restricted by inadequate pharmacokinetics and narrow therapeutic indices. Use of advanced drug delivery systems (ADDSs) may help to circumvent these problems. Various nanocarriers, affinity ligands, and polymer coatings provide ADDSs that have the potential to help optimize ATA pharmacokinetics, target drug delivery to sites of thrombosis, and sense pathologic changes in the vascular microenvironment, such as altered hemodynamic forces, expression of inflammatory markers, and structural differences between mature hemostatic and growing pathological clots. Delivery of ATAs using biomimetic synthetic carriers, host blood cells, and recombinant fusion proteins that are activated preferentially at sites of thrombus development has shown promising outcomes in preclinical models. Further development and translation of ADDSs that spare hemostatic fibrin clots hold promise for extending the utility of ATAs in the management of acute thrombotic disorders through rapid, transient, and targeted thromboprophylaxis. If the potential benefit of this technology is to be realized, a systematic and concerted effort is required to develop clinical trials and translate the use of ADDSs to the clinical arena.
C1 [Greineder, Colin F.; Howard, Melissa D.; Carnemolla, Ronald; Muzykantov, Vladimir R.] Univ Penn, Perelman Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA.
   [Greineder, Colin F.; Howard, Melissa D.; Carnemolla, Ronald; Muzykantov, Vladimir R.] Univ Penn, Perelman Sch Med, Ctr Targeted Therapeut & Translat Nanomed, Philadelphia, PA 19104 USA.
   [Greineder, Colin F.] Univ Penn, Perelman Sch Med, Dept Emergency Med, Philadelphia, PA 19104 USA.
   [Cines, Douglas B.] Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
RP Muzykantov, VR (reprint author), Univ Penn, Perelman Sch Med, Dept Pharmacol, TRC10-125,3600 Civ Ctr Blvd, Philadelphia, PA 19104 USA.
EM muzykant@mail.med.upenn.edu
OI Cines, Douglas/0000-0001-5986-504X; Greineder, Colin/0000-0001-9740-7672
FU National Institutes of Health, National Heart, Lung, and Blood Institute
   [HL087036, HL090697, HL091950]
FX This work was supported by National Institutes of Health, National
   Heart, Lung, and Blood Institute grants HL087036, HL090697, and
   HL091950.
CR Annese V, 2005, AM J GASTROENTEROL, V100, P1370, DOI 10.1111/j.1572-0241.2005.41412.x
   Armstead WM, 2011, PEDIATR CRIT CARE ME, V12, pE369, DOI 10.1097/PCC.0b013e3181fe40a7
   Armstead WM, 2010, J NEUROCHEM, V113, P303, DOI 10.1111/j.1471-4159.2010.06613.x
   Armstead WM, 2009, J CEREBR BLOOD F MET, V29, P1463, DOI 10.1038/jcbfm.2009.61
   Bax BE, 2000, BRIT J HAEMATOL, V109, P549, DOI 10.1046/j.1365-2141.2000.02059.x
   Bdeir K, 2003, BLOOD, V102, P3600, DOI 10.1182/blood-2003-03-0949
   BERGER H, 1988, BLOOD, V71, P1641
   Biagiotti S, 2011, J CONTROL RELEASE, V154, P306, DOI 10.1016/j.jconrel.2011.05.024
   BODE C, 1991, CIRCULATION, V84, P805
   Braunwald E, 2012, AM J RESP CRIT CARE, V185, P924, DOI 10.1164/rccm.201109-1745CI
   Buxton DB, 2009, NANOMEDICINE-UK, V4, P331, DOI [10.2217/nnm.09.8, 10.2217/NNM.09.8]
   Carnemolla R, 2011, IUBMB LIFE, V63, P632, DOI 10.1002/iub.474
   Chen HS, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-88
   Cheng ZL, 2012, SCIENCE, V338, P903, DOI 10.1126/science.1226338
   Collen D, 2000, CIRCULATION, V102, P1766
   Collen D, 2005, THROMB HAEMOSTASIS, V93, P627, DOI 10.1160/TH04-11-0724
   Danielyan K, 2008, CIRCULATION, V118, P1442, DOI 10.1161/CIRCULATIONAHA.107.750257
   Danielyan K, 2007, J PHARMACOL EXP THER, V321, P947, DOI 10.1124/jpet.107.120535
   Dichek DA, 1996, CIRCULATION, V93, P301
   Ding BS, 2008, BLOOD, V111, P1999, DOI 10.1182/blood-2007-07-103002
   Ding BS, 2009, AM J RESP CRIT CARE, V180, P247, DOI 10.1164/rccm.200809-1433OC
   Ding BS, 2005, BLOOD, V106, P4191, DOI 10.1182/blood-2005-05-2002
   Domenech C, 2011, BRIT J HAEMATOL, V153, P58, DOI 10.1111/j.1365-2141.2011.08588.x
   Doshi N, 2012, ADV MATER, V24, P3864, DOI 10.1002/adma.201200607
   Doshi N, 2009, P NATL ACAD SCI USA, V106, P21495, DOI 10.1073/pnas.0907127106
   Duncan R, 2003, NAT REV DRUG DISCOV, V2, P347, DOI 10.1038/nrd1088
   Dziubla TD, 2008, BIOMATERIALS, V29, P215, DOI 10.1016/j.biomaterials.2007.09.023
   Esmon CT, 2003, J THROMB HAEMOST, V1, P1343, DOI 10.1046/j.1538-7836.2003.00261.x
   Farokhzad OC, 2009, ACS NANO, V3, P16, DOI 10.1021/nn900002m
   Fernandes EGR, 2006, J MATER SCI-MATER M, V17, P105, DOI 10.1007/s10856-006-6813-5
   Ganguly K, 2006, J PHARMACOL EXP THER, V316, P1130, DOI 10.1124/jpet.105.093450
   Ganguly K, 2005, J PHARMACOL EXP THER, V312, P1106, DOI 10.1124/jpet.104.075770
   Ganguly K, 2007, J PHARMACOL EXP THER, V321, P158, DOI 10.1124/jpet.106.114405
   Gersh KC, 2010, J THROMB HAEMOST, V8, P1066, DOI 10.1111/j.1538-7836.2010.03802.x
   Gersh KC, 2011, BLOOD, V117, P4964, DOI 10.1182/blood-2010-10-310409
   Hardig BM, 2006, THROMB RES, V117, P713, DOI 10.1016/j.thromres.2005.05.027
   HEEREMANS JLM, 1995, THROMB HAEMOSTASIS, V73, P488
   Holme MN, 2012, NAT NANOTECHNOL, V7, P536, DOI [10.1038/nnano.2012.84, 10.1038/NNANO.2012.84]
   HOLVOET P, 1993, BLOOD, V81, P696
   Howard MD, 2008, J BIOMED NANOTECHNOL, V4, P133, DOI 10.1166/jbn.2008.021
   HUSAIN SS, 1991, BIOCHEMISTRY-US, V30, P5797, DOI 10.1021/bi00237a024
   Jin HQ, 2012, INT J PHARMACEUT, V434, P384, DOI 10.1016/j.ijpharm.2012.06.001
   KIELY JM, 1995, ARTERIOSCL THROM VAS, V15, P1211, DOI 10.1161/01.ATV.15.8.1211
   Kim AY, 2002, CIRC RES, V90, P205, DOI 10.1161/hh0202.105097
   Kim IS, 1998, ARCH PHARM RES, V21, P248, DOI 10.1007/BF02975283
   Kim Y, 2005, NANOTECHNOLOGY, V16, pS484, DOI 10.1088/0957-4484/16/7/024
   Knight LC, 2000, J NUCL MED, V41, P1056
   Korin N, 2012, SCIENCE, V337, P738, DOI 10.1126/science.1217815
   KUMADA T, 1988, BLOOD, V71, P728
   Laing ST, 2012, THROMB RES, V130, P629, DOI 10.1016/j.thromres.2011.11.010
   Lanza GM, 2010, STROKE, V41, pS42, DOI 10.1161/STROKEAHA.110.598656
   Leach JK, 2004, CLIN HEMORHEOL MICRO, V30, P225
   Leach JK, 2003, THROMB HAEMOSTASIS, V90, P64
   Magnani M, 2012, EXPERT OPIN BIOL TH, V12, P137, DOI 10.1517/14712598.2012.650163
   Merkel TJ, 2011, P NATL ACAD SCI USA, V108, P586, DOI 10.1073/pnas.1010013108
   Modery CL, 2011, BIOMATERIALS, V32, P9504, DOI 10.1016/j.biomaterials.2011.08.067
   Moreadith RW, 2003, ADV DRUG DELIVER REV, V55, P1337, DOI 10.1016/S0169-409X(03)00113-3
   Murciano JC, 2003, NAT BIOTECHNOL, V21, P891, DOI 10.1038/nbt846
   Murciano JC, 2003, BLOOD, V101, P3977, DOI 10.1182/blood-2002-09-2853
   Murciano JC, 2001, AM J RESP CRIT CARE, V164, P1295, DOI 10.1164/ajrccm.164.7.2010076
   Murciano JC, 2009, J CONTROL RELEASE, V139, P190, DOI 10.1016/j.jconrel.2009.07.003
   Muro S, 2005, CURR PHARM DESIGN, V11, P2383, DOI 10.2174/1381612054367274
   Muzykantov VR, 2013, EXPERT OPIN DRUG DEL, V10, P1, DOI 10.1517/17425247.2013.750292
   Muzykantov VR, 2010, EXPERT OPIN DRUG DEL, V7, P403, DOI 10.1517/17425241003610633
   Muzykantov VR, 1999, P NATL ACAD SCI USA, V96, P2379, DOI 10.1073/pnas.96.5.2379
   Muzykantov VR, 1996, ANAL BIOCHEM, V241, P109, DOI 10.1006/abio.1996.0384
   Muzykantov VR, 1996, AM J PHYSIOL-LUNG C, V270, pL704
   MUZYKANTOV VR, 1986, BIOCHIM BIOPHYS ACTA, V884, P355, DOI 10.1016/0304-4165(86)90184-4
   Muzykantov VR, 1996, J PHARMACOL EXP THER, V279, P1026
   NGUYEN PD, 1989, P SOC EXP BIOL MED, V192, P261
   Nordt TK, 2003, HEART, V89, P1358, DOI 10.1136/heart.89.11.1358
   Ortel TL, 2012, BLOOD, V120, P4699, DOI 10.1182/blood-2012-05-423228
   Perkins WR, 1997, THROMB HAEMOSTASIS, V77, P1174
   Peter K, 2000, CIRCULATION, V101, P1158
   Pisapia JM, 2012, EXP NEUROL, V233, P357, DOI 10.1016/j.expneurol.2011.10.029
   RAJAGOPALAN S, 1985, J CLIN INVEST, V75, P413, DOI 10.1172/JCI111715
   Rossi L, 2001, BIOTECHNOL APPL BIOC, V33, P85, DOI 10.1042/BA20000087
   RUNGE MS, 1991, P NATL ACAD SCI USA, V88, P10337, DOI 10.1073/pnas.88.22.10337
   RUNGE MS, 1987, P NATL ACAD SCI USA, V84, P7659, DOI 10.1073/pnas.84.21.7659
   SAKHAROV DV, 1995, CIRCULATION, V92, P1883
   SAKURAGAWA N, 1986, THROMB RES, V41, P627, DOI 10.1016/0049-3848(86)90359-2
   Scherpereel A, 2001, FASEB J, V15, P416, DOI 10.1096/fj.00-0022com
   Sen Gupta A, 2005, THROMB HAEMOSTASIS, V93, P106, DOI 10.1160/TH04-06-0340
   Shaw GJ, 2009, THROMB RES, V124, P306, DOI 10.1016/j.thromres.2009.01.008
   Simone EA, 2009, PHARM RES-DORD, V26, P250, DOI 10.1007/s11095-008-9744-7
   Spragg DD, 1997, P NATL ACAD SCI USA, V94, P8795, DOI 10.1073/pnas.94.16.8795
   Spyropoulos AC, 2012, BLOOD, V120, P2954, DOI 10.1182/blood-2012-06-415943
   Stein SC, 2009, J NEUROTRAUM, V26, P1585, DOI [10.1089/neu.2008.0720, 10.1089/neu.2008-0720]
   Tafur AJ, 2012, J THROMB HAEMOST, V10, P261, DOI 10.1111/j.1538-7836.2011.04572.x
   Trost JC, 2011, CRIT CARE MED, V39, P2346, DOI 10.1097/CCM.0b013e31821e855f
   Uesugi Y, 2010, J CONTROL RELEASE, V147, P269, DOI 10.1016/j.jconrel.2010.07.127
   vandenBrand MJBM, 1995, EUR HEART J, V16, P36, DOI 10.1093/eurheartj/16.suppl_L.36
   Varju I, 2011, J THROMB HAEMOST, V9, P979, DOI 10.1111/j.1538-7836.2011.04203.x
   Vyas SP, 2009, EXPERT OPIN DRUG DEL, V6, P499, DOI [10.1517/17425240902878002 , 10.1517/17425240902878002]
   Wang SS, 2009, J BIOMED MATER RES A, V91A, P753, DOI 10.1002/jbm.a.32234
   Wang XT, 2007, BIOCONJUGATE CHEM, V18, P791, DOI 10.1021/bc060322d
   YANG WP, 1994, BIOCHEMISTRY-US, V33, P2306, DOI 10.1021/bi00174a043
   Zaitsev S, 2006, BLOOD, V108, P1895, DOI 10.1182/blood-2005-11-012336
   Zaitsev S, 2012, BLOOD, V119, P4779, DOI 10.1182/blood-2011-12-398149
   Zaitsev S, 2010, BLOOD, V115, P5241, DOI 10.1182/blood-2010-01-261610
   Zaitzev S, 2010, J PHARMACOL EXP THER, V332, P1022, DOI 10.1124/jpet.109.159194
   Zhang LT, 1997, J BIOL CHEM, V272, P27053, DOI 10.1074/jbc.272.43.27053
NR 102
TC 40
Z9 41
U1 1
U2 67
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD AUG 29
PY 2013
VL 122
IS 9
BP 1565
EP 1575
DI 10.1182/blood-2013-03-453498
PG 11
WC Hematology
SC Hematology
GA 213KR
UT WOS:000324056500011
PM 23798715
OA gold
DA 2018-03-20
ER

PT J
AU Kessler, JH
   Khan, S
   Seifert, U
   Le Gall, S
   Chow, KM
   Paschen, A
   Bres-Vloemans, SA
   de Ru, A
   van Montfoort, N
   Franken, KLMC
   Benckhuijsen, WE
   Brooks, JM
   van Hall, T
   Ray, K
   Mulder, A
   Doxiadis, IIN
   van Swieten, PF
   Overkleeft, HS
   Prat, A
   Tomkinson, B
   Neefjes, J
   Kloetzel, PM
   Rodgers, DW
   Hersh, LB
   Drijfhout, JW
   van Veelen, PA
   Ossendorp, F
   Melief, CJM
AF Kessler, Jan H.
   Khan, Selina
   Seifert, Ulrike
   Le Gall, Sylvie
   Chow, K. Martin
   Paschen, Annette
   Bres-Vloemans, Sandra A.
   de Ru, Arnoud
   van Montfoort, Nadine
   Franken, Kees L. M. C.
   Benckhuijsen, Willemien E.
   Brooks, Jill M.
   van Hall, Thorbald
   Ray, Kallol
   Mulder, Arend
   Doxiadis, Ilias I. N.
   van Swieten, Paul F.
   Overkleeft, Hermen S.
   Prat, Annik
   Tomkinson, Birgitta
   Neefjes, Jacques
   Kloetzel, Peter M.
   Rodgers, David W.
   Hersh, Louis B.
   Drijfhout, Jan W.
   van Veelen, Peter A.
   Ossendorp, Ferry
   Melief, Cornelis J. M.
TI Antigen processing by nardilysin and thimet oligopeptidase generates
   cytotoxic T cell epitopes
SO NATURE IMMUNOLOGY
LA English
DT Article
ID TRIPEPTIDYL PEPTIDASE-II; DISTINCT PROTEOLYTIC PROCESSES; ARGININE
   DIBASIC CONVERTASE; SUBSTRATE-SPECIFICITY; PROTEASOME INHIBITORS;
   ENDOPLASMIC-RETICULUM; FLANKING SEQUENCES; BINDING-SITE; CYTOSOL;
   PATHWAY
AB Cytotoxic T lymphocytes (CTLs) recognize peptides presented by HLA class I molecules on the cell surface. The C terminus of these CTL epitopes is considered to be produced by the proteasome. Here we demonstrate that the cytosolic endopeptidases nardilysin and thimet oligopeptidase (TOP) complemented proteasome activity. Nardilysin and TOP were required, either together or alone, for the generation of a tumor-specific CTL epitope from PRAME, an immunodominant CTL epitope from Epstein-Barr virus protein EBNA3C, and a clinically important epitope from the melanoma protein MART-1. TOP functioned as C-terminal trimming peptidase in antigen processing, and nardilysin contributed to both the C-terminal and N-terminal generation of CTL epitopes. By broadening the antigenic peptide repertoire, nardilysin and TOP strengthen the immune defense against intracellular pathogens and cancer.
C1 [Kessler, Jan H.; Khan, Selina; Bres-Vloemans, Sandra A.; de Ru, Arnoud; van Montfoort, Nadine; Franken, Kees L. M. C.; Benckhuijsen, Willemien E.; Mulder, Arend; Doxiadis, Ilias I. N.; Drijfhout, Jan W.; van Veelen, Peter A.; Ossendorp, Ferry; Melief, Cornelis J. M.] Leiden Univ, Dept Immunohematol & Blood Transfus, Med Ctr, Leiden, Netherlands.
   [Seifert, Ulrike; Kloetzel, Peter M.] Humboldt Univ, Inst Biochem Charite, Fac Med, Berlin, Germany.
   [Le Gall, Sylvie] Ragon Inst MGH MIT & Harvard, Boston, MA USA.
   [Chow, K. Martin; Ray, Kallol; Rodgers, David W.; Hersh, Louis B.] Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY USA.
   [Chow, K. Martin; Ray, Kallol; Rodgers, David W.; Hersh, Louis B.] Univ Kentucky, Struct Biol Ctr, Lexington, KY USA.
   [Paschen, Annette] Univ Clin Essen, Dept Dermatol, Essen, Germany.
   [Brooks, Jill M.] Univ Birmingham, Canc Res UK Inst Canc Studies, Birmingham, W Midlands, England.
   [van Hall, Thorbald] Leiden Univ, Dept Clin Oncol, Med Ctr, Leiden, Netherlands.
   [van Swieten, Paul F.; Overkleeft, Hermen S.] Leiden Univ, Leiden Inst Chem, Leiden, Netherlands.
   [Prat, Annik] Clin Res Inst Montreal, Biochem Neuroendocrinol Lab, Montreal, PQ H2W 1R7, Canada.
   [Tomkinson, Birgitta] Uppsala Univ, Dept Med Biochem & Microbiol, Uppsala, Sweden.
   [Neefjes, Jacques] Netherlands Canc Inst, Div Cell Biol, Amsterdam, Netherlands.
RP Kessler, JH (reprint author), Leiden Univ, Dept Immunohematol & Blood Transfus, Med Ctr, Leiden, Netherlands.
EM j.h.kessler@amc.uva.nl
RI Kessler, Jan/C-5559-2009
OI Neefjes, Jacques/0000-0001-6763-2211; Overkleeft,
   Herman/0000-0001-6976-7005; van Veelen, Peter/0000-0002-7898-9408
FU Dutch Cancer Society [UL 2005-3245]; Stichting Vanderes
FX We thank T. Dannenberg and K. Textoris-Taube for technical assistance.
   Supported by the Dutch Cancer Society (UL 2005-3245) and Stichting
   Vanderes.
CR Altfeld M, 2006, PLOS MED, V3, P1851, DOI 10.1371/journal.pmed.0030403
   ANDROLEWICZ MJ, 1994, IMMUNITY, V1, P7, DOI 10.1016/1074-7613(94)90004-3
   BALOW RM, 1986, J BIOL CHEM, V261, P2409
   Benham AM, 1998, J IMMUNOL, V161, P83
   Berti DA, 2009, J BIOL CHEM, V284, P14105, DOI 10.1074/jbc.M807916200
   BROOKS JM, 1993, J EXP MED, V178, P879, DOI 10.1084/jem.178.3.879
   Chow KM, 2000, J BIOL CHEM, V275, P19545, DOI 10.1074/jbc.M909020199
   Chow KM, 2003, BIOCHEMISTRY-US, V42, P2239, DOI 10.1021/bi027178d
   Craiu A, 1997, P NATL ACAD SCI USA, V94, P10850, DOI 10.1073/pnas.94.20.10850
   Csuhai E, 1998, BIOCHEMISTRY-US, V37, P3787, DOI 10.1021/bi971969b
   Fumagalli P, 1998, GENOMICS, V47, P238, DOI 10.1006/geno.1997.5078
   Geier E, 1999, SCIENCE, V283, P978, DOI 10.1126/science.283.5404.978
   Herberts CA, 2006, J IMMUNOL, V176, P2697, DOI 10.4049/jimmunol.176.5.2697
   KAWAKAMI Y, 1994, J EXP MED, V180, P347, DOI 10.1084/jem.180.1.347
   Kessler BM, 2001, CHEM BIOL, V8, P913, DOI 10.1016/S1074-5521(01)00069-2
   Kessler JH, 2001, J EXP MED, V193, P73, DOI 10.1084/jem.193.1.73
   Kessler JH, 2003, HUM IMMUNOL, V64, P245, DOI 10.1016/S0198-8859(02)00787-5
   Kim SI, 2003, BIOCHEM J, V375, P111, DOI 10.1042/BJ20030490
   KNIGHT CG, 1995, BIOCHEM J, V308, P145, DOI 10.1042/bj3080145
   Le Gall S, 2007, J CLIN INVEST, V117, P3563, DOI 10.1172/JC132047
   Luckey CJ, 2001, J IMMUNOL, V167, P1212, DOI 10.4049/jimmunol.167.3.1212
   Luckey CJ, 1998, J IMMUNOL, V161, P112
   Marcilla M, 2007, MOL CELL PROTEOMICS, V6, P923, DOI 10.1074/mcp.M600302-MCP200
   Mo XY, 1999, J IMMUNOL, V163, P5851
   Mulder A, 2010, MOL IMMUNOL, V47, P809, DOI 10.1016/j.molimm.2009.10.004
   NEISIG A, 1995, J IMMUNOL, V154, P1273
   Oliveira V, 2002, EUR J BIOCHEM, V269, P4326, DOI 10.1046/j.1432-1033.2002.03129.x
   Oliveira V, 2001, BIOCHEMISTRY-US, V40, P4417, DOI 10.1021/bi002715k
   Parmentier N, 2010, NAT IMMUNOL, V11, P449, DOI 10.1038/ni.1862
   Portaro FCV, 1999, BIOCHEM BIOPH RES CO, V255, P596, DOI 10.1006/bbrc.1999.0251
   Reits E, 2004, IMMUNITY, V20, P495, DOI 10.1016/S1074-7613(04)00074-3
   Rock KL, 2004, NAT IMMUNOL, V5, P670, DOI 10.1038/ni1089
   ROELSE J, 1994, J EXP MED, V180, P1591, DOI 10.1084/jem.180.5.1591
   Romero P, 1997, J IMMUNOL, V159, P2366
   Saric T, 2004, J BIOL CHEM, V279, P46723, DOI 10.1074/jbc.M406537200
   Saric T, 2001, J BIOL CHEM, V276, P36474, DOI 10.1074/jbc.M105517200
   Saveanu L, 2005, NAT IMMUNOL, V6, P689, DOI 10.1038/ni1208
   Schneider J, 1998, INT J CANCER, V75, P451, DOI 10.1002/(SICI)1097-0215(19980130)75:3<451::AID-IJC20>3.0.CO;2-A
   Schwarz K, 2000, J IMMUNOL, V164, P6147, DOI 10.4049/jimmunol.164.12.6147
   Seifert U, 2003, NAT IMMUNOL, V4, P375, DOI 10.1038/ni905
   Shastri N, 2005, IMMUNOL REV, V207, P31, DOI 10.1111/j.0105-2896.2005.00321.x
   Sigman JA, 2005, BIOCHEM J, V388, P255, DOI 10.1042/BJ20041481
   Silva CL, 1999, BIOCHEM BIOPH RES CO, V255, P591, DOI 10.1006/bbrc.1999.0250
   Stoltze L, 1998, EUR J IMMUNOL, V28, P4029, DOI 10.1002/(SICI)1521-4141(199812)28:12<4029::AID-IMMU4029>3.0.CO;2-N
   Tenzer S, 2005, CELL MOL LIFE SCI, V62, P1025, DOI 10.1007/s00018-005-4528-2
   TOMKINSON B, 1990, BIOCHEM J, V267, P149, DOI 10.1042/bj2670149
   van Endert P, 2008, EUR J IMMUNOL, V38, P609, DOI 10.1002/eji.200838181
   van Swieten PF, 2007, BIOORG MED CHEM LETT, V17, P3402, DOI 10.1016/j.bmcl.2007.03.092
   Yewdell JW, 2007, CURR OPIN IMMUNOL, V19, P79, DOI 10.1016/j.coi.2006.11.010
   York IA, 2003, IMMUNITY, V18, P429, DOI 10.1016/S1074-7613(03)00058-X
NR 50
TC 62
Z9 62
U1 4
U2 17
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1529-2908
J9 NAT IMMUNOL
JI Nat. Immunol.
PD JAN
PY 2011
VL 12
IS 1
BP 45
EP U67
DI 10.1038/ni.1974
PG 11
WC Immunology
SC Immunology
GA 696TU
UT WOS:000285465100012
PM 21151101
DA 2018-03-20
ER

PT J
AU Rankin, SE
   Koganti, VR
   van Swol, F
   Malanoski, A
AF Rankin, Stephen E.
   Koganti, Venkat R.
   van Swol, Frank
   Malanoski, Anthony
TI Lattice Monte Carlo simulations of confinement effects on lyotropic
   surfactant liquid crystals
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
CT 231st National Meeting of the American-Chemical-Society
CY MAR 26-30, 2006
CL Atlanta, GA
SP Amer Chem Soc
C1 Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40508 USA.
   Sandia Natl Labs, Ctr Micro Engineered Mat, Livermore, CA 94550 USA.
   Univ New Mexico, Albuquerque, NM 87131 USA.
EM srankin@engr.uky.edu
RI Malanoski, Anthony/C-7814-2011
OI Malanoski, Anthony/0000-0001-6192-888X
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD MAR 26
PY 2006
VL 231
MA 396-COLL
PG 2
WC Chemistry, Multidisciplinary
SC Chemistry
GA 050YE
UT WOS:000238125903396
DA 2018-03-20
ER

PT J
AU Ayers, PW
   Liu, SB
   Li, TL
AF Ayers, Paul W.
   Liu, Shubin
   Li, Tonglei
TI Stability conditions for density functional reactivity theory: An
   interpretation of the total local hardness
SO PHYSICAL CHEMISTRY CHEMICAL PHYSICS
LA English
DT Article
ID HARD/SOFT ACID/BASE PRINCIPLE; DESCRIBING CHEMICAL-REACTIONS;
   FRONTIER-ELECTRON THEORY; FUKUI FUNCTION; VARIATIONAL-PRINCIPLES;
   MAXIMUM HARDNESS; ELECTROPHILICITY INDEX; ABSOLUTE HARDNESS; EMPIRICAL
   ENERGY; GENERAL-PURPOSE
AB The second-order Taylor series expansions commonly used in the density functional chemical reactivity theory are used to define local stability conditions for electronic states. Systems which satisfy these conditions are stable to infinitesimal perturbations due to approaching chemical reagents. The basic formalism considered here supersedes previous variational approaches to chemical reactivity theory like the electrophilicity, potentialphilicity, and chargephilicity. The total local hardness emerges naturally in this analysis, and can be clearly interpreted. When the total local hardness is small, the system is relatively insensitive to perturbations. Furthermore, minus the total local hardness is an energetically favorable perturbation of the external potential.
C1 [Ayers, Paul W.] McMaster Univ, Dept Chem, Hamilton, ON L8S 4M1, Canada.
   [Liu, Shubin] Univ N Carolina, Ctr Res Comp, Chapel Hill, NC 27599 USA.
   [Li, Tonglei] Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
RP Ayers, PW (reprint author), McMaster Univ, Dept Chem, 1280 Main St W, Hamilton, ON L8S 4M1, Canada.
EM ayers@mcmaster.ca
RI Ayers, Paul/A-1154-2008; Liu, Shubin/B-1502-2009
OI Ayers, Paul/0000-0003-2605-3883; Liu, Shubin/0000-0001-9331-0427
FU NSERC; Canada Research Chairs; Sharcnet
FX PWA acknowledges support from NSERC, the Canada Research Chairs, and
   Sharcnet.
CR Aizman A, 2005, TETRAHEDRON, V61, P889, DOI 10.1016/j.tet.2004.11.014
   Anderson JSM, 2007, PHYS CHEM CHEM PHYS, V9, P2371, DOI 10.1039/b700960g
   Anderson JSM, 2007, J CHEM THEORY COMPUT, V3, P358, DOI 10.1021/ct600164j
   Anderson JSM, 2007, J CHEM THEORY COMPUT, V3, P375, DOI 10.1021/ct6001658
   Ayers PW, 2008, J CHEM PHYS, V128, DOI 10.1063/1.2918731
   Ayers PW, 2008, J MATH CHEM, V43, P285, DOI 10.1007/s10910-006-9195-5
   Ayers PW, 2007, THEOR CHEM ACC, V118, P371, DOI 10.1007/s00214-007-0277-7
   Ayers PW, 2007, THEOR CHEM ACC, V117, P371, DOI 10.1007/s00214-006-0165-6
   Ayers PW, 2007, FARADAY DISCUSS, V135, P161, DOI 10.1039/b606877d
   Ayers PW, 2009, CHEM PHYS LETT, V480, P318, DOI 10.1016/j.cplett.2009.08.067
   Ayers PW, 2000, J CHEM PHYS, V113, P10886, DOI 10.1063/1.1327268
   Ayers PW, 2006, J CHEM PHYS, V124, DOI 10.1063/1.2196882
   Ayers PW, 2005, PHYS CHEM CHEM PHYS, V7, P1918, DOI 10.1039/b500996k
   Ayers PW, 2005, INT J QUANTUM CHEM, V101, P520, DOI 10.1002/qua.20307
   Ayers PW, 2000, THEOR CHEM ACC, V103, P353, DOI 10.1007/s002149900093
   Ayers PW, 2002, J CHEM PHYS, V116, P8731, DOI 10.1063/1.1467338
   Ayers PW, 2001, J CHEM PHYS, V115, P4438, DOI 10.1063/1.1379333
   Ayers PW, 2001, J AM CHEM SOC, V123, P2007, DOI 10.1021/ja002966g
   Ayers PW, 2001, THEOR CHEM ACC, V106, P271, DOI 10.1007/PL00012385
   Ayers PW, 2000, J AM CHEM SOC, V122, P2010, DOI 10.1021/ja9924039
   Ayers P. W., 2003, COMPUTATIONAL MED CH, P571
   AYERS PW, 2005, ADV COMPUTATIONAL ME, V4, P1175
   AYERS PW, 2010, UNPUB
   BERKOWITZ M, 1988, J CHEM PHYS, V88, P2554, DOI 10.1063/1.454034
   BERKOWITZ M, 1987, J AM CHEM SOC, V109, P4823, DOI 10.1021/ja00250a012
   BERKOWITZ M, 1985, J AM CHEM SOC, V107, P6811, DOI 10.1021/ja00310a011
   CARDENAS C, UNPUB
   Chamorro E, 2005, J PHYS CHEM A, V109, P10068, DOI 10.1021/jp053646s
   Chattaraj PK, 2003, J PHYS CHEM A, V107, P4973, DOI 10.1021/jp034707u
   CHATTARAJ PK, 1995, J CHEM PHYS, V103, P7645, DOI 10.1063/1.470284
   Chattaraj PK, 2007, PHYS CHEM CHEM PHYS, V9, P3853, DOI 10.1039/b705742c
   Chattaraj PK, 2006, CHEM REV, V106, P2065, DOI 10.1021/cr040109f
   Chermette H, 1999, J COMPUT CHEM, V20, P129, DOI 10.1002/(SICI)1096-987X(19990115)20:1<129::AID-JCC13>3.3.CO;2-1
   COHEN MH, 1995, J CHEM PHYS, V103, P3543, DOI 10.1063/1.470238
   COHEN MH, 1994, J CHEM PHYS, V101, P8988, DOI 10.1063/1.468026
   Cohen MH, 2007, J PHYS CHEM A, V111, P2229, DOI 10.1021/jp066449h
   Domingo LR, 2003, J ORG CHEM, V68, P6060, DOI 10.1021/jo030072j
   Gazquez JL, 2008, J MEX CHEM SOC, V52, P3
   Geerlings P, 2003, CHEM REV, V103, P1793, DOI 10.1021/cr990029p
   GHOSH SK, 1985, J CHEM PHYS, V83, P2976, DOI 10.1063/1.449846
   Gorling A, 1999, PHYS REV LETT, V83, P5459, DOI 10.1103/PhysRevLett.83.5459
   Hammett LP, 1937, J AM CHEM SOC, V59, P96, DOI 10.1021/ja01280a022
   HARBOLA MK, 1991, ISR J CHEM, V31, P395, DOI 10.1002/ijch.199100045
   JOHNSON PA, MODERN CHARGE DENSIT
   Lamsabhi AM, 2005, J PHYS ORG CHEM, V18, P1161, DOI 10.1002/poc.984
   Liu SB, 1999, J CHEM PHYS, V111, P6197, DOI 10.1063/1.479924
   Liu S., 2009, CHEM REACTIVITY THEO, P179
   Liu SB, 2009, ACTA PHYS-CHIM SIN, V25, P590, DOI 10.3866/PKU.WHXB20090332
   Liu SB, 2009, J CHEM PHYS, V131, DOI 10.1063/1.3231687
   Melin J, 2005, J CHEM SCI, V117, P387, DOI 10.1007/BF02708342
   NALEWAJSKI RF, 1982, J CHEM PHYS, V77, P399, DOI 10.1063/1.443620
   Parr RG, 1999, J AM CHEM SOC, V121, P1922, DOI 10.1021/ja983494x
   PARR RG, 1983, J AM CHEM SOC, V105, P7512, DOI 10.1021/ja00364a005
   PARR RG, 1978, J CHEM PHYS, V68, P3801, DOI 10.1063/1.436185
   PARR RG, 1991, J AM CHEM SOC, V113, P1854, DOI 10.1021/ja00005a072
   PARR RG, 1984, J AM CHEM SOC, V106, P4049, DOI 10.1021/ja00326a036
   Parr RG, 1989, DENSITY FUNCTIONAL T
   PEARSON RG, 1992, J PHYS CHEM-US, V96, P3283, DOI 10.1021/j100187a020
   PEARSON RG, 1987, J CHEM EDUC, V64, P561, DOI 10.1021/ed064p561
   Pearson R. G., 1997, CHEM HARDNESS
   PERDEW JP, 1982, PHYS REV LETT, V49, P1691, DOI 10.1103/PhysRevLett.49.1691
   Perez P, 2000, J AM CHEM SOC, V122, P4756, DOI 10.1021/ja994108u
   Sagvolden E, 2009, PHYS REV A, V79, DOI 10.1103/PhysRevA.79.026501
   Senet P, 1996, J CHEM PHYS, V105, P6471, DOI 10.1063/1.472498
   Senet P, 1997, J CHEM PHYS, V107, P2516, DOI 10.1063/1.474591
   YANG W, 1984, J CHEM PHYS, V81, P2862, DOI 10.1063/1.447964
   YANG WT, 1985, P NATL ACAD SCI USA, V82, P6723, DOI 10.1073/pnas.82.20.6723
   ZHOU ZX, 1989, J AM CHEM SOC, V111, P7371, DOI 10.1021/ja00201a014
NR 68
TC 7
Z9 7
U1 0
U2 10
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1463-9076
J9 PHYS CHEM CHEM PHYS
JI Phys. Chem. Chem. Phys.
PY 2011
VL 13
IS 10
BP 4427
EP 4433
DI 10.1039/c0cp01675f
PG 7
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA 724NY
UT WOS:000287584700030
PM 21253639
DA 2018-03-20
ER

PT J
AU Modekrutti, S
   Cammers, A
AF Modekrutti, Subrahmanyam
   Cammers, Arthur
TI Synthesis of triangulene derivatives: Study of ion-pairing in charged
   triangulenes
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
CT 246th National Meeting of the American-Chemical-Society (ACS)
CY SEP 08-12, 2013
CL Indianapolis, IN
SP Amer Chem Soc
C1 [Modekrutti, Subrahmanyam; Cammers, Arthur] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
EM snmo222@uky.edu
NR 0
TC 0
Z9 0
U1 0
U2 10
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD SEP 8
PY 2013
VL 246
MA 354-ORGN
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA 288NJ
UT WOS:000329618405485
DA 2018-03-19
ER

PT J
AU Wang, ZM
   Meenach, SA
AF Wang, Zimeng
   Meenach, Samantha A.
TI Synthesis and Characterization of Nanocomposite Microparticles (nCmP)
   for the Treatment of Cystic Fibrosis-Related Infections
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE cystic fibrosis; nanocomposite microparticles; pulmonary delivery; spray
   drying
ID DRY POWDER INHALATION; AEROSOL DISPERSION PERFORMANCE;
   PSEUDOMONAS-AERUGINOSA; PHYSICOCHEMICAL CHARACTERIZATION; ACETALATED
   DEXTRAN; MULTIFUNCTIONAL PARTICLES; PULMONARY DELIVERY;
   SUSTAINED-RELEASE; DRIED MANNITOL; DRUG-DELIVERY
AB Pulmonary antibiotic delivery is recommended as maintenance therapy for cystic fibrosis (CF) patients who experience chronic infections. However, abnormally thick and sticky mucus present in the respiratory tract of CF patients impairs mucus penetration and limits the efficacy of inhaled antibiotics. To overcome the obstacles of pulmonary antibiotic delivery, we have developed nanocomposite microparticles (nCmP) for the inhalation application of antibiotics in the form of dry powder aerosols.
   Azithromycin-loaded and rapamycin-loaded polymeric nanoparticles (NP) were prepared via nanoprecipitation and nCmP were prepared by spray drying and the physicochemical characteristics were evaluated.
   The nanoparticles were 200 nm in diameter both before loading into and after redispersion from nCmP. The NP exhibited smooth, spherical morphology and the nCmP were corrugated spheres about 1 mu m in diameter. Both drugs were successfully encapsulated into the NP and were released in a sustained manner. The NP were successfully loaded into nCmP with favorable encapsulation efficacy. All materials were stable at manufacturing and storage conditions and nCmP were in an amorphous state after spray drying. nCmP demonstrated desirable aerosol dispersion characteristics, allowing them to deposit into the deep lung regions for effective drug delivery.
   The described nCmP have the potential to overcome mucus-limited pulmonary delivery of antibiotics.
C1 [Wang, Zimeng; Meenach, Samantha A.] Univ Rhode Isl, Dept Chem Engn, 202 Crawford Hall,16 Greenhouse Rd, Kingston, RI 02881 USA.
   [Meenach, Samantha A.] Univ Rhode Isl, Dept Biomed & Pharmaceut Sci, Kingston, RI 02881 USA.
RP Meenach, SA (reprint author), Univ Rhode Isl, Dept Chem Engn, 202 Crawford Hall,16 Greenhouse Rd, Kingston, RI 02881 USA.; Meenach, SA (reprint author), Univ Rhode Isl, Dept Biomed & Pharmaceut Sci, Kingston, RI 02881 USA.
EM smeenach@uri.edu
FU National Institute of General Medical Sciences of the National
   Institutes of Health [P20GM103430]
FX The authors gratefully acknowledge financial support from an
   Institutional Development Award (IDeA) from the National Institute of
   General Medical Sciences of the National Institutes of Health under
   grant number P20GM103430. The content is solely the responsibility of
   the authors and does not necessarily represent the official views of the
   National Institutes of Health. The authors thank RI-INBRE for HPLC
   access and RIN2 for SEM, DLS, PXRD, and DSC access.
CR Abdulrahman BA, 2011, AUTOPHAGY, V7, P1359, DOI 10.4161/auto.7.11.17660
   Bachelder EM, 2008, J AM CHEM SOC, V130, P10494, DOI 10.1021/ja803947s
   Bootz A, 2004, EUR J PHARM BIOPHARM, V57, P369, DOI 10.1016/S0939-6411(03)00193-0
   Bowenand S-J, 2015, PAEDIAT CHILD HLTH, V25, P159
   Bradbury NA, 2015, ENCY CELL BIOL, P283
   Broaders KE, 2009, P NATL ACAD SCI USA, V106, P5497, DOI 10.1073/pnas.0901592106
   Chen YC, 2013, BIOMATERIALS, V34, P1115, DOI 10.1016/j.biomaterials.2012.10.034
   Chew NYK, 2002, J AEROSOL MED, V15, P325, DOI 10.1089/089426802760292672
   Chuchalin A, 2009, PULM PHARMACOL THER, V22, P526, DOI 10.1016/j.pupt.2009.06.001
   Collnot EM, 2006, J CONTROL RELEASE, V111, P35, DOI 10.1016/j.jconrel.2005.11.005
   Cook RO, 2005, J CONTROL RELEASE, V104, P79, DOI 10.1016/j.jconrel.2005.01.003
   COONEY GF, 1994, J CLIN PHARMACOL, V34, P255, DOI 10.1002/j.1552-4604.1994.tb03995.x
   Daniels T, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007639.pub2
   Dolovich MB, 2011, LANCET, V377, P1032, DOI 10.1016/S0140-6736(10)60926-9
   EDWARDS DA, 1995, J AEROSOL SCI, V26, P293, DOI 10.1016/0021-8502(94)00101-4
   FibrosisFoundation C, 2005, PAT REG 2005 ANN REP
   Geller DE, 2002, CHEST, V122, P219, DOI 10.1378/chest.122.1.219
   Heijerman H, 2009, J CYST FIBROS, V8, P295, DOI 10.1016/j.jcf.2009.04.005
   Hickey A.J., 2008, MODIFIED RELEASE DRU, V2, P573
   Hickey AJ, 2009, MODERN PHARM, P191
   Hickey AJ, 2007, J PHARM SCI-US, V96, P1282, DOI 10.1002/jps.20916
   Hoppentocht M, 2014, EUR J PHARM BIOPHARM, V86, P23, DOI 10.1016/j.ejpb.2013.10.019
   Ibrahim BM, 2011, EXPERT OPIN DRUG DEL, V8, P451, DOI 10.1517/17425247.2011.561310
   Jensen DMK, 2010, J CONTROL RELEASE, V142, P138, DOI 10.1016/j.jconrel.2009.10.010
   Kaialy W, 2015, EUR J PHARM SCI, V68, P56, DOI 10.1016/j.ejps.2014.12.005
   Kauffman KJ, 2012, INT J PHARMACEUT, V422, P356, DOI 10.1016/j.ijpharm.2011.10.034
   Kuzmov A, 2015, J CONTROL RELEASE, V219, P500, DOI 10.1016/j.jconrel.2015.07.024
   Li XJ, 2012, INT J PHARMACEUT, V433, P79, DOI 10.1016/j.ijpharm.2012.04.081
   Liand X, 2011, AAPS PHARMSCITECH, V12, P1420
   Littringer EM, 2012, EUR J PHARM BIOPHARM, V82, P194, DOI 10.1016/j.ejpb.2012.05.001
   Meenach SA, 2013, EUR J PHARM SCI, V49, P699, DOI 10.1016/j.ejps.2013.05.012
   Meenach SA, 2013, INT J NANOMED, V8, P275, DOI 10.2147/IJN.S30724
   Zhang J, 2012, ACTA PHYS-CHIM SIN, V28, P290, DOI [10.1021/mp2003785, 10.3866/PKU.WHXB201112121]
   Mert O, 2012, J CONTROL RELEASE, V157, P455, DOI 10.1016/j.jconrel.2011.08.032
   Milla CE, 2007, CLIN CHEST MED, V28, P319, DOI 10.1016/j.ccm.2007.02.006
   Mohammadi G, 2010, COLLOID SURFACE B, V80, P34, DOI 10.1016/j.colsurfb.2010.05.027
   Ong HX, 2014, AAPS J, V16, P269, DOI 10.1208/s12248-014-9560-4
   PISCITELLI SC, 1992, CLIN PHARMACY, V11, P137
   Rajan Sujatha, 2002, Semin Respir Infect, V17, P47, DOI 10.1053/srin.2002.31690
   REGELMANN WE, 1990, AM REV RESPIR DIS, V141, P914, DOI 10.1164/ajrccm/141.4_Pt_1.914
   Saiman L, 2003, JAMA-J AM MED ASSOC, V290, P1749, DOI 10.1001/jama.290.13.1749
   Sham JOH, 2004, INT J PHARM, V269, P457, DOI 10.1016/j.ijpharm.2003.09.041
   Southern KW, 2004, EUR RESPIR J, V24, P834, DOI 10.1183/09031936.04.00084304
   Stanojevic S, 2014, J CYST FIBROS, V13, P172, DOI 10.1016/j.jcf.2013.09.002
   Stegemann S, 2013, EUR J PHARM SCI, V48, P181, DOI 10.1016/j.ejps.2012.10.021
   Suarez S, 2000, Respir Care, V45, P652
   Tang BC, 2009, P NATL ACAD SCI USA, V106, P19268, DOI 10.1073/pnas.0905998106
   Thursfield RM, 2012, PAEDIATR RESPIR REV, V13, P215, DOI 10.1016/j.prrv.2012.04.003
   Ungaro F, 2006, EUR J PHARM SCI, V28, P423, DOI 10.1016/j.ejps.2006.05.005
   Wagner T, 2005, CHEST, V128, P912, DOI 10.1378/chest.128.2.912
   Watts AB, 2011, ADV DEL SCI TECHNOL, P335, DOI 10.1007/978-1-4419-9745-6_15
   Wilms EB, 2012, PEDIATR PULM, V47, P658, DOI 10.1002/ppul.21620
   Wu X, 2013, INT J NANOMED, V8, P1269, DOI 10.2147/IJN.S40904
   Wu X, 2013, DRUG DES DEV THER, V7, P59, DOI [10.2147/DDDT.540166, 10.2147/DDDT.S40166]
   Zhang ZL, 2014, J PHARM PHARMACOL, V66, P557, DOI 10.1111/jphp.12089
   Zhao M, 2008, POWDER TECHNOL, V187, P214, DOI 10.1016/j.powtec.2008.02.014
NR 56
TC 2
Z9 2
U1 3
U2 9
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
EI 1573-904X
J9 PHARM RES-DORDR
JI Pharm. Res.
PD AUG
PY 2016
VL 33
IS 8
BP 1862
EP 1872
DI 10.1007/s11095-016-1921-5
PG 11
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA DR5EK
UT WOS:000379925700005
PM 27091030
OA green_accepted
DA 2018-03-20
ER

PT J
AU Ambati, J
   Rankin, SE
AF Ambati, Jyothirmai
   Rankin, Stephen E.
TI DFT Calculations of Indirect Si-29-H-1 Spin-Spin Coupling Constants in
   Organoalkoxysilanes
SO JOURNAL OF PHYSICAL CHEMISTRY A
LA English
DT Article
ID NMR CHEMICAL-SHIFTS; DENSITY-FUNCTIONAL THEORY; ORGANIC-INORGANIC
   MATERIALS; SOL-GEL POLYCONDENSATION; AB-INITIO CALCULATIONS; BASIS-SET
   DEPENDENCE; POLARIZATION TRANSFER; BRIDGED POLYSILSESQUIOXANES;
   POLYMERIZATION REACTIONS; STATE NMR
AB The performance of four basis sets (6-311+G(2d,p), IGLO-III, cc-PVTZ, and 6-31G) is evaluated in order to find a quantum mechanical technique that can be used to accurately estimate Si-29-H-1 spin-spin coupling constants in organoalkoxysilanes. The 6-31G basis set with the B3LYP functional is found to be an accurate, efficient, and cost-effective density functional theory method for predicting spin spin coupling constants of organoalkoxysilanes. Knowledge of these scalar coupling constants and their dependence on structural variations is important to be able to fine-tune NMR experiments that rely on polarization transfer among nuclei, such as Si-29 distortionless enhancement by polarization transfer (DEPT). The effects of size and the number of unhydrolyzable alkyl groups attached to silicon and the effects of substitution of alkoxy groups with hydroxyl groups on Si-29-H-1 spin spin coupling constants are investigated using this DFT method. The results show that the predicted scalar coupling between silicon and organic groups depends weakly on the degree of hydrolysis of the alkoxysilanes. The effectiveness of this method is also illustrated for the determination of spin spin coupling constants in a species containing a siloxane bond.
C1 [Ambati, Jyothirmai; Rankin, Stephen E.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Rankin, SE (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM srankin@engr.uky.edu
RI Rankin, Stephen/A-3265-2013
OI Rankin, Stephen/0000-0002-8615-7564; Ambati,
   Jyothirmai/0000-0003-2420-3665
FU NSF [CTS-0348234]
FX This report is partially based on work supported by NSF through CAREER
   Grant Number CTS-0348234. We acknowledge the Department of Chemistry NMR
   Center and the Center for High Performance Computing at the University
   of Kentucky for providing facilities for this study.
CR Alam TM, 1996, MAGN RESON CHEM, V34, P603, DOI 10.1002/(SICI)1097-458X(199608)34:8<603::AID-OMR917>3.0.CO;2-L
   ASSINK RA, 1991, ANNU REV MATER SCI, V21, P491
   BANEY RH, 1995, CHEM REV, V95, P1409, DOI 10.1021/cr00037a012
   BECKE AD, 1993, J CHEM PHYS, V98, P5648, DOI 10.1063/1.464913
   Brinker C.J., 1990, SOL GEL SCI PHYS CHE
   BRUNET F, 1994, NEW J CHEM, V18, P1059
   Brunet F, 1998, J NON-CRYST SOLIDS, V231, P58, DOI 10.1016/S0022-3093(98)00403-7
   Brus J, 1996, CHEM LISTY, V90, P316
   Cammi R, 2000, J PHYS CHEM A, V104, P5631, DOI 10.1021/jp000156l
   Casanovas J, 1999, MAT SCI ENG B-SOLID, V68, P16, DOI 10.1016/S0921-5107(99)00337-2
   Casanovas J, 2000, CHEM PHYS LETT, V326, P523, DOI 10.1016/S0009-2614(00)00818-6
   Casserly TB, 2005, PLASMA PROCESS POLYM, V2, P669, DOI 10.1002/ppap.200500054
   Casserly TB, 2005, J PHYS CHEM B, V109, P13605, DOI 10.1021/jp044385+
   Contreras RH, 2000, ANNU REP NMR SPECTRO, V41, P55, DOI 10.1016/S0066-4103(00)41009-4
   Contreras R.H., 2003, ANNU REP NMR SPECTRO, V51, P167
   Corminboeuf C, 2002, CHEM PHYS LETT, V357, P1, DOI 10.1016/S0009-2614(02)00372-X
   Cypry M, 2007, POLIMERY-W, V52, P730
   Cypryk M, 1999, B POL ACAD SCI-CHEM, V47, P33
   Del Bene JE, 2003, CHEM PHYS LETT, V382, P100, DOI 10.1016/j.cplett.2003.10.006
   Deng W, 2006, J CHEM THEORY COMPUT, V2, P1028, DOI 10.1021/ct600110u
   DODDRELL DM, 1982, J MAGN RESON, V48, P323, DOI 10.1016/0022-2364(82)90286-4
   Dong HJ, 2007, J SOL-GEL SCI TECHN, V41, P11, DOI 10.1007/s10971-006-0115-8
   Dong HJ, 2003, J SOL-GEL SCI TECHN, V28, P5, DOI 10.1023/A:1025690300105
   FRANCL MM, 1982, J CHEM PHYS, V77, P3654, DOI 10.1063/1.444267
   FRISCH MJ, 2004, GAUSSIAN 03 REVISION
   Fukui H, 2006, NUC MAGN RESON, V35, P130
   HARRIS RK, 1983, NUCL MAGNETIC RESONA, P213
   Heine T, 2001, J PHYS CHEM A, V105, P620, DOI 10.1021/jp002495k
   Helgaker T, 1999, CHEM REV, V99, P293, DOI 10.1021/cr960017t
   Helgaker T, 1998, THEOR CHEM ACC, V99, P175, DOI 10.1007/s002140050321
   Helgaker T, 2000, J CHEM PHYS, V113, P9402, DOI 10.1063/1.1321296
   HUZINAGA S, 1965, J CHEM PHYS, V42, P1293, DOI 10.1063/1.1696113
   HUZINAGA S, 1971, APPROXIMATE ATOMIC F
   Jensen F, 2006, J CHEM THEORY COMPUT, V2, P1360, DOI 10.1021/ct600166u
   Knight CTG, 1999, ANAL CHEM, V71, P265, DOI 10.1021/ac980547k
   KUTZELNIGG W, 1991, NMR-BASIC PRINC PROG, V23, P165
   LEE CT, 1988, PHYS REV B, V37, P785, DOI 10.1103/PhysRevB.37.785
   LOY DA, 1995, CHEM REV, V95, P1431, DOI 10.1021/cr00037a013
   Lux P, 1996, MAGN RESON CHEM, V34, P173
   MALIER L, 1992, PHYS REV A, V46, P959, DOI 10.1103/PhysRevA.46.959
   Minch JM, 1994, CONCEPT MAGNETIC RES, V6, P41
   MORRIS GA, 1979, J AM CHEM SOC, V101, P760, DOI 10.1021/ja00497a058
   Okumoto S, 1998, J PHYS CHEM A, V102, P3991, DOI 10.1021/jp980705b
   Osipov AL, 2005, CHEM COMMUN, P3349, DOI 10.1039/b500679a
   OSTERHOLTZ FD, 1992, J ADHES SCI TECHNOL, V6, P127, DOI 10.1163/156856192X00106
   Pereira JCG, 1998, CHEM COMMUN, P1387, DOI 10.1039/a801816b
   POUXVIEL JC, 1987, J NON-CRYST SOLIDS, V89, P345, DOI 10.1016/S0022-3093(87)80277-6
   Rankin SE, 2000, MACROMOLECULES, V33, P7743, DOI 10.1021/ma0004920
   Rankin SE, 1997, J POLYM SCI POL CHEM, V35, P1293
   Rankin SE, 1998, AICHE J, V44, P1141, DOI 10.1002/aic.690440512
   Sanchez J, 1996, IND ENG CHEM RES, V35, P117, DOI 10.1021/ie950246q
   SCHINDLER M, 1982, J CHEM PHYS, V76, P1919, DOI 10.1063/1.443165
   Sefcik J, 2001, GEOCHIM COSMOCHIM AC, V65, P4435, DOI 10.1016/S0016-7037(01)00739-6
   Shea KJ, 2001, CHEM MATER, V13, P3306, DOI 10.1021/cm011074s
   Sykora J, 2006, MAGN RESON CHEM, V44, P669, DOI 10.1002/mrc.1810
   Thompson M. A., 2009, ARGUSLAB 4 0 1
   TSANTES G, 2003, ORGANOSILICON CHEM, V5, P334
   Vyboishchikov SF, 2006, CHEM-EUR J, V12, P8518, DOI 10.1002/chem.200600421
   Watson MA, 2004, CHEM-EUR J, V10, P4627, DOI 10.1002/chem.200306065
   Williams E. A., 1983, Annual reports on NMR spectroscopy. Vol.15, P235
   Wrackmeyer B, 2006, ANNU REP NMR SPECTRO, V57, P1, DOI 10.1016/S0066-4103(05)57001-7
   Wu J, 2009, POLYM REV, V49, P25, DOI 10.1080/15583720802656237
   Xue X, 1998, PHYS CHEM MINER, V26, P14, DOI 10.1007/s002690050157
   Xue XY, 2000, SOLID STATE NUCL MAG, V16, P245, DOI 10.1016/S0926-2040(00)00075-8
   Zhang ZP, 2003, J SOL-GEL SCI TECHN, V28, P159, DOI 10.1023/A:1026098729993
   Zhao JQ, 2008, POLYM POLYM COMPOS, V16, P483
NR 66
TC 11
Z9 11
U1 0
U2 13
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1089-5639
J9 J PHYS CHEM A
JI J. Phys. Chem. A
PD APR 29
PY 2010
VL 114
IS 16
BP 5279
EP 5286
DI 10.1021/jp911327a
PG 8
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA 586FM
UT WOS:000276888800007
PM 20361771
DA 2018-03-20
ER

PT J
AU Chen, ZQ
   Zhang, JJ
   Singh, S
   Peltier-Pain, P
   Thorson, JS
   Hinds, BJ
AF Chen, Zhiqiang
   Zhang, Jianjun
   Singh, Shanteri
   Peltier-Pain, Pauline
   Thorson, Jon S.
   Hinds, Bruce J.
TI Functionalized Anodic Aluminum Oxide Membrane-Electrode System for
   Enzyme Immobilization
SO ACS NANO
LA English
DT Article
DE biomimetic enzyme immobilization; membrane-electrode;
   glycosyltransferase; glycosylation; enzyme purification; sequential
   reactions
ID GLYCOSYLTRANSFERASE-CATALYZED REACTIONS; IN-VITRO CHARACTERIZATION;
   PROTEIN SEPARATION; SELF-SACRIFICE; REVERSIBILITY; ADSORPTION;
   RESISTANCE; MOLECULES; BINDING; BEADS
AB A nanoporous membrane system with directed flow carrying reagents to sequentially attached enzymes to mimic natures enzyme complex system was demonstrated. Genetically modified glycosylation enzyme, OleD Loki variant was immobilized onto nanometer-scale electrodes at the pore entrances/exits of anodic aluminum oxide membranes through His(6)-tag affinity binding. The enzyme activity was assessed in two reactions-a one-step "reverse" sugar nucleotide formation reaction (UDP-Glc) and a two-step sequential sugar nucleotide formation and sugar nucleotide based glycosylation reaction. For the one-step reaction, enzyme specific activity of 6-20 min(-1) on membrane supports was seen to be comparable to solution enzyme specific activity of 10 min(-1). UDP-Glc production efficiencies as high as 98% were observed at a flow rate of 05 mL/min, at which the substrate residence time over the electrode length down pore entrances was matched to the enzyme activity rate. This flow geometry also prevented an unwanted secondary product hydrolysis reaction, as observed in the test homogeneous solution. Enzyme utilization increased by a factor of 280 compared to test homogeneous conditions due to the continuous flow of fresh substrate over the enzyme. To mimic enzyme complex systems, a two-step sequential reaction using OleD Loki enzyme was performed at membrane pore entrances then exits. After UDP-Glc formation at the entrance electrode, aglycon 4-methylumbelliferone was supplied at the exit face of the reactor, affording overall 80% glycosylation efficiency. The membrane platform showed the ability to be regenerated with purified enzyme as well as directly from expression crude, thus demonstrating a single-step immobilization and purification process.
C1 [Chen, Zhiqiang; Hinds, Bruce J.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Zhang, Jianjun; Singh, Shanteri; Peltier-Pain, Pauline; Thorson, Jon S.] Univ Kentucky, Coll Pharm, Ctr Pharmaceut Res & Innovat, Lexington, KY 40536 USA.
RP Thorson, JS (reprint author), Univ Kentucky, Coll Pharm, Ctr Pharmaceut Res & Innovat, Lexington, KY 40536 USA.
EM jsthorson@uky.edu; bjhinds@uw.edu
RI chen, zhiqiang/O-5564-2016; zhang, jianjun/H-7529-2012; Thorson,
   Jon/L-3696-2013
OI Thorson, Jon/0000-0002-7148-0721; Singh, Shanteri/0000-0003-0960-4794
FU NIH [R01 DA018822, R37 AI52218]; DARPA [W911NF-09-0267]; National Center
   for Advancing Translational Sciences [UL1TR000117]; University of
   Kentucky College of Pharmacy; University of Kentucky Markey Cancer
   Center
FX We thank the Center for Nanoscale Science and Engineering for critical
   infrastructure. This work was supported in part by NIH grants R01
   DA018822 (to B.J.H.) and R37 AI52218 (to J.S.T.) and DARPA grant
   W911NF-09-0267 (to B.J.H), the National Center for Advancing
   Translational Sciences (UL1TR000117), the University of Kentucky College
   of Pharmacy and the University of Kentucky Markey Cancer Center.
CR Bao J, 2007, ACS NANO, V1, P293, DOI 10.1021/nn700189h
   Biggins JB, 2003, SCIENCE, V301, P1537, DOI 10.1126/science.1086695
   Bolam DN, 2007, P NATL ACAD SCI USA, V104, P5336, DOI 10.1073/pnas.0607897104
   Chen X, 2001, J AM CHEM SOC, V123, P2081, DOI 10.1021/ja005738v
   Chen ZQ, 2014, ADV FUNCT MATER, V24, P4317, DOI 10.1002/adfm.201303707
   Conrado RJ, 2008, CURR OPIN BIOTECH, V19, P492, DOI 10.1016/j.copbio.2008.07.006
   Dhathathreyan A, 2011, J PHYS CHEM B, V115, P6678, DOI 10.1021/jp1122085
   Fierobe HP, 2002, J BIOL CHEM, V277, P49621, DOI 10.1074/jbc.M207672200
   GALLEGO FL, 2010, CURR OPIN CHEM BIOL, V14, P174
   Gantt RW, 2013, P NATL ACAD SCI USA, V110, P7648, DOI 10.1073/pnas.1220220110
   Gantt RW, 2011, NAT PROD REP, V28, P1811, DOI 10.1039/c1np00045d
   Gantt RW, 2011, NAT CHEM BIOL, V7, P685, DOI [10.1038/NCHEMBIO.638, 10.1038/nchembio.638]
   Jirage KB, 1997, SCIENCE, V278, P655, DOI 10.1126/science.278.5338.655
   Kholodenko BN, 1996, BIOCHEM J, V313, P921, DOI 10.1042/bj3130921
   Kreft O, 2007, ANGEW CHEM INT EDIT, V46, P5605, DOI 10.1002/anie.200701173
   Kristensen C, 2005, P NATL ACAD SCI USA, V102, P1779, DOI 10.1073/pnas.0409233102
   Lam P, 1999, J ELECTROCHEM SOC, V146, P2517, DOI 10.1149/1.1391964
   Lazzara TD, 2011, ANAL CHEM, V83, P5624, DOI 10.1021/ac200725y
   Lewis SR, 2011, P NATL ACAD SCI USA, V108, P8577, DOI 10.1073/pnas.1101144108
   Liu Y, 2013, NAT NANOTECHNOL, V8, P187, DOI [10.1038/nnano.2012.264, 10.1038/NNANO.2012.264]
   Logan TC, 2007, ANAL CHEM, V79, P6592, DOI 10.1021/ac070705k
   Losey HC, 2002, CHEM BIOL, V9, P1305, DOI 10.1016/S1074-5521(02)00270-3
   Mateo C, 2006, TETRAHEDRON-ASYMMETR, V17, P320, DOI 10.1016/j.tetasy.2006.01.020
   Salles IM, 2007, METAB ENG, V9, P152, DOI 10.1016/j.ymben.2006.09.002
   Milka P, 2000, BIOTECHNOL BIOENG, V69, P344, DOI 10.1002/1097-0290(20000805)69:3<344::AID-BIT13>3.3.CO;2-4
   MOSBACH K, 1970, ACTA CHEM SCAND, V24, P2093, DOI 10.3891/acta.chem.scand.24-2093
   Nahalka J, 2003, CHEM-EUR J, V9, P373
   Oliveira GB, 2008, REACT FUNCT POLYM, V68, P27, DOI 10.1016/j.reactfunctpolym.2007.10.009
   Onda M, 1996, BIOTECHNOL BIOENG, V51, P163, DOI 10.1002/(SICI)1097-0290(19960720)51:2<163::AID-BIT5>3.0.CO;2-H
   Peltier-Pain P, 2012, ORG LETT, V14, P5086, DOI 10.1021/ol3023374
   Riva S, 2006, TRENDS BIOTECHNOL, V24, P219, DOI 10.1016/j.tibtech.2006.03.006
   Schoffelen S, 2012, SOFT MATTER, V8, P1736, DOI 10.1039/c1sm06452e
   Sheikh FG, 1998, P NATL ACAD SCI USA, V95, P2961, DOI 10.1073/pnas.95.6.2961
   Sigal GB, 1996, ANAL CHEM, V68, P490, DOI 10.1021/ac9504023
   Singh S, 2006, ACS CHEM BIOL, V1, P451, DOI 10.1021/cb6002898
   SRERE PA, 1973, P NATL ACAD SCI USA, V70, P2534, DOI 10.1073/pnas.70.9.2534
   Stephan M, 2014, ANALYST, V139, P1987, DOI 10.1039/c4an00009a
   Tanvir S, 2009, J MEMBRANE SCI, V329, P85, DOI 10.1016/j.memsci.2008.12.015
   Yu SF, 2001, NANO LETT, V1, P495, DOI 10.1021/nl010044l
   Zhang CS, 2006, J AM CHEM SOC, V128, P16420, DOI 10.1021/ja065950k
   Zhang CS, 2007, CHEMBIOCHEM, V8, P385, DOI 10.1002/cbic.200600509
   Zhang CS, 2006, SCIENCE, V313, P1291, DOI 10.1126/science.1130028
NR 42
TC 11
Z9 11
U1 4
U2 84
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936-0851
EI 1936-086X
J9 ACS NANO
JI ACS Nano
PD AUG
PY 2014
VL 8
IS 8
BP 8104
EP 8112
DI 10.1021/nn502181k
PG 9
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA AO0IM
UT WOS:000340992300055
PM 25025628
OA gold
DA 2018-03-20
ER

PT J
AU Ojogun, VA
   Lehmler, HJ
   Knutson, BL
AF Ojogun, Vivian A.
   Lehmler, Hans-Joachim
   Knutson, Barbara L.
TI Cationic-anionic vesicle templating from fluorocarbon/fluorocarbon and
   hydrocarbon/fluorocarbon surfactants
SO JOURNAL OF COLLOID AND INTERFACE SCIENCE
LA English
DT Article
DE Catanionic vesicles; Fluorinated surfactants; Silica; CPB; SPFO; HFDPC
ID MESOPOROUS SILICA SPHERES; PHASE-BEHAVIOR; CATANIONIC VESICLES; HOLLOW
   SPHERES; SODIUM PERFLUOROOCTANOATE; HYDROCARBON SURFACTANTS;
   ELECTRON-MICROSCOPY; CRYO-TRANSMISSION; AQUEOUS-SOLUTIONS;
   IONIC-STRENGTH
AB Spontaneous catanionic vesicle formation is studied in systems comprising fluorinated surfactants, the cationic/anionic fluorinated surfactant system of 1,1,2,2-tetrahydroperfluorododecylpyridinium chloride (HFDPC)/sodium perfluorooctanoate (SPFO) and the analogous mixed hydrocarbon/fluorocarbon surfactant system of cetylpyridinium bromide (CPB)/SPFO. Aggregate formation is explored in the anionic-rich surfactant system (weight fraction of anionic surfactant, gamma = 0.66-0.85) and a total surfactant concentration range of 0.1-2% wt/wt for the fluorinated system and 0.4-2.2% wt/wt for the mixed hydrocarbon/fluorocarbon system. Vesicle sizes range from approximately 40 to 200 nm for CPB/SPFO, as determined by negative staining transmission electron microscopy (TEM) and confirmed by dynamic light scattering. The primary vesicle diameter observed by TEM in the catanionic fluorinated/fluorinated surfactant system is smaller (20-50 nm). However. the relatively few larger vesicles (>= 100 nm) in the HFDPC/SPFO system dominate the dynamic light scattering measurements. Successful templating of silica hollow spheres is demonstrated in both HFDPC/SPFO and CPB/SPFO vesicle systems, using tetramethoxysilane (TMOS) as the silica precursor for the acid-catalyzed synthesis. The size of the resulting hollow silica particles is consistent with the templating of vesicles of the size range observed by TEM. Changes in zeta potential are used to monitor colloidal stability. At the conditions investigated (TMOS/surfactant weight ratios of 0.25-1.0. pH 3), the colloidal silica particles templated from fluorinated HFDPC/SPFO vesicles are more stable than the particles templated from the corresponding mixed fluorinated CPB/SPFO system. Further improvement of the stability of the colloidal particles is achieved in the CPB/SPFO systems by titrating the acid synthesis solution with base over the course of the particle synthesis. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Ojogun, Vivian A.; Knutson, Barbara L.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Lehmler, Hans-Joachim] Univ Iowa, Dept Occupat Environm Hlth, Iowa City, IA 52242 USA.
RP Knutson, BL (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM bknutson@engr.uky.edu
OI Lehmler, Hans-Joachim/0000-0001-9163-927X
FU Petroleum Research Fund [46138-AC]; US Department of Agriculture Biomass
   Research and Development Initiative [68-3875-7-608]; Energy and
   Environment Cabinet of the Commonwealth of Kentucky
FX This work is funded by the Petroleum Research Fund Grant 46138-AC, US
   Department of Agriculture Biomass Research and Development Initiative
   (Grant Agreement 68-3875-7-608) and the Energy and Environment Cabinet
   of the Commonwealth of Kentucky. Special thanks to Mary Gail Engle and
   Jim Begley at the University of Kentucky's Medical Center Imaging
   Facility for their assistance with the TEM images.
CR Asakawa T, 1996, LANGMUIR, V12, P1204, DOI 10.1021/la950758+
   ASAKAWA T, 1995, LANGMUIR, V11, P478, DOI 10.1021/la00002a019
   Baca M, 2006, CATAL LETT, V109, P207, DOI 10.1007/s10562-006-0079-x
   Begu S, 2007, J CONTROL RELEASE, V118, P1, DOI 10.1016/j.jconrel.2006.11.022
   Bergstrom M, 2001, LANGMUIR, V17, P993, DOI 10.1021/la000814t
   Botterhuis NE, 2006, CHEM-EUR J, V12, P1448, DOI 10.1002/chem.200500588
   BRASHER LL, 1995, LANGMUIR, V11, P4267, DOI 10.1021/la00011a017
   Brinker C.J., 1990, SOL GEL SCI PHYS CHE
   Coldren B, 2003, LANGMUIR, V19, P5632, DOI 10.1021/la034311+
   Danoff EJ, 2007, LANGMUIR, V23, P8965, DOI 10.1021/la070215n
   del Burgo P, 2006, J PHYS CHEM B, V110, P23524, DOI 10.1021/jp0645768
   Fischer A, 2002, J COLLOID INTERF SCI, V248, P163, DOI 10.1006/jcis.2001.8187
   Gonzalez-Perez A, 2004, J SURFACTANTS DETERG, V7, P387, DOI 10.1007/s11743-004-0323-9
   Gonzalez-Perez A, 2007, J AM CHEM SOC, V129, P756, DOI 10.1021/ja067228s
   Gradzielski M, 2003, J PHYS-CONDENS MAT, V15, pR655, DOI 10.1088/0953-8984/15/19/202
   Guittard F, 2001, J FLUORINE CHEM, V107, P363, DOI 10.1016/S0022-1139(00)00380-8
   Hah HJ, 2003, CHEM COMMUN, P1712, DOI 10.1039/b301521a
   Hentze HP, 2003, LANGMUIR, V19, P1069, DOI 10.1021/la020727w
   Hubert DHW, 2000, ADV MATER, V12, P1291, DOI 10.1002/1521-4095(200009)12:17<1291::AID-ADMA1291>3.3.CO;2-Q
   Hubert DHW, 2000, ADV MATER, V12, P1286, DOI 10.1002/1521-4095(200009)12:17<1286::AID-ADMA1286>3.0.CO;2-7
   Huibers PDT, 1999, LANGMUIR, V15, P7546, DOI 10.1021/la990367l
   Jung HT, 2002, P NATL ACAD SCI USA, V99, P15318, DOI 10.1073/pnas.242374499
   Jung HT, 2001, P NATL ACAD SCI USA, V98, P1353, DOI 10.1073/pnas.041420998
   Jung M, 1997, LANGMUIR, V13, P6877, DOI 10.1021/la9709812
   Kaler EW, 2005, SURF SCI CRC, V124, P289
   Kissa E., 1994, FLUORINATED SURFACTA
   Koenderink GH, 2001, LANGMUIR, V17, P6086, DOI 10.1021/la010181y
   KOPPEL DE, 1972, J CHEM PHYS, V57, P4814, DOI 10.1063/1.1678153
   Krafft MP, 1998, BIOCHIMIE, V80, P489, DOI 10.1016/S0300-9084(00)80016-4
   LAMPIETRO DJ, 1995, LANGMUIR, V15, P8590
   Letizia C, 2007, J PHYS CHEM B, V111, P898, DOI 10.1021/jp0646067
   Lootens D, 2003, J MATER CHEM, V13, P2072, DOI 10.1039/b305808p
   Lopez-Fontan JL, 2005, COLLOID POLYM SCI, V283, P862, DOI 10.1007/s00396-004-1228-7
   Marques EF, 1998, J PHYS CHEM B, V102, P6746, DOI 10.1021/jp980355t
   Marques EF, 2003, ADV COLLOID INTERFAC, V100, P83, DOI 10.1016/S0001-8686(02)00068-4
   Oelschlaeger C, 2002, LANGMUIR, V18, P3076, DOI 10.1021/la015687v
   Pasc-Banu A, 2004, COLLOID SURFACE A, V242, P195, DOI 10.1016/j.colsurfa.2004.05.003
   Regev O, 1996, J COLLOID INTERF SCI, V182, P95, DOI 10.1006/jcis.1996.0440
   RIESS JG, 1994, COLLOID SURFACE A, V84, P33, DOI 10.1016/0927-7757(93)02696-C
   Rossi S, 2001, LANGMUIR, V17, P2340, DOI 10.1021/la001444b
   SAFRAN SA, 1991, PHYS REV A, V43, P1071, DOI 10.1103/PhysRevA.43.1071
   Silva BFB, 2005, J COLLOID INTERF SCI, V290, P267, DOI 10.1016/j.jcis.2005.04.012
   Skerjanc J, 1999, LANGMUIR, V15, P5023, DOI 10.1021/la981710+
   Song CY, 2008, CATAL LETT, V120, P215, DOI 10.1007/s10562-007-9272-9
   STOKES EJ, 1997, FUNDAMENTALS INTERFA
   Szonyi S, 1993, PROG COLL POL SCI S, V93, P364
   Szonyi S, 1992, SPRINGER P PHYS, V66, P198
   TRABELSI H, 1993, LANGMUIR, V9, P1201, DOI 10.1021/la00029a009
   Trabelsi H, 2001, SUPRAMOL CHEM, V13, P583, DOI 10.1080/10610270108039791
   TREVINO L, 1994, COLLOID SURFACE A, V88, P223, DOI 10.1016/0927-7757(94)02789-7
   Tsuchiya K, 2004, LANGMUIR, V20, P2117, DOI 10.1021/la0302908
   Vautrin C, 2004, J PHYS CHEM B, V108, P7986, DOI 10.1021/jp037787a
   Wagner J, 2000, LANGMUIR, V16, P4080, DOI 10.1021/la991125o
   Wang K, 1999, J PHYS CHEM B, V103, P9237, DOI 10.1021/jp990821u
   Yeh YQ, 2006, LANGMUIR, V22, P6, DOI 10.1021/la052129y
   Yin HQ, 2007, LANGMUIR, V23, P4225, DOI 10.1021/la063221c
   Yin HQ, 2005, LANGMUIR, V21, P2656, DOI 10.1021/la047024u
   YU ZJ, 1992, LANGMUIR, V8, P2074, DOI 10.1021/la00044a032
   Yuet PK, 1996, LANGMUIR, V12, P3819, DOI 10.1021/la960321h
   Zhu YF, 2005, NANOTECHNOLOGY, V16, P2633, DOI 10.1088/0957-4484/16/11/027
   Zhu YF, 2005, MICROPOR MESOPOR MAT, V85, P75, DOI 10.1016/j.micromeso.2005.06.015
NR 61
TC 17
Z9 19
U1 0
U2 25
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0021-9797
J9 J COLLOID INTERF SCI
JI J. Colloid Interface Sci.
PD OCT 1
PY 2009
VL 338
IS 1
BP 82
EP 91
DI 10.1016/j.jcis.2009.06.022
PG 10
WC Chemistry, Physical
SC Chemistry
GA 489DX
UT WOS:000269401200011
PM 19589537
DA 2018-03-20
ER

PT J
AU Meyer, C
   Power, R
   Geddes, J
AF Meyer, Carolyn A.
   Power, Ronan F.
   Geddes, James W.
TI SELENIUM DEFICIENCY IS DETRIMENTAL TO MITOCHONDRIAL RESPIRATION
   FOLLOWING TRAUMATIC BRAIN INJURY
SO JOURNAL OF NEUROTRAUMA
LA English
DT Meeting Abstract
CT 33rd Annual National Neurotrauma Symposium
CY JUN 28-JUL 01, 2015
CL Santa Fe, NM
DE Mitochondria
C1 [Meyer, Carolyn; Geddes, James] Univ Kentucky, SCoBIRC, Lexington, KY 40506 USA.
   [Power, Ronan] Alltech Inc, Nutrigen, Nicholasville, KY USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0897-7151
EI 1557-9042
J9 J NEUROTRAUM
JI J. Neurotrauma
PD JUN 15
PY 2015
VL 32
IS 12
MA D8-12
BP A117
EP A117
PG 1
WC Critical Care Medicine; Clinical Neurology; Neurosciences
SC General & Internal Medicine; Neurosciences & Neurology
GA CV0OB
UT WOS:000363949000319
DA 2018-03-20
ER

PT J
AU Li, X
   Rankin, SE
AF Li, Xin
   Rankin, Stephen E.
TI Multiscale Modeling of the Effects of Unlimited Four-Membered Ring
   Formation on Sol-Gel Silica Film Molecular Structure
SO AICHE JOURNAL
LA English
DT Article
DE multiscale modeling; sol-gel silica; film; dynamic Monte Carlo;
   polycondensation; four-membered rings
ID MONTE-CARLO-SIMULATION; FUNCTIONAL-GROUP KINETICS; SI-29 NMR; HYDROLYSIS
   PSEUDOEQUILIBRIUM; CARLO/CONTINUUM MODEL; CONDENSATION RATES;
   CHEMICAL-KINETICS; NETWORK FORMATION; POLYMERIZATION; CYCLIZATION
AB A modified multiscale model of a sol-gel silica drying process is presented that treats first-shell substitution effects and unlimited four-membered ring cyclization. The inclusion of four-membered (8-atom) rings allows the model to simulate the formation of the tetrasiloxane rings and cubic silsesquioxane cages known to be prevalent components of sol-gel silica systems, as well as a full range of other ring-containing structures. The polymerization process is treated using a dynamic Monte Carlo method where a discrete population of one million monomers evolves according to kinetic rules, including unimolecular-like closure of three-bond blocks. Compared with prior simulations with extensive cyclization that allowed only three-membered rings, the molecular structures formed with unlimited four-membered ring are more complex, and the occurrence of "skinning" (the rapid formation of a gel only at the surface of the film) is more pronounced and leads to more severe structure gradients. (C) 2012 American Institute of Chemical Engineers AIChE J, 59:707-718, 2013
C1 [Li, Xin; Rankin, Stephen E.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Rankin, SE (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM srankin@engr.uky.edu
OI Rankin, Stephen/0000-0002-8615-7564
FU U.S. Department of Energy [DE-FG02-03ER46033, DE-FG02-07ER46375]
FX This report is based on work supported by the U.S. Department of Energy
   under grant numbers DE-FG02-03ER46033 and DE-FG02-07ER46375.
CR ASSINK RA, 1993, COLLOID SURFACE A, V74, P1, DOI 10.1016/0927-7757(93)80392-R
   ASSINK RA, 1988, J NON-CRYST SOLIDS, V99, P359, DOI 10.1016/0022-3093(88)90441-3
   BAILEY JK, 1990, J NON-CRYST SOLIDS, V125, P208, DOI 10.1016/0022-3093(90)90851-C
   Braatz RD, 2006, COMPUT CHEM ENG, V30, P1643, DOI 10.1016/j.compchemeng.2006.05.022
   Brinker CJ, 2006, CURR OPIN COLLOID IN, V11, P126, DOI 10.1016/j.cocis.2005.10.006
   Brunet F, 1998, J NON-CRYST SOLIDS, V231, P58, DOI 10.1016/S0022-3093(98)00403-7
   Cairncross RA, 1996, AICHE J, V42, P55, DOI 10.1002/aic.690420107
   Campo FA, 2011, J NON-CRYST SOLIDS, V357, P2046, DOI 10.1016/j.jnoncrysol.2011.02.025
   CAPOZZI CA, 1992, MATER LETT, V15, P130, DOI 10.1016/0167-577X(92)90028-I
   Cavallotti C, 2005, ELECTROCHIM ACTA, V50, P4566, DOI 10.1016/j.electacta.2004.10.092
   Chatterjee A, 2007, J COMPUT-AIDED MATER, V14, P253, DOI 10.1007/s10820-006-9042-9
   Cheimarios N, 2010, CHEM ENG SCI, V65, P5018, DOI 10.1016/j.ces.2010.06.004
   Crank J., 1988, FREE MOVING BOUNDARY
   Dollet A, 2004, SURF COAT TECH, V177, P245, DOI 10.1016/j.surfcoat.2003.09.040
   Doshi DA, 2003, J PHYS CHEM B, V107, P7683, DOI 10.1021/jp027214i
   Duskova-Smrckova M, 2002, J MATER SCI, V37, P4733, DOI 10.1023/A:1020843020379
   EARLEY CW, 1994, J PHYS CHEM-US, V98, P8693, DOI 10.1021/j100086a018
   FICHTHORN KA, 1991, J CHEM PHYS, V95, P1090, DOI 10.1063/1.461138
   GILLESPIE DT, 1976, J COMPUT PHYS, V22, P403, DOI 10.1016/0021-9991(76)90041-3
   Grosso D, 2004, ADV FUNCT MATER, V14, P309, DOI 10.1002/adfm.200305036
   Guerrier B, 1998, AICHE J, V44, P791, DOI 10.1002/aic.690440404
   Guliants VV, 2004, J MEMBRANE SCI, V235, P53, DOI 10.1016/j.memsci.2004.01.019
   Innocenzi P, 2007, J PHYS CHEM C, V111, P5345, DOI 10.1021/jp066566c
   Innocenzi P, 2011, CHEM MATER, V23, P2501, DOI 10.1021/cm200050r
   Innocenzi P, 2009, CHEM MATER, V21, P2555, DOI 10.1021/cm900288x
   Kamiya K, 1998, J NON-CRYST SOLIDS, V240, P202, DOI 10.1016/S0022-3093(98)00701-7
   Kasehagen LJ, 1997, MACROMOLECULES, V30, P3921, DOI 10.1021/ma9619142
   KELTS LW, 1989, J MATER RES, V4, P423, DOI 10.1557/JMR.1989.0423
   KLEMPERER WG, 1988, MATER RES SOC S P, V121, P15
   Li X, 2011, CHEM ENG SCI, V66, P1015, DOI 10.1016/j.ces.2010.11.007
   Li X, 2010, AICHE J, V56, P2946, DOI 10.1002/aic.12202
   Majumder D, 2006, AICHE J, V52, P4214, DOI 10.1002/aic.11030
   Malani A, 2010, J PHYS CHEM LETT, V1, P3219, DOI 10.1021/jz101046y
   MALIER L, 1992, PHYS REV A, V46, P959, DOI 10.1103/PhysRevA.46.959
   Ng LV, 1996, J PHYS CHEM-US, V100, P12517, DOI 10.1021/jp960089o
   NG LV, 1995, MACROMOLECULES, V28, P6471, DOI 10.1021/ma00123a012
   NITTA KH, 1994, J CHEM PHYS, V101, P4222, DOI 10.1063/1.467472
   POUXVIEL JC, 1987, J NON-CRYST SOLIDS, V94, P374, DOI 10.1016/S0022-3093(87)80072-8
   Rankin SE, 1999, IND ENG CHEM RES, V38, P3191, DOI 10.1021/ie990027v
   Rankin SE, 1998, AICHE J, V44, P1141, DOI 10.1002/aic.690440512
   Rankin SE, 2000, CHEM ENG SCI, V55, P1955, DOI 10.1016/S0009-2509(99)00486-8
   Rankin SE, 2000, MACROMOLECULES, V33, P7639, DOI 10.1021/ma000132c
   Rao NZ, 2004, J PHYS CHEM B, V108, P12418, DOI 10.1021/jp049169f
   Sanchez C, 2008, CHEM MATER, V20, P715
   Sanchez J, 1996, IND ENG CHEM RES, V35, P117, DOI 10.1021/ie950246q
   SANCHEZ J, 1994, J NON-CRYST SOLIDS, V167, P289, DOI 10.1016/0022-3093(94)90251-8
   Sarmoria C, 2001, COMPUT THEOR POLYM S, V11, P113, DOI 10.1016/S1089-3156(99)00088-4
   Schilstra MJ, 2009, METHOD ENZYMOL, V467, P381, DOI 10.1016/S0076-6879(09)67015-4
   Schumacher C, 2006, J PHYS CHEM B, V110, P319, DOI 10.1021/jp0551871
   SOMVARSKY J, 1994, POLYM BULL, V33, P369, DOI 10.1007/BF00314276
   SOMVARSKY J, 1994, POLYM BULL, V33, P377, DOI 10.1007/BF00314277
   Tallant DR, 1986, MATER RES SOC S P, V73, P261
   TANG AC, 1993, J MATER CHEM, V3, P893, DOI 10.1039/jm9930300893
   Vainrub A, 1996, MAT SCI ENG B-SOLID, V37, P197, DOI 10.1016/0921-5107(95)01486-1
   VANBEEK JJ, 1992, J NON-CRYST SOLIDS, V146, P111, DOI 10.1016/S0022-3093(05)80482-X
   Vlachos DG, 1997, AICHE J, V43, P3031, DOI 10.1002/aic.690431115
   WADA M, 1992, J NON-CRYST SOLIDS, V149, P203, DOI 10.1016/0022-3093(92)90068-U
   WEST JK, 1990, J NON-CRYST SOLIDS, V121, P51, DOI 10.1016/0022-3093(90)90103-S
   WIENER H, 1947, J AM CHEM SOC, V69, P17, DOI 10.1021/ja01193a005
   Zhang XQ, 2011, J AM CHEM SOC, V133, P6613, DOI 10.1021/ja110357k
NR 60
TC 1
Z9 1
U1 1
U2 23
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0001-1541
J9 AICHE J
JI AICHE J.
PD MAR
PY 2013
VL 59
IS 3
BP 707
EP 718
DI 10.1002/aic.13853
PG 12
WC Engineering, Chemical
SC Engineering
GA 124LQ
UT WOS:000317465700004
DA 2018-03-20
ER

PT J
AU Hinds, B
AF Hinds, Bruce J.
TI A blueprint for a nanoscale pump
SO NATURE NANOTECHNOLOGY
LA English
DT News Item
ID CARBON NANOTUBES; TRANSPORT; MEMBRANES
C1 Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Hinds, B (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM bjhinds@engr.uky.edu
CR Chopra N, 2005, ADV FUNCT MATER, V15, P858, DOI 10.1002/adfm.200400399
   Gong XJ, 2007, NAT NANOTECHNOL, V2, P709, DOI 10.1038/nnano.2007.320
   Hinds BJ, 2004, SCIENCE, V303, P62, DOI 10.1126/science.1092048
   Holt JK, 2006, SCIENCE, V312, P1034, DOI 10.1126/science.1126298
   Hummer G, 2001, NATURE, V414, P188, DOI 10.1038/35102535
   Joseph S, 2003, NANO LETT, V3, P1399, DOI 10.1021/nl0346326
   Kim S, 2007, NANO LETT, V7, P2806, DOI 10.1021/nl071414u
   Majumder M, 2005, NATURE, V438, P44, DOI 10.1038/43844a
   QUIRKE N, 2007, NATURE NANOTECH, V2, P87
NR 9
TC 10
Z9 11
U1 2
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1748-3387
J9 NAT NANOTECHNOL
JI Nat. Nanotechnol.
PD NOV
PY 2007
VL 2
IS 11
BP 673
EP 674
DI 10.1038/nnano.2007.354
PG 2
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA 235WR
UT WOS:000251265500006
PM 18654401
DA 2018-03-20
ER

PT J
AU Tang, S
   Floy, M
   Bhandari, R
   Sunkara, M
   Morris, AJ
   Dziubla, TD
   Hilt, JZ
AF Tang, Shuo
   Floy, Martha
   Bhandari, Rohit
   Sunkara, Manjula
   Morris, Andrew J.
   Dziubla, Thomas D.
   Hilt, J. Zach
TI Synthesis and Characterization of Thermoresponsive Hydrogels Based on
   N-Isopropylacrylamide Crosslinked with 4,4 '-Dihydroxybiphenyl
   Diacrylate
SO ACS OMEGA
LA English
DT Article
ID THERMOREVERSIBLE SWELLING BEHAVIOR; ACIDIC COMONOMERS; SOLUTE TRANSPORT;
   PHASE-TRANSITION; WATER; GELS; NETWORKS; THERMOCONTROL; POLYESTERS;
   DEPENDENCE
AB A novel crosslinker [4,4'-dihydroxybiphenyl diacrylate (44BDA)] was developed, and a series of temperature-responsive hydrogels were synthesized through free radical polymerization of N-isopropylacrylamide (NIPAAm) with 44BDA. The temperature-responsive behavior of the resulting gels was characterized by swelling studies, and the lower critical solution temperature (LCST) of the hydrogels was characterized through differential scanning calorimetry. Increased content of 44BDA led to a decreased swelling ratio and shifted the LCST to lower temperatures. These novel hydrogels also displayed resiliency through multiple swelling-deswelling cycles, and their temperature responsiveness was reversible. The successful synthesis of NIPAAm-based hydrogels crosslinked with 44BDA has led to a new class of temperature-responsive hydrogel systems with a variety of potential applications.
C1 [Tang, Shuo; Bhandari, Rohit; Dziubla, Thomas D.; Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, 177 F Paul Anderson Tower, Lexington, KY 40506 USA.
   [Floy, Martha] Kansas State Univ, Dept Chem Engn, 1005 Durland Hall 1701A Platt St, Manhattan, KS 66506 USA.
   [Sunkara, Manjula; Morris, Andrew J.] Univ Kentucky, Gill Heart Inst, Div Cardiovasc Med, 741 S Limestone St, Lexington, KY 40506 USA.
   [Tang, Shuo; Bhandari, Rohit; Sunkara, Manjula; Morris, Andrew J.; Dziubla, Thomas D.; Hilt, J. Zach] Univ Kentucky, Superfund Res Ctr, 900 S Limestone St, Lexington, KY 40536 USA.
RP Hilt, JZ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 F Paul Anderson Tower, Lexington, KY 40506 USA.; Hilt, JZ (reprint author), Univ Kentucky, Superfund Res Ctr, 900 S Limestone St, Lexington, KY 40536 USA.
EM zach.hilt@uky.edu
FU NSF-REU [EEC-1460486]; NIEHS/NIH [P42ES007380]
FX This research has been generously supported by the NSF-REU grant
   EEC-1460486 and the NIEHS/NIH grant P42ES007380. The content is solely
   the responsibility of the authors and does not necessarily represent the
   official views of NIH.
CR Ali W, 2015, ACS APPL MATER INTER, V7, P15696, DOI 10.1021/acsami.5b03878
   Ashraf S, 2016, MACROMOL RES, V24, P297, DOI 10.1007/s13233-016-4052-2
   BAE YH, 1991, PHARMACEUT RES, V8, P624, DOI 10.1023/A:1015860824953
   BAE YH, 1991, PHARMACEUT RES, V8, P531, DOI 10.1023/A:1015871732706
   BRAZEL CS, 1995, MACROMOLECULES, V28, P8016, DOI 10.1021/ma00128a007
   Bucatariu S, 2014, J POLYM RES, V21, DOI 10.1007/s10965-014-0580-7
   Chiu HC, 2002, MACROMOLECULES, V35, P5235, DOI 10.1021/ma0122021
   Diez-Pena E, 2004, AAPS PHARMSCITECH, V5
   FREITAS RFS, 1987, CHEM ENG SCI, V42, P97, DOI 10.1016/0009-2509(87)80213-0
   Fu G, 2010, MAT SCI ENG C-MATER, V30, P8, DOI 10.1016/j.msec.2009.07.017
   Fundueanu G, 2013, EUR J PHARM BIOPHARM, V85, P614, DOI 10.1016/j.ejpb.2013.03.023
   HIROKAWA Y, 1984, J CHEM PHYS, V81, P6379, DOI 10.1063/1.447548
   Huglin MB, 1997, POLYMER, V38, P5785, DOI 10.1016/S0032-3861(97)00135-3
   INOMATA H, 1995, POLYMER, V36, P875, DOI 10.1016/0032-3861(95)93120-B
   Iyer G, 2008, POLYMER, V49, P3737, DOI 10.1016/j.polymer.2008.06.037
   Jannesari A, 2005, J APPL POLYM SCI, V98, P1594, DOI 10.1002/app.22199
   Kim JH, 2002, POLYMER, V43, P7549, DOI 10.1016/S0032-3861(02)00675-4
   Kim YJ, 2005, BIOL PHARM BULL, V28, P323, DOI 10.1248/bpb.28.323
   Kim YG, 2014, FLUID PHASE EQUILIBR, V361, P200, DOI 10.1016/j.fluid.2013.11.004
   Klouda L, 2015, EUR J PHARM BIOPHARM, V97, P338, DOI 10.1016/j.ejpb.2015.05.017
   KRIGBAUM WR, 1983, MACROMOLECULES, V16, P1271, DOI 10.1021/ma00242a005
   Kuckling D, 2002, POLYMER, V43, P1533, DOI 10.1016/S0032-3861(01)00731-5
   Liang RN, 2015, TALANTA, V144, P115, DOI 10.1016/j.talanta.2015.05.064
   Lowe TL, 1999, LANGMUIR, V15, P4259, DOI 10.1021/la981194n
   Lue SJ, 2011, J MACROMOL SCI B, V50, P563, DOI 10.1080/00222341003784550
   Meenach SA, 2010, J POLYM SCI POL CHEM, V48, P3229, DOI 10.1002/pola.24087
   No JK, 2006, BIOL PHARM BULL, V29, P14, DOI 10.1248/bpb.29.14
   Paramasivaganesh K, 2013, J MOL STRUCT, V1048, P399, DOI 10.1016/j.molstruc.2013.04.072
   Parasuraman D, 2013, COLLOID POLYM SCI, V291, P1795, DOI 10.1007/s00396-013-2915-z
   Patil VS, 2015, POLYMER, V75, P88, DOI 10.1016/j.polymer.2015.08.034
   PRANGE MM, 1989, AICHE J, V35, P803, DOI 10.1002/aic.690350511
   Rahman M, 2015, J POLYM RES, V22, DOI 10.1007/s10965-015-0673-y
   SCHILD HG, 1992, PROG POLYM SCI, V17, P163, DOI 10.1016/0079-6700(92)90023-R
   Stile RA, 1999, MACROMOLECULES, V32, P7370, DOI 10.1021/ma990130w
   Tang S, 2017, MATER TODAY COMMUN, V10, P46, DOI 10.1016/j.mtcomm.2016.12.003
   Tokita M, 2012, POLYMER, V53, P5596, DOI 10.1016/j.polymer.2012.09.035
   Velada JL, 1998, MACROMOL CHEM PHYSIC, V199, P1127, DOI 10.1002/(SICI)1521-3935(19980601)199:6<1127::AID-MACP1127>3.0.CO;2-9
   Xue W, 2002, POLYMER, V43, P3069, DOI 10.1016/S0032-3861(02)00133-7
   Yoo M. K., 2004, CHARACTERIZATION STI, P173
   Zheng X, 1998, POLYM J, V30, P284, DOI 10.1295/polymj.30.284
NR 40
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2470-1343
J9 ACS OMEGA
JI ACS Omega
PD DEC
PY 2017
VL 2
IS 12
BP 8723
EP 8729
DI 10.1021/acsomega.7b01247
PG 7
WC Chemistry, Multidisciplinary
SC Chemistry
GA FR0IE
UT WOS:000418744400021
PM 29302630
OA gold
DA 2018-03-20
ER

PT J
AU Li, TL
   Zhou, PP
   Mattei, A
AF Li, Tonglei
   Zhou, Panpan
   Mattei, Alessandra
TI Electronic origin of pyridinyl N as a better hydrogen-bonding acceptor
   than carbonyl O
SO CRYSTENGCOMM
LA English
DT Article
ID DENSITY-FUNCTIONAL THEORY; HARD/SOFT ACID/BASE PRINCIPLE;
   CRYSTAL-STRUCTURES; INTERMOLECULAR INTERACTIONS; FUKUI FUNCTION;
   MOLECULAR-INTERACTIONS; STACKING INTERACTIONS; ORGANIC-CRYSTALS; ACIDS;
   SOFTNESS
AB A diarylamine compound, 2-(phenylamino) nicotinic acid, can form either the carboxyl acid-acid dimer or acid-pyridine chain in its polymorphic structures. Quantum mechanical calculations indicate that the hydrogen-bonding strength of the heterosynthon is stronger. Conceptual density functional theory is then used to understand the fundamental cause of pyridine N being a better hydrogen-bonding acceptor.
C1 [Li, Tonglei; Zhou, Panpan; Mattei, Alessandra] Univ Kentucky, Lexington, KY 40506 USA.
RP Li, TL (reprint author), Univ Kentucky, Lexington, KY 40506 USA.
FU NSF [DMR-1006364]
FX The study was supported by NSF (DMR-1006364).
CR Aakeroy CB, 2002, J AM CHEM SOC, V124, P14425, DOI 10.1021/ja027845q
   Aakeroy CB, 2001, ANGEW CHEM INT EDIT, V40, P3240, DOI 10.1002/1521-3773(20010903)40:17<3240::AID-ANIE3240>3.0.CO;2-X
   AAKEROY CB, 1993, CHEM SOC REV, V22, P397, DOI 10.1039/cs9932200397
   Aakeroy CB, 2007, CRYSTENGCOMM, V9, P46, DOI 10.1039/b614984g
   Alabugin IV, 2002, J AM CHEM SOC, V124, P3175, DOI 10.1021/ja012633z
   Ayers PW, 2007, THEOR CHEM ACC, V117, P371, DOI 10.1007/s00214-006-0165-6
   Ayers PW, 2007, FARADAY DISCUSS, V135, P161, DOI 10.1039/b606877d
   Ayers PW, 2009, CHEM PHYS LETT, V480, P318, DOI 10.1016/j.cplett.2009.08.067
   Ayers PW, 2006, J CHEM PHYS, V124, DOI 10.1063/1.2196882
   Aylward N, 2007, J THEOR BIOL, V244, P258, DOI 10.1016/j.jtbi.2006.07.031
   BERKOWITZ M, 1988, J CHEM PHYS, V88, P2554, DOI 10.1063/1.454034
   BERNSTEIN J, 1995, ANGEW CHEM INT EDIT, V34, P1555, DOI 10.1002/anie.199515551
   BOYS SF, 1970, MOL PHYS, V19, P553, DOI 10.1080/00268977000101561
   BRENEMAN CM, 1990, J COMPUT CHEM, V11, P361, DOI 10.1002/jcc.540110311
   CHATTARAJ PK, 1991, J AM CHEM SOC, V113, P1855, DOI 10.1021/ja00005a073
   Dabkowska I, 2005, J CHEM PHYS, V122, DOI 10.1063/1.1906205
   Desiraju GR, 2002, NAT MATER, V1, P77, DOI 10.1038/nmat726
   Dobes P, 2006, CHEM-EUR J, V12, P4297, DOI 10.1002/chem.200501269
   DOVESI R, 2006, CRYSTAL06 USERS MANU
   Dunitz JD, 2004, P NATL ACAD SCI USA, V101, P14309, DOI 10.1073/pnas.0405744101
   Dunitz JD, 2003, CHEM COMMUN, P545, DOI 10.1039/b211531j
   ETTER MC, 1991, J PHYS CHEM-US, V95, P4601, DOI 10.1021/j100165a007
   Feng SX, 2005, J PHYS CHEM A, V109, P7258, DOI 10.1021/jp0519666
   Frisch M. J., 2009, GAUSSIAN 09
   Fukuzawa K, 2006, J COMPUT CHEM, V27, P948, DOI 10.1002/jcc.20399
   Fukuzawa K, 2006, J PHYS CHEM B, V110, P16102, DOI 10.1021/jp060770i
   GAVEZZOTTI A, 1994, ACCOUNTS CHEM RES, V27, P309, DOI 10.1021/ar00046a004
   Geerlings P, 2003, CHEM REV, V103, P1793, DOI 10.1021/cr990029p
   Guo HB, 2004, J PHYS CHEM B, V108, P18065, DOI 10.1021/jp0480192
   HIRSHFELD FL, 1977, THEOR CHIM ACTA, V44, P129, DOI 10.1007/BF00549096
   HOHENBERG P, 1964, PHYS REV B, V136, pB864, DOI 10.1103/PhysRev.136.B864
   Hunter KC, 2007, J PHYS CHEM B, V111, P1858, DOI 10.1021/jp066902p
   Kohn W, 1996, J PHYS CHEM-US, V100, P12974, DOI 10.1021/jp960669l
   Kokalj A, 1999, J PHYS CHEM B, V103, P7222, DOI 10.1021/jp990788b
   Li TL, 2005, J AM CHEM SOC, V127, P1364, DOI 10.1021/ja0476009
   Li TL, 2009, CHEM-EUR J, V15, P361, DOI 10.1002/chem.200801056
   Long SH, 2008, CRYST GROWTH DES, V8, P4006, DOI 10.1021/cg800123z
   LOUSHIN SK, 1986, J CHEM PHYS, V84, P2720, DOI 10.1063/1.450347
   MADDOX J, 1988, NATURE, V335, P201
   McCrone W. C., 1965, PHYSICS CHEMISTRY OR, VII, P725
   Mohamed S, 2009, CRYST GROWTH DES, V9, P2881, DOI 10.1021/cg9001994
   Moller C, 1934, PHYS REV, V46, P0618, DOI 10.1103/PhysRev.46.618
   Morell C, 2005, J PHYS CHEM A, V109, P205, DOI 10.1021/jp046577a
   MULLIKEN RS, 1955, J CHEM PHYS, V23, P1833, DOI 10.1063/1.1740588
   NAKATSUJ.H, 1974, J AM CHEM SOC, V96, P30, DOI 10.1021/ja00808a005
   NAKATSUJ.H, 1974, J AM CHEM SOC, V96, P24, DOI 10.1021/ja00808a004
   Nalewajski RF, 2000, COMPUT CHEM, V24, P243, DOI 10.1016/S0097-8485(99)00070-4
   PARR RG, 1983, J AM CHEM SOC, V105, P7512, DOI 10.1021/ja00364a005
   PARR RG, 1995, ANNU REV PHYS CHEM, V46, P701, DOI 10.1146/annurev.pc.46.100195.003413
   Parr RG, 1989, DENSITY FUNCTIONAL T
   PEARSON RG, 1963, J AM CHEM SOC, V85, P3533, DOI 10.1021/ja00905a001
   PEARSON RG, 1966, SCIENCE, V151, P172, DOI 10.1126/science.151.3707.172
   POLITZER P, 1995, MODERN DENSITY FUNCT
   REED AE, 1983, J CHEM PHYS, V78, P4066, DOI 10.1063/1.445134
   REED AE, 1988, CHEM REV, V88, P899, DOI 10.1021/cr00088a005
   Riley KE, 2007, J PHYS CHEM B, V111, P5700, DOI 10.1021/jp067313m
   Rutledge LR, 2006, J PHYS CHEM B, V110, P19652, DOI 10.1021/jp061939v
   Sanderson K, 2007, NATURE, V450, P771, DOI 10.1038/450771a
   Sarma B, 2009, CRYST GROWTH DES, V9, P1546, DOI 10.1021/cg801145c
   Shattock TR, 2008, CRYST GROWTH DES, V8, P4533, DOI 10.1021/cg800565a
   Simon-Manso Y, 1998, J PHYS CHEM A, V102, P2029, DOI 10.1021/jp972733k
   Steiner T, 2001, ACTA CRYSTALLOGR B, V57, P103, DOI 10.1107/S0108768100014348
   SUBRAMANIAN S, 1994, COORDIN CHEM REV, V137, P357, DOI 10.1016/0010-8545(94)03008-E
   Vanommeslaeghe K, 2006, J CHEM THEORY COMPUT, V2, P1444, DOI 10.1021/ct600150n
   Vishweshwar P, 2003, CRYST GROWTH DES, V3, P783, DOI 10.1021/cg034037h
   Vondrasek J, 2005, J AM CHEM SOC, V127, P2615, DOI 10.1021/ja044607h
   YANG W, 1986, J AM CHEM SOC, V108, P5708, DOI 10.1021/ja00279a008
   YANG WT, 1985, P NATL ACAD SCI USA, V82, P6723, DOI 10.1073/pnas.82.20.6723
NR 68
TC 8
Z9 8
U1 1
U2 6
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1466-8033
J9 CRYSTENGCOMM
JI Crystengcomm
PY 2011
VL 13
IS 21
BP 6356
EP 6360
DI 10.1039/c1ce05967j
PG 5
WC Chemistry, Multidisciplinary; Crystallography
SC Chemistry; Crystallography
GA 832QN
UT WOS:000295821200013
DA 2018-03-20
ER

PT J
AU Das, S
   Nagpure, S
   Garlapalli, RK
   Wu, QL
   Islam, SZ
   Strzalka, J
   Rankin, SE
AF Das, Saikat
   Nagpure, Suraj
   Garlapalli, Ravinder K.
   Wu, Qingliu
   Islam, Syed Z.
   Strzalka, Joseph
   Rankin, Stephen E.
TI Pore orientation effects on the kinetics of mesostructure loss in
   surfactant templated titania thin films
SO PHYSICAL CHEMISTRY CHEMICAL PHYSICS
LA English
DT Article
ID SENSITIZED SOLAR-CELLS; MESOPOROUS NANOCRYSTALLINE ANATASE;
   X-RAY-SCATTERING; PHOTOVOLTAIC APPLICATIONS; CRYSTALLIZATION KINETICS;
   PHOTOCATALYTIC ACTIVITY; HEXAGONAL MESOPHASE; THERMAL-STABILITY; SILICA
   FILMS; TIO2 FILMS
AB The mesostructure loss kinetics are measured as a function of the orientation of micelles in 2D hexagonal close packed (HCP) columnar mesostructured titania thin films using in situ grazing incidence small angle X-ray scattering (GISAXS). Complementary supporting information is provided by ex situ scanning electron microscopy. Pluronic surfactant P123 acts as the template to synthesize HCP structured titania thin films. When the glass substrates are modified with crosslinked P123, the micelles of the HCP mesophase align orthogonal to the films, whereas a mix of parallel and orthogonal alignment is found on unmodified glass. The rate of mesostructure loss of orthogonally oriented (o-HCP) thin films (similar to 60 nm thickness) prepared on modified substrate is consistently found to be less by a factor of 2.5 +/- 0.35 than that measured for mixed orientation HCP films on unmodified substrates. The activation energy for mesostructure loss is only slightly greater for films on modified glass (155 +/- 25 kJ mol(-1)) than on unmodified (128 kJ mol(-1)), which implies that the rate difference stems from a greater activation entropy for mesostructure loss in o-HCP titania films. Nearly perfect orthogonal orientation of micelles on modified surfaces contributes to the lower rate of mesostructure loss by supporting the anisotropic stresses that develop within the films during annealing due to continuous curing, sintering and crystallization into the anatase phase during high temperature calcination (>450 degrees C). Because the film thickness dictates the propagation of orientation throughout the films and the degree of confinement, thicker (similar to 250 nm) films cast onto P123-modified substrates have a much lower activation energy for mesostructure loss (89 +/- 27 kJ mol(-1)) due to the mix of orientations found in the films. Thus, this kinetic study shows that thin P123-templated o-HCP titania films are not only better able to achieve good orthogonal alignment of the mesophase relative to thicker films or films on unmodified substrates, but that alignment of the mesophase in the films stabilizes the mesophase against thermally-induced mesostructure loss.
C1 [Das, Saikat; Nagpure, Suraj; Garlapalli, Ravinder K.; Islam, Syed Z.; Rankin, Stephen E.] Univ Kentucky, Chem & Mat Engn Dept, Lexington, KY USA.
   [Wu, Qingliu] Argonne Natl Lab, Chem Sci & Engn Div, 9700 S Cass Ave, Argonne, IL 60439 USA.
   [Strzalka, Joseph] Argonne Natl Lab, Adv Photon Source, Argonne, IL 60439 USA.
   [Das, Saikat] Univ Michigan, Dept Civil & Environm Engn, Ann Arbor, MI 48109 USA.
   [Garlapalli, Ravinder K.] Ohio Univ, Chem & Biomol Engn Dept, Athens, OH 45701 USA.
RP Rankin, SE (reprint author), Univ Kentucky, Chem & Mat Engn Dept, Lexington, KY USA.
EM srankin@engr.uky.edu
OI Islam, Syed/0000-0002-5149-8094
FU U.S. Department of Energy EPSCoR Implementation award
   [DE-FG02-07-ER46375]; NSF EPSCoR research infrastructure initiative
   [IIA-1355438]; U.S. Department of Energy, Office of Science, Office of
   Basic Energy Sciences [DE-AC02-06CH11357]
FX The titania thin film synthesis, characterization and GISAXS
   measurements were performed as part of a U.S. Department of Energy
   EPSCoR Implementation award supported by grant no. DE-FG02-07-ER46375.
   Analysis of the results was completed as part of an NSF EPSCoR research
   infrastructure initiative supported by grant no. IIA-1355438. The use of
   the Advanced Photon Source at Argonne National Laboratory for GISAXS
   measurements was supported by the U.S. Department of Energy, Office of
   Science, Office of Basic Energy Sciences, under Contract No.
   DE-AC02-06CH11357.
CR Adachi M, 2004, J AM CHEM SOC, V126, P14943, DOI 10.1021/ja048068s
   Agarwala S, 2010, ACS APPL MATER INTER, V2, P1844, DOI 10.1021/am100421e
   Alberius PCA, 2002, CHEM MATER, V14, P3284, DOI 10.1021/cm011209u
   Alem A, 2009, CERAM INT, V35, P1837, DOI 10.1016/j.ceramint.2008.10.034
   Arabatzis IM, 2003, APPL CATAL B-ENVIRON, V42, P187, DOI 10.1016/S0926-3373(02)00233-3
   AUGIS JA, 1978, J THERM ANAL, V13, P283, DOI 10.1007/BF01912301
   BANKS W, 1963, MAKROMOLEKUL CHEM, V59, P233
   Bass JD, 2008, J AM CHEM SOC, V130, P7882, DOI 10.1021/ja078140x
   Carreon MA, 2007, J MATER CHEM, V17, P82, DOI 10.1039/b612550f
   Cassiers K, 2004, J PHYS CHEM B, V108, P3713, DOI 10.1021/jp036830r
   Chang WL, 2009, EUR POLYM J, V45, P2749, DOI 10.1016/j.eurpolymj.2009.06.016
   Choi SY, 2004, ADV FUNCT MATER, V14, P335, DOI 10.1002/adfm.200305039
   Crepaldi EL, 2003, J AM CHEM SOC, V125, P9770, DOI 10.1021/ja030070g
   Das S, 2014, J PHYS CHEM C, V118, P968, DOI 10.1021/jp406165v
   Ding ZM, 1997, J POLYM SCI POL PHYS, V35, P1077, DOI 10.1002/(SICI)1099-0488(199705)35:7<1077::AID-POLB7>3.0.CO;2-T
   Gajjela SR, 2010, ENERG ENVIRON SCI, V3, P838, DOI 10.1039/b921360k
   Grosso D, 2001, ADV MATER, V13, P1085, DOI 10.1002/1521-4095(200107)13:14<1085::AID-ADMA1085>3.0.CO;2-Q
   Grosso D, 2003, CHEM MATER, V15, P4562, DOI 10.1021/cm031060h
   Haring A, 2012, MATERIALS, V5, P1890, DOI 10.3390/ma5101890
   Hazra SK, 2006, SENSOR ACTUAT B-CHEM, V115, P403, DOI 10.1016/j.snb.2005.10.002
   Huo KF, 2014, RSC ADV, V4, P17300, DOI 10.1039/c4ra01458h
   Islam SZ, 2016, MICROPOR MESOPOR MAT, V220, P120, DOI 10.1016/j.micromeso.2015.08.030
   Ismail AA, 2011, J MATER CHEM, V21, P11686, DOI 10.1039/c1jm10407a
   Jiang Z, 2015, J APPL CRYSTALLOGR, V48, P917, DOI 10.1107/S1600576715004434
   Jiang Z, 2012, J SYNCHROTRON RADIAT, V19, P627, DOI 10.1107/S0909049512022017
   Kirsch BL, 2004, J PHYS CHEM B, V108, P12698, DOI 10.1021/jp036442p
   Klotz M, 2000, CHEM MATER, V12, P1721, DOI 10.1021/cm991198t
   Koganti VR, 2006, NANO LETT, V6, P2567, DOI 10.1021/nl061992v
   Koganti VR, 2005, J PHYS CHEM B, V109, P3279, DOI 10.1021/jp045037a
   Kruger RA, 2011, ACS APPL MATER INTER, V3, P2031, DOI 10.1021/am200262w
   Lancelle-Beltran E, 2006, CHEM MATER, V18, P6152, DOI 10.1021/cm060925z
   Liu KS, 2005, MATER LETT, V59, P3308, DOI 10.1016/j.matlet.2005.05.062
   Lu YF, 1997, NATURE, V389, P364, DOI 10.1038/38699
   Maeda M, 2007, SURF COAT TECH, V201, P9309, DOI 10.1016/j.surfcoat.2007.04.094
   Malfatti L, 2006, MICROPOR MESOPOR MAT, V88, P304, DOI 10.1016/j.micromeso.2005.09.027
   Nagpure S, 2015, J PHYS CHEM C, V119, P22970, DOI 10.1021/acs.jpcc.5b06945
   Pan JH, 2011, CHEM ENG J, V170, P363, DOI 10.1016/j.cej.2010.11.040
   Rampaul A, 2003, POLYHEDRON, V22, P35, DOI 10.1016/S0277-5387(02)01333-5
   Rawolle M, 2012, CHEM SOC REV, V41, P5131, DOI 10.1039/c2cs15321a
   Regonini D, 2013, MAT SCI ENG R, V74, P377, DOI 10.1016/j.mser.2013.10.001
   Richman EK, 2008, NAT MATER, V7, P712, DOI 10.1038/nmat2257
   Si P, 2011, ACS NANO, V5, P7617, DOI 10.1021/nn202714c
   Smarsly B, 2004, CHEM MATER, V16, P2948, DOI 10.1021/cm0495966
   Soler-Illia GJDA, 2002, CHEM MATER, V14, P750, DOI 10.1021/cm011217a
   Stein A, 2014, CHEM MATER, V26, P259, DOI 10.1021/cm402184h
   Toro-Vazquez JE, 2002, J AM OIL CHEM SOC, V79, P855, DOI 10.1007/s11746-002-0570-y
   Uchida H, 2010, THIN SOLID FILMS, V518, P3169, DOI 10.1016/j.tsf.2009.08.050
   Wang CT, 2012, SURF COAT TECH, V206, P2622, DOI 10.1016/j.surfcoat.2011.11.025
   Wang KX, 2005, CHEM MATER, V17, P1269, DOI 10.1021/cm047912a
   Wu QL, 2012, THIN SOLID FILMS, V520, P3558, DOI 10.1016/j.tsf.2011.12.028
   Wu QL, 2011, J SOL-GEL SCI TECHN, V60, P81, DOI 10.1007/s10971-011-2553-1
   Wu QL, 2011, LANGMUIR, V27, P9557, DOI 10.1021/la201388n
   Wu QL, 2011, J PHYS CHEM C, V115, P11925, DOI 10.1021/jp2021193
   Yang PD, 1998, NATURE, V396, P152
   Zhang RY, 2012, NANO TODAY, V7, P344, DOI 10.1016/j.nantod.2012.06.012
   Zukalova M, 2005, NANO LETT, V5, P1789, DOI 10.1021/nl051401l
NR 56
TC 4
Z9 4
U1 1
U2 11
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1463-9076
EI 1463-9084
J9 PHYS CHEM CHEM PHYS
JI Phys. Chem. Chem. Phys.
PD JAN 28
PY 2016
VL 18
IS 4
BP 2896
EP 2905
DI 10.1039/c5cp05178a
PG 10
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA DC8YI
UT WOS:000369506000067
PM 26732799
DA 2018-03-20
ER

PT J
AU Oldham, ED
   Nunes, LM
   Varela-Ramirez, A
   Rankin, SE
   Knutson, BL
   Aguilera, RJ
   Lehmler, HJ
AF Oldham, Edward Davis
   Nunes, Larissa M.
   Varela-Ramirez, Armando
   Rankin, Stephen E.
   Knutson, Barbara L.
   Aguilera, Renato J.
   Lehmler, Hans-Joachim
TI Cytotoxic activity of triazole-containing alkyl beta-D-glucopyranosides
   on a human T-cell leukemia cell line
SO CHEMISTRY CENTRAL JOURNAL
LA English
DT Article
ID HYDROXYL GROUP STEREOCHEMISTRY; D-XYLOPYRANOSIDE SURFACTANTS;
   CLICK-CHEMISTRY; BICATENARY DERIVATIVES; CANCER-CELLS; FATTY-ACIDS;
   CARBOHYDRATE; GLYCOSIDES; BIOCOMPATIBILITY; GLYCOLIPIDS
AB Background: Simple glycoside surfactants represent a class of chemicals that are produced from renewable raw materials. They are considered to be environmentally safe and, therefore, are increasingly used as pharmaceuticals, detergents, and personal care products. Although they display low to moderate toxicity in cells in culture, the underlying mechanisms of surfactant-mediated cytotoxicity are poorly investigated.
   Results: We synthesized a series of triazole-linked (fluoro) alkyl beta-glucopyranosides using the copper-catalyzed azide-alkyne reaction, one of many popular "click" reactions that enable efficient preparation of structurally diverse compounds, and investigate the toxicity of this novel class of surfactant in the Jurkat cell line. Similar to other carbohydrate surfactants, the cytotoxicity of the triazole-linked alkyl beta-glucopyranosides was low, with IC50 values decreasing from 1198 to 24 mu M as the hydrophobic tail length increased from 8 to 16 carbons. The two alkyl beta-glucopyranosides with the longest hydrophobic tails caused apoptosis by mechanisms involving mitochondrial depolarization and caspase-3 activation.
   Conclusions: Triazole-linked, glucose-based surfactants 4a-g and other carbohydrate surfactants may cause apoptosis, and not necrosis, at low micromolar concentrations via induction of the intrinsic apoptotic cascade; however, additional studies are needed to fully explore the molecular mechanisms of their toxicity.
C1 [Oldham, Edward Davis] Univ Mary Washington, Dept Chem, Fredericksburg, VA 22401 USA.
   [Nunes, Larissa M.; Varela-Ramirez, Armando; Aguilera, Renato J.] Univ Texas El Paso, Border Biomed Res Ctr, Dept Biol Sci, Cytometry Screening & Imaging Core Facil, El Paso, TX 79968 USA.
   [Rankin, Stephen E.; Knutson, Barbara L.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Lehmler, Hans-Joachim] Univ Iowa, Dept Occupat & Environm Hlth, Iowa City, IA 52242 USA.
RP Aguilera, RJ (reprint author), Univ Texas El Paso, Border Biomed Res Ctr, Dept Biol Sci, Cytometry Screening & Imaging Core Facil, Biosci Res Bldg,500 West Univ Ave, El Paso, TX 79968 USA.
EM raguilera@utep.edu; hans-joachim-lehmler@uiowa.edu
OI Rankin, Stephen/0000-0002-8615-7564; Lehmler,
   Hans-Joachim/0000-0001-9163-927X
FU RCMI program [2G12MD007592]; National Center on Minority Health and
   Health Disparities; component of National Institutes of Health; National
   Science Foundation [CBET-0967381/0967390]; U.S. Department of
   Agriculture Biomass Research and Development Initiative [68-3A75-7-608];
   NIGMS SCORE [1SC3GM103713-01]
FX We thank Gladys Almodovar for critical review of the manuscript and cell
   culture expertise. We also thank the Cytometry, Screening and Imaging
   Core Facility at the University of Texas at El Paso (UTEP), supported by
   RCMI program Grant No. 2G12MD007592, to the Border Biomedical Research
   Center (BBRC) at UTEP, from the National Center on Minority Health and
   Health Disparities, a component of National Institutes of Health. The
   synthesis of the triazole-containing alkyl beta-D-glucoyranosides 4a-g
   was supported by grants from the National Science Foundation
   (CBET-0967381/0967390) and the U.S. Department of Agriculture Biomass
   Research and Development Initiative (Grant Agreement 68-3A75-7-608) to
   HJL. The cell culture work was supported by NIGMS SCORE Grant
   1SC3GM103713-01 to RJA.
CR Alvarez SG, 1997, SYNTHESIS-STUTTGART, P413
   Balgavy P, 1996, ADV COLLOID INTERFAC, V66, P23, DOI 10.1016/0001-8686(96)00295-3
   Brusa C, 2014, RSC ADV, V4, P9330, DOI 10.1039/c3ra46173d
   Clemente MJ, 2011, LANGMUIR, V27, P15236, DOI 10.1021/la203447e
   Dembitsky VM, 2004, LIPIDS, V39, P933, DOI 10.1007/s11745-004-1316-1
   Goodby JW, 2007, CHEM SOC REV, V36, P1971, DOI 10.1039/b708458g
   Hill K, 2008, SURFACTANT SCI SER, V143, P1
   Kamp F, 2006, PROSTAG LEUKOTR ESS, V75, P149, DOI 10.1016/j.plefa.2006.05.003
   Kasuya MCZ, 2004, BIOCHEM BIOPH RES CO, V316, P599, DOI 10.1016/j.bbrc.2004.02.094
   Kasuya MCZ, 2005, CHEM LETT, V34, P856, DOI 10.1246/cl.2005.856
   Leventis PA, 2010, ANNU REV BIOPHYS, V39, P407, DOI 10.1146/annurev.biophys.093008.131234
   Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1
   Li XS, 2009, COLLOID SURFACE B, V73, P65, DOI 10.1016/j.colsurfb.2009.04.023
   Li XS, 2008, NEW J CHEM, V32, P2169, DOI 10.1039/b805015e
   MILIUS A, 1991, NEW J CHEM, V15, P337
   Mohammed AI, 2012, TETRAHEDRON LETT, V53, P5081, DOI 10.1016/j.tetlet.2012.07.014
   Neto V, 2008, J CARBOHYD CHEM, V27, P231, DOI 10.1080/07328300802105365
   Neto V, 2010, TETRAHEDRON, V66, P4633, DOI 10.1016/j.tet.2010.03.115
   Oldham ED, 2013, CARBOHYD RES, V379, P68, DOI 10.1016/j.carres.2013.06.020
   Paul KJV, 2008, TETRAHEDRON LETT, V49, P6356, DOI 10.1016/j.tetlet.2008.08.073
   Queneau Y, 2008, CARBOHYD RES, V343, P1999, DOI 10.1016/j.carres.2008.02.008
   Razafindralambo H, 2011, PHYS CHEM CHEM PHYS, V13, P15291, DOI 10.1039/c1cp21365b
   Razafindralambo HL, 2012, J PHYS CHEM B, V116, P3998, DOI 10.1021/jp209765j
   Riess JG, 2000, CARBOHYD RES, V327, P147, DOI 10.1016/S0008-6215(00)00012-4
   Robles-Escajeda E, 2013, CELL BIOL TOXICOL, V29, P431, DOI 10.1007/s10565-013-9264-z
   Robles-Escajeda E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073508
   Rostovtsev VV, 2002, ANGEW CHEM INT EDIT, V41, P2596, DOI 10.1002/1521-3773(20020715)41:14<2596::AID-ANIE2596>3.0.CO;2-4
   Rowan AS, 2009, ORG BIOMOL CHEM, V7, P4029, DOI 10.1039/b909729e
   Sani FA, 2012, COLLOID SURFACE B, V97, P196, DOI 10.1016/j.colsurfb.2012.03.030
   SCHNEIDER U, 1977, INT J CANCER, V19, P621, DOI 10.1002/ijc.2910190505
   Schuster T, 2013, J FLUORINE CHEM, V154, P30, DOI 10.1016/j.jfluchem.2013.06.005
   Soderlind E, 2003, INT J PHARMACEUT, V252, P61
   Song SX, 2012, BIOORG MED CHEM LETT, V22, P2030, DOI 10.1016/j.bmcl.2012.01.069
   Song SX, 2010, TETRAHEDRON, V66, P9974, DOI 10.1016/j.tet.2010.10.033
   Stubenrauch C, 2001, CURR OPIN COLLOID IN, V6, P160, DOI 10.1016/S1359-0294(01)00080-2
   Varela-Ramirez A, 2011, CELL BIOL TOXICOL, V27, P159, DOI 10.1007/s10565-010-9178-y
   Xu WJ, 2012, CARBOHYD RES, V349, P12, DOI 10.1016/j.carres.2011.11.020
   ZARIF L, 1989, J FLUORINE CHEM, V44, P73, DOI 10.1016/S0022-1139(00)84372-9
   ZARIF L, 1990, J MED CHEM, V33, P1262, DOI 10.1021/jm00166a028
   Zhang HL, 2012, CARBOHYD RES, V354, P32, DOI 10.1016/j.carres.2012.03.006
   Zhang HL, 2011, MOL DIVERS, V15, P889, DOI 10.1007/s11030-011-9318-1
   Zhou CH, 2012, CURR MED CHEM, V19, P239
NR 42
TC 8
Z9 8
U1 1
U2 16
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1752-153X
J9 CHEM CENT J
JI Chem. Cent. J.
PD FEB 1
PY 2015
VL 9
AR 3
DI 10.1186/s13065-014-0072-1
PG 12
WC Chemistry, Multidisciplinary
SC Chemistry
GA CC0CU
UT WOS:000350003400001
PM 25705252
OA gold
DA 2018-03-20
ER

PT J
AU Reichel, D
   Bae, Y
AF Reichel, Derek A.
   Bae, Younsoo
TI Comparison of Dialysis- and Solvatofluorochromism-Based Methods to
   Determine Drug Release Rates from Polymer Nanoassemblies
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE controlled drug release; drug release kinetics; mathematical modeling;
   nanoparticles; solvatofluorochromism
ID CROSS-LINKED NANOASSEMBLIES; BLOCK-COPOLYMER MICELLES;
   ANTITUMOR-ACTIVITY; CELLULAR UPTAKE; NANOPARTICLES; DELIVERY;
   FORMULATIONS; CANCER; CYTOTOXICITY; STABILITY
AB Purpose To compare traditional dialysis-and novel solvatofluorochromism (SFC)-based methods for accurate determination of drug release profiles for nanoparticle drug carriers.
   Methods Polymer nanoassemblies (PNAs) varying in drug release patterns were prepared using poly(ethylene glycol), poly(ethylenimine), hydrophobic excipients (palmitate and deoxycholate), and model hydrophobic anticancer drugs with clinical relevance (carfilzomib and docetaxel). Nile blue (NB) was used as a model SFC dye quenching fluorescence in water yet emitting strong fluorescence in the presence of hydrophobic drugs within PNAs. Drug release kinetics were measured by dialysis-and SFC-based methods, and analyzed by mathematical modeling of free drug, spiked drug, and encapsulated drug release.
   Results The dialysis method overestimated drug remaining in PNAs because it included released drug in measurements, whereas the SFC method successfully distinguished drugs entrapped in PNAs from released in solution and thus provided more accurate drug release patterns. However, mathematical modeling revealed that the dialysis method would be less influenced than the SFC method by hydrophobic excipients modulating drug diffusion within PNAs.
   Conclusions In comparison to the dialysis-based method, the SFC-based method would allow for real-time spectroscopic determination of drug release from PNAs and potentially other nanoparticle drug carriers with improved convenience and accuracy.
C1 [Reichel, Derek; Bae, Younsoo] Univ Kentucky, Dept Pharmaceut Sci, Coll Pharm, 789 South Limestone, Lexington, KY 40536 USA.
RP Bae, Y (reprint author), Univ Kentucky, Dept Pharmaceut Sci, Coll Pharm, 789 South Limestone, Lexington, KY 40536 USA.
EM younsoo.bae@uky.edu
OI Bae, Younsoo/0000-0003-1360-3524
FU University of Kentucky College of Pharmacy Graduate School Allocated
   Year (GSAY) Fellowship
FX DR acknowledges financial support from the University of Kentucky
   College of Pharmacy Graduate School Allocated Year (GSAY) Fellowship.
CR Akter S, 2012, PHARM RES-DORDR, V29, P847, DOI 10.1007/s11095-011-0613-4
   Alani AWG, 2010, BIOMATERIALS, V31, P1765, DOI 10.1016/j.biomaterials.2009.11.038
   Ao L, 2015, J PHARMACOL EXP THER, V355, P168, DOI 10.1124/jpet.115.226993
   Bae Y, 2005, BIOCONJUGATE CHEM, V16, P122, DOI 10.1021/bc0498166
   Bae Y, 2010, THER DELIV, V1, P361, DOI 10.4155/TDE.10.28
   Bera A, 2015, J MATER CHEM B, V3, P8548, DOI 10.1039/c5tb01251a
   Beutel S, 2011, APPL MICROBIOL BIOT, V91, P1493, DOI 10.1007/s00253-011-3470-5
   Cao LQ, 1999, J MOL CATAL B-ENZYM, V6, P279, DOI 10.1016/S1381-1177(98)00083-6
   Cao P, 2013, BR J PHARM RES, V3, P536
   Cheng YY, 2008, EUR J MED CHEM, V43, P2291, DOI 10.1016/j.ejmech.2007.12.021
   Cho EJ, 2013, MOL PHARMACEUT, V10, P2093, DOI 10.1021/mp300697h
   Chu KS, 2013, NANOMED-NANOTECHNOL, V9, P686, DOI 10.1016/j.nano.2012.11.008
   Curtis LT, 2016, PHARM RES-DORDR, V33, P2552, DOI 10.1007/s11095-016-1981-6
   de Andrade DF, 2015, AAPS PHARMSCITECH, V16, P1409, DOI 10.1208/s12249-015-0330-0
   Dickerson M, 2016, J MATER CHEM B, V4, P394, DOI 10.1039/c5tb01613d
   Dickerson M, 2014, PHARM RES-DORDR, V31, P1254, DOI 10.1007/s11095-013-1246-6
   Dickerson M, 2013, THER DELIV, V4, P1431, DOI [10.4155/tde.13.105, 10.4155/TDE.13.105]
   Diou O, 2015, PHARM RES-DORDR, V32, P3188, DOI 10.1007/s11095-015-1696-0
   Duan RL, 2015, J TAIWAN INST CHEM E, V50, P43, DOI 10.1016/j.jtice.2014.12.027
   Eckman AM, 2012, PHARM RES-DORDR, V29, P1755, DOI 10.1007/s11095-012-0697-5
   Frick AA, 2014, CHEM COMMUN, V50, P3341, DOI 10.1039/c3cc49577a
   Fuchs K, 2015, INT J PHARMACEUT, V482, P68, DOI 10.1016/j.ijpharm.2014.11.041
   Fugit KD, 2015, J CONTROL RELEASE, V217, P82, DOI 10.1016/j.jconrel.2015.08.024
   Fugit KD, 2014, MOL PHARMACEUT, V11, P1314, DOI 10.1021/mp400765n
   Gillies ER, 2004, J AM CHEM SOC, V126, P11936, DOI 10.1021/ja0463738
   Gullotti E, 2012, J CONTROL RELEASE, V164, P170, DOI 10.1016/j.jconrel.2012.04.042
   Hopfner T, 2010, BIOPROC BIOSYST ENG, V33, P247, DOI 10.1007/s00449-009-0319-8
   Howard MD, 2011, PHARM RES-DORDR, V28, P2435, DOI 10.1007/s11095-011-0470-1
   Jaimes-Aguirre L, 2016, CURR PHARM DESIGN, V22, P2886, DOI 10.2174/1381612822666160217125028
   Jin G-W, 2013, J APP PHARM SCI, V3, P1
   KWON G, 1993, LANGMUIR, V9, P945, DOI 10.1021/la00028a012
   Lee HJ, 2013, NANO B, V2
   Lee HJ, 2013, PHARM RES-DORDR, V30, P2077, DOI 10.1007/s11095-013-1060-1
   Lee HJ, 2013, PHARM RES-DORDR, V30, P478, DOI 10.1007/s11095-012-0893-3
   Lee HJ, 2011, BIOMACROMOLECULES, V12, P2686, DOI 10.1021/bm200483t
   Lee HJ, 2010, THER DELIV, V1, P803, DOI 10.4155/TDE.10.70
   Li JW, 2014, DRUG DEV IND PHARM, V40, P980, DOI 10.3109/03639045.2013.795582
   Li ZY, 2015, J FUNCT FOODS, V19, P733, DOI 10.1016/j.jff.2015.09.058
   Luo S, 2014, J BIOMAT SCI-POLYM E, V25, P965, DOI 10.1080/09205063.2014.916095
   Modi S, 2013, MOL PHARMACEUT, V10, P3076, DOI 10.1021/mp400154a
   Ponta A, 2015, PHARM RES-DORDR, V32, P1752, DOI 10.1007/s11095-014-1573-2
   Ponta A, 2014, J DRUG TARGET, V22, P619, DOI 10.3109/1061186X.2014.910793
   Ponta Andrei, 2011, Pharmaceuticals (Basel), V4, P1281
   Ponta A, 2010, PHARM RES-DORDR, V27, P2330, DOI 10.1007/s11095-010-0120-z
   Reichel D, 2016, THER DELIV, V7, P665, DOI 10.4155/tde-2016-0041
   Reichel D, 2015, THER DELIV, V6, P1221, DOI 10.4155/tde.15.59
   RODA A, 1990, J LIPID RES, V31, P1433
   Salmela L, 2014, INT J PHARMACEUT, V472, P276, DOI 10.1016/j.ijpharm.2014.06.024
   Scott D, 2013, J PHARM DRUG DELIV R, V2, P2, DOI [10.4172/2325-9604.1000116, DOI 10.4172/2325-9604.1000116]
   Scott D, 2011, INT J NANOMED, V6, P2757, DOI 10.2147/IJN.S25427
   Stylianopoulos T, 2015, NANOMED-NANOTECHNOL, V11, P1893, DOI 10.1016/j.nano.2015.07.015
   Uchida Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050678
   Wasik S, 2013, EUR BIOPHYS J BIOPHY, V42, P549, DOI 10.1007/s00249-013-0904-2
   Wu H, 2013, BIOMATERIALS, V34, P1213, DOI 10.1016/j.biomaterials.2012.08.072
   Xie L, 2015, INT J PHARMACEUT, V488, P108, DOI 10.1016/j.ijpharm.2015.03.080
   Yadav S, 2015, ARTIF CELL NANOMED B, V43, P93, DOI 10.3109/21691401.2013.845569
   Zambito Y, 2012, INT J PHARMACEUT, V434, P28, DOI 10.1016/j.ijpharm.2012.05.020
   Zhou YS, 2016, J CONTROL RELEASE, V243, P11, DOI 10.1016/j.jconrel.2016.09.031
NR 58
TC 1
Z9 1
U1 3
U2 7
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
EI 1573-904X
J9 PHARM RES-DORDR
JI Pharm. Res.
PD FEB
PY 2017
VL 34
IS 2
BP 394
EP 407
DI 10.1007/s11095-016-2070-6
PG 14
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA EN5QI
UT WOS:000396060200013
PM 27873146
DA 2018-03-19
ER

PT J
AU Schlipf, DM
   Jones, CA
   Armbruster, ME
   Rushing, ES
   Wooten, KC
   Rankin, SE
   Knutson, BL
AF Schlipf, Daniel M.
   Jones, Cory A.
   Armbruster, Marie E.
   Rushing, Elliott S.
   Wooten, Kaitlyn C.
   Rankin, Stephen E.
   Knutson, Barbara L.
TI Flavonoid adsorption and stability on titania-functionalized silica
   nanoparticles
SO COLLOIDS AND SURFACES A-PHYSICOCHEMICAL AND ENGINEERING ASPECTS
LA English
DT Article
DE Nanoparticles; Titanosilicates; Nano harvesting; Adsorption;
   Functionalization
ID MESOPOROUS SILICA; ANTIOXIDANT ACTIVITY; QUERCETIN; STABILIZATION;
   COMPLEXATION; POTENTIALS; PREVENTION; PARTICLES; COATINGS; SPHERES
AB The interaction of flavonoids with silica surfaces is of interest for separation and recovery of these natural products with potential anti-oxidant and anti-inflammatory properties. The benefit of tailored silica materials for natural product separation is based on the ability to readily tune their surface functionality and pore structure. In this work, the adsorption of quercetin, a model plant-derived flavonoid, was measured on silica particles (450 nm diameter) that were non-functionalized, hydrophobically functionalized (16.2 mg decyl groups/g) or titania modified (0.33-9.83 mg TiO2/g). Quercetin interactions with these functionalized silica particles were interpreted from adsorption measurements on nonporous silica particles, which eliminate the potential diffusional and steric constraints of pores. Titania functionalized particles are found to exhibit significantly increased adsorption capacities compared to non-functionalized and decyl functionalized materials, presumably due to binding of quercetin to the metal oxide, and this capacity increased linearly with surface coverage of titania. The ability to recover the activity of bound quercetin is demonstrated using a 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay. This investigation provides guidelines for the surface modification of both porous and nonporous silica for the recovery of natural product flavonoids, taking advantage of the binding properties of the functionalized silica surface. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Schlipf, Daniel M.; Jones, Cory A.; Armbruster, Marie E.; Rushing, Elliott S.; Wooten, Kaitlyn C.; Rankin, Stephen E.; Knutson, Barbara L.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Knutson, BL (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 F Paul Anderson Tower, Lexington, KY 40506 USA.
EM bknut2@uky.edu
OI Rankin, Stephen/0000-0002-8615-7564
FU National Science Foundation Integrated Graduate Education and Research
   Training (IGERT) program on Bioactive Interfaces and Devices
   [DGE-0653710]; University of Kentucky Research Experience for
   Undergraduates (REU) program [EC-0851716]; United States Department of
   Agriculture Biomass Research and Development Initiative (BRDI) grant
   [2011-10006-30363]
FX This work was supported by the National Science Foundation Integrated
   Graduate Education and Research Training (IGERT) program on Bioactive
   Interfaces and Devices (grant # DGE-0653710), the University of Kentucky
   Research Experience for Undergraduates (REU) program # EC-0851716 and a
   United States Department of Agriculture Biomass Research and Development
   Initiative (BRDI) grant (award # 2011-10006-30363). We would like to
   thank Eric C. Price for his experimental assistance in lab during his
   independent study in chemical engineering. We would also like the thank
   Dr. Kim Anderson for use of her dynamic light scattering particle size
   analyzer. Thanks to Prachi Gupta and Sundar Prasanth in Dr. Thomas
   Dziubla's lab at the University of Kentucky for their helpful
   discussions regarding quercetin, its antioxidant activity and properties
   in solution.
CR Abou-El-Sherbini KS, 2011, J SOL-GEL SCI TECHN, V57, P57, DOI 10.1007/s10971-010-2324-4
   Alia M, 2006, TOXICOL APPL PHARM, V212, P110, DOI 10.1016/j.taap.2005.07.014
   Berlier G, 2013, J COLLOID INTERF SCI, V393, P109, DOI 10.1016/j.jcis.2012.10.073
   Bischoff SC, 2008, CURR OPIN CLIN NUTR, V11, P733, DOI 10.1097/MCO.0b013e32831394b8
   BRAND-WILLIAMS W, 1995, FOOD SCI TECHNOL-LEB, V28, P25
   Busuioc AM, 2006, APPL CATAL A-GEN, V312, P153, DOI 10.1016/j.apcata.2006.06.043
   Cai ZZ, 2012, PLANT CELL REP, V31, P461, DOI 10.1007/s00299-011-1165-0
   Carlotti ME, 2011, J INCL PHENOM MACRO, V70, P81, DOI 10.1007/s10847-010-9864-7
   Chen TJ, 2006, TOXICOLOGY, V223, P113, DOI 10.1016/j.tox.2006.03.007
   Dhawan S, 2011, J PHARM PHARMACOL, V63, P342, DOI 10.1111/j.2042-7158.2010.01225.x
   Fedyanina TV, 2008, COLLOID J+, V70, P215, DOI [10.1134/S1061933X08020154, 10.1007/s10595-008-2015-9]
   Finnegan MP, 2007, J PHYS CHEM C, V111, P1962, DOI 10.1021/jp063822c
   Fu Y, 2006, J PHYS CHEM B, V110, P9164, DOI 10.1021/jp054178p
   Gastaldi L, 2012, PHYS CHEM CHEM PHYS, V14, P11318, DOI 10.1039/c2cp41351e
   Guo XC, 1999, LANGMUIR, V15, P5535, DOI 10.1021/la990220u
   Hanprasopwattana A, 1996, LANGMUIR, V12, P3173, DOI 10.1021/la950808a
   Iler R. K., 1979, CHEM SILICA SOLUBILI
   Kamaruddin S, 2011, CATAL TODAY, V161, P53, DOI 10.1016/j.cattod.2010.10.038
   Kazakova OA, 2002, COLLOID J+, V64, P412, DOI 10.1023/A:1016807717891
   Kim JM, 2009, CERAM INT, V35, P1015, DOI 10.1016/j.ceramint.2008.04.011
   Kumar P, 2010, MICROPOR MESOPOR MAT, V132, P1, DOI 10.1016/j.micromeso.2010.02.007
   Kurepa J, 2014, PLANT J, V77, P443, DOI 10.1111/tpj.12361
   Li ZX, 2012, CHEM SOC REV, V41, P2590, DOI 10.1039/c1cs15246g
   Majewski P, 2011, APPL SURF SCI, V257, P9282, DOI 10.1016/j.apsusc.2011.04.145
   Martin-Aranda RM, 2010, TOP CATAL, V53, P141, DOI 10.1007/s11244-009-9419-6
   Morosanova EI, 2012, J ANAL CHEM+, V67, P14, DOI 10.1134/S1061934812010108
   Morosanova EI, 2012, TALANTA, V102, P114, DOI 10.1016/j.talanta.2012.07.043
   Murakami A, 2008, CANCER LETT, V269, P315, DOI 10.1016/j.canlet.2008.03.046
   Oksman-Caldentey KM, 2004, TRENDS PLANT SCI, V9, P433, DOI 10.1016/j.tplants.2004.07.006
   Piper-Feldkamp AR, 2013, J PHYS CHEM B, V117, P2113, DOI 10.1021/jp308305y
   Rasband W. S., 1997, NATL I HLTH
   RiceEvans CA, 1996, FREE RADICAL BIO MED, V20, P933, DOI 10.1016/0891-5849(95)02227-9
   Rothwell JA, 2005, J AGR FOOD CHEM, V53, P4355, DOI 10.1021/jf0483669
   Slowing LI, 2007, ADV FUNCT MATER, V17, P1225
   SRINIVASAN S, 1991, J CATAL, V131, P260, DOI 10.1016/0021-9517(91)90343-3
   STOBER W, 1968, J COLLOID INTERF SCI, V26, P62, DOI 10.1016/0021-9797(68)90272-5
   Wang C, 2010, COLLOID SURFACE A, V360, P184, DOI 10.1016/j.colsurfa.2010.02.030
   Wu JH, 2010, CHEM COMMUN, V46, P9031, DOI 10.1039/c0cc02763d
   Yang B, 2001, ANAL SCI, V17, P599, DOI 10.2116/analsci.17.599
NR 39
TC 4
Z9 4
U1 1
U2 76
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0927-7757
EI 1873-4359
J9 COLLOID SURFACE A
JI Colloid Surf. A-Physicochem. Eng. Asp.
PD AUG 5
PY 2015
VL 478
BP 15
EP 21
DI 10.1016/j.colsurfa.2015.03.039
PG 7
WC Chemistry, Physical
SC Chemistry
GA CH4UP
UT WOS:000354028700003
DA 2018-03-20
ER

PT J
AU Reneer, D
   Hisel, R
   Hoffman, J
   Kryscio, R
   Lusk, B
   Geddes, J
AF Reneer, Dexter V.
   Hisel, Richard D.
   Hoffman, Joshua M.
   Kryscio, Richard J.
   Lusk, Braden T.
   Geddes, James W.
TI BLAST-INDUCED BRAIN INJURY: INFLUENCE OF SHOCKWAVE COMPONENTS
SO JOURNAL OF NEUROTRAUMA
LA English
DT Meeting Abstract
CT 29th Annual National Neurotrauma Symposium
CY JUL 10-13, 2011
CL Hollywood Beach, FL
C1 [Reneer, Dexter; Geddes, James] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY USA.
   [Hoffman, Joshua; Lusk, Braden] Univ Kentucky, Dept Min Engn, Lexington, KY USA.
   [Kryscio, Richard] Univ Kentucky, Dept Biostat, Lexington, KY USA.
   [Hisel, Richard] GLR Enterprises LLC, Nicholasville, KY USA.
NR 0
TC 0
Z9 0
U1 0
U2 7
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0897-7151
J9 J NEUROTRAUM
JI J. Neurotrauma
PD JUN
PY 2011
VL 28
IS 6
BP A88
EP A88
PG 1
WC Critical Care Medicine; Clinical Neurology; Neurosciences
SC General & Internal Medicine; Neurosciences & Neurology
GA 788PT
UT WOS:000292457600278
DA 2018-03-20
ER

PT J
AU Duan, JH
   Mansour, HM
   Zhang, YD
   Deng, XM
   Chen, YX
   Wang, JW
   Pan, YF
   Zhao, JF
AF Duan, Jinghua
   Mansour, Heidi M.
   Zhang, Yangde
   Deng, Xingming
   Chen, Yuxiang
   Wang, Jiwei
   Pan, Yifeng
   Zhao, Jinfeng
TI Reversion of multidrug resistance by co-encapsulation of doxorubicin and
   curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Curcumin; Doxorubicin; Poly(butyl cyanoacrylate) nanoparticles;
   Multidrug resistance
ID SOLID LIPID NANOPARTICLES; POLYALKYLCYANOACRYLATE NANOPARTICLES;
   CANCER-THERAPY; CACO-2 CELLS; IN-VITRO; DEGRADATION; PACLITAXEL;
   DELIVERY; EXPRESSION; TUMOR
AB Co-encapsulated doxorubicin (DOX) and curcumin (CUR) in poly(butyl cyanoacrylate) nanoparticles (PBCA-NPs) were prepared with emulsion polymerization and interfacial polymerization. The mean particle size and mean zeta potential of CUR-DOX-PBCA-NPs were 133 +/- 5.34 nm in diameter and +32.23 +/- 4.56 mV, respectively. The entrapment efficiencies of doxorubicin and curcumin were 49.98 +/- 3.32% and 94.52 +/- 3.14%, respectively. Anticancer activities and reversal efficacy of the formulations and various combination approaches were assessed using 3-[4,5-dimethylthiazol-2-yl]2,5-diphenyltetrazolium bromide assay and western blotting. The results showed that the dual-agent loaded PBCA-NPs system had the similar cytotoxicity to co-administration of two single-agent loaded PBCA-NPs (DOX-PBCA-NPs + CUR-PBCA-NPs), which was slightly higher than that of the free drug combination (DOX + CUR) and one free drug/another agent loaded PBCA-NPs combination (DOX + CUR-PBCA-NPs or CUR + DOX-PBCA-NPs). The simultaneous administration of doxorubicin and curcumin achieved the highest reversal efficacy and down-regulation of P-glycoprotein in MCF-7/ADR cell lines, an MCF-7 breast carcer cell line resistant to adriamycin. Multidrug resistance can be enhanced by combination delivery of encapsulated cytotoxic drugs and reversal agents. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Duan, Jinghua; Zhang, Yangde; Chen, Yuxiang; Wang, Jiwei; Pan, Yifeng; Zhao, Jinfeng] Cent S Univ, Xiangya Hosp, Natl Hepatobiliary & Enter Surg Res Ctr, Changsha 410008, Hunan, Peoples R China.
   [Duan, Jinghua; Mansour, Heidi M.] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Drug Dev Div, Lexington, KY 40536 USA.
   [Deng, Xingming] Emory Univ, Sch Med, Div Canc Biol, Atlanta, GA 30322 USA.
   [Deng, Xingming] Emory Univ, Sch Med, Dept Radiat Oncol, Atlanta, GA 30322 USA.
RP Zhao, JF (reprint author), Cent S Univ, Xiangya Hosp, Natl Hepatobiliary & Enter Surg Res Ctr, Changsha 410008, Hunan, Peoples R China.
EM zhaojinfeng@hotmail.com
RI duan, jinghua/H-2738-2014
FU Lotus Scholars Program in Hunan Province, PR China [200734]
FX This study was supported by a Lotus Scholars Program (200734) in Hunan
   Province, PR China.
CR Aggarwal BB, 2003, ANTICANCER RES, V23, P363
   Aggarwal B.B., 2009, INT J BIOCHEM CELL B, V1, P40
   Ambruosi A, 2006, J MICROENCAPSUL, V23, P582, DOI 10.1080/02652040600788080
   Anand P, 2007, MOL PHARM, V4, P807, DOI 10.1021/mp700113r
   Andjelkovic T, 2008, CANCER BIOL THER, V7, P1024, DOI 10.4161/cbt.7.7.6036
   Antonio A., 2008, ONCOL REP, V20, P731
   Behan N, 2001, BIOMATERIALS, V22, P1335, DOI 10.1016/S0142-9612(00)00286-6
   Chen BA, 2008, INT J NANOMED, V3, P277
   Cheng AL, 2001, ANTICANCER RES, V21, P2895
   deVerdiere AC, 1997, BRIT J CANCER, V76, P198, DOI 10.1038/bjc.1997.362
   Dong XW, 2010, NANOMEDICINE-UK, V5, P597, DOI 10.2217/NNM.10.35
   Dong XW, 2009, CANCER RES, V69, P3918, DOI 10.1158/0008-5472.CAN-08-2747
   Duan JH, 2010, INT J PHARMACEUT, V400, P211, DOI 10.1016/j.ijpharm.2010.08.033
   Ebert B, 2007, TOXICOL SCI, V96, P227, DOI 10.1093/toxsci/kfl147
   Ganta S, 2009, MOL PHARMACEUT, V6, P928, DOI 10.1021/mp800240j
   Graf A, 2009, EXPERT OPIN DRUG DEL, V6, P371, DOI [10.1517/17425240902870413 , 10.1517/17425240902870413]
   Gu FX, 2007, NANO TODAY, V2, P14, DOI 10.1016/S1748-0132(07)70083-X
   Hou XL, 2008, INT J PHARM, V358, P224, DOI 10.1016/j.ijpharm.2008.03.010
   Kang KW, 2010, NANOMED-NANOTECHNOL, V6, P210, DOI 10.1016/j.nano.2009.12.006
   KANTE B, 1982, J PHARM SCI, V71, P786, DOI 10.1002/jps.2600710716
   Kunnumakkara AB, 2008, CANCER LETT, V269, P199, DOI 10.1016/j.canlet.2008.03.009
   Lage H, 2003, INT J ANTIMICROB AG, V22, P188, DOI 10.1016/S0924-8579(03)00203-6
   LENAERTS V, 1984, BIOMATERIALS, V5, P65, DOI 10.1016/0142-9612(84)90002-4
   Lv QZ, 2009, INT J PHARMACEUT, V372, P191, DOI 10.1016/j.ijpharm.2009.01.014
   Mitra A, 2003, J PHARM PHARMACOL, V55, P895, DOI 10.1211/0022357021341
   MULLER RH, 1990, BIOMATERIALS, V11, P590, DOI 10.1016/0142-9612(90)90084-4
   Notarbartolo M, 2005, CANCER LETT, V224, P53, DOI 10.1016/j.canlet.2004.10.051
   Reddy LH, 2004, J DRUG TARGET, V12, P443, DOI 10.1080/10611860400011406
   Soma CE, 2000, BIOMATERIALS, V21, P1
   Song XR, 2009, EUR J PHARM SCI, V37, P300, DOI 10.1016/j.ejps.2009.02.018
   Sullivan CO, 2004, BIOMATERIALS, V25, P4375, DOI 10.1016/j.biomaterials.2003.11.001
   Tang HD, 2010, NANOMEDICINE-UK, V5, P855, DOI [10.2217/nnm.10.67, 10.2217/NNM.10.67]
   Vansnick L., 1985, PHARM RES-DORDR, V2, P36
   Vauthier C, 2003, ADV DRUG DELIVER REV, V55, P519, DOI 10.1016/S0169-409X(03)00041-3
   Wohlgemuth M, 2000, J MICROENCAPSUL, V17, P437
   Wu J, 2007, J PHARM PHARM SCI, V10, P350
NR 36
TC 85
Z9 86
U1 5
U2 90
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD APR 15
PY 2012
VL 426
IS 1-2
BP 193
EP 201
DI 10.1016/j.ijpharm.2012.01.020
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 919XA
UT WOS:000302364300022
PM 22274587
DA 2018-03-20
ER

PT J
AU Parthasarathy, R
   Chow, KM
   Derafshi, Z
   Fautsch, MP
   Hetling, JR
   Rodgers, DW
   Hersh, LB
   Pepperberg, DR
AF Parthasarathy, Rajni
   Chow, K. Martin
   Derafshi, Zahra
   Fautsch, Michael P.
   Hetling, John R.
   Rodgers, David W.
   Hersh, Louis B.
   Pepperberg, David R.
TI Intravitreally delivered neprilysin reduces amyloid-beta in the mouse
   eye
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Meeting Abstract
CT Annual Meeting of the
   Association-for-Research-in-Vision-and-Ophthalmology (ARVO)
CY MAY 03-07, 2015
CL Denver, CO
SP Assoc Res Vis & Ophthalmol
C1 [Parthasarathy, Rajni; Pepperberg, David R.] Univ Illinois, Ophthalmol & Visual Sci, Chicago, IL USA.
   [Parthasarathy, Rajni; Derafshi, Zahra; Hetling, John R.; Pepperberg, David R.] Univ Illinois, Bioengn, Chicago, IL USA.
   [Chow, K. Martin; Rodgers, David W.; Hersh, Louis B.] Univ Kentucky, Mol & Cellular Biochem, Lexington, KY USA.
   [Fautsch, Michael P.] Mayo Clin, Ophthalmol, Rochester, MN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2015
VL 56
IS 7
MA 3991
PG 3
WC Ophthalmology
SC Ophthalmology
GA CT5ZY
UT WOS:000362891102197
DA 2018-03-20
ER

PT J
AU Rogers, C
   Williams, S
   Joshi, A
   Bondada, V
   Maamoun, A
   Lou, DY
   Geddes, J
AF Rogers, Colin
   Williams, Sophie
   Joshi, Aashish
   Bondada, Vimala
   Maamoun, Amy
   Lou, Dingyuan
   Geddes, James W.
TI CELLULAR LOCALIZATION OF CALPASTATIN SPLICE VARIANTS
SO JOURNAL OF NEUROTRAUMA
LA English
DT Meeting Abstract
CT 29th Annual National Neurotrauma Symposium
CY JUL 10-13, 2011
CL Hollywood Beach, FL
C1 [Rogers, Colin; Williams, Sophie; Joshi, Aahish; Bondada, Vimala; Maamoun, Amy; Lou, Dingyuan; Geddes, James] Univ Kentucky, Lexington, KY USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0897-7151
J9 J NEUROTRAUM
JI J. Neurotrauma
PD JUN
PY 2011
VL 28
IS 6
BP A32
EP A32
PG 1
WC Critical Care Medicine; Clinical Neurology; Neurosciences
SC General & Internal Medicine; Neurosciences & Neurology
GA 788PT
UT WOS:000292457600110
DA 2018-03-20
ER

PT J
AU Meenach, SA
   Otu, CG
   Anderson, KW
   Hilt, JZ
AF Meenach, Samantha A.
   Otu, Chinedu G.
   Anderson, Kimberly W.
   Hilt, J. Zach
TI Controlled synergistic delivery of paclitaxel and heat from
   poly(beta-amino ester)/iron oxide-based hydrogel nanocomposites
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Hydrogel; Nanocomposites; Poly(beta-amino ester) (PBAE); Hyperthermia;
   Paclitaxel; Cancer
ID CHITOSAN HYDROGELS; DRUG-RELEASE; HYPERTHERMIA; BIOCOMPATIBILITY; CELLS;
   MICE
AB Poly(beta-amino ester) (PBAE) biodegradable hydrogels were investigated for potential combined chemotherapeutic and heat delivery in the synergistic treatment of cancer. Hyperthermia, the heating of cancerous tissue from 41 to 45 degrees C, increases the efficacy of conventional cancer therapies such as irradiation and chemotherapy. The hydrogel nanocomposites in this work provide a drug delivery vehicle (via the biodegradable PBAE polymer network) and the ability to be heated remotely upon exposure to an alternating magnetic field (via iron oxide nanoparticles incorporated into the hydrogel matrix). PBAE macromers composed of poly(ethylene glycol) (N = 400) diacrylate (PEG400DA) or diethylene glycol diacrylate (DEGDA) with isobutylamine (IBA) were synthesized. Hydrogel nanocomposites were fabricated via free-radical polymerization to form a bulk hydrogel matrix entrapping both iron oxide nanoparticles and paclitaxel. The 2EG-IBA hydrogel exhibited complete degradation after approximately 7 weeks whereas the 9EG-IBA hydrogel degraded completely in 11 h. The hydrogels heated upon exposure to an alternating magnetic field throughout the degradation process. Additionally, the cytotoxicity of the degradation products was evaluated. Paclitaxel release was controlled via bulk degradation of the hydrogels. The tailorability of these nanocomposites makes them solid candidates for the synergistic treatment of cancer. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Meenach, Samantha A.; Anderson, Kimberly W.; Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Otu, Chinedu G.] Univ Kentucky, Dept Biol, Lexington, KY 40506 USA.
RP Hilt, JZ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 F Paul Anderson Tower, Lexington, KY 40506 USA.
EM s.meenach@uky.edu; chinedu.otu@uky.edu; kanderson@engr.uky.edu;
   hilt@engr.uky.edu
RI Bohorquez, Ana/G-8694-2012; Meenach, Samantha/F-7542-2014
FU Kentucky Science and Engineering Foundation [KSEF0148-502-06-188];
   Engineered Bioactive Interfaces & Devices NSF IGERT [DGE-0653710]; NSF
   IGERT REU [EEC-0851716]
FX Partial funding for this research was provided by the Kentucky Science
   and Engineering Foundation (Award Number KSEF0148-502-06-188). S.
   Meenach and J. Shapiro acknowledge the Engineered Bioactive Interfaces &
   Devices NSF IGERT (Award Number DGE-0653710) and NSF IGERT REU (Award
   Number EEC-0851716) for providing partial funding for this research,
   respectively.
CR *ACS, 2009, CANC FACTS FIG
   Anderson DG, 2006, ADV MATER, V18, P2614, DOI 10.1002/adma.200600529
   Babincova M, 2001, J MAGN MAGN MATER, V225, P109, DOI 10.1016/S0304-8853(00)01237-3
   Falk MH, 2001, INT J HYPERTHER, V17, P1, DOI 10.1080/02656730150201552
   Guedes MHA, 2005, J MAGN MAGN MATER, V293, P283, DOI 10.1016/j.jmmm.2005.02.052
   Hawkins AM, 2011, J APPL POLYM SCI, V122, P1420, DOI 10.1002/app.34093
   Hawkins AM, 2011, ACTA BIOMATER, V7, P1956, DOI 10.1016/j.actbio.2011.01.024
   Hawkins AM, 2009, PHARM RES-DORD, V26, P667, DOI 10.1007/s11095-008-9804-z
   Hildebrandt B, 2002, CRIT REV ONCOL HEMAT, V43, P33, DOI 10.1016/S1040-8428(01)00179-2
   Issels RD, 2008, EUR J CANCER, V44, P2546, DOI 10.1016/j.ejca.2008.07.038
   Meenach SA, 2009, ACTA BIOMATER, V6, P1039
   Meenach SA, 2009, J BIOMED MATER RES A, V91A, P903, DOI 10.1002/jbm.a.32322
   Meenach Samantha A., 2009, P131, DOI 10.1007/978-0-387-78608-7_7
   Michalakis J, 2007, ANN SURG ONCOL, V14, P1220, DOI 10.1245/s10434-006-9305-4
   Moroz P, 2002, INT J HYPERTHER, V18, P267, DOI 10.1080/02656730110108785
   Obara K, 2005, J CONTROL RELEASE, V110, P79, DOI 10.1016/j.jconrel.2005.09.026
   Peppas NA, 2006, ADV MATER, V18, P1345, DOI 10.1002/adma.200501612
   Satarkar NS, 2008, J CONTROL RELEASE, V130, P246, DOI 10.1016/j.jconrel.2008.06.008
   Satarkar NS, 2009, LAB CHIP, V9, P1773, DOI 10.1039/b822694f
   Sneed PK, 1998, INT J RADIAT ONCOL, V40, P287, DOI 10.1016/S0360-3016(97)00731-1
   Ta HT, 2008, J CONTROL RELEASE, V126, P205, DOI 10.1016/j.jconrel.2007.11.018
NR 21
TC 22
Z9 22
U1 0
U2 52
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD MAY 10
PY 2012
VL 427
IS 2
BP 177
EP 184
DI 10.1016/j.ijpharm.2012.01.052
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 919XC
UT WOS:000302364500005
PM 22326297
DA 2018-03-19
ER

PT J
AU Willis, L
   Hayes, D
   Mansour, HM
AF Willis, Lauren
   Hayes, Don, Jr.
   Mansour, Heidi M.
TI Therapeutic Liposomal Dry Powder Inhalation Aerosols for Targeted Lung
   Delivery
SO LUNG
LA English
DT Review
DE Pulmonary nanomedicine; Asthma; Chronic obstructive pulmonary disease;
   Cystic fibrosis; Tuberculosis; Lung cancer
ID INVASIVE PULMONARY ASPERGILLOSIS; PLACEBO-CONTROLLED TRIAL;
   AIR-WATER-INTERFACE; AMPHOTERICIN-B; DRUG-DELIVERY; ALVEOLAR
   MACROPHAGES; CYCLOSPORINE-A; IN-VITRO; CYSTIC-FIBROSIS; NANOCARRIER
   SYSTEMS
AB Therapeutic liposomal powders (i.e., lipospheres and proliposomes) for dry powder inhalation aerosol delivery, formulated with phospholipids similar to endogenous lung surfactant, offer unique opportunities in pulmonary nanomedicine while offering controlled release and enhanced stability. Many pulmonary diseases such as lung cancer, tuberculosis (TB), cystic fibrosis (CF), bacterial and fungal lung infections, asthma, and chronic obstructive pulmonary disease (COPD) could greatly benefit from this type of pulmonary nanomedicine approach that can be delivered in a targeted manner by dry powder inhalers (DPIs). These delivery systems may require smaller doses for efficacy, exhibit reduced toxicity, fewer side effects, controlled drug release over a prolonged time period, and increased formulation stability as inhaled powders. This state-of-the-art review presents these novel aspects in depth.
C1 [Willis, Lauren; Mansour, Heidi M.] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Drug Dev Div, Lexington, KY 40536 USA.
   [Hayes, Don, Jr.] Ohio State Univ, Coll Med, Dept Pediat, Columbus, OH 43205 USA.
   [Hayes, Don, Jr.] Ohio State Univ, Coll Med, Dept Internal Med, Columbus, OH 43205 USA.
   [Hayes, Don, Jr.] Nationwide Childrens Hosp, Lung Transplant Program, Columbus, OH 43205 USA.
   [Hayes, Don, Jr.] Nationwide Childrens Hosp, Heart Lung Transplant Program, Columbus, OH 43205 USA.
   [Mansour, Heidi M.] Univ Kentucky, Ctr Membrane Sci, Lexington, KY 40536 USA.
RP Mansour, HM (reprint author), Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Drug Dev Div, 789 S Limestone St, Lexington, KY 40536 USA.
EM heidi.mansour@uky.edu
CR Abu-Dahab R, 2001, EUR J PHARM SCI, V14, P37, DOI 10.1016/S0928-0987(01)00147-6
   Adi H, 2010, EUR J PHARM SCI, V40, P239, DOI 10.1016/j.ejps.2010.03.020
   Albasarah YY, 2010, J PHARM PHARMACOL, V62, P821, DOI [10.1211/jpp.62.07.0002, 10.1211/jpp.62.05.0002]
   ALLEN SD, 1994, J ANTIMICROB CHEMOTH, V34, P1001, DOI 10.1093/jac/34.6.1001
   Alves GP, 2004, POWDER TECHNOL, V145, P139, DOI 10.1016/j.powtec.2004.06.008
   Am. Cancer Soc, 2010, CANC FACTS FIG 2010
   Azarmi S, 2006, INT J PHARM, V319, P155, DOI 10.1016/j.ijpharm.2006.03.052
   Bailey MM, 2009, MED RES REV, V29, P196, DOI 10.1002/med.20140
   BARKER SA, 1994, INT J PHARM, V102, P159, DOI 10.1016/0378-5173(94)90051-5
   Behr J, 2009, J AEROSOL MED PULM D, V22, P121, DOI 10.1089/jamp.2008.0714
   Bi R, 2007, J BIOMED NANOTECHNOL, V3, P332, DOI 10.1166/jbn.2007.050
   CANONICO AE, 1994, J APPL PHYSIOL, V77, P415
   Carvalho TC, 2011, J AEROSOL MED PULM D, V24, P61, DOI 10.1089/jamp.2009.0794
   Castagnola E, 2007, J CHEMOTHERAPY, V19, P339, DOI 10.1179/joc.2007.19.3.339
   Changsan N, 2009, J DRUG TARGET, V17, P751, DOI 10.3109/10611860903079462
   Changsan N, 2009, J PHARM SCI-US, V98, P628, DOI 10.1002/jps.21441
   Chen J, 2006, DRUG DEV IND PHARM, V32, P719, DOI 10.1080/03639040500529077
   Chimote G, 2010, J BIOMED MATER RES B, V94B, P1, DOI 10.1002/jbm.b.31608
   Chimote G, 2009, J BIOMED MATER RES A, V89A, P281, DOI 10.1002/jbm.a.31959
   Chougule M, 2008, AAPS PHARMSCITECH, V9, P47, DOI 10.1208/s12249-007-9024-6
   Chougule M, 2007, INT J NANOMED, V2, P675
   Chougule MB, 2006, J NANOSCI NANOTECHNO, V6, P3001, DOI 10.1166/jnn.2006.405
   Corcoran TE, 2006, AM J TRANSPLANT, V6, P2765, DOI 10.1111/j.1600-6143.2006.01529.x
   Dailey LA, 2006, TOXICOL APPL PHARM, V215, P100, DOI 10.1016/j.tapp2.006.01.016
   Dandekar P, 2010, J AEROSOL MED PULM D, V23, P343, DOI 10.1089/jamp.2009.0784
   Darwis Y, 2002, STP PHARMA SCI, V12, P91
   DEBS RJ, 1987, AM REV RESPIR DIS, V135, P731
   Desai TR, 2002, J PHARM SCI, V91, P482, DOI 10.1002/jps.10021
   Desjardins A, 2002, J DRUG TARGET, V10, P47, DOI 10.1080/10611860290007522
   DIPIRO J, 2008, PHARMACOTHERAPY PATH
   El-Gendy N, 2009, J PHARM SCI-US, V98, P2731, DOI 10.1002/jps.21630
   El-Ridy MS, 2007, INT J PHARM, V330, P82, DOI 10.1016/j.ijpharm.2006.09.017
   EVERARD ML, 1995, THORAX, V50, P517, DOI 10.1136/thx.50.5.517
   Evora C, 1998, J CONTROL RELEASE, V51, P143, DOI 10.1016/S0168-3659(97)00149-1
   Gagnadoux F, 2008, J AEROSOL MED PULM D, V21, P61, DOI 10.1089/jamp.2007.0656
   Gautam A, 2002, GENE THER, V9, P353, DOI 10.1038/sj/gt/3301662
   Gibbons A, 2010, AAPS PHARMSCITECH, V11, P1411, DOI 10.1208/s12249-010-9500-2
   Gibbons AM, 2009, J MICROENCAPSUL, V26, P513, DOI 10.1080/02652040802466535
   Gilbert BE, 1996, J AEROSOL MED, V9, P111, DOI 10.1089/jam.1996.9.111
   GILBERT BE, 1993, TRANSPLANTATION, V56, P974, DOI 10.1097/00007890-199310000-00037
   GOLDBACH P, 1993, DRUG DEV IND PHARM, V19, P2611, DOI 10.3109/03639049309047204
   GOLDBACH P, 1993, DRUG DEV IND PHARM, V19, P2623, DOI 10.3109/03639049309047205
   Hajos F, 2008, INT J PHARMACEUT, V357, P286, DOI 10.1016/j.ijpharm.2008.01.046
   Heijerman H, 2009, J CYST FIBROS, V8, P295, DOI 10.1016/j.jcf.2009.04.005
   Hickey A.J., 2009, MODERN PHARM, V2, P191
   Hickey A.J., 2008, MODIFIED RELEASE DRU, V2, P573
   Huang WH, 2010, BIOL PHARM BULL, V33, P512, DOI 10.1248/bpb.33.512
   Joshi M, 2003, CLIN EXP PHARMACOL P, V30, P153, DOI 10.1046/j.1440-1681.2003.03813.x
   Joshi M, 2001, METHOD FIND EXP CLIN, V23, P531, DOI 10.1358/mf.2001.23.10.677118
   Joshi M, 2001, INT J PHARM, V223, P15, DOI 10.1016/S0378-5173(01)00705-0
   Kalantarian P, 2010, INT J NANOMED, V5, P763, DOI 10.2147/IJN.S12415
   Knight V, 1999, CANCER CHEMOTH PHARM, V44, P177, DOI 10.1007/s002800050965
   Knoop C, 2004, EUR RESPIR J, V23, P159, DOI 10.1183/09031936.03.00039203
   Koshkina NV, 2004, J AEROSOL MED, V17, P7, DOI 10.1089/089426804322994415
   Koshkina NV, 2001, CLIN CANCER RES, V7, P3258
   Koshkina NV, 2000, CLIN CANCER RES, V6, P2876
   Kurmi BD, 2010, EXPERT OPIN DRUG DEL, V7, P781, DOI 10.1517/17425247.2010.492212
   Lacy CF, 2008, DRUG INFORM HDB
   Latimer P, 2009, EXP BIOL MED, V234, P1244, DOI 10.3181/0901-RM-8
   Lawson KA, 2004, CANCER CHEMOTH PHARM, V54, P421, DOI 10.1007/s00280-004-0817-y
   Lowry CM, 2007, TRANSPL INFECT DIS, V9, P121, DOI 10.1111/j.1399-3062.2007.00209.x
   Lu Dongmei, 2005, AAPS PharmSciTech, V6, pE641, DOI 10.1208/pt060480
   Mansour H, 2001, LANGMUIR, V17, P6622, DOI 10.1021/la0108454
   Mansour HM, 2008, MOL PHARMACEUT, V5, P681, DOI 10.1021/mp700123p
   Mansour HM, 2007, LANGMUIR, V23, P3809, DOI 10.1021/la063053o
   Mansour HM, 2007, J PHARM SCI-US, V96, P377, DOI 10.1002/jps.20810
   Mansour HM, 2009, INT J NANOMED, V4, P299
   Mansour HM, 2011, LIPIDS NANOTECHNOLOG, P221
   MCLACHLAN G, 1995, GENE THER, V2, P614
   Misra A, 2009, EXPERT OPIN DRUG DEL, V6, P71, DOI [10.1517/17425240802652309, 10.1517/17425240802652309 ]
   Muttil P, 2007, EUR J PHARM SCI, V32, P140, DOI 10.1016/j.ejps.2007.06.006
   MYERS MA, 1993, EXP LUNG RES, V19, P1, DOI 10.3109/01902149309071077
   Naikwade SR, 2009, AAPS PHARMSCITECH, V10, P993, DOI 10.1208/s12249-009-9290-6
   Okusanya OO, 2009, ANTIMICROB AGENTS CH, V53, P3847, DOI 10.1128/AAC.00872-08
   Otterson GA, 2010, CLIN CANCER RES, V16, P2466, DOI 10.1158/1078-0432.CCR-09-3015
   Park CW, 2011, EUROPEAN PHARM REV, V16, P32
   Parthasarathy R, 1999, CANCER CHEMOTH PHARM, V43, P277, DOI 10.1007/s002800050895
   Patton JS, 2007, NAT REV DRUG DISCOV, V6, P67, DOI 10.1038/nrd2153
   Patton John S, 2004, Proc Am Thorac Soc, V1, P338, DOI 10.1513/pats.200409-049TA
   Perrie Y, 2010, PHARM DRUG DELIVERY
   Pison U, 2006, EUR J PHARMACOL, V533, P341, DOI 10.1016/j.ejphar.2005.12.068
   Rhee YS, 2011, INT J NANOTECHNOL, V8, P84, DOI 10.1504/IJNT.2011.037172
   Rijnders BJ, 2008, CLIN INFECT DIS, V46, P1401, DOI 10.1086/586739
   Ross HJ, 1997, CLIN CANCER RES, V3, P57
   Saari M, 1999, INT J PHARM, V181, P1, DOI 10.1016/S0378-5173(98)00398-6
   Saari SM, 1998, CHEST, V113, P1573, DOI 10.1378/chest.113.6.1573
   Saari SM, 2002, RESP MED, V96, P999, DOI 10.1053/rmed.2002.1393
   Sethuraman V, 2002, AAPS PHARMSCITECH, V3, P28
   Shah SP, 2004, DRUG DELIV, V11, P247, DOI 10.1080/10717540490467375
   Sharafkhaneh Amir, 2010, Int J Chron Obstruct Pulmon Dis, V5, P357, DOI 10.2147/COPD.S4215
   Slobbe L, 2008, PULM PHARMACOL THER, V21, P855, DOI 10.1016/j.pupt.2008.09.001
   Sung JC, 2009, PHARM RES-DORD, V26, P1847, DOI 10.1007/s11095-009-9894-2
   Tagalakis AD, 2008, MOL THER, V16, P907, DOI 10.1038/mt.2008.38
   Takazono T, 2009, ANTIMICROB AGENTS CH, V53, P3508, DOI 10.1128/AAC.00285-09
   TAYLOR KMG, 1993, DRUG DEV IND PHARM, V19, P123, DOI 10.3109/03639049309038764
   THOMAS DA, 1991, CHEST, V99, P1268, DOI 10.1378/chest.99.5.1268
   Verschraegen CF, 2004, CLIN CANCER RES, V10, P2319, DOI 10.1158/1078-0432.CCR-0929-3
   Vyas SP, 2005, INT J PHARM, V296, P12, DOI 10.1016/j.ijpharm.2005.02.003
   Vyas SP, 2004, INT J PHARM, V269, P37, DOI 10.1016/j.ijpharm.2003.08.017
   Vyas SP, 2007, EXPERT OPIN DRUG DEL, V4, P95, DOI 10.1517/17425247.4.2.95
   Waldrep JC, 1997, INT J PHARM, V152, P27, DOI 10.1016/S0378-5173(97)04912-0
   WALDREP JC, 1993, INT J PHARM, V97, P205, DOI 10.1016/0378-5173(93)90140-B
   Waldrep JC, 1998, INT J PHARM, V160, P239, DOI 10.1016/S0378-5173(97)00322-0
   Weers J, 2009, J AEROSOL MED PULM D, V22, P131, DOI 10.1089/jamp.2008.0693
   WEINSTEIN JN, 1984, PHARMACOL THERAPEUT, V24, P207, DOI 10.1016/0163-7258(84)90035-4
   World Health Organization, 2011, GLOB TUB CONTR
   Wijagkanalan W, 2008, MOL PHARMACOL, V74, P1183, DOI 10.1124/mol.108.050153
   Wittgen BPH, 2007, CLIN CANCER RES, V13, P2414, DOI 10.1158/1078-0432.CCR-06-1480
   Wu XA, 2011, INT J NANOTECHNOL, V8, P115, DOI 10.1504/IJNT.2011.037173
   WYDE PR, 1988, ANTIMICROB AGENTS CH, V32, P890, DOI 10.1128/AAC.32.6.890
   Xu J., 2010, NATL VITAL STAT REP, V58, P1
   Zakharian TY, 2005, J AM CHEM SOC, V127, P12508, DOI 10.1021/ja0546525
   Zaru M, 2009, J LIPOSOME RES, V19, P68, DOI 10.1080/08982100802610835
   Zhang J, 2011, ADV DRUG DELIVER REV, V63, P441, DOI 10.1016/j.addr.2010.11.002
   Zou YY, 2000, CANCER GENE THER, V7, P683, DOI 10.1038/sj.cgt.7700156
NR 115
TC 46
Z9 50
U1 0
U2 62
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0341-2040
J9 LUNG
JI Lung
PD JUN
PY 2012
VL 190
IS 3
BP 251
EP 262
DI 10.1007/s00408-011-9360-x
PG 12
WC Respiratory System
SC Respiratory System
GA 935PM
UT WOS:000303531900001
PM 22274758
DA 2018-03-20
ER

PT J
AU Poudel, PP
   Chen, J
   Cammers, A
AF Poudel, Pramod Prasad
   Chen, Jing
   Cammers, Arthur
TI Intramolecular pi-Stacking in Isostructural Conformational Probes
   Depends Strongly on Charge Separation, a Proton NMR Study
SO EUROPEAN JOURNAL OF ORGANIC CHEMISTRY
LA English
DT Article
DE pi-Stacking; Solution state; Crystalline state; Conformation; NMR
   anisotropy
ID CHEMICAL-SHIFT SIMULATION; FACE AROMATIC INTERACTIONS; ARENE-ARENE
   INTERACTIONS; RING CURRENT METHOD; TO-FACE; N-BENZYL-2-PHENYLPYRIDINIUM
   BROMIDE; CRYSTALLOGRAPHIC EVIDENCE; LINKER COMPOUNDS; SOLID-STATE;
   MOLECULES
AB Our Solution state conformational methods used previously to study a dicationic molecular template for intramolecular aromatic association were applied to a neutral hydrocarbon analogue to probe the effect of charge on conformation. Conformational analysis of the hydrocarbon revealed modest solvent dependence in largely unfolded molecules. Conformations found in the solid state were unfolded also corroborating the findings of the solution-state study. This study also adds solid-state evidence for three competing solution-state conformers previously predicted by calculations. In the absence of charge, the molecular template does not favor intramolecular association of aromatic substituents. These results agree with the chemical literature and previous reports of neutral hydrocarbon intramolecular association in the solution state.
C1 [Poudel, Pramod Prasad; Cammers, Arthur] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
   [Chen, Jing] Univ Kentucky, Coll Pharm, Lexington, KY 40536 USA.
RP Poudel, PP (reprint author), Univ Kentucky, Dept Chem, Chem Phys Bldg,505 Rose St, Lexington, KY 40506 USA.
EM a.cammers@ukv.edu
RI Cammers, Arthur/B-8681-2013
OI Cammers, Arthur/0000-0002-1682-3488
FU National Science Foundation USA [0111578]
FX The anthers thank the National Science Foundation USA (# 0111578) for
   funding this research: we are also grateful to the University of
   Kentucky's Center for Computational Sciences.
CR Alkorta I, 1998, NEW J CHEM, V22, P381, DOI 10.1039/a708743h
   Anslyn E. V., 2006, MODERN PHYS ORGANIC
   Avasthi K, 1998, INDIAN J CHEM B, V37, P754
   Avasthi K, 2005, J MOL STRUCT, V750, P179, DOI 10.1016/j.molstruc.2005.04.033
   Avasthi K, 2007, J MOL STRUCT, V827, P88, DOI 10.1016/j.molstruc.2006.05.022
   BEGA S, 2008, CHEM PHYS LETT, V455, P98
   Bello P, 2004, J PHYS ORG CHEM, V17, P71, DOI 10.1002/poc.694
   Bhayana B, 2007, ANGEW CHEM INT EDIT, V46, P6833, DOI 10.1002/anie.200700932
   Chen J, 2003, TETRAHEDRON LETT, V44, P1503, DOI 10.1016/S0040-4039(02)02793-4
   Chen J, 2003, EUR J ORG CHEM, P3861, DOI 10.1002/ejoc.200300302
   Coates GW, 1997, ANGEW CHEM INT EDIT, V36, P248, DOI 10.1002/anie.199702481
   Coates GW, 1998, J AM CHEM SOC, V120, P3641, DOI 10.1021/ja974072a
   Cockroft SL, 2007, ORG BIOMOL CHEM, V5, P1062, DOI 10.1039/b617576g
   Cockroft SL, 2006, CHEM COMMUN, P3806, DOI 10.1039/b608165g
   Cockroft SL, 2005, J AM CHEM SOC, V127, P8594, DOI 10.1021/ja050880n
   FUKAZAWA Y, 1995, TETRAHEDRON LETT, V36, P3349, DOI 10.1016/0040-4039(95)00538-N
   Fukazawa Y, 1999, TETRAHEDRON LETT, V40, P3591, DOI 10.1016/S0040-4039(99)00580-8
   FUKAZAWA Y, 1994, J AM CHEM SOC, V116, P8169, DOI 10.1021/ja00097a026
   Fukazawa Y, 1997, J SYN ORG CHEM JPN, V55, P1124, DOI 10.5059/yukigoseikyokaishi.55.1124
   FUKAZAWA Y, 1988, J AM CHEM SOC, V110, P8692, DOI 10.1021/ja00234a018
   Gardner RR, 2000, ORG LETT, V2, P2335, DOI 10.1021/ol006096j
   Gellman SH, 1996, BIOPHYS J, V71, P3523, DOI 10.1016/S0006-3495(96)79547-4
   Gung BW, 2007, J ORG CHEM, V72, P2469, DOI 10.1021/jo062526t
   Gung BW, 2006, J ORG CHEM, V71, P9261, DOI 10.1021/jo061235h
   Gung BW, 2005, J ORG CHEM, V70, P3641, DOI 10.1021/jo050049t
   Heaton NJ, 1998, J AM CHEM SOC, V120, P12371, DOI 10.1021/ja985529z
   Hof F, 2004, ANGEW CHEM INT EDIT, V43, P5056, DOI 10.1002/anie.200460781
   Hunter CA, 2001, J CHEM SOC PERK T 2, P651, DOI 10.1039/b008495f
   Isaacs N., 1995, PHYS ORGANIC CHEM
   Itahara T, 2007, J PHYS CHEM B, V111, P2025, DOI 10.1021/jp0664521
   Iwamoto H, 2001, TETRAHEDRON LETT, V42, P49, DOI 10.1016/S0040-4039(00)01876-1
   Jennings WB, 2001, ACCOUNTS CHEM RES, V34, P885, DOI 10.1021/ar0100475
   KARABATSOS GJ, 1970, TOP STEREOCHEM, V5, P167
   Kim E, 1998, J AM CHEM SOC, V120, P11192, DOI 10.1021/ja982620u
   Klod S, 2001, J CHEM SOC PERK T 2, P1893
   Marsella MJ, 2001, ORG LETT, V3, P885, DOI 10.1021/ol015511k
   Martin CB, 1999, J ORG CHEM, V64, P7807, DOI 10.1021/jo990765t
   Martin CB, 1999, J ORG CHEM, V64, P7802, DOI 10.1021/jo9907641
   Martin NH, 1998, THEOCHEM-J MOL STRUC, V454, P161, DOI 10.1016/S0166-1280(98)00286-3
   MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405
   Morimoto T, 2007, ANGEW CHEM INT EDIT, V46, P3672, DOI 10.1002/anie.200604371
   Mulla HR, 2000, J AM CHEM SOC, V122, P738, DOI 10.1021/ja993363b
   NEWCOMB LF, 1995, J AM CHEM SOC, V117, P6509, DOI 10.1021/ja00129a014
   NEWCOMB LF, 1994, J AM CHEM SOC, V116, P4993, DOI 10.1021/ja00090a057
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Perrin CL, 1998, J AM CHEM SOC, V120, P1044, DOI 10.1021/ja9727272
   Rashkin MJ, 2002, J AM CHEM SOC, V124, P1860, DOI 10.1021/ja016508z
   Ringer AL, 2006, CHEM-EUR J, V12, P3821, DOI 10.1002/chem.200501316
   Schaller T, 2007, J AM CHEM SOC, V129, P1293, DOI 10.1021/ja0666351
   Sheldrick G.M., 1997, SHELX97 PROGRAMS CRY
   Shetty AS, 1996, J AM CHEM SOC, V118, P1019, DOI 10.1021/ja9528893
   Sindkhedkar MD, 2000, J AM CHEM SOC, V122, P9271, DOI 10.1021/ja0003270
   Sinnokrot MO, 2006, J PHYS CHEM A, V110, P10656, DOI 10.1021/jp0610416
   WILLIAMS JH, 1993, ACCOUNTS CHEM RES, V26, P593, DOI 10.1021/ar00035a005
NR 54
TC 5
Z9 5
U1 7
U2 25
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY
SN 1434-193X
J9 EUR J ORG CHEM
JI Eur. J. Org. Chem.
PD NOV
PY 2008
IS 33
BP 5511
EP 5517
DI 10.1002/ejoc.200800663
PG 7
WC Chemistry, Organic
SC Chemistry
GA 381RN
UT WOS:000261553700003
DA 2018-03-19
ER

PT J
AU Ghosh, K
   Bashadi, S
   Lehmler, HJ
   Rankin, SE
   Knutson, BL
AF Ghosh, Kaustav
   Bashadi, Sarah
   Lehmler, Hans-Joachim
   Rankin, Stephen E.
   Knutson, Barbara L.
TI Pore size engineering in fluorinated surfactant templated mesoporous
   silica powders through supercritical carbon dioxide processing
SO MICROPOROUS AND MESOPOROUS MATERIALS
LA English
DT Article
DE mesoporous silica; pore expansion; supercritical carbon dioxide;
   self-assembly; aging time
ID THIN-FILMS; CONTROLLED-RELEASE; MOLECULAR-SIEVES; FLUID; WATER; CO2;
   FLUOROSURFACTANT; SYSTEMS; DRUG; PH
AB Pore expansion of fluorinated surfactant templated mesoporous silica powders is demonstrated as a function of pressurized CO2 processing conditions. Mesoporous silica powder is synthesized by sol-gel reaction induced precipitation in a base-catalyzed medium using 1-(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluoro-octyl)-pyridinium chloride (HFOPC) as a template and, immediately after filtration, the precipitated material is processed in gaseous and supercritical CO2 (88-344 bar, 45 degrees C) for 48 h. Characterization of the silica powders by XRD, TEM and N-2 adsorption reveals the formation of well-ordered materials with 2D hexagonal close-packed pore structure before and after CO2 processing. An optimal aging time (time from addition of silica precursor to the sol until the filtration of the hydrolyzed 7 sol) of 20 min prior to CO2 processing is identified. Proper aging time results in silica powder with significant pore expansion at all processing pressures while retaining the long-range structure of the material. The pore diameter of the mesoporous material increases with increasing CO2 pressure (from 2.60 nm (unprocessed) to 3.21 nm at 344 bar), but appears to level off above 100 bar. The pore expansion behavior is attributed to favorable CO2 penetration in the 'CO2-philic' fluorinated tails of the surfactant template. The CO2 expansion of base-catalyzed silica powders is significantly less than we previously observed for acid catalyzed, evaporation-driven thin film synthesis using fluorinated cationic surfactant templates. The effect of pH on self-assembly and increased silica condensation in basic conditions may inhibit pore expansion by CO2. (C) 2007 Elsevier Inc. All rights reserved.
C1 [Ghosh, Kaustav; Bashadi, Sarah; Rankin, Stephen E.; Knutson, Barbara L.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Lehmler, Hans-Joachim] Univ Iowa, Dept Environm & Occupat Hlth, Iowa City, IA 52242 USA.
RP Knutson, BL (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM bknutson@engr.uky.edu
RI Rankin, Stephen/A-3265-2013
OI Rankin, Stephen/0000-0002-8615-7564; Lehmler,
   Hans-Joachim/0000-0001-9163-927X
CR ASAKAWA T, 1995, LANGMUIR, V11, P478, DOI 10.1021/la00002a019
   AshrafKhorassani M, 1997, J CHROMATOGR A, V774, P37, DOI 10.1016/S0021-9673(97)00358-0
   BECK JS, 1992, J AM CHEM SOC, V114, P10834, DOI 10.1021/ja00053a020
   Beckman EJ, 2004, CHEM COMMUN, P1885, DOI 10.1039/b404406c
   Beckman EJ, 2004, J SUPERCRIT FLUID, V28, P121, DOI 10.1016/S0896-8446(03)00029-9
   Bein T, 1996, CHEM MATER, V8, P1636, DOI 10.1021/cm960148a
   Blin JL, 2000, LANGMUIR, V16, P4229, DOI 10.1021/la9914615
   BRANTON PJ, 1997, CHARACTERIZATION POR, V4, P668
   Chang SH, 1998, J SUPERCRIT FLUID, V13, P113, DOI 10.1016/S0896-8446(98)00042-4
   Doshi DA, 2000, SCIENCE, V290, P107, DOI 10.1126/science.290.5489.107
   FLETCHER PDI, 1985, J CHEM SOC FARAD T 1, V81, P2667, DOI 10.1039/f19858102667
   Fuertes AB, 2005, ELECTROCHIM ACTA, V50, P2799, DOI 10.1016/j.electacta.2004.11.027
   GARG A, 1994, MACROMOLECULES, V27, P5643, DOI 10.1021/ma00098a019
   Gelb LD, 1999, REP PROG PHYS, V62, P1573, DOI 10.1088/0034-4885/62/12/201
   Ghosh K, 2005, LANGMUIR, V21, P6145, DOI 10.1021/la050311t
   Ghosh K, 2007, J PHYS CHEM B, V111, P363, DOI 10.1021/jp0656680
   Guney O, 2002, AICHE J, V48, P856, DOI 10.1002/aic.690480419
   Hanrahan JP, 2005, LANGMUIR, V21, P4163, DOI 10.1021/la0470636
   Hanrahan JP, 2004, CHEM MATER, V16, P424, DOI 10.1021/cm034882n
   Holmes JD, 1998, LANGMUIR, V14, P6371, DOI 10.1021/la9806956
   Huang MH, 2002, CHEM MATER, V14, P5153, DOI 10.1021/cm0207043
   Hwang YK, 2005, MICROPOR MESOPOR MAT, V78, P245, DOI 10.1016/j.micromeso.2004.10.026
   Jacobson GB, 1999, J ORG CHEM, V64, P1201, DOI 10.1021/jo981825i
   Kimura T, 1998, CHEM COMMUN, P559, DOI 10.1039/a708463c
   Koga T, 2003, MACROMOLECULES, V36, P5236, DOI 10.1021/ma021265w
   Kruk M, 1997, LANGMUIR, V13, P6267, DOI 10.1021/la970776m
   Kruk M, 2001, CHEM MATER, V13, P3169, DOI 10.1021/cm0101069
   Lee S, 2006, J MICROENCAPSUL, V23, P741, DOI 10.1080/09687860600945552
   Liu H, 2005, LANGMUIR, V21, P379, DOI 10.1021/la047934b
   Liu NG, 2004, NANO LETT, V4, P551, DOI 10.1021/nl0350783
   Lu XB, 2003, IND ENG CHEM RES, V42, P653, DOI 10.1021/ie020422c
   Lu YF, 2001, NATURE, V410, P913, DOI 10.1038/35073544
   Ma YR, 2003, COLLOID SURFACE A, V229, P1, DOI 10.1016/j.colsurfa.2003.08.010
   Nicole L, 2004, CHEM COMMUN, P2312, DOI 10.1039/b408869g
   Niemeyer ED, 1998, J PHYS CHEM B, V102, P1474, DOI 10.1021/jp973157v
   *NIST, 2003, NIST CHEM WEBB NIST
   Osei-Prempeh G, 2005, MICROPOR MESOPOR MAT, V85, P16, DOI 10.1016/j.micromeso.2005.06.014
   Pai RA, 2004, SCIENCE, V303, P507, DOI 10.1126/science.1092627
   Pathak P, 2004, J AM CHEM SOC, V126, P10842, DOI 10.1021/ja046914t
   Qu FY, 2006, J SOLID STATE CHEM, V179, P2027, DOI 10.1016/j.jssc.2006.04.002
   Shah PS, 2004, J PHYS CHEM B, V108, P9574, DOI 10.1021/jp049827w
   Sirard SM, 2001, J PHYS CHEM B, V105, P766, DOI 10.1021/jp002592d
   Tan B, 2005, CHEM MATER, V17, P916, DOI 10.1021/cm048991t
   Tan B, 2004, LANGMUIR, V20, P6981, DOI 10.1021/la049474s
   TAN B, 2005, NANOTECHNOLOGY, V16, P8502
   TOEWS KL, 1995, ANAL CHEM, V67, P4040, DOI 10.1021/ac00118a002
   UNGER KK, 1988, CHARACTERIZATION POR
   VANGRIEKEN R, 2002, LANGMUIR, V6, P10
   Wang K, 1999, J PHYS CHEM B, V103, P9237, DOI 10.1021/jp990821u
   Wang K, 2000, LANGMUIR, V16, P1042, DOI 10.1021/la9909603
   YAZDI AV, 1995, J MATER RES, V10, P530, DOI 10.1557/JMR.1995.0530
   ZANG J, 2003, LANGMUIR, V19, P7616
   Zhang Y, 1997, J SUPERCRIT FLUID, V11, P115, DOI 10.1016/S0896-8446(97)00031-4
   Ziegler KJ, 2003, J SUPERCRIT FLUID, V27, P109, DOI 10.1016/S0896-8446(02)00231-0
NR 54
TC 5
Z9 5
U1 1
U2 21
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1387-1811
J9 MICROPOR MESOPOR MAT
JI Microporous Mesoporous Mat.
PD AUG 1
PY 2008
VL 113
IS 1-3
BP 106
EP 113
DI 10.1016/j.micromeso.2007.11.017
PG 8
WC Chemistry, Applied; Chemistry, Physical; Nanoscience & Nanotechnology;
   Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA 322GB
UT WOS:000257362100014
DA 2018-03-20
ER

PT J
AU Fugit, KD
   Anderson, BD
AF Fugit, Kyle D.
   Anderson, Bradley D.
TI The role of pH and ring-opening hydrolysis kinetics on liposomal release
   of topotecan
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Liposomes; Nanotechnology; Topotecan; Kinetics; Membrane binding;
   Permeability
ID CONVECTION-ENHANCED DELIVERY; BILAYER-LIPID MEMBRANE; ADVANCED SOLID
   TUMORS; PHYSICAL STABILITY; RIGOROUS THEORY; ONCOLOGY-GROUP;
   ION-TRANSPORT; IN-VIVO; PHASE-I; DRUG
AB The use of liposomal delivery systems for the treatment of cancer has been extensively researched because of their passive targeting to the vasculature of solid tumors. While their potential to provide prolonged retention and high drug encapsulation is desirable for anticancer agents, a mechanistic understanding is required to optimize and design liposomal drug delivery systems capable of controllable release tailored to tumor type and patient. Topotecan (TPT) is a topoisomerase I inhibitor that undergoes reversible, pH-sensitive ring-opening hydrolysis. TPT may benefit from liposomal formulation using active loading strategies to generate low intravesicular pH to prolong drug retention and increase drug encapsulation. This paper develops a mathematical model to describe TPT's permeability as a function of pH by accounting for the drug's ionization state, membrane binding, and ring-opening interconversion kinetics. Studies were conducted to determine the acid dissociation constant of TPT's phenolic -OH and interconversion kinetics between TPT's lactone and carboxylate forms. Using the constants determined from these studies and release studies conducted at varying pH, permeability coefficients and membrane binding constants for each species of TPT were determined. Based on this model, three permeable species were observed. Interestingly, the two most permeable species were zwitterionic forms of TPT, and the permeability of the lactone zwitterion was comparable to that of the neutral form of another camptothecin analogue. Furthermore, release was affected by based-catalyzed interconversion kinetics between TPT's lactone and carboxylate forms. At neutral pH, release was rate-limited by formation of the TPT lactone from the ring-opened carboxylate form. Based on these findings, the developed model describing liposomal release of TPT may be used in the future to evaluate and optimize loading and subsequent release of liposomal TPT formulations utilizing active loading strategies. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Fugit, Kyle D.; Anderson, Bradley D.] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40506 USA.
RP Anderson, BD (reprint author), Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, A323A ASTeCC Bldg, Lexington, KY 40506 USA.
EM bande2@uky.edu
FU National Cancer Institute [R25CA153954]
FX The project described was supported by Grant Number R25CA153954 from the
   National Cancer Institute. The content is solely the responsibility of
   the authors and does not necessarily represent the official views of the
   National Cancer Institute or the National Institutes of Health. The
   authors thank Laura Cheng for her aid in data collection.
CR Abraham SA, 2004, J CONTROL RELEASE, V96, P449, DOI 10.1016/j.jconrel.2004.02.017
   Batist G, 2009, CLIN CANCER RES, V15, P692, DOI 10.1158/1078-0432.CCR-08-0515
   Bemporad D, 2005, BBA-BIOMEMBRANES, V1718, P1, DOI 10.1016/j.bbamem.2005.07.009
   Bruce JN, 2011, NEUROSURGERY, V69, P1272, DOI 10.1227/NEU.0b013e3182233e24
   CEH B, 1995, LANGMUIR, V11, P3356, DOI 10.1021/la00009a016
   Ceh B, 1997, J COLLOID INTERF SCI, V185, P9, DOI 10.1006/jcis.1996.4555
   Charrois GJR, 2003, BBA-BIOMEMBRANES, V1609, P102, DOI 10.1016/S0005-2736(02)00661-2
   CHONN A, 1992, J BIOL CHEM, V267, P18759
   Clerc S, 1998, ANAL BIOCHEM, V259, P104, DOI 10.1006/abio.1998.2639
   Deeken JF, 2013, CANCER CHEMOTH PHARM, V71, P627, DOI 10.1007/s00280-012-2048-y
   Drummond DC, 2008, J PHARM SCI-US, V97, P4696, DOI 10.1002/jps.21358
   Drummond DC, 2010, J CONTROL RELEASE, V141, P13, DOI 10.1016/j.jconrel.2009.08.006
   EPSTEIN J, 1964, J AM CHEM SOC, V86, P4959, DOI 10.1021/ja01076a043
   FASSBERG J, 1992, J PHARM SCI, V81, P676, DOI 10.1002/jps.2600810718
   Fugit K.D., 2013, DYNAMIC NONSIN UNPUB
   Gabizon AA, 2002, J DRUG TARGET, V10, P535, DOI 10.1080/1061186021000043061
   GRIT M, 1992, CHEM PHYS LIPIDS, V62, P113, DOI 10.1016/0009-3084(92)90089-8
   GRIT M, 1993, CHEM PHYS LIPIDS, V64, P3, DOI 10.1016/0009-3084(93)90053-6
   GRIT M, 1989, INT J PHARM, V50, P1, DOI 10.1016/0378-5173(89)90173-7
   HARAN G, 1993, BIOCHIM BIOPHYS ACTA, V1151, P201, DOI 10.1016/0005-2736(93)90105-9
   Heimburg T, 2010, BIOPHYS CHEM, V150, P2, DOI 10.1016/j.bpc.2010.02.018
   Huang C. H. A, 1993, BIOCHEMISTRY-MOSCOW, V32, P11
   Vijay Joguparthi B.D.A., 2008, J PHARM SCI, V97, P433
   Vijay Joguparthi T.-X.X., 2008, J PHARM SCI, V97, P400
   Joguparthi V, 2008, INT J PHARM, V352, P17, DOI 10.1016/j.ijpharm.2007.10.003
   Kaspers GJL, 2013, J CLIN ONCOL, V31, P599, DOI 10.1200/JCO.2012.43.7384
   Kearney AS, 1996, INT J PHARM, V127, P229, DOI 10.1016/0378-5173(95)04218-0
   Kehrer DFS, 2001, ANTI-CANCER DRUG, V12, P89, DOI 10.1097/00001813-200102000-00002
   Kirpotin DB, 2006, CANCER RES, V66, P6732, DOI 10.1158/0008-5472.CAN-05-4199
   KODATI VR, 1993, BIOPHYS J, V64, P163, DOI 10.1016/S0006-3495(93)81351-1
   Koudelka S, 2012, J CONTROL RELEASE, V163, P322, DOI 10.1016/j.jconrel.2012.09.006
   Liu JJ, 2002, ANTI-CANCER DRUG, V13, P709, DOI 10.1097/00001813-200208000-00005
   Maeda H, 2001, ADV ENZYME REGUL, V41, P189, DOI 10.1016/S0065-2571(00)00013-3
   Mamot C, 2012, LANCET ONCOL, V13, P1234, DOI 10.1016/S1470-2045(12)70476-X
   Maurer-Spurej E, 1999, BBA-BIOMEMBRANES, V1416, P1, DOI 10.1016/S0005-2736(98)00204-1
   MAYER LD, 1990, BIOCHIM BIOPHYS ACTA, V1025, P143, DOI 10.1016/0005-2736(90)90091-2
   McGonigle KF, 2011, CANCER-AM CANCER SOC, V117, P3731, DOI 10.1002/cncr.25967
   Modi S, 2012, J CONTROL RELEASE, V162, P330, DOI 10.1016/j.jconrel.2012.07.001
   Montanari M, 2012, TUMORI, V98, P696, DOI 10.1700/1217.13491
   Noble CO, 2006, CANCER RES, V66, P2801, DOI 10.1158/0008-5472.CAN-05-3535
   O'Brien S, 2013, J CLIN ONCOL, V31, P676, DOI 10.1200/JCO.2012.46.2309
   Patankar NA, 2013, INVEST NEW DRUG, V31, P46, DOI 10.1007/s10637-012-9832-8
   Potter SLP, 2012, PEDIATR BLOOD CANCER, V58, P362, DOI 10.1002/pbc.23317
   Ramsay E, 2006, PHARM RES, V23, P2799, DOI 10.1007/s11095-006-9111-5
   Ramsay EC, 2008, CLIN CANCER RES, V14, P1208, DOI 10.1168/1078-0432.CCR-07-0780
   Romiti A., 2013, CANCER CHEMOTH PHARM, P1
   di Nunzio MR, 2012, J PHYS CHEM B, V116, P7522, DOI 10.1021/jp302923a
   Rose PG, 2012, GYNECOL ONCOL, V125, P158, DOI 10.1016/j.ygyno.2011.12.431
   Santana VM, 2003, CLIN CANCER RES, V9, P633
   Shirai O, 2006, ANAL BIOANAL CHEM, V386, P494, DOI 10.1007/s00216-006-0435-0
   Shirai O, 2006, J ELECTROANAL CHEM, V595, P53, DOI 10.1016/j.jelechem.2006.06.001
   Strel'tsov SA, 2001, MOL BIOL+, V35, P365, DOI 10.1023/A:1010422711817
   Taggar AS, 2006, J CONTROL RELEASE, V114, P78, DOI 10.1016/j.jconrel.2006.05.019
   Tejwani RW, 2009, J PHARM SCI-US, V98, P4534, DOI 10.1002/jps.21775
   Xiang TX, 1998, BIOPHYS J, V75, P2658, DOI 10.1016/S0006-3495(98)77711-2
   Xiang TX, 1997, BIOPHYS J, V72, P223, DOI 10.1016/S0006-3495(97)78661-2
   Xiang TX, 2002, PHARMACEUT RES, V19, P1215, DOI 10.1023/A:1019862629357
   YUAN F, 1994, CANCER RES, V54, P3352
   Zucker D, 2009, J CONTROL RELEASE, V139, P73, DOI 10.1016/j.jconrel.2009.05.036
   ZUIDAM NJ, 1995, J PHARM SCI, V84, P1113, DOI 10.1002/jps.2600840915
   [Anonymous], 2006, NCI CANC DRUG INFORM
NR 61
TC 18
Z9 18
U1 0
U2 37
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD JAN 28
PY 2014
VL 174
BP 88
EP 97
DI 10.1016/j.jconrel.2013.11.003
PG 10
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 293IL
UT WOS:000329964500011
PM 24231406
OA green_accepted
DA 2018-03-20
ER

PT J
AU Clark, J
   Naga, K
   Geddes, J
AF Clark, Jordan
   Naga, Kranthi Kumari
   Geddes, James W.
TI Cyclophilin D knockout, excitotoxic insult, and spinal cord injury
SO JOURNAL OF NEUROTRAUMA
LA English
DT Meeting Abstract
CT 26th Annual National-Neurotrauma-Society Symposium
CY JUL 27-30, 2008
CL Orlando, FL
SP Natl Neurotrauma Soc
C1 [Clark, Jordan; Naga, Kranthi; Geddes, James] Univ Kentucky, Lexington, KY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0897-7151
J9 J NEUROTRAUM
JI J. Neurotrauma
PD JUL
PY 2008
VL 25
IS 7
MA P84
BP 874
EP 874
PG 1
WC Critical Care Medicine; Clinical Neurology; Neurosciences
SC General & Internal Medicine; Neurosciences & Neurology
GA 326BX
UT WOS:000257634000094
DA 2018-03-20
ER

PT J
AU Ng, G
   Sharma, K
   Ward, SM
   Desrosiers, MD
   Stephens, LA
   Schoel, M
   Li, TL
   Lowell, CA
   Ling, CC
   Amrein, MW
   Shi, Y
AF Ng, Gilbert
   Sharma, Karan
   Ward, Sandra M.
   Desrosiers, Melanie D.
   Stephens, Leslie A.
   Schoel, Michael
   Li, Tonglei
   Lowell, Clifford A.
   Ling, Chang-Chun
   Amrein, Matthias W.
   Shi, Yan
TI Receptor-independent, lipid dependent mechanism of Syk kinase activation
   in dendritic cells
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
C1 [Ng, Gilbert; Sharma, Karan; Desrosiers, Melanie D.; Stephens, Leslie A.; Shi, Yan] Univ Calgary, Microbiol & Infect Dis, Calgary, AB, Canada.
   [Ward, Sandra M.; Ling, Chang-Chun] Univ Calgary, Chem, Calgary, AB, Canada.
   [Schoel, Michael; Amrein, Matthias W.] Univ Calgary, Biol & Anat, Calgary, AB, Canada.
   [Li, Tonglei] Univ Kentucky, Pharmaceut Sci, Lexington, KY USA.
   [Lowell, Clifford A.] Univ Calif San Francisco, Lab Med, San Francisco, CA 94143 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD APR 1
PY 2009
VL 182
SU 1
MA 134.71
PG 1
WC Immunology
SC Immunology
GA V44QN
UT WOS:000209763602292
DA 2018-03-20
ER

PT J
AU Su, X
   Wu, J
   Hinds, BJ
AF Su, Xin
   Wu, Ji
   Hinds, Bruce J.
TI Nanoscale Bubble Valves on MWCNT Membranes for Chemical Energy Storage
SO ADVANCED MATERIALS INTERFACES
LA English
DT Editorial Material
DE energy storage; MWCNT membranes; membranes; nanoscale bubbles; valves
ID CARBON NANOTUBE MEMBRANES; REDOX-FLOW BATTERY; WATER; NANOBUBBLES;
   SURFACE; GROWTH
C1 [Su, Xin; Wu, Ji; Hinds, Bruce J.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Hinds, Bruce J.] Univ Washington, Dept Mat Engn, Seattle, WA 98105 USA.
RP Hinds, BJ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM bjhinds@uw.edu
RI WU, JI/J-4580-2016; Su, Xin/M-1162-2013
OI Su, Xin/0000-0002-1615-2856
CR Andrews R, 2002, ACCOUNTS CHEM RES, V35, P1008, DOI 10.1021/ar010151m
   Abreu SBE, 2012, LANGMUIR, V28, P7360, DOI 10.1021/la300352f
   Che GL, 1998, NATURE, V393, P346, DOI 10.1038/30694
   Dai LM, 2012, SMALL, V8, P1130, DOI 10.1002/smll.201101594
   Ducker WA, 2009, LANGMUIR, V25, P8907, DOI 10.1021/la902011v
   Hinds BJ, 2004, SCIENCE, V303, P62, DOI 10.1126/science.1092048
   Holt JK, 2006, SCIENCE, V312, P1034, DOI 10.1126/science.1126298
   Huang CW, 2009, NANO LETT, V9, P4297, DOI 10.1021/nl902529y
   Ishida N, 2000, LANGMUIR, V16, P6377, DOI 10.1021/la000219r
   Li LY, 2011, ADV ENERGY MATER, V1, P394, DOI 10.1002/aenm.201100008
   Ljunggren S, 1997, COLLOID SURFACE A, V129, P151, DOI 10.1016/S0927-7757(97)00033-2
   Majumder M, 2005, NATURE, V438, P44, DOI 10.1038/43844a
   Majumder M, 2007, LANGMUIR, V23, P8624, DOI 10.1021/la700686k
   Meng DD, 2008, LAB CHIP, V8, P958, DOI 10.1039/b719918j
   METZ WD, 1978, SCIENCE, V200, P1471, DOI 10.1126/science.200.4349.1471
   Nagaraju DH, 2014, ADV ENERGY MATER, V4, DOI 10.1002/aenm.201300443
   Presser V, 2012, ADV ENERGY MATER, V2, P895, DOI 10.1002/aenm.201100768
   Slifka AJ, 2010, APPL PHYS EXPRESS, V3, DOI 10.1143/APEX.3.065103
   Smeets RMM, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.088101
   Swinnen S, 2010, CHEM PHYS LETT, V489, P148, DOI 10.1016/j.cplett.2010.02.060
   Tas NR, 2002, ANAL CHEM, V74, P2224, DOI 10.1021/ac011117o
   Tyrrell JWG, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.176104
   Wang W, 2012, ADV ENERGY MATER, V2, P487, DOI 10.1002/aenm.201100527
   Wei XL, 2013, ADV ENERGY MATER, V3, P1215, DOI 10.1002/aenm.201201112
   Weijs JH, 2013, PHYS REV LETT, V110, DOI 10.1103/PhysRevLett.110.054501
   Wu J, 2010, P NATL ACAD SCI USA, V107, P11698, DOI 10.1073/pnas.1004714107
   Xia XH, 2014, SMALL, V10, P766, DOI 10.1002/smll.201302224
   Zhang LJ, 2006, LANGMUIR, V22, P8109, DOI 10.1021/la060859f
   Zhang XH, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.136101
   Zhang XH, 2008, LANGMUIR, V24, P4756, DOI 10.1021/la703475q
   Zhao Y, 2013, ADV ENERGY MATER, V3, P1630, DOI 10.1002/aenm.201300627
NR 31
TC 1
Z9 1
U1 1
U2 17
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2196-7350
J9 ADV MATER INTERFACES
JI Adv. Mater. Interfaces
PD NOV 9
PY 2015
VL 2
IS 16
AR 1500102
DI 10.1002/admi.201500102
PG 4
WC Chemistry, Multidisciplinary; Materials Science, Multidisciplinary
SC Chemistry; Materials Science
GA DB0VC
UT WOS:000368224600001
DA 2018-03-20
ER

PT J
AU Scott, D
   Cao, PX
   Rohr, J
   Bae, Y
AF Scott, Daniel F.
   Cao, Pengxiao
   Rohr, Juergen
   Bae, Younsoo
TI In vivo evaluation of mithramycin analog nanoformulations
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
C1 [Scott, Daniel] Depauw Univ, Greencastle, IN 46135 USA.
   [Scott, Daniel; Cao, Pengxiao; Rohr, Jurgen; Bae, Younsoo] Univ Kentucky, Coll Pharm, Lexington, KY USA.
EM danielscott@depauw.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD MAR 22
PY 2015
VL 249
MA 395
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA VA9RR
UT WOS:000411186504504
DA 2018-03-19
ER

PT J
AU Song, ES
   Melikishvili, M
   Fried, MG
   Juliano, MA
   Juliano, L
   Rodgers, DW
   Hersh, LB
AF Song, Eun Suk
   Melikishvili, Manana
   Fried, Michael Gregory
   Juliano, Maria A.
   Juliano, Luiz
   Rodgers, David W.
   Hersh, Louis B.
TI Cysteine 904 Is Required for Maximal Insulin Degrading Enzyme Activity
   and Polyanion Activation
SO PLOS ONE
LA English
DT Article
ID MOLECULAR-BASIS; SUBSTRATE; RECOGNITION
AB Cysteine residues in insulin degrading enzyme have been reported as non-critical for its activity. We found that converting the twelve cysteine residues in rat insulin degrading enzyme (IDE) to serines resulted in a cysteine-free form of the enzyme with reduced activity and decreased activation by polyanions. Mutation of each cysteine residue individually revealed cysteine 904 as the key residue required for maximal activity and polyanion activation, although other cysteines affect polyanion binding to a lesser extent. Based on the structure of IDE, Asn 575 was identified as a potential hydrogen bond partner for Cys904 and mutation of this residue also reduced activity and decreased polyanion activation. The oligomerization state of IDE did not correlate with its activity, with the dimer being the predominant form in all the samples examined. These data suggest that there are several conformational states of the dimer that affect activity and polyanion activation.
C1 [Song, Eun Suk; Melikishvili, Manana; Fried, Michael G.; Rodgers, David W.; Hersh, Louis B.] Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40506 USA.
   [Song, Eun Suk; Melikishvili, Manana; Fried, Michael G.; Rodgers, David W.; Hersh, Louis B.] Univ Kentucky, Struct Biol Ctr, Lexington, KY USA.
   [Juliano, Maria A.; Juliano, Luiz] Univ Fed Sao Paulo, Dept Biophys, Escola Paulista Med, Sao Paulo, Brazil.
RP Hersh, LB (reprint author), Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40506 USA.
EM lhersh@uky.edu
RI Fluidos Complexos, INCT/H-9172-2013; Juliano, Luiz/D-7204-2012
OI Juliano, Luiz/0000-0002-5589-2822
FU United States National Institutes of Health [DA02243, AG19323, NS38041,
   DK54289]; Fundacao de Amparo Pesquisa do Estado de Sao Paulo FAPESP;
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)
FX This work was supported in part by United States National Institutes of
   Health grants DA02243 (to L. B. H), AG19323 (to L. B. H), NS38041 (to D.
   W. R), DK54289 (to M. G. F), Fundacao de Amparo Pesquisa do Estado de
   Sao Paulo FAPESP (to L.J and M.A.J), Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq) (to L.J and M.A.J). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Abdul-Hay SO, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020818
   Csuhai E, 1999, ANAL BIOCHEM, V269, P149, DOI 10.1006/abio.1999.4033
   Dam J, 2004, METHOD ENZYMOL, V384, P185
   Guo Q, 2010, J MOL BIOL, V395, P430, DOI 10.1016/j.jmb.2009.10.072
   Im H, 2007, J BIOL CHEM, V282, P25453, DOI 10.1074/jbc.M701590200
   Kim M, 2007, J BIOL CHEM, V282, P7825, DOI 10.1074/jbc.M609168200
   Laue T., 1992, ANAL ULTRACENTRIFUGA, P90
   Leissring MA, 2003, NEURON, V40, P1087, DOI 10.1016/S0896-6273(03)00787-6
   Li QX, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011327
   Malito E, 2008, BIOCHEMISTRY-US, V47, P12822, DOI 10.1021/bi801192h
   Manolopoulou M, 2009, J BIOL CHEM, V284, P14177, DOI 10.1074/jbc.M900068200
   Miller BC, 2003, P NATL ACAD SCI USA, V100, P6221, DOI 10.1073/pnas.1031520100
   Neant-Fery M, 2008, P NATL ACAD SCI USA, V105, P9582, DOI 10.1073/pnas.0801261105
   Noinaj N, 2012, J BIOL CHEM, V287, P48, DOI 10.1074/jbc.M111.264614
   Noinaj N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020864
   Ralat LA, 2011, J MOL BIOL, V406, P454, DOI 10.1016/j.jmb.2010.12.026
   Ralat LA, 2011, J BIOL CHEM, V286, P4670, DOI 10.1074/jbc.M110.173252
   Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0
   Shen YQ, 2006, NATURE, V443, P870, DOI 10.1038/nature05143
   Song ES, 2004, J BIOL CHEM, V279, P54216, DOI 10.1074/jbc.M411177200
   Song ES, 2001, J BIOL CHEM, V276, P1152, DOI 10.1074/jbc.M008702200
NR 21
TC 3
Z9 3
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 15
PY 2012
VL 7
IS 10
AR e46790
DI 10.1371/journal.pone.0046790
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 022WO
UT WOS:000309995100040
PM 23077523
OA gold
DA 2018-03-20
ER

PT J
AU Singh, R
   Brewer, MK
   Mashburn, CB
   Lou, DY
   Bondada, V
   Graham, B
   Geddes, JW
AF Singh, Ranjana
   Brewer, M. Kathryn
   Mashburn, Charles B.
   Lou, Dingyuan
   Bondada, Vimala
   Graham, Brantley
   Geddes, James W.
TI Calpain 5 Is Highly Expressed in the Central Nervous System (CNS),
   Carries Dual Nuclear Localization Signals, and Is Associated with
   Nuclear Promyelocytic Leukemia Protein Bodies
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID NEURONAL INTRANUCLEAR INCLUSIONS; PROSTATE-CANCER CELLS; IMPORTIN-ALPHA;
   SUBCELLULAR-LOCALIZATION; MU-CALPAIN; GENE; CLEAVAGE; DOMAINS; BRAIN;
   IDENTIFICATION
AB Calpain 5 (CAPN5) is a non-classical member of the calpain family. It lacks the EF hand motif characteristic of classical calpains but retains catalytic and Ca2+ binding domains, and it contains a unique C-terminal domain. TRA-3, an ortholog of CAPN5, has been shown to be involved in necrotic cell death in Caenorhabditis elegans. CAPN5 is expressed throughout the CNS, but its expression relative to other calpains and subcellular distribution has not been investigated previously. Based on relative mRNA levels, Capn5 is the second most highly expressed calpain in the rat CNS, with Capn2 mRNA being the most abundant. Unlike classical calpains, CAPN5 is a non-cytosolic protein localized to the nucleus and extra-nuclear locations. CAPN5 possesses two nuclear localization signals (NLS): an N-terminal monopartite NLS and a unique bipartite NLS closer to the C terminus. The C-terminal NLS contains a SUMO-interacting motif that contributes to nuclear localization, and mutation or deletion of both NLS renders CAPN5 exclusively cytosolic. Dual NLS motifs are common among transcription factors. Interestingly, CAPN5 is found in punctate domains associated with promyelocytic leukemia (PML) protein within the nucleus. PML nuclear bodies are implicated in transcriptional regulation, cell differentiation, cellular response to stress, viral defense, apoptosis, and cell senescence as well as protein sequestration, modification, and degradation. The roles of nuclear CAPN5 remain to be determined.
C1 [Singh, Ranjana; Brewer, M. Kathryn; Mashburn, Charles B.; Lou, Dingyuan; Bondada, Vimala; Graham, Brantley; Geddes, James W.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA.
   [Singh, Ranjana; Geddes, James W.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA.
RP Geddes, JW (reprint author), Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, 741 S Limestone St, Lexington, KY 40536 USA.
EM jgeddes@uky.edu
FU National Institutes of Health [P01NS058484, P30NS051220]; Kentucky
   Spinal Cord and Head Injury Research Trust
FX This work was supported, in whole or in part, by National Institutes of
   Health Grants P01NS058484 and P30NS051220. This work was also supported
   by the Kentucky Spinal Cord and Head Injury Research Trust.
CR Arrington DD, 2006, AM J PHYSIOL-CELL PH, V291, pC1159, DOI 10.1152/ajpcell.00207.2006
   Azam M, 2001, MOL CELL BIOL, V21, P2213, DOI 10.1128/MCB.21.6.2213-2220.2001
   Barnes TM, 1996, EMBO J, V15, P4477
   Bernardi R, 2007, NAT REV MOL CELL BIO, V8, P1006, DOI 10.1038/nrm2277
   Bhat RV, 1996, GLIA, V17, P169
   BIGNAMI A, 1974, J COMP NEUROL, V153, P27, DOI 10.1002/cne.901530104
   Borden KLB, 2002, MOL CELL BIOL, V22, P5259, DOI 10.1128/MCB.22.15.5259-5269.2002
   Brameier M, 2007, BIOINFORMATICS, V23, P1159, DOI 10.1093/bioinformatics/btm066
   de The H, 2012, J CELL BIOL, V198, P11, DOI 10.1083/jcb.201112044
   Dear N, 1997, GENOMICS, V45, P175, DOI 10.1006/geno.1997.4870
   Dundr M, 2012, CURR OPIN CELL BIOL, V24, P415, DOI 10.1016/j.ceb.2012.03.010
   Fischer U, 1997, CELL, V90, P1023, DOI 10.1016/S0092-8674(00)80368-2
   Forwood JK, 2001, J BIOL CHEM, V276, P46575, DOI 10.1074/jbc.M101668200
   Franco SJ, 2005, J CELL SCI, V118, P3829, DOI 10.1242/jcs.02562
   Franz T, 2004, MOL CELL BIOL, V24, P1649, DOI 10.1128/MCB.24.4.1649-1654.2004
   Fu LW, 2005, NEUROBIOL DIS, V20, P656, DOI 10.1016/j.nbd.2005.05.015
   Gafni J, 2004, J BIOL CHEM, V279, P20211, DOI 10.1074/jbc.M401267200
   Garcia M, 2005, BIOCHEM BIOPH RES CO, V338, P1241, DOI 10.1016/j.bbrc.2005.10.081
   Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002
   Gonzalez A, 2006, HUM REPROD, V21, P943, DOI 10.1093/humrep/dei443
   GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0
   Haacke A, 2007, J BIOL CHEM, V282, P18851, DOI 10.1074/jbc.M611914200
   Horton P, 2007, NUCLEIC ACIDS RES, V35, pW585, DOI 10.1093/nar/gkm259
   Hubener J, 2013, HUM MOL GENET, V22, P508, DOI 10.1093/hmg/dds449
   Joyce PI, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002602
   KAGEYAMA GH, 1982, NEUROSCIENCE, V7, P2337, DOI 10.1016/0306-4522(82)90199-3
   Kaur G, 2011, FASEB J, V25, P665, DOI 10.1096/fj.10-173351
   Kaytor MD, 1999, HUM MOL GENET, V8, P1657, DOI 10.1093/hmg/8.9.1657
   Kim MH, 2003, EXP NEUROL, V183, P109, DOI 10.1016/S0014-4886(03)00132-8
   Konig N, 2003, J CHEM NEUROANAT, V25, P129, DOI 10.1016/S0891-0618(02)00102-3
   Kosugi S, 2009, J BIOL CHEM, V284, P478, DOI 10.1074/jbc.M807017200
   Lallemand-Breitenbach V, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000661
   Lange A, 2007, J BIOL CHEM, V282, P5101, DOI 10.1074/jbc.R600026200
   Libertini SJ, 2007, CANCER RES, V67, P9001, DOI 10.1158/0008-5472.CAN-07-1072
   Lin DY, 2006, MOL CELL, V24, P341, DOI 10.1016/j.molcel.2006.10.019
   Liu Q, 1996, EMBO J, V15, P3555
   Liu XL, 2004, ANNU REV PHARMACOL, V44, P349, DOI 10.1146/annurev.pharmtox.44.101802.121804
   Ma H, 2001, J BIOL CHEM, V276, P28525, DOI 10.1074/jbc.M100603200
   Mahajan VB, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003001
   Maki M, 2012, FEBS J, V279, P1414, DOI 10.1111/j.1742-4658.2012.08560.x
   Marfori M, 2011, BBA-MOL CELL RES, V1813, P1562, DOI 10.1016/j.bbamcr.2010.10.013
   Matena K, 1998, GENOMICS, V48, P117, DOI 10.1006/geno.1997.5133
   Mellgren RL, 2007, J BIOL CHEM, V282, P2567, DOI 10.1074/jbc.M604560200
   Moore MW, 2005, E SCHERING RES FDN W, V50, P27
   MULLEN RJ, 1992, DEVELOPMENT, V116, P201
   MURAYAMA A, 1984, J BIOCHEM-TOKYO, V95, P1697, DOI 10.1093/oxfordjournals.jbchem.a134783
   Nardozzi JD, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-32
   Ono Y, 2012, BBA-PROTEINS PROTEOM, V1824, P224, DOI 10.1016/j.bbapap.2011.08.005
   Ozaki T, 2009, BBA-MOL CELL RES, V1793, P1848, DOI 10.1016/j.bbamcr.2009.10.002
   Pagni M, 2007, NUCLEIC ACIDS RES, V35, pW433, DOI 10.1093/nar/gkm352
   Palmeri D, 1999, MOL CELL BIOL, V19, P1218
   Pang XD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091025
   Pelley RP, 2006, CANCER RES, V66, P11754, DOI 10.1158/0008-5472.CAN-06-2918
   Penna I, 2008, MOL HUM REPROD, V14, P613, DOI 10.1093/molehr/gan055
   Raynaud F, 2008, INT J DEV BIOL, V52, P383, DOI 10.1387/ijdb.072448fr
   ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T
   Saez ME, 2008, CARDIOVASC DIABETOL, V7, DOI 10.1186/1475-2840-7-23
   Saez ME, 2007, BMC MED GENET, V8, DOI 10.1186/1471-2350-8-1
   Santiago A, 2009, CELL CYCLE, V8, P76, DOI 10.4161/cc.8.1.7493
   Santos DM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033468
   Schilling B, 2006, J BIOL CHEM, V281, P23686, DOI 10.1074/jbc.M513507200
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Seilhean D, 2004, ACTA NEUROPATHOL, V108, P81, DOI 10.1007/s00401-004-0855-x
   Shen TH, 2006, MOL CELL, V24, P331, DOI 10.1016/j.molcel.2006.09.013
   Shin SJ, 2004, PROTEOMICS, V4, P3359, DOI 10.1002/pmic.200400961
   Simoes AT, 2012, BRAIN, V135, P2428, DOI 10.1093/brain/aws177
   Skinner PJ, 1997, NATURE, V389, P971
   Sorimachi H, 2011, P JPN ACAD B-PHYS, V87, P287, DOI 10.2183/pjab.87.287
   Sternsdorf T, 1999, J BIOL CHEM, V274, P12555, DOI 10.1074/jbc.274.18.12555
   STUURMAN N, 1992, J CELL SCI, V101, P773
   Sudbeck P, 1997, J BIOL CHEM, V272, P27848, DOI 10.1074/jbc.272.44.27848
   Suzuki K, 2004, DIABETES, V53, pS12, DOI 10.2337/diabetes.53.2007.S12
   Syntichaki P, 2002, NATURE, V419, P939, DOI 10.1038/nature01108
   Takahashi J, 2003, NEUROBIOL DIS, V13, P230, DOI 10.1016/S0969-9961(03)-00080-9
   Takahashi J, 2002, BRAIN, V125, P1534, DOI 10.1093/brain/awf154
   Tirard M, 2012, P NATL ACAD SCI USA, V109, P21122, DOI 10.1073/pnas.1215366110
   Truant R, 1999, MOL CELL BIOL, V19, P1210
   Waghray A, 2004, BIOCHEM BIOPH RES CO, V324, P46, DOI 10.1016/j.bbrc.2004.09.012
   Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4
   Wang LJ, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-S1-S3
   Xue Y, 2006, NUCLEIC ACIDS RES, V34, pW254, DOI 10.1093/nar/gkl207
   Yamada M, 2001, AM J PATHOL, V159, P1785, DOI 10.1016/S0002-9440(10)63025-8
   Yamada M, 2001, ANN NEUROL, V49, P14, DOI 10.1002/1531-8249(200101)49:1<14::AID-ANA5>3.0.CO;2-X
   Yang HJ, 2008, J CELL PHYSIOL, V217, P569, DOI 10.1002/jcp.21565
   Yeurl PL, 2008, J CELL BIOCHEM, V103, P456, DOI 10.1002/jcb.21408
   YOSHIMURA N, 1984, J BIOL CHEM, V259, P9847
NR 86
TC 9
Z9 9
U1 0
U2 12
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUL 11
PY 2014
VL 289
IS 28
BP 19383
EP 19394
DI 10.1074/jbc.M114.575159
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AL7PL
UT WOS:000339326800015
PM 24838245
OA gold
DA 2018-03-20
ER

PT J
AU Gupta, P
   Authimoolam, SP
   Hilt, JZ
   Dziubla, TD
AF Gupta, Prachi
   Authimoolam, Sundar P.
   Hilt, J. Zach
   Dziubla, Thomas D.
TI Quercetin conjugated poly(beta-amino esters) nanogels for the treatment
   of cellular oxidative stress
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Oxidative stress; Antioxidants; Nanogels; Poly(beta-amino esters);
   Endothelial cells; Quercetin
ID DELIVERY; DAMAGE; NANOPARTICLES; ANTIOXIDANTS; INFLAMMATION;
   DISPOSITION; MECHANISMS; SYSTEMS; INJURY; RATS
AB P beta AE polymers have emerged as highly promising candidates for biomedical and drug delivery applications owing to their tunable, degradable and pH sensitive properties. These polymeric systems can serve as prodrug carriers for the delivery of bioactive compounds which suffer from poor aqueous solubility, low bioavailability and are biologically unstable, such as the antioxidant, quercetin. Using acrylate functionalized quercetin, it is possible to incorporate the polyphenol into the backbone of the polymer matrix, permitting slow release of the intact molecule which is perfectly timed with the polymer degradation. While formulating these quercetin conjugated P beta AE matrix into nanocarriers would allow for multiple delivery routes (oral, intravenous, inhalation etc.), well known oil-water nano-emulsion formulation methods are not amenable to the crosslinked hydrolytically sensitive nanoparticle/nanogel. In this work, a single-phase reaction-precipitation method was developed to formulate quercetin conjugated P beta AE nanogels (QNG) via reaction of acrylated quercetin (4-5 acrylate groups) with a secondary diamine under dilute conditions using acetonitrile as the reaction medium, resulting in a self-stabilized suspension. The proposed approach permits the post synthesis modification of the spherical nanogels with a PEGylated coating, enhancing their aqueous stability and stealth characteristics. Nanogel size was controlled by varying feed reactant concentrations, achieving drug loadings of 25-38 wt%. Uniform release of quercetin over 45-48 h was observed upon P beta AE ester hydrolysis under physiological conditions with its retained antioxidant activity over the extended times.
   Statement of Significance
   Here we present the first demonstration of using poly(beta amino ester) chemistry to form nanogels composed of a bioactive polyphenol for the control of cellular oxidative stress. Previous nanogel and nanoparticle approaches, which use a water phase, are not readily amenable to P beta AE chemistry due to their hydrolytic sensitivity. Here we demonstrate a simple approach to control particle size, modify surface chemistry and achieve highly regulated controlled release of active antioxidants, which can protect cells against external oxidative stress signals. This work has importance in the area of controlling material biocompatibility through augmenting the antioxidant status of cells. (C) 2015 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Gupta, Prachi; Authimoolam, Sundar P.; Hilt, J. Zach; Dziubla, Thomas D.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Dziubla, TD (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM dziubla@engr.uky.edu
FU Office of Naval Research (ONR DEPSCoR); National Center for Research
   Resources; National Center for Advancing Translational Sciences,
   National Institutes of Health [UL1TR000117]
FX The project described was supported by a grant from the Office of Naval
   Research (ONR DEPSCoR) and the National Center for Research Resources
   and the National Center for Advancing Translational Sciences, National
   Institutes of Health, through Grant UL1TR000117. The content is solely
   the responsibility of the authors and does not necessarily represent the
   official views of the Office of Naval Research or the NIH.
CR Anand P, 2007, MOL PHARM, V4, P807, DOI 10.1021/mp700113r
   Bhalla DK, 1999, J TOXICOL ENV HEAL B, V2, P31, DOI 10.1080/109374099281232
   Bose S, 2013, EUR J PHARM SCI, V48, P442, DOI 10.1016/j.ejps.2012.12.005
   Brey DM, 2008, ACTA BIOMATER, V4, P207, DOI 10.1016/j.actbio.2007.10.002
   Bucki R, 2003, J THROMB HAEMOST, V1, P1820, DOI 10.1046/j.1538-7836.2003.00294.x
   Canas P E, 1999, Acta Physiol Pharmacol Ther Latinoam, V49, P13
   Elms AR, 2011, INT J EMERG MED, V4, DOI 10.1186/1865-1380-4-54
   Fang R, 2011, J NANOBIOTECHNOL, V9, DOI 10.1186/1477-3155-9-19
   Galisteo M, 2004, MOL CELL BIOCHEM, V259, P91, DOI 10.1023/B:MCBI.0000021360.89867.64
   Ghibu S, 2012, BIOCHIMIE, V94, P932, DOI 10.1016/j.biochi.2011.02.015
   GUGLER R, 1975, EUR J CLIN PHARMACOL, V9, P229, DOI 10.1007/BF00614022
   Halliwell B, 2013, BRIT J CLIN PHARMACO, V75, P637, DOI 10.1111/j.1365-2125.2012.04272.x
   HOLDINESS MR, 1991, CLIN PHARMACOKINET, V20, P123, DOI 10.2165/00003088-199120020-00004
   Hollman PCH, 1996, FREE RADICAL BIO MED, V21, P703, DOI 10.1016/0891-5849(96)00129-3
   Huang DJ, 2005, J AGR FOOD CHEM, V53, P1841, DOI 10.1021/jf030723c
   Jacobs H, 2011, FREE RADICAL BIO MED, V51, P2118, DOI 10.1016/j.freeradbiomed.2011.09.013
   Jain AK, 2013, MOL PHARMACEUT, V10, P3459, DOI 10.1021/mp400311j
   Kerksick Chad, 2005, J Int Soc Sports Nutr, V2, P38, DOI 10.1186/1550-2783-2-2-38
   KOREN HS, 1995, ENVIRON HEALTH PERSP, V103, P235, DOI 10.2307/3432379
   Lamson D W, 2000, Altern Med Rev, V5, P196
   Lao LL, 2011, INT J PHARMACEUT, V418, P28, DOI 10.1016/j.ijpharm.2010.12.020
   Lee ES, 2003, J PHARM PHARMACOL, V55, P1169, DOI 10.1211/002357021396
   Lynn DM, 2000, J AM CHEM SOC, V122, P10761, DOI 10.1021/ja0015388
   Magalhaes LM, 2008, ANAL CHIM ACTA, V613, P1, DOI 10.1016/j.aca.2008.02.047
   Mc Bath RA, 2010, POLYM CHEM-UK, V1, P860, DOI 10.1039/c0py00074d
   Meenach SA, 2012, INT J PHARMACEUT, V427, P177, DOI 10.1016/j.ijpharm.2012.01.052
   Naito Y, 1998, DIGEST DIS SCI, V43, p30S
   Nyska A, 2002, TOXICOL PATHOL, V30, P620, DOI 10.1080/01926230290166724
   PENTLAND AP, 1994, ADV EXP MED BIOL, V366, P87
   Perez-Vizcaino F, 2009, PHARMACOL REP, V61, P67, DOI 10.1016/S1734-1140(09)70008-8
   Poulsen HE, 2005, EXP TOXICOL PATHOL, V57, P161, DOI 10.1016/j.etp.2005.05.015
   RICHTER C, 1995, BBA-MOL BASIS DIS, V1271, P67, DOI 10.1016/0925-4439(95)00012-S
   Rigg JL, 2005, J HEAD TRAUMA REHAB, V20, P389, DOI 10.1097/00001199-200507000-00010
   RITGER P L, 1987, Journal of Controlled Release, V5, P23, DOI 10.1016/0168-3659(87)90034-4
   SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771
   Simone E, 2010, METHODS MOL BIOL, V610, P145, DOI 10.1007/978-1-60327-029-8_9
   Steinberg D, 2002, CIRCULATION, V105, P2107, DOI 10.1161/01.CIR.0000014762.06201.06
   Wattamwar PP, 2012, ACTA BIOMATER, V8, P2529, DOI 10.1016/j.actbio.2012.03.022
   Wattamwar PP, 2010, ADV FUNCT MATER, V20, P147, DOI 10.1002/adfm.200900839
   Wilczewska AZ, 2012, PHARMACOL REP, V64, P1020, DOI 10.1016/S1734-1140(12)70901-5
   Zhou AL, 2008, J AGR FOOD CHEM, V56, P12081, DOI 10.1021/jf802413v
NR 41
TC 12
Z9 12
U1 2
U2 49
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742-7061
EI 1878-7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD NOV
PY 2015
VL 27
BP 194
EP 204
DI 10.1016/j.actbio.2015.08.039
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA CU8VK
UT WOS:000363822000017
PM 26318804
OA green_accepted
DA 2018-03-20
ER

PT J
AU Oz, HS
   Puleo, DA
AF Oz, Helieh S.
   Puleo, David A.
TI Animal Models for Periodontal Disease
SO JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
LA English
DT Review
ID ALVEOLAR BONE LOSS; LIGATURE-INDUCED PERIODONTITIS; GINGIVAL CREVICULAR
   FLUID; MURINE LESION MODEL; PORPHYROMONAS-GINGIVALIS;
   ACTINOBACILLUS-ACTINOMYCETEMCOMITANS; FUSOBACTERIUM-NUCLEATUM; HOST
   RESPONSE; INFLAMMATORY DISEASES; ANTIOXIDANT CAPACITY
AB Animal models and cell cultures have contributed new knowledge in biological sciences, including periodontology. Although cultured cells can be used to study physiological processes that occur during the pathogenesis of periodontitis, the complex host response fundamentally responsible for this disease cannot be reproduced in vitro. Among the animal kingdom, rodents, rabbits, pigs, dogs, and nonhuman primates have been used to model human periodontitis, each with advantages and disadvantages. Periodontitis commonly has been induced by placing a bacterial plaque retentive ligature in the gingival sulcus around the molar teeth. In addition, alveolar bone loss has been induced by inoculation or injection of human oral bacteria ( e. g., Porphyromonas gingivalis) in different animal models. While animal models have provided a wide range of important data, it is sometimes difficult to determine whether the findings are applicable to humans. In addition, variability in host responses to bacterial infection among individuals contributes significantly to the expression of periodontal diseases. A practical and highly reproducible model that truly mimics the natural pathogenesis of human periodontal disease has yet to be developed.
C1 [Oz, Helieh S.] Univ Kentucky, Coll Dent, Med Ctr, Ctr Oral Hlth Res, Lexington, KY 40536 USA.
   [Puleo, David A.] Univ Kentucky, Ctr Biomed Engn, Lexington, KY 40506 USA.
RP Oz, HS (reprint author), Univ Kentucky, Coll Dent, Med Ctr, Ctr Oral Hlth Res, Lexington, KY 40536 USA.
EM helieh.oz@uky.edu
FU National Institutes of Health [NIDCR-DE019177]; National Science
   Foundation [EPS-0814194]
FX This research was partially supported by grants from National Institutes
   of Health NIDCR-DE019177 (HO) and National Science Foundation,
   EPS-0814194 (DP).
CR Alayan J, 2007, J PERIODONTAL RES, V42, P97, DOI 10.1111/j.1600-0765.2006.00920.x
   Anthony J, 2010, J VET DENT, V27, P12, DOI 10.1177/089875641002700102
   Ardite E, 2000, LAB INVEST, V80, P735, DOI 10.1038/labinvest.3780077
   BAKER PJ, 1994, ARCH ORAL BIOL, V39, P1035, DOI 10.1016/0003-9969(94)90055-8
   BARON R, 1978, J PERIODONTAL RES, V13, P309, DOI 10.1111/j.1600-0765.1978.tb00185.x
   Beertsen W, 2008, J IMMUNOL, V180, P475, DOI 10.4049/jimmunol.180.1.475
   Breivik T, 2000, EUR J ORAL SCI, V108, P115, DOI 10.1034/j.1600-0722.2000.00774.x
   Bretz WA, 2005, J AM GERIATR SOC, V53, P1532, DOI 10.1111/j.1532-5415.2005.53468.x
   Brown LJ, 2002, PERIODONTOL 2000, V29, P223, DOI 10.1034/j.1600-0757.2002.290111.x
   Cai X, 2008, J PERIODONTAL RES, V43, P14, DOI 10.1111/j.1600-0765.2007.00989.x
   Chapple ILC, 2002, J CLIN PATHOL-MOL PA, V55, P367
   Chapple ILC, 1997, J CLIN PERIODONTOL, V24, P287, DOI 10.1111/j.1600-051X.1997.tb00760.x
   Chen PB, 1996, ORAL MICROBIOL IMMUN, V11, P274, DOI 10.1111/j.1399-302X.1996.tb00181.x
   Chen YK, 2010, EXPERT REV ANTICANC, V10, P1485, DOI [10.1586/era.10.108, 10.1586/ERA.10.108]
   de Pablo P, 2009, NAT REV RHEUMATOL, V5, P218, DOI 10.1038/nrrheum.2009.28
   Desvarieux M, 2005, CIRCULATION, V111, P576, DOI 10.1161/01.CIR.0000154582.37101.15
   DICK DS, 1966, ARCH ORAL BIOL, V11, P1095, DOI 10.1016/0003-9969(66)90167-1
   Ebersole J L, 1994, Periodontol 2000, V5, P112, DOI 10.1111/j.1600-0757.1994.tb00021.x
   EBERSOLE JL, 1991, INFECT IMMUN, V59, P3351
   EGELBERG J, 1965, Odontol Revy, V16, P31
   ENGLAND DC, 1954, GROWTH, V18, P207
   ENWONWU CO, 1994, J CLIN PERIODONTOL, V21, P643, DOI 10.1111/j.1600-051X.1994.tb00782.x
   ENWONWU CO, 1995, AM J CLIN NUTR, V61, p430S
   EVANS RT, 1992, ARCH ORAL BIOL, V37, P813, DOI 10.1016/0003-9969(92)90115-O
   Feuille F, 1996, INFECT IMMUN, V64, P2095
   Fiorucci S, 2002, IMMUNITY, V17, P769, DOI 10.1016/S1074-7613(02)00476-4
   GarciaLafuente A, 1997, AM J PHYSIOL-GASTR L, V272, pG10
   Garlet GP, 2004, J CLIN PERIODONTOL, V31, P671, DOI 10.1111/j.1600-051X.2004.00545.x
   Graves DT, 2008, J CLIN PERIODONTOL, V35, P89, DOI 10.1111/j.1600-051X.2007.01172.x
   GUPTA O. P., 1956, ORAL SURG ORAL MED AND ORAL PATHOL, V9, P592, DOI 10.1016/0030-4220(56)90319-X
   Gustafsson A, 1996, J CLIN PERIODONTOL, V23, P38, DOI 10.1111/j.1600-051X.1996.tb00502.x
   HAMP SE, 1972, J PERIODONTAL RES, P13
   HANEY JM, 1995, J CLIN PERIODONTOL, V22, P208
   Hojo K, 2008, BIOSCI BIOTECH BIOCH, V72, P1348, DOI 10.1271/bbb.70653
   Holt SC, 2005, PERIODONTOL 2000, V38, P72, DOI 10.1111/j.1600-0757.2005.00113.x
   HOLT SC, 1988, SCIENCE, V239, P55, DOI 10.1126/science.3336774
   HOLT SC, 1995, ORAL MICROBIOL IMMUN, V10, P321, DOI 10.1111/j.1399-302X.1995.tb00162.x
   Kesavalu L, 1997, MICROB PATHOGENESIS, V23, P317, DOI 10.1006/mpat.1997.0161
   Kesavalu L, 2007, ORAL MICROBIOL IMMUN, V22, P232, DOI 10.1111/j.1399-302X.2007.00346.x
   KESAVALU L, 1992, INFECT IMMUN, V60, P1455
   Kesavalu L, 1996, MICROB PATHOGENESIS, V20, P1, DOI 10.1006/mpat.1996.0001
   Kesavalu L, 1998, ORAL MICROBIOL IMMUN, V13, P373, DOI 10.1111/j.1399-302X.1998.tb00694.x
   Kesavalu L, 2007, INFECT IMMUN, V75, P1704, DOI 10.1128/IAI.00733-06
   KEY LL, 1994, BONE, V15, P431, DOI 10.1016/8756-3282(94)90821-4
   KIM HS, 1992, SCAND J GASTROENTERO, V27, P529, DOI 10.3109/00365529209000116
   Kinane DF, 2009, J CLIN PERIODONTOL, V36, P404, DOI 10.1111/j.1600-051X.2009.01396.x
   KING J D, 1947, Br Dent J, V83, ppassim
   Kirkwood KL, 2007, PERIODONTOL 2000, V43, P294, DOI 10.1111/j.1600-0757.2006.00166.x
   KLAUSEN B, 1991, J PERIODONTOL, V62, P59, DOI 10.1902/jop.1991.62.1.59
   KLAUSEN B, 1991, ARCH ORAL BIOL, V36, P685, DOI 10.1016/0003-9969(91)90022-M
   KORNMAN KS, 1981, J PERIODONTAL RES, V16, P363, DOI 10.1111/j.1600-0765.1981.tb00987.x
   KOWASHI Y, 1980, J PERIODONTAL RES, V15, P152
   Kuriyama T, 2000, MICROBES INFECT, V2, P1425, DOI 10.1016/S1286-4579(00)01296-X
   Kwon DH, 2010, J CLIN PERIODONTOL, V37, P390, DOI 10.1111/j.1600-051X.2010.01546.x
   LEONARD EP, 1979, AM J PATHOL, V96, P643
   Li KL, 1996, J PERIODONTAL RES, V31, P525, DOI 10.1111/j.1600-0765.1996.tb00516.x
   Liu PF, 2009, VACCINE, V27, P1589, DOI 10.1016/j.vaccine.2008.12.058
   MADDEN TE, 1994, METHOD ENZYMOL, V235, P106
   MAKI E, 1990, Aichi-Gakuin Journal of Dental Science, V28, P283
   MILLER WA, 1975, J PERIODONTOL, V46, P368, DOI 10.1902/jop.1975.46.6.368
   Nakajima K, 2006, J PERIODONTAL RES, V41, P527, DOI 10.1111/j.1600-0765.2006.00901.x
   Novak EA, 2010, INFECT IMMUN, V78, P2919, DOI 10.1128/IAI.01376-09
   Ohkawara T, 2002, GASTROENTEROLOGY, V123, P256, DOI 10.1053/gast.2002.34236
   Oortgiesen DAW, 2010, TISSUE ENG PART C-ME, V16, P133, DOI [10.1089/ten.tec.2009.0191, 10.1089/ten.TEC.2009.0191]
   Oz HS, 2010, J PERIODONTAL RES, V45, P94, DOI 10.1111/j.1600-0765.2009.01207.x
   Oz HS, 2008, MOLECULES, V13, P452, DOI 10.3390/molecules13020452
   Oz HS, 2007, TRANSL RES, V150, P122, DOI 10.1016/j.trsl.2006.12.010
   Oz HS, 2010, DIGEST DIS SCI, V55, P2194, DOI 10.1007/s10620-009-1031-x
   Oz HS, 2005, J NUTR BIOCHEM, V16, P297, DOI 10.1016/j.jnutbio.2004.09.007
   Oz HS, 2005, MED SCI MONITOR, V11, pBR69
   PAGE RC, 1981, J PERIODONTOL, V52, P60, DOI 10.1902/jop.1981.52.2.60
   Pavlica Z, 2004, AM J VET RES, V65, P1584, DOI 10.2460/ajvr.2004.65.1584
   PERSSON GR, 1993, J PERIODONTAL RES, V28, P294, DOI 10.1111/j.1600-0765.1993.tb02096.x
   Pierce DL, 2009, INFECT IMMUN, V77, P3294, DOI 10.1128/IAI.00262-09
   Pihlstrom BL, 2005, LANCET, V366, P1809, DOI 10.1016/S0140-6736(05)67728-8
   Polak D, 2009, J CLIN PERIODONTOL, V36, P406, DOI 10.1111/j.1600-051X.2009.01393.x
   Polejaeva IA, 2000, NATURE, V407, P86, DOI 10.1038/35024082
   ROETERINK CH, 1984, J PERIODONTAL RES, V19, P292, DOI 10.1111/j.1600-0765.1984.tb00820.x
   Salvi GE, 2005, J CLIN PERIODONTOL, V32, P108, DOI 10.1111/j.1600-051X.2005.00785.x
   Schenkein HA, 2006, PERIODONTOL 2000, V40, P77, DOI 10.1111/j.1600-0757.2005.00144.x
   SCHOU S, 1993, J PERIODONTOL, V64, P497, DOI 10.1902/jop.1993.64.6.497
   Sfakianakis A, 2001, EUR J ORAL SCI, V109, P393, DOI 10.1034/j.1600-0722.2001.00162.x
   Sharma CGD, 2006, J PERIODONTOL, V77, P1674, DOI 10.1902/jop.2006.060016
   SHAW JH, 1969, J DENT RES, V48, P486, DOI 10.1177/00220345690480033001
   SHAW JH, 1961, J DENT RES, V40, P614, DOI 10.1177/00220345610400033001
   Struillou X, 2010, OPEN DENTISTRY J, V29, P37
   Taubman M A, 1988, Adv Dent Res, V2, P328
   Taubman MA, 2005, J PERIODONTOL, V76, P2033, DOI 10.1902/jop.2005.76.11-S.2033
   TAUBMAN MA, 1983, J PERIODONTAL RES, V18, P393, DOI 10.1111/j.1600-0765.1983.tb00375.x
   TOTH A, 1986, J DENT RES, V65, P695, DOI 10.1177/00220345860650051301
   Tyrrell KL, 2002, J CLIN MICROBIOL, V40, P1044, DOI 10.1128/JCM.40.3.1044-1047.2002
   Waddington RJ, 2000, ORAL DIS, V6, P138
   Wang S, 2007, ORAL DIS, V13, P530, DOI 10.1111/j.1601-0825.2006.01337.x
   Weinberg MA, 1999, J CLIN PERIODONTOL, V26, P335, DOI 10.1034/j.1600-051X.1999.260601.x
   WEINREB M, 1994, J PERIODONTAL RES, V29, P35, DOI 10.1111/j.1600-0765.1994.tb01088.x
   WIKESJO UME, 1994, J PERIODONTOL, V65, P1151, DOI 10.1902/jop.1994.65.12.1151
   Xiong X, 2006, BJOG-INT J OBSTET GY, V113, P135, DOI 10.1111/j.1471-0528.2005.00827.x
   YAMASHITA K, 1991, INFECT IMMUN, V59, P1529
   Yoshimura M, 2008, ORAL MICROBIOL IMMUN, V23, P413, DOI 10.1111/j.1399-302X.2008.00444.x
   Yu JJ, 2007, BLOOD, V109, P3794, DOI 10.1182/blood-2005-09-010116
NR 100
TC 53
Z9 54
U1 0
U2 20
PU HINDAWI PUBLISHING CORPORATION
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 1110-7243
J9 J BIOMED BIOTECHNOL
JI J. Biomed. Biotechnol.
PY 2011
AR 754857
DI 10.1155/2011/754857
PG 8
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA 744LU
UT WOS:000289096800001
OA gold
DA 2018-03-20
ER

PT J
AU Dickerson, M
   Winquist, N
   Bae, Y
AF Dickerson, Matthew T.
   Winquist, Nickolas
   Bae, Younsoo
TI Photo-Inducible Crosslinked Nanoassemblies for pH-Controlled Drug
   Release
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE crosslinked nanoassemblies; drug carriers; drug delivery; nanoparticles;
   polymer micelles
ID POLYMERIC MICELLES; CANCER-THERAPY; ANTICANCER DRUGS; IONIC CORES;
   DELIVERY; NANOPARTICLES; DESIGN; CARRIERS; SYSTEMS; CHEMOTHERAPY
AB To control drug release from block copolymer nanoassemblies by variation in the degree of photo-crosslinking and inclusion of acid sensitive linkers.
   Poly(ethylene glycol)-poly(aspartate-hydrazide-cinnamate) (PEG-CNM) block copolymers were prepared and conjugated with a model drug, doxorubicin (DOX), through acid sensitive hydrazone linkers. The block copolymers formed photo-inducible, self-assembled nanoassemblies (piSNAs), which were used to produce photo-inducible crosslinked nanoassemblies (piCNAs) through UV crosslinking. The nanoassemblies were characterized to determine particle size, surface charge, pH- and crosslinking-dependent DOX release, in vitro cytotoxicity, and intracellular uptake as a function of photo-crosslinking degree.
   Nanoassemblies with varying photo-crosslinking degrees were successfully prepared while retaining particle size and surface charge. Photo-crosslinking caused no noticeable change in DOX release from the nanoassemblies at pH 7.4, but the DOX-loaded nanoassemblies modulated drug release as a function of crosslinking at pH 6.0. The nanoassemblies showed similar cytotoxicity regardless of crosslinking degrees, presumably due to the low cellular uptake and cell nucleus drug accumulation.
   Photo-crosslinking is useful to control drug release from pH-sensitive block copolymer nanoassemblies as a function of crosslinking without altering the particle properties, and thus providing unique tools to investigate the pharmaceutical effects of drug release on cellular response.
C1 [Dickerson, Matthew; Winquist, Nickolas; Bae, Younsoo] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
RP Bae, Y (reprint author), Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, 789 South Limestone, Lexington, KY 40536 USA.
EM younsoo.bae@uky.edu
FU NCI/NIH; National Cancer Institute Alliance for Nanotechnology
   [5R25CA153954]
FX MD acknowledges the University of Kentucky Cancer Nanotechnology
   Training Center (UK-CNTC) postdoctoral traineeship, supported by the
   NCI/NIH and part of the National Cancer Institute Alliance for
   Nanotechnology in Cancer (5R25CA153954).
CR Albanese A, 2012, ANNU REV BIOMED ENG, V14, P1, DOI [10.1146/annurev-bioeng-071811-150124, 10.1146/annurev.bioeng-071811-150124]
   Ali AH, 1998, J APPL POLYM SCI, V67, P441, DOI 10.1002/(SICI)1097-4628(19980118)67:3<441::AID-APP6>3.0.CO;2-M
   Anraku Y, 2011, CHEM COMMUN, V47, P6054, DOI 10.1039/c1cc11465d
   Atkins JH, 2002, NAT REV DRUG DISCOV, V1, P491, DOI 10.1038/nrd842
   Bae Y, 2005, MOL BIOSYST, V1, P242, DOI 10.1039/b500266d
   Bae Y, 2003, ANGEW CHEM INT EDIT, V42, P4640, DOI 10.1002/anie.200250653
   Bandak S, 1999, PHARMACEUT RES, V16, P841, DOI 10.1023/A:1018869818282
   Bontha S, 2006, J CONTROL RELEASE, V114, P163, DOI 10.1016/j.jconrel.2006.06.015
   Bourzac K, 2012, NATURE, V491, pS58, DOI 10.1038/491S58a
   Brannon-Peppas L, 2012, ADV DRUG DELIVER REV, V64, P206, DOI 10.1016/j.addr.2012.09.033
   Brigger I, 2012, ADV DRUG DELIVER REV, V64, P24, DOI 10.1016/j.addr.2012.09.006
   Cheng ZL, 2012, SCIENCE, V338, P903, DOI 10.1126/science.1226338
   Davis ME, 2008, NAT REV DRUG DISCOV, V7, P771, DOI 10.1038/nrd2614
   He CB, 2010, BIOMATERIALS, V31, P3657, DOI 10.1016/j.biomaterials.2010.01.065
   Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902
   Imai K, 2006, NAT REV CANCER, V6, P714, DOI 10.1038/nrc1913
   Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772
   Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6
   Jones AT, 2003, ADV DRUG DELIVER REV, V55, P1353, DOI 10.1016/j.addr.2003.07.002
   Kawabata-Shoda E, 2012, J CLIN PHARM THER, V37, P547, DOI 10.1111/j.1365-2710.2012.01332.x
   Kell DB, 2011, DRUG DISCOV TODAY, V16, P704, DOI 10.1016/j.drudis.2011.05.010
   Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167
   Kim JO, 2010, BIOMACROMOLECULES, V11, P919, DOI 10.1021/bm9013364
   Lee HJ, 2013, PHARM RES-DORDR, V30, P478, DOI 10.1007/s11095-012-0893-3
   Lee HJ, 2011, BIOMACROMOLECULES, V12, P2686, DOI 10.1021/bm200483t
   Lee HJ, 2010, THER DELIV, V1, P803, DOI 10.4155/TDE.10.70
   Li YL, 2010, CHEM COMMUN, V46, P121, DOI 10.1039/b916559b
   Maeda H, 2011, ADV DRUG DELIVER REV, V63, P129, DOI 10.1016/j.addr.2010.05.001
   Maeda H, 2010, BIOCONJUGATE CHEM, V21, P797, DOI 10.1021/bc100070g
   Mahon E, 2012, J CONTROL RELEASE, V161, P164, DOI 10.1016/j.jconrel.2012.04.009
   Matsumura Y, 2009, CANCER SCI, V100, P572, DOI 10.1111/j.1349-7006.2009.01103.x
   Mizutani H, 2005, LIFE SCI, V76, P1439, DOI 10.1016/j.lfs.2004.05.040
   O'Reilly RK, 2006, J POLYM SCI POL CHEM, V44, P5203, DOI 10.1002/pola.21602
   Oberoi HS, 2011, J CONTROL RELEASE, V153, P64, DOI 10.1016/j.jconrel.2011.03.028
   Oerlemans C, 2010, PHARM RES-DORDR, V27, P2569, DOI 10.1007/s11095-010-0233-4
   Peer D, 2007, NAT NANOTECHNOL, V2, P751, DOI 10.1038/nnano.2007.387
   Perrault SD, 2009, NANO LETT, V9, P1909, DOI 10.1021/nl900031y
   Petros RA, 2010, NAT REV DRUG DISCOV, V9, P615, DOI 10.1038/nrd2591
   Ruenraroengsak P, 2010, J CONTROL RELEASE, V141, P265, DOI 10.1016/j.jconrel.2009.10.032
   Sahay G, 2010, BIOMATERIALS, V31, P923, DOI 10.1016/j.biomaterials.2009.09.101
   Scott D, 2011, INT J NANOMED, V6, P2757, DOI 10.2147/IJN.S25427
   Shuai XT, 2004, BIOCONJUGATE CHEM, V15, P441, DOI 10.1021/bc034113u
   Stella VJ, 2010, J PHARM SCI-US, V99, P4755, DOI 10.1002/jps.22205
   Sun G, 2008, BIOMACROMOLECULES, V9, P1997, DOI 10.1021/bm800246x
   Sung SJ, 2006, POLYMER, V47, P2314, DOI 10.1016/j.polymer.2006.02.003
   Van Horn BA, 2007, MACROMOLECULES, V40, P1480, DOI 10.1021/ma061654g
   Vicent MJ, 2009, ADV DRUG DELIVER REV, V61, P1117, DOI 10.1016/j.addr.2009.08.001
   West Kevin R, 2005, Curr Drug Discov Technol, V2, P123, DOI 10.2174/1570163054866882
   Wood AJJ, 2001, NEW ENGL J MED, V344, P1393
   Yallapu MM, 2011, DRUG DISCOV TODAY, V16, P457, DOI 10.1016/j.drudis.2011.03.004
   Yokoyama M, 2010, EXPERT OPIN DRUG DEL, V7, P145, DOI 10.1517/17425240903436479
NR 51
TC 8
Z9 8
U1 0
U2 39
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
EI 1573-904X
J9 PHARM RES-DORDR
JI Pharm. Res.
PD MAY
PY 2014
VL 31
IS 5
BP 1254
EP 1263
DI 10.1007/s11095-013-1246-6
PG 10
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA AG8HE
UT WOS:000335658600013
PM 24254196
OA green_accepted
DA 2018-03-19
ER

PT J
AU Lilly, JL
   Berron, BJ
AF Lilly, Jacob L.
   Berron, Brad J.
TI The Role of Surface Receptor Density in Surface-Initiated
   Polymerizations for Cancer Cell Isolation
SO LANGMUIR
LA English
DT Article
ID CIRCULATING TUMOR-CELLS; METASTATIC BREAST-CANCER; POLY(ETHYLENE GLYCOL)
   DIACRYLATE; MESENCHYMAL TRANSITION; ISLETS; SURVIVAL; COATINGS; CAPTURE;
   SYSTEM; FILMS
AB Fluid biopsies potentially offer a minimally invasive alternative to traditional tissue biopsies for the continual monitoring of metastatic cancer. Current established technologies for isolating circulating tumor cells (CTCs) suffer from poor purity and yield and require fixatives that preclude the collection of viable cells for longitudinal analyses of biological function. Antigen specific lysis (ASL) is a rapid, high-purity method of cell isolation based on targeted protective coatings on antigen presenting cells and lysis depletion of unprotected antigen negative cells. In ASL, photoinitiators are specifically labeled on cell surfaces that enable subsequent surface-initiated polymerization. Critically, the significant determinants of process yield have yet to be investigated for this emerging technology. In this work, we show that the labeling density of photoinitiators is strongly correlated with the yield of intact cells during ASL by flow cytometry analysis. Results suggest ASL is capable of delivering similar to 25% of targeted cells after isolation using traditional antibody labeling approaches. Monomer formulations of two molecular weights of PEG-diacrylate (M-n similar to 575 and 3500) are examined. The gelation response during ASL polymerization is also investigated via protein microarray analogues on planar glass. Finally, a density threshold of photoinitiator labeling required for protection during lysis is determined for both monomer formulations. These results indicate ASL is a promising technology for high yield CTC isolation for rare -cell function assays and fluid biopsies.
C1 [Lilly, Jacob L.; Berron, Brad J.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Berron, BJ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM brad.berron@uky.edu
FU National Science Foundation [CBET-1351531]; National Cancer Institute
   (NCI) [R25CA153954]; National Cancer Institute Cancer Nanotechnology
   Training Center (NCI-CNTC);  [R01 HL127682-01]
FX This work was supported partially by R01 HL127682-01 and the National
   Science Foundation under Award CBET-1351531. The authors acknowledge the
   financial support from the National Cancer Institute (NCI) Grant
   R25CA153954 and a National Cancer Institute Cancer Nanotechnology
   Training Center (NCI-CNTC) Traineeship awarded to J.L.L. The views
   expressed in this manuscript do not represent the views of the NCI, NIH,
   NSF, or any other government agency or official. The authors thank Dr.
   Hadley D. Sikes and her lab at MIT for the use of a microarray
   calibration slide.
CR Aktas B, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2333
   Avens HJ, 2008, POLYMER, V49, P4762, DOI 10.1016/j.polymer.2008.08.054
   Avens HJ, 2011, J HISTOCHEM CYTOCHEM, V59, P76, DOI 10.1369/jhc.2010.955948
   Avens HJ, 2011, J NANOPART RES, V13, P331, DOI 10.1007/s11051-010-0034-z
   Bonnomet A, 2010, J MAMMARY GLAND BIOL, V15, P261, DOI 10.1007/s10911-010-9174-0
   Cahall CF, 2015, BREAST CANCER-BASIC, V9, P1, DOI 10.4137/BCBCR.S25461
   Cheung CY, 2006, BIOCONJUGATE CHEM, V17, P1036, DOI 10.1021/bc060023o
   Cima I, 2013, BIOMICROFLUIDICS, V7, DOI 10.1063/1.4780062
   Cohen SJ, 2009, ANN ONCOL, V20, P1223, DOI 10.1093/annonc/mdn786
   Cristofanilli M, 2004, NEW ENGL J MED, V351, P781, DOI 10.1056/NEJMoa040766
   Cruise GM, 1999, CELL TRANSPLANT, V8, P293, DOI 10.1177/096368979900800310
   de Bono JS, 2008, CLIN CANCER RES, V14, P6302, DOI 10.1158/1078-0432.CCR-08-0872
   Gorges TM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-178
   Hansen RR, 2008, BIOMACROMOLECULES, V9, P355, DOI 10.1021/bm700672z
   Kalluri R, 2010, J CLIN INVEST, V120, P1786, DOI 10.1172/JCI39104C1
   Kizilel S, 2004, LANGMUIR, V20, P8652, DOI 10.1021/la0496744
   Krohn A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100249
   Lee JK, 2012, BIOMACROMOLECULES, V13, P1136, DOI 10.1021/bm300037t
   Li P, 2013, LAB CHIP, V13, P602, DOI 10.1039/c2lc90148j
   Lillemeier BF, 2006, P NATL ACAD SCI USA, V103, P18992, DOI 10.1073/pnas.0609009103
   Lilly JL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115630
   Lilly JL, 2015, BIOMACROMOLECULES, V16, P541, DOI 10.1021/bm501594x
   Liu XL, 2013, NPG ASIA MATER, V5, DOI 10.1038/am.2013.43
   Malinowska KH, 2016, CURR OPIN BIOTECH, V39, P68, DOI 10.1016/j.copbio.2016.01.007
   Miller MC, 2010, J ONCOL, V2010, P1
   Munoz Z, 2014, BIOMATER SCI-UK, V2, P1063, DOI 10.1039/c4bm00070f
   Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622
   Panda P, 2008, LAB CHIP, V8, P1056, DOI 10.1039/b804234a
   Riethdorf S, 2007, CLIN CANCER RES, V13, P920, DOI 10.1158/1078-0432.CCR-06-1695
   Romero G, 2015, ACS APPL MATER INTER, V7, P17598, DOI 10.1021/acsami.5b06298
   Shah AM, 2012, ANAL CHEM, V84, P3682, DOI 10.1021/ac300190j
   Stott SL, 2010, P NATL ACAD SCI USA, V107, P18392, DOI 10.1073/pnas.1012539107
   Tomei AA, 2014, P NATL ACAD SCI USA, V111, P10514, DOI 10.1073/pnas.1402216111
   van de Stolpe A, 2011, CANCER RES, V71, P5955, DOI 10.1158/0008-5472.CAN-11-1254
   Wicha MS, 2011, J CLIN ONCOL, V29, P1508, DOI 10.1200/JCO.2010.34.0026
   Yu M, 2011, J CELL BIOL, V192, P373, DOI 10.1083/jcb.201010021
NR 36
TC 2
Z9 2
U1 1
U2 13
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0743-7463
J9 LANGMUIR
JI Langmuir
PD JUN 7
PY 2016
VL 32
IS 22
BP 5681
EP 5689
DI 10.1021/acs.langmuir.6b01146
PG 9
WC Chemistry, Multidisciplinary; Chemistry, Physical; Materials Science,
   Multidisciplinary
SC Chemistry; Materials Science
GA DO2SW
UT WOS:000377631300027
PM 27206735
OA green_accepted
DA 2018-03-19
ER

PT J
AU Stevens, CA
   Safazadeh, L
   Berron, BJ
AF Stevens, Christopher A.
   Safazadeh, Leila
   Berron, Brad J.
TI Thiol-Yne Adsorbates for Stable, Low-Density, Self-Assembled Mono layers
   on Gold
SO LANGMUIR
LA English
DT Article
ID SERUM-ALBUMIN ADSORPTION; FRICTIONAL-PROPERTIES; REDUCTIVE DESORPTION;
   ETHANOL SOLUTION; AU(111) SURFACE; CHAIN-LENGTH; MONOLAYERS; ALKYNES;
   FILMS; SAMS
AB We present a novel approach toward carboxylate-terminated, low-density monolayers on gold, which provides exceptional adsorbate stability and conformational freedom of interfacial functional groups. Adsorbates are synthesized through the thiol-yne addition of two thiol-containing head groups to an alkyne-containing tail group. The resulting monolayers have two distinct phases: a highly crystalline head phase adjacent to the gold substrate, and a reduced density tail phase, which is in contact with the environment. The ellipsometric thickness of 27 angstrom is consistent with the proposed structure, where a densely packed decanedithiol monolayer is capped with an 11 carbon long, second layer at 50% lateral chain density. The Fourier transform infrared peak at 1710 cm(-1) supports the presence of the carbonyl group. Further, the peaks associated with asymmetric and symmetric methylene stretching are shifted toward higher wavenumbers compared to those of well-packed self-assembled monolayers (SAMs), which shows a lower average crystallinity of the thiol-yne monolayers compared to a typical monolayer. Contact angle measurements indicate an intermediate surface energy for the thiol-yne monolayer surface, owing to the contribution of exposed methylene functionality at the surface in addition to the carbonyl terminal group. The conformational freedom at the surface was demonstrated through remodeling the thiol-yne surface under an applied potential. Changes in the receding contact angle in response to an external potential support the capacity for reorientation of the surface presenting groups. Despite the low packing at the solution interface, thiol-yne monolayers are resistant to water and ion transport (R-f similar to 10(5)), supporting the presence of a densely structured layer at the gold surface. Further, the electrochemical stability of the thiol-yne adsorbates exceeded that of well-packed SAMs, requiring a more reductive potential to desorb the thiol-yne monolayers from the gold surface. The thiol-yne monolayer approach is not limited to carboxylate functionality and is readily adapted for low-density monolayers of varied functionality.
C1 [Stevens, Christopher A.; Safazadeh, Leila; Berron, Brad J.] Univ Kentucky, Lexington, KY 40506 USA.
RP Berron, BJ (reprint author), Univ Kentucky, Lexington, KY 40506 USA.
EM brad.berron@uky.edu
FU American Chemical Society Petroleum Research Fund [52743-DNI5]
FX Acknowledgment is made to the Donors of the American Chemical Society
   Petroleum Research Fund (52743-DNI5) for partial support of this
   research. The authors thank John Leyton at the UK NMR facility for
   assistance in analysis of the LD-BMUA product. The authors also
   appreciate the assistance with gold wafer fabrication from Brian Wajdyk
   and Jacob Hempel at the UK Center for Nanoscalc Science and Engineering.
CR BAIN CD, 1989, J AM CHEM SOC, V111, P321, DOI 10.1021/ja00183a049
   BAIN CD, 1989, J AM CHEM SOC, V111, P7164, DOI 10.1021/ja00200a040
   Berron B, 2006, LANGMUIR, V22, P7235, DOI 10.1021/la0531650
   Brett CMA, 2003, ELECTROANAL, V15, P557, DOI 10.1002/elan.200390069
   Chan JW, 2010, MACROMOLECULES, V43, P4937, DOI 10.1021/ma1004452
   Chan JW, 2009, J AM CHEM SOC, V131, P5751, DOI 10.1021/ja8099135
   CHAUDHURY MK, 1992, SCIENCE, V256, P1539, DOI 10.1126/science.256.5063.1539
   Choi EJ, 2003, LANGMUIR, V19, P5464, DOI 10.1021/1a026811t
   Choi EJ, 2002, LANGMUIR, V18, P557, DOI 10.1021/la010964j
   Cornell W. D., 1995, J AM CHEM SOC, P117
   Dordi B, 2003, LANGMUIR, V19, P5780, DOI 10.1021/la0343066
   Everett W. R., 1995, ANAL CHIM ACTA, V307
   Fairbanks BD, 2010, MACROMOLECULES, V43, P4113, DOI 10.1021/ma1002968
   Fairbanks BD, 2009, MACROMOLECULES, V42, P211, DOI 10.1021/ma801903w
   Folkers J. P., 1992, LANGMUIR, V8
   Garg N, 1998, LANGMUIR, V14, P3815, DOI 10.1021/la980238p
   Hoyle CE, 2010, CHEM SOC REV, V39, P1355, DOI 10.1039/b901979k
   Jennings GK, 1998, LANGMUIR, V14, P6130, DOI 10.1021/la980333y
   Jennings G. K., 1998, STABILITY STRUCTURE
   Khan S, 2010, J BIOMED MATER RES A, V93A, P1209, DOI 10.1002/jbm.a.32698
   Lahann J, 2003, SCIENCE, V299, P371, DOI 10.1126/science.1078933
   LAIBINIS PE, 1991, J AM CHEM SOC, V113, P7152, DOI 10.1021/ja00019a011
   Lee S, 2000, LANGMUIR, V16, P2220, DOI 10.1021/1a9909345
   Lowe AB, 2010, J MATER CHEM, V20, P4745, DOI 10.1039/b917102a
   Lu XY, 2004, MACROMOL RAPID COMM, V25, P1606, DOI 10.1002/marc.200400256
   Luo M., 2010, J PHYS CHEM C, V114
   Luo MX, 2012, ACS APPL MATER INTER, V4, P890, DOI 10.1021/am201557k
   Luo MX, 2010, J PHYS CHEM C, V114, P20167, DOI 10.1021/jp108018f
   Ogawa A, 1999, J AM CHEM SOC, V121, P5108, DOI 10.1021/ja983949i
   Olivier G. K., 2009, ABSTR PAP AM CHEM SO, P237
   Olivier GK, 2009, LANGMUIR, V25, P2159, DOI 10.1021/la803057x
   Park HY, 2010, MACROMOLECULES, V43, P10188, DOI 10.1021/ma1020209
   Peng DK, 2008, NANO LETT, V8, P3336, DOI 10.1021/nl8017669
   Peng DK, 2007, LANGMUIR, V23, P10184, DOI 10.1021/la701607e
   Prodromidis MI, 2010, ELECTROCHIM ACTA, V55, P4227, DOI 10.1016/j.electacta.2009.01.081
   Schonherr H, 2003, LANGMUIR, V19, P10843, DOI 10.1021/la034887z
   Shon YS, 2000, J AM CHEM SOC, V122, P7556, DOI 10.1021/ja000403z
   Sumi T, 2004, J PHYS CHEM B, V108, P6422, DOI 10.1021/jp049558+
   Sumi T, 2003, J ELECTROANAL CHEM, V550, P321, DOI 10.1016/S0022-0728(03)00141-4
   Weisshaar D. E., 1992, J AM CHEM SOC, V114
   WHITESIDES GM, 1990, LANGMUIR, V6, P87, DOI 10.1021/la00091a013
   Xu S, 1998, J CHEM PHYS, V108, P5002, DOI 10.1063/1.475908
   Yadav JS, 2007, CHEM LETT, V36, P1474, DOI 10.1246/cl.2007.1474
NR 43
TC 7
Z9 8
U1 1
U2 66
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0743-7463
J9 LANGMUIR
JI Langmuir
PD MAR 4
PY 2014
VL 30
IS 8
BP 1949
EP 1956
DI 10.1021/la404940q
PG 8
WC Chemistry, Multidisciplinary; Chemistry, Physical; Materials Science,
   Multidisciplinary
SC Chemistry; Materials Science
GA AC4LY
UT WOS:000332494000005
PM 24512439
DA 2018-03-19
ER

PT J
AU Tyagi, P
   Hinds, BJ
AF Tyagi, Pawan
   Hinds, Bruce J.
TI Mechanism of ultrathin tunnel barrier failure due to
   mechanical-stress-induced nanosized hillocks and voids
SO JOURNAL OF VACUUM SCIENCE & TECHNOLOGY B
LA English
DT Article
DE alumina; atomic force microscopy; insulators; stress relaxation;
   transmission electron microscopy; tunnelling magnetoresistance; voids
   (solid)
ID THIN-FILMS; DIELECTRIC-BREAKDOWN; JUNCTIONS; MICROSTRUCTURE; BEHAVIOR
AB Understanding the failure mechanisms of ultrathin insulators is critical for reliably improving the device life of tunneling magnetoresistance devices, Josephson junctions, and novel molecular electrodes. The relaxation of mechanical stresses forms nanosized defects causing the failure of ultrathin similar to 2-nm alumina (Al2O3) insulators. Wafer curvature, atomic-force microscopy, and transmission-electron microscopy show that stress relaxation dramatically changed the morphology of ultrathin insulators. Time evolution of compressive stresses formed the nanohillocks, resulting in metallic shorts between two metal electrodes. The time evolution of tensile-stress relaxation fractured the insulator film to produce nanosized voids. These defects adversely affected the tunnel-barrier life and the junctions failed without the application of breakdown voltage. Deleterious effects of the stresses were mitigated by optimizing the insulator-growth methodology with a two-step process. The present work emphasizes the need to complement electrical-breakdown tests with the study of mechanical stresses and corresponding morphological changes for the comprehensive understanding of a tunnel-barrier failure mechanism. (C) 2010 American Vacuum Society. [DOI: 10.1116/1.3406143]
C1 [Tyagi, Pawan] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   Univ Kentucky, Ctr Nanoscale Sci & Engn, Lexington, KY 40506 USA.
RP Tyagi, P (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM bjhinds@engr.uky.edu
OI Tyagi, Pawan/0000-0002-7541-1344
FU Air Force Office of Scientific Research (DEPSCoR) [F49620-02-1-0225];
   National Science Foundation-Nanoscale Interdisciplinary Research Team
   (NSF-NIRT) [0609064]
FX The authors would like to thank the Air Force Office of Scientific
   Research (DEPSCoR) under Agreement No. F49620-02-1-0225 and National
   Science Foundation-Nanoscale Interdisciplinary Research Team (NSF-NIRT)
   (Grant No. 0609064). Pawan Tyagi thanks John Balk for help with data
   interpretation, Todd Hastings for assistance in stress measurement,
   Hequing. Huang for the help in AFM
CR Akerman J, 2006, IEEE T MAGN, V42, P2661, DOI 10.1109/TMAG.2006.879735
   Ashwell GJ, 2007, CHEM COMMUN, P1254, DOI 10.1039/b615538c
   BARDEEN J, 1972, PHYS REV B, V5, P72, DOI 10.1103/PhysRevB.5.72
   Chen W, 2006, J VAC SCI TECHNOL B, V24, P3217, DOI 10.1116/1.2366618
   Egerton RF, 2004, MICRON, V35, P399, DOI 10.1016/j.micron.2004.02.003
   Franca DR, 2004, MEAS SCI TECHNOL, V15, P859, DOI 10.1088/0957-0233/15/5/011
   HERRING C, 1952, PHYS REV, V85, P1060, DOI 10.1103/PhysRev.85.1060.2
   Jeon WS, 2002, J ELECTROCHEM SOC, V149, pC306, DOI 10.1149/1.1470659
   Kim D, 2000, THIN SOLID FILMS, V371, P278, DOI 10.1016/S0040-6090(00)00971-8
   Li H, 2002, MAT SCI ENG A-STRUCT, V323, P17
   Magtoto NP, 2001, SURF SCI, V472, pL157, DOI 10.1016/S0039-6028(00)00948-1
   Magtoto NP, 2000, APPL PHYS LETT, V77, P2228, DOI 10.1063/1.1313816
   Maunoury C, 2004, MAT SCI ENG B-SOLID, V109, P213, DOI 10.1016/j.mseb.2003.10.068
   Moodera JS, 1999, J MAGN MAGN MATER, V200, P248, DOI 10.1016/S0304-8853(99)00515-6
   Nakajima K, 2003, J APPL PHYS, V93, P9316, DOI 10.1063/1.1569975
   Niu C, 2001, J VAC SCI TECHNOL A, V19, P1947, DOI 10.1116/1.1333088
   Oepts W, 1999, J APPL PHYS, V86, P3863, DOI 10.1063/1.371300
   Oliver B, 2004, J APPL PHYS, V95, P1315, DOI 10.1063/1.1636255
   Park J, 2002, NATURE, V417, P722, DOI 10.1038/nature00791
   Schmalhorst J, 2004, J MAGN MAGN MATER, V272, pE1485, DOI 10.1016/j.jmmm.2003.12.717
   Stefanov P, 2004, APPL SURF SCI, V235, P80, DOI 10.1016/j.apsusc.2004.05.119
   Thomas A, 2008, APPL PHYS LETT, V93, DOI 10.1063/1.3001934
   TOWNSEND PH, 1987, J APPL PHYS, V62, P4438, DOI 10.1063/1.339082
   Tyagi P, 2007, J AM CHEM SOC, V129, P4929, DOI 10.1021/ja065789d
   Yoon KS, 2001, APPL PHYS LETT, V79, P1160, DOI 10.1063/1.1391407
   You B, 2003, J PHYS D APPL PHYS, V36, P2313, DOI 10.1088/0022-3727/36/19/001
NR 26
TC 13
Z9 13
U1 1
U2 14
PU A V S AMER INST PHYSICS
PI MELVILLE
PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA
SN 1071-1023
J9 J VAC SCI TECHNOL B
JI J. Vac. Sci. Technol. B
PD MAY
PY 2010
VL 28
IS 3
BP 517
EP 521
DI 10.1116/1.3406143
PG 5
WC Engineering, Electrical & Electronic; Nanoscience & Nanotechnology;
   Physics, Applied
SC Engineering; Science & Technology - Other Topics; Physics
GA 603BK
UT WOS:000278182700015
DA 2018-03-20
ER

PT J
AU Long, SH
   Muthusamy, V
   Willis, PG
   Parkin, S
   Cammers, A
AF Long, Sihui
   Muthusamy, Venkatraj
   Willis, Peter G.
   Parkin, Sean
   Cammers, Arthur
TI Inversion symmetry and local vs. dispersive interactions in the
   nucleation of hydrogen bonded cyclic n-mer and tape of
   imidazolecarboxamidines
SO BEILSTEIN JOURNAL OF ORGANIC CHEMISTRY
LA English
DT Article
DE counterpoise; crystal engineering; packing motif; solution conformation;
   Wallach's rule
ID SET SUPERPOSITION ERROR; ORGANIC-CRYSTALS; SOLID-STATE; RACEMIC
   CRYSTALS; PACKING; ENERGY; ACID; MOLECULES; DENSITY; DERIVATIVES
AB Substitutional changes to imidazolecarboxamidine that preserved intermolecular hydrogen bonding in the solid state were used to study the relationship between packing and the hydrogen bond motif. Various motifs competed, but the most common imidazolecarboxamidine crystalline phase was a C(i) symmetric dimer that established inversion centers by associating enantiomeric tautomers. Counter to intuition, the calculated gas-phase energies per molecule of the solid state atomic coordinates of the C(i) dimer motifs were higher than those of the C(1) dimer, trimer, tetramer and tape motifs, while the packing densities of C(i) dimers were found to be higher. This result was interpreted as an enhanced ability of the C(i) dimers to pack. If other motifs competed, the hydrogen bonds and conformations should be lower in energy than the C(i) dimer. The results detail the effect of packing on the conformation in these molecules. The results are interpreted as a rough measure of the energetic compromise between packing and the energies related to the coordinates involving one dihedral angle and hydrogen bonding. The results establish a connection between solution and solid phase conformation.
C1 [Long, Sihui; Muthusamy, Venkatraj; Willis, Peter G.; Parkin, Sean; Cammers, Arthur] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
RP Cammers, A (reprint author), Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
EM a.cammers@uky.edu
RI Cammers, Arthur/B-8681-2013; Parkin, Sean/E-7044-2011
OI Cammers, Arthur/0000-0002-1682-3488; 
CR Adalsteinsson H, 1996, J AM CHEM SOC, V118, P7689, DOI 10.1021/ja954267n
   Adler TB, 2006, ANGEW CHEM INT EDIT, V45, P3440, DOI 10.1002/anie.200600380
   Anderson KM, 2006, CRYST GROWTH DES, V6, P2109, DOI 10.1021/cg0603265
   Baures PW, 2002, CRYST GROWTH DES, V2, P653, DOI 10.1021/cg025549j
   Bertolasi V, 2001, ACTA CRYSTALLOGR B, V57, P591, DOI 10.1107/S010876810100814X
   Bowers JR, 2005, CRYST GROWTH DES, V5, P727, DOI 10.1021/cg0497391
   Brehmer TH, 2000, J PHYS ORG CHEM, V13, P63, DOI 10.1002/(SICI)1099-1395(200001)13:1<63::AID-POC194>3.0.CO;2-E
   BROCK CP, 1994, CHEM MATER, V6, P1118, DOI 10.1021/cm00044a010
   BROCK CP, 1991, J AM CHEM SOC, V113, P9811, DOI 10.1021/ja00026a015
   Cammers A, 2004, CRYSTENGCOMM, V6, P168, DOI 10.1039/b405096g
   Chaka AM, 1996, ACTA CRYSTALLOGR B, V52, P165, DOI 10.1107/S0108768195006987
   Das D, 2006, CHEM COMMUN, P555, DOI 10.1039/b514076e
   Desiraju GR, 2002, ACCOUNTS CHEM RES, V35, P565, DOI 10.1021/ar010054t
   Dunitz JD, 2000, HELV CHIM ACTA, V83, P2317, DOI 10.1002/1522-2675(20000906)83:9<2317::AID-HLCA2317>3.0.CO;2-R
   Dunitz JD, 2005, CRYST GROWTH DES, V5, P2180, DOI 10.1021/cg050098z
   Dunitz JD, 2005, ANGEW CHEM INT EDIT, V44, P1766, DOI 10.1002/anie.200460157
   ETTER MC, 1990, ACCOUNTS CHEM RES, V23, P120, DOI 10.1021/ar00172a005
   ETTER MC, 1990, ACTA CRYSTALLOGR B, V46, P256, DOI 10.1107/S0108768189012929
   Feng SX, 2006, J CHEM THEORY COMPUT, V2, P149, DOI 10.1021/ct050189a
   Fenniri H, 2002, J AM CHEM SOC, V124, P11064, DOI 10.1021/ja026164s
   FORESMAN JB, 1996, EXPLORING CHEM ELECT, P7
   GALLANT M, 1991, J ORG CHEM, V56, P2284, DOI 10.1021/jo00007a007
   *GAUSS INC, 2004, GAUSS 03 REV C 02
   Gavezzotti A, 2008, CRYSTENGCOMM, V10, P389, DOI 10.1039/b714349d
   Gladwell M., 2000, TIPPING POINT LITTLE
   Grossman RB, 2002, J AM CHEM SOC, V124, P13686, DOI 10.1021/ja026949y
   IMMIRZI A, 1977, ACTA CRYSTALLOGR A, V33, P216, DOI 10.1107/S0567739477000448
   Karamertzanis PG, 2006, J CHEM THEORY COMPUT, V2, P1184, DOI 10.1021/ct600111s
   Kitaigorodskii A.I., 1973, MOL CRYSTALS MOL
   Krische MJ, 2000, STRUCT BOND, V96, P3
   LEISEROWITZ L, 1968, J CHEM SOC A, P2372, DOI DOI 10.1039/J19690002372
   Lineberry AM, 2008, CRYST GROWTH DES, V8, P612, DOI 10.1021/cg700789y
   Melendez RE, 1998, TOP CURR CHEM, V198, P97
   MONDAL R, 2005, CRYSTENGCOMM, V7, P462, DOI DOI 10.1039/B509170P
   MUGUET FF, 1995, J CHEM PHYS, V102, P3648, DOI 10.1063/1.468593
   Philp D, 1998, J CHEM SOC PERK T 2, P1643, DOI 10.1039/a800931g
   Piana S, 2005, J AM CHEM SOC, V127, P1975, DOI 10.1021/ja043395l
   Reutzel-Edens SM, 2000, J CHEM SOC PERK T 2, V5, P913
   Schwiebert KE, 1996, J AM CHEM SOC, V118, P4018, DOI 10.1021/ja952836l
   Simon S, 1996, J CHEM PHYS, V105, P11024, DOI 10.1063/1.472902
   Steiner T, 2002, ANGEW CHEM INT EDIT, V41, P48, DOI 10.1002/1521-3773(20020104)41:1<48::AID-ANIE48>3.0.CO;2-U
   Steiner T, 1998, CHEM COMMUN, P891, DOI 10.1039/a708099i
   TAYLOR R, 1984, ACCOUNTS CHEM RES, V17, P320, DOI 10.1021/ar00105a004
   WALLACH O, 1895, LIEBIGS ANN CHEM, V286, P90
   Wheeler KA, 2008, ANGEW CHEM INT EDIT, V47, P78, DOI 10.1002/anie.200704007
   ZERKOWSKI JA, 1994, J AM CHEM SOC, V116, P2382, DOI 10.1021/ja00085a018
   ZERKOWSKI JA, 1994, J AM CHEM SOC, V116, P4298, DOI 10.1021/ja00089a019
NR 47
TC 1
Z9 1
U1 0
U2 4
PU BEILSTEIN-INSTITUT
PI FRANKFURT AM MAIN
PA TRAKEHNER STRASSE 7-9, FRANKFURT AM MAIN, 60487, GERMANY
SN 1860-5397
J9 BEILSTEIN J ORG CHEM
JI Beilstein J. Org. Chem.
PD JUL 7
PY 2008
VL 4
AR 23
DI 10.3762/bjoc.4.23
PG 10
WC Chemistry, Organic
SC Chemistry
GA 333XM
UT WOS:000258186900001
PM 18941494
OA gold
DA 2018-03-19
ER

PT J
AU Ghosh, K
   Vyas, SM
   Lehmler, HJ
   Rankin, SE
   Knutson, BL
AF Ghosh, Kaustav
   Vyas, Sandhya M.
   Lehmler, Hans-Joachim
   Rankin, Stephen E.
   Knutson, Barbara L.
TI Tailoring porous silica films through supercritical carbon dioxide
   processing of fluorinated surfactant templates
SO JOURNAL OF PHYSICAL CHEMISTRY B
LA English
DT Article
ID MESOPOROUS SILICA; THIN-FILMS; PORE-SIZE; INTERFACIAL-TENSION;
   HYDROCARBON SURFACTANTS; ELEVATED PRESSURES; IN-SITU; WATER;
   MICROEMULSIONS; CO2
AB The tailoring of porous silica thin films synthesized using perfluoroalkylpyridinium chloride surfactants as templating agents is achieved as a function of carbon dioxide processing conditions and surfactant tail length and branching. Well-ordered films with 2D hexagonal close-packed pore structure are obtained from sol-gel synthesis using the following cationic fluorinated surfactants as templates: 1-(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluoro-octyl)pyridinium chloride (HFOPC), 1-(3,3,4,4,5,5,6,6,7,8,8,8-dodecafluoro-7-trifluoromethyl -octyl)pyridinium chloride (HFDoMePC), and 1-(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluoro-decyl)pyridinium chloride (HFDePC). Processing the sol-gel film with CO2 (69-172 bar, 25 and 45 degrees C) immediately after coating results in significant increases in pore diameter relative to the unprocessed thin films (increasing from 20% to 80% depending on surfactant template and processing conditions). Pore expansion increases with CO2 processing pressure, surfactant tail length, and surfactant branching. The varying degree of CO2 induced expansion is attributed to the solvation of the "CO2-philic" fluorinated tail and is interpreted from interfacial behavior of HFOPC, HFDoMePC, and HFDePC at the CO2-water interface.
C1 Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   Univ Iowa, Dept Occupat & Environm Hlth, Iowa City, IA 52242 USA.
RP Knutson, BL (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM bknutson@engr.uky.edu
RI Rankin, Stephen/A-3265-2013
OI Rankin, Stephen/0000-0002-8615-7564; Lehmler,
   Hans-Joachim/0000-0001-9163-927X
CR Alberius PCA, 2002, CHEM MATER, V14, P3284, DOI 10.1021/cm011209u
   Andreas JM, 1938, J PHYS CHEM-US, V42, P1001, DOI 10.1021/j100903a002
   ASAKAWA T, 1995, LANGMUIR, V11, P478, DOI 10.1021/la00002a019
   Bancroft WD, 1913, J PHYS CHEM-US, V17, P501, DOI 10.1021/j150141a002
   Beckman EJ, 2004, CHEM COMMUN, P1885, DOI 10.1039/b404406c
   Beckman EJ, 2004, J SUPERCRIT FLUID, V28, P121, DOI 10.1016/S0896-8446(03)00029-9
   Bein T, 1996, CHEM MATER, V8, P1636, DOI 10.1021/cm960148a
   Besson S, 2003, J MATER CHEM, V13, P404, DOI 10.1039/b206698j
   Blin JL, 2000, LANGMUIR, V16, P4229, DOI 10.1021/la9914615
   Bothun GD, 2005, J PHYS CHEM B, V109, P24495, DOI 10.1021/jp0548772
   BRANTON PJ, 1997, CHARACTERIZATION POR, V4, P668
   Cagnol F, 2003, J MATER CHEM, V13, P61, DOI 10.1039/b209640b
   Cao CT, 2001, LANGMUIR, V17, P757, DOI 10.1021/la000849t
   Chen JY, 2005, J VAC SCI TECHNOL B, V23, P2034, DOI 10.1116/1.2050656
   CHUN BS, 1995, IND ENG CHEM RES, V34, P4371, DOI 10.1021/ie00039a029
   Ciaramella F, 2006, THIN SOLID FILMS, V495, P124, DOI 10.1016/j.tsf.2005.08.291
   Combes JR, 1999, LANGMUIR, V15, P7870, DOI 10.1021/la990495+
   da Rocha SRP, 1999, LANGMUIR, V15, P419, DOI 10.1021/la980844k
   da Rocha SRP, 2002, J PHYS CHEM B, V106, P13250, DOI 10.1021/jp021485b
   Dickson JL, 2005, IND ENG CHEM RES, V44, P1370, DOI 10.1021/ie048999c
   Doshi DA, 2000, SCIENCE, V290, P107, DOI 10.1126/science.290.5489.107
   Eastoe J, 2003, CURR OPIN COLLOID IN, V8, P267, DOI 10.1016/S1359-0294(03)00053-0
   Fan HY, 2001, MICROPOR MESOPOR MAT, V44, P625, DOI 10.1016/S1387-1811(01)00243-8
   FLEMING GK, 1986, MACROMOLECULES, V19, P2285, DOI 10.1021/ma00162a030
   Fuertes AB, 2005, ELECTROCHIM ACTA, V50, P2799, DOI 10.1016/j.electacta.2004.11.027
   Garnweitner G, 2003, J AM CHEM SOC, V125, P5626, DOI 10.1021/ja0342648
   Ghosh K, 2005, LANGMUIR, V21, P6145, DOI 10.1021/la050311t
   GOEL SK, 1993, POLYMER, V34, P1410, DOI 10.1016/0032-3861(93)90853-3
   Grosso D, 2002, CHEM MATER, V14, P931, DOI 10.1021/cm011255u
   Grosso D, 2002, CHEM COMMUN, P748, DOI 10.1039/b111499a
   Gupta G, 2005, CHEM MATER, V17, P6728, DOI 10.1021/cm051052w
   Hanrahan JP, 2005, LANGMUIR, V21, P4163, DOI 10.1021/la0470636
   Hanrahan JP, 2004, CHEM MATER, V16, P424, DOI 10.1021/cm034882n
   HARRISON K, 1994, LANGMUIR, V10, P3536, DOI 10.1021/la00022a028
   Hentze HP, 2003, TOP CURR CHEM, V226, P197, DOI 10.1007/b10829
   Hentze HP, 2003, CHEM MATER, V15, P708, DOI 10.1021/cm020832r
   Holmes JD, 1998, LANGMUIR, V14, P6371, DOI 10.1021/la9806956
   Huang MH, 2002, CHEM MATER, V14, P5153, DOI 10.1021/cm0207043
   Hwang YK, 2005, MICROPOR MESOPOR MAT, V78, P245, DOI 10.1016/j.micromeso.2004.10.026
   *IMAGEJ, 2006, IM PROC AN JAV
   Jacobson GB, 1999, J ORG CHEM, V64, P1201, DOI 10.1021/jo981825i
   Jang KS, 2004, CHEM COMMUN, P1514, DOI 10.1039/b404409f
   Ji M, 1999, J AM CHEM SOC, V121, P2631, DOI 10.1021/ja9840403
   KAHLWEIT M, 1999, MICROEMULSIONS CHEM, P37
   Keiper JS, 2002, J AM CHEM SOC, V124, P1834, DOI 10.1021/ja0122142
   Kho YW, 2003, FLUID PHASE EQUILIBR, V206, P179, DOI 10.1016/S0378-3812(02)00316-3
   Kimura T, 1998, CHEM COMMUN, P559, DOI 10.1039/a708463c
   Klotz M, 2000, J MATER CHEM, V10, P663, DOI 10.1039/a906181i
   Kruk M, 1999, LANGMUIR, V15, P1442, DOI 10.1021/la980789f
   Kunieda H, 1998, J PHYS CHEM B, V102, P831, DOI 10.1021/jp9726908
   Lee CT, 2000, J PHYS CHEM B, V104, P4448, DOI 10.1021/jp9941357
   Lee CT, 2003, J AM CHEM SOC, V125, P3181, DOI 10.1021/ja025735d
   Lee CT, 2001, J PHYS CHEM B, V105, P3540, DOI 10.1021/jp0033059
   Liu NG, 2004, NANO LETT, V4, P551, DOI 10.1021/nl0350783
   Lu YF, 1997, NATURE, V389, P364, DOI 10.1038/38699
   Lu YF, 2001, NATURE, V410, P913, DOI 10.1038/35073544
   Ma YR, 2003, COLLOID SURFACE A, V229, P1, DOI 10.1016/j.colsurfa.2003.08.010
   McLeod MC, 2003, J PHYS CHEM B, V107, P2693, DOI 10.1021/jp0218645
   Nicole L, 2004, CHEM COMMUN, P2312, DOI 10.1039/b408869g
   *NIST, 2006, NIST CHEM WEBB NIST
   OATES JD, 1989, J COLLOID INTERF SCI, V131, P307, DOI 10.1016/0021-9797(89)90175-6
   Osei-Prempeh G, 2005, MICROPOR MESOPOR MAT, V85, P16, DOI 10.1016/j.micromeso.2005.06.014
   Pai RA, 2004, SCIENCE, V303, P507, DOI 10.1126/science.1092627
   Psathas PA, 2002, J DISPER SCI TECHNOL, V23, P81, DOI 10.1081/DIS-120003306
   Psathas PA, 2002, J DISPER SCI TECHNOL, V23, P65, DOI 10.1081/DIS-120003305
   Rankin SE, 2004, MICROPOR MESOPOR MAT, V73, P197, DOI 10.1016/j.micromeso.2004.05.013
   Ryoo W, 2003, IND ENG CHEM RES, V42, P6348, DOI 10.1021/ie0300427
   Sagisaka M, 2004, LANGMUIR, V20, P2560, DOI 10.1021/la036074g
   Scanu LF, 2004, LANGMUIR, V20, P514, DOI 10.1021/la0347760
   Sirard SM, 2001, J PHYS CHEM B, V105, P766, DOI 10.1021/jp002592d
   Stone MT, 2004, J PHYS CHEM B, V108, P1962, DOI 10.1021/jp036224w
   Tan B, 2005, CHEM MATER, V17, P916, DOI 10.1021/cm048991t
   TURNER C, 2003, COLLOID SURF A, V213, P69
   Ulagappan N, 1996, CHEM COMMUN, P2759, DOI 10.1039/cc9960002759
   Wang K, 1999, J PHYS CHEM B, V103, P9237, DOI 10.1021/jp990821u
   Wang K, 2000, LANGMUIR, V16, P1042, DOI 10.1021/la9909603
   SPARTAN, 1998, SPARTAN STUD VERS
   WISSINGER RG, 1987, J POLYM SCI POL PHYS, V25, P2497, DOI 10.1002/polb.1987.090251206
   Wong EM, 2002, J PHYS CHEM B, V106, P6652, DOI 10.1021/jp014201g
   Yang H, 1997, J MATER CHEM, V7, P1285, DOI 10.1039/a608171a
   YAZDI AV, 1995, J MATER RES, V10, P530, DOI 10.1557/JMR.1995.0530
   YE W, 2006, POLYM SCI, V24, P95
   Zhang Y, 1997, J SUPERCRIT FLUID, V11, P115, DOI 10.1016/S0896-8446(97)00031-4
NR 83
TC 17
Z9 17
U1 1
U2 23
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1520-6106
J9 J PHYS CHEM B
JI J. Phys. Chem. B
PD JAN 18
PY 2007
VL 111
IS 2
BP 363
EP 370
DI 10.1021/jp0656680
PG 8
WC Chemistry, Physical
SC Chemistry
GA 124RY
UT WOS:000243388800009
PM 17214487
DA 2018-03-20
ER

PT J
AU Ghoshal, S
   Geddes, J
   Saatman, K
   Guttmann, R
AF Ghoshal, Sarbani
   Geddes, James W.
   Saatman, Kathryn E.
   Guttmann, Rodney P.
TI DEVELOPING BIOMARKERS FOR TRAUMATIC BRAIN INJURY USING PHAGE DISPLAY
SO JOURNAL OF NEUROTRAUMA
LA English
DT Meeting Abstract
CT 30th Annual National Neurotrauma Symposium
CY JUL 22-25, 2012
CL Phoenix, AZ
DE TBI; Phage Display; Biomarker
C1 [Geddes, James] Univ Kentucky, Dept Anat & Neurobiol, Spinal Cord & Brain Injury Res Ctr SCoBIRC, Lexington, KY 40506 USA.
   [Saatman, Kathryn] Univ Kentucky, Dept Physiol, Spinal Cord & Brain Injury Res Ctr SCoBIRC, Lexington, KY 40506 USA.
   [Guttmann, Rodney] Univ W Florida, Pensacola, FL 32514 USA.
NR 0
TC 0
Z9 0
U1 0
U2 4
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0897-7151
J9 J NEUROTRAUM
JI J. Neurotrauma
PD JUL
PY 2012
VL 29
IS 10
BP A115
EP A115
PG 1
WC Critical Care Medicine; Clinical Neurology; Neurosciences
SC General & Internal Medicine; Neurosciences & Neurology
GA 971YV
UT WOS:000306244400195
DA 2018-03-20
ER

PT J
AU Wattamwar, PP
   Biswal, D
   Cochran, DB
   Lyvers, AC
   Eitel, RE
   Anderson, KW
   Hilt, JZ
   Dziubla, TD
AF Wattamwar, Paritosh P.
   Biswal, Dipti
   Cochran, David B.
   Lyvers, Adam C.
   Eitel, Richard E.
   Anderson, Kimberly W.
   Hilt, J. Zach
   Dziubla, Thomas D.
TI Synthesis and characterization of poly(antioxidant beta-amino esters)
   for controlled release of polyphenolic antioxidants
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Antioxidant polymers; Polyphenols; Oxidative stress; Curcumin;
   Biocompatibility
ID ENDOTHELIAL-CELLS; OXIDATIVE STRESS; IN-VIVO; POLYMERS; FLAVONOIDS;
   DELIVERY; 2',7'-DICHLOROFLUORESCIN; CYTOTOXICITY; ENVIRONMENT; APOPTOSIS
AB Attenuation of cellular oxidative stress, which plays a central role in biomaterial-induced inflammation, provides an exciting opportunity to control the host tissue response to biomaterials. In the case of biodegradable polymers, biomaterial-induced inflammation is often a result of local accumulation of polymer degradation products, hence there is a need for new biomaterials that can inhibit this response. Antioxidant polymers, which have antioxidants incorporated into the polymer backbone, are a class of biomaterials that, upon degradation, release active antioxidants, which can scavenge free radicals and attenuate oxidative stress, resulting in improved material biocompatibility. In this work, we have synthesized poly(antioxidant beta-amino ester) (PA beta AE) biodegradable hydrogels of two polyphenolic antioxidants, quercetin and curcumin. The degradation characteristics of PA beta AE hydrogels and the antioxidant activity of PA beta AE degradation products were studied. Treatment of endothelial cells with PA beta AE degradation products protected cells from hydrogen-peroxide-induced oxidative stress. (C) 2012 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Wattamwar, Paritosh P.; Biswal, Dipti; Cochran, David B.; Lyvers, Adam C.; Eitel, Richard E.; Anderson, Kimberly W.; Hilt, J. Zach; Dziubla, Thomas D.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Dziubla, TD (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 FP Anderson Tower, Lexington, KY 40506 USA.
EM dziubla@engr.uky.edu
RI Eitel, Richard/E-2889-2010
OI Eitel, Richard/0000-0002-5090-2075
FU Office of Naval Research (ONR DEPSCoR)
FX We gratefully acknowledge Dr. James. W. Geddes for access to the
   fluorescent spectrophotometer and Ranjana Singh for her help with the
   instrument. We are also grateful to the Department of Chemistry NMR
   facility. This work was supported by the Office of Naval Research (ONR
   DEPSCoR).
CR Aggarwal BB, 2009, TRENDS PHARMACOL SCI, V30, P85, DOI 10.1016/j.tips.2008.11.002
   Anderson DG, 2006, ADV MATER, V18, P2614, DOI 10.1002/adma.200600529
   Anderson DG, 2003, ANGEW CHEM INT EDIT, V42, P3153, DOI 10.1002/anie.200351244
   Badylak SF, 2008, TISSUE ENG PT A, V14, P1835, DOI 10.1089/ten.tea.2007.0264
   Bat E, 2010, J BIOMED MATER RES A, V95A, P940, DOI 10.1002/jbm.a.32921
   Biswal D, 2011, POLYMER, V52, P5985, DOI 10.1016/j.polymer.2011.10.058
   Boudreaux CJ, 1996, J CONTROL RELEASE, V40, P223, DOI 10.1016/0168-3659(95)00189-1
   Choi YJ, 2005, J NUTR, V135, P707
   Choi YJ, 2003, J NUTR, V133, P985
   Fleming C, 2005, NAT CHEM BIOL, V1, P270, DOI 10.1038/nchembio730
   Fu K, 2000, PHARMACEUT RES, V17, P100, DOI 10.1023/A:1007582911958
   Jiang WW, 2007, J BIOMED MATER RES A, V82A, P492, DOI 10.1002/jbm.a.31175
   KAPLAN SS, 1992, J BIOMED MATER RES, V26, P1039, DOI 10.1002/jbm.820260806
   LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012
   Leonarduzzi G, 2010, CURR MED CHEM, V17, P74, DOI 10.2174/092986710789957760
   Li N, 2008, J AGR FOOD CHEM, V56, P3876, DOI 10.1021/jf073520n
   Liu WE, 2011, BIOMATERIALS, V32, P1796, DOI 10.1016/j.biomaterials.2010.11.029
   Matsuo M, 2005, BIOL PHARM BULL, V28, P253, DOI 10.1248/bpb.28.253
   Rota C, 1999, J BIOL CHEM, V274, P28161, DOI 10.1074/jbc.274.40.28161
   ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222
   Schmidt DR, 2007, J BIOMED MATER RES A, V83A, P617, DOI 10.1002/jbm.a.31270
   Spizzirri UG, 2009, BIOMACROMOLECULES, V10, P1923, DOI 10.1021/bm900325t
   Udipi K, 2000, J BIOMED MATER RES, V51, P549, DOI 10.1002/1097-4636(20000915)51:4<549::AID-JBM2>3.0.CO;2-Z
   Wachsberger PR, 2003, INT J HYPERTHER, V19, P507, DOI 10.1080/0265673031000078697
   Wang B, 2007, ANESTH ANALG, V105, P1027, DOI 10.1213/01.ane.0000281046.77228.91
   Wang YZ, 2006, BIOMATERIALS, V27, P3265, DOI 10.1016/j.biomaterials.2006.01.036
   Wattamwar PP, 2011, J BIOMED MATER RES A, V99A, P184, DOI 10.1002/jbm.a.33174
   Wattamwar PP, 2010, ADV FUNCT MATER, V20, P147, DOI 10.1002/adfm.200900839
   Williams SR, 2009, BIOMACROMOLECULES, V10, P155, DOI 10.1021/bm801058j
   Woo HB, 2005, BIOORG MED CHEM LETT, V15, P3782, DOI 10.1016/j.bmcl.2005.05.064
   Wrona M, 2008, FREE RADICAL BIO MED, V44, P56, DOI 10.1016/j.freeradbiomed.2007.09.005
NR 31
TC 26
Z9 26
U1 1
U2 25
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742-7061
J9 ACTA BIOMATER
JI Acta Biomater.
PD JUL
PY 2012
VL 8
IS 7
BP 2529
EP 2537
DI 10.1016/j.actbio.2012.03.022
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 974NK
UT WOS:000306442400011
PM 22426289
DA 2018-03-19
ER

PT J
AU Ponta, A
   Bae, Y
AF Ponta, Andrei
   Bae, Younsoo
TI PEG-poly(amino acid) Block Copolymer Micelles for Tunable Drug Release
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE controlled drug delivery; functional block copolymers; pH-sensitive drug
   release; polymer micelles; tunable drug release
ID POLYMERIC MICELLES; ANTITUMOR-ACTIVITY; INTRACELLULAR TRAFFICKING;
   POLY(ETHYLENE GLYCOL); ANTICANCER DRUG; CARRIER SYSTEM; CANCER-THERAPY;
   DELIVERY; ADRIAMYCIN; DESIGN
AB To achieve tunable pH-dependent drug release in tumor tissues.
   Poly(ethylene glycol)-poly(aspartic acid) [PEG-p(Asp)] containing 12 kDa PEG and pAsp (5, 15, and 35 repeating units) were prepared. Hydrazide linkers with spacers [glycine (Gly) and 4-aminobenzoate (Abz)] were introduced to PEG-p(Asp), followed by drug conjugation [doxorubicin (DOX)]. The block copolymer-drug conjugates were either reconstituted or dialyzed in aqueous solutions to prepare micelles. Drug release patterns were observed under sink conditions at pH 5.0 and 7.4, 37A degrees C, for 48 h.
   A collection of six block copolymers with different chain lengths and spacers was synthesized. Drug binding yields were 13-43.6%. The polymer-drug conjugates formed < 50 nm polymer micelles irrespective of polymer compositions. Gly-introduced polymer micelles showed marginal change in particle size (40 +/- 10 nm), while the size of Abz-micelles increased gradually from 10 to 40 nm as the polymer chain lengths increased. Drug release patterns of both Gly and Abz micelles were pH-dependent and tunable. The spacers appear to play a crucial role in controlling drug release and stability of polymer micelles in combination with block copolymer chain lengths.
   A drug delivery platform for tunable drug release was successfully developed with polymer micelles possessing spacer-modified hydrazone drug-binding linkers.
C1 [Ponta, Andrei; Bae, Younsoo] Univ Kentucky, Coll Pharm, Lexington, KY 40536 USA.
RP Bae, Y (reprint author), Univ Kentucky, Coll Pharm, 789 S Limestone, Lexington, KY 40536 USA.
EM younsoo.bae@uky.edu
FU Kentucky Lung Cancer Research Program
FX Authors acknowledge financial support provided by the Kentucky Lung
   Cancer Research Program.
CR Allen C, 1999, HOUS THEORY SOC, V16, P3, DOI 10.1080/14036099950150053
   ATKINS JH, 2002, NATURE REV CANC, V1, P645
   Bae Y, 2005, MOL BIOSYST, V1, P242, DOI 10.1039/b500266d
   Bae Y, 2003, ANGEW CHEM INT EDIT, V42, P4640, DOI 10.1002/anie.200250653
   Bae Y, 2005, BIOCONJUGATE CHEM, V16, P122, DOI 10.1021/bc0498166
   Bae Y, 2007, BIOCONJUGATE CHEM, V18, P1131, DOI 10.1021/bc060401p
   Bae Y, 2009, ADV DRUG DELIVER REV, V61, P768, DOI 10.1016/j.addr.2009.04.016
   Benelli R, 2009, INT J CANCER, V124, P2989, DOI 10.1002/ijc.24305
   Blanco E, 2009, EXP BIOL MED, V234, P123, DOI 10.3181/0808-MR-250
   Callahan J, 2009, BIOMACROMOLECULES, V10, P1704, DOI 10.1021/bm801514x
   CAMMAS S, 1995, MACROMOL CHEM PHYSIC, V196, P1899, DOI 10.1002/macp.1995.021960609
   Duncan R, 2003, NAT REV DRUG DISCOV, V2, P347, DOI 10.1038/nrd1088
   Duncan R, 2006, NAT REV CANCER, V6, P688, DOI 10.1038/nrc1958
   Fukushima S, 1999, COLLOID SURFACE B, V16, P227, DOI 10.1016/S0927-7765(99)00073-9
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Jain RK, 2002, NAT REV CANCER, V2, P266, DOI 10.1038/nrc778
   Jones AT, 2003, ADV DRUG DELIVER REV, V55, P1353, DOI 10.1016/j.addr.2003.07.002
   KANEKO T, 1991, BIOCONJUGATE CHEM, V2, P133, DOI 10.1021/bc00009a001
   Kataoka K, 2000, J CONTROL RELEASE, V64, P143, DOI 10.1016/S0168-3659(99)00133-9
   KATAOKA K, 1993, J CONTROL RELEASE, V24, P119
   Kratz F, 1999, CRIT REV THER DRUG, V16, P245, DOI 10.1615/CritRevTherDrugCarrierSyst.v16.i3.10
   KWON GS, 1995, ADV DRUG DELIVER REV, V16, P295, DOI 10.1016/0169-409X(95)00031-2
   Lavasanifar A, 2002, ADV DRUG DELIVER REV, V54, P169, DOI 10.1016/S0169-409X(02)00015-7
   Lee ES, 2008, J CONTROL RELEASE, V132, P164, DOI 10.1016/j.jconrel.2008.05.003
   Ma J, 2008, MOL CANCER THER, V7, P79, DOI 10.1158/1535-7163.MCT-07-0584
   MAEDA H, 1989, CRIT REV THER DRUG, V6, P193
   MATSUMURA Y, 1986, CANCER RES, V46, P6387
   Mayer LD, 2006, MOL CANCER THER, V5, P1854, DOI 10.1158/1535-7163.MCT-06-0118
   Nakanishi T, 2001, J CONTROL RELEASE, V74, P295, DOI 10.1016/S0168-3659(01)00341-8
   Patel M, 2003, ANTICANCER RES, V23, P447
   Putnam D, 1995, ADV POLYM SCI, V122, P55
   Scripture CD, 2006, NAT REV CANCER, V6, P546, DOI 10.1038/nrc.1887
   Senter Peter D, 2004, Mol Pharm, V1, P395, DOI 10.1021/mp040010x
   Stella B, 2000, J PHARM SCI, V89, P1452, DOI 10.1002/1520-6017(200011)89:11<1452::AID-JPS8>3.0.CO;2-P
   Suzuki H, 1996, ADV DRUG DELIVER REV, V19, P335, DOI 10.1016/0169-409X(96)00008-7
   Takakura Y, 1996, PHARMACEUT RES, V13, P820, DOI 10.1023/A:1016084508097
   Tsukioka Y, 2002, JPN J CANCER RES, V93, P1145, DOI 10.1111/j.1349-7006.2002.tb01217.x
   West Kevin R, 2005, Curr Drug Discov Technol, V2, P123, DOI 10.2174/1570163054866882
   YAMAOKA T, 1994, J PHARM SCI, V83, P601, DOI 10.1002/jps.2600830432
   Yokoyama M, 1998, J CONTROL RELEASE, V55, P219, DOI 10.1016/S0168-3659(98)00054-6
   YOKOYAMA M, 1990, J CONTROL RELEASE, V11, P269
NR 41
TC 52
Z9 54
U1 0
U2 65
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
J9 PHARM RES-DORDR
JI Pharm. Res.
PD NOV
PY 2010
VL 27
IS 11
BP 2330
EP 2342
DI 10.1007/s11095-010-0120-z
PG 13
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 669RN
UT WOS:000283368000008
PM 20372992
DA 2018-03-19
ER

PT J
AU Frimpong, RA
   Hilt, JZ
AF Frimpong, Reynolds A.
   Hilt, J. Zach
TI Magnetic nanoparticles in biomedicine: synthesis, functionalization and
   applications
SO NANOMEDICINE
LA English
DT Review
DE iron oxide; magnetic nanoparticles; stabilization; surface
   functionalization; synthesis
ID IRON-OXIDE NANOPARTICLES; TRANSFER RADICAL POLYMERIZATION; MODIFIED
   SUPERPARAMAGNETIC NANOPARTICLES; ONE-POT SYNTHESIS; FE3O4 NANOPARTICLES;
   CONTRAST AGENTS; DRUG-DELIVERY; IN-VIVO; BICONTINUOUS MICROEMULSIONS;
   POLY(ETHYLENE GLYCOL)
AB Magnetic nanoparticles continue to garner widespread interest in biomedical applications, such as visualization agents in MRI, therapeutic vehicles for drug delivery and heat mediators in hyperthermia. Recent advances in colloidal synthesis and surface-functionalization techniques have greatly contributed to the design of functionalized magnetic nanoparticles with controlled properties and multifunctional capabilities, which are harnessed for dual diagnostic and therapeutic purposes. The surface-functionalization methods in particular have aided in obtaining magnetic nanoparticles coated with molecules, with tailored functionalities that enhance their applications. In this article, the methods of synthesis and functionalization are examined, with emphasis on how these impact their biomedical applications.
C1 [Frimpong, Reynolds A.; Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Hilt, JZ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM hilt@engr.uky.edu
CR Al-Saadi A, 2009, J PHYS CHEM C, V113, P15260, DOI 10.1021/jp903100j
   Babincova M, 2007, OPTOELECTRON ADV MAT, V1, P644
   Babincova M, 2001, J MAGN MAGN MATER, V225, P109, DOI 10.1016/S0304-8853(00)01237-3
   Banerjee SS, 2007, CHEM MATER, V19, P3667, DOI 10.1021/cm070461k
   Barrera C, 2009, J COLLOID INTERF SCI, V329, P107, DOI 10.1016/j.jcis.2008.09.071
   Bautista MC, 2005, J MAGN MAGN MATER, V293, P20, DOI 10.1016/j.jmmm.2005.01.038
   BEE A, 1995, J MAGN MAGN MATER, V149, P6, DOI 10.1016/0304-8853(95)00317-7
   Berry CC, 2009, J PHYS D APPL PHYS, V42, DOI 10.1088/0022-3727/42/22/224003
   Berry CC, 2003, J PHYS D APPL PHYS, V36, pR198, DOI 10.1088/0022-3727/36/13/203
   Binder WH, 2007, MACROMOLECULES, V40, P3097, DOI 10.1021/ma0628376
   Biswas S, 2009, CHEM MATER, V21, P5644, DOI 10.1021/cm902854d
   Bomati-Miguel O, 2005, BIOMATERIALS, V26, P5695, DOI 10.1016/j.biomaterials.2005.02.020
   Boyer C, 2009, J MATER CHEM, V19, P111, DOI 10.1039/b815202k
   Bucak S, 2003, BIOTECHNOL PROGR, V19, P477, DOI 10.1021/bp0200853
   Cao HN, 2009, APPL SURF SCI, V255, P7974, DOI 10.1016/j.apsusc.2009.04.199
   Chastellain M, 2004, J Colloid Interface Sci, V278, P353, DOI 10.1016/j.jcis.2004.06.025
   De Palma R, 2007, CHEM MATER, V19, P1821, DOI 10.1021/cm0628000
   Duan HW, 2008, J PHYS CHEM C, V112, P8127, DOI 10.1021/jp8029083
   Edmondson S, 2004, CHEM SOC REV, V33, P14, DOI 10.1039/b210143m
   Esquivel J, 2007, J MATER SCI, V42, P9015, DOI 10.1007/s10853-007-1834-0
   Fan QL, 2007, BIOMATERIALS, V28, P5426, DOI 10.1016/j.biomaterials.2007.08.039
   Flesch C, 2005, J POLYM SCI POL CHEM, V43, P3221, DOI 10.1002/pola.20772
   Fortin JP, 2007, J AM CHEM SOC, V129, P2628, DOI 10.1021/ja067457e
   Frimpong RA, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/17/175101
   Frimpong RA, 2010, J MAGN MAGN MATER, V322, P326, DOI 10.1016/j.jmmm.2009.09.050
   Gao JH, 2009, ACCOUNTS CHEM RES, V42, P1097, DOI 10.1021/ar9000026
   Gao LZ, 2008, J PHYS CHEM C, V112, P17357, DOI 10.1021/jp805994h
   Gao LZ, 2007, NAT NANOTECHNOL, V2, P577, DOI 10.1038/nnano.2007.260
   Ge S, 2009, J PHYS CHEM C, V113, P13593, DOI 10.1021/jp902953t
   Gonzales-Weimuller M, 2009, J MAGN MAGN MATER, V321, P1947, DOI 10.1016/j.jmmm.2008.12.017
   Gupta AK, 2007, NANOMEDICINE-UK, V2, P23, DOI 10.2217/17435889.2.1.23
   Gupta AK, 2005, BIOMATERIALS, V26, P3995, DOI 10.1016/j.biomaterials.2004.10.012
   Gupta AK, 2004, IEEE T NANOBIOSCI, V3, P66, DOI 10.1109/TNB.2003.820277
   Hawkins AM, 2009, PHARM RES-DORD, V26, P667, DOI 10.1007/s11095-008-9804-z
   Hergt R, 1998, IEEE T MAGN, V34, P3745, DOI 10.1109/20.718537
   Hergt R, 2007, J MAGN MAGN MATER, V311, P187, DOI 10.1016/j.jmmm.2006.10.1156
   Hong RY, 2008, BIOCHEM ENG J, V42, P290, DOI 10.1016/j.bej.2008.07.009
   Hu FQ, 2006, ADV MATER, V18, P2553, DOI 10.1002/adma.200600385
   Hu FQ, 2009, J PHYS CHEM C, V113, P20855, DOI 10.1021/jp907216g
   Hu FX, 2006, BIOMACROMOLECULES, V7, P809, DOI 10.1021/bm050870e
   Huang G, 2009, J MATER CHEM, V19, P6367, DOI 10.1039/b902358e
   Huber DL, 2005, SMALL, V1, P482, DOI 10.1002/smll.200500006
   Huh YM, 2005, J AM CHEM SOC, V127, P12387, DOI 10.1021/ja052337c
   Hyeon T, 2001, J AM CHEM SOC, V123, P12798, DOI 10.1021/ja016812s
   Jain TK, 2005, MOL PHARMACEUT, V2, P194, DOI 10.1021/mp0500014
   Jeong U, 2007, ADV MATER, V19, P33, DOI 10.1002/adma.200600674
   Jia X, 2009, CHEM COMMUN, P968, DOI 10.1039/b813524j
   Jun YW, 2005, J AM CHEM SOC, V127, P5732, DOI 10.1021/ja0422155
   Kang SM, 2009, MACROMOL RES, V17, P259, DOI 10.1007/BF03218689
   Kim DK, 2003, CHEM MATER, V15, P1617, DOI 10.1021/cm021349j
   Kim DK, 2001, J MAGN MAGN MATER, V225, P30, DOI 10.1016/S0304-8853(00)01224-5
   Kohler N, 2006, SMALL, V2, P785, DOI 10.1002/smll.200600009
   Kohler N, 2005, LANGMUIR, V21, P8858, DOI 10.1021/la0503451
   Lai JJ, 2007, LANGMUIR, V23, P7385, DOI 10.1021/la062527g
   Lattuada M, 2007, LANGMUIR, V23, P2158, DOI 10.1021/la062092x
   Lee CM, 2009, MAGN RESON MED, V62, P1440, DOI 10.1002/mrm.22123
   Lee JH, 2007, NAT MED, V13, P95, DOI 10.1038/nm1467
   Lee Y, 2005, ADV FUNCT MATER, V15, P503, DOI 10.1002/adfm.200400187
   Li Z, 2005, ADV MATER, V17, P1001, DOI 10.1002/adma.200401545
   Li Z, 2005, ANGEW CHEM INT EDIT, V44, P123, DOI 10.1002/anie.200460715
   Li Z, 2004, CHEM MATER, V16, P1391, DOI 10.1021/cm035346y
   Loo AL, 2008, J MATER SCI, V43, P3649, DOI 10.1007/s10853-008-2581-6
   Lu AH, 2007, ANGEW CHEM INT EDIT, V46, P1222, DOI 10.1002/anie.200602866
   Lutz JF, 2006, BIOMACROMOLECULES, V7, P3132, DOI 10.1021/bm0607527
   Ma M, 2004, J MAGN MAGN MATER, V268, P33, DOI 10.1016/S0304-8853(03)00426-8
   Matsuno R, 2004, MACROMOLECULES, V37, P2203, DOI 10.1021/ma035523g
   McCarthy JR, 2008, ADV DRUG DELIVER REV, V60, P1241, DOI 10.1016/j.addr.2008.03.014
   Moroz P, 2002, INT J HYPERTHER, V18, P267, DOI 10.1080/02656730110108785
   Narain R, 2007, LANGMUIR, V23, P6299, DOI 10.1021/la700268g
   Neuberger T, 2005, J MAGN MAGN MATER, V293, P483, DOI 10.1016/j.jmmm.2005.01.064
   Pankhurst QA, 2009, J PHYS D APPL PHYS, V42, DOI 10.1088/0022-3727/42/22/224001
   Pankhurst QA, 2003, J PHYS D APPL PHYS, V36, pR167, DOI 10.1088/0022-3727/36/13/201
   Pellegrino T, 2004, NANO LETT, V4, P703, DOI 10.1021/nl035172j
   Pyun J, 2001, CHEM MATER, V13, P3436, DOI 10.1021/cm011065j
   Qiao RR, 2009, J MATER CHEM, V19, P6274, DOI 10.1039/b902394a
   Ramanujan RV, 2009, J MATER SCI, V44, P1381, DOI 10.1007/s10853-006-1064-x
   Rockenberger J, 1999, J AM CHEM SOC, V121, P11595, DOI 10.1021/ja993280v
   Satarkar NS, 2008, J CONTROL RELEASE, V130, P246, DOI 10.1016/j.jconrel.2008.06.008
   Schmidt AM, 2007, COLLOID POLYM SCI, V285, P953, DOI [10.1007/s00396-007-1667-z, 10.1007/S00396-007-1667-z]
   Shubayev VI, 2009, ADV DRUG DELIVER REV, V61, P467, DOI 10.1016/j.addr.2009.03.007
   Sun B, 2009, LANGMUIR, V25, P5969, DOI 10.1021/la804217w
   Sun C, 2008, ADV DRUG DELIVER REV, V60, P1252, DOI 10.1016/j.addr.2008.03.018
   Sun SH, 2004, J AM CHEM SOC, V126, P273, DOI 10.1021/ja0380852
   Sun SH, 2002, J AM CHEM SOC, V124, P8204, DOI 10.1021/ja026501x
   Tromsdorf UI, 2007, NANO LETT, V7, P2422, DOI 10.1021/nl071099b
   Veiseh O, 2005, NANO LETT, V5, P1003, DOI 10.1021/nl0502569
   Villanueva A, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/11/115103
   Wan J, 2007, CHEM COMMUN, P5004, DOI 10.1039/b712795b
   Wang L, 2009, ADV FUNCT MATER, V19, P2615, DOI 10.1002/adfm.200801689
   Wang X, 2005, NATURE, V437, P121, DOI 10.1038/nature03968
   Wang Y, 2003, NANO LETT, V3, P1555, DOI 10.1021/nl034731j
   WEISSLEDER R, 1990, RADIOLOGY, V175, P489, DOI 10.1148/radiology.175.2.2326474
   Willard MA, 2004, INT MATER REV, V49, P125, DOI 10.1179/095066004225021882
   Xie J, 2006, PURE APPL CHEM, V78, P1003, DOI 10.1351/pac200678051003
   Xie J, 2007, ADV MATER, V19, P3163, DOI 10.1002/adma.200701975
   Xu CJ, 2004, J AM CHEM SOC, V126, P9938, DOI 10.1021/ja0464802
   Yang SY, 2008, J MAGN MAGN MATER, V320, P2688, DOI 10.1016/j.jmmm.2008.05.048
   Yean S, 2005, J MATER RES, V20, P3255, DOI 10.1557/JMR.2005.0403
   Zeng Q, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2746064
   Zhang LY, 2007, J MAGN MAGN MATER, V311, P228, DOI 10.1016/j.jmmm.2006.11.179
   Zheng YH, 2006, MATER RES BULL, V41, P525, DOI 10.1016/j.materresbull.2005.09.015
   Zhou Y, 2008, CHEM ENG J, V138, P578, DOI 10.1016/j.cej.2007.07.030
NR 102
TC 77
Z9 77
U1 8
U2 99
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1743-5889
J9 NANOMEDICINE-UK
JI Nanomedicine
PD NOV
PY 2010
VL 5
IS 9
BP 1401
EP 1414
DI 10.2217/NNM.10.114
PG 14
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA 705KR
UT WOS:000286127800013
PM 21128722
DA 2018-03-20
ER

PT J
AU Long, SH
   Theiss, KL
   Mattei, A
   Loftin, CD
   Li, TL
AF Long, Sihui
   Theiss, Kathryn L.
   Mattei, Alessandra
   Loftin, Charles D.
   Li, Tonglei
TI Solid-State Properties of the Cyclooxygenase-1-Selective Inhibitor,
   SC-560
SO AAPS PHARMSCITECH
LA English
DT Article
DE COX-1 inhibitor; nonsteroidal anti-inflammatory drugs; solid state;
   solubility
C1 [Long, Sihui; Theiss, Kathryn L.; Mattei, Alessandra; Loftin, Charles D.; Li, Tonglei] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
RP Li, TL (reprint author), Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, 725 Rose St,Room 514, Lexington, KY 40536 USA.
EM tonglei@uky.edu
FU NSF [DMR-0449633]
FX We are thankful for the financial support by NSF (DMR-0449633).
CR Choi SH, 2008, FASEB J, V22, P1491, DOI 10.1096/fj.07-9411com
   Long SH, 2009, ACTA CRYSTALLOGR E, V65, pO360, DOI 10.1107/S1600536809001779
   Penning TD, 1997, J MED CHEM, V40, P1347, DOI 10.1021/jm960803q
   Teng XW, 2003, J PHARM PHARM SCI, V6, P205
NR 4
TC 0
Z9 0
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1530-9932
J9 AAPS PHARMSCITECH
JI AAPS PharmSciTech
PD JUN
PY 2010
VL 11
IS 2
BP 485
EP 488
DI 10.1208/s12249-010-9407-y
PG 4
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 612RY
UT WOS:000278921400001
PM 20306238
OA green_published
DA 2018-03-20
ER

PT J
AU Miller, AF
   Pitsawong, W
   Haynes, C
   Koder, R
   Rodgers, D
AF Miller, Anne-Frances
   Pitsawong, Warintra
   Haynes, Chad A.
   Koder, Ronald, Jr.
   Rodgers, David W.
TI Rate-Contributing Proton Transfers And Crystal Structures Of The
   Flavoenzyme Nitroreductase
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Experimental Biology Meeting
CY APR 02-06, 2016
CL San Diego, CA
SP Amer Assoc Anatomists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, Amer Soc Investigat Pathol, Amer Soc Nutr, Amer Soc Pharmacol & Expt Therapeut
C1 [Miller, Anne-Frances; Rodgers, David] Univ Kentucky, Lexington, KY USA.
   [Pitsawong, Warintra] Brandeis Univ, Waltham, MA USA.
   [Haynes, Chad] Booz Allen Hamilton, Washington, DC USA.
   [Koder, Ronald, Jr.] CUNY City Coll, New York, NY 10031 USA.
FU University of Kentuckty College of Arts and Sciences; Center for
   Pharmaceutical Development, NSF IUCRC
FX With support from the University of Kentuckty College of Arts and
   Sciences and the Center for Pharmaceutical Development, NSF IUCRC.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD APR
PY 2016
VL 30
SU 1
MA 636.1
PG 2
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA FB9FC
UT WOS:000406444006385
DA 2018-03-20
ER

PT J
AU Al-Sabbagh, M
   Romanos, G
   Price, SR
   Puleo, DA
   Robinson, FG
   Thomas, MV
AF Al-Sabbagh, Mohanad
   Romanos, Georgios
   Price, Scott R.
   Puleo, David A.
   Robinson, Fonda G.
   Thomas, Mark V.
TI Resistance of Mandibular Polyurethane Replicas to Fracture After Removal
   of Blocks From the Symphysis and Ramus
SO IMPLANT DENTISTRY
LA English
DT Article
DE displacement; load failure; ramus; donor
ID BIOMECHANICAL EVALUATION; BONE AUGMENTATION; PLACEMENT; TRAUMA; GRAFT
AB Background: When block grafts are harvested intraorally, the donor sites may act as stress concentrators and alter the structural integrity of the mandible.
   Purpose: The study aimed to compare displacement and load failure between intact polyurethane mandibular replicas and similar replicas from which blocks were taken at the symphysis or the ramus. It also aimed to identify trends of load failure.
   Materials and Methods: Thirty-five mandibular replicas were tested to failure with an electromagnetic material testing unit. The variables evaluated in this investigation were maximal load, displacement at maximal load, and fracture location.
   Results: Statistically significant differences in maximal load were detected between groups (P = 0.0008). Differences between fracture locations were also statistically significant (P < 0.0001). The mandibles from which blocks were removed at the symphysis were significantly more likely to break at a lower maximal load than were the control mandibles (P = 0.0010) or the mandibles from which blocks were removed at the ramus (P = 0.0162). They were also more likely than the control group to break at a lower displacement at maximal load (P = 0.0145).
   Conclusions: Location of the donor site significantly influences the structural integrity of mandibular replicas. In addition, the donor site significantly affects the location of mandibular fractures.
C1 [Al-Sabbagh, Mohanad; Price, Scott R.] Univ Kentucky, Coll Dent, Dept Oral Hlth Practice, Lexington, KY USA.
   [Al-Sabbagh, Mohanad] Univ Kentucky, Coll Dent, Dept Oral Hlth Practice, Periodontol, Lexington, KY USA.
   [Romanos, Georgios] SUNY Stony Brook, Sch Dent Med, Dept Periodontol, Stony Brook, NY USA.
   [Puleo, David A.] Univ Kentucky, Dept Biomed Engn, Lexington, KY USA.
   [Puleo, David A.] Univ Kentucky, Coll Engn, Res & Grad Studies, Lexington, KY USA.
   [Robinson, Fonda G.] Ohio State Univ, Coll Dent, Clin Adm & Patient Care, Columbus, OH 43210 USA.
   [Thomas, Mark V.] Univ Kentucky, Coll Dent, Dept Oral Hlth Practice, Lexington, KY USA.
RP Al-Sabbagh, M (reprint author), Univ Kentucky, Coll Dent, Dept Oral Hlth Practice, Div Periodontol, 800 Rose St, Lexington, KY 40536 USA.
EM malsa2@email.uky.edu
CR Bormann KH, 2009, J ORAL MAXIL SURG, V67, P1251, DOI 10.1016/j.joms.2008.09.022
   Bredbenner TL, 2000, ORAL SURG ORAL MED O, V90, P574, DOI 10.1067/moe.2000.111025
   Capelli M, 2003, INT J PERIODONT REST, V23, P277
   Gerbino G, 1999, J ORAL MAXIL SURG, V57, P777, DOI 10.1016/S0278-2391(99)90812-1
   GOLDSCHMIDT MJ, 1995, J ORAL MAXIL SURG, V53, P1145, DOI 10.1016/0278-2391(95)90620-7
   Haug RH, 1999, J ORAL MAXIL SURG, V57, P300, DOI 10.1016/S0278-2391(99)90677-8
   Haug RH, 2001, J ORAL MAXIL SURG, V59, P1199, DOI 10.1053/joms.2001.26726
   Hunt DR, 1999, INT J PERIODONT REST, V19, P165
   Kainulainen V., 2004, THESIS U OULU FINLAN
   Kainulainen VT, 2005, INT J ORAL MAX IMPL, V20, P245
   Madsen MJ, 2006, J ORAL MAXIL SURG, V64, P457, DOI 10.1016/j.joms.2005.11.018
   McAllister BS, 2007, J PERIODONTOL, V78, P377, DOI 10.1902/jop.2007.060048
   Misch C M, 2000, J Oral Implantol, V26, P42, DOI 10.1563/1548-1336(2000)026<0042:UOTMRA>2.3.CO;2
   Misch C M, 1995, Implant Dent, V4, P261, DOI 10.1097/00008505-199500440-00006
   Misch CM, 1999, J ORAL MAXIL SURG, V57, P1376, DOI 10.1016/S0278-2391(99)90882-0
   Montazem A, 2000, J ORAL MAXIL SURG, V58, P1368, DOI 10.1053/joms.2000.18268
   Peterson GP, 2005, J ORAL MAXIL SURG, V63, P1317, DOI 10.1016/j.joms.2005.05.301
   Pikos M A, 2000, Implant Dent, V9, P67, DOI 10.1097/00008505-200009010-00012
   SCHWIMMER A, 1983, AM J SPORT MED, V11, P262, DOI 10.1177/036354658301100415
   Tolman D E, 1995, Int J Oral Maxillofac Implants, V10, P275
   US Bureau of the Census, 1996, CURR POP REP P25 113
NR 21
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1056-6163
J9 IMPLANT DENT
JI Implant Dent.
PD JUN
PY 2017
VL 26
IS 3
BP 367
EP 372
DI 10.1097/ID.0000000000000540
PG 6
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA EW3JY
UT WOS:000402392800006
PM 28157815
DA 2018-03-20
ER

PT J
AU Xu, J
   Bhattacharyya, D
AF Xu, Jian
   Bhattacharyya, Dibakar
TI Fe/Pd nanoparticle immobilization in microfiltration membrane pores:
   Synthesis, characterization, and application in the dechlorination of
   polychlorinated biphenyls
SO INDUSTRIAL & ENGINEERING CHEMISTRY RESEARCH
LA English
DT Article; Proceedings Paper
CT Conference on Advanced Membrane Technol III Membrane Engineering for
   Process Intensification
CY JUN 11-15, 2006
CL Cetraro, ITALY
ID ULTRATHIN TIO2-GEL FILMS; BIMETALLIC NANOPARTICLES; TRICHLOROETHENE
   HYDRODECHLORINATION; CATALYTIC HYDRODECHLORINATION; METAL NANOPARTICLES;
   GOLD NANOPARTICLES; ZEROVALENT IRON; WATER; DEGRADATION; REDUCTION
AB Nanosized Fe/Pd bimetallic particles are an important category of materials in the area of reductive degradation of chlorinated organics. In this work, we prepared Fe/Pd nanoparticles in three steps: polymerization of acrylic acid (AA) in poly(vinylidene fluoride) (PVDF) microfiltration membrane pores, subsequent ion exchange of Fe2+, and chemical reduction (by borohydride) of ferrous ions bound to the carboxylic acid groups. Fe/Pd bimetallic nanoparticles were formed by the partial reduction of Pd2+ with Fe-0 nanoparticles. The functionalized membrane and the nanoparticles were characterized by scanning electron microscopy (SEM) and transmission electron microscopy (TEM). The membrane-supported nanoparticles exhibited high reactivity in the dechlorination of 2,2'-dichlorobiphenyl (DiCB) used as a model compound. The dechlorination mechanism and the role of water were probed by conducting the reaction in pure ethanol solution. Bulk Fe/Pd particles were also prepared to investigate the effect of particle size on the catalytic activity. The effect of Pd content on the catalytic activity was studied to understand and quantify the role of Pd in the bimetallic nanoparticle system. The high catalytic activity of Pd was confirmed by the low activation energy compared to those other catalytic systems.
C1 Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Bhattacharyya, D (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM db@engr.uky.edu
CR BODNARIUK P, 1989, J CATAL, V116, P459, DOI 10.1016/0021-9517(89)90112-7
   CHUANG FW, 1995, ENVIRON SCI TECHNOL, V29, P2460, DOI 10.1021/es00009a044
   Damle C, 2001, LANGMUIR, V17, P7156, DOI 10.1021/la0108353
   Fukasawa T, 2005, J AM CERAM SOC, V88, P2938, DOI [10.1111/j.1551-2916.2005.00503.x, 10.1111/j.1551-2916.2005.005030.x]
   GABRIEL EM, 1993, J APPL POLYM SCI, V48, P2081, DOI 10.1002/app.1993.070481202
   Gryglewicz G, 2006, CHEMOSPHERE, V62, P135, DOI 10.1016/j.chemosphere.2005.03.097
   He F, 2005, ENVIRON SCI TECHNOL, V39, P3314, DOI 10.1021/es048743y
   He JH, 2003, J AM CHEM SOC, V125, P11034, DOI 10.1021/ja035970b
   He JH, 2002, LANGMUIR, V18, P10005, DOI 10.1021/la0260584
   Henry CR, 1998, CRYST RES TECHNOL, V33, P1119, DOI 10.1002/(SICI)1521-4079(199810)33:7/8<1119::AID-CRAT1119>3.0.CO;2-V
   Ikeda S, 2004, J PHYS CHEM B, V108, P15599, DOI 10.1021/jp0478559
   Jain PK, 2006, J PHYS CHEM B, V110, P7238, DOI 10.1021/jp057170o
   Jiang CY, 2004, NAT MATER, V3, P721, DOI 10.1038/nmat1212
   Johnson TL, 1996, ENVIRON SCI TECHNOL, V30, P2634, DOI 10.1021/es9600901
   Jovanovic GN, 2005, IND ENG CHEM RES, V44, P5099, DOI 10.1021/ie049496+
   Liu YQ, 2005, CHEM MATER, V17, P5315, DOI 10.1021/cm0511217
   Liu YQ, 2005, ENVIRON SCI TECHNOL, V39, P1338, DOI 10.1021/es049195r
   Liu ZL, 2004, J PHYS CHEM B, V108, P8234, DOI 10.1021/jp049422b
   Lowry GV, 2004, ENVIRON SCI TECHNOL, V38, P5208, DOI 10.1021/es049835q
   Mika AM, 1997, J MEMBRANE SCI, V135, P81, DOI 10.1016/S0376-7388(97)00122-1
   Murena F, 2000, ENVIRON SCI TECHNOL, V34, P4382, DOI 10.1021/es000015x
   Nasef MM, 2006, J MEMBRANE SCI, V268, P96, DOI 10.1016/j.memsci.2005.06.009
   Nutt MO, 2005, ENVIRON SCI TECHNOL, V39, P1346, DOI 10.1021/es048560b
   Park KT, 1997, J PHYS CHEM B, V101, P5420, DOI 10.1021/jp9711398
   Patolsky F, 2004, NAT MATER, V3, P692, DOI 10.1038/nmat1205
   Paul S, 2003, NANO LETT, V3, P533, DOI 10.1021/nl034008t
   Pivin JC, 2006, J PHYS D APPL PHYS, V39, P2955, DOI 10.1088/0022-3727/39/14/013
   Ritchie SMC, 2001, ENVIRON SCI TECHNOL, V35, P3252, DOI 10.1021/es010617w
   Scott RWJ, 2005, J PHYS CHEM B, V109, P692, DOI 10.1021/jp0469665
   SHEN JY, 1993, J PHYS CHEM-US, V97, P8504, DOI 10.1021/j100134a020
   Su CM, 1999, ENVIRON SCI TECHNOL, V33, P163, DOI 10.1021/es980481a
   Tee YH, 2005, IND ENG CHEM RES, V44, P7062, DOI 10.1021/ie050086a
   Tomida T, 2001, IND ENG CHEM RES, V40, P3557, DOI 10.1021/ie0009839
   Wang TC, 2002, LANGMUIR, V18, P3370, DOI 10.1021/la015725a
   Wei JJ, 2006, WATER RES, V40, P348, DOI 10.1016/j.watres.2005.10.017
   Williams D. B., 1996, TRANSMISSION ELECT M
   Worden JG, 2004, CHEM MATER, V16, P3746, DOI 10.1021/cm048907+
   Xu J, 2005, ENVIRON PROG, V24, P358, DOI 10.1002/ep.10106
   Xu J, 2005, J NANOPART RES, V7, P449, DOI 10.1007/s11051-005-4273-3
   Yakushiji K, 2005, NAT MATER, V4, P57, DOI 10.1038/nmat1278
   YAMAGUCHI T, 1991, MACROMOLECULES, V24, P5522, DOI 10.1021/ma00020a006
   Zhou JS, 2005, J MEMBRANE SCI, V254, P89, DOI 10.1016/j.memsci.2004.12.043
NR 42
TC 98
Z9 100
U1 2
U2 41
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0888-5885
J9 IND ENG CHEM RES
JI Ind. Eng. Chem. Res.
PD APR 11
PY 2007
VL 46
IS 8
BP 2348
EP 2359
DI 10.1021/ie0611498
PG 12
WC Engineering, Chemical
SC Engineering
GA 153CF
UT WOS:000245408600016
DA 2018-03-19
ER

PT J
AU Yu, CG
   Yezierski, RP
   Joshi, A
   Raza, K
   Li, YZ
   Geddes, JW
AF Yu, Chen-Guang
   Yezierski, Robert P.
   Joshi, Aashish
   Raza, Kashif
   Li, YongChao
   Geddes, James W.
TI Targeting ERK2 with lentiviral shRNA improves tissue sparing and
   locomotor function after spinal cord injury
SO JOURNAL OF NEUROTRAUMA
LA English
DT Meeting Abstract
CT 26th Annual National-Neurotrauma-Society Symposium
CY JUL 27-30, 2008
CL Orlando, FL
SP Natl Neurotrauma Soc
C1 [Yu, Chen-Guang; Joshi, Aashish; Raza, Kashif; Li, Yanzhang; Geddes, James W.] Univ Kentucky, Lexington, KY USA.
   [Yezierski, Robert P.] Univ Florida, Gainesville, FL USA.
RI Yu, Chen Guang/C-6176-2011
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0897-7151
J9 J NEUROTRAUM
JI J. Neurotrauma
PD JUL
PY 2008
VL 25
IS 7
MA P227
BP 910
EP 910
PG 1
WC Critical Care Medicine; Clinical Neurology; Neurosciences
SC General & Internal Medicine; Neurosciences & Neurology
GA 326BX
UT WOS:000257634000234
DA 2018-03-20
ER

PT J
AU Koganti, VR
   Rankin, SE
AF Koganti, Venkat R.
   Rankin, Stephen E.
TI Nano-crystalline titania films with orthogonally aligned nanopore arrays
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
CT 231st National Meeting of the American-Chemical-Society
CY MAR 26-30, 2006
CL Atlanta, GA
SP Amer Chem Soc
C1 Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40508 USA.
EM vrkoga0@engr.uky.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD MAR 26
PY 2006
VL 231
MA 50-COLL
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA 050YE
UT WOS:000238125903050
DA 2018-03-20
ER

PT J
AU Hawkins, AM
   Milbrandt, TA
   Puleo, DA
   Hilt, JZ
AF Hawkins, Ashley M.
   Milbrandt, Todd A.
   Puleo, David A.
   Hilt, J. Zach
TI Synthesis and analysis of degradation, mechanical and toxicity
   properties of poly(beta-amino ester) degradable hydrogels
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Poly(beta-amino ester); Biodegradable hydrogels; Tissue regeneration;
   Cell attachment; Cytotoxicity
ID POLY(ETHYLENE GLYCOL) HYDROGELS; NETWORK PROPERTIES; POLYMER LIBRARY;
   CELL-LINES; DELIVERY; POLYANHYDRIDES; PROLIFERATION; NANOCOMPOSITE;
   BIOMATERIALS; COMPRESSION
AB Biodegradable hydrogels have been studied extensively in recent years for biomedical applications, including tissue engineering and drug delivery, due to their tunable properties and similarities to natural soft tissue In this work, two poly(B-amino ester) biodegradable hydrogel systems were synthesised and studied in vitro Different degradation profiles were observed, ranging from 7 h to 4 months, and the compressive modulus was shown to decrease as degradation proceeded mu cytotoxicity analysis was used to analyze the cellular response to the degradation products, and the hydrogel systems exhibited similar toxicity to poly( dl-lactide-co-glycolide) degradation products Finally, cell attachment was studied by seeding pluripotent mesenchymal cells directly onto the hydrogel surfaces followed by a live/dead assay and fluorescent imaging Cells showed significant viability at 24 h (98%) and slightly lower, but still substantial viability, at 48 h (72%) These hydrogels exhibited a range of properties and favorable cellular responses, all which indicate that these materials could be viable materials for tissue regeneration and other biomedical applications (C) 2011 Acta Materialia Inc Published by Elsevier Ltd All rights reserved
C1 [Hawkins, Ashley M.; Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Milbrandt, Todd A.] Univ Kentucky, Dept Orthopaed Surg, Lexington, KY 40536 USA.
   [Milbrandt, Todd A.] Shriners Hosp Children, Lexington, KY 40502 USA.
   [Puleo, David A.] Univ Kentucky, Ctr Biomed Engn, Lexington, KY 40506 USA.
RP Hilt, JZ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
FU NSF-IGERT; Kosair Charities, Inc.
FX The authors would like to acknowledge NSF-IGERT and Kosair Charities,
   Inc., for their funding support.
CR Anderson DG, 2006, ADV MATER, V18, P2614, DOI 10.1002/adma.200600529
   Anderson DG, 2004, P NATL ACAD SCI USA, V101, P16028, DOI 10.1073/pnas.0407218101
   Anderson DG, 2003, ANGEW CHEM INT EDIT, V42, P3153, DOI 10.1002/anie.200351244
   Ashton RS, 2007, BIOMATERIALS, V28, P5518, DOI 10.1016/j.biomaterials.2007.08.038
   Berski S, 2008, BIOMACROMOLECULES, V9, P2353, DOI 10.1021/bm800327s
   Brey DM, 2008, J BIOMED MATER RES A, V85A, P731, DOI 10.1002/jbm.a.31494
   Brey DM, 2008, ACTA BIOMATER, V4, P207, DOI 10.1016/j.actbio.2007.10.002
   Brey DM, 2010, J BIOMED MATER RES A, V93A, P807, DOI 10.1002/jbm.a.32769
   Bryant SJ, 2002, J BIOMED MATER RES, V59, P63, DOI 10.1002/jbm.1217
   Bryant SJ, 2003, J BIOMED MATER RES A, V64A, P70, DOI 10.1002/jbm.a.10319
   Burkoth AK, 2000, BIOMATERIALS, V21, P2395, DOI 10.1016/S0142-9612(00)00107-1
   GARN H, 1994, J IMMUNOL METHODS, V168, P253, DOI 10.1016/0022-1759(94)90062-0
   Green JJ, 2008, NANO LETT, V8, P3126, DOI 10.1021/nl8012665
   HAWKINS AM, J APPL POLY IN PRESS
   Hawkins AM, 2009, PHARM RES-DORD, V26, P667, DOI 10.1007/s11095-008-9804-z
   Hou S, 2007, MACROMOL BIOSCI, V7, P620, DOI 10.1002/mabi.200600256
   Ifkovits JL, 2007, TISSUE ENG, V13, P2369, DOI 10.1089/ten.2007.0093
   Joshi A, 2006, BIOMATERIALS, V27, P176, DOI 10.1016/j.biomaterials.2005.06.003
   Kashyap N, 2005, CRIT REV THER DRUG, V22, P107, DOI 10.1615/CritRevTherDrugCarrierSyst.v22.i2.10
   Keim T, 2010, J BIOMED MATER RES A, V92A, P702, DOI 10.1002/jbm.a.32195
   Kopecek J, 2003, EUR J PHARM SCI, V20, P1, DOI 10.1016/S0928-0987(03)00164-7
   Lei YG, 2009, BIOMATERIALS, V30, P254, DOI 10.1016/j.biomaterials.2008.09.027
   Liao SW, 2009, J AM CHEM SOC, V131, P17638, DOI 10.1021/ja907097t
   Lynn DM, 2000, J AM CHEM SOC, V122, P10761, DOI 10.1021/ja0015388
   Mc Bath RA, 2010, POLYM CHEM-UK, V1, P860, DOI 10.1039/c0py00074d
   Millon LE, 2009, J BIOMED MATER RES B, V90B, P922, DOI 10.1002/jbm.b.31364
   Mosley JR, 1998, BONE, V23, P313, DOI 10.1016/S8756-3282(98)00113-6
   Muniz EC, 2001, MACROMOLECULES, V34, P4480, DOI 10.1021/ma001192l
   Nascimento MSJ, 2004, PHARM BIOL, V42, P449, DOI 10.1080/13880200490894824
   OLOYEDE A, 1992, CONNECT TISSUE RES, V27, P211, DOI 10.3109/03008209209006997
   Pedro M, 2002, BIOORGAN MED CHEM, V10, P3725, DOI 10.1016/S0968-0896(02)00379-6
   Safranski DL, 2010, POLYMER, V51, P3130, DOI 10.1016/j.polymer.2010.05.029
   SAWHNEY AS, 1993, MACROMOLECULES, V26, P581, DOI 10.1021/ma00056a005
   Slaughter BV, 2009, ADV MATER, V21, P3307, DOI 10.1002/adma.200802106
   Stammen JA, 2001, BIOMATERIALS, V22, P799, DOI 10.1016/S0142-9612(00)00242-8
   Tan AR, 2008, J BIOMED MATER RES A, V87A, P1034, DOI 10.1002/jbm.a.31853
NR 36
TC 23
Z9 23
U1 0
U2 28
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742-7061
J9 ACTA BIOMATER
JI Acta Biomater.
PD MAY
PY 2011
VL 7
IS 5
BP 1956
EP 1964
DI 10.1016/j.actbio.2011.01.024
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 764RH
UT WOS:000290649500003
PM 21252001
DA 2018-03-20
ER

PT J
AU Li, HF
   Knutson, BL
   Nokes, SE
   Lynn, BC
   Flythe, MD
AF Li, Hsin-Fen
   Knutson, Barbara L.
   Nokes, Sue E.
   Lynn, Bert C.
   Flythe, Michael D.
TI Metabolic control of Clostridium thermocellum via inhibition of
   hydrogenase activity and the glucose transport rate
SO APPLIED MICROBIOLOGY AND BIOTECHNOLOGY
LA English
DT Article
DE Chemostat; Consolidated bioprocessing; Cellulosic biomass conversion;
   Cellulose; Metabolic engineering; Product selectivity; Continuous
   culture; Paraquat
ID METHYL VIOLOGEN; CONTINUOUS-CULTURE; ETHANOL-PRODUCTION;
   ESCHERICHIA-COLI; FERMENTATION; GROWTH; SELECTIVITY; PRODUCTS; BACTERIA;
   YIELDS
AB Clostridium thermocellum has the ability to catabolize cellulosic biomass into ethanol, but acetic acid, lactic acid, carbon dioxide, and hydrogen gas (H-2) are also produced. The effect of hydrogenase inhibitors (H-2, carbon monoxide (CO), and methyl viologen) on product selectivity was investigated. The anticipated effect of these hydrogenase inhibitors was to decrease acetate production. However, shifts to ethanol and lactate production are also observed as a function of cultivation conditions. When the sparge gas of cellobiose-limited chemostat cultures was switched from N-2 to H-2, acetate declined, and ethanol production increased 350%. In resting cell suspensions, lactate increased when H-2 or CO was the inhibitor or when the cells were held at elevated hyperbaric pressure (6.8 atm). In contrast, methyl-viologen-treated resting cells produced twice as much ethanol as the other treatments. The relationship of chemostat physiology to methyl viologen inhibition was revealed by glucose transport experiments, in which methyl viologen decreased the rate of glucose transport by 90%. C. thermocellum produces NAD(+) from NADH by H-2, lactate, and ethanol production. When the hydrogenases were inhibited, the latter two products increased. However, excess substrate availability causes fructose 1,6-diphosphate, the glycolytic intermediate that triggers lactate production, to increase. Compensatory ethanol production was observed when the chemostat fluid dilution rate or methyl viologen decreased substrate transport. This research highlights the complex effects of high concentrations of dissolved gases in fermentation, which are increasingly envisioned in microbial applications of H-2 production for the conversion of synthetic gases to chemicals.
C1 [Flythe, Michael D.] Univ Kentucky, Dept Anim & Food Sci, Lexington, KY 40546 USA.
   [Li, Hsin-Fen; Knutson, Barbara L.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Nokes, Sue E.] Univ Kentucky, Dept Biosyst & Agr Engn, Lexington, KY 40546 USA.
   [Lynn, Bert C.] Univ Kentucky, Dept Chem, Lexington, KY 40546 USA.
   [Flythe, Michael D.] ARS, Forage Anim Prod Res Unit, USDA, Lexington, KY 40546 USA.
RP Flythe, MD (reprint author), Univ Kentucky, Dept Anim & Food Sci, Lexington, KY 40546 USA.
EM michael.flythe@ars.usda.gov
RI Flythe, Michael/F-2500-2010
OI Flythe, Michael/0000-0002-8868-9169
FU Southeastern Sun Grant Center [DTOS59-07-G-0050]; Agricultural Research
   Service, USDA
FX The authors gratefully acknowledge the financial support of the
   Southeastern Sun Grant Center, administered by the University of
   Tennessee, grant number DTOS59-07-G-0050. MF was supported by the
   Agricultural Research Service, USDA. The authors would like to thank
   Gloria Gellin and Jerry Vice for the technical assistance.
CR Bailey JE, 1996, BIOTECHNOL BIOENG, V52, P109, DOI 10.1002/(SICI)1097-0290(19961005)52:1<109::AID-BIT11>3.3.CO;2-1
   Berberich JA, 2000, IND ENG CHEM RES, V39, P4500, DOI 10.1021/ie0001265
   Biswas S, 2011, ANTIMICROB AGENTS CH, V55, P1460, DOI 10.1128/AAC.01094-10
   Bothun GD, 2004, APPL MICROBIOL BIOT, V65, P149, DOI 10.1007/s00253-004-1554-1
   BUS JS, 1976, ENVIRON HEALTH PERSP, V16, P139, DOI 10.2307/3428594
   COTTA MA, 1982, J DAIRY SCI, V65, P226, DOI 10.3168/jds.S0022-0302(82)82181-4
   Datar RP, 2004, BIOTECHNOL BIOENG, V86, P587, DOI 10.1002/bit.20071
   Desvaux M, 2005, FEMS MICROBIOL REV, V29, P741, DOI 10.1016/j.femsre.2004.11.003
   Gaughran ERL, 1947, MICROBIOL MOL BIOL R, V11, P189
   GonzalezFlecha B, 1997, J BACTERIOL, V179, P382, DOI 10.1128/jb.179.2.382-388.1997
   Gottschalk G., 1986, BACTERIAL METABOLISM
   Henstra AM, 2007, CURR OPIN BIOTECH, V18, P200, DOI 10.1016/j.copbio.2007.03.008
   HOGSETT DA, 1992, APPL BIOCHEM BIOTECH, V34-5, P527, DOI 10.1007/BF02920576
   LAMED R, 1980, J BACTERIOL, V144, P569
   LAMED RJ, 1988, APPL ENVIRON MICROB, V54, P1216
   Lin MZ, 2004, J PHYS CHEM A, V108, P8287, DOI 10.1021/jp048854j
   MACMICHAEL GJ, 1988, J BACTERIOL, V170, P4995, DOI 10.1128/jb.170.10.4995-4998.1988
   Mitchell D., 2008, NOTE RISING FOOD PRI
   MURRAY WD, 1983, CAN J MICROBIOL, V29, P342, DOI 10.1139/m83-057
   Ozkan M, 2004, CAN J MICROBIOL, V50, P845, DOI 10.1139/W04-071
   Pimentel D., 2005, NAT RESOUR RES, V14, P65, DOI DOI 10.1007/S11053-005-4679-8
   RAO G, 1987, APPL ENVIRON MICROB, V53, P1232
   Reimann A, 1996, APPL MICROBIOL BIOT, V45, P47, DOI 10.1007/s002530050647
   Russell JB, 1996, RES MICROBIOL, V147, P528, DOI 10.1016/0923-2508(96)84008-3
   Rydzak T, 2009, J BIOTECHNOL, V140, P169, DOI 10.1016/j.jbiotec.2009.01.022
   Shin HS, 2002, APPL MICROBIOL BIOT, V58, P476, DOI 10.1007/s00253-001-0923-2
   STROBEL HJ, 1995, APPL ENVIRON MICROB, V61, P4012
   WEIMER PJ, 1977, APPL ENVIRON MICROB, V33, P289
   ZEIKUS JG, 1980, ANNU REV MICROBIOL, V34, P423, DOI 10.1146/annurev.mi.34.100180.002231
NR 29
TC 11
Z9 11
U1 0
U2 34
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0175-7598
J9 APPL MICROBIOL BIOT
JI Appl. Microbiol. Biotechnol.
PD FEB
PY 2012
VL 93
IS 4
BP 1777
EP 1784
DI 10.1007/s00253-011-3812-3
PG 8
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA 892UC
UT WOS:000300310100039
PM 22218768
DA 2018-03-20
ER

PT J
AU Clark, A
   Milbrandt, TA
   Hilt, JZ
   Puleo, DA
AF Clark, Amanda
   Milbrandt, Todd A.
   Hilt, J. Zach
   Puleo, David A.
TI Tailoring properties of microsphere-based poly(lactic-co-glycolic acid)
   scaffolds
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
LA English
DT Article
DE scaffolds; microspheres; biodegradable; poly(lactic-co-glycolic acid);
   compressive modulus; degradation
ID CELLS IN-VITRO; MECHANICAL-PROPERTIES; ARTICULAR-CARTILAGE; PLGA
   MICROSPHERES; PROTEIN DENATURATION; TIBIAL FRACTURES; BIOACTIVE GLASS;
   TRABECULAR BONE; HEAT-SHOCK; IGF-I
AB Biodegradable polymer scaffolds are being extensively investigated for uses in tissue engineering because of their versatility in fabrication methods and range of achievable chemical and mechanical properties. In this study, poly(lactic-co-glycolic acid) (PLGA) was used to make various types of microspheres that were processed into porous scaffolds that possessed a wide range of properties. A heat sintering step was used to fuse microspheres together around porogen particles that were subsequently leached out, allowing for a 10-fold increase in mechanical properties over other PLGA scaffolds. The sintering temperature was based on the glass transition temperature that ranged from 43 to 49 degrees C, which was low enough to enable drug loading. Degradation times were observed to be between 30 and 120 days, with an initial compressive modulus ranging from 10 to 100MPa, and after 5 days of degradation up to 10MPa was retained. These scaffolds were designed to allow for cell ingrowth, enable drug loading, and have an adjustable compressive modulus to be applicable for soft or hard tissue implants. This study combined well-established methods, such as double emulsion microspheres, polymer sintering, and salt leaching, to fabricate polymer scaffolds useful for different tissue engineering applications. (c) 2013 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 102A: 348-357, 2014.
C1 [Clark, Amanda; Milbrandt, Todd A.; Puleo, David A.] Univ Kentucky, Ctr Biomed Engn, Lexington, KY 40506 USA.
   [Milbrandt, Todd A.; Puleo, David A.] Univ Kentucky, Dept Orthopaed Surg, Lexington, KY USA.
   [Milbrandt, Todd A.] Shriners Hosp Children, Lexington, KY USA.
   [Hilt, J. Zach] Univ Kentucky, Lexington, KY USA.
RP Puleo, DA (reprint author), Univ Kentucky, Ctr Biomed Engn, Lexington, KY 40506 USA.
EM puleo@uky.edu
FU Kosair Charities, Inc.; Pediatric Orthopaedic Society of North America;
   NSF [EPS-0814194]; NSF IGERT traineeship [DGE-0653710]
FX Contract grant sponsor: Kosair Charities, Inc., Pediatric Orthopaedic
   Society of North America, and NSF; contract grant number: EPS-0814194;
   Contract grant sponsor: NSF IGERT traineeship to AC; contract grant
   number: DGE-0653710
CR Agrawal CM, 2001, J BIOMED MATER RES, V55, P141, DOI 10.1002/1097-4636(200105)55:2<141::AID-JBM1000>3.0.CO;2-J
   Anderson JM, 1997, ADV DRUG DELIVER REV, V28, P5, DOI 10.1016/S0169-409X(97)00048-3
   ARAKAWA T, 1991, PHARMACEUT RES, V8, P285, DOI 10.1023/A:1015825027737
   ASAKURA T, 1978, J BIOL CHEM, V253, P6423
   Borden M, 2002, BIOMATERIALS, V23, P551, DOI 10.1016/S0142-9612(01)00137-5
   Brown JL, 2008, J BIOMED MATER RES B, V86B, P396, DOI 10.1002/jbm.b.31033
   Burkersroda FV, 2002, BIOMATERIALS, V23, P4221, DOI DOI 10.1016/S0142-9612(02)00170-9
   Buschmann J, 2012, INJURY, V43, P1689, DOI 10.1016/j.injury.2012.06.004
   DiCarlo BB, 2009, P I MECH ENG H, V223, P63, DOI 10.1243/09544119JEIM424
   Fernandez-Martin F, 2000, J FOOD SCI, V65, P1002, DOI 10.1111/j.1365-2621.2000.tb09407.x
   Fu K, 2000, PHARMACEUT RES, V17, P100, DOI 10.1023/A:1007582911958
   Govender S, 2002, J BONE JOINT SURG AM, V84A, P2123, DOI 10.2106/00004623-200212000-00001
   Harris LD, 1998, J BIOMED MATER RES, V42, P396, DOI 10.1002/(SICI)1097-4636(19981205)42:3<396::AID-JBM7>3.3.CO;2-P
   HOFMANN GE, 1995, J EXP BIOL, V198, P1509
   Hou QP, 2003, BIOMATERIALS, V24, P1937, DOI 10.1016/S0142-9612(02)00562-8
   Houchin ML, 2008, J PHARM SCI-US, V97, P2395, DOI 10.1002/jps.21176
   Jabbarzadeh E, 2012, J BIOMED MATER RES B, V100B, P2187, DOI 10.1002/jbm.b.32787
   Jiang T, 2006, BIOMATERIALS, V27, P4894, DOI 10.1016/j.biomaterials.2006.05.025
   Jiang T, 2010, J BIOMED MATER RES A, V93A, P1193, DOI 10.1002/jbm.a.32615
   KAMPINGA HH, 1995, EXP CELL RES, V219, P536, DOI 10.1006/excr.1995.1262
   KENLEY RA, 1987, MACROMOLECULES, V20, P2398, DOI 10.1021/ma00176a012
   KITCHELL JP, 1985, METHOD ENZYMOL, V112, P436
   Lee JY, 2009, BIOMATERIALS, V30, P4325, DOI 10.1016/j.biomaterials.2009.04.042
   Liang-chang D., 1992, J CONTROL RELEASE, V19, P171
   Liao SW, 2007, TISSUE ENG, V13, P2855, DOI 10.1089/ten.2007.0009
   Lin ZY, 2010, J CONTROL RELEASE, V144, P190, DOI 10.1016/j.jconrel.2010.02.016
   Linnes MP, 2007, BIOMATERIALS, V28, P5298, DOI 10.1016/j.biomaterials.2007.08.020
   Liu HN, 2010, INT J NANOMED, V5, P299
   Lo H, 1995, Tissue Eng, V1, P15, DOI 10.1089/ten.1995.1.15
   LOTZ JC, 1990, J COMPUT ASSIST TOMO, V14, P107, DOI 10.1097/00004728-199001000-00020
   Lowry J, 2006, ANN R COLL SURG ENGL, V88, P334, DOI DOI 10.1308/RCSANN.2006.88.3.334A
   Lu HH, 2003, J BIOMED MATER RES A, V64A, P465, DOI 10.1002/jbm.a.10399
   Madry H, 2005, GENE THER, V12, P1171, DOI 10.1038/sj.gt.3302515
   Miao X, 2007, MAT SCI ENG C-BIO S, V27, P274, DOI 10.1016/j.msec.2006.05.008
   Mikos AG, 2000, ELECTRON J BIOTECHN, P315
   Nazarov R, 2004, BIOMACROMOLECULES, V5, P718, DOI 10.1021/bm034327e
   Nettesheim P, 1972, ORGAN TISSUE REGENER, P161
   NIELSEN HM, 1994, ACTA ORTHOP SCAND, V65, P37, DOI 10.3109/17453679408993715
   Pattison MA, 2005, BIOMATERIALS, V26, P2491, DOI 10.1016/j.biomaterials.2004.07.011
   Popp JR, 2012, J TISSUE ENG REGEN M, V6, P12, DOI 10.1002/term.390
   Prasad S, 2008, CLIN OTOLARYNGOL, V33, P304
   Schinagl RM, 1997, J ORTHOPAED RES, V15, P499, DOI 10.1002/jor.1100150404
   Sergerie K, 2009, J BIOMECH, V42, P510, DOI 10.1016/j.jbiomech.2008.11.026
   Shea LD, 2000, TISSUE ENG, V6, P605, DOI 10.1089/10763270050199550
   Stein D, 2005, J PERIODONTOL, V76, P1861, DOI 10.1902/jop.2005.76.11.1861
   THOMSON RC, 1995, J BIOMAT SCI-POLYM E, V7, P23
   Tracy MA, 1999, BIOMATERIALS, V20, P1057, DOI 10.1016/S0142-9612(99)00002-2
   WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220
   WESTRA A, 1971, INT J RADIAT BIOL RE, V19, P467, DOI 10.1080/09553007114550601
   Willie BM, 2010, SOFT MATTER, V6, P4976, DOI 10.1039/c0sm00262c
   Wu LB, 2004, BIOMATERIALS, V25, P5821, DOI 10.1016/j.biomaterials.2004.01.038
   Wu XS, 2001, J BIOMAT SCI-POLYM E, V12, P21, DOI 10.1163/156856201744425
   Yadav JK, 2009, J BIOSCIENCES, V34, P377, DOI 10.1007/s12038-009-0044-0
   Zolnik BS, 2008, J CONTROL RELEASE, V127, P137, DOI 10.1016/j.jconrel.2008.01.004
NR 54
TC 10
Z9 10
U1 1
U2 49
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1549-3296
EI 1552-4965
J9 J BIOMED MATER RES A
JI J. Biomed. Mater. Res. Part A
PD FEB
PY 2014
VL 102
IS 2
BP 348
EP 357
DI 10.1002/jbm.a.34706
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 269MT
UT WOS:000328246100006
PM 23533090
DA 2018-03-19
ER

PT J
AU Mattei, A
   Li, TL
AF Mattei, Alessandra
   Li, Tonglei
TI Interplay between molecular conformation and intermolecular interactions
   in conformational polymorphism: A molecular perspective from electronic
   calculations of tolfenamic acid
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Polymorphism; Molecular conformation; Intermolecular interactions;
   Conceptual density functional calculations
ID DENSITY-FUNCTIONAL THEORY; POLARIZABLE CONTINUUM MODEL;
   CHEMICAL-REACTIVITY; ORGANIC-CRYSTALS; DUAL DESCRIPTOR; HYDROGEN-BOND;
   SOLID-STATE; ENERGY; CRYSTALLIZATION; SOLVENT
AB Tolfenamic acid exhibits conformational polymorphism. The molecules in its two commonly occurred crystal structures form similar hydrogen-bonded dimers but differ in conformation. The conformational variance was analyzed by electronic calculation methods with the aim to unravel intrinsic connection between the conformational flexibility and intermolecular interactions in the polymorphs. The study was conducted mainly by conceptual density functional theory (OFT) and natural bond orbital (NBO) analysis. It is found that the conformational polymorphism is resulted from the energy competition between intramolecular pi-conjugation and intermolecular hydrogen bonding. By adapting conformation that departs from being the most energetically stable, tolfenamic acid molecules can strengthen the intermolecular hydrogen-bonding interactions in the crystals. The study illustrates how the molecule's electronic properties are influenced by conformational variation and, inherently, how the intermolecular interactions become regulated. Moreover, understanding molecular interaction and crystal packing necessitates electronic structure calculation and analysis, which can be further facilitated by utilizing DFT and NBO concepts. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Mattei, Alessandra; Li, Tonglei] Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
RP Li, TL (reprint author), Univ Kentucky, Dept Pharmaceut Sci, Room 375,Biol Pharmaceut Complex,789 S Limestone, Lexington, KY 40536 USA.
EM tonglei@uky.edu
FU NSF [DMR-0449633, DMR-1006364]
FX The authors acknowledge the Institute for High Performance Computing and
   the Center for Computational Sciences, University of Kentucky, for
   providing the computer resources. The study was supported by NSF
   (DMR-0449633 and DMR-1006364).
CR ADDADI L, 1985, ANGEW CHEM INT EDIT, V24, P466, DOI 10.1002/anie.198504661
   Amovilli C, 1998, ADV QUANTUM CHEM, V32, P227, DOI 10.1016/S0065-3276(08)60416-5
   ANDERSEN KV, 1989, J CHEM SOC PERK T 2, P1443, DOI 10.1039/p29890001443
   Aubrey-Medendorp C, 2008, PHARM RES, V25, P953, DOI 10.1007/s11095-007-9346-9
   Ayers PW, 2008, J MATH CHEM, V43, P285, DOI 10.1007/s10910-006-9195-5
   Ayers PW, 2007, CHEM-EUR J, V13, P8240, DOI 10.1002/chem.200700365
   Ayers PW, 2007, FARADAY DISCUSS, V135, P161, DOI 10.1039/b606877d
   Ayers PW, 2000, THEOR CHEM ACC, V103, P353, DOI 10.1007/s002149900093
   Ayers PW, 2002, J CHEM PHYS, V116, P8731, DOI 10.1063/1.1467338
   Barone V, 1997, J CHEM PHYS, V107, P3210, DOI 10.1063/1.474671
   BECKE AD, 1988, PHYS REV A, V38, P3098, DOI 10.1103/PhysRevA.38.3098
   BOYS SF, 1970, MOL PHYS, V19, P553, DOI 10.1080/00268977000101561
   Brittain H. G, 2009, POLYMORPHISM PHARM S
   Byrn S. R., 1999, SOLID STATE CHEM DRU
   Cardenas C, 2009, J PHYS CHEM A, V113, P8660, DOI 10.1021/jp902792n
   Davey RJ, 1997, J AM CHEM SOC, V119, P1767, DOI 10.1021/ja9626345
   Dennington II R., 2003, GAUSSVIEW VERSION 4
   Desiraju GR, 2007, ANGEW CHEM INT EDIT, V46, P8342, DOI 10.1002/anie.200700534
   Dobson JF, 2001, AUST J CHEM, V54, P513, DOI 10.1071/CH01052
   Dunitz JD, 2009, CHEM SOC REV, V38, P2622, DOI 10.1039/b822963p
   ETTER MC, 1990, ACCOUNTS CHEM RES, V23, P120, DOI 10.1021/ar00172a005
   Feng XT, 2009, J PHYS CHEM B, V113, P13381, DOI 10.1021/jp905885y
   Frenking G, 2000, CHEM REV, V100, P717, DOI 10.1021/cr980401l
   Geerlings P, 2003, CHEM REV, V103, P1793, DOI 10.1021/cr990029p
   Hollingsworth MD, 2002, SCIENCE, V295, P2410
   Huang Y, 2008, J PHYS CHEM A, V112, P305, DOI 10.1021/jp077178t
   Kohn W, 1998, PHYS REV LETT, V80, P4153, DOI 10.1103/PhysRevLett.80.4153
   Lee EH, 2008, CRYST GROWTH DES, V8, P91, DOI 10.1021/cg7008607
   Li TL, 2007, J PHARM SCI-US, V96, P755, DOI 10.1002/jps.20819
   Li TL, 2009, CHEM-EUR J, V15, P361, DOI 10.1002/chem.200801056
   Long SH, 2008, CRYST GROWTH DES, V8, P4006, DOI 10.1021/cg800123z
   Long SH, 2009, CRYST GROWTH DES, V9, P4993, DOI 10.1021/cg900786b
   Lopez-Mejias V, 2009, J AM CHEM SOC, V131, P4554, DOI 10.1021/ja806289a
   McCrone W. C., 1965, PHYSICS CHEMISTRY OR, VII, P725
   Morell C, 2005, J PHYS CHEM A, V109, P205, DOI 10.1021/jp046577a
   Nangia A, 2008, ACCOUNTS CHEM RES, V41, P595, DOI 10.1021/ar700203k
   Parmar MM, 2007, CRYST GROWTH DES, V7, P1635, DOI 10.1021/cg070074n
   Parr RG, 1999, J AM CHEM SOC, V121, P1922, DOI 10.1021/ja983494x
   PARR RG, 1984, J AM CHEM SOC, V106, P4049, DOI 10.1021/ja00326a036
   Parr RG, 1989, DENSITY FUNCTIONAL T
   PERDEW JP, 1982, PHYS REV LETT, V49, P1691, DOI 10.1103/PhysRevLett.49.1691
   Perez P, 2003, TETRAHEDRON, V59, P3117, DOI 10.1016/S0040-4020(03)00374-0
   Price SL, 2009, ACCOUNTS CHEM RES, V42, P117, DOI 10.1021/ar800147t
   REED AE, 1983, J CHEM PHYS, V78, P4066, DOI 10.1063/1.445134
   REED AE, 1988, CHEM REV, V88, P899, DOI 10.1021/cr00088a005
   Roy DR, 2008, J PHYS CHEM A, V112, P1612, DOI 10.1021/jp710820c
   Steiner T, 2002, ANGEW CHEM INT EDIT, V41, P48, DOI 10.1002/1521-3773(20020104)41:1<48::AID-ANIE48>3.0.CO;2-U
   Threlfall T, 2000, ORG PROCESS RES DEV, V4, P384, DOI 10.1021/op000058y
   Ugur I, 2009, J PHYS CHEM A, V113, P8704, DOI 10.1021/jp903371b
   Weissbuch I, 2003, CRYST GROWTH DES, V3, P125, DOI 10.1021/cg0200560
   YANG W, 1986, J AM CHEM SOC, V108, P5708, DOI 10.1021/ja00279a008
   YANG WT, 1985, P NATL ACAD SCI USA, V82, P6723, DOI 10.1073/pnas.82.20.6723
   Yu LA, 2010, ACCOUNTS CHEM RES, V43, P1257, DOI 10.1021/ar100040r
NR 53
TC 9
Z9 9
U1 1
U2 24
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
EI 1873-3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD OCT 14
PY 2011
VL 418
IS 2
SI SI
BP 179
EP 186
DI 10.1016/j.ijpharm.2011.04.062
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 834YJ
UT WOS:000296000100005
PM 21570454
DA 2018-03-20
ER

PT J
AU Long, SH
   Siegler, MA
   Mattei, A
   Li, TL
AF Long, Sihui
   Siegler, Maxime A.
   Mattei, Alessandra
   Li, Tonglei
TI Phase Transition from Two Z '=1 Forms to a Z '=2 Form of a Concomitant
   Conformational Polymorphic System
SO CRYSTAL GROWTH & DESIGN
LA English
DT Article
ID DENSITY-FUNCTIONAL THEORY; HYDROGEN-BOND PATTERNS; GRAPH-SET ANALYSIS;
   CRYSTAL-STRUCTURES; CARBOXYLIC-ACIDS; CRYSTALLOGRAPHIC SYMMETRY;
   MULTIPLE MOLECULES; ORGANIC-CRYSTALS; LATTICE ENERGY; X-RAY
AB Differential scanning calorimetry and hot-stage microscopy revealed two solid-solid phase transitions from two Z' = 1 polymorphs to a 2 = 2 form in a concomitant conformational polymorphic system of 2-(mesitylamino)nicotinic acid. Neat grinding and solvent-drop grinding experiments also confirmed that the high Z' form is thermodynamically stable. The finding adds to a few cases where a high Z' form is the most thermodynamically stable, apparently running contrary to a common notion that incomplete crystallization tends to produce metastable high Z' structures. The high Z' form of 2-(mesitylamino)nicotinic acid may be due to the combination of iso-energetic conformations and better packing. Lattice and conformational energy calculations were performed to provide further information about the intermolecular interactions of the polymorphs. Conformational search is in agreement with the conformers found in the three forms.
C1 [Li, Tonglei] Univ Kentucky, Coll Pharm 375, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
RP Li, TL (reprint author), Univ Kentucky, Coll Pharm 375, Dept Pharmaceut Sci, 789 S Limestone St, Lexington, KY 40536 USA.
EM tonglei@uky.edu
FU NSF [DMR-0449633, DMR-1006364]
FX T.L. and S.L. thank the NSF for financial support (DMR-0449633 and
   DMR-1006364). We also thank Drs. Sean Parkin and Arthur Cammers for
   helpful discussions.
CR AHLRICHS R, 1977, CHEM PHYS, V19, P119, DOI 10.1016/0301-0104(77)85124-0
   Aitipamula S, 2005, CHEM-EUR J, V11, P6727, DOI 10.1002/chem.200500400
   Anderson KM, 2008, CRYST GROWTH DES, V8, P2517, DOI 10.1021/cg8001527
   Anderson KM, 2007, CRYSTENGCOMM, V9, P328, DOI 10.1039/b701009e
   Anderson KM, 2006, CRYST GROWTH DES, V6, P2109, DOI 10.1021/cg0603265
   Anderson KM, 2006, CHEM COMMUN, P2138, DOI 10.1039/b602492k
   Anderson KM, 2009, CRYST GROWTH DES, V9, P1082, DOI 10.1021/cg8009089
   AZIZ RA, 1977, J CHEM PHYS, V67, P5719, DOI 10.1063/1.434827
   Babu NJ, 2006, CRYST GROWTH DES, V6, P1995, DOI 10.1021/cg060180+
   Babu NJ, 2010, CRYST GROWTH DES, V10, P1979, DOI 10.1021/cg100098z
   Batsanov AS, 2006, CRYSTENGCOMM, V8, P622, DOI 10.1039/b606327f
   BERKOVITCHYELLIN Z, 1982, J AM CHEM SOC, V104, P4052, DOI 10.1021/ja00379a003
   BERNSTEIN J, 1995, ANGEW CHEM INT EDIT, V34, P1555, DOI 10.1002/anie.199515551
   Beyer T, 2000, J PHYS CHEM B, V104, P2647, DOI 10.1021/jp9941413
   BOYS SF, 1970, MOL PHYS, V19, P553, DOI 10.1080/00268977000101561
   BROCK CP, 1994, CHEM MATER, V6, P1307, DOI 10.1021/cm00044a030
   BURGER A, 1979, MIKROCHIM ACTA, V2, P259
   Byrn S. R., 1999, SOLID STATE CHEM DRU
   Chandran SK, 2006, CRYSTENGCOMM, V8, P581, DOI 10.1039/b608029d
   Das D, 2006, CHEM COMMUN, P555, DOI 10.1039/b514076e
   Desiraju GR, 2007, CRYSTENGCOMM, V9, P91, DOI 10.1039/b614933b
   DESIRAJU GR, 1991, ACTA CRYSTALLOGR B, V47, P77, DOI 10.1107/S0108768190008850
   ETTER MC, 1990, ACCOUNTS CHEM RES, V23, P120, DOI 10.1021/ar00172a005
   ETTER MC, 1990, ACTA CRYSTALLOGR B, V46, P256, DOI 10.1107/S0108768189012929
   Feng SX, 2006, J CHEM THEORY COMPUT, V2, P149, DOI 10.1021/ct050189a
   FUJINAGA M, 1980, ACTA CRYSTALLOGR B, V36, P3196, DOI 10.1107/S0567740880011296
   HAGLER AT, 1979, J AM CHEM SOC, V101, P5131, DOI 10.1021/ja00512a003
   Hao X, 2005, CRYST GROWTH DES, V5, P2225, DOI 10.1021/cg050312j
   Hao X, 2005, ACTA CRYSTALLOGR B, V61, P218, DOI 10.1107/S0108768105004076
   HEPBURN J, 1975, CHEM PHYS LETT, V36, P451, DOI 10.1016/0009-2614(75)80278-8
   Kumar VSS, 2002, ANGEW CHEM INT EDIT, V41, P3848, DOI 10.1002/1521-3773(20021018)41:20<3848::AID-ANIE3848>3.0.CO;2-L
   Lee JM, 2002, J PHARM PHARMACOL, V54, P43, DOI 10.1211/0022357021771904
   Li TL, 2006, PHARM RES-DORDR, V23, P2326, DOI 10.1007/s11095-006-9006-5
   Long SH, 2008, CRYST GROWTH DES, V8, P4006, DOI 10.1021/cg800123z
   Long SH, 2008, CRYST GROWTH DES, V8, P3137, DOI 10.1021/cg800339h
   Long SH, 2006, ACTA CRYSTALLOGR E, V62, pO5664, DOI 10.1107/S1600536806048768
   Mahapatra S, 2010, CRYST GROWTH DES, V10, P3191, DOI 10.1021/cg100342k
   Nichol GS, 2006, CRYST GROWTH DES, V6, P451, DOI 10.1021/cg0503806
   *NON BV, 2002, COLLECT COMP SOFTW
   Ostwald W. Z., 1897, Z PHYS CHEM, V22, P289
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Rafilovich M, 2006, J AM CHEM SOC, V128, P12185, DOI 10.1021/ja063224b
   Roy S, 2006, CHEM-EUR J, V12, P3777, DOI 10.1002/chem.200501417
   Ruiz J, 2008, CRYSTENGCOMM, V10, P1928, DOI 10.1039/b812012a
   Sarma B, 2006, CHEM COMMUN, P4918, DOI 10.1039/b610323e
   Sarma B, 2010, CRYST GROWTH DES, V10, P2388, DOI 10.1021/cg100220z
   SAUNDERS VR, 2003, CRYSTAL2003 USERS MA
   Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930
   Steed JW, 2003, CRYSTENGCOMM, P169, DOI 10.1039/b304631a
   Steiner T, 2000, ACTA CRYSTALLOGR B, V56, P673, DOI 10.1107/S0108768100002652
   TAKASUKA M, 1982, J CHEM SOC PERK T 2, P1061, DOI 10.1039/p29820001061
   TING PC, 1990, J MED CHEM, V33, P2697, DOI 10.1021/jm00172a004
   Todd AM, 2006, CRYST GROWTH DES, V6, P1750, DOI 10.1021/cg060318o
   Trask AV, 2005, CHEM COMMUN, P880, DOI 10.1039/b416980h
   Wu Q, 2003, J CHEM PHYS, V118, P2498, DOI 10.1063/1.1535422
   Zencirci N, 2010, CRYST GROWTH DES, V10, P302, DOI 10.1021/cg901062n
NR 56
TC 14
Z9 14
U1 0
U2 15
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1528-7483
J9 CRYST GROWTH DES
JI Cryst. Growth Des.
PD FEB
PY 2011
VL 11
IS 2
BP 414
EP 421
DI 10.1021/cg101009g
PG 8
WC Chemistry, Multidisciplinary; Crystallography; Materials Science,
   Multidisciplinary
SC Chemistry; Crystallography; Materials Science
GA 713DC
UT WOS:000286714200007
DA 2018-03-20
ER

PT J
AU Wu, QL
   Subramanian, N
   Rankin, SE
AF Wu, Qingliu
   Subramanian, Navaladian
   Rankin, Stephen E.
TI Hierarchically Porous Titania Thin Film Prepared by Controlled Phase
   Separation and Surfactant Templating
SO LANGMUIR
LA English
DT Article
ID SOL-GEL PROCESS; CONTROLLED MULTISCALE POROSITY; HIGH PHOTOCATALYTIC
   ACTIVITY; MESOPOROUS SILICA MATERIAL; SUSTAINED DRUG-DELIVERY;
   LIQUID-CHROMATOGRAPHY; TIO2 NANOPARTICLES; FUEL-CELLS; MONOLITHS;
   SPHERES
AB Poly(propylene glycol) (PPG) of moderately high molecular weight (M(n) = 3500 Da) exhibits amphibious behavior in aqueous solution in that it is hydrophilic at low temperature but hydrophobic at high temperature. This property is utilized to generate porous titania thin films with a hierarchical structure consisting of macroporous voids/cracks in films with mesoporous walls. The smaller mesopores result from the self-assembly of the Pluronic block copolymer P123 to form micellar templates in well-ordered arrays with hexagonal symmetry. The larger pores are generated from the phase separation of PPG during aging of the films. The PPG acts to a limited degree as a swelling agent for the P123 micelles, but because the films are aged at a low temperature where PPG is hydrophilic, much of the PPG remains in the polar titania phase. Upon heating, the PPG phase separates to form randomly dispersed, large pores throughout the film while retaining the ordered mesoporous P123-templated structure in the matrix of the material. TEM and SEM imaging confirm that calcined titania thin films have interconnected hierarchical porous structures consisting of ordered mesopores 4-12 nm in diameter and macroporous voids >100 nm in size. The density and size of the voids increase as more PPG is added to the films.
C1 [Wu, Qing Liu; Subramanian, Navaladian; Rankin, Stephen E.] Univ Kentucky, Chem & Mat Engn Dept, Lexington, KY 40506 USA.
RP Rankin, SE (reprint author), Univ Kentucky, Chem & Mat Engn Dept, 177 FP Anderson Tower, Lexington, KY 40506 USA.
EM srankin@engr.uky.edu
RI Rankin, Stephen/A-3265-2013; wu, qingliu/C-7631-2012; Subramanian,
   Navaladian/K-4306-2012
OI Rankin, Stephen/0000-0002-8615-7564; Subramanian,
   Navaladian/0000-0002-0509-5438
FU U.S. Department of Energy [DE-FG02-07ER46375]
FX This report is partially based on work funded by the U.S. Department of
   Energy under Grant DE-FG02-07ER46375.
CR Alberius PCA, 2002, CHEM MATER, V14, P3284, DOI 10.1021/cm011209u
   Asahi R, 2001, SCIENCE, V293, P269, DOI 10.1126/science.1061051
   Bannat I, 2009, CHEM MATER, V21, P1645, DOI 10.1021/cm803455k
   Burda C, 2003, NANO LETT, V3, P1049, DOI 10.1021/nl034332o
   Chai GS, 2004, ADV MATER, V16, P2057, DOI 10.1002/adma.200400283
   Chen HR, 2005, ADV MATER, V17, P2010, DOI 10.1002/adma.200500221
   Choi SG, 2007, THIN SOLID FILMS, V516, P212, DOI 10.1016/j.tsf.2007.07.001
   Colombo P, 2010, J MATER SCI, V45, P5425, DOI 10.1007/s10853-010-4708-9
   Crepaldi EL, 2003, J AM CHEM SOC, V125, P9770, DOI 10.1021/ja030070g
   Davis SA, 1997, NATURE, V385, P420, DOI 10.1038/385420a0
   Falcaro P, 2009, CHEM MATER, V21, P2055, DOI 10.1021/cm802750w
   Fang BZ, 2009, CHEM MATER, V21, P789, DOI 10.1021/cm801467y
   Galarneau A, 2006, J SEP SCI, V29, P844, DOI 10.1002/jssc.200500511
   Gawel B, 2010, MATERIALS, V3, P2815, DOI 10.3390/ma3042815
   Grosso D, 2001, ADV MATER, V13, P1085, DOI 10.1002/1521-4095(200107)13:14<1085::AID-ADMA1085>3.0.CO;2-Q
   Grosso D, 2003, ADV FUNCT MATER, V13, P37, DOI 10.1002/adfm.200390002
   Ho W, 2006, CHEM COMMUN, P1115, DOI 10.1039/b515513d
   Imhof A, 1997, NATURE, V389, P948
   Imhof A, 1998, ADV MATER, V10, P697, DOI 10.1002/(SICI)1521-4095(199806)10:9<697::AID-ADMA697>3.0.CO;2-M
   Ishizuka N, 2001, COLLOID SURFACE A, V187, P273, DOI 10.1016/S0927-7757(01)00642-2
   Ishizuka N, 1998, J CHROMATOGR A, V797, P133, DOI 10.1016/S0021-9673(97)01202-8
   Ismail AA, 2010, CHEMSUSCHEM, V3, P1057, DOI 10.1002/cssc.201000158
   Khan MA, 2006, J PHYS CHEM B, V110, P6626, DOI 10.1021/jp057119k
   Kim J, 2010, NEW J CHEM, V34, P2971, DOI 10.1039/c0nj00493f
   Koganti VR, 2006, NANO LETT, V6, P2567, DOI 10.1021/nl061992v
   Konishi J, 2008, CHEM MATER, V20, P2165, DOI 10.1021/cm703351d
   Konishi J, 2006, CHEM MATER, V18, P6069, DOI 10.1021/cm0617485
   Konishi J, 2009, J CHROMATOGR A, V1216, P7375, DOI 10.1016/j.chroma.2009.06.016
   Kontos AI, 2008, PHYS STATUS SOLIDI-R, V2, P83, DOI 10.1002/pssr.200802006
   Lancelle-Beltran E, 2006, CHEM MATER, V18, P6152, DOI 10.1021/cm060925z
   LANCELLEBELTRAN E, 2006, NATURE, V18, P2579
   Lee YJ, 2001, ADV MATER, V13, P1259, DOI 10.1002/1521-4095(200108)13:16<1259::AID-ADMA1259>3.0.CO;2-U
   Li F, 2007, LANGMUIR, V23, P3996, DOI 10.1021/la062969s
   Lin HM, 2007, STUD SURF SCI CATAL, V165, P151
   Liu KS, 2005, J PHYS CHEM B, V109, P18719, DOI 10.1021/jp054546p
   Malfatti L, 2009, CHEM MATER, V21, P4846, DOI 10.1021/cm9013859
   Malfatti L, 2009, CHEM MATER, V21, P2763, DOI 10.1021/cm900289c
   Murai S, 2004, J PHYS CHEM B, V108, P16670, DOI 10.1021/jp0481658
   Nakanishi K, 2000, J SOL-GEL SCI TECHN, V17, P191, DOI 10.1023/A:1008707804908
   NAKANISHI K, 1991, J AM CERAM SOC, V74, P2518, DOI 10.1111/j.1151-2916.1991.tb06794.x
   Nakanishi K, 2008, CHEM MATER, V20, P1108, DOI 10.1021/cm702486b
   Nakanishi K, 2007, ACCOUNTS CHEM RES, V40, P863, DOI 10.1021/ar600034p
   Nakanishi K, 1997, J POROUS MAT, V4, P67, DOI 10.1023/A:1009627216939
   Peng TY, 2005, J PHYS CHEM B, V109, P4947, DOI 10.1021/jp044771r
   Qu FY, 2010, SOLID STATE SCI, V12, P851, DOI 10.1016/j.solidstatesciences.2010.02.005
   Sakatani Y, 2008, CHEM MATER, V20, P1049, DOI 10.1021/cm701986b
   Sanchez C, 2005, NAT MATER, V4, P277, DOI 10.1038/nmat1339
   Shi ZG, 2006, J NON-CRYST SOLIDS, V352, P4003, DOI 10.1016/j.jnoncrysol.2006.08.008
   Soler-illia GJD, 2002, CHEM REV, V102, P4093, DOI 10.1021/cr0200062
   Song LY, 2008, J COLLOID INTERF SCI, V328, P374, DOI 10.1016/j.jcis.2008.09.044
   Stengl V, 2010, NEW J CHEM, V34, P1999, DOI 10.1039/c0nj00167h
   Takahashi R, 2001, J AM CERAM SOC, V84, P1968
   Tominaka S, 2010, J POWER SOURCES, V195, P1054, DOI 10.1016/j.jpowsour.2009.08.082
   Uchida H, 2010, THIN SOLID FILMS, V518, P3169, DOI 10.1016/j.tsf.2009.08.050
   Wang CY, 2000, CHEM COMMUN, P1539, DOI 10.1039/b002988m
   Wang XC, 2005, LANGMUIR, V21, P2552, DOI 10.1021/la047979c
   Wang YQ, 1999, THIN SOLID FILMS, V349, P120, DOI 10.1016/S0040-6090(99)00239-4
   Wang ZY, 2008, J MATER CHEM, V18, P2194, DOI 10.1039/b719489g
   Wijnhoven JEGJ, 1998, SCIENCE, V281, P802, DOI 10.1126/science.281.5378.802
   Wu QL, 2011, J PHYS CHEM C, V115, P11925, DOI 10.1021/jp2021193
   Xu JC, 2005, J MOL CATAL A-CHEM, V226, P123, DOI 10.1016/j.molcata.2004.09.051
   Yamaki T, 2002, J MATER SCI LETT, V21, P33, DOI 10.1023/A:1014282225859
   Yang H., 2009, MICROPOR MESOPOR MAT, V127, P213
   Yang PD, 1998, SCIENCE, V282, P2244, DOI 10.1126/science.282.5397.2244
   Yu JC, 2003, CHEM MATER, V15, P2280, DOI 10.1021/cm0340781
   Yu JG, 2006, J PHOTOCH PHOTOBIO A, V182, P121, DOI 10.1016/j.jphotochem.2006.01.022
   Yu JG, 2009, RES CHEM INTERMEDIAT, V35, P653, DOI 10.1007/s11164-009-0107-8
   Yuan ZY, 2006, J MATER CHEM, V16, P663, DOI 10.1039/b512304f
   Zhang BJ, 2002, CHEM MATER, V14, P1369, DOI 10.1021/cm011251p
   Zhang HF, 2003, ADV MATER, V15, P78, DOI 10.1002/adma.200390017
   Zhang Y, 2009, ACS APPL MATER INTER, V1, P2789, DOI 10.1021/am900529e
   Zhao DY, 1999, CHEM MATER, V11, P1174, DOI 10.1021/cm980782j
   Zhao TB, 2010, CATAL LETT, V136, P266, DOI 10.1007/s10562-009-0131-8
NR 73
TC 21
Z9 21
U1 1
U2 49
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0743-7463
J9 LANGMUIR
JI Langmuir
PD AUG 2
PY 2011
VL 27
IS 15
BP 9557
EP 9566
DI 10.1021/la201388n
PG 10
WC Chemistry, Multidisciplinary; Chemistry, Physical; Materials Science,
   Multidisciplinary
SC Chemistry; Materials Science
GA 796ET
UT WOS:000293035300062
PM 21711020
DA 2018-03-20
ER

PT J
AU Yu, CG
   Crowdus, C
   Raza, K
   Geddes, J
AF Yu, Chen-Guang
   Crowdus, Carolyn
   Raza, Kashif
   Geddes, James W.
TI FENBENDAZOLE IMPROVES LOCOMOTOR RECOVERY AFTER SPINAL CORD INJURY IN
   MICE
SO JOURNAL OF NEUROTRAUMA
LA English
DT Meeting Abstract
CT 30th Annual National Neurotrauma Symposium
CY JUL 22-25, 2012
CL Phoenix, AZ
DE Pathogenic antibody responses; Paralysis; Fenbendazole
C1 [Yu, Chen Guang; Geddes, James] Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, Dept Anat & Neurobiol, Lexington, KY 40506 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0897-7151
J9 J NEUROTRAUM
JI J. Neurotrauma
PD JUL
PY 2012
VL 29
IS 10
BP A132
EP A133
PG 2
WC Critical Care Medicine; Clinical Neurology; Neurosciences
SC General & Internal Medicine; Neurosciences & Neurology
GA 971YV
UT WOS:000306244400226
DA 2018-03-20
ER

PT J
AU Garcia, M
   Badugu, R
   Bondada, V
   Joshi, A
   Geddes, JW
AF Garcia, Matthew
   Badugu, RamaKrishna
   Bondada, Vimala
   Joshi, Aashish
   Geddes, James W.
TI The calcium dependent cysteine protease mu-calpain is located in the
   mitochondrial intermembrane space
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 [Garcia, Matthew] St Jude Childrens Res Hosp, Memphis, TN 38105 USA.
   [Badugu, RamaKrishna; Bondada, Vimala; Geddes, James W.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2008
VL 22
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA V25GZ
UT WOS:000208467800786
DA 2018-03-20
ER

PT J
AU Li, TL
AF Li, Tonglei
TI Further understanding of the thermal motions of atoms in aspirin and
   acetaminophen crystals with conceptual density functional theory
SO CRYSTAL GROWTH & DESIGN
LA English
DT Article
ID VARIABLE-TEMPERATURE; NEUTRON-DIFFRACTION; CHEMICAL-REACTIVITY; FUKUI
   FUNCTION; AB-INITIO; PARAMETER; PRINCIPLE; SOFTNESS; HARDNESS; ACIDS
AB Following up on a previous report, further correlations between force constants of thermal motions of atoms in aspirin and acetarninophen single crystals and nuclear Fukui functions have been identified. It is believed that the energy barrier of the thermal vibration of one atom in an organic crystal is mainly dominated by the soft-soft type of interatomic interactions, which may be characterized by the nuclear Fukui functions.
C1 Univ Kentucky, Coll Pharm 514, Lexington, KY 40536 USA.
RP Li, TL (reprint author), Univ Kentucky, Coll Pharm 514, 725 Rose St, Lexington, KY 40536 USA.
EM tonglei@uky.edu
CR Ayers PW, 2007, FARADAY DISCUSS, V135, P161, DOI 10.1039/b606877d
   Ayers PW, 2006, J CHEM PHYS, V124, DOI 10.1063/1.2196882
   Balawender R, 2001, J CHEM PHYS, V114, P4441, DOI 10.1063/1.1346579
   BERKOWITZ M, 1987, J AM CHEM SOC, V109, P4823, DOI 10.1021/ja00250a012
   CHATTARAJ PK, 1991, J AM CHEM SOC, V113, P1855, DOI 10.1021/ja00005a073
   COHEN MH, 1995, J CHEM PHYS, V103, P3543, DOI 10.1063/1.470238
   COHEN MH, 1994, J CHEM PHYS, V101, P8988, DOI 10.1063/1.468026
   Dovesi R, 2005, Z KRISTALLOGR, V220, P571, DOI 10.1524/zkri.220.5.571.65065
   DUNITZ JD, 1988, J PHYS CHEM-US, V92, P856, DOI 10.1021/j100315a002
   Li TL, 2006, CRYST GROWTH DES, V6, P2000, DOI 10.1021/cg060238k
   PARR RG, 1983, J AM CHEM SOC, V105, P7512, DOI 10.1021/ja00364a005
   PEARSON RG, 1963, J AM CHEM SOC, V85, P3533, DOI 10.1021/ja00905a001
   PEARSON RG, 1966, SCIENCE, V151, P172, DOI 10.1126/science.151.3707.172
   TRUEBLOOD KN, 1983, ACTA CRYSTALLOGR B, V39, P120, DOI 10.1107/S0108768183002104
   Trueblood KN, 1996, ACTA CRYSTALLOGR A, V52, P770, DOI 10.1107/S0108767396005697
   VELA A, 1990, J AM CHEM SOC, V112, P1490, DOI 10.1021/ja00160a029
   Wilson CC, 2000, Z KRISTALLOGR, V215, P693, DOI 10.1524/zkri.2000.215.11.693
   Wilson CC, 2002, NEW J CHEM, V26, P1733, DOI 10.1039/b203775k
NR 18
TC 1
Z9 1
U1 0
U2 6
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1528-7483
J9 CRYST GROWTH DES
JI Cryst. Growth Des.
PD APR
PY 2008
VL 8
IS 4
BP 1110
EP 1112
DI 10.1021/cg070406o
PG 3
WC Chemistry, Multidisciplinary; Crystallography; Materials Science,
   Multidisciplinary
SC Chemistry; Crystallography; Materials Science
GA 283PS
UT WOS:000254649300008
DA 2018-03-20
ER

PT J
AU Song, ES
   Ozbil, M
   Zhang, TT
   Sheetz, M
   Lee, D
   Tran, D
   Li, S
   Prabhakar, R
   Hersh, LB
   Rodgers, DW
AF Song, Eun Suk
   Ozbil, Mehmet
   Zhang, Tingting
   Sheetz, Michael
   Lee, David
   Tran, Danny
   Li, Sheng
   Prabhakar, Rajeev
   Hersh, Louis B.
   Rodgers, David W.
TI An Extended Polyanion Activation Surface in Insulin Degrading Enzyme
SO PLOS ONE
LA English
DT Article
ID MASS-SPECTROMETRY; PROTEIN; EXCHANGE; RECOGNITION; SIMULATIONS;
   DEGRADATION; INSULYSIN; MODELS
AB Insulin degrading enzyme (IDE) is believed to be the major enzyme that metabolizes insulin and has been implicated in the degradation of a number of other bioactive peptides, including amyloid beta peptide (A beta), glucagon, amylin, and atrial natriuretic peptide. IDE is activated toward some substrates by both peptides and polyanions/anions, possibly representing an important control mechanism and a potential therapeutic target. A binding site for the polyanion ATP has previously been defined crystallographically, but mutagenesis studies suggest that other polyanion binding modes likely exist on the same extended surface that forms one wall of the substrate-binding chamber. Here we use a computational approach to define three potential ATP binding sites and mutagenesis and kinetic studies to confirm the relevance of these sites. Mutations were made at four positively charged residues (Arg 429, Arg 431, Arg 847, Lys 898) within the polyanion-binding region, converting them to polar or hydrophobic residues. We find that mutations in all three ATP binding sites strongly decrease the degree of activation by ATP and can lower basal activity and cooperativity. Computational analysis suggests conformational changes that result from polyanion binding as well as from mutating residues involved in polyanion binding. These findings indicate the presence of multiple polyanion binding modes and suggest the anion-binding surface plays an important conformational role in controlling IDE activity.
C1 [Song, Eun Suk; Hersh, Louis B.] Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY USA.
   [Song, Eun Suk; Hersh, Louis B.; Rodgers, David W.] Univ Kentucky, Struct Biol Ctr, Lexington, KY USA.
   [Ozbil, Mehmet; Zhang, Tingting; Prabhakar, Rajeev] Univ Miami, Dept Chem, Miami, FL 33124 USA.
   [Sheetz, Michael] Univ Kentucky, Ctr Computat Sci, Lexington, KY USA.
   [Lee, David; Tran, Danny; Li, Sheng] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
RP Prabhakar, R (reprint author), Univ Miami, Dept Chem, Miami, FL 33124 USA.
EM rpr@miami.edu; lhersh@uky.edu; david.rodgers@uky.edu
FU United States Department of Health and Human Services, National
   Institutes of Health [NS38041, DA02243, DA016176, GM110787, AI081982,
   GM020501, AI101436]; National Science Foundation [CHE1152846]
FX This work was supported by United States Department of Health and Human
   Services, National Institutes of Health grants NS38041 (DWR); DA02243,
   DA016176, and GM110787 (LBH); and AI081982, GM020501, and AI101436 (SL).
   RP gratefully acknowledges support from the National Science Foundation
   (CHE1152846). The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   Daura X, 1999, PROTEINS, V34, P269, DOI 10.1002/(SICI)1097-0134(19990215)34:3<269::AID-PROT1>3.0.CO;2-3
   de Tullio MB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059113
   DUCKWORTH WC, 1994, J BIOL CHEM, V269, P24575
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Guo Q, 2010, J MOL BIOL, V395, P430, DOI 10.1016/j.jmb.2009.10.072
   HAMEL FG, 1991, DIABETES, V40, P436, DOI 10.2337/diabetes.40.4.436
   Hamuro Y, 2002, J MOL BIOL, V323, P871, DOI 10.1016/S0022-2836(02)01003-3
   Hersh LB, 2006, CELL MOL LIFE SCI, V63, P2432, DOI 10.1007/s00018-006-6238-9
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.3.CO;2-L
   HOCKNEY RW, 1974, J COMPUT PHYS, V14, P148, DOI 10.1016/0021-9991(74)90010-2
   KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211
   Kim YG, 2013, NAT PROTOC, V8, P1730, DOI 10.1038/nprot.2013.104
   Krieger E, 2002, BIOINFORMATICS, V18, P315, DOI 10.1093/bioinformatics/18.2.315
   KUO WL, 1994, J BIOL CHEM, V269, P22599
   Kurochkin IV, 1998, FEBS LETT, V427, P153, DOI 10.1016/S0014-5793(98)00422-0
   Leissring MA, 2004, BIOCHEM J, V383, P439, DOI 10.1042/BJ20041081
   Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045
   Manolopoulou M, 2009, J BIOL CHEM, V284, P14177, DOI 10.1074/jbc.M900068200
   Marsh JJ, 2013, BIOCHEMISTRY-US, V52, P5491, DOI 10.1021/bi4007995
   MIYAMOTO S, 1992, J COMPUT CHEM, V13, P952, DOI 10.1002/jcc.540130805
   Noinaj N, 2012, J BIOL CHEM, V287, P48, DOI 10.1074/jbc.M111.264614
   Noinaj N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020864
   Oostenbrink C, 2004, J COMPUT CHEM, V25, P1656, DOI 10.1002/jcc.20090
   Qiu WQ, 1998, J BIOL CHEM, V273, P32730, DOI 10.1074/jbc.273.49.32730
   Rudovich N, 2009, J MOL MED-JMM, V87, P1145, DOI 10.1007/s00109-009-0540-6
   Shen YQ, 2006, NATURE, V443, P870, DOI 10.1038/nature05143
   Song ES, 2004, J BIOL CHEM, V279, P54216, DOI 10.1074/jbc.M411177200
   Song ES, 2003, J BIOL CHEM, V278, P49789, DOI 10.1074/jbc.M308983200
   Song ES, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046790
   Song ES, 2011, J BIOL CHEM, V286, P13852, DOI 10.1074/jbc.M110.191668
   Song ES, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009719
   Sowole MA, 2014, ANAL CHEM, V86, P6715, DOI 10.1021/ac501849n
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Tundo GR, 2013, J BIOL CHEM, V288, P2281, DOI 10.1074/jbc.M112.393108
   ZHANG ZQ, 1993, PROTEIN SCI, V2, P522
NR 37
TC 5
Z9 5
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 17
PY 2015
VL 10
IS 7
AR e0133114
DI 10.1371/journal.pone.0133114
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CN1RV
UT WOS:000358198700093
PM 26186535
OA gold
DA 2018-03-20
ER

PT J
AU Liu, M
   Yin, CM
   Chen, P
   Zhang, MT
   Parkin, S
   Zhou, PP
   Li, TL
   Yu, FQ
   Long, SH
AF Liu, Meng
   Yin, Chuming
   Chen, Peng
   Zhang, Mingtao
   Parkin, Sean
   Zhou, Panpan
   Li, Tonglei
   Yu, Faquan
   Long, Sihui
TI (CH)-C-sp2 center dot center dot center dot Cl hydrogen bond in the
   conformational polymorphism of 4-chloro-phenylanthranilic acid
SO CRYSTENGCOMM
LA English
DT Article
ID DENSITY-FUNCTIONAL THEORY; GRAPH-SET ANALYSIS; ORGANIC-CRYSTALS;
   ENERGIES; PATTERNS; HALOGEN; PACKING
AB Chlorine can participate in numerous interactions such as halogen bonding, hydrogen bonding, and London dispersion in the solid state. In this work, we report the influence of a chlorine substituent on the polymorphism of a potential anticancer drug, 4-chloro-phenylanthranilic acid (CPAA). Three polymorphs have been discovered for this compound, and the three forms were characterized by single-crystal X-ray diffraction, power X-ray diffraction (PXRD), FT-IR, and Raman spectroscopy. Both conformational flexibility of the molecule and the (CH)-C-sp2 center dot center dot center dot Cl hydrogen bond seem to lead to the polymorphism of the system. The phase behavior was investigated by differential scanning calorimetry (DSC), with the conclusion that form II converts to III upon heating. A conformational scan shows the conformational minima corresponds to the conformers existing in the polymorphs. Lattice energy calculations show energies of -106.70, -104.72, and -194.42 kJ mol(-1) for forms I to III, providing information on relative stability for each form. Hirshfeld analysis revealed that intermolecular interactions such as H center dot center dot center dot H, C center dot center dot center dot H, H center dot center dot center dot Cl, and H center dot center dot center dot O contribute to the stability of the crystal forms.
C1 [Liu, Meng; Yin, Chuming; Chen, Peng; Yu, Faquan; Long, Sihui] Wuhan Inst Technol, Sch Chem Engn & Pharm, Minist Educ, Key Lab Green Chem Proc, Wuhan, Hubei, Peoples R China.
   [Zhang, Mingtao; Li, Tonglei] Purdue Univ, Dept Ind & Phys Pharm, W Lafayette, IN 47907 USA.
   [Zhou, Panpan] Lanzhou Univ, Dept Chem, Lanzhou, Gansu, Peoples R China.
   [Parkin, Sean] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
RP Yu, FQ; Long, SH (reprint author), Wuhan Inst Technol, Sch Chem Engn & Pharm, Minist Educ, Key Lab Green Chem Proc, Wuhan, Hubei, Peoples R China.
EM fyuwucn@gmail.com; sihuilong@wit.edu.cn
OI peng, chen/0000-0002-0561-4816; zhou, pan pan/0000-0001-8111-8155
FU Natural Science Foundation of Hubei Province [2014CFB787]; President's
   Fund of Wuhan Institute of Technology [CX2016075]; National Natural
   Science Foundation of China [21403097]; Fundamental Research Funds for
   the Central Universities [lzujbky-2014-182]; NSF [DMR1006364]
FX ML and SL thanks Natural Science Foundation of Hubei Province
   (2014CFB787) and the President's Fund of Wuhan Institute of Technology
   (CX2016075) for financial support. PPZ acknowledges the financial
   support by the National Natural Science Foundation of China (Grant No.
   21403097) and the Fundamental Research Funds for the Central
   Universities (lzujbky-2014-182). TL is grateful to NSF for supporting
   the work (DMR1006364).
CR Arunan E, 2011, PURE APPL CHEM, V83, P1637, DOI 10.1351/PAC-REC-10-01-02
   Bag PP, 2012, CRYST GROWTH DES, V12, P2740, DOI 10.1021/cg300404r
   Bauer-Brandl A, 1999, J THERM ANAL CALORIM, V57, P7, DOI 10.1023/A:1010137505058
   Bauman DR, 2005, MOL PHARMACOL, V67, P60, DOI 10.1124/mol.104.006569
   BERNSTEIN J, 1995, ANGEW CHEM INT EDIT, V34, P1555, DOI 10.1002/anie.199515551
   Blagus A, 2007, J CHEM CRYSTALLOGR, V37, P473, DOI 10.1007/s10870-007-9196-7
   Boldyreva EV, 2015, CHEM-EUR J, V21, P15395, DOI 10.1002/chem.201501541
   BOYS SF, 1970, MOL PHYS, V19, P553, DOI 10.1080/00268977000101561
   Brittain H. G., 1999, POLYMORPHISM PHARM S
   Byrn S. R., 1999, SOLID STATE CHEM DRU
   Byrns MC, 2009, CHEM-BIOL INTERACT, V178, P221, DOI 10.1016/j.cbi.2008.10.024
   Cruz-Cabeza AJ, 2015, CHEM SOC REV, V44, P8619, DOI 10.1039/c5cs00227c
   Cruz-Cabeza AJ, 2014, CHEM REV, V114, P2170, DOI 10.1021/cr400249d
   Das D, 2006, CHEM-ASIAN J, V1, P231, DOI 10.1002/asia.200600046
   Desiraju GR, 2007, CRYSTENGCOMM, V9, P91, DOI 10.1039/b614933b
   DESIRAJU GR, 1989, J AM CHEM SOC, V111, P8725, DOI 10.1021/ja00205a027
   Dovesi R, 2014, INT J QUANTUM CHEM, V114, P1287, DOI 10.1002/qua.24658
   ETTER MC, 1990, ACCOUNTS CHEM RES, V23, P120, DOI 10.1021/ar00172a005
   ETTER MC, 1990, ACTA CRYSTALLOGR B, V46, P256, DOI 10.1107/S0108768189012929
   Fabian L, 2011, CRYST GROWTH DES, V11, P3522, DOI 10.1021/cg200429j
   Feng SX, 2006, J CHEM THEORY COMPUT, V2, P149, DOI 10.1021/ct050189a
   GNANAGURU K, 1985, J ORG CHEM, V50, P2337, DOI 10.1021/jo00213a027
   HIRSHFELD FL, 1977, THEOR CHIM ACTA, V44, P129, DOI 10.1007/BF00549096
   Kato F, 2006, INT J PHARM, V321, P18, DOI 10.1016/j.ijpharm.2006.04.020
   Kitamura M, 2006, CRYST GROWTH DES, V6, P1945, DOI 10.1021/cg050464e
   Kumar SS, 2014, CRYST GROWTH DES, V14, P1865, DOI 10.1021/cg5000205
   Li TL, 2006, PHARM RES-DORDR, V23, P2326, DOI 10.1007/s11095-006-9006-5
   Lopez-Majias V, 2015, CRYST GROWTH DES, V15, P3955, DOI 10.1021/acs.cgd.5b00570
   Lopez-Mejias V, 2012, J AM CHEM SOC, V134, P9872, DOI 10.1021/ja302601f
   Martin A., 2006, J CHEM RES, V9, P561
   McCrone W. C., 1965, PHYSICS CHEMISTRY OR, VII, P725
   Metrangolo P, 2005, ACCOUNTS CHEM RES, V38, P386, DOI 10.1021/ar0400995
   Nangia A, 2008, ACCOUNTS CHEM RES, V41, P595, DOI 10.1021/ar700203k
   Navon O, 1997, ANGEW CHEM INT EDIT, V36, P601, DOI 10.1002/anie.199706011
   Nonius, 2002, COLLECT
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Penning TM, 2006, MOL CELL ENDOCRINOL, V248, P182, DOI 10.1016/j.mce.2005.12.009
   PRICE SL, 1994, J AM CHEM SOC, V116, P4910, DOI 10.1021/ja00090a041
   SHARPLES D, 1982, J PHARM PHARMACOL, V34, P681, DOI 10.1111/j.2042-7158.1982.tb04704.x
   Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930
   Sheldrick GM, 2015, ACTA CRYSTALLOGR C, V71, P3, DOI 10.1107/S2053229614024218
   Spackman MA, 2009, CRYSTENGCOMM, V11, P19, DOI 10.1039/b818330a
   Ulrich CM, 2006, NAT REV CANCER, V6, P130, DOI 10.1038/nrc1801
   Vrcelj RM, 2001, J AM CHEM SOC, V123, P2291, DOI 10.1021/ja0031422
   Wangemann P., 1986, PFLUG ARCH        S2, V407, P128
   Weissbuch I, 2005, ANGEW CHEM INT EDIT, V44, P3226, DOI 10.1002/anie.200500164
   Wolf C, 2006, J ORG CHEM, V71, P3270, DOI 10.1021/jo060034a
   Wolff S. K., 2012, CRYSTALEXPLORER VERS
   Zinellu A, 2005, EUR J PHARM SCI, V24, P375, DOI 10.1016/j.ejps.2004.12.003
NR 49
TC 0
Z9 0
U1 9
U2 11
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1466-8033
J9 CRYSTENGCOMM
JI Crystengcomm
PD AUG 14
PY 2017
VL 19
IS 30
BP 4345
EP 4354
DI 10.1039/c7ce00772h
PG 10
WC Chemistry, Multidisciplinary; Crystallography
SC Chemistry; Crystallography
GA FC2VQ
UT WOS:000406697300013
DA 2018-03-20
ER

PT J
AU Xing, R
   Rankin, SE
AF Xing, Rong
   Rankin, Stephen E.
TI Three stage multilayer formation kinetics during adsorption of an
   anionic fluorinated surfactant onto germanium: Solution pH and salt
   effects
SO JOURNAL OF COLLOID AND INTERFACE SCIENCE
LA English
DT Article
DE Adsorption; Aggregation; Fluorinated surfactants; Oxides; ATR; Infrared
   spectroscopy
ID SODIUM DODECYL-SULFATE; GRAPHITE-SOLUTION INTERFACE; IONIC-STRENGTH;
   F-19 NMR; LITHIUM PERFLUOROOCTYLSULFONATES; CETYLTRIMETHYLAMMONIUM
   BROMIDE; POLYELECTROLYTE ADSORPTION; CETYLPYRIDINIUM BROMIDE; CATIONIC
   SURFACTANTS; AQUEOUS INTERFACE
AB The effects of solution pH, salt type and its concentration on the adsorption kinetics and the structural evolution of an anionic fluorinated surfactant, tetraethylammonium perfluorooctylsulfonate (TEA-FOS), at the hydroxylated Ge/aqueous solution interface are investigated by using Fourier transform infrared spectroscopy in attenuated total reflection mode (ATR-FTIR). The surface excess, the adsorption rate, the durations of three-stage adsorption and the molecular orientation of adsorbed TEA-FOS are all dependent on the pH of the solution. Consistent with the expected effects of solution pH on surface charge of the germanium oxide crystal surface, the most surfactant adsorbs at acidic pH 3.4 although a considerable amount still adsorbs at pH 10.0. Linear dichroism measurements suggest that the adsorbed surfactants prefer to form less-curved (flattened) multilayer admicelles, which pack more closely on the solid surface as the solution pH decreases. Under both acidic (pH 3.4) and basic (pH 10.0) conditions, the equilibrium surface excess first passes through a maximum as NaCl concentration increases, followed by a decrease. This suggests that excessive NaCl concentration is not favorable for multilayer formation due to increased electrostatic shielding which reduces the ion-pairing ability between TEA(+) and FOS-. In addition, infrared dichroism measurements of CF2 stretching show that salt type and its concentration influence the structural evolution of adsorbed surfactants. A moderate amount of NaCl favors the assembly of adsorbed micelles into ordered flattened aggregates, but an excess of NaCl makes adsorbed surfactants assemble randomly like spherical aggregates. Compared to Na+ and K+ ions, Ca2+ ions cause the adsorbed surfactants to pack more closely on the solid surface into flattened micellar aggregates. All of the effects of solution pH and salt can be rationalized based on Coulombic interactions between the substrate surface, surfactants and counter-ions. (c) 2013 Elsevier Inc. All rights reserved.
C1 [Xing, Rong; Rankin, Stephen E.] Univ Kentucky, Chem & Mat Engn Dept, Lexington, KY 40506 USA.
RP Rankin, SE (reprint author), Univ Kentucky, Chem & Mat Engn Dept, 177 FP Anderson Tower, Lexington, KY 40506 USA.
EM srankin@engr.uky.edu
OI Rankin, Stephen/0000-0002-8615-7564
FU Kentucky Science & Engineering Foundation [KSEF-148-502-02-17]; National
   Science Foundation (NSF) [DMR-0210517]
FX This report is based on work partially funded by the Kentucky Science &
   Engineering Foundation (Grant No. KSEF-148-502-02-17) and the National
   Science Foundation (NSF) (Grant No. DMR-0210517).
CR ASAKAWA T, 1991, LANGMUIR, V7, P2112, DOI 10.1021/la00058a025
   Atkin R, 2001, LANGMUIR, V17, P6155, DOI 10.1021/la001396v
   Atkin R, 2003, ADV COLLOID INTERFAC, V103, P219, DOI 10.1016/S0001-8686(03)00002-2
   Beach SA, 2006, REV ENVIRON CONTAM T, V186, P133, DOI 10.1007/0-387-32883-1_5
   Biswas SC, 1998, J COLLOID INTERF SCI, V205, P12, DOI 10.1006/jcis.1998.5574
   BITTING D, 1987, LANGMUIR, V3, P500, DOI 10.1021/la00076a011
   BOHMER MR, 1990, MACROMOLECULES, V23, P2288, DOI 10.1021/ma00210a027
   Bossev DP, 1999, J PHYS CHEM B, V103, P8259, DOI 10.1021/jp991398s
   Bossev DP, 1999, J PHYS CHEM B, V103, P8251, DOI 10.1021/jp991827m
   CARRE A, 1992, J COLLOID INTERF SCI, V154, P174, DOI 10.1016/0021-9797(92)90090-9
   Chen MH, 2009, SURF SCI, V603, P1878, DOI 10.1016/j.susc.2008.09.048
   Davis AN, 2003, COLLOID SURFACE A, V221, P69, DOI 10.1016/S0927-7757(03)00132-8
   Drach M, 2002, PHYS CHEM CHEM PHYS, V4, P5846, DOI 10.1039/b206860e
   Duval FP, 2006, LANGMUIR, V22, P1143, DOI 10.1021/la052032b
   Evenas L, 2002, LANGMUIR, V18, P8096, DOI 10.1021/la026014v
   Fang F, 2003, J CHEM PHYS, V119, P1053, DOI 10.1063/1.1578992
   Han Y, 2005, ANGEW CHEM INT EDIT, V44, P288, DOI 10.1002/anie.200460892
   Hankins NP, 1996, IND ENG CHEM RES, V35, P2844, DOI 10.1021/ie9506375
   Hoffmann H, 1997, J MOL LIQ, V72, P191, DOI 10.1016/S0167-7322(97)00039-1
   Hu XY, 2010, J PHYS CHEM B, V114, P8910, DOI 10.1021/jp101943m
   IMAE T, 1985, J COLLOID INTERF SCI, V108, P215, DOI 10.1016/0021-9797(85)90253-X
   IMAE T, 1986, J PHYS CHEM-US, V90, P5216, DOI 10.1021/j100412a065
   Israelachvili J. N., 1991, INTERMOLECULAR SURFA
   KNOBLICH A, 1995, LANGMUIR, V11, P2361, DOI 10.1021/la00007a008
   KOOPAL LK, 1995, J COLLOID INTERF SCI, V170, P85, DOI 10.1006/jcis.1995.1075
   Krafft MP, 1998, BIOCHIMIE, V80, P489, DOI 10.1016/S0300-9084(00)80016-4
   KUNG KHS, 1993, LANGMUIR, V9, P263, DOI 10.1021/la00025a050
   LAI CL, 1995, COLLOID SURFACE A, V104, P231, DOI 10.1016/0927-7757(95)03292-4
   Lamont R, 1997, J COLLOID INTERF SCI, V191, P303, DOI 10.1006/jcis.1997.4980
   Lamont RE, 1998, J AM CHEM SOC, V120, P7602, DOI 10.1021/ja9742895
   Lehmler HJ, 1999, CHEMTECH, V29, P7
   LIANOS P, 1980, J PHYS CHEM-US, V84, P3339, DOI 10.1021/j100462a003
   Lu SH, 2007, J COLLOID INTERF SCI, V316, P310, DOI 10.1016/j.jcis.2007.08.063
   Matsumoto M, 2000, COLLOID POLYM SCI, V278, P619, DOI 10.1007/s003960000293
   NASELLI C, 1989, J CHEM PHYS, V90, P3855, DOI 10.1063/1.455791
   Neivandt DJ, 1998, J PHYS CHEM B, V102, P5107, DOI 10.1021/jp980801c
   Nevskaia DM, 1998, J COLLOID INTERF SCI, V205, P97, DOI 10.1006/jcis.1998.5617
   Paria S, 2004, ADV COLLOID INTERFAC, V110, P75, DOI 10.1016/j.cis.2004.03.001
   Patil KG, 2010, J PHYS CHEM C, V114, P3549, DOI 10.1021/jp9086255
   Pavan PC, 1999, COLLOID SURFACE A, V154, P399, DOI 10.1016/S0927-7757(98)00847-4
   PORTE G, 1980, J PHYS CHEM-US, V84, P3105, DOI 10.1021/j100460a027
   Rojas OJ, 2002, LANGMUIR, V18, P8085, DOI 10.1021/la025989c
   SCHORR W, 1981, J PHYS CHEM-US, V85, P3160, DOI 10.1021/j150621a032
   SIRACUSA PA, 1986, J COLLOID INTERF SCI, V114, P184, DOI 10.1016/0021-9797(86)90251-1
   Sukhishvili SA, 1998, J CHEM PHYS, V109, P6861, DOI 10.1063/1.477253
   Sukhishvili SA, 1999, J PHYS CHEM B, V103, P472, DOI 10.1021/jp982565b
   SwansonVethamuthu M, 1996, LANGMUIR, V12, P2173, DOI 10.1021/la950964h
   Tabor RF, 2010, J COLLOID INTERF SCI, V346, P424, DOI 10.1016/j.jcis.2010.03.047
   VANDESTEEG HGM, 1992, LANGMUIR, V8, P2538, DOI 10.1021/la00046a030
   Velegol SB, 2000, LANGMUIR, V16, P2548, DOI 10.1021/la9910935
   Wang C, 2010, J CHEM ENG DATA, V55, P1994, DOI 10.1021/je900916e
   Wang K, 1999, J PHYS CHEM B, V103, P9237, DOI 10.1021/jp990821u
   Wanless EJ, 1997, LANGMUIR, V13, P1463, DOI 10.1021/la960861e
   Wanless EJ, 1996, J PHYS CHEM-US, V100, P3207, DOI 10.1021/jp952439x
   Watanabe H, 2000, RHEOL ACTA, V39, P110, DOI 10.1007/s003970050011
   Xing R, 2006, J PHYS CHEM B, V110, P295, DOI 10.1021/jp0549069
   Xing R, 2009, LANGMUIR, V25, P6486, DOI 10.1021/la9000939
NR 57
TC 5
Z9 5
U1 0
U2 41
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0021-9797
J9 J COLLOID INTERF SCI
JI J. Colloid Interface Sci.
PD JUL 1
PY 2013
VL 401
BP 88
EP 96
DI 10.1016/j.jcis.2013.03.024
PG 9
WC Chemistry, Physical
SC Chemistry
GA 150DW
UT WOS:000319371400012
PM 23602670
DA 2018-03-20
ER

PT J
AU Dawidziak, DM
   Sanchez, JG
   Wagner, JM
   Ganser-Pornillos, BK
   Pornillos, O
AF Dawidziak, Daria M.
   Sanchez, Jacint G.
   Wagner, Jonathan M.
   Ganser-Pornillos, Barbie K.
   Pornillos, Owen
TI Structure and catalytic activation of the TRIM23 RING E3 ubiquitin
   ligase
SO PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS
LA English
DT Article
DE crystal structure; dimer; E3 ligase; enzyme activation; tripartite
   motif; ubiquitination
ID REVERSE TRANSCRIPTION; CAPSID LATTICE; TRIM5-ALPHA; PROTEIN;
   POLYUBIQUITIN; CONJUGATION; MECHANISM; DIMER
AB Tripartite motif (TRIM) proteins comprise a large family of RING-type ubiquitin E3 ligases that regulate important biological processes. An emerging general model is that TRIMs form elongated antiparallel coiled-coil dimers that prevent interaction of the two attendant RING domains. The RING domains themselves bind E2 conjugating enzymes as dimers, implying that an active TRIM ligase requires higher-order oligomerization of the basal coiled-coil dimers. Here, we report crystal structures of the TRIM23 RING domain in isolation and in complex with an E2-ubiquitin conjugate. Our results indicate that TRIM23 enzymatic activity requires RING dimerization, consistent with the general model of TRIM activation.
C1 [Dawidziak, Daria M.; Sanchez, Jacint G.; Wagner, Jonathan M.; Ganser-Pornillos, Barbie K.; Pornillos, Owen] Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA.
RP Pornillos, O (reprint author), Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA.
EM opornillos@virginia.edu
OI Wagner, Jonathan M./0000-0001-9161-7222
FU NIH [R01-GM112508, F32-GM115007]
FX NIH, Grant/Award number: R01-GM112508; NIH fellowship, Grant/Award
   number: F32-GM115007.
CR Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925
   Arimoto K, 2010, P NATL ACAD SCI USA, V107, P15856, DOI 10.1073/pnas.1004621107
   Biasini M, 2014, NUCLEIC ACIDS RES, V42, pW252, DOI 10.1093/nar/gku340
   Campbell EM, 2016, J VIROL, V90, P1849, DOI 10.1128/JVI.01948-15
   Dou H, 2012, NAT STRUCT MOL BIOL, V19, P876, DOI 10.1038/nsmb.2379
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Fletcher AJ, 2015, EMBO J, V34, P2078, DOI 10.15252/embj.201490361
   Ganser-Pornillos BK, 2011, P NATL ACAD SCI USA, V108, P534, DOI 10.1073/pnas.1013426108
   Goldstone DC, 2014, P NATL ACAD SCI USA, V111, P9609, DOI 10.1073/pnas.1402448111
   Han K, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002388
   Koliopoulos MG, 2016, EMBO J, V35, P1204, DOI 10.15252/embj.201593741
   Li Y, 2014, CELL RES, V24, P762, DOI 10.1038/cr.2014.46
   Meroni G, 2005, BIOESSAYS, V27, P1147, DOI 10.1002/bies.20304
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Pertel T, 2011, NATURE, V472, P361, DOI 10.1038/nature09976
   Plechanovova A, 2012, NATURE, V489, P115, DOI 10.1038/nature11376
   Poole E, 2009, J VIROL, V83, P3581, DOI 10.1128/JVI.02072-08
   Sanchez JG, 2016, CELL REP, V16, P1315, DOI 10.1016/j.celrep.2016.06.070
   Sanchez JG, 2014, P NATL ACAD SCI USA, V111, P2494, DOI 10.1073/pnas.1318962111
   Stremlau M, 2004, NATURE, V427, P848, DOI 10.1038/nature02343
   Wagner JM, 2016, ELIFE, V5, DOI 10.7554/elife.16309
   Watanabe M, 2015, ELIFE, V4, DOI 10.7554/eLife.05615
   Weinert C, 2015, SCI REP-UK, V5, DOI 10.1038/srep10819
   Yudina Z, 2015, CELL REP, V12, P788, DOI 10.1016/j.celrep.2015.06.072
NR 24
TC 0
Z9 0
U1 5
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0887-3585
EI 1097-0134
J9 PROTEINS
JI Proteins
PD OCT
PY 2017
VL 85
IS 10
BP 1957
EP 1961
DI 10.1002/prot.25348
PG 5
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA FO7PT
UT WOS:000417069300015
PM 28681414
DA 2018-03-20
ER

PT J
AU Li, X
   Rankin, SE
AF Li, Xin
   Rankin, Stephen E.
TI Influence of unlimited 3-membered ring cyclization on a multiscale
   dynamic Monte Carlo/continuum model of drying and curing in sol-gel
   silica films
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Simulation; Polymerization; Films; Reaction engineering; Silica;
   Multiscale
ID MOLECULAR-SIZE DISTRIBUTION; CARLO-SIMULATION; 3-DIMENSIONAL POLYMERS;
   CONDENSATION RATES; CHEMICAL-KINETICS; DISTANCE MATRIX; POLYMERIZATION;
   POLYCONDENSATION; TETRAETHOXYSILANE; ELECTRODEPOSITION
AB The coating process of sol-gel silica films involves multiple length and time scales ranging from molecular to macroscopic. At the molecular scale, cyclization during polymerization is so extensive that it cannot be neglected or treated statistically. Here we present a multiscale model of a 1D sol-gel drying process coupled to a Monte Carlo polymerization model with unlimited cyclization. Because our model allows cyclic and cage-like siloxanes to form, it is better able to predict the silica gelation conversion than any other reported kinetic model. By studying the competition between molecular growth and cyclization, and the competition between mass transfer (drying) and reaction (gelation) on the drying process of the sol-gel silica film, we observe that cyclization delays the gelation, shrinks the molecular size, increases the likelihood of literal skinning, and leads to a molecular structure gradient inside the film. Although for simplicity our model just considers the possibility of forming 3-membered ring, it is the first multiscale model to couple unlimited cyclization in polycondensation with a continuum mass transfer process. Also it is the first model that can predict structure gradients caused by drying in sol-gel silica films. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Li, Xin; Rankin, Stephen E.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Rankin, SE (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM srankin@engr.uky.edu
RI Rankin, Stephen/A-3265-2013
OI Rankin, Stephen/0000-0002-8615-7564
FU U.S. Department of Energy [DE-FG02-03ER46033, DE-FG02-07ER46375]
FX This report is based on work supported by the U.S. Department of Energy
   under Grant numbers DE-FG02-03ER46033 and DE-FG02-07ER46375.
CR ASSINK RA, 1993, COLLOID SURFACE A, V74, P1, DOI 10.1016/0927-7757(93)80392-R
   BERSOHN M, 1983, J COMPUT CHEM, V4, P110, DOI 10.1002/jcc.540040115
   BONCHEV D, 1977, J CHEM PHYS, V67, P4517, DOI 10.1063/1.434593
   Cairncross RA, 1996, AICHE J, V42, P55, DOI 10.1002/aic.690420107
   CAPOZZI CA, 1992, MATER LETT, V15, P130, DOI 10.1016/0167-577X(92)90028-I
   Cruz RN, 1998, P AM MATH SOC, V126, P3715, DOI 10.1090/S0002-9939-98-04957-0
   Dollet A, 2004, SURF COAT TECH, V177, P245, DOI 10.1016/j.surfcoat.2003.09.040
   Drews TO, 2004, AICHE J, V50, P226, DOI 10.1002/aic.10021
   FICHTHORN KA, 1991, J CHEM PHYS, V95, P1090, DOI 10.1063/1.461138
   Flory PJ, 1941, J AM CHEM SOC, V63, P3096, DOI 10.1021/ja01856a063
   Flory PJ, 1941, J AM CHEM SOC, V63, P3083, DOI 10.1021/ja01856a061
   FORSMAN WC, 1976, J CHEM PHYS, V65, P4111, DOI 10.1063/1.432866
   HENDRICKSON R, 1995, COMPUT POLYMER SCI, V5, P135
   Ivanciuc O, 2001, J CHEM INF COMP SCI, V41, P536, DOI 10.1021/ci000086f
   Ivanciuc O, 2000, J CHEM INF COMP SCI, V40, P1412, DOI 10.1021/ci000068y
   Jensen KF, 1998, CURR OPIN SOLID ST M, V3, P562, DOI 10.1016/S1359-0286(98)80026-0
   Kamiya K, 1998, J NON-CRYST SOLIDS, V240, P202, DOI 10.1016/S0022-3093(98)00701-7
   Karakasidis TE, 2007, MAT SCI ENG C-BIO S, V27, P1082, DOI 10.1016/j.msec.2006.06.029
   Kasehagen LJ, 1997, MACROMOLECULES, V30, P3921, DOI 10.1021/ma9619142
   Li XH, 2007, J ELECTROCHEM SOC, V154, pD230, DOI 10.1149/1.2434686
   Li X, 2010, AICHE J, V56, P2946, DOI 10.1002/aic.12202
   MUELLER WR, 1987, J COMPUT CHEM, V8, P170
   Ng LV, 1996, J PHYS CHEM-US, V100, P12517, DOI 10.1021/jp960089o
   NG LV, 1995, MACROMOLECULES, V28, P6471, DOI 10.1021/ma00123a012
   NITTA KH, 1994, J CHEM PHYS, V101, P4222, DOI 10.1063/1.467472
   Olemskoi AI, 2001, PHYSICA A, V291, P79
   Praprotnik M, 2008, ANNU REV PHYS CHEM, V59, P545, DOI 10.1146/annurev.physchem.59.032607.093707
   Raimondeau S, 2002, CHEM ENG J, V90, P3, DOI 10.1016/S1385-8947(02)00065-7
   Rankin SE, 1998, AICHE J, V44, P1141, DOI 10.1002/aic.690440512
   Rankin SE, 2000, CHEM ENG SCI, V55, P1955, DOI 10.1016/S0009-2509(99)00486-8
   Rankin SE, 1998, CHEM MATER, V10, P2037, DOI 10.1021/cm980256s
   Rankin SE, 2000, MACROMOLECULES, V33, P7639, DOI 10.1021/ma000132c
   Sanchez J, 1996, IND ENG CHEM RES, V35, P117, DOI 10.1021/ie950246q
   SANCHEZ J, 1994, J NON-CRYST SOLIDS, V167, P289, DOI 10.1016/0022-3093(94)90251-8
   Sefcik J, 1997, AICHE J, V43, P2773, DOI 10.1002/aic.690431324
   SOMVARSKY J, 1994, POLYM BULL, V33, P377, DOI 10.1007/BF00314277
   TANG AC, 1993, J MATER CHEM, V3, P893, DOI 10.1039/jm9930300893
   Vainrub A, 1996, MAT SCI ENG B-SOLID, V37, P197, DOI 10.1016/0921-5107(95)01486-1
   WADA M, 1992, J NON-CRYST SOLIDS, V149, P203, DOI 10.1016/0022-3093(92)90068-U
   WEST JK, 1990, J NON-CRYST SOLIDS, V121, P51, DOI 10.1016/0022-3093(90)90103-S
NR 40
TC 3
Z9 3
U1 0
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 15
PY 2011
VL 66
IS 6
BP 1015
EP 1026
DI 10.1016/j.ces.2010.11.007
PG 12
WC Engineering, Chemical
SC Engineering
GA 716MR
UT WOS:000286974100001
DA 2018-03-20
ER

PT J
AU Jennings, CL
   Perry, EK
   Dziubla, TD
   Puleo, DA
AF Jennings, Cheryl L.
   Perry, Ellis K.
   Dziubla, Thomas D.
   Puleo, David A.
TI Sequential release of multiple drugs from flexible drug delivery films
SO INTERNATIONAL JOURNAL OF POLYMERIC MATERIALS AND POLYMERIC BIOMATERIALS
LA English
DT Article
DE Cytotoxicity; drug delivery; mechanical properties; plasticizer;
   sequential drug release
ID CITRIC-ACID ESTERS; PLASTICIZERS; SYSTEM; PIRFENIDONE; HYDROGEL;
   INFLAMMATION; TOXICITY; SCAFFOLD; RAT
AB Sequential release of drugs aligned with the phases of tissue healing could reduce scarring. To achieve this aim, layered film devices comprising cellulose acetate phthalate (CAP) and Pluronic F-127 (Pluronic) were loaded with ketoprofen, quercetin, and pirfenidone. Citrate plasticizers were added to impart flexibility. Release of two or three drugs in sequence over several days was obtained for all multilayered devices tested. Mechanical analysis showed that elongation increased and modulus decreased with the increasing plasticizer content. Release profiles can be tailored by order of layers, plasticizer concentration, and drug loading, making CAP-Pluronic an appealing system for inhibiting scar tissue formation.
C1 [Jennings, Cheryl L.; Perry, Ellis K.; Puleo, David A.] Univ Kentucky, F Joseph Halcomb MD Dept Biomed Engn 3, 522 Robot & Mfg Bldg, Lexington, KY 40506 USA.
   [Dziubla, Thomas D.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY USA.
RP Puleo, DA (reprint author), Univ Kentucky, F Joseph Halcomb MD Dept Biomed Engn 3, 522 Robot & Mfg Bldg, Lexington, KY 40506 USA.
EM puleo@uky.edu
FU National Institutes of Health [DE019645, AR060964]; NSF IGERT
   [DGE-0653710]
FX This research was funded by the National Institutes of Health (DE019645
   and AR060964). CJ was supported by NSF IGERT (DGE-0653710).
CR Aw MS, 2012, CHEM COMMUN, V48, P3348, DOI 10.1039/c2cc17690d
   Berg MC, 2006, BIOMACROMOLECULES, V7, P357, DOI 10.1021/bm050174e
   Card JW, 2003, TOXICOL SCI, V75, P169, DOI 10.1093/toxsci/kfg167
   COTRAN R. S., 1994, ROBBINS PATHOLOGIC B
   Dyondi D, 2013, INT J NANOMED, V8, P47, DOI 10.2147/IJN.S37953
   FINKELSTEIN M, 1959, TOXICOL APPL PHARM, V1, P283, DOI 10.1016/0041-008X(59)90113-9
   Gabbiani G, 2003, J PATHOL, V200, P500, DOI 10.1002/path.1427
   GERHARDT P, 1946, J BACTERIOL, V52, P283
   Gomathi K, 2003, BIOMATERIALS, V24, P2767, DOI 10.1016/S0142-9612(03)00059-0
   Hewitson TD, 2001, J NEPHROL, V14, P453
   Hu Q, 2009, NEPHROL DIAL TRANSPL, V24, P3033, DOI 10.1093/ndt/gfp245
   Huang SJ, 2009, EUR J PHARM SCI, V38, P64, DOI 10.1016/j.ejps.2009.06.002
   James MJ, 2001, INFLAMM RES, V50, P249, DOI 10.1007/s000110050750
   Jennings CL, 2016, J BIOACT COMPAT POL, V31, P323, DOI 10.1177/0883911515627178
   Jeon JH, 2008, BIOMATERIALS, V29, P3591, DOI 10.1016/j.biomaterials.2008.05.011
   Kabiri K, 2004, MACROMOL MATER ENG, V289, P653, DOI 10.1002/mame.200400010
   Kaneko M, 1998, CLIN EXP IMMUNOL, V113, P72, DOI 10.1046/j.1365-2249.1998.00618.x
   Karam JP, 2014, J CONTROL RELEASE, V192, P82, DOI 10.1016/j.jconrel.2014.06.052
   Klose D, 2006, INT J PHARMACEUT, V314, P198, DOI 10.1016/j.ijpharm.2005.07.031
   Kumar V., 1992, BASIC PATHOLOGY
   Kumari A, 2010, COLLOID SURFACE B, V75, P1, DOI 10.1016/j.colsurfb.2009.09.001
   Kwan P, 2009, HAND CLIN, V25, P511, DOI 10.1016/j.hcl.2009.06.007
   LaVan DA, 2003, NAT BIOTECHNOL, V21, P1184, DOI 10.1038/nbt876
   MEYERS DB, 1964, J PHARM SCI, V53, P774, DOI 10.1002/jps.2600530716
   Min J, 2014, BIOMATERIALS, V35, P2507, DOI 10.1016/j.biomaterials.2013.12.009
   Paik MY, 2010, MACROMOLECULES, V43, P4253, DOI 10.1021/ma902646t
   Paz Z, 2010, CLIN REV ALLERG IMMU, V38, P276, DOI 10.1007/s12016-009-8157-7
   Pinon-Segundo E, 2005, INT J PHARMACEUT, V294, P217, DOI 10.1016/j.ijpharm.2004.11.010
   Qi BW, 2010, EUR J PHARMACOL, V642, P134, DOI 10.1016/j.ejphar.2010.05.019
   Rabek CL, 2014, J BIOMATER APPL, V28, P779, DOI 10.1177/0885328213480979
   Ricci M, 2005, J CONTROL RELEASE, V107, P395, DOI 10.1016/j.jconrel.2005.06.023
   Schreml S, 2010, J AM ACAD DERMATOL, V63, P866, DOI 10.1016/j.jaad.2009.10.048
   Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276
   Shelke NB, 2007, INT J PHARM, V345, P51, DOI 10.1016/j.ijpharm.2007.05.036
   Shemesh M, 2014, J BIOMAT SCI-POLYM E, V25, P410, DOI 10.1080/09205063.2013.863748
   Siepmann F, 2006, J CONTROL RELEASE, V115, P298, DOI 10.1016/j.jconrel.2006.08.016
   Siepmann J, 2012, ADV DRUG DELIVER REV, V64, P163, DOI 10.1016/j.addr.2012.09.028
   Siepmann J., 2010, PHARM RES, V17, P1290
   Simonsen AC, 2004, J COLLOID INTERF SCI, V273, P291, DOI 10.1016/j.jcis.2003.12.035
   Sundararaj SC, 2016, J BIOMED MATER RES B, V104, P1302, DOI 10.1002/jbm.b.33472
   Sundararaj SC, 2014, ACTA BIOMATER, V10, P115, DOI 10.1016/j.actbio.2013.09.031
   Sundararaj SC, 2013, BIOMATERIALS, V34, P8835, DOI 10.1016/j.biomaterials.2013.07.093
   Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809
   Wood KC, 2005, LANGMUIR, V21, P1603, DOI 10.1021/la0476480
   2004, J VET PHARM THERAP, V27, P1
NR 45
TC 0
Z9 0
U1 4
U2 6
PU TAYLOR & FRANCIS AS
PI OSLO
PA KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY
SN 0091-4037
EI 1563-535X
J9 INT J POLYM MATER PO
JI Int. J. Polym. Mater. Polym. Biomat.
PY 2017
VL 66
IS 11
BP 569
EP 576
DI 10.1080/00914037.2016.1252352
PG 8
WC Materials Science, Biomaterials; Polymer Science
SC Materials Science; Polymer Science
GA ET6PN
UT WOS:000400413700004
PM 28736462
OA green_accepted
DA 2018-03-20
ER

PT J
AU Rankin, SE
   Ambati, J
AF Rankin, Stephen E.
   Ambati, Jyothirmai
TI PHYS 573-Ab initio calculation of H-1-Si-29 coupling constants in
   organoalkoxysilanes
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
CT 235th American-Chemical-Society National Meeting
CY APR 06-10, 2008
CL New Orleans, LA
SP Amer Chem Soc, Div Cellulose & Renewble Mat
C1 [Rankin, Stephen E.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM srankin@engr.uky.edu; Jyothirmai.Ambati@uky.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD APR 6
PY 2008
VL 235
MA 573-PHYS
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA 519OA
UT WOS:000271775109730
DA 2018-03-20
ER

PT J
AU Ghosh, G
   Mehta, I
   Comette, AL
   Anderson, KW
AF Ghosh, Gargi
   Mehta, Ishan
   Comette, Abagail L.
   Anderson, Kimberly W.
TI Measuring permeability with a whole cell-based biosensor as an alternate
   assay for angiogenesis: Comparison with common in vitro assays
SO BIOSENSORS & BIOELECTRONICS
LA English
DT Article
DE cell-based biosensor; angiogenesis; cytokines; permeability
ID ENDOTHELIAL GROWTH-FACTOR; NECROSIS-FACTOR-ALPHA; SELECTIVE ELECTRODES;
   CYTOKINES; VIVO; PROLIFERATION; ACTIVATION; KINASE; CANCER; VEGF
AB Angiogenesis plays cardinal role in normal developmental processes as well as in numerous pathologies. Multiple cytokines are released and act simultaneously to activate endothelial cells in vivo. The present study investigated the relative ability of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), tumor necrosis factor-alpha (TNF-alpha) in modulating cell monolayer permeability, migration, proliferation and tube formation individually and in combination. While the common methods for assaying angiogenesis were conducted for studying cell migration, proliferation and differentiation, endothelial cell monolayer permeability studies were carried out using a whole cell-based biosensor. The biosensor, consisting of a confluent monolayer of human umbilical vein endothelial cells (HUVECs) on a potassium ion-selective electrode, takes advantage of cell monolayer permeability dysfunction to detect the presence of small quantities of cytokines. When a confluent monolayer of cells was formed on the membrane surface, the response of the electrode toward the marker ion, potassium, was inhibited. The response obtained after exposing this sensor to different cytokines for I and 3 h, can be attributed to the modulation of monolayer permeability by these cytokines. The present study demonstrated that at the concentrations experimented with, the relative change in permeability assay in the presence of cytokines compared to the control was much higher than that observed in other assays, thereby bolstering the potential of the biosensor to act as a quick screening tool for angiogenesis. (C) 2007 Elsevier B.V. All rights reserved.
C1 [Ghosh, Gargi; Mehta, Ishan; Comette, Abagail L.; Anderson, Kimberly W.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Anderson, KW (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM gghos0@engr.uky.edu; ishan1222@gmail.com; alcom2@uky.edu;
   kanderson@engr.uky.edu
CR ASAHARA T, 1995, CIRCULATION, V92, P365
   Auerbach R, 2003, CLIN CHEM, V49, P32, DOI 10.1373/49.1.32
   Bates DO, 2002, J ANAT, V200, P581, DOI 10.1046/j.1469-7580.2002.00066.x
   Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5
   Brooks K A, 1996, Anal Chem, V68, P1439, DOI 10.1021/ac950915+
   BURKEGAFFNEY A, 1993, IMMUNOPHARMACOLOGY, V25, P1, DOI 10.1016/0162-3109(93)90025-L
   Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220
   CHA GS, 1989, TALANTA, V36, P271, DOI 10.1016/0039-9140(89)80106-7
   CHA MJ, 1995, ANAL CHIM ACTA, V315, P311, DOI 10.1016/0003-2670(95)00337-Y
   Dirix LY, 1997, BRIT J CANCER, V76, P238, DOI 10.1038/bjc.1997.368
   DVORAK HF, 1995, AM J PATHOL, V146, P1029
   FOLKMAN J, 1992, J BIOL CHEM, V267, P10931
   FOLKMAN J, 1990, J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4
   FRATERSCHRODER M, 1987, P NATL ACAD SCI USA, V84, P5277, DOI 10.1073/pnas.84.15.5277
   Ghosh G, 2007, ANAL BIOANAL CHEM, V387, P567, DOI 10.1007/s00216-006-0949-5
   Giraudo E, 1998, J BIOL CHEM, V273, P22128, DOI 10.1074/jbc.273.34.22128
   GOTO F, 1993, LAB INVEST, V69, P508
   Jiang WG, 1999, J CELL PHYSIOL, V181, P319, DOI 10.1002/(SICI)1097-4652(199911)181:2<319::AID-JCP14>3.3.CO;2-J
   Koch AE, 1998, ARTHRITIS RHEUM, V41, P951, DOI 10.1002/1529-0131(199806)41:6<951::AID-ART2>3.0.CO;2-D
   Koncki R, 1997, TRAC-TREND ANAL CHEM, V16, P528, DOI 10.1016/S0165-9936(97)00066-6
   Koolwijk P, 1996, J CELL BIOL, V132, P1177, DOI 10.1083/jcb.132.6.1177
   Kumar R, 1998, INT J ONCOL, V12, P749
   Lal BK, 2001, MICROVASC RES, V62, P252, DOI 10.1006/mvre.2001.2338
   May KML, 2005, ANAL BIOANAL CHEM, V382, P1010, DOI 10.1007/s00216-005-3224-2
   May KML, 2004, ANAL CHEM, V76, P4156, DOI 10.1021/ac049810+
   MORIMOTO A, 1991, BIOCHEM BIOPH RES CO, V179, P1042, DOI 10.1016/0006-291X(91)91924-2
   Naik MU, 2003, ARTERIOSCL THROM VAS, V23, P2165, DOI 10.1161/01.ATV.0000093982.84451.87
   Nakagami H, 2002, ARTERIOSCL THROM VAS, V22, P238, DOI 10.1161/hq0202.104001
   Nooteboom A, 2000, MEDIAT INFLAMM, V9, P235, DOI 10.1080/09629350020025755
   Patterson C, 1996, J CLIN INVEST, V98, P490, DOI 10.1172/JCI118816
   PEPPER MS, 1992, BIOCHEM BIOPH RES CO, V189, P824, DOI 10.1016/0006-291X(92)92277-5
   REYNOLDS LP, 1992, FASEB J, V6, P886
   Rousseau S, 2000, J BIOL CHEM, V275, P10661, DOI 10.1074/jbc.275.14.10661
   Sakong DS, 1996, SENSOR ACTUAT B-CHEM, V32, P161, DOI 10.1016/0925-4005(96)80126-2
   Sezer O, 2001, EUR J HAEMATOL, V66, P83, DOI 10.1034/j.1600-0609.2001.00348.x
   Staton CA, 2004, INT J EXP PATHOL, V85, P233, DOI 10.1111/j.0959-9673.2004.00396.x
   Stockton RA, 2004, J BIOL CHEM, V279, P46621, DOI 10.1074/jbc.M408877200
   WU LW, 2000, J BIOL CHEM, V275, P2096
   Xin XH, 2001, AM J PATHOL, V158, P1111, DOI 10.1016/S0002-9440(10)64058-8
NR 39
TC 10
Z9 10
U1 0
U2 13
PU ELSEVIER ADVANCED TECHNOLOGY
PI OXFORD
PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
   OXFORD OX5 1GB, OXON, ENGLAND
SN 0956-5663
J9 BIOSENS BIOELECTRON
JI Biosens. Bioelectron.
PD FEB 28
PY 2008
VL 23
IS 7
BP 1109
EP 1116
DI 10.1016/j.bios.2007.10.023
PG 8
WC Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical;
   Electrochemistry; Nanoscience & Nanotechnology
SC Biophysics; Biotechnology & Applied Microbiology; Chemistry;
   Electrochemistry; Science & Technology - Other Topics
GA 269AC
UT WOS:000253620900025
PM 18082392
DA 2018-03-19
ER

PT J
AU Zahran, EM
   Prodromidis, MI
   Bhattacharyya, D
   Bachas, LG
AF Zahran, Elsayed M.
   Prodromidis, Mamas I.
   Bhattacharyya, Dibakar
   Bachas, Leonidas G.
TI Palladium nanoparticle-decorated iron nanotubes hosted in a
   polycarbonate porous membrane: development, characterization, and
   performance as electrocatalysts of ascorbic acid
SO ANALYTICAL AND BIOANALYTICAL CHEMISTRY
LA English
DT Article
DE Nanoparticles/nanotechnology; Chemical sensors; Electroanalytical
   methods
ID ELECTRODEPOSITED PALLADIUM; ELECTROCHEMICAL SENSORS; NANOELECTRODE
   ENSEMBLES; GLUCOSE-OXIDASE; CARBON; FABRICATION;
   2,6-DICHLOROPHENOLINDOPHENOL; NANOWIRES; FILM
AB One-dimensional iron metallic nanotubes were prepared by electroless deposition within the pores of polycarbonate (PC) membranes. The longitudinal nucleation of the nanotubes along the pore walls was achieved by mounting the PC membrane between two halves of a U-shaped reaction tube. Palladium nanoparticles were post-deposited on the inner wall of the nanotubes. The composition, morphology, and structure of the Pd/Fe nanotubes were characterized by transmission electron microscopy, scanning electron microscopy, and inductively coupled plasma-atomic emission spectroscopy. A glassy carbon (GC) electrode modified with the free Pd/Fe bimetallic nanotubes (isolated after the dissolution of the host membranes) showed small improvement on the overpotential oxidation of ascorbic acid in comparison to the bare GC electrode. Alternatively, the Pd/Fe-polycarbonate membrane was covered with a sputtered gold thin layer of 10 nm from one side and mounted in a homemade electrochemical cell acting as the working electrode. The potential use of these functional membranes as catalytic surfaces for the electrochemical monitoring of ascorbic acid was investigated by cyclic voltammetry and amperometry. In the presence of a phosphate buffer solution, pH 7, Pd/Fe-polycarbonate membranes showed excellent electrocatalytic properties toward the oxidation of ascorbic acid even at potentials as low as 0 mV versus a Ag/AgCl reference electrode. In addition to the substantial lower overpotential, these electrodes offered selectivity over acetaminophen and uric acid, and a prolonged working stability without the need for maintenance. The electrodes were kept dry between different working days and retained their original activity for more than 1 week. Pd-polycarbonate and Fe-polycarbonate membranes were also developed for comparison purposes.
C1 [Zahran, Elsayed M.; Prodromidis, Mamas I.; Bachas, Leonidas G.] Univ Miami, Dept Chem, Coral Gables, FL 33146 USA.
   [Bhattacharyya, Dibakar] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Bachas, LG (reprint author), Univ Miami, Dept Chem, Coral Gables, FL 33146 USA.
EM bachas@miami.edu
RI Bachas, Leonidas/G-2479-2015
OI Bachas, Leonidas/0000-0002-3308-6264; Zahran,
   Elsayed/0000-0003-3456-515X; PRODROMIDIS, MAMANTOS
   (Mamas)/0000-0002-1309-403X
FU National Institute of Environmental Health Sciences (NIEHS); University
   of Miami
FX This work was supported in part by the National Institute of
   Environmental Health Sciences (NIEHS). We also acknowledge funding from
   the University of Miami. M. I. Prodromidis thanks the University of
   Ioannina, Ioannina, Greece for granting a sabbatical leave. E.M.Z
   acknowledges the National Research Center, Egypt for granting an
   academic leave.
CR Atta NF, 2010, SENSOR ACTUAT B-CHEM, V145, P299, DOI 10.1016/j.snb.2009.12.014
   Atta NF, 2009, SENSOR ACTUAT B-CHEM, V141, P566, DOI 10.1016/j.snb.2009.07.002
   Baron R, 2009, J NANOSCI NANOTECHNO, V9, P2274, DOI 10.1166/jnn.2009.SE14
   Campbell FW, 2010, ANAL BIOANAL CHEM, V396, P241, DOI 10.1007/s00216-009-3063-7
   Compton RG, 2011, UNDERSTANDING VOLTAMMETRY, 2ND EDITION, P1
   Florou AB, 2000, ANAL CHIM ACTA, V409, P113, DOI 10.1016/S0003-2670(00)00709-1
   Florou AB, 2000, ANAL CHIM ACTA, V423, P107, DOI 10.1016/S0003-2670(00)01081-3
   Haehnel V, 2010, ELECTROCHEM COMMUN, V12, P1116, DOI 10.1016/j.elecom.2010.05.043
   Kharton V. V., 2009, SOLID STATE ELECTROC
   Kim SK, 2011, SENSOR ACTUAT B-CHEM, V153, P246, DOI 10.1016/j.snb.2010.10.039
   Ksar F, 2009, CHEM MATER, V21, P1612, DOI 10.1021/cm803492j
   Lim SH, 2005, BIOSENS BIOELECTRON, V20, P2341, DOI 10.1016/j.bios.2004.08.005
   Lowe RD, 2006, ELECTROCHEM SOLID ST, V9, pH43, DOI 10.1149/1.2193071
   Luo XL, 2006, ELECTROANAL, V18, P319, DOI 10.1002/elan.200503415
   Meng H, 2011, J MATER CHEM, V21, P11352, DOI 10.1039/c1jm10361j
   MENON VP, 1995, ANAL CHEM, V67, P1920, DOI 10.1021/ac00109a003
   Moreno M, 2011, J AM CHEM SOC, V133, P4389, DOI 10.1021/ja108378x
   Perez-Lopez B, 2011, ANAL BIOANAL CHEM, V399, P1577, DOI 10.1007/s00216-010-4566-y
   Privett BJ, 2008, ANAL CHEM, V80, P4499, DOI 10.1021/ac8007219
   Safavi A, 2011, ELECTROANAL, V23, P1536, DOI 10.1002/elan.201000767
   Shaidarova LG, 2003, J ANAL CHEM+, V58, P886, DOI 10.1023/A:1025649620711
   Skoog D. A., 2007, PRINCIPLES INSTRUMEN
   Stergiou DV, 2010, ELECTROCHEM COMMUN, V12, P1307, DOI 10.1016/j.elecom.2010.07.006
   Wen D, 2010, BIOSENS BIOELECTRON, V26, P1056, DOI 10.1016/j.bios.2010.08.054
   Xian YZ, 2007, BIOSENS BIOELECTRON, V22, P2827, DOI 10.1016/j.bios.2006.11.020
   Xiao P, 2009, J NANOSCI NANOTECHNO, V9, P2426, DOI 10.1166/jnn.2009.SE21
   You JM, 2011, ELECTROANAL, V23, P2103, DOI 10.1002/elan.201100100
   Zahran EM, 2011, J MATER CHEM, V21, P10454, DOI 10.1039/c1jm11435b
NR 28
TC 2
Z9 2
U1 0
U2 51
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1618-2642
EI 1618-2650
J9 ANAL BIOANAL CHEM
JI Anal. Bioanal. Chem.
PD OCT
PY 2012
VL 404
IS 6-7
BP 1637
EP 1642
DI 10.1007/s00216-012-6291-1
PG 6
WC Biochemical Research Methods; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA 014AW
UT WOS:000309348400003
PM 22865103
DA 2018-03-19
ER

PT J
AU Long, SH
   Parkin, S
   Siegler, M
   Brock, CP
   Cammers, A
   Li, TL
AF Long, Sihui
   Parkin, Sean
   Siegler, Maxime A.
   Brock, Carolyn P.
   Cammers, Arthur
   Li, Tonglei
TI Polymorphism of an organic system effected by the directionality of
   hydrogen-bonding chains
SO CRYSTAL GROWTH & DESIGN
LA English
DT Article
ID GRAPH-SET ANALYSIS; CARBOXYLIC-ACIDS; PATTERNS; CRYSTALS; PACKING; FORMS
AB Four polymorphs of 2-[methyl(phenyl)amino] nicotinic acid were discovered, and their single crystal structures were obtained at 90 K. In addition, one monohydrate and one salt were also crystallized and measured. Among the crystal structures, there are 17 crystallographically independent conformations. More interestingly, the four anhydrate forms are tessellated similarly by stacking of one-dimension hydrogen-bonding chains and, yet, the directionalities of the hydrogen-bonding chains are unique in each polymorph.
C1 [Long, Sihui; Li, Tonglei] Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40506 USA.
   [Parkin, Sean; Siegler, Maxime; Brock, Carolyn P.; Cammers, Arthur] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
RP Li, TL (reprint author), Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40506 USA.
EM tonglei@uky.edu
RI Parkin, Sean/E-7044-2011; Cammers, Arthur/B-8681-2013
OI Cammers, Arthur/0000-0002-1682-3488
FU NSF [DMR-0449633]
FX T.L. and S.L. are grateful to NSF for the financial support of this
   study (DMR-0449633).
CR ALLEN FH, 2002, ACTA CRYSTALLOGR B, V58, P388
   ANDERSEN KV, 1989, J CHEM SOC PERK T 2, P1443, DOI 10.1039/p29890001443
   BERNSTEIN J, 1995, ANGEW CHEM INT EDIT, V34, P1555, DOI 10.1002/anie.199515551
   Bernstein J., 2002, POLYMORPHISM MOL CRY
   Beyer T, 2000, J PHYS CHEM B, V104, P2647, DOI 10.1021/jp9941413
   Brittain H. G., 1999, POLYMORPHISM PHARM S
   Byrn S. R., 1999, SOLID STATE CHEM DRU
   Chen S, 2005, J AM CHEM SOC, V127, P9881, DOI 10.1021/ja052098t
   ETTER MC, 1990, ACCOUNTS CHEM RES, V23, P120, DOI 10.1021/ar00172a005
   ETTER MC, 1990, ACTA CRYSTALLOGR B, V46, P256, DOI 10.1107/S0108768189012929
   Grell J, 1999, ACTA CRYSTALLOGR B, V55, P1030, DOI 10.1107/S0108768199007120
   HAGLER AT, 1979, J AM CHEM SOC, V101, P5131, DOI 10.1021/ja00512a003
   Hilfiker R, 2006, POLYMORPHISM PHARM I
   McCrone W. C., 1965, PHYSICS CHEMISTRY OR, VII, P725
   MURTHY HMK, 1982, ACTA CRYSTALLOGR B, V38, P315
   NANGIA A, 2008, ACC CHEM RES, V41
   Steed JW, 2003, CRYSTENGCOMM, P169, DOI 10.1039/b304631a
   TAKASUKA M, 1982, J CHEM SOC PERK T 2, P1061, DOI 10.1039/p29820001061
NR 18
TC 18
Z9 18
U1 0
U2 10
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1528-7483
J9 CRYST GROWTH DES
JI Cryst. Growth Des.
PD SEP
PY 2008
VL 8
IS 9
BP 3137
EP 3140
DI 10.1021/cg800339h
PG 4
WC Chemistry, Multidisciplinary; Crystallography; Materials Science,
   Multidisciplinary
SC Chemistry; Crystallography; Materials Science
GA 345DK
UT WOS:000258976100005
DA 2018-03-19
ER

PT J
AU Finch, L
   Fischer, J
   Gallant, M
   Goad, T
   Sachdev, G
   Huynh, T
AF Finch, Lenna
   Fischer, Jenn
   Gallant, Monica
   Goad, Tarah
   Sachdev, Gaurav
   Huynh, Toan
TI IMPROVING IDENTIFICATION AND DIAGNOSIS OF MALNUTRITION IN HOSPITALIZED
   PATIENTS
SO CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
CT 45th Critical Care Congress of the Society-of-Critical-Care-Medicine
CY FEB 20-24, 2016
CL Orlando, FL
SP Soc Crit Care Med
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0090-3493
EI 1530-0293
J9 CRIT CARE MED
JI Crit. Care Med.
PD DEC
PY 2015
VL 43
IS 12
SU 1
MA 844
PG 1
WC Critical Care Medicine
SC General & Internal Medicine
GA DK2XT
UT WOS:000374778401031
DA 2018-03-19
ER

PT J
AU Yewle, JN
   Wei, YN
   Puleo, DA
   Daunert, S
   Bachas, LG
AF Yewle, Jivan N.
   Wei, Yinan
   Puleo, David A.
   Daunert, Sylvia
   Bachas, Leonidas G.
TI Oriented Immobilization of Proteins on Hydroxyapatite Surface Using
   Bifunctional Bisphosphonates as Linkers
SO BIOMACROMOLECULES
LA English
DT Article
ID MOLECULAR RECOGNITION; BONE AFFINITY; SPACER LENGTH; CONJUGATION;
   OLIGONUCLEOTIDES; BIOCERAMICS; ATTACHMENT; STRATEGIES; PARTICLES;
   CHEMISTRY
AB Oriented immobilization of proteins is an important step in creating protein-based functional materials. In this study, a method was developed to orient proteins on hydroxyapatite (HA) surfaces, a widely used bone implant material, to improve protein bioactivity by employing enhanced green fluorescent protein (EGFP) and beta-lactamase as model proteins. These proteins have a serine or threonine at their N-terminus that was oxidized with periodate to obtain a single aldehyde group at the same location, which can be used for the site-specific immobilization of the protein. The HA surface was modified with bifunctional hydrazine bisphosphonates (HBPs) of various length and lipophilicity. The number of functional groups on the HBP-modified HA surface, determined by a 2,4,6-trinitrobenzenesulfonic acid (TNBS) assay, was found to be 2.8 X 10(-5) mol/mg of HA and unaffected by the length of HBPs. The oxidized proteins were immobilized on the HBP-modified HA surface in an oriented manner through formation of a hydrazone bond. The relative protein immobilization amounts through various HBPs were determined by fluorescence and bicinchoninic acid (BCA) assay and showed no significant effect by length and lipophilicity of HBPs. The relative amount of HBP-immobilized EGFP was found to be 10-15 fold that of adsorbed EGFP, whereas the relative amount of beta-lactamase immobilized through HBPs (2, 3, 4, 6, and 7) was not significantly different than adsorbed beta-lactamase. The enzymatic activity of HBP-immobilized beta-lactamase was measured with cefazolin as substrate, and it was found that the catalytic efficiency of HBP-immobilized beta-lactamase improved 2-5 fold over adsorbed beta-lactamase. The results obtained demonstrate the feasibility of our oriented immobilization approach and showed an increased activity of the oriented proteins in comparison with adsorbed proteins on the same hydroxyapatite surface matrix.
C1 [Bachas, Leonidas G.] Univ Miami, Dept Chem, Coral Gables, FL 33146 USA.
   [Yewle, Jivan N.; Wei, Yinan] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
   [Puleo, David A.; Daunert, Sylvia] Univ Kentucky, Ctr Biomed Engn, Lexington, KY 40506 USA.
   [Puleo, David A.; Daunert, Sylvia] Univ Miami, Miller Sch Med, Dept Biochem & Mol Biol, Coral Gables, FL 33146 USA.
RP Bachas, LG (reprint author), Univ Miami, Dept Chem, 1301 Mem Dr, Coral Gables, FL 33146 USA.
EM bachas@miami.edu
RI Bachas, Leonidas/G-2479-2015
OI Bachas, Leonidas/0000-0002-3308-6264
FU U.S. Army Medical Research and Materiel Command [W81XWH-09-1-0461];
   University of Kentucky; Lucille P. Markey Chair in Biochemistry and
   Molecular Biology of the Miller School of Medicine of the University of
   Miami
FX This work was funded by the U.S. Army Medical Research and Materiel
   Command (W81XWH-09-1-0461). J.Y. acknowledges support from the
   University of Kentucky in the form of an RCTF fellowship. We thank Dr.
   Emre Dikici and Dr. Xin Liu (University of Kentucky, Lexington, KY) for
   useful discussions. S.D. is grateful for support from the Gill Eminent
   Professorship of the University of Kentucky and the Lucille P. Markey
   Chair in Biochemistry and Molecular Biology of the Miller School of
   Medicine of the University of Miami.
CR Antsypovich SI, 2005, NUCLEOS NUCLEOT NUCL, V24, P211, DOI 10.1081/NCN-200055723
   Blower P, 2006, DALTON T, P1705, DOI 10.1039/b516860k
   Bouyer E, 1997, JOM-J MIN MET MAT S, V49, P58, DOI 10.1007/BF02915483
   Brogan KL, 2005, LANGMUIR, V21, P3054, DOI 10.1021/la047922q
   Cabana H, 2009, BIORESOURCE TECHNOL, V100, P3447, DOI 10.1016/j.biortech.2009.02.052
   Cao L., 2006, CARRIER BOUND IMMOBI, P169, DOI [10.1002/3527607668.ch3, DOI 10.1002/3527607668.CH3]
   Cao T, 2007, BIOTECHNOL BIOENG, V98, P1109, DOI 10.1002/bit.21503
   Costa L, 2009, NAT CLIN PRACT ONCOL, V6, P163, DOI 10.1038/ncponc1323
   De Maio A, 2003, J MOL CATAL B-ENZYM, V21, P253, DOI 10.1016/S1381-1177(02)00230-8
   Ehrenfest DMD, 2010, TRENDS BIOTECHNOL, V28, P198, DOI 10.1016/j.tibtech.2009.12.003
   Ehrick RS, 2008, BIOCONJUGATE CHEM, V19, P315, DOI 10.1021/bc700196q
   FIELDS R, 1968, BIOCHEM J, V108, P883, DOI 10.1042/bj1080883
   Gittens SA, 2005, ADV DRUG DELIVER REV, V57, P1011, DOI 10.1016/j.addr.2004.12.015
   Gittens SA, 2003, PHARMACEUT RES, V20, P978, DOI 10.1023/A:1024445903306
   GREENFIELD RS, 1990, CANCER RES, V50, P6600
   HENCH LL, 1975, ANNU REV MATER SCI, V5, P279, DOI 10.1146/annurev.ms.05.080175.001431
   Huang W, 1997, ANAL CHEM, V69, P4601, DOI 10.1021/ac970390g
   Ito Y, 2008, SOFT MATTER, V4, P46, DOI 10.1039/b708359a
   Kohn M, 2009, J PEPT SCI, V15, P393, DOI 10.1002/psc.1130
   Lee WH, 2012, J R SOC INTERFACE, V9, P918, DOI 10.1098/rsif.2011.0586
   Lin PC, 2010, MACROMOL CHEM PHYS, V211, P136, DOI 10.1002/macp.200900539
   Lumachi F, 2008, CURR MED CHEM, V15, P415, DOI 10.2174/092986708783497346
   Marina J. G., 1984, ANAL BIOCHEM, V136, P433
   Martin HJ, 2007, LANGMUIR, V23, P6645, DOI 10.1021/la063284v
   MIKOLAJCZYK SD, 1994, BIOCONJUGATE CHEM, V5, P636, DOI 10.1021/bc00030a020
   Morra M, 2006, EUR CELLS MATER, V12, P1
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Nouaimi M, 2001, ENZYME MICROB TECH, V29, P567, DOI 10.1016/S0141-0229(01)00429-X
   Pan HZ, 2006, J DRUG TARGET, V14, P425, DOI 10.1080/10611860600834219
   Puleo DA, 2002, BIOMATERIALS, V23, P2079, DOI 10.1016/S0142-9612(01)00339-8
   Puleo DA, 1997, J BIOMED MATER RES, V37, P222, DOI 10.1002/(SICI)1097-4636(199711)37:2<222::AID-JBM11>3.0.CO;2-G
   Raddatz S, 2002, NUCLEIC ACIDS RES, V30, P4793, DOI 10.1093/nar/gkf594
   Rao SV, 1998, MIKROCHIM ACTA, V128, P127, DOI 10.1007/BF01243043
   Richert L, 2010, SURF SCI, V604, P1445, DOI 10.1016/j.susc.2010.05.007
   Rusmini F, 2007, BIOMACROMOLECULES, V8, P1775, DOI 10.1021/bm061197b
   Saleemuddin M, 1999, Adv Biochem Eng Biotechnol, V64, P203
   SEEBERG AH, 1983, ANTIMICROB AGENTS CH, V23, P918, DOI 10.1128/AAC.23.6.918
   Sharon JL, 2008, BIOMATERIALS, V29, P3137, DOI 10.1016/j.biomaterials.2008.04.019
   SOBALLE K, 1993, ACTA ORTHOP SCAND, V64, pR1
   Tetala KKR, 2010, J SEP SCI, V33, P422, DOI 10.1002/jssc.200900635
   Uludag H, 2000, BIOTECHNOL PROGR, V16, P258, DOI 10.1021/bp990154m
   Uludag H, 2002, BIOTECHNOL PROGR, V18, P604, DOI 10.1021/bp0200447
   Variola F, 2011, NANOSCALE, V3, P335, DOI 10.1039/c0nr00485e
   Wang JQ, 2001, BIOMACROMOLECULES, V2, P700, DOI 10.1021/bm015517x
   Watanabe J., 2007, NANOBIOTECHNOLOGY, V3, P76
   Wazen RM, 2010, J BIOMED MATER RES B, V94B, P64, DOI 10.1002/jbm.b.31624
   WOLKE JGC, 1992, J THERM SPRAY TECHN, V1, P75
   Wong LS, 2009, CHEM REV, V109, P4025, DOI 10.1021/cr8004668
   Yewle JN, 2011, BIOCONJUGATE CHEM, V22, P2496, DOI 10.1021/bc2003132
   Yuan Y, 2008, J BIOMED MATER RES B, V86B, P245, DOI 10.1002/jbm.b.31012
   Zhang SF, 2007, CHEM SOC REV, V36, P507, DOI 10.1039/b512310k
   [Anonymous], 2009, THERMOSCIENTIFIC PIE
NR 52
TC 10
Z9 10
U1 0
U2 45
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1525-7797
EI 1526-4602
J9 BIOMACROMOLECULES
JI Biomacromolecules
PD JUN
PY 2012
VL 13
IS 6
BP 1742
EP 1749
DI 10.1021/bm201865r
PG 8
WC Biochemistry & Molecular Biology; Chemistry, Organic; Polymer Science
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA 954WO
UT WOS:000304978900005
PM 22559170
DA 2018-03-20
ER

PT J
AU Wagner', JM
   Chan, S
   Evans's, TJ
   Kahng, S
   Kim, J
   Arbing, MA
   Eisenberg, D
   Korotkov, KV
AF Wagner, Jonathan M.
   Chan, Sum
   Evans's, Timothy J.
   Kahng, Sara
   Kim, Jennifer
   Arbing, Mark A.
   Eisenberg, David
   Korotkov, Konstantin V.
TI Structures of EccB(1) and EccD1 from the core complex of the
   mycobacterial ESX-1 type VII secretion system
SO BMC STRUCTURAL BIOLOGY
LA English
DT Article
DE EccB; EccD; Mycobacterium tuberculosis; Type VII secretion system; ESX
ID O-GLYCOSYLATION SITES; PATHOGENIC MYCOBACTERIA; STRUCTURE PREDICTION;
   ELECTRON-DENSITY; DATA QUALITY; TUBERCULOSIS; VIRULENCE; SERVER;
   MEMBRANE; FEATURES
AB Background: The ESX-1 type VII secretion system is an important determinant of virulence in pathogenic mycobacteria, including Mycobacterium tuberculosis. This complicated molecular machine secretes folded proteins through the mycobacterial cell envelope to subvert the host immune response. Despite its important role in disease very little is known about the molecular architecture of the ESX-1 secretion system.
   Results: This study characterizes the structures of the soluble domains of two conserved core ESX-1 components EccB(1) and EccD1. The periplasmic domain of EccB(1) consists of 4 repeat domains and a central domain, which together form a quasi 2-fold symmetrical structure. The repeat domains of EccB(1) are structurally similar to a known peptidoglycan binding protein suggesting a role in anchoring the ESX-1 system within the periplasmic space. The cytoplasmic domain of EccD1has a ubiquitin-like fold and forms a dimer with a negatively charged groove.
   Conclusions: These structures represent a major step towards resolving the molecular architecture of the entire ESX-1 assembly and may contribute to ESX-1 targeted tuberculosis intervention strategies.
C1 [Wagner', Jonathan M.; Evans's, Timothy J.; Korotkov, Konstantin V.] Univ Kentucky, Dept Mol & Cellular Biochem, 741 South Limestone, Lexington, KY 40536 USA.
   [Wagner', Jonathan M.; Evans's, Timothy J.; Korotkov, Konstantin V.] Univ Kentucky, Struct Biol Ctr, 741 South Limestone, Lexington, KY 40536 USA.
   [Chan, Sum; Kahng, Sara; Kim, Jennifer; Arbing, Mark A.] Univ Calif Los Angeles, UCLA DOE Inst, Los Angeles, CA 90095 USA.
   [Eisenberg, David] Univ Calif Los Angeles, UCLA DOE Inst, Dept Biol Chem, Los Angeles, CA 90095 USA.
   [Eisenberg, David] Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA.
   [Eisenberg, David] Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA.
   [Wagner', Jonathan M.] Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA USA.
   [Wagner', Jonathan M.] Univ Virginia, Myles H Thaler Ctr AIDS & Human Retrovirus Res, Charlottesville, VA USA.
   [Evans's, Timothy J.] Univ Kentucky, Coll Agr Food & Environm, Div Regulatory Serv, Lexington, KY USA.
RP Korotkov, KV (reprint author), Univ Kentucky, Dept Mol & Cellular Biochem, 741 South Limestone, Lexington, KY 40536 USA.; Korotkov, KV (reprint author), Univ Kentucky, Struct Biol Ctr, 741 South Limestone, Lexington, KY 40536 USA.
EM kkorotkov@uky.edu
OI Korotkov, Konstantin/0000-0002-2182-6843
FU U.S. Department of Energy, Office of Biological and Environmental
   Research (BER) program [DE-FC02-02ER63421]; U.S. Department of Energy,
   Office of Science, Office of Basic Energy Sciences [W-31-109-Eng-38];
   Howard Hughes Medical Institute; National Institutes of Health
   [23616-002-06 F3:02]; TBSGC [AI068135, AI095208]; National Institute of
   General Medical Sciences of the National Institutes of Health
   [P20GM103486, P30GM110787]; National Institute of Allergy and Infectious
   Diseases [R01AI119022]
FX We thank Maksymilian Chruszcz, University of South Carolina, for
   assistance and advice on data processing. We thank the staff of the
   UCLA-DOE Institute Protein Expression Technology Center, supported by
   the U.S. Department of Energy, Office of Biological and Environmental
   Research (BER) program under Award Number DE-FC02-02ER63421, and the
   UCLA Crystallization Core for assistance in protein purification and
   crystallization screening. Authors thank staff members of beamline
   24-ID-C, and Southeast Regional Collaborative Access Team (SER-CAT) at
   the Advanced Photon Source, Argonne National Laboratory, for assistance
   during data collection. Use of the Advanced Photon Source was supported
   by the U.S. Department of Energy, Office of Science, Office of Basic
   Energy Sciences, under Contract No. W-31-109-Eng-38. Work performed in
   the laboratory of D.E. is supported by the Howard Hughes Medical
   Institute and National Institutes of Health grants 23616-002-06 F3:02,
   TBSGC P01 (AI068135), and TBSGC P01 (AI095208). Research reported in
   this publication was partially supported by an Institutional Development
   Award (IDeA) from the National Institute of General Medical Sciences of
   the National Institutes of Health under grant numbers P20GM103486 and
   P30GM110787, and by the National Institute of Allergy and Infectious
   Diseases grant number R01AI119022 to KVK.
CR Abendroth Jan, 2011, Journal of Structural and Functional Genomics, V12, P83, DOI 10.1007/s10969-011-9101-7
   Arbing MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081753
   Ates LS, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005190
   Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398
   Bitter W, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000507
   Bottai D, 2012, MOL MICROBIOL, V83, P1195, DOI 10.1111/j.1365-2958.2012.08001.x
   Bricogne G, 2003, ACTA CRYSTALLOGR D, V59, P2023, DOI 10.1107/S0907444903017694
   Bricogne G., 2011, BUSTER VERSION 2 10
   Champion MM, 2014, J PROTEOME RES, V13, P5151, DOI 10.1021/pr500484w
   Champion PAD, 2006, SCIENCE, V313, P1632, DOI 10.1126/science.1131167
   Champion PAD, 2009, MOL MICROBIOL, V73, P950, DOI 10.1111/j.1365-2958.2009.06821.x
   Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073
   Coros A, 2008, MOL MICROBIOL, V69, P794, DOI 10.1111/j.1365-2958.2008.06299.x
   Cowtan K, 2008, ACTA CRYSTALLOGR D, V64, P83, DOI 10.1107/S0907444907033938
   Daleke MH, 2011, J BIOL CHEM, V286, P19024, DOI 10.1074/jbc.M110.204966
   Drozdetskiy A, 2015, NUCLEIC ACIDS RES, V43, pW389, DOI 10.1093/nar/gkv332
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Evans P, 2006, ACTA CRYSTALLOGR D, V62, P72, DOI 10.1107/S0907444905036693
   Finn RD, 2014, NUCLEIC ACIDS RES, V42, pD222, DOI 10.1093/nar/gkt1223
   Gibson DG, 2011, METHOD ENZYMOL, V498, P349, DOI 10.1016/B978-0-12-385120-8.00015-2
   Gray TA, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001602
   Guinn KM, 2004, MOL MICROBIOL, V51, P359, DOI 10.1046/j.1365-2958.2003.03844.x
   Hansen JE, 1998, GLYCOCONJUGATE J, V15, P115, DOI 10.1023/A:1006960004440
   Hoffmann C, 2008, P NATL ACAD SCI USA, V105, P3963, DOI 10.1073/pnas.0709530105
   Houben D, 2012, CELL MICROBIOL, V14, P1287, DOI 10.1111/j.1462-5822.2012.01799.x
   Houben ENG, 2012, MOL MICROBIOL, V86, P472, DOI 10.1111/j.1365-2958.2012.08206.x
   Ioerger TR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075245
   Iwashkiw JA, 2013, MOL MICROBIOL, V89, P14, DOI 10.1111/mmi.12265
   Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337
   Karplus PA, 2012, SCIENCE, V336, P1030, DOI [10.1126/science.121823, 10.1126/science.1218231]
   Kelley LA, 2015, NAT PROTOC, V10, P845, DOI 10.1038/nprot.2015.053
   Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022
   Li H, 2005, PROTEINS, V61, P704, DOI 10.1002/prot.20660
   Majlessi L, 2005, J IMMUNOL, V174, P3570, DOI 10.4049/jimmunol.174.6.3570
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206
   McGowan S, 2012, P NATL ACAD SCI USA, V109, P12752, DOI 10.1073/pnas.1208424109
   McLaughlin B, 2007, PLOS PATHOG, V3, P1051, DOI 10.1371/journal.ppat.0030105
   Moon AF, 2010, PROTEIN SCI, V19, P901, DOI 10.1002/pro.368
   Murshudov GN, 2011, ACTA CRYSTALLOGR D, V67, P355, DOI 10.1107/S0907444911001314
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Painter J, 2006, ACTA CRYSTALLOGR D, V62, P439, DOI 10.1107/S0907444906005270
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pym AS, 2002, MOL MICROBIOL, V46, P709, DOI 10.1046/j.1365-2958.2002.03237.x
   Quiocho FA, 1997, STRUCTURE, V5, P997, DOI 10.1016/S0969-2126(97)00253-0
   Ramsdell TL, 2015, J MOL BIOL, V427, P1119, DOI 10.1016/j.jmb.2014.06.013
   Robert X, 2014, NUCLEIC ACIDS RES, V42, pW320, DOI 10.1093/nar/gku316
   Rosenberg OS, 2015, CELL, V161, P501, DOI 10.1016/j.cell.2015.03.040
   Sartain MJ, 2009, GLYCOBIOLOGY, V19, P38, DOI 10.1093/glycob/cwn102
   Serafini A, 2009, J BACTERIOL, V191, P6340, DOI 10.1128/JB.00756-09
   Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930
   Siegrist MS, 2014, MBIO, V5, DOI 10.1128/mBio.01073-14
   Siegrist MS, 2009, P NATL ACAD SCI USA, V106, P18792, DOI 10.1073/pnas.0900589106
   Soding J, 2005, NUCLEIC ACIDS RES, V33, pW244, DOI 10.1093/nar/gki408
   Tsirigos KD, 2015, NUCLEIC ACIDS RES, V43, pW401, DOI 10.1093/nar/gkv485
   Gey van Pittius N. C., 2006, BMC EVOL BIOL, V6, P95, DOI DOI 10.1186/1471-2148-6-95
   Weerdenburg EM, 2015, INFECT IMMUN, V83, P1778, DOI 10.1128/IAI.03050-14
   Zhang KYJ, 1997, METHOD ENZYMOL, V277, P53, DOI 10.1016/S0076-6879(97)77006-X
   Zhang XL, 2015, FASEB J, V29, P4804, DOI 10.1096/fj.15-270843
NR 58
TC 5
Z9 6
U1 0
U2 13
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472-6807
J9 BMC STRUCT BIOL
JI BMC Struct. Biol.
PD FEB 27
PY 2016
VL 16
AR 5
DI 10.1186/512900-016-0056-6
PG 11
WC Biophysics
SC Biophysics
GA DF3SW
UT WOS:000371269100001
PM 26922638
OA gold
DA 2018-03-20
ER

PT J
AU Frimpong, RA
   Hilt, JZ
AF Frimpong, Reynolds A.
   Hilt, J. Zach
TI Poly(n-isopropylacrylamide)-based hydrogel coatings on magnetite
   nanoparticles via atom transfer radical polymerization
SO NANOTECHNOLOGY
LA English
DT Article
ID IRON-OXIDE NANOPARTICLES; N-ISOPROPYLACRYLAMIDE; CONTRAST AGENTS;
   PARTICLES; FUNCTIONALIZATION; MICROSPHERES; HYPERTHERMIA; TEMPERATURE;
   SEPARATION; SYSTEM
AB Core magnetite (Fe(3)O(4)) nanoparticles have been functionalized with a model intelligent hydrogel system based on the temperature responsive polymer poly(n-isopropyl acrylamide) (PNIPAAm) to obtain magnetically responsive core-shell nanocomposites. Fe(3)O(4) nanoparticles were obtained from a one-pot co-precipitation method which provided either oleic acid (hydrophobic) or citric acid (hydrophilic) coated nanoparticles. Subsequent ligand exchange of these coatings with various bromine alkyl halides and a bromo silane provided initiating sites for functionalization with NIPAAm using atom transfer radical polymerization (ATRP). The bromine alkyl halides that were used were 2-bromo-2-methyl propionic acid (BMPA) and 2-bromopropionyl bromide (BPB). The bromo silane that was used was 3-bromopropyl trimethoxysilane (BPTS). The intelligent polymeric shell consists of NIPAAm crosslinked with poly(ethylene glycol) 400 dimethacrylate (PEG400DMA). Fourier transform infrared (FTIR) spectroscopy, thermogravimetric analysis (TGA), and transmission electron microscopy (TEM) were used to confirm the presence of the polymeric shell. Dynamic light scattering (DLS) was used to characterize the nanocomposites for particle size changes with temperature. Their magnetic and temperature responsiveness show great promise for further biomedical applications. This platform for functionalizing magnetic nanoparticles with intelligent hydrogels promises to impact a wide range of medical and biological applications of magnetic nanoparticles.
C1 [Frimpong, Reynolds A.; Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Hilt, JZ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM hilt@engr.uky.edu
CR Bucak S, 2003, BIOTECHNOL PROGR, V19, P477, DOI 10.1021/bp0200853
   Deng YH, 2003, ADV MATER, V15, P1729, DOI 10.1002/adma.200305459
   Fortin JP, 2007, J AM CHEM SOC, V129, P2628, DOI 10.1021/ja067457e
   Gravano SM, 2005, J POLYM SCI POL CHEM, V43, P3675, DOI 10.1002/pola.20823
   Gupta AK, 2005, BIOMATERIALS, V26, P3995, DOI 10.1016/j.biomaterials.2004.10.012
   Hilger I, 2002, ACAD RADIOL, V9, P198, DOI 10.1016/S1076-6332(03)80171-X
   Hu FX, 2006, BIOMACROMOLECULES, V7, P809, DOI 10.1021/bm050870e
   Hyeon T, 2001, J AM CHEM SOC, V123, P12798, DOI 10.1021/ja016812s
   Jain TK, 2005, MOL PHARMACEUT, V2, P194, DOI 10.1021/mp0500014
   JUNG CW, 1995, MAGN RESON IMAGING, V13, P661, DOI 10.1016/0730-725X(95)00024-B
   Kim DJ, 2003, MACROMOL RAPID COMM, V24, P517, DOI 10.1002/marc.200390076
   Kim DK, 2001, J MAGN MAGN MATER, V225, P256, DOI 10.1016/S0304-8853(00)01255-5
   Koneracka M, 1999, J MAGN MAGN MATER, V201, P427, DOI 10.1016/S0304-8853(99)00005-0
   LAIJ J, 2007, LANGMUIR, V23, P7385
   Lattuada M, 2007, LANGMUIR, V23, P2158, DOI 10.1021/la062092x
   Lin SY, 1999, POLYMER, V40, P2619, DOI 10.1016/S0032-3861(98)00512-6
   Liu XQ, 2006, J MAGN MAGN MATER, V306, P248, DOI 10.1016/j.jmmm.2006.03.049
   MASSART R, 1981, IEEE T MAGN, V17, P1247, DOI 10.1109/TMAG.1981.1061188
   Moroz P, 2002, INT J HYPERTHER, V18, P267, DOI 10.1080/02656730110108785
   Muller-Schulte D, 2006, J MAGN MAGN MATER, V302, P267, DOI 10.1016/j.jmmm.2005.05.043
   Oster J, 2001, J MAGN MAGN MATER, V225, P145, DOI 10.1016/S0304-8853(00)01243-9
   Palma R.D., 2007, CHEM MATER, V19, P1821, DOI DOI 10.1021/CM0628000
   Pyun J, 2001, CHEM MATER, V13, P3436, DOI 10.1021/cm011065j
   SCHILD HG, 1992, PROG POLYM SCI, V17, P163, DOI 10.1016/0079-6700(92)90023-R
   Shamim N, 2006, J COLLOID INTERF SCI, V304, P1, DOI 10.1016/j.jcis.2006.08.047
   Shtykova EV, 2007, J PHYS CHEM C, V111, P18078, DOI 10.1021/jp075235c
   Sun SH, 2002, J AM CHEM SOC, V124, P8204, DOI 10.1021/ja026501x
   Sun YB, 2006, CHEM COMMUN, P2765, DOI 10.1039/b604202c
   von Werne T, 2001, J AM CHEM SOC, V123, P7497, DOI 10.1021/ja010235q
   Wagner S, 2002, INVEST RADIOL, V37, P167, DOI 10.1097/00004424-200204000-00002
   Wakamatsu H, 2006, J MAGN MAGN MATER, V302, P327, DOI 10.1016/j.jmmm.2005.09.032
   Wang Y, 2003, NANO LETT, V3, P789, DOI 10.1021/nl034211o
   WEISSLEDER R, 1990, RADIOLOGY, V175, P489, DOI 10.1148/radiology.175.2.2326474
   Yu S, 2004, J MATER CHEM, V14, P2781, DOI 10.1039/b404964k
   Zhang J, 2001, J APPL POLYM SCI, V82, P1077, DOI 10.1002/app.1942
   Zhang JL, 2007, LANGMUIR, V23, P6342, DOI 10.1021/la0636199
   Zhang L, 2006, APPL SURF SCI, V253, P2611, DOI 10.1016/j.apsusc.2006.05.023
   Zheng GD, 2002, MACROMOLECULES, V35, P7612, DOI 10.1021/ma020421w
NR 38
TC 50
Z9 51
U1 4
U2 66
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0957-4484
J9 NANOTECHNOLOGY
JI Nanotechnology
PD APR 30
PY 2008
VL 19
IS 17
AR 175101
DI 10.1088/0957-4484/19/17/175101
PG 7
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary;
   Physics, Applied
SC Science & Technology - Other Topics; Materials Science; Physics
GA 279BJ
UT WOS:000254329700001
PM 21825659
DA 2018-03-20
ER

PT J
AU Osei-Prempeh, G
   Lehmler, HJ
   Rankin, SE
   Knutson, BL
AF Osei-Prempeh, Gifty
   Lehmler, Hans-Joachim
   Rankin, Stephen E.
   Knutson, Barbara L.
TI Direct Synthesis and Accessibility of Amine-Functionalized Mesoporous
   Silica Templated Using Fluorinated Surfactants
SO INDUSTRIAL & ENGINEERING CHEMISTRY RESEARCH
LA English
DT Article
ID CARBON-DIOXIDE; MOLECULAR-SIEVES; CO-CONDENSATION; PORE STRUCTURE;
   LIQUID CELL; ADSORPTION; SBA-15; MCM-41; CATALYSTS; SIZE
AB 3-Aminopropyl functionalized silica is synthesized directly using cationic fluorinated surfactants (C(6)F(13)C(2)H(2)NC(5)H(5)Cl (HFOPC) and C(8)F(17)C(2)H(2)NC(5)H(5)Cl (HFDePC)) and a hydrocarbon surfactant (C(16)H(33)N(CH(3))(3)Br (CTAB)) as templates. The resulting 3-aminopropyl finictionalized silica has a two-dimensional hexagonal pore structure, with greater order and surface area in the CTAB-templated material than the fluorinated-surfactant-templated materials. Greater amine incorporation is achieved using CTAB (1.44 mmol/g), with the least amine incorporation being observed in the HFDePC-templated material (0.92 mmol/g). The incorporation of fluorescein isothiocyanate (FITC) is used to qualitatively probe the accessibility of the amine groups. The reaction of benzaldehyde with the amine groups results in the incorporation of benzaldehyde, which is consistent with the higher accessibility of amines in fluorocarbon-surfactant-templated silica. The interaction of dry CO(2) with amines results in higher CO(2) sorbed in 3-aminopropyl-functionalized silica than nonfunctionalized silica, with greater amine accessibility being observed in the fluorocarbon-templated silica. The incorporation of perfluorooctyl in 3-aminopropyl-functionalized silica reduces the physisorption and CO(2)-amine interaction.
C1 [Rankin, Stephen E.; Knutson, Barbara L.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Osei-Prempeh, Gifty] W Virginia Univ, Inst Technol, Dept Chem Engn, Montgomery, WV 25136 USA.
   [Lehmler, Hans-Joachim] Univ Iowa, Coll Publ Hlth, Dept Occupat & Environm Hlth, Iowa City, IA 52242 USA.
RP Knutson, BL (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM bknutson@engr.uky.edu
RI Rankin, Stephen/A-3265-2013
OI Rankin, Stephen/0000-0002-8615-7564; Lehmler,
   Hans-Joachim/0000-0001-9163-927X
FU National Science Foundation [DMR-0210517]; USDA Biomass Research and
   Development Initiative [68-3A75-7-608]; Department of Chemical
   Engineering, WVU Institute of Technology
FX This material is based on work sponsored by the National Science
   Foundation (under Grant No. DMR-0210517), the USDA Biomass Research and
   Development Initiative Grant (No. 68-3A75-7-608), and the Department of
   Chemical Engineering, WVU Institute of Technology. We thank Dr. John
   Selegue (Department of Chemistry, University of Kentucky), Dr. Richard
   Eitel (Department of Chemical and Materials Engineering, University of
   Kentucky) for use of the TGA instrument for CO<INF>2</INF> adsorption
   analysis, and Ms. Margaret Grider (Center of Applied Energy Research,
   University of Kentucky) for CHN elemental analysis.
CR Abidi N, 2006, J MEMBRANE SCI, V270, P101, DOI 10.1016/j.memsci.2005.06.054
   BECK JS, 1992, J AM CHEM SOC, V114, P10834, DOI 10.1021/ja00053a020
   Bowe CA, 2003, J ENVIRON SCI HEAL A, V38, P2653, DOI 10.1081/ESE-120024454
   Cece A, 1996, J PHYS CHEM-US, V100, P7435, DOI 10.1021/jp953627q
   Chang ACC, 2003, ENERG FUEL, V17, P468, DOI 10.1021/ef020176h
   Chen C, 2009, CHEM COMMUN, P3627, DOI 10.1039/b905589d
   Choi S, 2009, CHEMSUSCHEM, V2, P796, DOI 10.1002/cssc.200900036
   Dias AMA, 2006, IND ENG CHEM RES, V45, P2341, DOI 10.1021/ie051017z
   Giulieri F, 1996, THIN SOLID FILMS, V284, P195, DOI 10.1016/S0040-6090(95)08304-9
   Gregg S. J., 1967, ADSORPTION SURFACE A
   Hartono SB, 2009, LANGMUIR, V25, P6413, DOI 10.1021/la900023p
   Hicks JC, 2008, INORG CHIM ACTA, V361, P3024, DOI 10.1016/j.ica.2008.01.002
   Hicks JC, 2006, LANGMUIR, V22, P2676, DOI 10.1021/la053024y
   Hiyoshi N, 2005, MICROPOR MESOPOR MAT, V84, P357, DOI 10.1016/j.micromeso.2005.06.010
   Holmes SM, 1998, J CHEM SOC FARADAY T, V94, P2025, DOI 10.1039/a801898g
   Huang HY, 2003, IND ENG CHEM RES, V42, P2427, DOI 10.1021/ie020440u
   Huh S, 2003, CHEM MATER, V15, P4247, DOI 10.1021/cm0210041
   Im HJ, 2000, ENVIRON SCI TECHNOL, V34, P2209, DOI 10.1021/es9911014
   Innocenzi P, 2003, J PHYS CHEM B, V107, P4711, DOI 10.1021/jp026609z
   Karukstis KK, 1997, J PHYS CHEM B, V101, P1968, DOI 10.1021/jp962537y
   KEKICHEFF P, 1989, J PHYS CHEM-US, V93, P2520, DOI 10.1021/j100343a056
   Khatri RA, 2006, ENERG FUEL, V20, P1514, DOI 10.1021/ef050402y
   Kim S, 2005, J PHYS CHEM B, V109, P6287, DOI 10.1021/jp045634x
   Kruk M, 1999, LANGMUIR, V15, P1442, DOI 10.1021/la980789f
   Kruk M, 1997, LANGMUIR, V13, P6267, DOI 10.1021/la970776m
   Kruk M, 2001, CHEM MATER, V13, P3169, DOI 10.1021/cm0101069
   Kubo K, 2002, LANGMUIR, V18, P8770, DOI 10.1021/la020350u
   Kumar D, 2001, COLLOID SURFACE A, V187, P109, DOI 10.1016/S0927-7757(01)00638-0
   Leal O, 1995, INORG CHIM ACTA, V240, P183, DOI 10.1016/0020-1693(95)04534-1
   Lim MH, 1999, CHEM MATER, V11, P3285, DOI 10.1021/cm990369r
   Macario A, 2005, MICROPOR MESOPOR MAT, V81, P139, DOI 10.1016/j.micromeso.2005.02.002
   Markowitz MA, 2000, J PHYS CHEM B, V104, P10820, DOI 10.1021/jp0008389
   McKittrick MW, 2005, J MOL CATAL A-CHEM, V237, P26, DOI 10.1016/j.molcata.2005.04.037
   McKittrick MW, 2003, CHEM MATER, V15, P1132, DOI 10.1021/cm020952z
   Meng LY, 2005, ANAL CHEM, V77, P5947, DOI 10.1021/ac050422x
   Mercier L, 1997, ADV MATER, V9, P500, DOI 10.1002/adma.19970090611
   Namli H, 2006, SPECTROCHIM ACTA A, V64, P93, DOI 10.1016/j.saa.2005.07.020
   Namli H, 2007, VIB SPECTROSC, V43, P274, DOI 10.1016/j.vibspec.2006.02.010
   Osei-Prempeh G, 2005, MICROPOR MESOPOR MAT, V85, P16, DOI 10.1016/j.micromeso.2005.06.014
   Osei-Prempeh G, 2008, IND ENG CHEM RES, V47, P530, DOI 10.1021/ie070538e
   Osei-Prempeh G, 2010, MICROPOR MESOPOR MAT, V129, P189, DOI 10.1016/j.micromeso.2009.09.015
   PINNAVAIA TJ, 2002, ACCESS NANOPOROUS MA
   Rankin SE, 2004, MICROPOR MESOPOR MAT, V73, P197, DOI 10.1016/j.micromeso.2004.05.013
   Ravikovitch PI, 1997, J PHYS CHEM B, V101, P3671, DOI 10.1021/jp9625321
   Ritter H, 2009, J PHYS CHEM C, V113, P10667, DOI 10.1021/jp901983j
   Sadasivan S, 2003, J MATER CHEM, V13, P1023, DOI 10.1039/b300851g
   STOBER W, 1968, J COLLOID INTERF SCI, V26, P62, DOI 10.1016/0021-9797(68)90272-5
   Tan B, 2005, NANOTECHNOLOGY, V16, pS502, DOI 10.1088/0957-4484/16/7/026
   Tan B, 2005, J PHYS CHEM B, V109, P23225, DOI 10.1021/jp054219h
   Tan B, 2004, J PHYS CHEM B, V108, P20122, DOI 10.1021/jp046425f
   Tan B, 2005, CHEM MATER, V17, P916, DOI 10.1021/cm048991t
   Tan B, 2004, LANGMUIR, V20, P6981, DOI 10.1021/la049474s
   THAM MK, 1973, J CHEM ENG DATA, V18, P385, DOI 10.1021/je60059a011
   Walcarius A, 2003, CHEM MATER, V15, P2161, DOI 10.1021/cm021310e
   Wang G, 2009, J SOLID STATE CHEM, V182, P1649, DOI 10.1016/j.jssc.2009.03.034
   Wang K, 2000, LANGMUIR, V16, P1042, DOI 10.1021/la9909603
   Wang XG, 2005, J CATAL, V233, P266, DOI 10.1016/j.jcat.2005.04.007
   Wei Q, 2006, J SOL-GEL SCI TECHN, V39, P103, DOI 10.1007/s10971-006-9171-3
   Wight AP, 2002, CHEM REV, V102, P3589, DOI 10.1021/cr010334m
   Yokoi T, 2004, J MATER CHEM, V14, P951, DOI 10.1039/b310576h
   Yokoi T, 2003, CHEM MATER, V15, P4536, DOI 10.1021/cm034499i
   Zeidan RK, 2006, ANGEW CHEM INT EDIT, V45, P6332, DOI 10.1002/anie.200602243
   Zheng F, 2005, IND ENG CHEM RES, V44, P3099, DOI 10.1021/ie049488t
   Zhu GR, 2006, J CHROMATOGR A, V1103, P257, DOI 10.1016/j.chroma.2005.11.026
NR 64
TC 8
Z9 8
U1 1
U2 38
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0888-5885
J9 IND ENG CHEM RES
JI Ind. Eng. Chem. Res.
PD MAY 4
PY 2011
VL 50
IS 9
BP 5510
EP 5522
DI 10.1021/ie101313t
PG 13
WC Engineering, Chemical
SC Engineering
GA 753HX
UT WOS:000289764000060
DA 2018-03-20
ER

PT J
AU Frasinyuk, MS
   Kwiatkowski, S
   Wagner, JM
   Evans, TJ
   Reed, RW
   Korotkov, KV
   Watt, DS
AF Frasinyuk, Mykhaylo S.
   Kwiatkowski, Stefan
   Wagner, Jonathan M.
   Evans, Timothy J.
   Reed, Robert W.
   Korotkov, Konstantin V.
   Watt, David S.
TI Pentapeptide boronic acid inhibitors of Mycobacterium tuberculosis
   MycP(1) protease
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Boronic acid; Pentapeptide; Protease; Inhibitor
ID SERINE-PROTEASE; DRUG DEVELOPMENT; SECRETION; TARGETS
AB Mycosin protease-1 (MycP(1)) cleaves ESX secretion-associated protein B (EspB) that is a virulence factor of Mycobacterium tuberculosis, and accommodates an octapeptide, AVKAASLG, as a short peptide substrate. Because peptidoboronic acids are known inhibitors of serine proteases, the synthesis and binding of a boronic acid analog of the pentapeptide cleavage product, AVKAA, was studied using MycPi variants from Mycobacterium therrnoresistible (MycP(1mth)), Mycobacterium smegmatis (MycP(1msm)) and M. tuberculosis (MycPimtu). We synthesized the boropentapeptide, HAlaValLysAlaAlaB(OH)2 (1) and the analogous pinanediol PD-protected HAlaValLysAlaAlaB02(PD) (2) using an Fmoc/Boc peptide strategy. The pinanediol boropentapeptide 2 displayed IC50 values 121.6 25.3 W14 for Mycloin,th, 93.2 37.3 JIM for MycPunsm and 37.9 5.2 jtM for Mycl3i.t.. Such relatively strong binding creates a chance for crystalizing the complex with 2 and finding the structure of the unknown MycPi catalytic site that would potentially facilitate the development of new anti-tuberculosis drugs. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Frasinyuk, Mykhaylo S.] Inst Bioorgan Chem & Petrochem, UA-9402660 Kiev, Ukraine.
   [Frasinyuk, Mykhaylo S.; Kwiatkowski, Stefan; Wagner, Jonathan M.; Evans, Timothy J.; Reed, Robert W.; Korotkov, Konstantin V.; Watt, David S.] Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA.
   [Kwiatkowski, Stefan; Watt, David S.] Univ Kentucky, Coll Pharm, Ctr Pharmaceut Res & Innovat, Lexington, KY 40536 USA.
   [Watt, David S.] Univ Kentucky, Lucille Parker Markey Canc Ctr, Lexington, KY 40536 USA.
RP Watt, DS (reprint author), Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA.
EM dwatt@uky.edu
OI Wagner, Jonathan M./0000-0001-9161-7222; Korotkov,
   Konstantin/0000-0002-2182-6843; Frasinyuk, Mykhaylo/0000-0003-3133-601X
FU NIH [P20 RR020171]; NIH/NIGMS [P20GM103486]
FX D.S.W. was supported by the Office of the Dean of the College of
   Medicine and by NIH Grant Number P20 RR020171 from the National
   Institute of General Medical Sciences to L. Hersh, PI. K.V.K. was
   supported by the NIH/NIGMS Grant P20GM103486. The contents are solely
   the responsibility of the authors and do not necessarily represent the
   official views of the NIH or the NIGMS.
CR Adams J, 2004, CANCER INVEST, V22, P304, DOI 10.1081/CNV-120030218
   BACHOVCHIN WW, 1988, BIOCHEMISTRY-US, V27, P7689, DOI 10.1021/bi00420a018
   BONE R, 1987, BIOCHEMISTRY-US, V26, P7609, DOI 10.1021/bi00398a012
   Bottai D., 2013, CURR PHARM DES
   Chen JM, 2010, DRUG DISCOV TODAY DI, V7, pe25
   Feltcher ME, 2010, FUTURE MICROBIOL, V5, P1581, DOI 10.2217/FMB.10.112
   Gozhina Olga V, 2014, J Pept Sci, V20, P20, DOI 10.1002/psc.2583
   Hamza A, 2014, J CHEM INF MODEL, V54, P1166, DOI 10.1021/ci500025r
   KNORR R, 1989, TETRAHEDRON LETT, V30, P1927, DOI 10.1016/S0040-4039(00)99616-3
   LeBeau AM, 2008, CHEM BIOL, V15, P665, DOI 10.1016/j.chembiol.2008.05.020
   Lechartier B, 2014, EMBO MOL MED, V6, P158, DOI 10.1002/emmm.201201772
   Lin G, 2008, J BIOL CHEM, V283, P34423, DOI 10.1074/jbc.M805324200
   Ohol YM, 2010, CELL HOST MICROBE, V7, P210, DOI 10.1016/j.chom.2010.02.006
   Roberts DM, 2013, FUTURE MICROBIOL, V8, P621, DOI [10.2217/FMB.13.25, 10.2217/fmb.13.25]
   Simeone R, 2009, CURR OPIN MICROBIOL, V12, P4, DOI 10.1016/j.mib.2008.11.003
   Smoum R, 2012, CHEM REV, V112, P4156, DOI 10.1021/cr608202m
   Solomonson M., 2013, J BIOL CHEM, V228, P17782
   Stenley S. A., 2003, P NATL ACAD SCI USA, V100, P13001
   Touchet S, 2011, CHEM SOC REV, V40, P3895, DOI 10.1039/c0cs00154f
   Villemagne B, 2012, EUR J MED CHEM, V51, P1, DOI 10.1016/j.ejmech.2012.02.033
   Wagner JM, 2013, J STRUCT BIOL, V184, P115, DOI 10.1016/j.jsb.2013.09.022
   WHO, GLOB TUB REP 2013
   Zhu YQ, 2010, J MED CHEM, V53, P1990, DOI 10.1021/jm901407s
   Kinder D. H., 1990, U.S Patent, Patent No. [4,963,655, 4963655]
NR 24
TC 4
Z9 4
U1 0
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
EI 1464-3405
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD AUG 1
PY 2014
VL 24
IS 15
BP 3546
EP 3548
DI 10.1016/j.bmcl.2014.05.056
PG 3
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA AL6FT
UT WOS:000339228700067
PM 24915878
OA green_accepted
DA 2018-03-20
ER

PT J
AU Crowdus, C
   Yu, CG
   Singh, R
   Power, R
   Pandya, J
   Patel, S
   Sullivan, P
   Rabchevsky, A
   Geddes, J
AF Crowdus, Carolyn
   Yu, Chen-Guang
   Singh, Ranjana
   Power, Ronan F.
   Pandya, Jignesh D.
   Patel, Samir
   Sullivan, Patrick G.
   Rabchevsky, Alexander
   Geddes, James W.
TI ENHANCING ENDOGENOUS PROTECTIVE MECHANISMS FOLLOWING SPINAL CORD INJRY
SO JOURNAL OF NEUROTRAUMA
LA English
DT Meeting Abstract
CT 30th Annual National Neurotrauma Symposium
CY JUL 22-25, 2012
CL Phoenix, AZ
DE spinal cord injury; antioxidant; selenium
C1 [Singh, Ranjana] Univ Kentucky, Dept Anat & Neurobiol, SCoBIRC, Lexington, KY 40536 USA.
   [Power, Ronan] Alltech Inc, Nicholasville, KY USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0897-7151
J9 J NEUROTRAUM
JI J. Neurotrauma
PD JUL
PY 2012
VL 29
IS 10
BP A82
EP A83
PG 2
WC Critical Care Medicine; Clinical Neurology; Neurosciences
SC General & Internal Medicine; Neurosciences & Neurology
GA 971YV
UT WOS:000306244400138
DA 2018-03-20
ER

PT J
AU Li, TL
   Ayers, PW
   Liu, SB
AF Li, Tonglei
   Ayers, Paul W.
   Liu, Shubin
TI Developing DFT concepts for characterizing intermolecular interactions
   in organic crystals
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
C1 Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY USA.
   McMaster Univ, Dept Chem, Hamilton, ON, Canada.
   Univ N Carolina, Ctr Res Comp, Chapel Hill, NC USA.
RI Liu, Shubin/B-1502-2009; Ayers, Paul/A-1154-2008
OI Liu, Shubin/0000-0001-9331-0427; Ayers, Paul/0000-0003-2605-3883
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD AUG 22
PY 2010
VL 240
MA 341-PHYS
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA V20UK
UT WOS:000208164705873
DA 2018-03-20
ER

PT J
AU Fisher, PD
   Venugopal, G
   Milbrandt, TA
   Hilt, JZ
   Puleo, DA
AF Fisher, Paul D.
   Venugopal, Ganesh
   Milbrandt, Todd A.
   Hilt, J. Zach
   Puleo, David A.
TI Hydroxyapatite-reinforced in situ forming PLGA systems for intraosseous
   injection
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
LA English
DT Article
DE in situ forming; injectable; PLGA; mechanical reinforcement;
   hydroxyapatite
ID PHASE INVERSION DYNAMICS; MECHANICAL-PROPERTIES; COMPOSITE SCAFFOLDS;
   DRUG-DELIVERY; INJECTABLE IMPLANT; CANCELLOUS BONE; FEMORAL-HEAD;
   RELEASE; CEMENT; PLA
AB In situ forming poly(lactic-co-glycolic acid) (PLGA) implants have not been strongly considered for bone applications because of their poor mechanical properties. Here, in situ forming scaffolds containing hydroxyapatite micro- and nanoparticles were characterized to determine their mechanical properties, injectability, and microarchitecture. Scaffolds were prepared with various concentrations of hydroxyapatite, as well as poly(-amino ester) microparticles that facilitate drug delivery. Strength was increased threefold, from 2 to 6 MPa, while compressive modulus was improved sixfold, from 24 to 141 MPa, via the addition of 30% nanohydroxyapatite, which provided greater benefits at equivalent concentrations compared to micro-hydroxyapatite. Scaffolds retained a uniformly porous microarchitecture, and hydroxyapatite particles were distributed evenly throughout the PLGA phase. Injectability, determined by the force required to inject 0.5 mL of material within 60 s, remained clinically acceptable at <50 N at 30% w/w hydroxyapatite and up to 10% w/w PBAE microparticles. Ex vivo injections into intact porcine femoral heads increased compressive modulus of trabecular bone from 81 to 180 MPa and strength from 3.5 to 5.9 MPa. This injectable scaffold offers mechanical reinforcement coupled with previously demonstrated drug delivery potential in a single injection for bone-weakening conditions, such as osteonecrosis or osteoporosis. (c) 2014 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 103: 2365-2373, 2015.
C1 [Fisher, Paul D.; Puleo, David A.] Univ Kentucky, Dept Biomed Engn, Lexington, KY 40506 USA.
   [Venugopal, Ganesh] NGimat LLC, Lexington, KY 40511 USA.
   [Milbrandt, Todd A.] Mayo Clin, Dept Orthopaed Surg, Rochester, MN 55905 USA.
   [Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Puleo, DA (reprint author), Univ Kentucky, Dept Biomed Engn, 522A Robot & Mfg Bldg, Lexington, KY 40506 USA.
EM puleo@uky.edu
CR Anderson DG, 2006, ADV MATER, V18, P2614, DOI 10.1002/adma.200600529
   Bohner M, 2005, BIOMATERIALS, V26, P1553, DOI 10.1016/j.biomaterials.2004.05.010
   Brodbeck KJ, 1999, J CONTROL RELEASE, V62, P333, DOI 10.1016/S0168-3659(99)00159-5
   BROWN TD, 1981, CLIN ORTHOP RELAT R, P240
   DiPisa Ja Fau-Sih GS, 1976, CLIN ORTHO RELAT RES, V121, P95
   Fisher PD, 2014, J BIOMAT SCI-POLYM E, V25, P1174, DOI 10.1080/09205063.2014.923368
   Fu SY, 2008, COMPOS PART B-ENG, V39, P933, DOI 10.1016/j.compositesb.2008.01.002
   Gad HA, 2008, AAPS PHARMSCITECH, V9, P878, DOI 10.1208/s12249-008-9126-9
   Graham PD, 1999, J CONTROL RELEASE, V58, P233, DOI 10.1016/S0168-3659(98)00158-8
   Guan LM, 2004, J BIOMED MATER RES A, V71A, P480, DOI 10.1002/jbm.a.30173
   Hatefi A, 2002, J CONTROL RELEASE, V80, P9, DOI 10.1016/S0168-3659(02)00008-1
   Hawkins AM, 2011, ACTA BIOMATER, V7, P1956, DOI 10.1016/j.actbio.2011.01.024
   Huang YX, 2008, J BIOMATER APPL, V22, P409, DOI 10.1177/0885328207077632
   Kempe S, 2008, J CONTROL RELEASE, V130, P220, DOI 10.1016/j.jconrel.2008.06.006
   KENLEY RA, 1987, MACROMOLECULES, V20, P2398, DOI 10.1021/ma00176a012
   Khairoun I, 1998, J MATER SCI-MATER M, V9, P425, DOI 10.1023/A:1008811215655
   Kim SS, 2006, BIOMATERIALS, V27, P1399, DOI 10.1016/j.biomaterials.2005.08.016
   Kothapalli CR, 2005, ACTA BIOMATER, V1, P653, DOI 10.1016/j.actbio.2005.06.005
   Alves HLR, 2008, J MATER SCI-MATER M, V19, P2241, DOI 10.1007/s10856-007-3329-6
   Leroux L, 1999, BONE, V25, P31
   Li BH, 1997, J BONE MINER RES, V12, P641, DOI 10.1359/jbmr.1997.12.4.641
   Parent M, 2013, J CONTROL RELEASE, V172, P292, DOI 10.1016/j.jconrel.2013.08.024
   Rezwan K, 2006, BIOMATERIALS, V27, P3413, DOI 10.1016/j.biomaterials.2006.01.039
   SAHA S, 1984, J BIOMED MATER RES, V18, P435, DOI 10.1002/jbm.820180411
   Schloegl W, 2012, EUR J PHARM BIOPHARM, V82, P554, DOI 10.1016/j.ejpb.2012.08.006
   SCHOENFELD CM, 1974, MED BIOL ENG, V12, P313, DOI 10.1007/BF02477797
   SHAH NH, 1993, J CONTROL RELEASE, V27, P139, DOI 10.1016/0168-3659(93)90217-S
   SHIVELY ML, 1995, J CONTROL RELEASE, V33, P237, DOI 10.1016/0168-3659(94)00097-E
   VERHEYEN CCPM, 1992, J BIOMED MATER RES, V26, P1277, DOI 10.1002/jbm.820261003
   Wang J X, 1993, Zhonghua Wai Ke Za Zhi, V31, P374
   Wei GB, 2004, BIOMATERIALS, V25, P4749, DOI 10.1016/j.biomaterials.2003.12.005
NR 31
TC 2
Z9 2
U1 1
U2 27
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1549-3296
EI 1552-4965
J9 J BIOMED MATER RES A
JI J. Biomed. Mater. Res. Part A
PD JUL
PY 2015
VL 103
IS 7
BP 2365
EP 2373
DI 10.1002/jbm.a.35375
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA CJ1LZ
UT WOS:000355246400016
PM 25424622
DA 2018-03-20
ER

PT J
AU Tan, B
   Rankin, SE
AF Tan, Bing
   Rankin, Stephen E.
TI Study of the effects of progressive changes in alkoxysilane structure on
   sol-gel reactivity
SO JOURNAL OF PHYSICAL CHEMISTRY B
LA English
DT Article
ID PERIODIC MESOPOROUS ORGANOSILICAS; ORGANIC-INORGANIC MATERIALS; HYBRID
   THIN-FILMS; SILICON ALKOXIDES; NANOCOMPOSITE MATERIALS; FTIR
   SPECTROSCOPY; ACIDIC CONDITIONS; BRIDGING GROUPS; WATER MIXTURES;
   METHANOL-WATER
AB Effects of the structure of an alkoxysilane on the early reaction kinetics of sol-gel polymerization are investigated in basic and acidic conditions. Six silanes, including tetraethoxysilane (TEOS), tetramethoxysilane (TMOS), methyltrimethoxysilane (MTMS), bis(trimethoxysilyl) ethane (BTMSE), bis(trimethoxysilyl) hexane (BTMSH), and bis(trimethoxysilylpropyl) amine (BTMSPA), are selected to examine the effects of progressive changes in the silane's structure. In basic conditions, reactivities of the silanes follow the pairwise trends TEOS, TMOS, TMOS > MTMS, MTMS < BTMSE, BTMSE. BTMSH, and BTMSH, BTMSPA. Hydrolysis rate coefficients of BTMSE, TMOS, MTMS, and BTMSPA are similar in value and are almost one order of magnitude larger than the coefficients of BTMSH and TEOS. In acidic conditions, the pairwise reactivity trends are TEOS approximate to TMOS, TMOS < MTMS, MTMS > BTMSE, BTMSE. BTMSH, and BTMSH > BTMSPA. The condensation rate coefficients of BTMSH and BTMPA are much smaller than the others. Theses relationships can be explained mainly on the basis of the expected inductive and steric factors of the silanes. Bulky organics attached to the silane lead to low reactivity in both acidic and basic conditions. A high electron density at silicon leads to a low reactivity in basic conditions but a high reactivity in acidic conditions (pH similar to 2.3). Only BTMSPA in basic conditions defies these trends, possibly because of the effects of solvation near the reactive silicon site.
C1 Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Rankin, SE (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 Anderson Hall, Lexington, KY 40506 USA.
EM srankin@engr.uky.edu
RI Rankin, Stephen/A-3265-2013
OI Rankin, Stephen/0000-0002-8615-7564
CR Angelome PC, 2005, J MATER CHEM, V15, P3903, DOI 10.1039/b506484h
   Angelome PC, 2005, CHEM MATER, V17, P322, DOI 10.1021/cm048559b
   Asefa T, 1999, NATURE, V402, P867
   ASSINK RA, 1988, J NON-CRYST SOLIDS, V99, P359, DOI 10.1016/0022-3093(88)90441-3
   ATTARD GS, 1995, NATURE, V378, P366, DOI 10.1038/378366a0
   Babonneau F, 1999, J MATER CHEM, V9, P175, DOI 10.1039/a805539d
   BANEY RH, 1995, CHEM REV, V95, P1409, DOI 10.1021/cr00037a012
   Bao XY, 2006, J PHYS CHEM B, V110, P2656, DOI 10.1021/jp0561120
   BECK JS, 1992, J AM CHEM SOC, V114, P10834, DOI 10.1021/ja00053a020
   BERNARDS TNM, 1991, J NON-CRYST SOLIDS, V134, P1, DOI 10.1016/0022-3093(91)90005-Q
   Brinker CJ, 1999, ADV MATER, V11, P579, DOI 10.1002/(SICI)1521-4095(199905)11:7<579::AID-ADMA579>3.0.CO;2-R
   Brinker C. J., 1990, SOL GEL SCI
   Burleigh MC, 2004, COLLOID POLYM SCI, V282, P728, DOI 10.1007/s00396-003-1004-0
   Burleigh MC, 2001, J PHYS CHEM B, V105, P9935, DOI 10.1021/jp011814k
   Canals I, 2001, J CHROMATOGR A, V911, P191, DOI 10.1016/S0021-9673(00)01271-1
   CAPOZZI CA, 1992, MATER LETT, V15, P130, DOI 10.1016/0167-577X(92)90028-I
   Dabbs DM, 2000, ANNU REV PHYS CHEM, V51, P601, DOI 10.1146/annurev.physchem.51.1.601
   Delak KM, 2005, CHEM MATER, V17, P3221, DOI 10.1021/cm048355v
   Etienne M, 2005, ELECTROCHEM COMMUN, V7, P1449, DOI 10.1016/j.elecom.2005.10.010
   Etienne M, 2002, NEW J CHEM, V26, P384, DOI 10.1039/b110741k
   Flodstrom K, 2004, LANGMUIR, V20, P680, DOI 10.1021/la030173c
   GRUNZIEN RM, 2006, CHEM MATER, V18, P1722
   Hatton BD, 2005, ADV FUNCT MATER, V15, P823, DOI 10.1002/adfm.200400221
   Hunks WJ, 2005, J MATER CHEM, V15, P764, DOI 10.1039/b412963f
   Hunks WJ, 2004, CHEM MATER, V16, P5465, DOI 10.1021/cm048986p
   Huo QS, 1996, CHEM MATER, V8, P1147, DOI 10.1021/cm960137h
   Iler R.K, 1979, CHEM SILICA
   Inagaki S, 1999, J AM CHEM SOC, V121, P9611, DOI 10.1021/ja9916658
   Ji XL, 2006, CHEM MATER, V18, P2265, DOI 10.1021/cm052764p
   Judeinstein P, 1996, J MATER CHEM, V6, P511, DOI 10.1039/jm9960600511
   KAY BD, 1988, J NON-CRYST SOLIDS, V104, P112, DOI 10.1016/0022-3093(88)90189-5
   Kay B. D., 1986, MATER RES SOC S P, V73, P157
   KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0
   Lebeau B, 1999, J MATER CHEM, V9, P2279, DOI 10.1039/a905155d
   Leffler J.E., 1989, RATES EQUILIBRIA ORG
   Lenza RFS, 2001, MAT RES, V4, P175
   LENZA RFS, 2001, MAT RES, P4
   Liang YC, 2005, J MATER CHEM, V15, P3919, DOI 10.1039/b504600a
   Loy DA, 1999, J AM CHEM SOC, V121, P5413, DOI 10.1021/ja982751v
   Loy DA, 2000, CHEM MATER, V12, P3624, DOI 10.1021/cm000451i
   Matejka L, 2001, MACROMOLECULES, V34, P6904, DOI 10.1021/ma010136x
   Matsumoto T, 2003, J MATER CHEM, V13, P1764, DOI 10.1039/b301465g
   MONNIER A, 1993, SCIENCE, V261, P1299, DOI 10.1126/science.261.5126.1299
   Muroya M, 1999, COLLOID SURFACE A, V157, P147, DOI 10.1016/S0927-7757(99)00054-0
   Nakanishi K, 2005, J MATER CHEM, V15, P3776, DOI 10.1039/b508415f
   Nicole L, 2005, J MATER CHEM, V15, P3598, DOI 10.1039/b506072a
   NOVAK BM, 1993, ADV MATER, V5, P422, DOI 10.1002/adma.19930050603
   Okumoto S, 1998, J PHYS CHEM A, V102, P3991, DOI 10.1021/jp980705b
   Olkhovyk O, 2005, J MATER CHEM, V15, P1517, DOI 10.1039/b500058k
   OSTERHOLTZ FD, 1992, J ADHES SCI TECHNOL, V6, P127, DOI 10.1163/156856192X00106
   PIANA K, 1995, CHEM MATER, V7, P1932, DOI 10.1021/cm00058a026
   Pohl E. R., 1985, MOL CHARACTERIZATION, P157
   POUCHERT CJ, 1985, ALDRICH LIBR FT IR S, V2
   POUXVIEL JC, 1987, J NON-CRYST SOLIDS, V94, P374, DOI 10.1016/S0022-3093(87)80072-8
   Pu ZC, 1997, J ADHES SCI TECHNOL, V11, P29
   Rankin SE, 1998, AICHE J, V44, P1141, DOI 10.1002/aic.690440512
   Rankin SE, 2000, CHEM ENG SCI, V55, P1955, DOI 10.1016/S0009-2509(99)00486-8
   Rankin SE, 1999, MAGN RESON CHEM, V37, pS27, DOI 10.1002/(SICI)1097-458X(199912)37:13<S27::AID-MRC576>3.0.CO;2-5
   Rao MS, 2003, J SOL-GEL SCI TECHN, V26, P553, DOI 10.1023/A:1020763719171
   ROUSSEAU F, 1995, CHEM MATER, V7, P828, DOI 10.1021/cm00053a004
   Sadasivan S, 2002, ANGEW CHEM INT EDIT, V41, P2151, DOI 10.1002/1521-3773(20020617)41:12<2151::AID-ANIE2151>3.0.CO;2-U
   Sanchez J, 1996, IND ENG CHEM RES, V35, P117, DOI 10.1021/ie950246q
   SANCHEZ J, 1992, J PHYS CHEM-US, V96, P8973, DOI 10.1021/j100201a051
   Sayari A, 2001, CHEM MATER, V13, P3151, DOI 10.1021/cm0110391
   Sefcik J, 1997, CATAL TODAY, V35, P205, DOI 10.1016/S0920-5861(96)00158-7
   Shea KJ, 2001, CHEM MATER, V13, P3306, DOI 10.1021/cm011074s
   Soler-Illia GJAA, 2006, CHEM-EUR J, V12, P4478, DOI 10.1002/chem.200500801
   Stein A, 2000, ADV MATER, V12, P1403, DOI 10.1002/1521-4095(200010)12:19<1403::AID-ADMA1403>3.0.CO;2-X
   Tan B, 2004, J PHYS CHEM B, V108, P20122, DOI 10.1021/jp046425f
   TAN B, 2005, THESIS U KENTUCKLY L
   Tejedor-Tejedor MI, 1998, CHEM MATER, V10, P3410, DOI 10.1021/cm980146l
   TOURKY AR, 1972, Z PHYS CHEM-LEIPZIG, V250, P49
   TREMILLON B, 1974, CHEM NON AQUEOUS SOL
   Vainrub A, 1996, J SOL-GEL SCI TECHN, V6, P279, DOI 10.1007/BF00402700
   Vainrub A, 1996, MAT SCI ENG B-SOLID, V37, P197, DOI 10.1016/0921-5107(95)01486-1
   Wahab MA, 2004, J SOLID STATE CHEM, V177, P3439, DOI 10.1016/j.jssc.2004.05.062
   Wen JY, 1996, CHEM MATER, V8, P1667, DOI 10.1021/cm9601143
   Yang S, 2002, CHEM MATER, V14, P369, DOI 10.1021/cm0106901
   Ying JY, 1999, ANGEW CHEM INT EDIT, V38, P56, DOI 10.1002/(SICI)1521-3773(19990115)38:1/2<56::AID-ANIE56>3.0.CO;2-E
   Yoon H-S, 1994, HWAHAK KONGHAK, V32, P557
   Yu CZ, 2004, CHEM MATER, V16, P889, DOI 10.1021/cm035011g
   Zelent B, 2004, J PHYS CHEM A, V108, P11141, DOI 10.1021/jp0475584
   ZHANG Z, 1995, J NON-CRYST SOLIDS, V189, P212, DOI 10.1016/0022-3093(95)00209-X
   Zhu HG, 2002, CHEM MATER, V14, P4886, DOI 10.1021/cm011742+
   Zhu HG, 2001, CHEM COMMUN, P2568, DOI 10.1039/b106938c
   ZUB YL, 2001, MENDELEEV COMMUN, P1
NR 86
TC 50
Z9 50
U1 3
U2 56
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1520-6106
J9 J PHYS CHEM B
JI J. Phys. Chem. B
PD NOV 16
PY 2006
VL 110
IS 45
BP 22353
EP 22364
DI 10.1021/jp060376k
PG 12
WC Chemistry, Physical
SC Chemistry
GA 103RZ
UT WOS:000241905700013
PM 17091975
DA 2018-03-20
ER

PT J
AU Satarkar, NS
   Meenach, SA
   Anderson, KW
   Hilt, JZ
AF Satarkar, Nitin S.
   Meenach, Samantha A.
   Anderson, Kimberly W.
   Hilt, J. Zach
TI Remote Actuation of Hydrogel Nanocomposites: Heating Analysis, Modeling,
   and Simulations
SO AICHE JOURNAL
LA English
DT Article
DE biomaterials; biomedical engineering; nanotechnology; heat transfer;
   composite materials
ID DRUG-DELIVERY; BLOOD-FLOW; HYPERTHERMIA; NANOPARTICLES; RELEASE;
   MICROENVIRONMENT; CANCER; GEL
AB Recently, there has been increasing interest in remote heating of polymer nanocomposites for applications such as actuators, microfluidic valves, drug delivery devices, and hyperthermia treatment of cancer. In this study, magnetic hydrogel nanocomposites of poly(ethylene glycol) (PEG) with varying amounts of iron oxide nanoparticle loadings were synthesized. The nanocomposites were remotely heated using an alternating magnetic field (AMF) at three different AMF amplitudes, and the resultant temperatures were recorded. The rate of the temperature rise and the steady state temperatures were analyzed with a heat transfer model, and a correlation of heat generation per unit mass with the nanoparticle loadings was established for different AMF amplitudes. The temperature rise data of a PEG system with different swelling properties were found to be accurately predicted by the model. Furthermore, the correlations were used to simulate the temperatures of the nanocomposite and the surrounding tissue for potential hyperthermia cancer treatment applications. (C) 2010 American Institute of Chemical Engineers AIChE J, 57: 852-860, 2011
C1 [Satarkar, Nitin S.; Meenach, Samantha A.; Anderson, Kimberly W.; Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Hilt, JZ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM hilt@engr.uky.edu
RI Meenach, Samantha/F-7542-2014
FU Kentucky Science and Engineering Foundation [1169-RDE-009]
FX This material is based in part on work supported by the Kentucky Science
   and Engineering Foundation grant 1169-RDE-009. The authors thank Churn
   Poh for assistance with thermal conductivity measurements, and Dr. J.
   Todd Hastings for assistance with COMSOL software.
CR ARKIN H, 1994, IEEE T BIO-MED ENG, V41, P97, DOI 10.1109/10.284920
   Babincova M, 2007, OPTOELECTRON ADV MAT, V1, P644
   Babincova M, 2001, J MAGN MAGN MATER, V225, P109, DOI 10.1016/S0304-8853(00)01237-3
   Bagaria HG, 2005, INT J HYPERTHER, V21, P57, DOI 10.1080/02656730410001726956
   Benitez R, 2007, J MATER PROCESS TECH, V190, P324, DOI [10.1016/j.jmatprotec.2007.02.016, 10.1016/j.matprotec.2007.02.016]
   Bikram M, 2007, J CONTROL RELEASE, V123, P219, DOI 10.1016/j.jconrel.2007.08.013
   Candeo A, 2009, IEEE T MAGN, V45, P1658, DOI 10.1109/TMAG.2009.2012769
   Chambers B, 1997, J HEAT TRANS-T ASME, V119, P102, DOI 10.1115/1.2824074
   Falk MH, 2001, INT J HYPERTHER, V17, P1, DOI 10.1080/02656730150201552
   Filipcsei G, 2007, ADV POLYM SCI, V206, P137, DOI 10.1007/12_2006_104
   Govorov AO, 2007, NANO TODAY, V2, P30, DOI 10.1016/S1748-0132(07)70017-8
   Hand JW, 1999, MAGNET RESON MED, V42, P183, DOI 10.1002/(SICI)1522-2594(199907)42:1<183::AID-MRM24>3.0.CO;2-I
   Hawkins AM, 2009, PHARM RES-DORD, V26, P667, DOI 10.1007/s11095-008-9804-z
   Hildebrandt B, 2002, CRIT REV ONCOL HEMAT, V43, P33, DOI 10.1016/S1040-8428(01)00179-2
   Horsman MR, 2007, CLIN ONCOL-UK, V19, P418, DOI 10.1016/j.clon.2007.03.015
   Lutz JF, 2008, J POLYM SCI POL CHEM, V46, P3459, DOI 10.1002/pola.22706
   MEENACH SA, 2009, ACTA BIOMAT IN PRESS
   Meenach SA, 2009, J BIOMED MATER RES A, V91A, P903, DOI 10.1002/jbm.a.32322
   Miyako E, 2008, SMALL, V4, P1711, DOI 10.1002/smll.200800601
   Mohr R, 2006, P NATL ACAD SCI USA, V103, P3540, DOI 10.1073/pnas.0600079103
   PARKER WJ, 1961, J APPL PHYS, V32, P1679, DOI 10.1063/1.1728417
   PENNES HH, 1948, J APPL PHYSIOL, V1, P93
   Ramanujan RV, 2009, J MATER SCI, V44, P1381, DOI 10.1007/s10853-006-1064-x
   Satarkar NS, 2008, J CONTROL RELEASE, V130, P246, DOI 10.1016/j.jconrel.2008.06.008
   Satarkar NS, 2009, LAB CHIP, V9, P1773, DOI 10.1039/b822694f
   Schexnailder P, 2009, COLLOID POLYM SCI, V287, P1, DOI 10.1007/s00396-008-1949-0
   Schmidt JJ, 2008, J BIOMED MATER RES A, V87A, P1113, DOI 10.1002/jbm.a.32287
   Sershen SR, 2005, ADV MATER, V17, P1366, DOI 10.1002/adma.200401239
   SONG CW, 1984, CANCER RES, V44, P4721
   Vaishnava PP, 2007, J APPL PHYS, V102, DOI 10.1063/1.2784080
   VAUPEL P, 1989, CANCER RES, V49, P6449
   Wang TW, 2007, J BIOMED MATER RES A, V83A, P828, DOI 10.1002/jbm.a.31411
   Wissler EH, 1998, J APPL PHYSIOL, V85, P35
   Wust P, 2002, LANCET ONCOL, V3, P487, DOI 10.1016/S1470-2045(02)00818-5
   Yakacki CM, 2009, J APPL POLYM SCI, V112, P3166, DOI 10.1002/app.29845
   Yang LQ, 2008, ADV MATER, V20, P2271, DOI 10.1002/adma.200702953
   Zeng XF, 2008, APPL PHYS LETT, V93, DOI 10.1063/1.2996271
NR 37
TC 10
Z9 10
U1 3
U2 36
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0001-1541
J9 AICHE J
JI AICHE J.
PD APR
PY 2011
VL 57
IS 4
BP 852
EP 860
DI 10.1002/aic.12309
PG 9
WC Engineering, Chemical
SC Engineering
GA 734KB
UT WOS:000288331900004
DA 2018-03-19
ER

PT J
AU Kryscio, DR
   Sathe, PM
   Lionberger, R
   Yu, L
   Bell, MA
   Jay, M
   Hilt, JZ
AF Kryscio, David R.
   Sathe, Pradeep M.
   Lionberger, Robert
   Yu, Lawrence
   Bell, Michael A.
   Jay, Michael
   Hilt, J. Zach
TI Spreadability measurements to assess structural equivalence (Q(3)) of
   topical formulations - A technical note
SO AAPS PHARMSCITECH
LA English
DT Article
DE Q(3) equivalence rheology; spreadability; topical formulations; vane
   method
ID YIELD STRESS MEASUREMENT; FOOD SPREADABILITY; VANE METHOD
C1 [Kryscio, David R.; Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Bell, Michael A.; Jay, Michael] Univ Kentucky, Ctr Pharmaceut Sci & Technol, Lexington, KY USA.
   [Sathe, Pradeep M.; Lionberger, Robert; Yu, Lawrence] US FDA, Off Gener Drugs, Rockville, MD 20855 USA.
RP Hilt, JZ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 F Paul Anderson Tower, Lexington, KY 40506 USA.
EM hilt@engr.uky.edu
RI Yu, Lawrence/L-6280-2016; Lionberger, Robert/L-4923-2017
OI Lionberger, Robert/0000-0002-0598-1771
CR Chow S.-C., 2000, DESIGN ANAL BIOAVAIL
   Daubert CR, 1998, J TEXTURE STUD, V29, P427, DOI 10.1111/j.1745-4603.1998.tb00814.x
   DZUY NQ, 1985, J RHEOL, V29, P335, DOI 10.1122/1.549794
   DZUY NQ, 1983, J RHEOL, V27, P321, DOI 10.1122/1.549709
   Juszczak L, 2004, J FOOD ENG, V63, P209, DOI 10.1016/j.jfoodeng.2003.07.002
   KOKINI JL, 1982, J TEXTURE STUD, V13, P211, DOI 10.1111/j.1745-4603.1982.tb01396.x
   Shah V P, 2001, Am J Clin Dermatol, V2, P275, DOI 10.2165/00128071-200102050-00001
   Shah VP, 1998, PHARMACEUT RES, V15, P167, DOI 10.1023/A:1011941929495
   YU LX, 2003, GPHA OGD JOINT M JUN
NR 9
TC 8
Z9 8
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 1530-9932
J9 AAPS PHARMSCITECH
JI AAPS PharmSciTech
PD MAR
PY 2008
VL 9
IS 1
BP 84
EP 86
DI 10.1208/s12249-007-9009-5
PG 3
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 276WU
UT WOS:000254175200011
PM 18446465
OA green_published
DA 2018-03-20
ER

PT J
AU Wagner, JM
   Evans, TJ
   Chen, J
   Zhu, HN
   Houben, ENG
   Bitter, W
   Korotkov, KV
AF Wagner, Jonathan M.
   Evans, Timothy J.
   Chen, Jing
   Zhu, Haining
   Houben, Edith N. G.
   Bitter, Wilbert
   Korotkov, Konstantin V.
TI Understanding specificity of the mycosin proteases in ESX/type VII
   secretion by structural and functional analysis
SO JOURNAL OF STRUCTURAL BIOLOGY
LA English
DT Article
DE MycP; Subtilisin; M. tuberculosis; Type VII secretion system; ESX; EspB
ID MYCOBACTERIUM-TUBERCULOSIS H37RV; CRYSTAL-STRUCTURE; OUTER-MEMBRANE;
   CELL-WALL; SUBTILISIN CARLSBERG; SERINE PROTEASES; ESAT-6 SECRETION;
   EGLIN-C; PROTEIN; SYSTEM
AB Mycobacteria use specialized ESX secretion systems to transport proteins across their cell membranes in order to manipulate their environment. In pathogenic Mycobacterium tuberculosis there are five paralogous ESX secretion systems, named ESX-1 through ESX-5. Each system includes a subtilisin-like protease (mycosin or MycP) as a core component essential for secretion. Here we report crystal structures of MycP(1) and MycP(3), the mycosins expressed by the ESX-1 and ESX-3 systems, respectively. In both mycosins the putative propeptide wraps around the catalytic domain and does not occlude the active site. The extensive contacts between the putative propeptide and catalytic domain, which include a disulfide bond, suggest that the N-terminal extension is an integral part of the active mycosin. The catalytic residues of MycP(1) and MycP(3) are located in a deep active site groove in contrast with an exposed active site in majority of subtilisins. We show that MycP(1) specifically cleaves ESX-1 secretion-associated protein B (EspB) in vitro at residues Ala358 and Ala386. We also systematically characterize the specificity of MycP(1) using peptide libraries, and show that it has evolved a narrow specificity relative to other subtilisins. Finally, comparison of the MycP(1) and MycP(3) structures suggest that both enzymes have stringent and different specificity profiles that result from the structurally distinct active site pockets, which could explain the system specific functioning of these proteases. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Wagner, Jonathan M.; Evans, Timothy J.; Chen, Jing; Zhu, Haining; Korotkov, Konstantin V.] Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA.
   [Wagner, Jonathan M.; Evans, Timothy J.; Chen, Jing; Zhu, Haining; Korotkov, Konstantin V.] Univ Kentucky, Struct Biol Ctr, Lexington, KY 40536 USA.
   [Houben, Edith N. G.; Bitter, Wilbert] Vrije Univ Amsterdam Med Ctr, Dept Med Microbiol & Infect Control, Amsterdam, Netherlands.
RP Korotkov, KV (reprint author), Univ Kentucky, Dept Mol & Cellular Biochem, 741 South Limestone, Lexington, KY 40536 USA.
EM kkorotkov@uky.edu
RI Houben, Edith/B-2110-2015; Zhu, Haining/A-6076-2008
OI Houben, Edith/0000-0002-8805-2002; Bitter, Wilbert/0000-0001-8347-6511;
   Korotkov, Konstantin/0000-0002-2182-6843; Wagner, Jonathan
   M./0000-0001-9161-7222
FU National Center for Research Resources [P20RR020171]; National Institute
   of General Medical Sciences from the National Institutes of Health
   [P20GM103486]; High-End Instrumentation Grant [S10RR029127]; U.S.
   Department of Energy, Office of Science, Office of Basic Energy Sciences
   [W-31-109-Eng-38]
FX The authors thank Roy Ummels for technical assistance; Christoph
   Grundner, Seattle BioMed, for providing M. thermoresistibile genomic
   DNA; Michael Berne, Tufts University, for N-terminal sequencing; Eun Suk
   Song, Travis Sexton and K. Martin Chow for advice and assistance with
   protease assays; Trevor P. Creamer for advice on CD measurements;
   Natalia Korotkova, Louis B. Hersh and Sidney W. Whiteheart for critical
   comments on the manuscript. We acknowledge the University of Kentucky
   Proteomics Core and Protein Analytical Core that are partially supported
   by grants from the National Center for Research Resources (P20RR020171)
   and the National Institute of General Medical Sciences (P20GM103486)
   from the National Institutes of Health. The Orbitrap mass spectrometer
   was acquired by High-End Instrumentation Grant S10RR029127 (to HZ). We
   thank staff members of Southeast Regional Collaborative Access Team
   (SER-CAT) at the Advanced Photon Source, Argonne National Laboratory,
   for assistance during data collection. Use of the Advanced Photon Source
   was supported by the U.S. Department of Energy, Office of Science,
   Office of Basic Energy Sciences, under Contract No. W-31-109-Eng-38.
   This study was supported in part by NIH Grant Number P20GM103486 (to
   KVK) from the National Institute of General Medical Sciences, its
   contents are solely the responsibility of the authors and do not
   necessarily represent the official views of the NIH or the NIGMS.
CR Abdallah AM, 2009, MOL MICROBIOL, V73, P329, DOI 10.1111/j.1365-2958.2009.06783.x
   Abdallah AM, 2007, NAT REV MICROBIOL, V5, P883, DOI 10.1038/nrmicro1773
   Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925
   Bernsel A, 2009, NUCLEIC ACIDS RES, V37, pW465, DOI 10.1093/nar/gkp363
   BODE W, 1987, EUR J BIOCHEM, V166, P673, DOI 10.1111/j.1432-1033.1987.tb13566.x
   Bottai D, 2012, MOL MICROBIOL, V83, P1195, DOI 10.1111/j.1365-2958.2012.08001.x
   Brennan PJ, 2003, TUBERCULOSIS, V83, P91, DOI 10.1016/S1472-9792(02)00089-6
   Brown GD, 2000, GENE, V254, P147, DOI 10.1016/S0378-1119(00)00277-8
   CARSTEN ME, 1953, J AM CHEM SOC, V75, P4451, DOI 10.1021/ja01114a017
   Chen JM, 2013, MOL MICROBIOL, V89, P1154, DOI 10.1111/mmi.12336
   Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073
   Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004
   Daleke MH, 2012, P NATL ACAD SCI USA, V109, P11342, DOI 10.1073/pnas.1119453109
   Daleke MH, 2011, J BIOL CHEM, V286, P19024, DOI 10.1074/jbc.M110.204966
   Dave JA, 2002, BMC MICROBIOL, V2, DOI 10.1186/1471-2180-2-30
   Dodson G, 1998, TRENDS BIOCHEM SCI, V23, P347, DOI 10.1016/S0968-0004(98)01254-7
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Fisher SJ, 2012, ACTA CRYSTALLOGR D, V68, P800, DOI 10.1107/S0907444912012589
   Floyd K, 2012, GLOBAL TUBERCULOSIS
   GALLAGHER T, 1995, STRUCTURE, V3, P907, DOI 10.1016/S0969-2126(01)00225-8
   Gao LY, 2004, MOL MICROBIOL, V53, P1677, DOI 10.1111/j.1365-2958.2004.04261.x
   Griffin JE, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002251
   GRON H, 1992, BIOCHEMISTRY-US, V31, P6011, DOI 10.1021/bi00141a008
   Guinn KM, 2004, MOL MICROBIOL, V51, P359, DOI 10.1046/j.1365-2958.2003.03844.x
   Hoffmann C, 2008, P NATL ACAD SCI USA, V105, P3963, DOI 10.1073/pnas.0709530105
   Holm L, 2010, NUCLEIC ACIDS RES, V38, pW545, DOI 10.1093/nar/gkq366
   Houben D, 2012, CELL MICROBIOL, V14, P1287, DOI 10.1111/j.1462-5822.2012.01799.x
   Houben ENG, 2012, MOL MICROBIOL, V86, P472, DOI 10.1111/j.1365-2958.2012.08206.x
   Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337
   Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022
   Kuo KL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039641
   Langer G, 2008, NAT PROTOC, V3, P1171, DOI 10.1038/nprot.2008.91
   Lesley Scott A., 2005, Journal of Structural and Functional Genomics, V6, P71, DOI 10.1007/s10969-005-2897-2
   London N, 2010, STRUCTURE, V18, P188, DOI 10.1016/j.str.2009.11.012
   Long F, 2008, ACTA CRYSTALLOGR D, V64, P125, DOI 10.1107/S0907444907050172
   Majlessi L, 2005, J IMMUNOL, V174, P3570, DOI 10.4049/jimmunol.174.6.3570
   Malen H, 2007, PROTEOMICS, V7, P1702, DOI 10.1002/pmic.200600853
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206
   McLaughlin B, 2007, PLOS PATHOG, V3, P1051, DOI 10.1371/journal.ppat.0030105
   MCPHALEN CA, 1985, P NATL ACAD SCI USA, V82, P7242, DOI 10.1073/pnas.82.21.7242
   MCPHALEN CA, 1988, BIOCHEMISTRY-US, V27, P6582, DOI 10.1021/bi00417a058
   Mishra KC, 2008, INFECT IMMUN, V76, P127, DOI 10.1128/IAI.00410-07
   Murshudov GN, 2011, ACTA CRYSTALLOGR D, V67, P355, DOI 10.1107/S0907444911001314
   Ohol YM, 2010, CELL HOST MICROBE, V7, P210, DOI 10.1016/j.chom.2010.02.006
   Painter J, 2006, ACTA CRYSTALLOGR D, V62, P439, DOI 10.1107/S0907444906005270
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pym AS, 2002, MOL MICROBIOL, V46, P709, DOI 10.1046/j.1365-2958.2002.03237.x
   Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x
   SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X
   Serafini A, 2009, J BACTERIOL, V191, P6340, DOI 10.1128/JB.00756-09
   SHINDE U, 1995, J MOL BIOL, V247, P390, DOI 10.1006/jmbi.1994.0147
   Siegrist MS, 2009, P NATL ACAD SCI USA, V106, P18792, DOI 10.1073/pnas.0900589106
   Siezen RJ, 1997, PROTEIN SCI, V6, P501
   SIEZEN RJ, 1991, PROTEIN ENG, V4, P719, DOI 10.1093/protein/4.7.719
   Simeone R, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002507
   Soding J, 2005, NUCLEIC ACIDS RES, V33, pW244, DOI 10.1093/nar/gki408
   Solomonson M, 2013, J BIOL CHEM, V288, P17782, DOI 10.1074/jbc.M113.462036
   Stoop EJM, 2012, TRENDS MICROBIOL, V20, P477, DOI 10.1016/j.tim.2012.07.001
   Strong M, 2006, P NATL ACAD SCI USA, V103, P8060, DOI 10.1073/pnas.0602606103
   TEPLYAKOV AV, 1990, J MOL BIOL, V214, P261, DOI 10.1016/0022-2836(90)90160-N
   van der Woude AD, 2013, J BACTERIOL, V195, P2050, DOI 10.1128/JB.02236-12
   Xu J, 2007, MOL MICROBIOL, V66, P787, DOI 10.1111/j.1365-2958.2007.05959.x
   Xue B, 2010, BBA-PROTEINS PROTEOM, V1804, P996, DOI 10.1016/j.bbapap.2010.01.011
   Zuber B, 2008, J BACTERIOL, V190, P5672, DOI 10.1128/JB.01919-07
NR 64
TC 13
Z9 14
U1 0
U2 13
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1047-8477
EI 1095-8657
J9 J STRUCT BIOL
JI J. Struct. Biol.
PD NOV
PY 2013
VL 184
IS 2
BP 115
EP 128
DI 10.1016/j.jsb.2013.09.022
PG 14
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 254MY
UT WOS:000327171000002
PM 24113528
OA green_accepted
DA 2018-03-20
ER

PT J
AU Gupta, SK
   Guzman, EAT
   Meenach, SA
AF Gupta, Sweta K.
   Guzman, Elisa A. Torrico
   Meenach, Samantha A.
TI Coadministration of a tumor-penetrating peptide improves the therapeutic
   efficacy of paclitaxel in a novel air-grown lung cancer 3D spheroid
   model
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE A549 adenocarcinoma cells; alternative cell culture; lung cancer;
   multicellular tumor spheroids; paclitaxel; tumor-penetrating peptide
   iRGD
ID MULTICELLULAR SPHEROIDS; ENGINEERING TUMORS; ANTICANCER DRUGS; SOLID
   TUMORS; CELL; CULTURE; SURFACE; MICROENVIRONMENT; ADENOCARCINOMA;
   GENERATION
AB Three-dimensional (3 D) cell culture platforms are increasingly being used in cancer research and drug development since they mimic avascular tumors in vitro. In this study, we focused on the development of a novel air-grown multicellular spheroid (MCS) model to mimic in vivo tumors for understanding lung cancer biology and improvement in the evaluation of aerosol anticancer therapeutics. 3 D MCS were formed using A549 lung adenocarcinoma cells, comprising cellular heterogeneity with respect to different proliferative and metabolic gradients. The growth kinetics, morphology and 3 D structure of air-grown MCS were characterized by brightfield, fluorescent and scanning electron microscopy. MCS demonstrated a significant decrease in growth when the tumor-penetrating peptide iRGD and paclitaxel (PTX) were coadministered as compared with PTX alone. It was also found that when treated with both iRGD and PTX, A549 MCS exhibited an increase in apoptosis and decrease in clonogenic survival capacity in contrast to PTX treatment alone. This study demonstrated that coadministration of iRGD resulted in the improvement of the tumor penetration ability of PTX in an in vitro A549 3 D MCS model. In addition, this is the first time a high-throughput air-grown lung cancer tumor spheroid model has been developed and evaluated.
C1 [Gupta, Sweta K.; Guzman, Elisa A. Torrico; Meenach, Samantha A.] Univ Rhode Isl, Coll Engn, Dept Chem Engn, Kingston, RI 02881 USA.
   [Meenach, Samantha A.] Univ Rhode Isl, Coll Pharm, Dept Biomed & Pharmaceut Sci, Kingston, RI 02881 USA.
RP Meenach, SA (reprint author), Univ Rhode Isl, 215A Pastore Hall,51 Lower Coll Rd, Kingston, RI 02881 USA.
EM smeenach@uri.edu
OI Meenach, Samantha/0000-0002-3833-2110
FU Alternatives Research & Development Foundation; Institutional
   Development Award (IDeA) Network for Biomedical Research Excellence from
   the National Institute of General Medical Sciences of the National
   Institutes of Health [P20GM103430]; National Science Foundation
   [1508868]
FX Grant sponsor: Alternatives Research & Development Foundation;; Grant
   sponsor: Institutional Development Award (IDeA) Network for Biomedical
   Research Excellence from the National Institute of General Medical
   Sciences of the National Institutes of Health; Grant number:
   P20GM103430; Grant sponsor: National Science Foundation; Grant number:
   1508868
CR Achilli TM, 2014, MOL PHARMACEUT, V11, P2071, DOI 10.1021/mp500002y
   Aref AR, 2013, INTEGR BIOL-UK, V5, P381, DOI 10.1039/c2ib20209c
   BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366
   Burdett E, 2010, TISSUE ENG PART B-RE, V16, P351, DOI [10.1089/ten.teb.2009.0676, 10.1089/ten.TEB.2009.0676]
   Carlin S, 2000, CANCER GENE THER, V7, P1529, DOI 10.1038/sj.cgt.7700264
   CARLSSON J, 1983, INT J CANCER, V31, P523, DOI 10.1002/ijc.2910310502
   Christian S, 2003, J CELL BIOL, V163, P871, DOI 10.1083/jcb.200304132
   Cincinelli R, 2007, BIOORGAN MED CHEM, V15, P4863, DOI 10.1016/j.bmc.2007.04.057
   Costa EC, 2014, BIOTECHNOL BIOENG, V111, P1672, DOI 10.1002/bit.25210
   Cui X, 2017, J R SOC INTERFACE, V14
   Cukierman E, 2002, CURR OPIN CELL BIOL, V14, P633, DOI 10.1016/S0955-0674(02)00364-2
   Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748
   Ekert JE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092248
   Fischbach C, 2007, NAT METHODS, V4, P855, DOI 10.1038/NMETH1085
   Fogal V, 2008, CANCER RES, V68, P7210, DOI 10.1158/0008-5472.CAN-07-6752
   Foty R, 2011, JOVE-J VIS EXP, DOI 10.3791/2720
   Friedrich J, 2007, INT J RADIAT BIOL, V83, P849, DOI 10.1080/09553000701727531
   Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793
   Harma V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010431
   Hehlgans S, 2009, RADIOTHER ONCOL, V92, P371, DOI 10.1016/j.radonc.2009.08.001
   Heldin CH, 2004, NAT REV CANCER, V4, P806, DOI 10.1038/nrc1456
   Ho WJ, 2010, CANCER SCI, V101, P2637, DOI 10.1111/j.1349-7006.2010.01723.x
   Indovina P, 2007, INT J ONCOL, V31, P1473
   Jin HJ, 2011, LAB CHIP, V11, P115, DOI [10.1039/c0lc00134a, 10.1039/c01c00134a]
   Kelly KA, 2008, PLOS MED, V5, P657, DOI 10.1371/journal.pmed.0050085
   Kelm JM, 2003, BIOTECHNOL BIOENG, V83, P173, DOI 10.1002/bit.10655
   Kong HJ, 2004, BIOMACROMOLECULES, V5, P1720, DOI 10.1021/bm049879r
   Lama R, 2013, BIOORGAN MED CHEM, V21, P922, DOI 10.1016/j.bmc.2012.12.007
   Lin RZ, 2006, CELL TISSUE RES, V324, P411, DOI 10.1007/s00441-005-0148-2
   Manoto SL, 2013, LASER SURG MED, V45, P186, DOI 10.1002/lsm.22121
   Meenach SA, 2016, INT J ONCOL, V48, P1701, DOI 10.3892/ijo.2016.3376
   Mikhail AS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062630
   Minchinton AI, 2006, NAT REV CANCER, V6, P583, DOI 10.1038/nrc1893
   Moran CA, 2006, ARCH PATHOL LAB MED, V130, P958
   Napolitano AP, 2007, TISSUE ENG, V13, P2087, DOI 10.1089/ten.2006.0190
   Nirmalanandhan VS, 2010, ASSAY DRUG DEV TECHN, V8, P581, DOI 10.1089/adt.2010.0276
   Oh P, 2004, NATURE, V429, P629, DOI 10.1038/nature02580
   Onozuka H, 2011, CANCER SCI, V102, P975, DOI 10.1111/j.1349-7006.2011.01880.x
   Palma A, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00105
   Schmitt A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118937
   Shikanov A, 2009, BIOMATERIALS, V30, P5476, DOI 10.1016/j.biomaterials.2009.06.054
   Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
   Singh S, 2009, CRIT REV THER DRUG, V26, P333, DOI 10.1615/CritRevTherDrugCarrierSyst.v26.i4.10
   Smalley KSM, 2006, IN VITRO CELL DEV-AN, V42, P242
   Sugahara KN, 2010, SCIENCE, V328, P1031, DOI 10.1126/science.1183057
   Teesalu T, 2009, P NATL ACAD SCI USA, V106, P16157, DOI 10.1073/pnas.0908201106
   Tzanakakis ES, 2001, CELL MOTIL CYTOSKEL, V48, P175, DOI 10.1002/1097-0169(200103)48:3<175::AID-CM1007>3.0.CO;2-2
   Vertrees RA, 2009, CANCER BIOL THER, V8, P356, DOI 10.4161/cbt.8.4.7432
   Xu WH, 2012, INT J NANOMED, V7, P2661, DOI 10.2147/IJN.S30445
   Yamada KM, 2007, CELL, V130, P601, DOI 10.1016/j.cell.2007.08.006
NR 50
TC 1
Z9 1
U1 36
U2 36
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD NOV 15
PY 2017
VL 141
IS 10
BP 2143
EP 2153
DI 10.1002/ijc.30913
PG 11
WC Oncology
SC Oncology
GA FH3OE
UT WOS:000411057400021
PM 28771722
DA 2018-03-20
ER

PT J
AU Geddes, J
   Bondada, V
   Sands, M
   Pistilli, C
   Dayaram, K
   Yu, CG
AF Geddes, James W.
   Bondada, Vimala
   Sands, Madison
   Pistilli, Christina
   Dayaram, Kavi
   Yu, Chen-Guang
TI FLUBENDAZOLE IMPROVES RECOVERY FOLLOWING SPINAL CORD INJURY IN RATS
SO JOURNAL OF NEUROTRAUMA
LA English
DT Meeting Abstract
CT 34th Annual National Neurotrauma Symposium
CY JUN 26-29, 2016
CL Lexington, KY
DE B cells; autoimmune; tubulin
C1 [Geddes, James; Bondada, Vimala; Sands, Madison; Pistilli, Christina; Dayaram, Kavi; Yu, Chen-Guang] Univ Kentucky, SCoBIRC, Lexington, KY 40506 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0897-7151
EI 1557-9042
J9 J NEUROTRAUM
JI J. Neurotrauma
PD JUL 1
PY 2016
VL 33
IS 13
MA PSA-108
BP A51
EP A51
PG 1
WC Critical Care Medicine; Clinical Neurology; Neurosciences
SC General & Internal Medicine; Neurosciences & Neurology
GA DP2QY
UT WOS:000378336200136
DA 2018-03-20
ER

PT J
AU Watts, AS
   Gavalas, VG
   Cammers, A
   Andrada, PS
   Alajarin, M
   Bachas, LG
AF Watts, Amanda S.
   Gavalas, Vasilis G.
   Cammers, Arthur
   Andrada, Pilar Sanchez
   Alajarin, Mateo
   Bachas, Leonidas G.
TI Nitrate-selective electrode based on a cyclic bis-thiourea ionophore
SO SENSORS AND ACTUATORS B-CHEMICAL
LA English
DT Article
DE ion-selective electrode; ionophore; bis-thiourea; nitrate
ID NEUTRAL LIPOPHILIC IONOPHORES; OF-THE-ART; MEMBRANE-ELECTRODE; DETECTION
   LIMIT; OPTICAL SENSORS; BULK OPTODES; CARRIER; ANIONS; RECOGNITION;
   DERIVATIVES
AB Compounds containing urea and thiourea groups can hydrogen bond oxoanions and, as such, represent a class of potential ionophores for anion-selective electrodes. We have evaluated cyclic and linear bis-thiourea compounds as ionophores in polymer membrane ion-selective electrodes. An improvement in the selectivity coefficient of nitrate against chloride of greater than one order of magnitude was observed with the cyclic ionophore in comparison to the Hofmeister lipophilicity series (log K-NO3(-pot),(Cl-) of -3.50 with ionophore versus -2.40 with no bis-thiourea ionophore), indicating the preference of the cyclic ionophore for nitrate. This preference for nitrate over chloride may be attributed to the spatial arrangement of the thiourea hydrogen atoms, which are capable of forming hydrogen bonds with nitrate, as well as the size of the ionophore binding cavity. In the lowest-energy conformation, all thiourea hydrogen atoms point toward a putative nitrate binding site, likely contributing to enhanced coordination. (c) 2006 Elsevier B.V. All rights reserved.
C1 Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
   Univ Murcia, Dept Organ Chem, Murcia, Spain.
RP Bachas, LG (reprint author), Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
EM bachas@uky.edu
RI Cammers, Arthur/B-8681-2013; Alajarin, Mateo/A-5421-2008; Bachas,
   Leonidas/G-2479-2015
OI Cammers, Arthur/0000-0002-1682-3488; Alajarin,
   Mateo/0000-0002-7112-5578; Bachas, Leonidas/0000-0002-3308-6264
CR Alajarin M, 1999, J ORG CHEM, V64, P1121, DOI 10.1021/jo981339v
   Amemiya S, 2000, ANAL CHEM, V72, P1618, DOI 10.1021/ac991167h
   Amemiya S, 1999, ANAL CHEM, V71, P1049, DOI 10.1021/ac980952b
   Andredakis GE, 2001, ANAL CHIM ACTA, V439, P273, DOI 10.1016/S0003-2670(01)00972-2
   Antonisse MMG, 1999, ELECTROANAL, V11, P1035, DOI 10.1002/(SICI)1521-4109(199910)11:14<1035::AID-ELAN1035>3.0.CO;2-I
   Ardakani M. M., 2004, Sensors and Actuators B (Chemical), VB101, P302, DOI 10.1016/j.snb.2004.03.011
   Asghari A, 2003, ANAL SCI, V19, P1121, DOI 10.2116/analsci.19.1121
   Badr IHA, 1999, ANAL CHEM, V71, P1371, DOI 10.1021/ac980896e
   Badr IHA, 2000, ANAL CHEM, V72, P4249, DOI 10.1021/ac000508k
   Bakker E, 1997, CHEM REV, V97, P3083, DOI 10.1021/cr940394a
   Ball JC, 1998, ACS SYM SER, V690, P248
   Ballarin B, 2000, J ELECTROANAL CHEM, V492, P7, DOI 10.1016/S0022-0728(00)00212-6
   Beer PD, 2001, ANGEW CHEM INT EDIT, V40, P486, DOI 10.1002/1521-3773(20010202)40:3<486::AID-ANIE486>3.0.CO;2-P
   Beer PD, 2005, TOP CURR CHEM, V255, P125, DOI 10.1007/b101165
   Berrocal MJ, 2000, ANAL CHEM, V72, P5295, DOI 10.1021/ac000241p
   BUCK RP, 1994, PURE APPL CHEM, V66, P2527, DOI 10.1351/pac199466122527
   Buhlmann P, 1997, TETRAHEDRON, V53, P1647, DOI 10.1016/S0040-4020(96)01094-0
   Buhlmann P, 1998, CHEM REV, V98, P1593, DOI 10.1021/cr970113+
   Capitan-Vallvey LF, 2005, ANAL CHEM, V77, P4459, DOI 10.1021/ac00117b
   Ceresa A, 2003, ANAL CHEM, V75, P133, DOI 10.1021/ac026055w
   CHANIOTAKIS NA, 1988, ANAL CHEM, V60, P188
   DINTEN O, 1991, ANAL CHEM, V63, P596, DOI 10.1021/ac00006a009
   DRAKENBERG T, 1972, TETRAHEDRON LETT, V13, P1743
   Gorski L, 2003, ELECTROANAL, V15, P1229, DOI 10.1002/elan.200302814
   Haushalter KA, 1996, J AM CHEM SOC, V118, P8891, DOI 10.1021/ja961380k
   Herges R, 2002, EUR J ORG CHEM, P3004
   HUTCHINS RS, 1995, ANAL CHEM, V67, P1654, DOI 10.1021/ac00106a002
   Jeon SW, 2003, ELECTROANAL, V15, P872, DOI 10.1002/elan.200390108
   Johnson RD, 2003, ANAL BIOANAL CHEM, V376, P328, DOI 10.1007/s00216-003-1931-0
   Khorasani JH, 2002, SENSOR ACTUAT B-CHEM, V87, P448, DOI 10.1016/S0925-4005(02)00294-0
   Le Goff T, 2002, ANAL CHEM, V74, P2596, DOI 10.1021/ac010985i
   Lee HK, 2004, TALANTA, V62, P293, DOI 10.1016/j.talanta.2003.07.016
   LEO A, 1971, CHEM REV, V71, P525, DOI 10.1021/cr60274a001
   Malinowska E, 2002, ANAL CHIM ACTA, V468, P133, DOI 10.1016/S0003-2670(02)00635-9
   Malon A, 2003, ANAL CHEM, V75, P3865, DOI 10.1021/ac026454r
   MOHAMADI F, 1990, J COMPUT CHEM, V11, P40
   Nishizawa S, 1998, ANAL CHIM ACTA, V358, P35, DOI 10.1016/S0003-2670(97)00569-2
   PARK SB, 1991, ELECTROANAL, V3, P909, DOI 10.1002/elan.1140030906
   Schmidtchen FP, 1997, CHEM REV, V97, P1609, DOI 10.1021/cr9603845
   SCHULTHESS P, 1984, HELV CHIM ACTA, V67, P1026, DOI 10.1002/hlca.19840670415
   Shahrokhian S, 2002, ANAL CHEM, V74, P3312, DOI 10.1021/ac020099n
   Sokalski T, 1999, ANAL CHEM, V71, P1204, DOI 10.1021/ac980944v
   Sokalski T, 1999, ANAL CHEM, V71, P1210, DOI 10.1021/ac9809332
   TSAGATAKIS JK, 1994, HELV CHIM ACTA, V77, P2191, DOI 10.1002/hlca.19940770812
   WALTER W, 1971, OMR-ORGAN MAGNET RES, V3, P733, DOI 10.1002/mrc.1270030613
   WIBERG KB, 1995, J AM CHEM SOC, V117, P4261, DOI 10.1021/ja00120a006
   WUTHIER U, 1984, ANAL CHEM, V56, P535, DOI 10.1021/ac00267a052
   Xiao KP, 1997, ANAL CHEM, V69, P1038, DOI 10.1021/ac961035d
   YANG XG, 1993, J AM CHEM SOC, V115, P193, DOI 10.1021/ja00054a026
NR 49
TC 20
Z9 21
U1 0
U2 9
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0925-4005
J9 SENSOR ACTUAT B-CHEM
JI Sens. Actuator B-Chem.
PD JAN 30
PY 2007
VL 121
IS 1
BP 200
EP 207
DI 10.1016/j.snb.2006.09.048
PG 8
WC Chemistry, Analytical; Electrochemistry; Instruments & Instrumentation
SC Chemistry; Electrochemistry; Instruments & Instrumentation
GA 137XN
UT WOS:000244326400023
DA 2018-03-19
ER

PT J
AU Clark, A
   Milbrandt, TA
   Hilt, JZ
   Puleo, DA
AF Clark, Amanda
   Milbrandt, Todd A.
   Hilt, J. Zach
   Puleo, David A.
TI Retention of insulin-like growth factor I bioactivity during the
   fabrication of sintered polymeric scaffolds
SO BIOMEDICAL MATERIALS
LA English
DT Article
DE scaffolds; poly(lactic-co-glycolic acid); insulin-like growth factor I;
   bioactivity; cartilage
ID MESENCHYMAL STEM-CELLS; GLYCOLIC ACID PLGA; IGF-I; BIODEGRADABLE
   MICROSPHERES; ARTICULAR CHONDROCYTES; DELIVERY SYSTEMS; PROTEIN RELEASE;
   BOVINE-MILK; BONE; COLLAGEN
AB The use of growth factors in tissue engineering offers an added benefit to cartilage regeneration. Growth factors, such as insulin-like growth factor I (IGF-I), increase cell proliferation and can therefore decrease the time it takes for cartilage tissue to regrow. In this study, IGF-I was released from poly(lactic-co-glycolic acid) (PLGA) scaffolds that were designed to have a decreased burst release often associated with tissue engineering scaffolds. The scaffolds were fabricated from IGF-I-loaded PLGA microspheres prepared by a double emulsion (W-1/O/W-2) technique. The microspheres were then compressed, sintered at 49 degrees C and salt leached. The bioactivity of soluble IGF-I was verified after being heat treated at 37, 43, 45, 49 and 60 degrees C. Additionally, the bioactivity of IGF-I was confirmed after being released from the sintered scaffolds. The triphasic release lasted 120 days resulting in 20%, 55% and 25% of the IGF-I being released during days 1-3, 4-58 and 59-120, respectively. Seeding bone marrow cells directly onto the IGF-I-loaded scaffolds showed an increase in cell proliferation, based on DNA content, leading to increased glycosaminoglycan production. The present results demonstrated that IGF-I remains active after being incorporated into heat-treated scaffolds, further enhancing tissue regeneration possibilities.
C1 [Clark, Amanda; Puleo, David A.] Univ Kentucky, Dept Biomed Engn, Lexington, KY 40506 USA.
   [Milbrandt, Todd A.] Univ Kentucky, Dept Orthopaed Surg, Lexington, KY USA.
   [Milbrandt, Todd A.] Shriners Hosp Children, Lexington, KY USA.
   [Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY USA.
RP Clark, A (reprint author), Univ Kentucky, Dept Biomed Engn, Lexington, KY 40506 USA.
EM puleo@uky.edu
FU Pediatric Orthopaedic Society of North America; NIH [AR060964]; NSF
   IGERT traineeship [DGE-0653710]
FX This research was supported in part by the Pediatric Orthopaedic Society
   of North America, the NIH (AR060964) and an NSF IGERT traineeship to AC
   (DGE-0653710).
CR Benita S., 2006, MICROENCAPSULATION M, P99
   BLACK J, 1984, BIOMATERIALS, V5, P11, DOI 10.1016/0142-9612(84)90061-9
   Capito RM, 2007, GENE THER, V14, P721, DOI 10.1038/sj.gt.3302918
   Clark A, 2013, J BIOMED MATER RES A, V102, P348
   COHEN S, 1991, PHARMACEUT RES, V8, P713, DOI 10.1023/A:1015841715384
   Coleman J, 2012, J BIOMAT SCI-POLYM E, V23, P1129, DOI [10.1163/092050611X576648, 10.1163/092050611x576648]
   COLLIER RJ, 1991, J DAIRY SCI, V74, P2905, DOI 10.3168/jds.S0022-0302(91)78473-7
   Crotts G, 1998, J MICROENCAPSUL, V15, P699, DOI 10.3109/02652049809008253
   Damien E, 2003, J BIOMED MATER RES A, V66A, P241, DOI 10.1002/jbm.a.10564
   Elisseeff J, 2001, J ORTHOPAED RES, V19, P1098, DOI 10.1016/S0736-0266(01)00054-7
   England JL, 2011, ANNU REV PHYS CHEM, V62, P257, DOI 10.1146/annurev-physchem-032210-103531
   Fu K, 2000, PHARMACEUT RES, V17, P100, DOI 10.1023/A:1007582911958
   Garcia JT, 1999, J MICROENCAPSUL, V16, P83, DOI 10.1080/026520499289338
   GENTRY LE, 1990, BIOCHEMISTRY-US, V29, P6851, DOI 10.1021/bi00481a014
   Ghaderi R, 1997, PHARMACEUT RES, V14, P1556, DOI 10.1023/A:1012122200381
   GUENTHER HL, 1982, EXPERIENTIA, V38, P979, DOI 10.1007/BF01953688
   Guo S, 2010, J DENT RES, V89, P219, DOI 10.1177/0022034509359125
   Hickey T, 2002, BIOMATERIALS, V23, P1649, DOI 10.1016/S0142-9612(01)00291-5
   HOCK JM, 1988, ENDOCRINOLOGY, V122, P254, DOI 10.1210/endo-122-1-254
   Jabbarzadeh E, 2012, J BIOMED MATER RES B, V100B, P2187, DOI 10.1002/jbm.b.32787
   Jaklenec A, 2008, BIOMATERIALS, V29, P1518, DOI 10.1016/j.biomaterials.2007.12.004
   Kang SH, 2006, J DAIRY SCI, V89, P402, DOI 10.3168/jds.S0022-0302(06)72104-X
   LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7
   Laffargue P, 2000, J BIOMED MATER RES, V49, P415, DOI 10.1002/(SICI)1097-4636(20000305)49:3<415::AID-JBM15>3.3.CO;2-Q
   LAWRENCE D, 1985, BIOCHEM BIOPH RES CO, V133, P1026, DOI 10.1016/0006-291X(85)91239-2
   Lee SJ, 2004, J BIOMAT SCI-POLYM E, V15, P1003, DOI 10.1163/1568562041526487
   Longobardi L, 2006, J BONE MINER RES, V21, P626, DOI 10.1359/JBMR.051213
   Lu W, 1995, PDA J Pharm Sci Technol, V49, P13
   LYONS RM, 1988, J CELL BIOL, V106, P1659, DOI 10.1083/jcb.106.5.1659
   Makadia HK, 2011, POLYMERS-BASEL, V3, P1377, DOI 10.3390/polym3031377
   Mao SR, 2007, INT J PHARM, V334, P137, DOI 10.1016/j.ijpharm.2006.10.036
   Martin I, 1998, J ORTHOPAED RES, V16, P181, DOI 10.1002/jor.1100160205
   McCall JD, 2012, BIOMACROMOLECULES, V13, P2410, DOI 10.1021/bm300671s
   MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P301, DOI 10.1210/endo-124-1-301
   McGee MA, 2000, WEAR, V241, P158, DOI 10.1016/S0043-1648(00)00370-7
   Meinel L, 2001, J CONTROL RELEASE, V70, P193, DOI 10.1016/S0168-3659(00)00352-7
   Morisset S, 2007, CLIN ORTHOP RELAT R, P221, DOI 10.1097/BLO.0b013e3180dca05f
   Nehrer S, 1997, BIOMATERIALS, V18, P769, DOI 10.1016/S0142-9612(97)00001-X
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   RAGHUVANSHI RS, 1993, INT J PHARM, V93, pR1, DOI 10.1016/0378-5173(93)90188-L
   Rajamannan NM, 2003, CIRCULATION, V107, P2181, DOI 10.1161/01.CIR.0000070591.21548.69
   Rhee SH, 2007, J BIOMED MATER RES A, V83A, P799, DOI 10.1002/jbm.a.31405
   Schwarz C, 2013, TISSUE ENG PT A, V19, P247, DOI [10.1089/ten.tea.2012.0265, 10.1089/ten.TEA.2012.0265]
   Schwendeman SP, 2002, CRIT REV THER DRUG, V19, P73, DOI 10.1615/CritRevTherDrugCarrierSyst.v19.i1.20
   Steinemann SG, 1996, INJURY, V27, P16
   Sundararaj SKC, 2015, J TISSUE ENG REGEN M, V9, pE202, DOI 10.1002/term.1670
   TABATA Y, 1993, J CONTROL RELEASE, V23, P55, DOI 10.1016/0168-3659(93)90070-L
   Uematsu K, 2005, BIOMATERIALS, V26, P4273, DOI 10.1016/j.biomaterials.2004.10.037
   van der Kraan PM, 2002, OSTEOARTHR CARTILAGE, V10, P631, DOI 10.1053/joca.2002.0806
   Veilleux N, 2005, OSTEOARTHR CARTILAGE, V13, P278, DOI 10.1016/j.joca.2004.12.013
   VREVEN J, 1973, BIOCHIM BIOPHYS ACTA, V293, P170, DOI 10.1016/0005-2744(73)90388-4
   WEINREB M, 1990, J BONE MINER RES, V5, P831
   Winkler L, 2006, MATERIALWISS WERKST, V37, P436, DOI 10.1002/mawe.200600016
   Yang YY, 2000, J CONTROL RELEASE, V69, P81, DOI 10.1016/S0168-3659(00)00291-1
   Yeo Y., 2001, BIOTECHNOL BIOPROC E, V6, P213, DOI DOI 10.1007/BF02931982
   Yun ZY, 2007, LAIT, V87, P139, DOI 10.1051/lait:2007005
NR 56
TC 2
Z9 2
U1 0
U2 20
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 1748-6041
EI 1748-605X
J9 BIOMED MATER
JI Biomed. Mater.
PD APR
PY 2014
VL 9
IS 2
AR 025015
DI 10.1088/1748-6041/9/2/025015
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA AB9DU
UT WOS:000332090900015
PM 24565886
OA green_accepted
DA 2018-03-19
ER

PT J
AU Long, SH
   Theiss, KL
   Li, TL
   Loftin, CD
AF Long, Sihui
   Theiss, Kathryn L.
   Li, Tonglei
   Loftin, Charles D.
TI Cyclooxygenase-1-selective inhibitor SC-560
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article
ID SELECTIVE CYCLOOXYGENASE-1; (COX)-1; CANCER
AB In the title compound, 5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazole (SC-560), C(17)H(12)ClF(3)N(2)O, a COX-1-selective inhibitor, the dihedral angles between the heterocycle and the chlorobenzene and methoxybenzene rings are 41.66 (6) and 43.08 (7)degrees, respectively. The dihedral angle between the two phenyl rings is 59.94 (6)degrees. No classic hydrogen bonds are possible in the crystal, and intermolecular interactions must be mainly of the dispersion type. This information may aid the identification of dosage formulations with improved oral bioavailability.
C1 [Long, Sihui; Theiss, Kathryn L.; Li, Tonglei; Loftin, Charles D.] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
RP Loftin, CD (reprint author), Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
EM cdloft2@uky.edu
FU NSF [DMR-0449633]
FX SL and TL are grateful for financial support by the NSF (DMR-0449633).
   The authors also thank Dr Sean Parkin for providing laboratory
   facilities and for helpful discussions.
CR Allen FH, 2002, ACTA CRYSTALLOGR B, V58, P380, DOI 10.1107/S0108768102003890
   Charlier C, 2004, ACTA CRYSTALLOGR C, V60, pO648, DOI 10.1107/S0108270104016117
   CHOI SH, 2008, J FED AM SOC EXP BIO, V22, P1491
   Cusimano A, 2007, CANCER BIOL THER, V6, P1461
   Hooft R. W. W., 1998, COLLECT
   Kundu N, 2002, CANCER RES, V62, P2343
   Norris T, 2005, ORG BIOMOL CHEM, V3, P1844, DOI 10.1039/b500413f
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Penning TD, 1997, J MED CHEM, V40, P1347, DOI 10.1021/jm960803q
   Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930
   Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145
   Sonar VN, 2004, ACTA CRYSTALLOGR C, V60, pO547, DOI 10.1107/S0108270104013848
   Teng XW, 2003, J PHARM PHARM SCI, V6, P205
   Tiano HF, 2002, CANCER RES, V62, P3395
   Zhu HJ, 2004, ACTA CRYSTALLOGR E, V60, pO2144, DOI 10.1107/S1600536804026789
NR 15
TC 1
Z9 1
U1 0
U2 3
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD FEB
PY 2009
VL 65
BP O360
EP U2483
DI 10.1107/S1600536809001779
PG 10
WC Crystallography
SC Crystallography
GA 402VH
UT WOS:000263040700222
PM 21581958
OA gold
DA 2018-03-20
ER

PT J
AU Long, SH
   Parkin, S
   Siegler, MA
   Cammers, A
   Li, TL
AF Long, Sihui
   Parkin, Sean
   Siegler, Maxime A.
   Cammers, Arthur
   Li, Tonglei
TI Polymorphism and Phase Behaviors of 2-(Phenylamino)nicotinic Acid
SO CRYSTAL GROWTH & DESIGN
LA English
DT Article
ID HYDROGEN-BOND PATTERNS; GRAPH-SET ANALYSIS; CONFORMATIONAL ISOMORPHISM;
   X-RAY; ORGANIC-COMPOUNDS; SOLID-STATE; POLYMERS; PSEUDOPOLYMORPH;
   CHEMISTRY; CRYSTALS
AB The discovery and phase transition studies of four polymorphs of 2-(phenylamino)nicotinic acid are described in this report. The four polymorphs were crystallized from solution under different conditions. All polymorphs differ in the degree of conjugation of the two aromatic rings and thus are of conformational polymorphism. Three of the four modifications have more than one conformer in the asymmetric unit. Due to the difference in conformation, all polymorphs display distinctive colors as well as different hydrogen-bonding arrangements. Phase behaviors of the four forms were studied by differential scanning calorimetry and hot-stage microscopy, indicating that metastable forms underwent phase transition to the stable one initiated by mechanical perturbation in solution or assisted by heating in the solid state. As such, this polymorphic system exhibits polychromism, conformational isomorphism, thermochromism, and mechanochromism. It may be valuable for further solid-state structure-property relationship studies.
C1 [Li, Tonglei] Univ Kentucky, Coll Pharm 514, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
   [Parkin, Sean; Siegler, Maxime A.; Cammers, Arthur] Univ Kentucky, Dept Chem, Lexington, KY 40536 USA.
RP Li, TL (reprint author), Univ Kentucky, Coll Pharm 514, Dept Pharmaceut Sci, 725 Rose St, Lexington, KY 40536 USA.
EM tonglei@uky.edu
RI Parkin, Sean/E-7044-2011; Cammers, Arthur/B-8681-2013
OI Cammers, Arthur/0000-0002-1682-3488
FU NSF [DMR-0449633]
FX T.L. and S.L. thank NSF for the financial support (DMR-0449633).
CR Ahn SY, 2006, J AM CHEM SOC, V128, P8441, DOI 10.1021/ja0573155
   BENEDETTI E, 1975, EUR POLYM J, V11, P585, DOI 10.1016/0014-3057(75)90009-9
   BERKOVITCHYELLIN Z, 1982, J AM CHEM SOC, V104, P4052, DOI 10.1021/ja00379a003
   Bernstein J, 2005, CRYST GROWTH DES, V5, P1661, DOI 10.1021/cg0580071
   BERNSTEIN J, 1995, ANGEW CHEM INT EDIT, V34, P1555, DOI 10.1002/anie.199515551
   Bernstein J., 1987, ORGANIC SOLID STATE, V32, P471
   Bernstein J., 2002, POLYMORPHISM MOL CRY
   Brittain HG, 2007, J PHARM SCI-US, V96, P705, DOI 10.1002/jps.20772
   Brittain H. G., 1999, POLYMORPHISM PHARM S
   Byrn S. R., 1999, SOLID STATE CHEM DRU
   Caira MR, 1998, TOP CURR CHEM, V198, P163
   Chen S, 2005, J AM CHEM SOC, V127, P9881, DOI 10.1021/ja052098t
   Chen SA, 2005, J AM CHEM SOC, V127, P17439, DOI 10.1021/ja056072d
   CORRADIN.P, 1969, T NEW YORK ACAD SCI, V31, P215, DOI 10.1111/j.2164-0947.1969.tb02902.x
   CORRADINI P, 1975, J POLYM SCI POL SYM, P1
   CORRADINI P, 1973, CHIM IND-MILAN, V55, P122
   Desiraju GR, 2004, CRYST GROWTH DES, V4, P1089, DOI 10.1021/cg030085q
   ETTER MC, 1990, ACCOUNTS CHEM RES, V23, P120, DOI 10.1021/ar00172a005
   ETTER MC, 1990, ACTA CRYSTALLOGR B, V46, P256, DOI 10.1107/S0108768189012929
   FUJINAGA M, 1980, ACTA CRYSTALLOGR B, V36, P3196, DOI 10.1107/S0567740880011296
   HALEBLIA.J, 1969, J PHARM SCI, V58, P911, DOI 10.1002/jps.2600580802
   Kermack WO, 1942, J CHEM SOC, P726, DOI 10.1039/jr9420000726
   Kumar VSS, 2002, ANGEW CHEM INT EDIT, V41, P3848, DOI 10.1002/1521-3773(20021018)41:20<3848::AID-ANIE3848>3.0.CO;2-L
   Lee JM, 2002, J PHARM PHARMACOL, V54, P43, DOI 10.1211/0022357021771904
   Long SH, 2006, ACTA CRYSTALLOGR E, V62, pO5664, DOI 10.1107/S1600536806048768
   McCrone W. C., 1965, PHYSICS CHEMISTRY OR, VII, P725
   McCrone W. C., 1957, FUSION METHODS CHEM
   Mnyukh Y., 2001, FUNDAMENTALS SOLID S
   Nangia A, 2006, CRYST GROWTH DES, V6, P2, DOI 10.1021/cg050343e
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   PAUL IC, 1973, ACCOUNTS CHEM RES, V6, P217, DOI 10.1021/ar50067a001
   PETRACCONE V, 1972, EUR POLYM J, V8, P99, DOI 10.1016/0014-3057(72)90086-9
   Seddon KR, 2004, CRYST GROWTH DES, V4, P1087, DOI 10.1021/cg030084y
   SHELDRICK G, 1997, SHELXL97 SHELXS97 CO
   SHELDRICK GM, 1995, XP SHELXTL PC COMPUT
   Streng WH, 1997, DRUG DISCOV TODAY, V2, P415, DOI 10.1016/S1359-6446(97)01077-5
   TAKASUKA M, 1982, J CHEM SOC PERK T 2, P1061, DOI 10.1039/p29820001061
   THOMAS JM, 1974, PHILOS T R SOC A, V277, P251, DOI 10.1098/rsta.1974.0051
   THRELFALL TL, 1995, ANALYST, V120, P2435, DOI 10.1039/an9952002435
   TING PC, 1990, J MED CHEM, V33, P2697, DOI 10.1021/jm00172a004
   Vippagunta SR, 2001, ADV DRUG DELIVER REV, V48, P3, DOI 10.1016/S0169-409X(01)00097-7
   VONGROTH PH, 1910, CHEM KRISTALLOGRAPHI, V3
   Groth P. H. v., 1919, CHEM KRISTALLOGRAPHI, V5
   Groth P. H. v., 1917, CHEM KRISTALLOGRAPHI, V4
   WINTER G, 1999, REACTIVITY MOL SOLID, V3, P241
   Wohler F., 1832, J ANN PHARM, V3, P249
   Yu L, 1998, PHARM SCI TECHNOL TO, V1, P118, DOI 10.1016/S1461-5347(98)00031-5
   Yu L, 2000, J AM CHEM SOC, V122, P585, DOI 10.1021/ja9930622
   Yu L, 2002, J PHYS CHEM A, V106, P544, DOI 10.1021/jp013019c
   STAMPA A, 1975, Patent No. 2409260
   2002, COLLECT COMPUTER SOF
NR 51
TC 29
Z9 29
U1 2
U2 29
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1528-7483
J9 CRYST GROWTH DES
JI Cryst. Growth Des.
PD NOV
PY 2008
VL 8
IS 11
BP 4006
EP 4013
DI 10.1021/cg800123z
PG 8
WC Chemistry, Multidisciplinary; Crystallography; Materials Science,
   Multidisciplinary
SC Chemistry; Crystallography; Materials Science
GA 369DW
UT WOS:000260675500026
DA 2018-03-19
ER

PT J
AU Fugit, KD
   Xiang, TX
   Choi, DH
   Kangarlou, S
   Csuhai, E
   Bummer, PM
   Anderson, BD
AF Fugit, Kyle D.
   Xiang, Tian-Xiang
   Choi, Du H.
   Kangarlou, Sogol
   Csuhai, Eva
   Bummer, Paul M.
   Anderson, Bradley D.
TI Mechanistic model and analysis of doxorubicin release from liposomal
   formulations
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Release kinetics; Liposomes; DOXIL; Dynamic dialysis; Mechanistic
   modeling; Cancer chemotherapy
ID TO-LIPID RATIO; DRUG-RELEASE; HYDROPHOBIC CAMPTOTHECIN; INTRALIPOSOMAL
   PH; TOPOTECAN; PERMEABILITY; PHARMACOKINETICS; ENCAPSULATION;
   COMPLEXATION; ACCUMULATION
AB Reliable and predictive models of drug release kinetics in vitro and in vivo are still lacking for liposomal formulations. Developing robust, predictive release models requires systematic, quantitative characterization of these complex drug delivery systems with respect to the physicochemical properties governing the driving force for release. These models must also incorporate changes in release due to the dissolution media and methods employed to monitor release. This paper demonstrates the successful development and application of a mathematical mechanistic model capable of predicting doxorubicin (DXR) release kinetics from liposomal formulations resembling the FDA-approved nanoformulation DOXIL (R) using dynamic dialysis. The model accounts for DXR equilibria (e.g. self-association, precipitation, ionization), the change in intravesicular pH due to ammonia release, and dialysis membrane transport of DXR. The model was tested using a Box-Behnken experimental design in which release conditions including extravesicular pH, ammonia concentration in the release medium, and the dilution of the formulation (i.e. suspension concentration) were varied. Mechanistic model predictions agreed with observed DXR release up to 19 h. The predictions were similar to a computer fit of the release data using an empirical model often employed for analyzing data generated from this type of experimental design. Unlike the empirical model, the mechanistic model was also able to provide reasonable predictions of release outside the tested design space. These results illustrate the usefulness of mechanistic modeling to predict drug release from liposomal formulations in vitro and its potential for future development of in vitro - in vivo correlations for complex nanoformulations. (c) 2015 Elsevier B.V. All rights reserved.
C1 [Fugit, Kyle D.; Xiang, Tian-Xiang; Kangarlou, Sogol; Bummer, Paul M.; Anderson, Bradley D.] Univ Kentucky, Dept Pharmaceut Sci, Coll Pharm, Lexington, KY 40536 USA.
   [Choi, Du H.] Inje Univ, Dept Pharmaceut Engn, Cinthae Si, Gyeongsangnam D, South Korea.
   [Csuhai, Eva] Transylvania Univ, Div Nat Sci & Math, Lexington, KY 40508 USA.
RP Anderson, BD (reprint author), Univ Kentucky, Dept Pharmaceut Sci, Coll Pharm, Lexington, KY 40536 USA.
EM bande2@uky.edu
FU FDA HHS [1U01FD004892-0]
CR Abraham SA, 2004, J CONTROL RELEASE, V96, P449, DOI 10.1016/j.jconrel.2004.02.017
   Abraham SA, 2002, BBA-BIOMEMBRANES, V1565, P41, DOI 10.1016/S0005-2736(02)00507-2
   Addeo R, 2008, CANCER CHEMOTH PHARM, V62, P285, DOI 10.1007/s00280-007-0605-6
   Barenholz Y, 2012, HANDBOOK OF HARNESSING BIOMATERIALS IN NANOMEDICINE: PREPARATION, TOXICITY, AND APPLICATIONS, P335
   Barenholz Y, 2012, J CONTROL RELEASE, V160, P117, DOI 10.1016/j.jconrel.2012.03.020
   Barsotti RJ, 2001, J PEDIATR-US, V138, pS11, DOI 10.1067/mpd.2001.111832
   Barsotti R.J., 2001, J PEDIAT S, V138, pS19
   Box G. E. P., 1960, TECHNOMETRICS, V2, P455, DOI DOI 10.1080/00401706.1960.10489912
   Chang HI, 2012, INT J NANOMED, V7, P49, DOI 10.2147/IJN.S26766
   Chiu GNC, 2005, J CONTROL RELEASE, V104, P271, DOI 10.1016/j.cornel.2005.02.009
   Csuhai E., 2014, J PHARM SCI, V104, P1087
   DIAZ J, 1995, CLIN CHEM, V41, P1048
   Dos Santos N, 2007, BBA-BIOMEMBRANES, V1768, P1367, DOI 10.1016/j.bbamen.2006.12.013
   Drummond DC, 2008, J PHARM SCI-US, V97, P4696, DOI 10.1002/jps.21358
   Drummond DC, 2006, CANCER RES, V66, P3271, DOI 10.1158/0008-5472.CAN-05-4007
   Fugit KD, 2015, J CONTROL RELEASE, V197, P10, DOI 10.1016/j.jconrel.2014.10.011
   Fugit KD, 2014, MOL PHARMACEUT, V11, P1314, DOI 10.1021/mp400765n
   Fugit KD, 2014, J CONTROL RELEASE, V174, P88, DOI 10.1016/j.jconrel.2013.11.003
   GABIZON A, 1994, CANCER RES, V54, P987
   Gabizon A, 2003, CLIN PHARMACOKINET, V42, P419, DOI 10.2165/00003088-200342050-00002
   GRIT M, 1993, CHEM PHYS LIPIDS, V64, P3, DOI 10.1016/0009-3084(93)90053-6
   GRIT M, 1989, INT J PHARM, V50, P1, DOI 10.1016/0378-5173(89)90173-7
   HARAN G, 1993, BIOCHIM BIOPHYS ACTA, V1151, P201, DOI 10.1016/0005-2736(93)90105-9
   Ishida O, 1999, INT J PHARM, V190, P49, DOI 10.1016/S0378-5173(99)00256-2
   Joguparthi V, 2008, INT J PHARM, V352, P17, DOI 10.1016/j.ijpharm.2007.10.003
   Joguparthi V, 2008, J PHARM SCI-US, V97, P433, DOI 10.1002/jps.21135
   Joguparthi V, 2008, J PHARM SCI-US, V97, P400, DOI 10.1002/jps.21125
   Johnston MJW, 2008, J LIPOSOME RES, V18, P145, DOI [10.1080/08982100802129372, 10.1080/08982100802129372 ]
   Johnston MJW, 2006, BBA-BIOMEMBRANES, V1758, P55, DOI 10.1016/j.bbamem.2006.01.009
   KIRBY C, 1981, BIOCHEM J, V199, P251, DOI 10.1042/bj1990251
   LEVY MY, 1990, INT J PHARM, V66, P29, DOI 10.1016/0378-5173(90)90381-D
   McCarron P. A., 2004, ENCY NANOSCI NANOTEC, V8, P469
   Modi S, 2013, PHARM RES-DORDR, V30, P3154, DOI 10.1007/s11095-013-1143-z
   Modi S, 2013, MOL PHARMACEUT, V10, P3076, DOI 10.1021/mp400154a
   Modi S, 2012, J CONTROL RELEASE, V162, P330, DOI 10.1016/j.jconrel.2012.07.001
   Moreno-Bautista G, 2011, COLLOID SURFACE A, V389, P299, DOI 10.1016/j.colsurfa.2011.07.032
   Musacchio T, 2011, FRONT BIOSCI-LANDMRK, V16, P1388, DOI 10.2741/3795
   Ponta A, 2015, PHARM RES-DORDR, V32, P1752, DOI 10.1007/s11095-014-1573-2
   Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883
   Taggar AS, 2006, J CONTROL RELEASE, V114, P78, DOI 10.1016/j.jconrel.2006.05.019
   Xiang TX, 1998, BIOPHYS J, V75, P2658, DOI 10.1016/S0006-3495(98)77711-2
   Xiang TX, 1997, BIOPHYS J, V72, P223, DOI 10.1016/S0006-3495(97)78661-2
NR 42
TC 10
Z9 12
U1 1
U2 44
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD NOV 10
PY 2015
VL 217
BP 82
EP 91
DI 10.1016/j.jconrel.2015.08.024
PG 10
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA CU4FC
UT WOS:000363481500008
PM 26310713
DA 2018-03-20
ER

PT J
AU Li, YZ
   Bondada, V
   Joshi, A
   Geddes, JW
AF Li, YongChao
   Bondada, Vimala
   Joshi, Aashish
   Geddes, James W.
TI Calpain 1 and Calpastatin expression is developmentally regulated in rat
   brain
SO EXPERIMENTAL NEUROLOGY
LA English
DT Article
DE Calcium; Apoptosis; Necrosis; Cell death; Injury
ID APOPTOSIS-INDUCING FACTOR; CELL-DEATH; MU-CALPAIN; HYPOXIA-ISCHEMIA;
   TRAUMATIC BRAIN; DIFFERENTIAL EXPRESSION; POSTNATAL DEVELOPMENT;
   CEREBRAL-CORTEX; NEURONAL DEATH; INJURY
AB Calpains and caspases are cysteine endopeptidases which share many similar substrates. Caspases are essential for caspase-dependent apoptotic death where calpains may play an augmentive role, while calpains are strongly implicated in necrotic cell death morphologies. Previous studies have demonstrated a down-regulation in the expression of many components of the caspase-dependent cell death pathway during CNS development. We therefore sought to determine if there is a corresponding upregulation of calpains. The major CNS calpains are the g-and m-isoforms, composed of the unique 80 kDa calpain 1 and 2 subunits, respectively, and the shared 28 kDa small subunit. In rat brain, relative protein and mRNA levels of calpain 1, calpain 2, caspase 3, and the endogenous calpain inhibitor-calpastatin, were evaluated using western blot and real-time RT-PCR. The developmental time points examined ranged from embryonic day IS until postnatal day 90. Calpain 1 and calpastatin protein and mRNA levels were low at early developmental time points and increased dramatically by P30. Conversely, caspase-3 expression was greatest at E18, and was rapidly downregulated by P30. Calpain 2 protein and mRNA levels were relatively constant throughout the E18-P90 age range examined. The inverse relationship of calpain I and caspase 3 levels during CNS development is consistent with the shift from caspase-dependent to caspase-independent cell death mechanisms following CNS injury in neonatal vs. adult rat brain. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Geddes, James W.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, SCoBIRC, Lexington, KY 40536 USA.
   [Joshi, Aashish; Geddes, James W.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA.
RP Geddes, JW (reprint author), Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, SCoBIRC, B477 BBSRB,741 S Limestone St, Lexington, KY 40536 USA.
EM jgeddes@uky.edu
FU NIH [PO1AG10836, PO1NS058484, P30NS051220]; Kentucky Spinal Cord and
   Brain Injury Research Trust
FX The funding for this research was provided by NIH grants PO1AG10836,
   PO1NS058484, and P30NS051220; and support from the Kentucky Spinal Cord
   and Brain Injury Research Trust.
CR AGHAJANIAN G. K., 1967, BRAIN RES, V6, P716, DOI 10.1016/0006-8993(67)90128-X
   Azam M, 2001, MOL CELL BIOL, V21, P2213, DOI 10.1128/MCB.21.6.2213-2220.2001
   Badugu R, 2008, J BIOL CHEM, V283, P3409, DOI 10.1074/jbc.M706851200
   Bittigau P, 2004, EXP TOXICOL PATHOL, V56, P83, DOI 10.1016/j.etp.2004.04.006
   Bittigau P, 2003, NEUROTOX RES, V5, P475, DOI 10.1007/BF03033158
   Blaschke AJ, 1996, DEVELOPMENT, V122, P1165
   BLOMGREN K, 1989, NEUROCHEM RES, V14, P1149, DOI 10.1007/BF00965622
   Cao GD, 2007, J NEUROSCI, V27, P9278, DOI 10.1523/JNEUROSCI.2826-07.2007
   Chakrabarti A K, 1993, Brain Res Dev Brain Res, V71, P107
   de la Rosa EJ, 2000, TRENDS NEUROSCI, V23, P454, DOI 10.1016/S0166-2236(00)01628-3
   Dong YN, 2006, J NEUROCHEM, V99, P206, DOI 10.1111/j.1471-4159.2006.04096.x
   Dutt P, 2006, BMC DEV BIOL, V6, DOI 10.1186/1471-213X-6-3
   EAYRS JT, 1959, J ANAT, V93, P385
   Erecinska M, 2004, PROG NEUROBIOL, V73, P397, DOI 10.1016/j.pneurobio.2004.06.003
   Franco SJ, 2005, J CELL SCI, V118, P3829, DOI 10.1242/jcs.02562
   Garcia M, 2005, BIOCHEM BIOPH RES CO, V338, P1241, DOI 10.1016/j.bbrc.2005.10.081
   Gill R, 2002, J CEREBR BLOOD F MET, V22, P420, DOI 10.1097/00004647-200204000-00006
   Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002
   Honda M, 2008, AM J PHYSIOL-CELL PH, V294, pC957, DOI 10.1152/ajpcell.00505.2007
   Honda S, 2004, J BIOL CHEM, V279, P10615, DOI 10.1074/jbc.M308841200
   Hu BR, 2000, J CEREBR BLOOD F MET, V20, P1294, DOI 10.1097/00004647-200009000-00003
   Huang YH, 2001, TRENDS MOL MED, V7, P355, DOI 10.1016/S1471-4914(01)02049-4
   Joshi A, 2009, EXP NEUROL, V218, P221, DOI 10.1016/j.expneurol.2009.04.013
   Kar P, 2008, ARCH BIOCHEM BIOPHYS, V470, P176, DOI 10.1016/j.abb.2007.11.018
   Kar P, 2007, ARCH BIOCHEM BIOPHYS, V466, P290, DOI 10.1016/j.abb.2007.07.022
   Kuchay SM, 2007, MOL CELL BIOL, V27, P6038, DOI 10.1128/MCB.00522-07
   Liu CL, 2004, NEUROSCIENCE, V127, P113, DOI 10.1016/j.neuroscience.2004.03.062
   Liu WF, 2002, J BIOL CHEM, V277, P8273, DOI 10.1074/jbc.M110768200
   Liu XL, 2004, ANNU REV PHARMACOL, V44, P349, DOI 10.1146/annurev.pharmtox.44.101802.121804
   Lu T, 2002, BBA-MOL CELL RES, V1590, P16, DOI 10.1016/S0167-4889(02)00193-3
   Madden SD, 2007, INT J DEV BIOL, V51, P415, DOI 10.1387/ijdb.062263sm
   Naga KK, 2007, J NEUROSCI, V27, P7469, DOI 10.1523/JNEUROSCI.0646-07.2007
   Pang Z, 2003, J NEUROPATH EXP NEUR, V62, P633, DOI 10.1093/jnen/62.6.633
   Polster BM, 2005, J BIOL CHEM, V280, P6447, DOI 10.1074/jbc.M413269200
   PorteraCailliau C, 1997, J COMP NEUROL, V378, P88, DOI 10.1002/(SICI)1096-9861(19970203)378:1<88::AID-CNE5>3.0.CO;2-G
   PorteraCailliau C, 1997, J COMP NEUROL, V378, P70
   PYSH JJ, 1970, BRAIN RES, V18, P325, DOI 10.1016/0006-8993(70)90332-X
   Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x
   Raynaud F, 2008, INT J DEV BIOL, V52, P383, DOI 10.1387/ijdb.072448fr
   Raynaud P, 2005, ARCH BIOCHEM BIOPHYS, V437, P69, DOI 10.1016/j.abb.2005.02.026
   Shimohama S, 2001, BIOCHEM BIOPH RES CO, V289, P1063, DOI 10.1006/bbrc.2001.6180
   SIMONSON L, 1985, BRAIN RES, V327, P153, DOI 10.1016/0006-8993(85)91509-4
   STURROCK RR, 1974, J ANAT, V117, P37
   SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135
   Suzuki K, 2004, DIABETES, V53, pS12, DOI 10.2337/diabetes.53.2007.S12
   Syntichaki P, 2002, NATURE, V419, P939, DOI 10.1038/nature01108
   Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4
   Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131
   Yakovlev AG, 2001, J NEUROSCI, V21, P7439
   Yeo W, 2004, DEV BIOL, V274, P233, DOI 10.1016/j.ydbio.2004.07.026
   Zhu C, 2005, CELL DEATH DIFFER, V12, P162, DOI 10.1038/sj.cdd.4401545
NR 51
TC 17
Z9 18
U1 0
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4886
EI 1090-2430
J9 EXP NEUROL
JI Exp. Neurol.
PD DEC
PY 2009
VL 220
IS 2
BP 316
EP 319
DI 10.1016/j.expneurol.2009.09.004
PG 4
WC Neurosciences
SC Neurosciences & Neurology
GA 528FV
UT WOS:000272428700014
PM 19751724
OA green_accepted
DA 2018-03-20
ER

PT J
AU Howard, MD
   Lu, XL
   Rinehart, JJ
   Jay, M
   Dziubla, TD
AF Howard, Melissa D.
   Lu, Xiuling
   Rinehart, John J.
   Jay, Michael
   Dziubla, Thomas D.
TI Carboxylesterase-Triggered Hydrolysis of Nanoparticle PEGylating Agents
SO LANGMUIR
LA English
DT Article
ID SOLID LIPID NANOPARTICLES; DRUG-DELIVERY SYSTEMS; OF-THE-ART; IN-VITRO;
   ANTIINFLAMMATORY AGENTS; CHEMOTHERAPY ADJUVANTS; PROTEIN ADSORPTION;
   SLN; STABILITY; LIPOSOMES
AB Despite the importance of PEGylation in achieving long nanoparticle circulation times, many nanoparticles are coated with PEGylating agents susceptible to enzymatic degradation. In this study, solid lipid nanoparticles (SLNs) prepared with ester-containing compounds were evaluated for their stability in the presence of carboxylesterase. SLN suspensions became turbid within 30 min of enzymatic exposure, indicating possible disassociation of a portion of the nanoparticles. The particle size of SLNs incubated with the enzyme was smaller than the size of controls, although their morphologies appeared similar in transmission electron microscopy images. Although SLNs offered some protection over micelles, PEG6000 monostearate was rapidly degraded within 15 min. Hydrolysis of polysorbate 60 was much slower, reaching only 36% in 2 h. These studies reveal the importance of confirming the stability of PEG surface coatings prior to undertaking in vivo experiments in small animal models, which can have considerably higher plasma esterase activity than humans.
C1 [Dziubla, Thomas D.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Howard, Melissa D.] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
   [Lu, Xiuling] Univ Connecticut, Sch Pharm, Dept Pharmaceut Sci, Storrs, CT 06269 USA.
   [Jay, Michael] Univ N Carolina, Eshelman Sch Pharm, Div Mol Pharmaceut, Chapel Hill, NC 27599 USA.
   [Jay, Michael] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
   [Rinehart, John J.] Univ Kentucky, Lucille P Markey Canc Ctr, Div Hematol Oncol Blood & Marrow Transplantat, Lexington, KY 40536 USA.
   [Rinehart, John J.] Univ Kentucky, Expt Therapeut Program, Lexington, KY 40536 USA.
RP Dziubla, TD (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 F Paul Anderson Tower, Lexington, KY 40506 USA.
EM dziubla@engr.uky.edu
FU NSF IGERT [DGE-0653710]; Philanthropic Educational Organization;
   University of Kentucky
FX We thank Dr. Paul Bummer for the use of the pH-stat and Dr. Younsoo Bae
   for the use of the SEC system. This work was supported by Grant
   DGE-0653710 from the NSF IGERT program, Philanthropic Educational
   Organization Scholar Award, and a University of Kentucky Dissertation
   Year Fellowship (M.D.H.).
CR ALLEN TM, 1994, ADV DRUG DELIVER REV, V13, P285, DOI 10.1016/0169-409X(94)90016-7
   Auguste DT, 2006, BIOMATERIALS, V27, P2599, DOI 10.1016/j.biomaterials.2005.08.036
   AURIOLA SOK, 1993, J PHARMACEUT BIOMED, V11, P1027, DOI 10.1016/0731-7085(93)80065-9
   Chen DB, 2001, CHEM PHARM BULL, V49, P1444, DOI 10.1248/cpb.49.1444
   Choi KY, 2011, BIOMATERIALS, V32, P1880, DOI 10.1016/j.biomaterials.2010.11.010
   Chow TH, 2009, J NUCL MED, V50, P2073, DOI 10.2967/jnumed.109.063503
   Dong X., 2009, CANCER RES, V21, P21
   Du H, 1997, BBA-BIOMEMBRANES, V1326, P236, DOI 10.1016/S0005-2736(97)00027-8
   Fundaro A, 2000, PHARMACOL RES, V42, P337, DOI 10.1006/phrs.2000.0695
   Hamidi M, 2006, DRUG DELIV, V13, P399, DOI 10.1080/10717540600814402
   Harris TJ, 2006, ANGEW CHEM INT EDIT, V45, P3161, DOI 10.1002/anie.200600259
   Howard MD, 2008, J BIOMED NANOTECHNOL, V4, P133, DOI 10.1166/jbn.2008.021
   Howard MD, 2011, LANGMUIR, V27, P1964, DOI 10.1021/la104262k
   Jia LJ, 2012, INT J BIOL MACROMOL, V50, P523, DOI 10.1016/j.ijbiomac.2012.01.024
   Kim DW, 2007, ANN ONCOL, V18, P2009, DOI 10.1093/annonc/mdm374
   Kirpotin D, 1996, FEBS LETT, V388, P115, DOI 10.1016/0014-5793(96)00521-2
   Li B, 2005, BIOCHEM PHARMACOL, V70, P1673, DOI 10.1016/j.bcp.2005.09.002
   Liederer BM, 2005, J PHARM SCI-US, V94, P2198, DOI 10.1002/jps.20452
   Lu XL, 2008, AAPS J, V10, P133, DOI 10.1208/s12248-008-9013-z
   Lu XL, 2009, AAPS J, V11, P120, DOI 10.1208/s12248-009-9086-3
   McPherson T, 1998, LANGMUIR, V14, P176, DOI 10.1021/la9706781
   Morel S, 1998, EUR J PHARM BIOPHARM, V45, P157, DOI 10.1016/S0939-6411(97)00107-0
   Morton CL, 2005, CANCER CHEMOTH PHARM, V56, P629, DOI 10.1007/s00280-005-1027-y
   Muller RH, 2000, EUR J PHARM BIOPHARM, V50, P161, DOI 10.1016/S0939-6411(00)00087-4
   Mumper RJ, 2003, J DISPER SCI TECHNOL, V24, P569, DOI 10.1081/DIS-120021814
   Neal JC, 1998, J PHARM SCI, V87, P1242, DOI 10.1021/js970462j
   Pan H, 2007, PHARM RES, V24, P2270, DOI 10.1007/s11095-007-9449-3
   PARR MJ, 1994, BBA-BIOMEMBRANES, V1195, P21, DOI 10.1016/0005-2736(94)90004-3
   Rasband W, 1997, IMAGEJ
   Romberg B, 2008, PHARM RES, V25, P55, DOI 10.1007/s11095-007-9348-7
   Satoh T, 1998, ANNU REV PHARMACOL, V38, P257, DOI 10.1146/annurev.pharmtox.38.1.257
   Su ZG, 2011, MOL PHARMACEUT, V8, P1641, DOI 10.1021/mp100463n
   Sun HL, 2009, BIOMATERIALS, V30, P6358, DOI 10.1016/j.biomaterials.2009.07.051
   Uner M, 2007, INT J NANOMED, V2, P289
   Vonarbourg A, 2006, BIOMATERIALS, V27, P4356, DOI 10.1016/j.biomaterials.2006.03.039
   WHITE KN, 1987, BIOCHEM PHARMACOL, V36, P2687, DOI 10.1016/0006-2952(87)90553-3
   Xu G, 2002, CLIN CANCER RES, V8, P2605
   Xu H, 2008, J CONTROL RELEASE, V130, P238, DOI 10.1016/j.jconrel.2008.05.009
   Zabaleta V, 2007, J PHARMACEUT BIOMED, V44, P1072, DOI 10.1016/j.jpba.2007.05.006
   Zhang ZP, 2008, PHARM RES-DORDR, V25, P1925, DOI 10.1007/s11095-008-9611-6
   Zhu D, 2008, INVEST RADIOL, V43, P129, DOI 10.1097/RLI.0b013e31815878dd
NR 41
TC 6
Z9 6
U1 0
U2 21
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0743-7463
J9 LANGMUIR
JI Langmuir
PD AUG 21
PY 2012
VL 28
IS 33
BP 12030
EP 12037
DI 10.1021/la302144r
PG 8
WC Chemistry, Multidisciplinary; Chemistry, Physical; Materials Science,
   Multidisciplinary
SC Chemistry; Materials Science
GA 991IX
UT WOS:000307695800010
PM 22830432
DA 2018-03-20
ER

PT J
AU Bhattacharyya, D
   Smuleac, V
   Xiao, L
   Lewis, S
AF Bhattacharyya, Dibakar
   Smuleac, Vasile
   Xiao, Li
   Lewis, Scott R.
TI Responsive membrane materials for toxic metal sorption at high capacity
   and environmental catalysis
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
CT 11th International Biorelated Polymer Symposium / 243rd National Spring
   Meeting of the American-Chemical-Society (ACS)
CY MAR 25-29, 2012
CL San Diego, CA
SP Amer Chem Soc, Div Polymer Chem Inc, Amer Chem Soc
C1 [Bhattacharyya, Dibakar; Smuleac, Vasile; Xiao, Li; Lewis, Scott] Univ Kentucky, Lexington, KY 40506 USA.
EM db@engr.uky.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD MAR 25
PY 2012
VL 243
MA 179-ENVR
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA 219AH
UT WOS:000324475104963
DA 2018-03-19
ER

PT J
AU Gupta, P
   Jordan, CT
   Mitov, MI
   Butterfield, DA
   Hilt, JZ
   Dziubla, TD
AF Gupta, Prachi
   Jordan, Carolyn T.
   Mitov, Mihail I.
   Butterfield, D. Allan
   Hilt, J. Zach
   Dziubla, Thomas D.
TI Controlled curcumin release via conjugation into PBAE nanogels enhances
   mitochondrial protection against oxidative stress
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Curcumin release; Poly(beta-amino esters); Nanogels; Seahorse bioscience
   XF96
ID ALZHEIMERS-DISEASE; TARGETED ANTIOXIDANTS; LIPID-PEROXIDATION; OBESE
   MICE; RAT-BRAIN; DYSFUNCTION; INFLAMMATION; INHIBITION; PATHWAYS;
   ESTERS)
AB Mitochondria are considered to be the "power plants" of the cell, but can also initiate and execute cell death, stimulated by oxidative stress (OS). OS induced mitochondria] dysfunction is characterized by a loss in oxygen consumption and reduced ATP production. Curcumin, as a potential therapeutic, has been explored as a candidate for mitochondrial OS suppression, but rapid metabolism and aqueous insolubility has prevented it from being effective. Further, efficient delivery of curcumin via the incorporation into nanocarriers has again been limited due to low drug loading capacities and/or significant burst release, resulting in acute cytotoxicity. Hence, to increase the therapeutic potential and reduce the toxic effects of curcumin, curcumin conjugated poly(beta-amino ester) nanogels (CNGs) were synthesized using Michael addition chemistry. This approach provided easy control over the nanogel size, with CNGs showing a uniform release of active curcumin over 48 h with no burst release. This controlled release system significantly increased the safety limit for curcumin, with a ten fold increase in the cytotoxic threshold, as compared to free curcumin. Further, real-time mitochondrial response analysis with the Seahorse XF96 showed effective and prolonged suppression of H2O2 induced mitochondrial oxidative stress upon pre-treating endothelial cells with CNGs and this potential of nanogels was studied at different pre-treatment times prior to H2O2 exposure. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Gupta, Prachi; Jordan, Carolyn T.; Hilt, J. Zach; Dziubla, Thomas D.] Univ Kentucky, Dept Chem & Mat Engn, F Paul Anderson Tower,512 Adm Dr, Lexington, KY 40506 USA.
   [Mitov, Mihail I.; Butterfield, D. Allan] Univ Kentucky, Markey Canc Ctr, Redox Metab Shared Resource Facil, 1095 VA Dr,Hlth Sci Res Bldg,Room 227, Lexington, KY 40536 USA.
   [Butterfield, D. Allan] Univ Kentucky, Dept Chem, Chem Phys Bldg, Lexington, KY 40506 USA.
RP Dziubla, TD (reprint author), Univ Kentucky, Dept Chem & Mat Engn, F Paul Anderson Tower,512 Adm Dr, Lexington, KY 40506 USA.
EM dziubla@engr.uky.edu
FU National Center for Research Resources; National Center for Advancing
   Translational Sciences, National Institutes of Health [UL1TR000117];
   National Institute of Dental and Craniofacial Research, National
   Institutes of Health [R43 DE02352301]; National Cancer Institute [P30
   CA177558]
FX This publication was supported in part by the National Center for
   Research Resources and the National Center for Advancing Translational
   Sciences, National Institutes of Health, through Grant UL1TR000117, by
   the National Institute of Dental and Craniofacial Research, National
   Institutes of Health through Grant R43 DE02352301, and by the National
   Cancer Institute grant P30 CA177558 (for RM SRF resource facilities).
   The content is solely the responsibility of the authors and does not
   necessarily represent the official views of the NIH.
CR Anand P, 2010, BIOCHEM PHARMACOL, V79, P330, DOI 10.1016/j.bcp.2009.09.003
   Basta G, 2005, ARTERIOSCL THROM VAS, V25, P1401, DOI 10.1161/01.ATV.0000167522.48370.5e
   Butterfield DA, 2014, BBA-MOL BASIS DIS, V1842, P1693, DOI 10.1016/j.bbadis.2014.06.010
   Chen Q, 2003, J BIOL CHEM, V278, P36027, DOI 10.1074/jbc.M304854200
   Drose S, 2012, ADV EXP MED BIOL, V748, P145, DOI 10.1007/978-1-4614-3573-0_6
   Fariss MW, 2005, MOL INTERV, V5, P94, DOI 10.1124/mi.5.2.7
   Federico A, 2012, J NEUROL SCI, V322, P254, DOI 10.1016/j.jns.2012.05.030
   Garcea G, 2004, BRIT J CANCER, V90, P1011, DOI 10.1038/sj.bjc.6601623
   Graham D, 2009, HYPERTENSION, V54, P322, DOI 10.1161/HYPERTENSIONAHA.109.130351
   Gupta P, 2015, ACTA BIOMATER, V27, P194, DOI 10.1016/j.actbio.2015.08.039
   Hirzel E, 2013, J RECEPT SIG TRANSD, V33, P304, DOI 10.3109/10799893.2013.822887
   Hsieh HL, 2013, BIOMED RES INT, DOI 10.1155/2013/484613
   Huang HC, 2012, J ALZHEIMERS DIS, V32, P981, DOI 10.3233/JAD-2012-120688
   Huang SXL, 2012, ENVIRON HEALTH PERSP, V120, P840, DOI 10.1289/ehp.1104287
   Ichikawa Y, 2014, J CLIN INVEST, V124, P617, DOI 10.1172/JCI72931
   Kuo JJ, 2012, INT J MOL MED, V30, P673, DOI 10.3892/ijmm.2012.1049
   Madrigal JLM, 2001, NEUROPSYCHOPHARMACOL, V24, P420, DOI 10.1016/S0893-133X(00)00208-6
   Marchi S., 2012, J SIGNAL TRANSDUCT, V2012, P2012, DOI DOI 10.1155/2012/329635
   Maritim AC, 2003, J BIOCHEM MOL TOXIC, V17, P24, DOI 10.1002/jbt.10058
   Martinez-Morua A, 2013, J ASIAN NAT PROD RES, V15, P905, DOI 10.1080/10286020.2013.802687
   Mishra S, 2008, ANN INDIAN ACAD NEUR, V11, P13, DOI 10.4103/0972-2327.40220
   Orrenius S, 2007, ANNU REV PHARMACOL, V47, P143, DOI 10.1146/annurev.pharmtox.47.120505.105122
   Reily C, 2013, REDOX BIOL, V1, P86, DOI 10.1016/j.redox.2012.11.009
   Reuter S, 2010, FREE RADICAL BIO MED, V49, P1603, DOI 10.1016/j.freeradbiomed.2010.09.006
   Ringman JM, 2012, ALZHEIMERS RES THER, V4, DOI 10.1186/alzrt146
   Robin J., 2011, DISCOV MED, V11, P106
   Rolo AP, 2006, TOXICOL APPL PHARM, V212, P167, DOI 10.1016/j.taap.2006.01.003
   Sheu SS, 2006, BBA-MOL BASIS DIS, V1762, P256, DOI 10.1016/j.bbadis.2005.10.007
   Smith RAJ, 2008, ANN NY ACAD SCI, V1147, P105, DOI 10.1196/annals.1427.003
   Sood PK, 2011, NEUROTOX RES, V20, P351, DOI 10.1007/s12640-011-9249-8
   Swomley AM, 2014, BBA-MOL BASIS DIS, V1842, P1248, DOI 10.1016/j.bbadis.2013.09.015
   Tapia E, 2014, FREE RADICAL RES, V48, P1342, DOI 10.3109/10715762.2014.954109
   Trujillo J, 2013, REDOX BIOL, V1, P448, DOI 10.1016/j.redox.2013.09.003
   Victor VM, 2009, CURR MED CHEM, V16, P4654, DOI 10.2174/092986709789878265
   Wattamwar PP, 2012, ACTA BIOMATER, V8, P2529, DOI 10.1016/j.actbio.2012.03.022
   Wattamwar PP, 2010, ADV FUNCT MATER, V20, P147, DOI 10.1002/adfm.200900839
   Zang QS, 2012, AM J PHYSIOL-HEART C, V302, pH1847, DOI 10.1152/ajpheart.00203.2011
   Zhang L, 2006, J ALZHEIMERS DIS, V10, P1
   Zhong HQ, 2015, REDOX BIOL, V4, P193, DOI 10.1016/j.redox.2014.12.011
   Zhu YG, 2004, ACTA PHARMACOL SIN, V25, P1606
NR 40
TC 0
Z9 0
U1 2
U2 13
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
EI 1873-3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD SEP 25
PY 2016
VL 511
IS 2
BP 1012
EP 1021
DI 10.1016/j.ijpharm.2016.07.071
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA DW7DD
UT WOS:000383810500032
PM 27492022
OA green_accepted
DA 2018-03-20
ER

PT J
AU Hamza, A
   Wagner, JM
   Evans, TJ
   Frasinyuk, MS
   Kwiatkowski, S
   Zhan, CG
   Watt, DS
   Korotkov, KV
AF Hamza, Adel
   Wagner, Jonathan M.
   Evans, Timothy J.
   Frasinyuk, Mykhaylo S.
   Kwiatkowski, Stefan
   Zhan, Chang-Guo
   Watt, David S.
   Korotkov, Konstantin V.
TI Novel Mycosin Protease MycP(1) Inhibitors Identified by Virtual
   Screening and 4D Fingerprints
SO JOURNAL OF CHEMICAL INFORMATION AND MODELING
LA English
DT Article
ID TUBERCULOSIS DRUG DISCOVERY; VII SECRETION SYSTEM;
   MYCOBACTERIUM-TUBERCULOSIS; CONFORMER GENERATION; SCORING FUNCTION;
   DOCKING; SHAPE; GLYCOSYLATION; PERSPECTIVE; VALIDATION
AB The rise of drug-resistant Mycobacterium tuberculosis lends urgency to the need for new drugs for the treatment of tuberculosis (TB). The identification of a serine protease, mycosin protease-1 (MycP(1)), as the crucial agent in hydrolyzing the virulence factor, ESX-secretion-associated protein B (EspB), potentially opens the door to new tuberculosis treatment options. Using the crystal structure of mycobacterial MycP, in the apo form, we performed an iterative ligand- and structure-based virtual screening (VS) strategy to identify novel, nonpeptide, small-molecule inhibitors against MycP(1) protease. Screening of similar to 485 000 ligands from databases at the Genomics Research Institute (GRI) at the University of Cincinnati and the National Cancer Institute (NCI) using our VS approach, which integrated a pharmacophore model and consensus molecular shape patterns of active ligands (4D fingerprints), identified 81 putative inhibitors, and in vitro testing subsequently confirmed two of them as active inhibitors. Thereafter, the lead structures of each VS round were used to generate a new 4D fingerprint that enabled virtual rescreening of the chemical libraries. Finally, the iterative process identified a number of diverse scaffolds as lead compounds that were tested and found to have micromolar IC50 values against the MycP(1) target. This study validated the efficiency of the SABRE 4D fingerprints as a means of identifying novel lead compounds in each screening round of the databases. Together, these results underscored the value of using a combination of in silico iterative ligand- and structure-based virtual screening of chemical libraries with experimental validation for the identification of promising structural scaffolds, such as the MycP(1) inhibitors.
C1 [Hamza, Adel; Wagner, Jonathan M.; Evans, Timothy J.; Frasinyuk, Mykhaylo S.; Kwiatkowski, Stefan; Watt, David S.; Korotkov, Konstantin V.] Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA.
   [Hamza, Adel; Wagner, Jonathan M.; Evans, Timothy J.; Korotkov, Konstantin V.] Univ Kentucky, Struct Biol Ctr, Lexington, KY 40536 USA.
   [Zhan, Chang-Guo; Watt, David S.] Univ Kentucky, Dept Pharmaceut Sci, Coll Pharm, Lexington, KY 40536 USA.
   [Frasinyuk, Mykhaylo S.; Kwiatkowski, Stefan; Zhan, Chang-Guo; Watt, David S.] Univ Kentucky, Ctr Pharmaceut Res & Innovat, Lexington, KY 40536 USA.
   [Frasinyuk, Mykhaylo S.] Inst Bioorgan Chem & Petrochem, UA-02660 Kiev 94, Ukraine.
RP Korotkov, KV (reprint author), Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA.
EM kkorotkov@uky.edu
OI Wagner, Jonathan M./0000-0001-9161-7222; Korotkov,
   Konstantin/0000-0002-2182-6843; Frasinyuk, Mykhaylo/0000-0003-3133-601X
FU National Institute of General Medical Sciences [P20GM103486]; NIH/NIGMS
   [P20GM103486]
FX The authors thank Professors Jurgen Bosch at the Johns Hopkins
   University and Jon Thorson at the University of Kentucky for valuable
   discussions. We acknowledge the Drug Synthesis and Chemistry Branch of
   National Cancer Institute for supplying most of the compounds used in
   the virtual screening and testing. We thank the University of Kentucky
   Information Technology department and Center for Computational Sciences
   for computing time on the Lipscomb High Performance Computing Cluster.
   We acknowledge the University of Kentucky Organic Synthesis Core that is
   partially supported by grant P20GM103486 from the National Institute of
   General Medical Sciences (to D.S.W.). This study was supported by
   NIH/NIGMS grant P20GM103486 (to K.V.K.), and its contents are solely the
   responsibility of the authors and do not necessarily represent the
   official views of the NIH or the NIGMS.
CR Arcus VL, 2006, DRUG DISCOV TODAY, V11, P28, DOI 10.1016/S1359-6446(05)03667-6
   Bottai D., 2013, CURR PHARM DESIGN, DOI [10.2174/1381612819666131118170717, DOI 10.2174/1381612819666131118170717]
   Brooks WH, 2007, J CHEM INF MODEL, V47, P1897, DOI 10.1021/ci700005t
   Brown GD, 2000, GENE, V254, P147, DOI 10.1016/S0378-1119(00)00277-8
   Chen JM, 2013, MOL MICROBIOL, V89, P1154, DOI 10.1111/mmi.12336
   Chen JM, 2010, DRUG DISCOV TODAY DI, V7, pe25
   Coupez B, 2006, CURR MED CHEM, V13, P2995, DOI 10.2174/092986706778521797
   Dave JA, 2002, BMC MICROBIOL, V2, DOI 10.1186/1471-2180-2-30
   Dror O, 2009, J CHEM INF MODEL, V49, P2333, DOI 10.1021/ci900263d
   Hamza A, 2013, J BIOMOL STRUCT DYN, V31, P1236, DOI 10.1080/07391102.2012.732341
   Hamza A, 2012, J CHEM INF MODEL, V52, P963, DOI 10.1021/ci200617d
   Hamza A, 2011, BIOORGAN MED CHEM, V19, P6077, DOI 10.1016/j.bmc.2011.08.040
   Hawkins PCD, 2012, J CHEM INF MODEL, V52, P2919, DOI 10.1021/ci300314k
   Hawkins PCD, 2010, J CHEM INF MODEL, V50, P572, DOI 10.1021/ci100031x
   Houben ENG, 2014, BBA-MOL CELL RES, V1843, P1707, DOI 10.1016/j.bbamcr.2013.11.003
   Irwin JJ, 2005, J CHEM INF MODEL, V45, P177, DOI 10.1021/ci049714+
   Kitchen DB, 2004, NAT REV DRUG DISCOV, V3, P935, DOI 10.1038/nrd1549
   Kolb P, 2009, CURR OPIN BIOTECH, V20, P429, DOI 10.1016/j.copbio.2009.08.003
   Kolb P, 2009, CURR TOP MED CHEM, V9, P755, DOI 10.2174/156802609789207091
   Koul A, 2011, NATURE, V469, P483, DOI 10.1038/nature09657
   Leach AR, 2006, J MED CHEM, V49, P5851, DOI 10.1021/jm060999m
   Mavridis L, 2007, J CHEM INF MODEL, V47, P1787, DOI 10.1021/ci7001507
   McLaughlin B, 2007, PLOS PATHOG, V3, P1051, DOI 10.1371/journal.ppat.0030105
   MCPHALEN CA, 1988, BIOCHEMISTRY-US, V27, P6582, DOI 10.1021/bi00417a058
   Mdluli K, 2006, CURR OPIN PHARMACOL, V6, P459, DOI 10.1016/j.coph.2006.06.004
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33
   Ohol YM, 2010, CELL HOST MICROBE, V7, P210, DOI 10.1016/j.chom.2010.02.006
   [Anonymous], OMEGA VERS 2 5 1
   Reddy AS, 2007, CURR PROTEIN PEPT SC, V8, P329
   Rester U, 2008, CURR OPIN DRUG DISC, V11, P559
   Roberts DM, 2013, FUTURE MICROBIOL, V8, P621, DOI [10.2217/FMB.13.25, 10.2217/fmb.13.25]
   Simeone R, 2009, CURR OPIN MICROBIOL, V12, P4, DOI 10.1016/j.mib.2008.11.003
   Solomonson M, 2013, J BIOL CHEM, V288, P17782, DOI 10.1074/jbc.M113.462036
   Sorna V, 2013, J MED CHEM, V56, P9496, DOI 10.1021/jm400870h
   Stambouli N, 2014, J BIOMOL STRUCT DYN, V32, P1202, DOI 10.1080/07391102.2013.819297
   Stambouli N, 2014, J BIOMOL STRUCT DYN, V32, P866, DOI 10.1080/07391102.2013.794373
   Stoop EJM, 2012, TRENDS MICROBIOL, V20, P477, DOI 10.1016/j.tim.2012.07.001
   Sun DM, 2013, PROTEIN CELL, V4, P921, DOI 10.1007/s13238-013-3089-7
   Svensson F, 2012, J CHEM INF MODEL, V52, P225, DOI 10.1021/ci2004835
   Taylor RD, 2002, J COMPUT AID MOL DES, V16, P151, DOI 10.1023/A:1020155510718
   Vainio MJ, 2009, J CHEM INF MODEL, V49, P492, DOI 10.1021/ci800315d
   Wagner JM, 2013, J STRUCT BIOL, V184, P115, DOI 10.1016/j.jsb.2013.09.022
   Wei NN, 2014, J CHEM INF MODEL, V54, P338, DOI 10.1021/ci4005496
   [Anonymous], 2013, WHO GLOB TUB REP
   Xu J, 2007, MOL MICROBIOL, V66, P787, DOI 10.1111/j.1365-2958.2007.05959.x
   Yan X, 2013, J CHEM INF MODEL, V53, P1967, DOI 10.1021/ci300601q
   Yang WC, 2012, BIOORG MED CHEM LETT, V22, P1629, DOI 10.1016/j.bmcl.2011.12.121
   Zhang W, 2013, ACS CHEM BIOL, V8, P796, DOI 10.1021/cb3005353
   Zhao QJ, 2011, CRIT REV EUKAR GENE, V21, P347, DOI 10.1615/CritRevEukarGeneExpr.v21.i4.50
   Zhou MQ, 2013, J NAT PROD, V76, P279, DOI 10.1021/np300890h
   Zhou MQ, 2012, ORG LETT, V14, P5424, DOI 10.1021/ol3024924
NR 51
TC 6
Z9 6
U1 4
U2 25
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1549-9596
EI 1549-960X
J9 J CHEM INF MODEL
JI J. Chem Inf. Model.
PD APR
PY 2014
VL 54
IS 4
BP 1166
EP 1173
DI 10.1021/ci500025r
PG 8
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Computer Science,
   Information Systems; Computer Science, Interdisciplinary Applications
SC Pharmacology & Pharmacy; Chemistry; Computer Science
GA AG1UH
UT WOS:000335201200014
PM 24628123
OA gold
DA 2018-03-20
ER

PT J
AU Towler, CS
   Li, TL
   Wikstrom, H
   Remick, DM
   Sanchez-Felix, MV
   Taylor, LS
AF Towler, Christopher S.
   Li, Tonglei
   Wikstroem, Hakan
   Remick, David M.
   Sanchez-Felix, Manuel V.
   Taylor, Lynne S.
TI An Investigation into the Influence of Counterion on the Properties of
   Some Amorphous Organic Salts
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE Amorphous; salts; glass transition; pK(a); counterion
ID DENSITY-FUNCTIONAL THEORY; MULTIVARIATE CALIBRATION-PROBLEM;
   GLASS-TRANSITION TEMPERATURES; FRONTIER-CONTROLLED REACTIONS;
   ACTIVITY-RELATIONSHIPS QSAR; CHEMICAL-REACTIVITY; SOLID DISPERSIONS;
   PHARMACEUTICAL SYSTEMS; ELECTRONIC-STRUCTURE; DISSOLUTION RATE
AB Amorphous solids and crystalline salts are both of interest as a means of improving the dissolution characteristics and apparent solubility of poorly water soluble active pharmaceutical ingredients which have low bioavailability in humans. The theory and selection of both crystalline drug substance salt forms and amorphous products have been extensively studied. However, less is known about the impact of different counterions on the properties of amorphous drug substance salts. In this study, several salts of either nicardipine or propranolol were prepared and characterized with respect to glass transition temperature, crystallization tendency and moisture sorption behavior. Although the moisture sorption behavior and crystallization tendency varied depending on the counterion used, no trends were readily apparent. The glass transition temperature was found to be dependent on the counterion used to form the salt, and was higher in all instances for the salts than for the neutral compound. Several molecular descriptors were calculated for the various counterions, and multivariate analysis was used to build a model that successfully correlated T-g with a number of these parameters. Important parameters which influenced T-g included counterion pK(a) and electrophilicity index. In conclusion, it is apparent that, as for crystalline salts, the counterion has an effect on the properties of amorphous materials.
C1 [Towler, Christopher S.; Wikstroem, Hakan; Taylor, Lynne S.] Purdue Univ, Dept Ind & Phys Pharm, W Lafayette, IN 47907 USA.
   [Li, Tonglei] Univ Kentucky, Coll Pharm, Lexington, KY 40536 USA.
   [Remick, David M.; Sanchez-Felix, Manuel V.] Eli Lilly & Co, Pharmaceut Sci Res & Dev, Indianapolis, IN 46285 USA.
RP Taylor, LS (reprint author), Purdue Univ, Dept Ind & Phys Pharm, 575 Stadium Mall Dr, W Lafayette, IN 47907 USA.
EM ltaylor@pharmacy.purdue.edu
OI Taylor, Lynne/0000-0002-4568-6021; Sanchez-Felix,
   Manuel/0000-0003-3960-9713
FU AstraZeneca RD Molndal
FX C.S.T. wishes to thank Eli Lilly for funding. H.W. acknowledges
   AstraZeneca R&D Molndal for funding. Pete Guerrieri is gratefully
   acknowledged for help with data collection.
CR AHLNECK C, 1990, INT J PHARM, V62, P87, DOI 10.1016/0378-5173(90)90221-O
   Alba-Simionesco C, 1999, J CHEM PHYS, V110, P5262, DOI 10.1063/1.478800
   Anderson JSM, 2007, J CHEM THEORY COMPUT, V3, P358, DOI 10.1021/ct600164j
   Avdeef A., 2003, ADSORPTION DRUG DEV
   Ayers PW, 2000, THEOR CHEM ACC, V103, P353, DOI 10.1007/s002149900093
   Ayers P. W., 2006, J CHEM PHYS, V124
   Basavoju S, 2006, CRYST GROWTH DES, V6, P2699, DOI 10.1021/cg060327x
   BECKE AD, 1988, PHYS REV A, V38, P3098, DOI 10.1103/PhysRevA.38.3098
   BERGE SM, 1977, J PHARM SCI, V66, P1, DOI 10.1002/jps.2600660104
   BERKOWITZ M, 1987, J AM CHEM SOC, V109, P4823, DOI 10.1021/ja00250a012
   CHATTARAJ PK, 1991, J AM CHEM SOC, V113, P1855, DOI 10.1021/ja00005a073
   CHIOU WL, 1971, J PHARM SCI-US, V60, P1281, DOI 10.1002/jps.2600600902
   CONSANI K, 1981, J CHEM PHYS, V74, P4774, DOI 10.1063/1.441756
   DUNN WJ, 1989, CHEMOMETR INTELL LAB, V6, P181, DOI 10.1016/0169-7439(89)80083-8
   EISENBERG A, 1970, RUBBER CHEM TECHNOL, V43, P156
   EISENBERG A, 1966, PROG SOLID STATE CHE, P407
   ERIKSSON L, 2001, MULTI MEGAVARIATE DA, P329
   EXARHOS GJ, 1974, J CHEM PHYS, V60, P4145, DOI 10.1063/1.1680881
   [Anonymous], 2004, GAUSS 03
   Geerlings P, 2003, CHEM REV, V103, P1793, DOI 10.1021/cr990029p
   Gift AD, 2007, J PHARMACEUT BIOMED, V43, P14, DOI 10.1016/j.jpba.2006.06.025
   GOULD PL, 1986, INT J PHARM, V33, P201, DOI 10.1016/0378-5173(86)90055-4
   Hancock BC, 2000, PHARMACEUT RES, V17, P397, DOI 10.1023/A:1007516718048
   Hancock BC, 1997, J PHARM SCI, V86, P1, DOI 10.1021/js9601896
   Hancock BC, 2002, INT J PHARM, V241, P73, DOI 10.1016/S0378-5173(02)00133-3
   HELLBERG S, 1986, ACTA CHEM SCAND B, V40, P135, DOI 10.3891/acta.chem.scand.40b-0135
   HIGUCHI WI, 1967, J PHARM SCI, V56, P200, DOI 10.1002/jps.2600560210
   HOHENBERG P, 1964, PHYS REV B, V136, pB864, DOI 10.1103/PhysRev.136.B864
   KAUSHAL AM, 2004, CRIT REV THER DRUG, V21, P113
   KLOPMAN G, 1968, J AM CHEM SOC, V90, P223, DOI 10.1021/ja01004a002
   Kohn W, 1996, J PHYS CHEM-US, V100, P12974, DOI 10.1021/jp960669l
   LEE CT, 1988, PHYS REV B, V37, P785, DOI 10.1103/PhysRevB.37.785
   Leuner C, 2000, EUR J PHARM BIOPHARM, V50, P47, DOI 10.1016/S0939-6411(00)00076-X
   Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1
   Lipinski CA, 2000, J PHARMACOL TOXICOL, V44, P235, DOI 10.1016/S1056-8719(00)00107-6
   Muller RH, 2001, ADV DRUG DELIVER REV, V47, P3, DOI 10.1016/S0169-409X(00)00118-6
   Parr RG, 1999, J AM CHEM SOC, V121, P1922, DOI 10.1021/ja983494x
   PARR RG, 1983, J AM CHEM SOC, V105, P7512, DOI 10.1021/ja00364a005
   PARR RG, 1978, J CHEM PHYS, V68, P3801, DOI 10.1063/1.436185
   PARR RG, 1995, ANNU REV PHYS CHEM, V46, P701, DOI 10.1146/annurev.pc.46.100195.003413
   PARR RG, 1984, J AM CHEM SOC, V106, P4049, DOI 10.1021/ja00326a036
   PEARSON RG, 1963, J AM CHEM SOC, V85, P3533, DOI 10.1021/ja00905a001
   PEARSON RG, 1966, SCIENCE, V151, P172, DOI 10.1126/science.151.3707.172
   Serajuddin ATM, 2007, ADV DRUG DELIVER REV, V59, P603, DOI 10.1016/j.addr.2007.05.010
   Serajuddin ATM, 1999, J PHARM SCI, V88, P1058, DOI 10.1021/js980403l
   SERAJUDDIN ATM, 1990, J PHARM SCI, V79, P463, DOI 10.1002/jps.2600790524
   SIMONELLI AP, 1976, J PHARM SCI, V65, P355, DOI 10.1002/jps.2600650310
   Singhal D, 2004, ADV DRUG DELIVER REV, V56, P335, DOI 10.1016/j.addr.2003.10.008
   SJOSTROM M, 1983, ANAL CHIM ACTA, V150, P61, DOI 10.1016/S0003-2670(00)85460-4
   Tong P, 2002, PHARMACEUT RES, V19, P649, DOI 10.1023/A:1015310213887
   Tong P, 1999, PHARM RES-DORDR, V16, P1186, DOI 10.1023/A:1018985110956
   Weuts I, 2005, EUR J PHARM SCI, V25, P387, DOI 10.1016/j.ejps.2005.04.011
   WOLD S, 1983, LECT NOTES MATH, V973, P286
   WOLD S, 1983, J CHEM INF COMP SCI, V23, P6, DOI 10.1021/ci00037a002
   YANG W, 1984, J CHEM PHYS, V81, P2862, DOI 10.1063/1.447964
   YANG WT, 1985, P NATL ACAD SCI USA, V82, P6723, DOI 10.1073/pnas.82.20.6723
   2002, HDB PHARM SALTS
NR 57
TC 22
Z9 22
U1 1
U2 19
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD NOV-DEC
PY 2008
VL 5
IS 6
BP 946
EP 955
DI 10.1021/mp8000342
PG 10
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 378KX
UT WOS:000261320800006
PM 19434850
DA 2018-03-20
ER

PT J
AU Schlipf, DM
   Zhou, SS
   Khan, MA
   Rankin, SE
   Knutson, BL
AF Schlipf, Daniel M.
   Zhou, Shanshan
   Khan, M. Arif
   Rankin, Stephen E.
   Knutson, Barbara L.
TI Effects of Pore Size and Tethering on the Diffusivity of Lipids Confined
   in Mesoporous Silica
SO ADVANCED MATERIALS INTERFACES
LA English
DT Article
ID FLUORESCENCE RECOVERY; SUPPORTED MEMBRANES; BILAYER MEMBRANES; LATERAL
   DIFFUSION; PHASE; MODEL; ADSORPTION; DELIVERY; PROTEIN; RECONSTITUTION
AB Incorporation of lipid assemblies on the surface and within pores of mesoporous silica particles provides for biomimetic approaches to analyte sensing and separations using high surface area platforms. This work investigates the effect of pore confinement on the location and the diffusivity of lipid assemblies in mesoporous silica spherical particles (SBAS) as a function of nanopore diameters (nonporous, 3.0, 5.4, and 9.1 nm), which span the range of the thickness of the 1,2-dipalmitoyl-sn-glycero-3-phosphocholine lipid bilayer (approximate to 4 nm). Large-diameter SBAS are imaged with sufficient spatial resolution to distinguish lipids at the exterior surface and in the center of the particles. Lipids incorporated on the silica by evaporation deposition exist as exterior lipid bilayers on all particles and lipid assemblies in the pores of 5.4 and 9.1 nm pore diameter materials. Lipid diffusivity increases with pore size and decreases in the presence of bilayer tethering functional groups. Lipid diffusivity in the core of the particles is similar to the surface diffusivity, consistent with long-range mobility in accessible, ordered (but randomly oriented) mesopores of SBAS materials. This work presents a framework for interpreting high density loading of lipid bilayers and their function within mesoporous materials.
C1 [Schlipf, Daniel M.; Zhou, Shanshan; Khan, M. Arif; Rankin, Stephen E.; Knutson, Barbara L.] Univ Kentucky, Dept Chem & Mat Engn, 177 F Paul Anderson Tower, Lexington, KY 40506 USA.
RP Knutson, BL (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 F Paul Anderson Tower, Lexington, KY 40506 USA.
EM bknut2@uky.edu
RI Khan, M. Arif/M-7620-2017
OI Khan, M. Arif/0000-0001-8471-4200
FU National Science Foundation Integrated Graduate Education and Research
   Training (IGERT) program on Bioactive Interfaces and Devices
   [DGE-0653710]; United States Department of Agriculture Biomass Research
   and Development Initiative (BRDI) grant [2011-10006-30363]; Kentucky
   Science and Engineering Foundation [KSEF-2929-RDE-016]; National Science
   Foundation [1355438]; University of Kentucky's Light Microscopy Core
FX This work was supported by the National Science Foundation Integrated
   Graduate Education and Research Training (IGERT) program on Bioactive
   Interfaces and Devices (grant no. DGE-0653710), the United States
   Department of Agriculture Biomass Research and Development Initiative
   (BRDI) grant (award no. 2011-10006-30363), and the Kentucky Science and
   Engineering Foundation (KSEF-2929-RDE-016). Additional particle
   characterization by FIB-SEM and work with nonporous particles was
   supported by National Science Foundation Cooperative Agreement No.
   1355438. The authors thank Jim Begley from the University of Kentucky's
   Light Microscopy Core for his training and support with FRAP
   measurements.
CR Ahmed S, 2011, SOFT MATTER, V7, P1936, DOI 10.1039/c0sm01045f
   Alberius PCA, 2002, CHEM MATER, V14, P3284, DOI 10.1021/cm011209u
   Arai N, 2013, MICROFLUID NANOFLUID, V14, P995, DOI 10.1007/s10404-012-1107-3
   Ashley CE, 2012, ACS NANO, V6, P2174, DOI 10.1021/nn204102q
   Ashley CE, 2011, NAT MATER, V10, P389, DOI [10.1038/NMAT2992, 10.1038/nmat2992]
   BARRETT EP, 1951, J AM CHEM SOC, V73, P373, DOI 10.1021/ja01145a126
   BAYERL TM, 1990, BIOPHYS J, V58, P357, DOI 10.1016/S0006-3495(90)82382-1
   BHAMBHANI MR, 1972, J COLLOID INTERF SCI, V38, P109, DOI 10.1016/0021-9797(72)90226-3
   Bothun GD, 2005, LANGMUIR, V21, P530, DOI 10.1021/la0496542
   Brunauer S, 1938, J AM CHEM SOC, V60, P309, DOI 10.1021/ja01269a023
   Buranda T, 2003, LANGMUIR, V19, P1654, DOI 10.1021/la026405
   Castanho MARB, 2006, EUR BIOPHYS J BIOPHY, V35, P92, DOI 10.1007/s00249-005-0007-9
   Chemburu S, 2010, MOLECULES, V15, P1932, DOI 10.3390/molecules15031932
   Claesson M, 2012, SENSOR ACTUAT B-CHEM, V166, P526, DOI 10.1016/j.snb.2012.03.002
   Claesson M, 2011, LANGMUIR, V27, P8974, DOI 10.1021/la201411b
   Davis RW, 2007, LANGMUIR, V23, P3864, DOI 10.1021/la062576t
   Deverall MA, 2005, BIOPHYS J, V88, P1875, DOI 10.1529/biophysj.104.050559
   Domanov YA, 2011, P NATL ACAD SCI USA, V108, P12605, DOI 10.1073/pnas.1102646108
   Gartmann N, 2009, ANGEW CHEM INT EDIT, V48, P6354, DOI 10.1002/anie.200902436
   Ghosh S, 2010, J PHYS CHEM B, V114, P5736, DOI 10.1021/jp911971p
   Gopalakrishnan G, 2009, LANGMUIR, V25, P5455, DOI 10.1021/la9006982
   Gudmand M, 2009, BIOPHYS J, V96, P4598, DOI 10.1016/j.bpj.2009.01.063
   Heinrich F, 2009, LANGMUIR, V25, P4219, DOI 10.1021/la8033275
   Jackman JA, 2012, MATERIALS, V5, P2637, DOI 10.3390/ma5122637
   Jaroniec M, 1999, LANGMUIR, V15, P5410, DOI 10.1021/la990136e
   Kang M, 2009, HANDB MOD BIOPHYS, V2, P187, DOI 10.1007/978-1-60761-314-5_8
   Katiyar A, 2006, SMALL, V2, P644, DOI 10.1002/smll.200500473
   Kaufmann S, 2003, CHEMPHYSCHEM, V4, P699, DOI 10.1002/cphc.200200537
   Khan MS, 2013, INT J MOL SCI, V14, P21561, DOI 10.3390/ijms141121561
   Kucerka N, 2011, BBA-BIOMEMBRANES, V1808, P2761, DOI 10.1016/j.bbamem.2011.07.022
   LANDE MB, 1995, J GEN PHYSIOL, V106, P67, DOI 10.1085/jgp.106.1.67
   Lebold T, 2012, ADV FUNCT MATER, V22, P106, DOI 10.1002/adfm.201101365
   LINDBLOM G, 1977, BIOPHYS CHEM, V6, P167, DOI 10.1016/0301-4622(77)87006-3
   Liu JW, 2009, J AM CHEM SOC, V131, P1354, DOI 10.1021/ja808018y
   Marrink SJ, 2005, CHEM PHYS LIPIDS, V135, P223, DOI 10.1016/j.chemphyslip.2005.03.001
   Mesa M, 2003, SOLID STATE SCI, V5, P1303, DOI 10.1016/S1293-2558(03)00185-7
   Nakabayashi H, 2010, LANGMUIR, V26, P7512, DOI 10.1021/la904316f
   Nordlund G, 2009, ACS NANO, V3, P2639, DOI 10.1021/nn9005413
   Oliynyk V, 2013, PHYS CHEM CHEM PHYS, V15, P2733, DOI 10.1039/c2cp43166a
   Pande AH, 2005, BIOPHYS J, V88, P4084, DOI 10.1529/biophysj.104.056788
   Pincet F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158457
   Piper-Feldkamp AR, 2013, J PHYS CHEM B, V117, P2113, DOI 10.1021/jp308305y
   Poudel KR, 2012, SOFT MATTER, V8, P11285, DOI 10.1039/c2sm26040a
   Ranall MV, 2011, BIOTECHNIQUES, V51, P35, DOI 10.2144/000113702
   Ratto TV, 2002, BIOPHYS J, V83, P3380, DOI 10.1016/S0006-3495(02)75338-1
   Roder F, 2011, ANAL CHEM, V83, P6792, DOI 10.1021/ac201294v
   Roggers RA, 2012, MOL PHARMACEUT, V9, P2770, DOI 10.1021/mp200613y
   Ross EE, 2008, LANGMUIR, V24, P1629, DOI 10.1021/la7033609
   Ross EE, 2011, LANGMUIR, V27, P8634, DOI 10.1021/la200952c
   Savarala S, 2010, LANGMUIR, V26, P12081, DOI 10.1021/la101304v
   Sayari A, 1997, CHEM MATER, V9, P2499, DOI 10.1021/cm970128o
   Schlipf DM, 2013, ACS APPL MATER INTER, V5, P10111, DOI 10.1021/am402754h
   Scomparin C, 2009, EUR PHYS J E, V28, P211, DOI 10.1140/epje/i2008-10407-3
   Sharma MK, 2007, LANGMUIR, V23, P7101, DOI 10.1021/la0634950
   SPECTOR AA, 1985, J LIPID RES, V26, P1015
   Takeuchi R, 2013, SENSOR ACTUAT B-CHEM, V181, P29, DOI 10.1016/j.snb.2013.01.039
   TOCANNE JF, 1994, PROG LIPID RES, V33, P203, DOI 10.1016/0163-7827(94)90027-2
   Wagner ML, 2000, BIOPHYS J, V79, P1400, DOI 10.1016/S0006-3495(00)76392-2
   Wang LS, 2010, ACS NANO, V4, P4371, DOI 10.1021/nn901376h
   Wang SH, 2013, SOFT MATTER, V9, P480, DOI 10.1039/c2sm26850g
   WU ES, 1977, BIOCHEMISTRY-US, V16, P3936, DOI 10.1021/bi00636a034
   Xing CY, 2008, J PHYS CHEM B, V112, P7086, DOI 10.1021/jp077305l
   Zhao DY, 2000, CHEM MATER, V12, P275, DOI 10.1021/cm9911363
   Zhong LN, 2013, LANGMUIR, V29, P299, DOI 10.1021/la303628n
NR 64
TC 2
Z9 2
U1 9
U2 21
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2196-7350
J9 ADV MATER INTERFACES
JI Adv. Mater. Interfaces
PD MAY 9
PY 2017
VL 4
IS 9
AR 1601103
DI 10.1002/admi.201601103
PG 10
WC Chemistry, Multidisciplinary; Materials Science, Multidisciplinary
SC Chemistry; Materials Science
GA EU4OM
UT WOS:000401009400011
DA 2018-03-20
ER

PT J
AU Tan, B
   Vyas, SM
   Lehmer, HJ
   Knutson, BL
   Rankin, SE
AF Tan, Bing
   Vyas, Sandhya M.
   Lehmer, Hans-Joachim
   Knutson, Barbara L.
   Rankin, Stephen E.
TI Synthesis of inorganic and organic-inorganic hybrid hollow particles
   using a cationic surfactant with a partially fluorinated tail
SO ADVANCED FUNCTIONAL MATERIALS
LA English
DT Article
ID MESOSTRUCTURED SILICA VESICLES; MESOSCOPICALLY ORDERED SILICA;
   MESOPOROUS SILICA; BRIDGED POLYSILSESQUIOXANES; NANOCOMPOSITE MATERIALS;
   CONTROLLED-RELEASE; SPHERICAL SILICA; SPHERES; NANOPARTICLES; SHELLS
AB A new partially fluorinated cationic surfactant, 1-(10-perfluorooctyldecyl)pyridinium bromide monohydrate, is synthesized and used as the template for mesoporous ceramic and inorganic-organic hybrid particles. Several hydrolyzed alkoxide precursors are shown to co-assemble with this surfactant to form hollow vesicle-like particles, and the effect of changing the alkoxide chemical structure on the formation of these particles is examined. Tetramethoxysilane produces cubic or columnar particles without hollow cavities, but all other tetra-n-alkoxysilanes tested up to the n-butoxide produce hollow particles. As the alkoxide length increases, the shell structure changes from multilayered (with Si(OC2H5)(4)) to a single thin layer (with Si(OC3H7)(4)) to a single thick layer (with Si(OC4H9)(4)). The stability of the fluorocarbon bilayers allows similar vesicular structures to be obtained in organic-inorganic hybrids prepared with bridged alkoxysilanes. Ethylene-bridged silanes display similar structures to tetra-alkoxysilanes. However, the hollow structures appear to partially collapse when the bridging chain is too long (octylene) and no hollow particles are formed with bis(trialkoxysilylpropyl)amines.
C1 Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   Ohio State Univ, Dept Chem, Columbus, OH 43210 USA.
   Univ Iowa, Dept Environm & Occupat Hlth, Iowa City, IA 52242 USA.
RP Rankin, SE (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 Anderson Hall, Lexington, KY 40506 USA.
EM srankin@engr.uky.edu
RI Rankin, Stephen/A-3265-2013
OI Rankin, Stephen/0000-0002-8615-7564; Lehmler,
   Hans-Joachim/0000-0001-9163-927X
CR BARRETT EP, 1951, J AM CHEM SOC, V73, P373, DOI 10.1021/ja01145a126
   Begu S, 2003, CHEM COMMUN, P640, DOI 10.1039/b210927a
   Botterhuis NE, 2006, CHEM-EUR J, V12, P1448, DOI 10.1002/chem.200500588
   Brigger I, 2002, ADV DRUG DELIVER REV, V54, P631, DOI 10.1016/S0169-409X(02)00044-3
   Brinker C.J., 1990, SOL GEL SCI PHYS CHE
   Buggy M, 2005, COMPOS PART A-APPL S, V36, P437, DOI 10.1016/j.compositesa.2004.10.002
   *CAMBRIDGESOFT, 2004, CHEM3D ULTR 9 0 1
   Cui K, 2004, MICROPOR MESOPOR MAT, V68, P61, DOI 10.1016/j.micromeso.2003.11.014
   Djojoputro H, 2006, J AM CHEM SOC, V128, P6320, DOI 10.1021/ja0607537
   Dominguez JM, 2003, MICROPOR MESOPOR MAT, V66, P341, DOI 10.1016/j.micromeso.2003.09.019
   Du JZ, 2004, ANGEW CHEM INT EDIT, V43, P5084, DOI 10.1002/anie.200454244
   Fan HY, 2005, ADV MATER, V17, P2587, DOI 10.1002/adma.200501088
   Hentze HP, 2003, CURR OPIN COLLOID IN, V8, P164, DOI 10.1016/S1359-0294(03)00018-9
   Hentze HP, 2003, LANGMUIR, V19, P1069, DOI 10.1021/la020727w
   Hirsh DJ, 1998, BIOPHYS J, V75, P1858, DOI 10.1016/S0006-3495(98)77626-X
   Hoffmann F, 2006, ANGEW CHEM INT EDIT, V45, P3216, DOI 10.1002/anie.200503075
   Hubert DHW, 2000, ADV MATER, V12, P1286, DOI 10.1002/1521-4095(200009)12:17<1286::AID-ADMA1286>3.0.CO;2-7
   Ikeuchi H, 2003, J MOL CATAL A-CHEM, V193, P207, DOI 10.1016/S1381-1169(02)00465-X
   Imae T, 1999, J COLLOID INTERF SCI, V212, P330, DOI 10.1006/jcis.1999.6094
   Jiang Y, 2006, COLLOID SURFACE B, V49, P55, DOI 10.1016/j.colsurfb.2006.02.012
   JIN RH, 1992, J MOL CATAL, V73, P215, DOI 10.1016/0304-5102(92)80074-Q
   Katagiri K, 1999, CHEM LETT, P661, DOI 10.1246/cl.1999.661
   Kay B. D., 1986, MATER RES SOC S P, V73, P157
   Kim SS, 1998, SCIENCE, V282, P1302, DOI 10.1126/science.282.5392.1302
   Krafft MP, 1998, BIOCHIMIE, V80, P489, DOI 10.1016/S0300-9084(00)80016-4
   Kruk M, 2001, CHEM MATER, V13, P3169, DOI 10.1021/cm0101069
   Lind A, 2003, CHEM MATER, V15, P813, DOI 10.1021/cm021243o
   Liu SQ, 2003, J PHYS CHEM B, V107, P10405, DOI 10.1021/jp034410w
   LOY DA, 1995, CHEM REV, V95, P1431, DOI 10.1021/cr00037a013
   Loy DA, 1999, CHEM MATER, V11, P3333, DOI 10.1021/cm990405m
   Lu Y, 2004, LANGMUIR, V20, P3464, DOI 10.1021/la036245h
   Lu YF, 2000, J AM CHEM SOC, V122, P5258, DOI 10.1021/ja9935862
   Mainardes RM, 2004, CURR DRUG TARGETS, V5, P449, DOI 10.2174/1389450043345407
   Mishima S, 2002, CHEM LETT, P1092, DOI 10.1246/cl.2002.1092
   MONNIER A, 1993, SCIENCE, V261, P1299, DOI 10.1126/science.261.5126.1299
   Moreau JJE, 2004, J SOL-GEL SCI TECHN, V31, P151, DOI 10.1023/B:JSST.0000047977.44966.53
   Moreau JJE, 2003, CHEM-EUR J, V9, P1594, DOI 10.1002/chem.200390183
   PATIL V, 1997, J AM CHEM SOC, V119
   Pevzner S, 2003, J AM CHEM SOC, V125, P652, DOI 10.1021/ja0289301
   Rana RK, 2002, ADV MATER, V14, P1414, DOI 10.1002/1521-4095(20021002)14:19<1414::AID-ADMA1414>3.0.CO;2-F
   Rankin SE, 2004, MICROPOR MESOPOR MAT, V73, P197, DOI 10.1016/j.micromeso.2004.05.013
   REBBIN V, 2002, MATER RES SOC S P, V726, DOI UNSP Q8.3.1
   Sayari A, 2001, CHEM MATER, V13, P3151, DOI 10.1021/cm0110391
   Shah J, 2005, CHEM COMMUN, P1598, DOI 10.1039/b413265c
   Shchukin DG, 2003, ANGEW CHEM INT EDIT, V42, P4472, DOI 10.1002/anie.200352068
   Shen LF, 1999, LANGMUIR, V15, P447, DOI 10.1021/la9807661
   Stein A, 2000, ADV MATER, V12, P1403, DOI 10.1002/1521-4095(200010)12:19<1403::AID-ADMA1403>3.0.CO;2-X
   STEWART JJP, 1989, J COMPUT CHEM, V10, P209, DOI 10.1002/jcc.540100208
   STEWART JJP, 1999, MOPAC 2000
   Tan B, 2005, ADV MATER, V17, P2368, DOI 10.1002/adma.200500344
   Tan B, 2005, LANGMUIR, V21, P8180, DOI 10.1021/la050618s
   Tan B, 2004, J PHYS CHEM B, V108, P20122, DOI 10.1021/jp046425f
   Tan B, 2005, CHEM MATER, V17, P916, DOI 10.1021/cm048991t
   Tan B, 2004, LANGMUIR, V20, P6981, DOI 10.1021/la049474s
   Tanev PT, 1996, SCIENCE, V271, P1267, DOI 10.1126/science.271.5253.1267
   Tanev PT, 1998, SUPRAMOL SCI, V5, P399, DOI 10.1016/S0968-5677(98)00039-X
   Vyas SM, 2006, NEW J CHEM, V30, P944, DOI 10.1039/b516039a
   Wahab MA, 2004, J SOLID STATE CHEM, V177, P3439, DOI 10.1016/j.jssc.2004.05.062
   Wang K, 1999, J PHYS CHEM B, V103, P9237, DOI 10.1021/jp990821u
   Yeh YQ, 2006, LANGMUIR, V22, P6, DOI 10.1021/la052129y
   Zhao DY, 1998, CURR OPIN SOLID ST M, V3, P111, DOI 10.1016/S1359-0286(98)80073-9
   [朱金红 Zhu Jinhong], 2004, [燃料化学学报, Journal of Fuel Chemistry and Technology], V32, P381
   ZUB YL, 2001, MENDELEEV COMMUN, P1
NR 63
TC 36
Z9 36
U1 0
U2 35
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY
SN 1616-301X
J9 ADV FUNCT MATER
JI Adv. Funct. Mater.
PD SEP 24
PY 2007
VL 17
IS 14
BP 2500
EP 2508
DI 10.1002/adfm.200600635
PG 9
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 218ME
UT WOS:000250018800032
DA 2018-03-20
ER

PT J
AU Ambati, J
   Saiyed, H
   Rankin, SE
AF Ambati, Jyothirmai
   Saiyed, Hamzah
   Rankin, Stephen E.
TI DFT investigation of NH3 physisorption on CuSO4 impregnated SiO2
SO PHYSICAL CHEMISTRY CHEMICAL PHYSICS
LA English
DT Article
ID SILICA-SUPPORTED COPPER; SELECTIVE CATALYTIC REDUCTION;
   DENSITY-FUNCTIONAL THEORY; AB-INITIO CALCULATIONS; CAGE-LIKE CLUSTERS;
   AMMONIA ADSORPTION; SULFATE PENTAHYDRATE; MESOPOROUS SILICA;
   SURFACE-ACIDITY; GAS-PHASE
AB In this quantum chemical investigation, NH3 physisorption onto a model of copper sulfate impregnated silica is compared with pure silica and copper sulfate adsorbents. The physisorption process is modeled as direct binding of the NH3 molecule to the adsorption site of the dry adsorbents and as displacement of a H2O molecule by NH3 in the hydrated complexes. The surface of silica is represented by a hydroxyl group attached to a silsesquioxane cage, H7Si8O12(OH) and silica impregnated with CuSO4 by the most stable configuration of the cluster containing a CuSO4 ion pair placed adjacent to the silica cage. H2O is systematically added to the dehydrated adsorbents to investigate the role of water in NH3 adsorption. Modeling hydrated environments of each type of adsorbent is focused on H2O molecules that directly coordinate with the active sites. The results indicate that the binding energy of adsorbing NH3 onto the mixed adsorbent is greater than in pure silica. This enhanced binding in the mixed adsorbent is consistent with improved Bronsted acidity of the silanol in the presence of CuSO4.
C1 [Ambati, Jyothirmai; Saiyed, Hamzah; Rankin, Stephen E.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Rankin, SE (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM srankin@engr.uky.edu
RI Rankin, Stephen/A-3265-2013
OI Rankin, Stephen/0000-0002-8615-7564; Ambati,
   Jyothirmai/0000-0003-2420-3665
FU National Science Foundation [CBET-0348234]; US Department of Energy
   [DE-FG02-07ER46375]
FX The authors thank the University of Kentucky Center for Computational
   Sciences for the use of their facility. This research was funded by
   National Science Foundation Grant (CBET-0348234) and US Department of
   Energy (DE-FG02-07ER46375).
CR Adrian-Scotto M, 2005, J MOL STRUC-THEOCHEM, V728, P231, DOI 10.1016/j.theochem.2005.02.006
   Ambati J, 2010, J PHYS CHEM A, V114, P12613, DOI 10.1021/jp105644p
   ANDERSON BG, 1995, J PHYS CHEM-US, V99, P14444, DOI 10.1021/j100039a037
   Anstrom M, 2002, CATAL LETT, V78, P281, DOI 10.1023/A:1014996215585
   Aomura Y, 2010, J CHROMATOGR A, V1217, P1838, DOI 10.1016/j.chroma.2010.01.039
   BACON GE, 1975, Z KRISTALLOGR, V141, P330, DOI 10.1524/zkri.1975.141.5-6.330
   Bersuker IB, 2001, CHEM REV, V101, P1067, DOI 10.1021/cr0004411
   Bromley ST, 2001, MICROPOR MESOPOR MAT, V44, P395, DOI 10.1016/S1387-1811(01)00206-2
   Bruhwiler D, 2010, NANOSCALE, V2, P887, DOI 10.1039/c0nr00039f
   Buzko V, 2007, INT J QUANTUM CHEM, V107, P2353, DOI 10.1002/qua.21338
   CAHNMANN HJ, 1957, ANAL CHEM, V29, P1307, DOI 10.1021/ac60129a018
   Centeno MA, 2001, J ALLOY COMPD, V323, P597, DOI 10.1016/S0925-8388(01)01186-0
   Chaban GM, 2002, J CHEM PHYS, V117, P2532, DOI 10.1063/1.1489997
   Chashchikhin V, 2011, PHYS CHEM CHEM PHYS, V13, P1440, DOI 10.1039/c0cp00821d
   Chen LF, 2006, MATER CHEM PHYS, V97, P236, DOI 10.1016/j.matchemphys.2005.08.043
   Chen SY, 2004, CHEM MATER, V16, P4174, DOI 10.1021/cm049247b
   Cheng HS, 1996, J PHYS CHEM-US, V100, P9800, DOI 10.1021/jp952623i
   Civalleri B, 1999, LANGMUIR, V15, P5829, DOI 10.1021/la981300l
   Civalleri B, 1999, CHEM PHYS LETT, V299, P443, DOI 10.1016/S0009-2614(98)01301-3
   Civalleri B, 1998, CHEM PHYS LETT, V292, P394, DOI 10.1016/S0009-2614(98)00749-0
   Crepeau G, 2006, J PHYS CHEM B, V110, P15172, DOI 10.1021/jp062252d
   Delabie A, 2000, MICROPOR MESOPOR MAT, V37, P209, DOI 10.1016/S1387-1811(99)00267-X
   Desmartin-Chomel A, 2006, J PHYS CHEM B, V110, P858, DOI 10.1021/jp0530698
   Eddaoudi M, 2007, STUD SURF SCI CATAL, V170, P2021
   Erdogan R, 2011, INT J QUANTUM CHEM, V111, P174, DOI 10.1002/qua.22400
   Erdogan R, 2010, SURF SCI, V604, P1029, DOI 10.1016/j.susc.2010.03.016
   FUBINI B, 1993, LANGMUIR, V9, P2712, DOI 10.1021/la00034a034
   Gang L, 1999, J CATAL, V186, P100, DOI 10.1006/jcat.1999.2524
   Gao B, 2004, J CHEM PHYS, V121, P8299, DOI 10.1063/1.1802011
   GLUSZAK TJ, 1992, CHEM PHYS LETT, V190, P36, DOI 10.1016/0009-2614(92)86098-3
   Gorogotskaya L. I., 1972, J STRUCT CHEM, V13, P600
   Grimme S, 2004, J COMPUT CHEM, V25, P1463, DOI 10.1002/jcc.20078
   Grimme S, 2007, ORG BIOMOL CHEM, V5, P741, DOI 10.1039/b615319b
   Grimme S, 2006, J COMPUT CHEM, V27, P1787, DOI 10.1002/jcc.20495
   HARRIS AD, 1979, J CHEM EDUC, V56, P417, DOI 10.1021/ed056p417
   HERTL W, 1969, NATURE, V223, P1150, DOI 10.1038/2231150a0
   Kanougi T, 2002, J MOL CATAL A-CHEM, V177, P289, DOI 10.1016/S1381-1169(01)00276-X
   Kargol M, 2005, THERMOCHIM ACTA, V434, P15, DOI 10.1016/j.tca.2005.01.003
   Kargol M, 2005, CHEM MATER, V17, P6117, DOI 10.1021/cm051120e
   Kickelbick G, 2003, PROG POLYM SCI, V28, P83, DOI 10.1016/S0079-6700(02)00019-9
   KIEL JHA, 1992, APPL CATAL B-ENVIRON, V1, P13, DOI 10.1016/0926-3373(92)80004-J
   KIEL JHA, 1992, APPL CATAL B-ENVIRON, V1, P41, DOI 10.1016/0926-3373(92)80005-K
   Kinrade SD, 2002, J CHEM SOC DALTON, P1250, DOI 10.1039/b107758a
   Kravchenko A. A., 2010, KHIM FIZ TEKHNOL POV, V1, P177
   KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0
   Kumar P, 2010, MICROPOR MESOPOR MAT, V132, P1, DOI 10.1016/j.micromeso.2010.02.007
   Lange B, 2008, SURF SCI, V602, P1207, DOI 10.1016/j.susc.2008.01.024
   Li GZ, 2001, J INORG ORGANOMET P, V11, P123, DOI 10.1023/A:1015287910502
   Liu YY, 2006, APPL CATAL A-GEN, V309, P91, DOI 10.1016/j.apcata.2006.04.042
   Manzano M, 2008, STUD SURF SCI CATAL, V174, P13
   Mayer I, 2007, J COMPUT CHEM, V28, P204, DOI 10.1002/jcc.20494
   McGowin A. E., 2006, CHROMATOGRAPHIC SCI, P584
   Mellot-Draznieks Caroline, 2002, Chemistry, V8, P4102, DOI 10.1002/1521-3765(20020916)8:18<4102::AID-CHEM4102>3.0.CO;2-3
   Meynen V., 2007, NANODESIGN COMBINED
   NEESE F, 2008, ORCA AB INITIO DENSI
   NG LV, 1995, MACROMOLECULES, V28, P6471, DOI 10.1021/ma00123a012
   PAPIRER E, 2000, ADSORPTION SILICA SU
   Pietrogiacomi D, 2002, APPL CATAL B-ENVIRON, V36, P217, DOI 10.1016/S0926-3373(01)00310-1
   Pietrogiacomi D, 2009, APPL CATAL B-ENVIRON, V89, P33, DOI 10.1016/j.apcatb.2008.11.021
   Rahaman O, 2010, J PHYS CHEM A, V114, P3556, DOI 10.1021/jp9090415
   REED AE, 1988, CHEM REV, V88, P899, DOI 10.1021/cr00088a005
   Roggero I, 2001, CHEM PHYS LETT, V341, P625, DOI 10.1016/S0009-2614(01)00530-9
   Roque-Malherbe R, 2008, J NANOSCI NANOTECHNO, V8, P5993, DOI 10.1166/jnn.2008.335
   Sablon K, 2008, NANOSCALE RES LETT, V3, P265, DOI 10.1007/s11671-008-9145-1
   Saha BB, 2007, PHILOS MAG, V87, P1113, DOI 10.1080/14786430601032386
   Santiago MAN, 2000, J CATAL, V193, P16, DOI 10.1006/jcat.2000.2883
   SAUER J, 1994, CHEM PHYS LETT, V218, P333, DOI 10.1016/0009-2614(94)00002-6
   SAUER J, 1984, INT J QUANTUM CHEM, V26, P793, DOI 10.1002/qua.560260519
   Senchenya IN, 1998, SURF SCI, V412-13, P141, DOI 10.1016/S0039-6028(98)00379-3
   Serna-Guerrero R, 2007, ENVIRON SCI TECHNOL, V41, P4761, DOI 10.1021/es0627996
   Shubina TE, 2009, HIGH PERFORMANCE COMPUTING IN SCIENCE AND ENGINEERING, GARCH/MUNICH 2007, P201, DOI 10.1007/978-3-540-69182-2_16
   Szczodrowski K, 2009, MICROPOR MESOPOR MAT, V124, P84, DOI 10.1016/j.micromeso.2009.04.035
   Tanaka T, 2002, THIN SOLID FILMS, V409, P51, DOI 10.1016/S0040-6090(02)00103-7
   UGLIENGO P, 1989, SURF SCI, V224, P498, DOI 10.1016/0039-6028(89)90928-X
   VARGHESE JN, 1985, ACTA CRYSTALLOGR B, V41, P184, DOI 10.1107/S0108768185001914
   Wallin M, 2004, APPL SURF SCI, V235, P487, DOI 10.1016/j.apsusc.2004.03.225
   WEST JK, 1990, J NON-CRYST SOLIDS, V121, P51, DOI 10.1016/0022-3093(90)90103-S
   WIBERG KB, 1968, J AM CHEM SOC, V90, P59, DOI 10.1021/ja01003a012
   WIBERG KB, 1968, TETRAHEDRON, V24, P1083, DOI 10.1016/0040-4020(68)88057-3
   WILDNER M, 1988, MINER PETROL, V39, P201, DOI 10.1007/BF01163035
   Xiong G, 2001, MICROPOR MESOPOR MAT, V42, P317, DOI 10.1016/S1387-1811(00)00340-1
   Yu JH, 2010, ACCOUNTS CHEM RES, V43, P1195, DOI 10.1021/ar900293m
   Zhang WH, 2002, CHEM MATER, V14, P3413, DOI 10.1021/cm011686c
NR 83
TC 7
Z9 7
U1 0
U2 27
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1463-9076
EI 1463-9084
J9 PHYS CHEM CHEM PHYS
JI Phys. Chem. Chem. Phys.
PY 2012
VL 14
IS 18
BP 6617
EP 6627
DI 10.1039/c2cp22539e
PG 11
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA 928AI
UT WOS:000302951500058
PM 22456452
DA 2018-03-20
ER

PT J
AU Gulati, GK
   Chen, T
   Hinds, BJ
AF Gulati, Gaurav Kumar
   Chen, Tao
   Hinds, Bruce J.
TI Programmable carbon nanotube membrane-based transdermal nicotine
   delivery with microdialysis validation assay
SO NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
LA English
DT Article
DE Microdialysis; CNT membrane; Nicotine; Smoking cessation; Remote
   counseling
ID SMOKING-CESSATION PROGRAM; IN-VIVO; IONTOPHORETIC DELIVERY;
   DRUG-DELIVERY; SKIN; PATCH; FLOW; REPLACEMENT; METABOLISM; TRANSPORT
AB To evaluate the performance of switchable carbon nanotubes (CNT) membrane devices for transdermal nicotine delivery, we have developed an in-vitro microdialysis method that allow us to detect variable transdermal fluxes of nicotine through CNT devices and can be applied directly to in-vivo studies. Microdialysis membranes were placed beneath the porcine skin and its nicotine levels increased 6-8 times when the CNT membrane on skin was turned from OFF to ON state by application of bias. Fluxes in the ON state were approximately 3 times that of commercial nicotine patches and switching times were less than two hours, thus suggesting the improved therapeutic potential of our device. Blue tooth enabled CNT devices that can be programmed by smartphone and coupled with remote counseling application for enhanced smoking cessation treatments. (C) 2016 Published by Elsevier Inc.
C1 [Gulati, Gaurav Kumar; Hinds, Bruce Jackson] Univ Washington, Mat Sci & Engn, Seattle, WA 98195 USA.
   [Chen, Tao] Univ Kentucky, Chem & Mat Engn, Lexington, KY USA.
RP Hinds, BJ (reprint author), Univ Washington, Mat Sci & Engn, Seattle, WA 98195 USA.
EM bjhinds@uw.edu
FU National Institutes of Health NIDA [R01DA018822]
FX SEM and TEM facilities support was provided by the Centre for Nanoscale
   Science and Engineering and Electron Microscopy Centre at the University
   of Kentucky, Lexington, KY. Financial support was provided by National
   Institutes of Health NIDA (R01DA018822).
CR ANDERSON C, 1994, J INVEST DERMATOL, V102, P807, DOI 10.1111/1523-1747.ep12378630
   AULT JM, 1994, PHARMACEUT RES, V11, P1631, DOI 10.1023/A:1018922123774
   Civljak M., 2013, COCHRANE DB SYST REV, V7, P1
   CROSS SE, 1995, J PHARM SCI, V84, P584, DOI 10.1002/jps.2600840513
   D'Amours M, 2003, J PHYS CHEM B, V107, P4811, DOI 10.1021/jp027223r
   Etter JF, 2006, TOB CONTROL, V15, DOI 10.1136/tc.2005.015487
   FEYERABEND C, 1985, BRIT J CLIN PHARMACO, V19, P239, DOI 10.1111/j.1365-2125.1985.tb02637.x
   HEGEMANN L, 1995, J INVEST DERMATOL, V104, P839, DOI 10.1111/1523-1747.ep12607019
   Hukkanen J, 2005, PHARMACOL REV, V57, P79, DOI 10.1124/pr.57.1.3
   Jakasa I, 2004, INT ARCH OCC ENV HEA, V77, P79, DOI 10.1007/s00420-003-0456-3
   Johnstone E, 2004, NICOTINE TOB RES, V6, P377, DOI 10.1080/14622200410001676440
   Kalaria DR, 2014, EUR J PHARM BIOPHARM, V88, P56, DOI 10.1016/j.ejpb.2014.02.002
   KORNITZER M, 1995, PREV MED, V24, P41, DOI 10.1006/pmed.1995.1006
   KYEREMATEN GA, 1990, BIOCHEM PHARMACOL, V40, P1747, DOI 10.1016/0006-2952(90)90351-K
   LAWLER JC, 1960, J INVEST DERMATOL, V34, P301, DOI 10.1038/jid.1960.52
   Lazev AB, 2004, NICOTINE TOB RES, V6, P281, DOI 10.1080/14622200410001676314
   Majumder M, 2005, NATURE, V438, P930, DOI 10.1038/438930b
   Majumder M, 2008, J MEMBRANE SCI, V316, P89, DOI 10.1016/j.memsci.2007.09.068
   Majumder M, 2007, LANGMUIR, V23, P8624, DOI 10.1021/la700686k
   Malinovskaja K, 2014, EUR J PHARM BIOPHARM, V88, P594, DOI 10.1016/j.ejpb.2014.08.010
   MULLER M, 1995, J CONTROL RELEASE, V37, P49, DOI 10.1016/0168-3659(95)00063-E
   Ogawa Y, 2015, ADV HEALTHC MATER, V4, P506, DOI 10.1002/adhm.201400457
   Paudel KS, 2012, J PHARM SCI-US, V101, P3823, DOI 10.1002/jps.23240
   Prausnitz MR, 1996, ADV DRUG DELIVER REV, V18, P395, DOI 10.1016/0169-409X(95)00081-H
   PUSKA P, 1995, TOB CONTROL, V4, P231, DOI DOI 10.1136/TC.4.3.231
   Rigotti NA, 2012, JAMA-J AM MED ASSOC, V308, P1573, DOI 10.1001/jama.2012.13043
   Selby P, 2013, J CLIN PSYCHOPHARM, V33, P667, DOI 10.1097/JCP.0b013e31829a829d
   SRINIVASAN V, 1990, INT J PHARM, V60, P133, DOI 10.1016/0378-5173(90)90298-I
   Strecher VJ, 2005, ADDICTION, V100, P682, DOI 10.1111/j.1360-0443.2005.01093.x
   Sun L, 2000, J AM CHEM SOC, V122, P12340, DOI 10.1021/ja002429w
   Swartz LHG, 2006, TOB CONTROL, V15, P7, DOI 10.1136/tc.2003.006189
   Tinkelman D, 2007, TOB CONTROL, V16, pI42, DOI 10.1136/tc.2007.019919
   Wilkinson SC, 2006, INT ARCH OCC ENV HEA, V79, P405, DOI 10.1007/s00420-005-0056-5
   Wu J, 2012, NAT NANOTECHNOL, V7, P133, DOI [10.1038/nnano.2011.240, 10.1038/NNANO.2011.240]
   Wu J, 2011, NANOSCALE, V3, P3321, DOI 10.1039/c1nr10303b
   Wu J, 2010, P NATL ACAD SCI USA, V107, P11698, DOI 10.1073/pnas.1004714107
   Zhan X, 2013, NANOSCALE RES LETT, V8, DOI 10.1186/1556-276X-8-279
   Zuo H., 1996, CURR SEP, V15, P63
NR 38
TC 1
Z9 1
U1 4
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1549-9634
EI 1549-9642
J9 NANOMED-NANOTECHNOL
JI Nanomed.-Nanotechnol. Biol. Med.
PD JAN
PY 2017
VL 13
IS 1
BP 1
EP 9
DI 10.1016/j.nano.2016.06.017
PG 9
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
SC Science & Technology - Other Topics; Research & Experimental Medicine
GA EO0HF
UT WOS:000396378200001
PM 27438911
DA 2018-03-20
ER

PT J
AU Naga, KK
   Geddes, JW
AF Naga, Kranthi Kumari
   Geddes, James W.
TI Dimebon Inhibits Calcium-Induced Swelling of Rat Brain Mitochondria But
   Does Not Alter Calcium Retention or Cytochrome C Release
SO NEUROMOLECULAR MEDICINE
LA English
DT Article
DE Alzheimer's disease; Apoptosis; Neurodegeneration; Cell death
ID PERMEABILITY TRANSITION; ALZHEIMERS-DISEASE; SYNAPTIC MITOCHONDRIA;
   OXIDATIVE DAMAGE; COGNITION; MEMBRANE; TARGET; BETA; MICE
AB Dimebon was originally introduced as an antihistamine and subsequently investigated as a possible therapeutic for a variety of disorders, including Alzheimer's disease. One putative mechanism underlying the neuroprotective properties of Dimebon is inhibition of mitochondrial permeability transition, based on the observation that Dimebon inhibited the swelling of rat liver mitochondria induced by calcium and other agents that induce permeability transition. Because liver and brain mitochondria differ substantially in their properties and response to conditions associated with opening of the permeability transition pore, we sought to determine whether Dimebon inhibited permeability transition in brain mitochondria. Dimebon reduced calcium-induced mitochondrial swelling but did not enhance the calcium retention capacity or impair calcium-induced cytochrome C release from non-synaptic mitochondria isolated from rat brain cerebral cortex. These findings indicate that Dimebon does not inhibit mitochondrial permeability transition, induced by excessive calcium uptake, in brain mitochondria.
C1 [Naga, Kranthi Kumari; Geddes, James W.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA.
   [Naga, Kranthi Kumari; Geddes, James W.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA.
RP Geddes, JW (reprint author), Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, B477 Biomed & Biol Sci Res Bldg BBSRB,741 S Limes, Lexington, KY 40536 USA.
EM jgeddes@uky.edu
FU NIH [PO1NS058484, PO1AG010836, R01NS062993, P30NS051220]; Kentucky
   Spinal Cord and Head Injury Research Trust
FX This research was supported by NIH grants PO1NS058484, PO1AG010836,
   R01NS062993, and P30NS051220, as well as funding from the Kentucky
   Spinal Cord and Head Injury Research Trust.
CR Abdul HM, 2008, FREE RADICAL BIO MED, V45, P1420, DOI 10.1016/j.freeradbiomed.2008.08.012
   Bachurin S, 2001, ANN NY ACAD SCI, V939, P425
   Bachurin SO, 2003, ANN NY ACAD SCI, V993, P334, DOI 10.1111/j.1749-6632.2003.tb07541.x
   Berman SB, 2000, EXP NEUROL, V164, P415, DOI 10.1006/exnr.2000.7438
   Bernardi P, 2006, FEBS J, V273, P2077, DOI 10.1111/j.1742-4658.2006.05213.x
   Brown MR, 2006, J BIOL CHEM, V281, P11658, DOI 10.1074/jbc.M510303200
   Brustovetsky N, 2002, J NEUROCHEM, V80, P207, DOI 10.1046/j.0022-3042.2001.00671.x
   Doody RS, 2008, LANCET, V372, P207, DOI 10.1016/S0140-6736(08)61074-0
   Du H, 2011, NEUROBIOL AGING, V32, P398, DOI 10.1016/j.neurobiolaging.2009.03.003
   Galenko-Iaroshevskii P A, 1996, Biull Eksp Biol Med, V121, P506
   Galenko-Iaroshevskii P A, 1995, Biull Eksp Biol Med, V119, P375
   Grigor'ev VV, 2003, B EXP BIOL MED+, V136, P474, DOI 10.1023/B:BEBM.0000017097.75818.14
   Hansson MJ, 2003, BRAIN RES, V960, P99, DOI 10.1016/S0006-8993(02)03798-8
   HAWORTH RA, 1979, ARCH BIOCHEM BIOPHYS, V195, P460, DOI 10.1016/0003-9861(79)90372-2
   Jicha GA, 2010, CLIN INTERV AGING, V5, P45
   Jo DG, 2010, NEUROBIOL AGING, V31, P917, DOI 10.1016/j.neurobiolaging.2008.07.003
   Kobayashi T, 2003, BRAIN RES, V960, P62, DOI 10.1016/S0006-8993(02)03767-8
   Kristian T, 2000, J NEUROCHEM, V74, P1999, DOI 10.1046/j.1471-4159.2000.0741999.x
   Lermontova NN, 2000, B EXP BIOL MED+, V129, P544, DOI 10.1007/BF02434871
   Lermontova NN, 2001, B EXP BIOL MED+, V132, P1079
   Lovell MA, 2009, FREE RADICAL BIO MED, V46, P1527, DOI 10.1016/j.freeradbiomed.2009.03.008
   MARKESBERY WR, 1981, ANN NEUROL, V10, P511
   Markesbery WR, 1997, FREE RADICAL BIO MED, V23, P134, DOI 10.1016/S0891-5849(96)00629-6
   MATEEVA IA, 1983, FARMAKOLOGIIA TOKSIK, V46, P27
   Miller G, 2010, SCIENCE, V327, P1309, DOI 10.1126/science.327.5971.1309
   Morota S, 2009, EXP NEUROL, V218, P353, DOI 10.1016/j.expneurol.2009.03.036
   Naga KK, 2007, J NEUROSCI, V27, P7469, DOI 10.1523/JNEUROSCI.0646-07.2007
   Reddy PH, 2009, EXP NEUROL, V218, P286, DOI 10.1016/j.expneurol.2009.03.042
   SHADURSKAYA S K, 1986, Byulleten' Eksperimental'noi Biologii i Meditsiny, V101, P700
   SHADURSKY KS, 1983, FARMAKOL TOKSIKOL, V46, P90
   Sonnen JA, 2008, FREE RADICAL BIO MED, V45, P219, DOI 10.1016/j.freeradbiomed.2008.04.022
   Wu J, 2008, MOL NEURODEGENER, V3, DOI 10.1186/1750-1326-3-15
   ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A
NR 33
TC 17
Z9 18
U1 0
U2 2
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1535-1084
J9 NEUROMOL MED
JI Neuromol. Med.
PD MAR
PY 2011
VL 13
IS 1
BP 31
EP 36
DI 10.1007/s12017-010-8130-x
PG 6
WC Neurosciences
SC Neurosciences & Neurology
GA 726VB
UT WOS:000287753400011
PM 20625939
OA green_accepted
DA 2018-03-20
ER

PT J
AU Hayes, D
   Galantowicz, M
   Yates, AR
   Preston, TJ
   Mansour, HM
   McConnell, PI
AF Hayes, Don, Jr.
   Galantowicz, Mark
   Yates, Andrew R.
   Preston, Thomas J.
   Mansour, Heidi M.
   McConnell, Patrick I.
TI Venovenous ECMO as a bridge to lung transplant and a protective strategy
   for subsequent primary graft dysfunction
SO JOURNAL OF ARTIFICIAL ORGANS
LA English
DT Article
DE Cystic fibrosis; Lung transplantation; Venovenous extracorporeal
   membrane oxygenation; Preventative; Primary graft dysfunction;
   Protective
ID EXTRACORPOREAL MEMBRANE-OXYGENATION; ISHLT WORKING GROUP; SURVIVAL;
   FAILURE; PREDICTORS; OUTCOMES; SUPPORT
AB Extracorporeal membrane oxygenation (ECMO) is an established therapy for primary graft dysfunction (PGD) in adults after lung transplant, while venovenous (VV) ECMO is an evolving therapy that can bridge patients to lung transplantation. This report describes a case of relatively quick improvement of grade 3 PGD, based on the PaO2/FIO2 (P/F) ratio, in a 17-year-old patient with cystic fibrosis who was bridged to lung transplantation with ambulatory VV ECMO and then received support with VV ECMO as a protective strategy during the initial phases of PGD after lung transplantation.
C1 [Hayes, Don, Jr.; Yates, Andrew R.] Ohio State Univ Coll Med, Nationwide Childrens Hosp, Dept Pediat, Columbus, OH 43205 USA.
   [Galantowicz, Mark; McConnell, Patrick I.] Ohio State Univ Coll Med, Nationwide Childrens Hosp, Dept Surg, Columbus, OH 43205 USA.
   [Preston, Thomas J.] Nationwide Childrens Hosp, Ctr Heart, Dept Cardiovasc Perfus, Columbus, OH USA.
   [Mansour, Heidi M.] Univ Kentucky Coll Pharm, Dept Pharmaceut Sci, Lexington, KY USA.
RP Hayes, D (reprint author), Ohio State Univ Coll Med, Nationwide Childrens Hosp, Dept Pediat, 700 Childrens Dr, Columbus, OH 43205 USA.
EM hayes.705@osu.edu
RI Yates, Andrew/E-4344-2011
CR Arcasoy SM, 2005, J HEART LUNG TRANSPL, V24, P1483, DOI 10.1016/j.healun.2004.11.314
   Christie JD, 2005, J HEART LUNG TRANSPL, V24, P1454, DOI 10.1016/j.healun.2004.11.049
   Christie JD, 2005, CHEST, V127, P161, DOI 10.1378/chest.127.1.161
   Christie JD, 2003, CHEST, V124, P1232, DOI 10.1378/chest.124.4.1232
   Christie JD, 1998, CHEST, V114, P51, DOI 10.1378/chest.114.1.51
   Fischer S, 2006, J THORAC CARDIOV SUR, V131, P719, DOI 10.1016/j.jtcvs.2005.10.050
   Fischer S, 2007, J HEART LUNG TRANSPL, V26, P472, DOI 10.1016/j.healun.2007.01.031
   Fiser SM, 2001, J HEART LUNG TRANSPL, V20, P631, DOI 10.1016/S1053-2498(01)00249-2
   Garcia JP, 2010, J THORAC CARDIOV SUR, V139, pE137, DOI 10.1016/j.jtcvs.2009.12.021
   Hartwig MG, 2012, ANN THORAC SURG, V93, P366, DOI 10.1016/j.athoracsur.2011.05.017
   Hayes D, 2012, J CYST FIBROS, V11, P40, DOI 10.1016/j.jcf.2011.07.009
   King RC, 2000, ANN THORAC SURG, V69, P1681, DOI 10.1016/S0003-4975(00)01425-9
   Mangi AA, 2010, J THORAC CARDIOV SUR, V140, P713, DOI 10.1016/j.jtcvs.2010.02.029
   Smits JMA, 2003, AM J TRANSPLANT, V3, P1400, DOI 10.1046/j.1600-6143.2003.00231.x
   Turner DA, 2011, CRIT CARE MED, V39, P2593, DOI 10.1097/CCM.0b013e3182282bbe
   Wigfield CH, 2007, J HEART LUNG TRANSPL, V26, P331, DOI 10.1016/j.healun.2006.12.010
NR 16
TC 14
Z9 14
U1 0
U2 13
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
   JAPAN
SN 1434-7229
J9 J ARTIF ORGANS
JI J. Artif. Organs
PD SEP
PY 2013
VL 16
IS 3
BP 382
EP 385
DI 10.1007/s10047-013-0699-z
PG 4
WC Engineering, Biomedical; Transplantation
SC Engineering; Transplantation
GA 228JY
UT WOS:000325183500014
PM 23508264
DA 2018-03-20
ER

PT J
AU Meenach, SA
   Hilt, JZ
   Anderson, KW
AF Meenach, Samantha A.
   Hilt, J. Zach
   Anderson, Kimberly W.
TI Poly(ethylene glycol)-based magnetic hydrogel nanocomposites for
   hyperthermia cancer therapy
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Hydrogel nanocomposite; Poly(ethylene glycol); Hyperthermia;
   Thermoablation; Magnetic
ID DRUG-RELEASE; POLYMERIZATION; NANOPARTICLES; BIOMATERIALS; COMPOSITE;
   PROTEIN; FIELD; OXIDE
AB Hyperthermia, the heating of cancerous tissues to between 41 and 45 degrees C, has been shown to improve the efficacy of cancer therapy when used in conjunction with irradiation and/or chemotherapy Here a novel method for remotely administering heat is presented. which involves the heating of tumor tissue using hydrogel nanocomposites containing magnetic nanopaticles which can be remotely heated upon exposure to an external alternating magnetic field (AMF) Specifically, this research explores the use of hydrogel nanocomposites based oil poly(ethylene glycol) methyl ether methacrylate and dimethacrylate with iron oxide as implantable biomaterials for thermal cancer therapy applications Swelling analysis of the systems indicated a dependence of ethylene glycol (EG) content and cross-linking density on swelling behavior where greater EG amount and lower cross-linking resulted in higher volume swelling ratios Both the entrapped iron oxide nanoparticles and hydrogel nanocomposites exhibited high cell viability for murine fibroblasts, indicating potential biocompatibility The hydrogels were heated in an AMF, and the heating response was shown to be dependent on both iron oxide loading in the gels and the strength of the magnetic field. As proof of concept of these systems as a thermal therapeutic the ability to selectively kill M059K glioblastoma cells in vitro with hydrogel nanocomposites exposed to an AMF was demonstrated (C) 2009 Acta Materialia Inc Published by Elsevier Ltd. All rights reserved
C1 [Meenach, Samantha A.; Hilt, J. Zach; Anderson, Kimberly W.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Hilt, JZ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 F Paul Anderson Tower, Lexington, KY 40506 USA.
RI Meenach, Samantha/F-7542-2014
FU Kentucky Science and Engineering Foundation [KSEF 1169-RDE-009];
   National Science Foundation
FX This research work was supported in part by a grant from the Kentucky
   Science and Engineering Foundation as per Grant Agreement #KSEF
   1169-RDE-009 with the Kentucky Science and Technology Corporation. In
   addition, the authors would like to acknowledge support for S.A. Meenach
   by the National Science Foundation IGERT Program on Engineered Bioactive
   Interfaces and Devices at the University of Kentucky.
CR Babincova M, 2001, J MAGN MAGN MATER, V225, P109, DOI 10.1016/S0304-8853(00)01237-3
   Bahadur D, 2003, SADHANA-ACAD P ENG S, V28, P639, DOI 10.1007/BF02706451
   Brazel CS, 2009, PHARM RES-DORD, V26, P644, DOI 10.1007/s11095-008-9773-2
   CORKHILL PH, 1989, BIOMATERIALS, V10, P3, DOI 10.1016/0142-9612(89)90002-1
   Degirmenbasi N, 2006, COLLOID SURFACE B, V48, P42, DOI 10.1016/j.colsurfb.2006.01.002
   DiRamio JA, 2005, BIOTECHNOL PROGR, V21, P1281, DOI 10.1021/bp0495670
   Elliott JE, 2001, CHEM ENG SCI, V56, P3173, DOI 10.1016/S0009-2509(00)00547-9
   Falk MH, 2001, INT J HYPERTHER, V17, P1, DOI 10.1080/02656730150201552
   Flory P. J., 1953, PRINCIPLES POLYM CHE
   Frimpong R.A., 2006, J BIOMED MATER RES A, V80, P1
   Frimpong R. A., 2007, NANOTECHNOLOGY THERA, P241
   Guedes MHA, 2005, J MAGN MAGN MATER, V293, P283, DOI 10.1016/j.jmmm.2005.02.052
   Hawkins AM, 2009, PHARM RES-DORD, V26, P667, DOI 10.1007/s11095-008-9804-z
   Hildebrandt B, 2002, CRIT REV ONCOL HEMAT, V43, P33, DOI 10.1016/S1040-8428(01)00179-2
   Horsman MR, 2007, CLIN ONCOL-UK, V19, P418, DOI 10.1016/j.clon.2007.03.015
   Issels RD, 2008, EUR J CANCER, V44, P2546, DOI 10.1016/j.ejca.2008.07.038
   JEON SI, 1991, J COLLOID INTERF SCI, V142, P149, DOI 10.1016/0021-9797(91)90043-8
   Jordan A, 1999, J MAGN MAGN MATER, V201, P413, DOI 10.1016/S0304-8853(99)00088-8
   Lutz JF, 2008, J POLYM SCI POL CHEM, V46, P3459, DOI 10.1002/pola.22706
   Meenach SA, 2009, J BIOMED MATER RES A, V91A, P903, DOI 10.1002/jbm.a.32322
   Meenach Samantha A., 2009, P131, DOI 10.1007/978-0-387-78608-7_7
   Mellott MB, 2001, BIOMATERIALS, V22, P929, DOI 10.1016/S0142-9612(00)00258-1
   Moroz P, 2002, INT J HYPERTHER, V18, P267, DOI 10.1080/02656730110108785
   Nagaoka S, 1984, INTERACTION BLOOD CO
   Okada A, 2006, MACROMOL MATER ENG, V291, P1449, DOI 10.1002/mame.200600260
   Peppas NA, 2006, ADV MATER, V18, P1345, DOI 10.1002/adma.200501612
   PEPPAS NA, 1976, J POLYM SCI POL CHEM, V14, P441, DOI 10.1002/pol.1976.170140215
   Peppas N. A., 1987, HYDROGELS MED PHARM, VI-III
   PEPPSA NA, 2000, EUR J PHARM BIOPHARM, V5, P27
   Satarkar NS, 2008, J CONTROL RELEASE, V130, P246, DOI 10.1016/j.jconrel.2008.06.008
   Satarkar NS, 2008, ACTA BIOMATER, V4, P11, DOI 10.1016/j.actbio.2007.07.009
   Satarkar NS, 2009, LAB CHIP, V9, P1773, DOI 10.1039/b822694f
   Schexnailder P, 2009, COLLOID POLYM SCI, V287, P1, DOI 10.1007/s00396-008-1949-0
   Sneed PK, 1998, INT J RADIAT ONCOL, V40, P287, DOI 10.1016/S0360-3016(97)00731-1
   Xiang YQ, 2006, EUR POLYM J, V42, P2125, DOI 10.1016/j.eurpolymj.2006.04.003
   Zhang DH, 2006, J PHYS CHEM B, V110, P12910, DOI 10.1021/jp061628k
NR 36
TC 92
Z9 92
U1 11
U2 89
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742-7061
J9 ACTA BIOMATER
JI Acta Biomater.
PD MAR
PY 2010
VL 6
IS 3
BP 1039
EP 1046
DI 10.1016/j.actbio.2009.10.017
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 560ZD
UT WOS:000274943500037
PM 19840875
DA 2018-03-19
ER

PT J
AU Li, XS
   Turanek, J
   Knotigova, P
   Kudlackova, H
   Masek, J
   Parkin, S
   Rankin, SE
   Knutson, BL
   Lehmler, HJ
AF Li, Xueshu
   Turanek, Jaroslav
   Knoetigova, Pavlina
   Kudlackova, Hana
   Masek, Josef
   Parkin, Sean
   Rankin, Stephen E.
   Knutson, Barbara L.
   Lehmler, Hans-Joachim
TI Hydrophobic tail length, degree of fluorination and headgroup
   stereochemistry are determinants of the biocompatibility of
   (fluorinated) carbohydrate surfactants
SO COLLOIDS AND SURFACES B-BIOINTERFACES
LA English
DT Article
DE Cytotoxicity; Haemolytic activity; Surfactant-lipid interactions; DPPC;
   Fluorescence anisotropy
ID CHAIN ALKYL GLYCOPYRANOSIDES; PHASE-TRANSITION; BIOMEDICAL APPLICATIONS;
   LYOTROPIC PROPERTIES; LIQUID VENTILATION; SUGAR SURFACTANTS;
   DRUG-DELIVERY; PERFLUOROOCTANOATE; ERYTHROCYTES; AMPHIPHILES
AB A series of hydrocarbon and fluorocarbon carbohydrate surfactants with different headgroups (i.e., gluco-, galacto- and maltopyranoside) and (fluorinated) alkyl tails (i.e., C(7) and C(14) to C(19)) was synthesized to investigate trends in their cytotoxicity and haemolytic activity, and how surfactant-lipid interactions of selected surfactants contribute to these two measures of biocompatibility. All surfactants displayed low cytotoxicity (EC(50) = 25 to >250 mu M) and low haemolytic activity (EC(50) = 0.2 to >3.3 mu M), with headgroup structure, tail length and degree of fluorination being important structural determinants for both endpoints. The EC(50) values of hydrocarbon and fluorocarbon glucopyranoside surfactants displayed a "cut-off" effect (i.e., a maximum with respect to the chain length). According to steady-state fluorescence anisotropy studies, short chain (C7) surfactants partitioned less readily into model membranes, which explains their low cytotoxicity and haemolytic activity. Interestingly, galactopyranosides were less toxic compared to glucopyranosides with the same hydrophobic tail. Although both surfactant types only differ in the stereochemistry of the 4-OH group, hexadecyl gluco- and galactopyranoside surfactants had similar apparent membrane partition coefficients. but differed in their overall effect on the phase behaviour of DPPC model membranes, as assessed using steady-state fluorescence anisotropy studies. These observations Suggest that highly selective surfactant-lipid interactions may be responsible for the differential cytotoxicity and, possible, haemolytic activity of hydrocarbon and fluorocarbon carbohydrate surfactants intended for a variety of pharmaceutical and biomedical applications. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Li, Xueshu; Lehmler, Hans-Joachim] Univ Iowa, Dept Occupat & Environm Hlth, Iowa City, IA 52242 USA.
   [Turanek, Jaroslav; Knoetigova, Pavlina; Kudlackova, Hana; Masek, Josef] Vet Res Inst Vvi, Dept Vaccinol & Immunotherapy, CS-62132 Brno, Czech Republic.
   [Parkin, Sean] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
   [Rankin, Stephen E.; Knutson, Barbara L.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Lehmler, HJ (reprint author), Univ Iowa, Dept Occupat & Environm Hlth, Iowa City, IA 52242 USA.
EM turanek@vri.cz; hans-joachim-lehmler@uiowa.edu
RI Parkin, Sean/E-7044-2011; Rankin, Stephen/A-3265-2013; Li,
   Xueshu/C-2262-2011; Masek, Josef/B-3734-2015
OI Rankin, Stephen/0000-0002-8615-7564; Masek, Josef/0000-0001-6788-8487;
   Lehmler, Hans-Joachim/0000-0001-9163-927X
FU National Institute of Environmental Health Sciences [ES12475]; National
   Science Foundation [NIRT 0210517]; Ministry of Agriculture of the Czech
   Republic [MZE-0002716202, NAZV QF-3115]
FX This work was supported by grants from the National Institute of
   Environmental Health Sciences (ES12475), the National Science Foundation
   (NIRT 0210517), the U.S. Department of Agriculture Biomass Research and
   Development Initiative (Grant Agreement 68-3A75-7-608) and the
   Department of Energy Development and Independence, Energy and
   Environment Cabinet of The Commonwealth of Kentucky. Additional support
   was provided by grants from the Ministry of Agriculture of the Czech
   Republic (grant No. MZE-0002716202) and NAZV QF-3115 to JT. Its contents
   are solely the responsibility of the authors and do not necessarily
   represent the official views of the funding agencies.
CR ABOUHILALE S, 1992, J AM OIL CHEM SOC, V69, P1, DOI 10.1007/BF02635867
   Balgavy P, 1996, ADV COLLOID INTERFAC, V66, P23, DOI 10.1016/0001-8686(96)00295-3
   BANK U, 1991, Allergie und Immunologie (Leipzig), V37, P119
   BILTONEN RL, 1993, CHEM PHYS LIPIDS, V64, P129, DOI 10.1016/0009-3084(93)90062-8
   HAEGERSTRAND H, 1992, BIOCHIM BIOPHYS ACTA, V1109, P117
   INOUE T, 1988, CHEM PHYS LIPIDS, V46, P25, DOI 10.1016/0009-3084(88)90109-0
   ISOMAA B, 1987, BIOCHIM BIOPHYS ACTA, V899, P93, DOI 10.1016/0005-2736(87)90243-4
   ISOMAA B, 1986, BIOCHIM BIOPHYS ACTA, V860, P510, DOI 10.1016/0005-2736(86)90548-1
   Kamp F, 2006, PROSTAG LEUKOTR ESS, V75, P149, DOI 10.1016/j.plefa.2006.05.003
   Kasuya MCZ, 2004, BIOCHEM BIOPH RES CO, V316, P599, DOI 10.1016/j.bbrc.2004.02.094
   Kasuya MCZ, 2005, CHEM LETT, V34, P856, DOI 10.1246/cl.2005.856
   Ladmiral V, 2006, J AM CHEM SOC, V128, P4823, DOI 10.1021/ja058364k
   Lakowicz J. R., 2006, PRINCIPLES FLUORESCE
   Lehmler HJ, 2007, EXPERT OPIN DRUG DEL, V4, P247, DOI 10.1517/17425247.4.3.247
   Lehmler HJ, 1999, CHEMTECH, V29, P7
   Li XS, 2008, NEW J CHEM, V32, P2169, DOI 10.1039/b805015e
   LOHNER K, 1991, CHEM PHYS LIPIDS, V57, P341, DOI 10.1016/0009-3084(91)90085-P
   MILIUS A, 1991, NEW J CHEM, V15, P337
   Milkereit G, 2004, CHEM PHYS LIPIDS, V127, P47, DOI 10.1016/j.chemphyslip.2003.09.007
   Mollinedo F, 2006, DRUG RESIST UPDATE, V9, P51, DOI 10.1016/j.durp.2006.04.002
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Petrovic Z, 2004, INDIAN J CHEM B, V43, P132
   Riess JG, 1999, MRS BULL, V24, P42
   Rozycka-Roszak B, 2007, THERMOCHIM ACTA, V453, P27, DOI 10.1016/j.tca.2006.10.027
   SHAFFER TH, 1992, PEDIATR PULM, V14, P102, DOI 10.1002/ppul.1950140208
   Soderlind E, 2006, EUR J PHARM BIOPHARM, V62, P254, DOI 10.1016/j.ejpb.2005.08.012
   Soderlind E, 2003, INT J PHARM, V252, P61, DOI 10.1016/S0378-5173(02)00599-9
   Soederlind E., 2006, EUR J PHARM BIOPHARM, V62, P254
   Turanek J, 2004, ANTI-CANCER DRUG, V15, P537, DOI 10.1097/01.cad.0000127147.57796.e5
   Vill V, 2000, CHEM PHYS LIPIDS, V104, P75, DOI 10.1016/S0009-3084(99)00119-X
   Vyas SM, 2006, NEW J CHEM, V30, P944, DOI 10.1039/b516039a
   Wolf P., 2004, FOOT, V14, P23
   Xie W, 2007, BBA-BIOMEMBRANES, V1768, P1299, DOI 10.1016/j.bbamem.2007.02.003
   ZARIF L, 1989, J FLUORINE CHEM, V44, P73, DOI 10.1016/S0022-1139(00)84372-9
   ZARIF L, 1990, J MED CHEM, V33, P1262, DOI 10.1021/jm00166a028
NR 35
TC 23
Z9 23
U1 2
U2 24
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0927-7765
J9 COLLOID SURFACE B
JI Colloid Surf. B-Biointerfaces
PD OCT 1
PY 2009
VL 73
IS 1
BP 65
EP 74
DI 10.1016/j.colsurfb.2009.04.023
PG 10
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
SC Biophysics; Chemistry; Materials Science
GA 479KF
UT WOS:000268657500010
PM 19481909
OA green_accepted
DA 2018-03-20
ER

PT J
AU Wu, QL
   Li, JC
   Deshpande, RD
   Subramanian, N
   Rankin, SE
   Yang, FQ
   Cheng, YT
AF Wu, Qingliu
   Li, Juchuan
   Deshpande, Rutooj D.
   Subramanian, Navaladian
   Rankin, Stephen E.
   Yang, Fuqian
   Cheng, Y-T.
TI Aligned TiO2 Nanotube Arrays As Durable Lithium-Ion Battery Negative
   Electrodes
SO JOURNAL OF PHYSICAL CHEMISTRY C
LA English
DT Article
ID DIFFUSION-INDUCED STRESS; TITANIA NANOTUBES; ANODIC-OXIDATION; LI;
   OXIDE; FABRICATION; ANATASE; FILMS; PARTICLES; EVOLUTION
AB Vertically aligned amorphous titania (TiO2) nanotubes are produced by anodizing Ti foils at various applied potentials in a neutral electrolyte solution containing fluoride ions. Pore size and wall thickness are tuned in the range from 30 to 70 nm and 17 to 35 nm, respectively, by adjusting the applied potential, in addition to tuning the tube length from 355 to 550 nm. Utilizing all of these films as negative electrode materials in lithium-ion batteries delivers stable capacities of 130-230 mAh g(-1) and 520-880 mAh cm(-3) up to 200 cycles. Microstructural analysis shows that there is no structural change or mechanical degradation in the active material, and the amorphous active material maintains good contact with the substrate/current collector. A continuum elasticity model for the tubular geometry is presented to understand the diffusion-induced stresses, fracture tendency, and stability in TiO2 nanotubes. Modeling results indicate that the fracture tendencies of nanotubes with the dimensions in this work are very small; stable reversible capacity retention results from the high ratio of inner to outer diameter of the tubes. In other words, tubes with thinner walls more easily accommodate expansion or contraction during the lithiation/delithiation process. A guideline for designing lithium-ion battery nanotube electrodes is given such that under specific conditions the fracture tendency is small and volumetric charge density is high.
C1 [Wu, Qing Liu; Li, Juchuan; Deshpande, Rutooj D.; Subramanian, Navaladian; Rankin, Stephen E.; Yang, Fuqian; Cheng, Yang-Tse] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Rankin, SE (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 FP Anderson Tower, Lexington, KY 40506 USA.
EM srankin@engr.uky.edu; fyang0@engr.uky.edu; ycheng@engr.uky.edu
RI wu, qingliu/C-7631-2012; Li, Juchuan/A-2992-2009; Cheng,
   Yang-Tse/B-5424-2012; Rankin, Stephen/A-3265-2013; Subramanian,
   Navaladian/K-4306-2012
OI Li, Juchuan/0000-0002-6587-5591; Cheng, Yang-Tse/0000-0003-0737-9212;
   Rankin, Stephen/0000-0002-8615-7564; Subramanian,
   Navaladian/0000-0002-0509-5438
FU U.S. DOE EPSCoR Implementation Award [DE-FG02-07ER46375]; NSF [CMME
   1000726]; General Motors Global RD Center
FX Financial support from a U.S. DOE EPSCoR Implementation Award to support
   TiO<INF>2</INF> nanotube synthesis and characterization (Grant No.
   DE-FG02-07ER46375), from an NSF award to support diffusion induced
   stress calculations (Grant No. CMME 1000726), and from General Motors
   Global R&D Center to support battery testing and analysis is gratefully
   acknowledged.
CR Armstrong AR, 2005, ADV MATER, V17, P862, DOI 10.1002/adma.200400795
   Baudrin E, 2007, ELECTROCHEM COMMUN, V9, P337, DOI 10.1016/j.elecom.2006.09.022
   Cai QY, 2005, J MATER RES, V20, P230, DOI 10.1557/JMR.2005.0020
   Carslaw HS, 1959, CONDUCTION HEAT SOLI
   Cheng YT, 2010, J ELECTROCHEM SOC, V157, pA508, DOI 10.1149/1.3298892
   Cheng YT, 2008, J APPL PHYS, V104, DOI 10.1063/1.3000442
   Cheng YT, 2009, J POWER SOURCES, V190, P453, DOI 10.1016/j.jpowsour.2009.01.021
   Christensen J, 2006, J ELECTROCHEM SOC, V153, pA1019, DOI 10.1149/1.2185287
   Deshpande R, 2010, J ELECTROCHEM SOC, V157, pA967, DOI 10.1149/1.3454762
   Deshpande R, 2010, J POWER SOURCES, V195, P5081, DOI 10.1016/j.jpowsour.2010.02.021
   Fang HT, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/22/225701
   Furukawa H, 2004, J ELECTROCHEM SOC, V151, pA527, DOI 10.1149/1.1649747
   Gong D, 2001, J MATER RES, V16, P3331, DOI 10.1557/JMR.2001.0457
   Hassan FMB, 2009, J ELECTROCHEM SOC, V156, pK227, DOI 10.1149/1.3232246
   Kavan L, 2004, CHEM MATER, V16, P477, DOI 10.1021/cm035046g
   Kavan L, 1996, J AM CHEM SOC, V118, P6716, DOI 10.1021/ja954172l
   Lindsay MJ, 2007, ELECTROCHIM ACTA, V52, P6401, DOI 10.1016/j.electacta.2007.04.027
   Lindsay MJ, 2009, ELECTROCHIM ACTA, V54, P3501, DOI 10.1016/j.electacta.2008.10.044
   Liu ZL, 2005, J POWER SOURCES, V143, P231, DOI 10.1016/j.jpowsour.2004.11.056
   Macak JM, 2005, ANGEW CHEM INT EDIT, V44, P7463, DOI 10.1002/anie.200502781
   MACDONALD DD, 1993, J ELECTROCHEM SOC, V140, pL27, DOI 10.1149/1.2056179
   Mor GK, 2003, J MATER RES, V18, P2588, DOI 10.1557/JMR.2003.0362
   Mor GK, 2006, SOL ENERG MAT SOL C, V90, P2011, DOI 10.1016/j.solmat.2006.04.007
   Ortiz GF, 2009, CHEM MATER, V21, P63, DOI 10.1021/cm801670u
   Park CM, 2010, CHEM SOC REV, V39, P3115, DOI 10.1039/b919877f
   Prussin S., 1961, Journal of Applied Physics, V32, P1876, DOI 10.1063/1.1728256
   Scrosati B, 2010, J POWER SOURCES, V195, P2419, DOI 10.1016/j.jpowsour.2009.11.048
   Tang YF, 2009, J MATER CHEM, V19, P5980, DOI 10.1039/b907480e
   Timoshenko S, 1951, THEORY ELASTICITY
   Verbrugge MW, 2009, J ELECTROCHEM SOC, V156, pA927, DOI 10.1149/1.3205485
   Wagemaker M, 2003, J AM CHEM SOC, V125, P840, DOI 10.1021/ja028165q
   Wang DH, 2008, CHEM MATER, V20, P3435, DOI 10.1021/cm8002589
   Wei Z, 2010, J SOLID STATE ELECTR, V14, P1045, DOI 10.1007/s10008-009-0910-6
   Winter M, 2009, Z PHYS CHEM, V223, P1395, DOI 10.1524/zpch.2009.6086
   Xu T, 2010, JOM-US, V62, P24, DOI 10.1007/s11837-010-0131-6
   Yang F, 2010, J APPL PHYS, P108
   Yang FQ, 2005, MAT SCI ENG A-STRUCT, V409, P153, DOI 10.1016/j.msea.2005.05.117
   Yang ZG, 2009, J POWER SOURCES, V192, P588, DOI 10.1016/j.jpowsour.2009.02.038
   Zaghib K, 1999, J POWER SOURCES, V81, P300, DOI 10.1016/S0378-7753(99)00209-8
NR 39
TC 80
Z9 82
U1 9
U2 105
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1932-7447
J9 J PHYS CHEM C
JI J. Phys. Chem. C
PD SEP 6
PY 2012
VL 116
IS 35
BP 18669
EP 18677
DI 10.1021/jp3072266
PG 9
WC Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science,
   Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA 999UD
UT WOS:000308339600014
DA 2018-03-20
ER

PT J
AU Long, SH
   Zhang, MT
   Zhou, PP
   Yu, FQ
   Parkin, S
   Li, TL
AF Long, Sihui
   Zhang, Mingtao
   Zhou, Panpan
   Yu, Faquan
   Parkin, Sean
   Li, Tonglei
TI Tautomeric Polymorphism of 4-Hydroxynicotinic Acid
SO CRYSTAL GROWTH & DESIGN
LA English
DT Article
ID DENSITY-FUNCTIONAL THEORY; SOLID-STATE NMR; X-RAY; CRYSTAL-STRUCTURES;
   HEMIHYDRATE; DESMOTROPY; PREFERENCE; ENERGIES; FENOBAM; ROBUST
AB 4-Hydroxynicotinic acid (4-HNA) was discovered to exist in the solid state as either 4-HNA or its tautomer 4-Oxo-1,4-dihydropyridine-3-carboxylic acid (4-ODHPCA) in three polymorphs and two hydrates. Packing motifs differ as each of the three oxygen atoms acts as the hydrogen-bond acceptor, respectively, in the anhydrate forms, while in the hydrate forms, water molecules participate in hydrogen bonding with 4-HNA. Phase behaviors of the forms were characterized by differential scanning calorimetry (DSC), hot stage microscopy (HSM), and thermogravimetric analysis (TGA). It was found that anhydrates I and II converted into III during heating; the two hydrate forms dehydrated at different temperatures and eventually transformed into anhydrate III, and sublimation of all five forms led to form III when the crystals were heated. Quantum mechanical calculations were performed providing further insight into the polymorphism.
C1 [Long, Sihui; Yu, Faquan] Wuhan Inst Technol, Sch Chem Engn & Pharm, Minist Educ, Key Lab Green Chem Proc, Wuhan 430073, Hubei, Peoples R China.
   [Zhang, Mingtao; Li, Tonglei] Purdue Univ, Dept Ind & Phys Pharm, W Lafayette, IN 47907 USA.
   [Zhou, Panpan] Lanzhou Univ, Dept Chem, Lanzhou 730000, Gansu, Peoples R China.
   [Parkin, Sean] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
RP Li, TL (reprint author), Purdue Univ, Dept Ind & Phys Pharm, W Lafayette, IN 47907 USA.
EM tonglei@purdue.edu
OI Zhang, Mingtao/0000-0001-9588-9751
FU Natural Science Foundation of Hubei Province [2014CFB787]; National
   Natural Science Foundation of China [21403097]; Fundamental Research
   Funds for the Central Universities [lzujbky-2014-182]; NSF [DMR1006364]
FX S.L. thanks the Natural Science Foundation of Hubei Province for
   financial support (Grant No. 2014CFB787). P.Z. acknowledges the
   financial support by the National Natural Science Foundation of China
   (Grant No. 21403097) and the Fundamental Research Funds for the Central
   Universities (Grant No. lzujbky-2014-182). T.L. is grateful to NSF for
   supporting the work (Grant No. DMR1006364) and to the Allen Chao
   Endowment.
CR Bauer M, 1998, J CHEM SOC PERK T 2, P475, DOI 10.1039/a708038g
   Bhatt PM, 2007, CHEM COMMUN, P2057, DOI 10.1039/b700506g
   Blake AJ, 2004, ACTA CRYSTALLOGR C, V60, pO226, DOI 10.1107/S0108270104003026
   Bocskei Z, 1998, ACTA CRYSTALLOGR C, V54, P808, DOI 10.1107/S0108270197019884
   BOYS SF, 1970, MOL PHYS, V19, P553, DOI 10.1080/00268977000101561
   BRIDGES JW, 1966, BIOCHEM J, V98, P451, DOI 10.1042/bj0980451
   Chierotti MR, 2008, CRYST GROWTH DES, V8, P1454, DOI 10.1021/cg701214k
   Chierotti MR, 2010, CHEM-EUR J, V16, P4347, DOI 10.1002/chem.200902485
   Dawson HM, 1913, J CHEM SOC, V103, P1308, DOI 10.1039/ct9130301308
   DESIRAJU GR, 1983, J CHEM SOC PERK T 2, P1025, DOI 10.1039/p29830001025
   Dogra SK, 2005, J MOL STRUCT, V737, P189, DOI 10.1016/j.molstruc.2004.10.060
   Dovesi R, 2014, INT J QUANTUM CHEM, V114, P1287, DOI 10.1002/qua.24658
   Elguero J, 2011, CRYST GROWTH DES, V11, P4731, DOI 10.1021/cg200970t
   Feng SX, 2006, J CHEM THEORY COMPUT, V2, P149, DOI 10.1021/ct050189a
   Garcia MA, 2002, HELV CHIM ACTA, V85, P2763
   Grinard V., 1929, ROCZNIKI CHEM, V9, P547
   Gupta SL, 2007, ACTA CRYSTALLOGR E, V63, pO2784, DOI 10.1107/S1600536807020958
   Hardy JD, 1940, J CLIN INVEST, V19, P649, DOI 10.1172/JCI101168
   Joseph A, 2015, CRYST GROWTH DES, V15, P3511, DOI 10.1021/acs.cgd.5b00594
   Li TL, 2006, PHARM RES-DORDR, V23, P2326, DOI 10.1007/s11095-006-9006-5
   Lill SON, 2014, CRYST GROWTH DES, V14, P3704, DOI 10.1021/cg500916u
   Long SH, 2015, CRYSTENGCOMM, V17, P5195, DOI 10.1039/c4ce02290d
   Matias EP, 2011, CRYST GROWTH DES, V11, P2803, DOI 10.1021/cg1015687
   Mirmehrabi M, 2004, J CRYST GROWTH, V260, P517, DOI 10.1016/j.jcrysgro.2003.08.061
   Nonius, 2002, COLLECT
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Santos RC, 2009, J PHYS CHEM B, V113, P14291, DOI 10.1021/jp906908n
   Schmidt A, 1999, J AM CHEM SOC, V121, P11291, DOI 10.1021/ja991204m
   Schmidt MU, 2011, ANGEW CHEM INT EDIT, V50, P7924, DOI 10.1002/anie.201101040
   Schmidt M. U., 2011, ANGEW CHEM, V123, P8070
   Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930
   Sheldrick G. M., 1995, SIEMENS ANAL XRAY IN
   Sheldrick G. M., 1997, SHELXL97 SHELXS97
   Thomas SP, 2014, CRYST GROWTH DES, V14, P3758, DOI 10.1021/cg500043n
   Thomas SP, 2012, CHEM COMMUN, V48, P10559, DOI 10.1039/c2cc34912d
   Tothadi S, 2012, CHEM-ASIAN J, V7, P330, DOI 10.1002/asia.201100638
   Weygand C, 1932, Z ANORG ALLG CHEM, V205, P414, DOI 10.1002/zaac.19322050408
   TENDELOO HJC, 1974, Patent No. 1362698
NR 38
TC 5
Z9 5
U1 4
U2 18
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1528-7483
EI 1528-7505
J9 CRYST GROWTH DES
JI Cryst. Growth Des.
PD MAY
PY 2016
VL 16
IS 5
BP 2573
EP 2580
DI 10.1021/acs.cgd.5b01639
PG 8
WC Chemistry, Multidisciplinary; Crystallography; Materials Science,
   Multidisciplinary
SC Chemistry; Crystallography; Materials Science
GA DL3FZ
UT WOS:000375520900017
DA 2018-03-20
ER

PT J
AU Scott, D
   Rohr, J
   Bae, Y
AF Scott, Daniel F.
   Rohr, Juergen
   Bae, Younsoo
TI Nanoparticulate formulations of mithramycin analogs for enhanced
   cytotoxicity
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE drug delivery; polymer micelles; controlled release; MTM; cancer
   chemotherapy
ID PRODUCER STREPTOMYCES-ARGILLACEUS; BIOSYNTHETIC-PATHWAY; TRANSCRIPTION
   FACTOR; PANCREATIC-CANCER; DRUG MITHRAMYCIN; POLYMER MICELLES; ANTITUMOR
   DRUG; PAGETS DISEASE; FACTOR FAMILY; MDR1 GENE
AB Mithramycin (MTM), a natural product of soil bacteria from the Streptomyces genus, displays potent anticancer activity but has been limited clinically by severe side effects and toxicities. Engineering of the MTM biosynthetic pathway has produced the 3-side-chain-modified analogs MTM SK (SK) and MTM SDK (SDK), which have exhibited increased anticancer activity and improved therapeutic index. However, these analogs still suffer from low bioavailability, short plasma retention time, and low tumor accumulation. In an effort to aid with these shortcomings, two nanoparticulate formulations, poly(ethylene glycol)-poly(aspartate hydrazide) self-assembled and cross-linked micelles, were investigated with regard to the ability to load and pH dependently release the drugs. Micelles were successfully formed with both nanoparticulate formulations of each drug analog, with an average size of 8.36 +/- 3.21 and 12.19 +/- 2.77 nm for the SK and SDK micelles and 29.56 +/- 4.67 nm and 30.48 +/- 7.00 nm for the SK and SDK cross-linked micelles respectively. All of the drug-loaded formulations showed a pH-dependent release of the drugs, which was accelerated as pH decreased from 7.4 to 5.0. The micelles retained biological activity of SK and SDK entrapped in the micelles, suppressing human A549 lung cancer cells effectively.
C1 [Scott, Daniel; Rohr, Juergen; Bae, Younsoo] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
RP Bae, Y (reprint author), Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, 789 S Limestone, Lexington, KY 40536 USA.
EM younsoo.bae@uky.edu
RI Rohr, Jurgen/G-5375-2014
OI Rohr, Jurgen/0000-0001-6447-5951
FU National Institutes of Health [CA 091901]; Kentucky Lung Cancer Research
   Program; NCI-CNTC; National Cancer Institute [5R25CA153954]
FX This research was supported in part by the National Institutes of Health
   (grant CA 091901 to JR) and the Kentucky Lung Cancer Research Program
   (to YB). DS acknowledges financial support from a NCI-CNTC postdoctoral
   traineeship, and the project described was supported by grant number
   5R25CA153954 from the National Cancer Institute. The content is solely
   the responsibility of the authors and does not necessarily represent the
   official views of the National Cancer Institute or the National
   Institutes of Health.
CR Abdelrahim M, 2004, CANCER RES, V64, P6740, DOI 10.1158/0008-5472.CAN-04-0713
   Alani AWG, 2010, BIOMATERIALS, V31, P1765, DOI 10.1016/j.biomaterials.2009.11.038
   Albertini V, 2006, NUCLEIC ACIDS RES, V34, P1721, DOI 10.1093/nar/gkl063
   Bae Y, 2007, BIOCONJUGATE CHEM, V18, P1131, DOI 10.1021/bc060401p
   Bae Y, 2009, ADV DRUG DELIVER REV, V61, P768, DOI 10.1016/j.addr.2009.04.016
   Becker ML, 2004, BIOCONJUGATE CHEM, V15, P699, DOI 10.1021/bc049946e
   Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111
   BLUME SW, 1991, J CLIN INVEST, V88, P1613, DOI 10.1172/JCI115474
   BROWN JH, 1965, NEW ENGL J MED, V272, P111, DOI 10.1056/NEJM196501212720301
   Chen HT, 2008, P NATL ACAD SCI USA, V105, P6596, DOI 10.1073/pnas.0707046105
   Frezard F, 1997, J INCLUS PHENOM MOL, V28, P51, DOI 10.1023/A:1007985811673
   Gao Y, 2011, CANCER RES, V71, P5182, DOI 10.1158/0008-5472.CAN-10-2016
   Gibson M, 2005, J AM CHEM SOC, V127, P17594, DOI 10.1021/ja055750t
   Gillies RJ, 2008, J NUCL MED, V49, p24S, DOI 10.2967/jnumed.107.047258
   Grohar PJ, 2011, JNCI-J NATL CANCER I, V103, P962, DOI 10.1093/jnci/djr156
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Howard MD, 2011, PHARM RES-DORDR, V28, P2435, DOI 10.1007/s11095-011-0470-1
   Jin HJ, 2011, J BIOL CHEM, V286, P19840, DOI 10.1074/jbc.M110.203687
   Jones AT, 2003, ADV DRUG DELIVER REV, V55, P1353, DOI 10.1016/j.addr.2003.07.002
   KENNEDY BJ, 1970, AM J MED, V49, P494, DOI 10.1016/S0002-9343(70)80044-4
   KOLLER CA, 1986, NEW ENGL J MED, V315, P1433, DOI 10.1056/NEJM198612043152301
   Lee HJ, 2011, BIOMACROMOLECULES, V12, P2686, DOI 10.1021/bm200483t
   MILLER DM, 1987, AM J MED SCI, V294, P388, DOI 10.1097/00000441-198711000-00015
   Ponta A, 2010, PHARM RES-DORDR, V27, P2330, DOI 10.1007/s11095-010-0120-z
   Remsing LL, 2003, J AM CHEM SOC, V125, P5745, DOI 10.1021/ja034162j
   Remsing LL, 2002, J AM CHEM SOC, V124, P1606, DOI 10.1021/ja0105156
   RYAN WG, 1970, NEW ENGL J MED, V283, P1171
   RYAN WG, 1970, J AMER MED ASSOC, V213, P1153, DOI 10.1001/jama.213.7.1153
   Safe S, 2005, EUR J CANCER, V41, P2438, DOI 10.1016/j.ejca.2005.08.006
   SASTRY M, 1995, J MOL BIOL, V251, P674, DOI 10.1006/jmbi.1995.0464
   SASTRY M, 1993, BIOCHEMISTRY-US, V32, P6588, DOI 10.1021/bi00077a012
   Seznec J, 2011, J NEURO-ONCOL, V101, P365, DOI 10.1007/s11060-010-0266-x
   Sleiman SF, 2011, J NEUROSCI, V31, P6858, DOI 10.1523/JNEUROSCI.0710-11.2011
   Smart T, 2008, NANO TODAY, V3, P38, DOI 10.1016/S1748-0132(08)70043-4
   SNYDER RC, 1991, BIOCHEMISTRY-US, V30, P4290, DOI 10.1021/bi00231a027
   Tagashira M, 2000, CHEM PHARM BULL, V48, P575
   Tagashira M, 2000, BIOL PHARM BULL, V23, P926
   TAKAKURA Y, 1990, PHARMACEUT RES, V7, P339, DOI 10.1023/A:1015807119753
   van Vlerken LE, 2007, PHARM RES, V24, P1405, DOI 10.1007/s11095-007-9284-6
   West Kevin R, 2005, Curr Drug Discov Technol, V2, P123, DOI 10.2174/1570163054866882
NR 40
TC 12
Z9 12
U1 0
U2 2
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2011
VL 6
BP 2757
EP 2767
DI 10.2147/IJN.S25427
PG 11
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA 857AC
UT WOS:000297685000001
PM 22114504
OA gold
DA 2018-03-19
ER

PT J
AU Bhattacharyya, D
   Smuleac, V
   Lewis, S
   Xiao, L
   Varma, R
AF Bhattacharyya, Dibakar
   Smuleac, Vasile
   Lewis, Scott R.
   Xiao, Li
   Varma, Rajender
TI Nanostructured membranes for green synthesis of nanoparticles and enzyme
   catalysis
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
CT 241st National Meeting and Exposition of the American-Chemical-Society
   (ACS)
CY MAR 27-31, 2011
CL Anaheim, CA
SP Amer Chem Soc
C1 Univ Kentucky, Lexington, KY USA.
   US EPA, Cincinnati, OH 45268 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD MAR 27
PY 2011
VL 241
MA 5-IEC
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA 782BO
UT WOS:000291982804902
DA 2018-03-19
ER

PT J
AU Patil, VS
   Gutierrez, AM
   Sunkara, M
   Morris, AJ
   Hilt, JZ
   Kalika, DS
   Dziubla, TD
AF Patil, Vinod S.
   Gutierrez, Angela M.
   Sunkara, Manjula
   Morris, Andrew J.
   Hilt, J. Zach
   Kalika, Douglass S.
   Dziubla, Thomas D.
TI Curcumin Acrylation for Biological and Environmental Applications
SO JOURNAL OF NATURAL PRODUCTS
LA English
DT Article
ID OXIDATIVE STRESS; POLYMERS; ANTIOXIDANT; STABILITY; ISOMERS; ESTERS)
AB Curcumin has recently gained interest for use in drug delivery, chemical sensing, and environmental applications. As a result, the development of synthesis strategies for the incorporation of curcumin into novel materials has become a priority. One such strategy, curcumin acrylation, involves the introduction of acrylate functional groups to the curcumin scaffold, with the potential generation of mono-, di-, and triacrylate curcumin species. The relative populations of these species in the resulting multiacrylate mixture can be controlled by the ratio of curcumin to acryloyl chloride in the initial reaction formulation. Characterization of the acrylation reaction and the resulting curcumin multiacrylate product is essential for the effective preparation of new curcumin-containing materials. In this work, a synthesis method for curcumin acrylation is presented and the resulting curcumin multiacrylate product is characterized via various techniques, i.e., HPLC, LCMS, and NMR, as a basis to establish the relationship between synthesis conditions and the extent of acrylation that is achieved.
C1 [Patil, Vinod S.; Gutierrez, Angela M.; Hilt, J. Zach; Kalika, Douglass S.; Dziubla, Thomas D.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Sunkara, Manjula; Morris, Andrew J.] Univ Kentucky, Div Cardiovasc Med, Gill Heart Inst, Lexington, KY 40536 USA.
RP Dziubla, TD (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM thomas.dziubla@uky.edu
FU National Institute of Environmental Health Sciences (NIEHS)
   [P42ES007380]; NSF I/UCRC Center for Pharmaceutical Development
   [IIP-1063879]
FX The project was supported by the National Institute of Environmental
   Health Sciences (NIEHS, Grant Number P42ES007380) and by the NSF I/UCRC
   Center for Pharmaceutical Development (IIP-1063879 and industrial
   contributions). The content is solely the responsibility of the authors
   and does not necessarily represent the official views of the National
   Institute of Environmental Health Sciences, the National Institutes of
   Health, nor the National Science Foundation.
CR Bisht Savita, 2007, Journal of Nanobiotechnology, V5, P3, DOI 10.1186/1477-3155-5-3
   Cassano R, 2012, REACT FUNCT POLYM, V72, P446, DOI 10.1016/j.reactfunctpolym.2012.04.003
   Cochran DB, 2016, J BIOMED MATER RES B, V104, P1438, DOI 10.1002/jbm.b.33486
   Glauert HP, 2008, ENVIRON TOXICOL PHAR, V25, P247, DOI 10.1016/j.etap.2007.10.025
   Gogoi B, 2013, SENSOR ACTUAT B-CHEM, V181, P144, DOI 10.1016/j.snb.2013.01.071
   Gupta P, 2015, ACTA BIOMATER, V27, P194, DOI 10.1016/j.actbio.2015.08.039
   Gururaj AE, 2002, BIOCHEM BIOPH RES CO, V297, P934, DOI 10.1016/S0006-291X(02)02306-9
   GUTSCHE CD, 1983, TETRAHEDRON, V39, P409, DOI 10.1016/S0040-4020(01)88541-0
   Ishii Yuji, 2005, Fukuoka Acta Medica, V96, P204
   Kawano S, 2013, CHINESE CHEM LETT, V24, P685, DOI 10.1016/j.cclet.2013.05.006
   Killi N, 2015, NEW J CHEM, V39, P4464, DOI 10.1039/c4nj01936a
   Kitture R, 2012, J APPL PHYS, V111, DOI 10.1063/1.3696001
   Li Y, 2012, FOOD SCI HUMAN WELLN, V1, P19, DOI DOI 10.1016/J.FSHW.2012.08.002
   Manju S, 2011, J COLLOID INTERF SCI, V359, P318, DOI 10.1016/j.jcis.2011.03.071
   Mitov MI, 2016, OXIDATIVE STRESS AND BIOMATERIALS, P145, DOI 10.1016/B978-0-12-803269-5.00006-1
   Motterlini R, 2000, FREE RADICAL BIO MED, V28, P1303, DOI 10.1016/S0891-5849(00)00294-X
   Nagao T, 2005, AM J CLIN NUTR, V81, P122
   Pan J, 2007, CHROMATOGRAPHIA, V66, P121, DOI 10.1365/s10337-007-0243-5
   Paradkar A, 2004, INT J PHARM, V271, P281, DOI 10.1016/j.ijpharm.2003.11.014
   Patil VS, 2015, POLYMER, V75, P88, DOI 10.1016/j.polymer.2015.08.034
   Payton F, 2007, J NAT PROD, V70, P143, DOI 10.1021/np060263s
   Pumera M, 2013, CHEM SOC REV, V42, P5987, DOI 10.1039/c3cs60132c
   Riddell N, 2009, ENVIRON SCI TECHNOL, V43, P7902, DOI 10.1021/es901261v
   SHARMA OP, 1976, BIOCHEM PHARMACOL, V25, P1811, DOI 10.1016/0006-2952(76)90421-4
   Tang HD, 2010, BIOMATERIALS, V31, P7139, DOI 10.1016/j.biomaterials.2010.06.007
   TONNESEN HH, 1986, Z LEBENSM UNTERS FOR, V183, P116, DOI 10.1007/BF01041928
   Wattamwar PP, 2012, ACTA BIOMATER, V8, P2529, DOI 10.1016/j.actbio.2012.03.022
   Zawadiak J, 2010, SPECTROCHIM ACTA A, V75, P925, DOI 10.1016/j.saa.2009.12.040
   Zhang AF, 2003, MACROMOL CHEM PHYSIC, V204, P328, DOI 10.1002/macp.200290086
NR 29
TC 0
Z9 0
U1 13
U2 16
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0163-3864
EI 1520-6025
J9 J NAT PROD
JI J. Nat. Prod.
PD JUL
PY 2017
VL 80
IS 7
BP 1964
EP 1971
DI 10.1021/acs.jnatprod.6b00951
PG 8
WC Plant Sciences; Chemistry, Medicinal; Pharmacology & Pharmacy
SC Plant Sciences; Pharmacology & Pharmacy
GA FC4NZ
UT WOS:000406818300002
PM 28661687
DA 2018-03-20
ER

PT J
AU Xu, WJ
   Osei-Prempeh, G
   Lema, C
   Oldham, ED
   Aguilera, RJ
   Parkin, S
   Rankin, SE
   Knutson, BL
   Lehmler, HJ
AF Xu, Wenjin
   Osei-Prempeh, Gifty
   Lema, Carolina F.
   Oldham, Edward Davis
   Aguilera, Renato J.
   Parkin, Sean
   Rankin, Stephen E.
   Knutson, Barbara L.
   Lehmler, Hans-Joachim
TI Synthesis, thermal properties, and cytotoxicity evaluation of
   hydrocarbon and fluorocarbon alkyl beta-D-xylopyranoside surfactants
SO CARBOHYDRATE RESEARCH
LA English
DT Article
DE Next-generation surfactants; Renewable precursors; Xylose;
   Structure-activity relationship; Structure-property relationship;
   Koenigs-Knorr reaction
ID LIQUID-CRYSTALLINE PROPERTIES; CELL LINES; D-XYLITOLS; D-XYLOSE;
   AMPHIPHILES; DERIVATIVES; GLYCOSIDES; XYLAN; BIOCOMPATIBILITY;
   GLUCOPYRANOSIDE
AB Alkyl beta-D-xylopyranosides are highly surface active, biodegradable surfactants that can be prepared from hemicelluloses and are of interest for use as pharmaceuticals, detergents, agrochemicals, and personal care products. To gain further insights into their structure-property and structure-activity relationships, the present study synthesized a series of hydrocarbon (-C6H13 to -C16H33) and fluorocarbon (-(CH2)(2)C6F13) alkyl beta-D-xylopyranosides in four steps from D-xylose by acylation or benzoylation, bromination, Koenigs- Knorr reaction, and hydrolysis, with the benzoyl protecting group giving better yields compared to the acyl group in the Koenigs-Knorr reaction. All alkyl beta-D-xylopyranosides formed thermotropic liquid crystals. The phase transition of the solid crystalline phase to a liquid crystalline phase increased linearly with the length of the hydrophobic tail. The clearing points were near constant for alkyl beta-D-xylopyranosides with a hydrophobic tail >= 8, but occurred at a significantly lower temperature for hexyl beta-D-xylopyranoside. Short and long-chain alkyl beta-D-xylopyranosides displayed no cytotoxicity at concentration below their aqueous solubility limit. Hydrocarbon and fluorocarbon alkyl beta-D-xylopyranosides with intermediate chain length displayed some toxicity at millimolar concentrations due to apoptosis. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Xu, Wenjin; Oldham, E. Davis; Lehmler, Hans-Joachim] Univ Iowa, Dept Occupat & Environm Hlth, Iowa City, IA 52242 USA.
   [Osei-Prempeh, Gifty] WVU Inst Technol, Dept Chem Engn, Montgomery, WV 25136 USA.
   [Lema, Carolina; Aguilera, Renato J.] Univ Texas El Paso, Dept Biol Sci, El Paso, TX 79968 USA.
   [Parkin, Sean] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
   [Rankin, Stephen E.; Knutson, Barbara L.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Lehmler, HJ (reprint author), Univ Iowa, Dept Occupat & Environm Hlth, Univ Iowa Res Pk,221 IREH, Iowa City, IA 52242 USA.
EM hans-joachim-lehmler@uiowa.edu
RI Rankin, Stephen/A-3265-2013
OI Rankin, Stephen/0000-0002-8615-7564
FU National Science Foundation [CBET-0967381/0967390]; U.S. Department of
   Agriculture Biomass Research and Development Initiative [68-3A75-7-608];
   Department of Energy Development and Independence, Energy and
   Environment Cabinet of The Commonwealth of Kentucky; National Center for
   Research Resources (NCRR) of the NIH [5G12RR008124]
FX This work was supported by the National Science Foundation
   (CBET-0967381/0967390), the U. S. Department of Agriculture Biomass
   Research and Development Initiative (Grant Agreement 68-3A75-7-608) and
   the Department of Energy Development and Independence, Energy and
   Environment Cabinet of The Commonwealth of Kentucky. The cell culture
   work was supported by Grant 5G12RR008124 to the Border Biomedical
   Research Center (BBRC), granted to the University of Texas at El Paso
   from the National Center for Research Resources (NCRR) of the NIH.
CR Balgavy P, 1996, ADV COLLOID INTERFAC, V66, P23, DOI 10.1016/0001-8686(96)00295-3
   BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761
   Bouxin F, 2010, CARBOHYD RES, V345, P2469, DOI 10.1016/j.carres.2010.09.003
   BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77
   BROWN CJ, 1966, J CHEM SOC A, P922, DOI 10.1039/j19660000922
   Camponovo J, 2009, J ORG CHEM, V74, P5071, DOI 10.1021/jo900554b
   CHEN CH, 1990, INT ARCH ALLER A IMM, V93, P249, DOI 10.1159/000235309
   Damez C, 2007, CARBOHYD RES, V342, P154, DOI 10.1016/j.carres.2006.11.013
   DEBRUYNE CK, 1966, NATURE, V209, P396, DOI 10.1038/209396b0
   Deyrieux AF, 2007, CYTOTECHNOLOGY, V54, P77, DOI 10.1007/s10616-007-9076-1
   FLETCHER HG, 1947, J AM CHEM SOC, V69, P921, DOI 10.1021/ja01196a054
   Goodby JW, 2007, CHEM SOC REV, V36, P1971, DOI 10.1039/b708458g
   Goodby JW, 1997, LIQ CRYST, V22, P497, DOI 10.1080/026782997209225
   Goodby JW, 1997, LIQ CRYST, V22, P367, DOI 10.1080/026782997209441
   HANESSIAN S, 1977, CARBOHYD RES, V53, pC13, DOI 10.1016/S0008-6215(00)85468-3
   Harmouch B, 1997, J CARBOHYD CHEM, V16, P479, DOI 10.1080/07328309708007329
   Harmouch B., 1997, COMUN J COM ESP DETE, V27, P379
   Hill K, 2008, SURFACTANT SCI SER, V143, P1
   Hoffmann B, 2000, CARBOHYD RES, V323, P192
   Hori R, 1958, YAKUGAKU ZASSHI, V78, P523
   Ishigami Y., 2001, J OLEO SCI, V50, P555
   ISOMAA B, 1987, BIOCHIM BIOPHYS ACTA, V899, P93, DOI 10.1016/0005-2736(87)90243-4
   ISOMAA B, 1986, BIOCHIM BIOPHYS ACTA, V860, P510, DOI 10.1016/0005-2736(86)90548-1
   Kartha KPR, 1996, TETRAHEDRON LETT, V37, P8807, DOI 10.1016/S0040-4039(96)01995-8
   Kasuya MCZ, 2004, BIOCHEM BIOPH RES CO, V316, P599, DOI 10.1016/j.bbrc.2004.02.094
   Kasuya MCZ, 2005, J CARBOHYD CHEM, V24, P705, DOI 10.1080/07328300500208107
   Kasuya MCZ, 2005, CHEM LETT, V34, P856, DOI 10.1246/cl.2005.856
   Kissa E., 2001, SURFACTANT SCI SERIE, V97
   Lehmer HJ, 2002, CHEMOSPHERE, V46, P485, DOI 10.1016/S0045-6535(01)00177-1
   Lehmler HJ, 2004, ACTA CRYSTALLOGR B, V60, P325, DOI 10.1107/S0108768104005609
   Lehmler HJ, 2001, J FLUORINE CHEM, V107, P141, DOI 10.1016/S0022-1139(00)00384-5
   Li XS, 2009, COLLOID SURFACE B, V73, P65, DOI 10.1016/j.colsurfb.2009.04.023
   Li XS, 2008, NEW J CHEM, V32, P2169, DOI 10.1039/b805015e
   MARTIN P, 2001, J THERM ANAL CALORIM, V63, P339
   Martinez A, 2010, J INORG BIOCHEM, V104, P967, DOI 10.1016/j.jinorgbio.2010.05.002
   Matsumura S, 1999, BIOTECHNOL LETT, V21, P17, DOI 10.1023/A:1005464025881
   MILIUS A, 1991, NEW J CHEM, V15, P337
   Mitchell SA, 2001, J ORG CHEM, V66, P2327, DOI 10.1021/jo005712m
   Mollinedo F, 2006, DRUG RESIST UPDATE, V9, P51, DOI 10.1016/j.durp.2006.04.002
   MUKERJEE P, 1982, J AM OIL CHEM SOC, V59, P573, DOI 10.1007/BF02636327
   Nakamura T, 2000, BIOTECHNOL LETT, V22, P1183, DOI 10.1023/A:1005693414683
   Noller CR, 1938, J AM CHEM SOC, V60, P1938, DOI 10.1021/ja01275a061
   Pavillard V, 2004, BIOCHEM PHARMACOL, V67, P1587, DOI 10.1016/j.bcp.2004.01.006
   Petrovic ZD, 2006, INDIAN J CHEM B, V45, P272
   Rojas O.J., 2009, INTERFACIAL PROPERTI, P449
   Rowan AS, 2009, ORG BIOMOL CHEM, V7, P4029, DOI 10.1039/b909729e
   Satge C, 2005, TETRAHEDRON, V61, P8405, DOI 10.1016/j.tet.2005.06.075
   Savic S, 2010, EXPERT OPIN DRUG DEL, V7, P353, DOI 10.1517/17425240903535833
   SCHNEIDER U, 1977, INT J CANCER, V19, P621, DOI 10.1002/ijc.2910190505
   Shaik N, 2009, INORG CHEM, V48, P1577, DOI 10.1021/ic801925k
   SHINODA K, 1972, J PHYS CHEM-US, V76, P909, DOI 10.1021/j100650a021
   SHINOYAMA H, 1991, B CHEM SOC JPN, V64, P291, DOI 10.1246/bcsj.64.291
   SHINOYAMA H, 1988, AGR BIOL CHEM TOKYO, V52, P2197
   Singh MK, 2009, CARBOHYD RES, V344, P1993, DOI 10.1016/j.carres.2009.06.024
   Singh M.K., 2009, INDIAN I SCI, P113
   Soderlind E, 2006, EUR J PHARM BIOPHARM, V62, P254, DOI 10.1016/j.ejpb.2005.08.012
   Soderlind E, 2003, INT J PHARM, V252, P61, DOI 10.1016/S0378-5173(02)00599-9
   Son JB, 2007, ORG LETT, V9, P3897, DOI 10.1021/ol7015115
   SUN RC, 1995, IND CROP PROD, V4, P127, DOI 10.1016/0926-6690(95)00025-8
   Van Doren HA, 2000, LIQ CRYST, V27, P63, DOI 10.1080/026782900203227
   Varela-Ramirez A, 2011, CELL BIOL TOXICOL, V27, P159, DOI 10.1007/s10565-010-9178-y
   ZARIF L, 1989, J FLUORINE CHEM, V44, P73, DOI 10.1016/S0022-1139(00)84372-9
   ZARIF L, 1990, J MED CHEM, V33, P1262, DOI 10.1021/jm00166a028
NR 63
TC 20
Z9 24
U1 1
U2 25
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0008-6215
EI 1873-426X
J9 CARBOHYD RES
JI Carbohydr. Res.
PD FEB 15
PY 2012
VL 349
BP 12
EP 23
DI 10.1016/j.carres.2011.11.020
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Applied; Chemistry, Organic
SC Biochemistry & Molecular Biology; Chemistry
GA 903OG
UT WOS:000301126700002
PM 22207000
OA green_accepted
DA 2018-03-20
ER

PT J
AU Xing, R
   Rankin, SE
AF Xing, Rong
   Rankin, Stephen E.
TI Reactive pore expansion during ammonia vapor post-treatment of ordered
   mesoporous silica prepared with mixed glucopyranoside and cationic
   surfactants
SO MICROPOROUS AND MESOPOROUS MATERIALS
LA English
DT Article
DE nanocasting; templating; self-assembly; processing; expansion
ID LIQUID-CRYSTALLINE PHASES; MCM-41 MOLECULAR-SIEVES; SIZE DISTRIBUTION;
   POROUS MATERIALS; ADSORPTION; SYSTEMS; ORGANIZATION; TEMPLATE; MICELLAR;
   AGGREGATION
AB n-Octyl-beta-D-glueopyranoside (C(8)G(1)) has the potential to serve as a functional, nonionic template for mesoporous oxides, but its use has been limited due to its propensity to form lamellar mesostructures. Here, 2D hexagonal-structured mesoporous silicas with variable pore sizes are synthesized with C(8)G(1) by the "nanocasting" technique (polycondensation of tetramethoxysilane in concentrated acidic solutions with evaporation) by mixing it with cetyltrimethylammonium bromide (CTAB) to promote ordering. In an effort to stabilize the silica network structure, a mild treatment with ammonia vapor at 50 degrees C is introduced. Without ammonia treatment, the pore diameter remains constant as the C(8)G(1):CTAB weight ratio increases even up to 0.3:1. When the as-made materials are treated with ammonia vapor, the degree of long-range order of the samples increases, and pore expansion is observed which increases in magnitude as the C(8)G(1) content increases. Large degrees of expansion increase pore size fluctuations but do not eliminate long-range order. Materials with well-ordered, uniform pores can be made with C(8)G(1)/CTAB mixtures by limiting the amount of ammonia or increasing the amount of silica precursor. A mechanistic study suggests that micelle swelling occurs with CTAB, but is limited by increased polycondensation of silica and favorable headgroup-silica interactions. With the glucopyranoside surfactant, the extent of expansion is greater not only because of a change in the physical interaction with silica, but also because the Maillard reaction occurs under surprisingly mild conditions. (c) 2007 Elsevier Inc. All rights reserved.
C1 [Xing, Rong; Rankin, Stephen E.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Rankin, SE (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 Anderson Hall, Lexington, KY 40506 USA.
EM srankin@engr.uky.edu
RI Rankin, Stephen/A-3265-2013
OI Rankin, Stephen/0000-0002-8615-7564
CR Antonietti M, 1998, ADV MATER, V10, P154, DOI 10.1002/(SICI)1521-4095(199801)10:2<154::AID-ADMA154>3.0.CO;2-I
   ATTARD GS, 1995, NATURE, V378, P366, DOI 10.1038/378366a0
   BAGSHAW SA, 1995, SCIENCE, V269, P1242, DOI 10.1126/science.269.5228.1242
   BARRETT EP, 1951, J AM CHEM SOC, V73, P373, DOI 10.1021/ja01145a126
   BECK JS, 1992, J AM CHEM SOC, V114, P10834, DOI 10.1021/ja00053a020
   Brinker CJ, 1999, ADV MATER, V11, P579, DOI 10.1002/(SICI)1521-4095(199905)11:7<579::AID-ADMA579>3.0.CO;2-R
   Brunauer S, 1938, J AM CHEM SOC, V60, P309, DOI 10.1021/ja01269a023
   Calabro DC, 1996, MICROPOROUS MATER, V7, P243, DOI 10.1016/S0927-6513(96)00045-4
   Ciesla U, 1999, MICROPOR MESOPOR MAT, V27, P131, DOI 10.1016/S1387-1811(98)00249-2
   Coleman NRB, 2001, MICROPOR MESOPOR MAT, V44, P73, DOI 10.1016/S1387-1811(01)00170-6
   Corma A, 1998, STUD SURF SCI CATAL, V117, P201
   Cortes AB, 2003, COLLOID POLYM SCI, V281, P319, DOI 10.1007/s00396-002-0779-8
   Davies CGA, 1997, FOOD CHEM, V60, P323, DOI 10.1016/S0308-8146(96)00338-X
   Feng PY, 2000, LANGMUIR, V16, P5304, DOI 10.1021/la991444f
   FIROUZI A, 1995, SCIENCE, V267, P1138, DOI 10.1126/science.7855591
   FRIBERG SE, 1992, LANGMUIR, V8, P372, DOI 10.1021/la00038a009
   Goltner CG, 1997, ADV MATER, V9, P431, DOI 10.1002/adma.19970090516
   Goltner CG, 2001, CHEM MATER, V13, P1617, DOI 10.1021/cm0010755
   Groenewolt M, 2004, LANGMUIR, V20, P7811, DOI 10.1021/la049147k
   Grygierczyk G, 2002, JPC-J PLANAR CHROMAT, V15, P449, DOI 10.1556/JPC.15.2002.6.11
   Guizard CG, 1999, J MATER CHEM, V9, P55, DOI 10.1039/a805867i
   Hentze HP, 1999, MACROMOLECULES, V32, P5803, DOI 10.1021/ma9904058
   Hind AR, 1997, LANGMUIR, V13, P6255, DOI 10.1021/la970559l
   HODGE JE, 1953, AGR FOOD CHEM, V1, P928
   Hoffmann B, 2001, CURR OPIN COLLOID IN, V6, P171, DOI 10.1016/S1359-0294(01)00075-9
   HUO QS, 1994, CHEM MATER, V6, P1176, DOI 10.1021/cm00044a016
   Inagaki S, 2002, NATURE, V416, P304, DOI 10.1038/416304a
   Innocenzi P.J., 2003, NONCRYST SOLIDS, V316, P309
   ISHIDA K, 1958, B CHEM SOC JPN, V31, P143, DOI 10.1246/bcsj.31.143
   Jaroniec M, 1999, LANGMUIR, V15, P5410, DOI 10.1021/la990136e
   Jung JH, 2000, CHEM COMMUN, P2343, DOI 10.1039/b007218o
   KHUSHALANI D, 1995, ADV MATER, V7, P842, DOI 10.1002/adma.19950071005
   Kinrade SD, 2001, J CHEM SOC DALTON, P961, DOI 10.1039/b010111g
   KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0
   Kruk M, 1997, LANGMUIR, V13, P6267, DOI 10.1021/la970776m
   Kruk M, 2001, CHEM MATER, V13, P3169, DOI 10.1021/cm0101069
   Lin HP, 2001, MICROPOR MESOPOR MAT, V44, P129, DOI 10.1016/S1387-1811(01)00176-7
   Lin HP, 2000, ADV MATER, V12, P103, DOI 10.1002/(SICI)1521-4095(200001)12:2<103::AID-ADMA103>3.0.CO;2-P
   Markowitz MA, 2000, LANGMUIR, V16, P1759, DOI 10.1021/la990809t
   MONNIER A, 1993, SCIENCE, V261, P1299, DOI 10.1126/science.261.5126.1299
   Nilsson F, 1996, LANGMUIR, V12, P902, DOI 10.1021/la950602+
   PARRILL TM, 1992, J MATER RES, V7, P2230, DOI 10.1557/JMR.1992.2230
   Persson G, 2003, LANGMUIR, V19, P5813, DOI 10.1021/la034492f
   Pinel C, 1997, ADV MATER, V9, P582, DOI 10.1002/adma.19970090715
   Polarz S, 2002, CHEM COMMUN, P2593, DOI 10.1039/b205708p
   Polarz S, 2001, ANGEW CHEM INT EDIT, V40, P4417, DOI 10.1002/1521-3773(20011203)40:23<4417::AID-ANIE4417>3.0.CO;2-P
   SAKYA P, 1994, J PHYS II, V4, P1311, DOI 10.1051/jp2:1994202
   Sayari A, 1999, J PHYS CHEM B, V103, P3651, DOI 10.1021/jp984504j
   Sayari A, 1997, CHEM MATER, V9, P2499, DOI 10.1021/cm970128o
   SCHEUING DR, 1991, COLLOID SURFACE, V55, P41, DOI 10.1016/0166-6622(91)80081-X
   Shu C.K., 1994, MAILLARD REACTIONS C, P140
   SING KSW, 1985, PURE APPL CHEM, V57, P603, DOI 10.1351/pac198557040603
   Song MG, 2002, LANGMUIR, V18, P6110, DOI 10.1021/la011691v
   Spickermann C.G., 2003, TOP CURR CHEM, V226, P29
   Stangar U.L., 2002, MATER RES SOC S P, V726, P111
   Stubenrauch C, 2001, CURR OPIN COLLOID IN, V6, P160, DOI 10.1016/S1359-0294(01)00080-2
   TANEV PT, 1995, SCIENCE, V267, P865, DOI 10.1126/science.267.5199.865
   VARTULI JC, 1994, CHEM MATER, V6, P2317, DOI 10.1021/cm00048a018
   Wei Y, 1999, CHEM MATER, V11, P2023, DOI 10.1021/cm981004u
   Wu GM, 2001, J PHYS D APPL PHYS, V34, P1301, DOI 10.1088/0022-3727/34/9/304
   Yuan ZY, 2004, COLLOID SURFACE A, V241, P95, DOI 10.1016/j.colsurfa.2004.04.015
   Yuan ZY, 2002, CHEM COMMUN, P504, DOI 10.1039/b200322h
   Zhao DY, 1998, J AM CHEM SOC, V120, P6024, DOI 10.1021/ja974025i
   Zhao XS, 1996, IND ENG CHEM RES, V35, P2075, DOI 10.1021/ie950702a
   Zhou Y, 2004, CHEM MATER, V16, P544, DOI 10.1021/cm034442w
   Zhou Y, 2003, ADV MATER, V15, P1452, DOI 10.1002/adma.200305265
NR 66
TC 5
Z9 5
U1 0
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1387-1811
J9 MICROPOR MESOPOR MAT
JI Microporous Mesoporous Mat.
PD FEB 1
PY 2008
VL 108
IS 1-3
BP 65
EP 76
DI 10.1016/j.micromeso.2007.03.028
PG 12
WC Chemistry, Applied; Chemistry, Physical; Nanoscience & Nanotechnology;
   Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA 253PF
UT WOS:000252529400008
DA 2018-03-20
ER

PT J
AU Zhang, XY
   Hurng, J
   Rateri, DL
   Daugherty, A
   Schmid-Schonbein, GW
   Shin, HY
AF Zhang, Xiaoyan
   Hurng, Jonathan
   Rateri, Debra L.
   Daugherty, Alan
   Schmid-Schoenbein, Geert W.
   Shin, Hainsworth Y.
TI Membrane cholesterol modulates the fluid shear stress response of
   polymorphonuclear leukocytes via its effects on membrane fluidity
SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
LA English
DT Article
DE flow; cell deactivation; pseudopod retraction; mechanotransduction;
   hypercholesterolemia
ID LOW-DENSITY-LIPOPROTEIN; SPONTANEOUSLY HYPERTENSIVE-RAT; SPUR CELL
   ANEMIA; BENZYL ALCOHOL; CIRCULATING LEUKOCYTES; SIGNAL-TRANSDUCTION;
   ENDOTHELIAL-CELLS; HUMAN NEUTROPHILS; HUMAN-FIBROBLASTS; IN-SITU
AB Zhang X, Hurng J, Rateri DL, Daugherty A, Schmid-Schonbein GW, Shin HY. Membrane cholesterol modulates the fluid shear stress response of polymorphonuclear leukocytes via its effects on membrane fluidity. Am J Physiol Cell Physiol 301: C451-C460, 2011. First published April 27, 2011; doi: 10.1152/ajpcell.00458.2010.-Continuous exposure of polymorphonuclear leukocytes (PMNLs) to circulatory hemodynamics points to fluid flow as a biophysical regulator of their activity. Specifically, fluid flow-derived shear stresses deactivate leukocytes via actions on the conformational activities of proteins on the cell surface. Because membrane properties affect activities of membrane-bound proteins, we hypothesized that changes in the physical properties of cell membranes influence PMNL sensitivity to fluid shear stress. For this purpose, we modified PMNL membranes and showed that the cellular mechanosensitivity to shear was impaired whether we increased, reduced, or disrupted the organization of cholesterol within the lipid bilayer. Notably, PMNLs with enriched membrane cholesterol exhibited attenuated pseudopod retraction responses to shear that were recovered by select concentrations of benzyl alcohol (a membrane fluidizer). In fact, PMNL responses to shear positively correlated (R-2 = 0.96; P < 0.0001) with cholesterol-related membrane fluidity. Moreover, in low-density lipoprotein receptor-deficient (LDLr-/-) mice fed a high-fat diet (a hypercholesterolemia model), PMNL shear-responses correlated (R-2 = 0.5; P < 0.01) with blood concentrations of unesterified (i.e., free) cholesterol. In this regard, the shear-responses of PMNLs gradually diminished and eventually reversed as free cholesterol levels in blood increased during 8 wk of the high-fat diet. Collectively, our results provided evidence that cholesterol is an important component of the PMNL mechanotransducing capacity and elevated membrane cholesterol impairs PMNL shear-responses at least partially through its impact on membrane fluidity. This cholesterol-linked perturbation may contribute to dysregulated PMNL activity (e. g., chronic inflammation) related to hypercholesterolemia and causal for cardiovascular pathologies (e. g., atherosclerosis).
C1 [Shin, Hainsworth Y.] Univ Kentucky, Ctr Biomed Engn, Wenner Gren Res Lab, Lexington, KY 40506 USA.
   [Hurng, Jonathan; Schmid-Schoenbein, Geert W.] Univ Calif San Diego, Inst Engn Med, Dept Bioengn, La Jolla, CA 92093 USA.
   [Rateri, Debra L.; Daugherty, Alan; Shin, Hainsworth Y.] Univ Kentucky, Saha Cardiovasc Res Ctr, Lexington, KY 40506 USA.
RP Shin, HY (reprint author), Univ Kentucky, Ctr Biomed Engn, Wenner Gren Res Lab, Lexington, KY 40506 USA.
EM hy.shin@uky.edu
RI Daugherty, Alan/C-8282-2009
FU National Institutes of Health [HL10881, HL083740]; University of
   Kentucky; American Heart Association; National Science Foundation
FX This work was supported by the National Institutes of Health (HL10881
   and HL083740), the University of Kentucky Research Support Fund, the
   American Heart Association (Beginning Grant-in-Aid), and the National
   Science Foundation (Kentucky Experimental Program to Stimulate
   Competitive Research-Bioengineering Initiative).
CR BENBASSAT H, 1977, CANCER RES, V37, P1307
   BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
   Butler PJ, 2001, FASEB J, V15, P216, DOI 10.1096/fj.01-0434fje
   Butler PJ, 2001, AM J PHYSIOL-CELL PH, V280, pC962
   Celedon G, 1998, AM J PHYSIOL-CELL PH, V275, pC1429
   CHABANEL A, 1983, BIOPHYS J, V44, P171, DOI 10.1016/S0006-3495(83)84288-X
   CHABANEL A, 1985, BIOCHIM BIOPHYS ACTA, V816, P142, DOI 10.1016/0005-2736(85)90402-X
   Chachisvilis M, 2006, P NATL ACAD SCI USA, V103, P15463, DOI 10.1073/pnas.0607224103
   Chen AY, 2010, AM J PHYSIOL-CELL PH, V299, pC1441, DOI 10.1152/ajpcell.00157.2010
   Coderch L, 2000, J CONTROL RELEASE, V68, P85, DOI 10.1016/S0168-3659(00)00240-6
   COOPER RA, 1980, J LIPID RES, V21, P1082
   FRIEDLANDER G, 1987, BIOCHIM BIOPHYS ACTA, V903, P341, DOI 10.1016/0005-2736(87)90224-0
   Fukuda S, 2004, J LEUKOCYTE BIOL, V75, P664, DOI 10.1189/jlb.1003464
   Fukuda S, 2004, CIRC RES, V95, P100, DOI 10.1161/01.RES.0000133677.77465.38
   Fukuda S, 2000, CIRC RES, V86, pE13
   GALEANO NF, 1994, J BIOL CHEM, V269, P511
   Getz GS, 2006, ARTERIOSCL THROM VAS, V26, P242, DOI 10.1161/01.ATV.0000201071.49029.17
   GLEASON MM, 1991, CIRC RES, V69, P216
   Goluszko P, 2005, INFECT IMMUN, V73, P7791, DOI 10.1128/IAI.73.12.7791-7796.2005
   Haidekker MA, 2000, AM J PHYSIOL-HEART C, V278, pH1401
   Kannan KB, 2007, J IMMUNOL, V178, P5253, DOI 10.4049/jimmunol.178.8.5253
   Kojda G, 1999, CARDIOVASC RES, V43, P562, DOI 10.1016/S0008-6363(99)00169-8
   Komai Y, 2005, ANN BIOMED ENG, V33, P1375, DOI 10.1007/s10439-005-6768-6
   LANGE Y, 1991, J LIPID RES, V32, P329
   LANGE Y, 1989, J BIOL CHEM, V264, P3786
   LENAZ G, 1987, BIOSCIENCE REP, V7, P823, DOI 10.1007/BF01119473
   LICHTENSTEIN IH, 1987, J LEUKOCYTE BIOL, V42, P156
   Makino A, 2006, AM J PHYSIOL-CELL PH, V290, pC1633, DOI 10.1152/ajpcell.00576.2005
   Makino A, 2005, AM J PHYSIOL-CELL PH, V288, pC863, DOI 10.1152/ajpcell.00358.2004
   Makino A, 2007, BIORHEOLOGY, V44, P221
   Marschel P, 2002, ANN BIOMED ENG, V30, P333, DOI 10.1114/1.1475342
   Marwali MR, 2003, BLOOD, V102, P215, DOI 10.1182/blood-2002-10-3195
   Mazzoni MC, 1996, CARDIOVASC RES, V32, P709, DOI 10.1016/0008-6363(96)00146-0
   Moazzam F, 1997, P NATL ACAD SCI USA, V94, P5338, DOI 10.1073/pnas.94.10.5338
   Mori N, 1999, AM J PHYSIOL-HEART C, V276, pH1647
   Nguyen DH, 2004, MECH AGEING DEV, V125, P641, DOI 10.1016/j.mad.2004.08.002
   Niggli V, 2004, EXP CELL RES, V296, P358, DOI 10.1016/j.yexcr.2004.02.015
   Oh H, 2009, ARTERIOSCL THROM VAS, V29, P1290, DOI 10.1161/ATVBAHA.109.189571
   Pierini LM, 2003, J BIOL CHEM, V278, P10831, DOI 10.1074/jbc.M212386200
   PITTMAN RC, 1982, J BIOL CHEM, V257, P7994
   Radel C, 2007, BIOCHEM BIOPH RES CO, V358, P626, DOI 10.1016/j.bbrc.2007.04.179
   Rader DJ, 2008, NATURE, V451, P904, DOI 10.1038/nature06796
   Rizzo V, 1998, J BIOL CHEM, V273, P26323, DOI 10.1074/jbc.273.41.26323
   Rizzo V, 1998, J BIOL CHEM, V273, P34724, DOI 10.1074/jbc.273.52.34724
   Rustemeijer C, 1997, ACTA DIABETOL, V34, P294, DOI 10.1007/s005920050091
   SAINTEMARIE J, 1990, FEBS LETT, V262, P13, DOI 10.1016/0014-5793(90)80141-5
   Seely AJE, 2003, CRIT CARE, V7, P291, DOI 10.1186/cc1853
   Shin HY, 2008, J CELL PHYSIOL, V214, P528, DOI 10.1002/jcp.21235
   Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052
   Stokes KY, 2001, CIRC RES, V88, P499
   Sugihara-Seki M, 2003, J BIOMECH ENG-T ASME, V125, P628, DOI 10.1115/1.1611515
   TOMONAGA A, 1983, MICROBIOL IMMUNOL, V27, P961, DOI 10.1111/j.1348-0421.1983.tb00662.x
   Tuluc F, 2003, INT IMMUNOPHARMACOL, V3, P1775, DOI 10.1016/j.intimp.2003.08.002
   WORTHEN GS, 1989, SCIENCE, V245, P183, DOI 10.1126/science.2749255
   YULI I, 1982, P NATL ACAD SCI-BIOL, V79, P5906, DOI 10.1073/pnas.79.19.5906
NR 55
TC 20
Z9 21
U1 0
U2 15
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6143
EI 1522-1563
J9 AM J PHYSIOL-CELL PH
JI Am. J. Physiol.-Cell Physiol.
PD AUG
PY 2011
VL 301
IS 2
BP C451
EP C460
DI 10.1152/ajpcell.00458.2010
PG 10
WC Cell Biology; Physiology
SC Cell Biology; Physiology
GA 797ZF
UT WOS:000293168400020
PM 21525434
OA gold
DA 2018-03-20
ER

PT J
AU Wagner, J
   Rodgers, D
AF Wagner, Jonathan M.
   Rodgers, David W.
TI Structure and Function of Thimet Oligopeptidase
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 [Wagner, Jonathan; Rodgers, David] Univ Kentucky, Coll Med, Struct Biol Ctr, Lexington, KY USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2009
VL 23
MA 504.1
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA V27OC
UT WOS:000208621500529
DA 2018-03-20
ER

PT J
AU Bae, Y
   Alani, AWG
   Rockich, NC
   Lai, TSZC
   Kwon, GS
AF Bae, Younsoo
   Alani, Adam W. G.
   Rockich, Nicole C.
   Lai, T. S. Z. Chung
   Kwon, Glen S.
TI Mixed pH-Sensitive Polymeric Micelles for Combination Drug Delivery
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE combination chemotherapy; drug delivery; mixed micelles; pH-controlled
   release; polymeric micelles
ID HSP90 INHIBITOR GELDANAMYCIN; TOPOISOMERASE-II; ANTICANCER DRUGS;
   CANCER-THERAPY; BREAST-CANCER; SIGNALING PATHWAYS; DNA-DAMAGE;
   CELL-DEATH; IN-VIVO; TARGET
AB To prepare mixed polymeric micelles that can carry two different drugs, doxorubicin (DOX) and 17-hydroxyethylamino-17-demethoxygeldanamycin (GDM-OH), for combination cancer chemotherapy.
   The pH-sensitive micelles were prepared from poly(ethylene glycol)-poly(aspartate hydrazide) block copolymers to which either DOX or GDM-OH is conjugated through acid-labile hydrazone bond (individual micelles). Mixed micelles were formed not only by simply mixing two different individual micelles in aqueous solutions (aqueous mixed micelles) but also by evaporating organic solvents from the organic/aqueous mixed solvents in which two block copolymers possessing different drugs were dissolved homogeneously (organic mixed micelles). Particle size measurements, pH-dependent drug release tests, cytotoxicity assays and western blot analysis were subsequently conducted.
   Individual and aqueous/organic mixed micelles showed clinically relevant particle size (< 100 nm) and pH-dependent drug release patterns. Mixed polymer micelles suppress cancer cell growth effectively in a drug concentration, mixing method and schedule-dependent way.
   Combination chemotherapy using polymeric micelles seems to minimize a schedule-dependent change in combination drug efficacy in comparison to drug combination using DMSO formulations.
C1 [Bae, Younsoo] Univ Kentucky, Coll Pharm, Lexington, KY 40536 USA.
   [Alani, Adam W. G.; Rockich, Nicole C.; Lai, T. S. Z. Chung; Kwon, Glen S.] Univ Wisconsin, Div Pharmaceut Sci, Sch Pharm, Madison, WI 53705 USA.
RP Bae, Y (reprint author), Univ Kentucky, Coll Pharm, 789 S Limestone, Lexington, KY 40536 USA.
EM younsoo.bae@uky.edu
RI Kwon, Glen/A-1919-2014; Alani, Adam/E-2327-2013
FU National Institutes of Health [R01 AI-43346-08]; Kentucky Lung Cancer
   Research Program
FX This work was partially supported by National Institutes of Health grant
   R01 AI-43346-08. Y.B. acknowledges research support provided by the
   Kentucky Lung Cancer Research Program.
CR Alani AWG, 2010, BIOMATERIALS, V31, P1765, DOI 10.1016/j.biomaterials.2009.11.038
   Atkins JH, 2002, NAT REV CANCER, V2, P645, DOI 10.1038/nrc900
   Bae Y, 2005, MOL BIOSYST, V1, P242, DOI 10.1039/b500266d
   Bae Y, 2003, ANGEW CHEM INT EDIT, V42, P4640, DOI 10.1002/anie.200250653
   Bae Y, 2005, BIOCONJUGATE CHEM, V16, P122, DOI 10.1021/bc0498166
   Bae Y, 2007, J CONTROL RELEASE, V122, P324, DOI 10.1016/j.jconrel.2007.05.038
   Bae Y, 2007, J CONTROL RELEASE, V122, P16, DOI 10.1016/j.jconrel.2007.06.005
   Bae Y, 2009, ADV DRUG DELIVER REV, V61, P768, DOI 10.1016/j.addr.2009.04.016
   Barker CR, 2006, INT J CANCER, V118, P2685, DOI 10.1002/ijc.21717
   Barker CR, 2006, NUCLEIC ACIDS RES, V34, P1148, DOI 10.1093/nar/gkj516
   Beliakoff J, 2004, ANTI-CANCER DRUG, V15, P651, DOI 10.1097/01.cad.0000136876.11928.be
   Bishop SC, 2007, CURR CANCER DRUG TAR, V7, P369, DOI 10.2174/156800907780809778
   Burgess DJ, 2008, P NATL ACAD SCI USA, V105, P9053, DOI 10.1073/pnas.0803513105
   Chang JT, 2006, BRIT J CANCER, V94, P870, DOI 10.1038/sj.bjc.6603008
   DEBOER C, 1970, J ANTIBIOT, V23, P442, DOI 10.7164/antibiotics.23.442
   Duncan R, 2006, NAT REV CANCER, V6, P688, DOI 10.1038/nrc1958
   Forrest ML, 2006, J CONTROL RELEASE, V116, P139, DOI 10.1016/j.jconrel.2006.07.003
   Fortune JM, 2000, PROG NUCLEIC ACID RE, V64, P221, DOI 10.1016/S0079-6603(00)64006-0
   Goetz MP, 2003, ANN ONCOL, V14, P1169, DOI 10.1093/annonc/mdg316
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hande KR, 1998, BBA-GENE STRUCT EXPR, V1400, P173, DOI 10.1016/S0167-4781(98)00134-1
   KAMAL A, 2003, NATURE, V425, P357
   Kasuya Y, 2001, J CONTROL RELEASE, V74, P203, DOI 10.1016/S0168-3659(01)00318-2
   KATAOKA K, 1993, J CONTROL RELEASE, V24, P119
   Kersting G, 2006, N-S ARCH PHARMACOL, V374, P21, DOI 10.1007/s00210-006-0091-0
   Kopecek J, 2000, EUR J PHARM BIOPHARM, V50, P61, DOI 10.1016/S0939-6411(00)00075-8
   Martin-Richard M, 2004, ONCOLOGY-BASEL, V66, P388, DOI 10.1159/000079487
   Nishiyama Nobuhiro, 2005, Drug Discov Today Technol, V2, P21, DOI 10.1016/j.ddtec.2005.05.007
   Pick E, 2007, CANCER RES, V67, P2932, DOI 10.1158/0008-5472.CAN-06-4511
   Powers MV, 2007, FEBS LETT, V581, P3758, DOI 10.1016/j.febslet.2007.05.040
   Scripture CD, 2006, NAT REV CANCER, V6, P546, DOI 10.1038/nrc.1887
   SENT, 2004, MOL PHARM, V1, P395
   Smalley KSM, 2006, MOL CANCER THER, V5, P1136, DOI 10.1158/1535-7163.MCT-06-0084
   Vicent MJ, 2005, ANGEW CHEM INT EDIT, V44, P4061, DOI 10.1002/anie.200462960
   West Kevin R, 2005, Curr Drug Discov Technol, V2, P123, DOI 10.2174/1570163054866882
   Workman P, 2007, NAT CHEM BIOL, V3, P455, DOI 10.1038/nchembio0807-455
   Xiao L, 2007, CURR MED CHEM, V14, P223, DOI 10.2174/092986707779313372
   Xu WP, 2007, CLIN CANCER RES, V13, P1625, DOI 10.1158/1078-0432.CCR-06-2966
   Yao Q, 2007, CLIN CANCER RES, V13, P1591, DOI 10.1158/1078-0432.CCR-06-1750
   Yoshida K, 2006, MOL CELL BIOL, V26, P3414, DOI 10.1128/MCB.26.9.3414-3431.2006
   Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079
NR 41
TC 40
Z9 42
U1 1
U2 40
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
J9 PHARM RES-DORDR
JI Pharm. Res.
PD NOV
PY 2010
VL 27
IS 11
BP 2421
EP 2432
DI 10.1007/s11095-010-0234-3
PG 12
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 669RN
UT WOS:000283368000017
PM 20700632
OA green_accepted
DA 2018-03-19
ER

PT J
AU Paudel, KS
   Wu, J
   Hinds, BJ
   Stinchcomb, AL
AF Paudel, Kalpana S.
   Wu, Ji
   Hinds, Bruce J.
   Stinchcomb, Audra L.
TI Programmable transdermal delivery of nicotine in hairless guinea pigs
   using carbon nanotube membrane pumps
SO JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE Diffusion; Controlled release; Drug Transport; Epithelial Delivery;
   Membrane Transport
ID TANDEM MASS-SPECTROMETRY; SMOKING-CESSATION; DRUG-DELIVERY; COTININE;
   SMOKERS; PLASMA; METAANALYSIS; REPLACEMENT; FLOW; METABOLISM
AB A compact switchable transdermal nicotine patch device was demonstrated to be effective in vivo in a hairless guinea pig animal model. This required the development and validation of a quantitative method for the simultaneous determination of cotinine and nicotine in hairless guinea pig plasma by liquid chromatographymass spectrometry. Nicotine metabolism in hairless guinea pigs is rapid and cotinine was found to be the viable nicotine marker. The portable carbon nanotube membrane device, powered by a 1.5 V watch battery, was demonstrated to be a power efficient method to pump nicotine at levels six to eight times that of passive diffusion. Cotinine blood plasma levels in hairless guinea pigs were seen to increase from 6 to 12 ng/mL when the patch was turned from passive diffusion to an active pumping state. These nicotine patch devices are highly promising for potential clinical applications, with programmed delivery based on remote counseling, in order to improve smoking cessation treatments. (C) 2012 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 101:38233832, 2012
C1 [Wu, Ji; Hinds, Bruce J.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40536 USA.
   [Paudel, Kalpana S.; Stinchcomb, Audra L.] Univ Kentucky, Coll Pharm, Lexington, KY 40536 USA.
   [Paudel, Kalpana S.] S Coll Sch Pharm, Dept Pharmaceut Sci, Knoxville, TN 37922 USA.
   [Stinchcomb, Audra L.] Univ Maryland, Dept Pharmaceut Sci, Sch Pharm, Baltimore, MD 21201 USA.
RP Hinds, BJ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40536 USA.
EM bjhinds@engr.uky.edu; astinchc@rx.umaryland.edu
RI WU, JI/F-6371-2013; WU, JI/J-4580-2016; WU, JI/F-6379-2013
FU NIH NIDA [R01DA018822]
FX Facility support was provided by the Center for Nanoscale Science and
   Engineering and Electron Microscopy Center at the University of
   Kentucky. Financial support from NIH NIDA (R01DA018822) is greatly
   appreciated by the authors.
CR Bahr JL, 2001, J AM CHEM SOC, V123, P6536, DOI 10.1021/ja010462s
   Barry BW, 2001, EUR J PHARM SCI, V14, P101, DOI 10.1016/S0928-0987(01)00167-1
   Baumann F, 2010, J CHROMATOGR B, V878, P107, DOI 10.1016/j.jchromb.2009.11.032
   Borland R, 2001, ADDICTION, V96, P881, DOI 10.1046/j.1360-0443.2001.9668819.x
   BROWN L, 1988, ANNU REV MED, V39, P221, DOI 10.1146/annurev.med.39.1.221
   Cognard E, 2003, CLIN CHEM LAB MED, V41, P1599, DOI 10.1515/CCLM.2003.243
   Etter JF, 2006, TOB CONTROL, V15, DOI 10.1136/tc.2005.015487
   FAGERSTROM KO, 1982, J BEHAV MED, V5, P343, DOI 10.1007/BF00846161
   GALEAZZI RL, 1985, EUR J CLIN PHARMACOL, V28, P301, DOI 10.1007/BF00543327
   Hall SM, 2002, ARCH GEN PSYCHIAT, V59, P930, DOI 10.1001/archpsyc.59.10.930
   Hinds BJ, 2004, SCIENCE, V303, P62, DOI 10.1126/science.1092048
   Hollis JF, 2007, TOB CONTROL, V16, pI53, DOI 10.1136/tc.2006.019794
   Holt JK, 2006, SCIENCE, V312, P1034, DOI 10.1126/science.1126298
   Hughes JR, 2003, TOB CONTROL, V12, P21, DOI 10.1136/tc.12.1.21
   Hummer G, 2001, NATURE, V414, P188, DOI 10.1038/35102535
   KASPERSON RE, 1988, RISK ANAL, V8, P177, DOI 10.1111/j.1539-6924.1988.tb01168.x
   KYEREMATEN GA, 1990, BIOCHEM PHARMACOL, V40, P1747, DOI 10.1016/0006-2952(90)90351-K
   LEVY D, 1989, J CLIN INVEST, V83, P2074, DOI 10.1172/JCI114119
   Lichtenstein E, 1996, HEALTH EDUC RES, V11, P243, DOI 10.1093/her/11.2.243
   Majumder M, 2005, NATURE, V438, P44, DOI 10.1038/43844a
   MATSUKURA S, 1979, CLIN PHARMACOL THER, V25, P555
   MCGOVREN JP, 1976, J PHARMACOL EXP THER, V199, P198
   Mello NK, 1996, NEUROPSYCHOPHARMACOL, V14, P375, DOI 10.1016/0893-133X(95)00274-H
   Miller EI, 2010, J CHROMATOGR B, V878, P725, DOI 10.1016/j.jchromb.2009.12.018
   Murphy SE, 2007, J CHROMATOGR B, V857, P1, DOI 10.1016/j.jchromb.2007.06.018
   Paudel KS, 2005, J PHARM SCI-US, V94, P1965, DOI 10.1002/jps.20398
   Prausnitz MR, 2008, NAT BIOTECHNOL, V26, P1261, DOI 10.1038/nbt.1504
   Ranade VV, 2011, Drug Delivery Systems, 3rd Edition, P1
   Robbins TW, 1999, NATURE, V398, P567, DOI 10.1038/19208
   ROSA M, 1992, CLIN PHARMACOL THER, V52, P324, DOI 10.1038/clpt.1992.149
   Shakleya DM, 2009, J CHROMATOGR B, V877, P3537, DOI 10.1016/j.jchromb.2009.08.033
   Shin HS, 2002, J CHROMATOGR B, V769, P177, DOI 10.1016/S1570-0232(02)00007-7
   SILAGY C, 1994, LANCET, V343, P139, DOI 10.1016/S0140-6736(94)90933-4
   Silagy C, 2004, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD000146.PUB2
   Stead LF, 2008, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD000146.PUB3
   Stolker AAM, 2003, J CHROMATOGR A, V1020, P35, DOI 10.1016/j.chroma.2003.08.056
   Sun L, 2000, J AM CHEM SOC, V122, P12340, DOI 10.1021/ja002429w
   Volkow ND, 2004, NAT REV NEUROSCI, V5, P963, DOI 10.1038/nrn1539
   Wills S., 2005, DRUGS ABUSE
   Wu J, 2012, NAT NANOTECHNOL, V7, P133, DOI [10.1038/nnano.2011.240, 10.1038/NNANO.2011.240]
   Wu J, 2011, NANOSCALE, V3, P3321, DOI 10.1039/c1nr10303b
   Wu J, 2010, P NATL ACAD SCI USA, V107, P11698, DOI 10.1073/pnas.1004714107
   Zeidenberg P, 1977, Compr Psychiatry, V18, P92
   Zhu SH, 2002, NEW ENGL J MED, V347, P1087, DOI 10.1056/NEJMsa020660
   Zhu SH, 1996, J CONSULT CLIN PSYCH, V64, P202, DOI 10.1037/0022-006X.64.1.202
NR 45
TC 7
Z9 8
U1 0
U2 32
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3549
EI 1520-6017
J9 J PHARM SCI-US
JI J. Pharm. Sci.
PD OCT
PY 2012
VL 101
IS 10
BP 3823
EP 3832
DI 10.1002/jps.23240
PG 10
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology &
   Pharmacy
SC Pharmacology & Pharmacy; Chemistry
GA 994XA
UT WOS:000307966600028
PM 22806243
DA 2018-03-20
ER

PT J
AU Park, JE
   Ao, L
   Chun, SE
   Reichel, DA
   Hu, D
   Han, S
   Ryoo, G
   Oh, Y
   Park, SH
   Min, JS
   Ryu, HM
   Bae, SK
   Lee, HY
   Kim, KB
   Jeong, HY
   Bae, Y
   Lee, W
AF Park, Ji Eun
   Ao, Lin
   Chun, Se-Eun
   Reichel, Derek A.
   Hu, Di
   Han, Songhee
   Ryoo, Gongmi
   Oh, Yunseok
   Park, Shin-Hyung
   Min, Jee Sun
   Ryu, Heon-Min
   Bae, Soo Kyung
   Lee, Ho-Young
   Kim, Kyung Bo
   Jeong, Hyunyoung
   Bae, Younsoo
   Lee, Wooin
TI POLYMER MICELLE FORMULATION OF PROTEASOME INHIBITOR CARFILZOMIB AS A
   POTENTIAL STRATEGY TO IMPROVE METABOLIC STABILITY AND ANTI-CANCER
   EFFICACY IN HUMAN MULTIPLE MYELOMA AND LUNG CANCER
SO DRUG METABOLISM AND PHARMACOKINETICS
LA English
DT Meeting Abstract
C1 [Park, Ji Eun; Chun, Se-Eun; Han, Songhee; Ryoo, Gongmi; Oh, Yunseok; Park, Shin-Hyung; Ryu, Heon-Min; Lee, Ho-Young; Lee, Wooin] Seoul Natl Univ, Seoul, South Korea.
   [Ao, Lin; Reichel, Derek A.; Kim, Kyung Bo; Bae, Younsoo] Univ Kentucky, Coll Pharm, Lexington, KY USA.
   [Hu, Di; Jeong, Hyun-Young] Univ Illinois, Chicago, IL USA.
   [Min, Jee Sun; Bae, Soo Kyung] Catholic Univ Korea, Coll Pharm, Bucheon, South Korea.
   [Min, Jee Sun; Bae, Soo Kyung] Catholic Univ Korea, Integrated Res Inst Pharmaceut Sci, Bucheon, South Korea.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU JAPANESE SOC STUDY XENOBIOTICS
PI TOKYO
PA INT MED INF CENTER SHINANOMACHI RENGAKAN, 35 SHINANO-MACHI SHINJUKU-KU,
   TOKYO, 160-0016, JAPAN
SN 1347-4367
EI 1880-0920
J9 DRUG METAB PHARMACOK
JI Drug Metab. Pharmacokinet.
PD JAN
PY 2017
VL 32
IS 1
SU S
MA P69
BP S46
EP S46
DI 10.1016/j.dmpk.2016.10.195
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA EO9MW
UT WOS:000397013800153
DA 2018-03-19
ER

PT J
AU Wagner, JM
   Zadrozny, KK
   Chrustowicz, J
   Purdy, MD
   Yeager, M
   Ganser-Pornillos, BK
   Pornillos, O
AF Wagner, Jonathan M.
   Zadrozny, Kaneil K.
   Chrustowicz, Jakub
   Purdy, Michael D.
   Yeager, Mark
   Ganser-Pornillos, Barbie K.
   Pornillos, Owen
TI Crystal structure of an HIV assembly and maturation switch
SO ELIFE
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; ROUS-SARCOMA-VIRUS; RNA PACKAGING SIGNAL;
   CAPSID PROTEIN; IN-VITRO; GAG POLYPROTEIN; CRYOELECTRON MICROSCOPY;
   DIMERIZATION DOMAIN; HELICAL STRUCTURE; INHIBITOR PA-457
AB Virus assembly and maturation proceed through the programmed operation of molecular switches, which trigger both local and global structural rearrangements to produce infectious particles. HIV-1 contains an assembly and maturation switch that spans the C-terminal domain (CTD) of the capsid (CA) region and the first spacer peptide (SP1) of the precursor structural protein, Gag. The crystal structure of the CTD-SP1 Gag fragment is a goblet-shaped hexamer in which the cup comprises the CTD and an ensuing type II beta-turn, and the stem comprises a 6-helix bundle. The beta-turn is critical for immature virus assembly and the 6-helix bundle regulates proteolysis during maturation. This bipartite character explains why the SP1 spacer is a critical element of HIV-1 Gag but is not a universal property of retroviruses. Our results also indicate that HIV-1 maturation inhibitors suppress unfolding of the CA-SP1 junction and thereby delay access of the viral protease to its substrate.
C1 [Wagner, Jonathan M.; Zadrozny, Kaneil K.; Chrustowicz, Jakub; Purdy, Michael D.; Yeager, Mark; Ganser-Pornillos, Barbie K.; Pornillos, Owen] Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22904 USA.
   [Yeager, Mark] Univ Virginia Hlth Syst, Div Cardiovasc Med, Dept Med, Charlottesville, VA 22908 USA.
RP Yeager, M; Ganser-Pornillos, BK; Pornillos, O (reprint author), Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22904 USA.; Yeager, M (reprint author), Univ Virginia Hlth Syst, Div Cardiovasc Med, Dept Med, Charlottesville, VA 22908 USA.
EM my3r@virginia.edu; bpornillos@virginia.edu; owp3a@eservices.virginia.edu
OI Wagner, Jonathan M./0000-0001-9161-7222
FU National Institutes of Health [R01-GM066087, P50-GM082545, P50-GM103297,
   F32-GM115007]
FX National Institutes of Health R01-GM066087 Mark Yeager Barbie K
   Ganser-Pornillos Owen Pornillos; National Institutes of Health
   P50-GM082545 Mark Yeager; National Institutes of Health P50-GM103297
   Owen Pornillos; National Institutes of Health F32-GM115007 Jonathan M
   Wagner
CR Accola MA, 2000, J VIROL, V74, P5395, DOI 10.1128/JVI.74.12.5395-5402.2000
   Accola MA, 1998, J VIROL, V72, P2072
   Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925
   Adamson CS, 2006, J VIROL, V80, P10957, DOI 10.1128/JVI.01369-06
   Adamson CS, 2009, EXPERT OPIN THER TAR, V13, P895, DOI 10.1517/14728220903039714
   Afonine PV, 2015, ACTA CRYSTALLOGR D, V71, P646, DOI 10.1107/S1399004714028132
   Al-Mawsawi LQ, 2014, RETROVIROLOGY, V11, DOI 10.1186/s12977-014-0124-6
   Amarasinghe GK, 2000, J MOL BIOL, V301, P491, DOI 10.1006/jmbi.2000.3979
   Bartonova V, 2008, J BIOL CHEM, V283, P32024, DOI 10.1074/jbc.M804230200
   Bharat TAM, 2012, NATURE, V487, P385, DOI 10.1038/nature11169
   Bothner B, 1998, J BIOL CHEM, V273, P673, DOI 10.1074/jbc.273.2.673
   Briggs JAG, 2009, P NATL ACAD SCI USA, V106, P11090, DOI 10.1073/pnas.0903535106
   Bush DL, 2014, ANNU REV VIROL, V1, P561, DOI 10.1146/annurev-virology-031413-085427
   Bush DL, 2014, J VIROL, V88, P5617, DOI 10.1128/JVI.02659-13
   Campbell S, 1999, J VIROL, V73, P2270
   CAMPBELL S, 1995, J VIROL, V69, P6487
   D'Souza V, 2004, NATURE, V431, P586, DOI 10.1038/nature02944
   Datta SAK, 2011, J VIROL, V85, P4111, DOI 10.1128/JVI.00006-11
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Fontana J, 2016, J VIROL, V90, P972, DOI 10.1128/JVI.02204-15
   Gamble TR, 1997, SCIENCE, V278, P849, DOI 10.1126/science.278.5339.849
   Ganser BK, 1999, SCIENCE, V283, P80, DOI 10.1126/science.283.5398.80
   Ganser-Pornillos BK, 2012, ADV EXP MED BIOL, V726, P441, DOI 10.1007/978-1-4614-0980-9_20
   Gipson B, 2007, J STRUCT BIOL, V157, P64, DOI 10.1016/j.jsb.2006.07.020
   Gitti RK, 1996, SCIENCE, V273, P231, DOI 10.1126/science.273.5272.231
   Gres AT, 2015, SCIENCE, V349, P99, DOI 10.1126/science.aaa5936
   Gross I, 2000, EMBO J, V19, P103, DOI 10.1093/emboj/19.1.103
   Guo XF, 2005, J VIROL, V79, P1803, DOI 10.1128/JVI.79.3.1803-1812.2005
   Keane SC, 2015, SCIENCE, V348, P917, DOI 10.1126/science.aaa9266
   Keller PW, 2008, J VIROL, V82, P6788, DOI 10.1128/JVI.00213-08
   Keller PW, 2013, J VIROL, V87, P13655, DOI 10.1128/JVI.01408-13
   Keller PW, 2011, J VIROL, V85, P1420, DOI 10.1128/JVI.01926-10
   Kelly BN, 2006, BIOCHEMISTRY-US, V45, P11257, DOI 10.1021/bi060927x
   KRAUSSLICH HG, 1995, J VIROL, V69, P3407
   Kuiken Carla, 2003, AIDS Reviews, V5, P52
   Lee SK, 2012, J BIOL CHEM, V287, P40867, DOI 10.1074/jbc.R112.399444
   Li F, 2006, VIROLOGY, V356, P217, DOI 10.1016/j.virol.2006.07.023
   Liang C, 2003, J VIROL, V77, P1772, DOI 10.1128/JVI.77.3.1772-1783.2003
   Liang C, 2002, J VIROL, V76, P11729, DOI 10.1128/JVI.76.22.11729-11737.2002
   Lin J, 2012, J VIROL, V86, P5959, DOI 10.1128/JVI.05990-11
   Lingappa JR, 2014, VIRUS RES, V193, P89, DOI 10.1016/j.virusres.2014.07.001
   Lu KG, 2013, J MOL BIOL, V425, P1815, DOI 10.1016/j.jmb.2013.02.002
   Ma YM, 2004, J VIROL, V78, P52, DOI 10.1128/JVI.78.1.52-60.2004
   Melamed D, 2004, J VIROL, V78, P9675, DOI 10.1128/JVI.78.18.9675-9688.2004
   Morellet N, 2005, PROTEIN SCI, V14, P375, DOI 10.1110/ps.041087605
   Newman JL, 2004, PROTEIN SCI, V13, P2101, DOI 10.1110/ps.04614804
   Nguyen AT, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-101
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   PETTIT SC, 1994, J VIROL, V68, P8017
   Pornillos O, 2011, NATURE, V469, P424, DOI 10.1038/nature09640
   Prabu-Jeyabalan M, 2000, J MOL BIOL, V301, P1207, DOI 10.1006/jmbi.2000.4018
   Rihn SJ, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003461
   Sakalian M, 2006, J VIROL, V80, P5716, DOI 10.1128/JVI.02743-05
   Schur FKM, 2016, SCIENCE, V353, P506, DOI 10.1126/science.aaf9620
   Schur FKM, 2015, J VIROL, V89, P10294, DOI 10.1128/JVI.01502-15
   Schur FKM, 2015, NATURE, V517, P505, DOI 10.1038/nature13838
   Tang C, 2002, NAT STRUCT BIOL, V9, P537, DOI 10.1038/nsb806
   von Schwedler UK, 2003, J VIROL, V77, P5439, DOI 10.1128/JVI.77.9.5439-5450.2003
   von Schwedler UK, 1998, EMBO J, V17, P1555, DOI 10.1093/emboj/17.6.1555
   Waki K, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002997
   Wiegers K, 1998, J VIROL, V72, P2846
   Worthylake DK, 1999, ACTA CRYSTALLOGR D, V55, P85, DOI 10.1107/S0907444998007689
   Wright ER, 2007, EMBO J, V26, P2218, DOI 10.1038/sj.emboj.7601664
   Yeager Mark, 2013, Methods Mol Biol, V955, P527, DOI 10.1007/978-1-62703-176-9_28
   Zhao GP, 2013, NATURE, V497, P643, DOI 10.1038/nature12162
   Zhou J, 2004, RETROVIROLOGY, V1, DOI [10.1186/1742-4690-1-15, DOI 10.1186/1742-4290-1-15]
NR 66
TC 12
Z9 12
U1 4
U2 6
PU ELIFE SCIENCES PUBLICATIONS LTD
PI CAMBRIDGE
PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND
SN 2050-084X
J9 ELIFE
JI eLife
PD JUL 14
PY 2016
VL 5
AR e17063
DI 10.7554/eLife.17063
PG 18
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA DS5VT
UT WOS:000380851800001
OA gold
DA 2018-03-20
ER

PT J
AU Lilly, JL
   Sheldon, PR
   Hoversten, LJ
   Romero, G
   Balasubramaniam, V
   Berron, BJ
AF Lilly, Jacob L.
   Sheldon, Phillip R.
   Hoversten, Liv J.
   Romero, Gabriela
   Balasubramaniam, Vivek
   Berron, Brad J.
TI Interfacial Polymerization for Colorimetric Labeling of Protein
   Expression in Cells
SO PLOS ONE
LA English
DT Article
ID TRANSFER RADICAL POLYMERIZATION; DNA POINT MUTATION; SIGNAL
   AMPLIFICATION; FILMS; SENSITIVITY
AB Determining the location of rare proteins in cells typically requires the use of on-sample amplification. Antibody based recognition and enzymatic amplification is used to produce large amounts of visible label at the site of protein expression, but these techniques suffer from the presence of nonspecific reactivity in the biological sample and from poor spatial control over the label. Polymerization based amplification is a recently developed alternative means of creating an on-sample amplification for fluorescence applications, while not suffering from endogenous labels or loss of signal localization. This manuscript builds upon polymerization based amplification by developing a stable, archivable, and colorimetric mode of amplification termed Polymer Dye Labeling. The basic concept involves an interfacial polymer grown at the site of protein expression and subsequent staining of this polymer with an appropriate dye. The dyes Evans Blue and eosin were initially investigated for colorimetric response in a microarray setting, where both specifically stained polymer films on glass. The process was translated to the staining of protein expression in human dermal fibroblast cells, and Polymer Dye Labeling was specific to regions consistent with desired protein expression. The labeling is stable for over 200 days in ambient conditions and is also compatible with modern mounting medium.
C1 [Lilly, Jacob L.; Sheldon, Phillip R.; Romero, Gabriela; Berron, Brad J.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Hoversten, Liv J.; Balasubramaniam, Vivek] Univ Colorado, Dept Pediat, Denver, CO 80202 USA.
RP Berron, BJ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM brad.berron@uky.edu
OI Hoversten, Liv/0000-0002-7732-6055
FU National Institute of Biomedical Imaging and Bioengineering [R21
   EB012188]; National Science Foundation [CBET-1351531]; National Cancer
   Institute [R25CA153954]
FX This work was supported by the National Institute of Biomedical Imaging
   and Bioengineering (R21 EB012188), the National Science Foundation
   (CBET-1351531), and the National Cancer Institute (R25CA153954). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR ADAMS JC, 1992, J HISTOCHEM CYTOCHEM, V40, P1457, DOI 10.1177/40.10.1527370
   Avens HJ, 2011, J HISTOCHEM CYTOCHEM, V59, P76, DOI 10.1369/jhc.2010.955948
   Avens HJ, 2011, J NANOPART RES, V13, P331, DOI 10.1007/s11051-010-0034-z
   Avens HJ, 2009, ABSTR PAP AM CHEM SO, V237
   Berron BJ, 2012, LAB CHIP, V12, P708, DOI 10.1039/c2lc21101g
   Berron BJ, 2011, BIOTECHNOL BIOENG, V108, P1521, DOI 10.1002/bit.23101
   Cruise GM, 1998, BIOTECHNOL BIOENG, V57, P655, DOI 10.1002/(SICI)1097-0290(19980320)57:6<655::AID-BIT3>3.0.CO;2-K
   De Matos LL, 2010, BIOMARK INSIGHTS, V5, P9
   Hansen RR, 2008, ANAL BIOANAL CHEM, V392, P167, DOI 10.1007/s00216-008-2259-6
   Hansen RR, 2008, BIOMACROMOLECULES, V9, P355, DOI 10.1021/bm700672z
   Hansen RR, 2009, ANAL BIOCHEM, V386, P285, DOI 10.1016/j.ab.2008.12.009
   Johnson LM, 2009, AUST J CHEM, V62, P877, DOI 10.1071/CH09095
   Kaastrup K, 2013, ANAL CHEM, V85, P8055, DOI 10.1021/ac4018988
   Kaastrup K, 2012, LAB CHIP, V12, P4055, DOI 10.1039/c2lc40584a
   Khire VS, 2006, MACROMOLECULES, V39, P5081, DOI 10.1021/ma060073o
   Lakowicz J. R, 1983, PRINCIPLES FLUORESCE, P187
   Lee JK, 2012, BIOMACROMOLECULES, V13, P1136, DOI 10.1021/bm300037t
   Lou XH, 2005, ANAL CHEM, V77, P4698, DOI 10.1021/ac050706h
   Moss L, 2002, J DENT RES, V81
   Okelo GO, 2007, BIOSENS BIOELECTRON, V23, P588, DOI [10.1016/j.bios.2007.06.011, 10.1016/j.bios.2007.06.01]
   Qian H, 2009, ANAL CHEM, V81, P9824, DOI 10.1021/ac900959v
   Qian H, 2009, ANAL CHEM, V81, P4536, DOI 10.1021/ac900401m
   Rojo M. G., 2010, FOLIA HISTOCHEMICA C, V47, P349
   Sikes HD, 2008, NAT MATER, V7, P52, DOI 10.1038/nmat2042
   Sikes HD, 2009, LAB CHIP, V9, P653, DOI 10.1039/b816198d
   Singh I., 2011, TXB HUMAN HISTOLOGY
   Woo HY, 2005, J AM CHEM SOC, V127, P14721, DOI 10.1021/ja052906g
   Wu YF, 2009, ANAL CHEM, V81, P7015, DOI 10.1021/ac9011254
NR 28
TC 4
Z9 4
U1 1
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 23
PY 2014
VL 9
IS 12
AR e115630
DI 10.1371/journal.pone.0115630
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AZ9UY
UT WOS:000348563300057
PM 25536421
OA gold
DA 2018-03-19
ER

PT J
AU Marsac, P
   Li, T
   Taylor, L
AF Marsac, Patrick J.
   Li, Tonglei
   Taylor, Lynne S.
TI Estimation of Drug-Polymer Miscibility and Solubility in Amorphous Solid
   Dispersions Using Experimentally Determined Interaction Parameters
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE amorphous; crystallization; miscibility; polymer
ID GLASS-TRANSITION TEMPERATURE; WATER-SOLUBLE DRUGS; SOFT CONTACT-LENSES;
   INDOMETHACIN CRYSTALLIZATION; MOLECULAR DISPERSIONS; DELIVERY SYSTEMS;
   BLENDS; POLY(VINYLPYRROLIDONE); BEHAVIOR; STATE
AB The amorphous form of a drug may provide enhanced solubility, dissolution rate, and bioavailability but will also potentially crystallize over time. Miscible polymeric additives provide a means to increase physical stability. Understanding the miscibility of drug-polymer systems is of interest to optimize the formulation of such systems. The purpose of this work was to develop experimental models which allow for more quantitative estimates of the thermodynamics of mixing amorphous drugs with glassy polymers.
   The thermodynamics of mixing several amorphous drugs with amorphous polymers was estimated by coupling solution theory with experimental data. The entropy of mixing was estimated using Flory-Huggins lattice theory. The enthalpy of mixing and any deviations from the entropy as predicted by Flory-Huggins lattice theory were estimated using two separate experimental techniques; (1) melting point depression of the crystalline drug in the presence of the amorphous polymer was measured using differential scanning calorimetry and (2) determination of the solubility of the drug in 1-ethyl-2-pyrrolidone. The estimated activity coefficient was used to calculate the free energy of mixing of the drugs in the polymers and the corresponding solubility.
   Mixtures previously reported as miscible showed various degrees of melting point depression while systems reported as immiscible or partially miscible showed little or no melting point depression. The solubility of several compounds in 1-ethyl-2-pyrrolidone predicts that most drugs have a rather low solubility in poly(vinylpyrrolidone).
   Miscibility of various drugs with polymers can be explored by coupling solution theories with experimental data. These approximations provide insight into the physical stability of drug-polymer mixtures and the thermodynamic driving force for crystallization.
C1 [Marsac, Patrick J.; Taylor, Lynne S.] Purdue Univ, Sch Pharm, Dept Ind & Phys Pharm, W Lafayette, IN 47907 USA.
   [Marsac, Patrick J.] Merck & Co Inc, Mat Characterizat & Technol Assessment, West Point, PA 19486 USA.
   [Li, Tonglei] Univ Kentucky, Coll Pharm, Lexington, KY 40536 USA.
RP Taylor, LS (reprint author), Purdue Univ, Sch Pharm, Dept Ind & Phys Pharm, W Lafayette, IN 47907 USA.
EM ltaylor@pharmacy.purdue.edu
OI Taylor, Lynne/0000-0002-4568-6021
FU Merck Research Laboratories; AstraZeneca; PhRMA Foundation; AFPE/AACP
FX This work was supported in part by a fellowship from Merck Research
   Laboratories. AstraZeneca is acknowledged for financial support. Jared
   Baird is thanked for his help in measuring the solubility of the model
   compounds in 1-ethyl-2-pyrrolidone. Hakan Wikstrom is thanked for his
   help in measuring the solubility of sucrose using HPLC and Sheri
   Shamblin is thanked for providing heat capacity values for indomethacin
   and sucrose. Professors George Zografi, Rodolfo Pinal, Ken Morris, and
   Steve Byrn are acknowledged for their input. The PhRMA Foundation is
   acknowledged for a pre-doctoral fellowship to PJM. LST thanks AFPE/AACP
   for a New Investigator Award.
CR Ahn SB, 1998, KOREA POLYM J, V6, P389
   Andronis V, 2000, J NON-CRYST SOLIDS, V271, P236, DOI 10.1016/S0022-3093(00)00107-1
   BARLOW JW, 1981, ANNU REV MATER SCI, V11, P299, DOI 10.1146/annurev.ms.11.080181.001503
   BUCKLES RG, 1983, J BIOMED MATER RES, V17, P109, DOI 10.1002/jbm.820170110
   CHEE KK, 1995, POLYMER, V36, P809, DOI 10.1016/0032-3861(95)93112-Y
   Chen JP, 2008, SOUTH MED J, V101, P174, DOI 10.1097/01.smj.0000286752.67205.e0
   COLEMAN MM, 1995, PROG POLYM SCI, V20, P1, DOI 10.1016/0079-6700(94)00038-4
   Coleman M. M., 1991, SPECIFIC INTERACTION
   Craig DQM, 2002, INT J PHARM, V231, P131, DOI 10.1016/S0378-5173(01)00891-2
   Crowley KJ, 2003, PHARMACEUT RES, V20, P1417, DOI 10.1023/A:1025706110520
   Di Martino P, 2004, J CRYST GROWTH, V265, P302, DOI 10.1016/j.jcrysgro.2004.02.023
   DIESTELHORST M, 1994, INT OPHTHALMOL, V18, P1, DOI 10.1007/BF00919405
   Emara LH, 2002, DRUG DEV IND PHARM, V28, P795, DOI 10.1081/DDC-120005625
   Fahr A, 2007, EXPERT OPIN DRUG DEL, V4, P403, DOI 10.1517/17425247.4.4.403
   Flory P. J., 1953, PRINCIPLES POLYM CHE
   FORD JL, 1986, PHARM ACTA HELV, V61, P69
   FREZZOTTI D, 1994, J THERM ANAL, V41, P1237, DOI 10.1007/BF02549918
   Greenhalgh DJ, 1999, J PHARM SCI, V88, P1182, DOI 10.1021/js9900856
   Gulsen D, 2005, CURR EYE RES, V30, P1071, DOI 10.1080/02713680500346633
   Hancock BC, 2000, PHARMACEUT RES, V17, P397, DOI 10.1023/A:1007516718048
   Heller J., 1985, CRC CRIT R THER DRUG, V1, P39
   Ifkovits JL, 2007, TISSUE ENG, V13, P2369, DOI 10.1089/ten.2007.0093
   Jeffrey G.A., 1997, INTRO HYDROGEN BONDI
   Kamdar AR, 2006, MACROMOLECULES, V39, P1496, DOI 10.1021/ma052214c
   Kaur IP, 2002, DRUG DEV IND PHARM, V28, P473
   Khougaz K, 2000, J PHARM SCI, V89, P1325, DOI 10.1002/1520-6017(200010)89:10<1325::AID-JPS10>3.3.CO;2-X
   Kimura H, 2001, OPHTHALMOLOGICA, V215, P143, DOI 10.1159/000050849
   Konno H, 2006, J PHARM SCI-US, V95, P2692, DOI 10.1002/jps.20697
   Kukreja N, 2008, PHARMACOL RES, V57, P171, DOI 10.1016/.i.phrs.2008.01.012
   LESHER GA, 1993, OPTOMETRY VISION SCI, V70, P1012, DOI 10.1097/00006324-199312000-00004
   Mandelkern L, 1964, CRYSTALLIZATION POLY
   MARMION VJ, 1976, T OPHTHAL SOC UK, V96, P319
   Marsac PJ, 2006, PHARM RES, V23, P2417, DOI 10.1007/s11095-006-9063-9
   Marsac PJ, 2006, PHARM RES, V23, P2306, DOI 10.1007/s11095-006-9047-9
   Meaurio E, 2005, MACROMOLECULES, V38, P1207, DOI 10.1021/ma047818f
   MOSKALA EJ, 1985, POLYMER, V26, P228, DOI 10.1016/0032-3861(85)90034-5
   MUMMANENI V, 1990, INT J PHARM, V66, P71, DOI 10.1016/0378-5173(90)90386-I
   NISHI T, 1975, MACROMOLECULES, V8, P909, DOI 10.1021/ma60048a040
   Packhaeuser CB, 2004, EUR J PHARM BIOPHARM, V58, P445, DOI 10.1016/uj.ejpb.2004.03.003
   PAINTER PC, 1991, MACROMOLECULES, V24, P5630, DOI 10.1021/ma00020a023
   Park Y, 2005, MACROMOLECULES, V38, P3703, DOI 10.1021/ma0473115
   PERRIN P, 1991, POLYMER, V32, P1468, DOI 10.1016/0032-3861(91)90428-L
   Rubinstein M, 2003, POLYM PHYS
   SALEKIGERHARDT A, 1994, PHARMACEUT RES, V11, P1166, DOI 10.1023/A:1018945117471
   Sandler S. I., 1999, CHEM ENG THERMODYNAM
   SCHNEIDER W, 1991, CARDIOLOGY, V79, P5, DOI 10.1159/000174917
   Serajuddin ATM, 1999, J PHARM SCI, V88, P1058, DOI 10.1021/js980403l
   Sethia S, 2003, CRIT REV THER DRUG, V20, P215, DOI 10.1615/CritRevTherDrugCarrierSyst.v20.i23.40
   Shamblin SL, 1996, J THERM ANAL, V47, P1567, DOI 10.1007/BF01992846
   Shamblin SL, 1999, J PHYS CHEM B, V103, P4113, DOI 10.1021/jp983964+
   Shamblin SL, 1998, J PHARM SCI, V87, P694, DOI 10.1021/JS9704801
   Sharkawi T, 2007, J PHARM SCI-US, V96, P2829, DOI 10.1002/jps.20957
   Six K, 2003, PHARMACEUT RES, V20, P1047, DOI 10.1023/A:1024414423779
   Six K, 2002, J THERM ANAL CALORIM, V68, P591, DOI 10.1023/A:1016056222881
   STEIN RS, 1994, MATER RES SOC SYMP P, V321, P531
   Sun CQ, 2004, J PHARM SCI-US, V93, P646, DOI 10.1002/jps.10595
   Tang XLC, 2002, PHARMACEUT RES, V19, P477, DOI 10.1023/A:1015147729564
   Taylor LS, 1998, J PHARM SCI, V87, P1615, DOI 10.1021/js9800174
   Taylor LS, 1997, PHARMACEUT RES, V14, P1691, DOI 10.1023/A:1012167410376
   TESFAMARIAM B, 2008, INVEST OPHTHALMOL, V51, P118
   TODD PA, 1990, DRUGS, V40, P880, DOI 10.2165/00003495-199040060-00009
   Tong P, 2001, J PHARM SCI, V90, P1991, DOI 10.1002/jps.1150
   Van den Mooter G, 2001, EUR J PHARM SCI, V12, P261, DOI 10.1016/S0928-0987(00)00173-1
   Vanhee S, 2000, MACROMOLECULES, V33, P3924, DOI 10.1021/ma9918102
   Vauthier C, 2003, ADV DRUG DELIVER REV, V55, P519, DOI 10.1016/S0169-409X(03)00041-3
   WALTMAN SR, 1970, INVEST OPHTH VISUAL, V9, P250
   Wan WK, 2007, NANOMEDICINE-UK, V2, P483, DOI 10.2217/17435889.2.4.483
   Yalkowsky SH, 1999, SOLUBILITY SOLUBILIZ
   YOSHIOKA M, 1995, J PHARM SCI, V84, P983, DOI 10.1002/jps.2600840814
   Young R.J., 1991, INTRO POLYM
   ZELENSKAYA MV, 1986, VESTN OFTALMOL, P14
NR 71
TC 196
Z9 201
U1 17
U2 90
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
J9 PHARM RES-DORD
JI Pharm. Res.
PD JAN
PY 2009
VL 26
IS 1
BP 139
EP 151
DI 10.1007/s11095-008-9721-1
PG 13
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 385CV
UT WOS:000261791600013
PM 18779927
DA 2018-03-20
ER

PT J
AU Rahman, MS
   Ambati, J
   Joshi, S
   Rankin, SE
AF Rahman, Mohammed Shahidur
   Ambati, Jyothirmai
   Joshi, Suvid
   Rankin, Stephen E.
TI Incorporation of isolated Ti sites into mesoporous silica thin films by
   sugar surfactant complexation
SO MICROPOROUS AND MESOPOROUS MATERIALS
LA English
DT Article
DE Titanosilicate; Complexation; Mixed surfactant; Templating;
   Self-assembly
ID METAL-SACCHARIDE CHEMISTRY; SOL-GEL CHEMISTRY; X-RAY-DIFFRACTION; SI
   MIXED OXIDES; TITANIA-SILICA; EPOXIDATION CATALYSTS; MOLECULAR-SIEVES;
   ACTIVE-SITES; HYDROGEN-PEROXIDE; IN-SITU
AB One of the challenges in transition metal heterogeneous catalysis is the generation of supports with well-defined porosity containing transition metal sites of uniform coordination, complexity, and spacing. For instance, tetrahedrally coordinated titanium atoms incorporated into a silica network are believed to be the active oxidation sites for heterogeneous epoxidation catalysis. Sol-gel chemistry provides an opportunity to produce well mixed metal oxides, but the high reactivity of titanium precursors compared to silicon precursors impedes the uniform incorporation of isolated tetracoordinated Ti(IV) sites. Here, a homogeneous distribution of titanium at the pore surface is promoted by a ligand-assisted templating method with n-dodecyl beta-D-maltoside (C(12)G(2)) surfactant. Preferential interactions or complexation between the titanium and maltose headgroups of this surfactant are hypothesized to promote homogeneous incorporation of titania only at the micelle/silica interface. To generate well-ordered materials with controlled titania site density, a mixed surfactant system of C(12)G(2) and cetyltrimethylammonium bromide (C(16)TAB) is used for pore templating. A series of Si-Ti mixed oxide thin films with different levels of titanium loading (from 1.15 to 11.1 atom% of cations) is synthesized by a solvent evaporation-driven self-assembly method with staged precursor addition to facilitate complexation between C(12)G(2) and the titanium precursor. The degrees of homogeneity (indicated by tetracoordinated Ti) in these films are compared with those of films synthesized with the same loading of titanium but without C(12)G(2) surfactant or without pre-complexation. The titanium in films synthesized using maltoside complexation is highly dispersed, while some fraction of octahedrally coordinated titanium atoms is generated without C(12)G(2) surfactant and without pre-complexation. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Rahman, Mohammed Shahidur; Ambati, Jyothirmai; Joshi, Suvid; Rankin, Stephen E.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Rankin, SE (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 FP Anderson Tower, Lexington, KY 40506 USA.
EM srankin@engr.uky.edu
OI Rankin, Stephen/0000-0002-8615-7564
FU National Science Foundation [CBET-0967390]; Kentucky Science and
   Engineering Foundation [KSEF-1204-RDE-009]; U.S. Department of Energy
   EPSCoR Implementation Award [DE-FG02-07ER46375]
FX This material is based upon initial film synthesis work supported by the
   National Science Foundation under Grant No. CBET-0967390 and the
   Kentucky Science and Engineering Foundation under Grant No.
   KSEF-1204-RDE-009, and further characterization by FTIR and XRD
   performed as part of a U.S. Department of Energy EPSCoR Implementation
   Award under Grant number DE-FG02-07ER46375. We thank Prof. Barbara
   Knutson for access to the UV-vis spectrometer and Dr. Alan Dozier for
   help with STEM.
CR Alba MD, 1996, J PHYS CHEM-US, V100, P2178, DOI 10.1021/jp9515895
   Alberius PCA, 2002, CHEM MATER, V14, P3284, DOI 10.1021/cm011209u
   Andrianainarivelo M, 1996, J MATER CHEM, V6, P1665, DOI 10.1039/jm9960601665
   AUVRAY X, 1989, J PHYS CHEM-US, V93, P7458, DOI 10.1021/j100358a040
   AUVRAY X, 1995, LANGMUIR, V11, P433, DOI 10.1021/la00002a012
   BARRETT EP, 1951, J AM CHEM SOC, V73, P373, DOI 10.1021/ja01145a126
   Beck C, 2001, J CATAL, V204, P428, DOI 10.1006/jcat.2001.3407
   Berube F, 2010, CHEM MATER, V22, P1988, DOI 10.1021/cm9030667
   Besson S, 2003, J MATER CHEM, V13, P404, DOI 10.1039/b206698j
   BLASCO T, 1995, J CATAL, V156, P65, DOI 10.1006/jcat.1995.1232
   BLASCO T, 1993, J AM CHEM SOC, V115, P11806, DOI 10.1021/ja00078a020
   Bocking D, 2009, J MATER SCI, V44, P6786, DOI 10.1007/s10853-009-3565-x
   Boissiere C, 2005, LANGMUIR, V21, P12362, DOI 10.1021/la050981z
   Brinker CJ, 1999, ADV MATER, V11, P579, DOI 10.1002/(SICI)1521-4095(199905)11:7<579::AID-ADMA579>3.0.CO;2-R
   Brunauer S, 1938, J AM CHEM SOC, V60, P309, DOI 10.1021/ja01269a023
   Cagnol F, 2003, J MATER CHEM, V13, P61, DOI 10.1039/b209640b
   Capel-Sanchez MC, 2010, CATAL TODAY, V158, P103, DOI 10.1016/j.cattod.2010.07.022
   Celik O, 2001, ANGEW CHEM INT EDIT, V40, P3800
   Chattopadhyay K, 2002, J INORG BIOCHEM, V91, P116, DOI 10.1016/S0162-0134(02)00427-0
   Che M, 2012, P ROY SOC A-MATH PHY, V468, P2113, DOI 10.1098/rspa.2012.0139
   Choi KM, 2013, J MATER CHEM A, V1, P2485, DOI 10.1039/c2ta01369j
   Choi KM, 2011, J COLLOID INTERF SCI, V359, P240, DOI 10.1016/j.jcis.2011.03.016
   Clerc M, 1996, J PHYS II, V6, P961, DOI 10.1051/jp2:1996110
   CLERICI MG, 1991, APPL CATAL, V68, P249
   CLERICI MG, 1993, J CATAL, V140, P71, DOI 10.1006/jcat.1993.1069
   Coles MP, 2000, CHEM MATER, V12, P122, DOI 10.1021/cm990444y
   Crepaldi EL, 2003, J AM CHEM SOC, V125, P9770, DOI 10.1021/ja030070g
   Crocker M, 1999, J CHEM SOC DALTON, P3791, DOI 10.1039/a905887g
   Dal Santo V, 2010, MOLECULES, V15, P3829, DOI 10.3390/molecules15063829
   deMan AJM, 1996, J PHYS CHEM-US, V100, P5025, DOI 10.1021/jp952790i
   DOEUFF S, 1987, J NON-CRYST SOLIDS, V89, P206, DOI 10.1016/S0022-3093(87)80333-2
   Doshi DA, 2003, J PHYS CHEM B, V107, P7683, DOI 10.1021/jp027214i
   Dusi M, 2000, CATAL REV, V42, P213, DOI 10.1081/CR-100100262
   DUTOIT DCM, 1995, J CATAL, V153, P165, DOI 10.1006/jcat.1995.1118
   El-Safty SA, 2004, CHEM MATER, V16, P384, DOI 10.1021/cm034282o
   Froba M, 1997, SOLID STATE IONICS, V101, P249, DOI 10.1016/S0167-2738(97)84038-6
   Gao HX, 1996, APPL CATAL A-GEN, V138, P27, DOI 10.1016/0926-860X(95)00276-6
   Gao XT, 1999, CATAL TODAY, V51, P233, DOI 10.1016/S0920-5861(99)00048-6
   GEETHA K, 1995, CARBOHYD RES, V271, P163, DOI 10.1016/0008-6215(95)00050-4
   GEOBALDO F, 1992, CATAL LETT, V16, P109, DOI 10.1007/BF00764360
   Gianotti E, 2007, J PHYS CHEM C, V111, P5083, DOI 10.1021/jp067506+
   Grosso D, 2002, CHEM MATER, V14, P931, DOI 10.1021/cm011255u
   Grosso D, 2001, CHEM MATER, V13, P1848, DOI 10.1021/cm001225b
   GUGLIELMI M, 1988, J NON-CRYST SOLIDS, V100, P16, DOI 10.1016/0022-3093(88)90004-X
   Hidalgo JM, 2008, CATAL LETT, V126, P179, DOI 10.1007/s10562-008-9602-6
   Holland MA, 2000, J MATER CHEM, V10, P2495, DOI 10.1039/b005408i
   Honma I, 2000, ADV MATER, V12, P1529, DOI 10.1002/1521-4095(200010)12:20<1529::AID-ADMA1529>3.0.CO;2-U
   Horiuchi Y, 2011, APPL CATAL A-GEN, V400, P1, DOI 10.1016/j.apcata.2011.04.027
   Huesing N, 2003, APPL CATAL A-GEN, V254, P297, DOI 10.1016/S0926-860X(03)00475-7
   Huo QS, 1996, CHEM MATER, V8, P1147, DOI 10.1021/cm960137h
   Husing N, 2003, J SOL-GEL SCI TECHN, V26, P615, DOI 10.1023/A:1020736407784
   Husing N, 2002, CHEM MATER, V14, P2429, DOI 10.1021/cm011310z
   Hutter R, 1995, J CHEM SOC CHEM COMM, P2487, DOI 10.1039/C39950002487
   HUTTER R, 1995, J CATAL, V153, P177, DOI 10.1006/jcat.1995.1119
   Hutter R, 1995, J CATAL, V157, P665, DOI 10.1006/jcat.1995.1332
   Igarashi N, 2005, MICROPOR MESOPOR MAT, V81, P97, DOI 10.1016/j.micromeso.2005.01.022
   Igarashi N, 2007, MICROPOR MESOPOR MAT, V104, P269, DOI 10.1016/j.micromeso.2007.02.041
   Inoue T, 2007, CHEM LETT, V36, P862, DOI 10.1246/cl.2007.862
   Jarupatrakorn J, 2002, J AM CHEM SOC, V124, P8380, DOI 10.1021/ja0202208
   Ji D, 2005, APPL CATAL A-GEN, V281, P39, DOI 10.1016/j.apcata.2004.11.010
   Klaas J, 1997, J PHYS CHEM B, V101, P1305, DOI 10.1021/jp9627133
   Klein S, 1996, J CATAL, V163, P476, DOI 10.1006/jcat.1996.0349
   Koyano KA, 1996, CHEM COMMUN, P145, DOI 10.1039/cc9960000145
   Kruk M, 1997, J PHYS CHEM B, V101, P583, DOI 10.1021/jp962000k
   Lafond V, 2004, CHEM MATER, V16, P5380, DOI 10.1021/cm0490569
   Lin HP, 2001, MICROPOR MESOPOR MAT, V44, P129, DOI 10.1016/S1387-1811(01)00176-7
   Lin KF, 2009, J CATAL, V263, P75, DOI 10.1016/j.jcat.2009.01.013
   Liu SH, 2012, CHEMCATCHEM, V4, P1462, DOI 10.1002/cctc.201200264
   Liu ZF, 1996, J CATAL, V159, P83, DOI 10.1006/jcat.1996.0066
   LIVAGE J, 1992, J NON-CRYST SOLIDS, V145, P11, DOI 10.1016/S0022-3093(05)80422-3
   MASCHMEYER T, 1995, NATURE, V378, P159, DOI 10.1038/378159a0
   Matheron M, 2005, J MATER CHEM, V15, P4741, DOI 10.1039/b510554d
   MendezVivar J, 1997, J SOL-GEL SCI TECHN, V8, P235, DOI 10.1007/BF02436846
   MORROW BA, 1990, J NON-CRYST SOLIDS, V120, P61, DOI 10.1016/0022-3093(90)90191-N
   Mukhopadhyay A, 1998, CARBOHYD RES, V311, P147, DOI 10.1016/S0008-6215(98)00186-4
   Murata C, 2003, J PHYS CHEM B, V107, P4364, DOI 10.1021/jp0277006
   Newalkar BL, 2001, CHEM MATER, V13, P552, DOI 10.1021/cm000748g
   Nishiyama N, 2002, CHEM MATER, V14, P4229, DOI 10.1021/cm0201246
   Notari B, 1996, ADV CATAL, V41, P253, DOI 10.1016/S0360-0564(08)60042-5
   Pena ML, 2001, MICROPOR MESOPOR MAT, V44, P345, DOI 10.1016/S1387-1811(01)00201-3
   Perez Y, 2003, J ORGANOMET CHEM, V679, P220, DOI 10.1016/S0022-328X(03)00591-6
   PETRINI G, 1991, STUD SURF SCI CATAL, V68, P761
   Pickup DM, 1999, J MATER CHEM, V9, P1299, DOI 10.1039/a809810g
   Pinho L, 2011, J PHYS CHEM C, V115, P22851, DOI 10.1021/jp2074623
   Pozzo RL, 1997, CATAL TODAY, V39, P219, DOI 10.1016/S0920-5861(97)00103-X
   Rahman MS, 2010, J COLLOID INTERF SCI, V342, P33, DOI 10.1016/j.jcis.2009.10.021
   Rajakovic VN, 2003, MAT SCI ENG C-BIO S, V23, P817, DOI 10.1016/j.msec.2003.09.089
   Rao CP, 2000, INORG CHIM ACTA, V297, P373, DOI 10.1016/S0020-1693(99)00364-3
   RAPPE AK, 1992, J AM CHEM SOC, V114, P10024, DOI 10.1021/ja00051a040
   Ren Y, 2012, CHEM SOC REV, V41, P4909, DOI 10.1039/c2cs35086f
   SALTMAN P, 1965, J CHEM EDUC, V42, P682, DOI 10.1021/ed042p682
   Sayari A, 1997, CHEM MATER, V9, P2499, DOI 10.1021/cm970128o
   Schroeder T., 2006, J CHEM SOC DA, V35, P1030
   SING KSW, 1985, PURE APPL CHEM, V57, P603, DOI 10.1351/pac198557040603
   Solberg SM, 2005, J PHYS CHEM B, V109, P24331, DOI 10.1021/jp054187y
   Sreethawong T, 2005, J MOL CATAL A-CHEM, V241, P23, DOI 10.1016/j.molcata.2005.07.009
   Sun DH, 2006, LANGMUIR, V22, P4793, DOI 10.1021/1053172o
   Tabacchi G, 2007, J PHYS CHEM C, V111, P4946, DOI 10.1021/jp0665168
   TANEV PT, 1994, NATURE, V368, P321, DOI 10.1038/368321a0
   Tani K, 2003, CHROMATOGRAPHIA, V57, P409, DOI 10.1007/BF02492416
   Thomas JM, 1999, J PHYS CHEM B, V103, P8809, DOI 10.1021/jp991991+
   Thomas JM, 2009, PHYS CHEM CHEM PHYS, V11, P2799, DOI 10.1039/b819249a
   Thompson M. A., 2004, ARGUSLAB 4 0 1
   TUEL A, 1995, ZEOLITES, V15, P236, DOI 10.1016/0144-2449(94)00059-2
   Tuysuz H, 2012, ADV CATAL, V55, P127, DOI 10.1016/B978-0-12-385516-9.00002-8
   Vayssilov GN, 1997, CATAL REV, V39, P209, DOI 10.1080/01614949709353777
   Wang XX, 2006, J CATAL, V238, P13, DOI 10.1016/j.jcat.2005.11.027
   Wu CW, 2003, J INORG ORGANOMET P, V13, P131, DOI 10.1023/A:1025832215586
   Yamashita H, 1998, J PHYS CHEM B, V102, P5870, DOI 10.1021/jp981343a
   Yamashita H, 2008, TOP CATAL, V47, P116, DOI 10.1007/s11244-007-9023-6
   YOLDAS BE, 1980, J NON-CRYST SOLIDS, V38-9, P81, DOI 10.1016/0022-3093(80)90398-1
   Zhang FZ, 2001, CATAL LETT, V72, P235, DOI 10.1023/A:1009061910392
   Zhang WH, 1996, J AM CHEM SOC, V118, P9164, DOI 10.1021/ja960594z
NR 113
TC 1
Z9 1
U1 1
U2 38
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1387-1811
EI 1873-3093
J9 MICROPOR MESOPOR MAT
JI Microporous Mesoporous Mat.
PD MAY 15
PY 2014
VL 190
BP 74
EP 83
DI 10.1016/j.micromeso.2014.01.025
PG 10
WC Chemistry, Applied; Chemistry, Physical; Nanoscience & Nanotechnology;
   Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA AG0JT
UT WOS:000335102500011
DA 2018-03-20
ER

PT J
AU Sundararaj, SC
   Thomas, MV
   Dziubla, TD
   Puleo, DA
AF Sundararaj, Sharath Kumar C.
   Thomas, Mark V.
   Dziubla, Thomas D.
   Puleo, David A.
TI Bioerodible system for sequential release of multiple drugs
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Multiple drug delivery; Sequential drug release; Zero-order release;
   Cellulose acetate phthalate; Pluronic F-127
ID GROWTH-FACTOR DELIVERY; SIZE DEFECT MODEL; IN-VIVO; TRANSFORMING
   GROWTH-FACTOR-BETA-1; BONE REGENERATION; POLYMER SYSTEM; DUAL DELIVERY;
   IGF-I; ANGIOGENESIS; SIMVASTATIN
AB Because many complex physiological processes are controlled by multiple biomolecules, comprehensive treatment of certain disease conditions may be more effectively achieved by administration of more than one type of drug. Thus, the objective of the present research was to develop a multilayered, polymer-based system for sequential delivery of multiple drugs. The polymers used were cellulose acetate phthalate (CAP) complexed with Pluronic F-127 (P). After evaluating morphology of the resulting CAPP system, in vitro release of small molecule drugs and a model protein was studied from both single and multilayered devices. Drug release from single-layered CAPP films followed zero-order kinetics related to surface erosion of the association polymer. Release studies from multilayered CAPP devices showed the possibility of achieving intermittent release of one type of drug as well as sequential release of more than one type of drug. Mathematical modeling accurately predicted the release profiles for both single layer and multilayered devices. The present CAPP association polymer-based multilayer devices can be used for localized, sequential delivery of multiple drugs for the possible treatment of complex disease conditions, and perhaps for tissue engineering applications, that require delivery of more than one type of biomolecule. (C) 2013 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Sundararaj, Sharath C.; Puleo, David A.] Univ Kentucky, Dept Biomed Engn, Lexington, KY 40506 USA.
   [Thomas, Mark V.] Univ Kentucky, Coll Dent, Lexington, KY 40536 USA.
   [Dziubla, Thomas D.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Puleo, DA (reprint author), Univ Kentucky, Dept Biomed Engn, Lexington, KY 40506 USA.
EM puleo@uky.edu
FU NIH [DE019645, AR060964]; Kentucky NASA EPSCoR [NNX08BA13A]
FX This research was supported by NIH (DE019645 and AR060964) and Kentucky
   NASA EPSCoR (NNX08BA13A). We dedicate this work in memory of Dr. Mark V.
   Thomas, who passed away as the studies were being conducted.
CR Barrett B, 2006, J PHARMACEUT BIOMED, V41, P517, DOI 10.1016/j.jpba.2005.11.020
   Basmanav FB, 2008, BIOMATERIALS, V29, P4195, DOI 10.1016/j.biomaterials.2008.07.017
   Borselli C, 2010, P NATL ACAD SCI USA, V107, P3287, DOI 10.1073/pnas.0903875106
   Bounaceur A, 2007, J SUPERCRIT FLUID, V41, P429, DOI 10.1016/j.supflu.2006.11.004
   Chen FM, 2010, BIOMATERIALS, V31, P6279, DOI 10.1016/j.biomaterials.2010.04.053
   Chen FM, 2009, BIOMATERIALS, V30, P5215, DOI 10.1016/j.biomaterials.2009.06.009
   Chen PY, 2010, NUTR RES, V30, P191, DOI 10.1016/j.nutres.2010.03.004
   Chen RR, 2007, PHARM RES, V24, P258, DOI 10.1007/s11095-006-9173-4
   Cunha BA, 2000, CLIN MICROBIOL INFEC, V6, P270, DOI 10.1046/j.1469-0691.2000.00058-2.x
   Dogan AK, 2005, J BIOMED MATER RES B, V74B, P504
   DOWLING HF, 1957, ARCH INTERN MED, V99, P536, DOI 10.1001/archinte.1957.00260040036003
   Elisseeff J, 2001, J ORTHOPAED RES, V19, P1098, DOI 10.1016/S0736-0266(01)00054-7
   Freeman CD, 1997, DRUGS, V54, P679, DOI 10.2165/00003495-199754050-00003
   Fukumoto T, 2003, OSTEOARTHR CARTILAGE, V11, P55, DOI 10.1053/joca.2002.0869
   Garcia-Ruiz C, 2006, ELECTROPHORESIS, V27, P266, DOI 10.1002/elps.200500430
   GATES KA, 1994, PHARMACEUT RES, V11, P1605, DOI 10.1023/A:1018913921956
   Ghaderi R, 1997, PHARMACEUT RES, V14, P1556, DOI 10.1023/A:1012122200381
   GOMBOTZ WR, 1995, BIOCONJUGATE CHEM, V6, P332, DOI 10.1021/bc00034a002
   Gopferich A, 2002, ADV DRUG DELIVER REV, V54, P911, DOI 10.1016/S0169-409X(02)00051-0
   Griffiths GS, 2011, J CLIN PERIODONTOL, V38, P43, DOI 10.1111/j.1600-051X.2010.01632.x
   Heller J, 2002, ADV DRUG DELIVER REV, V54, P1015, DOI 10.1016/S0169-409X(02)00055-8
   Hopfenberg H. B., 1976, CONTROLLED RELEASE P, P26
   Jain JP, 2005, J CONTROL RELEASE, V103, P541, DOI 10.1016/j.jconrel.2004.12.021
   Jaklenec A, 2008, BIOMATERIALS, V29, P1518, DOI 10.1016/j.biomaterials.2007.12.004
   Jeon JH, 2008, BIOMATERIALS, V29, P3591, DOI 10.1016/j.biomaterials.2008.05.011
   Jeon JH, 2008, J PERIODONTOL, V79, P1457, DOI [10.1902/jop.2008.080004, 10.1902/jop.2008.080004 ]
   Jeon JH, 2007, INT J PHARM, V340, P6, DOI 10.1016/j.ijpharm.2007.03.007
   Jiang HL, 2005, J CONTROL RELEASE, V108, P237, DOI 10.1016/j.jconrel.2005.08.006
   Johnny GC, 1988, ORAL SURG ORAL MED O, V66, P620
   Kabanov AV, 2002, J CONTROL RELEASE, V82, P189, DOI 10.1016/S0168-3659(02)00009-3
   Kempen DHR, 2009, BIOMATERIALS, V30, P2816, DOI 10.1016/j.biomaterials.2009.01.031
   Kumar N, 2002, ADV DRUG DELIVER REV, V54, P889, DOI 10.1016/S0169-409X(02)00050-9
   LYNCH SE, 1991, J PERIODONTOL, V62, P458, DOI 10.1902/jop.1991.62.7.458
   Nevins M, 2003, J PERIODONTOL, V74, P1282, DOI 10.1902/jop.2003.74.9.1282
   Nillesen STM, 2007, BIOMATERIALS, V28, P1123, DOI 10.1016/j.biomaterials.2006.10.029
   Patel ZS, 2008, BONE, V43, P931, DOI 10.1016/j.bone.2008.06.019
   Peattie RA, 2006, BIOMATERIALS, V27, P1868, DOI 10.1016/j.biomaterials.2005.09.035
   PONCHEL G, 1987, INT J PHARM, V38, P65, DOI 10.1016/0378-5173(87)90098-6
   Raiche AT, 2003, IEEE ENG MED BIOL, V22, P35, DOI 10.1109/MEMB.2003.1256270
   Raschke M, 2002, BONE, V30, P144, DOI 10.1016/S8756-3282(01)00640-8
   Richardson TP, 2001, NAT BIOTECHNOL, V19, P1029, DOI 10.1038/nbt1101-1029
   Riley CM, 2006, BIOMATERIALS, V27, P5935, DOI 10.1016/j.biomaterials.2006.08.029
   Rosen PS, 2001, J PERIODONTOL, V72, P1790
   Roxin P, 1998, DRUG DEV IND PHARM, V24, P1025, DOI 10.3109/03639049809089946
   Schmidmaier G, 2002, BONE, V31, P165, DOI 10.1016/S8756-3282(02)00798-6
   Simmons CA, 2004, BONE, V35, P562, DOI 10.1016/j.bone.2004.02.027
   Tengood JE, 2010, BIOMATERIALS, V31, P7805, DOI 10.1016/j.biomaterials.2010.07.010
   TODD PA, 1990, DRUGS, V40, P583, DOI 10.2165/00003495-199040040-00007
   Uhrich KE, 1999, CHEM REV, V99, P3181, DOI 10.1021/cr940351u
   Vernillo A T, 1998, Adv Dent Res, V12, P56
   Veys E.M, 1991, SCAND J RHEUMATOL, V19, P3
   XU X, 1993, PHARMACEUT RES, V10, P1144, DOI 10.1023/A:1018960016756
   Yilgor P, 2009, BIOMATERIALS, V30, P3551, DOI 10.1016/j.biomaterials.2009.03.024
   Young S, 2009, TISSUE ENG PT A, V15, P2347, DOI 10.1089/ten.tea.2008.0510
   Younger ASE, 1998, J BONE JOINT SURG AM, V80A, P60, DOI 10.2106/00004623-199801000-00011
NR 55
TC 8
Z9 8
U1 2
U2 35
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742-7061
EI 1878-7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD JAN
PY 2014
VL 10
IS 1
BP 115
EP 125
DI 10.1016/j.actbio.2013.09.031
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 292HR
UT WOS:000329893300013
PM 24096151
OA green_accepted
DA 2018-03-20
ER

PT J
AU Hawkins, AM
   Satarkar, NS
   Hilt, JZ
AF Hawkins, Ashley M.
   Satarkar, Nitin S.
   Hilt, J. Zach
TI Nanocomposite Degradable Hydrogels: Demonstration of Remote Controlled
   Degradation and Drug Release
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE degradable polymers; drug release; hydrogels; nanocomposite; remote
   control
ID BIOMATERIALS; DELIVERY; HYPERTHERMIA
AB To demonstrate remote controlled degradation of degradable nanocomposite hydrogels by application of an alternating magnetic field (AMF). Further, it was desired to study the AMF effect on the drug release properties of these systems.
   Degradable nanocomposite hydrogels were synthesized by incorporating iron oxide nanoparticles into a degradable hydrogel that exhibited temperature dependent degradation. Heating, degradation, and drug release studies were conducted by application of an AMF to determine if modulation of degradation and drug release could be attained.
   Hydrogels were successfully prepared, shown to have temperature dependent degradation, and shown to heat when exposed to the AMF. The degradation rate of the exposed samples was demonstrated to be higher than control samples, thus modulation of degradation was obtained. The release of a model drug from the system was modulated by exposure to the AMF.
   This is the first demonstration of remote controlled degradation using an AMF stimulus. Here, the proof of the concept has been presented, and there is great potential to enhance this effect through various methods. The ability to remotely control degradation of an implanted device opens a new area of improved medical devices.
C1 [Hawkins, Ashley M.; Satarkar, Nitin S.; Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Hilt, JZ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 F Paul Anderson Tower, Lexington, KY 40506 USA.
EM hilt@engr.uky.edu
FU National Science Foundation through an NSF IGERT [CTS-0609117]
FX This material is based in part on work supported by the National Science
   Foundation through an NSF IGERT traineeship and CTS-0609117 (NSF NIRT).
CR Anderson DG, 2006, ADV MATER, V18, P2614, DOI 10.1002/adma.200600529
   Brey DM, 2008, J BIOMED MATER RES A, V85A, P731, DOI 10.1002/jbm.a.31494
   Frimpong RA, 2007, J BIOMED MATER RES A, V80A, P1, DOI 10.1002/jbm.a.30962
   Griffith LG, 2000, ACTA MATER, V48, P263, DOI 10.1016/S1359-6454(99)00299-2
   Harris N, 2006, J PHYS CHEM B, V110, P10701, DOI 10.1021/jp0606208
   Hergt R, 2006, J PHYS-CONDENS MAT, V18, pS2919, DOI 10.1088/0953-8984/18/38/S26
   KAMATH KR, 1993, ADV DRUG DELIVER REV, V11, P59, DOI 10.1016/0169-409X(93)90027-2
   Kopecek J, 2003, EUR J PHARM SCI, V20, P1, DOI 10.1016/S0928-0987(03)00164-7
   Kretlow JD, 2007, ADV DRUG DELIVER REV, V59, P263, DOI 10.1016/j.addr.2007.03.013
   Lao LL, 2004, J MATER SCI-MATER M, V15, P1061, DOI 10.1023/B:JMSM.0000046386.78633.e5
   Lin CC, 2006, ADV DRUG DELIVER REV, V58, P1379, DOI 10.1016/j.addr.2006.09.004
   Nair LS, 2007, PROG POLYM SCI, V32, P762, DOI 10.1016/j.progpolymsci.2007.05.017
   Peppas NA, 2006, ADV MATER, V18, P1345, DOI 10.1002/adma.200501612
   Ratner BD, 2004, ANNU REV BIOMED ENG, V6, P41, DOI 10.1146/annurev.bioeng.6.040803.140027
   Satarkar NS, 2008, J CONTROL RELEASE, V130, P246, DOI 10.1016/j.jconrel.2008.06.008
   Satarkar NS, 2008, ACTA BIOMATER, V4, P11, DOI 10.1016/j.actbio.2007.07.009
   SAWHNEY AS, 1993, MACROMOLECULES, V26, P581, DOI 10.1021/ma00056a005
   Tjahjono IK, 2008, INT J HEAT MASS TRAN, V51, P1505, DOI 10.1016/j.ijheatmasstransfer.2007.07.047
NR 18
TC 35
Z9 35
U1 0
U2 29
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
J9 PHARM RES-DORD
JI Pharm. Res.
PD MAR
PY 2009
VL 26
IS 3
BP 667
EP 673
DI 10.1007/s11095-008-9804-z
PG 7
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 403XZ
UT WOS:000263116600020
PM 19118411
DA 2018-03-20
ER

PT J
AU Hayes, D
   Baker, PB
   Mansour, HM
   Peeples, ME
   Nicol, KK
AF Hayes, Don, Jr.
   Baker, Peter B.
   Mansour, Heidi M.
   Peeples, Mark E.
   Nicol, Kathleen K.
TI Interstitial Lung Disease in a Child with Antisynthetase Syndrome
SO LUNG
LA English
DT Article
DE Antisynthetase syndrome; Anti-Jo-1 antibody; Child; Interstitial lung
   disease
ID PULMONARY-FIBROSIS; ANTI-JO-1 ANTIBODIES; POLYMYOSITIS; DERMATOMYOSITIS;
   HYPERTENSION; JO-1
AB Antisynthetase Syndrome is associated with interstitial lung disease in adult patients, but this has not been described in children.
   A 13-year-old with interstitial lung disease due to Antisynthetase Syndrome and pulmonary arterial hypertension underwent emergent bilateral lung transplantation after a rapid clinical decline.
   We present the clinical, radiographic, and histological findings of a child with interstitial lung disease due to Antisynthetase Syndrome.
C1 [Hayes, Don, Jr.; Peeples, Mark E.] Ohio State Univ, Coll Med, Nationwide Childrens Hosp, Dept Pediat, Columbus, OH 43205 USA.
   [Baker, Peter B.; Nicol, Kathleen K.] Ohio State Univ, Coll Med, Nationwide Childrens Hosp, Dept Pathol, Columbus, OH 43205 USA.
   [Mansour, Heidi M.] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY USA.
RP Hayes, D (reprint author), Ohio State Univ, Coll Med, Nationwide Childrens Hosp, Dept Pediat, 700 Childrens Dr, Columbus, OH 43205 USA.
EM hayes.705@osu.edu
CR Andersen CU, 2012, RESP MED, V106, P875, DOI 10.1016/j.rmed.2012.02.015
   MARGUERIE C, 1990, Q J MED, V77, P1019, DOI 10.1093/qjmed/77.1.1019
   Marie I, 2002, ARTHRIT RHEUM-ARTHR, V47, P614, DOI 10.1002/art.10794
   Nadrous HF, 2005, CHEST, V128, P2393, DOI 10.1378/chest.128.4.2393
   NISHIKAI M, 1980, ARTHRITIS RHEUM, V23, P881, DOI 10.1002/art.1780230802
   Tillie-Leblond I, 2008, THORAX, V63, P53, DOI 10.1136/thx.2006.069237
   VazquezAbad D, 1996, ARTHRITIS RHEUM, V39, P292, DOI 10.1002/art.1780390218
   Watanabe K, 2011, RESP MED, V105, P1238, DOI 10.1016/j.rmed.2011.03.022
   YOSHIDA S, 1983, ARTHRITIS RHEUM, V26, P604, DOI 10.1002/art.1780260505
   Yousem SA, 2010, MODERN PATHOL, V23, P874, DOI 10.1038/modpathol.2010.65
NR 10
TC 3
Z9 3
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0341-2040
J9 LUNG
JI Lung
PD AUG
PY 2013
VL 191
IS 4
BP 441
EP 443
DI 10.1007/s00408-013-9468-2
PG 3
WC Respiratory System
SC Respiratory System
GA 184TQ
UT WOS:000321916800018
PM 23652349
DA 2018-03-20
ER

PT J
AU Gutierrez, J
   Eisenberg, R
   Herrensmith, G
   Tobin, T
   Li, TL
   Long, SH
AF Gutierrez, Julio
   Eisenberg, Rodney
   Herrensmith, Gabrielle
   Tobin, Thomas
   Li, Tonglei
   Long, Sihui
TI Solvatomorphism in
   (E)-2-(2,6-dichloro-4-hydroxybenzylidene)hydrazinecarboximidamide
SO ACTA CRYSTALLOGRAPHICA SECTION C-CRYSTAL STRUCTURE COMMUNICATIONS
LA English
DT Article
ID PSEUDOPOLYMORPH; GUANABENZ; CRYSTAL
AB The structures of orthorhombic (E)-4-(2-{[amino(iminio)-methyl] amino} vinyl)-3,5-dichlorophenolate dihydrate, C8H8-Cl2N4O center dot 2H(2)O, (I), triclinic (E)-4-(2-{[amino(iminio) methyl]amino} vinyl)-3,5-dichlorophenolate methanol disolvate, C8H8Cl2N4O center dot 2CH(4)O, (II), and orthorhombic (E)-amino[(2,6-dichloro-4-hydroxystyryl)amino]methaniminium acetate, C8H9Cl2N4O+center dot C2H3O2-, (III), all crystallize with one formula unit in the asymmetric unit, with the molecule in an E configuration and the phenol H atom transferred to the guanidine N atom. Although the molecules of the title compounds form extended chains via hydrogen bonding in all three forms, owing to the presence of different solvent molecules, those chains are connected differently in the individual forms. In (II), the molecules are all coplanar, while in (I) and (III), adjacent molecules are tilted relative to one another to varying degrees. Also, because of the variation in hydrogen-bond-formation ability of the solvents, the hydrogen-bonding arrangements vary in the three forms.
C1 [Li, Tonglei; Long, Sihui] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
   [Gutierrez, Julio; Herrensmith, Gabrielle; Tobin, Thomas] Univ Kentucky, Maxwell H Gluck Equine Ctr, Lexington, KY 40546 USA.
   [Eisenberg, Rodney] Frontier Biopharm, Richmond, KY 40475 USA.
RP Long, SH (reprint author), Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
EM longsihui@yahoo.com
FU National Horsemen's Benevolent and Protective Association; Alabama;
   Arizona; Arkansas, Canada; Charles Town (West Virginia), Florida; Iowa,
   Indiana; Kentucky; Louisiana; Michigan; Minnesota; Nebraska; Ohio;
   Oklahoma; Ontario (Canada); Oregon; Pennsylvania; Tampa Bay Downs
   (Florida), Texas; Washington State and West Virginia Horsemen's
   Benevolent and Protective Associations; Florida Horsemen's Charitable
   Foundation; Oklahoma Quarter Horse Racing Association; Neogen
   Corporation
FX Published as paper No. 394 from the Equine Pharmacology, Therapeutics
   and Toxicology Program at the Maxwell H. Gluck Equine Research Center
   and Department of Veterinary Science, University of Kentucky. Published
   as Kentucky Agricultural Experiment Station Article No. 10-14-123 with
   the approval of the Dean and Director, College of Agriculture and the
   Kentucky Agricultural Experimental Station. This work was made possible
   by research support from the National Horsemen's Benevolent and
   Protective Association and the Alabama, Arizona, Arkansas, Canada,
   Charles Town (West Virginia), Florida, Iowa, Indiana, Kentucky,
   Louisiana, Michigan, Minnesota, Nebraska, Ohio, Oklahoma, Ontario
   (Canada), Oregon, Pennsylvania, Tampa Bay Downs (Florida), Texas,
   Washington State and West Virginia Horsemen's Benevolent and Protective
   Associations and the Florida Horsemen's Charitable Foundation, the
   Oklahoma Quarter Horse Racing Association and the Neogen Corporation.
   The authors also thank Charlie Hughes for his assistance during the
   synthesis and Dr Sean Parkin for helpful discussions.
CR Allen FH, 2002, ACTA CRYSTALLOGR B, V58, P380, DOI 10.1107/S0108768102003890
   ATFANI M, 1986, CR ACAD SCI II, V302, P171
   BATS JW, 2000, COMMUNICATION
   Bernstein J, 2005, CRYST GROWTH DES, V5, P1661, DOI 10.1021/cg0580071
   BERNSTEIN J, 1995, ANGEW CHEM INT EDIT, V34, P1555, DOI 10.1002/anie.199515551
   Brittain HG, 2010, J PHARM SCI-US, V99, P3648, DOI 10.1002/jps.21966
   Desiraju GR, 2004, CRYST GROWTH DES, V4, P1089, DOI 10.1021/cg030085q
   Dincer M, 2005, ACTA CRYSTALLOGR C, V61, pO722, DOI 10.1107/S0108270105037522
   FLUCK ER, 1983, DRUG DEVELOP RES, V3, P91, DOI 10.1002/ddr.430030111
   Gug F, 2010, BIOCONJUGATE CHEM, V21, P279, DOI 10.1021/bc900314n
   Kolos N.N., 1999, KHIM GETEROTSIKL+, P1388
   Li WT, 2010, J MED CHEM, V53, P2409, DOI 10.1021/jm901501s
   Nangia A, 2006, CRYST GROWTH DES, V6, P2, DOI 10.1021/cg050343e
   [Anonymous], 1998, COLLECT
   Onuska KD, 1996, J CHEM CRYSTALLOGR, V26, P841, DOI 10.1007/BF01670317
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Ring JR, 2007, ACTA CRYSTALLOGR C, V63, pO392, DOI 10.1107/S0108270107023475
   Seddon KR, 2004, CRYST GROWTH DES, V4, P1087, DOI 10.1021/cg030084y
   Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930
NR 19
TC 2
Z9 2
U1 0
U2 9
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0108-2701
J9 ACTA CRYSTALLOGR C
JI Acta Crystallogr. Sect. C-Cryst. Struct. Commun.
PD AUG
PY 2011
VL 67
BP O310
EP O314
DI 10.1107/S0108270111023845
PN 8
PG 5
WC Chemistry, Multidisciplinary; Crystallography
SC Chemistry; Crystallography
GA 802NS
UT WOS:000293518900012
PM 21817799
DA 2018-03-20
ER

PT J
AU Mai, T
   Hilt, JZ
AF Mai, Trang
   Hilt, J. Zach
TI Magnetic nanoparticles: reactive oxygen species generation and potential
   therapeutic applications
SO JOURNAL OF NANOPARTICLE RESEARCH
LA English
DT Review
DE Magnetic nanoparticles; Oxidative stress; Antioxidant; Reactive oxygen
   species; Biomedicine
ID IRON-OXIDE NANOPARTICLES; CANCER-CELLS; OXIDATIVE STRESS; INDUCED
   APOPTOSIS; ZINC-OXIDE; DRUG-DELIVERY; ROS; ANTIOXIDANT;
   FUNCTIONALIZATION; CYTOTOXICITY
AB Magnetic nanoparticles have been demonstrated to produce reactive oxygen species (ROS), which play a major role in various cellular pathways, via Fenton and Haber-Weiss reaction. ROS act as a double-edged sword inside the body. At normal conditions, the generation of ROS is in balance with their elimination by scavenger systems, and they can promote cell proliferation as well as differentiation. However, at an increased level, they can cause damages to protein, lead to cellular apoptosis, and contribute to many diseases including cancer. Many recent studies proposed a variety of strategies to either suppress toxicity of ROS generation or exploit the elevated ROS levels for cancer therapy.
C1 [Mai, Trang; Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Mai, Trang] Vietnam Acad Sci & Technol, Inst Mat Sci, Hanoi, Vietnam.
RP Hilt, JZ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM zach.hilt@uky.edu
CR Ahamed M, 2015, CHEMOSPHERE, V135, P278, DOI 10.1016/j.chemosphere.2015.03.079
   Ahamed M, 2013, J NANOPART RES, V15, DOI 10.1007/s11051-012-1225-6
   Ahamed M, 2011, TOXICOLOGY, V283, P101, DOI 10.1016/j.tox.2011.02.010
   Ahmad J, 2013, ENVIRON TOXICOL, V30, P137
   Akhtar MJ, 2012, INT J NANOMED, V7, P845, DOI 10.2147/IJN.S29129
   Alhadlaq HA, 2015, CELL BIOSCI, V5, DOI 10.1186/s13578-015-0046-6
   Aljarrah K, 2012, WORLD J SURG ONCOL, V10, DOI 10.1186/1477-7819-10-62
   Amstad E, 2011, NANOSCALE, V3, P2819, DOI 10.1039/c1nr10173k
   Chen TJ, 2006, TOXICOLOGY, V223, P113, DOI 10.1016/j.tox.2006.03.007
   Cochran DB, 2013, BIOMATERIALS, V34, P9615, DOI 10.1016/j.biomaterials.2013.08.025
   Frimpong RA, 2010, NANOMEDICINE-UK, V5, P1401, DOI 10.2217/NNM.10.114
   Fu PP, 2014, J FOOD DRUG ANAL, V22, P64, DOI 10.1016/j.jfda.2014.01.005
   Guo DD, 2013, TOXICOL IN VITRO, V27, P731, DOI 10.1016/j.tiv.2012.12.001
   Guo SH, 2005, FREE RADICAL BIO MED, V39, P682, DOI 10.1016/j.freeradbiomed.2005.04.022
   Gupta AK, 2005, BIOMATERIALS, V26, P3995, DOI 10.1016/j.biomaterials.2004.10.012
   Hauser AK, 2016, BIOMATERIALS, V105, P127, DOI 10.1016/j.biomaterials.2016.07.032
   Hauser AK, 2016, NANOMEDICINE-UK, V11, P1769, DOI 10.2217/nnm-2016-0050
   Hauser AK, 2016, ACTA BIOMATER, V33, P322, DOI 10.1016/j.actbio.2015.10.009
   He F, 2015, INT J MOL SCI, V16, P27770, DOI 10.3390/ijms161126059
   Hsieh HC, 2015, J NANOPART RES, V17, DOI 10.1007/s11051-015-2886-8
   Huang G, 2013, THERANOSTICS, V3, P116, DOI 10.7150/thno.5411
   Issa B, 2013, INT J MOL SCI, V14, P21266, DOI 10.3390/ijms141121266
   Karihtala P, 2007, APMIS, V115, P81, DOI 10.1111/j.1600-0463.2007.apm_514.x
   Klein S, 2012, BIOCHEM BIOPH RES CO, V425, P393, DOI 10.1016/j.bbrc.2012.07.108
   Kruse AM, 2014, ACTA BIOMATER, V10, P2622, DOI 10.1016/j.actbio.2014.01.025
   Laurent S, 2011, INT J MOL EPIDEMIOL, V2, P367
   Lee SS, 2013, ACS NANO, V7, P9693, DOI 10.1021/nn4026806
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Manke A, 2013, BIOMED RES INT, DOI 10.1155/2013/942916
   McCarthy JR, 2008, ADV DRUG DELIVER REV, V60, P1241, DOI 10.1016/j.addr.2008.03.014
   Mesarosova M, 2014, TOXICOL LETT, V226, P303, DOI 10.1016/j.toxlet.2014.02.025
   Namdeo M, 2008, J NANOSCI NANOTECHNO, V8, P3247, DOI 10.1166/jnn.2008.399
   Nel A, 2006, SCIENCE, V311, P622, DOI 10.1126/science.1114397
   Novo E, 2008, FIBROGENESIS TISSUE, V1, DOI 10.1186/1755-1536-1-5
   Pankhurst QA, 2009, J PHYS D APPL PHYS, V42, DOI 10.1088/0022-3727/42/22/224001
   Pankhurst QA, 2003, J PHYS D APPL PHYS, V36, pR167, DOI 10.1088/0022-3727/36/13/201
   Poljsak B, 2011, OXID MED CELL LONGEV, DOI 10.1155/2011/194586
   Poljsak B, 2013, OXID MED CELL LONGEV, V2013, P1
   Ramesh V, 2012, MOL CELL BIOCHEM, V363, P225, DOI 10.1007/s11010-011-1174-x
   Richard PU, 2015, EXP OPIN DRUG DELIV, V12
   Sadeghi L, 2015, EXP TOXICOL PATHOL, V67, P197, DOI 10.1016/j.etp.2014.11.010
   Sahu NK, 2015, DALTON T, V44, P9103, DOI 10.1039/c4dt03470h
   Shen YJ, 2015, NANOSCALE, V7, P2941, DOI 10.1039/c4nr06269h
   Siddiqui MA, 2012, FOOD CHEM TOXICOL, V50, P641, DOI 10.1016/j.fct.2012.01.017
   Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803
   Tsuda T, 2000, BIOFACTORS, V13, P133, DOI 10.1002/biof.5520130122
   Wahab R, 2013, J BIOMED NANOTECHNOL, V9, P441, DOI 10.1166/jbn.2013.1593
   Wang DS, 2004, NANO LETT, V4, P409, DOI 10.1021/nl035010n
   Wattamwar PP, 2010, ADV FUNCT MATER, V20, P147, DOI 10.1002/adfm.200900839
   WEISSLEDER R, 1990, RADIOLOGY, V175, P489, DOI 10.1148/radiology.175.2.2326474
   WEISSLEDER R, 1987, AM J ROENTGENOL, V149, P723, DOI 10.2214/ajr.149.4.723
   Wenzel U, 2004, CARCINOGENESIS, V25, P703, DOI 10.1093/carcin/bgh079
   Wu W, 2008, NANOSCALE RES LETT, V3, P397, DOI 10.1007/s11671-008-9174-9
   Wydra RJ, 2015, ACTA BIOMATER, V25, P284, DOI 10.1016/j.actbio.2015.06.037
   Wydra RJ, 2015, RSC ADV, V5, P18888, DOI 10.1039/c4ra13564d
   Xia T, 2008, ACS NANO, V2, P2121, DOI 10.1021/nn800511k
   Yang WJ, 2013, MATERIALS, V6, P4689, DOI 10.3390/ma6104689
   Yu M, 2012, INT J MOL SCI, V13, P5554, DOI 10.3390/ijms13055554
NR 58
TC 0
Z9 0
U1 19
U2 26
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1388-0764
EI 1572-896X
J9 J NANOPART RES
JI J. Nanopart. Res.
PD JUL 19
PY 2017
VL 19
IS 7
AR 253
DI 10.1007/s11051-017-3943-2
PG 10
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA FB5TE
UT WOS:000406204000002
DA 2018-03-20
ER

PT J
AU Gotmare, SW
   Leontsev, SO
   Eitel, RE
AF Gotmare, Sunil W.
   Leontsev, Serhiy O.
   Eitel, Richard E.
TI Thermal Degradation and Aging of High-Temperature Piezoelectric Ceramics
SO JOURNAL OF THE AMERICAN CERAMIC SOCIETY
LA English
DT Article
ID FERROELECTRIC CERAMICS; DOMAIN STABILIZATION; TITANATE;
   (1-X)BISCO3-XPBTIO(3); SENSOR
AB The perovskite solid solution (1-x)BiScO(3)-xPbTiO(3) (BSPT) represents a new family of piezoelectric ceramics that are promising for high-temperature actuator applications. In the current work, BSPT and PZT ceramics were synthesized by the conventional mixed oxide method. Thermal degradation and aging at 250 degrees C for 1000 h for undoped BSPT with morphotropic phase boundary (MPB) x=0.64 and tetragonal x=0.66 compositions are compared with pure PZT with the MPB composition. The BSPT system showed reduced aging rates of the piezoelectric coefficient (2.1% and 0.8%/decade for MPB and tetragonal compositions, respectively), compared with the unmodified PZT ceramics (4.2%/decade). The Rayleigh measurement approach was used to conclude that in both the BSPT and PZT, the dominant aging mechanism was the suppression of the domain wall contributions associated with charge defect accumulation at domain walls. The large thermal stability of the poled domain state and low domain wall contributions yielded the lowest observed aging rates in the tetragonal BSPT samples suggesting that this material would be a strong candidate for high-temperature actuator applications above 200 degrees C.
C1 [Gotmare, Sunil W.; Leontsev, Serhiy O.; Eitel, Richard E.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Eitel, RE (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM reitel@engr.uky.edu
RI Eitel, Richard/E-2889-2010
OI Eitel, Richard/0000-0002-5090-2075
CR Chen S, 2006, J AM CERAM SOC, V89, P3270, DOI 10.1111/j.1551-2916.2006.01201.x
   Damjanovic D, 1997, J APPL PHYS, V82, P1788, DOI 10.1063/1.365981
   Eitel R, 2007, PHYS REV B, V75, DOI 10.1103/PhysRevB.75.094106
   Eitel RE, 2006, J APPL PHYS, V99, DOI 10.1063/1.2207738
   Eitel RE, 2002, JPN J APPL PHYS 1, V41, P2099, DOI 10.1143/JJAP.41.2099
   Eitel RE, 2001, JPN J APPL PHYS 1, V40, P5999, DOI 10.1143/JJAP.40.5999
   Genenko YA, 2007, PHYS REV B, V75, DOI 10.1103/PhysRevB.75.184107
   HAGEMANN HJ, 1978, J PHYS C SOLID STATE, V11, P3333, DOI 10.1088/0022-3719/11/15/031
   IKEGAMI S, 1967, J PHYS SOC JPN, V22, P725, DOI 10.1143/JPSJ.22.725
   Jaffe B., 1971, PIEZOELECTRIC CERAMI
   JONKER GH, 1972, J AM CERAM SOC, V55, P57, DOI 10.1111/j.1151-2916.1972.tb13404.x
   LAMBECK PV, 1986, J PHYS CHEM SOLIDS, V47, P453, DOI 10.1016/0022-3697(86)90042-9
   Lupascu DC, 2006, J AM CERAM SOC, V89, P224, DOI 10.1111/j.1551-2916.2005.00663.x
   MASON WP, 1955, J ACOUST SOC AM, V27, P73, DOI 10.1121/1.1907500
   McQuarrie M.C., 1955, American Ceramic Society Bulletin, V34, P402
   Pramanick A, 2009, J AM CERAM SOC, V92, P2291, DOI 10.1111/j.1551-2916.2009.03218.x
   ROBELS U, 1993, J APPL PHYS, V73, P3454, DOI 10.1063/1.352948
   SCHULZE WA, 1988, FERROELECTRICS, V87, P361, DOI 10.1080/00150198808201399
   TAKAHASHI M, 1970, JPN J APPL PHYS, V9, P1236, DOI 10.1143/JJAP.9.1236
   Zhang LX, 2006, PHYS REV B, V73, DOI 10.1103/PhysRevB.73.094121
   Zhang SJ, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1968419
NR 21
TC 14
Z9 14
U1 2
U2 38
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0002-7820
J9 J AM CERAM SOC
JI J. Am. Ceram. Soc.
PD JUL
PY 2010
VL 93
IS 7
BP 1965
EP 1969
DI 10.1111/j.1551-2916.2010.03663.x
PG 5
WC Materials Science, Ceramics
SC Materials Science
GA 612PY
UT WOS:000278914500028
DA 2018-03-19
ER

PT J
AU Lenihan, JS
   Ball, JC
   Gavalas, VG
   Lumpp, JK
   Hines, J
   Daunert, S
   Bachas, LG
AF Lenihan, Jeffrey S.
   Ball, J. Christopher
   Gavalas, Vasilis G.
   Lumpp, Janet K.
   Hines, John
   Daunert, Sylvia
   Bachas, Leonidas G.
TI Microfabrication of screen-printed nanoliter vials with embedded
   surface-modified electrodes
SO ANALYTICAL AND BIOANALYTICAL CHEMISTRY
LA English
DT Article
DE microfabrication; nanoliter vials; ion-selective sensing
ID GLASSY-CARBON ELECTRODES; FIBER MICRODISK ELECTRODES; ION-SELECTIVE
   ELECTRODES; CHIP-BASED NANOVIALS; POLYPYRROLE FILM; LASER ACTIVATION;
   CAPILLARY-ELECTROPHORESIS; ELECTROANALYTICAL SENSOR; SAMPLE
   INTRODUCTION; RECESSED MICRODISK
AB A self-contained ion-selective sensing system within a nanoliter-volume vial has been developed by integrating screen printing, laser ablation, and molecular imprinting techniques. Screen printing and laser ablation are used in tandem to fabricate nanoliter-volume vials with carbon and Ag/AgCl ring electrodes embedded in the sidewalls. Using multisweep cyclic voltammetry, the surface of the carbon electrode can be modified with a polypyrrole film. By polymerizing pyrrole in the presence of nitrate, pores complementary to the nitrate anion in size, shape, and charge distribution are formed in the resulting film. Electrochemical cells modified with this nitrate-imprinted polypyrrole film show a near-Nernstian response to nitrate, and excellent reproducibility. The integration of molecular recognition and electrochemical response in the nanoliter vials is demonstrated by the detection of as little as 0.36 ng nitrate in nanoliter-volume samples. The integration of tailored molecular recognition within nanoliter vials via established fabrication and imprinting protocols should result in a number of nanosensor devices with applications in BioMEMS and micro total analysis systems.
C1 Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
   American Univ, Dept Chem, Washington, DC 20016 USA.
   Univ Kentucky, Dept Elect & Comp Engn, Lexington, KY 40506 USA.
   NASA, Ames Res Ctr, Moffett Field, CA 94035 USA.
RP Bachas, LG (reprint author), Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
EM bachas@uky.edu
RI Bachas, Leonidas/G-2479-2015
OI Bachas, Leonidas/0000-0002-3308-6264
CR Adeloju SB, 2001, BIOSENS BIOELECTRON, V16, P133, DOI 10.1016/S0956-5663(00)00117-2
   Aguilar ZP, 2002, ANAL CHEM, V74, P3321, DOI 10.1021/ac0110348
   Bakker E, 1997, CHEM REV, V97, P3083, DOI 10.1021/cr940394a
   Ball JC, 2000, ELECTROANAL, V12, P685, DOI 10.1002/1521-4109(200005)12:9<685::AID-ELAN685>3.0.CO;2-8
   Ball JC, 2000, ANAL CHEM, V72, P497, DOI 10.1021/ac991163c
   BOWLING RJ, 1989, J AM CHEM SOC, V111, P1217, DOI 10.1021/ja00186a008
   Bratten CDT, 1998, CHEM COMMUN, P471, DOI 10.1039/a708233i
   Bratten CDT, 1998, ANAL CHEM, V70, P1164, DOI 10.1021/ac970982z
   Bratten CDT, 1997, ANAL CHEM, V69, P253, DOI 10.1021/ac960743w
   BUCK RP, 1994, PURE APPL CHEM, V66, P2527, DOI 10.1351/pac199466122527
   Cai XX, 2000, ELECTROANAL, V12, P631, DOI 10.1002/1521-4109(200005)12:9<631::AID-ELAN631>3.0.CO;2-7
   CHEN PH, 1995, ANAL CHEM, V67, P3115, DOI 10.1021/ac00114a004
   Chen PH, 1996, ANAL CHEM, V68, P3958, DOI 10.1021/ac960492r
   Clark RA, 1997, ANAL CHEM, V69, P259, DOI 10.1021/ac960559a
   DONG SJ, 1988, ANALYST, V113, P1525, DOI 10.1039/an9881301525
   DONG SJ, 1991, TALANTA, V38, P111, DOI 10.1016/0039-9140(91)80017-T
   Emmer A, 2005, ANAL CHIM ACTA, V542, P137, DOI 10.1016/j.aca.2005.03.062
   Ersoz A, 2002, ANAL BIOANAL CHEM, V372, P786, DOI 10.1007/s00216-002-1262-6
   Ersoz A, 2002, ANAL CHEM, V74, P4050, DOI 10.1021/ac025570r
   Farrell PC, 2003, ELECTROANAL, V15, P813, DOI 10.1002/elan.200390100
   Feeney R, 2000, ELECTROANAL, V12, P677, DOI 10.1002/1521-4109(200005)12:9<677::AID-ELAN677>3.0.CO;2-4
   Grosvenor AL, 2000, ANAL CHEM, V72, P2590, DOI 10.1021/ac991289+
   Henry CS, 1999, J ELECTROCHEM SOC, V146, P3367, DOI 10.1149/1.1392479
   Henry CS, 1999, ANAL CHEM, V71, P550, DOI 10.1021/ac980375r
   Hernandez EC, 1995, MIKROCHIM ACTA, V121, P63, DOI 10.1007/BF01248241
   Herrasti P, 2004, ELECTROCHIM ACTA, V49, P3693, DOI 10.1016/j.electacta.2004.01.074
   HULANICKI A, 1994, TALANTA, V41, P323, DOI 10.1016/0039-9140(94)80129-0
   HULANICKI A, 1994, ELECTROANAL, V6, P604, DOI 10.1002/elan.1140060713
   HUTCHINS RS, 1995, ANAL CHEM, V67, P1654, DOI 10.1021/ac00106a002
   Jager EWH, 2002, BIOMED MICRODEVICES, V4, P177, DOI 10.1023/A:1016092228965
   JANSSON M, 1992, J CHROMATOGR, V626, P310, DOI 10.1016/0021-9673(92)85427-U
   Johannessen EA, 2002, ANAL CHEM, V74, P2190, DOI 10.1021/ac011028b
   Li CM, 2005, SURF COAT TECH, V198, P474, DOI 10.1016/j.surfcoat.2004.10.065
   Liang HJ, 2005, ANAL CHIM ACTA, V542, P83, DOI 10.1016/j.aca.2005.02.007
   Litborn E, 1999, ANAL CHIM ACTA, V401, P11, DOI 10.1016/S0003-2670(99)00486-9
   Masalles C, 2002, ANAL BIOANAL CHEM, V372, P513, DOI 10.1007/s00216-001-1221-7
   MCDERMOTT MT, 1993, ANAL CHEM, V65, P937, DOI 10.1021/ac00055a017
   MICHALSKA A, 1993, ELECTROANAL, V5, P261, DOI 10.1002/elan.1140050312
   Michalska A, 2003, MICROCHIM ACTA, V143, P163, DOI 10.1007/s00604-003-0060-y
   Moerman R, 2005, ANAL CHEM, V77, P225, DOI 10.1021/ac0400515
   POON M, 1988, ANAL CHEM, V60, P1725, DOI 10.1021/ac00168a018
   Sandison ME, 2002, ANAL CHEM, V74, P5717, DOI 10.1021/ac025649w
   Shi YJ, 1997, BIOSENS BIOELECTRON, V12, P655, DOI 10.1016/S0956-5663(97)00020-1
   Shiigi H, 2005, J ELECTROCHEM SOC, V152, pH129, DOI 10.1149/1.1946367
   STERNITZKE KD, 1990, ANAL CHEM, V62, P1339, DOI 10.1021/ac00212a025
   Strein TG, 1999, ELECTROANAL, V11, P37, DOI 10.1002/(SICI)1521-4109(199901)11:1<37::AID-ELAN37>3.0.CO;2-4
   STREIN TG, 1991, ANAL CHEM, V63, P194, DOI 10.1021/ac00003a001
   Uang YM, 2003, BIOSENS BIOELECTRON, V19, P141, DOI 10.1016/S0956-5663(03)00168-4
   Vandaveer WR, 2003, ELECTROCHIM ACTA, V48, P3341, DOI 10.1016/S0013-4686(03)00403-1
   Yang HH, 2005, J AM CHEM SOC, V127, P1378, DOI 10.1021/ja0467622
   Yasukawa T, 2002, ANAL CHEM, V74, P5001, DOI 10.1021/ac025836u
   YONHIN BFY, 1993, ANAL CHEM, V65, P2067, DOI 10.1021/ac00063a022
   Young IT, 2003, J MICROSC-OXFORD, V212, P254, DOI 10.1111/j.1365-2818.2003.01252.x
NR 53
TC 11
Z9 11
U1 1
U2 10
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1618-2642
J9 ANAL BIOANAL CHEM
JI Anal. Bioanal. Chem.
PD JAN
PY 2007
VL 387
IS 1
BP 259
EP 265
DI 10.1007/s00216-006-0893-4
PG 7
WC Biochemical Research Methods; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA 118UN
UT WOS:000242968000040
PM 17115139
DA 2018-03-20
ER

PT J
AU Shin, HC
   Alani, AWG
   Cho, H
   Bae, Y
   Kolesar, JM
   Kwon, GS
AF Shin, Ho-Chul
   Alani, Adam W. G.
   Cho, Hyunah
   Bae, Younsoo
   Kolesar, Jill M.
   Kwon, Glen S.
TI A 3-in-1 Polymeric Micelle Nanocontainer for Poorly Water-Soluble Drugs
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE drug combination; heat shock protein 90; mammalian target of rapamycin;
   multiple drug solubilization; polymeric micelles; tanespimycin
ID BREAST-CANCER CELLS; PACLITAXEL-MEDIATED CYTOTOXICITY; IN-VIVO ANALYSIS;
   PHASE-II TRIAL; CREMOPHOR-FREE; LUNG-CANCER; 17-ALLYLAMINO GELDANAMYCIN;
   GENEXOL-PM; FORMULATION; 17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN
AB Poly(ethylene glycol)-block-poly(D,L-lactic acid) (PEG-b-PLA) micelles have a proven capacity for drug solubilization and have entered phase III clinical trials as a substitute for Cremophor EL in the delivery of paclitaxel in cancer therapy. PEG-b-PLA is less toxic than Cremophor EL, enabling a doubling of paclitaxel dose in clinical trials. We show that PEG-b-PLA micelles act as a 3-in-1 nanocontainer for paclitaxel, 17-allylamino-17-demethoxygeldanamycin (17-AAG), and rapamycin for multiple drug solubilization. 3-in-1 PEG-b-PLA micelles were ca. 40 nm in diameter; dissolved paclitaxel, 17-AAG, and rapamycin in water at 9.0 mg/mL; and were stable for 24 h at 25 degrees C. The half-life for in vitro drug release (t(1/2)) for 3-in-1 PEG-b-PLA micelles was 1-15 h under sink conditions and increased in the order of 17-AAG, paclitaxel, and rapamycin. The t(1/2) values correlated with log P-o/w, values, implicating a diffusion-controlled mechanism for drug release. The IC50 value of 3-in-1 PEG-b-PLA micelles for MCF-7 and 4T1 breast cancer cell lines was 114 +/- 10 and 25 +/- 1 nM, respectively; combination index (CI) analysis showed that 3-in-1 PEG-b-PLA micelles exert strong synergy in MCF-7 and 4T1 breast cancer cell lines. Notably, concurrent intravenous (iv) injection of paclitaxel, 17-AAG, and rapamycin using 3-in-1 PEG-b-PLA micelles was well-tolerated by FVB albino mice. Collectively, these results suggest that PEG-b-PLA micelles carrying paclitaxel, 17-AAG, and rapamycin will provide a simple yet safe and efficacious 3-in-1 nanomedicine for cancer therapy.
C1 [Shin, Ho-Chul; Cho, Hyunah; Kwon, Glen S.] Univ Wisconsin, Sch Pharm, Div Pharmaceut Sci, Madison, WI 53705 USA.
   [Alani, Adam W. G.] Oregon State Univ, Div Pharmaceut Sci, Coll Pharm, Corvallis, OR 97331 USA.
   [Bae, Younsoo] Univ Kentucky, Div Pharmaceut Sci, Coll Pharm, Lexington, KY 40536 USA.
   [Kolesar, Jill M.] Univ Wisconsin, Sch Pharm, Pharm Practice Div, Madison, WI 53792 USA.
RP Kwon, GS (reprint author), Univ Wisconsin, Sch Pharm, Div Pharmaceut Sci, 777 Highland Ave, Madison, WI 53705 USA.
EM gskwon@pharmacy.wisc.edu
RI Alani, Adam/E-2327-2013; Kwon, Glen/A-1919-2014
OI Shin, Ho-chul/0000-0001-5500-3901
FU NIAID NIH HHS [R01 AI043346]
CR Aliabadi Hamidreza Montazeri, 2006, Expert Opin Drug Deliv, V3, P139
   Bagatell R, 2007, CLIN CANCER RES, V13, P1783, DOI 10.1158/1078-0432.CCR-06-1892
   Bagnyukova T, 2010, CANCER BIOL THER, V10, P843, DOI 10.4161/cbt.10.9.13738
   Banerji U, 2005, CLIN CANCER RES, V11, P7023, DOI 10.1158/1078-0432.CCR-05-0518
   Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10
   Dancey JE, 2006, CANCER BIOL THER, V5, P1065, DOI 10.4161/cbt.5.9.3175
   FREIREICH EMIL J., 1966, CANCER CHEMOTHERAP REP, V50, P219
   Hennenfent KL, 2006, ANN ONCOL, V17, P735, DOI 10.1093/annonc/mdj100
   Kim DW, 2007, ANN ONCOL, V18, P2009, DOI 10.1093/annonc/mdm374
   Kim SC, 2001, J CONTROL RELEASE, V72, P191, DOI 10.1016/S0168-3659(01)00275-9
   Kwon GS, 2008, PHARM RES-DORD, V25, P2053, DOI 10.1007/s11095-008-9644-x
   Lee KS, 2008, BREAST CANCER RES TR, V108, P241, DOI 10.1007/s10549-007-9591-y
   Liggins RT, 1997, J PHARM SCI, V86, P1458, DOI 10.1021/js9605226
   LoPiccolo J, 2008, DRUG RESIST UPDATE, V11, P32, DOI 10.1016/j.drup.2007.11.003
   Marupudi NI, 2007, EXPERT OPIN DRUG SAF, V6, P609, DOI 10.1517/14740338.6.5.609
   Merlin JL, 2002, ANN ONCOL, V13, P1743, DOI 10.1093/annonc/mdf263
   Mondesire WH, 2004, CLIN CANCER RES, V10, P7031, DOI 10.1158/1078-0432.CCR-04-0361
   Munster PN, 2001, CLIN CANCER RES, V7, P2228
   Munster P. N., 2001, CLIN CANCER RES, V7, P2155
   Nguyen DM, 2001, ANN THORAC SURG, V72, P371, DOI 10.1016/S0003-4975(01)02787-4
   Pass HI, 2001, ANN THORAC SURG, V72, P378
   Raymond E, 2004, J CLIN ONCOL, V22, P2336, DOI 10.1200/JCO.2004.08.116
   Robinson BW, 2004, SEMIN ONCOL, V31, P2, DOI 10.1053/j.seminoncol.2004.03.021
   Roforth MM, 2008, ANTI-CANCER DRUG, V19, P681, DOI 10.1097/CAD.0b013e3283067681
   Sain N, 2006, MOL CANCER THER, V5, P1197, DOI 10.1158/1535-7163.MCT-05-0445
   Shin HC, 2009, J CONTROL RELEASE, V140, P294, DOI 10.1016/j.jconrel.2009.04.024
   Simamora P, 2001, INT J PHARM, V213, P25, DOI 10.1016/S0378-5173(00)00617-7
   Solit DB, 2008, DRUG DISCOV TODAY, V13, P38, DOI 10.1016/j.drudis.2007.10.007
   Solit DB, 2007, CLIN CANCER RES, V13, P1775, DOI 10.1158/1078-0432.CCR-06-1863
   Solit DB, 2003, CANCER RES, V63, P2139
   Sydor JR, 2006, P NATL ACAD SCI USA, V103, P17408, DOI 10.1073/pnas.0608372103
   ten Tije AJ, 2003, CLIN PHARMACOKINET, V42, P665, DOI 10.2165/00003088-200342070-00005
   Wang XR, 2009, EXPERT OPIN THER TAR, V13, P1193, DOI 10.1517/14728220903225008
   Xiong MP, 2009, J PHARM SCI-US, V98, P1577, DOI 10.1002/jps.21509
NR 34
TC 68
Z9 70
U1 3
U2 36
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD JUL-AUG
PY 2011
VL 8
IS 4
SI SI
BP 1257
EP 1265
DI 10.1021/mp2000549
PG 9
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 799SW
UT WOS:000293307400027
PM 21630670
OA green_accepted
DA 2018-03-19
ER

PT J
AU Ramineni, SK
   Cunningham, LL
   Dziubla, TD
   Puleo, DA
AF Ramineni, Sandeep K.
   Cunningham, Larry L., Jr.
   Dziubla, Thomas D.
   Puleo, David A.
TI Development of imiquimod-loaded mucoadhesive films for oral dysplasia
SO JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE oral cancer; mucosal drug delivery; biomaterials; polyvinylpyrrolidone;
   carboxymethylcellulose; 2-hydroxypropyl-ss-cyclodextrin; controlled
   release; delivery; polymeric drug carrier; solubility
ID HYDROXYPROPYL-BETA-CYCLODEXTRIN; BASAL-CELL CARCINOMA; IN-VIVO
   EVALUATION; 5-PERCENT CREAM; PHYSICOCHEMICAL CHARACTERIZATION; TOPICAL
   IMIQUIMOD; FORMULATION; DELIVERY; PATCHES; CANCER
AB Oral squamous dysplasia, which can usually be readily visualized as leukoplakia during an oral examination and confirmed by histology, is often considered a premalignant condition. Current treatments, however, focus on the final stages of disease, and treatments such as surgery can lead to postoperative disabilities. Hence, this study was designed to develop a noninvasive, mucoadhesive drug delivery system loaded with an immune response modifier, imiquimod, as a treatment for precancerous dysplastic lesions. Blends of polyvinylpyrrolidone and carboxymethylcellulose were used to prepare mucoadhesive films that were backed with poly(ethylene-co-vinyl acetate). Because of the hydrophobic nature of imiquimod, four loading methods (sonication, linoleic acid, 2-hydroxypropyl-beta-cyclodextrin, and acetate buffer) were compared. The formation of imiquimodcyclodextrin complexes and their solubility was studied by differential scanning calorimetry and phase solubility studies. All films achieved sustained release of drug for 3 h except those prepared by linoleic acid. The high solubility of imiquimod in acetate buffer facilitated high loading capacity and greater release (68%) of drug than did the other formulations (approximately 40%). In summary, a noninvasive and local approach with the potential to treat precancerous lesions may be achieved by this described mucoadhesive drug delivery system. (C) 2012 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 102:593603, 2013
C1 [Ramineni, Sandeep K.; Puleo, David A.] Univ Kentucky, Ctr Biomed Engn, Lexington, KY 40506 USA.
   [Cunningham, Larry L., Jr.] Univ Kentucky, Coll Dent, Lexington, KY 40536 USA.
   [Dziubla, Thomas D.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Puleo, DA (reprint author), Univ Kentucky, Ctr Biomed Engn, Lexington, KY 40506 USA.
EM puleo@uky.edu
FU National Institutes of Health [DE019645]; Kentucky NASA EPSCoR
   [NNX08BA13A]
FX This work was supported in part by the National Institutes of Health
   (DE019645) and Kentucky NASA EPSCoR (NNX08BA13A). The authors thank Dr.
   Heidi Mansour (University of Kentucky College of Pharmacy) for
   assistance with DSC measurements and gratefully recognize the
   contributions of Mr. J.D. Christensen and Ms. Laynie Boland toward early
   development of the films.
CR Ahuja A, 1997, DRUG DEV IND PHARM, V23, P489, DOI 10.3109/03639049709148498
   Allam JP, 2008, BRIT J DERMATOL, V158, P644, DOI 10.1111/j.1365-2133.2007.08374.x
   American Cancer Society, 2012, CANC FACTS FIG
   Averineni RK, 2009, PHARM DEV TECHNOL, V14, P199, DOI 10.1080/10837450802498928
   Baboota S, 2005, AAPS PHARMSCITECH, V6
   Beraldo H, 2002, BIOCHEM BIOPH RES CO, V296, P241, DOI 10.1016/S0006-291X(02)00865-3
   Chakrabarty AK, 2005, J AM ACAD DERMATOL, V52, pS35, DOI 10.1016/j.jaad.2004.06.045
   Choi JW, 2009, ANN DERMATOL, V21, P419, DOI 10.5021/ad.2009.21.4.419
   Chollet JL, 1999, PHARM DEV TECHNOL, V4, P35, DOI 10.1081/PDT-100101337
   Chowdary KPR, 2000, DRUG DEV IND PHARM, V26, P1217, DOI 10.1081/DDC-100100995
   Desai KGH, 2011, PHARM RES-DORDR, V28, P2599, DOI 10.1007/s11095-011-0489-3
   Doiphode D, 2008, J INCL PHENOM MACRO, V62, P43, DOI 10.1007/s10847-008-9435-3
   Donnelly RF, 2006, INT J PHARM, V307, P318, DOI 10.1016/j.ijpharm.2005.10.023
   Food Drug Administration, 2012, GUID IND Q3CTABLES L
   GALEY WR, 1976, J INVEST DERMATOL, V67, P713, DOI 10.1111/1523-1747.ep12598596
   Ganjian Shahrouz, 2009, Dermatol Online J, V15, P4
   GATES KA, 1994, PHARMACEUT RES, V11, P1605, DOI 10.1023/A:1018913921956
   Geisse J, 2004, J AM ACAD DERMATOL, V50, P722, DOI 10.1016/j.jaad.2003.11.066
   Higuchi T, 1965, ADV ANAL CHEM INSTRU, V4, P117
   Jones D, 2009, P I CIVIL ENG-GEOTEC, V162, P1, DOI [10.1680/geng.2009.162.1.1, 10.1109/RE-VOTE.2009.3]
   Liu J, 2006, INT J PHARM, V312, P137, DOI 10.1016/j.ijpharm.2006.01.011
   Luo K, 2008, MACROMOL BIOSCI, V8, P184, DOI 10.1002/mabi.200700185
   Jr Mayeaux EJ, 2009, FEMALE PATIENT S1, V34, pS1
   Mohamed MAH, 2011, CURR EYE RES, V36, P208, DOI 10.3109/02713683.2010.536294
   Monnaert V, 2004, J PHARMACOL EXP THER, V310, P745, DOI 10.1124/jpet.104.067512
   Muzio G, 2004, ACTA DERM-VENEREOL, V84, P168, DOI 10.1080/00015550310006789
   Neville BW, 2002, CA-CANCER J CLIN, V52, P195, DOI 10.3322/canjclin.52.4.195
   O'Neill VJ, 2002, BRIT J CANCER, V87, P933, DOI 10.1038/sj.bjc.6600591
   Patwardhan AM, 2010, J CLIN INVEST, V120, P1617, DOI 10.1172/JCI41678
   Perioli L, 2004, J CONTROL RELEASE, V99, P73, DOI 10.1016/j.jconrel.2004.06.005
   Shah D, 2010, INT J PHARM SCI REV, V2
   Shidhaye SS, 2008, AAPS PHARMSCITECH, V9, P909, DOI 10.1208/s12249-008-9125-x
   Spieth K, 2006, LANCET ONCOL, V7, P1036, DOI 10.1016/S1470-2045(06)70979-2
   Stella VJ, 1997, PHARMACEUT RES, V14, P556, DOI 10.1023/A:1012136608249
   Sterry W, 2002, BRIT J DERMATOL, V147, P1227, DOI 10.1046/j.1365-2133.2002.05069.x
   Szejtli J, 1998, CHEM REV, V98, P1743, DOI 10.1021/cr970022c
   Uekama K, 1998, CHEM REV, V98, P2045, DOI 10.1021/cr970025p
   van Seters M, 2008, NEW ENGL J MED, V358, P1465, DOI 10.1056/NEJMoa072685
   Wong CF, 1999, INT J PHARM, V180, P47, DOI 10.1016/S0378-5173(98)00402-5
NR 39
TC 13
Z9 13
U1 0
U2 20
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3549
EI 1520-6017
J9 J PHARM SCI-US
JI J. Pharm. Sci.
PD FEB
PY 2013
VL 102
IS 2
BP 593
EP 603
DI 10.1002/jps.23386
PG 11
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology &
   Pharmacy
SC Pharmacology & Pharmacy; Chemistry
GA 074CO
UT WOS:000313790100031
PM 23192692
OA green_accepted
DA 2018-03-20
ER

PT J
AU Authimoolam, SP
   Lakes, AL
   Puleo, DA
   Dziubla, TD
AF Authimoolam, Sundar P.
   Lakes, Andrew L.
   Puleo, David A.
   Dziubla, Thomas D.
TI Layer-by-Layers of Polymeric Micelles as a Biomimetic Drug-Releasing
   Network
SO MACROMOLECULAR BIOSCIENCE
LA English
DT Article
DE biomimetic; biotin-streptavidin; filomicelles; mucin; oral drug delivery
ID BLOCK-COPOLYMER MICELLES; CROSS-LINKED MICELLES; CERVICAL-MUCUS; GASTRIC
   MUCIN; ORAL-CAVITY; DELIVERY; AGGREGATION; MULTILAYERS; MICROSCOPY;
   SURFACES
AB Mucin networks are lubricous biofunctional coats formed through the continuous deposition of mucin glycoproteins. Previously, we demonstrated the synthesis of a mucin mimic using biotinylated-filomicelles crosslinked via streptavidin using a layer-by-layer approach. These networks recreate the fibrous nature of mucin and can serve as a drug-releasing network. In this work, the ability to vary the network properties by blending filomicelles with spherical micelles is demonstrated. In addition, the deposition of a dense polymer coating on the mucin network was shown to act as a barrier to control diffusion and improved the structural stability under simulated oral chemical conditions. These biomimetic coatings can be utilized as a delivery system, providing a tunable drug release for oral applications.
C1 [Authimoolam, Sundar P.; Lakes, Andrew L.; Dziubla, Thomas D.] Univ Kentucky, Dept Chem & Mat Engn, Coll Engn, 177 F Paul Anderson Tower, Lexington, KY 40506 USA.
   [Puleo, David A.] Univ Kentucky, Dept Biomed Engn, Coll Engn, 522 Robot Bldg, Lexington, KY 40506 USA.
RP Dziubla, TD (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Coll Engn, 177 F Paul Anderson Tower, Lexington, KY 40506 USA.
EM dziubla@engr.uky.edu
FU National Institutes of Health [R03 DE019496]
FX This work was funded by National Institutes of Health (Grant R03
   DE019496). Authors acknowledge Nihar Shah (Bluegrass Advanced Materials,
   LLC, Lexington, KY) for his insightful discussions.
CR Aas JA, 2005, J CLIN MICROBIOL, V43, P5721, DOI 10.1128/JCM.43.11.5721-5732.2005
   Authimoolam SP, 2014, BIOMACROMOLECULES, V15, P3099, DOI 10.1021/bm5006917
   Authimoolam SP, 2013, ADV HEALTHC MATER, V2, P983, DOI 10.1002/adhm.201200375
   Bansil R, 2006, CURR OPIN COLLOID IN, V11, P164, DOI 10.1016/j.cocis.2005.11.001
   Bollen CML, 1997, DENT MATER, V13, P258, DOI 10.1016/S0109-5641(97)80038-3
   Booth L, 2011, MATERIALS, V4, P857, DOI 10.3390/ma4050857
   BRADWAY SD, 1989, BIOCHEM J, V261, P887, DOI 10.1042/bj2610887
   Brunelli R, 2007, FASEB J, V21, P3872, DOI 10.1096/fj.07-8189com
   Cai SS, 2007, PHARM RES, V24, P2099, DOI 10.1007/s11095-007-9335-z
   Cao XX, 1999, BIOPHYS J, V76, P1250, DOI 10.1016/S0006-3495(99)77288-7
   Emoto K, 1999, LANGMUIR, V15, P5212, DOI 10.1021/la980918s
   Hong ZN, 2005, BIOMACROMOLECULES, V6, P3458, DOI 10.1021/bm0505843
   Jeon J, 2006, LANGMUIR, V22, P4629, DOI 10.1021/la053444n
   Kim BS, 2008, ACS NANO, V2, P386, DOI 10.1021/nn700408z
   Kim Y, 2005, NANOTECHNOLOGY, V16, pS484, DOI 10.1088/0957-4484/16/7/024
   Li JJ, 2015, RSC ADV, V5, P19484, DOI 10.1039/c4ra14376k
   Menarguez M, 2003, HUM REPROD, V18, P1782, DOI 10.1093/humrep/deg382
   Merritt J.H., 2005, CURR PROTOC MICROB B, V1B, P1, DOI DOI 10.1002/9780471729259.MC01B01S00
   Moore W E, 1994, Periodontol 2000, V5, P66, DOI 10.1111/j.1600-0757.1994.tb00019.x
   O'Reilly RK, 2006, CHEM SOC REV, V35, P1068, DOI 10.1039/b514858h
   Ostrander JW, 2001, J AM CHEM SOC, V123, P1101, DOI 10.1021/ja0029578
   Paster BJ, 2001, J BACTERIOL, V183, P3770, DOI 10.1128/JB.183.12.3770-3783.2001
   PRAKOBPHOL A, 1982, CARBOHYD RES, V108, P111, DOI 10.1016/S0008-6215(00)81896-0
   Read ES, 2007, CHEM COMMUN, P3021, DOI 10.1039/b701217a
   ROGERS DF, 1994, EUR RESPIR J, V7, P1690
   Simone EA, 2007, BIOMACROMOLECULES, V8, P3914, DOI 10.1021/bm700888h
   TABAK LA, 1982, J ORAL PATHOL MED, V11, P1, DOI 10.1111/j.1600-0714.1982.tb00138.x
   Wong CF, 1999, INT J PHARM, V180, P47, DOI 10.1016/S0378-5173(98)00402-5
   Wood KC, 2006, P NATL ACAD SCI USA, V103, P10207, DOI 10.1073/pnas.0602884103
   Zhu ZC, 2013, J CONTROL RELEASE, V171, P73, DOI 10.1016/j.jconrel.2013.06.031
NR 30
TC 0
Z9 0
U1 3
U2 18
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1616-5187
EI 1616-5195
J9 MACROMOL BIOSCI
JI Macromol. Biosci.
PD FEB
PY 2016
VL 16
IS 2
BP 242
EP 254
DI 10.1002/mabi.201500310
PG 13
WC Biochemistry & Molecular Biology; Materials Science, Biomaterials;
   Polymer Science
SC Biochemistry & Molecular Biology; Materials Science; Polymer Science
GA DD7DD
UT WOS:000370083000009
PM 26418812
OA green_accepted
DA 2018-03-20
ER

PT J
AU Hauser, AK
   Wydra, RJ
   Bhandari, R
   Rychahou, PG
   Evers, BM
   Anderson, KW
   Dziubla, TD
   Hilt, JZ
AF Hauser, Anastasia K.
   Wydra, Robert J.
   Bhandari, Rohit
   Rychahou, Piotr G.
   Evers, B. Mark
   Anderson, Kimberly W.
   Dziubla, Thomas D.
   Hilt, J. Zach
TI The role of ROS generation from magnetic nanoparticles in an alternating
   magnetic field on cytotoxicity (vol 25m pg 284, 2015)
SO ACTA BIOMATERIALIA
LA English
DT Correction
C1 [Hauser, Anastasia K.; Wydra, Robert J.; Bhandari, Rohit; Anderson, Kimberly W.; Dziubla, Thomas D.; Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, 177 F Paul Anderson Tower, Lexington, KY 40506 USA.
   [Rychahou, Piotr G.; Evers, B. Mark] Univ Kentucky, Dept Surg, Coll Med, Lexington, KY 40506 USA.
   [Evers, B. Mark] Univ Kentucky, Markey Canc Ctr, Lexington, KY 40506 USA.
RP Hilt, JZ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 F Paul Anderson Tower, Lexington, KY 40506 USA.
EM hilt@engr.uky.edu
CR Hauser AK, 2015, ACTA BIOMATER, V25, P284, DOI DOI 10.1016/J.ACTBIO.2015.06.037
   Karmakar A, 2011, J MATER CHEM, V21, P12761, DOI 10.1039/c1jm10569h
NR 2
TC 1
Z9 1
U1 1
U2 9
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742-7061
EI 1878-7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD MAR 15
PY 2016
VL 33
BP 322
EP 323
DI 10.1016/j.actbio.2015.10.009
PG 2
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA DH3LO
UT WOS:000372688700032
DA 2018-03-19
ER

PT J
AU Akenhead, ML
   Shin, HY
AF Akenhead, Michael L.
   Shin, Hainsworth Y.
TI The Contribution of Cell Surface Components to the Neutrophil
   Mechanosensitivity to Shear Stresses
SO AIMS BIOPHYSICS
LA English
DT Review
DE mechanotransduction; mechanobiology; circulation; fluid flow; leukocyte
AB This review discusses the regulation of neutrophils by fluid shear stress in the context of factors that may govern cell mechanosensitivity and its influence on cell functions. There is substantial evidence that mechanoreceptors located on the peripheral membrane contribute to the ability of shear stress to regulate cell activity. In the case of neutrophils, the formyl peptide receptor (FPR) and the CD18 integrins on the cell membrane have been shown to provide neutrophils with the ability to sense shear stresses in their local environment and alter their physiological state, accordingly. This configuration is also found for other types of cells, although they involve different cell-specific mechanoreceptors. Moreover, from an examination of the neutrophil mechanotransducing capacity, it is apparent that cellular mechanosensitivity depends on a number of factors that, if altered, contribute to dysregulation and ultimately pathophysiology. To exemplify this, we first describe the neutrophil responses to shear exposure. We then review two neutrophil mechanoreceptors, specifically FPR and CD18 integrins, which participate in controlling cell activity levels under physiological conditions. Next, we discuss the various factors that may alter neutrophil mechanosensitivity to shear stress and how these may underlie the circulatory pathobiology of two cardiovascular disease states: hypertension and hypercholesterolemia. Based on the material presented, it is conceivable that cell mechanosensitivity is a powerful global metric that permits a more efficient approach to understanding the contribution of mechanobiology to physiology and to disease processes.
C1 [Akenhead, Michael L.; Shin, Hainsworth Y.] Univ Kentucky, Dept Biomed Engn, 143 Graham Ave, Lexington, KY 40506 USA.
RP Shin, HY (reprint author), Univ Kentucky, Dept Biomed Engn, 143 Graham Ave, Lexington, KY 40506 USA.
EM hy.shin@uky.edu
CR Aggarwal BB, 2006, BIOCHEM PHARMACOL, V72, P1605, DOI 10.1016/j.bcp.2006.06.029
   Akenhead ML, 2014, BIOMECH MODEL MECHAN, V13, P861, DOI 10.1007/s10237-013-0541-9
   Akter K, 2011, BRIT J CLIN PHARMACO, V71, P365, DOI 10.1111/j.1365-2125.2010.03830.x
   BENBASSAT H, 1977, CANCER RES, V37, P1307
   Berk BC, 2001, ANN NY ACAD SCI, V947, P93
   BERLIN RD, 1977, P NATL ACAD SCI USA, V74, P1072, DOI 10.1073/pnas.74.3.1072
   Bodin S, 2005, MOL BIOL CELL, V16, P5773, DOI 10.1091/mbc.E05-04-0358
   Butler PJ, 2001, FASEB J, V15, P216, DOI 10.1096/fj.01-0434fje
   Butler PJ, 2001, AM J PHYSIOL-CELL PH, V280, pC962
   Cattaruzza M, 2000, FASEB J, V14, P991
   CHABANEL A, 1983, BIOPHYS J, V44, P171, DOI 10.1016/S0006-3495(83)84288-X
   Chachisvilis M, 2006, P NATL ACAD SCI USA, V103, P15463, DOI 10.1073/pnas.0607224103
   Chen AY, 2010, AM J PHYSIOL-CELL PH, V299, pC1441, DOI 10.1152/ajpcell.00157.2010
   Chen KD, 1999, J BIOL CHEM, V274, P18393, DOI 10.1074/jbc.274.26.18393
   Conway DE, 2013, CURR BIOL, V23, P1024, DOI 10.1016/j.cub.2013.04.049
   COOPER RA, 1978, J SUPRAMOL STR CELL, V8, P413, DOI 10.1002/jss.400080404
   Coughlin MF, 2004, BIOPHYS J, V87, P2035, DOI 10.1529/biophysj.104.042192
   DEWITZ TS, 1979, BLOOD CELLS, V5, P499
   Diacovo TG, 1996, BLOOD, V88, P146
   Ferraro JT, 2004, AM J PHYSIOL-CELL PH, V286, pC831, DOI 10.1152/ajpcell.00224.2003
   Friedland JC, 2009, SCIENCE, V323, P642, DOI 10.1126/science.1168441
   Fukuda S, 2004, CIRC RES, V95, P100, DOI 10.1161/01.RES.0000133677.77465.38
   Fukuda S, 2003, P NATL ACAD SCI USA, V100, P13152, DOI 10.1073/pnas.2336130100
   Fukuda S, 2000, CIRC RES, V86, pE13
   GERISCH G, 1981, J CELL SCI, V52, P1
   Goldmann WH, 2012, CELL BIOL INT, V36, P649, DOI 10.1042/CBI20120184
   Gu CX, 2001, BIOPHYS J, V80, P2678, DOI 10.1016/S0006-3495(01)76237-6
   Gudi S, 1998, P NATL ACAD SCI USA, V95, P2515, DOI 10.1073/pnas.95.5.2515
   Gudi SRP, 1996, CIRC RES, V79, P834
   Haidekker MA, 2000, AM J PHYSIOL-HEART C, V278, pH1401
   HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335
   HARRIS AG, 1993, AM J PHYSIOL, V264, pH909
   Haugh MG, 2015, J MECH BEHAV BIOMED, V42, P67, DOI 10.1016/j.jmbbm.2014.11.001
   Helmke BP, 1998, BIORHEOLOGY, V35, P437, DOI 10.1016/S0006-355X(99)80021-3
   Hentzen ER, 2000, BLOOD, V95, P911
   Hsieh HJ, 2014, J BIOMED SCI, V21, DOI 10.1186/1423-0127-21-3
   Iwasaki H, 2000, AM J PHYSIOL-HEART C, V278, pH521
   Jannat RA, 2010, J PHYS-CONDENS MAT, V22, DOI 10.1088/0953-8984/22/19/194117
   Jin ZG, 2003, CIRC RES, V93, P354, DOI 10.1161/01.RES.0000089257.94002.96
   Kamm Roger D, 2004, Mech Chem Biosyst, V1, P201
   Khatibzadeh N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057147
   KIM YM, 1994, ARCH BIOCHEM BIOPHYS, V309, P308, DOI 10.1006/abbi.1994.1118
   Komai Y, 2005, ANN BIOMED ENG, V33, P1375, DOI 10.1007/s10439-005-6768-6
   Koutsiaris AG, 2007, BIORHEOLOGY, V44, P375
   Lee D, 2007, J BIOL CHEM, V282, P4812, DOI 10.1074/jbc.M609994200
   Lee HJ, 2003, BIOCHEM BIOPH RES CO, V304, P399, DOI 10.1016/S0006-291X(03)00592-8
   Lee SE, 2007, J BIOMECH, V40, P2096, DOI 10.1016/j.jbiomech.2007.04.006
   LENAZ G, 1987, BIOSCIENCE REP, V7, P823, DOI 10.1007/BF01119473
   Lipowsky HH, 2005, MICROCIRCULATION, V12, P5, DOI 10.1080/10739680590894966
   Luo BH, 2009, J BIOL CHEM, V284, P3917, DOI 10.1074/jbc.M806312200
   Maingret F, 1999, J BIOL CHEM, V274, P26691, DOI 10.1074/jbc.274.38.26691
   Makino A, 2006, AM J PHYSIOL-CELL PH, V290, pC1633, DOI 10.1152/ajpcell.00576.2005
   Makino A, 2005, AM J PHYSIOL-CELL PH, V288, pC863, DOI 10.1152/ajpcell.00358.2004
   Makino A, 2007, BIORHEOLOGY, V44, P221
   Marki A., 2015, J LEUKOC BIOL
   Marschel P, 2002, ANN BIOMED ENG, V30, P333, DOI 10.1114/1.1475342
   Marwali MR, 2003, BLOOD, V102, P215, DOI 10.1182/blood-2002-10-3195
   MAZZONE A, 1995, HAEMATOLOGICA, V80, P161
   Mazzoni MC, 1996, CARDIOVASC RES, V32, P709, DOI 10.1016/0008-6363(96)00146-0
   McCleverty CJ, 2003, BIOCHEM J, V372, P121, DOI 10.1042/BJ20021273
   Migeotte I, 2006, CYTOKINE GROWTH F R, V17, P501, DOI 10.1016/j.cytogfr.2006.09.009
   Miles K, 2009, J IMMUNOL, V183, P2122, DOI 10.4049/jimmunol.0804187
   Milkiewicz M, 2007, J PHYSIOL-LONDON, V583, P753, DOI 10.1113/jphysiol.2007.136325
   Mitchell MJ, 2012, BIOPHYS J, V102, P1804, DOI 10.1016/j.bpj.2012.03.053
   Moazzam F, 1997, P NATL ACAD SCI USA, V94, P5338, DOI 10.1073/pnas.94.10.5338
   Niggli V, 2004, EXP CELL RES, V296, P358, DOI 10.1016/j.yexcr.2004.02.015
   NORIS M, 1995, CIRC RES, V76, P536
   Palumbo R, 2000, CIRCULATION, V102, P225
   Papaioannou Theodoros G, 2005, Hellenic J Cardiol, V46, P9
   Park H, 1998, J BIOL CHEM, V273, P32304, DOI 10.1074/jbc.273.48.32304
   Paszkowiak Jacek J, 2003, Vasc Endovascular Surg, V37, P47, DOI 10.1177/153857440303700107
   Pierini LM, 2003, J BIOL CHEM, V278, P10831, DOI 10.1074/jbc.M212386200
   Pohlman TH, 2000, J SURG RES, V89, P85, DOI 10.1006/jsre.1999.5801
   Puklin-Faucher E, 2006, J CELL BIOL, V175, P349, DOI 10.1083/jcb.200602071
   Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5
   Rizzo V, 1998, J BIOL CHEM, V273, P26323, DOI 10.1074/jbc.273.41.26323
   Rizzo V, 1998, J BIOL CHEM, V273, P34724, DOI 10.1074/jbc.273.52.34724
   Root R K, 1990, Trans Am Clin Climatol Assoc, V101, P207
   Schmid-Schonbein GW, 2006, ANNU REV BIOMED ENG, V8, P93, DOI 10.1146/annurev.bioeng.8.061505.095708
   Seely AJE, 2003, CRIT CARE, V7, P291, DOI 10.1186/cc1853
   Segel GB, 2011, J LEUKOCYTE BIOL, V89, P359, DOI 10.1189/jlb.0910538
   Shay-Salit A, 2002, P NATL ACAD SCI USA, V99, P9462, DOI 10.1073/pnas.142224299
   Sheikh S, 2003, BLOOD, V102, P2828, DOI 10.1182/blood-2003-01-0080
   SHEN K, 1995, CIRC RES, V76, P276
   Shin HY, 2008, J CELL PHYSIOL, V214, P528, DOI 10.1002/jcp.21235
   Shin HY, 2011, MECHANOBIOLOGY HANDBOOK, P139
   Shive MS, 2002, J BIOMED MATER RES, V62, P163, DOI 10.1002/jbm.10225
   Shive MS, 2000, P NATL ACAD SCI USA, V97, P6710, DOI 10.1073/pnas.110463197
   Shyy JY, 2002, CIRC RES, V91, P769, DOI 10.1161/01.RES.0000038487.19924.18
   Solomkin JS, 2007, SHOCK, V28, P334, DOI 10.1097/shk.0b013e318047b893
   Stepp DW, 1999, CIRCULATION, V100, P1555
   Su SS, 2008, ANN BIOMED ENG, V36, P298, DOI 10.1007/s10439-007-9406-7
   Su SS, 2010, CELL MOL BIOENG, V3, P20, DOI 10.1007/s12195-010-0111-5
   Sugihara-Seki M, 2003, J BIOMECH ENG-T ASME, V125, P628, DOI 10.1115/1.1611515
   Tarbell JM, 2005, ANN BIOMED ENG, V33, P1719, DOI 10.1007/s10439-005-8775-z
   Tarbell JM, 2006, J INTERN MED, V259, P339, DOI 10.1111/j.1365-2796.2006.01620.x
   Tatsukawa Y, 2008, HYPERTENS RES, V31, P1391, DOI 10.1291/hypres.31.1391
   Tedgui A, 2001, CIRC RES, V88, P877, DOI 10.1161/hh0901.090440
   Teravainen TP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071485
   TOMONAGA A, 1983, MICROBIOL IMMUNOL, V27, P961, DOI 10.1111/j.1348-0421.1983.tb00662.x
   Tuluc F, 2003, INT IMMUNOPHARMACOL, V3, P1775, DOI 10.1016/j.intimp.2003.08.002
   Tzima E, 2005, NATURE, V437, P426, DOI 10.1038/nature03952
   Watabe H, 2011, EXP CELL RES, V317, P2642, DOI 10.1016/j.yexcr.2011.07.015
   Watanabe J, 2010, AM J PHYSIOL-GASTR L, V298, pG842, DOI 10.1152/ajpgi.00468.2009
   Welch MD, 1997, CURR OPIN CELL BIOL, V9, P54, DOI 10.1016/S0955-0674(97)80152-4
   White CR, 2007, PHILOS T R SOC B, V362, P1459, DOI 10.1098/rstb.2007.2128
   WILES ME, 1994, J LEUKOCYTE BIOL, V56, P192
   Yasuda N, 2008, EMBO REP, V9, P179, DOI 10.1038/sj.embor.7401157
   YEAGLE PL, 1991, BIOCHIMIE, V73, P1303, DOI 10.1016/0300-9084(91)90093-G
   YULI I, 1982, P NATL ACAD SCI-BIOL, V79, P5906, DOI 10.1073/pnas.79.19.5906
   Zhang XY, 2014, ARTERIOSCL THROM VAS, V34, P587, DOI 10.1161/ATVBAHA.113.302868
   Zhang XY, 2013, J LEUKOCYTE BIOL, V93, P251, DOI 10.1189/jlb.0612302
   Zhang XY, 2011, AM J PHYSIOL-CELL PH, V301, pC451, DOI 10.1152/ajpcell.00458.2010
   Zhang YL, 2009, AM J PHYSIOL-CELL PH, V296, pC1391, DOI 10.1152/ajpcell.00549.2008
   Zhelev DV, 2004, BIOPHYS J, V87, P688, DOI 10.1529/biophysj.103.036699
   Zou YZ, 2004, NAT CELL BIOL, V6, P499, DOI 10.1038/ncb1137
NR 116
TC 0
Z9 0
U1 0
U2 0
PU AMER INST MATHEMATICAL SCIENCES-AIMS
PI SPRINGFIELD
PA PO BOX 2604, SPRINGFIELD, MO 65801-2604 USA
SN 2377-9098
J9 AIMS BIOPHYS
JI AIMS Biophys.
PY 2015
VL 2
IS 3
SI SI
BP 318
EP 335
DI 10.3934/biophy.2015.3.318
PG 18
WC Biophysics
SC Biophysics
GA V23PC
UT WOS:000215100300006
OA gold
DA 2018-03-19
ER

PT J
AU Fisher, PD
   Palomino, P
   Milbrandt, TA
   Hilt, JZ
   Puleo, DA
AF Fisher, Paul D.
   Palomino, Pablo
   Milbrandt, Todd A.
   Hilt, J. Zach
   Puleo, David A.
TI Improved small molecule drug release from in situ forming
   poly(lactic-co-glycolic acid) scaffolds incorporating poly(beta-amino
   ester) and hydroxyapatite microparticles
SO JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION
LA English
DT Article
DE In situ precipitation; injectable; PLGA; poly(-amino ester);
   simvastatin; clodronate
ID PHASE INVERSION DYNAMICS; DELIVERY SYSTEMS; INJECTABLE IMPLANT;
   BONE-RESORPTION; BIOCOMPATIBILITY; DIFFERENTIATION; OSTEOCLAST;
   PACLITAXEL; PROTEINS; STATINS
AB In situ forming implants are an attractive choice for controlled drug release into a fixed location. Currently, rapidly solidifying solvent exchange systems suffer from a high initial burst, and sustained release behavior is tied to polymer precipitation and degradation rate. The present studies investigated addition of hydroxyapatite (HA) and drug-loaded poly(-amino ester) (PBAE) microparticles to in situ forming poly(lactic-co-glycolic acid) (PLGA)-based systems to prolong release and reduce burst. PBAEs were synthesized, imbibed with simvastatin (osteogenic) or clodronate (anti-resorptive), and then ground into microparticles. Microparticles were mixed with or without HA into a PLGA solution, and the mixture was injected into buffer, leading to precipitation and creating solid scaffolds with embedded HA and PBAE microparticles. Simvastatin release was prolonged through 30days, and burst release was reduced from 81 to 39% when loaded into PBAE microparticles. Clodronate burst was reduced from 49 to 32% after addition of HA filler, but release kinetics were unaffected after loading into PBAE microparticles. Scaffold dry mass remained unchanged through day 15, with a pronounced increase in degradation rate after day 30, while wet scaffolds experienced a mass increase through day 25 due to swelling. Porosity and pore size changed throughout degradation, likely due to a combination of swelling and degradation. The system offers improved release kinetics, multiple release profiles, and rapid solidification compared to traditional in situ forming implants.
C1 [Fisher, Paul D.; Puleo, David A.] Univ Kentucky, Dept Biomed Engn, Lexington, KY 40506 USA.
   [Palomino, Pablo] Univ Florida, Dept Mat Sci & Engn, Gainesville, FL 32611 USA.
   [Milbrandt, Todd A.] Univ Kentucky, Dept Orthopaed Surg, Lexington, KY 40536 USA.
   [Milbrandt, Todd A.] Shriners Hosp Children, Dept Orthopaed Surg, Lexington, KY 40502 USA.
   [Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Puleo, DA (reprint author), Univ Kentucky, Dept Biomed Engn, Lexington, KY 40506 USA.
EM puleo@uky.edu
FU National Institutes of Health [AR060964]; National Science Foundation
   [EPS-0814194]; NSF IGERT [DGE-0653710]
FX This research was supported in part by the National Institutes of Health
   [AR060964] and National Science Foundation [EPS-0814194], and PDF
   received an NSF IGERT traineeship [DGE-0653710].
CR Allen TM, 2004, SCIENCE, V303, P1818, DOI 10.1126/science.1095833
   Anderson DG, 2006, ADV MATER, V18, P2614, DOI 10.1002/adma.200600529
   Anderson JM, 1997, ADV DRUG DELIVER REV, V28, P5, DOI 10.1016/S0169-409X(97)00048-3
   Bakhshi R, 2006, POLYM ADVAN TECHNOL, V17, P354, DOI 10.1002/pat.717
   Biondi M, 2008, ADV DRUG DELIVER REV, V60, P229, DOI 10.1016/j.addr.2007.08.038
   Brodbeck KJ, 1999, J CONTROL RELEASE, V62, P333, DOI 10.1016/S0168-3659(99)00159-5
   Burkersroda FV, 2002, BIOMATERIALS, V23, P4221, DOI DOI 10.1016/S0142-9612(02)00170-9
   Eliaz RE, 2000, PHARMACEUT RES, V17, P1546, DOI 10.1023/A:1007621512647
   Fredenberg S, 2011, INT J PHARMACEUT, V415, P34, DOI 10.1016/j.ijpharm.2011.05.049
   Frith JC, 2001, ARTHRITIS RHEUM, V44, P2201, DOI 10.1002/1529-0131(200109)44:9<2201::AID-ART374>3.0.CO;2-E
   Garg T, 2012, CRIT REV THER DRUG, V29, P1
   Ghayor C, 2011, J BIOL CHEM, V286, P24458, DOI 10.1074/jbc.M111.223297
   Graham PD, 1999, J CONTROL RELEASE, V58, P233, DOI 10.1016/S0168-3659(98)00158-8
   Hatefi A, 2002, J CONTROL RELEASE, V80, P9, DOI 10.1016/S0168-3659(02)00008-1
   Jeon O, 2011, J BIOMED MATER RES A, V98A, P72, DOI 10.1002/jbm.a.33098
   KENLEY RA, 1987, MACROMOLECULES, V20, P2398, DOI 10.1021/ma00176a012
   KIM SW, 1992, PHARMACEUT RES, V9, P283, DOI 10.1023/A:1015887213431
   Ko J, 2007, J CONTROL RELEASE, V123, P109, DOI 10.1016/j.jconrel.2007.07.012
   Kranz H, 2008, EUR J PHARM SCI, V34, P164, DOI 10.1016/j.ejps.2008.03.004
   LAMBERT WJ, 1995, J CONTROL RELEASE, V33, P189, DOI 10.1016/0168-3659(94)00083-7
   Liu H, 2012, J BIOMAT SCI-POLYM E, V23, P251, DOI 10.1163/092050610X549171
   Maeda T, 2004, J CELL BIOCHEM, V92, P458, DOI 10.1002/jcb.20072
   Meenach SA, 2012, INT J PHARMACEUT, V427, P177, DOI 10.1016/j.ijpharm.2012.01.052
   Miguel BS, 2009, TISSUE ENG PT A, V15, P2955, DOI [10.1089/ten.tea.2009.0009, 10.1089/ten.TEA.2009.0009]
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   OSTOVIC D, 1993, PHARMACEUT RES, V10, P470, DOI 10.1023/A:1018969112754
   Packhaeuser CB, 2004, EUR J PHARM BIOPHARM, V58, P445, DOI 10.1016/uj.ejpb.2004.03.003
   Parent M, 2013, J CONTROL RELEASE, V172, P292, DOI 10.1016/j.jconrel.2013.08.024
   Potineni A, 2003, J CONTROL RELEASE, V86, P223, DOI 10.1016/S0168-3659(02)00374-7
   Royals MA, 1999, J BIOMED MATER RES, V45, P231, DOI 10.1002/(SICI)1097-4636(19990605)45:3<231::AID-JBM11>3.0.CO;2-H
   SHAH NH, 1993, J CONTROL RELEASE, V27, P139, DOI 10.1016/0168-3659(93)90217-S
   SHIVELY ML, 1995, J CONTROL RELEASE, V33, P237, DOI 10.1016/0168-3659(94)00097-E
   Siepmann J, 2001, ADV DRUG DELIVER REV, V48, P139, DOI 10.1016/S0169-409X(01)00112-0
   Sokolsky-Papkov M, 2007, ADV DRUG DELIVER REV, V59, P187, DOI 10.1016/j.addr.2007.04.001
   Tang Y, 2008, INT J PHARMACEUT, V357, P119, DOI 10.1016/j.ijpharm.2008.01.053
   Uhrich KE, 1999, CHEM REV, V99, P3181, DOI 10.1021/cr940351u
   Veber DF, 2002, J MED CHEM, V45, P2615, DOI 10.1021/jm020017n
   Yewey G L, 1997, Pharm Biotechnol, V10, P93
   Zhang LF, 2007, CHEMMEDCHEM, V2, P1268, DOI 10.1002/cmdc.200700121
   Zhou TH, 1998, J CONTROL RELEASE, V55, P281, DOI 10.1016/S0168-3659(98)00061-3
NR 41
TC 6
Z9 6
U1 1
U2 30
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0920-5063
EI 1568-5624
J9 J BIOMAT SCI-POLYM E
JI J. Biomater. Sci.-Polym. Ed.
PD AUG
PY 2014
VL 25
IS 11
BP 1174
EP 1193
DI 10.1080/09205063.2014.923368
PG 20
WC Engineering, Biomedical; Materials Science, Biomaterials; Polymer
   Science
SC Engineering; Materials Science; Polymer Science
GA AL8QP
UT WOS:000339404300006
PM 24903524
OA green_accepted
DA 2018-03-20
ER

PT J
AU Holmes, SM
   Li, DF
   Parkin, S
   Clerac, R
   Wernsdorfer, W
   Wang, GB
   Yee, GT
   Tyagi, P
   Hinds, BJ
AF Holmes, Stephen M.
   Li, Dongfeng
   Parkin, Sean
   Clerac, Rodolphe
   Wernsdorfer, Wolfgang
   Wang, Guangbin
   Yee, Gordon T.
   Tyagi, Pawan
   Hinds, Bruce J.
TI Cyano-bridged octanuclear clusters that exhibit slow relaxation of the
   magnetization: Useful reagents for constructing molecule-based devices
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
CT 231st National Meeting of the American-Chemical-Society
CY MAR 26-30, 2006
CL Atlanta, GA
SP Amer Chem Soc
C1 Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
   CNRS, Ctr Rech Paul Pascal, F-33600 Pessac, France.
   Virginia Polytech Inst & State Univ, Dept Chem, Blacksburg, VA 24061 USA.
   CNRS, Lab Louis Neel, F-75700 Paris, France.
   Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM smholm2@uky.edu
RI LI, Dongfeng/F-9558-2015; Parkin, Sean/E-7044-2011; Clerac,
   Rodolphe/C-2800-2008
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD MAR 26
PY 2006
VL 231
MA 350-INOR
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA 050YE
UT WOS:000238125905347
DA 2018-03-20
ER

PT J
AU Wu, J
   Gerstandt, K
   Zhang, HB
   Liu, J
   Hinds, BJ
AF Wu, Ji
   Gerstandt, Karen
   Zhang, Hongbo
   Liu, Jie
   Hinds, Bruce J.
TI Electrophoretically induced aqueous flow through single-walled carbon
   nanotube membranes
SO NATURE NANOTECHNOLOGY
LA English
DT Article
ID CAPILLARY-ELECTROPHORESIS; ELECTROOSMOTIC FLOW; MASS-TRANSPORT;
   IONIC-DIFFUSION; DNA; FABRICATION; PORES; CHIPS; GAS
AB Electrophoresis, the motion of charged species through liquids and pores under the influence of an external electric field, has been the principle source of chemical pumping for numerous micro- and nanofluidic device platforms. Recent measurements of ion currents through single or few carbon nanotube channels have yielded values of ion mobility that range from close to the bulk mobility to values that are two to seven orders of magnitude higher than the bulk mobility. However, these experiments cannot directly measure ion flux. Experiments on membranes that contain a large number of nanotube pores allow the ion current and ion flux to be measured independently. Here, we report that the mobilities of ions within such membranes are approximately three times higher than the bulk mobility. Moreover, the induced electro-osmotic velocities are four orders of magnitude faster than those measured in conventional porous materials. We also show that a nanotube membrane can function as a rectifying diode due to ionic steric effects within the nanotubes.
C1 [Wu, Ji; Gerstandt, Karen; Hinds, Bruce J.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Zhang, Hongbo; Liu, Jie] Duke Univ, Dept Chem, Durham, NC 27708 USA.
RP Wu, J (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM bjhinds@engr.uky.edu
RI Liu, Jie/B-4440-2010; WU, JI/F-6379-2013; WU, JI/J-4580-2016; WU,
   JI/F-6371-2013
OI Liu, Jie/0000-0003-0451-6111; 
FU NIDA [5R01DA018822-05]; DARPA [W911NF-09-1-0267]; Unidym Inc.; Center
   for the Environmental Implications of NanoTechnology; NSF; EPA under an
   NSF [EF-0830093]
FX The authors thank J. Goldsmith, Xin Su and Xin Zhan for constructive
   discussions. This work was supported by NIDA (5R01DA018822-05) and DARPA
   (W911NF-09-1-0267). Critical infrastructure was provided by the
   University of Kentucky Center for Nanoscale Science and Engineering.
   J.L. and H.Z. acknowledge support from Unidym Inc. and the Center for
   the Environmental Implications of NanoTechnology (which is funded by the
   NSF and the EPA under an NSF cooperative agreement (EF-0830093)).
CR Bings NH, 2010, ANAL CHEM, V82, P4653, DOI 10.1021/ac1010469
   Choi W, 2011, J AM CHEM SOC, V133, P203, DOI 10.1021/ja108011g
   Daiguji H, 2005, NANO LETT, V5, P2274, DOI 10.1021/nl051646y
   DAUGHERTY NA, 1979, J CHEM EDUC, V56, P442, DOI 10.1021/ed056p442
   Dechadilok P, 2006, IND ENG CHEM RES, V45, P6953, DOI 10.1021/ie051387n
   Ferslew KE, 1998, ELECTROPHORESIS, V19, P6, DOI 10.1002/elps.1150190104
   Fornasiero F, 2008, P NATL ACAD SCI USA, V105, P17250, DOI 10.1073/pnas.0710437105
   Gupta A, 2007, APPL PHYS LETT, V91, DOI 10.1063/1.2775836
   Hinds BJ, 2004, SCIENCE, V303, P62, DOI 10.1126/science.1092048
   Holt JK, 2006, SCIENCE, V312, P1034, DOI 10.1126/science.1126298
   Kalman EB, 2008, ADV MATER, V20, P293, DOI 10.1002/adma.200701867
   Kim S, 2007, NANO LETT, V7, P2806, DOI 10.1021/nl071414u
   Kishi T, 1998, ELECTROPHORESIS, V19, P3, DOI 10.1002/elps.1150190103
   Komaromy-Hiller G., 1999, ANAL CHEM, V71, P338
   Kraly J, 2006, ANAL CHEM, V78, P4097, DOI 10.1021/ac060704c
   Lee CY, 2010, SCIENCE, V329, P1320, DOI 10.1126/science.1193383
   Liu HT, 2010, SCIENCE, V327, P64, DOI 10.1126/science.1181799
   Majumder M, 2005, NATURE, V438, P44, DOI 10.1038/43844a
   Majumder M, 2008, J MEMBRANE SCI, V316, P89, DOI 10.1016/j.memsci.2007.09.068
   Majumder M, 2007, LANGMUIR, V23, P8624, DOI 10.1021/la700686k
   Majumder M, 2011, ACS NANO, V5, P3867, DOI 10.1021/nn200222g
   Majumder M, 2010, LIFE SCI, V86, P563, DOI 10.1016/j.lfs.2009.04.006
   Miller SA, 2001, J AM CHEM SOC, V123, P12335, DOI 10.1021/ja011926p
   Mrestani Y, 1997, J CHROMATOGR B, V690, P321, DOI 10.1016/S0378-4347(96)00425-2
   Nagata H, 2005, ELECTROPHORESIS, V26, P2247, DOI 10.1002/elps.200410395
   Qi H, 2007, NANO LETT, V7, P2417, DOI 10.1021/nl071089a
   Qi H, 2006, CHEM MATER, V18, P5691, DOI 10.1021/cm061528r
   Qian C, 2006, J NANOSCI NANOTECHNO, V6, P1346, DOI 10.1166/jnn.2006.140
   Sanip SM, 2011, SEP PURIF TECHNOL, V78, P208, DOI 10.1016/j.seppur.2011.02.003
   Sarazin C, 2011, ELECTROPHORESIS, V32, P1282, DOI 10.1002/elps.201000626
   Scruggs NR, 2009, NANO LETT, V9, P3853, DOI 10.1021/nl9020683
   Sinville R, 2007, J SEP SCI, V30, P1714, DOI 10.1002/jssc.200700150
   Sun L, 2000, J AM CHEM SOC, V122, P12340, DOI 10.1021/ja002429w
   Sun XH, 2011, LANGMUIR, V27, P3150, DOI 10.1021/la104242p
   Tu CH, 2010, LANGMUIR, V26, P17656, DOI 10.1021/la102363y
   WOOLLEY AT, 1995, ANAL CHEM, V67, P3676, DOI 10.1021/ac00116a010
   Wu J, 2011, NANOSCALE, V3, P3321, DOI 10.1039/c1nr10303b
   Wu J, 2010, P NATL ACAD SCI USA, V107, P11698, DOI 10.1073/pnas.1004714107
NR 38
TC 65
Z9 65
U1 6
U2 108
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1748-3387
J9 NAT NANOTECHNOL
JI Nat. Nanotechnol.
PD FEB
PY 2012
VL 7
IS 2
BP 133
EP 139
DI 10.1038/NNANO.2011.240
PG 7
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA 894AJ
UT WOS:000300398900016
PM 22245860
OA green_accepted
DA 2018-03-20
ER

PT J
AU Clark, A
   Hilt, JZ
   Milbrandt, TA
   Puleo, DA
AF Clark, Amanda
   Hilt, J. Zach
   Milbrandt, Todd A.
   Puleo, David A.
TI Treating Proximal Tibial Growth Plate Injuries Using
   Poly(Lactic-co-Glycolic Acid) Scaffolds
SO BIORESEARCH OPEN ACCESS
LA English
DT Article
DE growth plate; insulin-like growth factor I; physeal injury;
   poly(lactic-co-glycolic acid); scaffold
ID BONE BRIDGE FORMATION; FACTOR-I; PHYSEAL INJURIES; STEM-CELLS;
   CARTILAGE; ARREST; MODEL; RABBITS; REGENERATION; CHONDROCYTES
AB Growth plate fractures account for nearly 18.5% of fractures in children. Depending on the type and severity of the injury, inhibited bone growth or angular deformity caused by bone forming in place of the growth plate can occur. The current treatment involves removal of the bony bar and replacing it with a filler substance, such as a free fat graft. Unfortunately, reformation of the bony bar frequently occurs, preventing the native growth plate from regenerating. The goal of this pilot study was to determine whether biodegradable scaffolds can enhance native growth plate regeneration following a simulated injury that resulted in bony bar formation in the proximal tibial growth plate of New Zealand white rabbits. After removing the bony bar, animals received one of the following treatments: porous poly(lactic-co-glycolic acid) (PLGA) scaffold; PLGA scaffold loaded with insulin-like growth factor I (IGF-I); PLGA scaffold loaded with IGF-I and seeded with autogenous bone marrow cells (BMCs) harvested at the time of implantation; or fat graft (as used clinically). The PLGA scaffold group showed an increased chondrocyte population and a reduced loss of the remaining native growth plate compared to the fat graft group (the control group). An additional increase in chondrocyte density was seen in scaffolds loaded with IGF-I, and even more so when BMCs were seeded on the scaffold. While there was no significant reduction in the angular deformation of the limbs, the PLGA scaffolds increased the amount of cartilage and reduced the amount of bony bar reformation.
C1 [Clark, Amanda; Puleo, David A.] Univ Kentucky, Dept Biomed Engn, Lexington, KY 40506 USA.
   [Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Milbrandt, Todd A.] Mayo Clin, Dept Orthoped Surg, Rochester, MN USA.
RP Puleo, DA (reprint author), Univ Kentucky, Dept Biomed Engn, 522A Robot & Mfg Bldg, Lexington, KY 40506 USA.
EM milbrandt.todd@mayo.edu; puleo@uky.edu
CR Anderson JM, 1997, ADV DRUG DELIVER REV, V28, P5, DOI 10.1016/S0169-409X(97)00048-3
   Asawa Y, 2012, CELL TRANSPLANT, V21, P1431, DOI 10.3727/096368912X640574
   Awad HA, 2004, BIOMATERIALS, V25, P3211, DOI 10.1016/j.biomaterials.2003.10.045
   Ballock RT, 2003, J BONE JOINT SURG AM, V85A, P715, DOI 10.2106/00004623-200304000-00021
   Basener CJ, 2009, J ORTHOP TRAUMA, V23, P663, DOI 10.1097/BOT.0b013e3181a4f25b
   Burdan F, 2009, FOLIA HISTOCHEM CYTO, V47, P5, DOI 10.2478/v10042-009-0007-1
   Chen F, 2003, J PEDIATR ORTHOPED, V23, P425, DOI 10.1097/00004694-200307000-00002
   Clark A, 2014, BIOMED MATER, V9, DOI 10.1088/1748-6041/9/2/025015
   Clark A, 2014, J BIOMED MATER RES A, V102, P348, DOI 10.1002/jbm.a.34706
   Damien E, 2003, J BIOMED MATER RES A, V66A, P241, DOI 10.1002/jbm.a.10564
   Fortier LA, 2011, CLIN ORTHOP RELAT R, V469, P2706, DOI 10.1007/s11999-011-1857-3
   Foster BK, 2000, J PEDIATR ORTHOPED, V20, P282, DOI 10.1097/00004694-200005000-00002
   Fu K, 2000, PHARMACEUT RES, V17, P100, DOI 10.1023/A:1007582911958
   Griffon DJ, 2006, ACTA BIOMATER, V2, P313, DOI 10.1016/j.actbio.2005.12.007
   Hasler CC, 2002, CLIN ORTHOP RELAT R, P242, DOI 10.1097/01.blo.0000037440.23683.a7
   Hernandez CJ, 2004, BONE, V35, P1095, DOI 10.1016/j.bone.2004.07.002
   HOCK JM, 1988, ENDOCRINOLOGY, V122, P254, DOI 10.1210/endo-122-1-254
   IANNOTTI JP, 1990, ORTHOP CLIN N AM, V21, P1
   JARAMILLO D, 1990, RADIOLOGY, V175, P767, DOI 10.1148/radiology.175.3.2343128
   JOHNSTONE EW, 2002, CLIN ORTHOP RELA FEB, P234
   Khoshhal KI, 2005, J AM ACAD ORTHOP SUR, V13, P47, DOI 10.5435/00124635-200501000-00007
   KITCHELL JP, 1985, METHOD ENZYMOL, V112, P436
   LANGENSKIOLD A, 1987, J PEDIATR ORTHOPED, V7, P389, DOI 10.1097/01241398-198707000-00002
   LANGENSKIOLD A, 1981, J PEDIATR ORTHOPED, V1, P3, DOI 10.1097/01241398-198101010-00002
   Lee CR, 2001, BIOMATERIALS, V22, P3145, DOI 10.1016/S0142-9612(01)00067-9
   Lee EH, 1998, J PEDIATR ORTHOPED, V18, P155, DOI 10.1097/00004694-199803000-00005
   LENNOX DW, 1983, J PEDIATR ORTHOPED, V3, P207, DOI 10.1097/01241398-198305000-00010
   Li L, 2004, J PEDIATR ORTHOPED, V24, P205, DOI 10.1097/01241398-200403000-00014
   Masters KS, 2005, BIOMATERIALS, V26, P2517, DOI 10.1016/j.biomaterials.2004.07.018
   MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P301, DOI 10.1210/endo-124-1-301
   MIZUTA T, 1987, J PEDIATR ORTHOPED, V7, P518, DOI 10.1097/01241398-198709000-00003
   Morisset S, 2007, CLIN ORTHOP RELAT R, P221, DOI 10.1097/BLO.0b013e3180dca05f
   Nazarov R, 2004, BIOMACROMOLECULES, V5, P718, DOI 10.1021/bm034327e
   Planka L, 2008, BMC BIOTECHNOL, V8, DOI 10.1186/1472-6750-8-70
   Ravi N., 2009, THESIS U KENTUCKY
   Shefelbine SJ, 2005, J BIOMECH, V38, P2440, DOI 10.1016/j.jbiomech.2004.10.019
   Sundararaj SK, 2012, J TISSUE ENG REGEN M
   Temenoff JS, 2000, BIOMATERIALS, V21, P431, DOI 10.1016/S0142-9612(99)00213-6
   Tobita M, 2002, ACTA ORTHOP SCAND, V73, P352, DOI 10.1080/000164702320155383
   Wattenbarger JM, 2002, J PEDIATR ORTHOPED, V22, P703, DOI 10.1097/00004694-200211000-00002
   Xian CJ, 2004, J ORTHOPAED RES, V22, P417, DOI 10.1016/j.orthres.2003.08.003
   Yun ZY, 2007, LAIT, V87, P139, DOI 10.1051/lait:2007005
   Zhang Y, 2001, J BIOMED MATER RES, V55, P304, DOI 10.1002/1097-4636(20010605)55:3<304::AID-JBM1018>3.0.CO;2-J
NR 43
TC 3
Z9 3
U1 0
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2164-7844
EI 2164-7860
J9 BIORESEARCH OPEN ACC
JI BioResearch Open Access
PD JUL
PY 2015
VL 4
IS 1
BP 65
EP 74
DI 10.1089/biores.2014.0034
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA CL9QD
UT WOS:000357312300006
PM 26309783
OA gold
DA 2018-03-19
ER

PT J
AU Satarkar, NS
   Johnson, D
   Marrs, B
   Andrews, R
   Poh, C
   Gharaibeh, B
   Saito, K
   Anderson, KW
   Hilt, JZ
AF Satarkar, Nitin S.
   Johnson, Don
   Marrs, Brock
   Andrews, Rodney
   Poh, Churn
   Gharaibeh, Belal
   Saito, Kozo
   Anderson, Kimberly W.
   Hilt, J. Zach
TI Hydrogel-MWCNT Nanocomposites: Synthesis, Characterization, and Heating
   with Radiofrequency Fields
SO JOURNAL OF APPLIED POLYMER SCIENCE
LA English
DT Article
DE hydrogels; nanocomposites; carbon nanotubes; radiofrequency; temperature
   responsive
ID WALLED CARBON NANOTUBES; INFRARED THERMOGRAPHY; PHASE-TRANSITION;
   TEMPERATURE; COMPOSITE; CELLS; GELS
AB Hydrogel nanocomposites are attractive biomaterials for numerous applications including tissue engineering, drug delivery, cancer treatment, sensors, and actuators. Here we present a nanocomposite of multiwalled carbon nanotubes (MWCNT) and temperature responsive N-isopropylacrylamide hydrogels. The lower critical solution temperature (LCST) of the nanocomposites was tailored for physiological applications by the addition of varying amounts of acrylamide (AAm). The addition of nanotubes contributed to interesting properties, including tailorability of temperature responsive swelling and mechanical strength of the resultant nanocomposites. The mechanical properties of the nanocomposites were studied over a range of temperatures (25-55 degrees C) to characterize the effect of nanotube addition. A radiofrequency (RF) field of 13.56 MHz was applied to the nanocomposite discs, and the resultant heating was characterized using in thermography. This is the first report on the use of RF to remotely heat MWCNT-hydrogel nanocomposites. (C) 2010 Wiley Periodicals, Inc. J Appl Polym Sci 117: 1813-1819, 2010
C1 [Satarkar, Nitin S.; Johnson, Don; Andrews, Rodney; Anderson, Kimberly W.; Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Marrs, Brock; Andrews, Rodney] Univ Kentucky, Ctr Appl Energy Res, Lexington, KY 40511 USA.
   [Poh, Churn; Gharaibeh, Belal; Saito, Kozo] Univ Kentucky, Dept Mech Engn, Inst Res Technol Dev, Lexington, KY 40506 USA.
RP Hilt, JZ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM hilt@engr.uky.edu
RI Gharaibeh, Burhan/A-7696-2017
FU Institute of Research for Technology Development (IR4TD); Bussan
   Nanotech Research Institute Inc.
FX Contract grant sponsor: Institute of Research for Technology Development
   (IR4TD), Bussan Nanotech Research Institute Inc.
CR Baughman RH, 2002, SCIENCE, V297, P787, DOI 10.1126/science.1060928
   Bhattacharyya S, 2008, BIOMACROMOLECULES, V9, P505, DOI 10.1021/bm7009976
   Bianco A, 2005, CHEM COMMUN, P571, DOI 10.1039/b410943k
   Boldor D, 2008, CHEM MATER, V20, P4011, DOI 10.1021/cm800428e
   Chakraborty S, 2007, J ELECTROANAL CHEM, V609, P155, DOI 10.1016/j.jelechem.2007.06.024
   Chakravarty P, 2008, P NATL ACAD SCI USA, V105, P8697, DOI 10.1073/pnas.0803557105
   Coleman JN, 2006, ADV MATER, V18, P1
   Dong L, 2007, SOFT MATTER, V3, P1223, DOI 10.1039/b706563a
   FRIMPONG RA, 2007, NANOTECHNOLOGY THERA, pCH10
   Frimpong RA, 2007, J BIOMED MATER RES A, V80A, P1, DOI 10.1002/jbm.a.30962
   Fujigaya T, 2008, ADV MATER, V20, P3610, DOI 10.1002/adma.200800494
   Gannon CJ, 2007, CANCER-AM CANCER SOC, V110, P2654, DOI 10.1002/cncr.23155
   Gil ES, 2004, PROG POLYM SCI, V29, P1173, DOI 10.1016/j.progpolymsci.2004.08.003
   Hou Y, 2009, ACS NANO, V3, P1057, DOI 10.1021/nn9000512
   Kim JW, 2007, LASER SURG MED, V39, P622, DOI 10.1002/lsm.20534
   Koerner H, 2004, NAT MATER, V3, P115, DOI 10.1038/nmat1059
   Lu FS, 2009, ADV MATER, V21, P139, DOI 10.1002/adma.200801491
   MacDonald RA, 2008, ACTA BIOMATER, V4, P1583, DOI 10.1016/j.actbio.2008.07.005
   Miyako E, 2008, SMALL, V4, P1711, DOI 10.1002/smll.200800601
   Omar MA, 2007, NDT&E INT, V40, P62, DOI 10.1016/j.ndteint.2006.07.013
   Ozarkar S, 2008, SMART MATER STRUCT, V17, DOI 10.1088/0964-1726/17/5/055016
   Paton KR, 2008, CARBON, V46, P1935, DOI 10.1016/j.carbon.2008.08.001
   Peppas NA, 2006, ADV MATER, V18, P1345, DOI 10.1002/adma.200501612
   Poland CA, 2008, NAT NANOTECHNOL, V3, P423, DOI 10.1038/nnano.2008.111
   Satarkar NS, 2008, J CONTROL RELEASE, V130, P246, DOI 10.1016/j.jconrel.2008.06.008
   Satarkar NS, 2009, LAB CHIP, V9, P1773, DOI 10.1039/b822694f
   Sershen SR, 2005, ADV MATER, V17, P1366, DOI 10.1002/adma.200401239
   Shi JH, 2005, J PHYS CHEM B, V109, P14789, DOI 10.1021/jp052677k
   Tsai YC, 2007, BIOSENS BIOELECTRON, V22, P3051, DOI 10.1016/j.bios.2007.01.005
   Wang MB, 2008, J BIOMED MATER RES A, V85A, P418, DOI 10.1002/jbm.a.31585
   Wang SF, 2005, BIOMACROMOLECULES, V6, P3067, DOI 10.1021/bm050378v
   Yang LQ, 2008, ADV MATER, V20, P2271, DOI 10.1002/adma.200702953
   Yang ZH, 2008, ADV MATER, V20, P2201, DOI 10.1002/adma.200701964
   YOSHIDA R, 1994, J BIOMAT SCI-POLYM E, V6, P585
NR 34
TC 21
Z9 22
U1 1
U2 34
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0021-8995
J9 J APPL POLYM SCI
JI J. Appl. Polym. Sci.
PD AUG 5
PY 2010
VL 117
IS 3
BP 1813
EP 1819
DI 10.1002/app.32138
PG 7
WC Polymer Science
SC Polymer Science
GA 608GK
UT WOS:000278571200068
DA 2018-03-19
ER

PT J
AU Osei-Prempeh, G
   Lehmler, HJ
   Rankin, SE
   Knutson, BL
AF Osei-Prempeh, Gifty
   Lehmler, Hans-Joachim
   Rankin, Stephen E.
   Knutson, Barbara L.
TI Synthesis of fluoro-functionalized mesoporous silica and application to
   fluorophilic separations
SO INDUSTRIAL & ENGINEERING CHEMISTRY RESEARCH
LA English
DT Article
ID PHASE PARALLEL SYNTHESIS; PORE-SIZE; FLUORINATED SURFACTANT;
   ORGANOSILICATE FILMS; CHAIN-LENGTH; MCM-41; MICELLES; SOLUBILIZATION;
   EXTRACTION; RODLIKE
AB Fluorocarbon-functionalized mesoporous silica is synthesized by the co-condensation of tetraalkoxysilane and fluoro-functionalized alkoxysilane precursors using a cationic fluorocarbon surfactant, C6F13C2H2NC5H5Cl (HFOPC) and C8F17C2H2NC5H5Cl (HFDePC), of a traditional hydrocarbon surfactant (C16H33N(CH3)(3)Br, CTAB) as templates. Fluorocarbon functionalization decreases the silica pore order, pore size, and surface area. The chain length of the fluorocarbon functional precursor and the surfactant template affects the pore order, the materials textural properties, and the fluorocarbon incorporation. Matching a fluorocarbon surfactant with a fluorocarbon functional precursor does not improve functional group incorporation; the incorporation of the perfluoro-octyl functional group is greater in CTAB-templated silica than in HFOPC-templated silica. The application of these mesoporous silica powders to fluorous separations is demonstrated using hydrocarbon and fluorocarbon-tagged anthraquinones. Dye elution through,a packed column of mesoporous silica occurs in a narrower band than that for fluorocarbon-functionalized silica gel, consistent with the high fluorocarbon content and smaller pore and particle sizes of the mesoporous material.
C1 [Osei-Prempeh, Gifty; Rankin, Stephen E.; Knutson, Barbara L.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Lehmler, Hans-Joachim] Univ Iowa, Dept Environm & Occupat Hlth, Iowa City, IA 52242 USA.
RP Knutson, BL (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM bknutson@engr.uky.edu
RI Osei-Prempeh, Gifty/C-8133-2009; Rankin, Stephen/A-3265-2013
OI Rankin, Stephen/0000-0002-8615-7564; Lehmler,
   Hans-Joachim/0000-0001-9163-927X
CR Bae JY, 2004, J MATER RES, V19, P2503, DOI 10.1557/JMR.2004.0315
   BORMAN S, 1997, CHEM ENG NEWS   0224
   Brittain SM, 2005, NAT BIOTECHNOL, V23, P463, DOI 10.1038/nbt1076
   Cardia MC, 2001, FARMACO, V56, P549, DOI 10.1016/S0014-827X(01)01082-5
   Curran D, 2001, GREEN CHEM, V3, pG3, DOI 10.1039/b100266j
   Gladysz J. A., 2004, HDB FLUOROUS CHEM
   Grun M, 1997, ADV MATER, V9, P254, DOI 10.1002/adma.19970090317
   Hatakeyama T., 1999, THERMAL ANAL FUNDAME
   HOFFMANN H, 1989, J COLLOID INTERF SCI, V129, P388, DOI 10.1016/0021-9797(89)90453-0
   Holmes SM, 1998, J CHEM SOC FARADAY T, V94, P2025, DOI 10.1039/a801898g
   Innocenzi P, 2003, J PHYS CHEM B, V107, P4711, DOI 10.1021/jp026609z
   Jaroniec M, 1999, LANGMUIR, V15, P5410, DOI 10.1021/la990136e
   Jung JI, 2004, J MATER CHEM, V14, P1988, DOI 10.1039/b401774a
   Kamiusuki T, 1999, J COLLOID INTERF SCI, V220, P123, DOI 10.1006/jcis.1999.6518
   Karukstis KK, 1997, J PHYS CHEM B, V101, P1968, DOI 10.1021/jp962537y
   Krafft MP, 1998, BIOCHIMIE, V80, P489, DOI 10.1016/S0300-9084(00)80016-4
   Kruk M, 1997, LANGMUIR, V13, P6267, DOI 10.1021/la970776m
   Kruk M, 2002, J AM CHEM SOC, V124, P6383, DOI 10.1021/ja025573I
   Kruk M, 2001, CHEM MATER, V13, P3169, DOI 10.1021/cm0101069
   Kumar D, 2001, COLLOID SURFACE A, V187, P109, DOI 10.1016/S0927-7757(01)00638-0
   Lebeau B, 2003, NEW J CHEM, V27, P166, DOI 10.1039/b206924p
   Lim MH, 1999, CHEM MATER, V11, P3285, DOI 10.1021/cm990369r
   Lin-Vien D, 1991, HDB INFRARED RAMAN C
   Osei-Prempeh G, 2005, MICROPOR MESOPOR MAT, V85, P16, DOI 10.1016/j.micromeso.2005.06.014
   Palmqvist AEC, 2003, CURR OPIN COLLOID IN, V8, P145, DOI 10.1016/S1359-0294(03)00020-7
   Patist A, 1997, LANGMUIR, V13, P432, DOI 10.1021/la960838t
   PINNAVAIA TJ, 2002, ACCESS NANOPOROUS MA
   Porcherie O, 2005, NEW J CHEM, V29, P538, DOI 10.1039/b417756h
   Simpson N., 2000, SOLID PHASE EXTRACTI
   STOBER W, 1968, J COLLOID INTERF SCI, V26, P62, DOI 10.1016/0021-9797(68)90272-5
   Tornblom M, 1997, J PHYS CHEM B, V101, P6028, DOI 10.1021/jp970899f
   Unsal E, 2004, CHROMATOGRAPHIA, V60, P553, DOI 10.1365/s10337-004-0416-4
   Wang K, 2000, LANGMUIR, V16, P1042, DOI 10.1021/la9909603
   Yan B., 2000, ANAL METHODS COMBINA
   Zhang QS, 2000, J ORG CHEM, V65, P8866, DOI 10.1021/jo000464f
   Zhang W, 2005, J COMB CHEM, V7, P893, DOI 10.1021/cc050061z
   Zhang W, 2004, CHEM REV, V104, P2531, DOI 10.1021/cr030600r
   Zhang W, 2002, J AM CHEM SOC, V124, P10443, DOI 10.1021/ja026947d
   Zhang W, 2002, TETRAHEDRON, V58, P3871, DOI 10.1016/S0040-4020(02)00209-0
NR 39
TC 8
Z9 8
U1 1
U2 18
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0888-5885
J9 IND ENG CHEM RES
JI Ind. Eng. Chem. Res.
PD FEB 6
PY 2008
VL 47
IS 3
BP 530
EP 538
DI 10.1021/ie070538e
PG 9
WC Engineering, Chemical
SC Engineering
GA 257CT
UT WOS:000252777500006
DA 2018-03-20
ER

PT J
AU Dickerson, M
   Howerton, B
   Bae, Y
   Glazer, EC
AF Dickerson, Matthew T.
   Howerton, Brock
   Bae, Younsoo
   Glazer, Edith C.
TI Light-sensitive ruthenium complex-loaded cross-linked polymeric
   nanoassemblies for the treatment of cancer
SO JOURNAL OF MATERIALS CHEMISTRY B
LA English
DT Article
ID DRUG-RELEASE; POLYPYRIDYL COMPLEXES; PLGA NANOPARTICLES; CELLULAR
   UPTAKE; DNA-BINDING; IN-VITRO; DELIVERY; LIGAND; REPAIR; WATER
AB This work focuses on improving the efficacy of photoactivatable Ru complexes for photodynamic therapy by employing cross-linked nanoassemblies (CNAs) as a delivery approach. The effects of complex photoactivation, hydrophobicity, and solution ionic strength and pH on complex loading and release from CNAs were analyzed. The cell cytotoxicity of CNA formulations was similar to free Ru complexes despite reduced or eliminated DNA interactions. The release rate and the amount of each Ru complex released (%) varied inversely with complex hydrophobicity, while the effect of solution ionic strength was dependent on complex hydrophobicity. Premature release of two photoactivatable prodrugs prior to irradiation was believed to account for higher activity in cells studies compared to DNA interaction studies; however, for photostable O-1(2) generator-loaded CNAs this cannot explain the high cytotoxicity and lack of DNA interactions because release was incomplete after 48 h. The cause remains unclear, but among other possibilities, accelerated release in a cell culture environment may be responsible.
C1 [Dickerson, Matthew; Glazer, Edith C.] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
   [Dickerson, Matthew; Howerton, Brock; Bae, Younsoo] Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
RP Glazer, EC (reprint author), Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
EM ec.glazer@uky.edu
FU American Cancer Society [RSG-13-079-01-CDD]; NCI/NIH; National Cancer
   Institute Alliance for Nanotechnology in Cancer [5R25CA153954]
FX This work was made possible through the support of the American Cancer
   Society (RSG-13-079-01-CDD). MD acknowledges the University of Kentucky
   Cancer Nanotechnology Training Center (UK-CNTC) postdoctoral
   traineeship, supported by the NCI/NIH and part of the National Cancer
   Institute Alliance for Nanotechnology in Cancer (5R25CA153954).
CR Al-Ahmady ZS, 2012, ACS NANO, V6, P9335, DOI 10.1021/nn302148p
   Allardyce CS, 2001, PLATIN MET REV, V45, P62
   Allen TM, 2004, SCIENCE, V303, P1818, DOI 10.1126/science.1095833
   Bae Y, 2003, ANGEW CHEM INT EDIT, V42, P4640, DOI 10.1002/anie.200250653
   Boerner LJK, 2005, CURR OPIN CHEM BIOL, V9, P135, DOI 10.1016/j.cbpa.2005.02.010
   BRANDT WW, 1954, CHEM REV, V54, P959, DOI 10.1021/cr60172a003
   Bruijnincx PCA, 2008, CURR OPIN CHEM BIOL, V12, P197, DOI 10.1016/j.cbpa.2007.11.013
   Cao PX, 2013, BRIT J PHARM RES, V3, P523, DOI 10.9734/BJPR/2013/4574
   Chen TF, 2010, INORG CHEM, V49, P6366, DOI 10.1021/ic100277w
   CHU G, 1994, J BIOL CHEM, V269, P787
   Dickerson M, 2014, INORG CHEM, V53, P10370, DOI 10.1021/ic5013796
   Dronkert MLG, 2001, MUTAT RES-DNA REPAIR, V486, P217, DOI 10.1016/S0921-8777(01)00092-1
   DWYER FP, 1952, NATURE, V170, P190, DOI 10.1038/170190a0
   Frasconi M, 2013, J AM CHEM SOC, V135, P11603, DOI 10.1021/ja405058y
   Fricker SP, 2007, DALTON T, P4903, DOI 10.1039/b705551j
   GarciaFresnadillo D, 1996, HELV CHIM ACTA, V79, P1222, DOI 10.1002/hlca.19960790428
   Gill MR, 2009, NAT CHEM, V1, P662, DOI [10.1038/NCHEM.406, 10.1038/nchem.406]
   Goldbach RE, 2011, CHEM-EUR J, V17, P9924, DOI 10.1002/chem.201101541
   Govender T, 1999, J CONTROL RELEASE, V57, P171, DOI 10.1016/S0168-3659(98)00116-3
   Groessl M, 2011, METALLOMICS, V3, P591, DOI 10.1039/c0mt00101e
   GROVER N, 1994, INORG CHEM, V33, P3544, DOI 10.1021/ic00094a018
   Hahn U, 2012, CHEM-EUR J, V18, P15424, DOI 10.1002/chem.201201126
   He CB, 2010, BIOMATERIALS, V31, P3657, DOI 10.1016/j.biomaterials.2010.01.065
   Heidary DK, 2014, CHEMBIOCHEM, V15, P507, DOI 10.1002/cbic.201300681
   Howerton BS, 2012, J AM CHEM SOC, V134, P8324, DOI 10.1021/ja3009677
   Hu Y, 2003, BIOMATERIALS, V24, P2395, DOI 10.1016/S0142-9612(03)00021-8
   Hufziger KT, 2014, J INORG BIOCHEM, V130, P103, DOI 10.1016/j.jinorgbio.2013.10.008
   Klajner M, 2010, J PHYS CHEM B, V114, P14041, DOI 10.1021/jp1044783
   Koch J. H., 1957, J BIOL SCI, V10, P342
   Lee HJ, 2013, PHARM RES-DORDR, V30, P478, DOI 10.1007/s11095-012-0893-3
   Lee HJ, 2011, BIOMACROMOLECULES, V12, P2686, DOI 10.1021/bm200483t
   Lentzen O., 2005, METALLOTHERAPEUTIC D, P359
   Mu L, 2003, J CONTROL RELEASE, V86, P33, DOI 10.1016/S0168-3659(02)00320-6
   Muller RH, 2004, J BIOTECHNOL, V113, P151, DOI 10.1016/j.jbiotec.2004.06.007
   Noll DM, 2006, CHEM REV, V106, P277, DOI 10.1021/cr040478b
   NOVAKOVA O, 1995, BIOCHEMISTRY-US, V34, P12369, DOI 10.1021/bi00038a034
   Panyam J, 2002, FASEB J, V16, DOI 10.1096/fj.02-0088com
   Puckett CA, 2008, BIOCHEMISTRY-US, V47, P11711, DOI 10.1021/bi800856t
   Puckett CA, 2007, J AM CHEM SOC, V129, P46, DOI 10.1021/ja0677564
   PYLE AM, 1989, J AM CHEM SOC, V111, P3051, DOI 10.1021/ja00190a046
   SANGSTER J, 1989, J PHYS CHEM REF DATA, V18, P1111, DOI 10.1063/1.555833
   Su WY, 2012, INT J PHARMACEUT, V426, P170, DOI 10.1016/j.ijpharm.2012.01.013
   TOGANO T, 1992, INORG CHIM ACTA, V195, P221, DOI 10.1016/S0020-1693(00)85316-5
   Wachter E, 2012, CHEM COMMUN, V48, P9649, DOI 10.1039/c2cc33359g
   Wang G, 2011, MOL PHARMACEUT, V8, P1025, DOI 10.1021/mp200028w
   Wang HJ, 2010, BIOMATERIALS, V31, P4129, DOI 10.1016/j.biomaterials.2010.01.089
   Yadav A, 2013, MOL CANCER THER, V12, P643, DOI 10.1158/1535-7163.MCT-12-1130
   Zava O, 2009, CHEMBIOCHEM, V10, P1796, DOI 10.1002/cbic.200900013
   Zhang CX, 2003, CURR OPIN CHEM BIOL, V7, P481, DOI 10.1016/S1367-5931(03)00081-4
   Zhang P, 2011, BIOMATERIALS, V32, P5524, DOI 10.1016/j.biomaterials.2011.04.022
NR 50
TC 17
Z9 17
U1 4
U2 22
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2050-750X
EI 2050-7518
J9 J MATER CHEM B
JI J. Mat. Chem. B
PY 2016
VL 4
IS 3
BP 394
EP 408
DI 10.1039/c5tb01613d
PG 15
WC Materials Science, Biomaterials
SC Materials Science
GA DA6UL
UT WOS:000367940900005
PM 26855780
OA green_accepted
DA 2018-03-19
ER

PT J
AU Akenhead, ML
   Horrall, NM
   Rowe, D
   Sethu, P
   Shin, HY
AF Akenhead, Michael L.
   Horrall, Nolan M.
   Rowe, Dylan
   Sethu, Palaniappan
   Shin, Hainsworth Y.
TI In Vitro Evaluation of the Link Between Cell Activation State and Its
   Rheological Impact on the Microscale Flow of Neutrophil Suspensions
SO JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME
LA English
DT Article
DE inflammation; viscosity; resistance; hematocrit; hemorrheology
ID DIFFERENTIATED HL-60 CELLS; FLUID SHEAR-STRESS; BLOOD-FLOW; HYDRODYNAMIC
   SHEAR; LEUKOCYTES; MIGRATION; ADHESION; MICROCIRCULATION; HEMODYNAMICS;
   RESISTANCE
AB Activated neutrophils have been reported to affect peripheral resistance, for example, by plugging capillaries or adhering to the microvasculature. In vivo and ex vivo data indicate that activated neutrophils circulating in the blood also influence peripheral resistance. We used viscometry and microvascular mimics for in vitro corroboration. The rheological impact of differentiated neutrophil-like HL-60 promyelocytes (dHL60s) or human neutrophil suspensions stimulated with 10nM fMet-Leu-Phe (fMLP) was quantified using a cone-plate rheometer (450 s(-1) shear rate). To evaluate their impact on microscale flow resistance, we used 10-mu m Isopore (R) membranes to model capillaries as well as single 200 x 50 mu m microchannels and networks of twenty 20 x 50 mu m microfluidic channels to mimic noncapillary microvasculature. Stimulation of dHL60 and neutrophil populations significantly altered their flow behavior as evidenced by their impact on suspension viscosity. Notably, hematocrit abrogated the impact of leukocyte activation on blood cell suspension viscosity. In micropore filters, activated cell suspensions enhanced flow resistance. This effect was further enhanced by the presence of erythrocytes. The resistance of our noncapillary microvascular mimics to flow of activated neutrophil suspensions was significantly increased only with hematocrit. Notably, it was elevated to a higher extent within the micronetwork chambers compared to the single-channel chambers. Collectively, our findings provide supportive evidence that activated neutrophils passing through the microcirculation may alter hemodynamic resistance due to their altered rheology in the noncapillary microvasculature. This effect is another way neutrophil activation due to chronic inflammation may, at least in part, contribute to the elevated hemodynamic resistance associated with cardiovascular diseases (e.g., hypertension and hypercholesterolemia).
C1 [Akenhead, Michael L.; Horrall, Nolan M.; Shin, Hainsworth Y.] Univ Kentucky, Dept Biomed Engn, Lexington, KY 40506 USA.
   [Rowe, Dylan] Paul L Dunbar High Sch, Math Sci & Technol Ctr, Lexington, KY 40513 USA.
   [Sethu, Palaniappan] Univ Alabama Birmingham, Div Cardiovasc Dis, Birmingham, AL 35294 USA.
RP Shin, HY (reprint author), Univ Kentucky, Dept Biomed Engn, Lexington, KY 40506 USA.
EM hy.shin@uky.edu
FU American Heart Association [09BGIA2250309]; National Science Foundation
   (NSF)-Kentucky Experimental Program on Stimulating Competitive Research
   [0814194]; NSF-Integrated Graduate Education and Research Training
   Program on Bioactive Interfaces [0653710]; Kentucky Opportunity
   Fellowship
FX This work was supported by an American Heart Association Beginning
   Grant-in-Aid (No. 09BGIA2250309) and a National Science Foundation
   (NSF)-Kentucky Experimental Program on Stimulating Competitive Research
   (No. 0814194) Bioengineering Initiative grant. We also acknowledge the
   support from an NSF-Integrated Graduate Education and Research Training
   Program on Bioactive Interfaces (No. 0653710) and a Kentucky Opportunity
   Fellowship, both of which were awarded to M.L.A. Finally, we would like
   to thank Ms. Xiaoyan Zhang Ph.D. for her assistance in establishing
   experimental protocols.
CR ADAMS RA, 1994, BIORHEOLOGY, V31, P603
   ARNDT H, 1993, HYPERTENSION, V21, P667, DOI 10.1161/01.HYP.21.5.667
   Bagge U., 1982, MICROCIRCULATION REV, V1, P89
   Baskurt OK, 2003, SEMIN THROMB HEMOST, V29, P435
   Besarab A, 1998, NEW ENGL J MED, V339, P584, DOI 10.1056/NEJM199808273390903
   Carrigan SO, 2005, IMMUNOLOGY, V115, P108, DOI 10.1111/j.1365-2567.2005.02131.x
   De Ville M, 2012, MICROFLUID NANOFLUID, V12, P953, DOI 10.1007/s10404-011-0929-8
   Doring Y., 2014, ARTERIOSCLER THROMB, V35, P485
   Eppihimer MJ, 1996, MICROVASC RES, V51, P187, DOI 10.1006/mvre.1996.0020
   Faivre M, 2006, BIORHEOLOGY, V43, P147
   Fang WC, 1997, CIRCULATION, V96, P194
   Freund JB, 2011, J FLUID MECH, V671, P466, DOI 10.1017/S0022112010005835
   Fukuda S, 2000, CIRC RES, V86, pE13
   GOLDSMITH HL, 1981, BIORHEOLOGY, V18, P531
   Goldsmith HL, 2001, BIOPHYS J, V81, P2020, DOI 10.1016/S0006-3495(01)75852-3
   Goyal M. R., 2013, BIOFLUID DYNAMICS HU
   Granger D. N., 2010, INTEGRATED SYSTEMS P
   HANSEN PR, 1995, CIRCULATION, V91, P1872
   HARRIS AG, 1993, AM J PHYSIOL, V264, pH909
   Hauert AB, 2002, INT J BIOCHEM CELL B, V34, P838, DOI 10.1016/S1357-2725(02)00010-9
   Helmke BP, 1997, AM J PHYSIOL-HEART C, V273, pH2884
   Helmke BP, 1998, BIORHEOLOGY, V35, P437, DOI 10.1016/S0006-355X(99)80021-3
   KARNIS A, 1963, NATURE, V200, P159, DOI 10.1038/200159a0
   KIKUCHI Y, 1994, MICROVASC RES, V47, P126, DOI 10.1006/mvre.1994.1008
   KIKUCHI Y, 1995, MICROVASC RES, V50, P288, DOI 10.1006/mvre.1995.1059
   Kim S, 2009, BIORHEOLOGY, V46, P181, DOI 10.3233/BIR-2009-0530
   KLITZMAN B, 1979, AM J PHYSIOL, V237, pH481
   Lima R, 2008, BIOMED MICRODEVICES, V10, P153, DOI 10.1007/s10544-007-9121-z
   Lipowsky HH, 2005, MICROCIRCULATION, V12, P5, DOI 10.1080/10739680590894966
   Makino A, 2006, AM J PHYSIOL-CELL PH, V290, pC1633, DOI 10.1152/ajpcell.00576.2005
   Makino A, 2005, AM J PHYSIOL-CELL PH, V288, pC863, DOI 10.1152/ajpcell.00358.2004
   Mazzoni MC, 1996, CARDIOVASC RES, V32, P709, DOI 10.1016/0008-6363(96)00146-0
   Meisel SR, 1998, J AM COLL CARDIOL, V31, P120, DOI 10.1016/S0735-1097(97)00424-5
   MERRILL EW, 1969, PHYSIOL REV, V49, P863
   Miller G. E., 2010, FUNDAMENTALS BIOMEDI
   Moazzam F, 1997, P NATL ACAD SCI USA, V94, P5338, DOI 10.1073/pnas.94.10.5338
   Neelamegham S, 1998, BLOOD, V92, P1626
   Popel AS, 2005, ANNU REV FLUID MECH, V37, P43, DOI 10.1146/annurev.fluid.37.042604.133933
   Pries AR, 1996, CARDIOVASC RES, V32, P654, DOI 10.1016/S0008-6363(96)00065-X
   Rainger GE, 1999, AM J PHYSIOL-HEART C, V276, pH858
   ROCHON YP, 1991, J LEUKOCYTE BIOL, V50, P434
   RUSSO RG, 1981, J CELL BIOL, V91, P459, DOI 10.1083/jcb.91.2.459
   Schmid-Schonbein GW, 2006, ANNU REV BIOMED ENG, V8, P93, DOI 10.1146/annurev.bioeng.8.061505.095708
   SCHMIDSCHONBEIN GW, 1987, FASEB J, V46, P2397
   SCHMIDSCHONBEIN GW, 1980, MICROVASC RES, V19, P45, DOI 10.1016/0026-2862(80)90083-7
   Sethu P, 2006, ANAL CHEM, V78, P5453, DOI 10.1021/ac060140c
   SHAM RL, 1991, BLOOD, V77, P363
   Shevkoplyas SS, 2003, MICROVASC RES, V65, P132, DOI 10.1016/S0026-2862(02)00034-1
   SUTTON DW, 1992, AM J PHYSIOL, V262, pH1646
   Taylor AD, 1996, BIOPHYS J, V71, P3488, DOI 10.1016/S0006-3495(96)79544-9
   USAMI S, 1993, ANN BIOMED ENG, V21, P77, DOI 10.1007/BF02368167
   WILLIAMS SA, 1992, INT J MICROCIRC, V11, P109
   WORTHEN GS, 1989, SCIENCE, V245, P183, DOI 10.1126/science.2749255
   Zhelev DV, 2004, BIOPHYS J, V87, P688, DOI 10.1529/biophysj.103.036699
NR 54
TC 0
Z9 0
U1 0
U2 4
PU ASME
PI NEW YORK
PA TWO PARK AVE, NEW YORK, NY 10016-5990 USA
SN 0148-0731
EI 1528-8951
J9 J BIOMECH ENG-T ASME
JI J. Biomech. Eng.-Trans. ASME
PD SEP
PY 2015
VL 137
IS 9
AR 091003
DI 10.1115/1.4030824
PG 10
WC Biophysics; Engineering, Biomedical
SC Biophysics; Engineering
GA CN9VO
UT WOS:000358798500003
OA green_published
DA 2018-03-19
ER

PT J
AU Yu, CG
   Yezierski, RP
   Joshi, A
   Raza, K
   Li, YZ
   Geddes, JW
AF Yu, Chen-Guang
   Yezierski, Robert P.
   Joshi, Aashish
   Raza, Kashif
   Li, YongChao
   Geddes, James W.
TI Involvement of ERK2 in traumatic spinal cord injury
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Article
DE extracellular signal-regulated protein kinase 2; locomotor function; RNA
   interference; spinal cord injury; tissue damage
ID SIGNAL-REGULATED KINASE; SMALL INTERFERING RNA; FUNCTIONAL DEFICITS;
   IMPROVES LOCOMOTOR; CONTUSION INJURY; ADULT-RAT; RECOVERY; EXPRESSION;
   MICE; PAIN
AB P>Activation of extracellular signal-regulated protein kinase 1/2 (ERK1/2) are implicated in the pathophysiology of spinal cord injury (SCI). However, the specific functions of individual ERK isoforms in neurodegeneration are largely unknown. We investigated the hypothesis that ERK2 activation may contribute to pathological and functional deficits following SCI and that ERK2 knockdown using RNA interference may provide a novel therapeutic strategy for SCI. Lentiviral ERK2 shRNA and siRNA were utilized to knockdown ERK2 expression in the spinal cord following SCI. Pre-injury intrathecal administration of ERK2 siRNA significantly reduced excitotoxic injury-induced activation of ERK2 (p < 0.001) and caspase 3 (p < 0.01) in spinal cord. Intraspinal administration of lentiviral ERK2 shRNA significantly reduced ERK2 expression in the spinal cord (p < 0.05), but did not alter ERK1 expression. Administration of the lentiviral ERK2 shRNA vector 1 week prior to severe spinal cord contusion injury resulted in a significant improvement in locomotor function (p < 0.05), total tissue sparing (p < 0.05), white matter sparing (p < 0.05), and gray matter sparing (p < 0.05) 6 weeks following severe contusive SCI. Our results suggest that ERK2 signaling is a novel target associated with the deleterious consequences of spinal injury.
C1 [Yu, Chen-Guang; Joshi, Aashish; Raza, Kashif; Li, Yanzhang; Geddes, James W.] Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA.
   [Yu, Chen-Guang; Joshi, Aashish; Raza, Kashif; Li, Yanzhang; Geddes, James W.] Univ Kentucky, Coll Med, Dept Anat & Neurobiol, Lexington, KY 40536 USA.
   [Yezierski, Robert P.] Univ Florida, Coll Dent, Dept Orthodont & Neurosci, Gainesville, FL USA.
   [Yezierski, Robert P.] Univ Florida, Coll Dent, Comprehens Ctr Pain Res, Gainesville, FL USA.
RP Yu, CG (reprint author), Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, B465,BBSRB,741 S Limestone St, Lexington, KY 40536 USA.
EM cyu4@uky.edu
RI Yu, Chen Guang/C-6176-2011
FU Paralysis Project of America; Kentucky Spinal Cord; Head Injury Research
   Trust; University of Florida Seed
FX This research was supported by the Paralysis Project of America, the
   Kentucky Spinal Cord and Head Injury Research Trust, and a University of
   Florida Seed grant. The authors wish to thank Dr George Smith for
   lentiviral-CMV-RNAi vectors, and Paula Thomason for manuscript editing.
CR Agrawal A, 2006, J IMMUNOL, V176, P5788, DOI 10.4049/jimmunol.176.10.5788
   Aigner A, 2006, J BIOTECHNOL, V124, P12, DOI 10.1016/j.jbiotec.2005.12.003
   Azari MF, 2006, J NEUROPATH EXP NEUR, V65, P914, DOI 10.1097/01.jnen.0000235855.77716.25
   Barrett LE, 2006, P NATL ACAD SCI USA, V103, P5155, DOI 10.1073/pnas.0510477103
   Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098
   BLIGHT AR, 1983, NEUROSCIENCE, V10, P521, DOI 10.1016/0306-4522(83)90150-1
   Breckpot K, 2007, GENE THER, V14, P847, DOI 10.1038/sj.gt.3302947
   Cai YQ, 2009, J NEUROCHEM, V111, P1000, DOI 10.1111/j.1471-4159.2009.06396.x
   Chen YC, 2007, HEPATOLOGY, V46, P200, DOI 10.1002/hep.21668
   Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p
   Crown ED, 2006, EXP NEUROL, V199, P397, DOI 10.1016/j.expneurol.2006.01.003
   El-Bohy AA, 1998, EXP NEUROL, V150, P143, DOI 10.1006/exnr.1997.6757
   French DD, 2007, J SPINAL CORD MED, V30, P477, DOI 10.1080/10790268.2007.11754581
   Genovese T, 2008, J PHARMACOL EXP THER, V325, P100, DOI 10.1124/jpet.107.131060
   Hetman M, 2004, EUR J BIOCHEM, V271, P2050, DOI 10.1111/j.1432-1033.2004.04133.x
   Hillard VH, 2004, J NEUROTRAUM, V21, P1405, DOI 10.1089/neu.2004.21.1405
   Klussmann S, 2005, J MOL MED-JMM, V83, P657, DOI 10.1007/s00109-005-0663-3
   Lankhorst AJ, 1999, J NEUROTRAUM, V16, P323, DOI 10.1089/neu.1999.16.323
   Lu Patrick Y., 2008, V437, P93, DOI 10.1007/978-1-59745-210-6_3
   Luo MC, 2005, MOL PAIN, V1, DOI 10.1186/1744-8069-1-29
   Madsen JR, 1998, EXP NEUROL, V154, P673, DOI 10.1006/exnr.1998.6974
   Magnuson DSK, 1999, EXP NEUROL, V156, P191, DOI 10.1006/exnr.1999.7016
   Matsumoto S, 2005, J BIOL CHEM, V280, P25687, DOI 10.1074/jbc.M412784200
   McTigue DM, 2007, EXP NEUROL, V205, P396, DOI 10.1016/j.expneurol.2007.02.009
   Meunier A, 2008, J NEUROSCI METH, V167, P148, DOI 10.1016/j.jneumeth.2007.07.022
   Nakazawa T, 2008, J NEUROSCI RES, V86, P136, DOI 10.1002/jnr.21472
   Oudega M, 1999, EUR J NEUROSCI, V11, P2453, DOI 10.1046/j.1460-9568.1999.00666.x
   Park E, 2004, J NEUROTRAUM, V21, P754, DOI 10.1089/0897715041269641
   Rabchevsky AG, 2000, EXP NEUROL, V164, P280, DOI 10.1006/exnr.2000.7399
   Rabchevsky AG, 2002, J NEUROSCI RES, V68, P7, DOI 10.1002/jnr.10187
   Reier PJ, 2002, PROG BRAIN RES, V137, P49
   Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936
   Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117
   Ruitenberg MJ, 2002, METHODS, V28, P182, DOI 10.1016/S1046-2023(02)00222-0
   Scheff SW, 2002, J NEUROTRAUM, V19, P1251, DOI 10.1089/08977150260338038
   Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099
   Teng YD, 1997, J NEUROSCI, V17, P4359
   Wells JEA, 2003, BRAIN, V126, P1628, DOI 10.1093/brain/awg178
   Wrathall JR, 1996, EXP NEUROL, V137, P119, DOI 10.1006/exnr.1996.0012
   Wrathall JR, 1997, EXP NEUROL, V145, P565, DOI 10.1006/exnr.1997.6506
   Xu QH, 2008, J NEUROSCI, V28, P14087, DOI 10.1523/JNEUROSCI.2406-08.2008
   Yu CG, 2005, MOL BRAIN RES, V138, P244, DOI 10.1016/j.molbrainres.2005.04.013
   YU CG, 2009, J NEUROTRAUMA A, V26, pS73
   Yu CG, 2007, NEUROCHEM RES, V32, P2046, DOI 10.1007/s11064-007-9347-4
   Zhao P, 2007, J NEUROSCI, V27, P2357, DOI 10.1523/JNEUROSCI.0138-07.2007
   Zhuang SG, 2006, J PHARMACOL EXP THER, V319, P991, DOI 10.1124/jpet.106.107367
NR 46
TC 14
Z9 21
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0022-3042
J9 J NEUROCHEM
JI J. Neurochem.
PD APR
PY 2010
VL 113
IS 1
BP 131
EP 142
DI 10.1111/j.1471-4159.2010.06579.x
PG 12
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 564AS
UT WOS:000275183500011
PM 20067580
OA gold
DA 2018-03-20
ER

PT J
AU Borgohain, R
   Selegue, JP
   Li, JC
   Cheng, YT
AF Borgohain, Rituraj
   Selegue, John P.
   Li, Juchuan
   Cheng, Y-T.
TI RuO2/CNO nano-composites for supercapacitor electrode materials
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
CT 243rd National Spring Meeting of the American-Chemical-Society
CY MAR 25-29, 2012
CL San Diego, CA
SP Amer Chem Soc
C1 [Borgohain, Rituraj; Selegue, John P.; Li, Juchuan; Cheng, Y-T.] Univ Kentucky, Lexington, KY 40503 USA.
EM b.rituraj@uky.edu
RI Cheng, Yang-Tse/B-5424-2012
OI Cheng, Yang-Tse/0000-0003-0737-9212
NR 0
TC 0
Z9 0
U1 0
U2 5
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD MAR 25
PY 2012
VL 243
MA 1121-INOR
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA 219JX
UT WOS:000324503201478
DA 2018-03-19
ER

PT J
AU Wu, J
   Zhan, X
   Hinds, BJ
AF Wu, Ji
   Zhan, Xin
   Hinds, Bruce J.
TI Ionic rectification by electrostatically actuated tethers on single
   walled carbon nanotube membranes
SO CHEMICAL COMMUNICATIONS
LA English
DT Article
ID MASS-TRANSPORT; CELL-MEMBRANES; CONDUCTION; CHANNELS; MODEL; FLOW;
   FUNCTIONALIZATION; SELECTIVITY; SIMULATION; FILTRATION
AB Large electrostatically actuating charged tethers (similar to 2.5 nm) at the tip entrances of single walled carbon nanotubes (i.d. similar to 1.5 nm) can dramatically enhance ionic gating at the CNT core entrance. Significant rectification of small ions at physiological ionic strengths is observed and this system closely mimics the function of protein channels.
C1 [Wu, Ji; Hinds, Bruce J.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Zhan, Xin] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
RP Hinds, BJ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM bjhinds@engr.uky.edu
RI WU, JI/F-6379-2013; WU, JI/F-6371-2013; WU, JI/J-4580-2016
FU NIDA [5R01DA018822-05]; DARPA [W911NF-09-1-0267]
FX We thank Dr Xin Su and Dr Dali Qian for constructive discussion and
   assistance. This work is financially supported by NIDA, 5R01DA018822-05
   and DARPA, W911NF-09-1-0267. Infrastructure provided by the Center for
   Nanoscale Science and Engineering and electron microscopy center.
CR Bahr JL, 2001, J AM CHEM SOC, V123, P6536, DOI 10.1021/ja010462s
   Cheng WWL, 2011, P NATL ACAD SCI USA, V108, P5272, DOI 10.1073/pnas.1014186108
   DEEN WM, 1987, AICHE J, V33, P1409, DOI 10.1002/aic.690330902
   Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69
   Giess F, 2004, BIOPHYS J, V87, P3213, DOI 10.1529/biophysj.104.046169
   Goldsmith J, 2011, J PHYS CHEM C, V115, P19158, DOI 10.1021/jp201467y
   Harrell CC, 2004, J AM CHEM SOC, V126, P15646, DOI 10.1021/ja044948v
   Hinds BJ, 2004, SCIENCE, V303, P62, DOI 10.1126/science.1092048
   Holt JK, 2006, SCIENCE, V312, P1034, DOI 10.1126/science.1126298
   Hummer G, 2001, NATURE, V414, P188, DOI 10.1038/35102535
   Jensen MO, 2010, P NATL ACAD SCI USA, V107, P5833, DOI 10.1073/pnas.0911691107
   Lefebvre X, 2003, SEP PURIF TECHNOL, V32, P117, DOI 10.1016/S1383-5866(03)00076-5
   Majumder M, 2005, NATURE, V438, P44, DOI 10.1038/43844a
   Majumder M, 2005, J AM CHEM SOC, V127, P9062, DOI 10.1021/ja043013b
   Majumder M, 2007, LANGMUIR, V23, P8624, DOI 10.1021/la700686k
   Majumder M, 2011, CHEM COMMUN, V47, P7683, DOI 10.1039/c1cc11134e
   Marban E, 2002, NATURE, V415, P213, DOI 10.1038/415213a
   Pike LJ, 2009, J LIPID RES, V50, pS323, DOI 10.1194/jlr.R800040-JLR200
   Schafer AI, 2000, DESALINATION, V131, P215, DOI 10.1016/S0011-9164(00)90020-1
   SINGER SJ, 1972, SCIENCE, V175, P720, DOI 10.1126/science.175.4023.720
   Siwy ZS, 2010, CHEM SOC REV, V39, P1115, DOI 10.1039/b909105j
   Sun L, 2000, J AM CHEM SOC, V122, P12340, DOI 10.1021/ja002429w
   TSONG TY, 1991, BIOPHYS J, V60, P297, DOI 10.1016/S0006-3495(91)82054-9
   Vlassiouk I, 2007, NANO LETT, V7, P552, DOI 10.1021/nl062924b
   Wu J, 2012, NAT NANOTECHNOL, V7, P133, DOI [10.1038/nnano.2011.240, 10.1038/NNANO.2011.240]
   Wu J, 2011, NANOSCALE, V3, P3321, DOI 10.1039/c1nr10303b
   Wu J, 2010, P NATL ACAD SCI USA, V107, P11698, DOI 10.1073/pnas.1004714107
   WUNDERLICH F, 1975, BIOCHEMISTRY-US, V14, P3730, DOI 10.1021/bi00688a002
NR 28
TC 11
Z9 11
U1 1
U2 35
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1359-7345
J9 CHEM COMMUN
JI Chem. Commun.
PY 2012
VL 48
IS 64
BP 7979
EP 7981
DI 10.1039/c2cc33355d
PG 3
WC Chemistry, Multidisciplinary
SC Chemistry
GA 974FF
UT WOS:000306415000024
PM 22773275
DA 2018-03-20
ER

PT J
AU Aubrey-Medendorp, C
   Swadley, MJ
   Li, TL
AF Aubrey-Medendorp, Clare
   Swadley, Matthew J.
   Li, Tonglei
TI The polymorphism of indomethacin: An analysis by density functional
   theory calculations
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE crystal packing; density functional theory; electronic calculation;
   Fukui function; indomethacin; polymorphism; quantum mechanics
ID CRYSTAL-STRUCTURE PREDICTION; STATIC DIPOLE POLARIZABILITY; GENERAL
   CHEMICAL-REACTIONS; ELECTROSTATIC FORCE THEORY; SMALL ORGANIC-MOLECULES;
   FUKUI FUNCTION; INTERACTING MOLECULES; GLOBAL SOFTNESS; BLIND TEST;
   REACTIVITY
AB Purpose. Indomethacin exhibits conformational polymorphism. Crystal structures of two polymorphs have been solved bearing different molecular conformations. Herein, the conformational variance in the crystals was examined by density functional theory (DFT) calculations in order to understand the mutual influence between electronic structures and crystal packing.
   Methods. Electronic structures of the two polymorphs and the single molecule of indomethacin were calculated with quantum mechanical methods. Electronic properties based upon conceptual density functional theory were thereby analyzed. A potential energy surface was generated with regard to the conformational flexibility, which was identified by the electronic analysis. Lattice energies of the two polymorphs were further calculated with an empirically augmented DFT method.
   Results. Electronic properties, including electronic and nuclear Fukui functions, provided a fundamental understanding of the energetic competition in the indomethacin molecule between delocalization of p-orbitals of two aromatic rings and steric repulsions. Two dihedral angles (the tau (1) and tau (2) in Fig. 1) were found playing a crucial role in affecting such competition and determining the variation of molecular conformations. The existing polymorphs, alpha- and gamma-forms, were located in local minima on the energy surface based on the two dihedral angles of their molecular conformations. Calculated lattice energies suggest the alpha-form is more stable than the gamma-form at the zero K.
   Conclusions. The polymorphism of indomethacin lies in various meta-stable conformations of the molecule that are results of different orientations between the two aromatic indole and phenyl rings. The analysis of electronic and nuclear Fukui functions permits the revelation of local energy barriers that determine the conformational diversity and, for the case of indomethacin, the conformational polymorphism.
C1 [Aubrey-Medendorp, Clare; Swadley, Matthew J.; Li, Tonglei] Univ Kentucky, Coll Pharm 514, Lexington, KY 40536 USA.
RP Li, TL (reprint author), Univ Kentucky, Coll Pharm 514, 725 Rose St, Lexington, KY 40536 USA.
EM tonglei@uky.edu
CR Anderson JSM, 2007, J CHEM THEORY COMPUT, V3, P358, DOI 10.1021/ct600164j
   Anderson JSM, 2007, J CHEM THEORY COMPUT, V3, P375, DOI 10.1021/ct6001658
   Ayers PW, 2007, FARADAY DISCUSS, V135, P161, DOI 10.1039/b606877d
   Ayers PW, 2006, J CHEM PHYS, V124, DOI 10.1063/1.2196882
   Ayers PW, 2000, THEOR CHEM ACC, V103, P353, DOI 10.1007/s002149900093
   Baekelandt BG, 1996, J CHEM PHYS, V105, P4664, DOI 10.1063/1.472329
   BERKOWITZ M, 1988, J CHEM PHYS, V88, P2554, DOI 10.1063/1.454034
   BERKOWITZ M, 1987, J AM CHEM SOC, V109, P4823, DOI 10.1021/ja00250a012
   Beyer T, 2001, CRYSTENGCOMM, DOI 10.1039/b108135g
   BONDI A, 1964, J PHYS CHEM-US, V68, P441, DOI 10.1021/j100785a001
   BORKA L, 1974, ACTA PHARM SUEC, V11, P295
   BUCKINGHAM AD, 1988, CHEM REV, V88, P963, DOI 10.1021/cr00088a008
   CHATTARAJ PK, 1991, J AM CHEM SOC, V113, P1855, DOI 10.1021/ja00005a073
   Chen XM, 2002, J AM CHEM SOC, V124, P15012, DOI 10.1021/ja017662o
   COHEN MH, 1994, J CHEM PHYS, V101, P8988, DOI 10.1063/1.468026
   Cox PJ, 2003, ACTA CRYSTALLOGR E, V59, pO986, DOI 10.1107/S160053680301290X
   Day GM, 2005, ACTA CRYSTALLOGR B, V61, P511, DOI 10.1107/S0108768105016563
   Doll K, 2001, INT J QUANTUM CHEM, V82, P1, DOI 10.1002/1097-461X(2001)82:1<1::AID-QUA1017>3.0.CO;2-W
   Feng SX, 2006, J CHEM THEORY COMPUT, V2, P149, DOI 10.1021/ct050189a
   Feng SX, 2005, J PHYS CHEM A, V109, P7258, DOI 10.1021/jp0519666
   Feynman RP, 1939, PHYS REV, V56, P340, DOI 10.1103/PhysRev.56.340
   GALDECKI Z, 1976, ROCZ CHEM, V50, P1139
   Geerlings P, 2003, CHEM REV, V103, P1793, DOI 10.1021/cr990029p
   HALGREN TA, 1992, J AM CHEM SOC, V114, P7827, DOI 10.1021/ja00046a032
   Hamdi N, 2004, J THERM ANAL CALORIM, V76, P985, DOI 10.1023/B:JTAN.0000032284.89029.06
   Hellmann H., 1937, EINFUHRUNG QUANTENCH
   KISTENMA.TJ, 1972, J AM CHEM SOC, V94, P1340, DOI 10.1021/ja00759a047
   Kohn W, 1996, J PHYS CHEM-US, V100, P12974, DOI 10.1021/jp960669l
   Legendre B, 2004, J THERM ANAL CALORIM, V76, P255, DOI 10.1023/B:JTAN.0000027824.55280.37
   Li TL, 2005, PHARM RES-DORDR, V22, P1964, DOI 10.1007/s11095-005-7392-8
   Li TL, 2006, PHARM RES-DORDR, V23, P2326, DOI 10.1007/s11095-006-9006-5
   Lommerse JPM, 2000, ACTA CRYSTALLOGR B, V56, P697, DOI 10.1107/S0108768100004584
   Motherwell WDS, 2002, ACTA CRYSTALLOGR B, V58, P647, DOI 10.1107/S0108768102005669
   NAKATSUJI H, 1973, J AM CHEM SOC, V95, P345, DOI 10.1021/ja00783a008
   NAKATSUJI H, 1973, J AM CHEM SOC, V95, P354, DOI 10.1021/ja00783a009
   PARR RG, 1983, J AM CHEM SOC, V105, P7512, DOI 10.1021/ja00364a005
   PARR RG, 1984, J AM CHEM SOC, V106, P4049, DOI 10.1021/ja00326a036
   PEARSON RG, 1963, J AM CHEM SOC, V85, P3533, DOI 10.1021/ja00905a001
   PEARSON RG, 1966, SCIENCE, V151, P172, DOI 10.1126/science.151.3707.172
   Simon-Manso Y, 1998, J PHYS CHEM A, V102, P2029, DOI 10.1021/jp972733k
   VELA A, 1990, J AM CHEM SOC, V112, P1490, DOI 10.1021/ja00160a029
   YANG W, 1984, J CHEM PHYS, V81, P2862, DOI 10.1063/1.447964
   YANG WT, 1985, P NATL ACAD SCI USA, V82, P6723, DOI 10.1073/pnas.82.20.6723
   YOSHIOKA M, 1994, J PHARM SCI, V83, P1700, DOI 10.1002/jps.2600831211
NR 44
TC 9
Z9 10
U1 3
U2 24
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
J9 PHARM RES
JI Pharm. Res.
PD APR
PY 2008
VL 25
IS 4
BP 953
EP 959
DI 10.1007/s11095-007-9346-9
PG 7
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 285AE
UT WOS:000254748900024
PM 17541732
DA 2018-03-20
ER

PT J
AU Liu, X
   Gillespie, M
   Ozel, AD
   Dikici, E
   Daunert, S
   Bachas, LG
AF Liu, Xin
   Gillespie, Megan
   Ozel, Ayca Demirel
   Dikici, Emre
   Daunert, Sylvia
   Bachas, Leonidas G.
TI Electrochemical properties and temperature dependence of a recombinant
   laccase from Thermus thermophilus
SO ANALYTICAL AND BIOANALYTICAL CHEMISTRY
LA English
DT Article
DE Thermus thermophilus; Laccase; Electrochemistry; Thermophilic; Enzyme
ID RIGIDOPORUS-LIGNOSUS; PLEUROTUS-OSTREATUS; CIRCULAR-DICHROISM; OXYGEN
   REDUCTION; FUNGAL LACCASES; PROTEINS; ENZYME; ELECTRODES; MEDIATORS
AB The electrochemical properties of a laccase from Thermus thermophilus HB27 (Tth-laccase) were characterized. The gene encoding the laccase was cloned and overexpressed in Escherichia coli. One-step purification of the corresponding apo-enzyme was achieved by nickel-affinity chromatography. Copper was incorporated into the apo-laccase as the cofactor to yield the holo-enzyme. The temperature-dependent catalytic activity of the laccase was investigated by spectrophotometric as well as electrochemical methods. Specifically, the catalytic properties of the enzyme were characterized by employing a photometric assay based on the oxidation of the substrate 2,2-azino-bis-(3-ethylbenzthiazoline-6-sulfonate) (ABTS). The electroactive substrate ABTS can be also monitored by cyclic voltammetry, thus allowing for determination of the enzymatic activity electrochemically. It was found that the recombinant laccase exhibited higher activity as the temperature increased up to 65 A degrees C. Spectroscopic studies of Tth-laccase based on circular dichroism and fluorescence measurements are consistent with a thermally stable secondary structure of the protein.
C1 [Liu, Xin; Gillespie, Megan; Ozel, Ayca Demirel; Dikici, Emre; Daunert, Sylvia; Bachas, Leonidas G.] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
   [Gillespie, Megan; Ozel, Ayca Demirel; Bachas, Leonidas G.] Univ Miami, Dept Chem, Coral Gables, FL 33146 USA.
   [Liu, Xin; Dikici, Emre; Daunert, Sylvia] Univ Miami, Miller Sch Med, Dept Biochem & Mol Biol, Miami, FL 33136 USA.
RP Bachas, LG (reprint author), Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
EM bachas@miami.edu
RI Bachas, Leonidas/G-2479-2015
OI Bachas, Leonidas/0000-0002-3308-6264
FU National Science Foundation; College of Arts and Sciences of the
   University of Kentucky; The Scientific and Technological Research
   Council of Turkey (TUBITAK)
FX This work was supported in part by a National Science Foundation-NIRT
   grant and incentive funds from the College of Arts and Sciences of the
   University of Kentucky. MG thanks the National Science Foundation for a
   NSF-IGERT Predoctoral Fellowship. ADO was funded by a Postdoctoral
   scholarship from The Scientific and Technological Research Council of
   Turkey (TUBITAK).
CR Barriere F, 2004, ELECTROCHEM COMMUN, V6, P237, DOI 10.1016/j.elecom.2003.12.006
   Barton SC, 2002, BIOSENS BIOELECTRON, V17, P1071, DOI 10.1016/S0956-5663(02)00100-8
   Bonomo RP, 2001, J INORG BIOCHEM, V83, P67, DOI 10.1016/S0162-0134(00)00130-6
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999
   Chemykh A, 2008, J APPL MICROBIOL, V105, P2065
   CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027
   Ducros V, 1998, NAT STRUCT BIOL, V5, P310, DOI 10.1038/nsb0498-310
   Garavaglia S, 2004, J MOL BIOL, V342, P1519, DOI 10.1016/j.jmb.2004.07.100
   Henne A, 2004, NAT BIOTECHNOL, V22, P547, DOI 10.1038/nbt956
   Iyer RB, 2002, EXTREMOPHILES, V6, P283, DOI 10.1007/s00792-001-0255-2
   Kelly SM, 2005, BBA-PROTEINS PROTEOM, V1751, P119, DOI 10.1016/j.bbapap.2005.06.005
   Li J, 2002, ANAL CHEM, V74, P3336, DOI 10.1021/ac015653s
   Li X, 2007, BIOCHEM BIOPH RES CO, V354, P21, DOI 10.1016/j.bbrc.2006.12.116
   Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036
   Mishra A, 2009, BIOCHEM ENG J, V46, P252, DOI 10.1016/j.bej.2009.02.016
   Nazaruk E, 2007, J BIOL INORG CHEM, V12, P335, DOI 10.1007/s00775-006-0193-7
   Papinutti L, 2008, BIORESOURCE TECHNOL, V99, P419, DOI 10.1016/j.biortech.2006.11.061
   Quaratino D, 2007, ANTON LEEUW INT J G, V91, P57, DOI 10.1007/s10482-006-9096-4
   Solano F, 2001, FEMS MICROBIOL LETT, V204, P175, DOI 10.1016/S0378-1097(01)00400-1
   Solomon EI, 1996, CHEM REV, V96, P2563, DOI 10.1021/cr950046o
   Stolarczyk K, 2008, ELECTROCHIM ACTA, V53, P3983, DOI 10.1016/j.electacta.2007.09.053
   THURSTON CF, 1994, MICROBIOL-SGM, V140, P19, DOI 10.1099/13500872-140-1-19
   Uthandi S, 2010, APPL ENVIRON MICROB, V76, P733, DOI 10.1128/AEM.01757-09
   VISHWANATH S, 1995, J MEMBRANE SCI, V108, P1, DOI 10.1016/0376-7388(95)00135-9
   ZIYAZAKI K, 2005, EXTREMOPHILES, V9, P415
NR 25
TC 10
Z9 12
U1 2
U2 30
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1618-2642
J9 ANAL BIOANAL CHEM
JI Anal. Bioanal. Chem.
PD JAN
PY 2011
VL 399
IS 1
BP 361
EP 366
DI 10.1007/s00216-010-4345-9
PG 6
WC Biochemical Research Methods; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA 700YJ
UT WOS:000285781200034
PM 21076916
DA 2018-03-20
ER

PT J
AU Aubrey-Medendorp, C
   Parkin, S
   Li, TL
AF Aubrey-Medendorp, Clare
   Parkin, Sean
   Li, Tonglei
TI The confusion of indexing aspirin crystals
SO JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Letter
DE wettability; contact angle; crystal packing; indexing; aspirin; X-ray
   diffraction
ID POLARIZING MICROSCOPE; POLYMORPHISM; BEHAVIOR; DRUGS; ACID
AB Much of the existing literature dealing with crystalline aspirin is vague or ambiguous with regard to indexing of the crystal faces. The inconsistency with which the indices of the dominant faces have been assigned leads to confusion in analysis of surface properties. To clarify this, we have conducted crystal growth experiments on aspirin, and indexed the crystal faces with X-ray diffraction (XRD), paying special attention to the placement of symmetry elements. The space group was confirmed as P2(1)/c, and the dominant face was (100). Contact angle measurements made on the two major faces of aspirin indicate the (100) face to be more hydrophobic than the (001) face, likely due to the acetyloxy moiety, not the carboxyl, exposed on the (100). (C) 2007 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 97:1361-1367, 2008.
C1 [Aubrey-Medendorp, Clare; Li, Tonglei] Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
   [Parkin, Sean] Univ Kentucky, Dept Chem, Lexington, KY 40536 USA.
RP Li, TL (reprint author), Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
EM tonglei@uky.edu
RI Parkin, Sean/E-7044-2011
CR Bond AD, 2007, ANGEW CHEM INT EDIT, V46, P618, DOI 10.1002/anie.200603373
   Bond AD, 2007, ANGEW CHEM INT EDIT, V46, P615, DOI 10.1002/anie.200602378
   Byrn S. R., 1999, SOLID STATE CHEM DRU
   Hammond RB, 2006, CRYST GROWTH DES, V6, P1324, DOI 10.1021/cg0505618
   Harrison A., 2002, FARADAY DISCUSS, V122, P363
   Kiang YH, 2004, INT J PHARM, V280, P17, DOI 10.1016/j.ijpharm.2004.04.022
   KIM Y, 1985, CHEM PHARM BULL, V33, P2641
   Kozu S., 1935, Proceedings of the Imperial Academy of Tokyo, V11, P381
   Li TL, 2005, J AM CHEM SOC, V127, P1364, DOI 10.1021/ja0476009
   MACKAY S, 1999, COMPREHENSIVE CRYSTA
   Meenan P, 1997, ACS SYM SER, V667, P2
   NIINI R, 1931, Z KRISTALLOGR, V79, P532
   Nitta I., 1937, SCI PAP I PHYS CHEM, V31, P125
   Nonius, 1997, KAPPACCD SERV SOFTW
   OTWINOWSKI Z, 1998, METHOD ENZYMOL, V276, P302
   SHELDRICK GM, 1990, SHELXTL PC INTEGRATE
   Suryanarayanan R, 2001, ADV DRUG DELIVER REV, V48, P1, DOI 10.1016/S0169-409X(01)00096-5
   Vippagunta SR, 2001, ADV DRUG DELIVER REV, V48, P3, DOI 10.1016/S0169-409X(01)00097-7
   Vishweshwar P, 2005, J AM CHEM SOC, V127, P16802, DOI 10.1021/ja056455b
   WATANABE A, 1982, CHEM PHARM BULL, V30, P2958
   WATANABE A, 1980, CHEM PHARM BULL, V28, P372
   Wheatley P. J., 1964, J CHEM SOC, P6036, DOI DOI 10.1039/JR9640006036
   Wilson CC, 2002, NEW J CHEM, V26, P1733, DOI 10.1039/b203775k
NR 23
TC 18
Z9 18
U1 1
U2 17
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0022-3549
J9 J PHARM SCI-US
JI J. Pharm. Sci.
PD APR
PY 2008
VL 97
IS 4
BP 1361
EP 1367
DI 10.1002/jps.21055
PG 7
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology &
   Pharmacy
SC Pharmacology & Pharmacy; Chemistry
GA 280LN
UT WOS:000254428400003
PM 17879379
DA 2018-03-20
ER

PT J
AU Borgohain, R
   Selegue, JP
   Cheng, YT
AF Borgohain, Rituraj
   Selegue, John P.
   Cheng, Y-T.
TI Ternary composites of delaminated-MnO2/PDDA/functionalized-CNOs for
   high-capacity supercapacitor electrodes
SO JOURNAL OF MATERIALS CHEMISTRY A
LA English
DT Article
ID PERFORMANCE ELECTROCHEMICAL CAPACITORS; CARBON NANO-ONIONS;
   MANGANESE-DIOXIDE; INTERCALATION; GRAPHENE; OXIDE; IONS; MNO2
AB Composite materials are synthesized by combining chemically functionalized carbon nano-onions (ONCNOs), a polyelectrolyte (polydiallyldimethylammonium chloride, PDDA) and delaminated layered-manganese oxides (MnO2). While carbon nano-onions are among the least studied carbon allotropes to date, extensive research has been reported on various types of crystalline and amorphous MnO2 to overcome their limitations for energy storage applications. We have developed a synergistically tuned synthesis of MnO2-based composites with ONCNOs via a sequential chemical deposition technique to achieve high-capacity supercapacitor electrodes with long-term stability. A composite with 55 wt% MnO2 on PDDA modified ONCNOs exhibits a high-capacitance of 218.6 F g(-1) in a symmetric two-electrode cell containing an aqueous electrolyte (1.0 M Na2SO4) with a high-energy density of 6.14 W h kg(-1). Analytical techniques, such as high-resolution transmission electron microscopy, X-ray diffraction, atomic force microscopy, thermogravimetric analysis, and electrochemical measurements (cyclic voltammetry, galvanostatic charge-discharge, and impedance), are employed to fully characterize the synthesized materials and to understand their electrochemical behavior. Emphasis is also given to understand the phenomenon that promotes higher capacitance and long-term stability of such composites based on MnO2 redox chemistry.
C1 [Borgohain, Rituraj; Selegue, John P.] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
   [Cheng, Y-T.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Borgohain, R (reprint author), Univ Wyoming, EORI, Sch Energy Dept 4068, 1000 E Univ Ave, Laramie, WY 82071 USA.
EM rborgoha@uwyo.edu
RI Cheng, Yang-Tse/B-5424-2012
OI Cheng, Yang-Tse/0000-0003-0737-9212
FU NSF (CMMI) [1000726]; NSF (Center for Advanced Materials) [EPS-0814194]
FX We are grateful for financial support from NSF (CMMI #1000726) and NSF
   (Center for Advanced Materials, Grant EPS-0814194, JPS). We thank Dr
   Lingbo Lu for the AFM Analysis and Dr Mahendra Shreeramoju for the HRTEM
   imaging of the NCNOs.
CR The An H., 2013, ADV NAT SCI NANOSCI, V4
   Borgohain R, 2014, CARBON, V66, P272, DOI 10.1016/j.carbon.2013.09.001
   Borgohain R, 2012, J PHYS CHEM C, V116, P15068, DOI 10.1021/jp301642s
   Fischer AE, 2007, NANO LETT, V7, P281, DOI 10.1021/nl062263i
   Gao QM, 2001, CHEM MATER, V13, P778, DOI 10.1021/cm000426c
   Hassan S, 2014, J POWER SOURCES, V249, P21, DOI 10.1016/j.jpowsour.2013.10.097
   Jiang RY, 2013, ELECTROCHIM ACTA, V104, P198, DOI 10.1016/j.electacta.2013.04.125
   Khomenko V, 2006, J POWER SOURCES, V153, P183, DOI 10.1016/j.jpowsour.2005.03.210
   Liu JW, 2010, CHEM MATER, V22, P5022, DOI 10.1021/cm101591p
   Liu X., 2013, J NANOMATER, V2013, P7, DOI DOI 10.1115/DETC2013-12904
   Liu Z, 2000, LANGMUIR, V16, P4154, DOI 10.1021/la9913755
   Lv P, 2012, ELECTROCHIM ACTA, V78, P515, DOI 10.1016/j.electacta.2012.06.085
   Ma Y, 1999, CHEM MATER, V11, P1972, DOI 10.1021/cm980399e
   Park S, 2009, J ELECTROCHEM SOC, V156, pA921, DOI 10.1149/1.3223964
   Pech D, 2010, NAT NANOTECHNOL, V5, P651, DOI [10.1038/nnano.2010.162, 10.1038/NNANO.2010.162]
   Plonska-Brzezinska ME, 2013, J MATER CHEM A, V1, P13703, DOI 10.1039/c3ta12628e
   Plonska-Brzezinska ME, 2010, ELECTROCHEM SOLID ST, V13, pK35, DOI 10.1149/1.3299252
   Raymundo-Pinero E, 2005, J ELECTROCHEM SOC, V152, pA229, DOI 10.1149/1.1834913
   Sivakkumar SR, 2007, ELECTROCHIM ACTA, V52, P7377, DOI 10.1016/j.electacta.2007.06.023
   Toupin M, 2002, CHEM MATER, V14, P3946, DOI 10.1021/cm020408q
   Wang CC, 2014, CHEM-EUR J, V20, P517, DOI 10.1002/chem.201303483
   Wang SY, 2011, J AM CHEM SOC, V133, P5182, DOI 10.1021/ja1112904
   Wang Y, 2012, J MATER CHEM, V22, P17584, DOI 10.1039/c2jm33558a
   Wei WF, 2011, CHEM SOC REV, V40, P1697, DOI 10.1039/c0cs00127a
   Zhao X, 2012, ACS NANO, V6, P5404, DOI 10.1021/nn3012916
   [Anonymous], 1957, Low Voltage Electrolytic Capacitor, Patent No. [2800616, US Patent 2800616]
NR 26
TC 8
Z9 8
U1 2
U2 43
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2050-7488
EI 2050-7496
J9 J MATER CHEM A
JI J. Mater. Chem. A
PY 2014
VL 2
IS 47
BP 20367
EP 20373
DI 10.1039/c4ta04439h
PG 7
WC Chemistry, Physical; Energy & Fuels; Materials Science,
   Multidisciplinary
SC Chemistry; Energy & Fuels; Materials Science
GA AT6RR
UT WOS:000345066900053
DA 2018-03-19
ER

PT J
AU Ramineni, SK
   Dziubla, TD
   Cunningham, LL
   Puleo, DA
AF Ramineni, Sandeep K.
   Dziubla, Thomas D.
   Cunningham, Larry L., Jr.
   Puleo, David A.
TI Local delivery of imiquimod in hamsters using mucoadhesive films and
   their residence time in human patients
SO ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMA; ORAL-CANCER RESEARCH; DRUG-DELIVERY;
   INTRAEPITHELIAL NEOPLASIA; EPITHELIAL DYSPLASIA; TOPICAL IMIQUIMOD;
   BUCCAL MUCOSA; MODEL; CARCINOGENESIS; PERMEABILITY
AB Objective. To investigate the ability of mucoadhesive films to locally deliver an immune response modifier (imiquimod) to oral mucosa.
   Study Design. After determining the residence time of films in hamster cheek pouches, drug-loaded films and commercially available imiquimod cream were tested for localization of drug in mucosal tissue. The residence time of drug-free films at different locations was also tested in humans.
   Results. Mucoadhesive films delivered imiquimod to the buccal mucosa with no measureable amounts in blood. In contrast, although the cream formulation resulted in higher tissue levels, it also led to significant systemic distribution of imiquimod. In humans, the films resided on tissue for up to 4 hours, increasing in the order of tongue < cheek < gingiva.
   Conclusion. Preclinical findings of localized imiquimod delivery in animals and residence in humans support future investigations of the mucoadhesive system in controlled clinical trials for treating oral precancerous lesions.
C1 [Ramineni, Sandeep K.; Puleo, David A.] Univ Kentucky, Dept Biomed Engn, Lexington, KY 40506 USA.
   [Dziubla, Thomas D.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Cunningham, Larry L., Jr.] Univ Kentucky, Coll Dent, Lexington, KY 40506 USA.
RP Puleo, DA (reprint author), Univ Kentucky, Dept Biomed Engn, 522A,Robot & Mfg Bldg, Lexington, KY 40506 USA.
EM puleo@uky.edu
CR [Anonymous], 2007, ALD PACK INS
   Allam JP, 2008, BRIT J DERMATOL, V158, P644, DOI 10.1111/j.1365-2133.2007.08374.x
   American Cancer Society, 2014, CANC FACTS FIG 2014
   Andrejevic S, 1996, INT J EXP PATHOL, V77, P7, DOI 10.1046/j.1365-2613.1996.956095.x
   Andrews GP, 2009, EUR J PHARM BIOPHARM, V71, P505, DOI 10.1016/j.ejpb.2008.09.028
   Burgalassi S, 1996, INT J PHARM, V133, P1, DOI 10.1016/0378-5173(95)04392-6
   Chollet JL, 1999, PHARM DEV TECHNOL, V4, P35, DOI 10.1081/PDT-100101337
   Cui ZR, 2002, PHARM RES-DORDR, V19, P947, DOI 10.1023/A:1016454003450
   de CMJS, 2013, LASER MED SCI, V28, P1017
   Dwivedi PP, 2009, MED MYCOL, V47, P157, DOI 10.1080/13693780802165797
   GALEY WR, 1976, J INVEST DERMATOL, V67, P713, DOI 10.1111/1523-1747.ep12598596
   Geisse J, 2004, J AM ACAD DERMATOL, V50, P722, DOI 10.1016/j.jaad.2003.11.066
   Gkoulioni V, 2010, ANTICANCER RES, V30, P2891
   Imbertson LM, 1998, J INVEST DERMATOL, V110, P734, DOI 10.1046/j.1523-1747.1998.00174.x
   Jay S, 2002, J PHARM SCI, V91, P2016, DOI 10.1002/jps.10198
   Kuffer R, 2002, ORAL ONCOL, V38, P125, DOI 10.1016/S1368-8375(01)00050-1
   Kulkarni U, 2009, J PHARM SCI-US, V98, P471, DOI 10.1002/jps.21436
   Lara Renata Nemetala, 2007, Oral Health Prev Dent, V5, P63
   Jr Mayeaux EJ, 2009, FEMALE PATIENT S1, V34, pS1
   Mognetti B, 2006, ORAL ONCOL, V42, P448, DOI 10.1016/j.oraloncology.2005.07.014
   Nagy A, 2001, DIABETES, V50, P2100, DOI 10.2337/diabetes.50.9.2100
   Nauta JM, 1996, HEAD NECK-J SCI SPEC, V18, P441, DOI 10.1002/(SICI)1097-0347(199609/10)18:5<441::AID-HED7>3.0.CO;2-5
   Park JS, 2003, ARCH PHARM RES, V26, P659, DOI 10.1007/BF02976717
   Perioli L, 2004, J CONTROL RELEASE, V99, P73, DOI 10.1016/j.jconrel.2004.06.005
   Ramineni SK, 2013, BIOMATER SCI-UK, V1, P753, DOI 10.1039/c3bm60064e
   Ramineni SK, 2013, J PHARM SCI-US, V102, P593, DOI 10.1002/jps.23386
   Ryu JB, 2009, CLIN MED INSIGHTS-TH, V1, P1557
   Schon MP, 2007, BRIT J DERMATOL, V157, P8, DOI 10.1111/j.1365-2133.2007.08265.x
   Sciubba J J, 2001, Am J Clin Dermatol, V2, P239, DOI 10.2165/00128071-200102040-00005
   Shklar G, 1999, J DENT RES, V78, P1768
   Siddavaram N, 2009, ORAL ONCOL, V45, pe31
   Sigurdsson HH, 2013, INT J PHARMACEUT, V453, P56, DOI 10.1016/j.ijpharm.2013.05.040
   Sohi H, 2010, DRUG DEV IND PHARM, V36, P254, DOI [10.3109/03639040903117348, 10.1080/03639040903117348]
   Spieth K, 2006, LANCET ONCOL, V7, P1036, DOI 10.1016/S1470-2045(06)70979-2
   van Seters M, 2008, NEW ENGL J MED, V358, P1465, DOI 10.1056/NEJMoa072685
   Yang Y, 2006, CARCINOGENESIS, V27, P578, DOI 10.1093/carcin/bgi234
NR 36
TC 3
Z9 3
U1 2
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 2212-4403
EI 1528-395X
J9 OR SURG OR MED OR PA
JI Oral Surg. Oral Med. Oral Pathol. Oral Radiol.
PD DEC
PY 2014
VL 118
IS 6
BP 667
EP 675
DI 10.1016/j.oooo.2014.08.015
PG 9
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA AX9WB
UT WOS:000347248900016
PM 25457885
DA 2018-03-20
ER

PT J
AU Pitsawong, W
   Haynes, CA
   Koder, RL
   Rodgers, DW
   Miller, AF
AF Pitsawong, Warintra
   Haynes, Chad A.
   Koder, Ronald, Jr.
   Rodgers, David W.
   Miller, Anne-Frances
TI Mechanism-Informed Refinement Reveals Altered Substrate-Binding Mode for
   Catalytically Competent Nitroreductase
SO STRUCTURE
LA English
DT Article
ID ESCHERICHIA-COLI NITROREDUCTASE; PENTAERYTHRITOL TETRANITRATE REDUCTASE;
   AMINO-ACID SUBSTITUTION; DIFFERENT REDOX STATES; CRYSTAL-STRUCTURE;
   CLOACAE NITROREDUCTASE; MORPHINONE REDUCTASE; FLAVIN REDUCTASE; HYDRIDE
   TRANSFER; VIBRIO-FISCHERI
AB Nitroreductase (NR) from Enterobacter cloacae reduces diverse nitroaromatics including herbicides, explosives, and prodrugs, and holds promise for bioremediation, prodrug activation, and enzyme-assisted synthesis. We solved crystal structures of NR complexes with bound substrate or analog for each of its two half-reactions. We complemented these with kinetic isotope effect (KIE) measurements elucidating H-transfer steps essential to each half-reaction. KIEs indicate hydride transfer from NADH to the flavin consistent with our structure of NR with the NADH analog nicotinic acid adenine dinucleotide (NAAD). The KIE on reduction of p-nitrobenzoic acid (p-NBA) also indicates hydride transfer, and requires revision of prior computational mechanisms. Our mechanistic information provided a structural restraint for the orientation of bound substrate, placing the nitro group closer to the flavin N5 in the pocket that binds the amide of NADH. KIEs show that solvent provides a proton, enabling accommodation of different nitro group placements, consistent with the broad repertoire of NR.
C1 [Pitsawong, Warintra; Koder, Ronald L., Jr.; Miller, Anne-Frances] Univ Kentucky, Dept Chem, 505 Rose St, Lexington, KY 40506 USA.
   [Haynes, Chad A.; Rodgers, David W.; Miller, Anne-Frances] Univ Kentucky, Dept Mol & Cellular Biochem, 741 South Limestone St, Lexington, KY 40536 USA.
   [Haynes, Chad A.; Rodgers, David W.; Miller, Anne-Frances] Univ Kentucky, Ctr Struct Biol, 741 South Limestone St, Lexington, KY 40536 USA.
   [Pitsawong, Warintra] Brandeis Univ, Dept Biochem, 415 South St, Waltham, MA 02453 USA.
   [Haynes, Chad A.] Booz Allen Hamilton, Washington, DC 20024 USA.
   [Koder, Ronald L., Jr.] CUNY City Coll, Dept Phys, 160 Convent Ave, New York, NY 10031 USA.
RP Miller, AF (reprint author), Univ Kentucky, Dept Chem, 505 Rose St, Lexington, KY 40506 USA.; Rodgers, DW; Miller, AF (reprint author), Univ Kentucky, Dept Mol & Cellular Biochem, 741 South Limestone St, Lexington, KY 40536 USA.
EM david.rodgers@uky.edu; afmill3r2@gmail.com
FU NSF I/UCRC [0969003]; University of Kentucky; NIH [NS38041, GM110787];
   NSF [MCB9904886]; NSF KY EPSCoR [IIA-1355438]
FX A.F.M. and W.P. acknowledge invaluable discussions with D. Ballou and A.
   Kohen, and support from NSF I/UCRC grant 0969003 to the Center for
   Pharmaceutical Development. A.F.M. recognizes WOCM for guidance. W.P.
   acknowledges the University of Kentucky for RCTF fellowship support.
   D.R. acknowledges support from NIH grants NS38041 and GM110787, and NSF
   grant MCB9904886. A.F.M. and D.R. acknowledge support from NSF KY EPSCoR
   grant IIA-1355438.
CR Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925
   Barna T, 2002, J BIOL CHEM, V277, P30976, DOI 10.1074/jbc.M202846200
   Barna TM, 2001, J MOL BIOL, V310, P433, DOI 10.1006/jmbi.2001.4779
   Basran J, 2003, J BIOL CHEM, V278, P43973, DOI 10.1074/jbc.M305983200
   BELASCO JG, 1983, J AM CHEM SOC, V105, P2475, DOI 10.1021/ja00346a062
   Berrisford JM, 2009, J BIOL CHEM, V284, P29773, DOI 10.1074/jbc.M109.032144
   Birrell JA, 2013, BIOCHEMISTRY-US, V52, P4048, DOI 10.1021/bi3016873
   Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254
   BRYANT C, 1991, J BIOL CHEM, V266, P4126
   Christofferson A, 2009, BIOCHEM SOC T, V37, P413, DOI 10.1042/BST0370413
   DeLano WL, 2002, PYMOL MOL GRAPHICS S
   Deng Z, 1999, NAT STRUCT BIOL, V6, P847
   Fagan RL, 2010, COMPREHENSIVE NATURAL PRODUCTS II: CHEMISTRY AND BIOLOGY, VOL 7: COFACTORS, P37
   Fraaije MW, 2000, TRENDS BIOCHEM SCI, V25, P126, DOI 10.1016/S0968-0004(99)01533-9
   Gannavaram S, 2013, BIOCHEMISTRY-US, V52, P1221, DOI 10.1021/bi3016235
   Gherasim C, 2015, J BIOL CHEM, V290, P11393, DOI 10.1074/jbc.M115.637132
   GLASOE PK, 1960, J PHYS CHEM-US, V64, P188, DOI 10.1021/j100830a521
   Grove JI, 2003, CANCER RES, V63, P5532
   Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505
   Guillen H, 2009, J AGR FOOD CHEM, V57, P10457, DOI 10.1021/jf9024135
   Haynes CA, 2002, J BIOL CHEM, V277, P11513, DOI 10.1074/jbc.M111334200
   HECHT HJ, 1995, NAT STRUCT BIOL, V2, P1109, DOI 10.1038/nsb1295-1109
   Isayev O, 2012, PROTEINS, V80, P2728, DOI 10.1002/prot.24157
   Johansson E, 2003, J MED CHEM, V46, P4009, DOI 10.1021/jm030843b
   Kobori T, 2001, J BIOL CHEM, V276, P2816, DOI 10.1074/jbc.M002617200
   Koder RL, 2002, BIOCHEMISTRY-US, V41, P14197, DOI 10.1021/bi025805t
   Koder RL, 1998, PROTEIN EXPRES PURIF, V13, P53, DOI 10.1006/prep.1997.0866
   Koder Jr R. L., 1998, BIOCHIM BIOPHYS ACTA, V1387, P394
   Koike H, 1998, J MOL BIOL, V280, P259, DOI 10.1006/jmbi.1998.1871
   Lovering AL, 2001, J MOL BIOL, V309, P203, DOI 10.1006/jmbi.2001.4653
   Massey V, 1980, BIOCHEM SOC T, V8, P246, DOI 10.1042/bst0080246
   McGaughey GB, 1998, J BIOL CHEM, V273, P15458, DOI 10.1074/jbc.273.25.15458
   Meah Y, 2000, P NATL ACAD SCI USA, V97, P10733, DOI 10.1073/pnas.190345597
   Mesecar AD, 1997, SCIENCE, V277, P202, DOI 10.1126/science.277.5323.202
   Nijvipakul S, 2010, BIOCHEMISTRY-US, V49, P9241, DOI 10.1021/bi1009985
   Nishino S, 2007, J PHYS CHEM A, V111, P7041, DOI 10.1021/jp0717600
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Page CC, 1999, NATURE, V402, P47
   PAI EF, 1988, BIOCHEMISTRY-US, V27, P4465, DOI 10.1021/bi00412a038
   Pal D, 2009, ANTIMICROB AGENTS CH, V53, P458, DOI 10.1128/AAC.00909-08
   Parkinson GN, 2000, J MED CHEM, V43, P3624, DOI 10.1021/jm000159m
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pitsawong W, 2014, J BIOL CHEM, V289, P15203, DOI 10.1074/jbc.M113.547117
   Pudney CR, 2009, FEBS J, V276, P4780, DOI 10.1111/j.1742-4658.2009.07179.x
   Race PR, 2007, J MOL BIOL, V368, P481, DOI 10.1016/j.jmb.2007.02.012
   Race PR, 2005, J BIOL CHEM, V280, P13256, DOI 10.1074/jbc.M409652200
   Rodgers DW, 1997, METHOD ENZYMOL, V276, P183, DOI 10.1016/S0076-6879(97)76059-2
   Roston D, 2013, MOLECULES, V18, P5543, DOI 10.3390/molecules18055543
   SCHOPFER LM, 1991, FLAVINS AND FLAVOPROTEINS 1990, P399
   Shen AL, 1999, J BIOL CHEM, V274, P5391, DOI 10.1074/jbc.274.9.5391
   Tanner JJ, 1996, BIOCHEMISTRY-US, V35, P13531, DOI 10.1021/bi961400v
   Tanner JJ, 1999, PROTEIN SCI, V8, P1725, DOI 10.1110/ps.8.9.1725
   Thomas SR, 2009, J BIOL CHEM, V284, P19659, DOI 10.1074/jbc.M109.013458
   WESTHEIMER FH, 1961, CHEM REV, V61, P265, DOI 10.1021/cr60211a004
   Williams EM, 2015, BIOCHEM J, V471, P131, DOI 10.1042/BJ20150650
   Yu TY, 2012, PROTEIN SCI, V21, P839, DOI 10.1002/pro.2068
   Zenno SH, 1996, J BACTERIOL, V178, P4731, DOI 10.1128/jb.178.15.4731-4733.1996
   Zhang P., 2007, THESIS
NR 58
TC 0
Z9 0
U1 10
U2 13
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0969-2126
EI 1878-4186
J9 STRUCTURE
JI Structure
PD JUL 5
PY 2017
VL 25
IS 7
BP 978
EP +
DI 10.1016/j.str.2017.05.002
PG 14
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA FB2NU
UT WOS:000405981300004
PM 28578873
DA 2018-03-20
ER

PT J
AU Satarkar, NS
   Hilt, JZ
AF Satarkar, Nitin S.
   Hilt, J. Zach
TI Hydrogel nanocomposites as remote-controlled biomaterials
SO ACTA BIOMATERIALIA
LA English
DT Article
DE hydrogel; nanocomposite; remote control; drug delivery; magnetic
ID MODULATED DRUG-DELIVERY; CONTROLLED-RELEASE; MAGNETIC-FIELDS; POLYMER
   GELS; HYPERTHERMIA; SYSTEMS
AB Nanocomposite hydrogels are a new class of intelligent materials which have recently attracted interest as biomaterials. In this study, magnetic nanocomposites of temperature-sensitive hydrogels have been developed and demonstrated to be responsive to alternating magnetic fields. Nanocomposites were synthesized by incorporation of superparamagnetic Fe3O4 particles in negative temperature-sensitive poly(N-isopropylacrylamide) hydrogels. The systems were characterized for temperature-responsive swelling, remote heating on application of an alternating magnetic field and remote-controlled drug delivery applications. The rise in temperature in external alternating magnetic field depends on the Fe3O4 particle loading of the system. Preliminary studies on remote-controlled drug release showed reduced release in the presence of an alternating magnetic field. (C) 2007 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Satarkar, Nitin S.; Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Hilt, JZ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM hilt@engr.uky.edu
CR Babincova M, 2001, J MAGN MAGN MATER, V225, P109, DOI 10.1016/S0304-8853(00)01237-3
   Bashir R, 2002, APPL PHYS LETT, V81, P3091, DOI 10.1063/1.1514825
   Beebe DJ, 2000, NATURE, V404, P588, DOI 10.1038/35007047
   EDELMAN ER, 1985, J BIOMED MATER RES, V19, P67, DOI 10.1002/jbm.820190107
   Frimpong R.A., 2006, J BIOMED MATER RES A, V80, P1
   Hergt R, 1998, IEEE T MAGN, V34, P3745, DOI 10.1109/20.718537
   Hilt JZ, 2006, CHEM MATER, V18, P5869, DOI 10.1021/cm061343k
   Hilt JZ, 2003, BIOMED MICRODEVICES, V5, P177, DOI 10.1023/A:1025786023595
   HIROTSU S, 1987, J CHEM PHYS, V87, P1392, DOI 10.1063/1.453267
   Hoffman A. S., 2002, ADV DRUG DELIVERY RE, V43, P3, DOI DOI 10.1016/S0169-409X(01)00239-3
   HSIEH DST, 1981, P NATL ACAD SCI-BIOL, V78, P1863, DOI 10.1073/pnas.78.3.1863
   KOST J, 1985, J BIOMED MATER RES, V19, P935, DOI 10.1002/jbm.820190805
   KOST J, 1987, J BIOMED MATER RES, V21, P1367, DOI 10.1002/jbm.820211202
   Lao LL, 2004, J MATER SCI-MATER M, V15, P1061, DOI 10.1023/B:JMSM.0000046386.78633.e5
   Liu TY, 2006, LANGMUIR, V22, P5974, DOI 10.1021/la060371e
   Liu TY, 2006, J MAGN MAGN MATER, V304, pE397, DOI 10.1016/j.jmmm.2006.01.203
   LOWMAN AM, 2004, ENCY CONTROLLED DRUG
   Miyata T, 1999, NATURE, V399, P766, DOI 10.1038/21619
   Peppas N, 2004, BIOMATERIALS SCI INT
   Peppas NA, 2000, EUR J PHARM BIOPHARM, V50, P27, DOI 10.1016/S0939-6411(00)00090-4
   Peppas NA, 2006, ADV MATER, V18, P1345, DOI 10.1002/adma.200501612
   Sershen S, 2002, ADV DRUG DELIVER REV, V54, P1225, DOI 10.1016/S0169-409X(02)00090-X
   Sershen SR, 2000, J BIOMED MATER RES, V51, P293, DOI 10.1002/1097-4636(20000905)51:3<293::AID-JBM1>3.0.CO;2-T
   Sershen SR, 2005, ADV MATER, V17, P1366, DOI 10.1002/adma.200401239
   Wang XM, 2005, J MAGN MAGN MATER, V293, P334, DOI 10.1016/j.jmmm.2005.02.028
   Xulu PM, 2000, MACROMOLECULES, V33, P1716, DOI 10.1021/ma990967r
   YOSHIDA R, 1993, ADV DRUG DELIVER REV, V11, P85, DOI 10.1016/0169-409X(93)90028-3
   Zrinyi M, 1998, POLYM GELS NETW, V6, P441, DOI 10.1016/S0966-7822(98)00033-1
   Zrinyi M, 2000, COLLOID POLYM SCI, V278, P98, DOI 10.1007/s003960050017
NR 29
TC 118
Z9 124
U1 6
U2 72
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742-7061
J9 ACTA BIOMATER
JI Acta Biomater.
PD JAN
PY 2008
VL 4
IS 1
BP 11
EP 16
DI 10.1016/j.actbio.2007.07.009
PG 6
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 243DB
UT WOS:000251774000002
PM 17855176
DA 2018-03-20
ER

PT J
AU Aher, A
   Papp, J
   Colburn, A
   Wan, HY
   Hatakeyama, E
   Prakash, P
   Weaver, B
   Bhattacharyya, D
AF Aher, Ashish
   Papp, Joseph K.
   Colburn, Andrew S.
   Wan, Hongyi
   Hatakeyama, Evan
   Prakash, Prakhar
   Weaver, Benjamin
   Bhattacharyya, Dibakar
TI Naphthenic acids removal from high TDS produced water by persulfate
   mediated iron oxide functionalized catalytic membrane, and by
   nanofiltration
SO CHEMICAL ENGINEERING JOURNAL
LA English
DT Article
DE Persulfate; Oil industry; Advanced oxidation; Nanoparticles; Separation;
   Degradation
ID ELECTROLESS PLATING SIEP; ACTIVATED PERSULFATE; ORGANIC CONTAMINANTS;
   CHEMICAL OXIDATION; CYCLOHEXANOIC ACID; RATE CONSTANTS; DEGRADATION;
   MECHANISM; TOXICITY; PLANT
AB Oil industries generate large amounts of produced water containing organic contaminants, such as naphthenic acids (NA) and very high concentrations of inorganic salts. Recovery of potable water from produced water can be highly energy intensive in some cases due to its high salt concentration, and safe discharge is more suitable. Here, we explored catalytic properties of iron oxide (FexOy nanoparticles) functionalized membranes in oxidizing NA from water containing high concentrations of total dissolved solids (TDS) using persulfate as an oxidizing agent. Catalytic decomposition of persulfate by FexOy functionalized membranes followed pseudo-first order kinetics with an apparent activation energy of 18 kcal/mol. FexOy functionalized membranes were capable of lowering the NA concentrations to less than discharge limits of 10 ppm at 40 degrees C. Oxidation state of iron during reaction was quantified. Membrane performance was investigated for extended period of time. A coupled process of advanced oxidation catalyzed by membrane and nanofiltration was also evaluated. Commercially available nanofiltration membranes were found capable of retaining NA from water containing high concentrations of dissolved salts. Commercial NF membranes, Dow NF270 (Dow), and NF8 (Nanostone) had NA rejection of 79% and 82%, respectively. Retentate from the nanofiltration was further treated with advanced oxidation catalyzed by FexOy functionalized membrane for removal of NA. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Aher, Ashish; Papp, Joseph; Colburn, Andrew; Wan, Hongyi; Bhattacharyya, Dibakar] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Hatakeyama, Evan; Prakash, Prakhar] Chevron Corp, Richmond, CA USA.
   [Weaver, Ben] Nanostone Corp, Oceanside, CA USA.
RP Bhattacharyya, D (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM db@uky.edu
FU Chevron Corporation; Nanostone Corporation; NSF EPSCOR Program
   [1355438]; NIH-NIEHS-SRC [P42ES007380]; NSF-REU program
FX The authors acknowledge the funding support of Chevron and Nanostone
   Corporations, NSF EPSCOR Program (Grant no. 1355438), and NIH-NIEHS-SRC
   (Award no: P42ES007380). Authors are thankful to DOW FLIMTECH and
   Nanostone water co. for providing the flat sheet nanofiltration
   membranes. Joseph Papp was also supported by the NSF-REU program. The
   authors also acknowledge the technical help of Michael Detisch, Dr.
   Rupam Sarma, Dr. M. Gui, John May and Tricia Coakley.
CR Adewuyi YG, 2015, CHEM ENG J, V281, P575, DOI 10.1016/j.cej.2015.06.114
   Aher A, 2017, CARBON, V116, P145, DOI 10.1016/j.carbon.2017.01.086
   Ahmad M, 2010, J CONTAM HYDROL, V115, P34, DOI 10.1016/j.jconhyd.2010.04.002
   Al-jibouri AKH, 2015, WATER AIR SOIL POLL, V226, DOI 10.1007/s11270-015-2600-6
   Alpatova A, 2015, J MEMBRANE SCI, V490, P227, DOI 10.1016/j.memsci.2015.05.001
   BATES RG, 1970, ANAL CHEM, V42, P867, DOI 10.1021/ac60290a006
   Block P. A., 2004, P 4 INT C REM CHLOR, P24
   Bowen WR, 1997, J MEMBRANE SCI, V126, P91, DOI 10.1016/S0376-7388(96)00276-1
   Brown LD, 2015, CHEMOSPHERE, V127, P276, DOI 10.1016/j.chemosphere.2015.02.003
   Chung TS, 2007, PROG POLYM SCI, V32, P483, DOI 10.1016/j.progpolymsci.2007.01.008
   Clemente JS, 2005, CHEMOSPHERE, V60, P585, DOI 10.1016/j.chemosphere.2005.02.065
   Colburn AS, 2016, IND ENG CHEM RES, V55, P4089, DOI 10.1021/acs.iecr.6b00098
   Drzewicz P, 2012, ENVIRON SCI TECHNOL, V46, P8984, DOI 10.1021/es3011546
   Drzewicz P, 2010, J PHYS CHEM A, V114, P12067, DOI 10.1021/jp105727s
   Elimelech M, 2006, J WATER SUPPLY RES T, V55, P3, DOI 10.2166/aqua.2005.064
   Fang GD, 2017, APPL CATAL B-ENVIRON, V202, P1, DOI 10.1016/j.apcatb.2016.09.006
   Gao YW, 2016, APPL CATAL B-ENVIRON, V185, P22, DOI 10.1016/j.apcatb.2015.12.002
   Gong F, 2015, CHEM ENG J, V267, P102, DOI 10.1016/j.cej.2015.01.010
   Gui MH, 2015, J MEMBRANE SCI, V488, P79, DOI 10.1016/j.memsci.2015.03.089
   Headley JV, 2016, MASS SPECTROM REV, V35, P311, DOI 10.1002/mas.21472
   Hernandez S, 2014, IND ENG CHEM RES, V53, P1130, DOI 10.1021/ie403353g
   Islam MS, 2012, INT J HYDROGEN ENERG, V37, P3477, DOI 10.1016/j.ijhydene.2011.11.024
   Islam MS, 2016, SCI TOTAL ENVIRON, V541, P238, DOI 10.1016/j.scitotenv.2015.09.091
   Islam SZ, 2016, SEP SCI TECHNOL, V51, P1176, DOI 10.1080/01496395.2015.1109661
   Johnson RL, 2008, ENVIRON SCI TECHNOL, V42, P9350, DOI 10.1021/es8019462
   Kim ES, 2011, SEP PURIF TECHNOL, V81, P418, DOI 10.1016/j.seppur.2011.08.016
   Kusic H, 2011, CHEM ENG J, V172, P109, DOI 10.1016/j.cej.2011.05.076
   Leng YQ, 2014, CHEM ENG J, V240, P338, DOI 10.1016/j.cej.2013.11.090
   Leshuk T, 2016, CHEMOSPHERE, V144, P1854, DOI 10.1016/j.chemosphere.2015.10.073
   Lewis SR, 2011, P NATL ACAD SCI USA, V108, P8577, DOI 10.1073/pnas.1101144108
   Liang CJ, 2007, CHEMOSPHERE, V66, P106, DOI 10.1016/j.chemosphere.2006.05.026
   Liang CJ, 2010, ENVIRON SCI TECHNOL, V44, P8203, DOI 10.1021/es903411a
   Liang C.-J., 2012, CHANGE, V2, P2
   Liang XM, 2011, J HAZARD MATER, V190, P168, DOI 10.1016/j.jhazmat.2011.03.022
   Liu H., 2015, ENV SCI TECHNOL
   Loganathan K, 2015, J ENVIRON MANAGE, V161, P113, DOI 10.1016/j.jenvman.2015.06.031
   MADHAVAN V, 1978, RADIAT RES, V76, P15, DOI 10.2307/3574923
   Majumder M, 2011, ACS NANO, V5, P3867, DOI 10.1021/nn200222g
   NETA P, 1977, J AM CHEM SOC, V99, P163, DOI 10.1021/ja00443a030
   NETA P, 1988, J PHYS CHEM REF DATA, V17, P1027, DOI 10.1063/1.555808
   Peng H, 2004, DESALINATION, V170, P137, DOI 10.1016/j.desal.2004.03.018
   Sandefur HN, 2016, ECOL ENG, V94, P75, DOI 10.1016/j.ecoleng.2016.05.066
   Sohrabi V, 2013, CHEMOSPHERE, V93, P2698, DOI 10.1016/j.chemosphere.2013.08.072
   Tollefsen KE, 2012, ENVIRON SCI TECHNOL, V46, P5143, DOI 10.1021/es204124w
   Usman M, 2012, CHEMOSPHERE, V87, P234, DOI 10.1016/j.chemosphere.2012.01.001
   Vaiopoulou E, 2015, BIORESOURCE TECHNOL, V179, P339, DOI 10.1016/j.biortech.2014.12.058
   Wang BL, 2015, ENVIRON SCI TECHNOL, V49, P5796, DOI 10.1021/es505809g
   Wang CJ, 2015, J ENVIRON MANAGE, V160, P254, DOI 10.1016/j.jenvman.2015.06.025
   Werber JR, 2016, NAT REV MATER, V1, DOI 10.1038/natrevmats.2016.18
NR 49
TC 1
Z9 1
U1 28
U2 29
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1385-8947
EI 1873-3212
J9 CHEM ENG J
JI Chem. Eng. J.
PD NOV 1
PY 2017
VL 327
BP 573
EP 583
DI 10.1016/j.cej.2017.06.128
PG 11
WC Engineering, Environmental; Engineering, Chemical
SC Engineering
GA FF1MO
UT WOS:000408663800062
PM 29398952
DA 2018-03-19
ER

PT J
AU Su, X
   Wu, J
   Hinds, BJ
AF Su, Xin
   Wu, Ji
   Hinds, Bruce J.
TI Catalytic activity of ultrathin Pt films on aligned carbon nanotube
   arrays
SO CARBON
LA English
DT Article
ID METHANOL FUEL-CELLS; SURFACE; PLATINUM; ELECTROCATALYSTS; OXIDATION;
   FUNCTIONALIZATION; ANODE; NANOPARTICLES; PERFORMANCE; REDUCTION
AB Uniform ultrathin Pt films were electrodeposited onto an aligned array of carbon nanotubes (CNTs) for high-area chemically stable methanol fuel cell anodes. Electrochemical treatment of the graphitic CNT surfaces by diazoniumbenzoic acid allowed for uniform Pt electroplating. The mass activity of the Pt thin film can reach 400 A/g at a scan rate of 20 mV/s and in a solution of 1 M CH(3)OH/0.5 M H(2)SO(4). A programmed pulse potential at 0 V was also seen to nearly eliminate the effects of carbon monoxide poisoning. The mass activity of Pt for methanol oxidation can be maintained at 300 A/g for more than 3000 s, which is 19 times of that under a constant potential of 0.7 V (vs. Ag/AgCl). (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Su, Xin; Wu, Ji; Hinds, Bruce J.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Hinds, BJ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM bjhinds@engr.uky.edu
RI Su, Xin/M-1162-2013; WU, JI/F-6379-2013; WU, JI/F-6371-2013; WU,
   JI/J-4580-2016
OI Su, Xin/0000-0002-1615-2856; 
FU DOE EPSCoR [DE-FG02-07ER46375]; NSF [0348544]; NIH NIDA [R01DA018822]
FX The authors would like to thank Rodney Andrews and Dali Qian from the
   Center for Applied Energy, University of Kentucky, for supplying MWCNTs.
   Facility support was provided by the Center for Nanoscale Science and
   Engineering and Electron Microscopy Center at the University of
   Kentucky. Financial support from DOE EPSCoR (DE-FG02-07ER46375), NSF
   CAREER (0348544), and NIH NIDA (R01DA018822) are greatly appreciated by
   the authors.
CR Andrews R, 2002, ACCOUNTS CHEM RES, V35, P1008, DOI 10.1021/ar010151m
   Bahr JL, 2001, J AM CHEM SOC, V123, P6536, DOI 10.1021/ja010462s
   Brandl W, 2004, THIN SOLID FILMS, V447, P181, DOI 10.1016/S0040-6090(03)01077-0
   Choi JH, 2003, J ELECTROCHEM SOC, V150, pA973, DOI 10.1149/1.1581011
   Combellas C, 2005, LANGMUIR, V21, P280, DOI 10.1021/la048106l
   D'Amours M, 2003, J PHYS CHEM B, V107, P4811, DOI 10.1021/jp027223r
   Guha A, 2007, CARBON, V45, P1506, DOI 10.1016/j.carbon.2007.03.023
   Hinds BJ, 2004, SCIENCE, V303, P62, DOI 10.1126/science.1092048
   Huang SM, 1999, J PHYS CHEM B, V103, P4223, DOI 10.1021/jp990342v
   Hull RV, 2006, CHEM MATER, V18, P1780, DOI 10.1021/cm0518978
   Iwasita T, 2002, ELECTROCHIM ACTA, V47, P3663, DOI 10.1016/S0013-4686(02)00336-5
   Li HQ, 2009, J AM CHEM SOC, V131, P15098, DOI 10.1021/ja906529g
   Li ZJ, 2005, LANGMUIR, V21, P11999, DOI 10.1021/la051608u
   Liu Y, 2008, CHEM MATER, V20, P2603, DOI 10.1021/cm703471x
   Majumder M, 2007, LANGMUIR, V23, P8624, DOI 10.1021/la700686k
   McGrath KM, 2004, J IND ENG CHEM, V10, P1063
   MORENOCASTILLA C, 1995, LANGMUIR, V11, P4386, DOI 10.1021/la00011a035
   Mu YY, 2005, J PHYS CHEM B, V109, P22212, DOI 10.1021/jp0555448
   Prabhuram J, 2007, ELECTROCHIM ACTA, V52, P2649, DOI 10.1016/j.electacta.2006.09.027
   Prehn K, 2008, J MEMBRANE SCI, V321, P123, DOI 10.1016/j.memsci.2008.04.041
   Service RF, 2007, SCIENCE, V315, P172, DOI 10.1126/science.315.5809.172
   Tang H, 2004, J COLLOID INTERF SCI, V269, P26, DOI 10.1016/S0021-9797(03)00608-8
   Tian N, 2007, SCIENCE, V316, P732, DOI 10.1126/science.1140484
   Wang RY, 2010, ADV MATER, V22, P1845, DOI 10.1002/adma.200903548
   Wilde PM, 2004, FUEL CELLS, V4, P180, DOI 10.1002/fuce.200400022
   Wu G, 2005, ELECTROCHEM COMMUN, V7, P1237, DOI 10.1016/j.elecom.2005.07.015
   Yang H, 2007, J PHYS CHEM C, V111, P19058, DOI 10.1021/jp075929l
   Yang HH, 2010, INT J HYDROGEN ENERG, V35, P2791, DOI 10.1016/j.ijhydene.2009.05.019
   Ye JL, 2009, J POWER SOURCES, V194, P683, DOI 10.1016/j.jpowsour.2009.06.032
   Zhang J, 2007, SCIENCE, V315, P220, DOI 10.1126/science.1134569
NR 30
TC 8
Z9 8
U1 0
U2 18
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0008-6223
J9 CARBON
JI Carbon
PD APR
PY 2011
VL 49
IS 4
BP 1145
EP 1150
DI 10.1016/j.carbon.2010.11.029
PG 6
WC Chemistry, Physical; Materials Science, Multidisciplinary
SC Chemistry; Materials Science
GA 717NR
UT WOS:000287055200012
PM 25132685
OA green_accepted
DA 2018-03-20
ER

PT J
AU Oldham, ED
   Seelam, S
   Lema, CF
   Aguilera, RJ
   Fiegel, J
   Rankin, SE
   Knutson, BL
   Lehmler, HJ
AF Oldham, Edward Davis
   Seelam, Srivenu
   Lema, Carolina F.
   Aguilera, Renato J.
   Fiegel, Jennifer
   Rankin, Stephen E.
   Knutson, Barbara L.
   Lehmler, Hans-Joachim
TI Synthesis and characterization of triazole-containing alkyl xyloside
   surfactants
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
CT 244th National Fall Meeting of the American-Chemical-Society (ACS)
CY AUG 19-23, 2012
CL Philadelphia, PA
SP Amer Chem Soc, Div Hist Chem, Amer Chem Soc
C1 [Oldham, E. Davis; Lehmler, Hans-Joachim] Univ Iowa, Dept Occupat & Environm Hlth, Iowa City, IA 52242 USA.
   [Seelam, Srivenu; Rankin, Stephen E.; Knutson, Barbara L.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Lema, Carolina F.; Aguilera, Renato J.] Univ Texas El Paso, Dept Biol Sci, El Paso, TX 79968 USA.
   [Fiegel, Jennifer] Univ Iowa, Dept Pharmaceut Sci & Expt Therapeut, Iowa City, IA 52242 USA.
   [Oldham, E. Davis; Lehmler, Hans-Joachim] Univ Iowa, Interdisciplinary Grad Program Human Toxicol, Iowa City, IA 52242 USA.
EM edward-oldham@uiowa.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD AUG 19
PY 2012
VL 244
MA 32-CARB
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA 220XX
UT WOS:000324621801189
DA 2018-03-20
ER

PT J
AU Adams, CA
   Melikishvili, M
   Rodgers, DW
   Rasimas, JJ
   Pegg, AE
   Fried, MG
AF Adams, Claire A.
   Melikishvili, Manana
   Rodgers, David W.
   Rasimas, Joseph J.
   Pegg, Anthony E.
   Fried, Michael Gregory
TI Topologies of Complexes Containing O-6-Alkylguanine-DNA Alkyltransferase
   and DNA
SO JOURNAL OF MOLECULAR BIOLOGY
LA English
DT Article
DE O-6-alkylguanine-DNA alkyltransferase; methylguanine methyltransferase;
   DNA repair; binding cooperativity; protein contacts
ID HUMAN O6-METHYLGUANINE-DNA METHYLTRANSFERASE; CROSS-LINKING;
   TOPOISOMERASE-I; PROTEIN INTERACTIONS; GEL-ELECTROPHORESIS; BINDING
   MECHANISM; REPAIR PROTEIN; NUCLEIC-ACIDS; LAC REPRESSOR; STRANDED DNAS
AB The mutagenic and cytotoxic effects of many alkylating agents are reduced by O-6-alkylguanine-DNA alkyltransferase (AGT). In humans, this protein not only protects the integrity of the genome, but also contributes to the resistance of tumors to DNA-alkylating chemotherapeutic agents. Here we describe and test models for cooperative multiprotein complexes of AGT with single-stranded and duplex DNAs that are based on in vitro binding data and the crystal structure of a 1:1 AGT-DNA complex. These models predict that cooperative assemblies contain a three-start helical array of proteins with dominant protein-protein interactions between the amino-terminal face of protein n and the carboxy-terminal face of protein n+3, and they predict that binding duplex DNA does not require large changes in B-form DNA geometry. Experimental tests using protein cross-linking analyzed by mass spectrometry, electrophoretic and analytical ultracentrifugation binding assays, and topological analyses with closed circular DNA show that the properties of multiprotein AGT-DNA complexes are consistent with these predictions. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Adams, Claire A.; Melikishvili, Manana; Rodgers, David W.; Fried, Michael G.] Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA.
   [Adams, Claire A.; Melikishvili, Manana; Rodgers, David W.; Fried, Michael G.] Univ Kentucky, Struct Biol Ctr, Lexington, KY 40536 USA.
   [Rasimas, Joseph J.; Pegg, Anthony E.] Penn State Univ, Dept Mol Physiol, Coll Med, Hershey, PA 17033 USA.
RP Fried, MG (reprint author), Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA.
EM michael.fried@uky.edu
FU NIH National Center for Research Resources (NCRR) [P20 RR020171]; NIH
   [GM-070662, CA-018137, CA-097209, NS-38041, DA-02243, RR-20171]; Medical
   Scientist Training Program [5 T32 GM-08601-05]
FX Mass spectrometric analyses were performed at the University of Kentucky
   Center for Structural Biology Protein Core Facility. This facility is
   supported in part by funds from NIH National Center for Research
   Resources (NCRR) grant P20 RR020171. We gratefully acknowledge the help
   of Dr. Carol Beach in acquiring these data. Research in this report was
   supported by NIH grants GM-070662 (to M.G.F.), CA-018137 and CA-097209
   (to A.E.P.), NS-38041, DA-02243, and RR-20171 (to D.W.R.), and Medical
   Scientist Training Program grant 5 T32 GM-08601-05 (to J.J.R.).
CR Ahmad S, 2004, BIOINFORMATICS, V20, P477, DOI 10.1093/bioinformatics/btg432
   Bender K, 1996, NUCLEIC ACIDS RES, V24, P2087, DOI 10.1093/nar/24.11.2087
   Benos PV, 2002, BIOESSAYS, V24, P466, DOI 10.1002/bies.10073
   Boeger H, 2005, FEBS LETT, V579, P899, DOI 10.1016/j.febslet.2004.11.027
   CANTOR CR, 1965, J MOL BIOL, V13, P65, DOI 10.1016/S0022-2836(65)80080-8
   Cavaluzzi MJ, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh015
   CHAN CL, 1993, ARCH BIOCHEM BIOPHYS, V300, P193, DOI 10.1006/abbi.1993.1027
   COHEN G, 1968, BIOPOLYMERS, V6, P1077, DOI 10.1002/bip.1968.360060805
   COHN EJ, 1943, PROTEINS AMINO ACIDS, P370
   CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170
   Coulter R, 2007, CHEM RES TOXICOL, V20, P1966, DOI 10.1021/tx700271j
   Daniels DS, 2000, EMBO J, V19, P1719, DOI 10.1093/emboj/19.7.1719
   Daniels DS, 2004, NAT STRUCT MOL BIOL, V11, P714, DOI 10.1038/nsmb791
   DAVIES GE, 1970, P NATL ACAD SCI USA, V66, P651, DOI 10.1073/pnas.66.3.651
   Duguid EM, 2005, J MOL BIOL, V350, P657, DOI 10.1016/j.jmb.2005.05.028
   Encell LP, 2000, CARCINOGENESIS, V21, P1397, DOI 10.1093/carcin/21.7.1397
   Fancy DA, 1999, P NATL ACAD SCI USA, V96, P6020, DOI 10.1073/pnas.96.11.6020
   Fang QM, 2008, BIOCHEMISTRY-US, V47, P10892, DOI 10.1021/bi8008664
   Federwisch M, 1997, FEBS LETT, V407, P333, DOI 10.1016/S0014-5793(97)00370-0
   FernandezBeros ME, 1996, FEBS LETT, V384, P265, DOI 10.1016/0014-5793(96)00317-1
   FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505
   Fried MG, 1996, BIOCHEMISTRY-US, V35, P15295, DOI 10.1021/bi960971k
   Gerson SL, 2002, J CLIN ONCOL, V20, P2388, DOI 10.1200/JCO.2002.06.110
   HA JH, 1992, J MOL BIOL, V228, P252, DOI 10.1016/0022-2836(92)90504-D
   Hegi ME, 2008, J CLIN ONCOL, V26, P4189, DOI 10.1200/JCO.2007.11.5964
   JARYARAM B, 2004, ANNU REV BIOPH BIOM, V33, P343
   JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224
   KANUGULA S, 1995, BIOCHEMISTRY-US, V34, P7113, DOI 10.1021/bi00021a024
   Kuo CC, 2007, INT J CANCER, V121, P2293, DOI 10.1002/ijc.22927
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lavon I, 2007, CANCER RES, V67, P8952, DOI 10.1158/0008-5472.CAN-06-3820
   LIEM LK, 1993, J MOL BIOL, V231, P950, DOI 10.1006/jmbi.1993.1344
   LIMA CD, 1994, NATURE, V367, P138, DOI 10.1038/367138a0
   LIUJOHNSON HN, 1986, CELL, V47, P995, DOI 10.1016/0092-8674(86)90814-7
   LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527
   LOVELESS A, 1969, NATURE, V223, P206, DOI 10.1038/223206a0
   Luscombe NM, 2000, GENOME BIOL, V1
   Luu KX, 2002, BIOCHEMISTRY-US, V41, P8689, DOI 10.1021/bi025857i
   Margison GP, 2002, BIOESSAYS, V24, P255, DOI 10.1002/bies.10063
   MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560
   MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X
   Melikishvili M, 2008, BIOCHEMISTRY-US, V47, P13754, DOI 10.1021/bi801666c
   NESTERENKO MV, 1994, J BIOCHEM BIOPH METH, V28, P239, DOI 10.1016/0165-022X(94)90020-5
   NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407
   Pegg AE, 2000, MUTAT RES-REV MUTAT, V462, P83, DOI 10.1016/S1383-5742(00)00017-X
   PEGG AE, 1995, PROG NUCLEIC ACID RE, V51, P167, DOI 10.1016/S0079-6603(08)60879-X
   PEGG AE, 1990, CANCER RES, V50, P6119
   PETERS K, 1977, ANNU REV BIOCHEM, V46, P523, DOI 10.1146/annurev.bi.46.070177.002515
   Pingoud A, 2005, CELL MOL LIFE SCI, V62, P685, DOI 10.1007/s00018-004-4513-1
   Ranson M, 2006, CLIN CANCER RES, V12, P1577, DOI 10.1158/1078-0432.CCR-05-2198
   Rasimas JJ, 2003, BIOCHEMISTRY-US, V42, P980, DOI 10.1021/bi026970b
   Rasimas JJ, 2003, J BIOL CHEM, V278, P7973, DOI 10.1074/jbc.M211854200
   Rasimas JJ, 2007, J BIOL CHEM, V282, P3357, DOI 10.1074/jbc.M608876200
   Record M T Jr, 1985, Adv Biophys, V20, P109
   RECORD MT, 1978, Q REV BIOPHYS, V11, P103, DOI 10.1017/S003358350000202X
   RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X
   ROY R, 1995, CARCINOGENESIS, V16, P405, DOI 10.1093/carcin/16.2.405
   SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5
   SNOW ET, 1987, CANCER INVEST, V5, P119, DOI 10.3109/07357908709018466
   Srivenugopal KS, 1996, BIOCHEMISTRY-US, V35, P1328, DOI 10.1021/bi9518205
   Stivers JT, 1997, BIOCHEMISTRY-US, V36, P5212, DOI 10.1021/bi962880t
   Tabancay AP, 2006, CURR TOP DEV BIOL, V76, P129, DOI 10.1016/S0070-2153(06)76005-7
   Tsodikov OV, 2001, BIOPHYS J, V81, P1960, DOI 10.1016/S0006-3495(01)75847-X
   Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61
   WOOD CL, 1985, J BIOL CHEM, V260, P1243
   Xu-Welliver M, 2002, CARCINOGENESIS, V23, P823, DOI 10.1093/carcin/23.5.823
   Zeman SM, 2001, METHOD ENZYMOL, V340, P51
NR 67
TC 23
Z9 23
U1 1
U2 3
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-2836
EI 1089-8638
J9 J MOL BIOL
JI J. Mol. Biol.
PD JUN 5
PY 2009
VL 389
IS 2
BP 248
EP 263
DI 10.1016/j.jmb.2009.03.067
PG 16
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 455CH
UT WOS:000266733700004
PM 19358853
OA green_accepted
DA 2018-03-20
ER

PT J
AU Wagner, JM
   Roganowicz, MD
   Skorupka, K
   Alam, SL
   Christense, D
   Doss, G
   Wan, YP
   Frank, GA
   Ganser-Pornillos, BK
   Sundquist, WI
   Pornillo, O
AF Wagner, Jonathan M.
   Roganowicz, Marcin D.
   Skorupka, Katarzyna
   Alam, Steven L.
   Christense, Devin
   Doss, Ginna
   Wan, Yueping
   Frank, Gabriel A.
   Ganser-Pornillos, Barbie K.
   Sundquist, Wesley I.
   Pornillo, Owen
TI Mechanism of B-box 2 domain-mediated higher-order assembly of the
   retroviral restriction factor TRIM5 alpha
SO ELIFE
LA English
DT Article
ID REVERSE TRANSCRIPTION; STRUCTURAL INSIGHT; CAPSID RECOGNITION; HIV-1
   RESTRICTION; RING DOMAIN; PROTEIN; BINDING; TRIM5; ASSOCIATION;
   INHIBITION
AB Restriction factors and pattern recognition receptors are important components of intrinsic cellular defenses against viral infection. Mammalian TRIM5 alpha proteins are restriction factors and receptors that target the capsid cores of retroviruses and activate ubiquitin-dependent antiviral responses upon capsid recognition. Here, we report crystallographic and functional studies of the TRIM5 alpha B-box 2 domain, which mediates higher-order assembly of TRI M5 proteins. The B-box can form both dimers and trimers, and the trimers can link multiple TRIM5 alpha proteins into a hexagonal net that matches the lattice arrangement of capsid subunits and enables avid capsid binding. Two modes of conformational flexibility allow TRIM5 alpha to accommodate the variable curvature of retroviral capsids. B-box mediated interactions also modulate TRIM5 alpha's E3 ubiquitin ligase activity, by stereochemically restricting how the N-terminal RING domain can dimerize. Overall, these studies define important molecular details of cellular recognition of retroviruses, and how recognition links to downstream processes to disable the virus.
C1 [Wagner, Jonathan M.; Roganowicz, Marcin D.; Skorupka, Katarzyna; Doss, Ginna; Wan, Yueping; Ganser-Pornillos, Barbie K.; Pornillo, Owen] Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22904 USA.
   [Alam, Steven L.; Christense, Devin; Sundquist, Wesley I.] Univ Utah, Dept Biochem, Salt Lake City, UT USA.
   [Frank, Gabriel A.] Ben Gurion Univ Negev, Natl Inst Biotechnol Negev, Beer Sheva, Israel.
   [Frank, Gabriel A.] Ben Gurion Univ Negev, Dept Life Sci, Beer Sheva, Israel.
RP Pornillo, O (reprint author), Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22904 USA.
EM owp3a@eservices.virginia.edu
OI Wagner, Jonathan M./0000-0001-9161-7222; Frank,
   Gabriel/0000-0001-8379-5133
FU National Institutes of Health [R01 GM112508, P50 GM082545, F32 G
   M115007]; Annette Lightner Foundation
FX National Institutes of Health R01 GM112508 Owen Pornillos; National
   Institutes of Health P50 GM082545 Barbie K Ganser-Pornillos Wesley I
   Sundquist; National Institutes of Health F32 G M115007 Jonathan M
   Wagner; Annette Lightner Foundation Owen Pornillos; The funders had no
   role in study design, data collection and interpretation, or the
   decision to submit the work for publication.
CR Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925
   Apulleiro JI, 2011, BIOINFORMATICS, V27, P582, DOI [1093/bioinfornaticsibtc1692, DOI 10.1093/BIOINFORMATICS/BTQ692]
   Bernado P, 2007, J AM CHEM SOC, V129, P5656, DOI 10.1021/ja069124n
   Biris N, 2013, J MOL BIOL, V425, P5032, DOI 10.1016/j.jmb.2013.07.025
   Biris N, 2012, P NATL ACAD SCI USA, V109, P13278, DOI 10.1073/pnas.1203536109
   Campbell EM, 2007, MOL BIOL CELL, V18, P2102, DOI 10.1091/mbc.E06-12-1075
   Campbell EM, 2016, J VIROL, V90, P1849, DOI 10.1128/JVI.01948-15
   Cole JL, 2004, METHOD ENZYMOL, V384, P212
   Diaz-Griffero F, 2006, VIROLOGY, V349, P300, DOI 10.1016/j.virol.2005.12.040
   Diaz-Griffero F, 2007, J VIROL, V81, P10362, DOI 10.1128/JVI.00703-07
   Diaz-Griffero F, 2006, VIROLOGY, V351, P404, DOI 10.1016/j.virol.2006.03.023
   Diaz-Griffero F, 2009, J VIROL, V83, P10737, DOI 10.1128/JVI.01307-09
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Fletcher AJ, 2015, EMBO J, V34, P2078, DOI 10.15252/embj.201490361
   Fribourgh JL, 2014, CELL HOST MICROBE, V16, P627, DOI 10.1016/j.chom.2014.09.021
   FUJINAGA M, 1993, J MOL BIOL, V234, P222, DOI 10.1006/jmbi.1993.1576
   Ganser-Pornillos BK, 2011, P NATL ACAD SCI USA, V108, P534, DOI 10.1073/pnas.1013426108
   Goldstone DC, 2014, P NATL ACAD SCI USA, V111, P9609, DOI 10.1073/pnas.1402448111
   Hanson MA, 2007, PROTEIN EXPRES PURIF, V56, P85, DOI 10.1016/j.pep.2007.06.003
   Jayanbakht H, 2005, J BIOL CHEM, V280, P26933, DOI [10.1074/jbcM502145200, DOI 10.1074/JBC.M502145200]
   Jayanbakht H, 2007, VIROLOGY, V367, P19, DOI [10.1016/j.virol.2007.04.034, DOI 10.1016/J.VIROL.2007.04.034]
   Kar AK, 2008, J VIROL, V82, P11669, DOI 10.1128/JVI.01559-08
   Koyalskyy DB, 2014, BIOCHEMISTRY-US, V53, P1466, DOI [10.1021/bi4014962, DOI 10.1021/BI4014962]
   Kremer JR, 1996, J STRUCT BIOL, V116, P71, DOI 10.1006/jsbi.1996.0013
   Langelier CR, 2008, J VIROL, V82, P11682, DOI 10.1128/JVI.01562-08
   Li X, 2011, J BIOL CHEM, V286, P27959, DOI 10.1074/jbc.M111.260406
   Li X, 2008, J VIROL, V82, P11495, DOI 10.1128/JVI.01548-08
   Li Y, 2014, CELL RES, V24, P762, DOI 10.1038/cr.2014.46
   Li YL, 2016, ELIFE, V5, DOI 10.7554/eLife.16269
   Lienlaf M, 2011, J VIROL, V85, P8725, DOI 10.1128/JVI.00497-11
   Meroni G, 2005, BIOESSAYS, V27, P1147, DOI 10.1002/bies.20304
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Pertel T, 2011, NATURE, V472, P361, DOI 10.1038/nature09976
   Piechanoyoya A, 2012, NATURE, V489, P115, DOI [10.1038/nature11376, DOI 10.1038/NATURE11376]
   Plechanovova A, 2011, NAT STRUCT MOL BIOL, V18, P1052, DOI 10.1038/nsmb.2108
   Pornillos O, 2011, NATURE, V469, P424, DOI 10.1038/nature09640
   Pornillos O, 2009, CELL, V137, P1282, DOI 10.1016/j.cell.2009.04.0634
   Roa A, 2012, J VIROL, V86, P1717, DOI 10.1128/JVI.05811-11
   Sanchez JG, 2014, P NATL ACAD SCI USA, V111, P2494, DOI 10.1073/pnas.1318962111
   Sawyer SL, 2005, P NATL ACAD SCI USA, V102, P2832, DOI 10.1073/pnas.0409853102
   Sayah DM, 2004, NATURE, V430, P569, DOI 10.1038/nature02777
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Sebastian S, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-40
   Shen YM, 2014, J CHEM THEORY COMPUT, V10, P4745, DOI 10.1021/ct500592m
   Stremlau M, 2006, P NATL ACAD SCI USA, V103, P5514, DOI 10.1073/pnas.0509996103
   Stremlau M, 2004, NATURE, V427, P848, DOI 10.1038/nature02343
   Weinert C, 2015, SCI REP-UK, V5, DOI 10.1038/srep10819
   Yang HT, 2012, P NATL ACAD SCI USA, V109, P18372, DOI 10.1073/pnas.1210903109
   Yap MW, 2007, VIROLOGY, V365, P302, DOI 10.1016/j.virol.2007.04.005
   Yudina Z, 2015, CELL REP, V12, P788, DOI 10.1016/j.celrep.2015.06.072
NR 50
TC 11
Z9 11
U1 1
U2 3
PU ELIFE SCIENCES PUBLICATIONS LTD
PI CAMBRIDGE
PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND
SN 2050-084X
J9 ELIFE
JI eLife
PD JUN 2
PY 2016
VL 5
AR e16309
DI 10.7554/elife.16309
PG 26
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA DS6KP
UT WOS:000380891000001
OA gold
DA 2018-03-20
ER

PT J
AU Hawkins, AM
   Bottom, CE
   Liang, Z
   Puleo, DA
   Hilt, JZ
AF Hawkins, Ashley M.
   Bottom, Chelsie E.
   Liang, Zhi
   Puleo, David A.
   Hilt, J. Zach
TI Magnetic Nanocomposite Sol-Gel Systems for Remote Controlled Drug
   Release
SO ADVANCED HEALTHCARE MATERIALS
LA English
DT Article
ID HYDROGEL NANOCOMPOSITES; SUSTAINED-RELEASE; PLURONIC(R) F127; DELIVERY
   SYSTEMS; COPOLYMER; NANOPARTICLES; GELATION; FORMULATIONS; DESTRUCTION;
   LIGHT
C1 [Hawkins, Ashley M.; Bottom, Chelsie E.; Liang, Zhi; Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Puleo, David A.] Univ Kentucky, Ctr Biomed Engn, Lexington, KY 40506 USA.
RP Hilt, JZ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 F Paul Anderson Tower, Lexington, KY 40506 USA.
EM hilt@engr.uky.edu
FU NSF-IGERT
FX The authors acknowledge NSF-IGERT for their support.
CR Alvarez-Lorenzo C, 2008, MINI-REV MED CHEM, V8, P1065, DOI 10.2174/138955708785909952
   Alvarez-Lorenzo C, 2009, PHOTOCHEM PHOTOBIOL, V85, P848, DOI 10.1111/j.1751-1097.2008.00530.x
   Blonder JM, 1999, LIFE SCI, V65, pPL261, DOI 10.1016/S0024-3205(99)00495-6
   Bukreeva TV, 2006, CRYSTALLOGR REP+, V51, P863, DOI 10.1134/S1063774506050178
   Cabana A, 1997, J COLLOID INTERF SCI, V190, P307, DOI 10.1006/jcis.1997.4880
   Chung YI, 2006, COLLOID SURFACE A, V284, P480, DOI 10.1016/j.colsurfa.2005.10.060
   FAJARDO LF, 1984, CANCER RES, V44, P4826
   Ghosh S, 2010, NANOSCALE RES LETT, V5, P195, DOI 10.1007/s11671-009-9465-9
   GILBERT J C, 1987, Journal of Controlled Release, V5, P113, DOI 10.1016/0168-3659(87)90002-2
   Harris N, 2006, J PHYS CHEM B, V110, P10701, DOI 10.1021/jp0606208
   Hawkins AM, 2009, PHARM RES-DORD, V26, P667, DOI 10.1007/s11095-008-9804-z
   Hergt R, 2006, J PHYS-CONDENS MAT, V18, pS2919, DOI 10.1088/0953-8984/18/38/S26
   Jeong B, 2002, ADV DRUG DELIVER REV, V54, P37, DOI 10.1016/S0169-409X(01)00242-3
   Jiang J, 2008, POLYMER, V49, P3561, DOI 10.1016/j.polymer.2008.05.038
   Joo MK, 2009, J MATER CHEM, V19, P5891, DOI 10.1039/b902208b
   Kam NWS, 2005, P NATL ACAD SCI USA, V102, P11600, DOI 10.1073/pnas.0502680102
   Kikuchi A, 2002, ADV DRUG DELIVER REV, V54, P53, DOI 10.1016/S0169-409X(01)00243-5
   Kong SD, 2010, NANO LETT, V10, P5088, DOI 10.1021/nl1033733
   Maroni A, 2010, INT J PHARMACEUT, V398, P1, DOI 10.1016/j.ijpharm.2010.07.026
   MARTINEZ AA, 1983, CANCER RES, V43, P2072
   Miyako E, 2009, LAB CHIP, V9, P788, DOI 10.1039/b816201h
   MORTENSEN K, 1993, MACROMOLECULES, V26, P805, DOI 10.1021/ma00056a035
   Mortensen K., 1993, TRENDS COLLOID INTER, P72
   Pandit NK, 1996, INT J PHARM, V145, P129, DOI 10.1016/S0378-5173(96)04748-5
   Qiao MX, 2005, INT J PHARM, V294, P103, DOI 10.1016/j.ijpharm.2005.01.017
   Qin J, 2009, ADV MATER, V21, P1354, DOI 10.1002/adma.200800764
   Ricci EJ, 2005, INT J PHARM, V288, P235, DOI 10.1016/j.ijpharm.2004.09.028
   Roy P, 2009, J CONTROL RELEASE, V134, P74, DOI 10.1016/j.jconrel.2008.11.011
   Satarkar NS, 2008, J CONTROL RELEASE, V130, P246, DOI 10.1016/j.jconrel.2008.06.008
   Satarkar NS, 2008, ACTA BIOMATER, V4, P11, DOI 10.1016/j.actbio.2007.07.009
   Satarkar NS, 2011, AICHE J, V57, P852, DOI 10.1002/aic.12309
   Satarkar NS, 2010, SOFT MATTER, V6, P2364, DOI 10.1039/b925218p
   Satarkar NS, 2009, LAB CHIP, V9, P1773, DOI 10.1039/b822694f
   SCHMOLKA IR, 1972, J BIOMED MATER RES, V6, P571, DOI 10.1002/jbm.820060609
   Sharma PK, 2004, INT J PHARM, V278, P361, DOI 10.1016/j.ijpharm.2004.03.029
   Skirtach AG, 2004, LANGMUIR, V20, P6988, DOI 10.1021/la048873k
   Thomas CR, 2010, J AM CHEM SOC, V132, P10623, DOI 10.1021/ja1022267
   Zentner GM, 2001, J CONTROL RELEASE, V72, P203, DOI 10.1016/S0168-3659(01)00276-0
   Zhang L, 2002, J CONTROL RELEASE, V85, P73, DOI 10.1016/S0168-3659(02)00273-0
NR 39
TC 14
Z9 15
U1 2
U2 34
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2192-2640
J9 ADV HEALTHC MATER
JI Adv. Healthc. Mater.
PD JAN 11
PY 2012
VL 1
IS 1
BP 96
EP 100
DI 10.1002/adhm.201100013
PG 5
WC Engineering, Biomedical; Nanoscience & Nanotechnology; Materials
   Science, Biomaterials
SC Engineering; Science & Technology - Other Topics; Materials Science
GA 092GY
UT WOS:000315109300009
PM 23184692
DA 2018-03-20
ER

PT J
AU Wu, XA
   Mansour, HM
AF Wu, Xiao
   Mansour, Heidi M.
TI Nanopharmaceuticals II: application of nanoparticles and nanocarrier
   systems in pharmaceutics and nanomedicine
SO INTERNATIONAL JOURNAL OF NANOTECHNOLOGY
LA English
DT Article
DE nanoparticles; nanomedicine; therapeutics; vaccination; chemotherapy;
   photodynamic therapy; diagnostics; theragnostics; multifunctional
ID CELL-PENETRATING PEPTIDES; SURFACTANT-POLYMER NANOPARTICLES; MEDIATED
   INTRACELLULAR DELIVERY; LONG-CIRCULATING LIPOSOMES; IRON-OXIDE
   NANOPARTICLES; TUMOR-TARGETED DELIVERY; GLYCOL)-MODIFIED GELATIN
   NANOPARTICLES; NANOTEMPLATE-ENGINEERED NANOPARTICLES; FUNCTIONALIZED
   MAGNETIC NANOPARTICLES; DOXORUBICIN-LOADED NANOPARTICLES
AB The principle aim of using nanoparticles in pharmaceutical delivery systems is to enable targeted and efficient delivery of the appropriate levels of therapeutic or diagnostic agents to the target sites with reduced, if any, side effects to the patient. Given the benefits that nanotechnology offers, much effort has focused on producing nanoparticles for the delivery of drugs (particularly anti-tumour drugs), photosensitisers, diagnostic agents and vaccines. These nanosystems can be modified to achieve desirable biological properties (e. g., long circulation in blood, targeting delivery, stimuli sensitivity and intracellular target) and perform various therapeutically or diagnostically important functions simultaneously. This paper reviews the application of nanoparticulate systems in vaccination, chemotherapy, photodynamic therapy, diagnostics, and drug/gene delivery. Multifunctional nanocarriers are also described. Additionally, nanopharmaceutical product development and related issues are briefly presented.
C1 [Wu, Xiao; Mansour, Heidi M.] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Drug Dev Div, Lexington, KY 40536 USA.
RP Mansour, HM (reprint author), Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Drug Dev Div, 789 S Limestone St, Lexington, KY 40536 USA.
EM xwu222@gmail.com; heidi.mansour@uky.edu
RI Mansour, Heidi/D-1074-2011; Wu, Xiao/A-4265-2011
FU Office of the Vice-Chancellor
FX Heidi M. Mansour is Assistant Professor of Pharmaceutical Sciences and
   Pharmaceutical Technology in the Drug Development Division at the
   University of Kentucky College of Pharmacy. She currently holds Faculty
   appointments and Graduate Faculty appointments in the College of
   Pharmacy at the University of Kentucky and at the University of North
   Carolina-Chapel Hill, the University of Kentucky Center for Membrane
   Sciences, and in the NSF IGERT and NSF REU research training programs
   joint with the University of Kentucky College of Engineering. Prior to
   her Faculty appointment at the University of Kentucky College of
   Pharmacy, she was an Instructor (both in the Graduate and Pharm. D.
   Programs) and a Postdoctoral Fellow and Scholar at the University of
   North Carolina at Chapel Hill, School of Pharmacy, in the Division of
   Molecular Pharmaceutics, receiving the 2007 UNC-Chapel Hill Postdoctoral
   Award for Research Excellence from the Office of the Vice-Chancellor. A
   Registered Pharmacist for over 10 years, she earned a BS in Pharmacy,
   PhD in Pharmaceutical Sciences with a PhD Major in Drug
   Delivery/Pharmaceutics (School of Pharmacy) and a PhD Minor in Advanced
   Physical and Biophysical Chemistry (Department of Chemistry), all from
   the University of Wisconsin-Madison. More information can be found on
   her websites http://pharmacy.mc.uky.edu/faculty/HeidiMansour.php and
   http://myprofile.cos.com/surfchemlungmed
CR Aline F, 2009, VACCINE, V27, P5284, DOI 10.1016/j.vaccine.2009.05.028
   ALLEN TM, 1992, CANCER RES, V52, P2431
   ALLEN TM, 1991, BIOCHIM BIOPHYS ACTA, V1066, P29, DOI 10.1016/0005-2736(91)90246-5
   Alonso MJ, 2004, BIOMED PHARMACOTHER, V58, P168, DOI 10.1016/j.biopha.2004.01.007
   Ambrosch F, 1997, VACCINE, V15, P1209, DOI 10.1016/S0264-410X(97)00015-7
   Arbab AS, 2006, EXPERT REV MED DEVIC, V3, P427, DOI 10.1586/17434440.3.4.427
   Astriab-Fisher A, 2002, PHARMACEUT RES, V19, P744, DOI 10.1023/A:1016136328329
   Ataman-Onal Y, 2006, J CONTROL RELEASE, V112, P175, DOI 10.1016/j.jconrel.2006.02.006
   Babincova M, 2008, IEEE T NANOBIOSCI, V7, P15, DOI 10.1109/TNB.2008.2000145
   Banerjee SS, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/18/185103
   BANGHAM AD, 1965, J MOL BIOL, V13, P238, DOI 10.1016/S0022-2836(65)80093-6
   Batrakova EV, 2008, J CONTROL RELEASE, V130, P98, DOI 10.1016/j.jconrel.2008.04.013
   Beacock-Sharp H, 2003, INT IMMUNOL, V15, P711, DOI 10.1093/intimm/dxg067
   Beduneau A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004343
   BEHR JP, 1993, ACCOUNTS CHEM RES, V26, P274, DOI 10.1021/ar00029a008
   Bendifallah N, 2006, BIOCONJUGATE CHEM, V17, P750, DOI 10.1021/bc050253q
   Bivas-Benita M, 2009, VACCINE, V27, P4010, DOI 10.1016/j.vaccine.2009.04.033
   Boddapati SV, 2008, NANO LETT, V8, P2559, DOI 10.1021/nl801908y
   BOMAN NL, 1994, CANCER RES, V54, P2830
   Brigger I, 2002, ADV DRUG DELIVER REV, V54, P631, DOI 10.1016/S0169-409X(02)00044-3
   Calderwood SK, 2006, TRENDS BIOCHEM SCI, V31, P164, DOI 10.1016/j.tibs.2006.01.006
   Cavazzana-Calvo M, 2000, SCIENCE, V288, P669, DOI 10.1126/science.288.5466.669
   Chatterjee DK, 2008, ADV DRUG DELIVER REV, V60, P1627, DOI 10.1016/j.addr.2008.08.003
   Chavanpatil MD, 2007, J PHARM SCI-US, V96, P3379, DOI 10.1002/jps.20961
   Chavanpatil MD, 2007, MOL PHARM, V4, P730, DOI 10.1021/mp070024d
   Chavanpatil MD, 2007, PHARM RES, V24, P803, DOI 10.1007/s11095-006-9203-2
   Chellat F, 2005, BIOMATERIALS, V26, P7260, DOI 10.1016/j.biomaterials.2005.05.044
   Chen HM, 2006, J AM CHEM SOC, V128, P13348, DOI 10.1021/ja064864h
   Chen WH, 2008, MOL PHARMACEUT, V5, P464, DOI 10.1021/mp700126c
   Chen WS, 2008, CANCER IMMUNOL IMMUN, V57, P517, DOI 10.1007/s00262-007-0390-4
   Chen YC, 2008, EXPERT OPIN DRUG DEL, V5, P1301, DOI 10.1517/17425240802568505 
   Cheng Y, 2008, J AM CHEM SOC, V130, P10643, DOI 10.1021/ja801631c
   CHIANNILKULACHAI N, 1990, CANCER CHEMOTH PHARM, V26, P122, DOI 10.1007/BF02897257
   CHIANNILKULCHAI N, 1989, SELECT CANCER THER, V5, P1, DOI 10.1089/sct.1989.5.1
   Chono S, 2008, J CONTROL RELEASE, V131, P64, DOI 10.1016/j.jconrel.2008.07.006
   Conwell CC, 2008, MOL THER, V16, P370, DOI 10.1038/sj.mt.6300356
   Cryan SA, 2006, MOL PHARMACEUT, V3, P104, DOI 10.1021/mp050070i
   Csaba Noemi, 2006, Expert Opin Drug Deliv, V3, P463, DOI 10.1517/17425247.3.4.463
   Csaba N, 2009, ADV DRUG DELIVER REV, V61, P140, DOI 10.1016/j.addr.2008.09.005
   D'Souza GGM, 2008, PHARM RES-DORDR, V25, P2567, DOI 10.1007/s11095-008-9674-4
   Danhier F, 2009, J CONTROL RELEASE, V140, P166, DOI 10.1016/j.jconrel.2009.08.011
   Danhier F, 2009, J CONTROL RELEASE, V133, P11, DOI 10.1016/j.jconrel.2008.09.086
   Davaran S, 2006, INT J NANOMED, V1, P535, DOI 10.2147/nano.2006.1.4.535
   DEHAAN A, 1995, VACCINE, V13, P1320, DOI 10.1016/0264-410X(95)00037-2
   Dong XW, 2009, CANCER RES, V69, P3918, DOI 10.1158/0008-5472.CAN-08-2747
   Dong XW, 2009, EUR J PHARM BIOPHARM, V72, P9, DOI 10.1016/j.ejpb.2008.11.012
   El Bayoumil T, 2009, CLIN CANCER RES, V15, P1973, DOI 10.1158/1078-0432.CCR-08-2392
   Elbayoumi TA, 2008, EXPERT OPIN DRUG DEL, V5, P1185, DOI [10.1517/17425240802497457, 10.1517/17425240802497457 ]
   Elbayoumi TA, 2007, EUR J PHARM SCI, V32, P159, DOI 10.1016/j.ejps.2007.05.113
   Elbayoumi TA, 2007, J LIPOSOME RES, V17, P1, DOI 10.1080/08982100601186474
   Elbayoumi TA, 2006, EUR J NUCL MED MOL I, V33, P1196, DOI 10.1007/s00259-006-0139-x
   ElBayoumi TA, 2009, MOL PHARMACEUT, V6, P246, DOI 10.1021/mp8001528
   Erdogan S, 2008, J MAGN RESON IMAGING, V27, P574, DOI 10.1002/jmri.21202
   Erdogan S, 2006, MOL PHARMACEUT, V3, P525, DOI 10.1021/mp060055t
   Fattal E, 1998, J CONTROL RELEASE, V53, P137, DOI 10.1016/S0168-3659(97)00246-0
   Fievez V, 2009, EUR J PHARM BIOPHARM, V73, P16, DOI 10.1016/j.ejpb.2009.04.009
   FISHER AMR, 1995, LASER SURG MED, V17, P2, DOI 10.1002/lsm.1900170103
   Florence AT, 2001, ADV DRUG DELIVER REV, V50, pS69, DOI 10.1016/S0169-409X(01)00184-3
   Fox E, 2007, EXPERT REV ANTICANC, V7, P447, DOI 10.1586/14737140.7.4.447
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Fretz MM, 2007, BIOCHEM J, V403, P335, DOI 10.1042/BJ20061808
   Fritsch C, 1998, ARCH DERMATOL, V134, P207, DOI 10.1001/archderm.134.2.207
   Gao D, 2006, NANO LETT, V6, P2383, DOI 10.1021/nl0617179
   Gao K, 2009, MOL PHARMACEUT, V6, P651, DOI 10.1021/mp800134q
   GIBAUD S, 1994, EUR J CANCER, V30A, P820, DOI 10.1016/0959-8049(94)90299-2
   Gilmore JL, 2008, J NEUROIMMUNE PHARM, V3, P83, DOI 10.1007/s11481-007-9099-6
   Gindy ME, 2009, EXPERT OPIN DRUG DEL, V6, P865, DOI 10.1517/17425240902932908
   Gomes ER, 1999, CELL BIOL TOXICOL, V15, P249, DOI 10.1023/A:1007615813184
   GREF R, 1994, SCIENCE, V263, P1600, DOI 10.1126/science.8128245
   Grill Alexander E, 2009, Recent Pat Drug Deliv Formul, V3, P137
   Gulyaev AE, 1999, PHARMACEUT RES, V16, P1564, DOI 10.1023/A:1018983904537
   Gupta B, 2005, ADV DRUG DELIVER REV, V57, P637, DOI 10.1016/j.addr.2004.10.007
   Gupta B, 2007, ONCOL RES, V16, P351
   Gupta Bhawna, 2006, Expert Opin Drug Deliv, V3, P177, DOI 10.1517/17425247.3.2.177
   Hamdy S, 2008, VACCINE, V26, P5046, DOI 10.1016/j.vaccine.2008.07.035
   Hamdy S, 2007, J BIOMED MATER RES A, V81A, P652, DOI 10.1002/jbm.a.31019
   Heer S., 2004, ADV MATER, V16, P23
   Hou CH, 2009, BIOMATERIALS, V30, P3956, DOI 10.1016/j.biomaterials.2009.04.020
   Hu KF, 2001, ADV DRUG DELIVER REV, V51, P149, DOI 10.1016/S0169-409X(01)00165-X
   Hyndman L, 2004, J CONTROL RELEASE, V99, P435, DOI 10.1016/j.jconrel.2004.07.023
   Ishida O, 2001, PHARMACEUT RES, V18, P1042, DOI 10.1023/A:1010960900254
   Ishihara T, 2009, DRUG DELIV, V16, P153, DOI 10.1080/10717540902722774
   Ito A, 2005, J BIOSCI BIOENG, V100, P1, DOI 10.1263/jbb.100.1
   Ito A, 2007, CANCER SCI, V98, P424, DOI 10.1111/j.1349-7006.2006.00382.x
   Jain AK, 2009, J CONTROL RELEASE, V136, P161, DOI 10.1016/j.jconrel.2009.02.010
   Jain TK, 2008, BIOMATERIALS, V29, P4012, DOI 10.1016/j.biomaterials.2008.07.004
   Jain TK, 2008, MOL PHARM, V5, P316, DOI 10.1021/mp7001285
   Jayanna PK, 2009, NANOMED-NANOTECHNOL, V5, P83, DOI 10.1016/j.nano.2008.07.006
   Jin SH, 2009, UROL CLIN N AM, V36, P179, DOI 10.1016/j.ucl.2009.02.005
   Kabanov A, 2005, ADV GENET, V53, P231, DOI 10.1016/S0065-2660(05)53009-8
   Kale AA, 2007, J LIPOSOME RES, V17, P197, DOI 10.1080/08982100701525035
   Kale AA, 2007, J DRUG TARGET, V15, P538, DOI 10.1080/10611860701498203
   Kale AA, 2007, BIOCONJUGATE CHEM, V18, P363, DOI 10.1021/bc060228x
   Kaplitt MG, 2007, LANCET, V369, P2097, DOI 10.1016/S0140-6736(07)60982-9
   Kaul G, 2002, PHARMACEUT RES, V19, P1061, DOI 10.1023/A:1016486910719
   Kaul G, 2004, J DRUG TARGET, V12, P585, DOI 10.1080/10611860400013451
   Khdair A, 2008, MOL PHARMACEUT, V5, P795, DOI 10.1021/mp800026t
   Khdair A, 2009, EUR J PHARM BIOPHARM, V71, P214, DOI 10.1016/j.ejpb.2008.08.017
   Kircher MF, 2003, CANCER RES, V63, P6838
   Kirkin V, 2004, BBA-MOL CELL RES, V1644, P229, DOI 10.1016/j.bbamcr.2003.08.009
   Kleemann E, 2005, J CONTROL RELEASE, V109, P299, DOI 10.1016/j.jconrel.2005.09.036
   Ko YT, 2009, GENE THER, V16, P52, DOI 10.1038/gt.2008.135
   Ko YT, 2009, MOL PHARMACEUT, V6, P971, DOI 10.1021/mp900006h
   Krishnamachari Y, 2009, ADV DRUG DELIVER REV, V61, P205, DOI 10.1016/j.addr.2008.12.013
   Kroll RA, 1998, NEUROSURGERY, V43, P879, DOI 10.1097/00006123-199810000-00090
   Kunath K, 2003, J CONTROL RELEASE, V89, P113, DOI 10.1016/S0168-3659(03)00076-2
   Lage H, 2006, CURR DRUG TARGETS, V7, P813, DOI 10.2174/138945006777709566
   LANGER R, 1976, NATURE, V263, P797, DOI 10.1038/263797a0
   Lawson LB, 2007, CLIN PHARMACOL THER, V82, P641, DOI 10.1038/sj.clpt.2007.6100425
   Levchenko TS, 2003, METHOD ENZYMOL, V372, P339
   Li SD, 2008, MOL THER, V16, P942, DOI 10.1038/mt.2008.51
   Li SD, 2008, J CONTROL RELEASE, V126, P77, DOI 10.1016/j.jconrel.2007.11.002
   Li SD, 2008, MOL THER, V16, P163, DOI 10.1038/sj.mt.6300323
   Li SD, 2007, J CONTROL RELEASE, V123, P181, DOI 10.1016/j.jconrel.2007.09.004
   Li SD, 2009, BBA-BIOMEMBRANES, V1788, P2259, DOI 10.1016/j.bbamem.2009.06.022
   Li SD, 2008, CURR OPIN INVEST DR, V9, P1317
   Liu F, 2007, J PHARMACOL EXP THER, V321, P777, DOI 10.1124/jpet.106.118117
   Liu JQ, 2001, BIOMACROMOLECULES, V2, P362, DOI 10.1021/bm015515c
   Lode Joerg, 2001, Pharmaceutical Research (New York), V18, P1613, DOI 10.1023/A:1013094801351
   Ma LW, 2001, J PHOTOCH PHOTOBIO B, V60, P108, DOI 10.1016/S1011-1344(01)00133-6
   Ma P, 2009, J BIOMED NANOTECHNOL, V5, P151, DOI 10.1166/jbn.2009.1021
   Mahe B, 2009, J INVEST DERMATOL, V129, P1156, DOI 10.1038/jid.2008.356
   Mahor S, 2007, INT J PHARM, V340, P13, DOI 10.1016/j.ijpharm.2007.03.006
   Malik Dhirendra Kumar, 2007, Current Drug Delivery, V4, P141
   McCarthy JR, 2007, NANOMEDICINE-UK, V2, P153, DOI 10.2217/17435889.2.2.153
   Mikhaylova M, 2009, CANCER GENE THER, V16, P217, DOI 10.1038/cgt.2008.79
   Minamimura T, 2000, INT J ONCOL, V16, P1153
   Misumi S, 2009, J IMMUNOL, V182, P6061, DOI 10.4049/jimmunol.0802928
   Moffatt S, 2006, INT J PHARMACEUT, V321, P143, DOI 10.1016/j.ijpharm.2006.05.007
   Moghimi SM, 2005, FASEB J, V19, P311, DOI 10.1096/fj.04-2747rev
   Moore A, 2000, RADIOLOGY, V214, P568, DOI 10.1148/radiology.214.2.r00fe19568
   Moroz P, 2002, INT J HYPERTHER, V18, P267, DOI 10.1080/02656730110108785
   Morschhauser F, 2007, LEUKEMIA LYMPHOMA, V48, P708, DOI 10.1080/10428190701190169
   Mowat AM, 2005, VACCINE, V23, P1797, DOI 10.1016/j.vaccine.2004.11.008
   Nakase I, 2008, ADV DRUG DELIVER REV, V60, P598, DOI 10.1016/j.addr.2007.10.006
   Nayak B, 2009, J MICROENCAPSUL, V26, P154, DOI [10.1080/02652040802211709, 10.1080/02652040802211709 ]
   Nitin N, 2004, J BIOL INORG CHEM, V9, P706, DOI 10.1007/s00775-004-0560-1
   Niven R, 1998, J PHARM SCI, V87, P1292, DOI 10.1021/js980087a
   O'Connor R, 2007, ANTICANCER RES, V27, P1267
   Park J, 2009, NANOMED-NANOTECHNOL, V5, P410, DOI 10.1016/j.nano.2009.02.002
   Paschke M, 2005, GENE, V350, P79, DOI 10.1016/j.gene.2005.02.005
   PASS HI, 1993, J NATL CANCER I, V85, P443, DOI 10.1093/jnci/85.6.443
   Patil Y, 2009, J CONTROL RELEASE, V136, P21, DOI 10.1016/j.jconrel.2009.01.021
   Patil Y, 2009, INT J PHARM, V367, P195, DOI 10.1016/j.ijpharm.2008.09.039
   Patil YB, 2009, BIOMATERIALS, V30, P859, DOI 10.1016/j.biomaterials.2008.09.056
   Pearse MJ, 2005, ADV DRUG DELIVER REV, V57, P465, DOI 10.1016/j.addr.2004.09.006
   Peetla C, 2008, MOL PHARM, V5, P418, DOI 10.1021/mp700140a
   Peetla C, 2009, MOL PHARMACEUT, V6, P1311, DOI 10.1021/mp900011h
   Peetla C, 2009, LANGMUIR, V25, P2369, DOI 10.1021/la803361y
   Peng Q, 1997, CANCER-AM CANCER SOC, V79, P2282
   Perez C, 2002, J PHARM PHARMACOL, V54, P301, DOI 10.1211/0022357021778448
   Popovtzer R, 2008, NANO LETT, V8, P4593, DOI 10.1021/nl8029114
   Prabaharan M, 2009, BIOMATERIALS, V30, P3009, DOI 10.1016/j.biomaterials.2009.02.011
   Purushotham S, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/30/305101
   Qi LF, 2007, EUR J CANCER, V43, P184, DOI 10.1016/j.ejca.2006.08.029
   Rao KS, 2008, BIOMATERIALS, V29, P4429, DOI 10.1016/j.biomaterials.2008.08.004
   Rao KS, 2009, EXPERT OPIN DRUG DEL, V6, P771, DOI 10.1517/17425240903081705
   Redhead HM, 2001, J CONTROL RELEASE, V70, P353, DOI 10.1016/S0168-3659(00)00367-9
   Ricci-Junior E, 2006, INT J PHARM, V310, P187, DOI 10.1016/j.ijpharm.2005.10.048
   Robson NC, 2003, IMMUNOLOGY, V110, P95, DOI 10.1046/j.1365-2567.2003.01705.x
   Rochlitz CF, 2001, SWISS MED WKLY, V131, P4
   Rose PG, 2005, ONCOLOGIST, V10, P205, DOI 10.1634/theoncologist.10-3-205
   Roux E, 2004, J CONTROL RELEASE, V94, P447, DOI 10.1016/j.jconrel.2003.10.024
   Roy I, 2003, J AM CHEM SOC, V125, P7860, DOI 10.1021/ja0343095
   Russell-Jones GJ, 2000, J CONTROL RELEASE, V65, P49, DOI 10.1016/S0168-3659(99)00231-X
   Sakurai F, 2000, J CONTROL RELEASE, V66, P255, DOI 10.1016/S0168-3659(99)00280-1
   Samia ACS, 2003, J AM CHEM SOC, V125, P15736, DOI 10.1021/ja0386905
   Santra S, 2009, SMALL, V5, P1862, DOI 10.1002/smll.200900389
   Saupe A, 2006, EXPERT OPIN DRUG DEL, V3, P345, DOI 10.1517/17425247.3.3.345
   Sawant RM, 2006, BIOCONJUGATE CHEM, V17, P943, DOI 10.1021/bc060080h
   Sawant RM, 2008, J DRUG TARGET, V16, P601, DOI 10.1080/10611860802228954
   Sawant RR, 2008, EUR J PHARM BIOPHARM, V70, P51, DOI 10.1016/j.ejpb.2008.04.016
   Scheerlinck JPY, 2008, DRUG DISCOV TODAY, V13, P882, DOI 10.1016/j.drudis.2008.06.016
   Pappalardo JS, 2009, J CONTROL RELEASE, V134, P41, DOI 10.1016/j.jconrel.2008.11.006
   SENIOR J, 1991, BIOCHIM BIOPHYS ACTA, V1062, P77, DOI 10.1016/0005-2736(91)90337-8
   Shubayev VI, 2009, ADV DRUG DELIVER REV, V61, P467, DOI 10.1016/j.addr.2009.03.007
   Sjolander S, 2001, VACCINE, V19, P4072, DOI 10.1016/S0264-410X(01)00110-4
   Sloat BR, 2006, PHARM RES, V23, P262, DOI 10.1007/s11095-005-9078-7
   Slutter B, 2009, J CONTROL RELEASE, V138, P113, DOI 10.1016/j.jconrel.2009.05.011
   Stein WD, 2004, CURR DRUG TARGETS, V5, P333, DOI 10.2174/1389450043345489
   Stella B, 2000, J PHARM SCI, V89, P1452, DOI 10.1002/1520-6017(200011)89:11<1452::AID-JPS8>3.0.CO;2-P
   Stockert JC, 2007, CURR MED CHEM, V14, P997, DOI 10.2174/092986707780362934
   STORM G, 1995, ADV DRUG DELIVER REV, V17, P31, DOI 10.1016/0169-409X(95)00039-A
   Sugita T, 2008, BRIT J PHARMACOL, V153, P1143, DOI 10.1038/sj.bjp.0707678
   Sun C, 2008, NANOMEDICINE-UK, V3, P495, DOI 10.2217/17435889.3.4.495
   Takayama K, 2009, BIOCONJUGATE CHEM, V20, P249, DOI 10.1021/bc800327f
   Tang W, 2008, BIOCHEM BIOPH RES CO, V369, P579, DOI 10.1016/j.bbrc.2008.02.066
   Tobio M, 1998, PHARMACEUT RES, V15, P270, DOI 10.1023/A:1011922819926
   Torchilin VP, 2007, BIOCHEM SOC T, V35, P816, DOI 10.1042/BST0350816
   Torchilin VP, 2008, BIOPOLYMERS, V90, P604, DOI 10.1002/bip.20989
   Torchilin VP, 2008, ADV DRUG DELIVER REV, V60, P548, DOI 10.1016/j.addr.2007.10.008
   Torchilin VP, 2007, PHARM RES, V24, P2333, DOI 10.1007/s11095-007-9463-5
   Torchilin VP, 2006, ADV DRUG DELIVER REV, V58, P1532, DOI 10.1016/j.addr.2006.09.009
   Tseng HY, 2009, IET NANOBIOTECHNOL, V3, P46, DOI 10.1049/iet-nbt.2008.0013
   van der Zee J, 2002, ANN ONCOL, V13, P1173, DOI 10.1093/annonc/mdf280
   Vasir JK, 2007, ADV DRUG DELIVER REV, V59, P718, DOI 10.1016/j.addr.2007.06.003
   Verma DD, 2007, PHARM RES, V24, P2131, DOI 10.1007/s11095-007-9334-0
   Verma IM, 1997, NATURE, V389, P239, DOI 10.1038/38410
   Vijayaraghavalu S, 2007, CURR OPIN INVEST DR, V8, P477
   Vila A, 2002, J CONTROL RELEASE, V78, P15, DOI 10.1016/S0168-3659(01)00486-2
   Vila A, 2002, POLYM ADVAN TECHNOL, V13, P851, DOI 10.1002/pat.280
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Wang CG, 2009, ANGEW CHEM INT EDIT, V48, P2759, DOI 10.1002/anie.200805282
   Wang JM, 2007, WORLD J GASTROENTERO, V13, P3171, DOI 10.3748/wjg.v13.i23.3171
   Wartlick H, 2004, J DRUG TARGET, V12, P461, DOI 10.1080/10611860400010697
   Weng KC, 2008, NANO LETT, V8, P2851, DOI 10.1021/nl801488u
   Wu X, 2009, MOL PHARMACEUT, V6, P1449, DOI 10.1021/mp900119u
   Wu X, 2009, PHARM RES-DORD, V26, P1995, DOI 10.1007/s11095-009-9915-1
   Yan F, 2003, PHOTOCHEM PHOTOBIOL, V78, P587, DOI 10.1562/0031-8655(2003)078<0587:TEOMIS>2.0.CO;2
   Yan WL, 2007, MOL IMMUNOL, V44, P3672, DOI 10.1016/j.molimm.2007.04.009
   Yan WL, 2009, INT J PHARM, V368, P56, DOI 10.1016/j.ijpharm.2008.09.053
   Yang KJ, 2008, J IMMUNOL, V180, P6159, DOI 10.4049/jimmunol.180.9.6159
   Yang ZR, 2007, CANCER GENE THER, V14, P599, DOI 10.1038/sj.cgt.7701054
   Yow HN, 2009, EUR J PHARM BIOPHARM, V72, P62, DOI 10.1016/j.ejpb.2008.11.004
   Zaro JL, 2009, MOL PHARMACEUT, V6, P337, DOI 10.1021/mp800239p
   Zhu DH, 2006, J NANOSCI NANOTECHNO, V6, P996, DOI 10.1166/jnn.2006.169
   Zhu D, 2008, INVEST RADIOL, V43, P129, DOI 10.1097/RLI.0b013e31815878dd
NR 217
TC 13
Z9 13
U1 2
U2 22
PU INDERSCIENCE ENTERPRISES LTD
PI GENEVA
PA WORLD TRADE CENTER BLDG, 29 ROUTE DE PRE-BOIS, CASE POSTALE 896, CH-1215
   GENEVA, SWITZERLAND
SN 1475-7435
J9 INT J NANOTECHNOL
JI Int. J. Nanotechnol.
PY 2011
VL 8
IS 1-2
BP 115
EP 145
DI 10.1504/IJNT.2011.037173
PG 31
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA 691OM
UT WOS:000285090700006
DA 2018-03-20
ER

PT J
AU Sundararaj, SC
   Al-Sabbagh, M
   Rabek, CL
   Dziubla, TD
   Thomas, MV
   Puleo, DA
AF Sundararaj, Sharath Kumar C.
   Al-Sabbagh, Mohanad
   Rabek, Cheryl L.
   Dziubla, Thomas D.
   Thomas, Mark V.
   Puleo, David A.
TI Comparison of sequential drug release in vitro and in vivo
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B-APPLIED BIOMATERIALS
LA English
DT Article
DE in vitro drug release; in vivo drug release; sequential drug delivery;
   cellulose acetate phthalate; Pluronic F-127
ID DELIVERY; MICROSPHERES; DEGRADATION; SYSTEM; POLYANHYDRIDES;
   NANOPARTICLES; POLYMERS; IMPLANTS; DESIGN; FILMS
AB Development of drug-delivery devices typically involves characterizing in vitro release performance with the inherent assumption that this will closely approximate in vivo performance. Yet, as delivery devices become more complex, for instance with a sequential drug release pattern, it is important to confirm that in vivo properties correlate with the expected programming achieved in vitro. In this work, a systematic comparison between in vitro and in vivo biomaterial erosion and sequential release was performed for a multilayered association polymer system comprising cellulose acetate phthalate and Pluronic F-127. After assessing the materials during incubation in phosphate-buffered saline, devices were implanted supracalvarially in rats. Devices with two different doses and with different erosion rates were harvested at increasing times post-implantation, and the in vivo thickness loss, mass loss, and the drug release profiles were compared with their in vitro counterparts. The sequential release of four different drugs observed in vitro was successfully translated to in vivo conditions. Results suggest, however, that the total erosion time of the devices was longer and that release rates of the four drugs were different, with drugs initially released more quickly and then more slowly in vivo. Many comparative studies of in vitro and in vivo drug release from biodegradable polymers involved a single drug, whereas this research demonstrated that sequential release of four drugs can be maintained following implantation. (c) 2015 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 104B: 1302-1310, 2016.
C1 [Sundararaj, Sharath C.; Rabek, Cheryl L.; Puleo, David A.] Univ Kentucky, Dept Biomed Engn, Lexington, KY 40506 USA.
   [Al-Sabbagh, Mohanad; Thomas, Mark V.] Univ Kentucky, Coll Dent, Div Periodont, Lexington, KY USA.
   [Dziubla, Thomas D.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY USA.
RP Puleo, DA (reprint author), Univ Kentucky, Dept Biomed Engn, Lexington, KY 40506 USA.
EM puleo@uky.edu
FU NIH [DE019645, AR060964]; Kentucky NASA EPSCoR [NNX08BA13A]
FX Contract grant sponsor: NIH; contract grant number: DE019645 and
   AR060964; Contract grant sponsor: Kentucky NASA EPSCoR; contract grant
   number: NNX08BA13A
CR Avgoustakis K, 2002, J CONTROL RELEASE, V79, P123, DOI 10.1016/S0168-3659(01)00530-2
   Bolgen N, 2005, J BIOMAT SCI-POLYM E, V16, P1537, DOI 10.1163/156856205774576655
   Caruso F, 2000, LANGMUIR, V16, P1485, DOI 10.1021/la991161n
   DOMB AJ, 1995, BIOMATERIALS, V16, P319, DOI 10.1016/0142-9612(95)93260-K
   Hsu BB, 2014, BIOMACROMOLECULES, V15, P2049, DOI 10.1021/bm5001839
   Hutmacher D, 1996, Int J Oral Maxillofac Implants, V11, P667
   Jain JP, 2011, BIODEGRADABLE POLYM, P1, DOI DOI 10.1002/9781118015810
   Kipper MJ, 2002, BIOMATERIALS, V23, P4405, DOI 10.1016/S0142-9612(02)00181-3
   Langer R, 1990, BIODEGRADABLE POLYM
   Lockwood NA, 2010, J BIOMAT SCI-POLYM E, V21, P529, DOI 10.1163/156856209X429175
   Mader K, 1997, PHARM RES-DORDR, V14, P820, DOI 10.1023/A:1012123127330
   Mashayekhi R, 2013, DARU, V21, DOI 10.1186/2008-2231-21-57
   Mittal G, 2007, J CONTROL RELEASE, V119, P77, DOI 10.1016/j.jconrel.2007.01.016
   Qiu XP, 2001, LANGMUIR, V17, P5375, DOI 10.1021/la010201w
   Schacht E H, 1990, Med Device Technol, V1, P15
   SCHMIDT C, 1995, J CONTROL RELEASE, V37, P83, DOI 10.1016/0168-3659(95)00067-I
   Suliman S, 2015, J CONTROL RELEASE, V197, P148, DOI 10.1016/j.jconrel.2014.11.003
   Sundararaj SC, 2014, ACTA BIOMATER, V10, P115, DOI 10.1016/j.actbio.2013.09.031
   Sundararaj SC, 2013, BIOMATERIALS, V34, P8835, DOI 10.1016/j.biomaterials.2013.07.093
   Tracy MA, 1999, BIOMATERIALS, V20, P1057, DOI 10.1016/S0142-9612(99)00002-2
   WILLIAMS DF, 1977, J BIOENG, V1, P231
   Williams D., 1981, ENG MED, V10, P5, DOI DOI 10.1243/EMED_JOUR_1981_010_004_02
   Wood KC, 2005, LANGMUIR, V21, P1603, DOI 10.1021/la0476480
   Xu HL, 2015, J CONTROL RELEASE, V199, P84, DOI 10.1016/j.jconrel.2014.12.012
   Yang LB, 2002, INT J PHARM, V235, P1, DOI 10.1016/S0378-5173(02)00004-2
   YAPAR EA, 2010, TURK J PHARM SCI, V7, P9
   Zolnik BS, 2008, J CONTROL RELEASE, V127, P137, DOI 10.1016/j.jconrel.2008.01.004
NR 27
TC 5
Z9 5
U1 5
U2 15
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1552-4973
EI 1552-4981
J9 J BIOMED MATER RES B
JI J. Biomed. Mater. Res. Part B
PD OCT
PY 2016
VL 104
IS 7
BP 1302
EP 1310
DI 10.1002/jbm.b.33472
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA DW6PM
UT WOS:000383773400003
PM 26111338
OA green_accepted
DA 2018-03-20
ER

PT J
AU Safazadeh, L
   Zehuri, VEF
   Pautler, SP
   Hastings, JT
   Berron, BJ
AF Safazadeh, Leila
   Zehuri, Victor E. F.
   Pautler, Samuel P.
   Hastings, J. Todd
   Berron, Brad J.
TI Relative Contribution of Lateral Packing Density to Albumin Adsorption
   on Monolayers
SO LANGMUIR
LA English
DT Article
ID SELF-ASSEMBLED MONOLAYERS; SURFACE-PLASMON RESONANCE; PROTEIN
   ADSORPTION; CELL-ADHESION; FUNCTIONAL-GROUPS; GOLD SURFACES; MONO
   LAYERS; BEHAVIOR; IMMOBILIZATION; ALKANETHIOLS
AB The effect of functional group density on protein adsorption is systematically studied to support ongoing efforts in molecular imprinting of surfaces and bulk materials. In these applications, functional commodity chemicals are molded to complement the shape and chemistry of the target molecule. Here, we study the relationship between bovine serum albumin adsorption and ligand density for carboxylate, alcohol, and alkyl terminal groups. Control surfaces consisting of densely packed self-assembled monolayers (SAMs) are contrasted with low-density SAMs formed through thiol yne chemistry. Direct comparison consistently yielded greater protein adsorption on low-density SAMs than conventional pure component SAMs of the same functional group. Critically, the carboxylate and alcohol low-density SAMS are more hydrophobic than their analogous dense SAMs. Mixed functional group, dense SAMs were formed with alkyl diluents to match the hydrophobicity of the low-density SAMs. Once hydrophobicity is matched, the dense carboxylate and alcohol SAMs have higher adsorption than the low-density SAMs. We conclude (1) surface charge and hydrophobicity trends dominate over surface density contributions; (2) when hydrophobicity is matched, greater adsorption occurs on dense hydrophilic groups than on lower",density hydrophilic groups; (3) when hydrophobicity is matched, greater adsorption occurs on lower density hydrophobic groups than on higher density hydrophobic groups.
C1 [Safazadeh, Leila; Zehuri, Victor E. F.; Berron, Brad J.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Hastings, J. Todd] Univ Kentucky, Dept Elect & Comp Engn, Lexington, KY 40506 USA.
   [Pautler, Samuel P.] Univ Missouri, Dept Bioengn, Columbia, MO 65211 USA.
RP Berron, BJ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.; Hastings, JT (reprint author), Univ Kentucky, Dept Elect & Comp Engn, Lexington, KY 40506 USA.
EM todd.hastings@uky.edu; brad.berron@uky.edu
FU National Science Foundation [EEC-0851716]; American Chemical Society
   [52743-DNIS]; University of Kentucky
FX This work was supported partially by the National Science Foundation
   under Award EEC-0851716. Acknowledgment is made to the Donors of the
   American Chemical Society Petroleum Research Fund (52743-DNIS) and the
   University of Kentucky Reese S. Terry professorship (J.T.H.) for partial
   support of this research. Funding agencies had no involvement in the
   study design; in the collection, analysis and interpretation of data; in
   the writing of the report; and in the decision to submit the article for
   publication. The authors also acknowledge U.K. Center for Nanoscale
   Science and Engineering for use of a sputtering machine, a spectroscopic
   ellipsometer, and spin coater.
CR Arima Y, 2007, J MATER CHEM, V17, P4079, DOI 10.1039/b708099a
   Arima Y, 2007, BIOMATERIALS, V28, P3074, DOI 10.1016/j.biomaterials.2007.03.013
   BAIN CD, 1989, LANGMUIR, V5, P723, DOI 10.1021/la00087a027
   Berron B, 2006, LANGMUIR, V22, P7235, DOI 10.1021/la0531650
   CARUSO F, 1995, COLLOID SURFACE A, V103, P147, DOI 10.1016/0927-7757(95)03230-B
   Caruso F, 1997, J COLLOID INTERF SCI, V186, P129, DOI 10.1006/jcis.1996.4625
   Chang Y, 2010, J BIOMED MATER RES A, V93A, P400, DOI 10.1002/jbm.a.32558
   Chen SF, 2005, J AM CHEM SOC, V127, P14473, DOI 10.1021/ja054169u
   Choi EJ, 2002, LANGMUIR, V18, P557, DOI 10.1021/la010964j
   CORSEL JW, 1986, J COLLOID INTERF SCI, V111, P544, DOI 10.1016/0021-9797(86)90058-5
   Dai Z, 2001, PHYS CHEM CHEM PHYS, V3, P3769, DOI 10.1039/b104570a
   DEBRUIJN HE, 1991, OPT COMMUN, V82, P425, DOI 10.1016/0030-4018(91)90353-F
   Disley DM, 1998, BIOSENS BIOELECTRON, V13, P1213, DOI 10.1016/S0956-5663(98)00059-1
   Faucheux N, 2004, BIOMATERIALS, V25, P2721, DOI 10.1016/j.biomaterials.2003.09.069
   Gao CL, 2010, BIOMATERIALS, V31, P1486, DOI 10.1016/j.biomaterials.2009.11.025
   Gudipati CS, 2005, LANGMUIR, V21, P3044, DOI 10.1021/la048015o
   Guo J., 2013, THESIS
   Harder P, 1998, J PHYS CHEM B, V102, P426, DOI 10.1021/jp972635z
   Hastings JT, 2007, OPT EXPRESS, V15, P17661, DOI 10.1364/OE.15.017661
   Higashi N, 1999, LANGMUIR, V15, P111, DOI 10.1021/la9803427
   Hoffman AS, 1999, J BIOMAT SCI-POLYM E, V10, P1011, DOI 10.1163/156856299X00658
   JOHNSON PB, 1972, PHYS REV B, V6, P4370, DOI 10.1103/PhysRevB.6.4370
   Jung LS, 1998, LANGMUIR, V14, P5636, DOI 10.1021/la971228b
   Kalltorp M, 2000, J MATER SCI-MATER M, V11, P191, DOI 10.1023/A:1008935826310
   KOTTKEMARCHANT K, 1989, BIOMATERIALS, V10, P147, DOI 10.1016/0142-9612(89)90017-3
   LAIBINIS PE, 1992, J AM CHEM SOC, V114, P1990, DOI 10.1021/ja00032a009
   Li LY, 2005, J PHYS CHEM B, V109, P2934, DOI 10.1021/jp0473321
   Li SS, 2013, J COLLOID INTERF SCI, V402, P284, DOI 10.1016/j.jcis.2013.04.003
   Lide D R, 2004, CRC HDB CHEM PHYS 20
   LOPEZ GP, 1993, J AM CHEM SOC, V115, P10774, DOI 10.1021/ja00076a038
   Lu XY, 2004, MACROMOL RAPID COMM, V25, P1606, DOI 10.1002/marc.200400256
   Luo MX, 2012, ACS APPL MATER INTER, V4, P890, DOI 10.1021/am201557k
   Martins MCL, 2003, J BIOMED MATER RES A, V67A, P158, DOI 10.1002/jbm.a.10096
   MRKSICH M, 1995, LANGMUIR, V11, P4383, DOI 10.1021/la00011a034
   MURAMATSU N, 1988, P NATL ACAD SCI USA, V85, P2984, DOI 10.1073/pnas.85.9.2984
   Ostuni E, 2003, LANGMUIR, V19, P1861, DOI 10.1021/la020649c
   Park JS, 2005, LANGMUIR, V21, P2902, DOI 10.1021/la0475573
   Park JS, 2004, LANGMUIR, V20, P5829, DOI 10.1021/la036424z
   Patel N, 1997, LANGMUIR, V13, P6485, DOI 10.1021/la970933h
   Peters Jr T., 1995, ALL ALBUMIN BIOCH GE
   PRIME KL, 1991, SCIENCE, V252, P1164, DOI 10.1126/science.252.5009.1164
   Ratner BD, 2004, BIOMATERIALS SCI INT
   Reimhult E, 2004, ANAL CHEM, V76, P7211, DOI 10.1021/ac0492970
   Roach P, 2005, J AM CHEM SOC, V127, P8168, DOI 10.1021/ja042898o
   Safazadeh L, 2015, LANGMUIR, V31, P2689, DOI 10.1021/acs.langmuir.5b00001
   Scotchford CA, 2002, J BIOMED MATER RES, V59, P84, DOI 10.1002/jbm.1220
   Shi QS, 2005, BIOTECHNOL PROGR, V21, P516, DOI 10.1021/bp049735o
   Shumaker-Parry JS, 2004, ANAL CHEM, V76, P907, DOI 10.1021/ac034962a
   Sigal GB, 1998, J AM CHEM SOC, V120, P3464, DOI 10.1021/ja970819l
   Silin V, 1997, J COLLOID INTERF SCI, V185, P94, DOI 10.1006/jcis.1996.4586
   SILIN VI, 1993, VIB SPECTROSC, V5, P133, DOI 10.1016/0924-2031(93)87064-Z
   Stevens CA, 2014, LANGMUIR, V30, P1949, DOI 10.1021/la404940q
   Tengvall P, 1998, BIOMATERIALS, V19, P407, DOI 10.1016/S0142-9612(97)00110-5
   Tidwell CD, 1997, LANGMUIR, V13, P3404, DOI 10.1021/la9604341
   Vaisocherova H, 2008, ANAL CHEM, V80, P7894, DOI 10.1021/ac8015888
   Vanderah DJ, 2004, J AM CHEM SOC, V126, P13639, DOI 10.1021/ja047744n
   Zheng J, 2004, LANGMUIR, V20, P8931, DOI 10.1021/la036345n
NR 57
TC 1
Z9 1
U1 3
U2 12
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0743-7463
J9 LANGMUIR
JI Langmuir
PD AUG 16
PY 2016
VL 32
IS 32
BP 8034
EP 8041
DI 10.1021/acs.langmuir.6b01885
PG 8
WC Chemistry, Multidisciplinary; Chemistry, Physical; Materials Science,
   Multidisciplinary
SC Chemistry; Materials Science
GA DT7GK
UT WOS:000381654900005
PM 27463892
DA 2018-03-19
ER

PT J
AU Meenach, SA
   Burdick, J
   Kunwar, A
   Wang, J
AF Meenach, Samantha A.
   Burdick, Jared
   Kunwar, Anurag
   Wang, Joseph
TI Metal/conducting-polymer composite nanowires
SO SMALL
LA English
DT Article
DE alloys; composites; electropolymerization; nanowires; porosity
ID TEMPLATE SYNTHESIS; POLYPYRROLE
C1 Arizona State Univ, Biodesign Inst, Dept Chem Engn & Chem & Biochem, Tempe, AZ 85287 USA.
RP Wang, J (reprint author), Arizona State Univ, Biodesign Inst, Dept Chem Engn & Chem & Biochem, Tempe, AZ 85287 USA.
EM joseph.wang@asu.edu
RI Wang, Joseph/C-6175-2011; Meenach, Samantha/F-7542-2014
CR Bentley AK, 2005, J CHEM EDUC, V82, P765, DOI 10.1021/ed082p765
   George PM, 2006, ADV MATER, V18, P577, DOI 10.1002/adma.200501242
   Hernandez RM, 2004, CHEM MATER, V16, P3431, DOI 10.1021/cm0496265
   JI C, 2002, APPL PHYS LETT, V84, P4437
   Ji CX, 2003, J PHYS CHEM B, V107, P4494, DOI 10.1021/jp0222200
   Kovtyukhova Nina I, 2002, Chemistry, V8, P4354, DOI 10.1002/1521-3765(20021004)8:19<4354::AID-CHEM4354>3.0.CO;2-1
   Li F, 2003, J AM CHEM SOC, V125, P16166, DOI 10.1021/ja038452
   MARTIN CR, 1995, ACCOUNTS CHEM RES, V28, P61, DOI 10.1021/ar00050a002
   Park S, 2004, J AM CHEM SOC, V126, P11772, DOI 10.1021/ja046077v
   Senior NA, 2006, NANOTECHNOLOGY, V17, P2311, DOI 10.1088/0957-4484/17/9/040
NR 10
TC 19
Z9 19
U1 0
U2 4
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY
SN 1613-6810
J9 SMALL
JI Small
PD FEB
PY 2007
VL 3
IS 2
BP 239
EP 243
DI 10.1002/smll.200600362
PG 5
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 136FL
UT WOS:000244207900009
PM 17199245
DA 2018-03-20
ER

PT J
AU Gui, MH
   Papp, JK
   Colburn, AS
   Meeks, ND
   Weaver, B
   Wilf, I
   Bhattacharyya, D
AF Gui, Minghui
   Papp, Joseph K.
   Colburn, Andrew S.
   Meeks, Noah D.
   Weaver, Benjamin
   Wilf, Ilan
   Bhattacharyya, Dibakar
TI Engineered iron/iron oxide functionalized membranes for selenium and
   other toxic metal removal from power plant scrubber water
SO JOURNAL OF MEMBRANE SCIENCE
LA English
DT Article
DE Surface modification; Polyelectrolyte; Nanoparticles; Nanocomposite
   membrane
ID ZERO-VALENT IRON; FILLED MICROPOROUS MEMBRANES; ZEROVALENT IRON;
   BIMETALLIC NANOPARTICLES; ENVIRONMENTAL REMEDIATION; HYDRODYNAMIC
   PERMEABILITY; PVDF MEMBRANES; ACRYLIC-ACID; SELENATE; TRICHLOROETHYLENE
AB The remediation of toxic metals from water with high concentrations of salt has been an emerging area for membrane separation. Cost-effective nanomaterials such as iron and iron oxide nanoparticles have been widely used in reductive and oxidative degradation of toxic organics. Similar procedures can be used for redox transformations of metal species (e.g. metal oxyanions to elemental metal), and/or adsorption of species on iron oxide surface. In this study, iron-functionalized membranes were developed for reduction and adsorption of selenium from coal-fired power plant scrubber water. Iron-functionalized membranes have advantages over iron suspension as the membrane prevents particle aggregation and dissolution. Both lab scale and full-scale membranes were prepared first by coating polyvinylidene fluoride (PVDF) membranes with polyacrylic acid (PAA), followed by ion exchange of ferrous ions and subsequent reduction to zero-valent iron nanoparticles. Water permeability of membranes decreased as the percent PAA functionalization increased, and the highest ion exchange capacity (IEC) was obtained at 20% PAA with highly pH responsive pores. Although high concentrations of sulfate and chloride in scrubber water decreased the reaction rate of selenium reduction, this was shown to be overcome by integration of nanofiltration (NF) and iron-functionalized membranes, and selenium concentration below 10 mu g/L was achieved. (C) 2015 Elsevier B.V All rights reserved.
C1 [Gui, Minghui; Papp, Joseph K.; Colburn, Andrew S.; Bhattacharyya, Dibakar] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Meeks, Noah D.] Southern Co Serv Inc, Birmingham, AL 35203 USA.
   [Weaver, Benjamin; Wilf, Ilan] Nanostone Sepro Membranes Inc, Oceanside, CA 92056 USA.
RP Bhattacharyya, D (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM db@engr.uky.edu
FU Southern Company in Birmingham, AL; National Institute of Environmental
   Health Sciences Superfund Research Program of the National Institutes of
   Health (NIH-NIEHS-SRP) [P42ES007380]; National Science Foundation
   Kentucky EPSCoR program (NSF) [1355438]; NSF [0814194]; NSF REU program
FX This project has been supported by Southern Company in Birmingham, AL,
   National Institute of Environmental Health Sciences Superfund Research
   Program of the National Institutes of Health (NIH-NIEHS-SRP) under Award
   no. P42ES007380, and by National Science Foundation Kentucky EPSCoR
   program (NSF Award no. 1355438). The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of NIH. XPS analysis was supported by NSF under Grant no.
   0814194. We thank the significant contributions of Nanostone/Sepro
   Membranes, Inc. in Oceanside, CA for joint development of full-scale
   functionalized membranes. Joseph Papp was also supported by the NSF REU
   program. We also thank Mr, Xinjun Teng (formerly of Southern Company
   Services, Inc.) for his role in initiating and managing Southern's
   contribution to this project in the early stages.
CR Auffan M, 2009, NAT NANOTECHNOL, V4, P634, DOI 10.1038/nnano.2009.242
   Beuermann S, 2002, MACROMOL SYMP, V182, P31, DOI 10.1002/1521-3900(200206)182:1<31::AID-MASY31>3.0.CO;2-7
   Brandrup J., 2003, POLYM HDB, pVII
   CHAPIRO A, 1981, EUR POLYM J, V17, P457, DOI 10.1016/0014-3057(81)90001-X
   Das S, 2013, APPL GEOCHEM, V28, P185, DOI 10.1016/j.apgeochem.2012.10.026
   Elimelech M, 2011, SCIENCE, V333, P712, DOI 10.1126/science.1200488
   Goldberg S, 2011, DYNAMICS AND BIOAVAILABILITY OF HEAVY METALS IN THE ROOTZONE, P65
   Greenlee LF, 2012, ENVIRON SCI TECHNOL, V46, P12913, DOI 10.1021/es303037k
   GROMOV VF, 1980, EUR POLYM J, V16, P529, DOI 10.1016/0014-3057(80)90137-8
   Gui M, 2013, IND ENG CHEM RES, V52, P10430, DOI 10.1021/ie400507c
   Gui MH, 2012, J NANOPART RES, V14, DOI 10.1007/s11051-012-0861-1
   He F, 2008, APPL CATAL B-ENVIRON, V84, P533, DOI 10.1016/j.apcatb.2008.05.008
   Hernandez S, 2014, IND ENG CHEM RES, V53, P1130, DOI 10.1021/ie403353g
   Hu K, 2007, J MEMBRANE SCI, V301, P19, DOI 10.1016/j.memsci.2007.05.031
   Huang QG, 2008, ENVIRON SCI TECHNOL, V42, P8884, DOI 10.1021/es8015588
   Huang YH, 2013, SEP PURIF TECHNOL, V118, P690, DOI 10.1016/j.seppur.2013.07.009
   Johnson RL, 2013, ENVIRON SCI TECHNOL, V47, P1573, DOI 10.1021/es304564q
   Kapur V, 1996, IND ENG CHEM RES, V35, P3179, DOI 10.1021/ie960015z
   Kim H, 2008, DESALINATION, V223, P212, DOI 10.1016/j.desal.2007.03.015
   Klas S, 2013, SEP PURIF TECHNOL, V116, P222, DOI 10.1016/j.seppur.2013.05.044
   Lalvani S. B., 2004, SELENIUM REMOVAL AGR
   Lemly AD, 2004, ECOTOX ENVIRON SAFE, V59, P44, DOI 10.1016/S0147-6513(03)00095-2
   Lewis SR, 2011, P NATL ACAD SCI USA, V108, P8577, DOI 10.1073/pnas.1101144108
   Liu F, 2011, J MEMBRANE SCI, V375, P1, DOI 10.1016/j.memsci.2011.03.014
   Lowry GV, 2012, ENVIRON SCI TECHNOL, V46, P6893, DOI 10.1021/es300839e
   Mika AM, 2001, IND ENG CHEM RES, V40, P1694, DOI 10.1021/ie000794q
   Mondal K, 2004, IND ENG CHEM RES, V43, P4922, DOI 10.1021/ie0307151
   MURPHY AP, 1988, IND ENG CHEM RES, V27, P187, DOI 10.1021/ie00073a033
   Myneni SCB, 1997, SCIENCE, V278, P1106, DOI 10.1126/science.278.5340.1106
   Olegario JT, 2010, J NANOPART RES, V12, P2057, DOI 10.1007/s11051-009-9764-1
   Peak D, 2002, ENVIRON SCI TECHNOL, V36, P1460, DOI 10.1021/es0156643
   Pignatello JJ, 2006, CRIT REV ENV SCI TEC, V36, P1, DOI 10.1080/10643380500326564
   Qiu SR, 2000, LANGMUIR, V16, P2230, DOI 10.1021/la990902h
   Rushton A., 1987, FILTRATION PRINCIPLE, P163
   Scheinost AC, 2008, ENVIRON SCI TECHNOL, V42, P1984, DOI 10.1021/es071573f
   Schellenger AEP, 2013, ENVIRON SCI TECHNOL, V47, P6254, DOI 10.1021/es4000033
   Schug TT, 2013, ENVIRON HEALTH PERSP, V121, P410, DOI 10.1289/ehp.1206091
   Smuleac V, 2011, J MEMBRANE SCI, V379, P131, DOI 10.1016/j.memsci.2011.05.054
   Su CM, 2001, ENVIRON SCI TECHNOL, V35, P4562, DOI 10.1021/es010768z
   Sun YP, 2006, ADV COLLOID INTERFAC, V120, P47, DOI 10.1016/j.cis.2006.03.001
   Tee YH, 2009, J PHYS CHEM C, V113, P9454, DOI 10.1021/jp809098z
   Tseng HH, 2011, J HAZARD MATER, V192, P500, DOI 10.1016/j.jhazmat.2011.05.047
   Wang CB, 1997, ENVIRON SCI TECHNOL, V31, P2154, DOI 10.1021/es970039c
   Winnik FM, 1998, CAN J CHEM, V76, P10, DOI 10.1139/cjc-76-1-10
   Xiao L, 2014, J MEMBRANE SCI, V457, P39, DOI 10.1016/j.memsci.2014.01.033
   Xu J, 2005, ENVIRON PROG, V24, P358, DOI 10.1002/ep.10106
   Xue XF, 2009, APPL CATAL B-ENVIRON, V89, P432, DOI 10.1016/j.apcatb.2008.12.024
   Yoon IH, 2011, APPL CATAL B-ENVIRON, V104, P185, DOI 10.1016/j.apcatb.2011.02.014
   Zhang WX, 2003, J NANOPART RES, V5, P323, DOI 10.1023/A:1025520116015
   Zhang YQ, 2005, J ENVIRON QUAL, V34, P487, DOI 10.2134/jeq2005.0487
   Zheng TH, 2008, ENVIRON SCI TECHNOL, V42, P4494, DOI 10.1021/es702214x
   Zingaro RA, 1997, ENVIRON INT, V23, P299, DOI 10.1016/S0160-4120(97)00032-9
NR 52
TC 16
Z9 16
U1 8
U2 74
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0376-7388
EI 1873-3123
J9 J MEMBRANE SCI
JI J. Membr. Sci.
PD AUG 15
PY 2015
VL 488
BP 79
EP 91
DI 10.1016/j.memsci.2015.03.089
PG 13
WC Engineering, Chemical; Polymer Science
SC Engineering; Polymer Science
GA CI5QS
UT WOS:000354814300007
PM 26327740
OA green_accepted
DA 2018-03-19
ER

PT J
AU Tharappel, JC
   Bower, CE
   Harris, JW
   Ramineni, SK
   Puleo, DA
   Roth, JS
AF Tharappel, Job C.
   Bower, Curtis E.
   Harris, Jennifer Whittington
   Ramineni, Sandeep K.
   Puleo, David A.
   Roth, John S.
TI Doxycycline administration improves fascial interface in hernia repair
SO JOURNAL OF SURGICAL RESEARCH
LA English
DT Article
DE Collagen; Doxycycline; Hernia; Matrix metalloproteinase
ID MATRIX METALLOPROTEINASE-2 ACTIVITY; INCISIONAL HERNIAS; DOSE
   DOXYCYCLINE; VASCULAR CHANGES; HYPERTENSION; DYSFUNCTION; PERIODONTITIS;
   INFLAMMATION; EXPRESSION; INHIBITOR
AB Background: Despite improvements in ventral hernia repair techniques, their recurrence rates are unacceptably high. Increased levels of matrix metalloproteinases (MMPs) and reduced collagen-1 to -3 ratios are implicated in incisional hernia formation. We have recently shown doxycycline treatment for 4wk after hernia repair reduced MMP levels, significantly increased collagen-1 to -3 ratios, and increased tensile strength of repaired interface fascia. However, this increase was not statistically significant. In this study, we extended treatment duration to determine whether this would impact the tensile strength of the repaired interface fascia.
   Materials and methods: Thirty-two male Spraguee Dawley rats underwent incision hernia creation and subsequent repair with polypropylene mesh. The animals received either saline (n=16) or doxycycline (n=16) beginning from 1 day before hernia repair until the end of survival time of 6 wk (n=16) or 12wk (n=16). Tissue samples were investigated for MMPs and collagen subtypes using Western blot procedures, and tensiometric analysis was performed.
   Results: At both 6 and 12 wk after hernia repair, the tensiometric strength of doxycycline treated mesh to fascia interface (MFI) tissue showed a statistically significant increase when compared with untreated control MFI. In both groups, collagen-1, -2, and -3 ratios were remarkably increased in doxycycline-treated MFI. At 6 wk, the doxycycline-treated MFI group showed a significant decrease in MMP-2, an increase in MMP-3, and no change in MMP-9. At 12 wk, MMP-9 showed a remarkable reduction, whereas MMP-2 and -3 protein levels increased in the doxycycline-treated MFI group.
   Conclusions: Doxycycline administration results in significantly improved strength of repaired fascial interface tissue along with a remarkable increase in collagen-1, -2, and -3 ratios. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Tharappel, Job C.; Bower, Curtis E.; Harris, Jennifer Whittington; Roth, J. Scott] Univ Kentucky, Dept Surg, Lexington, KY 40536 USA.
   [Ramineni, Sandeep K.; Puleo, David A.] Univ Kentucky, Dept Biomed Engn, Lexington, KY 40536 USA.
RP Roth, JS (reprint author), Univ Kentucky, Med Ctr, Dept Surg, Div Gen Surg, 800 Rose St,C 226 UKMC, Lexington, KY 40536 USA.
EM s.roth@uky.edu
FU Davol Inc., Warwick, RI; National Institutes of Health [AR060964]
FX This research was supported by a grant from Davol Inc., Warwick, RI.
   S.K.R. and D.A.P. were supported in part by the National Institutes of
   Health (AR060964). Authors' contributions: J.C.T. and J.S.R. contributed
   to study design. J.C.T., C.E.B., and J.W.H. performed the surgical
   procedures. JCT and S.K.R. collected the data. J.C.T., D.A.P., and
   J.S.R. made the critical revision of the article. J.S.R. was in charge
   of obtaining funding and final approval of the article. All authors
   contributed to analysis and interpretation and participated in writing
   the article. The authors acknowledge the gracious support provided by
   Ms. Linda Combs in preparing the manuscript.
CR Antonio RC, 2014, MOL CELL BIOCHEM, V386, P99, DOI 10.1007/s11010-013-1848-7
   Castro MM, 2009, FREE RADICAL BIO MED, V46, P1298, DOI 10.1016/j.freeradbiomed.2009.02.011
   Cerisano G, 2014, EUR HEART J, V35, P184, DOI 10.1093/eurheartj/eht420
   Dias CA, 2005, ANESTH ANALG, V101, P115, DOI 10.1213/01.ANE.0000153499.10558.F3
   Farb A, 2002, CIRCULATION, V106, P2379, DOI 10.1161/01.CIR.0000033973.06059.04
   Flum DR, 2003, ANN SURG, V237, P129, DOI 10.1097/00000658-200301000-00018
   Guimaraes DA, 2011, BASIC CLIN PHARMACOL, V108, P318, DOI 10.1111/j.1742-7843.2010.00656.x
   Hardinger Karen L, 2013, World J Transplant, V3, P68, DOI 10.5500/wjt.v3.i4.68
   Klinge U, 1999, EUR SURG RES, V31, P480, DOI 10.1159/000008728
   Klinge U., 2001, ABDOMINAL WALL HERNI, P286
   Lee HM, 2004, J PERIODONTOL, V75, P453, DOI 10.1902/jop.2004.75.3.453
   Luiendijk RW, 2000, NEW ENGL J MED, V343, P392
   Martinez MLL, 2008, EUR J PHARMACOL, V599, P110, DOI 10.1016/j.ejphar.2008.10.007
   McFadden EP, 2004, LANCET, V364, P1519, DOI 10.1016/S0140-6736(04)17275-9
   Mignatti P, 1996, MOL CELLULAR BIOL WO, P427
   MUDGE M, 1985, BRIT J SURG, V72, P70, DOI 10.1002/bjs.1800720127
   MURPHY G, 1994, ANN NY ACAD SCI, V732, P31, DOI 10.1111/j.1749-6632.1994.tb24722.x
   Nguyen PT, 2012, J INVEST SURG, V25, P330, DOI 10.3109/08941939.2011.639848
   OVERALL CM, 1991, J BIOL CHEM, V266, P14064
   Pierce LJ, 2011, SEMIN RADIAT ONCOL, V21, P1, DOI 10.1016/j.semradonc.2010.08.010
   POLLOCK AV, 1989, BRIT J SURG, V76, P953, DOI 10.1002/bjs.1800760926
   Poulose BK, 2012, HERNIA, V16, P179, DOI 10.1007/s10029-011-0879-9
   Rice RD, 2010, AESTHET PLAST SURG, V34, P290, DOI 10.1007/s00266-009-9449-2
   Rosenblatt J E, 1966, Antimicrob Agents Chemother (Bethesda), V6, P134
   Salameh JR, 2007, AM SURGEON, V73, P561
   Samson R, 2012, SEMIN VASC SURG, V25, P25, DOI 10.1053/j.semvascsurg.2012.03.004
   Schulze CJ, 2013, CRIT CARE MED, V41, P2512, DOI 10.1097/CCM.0b013e318292373c
   Souza-Costa DC, 2005, CHEST, V128, P3705, DOI 10.1378/chest.128.5.3705
   Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463
   Susa-Santos O, 2012, N-S ARCH PHARMACOL, V385, P685
   Tharappel JC, 2013, J SURG RES, V184, P699, DOI 10.1016/j.jss.2013.05.101
   van Ramshorst GH, 2010, WORLD J SURG, V34, P20, DOI 10.1007/s00268-009-0277-y
   Wilcox JR, 2012, WOUNDS, V24, P339
   WOESSNER JF, 1994, ANN NY ACAD SCI, V732, P11
   Yagan A, 2014, J PERIODONTOL, V85, P478, DOI 10.1902/jop.2013.130138
NR 35
TC 4
Z9 4
U1 0
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0022-4804
EI 1095-8673
J9 J SURG RES
JI J. Surg. Res.
PD AUG
PY 2014
VL 190
IS 2
BP 692
EP 698
DI 10.1016/j.jss.2014.05.013
PG 7
WC Surgery
SC Surgery
GA AM4DD
UT WOS:000339801800046
PM 24929536
DA 2018-03-20
ER

PT J
AU Fang, L
   Chow, KM
   Hou, SR
   Xue, L
   Chen, XB
   Rodgers, DW
   Zheng, F
   Zhan, CG
AF Fang, Lei
   Chow, K. Martin
   Hou, Shurong
   Xue, Liu
   Chen, Xiabin
   Rodgers, David W.
   Zheng, Fang
   Zhan, Chang-Guo
TI Rational Design, Preparation, and Characterization of a Therapeutic
   Enzyme Mutant with Improved Stability and Function for Cocaine
   Detoxification
SO ACS CHEMICAL BIOLOGY
LA English
DT Article
ID HUMAN BUTYRYLCHOLINESTERASE; TRANSITION-STATES; MOLECULAR-DYNAMICS;
   FUNCTION TRADEOFFS; IMMUNE-RESPONSES; STRUCTURAL BASES; MODEL PROTEIN;
   ESTERASE; STABILIZATION; SIMULATION
AB Cocaine esterase (CocE) is known as the most efficient natural enzyme for cocaine hydrolysis. The major obstacle to the clinical application of wild-type CocE is the thermoinstability with a half-life of only similar to 12 min at 37 degrees C. The previously designed T172R/G173Q mutant (denoted as enzyme E172-173) with an improved in vitro half-life of similar to 6 h at 37 degrees C is currently in clinical trial Phase H for cocaine overdose treatment. Through molecular modeling and dynamics simulation, we designed and characterized a promising new mutant of E172-173 with extra L196C/I301C mutations (denoted as enzyme E196-301) to produce cross-subunit disulfide bonds that stabilize the dimer structure. The cross-subunit disulfide bonds were confirmed by X-ray diffraction. The designed L196C/I301C mutations have not only considerably extended the in vitro half-life at 37 degrees C to >100 days, but also significantly improved the catalytic efficiency against cocaine by similar to 150%. In addition, the thermostable E196-301 can be PEGylated to significantly prolong the residence time in mice. The PEGylated E196-301 can fully protect mice from a lethal dose of cocaine (180 mg/kg, LD100) for at least 3 days, with an average protection time of similar to 94h. This is the longest in vivo protection of mice from the lethal dose of cocaine demonstrated within all studies using an exogenous enzyme reported so far. Hence, E196-301 may be developed to become a more valuable therapeutic enzyme for cocaine abuse treatment, and it demonstrates that a general design strategy and protocol to simultaneously improve both the stability and function are feasible for rational protein drug design.
C1 [Fang, Lei; Hou, Shurong; Xue, Liu; Chen, Xiabin; Zheng, Fang; Zhan, Chang-Guo] Univ Kentucky, Coll Pharm, Mol Modeling & Biopharmaceut Ctr, Lexington, KY 40536 USA.
   [Fang, Lei; Hou, Shurong; Xue, Liu; Chen, Xiabin; Zheng, Fang; Zhan, Chang-Guo] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
   [Chow, K. Martin; Rodgers, David W.] Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA.
   [Chow, K. Martin; Rodgers, David W.] Univ Kentucky, Struct Biol Ctr, Lexington, KY 40536 USA.
RP Zhan, CG (reprint author), Univ Kentucky, Coll Pharm, Mol Modeling & Biopharmaceut Ctr, 789 South Limestone St, Lexington, KY 40536 USA.
EM zhan@uky.edu
FU National Institutes of Health [R01 DA035552, R01 DA032910, R01 DA013930,
   R01 DA025100]; U.S. Department of Energy, Office of Science, Office of
   Basic Energy Sciences [W-31-109-Eng-38]; NIH Grant from the National
   Institute of General Medical Sciences [P20GM103486]
FX This work was supported by the National Institutes of Health (grants R01
   DA035552, R01 DA032910, R01 DA013930, and R01 DA025100 to Zhan). X-ray
   diffraction data were collected at Southeast Regional Collaborative
   Access Team (SER-CAT) 22-ID beamline at the Advanced Photon Source,
   Argonne National Laboratory. Supporting institutions may be found at
   www.ser-cat.org/members.html. We thank the staff of SER-CAT for
   assistance in data collection. Use of the Advanced Photon Source was
   supported by the U.S. Department of Energy, Office of Science, Office of
   Basic Energy Sciences, under Contract No.W-31-109-Eng-38. Use of the
   Protein Core of the Center for Molecular Medicine was supported by NIH
   Grant No. P20GM103486 from the National Institute of General Medical
   Sciences. The authors also acknowledge the Computer Center at the
   University of Kentucky for super-computing time on a Dell X-series
   Cluster with 384 nodes or 4768 processors.
CR Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925
   Beadle BM, 2002, J MOL BIOL, V321, P285, DOI 10.1016/S0022-2836(02)00599-5
   Bjork A, 2003, J MOL BIOL, V334, P811, DOI 10.1016/j.jmb.2003.10.006
   Bloom JD, 2004, BIOPHYS J, V86, P2758, DOI 10.1016/S0006-3495(04)74329-5
   Braman J, 2000, NUCLEIC ACID PROTOCOLS HANDBOOK, P835
   Brim RL, 2010, MOL PHARMACOL, V77, P593, DOI 10.1124/mol.109.060806
   Carrera MRA, 2004, P NATL ACAD SCI USA, V101, P10416, DOI 10.1073/pnas.0403795101
   Collins GT, 2012, J PHARMACOL EXP THER, V342, P205, DOI 10.1124/jpet.112.194639
   Collins GT, 2012, NEUROPSYCHOPHARMACOL, V37, P1092, DOI 10.1038/npp.2011.226
   Collins GT, 2011, DRUG ALCOHOL DEPEN, V118, P158, DOI 10.1016/j.drugalcdep.2011.03.015
   Collins GT, 2009, J PHARMACOL EXP THER, V331, P445, DOI 10.1124/jpet.108.150029
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   Duan Y, 2003, J COMPUT CHEM, V24, P1999, DOI 10.1002/jcc.10349
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Gao DQ, 2009, MOL PHARMACOL, V75, P318, DOI 10.1124/mol.108.049486
   Gao DQ, 2006, PROTEINS, V62, P99, DOI 10.1002/prot.20713
   Hamza A, 2005, J PHYS CHEM B, V109, P4776, DOI 10.1021/jp0447136
   Han ZL, 2009, APPL MICROBIOL BIOT, V85, P117, DOI 10.1007/s00253-009-2067-8
   Hou SR, 2013, ORG BIOMOL CHEM, V11, P7477, DOI 10.1039/c3ob41713a
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Kabashima T, 2001, BBA-PROTEIN STRUCT M, V1547, P214, DOI 10.1016/S0167-4838(01)00185-6
   Kamendulis LM, 1996, J PHARMACOL EXP THER, V279, P713
   Karila L, 2008, INT J NEUROPSYCHOPH, V11, P425, DOI 10.1017/S1461145707008097
   Ko MC, 2007, J PHARMACOL EXP THER, V320, P926, DOI 10.1124/jpet.106.114223
   Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022
   LANDRY DW, 1993, SCIENCE, V259, P1899, DOI 10.1126/science.8456315
   Larsen NA, 2002, NAT STRUCT BIOL, V9, P17, DOI 10.1038/nsb742
   Liu JJ, 2009, J AM CHEM SOC, V131, P11964, DOI 10.1021/ja903990p
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206
   Meijler MM, 2005, J AM CHEM SOC, V127, P2477, DOI 10.1021/ja043935e
   Merski M, 2012, P NATL ACAD SCI USA, V109, P16179, DOI 10.1073/pnas.1208076109
   Nagatani RA, 2007, BIOCHEMISTRY-US, V46, P6688, DOI 10.1021/bi700507d
   Narasimhan D, 2011, MOL PHARMACOL, V80, P1056, DOI 10.1124/mol.111.074997
   Narasimhan D, 2010, PROTEIN ENG DES SEL, V23, P537, DOI 10.1093/protein/gzq025
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Pan YM, 2005, P NATL ACAD SCI USA, V102, P16656, DOI 10.1073/pnas.0507332102
   Pan YM, 2007, J AM CHEM SOC, V129, P13537, DOI 10.1021/ja073724k
   Rodgers DW, 1997, METHOD ENZYMOL, V276, P183, DOI 10.1016/S0076-6879(97)76059-2
   RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5
   SHOICHET BK, 1995, P NATL ACAD SCI USA, V92, P452, DOI 10.1073/pnas.92.2.452
   STICKLE DF, 1992, J MOL BIOL, V226, P1143, DOI 10.1016/0022-2836(92)91058-W
   Sun H, 2002, J PHARMACOL EXP THER, V302, P710, DOI 10.1124/jpet.302.2.710
   Thomas VL, 2010, J MOL BIOL, V396, P47, DOI 10.1016/j.jmb.2009.11.005
   Tokuriki N, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000002
   UNODC (United Nations Office on Drugs and Crime), 2010, WORLD DRUG REP 2010
   Xi Zheng-Xiong, 2008, Curr Drug Abuse Rev, V1, P303
   Yang WC, 2009, BIOPHYS J, V96, P1931, DOI 10.1016/j.bpj.2008.11.051
   Zhan CG, 2005, J COMPUT CHEM, V26, P980, DOI 10.1002/jcc.20241
   Zheng F, 2008, J AM CHEM SOC, V130, P12148, DOI 10.1021/ja803646t
   Zheng F, 2010, BIOCHEMISTRY-US, V49, P9113, DOI 10.1021/bi1011628
NR 50
TC 15
Z9 15
U1 1
U2 24
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1554-8929
EI 1554-8937
J9 ACS CHEM BIOL
JI ACS Chem. Biol.
PD AUG
PY 2014
VL 9
IS 8
BP 1764
EP 1772
DI 10.1021/cb500257s
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AN3VT
UT WOS:000340517500019
PM 24919140
OA gold
DA 2018-03-20
ER

PT J
AU Swadley, MJ
   Li, TL
AF Swadley, Matthew J.
   Li, Tonglei
TI Reaction mechanism of 1,3,5-trinitro-s-triazine (RDX) deciphered by
   density functional theory
SO JOURNAL OF CHEMICAL THEORY AND COMPUTATION
LA English
DT Article
ID CONDENSED-PHASE DECOMPOSITION; NUCLEAR FUKUI FUNCTION;
   CYCLOTRIMETHYLENE-TRINITRAMINE; THERMAL-DECOMPOSITION;
   ELECTRONIC-STRUCTURE; ENERGETIC MATERIALS; AB-INITIO;
   ELECTRICAL-CONDUCTIVITY; EXPLOSIVE DECOMPOSITION; ELASTIC-CONSTANTS
AB 1,3,5-Trinitro-s-triazine, or cyclotrimethylene trinitramine, or RDX, is a sensitive, secondary explosive, which has been the subject of a number of studies regarding the sensitivity and mechanism of decomposition in energetic materials. Several initial mechanistic steps have been proposed for RDX decomposition, with no conclusive agreement upon any one as the definitive pathway. Our research utilizes density functional theory (DFT)-based calculations and concepts, particularly the nuclear Fukui function, to analyze the effects of additive/depletive electronic perturbation upon vapor conformers and crystal RDX structures. Since the nuclear Fukui function is a measure of the physical stress that a nucleus encounters upon a change in the electron population, it may provide useful information regarding the role of each atom in unimolecular decomposition. The results illustrate that both homolytic cleavage of N-N bonds and elimination of HONO from RDX exhibit favorability as initial steps in the decomposition of RDX in either phase. The nuclear Fukui function proved a valuable tool for gaining insight into the initial steps of unimolecular reactions.
C1 Univ Kentucky, Lexington, KY 40536 USA.
RP Li, TL (reprint author), Univ Kentucky, Lexington, KY 40536 USA.
EM tonglei@uky.edu
CR Balawender R, 2001, J CHEM PHYS, V114, P4441, DOI 10.1063/1.1346579
   BEHRENS R, 1992, J PHYS CHEM-US, V96, P8877, DOI 10.1021/j100201a036
   BEHRENS R, 1992, J PHYS CHEM-US, V96, P8891, DOI 10.1021/j100201a037
   BOTCHER TR, 1994, J PHYS CHEM-US, V98, P5441, DOI 10.1021/j100072a009
   Boyd S, 2006, J CHEM PHYS, V124, DOI 10.1063/1.2176621
   CAULDER SM, 2004, P C AM PHYS SOC TROP
   Chakraborty D, 2000, J PHYS CHEM A, V104, P2261, DOI 10.1021/jp9936953
   CHAMBERS GP, 2002, AIP C P, V620
   CHOI CS, 1972, ACTA CRYSTALL B-STRU, VB 28, P2857, DOI 10.1107/S0567740872007046
   CHOI M, 1995, J PHYS CHEM-US, V99, P15785, DOI 10.1021/j100043a016
   COHEN MH, 1994, J CHEM PHYS, V101, P8988, DOI 10.1063/1.468026
   De Proft F, 1998, J CHEM PHYS, V108, P7549, DOI 10.1063/1.476188
   Doll K, 2001, INT J QUANTUM CHEM, V82, P1, DOI 10.1002/1097-461X(2001)82:1<1::AID-QUA1017>3.0.CO;2-W
   DREMIN AN, 1992, PHILOS T ROY SOC A, V339, P355, DOI 10.1098/rsta.1992.0041
   ERSHOV AP, 1975, COMBUST EXPLO SHOCK+, V11, P798, DOI 10.1007/BF00744782
   ERSHOV AP, 1974, COMBUST EXPLO SHOCK+, V10, P776, DOI 10.1007/BF01463821
   Feng SX, 2005, J PHYS CHEM A, V109, P7258, DOI 10.1021/jp0519666
   Feynman RP, 1939, PHYS REV, V56, P340, DOI 10.1103/PhysRev.56.340
   Gilman JJ, 1996, SCIENCE, V274, P65, DOI 10.1126/science.274.5284.65
   Gilman J. J., 1992, CHEM PROPULSION INF, V589, P379
   Harris NJ, 1997, J AM CHEM SOC, V119, P6583, DOI 10.1021/ja970392i
   Haussuhl S, 2001, Z KRISTALLOGR, V216, P339, DOI 10.1524/zkri.216.6.339.20342
   Haycraft JJ, 2006, J CHEM PHYS, V124, DOI 10.1063/1.2141958
   Hellmann H., 1937, EINFUHRUNG QUANTENCH
   HOHENBERG P, 1964, PHYS REV B, V136, pB864, DOI 10.1103/PhysRev.136.B864
   Kohn W, 1996, J PHYS CHEM-US, V100, P12974, DOI 10.1021/jp960669l
   Kuklja MM, 2000, J APPL PHYS, V87, P2215, DOI 10.1063/1.372163
   Kuklja MM, 2003, APPL PHYS A-MATER, V76, P359, DOI 10.1007/s00339-002-1821-x
   Kuklja MM, 2001, J APPL PHYS, V89, P4156, DOI 10.1063/1.1350631
   Kuklja MM, 2000, J CHEM PHYS, V112, P3417, DOI 10.1063/1.480922
   Li TL, 2005, PHARM RES-DORDR, V22, P1964, DOI 10.1007/s11095-005-7392-8
   Luty T, 2002, J CHEM PHYS, V117, P1775, DOI 10.1063/1.1485968
   Maharrey S, 2005, J PHYS CHEM A, V109, P11236, DOI 10.1021/jp054188q
   OWENS FJ, 1979, J APPL PHYS, V51, P1494
   PACE MD, 1991, J PHYS CHEM-US, V95, P5858, DOI 10.1021/j100168a028
   PARR RG, 1995, ANNU REV PHYS CHEM, V46, P701, DOI 10.1146/annurev.pc.46.100195.003413
   Rice BM, 1997, J PHYS CHEM A, V101, P8720, DOI 10.1021/jp972062q
   Ryzhkov LR, 2005, CRYST GROWTH DES, V5, P2066, DOI 10.1021/cg050209u
   Schwarz RB, 2005, J APPL PHYS, V98, DOI 10.1063/1.2037865
   Sewell TD, 1998, J APPL PHYS, V83, P4142, DOI 10.1063/1.367168
   Tsiaousis D, 2005, J CHEM PHYS, V122, DOI 10.1063/1.1893653
   Ye S., 2002, KAYAKU GAKKAISHI, V63, P104
   ZHAO XS, 1988, J CHEM PHYS, V88, P801, DOI 10.1063/1.454158
   ZUBKOV PI, 1971, COMBUST EXPLO SHOCK+, V7, P253, DOI 10.1007/BF00748985
NR 44
TC 19
Z9 19
U1 0
U2 24
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1549-9618
EI 1549-9626
J9 J CHEM THEORY COMPUT
JI J. Chem. Theory Comput.
PD MAR-APR
PY 2007
VL 3
IS 2
BP 505
EP 513
DI 10.1021/ct600202e
PG 9
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA 145HG
UT WOS:000244855300015
PM 26637031
DA 2018-03-20
ER

PT J
AU Fourie, E
   Newsome, B
   Bachas, L
   Hennig, B
AF Fourie, Elani
   Newsome, Bradley J.
   Bachas, Leonidas G.
   Hennig, Bernhard
TI Differential cytotoxicity of PCBs bound to alumina nanoparticles
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
CT 241st National Meeting and Exposition of the American-Chemical-Society
   (ACS)
CY MAR 27-31, 2011
CL Anaheim, CA
SP Amer Chem Soc
C1 [Fourie, Elani; Newsome, Brad; Bachas, Leonidas; Hennig, Bernhardt] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD MAR 27
PY 2011
VL 241
MA 529-CHED
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA 782BO
UT WOS:000291982800509
DA 2018-03-20
ER

PT J
AU Nie, HC
   Su, YC
   Zhang, MT
   Song, Y
   Leone, A
   Taylor, LS
   Marsac, PJ
   Li, TL
   Byrn, SR
AF Nie, Haichen
   Su, Yongchao
   Zhang, Mingtao
   Song, Yang
   Leone, Anthony
   Taylor, Lynne S.
   Marsac, Patrick J.
   Li, Tonglei
   Byrn, Stephen R.
TI Solid-State Spectroscopic Investigation of Molecular Interactions
   between Clofazimine and Hypromellose Phthalate in Amorphous Solid
   Dispersions
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE amorphous; solid dispersion; drug-polymer interactions; acid-base
   interaction; solid-state NMR; ultrafast MAS; principal components
   analysis
ID ACID-BASE INTERACTIONS; DRUG-POLYMER INTERACTIONS; WATER-SOLUBLE DRUGS;
   NMR-SPECTROSCOPY; ANION SENSORS; STRUCTURAL-CHARACTERIZATION; PHYSICAL
   STABILITY; POLYACRYLIC-ACID; CRYSTALLIZATION; DISSOLUTION
AB It has been technically challenging to specify the detailed molecular interactions and binding motif between drugs and polymeric inhibitors in the solid state. To further investigate drug-polymer interactions from a molecular perspective, a solid dispersion of clofazimine (CLF) and hypromellose phthalate (HPMCP), with reported superior amorphous drug loading capacity and physical stability, was selected as a model system. The CLF HPMCP interactions in solid dispersions were investigated by various solid state spectroscopic methods including ultraviolet-visible (UV-vis), infrared (IR), and solid-state NMR (ssNMR) spectroscopy. Significant spectral changes suggest that protonated CLF is ionically bonded to the carboxylate from the phthalyl substituents of HPMCP. In addition, multivariate analysis of spectra was applied to optimize the concentration of polymeric inhibitor used to formulate the amorphous solid dispersions. Most interestingly, proton transfer between CLF and carboxylic acid was experimentally investigated from 2D H-1-H-1 homonuclear double quantum NMR spectra by utilizing the ultrafast magic-angle spinning (MAS) technique. The molecular interaction pattern and the critical bonding structure in CLF HPMCP dispersions were further delineated by successfully correlating ssNMR findings with quantum chemistry calculations. These high-resolution investigations provide critical structural information on active pharmaceutical-ingredient polymer interaction, which can be useful for rational selection of appropriate polymeric carriers, which are effective crystallization inhibitors for amorphous drugs.
C1 [Nie, Haichen; Zhang, Mingtao; Song, Yang; Taylor, Lynne S.; Li, Tonglei; Byrn, Stephen R.] Purdue Univ, Dept Ind & Phys Pharm, 575 Stadium Mall Dr, W Lafayette, IN 47907 USA.
   [Nie, Haichen] Teva Pharmaceut, Formulat Sci, 145 Brandywine Pkwy, W Chester, PA 19380 USA.
   [Su, Yongchao; Leone, Anthony] Merck Res Labs, 770 Sumneytown Pike, West Point, PA 19486 USA.
   [Song, Yang] Takeda Pharmaceut Inc, Global DMPK, 10410 Sci Ctr Dr, San Diego, CA 92121 USA.
   [Marsac, Patrick J.] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, 789 South Limestone St, Lexington, KY 40536 USA.
RP Byrn, SR (reprint author), Purdue Univ, Dept Ind & Phys Pharm, 575 Stadium Mall Dr, W Lafayette, IN 47907 USA.; Su, YC (reprint author), Merck Res Labs, 770 Sumneytown Pike, West Point, PA 19486 USA.
EM yongchao.su@merck.com; sbyrn@purdue.edu
RI Su, Yongchao/B-6749-2009
OI Su, Yongchao/0000-0001-5063-3218; Zhang, Mingtao/0000-0001-9588-9751;
   Taylor, Lynne/0000-0002-4568-6021
CR Abraham A, 2014, MOL PHARMACEUT, V11, P3754, DOI 10.1021/mp400629j
   Barbet-Massin E, 2014, J AM CHEM SOC, V136, P12489, DOI 10.1021/ja507382j
   BECKE AD, 1993, J CHEM PHYS, V98, P5648, DOI 10.1063/1.464913
   Berendt RT, 2006, TRAC-TREND ANAL CHEM, V25, P977, DOI 10.1016/j.trac.2006.07.006
   Bhardwaj SP, 2014, MOL PHARMACEUT, V11, P4228, DOI 10.1021/mp5004515
   Bolla G, 2012, CRYST GROWTH DES, V12, P6250, DOI 10.1021/cg301463z
   Brown SP, 2012, SOLID STATE NUCL MAG, V41, P1, DOI 10.1016/j.ssnmr.2011.11.006
   Childs SL, 2007, MOL PHARM, V4, P323, DOI 10.1021/mp0601345
   CHIOU WL, 1969, J PHARM SCI-US, V58, P1505, DOI 10.1002/jps.2600581218
   Cruz-Cabeza AJ, 2012, CRYSTENGCOMM, V14, P6362, DOI 10.1039/c2ce26055g
   Cui DT, 2011, J PHYS CHEM B, V115, P7788, DOI 10.1021/jp202138d
   ETTER MC, 1990, J AM CHEM SOC, V112, P8415, DOI 10.1021/ja00179a028
   ETTER MC, 1990, ACCOUNTS CHEM RES, V23, P120, DOI 10.1021/ar00172a005
   Evans LS, 2006, CHEM COMMUN, P965, DOI 10.1039/b517308f
   Farrugia KN, 2015, ORG BIOMOL CHEM, V13, P1662, DOI 10.1039/c4ob02091j
   Feike M, 1996, J MAGN RESON SER A, V122, P214, DOI 10.1006/jmra.1996.0197
   Frisch M. J., 2009, GAUSSIAN 09 REVISION
   Gale PA, 2000, COORDIN CHEM REV, V199, P181, DOI 10.1016/S0010-8545(99)00149-6
   GOLDBERG AH, 1966, J PHARM SCI, V55, P487, DOI 10.1002/jps.2600550508
   Kawabata Y, 2011, INT J PHARMACEUT, V420, P1, DOI 10.1016/j.ijpharm.2011.08.032
   Khougaz K, 2000, J PHARM SCI, V89, P1325, DOI 10.1002/1520-6017(200010)89:10<1325::AID-JPS10>3.3.CO;2-X
   Konno H, 2008, PHARM RES, V25, P969, DOI 10.1007/s11095-007-9331-3
   Konno H, 2006, J PHARM SCI-US, V95, P2692, DOI 10.1002/jps.20697
   Leuner C, 2000, EUR J PHARM BIOPHARM, V50, P47, DOI 10.1016/S0939-6411(00)00076-X
   Li ZJ, 2006, J AM CHEM SOC, V128, P8199, DOI 10.1021/ja0541332
   Miyazaki T, 2004, J PHARM SCI-US, V93, P2710, DOI 10.1002/jps.20182
   Miyazaki T, 2011, INT J PHARMACEUT, V407, P111, DOI 10.1016/j.ijpharm.2011.01.035
   Muto T, 2001, J ORG CHEM, V66, P6109, DOI 10.1021/jo010384r
   Narang AS, 2002, DRUG DEV IND PHARM, V28, P1001, DOI 10.1081/DDC-120006431
   Nie H, 2016, MOL PHARMACEUT, V13, P3541, DOI 10.1021/acs.molpharmaceut.6b00630
   Nie HC, 2015, MOL PHARMACEUT, V12, P2459, DOI 10.1021/acs.molpharmaceut.5b00162
   Pahovnik D, 2011, J PHARM SCI-US, V100, P4700, DOI 10.1002/jps.22662
   Patel JR, 2012, J PHARM SCI-US, V101, P641, DOI 10.1002/jps.22800
   Paudel A, 2014, J PHARM SCI-US, V103, P2635, DOI 10.1002/jps.23966
   Pavli M, 2011, INT J PHARMACEUT, V421, P110, DOI 10.1016/j.ijpharm.2011.09.019
   PERDEW JP, 1992, PHYS REV B, V45, P13244, DOI 10.1103/PhysRevB.45.13244
   Pham TN, 2010, MOL PHARMACEUT, V7, P1667, DOI 10.1021/mp100205g
   REED AE, 1985, J CHEM PHYS, V83, P735, DOI 10.1063/1.449486
   RYCHLEWSKA U, 1985, J AM CHEM SOC, V107, P4768, DOI 10.1021/ja00302a027
   Sarma B, 2009, CRYST GROWTH DES, V9, P1546, DOI 10.1021/cg801145c
   Sarode AL, 2013, MOL PHARMACEUT, V10, P3665, DOI 10.1021/mp400165b
   Serajuddin ATM, 1999, J PHARM SCI, V88, P1058, DOI 10.1021/js980403l
   Song Y, 2016, MOL PHARMACEUT, V13, P483, DOI 10.1021/acs.molpharmaceut.5b00708
   Song Y, 2015, MOL PHARMACEUT, V12, P857, DOI 10.1021/mp500692a
   Steele G., 2009, PHARM PREFORMULATION, P17
   Su YC, 2015, ANNU REV BIOCHEM, V84, P465, DOI 10.1146/annurev-biochem-060614-034206
   Suksai C, 2003, CHEM SOC REV, V32, P192, DOI 10.1039/b209598j
   Tatton AS, 2013, MOL PHARMACEUT, V10, P999, DOI 10.1021/mp300423r
   Telang C, 2009, J PHARM SCI-US, V98, P2149, DOI 10.1002/jps.21584
   Van Eerdenbrugh B, 2012, MOL PHARMACEUT, V9, P1459, DOI 10.1021/mp300059z
   Van Eerdenbrugh B, 2010, MOL PHARMACEUT, V7, P1328, DOI 10.1021/mp1001153
   Vogt F. G., 2015, EMAGRES, V4, P1
   Vogt FG, 2008, J PHARM SCI-US, V97, P4756, DOI 10.1002/jps.21336
   Wan H, 2003, RAPID COMMUN MASS SP, V17, P2639, DOI 10.1002/rcm.1229
   Wegiel LA, 2014, J PHARM PHARMACOL, V66, P244, DOI 10.1111/jphp.12079
   Wegiel LA, 2014, PHARM DEV TECHNOL, V19, P976, DOI 10.3109/10837450.2013.846374
   Wegiel LA, 2013, J PHARM SCI-US, V102, P171, DOI 10.1002/jps.23358
   Weuts I, 2005, EUR J PHARM SCI, V25, P387, DOI 10.1016/j.ejps.2005.04.011
   WOLINSKI K, 1990, J AM CHEM SOC, V112, P8251, DOI 10.1021/ja00179a005
   Yang FY, 2016, INT J PHARMACEUT, V500, P20, DOI 10.1016/j.ijpharm.2016.01.026
   Yoo SU, 2009, J PHARM SCI-US, V98, P4711, DOI 10.1002/jps.21779
   Yuan XD, 2015, MOL PHARMACEUT, V12, P4518, DOI 10.1021/acs.molpharmaceut.5b00705
NR 62
TC 13
Z9 13
U1 7
U2 25
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD NOV
PY 2016
VL 13
IS 11
BP 3964
EP 3975
DI 10.1021/acs.molpharmaceut.6b00740
PG 12
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA EB5PK
UT WOS:000387428300036
PM 27653759
DA 2018-03-20
ER

PT J
AU Parthasarathy, R
   Chow, KM
   Derafshi, Z
   Fautsch, MP
   Hetling, JR
   Rodgers, DW
   Hersh, LB
   Pepperberg, DR
AF Parthasarathy, Rajni
   Chow, K. Martin
   Derafshi, Zahra
   Fautsch, Michael P.
   Hetling, John R.
   Rodgers, David W.
   Hersh, Louis B.
   Pepperberg, David R.
TI Reduction of amyloid-beta levels in mouse eye tissues by intra-vitreally
   delivered neprilysin
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Amyloid-beta; Neprilysin; Intra-vitreal injection; C57BL/6J mouse; 5XFAD
   mouse; Electroretinogram
ID RETINAL-PIGMENT EPITHELIUM; MACULAR DEGENERATION; A-BETA;
   ALZHEIMERS-DISEASE; IN-VIVO; OXIDATIVE STRESS; DRUSEN DEPOSITS; PEPTIDE;
   MODEL; MECHANISMS
AB Amyloid-beta (A beta) is a group of aggregation-prone, 38- to 43-amino acid peptides generated in the eye and other organs. Numerous studies suggest that the excessive build-up of low-molecular-weight soluble oligomers of A beta plays a role in the progression of Alzheimer's disease and other brain degenerative diseases. Recent studies raise the hypothesis that excessive A beta levels may contribute also to certain retinal degenerative diseases. These findings, together with evidence that a major portion of A beta is released as monomer into the extracellular space, raise the possibility that a technology enabling the enzymatic break-down of monomeric A beta in the living eye under physiological conditions could prove useful for research on ocular A beta physiology and, perhaps ultimately, for therapeutic applications. Neprilysin (NEP), an endopeptidase known to cleave A beta monomer into inactive products, is a membrane-associated protein. However, sNEP, a recombinant form of the NEP catalytic domain, is soluble in aqueous medium. With the aim of determining the A beta-cleaving activity of exogenous sNEP in the microenvironment of the intact eye, we analyzed the effect of intra-vitreally delivered sNEP on ocular A beta levels in mice that exhibit readily measurable, aqueous buffer-extractable A beta(340) and A beta(42), two principal forms of A beta. Anesthetized 10-month wild-type (C57BL/6J) and 2-3-month 5XFAD transgenic mice received intravitreal injections of sNEP (0.004-10 mu g) in one eye and were sacrificed at defined post-treatment times (30 min - 12 weeks). Eye tissues (combined lens, vitreous, retina, RPE and choroid) were homogenized in phosphate-buffered saline, and analyzed for A beta(40) and A beta(42) (ELISA) and for total protein (Bradford assay). The fellow, untreated eye of each mouse served as control, and concentrations of A beta (pmol/g protein) in the treated eye were normalized to that of the untreated control eye. In C57BL/6J mice, as measured at 2 h after sNEP treatment, increasing amounts of injected sNEP yielded progressively greater reductions of A beta(40), ranging from 12% +/- 3% (mean +/- SEM; n = 3) with 4 ng sNEP to 85% 13% (n = 5) with 10 mu g sNEP. At 4 ng sNEP the average AN reduction reached >70% by 24 h following treatment and remained near this level for about 8 weeks. In 5XFAD mice, 10 mu g sNEP produced an A beta(40) decrease of 99% 1% (n = 4) and a substantial although smaller decrease in A beta(42) (42% 4- 36%; n = 4) within 24 h. Electroretinograms (ERGs) were recorded from eyes of C57BL/6J and 5XFAD mice at 9 days following treatment with 4 ng or 10 mu g sNEP, conditions that on average led, respectively, to an 82% and 91% A beta(40) reduction in C57BL/6J eyes, an 87% and 92% A beta(40) reduction in 5XFAD eyes, and a 23% and 52% A beta(42) reduction in 5XFAD eyes. In all cases, sNEP-treated eyes exhibited robust ERG responses, consistent with a general tolerance of the posterior eye tissues to the investigated conditions of sNEP treatment. The sNEP-mediated decrease of ocular Al) levels reported here represents a possible approach for determining effects of A beta reduction in normally functioning eyes and in models of retinal degenerative disease. (C) 2015 Published by Elsevier Ltd.
C1 [Parthasarathy, Rajni; Pepperberg, David R.] Univ Illinois, Dept Ophthalmol & Visual Sci, Lions Illinois Eye Res Inst, Illinois Eye & Ear Infirm, Chicago, IL 60612 USA.
   [Parthasarathy, Rajni; Derafshi, Zahra; Hetling, John R.; Pepperberg, David R.] Univ Illinois, Dept Bioengn, Chicago, IL 60612 USA.
   [Chow, K. Martin; Rodgers, David W.; Hersh, Louis B.] Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY USA.
   [Fautsch, Michael P.] Mayo Clin, Dept Ophthalmol, Rochester, MN USA.
RP Pepperberg, DR (reprint author), Univ Illinois, Dept Ophthalmol & Visual Sci, Lions Illinois Eye Res Inst, 1855 W Taylor St, Chicago, IL 60612 USA.
EM davipepp@uic.edu
FU BrightFocus Foundation (Clarksburg, MD); Illinois Society for the
   Prevention of Blindness (Chicago, IL); Research to Prevent Blindness
   (New York, NY); UIC Center for Clinical and Translational Science (CCTS)
   [UL1RR029879]; NIH [EY001792, EY023430, EY021727, GM110787]
FX We thank Ms. Tara Nguyen for expert technical assistance with
   intra-vitreal injections, Ms. Cindy K. Bahler for isolation of human
   vitreous, Dr. Scott M. Plafker for helpful discussions, and Dr. Douglas
   L. Feinstein and Mr. David J. Braun for providing mouse eye tissues used
   in early experiments. Supported by grants from the BrightFocus
   Foundation (Clarksburg, MD), the Illinois Society for the Prevention of
   Blindness (Chicago, IL), Research to Prevent Blindness (New York, NY)
   [Lew R. Wasserman Merit Award to Dr. Fautsch, and unrestricted awards to
   the University of Illinois at Chicago (UIC) Department of Ophthalmology
   and Visual Sciences and to the Department of Ophthalmology at Mayo
   Clinic], award UL1RR029879 from the UIC Center for Clinical and
   Translational Science (CCTS), and NIH grants EY001792, EY023430,
   EY021727 and GM110787.
CR Abramov E, 2009, NAT NEUROSCI, V12, P1567, DOI 10.1038/nn.2433
   Alexandrov PN, 2011, NEUROREPORT, V22, P623, DOI 10.1097/WNR.0b013e3283497334
   Bates KA, 2009, MOL PSYCHIATR, V14, P469, DOI 10.1038/mp.2008.96
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Benilova I, 2012, NAT NEUROSCI, V15, P349, DOI 10.1038/nn.3028
   Bruban J, 2011, NEUROBIOL DIS, V42, P55, DOI 10.1016/j.nbd.2011.01.004
   Burdick D, 1997, BRAIN RES, V746, P275, DOI 10.1016/S0006-8993(96)01262-0
   Cano M, 2010, VISION RES, V50, P652, DOI 10.1016/j.visres.2009.08.018
   Carson JA, 2002, J NEUROCHEM, V81, P1, DOI 10.1046/j.1471-4159.2002.00855.x
   Carvalho C, 2014, J ALZHEIMERS DIS, V38, P75, DOI 10.3233/JAD-130464
   Dahlgren KN, 2002, J BIOL CHEM, V277, P32046, DOI 10.1074/jbc.M201750200
   Dale GE, 2000, ACTA CRYSTALLOGR D, V56, P894, DOI 10.1107/S0907444900004947
   Dasari B, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-22
   Dentchev T, 2003, MOL VIS, V9, P184
   Ding JD, 2008, VISION RES, V48, P339, DOI 10.1016/j.visres.2007.07.025
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Dong ZZ, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-34
   Edwards MM, 2014, EXP EYE RES, V127, P252, DOI 10.1016/j.exer.2014.08.006
   Gu L, 2013, J NEUROCHEM, V126, P305, DOI 10.1111/jnc.12202
   Guo L, 2007, P NATL ACAD SCI USA, V104, P13444, DOI 10.1073/pnas.0703707104
   Guo LY, 2014, EXP EYE RES, V129, P31, DOI 10.1016/j.exer.2014.10.012
   Hersh LB, 2008, CURR ALZHEIMER RES, V5, P225, DOI 10.2174/156720508783954703
   Hetling JR, 1999, J PHYSIOL-LONDON, V516, P593, DOI 10.1111/j.1469-7793.1999.0593v.x
   Hubin E, 2014, CELL MOL LIFE SCI, V71, P3507, DOI 10.1007/s00018-014-1634-z
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   Itkin A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018250
   Iwata N, 2001, SCIENCE, V292, P1550, DOI 10.1126/science.1059946
   Janciauskiene S, 2011, EUR J OPHTHALMOL, V21, P104, DOI 10.5301/EJO.2010.2108
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kam JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013127
   Kummer MP, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt258
   Lee JH, 2012, J DRUG DELIV, DOI 10.1155/2012/527516
   LI CW, 1995, METHOD ENZYMOL, V248, P253
   Liu CQ, 2015, INT J MOL MED, V35, P169, DOI 10.3892/ijmm.2014.1993
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   Liu YX, 2007, PEPTIDES, V28, P2348, DOI 10.1016/j.peptides.2007.09.015
   Liu YX, 2010, MOL CELL NEUROSCI, V45, P101, DOI 10.1016/j.mcn.2010.05.014
   Liu YX, 2009, MOL THER, V17, P1381, DOI 10.1038/mt.2009.115
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Manzoni C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024909
   Morley JE, 2014, BIOCHEM PHARMACOL, V88, P479, DOI 10.1016/j.bcp.2013.12.018
   Nalivaeva N.N., 2012, INT J ALZHEIMERS DIS, DOI [http://dx.doi.org/10.1155/2012/383796, DOI 10.1155/2012/383796.ARTICLE]
   Ning A, 2008, INVEST OPHTH VIS SCI, V49, P5136, DOI 10.1167/iovs.08-1849
   Normando EM, 2009, EXP EYE RES, V89, P446, DOI 10.1016/j.exer.2009.05.004
   Oakley H, 2006, J NEUROSCI, V26, P10129, DOI 10.1523/JNEUROSCI.1202-06.2006
   Oddo S, 2006, AM J PATHOL, V168, P184, DOI 10.2353/ajpath.2006.050593
   Organisciak DT, 2010, PROG RETIN EYE RES, V29, P113, DOI 10.1016/j.preteyeres.2009.11.004
   Park SW, 2014, NEUROBIOL AGING, V35, P2013, DOI 10.1016/j.neurobiolaging.2014.03.008
   Parthasarathy R., 2014, IOVS, V2014, P35
   Pauwels K, 2012, J BIOL CHEM, V287, P5650, DOI 10.1074/jbc.M111.264473
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Prakasam A, 2010, J ALZHEIMERS DIS, V20, P1243, DOI 10.3233/JAD-2010-100210
   Pryor NE, 2012, INT J MOL SCI, V13, P3038, DOI 10.3390/ijms13033038
   Puzzo D, 2013, J ALZHEIMERS DIS, V33, pS111, DOI 10.3233/JAD-2012-129033
   Puzzo D, 2008, J NEUROSCI, V28, P14537, DOI 10.1523/JNEUROSCI.2692-08.2008
   Querfurth HW, 2010, NEW ENGL J MED, V362, P329, DOI 10.1056/NEJMra0909142
   Ripoli C, 2014, J NEUROSCI, V34, P12893, DOI 10.1523/JNEUROSCI.1201-14.2014
   Rogues BP, 1993, PHARMACOL REV, V45, P87
   Saido T, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006379
   Selkoe DJ, 2012, SCIENCE, V337, P1488, DOI 10.1126/science.1228541
   Sharma K, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00151
   Shirotani K, 2001, J BIOL CHEM, V276, P21895, DOI 10.1074/jbc.M008511200
   Solomonov I, 2012, J BIOL CHEM, V287, P20555, DOI 10.1074/jbc.M112.344036
   Soscia S.J., 2010, PLOS ONE, V3, pe9505, DOI [http://dx.doi.org/10.1371/journal.pone.0009505, DOI 10.1371/J0URNAL.P0NE.0009505]
   Tanzi RE, 2004, NEURON, V43, P605, DOI 10.1016/j.neuron.2004.08.024
   Tao Weng, 2006, Expert Opin Biol Ther, V6, P717, DOI 10.1517/14712598.6.7.717
   Turner AJ, 2001, BIOESSAYS, V23, P261, DOI 10.1002/1521-1878(200103)23:3<261::AID-BIES1036>3.0.CO;2-K
   Walsh DM, 2007, J NEUROCHEM, V101, P1172, DOI 10.1111/j.1471-4159.2006.04426.x
   Wang JQ, 2011, ANAT REC, V294, P1401, DOI 10.1002/ar.21438
   Wang JY, 2012, BIOCHEM BIOPH RES CO, V423, P73, DOI 10.1016/j.bbrc.2012.05.085
   Warmlander S, 2013, CHEMBIOCHEM, V14, P1692, DOI 10.1002/cbic.201300262
   Wildsmith KR, 2013, ALZHEIMERS RES THER, V5, DOI 10.1186/alzrt187
   Woodell A, 2014, ADV EXP MED BIOL, V801, P301, DOI 10.1007/978-1-4614-3209-8_38
   Yankner BA, 2009, J BIOL CHEM, V284, P4754, DOI 10.1074/jbc.R800018200
   Yoneda S, 2005, JPN J OPHTHALMOL, V49, P106, DOI 10.1007/s10384-004-0156-x
   Yoon SS, 2012, BIOMOL THER, V20, P245, DOI 10.4062/biomolther.2012.20.3.245
NR 77
TC 11
Z9 11
U1 0
U2 9
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD SEP
PY 2015
VL 138
BP 134
EP 144
DI 10.1016/j.exer.2015.06.027
PG 11
WC Ophthalmology
SC Ophthalmology
GA CQ7IV
UT WOS:000360777100017
PM 26142956
OA green_accepted
DA 2018-03-20
ER

PT J
AU Hu, B
   Chopra, N
   Tyagi, P
   Hinds, B
AF Hu, Bing
   Chopra, Nitin
   Tyagi, Pawan
   Hinds, Bruce J.
TI Selective lateral ZnO nanowire growth by surface diffusion on nanometer
   scale-patterned alumina on silicon
SO JOURNAL OF MATERIALS RESEARCH
LA English
DT Article
ID ZINC-OXIDE NANOWIRES; PHYSICAL VAPOR-DEPOSITION; ATOMIC LAYER
   DEPOSITION; MOLECULAR-BEAM EPITAXY; OPTICAL-PROPERTIES; CARBON NANOTUBE;
   THERMAL EVAPORATION; SI SUBSTRATE; THIN-FILMS; ARRAYS
AB Lateral ZnO nanowires (NWs) were selectively grown from the edge of a SiO(2)/Si-Al(2)O(3)-SiO(2)/Si multilayer structure for potential integration into devices using Si processing technology. Microstructural studies demonstrate a two-step growth process in which the tip region, with a diameter of similar to 10 nm, rapidly grew from the Al(2)O(3) surface and, later, a base growth with a diameter of similar to 22 nm overgrew the existing narrow ZnO NW, halting further tip growth. Kinetics studies showed that surface diffusion on the alumina seed surface determined ZnO NW growth rate.
C1 [Hu, Bing; Chopra, Nitin; Tyagi, Pawan; Hinds, Bruce] Univ Kentucky, Lexington, KY 40506 USA.
RP Hinds, B (reprint author), Univ Kentucky, Lexington, KY 40506 USA.
EM bjhinds@engr.uky.edu
RI Nitin, Chopra/F-8236-2011
OI Tyagi, Pawan/0000-0002-7541-1344
FU Air Force Office of Scientific Research [F49620-02-1-0225]; National
   Science Foundation [0348544]; National Science Foundation Nanoscale
   Interdisciplinary Research Teams (NSF NIRT) [0609064]; Department of
   Chemical and Materials Engineering, Center for Nanoscale Science and
   Engineering, and Electron Microscopy Center in University of Kentucky
FX The authors thank Dr. Janet K. Lumpp for providing the flow controller
   and Dr. John Balk for help in the fabrication of TEM samples. The
   authors thank the Air Force Office of Scientific Research, Defense
   Experimental Program to Stimulate Competitive Research (DEPSCoR) under
   agreement number F49620-02-1-0225, National Science Foundation CAREER
   (0348544), and National Science Foundation Nanoscale Interdisciplinary
   Research Teams (NSF NIRT) (0609064). Support was also provided by the
   Department of Chemical and Materials Engineering, Center for Nanoscale
   Science and Engineering, and Electron Microscopy Center in University of
   Kentucky.
CR Baxter JB, 2005, J CRYST GROWTH, V274, P407, DOI 10.1016/j.jcrysgro.2004.10.014
   BRENNER SS, 1956, ACTA METALL MATER, V4, P268, DOI 10.1016/0001-6160(56)90064-5
   Cha SN, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/23/235601
   Chopra N, 2005, NANOTECHNOLOGY, V16, P133, DOI 10.1088/0957-4484/16/1/027
   Chopra N, 2002, NANO LETT, V2, P1177, DOI 10.1021/nl0257061
   Comini E, 2002, APPL PHYS LETT, V81, P1869, DOI 10.1063/1.1504867
   Conley JF, 2005, NANOTECHNOLOGY, V16, P292, DOI 10.1088/0957-4484/16/2/020
   Duan XF, 2003, NATURE, V421, P241, DOI 10.1038/nature01353
   Elam JW, 2002, THIN SOLID FILMS, V414, P43, DOI 10.1016/S0040-6090(02)00427-3
   Fan HJ, 2006, J CRYST GROWTH, V287, P34, DOI [10.1016/j.jcrysgro.2005.10.038, 10.1016/.jcrysgro.2005.10.038]
   Feng L, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/40/405702
   Gao KY, 2003, APPL PHYS LETT, V83, P1830, DOI 10.1063/1.1609053
   Gao PX, 2007, APPL PHYS LETT, V91, DOI 10.1063/1.2794417
   Greyson EC, 2004, ADV MATER, V16, P1348, DOI 10.1002/adma.200400765
   Hausmann D, 2002, SCIENCE, V298, P402, DOI 10.1126/science.1073552
   Heo YW, 2006, APPL SURF SCI, V252, P7442, DOI 10.1016/j.apsusc.2005.08.094
   Heo YW, 2002, APPL PHYS LETT, V81, P3046, DOI 10.1063/1.1512829
   Hoivik ND, 2003, SENSOR ACTUAT A-PHYS, V103, P100, DOI 10.1016/S0924-4247(02)00319-9
   Hu B, 2010, APPL PHYS LETT, V97, DOI 10.1063/1.3514253
   Huang MH, 2001, SCIENCE, V292, P1897, DOI 10.1126/science.1060367
   Huang MH, 2001, ADV MATER, V13, P113, DOI 10.1002/1521-4095(200101)13:2<113::AID-ADMA113>3.0.CO;2-H
   Jeong MC, 2006, NANOTECHNOLOGY, V17, P526, DOI 10.1088/0957-4484/17/2/031
   Jie JS, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1854737
   Kim DS, 2009, J CRYST GROWTH, V311, P3216, DOI 10.1016/j.jcrysgro.2009.03.026
   Kim H, 2004, J NANOSCI NANOTECHNO, V4, P275, DOI 10.1166/jnn.2004.034
   Kong J, 2000, SCIENCE, V287, P622, DOI 10.1126/science.287.5453.622
   Law JBK, 2007, NANOTECHNOLOGY, V18, DOI 10.1088/0957-4484/18/5/055601
   Lee JS, 2006, NANO LETT, V6, P1487, DOI 10.1021/nl060883d
   Lee W, 2004, NANOTECHNOLOGY, V15, P1441, DOI 10.1088/0957-4484/15/11/010
   Lefebvre J, 2000, APPL PHYS LETT, V76, P3828, DOI 10.1063/1.126795
   Li SY, 2004, J APPL PHYS, V95, P3711, DOI 10.1063/1.1655685
   Pan ZW, 2009, ADV MATER, V21, P890, DOI 10.1002/adma.200802138
   Park J, 2003, J CRYST GROWTH, V258, P342, DOI 10.1016/S0022-0248(03)01549-5
   Park WI, 2004, ADV MATER, V16, P87, DOI 10.1002/adma.200305729
   Qin Y, 2008, J PHYS CHEM C, V112, P18734, DOI 10.1021/jp808869j
   Rackauskas S, 2009, APPL PHYS LETT, V95, DOI 10.1063/1.3258074
   Roy VAL, 2003, APPL PHYS LETT, V83, P141, DOI 10.1063/1.1589184
   Sekar A, 2005, J CRYST GROWTH, V277, P471, DOI 10.1016/j.jcrysro.2005.02.006
   TANG H, 2008, J MATER SCI, V44, P563
   Tans SJ, 1998, NATURE, V393, P49
   WAGNER RS, 1964, APPL PHYS LETT, V4, P89, DOI 10.1063/1.1753975
   Wang LS, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1851607
   Wang Z. L., 2004, J PHYS-CONDENS MAT, V16, P829, DOI DOI 10.1088/0953-8984/16/25/R01
   Xu F, 2006, NANOTECHNOLOGY, V17, P588, DOI 10.1088/0957-4484/17/2/041
   Yang PD, 2002, ADV FUNCT MATER, V12, P323, DOI 10.1002/1616-3028(20020517)12:5<323::AID-ADFM323>3.0.CO;2-G
   Zhu ZM, 2005, CHEM MATER, V17, P4227, DOI 10.1021/cm050584+
NR 46
TC 2
Z9 2
U1 0
U2 19
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0884-2914
J9 J MATER RES
JI J. Mater. Res.
PD SEP
PY 2011
VL 26
IS 17
BP 2224
EP 2231
DI 10.1557/jmr.2011.57
PG 8
WC Materials Science, Multidisciplinary
SC Materials Science
GA 836BT
UT WOS:000296083100011
DA 2018-03-20
ER

PT J
AU Schaefer, KA
   Toral, MA
   Velez, G
   Cox, AJ
   Baker, SA
   Borcherding, NC
   Colgan, DF
   Bondada, V
   Mashburn, CB
   Yu, CG
   Geddes, JW
   Tsang, SH
   Bassuk, AG
   Mahajan, VB
AF Schaefer, Kellie A.
   Toral, Marcus A.
   Velez, Gabriel
   Cox, Allison J.
   Baker, Sheila A.
   Borcherding, Nicholas C.
   Colgan, Diana F.
   Bondada, Vimala
   Mashburn, Charles B.
   Yu, Chen-Guang
   Geddes, James W.
   Tsang, Stephen H.
   Bassuk, Alexander G.
   Mahajan, Vinit B.
TI Calpain-5 Expression in the Retina Localizes to Photoreceptor Synapses
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE CAPN5; calpain; autosomal dominant neovascular inflammatory
   vitreoretinopathy; ADNIV
ID NEOVASCULAR INFLAMMATORY VITREORETINOPATHY; CELL-DEATH;
   NUCLEAR-LOCALIZATION; STATUS EPILEPTICUS; RAT RETINA; CAPN5; MOUSE;
   DEGENERATION; PROTEOLYSIS; CALPASTATIN
AB PURPOSE. We characterize calpain-5 (CAPN5) expression in retinal and neuronal subcellular compartments.
   METHODS. CAPN5 gene variants were classified using the exome variant server, and RNA-sequencing was used to compare expression of CAPN5 mRNA in the mouse and human retina and in retinoblastoma cells. Expression of CAPN5 protein was ascertained in humans and mice in silico, in mouse retina by immunohistochemistry, and in neuronal cancer cell lines and fractionated central nervous system tissue extracts by Western analysis with eight antibodies targeting different CAPN5 regions.
   RESULTS. Most CAPN5 genetic variation occurs outside its protease core; and searches of cancer and epilepsy/autism genetic databases found no variants similar to hyperactivating retinal disease alleles. The mouse retina expressed one transcript for CAPN5 plus those of nine other calpains, similar to the human retina. In Y79 retinoblastoma cells, the level of CAPN5 transcript was very low. Immunohistochemistry detected CAPN5 expression in the inner and outer nuclear layers and at synapses in the outer plexiform layer. Western analysis of fractionated retinal extracts confirmed CAPN5 synapse localization. Western blots of fractionated brain neuronal extracts revealed distinct subcellular patterns and the potential presence of autoproteolytic CAPN5 domains.
   CONCLUSIONS. CAPN5 is moderately expressed in the retina and, despite higher expression in other tissues, hyperactive disease mutants of CAPN5 only manifest as eye disease. At the cellular level, CAPN5 is expressed in several different functional compartments. CAPN5 localization at the photoreceptor synapse and with mitochondria explains the neural circuitry phenotype in human CAPN5 disease alleles.
C1 [Schaefer, Kellie A.; Toral, Marcus A.; Velez, Gabriel; Borcherding, Nicholas C.; Colgan, Diana F.; Mahajan, Vinit B.] Univ Iowa, Omics Lab, Iowa City, IA USA.
   [Schaefer, Kellie A.; Toral, Marcus A.; Velez, Gabriel; Baker, Sheila A.; Colgan, Diana F.; Mahajan, Vinit B.] Univ Iowa, Dept Ophthalmol & Visual Sci, 200 Hawkins Dr, Iowa City, IA 52242 USA.
   [Toral, Marcus A.; Velez, Gabriel; Borcherding, Nicholas C.] Univ Iowa, Med Sci Training Program, Iowa City, IA USA.
   [Cox, Allison J.; Bassuk, Alexander G.] Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA.
   [Baker, Sheila A.] Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA.
   [Bondada, Vimala; Mashburn, Charles B.; Yu, Chen-Guang; Geddes, James W.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY USA.
   [Tsang, Stephen H.] Columbia Univ, Inst Human Nutr, Barbara & Donald Jonas Stem Cell Lab, Dept Pathol & Cell Biol,Coll Phys & Surg, New York, NY 10032 USA.
   [Tsang, Stephen H.] Columbia Univ, Inst Human Nutr, Bernard & Shirlee Brown Glaucoma Lab, Dept Pathol & Cell Biol,Coll Phys & Surg, New York, NY 10032 USA.
   [Tsang, Stephen H.] New York Presbyterian Hosp, Edward S Harkness Eye Inst, New York, NY USA.
   [Bassuk, Alexander G.] Univ Iowa, Neurol, Iowa City, IA USA.
RP Mahajan, VB (reprint author), Univ Iowa, Dept Ophthalmol & Visual Sci, 200 Hawkins Dr, Iowa City, IA 52242 USA.
EM mahajanlab@gmail.com
OI Baker, Sheila/0000-0002-0259-0652
FU National Institutes of Health (NIH) [K08EY020530, R01EY024665,
   R01EY025225, R01EY024698, R21AG050437]; Doris Duke Charitable Foundation
   [2013103]; Research to Prevent Blindness (RPB; New York, NY, USA); NIH
   [T32GM007337]
FX VBM is Supported by National Institutes of Health (NIH) Grants
   K08EY020530, R01EY024665, R01EY025225, R01EY024698, and R21AG050437
   (VBM); Doris Duke Charitable Foundation Grant #2013103 and Research to
   Prevent Blindness (RPB; New York, NY, USA); and by NIH Grant T32GM007337
   (MT, GV, NCB).
CR The 1000 Genomes Project Consortium, 2008, 1000 GEN DEPPT CAT H
   Allen AS, 2013, NATURE, V501, P217, DOI 10.1038/nature12439
   Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632
   Appenzeller S, 2014, AM J HUM GENET, V95, P360, DOI 10.1016/j.ajhg.2014.08.013
   Araujo IM, 2008, J NEUROCHEM, V105, P666, DOI 10.1111/j.1471-4159.2007.05181.x
   AZARIAN SM, 1993, J CELL SCI, V105, P787
   Azuma M, 2000, CURR EYE RES, V21, P710, DOI 10.1076/0271-3683(200009)21:3;1-R;FT710
   Azuma M, 2008, SURV OPHTHALMOL, V53, P150, DOI 10.1016/j.survophthal.2007.12.006
   Azuma M, 2004, COMPARATIVE MED, V54, P533
   Azuma M, 2014, CURR EYE RES, V39, P421, DOI 10.3109/02713683.2013.845225
   Bamford S, 2004, BRIT J CANCER, V91, P355, DOI 10.1038/sj.bjc.6601894
   Bassuk AG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122352
   BENNETT SR, 1990, OPHTHALMOLOGY, V97, P1125
   Bononi A, 2015, METHODS, V77-78, P92, DOI 10.1016/j.ymeth.2014.10.002
   Buraczynska M, 2013, J DIABETES COMPLICAT, V27, P54, DOI 10.1016/j.jdiacomp.2012.07.005
   Campbell RL, 2012, BIOCHEM J, V447, P335, DOI 10.1042/BJ20120921
   Chinskey ND, 2014, INVEST OPHTH VIS SCI, V55, P688, DOI 10.1167/iovs.13-12951
   Cingolani P, 2012, FLY, V6, P80, DOI 10.4161/fly.19695
   Das A, 2008, CNS NEUROL DISORD-DR, V7, P313, DOI 10.2174/187152708784936699
   Dear N, 1997, GENOMICS, V45, P175, DOI 10.1006/geno.1997.4870
   Dear TN, 1999, MECH DEVELOP, V89, P201, DOI 10.1016/S0925-4773(99)00214-2
   Eswar N, 2003, NUCLEIC ACIDS RES, V31, P3375, DOI 10.1093/nar/gkg543
   Eswar N., 2007, CURR PROTOC PROTEIN, DOI DOI 10.1002/0471140864.PS0209S50
   The European Bioinformatics Institute, 2015, EML EBI
   Fan TJ, 2005, ACTA BIOCH BIOPH SIN, V37, P719, DOI 10.1111/j.1745-7270.2005.00108.x
   Feng ZH, 2011, SEIZURE-EUR J EPILEP, V20, P395, DOI 10.1016/j.seizure.2011.01.010
   Gao H, 2013, CELL BIOCHEM BIOPHYS, V66, P371, DOI 10.1007/s12013-012-9476-5
   Getz GS, 2012, AM J PATHOL, V181, P388, DOI 10.1016/j.ajpath.2012.04.027
   Hanna RA, 2008, NATURE, V456, P409, DOI 10.1038/nature07451
   Higuchi M, 2012, FASEB J, V26, P1204, DOI 10.1096/fj.11-187740
   Hoang MV, 2011, BBA-MOL BASIS DIS, V1812, P549, DOI 10.1016/j.bbadis.2010.08.008
   Horikawa Y, 2000, NAT GENET, V26, P163, DOI 10.1038/79876
   Huang J, 2006, BMC IMMUNOL, V7, DOI 10.1186/1471-2172-7-7
   Huang W, 2010, INVEST OPHTH VIS SCI, V51, P3049, DOI 10.1167/iovs.09-4364
   Imai S, 2010, J PHARMACOL EXP THER, V335, P645, DOI 10.1124/jpet.110.171298
   Kaur J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022181
   Landles C, 2010, J BIOL CHEM, V285, P8808, DOI 10.1074/jbc.M109.075028
   Liu S, 2014, BRAIN INJURY, V28, P133, DOI 10.3109/02699052.2013.860479
   Lopez-Meraz ML, 2009, BRAIN RES BULL, V78, P131, DOI 10.1016/j.brainresbull.2008.11.002
   Ma H, 2001, J BIOL CHEM, V276, P28525, DOI 10.1074/jbc.M100603200
   Mahajan VB, 2013, CLIN OPHTHALMOL, V7, P1339, DOI 10.2147/OPTH.S46450
   Mahajan VB, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003001
   Matena K, 1998, GENOMICS, V48, P117, DOI 10.1006/geno.1997.5133
   McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110
   MORGAN IG, 1976, NEUROSCIENCE, V1, P159, DOI 10.1016/0306-4522(76)90072-5
   Nakajima E, 2006, INVEST OPHTH VIS SCI, V47, P5469, DOI 10.1167/iovs.06-0567
   Nakajima E, 2011, INVEST OPHTH VIS SCI, V52, P7059, DOI 10.1167/iovs.11-7497
   Nakajima T, 2001, BBA-GENE STRUCT EXPR, V1519, P55, DOI 10.1016/S0167-4781(01)00212-3
   NHLBI Exome Sequencing Project (ESP), EX VAR 58 SERV
   Pan Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085850
   Paquet-Durand F, 2006, J NEUROCHEM, V96, P802, DOI 10.1111/j.1471-4159.2005.03628.x
   Picard M, 2015, TRENDS NEUROSCI, V38, P468, DOI 10.1016/j.tins.2015.06.001
   RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2
   Ryu M, 2012, J NEUROSCI RES, V90, P802, DOI 10.1002/jnr.22800
   Schultz DR, 2003, SEMIN ARTHRITIS RHEU, V32, P345, DOI 10.1053/sarh.2003.50005
   Sharma AK, 2007, CURR EYE RES, V32, P259, DOI 10.1080/02713680601161238
   Shinde VM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033266
   Shirasaki Y, 2006, J MED CHEM, V49, P3926, DOI 10.1021/jm060157a
   Singh R, 2014, J BIOL CHEM, V289, P19383, DOI 10.1074/jbc.M114.575159
   Smith AD, 1980, COMMENTARIES NEUROSC
   Stankewich MC, 2010, P NATL ACAD SCI USA, V107, P6022, DOI 10.1073/pnas.1001522107
   Storr SJ, 2015, PATHOBIOLOGY, V82, P133, DOI 10.1159/000430464
   Storr SJ, 2011, NAT REV CANCER, V11, P364, DOI 10.1038/nrc3050
   Supiot S, 2013, WORLD J GASTROENTERO, V19, P3249, DOI 10.3748/wjg.v19.i21.3249
   Tamada Y, 2005, BRAIN RES, V1050, P148, DOI 10.1016/j.brainres.2005.05.048
   Tamada Y, 2002, COMP BIOCHEM PHYS B, V131, P221, DOI 10.1016/S1096-4959(01)00489-4
   Tsao CY, 2009, J CHILD NEUROL, V24, P346, DOI 10.1177/0883073808323525
   TSUNG PK, 1985, EXP EYE RES, V41, P97, DOI 10.1016/0014-4835(85)90098-3
   Uhlen M, 2005, MOL CELL PROTEOMICS, V4, P1920, DOI 10.1074/mcp.M500279-MCP200
   Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419
   [Anonymous], 2004, COSMIC CAT SOM MUT C
   Wert KJ, 2015, HUM MOL GENET, V24, P4584, DOI 10.1093/hmg/ddv189
   Wert KJ, 2014, HUM MOL GENET, V23, P2665, DOI 10.1093/hmg/ddt661
   Wu C, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-11-r130
   Wu HV, 2006, MOL NEUROBIOL, V33, P215, DOI 10.1385/MN:33:3:215
   Xu J, 2009, J NEUROSCI, V29, P9330, DOI 10.1523/JNEUROSCI.2212-09.2009
   Yang J, 2013, NEURON, V80, P1175, DOI 10.1016/j.neuron.2013.08.034
   YOSHIMURA N, 1984, BIOCHEM J, V223, P47, DOI 10.1042/bj2230047
   Zatz M, 2005, NEW ENGL J MED, V352, P2413, DOI 10.1056/NEJMra043361
NR 79
TC 1
Z9 1
U1 1
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2016
VL 57
IS 6
BP 2509
EP 2521
DI 10.1167/iovs.15-18680
PG 13
WC Ophthalmology
SC Ophthalmology
GA DO8OA
UT WOS:000378041700018
PM 27152965
OA gold
DA 2018-03-20
ER

PT J
AU Hauser, AK
   Mitov, MI
   Daley, EF
   McGarry, RC
   Anderson, KW
   Hilt, JZ
AF Hauser, Anastasia K.
   Mitov, Mihail I.
   Daley, Emily F.
   McGarry, Ronald C.
   Anderson, Kimberly W.
   Hilt, J. Zach
TI Targeted iron oxide nanoparticles for the enhancement of radiation
   therapy
SO BIOMATERIALS
LA English
DT Article
DE Radiation; Cell penetrating peptide; Iron oxide nanoparticles; Reactive
   oxygen species; Seahorse mitochondrial stress test
ID MAGNETIC FLUID HYPERTHERMIA; LUNG-CANCER CELLS; TAT PEPTIDE; OXIDATIVE
   STRESS; IONIZING-RADIATION; MITOCHONDRIAL DYSFUNCTION; GOLD
   NANOPARTICLES; UP-REGULATION; TOXICITY; DELIVERY
AB To increase the efficacy of radiation, iron oxide nanoparticles can be utilized for their ability to produce reactive oxygen species (ROS). Radiation therapy promotes leakage of electrons from the electron transport chain and leads to an increase in mitochondrial production of the superoxide anion which is converted to hydrogen peroxide by superoxide dismutase. Iron oxide nanoparticles can then catalyze the reaction from hydrogen peroxide to the highly reactive hydroxyl radical. Therefore, the overall aim of this project was to utilize iron oxide nanoparticles conjugated to a cell penetrating peptide, TAT, to escape lysosomal encapsulation after internalization by cancer cells and catalyze hydroxyl radical formation. It was determined that TAT functionalized iron oxide nanoparticles and uncoated iron oxide nanoparticles resulted in permeabilization of the lysosomal membranes. Additionally, mitochondria! integrity was compromised when A549 cells were treated with both TAT-functionalized nanoparticles and radiation. Pre-treatment with TAT-functionalized nanoparticles also significantly increased the ROS generation associated with radiation. A long term viability study showed that TAT-functionalized nanoparticles combined with radiation resulted in a synergistic combination treatment. This is likely due to the TAT-functionalized nanoparticles sensitizing the cells to subsequent radiation therapy, because the nano particles alone did not result in significant toxicities. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Hauser, Anastasia K.; Daley, Emily F.; Anderson, Kimberly W.; Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, 177 F Paul Anderson Tower, Lexington, KY 40506 USA.
   [Mitov, Mihail I.; McGarry, Ronald C.] Univ Kentucky, Markey Canc Ctr, Lexington, KY 40506 USA.
RP Hilt, JZ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 F Paul Anderson Tower, Lexington, KY 40506 USA.
EM hilt@engr.uky.edu
FU Redox Metabolism (RM) Shared Resource Facility (SRF) of the University
   of Kentucky Markey Cancer Center [P30CA177558]; National Cancer
   Institute [R25CA153954]; National Science Foundation [DGE-1247392]
FX This research was supported by the Redox Metabolism (RM) Shared Resource
   Facility (SRF) of the University of Kentucky Markey Cancer Center
   (P30CA177558). The project described was partially supported by Grant
   Number R25CA153954 from the National Cancer Institute. The content is
   solely the responsibility of the authors and does not necessarily
   represent the official views of the National Cancer Institute or the
   National Institutes of Health. Additionally, this work was supported by
   the National Science Foundation Graduate Research Fellowship Program
   Grant No. DGE-1247392. Any opinions, findings, and conclusions or
   recommendations expressed in this material are those of the author(s)
   and do not necessarily reflect the views of the National Science
   Foundation.
CR Ahamed M., 2013, J NANOPART RES, P15
   Ahamed M, 2013, CURR PHARM DESIGN, V19, P6681, DOI 10.2174/1381612811319370011
   Alarifi S, 2014, BIOL TRACE ELEM RES, V159, P416, DOI 10.1007/s12011-014-9972-0
   Aranda A, 2013, TOXICOL IN VITRO, V27, P954, DOI 10.1016/j.tiv.2013.01.016
   Auffan M, 2008, ENVIRON SCI TECHNOL, V42, P6730, DOI 10.1021/es800086f
   Austin LA, 2011, BIOCONJUGATE CHEM, V22, P2324, DOI 10.1021/bc200386m
   Azzam EI, 2012, CANCER LETT, V327, P48, DOI 10.1016/j.canlet.2011.12.012
   Babincova M, 2008, IEEE T NANOBIOSCI, V7, P15, DOI 10.1109/TNB.2008.2000145
   Chacko BK, 2014, CLIN SCI, V127, P367, DOI 10.1042/CS20140101
   Cochran DB, 2013, BIOMATERIALS, V34, P9615, DOI 10.1016/j.biomaterials.2013.08.025
   Cohn CA, 2008, PART FIBRE TOXICOL, V5, DOI 10.1186/1743-8977-5-2
   de la Fuente JM, 2005, BIOCONJUGATE CHEM, V16, P1176, DOI 10.1021/bc050033+
   Dennis CL, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/39/395103
   Domenech M, 2013, ACS NANO, V7, P5091, DOI 10.1021/nn4007048
   Duvigneau JC, 2008, LAB INVEST, V88, P70, DOI 10.1038/labinvest.3700691
   Emerit J, 2001, BIOMED PHARMACOTHER, V55, P333, DOI 10.1016/S0753-3322(01)00068-3
   Grosso S, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.71
   Guicciardi ME, 2004, ONCOGENE, V23, P2881, DOI 10.1038/sj.onc.1207512
   Hauser AK, 2016, NANOMEDICINE-UK, V11, P1769, DOI 10.2217/nnm-2016-0050
   Hervouet E, 2007, BIOCHIMIE, V89, P1080, DOI 10.1016/j.biochi.2007.03.010
   Hill BG, 2012, BIOL CHEM, V393, P1485, DOI 10.1515/hsz-2012-0198
   Hu RL, 2011, ONCOL LETT, V2, P1161, DOI 10.3892/ol.2011.379
   Huang G, 2013, THERANOSTICS, V3, P116, DOI 10.7150/thno.5411
   Ito A, 2007, CANCER SCI, V98, P424, DOI 10.1111/j.1349-7006.2006.00382.x
   Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h
   Kam WWY, 2013, FREE RADICAL BIO MED, V65, P607, DOI 10.1016/j.freeradbiomed.2013.07.024
   Kehrer JP, 2000, TOXICOLOGY, V149, P43, DOI 10.1016/S0300-483X(00)00231-6
   Khan MI, 2012, BIOMATERIALS, V33, P1477, DOI 10.1016/j.biomaterials.2011.10.080
   Kirkegaard T, 2009, BBA-MOL CELL RES, V1793, P746, DOI 10.1016/j.bbamcr.2008.09.008
   Klein S, 2014, J PHYS CHEM B, V118, P6159, DOI 10.1021/jp5026224
   Klein S, 2012, BIOCHEM BIOPH RES CO, V425, P393, DOI 10.1016/j.bbrc.2012.07.108
   Konczol M, 2013, CHEM RES TOXICOL, V26, P693, DOI 10.1021/tx300503q
   Kornhuber J, 2010, J CELL PHYSIOL, V224, P152, DOI 10.1002/jcp.22112
   Laurent S, 2011, ADV COLLOID INTERFAC, V166, P8, DOI 10.1016/j.cis.2011.04.003
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Lewinski N, 2008, SMALL, V4, P26, DOI 10.1002/smll.200700595
   Luo C, 2015, ARCH TOXICOL, V89, P357, DOI 10.1007/s00204-014-1267-x
   McCormack PL, 2012, DRUGS, V72, P2013, DOI 10.2165/11209880-000000000-00000
   Oyelere AK, 2007, BIOCONJUGATE CHEM, V18, P1490, DOI 10.1021/bc070132i
   Palmacci S, 1993, SYNTHESIS POLYSACCHA
   Pan LM, 2012, J AM CHEM SOC, V134, P5722, DOI 10.1021/ja211035w
   Park EJ, 2014, ARCH TOXICOL, V88, P1607, DOI 10.1007/s00204-014-1210-1
   Rao KS, 2008, BIOMATERIALS, V29, P4429, DOI 10.1016/j.biomaterials.2008.08.004
   Song N, 2012, J PINEAL RES, V53, P335, DOI 10.1111/j.1600-079X.2012.01003.x
   Terman A, 2006, IUBMB LIFE, V58, P531, DOI 10.1080/15216540600904885
   Torchilin VP, 2008, ADV DRUG DELIVER REV, V60, P548, DOI 10.1016/j.addr.2007.10.008
   Trachootham D, 2006, CANCER CELL, V10, P241, DOI 10.1016/j.ccr.2006.08.009
   Tucci P., 2013, CELL DEATH DIS, P4
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010
   Voinov MA, 2011, J AM CHEM SOC, V133, P35, DOI 10.1021/ja104683w
   Wang CH, 2012, INT J PHARMACEUT, V430, P372, DOI 10.1016/j.ijpharm.2012.04.035
   WEISSLEDER R, 1989, AM J ROENTGENOL, V152, P167, DOI 10.2214/ajr.152.1.167
   Xu CJ, 2008, CHEM-ASIAN J, V3, P548, DOI 10.1002/asia.200700301
   Yamamori T, 2012, FREE RADICAL BIO MED, V53, P260, DOI 10.1016/j.freeradbiomed.2012.04.033
   Yang C, 2014, J NANOSCI NANOTECHNO, V14, P4813, DOI 10.1166/jnn.2014.9280
   Zhao M, 2003, EUR J BIOCHEM, V270, P3778, DOI 10.1046/j.1432-1033.2003.03765.x
   Zhou T, 2014, ADV FUNCT MATER, V24, P6922, DOI 10.1002/adfm.201401642
NR 57
TC 10
Z9 11
U1 12
U2 77
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
EI 1878-5905
J9 BIOMATERIALS
JI Biomaterials
PD OCT
PY 2016
VL 105
BP 127
EP 135
DI 10.1016/j.biomaterials.2016.07.032
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA DV9ZD
UT WOS:000383299800012
PM 27521615
OA green_accepted
DA 2018-03-19
ER

PT J
AU Ghosh, G
   Bachas, LG
   Anderson, KW
AF Ghosh, Gargi
   Bachas, Leonidas G.
   Anderson, Kimberly W.
TI Biosensor incorporating cell barrier architectures on ion selective
   electrodes for early screening of cancer
SO ANALYTICAL AND BIOANALYTICAL CHEMISTRY
LA English
DT Article
DE screening cancer; angiogenesis; cytokines; cell-based biosensor;
   ion-selective electrode
ID ENDOTHELIAL GROWTH-FACTOR; TUMOR-NECROSIS-FACTOR; BREAST-CANCER;
   ANTIBODY ARRAYS; FACTOR-ALPHA; BIOMARKER RESEARCH; COLORECTAL-CANCER;
   PERIPHERAL-BLOOD; SERUM LEVELS; PLASMA DNA
AB Angiogenesis occurs during the early phase of cancer. Recruitment of new blood vessels by existing cancer cells leads to the release of higher concentrations of cytokines as compared to cells in healthy individuals. Some of the common cytokines observed at higher concentrations, such as vascular endothelial growth factor, basic fibroblast growth factor, hepatocyte growth factor and tumor necrosis factor-alpha, are also known to induce increased permeability across an endothelial cell monolayer. A whole-cell-based biosensor has been developed that can detect the presence of small quantities of the abovementioned cytokines individually and in different combinations. It was observed that the biosensor could differentiate between the cytokine concentrations observed in the sera of healthy individuals and cancer patients. The biosensor was also evaluated by exposing it to actual serum. These results demonstrated that the sensor can distinguish between healthy individuals and cancer patients and that the corresponding biosensor responses correlate with the stages of cancer.
C1 [Ghosh, Gargi; Anderson, Kimberly W.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Bachas, Leonidas G.] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
RP Anderson, KW (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM kanderson@engr.uky.edu
RI Bachas, Leonidas/G-2479-2015
OI Bachas, Leonidas/0000-0002-3308-6264
CR Anker P, 2001, LEUKEMIA, V15, P289, DOI 10.1038/sj.leu.2402016
   Brooks K A, 1996, Anal Chem, V68, P1439, DOI 10.1021/ac950915+
   CHA GS, 1989, TALANTA, V36, P271, DOI 10.1016/0039-9140(89)80106-7
   CHA MJ, 1995, ANAL CHIM ACTA, V315, P311, DOI 10.1016/0003-2670(95)00337-Y
   Cronauer MV, 1997, PROSTATE, V31, P223
   Denis MG, 1997, INT J CANCER, V74, P540, DOI 10.1002/(SICI)1097-0215(19971021)74:5<540::AID-IJC11>3.0.CO;2-A
   Dirix LY, 1997, BRIT J CANCER, V76, P238, DOI 10.1038/bjc.1997.368
   Dunlop RJ, 2000, J PAIN SYMPTOM MANAG, V20, P214, DOI 10.1016/S0885-3924(00)00199-8
   EYK JEV, 2001, CURR OPIN MOL THER, V3, P546
   FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27
   FOLKMAN J, 1985, ADV CANCER RES, V43, P175, DOI 10.1016/S0065-230X(08)60946-X
   Ghosh G, 2008, BIOSENS BIOELECTRON, V23, P1109, DOI 10.1016/j.bios.2007.10.023
   Ghosh G, 2007, ANAL BIOANAL CHEM, V387, P567, DOI 10.1007/s00216-006-0949-5
   GIMBRONE MA, 1972, J EXP MED, V136, P261, DOI 10.1084/jem.136.2.261
   Granato AM, 2004, BREAST CANCER RES, V6, pR38, DOI 10.1186/bcr745
   Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7
   Haab BB, 2005, MOL CELL PROTEOMICS, V4, P377, DOI 10.1074/mcp.M500010-MCP200
   Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7
   Heer K, 2001, CLIN CANCER RES, V7, P3491
   Herrera LJ, 2005, CLIN CHEM, V51, P113, DOI 10.1373/clinchem.2004.039263
   HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149
   Koncki R, 1997, TRAC-TREND ANAL CHEM, V16, P528, DOI 10.1016/S0165-9936(97)00066-6
   Kopf E, 2007, INT J BIOCHEM CELL B, V39, P1305, DOI 10.1016/j.biocel.2007.04.029
   LEON SA, 1977, CANCER RES, V37, P646
   MARCI A, 2006, BIOMARKERS, V11, P184
   May KML, 2005, ANAL BIOANAL CHEM, V382, P1010, DOI 10.1007/s00216-005-3224-2
   May KML, 2004, ANAL CHEM, V76, P4156, DOI 10.1021/ac049810+
   Mulcahy HE, 1998, CLIN CANCER RES, V4, P271
   Muller V, 2005, CLIN CANCER RES, V11, P3678, DOI 10.1158/1078-0432.CCR-04-2469
   Nakagawa T, 2007, CLIN CANCER RES, V13, P4105, DOI 10.1158/1078-0432.CCR-07-0419
   Nedelkov D, 2006, MOL CELL PROTEOMICS, V5, P1811, DOI 10.1074/mcp.R600006-MCP200
   Oppenheim Joost, 1996, Cytokine and Growth Factor Reviews, V7, P279, DOI 10.1016/S1359-6101(96)00025-1
   Premkumar VG, 2007, BASIC CLIN PHARMACOL, V100, P387, DOI 10.1111/j.1742-7843.2007.00065.x
   Sakong DS, 1996, SENSOR ACTUAT B-CHEM, V32, P161, DOI 10.1016/0925-4005(96)80126-2
   Sanchez-Carbayo M, 2006, CLIN CHEM, V52, P1651, DOI 10.1373/clinchem.2005.059592
   Sezer O, 2001, EUR J HAEMATOL, V66, P83, DOI 10.1034/j.1600-0609.2001.00348.x
   Shaw JA, 2000, CLIN CANCER RES, V6, P1119
   SheenChen SM, 1997, BREAST CANCER RES TR, V43, P211, DOI 10.1023/A:1005736712307
   Sher YP, 2005, CLIN CANCER RES, V11, P173
   Silva JM, 2002, CLIN CANCER RES, V8, P3761
   Silva JM, 1999, CANCER RES, V59, P3251
   SLIUTZ G, 1995, CANCER LETT, V94, P227, DOI 10.1016/0304-3835(95)03853-O
   Srinivas PR, 2002, CLIN CHEM, V48, P1160
   Srinivas PR, 2001, LANCET ONCOL, V2, P698, DOI 10.1016/S1470-2045(01)00560-5
   Szlosarek P, 2006, EUR J CANCER, V42, P745, DOI 10.1016/j.ejca.2006.01.012
   Tabar L, 2003, LANCET, V361, P1405, DOI 10.1016/S0140-6736(03)13143-1
   Ueno K, 2001, LUNG CANCER-J IASLC, V31, P213, DOI 10.1016/S0169-5002(00)00187-2
   Yoshida N, 2002, BRIT J CANCER, V86, P1396, DOI 10.1038/sj/bjc/6600257
   Zangar RC, 2006, EXPERT REV PROTEOMIC, V3, P37, DOI 10.1586/14789450.3.1.37
   Zitt M, 2007, DIS MARKERS, V23, P51, DOI 10.1155/2007/891967
NR 50
TC 5
Z9 5
U1 2
U2 18
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1618-2642
J9 ANAL BIOANAL CHEM
JI Anal. Bioanal. Chem.
PD AUG
PY 2008
VL 391
IS 8
BP 2783
EP 2791
DI 10.1007/s00216-008-2192-8
PG 9
WC Biochemical Research Methods; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA 332DF
UT WOS:000258061500012
PM 18537028
DA 2018-03-19
ER

PT J
AU Nagpure, S
   Das, S
   Garlapalli, RK
   Strzalka, J
   Rankin, SE
AF Nagpure, Suraj
   Das, Saikat
   Garlapalli, Ravinder K.
   Strzalka, Joseph
   Rankin, Stephen E.
TI In Situ GISAXS Investigation of Low-Temperature Aging in Oriented
   Surfactant-Mesostructured Titania Thin Films
SO JOURNAL OF PHYSICAL CHEMISTRY C
LA English
DT Article
ID X-RAY-SCATTERING; CYLINDRICAL NANOPORE ARRAYS; HEXAGONAL MESOPOROUS
   FILMS; SILICA MCM-48 MEMBRANE; TIO2 NANOTUBE ARRAYS; BLOCK-COPOLYMERS;
   NANOSTRUCTURED FILMS; SOLVENT EVAPORATION; MECHANICAL-PROPERTIES;
   CRYSTALLINE WALLS
AB The mechanism of forming orthogonally oriented hexagonal close-packed (o-HCP) mesostructures during aging of surfactant-templated titania thin films is elucidated using in situ grazing incidence small-angle X-ray scattering (GISAXS) in a controlled-environment chamber. To promote orthogonal orientation, glass slides are modified with cross-linked Pluronic P123, to provide surfaces chemically neutral toward both blocks of mesophase template P123. At 4 degrees C and 80% RH, the o-HCP mesophase emerges in thin (similar to 60 nm) films by a direct disorder-to-order transition, with no intermediate ordered mesophase. The Pluronic/titania o-HCP GISAXS intensity emerges only after similar to 10-12 min, much slower than previously reported for small-molecule surfactants. The Avrami model applied to the data suggests 2D growth with nucleation at the start of the process with a half-life of 39.7 min for the aging time just after the induction period of 7 min, followed by a period consistent with ID growth kinetics. Surprisingly, films that are thicker (similar to 250 nm) or cast on unmodified slides form o-HCP mesophase domains, but by a different mechanism (2D growth with continuous nucleation) with faster and less complete orthogonal alignment. Thus, the o-HCP mesophase is favored not only by modifying the substrate but also by aging at 4 degrees C, which is below the lower consolute temperature (LCST) of the poly(propylene oxide) block of P123. Consistent with this, in situ GISAXS shows that films aged at room temperature (above the LCST of the PPO block) have a randomly oriented HCP mesostructure.
C1 [Nagpure, Suraj; Das, Saikat; Garlapalli, Ravinder K.; Rankin, Stephen E.] Univ Kentucky, Chem & Mat Engn Dept, Lexington, KY 40506 USA.
   [Strzalka, Joseph] Argonne Natl Lab, Xray Sci Div, Argonne, IL 60439 USA.
RP Rankin, SE (reprint author), Univ Kentucky, Chem & Mat Engn Dept, 177 FP Anderson Tower, Lexington, KY 40506 USA.
EM stephen.rankin@uky.edu
OI Rankin, Stephen/0000-0002-8615-7564
FU U.S. Department of Energy EPSCoR Implementation [DE-FG02-07-ER46375];
   U.S. Department of Energy, Office of Science, Office of Basic Energy
   Sciences [DE-AC02-06CH11357]; NSF EPSCoR [IIA-1355438]
FX All experiments were performed as part of a U.S. Department of Energy
   EPSCoR Implementation award supported by grant no. DE-FG02-07-ER46375.
   The use of the Advanced Photon Source at Argonne National Laboratory for
   GISAXS measurements was supported by the U.S. Department of Energy,
   Office of Science, Office of Basic Energy Sciences, under Contract No.
   DE-AC02-06CH11357. Final data analysis and refinement were completed as
   part of an NSF EPSCoR research infrastructure award (grant no.
   IIA-1355438).
CR Alberius PCA, 2002, CHEM MATER, V14, P3284, DOI 10.1021/cm011209u
   Alonso B, 2010, J PHYS CHEM C, V114, P11730, DOI 10.1021/jp101652a
   Avrami M, 1941, J CHEM PHYS, V9, P177, DOI 10.1063/1.1750872
   Avrami M., 1940, Journal of Chemical Physics, V8, P212, DOI 10.1063/1.1750631
   Avrami M, 1939, J CHEM PHYS, V7, P1103, DOI 10.1063/1.1750380
   Barth S, 2010, PROG MATER SCI, V55, P563, DOI 10.1016/j.pmatsci.2010.02.001
   Bearzotti A, 2004, J EUR CERAM SOC, V24, P1969, DOI 10.1016/S0955-2219(03)00521-1
   Bearzotti A, 2003, SENSOR ACTUAT B-CHEM, V95, P107, DOI 10.1016/S0925-4005(03)00416-7
   Besson S, 2003, J MATER CHEM, V13, P404, DOI 10.1039/b206698j
   Boudot M, 2014, CHEM MATER, V26, P1822, DOI 10.1021/cm403787v
   Brinker CJ, 2006, CURR OPIN COLLOID IN, V11, P126, DOI 10.1016/j.cocis.2005.10.006
   Brinker CJ, 2004, MRS BULL, V29, P631, DOI 10.1557/mrs2004.183
   Brinker CJ, 1999, ADV MATER, V11, P579, DOI 10.1002/(SICI)1521-4095(199905)11:7<579::AID-ADMA579>3.0.CO;2-R
   Cadby AJ, 2005, J PHYS CHEM B, V109, P17879, DOI 10.1021/jp0536753
   Cagnol F, 2003, J MATER CHEM, V13, P61, DOI 10.1039/b209640b
   Cauda V, 2012, CHEM MATER, V24, P4215, DOI 10.1021/cm302594s
   Chen X, 2007, CHEM REV, V107, P2891, DOI 10.1021/cr0500535
   Chen Z, 2010, NAT MATER, V9, P667, DOI [10.1038/NMAT2805, 10.1038/nmat2805]
   Coakley KM, 2005, ADV FUNCT MATER, V15, P1927, DOI 10.1002/adfm.200500364
   Coll C, 2013, ACCOUNTS CHEM RES, V46, P339, DOI 10.1021/ar3001469
   Collard X, 2013, J COLLOID INTERF SCI, V401, P23, DOI 10.1016/j.jcis.2013.02.051
   Das S, 2014, J PHYS CHEM C, V118, P968, DOI 10.1021/jp406165v
   Ding ZM, 1997, J POLYM SCI POL PHYS, V35, P1077, DOI 10.1002/(SICI)1099-0488(199705)35:7<1077::AID-POLB7>3.0.CO;2-T
   Doshi DA, 2003, J AM CHEM SOC, V125, P11646, DOI 10.1021/ja0295523
   Elbert J, 2014, ADV FUNCT MATER, V24, P1591, DOI 10.1002/adfm.201302304
   Farrell RA, 2010, J COLLOID INTERF SCI, V349, P449, DOI 10.1016/j.jcis.2010.04.041
   Faustini M, 2014, CHEM MATER, V26, P709, DOI 10.1021/cm402132y
   Flodstrom K, 2004, LANGMUIR, V20, P4885, DOI 10.1021/la049637c
   Fujita S, 2013, CHEM MATER, V25, P1584, DOI 10.1021/cm303950u
   Gibaud A, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.161403
   Gibaud A, 2003, J PHYS CHEM B, V107, P6114, DOI 10.1021/jp027612l
   Gong D, 2001, J MATER RES, V16, P3331, DOI 10.1557/JMR.2001.0457
   Grosso D, 2003, CHEM MATER, V15, P4562, DOI 10.1021/cm031060h
   Grosso D, 2004, ADV FUNCT MATER, V14, P309, DOI 10.1002/adfm.200305036
   Grosso D, 2002, CHEM MATER, V14, P931, DOI 10.1021/cm011255u
   Grosso D, 2003, J SOL-GEL SCI TECHN, V26, P561, DOI 10.1023/A:1020715803241
   Grosso D, 2002, CHEM COMMUN, P748, DOI 10.1039/b111499a
   Grosso D, 2001, CHEM MATER, V13, P1848, DOI 10.1021/cm001225b
   Grosso D, 2011, CHEM SOC REV, V40, P829, DOI 10.1039/c0cs00039f
   Guliants VV, 2004, J MEMBRANE SCI, V235, P53, DOI 10.1016/j.memsci.2004.01.019
   Guo DJ, 2012, ELECTROANAL, V24, P2035, DOI 10.1002/elan.201200450
   HAGFELDT A, 1995, CHEM REV, V95, P49, DOI 10.1021/cr00033a003
   Hazra SK, 2006, SENSOR ACTUAT B-CHEM, V115, P403, DOI 10.1016/j.snb.2005.10.002
   Holmes JD, 2002, STUD SURF SCI CATAL, V141, P337
   Huang E, 1998, MACROMOLECULES, V31, P7641, DOI 10.1021/ma980705+
   Huang E, 1999, MACROMOLECULES, V32, P5299, DOI 10.1021/ma990483v
   Huang JY, 2013, INT J PHOTOENERGY, DOI 10.1155/2013/761971
   Huinink HP, 2000, J CHEM PHYS, V112, P2452, DOI 10.1063/1.480811
   Innocenzi P, 2006, J PHYS CHEM B, V110, P10837, DOI 10.1021/jp060097x
   Innocenzi P, 2005, J SYNCHROTRON RADIAT, V12, P734, DOI 10.1107/S0909049505014585
   Innocenzi P, 2007, J PHYS CHEM C, V111, P5345, DOI 10.1021/jp066566c
   Innocenzi P, 2013, CHEM SOC REV, V42, P4198, DOI 10.1039/c3cs35377j
   Innocenzi P, 2010, J PHYS CHEM C, V114, P10806, DOI 10.1021/jp9099732
   Islam S. Z., 2016, MICROPOROUS MESOPORO, V220, P120
   Ismail AA, 2011, J MATER CHEM, V21, P11686, DOI 10.1039/c1jm10407a
   Jagannathan H, 2006, J VAC SCI TECHNOL B, V24, P2220, DOI 10.1116/1.2244543
   Jang KS, 2004, CHEM COMMUN, P1514, DOI 10.1039/b404409f
   Jena A. K., 1992, PHASE TRANSFORMATION
   Jiang CH, 2013, J MATER SCI TECHNOL, V29, P97, DOI 10.1016/j.jmst.2012.11.017
   Jiang Z, 2015, J APPL CRYSTALLOGR, V48, P917, DOI 10.1107/S1600576715004434
   Jiang Z, 2012, J SYNCHROTRON RADIAT, V19, P627, DOI 10.1107/S0909049512022017
   Keller A, 2013, PHYS CHEM CHEM PHYS, V15, P13637, DOI 10.1039/c3cp52033a
   Kellogg GJ, 1996, PHYS REV LETT, V76, P2503, DOI 10.1103/PhysRevLett.76.2503
   Kim SH, 2004, ADV MATER, V16, P226, DOI 10.1002/adma.200304906
   Klotz M, 2000, CHEM MATER, V12, P1721, DOI 10.1021/cm991198t
   Ko YS, 2011, MICROPOR MESOPOR MAT, V145, P141, DOI 10.1016/j.micromeso.2011.05.008
   Koganti VR, 2006, NANO LETT, V6, P2567, DOI 10.1021/nl061992v
   Koganti VR, 2014, J PHYS CHEM C, V118, P19450, DOI 10.1021/jp505651j
   Koganti VR, 2005, J PHYS CHEM B, V109, P3279, DOI 10.1021/jp045037a
   Koh CW, 2008, CHEM-ASIAN J, V3, P862, DOI 10.1002/asia.200700331
   Kolmogorov A. N., 1937, B ACAD SCI USSR PHYS, V1, P355
   Kothari R, 2014, MACROMOLECULES, V47, P8048, DOI 10.1021/ma501816d
   Kumar P, 2010, MICROPOR MESOPOR MAT, V132, P1, DOI 10.1016/j.micromeso.2010.02.007
   Lee KR, 2010, NANO, V5, P75, DOI 10.1142/S1793292010001950
   Lee YF, 2011, RSC ADV, V1, P401, DOI 10.1039/c1ra00204j
   Li X, 2008, J PHYS CHEM C, V112, P53, DOI 10.1021/jp0762727
   Li XS, 2004, LANGMUIR, V20, P9095, DOI 10.1021/la0486279
   Lindsay MJ, 2007, ELECTROCHIM ACTA, V52, P6401, DOI 10.1016/j.electacta.2007.04.027
   Lindsay MJ, 2009, ELECTROCHIM ACTA, V54, P3501, DOI 10.1016/j.electacta.2008.10.044
   Liu NG, 2004, NANO LETT, V4, P551, DOI 10.1021/nl0350783
   Liu YC, 2011, INT J PHOTOENERGY, DOI 10.1155/2011/619069
   Lu YF, 1997, NATURE, V389, P364, DOI 10.1038/38699
   Lund R, 2013, ADV POLYM SCI, V259, P51, DOI 10.1007/12_2012_204
   Lyakhova KS, 2004, J CHEM PHYS, V120, P1127, DOI 10.1063/1.1632475
   Macak JM, 2007, CURR OPIN SOLID ST M, V11, P3, DOI 10.1016/j.cossms.2007.08.004
   Malfatti L, 2006, CHEM MATER, V18, P4553, DOI 10.1021/cm060236n
   Maret M, 2014, MACROMOLECULES, V47, P7221, DOI 10.1021/ma501453k
   Melde BJ, 2010, ANAL BIOANAL CHEM, V398, P1565, DOI 10.1007/s00216-010-3688-6
   Mor GK, 2006, SOL ENERG MAT SOL C, V90, P2011, DOI 10.1016/j.solmat.2006.04.007
   Nakata K, 2012, J PHOTOCH PHOTOBIO C, V13, P169, DOI 10.1016/j.jphotochemrev.2012.06.001
   Nguyen TQ, 2000, SCIENCE, V288, P652, DOI 10.1126/science.288.5466.652
   Nishiyama N, 2001, J MEMBRANE SCI, V182, P235, DOI 10.1016/S0376-7388(00)00570-6
   Ogawa M, 1996, CHEM COMMUN, P1149, DOI 10.1039/cc9960001149
   OGAWA M, 1994, J AM CHEM SOC, V116, P7941, DOI 10.1021/ja00096a079
   Ogawa M, 1998, SUPRAMOL SCI, V5, P247, DOI 10.1016/S0968-5677(98)00015-7
   Ortiz GF, 2009, CHEM MATER, V21, P63, DOI 10.1021/cm801670u
   Pan JH, 2011, CHEM ENG J, V170, P363, DOI 10.1016/j.cej.2010.11.040
   Paradiso SP, 2014, ACS MACRO LETT, V3, P16, DOI 10.1021/mz400572r
   Park DH, 2001, IND ENG CHEM RES, V40, P6105, DOI 10.1021/ie0103761
   Park OH, 2008, ADV MATER, V20, P738, DOI 10.1002/adma.200701236
   Phillip WA, 2010, MACROMOLECULES, V43, P7763, DOI 10.1021/ma1012946
   Pickett GT, 1997, MACROMOLECULES, V30, P3097, DOI 10.1021/ma9617173
   Platschek B, 2011, ADV MATER, V23, P2395, DOI 10.1002/adma.201002828
   Plawsky JL, 2009, MATER TODAY, V12, P36, DOI 10.1016/S1369-7021(09)70179-8
   Rankin S. E., 2000, MRS ONLINE P LIBR, V636, pD121
   Regonini D, 2013, MAT SCI ENG R, V74, P377, DOI 10.1016/j.mser.2013.10.001
   Richman EK, 2008, NAT MATER, V7, P712, DOI 10.1038/nmat2257
   Ryan KM, 2003, J AM CHEM SOC, V125, P6284, DOI 10.1021/ja0345064
   Sarker S, 2014, J MATER CHEM A, V2, P4890, DOI 10.1039/c3ta15410f
   Shankar K, 2009, J PHYS CHEM C, V113, P6327, DOI 10.1021/jp809385x
   Smilgies DM, 2009, J APPL CRYSTALLOGR, V42, P1030, DOI [10.1107/S0021889809040126, 10.1107/S00218898090401]
   Soler-Illia GJAA, 2006, CHEM-EUR J, V12, P4478, DOI 10.1002/chem.200500801
   Soni SS, 2008, ADV MATER, V20, P1493, DOI 10.1002/adma.200701066
   Stein A, 2014, CHEM MATER, V26, P259, DOI 10.1021/cm402184h
   Su YL, 2002, MACROMOLECULES, V35, P6426, DOI 10.1021/ma0105284
   Tasinkevych M, 2001, J CHEM PHYS, V115, P8705, DOI 10.1063/1.1412606
   Thurn-Albrecht T, 2000, ADV MATER, V12, P787, DOI 10.1002/(SICI)1521-4095(200006)12:11<787::AID-ADMA787>3.0.CO;2-1
   Tian BZ, 2004, J AM CHEM SOC, V126, P865, DOI 10.1021/ja037877t
   Toro-Vazquez JE, 2002, J AM OIL CHEM SOC, V79, P855, DOI 10.1007/s11746-002-0570-y
   Urade VN, 2007, LANGMUIR, V23, P4268, DOI 10.1021/la062641z
   Urade VN, 2007, CHEM MATER, V19, P768, DOI 10.1021/cm062136n
   Urbanova V, 2014, Z ANORG ALLG CHEM, V640, P537, DOI 10.1002/zaac.201300442
   Villanueva-Cab J, 2014, NANO LETT, V14, P2305, DOI 10.1021/nl4046087
   Vivero-Escoto JL, 2012, SCI TECHNOL ADV MAT, V13, DOI 10.1088/1468-6996/13/1/013003
   Volksen W, 2010, CHEM REV, V110, P56, DOI 10.1021/cr9002819
   Wagner T, 2013, CHEM SOC REV, V42, P4036, DOI 10.1039/c2cs35379b
   Walcarius A, 2013, CHEM SOC REV, V42, P4098, DOI 10.1039/c2cs35322a
   Wang DH, 2003, ADV MATER, V15, P130, DOI 10.1002/adma.200390025
   Wang JF, 2012, CHEM SOC REV, V41, P1111, DOI 10.1039/c1cs15106a
   WANKA G, 1994, MACROMOLECULES, V27, P4145, DOI 10.1021/ma00093a016
   Wu QL, 2012, J PHYS CHEM C, V116, P18669, DOI 10.1021/jp3072266
   Yagi I, 2010, ELECTROCHEMISTRY, V78, P105, DOI 10.5796/electrochemistry.78.105
   Yamauchi Y, 2009, CHEM REC, V9, P321, DOI 10.1002/tcr.200900022
   Yang HF, 2005, J MATER CHEM, V15, P1217, DOI 10.1039/b414402c
   Yu JC, 2004, CHEM MATER, V16, P1523, DOI 10.1021/cm049955x
   Zhao YR, 2007, J PHYS CHEM B, V111, P13937, DOI 10.1021/jp073451f
   Zhou W, 2013, CHEMCATCHEM, V5, P885, DOI 10.1002/cctc.201200519
NR 137
TC 6
Z9 6
U1 2
U2 33
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1932-7447
J9 J PHYS CHEM C
JI J. Phys. Chem. C
PD OCT 8
PY 2015
VL 119
IS 40
BP 22970
EP 22984
DI 10.1021/acs.jpcc.5b06945
PG 15
WC Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science,
   Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA CT3JD
UT WOS:000362702100026
DA 2018-03-20
ER

PT J
AU Tyagi, P
   Holmes, SM
   Hinds, BJ
AF Tyagi, Pawan
   Holmes, Stephen M.
   Hinds, Bruce J.
TI INOR 548-Magnetic ordering induced by molecular spin-valve electrodes
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
C1 [Tyagi, Pawan; Hinds, Bruce J.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Holmes, Stephen M.] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
EM bjhinds@engr.uky.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD AUG 19
PY 2007
VL 234
MA 548-INOR
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA V12IW
UT WOS:000207593909498
DA 2018-03-20
ER

PT J
AU Ng, G
   Sharma, K
   Ward, SM
   Desrosiers, MD
   Stephens, LA
   Schoel, WM
   Li, TL
   Lowell, CA
   Ling, CC
   Amrein, MW
   Shi, Y
AF Ng, Gilbert
   Sharma, Karan
   Ward, Sandra M.
   Desrosiers, Melanie D.
   Stephens, Leslie A.
   Schoel, W. Michael
   Li, Tonglei
   Lowell, Clifford A.
   Ling, Chang-Chun
   Amrein, Matthias W.
   Shi, Yan
TI Receptor-Independent, Direct Membrane Binding Leads to Cell-Surface
   Lipid Sorting and Syk Kinase Activation in Dendritic Cells
SO IMMUNITY
LA English
DT Article
ID MONOSODIUM URATE CRYSTALS; URIC-ACID; TYROSINE KINASES; INNATE IMMUNITY;
   DANGER SIGNAL; PHAGOCYTOSIS; RAFTS; MACROPHAGES; INFLAMMATION; SYSTEM
AB Binding of particulate antigens by antigen-presenting cells is a critical step in immune activation. Previously, we demonstrated that uric acid crystals are potent adjuvants, initiating a robust adaptive immune response. However, the mechanisms of activation are unknown. By using atomic force microscopy as a tool for real-time single-cell activation analysis, we report that uric acid crystals could directly engage cellular membranes, particularly the cholesterol components, with a force substantially stronger than protein-based cellular contacts. Binding of particulate substances activated Syk kinase-dependent signaling in dendritic cells. These observations suggest a mechanism whereby immune cell activation can be triggered by solid structures via membrane lipid alteration without the requirement for specific cell-surface receptors, and a testable hypothesis for crystal-associated arthropathies, inflammation, and adjuvanticity.
C1 [Ng, Gilbert; Sharma, Karan; Desrosiers, Melanie D.; Stephens, Leslie A.; Shi, Yan] Univ Calgary, Dept Microbiol & Infect Dis, Immunol Res Grp, Calgary, AB T2N 4N1, Canada.
   [Ward, Sandra M.; Ling, Chang-Chun] Univ Calgary, Dept Chem, Immunol Res Grp, Calgary, AB T2N 4N1, Canada.
   [Schoel, W. Michael; Amrein, Matthias W.] Univ Calgary, Dept Biol & Anat, Immunol Res Grp, Calgary, AB T2N 4N1, Canada.
   [Li, Tonglei] Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
   [Lowell, Clifford A.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA.
   [Lowell, Clifford A.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA.
RP Shi, Y (reprint author), Univ Calgary, Dept Microbiol & Infect Dis, Immunol Res Grp, Calgary, AB T2N 4N1, Canada.
EM yshi@ucalgary.ca
RI Sharma, Kiran/C-5715-2014
OI Sharma, Kiran/0000-0002-1200-8857
FU NIAID NIH HHS [R21 AI064666-02, R21 AI064666]
CR ABRAM CL, 2007, SCI STKE, pRE2
   Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593
   Behrens MD, 2008, BLOOD, V111, P1472, DOI 10.1182/blood-2007-10-117184
   Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111
   Brown DA, 2006, PHYSIOLOGY, V21, P430, DOI 10.1152/physiol.00032.2006
   Chen CJ, 2006, J CLIN INVEST, V116, P2262, DOI 10.1172/JCI28075
   Crowley MT, 1997, J EXP MED, V186, P1027, DOI 10.1084/jem.186.7.1027
   Desrosiers MD, 2007, J IMMUNOL, V179, P1884, DOI 10.4049/jimmunol.179.3.1884
   Dietrich C, 2001, P NATL ACAD SCI USA, V98, P10642, DOI 10.1073/pnas.191168698
   Fitzer-Attas CJ, 2000, J EXP MED, V191, P669, DOI 10.1084/jem.191.4.669
   Fitzgerald KA, 2006, CELL, V125, P834, DOI 10.1016/j.cell.2006.05.014
   Gardiner EE, 2008, BLOOD, V111, P165, DOI 10.1182/blood-2007-04-086983
   Greenberg S, 2002, CURR OPIN IMMUNOL, V14, P136, DOI 10.1016/S0952-7915(01)00309-0
   Hu DE, 2004, CANCER RES, V64, P5059, DOI 10.1158/0008-5472.CAN-04-1586
   Hughes AL, 1996, J MOL EVOL, V42, P247, DOI 10.1007/BF02198851
   Humphrey MB, 2005, IMMUNOL REV, V208, P50, DOI 10.1111/j.0105-2896.2005.00325.x
   JANEWAY CA, 1989, COLD SH Q B, V54, P1
   Jordan MB, 2004, SCIENCE, V304, P1808, DOI 10.1126/science.1089926
   KOVACSOVICSBANKOWSKI M, 1995, SCIENCE, V267, P243, DOI 10.1126/science.7809629
   Kusumi A, 2004, TRAFFIC, V5, P213, DOI 10.1111/j.1600-0854.2004.0178.x
   Lanier LL, 1998, NATURE, V391, P703, DOI 10.1038/35642
   Liu-Bryan R, 2005, J IMMUNOL, V174, P5016, DOI 10.4049/jimmunol.174.8.5016
   Lohi O, 1998, APOPTOSIS, V3, P335, DOI 10.1023/A:1009672903627
   MANDEL N, 1994, J AM SOC NEPHROL, V5, pS37
   MANDEL NS, 1976, ARTHRITIS RHEUM, V19, P439, DOI 10.1002/1529-0131(197605/06)19:3+<439::AID-ART1780190719>3.0.CO;2-L
   Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516
   Moriya K, 1997, P NATL ACAD SCI USA, V94, P12539, DOI 10.1073/pnas.94.23.12539
   Panorchan P, 2006, J MOL BIOL, V358, P665, DOI 10.1016/j.jmb.2006.02.021
   Panorchan P, 2006, J CELL SCI, V119, P66, DOI 10.1242/jcs.02719
   Romer W, 2007, NATURE, V450, P670, DOI 10.1038/nature05996
   Scott P, 2006, J IMMUNOL, V177, P6370, DOI 10.4049/jimmunol.177.9.6370
   Shaw MH, 2008, CURR OPIN IMMUNOL, V20, P377, DOI 10.1016/j.coi.2008.06.001
   Shen ZH, 1997, J IMMUNOL, V158, P2723
   Shi Y, 2003, NATURE, V425, P516, DOI 10.1038/nature01991
   Shi Y, 2006, J IMMUNOL, V176, P3905, DOI 10.4049/jimmunol.176.7.3905
   Smyth CJ, 1998, GOUT HYPERURICEMIA O
   Stuart LM, 2008, NAT REV IMMUNOL, V8, P131, DOI 10.1038/nri2240
   Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126
   Underhill DM, 2002, ANNU REV IMMUNOL, V20, P825, DOI 10.1146/annurev.immunol.20.103001.114744
   van Meer G, 2005, EMBO REP, V6, P418, DOI 10.1038/sj.embor.7400410
   WAITE JH, 1981, SCIENCE, V212, P1038, DOI 10.1126/science.212.4498.1038
   Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0
   Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539
NR 43
TC 153
Z9 159
U1 2
U2 23
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1074-7613
J9 IMMUNITY
JI Immunity
PD NOV 14
PY 2008
VL 29
IS 5
BP 807
EP 818
DI 10.1016/j.immuni.2008.09.013
PG 12
WC Immunology
SC Immunology
GA 374IC
UT WOS:000261036000017
PM 18993083
OA gold
DA 2018-03-20
ER

PT J
AU Wydra, RJ
   Oliver, CE
   Anderson, KW
   Dziubla, TD
   Hilt, JZ
AF Wydra, Robert J.
   Oliver, Catherine E.
   Anderson, Kimberly W.
   Dziubla, Thomas D.
   Hilt, J. Zach
TI Accelerated generation of free radicals by iron oxide nanoparticles in
   the presence of an alternating magnetic field
SO RSC ADVANCES
LA English
DT Article
ID OXIDATIVE STRESS; IN-VITRO; DEGRADATION; HYPERTHERMIA; TOXICITY;
   PARTICLES; CATALYST; ATRAZINE; THERAPY; FLUID
AB The surfaces of iron oxide nanoparticles are capable of catalytically generating reactive oxygen species (ROS) through the Fenton and Haber-Weiss reactions. Fenton chemistry has been shown to be temperature dependent with an increase in activity up to 40 degrees C and then a decrease above this temperature as the hydrogen peroxide degrades into oxygen and water which limits the reaction. When exposed to an alternating magnetic field (AMF), iron oxide nanoparticles absorb the energy from the magnetic field and convert it into heat. In this study, we observed an increase in the degradation of methylene blue when a suspension of magnetite nanoparticles (Fe3O4) was exposed to an AMF indicating there was an increase in the ROS generation in response to the AMF. The increase in ROS generation compared to the Arrhenius prediction was both time and concentration dependent; in which we observed a decrease in ROS enhancement with increased time of exposure and concentration. We postulate that the decrease is due to agglomeration in the presence of the field. As the nanoparticles agglomerate, there is a decrease in surface area per mass limiting the reaction rate.
C1 [Wydra, Robert J.; Oliver, Catherine E.; Anderson, Kimberly W.; Dziubla, Thomas D.; Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Hilt, JZ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 F Paul Anderson Tower, Lexington, KY 40506 USA.
EM hilt@engr.uky.edu
FU NCI-CNTC; National Cancer Institute [R25CA153954]; NSF REU from National
   Science Foundation [EEC-1156667]
FX RW acknowledges the financial support from a NCI-CNTC predoctoral
   traineeship and the project described was supported by Grant Number
   R25CA153954 from the National Cancer Institute. The content is solely
   the responsibility of the authors and does not necessarily represent the
   official views of the National Cancer Institute or the National
   Institutes of Health. CO acknowledges the financial support by the NSF
   REU Grant Number EEC-1156667 from the National Science Foundation.
CR Berry C. C., 2009, J PHYS D, V42, P9
   Biswal SL, 2004, ANAL CHEM, V76, P6448, DOI 10.1021/ac0494580
   Byrom J, 2013, SOFT MATTER, V9, P9167, DOI 10.1039/c3sm50306b
   Chan KH, 2003, CHEMOSPHERE, V51, P305, DOI 10.1016/S0045-6535(02)00812-3
   Chu W, 2007, CHEMOSPHERE, V67, P755, DOI 10.1016/j.chemosphere.2006.10.039
   Cochran DB, 2013, BIOMATERIALS, V34, P9615, DOI 10.1016/j.biomaterials.2013.08.025
   Creixell M, 2011, ACS NANO, V5, P7124, DOI 10.1021/nn201822b
   de Souza WF, 2009, APPL CATAL A-GEN, V360, P205, DOI 10.1016/j.apcata.2009.03.023
   Dhakshinamoorthy A, 2012, CHEMSUSCHEM, V5, P46, DOI 10.1002/cssc.201100517
   Frimpong RA, 2010, NANOMEDICINE-UK, V5, P1401, DOI 10.2217/NNM.10.114
   Frimpong RA, 2010, J MAGN MAGN MATER, V322, P326, DOI 10.1016/j.jmmm.2009.09.050
   Ghosh P, 2012, J CHEM TECHNOL BIOT, V87, P914, DOI 10.1002/jctb.3699
   Hilger I, 2006, J PHYS-CONDENS MAT, V18, pS2951, DOI 10.1088/0953-8984/18/38/S28
   Hsieh S. C., 2012, J NANOPART RES, V14, P1
   Jordan A, 1999, J MAGN MAGN MATER, V201, P413, DOI 10.1016/S0304-8853(99)00088-8
   Krishnan KM, 2010, IEEE T MAGN, V46, P2523, DOI 10.1109/TMAG.2010.2046907
   Mahmoudi M, 2012, CHEM REV, V112, P2323, DOI 10.1021/cr2002596
   Malvindi MA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085835
   McCormack PL, 2012, DRUGS, V72, P2013, DOI 10.2165/11209880-000000000-00000
   Melgoza D, 2009, PHOTOCH PHOTOBIO SCI, V8, P596, DOI 10.1039/b817287k
   Moroz P, 2002, INT J HYPERTHER, V18, P267, DOI 10.1080/02656730110108785
   Naqvi S, 2010, INT J NANOMED, V5, P983, DOI 10.2147/IJN.S13244
   Nogueira V, 2008, CANCER CELL, V14, P458, DOI 10.1016/j.ccr.2008.11.003
   Pignatello JJ, 2006, CRIT REV ENV SCI TEC, V36, P1, DOI 10.1080/10643380500326564
   Polo-Corrales L., 2012, J APPL PHYS, V111, P3
   Rabin Y, 2002, INT J HYPERTHER, V18, P194, DOI 10.1080/02656730110116713
   Rosensweig RE, 2002, J MAGN MAGN MATER, V252, P370, DOI 10.1016/S0304-8853(02)00706-0
   Shahwan T, 2011, CHEM ENG J, V172, P258, DOI 10.1016/j.cej.2011.05.103
   Sharma G, 2014, NANOTOXICOLOGY, V8, P663, DOI 10.3109/17435390.2013.822115
   Stone JR, 2006, ANTIOXID REDOX SIGN, V8, P243, DOI 10.1089/ars.2006.8.243
   Stroh A, 2004, FREE RADICAL BIO MED, V36, P976, DOI 10.1016/j.freeradbiomed.2004.01.016
   Ursachi I, 2012, J COLLOID INTERF SCI, V377, P184, DOI 10.1016/j.jcis.2012.03.066
   van den Bos EJ, 2003, CELL TRANSPLANT, V12, P743, DOI 10.3727/000000003108747352
   Voinov MA, 2011, J AM CHEM SOC, V133, P35, DOI 10.1021/ja104683w
   Wang B, 2013, J PHYS CHEM C, V117, P383, DOI 10.1021/jp3101392
   Wydra RJ, 2013, MAT SCI ENG C-MATER, V33, P4660, DOI 10.1016/j.msec.2013.07.019
   Yallapu MM, 2011, BIOMATERIALS, V32, P1890, DOI 10.1016/j.biomaterials.2010.11.028
   Yu M, 2012, INT J MOL SCI, V13, P5554, DOI 10.3390/ijms13055554
   Zhang J, 2011, REACT KINET MECH CAT, V103, P299, DOI 10.1007/s11144-011-0323-2
   Zhang SX, 2009, J HAZARD MATER, V167, P560, DOI 10.1016/j.jhazmat.2009.01.024
NR 40
TC 13
Z9 14
U1 3
U2 40
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2046-2069
J9 RSC ADV
JI RSC Adv.
PY 2015
VL 5
IS 24
BP 18888
EP 18893
DI 10.1039/c4ra13564d
PG 6
WC Chemistry, Multidisciplinary
SC Chemistry
GA CC0BE
UT WOS:000349999200087
PM 25798231
OA green_accepted
DA 2018-03-19
ER

PT J
AU Li, TL
AF Li, Tonglei
TI Visualizing the locality of intermolecular interactions in organic
   crystals
SO JOURNAL OF MOLECULAR GRAPHICS & MODELLING
LA English
DT Article
DE density functional theory; Fukui function; organic crystal;
   intermolecular interaction; crystal packing; van der waals interaction;
   polarizability
ID DENSITY-FUNCTIONAL THEORY; FUKUI FUNCTION; SOFTNESS; ASPIRIN; HARDNESS;
   ENERGY; ACIDS; BASES
AB Density functional theory (DFT) provides a rigorous theoretical framework for analyzing and interpreting electronic structures of molecules and crystals. One electron density-based concept is the Fukui function, which describes the responding sensitivity of a molecular system to electronic perturbations. As a local property, the Fukui function is directly associated with local polarizability, so it may be capable of describing the intermolecular interaction in an organic crystal with regard to molecular packing. Herein, we demonstrate such an application to the aspirin single crystal and discuss potentials of the DFT-based concepts for studying electronic structures of organic crystals. (C) 2007 Elsevier Inc. All rights reserved.
C1 Univ Kentucky, Dept Pharmaceut Sci, Coll Pharm 514, Lexington, KY 40536 USA.
RP Li, TL (reprint author), Univ Kentucky, Dept Pharmaceut Sci, Coll Pharm 514, 725 Rose St, Lexington, KY 40536 USA.
EM tonglei@uky.edu
CR De Proft F, 1998, J CHEM PHYS, V108, P7549, DOI 10.1063/1.476188
   Doll K, 2001, INT J QUANTUM CHEM, V82, P1, DOI 10.1002/1097-461X(2001)82:1<1::AID-QUA1017>3.0.CO;2-W
   Feng SX, 2006, J CHEM THEORY COMPUT, V2, P149, DOI 10.1021/ct050189a
   Geerlings P, 2003, CHEM REV, V103, P1793, DOI 10.1021/cr990029p
   JAMESON CJ, 1980, J CHEM PHYS, V73, P5684, DOI 10.1063/1.440045
   Jin P, 2006, INT J QUANTUM CHEM, V106, P2347, DOI 10.1002/qua.20974
   KIM Y, 1985, CHEM PHARM BULL, V33, P2641
   Kohn W, 1996, J PHYS CHEM-US, V100, P12974, DOI 10.1021/jp960669l
   LEE CT, 1988, PHYS REV B, V37, P785, DOI 10.1103/PhysRevB.37.785
   Li TL, 2006, PHARM RES-DORDR, V23, P2326, DOI 10.1007/s11095-006-9006-5
   PARR RG, 1978, J CHEM PHYS, V68, P3801, DOI 10.1063/1.436185
   PARR RG, 1984, J AM CHEM SOC, V106, P4049, DOI 10.1021/ja00326a036
   Parr RG, 1989, DENSITY FUNCTIONAL T
   PEARSON RG, 1963, J AM CHEM SOC, V85, P3533, DOI 10.1021/ja00905a001
   PEARSON RG, 1966, SCIENCE, V151, P172, DOI 10.1126/science.151.3707.172
   VELA A, 1990, J AM CHEM SOC, V112, P1490, DOI 10.1021/ja00160a029
   WATANABE A, 1982, CHEM PHARM BULL, V30, P2958
   YANG WT, 1985, P NATL ACAD SCI USA, V82, P6723, DOI 10.1073/pnas.82.20.6723
NR 18
TC 0
Z9 0
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1093-3263
EI 1873-4243
J9 J MOL GRAPH MODEL
JI J. Mol. Graph.
PD FEB
PY 2008
VL 26
IS 6
BP 962
EP 965
DI 10.1016/j.jmgm.2007.08.001
PG 4
WC Biochemical Research Methods; Biochemistry & Molecular Biology; Computer
   Science, Interdisciplinary Applications; Crystallography; Mathematical &
   Computational Biology
SC Biochemistry & Molecular Biology; Computer Science; Crystallography;
   Mathematical & Computational Biology
GA 261HC
UT WOS:000253068700008
PM 17900952
DA 2018-03-20
ER

PT J
AU Rheiner, S
   Rychahou, P
   Bae, Y
AF Rheiner, Steven
   Rychahou, Piotr G.
   Bae, Younsoo
TI Effects of the Lipophilic Core of Polymer Nanoassemblies on
   Intracellular Delivery and Transfection of siRNA
SO AIMS BIOPHYSICS
LA English
DT Article
DE polymer nanoassemblies; gene therapy; siRNA delivery; non-viral vectors;
   cancer; nanotechnology
AB Despite effective gene silencing in vitro, in vivo delivery and transfection of siRNA remain challenging due to the lack of carriers that protect siRNA stably in the body. This study is focused to elucidate the correlation between complex stability and transfection efficiency of siRNA carriers. The carriers were prepared by using polymer nanoassemblies made of a cationic branched polymer [poly(ethylene imine): bPEI] to which hydrophilic poly(ethylene glycol) polymers were tethered covalently. These polymer tethered nanoassemblies (TNAs) were further modified with lipophilic chains (palmitate: PAL) in the core to stabilize siRNA TNAs complexes through ionic and hydrophobic interactions in combination. The effects of PAL in the core of TNAs were investigated with respect to in vitro transfection, intracellular gene delivery, and toxicity of the complexes, using a human colon cancer HT29 cell line stably expressing a luciferase reporter gene. A commercial transfection agent (RNAiMax) was used as a control. TNAs entrapping siRNA showed the greatest complex stability in the absence of PAL although TNAs with a greater PAL content induced effective intracellular siRNA delivery, while luciferase expression decreased as the amount of PAL increased in the core of TNAs. These results demonstrate that lipophilic components in carriers affect not only complex stability but also intracellular distribution and transfection of siRNA in cancer cells.
C1 [Rheiner, Steven; Bae, Younsoo] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, 789 South Limestone, Lexington, KY 40536 USA.
   [Rychahou, Piotr] Univ Kentucky, Markey Canc Ctr, 800 Rose St,CC140, Lexington, KY 40536 USA.
   [Rychahou, Piotr] Univ Kentucky, Coll Med, Dept Surg, 741 South Limestone, Lexington, KY 40536 USA.
RP Bae, Y (reprint author), Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, 789 South Limestone, Lexington, KY 40536 USA.
EM younsoo.bae@uky.edu
FU University of Kentucky Markey Cancer Center
FX This work is partially supported by the University of Kentucky Markey
   Cancer Center pilot project grant.
CR Akhtar S, 2007, ADV DRUG DELIVER REV, V59, P164, DOI 10.1016/j.addr.2007.03.010
   Akinc A, 2005, J GENE MED, V7, P657, DOI 10.1002/jgm.696
   Albanese A, 2012, ANNU REV BIOMED ENG, V14, P1, DOI [10.1146/annurev-bioeng-071811-150124, 10.1146/annurev.bioeng-071811-150124]
   Aliabadi HM, 2012, BIOMATERIALS, V33, P2546, DOI 10.1016/j.biomaterials.2011.11.079
   Ballarin-Gonzalez B, 2013, CANC LETT
   Bartlett DW, 2006, NUCLEIC ACIDS RES, V34, P322, DOI 10.1093/nar/gkj439
   Canton I, 2012, CHEM SOC REV
   Cevc G, 1999, ADV DRUG DELIVER REV, V38, P207, DOI 10.1016/S0169-409X(99)00030-7
   Fire A, 1999, TRENDS GENET, V15, P358, DOI 10.1016/S0168-9525(99)01818-1
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Fischer D, 1999, PHARMACEUT RES, V16, P1273, DOI 10.1023/A:1014861900478
   Gonzalez H, 1999, BIOCONJUGATE CHEM, V10, P1068, DOI 10.1021/bc990072j
   Grayson ACR, 2006, PHARM RES, V23, P1868, DOI 10.1007/s11095-006-9009-2
   Guo GY, 2013, INT J PHARMACEUT, V450, P44, DOI 10.1016/j.ijpharm.2013.04.024
   Guo PX, 2010, ADV DRUG DELIVER REV, V62, P650, DOI 10.1016/j.addr.2010.03.008
   He CB, 2010, BIOMATERIALS, V31, P3657, DOI 10.1016/j.biomaterials.2010.01.065
   Holzerny P, 2012, J CONTROL RELEASE, V157, P297, DOI 10.1016/j.jconrel.2011.08.023
   Hong J, 2014, BIOMATERIALS, V35, P7562, DOI 10.1016/j.biomaterials.2014.05.025
   Kim D, 2012, EUR J PHARM BIOPHARM, V81, P14, DOI 10.1016/j.ejpb.2012.01.013
   Kim HJ, 2014, BIOMATERIALS, V35, P4548, DOI 10.1016/j.biomaterials.2014.02.016
   Kurtulus I, 2014, POLYM CHEM-UK, V5, P1593, DOI 10.1039/c3py01244a
   Lv HT, 2006, J CONTROL RELEASE, V114, P100, DOI 10.1016/j.jconrel.2006.04.014
   Maeda H, 2000, J CONTROL RELEASE, V65, P271, DOI 10.1016/S0168-3659(99)00248-5
   Matsumoto S, 2009, BIOMACROMOLECULES, V10, P119, DOI 10.1021/bm800985e
   Mehrabadi FS, 2012, CURR OPIN SOLID ST M, V16, P310, DOI 10.1016/j.cossms.2013.01.003
   Merkel OM, 2011, BIOMATERIALS, V32, P2388, DOI 10.1016/j.biomaterials.2010.11.081
   Miteva M, 2014, BIOMATERIALS
   Nel AE, 2009, NAT MATER, V8, P543, DOI [10.1038/nmat2442, 10.1038/NMAT2442]
   Nelson CE, 2013, ACS NANO, V7, P8870, DOI 10.1021/nn403325f
   Noguchi A, 1998, FEBS LETT, V433, P169, DOI 10.1016/S0014-5793(98)00837-0
   Oh YK, 2009, ADV DRUG DELIVER REV, V61, P850, DOI 10.1016/j.addr.2009.04.018
   Pack DW, 2005, NAT REV DRUG DISCOV, V4, P581, DOI 10.1038/nrd1775
   Pasche S, 2005, J PHYS CHEM B, V109, P17545, DOI 10.1021/jp050431+
   Patel MM, 2005, BIOPHYS J, V88, P2089, DOI 10.1529/biophysj.104.052100
   Petros RA, 2010, NAT REV DRUG DISCOV, V9, P615, DOI 10.1038/nrd2591
   Resnier P, 2013, BIOMATERIALS, V34, P6429, DOI 10.1016/j.biomaterials.2013.04.060
   Richard I, 2013, BIOMACROMOLECULES, V14, P1732, DOI 10.1021/bm4000713
   Wightman L, 2001, J GENE MED, V3, P362, DOI 10.1002/jgm.187
   Xia W, 2012, J CONTROL RELEASE, V157, P427, DOI 10.1016/j.jconrel.2011.10.011
   Zhang SB, 2007, J CONTROL RELEASE, V123, P1, DOI 10.1016/j.jconrel.2007.07.016
   Zhu CH, 2010, BIOMATERIALS, V31, P2408, DOI 10.1016/j.biomaterials.2009.11.077
   Zintchenko A, 2008, BIOCONJUGATE CHEM, V19, P1448, DOI 10.1021/bc800065f
   Zuckerman JE, 2012, P NATL ACAD SCI USA, V109, P3137, DOI 10.1073/pnas.1200718109
NR 43
TC 3
Z9 3
U1 0
U2 0
PU AMER INST MATHEMATICAL SCIENCES-AIMS
PI SPRINGFIELD
PA PO BOX 2604, SPRINGFIELD, MO 65801-2604 USA
SN 2377-9098
J9 AIMS BIOPHYS
JI AIMS Biophys.
PY 2015
VL 2
IS 3
SI SI
BP 284
EP 302
DI 10.3934/biophy.2015.3.284
PG 19
WC Biophysics
SC Biophysics
GA V23PC
UT WOS:000215100300004
OA gold
DA 2018-03-19
ER

PT J
AU Daily, A
   Liu, SQ
   Bae, Y
   Bhatnagar, S
   Moscow, JA
AF Daily, Abigail
   Liu, Shuqian
   Bae, Younsoo
   Bhatnagar, Saloni
   Moscow, Jeffrey A.
TI Linear Chain PEGylated Recombinant Bacillus Thiaminolyticus Thiaminase I
   Enzyme Has Growth Inhibitory Activity against Lymphoid Leukemia Cell
   Lines
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID GENE-EXPRESSION; BREAST-CANCER; RESISTANCE; DRUG
AB Cancer cells acquire abnormalities in energy metabolism, collectively known as the Warburg effect, affecting substrate availability of thiamine-dependent enzymes. To investigate a strategy to exploit abnormal cancer-associated metabolism related to thiamine, we tested the cytotoxicity of native Bacillus thiaminolyticus thiaminase I enzyme, which digests thiamine, in the NCI60 cell line drug cytotoxicity screening program and found that leukemia cell lines were among the most sensitive to thiaminase I. We obtained additional lymphoid leukemia cell lines and confirmed that native thiaminase I and linear chain PEGylated thiaminase I enzyme (LCPTE) have cytotoxic activity in these cell lines. In addition, the IC50 of 3 of the 5 leukemia cell lines (Reh, RS4, and Jurkat) were at least 1,000-fold more sensitive than Molt-4 cells, which in turn, were among the most sensitive in the NCI60 panel. The 3 LCPTE-sensitive leukemia cell lines were also sensitive to removal of thiamine from the medium, thus suggesting the mechanism of action of LCPTE involves extracellular thiamine starvation. Surprisingly, rapamycin showed a protective effect against LCPTE toxicity in the 3 LCPTE-sensitive cell lines but not in the other 2 cell lines, suggesting involvement of an mTOR-dependent pathway. Immunoblot analysis of the LCPTE-sensitive cell lines after LCPTE exposure revealed changes in mTOR pathway phosphorylation. Nude mice bearing RS4 leukemia xenografts showed both tumor growth delay and prolonged survival after a single dose of LCPTE. Therefore, disruption of thiamine-dependent metabolism may be a novel therapeutic approach to target altered energy metabolism in leukemia and other cancers. Mol Cancer Ther; 10(9); 1563-70. (C)2011 AACR.
C1 [Daily, Abigail; Liu, Shuqian; Bhatnagar, Saloni; Moscow, Jeffrey A.] Univ Kentucky, Coll Med, Dept Pediat, Lexington, KY 40536 USA.
   [Bae, Younsoo] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
RP Moscow, JA (reprint author), Univ Kentucky, Coll Med, Dept Pediat, 740 S Limestone Room J457, Lexington, KY 40536 USA.
EM jmoscow@uky.edu
FU William Lawrence and Blanche Hughes Foundation; DanceBlue
FX The authors thank the support of the William Lawrence and Blanche Hughes
   Foundation and DanceBlue, an effort of the University of Kentucky
   student community to support pediatric oncology care and research.
CR Costello CA, 1996, J BIOL CHEM, V271, P3445, DOI 10.1074/jbc.271.7.3445
   FARBER S, 1948, NEW ENGL J MED, V238, P787, DOI 10.1056/NEJM194806032382301
   Fischer PM, 2009, CELL CYCLE, V8, P2535, DOI 10.4161/cc.8.16.9301
   Ganapathy V, 2004, PFLUG ARCH EUR J PHY, V447, P641, DOI 10.1007/s00424-003-1068-1
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Liu SQ, 2010, CANCER CHEMOTH PHARM, V66, P171, DOI 10.1007/s00280-009-1148-9
   Liu SQ, 2004, MOL CANCER RES, V2, P477
   Liu SQ, 2003, MOL CANCER RES, V1, P665
   Lu J, 2008, CLIN CHEM, V54, P901, DOI 10.1373/clinchem.2007.099077
   Menon S, 2008, Oncogene, V27 Suppl 2, pS43, DOI 10.1038/onc.2009.352
   RICHARDSON AD, 2010, CANCER BIOL THER, V10, P32
   Shoemaker RH, 2006, NAT REV CANCER, V6, P813, DOI 10.1038/nrc1951
   Zhao F, 2010, ONCOGENE, V29, P2962, DOI 10.1038/onc.2010.67
NR 13
TC 5
Z9 5
U1 0
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
EI 1538-8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD SEP
PY 2011
VL 10
IS 9
BP 1563
EP 1570
DI 10.1158/1535-7163.MCT-11-0003
PG 8
WC Oncology
SC Oncology
GA 817JR
UT WOS:000294668900004
PM 21697396
OA gold
DA 2018-03-19
ER

PT J
AU Schlipf, DM
   Rankin, SE
   Knutson, BL
AF Schlipf, Daniel M.
   Rankin, Stephen E.
   Knutson, Barbara L.
TI Pore-Size Dependent Protein Adsorption and Protection from Proteolytic
   Hydrolysis in Tailored Mesoporous Silica Particles
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE mesoporous silica; protein adsorption; protein protection; size
   selective; proteolytic hydrolysis; fluorescent protein
ID GREEN-FLUORESCENT PROTEIN; SPHERICAL-PARTICLES; SBA-15; PEPSIN; ENZYME;
   STABILIZATION; BIOCATALYSIS; SEPARATIONS; DELIVERY; SPHERES
AB Protein adsorption and interactions with mesoporous silica are of interest for a broad range of applications including drug delivery, chemical synthesis, biosensors, and bioseparations. A major challenge in designing mesoporous silica supports for tailored protein interaction is the differentiation of protein interactions at the surface of the particle from interactions within the pore, important features when considering mesoporous silica as a protective support for active proteins. In this investigation, the location of Enhanced Green Fluorescent Proteins (EGFPs) adsorbed on tailored mesoporous silica particles is examined as a function of pore diameter using proteolytic hydrolysis to distinguish between accessible and inaccessible proteins. Pore size control is achieved by tuning the hydrothermal aging temperature (60-110 degrees C) during synthesis, where the synthesis results in 5-15 mu m diameter spherical particles appropriate for imaging by confocal scanning laser microscopy (CSLM). In low pH environments, EGFP unfolds within pores and on the surface of particles, rendering it susceptible to proteolytic hydrolysis by the protease Pepsin A. Upon return to neutral pH, un-hydrolyzed EGFP regains its fluorescence and can be visualized within the mesoporous particles. The pore-size dependent loading and protection of EGFP (2.4 nm diameter x 4.2 nm) from proteolytic attack by Pepsin A (7.3 nm x 3.6 nm X 5.4 nm) is demonstrated by the retention of fluorescence in 7.3 nm pores. Larger-pored materials (> 9 nm) provide diminishing protection for EGFP, and the protection is greatly reduced with increasing pore size and pore size distribution breadth. Proteolytic hydrolysis is used to delineate the activity of pore-loaded versus surface-bound proteins and to establish that there is an optimal pore diameter for loading EGFP while protecting it from attack by a larger proteolytic enzyme.
C1 [Schlipf, Daniel M.; Rankin, Stephen E.; Knutson, Barbara L.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Knutson, BL (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 F Paul Anderson Tower, Lexington, KY 40506 USA.
EM bknut2@uky.edu
OI Rankin, Stephen/0000-0002-8615-7564
FU National Science Foundation Integrated Graduate Education and Research
   Training program on Bioactive Interfaces and Devices [DGE-0653710]
FX This manuscript is based on work funded by the National Science
   Foundation Integrated Graduate Education and Research Training program
   on Bioactive Interfaces and Devices (Grant DGE-0653710). The authors
   thank Jim Begley of the University of Kentucky Imaging Facility for help
   with the CSLM experiments.
CR Ambati J, 2012, ACTA BIOMATER, V8, P2096, DOI 10.1016/j.actbio.2012.02.012
   BARRETT EP, 1951, J AM CHEM SOC, V73, P373, DOI 10.1021/ja01145a126
   BHAMBHANI MR, 1972, J COLLOID INTERF SCI, V38, P109, DOI 10.1016/0021-9797(72)90226-3
   Brunauer S, 1938, J AM CHEM SOC, V60, P309, DOI 10.1021/ja01269a023
   Campanini B, 2005, PROTEIN SCI, V14, P1125, DOI 10.1110/ps.041190805
   Dordick JS, 2006, CURR OPIN BIOTECH, V17, P559, DOI 10.1016/j.copbio.2006.10.012
   Eggers DK, 2001, PROTEIN SCI, V10, P250, DOI 10.1110/ps.36201
   Gartmann N, 2009, ANGEW CHEM INT EDIT, V48, P6354, DOI 10.1002/anie.200902436
   Hartmann M, 2005, CHEM MATER, V17, P4577, DOI 10.1021/cm0485658
   Hartmann M, 2010, J MATER CHEM, V20, P844, DOI 10.1039/b907869j
   He J, 2008, AICHE J, V54, P2495, DOI 10.1002/aic.11561
   Hudson S, 2008, ANGEW CHEM INT EDIT, V47, P8582, DOI 10.1002/anie.200705238
   Katiyar A, 2006, SMALL, V2, P644, DOI 10.1002/smll.200500473
   Katiyar A, 2005, J CHROMATOGR A, V1069, P119, DOI 10.1016/j.chroma.2004.10.077
   Katiyar A, 2006, J CHROMATOGR A, V1122, P13, DOI 10.1016/j.chroma.2006.04.055
   Kim J, 2006, CHEM ENG SCI, V61, P1017, DOI 10.1016/j.ces.2005.05.067
   Kumar P, 2010, MICROPOR MESOPOR MAT, V132, P1, DOI 10.1016/j.micromeso.2010.02.007
   Lee CH, 2009, NANO TODAY, V4, P165, DOI 10.1016/j.nantod.2009.02.001
   Lin HP, 2000, J PHYS CHEM B, V104, P7885, DOI 10.1021/jp000010m
   Lu S, 2011, J PHYS CHEM B, V115, P13695, DOI 10.1021/jp206497u
   Lu S, 2011, J PHYS CHEM B, V115, P7744, DOI 10.1021/jp200778b
   Ma YJ, 2011, J COLLOID INTERF SCI, V356, P123, DOI 10.1016/j.jcis.2010.12.082
   Malik A, 2005, ANAL BIOCHEM, V340, P252, DOI 10.1016/j.ab.2005.02.022
   Manyar HG, 2008, J PHYS CHEM C, V112, P18110, DOI 10.1021/jp802420t
   Martin-Aranda RM, 2010, TOP CATAL, V53, P141, DOI 10.1007/s11244-009-9419-6
   Mesa M, 2003, SOLID STATE SCI, V5, P1303, DOI 10.1016/S1293-2558(03)00185-7
   Ormo M, 1996, SCIENCE, V273, P1392
   SIELECKI AR, 1990, J MOL BIOL, V214, P143, DOI 10.1016/0022-2836(90)90153-D
   Sotiropoulou S, 2005, BIOSENS BIOELECTRON, V20, P1674, DOI 10.1016/j.bios.2004.07.019
   Suh CW, 2004, J BIOTECHNOL, V112, P267, DOI 10.1016/j.jbiotec.2004.05.005
   Sun ZK, 2011, CHEM MATER, V23, P2176, DOI 10.1021/cm103704s
   Wang YJ, 2005, CHEM MATER, V17, P953, DOI 10.1021/cm0483137
   WARD WW, 1982, BIOCHEMISTRY-US, V21, P4535, DOI 10.1021/bi00262a003
   Yang F, 1996, NAT BIOTECHNOL, V14, P1246, DOI 10.1038/nbt1096-1246
   Yang H, 1998, J MATER CHEM, V8, P743, DOI 10.1039/a705746f
   Yang PP, 2012, CHEM SOC REV, V41, P3679, DOI 10.1039/c2cs15308d
   Zhao DY, 1998, SCIENCE, V279, P548, DOI 10.1126/science.279.5350.548
   Zhao DY, 2000, CHEM MATER, V12, P275, DOI 10.1021/cm9911363
NR 38
TC 21
Z9 21
U1 4
U2 67
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944-8244
EI 1944-8252
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD OCT
PY 2013
VL 5
IS 20
BP 10111
EP 10117
DI 10.1021/am402754h
PG 7
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA 242BR
UT WOS:000326212900035
PM 24063730
OA gold
DA 2018-03-20
ER

PT J
AU Mattei, A
   Li, TL
AF Mattei, Alessandra
   Li, Tonglei
TI Polymorph Formation and Nucleation Mechanism of Tolfenamic Acid in
   Solution: An Investigation of Pre-nucleation Solute Association
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE dimer; nucleation; polymorph; self-association; supersaturation
ID DENSITY-FUNCTIONAL THEORY; CRYSTAL NUCLEATION; ANTISOLVENT
   CRYSTALLIZATION; ORGANIC-CRYSTALS; SELF-ASSOCIATION; AQUEOUS-SOLUTION;
   SOLVENT; ENERGIES; TRANSFORMATION; PREDICTION
AB Crystallization from solution involves nucleation and growth; growth conditions greatly influence self-association behaviors of solute molecules in these steps, affecting crystal packing of organic molecules. We examined the role of pre-nucleation association to provide insights into the mutual influence between molecular conformation in solution and packing in the solid state.
   Crystallization experiments of tolfenamic acid were conducted in ethanol under different supersaturation conditions. UV spectroscopy was performed to study self-association of solute molecules in ethanol as a function of concentration. Intermolecular interaction energies of tolfenamic acid dimers were calculated with quantum mechanical methods.
   As supersaturation increased, growth of the most stable polymorph outpaced the metastable one, contradicting Ostwald's Rule of Stages. UV spectroscopy measurement suggests solute molecules exist as hydrogen-bonded dimers and more dimers form as total concentration increases. Hydrogen bonding in the most stable form is significantly stronger than that in the metastable form.
   With the fact that molecular conformation is different in the two polymorphs, as concentration increases, solute molecules rearrange their conformations to form stronger hydrogen-bonded dimers in solution, resulting in nucleation of the most stable form.
C1 [Mattei, Alessandra; Li, Tonglei] Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
RP Li, TL (reprint author), Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
EM tonglei@uky.edu
FU NSF [DMR-0449633, DMR-1006364]
FX The authors recognize Dr. Roger Zanon from Upsher-Smith Laboratories for
   his suggestion of the seeding experiment and thank Profs. B. D.
   Anderson, Z. J. Hilt, and S. Van Lanen for their advices and instrument
   support. The study was supported by NSF (DMR-0449633 and DMR-1006364).
CR Andersen KV, 1989, J CHEM SOC P2, V10, P1443
   Asherie N, 1996, PHYS REV LETT, V77, P4832, DOI 10.1103/PhysRevLett.77.4832
   Becker R, 1935, ANN PHYS-BERLIN, V24, P719
   Bernstein J., 1994, STRUCTURE CORRELATIO, V2, P431
   BOYS SF, 1970, MOL PHYS, V19, P553, DOI 10.1080/00268977000101561
   Brittain HG, 2011, J PHARM SCI-US, V100, P1260, DOI 10.1002/jps.22386
   Byrn S. R., 1999, SOLID STATE CHEM DRU
   CARDEW PT, 1985, P ROY SOC LOND A MAT, V398, P415, DOI 10.1098/rspa.1985.0043
   Chen J, 2011, CRYST GROWTH DES, V11, P887, DOI 10.1021/cg101556s
   Cote A, 2009, ORG PROCESS RES DEV, V13, P1276, DOI 10.1021/op900095n
   Davey RJ, 2001, CRYST GROWTH DES, V1, P59, DOI 10.1021/cg000009c
   Davey R.J., 2002, CRYSTENGCOMM    0716, V4, P257
   Dion M, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.246401
   Dobson JF, 2001, AUST J CHEM, V54, P513, DOI 10.1071/CH01052
   DOVESI R, 2006, CRYSTAL06 USERS MANU
   Erdemir D, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.115702
   Erdemir D, 2009, ACCOUNTS CHEM RES, V42, P621, DOI 10.1021/ar800217x
   ETTER MC, 1991, J PHYS CHEM-US, V95, P4601, DOI 10.1021/j100165a007
   Feng SX, 2006, J CHEM THEORY COMPUT, V2, P149, DOI 10.1021/ct050189a
   FRISCH MJ, 2004, GAUSSIAN 03 REVISION
   Galkin O, 1999, J PHYS CHEM B, V103, P10965, DOI 10.1021/jp992786x
   Galkin O, 2007, BIOPHYS J, V93, P902, DOI 10.1529/biophysj.106.103705
   Gavezzotti A, 1999, CHEM-EUR J, V5, P567, DOI 10.1002/(SICI)1521-3765(19990201)5:2<567::AID-CHEM567>3.3.CO;2-Y
   Gidalevitz D, 1997, ANGEW CHEM INT EDIT, V36, P955, DOI 10.1002/anie.199709551
   Gu CH, 2001, J PHARM SCI, V90, P1878, DOI 10.1002/jps.1137
   HAISA M, 1976, ACTA CRYSTALLOGR B, V32, P1283, DOI 10.1107/S0567740876012223
   HEPBURN J, 1975, CHEM PHYS LETT, V36, P451, DOI 10.1016/0009-2614(75)80278-8
   Hilfiker R, 2006, POLYMORPHISM PHARM I
   Huang J, 2008, J AM CHEM SOC, V130, P13973, DOI 10.1021/ja804836d
   Hughes CE, 2007, FARADAY DISCUSS, V136, P71, DOI 10.1039/b616611c
   Jiang SF, 2008, CRYST GROWTH DES, V8, P37, DOI 10.1021/cg070517n
   Kashchiev D, 2003, CRYST RES TECHNOL, V38, P555, DOI 10.1002/crat.200310070
   Kee NCS, 2009, CRYST GROWTH DES, V9, P3044, DOI 10.1021/cg800546u
   Kelly SM, 2005, BBA-PROTEINS PROTEOM, V1751, P119, DOI 10.1016/j.bbapap.2005.06.005
   Kitamura M, 2006, CRYST GROWTH DES, V6, P1214, DOI 10.1021/cg050635f
   Kitamura M, 2009, CRYSTENGCOMM, V11, P949, DOI 10.1039/b809332f
   Kohn W, 1998, PHYS REV LETT, V80, P4153, DOI 10.1103/PhysRevLett.80.4153
   Lahav M, 2001, CHEM ENG SCI, V56, P2245, DOI 10.1016/S0009-2509(00)00459-0
   Lee EH, 2008, CRYST GROWTH DES, V8, P91, DOI 10.1021/cg7008607
   Lee EH, 2006, PHARM RES, V23, P2375, DOI 10.1007/s11095-006-9045-y
   Li TL, 2006, PHARM RES-DORDR, V23, P2326, DOI 10.1007/s11095-006-9006-5
   Li TL, 2009, CHEM-EUR J, V15, P361, DOI 10.1002/chem.200801056
   Long SH, 2008, CRYST GROWTH DES, V8, P4006, DOI 10.1021/cg800123z
   Lopez-Mejias V, 2009, J AM CHEM SOC, V131, P4554, DOI 10.1021/ja806289a
   Mammino L, 2008, J MOL STRUC-THEOCHEM, V852, P36, DOI 10.1016/j.theochem.2007.12.020
   MORCILLO J, 1987, J MOL STRUCT, V157, P353, DOI 10.1016/0022-2860(87)87043-6
   Musumeci D, 2010, CRYST GROWTH DES, V10, P1661, DOI 10.1021/cg901225b
   MYERSON AS, 1991, J CRYST GROWTH, V110, P26, DOI 10.1016/0022-0248(91)90862-Y
   Ostwald W. Z., 1897, Z PHYS CHEM, V22, P289
   Parveen S, 2005, CHEM COMMUN, P1531, DOI 10.1039/b418603f
   Peral F, 1995, J MOL STRUCT, V372, P101, DOI 10.1016/0022-2860(95)08991-8
   Pouget EM, 2009, SCIENCE, V323, P1455, DOI 10.1126/science.1169434
   Rao C.N.R., 1961, ULTRAVIOLET VISIBLE
   Shore JD, 2000, J CHEM PHYS, V113, P6276, DOI 10.1063/1.1308517
   Sommerdijk NAJM, 2008, CHEM REV, V108, P4499, DOI 10.1021/cr078259o
   Surov AO, 2009, J PHARMACEUT BIOMED, V50, P831, DOI 10.1016/j.jpba.2009.06.045
   Vekilov PG, 2010, CRYST GROWTH DES, V10, P5007, DOI 10.1021/cg1011633
   Vekilov PG, 2004, CRYST GROWTH DES, V4, P671, DOI 10.1021/cg049977w
   Volmer M, 1939, KINETIK PHASENBILDUN
   Weissbuch I, 2003, CRYST GROWTH DES, V3, P125, DOI 10.1021/cg0200560
   Wu Q, 2002, J CHEM PHYS, V116, P515, DOI 10.1063/1.1424928
   Yu Lian, 2002, Journal of Pharmaceutical Sciences, V91, P2367, DOI 10.1002/jps.10225
   Zhang GGZ, 2002, J PHARM SCI, V91, P1089, DOI 10.1002/jps.10100
NR 63
TC 20
Z9 21
U1 5
U2 44
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
J9 PHARM RES-DORDR
JI Pharm. Res.
PD FEB
PY 2012
VL 29
IS 2
BP 460
EP 470
DI 10.1007/s11095-011-0574-7
PG 11
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 881RX
UT WOS:000299506700011
PM 21879384
DA 2018-03-20
ER

PT J
AU Lumpp, JK
   Bradley, KD
   Haines, RT
AF Lumpp, Janet K.
   Bradley, Kelly D.
   Haines, R. Trent
TI Kentucky Electronics Education Project (KEEP): Putting professional
   development into practice
SO INTERNATIONAL JOURNAL OF ENGINEERING EDUCATION
LA English
DT Article
DE professional development; pre-engineering; circuit building; Rasch
   analysis; grades 9-12; integrated curriculum
AB The Kentucky Electronics Education Project (KEEP) uses microelectronics to develop standards-based moths, science and technology curricula. KEEP provides training and support for teachers to build electronic circuits in their classrooms. This study examines over 200 student evaluations collected during Spring 2003 and 2004 of KEEP implementations. Rasch analysis and descriptive statistics indicate high student satisfaction with KEEP activities and a desire to learn more about the themes of the project. The goal of the project is to develop a K-16 learning environment, where students, teachers, university faculty and higher education students are engaged in curriculum development and enhancement.
C1 Univ Kentucky, Dept Elect & Comp Engn, Lexington, KY 40506 USA.
   Univ Kentucky, Educ Policy Studies & Evaluat Dept, Lexington, KY 40506 USA.
   Louisiana State Univ, Ctr Hlth Sci, Sch Publ Hlth, Juvenile Justice Program, New Orleans, LA 70122 USA.
RP Lumpp, JK (reprint author), Univ Kentucky, Dept Elect & Comp Engn, 453 F Paul Anderson Tower, Lexington, KY 40506 USA.
EM jklumpp@uky.edu
CR *AN ASS EMPL ED, 2005, ED SUPPL DEM US
   BALL L, 1997, ELECT NOW, V68, P48
   Darling-Hammond L., 1997, J STAFF DEV, V18, P38
   FOWLER FJ, 1993, SURVEY RES METHODOLO
   HAWKES M, 1972, PHI DELTA KAPPAN, V79, P30
   Hopkins K. D., 1998, ED PSYCHOL MEASUREME
   JAKEWORTH P, 1999, STUDIES ED EVALUATIO, V25, P277
   LUMPP JK, 2003, P EL COMP TECH C NEW
   Papanastasiou C., 2000, STUDIES ED EVALUATIO, V26, P27
   TAMBLYN, 2000, ED CANADA, V40, P16
   Wright B. D., 1982, RATING SCALE ANAL
NR 11
TC 0
Z9 0
U1 0
U2 4
PU TEMPUS PUBLICATIONS
PI DURRUS, BANTRY
PA IJEE , ROSSMORE,, DURRUS, BANTRY, COUNTY CORK 00000, IRELAND
SN 0949-149X
J9 INT J ENG EDUC
JI Int. J. Eng. Educ
PY 2007
VL 23
IS 5
BP 910
EP 915
PG 6
WC Education, Scientific Disciplines; Engineering, Multidisciplinary
SC Education & Educational Research; Engineering
GA 236ZK
UT WOS:000251342100011
DA 2018-03-20
ER

PT J
AU Luo, J
   Dziubla, T
   Eitel, R
AF Luo, Jin
   Dziubla, Thomas D.
   Eitel, Richard E.
TI A low temperature co-fired ceramic based microfluidic Clark-type oxygen
   sensor for real-time oxygen sensing
SO SENSORS AND ACTUATORS B-CHEMICAL
LA English
DT Article
DE Clark-type; Oxygen sensor; LTCC; Proton conductive electrolyte;
   Electrochemistry
ID DIFFUSION; ELECTRODE; PROBES; CELLS; RESPIRATION; CONSUMPTION;
   FABRICATION; TECHNOLOGY; MEMBRANE; NAFION
AB In this paper, a microfluidic platform for real-time monitoring of dissolved oxygen in a flowing microfluidic environment fabricated using low temperature co-fired ceramic (LTCC) technology is described. The fabricated Clark-type oxygen sensor consisted of three electrodes (working electrode, counter electrode and Ag/AgCl reference electrode), a solid-state proton conductive matrix (Nafion 117 membrane) and polydimethylosiloxane (PDMS) as the oxygen permeable membrane (OPM). The use of a solid-state proton conductive matrix as the electrolyte in the design of the oxygen sensor makes it feasible integrate this device in a typical LTCC fabrication process. Cyclic voltammetry and chronoamperometry measurement were used to characterize electrochemical properties of the developed oxygen sensor. The reduction current was linearly related with the dissolved oxygen concentration ranging from 0 to 8.1 mg/I under different flow conditions (0.0-1.0 ml/min). The residual currents of the oxygen sensor were less than 3.5% of that measured in oxygen saturated state, and the average response time was 10.9 s. The current device represents an improved Clark-type oxygen sensor with the advantages of easy fabrication, flexible configuration, fast response time, incorporation of microfluidic analyte introduction and real-time detection of dissolved oxygen. The potential applications include material synthesis, cell culture, biological assays incorporating controlled introduction of reagents or analytes and real-time monitoring of dissolved oxygen in a microfluidic environment. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Luo, Jin; Dziubla, Thomas] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Luo, Jin] Tsinghua Univ, Sch Mat Sci & Engn, State Key Lab New Ceram & Fine Proc, Beijing 100084, Peoples R China.
   [Eitel, Richard] Stevens Inst Technol, Dept Chem Engn & Mat Sci, Hoboken, NJ 07030 USA.
RP Luo, J (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.; Eitel, R (reprint author), Stevens Inst Technol, Dept Chem Engn & Mat Sci, Hoboken, NJ 07030 USA.
EM jluuky2014@sina.com; reitel@stevens.edu
RI Eitel, Richard/E-2889-2010
OI Eitel, Richard/0000-0002-5090-2075
FU Office of Naval Research Department of Defense Experimental Program;
   University of Kentucky Center for Clinical and Translational Science
   (CTSA)
FX The authors thank Dr. Yang-Tse Cheng (Department of Chemical and
   Materials Engineering, University of Kentucky) for providing
   experimental guidance and resources. The authors also thank Jiagang Xu,
   Jie Pan, Qinglin Zhang and Hoffmann Ilona for helping with
   electrochemical measurement. The project described was supported in part
   by the Office of Naval Research Department of Defense Experimental
   Program to Stimulate Competitive Research (ONR DEPSCoR) and University
   of Kentucky Center for Clinical and Translational Science (CTSA).
CR Banerjee S, 2016, SENSOR ACTUAT B-CHEM, V230, P434, DOI 10.1016/j.snb.2016.02.062
   Brandenburg A, 2016, SENSOR ACTUAT A-PHYS, V241, P145, DOI 10.1016/j.sna.2016.02.011
   CHA CS, 1990, SENSOR ACTUAT B-CHEM, V2, P239, DOI 10.1016/0925-4005(90)80148-S
   Chang-Yen DA, 2003, LAB CHIP, V3, P297, DOI 10.1039/b305358j
   COX ME, 1986, J POLYM SCI POL CHEM, V24, P621, DOI 10.1002/pola.1986.080240405
   Dmitriev RI, 2012, CELL MOL LIFE SCI, V69, P2025, DOI 10.1007/s00018-011-0914-0
   Dmitriev RI, 2012, ANAL CHEM, V84, P2930, DOI 10.1021/ac3000144
   Gerencser AA, 2009, ANAL CHEM, V81, P6868, DOI 10.1021/ac900881z
   Gongora-Rubio MR, 2001, SENSOR ACTUAT A-PHYS, V89, P222, DOI 10.1016/S0924-4247(00)00554-9
   Hartmann P, 1997, SENSOR ACTUAT B-CHEM, V38, P110, DOI 10.1016/S0925-4005(97)80179-7
   Haug AT, 2000, J ELECTROCHEM SOC, V147, P980, DOI 10.1149/1.1393300
   Hongsirikarn K, 2010, J POWER SOURCES, V195, P7213, DOI 10.1016/j.jpowsour.2010.05.005
   Huang SH, 2012, BIOMICROFLUIDICS, V6, DOI 10.1063/1.4772604
   Jurkow D, 2015, SENSOR ACTUAT A-PHYS, V233, P125, DOI 10.1016/j.sna.2015.05.023
   Kim CS, 2004, IEEE SENS J, V4, P568, DOI 10.1109/JSEN.2004.832857
   Kondrashina AV, 2013, ANALYST, V138, P4915, DOI 10.1039/c3an00658a
   LIPPITSCH ME, 1988, ANAL CHIM ACTA, V205, P1, DOI 10.1016/S0003-2670(00)82310-7
   Lu GY, 2016, SENSOR ACTUAT B-CHEM, V233, P347, DOI 10.1016/j.snb.2016.04.078
   Malecha K., 2009, J MICROMECH MICROENG, V19
   Malecha K, 2010, J MICROMECH MICROENG, P20
   Malecha K, 2013, SENSOR ACTUAT B-CHEM, V181, P486, DOI 10.1016/j.snb.2013.01.094
   Mauritz KA, 2004, CHEM REV, V104, P4535, DOI 10.1021/cr0207123
   McLaughlin GW, 2002, SENSOR ACTUAT B-CHEM, V83, P138, DOI 10.1016/S0925-4005(02)00021-7
   Medina-Rodriguez S, 2016, ANALYST, V141, P3090, DOI 10.1039/c6an00497k
   Mehta G, 2007, BIOMED MICRODEVICES, V9, P123, DOI 10.1007/s10544-006-9005-7
   Mestres P, 2009, EXPERT OPIN DRUG DIS, V4, P785, DOI 10.1517/17460440903018840
   Park J, 2013, SENSOR ACTUAT B-CHEM, V176, P913, DOI 10.1016/j.snb.2012.09.037
   Park J, 2010, SENSOR ACTUAT B-CHEM, V147, P263, DOI 10.1016/j.snb.2010.03.069
   Schneider J., 2016, ACTA PHYSL, P206
   SUZUKI H, 1993, SENSOR ACTUAT B-CHEM, V10, P91, DOI 10.1016/0925-4005(93)80031-6
   Suzuki H, 1998, SENSOR ACTUAT B-CHEM, V53, P140, DOI 10.1016/S0925-4005(99)00009-X
   Suzuki H, 2000, ANAL CHIM ACTA, V405, P57, DOI 10.1016/S0003-2670(99)00748-5
   Suzuki H, 2001, ANAL CHIM ACTA, V431, P249, DOI 10.1016/S0003-2670(00)01325-8
   Vollmer AP, 2005, LAB CHIP, V5, P1059, DOI 10.1039/b508097e
   von Heimburg D, 2005, RESP PHYSIOL NEUROBI, V146, P107, DOI 10.1016/j.resp.2004.12.013
   Wang P, 2011, SENSOR ACTUAT B-CHEM, V153, P145, DOI 10.1016/j.snb.2010.09.075
   Wu CC, 2005, SENSOR ACTUAT B-CHEM, V110, P342, DOI 10.1016/j.snb.2005.02.014
   Wu CC, 2010, TALANTA, V81, P228, DOI 10.1016/j.talanta.2009.11.062
   Yang Z, 1997, ANAL CHIM ACTA, V357, P41, DOI 10.1016/S0003-2670(97)00560-6
NR 39
TC 1
Z9 1
U1 8
U2 62
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0925-4005
J9 SENSOR ACTUAT B-CHEM
JI Sens. Actuator B-Chem.
PD MAR
PY 2017
VL 240
BP 392
EP 397
DI 10.1016/j.snb.2016.08.180
PG 6
WC Chemistry, Analytical; Electrochemistry; Instruments & Instrumentation
SC Chemistry; Electrochemistry; Instruments & Instrumentation
GA EF9AE
UT WOS:000390622300045
DA 2018-03-19
ER

PT J
AU Rhee, YS
   Mansour, HM
AF Rhee, Yun-Seok
   Mansour, Heidi M.
TI Nanopharmaceuticals I: nanocarrier systems in drug delivery
SO INTERNATIONAL JOURNAL OF NANOTECHNOLOGY
LA English
DT Article
DE liposomes; polymeric nanoparticles; polymeric micelles; lipid
   nanoparticles; microemulsions; nanogels; submicron lipid emulsions
ID SOLID LIPID NANOPARTICLES; INTRANASAL MUCOADHESIVE MICROEMULSIONS;
   MEDIATED INTRACELLULAR DELIVERY; FREE INTRAVENOUS MICROEMULSIONS;
   POLYMERIC MICELLE FORMULATION; FEMALE REPRODUCTIVE-TRACT;
   BLOCK-COPOLYMER MICELLES; DRY POWDER FORMULATIONS; TOPICAL DELIVERY;
   OCULAR DELIVERY
AB To achieve maximum pharmacological effects with minimum side effects of drugs, drugs should be delivered to target sites without significant distribution to non-target areas. Using pharmaceutical nanocarrier systems for drug delivery is a useful delivery platform for improving target specificity, therapeutic activity, and reducing toxicity of drugs. Various sophisticated nanocarrier systems have been developed for drug delivery, and this review focuses on liposomes, polymeric nanoparticles, polymeric micelles, lipid nanoparticles, microemulsions, nanogels, and submicron lipid emulsions. This review outlines and explores nanocarrier systems for drug delivery by various administration routes including parenteral, oral, transdermal, pulmonary, ocular, and mucosal and discusses the product development and related issues in nanopharmaceutical drug delivery.
C1 [Rhee, Yun-Seok; Mansour, Heidi M.] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Drug Dev Div, Lexington, KY 40536 USA.
RP Mansour, HM (reprint author), Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Drug Dev Div, 789 S Limestone St, Lexington, KY 40536 USA.
EM ysrhee@skku.edu; heidi.mansour@uky.edu
RI Mansour, Heidi/D-1074-2011
FU Office of the Vice-Chancellor
FX Heidi M. Mansour is an Assistant Professor of Pharmaceutical Sciences
   and Pharmaceutical Technology in the Drug Development Division at the
   University of Kentucky College of Pharmacy. She currently holds Faculty
   appointments and Graduate Faculty appointments in the College of
   Pharmacy at the University of Kentucky and at the University of North
   Carolina-Chapel Hill, the University of Kentucky Center for Membrane
   Sciences, and in the NSF IGERT and NSF REU research training programs
   joint with the University of Kentucky College of Engineering. Prior to
   her faculty appointment at the University of Kentucky College of
   Pharmacy, she was an Instructor (both in the Graduate and Pharm. D.
   Programs) and a Postdoctoral Fellow and Scholar at the University of
   North Carolina at Chapel Hill, School of Pharmacy, in the Division of
   Molecular Pharmaceutics, receiving the 2007 UNC-Chapel Hill Postdoctoral
   Award for Research Excellence from the Office of the Vice-Chancellor. A
   Registered Pharmacist for over 10 years, she earned a BS in Pharmacy,
   PhD in Pharmaceutical Sciences with a PhD Major in Drug
   Delivery/Pharmaceutics (School of Pharmacy) and a PhD Minor in Advanced
   Physical & Biophysical Chemistry (Department of Chemistry), all from the
   University of Wisconsin-Madison. More information can be found on her
   websites http://pharmacy.mc.uky.edu/faculty/HeidiMansour.php and
   http://myprofile.cos.com/surfchemlungmed
CR Alexis F, 2008, MOL PHARMACEUT, V5, P505, DOI 10.1021/mp800051m
   Aliabadi HM, 2008, CLIN PHARMACOKINET, V47, P619, DOI 10.2165/00003088-200847100-00001
   Almeida AJ, 2007, ADV DRUG DELIVER REV, V59, P478, DOI 10.1016/j.addr.2007.04.007
   Andersson M, 2008, ACTA OTO-LARYNGOL, V128, P666, DOI 10.1080/00016480701642197
   Araya H, 2006, DRUG METAB PHARMACOK, V21, P45, DOI 10.2133/dmpk.21.45
   ARIEN A, 1993, LIFE SCI, V53, P1279, DOI 10.1016/0024-3205(93)90573-L
   ATTWOOD D, 1974, J COLLOID INTERF SCI, V46, P249, DOI 10.1016/0021-9797(74)90008-3
   Bachhav YG, 2009, AAPS PHARMSCITECH, V10, P476, DOI 10.1208/s12249-009-9233-2
   Bachhav YG, 2009, INT J PHARM, V365, P175, DOI 10.1016/j.ijpharm.2008.08.021
   BADER H, 1984, ANGEW MAKROMOL CHEM, V123, P457, DOI 10.1002/apmc.1984.051230121
   Bailey MM, 2009, MED RES REV, V29, P196, DOI 10.1002/med.20140
   Bali Vikas, 2008, Recent Pat Drug Deliv Formul, V2, P136, DOI 10.2174/187221108784534072
   BANGHAM AD, 1965, J MOL BIOL, V13, P238, DOI 10.1016/S0022-2836(65)80093-6
   Baspinar Y, 2008, J OCUL PHARMACOL TH, V24, P399, DOI 10.1089/jop.2007.0088
   Bejjani R, 2005, MOL VIS, V11, P124
   BENNETT SN, 1995, NEW ENGL J MED, V333, P147, DOI 10.1056/NEJM199507203330303
   Betz G, 2001, INT J PHARM, V228, P147, DOI 10.1016/S0378-5173(01)00832-8
   Bi R, 2008, J DRUG TARGET, V16, P639, DOI [10.1080/10611860802201134, 10.1080/10611860802201134 ]
   Bisht S, 2008, MOL CANCER THER, V7, P3878, DOI 10.1158/1535-7163.MCT-08-0476
   Bivas-Benita M, 2004, J CONTROL RELEASE, V100, P145, DOI 10.1016/j.jconrel.2004.08.008
   Blackburn WH, 2009, BIOCONJUGATE CHEM, V20, P960, DOI 10.1021/bc800547c
   BRANNONPEPPAS L, 1995, INT J PHARM, V116, P1, DOI 10.1016/0378-5173(94)00324-X
   Bromberg L, 2008, J CONTROL RELEASE, V128, P99, DOI 10.1016/j.jconrel.2008.01.018
   Buech G, 2007, J OCUL PHARMACOL TH, V23, P292, DOI 10.1089/jop.2006.130
   Byrne JD, 2008, ADV DRUG DELIVER REV, V60, P1615, DOI 10.1016/j.addr.2008.08.005
   Calvo P, 1996, J PHARM PHARMACOL, V48, P1147, DOI 10.1111/j.2042-7158.1996.tb03911.x
   Calvo P, 1997, INT J PHARM, V153, P41, DOI 10.1016/S0378-5173(97)00083-5
   Calvo P, 1996, J PHARM SCI, V85, P530, DOI 10.1021/js950474+
   CARLFORS J, 1991, J DISPER SCI TECHNOL, V12, P467, DOI 10.1080/01932699108913146
   Carmignani C, 2002, DRUG DEV IND PHARM, V28, P101, DOI 10.1081/DDC-120001491
   Cavalli R, 2002, INT J PHARM, V238, P241, DOI 10.1016/S0378-5173(02)00080-7
   Changez M, 2000, DRUG DEV IND PHARM, V26, P507, DOI 10.1081/DDC-100101261
   Changsan N, 2009, J PHARM SCI-US, V98, P628, DOI 10.1002/jps.21441
   Chavanpatil MD, 2007, MOL PHARM, V4, P730, DOI 10.1021/mp070024d
   Chen Y, 2008, BIOL PHARM BULL, V31, P118, DOI 10.1248/bpb.31.118
   Chiappetta DA, 2007, EUR J PHARM BIOPHARM, V66, P303, DOI 10.1016/j.ejpb.2007.03.022
   CHOUDHARI KB, 1994, J MICROENCAPSUL, V11, P319, DOI 10.3109/02652049409040461
   Chougule M, 2007, INT J NANOMED, V2, P675
   COLLINS-GOLD L C, 1990, Advanced Drug Delivery Reviews, V5, P189, DOI 10.1016/0169-409X(90)90016-L
   Collins-Gold L, 2000, MOD DRUG DISCOVERY, V3, P44
   Constantinides PP, 2008, ADV DRUG DELIVER REV, V60, P757, DOI 10.1016/j.addr.2007.10.013
   Costantino HR, 2007, INT J PHARM, V337, P1, DOI 10.1016/j.ijpharm.2007.03.025
   Cui J, 2009, INT J PHARM, V371, P148, DOI 10.1016/j.ijpharm.2008.12.009
   D'Cruz OJ, 2008, J APPL TOXICOL, V28, P303, DOI 10.1002/jat.1280
   Darole PS, 2008, AAPS PHARMSCITECH, V9, P122, DOI 10.1208/s12249-007-9022-8
   Date AA, 2008, INT J PHARMACEUT, V355, P19, DOI 10.1016/j.ijpharm.2008.01.004
   Date AA, 2008, AAPS PHARMSCITECH, V9, P138, DOI 10.1208/s12249-007-9023-7
   Davda J, 2002, INT J PHARM, V233, P51, DOI 10.1016/S0378-5173(01)00923-1
   Dcruz OJ, 2007, TOXICOL PATHOL, V35, P910, DOI 10.1080/01926230701748115
   De Campos AM, 2003, EUR J PHARM SCI, V20, P73, DOI 10.1016/S0928-0987(03)00178-7
   De Campos AM, 2001, INT J PHARM, V224, P159, DOI 10.1016/S0378-5173(01)00760-8
   de la Fuente M, 2008, NANOMEDICINE-UK, V3, P845, DOI 10.2217/17435889.3.6.845
   Delie F, 2005, MOLECULES, V10, P65, DOI 10.3390/10010065
   Densmore Charles L., 2006, Current Drug Delivery, V3, P55, DOI 10.2174/156720106775197547
   des Rieux A, 2006, J CONTROL RELEASE, V116, P1, DOI 10.1016/j.jconrel.2006.08.013
   Desai MP, 1996, PHARMACEUT RES, V13, P1838, DOI 10.1023/A:1016085108889
   Deshmukh DD, 2008, INT J PHARM, V358, P128, DOI 10.1016/j.ijpharm.2008.02.026
   Devalapally H, 2007, J PHARM SCI-US, V96, P2547, DOI 10.1002/jps.20875
   Dwivedi V, 2009, VACCINE, V27, P473, DOI 10.1016/j.vaccine.2008.10.054
   Dziubla TD, 2008, BIOMATERIALS, V29, P215, DOI 10.1016/j.biomaterials.2007.09.023
   Maghraby GM, 2008, EUR J PHARM SCI, V34, P203, DOI 10.1016/j.ejps.2008.05.002
   El-Sayed A, 2008, J BIOL CHEM, V283, P23450, DOI 10.1074/jbc.M709387200
   Elsayed MMA, 2007, INT J PHARM, V332, P1, DOI 10.1016/j.ijpharm.2006.12.005
   Elshafeey AH, 2009, AAPS PHARMSCITECH, V10, P361, DOI 10.1208/s12249-009-9213-6
   Emerich DF, 2007, J DRUG TARGET, V15, P163, DOI 10.1080/10611860701231810
   Esmaeili F, 2007, NANOMED-NANOTECHNOL, V3, P161, DOI 10.1016/j.nano.2007.03.003
   FLORENCE AT, 2009, MORDERN PHARM, P453
   Floyd AG, 1999, PHARM SCI TECHNOL TO, V2, P134, DOI 10.1016/S1461-5347(99)00141-8
   Foger F, 2006, BIOMATERIALS, V27, P5855, DOI 10.1016/j.biomaterials.2006.08.004
   Francis MF, 2005, BIOMACROMOLECULES, V6, P2462, DOI 10.1021/bm0503165
   Francis MF, 2004, PURE APPL CHEM, V76, P1321, DOI 10.1351/pac200476071321
   Gajewska M, 2001, PHARMAZIE, V56, P220
   Gaudana R, 2009, PHARM RES-DORDR, V26, P1197, DOI 10.1007/s11095-008-9694-0
   Gershkovich P, 2008, CRIT REV THER DRUG, V25, P545, DOI 10.1615/CritRevTherDrugCarrierSyst.v25.i6.20
   Ghosh P. K., 2006, Current Drug Delivery, V3, P167, DOI 10.2174/156720106776359168
   Gupta Y, 2007, J PHARM PHARMACOL, V59, P935, DOI 10.1211/jpp.59.7.0004
   Gursoy RN, 2004, BIOMED PHARMACOTHER, V58, P173, DOI 10.1016/j.biopha.2004.02.001
   Han JH, 2001, INT J PHARM, V215, P207, DOI 10.1016/S0378-5173(00)00692-X
   Harmia T, 1986, J Microencapsul, V3, P3, DOI 10.3109/02652048609049580
   Hatakeyama H, 2007, INT J PHARM, V342, P194, DOI 10.1016/j.ijpharm.2007.04.037
   Herrero-Vanrell R, 2005, J CONTROL RELEASE, V102, P113, DOI 10.1016/j.jconrel.2004.10.001
   Heydenreich AV, 2003, INT J PHARM, V254, P83, DOI 10.1016/S0378-5173(02)00688-9
   Hong GB, 2008, BIOMED MICRODEVICES, V10, P693, DOI 10.1007/s10544-008-9180-9
   Hua L, 2004, DRUG DEV IND PHARM, V30, P657, DOI 10.1081/DDC-120039183
   Huang M, 2002, PHARMACEUT RES, V19, P1488, DOI 10.1023/A:1020404615898
   Huang SJ, 2009, EUR J PHARM SCI, V38, P64, DOI 10.1016/j.ejps.2009.06.002
   Hussain A, 2005, J CONTROL RELEASE, V103, P301, DOI 10.1016/j.jconrel.2004.11.034
   Hussain AA, 1998, ADV DRUG DELIVER REV, V29, P39, DOI 10.1016/S0169-409X(97)00060-4
   Huwyler J, 2008, INT J NANOMED, V3, P21
   Illum L, 2007, J PHARM SCI-US, V96, P473, DOI 10.1002/jps.20718
   Irache JM, 2005, MINI-REV MED CHEM, V5, P293, DOI 10.2174/1389557053175335
   Isojima T, 2008, ACS NANO, V2, P1799, DOI 10.1021/nn800089z
   Iwanaga K, 1999, J PHARM SCI, V88, P248, DOI 10.1021/js980235x
   Izquierdo P, 2007, SKIN PHARMACOL PHYS, V20, P263, DOI 10.1159/000106076
   Jadhav K. R., 2006, Current Drug Delivery, V3, P267, DOI 10.2174/156720106777731118
   Jain R, 2009, J BIOMED NANOTECHNOL, V5, P62, DOI 10.1166/jbn.2009.031
   Jamal KN, 2009, CLIN OPHTHALMOL, V3, P381
   Jayaraman SC, 1996, J PHARM SCI, V85, P1082, DOI 10.1021/js960040u
   Jogani VV, 2008, ALZ DIS ASSOC DIS, V22, P116, DOI 10.1097/WAD.0b013e318157205b
   Joshi M, 2008, INT J PHARM, V346, P124, DOI 10.1016/j.ijpharm.2007.05.060
   Joshi MD, 2009, EUR J PHARM BIOPHARM, V71, P161, DOI 10.1016/j.ejpb.2008.09.003
   Junping Wang, 2000, International Journal of Pharmaceutics (Kidlington), V203, P61, DOI 10.1016/S0378-5173(00)00410-5
   Justo OR, 2003, DRUG DELIV, V10, P201, DOI 10.1080/10717540390215627
   Kabanov AV, 2009, ANGEW CHEM INT EDIT, V48, P5418, DOI 10.1002/anie.200900441
   Kale AA, 2008, AAPS PHARMSCITECH, V9, P966, DOI 10.1208/s12249-008-9131-z
   Kapoor Y, 2008, INT J PHARM, V361, P222, DOI 10.1016/j.ijpharm.2008.05.028
   KATAOKA K, 1993, J CONTROL RELEASE, V24, P119
   Kaur IP, 2002, DRUG DEV IND PHARM, V28, P473
   Kaur P, 2008, INT J PHARMACEUT, V364, P27, DOI 10.1016/j.ijpharm.2008.07.030
   Khalil KA, 2008, INT J PHARMACEUT, V354, P39, DOI 10.1016/j.ijpharm.2007.12.003
   Kim DW, 2007, ANN ONCOL, V18, P2009, DOI 10.1093/annonc/mdm374
   Kirpotin DB, 2006, CANCER RES, V66, P6732, DOI 10.1158/0008-5472.CAN-05-4199
   Klaikherd A, 2009, J AM CHEM SOC, V131, P4830, DOI 10.1021/ja809475a
   Ko KT, 1998, J MICROENCAPSUL, V15, P197, DOI 10.3109/02652049809006849
   Ko YT, 2009, MOL PHARMACEUT, V6, P971, DOI 10.1021/mp900006h
   Koh DM, 2009, CANCER BIOMARK, V5, P89, DOI 10.3233/CBM-2009-0544
   Kumar M, 2008, INT J PHARM, V358, P285, DOI 10.1016/j.ijpharm.2008.03.029
   Kumar M, 2008, J DRUG TARGET, V16, P806, DOI [10.1080/10611860802476504, 10.1080/10611860802476504 ]
   Lademann J, 2007, EUR J PHARM BIOPHARM, V66, P159, DOI 10.1016/j.ejpb.2006.10.019
   Lallemand F, 2003, EUR J PHARM BIOPHARM, V56, P307, DOI 10.1016/S0939-6411(03)00138-3
   Lawrence MJ, 2000, ADV DRUG DELIVER REV, V45, P89, DOI 10.1016/S0169-409X(00)00103-4
   Lee ES, 2008, J CONTROL RELEASE, V129, P228, DOI 10.1016/j.jconrel.2008.04.024
   Lee KS, 2008, BREAST CANCER RES TR, V108, P241, DOI 10.1007/s10549-007-9591-y
   Li HY, 2006, PHARM RES, V23, P941, DOI 10.1007/s11095-006-0027-x
   Liu J, 2007, INT J PHARM, V328, P191, DOI 10.1016/j.ijpharm.2006.08.007
   Liu LH, 2008, BIOPOLYMERS, V90, P617, DOI 10.1002/bip.20998
   Lopez A, 2000, INT J PHARM, V202, P133, DOI 10.1016/S0378-5173(00)00427-0
   Lu XL, 2008, AAPS J, V10, P133, DOI 10.1208/s12248-008-9013-z
   Lu XL, 2009, AAPS J, V11, P120, DOI 10.1208/s12248-009-9086-3
   Mahmud A, 2007, J DRUG TARGET, V15, P553, DOI 10.1080/10611860701538586
   Maia CS, 2002, J DRUG TARGET, V10, P489, DOI 10.1080/1061186021000038364
   Mainardes RM, 2005, CURR DRUG TARGETS, V6, P363, DOI 10.2174/1389450053765914
   Mainardes Rubiana Mara, 2006, Current Drug Delivery, V3, P275
   Manosroi A, 2004, INT J PHARM, V270, P279, DOI 10.1016/j.ijpharm.2003.10.031
   Mansour HM, 2009, INT J NANOMED, V4, P299
   Marcato PD, 2008, J NANOSCI NANOTECHNO, V8, P2216, DOI 10.1166/jnn.2008.274
   Martins S, 2007, INT J NANOMED, V2, P595
   Matsumura Y, 2008, ADV DRUG DELIVER REV, V60, P899, DOI 10.1016/j.addr.2007.11.010
   Matsumura Y, 2007, J DRUG TARGET, V15, P507, DOI 10.1080/10611860701499888
   Matsumura Y, 2008, JPN J CLIN ONCOL, V38, P793, DOI 10.1093/jjco/hyn116
   Mehnert W, 2001, ADV DRUG DELIVER REV, V47, P165, DOI 10.1016/S0169-409X(01)00105-3
   MEISNER D, 1995, ADV DRUG DELIVER REV, V16, P75, DOI 10.1016/0169-409X(95)00016-Z
   Metselaar JM, 2002, MINI-REV MED CHEM, V2, P319, DOI 10.2174/1389557023405873
   Mikhaylova M, 2009, CANCER GENE THER, V16, P217, DOI 10.1038/cgt.2008.79
   Motwani SK, 2008, EUR J PHARM BIOPHARM, V68, P513, DOI 10.1016/j.ejpb.2007.09.009
   Muchow M, 2008, DRUG DEV IND PHARM, V34, P1394, DOI 10.1080/03639040802130061 
   Muller RH, 2000, EUR J PHARM BIOPHARM, V50, P161, DOI 10.1016/S0939-6411(00)00087-4
   Nornoo AO, 2008, INT J PHARM, V349, P108, DOI 10.1016/j.ijpharm.2007.07.042
   Nornoo AO, 2008, INT J PHARM, V349, P117, DOI 10.1016/j.ijpham.2007.07.043
   Nounou Mohamed I, 2008, Recent Pat Drug Deliv Formul, V2, P9, DOI 10.2174/187221108783331375
   Nounou Mohamed Mahmoud, 2005, Acta Pol Pharm, V62, P381
   Olbrich C, 1999, INT J PHARM, V180, P31, DOI 10.1016/S0378-5173(98)00404-9
   Owens DE, 2006, INT J PHARM, V307, P93, DOI 10.1016/j.ijpharm.2005.10.010
   Pandey R, 2005, TUBERCULOSIS, V85, P227, DOI 10.1016/j.tube.2004.11.003
   Panyam Jayanth, 2004, Current Drug Delivery, V1, P235, DOI 10.2174/1567201043334768
   Pardeike J, 2009, INT J PHARMACEUT, V366, P170, DOI 10.1016/j.ijpharm.2008.10.003
   Parveen S, 2008, J DRUG TARGET, V16, P108, DOI [10.1080/10611860701794353, 10.1080/10611860701794353 ]
   Patel Deepa, 2009, Current Drug Delivery, V6, P419
   PATEL N, 1998, DRUG DELIVERY LUNGS, V9, P160
   PAYNE NI, 1986, J PHARM SCI, V75, P325, DOI 10.1002/jps.2600750402
   Peetla C, 2009, MOL PHARMACEUT, V6, P1311, DOI 10.1021/mp900011h
   Peetla C, 2009, LANGMUIR, V25, P2369, DOI 10.1021/la803361y
   Perez-Cullell N, 2000, DRUG DELIV, V7, P7, DOI 10.1080/107175400266731
   Piras AM, 2008, INT J PHARMACEUT, V357, P260, DOI 10.1016/j.ijpharm.2008.01.035
   Porecha S, 2009, DRUG DELIV, V16, P128, DOI 10.1080/10717540802560381
   Porter CJH, 2001, ADV DRUG DELIVER REV, V50, P1
   Praetorius Natalie P, 2007, Recent Pat Drug Deliv Formul, V1, P37, DOI 10.2174/187221107779814104
   Puglia C, 2008, INT J PHARMACEUT, V357, P295, DOI 10.1016/j.ijpharm.2008.01.045
   Quan CY, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/33/335101
   Rao KS, 2008, BIOMATERIALS, V29, P4429, DOI 10.1016/j.biomaterials.2008.08.004
   Rhee YS, 2001, INT J PHARM, V228, P161, DOI 10.1016/S0378-5173(01)00827-4
   Rhee YS, 2007, ARCH PHARM RES, V30, P114, DOI 10.1007/BF02977787
   Richardson JL, 1996, J CONTROL RELEASE, V42, P133, DOI 10.1016/0168-3659(96)01451-4
   Rowe MD, 2009, BIOMACROMOLECULES, V10, P983, DOI 10.1021/bm900043e
   Rudolph C, 2004, MOL THER, V9, pS193
   Sahoo SK, 2008, DRUG DISCOV TODAY, V13, P144, DOI 10.1016/j.drudis.2007.10.021
   Samad Abdus, 2007, Current Drug Delivery, V4, P297, DOI 10.2174/156720107782151269
   Sanna V, 2007, J PHARM PHARMACOL, V59, P1057, DOI 10.1211/jpp.59.8.0002
   Santos P, 2008, SKIN PHARMACOL PHYS, V21, P246, DOI 10.1159/000140228
   Sarker Dipak K., 2005, Current Drug Delivery, V2, P297, DOI 10.2174/156720105774370267
   Schafer-Korting M, 2007, ADV DRUG DELIVER REV, V59, P427, DOI 10.1016/j.addr.2007.04.006
   SCHULMAN JH, 1959, J PHYS CHEM-US, V63, P1677, DOI 10.1021/j150580a027
   Sezgin Z, 2007, INT J PHARM, V332, P161, DOI 10.1016/j.ijpharm.2006.09.030
   Shah KA, 2007, INT J PHARM, V345, P163, DOI 10.1016/j.ijpharm.2007.05.061
   Shahiwala Aliasgar, 2007, Recent Pat Drug Deliv Formul, V1, P1, DOI 10.2174/187221107779814140
   Sham JOH, 2004, INT J PHARM, V269, P457, DOI 10.1016/j.ijpharm.2003.09.041
   Sharma S, 2006, PHARMAZIE, V61, P495
   Simard P, 2009, INT J PHARMACEUT, V381, P86, DOI 10.1016/j.ijpharm.2009.05.013
   Singh R, 2008, J PHARM SCI-US, V97, P2497, DOI 10.1002/jps.21183
   Singh R, 2009, EXP MOL PATHOL, V86, P215, DOI 10.1016/j.yexmp.2008.12.004
   Sommerville Mark L, 2003, AAPS PharmSciTech, V4, pE58
   Sommerville ML, 2002, PHARM DEV TECHNOL, V7, P273, DOI 10.1081/PDT-120005724
   Song KH, 2002, J CONTROL RELEASE, V84, P27, DOI 10.1016/S0168-3659(02)00238-9
   Soppimath KS, 2001, J CONTROL RELEASE, V70, P1, DOI 10.1016/S0168-3659(00)00339-4
   Spiclin P, 2001, INT J PHARM, V222, P271, DOI 10.1016/S0378-5173(01)00715-3
   Sultana Yasmin, 2006, Current Drug Delivery, V3, P207, DOI 10.2174/156720106776359186
   Sung JC, 2007, TRENDS BIOTECHNOL, V25, P563, DOI 10.1016/j.tibtech.2007.09.005
   Sznitowska M, 2001, EUR J PHARM BIOPHARM, V52, P159, DOI 10.1016/S0939-6411(01)00157-6
   Tadros T, 2004, ADV COLLOID INTERFAC, V108, P303, DOI 10.1016/j.cis.2003.10.023
   Takeuchi H, 2001, ADV DRUG DELIVER REV, V47, P39, DOI 10.1016/S0169-409X(00)00120-4
   Talegaonkar Sushama, 2008, Recent Pat Drug Deliv Formul, V2, P238
   Tam JM, 2008, J PHARM SCI-US, V97, P4915, DOI 10.1002/jps.21367
   Tamilvanan S, 2004, PROG LIPID RES, V43, P489, DOI 10.1016/j.plipres.2004.09.001
   Tamilvanan S, 2004, EUR J PHARM BIOPHARM, V58, P357, DOI 10.1016/j.ejpb.2004.03.033
   Tamura A, 2009, BIOMACROMOLECULES, V10, P1818, DOI 10.1021/bm900252d
   Thirawong N, 2008, J CONTROL RELEASE, V125, P236, DOI 10.1016/j.jconrel.2007.10.023
   Tiwari Sandip B., 2006, Current Drug Delivery, V3, P219, DOI 10.2174/156720106776359230
   Torchilin VP, 2007, BIOCHEM SOC T, V35, P816, DOI 10.1042/BST0350816
   Torchilin VP, 2007, PHARM RES-DORDR, V24, P1, DOI 10.1007/s11095-006-9132-0
   Torchilin V, 2009, EUR J PHARM BIOPHARM, V71, P431, DOI 10.1016/j.ejpb.2008.09.026
   Torchilin VP, 2008, BIOPOLYMERS, V90, P604, DOI 10.1002/bip.20989
   Torchilin VP, 2008, ADV DRUG DELIVER REV, V60, P548, DOI 10.1016/j.addr.2007.10.008
   Torchilin Vladimir P., 2005, Current Drug Delivery, V2, P319, DOI 10.2174/156720105774370221
   Traitel T, 2008, J BIOMAT SCI-POLYM E, V19, P755, DOI 10.1163/156856208784522065
   Tu JS, 2007, DRUG DEV IND PHARM, V33, P1142, DOI 10.1080/03639040701397381
   Valenta C, 2005, ADV DRUG DELIVER REV, V57, P1692, DOI 10.1016/j.addr.2005.07.004
   van Vlerken LE, 2007, PHARM RES, V24, P1405, DOI 10.1007/s11095-007-9284-6
   Vandamme TF, 2002, PROG RETIN EYE RES, V21, P15, DOI 10.1016/S1350-9462(01)00017-9
   Vasir JK, 2007, ADV DRUG DELIVER REV, V59, P718, DOI 10.1016/j.addr.2007.06.003
   Vinogradov SV, 2007, EXPERT OPIN DRUG DEL, V4, P5, DOI 10.1517/17425247.4.1.5
   Vyas TK, 2006, AAPS PHARMSCITECH, V7, DOI 10.1208/pt070108
   Vyas TK, 2006, J PHARM SCI-US, V95, P570, DOI 10.1002/jps.20480
   Vyas TK, 2005, J DRUG TARGET, V13, P317, DOI 10.1080/10611860500246217
   Wang H, 2009, EXPERT OPIN DRUG DEL, V6, P745, DOI 10.1517/17425240902889751
   Wasan KM, 2009, J PHARM SCI-US, V98, P379, DOI 10.1002/jps.21435
   Webb Murray S, 2007, Recent Pat Drug Deliv Formul, V1, P185, DOI 10.2174/187221107782331593
   WEINER N, 1989, ANTIMICROB AGENTS CH, V33, P1217, DOI 10.1128/AAC.33.8.1217
   Westesen K, 2000, COLLOID POLYM SCI, V278, P608, DOI 10.1007/s003969900257
   WRETLIND A, 1981, JPEN-PARENTER ENTER, V5, P230, DOI 10.1177/0148607181005003230
   Wu DC, 2008, J PHARM PHARM SCI, V11, P32, DOI 10.18433/J3988J
   Xiao YY, 2006, INT J PHARM, V319, P162, DOI 10.1016/j.ijpharm.2006.03.037
   Yamada A, 2008, CLIN CANCER RES, V14, P8161, DOI 10.1158/1078-0432.CCR-08-0159
   Yang W, 2008, INT J PHARM, V361, P177, DOI 10.1016/j.ijpharm.2008.05.003
   YOKOYAMA M, 1990, J CONTROL RELEASE, V11, P269
   Yoncheva K, 2007, INT J PHARM, V334, P156, DOI 10.1016/j.ijpharm.2006.10.016
   Yu CQ, 2009, INT J PHARMACEUT, V375, P16, DOI 10.1016/j.ijpharm.2009.03.006
   ZENG XM, 1995, INT J PHARM, V124, P149, DOI 10.1016/0378-5173(95)00104-Q
   Zhang PW, 2008, BIOL PHARM BULL, V31, P2316, DOI 10.1248/bpb.31.2316
   Zhang QS, 2009, J COLLOID INTERF SCI, V330, P330, DOI 10.1016/j.jcis.2008.09.077
   Zhang QZ, 2004, INT J PHARM, V275, P85, DOI 10.1016/j.ijpharm.2004.01.039
   ZIMMER A, 1995, ADV DRUG DELIVER REV, V16, P61, DOI 10.1016/0169-409X(95)00017-2
NR 241
TC 19
Z9 19
U1 1
U2 24
PU INDERSCIENCE ENTERPRISES LTD
PI GENEVA
PA WORLD TRADE CENTER BLDG, 29 ROUTE DE PRE-BOIS, CASE POSTALE 856, CH-1215
   GENEVA, SWITZERLAND
SN 1475-7435
EI 1741-8151
J9 INT J NANOTECHNOL
JI Int. J. Nanotechnol.
PY 2011
VL 8
IS 1-2
BP 84
EP 114
DI 10.1504/IJNT.2011.037172
PG 31
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA 691OM
UT WOS:000285090700005
DA 2018-03-20
ER

PT J
AU Readnower, R
   Geddes, J
   Sullivan, P
AF Readnower, Ryan
   Geddes, James W.
   Sullivan, Patrick G.
TI GENETIC ANALYSIS OF THE ROLE OF CYCLOPHILIN D IN TRAUMATIC BRAIN INJURY
   PATHOLOGY
SO JOURNAL OF NEUROTRAUMA
LA English
DT Meeting Abstract
CT 29th Annual National Neurotrauma Symposium
CY JUL 10-13, 2011
CL Hollywood Beach, FL
C1 [Readnower, Ryan; Geddes, James; Sullivan, Patrick] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0897-7151
J9 J NEUROTRAUM
JI J. Neurotrauma
PD JUN
PY 2011
VL 28
IS 6
BP A90
EP A90
PG 1
WC Critical Care Medicine; Clinical Neurology; Neurosciences
SC General & Internal Medicine; Neurosciences & Neurology
GA 788PT
UT WOS:000292457600282
DA 2018-03-20
ER

PT J
AU Wu, X
   Hayes, D
   Zwischenberger, JB
   Kuhn, RJ
   Mansour, HM
AF Wu, Xiao
   Hayes, Don, Jr.
   Zwischenberger, Joseph B.
   Kuhn, Robert J.
   Mansour, Heidi M.
TI Design and physicochemical characterization of advanced spray-dried
   tacrolimus multifunctional particles for inhalation
SO DRUG DESIGN DEVELOPMENT AND THERAPY
LA English
DT Article
DE dry powder inhaler (DPI); pulmonary nanomedicine; lung transplant;
   immunosuppression; lung surfactant; phospholipid colloidal
   self-assemblies; solid-state particle engineering design; organic
   solution advanced spray drying
ID STANDARDIZED ENTRAINMENT TUBES; BRONCHIOLITIS-OBLITERANS-SYNDROME;
   LUNG-TRANSPLANT RECIPIENTS; AIR-WATER-INTERFACE; DRY POWDER INHALERS;
   PULMONARY SURFACTANT; CYCLOSPORINE-A; DRUG-DELIVERY; NANOCARRIER
   SYSTEMS; AEROSOL PERFORMANCE
AB The aim of this study was to design, develop, and optimize respirable tacrolimus microparticles and nanoparticles and multifunctional tacrolimus lung surfactant mimic particles for targeted dry powder inhalation delivery as a pulmonary nanomedicine. Particles were rationally designed and produced at different pump rates by advanced spray-drying particle engineering design from organic solution in closed mode. In addition, multifunctional tacrolimus lung surfactant mimic dry powder particles were prepared by co-dissolving tacrolimus and lung surfactant mimic phospholipids in methanol, followed by advanced co-spray-drying particle engineering design technology in closed mode. The lung surfactant mimic phospholipids were 1,2-dipalmitoyl-sn-glycero-3-phosphocholine and 1,2-dipalmitoyl-sn-glycero-3-[phosphorrac- 1-glycerol]. Laser diffraction particle sizing indicated that the particle size distributions were suitable for pulmonary delivery, whereas scanning electron microscopy imaging indicated that these particles had both optimal particle morphology and surface morphology. Increasing the pump rate percent of tacrolimus solution resulted in a larger particle size. X-ray powder diffraction patterns and differential scanning calorimetry thermograms indicated that spray drying produced particles with higher amounts of amorphous phase. X-ray powder diffraction and differential scanning calorimetry also confirmed the preservation of the phospholipid bilayer structure in the solid state for all engineered respirable particles. Furthermore, it was observed in hot-stage micrographs that raw tacrolimus displayed a liquid crystal transition following the main phase transition, which is consistent with its interfacial properties. Water vapor uptake and lyotropic phase transitions in the solid state at varying levels of relative humidity were determined by gravimetric vapor sorption technique. Water content in the various powders was very low and well within the levels necessary for dry powder inhalation, as quantified by Karl Fisher coulometric titration. Conclusively, advanced spray-drying particle engineering design from organic solution in closed mode was successfully used to design and optimize solid-state particles in the respirable size range necessary for targeted pulmonary delivery, particularly for the deep lung. These particles were dry, stable, and had optimal properties for dry powder inhalation as a novel pulmonary nanomedicine.
C1 [Wu, Xiao; Mansour, Heidi M.] Univ Kentucky, Coll Pharm, Dept Pharmaceut, Sci Drug Dev Div, Lexington, KY 40536 USA.
   [Hayes, Don, Jr.] Ohio State Univ, Dept Pediat, Lung & Heart Lung Transplant Programs, Coll Med,Nationwide Childrens Hosp, Columbus, OH 43210 USA.
   [Hayes, Don, Jr.] Ohio State Univ, Dept Internal Med, Lung & Heart Lung Transplant Programs, Coll Med,Nationwide Childrens Hosp, Columbus, OH 43210 USA.
   [Hayes, Don, Jr.] Ohio State Univ, Coll Med, Davis Heart & Lung Res Inst, Columbus, OH 43210 USA.
   [Zwischenberger, Joseph B.] Univ Kentucky, Coll Med, Dept Pediat Biomed Engn Diagnost Radiol, Lexington, KY 40536 USA.
   [Zwischenberger, Joseph B.] Univ Kentucky, Coll Med, Dept Surg, Lexington, KY 40536 USA.
   [Kuhn, Robert J.] Univ Kentucky, Coll Pharm, Div Pharm Practice & Sci, Lexington, KY 40536 USA.
   [Mansour, Heidi M.] Univ Kentucky, Ctr Membrane Sci, Lexington, KY 40536 USA.
RP Mansour, HM (reprint author), Univ Kentucky, Coll Pharm, Dept Pharmaceut, Sci Drug Dev Div, 789 S Limestone St, Lexington, KY 40536 USA.
EM heidi.mansour@uky.edu
CR Almawi WY, 2000, NEPHROL DIAL TRANSPL, V15, P1916, DOI 10.1093/ndt/15.12.1916
   Alves GP, 2004, POWDER TECHNOL, V145, P139, DOI 10.1016/j.powtec.2004.06.008
   Andya JD, 1999, PHARMACEUT RES, V16, P350, DOI 10.1023/A:1018805232453
   Boehler A, 2003, EUR RESPIR J, V22, P1007, DOI 10.1183/09031936.03.00039103
   Borro JM, 2007, TRANSPL P, V39, P2416, DOI 10.1016/j.transproceed.2007.06.071
   Briffa N, 1997, EUR RESPIR J, V10, P2630, DOI 10.1183/09031936.97.10112630
   Canadas O, 2004, BIOCHEMISTRY-US, V43, P9926, DOI 10.1021/bi036227z
   Chew NYK, 2005, PHARM RES, V22, P148, DOI 10.1007/s11095-004-9020-4
   Chew NYK, 2001, PHARMACEUT RES, V18, P1570, DOI 10.1023/A:1013082531394
   CLARDY J, 1995, P NATL ACAD SCI USA, V92, P56, DOI 10.1073/pnas.92.1.56
   Corcoran TE, 2006, ADV DRUG DELIVER REV, V58, P1119, DOI 10.1016/j.addr.2006.07.016
   Estenne M, 2002, J HEART LUNG TRANSPL, V21, P297, DOI 10.1016/S1053-2498(02)00398-4
   Goerke J, 1998, BBA-MOL BASIS DIS, V1408, P79, DOI 10.1016/S0925-4439(98)00060-X
   Halloran PF, 1997, TRANSPLANT P, V29, P79, DOI 10.1016/S0041-1345(96)00015-2
   Hayes Jr D, 2012, TRANSPL INFECT DIS, P1
   Hayes Jr D, 2011, J CARDIOTHORAC SURG, V6, P1
   Hayes D, 2010, TRANSPL P, V42, P3876, DOI 10.1016/j.transproceed.2010.08.029
   Hickey A.J., 2009, MODERN PHARM, V2, P191
   Hickey A.J., 2008, MODIFIED RELEASE DRU, V2, P573
   Hickey AJ, 2007, J PHARM SCI-US, V96, P1282, DOI 10.1002/jps.20916
   Iacono AT, 2004, EUR RESPIR J, V23, P384, DOI 10.1183/09031936.04.00058504
   KEICHO N, 1991, CELL IMMUNOL, V132, P285, DOI 10.1016/0008-8749(91)90028-A
   KINO T, 1987, J ANTIBIOT, V40, P1249, DOI 10.7164/antibiotics.40.1249
   Knoop C, 2004, EUR RESPIR J, V23, P159, DOI 10.1183/09031936.03.00039203
   Kobashigawa JA, 2006, J HEART LUNG TRANSPL, V25, P434, DOI 10.1016/j.healun.2005.11.452
   Kur F, 1999, THORAC CARDIOV SURG, V47, P174, DOI 10.1055/s-2007-1013136
   Li DX, 2008, INT J PHARM, V355, P277, DOI 10.1016/j.ijpharm.2007.12.020
   Li XJ, 2011, AAPS PHARMSCITECH, V12, P1420, DOI 10.1208/s12249-011-9704-0
   Maa Y F, 1997, Pharm Dev Technol, V2, P213, DOI 10.3109/10837459709031441
   Mansour H, 2001, LANGMUIR, V17, P6622, DOI 10.1021/la0108454
   Mansour HM, 2008, MOL PHARMACEUT, V5, P681, DOI 10.1021/mp700123p
   Mansour HM, 2007, LANGMUIR, V23, P3809, DOI 10.1021/la063053o
   Mansour HM, 2007, J PHARM SCI-US, V96, P377, DOI 10.1002/jps.20810
   Mansour HM, 2010, J PHARM SCI-US, V99, P3430, DOI 10.1002/jps.22101
   Mansour HM, 2009, INT J NANOMED, V4, P299
   Mansour HM, 2011, LIPIDS NANOTECHNOLOG, P221
   Mansour HM, 2013, NANOMEDICIN IN PRESS
   Master L., 1991, SPRAY DRYING HDB
   Meenach SA, 2013, INT J NANOMED, V8, P275, DOI 10.2147/IJN.S30724
   Morrow MR, 2007, BIOPHYS J, V93, P164, DOI 10.1529/biophysj.106.102681
   Niven RW, 2011, ADV DRUG DELIVER REV, V63, P88, DOI 10.1016/j.addr.2010.10.004
   Park CW, 2012, ADV DRUG DELIVER REV, V64, P344, DOI 10.1016/j.addr.2011.08.004
   Park CW, 2011, EUROPEAN PHARM REV, V16, P32
   Patton JS, 2007, NAT REV DRUG DISCOV, V6, P67, DOI 10.1038/nrd2153
   Postle AD, 2001, COMP BIOCHEM PHYS A, V129, P65, DOI 10.1016/S1095-6433(01)00306-3
   Rhee YS, 2011, INT J NANOTECHNOL, V8, P84, DOI 10.1504/IJNT.2011.037172
   RONDEAU E, 1992, NEPHROLOGIE, V13, P137
   SAKR MF, 1993, J HEPATOL, V17, P301, DOI 10.1016/S0168-8278(05)80209-0
   SCHULZ H, 1998, PHARM SCI TECHNOL TO, V1, P326
   SIEKIERKA JJ, 1992, CURR OPIN IMMUNOL, V4, P548, DOI 10.1016/0952-7915(92)90024-9
   Sollohub K, 2010, J PHARM SCI-US, V99, P587, DOI 10.1002/jps.21963
   Taketomo C, 2009, PEDIAT DOSAGE HDB, P1173
   Taylor DO, 2007, J HEART LUNG TRANSPL, V26, P769, DOI 10.1016/j.healun.2007.06.004
   Trulock EP, 2007, J HEART LUNG TRANSPL, V26, P782, DOI 10.1016/j.healun.2007.06.003
   van den Berg JWK, 1999, THORAX, V54, P550, DOI 10.1136/thx.54.6.550
   Veldhuizen R, 1998, BBA-MOL BASIS DIS, V1408, P90, DOI 10.1016/S0925-4439(98)00061-1
   WIEDERRECHT G, 1993, ANN NY ACAD SCI, V696, P9, DOI 10.1111/j.1749-6632.1993.tb17137.x
   Willis L, 2012, LUNG, V190, P251, DOI 10.1007/s00408-011-9360-x
   Wu XA, 2010, KONA POWDER PART J, P3
   Wu XA, 2011, INT J NANOTECHNOL, V8, P115, DOI 10.1504/IJNT.2011.037173
   Xu Z, 2011, J ADHES SCI TECHNOL, V25, P451, DOI 10.1163/016942410X525669
   Xu Z, 2010, J PHARM SCI-US, V99, P3415, DOI 10.1002/jps.22100
   Xu Z, 2010, J PHARM SCI-US, V99, P3398, DOI 10.1002/jps.22107
   Yousem SA, 1996, J HEART LUNG TRANSPL, V15, P1
   Yu JW, 1997, CRIT REV THER DRUG, V14, P395
NR 65
TC 23
Z9 23
U1 0
U2 30
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177-8881
J9 DRUG DES DEV THER
JI Drug Des. Dev. Ther.
PY 2013
VL 7
BP 59
EP 72
DI 10.2147/DDDT.540166
PG 14
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 085CQ
UT WOS:000314590100001
PM 23403805
OA gold
DA 2018-03-20
ER

PT J
AU Gui, MH
   Smuleac, V
   Ormsbee, LE
   Sedlak, DL
   Bhattacharyya, D
AF Gui, Minghui
   Smuleac, Vasile
   Ormsbee, Lindell R.
   Sedlak, David L.
   Bhattacharyya, Dibakar
TI Iron oxide nanoparticle synthesis in aqueous and membrane systems for
   oxidative degradation of trichloroethylene from water
SO JOURNAL OF NANOPARTICLE RESEARCH
LA English
DT Article
DE Iron oxide nanoparticles; Functionalized membrane; Hydroxyl radical; TCE
   dechlorination; Hydrogen peroxide; Heterogeneous Fenton
ID ZERO-VALENT IRON; HYDROGEN-PEROXIDE DECOMPOSITION; MODIFIED FENTON
   REACTION; FE-PD NANOPARTICLES; ORGANIC-COMPOUNDS; CATALYTIC
   DECOMPOSITION; CHEMICAL OXIDATION; SURFACE; DECHLORINATION; PARTICLES
AB The potential for using hydroxyl radical (OH center dot) reactions catalyzed by iron oxide nanoparticles (NPs) to remediate toxic organic compounds was investigated. Iron oxide NPs were synthesized by controlled oxidation of iron NPs prior to their use for contaminant oxidation (by H2O2 addition) at near-neutral pH values. Cross-linked polyacrylic acid (PAA) functionalized polyvinylidene fluoride (PVDF) microfiltration membranes were prepared by in situ polymerization of acrylic acid inside the membrane pores. Iron and iron oxide NPs (80-100 nm) were directly synthesized in the polymer matrix of PAA/PVDF membranes, which prevented the agglomeration of particles and controlled the particle size. The conversion of iron to iron oxide in aqueous solution with air oxidation was studied based on X-ray diffraction, Mossbauer spectroscopy and BET surface area test methods. Trichloroethylene (TCE) was selected as the model contaminant because of its environmental importance. Degradations of TCE and H2O2 by NP surface generated OH center dot were investigated. Depending on the ratio of iron and H2O2, TCE conversions as high as 100 % (with about 91 % dechlorination) were obtained. TCE dechlorination was also achieved in real groundwater samples with the reactive membranes.
C1 [Gui, Minghui; Smuleac, Vasile; Bhattacharyya, Dibakar] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Ormsbee, Lindell E.] Univ Kentucky, Dept Civil Engn, Lexington, KY 40506 USA.
   [Sedlak, David L.] Univ Calif Berkeley, Dept Civil & Environm Engn, Berkeley, CA 94720 USA.
RP Bhattacharyya, D (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM db@engr.uky.edu
FU National Institute of Environmental Health Sciences (NIEHS) SRP;
   UK-NIEHS-SRP; US Department of Energy (DOE) KRCEE [DE-FG05-03OR23032]
FX This research was supported by a joint National Institute of
   Environmental Health Sciences (NIEHS) SRP Supplement grant between
   University of Kentucky (UK) and University of California at Berkeley,
   UK-NIEHS-SRP program and by the US Department of Energy (DOE) KRCEE
   programs (DE-FG05-03OR23032). We thank Dr. Frank E. Huggins from
   Department of Chemical and Materials Engineering at UK for Mossbauer
   spectroscopy analytical support.
CR Ahuja DK, 2007, CHEMOSPHERE, V66, P2193, DOI 10.1016/j.chemosphere.2006.08.035
   Ai ZH, 2007, J PHYS CHEM C, V111, P4087, DOI 10.1021/jp0655591
   Bell AT, 2003, SCIENCE, V299, P1688, DOI 10.1126/science.1083671
   CLAPP PA, 1989, ANAL CHIM ACTA, V218, P331, DOI 10.1016/S0003-2670(00)80309-8
   Costa RCC, 2008, APPL CATAL B-ENVIRON, V83, P131, DOI 10.1016/j.apcatb.2008.01.039
   Dhananjeyan MR, 2001, J PHYS CHEM B, V105, P12046, DOI 10.1021/jp011339q
   Fenton H. J. H., 1894, J CHEM SOC, V65, P899, DOI DOI 10.1039/CT8946500899
   Furukawa Y, 2002, ENVIRON SCI TECHNOL, V36, P5469, DOI 10.1021/es025533h
   GATES DD, 1995, J ENVIRON ENG-ASCE, V121, P639, DOI 10.1061/(ASCE)0733-9372(1995)121:9(639)
   Giraldi TR, 2009, J SOL-GEL SCI TECHN, V52, P299, DOI 10.1007/s10971-009-2014-2
   Guo L, 2006, LANGMUIR, V22, P7867, DOI 10.1021/la060975i
   He F, 2007, IND ENG CHEM RES, V46, P29, DOI 10.1021/ie0610896
   He F, 2008, APPL CATAL B-ENVIRON, V84, P533, DOI 10.1016/j.apcatb.2008.05.008
   Hu K, 2007, J MEMBRANE SCI, V301, P19, DOI 10.1016/j.memsci.2007.05.031
   Huang HH, 2001, WATER RES, V35, P2291, DOI 10.1016/S0043-1354(00)00496-6
   Huling SG, 2006, EPA ENG ISSUE
   Kanel SR, 2005, ENVIRON SCI TECHNOL, V39, P1291, DOI 10.1021/es048991u
   Keenan CR, 2008, ENVIRON SCI TECHNOL, V42, P1262, DOI 10.1021/es7025664
   Kim HS, 2010, ENVIRON SCI TECHNOL, V44, P1760, DOI 10.1021/es902772r
   KITAJIMA N, 1978, J PHYS CHEM-US, V82, P1505, DOI 10.1021/j100502a009
   Kwan WP, 2003, ENVIRON SCI TECHNOL, V37, P1150, DOI 10.1021/es020874g
   Kwan WP, 2002, ENVIRON SCI TECHNOL, V36, P1467, DOI 10.1021/es011109p
   Laine DF, 2007, MICROCHEM J, V85, P183, DOI 10.1016/j.microc.2006.07.002
   Lee C, 2009, J MOL CATAL A-CHEM, V311, P1, DOI 10.1016/j.molcata.2009.07.001
   Lee YN, 2001, APPL CATAL A-GEN, V215, P245, DOI 10.1016/S0926-860X(01)00536-1
   Lewis S, 2009, ENVIRON ENG SCI, V26, P849, DOI 10.1089/ees.2008.0277
   Lewis SR, 2011, P NATL ACAD SCI USA, V108, P8577, DOI 10.1073/pnas.1101144108
   Li K, 2007, ENVIRON SCI TECHNOL, V41, P1696, DOI 10.1021/es0607638
   Li YC, 2007, IND ENG CHEM RES, V46, P7984, DOI 10.1021/ie070393b
   Lim H, 2006, CHEM COMMUN, P463, DOI 10.1039/b513517f
   Lin SS, 1998, ENVIRON SCI TECHNOL, V32, P1417, DOI 10.1021/es970648k
   Miller CM, 1999, WATER RES, V33, P2805, DOI 10.1016/S0043-1354(98)00500-4
   MILLER CM, 1995, WATER RES, V29, P2353, DOI 10.1016/0043-1354(95)00059-T
   Nurmi JT, 2005, ENVIRON SCI TECHNOL, V39, P1221, DOI 10.1021/es049190u
   Peng S, 2006, J AM CHEM SOC, V128, P10676, DOI 10.1021/ja063969h
   Pham ALT, 2009, ENVIRON SCI TECHNOL, V43, P8930, DOI 10.1021/es902296k
   Pignatello JJ, 2006, CRIT REV ENV SCI TEC, V36, P1, DOI 10.1080/10643380500326564
   RAVIKUMAR JX, 1994, ENVIRON SCI TECHNOL, V28, P394, DOI 10.1021/es00052a009
   SALEH AM, 1984, CLAY MINER, V19, P745, DOI 10.1180/claymin.1984.019.5.05
   Savage N, 2005, J NANOPART RES, V7, P331, DOI 10.1007/s11051-005-7523-5
   SCHWERTMANN U, 1982, CLAY MINER, V17, P471, DOI 10.1180/claymin.1982.017.4.10
   Singh N, 2008, J MEMBRANE SCI, V309, P64, DOI 10.1016/j.memsci.2007.10.007
   Smuleac V, 2010, J MEMBRANE SCI, V346, P310, DOI 10.1016/j.memsci.2009.09.052
   Sun SP, 2011, J MOL CATAL A-CHEM, V349, P71, DOI 10.1016/j.molcata.2011.08.022
   Tee YH, 2009, J PHYS CHEM C, V113, P9454, DOI 10.1021/jp809098z
   Tratnyek PG, 2006, NANO TODAY, V1, P44, DOI 10.1016/S1748-0132(06)70048-2
   TYRE BW, 1991, J ENVIRON QUAL, V20, P832, DOI 10.2134/jeq1991.00472425002000040021x
   Valentine RL, 1998, J ENVIRON ENG-ASCE, V124, P31, DOI 10.1061/(ASCE)0733-9372(1998)124:1(31)
   Voinov MA, 2011, J AM CHEM SOC, V133, P35, DOI 10.1021/ja104683w
   Wang CB, 1997, ENVIRON SCI TECHNOL, V31, P2154, DOI 10.1021/es970039c
   Wang F, 1998, MACROMOL CHEM PHYSIC, V199, P1421, DOI 10.1002/macp.1998.021990721
   Watts RJ, 2005, J ENVIRON ENG-ASCE, V131, P612, DOI 10.1061/(ASCE)0733-9372(2005)131:4(612)
   Watts RJ, 1999, ENVIRON ENG SCI, V16, P93, DOI 10.1089/ees.1999.16.93
   Wycisk R, 1996, J MEMBRANE SCI, V119, P155, DOI 10.1016/0376-7388(96)00146-9
   Xu J, 2005, J NANOPART RES, V7, P449, DOI 10.1007/s11051-005-4273-3
   Xu J, 2008, J PHYS CHEM C, V112, P9133, DOI 10.1021/jp7097262
   Xu J, 2007, IND ENG CHEM RES, V46, P2348, DOI 10.1021/ie0611498
   Xue XF, 2009, APPL CATAL B-ENVIRON, V89, P432, DOI 10.1016/j.apcatb.2008.12.024
   Yeh C.K.-J., 2004, PRACT PERIOD HAZARD, V8, P161, DOI DOI 10.1061/(ASCE)1090-025X(2004)8:3(161
   Zelmanov G, 2008, WATER RES, V42, P492, DOI 10.1016/j.watres.2007.07.045
   Zhang WX, 2003, J NANOPART RES, V5, P323, DOI 10.1023/A:1025520116015
NR 61
TC 10
Z9 10
U1 4
U2 77
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1388-0764
J9 J NANOPART RES
JI J. Nanopart. Res.
PD MAY
PY 2012
VL 14
IS 5
AR 861
DI 10.1007/s11051-012-0861-1
PG 16
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA 943WH
UT WOS:000304155900021
DA 2018-03-19
ER

PT J
AU Jujjuri, S
   Knutson, BL
   Thakur, A
   Lynn, B
   Dittert, E
   Nokes, S
   Strobel, H
AF Jujjuri, Satyakrishna
   Knutson, Barbara L.
   Thakur, Anup
   Lynn, Bert C.
   Dittert, Ester
   Nokes, Sue E.
   Strobel, Herbert J.
TI FUEL 96-Metabolic profile of wild-type and ethanol-adapted Clostridium
   thermocellum in continuous culture
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
C1 [Jujjuri, Satyakrishna; Knutson, Barbara L.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Thakur, Anup; Lynn, Bert] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
   [Dittert, Ester; Nokes, Sue] Univ Kentucky, Dept Biosyst & Agr Engn, Lexington, KY 40546 USA.
   [Strobel, Herbert] Univ Kentucky, Dept Anim Sci, Lexington, KY 40546 USA.
EM jujjuri@uky.edu; bknutson@engr.uky.edu; apthak2@uky.edu;
   bclynn2@uky.edu; ester@uky.edu; snokes@bae.uky.edu; strobel@uky.ed
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD AUG 19
PY 2007
VL 234
MA 96-FUEL
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA V12IW
UT WOS:000207593903645
DA 2018-03-20
ER

PT J
AU Wu, QL
   Subramanian, N
   Strzalka, J
   Jiang, Z
   Rankin, SE
AF Wu, Qingliu
   Subramanian, Navaladian
   Strzalka, Joseph
   Jiang, Zhang
   Rankin, Stephen E.
TI Tuning the mesopore structure of 3D hexagonal thin films using butanol
   as a co-solvent
SO THIN SOLID FILMS
LA English
DT Article
DE Mesoporous; Titania; Thin films; 3D hexagonal; Grazing-incidence
   small-angle x-ray scattering
ID X-RAY-SCATTERING; DODECYL-SULFATE MICELLES; GRAZING-INCIDENCE;
   DRUG-DELIVERY; TITANIA FILMS; METAL-OXIDES; SILICA; COPOLYMER; ANGLE;
   SYSTEMS
AB Distorted 3D hexagonal (space group R-3m) mesoporous titania thin films with high visible-light transparency are produced by introducing a small amount of 1-butanol into sol-gel coating sols containing P123 as the primary pore template. The mesostructure of the titania thin films identified by grazing incidence small angle x-ray scattering (GISAXS), transmission electron microscopy and scanning electron microscopy has rhombohedral symmetry (space group R-3m) with the [111] direction normal to the substrate. In the absence of butanol at the ratio of P123:titania used, poorly ordered films which may contain 2D or 3D hexagonal domains form, but introducing as little as a 1:10 ratio (by mass) of 1-butanol to P123 (with ethanol as coating solvent) leads to a well-defined 3D hexagonal structure in the resulting films. Simulated GISAXS patterns obtained using the NANODIFT program confirm the assignment of the experimental patterns to this structure. The characterization results indicate that over a 1-butanol:P123 mass ratio of 0.1 to 2, the films are composed of ordered arrays of cage-like cavities, and that in contrast to the hypothesized role of butanol as a swelling agent, the pore size decreases with an increase in the ratio of 1-butanol to P123. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Wu, Qing Liu; Subramanian, Navaladian; Rankin, Stephen E.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Strzalka, Joseph; Jiang, Zhang] Argonne Natl Lab, Xray Sci Div, Argonne, IL 60439 USA.
RP Rankin, SE (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 FP Anderson Tower, Lexington, KY 40506 USA.
EM srankin@engr.uky.edu
RI Jiang, Zhang/A-3297-2012; Rankin, Stephen/A-3265-2013; Subramanian,
   Navaladian/K-4306-2012; wu, qingliu/C-7631-2012
OI Jiang, Zhang/0000-0003-3503-8909; Rankin, Stephen/0000-0002-8615-7564;
   Subramanian, Navaladian/0000-0002-0509-5438; 
FU U.S. Department of Energy [DE-FG02-07ER46375]; U.S. Department of
   Energy. Office of Science, Office of Basic Energy Science
   [DE-AC02-06CH11357]
FX This work was supported by the U.S. Department of Energy under grant
   number DE-FG02-07ER46375. The work at the Argonne National Laboratory
   was supported by the U.S. Department of Energy. Office of Science,
   Office of Basic Energy Science, under contract No. DE-AC02-06CH11357. We
   also gratefully thank Steven Gaik and Dr. Hillhouse at Purdue Univ. for
   valuable discussions on using the NANODIFT program.
CR Ismail Adel A, 2010, CHEMSUSCHEM, V3, P1057
   Alberius PCA, 2002, CHEM MATER, V14, P3284, DOI 10.1021/cm011209u
   ALMGREN M, 1983, J COLLOID INTERF SCI, V91, P256, DOI 10.1016/0021-9797(83)90330-2
   Armstrong J, 1996, J PHYS CHEM-US, V100, P1738, DOI 10.1021/jp951390s
   Babonneau D, 2010, J APPL CRYSTALLOGR, V43, P929, DOI 10.1107/S0021889810020352
   Bannat I, 2009, CHEM MATER, V21, P1645, DOI 10.1021/cm803455k
   BECK JS, 1992, J AM CHEM SOC, V114, P10834, DOI 10.1021/ja00053a020
   Bosc F, 2004, CHEM MATER, V16, P2208, DOI 10.1021/cm049893a
   Brinker CJ, 1999, ADV MATER, V11, P579, DOI 10.1002/(SICI)1521-4095(199905)11:7<579::AID-ADMA579>3.0.CO;2-R
   Choi SY, 2006, ADV FUNCT MATER, V16, P1731, DOI 10.1002/adfm.200500507
   Choi SY, 2004, ADV FUNCT MATER, V14, P335, DOI 10.1002/adfm.200305039
   DeLoach JD, 1999, J APPL PHYS, V85, P2377, DOI 10.1063/1.369553
   Eggiman BW, 2006, CHEM MATER, V18, P723, DOI 10.1021/cm0520766
   Fan J, 2008, CHEM MATER, V20, P909, DOI 10.1021/cm702328k
   Fang H, 2006, J NON-CRYST SOLIDS, V352, P2279, DOI 10.1016/j.jnoncrysol.2006.02.057
   Feng PY, 2000, LANGMUIR, V16, P5304, DOI 10.1021/la991444f
   Grosso D, 2001, CHEM MATER, V13, P1848, DOI 10.1021/cm001225b
   HAGFELDT A, 1995, CHEM REV, V95, P49, DOI 10.1021/cr00033a003
   Hayward RC, 2004, LANGMUIR, V20, P5998, DOI 10.1021/la030442z
   Hillhouse HW, 2001, MICROPOR MESOPOR MAT, V44, P639, DOI 10.1016/S1387-1811(01)00244-X
   Holmqvist P, 1998, J PHYS CHEM B, V102, P1149, DOI 10.1021/jp9730297
   Imperor-Clerc M, 2000, J AM CHEM SOC, V122, P11925, DOI 10.1021/ja002245h
   Jiang HL, 2010, J AM CHEM SOC, V132, P5586, DOI 10.1021/ja101541s
   Kleitz F, 2003, J PHYS CHEM B, V107, P14296, DOI 10.1021/jp036136b
   Koganti VR, 2006, NANO LETT, V6, P2567, DOI 10.1021/nl061992v
   KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0
   Kwon KW, 2001, POLYM J, V33, P404, DOI 10.1295/polymj.33.404
   Lam KF, 2006, J PHYS CHEM B, V110, P2187, DOI 10.1021/jp055577n
   Lazzari R, 2002, J APPL CRYSTALLOGR, V35, P406, DOI 10.1107/S0021889802006088
   Lee B, 2005, MACROMOLECULES, V38, P4311, DOI 10.1021/ma047562d
   Lee B, 2005, MACROMOLECULES, V38, P3395, DOI 10.1021/ma048214e
   Lee YC, 2010, J SOL-GEL SCI TECHN, V56, P33, DOI 10.1007/s10971-010-2269-7
   Liu KS, 2005, J PHYS CHEM B, V109, P18719, DOI 10.1021/jp054546p
   Lu YF, 1997, NATURE, V389, P364, DOI 10.1038/38699
   Lu ZD, 2010, ANAL CHEM, V82, P7249, DOI 10.1021/ac1011206
   Lufrano F, 2010, INT J ELECTROCHEM SC, V5, P903
   Ma CY, 2010, J AM CHEM SOC, V132, P2608, DOI 10.1021/ja906274t
   Matos JR, 2003, J AM CHEM SOC, V125, P821, DOI 10.1021/ja0283347
   MCGREEVY RJ, 1989, J COLLOID INTERF SCI, V127, P209, DOI 10.1016/0021-9797(89)90021-0
   Ren YH, 2010, MATERIALS, V3, P764, DOI 10.3390/ma3020764
   Ryan JV, 2000, NATURE, V406, P169
   Sakamoto Y, 2000, NATURE, V408, P449
   Sakamoto Y, 2002, J PHYS CHEM B, V106, P3118, DOI 10.1021/jp014094q
   Soler-Illia GJDA, 2000, NEW J CHEM, V24, P493, DOI 10.1039/b002518f
   Soni SS, 2006, J PHYS CHEM B, V110, P15157, DOI 10.1021/jp062159p
   Stein A, 2003, ADV MATER, V15, P763, DOI 10.1002/adma.200300007
   Takeuchi M, 2000, CATAL LETT, V66, P185, DOI 10.1023/A:1019095406121
   TANG H, 1994, J APPL PHYS, V75, P2042, DOI 10.1063/1.356306
   Tang SH, 2010, ADV FUNCT MATER, V20, P2442, DOI 10.1002/adfm.201000647
   Tate MP, 2007, J PHYS CHEM C, V111, P7645, DOI 10.1021/jp066111n
   Tate MP, 2006, J PHYS CHEM B, V110, P9882, DOI 10.1021/jp0566008
   Thallapally PK, 2010, DALTON T, V39, P1692, DOI 10.1039/b921118g
   Uchida H, 2010, THIN SOLID FILMS, V518, P3169, DOI 10.1016/j.tsf.2009.08.050
   Vivero-Escoto JL, 2010, SMALL, V6, P1952, DOI 10.1002/smll.200901789
   Wei TC, 2007, LANGMUIR, V23, P5689, DOI 10.1021/la062699d
   Yamauchi Y, 2005, J MATER CHEM, V15, P1137, DOI 10.1039/b418478e
   Yang PD, 1999, CHEM MATER, V11, P2813, DOI 10.1021/cm990185c
   ZANA R, 1995, ADV COLLOID INTERFAC, V57, P1, DOI 10.1016/0001-8686(95)00235-I
   Zhao YN, 2009, J AM CHEM SOC, V131, P8398, DOI 10.1021/ja901831u
NR 59
TC 4
Z9 4
U1 1
U2 27
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0040-6090
J9 THIN SOLID FILMS
JI Thin Solid Films
PD FEB 29
PY 2012
VL 520
IS 9
BP 3558
EP 3566
DI 10.1016/j.tsf.2011.12.028
PG 9
WC Materials Science, Multidisciplinary; Materials Science, Coatings &
   Films; Physics, Applied; Physics, Condensed Matter
SC Materials Science; Physics
GA 910HF
UT WOS:000301627100024
DA 2018-03-20
ER

PT J
AU Asafo-Adjei, TA
   Dziubla, TD
   Puleo, DA
AF Asafo-Adjei, Theodora A.
   Dziubla, Thomas D.
   Puleo, David A.
TI Tuning properties of poly(ethylene glycol)-block-poly(simvastatin)
   copolymers synthesized via triazabicyclodecene
SO REACTIVE & FUNCTIONAL POLYMERS
LA English
DT Article
DE Poly(simvastatin); Simvastatin; Diblock copolymer; Triazabicyclodecene;
   Drug delivery
ID RING-OPENING POLYMERIZATION; CYCLIC ESTERS; MOLECULAR-WEIGHT; L-LACTIDE;
   GUANIDINE; MECHANISM; CATALYST
AB Simvastatin was polymerized into copolymers to better control drug loading and release for therapeutic delivery. When using the conventional stannous octoate catalyst in ring-opening polymerization (ROP), reaction temperatures >= 200 degrees C were required, which promoted uncontrollable and undesirable side reactions. Triazabicyclodecene (TBD), a highly reactive guanidine base organocatalyst, was used as an alternative to polymerize simvastatin. Polymerization was achieved at 150 degrees C using 5 kDa methyl-terminated poly(ethylene glycol) (mPEG) as the initiator. ROP reactions with 2 kDa or 550 Da mPEG initiators were also successful using TBD at 150 degrees C instead of stannous octoate, which required a higher reaction temperature. Biodegradability of the poly(simvastatin) copolymer in phosphate-buffered saline was also improved, losing twice as much mass than the copolymer synthesized via stannous octoate. The three copolymers exhibited modified rates of simvastatin release, demonstrating tunability for drug delivery applications.
C1 [Asafo-Adjei, Theodora A.; Puleo, David A.] Univ Kentucky, Dept Biomed Engn, 522 Robot & Mfg Bldg, Lexington, KY 40506 USA.
   [Dziubla, Thomas D.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY USA.
RP Puleo, DA (reprint author), Univ Kentucky, Dept Biomed Engn, 522 Robot & Mfg Bldg, Lexington, KY 40506 USA.
EM puleo@uky.edu
FU National Institutes of Health [AR060964-02S1, EB017902]
FX This research was funded by the National Institutes of Health
   (AR060964-02S1 and EB017902).
CR Allen C, 2000, J CONTROL RELEASE, V63, P275, DOI 10.1016/S0168-3659(99)00200-X
   Ambrosio AMA, 2002, BIOMATERIALS, V23, P1667, DOI 10.1016/S0142-9612(01)00293-9
   Asafo-Adjei TA, 2014, RSC ADV, V4, P58287, DOI 10.1039/c4ra10310f
   CHEN CSH, 1975, J POLYM SCI POL CHEM, V13, P1183, DOI 10.1002/pol.1975.170130514
   Chuma A, 2008, J AM CHEM SOC, V130, P6749, DOI 10.1021/ja0764411
   Hiltunen K, 1997, MACROMOLECULES, V30, P373, DOI 10.1021/ma960919w
   Ikada Y, 2000, MACROMOL RAPID COMM, V21, P117, DOI 10.1002/(SICI)1521-3927(20000201)21:3<117::AID-MARC117>3.0.CO;2-X
   Kamber NE, 2007, CHEM REV, V107, P5813, DOI 10.1021/cr068415b
   Kiesewetter MK, 2010, MACROMOLECULES, V43, P2093, DOI 10.1021/ma9025948
   Labet M, 2009, CHEM SOC REV, V38, P3484, DOI 10.1039/b820162p
   Lohmeijer BGG, 2006, MACROMOLECULES, V39, P8574, DOI 10.1021/ma0619381
   Nederberg F, 2007, BIOMACROMOLECULES, V8, P153, DOI 10.1021/bm060795n
   Pepels MPF, 2013, MACROMOLECULES, V46, P4324, DOI 10.1021/ma400731c
   Pratt RC, 2006, J AM CHEM SOC, V128, P4556, DOI 10.1021/ja060662+
   Rakova G. V., 1967, POLYM SCI USSR, V9, P2916
   Save M, 2002, MACROMOL CHEM PHYSIC, V203, P889, DOI 10.1002/1521-3935(20020401)203:5/6<889::AID-MACP889>3.0.CO;2-O
   Simon L, 2007, J ORG CHEM, V72, P9656, DOI 10.1021/jo702088c
   Int Veld P. J. A., 1997, J POLYM SCI POL CHEM, V35, P219
   Zhong ZY, 2001, POLYM BULL, V46, P51, DOI 10.1007/s002890170088
NR 19
TC 0
Z9 0
U1 8
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1381-5148
EI 1873-166X
J9 REACT FUNCT POLYM
JI React. Funct. Polym.
PD OCT
PY 2017
VL 119
BP 37
EP 46
DI 10.1016/j.reactfunctpolym.2017.07.004
PG 10
WC Chemistry, Applied; Engineering, Chemical; Polymer Science
SC Chemistry; Engineering; Polymer Science
GA FJ0CK
UT WOS:000412375900005
PM 29217967
DA 2018-03-19
ER

PT J
AU Yu, CG
   Joshi, A
   Geddes, JW
AF Yu, Chen-Guang
   Joshi, Aashish
   Geddes, James W.
TI Intraspinal MDL28170 microinjection improves functional and pathological
   outcome following spinal cord injury
SO JOURNAL OF NEUROTRAUMA
LA English
DT Article
DE locomotion; neurodegeneration; neuroprotection; white matter sparing
ID CALPAIN I ACTIVATION; NEURONAL CELL-DEATH; NEUROLOGICAL FUNCTION;
   LOCOMOTOR FUNCTION; INHIBITORS; CYTOSKELETAL; DEGRADATION; RAT;
   EXPRESSION; APOPTOSIS
AB Although calpain (calcium-activated cysteine protease) inhibition represents a rational therapeutic target for spinal cord injury (SCI), few studies have reported improved functional outcomes with post-injury administration of calpain inhibitors. This reflects the weak potency and limited aqueous solubility of current calpain inhibitors. Previously, we demonstrated that intraspinal microinjection of the calpain inhibitor MDL28170 resulted in greater inhibition of calpain activity as compared to systemic administration of the same compound. In the present study, we evaluated the ability of intraspinal MDL28170 microinjection to spare spinal tissue and locomotor dysfunction following SCI. Contusion SCI was produced in female Long-Evans rats using the Infinite Horizon impactor at the 200-kdyn force setting. Open-field locomotion was evaluated until 6 weeks post-injury. Histological assessment of tissue sparing was performed at 6 weeks after SCI. The results demonstrate that MDL28170, administered with a single post-injury intraspinal microinjection (50 nmoles), significantly improves both locomotor function and pathological outcome measures following SCI.
C1 [Yu, Chen-Guang; Joshi, Aashish; Geddes, James W.] Univ Kentucky, Dept Anat & Neurobiol, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA.
RP Geddes, JW (reprint author), Univ Kentucky, Dept Anat & Neurobiol, Spinal Cord & Brain Injury Res Ctr, B477,Biomed & Biol Sci Res Bldg,741 S Limestone S, Lexington, KY 40536 USA.
EM jgeddes@uky.edu
RI Yu, Chen Guang/C-6176-2011
FU NINDS NIH HHS [R01 NS 045726]
CR Arataki S, 2005, J NEUROTRAUM, V22, P398, DOI 10.1089/neu.2005.22.398
   Banik N L, 1984, Prog Clin Biol Res, V146, P145
   Banik NL, 1997, BRAIN RES, V752, P301, DOI 10.1016/S0006-8993(96)01488-6
   BANIK NL, 1986, J NEUROL SCI, V73, P245, DOI 10.1016/0022-510X(86)90149-8
   Bano D, 2005, CELL, V120, P275, DOI 10.1016/j.cell.2004.11.049
   Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098
   BLIGHT AR, 1983, NEUROSCIENCE, V10, P521, DOI 10.1016/0306-4522(83)90150-1
   BRORSON JR, 1995, STROKE, V26, P1259, DOI 10.1161/01.STR.26.7.1259
   Cuerrier D, 2007, J BIOL CHEM, V282, P9600, DOI 10.1074/jbc.M610372200
   Cuzzocrea S, 2000, AM J PATHOL, V157, P2065, DOI 10.1016/S0002-9440(10)64845-6
   Das A, 2005, J NEUROSCI RES, V81, P551, DOI 10.1002/jnr.20581
   Hung KS, 2005, J NEUROPATH EXP NEUR, V64, P15, DOI 10.1093/jnen/64.1.15
   James T, 1998, J NEUROSCI RES, V51, P218, DOI 10.1002/(SICI)1097-4547(19980115)51:2<218::AID-JNR10>3.3.CO;2-#
   Kieran D, 2004, NEUROSCIENCE, V125, P427, DOI 10.1016/j.neuroscience.2004.01.046
   Kupina NC, 2001, J NEUROTRAUM, V18, P1229, DOI 10.1089/089771501317095269
   Magnuson DSK, 1999, EXP NEUROL, V156, P191, DOI 10.1006/exnr.1999.7016
   Majczynski H, 2007, J NEUROSCI METH, V163, P197, DOI 10.1016/j.jneumeth.2007.02.023
   Momeni HR, 2005, NEUROREPORT, V16, P1065, DOI 10.1097/00001756-200507130-00007
   Moore JD, 2002, BRIT J PHARMACOL, V135, P1069, DOI 10.1038/sj.bjp.0704538
   Neffe AT, 2005, CURR OPIN DRUG DISC, V8, P684
   O'Hanlon GM, 2003, BRAIN, V126, P2497, DOI 10.1093/brain/awg254
   Pianetti S, 2001, ONCOGENE, V20, P1287, DOI 10.1038/sj.onc.1204257
   Rabchevsky AG, 2001, J NEUROTRAUM, V18, P513, DOI 10.1089/089771501300227314
   Ray SK, 1999, BRAIN RES, V816, P375, DOI 10.1016/S0006-8993(98)01128-7
   Ray SK, 2003, BRAIN RES REV, V42, P169, DOI 10.1016/S0165-0173(03)00152-8
   Ray SK, 2002, J NEUROSCI RES, V70, P561, DOI 10.1002/jnr.10414
   Rock MT, 2000, EXP CELL RES, V261, P260, DOI 10.1006/excr.2000.5048
   Saatman KE, 2000, J CEREBR BLOOD F MET, V20, P66, DOI 10.1097/00004647-200001000-00010
   Sanders ML, 2006, BIOORG MED CHEM LETT, V16, P1965, DOI 10.1016/j.bmcl.2005.12.068
   Schaecher KE, 2001, NEUROCHEM RES, V26, P731, DOI 10.1023/A:1010903823668
   Schaub FJ, 2003, CIRC RES, V93, P515, DOI 10.1161/01.RES.0000093205.42313.7C
   Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099
   Schumacher PA, 2000, J NEUROCHEM, V74, P1646, DOI 10.1046/j.1471-4159.2000.0741646.x
   Schumacher PA, 1999, NEUROSCIENCE, V91, P733, DOI 10.1016/S0306-4522(98)00552-1
   Shields DC, 2000, J NEUROSCI RES, V61, P146
   Springer JE, 1997, J NEUROCHEM, V69, P1592, DOI 10.1046/j.1471-4159.1997.69041592.x
   Stewart MP, 1998, J CELL BIOL, V140, P699, DOI 10.1083/jcb.140.3.699
   Teng YD, 1997, J NEUROSCI, V17, P4359
   Wang K K, 1997, Adv Pharmacol, V37, P117
   WANG KKW, 1990, TRENDS PHARMACOL SCI, V11, P139, DOI 10.1016/0165-6147(90)90060-L
   WATANABE N, 1994, CYTOKINE, V6, P597, DOI 10.1016/1043-4666(94)90046-9
   Yu CG, 2000, NEUROREPORT, V11, P3203, DOI 10.1097/00001756-200009280-00031
   Yu CG, 2007, NEUROCHEM RES, V32, P2046, DOI 10.1007/s11064-007-9347-4
   Zhang SX, 2000, J NEUROPATH EXP NEUR, V59, P287, DOI 10.1093/jnen/59.4.287
   Zhang SX, 2003, J NEUROTRAUM, V20, P59, DOI 10.1089/08977150360517182
NR 45
TC 18
Z9 21
U1 0
U2 1
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0897-7151
J9 J NEUROTRAUM
JI J. Neurotrauma
PD JUL
PY 2008
VL 25
IS 7
BP 833
EP 840
DI 10.1089/neu.2007.0490
PG 8
WC Critical Care Medicine; Clinical Neurology; Neurosciences
SC General & Internal Medicine; Neurosciences & Neurology
GA 326BX
UT WOS:000257634000009
PM 18627259
OA green_published
DA 2018-03-20
ER

PT J
AU Scott, D
   Hamorsky, KT
   Ensor, CM
   Anderson, KW
   Daunert, S
AF Scott, Daniel F.
   Hamorsky, Krystal Teasley
   Ensor, C. Mark
   Anderson, Kimberly W.
   Daunert, Sylvia
TI Cyclic AMP Receptor Protein-Aequorin Molecular Switch for Cyclic AMP
SO BIOCONJUGATE CHEMISTRY
LA English
DT Article
ID ESCHERICHIA-COLI; BIOLUMINESCENCE IMMUNOASSAY; TRANSCRIPTION ACTIVATION;
   PHOTOPROTEIN AEQUORIN; ADENYLATE-CYCLASE; DOMAIN INSERTION; CAMP;
   GLUCOSE; MODULATION; BINDING
AB Molecular switches are designer molecules that combine the functionality of two individual proteins into one, capable of manifesting an "on/off" signal in response to a stimulus. These switches have unique properties and functionalities and thus, can be employed as nanosensors in a variety of applications. To that end, we have developed a bioluminescent molecular switch for cyclic AMP. Bioluminescence offers many advantages over fluorescence and other detection methods including the fact that there is essentially zero background signal in physiological fluids, allowing for more sensitive detection and monitoring. The switch was created by combining the properties of the cyclic AMP receptor protein (CRP), a transcriptional regulatory protein from E. Coli that binds selectively to cAMP with those of aequorin, a bioluminescent photoprotein native of the jellyfish Aequorea victoria. Genetic manipulation to split the genetic coding sequence of aequorin in two and genetically attach the fragments to the N and C termini of CRP resulted in a hybrid protein molecular switch. The conformational change experienced by CRP upon the binding of cyclic AMP is suspected to result in the observed loss of the bioluminescent signal from aequorin. The "on/off' bioluminescence can be modulated by cyclic AMP over a range of several orders of magnitude in a linear fashion in addition to the capacity to detect changes in cellular cyclic AMP of intact cells exposed to different external stimuli without the need to lyse the cells. We envision that the molecular switch could find applications in vitro as well as In Vivo cyclic AMP detection and/or imaging.
C1 [Daunert, Sylvia] Univ Miami, Miller Sch Med, Dept Biochem & Mol Biol, Miami, FL 33136 USA.
   [Scott, Daniel; Hamorsky, Krystal Teasley; Ensor, C. Mark; Daunert, Sylvia] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
   [Anderson, Kimberly W.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Daunert, S (reprint author), Univ Miami, Miller Sch Med, Dept Biochem & Mol Biol, R Bunn Gautier Bldg,1011 NW 15th St, Miami, FL 33136 USA.
EM sdaunert@med.miami.edu
FU National Institutes of Health; National Science Foundation; University
   of Kentucky; NSF-IGERT; Gill Eminent Professorship
FX This work was supported in part by grants from the National Institutes
   of Health and the National Science Foundation. K.T.H. is grateful for a
   Research Council Trust Fund Fellowship from the University of Kentucky.
   D.S. acknowledges support from NSF-IGERT and University of Kentucky
   Presidential Fellowships, and S.D. and K.W.A. from a Gill Eminent
   Professorship. S.D. is thankful to the University of Kentucky for a
   University Research Professorship. Finally, S.D. is grateful to the
   Miller School of Medicine of the University of Miami for the Lucille P.
   Markey Chair in Biochemistry and Molecular Biology.
CR AMIN N, 1995, J BIOL CHEM, V270, P11803, DOI 10.1074/jbc.270.20.11803
   Baird GS, 1999, P NATL ACAD SCI USA, V96, P11241, DOI 10.1073/pnas.96.20.11241
   Beavo JA, 2002, NAT REV MOL CELL BIO, V3, P710, DOI 10.1038/nrm911
   Busby S, 1999, J MOL BIOL, V293, P199, DOI 10.1006/jmbi.1999.3161
   CHARBONNEAU H, 1985, BIOCHEMISTRY-US, V24, P6762, DOI 10.1021/bi00345a006
   DECROMBRUGGHE B, 1984, SCIENCE, V224, P831, DOI 10.1126/science.6372090
   Deo SK, 2001, ANAL CHEM, V73, P1903, DOI 10.1021/ac001100q
   Gang J, 2005, J MICROBIOL BIOTECHN, V15, P1392
   Guntas G, 2004, J MOL BIOL, V336, P263, DOI 10.1016/j.jmb.2003.12.016
   Hamorsky KT, 2008, ANGEW CHEM INT EDIT, V47, P3718, DOI 10.1002/anie.200704440
   Harman JG, 2001, BBA-PROTEIN STRUCT M, V1547, P1, DOI 10.1016/S0167-4838(01)00187-X
   HARWOOD JP, 1975, J BIOL CHEM, V250, P4656
   Head JF, 2000, NATURE, V405, P372, DOI 10.1038/35012659
   Holz GG, 2004, DIABETES, V53, P5, DOI 10.2337/diabetes.53.1.5
   Jissy AK, 2010, J PHYS CHEM B, V114, P15311, DOI 10.1021/jp106732u
   Lewis JC, 2001, ANAL CHEM, V73, P3227, DOI 10.1021/ac0101914
   Lewis JC, 2000, BIOCONJUGATE CHEM, V11, P65, DOI 10.1021/bc9900800
   Malecki J, 2000, J BIOL CHEM, V275, P8480, DOI 10.1074/jbc.275.12.8480
   Mirasoli M, 2002, ANAL BIOCHEM, V306, P204, DOI 10.1006/abio.2002.5695
   Morozov A, 2003, NEURON, V39, P309, DOI 10.1016/S0896-6273(03)00404-5
   OHSAWA H, 1992, BOT MAG TOKYO, V105, P393, DOI 10.1007/BF02497654
   Ostermeier M, 2005, PROTEIN ENG DES SEL, V18, P359, DOI 10.1093/protein/gzi048
   Passner JM, 1997, P NATL ACAD SCI USA, V94, P2843, DOI 10.1073/pnas.94.7.2843
   Polit A, 2003, EUR J BIOCHEM, V270, P1413, DOI 10.1046/j.1432-1033.2003.03497.x
   REZNIKOFF WS, 1992, J BACTERIOL, V174, P655, DOI 10.1128/jb.174.3.655-658.1992
   SHIMOMUR.O, 1973, TETRAHEDRON LETT, P2963
   SHIMOMURA O, 1962, J CELL COMPAR PHYSL, V59, P223, DOI 10.1002/jcp.1030590302
   Shimomura O, 2006, PHOTOPROTEINS BIOANA, P1
   Taneoka A, 2009, BIOSENS BIOELECTRON, V25, P76, DOI 10.1016/j.bios.2009.06.004
   Torgersen KM, 2002, CELL SIGNAL, V14, P1, DOI 10.1016/S0898-6568(01)00214-5
   Vallee-Belisle A, 2010, CURR OPIN STRUC BIOL, V20, P518, DOI 10.1016/j.sbi.2010.05.001
   Williams C, 2004, NAT REV DRUG DISCOV, V3, P125, DOI 10.1038/nrd1306
   Zagotta WN, 2003, NATURE, V425, P200, DOI 10.1038/nature01922
NR 33
TC 6
Z9 6
U1 0
U2 9
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1043-1802
J9 BIOCONJUGATE CHEM
JI Bioconjugate Chem.
PD MAR
PY 2011
VL 22
IS 3
BP 475
EP 481
DI 10.1021/bc100486b
PG 7
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Multidisciplinary; Chemistry, Organic
SC Biochemistry & Molecular Biology; Chemistry
GA 735GM
UT WOS:000288401400020
PM 21329338
OA green_accepted
DA 2018-03-19
ER

PT J
AU Long, SH
   Li, TL
AF Long, Sihui
   Li, Tonglei
TI Controlled Formation of the Acid-Pyridine Heterosynthon over the
   Acid-Acid Homosynthon in 2-Anilinonicotinic Acids
SO CRYSTAL GROWTH & DESIGN
LA English
DT Article
ID DENSITY-FUNCTIONAL THEORY; HYDROGEN-BOND PATTERNS; ORGANIC-CRYSTALS;
   SUPRAMOLECULAR SYNTHONS; X-RAY; POLYMORPHISM
AB Four substituted 2-anilinonicotinic acids were synthesized, and their crystal structures were analyzed. It was found that by chemically introducing bulky functional groups to the aniline ring of the molecules, it is possible to dislodge the planar conformation due to steric repulsion. As a result, acid-pyridine heterosynthons, not acid-acid homosynthons, are formed in the crystals. The study is believed to offer a refreshing case of how a molecule's conformation can affect intermolecular interactions and consequent crystal packing.
C1 [Li, Tonglei] Univ Kentucky, Coll Pharm 514, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
RP Li, TL (reprint author), Univ Kentucky, Coll Pharm 514, Dept Pharmaceut Sci, 725 Rose St, Lexington, KY 40536 USA.
EM tonglei@uky.edu
FU NSF [DMR-0449633]
FX The authors are grateful to the NSF for the Financial support of this
   study (DMR-0449633).
CR Aakeroy CB, 2001, ANGEW CHEM INT EDIT, V40, P3240, DOI 10.1002/1521-3773(20010903)40:17<3240::AID-ANIE3240>3.0.CO;2-X
   Almarsson O, 2004, CHEM COMMUN, P1889, DOI 10.1039/b402150a
   Ayers PW, 2006, J CHEM PHYS, V124, DOI 10.1063/1.2196882
   Bernstein J., 2002, POLYMORPHISM MOL CRY
   BERSTEIN J, 1995, ANGEW CHEM INT EDIT, V34, P1555
   Brittain H. G., 1999, POLYMORPHISM PHARM S
   CORRADINI P, 1973, CHIM IND-MILAN, V55, P122
   Desiraju GR, 2007, ANGEW CHEM INT EDIT, V46, P8342, DOI 10.1002/anie.200700534
   DESIRAJU GR, 1995, ANGEW CHEM INT EDIT, V34, P2311, DOI 10.1002/anie.199523111
   Desiraju G. R, 1989, CRYSTAL ENG DESIGN O
   DESIRAJU GR, 2003, CRYSTAL DESIGN STRUC
   ETTER MC, 1990, ACCOUNTS CHEM RES, V23, P120, DOI 10.1021/ar00172a005
   ETTER MC, 1990, ACTA CRYSTALLOGR B, V46, P256, DOI 10.1107/S0108768189012929
   Geerlings P, 2003, CHEM REV, V103, P1793, DOI 10.1021/cr990029p
   Li TL, 2009, CHEM-EUR J, V15, P361, DOI 10.1002/chem.200801056
   Llinas A, 2008, DRUG DISCOV TODAY, V13, P198, DOI 10.1016/j.drudis.2007.11.006
   Long SH, 2008, CRYST GROWTH DES, V8, P4006, DOI 10.1021/cg800123z
   Long SH, 2008, CRYST GROWTH DES, V8, P3137, DOI 10.1021/cg800339h
   McCrone W. C., 1965, PHYSICS CHEMISTRY OR, VII, P725
   Nangia Ashwini, 2007, Journal of the Indian Institute of Science, V87, P133
   Nangia A, 2008, ACCOUNTS CHEM RES, V41, P595, DOI 10.1021/ar700203k
   Parr RG, 1989, DENSITY FUNCTIONAL T
   Shattock TR, 2008, CRYST GROWTH DES, V8, P4533, DOI 10.1021/cg800565a
   Steiner T, 2001, ACTA CRYSTALLOGR B, V57, P103, DOI 10.1107/S0108768100014348
   Steiner Thomas, 2002, Angew Chem Int Ed Engl, V41, P49
   Vishweshwar P, 2003, CRYST GROWTH DES, V3, P783, DOI 10.1021/cg034037h
NR 26
TC 17
Z9 17
U1 0
U2 5
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1528-7483
J9 CRYST GROWTH DES
JI Cryst. Growth Des.
PD DEC
PY 2009
VL 9
IS 12
BP 4993
EP 4997
DI 10.1021/cg900786b
PG 5
WC Chemistry, Multidisciplinary; Crystallography; Materials Science,
   Multidisciplinary
SC Chemistry; Crystallography; Materials Science
GA 525BL
UT WOS:000272188000003
DA 2018-03-20
ER

PT J
AU Rheiner, S
   Bae, Y
AF Rheiner, Steven
   Bae, Younsoo
TI Increased poly(ethylene glycol) density decreases transfection efficacy
   of siRNA/poly(ethylene imine) complexes
SO AIMS BIOENGINEERING
LA English
DT Article
DE nanoparticles; gene delivery; gene therapy; vectors; polyion complexes
ID GENE DELIVERY; SIRNA DELIVERY; CATIONIC LIPIDS; CELLULAR UPTAKE;
   IN-VITRO; PEGYLATION; POLYETHYLENIMINE; POLYMERS; POLYPLEXES; LIPOSOMES
AB Small interfering RNA (siRNA) inhibits specific gene expression in cells to treat genetic diseases including cancer, but siRNA-based cancer therapy is often hindered by inefficient siRNA delivery to tumor. Poly(ethylene glycol)-conjugated poly(ethylene imine) (PEG-PEI) is widely studied as a promising siRNA carrier. PEG-PEI can form ion complexes with siRNA and enhance siRNA gene silencing (transfection) due to its high buffering capacity. However, the transfection efficacy of PEG-PEI formulations changes due to variable polymer compositions. This study investigates the effects of PEG-related factors [molecular weight (PEG MW), substitution rate (PEG%), and short PEI contaminants] on siRNA transfection efficiency of PEG-PEI in a model human colon cancer cell line (HT29). High PEG density increased PEG-PEI mass to form complexes yet decreased in vitro transfection efficiency. Low PEG MW (550 Da, 2 kDa, and 5 kDa) induced complexation between PEG-PEI and siRNA at a reduced charge ratio (N/P ratio). Dialysis removed short PEI contaminants, and the dialyzed PEI with PEG (PEG-PEI-d) formed siRNA complexes with minimal particle size distribution than PEG-PEI. siRNA/PEG-PEI-d complexes showed transfection efficiency similar to siRNA/PEG-PEI complexes at a lower N/P ratio. These results conclude that PEG MW, density, and small PEI contaminants are three major factors influencing transfection of siRNA/PEI complexes.
C1 [Rheiner, Steven; Bae, Younsoo] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, 789 South Limestone, Lexington, KY 40536 USA.
RP Rheiner, S (reprint author), Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, 789 South Limestone, Lexington, KY 40536 USA.
EM younsoo.bae@uky.edu
CR Alexis F, 2008, MOL PHARMACEUT, V5, P505, DOI 10.1021/mp800051m
   Aliabadi HM, 2012, BIOMATERIALS, V33, P2546, DOI 10.1016/j.biomaterials.2011.11.079
   Aliabadi HM, 2013, J CONTROL RELEASE, V172, P219, DOI 10.1016/j.jconrel.2013.08.012
   Choudhury SR, 2016, NEUROPHARMA IN PRESS
   Dominska M, 2010, J CELL SCI, V123, P1183, DOI 10.1242/jcs.066399
   Fire A, 1999, TRENDS GENET, V15, P358, DOI 10.1016/S0168-9525(99)01818-1
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Fitzsimmons REB, 2012, ACTA BIOMATER, V8, P3941, DOI 10.1016/j.actbio.2012.07.015
   Forsbach A, 2012, IMMUNOL LETT, V141, P169, DOI 10.1016/j.imlet.2011.10.001
   Guo PX, 2010, ADV DRUG DELIVER REV, V62, P650, DOI 10.1016/j.addr.2010.03.008
   Holland JW, 1996, BIOCHEMISTRY-US, V35, P2618, DOI 10.1021/bi952000v
   Huang FW, 2010, ACTA BIOMATER, V6, P4285, DOI 10.1016/j.actbio.2010.06.016
   Lachelt U, 2015, CHEM REV, V115, P11043, DOI 10.1021/cr5006793
   Lee SY, 2010, J CONTROL RELEASE, V141, P339, DOI 10.1016/j.jconrel.2009.10.007
   Liu YY, 2013, BRAIN RES, V1490, P43, DOI 10.1016/j.brainres.2012.10.039
   Lv HT, 2006, J CONTROL RELEASE, V114, P100, DOI 10.1016/j.jconrel.2006.04.014
   Mao SR, 2006, BIOCONJUGATE CHEM, V17, P1209, DOI 10.1021/bc060129j
   Milla P, 2012, CURR DRUG METAB, V13, P105, DOI 10.2174/138920012798356934
   Mishra S, 2004, EUR J CELL BIOL, V83, P97, DOI 10.1078/0171-9335-00363
   Miteva M, 2015, BIOMATERIALS, V38, P97, DOI 10.1016/j.biomaterials.2014.10.036
   Ogris M, 2001, AAPS PHARMSCI, V3, part. no.
   Pandey AP, 2016, MAT SCI ENG C-MATER, V68, P904, DOI 10.1016/j.msec.2016.07.066
   Petersen H, 2002, BIOCONJUGATE CHEM, V13, P845, DOI 10.1021/bc025529v
   Resnier P, 2013, BIOMATERIALS, V34, P6429, DOI 10.1016/j.biomaterials.2013.04.060
   Rheiner S, 2015, BIOPHYSICS-USSR, V2, P284
   Tang GP, 2003, BIOMATERIALS, V24, P2351, DOI 10.1016/S0142-9612(03)00029-2
   Varkouhi AK, 2011, J CONTROL RELEASE, V151, P220, DOI 10.1016/j.jconrel.2010.11.004
   Wen SH, 2013, J APPL POLYM SCI, V128, P3807, DOI 10.1002/app.38444
   Wightman L, 2001, J GENE MED, V3, P362, DOI 10.1002/jgm.187
   Zhang SB, 2007, J CONTROL RELEASE, V123, P1, DOI 10.1016/j.jconrel.2007.07.016
   Zintchenko A, 2008, BIOCONJUGATE CHEM, V19, P1448, DOI 10.1021/bc800065f
NR 31
TC 3
Z9 3
U1 1
U2 3
PU AMER INST MATHEMATICAL SCIENCES-AIMS
PI SPRINGFIELD
PA PO BOX 2604, SPRINGFIELD, MO 65801-2604 USA
SN 2375-1495
J9 AIMS BIOENG
JI AIMS Bioeng.
PY 2016
VL 3
IS 4
BP 454
EP 467
DI 10.3934/bioeng.2016.4.454
PG 14
WC Engineering, Biomedical
SC Engineering
GA EO3QK
UT WOS:000396609100004
OA gold
DA 2018-03-19
ER

PT J
AU Li, XJ
   Vogt, FG
   Hayes, D
   Mansour, HM
AF Li, Xiaojian
   Vogt, Frederick G.
   Hayes, Don, Jr.
   Mansour, Heidi M.
TI Design, Characterization, and Aerosol Dispersion Performance Modeling of
   Advanced Co-Spray Dried Antibiotics with Mannitol as Respirable
   Microparticles/Nanoparticles for Targeted Pulmonary Delivery as Dry
   Powder Inhalers
SO JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE anti-infectives; glass transition; spray drying; pulmonary drug
   delivery; aerosols; particle size respiratory delivery; lung; confocal
   Raman microscopy; solid state particle engineering design
ID CYSTIC-FIBROSIS; PHYSICOCHEMICAL CHARACTERIZATION; DRUG-DELIVERY;
   PHYSICAL-CHARACTERIZATION; INHALATION DELIVERY; PARTICLES;
   NANOPARTICLES; TOBRAMYCIN; DEPOSITION
AB Dry powder inhalation aerosols of antibiotic drugs (a first-line aminoglycoside, tobramycin, and a first-line macrolide, azithromycin) and a sugar alcohol mucolytic agent (mannitol) as co-spray dried (co-SD) particles at various molar ratios of drug: mannitol were successfully produced by organic solution advanced co-spray drying from dilute solute concentration. These microparticulate/nanoparticulate aerosols consisting of various antibiotic drug: mannitol molar ratios were rationally designed with a narrow and unimodal primary particle size distribution, spherical particle shape, relatively smooth particle surface, and very low residual water content to minimize the interparticulate interactions and enhance in vitro aerosolization. These microparticulate/nanoparticulate inhalation powders were high-performing aerosols as reflected in the aerosol dispersion performance parameters of emitted dose, fine particle fraction (FPF), respirable fraction (RF), and mass median aerodynamic diameter (MMAD). The glass transition temperature (T-g) values were significantly above room temperature, which indicated that the co-SD powders were all in the amorphous glassy state. The T-g values for co-SD tobramycin: mannitol powders were significantly lower than those for co-SD azithromycin: mannitol powders. The interplay between aerosol dispersion performance parameters and T-g was modeled where higher T-g values (i.e., more ordered glass) were correlated with higher values in FPF and RF and lower values in MMAD. (C) 2014 Wiley Periodicals, Inc. and the American Pharmacists Association
C1 [Li, Xiaojian] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Drug Dev Div, Lexington, KY 40536 USA.
   [Vogt, Frederick G.] GlaxoSmithKline, Analyt Sci, Prod Dev, King Of Prussia, PA 19406 USA.
   [Hayes, Don, Jr.] Ohio State Univ, Coll Med, Dept Pediat, Lung Transplant Program, Columbus, OH 43205 USA.
   [Hayes, Don, Jr.] Ohio State Univ, Coll Med, Dept Pediat, Heart Lung Transplant Program, Columbus, OH 43205 USA.
   [Hayes, Don, Jr.] Ohio State Univ, Coll Med, Dept Internal Med, Lung Transplant Program, Columbus, OH 43205 USA.
   [Hayes, Don, Jr.] Ohio State Univ, Coll Med, Dept Internal Med, Heart Lung Transplant Program, Columbus, OH 43205 USA.
   [Hayes, Don, Jr.] Ohio State Univ, Coll Med, Davis Heart & Lung Res Inst, Columbus, OH 43205 USA.
   [Mansour, Heidi M.] Univ Arizona, Coll Pharm, Skaggs Pharmaceut Sci Ctr, Tucson, AZ 85721 USA.
RP Mansour, HM (reprint author), Univ Arizona, Coll Pharm, Skaggs Pharmaceut Sci Ctr, Tucson, AZ 85721 USA.
EM mansour@pharmacy.arizona.edu
RI Li, Xiaojian/N-3421-2015
FU UK Center of Membrane Sciences; Graduate School Academic Year
   Fellowship; Daniel R. Reedy Quality Achievement Fellowship
FX The authors gratefully acknowledge fellowship support from the UK Center
   of Membrane Sciences, the Graduate School Academic Year Fellowship, and
   the Daniel R. Reedy Quality Achievement Fellowship awarded to X. L. The
   authors thank Dr. Dicky Sick Ki Yu for SEM access, Dr. Tonglei Li for
   XRPD and HSM access, and Dr. Hilt for ATR- FTIR access.
CR Adi H, 2010, EUR J PHARM SCI, V40, P239, DOI 10.1016/j.ejps.2010.03.020
   DASH AK, 1991, PHARMACEUT RES, V8, P1159, DOI 10.1023/A:1015858503031
   Dunbar CA, 1998, KONA, V16, P7
   Finlay WH, 2008, ARLA
   Hickey AJ, 2009, MODERN PHARM, P191
   Hickey AJ, 2007, J PHARM SCI-US, V96, P1302, DOI 10.1002/jps.20943
   Hickey AJ, 2007, J PHARM SCI-US, V96, P1282, DOI 10.1002/jps.20916
   Imtiaz-Ul-Islam M, 2009, FOOD BIOPROD PROCESS, V87, P87, DOI 10.1016/j.fbp.2008.09.003
   Katzenstein ALA, 1998, AM J RESP CRIT CARE, V157, P1301, DOI 10.1164/ajrccm.157.4.9707039
   Li X, 2014, J AEROSOL MED PULM D
   Li XJ, 2014, EUR J PHARM SCI, V52, P191, DOI 10.1016/j.ejps.2013.10.016
   Li XJ, 2011, AAPS PHARMSCITECH, V12, P1420, DOI 10.1208/s12249-011-9704-0
   Mansour HM, 2007, AAPS PHARMSCITECH, V8, DOI 10.1208/pt0804099
   Mansour HM, 2007, J PHARM SCI-US, V96, P377, DOI 10.1002/jps.20810
   MCELVANEY NG, 1991, LANCET, V337, P392, DOI 10.1016/0140-6736(91)91167-S
   Meenach SA, 2013, EUR J PHARM SCI, V49, P699, DOI 10.1016/j.ejps.2013.05.012
   Meenach SA, 2013, INT J NANOMED, V8, P275, DOI 10.2147/IJN.S30724
   Murray J. F., 1988, TXB RESP MED
   Odziomek M, 2012, INT J PHARMACEUT, V433, P51, DOI 10.1016/j.ijpharm.2012.04.067
   Park CW, 2012, ADV DRUG DELIVER REV, V64, P344, DOI 10.1016/j.addr.2011.08.004
   RAABE OG, 1982, ANN OCCUP HYG, V26, P33, DOI 10.1093/annhyg/26.1.33
   Sethi S, 2007, AM J RESP CRIT CARE, V176, P356, DOI 10.1164/rccm.200703-417OC
   Sexauer WP, 2003, SEM RESP CRIT CARE M, V24, P717
   STAHLHOFEN W, 1980, AM IND HYG ASSOC J, V41, P385, DOI 10.1080/15298668091424933
   Suarez S, 2000, Respir Care, V45, P652
   TAYLOR RFH, 1992, THORAX, V47, P426, DOI 10.1136/thx.47.6.426
   Tiddens HAWM, 2002, PEDIATR PULM, V34, P228, DOI 10.1002/ppul.10134
   Aerosols, 2006, AER NAS SPRAYS MET D, P2617
   Usmani OS, 2005, AM J RESP CRIT CARE, V172, P1497, DOI 10.1164/rccm.200410-1414OC
   Westmeier R, 2008, J PHARM SCI-US, V97, P2299, DOI 10.1002/jps.21154
   Worlitzsch D, 2002, J CLIN INVEST, V109, P317, DOI 10.1172/JCI200213870
   Wu X., 2013, INT J NANOMED, V8, P1
   Wu X, 2013, DRUG DES DEV THER, V7, P59, DOI [10.2147/DDDT.540166, 10.2147/DDDT.S40166]
   Wu XA, 2010, KONA POWDER PART J, P3
   Xu Z, 2011, J ADHES SCI TECHNOL, V25, P451, DOI 10.1163/016942410X525669
   Yu L, 1999, J PHARM SCI, V88, P196, DOI 10.1021/js980323h
NR 36
TC 10
Z9 11
U1 0
U2 30
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3549
EI 1520-6017
J9 J PHARM SCI-US
JI J. Pharm. Sci.
PD SEP
PY 2014
VL 103
IS 9
SI SI
BP 2937
EP 2949
DI 10.1002/jps.23955
PG 13
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology &
   Pharmacy
SC Pharmacology & Pharmacy; Chemistry
GA AN4FB
UT WOS:000340541900033
PM 24740732
DA 2018-03-20
ER

PT J
AU Joshi, S
   Rao, A
   Knutson, BL
   Rankin, SE
AF Joshi, Suvid
   Rao, Alexander
   Knutson, Barbara L.
   Rankin, Stephen E.
TI Imprinted nonporous silica nanoparticles for saccharide adsorption
   without diffusion resistance[p] [p]
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
CT 11th International Biorelated Polymer Symposium / 243rd National Spring
   Meeting of the American-Chemical-Society (ACS)
CY MAR 25-29, 2012
CL San Diego, CA
SP Amer Chem Soc, Div Polymer Chem Inc, Amer Chem Soc
C1 [Joshi, Suvid; Knutson, Barbara L.; Rankin, Stephen E.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Rao, Alex] Univ Massachusetts, Dept Chem Engn, Amherst, MA 01003 USA.
EM suvid.joshi@uky.edu
NR 0
TC 0
Z9 0
U1 0
U2 4
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD MAR 25
PY 2012
VL 243
MA 286-COLL
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA 219AH
UT WOS:000324475103736
DA 2018-03-20
ER

PT J
AU Yu, Y
   Fursule, IA
   Mills, LC
   Englert, DL
   Berron, BJ
   Payne, CM
AF Yu, Yue
   Fursule, Ishan A.
   Mills, Landon C.
   Englert, Derek L.
   Berron, Brad J.
   Payne, Christina M.
TI CHARMM force field parameters for 2 '-hydroxybiphenyl-2-sulfinate,
   2-hydroxybiphenyl, and related analogs
SO JOURNAL OF MOLECULAR GRAPHICS & MODELLING
LA English
DT Article
DE Biodesulfurization; Dibenzothiophene; Parameterization; Petroleum
   refining; Organosulfur compound
ID MOLECULAR-DYNAMICS; FOSSIL-FUELS; MICROBIAL DESULFURIZATION;
   SULFUR-COMPOUNDS; DIBENZOTHIOPHENE; BIODESULFURIZATION;
   HYDRODESULFURIZATION; DERIVATIVES; DESULFINASE; NAPHTHALENE
AB 2'-Hydroxybiphenyl-2-sulfinate (HBPS) desulfinase (DszB) catalyzes the cleavage of the carbon-sulfur bond from HBPS in the final step of microbial 4S pathway desulfurization reactions. DszB is notable for its substrate specificity and exhibits product inhibition, both of which hinder the overall 4S pathway turnover rate. To understand the molecular-level contributions to substrate and inhibitor binding to DszB, we plan to perform molecular dynamic simulations bound to an array of naphthenic molecules and biphenyl analogues of HBPS. However, many of the small molecules we are interested in are not included in standard force field packages, and thus, we must first produce accurate molecular mechanics force fields. Here, we develop and validate CHARMM-compatible force field parameters for the HBPS substrate, the 2-hydroxybiphenyl product, and potential inhibitors including: 2,2'-biphenol, 2-biphenyl carboxylic acid, 1,8-naphthosultam, and 1,8-naphthosultone. The selected molecules represent biphenyl compounds having both a single and double functional group and the planar naphthenic molecule class, all likely present in the oil-rich environment surrounding DszB-producing microorganisms. The Force Field Toolkit (fITK) in VMD was used to optimize charge, bond distance, angle, and dihedral parameters. Optimized geometries were determined from quantum mechanical calculations. Molecular simulations of the molecules in explicit and implicit water solutions were conducted to assess the abilities of optimized parameters to recapitulate optimized geometries. Calculated infrared (IR) spectra were obtained and compared with experimental IR spectra for validation of the optimized MM parameters. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Yu, Yue; Fursule, Ishan A.; Mills, Landon C.; Berron, Brad J.; Payne, Christina M.] Univ Kentucky, Dept Chem & Mat Engn, 177 F Paul Anderson Tower, Lexington, KY 40506 USA.
   [Englert, Derek L.] Univ Kentucky, Dept Chem & Mat Engn, 4810 Alben Barkley Dr, Paducah, KY 42002 USA.
RP Payne, CM (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 F Paul Anderson Tower, Lexington, KY 40506 USA.
EM christy.payne@uky.edu
FU National Science Foundation [ACI-1053575]; American Chemical Society
   Petroleum Research Fund [53861-DNI4]
FX The computational resources for this work were provided by the Extreme
   Science and Engineering Discovery Environment (XSEDE) [47], which is
   supported by National Science Foundation grant number ACI-1053575.
   Additional computational resources for testing and data analysis were
   made available by the Center for Computational Sciences DLX cluster at
   the University of Kentucky. Acknowledgement is made to the Donors of the
   American Chemical Society Petroleum Research Fund for support of this
   research (53861-DNI4). We also thank Mingyang Sun for his technical
   support in graphical analysis.
CR ALMENNINGEN A, 1985, J MOL STRUCT, V128, P59, DOI 10.1016/0022-2860(85)85041-9
   BALASUBR.V, 1966, CHEM REV, V66, P567, DOI 10.1021/cr60244a001
   Brooks BR, 2009, J COMPUT CHEM, V30, P1545, DOI 10.1002/jcc.21287
   Caro A, 2008, BIODEGRADATION, V19, P599, DOI 10.1007/s10532-007-9165-z
   Carrales M., 1975, SULFUR CONTENT CRUDE
   Chen XM, 1996, ACTA CRYSTALLOGR C, V52, P1727, DOI 10.1107/S0108270196002065
   CRUICKSHANK DWJ, 1957, ACTA CRYSTALLOGR, V10, P504, DOI 10.1107/S0365110X57001826
   ElGamacy M, 2015, J CHEMINFORMATICS, V7, DOI 10.1186/s13321-015-0091-5
   Feig M, 2004, J MOL GRAPH MODEL, V22, P377, DOI 10.1016/j.jmgm.2003.12.005
   Folsom BR, 1999, APPL ENVIRON MICROB, V65, P4967
   Frisch M. J., 2009, GAUSSIAN09 REVISION
   Gallagher J.R., 1993, MICROBIAL DESULFURIZ
   Gray KA, 2003, CURR OPIN MICROBIOL, V6, P229, DOI 10.1016/S1369-5274(03)00065-1
   Gray KA, 1996, NAT BIOTECHNOL, V14, P1705, DOI 10.1038/nbt1296-1705
   GRAY MR, 1995, ENERG FUEL, V9, P500, DOI 10.1021/ef00051a015
   Guvench O, 2008, J MOL MODEL, V14, P667, DOI 10.1007/s00894-008-0305-0
   Holthausen M.C., 2001, CHEM GUIDE DENSITY F
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Javadli R, 2012, APPL PETROCHEM RES, V1, P3, DOI 10.1007/s13203-012-0006-6
   KABE T, 1992, IND ENG CHEM RES, V31, P1577, DOI 10.1021/ie00006a023
   Kilbane JJ, 2006, CURR OPIN BIOTECH, V17, P305, DOI 10.1016/j.copbio.2006.04.005
   KODAMA K, 1973, AGR BIOL CHEM TOKYO, V37, P45, DOI 10.1080/00021369.1973.10860640
   Le Borgne S, 2003, FUEL PROCESS TECHNOL, V81, P155, DOI 10.1016/S0378-3820(03)00007-9
   Leprince P., 2001, BST PETROLEUM REFINI, V3
   Li H., 2013, J CHEM SCI TECHNOL, V2, P209
   MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f
   Mackerell AD, 2004, J COMPUT CHEM, V25, P1584, DOI 10.1002/jcc.20082
   Mayne CG, 2013, J COMPUT CHEM, V34, P2757, DOI 10.1002/jcc.23422
   McFarland BL, 1999, CURR OPIN MICROBIOL, V2, P257, DOI 10.1016/S1369-5274(99)80045-9
   Morrow TI, 2002, J PHYS CHEM B, V106, P12807, DOI 10.1021/jp0267003
   Nakayama N, 2002, BBA-PROTEINS PROTEOM, V1598, P122, DOI 10.1016/S0167-4838(02)00365-5
   NELDER JA, 1965, COMPUT J, V7, P308, DOI 10.1093/comjnl/7.4.308
   Ohshiro T, 1999, BIOSCI BIOTECH BIOCH, V63, P1, DOI 10.1271/bbb.63.1
   Oldfield C, 1997, MICROBIOL-UK, V143, P2961, DOI 10.1099/00221287-143-9-2961
   PERRIN M, 1987, ACTA CRYSTALLOGR C, V43, P980, DOI 10.1107/S0108270187093351
   Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289
   Press WH, 1990, NUMERICAL RECIPES
   Rana MS, 2007, FUEL, V86, P1216, DOI 10.1016/j.fuel.2006.08.004
   Stein S.E., NIST STANDARD REFERE, V69
   Swaty TE, 2005, HYDROCARB PROCESS, V84, P35
   Tanner DE, 2011, J CHEM THEORY COMPUT, V7, P3635, DOI 10.1021/ct200563j
   Towns J, 2014, COMPUT SCI ENG, V16, P62, DOI 10.1109/MCSE.2014.80
   Vanommeslaeghe K, 2012, J CHEM INF MODEL, V52, P3144, DOI 10.1021/ci300363c
   Vanommeslaeghe K, 2010, J COMPUT CHEM, V31, P671, DOI 10.1002/jcc.21367
   Watkins LM, 2003, ARCH BIOCHEM BIOPHYS, V415, P14, DOI 10.1016/S0003-9861(03)00230-3
   Yu WB, 2012, J COMPUT CHEM, V33, P2451, DOI 10.1002/jcc.23067
NR 46
TC 2
Z9 2
U1 2
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1093-3263
EI 1873-4243
J9 J MOL GRAPH MODEL
JI J. Mol. Graph.
PD MAR
PY 2017
VL 72
BP 32
EP 42
DI 10.1016/j.jmgm.2016.12.005
PG 11
WC Biochemical Research Methods; Biochemistry & Molecular Biology; Computer
   Science, Interdisciplinary Applications; Crystallography; Mathematical &
   Computational Biology
SC Biochemistry & Molecular Biology; Computer Science; Crystallography;
   Mathematical & Computational Biology
GA EN2LM
UT WOS:000395841700005
PM 28027509
DA 2018-03-19
ER

PT J
AU Meenach, SA
   Anderson, AA
   Suthar, M
   Anderson, KW
   Hilt, JZ
AF Meenach, Samantha A.
   Anderson, A. Ashley
   Suthar, Mehul
   Anderson, Kimberly W.
   Hilt, J. Zach
TI Biocompatibility analysis of magnetic hydrogel nanocomposites based on
   poly(N-isopropylacrylamide) and iron oxide
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
LA English
DT Article
DE hydrogel; nanocomposites; magnetism; thermally responsive material;
   biocompatibility
ID POLYMER GELS; NANOPARTICLES; HYPERTHERMIA
AB With the growing interest in nanocomposites and their applications in biology and medicine, studies examining the biocompatibility of those materials are critical. Magnetic hydrogel nanocomposites based on poly (N-isopropylacrylamide) and iron oxide nanoparticles were fabricated via UV-polymerization with tetra(ethylene glycol) dimethacrylate acting as the crosslinking agent. hi vitro biocompatibility analysis via NIH 3T3 murine fibroblast cytotoxicity was investigated. The fibroblasts in both direct and indirect contact with the hydrogels exhibited favorable cell viability indicating minimal cytotoxicity of the systems. In addition, swelling studies indicated that hydrogels with lower crosslink densities yield higher swelling ratios and that the presence of magnetic nanoparticle did not affect the swelling response of the hydrogel systems. Upon exposure to an alternating magnetic field, the hydrogel nanocomposites with iron oxide nanoparticles showed the capability for remote heating. This evaluation shows that these hydrogels have the potential to be used in biomedical applications such as drug delivery and hyperthermia for cancer treatment. (C) 2008 Wiley Periodicals, Inc. J Biomed Mater Res 91A: 903-909, 2009
C1 [Meenach, Samantha A.; Anderson, A. Ashley; Suthar, Mehul; Anderson, Kimberly W.; Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Hilt, JZ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 F Paul Anderson Tower, Lexington, KY 40506 USA.
EM hilt@engr.uky.edu
RI Meenach, Samantha/F-7542-2014
FU Kentucky Science and Engineering Foundation; NSF-IGERT
FX Contract grant sponsors: Kentucky Science and Engineering Foundation,
   NSF-IGERT
CR Babincova M, 2001, J MAGN MAGN MATER, V225, P109, DOI 10.1016/S0304-8853(00)01237-3
   Bashir R, 2002, APPL PHYS LETT, V81, P3091, DOI 10.1063/1.1514825
   BISWAL D, 2008, BIOMED MICRODEVICES, V10, P1572
   Biswal D, 2006, POLYMER, V47, P7355, DOI 10.1016/j.polymer.2006.08.028
   Brunner TJ, 2006, ENVIRON SCI TECHNOL, V40, P4374, DOI 10.1021/es052069i
   Frimpong R.A., 2006, J BIOMED MATER RES A, V80, P1
   Frimpong R. A., 2007, NANOTECHNOLOGY THERA, P241
   Hergt R., 2006, J PHYS-CONDENS MAT, V18, P52919, DOI DOI 10.1088/0953-8984/18/38/S26
   Hilt JZ, 2006, CHEM MATER, V18, P5869, DOI 10.1021/cm061343k
   Hilt JZ, 2003, BIOMED MICRODEVICES, V5, P177, DOI 10.1023/A:1025786023595
   Hoffman A. S., 2002, ADV DRUG DELIVERY RE, V43, P3, DOI DOI 10.1016/S0169-409X(01)00239-3
   Liu WT, 2006, J BIOSCI BIOENG, V102, P1, DOI 10.1263/jbb.102.1
   Neuberger T, 2005, J MAGN MAGN MATER, V293, P483, DOI 10.1016/j.jmmm.2005.01.064
   Peppas NA, 2000, EUR J PHARM BIOPHARM, V50, P27, DOI 10.1016/S0939-6411(00)00090-4
   Peppas NA, 2006, ADV MATER, V18, P1345, DOI 10.1002/adma.200501612
   Satarkar NS, 2008, ACTA BIOMATER, V4, P11, DOI 10.1016/j.actbio.2007.07.009
   SCHILD HG, 1992, PROG POLYM SCI, V17, P163, DOI 10.1016/0079-6700(92)90023-R
   Williams D. F., 1986, DEFINITIONS BIOMATER
   Xulu PM, 2000, MACROMOLECULES, V33, P1716, DOI 10.1021/ma990967r
   Yang JK, 2007, MAT SCI ENG A-STRUCT, V449, P477, DOI 10.1016/j.msea.2006.02.336
   Zrinyi M, 1998, POLYM GELS NETW, V6, P441, DOI 10.1016/S0966-7822(98)00033-1
   Zrinyi M, 2000, COLLOID POLYM SCI, V278, P98, DOI 10.1007/s003960050017
NR 22
TC 39
Z9 39
U1 1
U2 39
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1549-3296
J9 J BIOMED MATER RES A
JI J. Biomed. Mater. Res. Part A
PD DEC 1
PY 2009
VL 91A
IS 3
BP 903
EP 909
DI 10.1002/jbm.a.32322
PG 7
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 517BW
UT WOS:000271588800028
PM 19090484
DA 2018-03-19
ER

PT J
AU Gutierrez, J
   Eisenberg, R
   Herrensmith, G
   Tobin, T
   Li, TL
   Long, SH
AF Gutierrez, Julio
   Eisenberg, Rodney
   Herrensmith, Gabrielle
   Tobin, Thomas
   Li, Tonglei
   Long, Sihui
TI Polymorphism in
   2-(4-hydroxy-2,6-dimethylanilino)-5,6-dihydro-4H-1,3-thiazin-3-ium
   chloride
SO ACTA CRYSTALLOGRAPHICA SECTION C-CRYSTAL STRUCTURE COMMUNICATIONS
LA English
DT Article
AB Details of the structures of two conformational polymorphs of the title compound, C(12)H(17)N(2)OS(+)center dot Cl(-), are reported. In form (I) (space group P (1) over bar), the two N-H groups of the cation are in a trans conformation, while in form (II) (space group P2(1)/c), they are in a cis arrangement. This results in different packing and hydrogen-bond arrangements in the two forms, both of which have extended chains lying along the a direction. In form (I), these chains are composed of centrosymmetric R(4)(2)(18) (N-H center dot center dot center dot Cl and O-H center dot center dot center dot Cl) hydrogen-bonded rings and R(2)(2)(18) (N-H center dot center dot center dot O) hydrogen-bonded rings. In form (II), the chains are formed by centrosymmetric R(4)(2)(18) (N-H center dot center dot center dot Cl and O-H center dot center dot center dot Cl) hydrogen-bonded rings and by R(4)(2)(12) (N-H center dot center dot center dot Cl) hydrogen-bonded rings.
C1 [Li, Tonglei; Long, Sihui] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
   [Gutierrez, Julio; Herrensmith, Gabrielle; Tobin, Thomas] Univ Kentucky, Maxwell H Gluck Equine Ctr, Lexington, KY 40546 USA.
   [Eisenberg, Rodney] Frontier Biopharm, Richmond, KY 40475 USA.
RP Long, SH (reprint author), Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
EM slong0@email.uky.edu
FU National Horsemen's Benevolent and Protective Association; West Virginia
   Horsemen's Benevolent; Protective Associations; Florida Horsemen's
   Charitable Foundation; Oklahoma Quarter Horse Racing Association; Neogen
   Corporation
FX Published as paper No. 392 from the Equine Pharmacology, Therapeutics
   and Toxicology Program at the Maxwell H. Gluck Equine Research Center
   and Department of Veterinary Science, University of Kentucky. Published
   as Kentucky Agricultural Experiment Station Article No. 10-14-123 with
   the approval of the Dean and Director, College of Agriculture and the
   Kentucky Agricultural Experimental Station. This work was made possible
   by research support from The National Horsemen's Benevolent and
   Protective Association and the Alabama, Arizona, Arkansas, Canada,
   Charles Town (West Virginia), Florida, Iowa, Indiana, Kentucky,
   Louisiana, Michigan, Minnesota, Nebraska, Ohio, Oklahoma, Ontario
   (Canada), Oregon, Pennsylvania, Tampa Bay Downs (Florida), Texas,
   Washington State, and West Virginia Horsemen's Benevolent and Protective
   Associations and the Florida Horsemen's Charitable Foundation, the
   Oklahoma Quarter Horse Racing Association and the Neogen Corporation.
   The authors also thank Charlie Hughes for his assistance during the
   synthesis and Dr Sean Parkin for helpful discussions.
CR BERNSTEIN J, 1995, ANGEW CHEM INT EDIT, V34, P1555, DOI 10.1002/anie.199515551
   Bernstein J., 2002, POLYMORPHISM MOL CRY
   BERNSTEIN J, 1987, Elsevier, V32, P471
   Kai H, 2007, BIOORG MED CHEM LETT, V17, P3925, DOI 10.1016/j.bmcl.2007.04.099
   McCrone W. C., 1965, PHYSICS CHEMISTRY OR, VII, P725
   MUTLIB AE, 1992, DRUG METAB DISPOS, V20, P840
   Nonius, 2002, COLLECT
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930
NR 9
TC 1
Z9 1
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0108-2701
J9 ACTA CRYSTALLOGR C
JI Acta Crystallogr. Sect. C-Cryst. Struct. Commun.
PD DEC
PY 2010
VL 66
BP O593
EP O595
DI 10.1107/S0108270110045099
PN 12
PG 3
WC Chemistry, Multidisciplinary; Crystallography
SC Chemistry; Crystallography
GA 692FD
UT WOS:000285137500015
PM 21123891
DA 2018-03-20
ER

PT J
AU Ambati, J
   Rankin, SE
AF Ambati, Jyothirmai
   Rankin, Stephen E.
TI Reaction-induced phase separation of bis(triethoxysilyl)ethane upon
   sot-gel polymerization in acidic conditions
SO JOURNAL OF COLLOID AND INTERFACE SCIENCE
LA English
DT Article
DE Organoalkoxysilane; Sol-gel polymerization; NMR; Signal loss; Microphase
   separation; Alkoxysilane; Bridged; Polymerization; In situ
ID SI-29 NMR-SPECTROSCOPY; SILICALITE-1 ZEOLITE SYNTHESIS; MESOPOROUS
   ORGANOSILICAS PMOS; SPIN-LATTICE-RELAXATION; POLARIZATION TRANSFER;
   CLEAR SOLUTIONS; BRIDGED POLYSILSESQUIOXANES; CONDENSATION-REACTIONS;
   ALKOXYSILANE POLYMERS; CHEMICAL-SHIFTS
AB While organically bridged alkoxysilane precursors such as bis(triethoxysilyl)ethane (BTESE) find increasing use in materials synthesis, their polymerization still has not been subject to detailed kinetic investigations. One factor complicating the measurement and interpretation of the behavior of these monomers is their tendency to aggregate during polymerization into small clusters or particles. Here, the phase behavior and kinetics of BTESE during polymerization in acidic water-ethanol solutions are investigated in situ using (29)Si NMR spectroscopy. Based on macroscopic observation of the colloidal stability of the reacting solutions, a ternary pseudo-phase diagram is constructed and solutions that seem from a macroscopic point of view to be favorable for kinetic investigation are probed in situ using (29)Si NMR. However, even when the solutions remain optically clear, the polymerization mixtures are sometimes prone to gradual loss of NMR signal. The rate of signal loss is found to be dependent on the initial composition as well as the pH of the reacting mixtures. We speculate that this phenomenon is caused by microphase separation of reaction intermediates formed early in the polymerization process. This phenomenon is likely to affect the formation and distribution of oligomers in the solution that eventually react together to form a material. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Ambati, Jyothirmai; Rankin, Stephen E.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Rankin, SE (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM srankin@engr.uky.edu
RI Rankin, Stephen/A-3265-2013
OI Rankin, Stephen/0000-0002-8615-7564; Ambati,
   Jyothirmai/0000-0003-2420-3665
FU National Science Foundation [CBET-0348234]; US Department of Energy
   [DE-FG02-07ER46375]
FX This report is based on research partially funded by the National
   Science Foundation (Grant No. CBET-0348234) and the US Department of
   Energy (Grant No. DE-FG02-07ER46375). We acknowledge the NMR facility at
   the University of Kentucky for providing access to the spectrometers,
   and Mr. John Layton for helpful discussions of the NMR experiments.
CR Aerts A, 2007, CHEM MATER, V19, P3448, DOI 10.1021/cm070693j
   Alam TM, 1996, MAGN RESON CHEM, V34, P603, DOI 10.1002/(SICI)1097-458X(199608)34:8<603::AID-OMR917>3.0.CO;2-L
   Alam TM, 1996, MATER RES SOC SYMP P, V435, P421, DOI 10.1557/PROC-435-421
   Ambati J, 2010, J PHYS CHEM A, V114, P12613, DOI 10.1021/jp105644p
   ASSINK RA, 1991, ANNU REV MATER SCI, V21, P491
   Blinka T. A., 1984, ADV ORGANOMET CHEM, V23, P193
   Brinker C.J., 1990, SOL GEL SCI PHYS CHE
   BRUNET F, 1994, NEW J CHEM, V18, P1059
   BRUNET F, 1991, J PHYS CHEM-US, V95, P945, DOI 10.1021/j100155a082
   Brunet F, 1998, J NON-CRYST SOLIDS, V231, P58, DOI 10.1016/S0022-3093(98)00403-7
   Brus J, 1996, CHEM LISTY, V90, P316
   BURTON DJ, 1983, POLYM COMMUN, V24, P278
   Cheng CH, 2006, J PHYS CHEM B, V110, P313, DOI 10.1021/jp055124i
   Cho H, 2006, J AM CHEM SOC, V128, P2324, DOI 10.1021/ja0559202
   Claridge T. D. W., 1999, HIGH RESOLUTION NMR
   Cui XH, 2008, LANGMUIR, V24, P10771, DOI 10.1021/la801705y
   Dabrowski A, 2007, CROAT CHEM ACTA, V80, P367
   Diaz-Benito B, 2010, COLLOID SURFACE A, V369, P53, DOI 10.1016/j.colsurfa.2010.07.036
   DODDRELL DM, 1982, J MAGN RESON, V48, P323, DOI 10.1016/0022-2364(82)90286-4
   Dong HJ, 2007, J SOL-GEL SCI TECHN, V41, P11, DOI 10.1007/s10971-006-0115-8
   Dong HJ, 2003, J SOL-GEL SCI TECHN, V28, P5, DOI 10.1023/A:1025690300105
   DOTSON NA, 1996, NONLINEAR POLYM
   DOUGHTY DH, 1990, ADV CHEM SER, P241
   Fedeyko JM, 2004, J PHYS CHEM B, V108, P12271, DOI 10.1021/jp047623+
   Follens LRA, 2008, PHYS CHEM CHEM PHYS, V10, P5574, DOI 10.1039/b805520c
   Franquet A, 2004, J ADHES SCI TECHNOL, V18, P765, DOI 10.1163/156856104840282
   GANSOW OA, 1972, J AM CHEM SOC, V94, P2550, DOI 10.1021/ja00762a081
   Gomez-Romero R., 2004, FUNCTIONAL HYBRID MA, P1
   HENCH LL, 1990, CHEM REV, V90, P33, DOI 10.1021/cr00099a003
   Hoebbel D, 1996, J SOL-GEL SCI TECHN, V7, P217, DOI 10.1007/BF00401040
   Hook RJ, 1996, J NON-CRYST SOLIDS, V195, P1, DOI 10.1016/0022-3093(95)00508-0
   Hunks WJ, 2005, J MATER CHEM, V15, P3716, DOI 10.1039/b504511h
   Jiang HM, 2006, IND ENG CHEM RES, V45, P8617, DOI 10.1021/ie0607550
   Kay B. D., 1986, MATER RES SOC S P, V73, P157
   KINRADE SD, 1988, INORG CHEM, V27, P4253, DOI 10.1021/ic00296a034
   KINTZINGER JP, 1981, OXYGEN 17 SILICON 29
   Kirschhock CEA, 1999, J PHYS CHEM B, V103, P4965, DOI 10.1021/jp990297r
   Knight CTG, 2006, PHYS CHEM CHEM PHYS, V8, P3099, DOI 10.1039/b606419a
   Kragten DD, 2003, J PHYS CHEM B, V107, P10006, DOI 10.1021/jp035110h
   Lebeau B, 2009, ORDERED POROUS SOLIDS: RECENT ADVANCES AND PROSPECTS, P283, DOI 10.1016/B978-0-444-53189-6.00011-1
   Lee K, 1997, J COLLOID INTERF SCI, V194, P78, DOI 10.1006/jcis.1997.5089
   Lee KT, 1998, COLLOID SURFACE A, V144, P115, DOI 10.1016/S0927-7757(98)00566-4
   LEVY GC, 1972, J MAGN RESON, V8, P399, DOI 10.1016/0022-2364(72)90058-3
   Li GZ, 2001, J INORG ORGANOMET P, V11, P123, DOI 10.1023/A:1015287910502
   Loy DA, 1999, J AM CHEM SOC, V121, P5413, DOI 10.1021/ja982751v
   LOY DA, 1995, CHEM REV, V95, P1431, DOI 10.1021/cr00037a013
   Loy DA, 1996, J AM CHEM SOC, V118, P8501, DOI 10.1021/ja961409k
   Lux P, 1996, MAGN RESON CHEM, V34, P100, DOI 10.1002/(SICI)1097-458X(199602)34:2<100::AID-OMR844>3.0.CO;2-4
   LUX P, 1993, MAGN RESON CHEM, V31, P623, DOI 10.1002/mrc.1260310704
   Matejka L, 2001, MACROMOLECULES, V34, P6904, DOI 10.1021/ma010136x
   Matinlinna JP, 2010, SILICON-NETH, V2, P87, DOI 10.1007/s12633-010-9041-z
   Mintova S, 2002, MICROPOR MESOPOR MAT, V55, P171, DOI 10.1016/S1387-1811(02)00401-8
   Myers SA, 2000, J CHEM SOC PERK T 2, P545, DOI 10.1039/a906569e
   Na W, 2010, MICROPOR MESOPOR MAT, V134, P72, DOI 10.1016/j.micromeso.2010.05.009
   Petry DP, 2009, J PHYS CHEM C, V113, P20827, DOI 10.1021/jp906276g
   Ponton A, 2002, J COLLOID INTERF SCI, V249, P209, DOI 10.1006/jcis.2002.8227
   POUXVIEL JC, 1987, J NON-CRYST SOLIDS, V89, P345, DOI 10.1016/S0022-3093(87)80277-6
   Pu ZC, 1997, J ADHES SCI TECHNOL, V11, P29
   Rankin SE, 2000, MACROMOLECULES, V33, P7743, DOI 10.1021/ma0004920
   Rankin SE, 1998, AICHE J, V44, P1141, DOI 10.1002/aic.690440512
   Rankin SE, 1999, J PHYS CHEM A, V103, P4233, DOI 10.1021/jp990304b
   Rimer JD, 2006, CHEM-EUR J, V12, P2926, DOI 10.1002/chem.200500684
   Sakka S., 2005, HDB SOL GEL SCI TECH
   Sanchez J, 1996, IND ENG CHEM RES, V35, P117, DOI 10.1021/ie950246q
   SEYFERTH D, 1993, MACROMOLECULES, V26, P407, DOI 10.1021/ma00055a001
   Shea KJ, 2001, ACCOUNTS CHEM RES, V34, P707, DOI 10.1021/ar000109b
   Shiraishi Y, 2010, NEW J CHEM, V34, P2841, DOI 10.1039/c0nj00423e
   Spirk S, 2008, ORGANOMETALLICS, V27, P500, DOI 10.1021/om701212j
   Stebbins JF, 2009, AM MINERAL, V94, P905, DOI 10.2138/am.2009.3184
   SUGAHARA Y, 1992, J NON-CRYST SOLIDS, V139, P25, DOI 10.1016/S0022-3093(05)80802-6
   Tan B, 2006, J PHYS CHEM B, V110, P22353, DOI 10.1021/jp060376k
   TAYLOR RB, 1991, CHEM ANAL
   Yang HQ, 2010, J PHYS CHEM C, V114, P22221, DOI 10.1021/jp108519f
   Yang SY, 2004, CHEM MATER, V16, P210, DOI 10.1021/cm030587r
   Yang SY, 2002, CHEM MATER, V14, P2803, DOI 10.1021/cm0200689
   Zhang ZP, 2003, J SOL-GEL SCI TECHN, V28, P159, DOI 10.1023/A:1026098729993
NR 76
TC 8
Z9 8
U1 0
U2 27
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0021-9797
J9 J COLLOID INTERF SCI
JI J. Colloid Interface Sci.
PD OCT 15
PY 2011
VL 362
IS 2
BP 345
EP 353
DI 10.1016/j.jcis.2011.06.064
PG 9
WC Chemistry, Physical
SC Chemistry
GA 810QP
UT WOS:000294142500014
PM 21788023
DA 2018-03-20
ER

PT J
AU He, ZW
   Satarkar, N
   Xie, T
   Cheng, YT
   Hilt, JZ
AF He, Zhengwang
   Satarkar, Nitin S.
   Xie, Tao
   Cheng, Y-T.
   Hilt, J. Zach
TI Remote Controlled Multishape Polymer Nanocomposites with Selective
   Radiofrequency Actuations
SO ADVANCED MATERIALS
LA English
DT Article
ID SHAPE-MEMORY POLYMERS; NANOPARTICLES; COMPOSITES; NETWORKS
AB A multicomposite shape memory polymer (SMP) with remote and selective triggering of the recovery of multiple temporary shapes in radiofrequency fields is demonstrated. Each deformed region can be independently actuated at a specific frequency based on the filler type in the region. In addition, the nanocomposite SMP exhibits multiple temporary shapes and multiple possible shape recovery routes.
C1 [Xie, Tao] Gen Motors Global Res & Dev, Chem Sci & Mat Syst Lab, Warren, MI 48090 USA.
   [He, Zhengwang; Satarkar, Nitin; Cheng, Yang-Tse; Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Xie, T (reprint author), Gen Motors Global Res & Dev, Chem Sci & Mat Syst Lab, 30500 Mound Rd, Warren, MI 48090 USA.
EM tao.xie@gm.com; hilt@engr.uky.edu
RI Xie, Tao/B-2323-2009; Xie, Tao/H-8633-2013; He, Zhengwang/C-6727-2017;
   Cheng, Yang-Tse/B-5424-2012
OI He, Zhengwang/0000-0003-4271-5728; Cheng, Yang-Tse/0000-0003-0737-9212
CR Behl M, 2007, MATER TODAY, V10, P20, DOI 10.1016/S1369-7021(07)70047-0
   Behl M, 2010, ADV MATER, V22, P3388, DOI 10.1002/adma.200904447
   Behl M, 2009, ADV FUNCT MATER, V19, P102, DOI 10.1002/adfm.200800850
   Bellin I, 2006, P NATL ACAD SCI USA, V103, P18043, DOI 10.1073/pnas.0608586103
   Gall K, 2004, J MICROELECTROMECH S, V13, P472, DOI 10.1109/JMEMS.2004.828727
   Gunes IS, 2009, CARBON, V47, P981, DOI 10.1016/j.carbon.2008.11.053
   Huang WM, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1880448
   Koerner H, 2004, NAT MATER, V3, P115, DOI 10.1038/nmat1059
   Kumar UN, 2010, J MATER CHEM, V20, P3404, DOI 10.1039/b923000a
   Lendlein A, 2002, SCIENCE, V296, P1673, DOI 10.1126/science.1066102
   Luo XF, 2010, ADV FUNCT MATER, V20, P2649, DOI 10.1002/adfm.201000052
   Luo XF, 2010, SOFT MATTER, V6, P2146, DOI 10.1039/c001295e
   Mather PT, 2009, ANNU REV MATER RES, V39, P445, DOI 10.1146/annurev-matsci-082908-145419
   Mohr R, 2006, P NATL ACAD SCI USA, V103, P3540, DOI 10.1073/pnas.0600079103
   Neuss S, 2009, BIOMATERIALS, V30, P1697, DOI 10.1016/j.biomaterials.2008.12.027
   Roh KH, 2006, J AM CHEM SOC, V128, P6796, DOI 10.1021/ja060836n
   Rousseau IA, 2010, J MATER CHEM, V20, P3431, DOI 10.1039/b923394f
   Small W, 2005, IEEE J SEL TOP QUANT, V11, P892, DOI 10.1109/JSTQE.2005.857748
   Wang RM, 2010, MACROMOL RAPID COMM, V31, P295, DOI 10.1002/marc.200900594
   Xiao XC, 2010, J MATER CHEM, V20, P3508, DOI 10.1039/c0jm00307g
   Xie T, 2008, CHEM MATER, V20, P2866, DOI 10.1021/cm800173c
   Xie T, 2010, ADV MATER, V22, P4390, DOI 10.1002/adma.201002825
   Xie T, 2010, NATURE, V464, P267, DOI 10.1038/nature08863
   Xie T, 2009, MACROMOL RAPID COMM, V30, P1823, DOI 10.1002/marc.200900409
   Xie T, 2009, POLYMER, V50, P1852, DOI 10.1016/j.polymer.2009.02.035
   Yakacki CM, 2009, J APPL POLYM SCI, V112, P3166, DOI 10.1002/app.29845
NR 26
TC 114
Z9 118
U1 8
U2 102
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0935-9648
J9 ADV MATER
JI Adv. Mater.
PD JUL 26
PY 2011
VL 23
IS 28
BP 3192
EP +
DI 10.1002/adma.201100646
PG 6
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 809YD
UT WOS:000294091700014
PM 21638345
DA 2018-03-20
ER

PT J
AU Hickman, AN
   Nokes, SE
   Sympson, WS
   Ruwaya, MJ
   Montross, M
   Knutson, BL
AF Hickman, Amanda N.
   Nokes, Sue E.
   Sympson, William S.
   Ruwaya, Mathew J.
   Montross, Michael
   Knutson, Barbara L.
TI The Confounding Effects of Particle Size and Substrate Bulk Density on
   Phanerochaete chrysosporium Pretreatment of Panicum virgatum
SO BIORESOURCES
LA English
DT Article
DE Phanerochaete chrysosporium; White rot fungi; Switchgrass; Biological
   pretreatment; Lignocellulose
ID MICROBIAL PRETREATMENT; FUNGAL PRETREATMENT;
   CERIPORIOPSIS-SUBVERMISPORA; LIGNOCELLULOSIC BIOMASS;
   ENZYMATIC-HYDROLYSIS; ETHANOL-PRODUCTION; COTTON STALKS; CORN STOVER;
   STRAW; SACCHARIFICATION
AB Phanerochaete chrysosporium treatment is less effective as a biological pretreatment on feedstock with larger particle sizes. We hypothesized that the improved effectiveness of the pretreatment when smaller particle sizes are used may be due to the inherently higher bulk density with smaller particle sizes. The effects of substrate bulk density and particle size on the efficacy of P. chrysosporium pretreatment of switchgrass (Panicum virgatum) was tested experimentally. Phanerochaete chrysosporium was grown on senesced switchgrass (2 different particle sizes) with various bulk densities. In all treatments, the fungal-pretreated samples released more glucose during enzymatic saccharification than the control sample. Substrate bulk density was a statistically significant factor in explaining the variation in the amount of glucose released per gram of substrate used. However, the particle size was not found to be a significant factor. On-farm switchgrass pretreatment may not require particle size reduction if the switchgrass is supplied in high-density bales.
C1 [Hickman, Amanda N.; Nokes, Sue E.; Sympson, William S.; Ruwaya, Mathew J.; Montross, Michael] Univ Kentucky, Dept Biosyst & Agr Engn, Lexington, KY USA.
   [Knutson, Barbara L.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY USA.
RP Nokes, SE (reprint author), Univ Kentucky, Dept Biosyst & Agr Engn, Lexington, KY USA.
EM sue.nokes@uky.edu
FU United States Department of Agriculture National Institute for Food and
   Agriculture, Biomass Research and Development Initiative grant
   [2011-10006-30363]; National Institute of Food and Agriculture, U.S.
   Department of Agriculture, Hatch-Multistate project [1003563]
FX The authors sincerely acknowledge the financial support of the United
   States Department of Agriculture National Institute for Food and
   Agriculture, Biomass Research and Development Initiative grant
   #2011-10006-30363. This is publication No. 16-05-030 of the Kentucky
   Agricultural Experiment Station and is published with the approval of
   the Director. This work is supported by the National Institute of Food
   and Agriculture, U.S. Department of Agriculture, Hatch-Multistate
   project under accession number 1003563.
CR Bak JS, 2009, BIOTECHNOL BIOENG, V104, P471, DOI 10.1002/bit.22423
   Bitra VSR, 2009, POWDER TECHNOL, V193, P32, DOI 10.1016/j.powtec.2009.02.010
   Couto SR, 2005, BIOCHEM ENG J, V22, P211, DOI 10.1016/j.bej.2004.09.013
   KONDO R, 1994, APPL ENVIRON MICROB, V60, P921
   Liong YY, 2012, BIORESOURCES, V7, P5500
   Liu JY, 2015, J CLEAN PROD, V104, P480, DOI 10.1016/j.jclepro.2015.04.094
   Lotjonen T, 2013, BIOMASS BIOENERG, V51, P53, DOI 10.1016/j.biombioe.2012.12.041
   Mahalaxmi S, 2010, APPL BIOCHEM BIOTECH, V162, P1414, DOI 10.1007/s12010-010-8917-0
   Mani S, 2006, BIOMASS BIOENERG, V30, P648, DOI 10.1016/j.biombioe.2005.01.004
   Montross M., 2015, COMMUNICATION
   Moreno AD, 2015, CRIT REV BIOTECHNOL, V35, P342, DOI 10.3109/07388551.2013.878896
   Pinto PA, 2012, BIORESOURCE TECHNOL, V111, P261, DOI 10.1016/j.biortech.2012.02.068
   Capareda S., 2015, BIORESOUR BIOPROCESS, V2, P1, DOI DOI 10.1186/S40643-015-0049-5
   Raimbault M., 1998, EJB, Electronic Journal of Biotechnology, V1, P1
   Ray A, 2012, APPL MICROBIOL BIOT, V93, P2075, DOI 10.1007/s00253-012-3907-5
   Richard TL, 2010, SCIENCE, V329, P793, DOI 10.1126/science.1189139
   Selig M., 2008, NRELTP51042629 LAP
   Shi J, 2009, BIOMASS BIOENERG, V33, P88, DOI 10.1016/j.biombioe.2008.04.016
   Shi J, 2008, BIORESOURCE TECHNOL, V99, P6556, DOI 10.1016/j.biortech.2007.11.069
   Shirkavand E, 2016, RENEW SUST ENERG REV, V54, P217, DOI 10.1016/j.rser.2015.10.003
   Steel RGD, 1980, PRINCIPLES PROCEDURE
   Wan CX, 2011, BIORESOURCE TECHNOL, V102, P7507, DOI 10.1016/j.biortech.2011.05.026
   Wan CX, 2010, BIORESOURCE TECHNOL, V101, P6398, DOI 10.1016/j.biortech.2010.03.070
NR 23
TC 0
Z9 0
U1 0
U2 4
PU NORTH CAROLINA STATE UNIV DEPT WOOD & PAPER SCI
PI RALEIGH
PA CAMPUS BOX 8005, RALEIGH, NC 27695-8005 USA
SN 1930-2126
J9 BIORESOURCES
JI BioResources
PD AUG
PY 2016
VL 11
IS 3
BP 7500
EP 7511
DI 10.15376/biores.11.3.7500-7511
PG 12
WC Materials Science, Paper & Wood
SC Materials Science
GA DY2KV
UT WOS:000384922400142
OA gold
DA 2018-03-20
ER

PT J
AU Sundararaj, SKC
   Cieply, RD
   Gupta, G
   Milbrandt, TA
   Puleo, DA
AF Sundararaj, Sharath Kumar C.
   Cieply, Ryan D.
   Gupta, Gautam
   Milbrandt, Todd A.
   Puleo, David A.
TI Treatment of growth plate injury using IGF-I-loaded PLGA scaffolds
SO JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE
LA English
DT Article
DE PLGA; IGF-I; growth plate; drug delivery; tissue engineering; scaffold
ID FIBRIN GLUE; STEM-CELLS; CARTILAGE; CHONDROCYTES; DELIVERY; THERAPY;
   RELEASE; ARREST; CANCER; DRUG
AB Growth plate fracture can lead to retarded growth and unequal limb length, which may have a lifelong effect on a person's physical stature. The goal of this research was to develop an in vivo tissue-engineering approach for the treatment of growth plate injury via localized delivery of insulin-like growth factor I (IGF-I) from cell-free poly(lactic-co-glycolic acid) (PLGA) scaffolds. Mass loss and drug release studies were conducted to study the scaffold degradation and IGF-I release patterns. In vitro cell studies showed that rat bone marrow stromal cells seeded on the porous scaffolds colonized the pores and deposited matrix within the scaffolds. These in vitro evaluations were followed by a proof-of-concept animal study involving implantation of scaffolds in proximal tibial growth plate defects in New Zealand white rabbits. Histological analysis of tissue sections from the in vivo studies showed regeneration of cartilage, albeit with disorganized structure, at the site of implantation of IGF-I-releasing scaffolds; in contrast, only bone was formed in empty defects and those treated with IGF-free scaffolds. The present findings show the potential for treating growth plate injury using in vivo tissue engineering techniques. Copyright (C) 2012 John Wiley & Sons, Ltd.
C1 [Sundararaj, Sharath Kumar C.; Gupta, Gautam; Puleo, David A.] Univ Kentucky, Ctr Biomed Engn, 209 Wenner Gren Lab, Lexington, KY 40506 USA.
   [Cieply, Ryan D.; Milbrandt, Todd A.] Univ Kentucky, Dept Orthoped Surg, Lexington, KY 40506 USA.
   [Milbrandt, Todd A.] Shriners Hosp Children, Lexington, KY USA.
RP Puleo, DA (reprint author), Univ Kentucky, Ctr Biomed Engn, 209 Wenner Gren Lab, Lexington, KY 40506 USA.
EM puleo@uky.edu
FU Kosair Charities Inc
FX This work was supported in part by Kosair Charities Inc. The authors
   also thank Linda A. Simmerman for her assistance with obtaining images
   of tissue sections and Amanda Clark for the SEM image.
CR Balhara B, 2012, INDIAN J PEDIATR, V79, P244, DOI 10.1007/s12098-011-0608-5
   Banakar UV, 1997, J BIOMATER APPL, V11, P377, DOI 10.1177/088532829701100402
   Boyer MI, 2007, ORTHOP CLIN N AM, V38, P103, DOI 10.1016/j.ocl.2006.10.002
   Chen F, 2003, J PEDIATR ORTHOPED, V23, P425, DOI 10.1097/00004694-200307000-00002
   Eid AM, 2002, INJURY, V33, P251, DOI 10.1016/S0020-1383(01)00109-7
   Faisant N, 2006, INT J PHARMACEUT, V314, P189, DOI 10.1016/j.ijpharm.2005.07.030
   Fortier LA, 1999, J ORTHOPAED RES, V17, P467, DOI 10.1002/jor.1100170403
   Giteau A, 2008, INT J PHARM, V350, P14, DOI 10.1016/j.ijpharm.2007.11.012
   Hasler CC, 2002, CLIN ORTHOP RELAT R, P242, DOI 10.1097/01.blo.0000037440.23683.a7
   Jain RA, 2000, BIOMATERIALS, V21, P2475, DOI 10.1016/S0142-9612(00)00115-0
   Jaklenec A, 2008, BIOMATERIALS, V29, P1518, DOI 10.1016/j.biomaterials.2007.12.004
   Kimura G, 1996, Int J Urol, V3, P39
   Klose D, 2008, INT J PHARMACEUT, V354, P95, DOI 10.1016/j.ijpharm.2007.10.030
   Lee CW, 2002, J PEDIATR ORTHOPED, V22, P565, DOI 10.1097/01.BPO.0000026337.10173.BD
   LEE EH, 1993, J PEDIATR ORTHOPED, V13, P368, DOI 10.1097/01241398-199305000-00018
   LeRoith D, 2003, CANCER LETT, V195, P127, DOI 10.1016/S0304-3835(03)00159-9
   Li L, 2004, J PEDIATR ORTHOPED, V24, P205, DOI 10.1097/01241398-200403000-00014
   Meinel L, 2001, J CONTROL RELEASE, V70, P193, DOI 10.1016/S0168-3659(00)00352-7
   Midyett LK, 2010, J CLIN ENDOCR METAB, V95, P611, DOI 10.1210/jc.2009-0570
   Munirah S, 2008, EUR CELLS MATER, V15, P41, DOI 10.22203/eCM.v015a04
   Nomori H, 2000, ANN THORAC SURG, V70, P1666, DOI 10.1016/S0003-4975(00)01936-6
   Oh SH, 2006, J MATER SCI-MATER M, V17, P131, DOI 10.1007/s10856-006-6816-2
   Patel MR, 2000, AM J ROENTGENOL, V175, P443, DOI 10.2214/ajr.175.2.1750443
   Raiche AT, 2004, BIOMATERIALS, V25, P677, DOI 10.1016/S0142-9612(03)00564-7
   Ranke MB, 2009, DTSCH ARZTEBL INT, V106, P703, DOI 10.3238/arztebl.2009.0703
   Ravi N, 2012, BIOMED MATER, V7, DOI 10.1088/1748-6041/7/5/055007
   Rinaldi S, 2009, INT J CANCER, V126, P1702
   Samani AA, 2007, ENDOCR REV, V28, P20, DOI 10.1210/er.2006-0001
   Tobita M, 2002, ACTA ORTHOP SCAND, V73, P352, DOI 10.1080/000164702320155383
   Tracy MA, 1999, BIOMATERIALS, V20, P1057, DOI 10.1016/S0142-9612(99)00002-2
   TRIPPEL SB, 1989, PEDIATR RES, V25, P76, DOI 10.1203/00006450-198901000-00017
   TRIPPEL SB, 1993, J BONE JOINT SURG AM, V75A, P177, DOI 10.2106/00004623-199302000-00004
   Umlauf D, 2010, CELL MOL LIFE SCI, V67, P4197, DOI 10.1007/s00018-010-0498-0
   Wang Z, 2009, CHINESE SCI BULL, V54, P2968, DOI 10.1007/s11434-009-0181-8
   Werner H, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-2
   Zheng Yi-xiong, 2006, J Zhejiang Univ Sci B, V7, P817, DOI 10.1631/jzus.2006.B0817
   Zhou FH, 2004, BONE, V35, P1307, DOI 10.1016/j.bone.2004.09.014
NR 37
TC 7
Z9 7
U1 0
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1932-6254
EI 1932-7005
J9 J TISSUE ENG REGEN M
JI J. Tissue Eng. Regen. Med.
PD DEC
PY 2015
VL 9
IS 12
BP E202
EP E209
DI 10.1002/term.1670
PG 8
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology; Engineering, Biomedical
SC Cell Biology; Biotechnology & Applied Microbiology; Engineering
GA DB4ZB
UT WOS:000368521100005
PM 23239617
DA 2018-03-20
ER

PT J
AU Lee, HJ
   Bae, Y
AF Lee, Hyun Jin
   Bae, Younsoo
TI Cross-Linked Nanoassemblies from Poly(ethylene glycol)-poly(aspartate)
   Block Copolymers as Stable Supramolecular Templates for Particulate Drug
   Delivery
SO BIOMACROMOLECULES
LA English
DT Article
ID POLYMERIC MICELLES; CANCER-THERAPY; CATIONIC DRUG; CORE;
   BIODISTRIBUTION; SYSTEMS; PLATFORM; DESIGN; NANOPARTICLES; THERAPEUTICS
AB Block copolymer cross-linked nanoassemblies (CNAs) were developed as stable supramolecular templates for particulate drug delivery. Poly(ethylene glycol)-poly(aspartate) [PEG-p(Asp)] block copolymers, consisting of PEG (5 or 12 kDa) and Asp (5, 14, 25, 33, and 37 repeating units), were used as scaffolds and grafts in combination to prepare a nanoassembly library of grafted nanoassemblies (GNAs) and CNAs. Four synthesis routes were tested to maximize the number of drug-binding Asp units per nanoassembly. Grafting-onto-scaffold and grafting-from-scaffold methods were used for GNA synthesis. Either partially or completely deprotected PEG-p(Asp) was cross-linked with diamine compounds to prepare CNAs. H-1 NMR and GPC measurements showed that GNAs and CNAs contained the maximum 183 and 253 Asp units, respectively. Initial screening of the nanoassemblies revealed that GNAs would be impractical for further development as drug carriers due to variable grafting efficiency and low product yields. CNAs were obtained in high yields and identified as a promising supramolecular template that can entrap and release ionizable drugs (doxorubicin), enhancing the particle stability of nanoassemblies in the pharmaceutically relevant pH ranges between 4 and 9. Light scattering measurements demonstrated that the particle size of CNAs remained uniform before and after drug entrapment, causing neither aggregation nor dissociation (<5 mg/mL).
C1 [Lee, Hyun Jin; Bae, Younsoo] Univ Kentucky, Coll Pharm, Lexington, KY 40536 USA.
RP Bae, Y (reprint author), Univ Kentucky, Coll Pharm, 789 S Limestone, Lexington, KY 40536 USA.
EM younsoo.bae@uky.edu
FU Kentucky Lung Cancer Research Program
FX Authors acknowledge financial support provided by the Kentucky Lung
   Cancer Research Program.
CR Atkins JH, 2002, NAT REV CANCER, V2, P645, DOI 10.1038/nrc900
   Bae Y, 2003, ANGEW CHEM INT EDIT, V42, P4640, DOI 10.1002/anie.200250653
   Bae Y, 2007, BIOCONJUGATE CHEM, V18, P1131, DOI 10.1021/bc060401p
   Bae Y, 2010, PHARM RES-DORDR, V27, P2421, DOI 10.1007/s11095-010-0234-3
   Bae Y, 2009, ADV DRUG DELIVER REV, V61, P768, DOI 10.1016/j.addr.2009.04.016
   Becker ML, 2004, BIOCONJUGATE CHEM, V15, P699, DOI 10.1021/bc049946e
   Bronich TK, 2005, J AM CHEM SOC, V127, P8236, DOI 10.1021/ja043042m
   Chen HT, 2008, P NATL ACAD SCI USA, V105, P6596, DOI 10.1073/pnas.0707046105
   Chen H, 2008, LANGMUIR, V24, P5213, DOI 10.1021/la703570m
   Cukierman E, 2010, BIOCHEM PHARMACOL, V80, P762, DOI 10.1016/j.bcp.2010.04.020
   Davis ME, 2008, NAT REV DRUG DISCOV, V7, P771, DOI 10.1038/nrd2614
   Decuzzi P, 2010, J CONTROL RELEASE, V141, P320, DOI 10.1016/j.jconrel.2009.10.014
   Dreher MR, 2006, J NATL CANCER I, V98, P335, DOI 10.1093/jnci/djj070
   Du JZ, 2009, BIOMACROMOLECULES, V10, P2169, DOI 10.1021/bm900345m
   Duncan R, 2003, NAT REV DRUG DISCOV, V2, P347, DOI 10.1038/nrd1088
   Ehtezazi T, 2000, PHARMACEUT RES, V17, P871, DOI 10.1023/A:1007520628237
   GALLES RJ, 2008, J NUCL MED, V49, pS24
   Gao HF, 2007, J AM CHEM SOC, V129, P6633, DOI 10.1021/ja0711617
   GAO ZS, 1993, MACROMOLECULES, V26, P7353, DOI 10.1021/ma00078a035
   Haag R, 2004, ANGEW CHEM INT EDIT, V43, P278, DOI 10.1002/anie.200301694
   HARADA A, 1995, MACROMOLECULES, V28, P5294, DOI 10.1021/ma00119a019
   Harada A, 2006, PROG POLYM SCI, V31, P949, DOI 10.1016/j.progpolymsci.2006.09.004
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Ihre HR, 2002, BIOCONJUGATE CHEM, V13, P443, DOI 10.1021/bc010102u
   Jain RK, 2002, NAT REV CANCER, V2, P266, DOI 10.1038/nrc778
   Jiwpanich S, 2010, J AM CHEM SOC, V132, P10683, DOI 10.1021/ja105059g
   KATAOKA K, 1993, J CONTROL RELEASE, V24, P119
   Kim JO, 2010, BIOMACROMOLECULES, V11, P919, DOI 10.1021/bm9013364
   Kim JO, 2009, J CONTROL RELEASE, V138, P197, DOI 10.1016/j.jconrel.2009.04.019
   Kim S, 2010, EXPERT OPIN DRUG DEL, V7, P49, DOI 10.1517/17425240903380446
   KWON GS, 1993, PHARMACEUT RES, V10, P970, DOI 10.1023/A:1018998203127
   Lai TC, 2010, PHARM RES-DORDR, V27, P2260, DOI 10.1007/s11095-010-0092-z
   Lee HJ, 2010, CHEM COMMUN, V46, P377, DOI 10.1039/b913732g
   Lee HJ, 2010, THER DELIV, V1, P803, DOI 10.4155/TDE.10.70
   Lee SM, 2009, J AM CHEM SOC, V131, P9311, DOI 10.1021/ja9017336
   Lehn JM, 2002, SCIENCE, V295, P2400, DOI 10.1126/science.1071063
   Li YL, 2008, MACROMOLECULES, V41, P6605, DOI 10.1021/ma801737p
   MAEDA H, 1989, CRIT REV THER DRUG, V6, P193
   Matsumoto K, 2005, MACROMOLECULES, V38, P9957, DOI 10.1021/ma0511651
   Matsumura Y, 2009, CANCER SCI, V100, P572, DOI 10.1111/j.1349-7006.2009.01103.x
   MEGANE F, 2009, ACCOUNTS CHEM RES, V42, P1141
   Mikhail AS, 2009, J CONTROL RELEASE, V138, P214, DOI 10.1016/j.jconrel.2009.04.010
   O'Reilly RK, 2006, CHEM SOC REV, V35, P1068, DOI 10.1039/b514858h
   Okuda T, 2006, J CONTROL RELEASE, V114, P69, DOI 10.1016/j.jconrel.2006.05.009
   Park CW, 2011, J POLYM SCI POL CHEM, V49, P203, DOI 10.1002/pola.24441
   Peer D, 2007, NAT NANOTECHNOL, V2, P751, DOI 10.1038/nnano.2007.387
   Ponta A, 2010, PHARM RES-DORDR, V27, P2330, DOI 10.1007/s11095-010-0120-z
   Prabaharan M, 2009, BIOMATERIALS, V30, P3009, DOI 10.1016/j.biomaterials.2009.02.011
   Ryu JH, 2010, J AM CHEM SOC, V132, P17227, DOI 10.1021/ja1069932
   SEYMOUR LW, 1987, J BIOMED MATER RES, V21, P1341, DOI 10.1002/jbm.820211106
   Such GK, 2007, NANO LETT, V7, P1706, DOI 10.1021/nl070698f
   Suzuki H, 1996, ADV DRUG DELIVER REV, V19, P335, DOI 10.1016/0169-409X(96)00008-7
   Takakura Y, 1996, PHARMACEUT RES, V13, P820, DOI 10.1023/A:1016084508097
   Torchilin V, 2011, ADV DRUG DELIVER REV, V63, P131, DOI 10.1016/j.addr.2010.03.011
   Vicent MJ, 2009, ADV DRUG DELIVER REV, V61, P1117, DOI 10.1016/j.addr.2009.08.001
   YOKOYAMA M, 1992, BIOCONJUGATE CHEM, V3, P295, DOI 10.1021/bc00016a007
NR 56
TC 34
Z9 34
U1 0
U2 23
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1525-7797
EI 1526-4602
J9 BIOMACROMOLECULES
JI Biomacromolecules
PD JUL
PY 2011
VL 12
IS 7
BP 2686
EP 2696
DI 10.1021/bm200483t
PG 11
WC Biochemistry & Molecular Biology; Chemistry, Organic; Polymer Science
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA 790VG
UT WOS:000292617700031
PM 21644544
DA 2018-03-19
ER

PT J
AU Orellana, BR
   Hilt, JZ
   Puleo, DA
AF Orellana, Bryan R.
   Hilt, J. Zach
   Puleo, David A.
TI Drug release from calcium sulfate-based composites
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B-APPLIED BIOMATERIALS
LA English
DT Article
DE calcium sulfate; drug delivery; synthetic bone graft; simvastatin;
   lysozyme
ID BONE MORPHOGENETIC PROTEINS; VERTICAL RIDGE AUGMENTATION; GRAFT
   SUBSTITUTES; PHOSPHATE; REGENERATION; SIMVASTATIN; DELIVERY; IMPLANT;
   PLASTER; PARIS
AB To help reduce the need for autografts, calcium sulfate (CS)-based bone graft substitutes are being developed to provide a stable platform to aid augmentation while having the ability to release a broad range of bioactive agents. CS has an excellent reputation as a biocompatible and osteoconductive substance, but addition of bioactive agents may further enhance these properties. Samples were produced with either directly loaded small, hydrophobic molecule (i.e., simvastatin), directly loaded hydrophilic protein (i.e., lysozyme), or 1 and 10 wt % of fast-degrading poly(-amino ester) (PBAE) particles containing protein. Although sustained release of directly loaded simvastatin was achieved, direct loading of small amounts of lysozyme resulted in highly variable release. Direct loading of a larger amount of protein generated a large burst, 65% of total loading, followed by sustained release of protein. Release of lysozyme from 1 wt % of PBAE particles embedded into CS was more controllable than when directly loaded, and for 10 wt % of protein-loaded PBAE particles, a higher burst was followed by sustained release, comparable to the results for the high direct loading. Compression testing determined that incorporation of directly loaded drug or drug-loaded PBAE particles weakened CS. In particular, PBAE particles had a significant effect on the strength of the composites, with a 25 and 80% decrease in strength for 1 and 10 wt % particle loadings, respectively. CS-based composites demonstrated the ability to sustainably release both macromolecules and small molecules, supporting the potential for these materials to release a range of therapeutic agents. (c) 2014 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 103B: 135-142, 2015.
C1 [Orellana, Bryan R.; Puleo, David A.] Univ Kentucky, Dept Biomed Engn, Lexington, KY 40506 USA.
   [Hilt, J. Zach] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY USA.
RP Puleo, DA (reprint author), Univ Kentucky, Dept Biomed Engn, Lexington, KY 40506 USA.
EM puleo@uky.edu
FU National Institutes of Health [DE019645]; Kentucky NASA EPSCoR
   [NNX08BA13A]
FX Contract grant sponsor: The National Institutes of Health; contract
   grant number: DE019645; Contract grant sponsor: Kentucky NASA EPSCoR;
   contract grant number: NNX08BA13A
CR Anderson DG, 2006, ADV MATER, V18, P2614, DOI 10.1002/adma.200600529
   Brey DM, 2008, ACTA BIOMATER, V4, P207, DOI 10.1016/j.actbio.2007.10.002
   Burdick JA, 2002, J CONTROL RELEASE, V83, P53, DOI 10.1016/S0168-3659(02)00181-5
   Chiapasco M, 2007, CLIN ORAL IMPLAN RES, V18, P432, DOI 10.1111/j.1600-0501.2007.01351.x
   Chiapasco M, 2009, INT J ORAL MAX IMPL, V24, P237
   Cho DC, 2012, ACTA NEUROCHIR, V154, P2215, DOI 10.1007/s00701-012-1516-9
   Clavero Jaime, 2003, Clin Implant Dent Relat Res, V5, P154, DOI 10.1111/j.1708-8208.2003.tb00197.x
   Gao CJ, 2007, J BIOMAT SCI-POLYM E, V18, P799, DOI 10.1163/156856207781367710
   Ginebra MP, 2012, ADV DRUG DELIVER REV, V64, P1090, DOI 10.1016/j.addr.2012.01.008
   Groeneveld EHJ, 2000, EUR J ENDOCRINOL, V142, P9, DOI 10.1530/eje.0.1420009
   Guarnieri R, 2006, INT J PERIODONT REST, V26, P79
   Guarnieri R, 2004, J PERIODONTOL, V75, P902, DOI 10.1902/jop.2004.75.6.902
   Hak DJ, 2007, J AM ACAD ORTHOP SUR, V15, P525, DOI 10.5435/00124635-200709000-00003
   Hawkins AM, 2013, J BIOMED MATER RES A, V102A, P400
   Hawkins AM, 2011, J APPL POLYM SCI, V122, P1420, DOI 10.1002/app.34093
   Hawkins AM, 2011, ACTA BIOMATER, V7, P1956, DOI 10.1016/j.actbio.2011.01.024
   Hitti RA, 2011, OPEN PATHOL J, V5, P33
   Jamali A, 2002, CALCIFIED TISSUE INT, V71, P172, DOI 10.1007/s00223-001-1087-x
   KAMATH KR, 1993, ADV DRUG DELIVER REV, V11, P59, DOI 10.1016/0169-409X(93)90027-2
   KENLEY RA, 1993, PHARMACEUT RES, V10, P1393, DOI 10.1023/A:1018902720816
   Kenny SM, 2003, J MATER SCI-MATER M, V14, P923, DOI 10.1023/A:1026394530192
   Lewis KN, 2006, J MATER SCI-MATER M, V17, P531, DOI 10.1007/s10856-006-8936-0
   Misch CE, 1999, J ORAL MAXIL SURG, V57, P700, DOI 10.1016/S0278-2391(99)90437-8
   Moore WR, 2001, AUST NZ J SURG, V71, P354, DOI 10.1046/j.1440-1622.2001.2128.x
   Nyan M, 2007, J PHARMACOL SCI, V104, P384, DOI 10.1254/jphs.SC0070184
   Orellana BR, 2013, J MECH BEHAV BIOMED, V26, P43, DOI 10.1016/j.jmbbm.2013.05.021
   Park J.B., 2009, MED ORAL PATOL ORAL, V14, P485
   Pecora G, 1997, ORAL SURG ORAL MED O, V84, P424, DOI 10.1016/S1079-2104(97)90043-3
   Puleo DA, 2002, BIOMATERIALS, V23, P2079, DOI 10.1016/S0142-9612(01)00339-8
   Ripamonti U, 2005, CYTOKINE GROWTH F R, V16, P357, DOI 10.1016/j.cytogfr.2005.02.006
   ROSENBLUM SF, 1993, J APPL BIOMATER, V4, P67, DOI 10.1002/jab.770040109
   Simion M, 2007, CLIN ORAL IMPLAN RES, V18, P620, DOI 10.1111/j.1600-0501.2007.01389.x
   Simion M, 2007, CLIN ORAL IMPLAN RES, V18, P86, DOI 10.1111/j.1600-0501.2006.01291.x
   Srinivasan C, 2005, J MICROENCAPSUL, V22, P127, DOI 10.1080/02652040400026400
   Tamimi F, 2009, BIOMATERIALS, V30, P6318, DOI 10.1016/j.biomaterials.2009.07.049
   Tay BKB, 1999, ORTHOP CLIN N AM, V30, P615, DOI 10.1016/S0030-5898(05)70114-0
   Thomas Mark V, 2005, J Long Term Eff Med Implants, V15, P599
   Thomas MV, 2009, J BIOMED MATER RES B, V88B, P597, DOI 10.1002/jbm.b.31269
   Triplett RG, 1996, J ORAL MAXIL SURG, V54, P486, DOI 10.1016/S0278-2391(96)90126-3
   Wang SY, 2009, BIOMATERIALS, V30, P2489, DOI 10.1016/j.biomaterials.2008.12.067
   Wattamwar PP, 2012, ACTA BIOMATER, V8, P2529, DOI 10.1016/j.actbio.2012.03.022
   Wozney JM, 2002, SPINE, V27, pS2, DOI 10.1097/01.BRS0000020725.01916.7E
   Wu Z, 2008, INT J ORAL MAX SURG, V37, P170, DOI 10.1016/j.ijom.2007.06.018
   YAMAZAKI Y, 1988, CLIN ORTHOP RELAT R, P240
   Yin H, 2012, J BIOMED MATER RES A, V100A, P2991, DOI 10.1002/jbm.a.34228
NR 45
TC 7
Z9 7
U1 2
U2 20
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1552-4973
EI 1552-4981
J9 J BIOMED MATER RES B
JI J. Biomed. Mater. Res. Part B
PD JAN
PY 2015
VL 103
IS 1
BP 135
EP 142
DI 10.1002/jbm.b.33181
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA AW3MT
UT WOS:000346191600016
PM 24788686
OA green_accepted
DA 2018-03-20
ER

PT J
AU Zhou, SS
   Schlipf, DM
   Guilfoil, EC
   Rankin, SE
   Knutson, BL
AF Zhou, Shanshan
   Schlipf, Daniel M.
   Guilfoil, Emma C.
   Rankin, Stephen E.
   Knutson, Barbara L.
TI Lipid Pore-Filled Silica Thin-Film Membranes for Biomimetic Recovery of
   Dilute Carbohydrates
SO LANGMUIR
LA English
DT Article
ID SOLID-STATE NMR; MESOPOROUS SILICA; FACILITATED TRANSPORT;
   RAMAN-SPECTROSCOPY; BILAYER FORMATION; AQUEOUS-SOLUTIONS;
   LIQUID-MEMBRANES; BORONIC ACIDS; SEPARATION; FRUCTOSE
AB Selectively permeable biological membranes containing lipophilic barriers inspire the design of biomimetic carrier mediated membranes for aqueous solute separation. The recovery of glucose, which can reversibly bind to boronic acid (BA) carriers, is examined in lipid pore-filled silica thin-film composite membranes with accessible mesopores. The successful incorporation of lipids (1,2-dipalmitoyl-sn-glycero-3-phosphocholine, DPPC) and BA carriers (4-((N-Boc-amino)methyl)phenylboronic acid, BAMP-BA) in the pores of mesoporous silica (similar to 10 nm pore diameter) through evaporation deposition is verified by confocal microscopy and differential scanning calorimetry. In the absence of BA carriers, lipids confined inside the pores of silica thin films (similar to 200 nm thick) provide a factor of 14 increase in diffusive transport resistance to glucose, relative to traditional supported lipid bilayers formed by vesicle fusion on the porous surface. The addition of lipid-immobilized BAMP-BA (59 mol % in DPPC) facilitates the transport of glucose through the membrane; glucose flux increases from 45 X 10(-8) to 225 x 10(-8) mol/m(2)/s in the presence of BAMP-BA. Furthermore, the transport can be improved by environmental factors including pH gradient (to control the binding and release of glucose) and temperature (to adjust lipid bilayer fluidity). The successful development of biomimetic nanocomposite membranes demonstrated here is an important step toward the efficient dilute aqueous solute upgrading or separations, such as the processing of carbohydrates from lignocellulose hydrolysates, using engineered carrier/catalyst/support systems.
C1 [Zhou, Shanshan; Schlipf, Daniel M.; Guilfoil, Emma C.; Rankin, Stephen E.; Knutson, Barbara L.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Knutson, BL (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM bknutson@engr.uky.edu
FU NSF Experimental Program to Stimulate Competitive Research (EPSCoR)
   grants [1355438, 1632854]; United States Department of Agriculture
   Biomass Research and Development Initiative (BRDI) grant
   [2011-10006-30363]
FX This work was supported by NSF Experimental Program to Stimulate
   Competitive Research (EPSCoR) grants (award nos. 1355438 and 1632854)
   and a United States Department of Agriculture Biomass Research and
   Development Initiative (BRDI) grant (award # 2011-10006-30363).
CR Abels C, 2013, BIORESOURCE TECHNOL, V149, P58, DOI 10.1016/j.biortech.2013.09.012
   Arai N, 2013, MICROFLUID NANOFLUID, V14, P995, DOI 10.1007/s10404-012-1107-3
   Assary RS, 2012, PHYS CHEM CHEM PHYS, V14, P16603, DOI 10.1039/c2cp41842h
   Barry J, 2009, J AM CHEM SOC, V131, P4490, DOI 10.1021/ja809217u
   BRIAN AA, 1984, P NATL ACAD SCI-BIOL, V81, P6159, DOI 10.1073/pnas.81.19.6159
   Brinker CJ, 1999, ADV MATER, V11, P579, DOI 10.1002/(SICI)1521-4095(199905)11:7<579::AID-ADMA579>3.0.CO;2-R
   BROOKS AA, 2008, J BIOTECHNOL, V7, P3752
   Cheema M. K., 2009, THESIS
   Claesson M, 2011, LANGMUIR, V27, P8974, DOI 10.1021/la201411b
   Di Luccio M, 2000, J MEMBRANE SCI, V174, P217, DOI 10.1016/S0376-7388(00)00385-9
   Duggan PJ, 2008, TETRAHEDRON, V64, P7122, DOI 10.1016/j.tet.2008.05.052
   Eeman M, 2010, BIOTECHNOL AGRON SOC, V14, P719
   El Kirat K, 2010, BBA-BIOMEMBRANES, V1798, P750, DOI 10.1016/j.bbamem.2009.07.026
   Ferraz HC, 2007, BRAZ J CHEM ENG, V24, P101, DOI 10.1590/S0104-66322007000100010
   Freeman S., 2009, BIOL SCI
   Fritzsching KJ, 2013, BBA-BIOMEMBRANES, V1828, P1889, DOI 10.1016/j.bbamem.2013.03.028
   Gardikis K, 2006, INT J PHARM, V318, P118, DOI 10.1016/j.ijpharm.2006.03.023
   Gardikis K, 2006, THERMOCHIM ACTA, V447, P1, DOI 10.1016/j.tca.2006.03.007
   IGAWA M, 1995, J MEMBRANE SCI, V98, P177, DOI 10.1016/0376-7388(94)00177-Z
   Kaghazchi T, 2006, DESALINATION, V190, P161, DOI 10.1016/j.desal.2005.06.031
   Karp ES, 2007, J MAGN RESON, V187, P112, DOI 10.1016/j.jmr.2007.04.004
   Kaufman Y, 2010, LANGMUIR, V26, P7388, DOI 10.1021/la904411b
   Koper I, 2007, MOL BIOSYST, V3, P651, DOI 10.1039/b707168j
   Koganti VR, 2006, NANO LETT, V6, P2567, DOI 10.1021/nl061992v
   Koganti VR, 2005, J PHYS CHEM B, V109, P3279, DOI 10.1021/jp045037a
   Koganti V. R., 2006, THESIS
   Kucerka N, 2011, BBA-BIOMEMBRANES, V1808, P2761, DOI 10.1016/j.bbamem.2011.07.022
   Kurian JK, 2010, BIORESOURCES, V5, P2404
   LANDE MB, 1995, J GEN PHYSIOL, V106, P67, DOI 10.1085/jgp.106.1.67
   LAWACZECK R, 1976, BIOCHIM BIOPHYS ACTA, V443, P313, DOI 10.1016/0005-2787(76)90496-2
   Li YF, 2015, CHEM SOC REV, V44, P103, DOI 10.1039/c4cs00215f
   Lundbaek JA, 2010, J R SOC INTERFACE, V7, P373, DOI 10.1098/rsif.2009.0443
   Malmali M, 2014, SEP PURIF TECHNOL, V132, P655, DOI 10.1016/j.seppur.2014.06.014
   MCMULLEN TPW, 1993, BIOCHEMISTRY-US, V32, P516, DOI 10.1021/bi00053a016
   Mohapatra S, 2009, MAT SCI ENG C-MATER, V29, P2254, DOI 10.1016/j.msec.2009.05.017
   Muter D, 2010, J PHYS CHEM LETT, V1, P1442, DOI 10.1021/jz100279y
   Pande AH, 2005, BIOPHYS J, V88, P4084, DOI 10.1529/biophysj.104.056788
   Paugam MF, 1996, CHEM COMMUN, P2539, DOI 10.1039/cc9960002539
   Richter RP, 2006, LANGMUIR, V22, P3497, DOI 10.1021/la052687c
   Sackmann E, 1996, SCIENCE, V271, P43, DOI 10.1126/science.271.5245.43
   Schlipf DM, 2017, ADV MATER INTERFACES, V4, DOI 10.1002/admi.201601103
   Schlipf DM, 2013, ACS APPL MATER INTER, V5, P10111, DOI 10.1021/am402754h
   Springsteen G, 2002, TETRAHEDRON, V58, P5291, DOI 10.1016/S0040-4020(02)00489-1
   Springsteen G, 2001, CHEM COMMUN, P1608, DOI 10.1039/b104895n
   Taherzadeh MJ, 2007, BIORESOURCES, V2, P707
   Tian ML, 2013, J CHROMATOGR SCI, V51, P819, DOI 10.1093/chromsci/bmt044
   TSUKAGOSHI K, 1991, J ORG CHEM, V56, P4089, DOI 10.1021/jo00013a002
   Voskuhl J, 2009, CHEM SOC REV, V38, P495, DOI 10.1039/b803782p
   Wattraint O, 2005, BBA-BIOMEMBRANES, V1713, P65, DOI 10.1016/j.bbamen.2005.05.005
   Weirich KL, 2010, BIOPHYS J, V98, P85, DOI 10.1016/j.bpj.2009.09.050
   Westmark PR, 1996, J AM CHEM SOC, V118, P11093, DOI 10.1021/ja961264h
   Wooten MKC, 2016, ACS APPL MATER INTER, V8, P21806, DOI 10.1021/acsami.6b06765
   Worsfold O, 2006, LANGMUIR, V22, P7078, DOI 10.1021/la060121y
   Yan J, 2004, TETRAHEDRON, V60, P11205, DOI 10.1016/j.tet.2004.08.051
   Zhang HH, 2016, J CHEM ENG DATA, V61, P213, DOI 10.1021/acs.jced.5b00481
   Zhao D, 1998, ADV MATER, V10, P1380, DOI 10.1002/(SICI)1521-4095(199811)10:16<1380::AID-ADMA1380>3.0.CO;2-8
   Zhao DY, 1998, J AM CHEM SOC, V120, P6024, DOI 10.1021/ja974025i
   Zhao YH, 2011, LANGMUIR, V27, P14554, DOI 10.1021/la203121u
NR 58
TC 0
Z9 0
U1 11
U2 11
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0743-7463
J9 LANGMUIR
JI Langmuir
PD DEC 12
PY 2017
VL 33
IS 49
BP 14156
EP 14166
DI 10.1021/acs.langmuir.7b03844
PG 11
WC Chemistry, Multidisciplinary; Chemistry, Physical; Materials Science,
   Multidisciplinary
SC Chemistry; Materials Science
GA FQ2SB
UT WOS:000418206500030
PM 29131638
DA 2018-03-20
ER

PT J
AU Chen, THH
   Bae, Y
   Furgeson, DY
   Kwon, GS
AF Chen, Tze-Haw H.
   Bae, Younsoo
   Furgeson, Darin Y.
   Kwon, Glen S.
TI Biodegradable hybrid recombinant block copolymers for non-viral gene
   transfection
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Elastin-like polypeptide (ELP); Hybrid recombinant polymer; Gene
   delivery; Thermo-responsive; Diethylenetriamine (DET)
ID ELASTIN-LIKE POLYPEPTIDE; INTELLIGENT BIOSYNTHETIC NANOBIOMATERIALS;
   INVERSE TEMPERATURE TRANSITION; PROTEIN-BASED POLYMERS; INTRACELLULAR
   DELIVERY; LOCAL HYPERTHERMIA; DNA CONDENSATION; PHASE-TRANSITION; FUSION
   PROTEIN; IN-VITRO
AB Thermal targeting of therapeutic genes can enhance local gene concentration to maximize their efficacy. However, lack of safe and efficient carriers has impeded the development of this delivery option. Herein, we report the preparation and evaluation of a hybrid recombinant material, p[Asp(DET)](53)ELP(1-90), that possess a thermo-responsive elastin-like polypeptide (ELP) segment and a diethylenetriamine (DET) modified poly-l-aspartic acid segment. The term, hybrid, indicates that the material was prepared by genetic engineering and synthetic chemistry. In summary, the thermal phase transition behavior and cytotoxicity of the biodegradable copolymer were studied. The polyplexes formed by the copolymer and pGL4 plasmid were characterized by dynamic light scattering and zeta-potential measurements. The polyplexes retained the thermal phase transition behavior conferred by the copolymer; however, they exhibited a two-step transition process not seen with the copolymer. The polyplexes also showed appreciable transfection efficiency with low cytotoxicity. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Chen, Tze-Haw H.; Kwon, Glen S.] Univ Wisconsin, Div Pharmaceut Sci, Sch Pharm, Madison, WI 53705 USA.
   [Bae, Younsoo] Univ Kentucky, Div Pharmaceut Sci, Lexington, KY 40536 USA.
   [Furgeson, Darin Y.] Univ Utah, Dept Pharmaceut & Pharmaceut Chem, Salt Lake City, UT 84112 USA.
RP Kwon, GS (reprint author), Univ Wisconsin, Div Pharmaceut Sci, Sch Pharm, 777 Highland Ave, Madison, WI 53705 USA.
EM gskwon@pharmacy.wisc.edu
RI Kwon, Glen/A-1919-2014
FU School of Pharmacy, University of Wisconsin-Madison
FX The authors would like to acknowledge the School of Pharmacy, University
   of Wisconsin-Madison for funding this research, and would also like to
   thank Mr. Tsz Chung Lai and Ms. Tracy Williamson for their valuable
   suggestions on the manuscript.
CR Bae Y, 2003, ANGEW CHEM INT EDIT, V42, P4640, DOI 10.1002/anie.200250653
   Bae Y, 2007, J CONTROL RELEASE, V122, P16, DOI 10.1016/j.jconrel.2007.06.005
   Berg K, 1999, CANCER RES, V59, P1180
   Betre H, 2006, BIOMATERIALS, V27, P91, DOI 10.1016/j.biomaterials.2005.05.071
   Bidwell GL, 2007, BIOCHEM PHARMACOL, V73, P620, DOI 10.1016/j.bcp.2006.10.028
   Bisht HS, 2006, BIOMACROMOLECULES, V7, P1169, DOI 10.1021/bm0509927
   Bloomfield VA, 1996, CURR OPIN STRUC BIOL, V6, P334, DOI 10.1016/S0959-440X(96)80052-2
   CAPPELLO J, 1990, BIOTECHNOL PROGR, V6, P198, DOI 10.1021/bp00003a006
   Cavallaro G, 2006, J CONTROL RELEASE, V115, P322, DOI 10.1016/j.jconrel.2006.07.027
   Chen THH, 2008, PHARM RES, V25, P683, DOI 10.1007/s11095-007-9382-5
   Cho YH, 2008, J PHYS CHEM B, V112, P13765, DOI 10.1021/jp8062977
   Cresce AV, 2008, MOL PHARMACEUT, V5, P891, DOI 10.1021/mp800054w
   DALY WH, 1988, TETRAHEDRON LETT, V29, P5859, DOI 10.1016/S0040-4039(00)82209-1
   Dreher MR, 2008, J AM CHEM SOC, V130, P687, DOI 10.1021/ja0764862
   Du FS, 2010, SOFT MATTER, V6, P835, DOI 10.1039/b915020j
   Frey W, 2003, LANGMUIR, V19, P1641, DOI 10.1021/la026359d
   Ganta S, 2008, J CONTROL RELEASE, V126, P187, DOI 10.1016/j.jconrel.2007.12.017
   Haider M, 2005, MOL PHARMACEUT, V2, P139, DOI 10.1021/mp049906s
   Hart SL, 2000, EXPERT OPIN THER PAT, V10, P199, DOI 10.1517/13543776.10.2.199
   Hinrichs WLJ, 1999, J CONTROL RELEASE, V60, P249, DOI 10.1016/S0168-3659(99)00075-9
   Itaka K, 2010, BIOMATERIALS, V31, P3707, DOI 10.1016/j.biomaterials.2009.11.072
   Kanayama N, 2006, CHEMMEDCHEM, V1, P439, DOI 10.1002/cmdc.200600008
   Kurisawa M, 2000, J CONTROL RELEASE, V69, P127, DOI 10.1016/S0168-3659(00)00297-2
   Lai TC, 2010, PHARM RES-DORDR, V27, P2260, DOI 10.1007/s11095-010-0092-z
   Lavigne MD, 2007, J GENE MED, V9, P44, DOI 10.1002/jgm.992
   Lim DW, 2008, BIOMACROMOLECULES, V9, P222, DOI 10.1021/bm7007982
   Liu WE, 2006, J CONTROL RELEASE, V116, P170, DOI 10.1016/j.jconrel.2006.06.026
   LUAN CH, 1991, BIOPOLYMERS, V31, P465, DOI 10.1002/bip.360310502
   MacKay JA, 2010, BIOMACROMOLECULES, V11, P2873, DOI 10.1021/bm100571j
   Massodi I, 2007, J DRUG TARGET, V15, P611, DOI 10.1080/10611860701502780
   Meyer DE, 2001, J CONTROL RELEASE, V74, P213, DOI 10.1016/S0168-3659(01)00319-4
   Meyer DE, 2002, BIOMACROMOLECULES, V3, P357, DOI 10.1021/bm015630n
   Meyer DE, 1999, NAT BIOTECHNOL, V17, P1112, DOI 10.1038/15100
   Meyer DE, 2001, CANCER RES, V61, P1548
   Miyata K, 2008, J AM CHEM SOC, V130, P16287, DOI 10.1021/ja804561g
   Murthy N, 2003, J CONTROL RELEASE, V89, P365, DOI 10.1016/S0168-3659(03)00099-3
   Nath N, 2003, ANAL CHEM, V75, P709, DOI 10.1021/ac0261855
   Rao GVR, 2002, LANGMUIR, V18, P1819, DOI 10.1021/la011188i
   Rincon AC, 2006, J BIOMED MATER RES A, V78A, P343, DOI 10.1002/jbm.a.30702
   Simnick AJ, 2010, ACS NANO, V4, P2217, DOI 10.1021/nn901732h
   Smith J, 1997, ADV DRUG DELIVER REV, V26, P135, DOI 10.1016/S0169-409X(97)00031-8
   Stefanelli C, 1999, FEBS LETT, V451, P95, DOI 10.1016/S0014-5793(99)00549-9
   Stefanelli C, 2000, BIOCHEM J, V347, P875, DOI 10.1042/0264-6021:3470875
   Sun SJ, 2005, BIOCONJUGATE CHEM, V16, P972, DOI 10.1021/bc0500701
   Tan PH, 2008, EXPERT OPIN BIOL TH, V8, P561, DOI [10.1517/14712590802066523, 10.1517/14712598.8.5.561 ]
   Tecle M, 2003, BIOCHEMISTRY-US, V42, P10343, DOI 10.1021/bi034325e
   Turk M, 2007, J TISSUE ENG REGEN M, V1, P377, DOI 10.1002/term.47
   URRY DW, 1991, J BIOACT COMPAT POL, V6, P263, DOI 10.1177/088391159100600306
   URRY DW, 1991, J AM CHEM SOC, V113, P4346, DOI 10.1021/ja00011a057
   URRY DW, 1985, BIOPOLYMERS, V24, P2345, DOI 10.1002/bip.360241212
   Urry DW, 1997, J PHYS CHEM B, V101, P11007, DOI 10.1021/jp972167t
   Xiong MP, 2007, CHEMMEDCHEM, V2, P1321, DOI 10.1002/cmdc.200700093
   Yamaoka T, 2003, BIOMACROMOLECULES, V4, P1680, DOI 10.1021/bm0341201
   Zintchenko A, 2006, BIOCONJUGATE CHEM, V17, P766, DOI 10.1021/bc050292z
NR 54
TC 7
Z9 7
U1 1
U2 16
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD MAY 1
PY 2012
VL 427
IS 1
BP 105
EP 112
DI 10.1016/j.ijpharm.2011.09.035
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 919XB
UT WOS:000302364400011
PM 21983093
DA 2018-03-19
ER

PT J
AU Das, S
   Wu, QL
   Garlapalli, RK
   Nagpure, S
   Strzalka, J
   Jiang, Z
   Rankin, SE
AF Das, Saikat
   Wu, Qingliu
   Garlapalli, Ravinder K.
   Nagpure, Suraj
   Strzalka, Joseph
   Jiang, Zhang
   Rankin, Stephen E.
TI In-Situ GISAXS Investigation of Pore Orientation Effects on the Thermal
   Transformation Mechanism in Mesoporous Titania Thin Films
SO JOURNAL OF PHYSICAL CHEMISTRY C
LA English
DT Article
ID X-RAY-SCATTERING; NANOCRYSTALLINE ANATASE; PHASE-SEPARATION; TIO2 FILMS;
   SILICA; CRYSTALLIZATION; PHOTOCATALYSIS; TEMPERATURE; SOL; ROUTE
AB This study addresses the effects of mesopore orientation on mesostructural stability and crystallization of titania thin films during calcination based on measurements with in-situ grazing incidence small angle X-ray scattering (GISAXS). Complementary supporting information is provided by ex-situ electron microscopy. Pluronic surfactant P123 (with average structure (EO)(20)(PO)(70)(EO)(20) where EO is an ethylene oxide unit and PO is a propylene oxide unit) serves as the template to synthesize titania thin films on P123-modified glass slides with 2D hexagonally close-packed cylindrical mesopores. The orientation of the pores at the top surface is controlled by sandwiching another P123-modified glass slide on top of the titania thin film to completely orient the pores orthogonal to the films in some samples. This provides the opportunity to directly observe how pore orientation affects the evolution of pore order and crystallinity during calcination. The results show that when the pores are oriented parallel to the substrate at the top surface (for unsandwiched films), the pore structure is stable upon calcination at 400 degrees C but that the structure is quickly lost due to crystallization throughout the film during calcination at 500 degrees C. Films with pores oriented orthogonal to the substrate at the top surface (sandwiched films) retain their long-range pore order even after calcination at 500 degrees C. The reasons for this difference are ascribed to greater resistance to anisotropic stress during heating of the orthogonally oriented pores and titania crystallization nucleation at the top surface of the films with orthogonally oriented pores.
C1 [Das, Saikat; Garlapalli, Ravinder K.; Nagpure, Suraj; Rankin, Stephen E.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Wu, Qingliu] Argonne Natl Lab, Chem Sci & Engn Div, Argonne, IL 60439 USA.
   [Strzalka, Joseph; Jiang, Zhang] Argonne Natl Lab, Xray Sci Div, Argonne, IL 60439 USA.
RP Rankin, SE (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 FP Anderson Tower, Lexington, KY 40506 USA.
EM srankin@engr.uky.edu
RI Jiang, Zhang/A-3297-2012
OI Jiang, Zhang/0000-0003-3503-8909; Rankin, Stephen/0000-0002-8615-7564
FU U.S. Department of Energy EPSCoR Implementation award
   [DE-FG02-07-ER46375]; U.S. Department of Energy, Office of Science,
   Office of Basic Energy Sciences [DE-AC02-06CH11357]
FX Titania thin film synthesis and characterization work was performed as
   part of a U.S. Department of Energy EPSCoR Implementation award
   supported by grant no. DE-FG02-07-ER46375. Use of the Advanced Photon
   Source at Argonne National Laboratory for GISAXS measurements was
   supported by the U.S. Department of Energy, Office of Science, Office of
   Basic Energy Sciences, under Contract No. DE-AC02-06CH11357.
CR Alberius PCA, 2002, CHEM MATER, V14, P3284, DOI 10.1021/cm011209u
   Angelome PC, 2007, J PHYS CHEM C, V111, P10886, DOI 10.1021/jp069020z
   Bass JD, 2008, J AM CHEM SOC, V130, P7882, DOI 10.1021/ja078140x
   Beyers E, 2005, J PHYS CHEM B, V109, P10081, DOI 10.1021/jp050310+
   Bosc F, 2003, CHEM MATER, V15, P2463, DOI 10.1021/cm031025a
   Brinker CJ, 1999, ADV MATER, V11, P579, DOI 10.1002/(SICI)1521-4095(199905)11:7<579::AID-ADMA579>3.0.CO;2-R
   Carreon MA, 2007, J MATER CHEM, V17, P82, DOI 10.1039/b612550f
   Cassiers K, 2004, J PHYS CHEM B, V108, P3713, DOI 10.1021/jp036830r
   Chatterjee P, 2012, SOFT MATTER, V8, P2956, DOI 10.1039/c2sm06982b
   Choi SY, 2006, ADV FUNCT MATER, V16, P1731, DOI 10.1002/adfm.200500507
   Choi SY, 2005, SMALL, V1, P226, DOI 10.1002/smll.200400038
   Choi SY, 2004, ADV FUNCT MATER, V14, P335, DOI 10.1002/adfm.200305039
   Crepaldi EL, 2003, J AM CHEM SOC, V125, P9770, DOI 10.1021/ja030070g
   Devi GS, 2002, SENSOR ACTUAT B-CHEM, V87, P122, DOI 10.1016/S0925-4005(02)00228-9
   Dewalque J, 2012, THIN SOLID FILMS, V520, P5272, DOI 10.1016/j.tsf.2012.03.044
   Docampo P, 2010, ADV FUNCT MATER, V20, P1787, DOI 10.1002/adfm.200902089
   Fukuda K, 2007, J AM CHEM SOC, V129, P202, DOI 10.1021/ja0668116
   Grosso D, 2001, ADV MATER, V13, P1085, DOI 10.1002/1521-4095(200107)13:14<1085::AID-ADMA1085>3.0.CO;2-Q
   Grosso D, 2003, CHEM MATER, V15, P4562, DOI 10.1021/cm031060h
   Guldin S, 2011, ENERG ENVIRON SCI, V4, P225, DOI 10.1039/c0ee00362j
   HAGFELDT A, 1995, CHEM REV, V95, P49, DOI 10.1021/cr00033a003
   Hanley TL, 2002, J PHYS CHEM B, V106, P1153, DOI 10.1021/jp012225h
   Hazra SK, 2006, SENSOR ACTUAT B-CHEM, V115, P403, DOI 10.1016/j.snb.2005.10.002
   Herregods SJF, 2013, J COLLOID INTERF SCI, V391, P36, DOI 10.1016/j.jcis.2012.07.098
   HOWARD CJ, 1991, ACTA CRYSTALLOGR B, V47, P462, DOI 10.1107/S010876819100335X
   Innocenzi P, 2010, J PHYS CHEM C, V114, P22385, DOI 10.1021/jp1042766
   Ismail AA, 2011, J MATER CHEM, V21, P11686, DOI 10.1039/c1jm10407a
   Jiang Z., GIXGUI MATLAB BASED
   Jiang Z, 2012, J SYNCHROTRON RADIAT, V19, P627, DOI 10.1107/S0909049512022017
   Kirsch BL, 2004, J PHYS CHEM B, V108, P12698, DOI 10.1021/jp036442p
   Klotz M, 2000, CHEM MATER, V12, P1721, DOI 10.1021/cm991198t
   Koganti VR, 2006, NANO LETT, V6, P2567, DOI 10.1021/nl061992v
   Lin CYW, 2012, PROG ORG COAT, V74, P645, DOI 10.1016/j.porgcoat.2011.09.030
   Liu YC, 2011, INT J PHOTOENERGY, DOI 10.1155/2011/619069
   Lu YF, 1997, NATURE, V389, P364, DOI 10.1038/38699
   Malfatti L, 2009, CHEM MATER, V21, P2763, DOI 10.1021/cm900289c
   Manurung P, 2013, CERAM INT, V39, P255, DOI 10.1016/j.ceramint.2012.06.019
   Matej Z, 2010, POWDER DIFFR, V25, P125, DOI 10.1154/1.3392371
   Nakata K, 2012, J PHOTOCH PHOTOBIO C, V13, P169, DOI 10.1016/j.jphotochemrev.2012.06.001
   Pan JH, 2011, CHEM ENG J, V170, P363, DOI 10.1016/j.cej.2010.11.040
   Rawolle M, 2011, SMALL, V7, P884, DOI 10.1002/smll.201001734
   Richman EK, 2008, NAT MATER, V7, P712, DOI 10.1038/nmat2257
   Smarsly B, 2005, LANGMUIR, V21, P3858, DOI 10.1021/la046916r
   Soler-Illia GJAA, 2012, NANOSCALE, V4, P2549, DOI 10.1039/c2nr11817c
   Soler-Illia GJDA, 2002, CHEM MATER, V14, P750, DOI 10.1021/cm011217a
   Soni SS, 2008, ADV MATER, V20, P1493, DOI 10.1002/adma.200701066
   Vivero-Escoto JL, 2012, SCI TECHNOL ADV MAT, V13, DOI 10.1088/1468-6996/13/1/013003
   Wang CT, 2012, SURF COAT TECH, V206, P2622, DOI 10.1016/j.surfcoat.2011.11.025
   Williford RE, 2005, J NON-CRYST SOLIDS, V351, P2217, DOI 10.1016/j.jnoncrysol.2005.06.001
   Wu QL, 2012, THIN SOLID FILMS, V520, P3558, DOI 10.1016/j.tsf.2011.12.028
   Wu QL, 2011, J SOL-GEL SCI TECHN, V60, P81, DOI 10.1007/s10971-011-2553-1
   Wu QL, 2011, LANGMUIR, V27, P9557, DOI 10.1021/la201388n
   Wu QL, 2011, J PHYS CHEM C, V115, P11925, DOI 10.1021/jp2021193
   Zhang RY, 2012, NANO TODAY, V7, P344, DOI 10.1016/j.nantod.2012.06.012
   Zhao LL, 2004, APPL CATAL A-GEN, V263, P171, DOI 10.1016/j.apcata.2003.12.022
   Zhou W, 2013, CHEMCATCHEM, V5, P885, DOI 10.1002/cctc.201200519
NR 56
TC 11
Z9 11
U1 1
U2 39
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1932-7447
J9 J PHYS CHEM C
JI J. Phys. Chem. C
PD JAN 16
PY 2014
VL 118
IS 2
BP 968
EP 976
DI 10.1021/jp406165v
PG 9
WC Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science,
   Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA 299SX
UT WOS:000330417100026
DA 2018-03-20
ER

PT J
AU Hu, B
   Yao, JY
   Hinds, BJ
AF Hu, Bing
   Yao, Jingyuan
   Hinds, Bruce J.
TI Nanogap electrodes formed at the exposed edge of Au/self-assembled
   monolayer/Al2O3/Au tunnel structures grown by atomic layer deposition
SO APPLIED PHYSICS LETTERS
LA English
DT Article
ID FABRICATION; MOLECULE; AU(111); AL2O3; FILM
AB Atomic layer deposition of high quality Al2O3 thin films onto Au electrodes was enabled by surface modification with a self-assembled monolayer of -OH groups that react with a monolayer of trimethylaluminum gas source. Ar ion milling was then used to expose the edge of the Au/insulator/Au structure for molecular electrode contacts. The junctions are characterized by atomic force microscope and tunnel current properties. The Au/self-assembled monolayer/Al2O3/Au tunnel junction, with a very thin oxide insulator layer (15.4 angstrom), is stable and has a small tunneling current density of about 0.20-0.75 A/cm(2) at 0.5 V. (C) 2010 American Institute of Physics. [doi: 10.1063/1.3514253]
C1 [Hu, Bing; Yao, Jingyuan; Hinds, Bruce J.] Univ Kentucky, Lexington, KY 40506 USA.
RP Hu, B (reprint author), Univ Kentucky, Lexington, KY 40506 USA.
EM bjhinds@engr.uky.edu
FU Air Force Office of Scientific Research (DEPS-CoR) [F49620-02-1-0225];
   NSF [0348544]; NSF NIRT [0609064]
FX The authors would like to thank Dr. John Balk for providing Au
   sputtering system and Xin Su for help with SEM microscopy. Facility
   support was provided by the Center for Nanoscale Science and Engineering
   and Electron Microscopy Center at the University of Kentucky. The
   authors thank the Air Force Office of Scientific Research (DEPS-CoR)
   under Agreement No. F49620-02-1-0225, NSF CAREER (Grant No. 0348544),
   and NSF NIRT (Grant No. 0609064).
CR Ashwell GJ, 2007, CHEM COMMUN, P1254, DOI 10.1039/b615538c
   Chen W, 2006, J VAC SCI TECHNOL B, V24, P3217, DOI 10.1116/1.2366618
   FISCHER CM, 1995, APPL PHYS LETT, V66, P3331, DOI 10.1063/1.113747
   GEDDES NJ, 1990, APPL PHYS LETT, V56, P1916, DOI 10.1063/1.103043
   Groner MD, 2002, THIN SOLID FILMS, V413, P186, DOI 10.1016/S0040-6090(02)00438-8
   Hyun M, 2001, B KOR CHEM SOC, V22, P213
   Ichimura AS, 2008, LANGMUIR, V24, P2487, DOI 10.1021/la703196b
   JOACHIM C, 1995, PHYS REV LETT, V74, P2102, DOI 10.1103/PhysRevLett.74.2102
   Kushmerick JG, 2002, J AM CHEM SOC, V124, P10654, DOI 10.1021/ja027090n
   Liang WJ, 2002, NATURE, V417, P725, DOI 10.1038/nature00790
   Lin HC, 2005, APPL PHYS LETT, V87, DOI 10.1063/1.2120904
   Mahapatro AK, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2183820
   MOODERA JS, 1982, APPL PHYS LETT, V41, P488, DOI 10.1063/1.93541
   Rampi MA, 2002, CHEM PHYS, V281, P373, DOI 10.1016/S0301-0104(02)00445-7
   Reed MA, 1997, SCIENCE, V278, P252, DOI 10.1126/science.278.5336.252
   SIMMONS JG, 1963, J APPL PHYS, V34, P1793, DOI 10.1063/1.1702682
   Tyagi P., 2007, P 2 IEEE INT C NANOM, P191
   Tyagi P, 2007, J AM CHEM SOC, V129, P4929, DOI 10.1021/ja065789d
   Zhou C, 1997, APPL PHYS LETT, V71, P611, DOI 10.1063/1.120195
NR 19
TC 2
Z9 2
U1 0
U2 15
PU AMER INST PHYSICS
PI MELVILLE
PA CIRCULATION & FULFILLMENT DIV, 2 HUNTINGTON QUADRANGLE, STE 1 N O 1,
   MELVILLE, NY 11747-4501 USA
SN 0003-6951
J9 APPL PHYS LETT
JI Appl. Phys. Lett.
PD NOV 15
PY 2010
VL 97
IS 20
AR 203111
DI 10.1063/1.3514253
PG 3
WC Physics, Applied
SC Physics
GA 684JC
UT WOS:000284545200059
DA 2018-03-20
ER

PT J
AU Luo, J
   Eitel, RE
AF Luo, Jin
   Eitel, Richard E.
TI A Biocompatible Low Temperature Co-fired Ceramic Substrate for
   Biosensors
SO INTERNATIONAL JOURNAL OF APPLIED CERAMIC TECHNOLOGY
LA English
DT Article
ID ANORTHITE-BASED GLASS; DIELECTRIC-PROPERTIES; LTCC APPLICATIONS;
   TECHNOLOGY; SYSTEM; FLOW; FILM; PCR
AB Low temperature co-fired ceramics (LTCC) are widely utilized in the fabrication of compact, three dimensional, and highly integrated microelectronic components. Typical applications include military and mobile electronics applications requiring custom, hermetic, and/or high reliability packaging. These characteristics make LTCC attractive for use in microfluidic and biomedical application. However, commercial LTCC systems are not designed for biomedical applications and have unknown cytocompatibility. In the current work, an LTCC tape has been developed starting with materials of known composition and biocompatibility, a commercially available lime silicate glass and alumina. Tapes achieve high density for sintering temperatures compatible with LTCC processing (850<T<1000 degrees C). The LTCC also exhibits low dielectric constant (K=9.3) and dielectric loss (tan d<0.005). A commercial gold electrode paste has also been co-fired with the LTCC, with no delamination, cracks nor camber observed. In vitro biocompatibility was subsequently evaluated using human umbilical vein endothelial cells (HUVECs). HUVECs are observed to attach and spread on fibronectin-coated LTCC substrates, and also in the leachate obtained by soaking LTCC in cell medium for 7days. These results establish that the developed LTCC material is biocompatible and suitable for in vitro applications utilizing live cells.
C1 [Luo, Jin; Eitel, Richard E.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Luo, J (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM jlu227@uky.edu
RI Eitel, Richard/E-2889-2010
OI Eitel, Richard/0000-0002-5090-2075
FU DEPSCOR/ONR; University of Kentucky Center for Clinical and
   Translational Science (CTSA)
FX The authors thank Dr. Kimberly Anderson (Department of Chemical and
   Materials Engineering, University of Kentucky) for providing
   experimental guidance and resources. The authors also thank William
   Mercke, David Cochran, Jennifer Fischer and Samantha Meenach for helping
   with cell culture experiments. The project described was supported in
   part by the DEPSCOR/ONR and University of Kentucky Center for Clinical
   and Translational Science (CTSA).
CR Bembnowicz P, 2011, OPT APPL, V41, P471
   Chang CR, 1999, J AM CERAM SOC, V82, P1725, DOI 10.1111/j.1151-2916.1999.tb01992.x
   Ciosek P, 2009, ANAL BIOANAL CHEM, V393, P2029, DOI 10.1007/s00216-009-2651-x
   Dai SXH, 2002, J AM CERAM SOC, V85, P828
   de Torres HB, 2010, SENSOR ACTUAT A-PHYS, V160, P109, DOI 10.1016/j.sna.2010.04.010
   Ewsuk K. G., 1990, CERAMIC T, V15, P279
   Ewsuk K. G., 1987, CERAM T CERAM POWD 2, V1, P967
   Feingold AH, 2002, P SOC PHOTO-OPT INS, V4931, P65
   Gongora-Rubio MR, 2001, SENSOR ACTUAT A-PHYS, V89, P222, DOI 10.1016/S0924-4247(00)00554-9
   Gongora-Rubio MR, 2004, SENSOR ACTUAT B-CHEM, V103, P468, DOI 10.1016/j.snb.2004.05.007
   Ibanez-Garcia N, 2006, SENSOR ACTUAT B-CHEM, V118, P67, DOI 10.1016/j.snb.2006.04.063
   Jantunen H, 2000, J EUR CERAM SOC, V20, P2331, DOI 10.1016/S0955-2219(00)00145-X
   Jones W. K., 2000, INT J MICROCIRCUITS, V23, P5
   Kemethmuller S, 2007, J AM CERAM SOC, V90, P64, DOI 10.1111/j.1551-2916.2006.01362.x
   Kumar CJD, 2008, J AM CERAM SOC, V91, P652, DOI 10.1111/j.1551-2916.2007.02160.x
   Liu JX, 2003, THIN SOLID FILMS, V429, P225, DOI 10.1016/S0040-6090(03)00146-9
   Lo CL, 2002, J AM CERAM SOC, V85, P2230, DOI 10.1111/j.1151-2916.2002.tb00440.x
   Rajesh S, 2012, INT J APPL CERAM TEC, V9, P52, DOI 10.1111/j.1744-7402.2011.02684.x
   Sadler DJ, 2003, IEEE T COMPON PACK T, V26, P309, DOI 10.1109/TCAPT.2003.815093
   Sebastian MT, 2008, INT MATER REV, V53, P57, DOI 10.1179/174328008X277524
   Sjogren G, 2000, J PROSTHET DENT, V84, P229, DOI 10.1067/mpr.2000.107227
   Smetana W, 2007, MICROELECTRON ENG, V84, P1240, DOI 10.1016/j.mee.2007.01.155
   Whitesides GM, 2006, NATURE, V442, P368, DOI 10.1038/nature05058
   Yager P, 2006, NATURE, V442, P412, DOI 10.1038/nature05064
   Zhang WL, 2012, INT J APPL CERAM TEC, V9, P60, DOI 10.1111/j.1744-7402.2010.02581.x
NR 25
TC 7
Z9 7
U1 0
U2 23
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1546-542X
EI 1744-7402
J9 INT J APPL CERAM TEC
JI Int. J. Appl. Ceram. Technol.
PD MAY
PY 2014
VL 11
IS 3
SI SI
BP 436
EP 442
DI 10.1111/ijac.12206
PG 7
WC Materials Science, Ceramics
SC Materials Science
GA AG7AP
UT WOS:000335570700004
DA 2018-03-19
ER

PT J
AU Leontsev, SO
   Eitel, RE
AF Leontsev, Serhiy O.
   Eitel, Richard E.
TI Dielectric and Piezoelectric Properties in Mn-Modified
   (1-x)BiFeO3-xBaTiO(3) Ceramics
SO JOURNAL OF THE AMERICAN CERAMIC SOCIETY
LA English
DT Article
ID BIFEO3-BATIO3 SOLID-SOLUTIONS; ROOM-TEMPERATURE; BIFEO3 CERAMICS;
   SYSTEM; PHASE; FILMS
AB In the current work, the bulk (1-x)BiFeO3-xBaTiO(3) system has been studied as a potential lead-free piezoelectric material. Barium titanate (BaTiO3) in solid solution with bismuth ferrite (BiFeO3) is observed to stabilize the perovskite structure and improve switching behavior. Samples with various content of BaTiO3 were prepared via solid-state route, and pure perovskite phase was confirmed by X-ray diffraction. Modification of the BaTiO3-BiFeO3 material with Mn improved DC resistivity by one to five orders of magnitude (7.6 x 1012 vs. 2.7 x 107 center dot m for 25 mol% BaTiO3 at room temperature) and polarization hysteresis measurements indicated "hard" ferroelectric behavior with the highest strain response at 33 mol% BaTiO3. Finally, low-field piezoelectric d(33) coefficient of 116 pC/N and ferroelectric transition temperature above 450 degrees C are reported for 25 mol% BaTiO3 composition.
C1 [Leontsev, Serhiy O.; Eitel, Richard E.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Leontsev, SO (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM leontsev@uky.edu
RI Eitel, Richard/E-2889-2010
OI Eitel, Richard/0000-0002-5090-2075
CR EGERTON L, 1959, J AM CERAM SOC, V42, P438, DOI 10.1111/j.1151-2916.1959.tb12971.x
   HALLIYAL A, 1987, AM CERAM SOC BULL, V66, P671
   He LX, 2000, J MATER SCI, V35, P2477, DOI 10.1023/A:1004717702149
   Itoh N., 2007, FERROELECTRICS, V356, P19
   Jaffe B., 1971, PIEZOELECTRIC CERAMI
   Jun YK, 2005, SOLID STATE COMMUN, V135, P133, DOI 10.1016/j.ssc.2005.03.038
   KUBEL F, 1990, ACTA CRYSTALLOGR B, V46, P698, DOI 10.1107/S0108768190006887
   Kumar MM, 1998, PHYS STATUS SOLIDI A, V165, P317, DOI 10.1002/(SICI)1521-396X(199801)165:1<317::AID-PSSA317>3.0.CO;2-Y
   Kumar MM, 2000, J APPL PHYS, V87, P855, DOI 10.1063/1.371953
   Kumar MM, 1999, J PHYS-CONDENS MAT, V11, P8131, DOI 10.1088/0953-8984/11/41/315
   Lebeugle D, 2007, APPL PHYS LETT, V91, DOI 10.1063/1.2753390
   Lebeugle D, 2007, PHYS REV B, V76, DOI 10.1103/PhysRevB.76.024116
   LEONTSEV SO, 2009, P 2009 14 US JAP SEM
   Liu HR, 2007, J SOL-GEL SCI TECHN, V41, P123, DOI 10.1007/s10971-006-0514-x
   Palai R, 2008, PHYS REV B, V77, DOI 10.1103/PhysRevB.77.014110
   Scott JF, 2008, J PHYS-CONDENS MAT, V20, DOI 10.1088/0953-8984/20/02/021001
   Shrout TR, 2007, J ELECTROCERAM, V19, P113, DOI 10.1007/s10832-007-9047-0
   SHROUT TR, 1987, AM CERAM SOC BULL, V66, P704
   Shvartsman VV, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2731312
   SOSNOWSKA I, 1982, J PHYS C SOLID STATE, V15, P4835, DOI 10.1088/0022-3719/15/23/020
   Ueda K, 1999, APPL PHYS LETT, V75, P555, DOI 10.1063/1.124420
   Wang J, 2003, SCIENCE, V299, P1719, DOI 10.1126/science.1080615
   Wang YP, 2004, APPL PHYS LETT, V84, P1731, DOI 10.1063/1.1667612
   Zhang SJ, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1968419
   Zhang SJ, 2005, IEEE T ULTRASON FERR, V52, P2131, DOI 10.1109/TUFFC.2005.1561684
NR 25
TC 181
Z9 186
U1 14
U2 171
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0002-7820
J9 J AM CERAM SOC
JI J. Am. Ceram. Soc.
PD DEC
PY 2009
VL 92
IS 12
BP 2957
EP 2961
DI 10.1111/j.1551-2916.2009.03313.x
PG 5
WC Materials Science, Ceramics
SC Materials Science
GA 524FO
UT WOS:000272129400021
DA 2018-03-19
ER

PT J
AU Islam, SZ
   Rankin, SE
AF Islam, Syed Z.
   Rankin, Stephen E.
TI Hydrazine-based synergistic Ti(III)/N doping of surfactant-templated
   TiO2 thin films for enhanced visible light photocatalysis
SO MATERIALS CHEMISTRY AND PHYSICS
LA English
DT Article
DE Chemical synthesis; Thin films; Nanostructures; Electrochemical
   properties; Non-crystalline materials
ID N-DOPED TIO2; NITROGEN-MODIFIED TITANIA; SOL-GEL PROCESS; MESOPOROUS
   TIO2; WATER; NANOPARTICLES; IRRADIATION; PERFORMANCE; FABRICATION;
   OXIDES
AB This study reports the preparation of titanium (Ti3+) and nitrogen co-doped cubic ordered mesoporous TiO2 thin films using N2H4 treatment. The resulting co-doped TiO2 (Ti3+-N-TiO2) thin films show significant enhancements in visible light absorption and photocatalytic activity. Cubic ordered mesoporous TiO2 thin films were prepared via a sol-gel method with Pluronic F127 as the pore template. After brief calcination, the TiO2 films were dipped into hydrazine hydrate which acts both as a nitrogen source and as a reducing agent, followed by heating at low temperature (90 degrees C). The hydrazine treatment period was varied from 5 to 20 h to obtain different degrees of reduction and nitrogen doping. X-ray photoelectron spectroscopy (XPS) analyses and UV-vis absorbance spectra of Ti3+-N-TiO2 films indicate that the incorporated N atoms and Ti3+ reduce the band gap of TiO2 and thus enhance the absorption of visible light. The corresponding visible light photocatalytic activity of Ti3+-N-TiO2 films was determined from the photocatalytic degradation of methylene blue under visible light illumination (at 455 nm). The Ti3+-N-TiO2 films prepared with 10 h of treatment show the optimum photocatalytic activity, with a pseudo first order rate coefficient of 0.12 h(-1), which is 3 times greater than that of undoped TiO2 films. Calcination temperature and time were varied prior to hydrazine treatment to confirm that a brief calcination at low temperature (10 min at 350 degrees C) gave the best photochemical activity. In photoelectrochemical water oxidation using a 455 nm LED, the Ti3+-N-TiO2 films prepared with 10 h of N2H4 treatment show about 4 times the photocurrent compared to undoped TiO2 films. The present study suggests that hydrazine induced doping is a promising approach to enable synergistic incorporation of N and Ti3+ into the lattice of surfactant-templated TiO2 films and enhanced visible light photoactivity, but that the benefits are limited by gradual mesostructure deterioration. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Islam, Syed Z.; Rankin, Stephen E.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Rankin, SE (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM srankin@engr.uky.edu
FU U.S. Department of Energy EPSCoR Implementation award
   [DE-FG02-07-ER46375]; National Science Foundation EPSCoR Research
   Infrastructure Initiative award [IIA-1355438]
FX Preliminary experiments to develop nitrogen doping and photocatalytic
   testing methods were performed as part of a U.S. Department of Energy
   EPSCoR Implementation award supported by grant no. DE-FG02-07-ER46375.
   The detailed study as a function of hydrazine exposure time and further
   analysis of the spectroscopic and structural characteristics of the
   doped films was performed as part of an National Science Foundation
   EPSCoR Research Infrastructure Initiative award supported by grant no.
   IIA-1355438. The authors thank Dr. Xudong Fan at Michigan State
   University for performing the TEM analysis of TiO<INF>2</INF> thin films
   and Prof. Y.T. Cheng for access to the XPS instrument at the University
   of Kentucky.
CR Aman N, 2010, J MATER CHEM, V20, P10876, DOI 10.1039/c0jm01342k
   Ao YH, 2009, MICROPOR MESOPOR MAT, V118, P382, DOI 10.1016/j.micromeso.2008.09.010
   Asahi R, 2001, SCIENCE, V293, P269, DOI 10.1126/science.1061051
   Banerjee S, 2014, J PHYS CHEM LETT, V5, P2543, DOI 10.1021/jz501030x
   Beranek R, 2011, ADV PHYS CHEM, V2011, DOI DOI 10.1155/2011/786759
   Bloh JZ, 2014, J PHYS CHEM C, V118, P21281, DOI 10.1021/jp507264g
   Burda C, 2003, NANO LETT, V3, P1049, DOI 10.1021/nl034332o
   Cao XP, 2012, J MATER CHEM, V22, P15309, DOI 10.1039/c2jm31576a
   Chen DM, 2008, APPL SURF SCI, V255, P2879, DOI 10.1016/j.apsusc.2008.08.032
   Chen XB, 2011, SCIENCE, V331, P746, DOI 10.1126/science.1200448
   Cong Y, 2007, J PHYS CHEM C, V111, P6976, DOI 10.1021/jp0685030
   Crepaldi EL, 2003, J AM CHEM SOC, V125, P9770, DOI 10.1021/ja030070g
   Das S, 2016, PHYS CHEM CHEM PHYS, V18, P2896, DOI 10.1039/c5cp05178a
   Duminica RD, 2007, SURF COAT TECH, V201, P9349, DOI 10.1016/j.surfcoat.2007.04.061
   Fakhouri H, 2014, APPL CATAL B-ENVIRON, V144, P12, DOI 10.1016/j.apcatb.2013.06.028
   Fan J, 2011, J ENVIRON ENG-ASCE, V137, P171, DOI 10.1061/(ASCE)EE.1943-7870.0000311
   Fattakhova-Rohlfing D, 2014, CHEM REV, V114, P9487, DOI 10.1021/cr500201c
   Fu J, 2013, CHEM ENG J, V219, P155, DOI 10.1016/j.cej.2013.01.032
   FUJISHIMA A, 1972, NATURE, V238, P37, DOI 10.1038/238037a0
   Gai LG, 2013, J SOLID STATE CHEM, V199, P271, DOI 10.1016/j.jssc.2013.01.010
   Grilli R, 2015, MATER CHEM PHYS, V159, P25, DOI 10.1016/j.matchemphys.2015.03.044
   Hanzu I, 2011, J PHYS CHEM C, V115, P5989, DOI 10.1021/jp1111982
   Hernandez S, 2015, PHYS CHEM CHEM PHYS, V17, P7775, DOI 10.1039/c4cp05857g
   Hidalgo D, 2014, INT J HYDROGEN ENERG, V39, P21512, DOI 10.1016/j.ijhydene.2014.02.163
   Hidetaka I., 2010, CHEM PHYS LETT, V489, P81
   HOWARD CJ, 1991, ACTA CRYSTALLOGR B, V47, P462, DOI 10.1107/S010876819100335X
   Hu SZ, 2014, J POWER SOURCES, V250, P30, DOI 10.1016/j.jpowsour.2013.10.132
   Islam SZ, 2016, MICROPOR MESOPOR MAT, V220, P120, DOI 10.1016/j.micromeso.2015.08.030
   Jia T., 2014, INT J PHOTOENERGY, V2014, P1
   Katsanaki AV, 2013, APPL CATAL B-ENVIRON, V140, P619, DOI 10.1016/j.apcatb.2013.04.070
   Kisch H, 2007, J PHYS CHEM C, V111, P11445, DOI 10.1021/jp066457y
   Lan M., 2008, APPL SURF SCI, V255, P2574
   Lewis NS, 2007, SCIENCE, V315, P798, DOI 10.1126/science.1137014
   Li DZ, 2007, J SOLID STATE CHEM, V180, P2630, DOI 10.1016/j.jssc.2007.07.009
   Li JT, 2015, CATAL SCI TECHNOL, V5, P1360, DOI 10.1039/c4cy00974f
   Lin H, 2010, J APPL PHYS, V107, DOI 10.1063/1.3428514
   Liu EQ, 2012, CHINESE J CATAL, V33, P1665, DOI 10.1016/S1872-2067(11)60437-3
   Liu G, 2010, J MATER CHEM, V20, P831, DOI [10.1039/b909930a, 10.1039/B909930A]
   Liu SH, 2012, APPL ENERG, V100, P148, DOI 10.1016/j.apenergy.2012.03.063
   Mao CY, 2014, ANGEW CHEM INT EDIT, V53, P10485, DOI 10.1002/anie.201406017
   Nakano Y, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1896450
   Nolan NT, 2012, J HAZARD MATER, V211, P88, DOI 10.1016/j.jhazmat.2011.08.074
   Pelaez M, 2013, CHEM COMMUN, V49, P10118, DOI 10.1039/c3cc44415e
   Pelaez M, 2012, APPL CATAL B-ENVIRON, V125, P331, DOI 10.1016/j.apcatb.2012.05.036
   Rane KS, 2006, J SOLID STATE CHEM, V179, P3033, DOI 10.1016/j.jssc.2006.05.033
   Sakai N, 2004, J AM CHEM SOC, V126, P5851, DOI 10.1021/ja0394582
   Selvam K, 2012, APPL CATAL A-GEN, V413, P213, DOI 10.1016/j.apcata.2011.11.011
   Selvam K, 2012, RSC ADV, V2, P2848, DOI 10.1039/c2ra01178f
   Soni SS, 2008, ADV MATER, V20, P1493, DOI 10.1002/adma.200701066
   Spadavecchia F, 2011, J PHYS CHEM C, V115, P6381, DOI 10.1021/jp2003968
   Su J, 2014, RSC ADV, V4, P13979, DOI 10.1039/c3ra47757f
   Sun HQ, 2008, SOL ENERG MAT SOL C, V92, P76, DOI 10.1016/j.solmat.2007.09.003
   Sun HQ, 2009, J PHOTOCH PHOTOBIO A, V201, P15, DOI 10.1016/j.jphotochem.2008.08.021
   Varghese OK, 2009, NANO LETT, V9, P731, DOI 10.1021/nl803258p
   Wang J, 2009, J AM CHEM SOC, V131, P12290, DOI 10.1021/ja903781h
   Wang JG, 2013, APPL CATAL B-ENVIRON, V134, P198, DOI 10.1016/j.apcatb.2013.01.006
   Wu QL, 2011, LANGMUIR, V27, P9557, DOI 10.1021/la201388n
   Wu YC, 2014, J ALLOY COMPD, V604, P164, DOI 10.1016/j.jallcom.2014.03.023
   Xu JJ, 2010, APPL SURF SCI, V256, P4397, DOI 10.1016/j.apsusc.2010.02.037
   Yang GD, 2010, J MATER CHEM, V20, P5301, DOI 10.1039/c0jm00376j
   Yokosuka Y, 2009, RES CHEM INTERMEDIAT, V35, P43, DOI 10.1007/s11164-008-0019-z
   Zakrzewska K, 2015, INT J HYDROGEN ENERG, V40, P815, DOI 10.1016/j.ijhydene.2014.09.097
   Zalas M, 2014, CATAL TODAY, V230, P91, DOI 10.1016/j.cattod.2013.12.032
   Zhang HJ, 2009, J MATER CHEM, V19, P5089, DOI 10.1039/b821991e
   Zhou Wq, 2013, CHINESE J CATAL, V34, P1250, DOI 10.1016/S1872-2067(12)60578-6
   Zuo F, 2012, ANGEW CHEM INT EDIT, V51, P6223, DOI 10.1002/anie.201202191
   Zuo F, 2010, J AM CHEM SOC, V132, P11856, DOI 10.1021/ja103843d
NR 67
TC 6
Z9 6
U1 11
U2 45
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0254-0584
EI 1879-3312
J9 MATER CHEM PHYS
JI Mater. Chem. Phys.
PD OCT 1
PY 2016
VL 182
BP 382
EP 393
DI 10.1016/j.matchemphys.2016.07.046
PG 12
WC Materials Science, Multidisciplinary
SC Materials Science
GA DW3EM
UT WOS:000383524900047
DA 2018-03-20
ER

PT J
AU Tan, B
   Rankin, SE
AF Tan, Bing
   Rankin, Stephen E.
TI Effects of progressive changes in organoalkoxysilane structure on the
   gelation and pore structure of templated and non-templated sol-gel
   materials
SO JOURNAL OF NON-CRYSTALLINE SOLIDS
LA English
DT Article
DE micelles; porosity; nanocomposites; silicates; organic-inorganic
   hybrids; sol-gels (xerogels); solution chemistry
ID MESOPOROUS MOLECULAR-SIEVES; ORGANIC-INORGANIC MATERIALS; BRIDGED
   POLYSILSESQUIOXANES; COMPOSITE-MATERIALS; SILICA; ADSORPTION; SIZE;
   POLYMERIZATION; CYCLIZATION; MECHANISM
AB We study how progressive changes in silane structure affect the synthesis and properties of organosilicas. Tetraethoxysilane (TEOS), tetramethoxysilane (TMOS), methyltrimethoxysilane (MTMS), bis(trimethoxysilyl)ethane (BTMSE), bis(trimethoxysilyl)hexane (BTMSH), and bis(trimethoxysilylpropyl)amine (BTMSPA) are used as precursors in non-templated base and acid-catalyzed sol-gel processes, and in templated processes with cetyltrimethylammonium bromide (CTAB) and polyoxyethylene 10 lauryl ether (C12E10). The gel time of materials made without templates is mainly controlled by the structure of the silane rather than its reactivity. For instance, a dangling methyl group (MTMS) inhibits gelation, while a short bridging chain (BTMSE) promotes gelation. In basic conditions, mesoporous materials are obtained with TEOS and TMOS, while microporous materials are obtained with organically modified silanes without added amine. Dipropylamine, originally added as a catalyst, in fact templates mesopores in BTMSH-derived organosilica. In acidic conditions without pore templates, all products are microporous. In the presence of CTAB, mesopore templating occurs with TEOS. TMOS. BTMSE, and BTMSPA. With C12E10, mesopore templating occurs with TEOS, TMOS, and BTMSE. Surprisingly, the BTMSE-based material has the most uniform mesopores of all samples in the C12E10 series. Mesopore templating fails when a dangling organic limits the formation of stable pore walls (MTMS) or a large hydrophobic chain disrupts the formation surfactant micelles (BTMSH). (c) 2006 Elsevier B.V. All rights reserved.
C1 Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Rankin, SE (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM srankin@engr.uky.edu
RI Rankin, Stephen/A-3265-2013
OI Rankin, Stephen/0000-0002-8615-7564
CR ASSINK RA, 1988, J NON-CRYST SOLIDS, V99, P359, DOI 10.1016/0022-3093(88)90441-3
   BECK JS, 1992, J AM CHEM SOC, V114, P10834, DOI 10.1021/ja00053a020
   Boissiere C, 2000, CHEM MATER, V12, P2902, DOI 10.1021/cm991188s
   Boissiere C, 2001, CHEM MATER, V13, P3580, DOI 10.1021/cm011031b
   Brevett C.S., 1991, J INORG ORGANOMET P, V1, P335
   BRINEKR CJ, 1990, SOL GEL SCI PHYS CHE
   DAY VW, 1985, J AM CHEM SOC, V107, P8262, DOI 10.1021/ja00312a077
   Flory PJ, 1941, J AM CHEM SOC, V63, P3083, DOI 10.1021/ja01856a061
   Goto Y, 2002, CHEM COMMUN, P2410, DOI 10.1039/b207825b
   Hayward RC, 2001, MICROPOR MESOPOR MAT, V44, P619, DOI 10.1016/S1387-1811(01)00242-6
   Hunks WJ, 2004, CHEM COMMUN, P2426, DOI 10.1039/b410397a
   Hunks WJ, 2004, CHEM MATER, V16, P5465, DOI 10.1021/cm048986p
   HUO QS, 1994, NATURE, V368, P317, DOI 10.1038/368317a0
   HUO QS, 1994, CHEM MATER, V6, P1176, DOI 10.1021/cm00044a016
   Jaroniec M, 1999, LANGMUIR, V15, P5410, DOI 10.1021/la990136e
   Judeinstein P, 1996, J MATER CHEM, V6, P511, DOI 10.1039/jm9960600511
   KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0
   Kruk M, 1997, LANGMUIR, V13, P6267, DOI 10.1021/la970776m
   Kumar D, 2001, COLLOID SURFACE A, V187, P109, DOI 10.1016/S0927-7757(01)00638-0
   Loy DA, 1999, J AM CHEM SOC, V121, P5413, DOI 10.1021/ja982751v
   LOY DA, 1995, CHEM REV, V95, P1431, DOI 10.1021/cr00037a013
   Loy DA, 2000, CHEM MATER, V12, P3624, DOI 10.1021/cm000451i
   Loy DA, 1999, CHEM MATER, V11, P3333, DOI 10.1021/cm990405m
   Matejka L, 2000, J NON-CRYST SOLIDS, V270, P34, DOI 10.1016/S0022-3093(00)00074-0
   MONNIER A, 1993, SCIENCE, V261, P1299, DOI 10.1126/science.261.5126.1299
   NG LV, 1995, MACROMOLECULES, V28, P6471, DOI 10.1021/ma00123a012
   OVIATT HW, 1993, CHEM MATER, V5, P943, DOI 10.1021/cm00031a012
   Rankin SE, 2000, MACROMOLECULES, V33, P7639, DOI 10.1021/ma000132c
   Rao MS, 2003, J SOL-GEL SCI TECHN, V26, P553, DOI 10.1023/A:1020763719171
   Sayari A, 2001, CHEM MATER, V13, P3151, DOI 10.1021/cm0110391
   Sefcik J, 2003, J PHYS CHEM B, V107, P52, DOI 10.1021/jp026361d
   Shea KJ, 2001, CHEM MATER, V13, P3306, DOI 10.1021/cm011074s
   SING KSW, 1985, PURE APPL CHEM, V57, P603, DOI 10.1351/pac198557040603
   Stein A, 2000, ADV MATER, V12, P1403, DOI 10.1002/1521-4095(200010)12:19<1403::AID-ADMA1403>3.0.CO;2-X
   Tan B, 2004, J PHYS CHEM B, V108, P20122, DOI 10.1021/jp046425f
   Tan B, 2006, J PHYS CHEM B, V110, P22353, DOI 10.1021/jp060376k
   TANEV PT, 1995, SCIENCE, V267, P865, DOI 10.1126/science.267.5199.865
   Vinu A, 2004, CHEM MATER, V16, P3056, DOI 10.1021/cm049718u
   Wright J. D., 2000, SOL GEL MAT CHEM APP
   Yang J, 2003, STUD SURF SCI CATAL, V146, P775
   Ying JY, 1999, ANGEW CHEM INT EDIT, V38, P56, DOI 10.1002/(SICI)1521-3773(19990115)38:1/2<56::AID-ANIE56>3.0.CO;2-E
   Yiu HHP, 2001, PHYS CHEM CHEM PHYS, V3, P2983, DOI 10.1039/b104729a
   ZHANG Z, 1995, J NON-CRYST SOLIDS, V189, P212, DOI 10.1016/0022-3093(95)00209-X
   Zub YL, 2001, MENDELEEV COMMUN, P208
NR 44
TC 15
Z9 15
U1 0
U2 39
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-3093
EI 1873-4812
J9 J NON-CRYST SOLIDS
JI J. Non-Cryst. Solids
PD DEC 15
PY 2006
VL 352
IS 52-54
BP 5453
EP 5462
DI 10.1016/j.jnoncrysol.2006.09.026
PG 10
WC Materials Science, Ceramics; Materials Science, Multidisciplinary
SC Materials Science
GA 118CJ
UT WOS:000242919300001
DA 2018-03-20
ER

PT J
AU Akenhead, ML
   Fukuda, S
   Schmid-Schonbein, GW
   Shin, HY
AF Akenhead, Michael L.
   Fukuda, Shunichi
   Schmid-Schoenbein, Geert W.
   Shin, Hainsworth Y.
TI Fluid shear-induced cathepsin B release in the control of Mac1-dependent
   neutrophil adhesion
SO JOURNAL OF LEUKOCYTE BIOLOGY
LA English
DT Article
DE mechanotransduction; mechanobiology; integrins; leukocytes; cell
   signaling
ID SPONTANEOUSLY HYPERTENSIVE-RAT; CIRCULATING LEUKOCYTES;
   POLYMORPHONUCLEAR LEUKOCYTES; ACTIVATED PLATELETS; ENDOTHELIAL-CELLS;
   STRESS RESPONSE; P-SELECTIN; IN-VIVO; CLEAVAGE; MECHANISMS
AB There is compelling evidence that circulatory hemodynamics prevent neutrophil activation, including adhesion to microvessels, in the microcirculation. However, the underlying mechanism or mechanisms by which that mechanoregulation occurs remain unresolved. Here, we report evidence that exposure to fluid shear stress (FSS) promotes neutrophils to release cathepsin B (ctsB) and that this autocrine regulatory event is antiadhesive for neutrophils on endothelial surfaces through Mac1-selective regulation. We used a combined cell-engineering and immunocytochemistry approach to find that ctsB was capable of cleaving Mac1 integrins on neutrophils and demonstrated that this proteolysis alters their adhesive functions. Under no-flow conditions, ctsB enhanced neutrophil migration though a putative effect on pseudopod retraction rates. We also established a flow-based cell detachment assay to verify the role of ctsB in the control of neutrophil adhesion by fluid flow stimulation. Fluid flow promoted neutrophil detachment from platelet and endothelial layers that required ctsB, consistent with its fluid shear stress-induced release. Notably, compared with leukocytes from wild-type mice, those from ctsB-deficient (ctsB2/2) mice exhibited an impaired CD18 cleavage response to FSS, significantly elevated baseline levels of CD18 surface expression, and an enhanced adhesive capacity to mildly inflamed post-capillary venules. Taken together, the results of the present study support a role for ctsB in a hemodynamic control mechanism that is antiadhesive for leukocytes on endothelium. These results have implications in the pathogenesis of chronic inflammation, microvascular dysfunction, and cardiovascular diseases involving sustained neutrophil activation in the blood and microcirculation.
C1 [Akenhead, Michael L.; Shin, Hainsworth Y.] Univ Kentucky, Dept Biomed Engn, 143 Graham Ave,514D Robot & Mfg Bldg, Lexington, KY 40506 USA.
   [Fukuda, Shunichi] Natl Hosp Org Kyoto Med Ctr, Dept Neurosurg, Kyoto, Japan.
   [Fukuda, Shunichi; Schmid-Schonbein, Geert W.] Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA.
RP Shin, HY (reprint author), Univ Kentucky, Dept Biomed Engn, 143 Graham Ave,514D Robot & Mfg Bldg, Lexington, KY 40506 USA.
EM hy.shin@uky.edu
FU National Heart, Lung, and Blood Institute [HL-10881]; U.S. National
   Institutes of Health [HL-083740-01, HL-43024]; National Science
   Foundation Integrative Graduate Education and Research Traineeship
   program [0653710]; National Science Foundation Kentucky Experimental
   Program to Stimulate Competitive Research Bioengineering Initiative
   [0814194]; pilot award of an Institutional Development Award program
   from the National Institute of General Medical Sciences of the U.S.
   National Institutes of Health [P20GM103527]; University of Kentucky Max
   Steckler Fellowship
FX This work was supported in part by the National Heart, Lung, and Blood
   Institute (Grant HL-10881 to G.W.S.S.), the U.S. National Institutes of
   Health (Grants HL-083740-01 and HL-43024 to H.Y.S. and G.W.S.S.), a
   National Science Foundation Integrative Graduate Education and Research
   Traineeship program (Grant 0653710 to M.L.A.), a National Science
   Foundation Kentucky Experimental Program to Stimulate Competitive
   Research Bioengineering Initiative (Grant 0814194 to H.Y.S.), a pilot
   award of an Institutional Development Award program from the National
   Institute of General Medical Sciences of the U.S. National Institutes of
   Health (Grant P20GM103527 to H.Y.S.), and a University of Kentucky Max
   Steckler Fellowship (to M.L.A.). We thank Dr. Christoph Peters,
   University of Freiburg (Freiburg, Germany), and Dr. Gregory J. Gores,
   Mayo Medical School, Clinic, and Foundation (Rochester, MN, USA) for
   kindly providing the ctsB<SUP>-/-</SUP> mice. We also thank Clint
   Branham and Jacob Schlarman, University of Kentucky, for help with flow
   studies.
CR Akenhead ML, 2014, BIOMECH MODEL MECHAN, V13, P861, DOI 10.1007/s10237-013-0541-9
   ANDERSON DC, 1986, J IMMUNOL, V137, P15
   Balaji KN, 2002, J EXP MED, V196, P493, DOI 10.1084/jem.20011836
   Berk BC, 2002, DRUG NEWS PERSPECT, V15, P133, DOI 10.1358/dnp.2002.15.3.704684
   BOHLEY P, 1992, EXPERIENTIA, V48, P151, DOI 10.1007/BF01923508
   Chen AY, 2010, AM J PHYSIOL-CELL PH, V299, pC1441, DOI 10.1152/ajpcell.00157.2010
   Coughlin MF, 2004, BIOPHYS J, V87, P2035, DOI 10.1529/biophysj.104.042192
   DEWITZ TS, 1977, J LAB CLIN MED, V90, P728
   Dhurat Rachita, 2014, J Cutan Aesthet Surg, V7, P189, DOI 10.4103/0974-2077.150734
   Diacovo TG, 1996, BLOOD, V88, P146
   Diez-Fraile A, 2003, CAN J VET RES, V67, P235
   Frosch BA, 1999, APMIS, V107, P28, DOI 10.1111/j.1699-0463.1999.tb01523.x
   Fukuda S, 2004, J LEUKOCYTE BIOL, V75, P664, DOI 10.1189/jlb.1003464
   Fukuda S, 2004, CIRC RES, V95, P100, DOI 10.1161/01.RES.0000133677.77465.38
   Fukuda S, 2003, P NATL ACAD SCI USA, V100, P13152, DOI 10.1073/pnas.2336130100
   Fukuda S, 2000, CIRC RES, V86, pE13
   Fukuda S, 2002, J LEUKOCYTE BIOL, V72, P133
   Ganguly A., 2012, JOVE-J VIS EXP, V66, pe4032, DOI DOI 10.3791/4032
   HARRIS AG, 1993, AM J PHYSIOL, V264, pH909
   Helmke BP, 1998, BIORHEOLOGY, V35, P437, DOI 10.1016/S0006-355X(99)80021-3
   Hentzen ER, 2000, BLOOD, V95, P911
   Konstantopoulos K, 1998, CIRCULATION, V98, P873
   Makino A, 2006, AM J PHYSIOL-CELL PH, V290, pC1633, DOI 10.1152/ajpcell.00576.2005
   Makino A, 2005, AM J PHYSIOL-CELL PH, V288, pC863, DOI 10.1152/ajpcell.00358.2004
   Marschel P, 2002, ANN BIOMED ENG, V30, P333, DOI 10.1114/1.1475342
   MAZZONE A, 1995, HAEMATOLOGICA, V80, P161
   McCracken Jenna M, 2014, J Cell Death, V7, P15, DOI 10.4137/JCD.S11038
   Meijering E, 2012, METHOD ENZYMOL, V504, P183, DOI 10.1016/B978-0-12-391857-4.00009-4
   Mine S, 2001, INTERNAL MED, V40, P1085, DOI 10.2169/internalmedicine.40.1085
   Moazzam F, 1997, P NATL ACAD SCI USA, V94, P5338, DOI 10.1073/pnas.94.10.5338
   Pfaff M, 1999, FEBS LETT, V460, P17, DOI 10.1016/S0014-5793(99)01250-8
   Podgorski I, 2003, BIOCHEM SOC SYMP, V70, P263, DOI 10.1042/bss0700263
   Potter DR, 2008, CIRC RES, V102, P770, DOI 10.1161/CIRCRESAHA.107.160226
   Rezvan A, 2011, ANTIOXID REDOX SIGN, V15, P1433, DOI 10.1089/ars.2010.3365
   Root R K, 1990, Trans Am Clin Climatol Assoc, V101, P207
   Roshy S, 2003, CANCER METAST REV, V22, P271, DOI 10.1023/A:1023007717757
   Sheikh S, 1996, BLOOD, V87, P5040
   Shin HY, 2008, J CELL PHYSIOL, V214, P528, DOI 10.1002/jcp.21235
   Shin HY, 2011, MECHANOBIOLOGY HANDBOOK, P139
   Shive MS, 2000, P NATL ACAD SCI USA, V97, P6710, DOI 10.1073/pnas.110463197
   Singer G, 2007, MICROCIRCULATION, V14, P375, DOI 10.1080/10739680701283158
   Sreeramkumar V, 2014, SCIENCE, V346, P1234, DOI 10.1126/science.1256478
   Sugihara-Seki M, 2003, J BIOMECH ENG-T ASME, V125, P628, DOI 10.1115/1.1611515
   Traub O, 1998, ARTERIOSCL THROM VAS, V18, P677, DOI 10.1161/01.ATV.18.5.677
   Yasu T, 1999, J AM COLL CARDIOL, V34, P578, DOI 10.1016/S0735-1097(99)00209-0
   Zen K, 2011, BLOOD, V117, P4885, DOI 10.1182/blood-2010-05-287722
   Zhang XY, 2014, ARTERIOSCL THROM VAS, V34, P587, DOI 10.1161/ATVBAHA.113.302868
   Zhang XY, 2013, J LEUKOCYTE BIOL, V93, P251, DOI 10.1189/jlb.0612302
   Zhang XY, 2011, AM J PHYSIOL-CELL PH, V301, pC451, DOI 10.1152/ajpcell.00458.2010
   Zhelev DV, 2004, BIOPHYS J, V87, P688, DOI 10.1529/biophysj.103.036699
NR 50
TC 0
Z9 0
U1 1
U2 2
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0741-5400
EI 1938-3673
J9 J LEUKOCYTE BIOL
JI J. Leukoc. Biol.
PD JUL
PY 2017
VL 102
IS 1
BP 117
EP 126
DI 10.1189/jlb.3A0716-317RR
PG 10
WC Cell Biology; Hematology; Immunology
SC Cell Biology; Hematology; Immunology
GA FA3ZU
UT WOS:000405384400012
PM 28389621
OA green_published
DA 2018-03-19
ER

PT J
AU Frimpong, RA
   Fraser, S
   Hilt, JZ
AF Frimpong, Reynolds A.
   Fraser, Stew
   Hilt, J. Zach
TI Synthesis and temperature response analysis of magnetic-hydrogel
   nanocomposites
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
LA English
DT Article
DE N-isopropylacrylamide; poly(ethylene glycol); magnetic nanoparticles;
   superparamagnetic; responsive hydrogels
ID POLYMER MATRICES; DRUG RELEASE; GELS; FIELDS
AB Magnetically responsive hydrogel networks based on composites of magnetic nanoparticles and temperature responsive hydrogels were developed. These systems show great promise as active components of microscale and nanoscale devices and are expected to have a wide applicability in various biomedical applications. Specifically, nanocomposite hydrogel systems based on the temperature sensitive N-isopropylacrylamide hydrogels crosslinked with ethylene glycol dimethacrylate, tetraethylene glycol dimethacrylate, and poly(ethylene glycol) 400 dimethacrylate (PEG400DMA) were synthesized and characterized. The composite systems were synthesized by UV free-radical polymerization. Iron oxide magnetic nanoparticles were incorporated into the hydrogel systems by polymerizing mixtures of the nanoparticles and monomer solutions. The swelling response of these composite systems to different crosslinking molecular weights, temperature, and the effect of the presence of the magnetic nanoparticles were examined. (c) 2006 Wiley Periodicals, Inc.
C1 Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY USA.
RP Hilt, JZ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 F Paul Anderson Tower, Lexington, KY USA.
EM hilt@engr.uky.edu
CR Bashir R, 2002, APPL PHYS LETT, V81, P3091, DOI 10.1063/1.1514825
   Beebe DJ, 2000, NATURE, V404, P588, DOI 10.1038/35007047
   Bekiari V, 2004, LANGMUIR, V20, P7972, DOI 10.1021/la048866w
   BRAZEL CS, 1995, MACROMOLECULES, V28, P8016, DOI 10.1021/ma00128a007
   EDELMAN ER, 1985, J BIOMED MATER RES, V19, P67, DOI 10.1002/jbm.820190107
   EDELMAN ER, 1987, J BIOMED MATER RES, V21, P339, DOI 10.1002/jbm.820210307
   Hiergeist R, 1999, J MAGN MAGN MATER, V201, P420, DOI 10.1016/S0304-8853(99)00145-6
   Hilt JZ, 2003, BIOMED MICRODEVICES, V5, P177, DOI 10.1023/A:1025786023595
   HIROTSU S, 1987, J CHEM PHYS, V87, P1392, DOI 10.1063/1.453267
   Hoffman A. S., 2002, ADV DRUG DELIVERY RE, V43, P3, DOI DOI 10.1016/S0169-409X(01)00239-3
   KOST J, 1986, PHARM INT, V7, P60
   Leobandung W, 2003, J APPL POLYM SCI, V87, P1678, DOI 10.1002/app.11612
   Liang L, 2000, LANGMUIR, V16, P9895, DOI 10.1021/la000279v
   Mellott MB, 2001, BIOMATERIALS, V22, P929, DOI 10.1016/S0142-9612(00)00258-1
   Pardo-Yissar V, 2001, ADV MATER, V13, P1320, DOI 10.1002/1521-4095(200109)13:17<1320::AID-ADMA1320>3.0.CO;2-8
   Peppas NA, 2000, EUR J PHARM BIOPHARM, V50, P27, DOI 10.1016/S0939-6411(00)00090-4
   Peppas N. A., 1986, HYDROGELS MED PHARM
   Rosensweig RE, 2002, J MAGN MAGN MATER, V252, P370, DOI 10.1016/S0304-8853(02)00706-0
   Sershen SR, 2005, ADV MATER, V17, P1366, DOI 10.1002/adma.200401239
   Xulu PM, 2000, MACROMOLECULES, V33, P1716, DOI 10.1021/ma990967r
NR 20
TC 54
Z9 54
U1 1
U2 33
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1549-3296
J9 J BIOMED MATER RES A
JI J. Biomed. Mater. Res. Part A
PD JAN
PY 2007
VL 80A
IS 1
BP 1
EP 6
DI 10.1002/jbm.a.30962
PG 6
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 114PN
UT WOS:000242678200001
PM 16941587
OA gold
DA 2018-03-20
ER

PT J
AU Park, SH
   Baker, A
   Eitel, RE
   Randall, CA
   Uchino, K
AF Park, Seung-Ho
   Baker, Amanda
   Eitel, Richard E.
   Randall, Clive A.
   Uchino, Kenji
TI Active Optical Fiber Alignment with a Piezoelectric Ultrasonic Motor
   Integrated Into Low Temperature Cofired Ceramics
SO JOURNAL OF INTELLIGENT MATERIAL SYSTEMS AND STRUCTURES
LA English
DT Article
DE piezoelectric; optical fiber; alignment; cofiring; ultrasonic motor;
   LTCC; integration
ID PZT THICK-FILMS; LTCC; DEVICES; MODULE
AB The major goal of this research was to integrate an ultrasonic motor into a ceramic package for an active optical fiber alignment. Two degrees of freedom ultrasonic motor was successfully cofired with commercial low temperature cofired ceramic green tapes as well as with silver electrodes without encountering serious delamination, camber, and inter diffusion issues. High-power piezoelectric ceramics that can be sintered at 900 degrees C was used for the ultrasonic motor. The motor successfully achieved fiber-to-laser optical alignment. Once alignment was achieved, a pre-stressed structure maintained the position of the fiber without any external electrical field or adhesive material. This package design provided a unique ability to adjust and realign an optical fiber.
C1 [Park, Seung-Ho; Uchino, Kenji] Micromechatronics Inc, State Coll, PA 16803 USA.
   [Park, Seung-Ho; Baker, Amanda; Randall, Clive A.; Uchino, Kenji] Penn State Univ, Mat Res Inst, University Pk, PA 16802 USA.
   [Eitel, Richard E.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Park, SH (reprint author), Micromechatronics Inc, State Coll, PA 16803 USA.
EM sxp953@gmail.com
RI Eitel, Richard/E-2889-2010
OI Eitel, Richard/0000-0002-5090-2075
FU Office of Naval Research, USA [N00014-99-1-0754]; Center for Dielectric
   Studies; Center for Optical Technologies
FX This work was supported by the Office of Naval Research, USA through the
   Contract N00014-99-1-0754, the Center for Dielectric Studies, and the
   Center for Optical Technologies.
CR AOSHIMA S, 1992, IEEE PHOTONIC TECH L, V4, P462, DOI 10.1109/68.136487
   Baker A, 2005, INT J APPL CERAM TEC, V2, P514, DOI 10.1111/j.1744-7402.2005.02052.x
   CHUN J, 2006, OPT ENG, V45
   Donnelly NJ, 2008, J AM CERAM SOC, V91, P1013, DOI 10.1111/j.1551-2916.2007.02230.x
   Donnelly NJ, 2009, J AM CERAM SOC, V92, P405, DOI 10.1111/j.1551-2916.2008.02891.x
   EITEL RE, 2005, P IMAPS ACERS 1 INT
   Field LA, 1996, SENSOR ACTUAT A-PHYS, V53, P311, DOI 10.1016/0924-4247(96)80154-3
   Golonka LJ, 2005, MICROELECTRON INT, V22, P13, DOI 10.1108/13565360510592171
   Hrovat M, 2006, J EUR CERAM SOC, V26, P897, DOI 10.1016/j.jeurceramsoc.2004.12.025
   Hrovat M, 2003, J MATER SCI LETT, V22, P1193, DOI 10.1023/A:1025388214955
   Imanaka Y., 2005, MULTILAYERED LOW TEM, P1
   Juuti J, 2004, SENSOR ACTUAT A-PHYS, V110, P361, DOI 10.1016/j.sna.2003.10.055
   KIKUYA Y, 1993, OPT LETT, V18, P864, DOI 10.1364/OL.18.000864
   Kosaka H, 1996, ELECTRON LETT, V32, P1991, DOI 10.1049/el:19961311
   Krulevitch P, 1996, J MICROELECTROMECH S, V5, P270, DOI 10.1109/84.546407
   Lim K., 2007, J EUR CERAM SOC, V27, P4159
   Murata N, 1998, P ELECTR C, P1178, DOI 10.1109/ECTC.1998.678869
   NAKAMURA K, 1991, IEEE T ULTRASON FERR, V38, P481, DOI 10.1109/58.84293
   Ngamjarurojana A, 2008, CERAM INT, V34, P705, DOI 10.1016/j.ceramint.2007.09.012
   Owen M, 2000, IEEE TRANS ADV PACK, V23, P182, DOI 10.1109/6040.846631
   Park SH, 2008, JPN J APPL PHYS, V47, P313, DOI 10.1143/JJAP.47.313
   Park SH, 2006, JPN J APPL PHYS 1, V45, P2667, DOI 10.1143/JJAP.45.2667
   PARK SH, 2006, P ACT 2006 BREM GERM, P432
   Park TG, 2006, MATER CHEM PHYS, V98, P1, DOI 10.1016/j.matchemphys.2004.09.049
   TAKAHASHI S, 1993, JPN J APPL PHYS 1, V32, P2422, DOI 10.1143/JJAP.32.2422
   TSENG Y, 2003, IEEE T COMPON PACK T, V25, P541
   Tuominen J, 2006, J OPT A-PURE APPL OP, V8, pS398, DOI 10.1088/1464-4258/8/7/S17
   ZARNIK M, 2005, P 6 INT C THERM MECH, P338
   Zhang ZY, 2005, J LIGHTWAVE TECHNOL, V23, P567, DOI 10.1109/JLT.2004.841259
   HAAKE JM, 1996, Patent No. 5553182
   UCHINO K, 2007, Patent No. 7501743
NR 31
TC 6
Z9 6
U1 0
U2 23
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1045-389X
J9 J INTEL MAT SYST STR
JI J. Intell. Mater. Syst. Struct.
PD MAR
PY 2010
VL 21
IS 4
BP 469
EP 479
DI 10.1177/1045389X09357254
PG 11
WC Materials Science, Multidisciplinary
SC Materials Science
GA 563XB
UT WOS:000275169400007
DA 2018-03-19
ER

PT J
AU Rahman, MS
   Rankin, SE
AF Rahman, Mohammed Shahidur
   Rankin, Stephen E.
TI Lyotropic phase behavior of aqueous cationic/maltoside surfactant
   mixtures and predictive synthesis of ordered mesoporous silica using
   these surfactants
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
CT 231st National Meeting of the American-Chemical-Society
CY MAR 26-30, 2006
CL Atlanta, GA
SP Amer Chem Soc
C1 Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM msrahman@uky.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD MAR 26
PY 2006
VL 231
MA 196-COLL
PG 2
WC Chemistry, Multidisciplinary
SC Chemistry
GA 050YE
UT WOS:000238125903196
DA 2018-03-20
ER

PT J
AU Zhang, XY
   Hurng, J
   Chan, D
   Rateri, D
   Daugherty, A
   Schmid-Schonbein, G
   Shin, H
AF Zhang, Xiaoyan
   Hurng, Jonathan
   Chan, Darby
   Rateri, Debra L.
   Daugherty, Alan
   Schmid-Schoenbein, Geert W.
   Shin, Hainsworth Y.
TI Enhancement of Membrane Cholesterol Attenuates the Leukocyte Shear
   Stress Response
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 [Zhang, Xiaoyan; Shin, Hainsworth] Univ Kentucky, Ctr Biomed Engn, Lexington, KY 40506 USA.
   [Rateri, Debra; Daugherty, Alan] Univ Kentucky, Cardiovasc Res Ctr, Lexington, KY 40506 USA.
   [Hurng, Jonathan; Chan, Darby; Schmid-Schonbein, Geert] Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2010
VL 24
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA V28IW
UT WOS:000208675504763
DA 2018-03-20
ER

PT J
AU Hinds, BJ
AF Hinds, Bruce J.
TI INOR 556-Aligned carbon nanotube membranes as dramatic fluid flow and
   biomimetic platforms
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
CT 235th American-Chemical-Society National Meeting
CY APR 06-10, 2008
CL New Orleans, LA
SP Amer Chem Soc
C1 [Hinds, Bruce J.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM bjhinds@engr.uky.edu
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD APR 6
PY 2008
VL 235
MA 556-INOR
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA 519OA
UT WOS:000271775106552
DA 2018-03-20
ER

PT J
AU Hinds, B
AF Hinds, Bruce J.
TI Dramatic transport properties of carbon nanotube membranes for a robust
   protein channel mimetic platform
SO CURRENT OPINION IN SOLID STATE & MATERIALS SCIENCE
LA English
DT Review
DE Carbon nanotubes; Biomimetic; Water purification; Energy storage; Drug
   delivery; Membrane separations; Protein channel mimetics; Nanofluidics;
   Ion current
ID CHEMICAL-VAPOR-DEPOSITION; ELECTROOSMOTIC FLOW; MASS-TRANSPORT; FORCE
   MICROSCOPY; IONIC-DIFFUSION; WATER; MODEL; FUNCTIONALIZATION;
   PURIFICATION; DESALINATION
AB Carbon nanotube (CNT) membranes offer an exciting opportunity to mimic natural protein channels due to (1) a mechanism for dramatically enhanced fluid flow, (2) ability to place 'gatekeeper' chemistry at the entrance to pores, and (3) being electrically conductive to localize electric field or perform electrochemical transformations. The transport mechanisms through CNT membranes are primarily (1) ionic diffusion near bulk expectation, (2) gas flow enhanced 1-2 orders of magnitude primarily due to specular reflection, and (3) fluid flow 4-5 orders of magnitude faster than conventional materials due to a nearly ideal slip-boundary interface. Transport can be modulated by 'gatekeeper' chemistry at the pore entrance using steric hindrance, electrostatic attraction/repulsion, or biochemical state. Electroosmotic flow is seen to be highly power efficient and can act as a pump through regions of chemical selectivity. The fundamental requirements of mimicking protein channels are present in the CNT membrane system. This membrane structure is mechanically far more robust than lipid bilayer films, allowing for large-scale chemical separations, delivery or sensing based on the principles of protein channels. Applications ranging from water purification, energy generation and bio-separations are highlighted. (C) 2011 Elsevier Ltd. All rights reserved.
C1 Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Hinds, B (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM bjhinds@engr.uky.edu
FU NSF [0348544]; DOE EPSCoR [DE-FG02-07ER46375]; DARPA [W911NF-09-1-0267];
   NIH NIDA [R01DA018822]
FX The author would like to thanks students and post-doctoral fellows that
   contributed over the years to the research program on CNT membranes. In
   particular Nitin Chopra, Mainak Majumder, Karen Gerstandt, Xin Su, Dr.
   Ji Wu, Dr. Xinghau Sun. Support was provided by NSF CAREER (0348544),
   DOE EPSCoR (DE-FG02-07ER46375), DARPA (W911NF-09-1-0267) and NIH NIDA
   (R01DA018822).
CR Andrews R, 1999, CHEM PHYS LETT, V303, P467, DOI 10.1016/S0009-2614(99)00282-1
   Bahr JL, 2001, J AM CHEM SOC, V123, P6536, DOI 10.1021/ja010462s
   Bahr JL, 2001, CHEM MATER, V13, P3823, DOI 10.1021/cm0109903
   Che G, 1998, CHEM MATER, V10, P260, DOI 10.1021/cm970412f
   Corry B, 2008, J PHYS CHEM B, V112, P1427, DOI 10.1021/jp709845u
   Fornasiero F, 2008, P NATL ACAD SCI USA, V105, P17250, DOI 10.1073/pnas.0710437105
   Goldsmith J, J PHYS CHEM C UNPUB
   Goldsmith J, 2010, J PHYS CHEM LETT, V1, P528, DOI 10.1021/jz900173w
   Gong XJ, 2007, NAT NANOTECHNOL, V2, P709, DOI 10.1038/nnano.2007.320
   Hilal N, 2004, DESALINATION, V170, P281, DOI 10.1016/j.desal.2004.01.007
   Hille B., 1984, IONIC CHANNELS EXCIT
   Hinds BJ, 2004, SCIENCE, V303, P62, DOI 10.1126/science.1092048
   Hinds B, 2007, NAT NANOTECHNOL, V2, P673, DOI 10.1038/nnano.2007.354
   Holt JK, 2006, SCIENCE, V312, P1034, DOI 10.1126/science.1126298
   Huang SM, 2002, J PHYS CHEM B, V106, P3543, DOI 10.1021/jp014047y
   Hull RV, 2006, CHEM MATER, V18, P1780, DOI 10.1021/cm0518978
   Hummer G, 2001, NATURE, V414, P188, DOI 10.1038/35102535
   Jia YX, 2010, SEP PURIF TECHNOL, V75, P55, DOI 10.1016/j.seppur.2010.07.011
   Joseph S, 2008, NANO LETT, V8, P452, DOI 10.1021/nl072385q
   Kim S, 2007, NANO LETT, V7, P2806, DOI 10.1021/nl071414u
   Lauga Eric, 2005, HDB EXPT FLUID DYNAM
   Lee CY, 2010, SCIENCE, V329, P1320, DOI 10.1126/science.1193383
   Lee J, 2010, J APPL PHYS, V108
   Li D, 2010, J MATER CHEM, V20, P4551, DOI 10.1039/b924553g
   LOEB S, 1976, J MEMBRANE SCI, V1, P49, DOI 10.1016/S0376-7388(00)82257-7
   Majumder M, 2005, NATURE, V438, P44, DOI 10.1038/43844a
   Majumder M, 2005, J AM CHEM SOC, V127, P9062, DOI 10.1021/ja043013b
   Majumder M, 2008, J MEMBRANE SCI, V316, P89, DOI 10.1016/j.memsci.2007.09.068
   Majumder M, 2007, LANGMUIR, V23, P8624, DOI 10.1021/la700686k
   Majumder M, 2011, ACS NANO, V5, P3867, DOI 10.1021/nn200222g
   Mao ZG, 2001, J PHYS CHEM B, V105, P6916, DOI 10.1021/jp0103272
   Mauter MS, 2010, ACS NANO, V4, P6651, DOI 10.1021/nn102047j
   Merkulov VI, 2002, APPL PHYS LETT, V80, P4816, DOI 10.1063/1.1487920
   Mi WL, 2007, J MEMBRANE SCI, V304, P1, DOI 10.1016/j.memsci.2007.07.021
   Miller SA, 2004, J AM CHEM SOC, V126, P6226, DOI 10.1021/ja0496322
   Miller SA, 2002, J ELECTROANAL CHEM, V522, P66, DOI 10.1016/S0022-0728(02)00648-4
   Miller SA, 2001, J AM CHEM SOC, V123, P12335, DOI 10.1021/ja011926p
   Mitchell CA, 2002, MACROMOLECULES, V35, P8825, DOI 10.1021/ma020890y
   Mulder M, 1994, BASIC PRINCIPLES MEM
   Murata K, 2000, NATURE, V407, P599
   Nednoor P, 2005, CHEM MATER, V17, P3595, DOI 10.1021/cm047844s
   Nednoor P, 2007, J MATER CHEM, V17, P1755, DOI 10.1039/b703365f
   Ohba T, 2005, NANO LETT, V5, P227, DOI 10.1021/nl048327b
   Park J, 2010, DESALIN WATER TREAT, V15, P76, DOI 10.5004/dwt.2010.1670
   Qian D, 2000, APPL PHYS LETT, V76, P2868, DOI 10.1063/1.126500
   Ren ZF, 1998, SCIENCE, V282, P1105, DOI 10.1126/science.282.5391.1105
   Shannon MA, 2008, NATURE, V452, P301, DOI 10.1038/nature06599
   Sinnott SB, 1999, CHEM PHYS LETT, V315, P25, DOI 10.1016/S0009-2614(99)01216-6
   Skoulidas AI, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.185901
   Sokhan VP, 2002, J CHEM PHYS, V117, P8531, DOI 10.1063/1.1512643
   Srivastava A, 2004, NAT MATER, V3, P610, DOI 10.1038/nmat1192
   Su X, 2011, CARBON, V49, P1145, DOI 10.1016/j.carbon.2010.11.029
   Sun L, 2000, J AM CHEM SOC, V122, P12340, DOI 10.1021/ja002429w
   Sun XH, 2011, LANGMUIR, V27, P3150, DOI 10.1021/la104242p
   Walters DA, 2001, CHEM PHYS LETT, V338, P14, DOI 10.1016/S0009-2614(01)00072-0
   Wei BQ, 2002, NATURE, V416, P495, DOI 10.1038/416495a
   Wong SS, 1998, J AM CHEM SOC, V120, P8557, DOI 10.1021/ja9817803
   Wong-Ekkabut J, 2010, NAT NANOTECHNOL, V5, P555, DOI 10.1038/nnano.2010.152
   Wu HQ, 2010, J MEMBRANE SCI, V362, P374, DOI 10.1016/j.memsci.2010.06.064
   Wu J, RCS NANOTECHNOL, DOI [10.1039/c1nr10303b, DOI 10.1039/C1NR10303B]
   Wu J, 2010, P NATL ACAD SCI USA, V107, P11698, DOI 10.1073/pnas.1004714107
   Yu MA, 2010, J AM CHEM SOC, V132, P8285, DOI 10.1021/ja9091769
   Yu M, 2009, NANO LETT, V9, P225, DOI 10.1021/nl802816h
   Zhang M, 2000, JPN J APPL PHYS 2, V39, pL1242, DOI 10.1143/JJAP.39.L1242
   Zheng J, 2005, J CHEM PHYS, V122, DOI 10.1063/1.1908619
   Zhou WW, 2009, NANO RES, V2, P593, DOI [10.1007/S12274-009-9068-X, 10.1007/s12274-009-9068-x]
NR 66
TC 28
Z9 28
U1 2
U2 68
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1359-0286
J9 CURR OPIN SOLID ST M
JI Curr. Opin. Solid State Mat. Sci.
PD FEB
PY 2012
VL 16
IS 1
SI SI
BP 1
EP 9
DI 10.1016/j.cossms.2011.05.003
PG 9
WC Materials Science, Multidisciplinary; Physics, Applied; Physics,
   Condensed Matter
SC Materials Science; Physics
GA 882YQ
UT WOS:000299600200001
DA 2018-03-20
ER

PT J
AU Kanthamneni, N
   Sharma, S
   Meenach, SA
   Billet, B
   Zhao, JC
   Bachelder, EM
   Ainslie, KM
AF Kanthamneni, Naveen
   Sharma, Sadhana
   Meenach, Samantha A.
   Billet, Beau
   Zhao, Ji-Cheng
   Bachelder, Eric M.
   Ainslie, Kristy M.
TI Enhanced stability of horseradish peroxidase encapsulated in acetalated
   dextran microparticles stored outside cold chain conditions
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Acid sensitive polymer; Horseradish peroxidase; Microparticle; Storage;
   Vaccines
ID SOLVENT EXTRACTION/EVAPORATION METHOD; IN-VITRO; PLGA MICROSPHERES;
   RELEASE PROFILES; PROTEIN ANTIGENS; NANOPARTICLES; FORMULATIONS;
   CHALLENGES; VACCINES; SYSTEMS
AB Micro- and nanoparticles have been shown to improve the efficacy of safer protein-based (subunit) vaccines. Here, we evaluate a method of improving the vaccine stability outside cold chain conditions by encapsulation of a model enzyme, horseradish peroxidase (HRP), in an acid-sensitive, tunable biodegradable polymer, acetalated dextran (Ac-DEX). Vaccines that are stable outside the cold chain would be desirable for use in developing nations. Ac-DEX particles encapsulating HRP were prepared using two different methods, probe sonication and homogenization. These particles were stored under different storage conditions (-20 degrees C, 4 degrees C, 25 degrees C or 45 degrees C) for a period of 3 months. On different days, the particles were characterized for various physical and chemical measurements. At all conditions, Ac-DEX particles remained spherical in nature, as compared to PLGA particles that fused together starting at day 3 at 45 degrees C. Furthermore, our results indicated that encapsulation of HRP in Ac-DEX reduces its storage temperature dependence and enhances its stability outside cold chain conditions. Homogenized particles performed better than probe sonicated particles and retained 70% of the enzyme's initial activity as compared to free HRP that retained only 40% of the initial activity after 3 months of storage at 25 degrees C or 45 degrees C. Additionally, HRP activity was more stable when encapsulated in Ac-DEX, and the variance in enzyme activity between the different storage temperatures was not observed for either particle preparation. This suggests that storage at a constant temperature is not required with vaccines encapsulated in Ac-DEX particles. Overall, our results suggest that an Ac-DEX based micro-/nanoparticles system has wide applications as vaccines and drug delivery carriers, including those in developing nations. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Kanthamneni, Naveen; Sharma, Sadhana; Meenach, Samantha A.; Bachelder, Eric M.; Ainslie, Kristy M.] Ohio State Univ, Div Pharmaceut, Coll Pharm, Columbus, OH 43210 USA.
   [Billet, Beau; Zhao, Ji-Cheng] Ohio State Univ, Coll Engn, Columbus, OH 43210 USA.
RP Ainslie, KM (reprint author), 242 Pk Hall,500 W 12th Ave, Columbus, OH 43210 USA.
EM ainslie@pharmacy.ohio-state.edu
RI Zhao, Ji-Cheng (JC)/H-4387-2012; Kanthamneni, Naveen/N-7082-2016;
   Meenach, Samantha/F-7542-2014
OI Zhao, Ji-Cheng (JC)/0000-0002-4426-1080; Kanthamneni,
   Naveen/0000-0002-5794-9642; Ainslie, Kristy/0000-0002-1820-8382
FU OSU College of Pharmacy;  [W911NF-10-1-0264 DARPA]
FX The authors gratefully acknowledge the help and support of Kevin
   Kauffman, Kevin Peine, and Ashley Bowden in this project. SEM images
   presented in this report were generated using the instruments and
   services at the Campus Microscopy and Imaging Facility, the Ohio State
   University. This work was funded in part by W911NF-10-1-0264 DARPA as
   well as OSU College of Pharmacy Start-up funds.
CR Amorij JP, 2008, PHARM RES-DORDR, V25, P1256, DOI 10.1007/s11095-008-9559-6
   Bachelder EM, 2008, J AM CHEM SOC, V130, P10494, DOI 10.1021/ja803947s
   Bachelder EM, 2010, MOL PHARMACEUT, V7, P826, DOI 10.1021/mp900311x
   Broaders KE, 2009, P NATL ACAD SCI USA, V106, P5497, DOI 10.1073/pnas.0901592106
   Carpenter JF, 1997, PHARMACEUT RES, V14, P969, DOI 10.1023/A:1012180707283
   Carrasquillo KG, 1999, J PHARM SCI, V88, P166, DOI 10.1021/js980272o
   Chen DX, 2009, EXPERT REV VACCINES, V8, P547, DOI [10.1586/erv.09.20, 10.1586/ERV.09.20]
   Coleman J., 2011, J BIOMATER SCI POLYM
   Hermanson G. T., 1996, BIOCONJUGATE TECHNIQ
   Howland SW, 2008, J IMMUNOL, V180, P1576, DOI 10.4049/jimmunol.180.3.1576
   Kauffman K.J., 2011, INT J PHARM IN PRESS
   Lauring AS, 2010, NAT BIOTECHNOL, V28, P573, DOI 10.1038/nbt.1635
   Le Goff GC, 2011, ANAL CHEM, V83, P3610, DOI 10.1021/ac200306d
   Li SJ, 2004, BIOSYSTEMS, V77, P25, DOI 10.1016/j.biosystems.2004.03.001
   Lu L, 2000, BIOMATERIALS, V21, P1837, DOI 10.1016/S0142-9612(00)00047-8
   Manolova V, 2008, EUR J IMMUNOL, V38, P1404, DOI 10.1002/eji.200737984
   Matthias DM, 2007, VACCINE, V25, P3980, DOI 10.1016/j.vaccine.2007.02.052
   Mohanan D., 2011, EUR J PHARM BIOPHARM
   Mundargi RC, 2008, J CONTROL RELEASE, V125, P193, DOI 10.1016/j.jconrel.2007.09.013
   Naessens M, 2005, J CHEM TECHNOL BIOT, V80, P845, DOI 10.1002/jctb.1322
   Perrie Y, 2008, INT J PHARMACEUT, V364, P272, DOI 10.1016/j.ijpharm.2008.04.036
   Rice-Ficht AC, 2010, CURR OPIN MICROBIOL, V13, P106, DOI 10.1016/j.mib.2009.12.001
   Rogers B., 2010, AAOHN J, V58, P345
   Rogers B, 2010, AAOHN J, V58, P337, DOI [10.3928/08910162-20100801-03, 10.3928/08910162-20100716-02]
   Rouse JJ, 2007, INT J PHARM, V339, P112, DOI 10.1016/j.ijpharm.2007.02.026
   Silva RA, 2007, INT J BIOL MACROMOL, V41, P404, DOI 10.1016/j.ijbiomac.2007.05.014
   Singh L, 2004, BIOMATERIALS, V25, P2611, DOI 10.1016/j.biomaterials.2003.09.040
   Singh M, 2007, EXPERT REV VACCINES, V6, P797, DOI 10.1586/14760584.6.5.797
   Sloat BR, 2010, INT J PHARMACEUT, V393, P197, DOI 10.1016/j.ijpharm.2010.04.003
   Solbrig CM, 2007, MOL PHARMACEUT, V4, P47, DOI 10.1021/mp060107e
   Temocin Z, 2009, BIOPROC BIOSYST ENG, V32, P467, DOI 10.1007/s00449-008-0266-9
   Wirkas T, 2007, VACCINE, V25, P691, DOI 10.1016/j.vaccine.2006.08.028
   Yang YY, 2000, J CONTROL RELEASE, V69, P81, DOI 10.1016/S0168-3659(00)00291-1
   Yang YY, 2001, BIOMATERIALS, V22, P231, DOI 10.1016/S0142-9612(00)00178-2
NR 34
TC 23
Z9 23
U1 2
U2 27
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
EI 1873-3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD JUL 15
PY 2012
VL 431
IS 1-2
BP 101
EP 110
DI 10.1016/j.ijpharm.2012.04.043
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 945BB
UT WOS:000304246700014
PM 22548844
DA 2018-03-20
ER

PT J
AU Cahall, CF
   Lilly, JL
   Hirschowitz, EA
   Berron, BJ
AF Cahall, Calvin F.
   Lilly, Jacob L.
   Hirschowitz, Edward A.
   Berron, Brad J.
TI A Quantitative Perspective on Surface Marker Selection for the Isolation
   of Functional Tumor Cells
SO BREAST CANCER-BASIC AND CLINICAL RESEARCH
LA English
DT Article
DE fluid biopsy; cell sorting; immunostaining; breast cancer; cancer lines
ID METASTATIC BREAST-CANCER; EPITHELIAL-MESENCHYMAL TRANSITION;
   INTERCELLULAR-ADHESION MOLECULE-1; PROGESTERONE-RECEPTORS; PROTEIN
   EXPRESSION; FLOW-CYTOMETRY; LUNG-CANCER; E-CADHERIN; INVASION; CARCINOMA
AB Much effort has gone into developing fluid biopsies of patient peripheral blood for the monitoring of metastatic cancers. One common approach is to isolate and analyze tumor cells in the peripheral blood. Widespread clinical implementation of this approach has been hindered by the current choice of targeting epithelial markers known to be highly variable in primary tumor sites. Here, we review current antigen-based tumor cell isolation strategies and offer biological context for commonly studied cancer surface markers. Expression levels of the most common markers are quantitated for three breast cancer and two non-small cell lung cancer (NSCLC) lineage models. These levels are contrasted with that present on healthy peripheral blood mononuclear cells (PBMC) for comparison to expected background levels in a fluid biopsy setting. A key feature of this work is establishing a metric of markers per square micrometer. This describes an average marker density on the cell membrane surface, which is a critical metric for emerging isolation strategies. These results serve to extend expression of key tumor markers in a sensitive and dynamic manner beyond traditional positive/negative immunohistochemical staining to guide future fluid biopsy targeting strategies.
C1 [Cahall, Calvin F.; Lilly, Jacob L.; Berron, Brad J.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Hirschowitz, Edward A.] Univ Kentucky, Albert B Chandler Med Ctr, Dept Internal Med, Div Pulm & Crit Care Med, Lexington, KY 40536 USA.
RP Berron, BJ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM brad.berron@uky.edu
FU NCI NIH HHS [R25 CA153954]
CR Afify A, 2009, EXP MOL PATHOL, V86, P95, DOI 10.1016/j.yexmp.2008.12.003
   Aktas B, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2333
   Ali S, 2000, J MAMMARY GLAND BIOL, V5, P271, DOI 10.1023/A:1009594727358
   Allard WJ, 2004, CLIN CANCER RES, V10, P6897, DOI 10.1158/1078-0432.CCR-04-0378
   Ashworth TR, 1869, AUSTR MED J, V14, P146
   Beer AJ, 2008, J NUCL MED, V49, P255, DOI 10.2967/jnumed.107.045526
   Bhagat AAS, 2010, MED BIOL ENG COMPUT, V48, P999, DOI 10.1007/s11517-010-0611-4
   Bhargava R, 2005, MODERN PATHOL, V18, P1027, DOI 10.1038/modpathol.3800438
   Bonnomet A, 2010, J MAMMARY GLAND BIOL, V15, P261, DOI 10.1007/s10911-010-9174-0
   Budinsky AC, 1997, INT J CANCER, V71, P1086, DOI 10.1002/(SICI)1097-0215(19970611)71:6<1086::AID-IJC27>3.0.CO;2-A
   Chavez Kathryn J, 2010, Breast Dis, V32, P35, DOI 10.3233/BD-2010-0307
   Choi SY, 2012, LAB CHIP, V12, P1427, DOI 10.1039/c2lc21225k
   Cohen SJ, 2008, J CLIN ONCOL, V26, P3213, DOI 10.1200/JCO.2007.15.8923
   Cristofanilli M, 2005, J CLIN ONCOL, V23, P1420, DOI 10.1200/JCO.2005.08.140
   Cristofanilli M, 2004, NEW ENGL J MED, V351, P781, DOI 10.1056/NEJMoa040766
   de Bono JS, 2008, CLIN CANCER RES, V14, P6302, DOI 10.1158/1078-0432.CCR-08-0872
   Deroo BJ, 2006, J CLIN INVEST, V116, P561, DOI 10.1172/JCI27987
   Dewitt S, 2007, J LEUKOCYTE BIOL, V81, P1160, DOI 10.1189/jlb.1106710
   Eccles SA, 2001, J MAMMARY GLAND BIOL, V6, P393
   EVANS E, 1989, BIOPHYS J, V56, P151, DOI 10.1016/S0006-3495(89)82660-8
   Gan Stephanie D, 2013, J Invest Dermatol, V133, pe12, DOI 10.1038/jid.2013.287
   Gorges TM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-178
   Hajra KM, 1999, ONCOGENE, V18, P7274, DOI 10.1038/sj.onc.1203336
   HARRIS AL, 1989, J STEROID BIOCHEM, V34, P123, DOI 10.1016/0022-4731(89)90072-1
   Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779
   Herzenberg LA, 2002, CLIN CHEM, V48, P1819
   Holliday DL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2889
   Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727
   Ibrahim SF, 2003, CURR OPIN BIOTECH, V14, P5, DOI 10.1016/S0958-1669(02)00009-5
   Jain J, 2013, CANCER RES, V73, P2310, DOI 10.1158/0008-5472.CAN-12-2956
   Jin H, 2004, BRIT J CANCER, V90, P561, DOI 10.1038/sj.bjc.6601576
   Joosse SA, 2013, CANCER RES, V73, P8, DOI 10.1158/0008-5472.CAN-12-3422
   Kalluri R, 2010, J CLIN INVEST, V120, P1786, DOI 10.1172/JCI39104C1
   Kawata M, 2012, J BIOCHEM, V151, P205, DOI 10.1093/jb/mvr136
   Konigsberg R, 2011, ACTA ONCOL, V50, P700, DOI 10.3109/0284186X.2010.549151
   Konecny G, 2003, J NATL CANCER I, V95, P142, DOI 10.1093/jnci/95.2.142
   Lecharpentier A, 2011, BRIT J CANCER, V105, P1338, DOI 10.1038/bjc.2011.405
   Liu SP, 2013, GASTROENTEROLOGY, V144, P1031, DOI 10.1053/j.gastro.2013.01.046
   Liu XD, 2008, CELL MOTIL CYTOSKEL, V65, P935, DOI 10.1002/cm.20315
   Livasy CA, 2006, MODERN PATHOL, V19, P264, DOI 10.1038/modpathol.3800528
   Lopez JI, 2005, CANCER RES, V65, P6755, DOI 10.1158/0008-5472.CAN-05-0863
   Lustberg MB, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3622
   Maheswaran S, 2008, NEW ENGL J MED, V359, P366, DOI 10.1056/NEJMoa0800668
   McCabe A, 2005, J NATL CANCER I, V97, P1808, DOI 10.1093/jnci/dji427
   MCGUIRE WL, 1977, CANCER, V39, P2934, DOI 10.1002/1097-0142(197706)39:6<2934::AID-CNCR2820390680>3.0.CO;2-P
   Miller MC, 2010, J ONCOL, V2010, DOI DOI 10.1155/2010/617421
   Nagrath S, 2007, NATURE, V450, P1235, DOI 10.1038/nature06385
   O'Hanlon DM, 2002, EUR J CANCER, V38, P2252, DOI 10.1016/S0959-8049(02)00218-6
   OSBORNE CK, 1980, CANCER, V46, P2884, DOI 10.1002/1097-0142(19801215)46:12+<2884::AID-CNCR2820461429>3.0.CO;2-U
   Osta WA, 2004, CANCER RES, V64, P5818, DOI 10.1158/0008-5472.CAN-04-0754
   OWEN CS, 1984, J IMMUNOL METHODS, V73, P41, DOI 10.1016/0022-1759(84)90029-2
   Paulie S, 2003, ELS, P1
   Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433
   Strakova Z, 2008, CELL TISSUE RES, V332, P479, DOI 10.1007/s00441-008-0604-x
   Sun JJ, 1999, J CANCER RES CLIN, V125, P28, DOI 10.1007/s004320050238
   Sununliganon L, 2012, CYTOTECHNOLOGY, V64, P53, DOI 10.1007/s10616-011-9390-5
   Takao M, 2011, CYTOM PART A, V79A, P107, DOI 10.1002/cyto.a.21014
   Thiel A, 1998, IMMUNOTECHNOLOGY, V4, P89, DOI 10.1016/S1380-2933(98)00010-4
   Thiery JP, 2013, CANCER CELL, V23, P272, DOI 10.1016/j.ccr.2013.03.004
   Toole BP, 2002, GLYCOBIOLOGY, V12, p37R, DOI 10.1093/glycob/12.3.37R
   Wicha MS, 2011, J CLIN ONCOL, V29, P1508, DOI 10.1200/JCO.2010.34.0026
   Yang J, 1999, BIOPHYS J, V76, P3307, DOI 10.1016/S0006-3495(99)77483-7
   Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009
   Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0
   Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522
NR 65
TC 5
Z9 5
U1 0
U2 2
PU LIBERTAS ACAD
PI AUCKLAND
PA PO BOX 300-874, ALBANY 0752, AUCKLAND, 00000, NEW ZEALAND
SN 1178-2234
J9 BREAST CANCER-BASIC
JI Breast Cancer-Basic Clin. Res.
PY 2015
VL 9
SU 1
BP 1
EP 11
DI 10.4137/BCBCR.S25461
PG 11
WC Oncology
SC Oncology
GA DA6CE
UT WOS:000367888600001
PM 26309407
OA gold
DA 2018-03-19
ER

PT J
AU Rahman, MS
   Rankin, SE
AF Rahman, Mohammed Shahidur
   Rankin, Stephen E.
TI Predictive synthesis of ordered mesoporous silica with maltoside and
   cationic surfactants based on aqueous lyotropic phase behavior
SO JOURNAL OF COLLOID AND INTERFACE SCIENCE
LA English
DT Article
DE n-Dodecyl-beta-D-maltoside; Liquid crystal; Nanocasting; Mixed
   surfactants; Templating; Self-assembly
ID SUGAR-BASED SURFACTANTS; X-RAY-DIFFRACTION; MOLECULAR-SIEVES;
   CETYLTRIMETHYLAMMONIUM BROMIDE; NONIONIC SURFACTANT; THERMAL-STABILITY;
   TEMPLATING ROUTE; BLOCK-COPOLYMER; CUBIC STRUCTURE; POLAR-SOLVENTS
AB Self-assembled nonionic alkyl glycoside surfactants are of interest for creating functional adsorption and catalytic sites at the surface of mesoporous sol-gel-derived materials, but they typically impart poor long-range order when they are used as pore templates. Improved order and control over the functional site density can be achieved by mixing the alkyl polyglycoside surfactant with a cationic surfactant. Here, we investigate the rarely reported lyotropic liquid crystalline (LLC) phase behavior of aqueous solutions of a nonionic disaccharide surfactant, n-dodecyl-beta-D-maltoside (C(12)G(2)/DM), and cetyltrimethylammonium bromide (C(16)TAB) by low-angle powder X-ray diffraction (XRD) and polarized optical microscopy (POM). An approximate ternary phase diagram of the C(16)TAB-C(12)G(2)-water system is developed at 50 degrees C, which includes 2-D hexagonal (P6mm symmetry), bicontinuous cubic (Ia (3) over bard symmetry), lamellar, and rectangular (cmm symmetry) LLC phases. By replacing the volume of water in the phase diagram with an equivalent Volume of silica, ordered mesoporous materials are prepared by a nanocasting technique with variable C(12)G(2)/C(16)TAB ratios. For large regions of the phase diagram, this approach is predictive. However, silica materials synthesized with comparatively high C(12)G(2)/C(16)TAB ratios are only poorly ordered in a way that does not correspond to their lyotropic liquid crystalline phase behavior. Also, in contrast with our previous Study of mixed C(16)TAB/n-octyl-b-D-glucopyranoside templating [37] the boundary between hexagonal and bicontinuous cubic materials is shifted towards higher surfactant content than in the aqueous LLC system. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Rahman, Mohammed Shahidur; Rankin, Stephen E.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Rankin, SE (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 FP Anderson Tower, Lexington, KY 40506 USA.
EM srankin@engr.uky.edu
RI Rankin, Stephen/A-3265-2013
OI Rankin, Stephen/0000-0002-8615-7564
FU National Science Foundation [CBET-0348234]; US Department of Agriculture
   Biomass Research and Development Initiative [68-3A75-7-608]; Kentucky
   Science and Engineering Foundation [KSEF-1204-RDE-009]
FX This material is based upon work supported by the National Science
   Foundation under Grant No. CBET-0348234, the US Department of
   Agriculture Biomass Research and Development Initiative (Grant Agreement
   68-3A75-7-608), and the Kentucky Science and Engineering Foundation
   under Grant No. KSEF-1204-RDE-009. We thank Prof K.W. Anderson for
   access to the optical microscope and Dr. A. Dozier for help with TEM.
CR Acharya DP, 2004, J PHYS CHEM B, V108, P1790, DOI 10.1021/jp036096b
   Alberius PCA, 2002, CHEM MATER, V14, P3284, DOI 10.1021/cm011209u
   ATTARD GS, 1995, NATURE, V378, P366, DOI 10.1038/378366a0
   AUVRAY X, 1989, J PHYS CHEM-US, V93, P7458, DOI 10.1021/j100358a040
   AUVRAY X, 1991, LANGMUIR, V7, P2385, DOI 10.1021/la00058a069
   AUVRAY X, 1995, LANGMUIR, V11, P433, DOI 10.1021/la00002a012
   BAGSHAW SA, 1995, SCIENCE, V269, P1242, DOI 10.1126/science.269.5228.1242
   BARRETT EP, 1951, J AM CHEM SOC, V73, P373, DOI 10.1021/ja01145a126
   Beck JS, 1996, CURR OPIN SOLID ST M, V1, P76, DOI 10.1016/S1359-0286(96)80014-3
   BECK JS, 1992, J AM CHEM SOC, V114, P10834, DOI 10.1021/ja00053a020
   Boyd BJ, 2001, LANGMUIR, V17, P6100, DOI 10.1021/la001484f
   Boyd BJ, 2000, LANGMUIR, V16, P7359, DOI 10.1021/la991573w
   Brunauer S, 1938, J AM CHEM SOC, V60, P309, DOI 10.1021/ja01269a023
   CHARVOLIN J, 1993, LIQ CRYST, V13, P829, DOI 10.1080/02678299308027296
   Chen DH, 2006, J MATER CHEM, V16, P1511, DOI 10.1039/b517975k
   Chen DH, 2005, CHEM MATER, V17, P3228, DOI 10.1021/cm050209h
   Chen FX, 1997, CHEM MATER, V9, P2685, DOI 10.1021/cm9703942
   Corma A, 1997, CHEM REV, V97, P2373, DOI 10.1021/cr960406n
   Dai LR, 2001, COLLOID SURFACE A, V181, P151, DOI 10.1016/S0927-7757(00)00791-3
   de G.J., 2002, CHEM REV, V102, P4093
   Drummond CJ, 1998, COLLOID SURFACE A, V141, P131, DOI 10.1016/S0927-7757(98)00209-X
   Farnik D, 2005, POLYM PREPR AM CHEM, V46, P1140
   FONTELL K, 1990, COLLOID POLYM SCI, V268, P264, DOI 10.1007/BF01490251
   Garcia MT, 1997, CHEMOSPHERE, V35, P545
   Grun M, 1996, J CHROMATOGR A, V740, P1, DOI 10.1016/0021-9673(96)00205-1
   Gustafsson S, 1996, J COLLOID INTERF SCI, V180, P564, DOI 10.1006/jcis.1996.0337
   HAGSLATT H, 1992, LIQ CRYST, V12, P667, DOI 10.1080/02678299208029102
   HAGSLATT H, 1994, LIQ CRYST, V17, P157, DOI 10.1080/02678299408036557
   HAJDUK DA, 1994, MACROMOLECULES, V27, P4063, DOI 10.1021/ma00093a006
   Hayward RC, 2004, LANGMUIR, V20, P5998, DOI 10.1021/la030442z
   HUO QS, 1994, NATURE, V368, P317, DOI 10.1038/368317a0
   HUO QS, 1994, CHEM MATER, V6, P1176, DOI 10.1021/cm00044a016
   HUSING N, 2003, SILICON CHEM, P451
   HUSSON F, 1960, ACTA CRYSTALLOGR, V13, P668, DOI 10.1107/S0365110X60001576
   INAGAKI S, 1993, J CHEM SOC CHEM COMM, P680, DOI 10.1039/c39930000680
   ISRAELACHVILI JN, 1998, INTERMOLECULAR SURFA, P366
   Jaroniec M, 1999, LANGMUIR, V15, P5410, DOI 10.1021/la990136e
   JUNG JH, 1938, J CHEM SOC P2, P1938
   Kim JM, 2002, J PHYS CHEM B, V106, P2552, DOI 10.1021/jp014280w
   Kim SS, 2000, CHEM COMMUN, P835, DOI 10.1039/b001012j
   Kisler JM, 2001, MICROPOR MESOPOR MAT, V44, P769
   KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0
   Kruk M, 2001, CHEM MATER, V13, P3169, DOI 10.1021/cm0101069
   Kruk M, 1997, J PHYS CHEM B, V101, P583, DOI 10.1021/jp962000k
   Lavrencic-Stangar U, 2002, MATER RES SOC SYMP P, V726, P111
   Lavrencic-Stangar U., 2003, SILICON CHEM, V2, P157
   Lind A, 2002, LANGMUIR, V18, P1380, DOI 10.1021/la011240a
   Linden M, 1999, CHEM MATER, V11, P3002, DOI 10.1021/cm991082x
   Maschmeyer T, 1998, CURR OPIN SOLID ST M, V3, P71, DOI 10.1016/S1359-0286(98)80068-5
   MONNIER A, 1993, SCIENCE, V261, P1299, DOI 10.1126/science.261.5126.1299
   MORIHARA K, 1994, B CHEM SOC JPN, V67, P1078, DOI 10.1246/bcsj.67.1078
   Nilsson F, 1996, LANGMUIR, V12, P902, DOI 10.1021/la950602+
   Pang JB, 2004, CHEM COMMUN, P682, DOI 10.1039/b316501a
   Pindzola BA, 2003, J AM CHEM SOC, V125, P2940, DOI 10.1021/ja0208106
   ROSEVEAR FB, 1968, J SOC COSMET CHEM, V19, P581
   ROSEVEAR FB, 1954, J AM OIL CHEM SOC, V31, P628, DOI 10.1007/BF02545595
   Ryoo R, 1996, J PHYS CHEM-US, V100, P17718, DOI 10.1021/jp9620835
   RYOO R, 1995, J CHEM SOC CHEM COMM, P711, DOI 10.1039/c39950000711
   Ryoo R, 1999, J PHYS CHEM B, V103, P7435, DOI 10.1021/jp9911649
   Sayari A, 1996, STUD SURF SCI CATAL, V102, P1
   Sayari A, 1997, CHEM MATER, V9, P2499, DOI 10.1021/cm970128o
   SCHMID KT, 2001, DETERGENCY SPECIALTY, V98
   SING KSW, 1985, PURE APPL CHEM, V57, P603, DOI 10.1351/pac198557040603
   SODERBERG I, 1995, COLLOID SURFACE A, V102, P91, DOI 10.1016/0927-7757(95)03250-H
   TANEV PT, 1995, SCIENCE, V267, P865, DOI 10.1126/science.267.5199.865
   Tanford C, 1980, HYDROPHOBIC EFFECT F
   Templin M, 1997, SCIENCE, V278, P1795, DOI 10.1126/science.278.5344.1795
   WARNHEIM T, 1988, J COLLOID INTERF SCI, V125, P627, DOI 10.1016/0021-9797(88)90030-6
   WARR GG, 1986, J PHYS CHEM-US, V90, P4581, DOI 10.1021/j100410a022
   Xing R, 2007, J COLLOID INTERF SCI, V316, P930, DOI 10.1016/j.jcis.2007.08.019
   Yang B, 2006, COLLOID SURFACE A, V277, P171, DOI 10.1016/j.colsurfa.2005.11.058
   Ying JY, 1999, ANGEW CHEM INT EDIT, V38, P56, DOI 10.1002/(SICI)1521-3773(19990115)38:1/2<56::AID-ANIE56>3.0.CO;2-E
   Zhang WZ, 1997, CHEM MATER, V9, P2491, DOI 10.1021/cm970354y
   Zhao D, 1998, ADV MATER, V10, P1380, DOI 10.1002/(SICI)1521-4095(199811)10:16<1380::AID-ADMA1380>3.0.CO;2-8
   Zhao DY, 1999, CHEM MATER, V11, P2668, DOI 10.1021/cm980755t
   Zhao W, 2003, CHEM MATER, V15, P4160, DOI 10.1021/cm034570k
NR 76
TC 5
Z9 5
U1 2
U2 16
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0021-9797
J9 J COLLOID INTERF SCI
JI J. Colloid Interface Sci.
PD FEB 1
PY 2010
VL 342
IS 1
BP 33
EP 42
DI 10.1016/j.jcis.2009.10.021
PG 10
WC Chemistry, Physical
SC Chemistry
GA 544NW
UT WOS:000273665900005
PM 19900681
DA 2018-03-20
ER

PT J
AU Shin, HY
   Underwood, RM
   Fannon, MW
AF Shin, Hainsworth Y.
   Underwood, Ryan Matthew
   Fannon, Michael W.
TI Fluid Pressure Is a Magnitude-Dependent Modulator of Early Endothelial
   Tubulogenic Activity: Implications Related to a Potential
   Tissue-Engineering Control Parameter
SO TISSUE ENGINEERING PART A
LA English
DT Article
ID FIBROBLAST-GROWTH-FACTOR; SUSTAINED HYDROSTATIC-PRESSURE; ANGIOGENESIS
   IN-VITRO; VEGF-C; CELL PROLIFERATION; CYCLIC PRESSURE; INTERSTITIAL
   FLOW; STIMULATES PROLIFERATION; 3-DIMENSIONAL COLLAGEN; LYMPHATIC
   FUNCTION
AB A significant barrier to the success of engineered tissues is the inadequate transport of nutrients and gases to, and waste away from, cells within the constructs, after implantation. Generation of microtubular networks by endothelial cells in engineered constructs to mimic the in vivo transport scheme is essential for facilitating tissue survival by promoting the in vitro formation of microvessels that integrate with host microvasculature, after implantation. Previously, we reported that select pressures stimulate endothelial proliferation involving protubulogenic molecules such as fibroblast growth factor-2 (FGF-2) and vascular endothelial growth factor-C (VEGF-C). Based on this, we investigated fluid pressure as a selective modulator of early tubulogenic activity with the intent of assessing the potential utility of this mechanical stimulus as a tissue-engineering control parameter. For this purpose, we used a custom pressure system to expose two-dimensional (2D) and three-dimensional (3D) cultures of endothelial cells to static pressures of 0 (controls), 20, or 40 mmHg for 3 days. Compared to controls, 2D endothelial cultures exposed to 20, but not 40 mmHg, exhibited significantly (p<0.05) enhanced cell growth that depended on VEGF receptor-3 (VEGFR-3), a receptor for VEGF-C. Moreover, endothelial cells grown on microbeads and suspended in 3D collagen gels under 20 mmHg, but not 40 mmHg, displayed significantly (p<0.05) increased sprout formation. Interestingly, pressure-dependent proliferation and sprout formation occurred in parallel with pressure-sensitive upregulation of VEGF-C and VEGFR-3 expression and were sensitive to local FGF-2 levels. Collectively, the results of the present study provided evidence that early endothelial-related tubulogenic activity depends on local hydrostatic pressure levels in the context of local growth factor conditions. In addition to relevance to microvascular diseases associated with interstitial hypertension (e.g., cancer and glaucoma), these findings provided first insight into the potential utility of hydrostatic pressure as a fine-tune control parameter to optimize microvascularization of tissue-engineering constructs in the in vitro setting before their implantation.
C1 [Shin, Hainsworth Y.] Univ Kentucky, Ctr Biomed Engn, Wenner Gren Res Lab 213, Lexington, KY 40506 USA.
   [Fannon, Michael W.] Univ Kentucky, Med Ctr, Dept Ophthalmol & Visual Sci, Lexington, KY 40506 USA.
RP Shin, HY (reprint author), Univ Kentucky, Ctr Biomed Engn, Wenner Gren Res Lab 213, 600 Rose St, Lexington, KY 40506 USA.
EM hy.shin@uky.edu
FU University of Kentucky; AHA; NSF-Kentucky EPS-CoR Bioengineering
   Initiative; NIH [HL086644]; Research to Prevent Blindness
FX This work was supported by the University of Kentucky Research Support
   Fund (PI: H. Shin, Ph.D.), an AHA Beginning-Grant-in-Aid (PI: H. Shin),
   an NSF-Kentucky EPS-CoR Bioengineering Initiative grant (PI: R. Andrews,
   Ph.D.), an NIH R01 grant (HL086644; PI: M. Fannon), and a Research to
   Prevent Blindness grant (PI: M. Fannon). We thank S. Lai-Fook, Ph.D.,
   and E. Bruce, Ph.D., of the Center for Biomedical Engineering at the
   University of Kentucky for their technical and material assistance with
   setting up the pressure system. We also thank X. Lei for repeating some
   final replicate experiments and Xiaoyan Zhang, M.Sc., for flow
   cytometric analyses.
CR ACEVEDO AD, 1993, J CELL PHYSIOL, V157, P603, DOI 10.1002/jcp.1041570321
   Arinaga M, 2003, CANCER, V97, P457, DOI 10.1002/cncr.11073
   Aurello P, 2009, ONCOL RES, V17, P405, DOI 10.3727/096504009788912525
   Bayless KJ, 2003, BIOCHEM BIOPH RES CO, V312, P903, DOI 10.1016/j.bbrc.2003.11.017
   BOUCHER Y, 1992, CANCER RES, V52, P5110
   Cao RH, 2004, CIRC RES, V94, P664, DOI 10.1161/01.RES.0000118600.91698.BB
   Cao Yihai, 2008, Lymphatic Research and Biology, V6, P145, DOI 10.1089/lrb.2008.1007
   Carmeliet P, 2001, NAT BIOTECHNOL, V19, P1019, DOI 10.1038/nbt1101-1019
   Chang LK, 2004, P NATL ACAD SCI USA, V101, P11658, DOI 10.1073/pnas.0404272101
   Chien S, 2007, AM J PHYSIOL-HEART C, V292, pH1209, DOI 10.1152/ajpheart.01047.2006
   DAVIS GE, 1995, EXP CELL RES, V216, P113, DOI 10.1006/excr.1995.1015
   Dietrich Franziska, 2006, Angiogenesis, V9, P111, DOI 10.1007/s10456-006-9037-x
   Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358
   FOLKMAN J, 1975, ANN INTERN MED, V82, P96, DOI 10.7326/0003-4819-82-1-96
   Fong A, 2009, AUST FAM PHYSICIAN, V38, P774
   Freed LE, 2006, TISSUE ENG, V12, P3285, DOI 10.1089/ten.2006.12.3285
   Gan LM, 2000, BIOCHEM BIOPH RES CO, V272, P490, DOI 10.1006/bbrc.2000.2663
   Goldman J, 2007, AM J PHYSIOL-HEART C, V292, pH2176, DOI 10.1152/ajpheart.01011.2006
   Griffith CK, 2005, TISSUE ENG, V11, P257, DOI 10.1089/ten.2005.11.257
   Hasel C, 2005, AM J PHYSIOL-CELL PH, V289, pC312, DOI 10.1152/ajpcell.00107.2004
   Helm CLE, 2007, BIOTECHNOL BIOENG, V96, P167, DOI 10.1002/bit.21185
   HISHIKAWA K, 1992, EUR J PHARMACOL, V215, P329, DOI 10.1016/0014-2999(92)90051-5
   HISHIKAWA K, 1995, HYPERTENSION, V25, P449, DOI 10.1161/01.HYP.25.3.449
   Holopainen T, 2011, J SURG ONCOL, V103, P484, DOI 10.1002/jso.21808
   Jenny B, 2006, J PATHOL, V209, P34, DOI 10.1002/path.1943
   Jih Yng-Jyh, 2001, Angiogenesis, V4, P313, DOI 10.1023/A:1016080321956
   Kannan RY, 2005, BIOMATERIALS, V26, P1857, DOI 10.1016/j.biomaterials.2004.07.006
   KATO S, 1994, VIRCHOWS ARCH, V425, P385
   Kirkin V, 2004, INT J CANCER, V112, P986, DOI 10.1002/ijc.20509
   Koh W, 2008, METHOD ENZYMOL, V443, P83, DOI [10.1016/S0076-6879(08)021105-3, 10.1016/S0076-6879(08)02005-3]
   Krishnan L, 2008, CARDIOVASC RES, V78, P324, DOI 10.1093/cvr/cvn055
   Kumar Ravindra, 2008, Ethn Dis, V18, pS2
   Lavine KJ, 2006, GENE DEV, V20, P1651, DOI 10.1101/gad.1411406
   Lin CI, 2008, CELL MOL LIFE SCI, V65, P2740, DOI 10.1007/s00018-008-8314-9
   Loffredo F, 2008, CIRC RES, V103, P128, DOI 10.1161/CIRCRESAHA.108.180604
   Lynch SS, 2007, ANN PHARMACOTHER, V41, P614, DOI 10.1345/aph.1H316
   Melero-Martin JM, 2008, CIRC RES, V103, P194, DOI 10.1161/CIRCRESAHA.108.178590
   Muller-Marschhausen K, 2008, AM J PHYSIOL-CELL PH, V294, pC324, DOI 10.1152/ajpcell.00319.2007
   Nakatsu MN, 2008, METHOD ENZYMOL, V443, P65, DOI 10.1016/S0076-6879(08)02004-1
   Nathan SS, 2008, J ORTHOP RES, V26, P1520, DOI 10.1002/jor.20633
   NEHLS V, 1995, MICROVASC RES, V50, P311, DOI 10.1006/mvre.1995.1061
   Ng CP, 2004, MICROVASC RES, V68, P258, DOI 10.1016/j.mvr.2004.08.002
   Park HR, 2008, PATHOL RES PRACT, V204, P575, DOI 10.1016/j.prp.2008.01.015
   Pepper MS, 1998, J CELL PHYSIOL, V177, P439, DOI 10.1002/(SICI)1097-4652(199812)177:3<439::AID-JCP7>3.0.CO;2-2
   Persaud K, 2004, J CELL SCI, V117, P2745, DOI 10.1242/jcs.01138
   Salwen SA, 1998, MED BIOL ENG COMPUT, V36, P520, DOI 10.1007/BF02523225
   Schwartz EA, 1999, CIRC RES, V84, P315
   Shin HY, 2004, ENDOTHELIUM-J ENDOTH, V11, P285, DOI 10.1080/10623320490904205
   Shin HY, 2003, ENDOTHELIUM-J ENDOTH, V10, P179, DOI 10.1080/10623320390237883
   Shin HY, 2002, ANN BIOMED ENG, V30, P297, DOI 10.1114/1.1458595
   Shin HY, 2002, PHYSIOL GENOMICS, V11, P245, DOI 10.1152/physiolgenomics.00068.2002
   Shiu Yan-Ting, 2005, Critical Reviews in Biomedical Engineering, V33, P431
   Silverman MD, 1999, AM J PHYSIOL-CELL PH, V277, pC233
   Starke RD, 2011, BLOOD, V117, P1071, DOI 10.1182/blood-2010-01-264507
   SUMPIO BE, 1994, J CELL PHYSIOL, V158, P133, DOI 10.1002/jcp.1041580117
   Suzuma I, 2001, DIABETES, V50, P444, DOI 10.2337/diabetes.50.2.444
   Swartz MA, 2002, ANN NY ACAD SCI, V979, P197, DOI 10.1111/j.1749-6632.2002.tb04880.x
   Swartz MA, 2001, MICROSC RES TECHNIQ, V55, P92, DOI 10.1002/jemt.1160
   Tammela T, 2011, NAT CELL BIOL, V13, P1202, DOI 10.1038/ncb2331
   Tille JC, 2003, EXP CELL RES, V285, P286, DOI 10.1016/S0014-4827(03)00053-3
   Tuder RM, 2002, ANTIOXID REDOX SIGN, V4, P833, DOI 10.1089/152308602760598990
   Ucuzian AA, 2007, WORLD J SURG, V31, P654, DOI 10.1007/s00268-006-0763-4
   Vouyouka AG, 1998, J MOL CELL CARDIOL, V30, P609, DOI 10.1006/jmcc.1997.0625
   Yucel YH, 2009, EXP EYE RES, V89, P810, DOI 10.1016/j.exer.2009.08.010
   Zheng W, 2001, AM J PHYSIOL-HEART C, V280, pH909
NR 65
TC 1
Z9 1
U1 0
U2 2
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937-3341
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD DEC
PY 2012
VL 18
IS 23-24
BP 2590
EP 2600
DI 10.1089/ten.tea.2011.0588
PG 11
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology
SC Cell Biology; Biotechnology & Applied Microbiology
GA 044DY
UT WOS:000311600800019
PM 22793042
OA green_published
DA 2018-03-20
ER

PT J
AU Meyer, CA
   Singh, R
   Jones, MT
   Yu, CG
   Power, RF
   Geddes, JW
AF Meyer, Carolyn A.
   Singh, Ranjana
   Jones, Mackenzie T.
   Yu, Chen-Guang
   Power, Ronan F.
   Geddes, James W.
TI Dietary Supplementation with Organoselenium Accelerates Recovery of
   Bladder Expression, but Does Not Improve Locomotor Function, following
   Spinal Cord Injury
SO PLOS ONE
LA English
DT Article
ID GLUTATHIONE-PEROXIDASE; PARKINSONS-DISEASE; TISSUE RETENTION; OXIDATIVE
   DAMAGE; SELENOPROTEIN-P; RATING-SCALE; CELL-DEATH; IN-VITRO; SELENIUM;
   BRAIN
AB Selenium is an essential element required for activity of several antioxidant enzymes, including glutathione peroxidase. Because of the critical role of the antioxidant system in responding to traumatic events, we hypothesized that dietary selenium supplementation would enhance neuroprotection in a rodent model of spinal cord injury. Rats were maintained on either a control or selenium-enriched diet prior to, and following, injury. Dietary selenium supplementation, provided as selenized yeast added to normal rat chow, resulted in a doubling of selenium levels in the spinal cord. Dietary selenium reduced the time required for recovery of bladder function following thoracic spinal cord injury. However, this was not accompanied by improvement in locomotor function or tissue sparing.
C1 [Meyer, Carolyn A.; Singh, Ranjana; Jones, Mackenzie T.; Yu, Chen-Guang; Geddes, James W.] Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, Lexington, KY USA.
   [Meyer, Carolyn A.; Singh, Ranjana; Geddes, James W.] Univ Kentucky, Coll Med, Dept Anat & Neurobiol, Lexington, KY USA.
   [Power, Ronan F.] Alltech, Ctr Anim Nutrigen & Appl Anim Nutr, Nicholasville, KY USA.
RP Geddes, JW (reprint author), Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, Lexington, KY USA.; Geddes, JW (reprint author), Univ Kentucky, Coll Med, Dept Anat & Neurobiol, Lexington, KY USA.
EM jgeddes@uky.edu
FU NIH [T32 NS07789, P30 NS051220]; Kentucky Spinal Cord and Head Injury
   Research Trust; Admiral Sheeley Endowment for Spinal Cord and Brain
   Injury Research; Alltech Inc. (Nicholasville, KY)
FX CAM was supported by NIH T32 NS07789 and the research was supported by
   NIH P30 NS051220, the Kentucky Spinal Cord and Head Injury Research
   Trust, and the Admiral Sheeley Endowment for Spinal Cord and Brain
   Injury Research (JWG). Alltech Inc. (Nicholasville, KY) provided support
   in the form of salary for RFP and animal diets, but did not have any
   additional role in the study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.; C.A.M. was
   supported by NIH T32 NS07789 and the research was supported by NIH P30
   NS051220, the Kentucky Spinal Cord and Head Injury Research Trust, and
   the Admiral Sheeley Endowment for Spinal Cord and Brain Injury Research
   (J.W.G). We thank Dr. Richard Kryscio for assistance with the
   statistical analysis. Alltech Inc. (Nicholasville, KY) provided support
   in the form of salary for R.F.P and animal diets, but did not have any
   additional role in the study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Anderson D K, 1985, Cent Nerv Syst Trauma, V2, P257
   BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1
   BEHNE D, 1988, BIOCHIM BIOPHYS ACTA, V966, P12, DOI 10.1016/0304-4165(88)90123-7
   Bellinger FP, 2012, J PARKINSON DIS, V2, P115, DOI 10.3233/JPD-2012-11052
   Bierla K, 2012, TRAC-TREND ANAL CHEM, V41, P122, DOI 10.1016/j.trac.2012.08.006
   Burk RF, 2009, BBA-GEN SUBJECTS, V1790, P1441, DOI 10.1016/j.bbagen.2009.03.026
   BURK RF, 1972, J NUTR, V102, P1049
   Chen XB, 2015, EUR REV MED PHARMACO, V19, P4434
   Center NSCIS, 2013, SPIN CORD INJ FACTS
   DAWSON DA, 1995, NEUROSCI LETT, V185, P65, DOI 10.1016/0304-3940(94)11226-9
   Ellwanger JH, 2015, NUTRITION, V31, P359, DOI 10.1016/j.nut.2014.07.004
   Ferrero SL, 2015, J NEUROTRAUM, V32, P200, DOI 10.1089/neu.2013.3247
   Griffiths JC, 2006, INT J TOXICOL, V25, P465, DOI 10.1080/10915810600959626
   Grulova I, 2013, SPINE J, V13, P1881, DOI 10.1016/j.spinee.2013.06.073
   Hall ED, 2011, NEUROTHERAPEUTICS, V8, P152, DOI 10.1007/s13311-011-0026-4
   Hausmann O, 2003, SPINAL CORD, V41, P369, DOI 10.1038/sj.sc.3101483
   Hill KE, 2007, J BIOL CHEM, V282, P10972, DOI 10.1074/jbc.M700436200
   Kjell J, 2014, SPINAL CORD, V52, P186, DOI 10.1038/sc.2013.166
   Kryukov GV, 2003, SCIENCE, V300, P1439, DOI 10.1126/science.1083516
   Liebscher T, 2005, ANN NEUROL, V58, P706, DOI 10.1002/ana.20627
   Lovell MA, 2009, FREE RADICAL BIO MED, V46, P1527, DOI 10.1016/j.freeradbiomed.2009.03.008
   MICHEL RP, 1988, J MICROSC-OXFORD, V150, P117, DOI 10.1111/j.1365-2818.1988.tb04603.x
   Nuttall KL, 2006, ANN CLIN LAB SCI, V36, P409
   Ogawa A, 1999, CEREBROVASC DIS, V9, P112, DOI 10.1159/000015908
   Ozsoy O, 2012, RESTOR NEUROL NEUROS, V30, P363, DOI 10.3233/RNN-2012-110203
   PARNHAM MJ, 1987, INT J TISSUE REACT, V9, P45
   PROHASKA JR, 1977, BIOCHEM BIOPH RES CO, V76, P437, DOI 10.1016/0006-291X(77)90744-6
   PROHASKA JR, 1976, J NEUROCHEM, V27, P1379, DOI 10.1111/j.1471-4159.1976.tb02619.x
   Pruss H, 2011, BRAIN PATHOL, V21, P652, DOI 10.1111/j.1750-3639.2011.00488.x
   Rabchevsky AG, 2002, J NEUROSCI RES, V68, P7, DOI 10.1002/jnr.10187
   Rabchevsky AG, 2007, GLIA, V55, P831, DOI 10.1002/glia.20508
   SALBE AD, 1990, J NUTR, V120, P207
   Scheff SW, 2002, J NEUROTRAUM, V19, P1251, DOI 10.1089/08977150260338038
   Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099
   Sharp KG, 2014, EXP NEUROL, V254, P1, DOI 10.1016/j.expneurol.2013.12.019
   Song KD, 2013, ANIM SCI J, V84, P238, DOI [10.1111/j.1740-0929.2012.01060.x, 10.1111/j.17]
   SPALLHOLZ JE, 1994, FREE RADICAL BIO MED, V17, P45, DOI 10.1016/0891-5849(94)90007-8
   Spallholz JE, 1997, BIOMED ENVIRON SCI, V10, P260
   Steinbrenner H, 2009, BBA-GEN SUBJECTS, V1790, P1478, DOI 10.1016/j.bbagen.2009.02.014
   Papp LV, 2007, ANTIOXID REDOX SIGN, V9, P775, DOI 10.1089/ars.2007.1528
   Vinceti M, 2013, NEUROTOXICOLOGY, V38, P25, DOI 10.1016/j.neuro.2013.05.016
   Wrobel JK, 2013, NUTR CANCER, V65, P563, DOI 10.1080/01635581.2013.775315
   Xiong YQ, 2007, J NEUROCHEM, V100, P639, DOI 10.1111/j.1471-4159.2006.04312.x
   Yeo JE, 2008, CELL PHYSIOL BIOCHEM, V21, P225, DOI 10.1159/000113764
   Yeo JE, 2007, BBA-MOL BASIS DIS, V1772, P1199, DOI 10.1016/j.bbadis.2007.09.004
   Yip PK, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-6
NR 46
TC 1
Z9 1
U1 1
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 29
PY 2016
VL 11
IS 1
AR e0147716
DI 10.1371/journal.pone.0147716
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DC9GH
UT WOS:000369528600050
PM 26824231
OA gold
DA 2018-03-20
ER

PT J
AU Goldsmith, J
   Hinds, BJ
AF Goldsmith, Jacob
   Hinds, Bruce J.
TI Simulation of Steady-State Methanol Flux through a Model Carbon Nanotube
   Catalyst Support
SO JOURNAL OF PHYSICAL CHEMISTRY C
LA English
DT Article
ID MOLECULAR-DYNAMICS; FUEL-CELLS; LIQUID WATER; TRANSPORT; MEMBRANES;
   DIFFUSION; OXIDATION; ETHANOL; ELECTROCATALYSTS; ADSORPTION
AB Nonequilibrium molecular dynamic (MD) simulations were performed to show transport of a water-methanol solution through a novel catalysis membrane, constructed from single-walled carbon nanotubes (CNTs) with a Pt monolayer catalyst at the membrane's exit. These calculations are directed toward understanding methanol transport dynamics in the CNT core, past the Pt coating, and to find the conditions for optimal efficiency as a function of both CNT diameter and pressure. Probability density function calculations for various methanol observables show that methanol primarily travels along the pore wall, which is ideal for methanol to interact efficiently with a catalyst at the exit. From the percent of methanol that passed through the pores within the minimum of the Lennard-Jones potential (2(sigma pt-O)(1/6)), we estimate the residence time of methanol flux past the Pt monolayer in the range of 2-6 Ps. The mass transport percent efficiency of the methanol flowing past the catalyst site is as high as 86% for (10,10) CNTs at flow velocities near 100 cm/s. Optimal diameters are ca. 1 nm, and flow rates should be < 100 cm/s.
C1 [Goldsmith, Jacob; Hinds, Bruce J.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Hinds, BJ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM bjhinds@engr.uky.edu
FU DARPA [W911NF-09-1-0267]
FX This work was financially supported by DARPA (W911NF-09-1-0267).
CR Adzic RR, 2007, TOP CATAL, V46, P249, DOI 10.1007/s11244-007-9003-x
   Armor JN, 2001, APPL CATAL A-GEN, V222, P91, DOI 10.1016/S0926-860X(01)00833-X
   Berezhkovskii A, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.064503
   Bond GC, 2008, CATAL REV, V50, P532, DOI 10.1080/01614940802480338
   Burghaus U, 2007, CHEM PHYS LETT, V442, P344, DOI 10.1016/j.cplett.2007.05.094
   Byl O, 2006, J AM CHEM SOC, V128, P12090, DOI 10.1021/ja057856u
   Goldsmith J, 2010, J PHYS CHEM LETT, V1, P528, DOI 10.1021/jz900173w
   Greeley J, 2002, ANNU REV PHYS CHEM, V53, P319, DOI 10.1146/annurev.physchem.53.100301.131630
   Hanasaki I, 2006, J CHEM PHYS, V124, DOI 10.1063/1.2187971
   Hartnig C, 2003, ELECTROCHIM ACTA, V48, P3751, DOI 10.1016/S0013-4686(03)00508-5
   Holt JK, 2006, SCIENCE, V312, P1034, DOI 10.1126/science.1126298
   Houk K., 2008, NATURE, P455
   Hu LB, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2561032
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Iwasita T, 2002, ELECTROCHIM ACTA, V47, P3663, DOI 10.1016/S0013-4686(02)00336-5
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Joseph S, 2008, NANO LETT, V8, P452, DOI 10.1021/nl072385q
   Kale L, 1999, J COMPUT PHYS, V151, P283, DOI 10.1006/jcph.1999.6201
   Kim S, 2007, NANO LETT, V7, P2806, DOI 10.1021/nl071414u
   Kua J, 1999, J AM CHEM SOC, V121, P10928, DOI 10.1021/ja9844074
   Leung K, 2009, J COMPUT THEOR NANOS, V6, P1948, DOI 10.1166/jctn.2009.1250
   Lu LH, 2007, FLUID PHASE EQUILIBR, V261, P191, DOI 10.1016/j.fluid.2007.07.057
   Maginn EJ, 2010, IND ENG CHEM RES, V49, P3059, DOI 10.1021/ie901898k
   Majumder M, 2005, NATURE, V438, P44, DOI 10.1038/43844a
   Majumder M, 2005, J AM CHEM SOC, V127, P9062, DOI 10.1021/ja043013b
   Majumder M, 2007, LANGMUIR, V23, P8624, DOI 10.1021/la700686k
   Meng H, 2006, ELECTROCHEM COMMUN, V8, P588, DOI 10.1016/j.elecom.2006.01.020
   MINK J, 1991, CAN J CHEM, V69, P1857
   Mitchell PCH, 1997, J MOL CATAL A-CHEM, V119, P223, DOI 10.1016/S1381-1169(96)00486-4
   Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289
   Pollack MG, 2000, APPL PHYS LETT, V77, P1725, DOI 10.1063/1.1308534
   Razmi H, 2008, ELECTROCHIM ACTA, V53, P8178, DOI 10.1016/j.electacta.2008.06.033
   Selvarani G, 2009, J PHYS CHEM C, V113, P7461, DOI 10.1021/jp810970d
   Shao Q, 2007, J PHYS CHEM C, V111, P15677, DOI 10.1021/jp0736140
   Shao YY, 2009, J MATER CHEM, V19, P46, DOI 10.1039/b808370c
   Sholl DS, 2006, ACCOUNTS CHEM RES, V39, P403, DOI 10.1021/ar0402199
   Su X, 2011, CARBON, V49, P1145, DOI 10.1016/j.carbon.2010.11.029
   Takaiwa D, 2008, P NATL ACAD SCI USA, V105, P39, DOI 10.1073/pnas.0707917105
   Tarmyshov KB, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2472357
   Wang DL, 2010, ELECTROCHIM ACTA, V55, P2964, DOI 10.1016/j.electacta.2010.01.031
   Whitby M, 2007, NAT NANOTECHNOL, V2, P87, DOI 10.1038/nnano.2006.175
   Ye F, 2009, J ELECTROCHEM SOC, V156, pB981, DOI 10.1149/1.3151868
   Zang J, 2009, ACS NANO, V3, P1548, DOI 10.1021/nn9001837
   Zhang QX, 2002, J CHEM PHYS, V117, P808, DOI 10.1063/1.1483297
   Zheng J, 2005, J CHEM PHYS, V122, DOI 10.1063/1.1908619
   Zhong CJ, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/6/062001
   Zhu FQ, 2002, BIOPHYS J, V83, P154, DOI 10.1016/S0006-3495(02)75157-6
NR 47
TC 7
Z9 7
U1 0
U2 32
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1932-7447
J9 J PHYS CHEM C
JI J. Phys. Chem. C
PD OCT 6
PY 2011
VL 115
IS 39
BP 19158
EP 19164
DI 10.1021/jp201467y
PG 7
WC Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science,
   Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA 825BI
UT WOS:000295245500032
DA 2018-03-20
ER

PT J
AU Sarma, R
   Islam, MS
   Miller, AF
   Bhattacharyya, D
AF Sarma, Rupam
   Islam, Md. Saiful
   Miller, Anne-Frances
   Bhattacharyya, Dibakar
TI Layer-by-Layer-Assembled Laccase Enzyme on Stimuli -Responsive Membranes
   for Chloro-Organics Degradation
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE functionalized membrdne; layer-by-layer assembly; enzyme immobilization;
   laccase; catalysis; trichlorophenol
ID FUNCTIONALIZED MEMBRANES; TRAMETES-VERSICOLOR; WATER-PURIFICATION;
   BISPHENOL-A; IMMOBILIZATION; REMOVAL; CHLOROPHENOLS; PERFORMANCE;
   BIOSENSORS; CARBON
AB Functionalized, membranes provide versatile platforms for the incorporation of biocatalysts and nanostructured materials for efficient and benign environmental remediation. The existing techniques for remediating chloro-organics in water consist of both physical and chemical means mostly using metal oxide-based catalysts, despite associated environmental concerns. To offer bioinspired remediation as an alternative, we herein demonstrate a layer-by-layer approach to immobilize laccase enzyme onto pH-responsive functionalized membranes for the degradation of chloro-organics in water. The efficacy of these bioinspired membranes toward dechlorination of 2,4,6-trichlorophenol (TCP) is demonstrated under a pressure-driven continuous flow mode (convective flow) for the first time to the best of our knowledge. Over 80% of the initial TCP was degraded at an optimum flow rate under an applied air pressure of about 0.7 bar or lower. This corresponds to degradation of a substantial amount of the initial substrate in only 36 s residence time, whereas it takes hours for degradation in a batch reaction. This, in fact, demonstrates an energy efficient flow-through system with potentially large-scale applications. Comparison of the stability of the enzyme in the solution phase versus immobilized on the membrane phase showed a loss of some 65% of enzyme activity in the solution phase after 22 d, whereas the membrane-bound enzyme lost only a negligible percentage of the activity in a comparable time span. Finally, the membrane was exposed to rigorous cycles of TCP degradation trials to study its reusability. The primary results reveal a loss of only 14% of the initial activity after 4 cycles of use in a period of 25 d, demonstrating its potential to be reused. Regeneration of the functionalized membrane was also validated by dislodging the immobilised enzyme,followed by immobilization of fresh enzyme onto the membrane.
C1 [Sarma, Rupam; Islam, Md. Saiful; Miller, Anne-Frances; Bhattacharyya, Dibakar] Univ Kentucky, Dept Chem & Mat Engn, 177 F Paul Anderson Tower, Lexington, KY 40506 USA.
RP Bhattacharyya, D (reprint author), Univ Kentucky, Dept Chem & Mat Engn, 177 F Paul Anderson Tower, Lexington, KY 40506 USA.
EM db@uky.edu
RI Miller, Anne-Frances/M-7703-2017
FU NSF KY EPSCoR grant [1355438]; NIH-NIEHS-SRC [P42ES007380]
FX This research was supported by NSF KY EPSCoR grant (grant no.: 1355438)
   and by NIH-NIEHS-SRC (award number: P42ES007380).
CR Agency for Toxic Substances and Disease Registry (ATSDR), 1999, TOX PROF CHLOR
   Bhattacharyya D, 1996, BIOFUNCTIONAL MEMBRANES, P117
   Brena Beatriz M., 2006, V22, P15
   Cao L, 2005, CARRIER-BOUND IMMOBILIZED ENZYMES: PRINCIPLES, APPLICATIONS AND DESIGN, P1, DOI 10.1002/3527607668
   Chen YY, 2016, ENVIRON SCI TECHNOL, V50, P8799, DOI 10.1021/acs.est.6b01641
   Cho Y, 2012, SOFT MATTER, V8, P10271, DOI 10.1039/c2sm26562a
   Dai YR, 2016, J HAZARD MATER, V317, P485, DOI 10.1016/j.jhazmat.2016.06.017
   Darvishmanesh S, 2015, CURR OPIN CHEM ENG, V8, P98, DOI 10.1016/j.coche.2015.04.002
   Datta S, 2008, IND ENG CHEM RES, V47, P4586, DOI 10.1021/ie800142d
   Dec J., 2000, PESTICIDE BIOTRANSFO, P182
   Diez MC, 2012, J ENVIRON MANAGE, V95, pS83, DOI 10.1016/j.jenvman.2010.09.024
   Dotzauer DM, 2006, NANO LETT, V6, P2268, DOI 10.1021/nl061700q
   Gaitan IJ, 2011, BIORESOURCE TECHNOL, V102, P3632, DOI 10.1016/j.biortech.2010.11.040
   Gui MH, 2015, J MEMBRANE SCI, V488, P79, DOI 10.1016/j.memsci.2015.03.089
   Gui M, 2013, IND ENG CHEM RES, V52, P10430, DOI 10.1021/ie400507c
   Hamby DM, 1996, SCI TOTAL ENVIRON, V191, P203, DOI 10.1016/S0048-9697(96)05264-3
   He F, 2014, RSC ADV, V4, P105, DOI 10.1039/c3ra44789h
   Hernandez S, 2016, ACS SUSTAIN CHEM ENG, V4, P907, DOI 10.1021/acssuschemeng.5b01005
   Homaei Ahmad Abolpour, 2013, J Chem Biol, V6, P185, DOI 10.1007/s12154-013-0102-9
   Hu XF, 2012, RSC ADV, V2, P12378, DOI 10.1039/c2ra21661b
   Jochems P, 2011, GREEN CHEM, V13, P1609, DOI 10.1039/c1gc15178a
   Jolivalt C, 2000, J MEMBRANE SCI, V180, P103, DOI 10.1016/S0376-7388(00)00522-6
   Kim YD, 2001, BIOTECHNOL BIOENG, V72, P475, DOI 10.1002/1097-0290(20010220)72:4<475::AID-BIT1009>3.0.CO;2-F
   Kirwan LJ, 2003, LANGMUIR, V19, P5802, DOI 10.1021/la027012d
   Lee KP, 2011, J MEMBRANE SCI, V370, P1, DOI 10.1016/j.memsci.2010.12.036
   Lewis SR, 2011, P NATL ACAD SCI USA, V108, P8577, DOI 10.1073/pnas.1101144108
   Li GH, 2017, J MEMBRANE SCI, V525, P89, DOI 10.1016/j.memsci.2016.10.033
   Lin JH, 2015, INT J BIOL MACROMOL, V78, P1, DOI 10.1016/j.ijbiomac.2015.03.033
   Liu GQ, 2010, J MEMBRANE SCI, V354, P198, DOI 10.1016/j.memsci.2010.02.047
   Liu YY, 2012, BIORESOURCE TECHNOL, V115, P21, DOI 10.1016/j.biortech.2011.11.015
   Madhavi V, 2009, BIORESOURCES, V4, P1694
   Mohamad NR, 2015, BIOTECHNOL BIOTEC EQ, V29, P205, DOI 10.1080/13102818.2015.1008192
   MORIYAMA S, 1980, AGR BIOL CHEM TOKYO, V44, P2047, DOI 10.1080/00021369.1980.10864285
   [National Toxicology Program (NTP) U. S. D. o. H. a. H. Services], 2014, REP CARC
   Penu R, 2013, CENT EUR J CHEM, V11, P968, DOI 10.2478/s11532-013-0222-7
   Pera-Titus M, 2004, APPL CATAL B-ENVIRON, V47, P219, DOI 10.1016/j.apcatb.2003.09.010
   Rother C., 2014, ENCY IND BIOTECHNOLO, P1
   ROYARCAND L, 1991, ENZYME MICROB TECH, V13, P194, DOI 10.1016/0141-0229(91)90128-W
   Shannon MA, 2008, NATURE, V452, P301, DOI 10.1038/nature06599
   Sheldon RA, 2013, CHEM SOC REV, V42, P6223, DOI 10.1039/c3cs60075k
   Spinelli D, 2013, PROCESS BIOCHEM, V48, P218, DOI 10.1016/j.procbio.2012.12.005
   Stuart MAC, 2010, NAT MATER, V9, P101, DOI [10.1038/NMAT2614, 10.1038/nmat2614]
   Tokarev I, 2009, ADV MATER, V21, P241, DOI 10.1002/adma.200801408
   Tutem E, 1998, WATER RES, V32, P2315, DOI 10.1016/S0043-1354(97)00476-4
   Wandera D, 2010, J MEMBRANE SCI, V357, P6, DOI 10.1016/j.memsci.2010.03.046
   Wang SW, 2014, NANOSCALE, V6, P6468, DOI 10.1039/c4nr01166j
   Wang Y, 2012, CHINESE CHEM LETT, V23, P197, DOI 10.1016/j.cclet.2011.10.011
   Xiao L, 2015, IND ENG CHEM RES, V54, P4174, DOI 10.1021/ie504149t
   Xiao L, 2014, J MEMBRANE SCI, V457, P39, DOI 10.1016/j.memsci.2014.01.033
   Xiaozhen Liu, 2014, Advanced Materials Research, V1010-1012, P830, DOI 10.4028/www.scientific.net/AMR.1010-1012.830
   Xu P, 2006, TRENDS MICROBIOL, V14, P398, DOI 10.1016/j.tim.2006.07.002
   Xu R, 2013, ACS APPL MATER INTER, V5, P12554, DOI 10.1021/am403849q
   Zhang XY, 2015, SCI REP-UK, V5, DOI 10.1038/srep09940
NR 53
TC 2
Z9 2
U1 16
U2 31
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944-8244
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD MAY 3
PY 2017
VL 9
IS 17
BP 14858
EP 14867
DI 10.1021/acsami.7b01999
PG 10
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA EU1SY
UT WOS:000400802700033
PM 28397501
DA 2018-03-19
ER

PT J
AU Rychahou, PG
   Bae, Y
   Zaytseva, Y
   Lee, EY
   Weiss, HL
   Evers, BM
AF Rychahou, Piotr G.
   Bae, Younsoo
   Zaytseva, Yekaterina
   Lee, Eun Y.
   Weiss, Heidi L.
   Evers, B. Mark
TI Colorectal cancer lung metastasis treatment with lung-selective PI3K
   pathway inhibition
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the American-Association-for-Cancer-Research
   (AACR)
CY APR 18-22, 2015
CL Philadelphia, PA
SP Amer Assoc Canc Res
C1 [Rychahou, Piotr G.; Bae, Younsoo; Zaytseva, Yekaterina; Lee, Eun Y.; Weiss, Heidi L.; Evers, B. Mark] Univ Kentucky, Lexington, KY USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD AUG 1
PY 2015
VL 75
SU 15
MA 4385
DI 10.1158/1538-7445.AM2015-4385
PG 2
WC Oncology
SC Oncology
GA DF8HA
UT WOS:000371597104018
DA 2018-03-19
ER

PT J
AU Zhan, DY
   Shin, HY
AF Zhan, Dongying
   Shin, Hainsworth Y.
TI Shear-Induced Cleavage of CD18 Integrins on Human Granulocytes,
   Monocytes and Lymphocytes
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Experimental Biology Meeting 2011
CY APR 09-13, 2011
CL Washington, DC
SP Amer Assoc Anatomists (AAA), Amer Physiolog Soc (APS), Amer Soc Biochem & Mol Biol (ASBMB), Amer Soc Investigat Pathol (ASIP), Amer Soc Nutrit (ASN), Amer Soc Pharmacol & Expt Therapeut (ASPET)
C1 [Zhan, Dongying; Shin, Hainsworth Y.] Univ Kentucky, Ctr Biomed Engn, Lexington, KY 40506 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2011
VL 25
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 032IE
UT WOS:000310708403690
DA 2018-03-20
ER

PT J
AU Berron, BJ
   May, AM
   Zheng, Z
   Balasubramaniam, V
   Bowman, CN
AF Berron, Brad J.
   May, Allison M.
   Zheng, Zheng
   Balasubramaniam, Vivek
   Bowman, Christopher N.
TI Antigen-responsive, microfluidic valves for single use diagnostics
SO LAB ON A CHIP
LA English
DT Article
ID POLYMERIZATION-BASED AMPLIFICATION; POLY(ETHYLENE GLYCOL) HYDROGELS;
   INITIATION; FILMS; BETA
AB The growing need for medical diagnostics in resource limited settings is driving the development of simple, standalone immunoassay devices. A capillary flow device using polymerization based amplification is capable of blocking a microfluidic channel in response to target biomaterials, enabling multiple modes of detection that require little or no supplemental instrumentation.
C1 [Berron, Brad J.; May, Allison M.; Zheng, Zheng; Bowman, Christopher N.] Univ Colorado, Boulder, CO 80309 USA.
   [Berron, Brad J.] Univ Kentucky, Lexington, KY USA.
   [Balasubramaniam, Vivek] Univ Colorado, Dept Pediat, Denver, CO 80045 USA.
RP Bowman, CN (reprint author), Univ Colorado, UCB 424, Boulder, CO 80309 USA.
EM Christopher.Bowman@Colorado.edu
RI Bowman, Christopher/B-1490-2008
OI Bowman, Christopher/0000-0001-8458-7723
FU NIH [R21 CA 127884, 5T32 HL007670-18, R21 EB012188]
FX This work was supported by NIH R21 CA 127884, NIH 5T32 HL007670-18, and
   NIH R21 EB012188.
CR Ashley JF, 2011, LAB CHIP, V11, P2772, DOI 10.1039/c1lc20189a
   Avens HJ, 2011, J HISTOCHEM CYTOCHEM, V59, P76, DOI 10.1369/jhc.2010.955948
   Avens HJ, 2011, J NANOPART RES, V13, P331, DOI 10.1007/s11051-010-0034-z
   Berron BJ, 2011, BIOTECHNOL BIOENG, V108, P1521, DOI 10.1002/bit.23101
   Cho YK, 2007, LAB CHIP, V7, P565, DOI 10.1039/b616115d
   IWATA H, 1992, BIOMATERIALS, V13, P891, DOI 10.1016/0142-9612(92)90111-Z
   IWATA H, 1991, J POLYM SCI POL CHEM, V29, P1217, DOI 10.1002/pola.1991.080290818
   Johnson LM, 2009, BIOMACROMOLECULES, V10, P3114, DOI 10.1021/bm900846m
   Johnson LM, 2009, AUST J CHEM, V62, P877, DOI 10.1071/CH09095
   Khire VS, 2007, MACROMOLECULES, V40, P5669, DOI 10.1021/ma070146j
   Lin CC, 2011, P NATL ACAD SCI USA, V108, P6380, DOI 10.1073/pnas.1014026108
   McCall JD, 2011, BIOMACROMOLECULES, V12, P1051, DOI 10.1021/bm101379v
   Ng AHC, 2010, ANAL BIOANAL CHEM, V397, P991, DOI 10.1007/s00216-010-3678-8
   Sikes HD, 2008, NAT MATER, V7, P52, DOI 10.1038/nmat2042
   Sikes HD, 2009, LAB CHIP, V9, P653, DOI 10.1039/b816198d
   Urdea Mickey, 2006, Nature, V444 Suppl 1, P73, DOI 10.1038/nature05448
   Yager P, 2006, NATURE, V442, P412, DOI 10.1038/nature05064
   Yi CQ, 2006, ANAL BIOANAL CHEM, V384, P1259, DOI 10.1007/s00216-005-0252-x
NR 18
TC 10
Z9 10
U1 0
U2 19
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1473-0197
J9 LAB CHIP
JI Lab Chip
PY 2012
VL 12
IS 4
BP 708
EP 710
DI 10.1039/c2lc21101g
PG 3
WC Biochemical Research Methods; Chemistry, Multidisciplinary; Chemistry,
   Analytical; Nanoscience & Nanotechnology
SC Biochemistry & Molecular Biology; Chemistry; Science & Technology -
   Other Topics
GA 880CB
UT WOS:000299380800006
PM 22218407
OA green_accepted
DA 2018-03-19
ER

PT J
AU Yu, CG
   Yezierski, R
   Joshi, A
   Raza, K
   Li, YZ
   Geddes, J
AF Yu, Chen-Guang
   Yezierski, Robert P.
   Joshi, Aashish
   Raza, Kashif
   Li, YongChao
   Geddes, James W.
TI RNAI APPROACH REVEALS A SPECIFIC ROLE OF ERK2 IN THE DELETERIOUS
   CONSEQUENCES OF SPINAL CORD INJURY
SO JOURNAL OF NEUROTRAUMA
LA English
DT Meeting Abstract
CT 2nd Joint Symposium of the
   National-and-International-Neurotrauma-Societies
CY SEP 07-11, 2009
CL Santa Barbara, CA
SP Natl & Int Neurotrauma Soc
C1 [Yu, Chen-Guang; Joshi, Aashish; Raza, Kashif; Li, Yanzhang; Geddes, James] Univ Kentucky, Lexington, KY USA.
   [Yezierski, Robert] Univ Florida, Gainesville, FL USA.
RI Yu, Chen Guang/C-6176-2011
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0897-7151
J9 J NEUROTRAUM
JI J. Neurotrauma
PD AUG
PY 2009
VL 26
IS 8
MA P285
BP A73
EP A73
PG 1
WC Critical Care Medicine; Clinical Neurology; Neurosciences
SC General & Internal Medicine; Neurosciences & Neurology
GA 479AF
UT WOS:000268629900303
DA 2018-03-20
ER

PT J
AU Zhang, XY
   Lu, W
   Kwan, K
   Bhattacharyya, D
   Wei, YA
AF Zhang, Xinyi
   Lu, Wei
   Kwan, Kevin
   Bhattacharyya, Dibakar
   Wei, Yinan
TI Dual-Functional-Tag-Facilitated Protein Labeling and Immobilization
SO ACS OMEGA
LA English
DT Article
ID NEWLY SYNTHESIZED PROTEINS; GLUTATHIONE-S-TRANSFERASE; IN-SITU
   VISUALIZATION; RECOMBINANT PROTEINS; ESCHERICHIA-COLI; CLICK CHEMISTRY;
   INORGANIC PYROPHOSPHATASE; STEP PURIFICATION; LIVING CELLS; AFFINITY TAG
AB An important strategy in the construction of biomimetic membranes and devices is to use natural proteins as the functional components for incorporation in a polymeric or nanocomposite matrix. Toward this goal, an important step is to immobilize proteins with high efficiency and precision without disrupting the protein function. Here, we developed a dual-functional tag containing histidine and the non-natural amino acid azidohomoalanine (AHA). AHA is metabolically incorporated into the protein, taking advantage of the Met-tRNA and Met-tRNA synthetase. Histidine in the tag can facilitate metal-affinity purification, whereas AHA can react with an alkyne-functionalized probe or surface via well-established click chemistry. We tested the performance of the tag using two model proteins, green fluorescence protein and an enzyme pyrophosphatase. We found that the addition of the tag and the incorporation of AHA did not significantly impair the properties of these proteins, and the histidine-AHA tag can facilitate protein purification, immobilization, and labeling.
C1 [Zhang, Xinyi; Lu, Wei; Kwan, Kevin; Wei, Yinan] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
   [Bhattacharyya, Dibakar] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Wei, YA (reprint author), Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
EM yinan.wei@uky.edu
FU Kentucky NSF EPSCoR RII Award [1355438]; University of Kentucky
FX We would like to thank Drs. Jing Chen and Haining Zhu for their help
   with the mass spectroscopy peptide fingerprinting analysis. This work
   was supported by the Kentucky NSF EPSCoR RII Award 1355438 (to D.B. and
   Y.W.) and the Igniting Research Collaboration Award from the University
   of Kentucky (to Y.W.).
CR Agard NJ, 2006, ACS CHEM BIOL, V1, P644, DOI 10.1021/cb6003228
   Antos JM, 2009, J AM CHEM SOC, V131, P10800, DOI 10.1021/ja902681k
   Avti PK, 2013, MOLECULES, V18, P9531, DOI 10.3390/molecules18089531
   BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8
   Bundy BC, 2010, BIOCONJUGATE CHEM, V21, P255, DOI 10.1021/bc9002844
   Carrico IS, 2007, NAT CHEM BIOL, V3, P321, DOI 10.1038/nchembio878
   Chin JW, 2002, J AM CHEM SOC, V124, P9026, DOI 10.1021/ja027007w
   Deal RB, 2010, SCIENCE, V328, P1161, DOI 10.1126/science.1186777
   Dieterich DC, 2010, NAT NEUROSCI, V13, P897, DOI 10.1038/nn.2580
   Einhauer A, 2001, J BIOCHEM BIOPH METH, V49, P455, DOI 10.1016/S0165-022X(01)00213-5
   EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610
   Exner MP, 2017, CHEMBIOCHEM, V18, P85, DOI 10.1002/cbic.201600537
   Gajadeera CS, 2015, J STRUCT BIOL, V189, P81, DOI 10.1016/j.jsb.2014.12.003
   Gottschling D, 1998, BIOCONJUGATE CHEM, V9, P831, DOI 10.1021/bc980074o
   GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1
   Hatzenpichler R, 2014, ENVIRON MICROBIOL, V16, P2568, DOI 10.1111/1462-2920.12436
   HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4
   Honegger A., 1997, BIOTECHNIQUES, V22, P140
   HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204
   Kiick KL, 2002, P NATL ACAD SCI USA, V99, P19, DOI 10.1073/pnas.012583299
   KNAPPIK A, 1994, BIOTECHNIQUES, V17, P754
   Kramer G, 2011, METHODS MOL BIOL, V753, P169, DOI 10.1007/978-1-61779-148-2_12
   LAHTI R, 1985, BIOCHEMISTRY-US, V24, P3526, DOI 10.1021/bi00335a021
   Lai YT, 2015, P NATL ACAD SCI USA, V112, P2948, DOI 10.1073/pnas.1419598112
   Lang K, 2012, NAT CHEM, V4, P298, DOI 10.1038/nchem.1250
   Li CK, 2011, BMC BIOTECHNOL, V11, DOI 10.1186/1472-6750-11-92
   Lin CW, 2006, J AM CHEM SOC, V128, P4542, DOI 10.1021/ja0604111
   Link AJ, 2003, J AM CHEM SOC, V125, P11164, DOI 10.1021/ja036765z
   Ma Y, 2014, MOLECULES, V19, P1004, DOI 10.3390/molecules19011004
   Martell J, 2014, MOLECULES, V19, P1378, DOI 10.3390/molecules19021378
   McClatchy DB, 2015, J PROTEOME RES, V14, P4815, DOI 10.1021/acs.jproteome.5b00653
   Nock S, 1997, FEBS LETT, V414, P233, DOI 10.1016/S0014-5793(97)01040-5
   Pedelacq JD, 2006, NAT BIOTECHNOL, V24, P79, DOI 10.1038/nbt1172
   Reddington SC, 2015, CURR OPIN CHEM BIOL, V29, P94, DOI 10.1016/j.cbpa.2015.10.002
   SASSENFELD HM, 1984, BIO-TECHNOL, V2, P76, DOI 10.1038/nbt0184-76
   SCHMIDT TGM, 1993, PROTEIN ENG, V6, P109, DOI 10.1093/protein/6.1.109
   Schmidt TGM, 2007, NAT PROTOC, V2, P1528, DOI 10.1038/nprot.2007.209
   Shah NH, 2014, CHEM SCI, V5, P446, DOI 10.1039/c3sc52951g
   Simon M, 2014, MOL CANCER THER, V13, P375, DOI 10.1158/1535-7163.MCT-13-0523
   Skerra A, 2000, METHOD ENZYMOL, V326, P271
   SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4
   tom Dieck S., 2015, NAT METHODS, V12, P411, DOI DOI 10.1038/NMETH.3319
   Uchinomiya S, 2013, CHEM COMMUN, V49, P5022, DOI 10.1039/c3cc41979g
   Uttamapinant C, 2010, P NATL ACAD SCI USA, V107, P10914, DOI 10.1073/pnas.0914067107
   Wang JP, 2014, BIOCONJUGATE CHEM, V25, P178, DOI 10.1021/bc400498p
   Wang YD, 2011, J VIROL, V85, P4510, DOI 10.1128/JVI.01925-10
   Zabel U, 1999, J BIOL CHEM, V274, P18149, DOI 10.1074/jbc.274.26.18149
   Zakeri B, 2012, P NATL ACAD SCI USA, V109, pE690, DOI 10.1073/pnas.1115485109
   Zakeri B, 2010, J AM CHEM SOC, V132, P4526, DOI 10.1021/ja910795a
   Zhong M, 2010, BIOCONJUGATE CHEM, V21, P1177, DOI 10.1021/bc9005392
   Zhou Z, 2007, ACS CHEM BIOL, V2, P337, DOI 10.1021/cb700054k
NR 51
TC 0
Z9 0
U1 5
U2 6
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2470-1343
J9 ACS OMEGA
JI ACS Omega
PD FEB
PY 2017
VL 2
IS 2
BP 522
EP 528
DI 10.1021/acsomega.6b00512
PG 7
WC Chemistry, Multidisciplinary
SC Chemistry
GA EN2TO
UT WOS:000395863300018
OA gold
DA 2018-03-19
ER

PT J
AU Luo, J
   Eitel, R
AF Luo, Jin
   Eitel, Richard E.
TI Sintering behavior and biocompatibility of a low temperature co-fired
   ceramic for microfluidic biosensors
SO INTERNATIONAL JOURNAL OF APPLIED CERAMIC TECHNOLOGY
LA English
DT Article
DE bioceramics; layered ceramics; low temperature; LTCC; tape casting
ID BIOACTIVE GLASS; DIELECTRIC-PROPERTIES; BOROSILICATE GLASS; PRACTICAL
   APPROACH; LTCC APPLICATIONS; VISCOUS-FLOW; DISSOLUTION; TECHNOLOGY;
   COMPOSITES; DEVICES
AB A low temperature co-fired ceramic (LTCC) has been formulated and evaluated for in-vitro microfluidic sensors and cell culture applications. Using a 75/25 vol% glass to alumina ratio, high density was achieved for sintering temperatures <900 degrees C. No toxicity was observed in the leachate medium obtained by soaking LTCC in cell medium for 5 days. The human umbilical vein endothelial cells (HUVECs) also attached on the fibronectin-coated LTCC after 14hours and proliferated after 74hours. On the basis of these results, the current LTCC formulation is a viable candidate for the continued development of LTCC-based microfluidic biosensors.
C1 [Luo, Jin] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [Luo, Jin] Tsinghua Univ, State Key Lab New Ceram & Fine Proc, Sch Mat Sci & Engn, Beijing, Peoples R China.
   [Eitel, Richard] Stevens Inst Technol, Dept Chem Engn & Mat Sci, Hoboken, NJ 07030 USA.
RP Luo, J (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.; Luo, J (reprint author), Tsinghua Univ, State Key Lab New Ceram & Fine Proc, Sch Mat Sci & Engn, Beijing, Peoples R China.; Eitel, R (reprint author), Stevens Inst Technol, Dept Chem Engn & Mat Sci, Hoboken, NJ 07030 USA.
EM jluuky2014@sina.com; reitel@stevens.edu
RI Eitel, Richard/E-2889-2010
OI Eitel, Richard/0000-0002-5090-2075
FU DEPSCOR/ONR; University of Kentucky Center for Clinical and
   Translational Science (CTSA)
FX The authors thank Dr. Kimberly Anderson (Department of Chemical and
   Materials Engineering, University of Kentucky) for providing
   experimental guidance and resources. The authors also thank William
   Mercke, David Cochran, Jennifer Fischer, and Samantha Meenach for
   helping with cell culture experiments. The project described was
   supported in part by the DEPSCOR/ONR and University of Kentucky Center
   for Clinical and Translational Science (CTSA).
CR Ahn CH, 2004, P IEEE, V92, P154, DOI 10.1109/JPROC.2003.820548
   Asoo B, 2000, J BIOMED MATER RES, V52, P488, DOI 10.1002/1097-4636(20001205)52:3<488::AID-JBM6>3.0.CO;2-W
   Bembnowicz P, 2011, OPT APPL, V41, P471
   Bjorkvik L, 2016, INT J APPL GLASS SCI, V7, P154, DOI 10.1111/ijag.12198
   Brandenburg A, 2016, SENSOR ACTUAT A-PHYS, V241, P145, DOI 10.1016/j.sna.2016.02.011
   Chang CR, 1999, J AM CERAM SOC, V82, P1725, DOI 10.1111/j.1151-2916.1999.tb01992.x
   Christodouleas DC, 2015, ANAL CHEM, V87, P9170, DOI 10.1021/acs.analchem.5b01612
   Chung TW, 2003, BIOMATERIALS, V24, P4655, DOI 10.1016/S0142-9612(03)00361-1
   Dai SXH, 2002, J AM CERAM SOC, V85, P828
   Erickson D, 2004, ANAL CHIM ACTA, V507, P11, DOI 10.1016/j.aca.2003.09.019
   Georgiev DG, 2005, J MATER SCI, V40, P5641, DOI 10.1007/s10853-005-1291-6
   Gongora-Rubio MR, 2001, SENSOR ACTUAT A-PHYS, V89, P222, DOI 10.1016/S0924-4247(00)00554-9
   Gongora-Rubio MR, 2004, SENSOR ACTUAT B-CHEM, V103, P468, DOI 10.1016/j.snb.2004.05.007
   Henstock JR, 2015, ACTA BIOMATER, V11, P17, DOI 10.1016/j.actbio.2014.09.025
   Ibanez-Garcia N, 2006, SENSOR ACTUAT B-CHEM, V118, P67, DOI 10.1016/j.snb.2006.04.063
   Jantunen H, 2000, J EUR CERAM SOC, V20, P2331, DOI 10.1016/S0955-2219(00)00145-X
   Jurkow D, 2015, SENSOR ACTUAT A-PHYS, V233, P125, DOI 10.1016/j.sna.2015.05.023
   Kemethmuller S, 2007, J AM CERAM SOC, V90, P64, DOI 10.1111/j.1551-2916.2006.01362.x
   Khang D, 2008, BIOMATERIALS, V29, P970, DOI 10.1016/j.biomaterials.2007.11.009
   Kim IS, 2010, J NANOSCI NANOTECHNO, V10, P3453, DOI 10.1166/jnn.2010.2340
   Lim WB, 2009, J EUR CERAM SOC, V29, P711, DOI 10.1016/j.jeurceramsoc.2008.07.058
   Lo CL, 2002, J AM CERAM SOC, V85, P2230, DOI 10.1111/j.1151-2916.2002.tb00440.x
   Mohanram A, 2005, J AM CERAM SOC, V88, P2681, DOI 10.1111/j.1551-2916.2005.00497.x
   Muller R, 2009, J AM CERAM SOC, V92, P1703, DOI 10.1111/j.1551-2916.2009.03089.x
   Parthasarathy KS, 2007, MAGN RESON IMAGING, V25, P1333, DOI 10.1016/j.mri.2007.03.020
   Rahaman MN, 2011, ACTA BIOMATER, V7, P2355, DOI 10.1016/j.actbio.2011.03.016
   Rajesh S, 2012, INT J APPL CERAM TEC, V9, P52, DOI 10.1111/j.1744-7402.2011.02684.x
   Sadler DJ, 2003, IEEE T COMPON PACK T, V26, P309, DOI 10.1109/TCAPT.2003.815093
   Sebastian MT, 2008, INT MATER REV, V53, P57, DOI 10.1179/174328008X277524
   Sjogren G, 2000, J PROSTHET DENT, V84, P229, DOI 10.1067/mpr.2000.107227
   Smetana W, 2007, MICROELECTRON ENG, V84, P1240, DOI 10.1016/j.mee.2007.01.155
   Su HH, 1997, AM CERAM SOC BULL, V76, P72
   Su HH, 1996, J AM CERAM SOC, V79, P3211, DOI 10.1111/j.1151-2916.1996.tb08097.x
   TENG MAO-HUA, 2002, W PACIFIC EARTH SCI, V2, P171
   Valerio P, 2004, BIOMATERIALS, V25, P2941, DOI 10.1016/j.biomaterials.2003.09.086
   Vasudev A, 2013, MICROFLUID NANOFLUID, V14, P683, DOI 10.1007/s10404-012-1087-3
   Verne E, 2003, J EUR CERAM SOC, V23, P675, DOI 10.1016/S0955-2219(02)00164-4
   Whitesides GM, 2006, NATURE, V442, P368, DOI 10.1038/nature05058
   Williams DF, 2008, BIOMATERIALS, V29, P2941, DOI 10.1016/j.biomaterials.2008.04.023
   Xie RJ, 2005, J EUR CERAM SOC, V25, P417, DOI 10.1016/j.jeurceramsoc.2004.01.022
   Zhang SL, 2006, MRS BULL, V31, P114
   Zhang WL, 2013, INT J APPL CERAM TEC, V10, P354, DOI 10.1111/j.1744-7402.2011.02747.x
   Zhang WL, 2012, INT J APPL CERAM TEC, V9, P60, DOI 10.1111/j.1744-7402.2010.02581.x
NR 43
TC 1
Z9 1
U1 2
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1546-542X
EI 1744-7402
J9 INT J APPL CERAM TEC
JI Int. J. Appl. Ceram. Technol.
PD MAR-APR
PY 2017
VL 14
IS 2
BP 99
EP 107
DI 10.1111/ijac.12648
PG 9
WC Materials Science, Ceramics
SC Materials Science
GA EP6SP
UT WOS:000397509500001
DA 2018-03-19
ER

PT J
AU Zhang, H
   Hollis, CP
   Zhang, Q
   Li, TL
AF Zhang, Hua
   Hollis, Christin P.
   Zhang, Qiang
   Li, Tonglei
TI Preparation and antitumor study of camptothecin nanocrystals
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Camptothecin; Nanocrystals; Nanosuspension; MCF-7; Antitumor efficacy
ID IN-VIVO; POLYMERIC MICELLES; CRYSTALLIZATION; NANOPARTICLES; BINDING;
   NANOSUSPENSIONS; STABILIZATION; FORMULATIONS; INHIBITION; PATHWAYS
AB Camptothecin (CPT) is a potent, broad spectrum antitumor agent that inhibits the activity of DNA topoisomerase I. Due to its poor solubility and stability and consequent delivery challenges, its clinical use is nevertheless limited. We aim to use nanocrystal formulation as a way to circumvent the difficult solubilization practice. Specifically, camptothecin nanocrystals were prepared with a sonication-precipitation method without additional stabilizing surfactants. Particle characteristics, cellular cytotoxicity, and animal antitumor effect were examined. CPT nanocrystals were tested to be more potent to MCF-7 cells than CPT solution in vitro. When tested in MCF-7 xenografted BALB/c mice, the CPT nanocrystals exhibited significant suppression of tumor growth. The drug concentration in the tumor was five times more at 24 h by using the nanocrystal treatment than by using the drug salt solution. Storage stability study indicated that the nanocrystals were stable for at least six months. Overall, CPT nanocrystals were considered to be potentially feasible to overcome formulation challenges for drug delivery and to be used in clinic. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Zhang, Hua; Zhang, Qiang] Peking Univ, Dept Pharmaceut, Sch Pharmaceut Sci, Beijing 100191, Peoples R China.
   [Hollis, Christin P.; Li, Tonglei] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
RP Zhang, Q (reprint author), Peking Univ, Dept Pharmaceut, Sch Pharmaceut Sci, Room 408,Pharm Bldg,38 Xueyuan Rd, Beijing 100191, Peoples R China.
EM zqdodo@bjmu.edu.cn; tonglei@uky.edu
FU DOD [BC050287]
FX The authors acknowledge the financial support from DOD Idea Award Grant
   #: BC050287.
CR Barreiro-Iglesias R, 2004, J CONTROL RELEASE, V97, P537, DOI 10.1016/j.jconrel.2004.04.007
   BURKE TG, 1993, ANAL BIOCHEM, V212, P285, DOI 10.1006/abio.1993.1325
   Cortesi R, 1997, INT J PHARM, V159, P95, DOI 10.1016/S0378-5173(97)00275-5
   Diaz-Moscoso A, 2010, J CONTROL RELEASE, V143, P318, DOI 10.1016/j.jconrel.2010.01.016
   Fan HL, 2010, POLYMER, V51, P5107, DOI 10.1016/j.polymer.2010.09.004
   FASSBERG J, 1992, J PHARM SCI, V81, P676, DOI 10.1002/jps.2600810718
   Gabr A, 1997, CANCER RES, V57, P4811
   Gratton SEA, 2008, P NATL ACAD SCI USA, V105, P11613, DOI 10.1073/pnas.0801763105
   Guo Z, 2005, J CRYST GROWTH, V273, P555, DOI 10.1016/j.jcrysgro.2004.09.049
   HEM SL, 1967, ULTRASONICS, V5, P202, DOI 10.1016/0041-624X(67)90061-3
   HERTZBERG RP, 1989, BIOCHEMISTRY-US, V28, P4629, DOI 10.1021/bi00437a018
   Hobbs SK, 1998, P NATL ACAD SCI USA, V95, P4607, DOI 10.1073/pnas.95.8.4607
   Hong MH, 2010, J CONTROL RELEASE, V141, P22, DOI 10.1016/j.jconrel.2009.08.024
   Kaerger JS, 2004, PHARM RES, V21, P372, DOI 10.1023/B:PHAM.0000016252.97296.f1
   Kawano K, 2006, J CONTROL RELEASE, V112, P329, DOI 10.1016/j.jconrel.2006.03.012
   Kunii R, 2007, EUR J PHARM BIOPHARM, V67, P9, DOI 10.1016/j.ejpb.2007.01.012
   Liu F, 2010, J PHARM SCI-US, V99, P3542, DOI 10.1002/jps.22112
   Maeda H, 2001, ADV ENZYME REGUL, V41, P189, DOI 10.1016/S0065-2571(00)00013-3
   Mayer LD, 2000, J LIPOSOME RES, V10, P99, DOI 10.3109/08982100009029381
   Merisko-Liversidge E, 2003, EUR J PHARM SCI, V18, P113, DOI 10.1016/S0928-0987(02)00251-8
   Miura H, 2004, J CONTROL RELEASE, V97, P101, DOI 10.1016/j.jconrel.2004.03.009
   Opanasopit P, 2004, PHARM RES, V21, P2001, DOI 10.1023/B:PHAM.0000048190.53439.eb
   POTMESIL M, 1994, CANCER RES, V54, P1431
   Rabinow BE, 2004, NAT REV DRUG DISCOV, V3, P785, DOI 10.1038/nrd1494
   Rejman J., 2004, BIOCHEM J, V377, P156
   Saetern AM, 2004, ANTI-CANCER DRUG, V15, P899, DOI 10.1097/00001813-200410000-00011
   Selvi B, 2008, J PHARM SCI-US, V97, P4379, DOI 10.1002/jps.21314
   Torchilin VP, 2007, PHARM RES-DORDR, V24, P1, DOI 10.1007/s11095-006-9132-0
   Van Eerdenbrugh B, 2008, INT J PHARMACEUT, V364, P64, DOI 10.1016/j.ijpharm.2008.07.023
   Venditto VJ, 2010, MOL PHARMACEUT, V7, P307, DOI 10.1021/mp900243b
   WALL ME, 1966, J AM CHEM SOC, V88, P3888, DOI 10.1021/ja00968a057
   WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107
   Yang SC, 1999, J CONTROL RELEASE, V59, P299, DOI 10.1016/S0168-3659(99)00007-3
   Yu DS, 2005, J CONTROL RELEASE, V110, P90, DOI 10.1016/j.jconrel.2005.09.050
   Zhao XH, 2010, J SUPERCRIT FLUID, V51, P412, DOI 10.1016/j.supflu.2009.10.004
   Zhao YX, 2010, INT J PHARMACEUT, V392, P64, DOI 10.1016/j.ijpharm.2010.03.027
   Zhou LN, 2010, CANCER LETT, V297, P56, DOI 10.1016/j.canlet.2010.04.024
   Zuhorn IS, 2002, J BIOL CHEM, V277, P18021, DOI 10.1074/jbc.M111257200
NR 38
TC 70
Z9 79
U1 2
U2 50
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD AUG 30
PY 2011
VL 415
IS 1-2
BP 293
EP 300
DI 10.1016/j.ijpharm.2011.05.075
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 799RX
UT WOS:000293304900038
PM 21679755
DA 2018-03-20
ER

PT J
AU Kalra, A
   Tishmack, P
   Lubach, JW
   Munson, EJ
   Taylor, LS
   Byrn, SR
   Li, TL
AF Kalra, Arjun
   Tishmack, Patrick
   Lubach, Joseph W.
   Munson, Eric J.
   Taylor, Lynne S.
   Byrn, Stephen R.
   Li, Tonglei
TI Impact of Supramolecular Aggregation on the Crystallization Kinetics of
   Organic Compounds from the Supercooled Liquid State
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE glass-forming ability; crystallization; nucleation; amorphous;
   spectroscopy; molecular interactions
ID GLASS-FORMING ABILITY; MOLECULAR GLASSES; TOLFENAMIC ACID; TRANSITION
   TEMPERATURE; PHARMACEUTICAL SOLIDS; STRUCTURAL RELAXATION; SOLUBILITY
   ADVANTAGE; PHYSICAL STABILITY; UNDERCOOLED MELTS; THERMAL-BEHAVIOR
AB Despite numerous challenges in their theoretical description and practical implementation, amorphous drugs are of growing importance to the pharmaceutical industry. One such challenge is to gain molecular level understanding of the propensity of a molecule to form and remain as a glassy solid. In this study, a series of structurally similar diarylamine compounds was examined to elucidate the role of supra molecular aggregation on crystallization kinetics from supercooled liquid state. The structural similarity of the compounds makes it easier to isolate the molecular features that affect crystallization kinetics and glass forming ability of these compounds. To examine the role of hydrogen-bonded aggregation and motifs on crystallization kinetics, a combination of thermal and spectroscopic techniques was employed. Using variable temperature FTIR, Raman, and solid-state NMR spectroscopies, the presence of hydrogen bonding in the melt and glassy state was examined and correlated with observed phase transition behaviors. Spectroscopic results revealed that the formation of hydrogen-bonded aggregates involving carboxylic acid and pyridine nitrogen (acid pyridine aggregates) between neighboring molecules in the melt state impedes crystallization, while the presence of carboxylic acid dimers (acid acid dimers) in the melt favors crystallization. This study suggests that glass formation of small molecules is influenced by the type of intermolecular interactions present in the melt state and the kinetics associated with the molecules to assemble into a crystalline lattice. For the compounds that form acid pyridine aggregates, the formation of energy degenerate chains, produced due to conformational flexibility of the molecules, presents a kinetic barrier to crystallization. The poor crystallization tendency of these aggregates stems from the highly directional hydrogen-bonding interactions needed to form the acid pyridine chains. Conversely, for the compounds that form acid acid dimers, the nondirectional van der Waals forces needed to construct a nucleus promote rapid assembly and crystallization.
C1 [Kalra, Arjun; Taylor, Lynne S.; Byrn, Stephen R.; Li, Tonglei] Purdue Univ, Coll Pharm, Department Ind & Phys Pharm, RHPH Bldg,Room 124B,575 Stadium Mall Dr, W Lafayette, IN 47907 USA.
   [Tishmack, Patrick] SSCI, W Lafayette, IN 47906 USA.
   [Lubach, Joseph W.] Genentech Inc, San Francisco, CA 94080 USA.
   [Munson, Eric J.] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40508 USA.
RP Li, TL (reprint author), Purdue Univ, Coll Pharm, Department Ind & Phys Pharm, RHPH Bldg,Room 124B,575 Stadium Mall Dr, W Lafayette, IN 47907 USA.
EM tonglei@purdue.edu
OI Lubach, Joseph/0000-0002-5806-0204
FU PRF (Purdue Research Foundation); CPPR (Center for Pharmaceutical
   Processing Research); NSF I/UCRC Center for Pharmaceutical Development
   [IIP-1540011]
FX The authors would like to thank Dr. Keith Chadwick (Purdue University)
   for valuable discussions. Financial support from PRF (Purdue Research
   Foundation) and CPPR (Center for Pharmaceutical Processing Research) is
   acknowledged. The authors (E.J.M.) would also like to thank NSF I/UCRC
   Center for Pharmaceutical Development (IIP-1540011 and industrial
   contributions) for financial support.
CR Alhalaweh A, 2015, INT J PHARMACEUT, V495, P312, DOI 10.1016/j.ijpharm.2015.08.101
   Alhalaweh A, 2014, MOL PHARMACEUT, V11, P3123, DOI 10.1021/mp500303a
   Aliev A. E., 2003, STRUCT BOND, V108, P1
   ANDERSEN KV, 1989, J CHEM SOC PERK T 2, P1443, DOI 10.1039/p29890001443
   Babu NJ, 2011, CRYST GROWTH DES, V11, P2662, DOI 10.1021/cg200492w
   Baird JA, 2010, J PHARM SCI-US, V99, P3787, DOI 10.1002/jps.22197
   Baran J, 2005, J MOL STRUCT, V744, P301, DOI 10.1016/j.molstruc.2004.10.052
   Bhugra C, 2008, J PHARM SCI-US, V97, P1329, DOI 10.1002/jps.21138
   Bouzidi L, 2010, LANGMUIR, V26, P4311, DOI 10.1021/la903420n
   Chelli R, 2002, J CHEM PHYS, V116, P6205, DOI 10.1063/1.1454993
   Cui Y, 2007, INT J PHARMACEUT, V339, P3, DOI 10.1016/j.ijpharm.2007.04.021
   Davey RJ, 2013, ANGEW CHEM INT EDIT, V52, P2166, DOI 10.1002/anie.201204824
   Delori A, 2012, CRYSTENGCOMM, V14, P2350, DOI 10.1039/c2ce06582g
   Descamps M, 2014, J PHARM SCI-US, V103, P2615, DOI 10.1002/jps.24016
   Dirama T. E., 2005, J CHEM PHYS, V122, P8
   Dovesi R, 2005, Z KRISTALLOGR, V220, P571, DOI 10.1524/zkri.220.5.571.65065
   Duddu SP, 1997, PHARMACEUT RES, V14, P596, DOI 10.1023/A:1012196826905
   Eren RN, 2012, TETRAHEDRON, V68, P10130, DOI 10.1016/j.tet.2012.09.103
   Feng SX, 2006, J CHEM THEORY COMPUT, V2, P149, DOI 10.1021/ct050189a
   Frisch M. J., 2009, GAUSSIAN 09 REVISION
   GOTZE W, 1992, REP PROG PHYS, V55, P241, DOI 10.1088/0034-4885/55/3/001
   Gradys A, 2005, MAT SCI ENG A-STRUCT, V413, P442, DOI 10.1016/j.msea.2005.08.167
   Habgood M, 2013, CRYST GROWTH DES, V13, P1771, DOI 10.1021/cg400109j
   Hancock BC, 2000, PHARMACEUT RES, V17, P397, DOI 10.1023/A:1007516718048
   Jabeen S, 2012, SPECTROCHIM ACTA A, V96, P972, DOI 10.1016/j.saa.2012.07.129
   JABRANE S, 1995, THERMOCHIM ACTA, V258, P33, DOI 10.1016/0040-6031(94)02235-G
   Kashchiev D, 2003, CRYST RES TECHNOL, V38, P555, DOI 10.1002/crat.200310070
   Kawakami K, 2005, J PHARM SCI-US, V94, P948, DOI 10.1002/jps.20298
   Kawakami K, 2014, MOL PHARMACEUT, V11, P1835, DOI 10.1021/mp400679m
   Kawakami K, 2012, J PHARM SCI-US, V101, P3239, DOI 10.1002/jps.23166
   Kumar SS, 2014, CRYST GROWTH DES, V14, P1865, DOI 10.1021/cg5000205
   Laventure A, 2013, NEW J CHEM, V37, P3881, DOI 10.1039/c3nj00709j
   Lebel O, 2006, J AM CHEM SOC, V128, P10372, DOI 10.1021/ja063353s
   Long SH, 2008, CRYST GROWTH DES, V8, P4006, DOI 10.1021/cg800123z
   Long SH, 2008, CRYST GROWTH DES, V8, P3137, DOI 10.1021/cg800339h
   Long SH, 2010, CRYST GROWTH DES, V10, P2465, DOI 10.1021/cg100227s
   Long SH, 2009, CRYST GROWTH DES, V9, P4993, DOI 10.1021/cg900786b
   Mahlin D, 2011, MOL PHARMACEUT, V8, P498, DOI 10.1021/mp100339c
   Mattei A, 2012, PHARM RES-DORDR, V29, P460, DOI 10.1007/s11095-011-0574-7
   Meunier A, 2010, ORG LETT, V12, P1896, DOI 10.1021/ol100139t
   Murdande SB, 2011, PHARM DEV TECHNOL, V16, P187, DOI 10.3109/10837451003774377
   Newman A, 2012, J PHARM SCI-US, V101, P1355, DOI 10.1002/jps.23031
   Plante A, 2009, J PHYS CHEM B, V113, P14884, DOI 10.1021/jp905268a
   Rodriguez-Spong B, 2004, ADV DRUG DELIVER REV, V56, P241, DOI 10.1016/j.addr.2003.10.005
   SBIT M, 1987, ACTA CRYSTALLOGR C, V43, P926, DOI 10.1107/S0108270187093557
   SeethaLekshmi S, 2012, CRYST GROWTH DES, V12, P4283, DOI 10.1021/cg300812v
   Shintani H, 2006, NAT PHYS, V2, P200, DOI 10.1038/nphys235
   Simon S, 1996, J CHEM PHYS, V105, P11024, DOI 10.1063/1.472902
   SINITI M, 1993, THERMOCHIM ACTA, V224, P105, DOI 10.1016/0040-6031(93)80160-C
   Siniti M, 1999, THERMOCHIM ACTA, V325, P171, DOI 10.1016/S0040-6031(98)00576-0
   SINITI M, 1993, THERMOCHIM ACTA, V224, P97, DOI 10.1016/0040-6031(93)80159-8
   Spackman MA, 2009, CRYSTENGCOMM, V11, P19, DOI 10.1039/b818330a
   Tanaka H, 1999, J CHEM PHYS, V111, P3175, DOI 10.1063/1.479597
   Tanaka H, 2005, J NON-CRYST SOLIDS, V351, P678, DOI 10.1016/j.jnoncrysol.2005.01.070
   Tanaka H, 2005, J NON-CRYST SOLIDS, V351, P3385, DOI 10.1016/j.jnoncrysol.2005.09.009
   TURNBULL D, 1969, CONTEMP PHYS, V10, P473, DOI 10.1080/00107516908204405
   Uhlmann D. R., 1972, Journal of Non-Crystalline Solids, V7, P337, DOI 10.1016/0022-3093(72)90269-4
   Wang RY, 2009, J MATER CHEM, V19, P2747, DOI 10.1039/b820294j
   Wuest JD, 2009, TETRAHEDRON, V65, P7393, DOI 10.1016/j.tet.2009.07.026
   Wyttenbach N, 2016, MOL PHARMACEUT, V13, P241, DOI 10.1021/acs.molpharmaceut.5b00688
   Yu L, 2000, ORG PROCESS RES DEV, V4, P396, DOI 10.1021/op000028v
   Yu L, 2001, ADV DRUG DELIVER REV, V48, P27, DOI 10.1016/S0169-409X(01)00098-9
NR 62
TC 4
Z9 4
U1 4
U2 13
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD JUN
PY 2017
VL 14
IS 6
BP 2126
EP 2137
DI 10.1021/acs.molpharmaceut.7b00245
PG 12
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA EX0ZY
UT WOS:000402950500027
PM 28485947
DA 2018-03-20
ER

PT J
AU Leontsev, SO
   Eitel, RE
AF Leontsev, Serhiy O.
   Eitel, Richard E.
TI Origin and magnitude of the large piezoelectric response in the
   lead-free (1-x)BiFeO3-xBaTiO(3) solid solution
SO JOURNAL OF MATERIALS RESEARCH
LA English
DT Article
ID ZIRCONATE-TITANATE CERAMICS; DOMAIN-WALL; FERROELECTRIC PROPERTIES;
   TEMPERATURE; PERMITTIVITY; COEFFICIENT; DEPENDENCE; BIFEO3; PZT
AB Mechanisms and magnitudes of the large piezoelectric response observed in lead-free (1-x) BiFeO3-xBaTiO(3) (BFBT) ceramics are investigated. Preceding studies reported significant strain hysteresis and hard ferroelectric behavior in BFBT leading to a small low-field piezoelectric coefficient, instability of the poled domain state, and rapid degradation of piezoelectric properties. The current investigation shows that under application of a suitable direct current (dc) bias to stabilize the ferroelectric phase low- and high-field piezoelectric coefficients (d(33)) of 150 pC/N and 250 pC/N are observed for the composition 0.67BiFeO(3)-0.33BaTiO(3) + 0.1 wt% MnO with a Curie temperature of 605 degrees C. Such enhancement of electromechanical properties under dc bias is in contrast to the expected behavior in traditional piezoelectric materials such as soft lead zirconate titanate (PZT). The large piezoelectric coefficients confirm strong intrinsic and extrinsic contributions to the piezoelectric response in BFBT, which coupled with high ferroelectric Curie temperature T-C > 500 degrees C, suggests BFBT-based materials as promising lead-free alternatives to PZT piezoceramics.
C1 [Leontsev, Serhiy O.; Eitel, Richard E.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
RP Leontsev, SO (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM leontsev@uky.edu
RI Eitel, Richard/E-2889-2010
OI Eitel, Richard/0000-0002-5090-2075
CR Akdogan EK, 2008, APPL PHYS LETT, V92, DOI 10.1063/1.2897033
   Berlincourt D.A., 1964, PHYS ACOUSTICS PRINC
   Catalan G, 2009, ADV MATER, V21, P2463, DOI 10.1002/adma.200802849
   Dai YJ, 2010, J AM CERAM SOC, V93, P1108, DOI 10.1111/j.1551-2916.2009.03535.x
   Damjanovic D, 1996, J PHYS D APPL PHYS, V29, P2057, DOI 10.1088/0022-3727/29/7/046
   Damjanovic D, 1997, J APPL PHYS, V82, P1788, DOI 10.1063/1.365981
   Eitel R, 2007, PHYS REV B, V75, DOI 10.1103/PhysRevB.75.094106
   Eitel RE, 2006, J APPL PHYS, V99, DOI 10.1063/1.2207738
   GRAY RB, 1949, TRANSDUCER METHOD MA
   Hall DA, 2001, J MATER SCI, V36, P4575, DOI 10.1023/A:1017959111402
   Hill NA, 2000, J PHYS CHEM B, V104, P6694, DOI 10.1021/jpc00114x
   Hiruma Y, 2009, CERAM INT, V35, P117, DOI 10.1016/j.ceramint.2007.10.023
   Hollenstein E, 2005, APPL PHYS LETT, V87, DOI 10.1063/1.2123387
   Horibe Y, 2005, JPN J APPL PHYS 1, V44, P7148, DOI 10.1143/JJAP.44.7148
   Itoh N, 2007, FERROELECTRICS, V356, P311, DOI 10.1080/00150190701508860
   JAFFE H, 1958, J AM CERAM SOC, V41, P494, DOI 10.1111/j.1151-2916.1958.tb12903.x
   Jona F., 1993, FERROELECTRIC CRYSTA
   Kitagawa S, 2008, FERROELECTRICS, V376, P318, DOI 10.1080/00150190802440948
   Kumar MM, 2000, J APPL PHYS, V87, P855, DOI 10.1063/1.371953
   Leontsev SO, 2009, J AM CERAM SOC, V92, P2957, DOI 10.1111/j.1551-2916.2009.03313.x
   LI SP, 1993, MATER LETT, V17, P21, DOI 10.1016/0167-577X(93)90141-J
   MICHEL C, 1969, SOLID STATE COMMUN, V7, P865, DOI 10.1016/0038-1098(69)90429-3
   Ozaki T, 2009, FERROELECTRICS, V385, P155, DOI 10.1080/00150190902889267
   Perrin V, 2000, J ELECTROCERAM, V4, P189, DOI 10.1023/A:1009972028356
   Pramanick A, 2009, J AM CERAM SOC, V92, P2291, DOI 10.1111/j.1551-2916.2009.03218.x
   ROBERTS S, 1947, PHYS REV, V71, P890, DOI 10.1103/PhysRev.71.890
   Scott JF, 2010, CHEMPHYSCHEM, V11, P341, DOI 10.1002/cphc.200900906
   Shrout TR, 2007, J ELECTROCERAM, V19, P113, DOI 10.1007/s10832-007-9047-0
   Shvartsman VV, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2731312
   Takenaka T, 2008, JPN J APPL PHYS, V47, P3787, DOI 10.1143/JJAP.47.3787
   Wada S, 2008, FERROELECTRICS, V373, P11, DOI 10.1080/00150190802408531
   Wang J, 2003, SCIENCE, V299, P1719, DOI 10.1126/science.1080615
   Yoneda Y, 2008, JPN J APPL PHYS, V47, P7590, DOI 10.1143/JJAP.47.7590
   Zeches RJ, 2009, SCIENCE, V326, P977, DOI 10.1126/science.1177046
   ZHANG QM, 1988, J APPL PHYS, V64, P6445, DOI 10.1063/1.342059
   ZHANG QM, 1994, J APPL PHYS, V75, P454, DOI 10.1063/1.355874
   Zhang ST, 2008, J APPL PHYS, V103, DOI 10.1063/1.2838476
   Zhang ST, 2007, APPL PHYS LETT, V91, DOI 10.1063/1.2783200
   Zhang SJ, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1968419
   [Anonymous], 1961, P I RADIO ENG, V49, P1161
NR 40
TC 29
Z9 29
U1 2
U2 33
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0884-2914
J9 J MATER RES
JI J. Mater. Res.
PD JAN
PY 2011
VL 26
IS 1
BP 9
EP 17
DI 10.1557/jmr.2010.44
PG 9
WC Materials Science, Multidisciplinary
SC Materials Science
GA 793KT
UT WOS:000292821500002
DA 2018-03-19
ER

PT J
AU deKrafft, KE
   Wang, C
   Xie, ZG
   Su, X
   Hinds, BJ
   Lin, WB
AF deKrafft, Kathryn E.
   Wang, Cheng
   Xie, Zhigang
   Su, Xin
   Hinds, Bruce J.
   Lin, Wenbin
TI Electrochemical Water Oxidation with Carbon-Grafted Iridium Complexes
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE water oxidation; electrocatalysis; diazonium grafting; carbon electrode;
   water splitting
ID AMMONIUM-NITRATE; DIAZONIUM SALTS; H-2 PRODUCTION; SINGLE-SITE;
   EFFICIENT; CATALYSTS; OXYGEN; REDUCTION; SURFACES; ELECTRODES
AB Hydrogen,production from water splitting provides a; potential solution to storing harvested solar energy in chemical fuels,, but this process requires active and robust catalysts that can oxidize water to provide a source of electrons for proton reduction. Here we report the direct, covalent grafting of molecular Ir complexes onto carbon electrodes, with up to a monolayer coverage. Carbon-grafted Ir complexes electrochemically oxidize water with a turnover frequency of up to 3.3 s(-1) and a turnover number of 644 during the first hour. Electrochemical water oxidation with grafted catalysts gave enhanced rates and stability compared to chemically driven water oxidation with the corresponding molecular catalysts. This strategy provides away to systematically evaluate catalysts under tunable conditions, potentially providing new insights into electrochemical water oxidation processes and water oxidation catalyst design.
C1 [Su, Xin; Hinds, Bruce J.] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
   [deKrafft, Kathryn E.; Wang, Cheng; Xie, Zhigang; Lin, Wenbin] Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA.
RP Hinds, BJ (reprint author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.
EM bjhinds@engr.uky.edu; wlin@unc.edu
RI Wang, Cheng/D-4487-2015; Su, Xin/M-1162-2013; Lin, Wenbin/B-4151-2010
OI Wang, Cheng/0000-0002-7906-8061; Su, Xin/0000-0002-1615-2856; Lin,
   Wenbin/0000-0001-7035-7759; Xie, Zhigang/0000-0003-2974-1825
FU UNC EFRC: Solar Fuels, an Energy Frontier Research Center; U.S.
   Department of Energy, Office of Science, Office of Basic Energy Sciences
   [DE-SC0001011]; UNC; NSF; UNC Department of Chemistry; DOE EPSCoR
   [DE-FG02-07ER46375]; DARPA [W911NF-09-1-0267]
FX This material is based upon work supported as part of the UNC EFRC:
   Solar Fuels, an Energy Frontier Research Center funded by the U.S.
   Department of Energy, Office of Science, Office of Basic Energy Sciences
   under Award DE-SC0001011. KEd acknowledges support from the UNC Graduate
   School for a Dissertation Completion Fellowship. C.W. acknowledges
   support from the NSF and from the UNC Department of Chemistry for the
   Ernest L. Eliel fellowship. X.S. and B.J.H. acknowledge funding support
   from DOE EPSCoR (DE-FG02-07ER46375) and DARPA (W911NF-09-1-0267).
CR Allongue P, 1997, J AM CHEM SOC, V119, P201, DOI 10.1021/ja963354s
   Blakemore JD, 2010, J AM CHEM SOC, V132, P16017, DOI 10.1021/ja104775J
   Boutadla Y, 2009, ORGANOMETALLICS, V28, P433, DOI 10.1021/om800909w
   Chen ZF, 2010, P NATL ACAD SCI USA, V107, P7225, DOI 10.1073/pnas.1001132107
   Chen ZF, 2009, J AM CHEM SOC, V131, P15580, DOI 10.1021/ja906391w
   Concepcion JJ, 2009, ACCOUNTS CHEM RES, V42, P1954, DOI 10.1021/ar9001526
   Duan LL, 2009, J AM CHEM SOC, V131, P10397, DOI 10.1021/ja9034686
   Eisenberg R, 2008, INORG CHEM, V47, P1697, DOI 10.1021/ic800155g
   Ellis WC, 2010, J AM CHEM SOC, V132, P10990, DOI 10.1021/ja104766z
   ENGSTROM RC, 1984, ANAL CHEM, V56, P136, DOI 10.1021/ac00266a005
   Fillol JL, 2011, NAT CHEM, V3, P807, DOI [10.1038/NCHEM.1140, 10.1038/nchem.1140]
   Fukuzumi S, 2011, ENERG ENVIRON SCI, V4, P2754, DOI 10.1039/c1ee01551f
   Geletii YV, 2009, J AM CHEM SOC, V131, P7522, DOI 10.1021/ja901373m
   GERSTEN SW, 1982, J AM CHEM SOC, V104, P4029, DOI 10.1021/ja00378a053
   Gong KP, 2009, SCIENCE, V323, P760, DOI 10.1126/science.1168049
   Grotjahn DB, 2011, J AM CHEM SOC, V133, P19024, DOI 10.1021/ja203095k
   Gust D, 2009, ACCOUNTS CHEM RES, V42, P1890, DOI 10.1021/ar900209b
   Helm ML, 2011, SCIENCE, V333, P863, DOI 10.1126/science.1205864
   Hong DC, 2012, ENERG ENVIRON SCI, V5, P5708, DOI 10.1039/c2ee02964b
   Hou Y, 2010, NANO LETT, V10, P2727, DOI 10.1021/nl101723g
   Hull JF, 2009, J AM CHEM SOC, V131, P8730, DOI 10.1021/ja901270f
   Jiao F, 2009, ANGEW CHEM INT EDIT, V48, P1841, DOI 10.1002/anie.200805534
   Kanan MW, 2008, SCIENCE, V321, P1072, DOI 10.1126/science.1162018
   Kanan MW, 2009, CHEM SOC REV, V38, P109, DOI 10.1039/b802885k
   Le Goff A, 2009, SCIENCE, V326, P1384, DOI 10.1126/science.1179773
   Lewis NS, 2006, P NATL ACAD SCI USA, V103, P15729, DOI 10.1073/pnas.0603395103
   McDaniel ND, 2008, J AM CHEM SOC, V130, P210, DOI 10.1021/ja074478f
   Murakami M, 2011, J AM CHEM SOC, V133, P11605, DOI 10.1021/ja2024965
   Nakagawa T, 2009, J AM CHEM SOC, V131, P15578, DOI 10.1021/ja9063298
   Pinson J, 2005, CHEM SOC REV, V34, P429, DOI 10.1039/b406228k
   Ruther RE, 2011, J AM CHEM SOC, V133, P5692, DOI 10.1021/ja200210t
   Schley ND, 2011, J AM CHEM SOC, V133, P10473, DOI 10.1021/ja2004522
   Toma FM, 2010, NAT CHEM, V2, P826, DOI [10.1038/NCHEM.761, 10.1038/nchem.761]
   Turner JA, 2004, SCIENCE, V305, P972, DOI 10.1126/science.1103197
   Wagner C.D., NIST XRAY PHOTOELECT
   Wang C, 2011, J AM CHEM SOC, V133, P13445, DOI 10.1021/ja203564w
   Yagi M, 2005, J PHYS CHEM B, V109, P21489, DOI 10.1021/jp0550208
   Yin QS, 2010, SCIENCE, V328, P342, DOI 10.1126/science.1185372
   Youngblood WJ, 2009, ACCOUNTS CHEM RES, V42, P1966, DOI 10.1021/ar9002398
   Youngblood WJ, 2009, J AM CHEM SOC, V131, P926, DOI 10.1021/ja809108y
   Zanello P., 2003, INORGANIC ELECTROCHE
   Zhong DK, 2009, J AM CHEM SOC, V131, P6086, DOI 10.1021/ja9016478
NR 42
TC 33
Z9 33
U1 3
U2 45
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944-8244
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD FEB
PY 2012
VL 4
IS 2
BP 608
EP 613
DI 10.1021/am2018095
PG 6
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA 897IW
UT WOS:000300644500018
PM 22292527
DA 2018-03-20
ER

PT J
AU Fugit, KD
   Anderson, BD
AF Fugit, Kyle D.
   Anderson, Bradley D.
TI Ion-Pairing Contribution to the Liposomal Transport of Topotecan as
   Revealed by Mechanistic Modeling
SO JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE structure-transport relationship; zwitterion; passive
   diffusion/transport; nanoparticles; mathematical model; liposomes;
   ion-pairing; controlled release; computational ADME; cancer
ID HYDROPHOBIC CAMPTOTHECIN; INTRALIPOSOMAL PH; RIGOROUS THEORY;
   ENCAPSULATION; PERMEABILITY; DOXORUBICIN; RELEASE; HYDROLYSIS; GRADIENT;
   BINDING
AB Actively loaded liposomal formulations of anticancer agents have been widely explored due to their high drug encapsulation efficiencies and prolonged drug retention. Mathematical models to predict and optimize drug loading and release kinetics from these nanoparticle formulations would be useful in their development and may allow researchers to tune release profiles. Such models must account for the driving forces as influenced by the physicochemical properties of the drug and the microenvironment, and the liposomal barrier properties. This study employed mechanistic modeling to describe the active liposomal loading and release kinetics of the anticancer agent topotecan (TPT). The model incorporates ammonia transport resulting in generation of a pH gradient, TPT dimerization, TPT lactone ring-opening and -closing interconversion kinetics, chloride transport, and transport of TPT-chloride ion-pairs to describe the active loading and release kinetics of TPT in the presence of varying chloride concentrations. Model-based predictions of the kinetics of active loading at varying loading concentrations of TPT and release under dynamic dialysis conditions were in reasonable agreement with experiments. These findings identify key attributes to consider in optimizing and predicting loading and release of liposomal TPT that may also be applicable to liposomal formulations of other weakly basic pharmaceuticals. (C) 2017 American Pharmacists Association (R). Published by Elsevier Inc. All rights reserved.
C1 [Fugit, Kyle D.] Metr Contract Serv, Dept Pharmaceut Dev, Greenville, NC 27834 USA.
   [Anderson, Bradley D.] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
RP Anderson, BD (reprint author), Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
EM bande2@email.uky.edu
FU National Cancer Institute [R25CA153954]
FX This project was supported by Grant Number R25CA153954 from the National
   Cancer Institute. The content is solely the responsibility of the
   authors and does not necessarily represent the official views of the
   National Cancer Institute or the National Institutes of Health.
CR Abraham SA, 2004, J CONTROL RELEASE, V96, P449, DOI 10.1016/j.jconrel.2004.02.017
   Baxter NJ, 1996, J CHEM SOC FARADAY T, V92, P231, DOI 10.1039/ft9969200231
   Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442
   Bocian W, 2004, CHEM-EUR J, V10, P5776, DOI 10.1002/chem.200305624
   Brigger I, 2002, ADV DRUG DELIVER REV, V54, P631, DOI 10.1016/S0169-409X(02)00044-3
   BURKE TG, 1994, J PHARM SCI, V83, P967, DOI 10.1002/jps.2600830710
   CEH B, 1995, LANGMUIR, V11, P3356, DOI 10.1021/la00009a016
   Ceh B, 1997, J COLLOID INTERF SCI, V185, P9, DOI 10.1006/jcis.1996.4555
   Charrois GJR, 2003, BBA-BIOMEMBRANES, V1609, P102, DOI 10.1016/S0005-2736(02)00661-2
   Drummond DC, 2010, J CONTROL RELEASE, V141, P13, DOI 10.1016/j.jconrel.2009.08.006
   Drummond DC, 2006, CANCER RES, V66, P3271, DOI 10.1158/0008-5472.CAN-05-4007
   FASSBERG J, 1992, J PHARM SCI, V81, P676, DOI 10.1002/jps.2600810718
   Fugit KD, 2015, J CONTROL RELEASE, V217, P82, DOI 10.1016/j.jconrel.2015.08.024
   Fugit KD, 2015, J CONTROL RELEASE, V197, P10, DOI 10.1016/j.jconrel.2014.10.011
   Fugit KD, 2014, MOL PHARMACEUT, V11, P1314, DOI 10.1021/mp400765n
   Fugit KD, 2014, J CONTROL RELEASE, V174, P88, DOI 10.1016/j.jconrel.2013.11.003
   GABIZON A, 1994, CANCER RES, V54, P987
   GRIT M, 1993, CHEM PHYS LIPIDS, V64, P3, DOI 10.1016/0009-3084(93)90053-6
   GRIT M, 1989, INT J PHARM, V50, P1, DOI 10.1016/0378-5173(89)90173-7
   HARAN G, 1993, BIOCHIM BIOPHYS ACTA, V1151, P201, DOI 10.1016/0005-2736(93)90105-9
   HUANG TH, 1993, BIOCHEMISTRY-US, V32, P13277, DOI 10.1021/bi00211a041
   Joguparthi V, 2008, INT J PHARM, V352, P17, DOI 10.1016/j.ijpharm.2007.10.003
   Joguparthi V, 2008, J PHARM SCI-US, V97, P433, DOI 10.1002/jps.21135
   Joguparthi V, 2008, J PHARM SCI-US, V97, P400, DOI 10.1002/jps.21125
   Knecht V, 2013, BIOPHYS J, V104, P818, DOI 10.1016/j.bpj.2012.12.056
   La-Beck NM, 2012, CANCER CHEMOTH PHARM, V69, P43, DOI 10.1007/s00280-011-1664-2
   Liu JJ, 2002, ANTI-CANCER DRUG, V13, P709, DOI 10.1097/00001813-200208000-00005
   Maeda H, 2013, ADV DRUG DELIVER REV, V65, P71, DOI 10.1016/j.addr.2012.10.002
   MAYER LD, 1990, BIOCHIM BIOPHYS ACTA, V1025, P143, DOI 10.1016/0005-2736(90)90091-2
   Modi S, 2013, MOL PHARMACEUT, V10, P3076, DOI 10.1021/mp400154a
   Modi S, 2012, J CONTROL RELEASE, V162, P330, DOI 10.1016/j.jconrel.2012.07.001
   PAPAHADJOPOULOS D, 1991, P NATL ACAD SCI USA, V88, P11460, DOI 10.1073/pnas.88.24.11460
   Strel'tsov S. A., 2001, Molekulyarnaya Biologiya (Moscow), V35, P432
   Streltsov S, 2003, BIOPOLYMERS, V72, P442, DOI 10.1002/bip.10479
   SUBRAMANIAN D, 1995, ONCOL RES, V7, P461
   Tardi P, 2000, CANCER RES, V60, P3389
   WALTER A, 1986, J MEMBRANE BIOL, V90, P207, DOI 10.1007/BF01870127
   Xiang TX, 1997, BIOPHYS J, V72, P223, DOI 10.1016/S0006-3495(97)78661-2
NR 38
TC 0
Z9 0
U1 1
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3549
EI 1520-6017
J9 J PHARM SCI-US
JI J. Pharm. Sci.
PD APR
PY 2017
VL 106
IS 4
BP 1149
EP 1161
DI 10.1016/j.xphs.2016.12.011
PG 13
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology &
   Pharmacy
SC Pharmacology & Pharmacy; Chemistry
GA ET6KB
UT WOS:000400399500027
PM 28007561
DA 2018-03-20
ER

PT J
AU Li, TL
   Ayers, PW
   Liu, SB
   Swadley, MJ
   Aubrey-Medendorp, C
AF Li, Tonglei
   Ayers, Paul W.
   Liu, Shubin
   Swadley, Matthew J.
   Aubrey-Medendorp, Clare
TI Crystallization Force-A Density Functional Theory Concept for Revealing
   Intermolecular Interactions and Molecular Packing in Organic Crystals
SO CHEMISTRY-A EUROPEAN JOURNAL
LA English
DT Article
DE density functional calculations; Fukui function; intermolecular
   interactions; polymorphism; solid-state structures
ID FRONTIER-CONTROLLED REACTIONS; STATIC DIPOLE POLARIZABILITY; NEGATIVE
   FUKUI FUNCTIONS; STRUCTURE PREDICTION; CHEMICAL-REACTIVITY;
   ELECTRONIC-STRUCTURE; GLOBAL SOFTNESS; HYDROGEN-BOND; BLIND TEST;
   HARDNESS
AB Organic molecules are prone to polymorphic formation in the solid state due to the rich diversity Of functional groups that results in comparable intermolecular interactions, which can be greatly affected by the selection of solvent and other crystallization conditions. Intermolecular interactions are typically weak forces. such as van der Waals and stronger short-range ones including hydrogen bonding, that are believed to determine the packing of organic molecules during the crystal-growth process. A different packing of the same molecules leads to the formation of a new crystal structure. To disclose the underlying causes that drive the molecule to have various packing motifs in the solid state, an electronic concept or function within the framework of Conceptual density functional theory has been developed. namely, crystallization force. The concept aims to describe the local change in electronic structure as a result of the self-assembly process of crystallization and may likely quantity the locality of intermolecular interactions that directs the molecular packing in a crystal. To assess the applicability of the concept, 5-methyl-2-[(2-nitrophenyl)amino]-3-thiophenecarbonitrile, so-called ROY, which is known to have the largest number of solved polymorphs. has been examined. Electronic calculations were conducted on the seven available crystal structures as well as on the single molecule. The electronic structures were analyzed and crystallization force values were obtained. The results indicate that the crystallization forces are able to reveal intermolecular interactions in the crystals, in particular, the close contacts that are formed between molecules. Strong correlations exist between the total crystallization force and lattice energy of a crystal Structure, further Suggesting the underlying connection between the crystallization force and molecular packing.
C1 [Li, Tonglei; Swadley, Matthew J.; Aubrey-Medendorp, Clare] Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
   [Ayers, Paul W.] McMaster Univ, Dept Chem, Hamilton, ON, Canada.
   [Liu, Shubin] Univ N Carolina, Renaissance Comp Inst, Chapel Hill, NC USA.
RP Li, TL (reprint author), Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
EM tonglei@uky.edu
RI Ayers, Paul/A-1154-2008; Liu, Shubin/B-1502-2009
OI Ayers, Paul/0000-0003-2605-3883; Liu, Shubin/0000-0001-9331-0427
FU NSF [DMR-0449633]; University of Kentucky Center for Computational
   Sciences
FX The research wits supported by, the NSF (DMR-0449633). C.A.M.
   acknowledges her gratitude to the University of Kentucky Center for
   Computational Sciences for her fellowship.
CR Aakeroy CB, 1997, ACTA CRYSTALLOGR B, V53, P569, DOI 10.1107/S0108768197008446
   Anderson JSM, 2007, J CHEM THEORY COMPUT, V3, P358, DOI 10.1021/ct600164j
   Aubrey-Medendorp C, 2008, PHARM RES, V25, P953, DOI 10.1007/s11095-007-9346-9
   Ayers PW, 2007, FARADAY DISCUSS, V135, P161, DOI 10.1039/b606877d
   Ayers PW, 2006, PHYS CHEM CHEM PHYS, V8, P3387, DOI 10.1039/b606167b
   Ayers PW, 2000, THEOR CHEM ACC, V103, P353, DOI 10.1007/s002149900093
   Ayers PW, 2002, J CHEM PHYS, V116, P8731, DOI 10.1063/1.1467338
   Ayers P.W., 2006, J CHEM PHYS, V124
   Balawender R, 2001, J CHEM PHYS, V114, P4441, DOI 10.1063/1.1346579
   BECKE AD, 1988, PHYS REV A, V38, P3098, DOI 10.1103/PhysRevA.38.3098
   BERKOWITZ M, 1988, J CHEM PHYS, V88, P2554, DOI 10.1063/1.454034
   BERKOWITZ M, 1987, J AM CHEM SOC, V109, P4823, DOI 10.1021/ja00250a012
   BERNSTEIN J, 1995, ANGEW CHEM INT EDIT, V34, P1555, DOI 10.1002/anie.199515551
   Bernstein J., 2002, POLYMORPHISM MOL CRY
   Bernstein J., 1995, ANGEW CHEM, V107, P1689
   BEYER T, 2001, CRYSTENGCOMM, V3, P213
   BONDI A, 1964, J PHYS CHEM-US, V68, P441, DOI 10.1021/j100785a001
   Bultinck P, 2003, J MATH CHEM, V34, P67, DOI 10.1023/A:1025136721324
   Bultinck P, 2003, J CHEM PHYS, V118, P4349, DOI 10.1063/1.1542875
   BULTNICK P, 2007, J CHEM  PHYS, P127
   Byrn S. R., 1999, SOLID STATE CHEM DRU
   CHATTARAJ PK, 1991, J AM CHEM SOC, V113, P1855, DOI 10.1021/ja00005a073
   Chen S, 2005, J AM CHEM SOC, V127, P9881, DOI 10.1021/ja052098t
   COHEN MH, 1994, J CHEM PHYS, V101, P8988, DOI 10.1063/1.468026
   Day GM, 2005, ACTA CRYSTALLOGR B, V61, P511, DOI 10.1107/S0108768105016563
   De Proft F, 1998, J CHEM PHYS, V108, P7549, DOI 10.1063/1.476188
   Desiraju GR, 2002, ACCOUNTS CHEM RES, V35, P565, DOI 10.1021/ar010054t
   Dovesi R, 2005, Z KRISTALLOGR, V220, P571, DOI 10.1524/zkri.220.5.571.65065
   Dunitz JD, 2005, ANGEW CHEM INT EDIT, V44, P1766, DOI 10.1002/anie.200460157
   DUNITZ JD, 2005, ANGEW CHEM, V117, P1796
   ETTER MC, 1990, ACCOUNTS CHEM RES, V23, P120, DOI 10.1021/ar00172a005
   Feng SX, 2006, J CHEM THEORY COMPUT, V2, P149, DOI 10.1021/ct050189a
   FRISCH MJ, 2004, GAUSSIAN 03 REVISION
   Fuentealba P, 2000, J CHEM PHYS, V113, P2544, DOI 10.1063/1.1305879
   Geerlings P, 2003, CHEM REV, V103, P1793, DOI 10.1021/cr990029p
   HALGREN TA, 1992, J AM CHEM SOC, V114, P7827, DOI 10.1021/ja00046a032
   HELLMANN H, 1939, PHYS REV, V56, P340
   Hoeben FJM, 2005, CHEM REV, V105, P1491, DOI 10.1021/cr030070z
   HOHENBERG P, 1964, PHYS REV B, V136, pB864, DOI 10.1103/PhysRev.136.B864
   KLOPMAN G, 1968, J AM CHEM SOC, V90, P223, DOI 10.1021/ja01004a002
   Kohn W, 1996, J PHYS CHEM-US, V100, P12974, DOI 10.1021/jp960669l
   LEE CT, 1988, PHYS REV B, V37, P785, DOI 10.1103/PhysRevB.37.785
   Li TL, 2007, J PHARM SCI-US, V96, P755, DOI 10.1002/jps.20819
   Liu S, 2007, J CHEM PHYS, V126
   Lommerse JPM, 2000, ACTA CRYSTALLOGR B, V56, P697, DOI 10.1107/S0108768100004584
   Melin J, 2007, J PHYS CHEM A, V111, P10017, DOI 10.1021/jp075573d
   Metrangolo P, 2008, STRUCT BOND, V126, P105, DOI 10.1007/430_2007_060
   Meyer EA, 2003, ANGEW CHEM INT EDIT, V42, P1210, DOI 10.1002/anie.200390319
   Meyer E. A., 2003, ANGEW CHEM, V115, P1244
   MOROKUMA K, 1977, ACCOUNTS CHEM RES, V10, P294, DOI 10.1021/ar50116a004
   Motherwell WDS, 2002, ACTA CRYSTALLOGR B, V58, P647, DOI 10.1107/S0108768102005669
   NAKATSUJ.H, 1974, J AM CHEM SOC, V96, P24, DOI 10.1021/ja00808a004
   Neumann M. A., 2008, ANGEW CHEM, V120, P2461
   Neumann MA, 2008, ANGEW CHEM INT EDIT, V47, P2427, DOI 10.1002/anie.200704247
   PARR RG, 1983, J AM CHEM SOC, V105, P7512, DOI 10.1021/ja00364a005
   PARR RG, 1995, ANNU REV PHYS CHEM, V46, P701, DOI 10.1146/annurev.pc.46.100195.003413
   PARR RG, 1984, J AM CHEM SOC, V106, P4049, DOI 10.1021/ja00326a036
   Parr RG, 1989, DENSITY FUNCTIONAL T
   PEARSON RG, 1963, J AM CHEM SOC, V85, P3533, DOI 10.1021/ja00905a001
   PEARSON RG, 1966, SCIENCE, V151, P172, DOI 10.1126/science.151.3707.172
   PERDEW JP, 1982, PHYS REV LETT, V49, P1691, DOI 10.1103/PhysRevLett.49.1691
   Roy RK, 1999, J CHEM PHYS, V110, P8236, DOI 10.1063/1.478792
   Simon-Manso Y, 1998, J PHYS CHEM A, V102, P2029, DOI 10.1021/jp972733k
   Steiner T, 2002, ANGEW CHEM INT EDIT, V41, P48, DOI 10.1002/1521-3773(20020104)41:1<48::AID-ANIE48>3.0.CO;2-U
   Steiner T., 2002, ANGEW CHEM, V114, P50
   THOMPSON D, 2000, OPENDX PATHS VISUALI
   VELA A, 1990, J AM CHEM SOC, V112, P1490, DOI 10.1021/ja00160a029
   Vishweshwar P, 2006, J PHARM SCI-US, V95, P499, DOI 10.1002/jps.20578
   WANG W, 1984, J CHEM PHYS, V81, P2862
   Wu Q, 2002, J CHEM PHYS, V116, P515, DOI 10.1063/1.1424928
   YANG W, 1986, J AM CHEM SOC, V108, P5708, DOI 10.1021/ja00279a008
   Yang WT, 2000, PHYS REV LETT, V84, P5172, DOI 10.1103/PhysRevLett.84.5172
   YANG WT, 1985, P NATL ACAD SCI USA, V82, P6723, DOI 10.1073/pnas.82.20.6723
   Yu L, 2000, J AM CHEM SOC, V122, P585, DOI 10.1021/ja9930622
NR 74
TC 22
Z9 23
U1 1
U2 39
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY
SN 0947-6539
J9 CHEM-EUR J
JI Chem.-Eur. J.
PY 2009
VL 15
IS 2
BP 361
EP 371
DI 10.1002/chem.200801056
PG 11
WC Chemistry, Multidisciplinary
SC Chemistry
GA 394ZK
UT WOS:000262491500010
PM 19034948
DA 2018-03-20
ER

PT J
AU Gupta, SL
   Long, SH
   Li, TL
AF Gupta, Salin
   Long, Sihui
   Li, Tonglei
TI 6-Oxo-1,6-dihydropyridine-3-carboxylic acid
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article
AB The title compound, C6H5NO3, commonly known as 6-hydroxynicotinic acid, is found to be a tautomer of it. Four molecules, all adopting a planar conformation, are found in the asymmetric unit. The compound forms hydrogen-bonded sheets parallel to the [ 001] direction via intermolecular N-H center dot center dot center dot O and O-H center dot center dot center dot O hydrogen bonds. Each sheet consists of interconnected dimers created by R-2(2)(8) N-H center dot center dot center dot O hydrogen-bonded motifs and infinite chains formed by C( 7) hydrogen-bonded motifs. Alternatively, these sheets can be viewed as infinitely fused 32-membered hydrogen-bonded rings.
C1 Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40506 USA.
RP Li, TL (reprint author), Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40506 USA.
EM tonglei@uky.edu
CR Dogra SK, 2005, J MOL STRUCT, V737, P189, DOI 10.1016/j.molstruc.2004.10.060
   ETTER MC, 1990, ACCOUNTS CHEM RES, V23, P120, DOI 10.1021/ar00172a005
   Long SH, 2006, ACTA CRYSTALLOGR E, V62, pO5664, DOI 10.1107/S1600536806048768
   Nonius, 2002, COLLECT
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Sheldrick G. M., 1997, SHELXL97 SHELXS97
   SHELDRICK GM, 1995, XP SHELXTL PC
   Tinschert A, 1997, ARCH MICROBIOL, V168, P355, DOI 10.1007/s002030050509
NR 8
TC 2
Z9 2
U1 0
U2 6
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD JUN
PY 2007
VL 63
BP O2784
EP U1783
DI 10.1107/S1600536807020958
PN 6
PG 12
WC Crystallography
SC Crystallography
GA 191GD
UT WOS:000248118400170
DA 2018-03-20
ER

PT J
AU Dirk, LMA
   Schmidt, JJ
   Cai, Y
   Barnes, JC
   Hanger, KM
   Nayak, NR
   Williams, MA
   Grossman, RB
   Houtz, RL
   Rodgers, DW
AF Dirk, Lynnette M. A.
   Schmidt, Jack J.
   Cai, Yiying
   Barnes, Jonathan C.
   Hanger, Katherine M.
   Nayak, Nihar R.
   Williams, Mark A.
   Grossman, Robert B.
   Houtz, Robert L.
   Rodgers, David W.
TI Insights into the substrate specificity of plant peptide deformylase, an
   essential enzyme with potential for the development of novel
   biotechnology applications in agriculture
SO BIOCHEMICAL JOURNAL
LA English
DT Article
DE Arabidopsis; actinonin; chloroplast; co-translational; peptide
   deformylase; protein processing
ID TERMINAL METHIONINE EXCISION; POLYPEPTIDE DEFORMYLASE;
   CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; DRUG DESIGN; TARGET; SITE;
   IDENTIFICATION; UNIVERSALITY; RECOGNITION
AB The crystal structure of AtPDF1B [Arabidopsis thaliana PDF (peptide deformylase) 1B; EC 3.5.1.88], a plant specific deformylase, has been determined at a resolution of 2.4 angstrom (1 angstrom=0.1 nm). The overall fold of AtPDF1B is similar to other peptide deformylases that have been reported. Evidence from the crystal structure and gel filtration chromatography indicates that AtPDF1B exists as a symmetric dimer. PDF1B is essential in plants and has a preferred substrate specificity towards the PS II (photosystem II) D1 polypeptide. Comparative analysis of AtPDF1B, AtPDF1A, and the type 1B deformylase from Escherichia coli, identifies a number of differences in substrate binding subsites that might account for variations in sequence preference. A model of the N-terminal five amino acids from the D1 polypeptide bound in the active site of AtPDF1B suggests an influence of Tyr(178) as a structural determinant for polypeptide substrate specificity through hydrogen bonding with Thr(2) in the D1 sequence. Kinetic analyses using a polypeptide mimic of the D1 N-terminus was performed on AtPDF1B mutated at Tyr(178) to alanine, phenylalanine or arginine (equivalent residue in AtPDF1A). The results suggest that, whereas Tyr(178) can influence catalytic activity, other residues contribute to the overall preference for the D I polypeptide.
C1 [Schmidt, Jack J.; Cai, Yiying; Rodgers, David W.] Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA.
   [Schmidt, Jack J.; Cai, Yiying; Rodgers, David W.] Univ Kentucky, Struct Biol Ctr, Lexington, KY 40536 USA.
   [Dirk, Lynnette M. A.; Nayak, Nihar R.; Williams, Mark A.; Houtz, Robert L.] Univ Kentucky, Dept Hort, Plant Physiol Biochem Mol Biol Program, Lexington, KY 40546 USA.
   [Barnes, Jonathan C.; Grossman, Robert B.] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
   [Hanger, Katherine M.] Univ Kentucky, Coll Pharm, Lexington, KY 40536 USA.
RP Rodgers, DW (reprint author), Univ Kentucky, Dept Mol & Cellular Biochem, Biomed Biol Sci Res Bldg,Rm 269,741 S Limestone, Lexington, KY 40536 USA.
EM david.rodgers@uky.edu
FU NCRR NIH HHS [P20 RR20171]; NINDS NIH HHS [NS38041]
CR Becker A, 1998, J BIOL CHEM, V273, P11413, DOI 10.1074/jbc.273.19.11413
   Becker A, 1998, NAT STRUCT BIOL, V5, P1053, DOI 10.1038/4162
   Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254
   Case DA, 2005, J COMPUT CHEM, V26, P1668, DOI 10.1002/jcc.20290
   Chan MK, 1997, BIOCHEMISTRY-US, V36, P13904, DOI 10.1021/bi9711543
   Dirk LMA, 2002, ARCH BIOCHEM BIOPHYS, V406, P135, DOI 10.1016/S0003-9861(02)00426-5
   Dirk LMA, 2001, PLANT PHYSIOL, V127, P97, DOI 10.1104/pp.127.1.97
   Fieulaine S, 2005, J BIOL CHEM, V280, P42315, DOI 10.1074/jbc.M507155200
   Giglione C, 2004, CELL MOL LIFE SCI, V61, P1455, DOI 10.1007/s00018-004-3466-8
   Giglione C, 2003, EMBO J, V22, P13, DOI 10.1093/emboj/cdg007
   Giglione C, 2001, TRENDS PLANT SCI, V6, P566, DOI 10.1016/S1360-1385(01)02151-3
   Giglione C, 2000, EMBO J, V19, P5916, DOI 10.1093/emboj/19.21.5916
   Hou CX, 2007, PLANT BIOTECHNOL J, V5, P275, DOI 10.1111/j.1467-7652.2007.00238.x
   Hou CX, 2004, AM J BOT, V91, P1304, DOI 10.3732/ajb.91.9.1304
   Hu YJ, 1999, BIOCHEMISTRY-US, V38, P643, DOI 10.1021/bi9820412
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224
   Kettunen R, 1996, PLANT PHYSIOL, V111, P1183, DOI 10.1104/pp.111.4.1183
   Kumar A, 2002, STRUCTURE, V10, P357, DOI 10.1016/S0969-2126(02)00719-0
   Lee MD, 2004, J CLIN INVEST, V114, P1107, DOI 10.1172/JCI200422269
   Lee MD, 2003, BIOCHEM BIOPH RES CO, V312, P309, DOI 10.1016/j.bbrc.2003.10.123
   Leeds JA, 2006, CURR OPIN PHARMACOL, V6, P445, DOI 10.1016/j.coph.2006.06.003
   Mazel D, 1997, J MOL BIOL, V266, P939, DOI 10.1006/jmbi.1996.0835
   MAZEL D, 1994, EMBO J, V13, P914
   Meinnel T, 1996, J MOL BIOL, V262, P375, DOI 10.1006/jmbi.1996.0521
   Meinnel T, 1999, BIOCHEMISTRY-US, V38, P4287, DOI 10.1021/bi982622r
   Nguyen KT, 2003, BIOCHEMISTRY-US, V42, P9952, DOI 10.1021/bi0346446
   NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Ragusa S, 1999, J MOL BIOL, V289, P1445, DOI 10.1006/jmbi.1999.2832
   Rajagopalan PTR, 1997, BIOCHEMISTRY-US, V36, P13910, DOI 10.1021/bi971155v
   Rodgers DW, 1997, METHOD ENZYMOL, V276, P183, DOI 10.1016/S0076-6879(97)76059-2
   Serero A, 2003, J BIOL CHEM, V278, P52953, DOI 10.1074/jbc.M309770200
   Serero A, 2001, J MOL BIOL, V314, P695, DOI 10.1006/jmbi.2001.5175
   Walter RF, 2005, CURR ISSUES MOL BIOL, V7, P57
   Wei YM, 1997, ANAL BIOCHEM, V250, P29, DOI 10.1006/abio.1997.2194
   Yuan ZY, 2006, BIOCHEM PHARMACOL, V71, P1042, DOI 10.1016/j.bcp.2005.10.015
   Zhou ZC, 2005, J BIOL CHEM, V280, P42391, DOI 10.1074/jbc.M506370200
NR 38
TC 9
Z9 10
U1 0
U2 6
PU PORTLAND PRESS LTD
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND
SN 0264-6021
EI 1470-8728
J9 BIOCHEM J
JI Biochem. J.
PD AUG 1
PY 2008
VL 413
BP 417
EP 427
DI 10.1042/BJ20071641
PN 3
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 332JY
UT WOS:000258080500004
PM 18412546
OA gold
DA 2018-03-20
ER

PT J
AU Rheiner, S
   Reichel, D
   Rychahou, P
   Izumi, T
   Yang, HS
   Bae, Y
AF Rheiner, Steven
   Reichel, Derek A.
   Rychahou, Piotr G.
   Izumi, Tadahide
   Yang, Hsin-Sheng
   Bae, Younsoo
TI Polymer nanoassemblies with hydrophobic pendant groups in the core
   induce false positive siRNA transfection in luciferase reporter assays
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Polymer nanoassemblies; Gene delivery; siRNA; False transfection;
   Luciferase reporter assays; Polyethylenimine
ID INDUCED GENE-EXPRESSION; UBIQUITIN-PROTEASOME PATHWAY; LINEAR
   POLYETHYLENIMINE; INTRACELLULAR DELIVERY; OXIDATIVE STRESS; ER STRESS;
   IN-VITRO; CELL; NANOPARTICLES; CYTOTOXICITY
AB Poly(ethylene glycol)-conjugated polyethylenimine (PEG-PEI) is a widely studied cationic polymer used to develop non-viral vectors for siRNA therapy of genetic disorders including cancer. Cell lines stably expressing luciferase reporter protein typically evaluate the transfection efficacy of siRNA/PEG-PEI complexes, however recent findings revealed that PEG-PEI can reduce luciferase expression independent of siRNA. This study elucidates a cause of the false positive effect in luciferase assays by using polymer nanoassemblies (PNAs) made from PEG, PEI, poly-(L-lysine) (PLL), palmitate (PAL), and deoxycholate (DOC): PEG-PEI (2P), PEG-PEI-PAL (3P), PEG-PLL (2P'), PEG-PLL-PAL (3P'), and PEG-PEI-DOC (2PD). In vitro transfection and western blot assays of luciferase using a colorectal cancer cell line expressing luciferase (HT29/LUC) concluded that 2P and 2P' caused no luciferase expression reduction while hydrophobically modified PNAs induced a 35-50% reduction (3P' < 2PD < 3P). Although cell viability remained stagnant, 3P triggered cellular stress responses including increased membrane porosity and decreased ATP and cellular protein concentrations. Raman spectroscopy suggested that hydrophobic groups influence PNA conformation changes, which may have caused over-ubiquitination and degradation of luciferase in the cells. These results indicate that hydrophobically modified PEG-PEI induces cellular distress causing over-ubiquitination of the luciferase protein, producing false positive siRNA transfection in the luciferase assay. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Rheiner, Steven; Reichel, Derek; Bae, Younsoo] Univ Kentucky, Dept Pharmaceut Sci, Coll Pharm, 789 South Limestone, Lexington, KY 40536 USA.
   [Rychahou, Piotr; Yang, Hsin-Sheng] Univ Kentucky, Markey Canc Ctr, 800 Rose St,CC140, Lexington, KY 40536 USA.
   [Rychahou, Piotr] Univ Kentucky, Dept Surg, Coll Med, 741 South Limestone, Lexington, KY 40536 USA.
   [Izumi, Tadahide; Yang, Hsin-Sheng] Univ Kentucky, Dept Toxicol & Canc Biol, Coll Med, 1095 VA Dr, Lexington, KY 40536 USA.
RP Bae, Y (reprint author), Univ Kentucky, Dept Pharmaceut Sci, Coll Pharm, 789 South Limestone, Lexington, KY 40536 USA.
EM younsoo.bae@uky.edu
FU University of Kentucky Cancer Nanotechnology Training Center (UK CNTC);
   NCI/NIH; National Cancer Institute Alliance; University of Kentucky
   Markey Cancer Center pilot grant; University of Kentucky GSAY fellowship
FX The authors acknowledge the financial support from the University of
   Kentucky Cancer Nanotechnology Training Center (UK CNTC), funded by the
   NCI/NIH and part of the National Cancer Institute Alliance. This work is
   partially supported by the University of Kentucky Markey Cancer Center
   pilot grant. Derek Reichel acknowledges financial support from the
   University of Kentucky GSAY fellowship.
CR Aberle AM, 1998, BIOCHEMISTRY-US, V37, P6533, DOI 10.1021/bi9801154
   Alcazar O, 1997, DIABETES, V46, P1153, DOI 10.2337/diabetes.46.7.1153
   Auld DS, 2008, ACS CHEM BIOL, V3, P463, DOI 10.1021/cb8000793
   Bartlett DW, 2006, NUCLEIC ACIDS RES, V34, P322, DOI 10.1093/nar/gkj439
   Choy G, 2003, BIOTECHNIQUES, V35, P1022
   Cunha DA, 2008, J CELL SCI, V121, P2308, DOI 10.1242/jcs.026062
   Davis ME, 2010, NATURE, V464, P1067, DOI 10.1038/nature08956
   Ding WX, 2007, AM J PATHOL, V171, P513, DOI 10.2353/ajpath.2007.070188
   Dootz R, 2006, LANGMUIR, V22, P1735, DOI 10.1021/la052739y
   Fella C, 2008, EUR J PHARM SCI, V34, P309, DOI 10.1016/j.ejps.2008.05.004
   Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8
   Helmfors H, 2015, ANAL BIOCHEM, V484, P136, DOI 10.1016/j.ab.2015.05.023
   Hollins AJ, 2007, J DRUG TARGET, V15, P83, DOI 10.1080/10611860601151860
   Ishii M, 2015, ARCH BIOCHEM BIOPHYS, V566, P26, DOI 10.1016/j.abb.2014.12.009
   Kim DH, 2007, NAT REV GENET, V8, P173, DOI 10.1038/nrg2006
   Kirkin V, 2009, MOL CELL, V34, P259, DOI 10.1016/j.molcel.2009.04.026
   Koyama T, 2011, FREE RADICAL BIO MED, V51, P1258, DOI 10.1016/j.freeradbiomed.2011.05.028
   Lee SJ, 2016, ADV DRUG DELIVER REV, V104, P2, DOI 10.1016/j.addr.2016.05.010
   Listenberger LL, 2001, J BIOL CHEM, V276, P14890, DOI 10.1074/jbc.M010286200
   Liu YY, 2013, BRAIN RES, V1490, P43, DOI 10.1016/j.brainres.2012.10.039
   Lv HT, 2006, J CONTROL RELEASE, V114, P100, DOI 10.1016/j.jconrel.2006.04.014
   Malek A, 2008, J DRUG TARGET, V16, P124, DOI [10.1080/10611860701849058, 10.1080/10611860701849058 ]
   Nelson CE, 2013, ACS NANO, V7, P8870, DOI 10.1021/nn403325f
   O'Brien J, 2000, EUR J BIOCHEM, V267, P5421, DOI 10.1046/j.1432-1327.2000.01606.x
   Omidi Y, 2005, J DRUG TARGET, V13, P431, DOI 10.1080/10611860500418881
   Omidi Y, 2003, J DRUG TARGET, V11, P311, DOI 10.1080/10611860310001636908
   Orlowski RZ, 1999, CELL DEATH DIFFER, V6, P303, DOI 10.1038/sj.cdd.4400505
   Pandey AP, 2016, MAT SCI ENG C-MATER, V68, P904, DOI 10.1016/j.msec.2016.07.066
   Patil Y, 2009, INT J PHARM, V367, P195, DOI 10.1016/j.ijpharm.2008.09.039
   Reichel D., 2016, PHARM RES, P1
   Reichel D, 2016, THER DELIV, V7, P665, DOI 10.4155/tde-2016-0041
   Rheiner S, 2015, AIMS BIOPHYS, V2, P284, DOI 10.3934/biophy.2015.3.284
   Rheiner S, 2016, AIMS BIOENG, V3, P454, DOI 10.3934/bioeng.2016.4.454
   Romero G, 2010, BIOMACROMOLECULES, V11, P2993, DOI 10.1021/bm1007822
   Shang F, 2011, FREE RADICAL BIO MED, V51, P5, DOI 10.1016/j.freeradbiomed.2011.03.031
   Spriggs KA, 2010, MOL CELL, V40, P228, DOI 10.1016/j.molcel.2010.09.028
   Suganami T, 2007, ARTERIOSCL THROM VAS, V27, P84, DOI 10.1161/01.ATV.0000251608.09329.9a
   Thorne N, 2010, CHEM BIOL, V17, P646, DOI 10.1016/j.chembiol.2010.05.012
   Tiwari BS, 2002, PLANT PHYSIOL, V128, P1271, DOI 10.1104/pp.010999
   Wightman L, 2001, J GENE MED, V3, P362, DOI 10.1002/jgm.187
   Wittrup A, 2015, NAT REV GENET, V16, P543, DOI 10.1038/nrg3978
   Xue HY, 2014, NANOMEDICINE-UK, V9, P295, DOI 10.2217/nnm.13.204
   York SS, 2003, MACROMOLECULES, V36, P7348, DOI 10.1021/ma030016k
   Yoshida H, 2007, FEBS J, V274, P630, DOI 10.1111/j.1742-4658.2007.05639.x
   Zintchenko A, 2008, BIOCONJUGATE CHEM, V19, P1448, DOI 10.1021/bc800065f
NR 45
TC 0
Z9 0
U1 5
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
EI 1873-3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD AUG 7
PY 2017
VL 528
IS 1-2
BP 536
EP 546
DI 10.1016/j.ijpharm.2017.06.056
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA FE1WF
UT WOS:000408007600049
PM 28629980
DA 2018-03-19
ER

EF